<SEC-DOCUMENT>0000078003-20-000060.txt : 20200806
<SEC-HEADER>0000078003-20-000060.hdr.sgml : 20200806
<ACCEPTANCE-DATETIME>20200806161038
ACCESSION NUMBER:		0000078003-20-000060
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		118
CONFORMED PERIOD OF REPORT:	20200628
FILED AS OF DATE:		20200806
DATE AS OF CHANGE:		20200806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PFIZER INC
		CENTRAL INDEX KEY:			0000078003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				135315170
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03619
		FILM NUMBER:		201081698

	BUSINESS ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		2125732323

	MAIL ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PFIZER CHARLES & CO INC
		DATE OF NAME CHANGE:	19710908
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>pfe-06282020x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:5adb5a2f47574ea790ad73a7cc5a5ca3,x:985107623ac5403b9d028f2f89cfa68a-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2020 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:sheci="http://fasb.org/stm/sheci/2020-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2020-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2020-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2020-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2020-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2020-01-31" xmlns:equity="http://fasb.org/dis/equity/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:ides="http://fasb.org/dis/ides/2020-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2020-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2020-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2020-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2020-01-31" xmlns:ei="http://fasb.org/dis/ei/2020-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2020-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2020-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2020-01-31" xmlns:srt-all="http://fasb.org/srt-all/2020-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2020-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2020-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2020-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2020-01-31" xmlns:se="http://fasb.org/dis/se/2020-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2020-01-31" xmlns:hco="http://fasb.org/dis/hco/2020-01-31" xmlns:soi="http://fasb.org/stm/soi/2020-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2020-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:debt="http://fasb.org/dis/debt/2020-01-31" xmlns:spc="http://fasb.org/stm/spc/2020-01-31" xmlns:ts="http://fasb.org/dis/ts/2020-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:rd="http://fasb.org/dis/rd/2020-01-31" xmlns:sr="http://fasb.org/dis/sr/2020-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:edco="http://fasb.org/dis/edco/2020-01-31" xmlns:guar="http://fasb.org/dis/guar/2020-01-31" xmlns:te="http://fasb.org/dis/te/2020-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:ni="http://fasb.org/dis/ni/2020-01-31" xmlns:dr="http://fasb.org/dis/dr/2020-01-31" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2020-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2020-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2020-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2020-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2020-01-31" xmlns:iago="http://fasb.org/dis/iago/2020-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2020-01-31" xmlns:con="http://fasb.org/dis/con/2020-01-31" xmlns:leas="http://fasb.org/dis/leas/2020-01-31" xmlns:com="http://fasb.org/stm/com/2020-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2020-01-31" xmlns:inv="http://fasb.org/dis/inv/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2020-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2020-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2020-01-31" xmlns:oi="http://fasb.org/dis/oi/2020-01-31" xmlns:pfe="http://www.pfizer.com/20200628" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2020-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2020-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:cn-part="http://fasb.org/cn-part/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2020-01-31" xmlns:srt-std="http://fasb.org/srt-std/2020-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2020-01-31" xmlns:re="http://fasb.org/dis/re/2020-01-31" xmlns:ir="http://fasb.org/dis/ir/2020-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2020-01-31" xmlns:soc="http://fasb.org/stm/soc/2020-01-31" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2020-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2020-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2020-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2020-01-31" xmlns:regop="http://fasb.org/dis/regop/2020-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2020-01-31" xmlns:ero="http://fasb.org/dis/ero/2020-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2020-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2020-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:invco="http://fasb.org/dis/invco/2020-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2020-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2020-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2020-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2020-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2020-01-31" xmlns:aro="http://fasb.org/dis/aro/2020-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2020-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2020-01-31" xmlns:pay="http://fasb.org/dis/pay/2020-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2020-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2020-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2020-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2020-01-31" xmlns:eps="http://fasb.org/dis/eps/2020-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2020-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2020-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:crcrb="http://fasb.org/dis/crcrb/2020-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2020-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2020-01-31" xmlns:lea="http://fasb.org/dis/lea/2020-01-31" xmlns:disops="http://fasb.org/dis/disops/2020-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2020-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2020-01-31" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2020-01-31" xmlns:nt="http://fasb.org/dis/nt/2020-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2020-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2020-01-31" xmlns:cce="http://fasb.org/dis/cce/2020-01-31" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2020-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2020-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2020-01-31" xmlns:acec="http://fasb.org/dis/acec/2020-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2020-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2020-01-31" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2020-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2020-01-31" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:cc="http://fasb.org/dis/cc/2020-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2020-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2020-01-31" xmlns:ru="http://fasb.org/dis/ru/2020-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2020-01-31" xmlns:foct="http://fasb.org/dis/foct/2020-01-31" xmlns:sec-re="http://fasb.org/dis/sec-re/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2020-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2020-01-31" xmlns:diha="http://fasb.org/dis/diha/2020-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ap="http://fasb.org/dis/ap/2020-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2020-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:eui="http://fasb.org/dis/eui/2020-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="FD2020Q2YTD" name="dei:AmendmentFlag" id="Fact-B0D389DC799E7D024A3694757D9E3A03-wk-Fact-B0D389DC799E7D024A3694757D9E3A03" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-7E16EF88150545EF367C94757D9D24AD-wk-Fact-7E16EF88150545EF367C94757D9D24AD">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-CEDB9E353C5AB597A42394757D9D22C6-wk-Fact-CEDB9E353C5AB597A42394757D9D22C6">Q2</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="dei:DocumentFiscalYearFocus" id="Fact-046AEFF956A35C8C2CCA94757D9E446D-wk-Fact-046AEFF956A35C8C2CCA94757D9E446D">2020</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="dei:EntityCentralIndexKey" id="Fact-C91EA2BD30816293114B94757D9D34F0-wk-Fact-C91EA2BD30816293114B94757D9D34F0">0000078003</ix:nonNumeric><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FI2019Q4" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact-AA58F5E3D16407426BC394757CD865C7-wk-Fact-AA58F5E3D16407426BC394757CD865C7">16789000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FI2020Q2" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact-43361FC2439255EC9C0794757CD9C825-wk-Fact-43361FC2439255EC9C0794757CD9C825">16889000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FI2019Q4" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" id="Fact-8F6198A5B84A323EA04194757CDD184D-wk-Fact-8F6198A5B84A323EA04194757CDD184D">527000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FI2020Q2" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" id="Fact-EA1E0B8D16648EC1813394757CDA0B29-wk-Fact-EA1E0B8D16648EC1813394757CDA0B29">525000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-B2C9D3D493F51DFD6D8D94757CAD8A87-wk-Fact-B2C9D3D493F51DFD6D8D94757CAD8A87">0.02625</ix:nonFraction><ix:nonFraction decimals="-8" unitRef="usd" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" name="us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" id="Fact-B8025FEC587092737E4492D05287317F-wk-Fact-B8025FEC587092737E4492D05287317F" sign="-">1400000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FD2020Q2YTD_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember" name="us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" id="Fact-409A4875BAFBBD8061B892D06CF3BC98-wk-Fact-409A4875BAFBBD8061B892D06CF3BC98" sign="-">550000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FI2019Q4" name="us-gaap:LongTermDebtCurrent" id="Fact-354E4103E704EECCE02B94757CDB72E6-wk-Fact-354E4103E704EECCE02B94757CDB72E6">1462000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FI2020Q2" name="us-gaap:LongTermDebtCurrent" id="Fact-A775AC2F22450F075D8194757CD9A894-wk-Fact-A775AC2F22450F075D8194757CD9A894">1481000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" name="us-gaap:ProceedsFromCollaborators" id="Fact-0E193E757E07794025F679147DDD6D3D-wk-Fact-0E193E757E07794025F679147DDD6D3D">30000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_pfe_PumaTechnologiesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" name="us-gaap:ProceedsFromCollaborators" id="Fact-7575AC2390FECF899875791421411CBB-wk-Fact-7575AC2390FECF899875791421411CBB">40000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FD2019Q2YTD" name="us-gaap:ProceedsFromLegalSettlements" id="Fact-B8C9A592AB43457FFC677912F0F2CFCD-wk-Fact-B8C9A592AB43457FFC677912F0F2CFCD">82000000</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="pfe-20200628.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="FD2020Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q3Aug3-3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-08-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20271.000Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20271.000Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20220.250Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20220.250Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q3Jan1-Jul31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1Jan1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Jan01">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q2Jan1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q2Oct1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-10-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q2Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q2Apr9_srt_CounterpartyNameAxis_pfe_BioNTechSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechSEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-04-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q2Apr30_srt_CounterpartyNameAxis_pfe_ValnevaSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ValnevaSEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_CounterpartyNameAxis_pfe_BioNTechSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechSEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q2Apr9-9_srt_CounterpartyNameAxis_pfe_BioNTechSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechSEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-09</xbrli:startDate>
			<xbrli:endDate>2020-04-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_CounterpartyNameAxis_pfe_BioNTechSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechSEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q3Jul30-Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-30</xbrli:startDate>
			<xbrli:endDate>2019-07-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_CounterpartyNameAxis_pfe_ValnevaSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ValnevaSEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Jul31_dei_LegalEntityAxis_pfe_GSKMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:GSKMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_CounterpartyNameAxis_pfe_ValnevaSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ValnevaSEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_RangeAxis_srt_MinimumMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q3Jul1-31_srt_CounterpartyNameAxis_pfe_BioNTechSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechSEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-07-01</xbrli:startDate>
			<xbrli:endDate>2020-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-07-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q2Jun1-28_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-06-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_RangeAxis_srt_MaximumMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_ManufacturingCostReductionMember_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:ManufacturingCostReductionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_BusinessIntegrationCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:BusinessIntegrationCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RestructuringCostAndReserveAxis_pfe_BusinessIntegrationCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:BusinessIntegrationCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_RestructuringCostAndReserveAxis_pfe_ManufacturingCostReductionMember_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:ManufacturingCostReductionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_RestructuringPlanAxis_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q2Oct1-Jun28_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-10-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViiVMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViiVMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_CounterpartyNameAxis_pfe_MylanMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MylanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViiVMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViiVMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_CK1AssetsSoldToBiogenIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:CK1AssetsSoldToBiogenIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_GeneTherapiesMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GeneTherapiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchDevelopmentAndMedicalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AllogeneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_BusinessAcquisitionAxis_pfe_ViiVMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ViiVMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_CounterpartyNameAxis_pfe_PumaTechnologiesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:PumaTechnologiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_BioNTechSEMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:BioNTechSEMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AllogeneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CortexymeInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CortexymeInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_KingMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:KingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_BioNTechSEMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:BioNTechSEMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_BusinessAcquisitionAxis_pfe_ViiVMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ViiVMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AnacorMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AnacorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViiVMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViiVMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:EliLillyCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViiVMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViiVMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_CounterpartyNameAxis_pfe_PumaTechnologiesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:PumaTechnologiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:EliLillyCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2021Q2Apr1-30_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2021-04-01</xbrli:startDate>
			<xbrli:endDate>2021-04-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_IncomeTaxesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:IncomeTaxesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q3Jul1-31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-07-01</xbrli:startDate>
			<xbrli:endDate>2020-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_DebtInstrumentAxis_pfe_LongTermDebtIssuedFirstQuarter2020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:LongTermDebtIssuedFirstQuarter2020Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnFinanceB.V.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DebtInstrumentAxis_pfe_SeniorNotesDue2047Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorNotesDue2047Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:ParentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnFinanceB.V.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:ParentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnFinanceB.V.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnFinanceB.V.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnFinanceB.V.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:ParentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:ParentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_pfe_HedgedItemAxis_us-gaap_SalesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:HedgedItemAxis">us-gaap:SalesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_pfe_HedgedItemAxis_us-gaap_SalesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:HedgedItemAxis">us-gaap:SalesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_EquitySecuritiesByIndustryAxis_us-gaap_FinancialServicesSectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">us-gaap:FinancialServicesSectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchDevelopmentAndMedicalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchDevelopmentAndMedicalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchDevelopmentAndMedicalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchDevelopmentAndMedicalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchDevelopmentAndMedicalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchDevelopmentAndMedicalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q4Jun29-Dec31_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-06-29</xbrli:startDate>
			<xbrli:endDate>2020-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q2May4-4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-05-04</xbrli:startDate>
			<xbrli:endDate>2020-05-04</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q2May4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-05-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Dec14-14">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-14</xbrli:startDate>
			<xbrli:endDate>2018-12-14</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2Jun27">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-27</xbrli:startDate>
			<xbrli:endDate>2019-06-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-09-24</xbrli:startDate>
			<xbrli:endDate>2019-09-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2Apr25-25">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-25</xbrli:startDate>
			<xbrli:endDate>2019-04-25</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q2Apr23_Apr232020">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-23</xbrli:startDate>
			<xbrli:endDate>2020-04-23</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q4Dec13-13">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-12-13</xbrli:startDate>
			<xbrli:endDate>2019-12-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q2Jun25-25">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-06-25</xbrli:startDate>
			<xbrli:endDate>2020-06-25</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q1Mar01-Mar31_srt_LitigationCaseAxis_pfe_PfizerVersusZydusMember_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerVersusZydusMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q2Feb01-Apr30_srt_LitigationCaseAxis_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerandBMSVersusSeveralGenericManufacturersMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-01</xbrli:startDate>
			<xbrli:endDate>2017-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q1Jan1-31_srt_LitigationCaseAxis_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerVersusViwitPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Oct01-Oct31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q3Jul1-31_srt_LitigationCaseAxis_pfe_NHSScotlandvs.DrReddysMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_PatentInfringementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:NHSScotlandvs.DrReddysMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-07-01</xbrli:startDate>
			<xbrli:endDate>2020-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Jun01-Jun30_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2013Q1MonthOfMarch_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_EnvironmentalRemediationLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:EnvironmentalRemediationLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-03-01</xbrli:startDate>
			<xbrli:endDate>2013-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ProductOrServiceAxis_pfe_EpiPenMember_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct01-Oct31_srt_LitigationCaseAxis_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_srt_ProductOrServiceAxis_pfe_DocetaxelMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:DocetaxelMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q1Mar01-Mar31_srt_LitigationCaseAxis_pfe_PfizerVersusGenericCompaniesMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerVersusGenericCompaniesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Nov2017">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-11-01</xbrli:startDate>
			<xbrli:endDate>2017-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_LitigationCaseAxis_pfe_ClassActionVersusWyethMember_srt_ProductOrServiceAxis_pfe_HormoneTherapyProductsMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:ClassActionVersusWyethMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:HormoneTherapyProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3Sep01-Sep30_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_EnvironmentalRemediationLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:EnvironmentalRemediationLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-09-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:BusinessCombinationsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:PurchaseAccountingAdjustmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:CertainSignificantItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:PurchaseAccountingAdjustmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:BusinessCombinationsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:BusinessCombinationsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:CertainSignificantItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:CertainSignificantItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:PurchaseAccountingAdjustmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:BusinessCombinationsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:PurchaseAccountingAdjustmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:CertainSignificantItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EffexorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_FragminMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalatanXalacomMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_PanzygaMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PanzygaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_TotalSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_PfizerCentreOneMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_MektoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LipitorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EffexorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_OtherAntiinfectivesMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NorvascMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_TotalAllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_TotalSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_SutentMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherUpjohnProductsMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherUpjohnProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherUpjohnProductsMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherUpjohnProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_RetacritMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_VfendMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_XtandiAllianceRevenuesMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LipitorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_TotalAllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_MektoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_MektoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_TotalAllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LipitorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_MektoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_OtherHospitalProductsMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_TotalAllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_OtherAntiinfectivesMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_OtherHospitalProductsMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EffexorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_NimenrixMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalatanXalacomMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_OtherHospitalProductsMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZoloftMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZoloftMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_RetacritMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_PanzygaMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PanzygaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_ConsumerHealthcareReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:ConsumerHealthcareReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_XtandiAllianceRevenuesMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NorvascMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_NimenrixMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_PfizerCentreOneMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_SutentMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_VyndaqelMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_FragminMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_TotalBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalBiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_OtherAntiinfectivesMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_FragminMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_SutentMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_PfizerCentreOneMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LipitorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_TotalSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherUpjohnProductsMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherUpjohnProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_NimenrixMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_FragminMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalatanXalacomMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_RetacritMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_OtherHospitalProductsMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_ConsumerHealthcareReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:ConsumerHealthcareReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_VyndaqelMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_SutentMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_OtherAntiinfectivesMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_PanzygaMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PanzygaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalatanXalacomMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EffexorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_PfizerCentreOneMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_VyndaqelMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_VfendMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_NimenrixMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_ConsumerHealthcareReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:ConsumerHealthcareReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZoloftMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_VfendMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NorvascMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherUpjohnProductsMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherUpjohnProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_VyndaqelMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_RetacritMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZoloftMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NorvascMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_ConsumerHealthcareReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:ConsumerHealthcareReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_XtandiAllianceRevenuesMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_VfendMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_TotalSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_TotalBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalBiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_PanzygaMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PanzygaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_TotalBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalBiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_XtandiAllianceRevenuesMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-30</xbrli:startDate>
			<xbrli:endDate>2020-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_TotalBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalBiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="Accounting_standard">
		<xbrli:measure>pfe:Accounting_standard</xbrli:measure>
	</xbrli:unit><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="Operating_Segment">
		<xbrli:measure>pfe:Operating_Segment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="iso4217_EUR">
		<xbrli:measure>iso4217:EUR</xbrli:measure>
	</xbrli:unit><xbrli:unit id="class_action">
		<xbrli:measure>pfe:class_action</xbrli:measure>
	</xbrli:unit><xbrli:unit id="plaintiff">
		<xbrli:measure>pfe:plaintiff</xbrli:measure>
	</xbrli:unit><xbrli:unit id="lawsuit">
		<xbrli:measure>pfe:lawsuit</xbrli:measure>
	</xbrli:unit><xbrli:unit id="lagoon">
		<xbrli:measure>pfe:lagoon</xbrli:measure>
	</xbrli:unit><xbrli:unit id="Patent">
		<xbrli:measure>pfe:Patents</xbrli:measure>
	</xbrli:unit><xbrli:unit id="Defendant">
		<xbrli:measure>pfe:Defendant</xbrli:measure>
	</xbrli:unit><xbrli:unit id="manufacturer">
		<xbrli:measure>pfe:manufacturer</xbrli:measure>
	</xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8351242e7867-wk-Fact-0062B855A4905ABE3A7094757D9632CA" toRefs="TextSelection-2167C2B3C67E3F1A9F6094757DBA8899-0-wk-Footnote-2167C2B3C67E3F1A9F6094757DBA8899_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e2025-wk-Fact-011D17ED46D6C704909994757CE026FE" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e5060-wk-Fact-0133CD4E7227C37B6E9194757D1DFC1C" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e5060-wk-Fact-0133CD4E7227C37B6E9194757D1DFC1C" toRefs="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e5060-wk-Fact-0133CD4E7227C37B6E9194757D1DFC1C" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1764-wk-Fact-014A34208FA34FFBCC4994757D221D12" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e5505-wk-Fact-02A1D5D7B6684CF717F394757CCC45F0" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e2831-wk-Fact-02FDFD3FA6ACE12CEA1F94757D6D0CCF" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e4154-wk-Fact-0311E1C11EAA0D64120894757D282E1A d8336633e11406-wk-Fact-0311E1C11EAA0D64120894757D282E1A" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e1634-wk-Fact-03460BEA869B48E0CF7894757D6EE332" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8351242e1585-wk-Fact-03AFF2EF3B741A9220ED94757D3DA6D1" toRefs="TextSelection-A2DA5EF7B6FED024F0D494757DBA101E-0-wk-Footnote-A2DA5EF7B6FED024F0D494757DBA101E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1231-wk-Fact-03C451138AD2D3E686ED94757CA8870B" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10398-wk-Fact-03DE33E0BDCBEEE2BFF194757D58A455" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e14487-wk-Fact-0401261FCCFCA256A06E94757CBC98A8" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e6029-wk-Fact-0415E305501AF9B9FFBB94757D23F5EF" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e6029-wk-Fact-0415E305501AF9B9FFBB94757D23F5EF" toRefs="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e6029-wk-Fact-0415E305501AF9B9FFBB94757D23F5EF" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e12831-wk-Fact-044F5FDB0329BCA40A6794757CBD27D2" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1245-wk-Fact-04615CE3AF3CBC3B5C8794757D5092E9" toRefs="TextSelection-04B9B25659DF96CA86BF94757DB5CCE1-0-wk-Footnote-04B9B25659DF96CA86BF94757DB5CCE1_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8340406e1245-wk-Fact-04615CE3AF3CBC3B5C8794757D5092E9" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10827-wk-Fact-054BF18A0129DBDADDAA94757D7C3D2F" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8351242e7340-wk-Fact-0572F3E504E5D75C810D94757D8292B7" toRefs="TextSelection-DA70407E988FF7F4292CB0A472718D04-0-wk-Footnote-DA70407E988FF7F4292CB0A472718D04_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e3237-wk-Fact-05B58E4BDA3C96C172AE94757D61A5B0 d8356748e2152-wk-Fact-05B58E4BDA3C96C172AE94757D61A5B0" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1936-wk-Fact-05DE67BF183EFC3302F894757D673D16 d8356748e1531-wk-Fact-05DE67BF183EFC3302F894757D673D16" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8342960e1031-wk-Fact-05F3838F2F88BF0B809094757CC6BB77" toRefs="TextSelection-BA004C096D54F3EE7B8394757DBF9C64-0-wk-Footnote-BA004C096D54F3EE7B8394757DBF9C64_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1499-wk-Fact-05F41C05FF959B0D282094757CDBBAC3 d8336625e4129-wk-Fact-05F41C05FF959B0D282094757CDBBAC3" toRefs="TextSelection-467F12A5D203A9A15C3A94757DB81B0A-0-wk-Footnote-467F12A5D203A9A15C3A94757DB81B0A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8316808e1499-wk-Fact-05F41C05FF959B0D282094757CDBBAC3 d8336625e4129-wk-Fact-05F41C05FF959B0D282094757CDBBAC3" toRefs="TextSelection-9F5C431DBFAA147134E594757DBBC55E-0-wk-Footnote-9F5C431DBFAA147134E594757DBBC55E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8342313e2012-wk-Fact-0639ADEDE6FCAADD47BB54402D928BD5" toRefs="TextSelection-9FA189BA88B1C6F34587B0A6A8B90D7C-0-wk-Footnote-9FA189BA88B1C6F34587B0A6A8B90D7C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2786-wk-Fact-066BFF2F5B504A5CD41294757D064180 d8336633e2132-wk-Fact-066BFF2F5B504A5CD41294757D064180" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8301124e2786-wk-Fact-066BFF2F5B504A5CD41294757D064180 d8336633e2132-wk-Fact-066BFF2F5B504A5CD41294757D064180" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e7891-wk-Fact-066E69F57B7DF80E550194757D597E52 d8336633e15157-wk-Fact-066E69F57B7DF80E550194757D597E52" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e5559-wk-Fact-066F1B2C39D1A83ADDB294757D9EC44C" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1214-wk-Fact-06B216BCF27965D7A6A694757D11CF28 d8351242e8332-wk-Fact-06B216BCF27965D7A6A694757D11CF28" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e5769-wk-Fact-070B56B824B87F2A371A94757D18F7F9" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10714-wk-Fact-07227B9D4AC3775762FA94757CFC4DBE" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7340-wk-Fact-0739ED261CA0E3B259D394757D5A4733" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7340-wk-Fact-0739ED261CA0E3B259D394757D5A4733" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7135-wk-Fact-0746A502EECEDB0C1D9394757D555939" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7135-wk-Fact-0746A502EECEDB0C1D9394757D555939" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e11249-wk-Fact-076F89258C6280289A5E94757D34A300" toRefs="TextSelection-33990A088D8DAE29233C94757DC283BE-0-wk-Footnote-33990A088D8DAE29233C94757DC283BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8357160e2487-wk-Fact-08957AC6DAC01F29518A94757CFC95E1" toRefs="TextSelection-76B1871DA30219820FCB63105DB9E5C3-0-wk-Footnote-76B1871DA30219820FCB63105DB9E5C3_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1507-wk-Fact-08ABD4A7A57B250F299B94757D04A592" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1546-wk-Fact-08DD19481DA8379F656094757D9154A8" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e3323-wk-Fact-08FE59EF359A8EB1141294757D17D52E" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e3323-wk-Fact-08FE59EF359A8EB1141294757D17D52E" toRefs="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e3323-wk-Fact-08FE59EF359A8EB1141294757D17D52E" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e9074-wk-Fact-099EACAC9FBD97BB278994757CD0F95C" toRefs="TextSelection-FE68345D83BB191130EF94757DC1B5E5-0-wk-Footnote-FE68345D83BB191130EF94757DC1B5E5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e2517-wk-Fact-0A439D2D9035C084D32594757D7076B0" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e8822-wk-Fact-0A9DF58A6CB5A7F6545994757D8DB53B" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2391-wk-Fact-0AB8223F29C3E844972694757CBD7239" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2806-wk-Fact-0AC5548725395D35A56C94757D003303 d8336633e5829-wk-Fact-0AC5548725395D35A56C94757D003303" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8301124e2806-wk-Fact-0AC5548725395D35A56C94757D003303 d8336633e5829-wk-Fact-0AC5548725395D35A56C94757D003303" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e10042-wk-Fact-0ACF20D2E36512CA3FFF94757CB9E5D6" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8357160e3542-wk-Fact-0B05DCE0E371ABB7EA7494757D52B21E" toRefs="TextSelection-2DE900A873C344A165FE94757DBF7A4D-0-wk-Footnote-2DE900A873C344A165FE94757DBF7A4D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7193-wk-Fact-0B2C64A2B5311E2D9BF394757D63AA66" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7193-wk-Fact-0B2C64A2B5311E2D9BF394757D63AA66" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1720-wk-Fact-0C05260CF79B14B3930694757D1319B9" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e7738-wk-Fact-0C3EA3961095E3F8A34994757CCEFE8A d8336633e15004-wk-Fact-0C3EA3961095E3F8A34994757CCEFE8A" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1308-wk-Fact-0C70E0AC22CEB94822F594757CC8BF0F" toRefs="TextSelection-CDCE760DEFA7F631840C94757DB86187-0-wk-Footnote-CDCE760DEFA7F631840C94757DB86187_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2881-wk-Fact-0D1CD905D92C101F2A7094757D18615E" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312053e1348-wk-Fact-0D58D4B7AB8E12C40B7994757CE6D530" toRefs="TextSelection-9459A99A0EC8DD1CD04094757DBA4F65-0-wk-Footnote-9459A99A0EC8DD1CD04094757DBA4F65_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2101-wk-Fact-0D9B88019461C261B2D994757D33A088" toRefs="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2867-wk-Fact-0DADC806FCB0F8DE89E394757CFF07B6" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e2440-wk-Fact-0DCDEC1F3DFA047B631094757CEF6953" toRefs="TextSelection-D29E26CC6CF7C6248CEE94757DBD9743-0-wk-Footnote-D29E26CC6CF7C6248CEE94757DBD9743_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2848-wk-Fact-0DEB9E1626C9961FC0CB94757D4307A4" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e5858-wk-Fact-0E667667A379AE13037394757D3C7D79" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e2112-wk-Fact-0EA469F78A7AA9B0154B94757D0F21D4" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e14137-wk-Fact-0EDCB34EA1247F2C3A2394757D8F0EC3" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336625e4284-wk-Fact-0EF563315BCCD33D4EF194757D29687F" toRefs="TextSelection-F8EDCEC3C21F54D90F7894757DBBCD6D-0-wk-Footnote-F8EDCEC3C21F54D90F7894757DBBCD6D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e3554-wk-Fact-0F151736606908F5607394757D16AC47" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8357160e1370-wk-Fact-0F2346B28DB4629CBB7594757CCA9BA4" toRefs="TextSelection-B511D685B8F037FD258094757DBFC8C5-0-wk-Footnote-B511D685B8F037FD258094757DBFC8C5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8340406e1094-wk-Fact-0F4E421B90BAC3CEFBC094757D951011" toRefs="TextSelection-04B9B25659DF96CA86BF94757DB5CCE1-0-wk-Footnote-04B9B25659DF96CA86BF94757DB5CCE1_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1094-wk-Fact-0F4E421B90BAC3CEFBC094757D951011" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8351242e3334-wk-Fact-0FAA0A010479FD1F2D6594757CB8122B" toRefs="TextSelection-8224B42439E7CCC8C3C594757DBA701B-0-wk-Footnote-8224B42439E7CCC8C3C594757DBA701B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e3535-wk-Fact-0FE975CFD0CEBAC8988A94757CCB8E12" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10753-wk-Fact-1085284E00DE2A425A0894757DA63E92" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2418-wk-Fact-10C0D0D972663C0BC95494757CF12E8C" toRefs="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2083-wk-Fact-10C0D76C934B5C1793A994757D4985D4" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2475-wk-Fact-10EDC1B88A166120EB9394757D13AAEA" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e3453-wk-Fact-10F3E77A26DA7DA0E29F94757D3034FC" toRefs="TextSelection-9BC3436E7B9C00975CD394757DC16C56-0-wk-Footnote-9BC3436E7B9C00975CD394757DC16C56_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1732-wk-Fact-112070D1A1180C6F8D5194757D199924" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e3553-wk-Fact-112FF7A0087A9422819094757D2BF4D9" toRefs="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8336633e3553-wk-Fact-112FF7A0087A9422819094757D2BF4D9" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7912-wk-Fact-1156EEDC3AF7E03F6D9894757D9E9130" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7912-wk-Fact-1156EEDC3AF7E03F6D9894757D9E9130" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1600-wk-Fact-115B1B8C87DB19F5829C94757D60A004 d8316808e2237-wk-Fact-115B1B8C87DB19F5829C94757D60A004" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e5253-wk-Fact-11AD19C653F542C874C794757D691F63" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e12526-wk-Fact-11CE3C1F979CA5EE8A3C94757CAC8219" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2141-wk-Fact-1226C5A8B6BDD831984C94757CAB3BF0" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2520-wk-Fact-126B087E9A05FE5529B194757D03D1C9" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2584-wk-Fact-127515899B5DE626CC8194757D3ECA81" toRefs="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e14022-wk-Fact-1361821B6A5511EF50EA94757CB26293" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e1479-wk-Fact-1369E6DF1C524EDEE9A694757CC1938A" toRefs="TextSelection-D29E26CC6CF7C6248CEE94757DBD9743-0-wk-Footnote-D29E26CC6CF7C6248CEE94757DBD9743_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8301124e1221-wk-Fact-137D234567F2A002B07194757D5099CA" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1221-wk-Fact-137D234567F2A002B07194757D5099CA" toRefs="TextSelection-8C3C45B5D6B304AC979B94757DB5023F-0-wk-Footnote-8C3C45B5D6B304AC979B94757DB5023F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1534-wk-Fact-13980DEBF0DE0B3F0CC794757D1BBA04" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8342313e1993-wk-Fact-13C462C75A1858B9415654402D698FE6" toRefs="TextSelection-9FA189BA88B1C6F34587B0A6A8B90D7C-0-wk-Footnote-9FA189BA88B1C6F34587B0A6A8B90D7C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e2062-wk-Fact-13DB6A96944CAA1A9DE694757CF73050" toRefs="TextSelection-9161826AA31A3194474594757DB9E2CF-0-wk-Footnote-9161826AA31A3194474594757DB9E2CF_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e1939-wk-Fact-13F1515D747E5BC2D79E94757CDD1906" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336625e2586-wk-Fact-13FB46151EC8E0F07C8894757D671597" toRefs="TextSelection-83180A323F26770F5F9D94757DBB7831-0-wk-Footnote-83180A323F26770F5F9D94757DBB7831_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e6862-wk-Fact-1437F24F4D59D041AD5194757D907B35" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2345-wk-Fact-14555130D0BB52E432C294757D65777B" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e1653-wk-Fact-146CA4CF4749BABED82294757D1CFAEF" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e8139-wk-Fact-146D88A01BA77360B4DB94757DA58B4B" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e8139-wk-Fact-146D88A01BA77360B4DB94757DA58B4B" toRefs="TextSelection-4F6B4AE2D2C9909DF73D94757DC29A3E-0-wk-Footnote-4F6B4AE2D2C9909DF73D94757DC29A3E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8415180e8139-wk-Fact-146D88A01BA77360B4DB94757DA58B4B" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10379-wk-Fact-14DC4260C1A11D0782B494757D550824" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e4395-wk-Fact-14DF655044E2528ED8EB94757D99A922" toRefs="TextSelection-859D29FA558EAC3F73C294757DC172D8-0-wk-Footnote-859D29FA558EAC3F73C294757DC172D8_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1393-wk-Fact-16EB2E72AB574E14B22194757CD34D79" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e927-wk-Fact-1769F431190664966C6E94757D75CC58 d8415180e2267-wk-Fact-1769F431190664966C6E94757D75CC58 d8415180e4667-wk-Fact-1769F431190664966C6E94757D75CC58" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e10805-wk-Fact-17964A9D32951C373D6394757D89737D" toRefs="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8336633e10805-wk-Fact-17964A9D32951C373D6394757D89737D" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2648-wk-Fact-17AFA0CD14201AA75F3794757CE4EBFE" toRefs="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2581-wk-Fact-1891EFA6F636FA196DF794757D4ABF57" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7546-wk-Fact-196CA4F9D93284F17A0194757CFB1334" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7546-wk-Fact-196CA4F9D93284F17A0194757CFB1334" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e966-wk-Fact-1987ADB564F749FC403294757D32C9CF d8415180e3543-wk-Fact-1987ADB564F749FC403294757D32C9CF d8415180e4719-wk-Fact-1987ADB564F749FC403294757D32C9CF" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2519-wk-Fact-19C43A79023CA42B86EA94757D12F049" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e6717-wk-Fact-1A182C74458013C503BA94757D323D60" toRefs="TextSelection-FE68345D83BB191130EF94757DC1B5E5-0-wk-Footnote-FE68345D83BB191130EF94757DC1B5E5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10808-wk-Fact-1A1E0EDA654D59F9D7FD94757D7CE696" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e9360-wk-Fact-1A38F0D11E57E09F813994757D942D38" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10247-wk-Fact-1A5FECFDC88986C24EF594757D80E29D" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2565-wk-Fact-1A602D6AF23843C2BB1894757CDAEB96" toRefs="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e1673-wk-Fact-1AB5EE46A517FE80526894757CDD6A28" toRefs="TextSelection-B06D4F08D7061C0CFA5894757DB76AD8-0-wk-Footnote-B06D4F08D7061C0CFA5894757DB76AD8_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e3079-wk-Fact-1AC328FD09CA718A54B294757CAD4A93" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2463-wk-Fact-1AE830A789111962733194757CE1B056" toRefs="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e3604-wk-Fact-1B231CD712DFE5467E5994757D88041A" toRefs="TextSelection-2B5AD3FFF4626D02F1E394757DB79B83-0-wk-Footnote-2B5AD3FFF4626D02F1E394757DB79B83_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2157-wk-Fact-1BF4E8A74A053F182A6294757CB3BD1E" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10452-wk-Fact-1C3E607A0B96B4E13C6A94757D7DBECB" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e6659-wk-Fact-1C41D8D03DE049895B2094757D9C99B7" toRefs="TextSelection-FE68345D83BB191130EF94757DC1B5E5-0-wk-Footnote-FE68345D83BB191130EF94757DC1B5E5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e5579-wk-Fact-1C6897C10CB6E03B97C094757D014B98" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2436-wk-Fact-1C81E7C063C3183FB22C94757D26F7B6" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e4312-wk-Fact-1CECC326E870388701E494757D14ABBF" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e4312-wk-Fact-1CECC326E870388701E494757D14ABBF" toRefs="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e4312-wk-Fact-1CECC326E870388701E494757D14ABBF" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312053e1309-wk-Fact-1D4A2167CADD270AD7B494757CE56E80" toRefs="TextSelection-9459A99A0EC8DD1CD04094757DBA4F65-0-wk-Footnote-9459A99A0EC8DD1CD04094757DBA4F65_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2501-wk-Fact-1D95D82D28060BA3A08A94757CE1514E" toRefs="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2482-wk-Fact-1DAA0E1B0E6665C79D5F94757CCA5C7B" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2145-wk-Fact-1DC168387E9062FD753994757D57860A" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e11124-wk-Fact-1E0FA72C88E0180817A294757D917CD7" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1321-wk-Fact-1E1B5B900670A3CC9D3594757D1F6A23" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e6746-wk-Fact-1E1B86E2273523F6FBAD94757D16A070" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e3800-wk-Fact-1E53EA3EE5FA31F56ABC94757CCC7BB4" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2016-wk-Fact-1E7D497146AE795F1C1994757D095745" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8351242e1621-wk-Fact-1EA60045B6EB866A340E94757D49440D" toRefs="TextSelection-A2DA5EF7B6FED024F0D494757DBA101E-0-wk-Footnote-A2DA5EF7B6FED024F0D494757DBA101E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e1860-wk-Fact-1EB64412D2D80070B55B94757D5A4E16" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e11234-wk-Fact-1F784513FF9C94CFD4A694757D890961" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8356748e2345-wk-Fact-1F9015BD5A5A1530EFBA94757D43CEBC" toRefs="TextSelection-6979FD063E456189966A94757DC072A0-0-wk-Footnote-6979FD063E456189966A94757DC072A0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e5520-wk-Fact-1FD9113D58C3CC135A9A94757D26E7FF" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8351242e7321-wk-Fact-1FEE3FFA0E7F81909D6294757D83017E" toRefs="TextSelection-DA70407E988FF7F4292CB0A472718D04-0-wk-Footnote-DA70407E988FF7F4292CB0A472718D04_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8342313e1780-wk-Fact-200E77F96A765ED4495194757CB8CCE6" toRefs="TextSelection-A197F5EE18ACAFCFDBE294757DBCD32F-0-wk-Footnote-A197F5EE18ACAFCFDBE294757DBCD32F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1616-wk-Fact-2024C15FEA8B459878AD94757CF5A215" toRefs="TextSelection-16CE381F2099EFC2DA1C94757DB87C39-0-wk-Footnote-16CE381F2099EFC2DA1C94757DB87C39_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e9848-wk-Fact-208A12CB637A2CA687FC94757D93B898" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e5167-wk-Fact-20A8453F774E2321859294757CD699F4" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8351242e1566-wk-Fact-20C9854FC8CD379D96E594757D4BB09E" toRefs="TextSelection-A2DA5EF7B6FED024F0D494757DBA101E-0-wk-Footnote-A2DA5EF7B6FED024F0D494757DBA101E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8356748e2403-wk-Fact-2183DCBEF0EE0B13B7AC94757CC13062" toRefs="TextSelection-6979FD063E456189966A94757DC072A0-0-wk-Footnote-6979FD063E456189966A94757DC072A0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2278-wk-Fact-2296B04F377E05B8D07C94757D190B3D" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e2092-wk-Fact-2298D4CD7D2F6AE1C57E94757D628353" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e4377-wk-Fact-22F02950F23AAC5E6D9094757CD8334C" toRefs="TextSelection-859D29FA558EAC3F73C294757DC172D8-0-wk-Footnote-859D29FA558EAC3F73C294757DC172D8_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e3643-wk-Fact-22FE89F9AF8C0AF9DC8494757D8695DC" toRefs="TextSelection-2B5AD3FFF4626D02F1E394757DB79B83-0-wk-Footnote-2B5AD3FFF4626D02F1E394757DB79B83_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2120-wk-Fact-2325A2D864C8B2E0F2E194757D22414D" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e3204-wk-Fact-23913CAAF810667AF3C194757D16D9A2" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e3204-wk-Fact-23913CAAF810667AF3C194757D16D9A2" toRefs="TextSelection-6EDC28E4739B45A7AA7C94757DBD8D30-0-wk-Footnote-6EDC28E4739B45A7AA7C94757DBD8D30_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e3204-wk-Fact-23913CAAF810667AF3C194757D16D9A2" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1704-wk-Fact-239CF4E3D5F1905A2F0794757CB54D24 d8415180e3563-wk-Fact-239CF4E3D5F1905A2F0794757CB54D24" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8340406e1704-wk-Fact-239CF4E3D5F1905A2F0794757CB54D24 d8415180e3563-wk-Fact-239CF4E3D5F1905A2F0794757CB54D24" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e8191-wk-Fact-23F2FB78F6495A427ED994757D2D3461" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e8191-wk-Fact-23F2FB78F6495A427ED994757D2D3461" toRefs="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e8191-wk-Fact-23F2FB78F6495A427ED994757D2D3461" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e8044-wk-Fact-2434BB068F426C5FA43394757D97AF9A" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e8044-wk-Fact-2434BB068F426C5FA43394757D97AF9A" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1133-wk-Fact-2457446A2FA3FC6A69CC94757D187F7E" toRefs="TextSelection-04B9B25659DF96CA86BF94757DB5CCE1-0-wk-Footnote-04B9B25659DF96CA86BF94757DB5CCE1_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8340406e1133-wk-Fact-2457446A2FA3FC6A69CC94757D187F7E" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7379-wk-Fact-2460B59E617CE183933A94757CDEE668" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7379-wk-Fact-2460B59E617CE183933A94757CDEE668" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8357160e1410-wk-Fact-24A5AF8F393541B6128994757CD2381D" toRefs="TextSelection-B511D685B8F037FD258094757DBFC8C5-0-wk-Footnote-B511D685B8F037FD258094757DBFC8C5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2380-wk-Fact-24B4A8ECAE3E2474912094757CDF68AE" toRefs="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1307-wk-Fact-24C0070845257F719EAD94757D4D72E4" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e13748-wk-Fact-24C95C268DFE3FCA16AE94757D94AA45" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e993-wk-Fact-2564D80CF4863AD3560094757D2FB6D5" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8329819e929-wk-Fact-25892BA475209169BE1A94757D0BD496" toRefs="TextSelection-09307D44CBA12BFE03A594757DBC3C9D-0-wk-Footnote-09307D44CBA12BFE03A594757DBC3C9D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e12546-wk-Fact-25E3F63155D4E5079AF694757D939426" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e14529-wk-Fact-25E53374D4007C779F5294757D853F4E" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336625e2625-wk-Fact-2617EC9BFAF0558F600394757D657721" toRefs="TextSelection-83180A323F26770F5F9D94757DBB7831-0-wk-Footnote-83180A323F26770F5F9D94757DBB7831_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8314038e1256-wk-Fact-261CF8B516535CC742D694757D9DD941" toRefs="TextSelection-681F29FE9DC6BC582B6D94757DB90D8C-0-wk-Footnote-681F29FE9DC6BC582B6D94757DB90D8C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2426-wk-Fact-263AD80EFD0DF942862794757CB97E50" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1303-wk-Fact-267AF4FFCF5DAE94DBAA94757CC00E91" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2046-wk-Fact-267FFBCE28C10DEF50F494757D2204BE" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8308070e2138-wk-Fact-269B485E7EDA949BAD5F94757D657E36" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2138-wk-Fact-269B485E7EDA949BAD5F94757D657E36" toRefs="TextSelection-4E9FC68D27E299B9BB2A92DC4EB2F91A-0-wk-Footnote-4E9FC68D27E299B9BB2A92DC4EB2F91A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8357160e1448-wk-Fact-26C4DDEC9074D8280D9794757CCF8BA1" toRefs="TextSelection-B511D685B8F037FD258094757DBFC8C5-0-wk-Footnote-B511D685B8F037FD258094757DBFC8C5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1515-wk-Fact-26DE7C056ED7F6339E0F94757D946476" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e7059-wk-Fact-2723AAC37A7D7F6511E094757D2E3BF6" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e7059-wk-Fact-2723AAC37A7D7F6511E094757D2E3BF6" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e4490-wk-Fact-2730F9B3BF2B3A2553D594757D809149" toRefs="TextSelection-C185F8237D4ED950685B94757DC105E4-0-wk-Footnote-C185F8237D4ED950685B94757DC105E4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e1879-wk-Fact-273C64BCA1A40F3A50D394757CD85863" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e5672-wk-Fact-28CC293C11C25B9C4E6E94757D8F7B1C" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e7079-wk-Fact-28D2817A0C35A9673F5F94757D2009C5" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e7079-wk-Fact-28D2817A0C35A9673F5F94757D2009C5" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8351242e4862-wk-Fact-290DB7E326ACD87BB2AE94757D855347" toRefs="TextSelection-11358084CF50DEC3FF92628C52236CBA-0-wk-Footnote-11358084CF50DEC3FF92628C52236CBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e2158-wk-Fact-290DFAF3630836A5405894757D92CBB7" toRefs="TextSelection-9BC3436E7B9C00975CD394757DC16C56-0-wk-Footnote-9BC3436E7B9C00975CD394757DC16C56_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e3254-wk-Fact-2934BA4BF607819E093694757D2AAA19" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2081-wk-Fact-294468E799E3C655921694757D428F2B" toRefs="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1834-wk-Fact-2979655C6D134159C89394757D499DAA d8356748e1102-wk-Fact-2979655C6D134159C89394757D499DAA" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e2877-wk-Fact-29D102D394E88CA6D8DC94757D641310" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e6286-wk-Fact-29FB03A603A2B2F710FD94757D2DA0BB" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1666-wk-Fact-2A0EE9005DC8F1672AF194757D5C8E60 d8415180e2287-wk-Fact-2A0EE9005DC8F1672AF194757D5C8E60" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8340406e1666-wk-Fact-2A0EE9005DC8F1672AF194757D5C8E60 d8415180e2287-wk-Fact-2A0EE9005DC8F1672AF194757D5C8E60" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e1502-wk-Fact-2A97CB7CBC5000EECE0F94757CE3B4C8" toRefs="TextSelection-A2331388F2C895076E3994757DB73022-0-wk-Footnote-A2331388F2C895076E3994757DB73022_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e5466-wk-Fact-2AB8FDBDC0EF4D28AFBE94757CD8C9DF" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7360-wk-Fact-2AF25534B2A95420B2CC94757D5E2E55" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7360-wk-Fact-2AF25534B2A95420B2CC94757D5E2E55" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e9808-wk-Fact-2AFFCF1916589B62C56494757D956455" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312053e1329-wk-Fact-2B2DFC11DDDCB317D2C994757CE2E0A2" toRefs="TextSelection-9459A99A0EC8DD1CD04094757DBA4F65-0-wk-Footnote-9459A99A0EC8DD1CD04094757DBA4F65_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e3426-wk-Fact-2B5CC988DB54D9E2126D94757D6035E4" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7619-wk-Fact-2B65B5D59AAE94EB07C394757D4A2A4B" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7619-wk-Fact-2B65B5D59AAE94EB07C394757D4A2A4B" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1749-wk-Fact-2BC7C8565E04B1B2A1F794757D407F8C" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e3064-wk-Fact-2C0450D46BE2A068263194757CADD7DF" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2788-wk-Fact-2C16CBC888D1DBA772D994757D213C35" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e5186-wk-Fact-2C4A0D66E79C36E0AD3A94757CD125ED" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e4351-wk-Fact-2C546F3214B511F790B394757D11B2FB" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e4351-wk-Fact-2C546F3214B511F790B394757D11B2FB" toRefs="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e4351-wk-Fact-2C546F3214B511F790B394757D11B2FB" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8351242e4784-wk-Fact-2C55CE6AF1C796A4ED5994757D51DA44" toRefs="TextSelection-11358084CF50DEC3FF92628C52236CBA-0-wk-Footnote-11358084CF50DEC3FF92628C52236CBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e6896-wk-Fact-2C8B37C90E999E0983A494757D3A0FE2" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e4344-wk-Fact-2CF63F468B7D0CABA3CE94757D561921" toRefs="TextSelection-859D29FA558EAC3F73C294757DC172D8-0-wk-Footnote-859D29FA558EAC3F73C294757DC172D8_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e13513-wk-Fact-2D5D0BDDCB3AC167E0BC94757D826702" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336625e2702-wk-Fact-2D9E3E8DD330C83B27D894757D6B6917" toRefs="TextSelection-83180A323F26770F5F9D94757DBB7831-0-wk-Footnote-83180A323F26770F5F9D94757DBB7831_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2546-wk-Fact-2DA0B9B079BAAF2177CF94757CDF2206" toRefs="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372420e5823-wk-Fact-2DB662656B0870E5C58B94757D7A7265" toRefs="TextSelection-286F4719195A28A9913594757DC0B1B8-0-wk-Footnote-286F4719195A28A9913594757DC0B1B8_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8301124e1440-wk-Fact-2DD85B64A9010E6C213294757D013277" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1440-wk-Fact-2DD85B64A9010E6C213294757D013277" toRefs="TextSelection-A6080F3BC2CE36268D0F94757DB590DE-0-wk-Footnote-A6080F3BC2CE36268D0F94757DB590DE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e8158-wk-Fact-2E372A7C63982BD2808894757D9722C9" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e8158-wk-Fact-2E372A7C63982BD2808894757D9722C9" toRefs="TextSelection-4F6B4AE2D2C9909DF73D94757DC29A3E-0-wk-Footnote-4F6B4AE2D2C9909DF73D94757DC29A3E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8415180e8158-wk-Fact-2E372A7C63982BD2808894757D9722C9" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2679-wk-Fact-2E87EA97E71121C08FCB94757D27917E" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2220-wk-Fact-2EE2705D1EB743C59AA194757CB0642B" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e3053-wk-Fact-2F018DCBB03DFD12F06194757D0FC6D9" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e3033-wk-Fact-2F0D93C254F8FED5D44E94757CFAFADA" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1549-wk-Fact-2F3BC9DA02E9792A81E594757D1AA1BE" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e5220-wk-Fact-2F4D955985202F933AFB94757DA34DE9" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2775-wk-Fact-2F748880967716EA5ADE94757D1C1B2D" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2229-wk-Fact-2F9D078A1939922E232F94757CC0E69B" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e1440-wk-Fact-2FCF66786C77668C7F1694757CC07AEE" toRefs="TextSelection-D29E26CC6CF7C6248CEE94757DBD9743-0-wk-Footnote-D29E26CC6CF7C6248CEE94757DBD9743_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2043-wk-Fact-2FD155A9458FEA78C7F194757CE25240" toRefs="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10173-wk-Fact-30038D93D81522EF2C4494757CB8E85E" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e4532-wk-Fact-30276A818E374D50F86494757D58EE99" toRefs="TextSelection-AFB627DC6F652A9A0A0594757DC251B0-0-wk-Footnote-AFB627DC6F652A9A0A0594757DC251B0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e5856-wk-Fact-30F55F47EE0BC5CF4FF794757D0F23CF" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e5856-wk-Fact-30F55F47EE0BC5CF4FF794757D0F23CF" toRefs="TextSelection-6EDC28E4739B45A7AA7C94757DBD8D30-0-wk-Footnote-6EDC28E4739B45A7AA7C94757DBD8D30_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e5856-wk-Fact-30F55F47EE0BC5CF4FF794757D0F23CF" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2906-wk-Fact-31ABED2FAA0C5EDD3D7994757D5F8CB1" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1701-wk-Fact-31B843C71D5C57C7970294757D210FDA" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1140-wk-Fact-31FAC3AF75C5A095FC3294757D6F298C" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e14099-wk-Fact-3217AF55C96F288D0DBD94757CBAA3B1" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2386-wk-Fact-324F49A292903AEB38B894757D2BD1AB" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8351242e1603-wk-Fact-32BCE63F2B148B65B2BD94757D4ABD8F" toRefs="TextSelection-A2DA5EF7B6FED024F0D494757DBA101E-0-wk-Footnote-A2DA5EF7B6FED024F0D494757DBA101E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e3243-wk-Fact-32E4A4F33D07CCC35B5994757D24CC85" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e3243-wk-Fact-32E4A4F33D07CCC35B5994757D24CC85" toRefs="TextSelection-6EDC28E4739B45A7AA7C94757DBD8D30-0-wk-Footnote-6EDC28E4739B45A7AA7C94757DBD8D30_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e3243-wk-Fact-32E4A4F33D07CCC35B5994757D24CC85" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e5973-wk-Fact-334697846783F070800594757CEB5638" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e5973-wk-Fact-334697846783F070800594757CEB5638" toRefs="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e5973-wk-Fact-334697846783F070800594757CEB5638" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e9938-wk-Fact-3383068A828B707166B194757D4D0A42" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e8242-wk-Fact-338E913FDA175BCEBC1794757D8FAE73" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e2217-wk-Fact-33B4F9AF3A76075CF90094757CD1C085" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e2217-wk-Fact-33B4F9AF3A76075CF90094757CD1C085" toRefs="TextSelection-9BC3436E7B9C00975CD394757DC16C56-0-wk-Footnote-9BC3436E7B9C00975CD394757DC16C56_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2521-wk-Fact-33CF13183D5E3D8446A994757CD4AE22" toRefs="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e1568-wk-Fact-348F989B829127D79CF794757D4C6631" toRefs="TextSelection-AB3DF04F3446139615AC94757DB7D909-0-wk-Footnote-AB3DF04F3446139615AC94757DB7D909_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1158-wk-Fact-3499C6CE8F54FB430EAD94757D6E3CBC" toRefs="TextSelection-4E74A09462C596E2363694757DB8EB14-0-wk-Footnote-4E74A09462C596E2363694757DB8EB14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e9767-wk-Fact-34BB026C07BB62277DBC94757CB6F69E" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e2042-wk-Fact-3502C1166F5ABE6DC55E94757CCC6B1B" toRefs="TextSelection-9161826AA31A3194474594757DB9E2CF-0-wk-Footnote-9161826AA31A3194474594757DB9E2CF_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1933-wk-Fact-3508D42A7ED6A8C436DE94757D080CE2" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e12472-wk-Fact-354E12AEFC04C5034D5B94757D921C80" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-354E4103E704EECCE02B94757CDB72E6-wk-Fact-354E4103E704EECCE02B94757CDB72E6" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10286-wk-Fact-358A86952AF68F57BF8A94757D2D05E3" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372420e5803-wk-Fact-35AE4CA011AF5ED4C8B994757D74E218" toRefs="TextSelection-286F4719195A28A9913594757DC0B1B8-0-wk-Footnote-286F4719195A28A9913594757DC0B1B8_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1580-wk-Fact-361AD8CFC0B46CF2632394757D0A716D d8316808e2217-wk-Fact-361AD8CFC0B46CF2632394757D0A716D" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e4247-wk-Fact-366496A263381BEBAC8094757D116F08" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e4247-wk-Fact-366496A263381BEBAC8094757D116F08" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e6766-wk-Fact-36A1278749B1A6EBD0EE94757D199E89" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e9068-wk-Fact-36E7CFCCB407CFADF4BD94757D88D126" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10847-wk-Fact-371E5DEB4BB6100754FB94757DA1FAFE" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e3662-wk-Fact-372F8BB1048027009D0C94757D85F7F7" toRefs="TextSelection-2B5AD3FFF4626D02F1E394757DB79B83-0-wk-Footnote-2B5AD3FFF4626D02F1E394757DB79B83_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2651-wk-Fact-375CE2F1DA250039888894757D5B5BA6" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e3571-wk-Fact-3796F5D99D503A9EF47494757D899973" toRefs="TextSelection-823D9AE8DB976ECBCA9594757DB72C08-0-wk-Footnote-823D9AE8DB976ECBCA9594757DB72C08_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e3293-wk-Fact-382681D10D85986FB7E894757D20CDB3" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e5447-wk-Fact-38BF97B5966F919766EC94757CA703FC" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1588-wk-Fact-38DB99ED289778FC0EC794757CF0235A" toRefs="TextSelection-1DD42ADAC2DF4C519E7594757DB84698-0-wk-Footnote-1DD42ADAC2DF4C519E7594757DB84698_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2018-wk-Fact-392A8B2D61CA7072524094757D40CAB7" toRefs="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1593-wk-Fact-3983BB3504AC4457A05494757D01EDF0" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7453-wk-Fact-399031A0BA1EB364EEE6955D6DD9525C" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7453-wk-Fact-399031A0BA1EB364EEE6955D6DD9525C" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2813-wk-Fact-39B247651891576D7B7A94757D210D60 d8336633e4214-wk-Fact-39B247651891576D7B7A94757D210D60 d8336633e11466-wk-Fact-39B247651891576D7B7A94757D210D60" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8307028e2813-wk-Fact-39B247651891576D7B7A94757D210D60 d8336633e4214-wk-Fact-39B247651891576D7B7A94757D210D60 d8336633e11466-wk-Fact-39B247651891576D7B7A94757D210D60" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7414-wk-Fact-39C4783BCFAA4ABC800E6391E2F164B1" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7414-wk-Fact-39C4783BCFAA4ABC800E6391E2F164B1" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e864-wk-Fact-39CFEE5D7F0B06CD9DA094757D10AD76" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e11154-wk-Fact-3A37D8CBC7B234B9BABE94757CAB9E45" toRefs="TextSelection-FE68345D83BB191130EF94757DC1B5E5-0-wk-Footnote-FE68345D83BB191130EF94757DC1B5E5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8357160e1674-wk-Fact-3A788F544AFD2EC09A8A94757CF7CB44" toRefs="TextSelection-84058C93858F4EB1F00C631013E8EF74-0-wk-Footnote-84058C93858F4EB1F00C631013E8EF74_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e8005-wk-Fact-3A87DB55E2FD4B6878A094757D7E9E08" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e8005-wk-Fact-3A87DB55E2FD4B6878A094757D7E9E08" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e3659-wk-Fact-3A9B32710A1CE30C5C917DAAF1BA82D7" toRefs="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8336633e3659-wk-Fact-3A9B32710A1CE30C5C917DAAF1BA82D7" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2229-wk-Fact-3AC307C0C4ECA1CCA0B494757CC80CD1" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1912-wk-Fact-3B846BC02192BD53F89B94757CDEE0F4" toRefs="TextSelection-3F1FDE51F00C4F037BC194757DB9000C-0-wk-Footnote-3F1FDE51F00C4F037BC194757DB9000C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336625e4304-wk-Fact-3BF504D49EB0EC30CF2A94757D310539" toRefs="TextSelection-F8EDCEC3C21F54D90F7894757DBBCD6D-0-wk-Footnote-F8EDCEC3C21F54D90F7894757DBBCD6D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e11011-wk-Fact-3C10FB8DF4A946A1047094757CB010DE" toRefs="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8336633e11011-wk-Fact-3C10FB8DF4A946A1047094757CB010DE" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e4683-wk-Fact-3C17EF2AE779923FF12094757D2065E5" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e4683-wk-Fact-3C17EF2AE779923FF12094757D2065E5" toRefs="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e4683-wk-Fact-3C17EF2AE779923FF12094757D2065E5" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e3486-wk-Fact-3C3F27909C4BDBE69AF194757CE1FE25" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e1517-wk-Fact-3C967CCCA2C5A8BFE04094757CC4026C" toRefs="TextSelection-D29E26CC6CF7C6248CEE94757DBD9743-0-wk-Footnote-D29E26CC6CF7C6248CEE94757DBD9743_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1940-wk-Fact-3CC60BCCBCF2CF508B1694757D16B042" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1100-wk-Fact-3CE8433BEC1FEF1715C594757D56EECD" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8340406e1075-wk-Fact-3E4926A75899DF8AB69294757D02E114" toRefs="TextSelection-04B9B25659DF96CA86BF94757DB5CCE1-0-wk-Footnote-04B9B25659DF96CA86BF94757DB5CCE1_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1075-wk-Fact-3E4926A75899DF8AB69294757D02E114" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e3217-wk-Fact-3E9B45FC40C0B53734B894757D6021C6 d8356748e2132-wk-Fact-3E9B45FC40C0B53734B894757D6021C6" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10491-wk-Fact-3EA1514AE1ADA2AD3F6494757D8089A9" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e10545-wk-Fact-3F18B676756C784E4C0D94757CB66A64" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e7223-wk-Fact-3F6A0F8D36D9FD50EACD94757D9D5AA4" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8340406e1160-wk-Fact-3F6D04965D3F8AC6296C94757D442373" toRefs="TextSelection-04B9B25659DF96CA86BF94757DB5CCE1-0-wk-Footnote-04B9B25659DF96CA86BF94757DB5CCE1_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1160-wk-Fact-3F6D04965D3F8AC6296C94757D442373" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2072-wk-Fact-3FC60AB14A091D74606194757D68E2E6" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1932-wk-Fact-40152B99BE243EC4A4DA94757CE024F4" toRefs="TextSelection-3F1FDE51F00C4F037BC194757DB9000C-0-wk-Footnote-3F1FDE51F00C4F037BC194757DB9000C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e3198-wk-Fact-4083035A9265D74B487394757CDE895C d8356748e2113-wk-Fact-4083035A9265D74B487394757CDE895C" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e4332-wk-Fact-40A2A359765A16FF703294757D1A2BA3" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e4332-wk-Fact-40A2A359765A16FF703294757D1A2BA3" toRefs="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e4332-wk-Fact-40A2A359765A16FF703294757D1A2BA3" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2438-wk-Fact-40B5B65787722B300CCA94757D4E39DB" toRefs="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e5540-wk-Fact-40BFA256F2604E1D69E694757D5745F9" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e3493-wk-Fact-40DBE0BFFEA0FFC750D994757D7B3215" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e3493-wk-Fact-40DBE0BFFEA0FFC750D994757D7B3215" toRefs="TextSelection-9BC3436E7B9C00975CD394757DC16C56-0-wk-Footnote-9BC3436E7B9C00975CD394757DC16C56_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8356748e2383-wk-Fact-4140131424BB26DB8A6194757CD6155F" toRefs="TextSelection-6979FD063E456189966A94757DC072A0-0-wk-Footnote-6979FD063E456189966A94757DC072A0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e7851-wk-Fact-41A19ED1C18BA2C59FD594757CC95BFE d8336633e15117-wk-Fact-41A19ED1C18BA2C59FD594757CC95BFE" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2275-wk-Fact-41DCE73B8353AB2C4A8294757CC7A0E2" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e13062-wk-Fact-41F806F874E498F7473D94757D8FFC10" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2019-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B d8301124e930-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B d8336633e5598-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8340406e2019-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B d8301124e930-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B d8336633e5598-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8340406e2019-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B d8301124e930-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B d8336633e5598-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="4" fromRefs="d8340406e2019-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B d8301124e930-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B d8336633e5598-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1991-wk-Fact-4205FA0CADA9C7C75F1194757CAF3BC4" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e5486-wk-Fact-423E2315CDCB857D87F794757D3B33EB" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e7791-wk-Fact-427A772CBA10468F664594757D453976 d8336633e15057-wk-Fact-427A772CBA10468F664594757D453976" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1555-wk-Fact-42AE1B3E358159102DA894757CCA438F" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e5992-wk-Fact-42F54CD6BB1EE7437A9894757D251875" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e5992-wk-Fact-42F54CD6BB1EE7437A9894757D251875" toRefs="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e5992-wk-Fact-42F54CD6BB1EE7437A9894757D251875" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e5810-wk-Fact-4311DCC0A7382F4BE88494757D3C948A" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8314038e1215-wk-Fact-432173AA1624AC93425594757D771AAC" toRefs="TextSelection-681F29FE9DC6BC582B6D94757DB90D8C-0-wk-Footnote-681F29FE9DC6BC582B6D94757DB90D8C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10305-wk-Fact-4332974BA308B68F084594757D7E748A" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-43361FC2439255EC9C0794757CD9C825-wk-Fact-43361FC2439255EC9C0794757CD9C825" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e5208-wk-Fact-436FB3A1151F0EA4A92E94757CCA2C1F" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e5208-wk-Fact-436FB3A1151F0EA4A92E94757CCA2C1F" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e968-wk-Fact-438C70CDE0164785DD1D6EDE8D2EB280" toRefs="TextSelection-A69940B73F64268F0EB092D9B88F9F01-0-wk-Footnote-A69940B73F64268F0EB092D9B88F9F01_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8307028e968-wk-Fact-438C70CDE0164785DD1D6EDE8D2EB280" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8357160e1714-wk-Fact-43BAC5F7B8A55604118A94757CF8D187" toRefs="TextSelection-84058C93858F4EB1F00C631013E8EF74-0-wk-Footnote-84058C93858F4EB1F00C631013E8EF74_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2074-wk-Fact-44A3EBC245B59B1EDEFE94757CA83343" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1803-wk-Fact-44B0C90D865A67954DB694757D580795" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e5838-wk-Fact-44C12AC03CA4B50FB0EC94757D37E891" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e5970-wk-Fact-45009E6C6C76A6D4EBFD94757D064F15" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10679-wk-Fact-4530C68B63EB9C8D923963A2911A73D6" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2350-wk-Fact-457A42E5EFF17C82E7B994757D023187" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2304-wk-Fact-458F8B2744B5838D7DD994757D5BA906" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e10081-wk-Fact-469C94508C3D19FD04B494757D87315E" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2687-wk-Fact-469E3365E76E79BE433894757CCE1E1E" toRefs="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e14253-wk-Fact-46C30A88DFF3DBBC269A94757D92355F" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8340406e1198-wk-Fact-46F68B2D547259497F6A94757CB8B7C5" toRefs="TextSelection-04B9B25659DF96CA86BF94757DB5CCE1-0-wk-Footnote-04B9B25659DF96CA86BF94757DB5CCE1_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1198-wk-Fact-46F68B2D547259497F6A94757CB8B7C5" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2164-wk-Fact-476B18F8EF4E7B05E20394757CD2DBCA" toRefs="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7507-wk-Fact-477D98C4B7AC60774FF994757DA3ED14" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7507-wk-Fact-477D98C4B7AC60774FF994757DA3ED14" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2163-wk-Fact-479C56CF0F843B8D425E94757CC58178" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e7683-wk-Fact-47CB9748E3671019B33694757D79B9D0" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e7683-wk-Fact-47CB9748E3671019B33694757D79B9D0" toRefs="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e7683-wk-Fact-47CB9748E3671019B33694757D79B9D0" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2699-wk-Fact-47E4B6DB5C9B3F16044E94757D1BCF19" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2301-wk-Fact-4825D5CD0C1E297EA03E94757D6ECCCE" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e3382-wk-Fact-482EC9E9C634BBA5161694757D0F9FAE" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e3382-wk-Fact-482EC9E9C634BBA5161694757D0F9FAE" toRefs="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e3382-wk-Fact-482EC9E9C634BBA5161694757D0F9FAE" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2026-wk-Fact-483AF33471D66FEACAE994757D64E37B" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7154-wk-Fact-4872D1EBBF4E1852EC3494757D07D096" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7154-wk-Fact-4872D1EBBF4E1852EC3494757D07D096" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e7539-wk-Fact-48A6C3F999379D6B924394757D7AF0E5" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e7539-wk-Fact-48A6C3F999379D6B924394757D7AF0E5" toRefs="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e7539-wk-Fact-48A6C3F999379D6B924394757D7AF0E5" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e2129-wk-Fact-48DD10795AE6A50CB75294757CF3076B" toRefs="TextSelection-420C4A044883B0052AE85E76395259A9-0-wk-Footnote-420C4A044883B0052AE85E76395259A9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e9385-wk-Fact-490104B7571E3A2E212094757D19310E" toRefs="TextSelection-A6E5E77EFF2BB738D44C94757DBDF083-0-wk-Footnote-A6E5E77EFF2BB738D44C94757DBDF083_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e9265-wk-Fact-493830DEE8D1E80A700694757D1E02C5" toRefs="TextSelection-A6E5E77EFF2BB738D44C94757DBDF083-0-wk-Footnote-A6E5E77EFF2BB738D44C94757DBDF083_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7086-wk-Fact-49D11DC2C94C1C47212E94757D5FB74C" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7086-wk-Fact-49D11DC2C94C1C47212E94757D5FB74C" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e11191-wk-Fact-4A39A4BCF3749653D06D94757D00D6F3" toRefs="TextSelection-33990A088D8DAE29233C94757DC283BE-0-wk-Footnote-33990A088D8DAE29233C94757DC283BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312053e1369-wk-Fact-4A51A364B44D351B488B94757CE2261B" toRefs="TextSelection-9459A99A0EC8DD1CD04094757DBA4F65-0-wk-Footnote-9459A99A0EC8DD1CD04094757DBA4F65_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e1537-wk-Fact-4A6F9B60CE268B4FFEDC94757CBF9263" toRefs="TextSelection-D29E26CC6CF7C6248CEE94757DBD9743-0-wk-Footnote-D29E26CC6CF7C6248CEE94757DBD9743_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2814-wk-Fact-4A7A8328763CC8358F7194757D1D40BA" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1076-wk-Fact-4A938A8D8BA21B630E4F94757CBAE369" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e8119-wk-Fact-4B0483818642973A551F94757D019625" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e8119-wk-Fact-4B0483818642973A551F94757D019625" toRefs="TextSelection-4F6B4AE2D2C9909DF73D94757DC29A3E-0-wk-Footnote-4F6B4AE2D2C9909DF73D94757DC29A3E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8415180e8119-wk-Fact-4B0483818642973A551F94757D019625" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1390-wk-Fact-4B0A3E94BBBA400AC84C94757D168B19 d8357160e3633-wk-Fact-4B0A3E94BBBA400AC84C94757D168B19" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2648-wk-Fact-4B4218478A969AE4E17A94757D59AFA8" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10565-wk-Fact-4B82DFDFC48F6984C14894757CBA0C82" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e5313-wk-Fact-4B8ABD514A7533B0DD2D94757CEB8E0E" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e14214-wk-Fact-4BC9CEEA08F3A0DD592F94757CB7DE38" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e7988-wk-Fact-4BFC2EA8E8A0BCD7965C94757D916146" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1036-wk-Fact-4C72B86F9525A44C403B94757CF4AB54" toRefs="TextSelection-4E74A09462C596E2363694757DB8EB14-0-wk-Footnote-4E74A09462C596E2363694757DB8EB14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1852-wk-Fact-4C76179C274DDE6FE76E94757D246CA2" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10100-wk-Fact-4D1BE9253D5F410A0D8294757D39F930" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10866-wk-Fact-4D23F6FF7E43AD5A2E8294757CB25D84" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e5417-wk-Fact-4D4D0A148BCFEEA47A9894757D551B15" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e908-wk-Fact-4DB60D98BED9F2D7592094757D057DF4 d8415180e2248-wk-Fact-4DB60D98BED9F2D7592094757D057DF4 d8415180e4648-wk-Fact-4DB60D98BED9F2D7592094757D057DF4" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e3320-wk-Fact-4E46F2B386CE7BF8977294757CBBCA8A d8356748e2318-wk-Fact-4E46F2B386CE7BF8977294757CBBCA8A" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10061-wk-Fact-4E6EDE18D87BADEBD5D594757DA51E46" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8357160e2113-wk-Fact-4EA24C13139AF186ABC594757CFF3B82 d8357160e2150-wk-Fact-4EA24C13139AF186ABC594757CFF3B82" toRefs="TextSelection-B511D685B8F037FD258094757DBFC8C5-0-wk-Footnote-B511D685B8F037FD258094757DBFC8C5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1372-wk-Fact-4ECA9E2FD645BEFF2FE194757CB235DC" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2593-wk-Fact-4F381BE015AE04126EB994757CB534B2" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e13021-wk-Fact-4F58C9049DEAAC5BA58594757CB32E71" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1567-wk-Fact-4FABC049EDFD60A33BC994757D951454" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1368-wk-Fact-4FD042AF6C7E165B3EAF94757D1120B8" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e4371-wk-Fact-5073FE007ED4EF41D79494757D16D857" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e4371-wk-Fact-5073FE007ED4EF41D79494757D16D857" toRefs="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e4371-wk-Fact-5073FE007ED4EF41D79494757D16D857" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2265-wk-Fact-50D4A8FFA49F4D1E126994757CD3C559" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e3044-wk-Fact-51872B65420AB7367EDA94757D7EDA33" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8301124e1096-wk-Fact-519D1AE2B3692880237794757CFE232A" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1096-wk-Fact-519D1AE2B3692880237794757CFE232A" toRefs="TextSelection-8C3C45B5D6B304AC979B94757DB5023F-0-wk-Footnote-8C3C45B5D6B304AC979B94757DB5023F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e3550-wk-Fact-51F33580094F704AE1CA94757D87F7E8" toRefs="TextSelection-823D9AE8DB976ECBCA9594757DB72C08-0-wk-Footnote-823D9AE8DB976ECBCA9594757DB72C08_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e14153-wk-Fact-52053A7518B63417490094757CA936F0" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1685-wk-Fact-5210DA15DEEFCDAFC83494757D61140E d8415180e2306-wk-Fact-5210DA15DEEFCDAFC83494757D61140E" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8340406e1685-wk-Fact-5210DA15DEEFCDAFC83494757D61140E d8415180e2306-wk-Fact-5210DA15DEEFCDAFC83494757D61140E" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1012-wk-Fact-52692B1D3913040E2AAA94757D1705E9" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2484-wk-Fact-527CDF2F111A3CFDCAC094757CB3C447" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e7182-wk-Fact-52E1818462885A5EFE0D94757D8CDA9B" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e7182-wk-Fact-52E1818462885A5EFE0D94757D8CDA9B" toRefs="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e7182-wk-Fact-52E1818462885A5EFE0D94757D8CDA9B" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e4603-wk-Fact-5312CAFDB12F1C38667794757CD7C311" toRefs="TextSelection-AFB627DC6F652A9A0A0594757DC251B0-0-wk-Footnote-AFB627DC6F652A9A0A0594757DC251B0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e3525-wk-Fact-5340A136A6910F813F5A94757D1D656C" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8340406e1113-wk-Fact-536622A1B5CBD4FE87F994757D2524BD" toRefs="TextSelection-04B9B25659DF96CA86BF94757DB5CCE1-0-wk-Footnote-04B9B25659DF96CA86BF94757DB5CCE1_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1113-wk-Fact-536622A1B5CBD4FE87F994757D2524BD" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e3216-wk-Fact-53C5AB131903D4621F5994757D60BCAC" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e8346-wk-Fact-5412E02A9288B4E9968694757D311429" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e8346-wk-Fact-5412E02A9288B4E9968694757D311429" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1847-wk-Fact-54C9F8EBEE78F97A618894757D000BCB" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e10663-wk-Fact-550D4302BA6804DA1DE694757D9284DA" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1745-wk-Fact-551A923D6EEA0DEA4EF694757D1C99C3" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e7911-wk-Fact-5570A8AC6555BCC3538194757CDE6165 d8336633e15177-wk-Fact-5570A8AC6555BCC3538194757CDE6165" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e5294-wk-Fact-562BF7F5C92ED48A7C3D94757D41E597" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e4061-wk-Fact-565D7337C380201E7A3794757D2441F6 d8336633e11313-wk-Fact-565D7337C380201E7A3794757D2441F6" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1347-wk-Fact-56CEFFBCED15FDD6F4D194757CDCF5D5" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e13788-wk-Fact-56FFC68F0A60EB61A79194757CB4018F" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1724-wk-Fact-57301CD194F92FB7EE9A94757CC61DC1 d8415180e3582-wk-Fact-57301CD194F92FB7EE9A94757CC61DC1" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8340406e1724-wk-Fact-57301CD194F92FB7EE9A94757CC61DC1 d8415180e3582-wk-Fact-57301CD194F92FB7EE9A94757CC61DC1" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e5099-wk-Fact-573125655D86999E611594757D0F25B4" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e5099-wk-Fact-573125655D86999E611594757D0F25B4" toRefs="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e5099-wk-Fact-573125655D86999E611594757D0F25B4" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e1790-wk-Fact-57807C2334726A33D68294757CD97546" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336625e2546-wk-Fact-578926C69776E0961EBC94757D74A38D" toRefs="TextSelection-83180A323F26770F5F9D94757DBB7831-0-wk-Footnote-83180A323F26770F5F9D94757DBB7831_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e2432-wk-Fact-578F2DA28EA41AE9382194757CEEAB1C" toRefs="TextSelection-D29E26CC6CF7C6248CEE94757DBD9743-0-wk-Footnote-D29E26CC6CF7C6248CEE94757DBD9743_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2667-wk-Fact-57AFB05C46254859A5D694757D6FE43D" toRefs="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2612-wk-Fact-57D63ECE81675F0F4F2394757D0586AC" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2268-wk-Fact-5813093241A54AAC971594757D47CE74" toRefs="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e7663-wk-Fact-5832CEAF471BE71C047B94757D1A7F51" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e7663-wk-Fact-5832CEAF471BE71C047B94757D1A7F51" toRefs="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e7663-wk-Fact-5832CEAF471BE71C047B94757D1A7F51" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2171-wk-Fact-5855D3292457CBC841DF94757D03D95D" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e2186-wk-Fact-5864C6C0C3A1C625197294757D73F154" toRefs="TextSelection-420C4A044883B0052AE85E76395259A9-0-wk-Footnote-420C4A044883B0052AE85E76395259A9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1182-wk-Fact-59195E3D3D8D530EB03F94757D003A33" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8351242e3279-wk-Fact-591CA5BD37BEF066C61294757D3FA07C" toRefs="TextSelection-8224B42439E7CCC8C3C594757DBA701B-0-wk-Footnote-8224B42439E7CCC8C3C594757DBA701B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1163-wk-Fact-592D27AEE4D0FDEDCA3094757CFE923B" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e5579-wk-Fact-594699073675166A837B94757D1BBB71" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8340406e1283-wk-Fact-59753A9A46BF0BDDA65E94757CBF6EA3" toRefs="TextSelection-04B9B25659DF96CA86BF94757DB5CCE1-0-wk-Footnote-04B9B25659DF96CA86BF94757DB5CCE1_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1283-wk-Fact-59753A9A46BF0BDDA65E94757CBF6EA3" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2032-wk-Fact-599CD01F617B5421030A94757D29E0E8" toRefs="TextSelection-A69940B73F64268F0EB092D9B88F9F01-0-wk-Footnote-A69940B73F64268F0EB092D9B88F9F01_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8307028e2032-wk-Fact-599CD01F617B5421030A94757D29E0E8" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e7777-wk-Fact-59A686060A7AF1F7275494757D530630 d8336633e15043-wk-Fact-59A686060A7AF1F7275494757D530630" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8307028e1365-wk-Fact-59E2FF5E7ACF702D9F4B94757D3339C6 d8357160e2586-wk-Fact-59E2FF5E7ACF702D9F4B94757D3339C6" toRefs="TextSelection-76B1871DA30219820FCB63105DB9E5C3-0-wk-Footnote-76B1871DA30219820FCB63105DB9E5C3_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1365-wk-Fact-59E2FF5E7ACF702D9F4B94757D3339C6 d8357160e2586-wk-Fact-59E2FF5E7ACF702D9F4B94757D3339C6" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e2981-wk-Fact-59F11DF08C5C36F85F9694757CF96B93" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e8861-wk-Fact-5A3DCFE782B686C3474B94757CB5ED2D" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e1960-wk-Fact-5A9323DDE96F467D4EB294757CDEBFD7" toRefs="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1783-wk-Fact-5B9F6B76D55DFFB89B5094757D04FD74" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e3098-wk-Fact-5BE19AFA21A4738F24FF94757D6A31FE" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1847-wk-Fact-5C2821D98F34452F3A6F94757D2D141F" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e5334-wk-Fact-5C78C5042C9CAAB17DD594757D1E08DF" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2945-wk-Fact-5CBFB8246EFB61DA16CD94757CE0475C" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2164-wk-Fact-5CC1D14D1DDE8826CA7B94757D19D277" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e5149-wk-Fact-5D38E93A2B498707F2E694757D15B8FB" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e14002-wk-Fact-5D5C63A4F1FD671C14E194757CAF5BD0" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7433-wk-Fact-5DF4EF1F1BCC2D34B6F86391E6AAE21C" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7433-wk-Fact-5DF4EF1F1BCC2D34B6F86391E6AAE21C" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e8321-wk-Fact-5E91C36A351B5607652E94757D8FBDF9" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e8321-wk-Fact-5E91C36A351B5607652E94757D8FBDF9" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10545-wk-Fact-5EE554E0F23105B14A0A94757CD8E1B6" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e3237-wk-Fact-5FC136C8E0978EE4BFD794757D39F20F" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e8842-wk-Fact-5FF93BEF0CD0E0592D9894757CB94FC4" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10584-wk-Fact-5FFC08B63DBE9AEB9BB794757CFD2C69" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e7559-wk-Fact-5FFC27FB28BF9BC0914794757D12B245" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e7559-wk-Fact-5FFC27FB28BF9BC0914794757D12B245" toRefs="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e7559-wk-Fact-5FFC27FB28BF9BC0914794757D12B245" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1892-wk-Fact-603FB52F232889DFBADE94757D592C93 d8356748e1160-wk-Fact-603FB52F232889DFBADE94757D592C93" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7047-wk-Fact-60CA995A5DF3128B16AC94757CF80B83" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7047-wk-Fact-60CA995A5DF3128B16AC94757CF80B83" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e14869-wk-Fact-6101468A882D99277B2994757CB9521F" toRefs="TextSelection-DD7734E5853B41ABE8C8546D7049626E-0-wk-Footnote-DD7734E5853B41ABE8C8546D7049626E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8336633e14869-wk-Fact-6101468A882D99277B2994757CB9521F" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8301124e1739-wk-Fact-610F8D5433DAF2EB576E94757CAC2094" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1739-wk-Fact-610F8D5433DAF2EB576E94757CAC2094" toRefs="TextSelection-68FC3C25B884A32675EA544FA892CE0F-0-wk-Footnote-68FC3C25B884A32675EA544FA892CE0F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10772-wk-Fact-61E83372368ABBBF6C3294757D74D153" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7286-wk-Fact-61F05B8390D8DD312E7E94757D01400F" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7286-wk-Fact-61F05B8390D8DD312E7E94757D01400F" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e3059-wk-Fact-623288D955847BE5D34C94757D0703C1" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2210-wk-Fact-629B718CAC92C35F38D794757D1FE07E" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1567-wk-Fact-629F8031543C0F8CAEA494757CD21E49" toRefs="TextSelection-1DD42ADAC2DF4C519E7594757DB84698-0-wk-Footnote-1DD42ADAC2DF4C519E7594757DB84698_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e10678-wk-Fact-62CBE8210B463E54DCAE94757D849437 d8336633e10738-wk-Fact-62CBE8210B463E54DCAE94757D849437" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2608-wk-Fact-62DE4C98CF58FC6052F494757D0396A6" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1081-wk-Fact-62FCD6839EDD133C913794757D242018" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e10376-wk-Fact-639B93DD7566754E1E9694757D832F48" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1527-wk-Fact-64508C9369D213E8ACFA94757CCC5964" toRefs="TextSelection-1DD42ADAC2DF4C519E7594757DB84698-0-wk-Footnote-1DD42ADAC2DF4C519E7594757DB84698_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2769-wk-Fact-648A257E45E63BD933AE94757D2F45DA" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1575-wk-Fact-648B9F5A2071A01EE88194757D23C23C" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8301124e1719-wk-Fact-64D918D7F7D3CCF5532194757CC5E46E" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1719-wk-Fact-64D918D7F7D3CCF5532194757CC5E46E" toRefs="TextSelection-68FC3C25B884A32675EA544FA892CE0F-0-wk-Footnote-68FC3C25B884A32675EA544FA892CE0F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1386-wk-Fact-64EEACF271CD8A6661EF94757CA9B5E3" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1211-wk-Fact-6511CCFA698C5A19F60894757CB5C2AF" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e3141-wk-Fact-6538F77FA787A6ABAE0994757CB51CDA" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e7702-wk-Fact-653C3FF814F712F87A4D94757D2002AC" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e7702-wk-Fact-653C3FF814F712F87A4D94757D2002AC" toRefs="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e7702-wk-Fact-653C3FF814F712F87A4D94757D2002AC" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e4227-wk-Fact-65591C40B6FF9A07FC1694757D0FFC2A" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e4227-wk-Fact-65591C40B6FF9A07FC1694757D0FFC2A" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8351242e1548-wk-Fact-66612970542295C5EAA894757D5D6124" toRefs="TextSelection-A2DA5EF7B6FED024F0D494757DBA101E-0-wk-Footnote-A2DA5EF7B6FED024F0D494757DBA101E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2526-wk-Fact-669B95F4C67830F92DEA94757D66C77B" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e9054-wk-Fact-67200BFFCD97D83C7D8E94757D555E87" toRefs="TextSelection-FE68345D83BB191130EF94757DC1B5E5-0-wk-Footnote-FE68345D83BB191130EF94757DC1B5E5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2482-wk-Fact-6846E2B46425F1D8EBA694757CDA487C" toRefs="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e9108-wk-Fact-68B318E9C2DB946F864A94757D889244" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2183-wk-Fact-68D0815BB8658ED83E2294757CBEB1FA" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e5378-wk-Fact-68D35D8323640620312994757D5EC94F" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2365-wk-Fact-68FD1EE0237F3359546394757CC70A3B" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e4207-wk-Fact-69643034125B7437E33E94757D134BD5" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e4207-wk-Fact-69643034125B7437E33E94757D134BD5" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e10314-wk-Fact-699171B0726A36F4B73394757CB0310F" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1713-wk-Fact-69B15CEEDF1C91237BB494757CA88761" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e9127-wk-Fact-69B5FF4C482B5ABEA96994757CA8B7DD" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8342960e1050-wk-Fact-69F9CBEEF2E7911E725F94757CC7E199" toRefs="TextSelection-BA004C096D54F3EE7B8394757DBF9C64-0-wk-Footnote-BA004C096D54F3EE7B8394757DBF9C64_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e1706-wk-Fact-6A34EC9ACE0CB4BA0A7B94757D93E196" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e12772-wk-Fact-6A6B16B2145812FF4A4D94757D88E004" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2832-wk-Fact-6AE9A7E5A8423D56EB6794757D15EE65 d8336633e8921-wk-Fact-6AE9A7E5A8423D56EB6794757D15EE65" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8307028e2832-wk-Fact-6AE9A7E5A8423D56EB6794757D15EE65 d8336633e8921-wk-Fact-6AE9A7E5A8423D56EB6794757D15EE65" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8342313e1817-wk-Fact-6AFEFA4A1DCA7261A60294757D43054F" toRefs="TextSelection-EF26E2A19056A9953CCA94757DBCDE30-0-wk-Footnote-EF26E2A19056A9953CCA94757DBCDE30_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2560-wk-Fact-6B0D0523D801B89879B094757D4B3266" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e3160-wk-Fact-6B111BE422485683C25B94757D205012" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1333-wk-Fact-6B2383F2FE5E4F5C1F8094757D03DB8C" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e5200-wk-Fact-6B2DEA1574A1AAC388A194757D2E9D03" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e3624-wk-Fact-6B84B600E6054E02ECF394757CEEFFA4" toRefs="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8336633e3624-wk-Fact-6B84B600E6054E02ECF394757CEEFFA4" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e1594-wk-Fact-6BC4DEBEF668519175DE94757D1D6772" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8351242e7848-wk-Fact-6C93273338F344A1EC9D94757D345F29" toRefs="TextSelection-2167C2B3C67E3F1A9F6094757DBA8899-0-wk-Footnote-2167C2B3C67E3F1A9F6094757DBA8899_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e14720-wk-Fact-6CC9C84BFB612CF3CEE194757D856D94" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e947-wk-Fact-6D0243B400427DDF73DD94757D73B062 d8415180e3524-wk-Fact-6D0243B400427DDF73DD94757D73B062 d8415180e4701-wk-Fact-6D0243B400427DDF73DD94757D73B062" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e13042-wk-Fact-6D6F3CF5110AF0381DE894757D81F105" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e8100-wk-Fact-6E0224238BF2056CE73A94757CD9F96F" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e8100-wk-Fact-6E0224238BF2056CE73A94757CD9F96F" toRefs="TextSelection-4F6B4AE2D2C9909DF73D94757DC29A3E-0-wk-Footnote-4F6B4AE2D2C9909DF73D94757DC29A3E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8415180e8100-wk-Fact-6E0224238BF2056CE73A94757CD9F96F" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e2558-wk-Fact-6E65BB85082AE89519F994757CADB602" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e1498-wk-Fact-6F2CE97D1E80554AD52594757CBE2E5A" toRefs="TextSelection-D29E26CC6CF7C6248CEE94757DBD9743-0-wk-Footnote-D29E26CC6CF7C6248CEE94757DBD9743_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e1588-wk-Fact-6F4079F311DB52E2A33594757D365375" toRefs="TextSelection-AB3DF04F3446139615AC94757DB7D909-0-wk-Footnote-AB3DF04F3446139615AC94757DB7D909_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e11230-wk-Fact-6F6B5B603006C5DC41F794757D7CCE24" toRefs="TextSelection-33990A088D8DAE29233C94757DC283BE-0-wk-Footnote-33990A088D8DAE29233C94757DC283BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1636-wk-Fact-6FB75BBD46792B84303694757CCB8587" toRefs="TextSelection-16CE381F2099EFC2DA1C94757DB87C39-0-wk-Footnote-16CE381F2099EFC2DA1C94757DB87C39_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e4359-wk-Fact-6FB75C33A442EECAAC2194757CF9FAAF" toRefs="TextSelection-859D29FA558EAC3F73C294757DC172D8-0-wk-Footnote-859D29FA558EAC3F73C294757DC172D8_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e9319-wk-Fact-7015F6E30333F20A4CA094757D862B59" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e3194-wk-Fact-7055D02214C4DCDBF2D794757D530978" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10026-wk-Fact-7097BD769E5D82E2973294757D7E414B" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e2102-wk-Fact-7104406F477A093FDE41955D6E1319E3" toRefs="TextSelection-9161826AA31A3194474594757DB9E2CF-0-wk-Footnote-9161826AA31A3194474594757DB9E2CF_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1867-wk-Fact-715B435D745D4142E92394757CBCE93E" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10927-wk-Fact-71BC4F00B5A98A968BFB94757D63CCD9" toRefs="TextSelection-D895C9E8DF19B244540094757DC27744-0-wk-Footnote-D895C9E8DF19B244540094757DC27744_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1808-wk-Fact-71E3A38CC9A24B60F06494757CF5F71C" toRefs="TextSelection-23DF6508A1F2A3B1745994757DB98CA0-0-wk-Footnote-23DF6508A1F2A3B1745994757DB98CA0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1526-wk-Fact-72309F9168907BDAA94794757D07D3DF" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10193-wk-Fact-72CA6214585A5C8E5F0694757D4CBC86" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7658-wk-Fact-72D47C5CC041D7DBF47F955D6F25B06E" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7658-wk-Fact-72D47C5CC041D7DBF47F955D6F25B06E" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336625e2508-wk-Fact-732C702072B79FA479FA94757D6913F9" toRefs="TextSelection-83180A323F26770F5F9D94757DBB7831-0-wk-Footnote-83180A323F26770F5F9D94757DBB7831_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372420e5784-wk-Fact-7363C996912428EF761094757D8CDD06" toRefs="TextSelection-286F4719195A28A9913594757DC0B1B8-0-wk-Footnote-286F4719195A28A9913594757DC0B1B8_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2629-wk-Fact-73C8A01061ED49259E2594757CE5569D" toRefs="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e8172-wk-Fact-73D648F5F2FEA3A8D53594757D2191CE" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e8172-wk-Fact-73D648F5F2FEA3A8D53594757D2191CE" toRefs="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e8172-wk-Fact-73D648F5F2FEA3A8D53594757D2191CE" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e8212-wk-Fact-73D86692FF1AB4C6A16994757D919ACA" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e8212-wk-Fact-73D86692FF1AB4C6A16994757D919ACA" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e5119-wk-Fact-73E5652390B0B6E33FBC94757CCAE2A9" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e5119-wk-Fact-73E5652390B0B6E33FBC94757CCAE2A9" toRefs="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e5119-wk-Fact-73E5652390B0B6E33FBC94757CCAE2A9" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e6533-wk-Fact-73F49BAF1651352ADB8A94757D370266" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e4306-wk-Fact-73FE98C3916C85F549F794757D5AEA40" toRefs="TextSelection-859D29FA558EAC3F73C294757DC172D8-0-wk-Footnote-859D29FA558EAC3F73C294757DC172D8_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8357160e1429-wk-Fact-744F5D509D408BC3A18C94757CC8DCAC" toRefs="TextSelection-B511D685B8F037FD258094757DBFC8C5-0-wk-Footnote-B511D685B8F037FD258094757DBFC8C5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336625e2527-wk-Fact-74E1087E683DE833774594757D710EBE" toRefs="TextSelection-83180A323F26770F5F9D94757DBB7831-0-wk-Footnote-83180A323F26770F5F9D94757DBB7831_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e3179-wk-Fact-74F211B6DF9332B7854594757CED7C21" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e5915-wk-Fact-75007AA8D5BB2FDFE2F694757D2299DA" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e5915-wk-Fact-75007AA8D5BB2FDFE2F694757D2299DA" toRefs="TextSelection-6EDC28E4739B45A7AA7C94757DBD8D30-0-wk-Footnote-6EDC28E4739B45A7AA7C94757DBD8D30_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e5915-wk-Fact-75007AA8D5BB2FDFE2F694757D2299DA" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e4027-wk-Fact-7527AF621EA7D105014694757D491C4F d8336633e11279-wk-Fact-7527AF621EA7D105014694757D491C4F" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e4438-wk-Fact-757B28C92C06735A064A94757D563E75" toRefs="TextSelection-C185F8237D4ED950685B94757DC105E4-0-wk-Footnote-C185F8237D4ED950685B94757DC105E4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7228-wk-Fact-75A819750D40D13F5F4D94757D59DF46" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7228-wk-Fact-75A819750D40D13F5F4D94757D59DF46" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e3781-wk-Fact-75ED33FE12B125B9E0C094757D134293" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e7264-wk-Fact-75FF99F8C13B7B51000994757D64A357" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1144-wk-Fact-7647F4EED80B8447B7B494757D2B6C57" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e6454-wk-Fact-7693E162BA55D1667FBC94757D2195F2" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e6674-wk-Fact-76B77AEDB628C2C133C594757CF2E937" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7174-wk-Fact-76C07D2D66C0388F0C0594757D012C55" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7174-wk-Fact-76C07D2D66C0388F0C0594757D012C55" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e4744-wk-Fact-76C2DA9EBF5CD4536E0394757D100987" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e4744-wk-Fact-76C2DA9EBF5CD4536E0394757D100987" toRefs="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e4744-wk-Fact-76C2DA9EBF5CD4536E0394757D100987" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1877-wk-Fact-76D99E72799A7D1A6EEF94757D204BD6" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e12505-wk-Fact-7710E5E7409968676DDF94757CB9616B" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e4598-wk-Fact-772041FC75DDB73FA59D94757D1262E8" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e4598-wk-Fact-772041FC75DDB73FA59D94757D1262E8" toRefs="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e4598-wk-Fact-772041FC75DDB73FA59D94757D1262E8" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e14118-wk-Fact-772E453E27BB5E8A941894757D862BB8" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e4041-wk-Fact-780C5B60A58937B5CFA594757D14130D d8336633e11293-wk-Fact-780C5B60A58937B5CFA594757D14130D" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1921-wk-Fact-7815B96C1DE73848E04C94757D28CB62" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2475-wk-Fact-781D2814C0D7F0668EE394757D69DD6C" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e949-wk-Fact-785332B79AA4618521F26EDD705A45C3" toRefs="TextSelection-A69940B73F64268F0EB092D9B88F9F01-0-wk-Footnote-A69940B73F64268F0EB092D9B88F9F01_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8307028e949-wk-Fact-785332B79AA4618521F26EDD705A45C3" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8351242e4823-wk-Fact-787DD497342D45C6DCBD94757D3F332F" toRefs="TextSelection-11358084CF50DEC3FF92628C52236CBA-0-wk-Footnote-11358084CF50DEC3FF92628C52236CBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1430-wk-Fact-788604D6690A503EC72D94757D52CBCB d8312059e1717-wk-Fact-788604D6690A503EC72D94757D52CBCB" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e4570-wk-Fact-78CEBCE2B596295642A894757D5C66CC" toRefs="TextSelection-AFB627DC6F652A9A0A0594757DC251B0-0-wk-Footnote-AFB627DC6F652A9A0A0594757DC251B0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e6408-wk-Fact-78E877E7F508BB5A1CBD94757D8CBBF4" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1982-wk-Fact-78F2B6044F533AECF79494757D13E2F0" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2495-wk-Fact-78F48FB31891A5F2CA2794757CAAA5B9" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2054-wk-Fact-792F383C3FEE0FE8090C94757CAF87DA" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e4472-wk-Fact-7948B0B6844BD3D387BA94757CDB9B0C" toRefs="TextSelection-C185F8237D4ED950685B94757DC105E4-0-wk-Footnote-C185F8237D4ED950685B94757DC105E4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2234-wk-Fact-795A73536189346A46BA94757D101516" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1893-wk-Fact-7973D60AC4E2ED9EA6D394757CF8B7E7" toRefs="TextSelection-3F1FDE51F00C4F037BC194757DB9000C-0-wk-Footnote-3F1FDE51F00C4F037BC194757DB9000C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2562-wk-Fact-7A14B07B1D3BB0FC8DEC94757D153837" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8351242e7379-wk-Fact-7A8A1B93604E236BB74394757D812BD2" toRefs="TextSelection-DA70407E988FF7F4292CB0A472718D04-0-wk-Footnote-DA70407E988FF7F4292CB0A472718D04_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e2071-wk-Fact-7AA1C77DB5A3B4644A4C94757CE5FE83" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e5080-wk-Fact-7AE0949565F5D585B74E94757D172848" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e5080-wk-Fact-7AE0949565F5D585B74E94757D172848" toRefs="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e5080-wk-Fact-7AE0949565F5D585B74E94757D172848" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1138-wk-Fact-7AFC70661380E28E616594757CC3AFAE" toRefs="TextSelection-4E74A09462C596E2363694757DB8EB14-0-wk-Footnote-4E74A09462C596E2363694757DB8EB14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2604-wk-Fact-7B35AE5A591127B6882494757D496AF1" toRefs="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1121-wk-Fact-7B3AE2978F7C733A20D394757D149216" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e941-wk-Fact-7B3C46A754BAB4A857A994757D1275BE" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e8152-wk-Fact-7B71E458C4CB31B9B78E94757CEB94F1" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e8152-wk-Fact-7B71E458C4CB31B9B78E94757CEB94F1" toRefs="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e8152-wk-Fact-7B71E458C4CB31B9B78E94757CEB94F1" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2504-wk-Fact-7BA1645714435EB2B3AB94757CC0F691" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e9207-wk-Fact-7BC374D8582E6B3D7CE3A1CD2E1DD218" toRefs="TextSelection-A6E5E77EFF2BB738D44C94757DBDF083-0-wk-Footnote-A6E5E77EFF2BB738D44C94757DBDF083_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2370-wk-Fact-7BD0F552906AEDAE43AB94757D064290" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e6994-wk-Fact-7BEE24816749E03906BD94757D9C4726" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1907-wk-Fact-7C3725C3864FB58D26F294757DA59FB9" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2209-wk-Fact-7C60FDCC13DD0DFF94DB94757D194622" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e7099-wk-Fact-7D1153C7730B6D08B22194757D258E58" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e7099-wk-Fact-7D1153C7730B6D08B22194757D258E58" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1788-wk-Fact-7D400BB69B8260DBFA0194757D7158A5" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e8302-wk-Fact-7D6E2CB63598393A1F6E94757D15BA01" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e8302-wk-Fact-7D6E2CB63598393A1F6E94757D15BA01" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1666-wk-Fact-7DBB915490EEA28AD34F94757D1C965F" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e981-wk-Fact-7DC06283FD051672522094757D4872EE" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e12419-wk-Fact-7DD25CF4297877D69E8D94757CAEE705" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2501-wk-Fact-7DFB45BE4A92C05A7CE494757D5BC48C" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1411-wk-Fact-7E093B7D90D64F5B13A494757D3BA82F d8312059e1698-wk-Fact-7E093B7D90D64F5B13A494757D3BA82F" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e3904-wk-Fact-7E1F4D7F45796F888D3994757D152AA2" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e5189-wk-Fact-7E38933CC8C6B3F78FD894757D1176A3" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e5189-wk-Fact-7E38933CC8C6B3F78FD894757D1176A3" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e3758-wk-Fact-7E6C55D0D09E306D959A94757D35315B" toRefs="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8336633e3758-wk-Fact-7E6C55D0D09E306D959A94757D35315B" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e4186-wk-Fact-7E8FD767BFA321ADA8D194757D17C3EB" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e4186-wk-Fact-7E8FD767BFA321ADA8D194757D17C3EB" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e3982-wk-Fact-7E9393AC0EF93702DEB094757D86B0EE" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e2800-wk-Fact-7EC912EE8439671A25BF94757D7D989C" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2628-wk-Fact-7ECB63F5AF06861C1CE494757D0884D8" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e14585-wk-Fact-7F0F15290F5E885CE3D794757CBEF8C8" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1975-wk-Fact-7F22D0DB6525173F13B494757CADCE97 d8356748e1570-wk-Fact-7F22D0DB6525173F13B494757CADCE97" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e4724-wk-Fact-7F531F08E0D50D0C134294757D23AAA5" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e4724-wk-Fact-7F531F08E0D50D0C134294757D23AAA5" toRefs="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e4724-wk-Fact-7F531F08E0D50D0C134294757D23AAA5" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7565-wk-Fact-7F5B6E7E28432773681794757D7346F3" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7565-wk-Fact-7F5B6E7E28432773681794757D7346F3" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e5168-wk-Fact-7F7EA65841FA3F8EDE9D94757D1F6A7C" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e973-wk-Fact-8056831472C93DFFBF7B94757D474450" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2859-wk-Fact-80889F71FE2525C70D9194757D2B8EDC" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2145-wk-Fact-81D654407A04152B766994757CDD8A45" toRefs="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8351242e7282-wk-Fact-8289F953B8E0A1E31F6E94757D81004F" toRefs="TextSelection-DA70407E988FF7F4292CB0A472718D04-0-wk-Footnote-DA70407E988FF7F4292CB0A472718D04_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e5353-wk-Fact-82E28E032D731899B0B694757D3E73D0" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e8882-wk-Fact-82E5812A435DA211399494757D905CAA" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2862-wk-Fact-82EF2E3D703744E0C13B94757D266699" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8301124e1681-wk-Fact-82F380CF07CFB5944E8F94757D071BF6" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1681-wk-Fact-82F380CF07CFB5944E8F94757D071BF6" toRefs="TextSelection-68FC3C25B884A32675EA544FA892CE0F-0-wk-Footnote-68FC3C25B884A32675EA544FA892CE0F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1619-wk-Fact-82FCBDB83EA92437E26C94757D5A5E10 d8316808e2257-wk-Fact-82FCBDB83EA92437E26C94757D5A5E10" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1789-wk-Fact-82FFBC9E02C7EA63F21C94757D1C5F54" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e6955-wk-Fact-8333570EE1A66789FB2C94757D365212" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e14907-wk-Fact-8376F4C46168FF741E3C94757D90B25B" toRefs="TextSelection-DD7734E5853B41ABE8C8546D7049626E-0-wk-Footnote-DD7734E5853B41ABE8C8546D7049626E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8336633e14907-wk-Fact-8376F4C46168FF741E3C94757D90B25B" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e3677-wk-Fact-8434DE738E1AB342D96E94757CCBDE53" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2255-wk-Fact-84746CEAE1028754282894757D242276" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2411-wk-Fact-8570BDBA5E94557A549C94757D4F36AD" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1077-wk-Fact-8594983BDE02438B8CB794757D6E309D" toRefs="TextSelection-4E74A09462C596E2363694757DB8EB14-0-wk-Footnote-4E74A09462C596E2363694757DB8EB14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e2081-wk-Fact-8631DD50CCB968472578955D6DC81456" toRefs="TextSelection-9161826AA31A3194474594757DB9E2CF-0-wk-Footnote-9161826AA31A3194474594757DB9E2CF_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e3010-wk-Fact-86D8DED1361AFC8ED58C94757D5FCC72" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e1820-wk-Fact-871135383070AF575BE394757CEC460F" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10947-wk-Fact-871E915D2D6F3FDC5AE494757D0F306E" toRefs="TextSelection-D895C9E8DF19B244540094757DC27744-0-wk-Footnote-D895C9E8DF19B244540094757DC27744_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e5951-wk-Fact-8756F2FE82655E80079594757D3B1E62" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10359-wk-Fact-87D917DF76C4DF6A2AA894757D7F7619" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e10876-wk-Fact-87E8BDB2D145CE8F51DF94757CB079E4" toRefs="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8336633e10876-wk-Fact-87E8BDB2D145CE8F51DF94757CB079E4" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e13553-wk-Fact-884749ED8C7327C2FD2094757D8E56E9" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e6219-wk-Fact-886DF198F4CB9AB4242C94757D9970F3" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e14370-wk-Fact-892DE8B531A6E01C09E194757CBBECA5" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e8232-wk-Fact-8936184B1403F72707B294757CFAA700" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e8232-wk-Fact-8936184B1403F72707B294757CFAA700" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e1960-wk-Fact-8971E1C78383330CB40E94757CD5511C" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e9880-wk-Fact-8A47D4A42EA4801E113F94757D561064" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e11105-wk-Fact-8AA71470C6F49FFEF87594757CBC671E" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e3263-wk-Fact-8AC90BDE6611C4D9613F94757D10F366" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e3263-wk-Fact-8AC90BDE6611C4D9613F94757D10F366" toRefs="TextSelection-6EDC28E4739B45A7AA7C94757DBD8D30-0-wk-Footnote-6EDC28E4739B45A7AA7C94757DBD8D30_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e3263-wk-Fact-8AC90BDE6611C4D9613F94757D10F366" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e5691-wk-Fact-8ACA3083C920B54F8AEC94757D564AB6" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8301124e1420-wk-Fact-8B19463082CE6440AD3394757D03C123" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1420-wk-Fact-8B19463082CE6440AD3394757D03C123" toRefs="TextSelection-A6080F3BC2CE36268D0F94757DB590DE-0-wk-Footnote-A6080F3BC2CE36268D0F94757DB590DE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8340406e1179-wk-Fact-8B3A1BD0379B26183EE994757D074D8C" toRefs="TextSelection-04B9B25659DF96CA86BF94757DB5CCE1-0-wk-Footnote-04B9B25659DF96CA86BF94757DB5CCE1_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1179-wk-Fact-8B3A1BD0379B26183EE994757D074D8C" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2971-wk-Fact-8BC82C6DDA70A7A2CF9894757D0335F3" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e5931-wk-Fact-8C0A92F009A247D99EC694757D0E2AFB" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1866-wk-Fact-8C29FB80663D2D3FF01694757D04376B" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1955-wk-Fact-8CA5088693E8928A2F7194757D5C8489 d8356748e1550-wk-Fact-8CA5088693E8928A2F7194757D5C8489" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e2961-wk-Fact-8CCA7F0CCF44F7EE009F94757CB0EAEE" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e3405-wk-Fact-8DD16E5EDE18E934E20F94757D84AC18" toRefs="TextSelection-B92DE04072B96160C46394757DB7ADA1-0-wk-Footnote-B92DE04072B96160C46394757DB7ADA1_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10119-wk-Fact-8DE5439DE42185EAD27394757D638D67" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8301124e1700-wk-Fact-8DE79CAD5240FF8E772794757CFDD19F" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1700-wk-Fact-8DE79CAD5240FF8E772794757CFDD19F" toRefs="TextSelection-68FC3C25B884A32675EA544FA892CE0F-0-wk-Footnote-68FC3C25B884A32675EA544FA892CE0F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e8212-wk-Fact-8EC2BB5B4C87C28113B894757D7D006B" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e8212-wk-Fact-8EC2BB5B4C87C28113B894757D7D006B" toRefs="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e8212-wk-Fact-8EC2BB5B4C87C28113B894757D7D006B" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e3300-wk-Fact-8EF576E428EEA952509894757D5DA535 d8356748e2298-wk-Fact-8EF576E428EEA952509894757D5DA535" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e5912-wk-Fact-8F10AC75EAF3DB11CBFC94757D61D1B8" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2714-wk-Fact-8F362BEF2AB5D5597E6394757CFFD802 d8314038e2485-wk-Fact-8F362BEF2AB5D5597E6394757CFFD802" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2931-wk-Fact-8F56B752B32B070AE71194757D815A0F" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e7249-wk-Fact-8F5ED7D1B0A0EF78888F94757D1CDBFD" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-8F6198A5B84A323EA04194757CDD184D-wk-Fact-8F6198A5B84A323EA04194757CDD184D" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e2177-wk-Fact-8F668F0BF6E37C3A8D6394757D92EEEB" toRefs="TextSelection-9BC3436E7B9C00975CD394757DC16C56-0-wk-Footnote-9BC3436E7B9C00975CD394757DC16C56_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1257-wk-Fact-902EBA952C8391060B6994757CB1FFC1" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2101-wk-Fact-9072FFD068100079F81B94757D26A3EC" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1612-wk-Fact-9116D9DA0452E7895E8B94757D09EEB9" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e5373-wk-Fact-917DA1C330410587B66094757D7DD34A" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2545-wk-Fact-91CD03BF7899EC259FA294757CBB3C78" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2248-wk-Fact-9209A09A308FD4F6E18194757D3C8964" toRefs="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e2752-wk-Fact-920B734C19194AC1B01F94757D8C8380" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2847-wk-Fact-920C774D6C3160546F7D94757DA37E07 d8336633e13082-wk-Fact-920C774D6C3160546F7D94757DA37E07" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8301124e2847-wk-Fact-920C774D6C3160546F7D94757DA37E07 d8336633e13082-wk-Fact-920C774D6C3160546F7D94757DA37E07" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1952-wk-Fact-926EAF034EA59D57AB4A94757D085C80" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2594-wk-Fact-92C5E71226171D8AEF1294757CAFE14B" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312053e1269-wk-Fact-93B22A2A5674F48F52DF94757CE4EB2F" toRefs="TextSelection-9459A99A0EC8DD1CD04094757DBA4F65-0-wk-Footnote-9459A99A0EC8DD1CD04094757DBA4F65_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1218-wk-Fact-93E10BD448FBEAA578FD94757D709889" toRefs="TextSelection-04B9B25659DF96CA86BF94757DB5CCE1-0-wk-Footnote-04B9B25659DF96CA86BF94757DB5CCE1_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8340406e1218-wk-Fact-93E10BD448FBEAA578FD94757D709889" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e6828-wk-Fact-93E2B34C852B38B85FA394757D2258B2" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8308070e1050-wk-Fact-9485DE235A3009893D3694757CC67D4F d8308070e2910-wk-Fact-9485DE235A3009893D3694757CC67D4F" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1050-wk-Fact-9485DE235A3009893D3694757CC67D4F d8308070e2910-wk-Fact-9485DE235A3009893D3694757CC67D4F" toRefs="TextSelection-FE05511B3F59D62E086994757DB6CDC4-0-wk-Footnote-FE05511B3F59D62E086994757DB6CDC4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2456-wk-Fact-9509BBD7999258CA6CC694757D1611AA" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8357160e2297-wk-Fact-9571AA75C6659383FDA794757CCEA9E9 d8357160e2335-wk-Fact-9571AA75C6659383FDA794757CCEA9E9" toRefs="TextSelection-84058C93858F4EB1F00C631013E8EF74-0-wk-Footnote-84058C93858F4EB1F00C631013E8EF74_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1971-wk-Fact-960E53D0B504F694E33294757D577481" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1764-wk-Fact-961167284F5E861B1C9094757D0AD393" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312053e1289-wk-Fact-964325EF1A54729D824194757CE58552" toRefs="TextSelection-9459A99A0EC8DD1CD04094757DBA4F65-0-wk-Footnote-9459A99A0EC8DD1CD04094757DBA4F65_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10660-wk-Fact-964D5983FAFE8F814A6063A28D7FB945" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1016-wk-Fact-964F368B32E366CCC9BC94757CFB473E" toRefs="TextSelection-4E74A09462C596E2363694757DB8EB14-0-wk-Footnote-4E74A09462C596E2363694757DB8EB14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8357160e1758-wk-Fact-96604F15C352A725BF5594757CF6074A d8357160e2506-wk-Fact-96604F15C352A725BF5594757CF6074A" toRefs="TextSelection-76B1871DA30219820FCB63105DB9E5C3-0-wk-Footnote-76B1871DA30219820FCB63105DB9E5C3_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e9149-wk-Fact-9686F21840EBB7B77D77A1CD25DC8AFE" toRefs="TextSelection-A6E5E77EFF2BB738D44C94757DBDF083-0-wk-Footnote-A6E5E77EFF2BB738D44C94757DBDF083_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e9093-wk-Fact-96E3B27F72377D1E7FE194757D98AE8A" toRefs="TextSelection-FE68345D83BB191130EF94757DC1B5E5-0-wk-Footnote-FE68345D83BB191130EF94757DC1B5E5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2201-wk-Fact-9786DDF8A69B3054F6C594757D0258B2" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e13472-wk-Fact-97B0ABF7AD141BFC956394757D9158BA" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e5819-wk-Fact-97E6BE9DD3E7475F229D94757D38F45F" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e3530-wk-Fact-981984D45830B3785BF594757D89A644" toRefs="TextSelection-823D9AE8DB976ECBCA9594757DB72C08-0-wk-Footnote-823D9AE8DB976ECBCA9594757DB72C08_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2734-wk-Fact-98256D21B98CE406359794757D62CC7A d8314038e2506-wk-Fact-98256D21B98CE406359794757D62CC7A" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e8193-wk-Fact-983ACA3C5EAC7B373D6394757D08EA2C" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e8193-wk-Fact-983ACA3C5EAC7B373D6394757D08EA2C" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e6494-wk-Fact-9864AFACC9ABDC5E1CF694757CC9DE4C" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1479-wk-Fact-98787FFB4C950A5BBD0194757CE6C4FB d8336625e4109-wk-Fact-98787FFB4C950A5BBD0194757CE6C4FB" toRefs="TextSelection-467F12A5D203A9A15C3A94757DB81B0A-0-wk-Footnote-467F12A5D203A9A15C3A94757DB81B0A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8316808e1479-wk-Fact-98787FFB4C950A5BBD0194757CE6C4FB d8336625e4109-wk-Fact-98787FFB4C950A5BBD0194757CE6C4FB" toRefs="TextSelection-9F5C431DBFAA147134E594757DBBC55E-0-wk-Footnote-9F5C431DBFAA147134E594757DBBC55E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e2166-wk-Fact-98D14E7EA5371F942F3394757CCE8CDC" toRefs="TextSelection-420C4A044883B0052AE85E76395259A9-0-wk-Footnote-420C4A044883B0052AE85E76395259A9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e4325-wk-Fact-994F255F78B05FBADDEC94757D595A9A" toRefs="TextSelection-859D29FA558EAC3F73C294757DC172D8-0-wk-Footnote-859D29FA558EAC3F73C294757DC172D8_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e5398-wk-Fact-99DCC47DA679E57EDCE694757D4966B0" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8329819e910-wk-Fact-9A056798B17100CAB31894757D0A17AE" toRefs="TextSelection-09307D44CBA12BFE03A594757DBC3C9D-0-wk-Footnote-09307D44CBA12BFE03A594757DBC3C9D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8351242e4842-wk-Fact-9A214797BCD7FFF4A83494757D3BB1A1" toRefs="TextSelection-11358084CF50DEC3FF92628C52236CBA-0-wk-Footnote-11358084CF50DEC3FF92628C52236CBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2284-wk-Fact-9A3535709176CD3B928494757D5A0A52" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8351242e3297-wk-Fact-9AC586B89CDBD7EC4F6194757CAFC880" toRefs="TextSelection-8224B42439E7CCC8C3C594757DBA701B-0-wk-Footnote-8224B42439E7CCC8C3C594757DBA701B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2013-wk-Fact-9B484215869CDB3979AE94757D159E88" toRefs="TextSelection-A69940B73F64268F0EB092D9B88F9F01-0-wk-Footnote-A69940B73F64268F0EB092D9B88F9F01_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8307028e2013-wk-Fact-9B484215869CDB3979AE94757D159E88" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e4704-wk-Fact-9B5EAA42679A56C367D494757D12A858" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e4704-wk-Fact-9B5EAA42679A56C367D494757D12A858" toRefs="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e4704-wk-Fact-9B5EAA42679A56C367D494757D12A858" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2058-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9 d8301124e969-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9 d8336633e12850-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9 d8308070e877-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8340406e2058-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9 d8301124e969-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9 d8336633e12850-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9 d8308070e877-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8340406e2058-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9 d8301124e969-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9 d8336633e12850-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9 d8308070e877-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="4" fromRefs="d8340406e2058-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9 d8301124e969-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9 d8336633e12850-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9 d8308070e877-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e5359-wk-Fact-9B8010AEEE0CA7C861B494757D62CEEB" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2320-wk-Fact-9BECE1ABEA4FD6DB7B8A94757D65CB34" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1303-wk-Fact-9C03A5BC963DD5615ABA94757D2C3607" toRefs="TextSelection-04B9B25659DF96CA86BF94757DB5CCE1-0-wk-Footnote-04B9B25659DF96CA86BF94757DB5CCE1_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8340406e1303-wk-Fact-9C03A5BC963DD5615ABA94757D2C3607" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8307028e1346-wk-Fact-9C96864A6997B214807194757D2B762A d8357160e2527-wk-Fact-9C96864A6997B214807194757D2B762A" toRefs="TextSelection-76B1871DA30219820FCB63105DB9E5C3-0-wk-Footnote-76B1871DA30219820FCB63105DB9E5C3_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1346-wk-Fact-9C96864A6997B214807194757D2B762A d8357160e2527-wk-Fact-9C96864A6997B214807194757D2B762A" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e14447-wk-Fact-9CEB92503A38A9B5DBE094757CB7FA3C" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e6300-wk-Fact-9D649DDE4C8F1EF5140994757D200949" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e3366-wk-Fact-9D99FC5004F5F45EB50094757D8BBD01" toRefs="TextSelection-B92DE04072B96160C46394757DB7ADA1-0-wk-Footnote-B92DE04072B96160C46394757DB7ADA1_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e1443-wk-Fact-9D9F803549723F3037FC94757CE1E2E0" toRefs="TextSelection-A2331388F2C895076E3994757DB73022-0-wk-Footnote-A2331388F2C895076E3994757DB73022_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2062-wk-Fact-9F156B344E4DD52CA8B394757CE34982" toRefs="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1057-wk-Fact-9F5350C0F6B6CC70CC8D94757CEE92D7" toRefs="TextSelection-4E74A09462C596E2363694757DB8EB14-0-wk-Footnote-4E74A09462C596E2363694757DB8EB14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e7722-wk-Fact-9F5CE5F094EEBC828DF194757D8C0D9D" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e7722-wk-Fact-9F5CE5F094EEBC828DF194757D8C0D9D" toRefs="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e7722-wk-Fact-9F5CE5F094EEBC828DF194757D8C0D9D" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2399-wk-Fact-9F6032E503A2CA1767B194757CDC4DEA" toRefs="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e4080-wk-Fact-9F791EE0835763BF87F894757D6D6836 d8336633e11332-wk-Fact-9F791EE0835763BF87F894757D6D6836" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e2792-wk-Fact-9FD771621D23274287A294757D1BC8FA" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7066-wk-Fact-9FF11DED732028F079FF94757D67BC5A" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7066-wk-Fact-9FF11DED732028F079FF94757D67BC5A" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1329-wk-Fact-A00DF4727012C4B9EC3194757D104907" toRefs="TextSelection-CDCE760DEFA7F631840C94757DB86187-0-wk-Footnote-CDCE760DEFA7F631840C94757DB86187_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e8283-wk-Fact-A078219576BC94A6431D94757D13F215" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e8283-wk-Fact-A078219576BC94A6431D94757D13F215" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e3347-wk-Fact-A0AE794A669CD8E4D60C94757D85F3D2" toRefs="TextSelection-B92DE04072B96160C46394757DB7ADA1-0-wk-Footnote-B92DE04072B96160C46394757DB7ADA1_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8314038e1196-wk-Fact-A19967903AAC6CD9F1E494757D7857A3" toRefs="TextSelection-681F29FE9DC6BC582B6D94757DB90D8C-0-wk-Footnote-681F29FE9DC6BC582B6D94757DB90D8C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e7111-wk-Fact-A1B634793474C63E20E77DAA79965C6D" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e2110-wk-Fact-A1C25D709E6E2BCC622F94757CE0C08D" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2912-wk-Fact-A1F913431B3403C9FEC994757D9D5A01" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2368-wk-Fact-A21DC12905CBC163AED994757D2EAC03" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e7412-wk-Fact-A21E82052DF984C0370594757D762D70" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2297-wk-Fact-A25CEEC8C1AE2DADBEC594757D293164" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8351242e1640-wk-Fact-A2CF9469A723FA507B4C94757D43EBF4" toRefs="TextSelection-A2DA5EF7B6FED024F0D494757DBA101E-0-wk-Footnote-A2DA5EF7B6FED024F0D494757DBA101E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1328-wk-Fact-A2D758AD8E8FD5AADF3B94757CF0099C" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1777-wk-Fact-A31D6CBE4C3463BD783494757D2A1AEA" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e3623-wk-Fact-A331008C1C4E5584FBBC94757D85F6B9" toRefs="TextSelection-2B5AD3FFF4626D02F1E394757DB79B83-0-wk-Footnote-2B5AD3FFF4626D02F1E394757DB79B83_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1366-wk-Fact-A332B2F7F76D0113E2A094757CC0E90D" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1478-wk-Fact-A40179DC2229E8A9AD6B94757D2F9DF6" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e6698-wk-Fact-A40FA5F841627A3B361294757D3A0A50" toRefs="TextSelection-FE68345D83BB191130EF94757DC1B5E5-0-wk-Footnote-FE68345D83BB191130EF94757DC1B5E5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e7578-wk-Fact-A4F33B25B1F596F9D7C294757D2733CF" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e7578-wk-Fact-A4F33B25B1F596F9D7C294757D2733CF" toRefs="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e7578-wk-Fact-A4F33B25B1F596F9D7C294757D2733CF" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1789-wk-Fact-A5431E8C2912D62E362094757CF2BE8E" toRefs="TextSelection-23DF6508A1F2A3B1745994757DB98CA0-0-wk-Footnote-23DF6508A1F2A3B1745994757DB98CA0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e7452-wk-Fact-A5C037C17E00CF7C78FE94757D5EE39D" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e7641-wk-Fact-A5D88487E443ABA949BF94757D39E6F7" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e5726-wk-Fact-A617E7F74433A22C70F794757DA55FFF" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2839-wk-Fact-A62E7998A018A606CB9B94757D1FEF54" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2669-wk-Fact-A66CB11E7205BECF278B94757D98ABC2" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e960-wk-Fact-A6719A6CE4DE88C80E8394757D222E89" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e3944-wk-Fact-A6C23BB629BE687A706594757D7617FA" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2185-wk-Fact-A724B0094E4DB323816594757D52FEEC" toRefs="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8307028e1056-wk-Fact-A72909DE8208FAB8084794757D31B877 d8342960e1004-wk-Fact-A72909DE8208FAB8084794757D31B877" toRefs="TextSelection-6816050F6F7DBFCD3C5B94757DBEA485-0-wk-Footnote-6816050F6F7DBFCD3C5B94757DBEA485_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1056-wk-Fact-A72909DE8208FAB8084794757D31B877 d8342960e1004-wk-Fact-A72909DE8208FAB8084794757D31B877" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e8748-wk-Fact-A73DD4823D1FAAF157BF94757CB25343" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-A775AC2F22450F075D8194757CD9A894-wk-Fact-A775AC2F22450F075D8194757CD9A894" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8314038e1236-wk-Fact-A7A8B2FD88766217F16094757D50D04F" toRefs="TextSelection-681F29FE9DC6BC582B6D94757DB90D8C-0-wk-Footnote-681F29FE9DC6BC582B6D94757DB90D8C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e7598-wk-Fact-A7CCC86802BC2190FB1994757CEDE354" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e7598-wk-Fact-A7CCC86802BC2190FB1994757CEDE354" toRefs="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e7598-wk-Fact-A7CCC86802BC2190FB1994757CEDE354" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e4115-wk-Fact-A8241CECE526F96581AE94757CF0E2F1 d8336633e11367-wk-Fact-A8241CECE526F96581AE94757CF0E2F1" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1653-wk-Fact-A82EF1B25256A6FE603294757D5228D4" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e3719-wk-Fact-A88ABBED02CE57879DE594757CE47EAA" toRefs="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8336633e3719-wk-Fact-A88ABBED02CE57879DE594757CE47EAA" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1460-wk-Fact-A89179620F4ADD5E911294757CF30C7B d8336625e4088-wk-Fact-A89179620F4ADD5E911294757CF30C7B" toRefs="TextSelection-467F12A5D203A9A15C3A94757DB81B0A-0-wk-Footnote-467F12A5D203A9A15C3A94757DB81B0A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8316808e1460-wk-Fact-A89179620F4ADD5E911294757CF30C7B d8336625e4088-wk-Fact-A89179620F4ADD5E911294757CF30C7B" toRefs="TextSelection-9F5C431DBFAA147134E594757DBBC55E-0-wk-Footnote-9F5C431DBFAA147134E594757DBBC55E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2653-wk-Fact-A8DB7D24D8C907F2E56094757D1D1AC3" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e1603-wk-Fact-A8FD8B76C5AB70D75DBF94757CDE77D4" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1872-wk-Fact-A90E01F4F7B0E1568EDA94757D6D8CFD d8356748e1141-wk-Fact-A90E01F4F7B0E1568EDA94757D6D8CFD" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1323-wk-Fact-A9E0B30BE08222818D3E94757CCA5EEE" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1808-wk-Fact-AA0D8DE25A28BD3E886994757D30BAE9" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-AA58F5E3D16407426BC394757CD865C7-wk-Fact-AA58F5E3D16407426BC394757CD865C7" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8357160e2546-wk-Fact-AA5991AA2CE0B64BF6CF94757CCBAA43" toRefs="TextSelection-76B1871DA30219820FCB63105DB9E5C3-0-wk-Footnote-76B1871DA30219820FCB63105DB9E5C3_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e2196-wk-Fact-AA84F6B275E57DCDD15C94757CF155B2" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e2196-wk-Fact-AA84F6B275E57DCDD15C94757CF155B2" toRefs="TextSelection-9BC3436E7B9C00975CD394757DC16C56-0-wk-Footnote-9BC3436E7B9C00975CD394757DC16C56_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e3963-wk-Fact-AAD74F0EFA0B4EA93F7D94757D17DF5B" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e12491-wk-Fact-AAF16B56D807C054332894757CBC5D15" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10154-wk-Fact-AAF3C1C15A87A9E0791F94757D585239" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e8288-wk-Fact-ACC0B84B657C3CD00CFC94757D4FE802" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e8288-wk-Fact-ACC0B84B657C3CD00CFC94757D4FE802" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e11115-wk-Fact-ACE7D9A9276B682B9DB094757D5AF1D5" toRefs="TextSelection-FE68345D83BB191130EF94757DC1B5E5-0-wk-Footnote-FE68345D83BB191130EF94757DC1B5E5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10007-wk-Fact-AD3188356864105593EE94757CDE3AA3" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8357160e3562-wk-Fact-AD667A5DC0327AE34FF994757D53D517" toRefs="TextSelection-2DE900A873C344A165FE94757DBF7A4D-0-wk-Footnote-2DE900A873C344A165FE94757DBF7A4D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e4419-wk-Fact-ADE35C801D052BCE925B94757D577C42" toRefs="TextSelection-C185F8237D4ED950685B94757DC105E4-0-wk-Footnote-C185F8237D4ED950685B94757DC105E4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e7201-wk-Fact-AF4E88391CCB32EE29BF94757D2B4EC4" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e7201-wk-Fact-AF4E88391CCB32EE29BF94757D2B4EC4" toRefs="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e7201-wk-Fact-AF4E88391CCB32EE29BF94757D2B4EC4" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e8024-wk-Fact-AF51AD4BAD86F0B6155B94757D5FA1C5" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e8024-wk-Fact-AF51AD4BAD86F0B6155B94757D5FA1C5" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e8008-wk-Fact-AF62571E69854E8457D694757D8D5035" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1874-wk-Fact-AF679C0C7A88919A718094757CFBF4E0" toRefs="TextSelection-3F1FDE51F00C4F037BC194757DB9000C-0-wk-Footnote-3F1FDE51F00C4F037BC194757DB9000C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e14680-wk-Fact-AF977AD81CDE8A1EAB0994757CABF14E" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e7832-wk-Fact-B00A363AE1BB1F3479D994757D183B47 d8336633e15098-wk-Fact-B00A363AE1BB1F3479D994757D183B47" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8351242e3352-wk-Fact-B02201B22AB44168B6C494757CC5A140" toRefs="TextSelection-8224B42439E7CCC8C3C594757DBA701B-0-wk-Footnote-8224B42439E7CCC8C3C594757DBA701B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e12452-wk-Fact-B058DCB1AE06D394D07494757D832A1B" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1503-wk-Fact-B07226375662B3FA103594757D67E5BF" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e3044-wk-Fact-B0814DE9CC612AE11DD594757D3226D5" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e11210-wk-Fact-B09391D35897D9D4E22494757D809B12" toRefs="TextSelection-33990A088D8DAE29233C94757DC283BE-0-wk-Footnote-33990A088D8DAE29233C94757DC283BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e8307-wk-Fact-B0C69CDE8303781F976E94757D9A42B7" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e8307-wk-Fact-B0C69CDE8303781F976E94757D9A42B7" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8351242e4765-wk-Fact-B0EAB8BEE5D94E16A4A394757CB05C4E" toRefs="TextSelection-11358084CF50DEC3FF92628C52236CBA-0-wk-Footnote-11358084CF50DEC3FF92628C52236CBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e3472-wk-Fact-B0FAADCDDE37BDAB2D9594757D5E794A" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e3472-wk-Fact-B0FAADCDDE37BDAB2D9594757D5E794A" toRefs="TextSelection-9BC3436E7B9C00975CD394757DC16C56-0-wk-Footnote-9BC3436E7B9C00975CD394757DC16C56_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2563-wk-Fact-B17D04EC8E4349EFFEF394757D1A00C1" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e3065-wk-Fact-B187FB0A3E73BF7B3DE094757D8267D6" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1802-wk-Fact-B1C06142FF81EF258FE994757DA46AF3" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1166-wk-Fact-B1D6C20091518E36CFA194757CC3358D" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e9442-wk-Fact-B269C96FEDB20D2F2CE794757D1AD759" toRefs="TextSelection-A6E5E77EFF2BB738D44C94757DBDF083-0-wk-Footnote-A6E5E77EFF2BB738D44C94757DBDF083_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e922-wk-Fact-B28669D670A8C56C545994757D2ED7A9" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1096-wk-Fact-B2C102786FCBB8D401A594757D1B8EEE" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2057-wk-Fact-B2CACAAABE963B0BFD8F94757D10087A" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2984-wk-Fact-B33CD1A22EADB7B396EE94757D139837" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8357160e1634-wk-Fact-B35C636D04B27499B3AB94757CCFE464" toRefs="TextSelection-84058C93858F4EB1F00C631013E8EF74-0-wk-Footnote-84058C93858F4EB1F00C631013E8EF74_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e1539-wk-Fact-B35D2CD0AC8469F52A1194757DA775AF" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e1545-wk-Fact-B36E26A497B12F4F06CB94757CFB7641" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e1574-wk-Fact-B38C1AE72C31DF2CFAFA94757CDDB0D8" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e4008-wk-Fact-B39352F261C00A65738694757D51EB5C d8336633e11260-wk-Fact-B39352F261C00A65738694757D51EB5C" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8356748e2364-wk-Fact-B3F82E5E9DDB5FAA6C2D94757D393DCC" toRefs="TextSelection-6979FD063E456189966A94757DC072A0-0-wk-Footnote-6979FD063E456189966A94757DC072A0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1185-wk-Fact-B42383D404EA70302F8C94757D686185" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8301124e1076-wk-Fact-B436D7020EEC746BCB4A94757D090189" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1076-wk-Fact-B436D7020EEC746BCB4A94757D090189" toRefs="TextSelection-8C3C45B5D6B304AC979B94757DB5023F-0-wk-Footnote-8C3C45B5D6B304AC979B94757DB5023F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8357160e2170-wk-Fact-B43FA979F49F2E3A20DE94757CFC75DD d8357160e2208-wk-Fact-B43FA979F49F2E3A20DE94757CFC75DD" toRefs="TextSelection-B511D685B8F037FD258094757DBFC8C5-0-wk-Footnote-B511D685B8F037FD258094757DBFC8C5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e1686-wk-Fact-B46A5ED3FA0B101BE7A594757CD525E3" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2795-wk-Fact-B48CBE8AC02E90DAEA4594757D145DE6" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e4558-wk-Fact-B4AE696827B3D39F948494757D114B10" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e4558-wk-Fact-B4AE696827B3D39F948494757D114B10" toRefs="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e4558-wk-Fact-B4AE696827B3D39F948494757D114B10" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10621-wk-Fact-B53EC4023A670C9BFD9694757CFA2072" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e6010-wk-Fact-B541C3D3DAB4589EDF8994757D7AA019" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e6010-wk-Fact-B541C3D3DAB4589EDF8994757D7AA019" toRefs="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e6010-wk-Fact-B541C3D3DAB4589EDF8994757D7AA019" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e5560-wk-Fact-B54EEE815409E49E0D1894757D4EDBA5" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1453-wk-Fact-B5534107AC881736B01B94757D23BE41" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2000-wk-Fact-B56556CFBF45225D098894757D0D84DC d8301124e911-wk-Fact-B56556CFBF45225D098894757D0D84DC d8336633e1898-wk-Fact-B56556CFBF45225D098894757D0D84DC" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8340406e2000-wk-Fact-B56556CFBF45225D098894757D0D84DC d8301124e911-wk-Fact-B56556CFBF45225D098894757D0D84DC d8336633e1898-wk-Fact-B56556CFBF45225D098894757D0D84DC" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8340406e2000-wk-Fact-B56556CFBF45225D098894757D0D84DC d8301124e911-wk-Fact-B56556CFBF45225D098894757D0D84DC d8336633e1898-wk-Fact-B56556CFBF45225D098894757D0D84DC" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="4" fromRefs="d8340406e2000-wk-Fact-B56556CFBF45225D098894757D0D84DC d8301124e911-wk-Fact-B56556CFBF45225D098894757D0D84DC d8336633e1898-wk-Fact-B56556CFBF45225D098894757D0D84DC" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2182-wk-Fact-B5BD6F0023F06259AE3494757D06AF3E" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2542-wk-Fact-B5E50DD48766F6B1EB8294757CBDBCD9" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e1553-wk-Fact-B628E15DE73F0869904394757D92C37B" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e11135-wk-Fact-B698D162AA64B4E9F22494757CB607DE" toRefs="TextSelection-FE68345D83BB191130EF94757DC1B5E5-0-wk-Footnote-FE68345D83BB191130EF94757DC1B5E5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e9968-wk-Fact-B6F824A1D38474F2D25894757CD26487" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336625e2723-wk-Fact-B6FF2688963BD7DB8BDA94757D710150" toRefs="TextSelection-83180A323F26770F5F9D94757DBB7831-0-wk-Footnote-83180A323F26770F5F9D94757DBB7831_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e11196-wk-Fact-B742EA2DDFFBC1EE5A0694757CB11B81" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8301124e1201-wk-Fact-B756BD8131D12427D5A094757CC10C5E" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1201-wk-Fact-B756BD8131D12427D5A094757CC10C5E" toRefs="TextSelection-8C3C45B5D6B304AC979B94757DB5023F-0-wk-Footnote-8C3C45B5D6B304AC979B94757DB5023F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1246-wk-Fact-B7AFA2301099E9BDE10E94757D091A88" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7600-wk-Fact-B7B4528B4555854FBA2594757D748585" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7600-wk-Fact-B7B4528B4555854FBA2594757D748585" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8307028e883-wk-Fact-B816481FF01850756E6D94757D1C86F4" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e883-wk-Fact-B816481FF01850756E6D94757D1C86F4" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e3904-wk-Fact-B82DC8F0C3F61B78FD6994757D46FE68" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8357160e2240-wk-Fact-B8329B46741B139CE66594757CCCCF54 d8357160e2277-wk-Fact-B8329B46741B139CE66594757CCCCF54" toRefs="TextSelection-84058C93858F4EB1F00C631013E8EF74-0-wk-Footnote-84058C93858F4EB1F00C631013E8EF74_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2456-wk-Fact-B8780C1262D682FB127794757D09FED8" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2210-wk-Fact-B87A51A9779CD1CF018694757CE399DF" toRefs="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e3411-wk-Fact-B92928DFC343D1C01A7994757D3B4E3A" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8357160e1469-wk-Fact-B95DB11055F98712D70094757CD0068E" toRefs="TextSelection-B511D685B8F037FD258094757DBFC8C5-0-wk-Footnote-B511D685B8F037FD258094757DBFC8C5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1268-wk-Fact-B96D2283B28701563E7A94757CF94EFC" toRefs="TextSelection-CDCE760DEFA7F631840C94757DB86187-0-wk-Footnote-CDCE760DEFA7F631840C94757DB86187_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2465-wk-Fact-B98065EB23404AACB87094757D6BD6BE" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336625e4263-wk-Fact-B993CE1535AAAD9D78CF94757D18D0D5" toRefs="TextSelection-F8EDCEC3C21F54D90F7894757DBBCD6D-0-wk-Footnote-F8EDCEC3C21F54D90F7894757DBBCD6D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1169-wk-Fact-B99B2E1079DF1F86DF1A94757D24E100" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e8341-wk-Fact-BA21BD3D4A33641CD2FE94757D8EFCEB" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e8341-wk-Fact-BA21BD3D4A33641CD2FE94757D8EFCEB" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1434-wk-Fact-BA35612EAE6C91BF6D5494757D30D0C0" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e4551-wk-Fact-BB799260ED60F412F4DC94757D59055E" toRefs="TextSelection-AFB627DC6F652A9A0A0594757DC251B0-0-wk-Footnote-AFB627DC6F652A9A0A0594757DC251B0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1450-wk-Fact-BB8522BC4D5C3EA5BD8694757CB166F6 d8312059e1737-wk-Fact-BB8522BC4D5C3EA5BD8694757CB166F6" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e5274-wk-Fact-BBC46AA267DCADC2619E94757D4B1DD3" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e4585-wk-Fact-BBF6210C8041EAAE938194757D0EFB62" toRefs="TextSelection-AFB627DC6F652A9A0A0594757DC251B0-0-wk-Footnote-AFB627DC6F652A9A0A0594757DC251B0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e4457-wk-Fact-BC8DE56F3BD25EC7962894757D5CD864" toRefs="TextSelection-C185F8237D4ED950685B94757DC105E4-0-wk-Footnote-C185F8237D4ED950685B94757DC105E4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2588-wk-Fact-BCA7EB2A102DF56C060B94757D2C4CD4" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e5876-wk-Fact-BCDF3704B801D84F71C794757D8BEE37" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e5876-wk-Fact-BCDF3704B801D84F71C794757D8BEE37" toRefs="TextSelection-6EDC28E4739B45A7AA7C94757DBD8D30-0-wk-Footnote-6EDC28E4739B45A7AA7C94757DBD8D30_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e5876-wk-Fact-BCDF3704B801D84F71C794757D8BEE37" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1277-wk-Fact-BCE8A138729B45E61B7F94757D2C3132 d8351242e8312-wk-Fact-BCE8A138729B45E61B7F94757D2C3132" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e4897-wk-Fact-BD0329CC1D00D62B9E9F94757D234485" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7321-wk-Fact-BD41F7186105B7884BC694757D5BC2AE" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7321-wk-Fact-BD41F7186105B7884BC694757D5BC2AE" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2445-wk-Fact-BDC31C12896D043747B194757D5B35D6" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1757-wk-Fact-BDC4E0314FD64F1F888394757D72DA26" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2102-wk-Fact-BE013A8321BCFA54741E94757D80A8CE" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1441-wk-Fact-BE2B9931D467A3220D4894757CFCC65C d8336625e4068-wk-Fact-BE2B9931D467A3220D4894757CFCC65C" toRefs="TextSelection-467F12A5D203A9A15C3A94757DB81B0A-0-wk-Footnote-467F12A5D203A9A15C3A94757DB81B0A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8316808e1441-wk-Fact-BE2B9931D467A3220D4894757CFCC65C d8336625e4068-wk-Fact-BE2B9931D467A3220D4894757CFCC65C" toRefs="TextSelection-9F5C431DBFAA147134E594757DBBC55E-0-wk-Footnote-9F5C431DBFAA147134E594757DBBC55E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e7319-wk-Fact-BE33935DCA8AF32376B994757D5F4D6D" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e8327-wk-Fact-BEED3353022DC3D9583494757DA5ED38" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e8327-wk-Fact-BEED3353022DC3D9583494757DA5ED38" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e9340-wk-Fact-BFBC825D4CA85CD2E41D94757CB1220B" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e9919-wk-Fact-BFD0D11A54AFC7EC342E94757D4DA77D" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2410-wk-Fact-BFED46F6560D1E80618094757D5C3010" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e11215-wk-Fact-C04FC7C13AC6C8C6DD6594757CB52AB5" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1349-wk-Fact-C06B1B3B80ECC6BED32E94757D69AF05" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e12586-wk-Fact-C072E92255A07EC2BC3294757CB644FB" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10080-wk-Fact-C076F9FF805FD19B813594757D054DF5" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2756-wk-Fact-C0AA245678498A8977C494757D60CCA2" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8351242e7359-wk-Fact-C0B91802E709F9C8087C94757D805460" toRefs="TextSelection-DA70407E988FF7F4292CB0A472718D04-0-wk-Footnote-DA70407E988FF7F4292CB0A472718D04_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1188-wk-Fact-C1A3AA27451A8B8C11F594757D159C90" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1594-wk-Fact-C1DCC252D5C1E6770C2A94757D2726E3" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e6843-wk-Fact-C1DE3E07544739B2E3BC94757CEAD328" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8357160e3522-wk-Fact-C25CFEE5C6642AEA5F2D94757D52C936" toRefs="TextSelection-2DE900A873C344A165FE94757DBF7A4D-0-wk-Footnote-2DE900A873C344A165FE94757DBF7A4D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1546-wk-Fact-C2CB94D8321D93BAD2DD94757D57F0A3" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336625e2606-wk-Fact-C2D1AFE34B96F2CC1CC194757D6DD63A" toRefs="TextSelection-83180A323F26770F5F9D94757DBB7831-0-wk-Footnote-83180A323F26770F5F9D94757DBB7831_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e11158-wk-Fact-C3A560E1E22FD2CFF01C94757CA92EB0" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e12625-wk-Fact-C3BB46722B4E99BC08FB94757D912C94" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e7679-wk-Fact-C3E7A0CC1F9E87A7290394757D55B8EE" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e3386-wk-Fact-C42CFD3A1CA3D15C54F494757D5933EF" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1632-wk-Fact-C461CCF052CAC13CE0B494757D759AEB" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e12438-wk-Fact-C4994D3207A335AAB81294757D8D7CB7" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e9899-wk-Fact-C5060A64152E4CD16E7D94757D9B8FAB" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8351242e4803-wk-Fact-C5258C9AE0E9A683474194757D833A8F" toRefs="TextSelection-11358084CF50DEC3FF92628C52236CBA-0-wk-Footnote-11358084CF50DEC3FF92628C52236CBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8301124e1116-wk-Fact-C54AB828E036C88403BC94757CCD9057" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1116-wk-Fact-C54AB828E036C88403BC94757CCD9057" toRefs="TextSelection-8C3C45B5D6B304AC979B94757DB5023F-0-wk-Footnote-8C3C45B5D6B304AC979B94757DB5023F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e5765-wk-Fact-C5B823B21E48CD41CEFE94757CE0A878" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2099-wk-Fact-C5EA1CFA2BAB5B0EAA7094757D07F215" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e7872-wk-Fact-C6B8B0E3BE0B6E14FCC394757D2F7284 d8336633e15138-wk-Fact-C6B8B0E3BE0B6E14FCC394757D2F7284" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e1998-wk-Fact-C6C094F211EFE1192A7994757D666DEC" toRefs="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8357160e1389-wk-Fact-C6E2684E0011DA4FD7EC94757CCDA666" toRefs="TextSelection-B511D685B8F037FD258094757DBFC8C5-0-wk-Footnote-B511D685B8F037FD258094757DBFC8C5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2887-wk-Fact-C6F72F041602CA931A9F94757D2D2964" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e1613-wk-Fact-C7083099744AE4148D4994757D2CC599" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1352-wk-Fact-C73E7DEFCE404DDC8E6A94757CFD4810" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e1459-wk-Fact-C74CEACCB68A148A68AC94757CC0788F" toRefs="TextSelection-D29E26CC6CF7C6248CEE94757DBD9743-0-wk-Footnote-D29E26CC6CF7C6248CEE94757DBD9743_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8301124e1460-wk-Fact-C78E60BC91B631C2A94794757CC3905D" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1460-wk-Fact-C78E60BC91B631C2A94794757CC3905D" toRefs="TextSelection-A6080F3BC2CE36268D0F94757DB590DE-0-wk-Footnote-A6080F3BC2CE36268D0F94757DB590DE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1822-wk-Fact-C7C942686CBC263C1D7194757CC2FF25" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e3281-wk-Fact-C825A8BB25BE38B63BB194757D30A6AC d8356748e2279-wk-Fact-C825A8BB25BE38B63BB194757D30A6AC" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7639-wk-Fact-C8791891FDD5606F4FF0955D6DF370FF" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7639-wk-Fact-C8791891FDD5606F4FF0955D6DF370FF" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8357160e1817-wk-Fact-C88BA43C1A9DADCD4A5494757CC8E62B d8357160e2565-wk-Fact-C88BA43C1A9DADCD4A5494757CC8E62B" toRefs="TextSelection-76B1871DA30219820FCB63105DB9E5C3-0-wk-Footnote-76B1871DA30219820FCB63105DB9E5C3_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1470-wk-Fact-C8984FE48C4ADA9BA0CA94757CCB4FED d8312059e1757-wk-Fact-C8984FE48C4ADA9BA0CA94757CCB4FED" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1853-wk-Fact-C920A45D5E66EC197B2A94757CF0CD54 d8356748e1121-wk-Fact-C920A45D5E66EC197B2A94757CF0CD54" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e2598-wk-Fact-C938A9B7922E6371EB0F94757CEF9930" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e1653-wk-Fact-C9BE48676477EEA3C2DA94757CE814D1" toRefs="TextSelection-B06D4F08D7061C0CFA5894757DB76AD8-0-wk-Footnote-B06D4F08D7061C0CFA5894757DB76AD8_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e7126-wk-Fact-CA0C786AD2F0B41A91817DAA79E6E7CB" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e5877-wk-Fact-CAAA50A9A982EC80885B94757CFEC886" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1483-wk-Fact-CAC433338BBE1188257594757D6FCE44" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8357160e1693-wk-Fact-CAF20A4833F6E5216BE394757CF277B4" toRefs="TextSelection-84058C93858F4EB1F00C631013E8EF74-0-wk-Footnote-84058C93858F4EB1F00C631013E8EF74_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e3923-wk-Fact-CAF86E02454555A404D294757CCA9409" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10340-wk-Fact-CB04EC46BE3C2AE76E6E94757D59A008" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e11096-wk-Fact-CB195E4B49470C94E41C94757D5B8154" toRefs="TextSelection-FE68345D83BB191130EF94757DC1B5E5-0-wk-Footnote-FE68345D83BB191130EF94757DC1B5E5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e8063-wk-Fact-CB1E1E66274A527AAF7194757D9AD724" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e8063-wk-Fact-CB1E1E66274A527AAF7194757D9AD724" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1686-wk-Fact-CB3CE131F76D1BC5C4AF94757D6BFF4D" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1547-wk-Fact-CBF2AF5A3799937C03F394757CFD6A73" toRefs="TextSelection-1DD42ADAC2DF4C519E7594757DB84698-0-wk-Footnote-1DD42ADAC2DF4C519E7594757DB84698_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e8901-wk-Fact-CC73D199AFE6851BDA0294757CAED89E" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e5228-wk-Fact-CC96A91FB3B7AD21FC6E94757CCDA70E" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e5228-wk-Fact-CC96A91FB3B7AD21FC6E94757CCDA70E" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8308070e2119-wk-Fact-CCC6307773ADBF2D8B0394757D147293" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2119-wk-Fact-CCC6307773ADBF2D8B0394757D147293" toRefs="TextSelection-4E9FC68D27E299B9BB2A92DC4EB2F91A-0-wk-Footnote-4E9FC68D27E299B9BB2A92DC4EB2F91A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e14386-wk-Fact-CCC935C176C282D817B794757CBC059A" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1527-wk-Fact-CCE3024E0C6DEE0D773194757D1EE899" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e1615-wk-Fact-CD30CA356357FE6A950B94757CE59164" toRefs="TextSelection-B06D4F08D7061C0CFA5894757DB76AD8-0-wk-Footnote-B06D4F08D7061C0CFA5894757DB76AD8_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2390-wk-Fact-CD69F0255956248BF5A794757CDCB6CF" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e5248-wk-Fact-CD7B6D54813C77F7056C94757CCBF9C3" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e5248-wk-Fact-CD7B6D54813C77F7056C94757CCBF9C3" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e3262-wk-Fact-CDED57DD355FBFDCE83394757D0D0D08 d8356748e2260-wk-Fact-CDED57DD355FBFDCE83394757D0D0D08" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e3407-wk-Fact-CE26F77FF346C4DE6B0594757D644E3B" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e3179-wk-Fact-CEDDD667A11CAC08820D94757D0E749E d8356748e2094-wk-Fact-CEDDD667A11CAC08820D94757D0E749E" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1640-wk-Fact-CF088F9FE2A75408C8A794757D1586DE d8316808e2277-wk-Fact-CF088F9FE2A75408C8A794757D1586DE" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1677-wk-Fact-CF4867B1F96B94735AD594757D0E90B4" toRefs="TextSelection-16CE381F2099EFC2DA1C94757DB87C39-0-wk-Footnote-16CE381F2099EFC2DA1C94757DB87C39_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e10445-wk-Fact-CF51E0E503957DBEE07394757CACD840" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e5790-wk-Fact-CFA8D8DE9A17CA78BDB894757CE71BFF" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e2897-wk-Fact-CFC646220F28061D991894757D5C03BB" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1233-wk-Fact-CFF1903136C1AC56DF3A94757D2B131B d8351242e8351-wk-Fact-CFF1903136C1AC56DF3A94757D2B131B" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e2131-wk-Fact-D01BD086F56ADFA6D29E94757CD09A97" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2456-wk-Fact-D037126BFACE01B81D3B94757D11D201" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1917-wk-Fact-D0B1BB14EB1C0097910C94757D5D09B2 d8356748e1512-wk-Fact-D0B1BB14EB1C0097910C94757D5D09B2" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e14084-wk-Fact-D10B00BA2429F63E86A694757CAB096A" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e7219-wk-Fact-D17741D648E58B172B9E94757D81B725" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e7219-wk-Fact-D17741D648E58B172B9E94757D81B725" toRefs="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e7219-wk-Fact-D17741D648E58B172B9E94757D81B725" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e985-wk-Fact-D1A152F767D859E8CCE694757CBAD374" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e3568-wk-Fact-D21BDBDB5A3496D15C0F94757CC0FECE" toRefs="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8336633e3568-wk-Fact-D21BDBDB5A3496D15C0F94757CC0FECE" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e2819-wk-Fact-D2552EB7B44850CC209094757CF5FB9B" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1100-wk-Fact-D29057E6A396E534364794757CF999F3" toRefs="TextSelection-4E74A09462C596E2363694757DB8EB14-0-wk-Footnote-4E74A09462C596E2363694757DB8EB14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10526-wk-Fact-D299C7D480FAACA386FA94757CA95699" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2892-wk-Fact-D2B6E10475D8BB804CE094757CFEFBD9" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e4175-wk-Fact-D2F433B8AA4C0088F7B694757DA65630 d8336633e11427-wk-Fact-D2F433B8AA4C0088F7B694757DA65630" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e5598-wk-Fact-D2F686C8FF4197FE1E1D94757D4328BD" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e1979-wk-Fact-D32BE49AC04B6AB1E7A894757CE0BC21" toRefs="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e7705-wk-Fact-D37856BCED8C1D2C7F3494757D99EE35 d8336633e14971-wk-Fact-D37856BCED8C1D2C7F3494757D99EE35" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e2046-wk-Fact-D38C84ADA6DF1DEBDA9794757CDF6D15" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10908-wk-Fact-D421852A3121926EC88F94757D45D1D2" toRefs="TextSelection-D895C9E8DF19B244540094757DC27744-0-wk-Footnote-D895C9E8DF19B244540094757DC27744_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e6551-wk-Fact-D43F780191672677C09E94757CEA1326" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e3657-wk-Fact-D46584CE1C6A5715E12694757D220D63" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e5895-wk-Fact-D529846875F26AE83EA994757D27042F" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e5895-wk-Fact-D529846875F26AE83EA994757D27042F" toRefs="TextSelection-6EDC28E4739B45A7AA7C94757DBD8D30-0-wk-Footnote-6EDC28E4739B45A7AA7C94757DBD8D30_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e5895-wk-Fact-D529846875F26AE83EA994757D27042F" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e3362-wk-Fact-D581CDA4BE4F221B6C2C94757D180462" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e3362-wk-Fact-D581CDA4BE4F221B6C2C94757D180462" toRefs="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e3362-wk-Fact-D581CDA4BE4F221B6C2C94757D180462" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e1467-wk-Fact-D58E0C9AEC0FAB141C2794757D361983" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2926-wk-Fact-D5B6EF098B9CCBC6106394757D9FD69A" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1004-wk-Fact-D5D209CEACE094C3706A94757D602BEE" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2126-wk-Fact-D607D2703E69C5FECFE694757CDCD329" toRefs="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8351242e3371-wk-Fact-D62B36AD2263CAB0455594757CBD05B4" toRefs="TextSelection-8224B42439E7CCC8C3C594757DBA701B-0-wk-Footnote-8224B42439E7CCC8C3C594757DBA701B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1496-wk-Fact-D68E718B4C6944A5CD6A94757CD29C96" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2437-wk-Fact-D6AF3AA50A2C3B4FED5094757D009316" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2092-wk-Fact-D6CFF981EC1FB58C377894757D2A6D00" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2035-wk-Fact-D6F7C72544CA78BD37CE94757D0672FB" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e2147-wk-Fact-D71486B20EB7956A050C94757CCBBD46" toRefs="TextSelection-420C4A044883B0052AE85E76395259A9-0-wk-Footnote-420C4A044883B0052AE85E76395259A9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e13707-wk-Fact-D73A14317FBAE5FF36E694757CA8E1DF" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e10896-wk-Fact-D75526E67D4914D634987DAA85CEF4A3" toRefs="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8336633e10896-wk-Fact-D75526E67D4914D634987DAA85CEF4A3" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e10391-wk-Fact-D75B034453F0D830B56B94757CB44AE9" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e3072-wk-Fact-D797AF9402BF1599A6F594757D5776AE" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e9322-wk-Fact-D7D683B723E19620193294757D1D9320" toRefs="TextSelection-A6E5E77EFF2BB738D44C94757DBDF083-0-wk-Footnote-A6E5E77EFF2BB738D44C94757DBDF083_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2500-wk-Fact-D7ECD9F4548C3411A1AB94757D1B3553" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e8801-wk-Fact-D86287A5407ADF62135F94757CB299CF" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2190-wk-Fact-D935FF0C642A1173F2D694757D1F4344" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1302-wk-Fact-D948D8A0A120E105480A94757D261CF9" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2118-wk-Fact-D9A205E489D5B6E9EB3A94757D04C021" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e8768-wk-Fact-D9ACACC3158032862FBC94757CBB3D3D" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1497-wk-Fact-DAA11F34E77442AAEC1894757D191631" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2964-wk-Fact-DAA4B71118EB1D4285A994757D1B59B8" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e9035-wk-Fact-DB4CC75A37E92F7B141794757D9F9E31" toRefs="TextSelection-FE68345D83BB191130EF94757DC1B5E5-0-wk-Footnote-FE68345D83BB191130EF94757DC1B5E5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2951-wk-Fact-DB5758891218A2CD53FA94757D09D2D4" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1529-wk-Fact-DBC68DCD2CB0DEC8D8FB94757D61B962" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e7119-wk-Fact-DC149FAE791DF73A9F4E94757CEB25E2" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e7119-wk-Fact-DC149FAE791DF73A9F4E94757CEB25E2" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1896-wk-Fact-DC5D094960D8362E8AE194757D1CEABE" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e1623-wk-Fact-DD285CCCCC909E22C8F494757CF80EDC" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e3223-wk-Fact-DD2C0BC1E91919220B7394757CCC3C6C" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e3223-wk-Fact-DD2C0BC1E91919220B7394757CCC3C6C" toRefs="TextSelection-6EDC28E4739B45A7AA7C94757DBD8D30-0-wk-Footnote-6EDC28E4739B45A7AA7C94757DBD8D30_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e3223-wk-Fact-DD2C0BC1E91919220B7394757CCC3C6C" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2725-wk-Fact-DD3041593AC72587B67894757D2924BD" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7472-wk-Fact-DD66129D925AD6B2D1A4955D6DF5306E" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7472-wk-Fact-DD66129D925AD6B2D1A4955D6DF5306E" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e1482-wk-Fact-DD70750D757F8E36AEFE94757D511014 d8312059e3483-wk-Fact-DD70750D757F8E36AEFE94757D511014" toRefs="TextSelection-A2331388F2C895076E3994757DB73022-0-wk-Footnote-A2331388F2C895076E3994757DB73022_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e3644-wk-Fact-DDAEB6E7FE68CC5DB4FB7DAAEFDFB98D" toRefs="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8336633e3644-wk-Fact-DDAEB6E7FE68CC5DB4FB7DAAEFDFB98D" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7247-wk-Fact-DDBF519A26B8B268AC5394757D7DE917" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7247-wk-Fact-DDBF519A26B8B268AC5394757D7DE917" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e6260-wk-Fact-DDE80D633A2B28C2D4B194757D63F34A" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e4508-wk-Fact-DE2B16204B073DAB2AEC94757CBCDCAA" toRefs="TextSelection-C185F8237D4ED950685B94757DC105E4-0-wk-Footnote-C185F8237D4ED950685B94757DC105E4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1656-wk-Fact-DE3B1C32E7AF56EA37C694757CFE73CD" toRefs="TextSelection-16CE381F2099EFC2DA1C94757DB87C39-0-wk-Footnote-16CE381F2099EFC2DA1C94757DB87C39_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2210-wk-Fact-DE8B64A6B5C352DD3FEB94757D21E4DC" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8308070e1621-wk-Fact-DEA22D82FF9A17E3E27894757D6F6298" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1621-wk-Fact-DEA22D82FF9A17E3E27894757D6F6298" toRefs="TextSelection-4E9FC68D27E299B9BB2A92DC4EB2F91A-0-wk-Footnote-4E9FC68D27E299B9BB2A92DC4EB2F91A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e1549-wk-Fact-DEE82D8D87D1D1AA50F194757CE0C55D" toRefs="TextSelection-AB3DF04F3446139615AC94757DB7D909-0-wk-Footnote-AB3DF04F3446139615AC94757DB7D909_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e3301-wk-Fact-DF27017CA613A930B87894757D82C5EA" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e8715-wk-Fact-DF376F2902A29228A30394757D95B369" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e8787-wk-Fact-DFAA9788CAC84F0B9CBE94757D9006BC" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e4135-wk-Fact-DFF13E5F684FBEC9822394757D143E71 d8336633e11387-wk-Fact-DFF13E5F684FBEC9822394757D143E71" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e6428-wk-Fact-DFF51302F0E70A31845B94757D802056" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e6305-wk-Fact-E0BAE04C3F7AAC74123D94757D287414" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e1530-wk-Fact-E0F430906659E697076D94757CE4D373" toRefs="TextSelection-AB3DF04F3446139615AC94757DB7D909-0-wk-Footnote-AB3DF04F3446139615AC94757DB7D909_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8351242e3315-wk-Fact-E1670DD42B676FA2293C94757D4E7C71" toRefs="TextSelection-8224B42439E7CCC8C3C594757DBA701B-0-wk-Footnote-8224B42439E7CCC8C3C594757DBA701B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1680-wk-Fact-E1C7AF863456D04209EB94757D12EC91 d8329819e1116-wk-Fact-E1C7AF863456D04209EB94757D12EC91" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10266-wk-Fact-E2B7192F841B652DD3E194757D025EED" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1277-wk-Fact-E385EE5548C3D0B6620294757D260E17" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8308070e1641-wk-Fact-E3F1771420A95515D37594757D7358CA" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1641-wk-Fact-E3F1771420A95515D37594757D7358CA" toRefs="TextSelection-4E9FC68D27E299B9BB2A92DC4EB2F91A-0-wk-Footnote-4E9FC68D27E299B9BB2A92DC4EB2F91A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e5633-wk-Fact-E4061A0544587530FE5694757D9C3208" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e1769-wk-Fact-E484E0BFE436CFD6A91994757CF4398D" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e14945-wk-Fact-E4A62043A54AC1E498B094757CACAA7C" toRefs="TextSelection-DD7734E5853B41ABE8C8546D7049626E-0-wk-Footnote-DD7734E5853B41ABE8C8546D7049626E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8336633e14945-wk-Fact-E4A62043A54AC1E498B094757CACAA7C" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1125-wk-Fact-E50549595D0042E610B994757D288E28" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2324-wk-Fact-E5344C9D61E5386447CC94757D5DBD84" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e8734-wk-Fact-E53668C499D5B6EED42794757CBA0E04" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10640-wk-Fact-E5461C2F47C5805246B594757CD11E3E" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336625e4243-wk-Fact-E5773A2CC07AA52848B394757D195108" toRefs="TextSelection-F8EDCEC3C21F54D90F7894757DBBCD6D-0-wk-Footnote-F8EDCEC3C21F54D90F7894757DBBCD6D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e8251-wk-Fact-E5ACC24ECADCC36DF22594757D7E0534" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e8251-wk-Fact-E5ACC24ECADCC36DF22594757D7E0534" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2137-wk-Fact-E5B2171A194CD45335C794757CE7F3C1" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e3386-wk-Fact-E5ED2D8BFF7F93B9B97494757D832764" toRefs="TextSelection-B92DE04072B96160C46394757DB7ADA1-0-wk-Footnote-B92DE04072B96160C46394757DB7ADA1_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e10971-wk-Fact-E660298A415643D957F994757D82F91C" toRefs="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8336633e10971-wk-Fact-E660298A415643D957F994757D82F91C" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e4194-wk-Fact-E682A060B9E084CD78DB94757CBF7369 d8336633e11446-wk-Fact-E682A060B9E084CD78DB94757CBF7369" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e10506-wk-Fact-E6A6BB806B084AB6D48994757D8EAE58" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8308070e1031-wk-Fact-E717A38DCA77168761C894757CC8AD9A" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e1031-wk-Fact-E717A38DCA77168761C894757CC8AD9A" toRefs="TextSelection-FE05511B3F59D62E086994757DB6CDC4-0-wk-Footnote-FE05511B3F59D62E086994757DB6CDC4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2523-wk-Fact-E756C4C43674CBFEFEA494757CE1093D" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2544-wk-Fact-E75C406B14955CDB7D3B94757D138744" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2608-wk-Fact-E78126B8699A77F8DCC594757D1B1CAA" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e4618-wk-Fact-E7A174C8A21CBC1EF5C394757D1205B4" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e4618-wk-Fact-E7A174C8A21CBC1EF5C394757D1205B4" toRefs="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e4618-wk-Fact-E7A174C8A21CBC1EF5C394757D1205B4" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2540-wk-Fact-E7D7D44563418D8D6DC894757D062085" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7951-wk-Fact-E7F68194ACA2953195D194757D3ADA6D" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7951-wk-Fact-E7F68194ACA2953195D194757D3ADA6D" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2190-wk-Fact-E80F3653B15E3D94B76194757D344502" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e10820-wk-Fact-E82571DEE2C15F9E1D7094757D82377C" toRefs="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8336633e10820-wk-Fact-E82571DEE2C15F9E1D7094757D82377C" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2990-wk-Fact-E8491F91CE829080A31A94757CDF3CE5" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8307028e1037-wk-Fact-E854D651F5C65603680B94757D20C5D0 d8342960e985-wk-Fact-E854D651F5C65603680B94757D20C5D0" toRefs="TextSelection-6816050F6F7DBFCD3C5B94757DBEA485-0-wk-Footnote-6816050F6F7DBFCD3C5B94757DBEA485_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1037-wk-Fact-E854D651F5C65603680B94757D20C5D0 d8342960e985-wk-Fact-E854D651F5C65603680B94757D20C5D0" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372420e5765-wk-Fact-E864359E96F7D020F0CE94757D7CD99F" toRefs="TextSelection-286F4719195A28A9913594757DC0B1B8-0-wk-Footnote-286F4719195A28A9913594757DC0B1B8_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2632-wk-Fact-E8B0E5833864611B38D294757CAF72E7" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e4578-wk-Fact-E8B92084BD875BA1E86894757D134EDA" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e4578-wk-Fact-E8B92084BD875BA1E86894757D134EDA" toRefs="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e4578-wk-Fact-E8B92084BD875BA1E86894757D134EDA" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e1462-wk-Fact-E911ACF0DB03AEB6DA8594757CE5E26F" toRefs="TextSelection-A2331388F2C895076E3994757DB73022-0-wk-Footnote-A2331388F2C895076E3994757DB73022_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e3040-wk-Fact-EA0DB488C3931FDD51EB94757D052620" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-EA1E0B8D16648EC1813394757CDA0B29-wk-Fact-EA1E0B8D16648EC1813394757CDA0B29" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2695-wk-Fact-EA79252BF7CF8534CF3894757D00B0A3 d8314038e2466-wk-Fact-EA79252BF7CF8534CF3894757D00B0A3" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8301124e1481-wk-Fact-EAC3B24ACD51EAB9C1FF94757CE2E89A" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1481-wk-Fact-EAC3B24ACD51EAB9C1FF94757CE2E89A" toRefs="TextSelection-A6080F3BC2CE36268D0F94757DB590DE-0-wk-Footnote-A6080F3BC2CE36268D0F94757DB590DE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e4916-wk-Fact-EB1FC1F3016D395DFAD794757D2A199B" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7267-wk-Fact-EB6D0A7F7C143C2F6D1E94757D00635E" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7267-wk-Fact-EB6D0A7F7C143C2F6D1E94757D00635E" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7970-wk-Fact-EBD6CF2E62976239B60E94757D5080D2" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7970-wk-Fact-EBD6CF2E62976239B60E94757D5080D2" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1822-wk-Fact-EC1267F1CEEA206E48DB94757D3D71EF" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e6678-wk-Fact-EC785A34B39A8E6060B794757DA5646C" toRefs="TextSelection-FE68345D83BB191130EF94757DC1B5E5-0-wk-Footnote-FE68345D83BB191130EF94757DC1B5E5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2121-wk-Fact-ED12AC0ED4563B7B91D294757D6E4FFF" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e7758-wk-Fact-ED5AE72D950E62950F0794757CE72E3D d8336633e15024-wk-Fact-ED5AE72D950E62950F0794757CE72E3D" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2240-wk-Fact-ED78EBC18DA3BA3A4CA194757DA645DC" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8357160e1654-wk-Fact-ED8B7846450D797501C094757CFAC023" toRefs="TextSelection-84058C93858F4EB1F00C631013E8EF74-0-wk-Footnote-84058C93858F4EB1F00C631013E8EF74_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10472-wk-Fact-EE3B286DC2CC60A1348594757D084ADB" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1119-wk-Fact-EE4346B259E22FC41F1F94757CFCEB7F" toRefs="TextSelection-4E74A09462C596E2363694757DB8EB14-0-wk-Footnote-4E74A09462C596E2363694757DB8EB14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e10429-wk-Fact-EE5FCC32DD1F49FD716794757D8499D5" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2755-wk-Fact-EF6B358EA8E9123BB65194757D5C81E7 d8314038e2526-wk-Fact-EF6B358EA8E9123BB65194757D5C81E7" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1827-wk-Fact-EF93AF87BA61CC2CECEB94757CBC24E3" toRefs="TextSelection-23DF6508A1F2A3B1745994757DB98CA0-0-wk-Footnote-23DF6508A1F2A3B1745994757DB98CA0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e14514-wk-Fact-EFC543C17B8D59BB663F94757CAE19EF" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e3510-wk-Fact-F040B63D0E69CA163CDE94757D8588FB" toRefs="TextSelection-823D9AE8DB976ECBCA9594757DB72C08-0-wk-Footnote-823D9AE8DB976ECBCA9594757DB72C08_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e3014-wk-Fact-F0D947E3D319A071650894757D8FBF1A" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8351242e7301-wk-Fact-F107D07691956E457F2694757D819FCD" toRefs="TextSelection-DA70407E988FF7F4292CB0A472718D04-0-wk-Footnote-DA70407E988FF7F4292CB0A472718D04_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10733-wk-Fact-F1157F3F3D62CE169F0094757CD5A45F" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e4094-wk-Fact-F12EBCA49A1647F7C9C194757CB75C07 d8336633e11346-wk-Fact-F12EBCA49A1647F7C9C194757CB75C07" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8301124e1137-wk-Fact-F13DA5DDDB9A69F13A7994757D8778B5" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1137-wk-Fact-F13DA5DDDB9A69F13A7994757D8778B5" toRefs="TextSelection-8C3C45B5D6B304AC979B94757DB5023F-0-wk-Footnote-8C3C45B5D6B304AC979B94757DB5023F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1886-wk-Fact-F175F1A05A293F5B33DF94757DA50565" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e1486-wk-Fact-F17EC0EBDAE2EB6346E094757D109BAC" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2575-wk-Fact-F181CF0072905CD126F394757D6959D8" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e10410-wk-Fact-F2364CCA95BCB9FF67BA94757CBE23AB" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e1526-wk-Fact-F24CEBFF8EB173EDA53294757CD99979" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2873-wk-Fact-F25133D545839D7AE1D294757D02FFFC" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1833-wk-Fact-F28698BCE434ADB508FA94757D1736FA" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10212-wk-Fact-F2DA33B091A2333965BF94757D0DA3A2" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8308070e2001-wk-Fact-F2E6F2C6A9C76A98DCDF94757D59E284" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e7184-wk-Fact-F2F1A0934B119BCED20494757D9F5C1A" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2253-wk-Fact-F30E96B44D3E4509219994757D1F511F" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e1520-wk-Fact-F3381BD200AEE22A790894757D7247BF" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7931-wk-Fact-F35FE93745C53320FB9394757D667FF4" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7931-wk-Fact-F35FE93745C53320FB9394757D667FF4" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e1500-wk-Fact-F3A733B52C3E9E10B03494757CDA0945" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e10911-wk-Fact-F3B0AC6951DEEF5E98DC94757CA9786E" toRefs="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8336633e10911-wk-Fact-F3B0AC6951DEEF5E98DC94757CA9786E" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2076-wk-Fact-F3EB43E530A63806272994757D14737C" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7526-wk-Fact-F438821E9550CEA8E25A94757D043BA1" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7526-wk-Fact-F438821E9550CEA8E25A94757D043BA1" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e9987-wk-Fact-F43BB2EB7D4C6E45428094757CDA03D2" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e5784-wk-Fact-F44ADBD39CBA320A835394757D7CED0E" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e7105-wk-Fact-F48D67680627D6924C7394757D8E45FB" toRefs="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8415180e7105-wk-Fact-F48D67680627D6924C7394757D8E45FB" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336625e2567-wk-Fact-F4AF4992B1DFCF6708C794757D66A5A2 d8336625e2644-wk-Fact-F4AF4992B1DFCF6708C794757D66A5A2" toRefs="TextSelection-83180A323F26770F5F9D94757DBB7831-0-wk-Footnote-83180A323F26770F5F9D94757DBB7831_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e4621-wk-Fact-F4C1ADE521CCDFE17FBB94757D99CF2B" toRefs="TextSelection-AFB627DC6F652A9A0A0594757DC251B0-0-wk-Footnote-AFB627DC6F652A9A0A0594757DC251B0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e7601-wk-Fact-F53C3D63E9620E8FB80594757CCA75EE" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e2038-wk-Fact-F55F7448D6FD457E7D3094757CC42D99 d8301124e950-wk-Fact-F55F7448D6FD457E7D3094757CC42D99 d8336633e9146-wk-Fact-F55F7448D6FD457E7D3094757CC42D99 d8308070e858-wk-Fact-F55F7448D6FD457E7D3094757CC42D99" toRefs="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8340406e2038-wk-Fact-F55F7448D6FD457E7D3094757CC42D99 d8301124e950-wk-Fact-F55F7448D6FD457E7D3094757CC42D99 d8336633e9146-wk-Fact-F55F7448D6FD457E7D3094757CC42D99 d8308070e858-wk-Fact-F55F7448D6FD457E7D3094757CC42D99" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8340406e2038-wk-Fact-F55F7448D6FD457E7D3094757CC42D99 d8301124e950-wk-Fact-F55F7448D6FD457E7D3094757CC42D99 d8336633e9146-wk-Fact-F55F7448D6FD457E7D3094757CC42D99 d8308070e858-wk-Fact-F55F7448D6FD457E7D3094757CC42D99" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="4" fromRefs="d8340406e2038-wk-Fact-F55F7448D6FD457E7D3094757CC42D99 d8301124e950-wk-Fact-F55F7448D6FD457E7D3094757CC42D99 d8336633e9146-wk-Fact-F55F7448D6FD457E7D3094757CC42D99 d8308070e858-wk-Fact-F55F7448D6FD457E7D3094757CC42D99" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1847-wk-Fact-F581216089FF320C328694757CD49968" toRefs="TextSelection-23DF6508A1F2A3B1745994757DB98CA0-0-wk-Footnote-23DF6508A1F2A3B1745994757DB98CA0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8357160e1615-wk-Fact-F5BA4E904B30B0A0A9DC94757CCE56D0" toRefs="TextSelection-84058C93858F4EB1F00C631013E8EF74-0-wk-Footnote-84058C93858F4EB1F00C631013E8EF74_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e2229-wk-Fact-F5BC31DCC6B0367BD58894757CDB9BE9" toRefs="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1266-wk-Fact-F5E011F8B735031318D994757D0A265D" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e1286-wk-Fact-F618699466962C9B165B94757CEEF703" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2744-wk-Fact-F68119AE4BA283A0E74494757D5699A2" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e7812-wk-Fact-F6DA9F6F4CDC4D1208C294757D3DEB55 d8336633e15078-wk-Fact-F6DA9F6F4CDC4D1208C294757D3DEB55" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10433-wk-Fact-F7818AB402D4FDFA360A94757D088A7E" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336625e2664-wk-Fact-F783B181694B408C809794757D6B5422" toRefs="TextSelection-83180A323F26770F5F9D94757DBB7831-0-wk-Footnote-83180A323F26770F5F9D94757DBB7831_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8312059e1634-wk-Fact-F7DAC00A60C60846547B94757CE11E6F" toRefs="TextSelection-B06D4F08D7061C0CFA5894757DB76AD8-0-wk-Footnote-B06D4F08D7061C0CFA5894757DB76AD8_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e3343-wk-Fact-F7F177E6405946748C2A94757D258C32" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e3343-wk-Fact-F7F177E6405946748C2A94757D258C32" toRefs="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e3343-wk-Fact-F7F177E6405946748C2A94757D258C32" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1808-wk-Fact-F8480927DA2450FB9AB294757D637386" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e3434-wk-Fact-F86B001A7C15B351060B94757CD7A389" toRefs="TextSelection-9BC3436E7B9C00975CD394757DC16C56-0-wk-Footnote-9BC3436E7B9C00975CD394757DC16C56_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e5745-wk-Fact-F90EF4CFE321BC6F7A3494757D56ED60" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1768-wk-Fact-F92309C5686C80B6F12094757D26F9AA" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336625e2683-wk-Fact-F98C90F9224CC0E01A5794757D69B0D8" toRefs="TextSelection-83180A323F26770F5F9D94757DBB7831-0-wk-Footnote-83180A323F26770F5F9D94757DBB7831_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8301124e2827-wk-Fact-F996AE0BB974A9291E5D94757CB473E1 d8336633e9380-wk-Fact-F996AE0BB974A9291E5D94757CB473E1" toRefs="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8301124e2827-wk-Fact-F996AE0BB974A9291E5D94757CB473E1 d8336633e9380-wk-Fact-F996AE0BB974A9291E5D94757CB473E1" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1661-wk-Fact-FA941197011A51FBD4DF94757D289899 d8329819e1097-wk-Fact-FA941197011A51FBD4DF94757D289899" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1409-wk-Fact-FAA57939ED1473B9187894757D259554 d8357160e3500-wk-Fact-FAA57939ED1473B9187894757D259554" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e10002-wk-Fact-FABFB96784AE0E40057C94757CBC23CF" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e3126-wk-Fact-FAD43102CBD17909063494757CE9364E" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e10966-wk-Fact-FAE23785D8D757DC211B94757D5BFB03" toRefs="TextSelection-D895C9E8DF19B244540094757DC27744-0-wk-Footnote-D895C9E8DF19B244540094757DC27744_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e8262-wk-Fact-FB427E54FB33B137568A94757D7D2609" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e12605-wk-Fact-FB4B7F31E75AF61C8C1B94757CB6CB4D" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8340406e1264-wk-Fact-FB5675ACB41E944F604C94757D1A61F2" toRefs="TextSelection-04B9B25659DF96CA86BF94757DB5CCE1-0-wk-Footnote-04B9B25659DF96CA86BF94757DB5CCE1_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8340406e1264-wk-Fact-FB5675ACB41E944F604C94757D1A61F2" toRefs="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8316808e1288-wk-Fact-FB5C3E831211DA67818F94757CFBBA25" toRefs="TextSelection-CDCE760DEFA7F631840C94757DB86187-0-wk-Footnote-CDCE760DEFA7F631840C94757DB86187_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e12565-wk-Fact-FB658162A265137F4D2C94757D910349" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e7724-wk-Fact-FB813AC829F4A188FEBA94757D2D36C8 d8336633e14990-wk-Fact-FB813AC829F4A188FEBA94757D2D36C8" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e2634-wk-Fact-FC09E3AC9855BA04E2AC94757D2ED7CA" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e5652-wk-Fact-FC2B2CD24A88257F990394757CB35835" toRefs="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e1673-wk-Fact-FC3B1DFA5581B90199D694757D2565A3" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d8372444e7238-wk-Fact-FC494931B0AF7CE356B794757D314170" toRefs="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d8372444e7238-wk-Fact-FC494931B0AF7CE356B794757D314170" toRefs="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8372444e7238-wk-Fact-FC494931B0AF7CE356B794757D314170" toRefs="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e12812-wk-Fact-FC6199412C81449DCEDC94757CB8CF8E" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e903-wk-Fact-FCEFDC9E796190874A2D94757D27BB31" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e5239-wk-Fact-FD9AFC22FEA2E091BFC594757D404E95" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e10294-wk-Fact-FE201EAFE1503AB0772B94757D8F33AD" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8415180e3322-wk-Fact-FF8C7011D05EB3AB087F94757D62A58B" toRefs="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8307028e1258-wk-Fact-FFBCEDF314C46C81ABEE94757D18EE64 d8351242e8293-wk-Fact-FFBCEDF314C46C81ABEE94757D18EE64" toRefs="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8336633e10777-wk-Fact-FFD71DCF3ECC62BAAB9494757CB88D9F" toRefs="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"></ix:relationship></ix:resources></ix:header></div><div><a id="s95C0C275016B56E8BD88AFF1BD854E32"></a></div><div style="line-height:120%;text-align:center;font-size:15pt;"><span style="font-family:inherit;font-size:15pt;">UNITED STATES</span></div><div style="line-height:120%;text-align:center;font-size:15pt;"><span style="font-family:inherit;font-size:15pt;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">WASHINGTON, D.C. 20549</span></div><div style="line-height:120%;text-align:center;font-size:15pt;"><span style="font-family:inherit;font-size:15pt;">FORM </span><span style="font-family:inherit;font-size:15pt;"><span><ix:nonNumeric id="d8381580e699-wk-Fact-9122839B392AAF7E7FFA94757D0DD201" name="dei:DocumentType" contextRef="FD2020Q2YTD">10-Q</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:15pt;"> </span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8381580e706-wk-Fact-3D854C892B013741F6B394757CF248B4" name="dei:DocumentQuarterlyReport" contextRef="FD2020Q2YTD" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:9.5pt;">  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)</span></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">For the quarterly period ended </span><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d8381580e718-wk-Fact-BCE549B69EAD65703B6D94757CF755BF" name="dei:DocumentPeriodEndDate" contextRef="FD2020Q2YTD" format="ixt:datemonthdayyearen">June 28, 2020</ix:nonNumeric></span></span></span><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;"> </span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">OR</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8381580e731-wk-Fact-EAC1BEE25111358FD8B194757CFF1422" name="dei:DocumentTransitionReport" contextRef="FD2020Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">  </span><span style="font-family:inherit;font-size:9.5pt;">  TRANSITION REPORT PURSUANT TO SECTION 13</span></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">For the transition period from _______ to _______</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:9.5pt;">COMMISSION FILE NUMBER </span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8381580e754-wk-Fact-7738B390E76E8D29FE8294757CFE63ED" name="dei:EntityFileNumber" contextRef="FD2020Q2YTD">1-3619</ix:nonNumeric></span></span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">----</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:15pt;"><span style="font-family:inherit;font-size:15pt;"><span><ix:nonNumeric id="d8381580e765-wk-Fact-026972AF1D09401A73AF94757D0E4D6C" name="dei:EntityRegistrantName" contextRef="FD2020Q2YTD">PFIZER INC</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:15pt;">.</span><span style="font-family:inherit;font-size:15pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(Exact name of registrant as specified in its charter)</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonNumeric id="d8381580e787-wk-Fact-D4967F601D50F5887E9A94757D45823E" name="dei:EntityIncorporationStateCountryCode" contextRef="FD2020Q2YTD" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8381580e792-wk-Fact-99165F3B6A3ECCFF8C7194757D46D4A6" name="dei:EntityTaxIdentificationNumber" contextRef="FD2020Q2YTD">13-5315170</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(State of Incorporation)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(I.R.S. Employer Identification No.)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span><ix:nonNumeric id="d8381580e808-wk-Fact-32BB57587E166179116294757CFABAD7" name="dei:EntityAddressAddressLine1" contextRef="FD2020Q2YTD"><span style="font-size:9.5pt;">235 East 42</span><span style="font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">nd</sup></span><span style="font-size:9.5pt;"> Street</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:9.5pt;">, </span><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonNumeric id="d8381580e817-wk-Fact-A5BB1E4C2B71E53BD3B594757CF908D4" name="dei:EntityAddressCityOrTown" contextRef="FD2020Q2YTD">New York</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:9.5pt;">, </span><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonNumeric id="d8381580e821-wk-Fact-5F4D1CCD96E5E775185394757D0FD2F5" name="dei:EntityAddressStateOrProvince" contextRef="FD2020Q2YTD" format="ixt-sec:stateprovnameen">New York</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:9.5pt;">&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8381580e825-wk-Fact-59B35C0105F507E50A6C94757CF8A235" name="dei:EntityAddressPostalZipCode" contextRef="FD2020Q2YTD">10017</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:9.5pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(Address of principal executive offices)&#160;&#160;(zip code)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:9.5pt;">(</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8381580e835-wk-Fact-811ACF767DE29BC0C7EB94757CFFDC83" name="dei:CityAreaCode" contextRef="FD2020Q2YTD">212</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:9.5pt;">) </span><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonNumeric id="d8381580e839-wk-Fact-7FB4896AA6793DC9FEE594757CFC2A44" name="dei:LocalPhoneNumber" contextRef="FD2020Q2YTD">733-2323</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:9.5pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(Registrant&#8217;s telephone number)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:40%;"></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;text-decoration:underline;">Securities registered pursuant to Section 12(b) of the Act:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Trading Symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonNumeric id="d8381580e940-wk-Fact-0CA0E2EC622CC66D534D94757D09FC9D" name="dei:Security12bTitle" contextRef="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">Common Stock, $.05 par value</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonNumeric id="d8381580e950-wk-Fact-C1521C6A7D703728D9F094757D32F534" name="dei:TradingSymbol" contextRef="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">PFE</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonNumeric id="d8381580e960-wk-Fact-EFE7045D207191EA2DD594757D058D76" name="dei:SecurityExchangeName" contextRef="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonNumeric id="d8381580e966-wk-Fact-2668CCB3778360302DC194757D088972" name="dei:Security12bTitle" contextRef="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20220.250Member">0.250% Notes due 2022</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonNumeric id="d8381580e976-wk-Fact-EF4BB0BA7A970CA879D794757D0DDD25" name="dei:TradingSymbol" contextRef="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20220.250Member">PFE22</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonNumeric id="d8381580e986-wk-Fact-C78E5881EF1E22925E7494757D01407C" name="dei:SecurityExchangeName" contextRef="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20220.250Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonNumeric id="d8381580e992-wk-Fact-7B961DE3B1216737233094757D0BDB35" name="dei:Security12bTitle" contextRef="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20271.000Member">1.000% Notes due 2027</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonNumeric id="d8381580e1002-wk-Fact-6DE3DA4E4E7B6758238694757D0EA031" name="dei:TradingSymbol" contextRef="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20271.000Member">PFE27</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonNumeric id="d8381580e1012-wk-Fact-6755B97D0B42CD6B6B5294757D023A52" name="dei:SecurityExchangeName" contextRef="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20271.000Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:21.44249512670565%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:31%;"></td><td style="width:25%;"></td><td style="width:21%;"></td><td style="width:23%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonNumeric id="d8381580e1032-wk-Fact-4ED87A94A6CA73A8670194757D413861" name="dei:EntityCurrentReportingStatus" contextRef="FD2020Q2YTD">Yes</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Wingdings;font-size:10pt;">x</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">No</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#9744;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:21.44249512670565%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:31%;"></td><td style="width:25%;"></td><td style="width:21%;"></td><td style="width:23%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8381580e1070-wk-Fact-645DEF4892946DFA62F994757CC2B68C" name="dei:EntityInteractiveDataCurrent" contextRef="FD2020Q2YTD">Yes</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Wingdings;font-size:10pt;">x</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">No</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:justify;padding-left:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#9744;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonNumeric id="d8381580e1095-wk-Fact-1D9058BA707BC2875EFF94757CFF5085" name="dei:EntityFilerCategory" contextRef="FD2020Q2YTD" format="ixt-sec:entityfilercategoryen">Large Accelerated filer</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:9.5pt;">  </span><span style="font-family:Wingdings;font-size:10pt;">x</span><span style="font-family:inherit;font-size:9.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accelerated filer  </span><span style="font-family:inherit;font-size:10pt;">&#9744;</span><span style="font-family:inherit;font-size:9.5pt;"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Non-accelerated filer&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;">&#9744;</span><span style="font-family:inherit;font-size:9.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Smaller reporting company&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8381580e1111-wk-Fact-56FC8E8299454E0DA54994757CF57E98" name="dei:EntitySmallBusiness" contextRef="FD2020Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:9.5pt;">&#160;&#160;&#160;&#160;Emerging growth company&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8381580e1116-wk-Fact-6B9B899BB0E7540658BC94757CF68316" name="dei:EntityEmergingGrowthCompany" contextRef="FD2020Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:9.5pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="font-family:inherit;font-size:10pt;">&#9744;</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:21.44249512670565%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:31%;"></td><td style="width:25%;"></td><td style="width:21%;"></td><td style="width:23%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Yes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8381580e1154-wk-Fact-847DBDFA2E2D9BC031A094757D3F2790" name="dei:EntityShellCompany" contextRef="FD2020Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">No</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:justify;padding-left:4px;font-size:10pt;"><span style="font-family:Wingdings;font-size:10pt;">x</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:9.5pt;">At </span><span style="font-family:inherit;font-size:9.5pt;text-align:center;">August&#160;3, 2020</span><span style="font-family:inherit;font-size:9.5pt;">,</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8381580e1177-wk-Fact-152085F06FE866B029B994757CF87340" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2020Q3Aug3-3" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,556,879,807</ix:nonFraction></span></span><span style="font-family:inherit;font-size:9.5pt;"> shares of the issuer&#8217;s voting common stock were outstanding.</span></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="s36D2E263EECA5A4E90C21FD805DBCF40"></a></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.71150097465888%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:94%;"></td><td style="width:6%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s05DCC394640A55F2AF2B3ED3ED367694"><span style="font-family:inherit;font-size:9pt;font-weight:bold;color:#000000;text-decoration:none;">PART I.&#160;&#160;FINANCIAL INFORMATION</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Page</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sA6CFF88ACDA3512DB8D24330DE5AB773"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Item 1.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sA6CFF88ACDA3512DB8D24330DE5AB773"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Financial Statements</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Condensed Consolidated Statements of Income for the three and six months ended June 28, 2020 and June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#s57DC844E72095ED2A8529514BB16FC79">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Condensed Consolidated Statements of Comprehensive Income for the three and six months ended June 28, 2020 and June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sCEEB0BC2114659AFB49695EC43A1CE80">6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Condensed Consolidated Balance Sheets as of June 28, 2020 and December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#s2673EFFD583958BD98326F8D14AEC9A8">7</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Condensed Consolidated Statements of Equity for the three and six months ended June 28, 2020 and June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#s0D7DE5598E4F5CB9A2913234B923BB5C">8</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Condensed Consolidated Statements of Cash Flows for the six months ended June 28, 2020 and June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#s84609C23E00457D5A43F67081A85709D">10</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s0B1BD583C8DB5F5C90B16A94CD41E35C"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Notes to Condensed Consolidated Financial Statements</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#s0B1BD583C8DB5F5C90B16A94CD41E35C">11</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s2333F9D7259D57F89C220CA85855F82B"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Report of Independent Registered Public Accounting Firm</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#s2333F9D7259D57F89C220CA85855F82B">45</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sD3535876C7525D6FBFFD968AF3A609F6"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Item 2.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sD3535876C7525D6FBFFD968AF3A609F6"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Management</span></a><span style="font-family:inherit;font-size:9pt;">&#8217;</span><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sD3535876C7525D6FBFFD968AF3A609F6"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">s Discussion and Analysis of Financial Condition and Results of Operations</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sBC909420D8D35A8DBC54AC80D5E5905D">46</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s8C3F2F5E6C075CE18D73BFD17E93EFAC"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Item 3.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s8C3F2F5E6C075CE18D73BFD17E93EFAC"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Quantitative and Qualitative Disclosures About Market Risk</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#s8C3F2F5E6C075CE18D73BFD17E93EFAC">98</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s3B5A6803D1E0568795CF4BE26CFAB647"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Item 4.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s3B5A6803D1E0568795CF4BE26CFAB647"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Controls and Procedures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#s3B5A6803D1E0568795CF4BE26CFAB647">98</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s15F7FCCC9327523396FEF259E59BAA64"><span style="font-family:inherit;font-size:9pt;font-weight:bold;color:#000000;text-decoration:none;">PART II.&#160;&#160;OTHER INFORMATION</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s42AFFB7F13E8573A9C54AAFD22B58513"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Item 1.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s42AFFB7F13E8573A9C54AAFD22B58513"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Legal Proceedings</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#s42AFFB7F13E8573A9C54AAFD22B58513">98</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sC7FEC17674E758BE9B1A40668E038F1B"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Item 1A.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sC7FEC17674E758BE9B1A40668E038F1B"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Risk Factors</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sC7FEC17674E758BE9B1A40668E038F1B">98</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sDF7DE0DF02AA555BA976CA650421A5F4"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Item 2.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sDF7DE0DF02AA555BA976CA650421A5F4"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sDF7DE0DF02AA555BA976CA650421A5F4">100</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sC2754211509258DBBA8765C657CDD6F0"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Item 3.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sC2754211509258DBBA8765C657CDD6F0"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Defaults Upon Senior Securities</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sC2754211509258DBBA8765C657CDD6F0">100</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s1165DBDD5BB35533A4D0604D1CDA39D7"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Item 4.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s1165DBDD5BB35533A4D0604D1CDA39D7"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Mine Safety Disclosures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#s1165DBDD5BB35533A4D0604D1CDA39D7">100</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s9F7A6EE2D68F5973BA4CB44B51FD313C"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Item 5.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s9F7A6EE2D68F5973BA4CB44B51FD313C"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Other Information</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#s9F7A6EE2D68F5973BA4CB44B51FD313C">100</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sD11466CC9AA25E9D8687CB6B5E0C041B"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Item 6.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sD11466CC9AA25E9D8687CB6B5E0C041B"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Exhibits</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sD11466CC9AA25E9D8687CB6B5E0C041B">101</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s0B0121F1585B59C0886B3FFD8E459558"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Signature</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#s0B0121F1585B59C0886B3FFD8E459558">102</a></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2</span></div></div><hr style="page-break-after:always"></hr><div><a id="s6434AD0A0F095E3C8A37D64651EC29AD"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">GLOSSARY OF DEFINED TERMS</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unless the context requires otherwise, references to &#8220;Pfizer,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; in this Quarterly Report on Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below:</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:25%;"></td><td style="width:75%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">2019 Financial Report</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Financial Report for the fiscal year ended December 31, 2019, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">2019 Form 10-K</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Annual Report on Form 10-K for the fiscal year ended December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">ACA (Also referred to as U.S. Healthcare Legislation)</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">ACIP</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Advisory Committee on Immunization Practices</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">ALK</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">anaplastic lymphoma kinase</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Alliance revenues</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Allogene</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Allogene Therapeutics, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">AML</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Acute Myeloid Leukemia</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Anacor</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Anacor Pharmaceuticals, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Array</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Array BioPharma Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Astellas</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc. </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">ATTR-CM</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">transthyretin amyloid cardiomyopathy</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Bamboo</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Bamboo Therapeutics, Inc.</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">BioNTech</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">BioNTech SE</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Biopharma</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Pfizer Biopharmaceuticals Group</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">BMS</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Bristol-Myers Squibb Company</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">CDC</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Centers for Disease Control and Prevention</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">cGMP</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">current Good Manufacturing Practices</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">COVID-19</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">novel coronavirus disease of 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Developed Markets</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S., Western Europe, Japan, Canada, South Korea, Australia, Scandinavian countries, Finland and <br/>New Zealand</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">EMA</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">European Medicines Agency</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Emerging Markets</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), <br/>Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">EPS</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">earnings per share</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">EU</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">European Union</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Exchange Act</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Securities Exchange Act of 1934, as amended</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">FASB</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Financial Accounting Standards Board</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">FDA</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Food and Drug Administration</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">GAAP</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Generally Accepted Accounting Principles</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">GIST</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">gastrointestinal stromal tumors</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">GPD</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Global Product Development organization</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">GSK</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">GlaxoSmithKline plc</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">hGH-CTP</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">human growth hormone</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Hospira</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Hospira, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">IBT</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income before tax</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">ICU Medical</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">ICU Medical, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">IPR&amp;D</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">in-process research and development</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">IRS</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Internal Revenue Service</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">IV</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">intravenous</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">J&amp;J</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Johnson &amp; Johnson</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">JV</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Joint Venture</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">King</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">King Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">LDL</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">low density lipoprotein</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">LIBOR</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">London Interbank Offered Rate</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Lilly</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Eli Lilly &amp; Company</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">MCO</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">managed care organization</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">mCRC</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">metastatic colorectal cancer</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">MD&amp;A</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Medivation</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Medivation LLC (formerly Medivation, Inc.)</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:center;padding-left:0px;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:25%;"></td><td style="width:75%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Meridian</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Meridian Medical Technologies, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Moody&#8217;s</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Moody&#8217;s Investors Service</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Mylan</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Mylan N.V.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">NDA</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">new drug application</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">NSCLC</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">non-small cell lung cancer</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">OPKO</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">OPKO Health, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">PARP</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">poly ADP ribose polymerase</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">PBM</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">pharmacy benefit manager</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Pharmacia</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Pharmacia Corporation</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">PP&amp;E</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">property, plant &amp; equipment</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">PsA</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">psoriatic arthritis</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Quarterly Report on Form 10-Q</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Quarterly Report on Form 10-Q for the quarterly period ended June 28, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">RA</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">rheumatoid arthritis</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">RCC</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">renal cell carcinoma</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">R&amp;D</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">research and development</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Sandoz</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Sandoz, Inc., a division of Novartis AG</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">SEC</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Securities and Exchange Commission</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">SI&amp;A</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">selling, informational and administrative</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">S&amp;P</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Standard and Poor&#8217;s</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">TCJA</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">legislation commonly referred to as the U.S. Tax Cuts and Jobs Act of 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Therachon</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Therachon Holding AG</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">UC</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">ulcerative colitis</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">U.K.</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">United Kingdom</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">U.S.</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">United States</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Valneva</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Valneva SE</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">ViiV</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">ViiV Healthcare Limited</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">VBP</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Volume-based procurement</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">WRDM</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Worldwide Research, Development and Medical</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4</span></div></div><hr style="page-break-after:always"></hr><div><a id="s05DCC394640A55F2AF2B3ED3ED367694"></a></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I&#160;- FINANCIAL INFORMATION</span></div><div><a id="sA6CFF88ACDA3512DB8D24330DE5AB773"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1. Financial Statements</span></div><div><a id="s57DC844E72095ED2A8529514BB16FC79"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e908-wk-Fact-4DB60D98BED9F2D7592094757D057DF4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,801</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e927-wk-Fact-1769F431190664966C6E94757D75CC58" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,264</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e947-wk-Fact-6D0243B400427DDF73DD94757D73B062" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">23,829</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e966-wk-Fact-1987ADB564F749FC403294757D32C9CF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">26,382</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Costs and expenses:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of sales</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1075-wk-Fact-3E4926A75899DF8AB69294757D02E114" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,281</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1094-wk-Fact-0F4E421B90BAC3CEFBC094757D951011" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,576</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1113-wk-Fact-536622A1B5CBD4FE87F994757D2524BD" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,658</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1133-wk-Fact-2457446A2FA3FC6A69CC94757D187F7E" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,009</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, informational and administrative expenses</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1160-wk-Fact-3F6D04965D3F8AC6296C94757D442373" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,030</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1179-wk-Fact-8B3A1BD0379B26183EE994757D074D8C" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,511</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1198-wk-Fact-46F68B2D547259497F6A94757CB8B7C5" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,903</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1218-wk-Fact-93E10BD448FBEAA578FD94757D709889" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,850</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1245-wk-Fact-04615CE3AF3CBC3B5C8794757D5092E9" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,132</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1264-wk-Fact-FB5675ACB41E944F604C94757D1A61F2" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,842</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1283-wk-Fact-59753A9A46BF0BDDA65E94757CBF6EA3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,856</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1303-wk-Fact-9C03A5BC963DD5615ABA94757D2C3607" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,544</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1328-wk-Fact-A2D758AD8E8FD5AADF3B94757CF0099C" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">905</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1347-wk-Fact-56CEFFBCED15FDD6F4D194757CDCF5D5" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,184</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1366-wk-Fact-A332B2F7F76D0113E2A094757CC0E90D" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,790</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1386-wk-Fact-64EEACF271CD8A6661EF94757CA9B5E3" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,367</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1411-wk-Fact-7E093B7D90D64F5B13A494757D3BA82F" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">362</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8340406e1430-wk-Fact-788604D6690A503EC72D94757D52CBCB" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">115</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1450-wk-Fact-BB8522BC4D5C3EA5BD8694757CB166F6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">431</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8340406e1470-wk-Fact-C8984FE48C4ADA9BA0CA94757CCB4FED" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">69</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1496-wk-Fact-D68E718B4C6944A5CD6A94757CD29C96" name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1515-wk-Fact-26DE7C056ED7F6339E0F94757D946476" name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8340406e1534-wk-Fact-13980DEBF0DE0B3F0CC794757D1BBA04" name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1555-wk-Fact-42AE1B3E358159102DA894757CCA438F" name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8340406e1580-wk-Fact-361AD8CFC0B46CF2632394757D0A716D" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">862</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1600-wk-Fact-115B1B8C87DB19F5829C94757D60A004" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">126</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8340406e1619-wk-Fact-82FCBDB83EA92437E26C94757D5A5E10" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">641</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1640-wk-Fact-CF088F9FE2A75408C8A794757D1586DE" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">218</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations before provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1666-wk-Fact-2A0EE9005DC8F1672AF194757D5C8E60" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,953</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1685-wk-Fact-5210DA15DEEFCDAFC83494757D61140E" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,141</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1704-wk-Fact-239CF4E3D5F1905A2F0794757CB54D24" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,838</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1724-wk-Fact-57301CD194F92FB7EE9A94757CC61DC1" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,463</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1749-wk-Fact-2BC7C8565E04B1B2A1F794757D407F8C" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">519</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8340406e1768-wk-Fact-F92309C5686C80B6F12094757D26F9AA" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">915</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1788-wk-Fact-7D400BB69B8260DBFA0194757D7158A5" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">993</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8340406e1808-wk-Fact-F8480927DA2450FB9AB294757D637386" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">481</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1834-wk-Fact-2979655C6D134159C89394757D499DAA" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,434</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1853-wk-Fact-C920A45D5E66EC197B2A94757CF0CD54" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,056</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1872-wk-Fact-A90E01F4F7B0E1568EDA94757D6D8CFD" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,845</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1892-wk-Fact-603FB52F232889DFBADE94757D592C93" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,945</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1917-wk-Fact-D0B1BB14EB1C0097910C94757D5D09B2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1936-wk-Fact-05DE67BF183EFC3302F894757D673D16" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1955-wk-Fact-8CA5088693E8928A2F7194757D5C8489" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e1975-wk-Fact-7F22D0DB6525173F13B494757CADCE97" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income before allocation to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2000-wk-Fact-B56556CFBF45225D098894757D0D84DC" name="us-gaap:ProfitLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,434</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2019-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B" name="us-gaap:ProfitLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,056</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2038-wk-Fact-F55F7448D6FD457E7D3094757CC42D99" name="us-gaap:ProfitLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,845</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2058-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9" name="us-gaap:ProfitLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,945</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Net income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2083-wk-Fact-10C0D76C934B5C1793A994757D4985D4" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2102-wk-Fact-BE013A8321BCFA54741E94757D80A8CE" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2121-wk-Fact-ED12AC0ED4563B7B91D294757D6E4FFF" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2141-wk-Fact-1226C5A8B6BDD831984C94757CAB3BF0" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Pfizer Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2171-wk-Fact-5855D3292457CBC841DF94757D03D95D" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2190-wk-Fact-E80F3653B15E3D94B76194757D344502" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,046</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2210-wk-Fact-629B718CAC92C35F38D794757D1FE07E" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,828</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2229-wk-Fact-3AC307C0C4ECA1CCA0B494757CC80CD1" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,929</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Earnings per common share&#8211;&#8211;basic</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2426-wk-Fact-263AD80EFD0DF942862794757CB97E50" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="FD2020Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.62</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2445-wk-Fact-BDC31C12896D043747B194757D5B35D6" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.91</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2465-wk-Fact-B98065EB23404AACB87094757D6BD6BE" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="FD2020Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2484-wk-Fact-527CDF2F111A3CFDCAC094757CB3C447" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.59</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2504-wk-Fact-7BA1645714435EB2B3AB94757CC0F691" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="FD2020Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2523-wk-Fact-E756C4C43674CBFEFEA494757CE1093D" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2542-wk-Fact-B5E50DD48766F6B1EB8294757CBDBCD9" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="FD2020Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2562-wk-Fact-7A14B07B1D3BB0FC8DEC94757D153837" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2593-wk-Fact-4F381BE015AE04126EB994757CB534B2" name="us-gaap:EarningsPerShareBasic" contextRef="FD2020Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.62</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2612-wk-Fact-57D63ECE81675F0F4F2394757D0586AC" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.91</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2632-wk-Fact-E8B0E5833864611B38D294757CAF72E7" name="us-gaap:EarningsPerShareBasic" contextRef="FD2020Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2651-wk-Fact-375CE2F1DA250039888894757D5B5BA6" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.59</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Earnings per common share&#8211;&#8211;diluted</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2848-wk-Fact-0DEB9E1626C9961FC0CB94757D4307A4" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="FD2020Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.61</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2867-wk-Fact-0DADC806FCB0F8DE89E394757CFF07B6" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.89</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2887-wk-Fact-C6F72F041602CA931A9F94757D2D2964" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="FD2020Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2906-wk-Fact-31ABED2FAA0C5EDD3D7994757D5F8CB1" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.56</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2926-wk-Fact-D5B6EF098B9CCBC6106394757D9FD69A" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="FD2020Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2945-wk-Fact-5CBFB8246EFB61DA16CD94757CE0475C" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2964-wk-Fact-DAA4B71118EB1D4285A994757D1B59B8" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="FD2020Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e2984-wk-Fact-B33CD1A22EADB7B396EE94757D139837" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e3014-wk-Fact-F0D947E3D319A071650894757D8FBF1A" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2020Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.61</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e3033-wk-Fact-2F0D93C254F8FED5D44E94757CFAFADA" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.89</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e3053-wk-Fact-2F018DCBB03DFD12F06194757D0FC6D9" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2020Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e3072-wk-Fact-D797AF9402BF1599A6F594757D5776AE" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.56</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average shares&#8211;&#8211;basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e3179-wk-Fact-CEDDD667A11CAC08820D94757D0E749E" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2020Q2QTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,554</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e3198-wk-Fact-4083035A9265D74B487394757CDE895C" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,562</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e3217-wk-Fact-3E9B45FC40C0B53734B894757D6021C6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2020Q2YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,550</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e3237-wk-Fact-05B58E4BDA3C96C172AE94757D61A5B0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,598</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average shares&#8211;&#8211;diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e3262-wk-Fact-CDED57DD355FBFDCE83394757D0D0D08" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2020Q2QTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,619</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e3281-wk-Fact-C825A8BB25BE38B63BB194757D30A6AC" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,672</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e3300-wk-Fact-8EF576E428EEA952509894757D5DA535" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2020Q2YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,616</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8340406e3320-wk-Fact-4E46F2B386CE7BF8977294757CBBCA8A" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,711</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-04B9B25659DF96CA86BF94757DB5CCE1-0-wk-Footnote-04B9B25659DF96CA86BF94757DB5CCE1_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Excludes amortization of intangible assets, except as disclosed in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.</span></div></ix:footnote></td></tr></table><ix:footnote id="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;padding-bottom:53px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts may not add due to rounding.</span></div></ix:footnote><div style="line-height:120%;text-align:center;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Notes to Condensed Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5</span></div></div><hr style="page-break-after:always"></hr><div><a id="sCEEB0BC2114659AFB49695EC43A1CE80"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER&#160;INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income before allocation to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e911-wk-Fact-B56556CFBF45225D098894757D0D84DC" name="us-gaap:ProfitLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,434</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e930-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B" name="us-gaap:ProfitLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,056</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e950-wk-Fact-F55F7448D6FD457E7D3094757CC42D99" name="us-gaap:ProfitLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,845</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e969-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9" name="us-gaap:ProfitLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,945</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments, net</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e1076-wk-Fact-B436D7020EEC746BCB4A94757D090189" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">242</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e1096-wk-Fact-519D1AE2B3692880237794757CFE232A" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">485</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e1116-wk-Fact-C54AB828E036C88403BC94757CCD9057" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,513</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e1137-wk-Fact-F13DA5DDDB9A69F13A7994757D8778B5" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">161</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reclassification adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e1163-wk-Fact-592D27AEE4D0FDEDCA3094757CFE923B" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e1182-wk-Fact-59195E3D3D8D530EB03F94757D003A33" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e1201-wk-Fact-B756BD8131D12427D5A094757CC10C5E" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e1221-wk-Fact-137D234567F2A002B07194757D5099CA" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e1246-wk-Fact-B7AFA2301099E9BDE10E94757D091A88" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">242</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e1266-wk-Fact-F5E011F8B735031318D994757D0A265D" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">485</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e1286-wk-Fact-F618699466962C9B165B94757CEEF703" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,513</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e1307-wk-Fact-24C0070845257F719EAD94757D4D72E4" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">159</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized holding gains/(losses) on derivative financial instruments, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e1333-wk-Fact-6B2383F2FE5E4F5C1F8094757D03DB8C" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">213</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e1352-wk-Fact-C73E7DEFCE404DDC8E6A94757CFD4810" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">176</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e1372-wk-Fact-4ECA9E2FD645BEFF2FE194757CB235DC" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">288</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e1393-wk-Fact-16EB2E72AB574E14B22194757CD34D79" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">91</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reclassification adjustments for gains included in net income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e1420-wk-Fact-8B19463082CE6440AD3394757D03C123" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">186</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e1440-wk-Fact-2DD85B64A9010E6C213294757D013277" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">81</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e1460-wk-Fact-C78E60BC91B631C2A94794757CC3905D" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">167</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e1481-wk-Fact-EAC3B24ACD51EAB9C1FF94757CE2E89A" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">343</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e1507-wk-Fact-08ABD4A7A57B250F299B94757D04A592" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e1526-wk-Fact-72309F9168907BDAA94794757D07D3DF" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">256</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e1546-wk-Fact-08DD19481DA8379F656094757D9154A8" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">455</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e1567-wk-Fact-4FABC049EDFD60A33BC994757D951454" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">252</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized holding gains/(losses) on available-for-sale securities, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e1593-wk-Fact-3983BB3504AC4457A05494757D01EDF0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e1612-wk-Fact-9116D9DA0452E7895E8B94757D09EEB9" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e1632-wk-Fact-C461CCF052CAC13CE0B494757D759AEB" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e1653-wk-Fact-A82EF1B25256A6FE603294757D5228D4" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reclassification adjustments for losses included in net income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e1681-wk-Fact-82F380CF07CFB5944E8F94757D071BF6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">44</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e1700-wk-Fact-8DE79CAD5240FF8E772794757CFDD19F" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e1719-wk-Fact-64D918D7F7D3CCF5532194757CC5E46E" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">59</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e1739-wk-Fact-610F8D5433DAF2EB576E94757CAC2094" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">37</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e1764-wk-Fact-961167284F5E861B1C9094757D0AD393" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">87</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e1783-wk-Fact-5B9F6B76D55DFFB89B5094757D04FD74" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e1802-wk-Fact-B1C06142FF81EF258FE994757DA46AF3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e1822-wk-Fact-EC1267F1CEEA206E48DB94757D3D71EF" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">70</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefit plans: actuarial gains/(losses), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e1847-wk-Fact-54C9F8EBEE78F97A618894757D000BCB" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e1866-wk-Fact-8C29FB80663D2D3FF01694757D04376B" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e1886-wk-Fact-F175F1A05A293F5B33DF94757DA50565" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">160</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e1907-wk-Fact-7C3725C3864FB58D26F294757DA59FB9" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reclassification adjustments related to amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e1933-wk-Fact-3508D42A7ED6A8C436DE94757D080CE2" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">67</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e1952-wk-Fact-926EAF034EA59D57AB4A94757D085C80" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">60</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e1971-wk-Fact-960E53D0B504F694E33294757D577481" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e1991-wk-Fact-4205FA0CADA9C7C75F1194757CAF3BC4" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">121</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reclassification adjustments related to settlements, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e2016-wk-Fact-1E7D497146AE795F1C1994757D095745" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e2035-wk-Fact-D6F7C72544CA78BD37CE94757D0672FB" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e2054-wk-Fact-792F383C3FEE0FE8090C94757CAF87DA" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">66</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e2074-wk-Fact-44A3EBC245B59B1EDEFE94757CA83343" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e2099-wk-Fact-C5EA1CFA2BAB5B0EAA7094757D07F215" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">68</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e2118-wk-Fact-D9A205E489D5B6E9EB3A94757D04C021" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">41</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e2137-wk-Fact-E5B2171A194CD45335C794757CE7F3C1" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e2157-wk-Fact-1BF4E8A74A053F182A6294757CB3BD1E" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e2182-wk-Fact-B5BD6F0023F06259AE3494757D06AF3E" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">153</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e2201-wk-Fact-9786DDF8A69B3054F6C594757D0258B2" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e2220-wk-Fact-2EE2705D1EB743C59AA194757CB0642B" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">122</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e2240-wk-Fact-ED78EBC18DA3BA3A4CA194757DA645DC" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">137</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefit plans: prior service costs and other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e2265-wk-Fact-50D4A8FFA49F4D1E126994757CD3C559" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e2284-wk-Fact-9A3535709176CD3B928494757D5A0A52" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e2304-wk-Fact-458F8B2744B5838D7DD994757D5BA906" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e2324-wk-Fact-E5344C9D61E5386447CC94757D5DBD84" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reclassification adjustments related to amortization of prior service costs and other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e2350-wk-Fact-457A42E5EFF17C82E7B994757D023187" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e2370-wk-Fact-7BD0F552906AEDAE43AB94757D064290" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e2390-wk-Fact-CD69F0255956248BF5A794757CDCB6CF" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">89</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e2411-wk-Fact-8570BDBA5E94557A549C94757D4F36AD" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">93</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e2437-wk-Fact-D6AF3AA50A2C3B4FED5094757D009316" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e2456-wk-Fact-B8780C1262D682FB127794757D09FED8" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e2475-wk-Fact-781D2814C0D7F0668EE394757D69DD6C" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e2495-wk-Fact-78F48FB31891A5F2CA2794757CAAA5B9" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e2520-wk-Fact-126B087E9A05FE5529B194757D03D1C9" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e2540-wk-Fact-E7D7D44563418D8D6DC894757D062085" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e2560-wk-Fact-6B0D0523D801B89879B094757D4B3266" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">85</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e2581-wk-Fact-1891EFA6F636FA196DF794757D4ABF57" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">92</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive loss, before tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e2608-wk-Fact-62DE4C98CF58FC6052F494757D0396A6" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e2628-wk-Fact-7ECB63F5AF06861C1CE494757D0884D8" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">669</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e2648-wk-Fact-4B4218478A969AE4E17A94757D59AFA8" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,882</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e2669-wk-Fact-A66CB11E7205BECF278B94757D98ABC2" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">296</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax provision/(benefit) on other comprehensive loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e2695-wk-Fact-EA79252BF7CF8534CF3894757D00B0A3" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">113</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e2714-wk-Fact-8F362BEF2AB5D5597E6394757CFFD802" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">59</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e2734-wk-Fact-98256D21B98CE406359794757D62CC7A" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">265</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e2755-wk-Fact-EF6B358EA8E9123BB65194757D5C81E7" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive loss before allocation to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e2786-wk-Fact-066BFF2F5B504A5CD41294757D064180" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">127</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e2806-wk-Fact-0AC5548725395D35A56C94757D003303" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">610</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e2827-wk-Fact-F996AE0BB974A9291E5D94757CB473E1" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,617</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e2847-wk-Fact-920C774D6C3160546F7D94757DA37E07" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">262</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive income before allocation to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e2873-wk-Fact-F25133D545839D7AE1D294757D02FFFC" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,307</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e2892-wk-Fact-D2B6E10475D8BB804CE094757CFEFBD9" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,446</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e2912-wk-Fact-A1F913431B3403C9FEC994757D9D5A01" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,227</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e2931-wk-Fact-8F56B752B32B070AE71194757D815A0F" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,683</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Comprehensive income/(loss) attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8301124e2951-wk-Fact-DB5758891218A2CD53FA94757D09D2D4" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e2971-wk-Fact-8BC82C6DDA70A7A2CF9894757D0335F3" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e2990-wk-Fact-E8491F91CE829080A31A94757CDF3CE5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e3010-wk-Fact-86D8DED1361AFC8ED58C94757D5FCC72" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive income attributable to Pfizer Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e3040-wk-Fact-EA0DB488C3931FDD51EB94757D052620" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,312</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e3059-wk-Fact-623288D955847BE5D34C94757D0703C1" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,434</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e3079-wk-Fact-1AC328FD09CA718A54B294757CAD4A93" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8301124e3098-wk-Fact-5BE19AFA21A4738F24FF94757D6A31FE" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,669</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-8C3C45B5D6B304AC979B94757DB5023F-0-wk-Footnote-8C3C45B5D6B304AC979B94757DB5023F_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts in the </span><span style="font-family:inherit;font-size:9pt;">second quarter</span><span style="font-family:inherit;font-size:9pt;"> of 2020 include losses from the weakening of certain major currencies against the U.S. dollar, partially offset by a </span><span style="font-family:inherit;font-size:9pt;">gain</span><span style="font-family:inherit;font-size:9pt;"> of approximately </span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d8301124e3125-wk-Fact-9BF42E717180B5F1346794757D9BF953" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">380</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;"> pre-tax (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d8301124e3129-wk-Fact-2763BBDB57DA534C711D94757D9AD50C" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">291</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;"> after-tax) related to foreign currency translation adjustments and the impact of our net investment hedging program, both attributable to our equity method investment in the GSK Consumer Healthcare joint venture. Amounts in </span><span style="font-family:inherit;font-size:9pt;">the first six months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;">2020</span><span style="font-family:inherit;font-size:9pt;"> include a </span><span style="font-family:inherit;font-size:9pt;">loss</span><span style="font-family:inherit;font-size:9pt;"> of approximately </span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d8301124e3146-wk-Fact-7D2CDF570E4A165119D754555A079873" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-8" scale="9" sign="-" format="ixt:numdotdecimal">1.2</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:9pt;"> pre-tax (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d8301124e3150-wk-Fact-EC4BE606149B17B66782545594D6136A" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">902</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;"> after-tax) related to foreign currency translation adjustments and the impact of our net investment hedging program, both attributable to our equity method investment in the GSK Consumer Healthcare joint venture and losses from the weakening of certain major currencies against the U.S. dollar, partially offset by the results of our net investment hedging program. For additional information on the GSK Consumer Healthcare joint venture, see </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 2B</span><span style="font-family:inherit;font-size:9pt;">. </span><span style="font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Acquisition, Equity-Method Investment and Licensing Arrangements</span><span style="font-family:inherit;font-size:9pt;">: </span><span style="font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Equity-Method Investment</span><span style="font-family:inherit;font-size:9pt;font-style:italic;">.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-A6080F3BC2CE36268D0F94757DB590DE-0-wk-Footnote-A6080F3BC2CE36268D0F94757DB590DE_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassified into </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions&#8212;net </span><span style="font-family:inherit;font-size:9pt;">and </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:9pt;"> in the condensed consolidated statements of income. For additional information on amounts reclassified into </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions&#8212;net </span><span style="font-family:inherit;font-size:9pt;">and </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:9pt;">, see </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 7E. Financial Instruments: Derivative Financial Instruments and Hedging Activities.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-68FC3C25B884A32675EA544FA892CE0F-0-wk-Footnote-68FC3C25B884A32675EA544FA892CE0F_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassified into </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions&#8212;net.</span></div></ix:footnote></td></tr></table><ix:footnote id="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;padding-bottom:13px;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts may not add due to rounding.</span></div></ix:footnote><div style="line-height:120%;text-align:center;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Notes to Condensed Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6</span></div></div><hr style="page-break-after:always"></hr><div><a id="s2673EFFD583958BD98326F8D14AEC9A8"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">December&#160;31, <br/>2019</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Unaudited)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e864-wk-Fact-39CFEE5D7F0B06CD9DA094757D10AD76" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,801</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e883-wk-Fact-B816481FF01850756E6D94757D1C86F4" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,305</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e903-wk-Fact-FCEFDC9E796190874A2D94757D27BB31" name="us-gaap:OtherShortTermInvestments" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,581</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e922-wk-Fact-B28669D670A8C56C545994757D2ED7A9" name="us-gaap:OtherShortTermInvestments" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,525</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restricted short-term investments</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e949-wk-Fact-785332B79AA4618521F26EDD705A45C3" name="us-gaap:RestrictedInvestmentsCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,412</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e968-wk-Fact-438C70CDE0164785DD1D6EDE8D2EB280" name="us-gaap:RestrictedInvestmentsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Trade accounts receivable, less allowance for doubtful accounts: 2020&#8212;$525; 2019&#8212;$527</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e993-wk-Fact-2564D80CF4863AD3560094757D2FB6D5" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,128</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1012-wk-Fact-52692B1D3913040E2AAA94757D1705E9" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,724</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Inventories</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1037-wk-Fact-E854D651F5C65603680B94757D20C5D0" name="us-gaap:InventoryNet" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,564</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1056-wk-Fact-A72909DE8208FAB8084794757D31B877" name="us-gaap:InventoryNet" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,283</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1081-wk-Fact-62FCD6839EDD133C913794757D242018" name="pfe:OtherTaxAssetsCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1100-wk-Fact-3CE8433BEC1FEF1715C594757D56EECD" name="pfe:OtherTaxAssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,344</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1125-wk-Fact-E50549595D0042E610B994757D288E28" name="us-gaap:OtherAssetsCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,513</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1144-wk-Fact-7647F4EED80B8447B7B494757D2B6C57" name="us-gaap:OtherAssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,622</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1169-wk-Fact-B99B2E1079DF1F86DF1A94757D24E100" name="us-gaap:AssetsCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">46,424</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1188-wk-Fact-C1A3AA27451A8B8C11F594757D159C90" name="us-gaap:AssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">32,803</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Equity-method investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1214-wk-Fact-06B216BCF27965D7A6A694757D11CF28" name="us-gaap:EquityMethodInvestments" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15,578</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1233-wk-Fact-CFF1903136C1AC56DF3A94757D2B131B" name="us-gaap:EquityMethodInvestments" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17,133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1258-wk-Fact-FFBCEDF314C46C81ABEE94757D18EE64" name="us-gaap:OtherLongTermInvestments" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,142</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1277-wk-Fact-BCE8A138729B45E61B7F94757D2C3132" name="us-gaap:OtherLongTermInvestments" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,014</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Property, plant and equipment, less accumulated depreciation: 2020&#8212;$16,889; 2019&#8212;$16,789</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1302-wk-Fact-D948D8A0A120E105480A94757D261CF9" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14,113</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1321-wk-Fact-1E1B5B900670A3CC9D3594757D1F6A23" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,967</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Identifiable intangible assets, less accumulated amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1346-wk-Fact-9C96864A6997B214807194757D2B762A" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">33,541</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1365-wk-Fact-59E2FF5E7ACF702D9F4B94757D3339C6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35,370</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1390-wk-Fact-4B0A3E94BBBA400AC84C94757D168B19" name="us-gaap:Goodwill" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">58,449</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1409-wk-Fact-FAA57939ED1473B9187894757D259554" name="us-gaap:Goodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">58,653</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Noncurrent deferred tax assets and other noncurrent tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1434-wk-Fact-BA35612EAE6C91BF6D5494757D30D0C0" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,360</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1453-wk-Fact-B5534107AC881736B01B94757D23BE41" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,099</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1478-wk-Fact-A40179DC2229E8A9AD6B94757D2F9DF6" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,327</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1497-wk-Fact-DAA11F34E77442AAEC1894757D191631" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,450</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1527-wk-Fact-CCE3024E0C6DEE0D773194757D1EE899" name="us-gaap:Assets" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">177,934</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1546-wk-Fact-C2CB94D8321D93BAD2DD94757D57F0A3" name="us-gaap:Assets" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">167,489</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Liabilities and Equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Short-term borrowings, including current portion of long-term debt: 2020&#8212;$1,481; 2019&#8212;$1,462</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1661-wk-Fact-FA941197011A51FBD4DF94757D289899" name="us-gaap:DebtCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,084</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1680-wk-Fact-E1C7AF863456D04209EB94757D12EC91" name="us-gaap:DebtCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,195</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Trade accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1701-wk-Fact-31B843C71D5C57C7970294757D210FDA" name="us-gaap:AccountsPayableCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,872</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1720-wk-Fact-0C05260CF79B14B3930694757D1319B9" name="us-gaap:AccountsPayableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,220</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Dividends payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1745-wk-Fact-551A923D6EEA0DEA4EF694757D1C99C3" name="us-gaap:DividendsPayableCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1764-wk-Fact-014A34208FA34FFBCC4994757D221D12" name="us-gaap:DividendsPayableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,104</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income taxes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1789-wk-Fact-82FFBC9E02C7EA63F21C94757D1C5F54" name="us-gaap:TaxesPayableCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,445</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1808-wk-Fact-AA0D8DE25A28BD3E886994757D30BAE9" name="us-gaap:TaxesPayableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">980</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued compensation and related items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1833-wk-Fact-F28698BCE434ADB508FA94757D1736FA" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,042</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1852-wk-Fact-4C76179C274DDE6FE76E94757D246CA2" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,720</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1877-wk-Fact-76D99E72799A7D1A6EEF94757D204BD6" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,168</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1896-wk-Fact-DC5D094960D8362E8AE194757D1CEABE" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,083</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1921-wk-Fact-7815B96C1DE73848E04C94757D28CB62" name="us-gaap:LiabilitiesCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">32,723</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e1940-wk-Fact-3CC60BCCBCF2CF508B1694757D16B042" name="us-gaap:LiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">37,304</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Long-term debt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2013-wk-Fact-9B484215869CDB3979AE94757D159E88" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50,529</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2032-wk-Fact-599CD01F617B5421030A94757D29E0E8" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35,955</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Pension benefit obligations, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2057-wk-Fact-B2CACAAABE963B0BFD8F94757D10087A" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,344</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2076-wk-Fact-F3EB43E530A63806272994757D14737C" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,638</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Postretirement benefit obligations, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2101-wk-Fact-9072FFD068100079F81B94757D26A3EC" name="us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,086</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2120-wk-Fact-2325A2D864C8B2E0F2E194757D22414D" name="us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,124</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Noncurrent deferred tax liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2145-wk-Fact-1DC168387E9062FD753994757D57860A" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,409</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2164-wk-Fact-5CC1D14D1DDE8826CA7B94757D19D277" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,578</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other taxes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2190-wk-Fact-D935FF0C642A1173F2D694757D1F4344" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,468</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2209-wk-Fact-7C60FDCC13DD0DFF94DB94757D194622" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12,126</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2234-wk-Fact-795A73536189346A46BA94757D101516" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,812</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2253-wk-Fact-F30E96B44D3E4509219994757D1F511F" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,317</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2278-wk-Fact-2296B04F377E05B8D07C94757D190B3D" name="us-gaap:Liabilities" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">113,370</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2297-wk-Fact-A25CEEC8C1AE2DADBEC594757D293164" name="us-gaap:Liabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">104,042</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Commitments and Contingencies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2368-wk-Fact-A21DC12905CBC163AED994757D2EAC03" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2020Q2" unitRef="usd" xsi:nil="true" scale="0" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2386-wk-Fact-324F49A292903AEB38B894757D2BD1AB" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2019Q4" unitRef="usd" xsi:nil="true" scale="0" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2456-wk-Fact-D037126BFACE01B81D3B94757D11D201" name="us-gaap:PreferredStockValue" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2475-wk-Fact-10EDC1B88A166120EB9394757D13AAEA" name="us-gaap:PreferredStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2500-wk-Fact-D7ECD9F4548C3411A1AB94757D1B3553" name="us-gaap:CommonStockValue" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">470</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2519-wk-Fact-19C43A79023CA42B86EA94757D12F049" name="us-gaap:CommonStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">468</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Additional paid-in capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2544-wk-Fact-E75C406B14955CDB7D3B94757D138744" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">87,886</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2563-wk-Fact-B17D04EC8E4349EFFEF394757D1A00C1" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">87,428</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Treasury stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8307028e2588-wk-Fact-BCA7EB2A102DF56C060B94757D2C4CD4" name="us-gaap:TreasuryStockValue" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">110,978</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8307028e2608-wk-Fact-E78126B8699A77F8DCC594757D1B1CAA" name="us-gaap:TreasuryStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">110,801</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Retained earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2634-wk-Fact-FC09E3AC9855BA04E2AC94757D2ED7CA" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">100,203</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2653-wk-Fact-A8DB7D24D8C907F2E56094757D1D1AC3" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">97,670</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated other comprehensive loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8307028e2679-wk-Fact-2E87EA97E71121C08FCB94757D27917E" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">13,246</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8307028e2699-wk-Fact-47E4B6DB5C9B3F16044E94757D1BCF19" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11,640</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total Pfizer Inc. shareholders&#8217; equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2725-wk-Fact-DD3041593AC72587B67894757D2924BD" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">64,336</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2744-wk-Fact-F68119AE4BA283A0E74494757D5699A2" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63,143</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Equity attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2769-wk-Fact-648A257E45E63BD933AE94757D2F45DA" name="us-gaap:MinorityInterest" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">228</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2788-wk-Fact-2C16CBC888D1DBA772D994757D213C35" name="us-gaap:MinorityInterest" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">303</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2813-wk-Fact-39B247651891576D7B7A94757D210D60" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">64,564</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2832-wk-Fact-6AE9A7E5A8423D56EB6794757D15EE65" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63,447</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total liabilities and equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2862-wk-Fact-82EF2E3D703744E0C13B94757D266699" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">177,934</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8307028e2881-wk-Fact-0D1CD905D92C101F2A7094757D18615E" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">167,489</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><ix:footnote id="TextSelection-A69940B73F64268F0EB092D9B88F9F01-0-wk-Footnote-A69940B73F64268F0EB092D9B88F9F01_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><span style="font-family:inherit;font-size:8pt;">The balance as of June 28, 2020 reflects the Upjohn Inc. and Upjohn Finance B.V. debt issuances. For additional information see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7D. Financial Instruments: </span><span style="font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Long-Term Debt</span></ix:footnote><span style="font-family:inherit;font-size:8pt;font-style:italic;">.</span></div></td></tr></table><ix:footnote id="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;padding-bottom:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></ix:footnote><div style="line-height:120%;padding-bottom:66px;text-align:center;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Notes to Condensed Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7</span></div></div><hr style="page-break-after:always"></hr><div><a id="s0D7DE5598E4F5CB9A2913234B923BB5C"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="46"></td></tr><tr><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="36" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">PFIZER INC. SHAREHOLDERS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Preferred Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Treasury Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">(MILLIONS, EXCEPT PREFERRED SHARES)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Shares</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Stated Value</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Shares</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Par Value</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Add&#8217;l </span></div><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Paid-In Capital</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Shares</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Cost</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Retained Earnings</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Accum. Other Comp. </span></div><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Loss</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Share-</span></div><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">holders&#8217; Equity</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Non-controlling interests</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Total Equity</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Balance, March 29, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e1467-wk-Fact-D58E0C9AEC0FAB141C2794757D361983" name="us-gaap:SharesIssued" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">417</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e1486-wk-Fact-F17EC0EBDAE2EB6346E094757D109BAC" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e1500-wk-Fact-F3A733B52C3E9E10B03494757CDA0945" name="us-gaap:SharesIssued" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">9,393</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e1520-wk-Fact-F3381BD200AEE22A790894757D7247BF" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">470</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e1539-wk-Fact-B35D2CD0AC8469F52A1194757DA775AF" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">87,680</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e1553-wk-Fact-B628E15DE73F0869904394757D92C37B" name="us-gaap:SharesIssued" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">3,841</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e1574-wk-Fact-B38C1AE72C31DF2CFAFA94757CDDB0D8" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">111,010</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e1594-wk-Fact-6BC4DEBEF668519175DE94757D1D6772" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">101,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e1613-wk-Fact-C7083099744AE4148D4994757D2CC599" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">13,131</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e1634-wk-Fact-03460BEA869B48E0CF7894757D6EE332" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">65,026</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e1653-wk-Fact-146CA4CF4749BABED82294757D1CFAEF" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">312</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e1673-wk-Fact-FC3B1DFA5581B90199D694757D2565A3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">65,338</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e1820-wk-Fact-871135383070AF575BE394757CEC460F" name="us-gaap:ProfitLoss" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e1860-wk-Fact-1EB64412D2D80070B55B94757D5A4E16" name="us-gaap:ProfitLoss" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e1879-wk-Fact-273C64BCA1A40F3A50D394757CD85863" name="us-gaap:ProfitLoss" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e1898-wk-Fact-B56556CFBF45225D098894757D0D84DC" name="us-gaap:ProfitLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,434</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Other&#160;comprehensive income/(loss), net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e2071-wk-Fact-7AA1C77DB5A3B4644A4C94757CE5FE83" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">115</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e2092-wk-Fact-2298D4CD7D2F6AE1C57E94757D628353" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">115</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e2112-wk-Fact-0EA469F78A7AA9B0154B94757D0F21D4" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e2132-wk-Fact-066BFF2F5B504A5CD41294757D064180" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">127</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Cash dividends declared:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e2517-wk-Fact-0A439D2D9035C084D32594757D7076B0" name="us-gaap:DividendsCommonStockCash" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,223</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e2558-wk-Fact-6E65BB85082AE89519F994757CADB602" name="us-gaap:DividendsCommonStockCash" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,223</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e2598-wk-Fact-C938A9B7922E6371EB0F94757CEF9930" name="us-gaap:DividendsCommonStockCash" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,223</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e2752-wk-Fact-920B734C19194AC1B01F94757D8C8380" name="us-gaap:DividendsPreferredStockCash" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e2792-wk-Fact-9FD771621D23274287A294757D1BC8FA" name="us-gaap:DividendsPreferredStockCash" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e2831-wk-Fact-02FDFD3FA6ACE12CEA1F94757D6D0CCF" name="us-gaap:DividendsPreferredStockCash" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e3044-wk-Fact-B0814DE9CC612AE11DD594757D3226D5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e3064-wk-Fact-2C0450D46BE2A068263194757CADD7DF" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Share-based payment transactions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e3126-wk-Fact-FAD43102CBD17909063494757CE9364E" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e3141-wk-Fact-6538F77FA787A6ABAE0994757CB51CDA" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e3160-wk-Fact-6B111BE422485683C25B94757D205012" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">221</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e3179-wk-Fact-74F211B6DF9332B7854594757CED7C21" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e3194-wk-Fact-7055D02214C4DCDBF2D794757D530978" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e3254-wk-Fact-2934BA4BF607819E093694757D2AAA19" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e3293-wk-Fact-382681D10D85986FB7E894757D20CDB3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Purchases of common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e3411-wk-Fact-B92928DFC343D1C01A7994757D3B4E3A" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e3426-wk-Fact-2B5CC988DB54D9E2126D94757D6035E4" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e3486-wk-Fact-3C3F27909C4BDBE69AF194757CE1FE25" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e3525-wk-Fact-5340A136A6910F813F5A94757D1D656C" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Preferred stock conversions and redemptions</span><span style="font-family:inherit;font-size:6.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e3553-wk-Fact-112FF7A0087A9422819094757D2BF4D9" name="pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">417</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e3568-wk-Fact-D21BDBDB5A3496D15C0F94757CC0FECE" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e3624-wk-Fact-6B84B600E6054E02ECF394757CEEFFA4" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e3644-wk-Fact-DDAEB6E7FE68CC5DB4FB7DAAEFDFB98D" name="pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e3659-wk-Fact-3A9B32710A1CE30C5C917DAAF1BA82D7" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">31</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e3719-wk-Fact-A88ABBED02CE57879DE594757CE47EAA" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e3758-wk-Fact-7E6C55D0D09E306D959A94757D35315B" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e3904-wk-Fact-B82DC8F0C3F61B78FD6994757D46FE68" name="us-gaap:StockholdersEquityOther" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e3944-wk-Fact-A6C23BB629BE687A706594757D7617FA" name="us-gaap:StockholdersEquityOther" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e3963-wk-Fact-AAD74F0EFA0B4EA93F7D94757D17DF5B" name="us-gaap:StockholdersEquityOther" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e3982-wk-Fact-7E9393AC0EF93702DEB094757D86B0EE" name="us-gaap:StockholdersEquityOther" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Balance, June 28, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e4008-wk-Fact-B39352F261C00A65738694757D51EB5C" name="us-gaap:SharesIssued" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e4027-wk-Fact-7527AF621EA7D105014694757D491C4F" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e4041-wk-Fact-780C5B60A58937B5CFA594757D14130D" name="us-gaap:SharesIssued" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">9,394</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e4061-wk-Fact-565D7337C380201E7A3794757D2441F6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">470</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e4080-wk-Fact-9F791EE0835763BF87F894757D6D6836" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">87,886</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e4094-wk-Fact-F12EBCA49A1647F7C9C194757CB75C07" name="us-gaap:SharesIssued" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">3,840</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e4115-wk-Fact-A8241CECE526F96581AE94757CF0E2F1" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">110,978</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e4135-wk-Fact-DFF13E5F684FBEC9822394757D143E71" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">100,203</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e4154-wk-Fact-0311E1C11EAA0D64120894757D282E1A" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">13,246</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e4175-wk-Fact-D2F433B8AA4C0088F7B694757DA65630" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">64,336</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e4194-wk-Fact-E682A060B9E084CD78DB94757CBF7369" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">228</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e4214-wk-Fact-39B247651891576D7B7A94757D210D60" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">64,564</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="46" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="36" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">PFIZER INC. SHAREHOLDERS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Preferred Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Treasury Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">(MILLIONS, EXCEPT PREFERRED SHARES)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Stated Value</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Shares</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Par Value</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Add&#8217;l </span></div><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Paid-In Capital</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Shares</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Cost</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Retained Earnings</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Accum. Other Comp. </span></div><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Loss</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Share-</span></div><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">holders&#8217; Equity</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Non-controlling interests</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Total Equity</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Balance, March 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e5167-wk-Fact-20A8453F774E2321859294757CD699F4" name="us-gaap:SharesIssued" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">466</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e5186-wk-Fact-2C4A0D66E79C36E0AD3A94757CD125ED" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e5200-wk-Fact-6B2DEA1574A1AAC388A194757D2E9D03" name="us-gaap:SharesIssued" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">9,358</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e5220-wk-Fact-2F4D955985202F933AFB94757DA34DE9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">468</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e5239-wk-Fact-FD9AFC22FEA2E091BFC594757D404E95" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">86,635</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e5253-wk-Fact-11AD19C653F542C874C794757D691F63" name="us-gaap:SharesIssued" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">3,801</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e5274-wk-Fact-BBC46AA267DCADC2619E94757D4B1DD3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">110,781</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e5294-wk-Fact-562BF7F5C92ED48A7C3D94757D41E597" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">93,388</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e5313-wk-Fact-4B8ABD514A7533B0DD2D94757CEB8E0E" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">10,923</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e5334-wk-Fact-5C78C5042C9CAAB17DD594757D1E08DF" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">58,806</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e5353-wk-Fact-82E28E032D731899B0B694757D3E73D0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">352</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e5373-wk-Fact-917DA1C330410587B66094757D7DD34A" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">59,158</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e5520-wk-Fact-1FD9113D58C3CC135A9A94757D26E7FF" name="us-gaap:ProfitLoss" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,046</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e5560-wk-Fact-B54EEE815409E49E0D1894757D4EDBA5" name="us-gaap:ProfitLoss" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,046</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e5579-wk-Fact-594699073675166A837B94757D1BBB71" name="us-gaap:ProfitLoss" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e5598-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B" name="us-gaap:ProfitLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,056</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Other&#160;comprehensive income/(loss), net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e5769-wk-Fact-070B56B824B87F2A371A94757D18F7F9" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">613</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e5790-wk-Fact-CFA8D8DE9A17CA78BDB894757CE71BFF" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">613</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e5810-wk-Fact-4311DCC0A7382F4BE88494757D3C948A" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e5829-wk-Fact-0AC5548725395D35A56C94757D003303" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">610</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Cash dividends declared:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Common stock </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e6219-wk-Fact-886DF198F4CB9AB4242C94757D9970F3" name="us-gaap:DividendsCommonStockCash" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,994</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e6260-wk-Fact-DDE80D633A2B28C2D4B194757D63F34A" name="us-gaap:DividendsCommonStockCash" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,994</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e6300-wk-Fact-9D649DDE4C8F1EF5140994757D200949" name="us-gaap:DividendsCommonStockCash" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,994</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e6454-wk-Fact-7693E162BA55D1667FBC94757D2195F2" name="us-gaap:DividendsPreferredStockCash" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e6494-wk-Fact-9864AFACC9ABDC5E1CF694757CC9DE4C" name="us-gaap:DividendsPreferredStockCash" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e6533-wk-Fact-73F49BAF1651352ADB8A94757D370266" name="us-gaap:DividendsPreferredStockCash" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e6746-wk-Fact-1E1B86E2273523F6FBAD94757D16A070" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e6766-wk-Fact-36A1278749B1A6EBD0EE94757D199E89" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Share-based payment transactions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e6828-wk-Fact-93E2B34C852B38B85FA394757D2258B2" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e6843-wk-Fact-C1DE3E07544739B2E3BC94757CEAD328" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e6862-wk-Fact-1437F24F4D59D041AD5194757D907B35" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">329</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e6896-wk-Fact-2C8B37C90E999E0983A494757D3A0FE2" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e6955-wk-Fact-8333570EE1A66789FB2C94757D365212" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">324</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e6994-wk-Fact-7BEE24816749E03906BD94757D9C4726" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">324</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Purchases of common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e7111-wk-Fact-A1B634793474C63E20E77DAA79965C6D" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e7126-wk-Fact-CA0C786AD2F0B41A91817DAA79E6E7CB" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e7184-wk-Fact-F2F1A0934B119BCED20494757D9F5C1A" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e7223-wk-Fact-3F6A0F8D36D9FD50EACD94757D9D5AA4" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Preferred stock conversions and redemptions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e7249-wk-Fact-8F5ED7D1B0A0EF78888F94757D1CDBFD" name="pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e7264-wk-Fact-75FF99F8C13B7B51000994757D64A357" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e7319-wk-Fact-BE33935DCA8AF32376B994757D5F4D6D" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e7412-wk-Fact-A21E82052DF984C0370594757D762D70" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e7452-wk-Fact-A5C037C17E00CF7C78FE94757D5EE39D" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e7601-wk-Fact-F53C3D63E9620E8FB80594757CCA75EE" name="us-gaap:StockholdersEquityOther" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e7641-wk-Fact-A5D88487E443ABA949BF94757D39E6F7" name="us-gaap:StockholdersEquityOther" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e7679-wk-Fact-C3E7A0CC1F9E87A7290394757D55B8EE" name="us-gaap:StockholdersEquityOther" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Balance, June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e7705-wk-Fact-D37856BCED8C1D2C7F3494757D99EE35" name="us-gaap:SharesIssued" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">458</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e7724-wk-Fact-FB813AC829F4A188FEBA94757D2D36C8" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e7738-wk-Fact-0C3EA3961095E3F8A34994757CCEFE8A" name="us-gaap:SharesIssued" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">9,363</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e7758-wk-Fact-ED5AE72D950E62950F0794757CE72E3D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">468</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e7777-wk-Fact-59A686060A7AF1F7275494757D530630" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">86,963</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e7791-wk-Fact-427A772CBA10468F664594757D453976" name="us-gaap:SharesIssued" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">3,801</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e7812-wk-Fact-F6DA9F6F4CDC4D1208C294757D3DEB55" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">110,786</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e7832-wk-Fact-B00A363AE1BB1F3479D994757D183B47" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">94,440</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e7851-wk-Fact-41A19ED1C18BA2C59FD594757CC95BFE" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11,535</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e7872-wk-Fact-C6B8B0E3BE0B6E14FCC394757D2F7284" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">59,568</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e7891-wk-Fact-066E69F57B7DF80E550194757D597E52" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">357</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e7911-wk-Fact-5570A8AC6555BCC3538194757CDE6165" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">59,924</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:280px;text-align:justify;padding-left:18px;text-indent:-18px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">See end of tables for notes.</span></div><div style="line-height:120%;padding-bottom:73px;text-align:center;padding-left:18px;text-indent:-18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Notes to Condensed Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="46"></td></tr><tr><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="36" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">PFIZER INC. SHAREHOLDERS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Preferred Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Treasury Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">(MILLIONS, EXCEPT PREFERRED SHARES)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Shares</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Stated Value</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Shares</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Par Value</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Add&#8217;l</span></div><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Paid-In Capital</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Shares</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Cost</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Retained Earnings</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Accum. Other Comp.</span></div><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Loss</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Share-</span></div><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">holders&#8217; Equity</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Non-controlling interests</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Total Equity</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Balance, January&#160;1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e8715-wk-Fact-DF376F2902A29228A30394757D95B369" name="us-gaap:SharesIssued" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">431</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e8734-wk-Fact-E53668C499D5B6EED42794757CBA0E04" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e8748-wk-Fact-A73DD4823D1FAAF157BF94757CB25343" name="us-gaap:SharesIssued" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">9,369</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e8768-wk-Fact-D9ACACC3158032862FBC94757CBB3D3D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">468</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e8787-wk-Fact-DFAA9788CAC84F0B9CBE94757D9006BC" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">87,428</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e8801-wk-Fact-D86287A5407ADF62135F94757CB299CF" name="us-gaap:SharesIssued" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">3,835</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e8822-wk-Fact-0A9DF58A6CB5A7F6545994757D8DB53B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">110,801</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e8842-wk-Fact-5FF93BEF0CD0E0592D9894757CB94FC4" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">97,670</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e8861-wk-Fact-5A3DCFE782B686C3474B94757CB5ED2D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11,640</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e8882-wk-Fact-82E5812A435DA211399494757D905CAA" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63,143</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e8901-wk-Fact-CC73D199AFE6851BDA0294757CAED89E" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">303</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e8921-wk-Fact-6AE9A7E5A8423D56EB6794757D15EE65" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63,447</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e9068-wk-Fact-36E7CFCCB407CFADF4BD94757D88D126" name="us-gaap:ProfitLoss" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,828</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e9108-wk-Fact-68B318E9C2DB946F864A94757D889244" name="us-gaap:ProfitLoss" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,828</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e9127-wk-Fact-69B5FF4C482B5ABEA96994757CA8B7DD" name="us-gaap:ProfitLoss" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e9146-wk-Fact-F55F7448D6FD457E7D3094757CC42D99" name="us-gaap:ProfitLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,845</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Other&#160;comprehensive income/(loss), net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e9319-wk-Fact-7015F6E30333F20A4CA094757D862B59" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,605</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e9340-wk-Fact-BFBC825D4CA85CD2E41D94757CB1220B" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,605</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e9360-wk-Fact-1A38F0D11E57E09F813994757D942D38" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e9380-wk-Fact-F996AE0BB974A9291E5D94757CB473E1" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,617</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Cash dividends declared:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e9767-wk-Fact-34BB026C07BB62277DBC94757CB6F69E" name="us-gaap:DividendsCommonStockCash" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,294</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e9808-wk-Fact-2AFFCF1916589B62C56494757D956455" name="us-gaap:DividendsCommonStockCash" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,294</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e9848-wk-Fact-208A12CB637A2CA687FC94757D93B898" name="us-gaap:DividendsCommonStockCash" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,294</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e10002-wk-Fact-FABFB96784AE0E40057C94757CBC23CF" name="us-gaap:DividendsPreferredStockCash" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e10042-wk-Fact-0ACF20D2E36512CA3FFF94757CB9E5D6" name="us-gaap:DividendsPreferredStockCash" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e10081-wk-Fact-469C94508C3D19FD04B494757D87315E" name="us-gaap:DividendsPreferredStockCash" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e10294-wk-Fact-FE201EAFE1503AB0772B94757D8F33AD" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e10314-wk-Fact-699171B0726A36F4B73394757CB0310F" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Share-based payment transactions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e10376-wk-Fact-639B93DD7566754E1E9694757D832F48" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e10391-wk-Fact-D75B034453F0D830B56B94757CB44AE9" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e10410-wk-Fact-F2364CCA95BCB9FF67BA94757CBE23AB" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">473</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e10429-wk-Fact-EE5FCC32DD1F49FD716794757D8499D5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e10445-wk-Fact-CF51E0E503957DBEE07394757CACD840" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">208</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e10506-wk-Fact-E6A6BB806B084AB6D48994757D8EAE58" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">266</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e10545-wk-Fact-3F18B676756C784E4C0D94757CB66A64" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">266</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Purchases of common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e10663-wk-Fact-550D4302BA6804DA1DE694757D9284DA" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e10678-wk-Fact-62CBE8210B463E54DCAE94757D849437" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e10738-wk-Fact-62CBE8210B463E54DCAE94757D849437" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e10777-wk-Fact-FFD71DCF3ECC62BAAB9494757CB88D9F" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Preferred stock conversions and redemptions</span><span style="font-family:inherit;font-size:6.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e10805-wk-Fact-17964A9D32951C373D6394757D89737D" name="pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">431</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e10820-wk-Fact-E82571DEE2C15F9E1D7094757D82377C" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e10876-wk-Fact-87E8BDB2D145CE8F51DF94757CB079E4" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e10896-wk-Fact-D75526E67D4914D634987DAA85CEF4A3" name="pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e10911-wk-Fact-F3B0AC6951DEEF5E98DC94757CA9786E" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">31</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e10971-wk-Fact-E660298A415643D957F994757D82F91C" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e11011-wk-Fact-3C10FB8DF4A946A1047094757CB010DE" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e11105-wk-Fact-8AA71470C6F49FFEF87594757CBC671E" name="us-gaap:StockholdersEquityOther" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e11124-wk-Fact-1E0FA72C88E0180817A294757D917CD7" name="us-gaap:StockholdersEquityOtherShares" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e11158-wk-Fact-C3A560E1E22FD2CFF01C94757CA92EB0" name="us-gaap:StockholdersEquityOther" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e11196-wk-Fact-B742EA2DDFFBC1EE5A0694757CB11B81" name="us-gaap:StockholdersEquityOther" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e11215-wk-Fact-C04FC7C13AC6C8C6DD6594757CB52AB5" name="us-gaap:StockholdersEquityOther" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e11234-wk-Fact-1F784513FF9C94CFD4A694757D890961" name="us-gaap:StockholdersEquityOther" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Balance, June 28, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e11260-wk-Fact-B39352F261C00A65738694757D51EB5C" name="us-gaap:SharesIssued" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e11279-wk-Fact-7527AF621EA7D105014694757D491C4F" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e11293-wk-Fact-780C5B60A58937B5CFA594757D14130D" name="us-gaap:SharesIssued" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">9,394</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e11313-wk-Fact-565D7337C380201E7A3794757D2441F6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">470</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e11332-wk-Fact-9F791EE0835763BF87F894757D6D6836" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">87,886</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e11346-wk-Fact-F12EBCA49A1647F7C9C194757CB75C07" name="us-gaap:SharesIssued" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">3,840</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e11367-wk-Fact-A8241CECE526F96581AE94757CF0E2F1" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">110,978</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e11387-wk-Fact-DFF13E5F684FBEC9822394757D143E71" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">100,203</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e11406-wk-Fact-0311E1C11EAA0D64120894757D282E1A" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">13,246</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e11427-wk-Fact-D2F433B8AA4C0088F7B694757DA65630" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">64,336</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e11446-wk-Fact-E682A060B9E084CD78DB94757CBF7369" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">228</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e11466-wk-Fact-39B247651891576D7B7A94757D210D60" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">64,564</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="46" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="36" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">PFIZER INC. SHAREHOLDERS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Preferred Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Treasury Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">(MILLIONS, EXCEPT PREFERRED SHARES)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Stated Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Par Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Add&#8217;l</span></div><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Paid-In Capital</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Cost</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Retained Earnings</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Accum. Other Comp.</span></div><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Loss</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Share-</span></div><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">holders&#8217; Equity</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Non-controlling interests</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Total Equity</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Balance, January&#160;1, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e12419-wk-Fact-7DD25CF4297877D69E8D94757CAEE705" name="us-gaap:SharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">478</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e12438-wk-Fact-C4994D3207A335AAB81294757D8D7CB7" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e12452-wk-Fact-B058DCB1AE06D394D07494757D832A1B" name="us-gaap:SharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">9,332</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e12472-wk-Fact-354E12AEFC04C5034D5B94757D921C80" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">467</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e12491-wk-Fact-AAF16B56D807C054332894757CBC5D15" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">86,253</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e12505-wk-Fact-7710E5E7409968676DDF94757CB9616B" name="us-gaap:SharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">3,615</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e12526-wk-Fact-11CE3C1F979CA5EE8A3C94757CAC8219" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">101,610</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e12546-wk-Fact-25E3F63155D4E5079AF694757D939426" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">89,554</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e12565-wk-Fact-FB658162A265137F4D2C94757D910349" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11,275</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e12586-wk-Fact-C072E92255A07EC2BC3294757CB644FB" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63,407</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e12605-wk-Fact-FB4B7F31E75AF61C8C1B94757CB6CB4D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e12625-wk-Fact-C3BB46722B4E99BC08FB94757D912C94" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63,758</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e12772-wk-Fact-6A6B16B2145812FF4A4D94757D88E004" name="us-gaap:ProfitLoss" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,929</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e12812-wk-Fact-FC6199412C81449DCEDC94757CB8CF8E" name="us-gaap:ProfitLoss" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,929</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e12831-wk-Fact-044F5FDB0329BCA40A6794757CBD27D2" name="us-gaap:ProfitLoss" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e12850-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9" name="us-gaap:ProfitLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,945</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Other&#160;comprehensive income/(loss), net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e13021-wk-Fact-4F58C9049DEAAC5BA58594757CB32E71" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">260</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e13042-wk-Fact-6D6F3CF5110AF0381DE894757D81F105" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">260</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e13062-wk-Fact-41F806F874E498F7473D94757D8FFC10" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e13082-wk-Fact-920C774D6C3160546F7D94757DA37E07" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">262</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Cash dividends declared:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Common stock </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e13472-wk-Fact-97B0ABF7AD141BFC956394757D9158BA" name="us-gaap:DividendsCommonStockCash" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,062</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e13513-wk-Fact-2D5D0BDDCB3AC167E0BC94757D826702" name="us-gaap:DividendsCommonStockCash" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,062</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e13553-wk-Fact-884749ED8C7327C2FD2094757D8E56E9" name="us-gaap:DividendsCommonStockCash" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,062</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e13707-wk-Fact-D73A14317FBAE5FF36E694757CA8E1DF" name="us-gaap:DividendsPreferredStockCash" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e13748-wk-Fact-24C95C268DFE3FCA16AE94757D94AA45" name="us-gaap:DividendsPreferredStockCash" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e13788-wk-Fact-56FFC68F0A60EB61A79194757CB4018F" name="us-gaap:DividendsPreferredStockCash" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e14002-wk-Fact-5D5C63A4F1FD671C14E194757CAF5BD0" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e14022-wk-Fact-1361821B6A5511EF50EA94757CB26293" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Share-based payment transactions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e14084-wk-Fact-D10B00BA2429F63E86A694757CAB096A" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">31</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e14099-wk-Fact-3217AF55C96F288D0DBD94757CBAA3B1" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e14118-wk-Fact-772E453E27BB5E8A941894757D862BB8" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">712</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e14137-wk-Fact-0EDCB34EA1247F2C3A2394757D8F0EC3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e14153-wk-Fact-52053A7518B63417490094757CA936F0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">312</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e14214-wk-Fact-4BC9CEEA08F3A0DD592F94757CB7DE38" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">402</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e14253-wk-Fact-46C30A88DFF3DBBC269A94757D92355F" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">402</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Purchases of common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e14370-wk-Fact-892DE8B531A6E01C09E194757CBBECA5" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">180</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e14386-wk-Fact-CCC935C176C282D817B794757CBC059A" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,865</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e14447-wk-Fact-9CEB92503A38A9B5DBE094757CB7FA3C" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,865</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e14487-wk-Fact-0401261FCCFCA256A06E94757CBC98A8" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,865</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Preferred stock conversions and redemptions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e14514-wk-Fact-EFC543C17B8D59BB663F94757CAE19EF" name="pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">20</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e14529-wk-Fact-25E53374D4007C779F5294757D853F4E" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e14585-wk-Fact-7F0F15290F5E885CE3D794757CBEF8C8" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e14680-wk-Fact-AF977AD81CDE8A1EAB0994757CABF14E" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e14720-wk-Fact-6CC9C84BFB612CF3CEE194757D856D94" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Other</span><span style="font-family:inherit;font-size:6.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e14869-wk-Fact-6101468A882D99277B2994757CB9521F" name="us-gaap:StockholdersEquityOther" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e14907-wk-Fact-8376F4C46168FF741E3C94757D90B25B" name="us-gaap:StockholdersEquityOther" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e14945-wk-Fact-E4A62043A54AC1E498B094757CACAA7C" name="us-gaap:StockholdersEquityOther" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">Balance, June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e14971-wk-Fact-D37856BCED8C1D2C7F3494757D99EE35" name="us-gaap:SharesIssued" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">458</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e14990-wk-Fact-FB813AC829F4A188FEBA94757D2D36C8" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e15004-wk-Fact-0C3EA3961095E3F8A34994757CCEFE8A" name="us-gaap:SharesIssued" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">9,363</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e15024-wk-Fact-ED5AE72D950E62950F0794757CE72E3D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">468</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e15043-wk-Fact-59A686060A7AF1F7275494757D530630" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">86,963</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e15057-wk-Fact-427A772CBA10468F664594757D453976" name="us-gaap:SharesIssued" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">3,801</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e15078-wk-Fact-F6DA9F6F4CDC4D1208C294757D3DEB55" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">110,786</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e15098-wk-Fact-B00A363AE1BB1F3479D994757D183B47" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">94,440</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span>(<ix:nonFraction id="d8336633e15117-wk-Fact-41A19ED1C18BA2C59FD594757CC95BFE" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11,535</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e15138-wk-Fact-C6B8B0E3BE0B6E14FCC394757D2F7284" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">59,568</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e15157-wk-Fact-066E69F57B7DF80E550194757D597E52" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">357</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;"><span><ix:nonFraction id="d8336633e15177-wk-Fact-5570A8AC6555BCC3538194757CDE6165" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">59,924</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup><ix:footnote id="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-16D720E2797C387B08C294757DB6E91E-1">&#160;</ix:footnote></span></div></td><td style="vertical-align:top;"><ix:continuation id="TextSelection-16D720E2797C387B08C294757DB6E91E-1"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:8pt;">On May 4, 2020, all outstanding shares of Pfizer&#8217;s Series A convertible perpetual preferred stock were converted into shares of Pfizer common stock. See </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 11.</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Equity</span><span style="font-family:inherit;font-size:8pt;"> for additional information.</span></div></ix:continuation></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-DD7734E5853B41ABE8C8546D7049626E-0-wk-Footnote-DD7734E5853B41ABE8C8546D7049626E_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:8pt;">The increase to </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Retained earnings </span><span style="font-family:inherit;font-size:8pt;">represents the cumulative effect of the adoption of a new accounting standard in the first quarter of 2019 for leases. For additional information, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2019</span><span style="font-family:inherit;font-size:8pt;"> in our 2019 Financial Report.</span></div></ix:footnote></td></tr></table><ix:footnote id="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;padding-bottom:266px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></ix:footnote><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Notes to Condensed Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9</span></div></div><hr style="page-break-after:always"></hr><div><a id="s84609C23E00457D5A43F67081A85709D"></a></div><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:76%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;text-decoration:underline;">Operating Activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Net income before allocation to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e858-wk-Fact-F55F7448D6FD457E7D3094757CC42D99" name="us-gaap:ProfitLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,845</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e877-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9" name="us-gaap:ProfitLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,945</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Depreciation and amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e941-wk-Fact-7B3C46A754BAB4A857A994757D1275BE" name="pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,469</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e960-wk-Fact-A6719A6CE4DE88C80E8394757D222E89" name="pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,073</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Asset write-offs and impairments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e985-wk-Fact-D1A152F767D859E8CCE694757CBAD374" name="pfe:AssetWriteOffsAndAssetImpairmentCharges" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e1004-wk-Fact-D5D209CEACE094C3706A94757D602BEE" name="pfe:AssetWriteOffsAndAssetImpairmentCharges" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">178</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">TCJA impact</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e1031-wk-Fact-E717A38DCA77168761C894757CC8AD9A" name="us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e1050-wk-Fact-9485DE235A3009893D3694757CC67D4F" name="us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">285</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e1076-wk-Fact-4A938A8D8BA21B630E4F94757CBAE369" name="pfe:DeconsolidationGainLossAmountNetOfCashConveyed" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e1096-wk-Fact-B2C102786FCBB8D401A594757D1B8EEE" name="pfe:DeconsolidationGainLossAmountNetOfCashConveyed" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Deferred taxes from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e1121-wk-Fact-7B3AE2978F7C733A20D394757D149216" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e1140-wk-Fact-31FAC3AF75C5A095FC3294757D6F298C" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">160</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Share-based compensation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e1166-wk-Fact-B1D6C20091518E36CFA194757CC3358D" name="us-gaap:ShareBasedCompensation" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">258</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e1185-wk-Fact-B42383D404EA70302F8C94757D686185" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">384</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Benefit plan contributions in excess of expense/income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e1211-wk-Fact-6511CCFA698C5A19F60894757CB5C2AF" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">418</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e1231-wk-Fact-03C451138AD2D3E686ED94757CA8870B" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">313</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other adjustments, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e1257-wk-Fact-902EBA952C8391060B6994757CB1FFC1" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">361</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e1277-wk-Fact-E385EE5548C3D0B6620294757D260E17" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">462</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other changes in assets and liabilities, net of acquisitions and divestitures</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e1303-wk-Fact-267AF4FFCF5DAE94DBAA94757CC00E91" name="us-gaap:IncreaseDecreaseInOperatingCapital" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,229</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e1323-wk-Fact-A9E0B30BE08222818D3E94757CCA5EEE" name="us-gaap:IncreaseDecreaseInOperatingCapital" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,051</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Net cash provided by operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e1349-wk-Fact-C06B1B3B80ECC6BED32E94757D69AF05" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,688</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e1368-wk-Fact-4FD042AF6C7E165B3EAF94757D1120B8" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,309</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;text-decoration:underline;">Investing Activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Purchases of property, plant and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e1483-wk-Fact-CAC433338BBE1188257594757D6FCE44" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">942</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e1503-wk-Fact-B07226375662B3FA103594757D67E5BF" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">939</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Purchases of short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e1529-wk-Fact-DBC68DCD2CB0DEC8D8FB94757D61B962" name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,141</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e1549-wk-Fact-2F3BC9DA02E9792A81E594757D1AA1BE" name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,063</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Proceeds from redemptions/sales of short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e1575-wk-Fact-648B9F5A2071A01EE88194757D23C23C" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,595</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e1594-wk-Fact-C1DCC252D5C1E6770C2A94757D2726E3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,001</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e1621-wk-Fact-DEA22D82FF9A17E3E27894757D6F6298" name="pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,949</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e1641-wk-Fact-E3F1771420A95515D37594757D7358CA" name="pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,717</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Purchases of long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e1666-wk-Fact-7DBB915490EEA28AD34F94757D1C965F" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">168</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e1686-wk-Fact-CB3CE131F76D1BC5C4AF94757D6BFF4D" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">123</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Proceeds from redemptions/sales of long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e1713-wk-Fact-69B15CEEDF1C91237BB494757CA88761" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">536</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e1732-wk-Fact-112070D1A1180C6F8D5194757D199924" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">142</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Acquisitions of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e1757-wk-Fact-BDC4E0314FD64F1F888394757D72DA26" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e1777-wk-Fact-A31D6CBE4C3463BD783494757D2A1AEA" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">267</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other investing activities, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e1803-wk-Fact-44B0C90D865A67954DB694757D580795" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e1822-wk-Fact-C7C942686CBC263C1D7194757CC2FF25" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">179</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Net cash provided by/(used in) investing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e1847-wk-Fact-5C2821D98F34452F3A6F94757D2D141F" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">13,082</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e1867-wk-Fact-715B435D745D4142E92394757CBCE93E" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,648</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;text-decoration:underline;">Financing Activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Proceeds from short-term borrowings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e1982-wk-Fact-78F2B6044F533AECF79494757D13E2F0" name="us-gaap:ProceedsFromShortTermDebt" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12,352</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e2001-wk-Fact-F2E6F2C6A9C76A98DCDF94757D59E284" name="us-gaap:ProceedsFromShortTermDebt" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,956</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Principal payments on short-term borrowings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e2026-wk-Fact-483AF33471D66FEACAE994757D64E37B" name="us-gaap:RepaymentsOfShortTermDebt" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,166</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e2046-wk-Fact-267FFBCE28C10DEF50F494757D2204BE" name="us-gaap:RepaymentsOfShortTermDebt" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,375</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e2072-wk-Fact-3FC60AB14A091D74606194757D68E2E6" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,273</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e2092-wk-Fact-D6CFF981EC1FB58C377894757D2A6D00" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,719</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Proceeds from issuance of long-term debt</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e2119-wk-Fact-CCC6307773ADBF2D8B0394757D147293" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,606</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e2138-wk-Fact-269B485E7EDA949BAD5F94757D657E36" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,942</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Principal payments on long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e2163-wk-Fact-479C56CF0F843B8D425E94757CC58178" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,181</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e2183-wk-Fact-68D0815BB8658ED83E2294757CBEB1FA" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,355</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Purchases of common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e2210-wk-Fact-DE8B64A6B5C352DD3FEB94757D21E4DC" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e2229-wk-Fact-2F9D078A1939922E232F94757CC0E69B" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,865</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Cash dividends paid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e2255-wk-Fact-84746CEAE1028754282894757D242276" name="us-gaap:PaymentsOfOrdinaryDividends" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,216</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e2275-wk-Fact-41DCE73B8353AB2C4A8294757CC7A0E2" name="us-gaap:PaymentsOfOrdinaryDividends" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,047</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Proceeds from exercise of stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e2301-wk-Fact-4825D5CD0C1E297EA03E94757D6ECCCE" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">158</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e2320-wk-Fact-9BECE1ABEA4FD6DB7B8A94757D65CB34" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">248</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other financing activities, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e2345-wk-Fact-14555130D0BB52E432C294757D65777B" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">321</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e2365-wk-Fact-68FD1EE0237F3359546394757CC70A3B" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">541</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Net cash provided by/(used in) financing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e2391-wk-Fact-0AB8223F29C3E844972694757CBD7239" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,959</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e2410-wk-Fact-BFED46F6560D1E80618094757D5C3010" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">9,318</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e2436-wk-Fact-1C81E7C063C3183FB22C94757D26F7B6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">70</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e2456-wk-Fact-9509BBD7999258CA6CC694757D1611AA" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">28</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Net increase in cash and cash equivalents and restricted cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e2482-wk-Fact-1DAA0E1B0E6665C79D5F94757CCA5C7B" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">495</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e2501-wk-Fact-7DFB45BE4A92C05A7CE494757D5BC48C" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">612</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e2526-wk-Fact-669B95F4C67830F92DEA94757D66C77B" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,350</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e2545-wk-Fact-91CD03BF7899EC259FA294757CBB3C78" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,225</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Cash and cash equivalents and restricted cash and cash equivalents, at end of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e2575-wk-Fact-F181CF0072905CD126F394757D6959D8" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,845</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e2594-wk-Fact-92C5E71226171D8AEF1294757CAFE14B" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,837</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;text-decoration:underline;">Supplemental Cash Flow Information</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Cash paid (received) during the period for:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e2756-wk-Fact-C0AA245678498A8977C494757D60CCA2" name="us-gaap:IncomeTaxesPaidNet" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,290</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e2775-wk-Fact-2F748880967716EA5ADE94757D1C1B2D" name="us-gaap:IncomeTaxesPaidNet" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,136</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Interest paid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e2795-wk-Fact-B48CBE8AC02E90DAEA4594757D145DE6" name="us-gaap:InterestPaidNet" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">910</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8308070e2814-wk-Fact-4A7A8328763CC8358F7194757D1D40BA" name="us-gaap:InterestPaidNet" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">809</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Interest rate hedges</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e2839-wk-Fact-A62E7998A018A606CB9B94757D1FEF54" name="pfe:InterestReceivedInterestRateHedges" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">66</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8308070e2859-wk-Fact-80889F71FE2525C70D9194757D2B8EDC" name="pfe:InterestReceivedInterestRateHedges" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">72</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-FE05511B3F59D62E086994757DB6CDC4-0-wk-Footnote-FE05511B3F59D62E086994757DB6CDC4_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As a result of the enactment of the TCJA in December 2017, Pfizer&#8217;s </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Provision/(benefit) for taxes on income</span><span style="font-family:inherit;font-size:8pt;"> for the </span><span style="font-family:inherit;font-size:8pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:8pt;"> was favorably impacted by approximately </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8308070e2910-wk-Fact-9485DE235A3009893D3694757CC67D4F" name="us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">285</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">, primarily as a result of additional guidance issued by the U.S. Department of Treasury.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-4E9FC68D27E299B9BB2A92DC4EB2F91A-0-wk-Footnote-4E9FC68D27E299B9BB2A92DC4EB2F91A_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Includes </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8308070e2937-wk-Fact-8877DD9876BC33FFFCE292DDB7C09E1E" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="FD2020Q2QTD_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">11.4</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn long-term debt issuances in the second quarter of 2020, which are included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments</span><span style="font-family:inherit;font-size:8pt;"> in the condensed consolidated balance sheet. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Notes 7A. Financial Instruments: </span><span style="font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Fair Value Measurements</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Financial Instruments: 7D. </span><span style="font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Long-Term Debt</span><span style="font-family:inherit;font-size:8pt;">).</span></div></ix:footnote></td></tr></table><ix:footnote id="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;padding-bottom:20px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></ix:footnote><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Notes to Condensed Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10</span></div></div><hr style="page-break-after:always"></hr><div><a id="s0B1BD583C8DB5F5C90B16A94CD41E35C"></a></div><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s9F64717787FE5DDCB90836F5636CDEC3"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Note 1. </span><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="TextSelection-E1BD266DE2FA7BA8580994757DB6202A-0-wk-Fact-4AF9ADB3EED08BD12E8E94757CC45897" continuedAt="TextSelection-E1BD266DE2FA7BA8580994757DB6202A-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Basis of Presentation and Significant Accounting Policies</span></ix:nonNumeric></div><ix:continuation id="TextSelection-E1BD266DE2FA7BA8580994757DB6202A-1" continuedAt="TextSelection-E1BD266DE2FA7BA8580994757DB6202A-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="TextSelection-8BB7502059171F7F3C4094757DB61183-0-wk-Fact-69F6A976652BF56BDEEA94757CC3AAFF" continuedAt="TextSelection-8BB7502059171F7F3C4094757DB61183-1" escape="true">Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="TextSelection-8BB7502059171F7F3C4094757DB61183-1"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes in this Quarterly Report on Form 10-Q.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the </span><span style="font-family:inherit;font-size:10pt;">three and six months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;">May&#160;24, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">May&#160;26, 2019</span><span style="font-family:inherit;font-size:10pt;">. The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the </span><span style="font-family:inherit;font-size:10pt;">three and six months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> Financial Report.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the beginning of our 2019 fiscal year, we began to manage our commercial operations through a new global structure consisting of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8305411e780-wk-Fact-E7763423A0FDBAB3799A94757CC3EC7A" name="us-gaap:NumberOfOperatingSegments" contextRef="D2019Q3Jan1-Jul31" unitRef="Operating_Segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> business segments&#8211;&#8211;Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and through </span><span style="font-family:inherit;font-size:10pt;">July&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, Consumer Healthcare. Biopharma and Upjohn are the only reportable segments. For additional information, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 14</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan).</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">As a result, revenues and expenses associated with Meridian and Mylan-Japan are reported in our Upjohn business beginning in the first quarter of 2020. In 2019, revenues and expenses from Meridian and Mylan-Japan were recorded in our Biopharma business. We performed certain reclassifications between the Biopharma and Upjohn segments to conform 2019 segment revenues and expenses associated with Meridian and Mylan-Japan to the current presentation. There was no impact to our consolidated financial statements.</span><span style="font-family:inherit;font-size:10pt;"> For additional information, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 14.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisitions and other business development activities completed in 2019 and in the first half of 2020, including the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture, impacted financial results in the periods presented.</span><span style="font-family:inherit;font-size:10pt;"> </span><span>For additional information, see Notes to Consolidated Financial Statements&#8212;</span><span style="font-style:italic;">Note 1A. Basis of Presentation and Significant Accounting Policies: Basis of Presentation</span><span> in our 2019 Financial Report, and </span><span style="font-style:italic;">Note 2</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.</span></div></ix:continuation><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the first quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, as of January 1, </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, we adopted </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8305411e839-wk-Fact-4ED1B6A1CF428384FF4C94757CC3AA54" name="pfe:NumberOfAccountingStandardsAdopted" contextRef="I2020Q1Jan1" unitRef="Accounting_standard" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> new accounting standards. See </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1B</span><span style="font-family:inherit;font-size:10pt;"> for further information.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. </span><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-7CC50CB94F4F1836879A94757DB62CA3-0-wk-Fact-4D3457EC6890D7C927BB94757CC54A08" continuedAt="TextSelection-7CC50CB94F4F1836879A94757DB62CA3-1" escape="true"><span style="font-weight:bold;text-decoration:underline;">Adoption of New Accounting Standards in 2020</span></ix:nonNumeric></div><ix:continuation id="TextSelection-7CC50CB94F4F1836879A94757DB62CA3-1" continuedAt="TextSelection-7CC50CB94F4F1836879A94757DB62CA3-2"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 1, </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, we adopted </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8305411e862-wk-Fact-4ED1B6A1CF428384FF4C94757CC3AA54" name="pfe:NumberOfAccountingStandardsAdopted" contextRef="I2020Q1Jan1" unitRef="Accounting_standard" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> new accounting standards.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Credit Losses on Financial Instruments</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;We adopted a new accounting standard for credit losses on financial instruments, which replaces the probable initial recognition threshold for incurred loss estimates under prior guidance with a methodology that reflects expected credit loss estimates. The standard generally impacts financial assets that have a contractual right to receive cash and are not accounted for at fair value through net income, such as accounts receivable and held-to-maturity debt securities. The new guidance requires us to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for certain financial instruments, using information such as historical experience, current economic conditions and information, and the use of reasonable and supportable forecasted information. The standard also </span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-7CC50CB94F4F1836879A94757DB62CA3-2" continuedAt="TextSelection-7CC50CB94F4F1836879A94757DB62CA3-3"><ix:continuation id="TextSelection-E1BD266DE2FA7BA8580994757DB6202A-2" continuedAt="TextSelection-E1BD266DE2FA7BA8580994757DB6202A-3"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">amends existing impairment guidance for available-for-sale debt securities to incorporate a credit loss allowance and allows for reversals of credit impairments in the event the issuer&#8217;s credit improves.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We adopted the new accounting standard utilizing the modified retrospective method and, therefore, no adjustments were made to amounts in our prior period financial statements. The cumulative effect of adopting the standard as an adjustment to the opening balance of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Retained earnings</span><span style="font-family:inherit;font-size:10pt;"> was not material. The impact of adoption did not have a material impact on our condensed consolidated statement of income for the </span><span style="font-family:inherit;font-size:10pt;">three and six months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;"> or condensed consolidated statement of cash flows for the </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;">, nor on our condensed consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;">. For additional information, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1C</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Goodwill Impairment Testing</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;We prospectively adopted the new standard, which eliminates the requirement to perform a hypothetical purchase price allocation to measure goodwill impairment. Under the new guidance, the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount, and recognizing an impairment charge for the amount by which the carrying amount of the reporting unit exceeds its fair value. There was no impact to our condensed consolidated financial statements from the adoption of this new standard.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Implementation Costs in a Cloud Computing Arrangement</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;We prospectively adopted the new standard related to customers&#8217; accounting for implementation costs incurred in a cloud computing arrangement that is considered a service contract. The new guidance aligns the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The adoption of this guidance did not have a material impact on our condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Collaboration Agreements</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;We prospectively adopted the new standard, which provides new guidance clarifying the interaction between the accounting for collaborative arrangements and revenue from contracts with customers. There was no impact to our condensed consolidated financial statements from the adoption of this new standard.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 1, 2019, we adopted </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8305411e967-wk-Fact-3F0AFADB8C5F5A9A448C94757CC49AF8" name="pfe:NumberOfAccountingStandardsAdopted" contextRef="I2019Q1Jan01" unitRef="Accounting_standard" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> new accounting standards. For additional information, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2019 </span><span style="font-family:inherit;font-size:10pt;">included in our 2019 Financial Report.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">C. Revenues and Trade Accounts Receivable</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Deductions from Revenues&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;">Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8305411e995-wk-Fact-74056B78B0612109EF7094757CC5D9C0" name="pfe:RebatesAndDiscountsAccrual" contextRef="FI2020Q2" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.5</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8305411e1003-wk-Fact-8D3FE40E2EC5A09D209D94757CC3F970" name="pfe:RebatesAndDiscountsAccrual" contextRef="FI2019Q4" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.7</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="pfe:ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock" id="TextSelection-B6B09B0F56D7AD09960C94757DB61718-0-wk-Fact-4411AC0DD4256C93E76D94757CC3AF57" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides information about the balance sheet classification of these accruals:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reserve against </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Trade accounts receivable, less allowance for doubtful accounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8305411e1140-wk-Fact-10512A2C50EB9E54210794757D042EAD" name="pfe:RebatesAndDiscountsAccrual" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,129</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8305411e1159-wk-Fact-C22F5A4B00C48E6E2C6794757D03D5BF" name="pfe:RebatesAndDiscountsAccrual" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,257</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued rebates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8305411e1227-wk-Fact-52230EEF4B30BB42551E94757D059357" name="pfe:AccruedRebates" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,210</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8305411e1246-wk-Fact-FC0D1467FED43488377394757D067F69" name="pfe:AccruedRebates" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,285</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accruals</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8305411e1271-wk-Fact-5D45C986E5309044F54094757D041546" name="pfe:OtherAccruals" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">576</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8305411e1290-wk-Fact-6F3D79DAE47BD65700D394757D04FDB0" name="pfe:OtherAccruals" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">581</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8305411e1315-wk-Fact-3B46D7493FD1D060E11394757D0669E0" name="pfe:RebatesAndDiscountsAccrual" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">598</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8305411e1334-wk-Fact-5E20B65AD8FA8FA778AD94757D05EA97" name="pfe:RebatesAndDiscountsAccrual" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">565</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accrued rebates and other accruals</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8305411e1364-wk-Fact-6D53FDF95DA77A948DA694757D0531FD" name="pfe:RebatesAndDiscountsAccrual" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,512</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8305411e1383-wk-Fact-03FFCDBA53AB458CE1DC94757D03645E" name="pfe:RebatesAndDiscountsAccrual" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,689</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Trade Accounts Receivable&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;">Trade accounts receivable are stated at their net realizable value. The allowance for credit losses against gross trade accounts receivable reflects the best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, </span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-7CC50CB94F4F1836879A94757DB62CA3-3"><ix:continuation id="TextSelection-E1BD266DE2FA7BA8580994757DB6202A-3"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">three and six months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;">, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements.</span></div></ix:continuation></ix:continuation><div><a id="s96B8639063B25582A9CE24C2CC2B8C2D"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Note 2. </span><ix:nonNumeric contextRef="FD2020Q2YTD" name="pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock" id="TextSelection-2771421B13C7460A0EBF94757DB79F23-0-wk-Fact-60CCE39456C7465BA0E394757D88F911" continuedAt="TextSelection-2771421B13C7460A0EBF94757DB79F23-1" escape="true"><span style="font-weight:bold;text-decoration:underline;">Acquisition, Equity-Method Investment and Licensing Arrangements</span></ix:nonNumeric></div><ix:continuation id="TextSelection-2771421B13C7460A0EBF94757DB79F23-1" continuedAt="TextSelection-2771421B13C7460A0EBF94757DB79F23-2"><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. </span><span style="font-weight:bold;text-decoration:underline;">Acquisition</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Array BioPharma Inc.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">July&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e719-wk-Fact-3B7CF3078C2C97E5B55894757D8885E8" name="us-gaap:BusinessAcquisitionSharePrice" contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">48</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share in cash. The total fair value of the consideration transferred for Array was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e723-wk-Fact-9688C7D5006E3F63EA6E94757D89E7FC" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="D2019Q3Jul30-Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">11.2</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e727-wk-Fact-4C3F3AFBD3CBFE139E4D94757D89A634" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="D2019Q3Jul30-Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">10.9</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;">, net of cash acquired). Array&#8217;s portfolio includes Braftovi (encorafenib) and Mektovi (binimetinib). The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not yet been finalized.</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. </span><span style="font-weight:bold;text-decoration:underline;">Equity-Method Investment</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Formation of GSK Consumer Healthcare Joint Venture</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">July&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name. In exchange for contributing our Consumer Healthcare business to the joint venture, we received a </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8302032e749-wk-Fact-923536071B10D741FA9C94757D85FCA9" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">32</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> equity stake in the new company and GSK owns the remaining </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8302032e753-wk-Fact-3638E46AA0F8C173472594757D8C98B4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="I2019Q3Jul31_dei_LegalEntityAxis_pfe_GSKMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">68</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">. Upon the closing of the transaction, we deconsolidated our Consumer Healthcare business and recognized a pre-tax gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e757-wk-Fact-C6406BA65157010AD90494757D8B1E4E" name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">8.1</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e761-wk-Fact-632DBB6A57751E7AADD894757D88AADE" name="pfe:DeconsolidationGainLossAmountNetOfTax" contextRef="FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.4</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;">, net of tax) in our fiscal third quarter of 2019 in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">(Gain) on completion of Consumer Healthcare JV transaction</span><span style="font-family:inherit;font-size:10pt;"> for the difference in the fair value of our </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8302032e770-wk-Fact-923536071B10D741FA9C94757D85FCA9" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">32</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> equity stake in the new company and the carrying value of our Consumer Healthcare business. We may record additional adjustments to the gain in future periods, which we do not expect to have a material impact on our consolidated financial statements. Our financial results, and our Consumer Healthcare segment&#8217;s operating results, for the </span><span style="font-family:inherit;font-size:10pt;">second quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> reflect three months of Consumer Healthcare segment operations</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">and for</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">the first six months of</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">2019 reflect six months of Consumer Healthcare segment operations,</span><span style="font-family:inherit;font-size:10pt;"> while financial results for the </span><span style="font-family:inherit;font-size:10pt;">second quarter</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">and first</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">six months</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> do not reflect any contribution from the Consumer Healthcare business.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are accounting for our interest in GSK Consumer Healthcare as an equity-method investment. The carrying value of our</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:inherit;font-size:10pt;">investment in GSK Consumer Healthcare is approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e823-wk-Fact-534D98444857F49F204094757D88F403" name="us-gaap:EquityMethodInvestments" contextRef="FI2020Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">15.4</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e831-wk-Fact-1ED723775ACC5C8A35DA94757D8995B3" name="us-gaap:EquityMethodInvestments" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">17.0</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and is reported as a private equity investment in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Equity-method investments </span><span style="font-family:inherit;font-size:10pt;">line in our condensed consolidated balance sheet. We record our share of earnings from the GSK Consumer Healthcare joint venture on a quarterly basis on a one-quarter lag in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:10pt;"> commencing from August 1, 2019. Therefore, we recorded our share of the joint venture&#8217;s earnings generated in the first quarter of 2020, which totaled approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e848-wk-Fact-35111911F7F1C01D532E94757D8BB804" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">129</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, in our operating results in the </span><span style="font-family:inherit;font-size:10pt;">second quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">. Our total share of the joint venture&#8217;s earnings generated in the fourth quarter of 2019 and the first quarter of 2020, which we recorded in our operating results for </span><span style="font-family:inherit;font-size:10pt;">the first six months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e869-wk-Fact-CF98C918B1FD647F8163596FD20366C9" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">140</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. See </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 4</span><span style="font-family:inherit;font-size:10pt;">. As of the July 31, 2019 closing date, we estimated that the fair value of our investment in GSK Consumer Healthcare was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e877-wk-Fact-74F5A63BAFC58E7A74C794757D8A4E69" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">15.7</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> and that </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8302032e881-wk-Fact-923536071B10D741FA9C94757D85FCA9" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">32</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the underlying equity in the carrying value of the net assets of GSK Consumer Healthcare was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e886-wk-Fact-F2EFF4229B0DB1A000BE94757D8705DB" name="us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets" contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">11.2</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;">, resulting in an initial basis difference of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e890-wk-Fact-9F171483A009A8689B7494757D88C84E" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">4.5</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;">. In the fourth quarter of 2019, we preliminarily completed the allocation of the basis difference, which resulted from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the joint venture, primarily to inventory, definite-lived intangible assets, indefinite-lived intangible assets, related deferred tax liabilities and equity method goodwill within the investment account. We recorded the amortization of basis differences allocated to inventory, definite-lived intangible assets and related deferred tax liabilities in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:10pt;"> commencing August 1, 2019. During the fourth quarter of 2019, GSK Consumer Healthcare revised the initial carrying value of the net assets of the joint venture and our </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8302032e898-wk-Fact-923536071B10D741FA9C94757D85FCA9" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">32</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> share of the underlying equity in the carrying value of the net assets of GSK Consumer Healthcare was reduced to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e902-wk-Fact-A55474F99E0F2AF6917794757D8C49C6" name="us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">11.0</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> and our initial basis difference was increased to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e906-wk-Fact-7008CF61FF0FA949279D94757D8AC958" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">4.8</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;">. The adjustment was allocated to equity method goodwill within the investment account. The amortization of these basis differences for the first quarter of 2020 totaling approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e911-wk-Fact-17A4AF4B11945BBDB47294757D874363" name="pfe:EquityMethodInvestmentExcessBasisAmortization" contextRef="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of expense is included in our operating results in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:inherit;font-size:10pt;">in</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">the </span><span style="font-family:inherit;font-size:10pt;">second quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">. The total amortization of these basis differences for the fourth quarter of 2019 and the first quarter of 2020, which was included in our operating results in </span><span style="font-family:inherit;font-size:10pt;">the first six months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e940-wk-Fact-FB81F282C8061B0BD248596860BF46DA" name="pfe:EquityMethodInvestmentExcessBasisAmortization" contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">48</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of expense. See </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 4. </span><span style="font-family:inherit;font-size:10pt;">Amortization of </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-2771421B13C7460A0EBF94757DB79F23-2" continuedAt="TextSelection-2771421B13C7460A0EBF94757DB79F23-3"><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">basis differences on inventory and related deferred tax liabilities has been completely recognized by the second quarter of 2020. Basis differences on definite-lived intangible assets and related deferred tax liabilities are being amortized over the lives of the underlying assets, which range from </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8302032e951-wk-Fact-BB67015EAA9964FC846C79339BCE6373" name="pfe:EquityMethodInvestmentExcessBasisAmortizationPeriod" contextRef="FD2020Q2YTD_srt_RangeAxis_srt_MinimumMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" format="ixt-sec:duryear">6</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8302032e955-wk-Fact-D88B17FB8BC382BCAC7894757D8A021A" name="pfe:EquityMethodInvestmentExcessBasisAmortizationPeriod" contextRef="FD2020Q2YTD_srt_RangeAxis_srt_MaximumMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" format="ixt-sec:duryear">20</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;">. GSK Consumer Healthcare is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other comprehensive income</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in the value of our investment from December 31, 2019 to </span><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;"> is primarily due to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e972-wk-Fact-B5BFC10FBD677AADEEAB5E4E6E80CBE3" name="pfe:EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-8" scale="9" sign="-" format="ixt:numdotdecimal">1.1</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> in pre-tax foreign currency translation adjustments (see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 6</span><span style="font-family:inherit;font-size:10pt;">), as well as a dividend of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e980-wk-Fact-CEC9202BBFBA0680D58E5E4934805AA6" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" contextRef="D2020Q2Jun1-28_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">519</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which was received from the GSK Consumer Healthcare joint venture in June 2020.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a part of Pfizer, pre-tax income on a management business unit basis for the Consumer Healthcare business was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e1060-wk-Fact-5E6EE1EC31AF006B10B394757D8A38B1" name="pfe:DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss" contextRef="FD2019Q2QTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">274</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">second quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e1072-wk-Fact-962139B23FDF72F0728C955D6E007AD2" name="pfe:DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss" contextRef="FD2019Q2YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">554</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:EquityMethodInvestmentsTextBlock" id="TextSelection-7D37DC0F77D0555B705F94757DB61FCD-0-wk-Fact-C06EEAAB58F0373F802894757D87D5B4" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.05068226120858%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:77%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Summarized financial information for our equity method investee, GSK Consumer Healthcare, as of and for the three and six months ending March 31, 2020, the most recent period available, is as follows:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 31, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8302032e1169-wk-Fact-BD6650750B49E38F1BD694757DA1B96E" name="us-gaap:AssetsCurrent" contextRef="I2020Q2Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,213</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8302032e1189-wk-Fact-2E96A5AE76D12A2A44E894757D9FBC46" name="us-gaap:AssetsNoncurrent" contextRef="I2020Q2Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">37,627</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8302032e1219-wk-Fact-F3872A27A7CDFD4E71F294757DA0EF87" name="us-gaap:Assets" contextRef="I2020Q2Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">45,840</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8302032e1270-wk-Fact-8744AD2F441C0FD2719394757DA0261A" name="us-gaap:LiabilitiesCurrent" contextRef="I2020Q2Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,524</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8302032e1290-wk-Fact-F8A2CA4DF6FC65A31AAB94757DA2B97A" name="us-gaap:LiabilitiesNoncurrent" contextRef="I2020Q2Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,152</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8302032e1320-wk-Fact-23970D49D92D797BCAC194757DA016DB" name="us-gaap:Liabilities" contextRef="I2020Q2Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,677</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity attributable to shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8302032e1371-wk-Fact-77F8A3C973FF1BC63CB894757D9FE048" name="us-gaap:StockholdersEquity" contextRef="I2020Q2Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35,031</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8302032e1392-wk-Fact-0F9D4325CE6DF69F5FC794757DA1AD23" name="us-gaap:MinorityInterest" contextRef="I2020Q2Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8302032e1422-wk-Fact-181ACBA773F2BD3296D794757DA05DF4" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2020Q2Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35,163</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.05068226120858%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:54%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8302032e1510-wk-Fact-8B7D97748BECD855AC4294757D425CB1" name="us-gaap:Revenues" contextRef="D2020Q2Jan1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,503</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8302032e1529-wk-Fact-230BFF8F7536A1E2C3C259652FBAE6D8" name="us-gaap:Revenues" contextRef="D2020Q2Oct1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,691</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8302032e1549-wk-Fact-7CFB77353A6D493129C194757D410F81" name="us-gaap:CostOfRevenue" contextRef="D2020Q2Jan1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,394</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8302032e1569-wk-Fact-7BCDF0748EC9489D86BA596531159DDC" name="us-gaap:CostOfRevenue" contextRef="D2020Q2Oct1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,205</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross profit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8302032e1600-wk-Fact-E91F453C2EB917CE78F494757D4210EC" name="us-gaap:GrossProfit" contextRef="D2020Q2Jan1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,109</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8302032e1619-wk-Fact-509C963AEDDB4A3BC16D596532BE05CD" name="us-gaap:GrossProfit" contextRef="D2020Q2Oct1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,486</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8302032e1639-wk-Fact-B9D541C3B888CD647C9294757D4160D6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="D2020Q2Jan1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">425</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8302032e1658-wk-Fact-6472BE53B0F023B4060459653454BDC9" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="D2020Q2Oct1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">471</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8302032e1683-wk-Fact-DC5193E7F7CCB9B8399494757D42FBFE" name="us-gaap:ProfitLoss" contextRef="D2020Q2Jan1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">425</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8302032e1702-wk-Fact-DC267EA5300FF89BDC25596535E4AED6" name="us-gaap:ProfitLoss" contextRef="D2020Q2Oct1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">471</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income attributable to shareholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8302032e1727-wk-Fact-6B8672F42AD20E9A05B594757D424936" name="us-gaap:NetIncomeLoss" contextRef="D2020Q2Jan1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">405</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8302032e1746-wk-Fact-33DF8D0157C77FF21068596537AA9905" name="us-gaap:NetIncomeLoss" contextRef="D2020Q2Oct1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">441</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">C. </span><span style="font-weight:bold;text-decoration:underline;">Licensing Arrangements</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Agreement with Valneva SE</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">April&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, we signed an agreement to co-develop and commercialize Valneva&#8217;s Lyme disease vaccine candidate VLA15. VLA15 is the only active Lyme disease vaccine program in clinical development today, and covers six serotypes that are prevalent in North America and Europe. Valneva and Pfizer will work closely together throughout the development of VLA15. Valneva is eligible to receive a total of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e1776-wk-Fact-CF1D1EAA5DFFB410710E599315B3AC09" name="pfe:ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1" contextRef="I2020Q2Apr30_srt_CounterpartyNameAxis_pfe_ValnevaSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">308</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash payments consisting of a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e1780-wk-Fact-8E238C10486452CF3D09598280E84FD3" name="pfe:PaymentForLicensingArrangement" contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_pfe_ValnevaSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">130</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment, which was paid and recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expenses </span><span style="font-family:inherit;font-size:10pt;">in our fiscal second quarter of 2020, as well as </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e1788-wk-Fact-2733350B2DACC996A0D7599956D0D18A" name="pfe:ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure" contextRef="I2020Q2Apr30_srt_CounterpartyNameAxis_pfe_ValnevaSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in development milestones and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e1793-wk-Fact-993C8C7240EDCA4A29EE599C5A5C89A7" name="pfe:ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure" contextRef="I2020Q2Apr30_srt_CounterpartyNameAxis_pfe_ValnevaSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">143</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in early commercialization milestones. Under the terms of the agreement, Valneva will fund </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8302032e1797-wk-Fact-75E701D64E989BEC52F859AFEA3015A3" name="pfe:ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage" contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_pfe_ValnevaSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">30</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of all development costs through completion of the development program, and in return we will pay Valneva tiered royalties. We will lead late-stage development and have sole control over commercialization.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Agreement with BioNTech SE</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">April&#160;9, 2020</span><span style="font-family:inherit;font-size:10pt;">, we signed a global agreement with BioNTech to co-develop a potential first-in-class, mRNA-based coronavirus vaccine program, BNT162, aimed at preventing COVID-19 infection. The collaboration aims to rapidly advance multiple COVID-19 vaccine candidates into human clinical testing based on BioNTech&#8217;s proprietary mRNA vaccine platforms, with the objective of ensuring rapid worldwide access to the vaccine, if approved. The collaboration will leverage our broad expertise in vaccine R&amp;D, regulatory capabilities, and global manufacturing and distribution network. In connection with the agreement, we paid BioNTech an upfront cash payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e1811-wk-Fact-EFBFCC97311C8789023B59BE7193DA52" name="pfe:PaymentForLicensingArrangement" contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_pfe_BioNTechSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">72</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which was recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expenses </span><span style="font-family:inherit;font-size:10pt;">in our fiscal second quarter of 2020, and we made an equity investment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e1819-wk-Fact-EC82D6293102A225E84C5A51735B8A05" name="pfe:LicensingArrangementValueOfSharesPurchased" contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_pfe_BioNTechSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">113</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in common stock of BioNTech. BioNTech is eligible to receive potential future milestone payments of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e1823-wk-Fact-70E8C2166B9CBC5236F15A323FA672AF" name="pfe:ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure" contextRef="I2020Q2Apr9_srt_CounterpartyNameAxis_pfe_BioNTechSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">563</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for a total consideration of </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-2771421B13C7460A0EBF94757DB79F23-3"><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e1828-wk-Fact-730FE25CAE8F28A2B32A59C2853A6479" name="pfe:ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1" contextRef="I2020Q2Apr9_srt_CounterpartyNameAxis_pfe_BioNTechSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">748</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. While Pfizer and BioNTech will share development costs equally if the vaccine is approved and successfully commercialized, Pfizer will be responsible for all of the development costs until commercialization of the vaccine. Thereafter, BioNTech would repay Pfizer its </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8302032e1832-wk-Fact-3FEB43AAAF175E5DEB2A5A556CB430BA" name="pfe:ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed" contextRef="D2020Q2Apr9-9_srt_CounterpartyNameAxis_pfe_BioNTechSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction> percent</span></span><span style="font-family:inherit;font-size:10pt;"> share of these development costs through reductions in gross profit sharing and milestone payments to BioNTech over time. BioNTech and Pfizer will also work jointly to commercialize the vaccine worldwide (excluding China, which is subject to a separate collaboration between BioNTech and Shanghai Fosun Pharmaceutical (Group) Co., Ltd) if development is successful and regulatory approval is obtained. We made an additional investment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8302032e1836-wk-Fact-A1B7E8A165028C93312692E0ECD772A0" name="pfe:LicensingArrangementValueOfSharesPurchased" contextRef="D2020Q3Jul1-31_srt_CounterpartyNameAxis_pfe_BioNTechSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in common stock of BioNTech as part of an underwritten equity offering by BioNTech, which closed in July 2020 in our fiscal third quarter of 2020.</span></div></ix:continuation><div><a id="sCC2014E3B0A15A8B8176B4C9FE0C5586"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Note 3. </span><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="TextSelection-7FA28E1BF698ADFB2C6E94757DB8599C-0-wk-Fact-6B1D7E9364894BE5981494757D6A75FD" continuedAt="TextSelection-7FA28E1BF698ADFB2C6E94757DB8599C-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span></ix:nonNumeric></div><ix:continuation id="TextSelection-7FA28E1BF698ADFB2C6E94757DB8599C-1" continuedAt="TextSelection-7FA28E1BF698ADFB2C6E94757DB8599C-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For example: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and R&amp;D, as well as groups such as information technology, shared services and corporate operations.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Transforming to a More Focused Company Program</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">With the formation of the GSK Consumer Healthcare joint venture and the anticipated combination of Upjohn, our global, primarily off-patent branded and generics business, with Mylan, Pfizer is transforming itself into a more focused, global leader in science-based innovative medicines.&#160;As a result, we began in the fourth quarter of 2019, to identify and undertake efforts to ensure our cost base aligns appropriately with our Biopharmaceutical revenue base as a result of both the completed GSK Consumer Healthcare and expected Upjohn transactions.&#160;While certain direct costs have transferred or will transfer to the GSK Consumer Healthcare joint venture and to the Upjohn entities, there are indirect costs which are not expected to transfer. In addition, we are taking steps to restructure our organizations to appropriately support and drive the purpose of the three core functions of our focused innovative medicines business: R&amp;D, Manufacturing and Commercial.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect the costs associated with this multi-year program to be incurred from 2020 through 2022 and to total approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8312059e735-wk-Fact-3044648FBF0869E18E3D94757D690C20" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" contextRef="FI2020Q2_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.2</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> on a pre-tax basis, with substantially all of the costs to be cash expenditures. Actions may include, among others, changes in location of certain activities, expanded use and co-location of centers of excellence and shared services, and increased use of digital technologies. The associated actions and the specific costs will primarily include severance and benefit plan impacts, exit costs as well as associated implementation costs.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Also as part of this program, in connection with the legacy cost reduction initiatives, primarily related to manufacturing activities, we expect to incur costs of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8312059e742-wk-Fact-8CEB189489541EA402C392E3F246022C" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" contextRef="FI2020Q2_us-gaap_RestructuringCostAndReserveAxis_pfe_ManufacturingCostReductionMember_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">400</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, with approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e746-wk-Fact-2048BE2E605F41EAFDC792E8102BD13E" name="pfe:RestructuringandRelatedCostNoncashChargesPercentage" contextRef="FD2020Q2YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_ManufacturingCostReductionMember_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the costs to be non-cash. The costs associated with this effort are expected to be incurred from 2020 through 2022, and will primarily include implementation costs, product transfer costs, exit costs, as well as accelerated depreciation. </span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From the start of this program in the fourth quarter of 2019 through </span><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;">, we incurred approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8312059e758-wk-Fact-71E37D7C4239114B57BC94757D688F90" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextRef="D2020Q2Oct1-Jun28_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">549</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with this program.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Current-Period Key Activities</span></div><div style="line-height:120%;padding-top:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;">, we incurred costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8312059e776-wk-Fact-9EE2124DE8C10D3059A894757D6C98F4" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextRef="FD2020Q2YTD_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">566</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> composed primarily of the Transforming to a More Focused Company program. For the first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of 2019, we incurred costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8312059e784-wk-Fact-2A534AEA1951A5F2C0C894757D678690" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> composed of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8312059e789-wk-Fact-8BAE85BFD1B5B8B966645E5EEC6A6155" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextRef="FD2019Q2YTD_us-gaap_RestructuringPlanAxis_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">180</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with the 2017-2019 and Organizing for Growth initiatives, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8312059e793-wk-Fact-F96984E379A064B8E7D35E5F2BC626FB" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RestructuringCostAndReserveAxis_pfe_BusinessIntegrationCostsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">51</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with the integration of Hospira, and income of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8312059e797-wk-Fact-741446EAC586E57B9EED5E619FA50919" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextRef="FD2019Q2YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_BusinessIntegrationCostsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">199</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> primarily due to the reversal of certain accruals upon the effective favorable settlement of an IRS audit for multiple tax years and other acquisition-related initiatives.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-7FA28E1BF698ADFB2C6E94757DB8599C-2" continuedAt="TextSelection-7FA28E1BF698ADFB2C6E94757DB8599C-3"><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="TextSelection-19802FF900512064EAC594757DB8DA56-0-wk-Fact-601C5DF99DAD43FCA07594757D67D3AB" continuedAt="TextSelection-19802FF900512064EAC594757DB8DA56-1" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Arial;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restructuring charges/(credits):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee terminations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e1193-wk-Fact-A8FBB11639AD83895C4894757CDEA58B" name="us-gaap:SeveranceCosts1" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">346</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8312059e1212-wk-Fact-7D82876FC21450C441F094757CE0617F" name="us-gaap:SeveranceCosts1" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">166</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e1233-wk-Fact-4BFF46406B679E0E244394757D43CFE3" name="us-gaap:SeveranceCosts1" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">371</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8312059e1252-wk-Fact-C9858E63429CB08F8D3494757D394EAE" name="us-gaap:SeveranceCosts1" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">167</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset impairments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8312059e1273-wk-Fact-C868499F38EA8FF492E494757CDAFCD5" name="pfe:RestructuringAssetImpairmentCharges" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8312059e1293-wk-Fact-E7AD67D5365008E93D0894757CE22B3E" name="pfe:RestructuringAssetImpairmentCharges" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e1313-wk-Fact-32CED524A743CA91703C94757CEB29A2" name="pfe:RestructuringAssetImpairmentCharges" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e1333-wk-Fact-1AA9902274635EAEF3A494757CF00987" name="pfe:RestructuringAssetImpairmentCharges" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exit costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e1358-wk-Fact-D6E7AF49487BBF1CE4B094757CDCAEFE" name="us-gaap:BusinessExitCosts1" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e1377-wk-Fact-25C401F2C40DB5B7A09E94757CE4D3D3" name="us-gaap:BusinessExitCosts1" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">31</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e1396-wk-Fact-821797DEB7FD7085AAE994757CED2C67" name="us-gaap:BusinessExitCosts1" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e1416-wk-Fact-4070C352C0113B782C2494757D4564CA" name="us-gaap:BusinessExitCosts1" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restructuring charges</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e1443-wk-Fact-9D9F803549723F3037FC94757CE1E2E0" name="us-gaap:RestructuringCharges" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">340</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8312059e1462-wk-Fact-E911ACF0DB03AEB6DA8594757CE5E26F" name="us-gaap:RestructuringCharges" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">144</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e1482-wk-Fact-DD70750D757F8E36AEFE94757D511014" name="us-gaap:RestructuringCharges" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">396</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8312059e1502-wk-Fact-2A97CB7CBC5000EECE0F94757CE3B4C8" name="us-gaap:RestructuringCharges" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">134</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transaction costs</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e1530-wk-Fact-E0F430906659E697076D94757CE4D373" name="pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e1549-wk-Fact-DEE82D8D87D1D1AA50F194757CE0C55D" name="pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e1568-wk-Fact-348F989B829127D79CF794757D4C6631" name="pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e1588-wk-Fact-6F4079F311DB52E2A33594757D365375" name="pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Integration costs and other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e1615-wk-Fact-CD30CA356357FE6A950B94757CE59164" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e1634-wk-Fact-F7DAC00A60C60846547B94757CE11E6F" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e1653-wk-Fact-C9BE48676477EEA3C2DA94757CE814D1" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e1673-wk-Fact-1AB5EE46A517FE80526894757CDD6A28" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">64</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e1698-wk-Fact-7E093B7D90D64F5B13A494757D3BA82F" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">362</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8312059e1717-wk-Fact-788604D6690A503EC72D94757D52CBCB" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">115</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e1737-wk-Fact-BB8522BC4D5C3EA5BD8694757CB166F6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">431</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8312059e1757-wk-Fact-C8984FE48C4ADA9BA0CA94757CCB4FED" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">69</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net periodic benefit costs recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e1786-wk-Fact-AF06A50586873888380194757CE6EDA3" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e1805-wk-Fact-81D3D22CEB2AD8305E7C94757CDB83C9" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e1824-wk-Fact-42CF5714248F45F16C4994757D4AE685" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e1844-wk-Fact-35C52AB5F0D672D4BCB394757CDACC01" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additional depreciation&#8211;&#8211;asset restructuring</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;</sup></span><span style="font-family:inherit;font-size:10pt;">recorded in our condensed consolidated statements of income as follows</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span><span style="font-family:inherit;font-size:10pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e1960-wk-Fact-5A9323DDE96F467D4EB294757CDEBFD7" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e1979-wk-Fact-D32BE49AC04B6AB1E7A894757CE0BC21" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e1998-wk-Fact-C6C094F211EFE1192A7994757D666DEC" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2018-wk-Fact-392A8B2D61CA7072524094757D40CAB7" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2043-wk-Fact-2FD155A9458FEA78C7F194757CE25240" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2062-wk-Fact-9F156B344E4DD52CA8B394757CE34982" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2081-wk-Fact-294468E799E3C655921694757D428F2B" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2101-wk-Fact-0D9B88019461C261B2D994757D33A088" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2126-wk-Fact-D607D2703E69C5FECFE694757CDCD329" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2145-wk-Fact-81D654407A04152B766994757CDD8A45" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8312059e2164-wk-Fact-476B18F8EF4E7B05E20394757CD2DBCA" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2185-wk-Fact-A724B0094E4DB323816594757D52FEEC" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total additional depreciation&#8211;&#8211;asset restructuring</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2210-wk-Fact-B87A51A9779CD1CF018694757CE399DF" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2229-wk-Fact-F5BC31DCC6B0367BD58894757CDB9BE9" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2248-wk-Fact-9209A09A308FD4F6E18194757D3C8964" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2268-wk-Fact-5813093241A54AAC971594757D47CE74" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Implementation costs recorded in our condensed consolidated statements of income as follows</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup></span><span style="font-family:inherit;font-size:10pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2380-wk-Fact-24B4A8ECAE3E2474912094757CDF68AE" name="pfe:ImplementationCosts" contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2399-wk-Fact-9F6032E503A2CA1767B194757CDC4DEA" name="pfe:ImplementationCosts" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2418-wk-Fact-10C0D0D972663C0BC95494757CF12E8C" name="pfe:ImplementationCosts" contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2438-wk-Fact-40B5B65787722B300CCA94757D4E39DB" name="pfe:ImplementationCosts" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">31</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2463-wk-Fact-1AE830A789111962733194757CE1B056" name="pfe:ImplementationCosts" contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2482-wk-Fact-6846E2B46425F1D8EBA694757CDA487C" name="pfe:ImplementationCosts" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2501-wk-Fact-1D95D82D28060BA3A08A94757CE1514E" name="pfe:ImplementationCosts" contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">78</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2521-wk-Fact-33CF13183D5E3D8446A994757CD4AE22" name="pfe:ImplementationCosts" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2546-wk-Fact-2DA0B9B079BAAF2177CF94757CDF2206" name="pfe:ImplementationCosts" contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2565-wk-Fact-1A602D6AF23843C2BB1894757CDAEB96" name="pfe:ImplementationCosts" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2584-wk-Fact-127515899B5DE626CC8194757D3ECA81" name="pfe:ImplementationCosts" contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2604-wk-Fact-7B35AE5A591127B6882494757D496AF1" name="pfe:ImplementationCosts" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total implementation costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2629-wk-Fact-73C8A01061ED49259E2594757CE5569D" name="pfe:ImplementationCosts" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2648-wk-Fact-17AFA0CD14201AA75F3794757CE4EBFE" name="pfe:ImplementationCosts" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2667-wk-Fact-57AFB05C46254859A5D694757D6FE43D" name="pfe:ImplementationCosts" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">99</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2687-wk-Fact-469E3365E76E79BE433894757CCE1E1E" name="pfe:ImplementationCosts" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">69</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total costs associated with acquisitions and cost-reduction/productivity initiatives</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2718-wk-Fact-19F02225A57F3A01328394757CDECC6E" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">449</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8312059e2737-wk-Fact-1EC7B4190567F243D63094757CE366F4" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">59</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2758-wk-Fact-0D4CA64BE5B7259FDCE694757CCFF5C7" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">566</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8312059e2777-wk-Fact-5DB4753E6EBACF12BB1C94757D3AF655" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-A2331388F2C895076E3994757DB73022-0-wk-Footnote-A2331388F2C895076E3994757DB73022_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-A2331388F2C895076E3994757DB73022-1"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first six months of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, restructuring charges mainly represent employee termination costs associated with our Transforming to a More Focused Company cost reduction program. In the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">, restructuring credits mostly represent the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of an IRS audit for multiple tax years. See Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 5D. Tax Matters: Tax Contingencies </span><span style="font-family:inherit;font-size:8pt;">in our 2019 Financial Report.</span></div></ix:footnote></td></tr></table><ix:continuation id="TextSelection-A2331388F2C895076E3994757DB73022-1"><div style="line-height:120%;padding-bottom:1px;padding-top:2px;padding-left:24px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The restructuring activities for </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, Biopharma (</span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8312059e2848-wk-Fact-EA59B8E893033E1F5A8D5E68C1B993BF" name="us-gaap:RestructuringCharges" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">12</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); Upjohn (</span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8312059e2852-wk-Fact-E32201E74992D57252A65E688511FFF3" name="us-gaap:RestructuringCharges" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); and Other (</span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8312059e2856-wk-Fact-B76088ECB4E3516973635E68F242648C" name="us-gaap:RestructuringCharges" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">352</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> charge).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, Biopharma (</span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8312059e2876-wk-Fact-AD3D4D1457A07D882DF15E6940659B3D" name="us-gaap:RestructuringCharges" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); Upjohn (</span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8312059e2880-wk-Fact-B9D87D308F85678EFCE25E698F32FDD1" name="us-gaap:RestructuringCharges" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> charge); and Other (</span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8312059e2884-wk-Fact-0A8242825A1620571D405E69D496F26A" name="us-gaap:RestructuringCharges" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">393</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> charge).</span></div></td></tr></table><div style="line-height:120%;padding-bottom:1px;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The restructuring activities for </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">, Biopharma (</span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8312059e2911-wk-Fact-E34D5EF6437025BF0CF25E6808A5B9D8" name="us-gaap:RestructuringCharges" contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">62</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); Upjohn (</span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8312059e2915-wk-Fact-10BEF3BA9211D48E0BFB5E67A380452C" name="us-gaap:RestructuringCharges" contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); and Other (</span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8312059e2919-wk-Fact-707CA11A39A1C8DEB50B5E684038ABA9" name="us-gaap:RestructuringCharges" contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">74</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> credit).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">, Biopharma (</span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8312059e2942-wk-Fact-1D406BE4FDC47F4798D25E695FB21A0B" name="us-gaap:RestructuringCharges" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">48</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); Upjohn (</span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8312059e2946-wk-Fact-ACC1801CE3C4D765E1F25E69AC7D9821" name="us-gaap:RestructuringCharges" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">22</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); and Other (</span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8312059e2950-wk-Fact-8BDC7532509814BA5BC25E69F424ADEA" name="us-gaap:RestructuringCharges" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">63</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> credit).</span></div></td></tr></table><div style="line-height:120%;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Restructuring costs identified as Other are for restructuring activities associated with corporate enabling functions, WRDM, GPD and other manufacturing and commercial operations, as applicable. For the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, restructuring costs identified as Other primarily relate to corporate enabling functions.</span></div></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-AB3DF04F3446139615AC94757DB7D909-0-wk-Footnote-AB3DF04F3446139615AC94757DB7D909_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Transaction costs represent external costs for banking, legal, accounting and other similar services.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-B06D4F08D7061C0CFA5894757DB76AD8-0-wk-Footnote-B06D4F08D7061C0CFA5894757DB76AD8_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Integration costs and other represent external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, integration costs and other were mostly related to our acquisition of Array. In the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">, integration costs and other were primarily related to our acquisition of Hospira.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Additional depreciation&#8211;&#8211;asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</span></div></ix:footnote></td></tr></table></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-19802FF900512064EAC594757DB8DA56-1" continuedAt="TextSelection-19802FF900512064EAC594757DB8DA56-2"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-19802FF900512064EAC594757DB8DA56-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</span></div></ix:continuation></ix:footnote></td></tr></table><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="TextSelection-E4FF1A51E74D6B89167094757DB83453-0-wk-Fact-955F718C8503DFDAE6D294757D682D5E" continuedAt="TextSelection-E4FF1A51E74D6B89167094757DB83453-1" escape="true"><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.05068226120858%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of and changes in our restructuring accruals:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Employee</span></div><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Termination</span></div><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Costs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Asset</span></div><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Impairment</span></div><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Charges</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Exit Costs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Accrual</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Balance, December 31, 2019</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8312059e3347-wk-Fact-A0AE794A669CD8E4D60C94757D85F3D2" name="us-gaap:RestructuringReserve" contextRef="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">887</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8312059e3366-wk-Fact-9D99FC5004F5F45EB50094757D8BBD01" name="us-gaap:RestructuringReserve" contextRef="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8312059e3386-wk-Fact-E5ED2D8BFF7F93B9B97494757D832764" name="us-gaap:RestructuringReserve" contextRef="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8312059e3405-wk-Fact-8DD16E5EDE18E934E20F94757D84AC18" name="us-gaap:RestructuringReserve" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">933</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Provision</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8312059e3425-wk-Fact-FEFDA0AF1539302FEE1294757D86CE6B" name="us-gaap:RestructuringCharges" contextRef="FD2020Q2YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">371</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8312059e3444-wk-Fact-91AF3B300F81D255EED394757D8345EF" name="us-gaap:RestructuringCharges" contextRef="FD2020Q2YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8312059e3463-wk-Fact-C410BE51BDC1C8EC170F94757D84A449" name="us-gaap:RestructuringCharges" contextRef="FD2020Q2YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8312059e3483-wk-Fact-DD70750D757F8E36AEFE94757D511014" name="us-gaap:RestructuringCharges" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">396</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Utilization and other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8312059e3510-wk-Fact-F040B63D0E69CA163CDE94757D8588FB" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" contextRef="FD2020Q2YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">341</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8312059e3530-wk-Fact-981984D45830B3785BF594757D89A644" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" contextRef="FD2020Q2YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8312059e3550-wk-Fact-51F33580094F704AE1CA94757D87F7E8" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" contextRef="FD2020Q2YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8312059e3571-wk-Fact-3796F5D99D503A9EF47494757D899973" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">378</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Balance, June 28, 2020</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8312059e3604-wk-Fact-1B231CD712DFE5467E5994757D88041A" name="us-gaap:RestructuringReserve" contextRef="FI2020Q2_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">918</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8312059e3623-wk-Fact-A331008C1C4E5584FBBC94757D85F6B9" name="us-gaap:RestructuringReserve" contextRef="FI2020Q2_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8312059e3643-wk-Fact-22FE89F9AF8C0AF9DC8494757D8695DC" name="us-gaap:RestructuringReserve" contextRef="FI2020Q2_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8312059e3662-wk-Fact-372F8BB1048027009D0C94757D85F7F7" name="us-gaap:RestructuringReserve" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">951</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-B92DE04072B96160C46394757DB7ADA1-0-wk-Footnote-B92DE04072B96160C46394757DB7ADA1_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:8pt;"> (</span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8312059e3716-wk-Fact-F23B221CCF86FFDD224494757D67DF89" name="us-gaap:RestructuringReserve" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">714</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">) and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:inherit;font-size:8pt;"> (</span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8312059e3724-wk-Fact-7D5A017C9059415B7FB094757D69E3E9" name="us-gaap:RestructuringReserve" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">219</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">).</span></div></ix:footnote></td></tr></table></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-E4FF1A51E74D6B89167094757DB83453-1" continuedAt="TextSelection-E4FF1A51E74D6B89167094757DB83453-2"><ix:continuation id="TextSelection-7FA28E1BF698ADFB2C6E94757DB8599C-3" continuedAt="TextSelection-7FA28E1BF698ADFB2C6E94757DB8599C-4"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-823D9AE8DB976ECBCA9594757DB72C08-0-wk-Footnote-823D9AE8DB976ECBCA9594757DB72C08_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Includes adjustments for foreign currency translation.</span></div></ix:footnote></td></tr></table></ix:continuation></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-E4FF1A51E74D6B89167094757DB83453-2" continuedAt="TextSelection-E4FF1A51E74D6B89167094757DB83453-3"><ix:continuation id="TextSelection-7FA28E1BF698ADFB2C6E94757DB8599C-4" continuedAt="TextSelection-7FA28E1BF698ADFB2C6E94757DB8599C-5"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-2B5AD3FFF4626D02F1E394757DB79B83-0-wk-Footnote-2B5AD3FFF4626D02F1E394757DB79B83_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-E4FF1A51E74D6B89167094757DB83453-3"><ix:continuation id="TextSelection-7FA28E1BF698ADFB2C6E94757DB8599C-5"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other current liabilities </span><span style="font-family:inherit;font-size:8pt;">(</span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8312059e3802-wk-Fact-E77EE9F302EB09217A6794757D6CF63D" name="us-gaap:RestructuringReserve" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">625</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">) and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other noncurrent liabilities </span><span style="font-family:inherit;font-size:8pt;">(</span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8312059e3810-wk-Fact-7B25C61B791D15A8074C94757D6AD164" name="us-gaap:RestructuringReserve" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">326</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">).</span></div></ix:continuation></ix:continuation></ix:footnote></td></tr></table><div><a id="s65C9E3BE10C15A6BBA8759B343FA5D6B"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Note 4. </span><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="TextSelection-5A0F3A58699358E2ABB894757DB9FB98-0-wk-Fact-99AF92853BA2C59D8A1E94757D76F712" continuedAt="TextSelection-5A0F3A58699358E2ABB894757DB9FB98-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Other (Income)/Deductions&#8212;Net</span></ix:nonNumeric></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="TextSelection-503969B88D57E7238BC594757DB9CE05-0-wk-Fact-E4E2306FB0148534334A94757D7811E0" continuedAt="TextSelection-503969B88D57E7238BC594757DB9CE05-1" escape="true"><ix:continuation id="TextSelection-5A0F3A58699358E2ABB894757DB9FB98-1" continuedAt="TextSelection-5A0F3A58699358E2ABB894757DB9FB98-2"><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Interest income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8316808e1016-wk-Fact-964F368B32E366CCC9BC94757CFB473E" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8316808e1036-wk-Fact-4C72B86F9525A44C403B94757CF4AB54" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">59</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8316808e1057-wk-Fact-9F5350C0F6B6CC70CC8D94757CEE92D7" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8316808e1077-wk-Fact-8594983BDE02438B8CB794757D6E309D" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">125</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Interest expense</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8316808e1100-wk-Fact-D29057E6A396E534364794757CF999F3" name="us-gaap:InterestExpense" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">372</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e1119-wk-Fact-EE4346B259E22FC41F1F94757CFCEB7F" name="us-gaap:InterestExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">389</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e1138-wk-Fact-7AFC70661380E28E616594757CC3AFAE" name="us-gaap:InterestExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">762</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e1158-wk-Fact-3499C6CE8F54FB430EAD94757D6E3CBC" name="us-gaap:InterestExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Net interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e1183-wk-Fact-404EAFCD30C367D1A17894757CF808CB" name="us-gaap:InterestRevenueExpenseNet" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">353</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e1202-wk-Fact-B87245E261CCD989C48994757CF6E0A0" name="us-gaap:InterestRevenueExpenseNet" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">330</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e1221-wk-Fact-EC26EAE54B3545FD00DE94757CD8339C" name="us-gaap:InterestRevenueExpenseNet" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">709</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e1241-wk-Fact-F4F93786AF3B88CEBCFD94757CEFAE24" name="us-gaap:InterestRevenueExpenseNet" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">625</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Royalty-related income</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8316808e1268-wk-Fact-B96D2283B28701563E7A94757CF94EFC" name="us-gaap:RoyaltyIncomeNonoperating" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">191</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8316808e1288-wk-Fact-FB5C3E831211DA67818F94757CFBBA25" name="us-gaap:RoyaltyIncomeNonoperating" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">231</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8316808e1308-wk-Fact-0C70E0AC22CEB94822F594757CC8BF0F" name="us-gaap:RoyaltyIncomeNonoperating" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">311</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8316808e1329-wk-Fact-A00DF4727012C4B9EC3194757D104907" name="us-gaap:RoyaltyIncomeNonoperating" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">320</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Net (gains)/losses on asset disposals</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e1355-wk-Fact-1A4578D74B4E3B2593EF94757CF70411" name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e1374-wk-Fact-9F69DC0C27E0F6B8AA8794757CF6D438" name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e1393-wk-Fact-F2F76B3D89CC29CA91F794757CE5AC52" name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8316808e1413-wk-Fact-6D9DFD763F138C2C847894757D0A7A8D" name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Net gains recognized during the period on equity securities</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8316808e1441-wk-Fact-BE2B9931D467A3220D4894757CFCC65C" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">732</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8316808e1460-wk-Fact-A89179620F4ADD5E911294757CF30C7B" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8316808e1479-wk-Fact-98787FFB4C950A5BBD0194757CE6C4FB" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">478</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8316808e1499-wk-Fact-05F41C05FF959B0D282094757CDBBAC3" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">147</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Income from collaborations, out-licensing arrangements and sales of compound/product rights</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8316808e1527-wk-Fact-64508C9369D213E8ACFA94757CCC5964" name="pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8316808e1547-wk-Fact-CBF2AF5A3799937C03F394757CFD6A73" name="pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8316808e1567-wk-Fact-629F8031543C0F8CAEA494757CD21E49" name="pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">215</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8316808e1588-wk-Fact-38DB99ED289778FC0EC794757CF0235A" name="pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">104</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Net periodic benefit credits other than service costs</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8316808e1616-wk-Fact-2024C15FEA8B459878AD94757CF5A215" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">108</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8316808e1636-wk-Fact-6FB75BBD46792B84303694757CCB8587" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8316808e1656-wk-Fact-DE3B1C32E7AF56EA37C694757CFE73CD" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">175</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8316808e1677-wk-Fact-CF4867B1F96B94735AD594757D0E90B4" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">91</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Certain legal matters, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e1704-wk-Fact-D0135C395BAED2FE95EC94757CF4F3E2" name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e1723-wk-Fact-8E42A3831E1D14364FEE94757CFB1583" name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e1742-wk-Fact-CBBE8EDA374D1CE7F34694757CE7FAA0" name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e1762-wk-Fact-778A41E9A7F0F3B927E394757D176908" name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Certain asset impairments</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e1789-wk-Fact-A5431E8C2912D62E362094757CF2BE8E" name="us-gaap:AssetImpairmentCharges" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e1808-wk-Fact-71E3A38CC9A24B60F06494757CF5F71C" name="us-gaap:AssetImpairmentCharges" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e1827-wk-Fact-EF93AF87BA61CC2CECEB94757CBC24E3" name="us-gaap:AssetImpairmentCharges" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e1847-wk-Fact-F581216089FF320C328694757CD49968" name="us-gaap:AssetImpairmentCharges" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">160</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Business and legal entity alignment costs</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(g)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e1874-wk-Fact-AF679C0C7A88919A718094757CFBF4E0" name="pfe:BusinessAlignmentCosts" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e1893-wk-Fact-7973D60AC4E2ED9EA6D394757CF8B7E7" name="pfe:BusinessAlignmentCosts" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">137</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e1912-wk-Fact-3B846BC02192BD53F89B94757CDEE0F4" name="pfe:BusinessAlignmentCosts" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e1932-wk-Fact-40152B99BE243EC4A4DA94757CE024F4" name="pfe:BusinessAlignmentCosts" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">256</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net losses on early retirement of debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e1957-wk-Fact-2F9CB48F881108F84DE494757CF6F586" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e1976-wk-Fact-9B6666350119AE83397C5E7247581F5B" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e1995-wk-Fact-03E558327BD22A84183494757D078BB7" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e2015-wk-Fact-80B2E8867002EBA1C8C25E7247542FCD" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">138</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">GSK Consumer Healthcare JV equity method (income)/loss</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(h)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8316808e2042-wk-Fact-3502C1166F5ABE6DC55E94757CCC6B1B" name="pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">126</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e2062-wk-Fact-13DB6A96944CAA1A9DE694757CF73050" name="pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8316808e2081-wk-Fact-8631DD50CCB968472578955D6DC81456" name="pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">92</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e2102-wk-Fact-7104406F477A093FDE41955D6E1319E3" name="pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Other, net</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(i)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e2129-wk-Fact-48DD10795AE6A50CB75294757CF3076B" name="pfe:OtherNonoperatingIncomeExpenseNet" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8316808e2147-wk-Fact-D71486B20EB7956A050C94757CCBBD46" name="pfe:OtherNonoperatingIncomeExpenseNet" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8316808e2166-wk-Fact-98D14E7EA5371F942F3394757CCE8CDC" name="pfe:OtherNonoperatingIncomeExpenseNet" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">107</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8316808e2186-wk-Fact-5864C6C0C3A1C625197294757D73F154" name="pfe:OtherNonoperatingIncomeExpenseNet" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">318</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8316808e2217-wk-Fact-361AD8CFC0B46CF2632394757D0A716D" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">862</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e2237-wk-Fact-115B1B8C87DB19F5829C94757D60A004" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">126</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8316808e2257-wk-Fact-82FCBDB83EA92437E26C94757D5A5E10" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">641</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8316808e2277-wk-Fact-CF088F9FE2A75408C8A794757D1586DE" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">218</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><ix:footnote id="TextSelection-4E74A09462C596E2363694757DB8EB14-0-wk-Footnote-4E74A09462C596E2363694757DB8EB14_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-4E74A09462C596E2363694757DB8EB14-1"><span style="font-family:inherit;font-size:8pt;">Interest income decreased in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first six months of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;">, primarily driven by a lower investment balance and lower short-term interest rates. Interest expense decreased in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> mainly as a result of the retirement of higher-coupon debt and the issuance of new debt with a lower coupon than the debt outstanding for the comparative prior year period. Interest expense increased in the first six months of </span><span style="font-family:inherit;font-size:8pt;">2020</span></ix:footnote><span style="font-family:inherit;font-size:8pt;"><ix:continuation id="TextSelection-4E74A09462C596E2363694757DB8EB14-1">, mainly as a result of an increased commercial paper balance due to the acquisition of Array.</ix:continuation> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-CDCE760DEFA7F631840C94757DB86187-0-wk-Footnote-CDCE760DEFA7F631840C94757DB86187_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Royalty-related income for the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;">first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> included a one-time favorable resolution in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> of a legal dispute for </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8316808e2387-wk-Fact-BC8FD17D240F881485EF955D6E14938E" name="us-gaap:ProceedsFromLegalSettlements" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">82</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-467F12A5D203A9A15C3A94757DB81B0A-0-wk-Footnote-467F12A5D203A9A15C3A94757DB81B0A_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The gains in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> include, among other things, unrealized gains of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8316808e2412-wk-Fact-40CA1F17BEB2D0A8797794757D7513C7" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">508</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> related to our investment in Allogene and unrealized gains of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8316808e2416-wk-Fact-76C1FFB30BC3D7CAB9DD5E86ECE05D86" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_BioNTechSEMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">61</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> related to our investment in BioNTech. The gains in the first six months of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> include, among other things, unrealized gains of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8316808e2425-wk-Fact-99A0E87C3E7ACC2850CE955D6EE5B821" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">374</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> related to our investment in Allogene and unrealized gains of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8316808e2429-wk-Fact-3AA2852FACA286ED4B105E88C274918E" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_BioNTechSEMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">127</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> related to our investment in BioNTech. The gains in the first six months of 2019 included, among other things, unrealized gains of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8316808e2433-wk-Fact-2E7CCABE8F52D073CFF95E890E465015" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CortexymeInc.Member" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">104</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> related to our investment in Cortexyme, Inc. For additional information on investments, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7B</span><span style="font-family:inherit;font-size:8pt;">.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-1DD42ADAC2DF4C519E7594757DB84698-0-wk-Footnote-1DD42ADAC2DF4C519E7594757DB84698_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In the </span><span style="font-family:inherit;font-size:8pt;">second</span><span style="font-family:inherit;font-size:8pt;"> quarter and first six months of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;">, mainly includes, among other things, </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8316808e2480-wk-Fact-076A4EF6E989B0D0BF915EA36245A333" name="us-gaap:ProceedsFromCollaborators" contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_pfe_PumaTechnologiesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> of milestone income from Puma Biotechnology, Inc. related to Neratinib regulatory approvals in the EU, and </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8316808e2484-wk-Fact-46C080B02D09D39370335EA5F6BBED9F" name="us-gaap:ProceedsFromCollaborators" contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> of milestone income from Lilly related to the first commercial sale in the U.S. of LOXO-292 for the treatment of RET fusion-positive NSCLC. The first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> also includes an upfront payment to us of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8316808e2497-wk-Fact-E30C39F1D1B0A522812494757D759DA6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" contextRef="FI2020Q2_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_CK1AssetsSoldToBiogenIncMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> from our sale of our CK1 assets to Biogen, Inc. In the first six months of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">, primarily included </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8316808e2505-wk-Fact-09145C555748A1AAD94394757D7A865F" name="us-gaap:ProceedsFromCollaborators" contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_pfe_MylanMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">68</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> in milestone income from Mylan Pharmaceuticals Inc. related to the FDA&#8217;s approval and launch of Wixela Inhub</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:8pt;">, a generic of Advair Diskus</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:8pt;">.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-16CE381F2099EFC2DA1C94757DB87C39-0-wk-Footnote-16CE381F2099EFC2DA1C94757DB87C39_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 10</span><span style="font-family:inherit;font-size:8pt;">.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-23DF6508A1F2A3B1745994757DB98CA0-0-wk-Footnote-23DF6508A1F2A3B1745994757DB98CA0_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The first six months of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> included intangible asset impairment charges of: (i) </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8316808e2562-wk-Fact-2B4544E46E026330A34D94757D777099" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_GeneTherapiesMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">90</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> related to WRDM IPR&amp;D, for a pre-clinical stage asset from our acquisition of Bamboo for gene therapies for the potential treatment of patients with certain rare diseases, which was the result of a determination to not use certain Bamboo IPR&amp;D acquired in future rare disease development, (ii) </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8316808e2566-wk-Fact-84E9DF43D0B1B29C362C94757D772A85" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_KingMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> related to an Upjohn finite-lived developed technology right, acquired in connection with our acquisition of King, for government defense products and reflected, among other things, updated commercial forecasts including manufacturing cost assumptions, and (iii) </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8316808e2570-wk-Fact-DF65CCCD5564D3A109FC5EAB28D92765" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AnacorMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> related to a finite-lived developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus marketed in the U.S. market only, </span><span style="font-family:inherit;font-size:8pt;text-align:center;">associated with Biopharma and reflected</span><span style="font-family:inherit;font-size:8pt;">, among other things, updated commercial forecasts. In addition, the first six months of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> included other asset impairments of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8316808e2583-wk-Fact-B69E12C6AA0189ADD97B94757D77BC32" name="us-gaap:OtherAssetImpairmentCharges" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-3F1FDE51F00C4F037BC194757DB9000C-0-wk-Footnote-3F1FDE51F00C4F037BC194757DB9000C_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first six months of 2019, represents incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(h)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-9161826AA31A3194474594757DB9E2CF-0-wk-Footnote-9161826AA31A3194474594757DB9E2CF_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Includes our share of the GSK Consumer Healthcare joint venture&#8217;s earnings and the amortization of basis differences, which resulted from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the joint venture. See </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 2B</span><span style="font-family:inherit;font-size:8pt;"> for additional information.</span></div></ix:footnote></td></tr></table></ix:continuation></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-503969B88D57E7238BC594757DB9CE05-1" continuedAt="TextSelection-503969B88D57E7238BC594757DB9CE05-2"><ix:continuation id="TextSelection-5A0F3A58699358E2ABB894757DB9FB98-2" continuedAt="TextSelection-5A0F3A58699358E2ABB894757DB9FB98-3"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup>&#160;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-420C4A044883B0052AE85E76395259A9-0-wk-Footnote-420C4A044883B0052AE85E76395259A9_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-503969B88D57E7238BC594757DB9CE05-2"><ix:continuation id="TextSelection-5A0F3A58699358E2ABB894757DB9FB98-3"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> includes, among other things, dividend income of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8316808e2662-wk-Fact-71D18AE80705CBBAADD594757D794DFA" name="us-gaap:InvestmentIncomeDividend" contextRef="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViiVMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">76</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> from our investment in ViiV, and charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8316808e2666-wk-Fact-097E9B6C0D40541553845EAFD3825BC7" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="FD2020Q2QTD_us-gaap_BusinessAcquisitionAxis_pfe_ViiVMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">86</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">, reflecting the change in the fair value of contingent consideration. The first six months of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> includes, among other things, dividend income of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8316808e2675-wk-Fact-D5D32FD407DDC5273865955D6DF4E00F" name="us-gaap:InvestmentIncomeDividend" contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViiVMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">153</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> from our investment in ViiV and charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8316808e2679-wk-Fact-D38805B1BD1B06E9E56E5EAEEB8EF0D8" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="FD2020Q2YTD_us-gaap_BusinessAcquisitionAxis_pfe_ViiVMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">99</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">, reflecting the change in the fair value of contingent consideration. The </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> included, among other things, charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8316808e2691-wk-Fact-9C052873C6DAE7D4D52194757D783D82" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">81</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">, reflecting the change in the fair value of contingent consideration, dividend income of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8316808e2696-wk-Fact-68BAAAE2FACDAD5DABE694757D76ACC5" name="us-gaap:InvestmentIncomeDividend" contextRef="FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViiVMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">76</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:8pt;"> from our investment in ViiV, and </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8316808e2812-wk-Fact-9A10E6CBB57ACDEDCA0A5EB812D6A565" name="us-gaap:InsuranceRecoveries" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> of income from insurance recoveries related to Hurricane Maria. The first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> included, among other things, dividend income of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8316808e2824-wk-Fact-625787D364A8EDA65710955D6DFF81D9" name="us-gaap:InvestmentIncomeDividend" contextRef="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViiVMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">140</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> from our investment in ViiV and </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8316808e2828-wk-Fact-D83B6F01F3FE9AE97EAE5EB85E463C5E" name="us-gaap:InsuranceRecoveries" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> of income from insurance recoveries related to Hurricane Maria.</span></div></ix:continuation></ix:continuation></ix:footnote></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17</span></div></div><hr style="page-break-after:always"></hr><div><a id="s6D4711D54D3F51F095D48782A695C6FA"></a></div><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Note 5. </span><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:IncomeTaxDisclosureTextBlock" id="TextSelection-15E468F2F9C33B25026F94757DBA81D5-0-wk-Fact-291E90AB2E484902A29E94757CE7D93E" continuedAt="TextSelection-15E468F2F9C33B25026F94757DBA81D5-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Tax Matters</span></ix:nonNumeric></div><ix:continuation id="TextSelection-15E468F2F9C33B25026F94757DBA81D5-1" continuedAt="TextSelection-15E468F2F9C33B25026F94757DBA81D5-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. Taxes on Income from Continuing Operations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our effective tax rate for continuing operations was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8314038e710-wk-Fact-F3062759B0719C4D154794757CE7292C" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2020Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">13.1</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;">, compared to </span><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8314038e722-wk-Fact-E82F9EC034F593DFD41F94757CE8EA3D" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2019Q2QTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">22.1</ix:nonFraction>)%</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> and was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8314038e735-wk-Fact-AC6996334D6D144D39925EC2B6F5DD76" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2020Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">12.7</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">the first six months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;">, compared to </span><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8314038e747-wk-Fact-89826C68E211AFDE37EF5EC2D0EE6F95" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2019Q2YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">5.7</ix:nonFraction>)%</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">the first six months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">higher</span><span style="font-family:inherit;font-size:10pt;"> effective tax rate for the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter and first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> in comparison with the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> was primarily due to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the non-recurrence of the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8314038e790-wk-Fact-E53DDF0FDCEB9B4100797910AEA53F64" name="us-gaap:IncomeTaxReconciliationTaxSettlements" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-8" scale="9" sign="-" format="ixt:numdotdecimal">1.4</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> tax benefit, representing taxes and interest, recorded in the second quarter of 2019 due to the favorable settlement of an IRS audit for multiple tax years (see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 5D. Tax Matters: Tax Contingencies </span><span style="font-family:inherit;font-size:10pt;">in our 2019 Financial Report); and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the non-recurrence of the tax benefit recorded in the first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of 2019 as a result of additional guidance issued by the U.S. Department of Treasury related to the TCJA,</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our initial estimated </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8314038e822-wk-Fact-1A09897409F217F67ED394757CE74368" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" contextRef="FI2020Q2" unitRef="usd" decimals="-9" scale="9" format="ixt:numdotdecimal">15</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> repatriation tax liability on accumulated post-1986 foreign earnings for which we elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, payment over eight years through 2026 is reported in current </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">taxes payable </span><span style="font-family:inherit;font-size:10pt;">(approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8314038e834-wk-Fact-891F41E413F59F55794B94757CE57245" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_IncomeTaxesPayableMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.4</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;">) and the remaining liability is reported in noncurrent </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other taxes payable</span><span style="font-family:inherit;font-size:10pt;"> in our condensed consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;">. The second installment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8314038e847-wk-Fact-295400FBD13AB0A2871494757CE7779A" name="pfe:PaymentForRepatriationTax" contextRef="D2020Q3Jul1-31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">680</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> was paid in July 2020, which was originally due to be paid in April 2020 but was extended to July 2020 by the IRS in response to the COVID-19 pandemic. The third installment of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8314038e851-wk-Fact-36CEB3B6DC27263F50EF5EC6452042D4" name="pfe:PaymentForRepatriationTax" contextRef="D2021Q2Apr1-30_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">750</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> is due in April 2021. Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was signed into law in the U.S. to provide certain relief as a result of the COVID-19 pandemic. In addition, governments around the world have enacted or implemented various forms of tax relief measures in response to the economic conditions in the wake of COVID-19. As of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;">, neither the CARES Act nor changes to income tax laws or regulations in other jurisdictions had a significant impact on our effective tax rate.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. Tax Contingencies</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. With respect to Pfizer, the IRS has issued a Revenue Agent&#8217;s Report (RAR) for tax years 2011-2013. We are not in agreement with the RAR and are currently appealing certain disputed issues. Tax years 2014-2015 are currently under audit. Tax years 2016-2020 are open, but not under audit. All other tax years are closed.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the open audit years in the U.S., we have open audit years in other major tax jurisdictions, such as Canada (2013-2020), Japan (2017-2020), Europe (2011-2020, primarily reflecting Ireland, the U.K., France, Italy, Spain and Germany), Latin America (1998-2020, primarily reflecting Brazil) and Puerto Rico (2015-2020).</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-15E468F2F9C33B25026F94757DBA81D5-2" continuedAt="TextSelection-15E468F2F9C33B25026F94757DBA81D5-3"><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">C. </span><span style="font-weight:bold;text-decoration:underline;">Tax Provision/(Benefit) on Other Comprehensive Loss</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" id="TextSelection-90B5518319E8C393415B94757DBAA12D-0-wk-Fact-98291030996B49A589F494757CE619EA" continuedAt="TextSelection-90B5518319E8C393415B94757DBAA12D-1" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Tax provision/(benefit) on</span><span style="font-family:inherit;font-size:10pt;">&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">other comprehensive loss</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency translation adjustments, net</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e1196-wk-Fact-A19967903AAC6CD9F1E494757D7857A3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8314038e1215-wk-Fact-432173AA1624AC93425594757D771AAC" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8314038e1236-wk-Fact-A7A8B2FD88766217F16094757D50D04F" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">192</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e1256-wk-Fact-261CF8B516535CC742D694757D9DD941" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unrealized holding gains/(losses) on derivative financial instruments, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e1276-wk-Fact-7ECA69C30539623284F694757D74480C" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8314038e1295-wk-Fact-6D54B018E862C618DAA594757D740800" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">53</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8314038e1315-wk-Fact-33CE4984F56A06364F7594757D96B5B7" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">82</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e1336-wk-Fact-12514F8D64CDE8BD49E994757D461B29" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments for gains included in net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8314038e1361-wk-Fact-8469778C9496064B650A94757D6F3848" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8314038e1381-wk-Fact-B8AEA80006F385C431D594757D7673CB" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8314038e1401-wk-Fact-ED0FA601498740142B1294757D44BC1F" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8314038e1422-wk-Fact-BE0F972996B4BF2E6DAF94757D9AD5AB" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">59</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e1448-wk-Fact-250B8DF8DC8AE23FEEA594757D713EE2" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8314038e1467-wk-Fact-26E2276B08CF0FDDC10D94757D72686F" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">57</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8314038e1487-wk-Fact-CEE926E74E46FC8E8EBC94757D9F2ADF" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">102</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8314038e1508-wk-Fact-4EC5A96B399A0E1069A194757D9EA225" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">53</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unrealized holding gains/(losses) on available-for-sale securities, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e1534-wk-Fact-37FCAEDBC81E29660E8194757D6DA92F" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8314038e1553-wk-Fact-36BA777B033023E3144C94757D73F9AF" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8314038e1573-wk-Fact-9890B6F9995AD4D3B51F94757D9B01C6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e1594-wk-Fact-8BDC84BB493C463CE09094757DA3F18E" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments for losses included in net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e1619-wk-Fact-6F1C173D3634D81DAB1194757D6FC35E" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e1638-wk-Fact-0A08A6B4BBFBEF80962694757D782477" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e1657-wk-Fact-1A514B2A7E5889BF73CA94757D33BD55" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e1677-wk-Fact-802037155B7EA521C51094757DA20C29" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e1702-wk-Fact-237FCAEA250F9CAFEC9C94757D717036" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e1721-wk-Fact-2992F030458BE4293ADC94757D706AAD" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e1740-wk-Fact-1D57517A1FA0183AD32A94757D3C5422" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e1760-wk-Fact-65C4D29FFC7384C8E4ED94757DA267EB" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Benefit plans: actuarial gains/(losses), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e1785-wk-Fact-EFF9593C2CF339BCA5E694757D793695" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8314038e1804-wk-Fact-2D01765BD69A58F6B10A94757D7991BE" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8314038e1824-wk-Fact-8FEB1D1A2D1774BA1FFC94757DA63FE6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8314038e1845-wk-Fact-1460135BE6B8CC010F6D94757D9A06B3" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments related to amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e1872-wk-Fact-E57D12E5194ADC5D1D6C94757D77F40E" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e1891-wk-Fact-D3D74205CA9F62CD361494757D6E4120" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e1910-wk-Fact-D103D04106A9A45B07B494757D4E04D6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">31</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e1930-wk-Fact-5E6118860B4C7943D56994757DA067E8" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments related to settlements, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e1955-wk-Fact-9DA7CBFC1C8970B733E194757D76D2E0" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e1974-wk-Fact-45E661C0E049AC539B9294757D703381" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e1993-wk-Fact-6FEEBB85CA4AA07D99E494757DA4457E" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e2013-wk-Fact-EF6ED68B565FE86766BC94757D4C9567" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e2038-wk-Fact-B35A64CE926FA5048A1894757D7302EB" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e2057-wk-Fact-1E060F47EED4E5F9A0D494757D703D42" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e2076-wk-Fact-5B9D9874245E2957311294757D997810" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">20</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e2096-wk-Fact-583617E730ECC7E2AAAB94757D3D0708" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e2121-wk-Fact-56116A021CEB432C2C7194757D788CBF" name="pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e2140-wk-Fact-6408796BA5CA5F8FAA2A94757D70751A" name="pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e2159-wk-Fact-48D1689CB46364E7E3DB94757DA2976A" name="pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">43</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e2179-wk-Fact-2EC9420EBF5445C3F59294757D41DDF6" name="pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments related to amortization of prior service costs and other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8314038e2204-wk-Fact-330011D48BA279F8FD1094757D78B0B2" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8314038e2224-wk-Fact-82F14DEA001DE85F18CE94757D72A58A" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8314038e2244-wk-Fact-0D828A1C0764262CFE9D94757D374336" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">21</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8314038e2265-wk-Fact-C84E67B2A279ABF75BC294757DA345B7" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e2291-wk-Fact-507422AE0FC0B21956FC94757D7198E6" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e2310-wk-Fact-98E482B40D23703F660694757D70A15D" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e2329-wk-Fact-E9EB3C88390D38C8A9BF94757D98AC98" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e2349-wk-Fact-D416CF92B5509B2832CD94757D494FC5" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8314038e2374-wk-Fact-C9826BB516E3180B5A5B94757D6C4A44" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8314038e2394-wk-Fact-12A30AB8B561EA3E3F3994757D6FD842" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8314038e2414-wk-Fact-67D1A8A636603075FCC494757D4BA7A5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8314038e2435-wk-Fact-FAD95AB970A6CE84727B94757D9C4B1E" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Tax provision/(benefit) on other comprehensive loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8314038e2466-wk-Fact-EA79252BF7CF8534CF3894757D00B0A3" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">113</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8314038e2485-wk-Fact-8F362BEF2AB5D5597E6394757CFFD802" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">59</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8314038e2506-wk-Fact-98256D21B98CE406359794757D62CC7A" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">265</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8314038e2526-wk-Fact-EF6B358EA8E9123BB65194757D5C81E7" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div></div></ix:nonNumeric></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-90B5518319E8C393415B94757DBAA12D-1" continuedAt="TextSelection-90B5518319E8C393415B94757DBAA12D-2"><ix:continuation id="TextSelection-15E468F2F9C33B25026F94757DBA81D5-3" continuedAt="TextSelection-15E468F2F9C33B25026F94757DBA81D5-4"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-681F29FE9DC6BC582B6D94757DB90D8C-0-wk-Footnote-681F29FE9DC6BC582B6D94757DB90D8C_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-90B5518319E8C393415B94757DBAA12D-2"><ix:continuation id="TextSelection-15E468F2F9C33B25026F94757DBA81D5-4"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.</span></div></ix:continuation></ix:continuation></ix:footnote></td></tr></table><div><a id="s1AAE181E3B2E5328B6D17C9B952369B1"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Note 6. </span><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="TextSelection-8D3803783B1470E396CB94757DBA2793-0-wk-Fact-DE14FC49D22B1F8120C594757D8A07BC" continuedAt="TextSelection-8D3803783B1470E396CB94757DBA2793-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</span></ix:nonNumeric></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="TextSelection-3116A04D009548FDA44D94757DBA339D-0-wk-Fact-ED90C3E03342B294461D94757D86C50E" continuedAt="TextSelection-3116A04D009548FDA44D94757DBA339D-1" escape="true"><ix:continuation id="TextSelection-8D3803783B1470E396CB94757DBA2793-1" continuedAt="TextSelection-8D3803783B1470E396CB94757DBA2793-2"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the changes, net of tax, in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive loss</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Net Unrealized Gains/(Losses)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Benefit Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Foreign Currency Translation Adjustments </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Derivative Financial Instruments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Available-For-Sale Securities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Actuarial Gains/(Losses)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Prior Service (Costs)/Credits and Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Accumulated Other Comprehensive Income/(Loss)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Balance, December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8312053e1146-wk-Fact-DE8475D255C7EE89398594757CE61C72" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5,952</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8312053e1166-wk-Fact-7B301604CAA13A7C621694757CE446A3" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8312053e1186-wk-Fact-AFC9897520C6B134970B94757CE358B3" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">35</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8312053e1206-wk-Fact-A60457FD9E7B53D7995094757CE25F58" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6,257</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8312053e1226-wk-Fact-7C4D0C0B86297CAA096494757CE1826F" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">584</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8312053e1246-wk-Fact-75EDE949855DDE71A06D94757CE8D911" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11,640</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other comprehensive income/(loss)</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8312053e1269-wk-Fact-93B22A2A5674F48F52DF94757CE4EB2F" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,310</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8312053e1289-wk-Fact-964325EF1A54729D824194757CE58552" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">353</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8312053e1309-wk-Fact-1D4A2167CADD270AD7B494757CE56E80" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">44</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8312053e1329-wk-Fact-2B2DFC11DDDCB317D2C994757CE2E0A2" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">79</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8312053e1348-wk-Fact-0D58D4B7AB8E12C40B7994757CE6D530" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">65</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8312053e1369-wk-Fact-4A51A364B44D351B488B94757CE2261B" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,605</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Balance, June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8312053e1400-wk-Fact-01070978017D3A5955FA94757CE3B710" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">7,262</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8312053e1420-wk-Fact-5D626F8BA3AF19C7FDA494757CE4D631" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">333</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8312053e1441-wk-Fact-F37B775487717C15831194757CE1E675" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8312053e1460-wk-Fact-39B9C9FB9AF4AE93494994757CE694B6" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6,178</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8312053e1480-wk-Fact-2607F27CC1B9FA6307A494757CE398B6" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">518</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8312053e1500-wk-Fact-B09FAC91CEFCADA6B17C94757CE170B9" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">13,246</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr></table></div></div></ix:continuation></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-3116A04D009548FDA44D94757DBA339D-1" continuedAt="TextSelection-3116A04D009548FDA44D94757DBA339D-2"><ix:continuation id="TextSelection-8D3803783B1470E396CB94757DBA2793-2" continuedAt="TextSelection-8D3803783B1470E396CB94757DBA2793-3"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-9459A99A0EC8DD1CD04094757DBA4F65-0-wk-Footnote-9459A99A0EC8DD1CD04094757DBA4F65_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-3116A04D009548FDA44D94757DBA339D-2"><ix:continuation id="TextSelection-8D3803783B1470E396CB94757DBA2793-3"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8312053e1545-wk-Fact-BE6E404B25AA5E89CECF9D3B7019A5B9" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> loss for the first six months of 2020. Includes after-tax </span><span style="font-family:inherit;font-size:8pt;">losses</span><span style="font-family:inherit;font-size:8pt;"> of approximately </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8312053e1555-wk-Fact-EC4BE606149B17B66782545594D6136A" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">902</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> related to foreign currency translation adjustments and the impact of our net investment hedging program, both attributable to our equity method investment in GSK Consumer Healthcare (see</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> Note 2B</span><span style="font-family:inherit;font-size:8pt;">), and losses from the weakening of certain major currencies against the U.S. dollar. These </span><span style="font-family:inherit;font-size:8pt;">losses</span><span style="font-family:inherit;font-size:8pt;"> were partially offset by the results of our net investment hedging program.</span></div></ix:continuation></ix:continuation></ix:footnote></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19</span></div></div><hr style="page-break-after:always"></hr><div><a id="s1D9B3C3797C25A81AABAEA59FDA43329"></a></div><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Note 7. </span><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="TextSelection-A660979E9FD00EF5F81A94757DBB7351-0-wk-Fact-CC5462AAB66C01ED4A7894757CC9C69B" continuedAt="TextSelection-A660979E9FD00EF5F81A94757DBB7351-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Financial Instruments</span></ix:nonNumeric></div><ix:continuation id="TextSelection-A660979E9FD00EF5F81A94757DBB7351-1" continuedAt="TextSelection-A660979E9FD00EF5F81A94757DBB7351-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. </span><span style="font-weight:bold;text-decoration:underline;">Fair Value Measurements</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"> </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="TextSelection-37FC76D858F979F1748C94757DBB18E5-0-wk-Fact-9E5BBB26E31C14AFFE9C94757CC9794B" continuedAt="TextSelection-37FC76D858F979F1748C94757DBB18E5-1" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the financial assets and liabilities measured at fair value using a market approach on a recurring basis by balance sheet categories and fair value hierarchy level as defined in Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1E. Basis of Presentation and Significant Accounting Policies: Fair Value </span><span style="font-family:inherit;font-size:10pt;">in our 2019 Financial Report: </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Level 2</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Financial assets measured at fair value on a recurring basis:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Classified as equity securities with readily determinable fair values:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Money market funds</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e1548-wk-Fact-66612970542295C5EAA894757D5D6124" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,033</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e1566-wk-Fact-20C9854FC8CD379D96E594757D4BB09E" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e1585-wk-Fact-03AFF2EF3B741A9220ED94757D3DA6D1" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,033</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e1603-wk-Fact-32BCE63F2B148B65B2BD94757D4ABD8F" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">705</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e1621-wk-Fact-1EA60045B6EB866A340E94757D49440D" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e1640-wk-Fact-A2CF9469A723FA507B4C94757D43EBF4" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">705</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Classified as available-for-sale debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Government and agency&#8212;non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e1916-wk-Fact-51729F8A79FB6212C36894757CBE9483" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,218</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e1935-wk-Fact-5F45C619AC7AF9BCD93F94757D3847E9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e1954-wk-Fact-6A7C8F68DED7856BBFFA94757D518133" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,218</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e1974-wk-Fact-68EFE825964CAF71402694757D7139E7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,863</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e1993-wk-Fact-D9A14445EA184E4B100F94757D3CE6C1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2013-wk-Fact-DEC1FCCCEA01D2CFAAC994757D3CEBF6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,863</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Government and agency&#8212;U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2038-wk-Fact-17BFBFFC8E726CC3B4A394757D651B12" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2057-wk-Fact-4AF966115F483B95688B94757D2E066F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2076-wk-Fact-FEC3A79B68EE2EE85D7294757CBC320E" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2096-wk-Fact-CEEDD0609A221494410A94757CB23075" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">811</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2115-wk-Fact-A8B4BE78EEF25DAFE36994757D84843B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2135-wk-Fact-6FAA6A750D8C3D55345D94757CBD839E" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">811</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Corporate and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2161-wk-Fact-5286C28D1D7D770F116C94757D40F903" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,440</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2180-wk-Fact-660E1616C4AF57FB4AA394757CBB9A76" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2199-wk-Fact-4D7AD80601DC4DA481B094757D42F529" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,440</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2219-wk-Fact-91744BF98375B7AEA12294757D38E50D" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,013</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2238-wk-Fact-3DAFBDEA26361F49311894757D4C2EE3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2258-wk-Fact-C249FF18F1801C52A43394757D3FC69C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,013</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2283-wk-Fact-BFE2CDEBB87C375E3C7394757D84D268" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,672</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2302-wk-Fact-2582DE260411A2124ECA94757D4DBF9D" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2321-wk-Fact-C6DB2032032BC607F2B494757D536B73" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,672</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2341-wk-Fact-614AEDA00527EAFB0D5394757D4A4E7C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,687</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2360-wk-Fact-B824D2FB2B2EBC47F81394757D44A7D5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2380-wk-Fact-C2A260126E20D20AA72394757D30C5B9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,687</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2405-wk-Fact-0532EA1A1B46197D465794757CBD7C6E" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">20,705</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2424-wk-Fact-CB9227A016A7DB50211D94757D4DEC6C" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2443-wk-Fact-85F07BE5D1FF8956526294757CC038D5" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">20,705</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2463-wk-Fact-6D361B65F37A1ACA792594757D4788AF" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,392</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2482-wk-Fact-FDFD684E645EFEDC403794757D3DD52E" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2502-wk-Fact-CB9F8F402A96B52914E994757CC1B3E3" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,392</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Derivative assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2783-wk-Fact-DC8F00FE7B58DC0B667594757D45DB5C" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2802-wk-Fact-6511075C43A530FD0B7F94757CC48D76" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2821-wk-Fact-A995F45E600C7F97576394757D4B05E6" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2841-wk-Fact-5AE6E6E0728B5DF3760394757D3FE9AD" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2860-wk-Fact-64AC7894DBF70816399C94757D4C42B6" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2880-wk-Fact-FBFE7903BD0565772AB094757CB2B274" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2905-wk-Fact-94EEDF40906E2824AE7B94757D406B3E" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">413</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2924-wk-Fact-4CDAA1A423E12BF41DAA94757D3E809C" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2943-wk-Fact-98D1E7C4F67D902463E494757D473F9F" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">413</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2963-wk-Fact-B5925ABFDC28B9B400E994757D2F1F06" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">413</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e2982-wk-Fact-C87F260438FB28B4601A94757D4D1604" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3002-wk-Fact-EBE3169E637E0897012694757D327C27" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">413</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3027-wk-Fact-15EAF0775B81FCAC127E94757CE7D74C" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">431</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3046-wk-Fact-79A1AAE466C9780A86E494757D3D3E4D" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3065-wk-Fact-EEBD25D39F530AF0EDBF94757CAFCFC1" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">431</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3085-wk-Fact-24B749F75EEA8C6DF6B594757D444B4A" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3104-wk-Fact-563B941649E081FD464F94757CBE79D1" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3124-wk-Fact-77E0D5059B7D34A0C09994757D834902" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Classified as equity securities with readily determinable fair values</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3279-wk-Fact-591CA5BD37BEF066C61294757D3FA07C" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,072</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3297-wk-Fact-9AC586B89CDBD7EC4F6194757CAFC880" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,046</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3315-wk-Fact-E1670DD42B676FA2293C94757D4E7C71" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3334-wk-Fact-0FAA0A010479FD1F2D6594757CB8122B" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,902</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3352-wk-Fact-B02201B22AB44168B6C494757CC5A140" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,863</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3371-wk-Fact-D62B36AD2263CAB0455594757CBD05B4" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Classified as available-for-sale debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Government and agency&#8212;U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3653-wk-Fact-4EC64304994653C6A6D694757D423313" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">243</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3672-wk-Fact-3F825C3786DBB61EB71094757D73A5BD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3691-wk-Fact-282FD8B27D5D311E0D3994757D4D8B7D" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">243</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3711-wk-Fact-22743DEE50EEB948B87094757CD75A97" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">303</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3730-wk-Fact-A7F95BF63AE551CBAB6794757D5481AE" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3750-wk-Fact-819276D963F06D06C0AE94757D33284A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">303</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Corporate and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3775-wk-Fact-47B3867FBEDC456EDB9594757D4B193D" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3794-wk-Fact-4C589702EEC16BCB9BE594757CC4C550" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3813-wk-Fact-7404D5E4A5E94CC28EFB94757CC50427" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3833-wk-Fact-FC69E5804CC59567EF2894757CE901DB" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3852-wk-Fact-9E5DC4DC043B84742E6694757D3D30BA" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3872-wk-Fact-75D5577BAE2F9A5617C594757CEA0726" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3897-wk-Fact-C50717BF44CB082CCF7494757D3A7813" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">254</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3916-wk-Fact-D9838C40189706C10B5294757D353F5D" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3935-wk-Fact-308B871F5C8A79BC7A5494757D7F4265" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">254</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3955-wk-Fact-C4B64F882E730CDAE36794757D7B7670" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">315</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3974-wk-Fact-6B3C4A6B9AE9E8A2163A94757CEA3F7E" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e3994-wk-Fact-9AF1DEC5331BF586BBD294757D3E38BE" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">315</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4019-wk-Fact-35892B83D888A8B6714994757D461936" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,326</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4038-wk-Fact-24873C8C77CEDC8D2EB494757D4E6E1B" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,046</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4057-wk-Fact-48594DAEBE1A181E2B2394757D52CB08" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">280</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4077-wk-Fact-BAF4BFDB71207EA0981A94757CBBC1DC" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,216</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4096-wk-Fact-A4CA4BB921F4C21D4A5894757D7F1B02" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,863</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4116-wk-Fact-5CE5F239710C3B64F09C94757D48C905" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">354</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Derivative assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4397-wk-Fact-0D0CA3F9E67E30CEBE5394757CC43F65" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4416-wk-Fact-480817A8340F413FD79F94757D4F2C56" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4435-wk-Fact-5684F36778A54D13329194757D5386DC" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4455-wk-Fact-CB746A9A3946D79B39E694757CB9F8F6" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">266</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4474-wk-Fact-21E220FF02E91EBD575E94757D3BA7C7" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4494-wk-Fact-A71CD6E5722C55626DC394757D46691A" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">266</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4519-wk-Fact-05693C9F74B7C7AA7AF694757D43DB56" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">221</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4538-wk-Fact-420357463B0346814B6F94757D44D606" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4557-wk-Fact-2101E561A5879EB0864394757D2FAC26" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">221</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4577-wk-Fact-BAE5E7824F189D809C3294757CE8ECEA" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">261</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4596-wk-Fact-5016F686151C62EAF2DD94757D41914A" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4616-wk-Fact-D8B2DF1FCAE6F04D8A5194757D55E63B" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">261</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total derivative assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4641-wk-Fact-FCA57C3A4681DF490FE894757D4BDFD1" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">362</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4660-wk-Fact-2182225A97E74833536B94757CC21CA9" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4679-wk-Fact-48EC434550E294D18A9A94757D459E4D" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">362</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4699-wk-Fact-97E928B41B23FDFD0C1294757CBFFA3C" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">526</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4718-wk-Fact-72F9B29990F7570325A794757CC1BD1B" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4738-wk-Fact-541C9156D603BBB6AF8794757D373ADE" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">526</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Insurance contracts</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4765-wk-Fact-B0EAB8BEE5D94E16A4A394757CB05C4E" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">578</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4784-wk-Fact-2C55CE6AF1C796A4ED5994757D51DA44" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4803-wk-Fact-C5258C9AE0E9A683474194757D833A8F" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">578</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4823-wk-Fact-787DD497342D45C6DCBD94757D3F332F" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">575</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4842-wk-Fact-9A214797BCD7FFF4A83494757D3BB1A1" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4862-wk-Fact-290DB7E326ACD87BB2AE94757D855347" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">575</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total other noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4888-wk-Fact-51CCF3E36BF136D5A51494757D4FE3A5" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">940</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4907-wk-Fact-B028417E4A072B8DE74194757D531D30" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4926-wk-Fact-3CFF9A3F87977020AC4994757CE93BE6" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">940</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4946-wk-Fact-13E2EB9C3878BFD2FFAF94757D6BCD5D" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,102</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4965-wk-Fact-33B72E9B20D5A269E79694757D7DE89E" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e4985-wk-Fact-38380FC548FAF9688FB394757D47998B" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,102</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e5015-wk-Fact-458BC42ACF56C0C00F1294757D42AD7D" name="us-gaap:Assets" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">24,402</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e5034-wk-Fact-944ACA21902C1A615DB094757CE82B87" name="us-gaap:Assets" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,046</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e5054-wk-Fact-52DAB6D7B762C84FF97C94757D4A6101" name="us-gaap:Assets" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">22,355</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e5073-wk-Fact-DF18E25DE31D735CE5FF94757D4FDA1E" name="us-gaap:Assets" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,176</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e5092-wk-Fact-3258FBBE5C6610BD68E194757CC5B5F3" name="us-gaap:Assets" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,863</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e5112-wk-Fact-706538E2BA2E54652D3994757D52E7F5" name="us-gaap:Assets" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,313</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Financial liabilities measured at fair value on a recurring basis:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Derivative liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e5649-wk-Fact-AC0B296B5A6EBA950F3A94757D441EA5" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">127</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e5668-wk-Fact-9EE02906DA7A45C5999594757D480F42" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e5688-wk-Fact-FF84F4185DEB7268441694757D489D66" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">127</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e5707-wk-Fact-76DE5EB5C5DF5A372F9494757CE8411F" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">114</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e5726-wk-Fact-DB8EB962F643334319A294757D29A1B3" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e5746-wk-Fact-7F33E3EEEB2C7F9E5D4F94757D72F332" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">114</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e5766-wk-Fact-338149ABCEA12CB85EDB94757D54B0B1" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">127</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e5785-wk-Fact-19AC8AC5EEBE14C5C86994757D505B0F" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e5804-wk-Fact-FA7CDAD2E0FE077D2B2294757CC1AF75" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">127</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e5824-wk-Fact-1A411667652C4392098B94757D523BBF" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">114</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e5843-wk-Fact-53787B8006C71FE8452294757D50AFAC" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e5863-wk-Fact-3028F4451F2736AFFB6794757DA44501" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">114</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Derivative liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e6144-wk-Fact-FBBDED7A6E85BF92687494757CAFE1C6" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">866</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e6163-wk-Fact-3D22450D16FCE8002B9394757D513D01" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e6182-wk-Fact-B81FAC97C51D75C709A194757D47E2FD" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">866</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e6202-wk-Fact-1D8300B1655962B921EB94757CECE556" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">604</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e6221-wk-Fact-92F86B087211FF5A96AA94757D32F1F3" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e6241-wk-Fact-F4B0A1C5A397D314C2E894757CBFB71E" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">604</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e6267-wk-Fact-02DA181659C62C2D5C2A94757D502B5A" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">866</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e6286-wk-Fact-AEE02E937098A502470A94757CE35BB1" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e6305-wk-Fact-71959F1BE99285069A2894757D388B97" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">866</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e6325-wk-Fact-F3BE67581CC42400330694757D42EF3A" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">604</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e6344-wk-Fact-7E5CDB1865C1203E189994757D44B473" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e6364-wk-Fact-412197EC6F0B972C673894757D54E628" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">604</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e6394-wk-Fact-BE27B78E4B159A0D9E3694757D3659AB" name="us-gaap:DerivativeLiabilities" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">993</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e6413-wk-Fact-CCC80B4399231D05F2B494757D47F1A1" name="us-gaap:DerivativeLiabilities" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e6433-wk-Fact-BB8921A12446F45BA5E594757CB2D1AF" name="us-gaap:DerivativeLiabilities" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">993</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e6452-wk-Fact-4EBF22B3432CAEA9026F94757CC6832F" name="us-gaap:DerivativeLiabilities" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">718</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e6471-wk-Fact-6C42D62A74E4224FDB1194757D7CFB35" name="us-gaap:DerivativeLiabilities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8351242e6491-wk-Fact-B5DA7287E69D1D5E313294757D5434CB" name="us-gaap:DerivativeLiabilities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">718</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-A2DA5EF7B6FED024F0D494757DBA101E-0-wk-Footnote-A2DA5EF7B6FED024F0D494757DBA101E_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8351242e6509-wk-Fact-FF9524E6BB352641CEF36EAEF8842218" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="FD2020Q2YTD_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">11.4</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn debt transactions (see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7D</span><span style="font-family:inherit;font-size:8pt;">) are invested in money market funds and included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments </span><span style="font-family:inherit;font-size:8pt;">in the condensed consolidated balance sheet.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-8224B42439E7CCC8C3C594757DBA701B-0-wk-Footnote-8224B42439E7CCC8C3C594757DBA701B_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, long-term equity securities of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8351242e6538-wk-Fact-7BE740157FA0927B8E5B94757CC92FDA" name="pfe:EquitySecuritiesFVNIRestrictedNoncurrent" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">163</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> and as of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:8pt;">, long-term equity securities of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8351242e6546-wk-Fact-61F25B81E0B8ABC9E44E94757CC98438" name="pfe:EquitySecuritiesFVNIRestrictedNoncurrent" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">176</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> were held in restricted trusts for benefits attributable to various U.S. non-qualified employee benefit plans.</span></div></ix:footnote></td></tr></table></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-37FC76D858F979F1748C94757DBB18E5-1" continuedAt="TextSelection-37FC76D858F979F1748C94757DBB18E5-2"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-11358084CF50DEC3FF92628C52236CBA-0-wk-Footnote-11358084CF50DEC3FF92628C52236CBA_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-37FC76D858F979F1748C94757DBB18E5-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other noncurrent assets include life insurance policies held in restricted trusts attributable to the funding of various U.S. non-qualified employee benefit plans. The underlying invested assets in these insurance contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (income)/deductions</span><span style="font-family:inherit;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">net</span><span style="font-family:inherit;font-size:8pt;"> in the condensed consolidated statements of income (see</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> Note 4</span><span style="font-family:inherit;font-size:8pt;">).</span></div></ix:continuation></ix:footnote></td></tr></table></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-A660979E9FD00EF5F81A94757DBB7351-2" continuedAt="TextSelection-794575A1292A61F2842494757DBBF969-0"><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="TextSelection-1F9EE9D6AB95F5A422F294757DBB78B8-0-wk-Fact-9636B1A5E02F4FABACF194757CC938AB" continuedAt="TextSelection-1F9EE9D6AB95F5A422F294757DBB78B8-1" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:42%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the financial liabilities not measured at fair value on a recurring basis, including the carrying values and estimated fair values using a market approach:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Estimated Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt, excluding the current portion</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e7282-wk-Fact-8289F953B8E0A1E31F6E94757D81004F" name="us-gaap:LongTermDebtFairValue" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50,529</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e7301-wk-Fact-F107D07691956E457F2694757D819FCD" name="us-gaap:LongTermDebtFairValue" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">59,121</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e7321-wk-Fact-1FEE3FFA0E7F81909D6294757D83017E" name="us-gaap:LongTermDebtFairValue" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">59,121</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e7340-wk-Fact-0572F3E504E5D75C810D94757D8292B7" name="us-gaap:LongTermDebtFairValue" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35,955</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e7359-wk-Fact-C0B91802E709F9C8087C94757D805460" name="us-gaap:LongTermDebtFairValue" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">40,842</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e7379-wk-Fact-7A8A1B93604E236BB74394757D812BD2" name="us-gaap:LongTermDebtFairValue" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">40,842</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-1F9EE9D6AB95F5A422F294757DBB78B8-1" continuedAt="TextSelection-1F9EE9D6AB95F5A422F294757DBB78B8-2"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-DA70407E988FF7F4292CB0A472718D04-0-wk-Footnote-DA70407E988FF7F4292CB0A472718D04_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-1F9EE9D6AB95F5A422F294757DBB78B8-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8351242e7403-wk-Fact-FF9524E6BB352641CEF36EAEF8842218" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="FD2020Q2YTD_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">11.4</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn debt transactions (see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7D</span><span style="font-family:inherit;font-size:8pt;">) are invested in money market funds and included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments </span><span style="font-family:inherit;font-size:8pt;">in the condensed consolidated balance sheet.</span></div></ix:continuation></ix:footnote></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, and short-term borrowings not measured at fair value on a recurring basis were not significant as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs. The fair value measurements of our private equity securities, which represent investments in the life sciences sector, are based on Level 3 inputs using a market approach.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had long-term receivables whose fair value is based on Level 3 inputs. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the differences between the estimated fair values and carrying values of these receivables were not significant.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Total Short-Term and Long-Term Investments and Equity-Method Investments</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:MarketableSecuritiesTextBlock" id="TextSelection-3B041622CBA2D9F043B794757DBB6046-0-wk-Fact-C699C2159CA77457850594757CC79FB9" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:63%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table represents our investments by classification type:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity securities with readily determinable fair values</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e7848-wk-Fact-6C93273338F344A1EC9D94757D345F29" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,033</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e7867-wk-Fact-0062B855A4905ABE3A7094757D9632CA" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">705</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e7887-wk-Fact-D12088AF2B84A688720E94757D923060" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,672</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e7906-wk-Fact-58D249F71657AAA7951094757D3404E9" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,687</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Held-to-maturity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e7931-wk-Fact-8D13847D02CC85F4058794757D32681D" name="us-gaap:HeldToMaturitySecuritiesCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">288</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e7950-wk-Fact-B94608FCBEAED35CAC0E94757D95E893" name="us-gaap:HeldToMaturitySecuritiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e7980-wk-Fact-34460712EBCE8630161A94757D364700" name="us-gaap:ShortTermInvestments" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">20,993</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e7999-wk-Fact-461073F79378DD0C88EA94757D96B544" name="us-gaap:ShortTermInvestments" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,525</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity securities with readily determinable fair values</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e8116-wk-Fact-94EB0312C6CB9501083E94757D938FCF" name="pfe:EquitySecuritiesFVNINoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,072</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e8135-wk-Fact-746631D92A859C874D8394757D93611C" name="pfe:EquitySecuritiesFVNINoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,902</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e8155-wk-Fact-3CEF4A6CEC73C33FCCF994757D365ED1" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">254</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e8174-wk-Fact-B2C06F5604F95B6F1D8C94757D94EC08" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">315</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Held-to-maturity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e8200-wk-Fact-FEC0DC267FE14F73E80594757D95A805" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">43</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e8219-wk-Fact-6FED084D74B1A999735694757D332573" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Private equity securities at cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e8244-wk-Fact-E0E1AB7E6C9E4707573094757D94F890" name="pfe:PrivateEquityInvestments" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">772</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e8263-wk-Fact-24C59A7A7528D3CCBAAF94757D349138" name="pfe:PrivateEquityInvestments" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">756</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Total Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e8293-wk-Fact-FFBCEDF314C46C81ABEE94757D18EE64" name="us-gaap:OtherLongTermInvestments" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,142</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e8312-wk-Fact-BCE8A138729B45E61B7F94757D2C3132" name="us-gaap:OtherLongTermInvestments" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,014</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity-method investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e8332-wk-Fact-06B216BCF27965D7A6A694757D11CF28" name="us-gaap:EquityMethodInvestments" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15,578</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e8351-wk-Fact-CFF1903136C1AC56DF3A94757D2B131B" name="us-gaap:EquityMethodInvestments" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17,133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term investments and equity-method investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e8381-wk-Fact-E78BCC7A156D3417B34F94757D9245CF" name="us-gaap:LongTermInvestments" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">18,720</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e8400-wk-Fact-B55C00037C5C2F34E16594757D3A1262" name="us-gaap:LongTermInvestments" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">20,147</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Held-to-maturity cash equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e8425-wk-Fact-B7DE41EB9B150DFDE59C94757D963CFC" name="pfe:HeldToMaturityCashEquivalents" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">119</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8351242e8444-wk-Fact-2B031016A863CE33C3D994757D367D09" name="pfe:HeldToMaturityCashEquivalents" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">163</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-2167C2B3C67E3F1A9F6094757DBA8899-0-wk-Footnote-2167C2B3C67E3F1A9F6094757DBA8899_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-2167C2B3C67E3F1A9F6094757DBA8899-1"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:8pt;">, equity securities with readily determinable fair values included money market funds primarily invested in U.S. Treasury and government debt. As of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8351242e8700-wk-Fact-FF9524E6BB352641CEF36EAEF8842218" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="FD2020Q2YTD_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">11.4</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn debt transactions (see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7D</span><span style="font-family:inherit;font-size:8pt;">) are invested in money market funds and included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments </span><span style="font-family:inherit;font-size:8pt;">in the condensed consolidated balance sheet.</span></div></ix:footnote></td></tr></table><ix:continuation id="TextSelection-2167C2B3C67E3F1A9F6094757DBA8899-1"><div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21</span></div></div><hr style="page-break-after:always"></hr><div><a id="sF5868EFDA95E5E66A085583EC2FD6A2B"></a></div><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-794575A1292A61F2842494757DBBF969-0" continuedAt="TextSelection-794575A1292A61F2842494757DBBF969-1"><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. Investments</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Debt Securities</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:HeldToMaturitySecuritiesTextBlock" id="TextSelection-ACE664A967E79929E92C94757DBC57EC-0-wk-Fact-6342866ADBAFBEFF4FA894757D947A24" continuedAt="TextSelection-ACE664A967E79929E92C94757DBC57EC-1" escape="true"><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="TextSelection-342B0A6E8A0919B04A6194757DBCFF59-0-wk-Fact-9E6D2AADD6AAA49E56FB94757D955EEE" continuedAt="TextSelection-342B0A6E8A0919B04A6194757DBCFF59-1" escape="true"><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="TextSelection-E91C0C0879A4EDF21B7994757DBCB0F1-0-wk-Fact-AE06CE06638E6BD9FF3994757D96FCDD" continuedAt="TextSelection-E91C0C0879A4EDF21B7994757DBCB0F1-1" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="49"></td></tr><tr><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td></tr><tr><td colspan="49" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">At June 28, 2020, our investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt securities at June 28, 2020 and December 31, 2019 is as follows, including, as of June 28, 2020, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Gross Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Maturities (in Years)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Gross Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Amortized Cost</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Fair Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Within 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Over 1<br/>to 5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Over 5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Amortized Cost</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Fair Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;text-decoration:underline;">Available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Government and agency</span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:7.5pt;">non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2031-wk-Fact-1E07A332CF81E75EE89194757D6ADCD5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,209</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2050-wk-Fact-E66B31F2784722FE09B194757D65E6DC" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(<ix:nonFraction id="d8336625e2070-wk-Fact-40916FC0ADB6E253C26C94757D741209" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2090-wk-Fact-4A18193DE354B450296194757D62FA67" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,218</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2109-wk-Fact-6414B3AAA36AB6F8996C94757D70F52B" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,218</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2129-wk-Fact-F75DADC0A525A623B0ED94757CACD9F0" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2148-wk-Fact-EA6B7B499B7AE194F97C94757D648C7E" name="pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2167-wk-Fact-4A18193DE354B450296194757D62FA67" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,218</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2187-wk-Fact-642C8BB986C4F5B5C73194757CAE6A32" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,895</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2206-wk-Fact-0EDA6E34A013B2EEDB5594757D75DD41" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(<ix:nonFraction id="d8336625e2225-wk-Fact-BB099DC5543875AE717E94757D78C4A1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2246-wk-Fact-7FBDD6E8D622F1C7D81C94757CAD2655" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,863</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Government and agency&#8211;&#8211;U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2266-wk-Fact-2C86808B55E15957B66894757CAA2949" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">257</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2285-wk-Fact-90AE9B5AC2525DE17E8F94757D72B1FD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(<ix:nonFraction id="d8336625e2304-wk-Fact-DF2A674AE873D015FD5394757D6572B0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2325-wk-Fact-6487B8AC6FEFCF90D47A94757CA831E7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">257</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2344-wk-Fact-9EA1ABD3FD2E807E66E994757D648183" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2364-wk-Fact-514FF59A5657F6BD97C394757D714DD4" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">243</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2383-wk-Fact-D85C48A562FC506974F694757D64E0B9" name="pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2402-wk-Fact-6487B8AC6FEFCF90D47A94757CA831E7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">257</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2422-wk-Fact-297354A5E6681F5E817394757CABD662" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,120</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2441-wk-Fact-1043055DC7FA32531FF894757CAC00DE" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(<ix:nonFraction id="d8336625e2460-wk-Fact-09ED68A78CE22A2CB6B194757D62D846" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2481-wk-Fact-9B9C8C3919447C777A6294757D768CC6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,114</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Corporate and other</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2508-wk-Fact-732C702072B79FA479FA94757D6913F9" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,450</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2527-wk-Fact-74E1087E683DE833774594757D710EBE" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(<ix:nonFraction id="d8336625e2546-wk-Fact-578926C69776E0961EBC94757D74A38D" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2567-wk-Fact-F4AF4992B1DFCF6708C794757D66A5A2" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,451</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2586-wk-Fact-13FB46151EC8E0F07C8894757D671597" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,440</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2606-wk-Fact-C2D1AFE34B96F2CC1CC194757D6DD63A" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2625-wk-Fact-2617EC9BFAF0558F600394757D657721" name="pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2644-wk-Fact-F4AF4992B1DFCF6708C794757D66A5A2" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,451</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2664-wk-Fact-F783B181694B408C809794757D6B5422" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,027</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2683-wk-Fact-F98C90F9224CC0E01A5794757D69B0D8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(<ix:nonFraction id="d8336625e2702-wk-Fact-2D9E3E8DD330C83B27D894757D6B6917" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2723-wk-Fact-B6FF2688963BD7DB8BDA94757D710150" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,025</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;text-decoration:underline;">Held-to-maturity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Time deposits and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e2998-wk-Fact-DC6E4AEFC0FD552F3D5894757D624BB9" name="us-gaap:HeldToMaturitySecurities" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">228</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3017-wk-Fact-F094CA2E41682574DB4194757D63D0B4" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3036-wk-Fact-1F32493351FB24825AF894757D6C959A" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3056-wk-Fact-756D80E9EED3D31D746694757D6159D7" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">228</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3075-wk-Fact-A82459496C31F2967C7D94757D71FCBD" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">189</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3095-wk-Fact-251A625674A554C58A6794757D6FED0B" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3114-wk-Fact-2944C8AA1DFD1C47A10394757D653615" name="pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3133-wk-Fact-DC6E4AEFC0FD552F3D5894757D624BB9" name="us-gaap:HeldToMaturitySecurities" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">228</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3153-wk-Fact-3D41AF66A3C3EEB4111794757D72423B" name="us-gaap:HeldToMaturitySecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">535</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3172-wk-Fact-A3F186CD360BA4F4CE3894757CAC5CC1" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3191-wk-Fact-198D3E938169E4A6D18994757D6A0AF7" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3211-wk-Fact-4D094E88040B9ACC57F594757CAA8B54" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">535</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Government and agency</span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:7.5pt;">non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3240-wk-Fact-E557914714CCF575AD4794757D61A03B" name="us-gaap:HeldToMaturitySecurities" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3259-wk-Fact-11E715FD31BB5FDBC8AC94757D6A7D51" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3278-wk-Fact-0E253A74A2AF0E86559494757D6CA87D" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3298-wk-Fact-63F766BB1A3D4C74BD4394757D6258FD" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3317-wk-Fact-4C132DEE5FABD0C31FF294757D62258F" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">218</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3337-wk-Fact-9D80D3A1CB3B1C0CE4C794757CAADF76" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3356-wk-Fact-3E18E44D9F965ECBDA2294757D6C5D67" name="pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3375-wk-Fact-E557914714CCF575AD4794757D61A03B" name="us-gaap:HeldToMaturitySecurities" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3395-wk-Fact-CD83713B6DCDE515E8E994757D78ACCF" name="us-gaap:HeldToMaturitySecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">803</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3414-wk-Fact-436E153961D73D91280494757D74B323" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3433-wk-Fact-A5FB5537AFEEE69F806794757D65FD6E" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3453-wk-Fact-03B7F5A9F53949E7B9D794757D756D0E" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">803</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Total debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3484-wk-Fact-D78AE22FD9CF08F60B3A94757D6B9F16" name="pfe:DebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,366</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3503-wk-Fact-03AAD0BFD65906FA4EA494757D637ADD" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(<ix:nonFraction id="d8336625e3523-wk-Fact-F63BBA7676F4DC45582394757D6F20F3" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3543-wk-Fact-3B838EA6B866B17EB04F94757D6778DC" name="us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,376</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3562-wk-Fact-6B5CC83C4CEC57792B4194757D6CFAD4" name="pfe:DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,079</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3582-wk-Fact-164570A44E7F8FB9FF2494757CA8AC8A" name="pfe:DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">263</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3601-wk-Fact-0850F78FA1C2AD5E1A9194757D73BE92" name="pfe:DebtSecuritiesMaturitiesAfterYearFiveFairValue" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3620-wk-Fact-3B838EA6B866B17EB04F94757D6778DC" name="us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,376</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3640-wk-Fact-6CA713A3D04E0BED22CE94757D6CF866" name="pfe:DebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,380</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3659-wk-Fact-8DFB2F34A68C8EAB957C94757D66DDC5" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(<ix:nonFraction id="d8336625e3678-wk-Fact-2B36A65E8537353058C394757D763B9F" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8336625e3699-wk-Fact-1CD5ADB0CDE00D32B6EF94757CA97228" name="us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,340</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-ACE664A967E79929E92C94757DBC57EC-1" continuedAt="TextSelection-ACE664A967E79929E92C94757DBC57EC-2"><ix:continuation id="TextSelection-342B0A6E8A0919B04A6194757DBCFF59-1" continuedAt="TextSelection-342B0A6E8A0919B04A6194757DBCFF59-2"><ix:continuation id="TextSelection-E91C0C0879A4EDF21B7994757DBCB0F1-1" continuedAt="TextSelection-E91C0C0879A4EDF21B7994757DBCB0F1-2"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></ix:continuation></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-83180A323F26770F5F9D94757DBB7831-0-wk-Footnote-83180A323F26770F5F9D94757DBB7831_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-ACE664A967E79929E92C94757DBC57EC-2"><ix:continuation id="TextSelection-342B0A6E8A0919B04A6194757DBCFF59-2"><ix:continuation id="TextSelection-E91C0C0879A4EDF21B7994757DBCB0F1-2"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Primarily issued by a diverse group of corporations.</span></div></ix:continuation></ix:continuation></ix:continuation></ix:footnote></td></tr></table><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For our portfolio of available-for-sale and held-to-maturity debt securities, any expected credit losses would be immaterial to the financial statements. </span></div><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Equity Securities</span><ix:nonNumeric contextRef="FD2020Q2YTD" name="pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" id="TextSelection-A377257B9B0B656B51C394757DBBAB24-0-wk-Fact-2E7A01FAF70A61FF2B1A94757D9468F8" continuedAt="TextSelection-A377257B9B0B656B51C394757DBBAB24-1" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:52%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the calculation of the portion of unrealized gains for the period that relates to equity securities, excluding equity method investments, still held at the reporting date:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net gains recognized during the period on equity securities</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a</sup></span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8336625e4068-wk-Fact-BE2B9931D467A3220D4894757CFCC65C" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">732</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8336625e4088-wk-Fact-A89179620F4ADD5E911294757CF30C7B" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8336625e4109-wk-Fact-98787FFB4C950A5BBD0194757CE6C4FB" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">478</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8336625e4129-wk-Fact-05F41C05FF959B0D282094757CDBBAC3" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">147</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Net (gains)/losses recognized during the period on equity securities sold during the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8336625e4150-wk-Fact-2B90710458B1C6E419A294757D18ECC2" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8336625e4169-wk-Fact-C57EB7AF3932DFA034B094757D1A76BF" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8336625e4189-wk-Fact-98B4C3B5DE39A4626AC594757D79586E" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8336625e4210-wk-Fact-98DD9B148BF5E010632094757D2EB733" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unrealized gains during the reporting period on equity securities still held at the reporting date</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8336625e4243-wk-Fact-E5773A2CC07AA52848B394757D195108" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">733</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8336625e4263-wk-Fact-B993CE1535AAAD9D78CF94757D18D0D5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">31</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8336625e4284-wk-Fact-0EF563315BCCD33D4EF194757D29687F" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">459</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8336625e4304-wk-Fact-3BF504D49EB0EC30CF2A94757D310539" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">137</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></ix:nonNumeric></div><ix:continuation id="TextSelection-A377257B9B0B656B51C394757DBBAB24-1" continuedAt="TextSelection-A377257B9B0B656B51C394757DBBAB24-2"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-9F5C431DBFAA147134E594757DBBC55E-0-wk-Footnote-9F5C431DBFAA147134E594757DBBC55E_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The net gains on investments in equity securities are reported in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (income)/deductions</span><span style="font-family:inherit;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">net.</span><span style="font-family:inherit;font-size:8pt;"> For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:inherit;font-size:8pt;">.</span></div></ix:footnote></td></tr></table></ix:continuation></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-A377257B9B0B656B51C394757DBBAB24-2" continuedAt="TextSelection-A377257B9B0B656B51C394757DBBAB24-3"><ix:continuation id="TextSelection-794575A1292A61F2842494757DBBF969-1" continuedAt="TextSelection-794575A1292A61F2842494757DBBF969-2"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)<ix:footnote id="TextSelection-F8EDCEC3C21F54D90F7894757DBBCD6D-0-wk-Footnote-F8EDCEC3C21F54D90F7894757DBBCD6D_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-F8EDCEC3C21F54D90F7894757DBBCD6D-1"> </ix:footnote></sup><ix:continuation id="TextSelection-F8EDCEC3C21F54D90F7894757DBBCD6D-1" continuedAt="TextSelection-F8EDCEC3C21F54D90F7894757DBBCD6D-2">&#160;</ix:continuation></span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><ix:continuation id="TextSelection-F8EDCEC3C21F54D90F7894757DBBCD6D-2"><ix:continuation id="TextSelection-A377257B9B0B656B51C394757DBBAB24-3"><ix:continuation id="TextSelection-794575A1292A61F2842494757DBBF969-2" continuedAt="TextSelection-74D3EAFE7BF6C3705E0594757DBC73C2-0"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. Since January 1, 2018, there were cumulative impairments and downward adjustments of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8336625e4355-wk-Fact-E2553A8C3F43098D69D594757D95713F" name="pfe:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">67</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> and upward adjustments of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8336625e4359-wk-Fact-B9FF9F4B358898BA15B394757D9701CE" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">66</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">. Impairments, downward and upward adjustments were not significant in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and the first six months of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">.</span></div></ix:continuation></ix:continuation></ix:continuation></td></tr></table><div><a id="s7D179E6CDBE2567BA2297494A04EF207"></a></div><ix:continuation id="TextSelection-74D3EAFE7BF6C3705E0594757DBC73C2-0" continuedAt="TextSelection-74D3EAFE7BF6C3705E0594757DBC73C2-1"><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">C. Short-Term Borrowings</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfShortTermDebtTextBlock" id="TextSelection-D9E14A665243AE9FA93894757DBC6979-0-wk-Fact-1579A4B384940F22B93494757CEA17CD" continuedAt="TextSelection-D9E14A665243AE9FA93894757DBC6979-1" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term borrowings include:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8329819e825-wk-Fact-DB3D21B5305018AF1C3A94757D0AD6DD" name="us-gaap:CommercialPaper" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,660</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8329819e844-wk-Fact-2AFA9323EC10EA5807E894757D0CD47F" name="us-gaap:CommercialPaper" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,915</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of long-term debt, principal amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8329819e864-wk-Fact-A1A9572C0E944C54F3F994757D0B7204" name="pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,481</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8329819e883-wk-Fact-2E3ED2641721F5EFED6494757D0C9F62" name="pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,458</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other short-term borrowings, principal amount</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8329819e910-wk-Fact-9A056798B17100CAB31894757D0A17AE" name="us-gaap:OtherShortTermBorrowings" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">956</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8329819e929-wk-Fact-25892BA475209169BE1A94757D0BD496" name="us-gaap:OtherShortTermBorrowings" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">860</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total short-term borrowings, principal amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8329819e954-wk-Fact-6AE38239D4219F1C41B294757D0B22C0" name="pfe:ShorttermDebtGross" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,097</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8329819e973-wk-Fact-B60F013139C457A9ECBF94757D0A9191" name="pfe:ShorttermDebtGross" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,233</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net fair value adjustments related to hedging and purchase accounting</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8329819e998-wk-Fact-9450C9ACB6D8D6019CA794757D0C7E34" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8329819e1017-wk-Fact-C68FFFD1E9EDF6A3DB1994757D0C6D02" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unamortized discounts, premiums and debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8329819e1042-wk-Fact-7B9F2AA22ADCA16F04FC94757D0C05F8" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8329819e1062-wk-Fact-34052216BDBE13832D7F94757D0BA7C7" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">43</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Short-term borrowings, including current portion of long-term debt</span><span style="font-family:inherit;font-size:10pt;">, carried at historical proceeds, as adjusted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8329819e1097-wk-Fact-FA941197011A51FBD4DF94757D289899" name="us-gaap:DebtCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,084</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8329819e1116-wk-Fact-E1C7AF863456D04209EB94757D12EC91" name="us-gaap:DebtCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,195</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:nonNumeric></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-D9E14A665243AE9FA93894757DBC6979-1" continuedAt="TextSelection-D9E14A665243AE9FA93894757DBC6979-2"><ix:continuation id="TextSelection-74D3EAFE7BF6C3705E0594757DBC73C2-1" continuedAt="TextSelection-74D3EAFE7BF6C3705E0594757DBC73C2-2"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-09307D44CBA12BFE03A594757DBC3C9D-0-wk-Footnote-09307D44CBA12BFE03A594757DBC3C9D_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><ix:continuation id="TextSelection-D9E14A665243AE9FA93894757DBC6979-2" continuedAt="TextSelection-D9E14A665243AE9FA93894757DBC6979-3"><ix:continuation id="TextSelection-74D3EAFE7BF6C3705E0594757DBC73C2-2" continuedAt="TextSelection-74D3EAFE7BF6C3705E0594757DBC73C2-3"><span style="font-family:inherit;font-size:8pt;">Other short-term borrowings primarily include cash collateral. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7E</span></ix:continuation></ix:continuation><span style="font-family:inherit;font-size:8pt;"><ix:continuation id="TextSelection-D9E14A665243AE9FA93894757DBC6979-3"><ix:continuation id="TextSelection-74D3EAFE7BF6C3705E0594757DBC73C2-3" continuedAt="TextSelection-06FA75E9860804F8B1E994757DBD3C90-0">.</ix:continuation></ix:continuation> </span></div></ix:footnote></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22</span></div></div><hr style="page-break-after:always"></hr><div><a id="s526A43F05F325B1CB11ED71C3C2FDF08"></a></div><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-06FA75E9860804F8B1E994757DBD3C90-0" continuedAt="TextSelection-06FA75E9860804F8B1E994757DBD3C90-1"><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">D. </span><span style="font-weight:bold;text-decoration:underline;">Long-Term Debt</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">New Issuances</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="TextSelection-0B0F3640B427F8D79BCD94757DBD3BDC-0-wk-Fact-033CF5F0A842F012BE0F94757D8BEAE7" continuedAt="TextSelection-0B0F3640B427F8D79BCD94757DBD3BDC-1" escape="true"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:60%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the second quarter of 2020, we issued the following senior unsecured notes:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturity Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of June&#160;28, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Pfizer Inc.</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e903-wk-Fact-2B3D4239B5C3D2E4BACE6E2AB54F9572" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.800</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;28, 2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e928-wk-Fact-EC3D95B498D732C8A49062B280E47D49" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e938-wk-Fact-3112A444D5581CE12B086E2AB58B2CFA" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.700</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;28, 2030</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e958-wk-Fact-1FA46A2434BD4037312A62B27FA8DC06" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e973-wk-Fact-F8B0F7DF3DF169D49D4B6E2AB5E2F31A" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.550</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;28, 2040</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e993-wk-Fact-16F6402C3D27347AC27362B27FB48AF9" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e1008-wk-Fact-1B68A2021D10A36356186E2AB5F43958" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.700</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;28, 2050</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e1028-wk-Fact-4FE832EE652DB0BFC19C62B27FAE9490" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,250</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e1068-wk-Fact-52255E4494E199DFF13A62B27FFFDA86" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Upjohn Inc., a wholly-owned subsidiary of Pfizer Inc.</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e1117-wk-Fact-3A3F9E9573BED94CECE96E2AB576ACEA" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.125</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 22, 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e1142-wk-Fact-0FC0F209129EAE86AC5062B5823DDFE3" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e1152-wk-Fact-13D7F474D284315AAC0F6E2AB5FAB98A" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.650</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 22, 2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e1172-wk-Fact-69D18EA5F2F06ECBB85462B5818CB8E2" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e1187-wk-Fact-436D89FE9F0C79B3488A6E2AB60CED32" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.300</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 22, 2027</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e1207-wk-Fact-9E0105460CD66A26DA3E62B57F93D91C" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e1222-wk-Fact-DCB68471D8E265A85F006E2AB6067B11" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.700</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 22, 2030</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e1242-wk-Fact-97E3E87FDB73BAA7FF9162B582261B0C" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,450</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e1257-wk-Fact-80C9C7989035C441E8F66E2AB600433E" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">3.850</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 22, 2040</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e1277-wk-Fact-0580CEB5C775C240F53E62B57F7CDA48" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e1292-wk-Fact-55A7A50436A17875DA886E2AB591F4F0" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">4.000</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 22, 2050</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e1312-wk-Fact-A14C3D5F01779D1B472A62B580A23EAF" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e1352-wk-Fact-023145D17C9F66D6842662B57FE27319" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,450</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Upjohn Finance B.V., a wholly-owned subsidiary of Upjohn Inc.</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e1400-wk-Fact-259A75EBC5B9155331DD6E2AB5DA7B6B" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.816</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 23, 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8364;</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e1425-wk-Fact-2CC741B37468B4EB7E7962B74D4B9AA4" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="iso4217_EUR" decimals="-6" scale="6" format="ixt:numdotdecimal">750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e1435-wk-Fact-D84A9DFE6BD8F1408DE66E2AB597194A" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.023</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 23, 2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e1455-wk-Fact-31DC3AA563E6F9E64E1962B74CB9AD9B" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="iso4217_EUR" decimals="-6" scale="6" format="ixt:numdotdecimal">750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e1470-wk-Fact-DE86B0DC7A72F0243B116E2AB5E89C96" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.362</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 23, 2027</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e1490-wk-Fact-B36932A918E6F9598D8462B74D5B37B3" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="iso4217_EUR" decimals="-6" scale="6" format="ixt:numdotdecimal">850</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e1506-wk-Fact-C7DC185FDB6E6BBA96466E2AB5EEE427" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.908</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 23, 2032</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e1526-wk-Fact-CED0DD1F7C325FCC944962B74C8C03F8" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="iso4217_EUR" decimals="-6" scale="6" format="ixt:numdotdecimal">1,250</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8364;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e1566-wk-Fact-317E8464F89DC9096D5F62B74C5A83F5" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember" unitRef="iso4217_EUR" decimals="-6" scale="6" format="ixt:numdotdecimal">3,600</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The notes may be redeemed by us at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest. The weighted-average effective interest rate for the notes at issuance was </span><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8342313e1580-wk-Fact-3E37264C56735C7578BD62D32C3B71E9" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.11</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:8pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In June 2020, Upjohn Inc. and Upjohn Finance B.V. completed privately placed debt offerings in connection with the previously announced proposed Reverse Morris Trust transaction that will ultimately combine Upjohn and Mylan to form a new company, Viatris. The notes may be redeemed by Upjohn Inc. and Upjohn Finance B.V., as applicable, at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest. The weighted-average effective interest rates at issuance were </span><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8342313e1593-wk-Fact-D7A09F7BBFEFBA72380962D5CEF4A3EF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.95</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:8pt;"> for the </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8342313e1597-wk-Fact-F2F00160251F404AA6566E2BC2FFDD9D" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember" unitRef="usd" decimals="-7" scale="9" format="ixt:numdotdecimal">7.45</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8pt;"> notes and </span><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8342313e1601-wk-Fact-008FBC80BEA7A0F99CA162D6766AA699" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">1.37</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:8pt;"> for the </span><span style="font-family:inherit;font-size:8pt;"><span>&#8364;<ix:nonFraction id="d8342313e1605-wk-Fact-A4DDA4433ECD4D0ED61A6E2BE65231D9" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember" unitRef="iso4217_EUR" decimals="-7" scale="9" format="ixt:numdotdecimal">3.60</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8pt;"> notes. If the proposed transaction with Mylan does not close on or prior to February 1, 2021, or if, prior to such date, Upjohn Inc. and Mylan notify the trustee that the business combination agreement for the proposed transaction with Mylan is terminated, or the transaction will not otherwise be pursued, the notes must be redeemed at redemption prices equal to </span><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8342313e1609-wk-Fact-6AC4751F84A34A0941906E2E3C048870" name="us-gaap:DebtInstrumentRedemptionPricePercentage" contextRef="FD2020Q2YTD_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">101</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:8pt;"> of their respective principal amounts, plus accrued and unpaid interest. Pfizer has guaranteed these notes, and such guarantees will automatically and unconditionally terminate without the consent of holders of the notes upon the proposed distribution to Pfizer&#8217;s stockholders of all of the issued and outstanding shares of Upjohn Inc.&#8217;s common stock held by Pfizer (the Distribution). Upjohn Inc. has guaranteed the notes issued by Upjohn Finance B.V., and Upjohn Inc. will remain a guarantor of such notes post Distribution. Following the separation, Upjohn Inc. and Upjohn Finance B.V., as applicable, will remain the obligor. The proceeds from the financings will be used in part to fund a cash distribution from Upjohn Inc. to Pfizer immediately prior to the Distribution. In the interim, the </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8342313e1614-wk-Fact-FF9524E6BB352641CEF36EAEF8842218" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="FD2020Q2YTD_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">11.4</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8pt;"> of proceeds are classified as </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments</span><span style="font-family:inherit;font-size:8pt;"> in the condensed consolidated balance sheet as of June 28, 2020 pursuant to the terms of the transaction agreements.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:60%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the first quarter of 2020, we issued the following senior unsecured notes:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturity Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of June 28, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.625%</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April&#160;1, 2030</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e1780-wk-Fact-200E77F96A765ED4495194757CB8CCE6" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,250</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term debt issued in the first quarter of 2020</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e1817-wk-Fact-6AFEFA4A1DCA7261A60294757D43054F" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_pfe_LongTermDebtIssuedFirstQuarter2020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,250</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-A197F5EE18ACAFCFDBE294757DBCD32F-0-wk-Footnote-A197F5EE18ACAFCFDBE294757DBCD32F_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The notes may be redeemed by us at any time, in whole, or in part, at a redemption price plus accrued and unpaid interest.</span></div></ix:footnote></td></tr></table></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-0B0F3640B427F8D79BCD94757DBD3BDC-1" continuedAt="TextSelection-0B0F3640B427F8D79BCD94757DBD3BDC-2"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-EF26E2A19056A9953CCA94757DBCDE30-0-wk-Footnote-EF26E2A19056A9953CCA94757DBCDE30_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-0B0F3640B427F8D79BCD94757DBD3BDC-2" continuedAt="TextSelection-FE76220610DB0A0063DC94757DBDB168-0"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The effective interest rate for the notes at issuance was </span><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8342313e1849-wk-Fact-B319AD60CC511A7847B494757D8A64AF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.67</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:8pt;">.</span></div></ix:continuation></ix:footnote></td></tr></table></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-06FA75E9860804F8B1E994757DBD3C90-1" continuedAt="TextSelection-E33CE246B2F81DDBB5D894757DBE8574-0"><ix:continuation id="TextSelection-FE76220610DB0A0063DC94757DBDB168-0" continuedAt="TextSelection-FE76220610DB0A0063DC94757DBDB168-1"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">December&#160;31, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term debt, principal amount</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e1993-wk-Fact-13C462C75A1858B9415654402D698FE6" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">49,187</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e2012-wk-Fact-0639ADEDE6FCAADD47BB54402D928BD5" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">34,820</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net fair value adjustments related to hedging and purchase accounting</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e2032-wk-Fact-FFC12129B6F28DF504F954402D4881FE" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,654</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e2051-wk-Fact-E503C53E22F263FD701354402D601BE4" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,305</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unamortized discounts, premiums and debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8342313e2076-wk-Fact-98F2869D66E178D172FC54402DA3E361" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">317</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8342313e2096-wk-Fact-3BB24A30AC901CF8B5B754402D7AD3ED" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">176</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e2122-wk-Fact-5FBAF0E5470A0CAAD6C154402D71F64B" name="us-gaap:OtherLongTermDebt" contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e2141-wk-Fact-51B29DDE9738C408543854402D9B17CF" name="us-gaap:OtherLongTermDebt" contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term debt, carried at historical proceeds, as adjusted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e2171-wk-Fact-F6C8BEC9CD637723D29154402D51F517" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50,529</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e2190-wk-Fact-2356819B47B4A00067B154402D88D0A0" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35,955</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e2215-wk-Fact-0D58C0B8EC08D7F1C42C54402D3F5E59" name="us-gaap:LongTermDebtCurrent" contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,481</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342313e2234-wk-Fact-60933D7A9C1B93239F0054402D225C0A" name="us-gaap:LongTermDebtCurrent" contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,462</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-FE76220610DB0A0063DC94757DBDB168-1" continuedAt="TextSelection-FE76220610DB0A0063DC94757DBDB168-2"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-9FA189BA88B1C6F34587B0A6A8B90D7C-0-wk-Footnote-9FA189BA88B1C6F34587B0A6A8B90D7C_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-FE76220610DB0A0063DC94757DBDB168-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8342313e2257-wk-Fact-FF9524E6BB352641CEF36EAEF8842218" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="FD2020Q2YTD_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">11.4</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn debt transactions are invested in money market funds and included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments </span><span style="font-family:inherit;font-size:8pt;">in the condensed consolidated balance sheet.</span></div></ix:continuation></ix:footnote></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Retirements</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2020, we repurchased at par all </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8342313e2276-wk-Fact-1FD189B7CE185C6CBE3594757D8B58C8" name="us-gaap:DebtInstrumentRepurchaseAmount" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_pfe_SeniorNotesDue2047Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="9" format="ixt:numdotdecimal">1.065</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> principal amount outstanding of our senior unsecured notes that were due in 2047 before the maturity date, which did not have a material impact on our condensed consolidated financial statements.</span></div></ix:continuation><div><a id="sAC66B59F78785AA8BD8DECD83E4B8CF1"></a></div><ix:continuation id="TextSelection-E33CE246B2F81DDBB5D894757DBE8574-0" continuedAt="TextSelection-E33CE246B2F81DDBB5D894757DBE8574-1"><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">E. </span><span style="font-weight:bold;text-decoration:underline;">Derivative Financial Instruments and Hedging Activities</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Foreign Exchange Risk</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. We manage our foreign exchange risk, in part, through operational means, including managing same-currency revenues in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. We also manage our foreign exchange risk, depending on market conditions, through fair value, cash flow, and net investment hedging programs through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to protect net income against the impact of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The derivative financial instruments primarily hedge or offset exposures in the </span><span style="font-family:inherit;font-size:10pt;">euro, U.K. pound, Japanese yen, Swedish krona and Chinese renminbi</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a part of our cash flow hedging program, we designate foreign exchange contracts to hedge a portion of our forecasted </span><span style="font-family:inherit;font-size:10pt;">euro, Japanese yen, Chinese renminbi, Canadian dollar, U.K. pound and Australian dollar</span><span style="font-family:inherit;font-size:10pt;">-denominated intercompany inventory sales expected to occur no more than </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8372444e723-wk-Fact-CBBF9E28054D0C08337794757D338FA9" name="us-gaap:DerivativeTermOfContract" contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember" format="ixt-sec:durwordsen">two years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> from the date of each hedge. </span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Interest Rate Risk</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our interest-bearing investments and borrowings are subject to interest rate risk. With respect to our investments, we strive to maintain a predominantly floating-rate basis position, but our strategy may change based on prevailing market conditions. We currently borrow primarily on a long-term, fixed-rate basis. From time to time, depending on market conditions, we will change the profile of our outstanding debt by entering into derivative financial instruments like interest rate swaps. We entered into derivative financial instruments to hedge or offset the fixed interest rates on the hedged item, matching the amount and timing of the hedged item. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock" id="TextSelection-A1EEAC2FB1F1AFE84C2194757DBE3C80-0-wk-Fact-6F79B03E992FD4039AF494757CF01171" continuedAt="TextSelection-A1EEAC2FB1F1AFE84C2194757DBE3C80-1" escape="true"><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" id="TextSelection-51EDC22604A5FE04526F94757DBE6A95-0-wk-Fact-E2DD91C7FC6D6FA9DE3D94757CEF6B40" continuedAt="TextSelection-51EDC22604A5FE04526F94757DBE6A95-1" escape="true"><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" id="TextSelection-5FC4DFE1885069BB918694757DBED53E-0-wk-Fact-36D4F1AA1B952255D0C994757CF076FA" continuedAt="TextSelection-5FC4DFE1885069BB918694757DBED53E-1" escape="true"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Notional</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Notional</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liability</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign exchange contracts</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8372444e1440-wk-Fact-2FCF66786C77668C7F1694757CC07AEE" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">22,543</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8372444e1459-wk-Fact-C74CEACCB68A148A68AC94757CC0788F" name="us-gaap:DerivativeAssets" contextRef="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">551</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8372444e1479-wk-Fact-1369E6DF1C524EDEE9A694757CC1938A" name="us-gaap:DerivativeLiabilities" contextRef="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">914</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8372444e1498-wk-Fact-6F2CE97D1E80554AD52594757CBE2E5A" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">25,193</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8372444e1517-wk-Fact-3C967CCCA2C5A8BFE04094757CC4026C" name="us-gaap:DerivativeAssets" contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">591</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8372444e1537-wk-Fact-4A6F9B60CE268B4FFEDC94757CBF9263" name="us-gaap:DerivativeLiabilities" contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">662</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8372444e1557-wk-Fact-E3C7635147C52DD5C13094757CC7FE0E" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,995</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8372444e1576-wk-Fact-541D729563AD559BF79894757CC2BE5E" name="us-gaap:DerivativeAssets" contextRef="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">158</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8372444e1595-wk-Fact-1A72D71D4E26F80408FC94757CC9544D" name="us-gaap:DerivativeLiabilities" contextRef="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8372444e1615-wk-Fact-2C5F07B2692C4575353D94757CC17F26" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,645</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8372444e1634-wk-Fact-F4DB9395DC431A691DF494757CBE344E" name="us-gaap:DerivativeAssets" contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">318</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8372444e1654-wk-Fact-B8DA90B6BC0F3BF38AF094757CC22601" name="us-gaap:DerivativeLiabilities" contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8372444e1699-wk-Fact-EF59D41F05B564884D4B94757CC503FD" name="us-gaap:DerivativeAssets" contextRef="FI2020Q2_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">708</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8372444e1718-wk-Fact-FEF5FC1AB63FCEC3FDD494757CC7CD11" name="us-gaap:DerivativeLiabilities" contextRef="FI2020Q2_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">914</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8372444e1758-wk-Fact-D15D4211FBE5F3D7085C94757CC1EC75" name="us-gaap:DerivativeAssets" contextRef="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">909</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8372444e1778-wk-Fact-94564ED7564E7B20826394757CBF7C4E" name="us-gaap:DerivativeLiabilities" contextRef="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">662</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives not designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8372444e2064-wk-Fact-C84426DB7ABC017AB03994757CC65974" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14,433</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8372444e2078-wk-Fact-67655BF5CE81FCA534DC94757CBF2DDD" name="us-gaap:DerivativeAssets" contextRef="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8372444e2097-wk-Fact-712E7CF93E1F174A1A0494757CC56179" name="us-gaap:DerivativeLiabilities" contextRef="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">79</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8372444e2122-wk-Fact-8FFEB3B89F44DFC327BB94757CC6E444" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">19,623</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8372444e2136-wk-Fact-25070E1B903A800EB04C94757CC7F381" name="us-gaap:DerivativeAssets" contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">82</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8372444e2156-wk-Fact-F9E1092602035AC060FE94757CC4C361" name="us-gaap:DerivativeLiabilities" contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8372444e2335-wk-Fact-5E159B347A43D21021F294757CBED907" name="us-gaap:DerivativeAssets" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">792</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8372444e2355-wk-Fact-A07DF5A15792C8E6AC2394757CC6B50C" name="us-gaap:DerivativeLiabilities" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">993</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8372444e2394-wk-Fact-5998C1A606152BA5557594757CC2A2DB" name="us-gaap:DerivativeAssets" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">992</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8372444e2414-wk-Fact-719C354B7E0D7018DC5494757CBFB673" name="us-gaap:DerivativeLiabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">718</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-E33CE246B2F81DDBB5D894757DBE8574-1" continuedAt="TextSelection-E33CE246B2F81DDBB5D894757DBE8574-2"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-A1EEAC2FB1F1AFE84C2194757DBE3C80-1" continuedAt="TextSelection-A1EEAC2FB1F1AFE84C2194757DBE3C80-2"><ix:continuation id="TextSelection-51EDC22604A5FE04526F94757DBE6A95-1" continuedAt="TextSelection-51EDC22604A5FE04526F94757DBE6A95-2"><ix:continuation id="TextSelection-5FC4DFE1885069BB918694757DBED53E-1" continuedAt="TextSelection-5FC4DFE1885069BB918694757DBED53E-2"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></ix:continuation></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-D29E26CC6CF7C6248CEE94757DBD9743-0-wk-Footnote-D29E26CC6CF7C6248CEE94757DBD9743_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-A1EEAC2FB1F1AFE84C2194757DBE3C80-2"><ix:continuation id="TextSelection-51EDC22604A5FE04526F94757DBE6A95-2"><ix:continuation id="TextSelection-5FC4DFE1885069BB918694757DBED53E-2"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8372444e2432-wk-Fact-578F2DA28EA41AE9382194757CEEAB1C" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2020Q2_pfe_HedgedItemAxis_us-gaap_SalesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.2</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8pt;"> as of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8372444e2440-wk-Fact-0DCDEC1F3DFA047B631094757CEF6953" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_pfe_HedgedItemAxis_us-gaap_SalesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.9</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8pt;"> as of December 31, 2019.</span></div></ix:continuation></ix:continuation></ix:continuation></ix:footnote></td></tr></table><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="TextSelection-18635C5601A80E7FBC4B94757DBE47F2-0-wk-Fact-143CB97F9A8120B20D4E94757CF17487" continuedAt="TextSelection-18635C5601A80E7FBC4B94757DBE47F2-1" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:34%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Amount of<br/>Gains/(Losses)<br/>Recognized in OID</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Amount of Gains/(Losses)<br/>Recognized in OCI</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">,</sup></span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#160;(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Amount of Gains/(Losses)<br/>Reclassified from<br/>OCI into OID and COS</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a), (b)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign exchange contracts</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e3204-wk-Fact-23913CAAF810667AF3C194757D16D9A2" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">187</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8372444e3223-wk-Fact-DD2C0BC1E91919220B7394757CCC3C6C" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">204</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e3243-wk-Fact-32E4A4F33D07CCC35B5994757D24CC85" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">172</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e3263-wk-Fact-8AC90BDE6611C4D9613F94757D10F366" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">48</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Amount excluded from effectiveness testing recognized in earnings based on an amortization approach</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e3323-wk-Fact-08FE59EF359A8EB1141294757D17D52E" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e3343-wk-Fact-F7F177E6405946748C2A94757D258C32" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e3362-wk-Fact-D581CDA4BE4F221B6C2C94757D180462" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e3382-wk-Fact-482EC9E9C634BBA5161694757D0F9FAE" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Derivative Financial Instruments in Fair Value Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e3535-wk-Fact-0FE975CFD0CEBAC8988A94757CCB8E12" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e3554-wk-Fact-0F151736606908F5607394757D16AC47" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">483</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Hedged item </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8372444e3657-wk-Fact-D46584CE1C6A5715E12694757D220D63" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8372444e3677-wk-Fact-8434DE738E1AB342D96E94757CCBDE53" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">483</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e3781-wk-Fact-75ED33FE12B125B9E0C094757D134293" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e3800-wk-Fact-1E53EA3EE5FA31F56ABC94757CCC7BB4" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Hedged item </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e3904-wk-Fact-7E1F4D7F45796F888D3994757D152AA2" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e3923-wk-Fact-CAF86E02454555A404D294757CCA9409" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8372444e4186-wk-Fact-7E8FD767BFA321ADA8D194757D17C3EB" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">144</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8372444e4207-wk-Fact-69643034125B7437E33E94757D134BD5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">48</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e4227-wk-Fact-65591C40B6FF9A07FC1694757D0FFC2A" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e4247-wk-Fact-366496A263381BEBAC8094757D116F08" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">The portion on foreign exchange contracts excluded from the assessment of hedge effectiveness</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e4312-wk-Fact-1CECC326E870388701E494757D14ABBF" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e4332-wk-Fact-40A2A359765A16FF703294757D1A2BA3" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e4351-wk-Fact-2C546F3214B511F790B394757D11B2FB" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e4371-wk-Fact-5073FE007ED4EF41D79494757D16D857" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">31</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign currency short-term borrowings</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e4558-wk-Fact-B4AE696827B3D39F948494757D114B10" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8372444e4578-wk-Fact-E8B92084BD875BA1E86894757D134EDA" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e4598-wk-Fact-772041FC75DDB73FA59D94757D1262E8" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e4618-wk-Fact-E7A174C8A21CBC1EF5C394757D1205B4" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign currency long-term debt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8372444e4683-wk-Fact-3C17EF2AE779923FF12094757D2065E5" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8372444e4704-wk-Fact-9B5EAA42679A56C367D494757D12A858" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e4724-wk-Fact-7F531F08E0D50D0C134294757D23AAA5" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e4744-wk-Fact-76C2DA9EBF5CD4536E0394757D100987" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e4897-wk-Fact-BD0329CC1D00D62B9E9F94757D234485" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8372444e4916-wk-Fact-EB1FC1F3016D395DFAD794757D2A199B" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">All other net</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e5060-wk-Fact-0133CD4E7227C37B6E9194757D1DFC1C" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e5080-wk-Fact-7AE0949565F5D585B74E94757D172848" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e5099-wk-Fact-573125655D86999E611594757D0F25B4" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e5119-wk-Fact-73E5652390B0B6E33FBC94757CCAE2A9" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e5149-wk-Fact-5D38E93A2B498707F2E694757D15B8FB" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8372444e5168-wk-Fact-7F7EA65841FA3F8EDE9D94757D1F6A7C" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e5189-wk-Fact-7E38933CC8C6B3F78FD894757D1176A3" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8372444e5208-wk-Fact-436FB3A1151F0EA4A92E94757CCA2C1F" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">216</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e5228-wk-Fact-CC96A91FB3B7AD21FC6E94757CCDA70E" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">228</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e5248-wk-Fact-CD7B6D54813C77F7056C94757CCBF9C3" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-E33CE246B2F81DDBB5D894757DBE8574-2" continuedAt="TextSelection-E33CE246B2F81DDBB5D894757DBE8574-3"><ix:continuation id="TextSelection-18635C5601A80E7FBC4B94757DBE47F2-1" continuedAt="TextSelection-18635C5601A80E7FBC4B94757DBE47F2-2"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:34%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Amount of<br/>Gains/(Losses)<br/>Recognized in OID</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Amount of Gains/(Losses)<br/>Recognized in OCI</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:pt">(a)</sup></span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:pt">,</sup></span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:pt">&#160;(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Amount of Gains/(Losses)<br/>Reclassified from<br/>OCI into OID and COS</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:pt">(a), (b)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Six Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign exchange contracts</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8372444e5856-wk-Fact-30F55F47EE0BC5CF4FF794757D0F23CF" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">341</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e5876-wk-Fact-BCDF3704B801D84F71C794757D8BEE37" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e5895-wk-Fact-D529846875F26AE83EA994757D27042F" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">126</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e5915-wk-Fact-75007AA8D5BB2FDFE2F694757D2299DA" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">257</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Amount excluded from effectiveness testing recognized in earnings based on an amortization approach</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e5973-wk-Fact-334697846783F070800594757CEB5638" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e5992-wk-Fact-42F54CD6BB1EE7437A9894757D251875" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e6010-wk-Fact-B541C3D3DAB4589EDF8994757D7AA019" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">41</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e6029-wk-Fact-0415E305501AF9B9FFBB94757D23F5EF" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">86</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Derivative Financial Instruments in Fair Value Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e6286-wk-Fact-29FB03A603A2B2F710FD94757D2DA0BB" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">392</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e6305-wk-Fact-E0BAE04C3F7AAC74123D94757D287414" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">813</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Hedged item</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8372444e6408-wk-Fact-78E877E7F508BB5A1CBD94757D8CBBF4" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">392</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8372444e6428-wk-Fact-DFF51302F0E70A31845B94757D802056" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">813</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e6551-wk-Fact-D43F780191672677C09E94757CEA1326" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Hedged item</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e6674-wk-Fact-76B77AEDB628C2C133C594757CF2E937" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e7059-wk-Fact-2723AAC37A7D7F6511E094757D2E3BF6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">240</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8372444e7079-wk-Fact-28D2817A0C35A9673F5F94757D2009C5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e7099-wk-Fact-7D1153C7730B6D08B22194757D258E58" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e7119-wk-Fact-DC149FAE791DF73A9F4E94757CEB25E2" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:18px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">The portion of foreign exchange contracts excluded from the assessment of hedge effectiveness</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e7182-wk-Fact-52E1818462885A5EFE0D94757D8CDA9B" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">176</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e7201-wk-Fact-AF4E88391CCB32EE29BF94757D2B4EC4" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">93</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e7219-wk-Fact-D17741D648E58B172B9E94757D81B725" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e7238-wk-Fact-FC494931B0AF7CE356B794757D314170" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign currency short-term borrowings</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e7539-wk-Fact-48A6C3F999379D6B924394757D7AF0E5" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e7559-wk-Fact-5FFC27FB28BF9BC0914794757D12B245" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e7578-wk-Fact-A4F33B25B1F596F9D7C294757D2733CF" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e7598-wk-Fact-A7CCC86802BC2190FB1994757CEDE354" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign currency long-term debt</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e7663-wk-Fact-5832CEAF471BE71C047B94757D1A7F51" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e7683-wk-Fact-47CB9748E3671019B33694757D79B9D0" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e7702-wk-Fact-653C3FF814F712F87A4D94757D2002AC" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e7722-wk-Fact-9F5CE5F094EEBC828DF194757D8C0D9D" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8372444e7988-wk-Fact-4BFC2EA8E8A0BCD7965C94757D916146" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8372444e8008-wk-Fact-AF62571E69854E8457D694757D8D5035" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">124</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">All other net</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e8152-wk-Fact-7B71E458C4CB31B9B78E94757CEB94F1" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e8172-wk-Fact-73D648F5F2FEA3A8D53594757D2191CE" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8372444e8191-wk-Fact-23F2FB78F6495A427ED994757D2D3461" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e8212-wk-Fact-8EC2BB5B4C87C28113B894757D7D006B" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8372444e8242-wk-Fact-338E913FDA175BCEBC1794757D8FAE73" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(<ix:nonFraction id="d8372444e8262-wk-Fact-FB427E54FB33B137568A94757D7D2609" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">124</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e8283-wk-Fact-A078219576BC94A6431D94757D13F215" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">139</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e8302-wk-Fact-7D6E2CB63598393A1F6E94757D15BA01" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">188</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e8321-wk-Fact-5E91C36A351B5607652E94757D8FBDF9" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">251</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372444e8341-wk-Fact-BA21BD3D4A33641CD2FE94757D8EFCEB" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">398</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">OID = Other (income)/deductions&#8212;net, included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:inherit;font-size:8pt;"> in the condensed consolidated statements of income</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">.</span><span style="font-family:inherit;font-size:8pt;"> COS = Cost of Sales, included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:8pt;"> in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other comprehensive loss&#8211;&#8211;Unrealized holding gains/(losses) on derivative financial instruments, net</span><span style="font-family:inherit;font-size:8pt;">. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the gains and losses are included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other comprehensive loss&#8211;&#8211;Foreign currency translation adjustments, net.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-6EDC28E4739B45A7AA7C94757DBD8D30-0-wk-Footnote-6EDC28E4739B45A7AA7C94757DBD8D30_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-6EDC28E4739B45A7AA7C94757DBD8D30-1"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The amounts reclassified from OCI into COS were:</span></div></ix:footnote></td></tr></table><ix:continuation id="TextSelection-6EDC28E4739B45A7AA7C94757DBD8D30-1" continuedAt="TextSelection-6EDC28E4739B45A7AA7C94757DBD8D30-2"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:12px;"><div style="line-height:120%;font-size:8pt;text-indent:-12px;"><span style="font-family:inherit;font-size:8pt;">a net </span><span style="font-family:inherit;font-size:8pt;">gain</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8372444e8423-wk-Fact-E3F86E54DF8A3C6FC08F6EB5A5D2AC70" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:12px;"><div style="line-height:120%;font-size:8pt;text-indent:-12px;"><span style="font-family:inherit;font-size:8pt;">a net </span><span style="font-family:inherit;font-size:8pt;">gain</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8372444e8446-wk-Fact-691E55F5092FFE3D19E994757CF0D6A1" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">150</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> in the first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:12px;"><div style="line-height:120%;font-size:8pt;text-indent:-12px;"><span style="font-family:inherit;font-size:8pt;">a net </span><span style="font-family:inherit;font-size:8pt;">gain</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8372444e8469-wk-Fact-7493B3439B8F389A067B94757CEE6BD1" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">59</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:12px;"><div style="line-height:120%;font-size:8pt;text-indent:-12px;"><span style="font-family:inherit;font-size:8pt;">a net </span><span style="font-family:inherit;font-size:8pt;">gain</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8372444e8492-wk-Fact-31146AA67167AA79BC2062F40C176931" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">103</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> in the first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax </span><span style="font-family:inherit;font-size:8pt;">gain</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8372444e8515-wk-Fact-21D05D3EA5186FE09E3A94757D344954" name="us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">102</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> within the next 12 months into income</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">. </span><span style="font-family:inherit;font-size:8pt;">The maximum length of time over which we are hedging future foreign exchange cash flow relates to our </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8372444e8523-wk-Fact-D2A6EC924DA5C0E8196B94757D33D0FA" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.8</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8pt;"> U.K. pound debt maturing in 2043.</span></div></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"><ix:continuation id="TextSelection-6EDC28E4739B45A7AA7C94757DBD8D30-2"></ix:continuation>(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The amounts reclassified from OCI were reclassified into OID.</span></div></ix:footnote></td></tr></table></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-18635C5601A80E7FBC4B94757DBE47F2-2" continuedAt="TextSelection-18635C5601A80E7FBC4B94757DBE47F2-3"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-1"><ix:continuation id="TextSelection-18635C5601A80E7FBC4B94757DBE47F2-3"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Long-term debt includes foreign currency long-term borrowings with carrying values of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8372444e8557-wk-Fact-37558442FE4310FB963594757D3574C5" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.0</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8pt;"> as of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, which are used as hedging instruments in net investment hedges.</span></div></ix:continuation></ix:footnote></td></tr></table></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">26</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-E33CE246B2F81DDBB5D894757DBE8574-3" continuedAt="TextSelection-EDFA251B3D79700DDF1494757DBE2918-0"><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="TextSelection-F7D096FD0FC21C6DABBF94757DBEA7B0-0-wk-Fact-B62669295182431200B794757D3571FA" continuedAt="TextSelection-F7D096FD0FC21C6DABBF94757DBEA7B0-1" escape="true"><ix:continuation id="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-1"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:26%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:1px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the amounts recorded in our condensed consolidated balance sheet related to cumulative basis adjustments for fair value hedges:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to </span></div><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to </span></div><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Carrying Amount</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Carrying Amount of Hedged Assets/Liabilities</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Active Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Discontinued Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Carrying Amount of Hedged Assets/Liabilities</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Active Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Discontinued Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372444e9149-wk-Fact-9686F21840EBB7B77D77A1CD25DC8AFE" name="us-gaap:HedgedAssetFairValueHedge" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372444e9168-wk-Fact-36E9EBB96B319DFEBB5AA1CD293A8034" name="us-gaap:HedgedAssetFairValueHedgeCumulativeIncreaseDecrease" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372444e9188-wk-Fact-D2FC78130C87782A35B0A1CD2BB5F206" name="us-gaap:HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372444e9207-wk-Fact-7BC374D8582E6B3D7CE3A1CD2E1DD218" name="us-gaap:HedgedAssetFairValueHedge" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372444e9226-wk-Fact-BBA7101DDA6802CF087FA1CD3193BA19" name="us-gaap:HedgedAssetFairValueHedgeCumulativeIncreaseDecrease" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372444e9246-wk-Fact-16785AEB31C380870D01A1CD33F8267B" name="us-gaap:HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372444e9265-wk-Fact-493830DEE8D1E80A700694757D1E02C5" name="us-gaap:HedgedAssetFairValueHedge" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372444e9283-wk-Fact-355795BCB10BB5225D5E94757D1E22D3" name="us-gaap:HedgedAssetFairValueHedgeCumulativeIncreaseDecrease" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372444e9302-wk-Fact-88338D8D5B185C52242D94757D1B3210" name="us-gaap:HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372444e9322-wk-Fact-D7D683B723E19620193294757D1D9320" name="us-gaap:HedgedAssetFairValueHedge" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372444e9341-wk-Fact-D1B69DB071FAA5ADCF1994757D211902" name="us-gaap:HedgedAssetFairValueHedgeCumulativeIncreaseDecrease" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372444e9361-wk-Fact-AF6B866DA26DF755DDAA94757D1EF422" name="us-gaap:HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372444e9385-wk-Fact-490104B7571E3A2E212094757D19310E" name="us-gaap:HedgedLiabilityFairValueHedge" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,023</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372444e9403-wk-Fact-EDCFA3618A0D30F9383B94757D1F6393" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372444e9422-wk-Fact-61695B3584E82F04120494757D1DD692" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,181</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372444e9442-wk-Fact-B269C96FEDB20D2F2CE794757D1AD759" name="us-gaap:HedgedLiabilityFairValueHedge" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,092</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372444e9461-wk-Fact-20C138C5667734B8A40694757D1E9B82" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">266</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372444e9481-wk-Fact-DBC865FEEF9FF10BA2C694757D213432" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">690</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-F7D096FD0FC21C6DABBF94757DBEA7B0-1" continuedAt="TextSelection-F7D096FD0FC21C6DABBF94757DBEA7B0-2"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-A6E5E77EFF2BB738D44C94757DBDF083-0-wk-Footnote-A6E5E77EFF2BB738D44C94757DBDF083_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-F7D096FD0FC21C6DABBF94757DBEA7B0-2"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</span></div></ix:continuation></ix:footnote></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of our derivative financial instruments are covered by associated credit-support agreements that have credit-risk-related contingent features designed to reduce both counterparties&#8217; exposure to risk of defaulting on amounts owed by the other party. As of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;">, the aggregate fair value of these derivative financial instruments that are in a net liability position was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8372444e9529-wk-Fact-DC960FFC71EF6609219A94757CEE3ADC" name="us-gaap:DerivativeNetLiabilityPositionAggregateFairValue" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">928</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, for which we have posted collateral of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8372444e9533-wk-Fact-78C3BA81B60B25E6BA7794757CF1AEE8" name="us-gaap:CollateralAlreadyPostedAggregateFairValue" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">922</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in the normal course of business. If there had been a downgrade to below an A rating by S&amp;P or the equivalent rating by Moody&#8217;s, we would not have been required to post any additional collateral to our counterparties.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;">, we received cash collateral of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8372444e9544-wk-Fact-212F7BE47AEBD1EEBC9D94757CF1A261" name="us-gaap:SecuritiesReceivedAsCollateral" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">858</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> from various counterparties. The collateral primarily supports the approximate fair value of our derivative contracts. With respect to the collateral received, the obligations are reported in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Short-term borrowings, including current portion of long-term debt.</span></div></ix:continuation><div><a id="s99FA3DE4F7BB5D7488E9701A494D418D"></a></div><ix:continuation id="TextSelection-EDFA251B3D79700DDF1494757DBE2918-0"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">F. Credit Risk</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On an ongoing basis, we review the creditworthiness of counterparties to our foreign exchange and interest rate agreements and do not expect to incur a significant loss from failure of any counterparties to perform under the agreements. There are no significant concentrations of credit risk related to our financial instruments with any individual counterparty. For additional information about concentrations of certain credit risk related to certain significant customers, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 17C. Segment, Geographic and Other Revenue Information: Other Revenue Information </span><span style="font-family:inherit;font-size:10pt;">in Pfizer&#8217;s </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> Financial Report. As of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had amounts due from a well-diversified, high quality group of banks (</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8342403e713-wk-Fact-A6A9DDBC3438CEEC8F9794757D24DA9B" name="us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" contextRef="FD2020Q2YTD_us-gaap_EquitySecuritiesByIndustryAxis_us-gaap_FinancialServicesSectorMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.9</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;">) from around the world. For details about our investments, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 7B </span><span style="font-family:inherit;font-size:10pt;">above</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">. </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In general, there is no requirement for collateral from customers. However, derivative financial instruments are executed under credit-support agreements that provide for the ability to request to receive cash collateral, depending on levels of exposure, our credit rating and the credit rating of the counterparty, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 7E</span><span style="font-family:inherit;font-size:10pt;"> above.</span></div></ix:continuation><div><a id="s10EDB8928F14502787EAA7B073D95827"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Note 8. </span><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:InventoryDisclosureTextBlock" id="TextSelection-7B0F479523B1900F5BF894757DBF9BFE-0-wk-Fact-1BF47749336033CA94DA94757D48645D" continuedAt="TextSelection-7B0F479523B1900F5BF894757DBF9BFE-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Inventories</span></ix:nonNumeric></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="TextSelection-5F0194A0A7C538E0DF7194757DBF5ACF-0-wk-Fact-02EF8C57A827F6DCD67A94757D47A039" continuedAt="TextSelection-5F0194A0A7C538E0DF7194757DBF5ACF-1" escape="true"><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock" id="TextSelection-8AC5724F2353C663019C94757DBF307C-0-wk-Fact-590F03BDB685195392F294757D482348" continuedAt="TextSelection-8AC5724F2353C663019C94757DBF307C-1" escape="true"><ix:continuation id="TextSelection-7B0F479523B1900F5BF894757DBF9BFE-1" continuedAt="TextSelection-7B0F479523B1900F5BF894757DBF9BFE-2"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inventories</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342960e851-wk-Fact-14CA00AE18E4FD4C971E94757CCC8D07" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,002</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342960e870-wk-Fact-96EDE76DCE3E91132D8394757CC73DFD" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342960e890-wk-Fact-1C7BE7FA88F770FEB3FB94757CC71AF7" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,810</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342960e909-wk-Fact-40F7DC6CA5FF5132288194757CC83DEE" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,743</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials and supplies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342960e934-wk-Fact-E398DF098C9F6EDE1E3794757CC6DF55" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">752</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342960e953-wk-Fact-A8FCCB5A5E91619D1A7F94757CCD8102" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">790</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inventories</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342960e985-wk-Fact-E854D651F5C65603680B94757D20C5D0" name="us-gaap:InventoryNet" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,564</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342960e1004-wk-Fact-A72909DE8208FAB8084794757D31B877" name="us-gaap:InventoryNet" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,283</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncurrent inventories not included above</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342960e1031-wk-Fact-05F3838F2F88BF0B809094757CC6BB77" name="us-gaap:InventoryNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">962</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8342960e1050-wk-Fact-69F9CBEEF2E7911E725F94757CC7E199" name="us-gaap:InventoryNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">714</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-6816050F6F7DBFCD3C5B94757DBEA485-0-wk-Footnote-6816050F6F7DBFCD3C5B94757DBEA485_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The change from </span><span style="font-family:inherit;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:8pt;"> reflects increases for certain products, including inventory build for new product launches, network strategy and market demand, partially offset by a decrease due to foreign exchange.</span></div></ix:footnote></td></tr></table></ix:continuation></ix:nonNumeric></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-5F0194A0A7C538E0DF7194757DBF5ACF-1" continuedAt="TextSelection-5F0194A0A7C538E0DF7194757DBF5ACF-2"><ix:continuation id="TextSelection-8AC5724F2353C663019C94757DBF307C-1" continuedAt="TextSelection-8AC5724F2353C663019C94757DBF307C-2"><ix:continuation id="TextSelection-7B0F479523B1900F5BF894757DBF9BFE-2" continuedAt="TextSelection-7B0F479523B1900F5BF894757DBF9BFE-3"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></ix:continuation></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-BA004C096D54F3EE7B8394757DBF9C64-0-wk-Footnote-BA004C096D54F3EE7B8394757DBF9C64_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-5F0194A0A7C538E0DF7194757DBF5ACF-2"><ix:continuation id="TextSelection-8AC5724F2353C663019C94757DBF307C-2"><ix:continuation id="TextSelection-7B0F479523B1900F5BF894757DBF9BFE-3"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other noncurrent assets</span><span style="font-family:inherit;font-size:8pt;">. There are no recoverability issues associated with these amounts.</span></div></ix:continuation></ix:continuation></ix:continuation></ix:footnote></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">27</span></div></div><hr style="page-break-after:always"></hr><div><a id="s8FEA5832D00352D5BEB181D31A6A9A29"></a></div><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Note 9. </span><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="TextSelection-10CDD905D95D20A8B03994757DBF955D-0-wk-Fact-C516E0E5F64A4D7C866594757D5FFDDF" continuedAt="TextSelection-10CDD905D95D20A8B03994757DBF955D-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Identifiable Intangible Assets and Goodwill</span></ix:nonNumeric></div><ix:continuation id="TextSelection-10CDD905D95D20A8B03994757DBF955D-1" continuedAt="TextSelection-10CDD905D95D20A8B03994757DBF955D-2"><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. Identifiable Intangible Assets</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Balance Sheet Information</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="TextSelection-49F443CEDF83606E5E8D94757DBFBF87-0-wk-Fact-202C33A0DE1DDFB3F2FD94757D5ECF3E" continuedAt="TextSelection-49F443CEDF83606E5E8D94757DBFBF87-1" escape="true"><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="TextSelection-BA125A605A5CDA1D10A294757DC0412F-0-wk-Fact-FF8B4A8FFBC9C6AF34B094757D5F18E6" continuedAt="TextSelection-BA125A605A5CDA1D10A294757DC0412F-1" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identifiable</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets, less</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identifiable</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets, less</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Finite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed technology rights</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e1370-wk-Fact-0F2346B28DB4629CBB7594757CCA9BA4" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">89,927</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8357160e1389-wk-Fact-C6E2684E0011DA4FD7EC94757CCDA666" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">64,683</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e1410-wk-Fact-24A5AF8F393541B6128994757CD2381D" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">25,244</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e1429-wk-Fact-744F5D509D408BC3A18C94757CC8DCAC" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">88,730</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8357160e1448-wk-Fact-26C4DDEC9074D8280D9794757CCF8BA1" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63,106</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e1469-wk-Fact-B95DB11055F98712D70094757CD0068E" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">25,625</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brands</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e1489-wk-Fact-DFEAAD4DBDBA20E4EAF994757CFA7DD2" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">922</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8357160e1508-wk-Fact-2E81D311A44E1DD6F32A94757CF7843D" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">757</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e1528-wk-Fact-B87FFF5883EBC20842DD94757CFA6E1A" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">165</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e1548-wk-Fact-5C7BFE7506CDA1FB98F194757CCF076B" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">922</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8357160e1567-wk-Fact-FC92CCED3441A49415F894757CF8785A" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">741</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e1588-wk-Fact-A54987DFE8FA57948EA394757CFB3A67" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">181</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing agreements and other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e1615-wk-Fact-F5BA4E904B30B0A0A9DC94757CCE56D0" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,327</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8357160e1634-wk-Fact-B35C636D04B27499B3AB94757CCFE464" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,226</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e1654-wk-Fact-ED8B7846450D797501C094757CFAC023" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,101</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e1674-wk-Fact-3A788F544AFD2EC09A8A94757CF7CB44" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,772</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8357160e1693-wk-Fact-CAF20A4833F6E5216BE394757CF277B4" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,191</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e1714-wk-Fact-43BAC5F7B8A55604118A94757CF8D187" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">582</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e1739-wk-Fact-1DA1AC35DA188A5457BD94757CCD218C" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">93,176</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8357160e1758-wk-Fact-96604F15C352A725BF5594757CF6074A" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">66,667</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e1778-wk-Fact-8D951462795DF6FEFC9194757CF33569" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">26,509</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e1798-wk-Fact-A3BA229A6FAF723BE35294757CF962D3" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">91,425</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8357160e1817-wk-Fact-C88BA43C1A9DADCD4A5494757CC8E62B" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">65,037</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e1838-wk-Fact-856C564E1C2A8B11731F94757CCE776F" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">26,387</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Indefinite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brands</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e1991-wk-Fact-62B9B1AE8FA3F7D9F7C194757CF49ABC" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,991</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e2028-wk-Fact-62B9B1AE8FA3F7D9F7C194757CF49ABC" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,991</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e2048-wk-Fact-C0DC43D9DE8D413F569094757CC94870" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,991</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e2086-wk-Fact-C0DC43D9DE8D413F569094757CC94870" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,991</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e2113-wk-Fact-4EA24C13139AF186ABC594757CFF3B82" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,518</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e2150-wk-Fact-4EA24C13139AF186ABC594757CFF3B82" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,518</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e2170-wk-Fact-B43FA979F49F2E3A20DE94757CFC75DD" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,919</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e2208-wk-Fact-B43FA979F49F2E3A20DE94757CFC75DD" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,919</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing agreements</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#160;</sup></span><span style="font-family:inherit;font-size:10pt;">and other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e2240-wk-Fact-B8329B46741B139CE66594757CCCCF54" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">523</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e2277-wk-Fact-B8329B46741B139CE66594757CCCCF54" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">523</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e2297-wk-Fact-9571AA75C6659383FDA794757CCEA9E9" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,073</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e2335-wk-Fact-9571AA75C6659383FDA794757CCEA9E9" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,073</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e2360-wk-Fact-43135ACDDC4EC0B4420494757CF927EE" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,032</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e2397-wk-Fact-43135ACDDC4EC0B4420494757CF927EE" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,032</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e2417-wk-Fact-42A981469076412426ED94757CF567DE" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,983</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e2455-wk-Fact-42A981469076412426ED94757CF567DE" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,983</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e2487-wk-Fact-08957AC6DAC01F29518A94757CFC95E1" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">100,208</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8357160e2506-wk-Fact-96604F15C352A725BF5594757CF6074A" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">66,667</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e2527-wk-Fact-9C96864A6997B214807194757D2B762A" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">33,541</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e2546-wk-Fact-AA5991AA2CE0B64BF6CF94757CCBAA43" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">100,408</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8357160e2565-wk-Fact-C88BA43C1A9DADCD4A5494757CC8E62B" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">65,037</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e2586-wk-Fact-59E2FF5E7ACF702D9F4B94757D3339C6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35,370</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-B511D685B8F037FD258094757DBFC8C5-0-wk-Footnote-B511D685B8F037FD258094757DBFC8C5_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The changes in the gross carrying amount of </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8pt;"> primarily reflect the transfer of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8357160e2621-wk-Fact-87DFE98F10CC2B76E9EC78FADA508540" name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.4</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8pt;"> from </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8pt;"> to </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8pt;"> to reflect the approval of Braftovi in combination with Erbitux</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:inherit;font-size:8pt;"> (cetuximab), for the treatment of BRAF</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">V600E</sup></span><span style="font-family:inherit;font-size:8pt;">-mutant metastatic colorectal cancer after prior therapy.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-84058C93858F4EB1F00C631013E8EF74-0-wk-Footnote-84058C93858F4EB1F00C631013E8EF74_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The changes in the gross carrying amount of </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Licensing agreements and other</span><span style="font-family:inherit;font-size:8pt;"> primarily reflect the transfer of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8357160e2655-wk-Fact-729E6527626A1D3D2C7E78FF439D6A1C" name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="FD2020Q2YTD_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">550</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> from Indefinite-lived </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Licensing agreements and other</span><span style="font-family:inherit;font-size:8pt;"> to finite-lived </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Licensing agreements and other</span><span style="font-family:inherit;font-size:8pt;"> to reflect the approval in the U.S. of several products subject to out-licensing arrangements acquired from Array.</span></div></ix:footnote></td></tr></table></ix:nonNumeric></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-49F443CEDF83606E5E8D94757DBFBF87-1" continuedAt="TextSelection-49F443CEDF83606E5E8D94757DBFBF87-2"><ix:continuation id="TextSelection-BA125A605A5CDA1D10A294757DC0412F-1" continuedAt="TextSelection-BA125A605A5CDA1D10A294757DC0412F-2"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-76B1871DA30219820FCB63105DB9E5C3-0-wk-Footnote-76B1871DA30219820FCB63105DB9E5C3_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-49F443CEDF83606E5E8D94757DBFBF87-2"><ix:continuation id="TextSelection-BA125A605A5CDA1D10A294757DC0412F-2"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The </span><span style="font-family:inherit;font-size:8pt;">decrease</span><span style="font-family:inherit;font-size:8pt;"> in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">I</span><span style="font-family:inherit;font-size:8pt;font-style:italic;text-align:right;">dentifiable intangible assets, less accumulated amortization</span><span style="font-family:inherit;font-size:8pt;text-align:right;">, </span><span style="font-family:inherit;font-size:8pt;">is primarily due to amortization.</span></div></ix:continuation></ix:continuation></ix:footnote></td></tr></table><ix:nonNumeric contextRef="FD2020Q2YTD" name="pfe:IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock" id="TextSelection-08AC202A9CCE3AD0769794757DC05F25-0-wk-Fact-12E6B9FA1B79EDB423B394757D5EC71A" escape="true"><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Biopharma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">WRDM</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed technology rights</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e2899-wk-Fact-C05530C48EF422038F3194757CE98766" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">99</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e2914-wk-Fact-48816A42EEC8706CBB6394757CEB4B9C" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e2929-wk-Fact-6E0933952A2F4C2D7D8094757CEB2A66" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brands, finite-lived</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e2949-wk-Fact-518DBC410B98B13882F794757CEA7CD3" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e2964-wk-Fact-227DB37883E433CEDCF694757CEBB345" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e2978-wk-Fact-2E181D99BE28FF78B3E894757CE42FD7" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brands, indefinite-lived</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e2998-wk-Fact-3082ED9734599A94B50A94757CED4D82" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e3013-wk-Fact-98288C8E81572474464B94757CECACFB" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e3028-wk-Fact-AF0769565EF8181AFD4894757CEBA65F" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e3048-wk-Fact-05AD82C65540CA72613394757CEDE78A" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">94</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e3063-wk-Fact-78B3D1B0B3D3AFCAF40694757CEF8D24" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e3077-wk-Fact-FB04F19E48FE01964E1994757CEBE30C" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing agreements and other, finite-lived</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e3098-wk-Fact-A549B1016CA7309F974094757CEA875C" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">99</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e3113-wk-Fact-5F6D653ADEEB5971D01794757CEA1228" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e3128-wk-Fact-306AE6B24654A4D62E4B94757CEBE091" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing agreements and other, indefinite-lived</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e3149-wk-Fact-079A48DF84909BAEA7D394757CE946FD" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e3164-wk-Fact-657913F2C5061D6C890294757CE91CC1" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e3178-wk-Fact-A6E574FCC51CCD75D29294757CEBAEB5" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Amortization</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total amortization expense for finite-lived intangible assets was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8357160e3224-wk-Fact-BB2256684D5DC3777F8494757D5E87D2" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2020Q2QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">917</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8357160e3236-wk-Fact-27AB05FFCC8FCC591C3B630426E68474" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q2QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.2</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8357160e3249-wk-Fact-5506CA5C5545248CD29A955D6E4CA9A4" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2020Q2YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.8</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> for the first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8357160e3261-wk-Fact-0C2D3BAB4843F275163F94757D5F317B" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q2YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.4</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> for the first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. Goodwill</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfGoodwillTextBlock" id="TextSelection-08D273A33DB896673DF094757DC0C104-0-wk-Fact-CAE1323C919A6D60245594757D5F6AF1" continuedAt="TextSelection-08D273A33DB896673DF094757DC0C104-1" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of and changes in the carrying amount of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Biopharma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e3461-wk-Fact-8FC69D5980FE7976569094757D543340" name="us-gaap:Goodwill" contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">48,202</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e3480-wk-Fact-FF500880D4BEE88ACA9394757D52EE76" name="us-gaap:Goodwill" contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,451</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e3500-wk-Fact-FAA57939ED1473B9187894757D259554" name="us-gaap:Goodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">58,653</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8357160e3522-wk-Fact-C25CFEE5C6642AEA5F2D94757D52C936" name="us-gaap:GoodwillOtherIncreaseDecrease" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">155</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8357160e3542-wk-Fact-0B05DCE0E371ABB7EA7494757D52B21E" name="us-gaap:GoodwillOtherIncreaseDecrease" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">49</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8357160e3562-wk-Fact-AD667A5DC0327AE34FF994757D53D517" name="us-gaap:GoodwillOtherIncreaseDecrease" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">204</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e3594-wk-Fact-9152D12DFE1CD004F9C494757D54DF86" name="us-gaap:Goodwill" contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">48,047</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e3613-wk-Fact-D96511AD0232BE6F815594757D54642A" name="us-gaap:Goodwill" contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,401</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8357160e3633-wk-Fact-4B0A3E94BBBA400AC84C94757D168B19" name="us-gaap:Goodwill" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">58,449</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-08D273A33DB896673DF094757DC0C104-1" continuedAt="TextSelection-08D273A33DB896673DF094757DC0C104-2"><ix:continuation id="TextSelection-10CDD905D95D20A8B03994757DBF955D-2" continuedAt="TextSelection-10CDD905D95D20A8B03994757DBF955D-3"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-2DE900A873C344A165FE94757DBF7A4D-0-wk-Footnote-2DE900A873C344A165FE94757DBF7A4D_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-08D273A33DB896673DF094757DC0C104-2"><ix:continuation id="TextSelection-10CDD905D95D20A8B03994757DBF955D-3"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Primarily represents the impact of foreign exchange.</span></div></ix:continuation></ix:continuation></ix:footnote></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28</span></div></div><hr style="page-break-after:always"></hr><div><a id="s1B889559790D5BF48D1D27A55DC1BDD7"></a></div><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Note 10. </span><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="TextSelection-6C66A73D1B4F00798FF594757DC040AD-0-wk-Fact-F9A10F362D481545A0F894757D3B2676" continuedAt="TextSelection-6C66A73D1B4F00798FF594757DC040AD-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Pension and Postretirement Benefit Plans</span></ix:nonNumeric></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="TextSelection-862EFA995A276D89561494757DC04291-0-wk-Fact-E87FF9778565EAF99F2C94757CBA563F" escape="true"><ix:continuation id="TextSelection-6C66A73D1B4F00798FF594757DC040AD-1" continuedAt="TextSelection-6C66A73D1B4F00798FF594757DC040AD-2"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.635477582846%;border-collapse:collapse;text-align:left;"><tr><td colspan="33"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td colspan="33" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of net periodic benefit cost/(credit):</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S.</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Supplemental</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Postretirement</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e1607-wk-Fact-8A0E6BA550C63AF3006894757D7743C2" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e1626-wk-Fact-CED160251840E4E9757A94757CF3394F" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e1646-wk-Fact-67AE548A712CDDD394F494757CF3F858" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e1665-wk-Fact-5F30C7B2C6EF0625FB9794757D988854" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e1684-wk-Fact-45D00912EC3174F4988794757D5F6E7E" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e1704-wk-Fact-F358B7D86D437E784A0C94757D6C5E83" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">31</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e1723-wk-Fact-1223798DED1AE5B8B44B94757CFDAFBC" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e1742-wk-Fact-D18AB70D2243CD2B790194757D50152C" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e1762-wk-Fact-CFFD731946630FA5173294757D0EC603" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">131</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e1781-wk-Fact-E04A84A75625863ABCB694757CF76FD7" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">157</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e1800-wk-Fact-5520EADB6F6532501EF394757CF3215F" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e1820-wk-Fact-9696A2CF54209646707A94757DA65D25" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e1839-wk-Fact-D2A42FAB207E3BB8165C94757CF71001" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e1859-wk-Fact-5ECCBF7D71F1C10F58F994757CCE5AD5" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">54</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e1878-wk-Fact-844CDA821062E6BD53F794757DA1758B" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e1897-wk-Fact-0A4CE2493D02F490DE6794757CFE8BA1" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expected return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e1922-wk-Fact-B06E1980D09EE18796F594757D98AB4D" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">251</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e1942-wk-Fact-BAFFDD51D66E4249CC7F94757DA1B948" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">223</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e1962-wk-Fact-4CCE979448BE3880158494757D550DF3" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e1982-wk-Fact-802AE66AED266C8725E294757D5173E1" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e2001-wk-Fact-126176494D5B335BE1C494757D0C4549" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e2022-wk-Fact-49590B14C26E8646597594757D759878" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e2042-wk-Fact-C15417592F592AB2F92994757CEBB96E" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e2062-wk-Fact-AF90CA6D6B01D206093194757DA7AD4C" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Actuarial losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2249-wk-Fact-93B311D39123F3627B7894757CFDB31D" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2268-wk-Fact-6CA79F4CBC2771D45A8694757D664BE5" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">37</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2287-wk-Fact-33917F70688B36ADD36494757CD2FBCC" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2307-wk-Fact-FCDCE881061046BC909894757D0A7065" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2326-wk-Fact-13288FECE518570E807894757CD4BA82" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2346-wk-Fact-CE2FEC4590F4B32F0AFE94757D6DA566" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">20</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2365-wk-Fact-15912605162B0B27D62794757CF85C35" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2384-wk-Fact-5F88E5DDF560425747C494757D9FBF5E" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prior service credits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e2409-wk-Fact-C662480C0E50DA054C1994757D9013FF" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e2429-wk-Fact-F1857CF94326E015313C94757CB87D38" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2449-wk-Fact-E00D3615F4D81E96B8B294757D7BBA3D" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2469-wk-Fact-2BAC77BAF82AA411D39894757D9E6A08" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e2488-wk-Fact-F77193A231B7FA21F36994757D77F0DE" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e2509-wk-Fact-597CFD180CE6C5E6A85C94757D982444" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e2529-wk-Fact-7F2E26BF854F77C2CC9094757D99CE84" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">43</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e2549-wk-Fact-DCA93998C4A3F799735794757D982123" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2576-wk-Fact-6CBF864E2961504A12DB94757CD2806F" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2595-wk-Fact-43962E984AB2A62DA7C694757DA10000" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2614-wk-Fact-5F2E809FE189F196C55694757D306A7C" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2634-wk-Fact-CFA766634729A8F6300E94757D619106" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2653-wk-Fact-8BB84DDD0005CCE0C40894757D4FACE5" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2673-wk-Fact-D0D7F0F7707B3E87906094757D0A1D69" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2692-wk-Fact-C1661600E4448EFBD0AB94757DA7CBB2" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2711-wk-Fact-E976B7ECD21D7D7B2E0894757CAAF95F" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Special termination benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2736-wk-Fact-FEF1DA28980DC329CE8C94757D9DC823" name="us-gaap:DefinedBenefitPlanSpecialTerminationBenefits" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2755-wk-Fact-F61FAFB8F521C98C7C4294757D082A31" name="us-gaap:DefinedBenefitPlanSpecialTerminationBenefits" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2774-wk-Fact-618CBFA355001747A53F94757D8EA4E9" name="us-gaap:DefinedBenefitPlanSpecialTerminationBenefits" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2794-wk-Fact-6D11C4A43914FD02D6DE94757CF59807" name="us-gaap:DefinedBenefitPlanSpecialTerminationBenefits" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2813-wk-Fact-0D267565F8548AD0F4B094757D79A699" name="us-gaap:DefinedBenefitPlanSpecialTerminationBenefits" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2833-wk-Fact-735E91E10251837304A394757D6D4282" name="us-gaap:DefinedBenefitPlanSpecialTerminationBenefits" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2852-wk-Fact-818B45C59E5295D57CEC94757DA3E1BE" name="us-gaap:DefinedBenefitPlanSpecialTerminationBenefits" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2871-wk-Fact-E31B6E1B030324C2785A94757D908F5F" name="us-gaap:DefinedBenefitPlanSpecialTerminationBenefits" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net periodic benefit cost/(credit) reported in income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e2901-wk-Fact-03638A3FE9F6DEABE42094757CF66E73" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">83</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e2921-wk-Fact-569ABF20101276D3F33394757CB2B9DD" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2942-wk-Fact-A79A69EE5FF1341B264F94757D55549B" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2961-wk-Fact-0484268376D2F2A3A68D94757CFF7FF1" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e2980-wk-Fact-FE4AAA62177D49B766D194757D7ADFB0" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e3000-wk-Fact-858B05D1EC7B77F4C37594757D6E6FBF" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e3019-wk-Fact-0CCCC7C6B12548EF9A2E94757D530CED" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2020Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e3039-wk-Fact-04FF5CFA56B2C55F794094757CF522A1" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2019Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td colspan="33" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S.</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Supplemental</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Postretirement</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e3899-wk-Fact-C966FE1217910DE3ABE694757CC3106C" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e3918-wk-Fact-7DF4148F3A92339C0A3F94757CB7E54B" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e3938-wk-Fact-D43F7EB6258E84BF7E5694757D2BE9F0" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e3957-wk-Fact-394A995203A612A26E0994757D28CC73" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e3976-wk-Fact-7C66E5B3FAC766AE22B794757CEEC058" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">72</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e3996-wk-Fact-97881A4FB86B00148A2B94757D261E26" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4015-wk-Fact-1CA2C7F4D12568AAED6994757D7BE3EF" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4034-wk-Fact-53B245957441E22EE4A594757CDBEEFC" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4054-wk-Fact-A023A66317D5ED5867FB94757CB18D04" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">262</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4073-wk-Fact-5AE2182B13B4CEF4C73794757D2CF199" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">315</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4092-wk-Fact-C06CABC15DA14C11FF5594757D2AE2FF" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4112-wk-Fact-1A9BAC56131373D1A8C494757D3375BF" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4131-wk-Fact-42AE4996AE177FA236A394757CD11CBD" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">82</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4151-wk-Fact-DA44B2F63C0376FF208194757CD0CB29" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">109</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4170-wk-Fact-0986444DADBF5856B95694757CB9C5CE" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4189-wk-Fact-578F006D640F90FE6D6994757CED7830" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expected return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e4214-wk-Fact-4FA4F93E26ADD0787AA694757D101185" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">503</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e4234-wk-Fact-D2E448D40BAAF65BAC8894757CB569ED" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">445</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4254-wk-Fact-86387ADB0CDA28791A3294757CD390BC" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4274-wk-Fact-B911AAAF89C2FE235BCA94757D21CD37" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e4293-wk-Fact-3942B825C87E1470A01094757CD14464" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">153</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e4314-wk-Fact-55A505C832573019983194757CD4C565" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">160</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e4334-wk-Fact-BF26E6FFFF77B2936C1394757D251B69" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e4354-wk-Fact-B11719A8D4E495C277B194757CD4A6A5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Actuarial losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4549-wk-Fact-2EC458A90E1B56D867AE94757CD1D3AA" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">64</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4568-wk-Fact-DC691DF21ACF6174AF3094757CD547B2" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">74</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4587-wk-Fact-0CFC631FFCB8BDA9416C94757D2C8121" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4607-wk-Fact-E17FE0E5DD807040E21594757D231D49" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4626-wk-Fact-5FF15C7FD69DACE707E394757CB3D138" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">62</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4646-wk-Fact-99A89FB4D21C1D68F53494757CCD0A0F" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">41</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4665-wk-Fact-DFF679DE86AA442135FA94757D2A2469" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4684-wk-Fact-9395603C040D04A3E29894757CF282C8" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prior service credits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e4709-wk-Fact-018F7777F5A4988D2FD294757D121DCA" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e4729-wk-Fact-6A9B12BC065B471F391B94757D277E0E" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4749-wk-Fact-FA02EE27136AFA6D96F094757CD55AE6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4769-wk-Fact-8600724A667F7C107E7F94757D1E1F98" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e4788-wk-Fact-3407605A9D652DFE90CA94757CDF90AB" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e4809-wk-Fact-741D4D9739EDAA66166594757D043AD2" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e4829-wk-Fact-71EF664358F7AC4D77F294757D7D3040" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">86</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e4849-wk-Fact-7AB287253C2826281A4E94757CB7A875" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">89</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4875-wk-Fact-EE0CC097563E8EE1C71694757CEC1429" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">20</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4894-wk-Fact-107324D1959BD11060E994757D31C047" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4913-wk-Fact-E1C3EC8BA4E738E81A4B94757CEE03E3" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">44</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4933-wk-Fact-DAEC64A519CE1A4EBC0A94757CD30823" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4952-wk-Fact-8D6BE01FBE41D16A6CDE94757CED03D5" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4972-wk-Fact-46A8399C200FF03D695894757CC1B39D" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e4991-wk-Fact-AB9B2C9037487774B82494757D2BDF3C" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e5010-wk-Fact-695280579C624DE4737894757D3F4332" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Special termination benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e5035-wk-Fact-69697D056FD8BE2650F394757CB775CD" name="us-gaap:DefinedBenefitPlanSpecialTerminationBenefits" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e5054-wk-Fact-CCF8EF89DBF6968FDE9B94757CCB90CB" name="us-gaap:DefinedBenefitPlanSpecialTerminationBenefits" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e5073-wk-Fact-3246F936E711F93EDC5794757D1E99E6" name="us-gaap:DefinedBenefitPlanSpecialTerminationBenefits" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e5093-wk-Fact-D88A927EE32742928CF594757CD5C32D" name="us-gaap:DefinedBenefitPlanSpecialTerminationBenefits" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e5112-wk-Fact-9CF0B0C1C64F07BA8B3294757D232E83" name="us-gaap:DefinedBenefitPlanSpecialTerminationBenefits" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e5132-wk-Fact-0A109F12214E8787069B94757D2DCD8B" name="us-gaap:DefinedBenefitPlanSpecialTerminationBenefits" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e5151-wk-Fact-FBA6799618AA470B679094757CB47DD9" name="us-gaap:DefinedBenefitPlanSpecialTerminationBenefits" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e5170-wk-Fact-C6ABBF9E804027B403D294757D2FD3AA" name="us-gaap:DefinedBenefitPlanSpecialTerminationBenefits" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net periodic benefit cost/(credit) reported in income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e5200-wk-Fact-5A97434FFD808A04AB1794757D2D057B" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">159</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e5220-wk-Fact-4D2A5C653703ADAEF66194757CDAD6E1" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e5241-wk-Fact-43E0AE005A8224139B4894757D24D0D3" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e5260-wk-Fact-0243292AC7ECF384807094757D29F0B1" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e5279-wk-Fact-B22726FB6CA500CEABE294757D1613CA" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8372420e5299-wk-Fact-6855CF96A7F97DB0DA4594757CB1DFD3" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e5318-wk-Fact-7421330FDB0F5938BC4F94757D164088" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">60</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8372420e5338-wk-Fact-B447540A0E9C595AEFFE94757D2F88DB" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2019Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="pfe:ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock" id="TextSelection-B1B1FE4E46EFE71E586B94757DC0F9B6-0-wk-Fact-64E2770B8AF780A808AD94757D2925FF" continuedAt="TextSelection-B1B1FE4E46EFE71E586B94757DC0F9B6-1" escape="true"><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:47%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the amounts we contributed, and the amounts we expect to contribute during 2020, to our pension and postretirement plans from our general assets for the periods indicated:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S. Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S. Supplemental (Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Postretirement Plans</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Contributions from our general assets for the six months ended June 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372420e5685-wk-Fact-BEA910CC7097248EF9BD94757D8D24B6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372420e5704-wk-Fact-6919A01C1B8A8058F9D694757D90E44C" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">150</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372420e5724-wk-Fact-6E1144FFE02DFD09A16794757D82DC24" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">116</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372420e5743-wk-Fact-ADF0D5020F8FD777B95294757D8F440B" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="FD2020Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">64</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Expected contributions from our general assets during 2020</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372420e5765-wk-Fact-E864359E96F7D020F0CE94757D7CD99F" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear" contextRef="FI2020Q2_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,253</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372420e5784-wk-Fact-7363C996912428EF761094757D8CDD06" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear" contextRef="FI2020Q2_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">183</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372420e5803-wk-Fact-35AE4CA011AF5ED4C8B994757D74E218" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear" contextRef="FI2020Q2_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">185</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d8372420e5823-wk-Fact-2DB662656B0870E5C58B94757D7A7265" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear" contextRef="FI2020Q2_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">137</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-B1B1FE4E46EFE71E586B94757DC0F9B6-1" continuedAt="TextSelection-B1B1FE4E46EFE71E586B94757DC0F9B6-2"><ix:continuation id="TextSelection-6C66A73D1B4F00798FF594757DC040AD-2" continuedAt="TextSelection-6C66A73D1B4F00798FF594757DC040AD-3"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-286F4719195A28A9913594757DC0B1B8-0-wk-Footnote-286F4719195A28A9913594757DC0B1B8_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-B1B1FE4E46EFE71E586B94757DC0F9B6-2"><ix:continuation id="TextSelection-6C66A73D1B4F00798FF594757DC040AD-3"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Contributions expected to be made for </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> are inclusive of amounts contributed during the </span><span style="font-family:inherit;font-size:8pt;">six months ended June 28, 2020</span><span style="font-family:inherit;font-size:8pt;">. The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments. For the U.S. qualified plans, we plan to make a </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8372420e5919-wk-Fact-5A101E66210BE38BFEC894757DA5C6AD" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="D2020Q4Jun29-Dec31_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="usd" decimals="-7" scale="9" format="ixt:numdotdecimal">1.25</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8pt;"> voluntary contribution in the second half of 2020.</span></div></ix:continuation></ix:continuation></ix:footnote></td></tr></table><div><a id="s694ac9367b284a9494e552b8fbd475cb"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Note 11. </span><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="TextSelection-2C0862EB3E45679CF8E1633CB04B10A3-0-wk-Fact-BB3667F91051469F2EBF633D59A78119" continuedAt="TextSelection-2C0862EB3E45679CF8E1633CB04B10A3-1" escape="true"><span style="font-weight:bold;text-decoration:underline;">Equity</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"> </span></ix:nonNumeric></div><ix:continuation id="TextSelection-2C0862EB3E45679CF8E1633CB04B10A3-1" continuedAt="TextSelection-2C0862EB3E45679CF8E1633CB04B10A3-2"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. Preferred Stock</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to May 4, 2020, Pfizer&#8217;s Series A convertible perpetual preferred stock (the Series A Preferred Stock) was held by an employee stock ownership plan trust (the Trust). All outstanding shares of Series A Preferred Stock were converted, at the direction of the independent fiduciary under the Trust and in accordance with the certificate of designations for the Series A Preferred Stock, into shares of Pfizer common stock on May 4, 2020. The Trust received an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8352055e702-wk-Fact-837037F981A4F7FE313994757D9F0609" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="D2020Q2May4-4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,070,369</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of Pfizer common stock upon conversion, with </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8352055e706-wk-Fact-139531B224829D473DC094757DA47D96" name="us-gaap:PreferredStockSharesOutstanding" contextRef="I2020Q2May4" unitRef="shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">zero</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of Series A Preferred Stock remaining outstanding as a result of the conversion.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-2C0862EB3E45679CF8E1633CB04B10A3-2"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. Dividends</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:DividendsDeclaredTableTextBlock" id="TextSelection-B33D97891A4C134539C6633F51057236-0-wk-Fact-25B646872BA1E732B3F4634004069935" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes quarterly cash dividends:</span></div></td></tr><tr><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date Declared</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividend Per</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date Declared</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividend Per Share</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 13, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 6, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8352055e962-wk-Fact-85F65DD82325B178C66594757CFD849B" name="us-gaap:CommonStockDividendsPerShareDeclared" contextRef="D2019Q4Dec13-13" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.38</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 14, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 1, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8352055e997-wk-Fact-2CF0A869020E2EEBB6EB634AD40A53A7" name="us-gaap:CommonStockDividendsPerShareDeclared" contextRef="D2018Q4Dec14-14" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 23, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 5, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8352055e1027-wk-Fact-38FFB29DB2E02FCAD7CF634AAC8B3855" name="us-gaap:CommonStockDividendsPerShareDeclared" contextRef="D2020Q2Apr23_Apr232020" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.38</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 25, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 7, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8352055e1062-wk-Fact-FA418604F1FC47CDDF3F634AD7AD39AC" name="us-gaap:CommonStockDividendsPerShareDeclared" contextRef="D2019Q2Apr25-25" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 25, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8352055e1092-wk-Fact-3085C64D47708F3D1BD5634AAC9340F6" name="us-gaap:CommonStockDividendsPerShareDeclared" contextRef="D2020Q2Jun25-25" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.38</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 3, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8352055e1127-wk-Fact-4143CB1C95950518012A634ADB63B785" name="us-gaap:CommonStockDividendsPerShareDeclared" contextRef="D2019Q2Jun27" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 24, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 2, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8352055e1193-wk-Fact-7BE8DA4E56FB81F33720634ADF329259" name="us-gaap:CommonStockDividendsPerShareDeclared" contextRef="D2019Q3" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><a id="sC53407A49BAF5C52B97B1DDE56DCE409"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Note 12. </span><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:EarningsPerShareTextBlock" id="TextSelection-4380F86A09A2E4DDA07194757DC07F50-0-wk-Fact-8FD19B660B534F4C402D94757CFCBDBE" continuedAt="TextSelection-4380F86A09A2E4DDA07194757DC07F50-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</span></ix:nonNumeric></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="TextSelection-BAAAF81361CEA24550F094757DC11387-0-wk-Fact-34877EB99C4970166C2794757CFBE271" continuedAt="TextSelection-BAAAF81361CEA24550F094757DC11387-1" escape="true"><ix:continuation id="TextSelection-4380F86A09A2E4DDA07194757DC07F50-1" continuedAt="TextSelection-4380F86A09A2E4DDA07194757DC07F50-2"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:52%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the detailed calculation of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">EPS</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(IN MILLIONS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">EPS Numerator&#8211;&#8211;Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1102-wk-Fact-2979655C6D134159C89394757D499DAA" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,434</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1121-wk-Fact-C920A45D5E66EC197B2A94757CF0CD54" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,056</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1141-wk-Fact-A90E01F4F7B0E1568EDA94757D6D8CFD" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,845</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1160-wk-Fact-603FB52F232889DFBADE94757D592C93" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,945</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Net income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1180-wk-Fact-AC8A94205E4FF68F9F3694757D49E298" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1199-wk-Fact-7A36A559DC490566437C94757D3C7471" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1218-wk-Fact-C329D124C5801810FE0C94757D347999" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1238-wk-Fact-604FE0F79757762E5E8C94757CCFB893" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to Pfizer Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1263-wk-Fact-1CF3FF61B59C9EBB9C9994757D3E3AB3" name="us-gaap:IncomeLossFromContinuingOperations" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1282-wk-Fact-E7ECE7800082856A7A1094757D39605C" name="us-gaap:IncomeLossFromContinuingOperations" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,046</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1301-wk-Fact-4A9CCA0D3C475FAD52C694757D3900B8" name="us-gaap:IncomeLossFromContinuingOperations" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,828</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1321-wk-Fact-465C45AD0AF6E5F0BC6C94757D2C168A" name="us-gaap:IncomeLossFromContinuingOperations" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,929</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Preferred stock dividends&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1346-wk-Fact-F9E6F4AE79CD02D810A994757D401975" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1365-wk-Fact-F7CCA6E7C71004067D5E94757D402809" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1384-wk-Fact-A0F2B8C76CEC5D3EEADE94757D28154B" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1404-wk-Fact-A0593EA50670403DBD0194757D33B2B7" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1429-wk-Fact-E9B299C5DCCAC1091C9C94757D3B698F" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1448-wk-Fact-BB4B1F24703C7617826494757D4169BB" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,045</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1467-wk-Fact-23F8672CEEE9B2454CCC94757D355E2C" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,828</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1487-wk-Fact-CD9F62E0AB686EA2160894757D38EB6F" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,929</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1512-wk-Fact-D0B1BB14EB1C0097910C94757D5D09B2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1531-wk-Fact-05DE67BF183EFC3302F894757D673D16" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1550-wk-Fact-8CA5088693E8928A2F7194757D5C8489" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1570-wk-Fact-7F22D0DB6525173F13B494757CADCE97" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1600-wk-Fact-11A391AB7EC29FE56C8194757D44B325" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1619-wk-Fact-E8DC3F36C1484A7598DD94757D412AB0" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,045</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1639-wk-Fact-CBE74642929D5FE6AE4E94757CED0E9A" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,828</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1658-wk-Fact-D566F33C0450F49C95E994757D7B3B2F" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,929</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">EPS Numerator&#8211;&#8211;Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1767-wk-Fact-E0F82560F34C81B9ADE594757D47F841" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1786-wk-Fact-B9F608288C5AC6E377DC94757D3E37FA" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,046</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1806-wk-Fact-48548F0A6A5A6C9A7DA994757D37EE18" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,828</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1825-wk-Fact-5CF1FB104F54EA6CCDE094757D2A8412" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,929</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1845-wk-Fact-C570458300ACBEDF93DD94757D39134F" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1864-wk-Fact-A46A2B659FBFF5DE296C94757D3E1EC5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1883-wk-Fact-4244BE93446A2982839C94757D8068CB" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1903-wk-Fact-2233B315E6E073D059A694757D7AFB08" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1933-wk-Fact-FC0A7ED4816CF00DCA6494757D460073" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1952-wk-Fact-A572FAF534B34CC5432094757D3FA3CE" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,046</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1972-wk-Fact-0A993D6EBB97EDD9C20D94757D312BB1" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,828</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e1991-wk-Fact-2D0FCD88B17D4D8FA67594757CD6DAC9" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,929</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">EPS Denominator</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e2094-wk-Fact-CEDDD667A11CAC08820D94757D0E749E" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2020Q2QTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,554</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e2113-wk-Fact-4083035A9265D74B487394757CDE895C" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,562</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e2132-wk-Fact-3E9B45FC40C0B53734B894757D6021C6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2020Q2YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,550</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e2152-wk-Fact-05B58E4BDA3C96C172AE94757D61A5B0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,598</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common-share equivalents: stock options, stock issuable under employee compensation plans and convertible preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e2177-wk-Fact-9575A68D8FEC4A1DD04394757D38012E" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2020Q2QTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">65</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e2196-wk-Fact-EC2E7F8D528A88AAC11994757D3D9309" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">110</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e2215-wk-Fact-71C844C0735999FB98A094757D7BE586" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2020Q2YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">66</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e2235-wk-Fact-EDC8EE2FFDAD42D9FF4E94757D7E3374" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">112</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e2260-wk-Fact-CDED57DD355FBFDCE83394757D0D0D08" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2020Q2QTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,619</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e2279-wk-Fact-C825A8BB25BE38B63BB194757D30A6AC" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,672</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e2298-wk-Fact-8EF576E428EEA952509894757D5DA535" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2020Q2YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,616</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e2318-wk-Fact-4E46F2B386CE7BF8977294757CBBCA8A" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,711</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Anti-dilutive common stock equivalents</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e2345-wk-Fact-1F9015BD5A5A1530EFBA94757D43CEBC" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2020Q2QTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e2364-wk-Fact-B3F82E5E9DDB5FAA6C2D94757D393DCC" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e2383-wk-Fact-4140131424BB26DB8A6194757CD6155F" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2020Q2YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8356748e2403-wk-Fact-2183DCBEF0EE0B13B7AC94757CC13062" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:continuation></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-BAAAF81361CEA24550F094757DC11387-1" continuedAt="TextSelection-BAAAF81361CEA24550F094757DC11387-2"><ix:continuation id="TextSelection-4380F86A09A2E4DDA07194757DC07F50-2" continuedAt="TextSelection-4380F86A09A2E4DDA07194757DC07F50-3"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-6979FD063E456189966A94757DC072A0-0-wk-Footnote-6979FD063E456189966A94757DC072A0_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-BAAAF81361CEA24550F094757DC11387-2"><ix:continuation id="TextSelection-4380F86A09A2E4DDA07194757DC07F50-3"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</span></div></ix:continuation></ix:continuation></ix:footnote></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">30</span></div></div><hr style="page-break-after:always"></hr><div><a id="sAFBB238416CA5C97A846E3AAEE77E6DB"></a></div><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Note 13. </span><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="TextSelection-54520FF336DB7E29D5B594757DC1F14C-0-wk-Fact-FBB0BAD5276EFDAC3BF194757CBD1883" continuedAt="TextSelection-54520FF336DB7E29D5B594757DC1F14C-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Contingencies and Certain Commitments</span></ix:nonNumeric></div><ix:continuation id="TextSelection-54520FF336DB7E29D5B594757DC1F14C-1" continuedAt="TextSelection-54520FF336DB7E29D5B594757DC1F14C-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies. For a discussion of our tax contingencies, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 5B.</span><span style="font-family:inherit;font-size:10pt;"> For a discussion of our legal contingencies, see below.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. Legal Proceedings</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our legal contingencies include, but are not limited to, the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. We are the plaintiff in the majority of these actions. An adverse outcome in actions in which we are the plaintiff could result in loss of patent protection for a drug, a significant loss of revenues from that drug or impairment of the value of associated assets.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial and other matters, which can include merger-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other jurisdictions.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, which could be substantial, and/or criminal charges.</span><span style="font-family:Arial;font-size:8pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations in the period in which the amounts are accrued and/or our cash flows in the period in which the amounts are paid.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader&#8217;s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. As a result of considering qualitative factors in our determination of principal matters, there are some matters discussed below with respect to which management believes that the likelihood of possible loss in excess of amounts accrued is remote.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-54520FF336DB7E29D5B594757DC1F14C-2" continuedAt="TextSelection-54520FF336DB7E29D5B594757DC1F14C-3"><div style="line-height:120%;padding-bottom:6px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-weight:bold;text-decoration:underline;">A1.</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"> </span><span style="font-weight:bold;text-decoration:underline;">Legal Proceedings&#8211;&#8211;Patent Litigation</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Like other pharmaceutical companies, we are involved in numerous suits relating to our patents, including but not limited to, those discussed below. Most of the suits involve claims by generic drug manufacturers that patents covering our products, processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents on a number of our products that are discussed below, patent rights to certain of our products are being challenged in various other jurisdictions. We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for allegedly causing delay of generic entry. Additionally, our licensing and collaboration partners face challenges by generic drug manufacturers to patents covering products for which we have licenses or co-promotion rights. </span><span style="font-family:inherit;font-size:10pt;">We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others.</span><span style="font-family:inherit;font-size:10pt;"> Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the U.S. In October 2017, the Patent Trial and Appeal Board (PTAB) refused to initiate proceedings as to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383765e789-wk-Fact-5C8CB8F598CAEF84107894757DA7A368" name="pfe:GainContingencyPatentsWithoutCourtProceedingsNumber" contextRef="D2017Q4Oct01-Oct31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> patents. In June 2018, the PTAB ruled on another patent, holding that </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383765e793-wk-Fact-D5F27759E5862BD4204694757CD11378" name="us-gaap:GainContingencyPatentsFoundInfringedUponNumber" contextRef="D2018Q2Jun01-Jun30_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> claim was valid and that all other claims were invalid. The party challenging that patent appealed the decision. In November 2019, the U.S. Court of Appeals for the Federal Circuit vacated the PTAB&#8217;s ruling and requested that the PTAB redecide the challenge.</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">In March and June 2019, an additional patent was found invalid in separate proceedings by the PTAB. We appealed. In January 2020, the U.S. Court of Appeals for the Federal Circuit vacated the original decision and requested that the PTAB redecide the case. Challenges to other patents remain pending in jurisdictions outside the U.S.</span><span style="font-family:inherit;font-size:10pt;color:#1f497d;"> </span><span style="font-family:inherit;font-size:10pt;">The invalidation of all of the patents in our pneumococcal portfolio could potentially allow a competitor pneumococcal vaccine into the marketplace. In the event that any of the patents are found valid and infringed, a competitor pneumococcal vaccine might be prohibited from entering the market or required to pay Pfizer a royalty. We are also subject to patent litigation pursuant to which one or more third parties seek damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our Hospira subsidiaries are involved in patent and patent-related disputes over their attempts to bring generic pharmaceutical and biosimilar products to market. </span><span style="font-family:inherit;font-size:10pt;">If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold in the event that we or one of our subsidiaries, like Hospira, is found to have willfully infringed valid patent rights of a third party.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Actions In Which We Are The Plaintiff</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">EpiPen</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz in the U.S. District Court for the District of New Jersey in connection with Sandoz&#8217;s abbreviated new drug application filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Xeljanz (tofacitinib)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning in 2017, we brought patent-infringement actions against several generic manufacturers that filed separate abbreviated new drug applications with the FDA seeking approval to market their generic versions of tofacitinib tablets in </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> or both of 5 mg and 10 mg dosage strengths, and in both immediate and extended release forms. To date, actions against the following generic manufacturers have been settled on terms not material to Pfizer: (i) MicroLabs USA Inc. and MicroLabs Ltd.; (ii) Sun Pharmaceutical Industries Ltd.; (iii) Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., Huahai US Inc. and Solco Healthcare US, LLC; (iv) Breckenridge Pharmaceutical Inc., Pensa Pharma S.A. and Laboratorios Del Dr. Esteve, S.A.; and (v) Ajanta Pharma Ltd. and Ajanta Pharma USA Inc. The remaining actions continue as described below.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2017, we brought a patent-infringement action against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, Zydus) in the U.S. District Court for the District of Delaware asserting the infringement and validity of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383765e835-wk-Fact-98F60AD39D22D47828D894757D5BF72E" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" contextRef="D2017Q1Mar01-Mar31_srt_LitigationCaseAxis_pfe_PfizerVersusZydusMember_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> patents: the patent covering the active ingredient expiring in December 2025, the patent covering an enantiomer of tofacitinib expiring in 2022, and the patent covering a polymorphic form of tofacitinib expiring in 2023, which Zydus challenged in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2018, we brought a separate patent infringement action against Teva Pharmaceuticals USA, Inc. (Teva) in the U.S. District Court for the District of Delaware asserting the infringement and validity of our patent covering extended release </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-54520FF336DB7E29D5B594757DC1F14C-3" continuedAt="TextSelection-54520FF336DB7E29D5B594757DC1F14C-4"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">formulations of tofacitinib that was challenged by Teva in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 11 mg extended release tablets.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Inlyta (axitinib)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2018, Apotex Inc. notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Inlyta. Apotex Inc. asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In May 2018, we filed suit against Apotex Inc. in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2019, Glenmark Pharmaceuticals Limited (Glenmark) notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Inlyta. Glenmark asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In June 2019, we filed suit against Glenmark in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Kerydin (tavaborole)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2018, several generic companies notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Kerydin. The generic companies</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span><span style="font-family:inherit;font-size:10pt;">assert the invalidity and non-infringement of methods of use and formulation patents for tavaborole that expire in 2026 and 2027, including pediatric exclusivity. In October 2018, Anacor, our wholly-owned subsidiary</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">,</span><span style="font-family:inherit;font-size:10pt;"> filed infringement lawsuits against each of the generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia.</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Ibrance (palbociclib)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2019, several generic companies notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Ibrance. The generic companies assert the invalidity and non-infringement of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383765e881-wk-Fact-517DC4A0A8649EF8390394757DA7F672" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" contextRef="D2019Q1Mar01-Mar31_srt_LitigationCaseAxis_pfe_PfizerVersusGenericCompaniesMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> composition of matter patents and a method of use patent covering palbociclib, each of which expire in 2023. In April 2019, we brought patent infringement actions against each of the generic filers in various federal courts, asserting the validity and infringement of the patents challenged by the generic companies.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Chantix (varenicline)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020, we brought a patent infringement action against Viwit Pharmaceutical Co. Ltd. (Viwit) in the U.S. District Court for the District of Delaware asserting the validity and infringement of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383765e891-wk-Fact-80F2A51C6FD70B3273D494757DA0166E" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" contextRef="D2020Q1Jan1-31_srt_LitigationCaseAxis_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> patents challenged by Viwit in its abbreviated new drug application seeking approval to market a generic version of varenicline, 0.5 mg and 1.0 mg tablets.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Lyrica (pregabalin)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2014, Generics (U.K.) Ltd (trading as Mylan) filed an invalidity action against the Lyrica pain use patent in the High Court of Justice in London. Subsequently, Actavis Group PTC ehf filed an invalidity action in the same court, and Pfizer sued for infringement against Actavis Group PTC ehf, Actavis U.K. Ltd and Caduceus Pharma Ltd (together, Actavis), in addition to requesting preliminary relief. Our request for preliminary relief was denied in a January 2015 hearing, and the denial subsequently was confirmed on appeal.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2015, the National Health Service (NHS) England was ordered by the High Court, as an intermediary, to issue guidance for prescribers and pharmacists directing the prescription and dispensing of Lyrica by brand when pregabalin was prescribed for the treatment of neuropathic pain. NHS Wales and NHS Northern Ireland also issued prescribing guidance. The guidance to prescribe and dispense Lyrica for neuropathic pain was withdrawn upon patent expiration in July 2017. </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also filed infringement actions against (i) Teva UK Ltd, and (ii) Dr. Reddy&#8217;s Laboratories (UK) Ltd and Caduceus Pharma Ltd (together, Dr. Reddy&#8217;s) in February 2015, seeking the same relief as in the action against Actavis. Dr. Reddy&#8217;s filed an invalidity counterclaim. These actions were stayed pending the outcome of the Mylan and Actavis cases.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Mylan and Actavis invalidity actions were heard in the High Court at the same time as the Actavis infringement action. The High Court ruled against us, holding that the asserted claims were either not infringed or invalid, and appeals followed. In November 2018, the U.K. Supreme Court ruled that all the relevant claims directed to neuropathic pain were invalid.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2015, after Sandoz GmbH and Sandoz Ltd (together, Sandoz) launched a full label generic pregabalin product, we obtained from the High Court a preliminary injunction enjoining Sandoz from further sales of the product and ordering Sandoz to identify the parties holding its product. Sandoz identified wholesaler AAH Pharmaceuticals Ltd and pharmacy chain Lloyds Pharmacy Ltd (supplied by AAH), and we requested that these parties cease further sales and withdraw the Sandoz full label product. In October 2015, Lloyds was added to the Sandoz action, and we obtained a preliminary order from the High Court requiring Lloyds to advise its pharmacists that the Sandoz full label product should not be dispensed. In November 2015, the High Court confirmed the preliminary injunction against Sandoz and Lloyds. Sandoz filed an invalidity counterclaim. Upon </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-54520FF336DB7E29D5B594757DC1F14C-4" continuedAt="TextSelection-54520FF336DB7E29D5B594757DC1F14C-5"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">agreement of the parties, in December 2015, the proceedings against Lloyds were discontinued, and the proceedings against Sandoz were stayed pending outcome of the Mylan and Actavis cases. The preliminary injunction against Sandoz remained in place until patent expiration in July 2017.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2020, Dr. Reddy&#8217;s filed a claim for damages in connection with the above-referenced legal actions. In July 2020, the Scottish Ministers and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383765e931-wk-Fact-417259D790620A289744A1BB5E08E13A" name="us-gaap:LossContingencyNumberOfPlaintiffs" contextRef="D2020Q3Jul1-31_srt_LitigationCaseAxis_pfe_NHSScotlandvs.DrReddysMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_PatentInfringementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="plaintiff" decimals="INF" scale="0" format="ixt-sec:numwordsen">fourteen</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> Scottish Health Boards (together, NHS Scotland) filed a claim for damages in connection with the above-referenced legal action concerning Sandoz.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Matter Involving Our Collaboration/Licensing Partners</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Eliquis</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February, March, and April 2017, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383765e944-wk-Fact-717593CB12402352612B94757CEBB13E" name="pfe:GainContingencyNumberofDefendants" contextRef="D2017Q2Feb01-Apr30_srt_LitigationCaseAxis_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember" unitRef="Defendant" decimals="INF" scale="0" format="ixt-sec:numwordsen">twenty-five</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed abbreviated new drug applications seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383765e948-wk-Fact-3AFB1E118B1118EB033F94757DA25F8B" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" contextRef="D2017Q2Feb01-Apr30_srt_LitigationCaseAxis_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> patents listed in the Orange Book for Eliquis. </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383765e952-wk-Fact-565D1C6B35A0D674DBB494757CB69824" name="pfe:GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" contextRef="D2017Q2Feb01-Apr30_srt_LitigationCaseAxis_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">One</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> of the patents expired in December 2019 and the remaining patents currently are set to expire in 2026 and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. In April 2017, BMS and Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia, asserting that each of the generic companies&#8217; proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the 2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383765e956-wk-Fact-3AFB1E118B1118EB033F94757DA25F8B" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" contextRef="D2017Q2Feb01-Apr30_srt_LitigationCaseAxis_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> patents. In August 2020, the U.S. District Court for the District of Delaware ruled that both the 2026 patent and the 2031 patent are valid and infringed by the proposed generic products. The decision is subject to appeal. Prior to the August 2020 ruling, we and BMS settled with certain of the generic companies on terms not material to Pfizer, and we and BMS may settle with other generic companies in the future.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A2. Legal Proceedings&#8211;&#8211;Product Litigation</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Like other pharmaceutical companies, we are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Asbestos</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. Claims against American Optical and numerous other defendants are pending in various federal and state courts seeking damages for alleged personal injury from exposure to asbestos and other allegedly hazardous materials. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerous lawsuits are pending against Pfizer in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There also&#160;are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Effexor</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning in May 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants&#8217; allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">34</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-54520FF336DB7E29D5B594757DC1F14C-5" continuedAt="TextSelection-54520FF336DB7E29D5B594757DC1F14C-6"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2014, the District Court dismissed the direct purchaser plaintiffs&#8217; claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff claims. In January 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court&#8217;s decisions and remanded the claims to the District Court.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Lipitor</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Antitrust Actions</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning in November 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain affiliates of Pfizer, and, in most of the actions, Ranbaxy, Inc. (Ranbaxy) and certain affiliates of Ranbaxy. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants&#8217; allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor, and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re Lipitor Antitrust Litigation MDL-2332</span><span style="font-family:inherit;font-size:10pt;">) in the U.S. District</span><span style="font-family:inherit;font-size:10pt;color:#0000ff;"> </span><span style="font-family:inherit;font-size:10pt;">Court for the District of New Jersey. </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2013 and 2014, the District Court dismissed with prejudice the claims by direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs have appealed the District Court&#8217;s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court&#8217;s decisions and remanded the claims to the District Court.</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Also, in January 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Personal Injury Actions</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed type 2 diabetes purportedly as a result of the ingestion of Lipitor. Plaintiffs seek compensatory and punitive damages. </span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2014, the federal actions were transferred for consolidated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Products Liability Litigation (No. II) MDL-2502</span><span style="font-family:inherit;font-size:10pt;">) in the U.S. District Court for the District of South Carolina. Since 2016, certain cases in the Multi-District Litigation were remanded to certain state courts. In January 2017, the District Court granted our motion for summary judgment, dismissing substantially all of the remaining cases pending in the Multi-District Litigation. In January 2017, the plaintiffs appealed the District Court&#8217;s decision to the U.S. Court of Appeals for the Fourth Circuit. In June 2018, the U.S. Court of Appeals for the Fourth Circuit affirmed the District Court&#8217;s decision.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Viagra</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since April 2016, a Multi-District Litigation has been pending in the U.S. District Court for the Northern District of California (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In Re: Viagra (Sildenafil Citrate) Products Liability Litigation, MDL-2691</span><span style="font-family:inherit;font-size:10pt;">), in which plaintiffs allege that they developed melanoma and/or the exacerbation of melanoma purportedly as a result of the ingestion of Viagra. Additional cases filed against Lilly with respect to Cialis have also been consolidated in the Multi-District Litigation </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">(In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation, MDL-2691</span><span style="font-family:inherit;font-size:10pt;">). In January 2020, the District Court granted our and Lilly&#8217;s motion to exclude all of plaintiffs&#8217; general causation opinions. As a result, in April 2020, the District Court entered summary judgment in favor of defendants and dismissed all of plaintiffs&#8217; claims. In April 2020, plaintiffs filed a notice of appeal in the U.S. Court of Appeals for the Ninth Circuit. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">35</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-54520FF336DB7E29D5B594757DC1F14C-6" continuedAt="TextSelection-54520FF336DB7E29D5B594757DC1F14C-7"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">EpiPen</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning in February 2017, purported class actions were filed in various federal courts by indirect purchasers of EpiPen against Pfizer, and/or its affiliates King and Meridian, and/or various entities affiliated with Mylan, and Mylan Chief Executive Officer, Heather Bresch. The plaintiffs in these actions seek to represent U.S. nationwide classes comprising persons or entities who paid for any portion of the end-user purchase price of an EpiPen between 2009 until the cessation of the defendants&#8217; allegedly unlawful conduct. In February 2020, a similar lawsuit was filed in the U.S. District Court for the District of Kansas against Pfizer, King, Meridian and the Mylan entities on behalf of a purported U.S. nationwide class of direct purchaser plaintiffs who purchased EpiPen devices directly from the defendants (the 2020 Lawsuit). Against Pfizer and/or its affiliates, plaintiffs in these actions generally allege that Pfizer&#8217;s and/or its affiliates&#8217; settlement of patent litigation regarding EpiPen delayed market entry of generic EpiPen in violation of federal antitrust laws and various state antitrust laws. At least </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383765e1067-wk-Fact-CE168D9156E09ED8FE0C94757DA7922B" name="pfe:LossContingencyNumberOfLawsuits" contextRef="FI2020Q2_srt_ProductOrServiceAxis_pfe_EpiPenMember_srt_RangeAxis_srt_MinimumMember" unitRef="lawsuit" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> lawsuit also alleges that Pfizer and/or Mylan violated the federal Racketeer Influenced and Corrupt Organizations Act (RICO). Plaintiffs also filed various federal antitrust, state consumer protection and unjust enrichment claims against, and relating to conduct attributable solely to, Mylan and/or its affiliates regarding EpiPen. Plaintiffs seek treble damages for alleged overcharges for EpiPen since 2011. In August 2017, all of these actions, except for the 2020 Lawsuit, were consolidated for coordinated pre-trial proceedings in a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re: EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation, MDL-2785</span><span style="font-family:inherit;font-size:10pt;">) in the U.S. District Court for the District of Kansas with other EpiPen-related actions against Mylan and/or its affiliates to which Pfizer, King and Meridian are not parties.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2020, a new lawsuit was filed in the District of Colorado on behalf of indirect purchasers. Plaintiff represents a putative U.S. nationwide class of persons or entities who paid for any portion of the end-user purchase price of certain refill or replacement EpiPens since 2010. Plaintiff alleges that Pfizer and Meridian misrepresented the shelf-life and expiration date of EpiPen, in violation of the federal RICO statute. Plaintiff seeks treble damages for alleged unnecessary replacement or refill purchases of EpiPens by members of the putative class.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nexium 24HR and Protonix</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A number of individual and multi-plaintiff lawsuits have been filed against Pfizer, certain of its subsidiaries and/or other pharmaceutical manufacturers in various federal and state courts alleging that the plaintiffs developed kidney-related injuries purportedly as a result of the ingestion of certain proton pump inhibitors. The cases against Pfizer involve Protonix and/or Nexium 24HR and seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement. In August 2017, the federal actions were ordered transferred for coordinated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re: Proton-Pump Inhibitor Products Liability Litigation</span><span style="font-family:inherit;font-size:10pt;"> (No. II)) in the U.S. District Court for the District of New Jersey. On July&#160;31, 2019, we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name. As part of the joint venture transaction, the joint venture has agreed to assume, and to indemnify Pfizer for, liabilities arising out of such litigation to the extent related to Nexium 24HR.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Docetaxel</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Personal Injury Actions</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed permanent hair loss. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek compensatory and punitive damages.</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2016, the federal cases were transferred for coordinated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re Taxotere (Docetaxel) Products Liability Litigation, MDL-2740</span><span style="font-family:inherit;font-size:10pt;">) in the U.S. District Court for the Eastern District of Louisiana.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Mississippi Attorney General Government Action</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2018, the Attorney General of Mississippi filed a complaint in Mississippi state court against the manufacturer of the branded product and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383765e1121-wk-Fact-E30ECA96C0BC87F811C194757DA214BE" name="pfe:LossContingencyNumberOfDefendantsOtherThanMainDefendant" contextRef="D2018Q4Oct01-Oct31_srt_LitigationCaseAxis_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_srt_ProductOrServiceAxis_pfe_DocetaxelMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember" unitRef="manufacturer" decimals="INF" scale="0" format="ixt-sec:numwordsen">eight</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> other manufacturers including Pfizer and Hospira, alleging, with respect to Pfizer and Hospira, a failure to warn about a risk of permanent hair loss in violation of the Mississippi Consumer Protection Act. The action seeks civil penalties and injunctive relief.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Array Securities Litigation</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2017, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383765e1131-wk-Fact-3A3F4CD6AC452C84201794757CD805EA" name="pfe:LossContingencyClassActionsFiledNumber" contextRef="D2017Q4Nov2017" unitRef="class_action" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> purported class actions were filed in the U.S. District Court for the District of Colorado alleging that Array, which we acquired in July 2019 and is our wholly owned subsidiary, and certain of its former officers violated federal securities laws in connection with certain disclosures made, or omitted, by Array regarding the NRAS-mutant melanoma program. In March 2018, the actions were consolidated into a single proceeding. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-54520FF336DB7E29D5B594757DC1F14C-7" continuedAt="TextSelection-54520FF336DB7E29D5B594757DC1F14C-8"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Zantac </span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A number of lawsuits have been filed against Pfizer in various federal and state courts alleging that plaintiffs developed various types of cancer, or face an increased risk of developing cancer, purportedly as a result of the ingestion of Zantac. The significant majority of these cases also name other defendants that have historically manufactured and/or sold Zantac. Pfizer has not sold Zantac since 2006, and only sold an over-the-counter version of the product. Plaintiffs seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement.</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2020, the federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re Zantac/Ranitidine NDMA Litigation, MDL-2924</span><span style="font-family:inherit;font-size:10pt;">) in the U.S. District Court for the Southern District of Florida. In June 2020: (i) plaintiffs in the Multi-District Litigation filed against Pfizer and many other defendants a consolidated consumer class action complaint alleging, among other things, violations of the RICO statute and consumer protection statutes of all 50 states, and a consolidated third-party payor class action complaint alleging violation of the RICO statute and seeking reimbursement for payments made for the prescription version of Zantac; (ii) Pfizer received service of a Canadian class action complaint naming Pfizer and other defendants, and seeking compensatory and punitive damages for personal injury and economic loss, allegedly arising from the defendants&#8217; sale of Zantac in Canada; and (iii) the State of New Mexico filed a civil action against Pfizer and many other defendants, alleging various state statutory and common law claims in connection with the defendants&#8217; alleged sale of Zantac in New Mexico.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A3. Legal Proceedings&#8211;&#8211;Commercial and Other Matters</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Monsanto-Related Matters</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia &amp; Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operations to a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia&#8217;s former agricultural business. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business, and has been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto&#8217;s chemical businesses. As the result of its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia&#8217;s indemnification obligations relating to Former Monsanto&#8217;s chemical businesses are primarily limited to sites that Solutia has owned or operated. In addition, in connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities primarily related to Former Monsanto&#8217;s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia&#8217;s and New Monsanto&#8217;s assumption of, and agreement to indemnify Pharmacia for, these liabilities apply to pending actions and any future actions related to Former Monsanto&#8217;s chemical businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia and/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto&#8217;s chemical businesses, and have been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Environmental Matters</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2009, we submitted to the U.S. Environmental Protection Agency (EPA) a corrective measures study report with regard to Pharmacia&#8217;s discontinued industrial chemical facility in North Haven, Connecticut. In September 2010, our corrective measures study report was approved by the EPA, and we commenced construction of the site remedy in late 2011 under an Updated Administrative Order on Consent with the EPA. In September 2019, the EPA acknowledged that construction of the site remedy has been completed.</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Also, in 2009, we submitted a revised site-wide feasibility study with regard to Wyeth Holdings Corporation&#8217;s (formerly, American Cyanamid Company) discontinued industrial chemical facility in Bound Brook, New Jersey. In July 2011, Wyeth Holdings Corporation finalized an Administrative Settlement Agreement and Order on Consent for Removal Action (the 2011 Administrative Settlement Agreement) with the EPA with regard to the Bound Brook facility. In May 2012, we completed construction of an interim remedy to address the discharge of impacted groundwater from that facility to the Raritan River. In September 2012, the EPA issued a final remediation plan for the Bound Brook facility&#8217;s main plant area, which is generally in accordance with one of the remedies evaluated in our revised site-wide feasibility study. In March 2013, Wyeth Holdings Corporation (now Wyeth Holdings LLC) entered into an Administrative Settlement Agreement and Order on Consent with the </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">37</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-54520FF336DB7E29D5B594757DC1F14C-8" continuedAt="TextSelection-54520FF336DB7E29D5B594757DC1F14C-9"><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EPA to allow us to undertake detailed engineering design of the remedy for the main plant area and to perform a focused feasibility study for </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383765e1176-wk-Fact-1C233DE5CB2F27196C1694757DA33716" name="pfe:FeasibilityStudyNumberOfLagoons" contextRef="D2013Q1MonthOfMarch_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_EnvironmentalRemediationLitigationMember" unitRef="lagoon" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> adjacent lagoons. In September 2015, the U.S., on behalf of the EPA, filed a complaint and consent decree with the federal District Court for the District of New Jersey that allows Wyeth Holdings LLC to complete the design and to implement the remedy for the main plant area. In December 2015, the consent decree (which supersedes the 2011 Administrative Settlement Agreement) was entered by the District Court. In September 2018, the EPA issued a final remediation plan for the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383765e1180-wk-Fact-BF50E52F0CC2EDC892A694757DA027BB" name="pfe:FeasibilityStudyNumberOfLagoons" contextRef="D2018Q3Sep01-Sep30_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_EnvironmentalRemediationLitigationMember" unitRef="lagoon" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> adjacent lagoons, which is generally in accordance with one of the remedies evaluated in our focused feasibility study, and in September 2019, Wyeth Holdings LLC entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the lagoons. </span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have accrued for the estimated costs of the site remedies for the North Haven and Bound Brook facilities.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contracts with Iraqi Ministry of Health</span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2017, a number of United States service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia against a number of pharmaceutical and medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health, and seeks monetary relief. In July 2020, the District Court granted defendants&#8217; motions to dismiss and dismissed all of plaintiffs&#8217; claims. In July 2018, the U.S. Department of Justice requested documents related to this matter, which have been provided.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Allergan Complaint for Indemnity</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, Pfizer was named as a defendant in a third-party complaint for indemnity, along with King, filed by Allergan Finance LLC (Allergan) in a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re National Prescription Opiate Litigation MDL 2804</span><span style="font-family:inherit;font-size:10pt;">) in the U.S. District Court for the Northern District of Ohio. The lawsuit asserted claims for indemnity related to Kadian, which was owned for a short period by King in 2008, prior to Pfizer's acquisition of King in 2010. In December 2018, the District Court dismissed the lawsuit. In February 2019, Allergan filed a similar complaint in the Supreme Court of the State of New York, asserting claims for indemnity related to Kadian.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Breach of Contract&#8211;&#8211;Xalkori</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pfizer is a defendant in a breach of contract action brought by New York University (NYU) in the Supreme Court of the State of New York (Supreme Court). NYU alleges that it is entitled to royalties on Pfizer&#8217;s sales of</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">Xalkori under the terms of a Research and License Agreement between NYU and Sugen, Inc. Sugen, Inc. was acquired by Pharmacia in August 1999, and </span><span style="font-family:inherit;font-size:10pt;color:#212529;">Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.</span><span style="font-family:inherit;font-size:10pt;"> The action was originally filed in 2013. In December 2015, the Supreme Court dismissed the action and, in May 2017, the New York State Appellate Division reversed the decision and remanded the proceedings to the Supreme Court. In January 2020, the Supreme Court denied both parties&#8217; summary judgment motions.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A4. Legal Proceedings&#8211;&#8211;Government Investigations</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Like other pharmaceutical companies, we are subject to extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. Criminal charges, substantial fines and/or civil penalties, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as reputational harm and increased public interest in the matter could result from government investigations in the U.S. and other jurisdictions in which we do business. In addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government.</span><span style="font-family:inherit;font-size:10pt;"> Among the investigations by government agencies are the matters discussed below.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Greenstone Investigations</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">U.S. Department of Justice Antitrust Division Investigation</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since July 2017, the U.S. Department of Justice's Antitrust Division has been investigating our Greenstone generics business. We believe this is related to an ongoing broader antitrust investigation of the generic pharmaceutical industry. The government has been obtaining information from Greenstone.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">State Attorneys General Generics Antitrust Litigation</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2018, Greenstone received requests for information from the Antitrust Department of the Connecticut Office of the Attorney General. In May 2019, Attorneys General of more than 40 states plus the District of Columbia and Puerto Rico filed a </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">38</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-54520FF336DB7E29D5B594757DC1F14C-9" continuedAt="TextSelection-54520FF336DB7E29D5B594757DC1F14C-10"><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">complaint against a number of pharmaceutical companies, including Greenstone and Pfizer. The matter has been consolidated with a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re: Generic Pharmaceuticals Pricing Antitrust Litigation MDL No. 2724)</span><span style="font-family:inherit;font-size:10pt;"> in the Eastern District of Pennsylvania. As to Greenstone and Pfizer, the complaint alleges anticompetitive conduct in violation of federal and state antitrust laws and state consumer protection laws. In June 2020, the State Attorneys General filed a new complaint against a large number of companies, including Greenstone and Pfizer, making similar allegations, but concerning a new set of drugs. This complaint was transferred to the Multi-District Litigation in July 2020.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Subpoena relating to Manufacturing of Quillivant XR</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2018, we received a subpoena from the U.S. Attorney&#8217;s Office for the Southern District of New York (SDNY) seeking records relating to our relationship with another drug manufacturer and its production and manufacturing of drugs including, but not limited to, Quillivant XR. We have produced records pursuant to the subpoena.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Government Inquiries relating to Meridian Medical Technologies </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2019, we received a civil investigative demand from the U.S. Attorney&#8217;s Office for the SDNY. The civil investigative demand seeks records and information related to alleged quality issues involving the manufacture of auto-injectors at our Meridian site. In August 2019, we received a HIPAA subpoena from the U.S. Attorney&#8217;s Office for the Eastern District of Missouri seeking similar records and information. We are producing records in response to these requests. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">U.S. Department of Justice/SEC Inquiry relating to Russian Operations</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2019, we received an informal request from the U.S. Department of Justice&#8217;s FCPA Unit seeking documents relating to our operations in Russia. In September 2019, we received a similar request from the SEC&#8217;s FCPA unit. We are producing records pursuant to these requests. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contracts with Iraqi Ministry of Health</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 13A3. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Contingencies and Certain Commitments</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Legal Proceedings&#8211;&#8211;Commercial and Other Matters&#8211;&#8211;Contracts with Iraqi Ministry of Health</span><span style="font-family:inherit;font-size:10pt;"> above for information regarding U.S. government investigations related to contracts with the Iraqi Ministry of Health.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Docetaxel</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Mississippi Attorney General Government Action</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 13A2. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Contingencies and Certain Commitments</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Legal Proceedings</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Product Litigation</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Docetaxel</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Mississippi Attorney General Government Action</span><span style="font-family:inherit;font-size:10pt;"> above for information regarding a government action related to Docetaxel marketing practices.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">U.S. Department of Justice Inquiries relating to India Operations</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2020, we received an informal request from the U.S. Department of Justice's Consumer Protection Branch seeking documents relating to our manufacturing operations in India, including at our former facility located at Irrungattukottai in India. In April 2020, we received a similar request from the U.S. Attorney&#8217;s Office for the SDNY regarding a civil investigation concerning operations at our facilities in India. We are producing records pursuant to these requests.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">U.S. Department of Justice Inquiry relating to China Operations</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2020, we received an informal request from the U.S. Department of Justice's FCPA Unit seeking documents relating to our operations in China. We will be producing records pursuant to this request.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Zantac</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">State of New Mexico Civil Action</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 13A2. Contingencies and Certain Commitments: Legal Proceedings&#8211;&#8211;Product Litigation&#8211;&#8211;Zantac</span><span style="font-family:inherit;font-size:10pt;"> above for information regarding a civil action filed by the State of New Mexico alleging various state statutory and common law claims in connection with the defendants&#8217; alleged sale of Zantac in New Mexico.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A5. Legal Proceedings&#8211;&#8211;Matters Resolved During the First Six Months of 2020</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the first six months of 2020, certain matters, including the matter discussed below, were resolved or were the subject of definitive settlement agreements or settlement agreements-in-principle.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Hormone Therapy Consumer Class Action</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A certified consumer class action was pending against Wyeth in the U.S. District Court for the Southern District of California based on the alleged off-label marketing of its hormone therapy products. The case was originally filed in December 2003. The class consisted of California consumers who purchased Wyeth&#8217;s hormone-replacement products between January 1995 and January 2003 and who did not seek personal injury damages therefrom. The class sought compensatory and punitive damages, including a full refund of the purchase price. In March 2020, the parties reached an agreement, and obtained preliminary court approval, to resolve this matter for </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8383765e1362-wk-Fact-2CB88DD71658CFBC7A8294757D9AB161" name="us-gaap:PaymentsForLegalSettlements" contextRef="FD2020Q2QTD_srt_LitigationCaseAxis_pfe_ClassActionVersusWyethMember_srt_ProductOrServiceAxis_pfe_HormoneTherapyProductsMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">200</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which was paid in full in the second quarter of 2020.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-54520FF336DB7E29D5B594757DC1F14C-10"><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. Guarantees and Indemnifications</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss. These indemnifications are generally subject to various restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;">, the estimated fair value of these indemnification obligations was not significant. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, in connection with our entry into certain agreements, our counterparties may agree to indemnify us. For example, our collaboration agreement with EMD Serono, Inc. to co-promote Rebif in the U.S. expired at the end of 2015 and included certain indemnity provisions. Patent litigation brought by Biogen Idec MA Inc. against EMD Serono Inc. and Pfizer is pending in the U.S. District Court for the District of New Jersey and the United States Court of Appeals for the Federal Circuit. EMD Serono Inc. has acknowledged that it is obligated to satisfy any award of damages.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pfizer Inc. has also guaranteed the long-term debt of certain companies that it acquired and that now are subsidiaries of Pfizer. See </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 7D</span><span style="font-family:inherit;font-size:10pt;"> for additional information.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">C. Contingent Consideration for Acquisitions</span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may be required to make contingent consideration payments to sellers for certain prior business combinations. For additional information, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1D. Basis of Presentation and Significant Accounting Policies: Acquisition</span><span style="font-family:inherit;font-size:10pt;">s in our 2019 Financial Report. The estimated fair value of contingent consideration as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;"> is </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8383765e1400-wk-Fact-92DEA2F2246A94F90A3A94757D98A723" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">727</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8383765e1404-wk-Fact-608994AE6B240429000194757D450F9C" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">157</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> is recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8383765e1413-wk-Fact-D95F57A84F39F1F4220994757DA6074A" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">570</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> is recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other noncurrent liabilities </span><span style="font-family:inherit;font-size:10pt;">in our condensed consolidated balance sheet. The estimated fair value of contingent consideration as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8383765e1425-wk-Fact-32A10D3C33BFD555F97494757CEE5C77" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">711</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8383765e1429-wk-Fact-B1DFC7B7CC3736C71BA994757CF15ABB" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">160</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> was recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8383765e1438-wk-Fact-4C6C0A417E2429DF131394757DA20891" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">551</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> was recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other noncurrent liabilities </span><span style="font-family:inherit;font-size:10pt;">in our condensed consolidated balance sheet. The increase in the contingent consideration balance from December 31, 2019 is primarily due to fair value adjustments, partially offset by payments made upon the achievement of certain milestones.</span></div></ix:continuation><div><a id="s64D1D00ACBA85A29BF301CC325126894"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Note 14. </span><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:SegmentReportingDisclosureTextBlock" id="TextSelection-31CB92B2FCB9ECA4894394757DC257B4-0-wk-Fact-A6ED1071B2B6B7FCE64494757D46BD01" continuedAt="TextSelection-31CB92B2FCB9ECA4894394757DC257B4-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Segment, Geographic and Other Revenue Information</span></ix:nonNumeric></div><ix:continuation id="TextSelection-31CB92B2FCB9ECA4894394757DC257B4-1" continuedAt="TextSelection-31CB92B2FCB9ECA4894394757DC257B4-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. </span><span style="font-weight:bold;text-decoration:underline;">Segment Information</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the beginning of our fiscal year 2019, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8415180e721-wk-Fact-E7763423A0FDBAB3799A94757CC3EC7A" name="us-gaap:NumberOfOperatingSegments" contextRef="D2019Q3Jan1-Jul31" unitRef="Operating_Segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> distinct business segments: Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and through </span><span style="font-family:inherit;font-size:10pt;">July&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, Pfizer&#8217;s Consumer Healthcare business (Consumer Healthcare), each led by a single manager. Each operating segment has responsibility for its commercial activities. Upjohn is, and through </span><span style="font-family:inherit;font-size:10pt;">July&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> Consumer Healthcare was, responsible for its own R&amp;D activities while Biopharma receives its R&amp;D services from GPD and WRDM. These services include IPR&amp;D projects for new investigational products and additional indications for in-line products. Each business has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation. Biopharma and Upjohn are the only reportable segments.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan).</span><span style="font-family:inherit;font-size:10pt;"> As a result, revenues and expenses associated with Meridian and Mylan-Japan are reported in our Upjohn business beginning in the first quarter of 2020. In 2019, revenues and expenses from Meridian and Mylan-Japan were recorded in our Biopharma business. We have revised prior-period information (Revenues and Earnings, as defined by management) to conform to the current management structure.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisitions and other business development activities completed in 2019 and in the first half of 2020, including the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture, impacted financial results in the periods presented.</span><span style="font-family:inherit;font-size:10pt;"> </span><span>For additional information, see Notes to Consolidated Financial Statements&#8212;</span><span style="font-style:italic;">Note 1A. Basis of Presentation and Significant Accounting Policies: Basis of Presentation</span><span> in our 2019 Financial Report, and </span><span style="font-style:italic;">Note 2</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">40</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-31CB92B2FCB9ECA4894394757DC257B4-2" continuedAt="TextSelection-31CB92B2FCB9ECA4894394757DC257B4-3"><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Operating Segments</span></div><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:16pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:10%;"></td><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:49%;"></td></tr><tr><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Some additional information about our Biopharma and Upjohn business segments follows:</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="pfizerlogo2816.jpg" alt="pfizerlogo2816.jpg" style="height:33px;width:57px;"></img></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:16pt;"><span style="font-family:inherit;font-size:16pt;font-weight:bold;">Pfizer</span></div><div style="padding-left:72px;text-indent:-72px;font-size:16pt;"><span style="font-family:inherit;font-size:16pt;font-weight:bold;">Biopharmaceuticals</span></div><div style="padding-left:72px;text-indent:-72px;font-size:16pt;"><span style="font-family:inherit;font-size:16pt;font-weight:bold;">Group</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="upjohnlogo.jpg" alt="upjohnlogo.jpg" style="height:77px;width:201px;"></img></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px dotted #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Biopharma is a science-based innovative medicines business that includes six business units &#8211; Oncology, Inflammation &amp; Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. The Hospital unit commercializes our global portfolio of sterile injectable and anti-infective medicines and includes Pfizer&#8217;s contract manufacturing operation, Pfizer CentreOne. Each business unit is committed to delivering breakthroughs that change patients&#8217; lives.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px dotted #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Upjohn is a global, primarily off-patent branded and generic medicines business, which includes a portfolio of 20 globally recognized solid oral dose brands, as well as a U.S.-based generics platform, Greenstone.</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Select products include:<br/></span><span style="font-family:inherit;font-size:9pt;font-style:italic;">- Ibrance</span></div><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">- </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Eliquis</span></div><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">- </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Prevnar 13/Prevenar 13</span></div><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">- </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Xeljanz<br/></span><span style="font-family:inherit;font-size:9pt;">- </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Enbrel </span><span style="font-family:inherit;font-size:9pt;">(outside the U.S. and Canada)<br/></span><span style="font-family:inherit;font-size:9pt;font-style:italic;">- Vyndaqel/Vyndamax</span></div><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">- </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Chantix/Champix</span></div><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">- Xtandi</span></div><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">- </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Sutent</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Select products include:<br/></span><span style="font-family:inherit;font-size:9pt;font-style:italic;">- Lipitor</span></div><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">- </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Lyrica<br/>- Norvasc</span></div><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">- Celebrex</span></div><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">- Viagra</span></div><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">- </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Certain generic medicines</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Other Costs and Business Activities</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain pre-tax costs are not allocated to our operating segment results, such as costs associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">WRDM&#8211;&#8211;the R&amp;D and Medical expenses managed by our WRDM organization, which is generally responsible for research projects for our Biopharma portfolio until proof-of-concept is achieved and then for transitioning those projects to the GPD organization for possible clinical and commercial development. R&amp;D spending may include upfront and milestone payments for intellectual property rights. The WRDM organization also has responsibility for certain science-based and other platform-services organizations, which provide end-to-end technical expertise and other services to the various R&amp;D projects, as well as the Worldwide Medical and Safety group, which ensures that Pfizer provides all stakeholders&#8211;&#8211;including patients, healthcare providers, pharmacists, payers and health authorities&#8211;&#8211;with complete and up-to-date information on the risks and benefits associated with Pfizer products so that they can make appropriate decisions on how and when to use Pfizer&#8217;s medicines.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">GPD&#8211;&#8211;the costs associated with our GPD organization, which is generally responsible for clinical trials from WRDM in the Biopharma portfolio, including late stage portfolio spend. GPD also provides technical support and other services to Pfizer R&amp;D projects. GPD is responsible for facilitating all regulatory submissions and interactions with regulatory agencies.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other&#8211;&#8211;the operating results of our Consumer Healthcare business, through July 31, 2019, and costs associated with other commercial activities not managed as part of Biopharma or Upjohn, including all strategy, business development, portfolio management and valuation capabilities, which previously had been reported in various parts of the organization.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate and Other Unallocated&#8211;&#8211;the costs associated with corporate enabling functions (such as digital, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance, and worldwide procurement), patient advocacy activities and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments, as well as overhead expenses associated with our manufacturing (which include manufacturing variances associated with production) and commercial operations that are not directly assessed to an operating segment, as business unit (segment) management does not manage these costs. </span><span style="font-size:10pt;">Corporate and Other Unallocated also includes our share of earnings from the GSK Consumer Healthcare joint venture and other charges related to the GSK Consumer Healthcare joint venture, primarily representing our pro-rata share of restructuring and business combination accounting charges recorded by the GSK Consumer Healthcare joint venture.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and PP&amp;E; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) certain significant items, representing substantive and/or unusual, and in some cases recurring, items (such as gains on the completion of joint venture transactions, restructuring charges, legal charges or gains and losses from equity securities) that </span></div></td></tr></table></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">41</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-31CB92B2FCB9ECA4894394757DC257B4-3" continuedAt="TextSelection-31CB92B2FCB9ECA4894394757DC257B4-4"><div style="line-height:120%;padding-left:12px;text-align:left;"><span style="font-family:inherit;font-size:10pt;">are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Segment Assets</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We manage our assets on a Total Company basis, not by operating segment, as many of our operating assets are shared or commingled (such as accounts receivable, as many of our customers are served by multiple operating segments). Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8415180e973-wk-Fact-8056831472C93DFFBF7B94757D474450" name="us-gaap:Assets" contextRef="FI2020Q2" unitRef="usd" decimals="-9" scale="9" format="ixt:numdotdecimal">178</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8415180e981-wk-Fact-7DC06283FD051672522094757D4872EE" name="us-gaap:Assets" contextRef="FI2019Q4" unitRef="usd" decimals="-9" scale="9" format="ixt:numdotdecimal">167</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Selected Income Statement Information</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="TextSelection-D872EE9AAC4BBFF119BA94757DC2771E-0-wk-Fact-9BC8623A09DFCF83535694757D4A5C9E" continuedAt="TextSelection-D872EE9AAC4BBFF119BA94757DC2771E-1" escape="true"><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" id="TextSelection-4B4807FB53EBB4E5981F94757DC3223D-0-wk-Fact-6821C7B4B9BCFF4BF38494757D45D00C" continuedAt="TextSelection-4B4807FB53EBB4E5981F94757DC3223D-1" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides selected income statement information by reportable segment:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Earnings</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reportable Segments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Biopharma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span><ix:nonFraction id="d8415180e1487-wk-Fact-E530D6E39D8505E5003694757CCFA73A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,795</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e1506-wk-Fact-18B80BD812B25AC11E4B94757D931F40" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,432</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e1526-wk-Fact-F24CEBFF8EB173EDA53294757CD99979" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,650</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e1545-wk-Fact-B36E26A497B12F4F06CB94757CFB7641" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,071</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span><ix:nonFraction id="d8415180e1565-wk-Fact-A21C28FF8A57FE35FCD194757CD6CDBA" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,006</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e1584-wk-Fact-D592491E3EF4A54AF04994757CD40AAC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,970</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e1603-wk-Fact-A8FD8B76C5AB70D75DBF94757CDE77D4" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,168</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e1623-wk-Fact-DD285CCCCC909E22C8F494757CF80EDC" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,973</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Total reportable segments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span><ix:nonFraction id="d8415180e1648-wk-Fact-E6C7B7DCAE845EA31C2194757CDF5928" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,801</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e1667-wk-Fact-64E767AB6C7D8A4A5A7494757CD12DBF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12,402</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e1686-wk-Fact-B46A5ED3FA0B101BE7A594757CD525E3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,818</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e1706-wk-Fact-6A34EC9ACE0CB4BA0A7B94757D93E196" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,044</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other business activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span><ix:nonFraction id="d8415180e1731-wk-Fact-243B7A41AFF6BF2DF5A994757CD78EDF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e1750-wk-Fact-81BF6740D6D17855E9B394757CF0E3F6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">862</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8415180e1769-wk-Fact-E484E0BFE436CFD6A91994757CF4398D" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,530</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8415180e1790-wk-Fact-57807C2334726A33D68294757CD97546" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,193</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reconciling Items:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Corporate and other unallocated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span><ix:nonFraction id="d8415180e1901-wk-Fact-46B4B5A3C9CD840FB17E94757CD3097A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e1920-wk-Fact-1FBA4709E25A6997DE7594757CD0F723" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8415180e1939-wk-Fact-13F1515D747E5BC2D79E94757CDD1906" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,136</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8415180e1960-wk-Fact-8971E1C78383330CB40E94757CD5511C" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,399</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Purchase accounting adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span><ix:nonFraction id="d8415180e1987-wk-Fact-F86D74D8E948CB139FC994757CF9C767" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e2006-wk-Fact-1BC8D13D40A2D1BF93BA94757D9688FD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8415180e2025-wk-Fact-011D17ED46D6C704909994757CE026FE" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2020Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">910</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8415180e2046-wk-Fact-D38C84ADA6DF1DEBDA9794757CDF6D15" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,178</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span><ix:nonFraction id="d8415180e2072-wk-Fact-806DF2F3D85134AC6CAC94757CCFBA02" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e2091-wk-Fact-971D0CC8CD08BAD2A4F394757D97DDC1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8415180e2110-wk-Fact-A1C25D709E6E2BCC622F94757CE0C08D" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2020Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">21</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e2131-wk-Fact-D01BD086F56ADFA6D29E94757CD09A97" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">176</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Certain significant items</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span><ix:nonFraction id="d8415180e2158-wk-Fact-290DFAF3630836A5405894757D92CBB7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e2177-wk-Fact-8F668F0BF6E37C3A8D6394757D92EEEB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8415180e2196-wk-Fact-AA84F6B275E57DCDD15C94757CF155B2" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2020Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">268</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8415180e2217-wk-Fact-33B4F9AF3A76075CF90094757CD1C085" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">309</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span><ix:nonFraction id="d8415180e2248-wk-Fact-4DB60D98BED9F2D7592094757D057DF4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,801</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e2267-wk-Fact-1769F431190664966C6E94757D75CC58" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,264</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e2287-wk-Fact-2A0EE9005DC8F1672AF194757D5C8E60" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,953</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e2306-wk-Fact-5210DA15DEEFCDAFC83494757D61140E" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,141</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Earnings</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reportable Segments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Biopharma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e2761-wk-Fact-ACEB1288AC96A67A007394757D7A8456" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">19,802</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e2780-wk-Fact-EF53E62F4536F95DB71494757CF24DD5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">18,477</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e2800-wk-Fact-7EC912EE8439671A25BF94757D7D989C" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,379</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e2819-wk-Fact-D2552EB7B44850CC209094757CF5FB9B" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,954</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e2839-wk-Fact-9907871A98EACE7FAB8F94757D7CC4C8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,027</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e2858-wk-Fact-1682782C7F68183CECD594757D5D9095" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,184</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e2877-wk-Fact-29D102D394E88CA6D8DC94757D641310" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,359</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e2897-wk-Fact-CFC646220F28061D991894757D5C03BB" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,251</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Total reportable segments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e2923-wk-Fact-ACE67986053B3153CF0794757D68C5BD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">23,829</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e2942-wk-Fact-836FD402E1CA513AB7A194757D284A21" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">24,661</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e2961-wk-Fact-8CCA7F0CCF44F7EE009F94757CB0EAEE" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15,738</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e2981-wk-Fact-59F11DF08C5C36F85F9694757CF96B93" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,206</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other business activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e3006-wk-Fact-3DECA58B1AC0CB1EADC2637BE6201433" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e3025-wk-Fact-678267F9DCD3A09FF48494757D724476" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,721</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8415180e3044-wk-Fact-51872B65420AB7367EDA94757D7EDA33" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3,019</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8415180e3065-wk-Fact-B187FB0A3E73BF7B3DE094757D8267D6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,306</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reconciling Items:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Corporate and other unallocated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e3178-wk-Fact-3B9E4BFE42603B35260C955D6E6EE07F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e3197-wk-Fact-5AD8B6162EC4B7A4D4FB955D6E5FA6F2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8415180e3216-wk-Fact-53C5AB131903D4621F5994757D60BCAC" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,245</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8415180e3237-wk-Fact-5FC136C8E0978EE4BFD794757D39F20F" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,676</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Purchase accounting adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e3263-wk-Fact-E4FFEDBB5DC5F854F56E94757D7EEB40" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e3282-wk-Fact-2EEA4C28DE78F55C998494757D8D18BB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8415180e3301-wk-Fact-DF27017CA613A930B87894757D82C5EA" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2020Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,722</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8415180e3322-wk-Fact-FF8C7011D05EB3AB087F94757D62A58B" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,217</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e3348-wk-Fact-7DA4198AE266BF0806EC94757D7C2F5A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e3367-wk-Fact-FA7984ECC1DFE7CFBAFA94757D910C75" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8415180e3386-wk-Fact-C42CFD3A1CA3D15C54F494757D5933EF" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2020Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e3407-wk-Fact-CE26F77FF346C4DE6B0594757D644E3B" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">148</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Certain significant items</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span><ix:nonFraction id="d8415180e3434-wk-Fact-F86B001A7C15B351060B94757CD7A389" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e3453-wk-Fact-10F3E77A26DA7DA0E29F94757D3034FC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8415180e3472-wk-Fact-B0FAADCDDE37BDAB2D9594757D5E794A" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2020Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">879</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d8415180e3493-wk-Fact-40DBE0BFFEA0FFC750D994757D7B3215" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">691</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e3524-wk-Fact-6D0243B400427DDF73DD94757D73B062" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">23,829</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e3543-wk-Fact-1987ADB564F749FC403294757D32C9CF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">26,382</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e3563-wk-Fact-239CF4E3D5F1905A2F0794757CB54D24" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,838</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d8415180e3582-wk-Fact-57301CD194F92FB7EE9A94757CC61DC1" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,463</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="font-family:inherit;font-size:8pt;">. Biopharma&#8217;s earnings </span><span style="font-family:inherit;font-size:8pt;text-align:center;">include d</span><span style="font-family:inherit;font-size:8pt;">ividend income of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8415180e3615-wk-Fact-71D18AE80705CBBAADD594757D794DFA" name="us-gaap:InvestmentIncomeDividend" contextRef="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViiVMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">76</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8415180e3628-wk-Fact-68BAAAE2FACDAD5DABE694757D76ACC5" name="us-gaap:InvestmentIncomeDividend" contextRef="FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViiVMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">76</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:8pt;">, and </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8415180e3640-wk-Fact-D5D32FD407DDC5273865955D6DF4E00F" name="us-gaap:InvestmentIncomeDividend" contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViiVMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">153</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> in </span><span style="font-family:inherit;font-size:8pt;">the first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8415180e3653-wk-Fact-625787D364A8EDA65710955D6DFF81D9" name="us-gaap:InvestmentIncomeDividend" contextRef="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViiVMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">140</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> in </span><span style="font-family:inherit;font-size:8pt;">the first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:8pt;"> from our investment in ViiV. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-9BC3436E7B9C00975CD394757DC16C56-0-wk-Footnote-9BC3436E7B9C00975CD394757DC16C56_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-9BC3436E7B9C00975CD394757DC16C56-1"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.</span></div></ix:footnote></td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-9BC3436E7B9C00975CD394757DC16C56-1"><ix:continuation id="TextSelection-D872EE9AAC4BBFF119BA94757DC2771E-1"><ix:continuation id="TextSelection-4B4807FB53EBB4E5981F94757DC3223D-1"></ix:continuation></ix:continuation></ix:continuation>Equity in the net income of investees accounted for by the equity method is not significant for any of our operating segments.</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The operating segment information does not purport to represent the revenues, costs and income from continuing operations before provision for taxes on income that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">42</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-31CB92B2FCB9ECA4894394757DC257B4-4" continuedAt="TextSelection-31CB92B2FCB9ECA4894394757DC257B4-5"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. Geographic Information</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="TextSelection-620403C2A4D86FC8D65B94757DC2C501-0-wk-Fact-A49954CEA3CD402E4E6194757D4B0E45" continuedAt="TextSelection-620403C2A4D86FC8D65B94757DC2C501-1" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides revenues by geographic area:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8415180e4198-wk-Fact-A2312FBD3DF36214454394757D4E99B6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,402</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8415180e4217-wk-Fact-D1AE1A5ED765BE15987994757D582336" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,335</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8415180e4231-wk-Fact-B9F4556D7FB1F41A2C9C94757D4ED4CD" name="pfe:PercentageChangeInRevenue" contextRef="FD2020Q2QTD_srt_StatementGeographicalAxis_country_US" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8415180e4251-wk-Fact-81D003F6CDA6BD349D8094757CDF84A9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,053</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8415180e4269-wk-Fact-1675732881C58BA8354494757CFAB9D4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12,510</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8415180e4282-wk-Fact-FDCAA086490708B3C91C94757D7F0A2D" name="pfe:PercentageChangeInRevenue" contextRef="FD2020Q2YTD_srt_StatementGeographicalAxis_country_US" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed Europe</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8415180e4306-wk-Fact-73FE98C3916C85F549F794757D5AEA40" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,088</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8415180e4325-wk-Fact-994F255F78B05FBADDEC94757D595A9A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,228</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8415180e4344-wk-Fact-2CF63F468B7D0CABA3CE94757D561921" name="pfe:PercentageChangeInRevenue" contextRef="FD2020Q2QTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8415180e4359-wk-Fact-6FB75C33A442EECAAC2194757CF9FAAF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,009</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8415180e4377-wk-Fact-22F02950F23AAC5E6D9094757CD8334C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,315</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8415180e4395-wk-Fact-14DF655044E2528ED8EB94757D99A922" name="pfe:PercentageChangeInRevenue" contextRef="FD2020Q2YTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed Rest of World</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8415180e4419-wk-Fact-ADE35C801D052BCE925B94757D577C42" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,552</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8415180e4438-wk-Fact-757B28C92C06735A064A94757D563E75" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,639</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8415180e4457-wk-Fact-BC8DE56F3BD25EC7962894757D5CD864" name="pfe:PercentageChangeInRevenue" contextRef="FD2020Q2QTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8415180e4472-wk-Fact-7948B0B6844BD3D387BA94757CDB9B0C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,008</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8415180e4490-wk-Fact-2730F9B3BF2B3A2553D594757D809149" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,174</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8415180e4508-wk-Fact-DE2B16204B073DAB2AEC94757CBCDCAA" name="pfe:PercentageChangeInRevenue" contextRef="FD2020Q2YTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging Markets</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8415180e4532-wk-Fact-30276A818E374D50F86494757D58EE99" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,759</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8415180e4551-wk-Fact-BB799260ED60F412F4DC94757D59055E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,062</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8415180e4570-wk-Fact-78CEBCE2B596295642A894757D5C66CC" name="pfe:PercentageChangeInRevenue" contextRef="FD2020Q2QTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8415180e4585-wk-Fact-BBF6210C8041EAAE938194757D0EFB62" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,759</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8415180e4603-wk-Fact-5312CAFDB12F1C38667794757CD7C311" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,383</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8415180e4621-wk-Fact-F4C1ADE521CCDFE17FBB94757D99CF2B" name="pfe:PercentageChangeInRevenue" contextRef="FD2020Q2YTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8415180e4648-wk-Fact-4DB60D98BED9F2D7592094757D057DF4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,801</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8415180e4667-wk-Fact-1769F431190664966C6E94757D75CC58" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,264</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8415180e4681-wk-Fact-0EA461F9F4B025BD6D7094757D4CA694" name="pfe:PercentageChangeInRevenue" contextRef="FD2020Q2QTD" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8415180e4701-wk-Fact-6D0243B400427DDF73DD94757D73B062" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">23,829</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8415180e4719-wk-Fact-1987ADB564F749FC403294757D32C9CF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">26,382</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8415180e4732-wk-Fact-82EB19D656D93F3B117F94757D984AB6" name="pfe:PercentageChangeInRevenue" contextRef="FD2020Q2YTD" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-859D29FA558EAC3F73C294757DC172D8-0-wk-Footnote-859D29FA558EAC3F73C294757DC172D8_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.</span><span style="font-family:inherit;font-size:8pt;"> Revenues denominated in euros were </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8415180e4765-wk-Fact-9908DE2B11A192768D8694757D3DA691" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.7</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8415180e4777-wk-Fact-9F332E38931F452BA65294757D49B5C4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.8</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:8pt;">, and were </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8415180e4800-wk-Fact-9E9085FF3B339F6A258F955D6F0DE764" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">3.2</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8pt;"> in </span><span style="font-family:inherit;font-size:8pt;">the first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d8415180e4812-wk-Fact-47E858153D87071D86D9955D6F108090" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">3.5</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8pt;"> in </span><span style="font-family:inherit;font-size:8pt;">the first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:8pt;text-align:center;">.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-C185F8237D4ED950685B94757DC105E4-0-wk-Footnote-C185F8237D4ED950685B94757DC105E4_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.</span></div></ix:footnote></td></tr></table></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-620403C2A4D86FC8D65B94757DC2C501-1" continuedAt="TextSelection-620403C2A4D86FC8D65B94757DC2C501-2"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-AFB627DC6F652A9A0A0594757DC251B0-0-wk-Footnote-AFB627DC6F652A9A0A0594757DC251B0_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-620403C2A4D86FC8D65B94757DC2C501-2"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.</span></div></ix:continuation></ix:footnote></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">C. </span><span style="font-weight:bold;text-decoration:underline;">Other Revenue Information</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Significant Product Revenues</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="TextSelection-4B6CE4DCEEAA26D6AD9D94757DC302F1-0-wk-Fact-9B9A6A1E9ED3CFE5FE4E94757D4A9303" continuedAt="TextSelection-4B6CE4DCEEAA26D6AD9D94757DC302F1-1" escape="true"><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides detailed revenue information for several of our major products:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">PRODUCT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">PRIMARY INDICATION OR CLASS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">TOTAL REVENUES</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e5171-wk-Fact-9D6F9F14A64FFA2B405D94757D4F07B3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,801</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e5190-wk-Fact-4AB009D1627E97C45D0294757D5E0C6F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,264</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e5210-wk-Fact-F9FD6AF468DA8EF60C5994757CE277D8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">23,829</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e5229-wk-Fact-43D2DA21439F004C93D694757D0B7C53" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">26,382</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e5264-wk-Fact-51315BFC3EFD807B35A494757D79D615" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,795</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e5283-wk-Fact-A054FF6C23099D448D2294757CD9B526" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,432</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e5303-wk-Fact-7A65F06A8B6D89F3196D94757D3ED197" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">19,802</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e5322-wk-Fact-2B1B9101B3EF21429F7894757D7FE12F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">18,477</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Internal Medicine</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e5359-wk-Fact-9B8010AEEE0CA7C861B494757D62CEEB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,279</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e5378-wk-Fact-68D35D8323640620312994757D5EC94F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,243</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e5398-wk-Fact-99DCC47DA679E57EDCE694757D4966B0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,610</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e5417-wk-Fact-4D4D0A148BCFEEA47A9894757D551B15" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,380</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Eliquis alliance revenues and direct sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e5447-wk-Fact-38BF97B5966F919766EC94757CA703FC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,272</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e5466-wk-Fact-2AB8FDBDC0EF4D28AFBE94757CD8C9DF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,085</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e5486-wk-Fact-423E2315CDCB857D87F794757D3B33EB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,572</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e5505-wk-Fact-02A1D5D7B6684CF717F394757CCC45F0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,096</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Chantix/Champix</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">An aid to smoking cessation treatment in adults 18 years of age or older</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e5540-wk-Fact-40BFA256F2604E1D69E694757D5745F9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">235</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e5559-wk-Fact-066F1B2C39D1A83ADDB294757D9EC44C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">276</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e5579-wk-Fact-1C6897C10CB6E03B97C094757D014B98" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">505</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e5598-wk-Fact-D2F686C8FF4197FE1E1D94757D4328BD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">549</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Premarin family</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Symptoms of menopause</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e5633-wk-Fact-E4061A0544587530FE5694757D9C3208" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">152</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e5652-wk-Fact-FC2B2CD24A88257F990394757CB35835" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">193</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e5672-wk-Fact-28CC293C11C25B9C4E6E94757D8F7B1C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">304</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e5691-wk-Fact-8ACA3083C920B54F8AEC94757D564AB6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">361</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">BMP2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Development of bone and cartilage</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e5726-wk-Fact-A617E7F74433A22C70F794757DA55FFF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">57</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e5745-wk-Fact-F90EF4CFE321BC6F7A3494757D56ED60" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">79</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e5765-wk-Fact-C5B823B21E48CD41CEFE94757CE0A878" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">127</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e5784-wk-Fact-F44ADBD39CBA320A835394757D7CED0E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">145</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Toviaz</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Overactive bladder</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e5819-wk-Fact-97E6BE9DD3E7475F229D94757D38F45F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">64</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e5838-wk-Fact-44C12AC03CA4B50FB0EC94757D37E891" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">65</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e5858-wk-Fact-0E667667A379AE13037394757D3C7D79" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">124</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e5877-wk-Fact-CAAA50A9A982EC80885B94757CFEC886" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">125</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other Internal Medicine</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e5912-wk-Fact-8F10AC75EAF3DB11CBFC94757D61D1B8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">498</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e5931-wk-Fact-8C0A92F009A247D99EC694757D0E2AFB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">544</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e5951-wk-Fact-8756F2FE82655E80079594757D3B1E62" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">978</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e5970-wk-Fact-45009E6C6C76A6D4EBFD94757D064F15" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,103</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Oncology</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e6011-wk-Fact-B3ED622B6D5333AADB4C94757D4DE93E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,647</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e6030-wk-Fact-4A8A6D2C43101EDB612F94757D38DA90" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,236</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e6050-wk-Fact-BBFDDD0F99EBDF64EB1694757D9ECC85" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,082</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e6069-wk-Fact-91B475D5B7F71E7C7FAB94757D49A574" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,198</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Ibrance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Metastatic breast cancer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6099-wk-Fact-292A39A61B95A38DAE4294757D641FCC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,349</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6118-wk-Fact-1D7D14E19D54858958AD94757D7F7B9C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,261</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6138-wk-Fact-BA188523CDC08C3BD91894757D830D48" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,598</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6157-wk-Fact-F0BFBC7B811B1816201694757CB6F0E5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,394</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Xtandi alliance revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Non-metastatic and metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6192-wk-Fact-75BFCA05A7149AE95CBC94757D351323" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_XtandiAllianceRevenuesMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">266</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6211-wk-Fact-1ABC18BB58EC4350C49A94757DA469FD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_XtandiAllianceRevenuesMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">201</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6231-wk-Fact-8E0A3D13B1EAB4274CE094757CF24199" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_XtandiAllianceRevenuesMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">475</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6250-wk-Fact-790962E6E46F5DAE16C594757D8B4C11" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_XtandiAllianceRevenuesMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">369</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Sutent</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6285-wk-Fact-BD96C76E9201FF7471B894757CBB75BF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_SutentMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">209</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6304-wk-Fact-A328552D6AA9AECA214D94757D7B82D3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_SutentMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">248</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6324-wk-Fact-BB5180129FF25C4F156F94757CF77B4B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_SutentMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">414</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6343-wk-Fact-D710DD8F9085F4C6427994757D0D2639" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_SutentMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">480</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Inlyta</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Advanced RCC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6378-wk-Fact-7AF794137FFB59B04D9F94757CFF8758" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">195</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6397-wk-Fact-2273A659770771A4C8E794757D3A8C78" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">104</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6417-wk-Fact-BBAF1253B0331C702CFD94757DA1EAEE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">364</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6436-wk-Fact-2A64A333F62F8B0205CF94757DA2BE21" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">177</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Xalkori</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">ALK-positive and ROS1-positive advanced NSCLC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6471-wk-Fact-EDF0BD718B103083D4FF94757CF1661F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">138</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6490-wk-Fact-0EEA33BB8E1D16B6B52C94757D0D7D9B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6510-wk-Fact-B63690318E396E789ECB94757D9C1E5B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">287</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6529-wk-Fact-FAD26D1BF97B169BA9FF94757D99D923" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">255</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Bosulif</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Philadelphia&#160;chromosome&#8211;positive&#160;chronic myelogenous leukemia</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6564-wk-Fact-EB3DFF950D41939251B594757D31A223" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">113</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6583-wk-Fact-DDAB8DA858C2046EFB9194757D6613BB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6603-wk-Fact-1769FC90ED8A5212B02994757CDC0199" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">213</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6622-wk-Fact-8C0B1A948B1F38EC51F194757CF43642" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">177</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Retacrit</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Anemia</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6659-wk-Fact-1C41D8D03DE049895B2094757D9C99B7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_RetacritMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">87</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6678-wk-Fact-EC785A34B39A8E6060B794757DA5646C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_RetacritMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6698-wk-Fact-A40FA5F841627A3B361294757D3A0A50" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_RetacritMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">176</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6717-wk-Fact-1A182C74458013C503BA94757D323D60" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_RetacritMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">82</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Braftovi</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">In combination with Mektovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation and, in combination with Erbitux</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:7.5pt;">&#160;(cetuximab), for the treatment of BRAF</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">V600E</sup></span><span style="font-family:inherit;font-size:7.5pt;">-mutant metastatic colorectal cancer after prior therapy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6760-wk-Fact-8228BFAFD6135B5FE0EB94757CFE18C3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6779-wk-Fact-28494D2507D848DC656E94757D06BDB4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6799-wk-Fact-29DB3832C423CF07297E955D6F26B078" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">74</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6818-wk-Fact-1BBA8D8FF8C715716BEF955D6DE660AB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Mektovi</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">In combination with Braftovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6853-wk-Fact-FC0002C8DB53C863C0BF94757CD36F6D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_MektoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6872-wk-Fact-962C0D7F7FA2360CD92194757CFD68D9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_MektoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6892-wk-Fact-6E956A6B353850312446955D6DCF921A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_MektoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">69</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6911-wk-Fact-A7D9E8CC87E296B446CB955D6F275827" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_MektoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other Oncology</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6946-wk-Fact-3FF1B5A349253F7F72E994757CF3173A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">221</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6965-wk-Fact-51B9585A97281577F55894757D56D291" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e6985-wk-Fact-082321B1195122177BB094757D5150F1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">412</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7004-wk-Fact-8EADFB562DCF6F518C5D94757D7A8BBF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">262</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Hospital</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a), (c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e7047-wk-Fact-60CA995A5DF3128B16AC94757CF80B83" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,794</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e7066-wk-Fact-9FF11DED732028F079FF94757D67BC5A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,838</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e7086-wk-Fact-49D11DC2C94C1C47212E94757D5FB74C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,807</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e7105-wk-Fact-F48D67680627D6924C7394757D8E45FB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,665</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Sulperazon</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Bacterial infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7135-wk-Fact-0746A502EECEDB0C1D9394757D555939" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">102</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7154-wk-Fact-4872D1EBBF4E1852EC3494757D07D096" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">165</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7174-wk-Fact-76C07D2D66C0388F0C0594757D012C55" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">289</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7193-wk-Fact-0B2C64A2B5311E2D9BF394757D63AA66" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">342</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Medrol</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Anti-inflammatory glucocorticoid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7228-wk-Fact-75A819750D40D13F5F4D94757D59DF46" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">78</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7247-wk-Fact-DDBF519A26B8B268AC5394757D7DE917" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">120</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7267-wk-Fact-EB6D0A7F7C143C2F6D1E94757D00635E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">207</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7286-wk-Fact-61F05B8390D8DD312E7E94757D01400F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">240</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Zithromax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Bacterial infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7321-wk-Fact-BD41F7186105B7884BC694757D5BC2AE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7340-wk-Fact-0739ED261CA0E3B259D394757D5A4733" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">73</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7360-wk-Fact-2AF25534B2A95420B2CC94757D5E2E55" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">193</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7379-wk-Fact-2460B59E617CE183933A94757CDEE668" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">177</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Precedex</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Sedation agent in surgery or intensive care</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7414-wk-Fact-39C4783BCFAA4ABC800E6391E2F164B1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">114</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7433-wk-Fact-5DF4EF1F1BCC2D34B6F86391E6AAE21C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7453-wk-Fact-399031A0BA1EB364EEE6955D6DD9525C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">156</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7472-wk-Fact-DD66129D925AD6B2D1A4955D6DF5306E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Vfend</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Fungal infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7507-wk-Fact-477D98C4B7AC60774FF994757DA3ED14" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_VfendMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7526-wk-Fact-F438821E9550CEA8E25A94757D043BA1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_VfendMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">94</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7546-wk-Fact-196CA4F9D93284F17A0194757CFB1334" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_VfendMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">149</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7565-wk-Fact-7F5B6E7E28432773681794757D7346F3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_VfendMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">178</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Panzyga</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Primary humoral immunodeficiency</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7600-wk-Fact-B7B4528B4555854FBA2594757D748585" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_PanzygaMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7619-wk-Fact-2B65B5D59AAE94EB07C394757D4A2A4B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_PanzygaMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">44</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7639-wk-Fact-C8791891FDD5606F4FF0955D6DF370FF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_PanzygaMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">136</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7658-wk-Fact-72D47C5CC041D7DBF47F955D6F25B06E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_PanzygaMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">61</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:2pt;"><span style="font-family:inherit;font-size:2pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-4B6CE4DCEEAA26D6AD9D94757DC302F1-1" continuedAt="TextSelection-4B6CE4DCEEAA26D6AD9D94757DC302F1-2"><ix:continuation id="TextSelection-31CB92B2FCB9ECA4894394757DC257B4-5" continuedAt="TextSelection-31CB92B2FCB9ECA4894394757DC257B4-6"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">PRODUCT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">PRIMARY INDICATION OR CLASS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Zyvox</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Bacterial infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7912-wk-Fact-1156EEDC3AF7E03F6D9894757D9E9130" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7931-wk-Fact-F35FE93745C53320FB9394757D667FF4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7951-wk-Fact-E7F68194ACA2953195D194757D3ADA6D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">125</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e7970-wk-Fact-EBD6CF2E62976239B60E94757D5080D2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">134</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Fragmin</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Treatment/prevention of venous thromboembolism</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8005-wk-Fact-3A87DB55E2FD4B6878A094757D7E9E08" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_FragminMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8024-wk-Fact-AF51AD4BAD86F0B6155B94757D5FA1C5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_FragminMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8044-wk-Fact-2434BB068F426C5FA43394757D97AF9A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_FragminMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">118</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8063-wk-Fact-CB1E1E66274A527AAF7194757D9AD724" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_FragminMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">123</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:7.5pt;">Pfizer CentreOne</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8100-wk-Fact-6E0224238BF2056CE73A94757CD9F96F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_PfizerCentreOneMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">224</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8119-wk-Fact-4B0483818642973A551F94757D019625" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_PfizerCentreOneMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">204</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8139-wk-Fact-146D88A01BA77360B4DB94757DA58B4B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_PfizerCentreOneMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">376</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8158-wk-Fact-2E372A7C63982BD2808894757D9722C9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_PfizerCentreOneMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">380</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other Anti-infectives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8193-wk-Fact-983ACA3C5EAC7B373D6394757D08EA2C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_OtherAntiinfectivesMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">367</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8212-wk-Fact-73D86692FF1AB4C6A16994757D919ACA" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_OtherAntiinfectivesMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">420</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8232-wk-Fact-8936184B1403F72707B294757CFAA700" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_OtherAntiinfectivesMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">811</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8251-wk-Fact-E5ACC24ECADCC36DF22594757D7E0534" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_OtherAntiinfectivesMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">825</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:7.5pt;">All other Hospital</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8288-wk-Fact-ACC0B84B657C3CD00CFC94757D4FE802" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_OtherHospitalProductsMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">603</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8307-wk-Fact-B0C69CDE8303781F976E94757D9A42B7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_OtherHospitalProductsMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">544</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8327-wk-Fact-BEED3353022DC3D9583494757DA5ED38" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_OtherHospitalProductsMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,245</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8346-wk-Fact-5412E02A9288B4E9968694757D311429" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_OtherHospitalProductsMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,124</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Vaccines</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e8386-wk-Fact-74E4240EE356FD32937194757D598199" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,247</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e8405-wk-Fact-9219053E894437AE654A94757CA730AC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,375</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e8425-wk-Fact-ED21A5999CE70D92B7B894757D82FAD8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,857</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e8444-wk-Fact-30A55A76D09149193DEF94757CF9F6E0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,988</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Prevnar 13/Prevenar 13</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Pneumococcal disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8474-wk-Fact-F0FB32A7863EE7ED7F4694757D7AEFEA" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,116</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8493-wk-Fact-DDDCDB827DE1BA9AE0A094757D605ED8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,179</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8513-wk-Fact-3464C800C7CFB593F5A094757D025356" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,566</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8532-wk-Fact-5482D0C9A48409F518C294757CD32973" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,665</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Nimenrix</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Meningococcal disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8567-wk-Fact-35F819121227A1B2716394757CD7F3B5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_NimenrixMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8586-wk-Fact-EB493894E6854666775C94757DA43288" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_NimenrixMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8606-wk-Fact-9BCD3F039A9501E12FF494757D93C184" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_NimenrixMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">130</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8625-wk-Fact-6A8F17526ED378430AC394757D37D095" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_NimenrixMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">107</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other Vaccines</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8660-wk-Fact-B7370F44810A4DAB73E594757D4E7849" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8679-wk-Fact-4439A451532C5A8CA16A94757CD79850" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">138</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8699-wk-Fact-DC223973F9A5716A8E8A94757CD62EB0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">161</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8718-wk-Fact-C24556ADCE00898BD21594757D0D7A3A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">215</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Inflammation &amp; Immunology (I&amp;I)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e8759-wk-Fact-A2939B732AE13241120294757D09B001" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,149</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e8778-wk-Fact-8E31E2F76BD952A8034B94757D5D45BC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,219</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e8798-wk-Fact-6C9BC4C3EBFF03DDD76D94757D620C88" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,127</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e8817-wk-Fact-5E3946E8DF0B8A26D57594757D5D19AE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,256</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Xeljanz</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">RA, PsA, UC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8847-wk-Fact-CB4934D4AC7BE3EE5C8B94757DA16687" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">635</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8866-wk-Fact-34DF1ED7A975EB8009FD94757CFCA377" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">613</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8886-wk-Fact-6AECEE089D57AA13D6BC94757D97FE05" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,086</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8905-wk-Fact-F08B0F8C37F8C93A4C4094757DA47314" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,036</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Enbrel (Outside the U.S. and Canada)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8940-wk-Fact-5FB2575DB6C40C4A523694757CD6C03F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">337</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8959-wk-Fact-EF95E23BF627189BD8D394757CD6C3BC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">420</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8979-wk-Fact-855E65BE498CA482464E94757D972E8A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">684</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e8998-wk-Fact-901FD30A6584FD962DA994757CDAFF61" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">871</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Inflectra/Remsima</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Crohn&#8217;s disease, pediatric Crohn&#8217;s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9035-wk-Fact-DB4CC75A37E92F7B141794757D9F9E31" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">150</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9054-wk-Fact-67200BFFCD97D83C7D8E94757D555E87" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">153</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9074-wk-Fact-099EACAC9FBD97BB278994757CD0F95C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">308</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9093-wk-Fact-96E3B27F72377D1E7FE194757D98AE8A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">291</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other I&amp;I</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9128-wk-Fact-F9ECD4E61F7F416505A994757D4CE755" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9147-wk-Fact-A47F0900AE72842784C694757D57B6DC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9167-wk-Fact-D9342B24F3BFBFBB0B2C94757CF2922B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">48</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9186-wk-Fact-E28730D95B8DDFD41B3A94757DA7C4C1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">59</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Rare Disease</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e9226-wk-Fact-E3472375FCBC04FE226794757CFEC2C2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">681</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e9245-wk-Fact-7B91BBEA47E9777B17C594757D58AE44" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">521</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e9265-wk-Fact-32B84237D873D169405294757D4B1427" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,319</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e9284-wk-Fact-08811F0E0890B477F67294757D0E6EA8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">991</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Vyndaqel/Vyndamax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">ATTR-cardiomyopathy and polyneuropathy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9314-wk-Fact-16BA4BA96D497FE8841494757D0E0F19" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_VyndaqelMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">277</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9333-wk-Fact-1DEBA46DDE9F43EFD62794757D56A729" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_VyndaqelMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9353-wk-Fact-E43590991626F7E0420C94757D7D244F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_VyndaqelMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">508</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9372-wk-Fact-2B8C407B0F9D1E1697FF94757D8D7AFF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_VyndaqelMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">104</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">BeneFIX</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Hemophilia B</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9407-wk-Fact-FADD415BA7D4A949D7E294757CD85B2F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">109</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9426-wk-Fact-35DD337C5BA3CE10748094757D38DE10" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">121</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9446-wk-Fact-B601AC275D35D91FAA5B94757D96646A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">230</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9465-wk-Fact-9E28BED123C461A036F694757D3A4E75" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">247</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Genotropin</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Replacement of human growth hormone</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9500-wk-Fact-EA6415464295103AEF2B94757DA2049F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">106</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9519-wk-Fact-6E0A84456242D8C091A194757CB4E6D0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">125</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9539-wk-Fact-12D147AF9E825EFFF01094757D7C5FF5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">209</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9558-wk-Fact-8FEC3BDE742F3804D88D94757CFF667C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">232</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Refacto AF/Xyntha</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Hemophilia A</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9593-wk-Fact-3033AFEEE9DAC2AA502F94757D5A3A33" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">91</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9612-wk-Fact-1008A58E5163A037E91694757DA76A0E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">108</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9632-wk-Fact-57B4C0AD54F70ED15DEB94757D0994FB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">181</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9651-wk-Fact-3F107AD41D30272FF55994757D9AE730" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">214</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Somavert</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Acromegaly</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9686-wk-Fact-C3FC40ABABE9A40ADF4194757D2AFAF8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">67</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9705-wk-Fact-3E2ECD68BC9BCE0AEB1994757DA672E1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">68</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9725-wk-Fact-04D691259FB1FD1AF5E494757D0719B5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">131</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9744-wk-Fact-A36E93BCD1D69A5C434B94757D27570F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">128</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other Rare Disease</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9780-wk-Fact-6BB9C2EB3E8AA601D81B94757D4D8A03" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">31</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9799-wk-Fact-F91FD24844F3AF40238A94757D7F6262" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9819-wk-Fact-DB477F1734A1E9EA210A94757D0C3C05" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">61</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9838-wk-Fact-DE40C96E4948EABC1B9994757D9FA9A4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">66</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">UPJOHN</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e9880-wk-Fact-8A47D4A42EA4801E113F94757D561064" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,006</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e9899-wk-Fact-C5060A64152E4CD16E7D94757D9B8FAB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,970</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e9919-wk-Fact-BFD0D11A54AFC7EC342E94757D4DA77D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,027</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e9938-wk-Fact-3383068A828B707166B194757D4D0A42" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,184</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Lipitor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Reduction of LDL cholesterol</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9968-wk-Fact-B6F824A1D38474F2D25894757CD26487" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">431</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e9987-wk-Fact-F43BB2EB7D4C6E45428094757CDA03D2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">407</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10007-wk-Fact-AD3188356864105593EE94757CDE3AA3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">836</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10026-wk-Fact-7097BD769E5D82E2973294757D7E414B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,029</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Lyrica</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10061-wk-Fact-4E6EDE18D87BADEBD5D594757DA51E46" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">349</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10080-wk-Fact-C076F9FF805FD19B813594757D054DF5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,175</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10100-wk-Fact-4D1BE9253D5F410A0D8294757D39F930" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">706</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10119-wk-Fact-8DE5439DE42185EAD27394757D638D67" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,362</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Norvasc</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Hypertension</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10154-wk-Fact-AAF3C1C15A87A9E0791F94757D585239" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10173-wk-Fact-30038D93D81522EF2C4494757CB8E85E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">216</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10193-wk-Fact-72CA6214585A5C8E5F0694757D4CBC86" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">419</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10212-wk-Fact-F2DA33B091A2333965BF94757D0DA3A2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">516</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Celebrex</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Arthritis pain and inflammation, acute pain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10247-wk-Fact-1A5FECFDC88986C24EF594757D80E29D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">139</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10266-wk-Fact-E2B7192F841B652DD3E194757D025EED" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">174</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10286-wk-Fact-358A86952AF68F57BF8A94757D2D05E3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">295</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10305-wk-Fact-4332974BA308B68F084594757D7E748A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">347</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Viagra</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Erectile dysfunction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10340-wk-Fact-CB04EC46BE3C2AE76E6E94757D59A008" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">94</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10359-wk-Fact-87D917DF76C4DF6A2AA894757D7F7619" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">114</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10379-wk-Fact-14DC4260C1A11D0782B494757D550824" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10398-wk-Fact-03DE33E0BDCBEEE2BFF194757D58A455" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">259</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Effexor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Depression and certain anxiety disorders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10433-wk-Fact-F7818AB402D4FDFA360A94757D088A7E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">86</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10452-wk-Fact-1C3E607A0B96B4E13C6A94757D7DBECB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">86</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10472-wk-Fact-EE3B286DC2CC60A1348594757D084ADB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">163</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10491-wk-Fact-3EA1514AE1ADA2AD3F6494757D8089A9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">163</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Zoloft</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Depression and certain anxiety disorders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10526-wk-Fact-D299C7D480FAACA386FA94757CA95699" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">79</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10545-wk-Fact-5EE554E0F23105B14A0A94757CD8E1B6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">73</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10565-wk-Fact-4B82DFDFC48F6984C14894757CBA0C82" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">157</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10584-wk-Fact-5FFC08B63DBE9AEB9BB794757CFD2C69" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">143</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:7.5pt;">EpiPen</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Epinephrine injection used in treatment of life-threatening allergic reactions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10621-wk-Fact-B53EC4023A670C9BFD9694757CFA2072" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">64</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10640-wk-Fact-E5461C2F47C5805246B594757CD11E3E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">67</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10660-wk-Fact-964D5983FAFE8F814A6063A28D7FB945" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">136</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10679-wk-Fact-4530C68B63EB9C8D923963A2911A73D6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">123</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Xalatan/Xalacom</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Glaucoma and ocular hypertension</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10714-wk-Fact-07227B9D4AC3775762FA94757CFC4DBE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">65</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10733-wk-Fact-F1157F3F3D62CE169F0094757CD5A45F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">72</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10753-wk-Fact-1085284E00DE2A425A0894757DA63E92" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">126</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10772-wk-Fact-61E83372368ABBBF6C3294757D74D153" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10808-wk-Fact-1A1E0EDA654D59F9D7FD94757D7CE696" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherUpjohnProductsMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">476</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10827-wk-Fact-054BF18A0129DBDADDAA94757D7C3D2F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherUpjohnProductsMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">587</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10847-wk-Fact-371E5DEB4BB6100754FB94757DA1FAFE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherUpjohnProductsMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">968</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d8415180e10866-wk-Fact-4D23F6FF7E43AD5A2E8294757CB25D84" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherUpjohnProductsMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,109</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">CONSUMER HEALTHCARE BUSINESS</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e10908-wk-Fact-D421852A3121926EC88F94757D45D1D2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_ConsumerHealthcareReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e10927-wk-Fact-71BC4F00B5A98A968BFB94757D63CCD9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_ConsumerHealthcareReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">862</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e10947-wk-Fact-871E915D2D6F3FDC5AE494757D0F306E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_ConsumerHealthcareReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e10966-wk-Fact-FAE23785D8D757DC211B94757D5BFB03" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_ConsumerHealthcareReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,721</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Total Alliance revenues</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e11001-wk-Fact-7D53DA141A1661E350C494757CD27C31" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_TotalAllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,404</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e11020-wk-Fact-19FE32C2E94B0BB6335F94757DA09738" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_TotalAllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,187</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e11040-wk-Fact-764DE6C24A3192A6595F94757CD7F4D4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_TotalAllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,786</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e11059-wk-Fact-086484E238165C35805A94757CD31940" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_TotalAllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,277</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Total Biosimilars</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e11096-wk-Fact-CB195E4B49470C94E41C94757D5B8154" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_TotalBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">289</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e11115-wk-Fact-ACE7D9A9276B682B9DB094757D5AF1D5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_TotalBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">217</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e11135-wk-Fact-B698D162AA64B4E9F22494757CB607DE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_TotalBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">578</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e11154-wk-Fact-3A37D8CBC7B234B9BABE94757CAB9E45" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_TotalBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">396</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Total Sterile Injectable Pharmaceuticals</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(f)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e11191-wk-Fact-4A39A4BCF3749653D06D94757D00D6F3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_TotalSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,237</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e11210-wk-Fact-B09391D35897D9D4E22494757D809B12" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_TotalSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,218</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e11230-wk-Fact-6F6B5B603006C5DC41F794757D7CCE24" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_TotalSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,644</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d8415180e11249-wk-Fact-076F89258C6280289A5E94757D34A300" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_TotalSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,455</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan).</span><span style="font-family:inherit;font-size:7.5pt;"> As a result, revenues associated with our Meridian subsidiary, except for product revenues for EpiPen sold in Canada, and Mylan-Japan, are reported in our Upjohn business beginning in the first quarter of 2020. We have reclassified revenues associated with our Meridian subsidiary and Mylan-Japan from the Hospital and Internal Medicine categories to the Upjohn business to conform 2019 product revenues to the current presentation.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-FE68345D83BB191130EF94757DC1B5E5-0-wk-Footnote-FE68345D83BB191130EF94757DC1B5E5_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. Hospital also includes Pfizer CentreOne</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span><span style="font-family:inherit;font-size:7.5pt;">. All other Hospital primarily includes revenues from legacy Sterile Injectables Pharmaceuticals (SIP) products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in &#8220;All other Anti-infectives&#8221;.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-4F6B4AE2D2C9909DF73D94757DC29A3E-0-wk-Footnote-4F6B4AE2D2C9909DF73D94757DC29A3E_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-D895C9E8DF19B244540094757DC27744-0-wk-Footnote-D895C9E8DF19B244540094757DC27744_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">On </span><span style="font-family:inherit;font-size:7.5pt;">July&#160;31, 2019</span><span style="font-family:inherit;font-size:7.5pt;">, Pfizer&#8217;s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK&#8217;s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Note 2B</span><span style="font-family:inherit;font-size:7.5pt;">.</span></div></ix:footnote></td></tr></table></ix:continuation></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-4B6CE4DCEEAA26D6AD9D94757DC302F1-2" continuedAt="TextSelection-4B6CE4DCEEAA26D6AD9D94757DC302F1-3"><ix:continuation id="TextSelection-31CB92B2FCB9ECA4894394757DC257B4-6" continuedAt="TextSelection-31CB92B2FCB9ECA4894394757DC257B4-7"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(f)</sup>&#160;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-33990A088D8DAE29233C94757DC283BE-0-wk-Footnote-33990A088D8DAE29233C94757DC283BE_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-4B6CE4DCEEAA26D6AD9D94757DC302F1-3"><ix:continuation id="TextSelection-31CB92B2FCB9ECA4894394757DC257B4-7"><div style="line-height:120%;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.</span></div></ix:continuation></ix:continuation></ix:footnote></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">44</span></div></div><hr style="page-break-after:always"></hr><div><a id="s2333F9D7259D57F89C220CA85855F82B"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Report of Independent Registered Public Accounting Firm</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">To the Board of Directors and Shareholders of Pfizer Inc.:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Results of Review of Interim Financial Information</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have reviewed the condensed consolidated balance sheet of Pfizer Inc. and subsidiaries (the Company) as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;">, the related condensed consolidated statements of income, comprehensive income and equity for the </span><span style="font-family:inherit;font-size:10pt;">three-month and six-month</span><span style="font-family:inherit;font-size:10pt;"> periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the related condensed consolidated statements of cash flows for the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;">-month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and the related notes (collectively, the consolidated interim financial information). Based on our reviews, we are not aware of any material modifications that should be made to the consolidated interim financial information for it to be in conformity with U.S. generally accepted accounting principles.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheet of the Company as of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, and the related consolidated statements of income, comprehensive income, equity, and cash flows for the year then ended (not presented herein); and in our report dated </span><span style="font-family:inherit;font-size:10pt;">February&#160;27, 2020</span><span style="font-family:inherit;font-size:10pt;">, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying condensed consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.</span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Basis for Review Results</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This consolidated interim financial information is the responsibility of the Company&#8217;s management. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We conducted our reviews in accordance with the standards of the PCAOB. A review of consolidated interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the PCAOB, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ KPMG LLP</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">New York, New York</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August&#160;6, 2020</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">45</span></div></div><hr style="page-break-after:always"></hr><div><a id="sBC909420D8D35A8DBC54AC80D5E5905D"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Introduction</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout this MD&amp;A. Our MD&amp;A is provided in addition to the accompanying condensed consolidated financial statements and footnotes to assist readers in understanding Pfizer&#8217;s results of operations, financial condition and cash flows. All trademarks in this MD&amp;A are the property of their respective owners. The MD&amp;A is organized as follows:</span></div><div style="line-height:100%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:2%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:19%;"></td><td style="width:19%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-style:italic;" href="#s18296744AC5E5B469085F793EE05D11D"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Overview of Our Performance, Operating Environment, Strategy and Outlook</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#s18296744AC5E5B469085F793EE05D11D">47</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This section provides information about the following: Our Business; Our Business Development Initiatives; our performance during the second quarter and first six months of 2020 and 2019; Our Operating Environment; The Global Economic Environment; Our Strategy; and Our Financial Guidance for 2020.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-style:italic;" href="#s5F981A9D353655258DC4E106299EB43C"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#s5F981A9D353655258DC4E106299EB43C">57</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This section discusses our disclosures for those accounting policies and estimates that we consider important in understanding our consolidated financial statements.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-style:italic;" href="#s6DA66313DC9B5DAD879A4DFA5491228D"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Analysis of the Condensed Consolidated Statements of Income</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#s6DA66313DC9B5DAD879A4DFA5491228D">58</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This section includes the following sub-sections:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">&#9675;  </span><a style="font-family:inherit;font-size:9pt;font-style:italic;" href="#s0736475C989052698F67D0638F4F6010"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Revenues by Operating Segment and Geography</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#s0736475C989052698F67D0638F4F6010">59</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This sub-section provides an overview of revenues by operating segment and geography as well as revenue deductions.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">&#9675;  </span><a style="font-family:inherit;font-size:9pt;font-style:italic;" href="#s976167A62B9D5FB6BE937E6A3353F212"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Revenues&#8211;&#8211;Selected Product Discussion</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#s976167A62B9D5FB6BE937E6A3353F212">64</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This sub-section provides an overview of several of our biopharmaceutical products.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">&#9675;  </span><a style="font-family:inherit;font-size:9pt;font-style:italic;" href="#s418A2D1D9937533DBFA5279BB62806A3"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Product Developments&#8211;&#8211;Biopharmaceutical</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#s418A2D1D9937533DBFA5279BB62806A3">69</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This sub-section provides an overview of important biopharmaceutical product developments.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">&#9675;  </span><a style="font-family:inherit;font-size:9pt;font-style:italic;" href="#s1A92BF9EEF8757AFAA82D0174D182E74"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Costs and Expenses</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#s1A92BF9EEF8757AFAA82D0174D182E74">72</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This sub-section provides a discussion about our costs and expenses.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">&#9675;  </span><a style="font-family:inherit;font-size:9pt;font-style:italic;" href="#s931D11AD61AA54599A068FF5E2A002FB"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Provision/(Benefit) for Taxes on Income</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#s931D11AD61AA54599A068FF5E2A002FB">75</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This sub-section provides a discussion of items impacting our tax provisions.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">&#9675;  </span><a style="font-family:inherit;font-size:9pt;font-style:italic;" href="#sB2A85AA439F458C0992C898083906DF4"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Non-GAAP Financial Measure (Adjusted Income)</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#sB2A85AA439F458C0992C898083906DF4">75</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This sub-section provides a discussion of an alternative view of performance used by management.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-style:italic;" href="#sA30E594F3C5B544CA232485FF3DF9CE6"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Analysis of Operating Segment Information</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#sA30E594F3C5B544CA232485FF3DF9CE6">81</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This section provides a discussion of the performance of each of our operating segments.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-style:italic;" href="#s9C39D289ECA35993A0DC1AE940DB481F"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Analysis of the Condensed Consolidated Statements of Cash Flows</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#s9C39D289ECA35993A0DC1AE940DB481F">88</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This section provides an analysis of our cash flows for the first six months of 2020 and 2019.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-style:italic;" href="#s683E43952F88598F9D86F87273D7B54F"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Analysis of Financial Condition, Liquidity and Capital Resources</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#s683E43952F88598F9D86F87273D7B54F">89</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This section provides an analysis of selected measures of our liquidity and of our capital resources as of June 28, 2020 and December 31, 2019, as well as a discussion of our outstanding debt and other commitments that existed as of June 28, 2020 and December 31, 2019. Included in the discussion of outstanding debt is a discussion of the amount of financial capacity available to help fund Pfizer&#8217;s future activities.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-style:italic;" href="#s813CF60B975851DFA03D854F39CC9ADD"><span style="font-family:inherit;font-size:10pt;font-style:italic;">New Accounting Standards</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#s813CF60B975851DFA03D854F39CC9ADD">93</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This section discusses accounting standards that we have recently adopted, as well as those that recently have been issued, but not yet adopted.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-style:italic;" href="#sE7A89D218CBF544EB08D3DAA9D030F13"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Forward-Looking Information and Factors That May Affect Future Results</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#sE7A89D218CBF544EB08D3DAA9D030F13">93</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This section provides a description of the risks and uncertainties that could cause actual results to differ materially from those discussed in forward-looking statements presented in this MD&amp;A. </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain amounts in this MD&amp;A may not add due to rounding. All percentages have been calculated using unrounded amounts.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">46</span></div></div><hr style="page-break-after:always"></hr><div><a id="s18296744AC5E5B469085F793EE05D11D"></a></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">OVERVIEW OF OUR PERFORMANCE, OPERATING ENVIRONMENT, STRATEGY AND OUTLOOK</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Our Business</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture and distribution of healthcare products, including innovative medicines and vaccines. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Our revenues are derived from the sale of our products and, to a much lesser extent, from alliance agreements, under which we co-promote products discovered or developed by other companies or us (Alliance revenues).</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the beginning of our 2019 fiscal year, we began to manage our commercial operations through a new global structure consisting of three business segments&#8211;&#8211;Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and, through </span><span style="font-family:inherit;font-size:10pt;">July&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, Consumer Healthcare. Biopharma and Upjohn are the only reportable segments. For additional information about this operating structure, see Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 14A. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Segment, Geographic and Other Revenue Information</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Segment Information</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:inherit;font-size:10pt;">and the &#8220;Commercial Operations&#8221; section in Part I, Item 1, &#8220;Business&#8221; of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form 10-K.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan).</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">As a result, revenues and expenses associated with Meridian and Mylan-Japan are reported in our Upjohn business beginning in the first quarter of 2020. In 2019, revenues and expenses from Meridian and Mylan-Japan were recorded in our Biopharma business. We performed certain reclassifications between the Biopharma and Upjohn segments to conform 2019 segment revenues and expenses associated with Meridian and Mylan-Japan to the current presentation. There was no impact to our consolidated financial statements.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The majority of our revenues come from the manufacture and sale of biopharmaceutical products. As explained more fully in our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> Form 10-K, the biopharmaceutical industry is highly competitive and highly regulated. As a result, we face a number of industry-specific factors and challenges, which can significantly impact our results. These factors include, among others: the loss or expiration of intellectual property rights and the expiration of co-promotion and licensing rights, the ability to replenish innovative biopharmaceutical products, healthcare legislation, pipeline productivity, the regulatory environment, pricing and access pressures, product manufacturing and competition. We also face challenges as a result of the global economic environment. For additional information about these factors and challenges, see the &#8220;Our Operating Environment&#8221; and &#8220;The Global Economic Environment&#8221; sections of this MD&amp;A and in our 2019 Financial Report and Part I, Item 1A, &#8220;Risk Factors&#8221; of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> Form 10-K and Part II, Item 1A, &#8220;Risk Factors&#8221; of this Quarterly Report on Form 10-Q. </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The financial information included in our condensed consolidated financial statements for our subsidiaries operating outside the U.S. is as of and for the </span><span style="font-family:inherit;font-size:10pt;">three and six months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;">May&#160;24, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">May&#160;26, 2019</span><span style="font-family:inherit;font-size:10pt;">. The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the </span><span style="font-family:inherit;font-size:10pt;">three and six months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">References to operational variances in this MD&amp;A pertain to period-over-period growth rates that exclude the impact of foreign exchange. The operational variances are determined by multiplying or dividing, as appropriate, our current period U.S. dollar results by the current period average foreign exchange rates and then multiplying or dividing, as appropriate, those amounts by the prior-year period average foreign exchange rates. Although exchange rate changes are part of our business, they are not within our control. Exchange rate changes, however, can mask positive or negative trends in the business; therefore, we believe presenting operational variances provides useful information to evaluate the results of our business.</span></div><div style="line-height:120%;padding-top:8px;font-size:11pt;"><span style="font-size:11pt;font-weight:bold;text-decoration:underline;">Our Business Development Initiatives</span><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;"> </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are committed to capitalizing on growth opportunities by advancing our own pipeline and maximizing the value of our in-line products, as well as through various forms of business development, which can include alliances, licenses, joint ventures, collaborations, equity- or debt-based investments, dispositions, mergers and acquisitions. We view our business development activity as an enabler of our strategies, and we seek to generate earnings growth and enhance shareholder value by pursuing a disciplined, strategic and financial approach to evaluating business development opportunities. We continue to evaluate business development transactions that have the potential to strengthen our businesses and their capabilities, such as our acquisitions of Array, Therachon, Hospira, Medivation, Anacor and AstraZeneca&#8217;s small molecule anti-infectives business, as well as collaborations, and alliance and license agreements with other companies. We assess our businesses, assets and scientific capabilities/portfolio as part of our regular, ongoing portfolio review process and also continue to consider business development activities that will advance our businesses.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">47</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our significant recent business development activities include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Agreement with Valneva SE</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;On </span><span style="font-family:inherit;font-size:10pt;">April&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, we signed an agreement to co-develop and commercialize Valneva&#8217;s Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical studies. In June 2020, Valneva announced that the antitrust-related condition precedent was met and, consequently, the agreement became effective. VLA15 is the only active Lyme disease vaccine program in clinical development today, and covers six serotypes that are prevalent in North America and Europe. For additional information, see Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 2C. </span><span style="font-style:italic;font-weight:normal;text-decoration:none;">Acquisition, Equity-Method Investment and Licensing Arrangements</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: </span><span style="font-style:italic;font-weight:normal;text-decoration:none;">Licensing Arrangements</span><span style="font-family:inherit;font-size:10pt;color:#0000ff;font-style:italic;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Agreement with BioNTech SE</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;On </span><span style="font-family:inherit;font-size:10pt;">April&#160;9, 2020</span><span style="font-family:inherit;font-size:10pt;">, we signed a global agreement with BioNTech to co-develop a potential first-in-class, mRNA-based coronavirus vaccine program, BNT162, aimed at preventing COVID-19 infection. The collaboration aims to rapidly advance multiple COVID-19 vaccine candidates into human clinical testing based on BioNTech&#8217;s proprietary mRNA vaccine platforms, with the objective of ensuring rapid worldwide access to the vaccine, if approved. The collaboration will leverage our broad expertise in vaccine R&amp;D, regulatory capabilities, and global manufacturing and distribution network. We and BioNTech plan to jointly conduct clinical trials for the COVID-19 vaccine candidates initially in the U.S. and Europe across multiple sites. For additional information, including information regarding our COVID-19 vaccine development program, see the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;The Global Economic Environment&#8221;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">and &#8220;Product Developments&#8212;Biopharmaceutical&#8221; sections of this </span><span style="font-family:inherit;font-size:10pt;text-align:center;">MD&amp;A and </span><span style="font-family:inherit;font-size:10pt;">Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 2C. </span><span style="font-style:italic;font-weight:normal;text-decoration:none;">Acquisition, Equity-Method Investment and Licensing Arrangements</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: </span><span style="font-style:italic;font-weight:normal;text-decoration:none;">Licensing Arrangements</span><span style="font-family:inherit;font-size:10pt;color:#0000ff;font-style:italic;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Formation of a New Consumer Healthcare Joint Venture</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;On </span><span style="font-family:inherit;font-size:10pt;">July&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name. The joint venture develops and markets brands in the oral health, pain relief, respiratory, nutrition/gastro-intestinal and skin health categories and is one of the world&#8217;s leading over-the-counter healthcare companies. Our financial results, and our Consumer Healthcare segment&#8217;s operating results, for the </span><span style="font-family:inherit;font-size:10pt;">second quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> reflect three months of Consumer Healthcare segment operations</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">and for</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">the first six months of</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">2019 reflect six months of Consumer Healthcare segment operations,</span><span style="font-family:inherit;font-size:10pt;"> while financial results for the </span><span style="font-family:inherit;font-size:10pt;">second quarter</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">and first</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">six months</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> do not reflect any contribution from the Consumer Healthcare business. For additional information, see Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 2B. </span><span style="font-style:italic;font-weight:normal;text-decoration:none;">Acquisition, Equity-Method Investment and Licensing Arrangements</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: </span><span style="font-style:italic;font-weight:normal;text-decoration:none;">Equity-Method Investment</span><span style="font-family:inherit;font-size:10pt;color:#0000ff;font-style:italic;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Agreement to Combine Upjohn with Mylan N.V.</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;On July 29, 2019, we announced that we entered into a definitive agreement to combine Upjohn with Mylan, creating a new global pharmaceutical company, Viatris. Under the terms of the agreement, which is structured as an all-stock, Reverse Morris Trust transaction, Upjohn is expected to be spun off to Pfizer&#8217;s shareholders and, immediately thereafter, combined with Mylan. Pfizer shareholders would own </span><span style="font-family:inherit;font-size:10pt;">57%</span><span style="font-family:inherit;font-size:10pt;"> of the combined new company, and former Mylan shareholders would own </span><span style="font-family:inherit;font-size:10pt;">43%</span><span style="font-family:inherit;font-size:10pt;">. The transaction is expected to be tax free to Pfizer and Pfizer shareholders. The transaction was approved by Mylan&#8217;s shareholders in June 2020 and is anticipated to close in the fourth quarter of 2020, subject to customary closing conditions, including receipt of the remaining required regulatory approvals. In June 2020, Upjohn Inc. and Upjohn Finance B.V. (a wholly-owned subsidiary of Upjohn Inc.) completed privately placed debt offerings in connection with the transaction. For additional information, see Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 7D. Financial Instruments: Long-Term Debt </span><span style="font-family:inherit;font-size:10pt;">and the &#8220;Analysis of Financial Condition, Liquidity and Capital Resources&#8221; section of this MD&amp;A. We expect to incur costs of approximately $700 million in connection with separating Upjohn, of which approximately 30% has been incurred since inception and through the first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;">. Such charges include costs and expenses related to separation of legal entities and anticipated transaction costs.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For a description of the more significant recent transactions through February&#160;27, 2020, the filing date of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> Form 10-K, see the &#8220;Our Business Development Initiatives&#8221; section of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> Financial Report.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Our </span><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Second</span><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;"> Quarter </span><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-align:center;text-decoration:underline;">2020</span><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;"> and </span><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">First Six Months of</span><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;"> </span><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-align:center;text-decoration:underline;">2020</span><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;"> Performance</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Revenues</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">$1.5 billion</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">11%</span><span style="font-family:inherit;font-size:10pt;">, in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;">, compared to the same period in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;">, reflecting an operational </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$1.2 billion</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">9%</span><span style="font-family:inherit;font-size:10pt;">, as well as </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact of foreign exchange of </span><span style="font-family:inherit;font-size:10pt;">$277 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">2%</span><span style="font-family:inherit;font-size:10pt;">. Excluding the impact of the Consumer Healthcare transaction, revenues </span><span style="font-family:inherit;font-size:10pt;">decreased</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">3%</span><span style="font-family:inherit;font-size:10pt;"> operationally, reflecting a </span><span style="font-family:inherit;font-size:10pt;">31%</span><span style="font-family:inherit;font-size:10pt;"> operational </span><span style="font-family:inherit;font-size:10pt;">decline</span><span style="font-family:inherit;font-size:10pt;"> in our Upjohn business mainly due to the U.S. loss of exclusivity of Lyrica, which was partially offset by </span><span style="font-family:inherit;font-size:10pt;">6%</span><span style="font-family:inherit;font-size:10pt;"> operational </span><span style="font-family:inherit;font-size:10pt;">growth</span><span style="font-family:inherit;font-size:10pt;"> in our Biopharma business. Excluding the impact of Lyrica in the U.S., Upjohn revenues declined 6% operationally. Revenues for the </span><span style="font-family:inherit;font-size:10pt;">second quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> included an estimated net </span><span style="font-family:inherit;font-size:10pt;">unfavorable impact of approximately $500 million, or 4%, due to COVID-19, primarily reflecting unfavorable disruptions to wellness visits for pediatric and adult patients in the U.S. and lower demand for certain products in China, partially offset by increased U.S. demand for certain sterile injectable products as well as increased adult demand for Prevenar 13 in certain international markets.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">48</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">decreased</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">$2.6 billion</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">10%</span><span style="font-family:inherit;font-size:10pt;">, in </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">the first six months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;">, compared to the same period in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;">, reflecting an operational </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$2.1 billion</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">8%</span><span style="font-family:inherit;font-size:10pt;">, as well as </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact of foreign exchange of </span><span style="font-family:inherit;font-size:10pt;">$411 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">2%</span><span style="font-family:inherit;font-size:10pt;">. Excluding the impact of the Consumer Healthcare transaction, revenues </span><span style="font-family:inherit;font-size:10pt;">decreased</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">2%</span><span style="font-family:inherit;font-size:10pt;"> operationally, reflecting a </span><span style="font-family:inherit;font-size:10pt;">34%</span><span style="font-family:inherit;font-size:10pt;"> operational </span><span style="font-family:inherit;font-size:10pt;">decline</span><span style="font-family:inherit;font-size:10pt;"> in our Upjohn business mainly due to the U.S. loss of exclusivity of Lyrica, which was partially offset by </span><span style="font-family:inherit;font-size:10pt;">9%</span><span style="font-family:inherit;font-size:10pt;"> operational </span><span style="font-family:inherit;font-size:10pt;">growth</span><span style="font-family:inherit;font-size:10pt;"> in our Biopharma business. Excluding the impact of Lyrica in the U.S., Upjohn revenues declined 11% operationally. Revenues for </span><span style="font-family:inherit;font-size:10pt;">the first six months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">included an estimated net unfavorable impact of approximately $350 million, or 1%, due to COVID-19, primarily reflecting unfavorable disruptions to wellness visits for pediatric and adult patients in the U.S. and lower demand for certain products in China, partially offset by increased U.S. demand for certain sterile injectable products as well as increased adult demand for Prevenar 13 in certain international markets.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See the &#8220;Analysis of the Condensed Consolidated Statements of Income&#8211;&#8211;Revenues by Operating Segment and Geography&#8221; section below for more information, including a discussion of key drivers of our revenue performance.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For worldwide revenues and revenues by geography, for selected products, see the discussion in the &#8220;Analysis of the Condensed Consolidated Statements of Income&#8211;&#8211;Revenues&#8211;&#8211;Selected Product Discussion&#8221; section of this MD&amp;A. For additional information regarding the primary indications or class of certain products, see Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 14C. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Segment, Geographic and Other Revenue Information</span><span style="font-family:inherit;font-size:10pt;">: </span><span style="font-style:italic;font-weight:normal;text-decoration:none;">Other Revenue Information</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Income from Continuing Operations Before Provision/(Benefit) for Taxes on Income</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following provides an analysis of the </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">second quarter and first six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:64%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Income from continuing operations before provision/(benefit) for taxes on income, </span><span style="font-family:inherit;font-size:9.5pt;">for the three and six months ended June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">4,141</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">8,463</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Unfavorable change in revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(1,463</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(2,552</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Favorable/(Unfavorable) changes:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Lower</span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">&#160;Cost of sales</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">295</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">351</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Lower </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Selling, informational and administrative expenses</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">481</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">947</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Higher </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expenses</span><span style="font-family:inherit;font-size:9pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(290</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(311</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Lower </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Amortization of intangible assets</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">279</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">577</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Higher</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;Restructuring charges and certain acquisition-related costs</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(478</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(500</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Higher net gains recognized during the period on equity-securities</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">696</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">331</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Lower business and legal entity alignment costs</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">137</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">256</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Lower asset impairment charges</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">10</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">160</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Non-recurrence of net losses on early retirement of debt</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">138</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Higher income from collaborations, out-licensing arrangements and sales of compound/product rights</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">78</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">111</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">GSK Consumer Healthcare JV equity method income</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">126</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">92</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Higher net periodic benefit credits other than service costs</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">57</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">85</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Unfavorable change in the fair value of contingent consideration</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(89</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Higher net interest expense</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(23</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(84</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Non-recurrence of insurance recoveries related to Hurricane Maria in 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(25</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(50</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">All other items, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(65</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(86</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Income from continuing operations before provision/(benefit) for taxes on income, </span><span style="font-family:inherit;font-size:9.5pt;">for the three and six months ended June 28, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">3,953</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">7,838</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">See the &#8220;Costs and Expenses&#8211;&#8211;Cost of Sales&#8221; section of this MD&amp;A.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">See the &#8220;Costs and Expenses&#8211;&#8211;Selling, Informational and Administrative (SI&amp;A) Expenses&#8221; section of this MD&amp;A.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">See the &#8220;Costs and Expenses&#8211;&#8211;Research and Development (R&amp;D) Expenses&#8221; section of this MD&amp;A.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">See the &#8220;Costs and Expenses&#8211;&#8211;Amortization of Intangible Assets&#8221; section of this MD&amp;A.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">See the &#8220;Costs and Expenses&#8211;&#8211;</span><span style="font-size:8pt;font-weight:normal;text-decoration:none;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:inherit;font-size:8pt;">&#8221; section of this MD&amp;A.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">See Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4. </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (Income)/Deductions&#8212;Net</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For information on our tax provision and effective tax rate see the &#8220;Provision/(Benefit) for Taxes on Income&#8221; section of this MD&amp;A and Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 5</span><span style="font-family:inherit;font-size:10pt;">.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Tax Matters</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">49</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:10px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Our Operating Environment</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Industry-Specific Challenges</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Intellectual Property Rights and Collaboration/Licensing Rights</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The loss, expiration or invalidation of intellectual property rights, patent litigation settlements with manufacturers and the expiration of co-promotion and licensing rights can have a material adverse effect on our revenues. </span><span style="font-family:Times New Roman;font-size:10pt;">Certain of our current products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years, and we expect certain products to face significantly increased generic competition over the next few years.</span><span style="font-family:inherit;font-size:10pt;"> For example, Lyrica lost patent protection in the U.S. in June 2019 and multi-source generic competition began in July 2019. Also, the basic product patent for Chantix in the U.S. will expire in November 2020. </span><span style="font-family:Times New Roman;font-size:10pt;">We expect the impact of reduced revenues due to patent expiries will be significant in 2020, then moderating downward to a much lower level from 2021 through 2025.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For additional information, including the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires and recent and expected losses of product exclusivity, see the &#8220;Patents and Other Intellectual Property Rights&#8221; section in Part I, Item 1, &#8220;Business&#8221; of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We will continue to aggressively defend our patent rights whenever we deem appropriate. For a discussion of certain recent developments with respect to patent litigation, see Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 13A1. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Contingencies and Certain Commitments</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Legal Proceedings</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Patent Litigation</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Regulatory Environment/Pricing and Access&#8211;&#8211;U.S. Healthcare Legislation</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2010, the ACA was enacted in the U.S. For additional information, see the &#8220;Government Regulation and Price Constraints&#8221; section in Part I, Item 1, &#8220;Business&#8221;, of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:60%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td colspan="17" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recorded the following amounts as a result of the U.S. Healthcare Legislation:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Reduction to </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:9.5pt;">, related to the Medicare &#8220;coverage gap&#8221; discount provision</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">216</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">154</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">350</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">289</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Selling, informational and administrative expenses</span><span style="font-family:inherit;font-size:9.5pt;">, related to the fee payable to the federal government (which is not deductible for U.S. income tax purposes), based on our prior-calendar-year share relative to other companies of branded prescription drug sales to specified government programs. </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">71</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">70</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">110</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">121</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Regulatory Environment/Pricing and Access&#8211;&#8211;Government and Other Payer Group Pressures</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The pricing of medicines by pharmaceutical manufacturers and the cost of healthcare, which includes medicines, medical services and hospital services, continues to be important to payers, governments, patients, and other stakeholders. Governments, MCOs and other payor groups continue to seek increasing discounts on our products through a variety of means and could have a material adverse impact on our results of operations. We believe that medicines are amongst the most powerful tools for patients in curing, treating and preventing illness and disability, and that all patients should have appropriate access to the medicines their doctors prescribe. We may consider a number of factors when determining a medicine&#8217;s price, including, for example, its impact on patients and their disease, other available treatments, the medicine&#8217;s potential to reduce other healthcare costs (such as hospital stays), and affordability. Within the U.S., in particular, we may also engage with patients, doctors and healthcare plans regarding their views. We also negotiate with insurers, including PBMs and MCOs, often providing significant discounts to them from the list price. The price that patients pay in the U.S. for the medicines their physicians prescribe is ultimately set by healthcare providers and insurers. On average, in the U.S., insurers impose a higher out-of-pocket burden on patients for prescription medicines than for comparably-priced medical services. Private third-party payers and federal and state governments in the U.S. continue to take action to manage the utilization of drugs and control the cost of drugs, including increasingly employing formularies to control costs by taking into account discounts in connection with decisions about formulary inclusion or favorable formulary placement. For example, in July 2020, President Trump announced that he had signed four Executive Orders related to drug pricing, including orders addressing Part D rebate reform, the provision of deeply discounted insulin and/or an EpiPen to patients of Federally Qualified Health Centers, drug importation from Canada, and most favored nation pricing for Medicare. We will continue to work with insurance providers, governments and others to improve access to today&#8217;s innovative treatments. </span><span style="font-family:Times New Roman;font-size:10pt;">Certain governments, including the different EU member states, the U.K., China, Japan, Canada, South Korea and some other international markets, provide healthcare at low-to-zero direct cost to consumers at the point of care and have significant power as large single payers to regulate pharmaceutical prices or patient reimbursement levels to control costs for the government-sponsored healthcare system, particularly under recent global </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">50</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">financing pressures.</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;">Governments may use a variety of cost-containment measures for our pharmaceutical products, including price cuts, mandatory rebates, health technology assessments, forced localization as a condition of market access, &#8220;international reference pricing&#8221; (i.e., the practice of a country linking its regulated medicine prices to those of other countries), quality consistency evaluation processes and volume-based procurement.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In China, a centralized VBP program was initiated in 2018. Under this procurement model, a tender process has been established where a certain portion of included molecule volumes are guaranteed to tender winners. The program is intended to contain healthcare costs by driving utilization of generics that have passed quality consistency evaluation, which has resulted in dramatic price cuts for off-patent medicines. Upjohn and most off-patent originators were not successful in the first bidding process under this pilot, which was finalized in December 2018 and implemented in March 2019, and most contracts went to local generic companies. This pilot program covered 25 molecules, including atorvastatin calcium tablets (Lipitor) and amlodipine besylate tablets (Norvasc). In April 2020, China implemented another round of expansion of the national VBP program, which covers 33 new molecules, including Biopharma&#8217;s Zithromax tablets and Diflucan capsules and no Upjohn products. Biopharma was not successful in the bidding process for this expansion. In June 2020, China announced the latest round of the expansion of the VBP program, which is expected to be implemented in November 2020 and includes Biopharma&#8217;s Xeljanz and Zyvox tablets and Upjohn&#8217;s Viagra, Zoloft and Celebrex. </span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For additional information, see the &#8220;Government Regulation and Price Constrains&#8221; section in Part I, Item 1, &#8220;Business&#8221; of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Other Industry-Specific Challenges</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Regulatory agencies periodically inspect our drug manufacturing facilities to evaluate compliance with cGMP or other applicable requirements. Failure to comply with these requirements may subject us to possible legal or regulatory actions, such as warning letters, suspension of manufacturing, seizure of product, injunctions, debarment, recall of a product, delays or denials of product approvals, import bans or denials of import certifications, any of which could have a material adverse effect on our business, financial condition and results of operations. In December 2019-January 2020, for example, the FDA conducted an inspection of our McPherson facility and issued an inspection report noting several findings to which Pfizer responded. Based on the outcome of this inspection, the FDA upgraded the inspection classification of the McPherson site to Voluntary Action Indicated (VAI) from Official Action Indicated. VAI status will allow supplements, including those for manufacturing changes/improvements and new products, to proceed for approval following the normal FDA process for a site with an acceptable compliance status. For additional information, see the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Operating Environment&#8211;&#8211;Industry-Specific Challenges&#8211;&#8211;Product Manufacturing&#8221; section of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> Financial Report.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We and other pharmaceutical companies continue to face industry-specific challenges that can significantly impact our business, including, among others, the regulatory environment, pipeline productivity, product manufacturing and competition. For additional information, see the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Operating Environment&#8211;&#8211;Industry-Specific Challenges&#8211;&#8211;Regulatory Environment&#8211;&#8211;Pipeline Productivity&#8221;, &#8220;&#8211;&#8211;Product Manufacturing&#8221; and &#8220;&#8211;&#8211;Competition&#8221;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">sections of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;text-align:center;"> Financial Report</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;color:#212529;">and Part I, Item 1A, &#8220;Risk Factors&#8221; of our 2019 Form 10-K </span><span style="font-family:inherit;font-size:10pt;">and Part II, Item 1A, &#8220;Risk Factors&#8221; of this Quarterly Report on Form 10-Q</span><span style="font-family:inherit;font-size:10pt;color:#212529;">.</span></div><div style="line-height:120%;padding-top:10px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">The Global Economic Environment</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the industry-specific factors discussed above, we, like other businesses of our size, are exposed to the economic cycle, which impacts our biopharmaceutical operations globally. </span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">COVID-19 Pandemic. </span><span style="font-family:inherit;font-size:10pt;">In December 2019, illnesses associated with COVID-19 were reported and the virus has since caused widespread and significant disruptions to daily life and economies across geographies. The World Health Organization has classified the outbreak as a pandemic. Our business, operations and financial condition and results have been impacted to varying degrees, primarily during the second quarter of 2020. We currently anticipate an ongoing, gradual global recovery from the first-half 2020 macroeconomic and healthcare impacts of the COVID-19 pandemic. For additional information on the impact of COVID-19 on our revenues, please see the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Second Quarter 2020 and First Six Months of 2020 Performance&#8221; section of this MD&amp;A.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pfizer&#8217;s Response to COVID-19</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are fully committed to confronting the public health challenge posed by the COVID-19 pandemic by collaborating with industry partners and academic institutions to develop potential approaches to prevent and treat COVID-19. Our researchers and scientists also have been exploring potential new uses of existing medicines in our portfolio that may be able to help infected patients. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">51</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In response to the COVID-19 pandemic, in March 2020, we issued a five-point plan calling on the biopharmaceutical industry to join us in committing to unprecedented collaboration to combat COVID-19. Subsequently, we announced some important advances in the battle against the COVID-19 pandemic, including, among others:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We and The Pfizer Foundation announced the commitment of $40 million in medical and charitable cash grants to help combat the health effects of the COVID-19 pandemic in the U.S. and around the world. The Pfizer Foundation is a charitable organization established by Pfizer Inc. It is a separate legal entity from Pfizer Inc. with distinct legal restrictions.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We confirmed a lead compound and analogues in our portfolio are potent inhibitors of the SARS-CoV-2 3C-like protease, based on the results of initial screening assays. In addition, preliminary data suggest the lead protease inhibitor shows antiviral activity against SARS-CoV-2, the virus that causes COVID-19. Consequently, we are continuing to perform pre-clinical confirmatory studies, including further anti-viral profiling and assessment of the suitability of the lead molecule for IV administration clinically. In July 2020, we published the chemical structure of a 3C-like (3CL) protease inhibitor and its in vitro activity against coronaviruses, including SARS-CoV-2. In parallel, we are also investing in materials with the aim of accelerating the start of a potential clinical study of the lead molecule to the third quarter of 2020, subject to positive completion of the pre-clinical confirmatory studies and regulatory approval.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We entered into a global agreement with BioNTech to co-develop a potential first-in-class, mRNA-based coronavirus vaccine program, BNT162, aimed at preventing COVID-19 infection. As part of this co-development program, which we refer to as Project Lightspeed, we and BioNTech announced in July 2020 the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a single nucleoside-modified messenger RNA candidate. After extensive review of preclinical and clinical data from Phase 1/2 clinical trials, and in consultation with the FDA&#8217;s Center for Biologics Evaluation and Research and other global regulators, we and BioNTech chose to advance the BNT162b2 vaccine candidate into the Phase 2/3 study, at a 30 &#181;g dose level in a 2 dose regimen. BNT162b2, which received Fast Track designation from the FDA in July 2020, encodes an optimized SARS-CoV-2 full length spike glycoprotein, which is the target of virus neutralizing antibodies. If the Phase 2/3 trial is successful, we and BioNTech expect to be ready to seek Emergency Use Authorization or some form of regulatory approval as early as October 2020. If authorization or approval is obtained, the companies currently aim to supply globally (excluding China) up to 100 million doses by the end of 2020 and approximately 1.3 billion doses by the end of 2021. Also in July and August 2020, we and BioNTech announced agreements with the following governments: (i) with the U.K. government for 30 million doses of BNT162, to be delivered in 2020 and 2021, subject to clinical success and regulatory approval or authorization; (ii) with the U.S. government, under which the U.S. government will pay $1.95 billion, in installments as vaccine quantities are delivered, for the first 100 million doses of BNT162, subject to regulatory approval or Emergency Use Authorization from the FDA, as well as the ability for the U.S. government to acquire up to an additional 500 million doses; (iii) with the government of Japan to supply 120 million doses of BNT162, subject to clinical success and regulatory approval, beginning in 2021; and (iv) with the government of Canada to supply BNT162, subject to clinical success and Health Canada approval, over the course of 2021. For additional information on our collaboration with BioNTech, see the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Business Development Initiatives&#8221; section of this </span><span style="font-family:inherit;font-size:10pt;text-align:center;">MD&amp;A and </span><span style="font-family:inherit;font-size:10pt;">Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 2C. Acquisition, Equity-Method Investment and Licensing Arrangements: Licensing Arrangements</span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Despite our significant investments and efforts, our development programs for any potential treatment or vaccine for COVID-19 may not be successful as the risk of failure is significant and there can be no certainty these efforts will yield a successful product or that these costs will ultimately be recouped. In addition, we may change the way we approach or provide additional research funding for potential drug and/or vaccine development related to COVID-19. We will continue to share information from our research that could benefit the global effort to respond to this unprecedented healthcare crisis.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impact of COVID-19 on Pfizer&#8217;s Business and Operations </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are continuing to monitor the latest developments regarding the COVID-19 pandemic on our business, operations, and financial condition and results, and have made certain assumptions regarding the pandemic for purposes of our operational planning and financial projections, including assumptions regarding the duration and severity of the pandemic and the global macroeconomic impact of the pandemic. For additional information, please also see our financial guidance set forth in the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Financial Guidance for 2020&#8221; section of this MD&amp;A. Despite careful tracking and planning, however, we are unable to accurately predict the extent of the impact of the pandemic on our business, operations and financial condition and results due to the uncertainty of future developments. In particular, we believe the ultimate impact on our business, operations and financial condition and results will be affected by the speed and extent of the continued spread of the coronavirus globally, the duration of the pandemic, new information that may emerge concerning the severity and incidence of COVID-19, the safety, efficacy and availability of a vaccine and treatments for COVID-19, the global macroeconomic impact of the pandemic and governmental or regulatory actions to contain the virus or control supply of medicines. We are focused on all aspects of our business and are implementing measures aimed at mitigating issues where possible, including by using digital technology to assist in operations for our commercial, manufacturing, R&amp;D and enabling functions globally.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">52</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Our Colleagues</span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">.</span><span style="font-family:inherit;font-size:10pt;"> Our colleagues and customers have both experienced disruptions to the normal ways of working. At this time, our colleagues in most locations who are able to perform their job functions outside of our facilities continue to work remotely. Certain of our colleagues, primarily those in the Pfizer Global Supply and Worldwide Research and Development organizations, have roles for which their physical presence at our facilities is required to perform their job functions. These colleagues continue to report to work and are subject to strict protocols intended to reduce the risk of transmission, including social distancing, maintaining contact logs, increased cleaning and use of personal protective equipment as necessary.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Our Sales and Marketing</span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">.</span><span style="font-family:inherit;font-size:10pt;"> We have experienced an impact on our sales and marketing activities due to widespread restrictions on in-person meetings with healthcare professionals and the refocused attention of the medical community on fighting COVID-19. Access to prescribers for sales force colleagues during the second quarter of 2020 was mixed, with those in most international markets able to meet with healthcare professionals for most of the quarter, while those in the U.S. were unable to meet in-person with healthcare professionals for nearly all of the quarter. At this time, no U.S. sales force colleagues are meeting in-person with healthcare professionals due to COVID-19-related safety concerns. We are actively reviewing and assessing epidemiological data and our colleagues remain ready to resume in-person engagements with healthcare professionals on a location-by-location basis as soon as it is safe to do so.</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the lower number of in-person meetings with prescribers and restrictions on patient movements due to government-mandated work-from-home or shelter-in-place policies, the rate of new prescriptions for certain products and of vaccination rates for most vaccines slowed in certain markets, which negatively impacted our second quarter 2020 financial results. These declines were partially offset by certain of our medicines and vaccines that saw increased demand in certain markets compared to the prior-year quarter, including Prevenar 13 for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">streptococcus pneumoniae</span><span style="font-family:inherit;font-size:10pt;"> in adults in international markets as well as certain sterile injectable products utilized in the intubation and ongoing treatment of mechanically-ventilated COVID-19 patients.</span></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the pandemic, we have adapted our promotional platform by amplifying our existing digital capabilities to reach healthcare professionals and customers to provide critical education and information, including increasing the scale of our remote engagement. All of our U.S. sales representatives are digitally enabled, and we are currently conducting virtual detailing and remote sampling, which has proven to be an efficient way to interact with healthcare providers during the crisis. </span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Our Manufacturing and Supply Chain.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">Our manufacturing and supply chain professionals have been working continuously in an effort to ensure continued patient access to our medicines and vaccines. Across our plant network, we have implemented our preparedness plan to control site operations. To date, we have not seen a significant disruption in our supply chain, and all of our manufacturing sites around the world have continued to operate at or near normal levels. So far, we have been able to mitigate distribution issues that have arisen, including by using newly available excess capacity in commercial airplanes to transport inventory. In addition, we have taken steps to scale up manufacturing operations at risk to accelerate our ability to supply a potential novel treatment or potential vaccine for COVID-19 if we receive regulatory approval. We are also committed to offering any excess manufacturing capacity and to potentially shifting production in order to support others&#8217; efforts to manufacture any lifesaving breakthroughs that may be developed to combat COVID-19.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Our Clinical Trials</span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">.</span><span style="font-family:inherit;font-size:10pt;"> After a brief pause to the recruitment portion of certain ongoing clinical studies and a delay to most new study starts, in late-April 2020 we restarted recruitment across the development portfolio, including new study starts. We continue to work closely with clinical trial sites to understand their needs and are performing remote monitoring, where appropriate, to oversee study conduct. In addition, processes to enable tele-health and home healthcare are being utilized where appropriate to continue the data collection process and support patient safety.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Our Products.</span><span style="font-family:inherit;font-size:10pt;"> Our portfolio of products comprises medicines and vaccines which may experience varying impacts from the COVID-19 pandemic. Some of our products, such as Eliquis and Ibrance, are medically necessary but also more reliant on maintenance therapy with continuing patients in addition to new patients. Certain other products, such as Vyndaqel/Vyndamax, Chantix/Champix and products used in certain elective surgeries, are more reliant on new patient starts and typically require doctor visits, including wellness visits. Other medicines have been identified as medically necessary for treatment in the pandemic, such as certain of our Hospital sterile injectable products. A large proportion of our portfolio comprises oral or self-injected medicines that do not require a visit to an infusion center or a physician&#8217;s office for administration, but vaccines and physician-administered medicines which do require office visits were impacted by COVID-19-related mobility restrictions or limitations during the second quarter of 2020. Specialty pharmacy channels, from which we derive a majority of our revenue, enable direct delivery of these specialty medicines to patients.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Our Financial Condition and Access to Capital Markets.</span><span style="font-family:inherit;font-size:10pt;"> Due to our significant operating cash flows, as well as our financial assets, access to capital markets and revolving credit agreements, we believe we have, and will maintain, the ability to meet liquidity needs for the foreseeable future.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We will continue to pursue efforts to maintain the continuity of our operations while monitoring for new developments related to the COVID-19 pandemic, which are unpredictable. Future COVID-19 developments could result in additional favorable or unfavorable impacts on our business, operations or financial condition and results. If we experience significant disruption in our manufacturing or supply chains or significant disruptions in clinical trials or other operations, or if demand for our products is </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">53</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ultimately significantly reduced as a result of the COVID-19 pandemic, we could experience a material adverse impact on our business, operations and financial condition and results. For additional information, please also see Part II, Item 1A, &#8220;Risk Factors&#8221; of this Quarterly Report on Form 10-Q. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For other global economic environment matters impacting our business, see the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;The Global Economic Environment&#8221;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">section of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;text-align:center;"> Financial Report</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These and other industry-wide factors that may affect our businesses should be considered along with information presented in the &#8220;Forward-Looking Information and Factors That May Affect Future Results&#8221; section of this MD&amp;A and in Part I, Item 1A, &#8220;Risk Factors&#8221; of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> Form 10-K and Part II, Item 1A, &#8220;Risk Factors&#8221; of this Quarterly Report on Form 10-Q.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Our Strategy</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">We believe that our medicines provide significant value for both healthcare providers and patients, not only from the improved treatment of diseases but also from a reduction in other healthcare costs, such as emergency room or hospitalization costs, as well as improvements in health, wellness and productivity. We continue to actively engage in dialogues about the value of our medicines and how we can best work with patients, physicians and payers to prevent and treat disease and improve outcomes. We continue to work within the current legal and pricing structures, as well as continue to review our pricing arrangements and contracting methods with payers, to maximize patient access and minimize any adverse impact on our revenues. We remain firmly committed to fulfilling our Company&#8217;s purpose: </span><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Breakthroughs that change patients&#8217; lives</span><span style="font-family:Times New Roman;font-size:10pt;">. By doing so, we expect to create value for the patients we serve and for our colleagues and shareholders.</span><span style="font-family:inherit;font-size:10pt;"> For a more comprehensive discussion of our strategy including additional discussion of certain items below, see the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Strategy&#8221;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">section of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;text-align:center;"> Financial Report</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Organizing for Growth</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe we have one of the strongest pipelines we have had in over a decade, and believe we are well positioned for future growth. Additional patent expiries will continue over several years, and we expect the impact of reduced revenues due to patent expiries will be significant in 2020, then moderating downward to a much lower level from 2021 through 2025. This confluence of events has provided us an opportunity to look at and refine how we organize our business to best achieve sustainable growth and to deliver our medicines and vaccines to the maximum number of people who need them.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the beginning of our fiscal year 2019, we began to manage our commercial operations through a new global structure consisting of three businesses, each led by a single manager&#8212;Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and, through July 31, 2019, Pfizer&#8217;s Consumer Healthcare business. We designed this new global structure to take advantage of new growth opportunities driven by the evolving and unique dynamics of relevant markets. For additional information about each business, see Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 14A. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Segment, Geographic and Other Revenue Information</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Segment Information. </span><span style="font-family:inherit;font-size:10pt;">As part of our Organizing for Growth initiative, we also reorganized our R&amp;D operations, as explained in the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Strategy&#8211;&#8211;Organizing for Growth&#8221; section of our 2019 Financial Report.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subsequent to the re-alignment of our commercial operations in 2019, on July 29, 2019, we announced that we entered into a definitive agreement to combine Upjohn with Mylan, creating a new global pharmaceutical company, Viatris. For additional information, see the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Business Development Initiatives&#8221; section above in this MD&amp;A. We believe the new company will transform and accelerate Upjohn&#8217;s and Mylan&#8217;s ability to serve patients&#8217; needs and expand their capabilities across more than 165 markets. The combination will drive a sustainable, diverse and differentiated portfolio of prescription medicines, complex generics, over-the-counter products and biosimilars supported by commercial and regulatory expertise, established infrastructure, R&amp;D capabilities and manufacturing and supply chain excellence.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As we prepare for expected growth, we are focused on creating a simpler, more efficient organization by streamlining structures, processes and governance within each business and the functions that support them. As our innovative pipeline matures based on anticipated progression of current trials and the initiation of new pivotal trials, including new trials for medicines we may acquire or in-license, we will need to increase our R&amp;D investments. In addition, as our pipeline potentially delivers new commercialization opportunities, we will need to increase our investments in new-market-creation activities. We have initiated an enterprise-wide digital effort to accelerate drug development, enhance experiences (patient and physician) and access and leverage technology and robotics to simplify and automate our processes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Transforming to a More Focused Company</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">With the formation of the GSK Consumer Healthcare joint venture and the anticipated combination of Upjohn, our global, primarily off-patent branded and generics business, with Mylan, Pfizer is transforming itself into a more focused, global leader in science-based innovative medicines.&#160;As a result, we began, in the fourth quarter of 2019, to identify and undertake efforts to ensure our cost base aligns appropriately with our Biopharmaceutical revenue base, which is expected to be 20% less (based on </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">54</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the midpoint of the range for 2020 New Pfizer revenue guidance, compared to 2019 Total Company reported revenue) as a result of both the completed GSK Consumer Healthcare and expected Upjohn transactions. While certain direct costs have transferred or will transfer to the GSK Consumer Healthcare joint venture and to the Upjohn entities, there are indirect costs which are not expected to transfer. In addition, we are taking steps to restructure our organizations to appropriately support and drive the purpose of the three core functions of our focused innovative medicines business: R&amp;D, Manufacturing and Commercial.</span><span style="font-family:inherit;font-size:10pt;"> For additional information, see the &#8220;Costs and Expenses&#8211;&#8211;</span><span style="font-weight:normal;text-decoration:none;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:inherit;font-size:10pt;">&#8221; section of this MD&amp;A.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Our Financial Guidance for </span><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-align:center;text-decoration:underline;">2020</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">July&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;">, we increased our 2020 financial guidance for Total Company and New Pfizer revenues and Adjusted diluted EPS and reaffirmed all other financial guidance components. </span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The guidance reflects management&#8217;s current expectations for operational performance, foreign exchange rates as well as various COVID-19-related uncertainties, primarily those related to the severity, duration and global macroeconomic impact of the pandemic. Key guidance assumptions regarding these uncertainties broadly reflect an ongoing, gradual global recovery from the first half of 2020 macroeconomic and healthcare impacts of the COVID-19 pandemic. Specific COVID-19-related assumptions include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patient visits with physicians, vaccination rates and the number of elective surgical procedures will gradually increase from second-quarter 2020 levels, beginning in the third quarter of 2020;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">New-to-brand prescription trends for certain key products will gradually improve from second-quarter 2020 levels, beginning in the third quarter of 2020;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gradual improvement in access to U.S. healthcare professionals for sales force colleagues;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Clinical trial enrollment, including new study starts, continues throughout the remainder of 2020;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pfizer&#8217;s manufacturing and supply chain activities continue to not be materially disrupted; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pfizer&#8217;s investments in potential treatments and a potential vaccine for COVID-19 continue throughout 2020.</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">However, updated financial guidance does not include any revenues from a potential COVID-19 vaccine.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Based on results to date and these assumptions for the remainder of the year, Pfizer increased its 2020 financial guidance for Total Company revenues and Adjusted diluted EPS and reaffirmed all other Total Company financial guidance components.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.1219512195122%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pfizer&#8217;s updated 2020 financial guidance is presented below</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a), (b)</sup></span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$48.6 to $50.6 billion</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">(previously $48.5 to $50.5 billion)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Adjusted cost of sales as a percentage of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">19.5% to 20.5%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Adjusted selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$11.5 to $12.5 billion</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Adjusted research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$8.6 to $9.0 billion</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Adjusted other (income)/deductions</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Approximately $800 million of income</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Effective tax rate on adjusted income</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Approximately 15.0%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Adjusted diluted EPS</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$2.85 to $2.95</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">(previously $2.82 to $2.92)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> financial guidance reflects the following:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Financial guidance for Total Company reflects a full-year 2020 contribution from Biopharma and Upjohn, the current construct of the company, and excludes any impact from the pending Upjohn combination with Mylan.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Does not assume the completion of any business development transactions&#160;not completed as of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, including any one-time upfront payments associated with such transactions.</span><span style="font-family:inherit;font-size:8pt;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Includes Pfizer&#8217;s pro rata share of the GSK Consumer Healthcare joint venture anticipated earnings, which is recorded in Adjusted other (income)/deductions on a one-quarter lag. Therefore, 2020 financial guidance for Adjusted other (income)/deductions and Adjusted diluted EPS reflects Pfizer&#8217;s share of the joint venture&#8217;s earnings that were generated in the fourth quarter of 2019 and in the first quarter of 2020 (recorded by Pfizer in the first six months of 2020) as well as Pfizer&#8217;s share of the joint venture&#8217;s projected earnings during the second and third quarters of 2020.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Reflects an anticipated negative revenue impact of </span><span style="font-family:inherit;font-size:8pt;">$2.4 billion</span><span style="font-family:inherit;font-size:8pt;"> due to recent and expected generic and biosimilar competition for certain products that have recently lost or are anticipated to soon lose patent protection.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exchange rates assumed are a blend of actual exchange rates in effect through second-quarter 2020 and mid-July 2020 rates for the remainder of the year. Financial guidance reflects the anticipated unfavorable impact of approximately </span><span style="font-family:inherit;font-size:8pt;">$0.6 billion</span><span style="font-family:inherit;font-size:8pt;"> on revenues and approximately </span><span style="font-family:inherit;font-size:8pt;">$0.05</span><span style="font-family:inherit;font-size:8pt;"> on Adjusted diluted EPS as a result of changes in foreign exchange rates relative to the U.S. dollar compared to foreign exchange rates from 2019. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Guidance for adjusted diluted EPS assumes diluted weighted-average shares outstanding of approximately </span><span style="font-family:inherit;font-size:8pt;">5.6 billion</span><span style="font-family:inherit;font-size:8pt;"> shares, which assumes no share repurchases in 2020.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For an understanding of Adjusted income and its components and Adjusted diluted EPS (all of which are non-GAAP financial measures), see the &#8220;Non-GAAP Financial Measure (Adjusted Income)&#8221; section of this MD&amp;A.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">55</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning in 2020, Upjohn began managing Pfizer&#8217;s Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan). As a result, revenues and expenses associated with Meridian and Mylan-Japan are reported in Pfizer&#8217;s Upjohn business beginning in the first quarter of 2020.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pfizer, Upjohn and Mylan agreed (simultaneous with their entry into the transaction agreements governing the proposed combination of Upjohn and Mylan) to review and negotiate in good faith a potential transfer of Pfizer&#8217;s Meridian Medical Technologies business (the Meridian Business) to Upjohn, such that it would be sold to Mylan in the pending transaction for the Upjohn business. The Meridian Business supplies EpiPen Auto-Injectors to Mylan under a supply agreement expiring December 31, 2020 (the EpiPen Supply Agreement). Instead of entering into an agreement to transfer the Meridian Business to Mylan, the parties have agreed to extend the EpiPen Supply Agreement for an additional four-year period through December 31, 2024, with an option for Mylan to further extend the term for an additional one-year period thereafter.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pfizer and Mylan have also reached a preliminary agreement on the general terms under which Pfizer would transfer certain Pfizer assets that currently form part of the Mylan-Japan collaboration to Mylan or, following the proposed combination of Upjohn and Mylan, to Viatris. Any such proposed transaction would be subject to the finalization and execution of a definitive agreement that would contain customary closing conditions, including but not limited to, receipt of any necessary regulatory approvals</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">. </span><span style="font-family:inherit;font-size:10pt;">There can be no assurance that any agreement or transaction will result from these negotiations, and if the parties are unsuccessful in their efforts to negotiate the terms of such potential transactions, the Pfizer assets that currently form part of the Mylan-Japan collaboration will remain with Pfizer.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">2020 Financial Guidance for New Pfizer</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.34146341463415%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">2020 updated financial guidance for New Pfizer is presented below</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a), (b)</sup></span><span style="font-family:inherit;font-size:9.5pt;">:</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Revenues</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$40.8 to $42.4 billion</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">(previously $40.7 to $42.3 billion)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Adjusted IBT Margin</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Approximately 37.0%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Adjusted Diluted EPS</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$2.28 to $2.38</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">(previously $2.25 to $2.35)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Operating Cash Flow</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$10.0 to $11.0 billion</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The financial guidance for New Pfizer reflects a full-year 2020 view of the company assuming the pending Upjohn combination with Mylan was completed at the beginning of 2020 and reflects contributions from the Biopharma business as it is presently being managed, which excludes contributions from Pfizer&#8217;s Meridian subsidiary and the Pfizer-Mylan strategic collaboration in Japan (Mylan-Japan). Pfizer&#8217;s Meridian subsidiary and Mylan-Japan were managed by Pfizer&#8217;s Biopharma business in 2019, but were moved to Upjohn in 2020. Financial guidance for New Pfizer also includes the full-year effect of the following items that assume the completion of the Upjohn combination with Mylan: (i) $12 billion of net proceeds from Upjohn to be retained by Pfizer, which Pfizer will use to repay its own existing indebtedness; and (ii) other transaction-related items, such as income from transition services agreements between Pfizer and Viatris. In addition, 2020 financial guidance for New Pfizer Adjusted IBT Margin and Adjusted diluted EPS reflects Pfizer&#8217;s share of the GSK Consumer Healthcare joint venture&#8217;s earnings that were generated in the fourth quarter of 2019 and in the first quarter of 2020 (recorded by Pfizer in the first six months of 2020), as well as Pfizer&#8217;s share of the GSK Consumer Healthcare joint venture&#8217;s projected earnings during the second and third quarters of 2020.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For additional information regarding an understanding of Adjusted income and its components and Adjusted diluted EPS (all of which are non-GAAP financial measures), see the &#8220;Non-GAAP Financial Measure (Adjusted Income)&#8221; section of this MD&amp;A.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Adjusted income before tax margin (Adjusted IBT margin) is defined as revenue less the sum of Adjusted cost of sales, Adjusted SI&amp;A expenses, Adjusted R&amp;D expenses, Adjusted amortization of intangible assets and Adjusted other (income)/deductions as a percentage of revenue. Adjusted IBT margin is presented because management believes this performance measure supplements investors&#8217; and other readers&#8217; understanding and assessment of the financial performance of New Pfizer. Adjusted IBT margin is not, and should not be viewed as, a substitute for U.S. GAAP income before tax margin.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Includes a </span><span style="font-family:inherit;font-size:8pt;">$1.25 billion</span><span style="font-family:inherit;font-size:8pt;"> voluntary contribution to the U.S. qualified pension plans, planned for the second half of 2020.</span></div></td></tr></table><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">2020 Financial Guidance for Upjohn</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.34146341463415%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">2020 reaffirmed financial guidance for Upjohn is presented below</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span><span style="font-family:inherit;font-size:9.5pt;">:</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Revenues</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$8.0 to $8.5 billion</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Adjusted EBITDA</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$3.8 to $4.2 billion</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Financial guidance for Upjohn reflects a full-year 2020 contribution from the Upjohn business as it is presently being managed, which includes contributions from Pfizer&#8217;s Meridian subsidiary and the Pfizer-Mylan strategic collaboration in Japan (Mylan-Japan). Pfizer&#8217;s Meridian subsidiary and Mylan-Japan were managed by Pfizer&#8217;s Biopharma business in 2019 but were moved to Upjohn in 2020.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Adjusted Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA) is defined as reported U.S. GAAP net income, and its components, adjusted for interest expense, provision for taxes on income and depreciation and amortization, further adjusted to exclude purchase accounting adjustments, acquisition-related costs, discontinued operations and certain significant items (some of which may recur, such as gains on the completion of joint venture transactions, restructuring charges, legal charges or net gains and losses on equity securities, but which management does not believe are reflective of ongoing core operations). Adjusted EBITDA is presented because management believes this performance measure supplements investors&#8217; and other readers&#8217; understanding and assessment of the financial performance of Upjohn. Adjusted EBITDA as defined is not a measurement of financial performance under GAAP, and should not be considered as an alternative to net income or cash flow from operations determined in accordance with GAAP.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">56</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pfizer does not provide guidance for GAAP Reported financial measures (other than revenues) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP Reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of pending litigation, unusual gains and losses, acquisition-related expenses, gains and losses from equity securities and potential future asset impairments without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP Reported results for the guidance period.</span><span style="font-family:Arial;font-size:8pt;"> </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For information about our actual costs and anticipated costs and cost savings associated with our Transforming to a More Focused Company program, see the &#8220;Costs and Expenses&#8211;&#8211;Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives&#8221; section of this MD&amp;A and Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 3</span><span style="font-family:inherit;font-size:10pt;">.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> financial guidance is subject to a number of assumptions, as well as factors and uncertainties as described in the &#8220;Our Operating Environment&#8221;, &#8220;The Global Economic Environment&#8221;, &#8220;Our Strategy&#8221; and &#8220;Forward-Looking Information and Factors That May Affect Future Results&#8221; sections of this MD&amp;A; Part I, Item 1A, &#8220;Risk Factors&#8221; of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> Form 10-K, and Part II, Item 1A, &#8220;Risk Factors&#8221; of this Quarterly Report on Form 10-Q.</span></div><div><a id="s5F981A9D353655258DC4E106299EB43C"></a></div><div style="line-height:120%;padding-top:10px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">SIGNIFICANT ACCOUNTING POLICIES AND APPLICATION OF CRITICAL ACCOUNTING ESTIMATES AND ASSUMPTIONS</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For a description of our significant accounting policies, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1. Basis of Presentation and Significant Accounting Policies </span><span style="font-family:inherit;font-size:10pt;">in our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> Financial Report</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">. </span><span style="font-family:inherit;font-size:10pt;">Of these policies, the following are considered critical to an understanding of our consolidated financial statements as they require the application of the most subjective and the most complex judgments: Acquisitions (Note 1D); Fair Value (Note 1E); Revenues (Note 1G); Asset Impairments (Note 1L); Tax Assets and Liabilities and Income Tax Contingencies (Note 1P); Pension and Postretirement Benefit Plans (Note 1Q); and Legal and Environmental Contingencies (Note 1R).</span></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For a discussion about the critical accounting estimates and assumptions impacting our consolidated financial statements, see the &#8220;Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions&#8221; section of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> Financial Report. See also Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1C. Basis of Presentation and Significant Accounting Policies: Estimates and Assumptions</span><span style="font-family:inherit;font-size:10pt;"> in our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> Financial Report for a discussion about the risks associated with estimates and assumptions.</span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For a discussion of recently adopted accounting standards and significant accounting policies, see Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1B. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Adoption of New Accounting Standards in 2020 </span><span style="font-family:inherit;font-size:10pt;">and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1C. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Revenues and Trade Accounts Receivable.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">57</span></div></div><hr style="page-break-after:always"></hr><div><a id="s6DA66313DC9B5DAD879A4DFA5491228D"></a></div><div><br/></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">ANALYSIS OF THE CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.24561403508771%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of the condensed consolidated statements of income:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">11,801</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">13,264</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(11</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">23,829</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">26,382</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(10</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,281</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,576</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(11</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,658</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,009</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">19.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">19.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">19.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">19.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, informational and administrative expenses</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,030</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,511</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(14</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,903</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6,850</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(14</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">25.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">26.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">24.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">26.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development expenses</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,132</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,842</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">16</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,856</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,544</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">18.1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">13.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">16.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">13.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">905</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,184</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(24</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,790</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,367</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(24</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">7.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">7.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">362</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(115</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">431</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(69</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3.1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(0.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(0.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(862</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">126</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(641</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">218</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income from continuing operations before provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,953</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,141</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">7,838</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8,463</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">33.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">31.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">32.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">32.1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">519</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(915</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">993</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(481</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Effective tax rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">13.1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(22.1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">12.7</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(5.7</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,434</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,056</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(32</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6,845</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8,945</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(23</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">29.1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">38.1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">28.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">33.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income before allocation to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,434</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,056</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(32</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6,845</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8,945</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(23</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">29.1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">38.1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">28.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">33.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Less: Net income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(19</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">17</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">15</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income attributable to Pfizer Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,426</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,046</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(32</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6,828</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8,929</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(24</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">29.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">38.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">28.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">33.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Earnings per common share&#8211;&#8211;basic</span><span style="font-family:inherit;font-size:9pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.62</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.91</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(32</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.23</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.59</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(23</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.62</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.91</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(32</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.23</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.59</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(23</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Earnings per common share&#8211;&#8211;diluted</span><span style="font-family:inherit;font-size:9pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.61</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.89</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(31</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.22</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.56</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(22</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.61</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.89</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(31</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.22</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.56</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(22</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:1px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">* Indicates calculation not meaningful or result is equal to or greater than 100%.</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Excludes amortization of intangible assets, except as disclosed in Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">58</span></div></div><hr style="page-break-after:always"></hr><div><a id="s0736475C989052698F67D0638F4F6010"></a></div><div><br/></div><div style="line-height:120%;padding-top:10px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Revenues by Operating Segment and Geography</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following graphs show revenues by operating segment and geography:</span></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Second Quarter</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><img src="chart-279c9b6159565ded8a4.jpg" alt="chart-279c9b6159565ded8a4.jpg" style="height:257px;width:337px;"></img><span style="font-family:inherit;font-size:10pt;">  </span><img src="chart-27876a64791f5b87818.jpg" alt="chart-27876a64791f5b87818.jpg" style="height:257px;width:337px;"></img></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-align:right;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:297px;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="3"></td></tr><tr><td style="width:182px;"></td><td style="width:5px;"></td><td style="width:109px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 Revenues by Geography</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">% of Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">46%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">54%</span></div></td></tr></table></div></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:297px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:182px;"></td><td style="width:5px;"></td><td style="width:109px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 Revenues by Geography</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">% of Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">48%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">52%</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></div></div><div style="line-height:120%;padding-top:13px;text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">First </span><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Six Months</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><img src="chart-e6285fd93bdf59a14df.jpg" alt="chart-e6285fd93bdf59a14df.jpg" style="height:257px;width:337px;"></img><span style="font-family:inherit;font-size:10pt;">  </span><img src="chart-69c730ef7bbe3f2b2ca.jpg" alt="chart-69c730ef7bbe3f2b2ca.jpg" style="height:257px;width:337px;"></img></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:297px;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="3"></td></tr><tr><td style="width:182px;"></td><td style="width:5px;"></td><td style="width:109px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 Revenues by Geography</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">% of Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">46%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">54%</span></div></td></tr></table></div></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:297px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:182px;"></td><td style="width:5px;"></td><td style="width:109px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 Revenues by Geography</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">% of Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">47%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">53%</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">59</span></div></div><hr style="page-break-after:always"></hr><div><a id="sDBF8E89E0F8E5067BC86E6C3AB003329"></a></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="34"></td></tr><tr><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td colspan="34" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables provide worldwide revenues by operating segment and geography:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="32" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Arial;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Worldwide</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">World-wide</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Inter-national</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change in Revenues</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Operating Segments</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span><span style="font-family:inherit;font-size:9.5pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Biopharma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">9,795</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">9,432</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">5,045</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">4,667</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">4,750</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">4,765</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">2,006</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">2,970</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">357</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,245</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,648</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,725</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(32</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(71</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Consumer Healthcare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">862</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">423</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">439</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(100</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(100</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(100</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">11,801</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">13,264</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">5,402</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">6,335</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">6,399</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">6,929</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(11</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(15</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td colspan="34" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="32" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Worldwide</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">World-wide</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Inter-national</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change in Revenues</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Operating Segments</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span><span style="font-family:inherit;font-size:9.5pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Biopharma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">19,802</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">18,477</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">10,258</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">9,128</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">9,544</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">9,349</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">12</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">4,027</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">6,184</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">795</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">2,518</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">3,232</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">3,666</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(35</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(68</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(12</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Consumer Healthcare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,721</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">864</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">857</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(100</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(100</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(100</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">23,829</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">26,382</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">11,053</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">12,510</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">12,776</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">13,872</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(10</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(12</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For additional information about each operating segment, see the &#8220;Analysis of Operating Segment Information&#8221; section of this MD&amp;A and Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 14A. </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Segment, Geographic and Other Revenue Information</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">: Segment Information.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">60</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Second Quarter</span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;text-decoration:underline;">2020</span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;"> vs. </span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Second Quarter</span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;text-decoration:underline;">2019</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:66%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following provides an analysis of the worldwide change in revenues by geographic areas in the second quarter of 2020:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended June 28, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Worldwide</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">International</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Operational growth/(decline):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Continued growth from certain key brands</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">351</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">192</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">159</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Higher revenues for the rare disease business driven by the U.S. launches of Vyndaqel in May 2019 and Vyndamax in September 2019 for ATTR-CM; and in international markets, primarily driven by the March 2019 launch of the ATTR-CM indication in Japan and the February 2020 approval of the ATTR-CM indication in the EU</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">175</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">128</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">47</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Higher revenues for Inlyta, primarily in the U.S., driven by increased demand resulting from the second quarter of 2019 U.S. FDA approvals for the combinations of certain immune checkpoint inhibitors plus Inlyta for the first-line treatment of patients with advanced RCC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">93</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">72</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">21</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Higher revenues for Biosimilars, primarily in the U.S., driven by strong volume performance from Retacrit and new product launches </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">78</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">55</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">23</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Higher revenues for Xtandi primarily driven by continued strong demand in the metastatic and non-metastatic castration-resistant prostate cancer indications as well as the metastatic (mCSPC) castration-sensitive prostate cancer indication, which was approved in the U.S. in December 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">64</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">64</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Growth in revenues for Lipitor and Norvasc, reflecting significant revenue declines in the prior-year period associated with the VBP program in China, which was initially implemented in certain cities in March 2019, and expanded nationwide beginning in December 2019, resulting in significant volume and price erosion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">55</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">10</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">45</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Lower revenues for Consumer Healthcare reflecting the July 31, 2019 completion of the Consumer Healthcare joint venture transaction with GSK. As a result, for the second quarter of 2019, revenues reflect three months of Consumer Healthcare segment operations, while for the second quarter of 2020, there is no contribution from the Consumer Healthcare business</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(862</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(423</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(439</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Lower worldwide revenues for Lyrica, primarily in the U.S., reflecting the expected significantly lower volumes associated with multi-source generic competition that began in the U.S. in July 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(826</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(784</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(42</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Lower revenues for Enbrel internationally, primarily reflecting continued biosimilar competition in most developed Europe markets, as well as in Japan and Brazil, all of which is expected to continue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(66</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(66</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Decline in revenues for Revatio driven by lower U.S. Oral Suspension formulation sales and pricing pressures due to multi-source generic competition</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(34</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(33</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Decline in Prevnar 13/Prevenar 13 revenues primarily in the U.S., reflecting the expected unfavorable impact of disruptions to wellness visits for pediatric and adult patients due to COVID-19-related mobility restrictions or limitations, partially offset by the favorable impact of timing associated with government purchases for the pediatric indication, compared to the prior-year period. The decline in the U.S. was partially offset by growth in international markets primarily reflecting significantly increased adult uptake in Germany and certain other markets resulting from greater vaccine awareness for respiratory illnesses, including specifically pneumococcal disease, due to the COVID-19 pandemic, as well as continued strong pediatric uptake in China</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(28</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(132</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">103</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Other operational factors, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(185</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(82</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(103</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Operational growth/(decline), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(1,186</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(933</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(253</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Unfavorable impact of foreign exchange</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(277</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(277</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:9.5pt;">&#160;decrease</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(1,463</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(933</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(530</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-size:8pt;">Certain key brands represent Ibrance, Eliquis and Xeljanz.</span><span style="font-family:inherit;font-size:8pt;"> See the &#8220;Analysis of the Condensed Consolidated Statements of Income&#8211;&#8211;Revenues&#8211;&#8211;Selected Product Discussion&#8221; section of this MD&amp;A for product analysis information.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues for the </span><span style="font-family:inherit;font-size:10pt;">second quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> included an estimated net </span><span style="font-family:inherit;font-size:10pt;">unfavorable impact of approximately $500 million, or 4%, due to COVID-19, primarily reflecting unfavorable disruptions to wellness visits for pediatric and adult patients in the U.S. and lower demand for certain products in China, partially offset by increased U.S. demand for certain sterile injectable products as well as increased adult demand for Prevenar 13 in certain international markets.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging markets revenues </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">$303 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">10%</span><span style="font-family:inherit;font-size:10pt;">, in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">$2.8 billion</span><span style="font-family:inherit;font-size:10pt;"> from </span><span style="font-family:inherit;font-size:10pt;">$3.1 billion</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, reflecting an operational </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$95 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">3%</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact from foreign exchange of approximately </span><span style="font-family:inherit;font-size:10pt;">7%</span><span style="font-family:inherit;font-size:10pt;">. The operational </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in emerging markets was primarily driven by lower revenues for </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">61</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consumer Healthcare reflecting the July 31, 2019 completion of the Consumer Healthcare joint venture transaction with GSK and Sulperazon, in our Biopharma segment, partially offset primarily by growth from Prevenar 13 and Eliquis in our Biopharma segment and Lipitor and Norvasc in our Upjohn segment.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Revenues&#8211;&#8211;First </span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Six Months</span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;"> of </span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2020</span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;"> vs. First </span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Six Months</span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;"> of </span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2019</span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;"> </span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following provides an analysis of the change in worldwide revenues by geographic areas in the first six months of 2020:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended June 28, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Worldwide</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">International</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Operational growth/(decline):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Continued growth from certain key brands</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">812</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">494</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">318</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Higher revenues for the rare disease business driven by the U.S. launches of Vyndaqel in May 2019 and Vyndamax in September 2019 for ATTR-CM; and in international markets, primarily driven by the March 2019 launch of the ATTR-CM indication in Japan and the February 2020 approval of the ATTR-CM indication in the EU</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">353</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">268</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">85</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Higher revenues for the Hospital business in the U.S., primarily driven by increased demand for certain sterile injectable products utilized in the intubation and ongoing treatment of mechanically-ventilated COVID-19 patients as well as continued growth from Panzyga following its November 2018 U.S. launch</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">212</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">207</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Higher revenues for Inlyta, primarily in the U.S., driven by increased demand resulting from the second quarter of 2019 U.S. FDA approvals for the combinations of certain immune checkpoint inhibitors plus Inlyta for the first-line treatment of patients with advanced RCC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">191</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">155</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">35</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Higher revenues for Biosimilars, primarily in the U.S., driven by strong volume performance from Retacrit, new product launches and steady volume and share growth in the U.S. for Inflectra, across hospital channels, clinics and alternate sites of care </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">190</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">149</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">41</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Higher revenues for Xtandi primarily driven by continued strong demand in the metastatic and non-metastatic castration-resistant prostate cancer indications as well as the metastatic (mCSPC) castration-sensitive prostate cancer indication, which was approved in the U.S. in December 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">106</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">106</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Lower revenues for Consumer Healthcare reflecting the July 31, 2019 completion of the Consumer Healthcare joint venture transaction with GSK. As a result, for the first six months of 2019, revenues reflect six months of Consumer Healthcare segment operations, while for the first six months of 2020, there is no contribution from the Consumer Healthcare business</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(1,721</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(864</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(857</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Lower worldwide revenues for Lyrica, primarily in the U.S., reflecting the expected significantly lower volumes associated with multi-source generic competition that began in the U.S. in July 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(1,655</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(1,592</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(63</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Declines in revenues for Lipitor and Norvasc, primarily resulting from the VBP program in China, which was initially implemented in certain cities in March 2019, and expanded nationwide beginning in December 2019, resulting in significant volume and price erosion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(254</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">12</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(266</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Lower revenues for Enbrel internationally, primarily reflecting continued biosimilar competition in most developed Europe markets, as well as in Brazil and Japan, all of which is expected to continue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(159</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(159</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Decline in revenues for Revatio driven by lower U.S. Oral Suspension formulation sales and pricing pressures due to multi-source generic competition</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(58</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(55</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Decline in Prevnar 13/Prevenar 13 revenues primarily in the U.S., reflecting the expected unfavorable impact of disruptions to wellness visits for pediatric and adult patients due to COVID-19-related mobility restrictions or limitations, partially offset by the favorable impact of timing associated with government purchases for the pediatric indication, compared to the prior-year period. The decline in the U.S. was partially offset by growth in international markets primarily reflecting significantly increased adult uptake in Germany and certain other markets resulting from greater vaccine awareness for respiratory illnesses, including specifically pneumococcal disease, due to the COVID-19 pandemic, as well as continued strong pediatric uptake in China</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(47</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(215</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">169</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Other operational factors, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(113</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(121</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Operational growth/(decline), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(2,141</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(1,457</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(684</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Unfavorable impact of foreign exchange</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(411</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(411</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:9.5pt;">&#160;decrease</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(2,552</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(1,457</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(1,096</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">62</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-size:8pt;">Certain key brands represent Ibrance, Eliquis and Xeljanz.</span><span style="font-family:inherit;font-size:8pt;"> See the &#8220;Analysis of the Condensed Consolidated Statements of Income&#8211;&#8211;Revenues&#8211;&#8211;Selected Product Discussion&#8221; section of this MD&amp;A for product analysis information.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues for </span><span style="font-family:inherit;font-size:10pt;">the first six months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">included an estimated net unfavorable impact of approximately $350 million, or 1%, due to COVID-19, primarily reflecting unfavorable disruptions to wellness visits for pediatric and adult patients in the U.S. and lower demand for certain products in China, partially offset by increased U.S. demand for certain sterile injectable products as well as increased adult demand for Prevenar 13 in certain international markets.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging markets revenues </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">$624 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">10%</span><span style="font-family:inherit;font-size:10pt;">, in the first </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">$5.8 billion</span><span style="font-family:inherit;font-size:10pt;"> from </span><span style="font-family:inherit;font-size:10pt;">$6.4 billion</span><span style="font-family:inherit;font-size:10pt;"> in the first </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, reflecting an operational </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$328 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">5%</span><span style="font-family:inherit;font-size:10pt;">. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact of approximately </span><span style="font-family:inherit;font-size:10pt;">5%</span><span style="font-family:inherit;font-size:10pt;"> on emerging markets revenues. The operational </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in emerging markets was primarily driven by lower revenues for Consumer Healthcare reflecting the July 31, 2019 completion of the Consumer Healthcare joint venture transaction with GSK, Lipitor and Norvasc in our Upjohn segment and Sulperazon in our Biopharma segment, partially offset by growth from Prevenar 13, Eliquis, certain anti-infective products, primarily Zavicefta and Zithromax, Ibrance and Xalkori in our Biopharma segment.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Revenue Deductions</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on gross sales for a reporting period. Historically, our adjustments of estimates, to reflect actual results or updated expectations, have not been material to our overall business. On a quarterly basis, our adjustments of estimates to reflect actual results generally have been less than 1% of revenues, and have resulted in either a net increase or a net decrease in revenues. Product-specific rebates, however, can have a significant impact on year-over-year individual product growth trends. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides information about revenue deductions:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare rebates</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">164</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">351</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">359</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">785</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid and related state program rebates</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">317</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">459</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">634</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,028</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Performance-based contract rebates</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a), (b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">972</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">972</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,882</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,861</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chargebacks</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,368</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,368</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,787</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,924</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales allowances</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,236</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,454</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,666</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,814</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales returns and cash discounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">271</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">477</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">542</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">804</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,329</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,082</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,871</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,216</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"> </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Rebates are product-specific and, therefore, for any given year are impacted by the mix of products sold.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Performance-based contract rebates include contract rebates with MCOs within the U.S., including health maintenance organizations and PBMs, who receive rebates based on the achievement of contracted performance terms and claims under these contracts. Outside the U.S., performance-based contract rebates include rebates to wholesalers/distributors based on achievement of contracted performance for specific products or sales milestones.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Chargebacks primarily represent reimbursements to U.S. wholesalers for honoring contracted prices to third parties.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Sales allowances primarily represent price reductions that are contractual or legislatively mandated outside the U.S., discounts and distribution fees.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the three months ended </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, associated with the following segments: Biopharma (</span><span style="font-family:inherit;font-size:8pt;">$3.2 billion</span><span style="font-family:inherit;font-size:8pt;">) and Upjohn (</span><span style="font-family:inherit;font-size:8pt;">$1.1 billion</span><span style="font-family:inherit;font-size:8pt;">). For the three months ended </span><span style="font-family:inherit;font-size:8pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:8pt;">, associated with the following segments: Biopharma (</span><span style="font-family:inherit;font-size:8pt;">$3.0 billion</span><span style="font-family:inherit;font-size:8pt;">), Upjohn (</span><span style="font-family:inherit;font-size:8pt;">$1.9 billion</span><span style="font-family:inherit;font-size:8pt;">) and Other (</span><span style="font-family:inherit;font-size:8pt;">$0.2 billion</span><span style="font-family:inherit;font-size:8pt;">). For the </span><span style="font-family:inherit;font-size:8pt;">six</span><span style="font-family:inherit;font-size:8pt;"> months ended </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, associated with the following segments: Biopharma (</span><span style="font-family:inherit;font-size:8pt;">$6.6 billion</span><span style="font-family:inherit;font-size:8pt;">) and Upjohn (</span><span style="font-family:inherit;font-size:8pt;">$2.3 billion</span><span style="font-family:inherit;font-size:8pt;">). For the </span><span style="font-family:inherit;font-size:8pt;">six</span><span style="font-family:inherit;font-size:8pt;"> months ended </span><span style="font-family:inherit;font-size:8pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:8pt;">, associated with the following segments: Biopharma (</span><span style="font-family:inherit;font-size:8pt;">$5.7 billion</span><span style="font-family:inherit;font-size:8pt;">), Upjohn (</span><span style="font-family:inherit;font-size:8pt;">$4.2 billion</span><span style="font-family:inherit;font-size:8pt;">) and Other (</span><span style="font-family:inherit;font-size:8pt;">$0.3 billion</span><span style="font-family:inherit;font-size:8pt;">).</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue deductions for the </span><span style="font-family:inherit;font-size:10pt;">second quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">decreased</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">15%</span><span style="font-family:inherit;font-size:10pt;">, compared to the </span><span style="font-family:inherit;font-size:10pt;">second quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;">, and total revenue deductions for </span><span style="font-family:inherit;font-size:10pt;">the first six months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">decreased</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">13%</span><span style="font-family:inherit;font-size:10pt;">, compared to </span><span style="font-family:inherit;font-size:10pt;">the first six months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;">, primarily as a result of:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a decrease in Medicaid and Medicare rebates, driven by a significant decrease in Lyrica sales in the U.S. due to multi-source generic competition that began in July 2019; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a decrease in sales returns and cash discounts, primarily due to the non-recurrence of a sales return reserve recorded for Lyrica in the prior year in advance of anticipated multi-source generic competition that began in the U.S. in July 2019.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For information on our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts, including the balance sheet classification of these accruals, see Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1C. Basis of Presentation and Significant Accounting Policies: Revenues and Trade Accounts Receivable</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">63</span></div></div><hr style="page-break-after:always"></hr><div><a id="s976167A62B9D5FB6BE937E6A3353F212"></a></div><div><br/></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Revenues&#8211;&#8211;Selected Product Discussion</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The tables below provide worldwide revenues and revenues by geography, for selected products. References to total change pertain to period-over-period growth rates that include foreign exchange. The difference between the total change and operational change represents the impact of foreign exchange. Amounts may not add due to rounding. All percentages have been calculated using unrounded amounts. An asterisk (*) indicates the calculation is not meaningful or results are equal to or greater than 100%.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Ibrance</span><span style="font-family:inherit;font-size:10pt;"> (Biopharma):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.49122807017544%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:6%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">927</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">831</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">11</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,779</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,572</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">13</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">422</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">430</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">819</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">822</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">4</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,349</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,261</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">2,598</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">2,394</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">10</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The operational </span><span style="font-family:inherit;font-size:10pt;">growth</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter and first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> in the U.S. was mainly driven by increased cyclin-dependent kinase (CDK) class penetration and Ibrance&#8217;s continued CDK market share leadership in metastatic breast cancer. The operational </span><span style="font-family:inherit;font-size:10pt;">growth</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter and first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> internationally reflects the continued strong volume growth in most markets, partially offset by pricing pressures in certain developed Europe markets.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Eliquis alliance revenues and direct sales </span><span style="font-family:inherit;font-size:10pt;">(Biopharma): Eliquis has been jointly developed and is commercialized by Pfizer and BMS. Pfizer funds between 50% and 60% of all development costs depending on the study. Profits and losses are shared equally on a global basis, except in certain countries where Pfizer commercializes Eliquis and pays BMS compensation based on a percentage of net sales. We have full commercialization rights in certain smaller markets. BMS supplies the product to us at cost plus a percentage of the net sales to end-customers in these markets. Eliquis is part of the Novel Oral Anticoagulant market; the agents in this class were developed as alternative treatment options to warfarin in appropriate patients.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.49122807017544%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:6%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">722</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">626</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">15</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,527</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,227</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">24</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">550</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">459</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">20</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">25</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,045</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">869</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">20</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">24</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,272</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,085</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">17</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">19</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">2,572</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">2,096</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">23</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">24</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The worldwide operational </span><span style="font-family:inherit;font-size:10pt;">growth</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter and first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> was primarily driven by higher demand due to continued adoption in non-valvular atrial fibrillation as well as oral anti-coagulant market share gains, partially offset by a lower net price. In the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;">, U.S. growth was also unfavorably impacted by a lower net price and COVID-19-related wholesaler buying patterns.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Prevnar 13/Prevenar 13</span><span style="font-family:inherit;font-size:10pt;"> (Biopharma):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.49122807017544%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">481</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">612</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(22</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,275</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,490</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(14</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">International</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">636</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">567</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">12</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">18</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,291</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,175</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">10</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">14</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,116</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,179</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">2,566</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">2,665</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">decline</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter and first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> in the U.S. primarily reflects the expected unfavorable impact of disruptions to wellness visits for pediatric and adult patients due to COVID-19-related mobility restrictions or limitations, partially offset by the favorable impact of timing associated with government purchases for the pediatric indication, compared to the prior-year period.</span></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The operational </span><span style="font-family:inherit;font-size:10pt;">growth</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter and first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> internationally primarily reflects significantly increased adult uptake in Germany and certain other markets resulting from greater vaccine awareness for respiratory illnesses, including specifically pneumococcal disease, due to the COVID-19 pandemic, as well as continued strong pediatric uptake in China.</span></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On June 26, 2019, the ACIP voted to revise the pneumococcal vaccination guidelines and recommend Prevnar 13 for adults 65 and older based on the shared clinical decision making of the provider and patient, which means the decision to </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">64</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">vaccinate should be made at the individual level between health care providers and their patients, maintaining reimbursement. The recommendation reaffirms that there remains vaccine preventable pneumococcal disease in the population of adults 65 years or older, which may be prevented through direct vaccination. The ACIP&#8217;s recommendation was approved by the directors at the CDC and U.S. Department of Health and Human Services, and published by the CDC in the Morbidity and Mortality Weekly Report in the fourth quarter of 2019. The ACIP&#8217;s latest recommendation did not have an impact on Prevnar 13 revenues in 2019, due to timing of the Morbidity and Mortality Weekly Report publication, nor was there impact in the first half of 2020. We expect Prevnar 13 revenues from the adult indication to decline through the remainder of the year.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Xeljanz </span><span style="font-family:inherit;font-size:10pt;">(Biopharma):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.49122807017544%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">458</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">458</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">744</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">756</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(2</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">177</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">155</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">14</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">20</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">343</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">279</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">23</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">28</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">635</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">613</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,086</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,036</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">6</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. revenue was flat in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">decline</span><span style="font-family:inherit;font-size:10pt;">d in the first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> primarily due to a lower net price due to higher rebating from commercial contracts signed in 2019. These declines were offset by continued strong demand across all approved indications. </span></div><div style="line-height:120%;padding-top:4px;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The operational </span><span style="font-family:inherit;font-size:10pt;">growth</span><span style="font-family:inherit;font-size:10pt;"> internationally in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter and first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> was mainly driven by continued uptake in the RA indication and, to a lesser extent, from the recent launch of the UC indication in certain developed markets.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Lipitor </span><span style="font-family:inherit;font-size:10pt;">(Upjohn):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.49122807017544%;border-collapse:collapse;text-align:left;"><tr><td colspan="27"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">43</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">30</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">44</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">67</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">51</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">33</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">International</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">388</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">377</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">7</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">768</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">979</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(21</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(19</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">431</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">407</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">10</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">836</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,029</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(19</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(16</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The worldwide operational </span><span style="font-family:inherit;font-size:10pt;">growth</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter primarily reflects significant revenue declines in the prior-year period associated with the VBP program in China, which was initially implemented in certain cities in March 2019, and expanded nationwide beginning in December 2019, resulting in significant volume and price erosion. The worldwide operational </span><span style="font-family:inherit;font-size:10pt;">decline</span><span style="font-family:inherit;font-size:10pt;"> in the first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> primarily resulted from the VBP program mentioned above.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:12px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-12px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Lyrica</span><span style="font-family:inherit;font-size:10pt;"> (Upjohn):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.49122807017544%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">51</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">835</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(94</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">132</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,724</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(92</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">298</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">340</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(13</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(12</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">574</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">638</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(10</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(10</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">349</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,175</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(70</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(70</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">706</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">2,362</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(70</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(70</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The worldwide </span><span style="font-family:inherit;font-size:10pt;">decline</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter and first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> was primarily driven by the U.S. due to the expected significantly lower volumes driven by multi-source generic competition that began in the U.S. in July 2019.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Enbrel </span><span style="font-family:inherit;font-size:10pt;">(Biopharma, outside the U.S. and Canada):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.49122807017544%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">International</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">337</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">420</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(20</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(16</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">684</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">871</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(21</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(18</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">337</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">420</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(20</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(16</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">684</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">871</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(21</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(18</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">65</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The worldwide operational </span><span style="font-family:inherit;font-size:10pt;">decline</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter and first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> was primarily due to continued biosimilar competition in most developed Europe markets as well as in Brazil and Japan, all of which is expected to continue.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Vyndaqel/Vyndamax </span><span style="font-family:inherit;font-size:10pt;">(Biopharma):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.49122807017544%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:6%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">145</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">8</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">272</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">8</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">131</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">55</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">236</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">96</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">*</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">277</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">63</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">*</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">*</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">508</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">104</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">*</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">*</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">growth</span><span style="font-family:inherit;font-size:10pt;"> in the U.S. in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter and first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> was driven by the launches of Vyndaqel in May 2019 and Vyndamax in September 2019 for the treatment of ATTR-CM. The operational </span><span style="font-family:inherit;font-size:10pt;">growth</span><span style="font-family:inherit;font-size:10pt;"> in international markets in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter and first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> was primarily driven by the March 2019 launch of the ATTR-CM indication in Japan and the February 2020 approval of the ATTR-CM indication in the EU.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Chantix/Champix</span><span style="font-family:inherit;font-size:10pt;"> (Biopharma):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.49122807017544%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">179</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">227</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(21</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">390</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">439</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(11</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">56</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">49</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">15</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">20</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">115</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">110</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">235</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">276</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(15</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(14</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">505</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">549</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The worldwide operational revenue </span><span style="font-family:inherit;font-size:10pt;">decline</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter and first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> was driven by the U.S. and primarily reflects expected lower demand resulting from reduced doctor visits, including wellness visits when Chantix is typically prescribed, due to COVID-19-related mobility restrictions or limitations. The decline was partially offset by increased demand in Spain as a result of government reimbursement starting in January 2020.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Xtandi alliance revenues </span><span style="font-family:inherit;font-size:10pt;">(Biopharma): Xtandi is being developed and commercialized through a collaboration with Astellas. The two companies share equally in the gross profits (losses) related to U.S. net sales of Xtandi. Subject to certain exceptions, Pfizer and Astellas also share equally all Xtandi commercialization costs attributable to the U.S. market. Pfizer and Astellas also share certain development and other collaboration expenses, and Pfizer receives tiered royalties as a percentage of international Xtandi net sales (recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:inherit;font-size:10pt;">).</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.49122807017544%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:6%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">266</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">201</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">32</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">475</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">369</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">29</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">266</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">201</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">32</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">32</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">475</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">369</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">29</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">29</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">growth</span><span style="font-family:inherit;font-size:10pt;"> in the U.S. in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter and first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> was primarily driven by continued strong demand for Xtandi in the metastatic (mCRPC) and non-metastatic (nmCRPC) castration-resistant prostate cancer indications, as well as the metastatic (mCSPC) castration-sensitive prostate cancer indication, which was approved in the U.S. in December 2019. </span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Norvasc </span><span style="font-family:inherit;font-size:10pt;">(Upjohn):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.49122807017544%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">7</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">11</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(32</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">16</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">21</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(23</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">215</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">205</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">9</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">403</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">495</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(19</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(16</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">222</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">216</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">419</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">516</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(19</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(16</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The worldwide operational </span><span style="font-family:inherit;font-size:10pt;">growth</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> reflects significant revenue declines in the prior-year period associated with the VBP program in China, which was initially implemented in certain cities in March 2019, and </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">66</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:4px;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">expanded nationwide beginning in December 2019, resulting in significant volume and price erosion. The worldwide operational </span><span style="font-family:inherit;font-size:10pt;">decline</span><span style="font-family:inherit;font-size:10pt;"> in the first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> primarily resulted from the VBP program mentioned above.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Sutent</span><span style="font-family:inherit;font-size:10pt;"> (Biopharma):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.49122807017544%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">61</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">82</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(26</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">113</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">153</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(26</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">148</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">166</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(11</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">301</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">327</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(8</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(4</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">209</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">248</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(16</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(13</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">414</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">480</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(14</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(11</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The worldwide operational </span><span style="font-family:inherit;font-size:10pt;">decline</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter and first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> reflects continued erosion as a result of increased competition in the U.S. and key international developed markets, partially offset by growth in certain emerging markets.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Inlyta</span><span style="font-family:inherit;font-size:10pt;"> (Biopharma):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.49122807017544%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:6%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">132</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">60</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">248</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">93</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">63</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">44</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">43</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">48</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">116</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">84</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">38</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">42</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">195</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">104</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">87</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">89</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">364</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">177</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">*</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">*</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The worldwide operational </span><span style="font-family:inherit;font-size:10pt;">growth</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter and first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> was primarily due to increased demand in the U.S. from the FDA approvals in the second quarter of 2019 for combinations of certain immune checkpoint inhibitors plus Inlyta for the first-line treatment of patients with advanced RCC.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Inflectra/Remsima </span><span style="font-family:inherit;font-size:10pt;">(Biopharma):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.49122807017544%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">72</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">74</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(3</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">156</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">132</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">18</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">78</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">78</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">5</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">153</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">159</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(4</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(1</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">150</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">153</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">308</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">291</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The worldwide operational revenue </span><span style="font-family:inherit;font-size:10pt;">growth</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter and first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> was primarily driven by switch-to-biosimilar products policies implemented in Canada and steady volume and share growth in the U.S. across hospital channels, clinics and alternate sites of care, partially offset by pricing pressures globally as well as competitive pressures internationally. </span></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">While Inflectra has achieved parity access to Remicade</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (infliximab) in Medicare Part B, in the U.S., nearly half of all commercial patients are not able to access Inflectra due to exclusionary conduct by J&amp;J. In September 2017, Pfizer filed suit in the U.S. District Court for the Eastern District of Pennsylvania against J&amp;J alleging that J&amp;J&#8217;s exclusionary contracts and other anticompetitive practices concerning Remicade violate federal antitrust laws. In June 2019, Pfizer received a Civil Investigative Demand from the Federal Trade Commission (FTC) seeking documents and information relating to the alleged conduct and market conditions at issue in Pfizer&#8217;s lawsuit against J&amp;J. Pfizer understands that the FTC&#8217;s investigation is focused on J&amp;J&#8217;s alleged conduct at issue in Pfizer&#8217;s lawsuit against J&amp;J.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Premarin</span><span style="font-family:inherit;font-size:10pt;"> family of products (Biopharma):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.49122807017544%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">142</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">182</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(22</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">283</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">340</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(17</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">10</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">11</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">20</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">21</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(3</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">152</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">193</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(21</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(21</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">304</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">361</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(16</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(16</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">67</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The worldwide operational </span><span style="font-family:inherit;font-size:10pt;">decline</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter and first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> was primarily driven by continued competitive pressures in the U.S., which is expected to continue.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Celebrex </span><span style="font-family:inherit;font-size:10pt;">(Upjohn):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.49122807017544%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">10</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">16</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(33</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">22</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">30</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(28</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">129</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">158</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(18</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(17</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">274</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">317</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(14</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(13</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">139</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">174</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(20</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(18</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">295</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">347</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(15</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(14</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The worldwide operational </span><span style="font-family:inherit;font-size:10pt;">decline</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter and first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> was primarily driven by lower volume in certain developed markets, primarily in Japan, in anticipation of generic competition that began in June 2020, Pfizer&#8217;s third quarter for international subsidiaries, following patent expiration in November 2019, partially offset by higher volumes in China. The first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;text-align:center;"> were also impacted by pricing pressures and lower volumes in certain other emerging markets. </span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Sulperazon</span><span style="font-family:inherit;font-size:10pt;"> (Biopharma):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.49122807017544%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">102</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">165</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(38</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(36</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">289</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">342</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(16</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(13</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">102</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">165</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(38</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(36</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">289</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">342</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(16</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(13</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The international operational </span><span style="font-family:inherit;font-size:10pt;">decline</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter and first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> was primarily driven by lower demand in China due to lower infection rates driven by fewer elective surgical procedures, shorter in-patient hospital stays and improved infection control compared to the prior year period.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Xalkori </span><span style="font-family:inherit;font-size:10pt;">(Biopharma):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.49122807017544%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:6%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">37</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">41</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(8</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">77</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">75</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">100</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">92</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">14</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">210</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">180</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">17</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">21</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">138</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">133</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">287</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">255</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">12</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">15</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The worldwide operational </span><span style="font-family:inherit;font-size:10pt;">growth</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter and first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> primarily resulted from growth in China, following the impact of inclusion of Xalkori in the 2019 National Reimbursement Drug List.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Viagra </span><span style="font-family:inherit;font-size:10pt;">(Upjohn):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.49122807017544%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">11</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">13</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(15</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">28</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">52</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(46</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">83</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">102</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(18</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(15</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">193</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">207</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(6</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(4</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">94</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">114</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(18</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(15</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">222</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">259</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(15</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(13</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The worldwide operational </span><span style="font-family:inherit;font-size:10pt;">decline</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter and first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> was primarily driven by emerging markets, primarily China, resulting from mobility restrictions due to COVID-19. The worldwide operational </span><span style="font-family:inherit;font-size:10pt;">decline</span><span style="font-family:inherit;font-size:10pt;"> in the first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> was also impacted by continued volume erosion due to multi-source generic competition in the U.S. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">68</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Alliance revenues</span><span style="font-family:inherit;font-size:10pt;"> (Biopharma):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.49122807017544%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:6%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oper.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">996</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">835</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">19</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">2,018</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,610</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">25</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">International</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">408</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">352</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">16</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">19</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">769</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">666</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">15</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">18</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,404</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,187</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">18</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">19</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">2,786</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">2,277</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">22</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">23</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The worldwide operational growth in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter and first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> was primarily due to increases in Eliquis and Xtandi alliance revenues included in the above discussion.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 14C.</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Segment, Geographic and Other Revenue Information</span><span style="font-family:inherit;font-size:10pt;">: </span><span style="font-style:italic;font-weight:normal;text-decoration:none;">Other Revenue Information</span><span style="font-family:inherit;font-size:10pt;"> for additional information regarding the primary indications or class of the selected products discussed above.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 13.</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Contingencies and Certain Commitments</span><span style="font-family:inherit;font-size:10pt;"> for a discussion of recent developments concerning patent and product litigation relating to certain of the products discussed above.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See the &#8220;Patents and Other Intellectual Property Rights&#8221; section in Part I, Item 1, &#8220;Business&#8221; of our 2019 Form 10-K for information regarding the expiration of various patent rights.</span></div><div><a id="s418A2D1D9937533DBFA5279BB62806A3"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Product Developments&#8212;Biopharmaceutical</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We continue to invest in R&amp;D to provide potential future sources of revenues through the development of new products, as well as through additional uses for in-line and alliance products. Notwithstanding our efforts, there are no assurances as to when, or if, we will receive regulatory approval for additional indications for existing products or any of our other products in development.</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We continue to strengthen our global R&amp;D organization and pursue strategies intended to improve innovation and overall productivity in R&amp;D to achieve a sustainable pipeline that will deliver value in the near term and over time. </span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For additional information about our R&amp;D organization, see the &#8220;Research and Development&#8221; section in Part I, Item 1, &#8220;Business&#8221; of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A comprehensive update of Pfizer&#8217;s development pipeline was published as of </span><span style="font-family:inherit;font-size:10pt;">July&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;"> and is available at www.pfizer.com/science/drug-product-pipeline. It includes an overview of our research and a list of compounds in development with targeted indication and phase of development, as well as mechanism of action for some candidates in Phase 1 and all candidates from Phase 2 through registration.</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following series of tables provides information about significant regulatory actions by, and filings pending with, the FDA and regulatory authorities in the EU and Japan, as well as additional indications and new drug candidates in late-stage development.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.24561403508771%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:26%;"></td><td style="width:58%;"></td><td style="width:16%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">RECENT FDA APPROVALS</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">PRODUCT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">INDICATION</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">DATE APPROVED</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Bavencio (avelumab)</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">For the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy, which is being developed in collaboration with Merck KGaA, Germany</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June 2020</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Nyvepria (pegfilgrastim-apgf)</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">A biosimilar to Neulasta</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:7.5pt;">&#160;(pegfilgrastim) to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June 2020</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Braftovi (encorafenib)</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Braftovi (encorafenib) in combination with Erbitux</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:7.5pt;">&#160;(cetuximab) for the treatment of </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">BRAF</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">V600E</sup></span><span style="font-family:inherit;font-size:7.5pt;">-mutant metastatic colorectal cancer after prior therapy</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">April 2020</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Xtandi (enzalutamide)</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Treatment of metastatic castration-sensitive prostate cancer, which is being developed through a collaboration with Astellas</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">December 2019</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Abrilada</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;</sup></span><span style="font-family:inherit;font-size:7.5pt;">(adalimumab-afzb)</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">A biosimilar to Humira</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174; </sup></span><span style="font-family:inherit;font-size:7.5pt;">(adalimumab) for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, UC and plaque psoriasis</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">November 2019</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Neulasta</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174; </sup></span><span style="font-family:inherit;font-size:7.5pt;">is a registered U.S. trademark of Amgen Inc.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Erbitux</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174; </sup></span><span style="font-family:inherit;font-size:7.5pt;">is a registered trademark of ImClone LLC.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Humira</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:7.5pt;"> is a registered trademark of AbbVie Biotechnology Ltd. Pfizer is working to make Abrilada available to U.S. patients as soon as feasible based on the terms of its agreement with AbbVie. Current plans are to launch Abrilada in 2023.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">69</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.24561403508771%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:26%;"></td><td style="width:58%;"></td><td style="width:16%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">PENDING U.S. NDAs AND SUPPLEMENTAL FILINGS</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">PRODUCT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">PROPOSED INDICATION</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">DATE FILED*</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">tanezumab</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">For patients with chronic pain due to moderate-to-severe osteoarthritis (OA) who have experienced inadequate pain relief with other analgesics, which is being developed in collaboration with Lilly</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">March 2020</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">The date set forth in this column is the date on which the FDA accepted our submission.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.635477582846%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:21%;"></td><td style="width:51%;"></td><td style="width:14%;"></td><td style="width:14%;"></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">REGULATORY APPROVALS AND FILINGS IN THE EU AND JAPAN</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">PRODUCT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">DESCRIPTION OF EVENT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">DATE APPROVED</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">DATE FILED*</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Bosulif (bosutinib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Application approved in Japan for the first-line treatment of chronic myelogenous leukemia (CML)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June 2020</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Daurismo (glasdegib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Application approved in the EU for Daurismo (glasdegib) in combination with low-dose cytarabine, a type of chemotherapy, for the treatment of newly diagnosed (de novo or secondary) AML in adult patients who are not candidates for standard chemotherapy</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June 2020</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Bavencio (avelumab)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Application filed in the EU for first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma, which is being developed in collaboration with Merck KGaA, Germany</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Braftovi (encorafenib)</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Application approved in the EU for Braftovi (encorafenib) in combination with Erbitux</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:7.5pt;">&#160;(cetuximab), for the treatment of adult patients with mCRC with a BRAF mutation, who have received prior systemic therapy, which is being developed in collaboration with the Pierre Fabre Group</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June 2020</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Bavencio (avelumab)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Application filed in Japan for first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma, which is being developed in collaboration with Merck KGaA, Germany</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">May 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Ruxience (rituximab)</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Application approved in the EU for a biosimilar to MabThera</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:7.5pt;">&#160;(rituximab) for the treatment of non-Hodgkin&#8217;s lymphoma, chronic lymphocytic leukemia, RA, granulomatosis with polyangiitis and microscopic polyangiitis, and pemphigus vulgaris</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">April 2020</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Staquis (crisaborole)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Application approved in the EU for the treatment of mild to moderate atopic dermatitis in adults and pediatric patients from 2&#160;years of age with &#8804;&#160;40% body surface area affected</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">March 2020</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">tanezumab</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Application filed in the EU for adult patients with moderate to severe chronic pain associated with OA for whom treatment with NSAIDs and/or an opioid is ineffective, not tolerated or inappropriate </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">March 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Braftovi (encorafenib) and Mektovi (binimetinib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Application filed in Japan for second-or-third-line treatment of </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">BRAF-</span><span style="font-family:inherit;font-size:7.5pt;">mutant mCRC in patients who have received prior systemic therapy, which is being developed in collaboration with Ono Pharmaceutical Co., Ltd. </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">March 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Vyndaqel (tafamidis free acid)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Application approved in the EU for </span><span style="font-family:inherit;font-size:7.5pt;color:#333333;">a once-daily 61 mg oral capsule, for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">February 2020</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Amsparity (adalimumab)</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Application approved in the EU for a biosimilar to Humira</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:7.5pt;">&#160;(adalimumab) for the treatment of certain patients with RA, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn&#8217;s disease, UC, uveitis, and pediatric plaque psoriasis</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">February 2020</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Xeljanz (tofacitinib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Application approved in the EU for Xeljanz (tofacitinib) 11 mg prolonged release tablets in combination with methotrexate&#160;for the treatment of moderate to severe active rheumatoid arthritis&#160;in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">December 2019</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Bavencio (avelumab)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Application approved in Japan for Bavencio (avelumab) in combination with Inlyta (axitinib) for the first-line treatment of advanced RCC, which is being developed in collaboration with Merck KGaA, Germany</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">December 2019</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Bavencio (avelumab)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Application approved in the EU for Bavencio (avelumab) in combination with Inlyta (axitinib) for the first-line treatment of advanced RCC, which is being developed in collaboration with Merck KGaA, Germany</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">October 2019</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">PF-06881894</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Application filed in the EU for a potential biosimilar to Neulasta</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:7.5pt;">&#160;(pegfilgrastim)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">October 2019</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Rituximab Pfizer (rituximab)</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Application approved in Japan for a biosimilar to Rituxan</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:7.5pt;">&#160;(rituximab) for the treatment of CD20-positive, B-cell non-Hodgkin&#8217;s Lymphoma, CD20-positive, B-cell lymphoproliferative disease under immunosuppression, and Granulomatosis with polyangiitis, and microscopic polyangiitis</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">September 2019</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Xtandi (enzalutamide)</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Application filed in the EU for the treatment of metastatic castration-sensitive prostate cancer, which is being developed through a collaboration with Astellas</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">July 2019</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">For applications in the EU, the dates set forth in this column are the dates on which the EMA validated our submissions.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Erbitux</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174; </sup></span><span style="font-family:inherit;font-size:7.5pt;">is a registered trademark of ImClone LLC.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">MabThera</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:7.5pt;"> is a registered trademark of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:7.5pt;">F. Hoffman-La Roche AG.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Humira</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:7.5pt;"> is a registered trademark of AbbVie Biotechnology Ltd. Pfizer does not currently plan to commercialize Amsparity in the EU due to unfavorable market conditions.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Neulasta</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:7.5pt;"> is a registered trademark of Amgen Inc.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Rituxan</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:7.5pt;"> is a registered trademark of Biogen MA Inc. </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">70</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.24561403508771%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:22%;"></td><td style="width:78%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">LATE-STAGE CLINICAL PROGRAMS FOR ADDITIONAL USES AND DOSAGE FORMS<br/>FOR IN-LINE AND IN-REGISTRATION PRODUCTS</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">PRODUCT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">PROPOSED INDICATION</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Bavencio (avelumab)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">A monoclonal antibody that inhibits PD-L1 for the first-line treatment of stage IIIb/IV non-small cell lung cancer, which is being developed in collaboration with Merck KGaA, Germany</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Daurismo (glasdegib)</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">A smoothened inhibitor, in combination with cytarabine and daunorubicin, for the treatment of AML</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Ibrance (palbociclib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Treatment of HER2+ advanced breast cancer, in collaboration with the Alliance Foundation Trials, LLC</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Ibrance (palbociclib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Treatment of high-risk early breast cancer, in collaboration with the German Breast Group</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Lorbrena (lorlatinib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Treatment of patients with metastatic non-small cell lung cancer whose tumors are ALK-positive as detected by an FDA-approved test</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Xeljanz (tofacitinib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Treatment of ankylosing spondylitis</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Xtandi (enzalutamide)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Treatment of non-metastatic castration-sensitive prostate cancer, which is being developed through a collaboration with Astellas</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Talzenna (talazoparib)</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">An oral PARP inhibitor, in combination with Xtandi (enzalutamide), for the treatment of metastatic castration-resistant prostate cancer</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">In May&#160;2020, we accepted the recommendation of the independent Data Monitoring Committee to stop the Non-Intensive cohort of the Phase 3 clinical trial for BRIGHT AML 1019, as it is unlikely to show a statistically significant improvement in the primary endpoint of overall survival. No important new safety signals were observed in patients treated with glasdegib. A separate cohort of BRIGHT AML 1019 evaluates glasdegib in combination with intensive chemotherapy (cytarabine and daunorubicin) for the treatment of adult patients with previously untreated AML, and the cohort is ongoing and remains blinded.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2020, we and the Austrian Breast &amp; Colorectal Cancer Study Group and the Alliance Foundation announced that following a preplanned efficacy and futility analysis, the independent Data Monitoring Committee of the collaborative Ibrance (palbociclib) Phase 3 early breast cancer PALbociclib CoLlaborative Adjuvant Study (PALLAS) determined that the trial is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival. No unexpected new safety signals were observed in patients receiving Ibrance. When available, the full results from the PALLAS study will be shared with the scientific community.</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.24561403508771%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:22%;"></td><td style="width:78%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">NEW DRUG CANDIDATES IN LATE-STAGE DEVELOPMENT</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">CANDIDATE</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">PROPOSED INDICATION</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">abrocitinib (PF-04965842)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">A Janus kinase 1 (JAK1) inhibitor for the treatment of moderate-to-severe atopic dermatitis</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">aztreonam-avibactam <br/>(PF-06947387)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">A beta lactam/beta lactamase inhibitor for the treatment of patients with infections caused by Gram-negative bacteria, including those that produce metallo-beta-lactamases, for which there are limited or no treatment options</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">fidanacogene elaparvovec (PF-06838435)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">An investigational gene therapy for the treatment of hemophilia B</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">PF-06482077</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">A 20-Valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease and pneumonia caused by </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Streptococcus pneumoniae</span><span style="font-family:inherit;font-size:7.5pt;">&#160;serotypes covered by the vaccine in adults 18 years of age and older</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">PF-06482077</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">A 20-Valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease and pneumonia caused by </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Streptococcus pneumoniae</span><span style="font-family:inherit;font-size:7.5pt;">&#160;serotypes covered by the vaccine in infants</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">PF-06425090</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">A prophylactic vaccine for prevention of primary clostridioides</span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">&#160;</span><span style="font-family:inherit;font-size:7.5pt;">difficile infection (CDI) in individuals</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">PF-06886992</span></div><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A,B,C,W and Y in persons one&#160;through 25 years of age</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">PF-06928316</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">A respiratory syncytial virus vaccine for the prevention of RSV disease in young infants through maternal immunization and in older adults through direct&#160;immunization</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">PF-07302048 (BNT162)</span></div><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">A messenger RNA-based vaccine for the prevention of SARS-CoV-2, the virus that causes COVID-19 disease, in partnership with BioNTech</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">PF-07265803</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">An oral inhibitor of p38 mitogen-activated protein kinase for the treatment of patients with symptomatic dilated cardiomyopathy due to a Lamin A/C gene mutation</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">ritlecitinib (PF-06651600)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">A selective dual Janus kinase 3 (JAK3) and Tyrosine kinase Expressed in hepatocellular Carcinoma (TEC) family inhibitor for the treatment of patients with moderate to severe alopecia areata</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">sasanlimab (PF-06801591)</span></div><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">A monoclonal antibody that inhibits PD-1, in combination with Bacillus Calmette-Guerin (BCG), for the treatment of non-muscle invasive bladder cancer</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">somatrogon (PF-06836922)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">A long-acting hGH-CTP for the treatment of growth hormone deficiency in children, which is being developed in collaboration with OPKO</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">somatrogon (PF-06836922)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">A long-acting hGH-CTP for the treatment of growth hormone deficiency in adults, which is being developed in collaboration with OPKO</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">tanezumab</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">An anti-nerve growth factor monoclonal antibody for the treatment of cancer pain, which is being developed in collaboration with Lilly</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additional product-related programs are in various stages of discovery and development.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">71</span></div></div><hr style="page-break-after:always"></hr><div><a id="s1A92BF9EEF8757AFAA82D0174D182E74"></a></div><div><br/></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Costs and Expenses</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The changes in expenses below reflect, among other things, a decline in expenses resulting from the July 31, 2019 completion of the Consumer Healthcare JV transaction with GSK (see Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 2B.</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Acquisition, Equity-Method Investment and Licensing Arrangements</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Equity-Method Investment</span><span style="font-family:inherit;font-size:10pt;">). In addition, the COVID-19 pandemic impacted certain operating expenses in the second quarter and first six months of 2020.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Cost of Sales</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">2,281</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">2,576</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(11</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">4,658</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">5,009</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">As a percentage of </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">19.3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">19.4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">19.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">19.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">decreased</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">$295 million</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$351 million</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">the first six months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;">, primarily due to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the favorable impact of the July 31, 2019 completion of the Consumer Healthcare joint venture transaction with GSK; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a favorable impact of foreign exchange,</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the unfavorable impact of incremental costs incurred in response to the COVID-19 pandemic.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales </span><span style="font-family:inherit;font-size:10pt;">in </span><span style="font-family:inherit;font-size:10pt;">the first six months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;text-align:center;"> was also partially offset by </span><span style="font-family:inherit;font-size:10pt;">the net increase in sales volumes for various products within our product portfolio.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The slight </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;"> as a percentage of revenues in the </span><span style="font-family:inherit;font-size:10pt;">second quarter of 2020</span><span style="font-family:inherit;font-size:10pt;">, compared to the same period in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, was primarily due to all of the factors discussed above, as well as a favorable change in product mix, primarily driven by revenue growth in the Oncology portfolio and Vyndaqel, and an increase in alliance revenues, which have no associated cost of sales, partially offset by the impact of the lower Lyrica revenues in developed markets due to U.S. multi-source generic competition that began in July 2019.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;"> as a percentage of revenues in </span><span style="font-family:inherit;font-size:10pt;">the first six months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;">, compared to the same period in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, was primarily due to all of the factors discussed above, as well as the impact of the lower Lyrica revenues in developed markets due to U.S. multi-source generic competition that began in July 2019, partially offset by a favorable change in product mix, primarily driven by revenue growth in the Oncology portfolio and Vyndaqel, and an increase in alliance revenues, which have no associated cost of sales.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Selling, Informational and Administrative (SI&amp;A) Expenses</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%<br/>&#160;Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%<br/>&#160;Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">3,030</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">3,511</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(14</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">5,903</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">6,850</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(14</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">As a percentage of </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">25.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">26.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">24.8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">26.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SI&amp;A expenses </span><span style="font-family:inherit;font-size:10pt;">decreased</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">$481 million</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;">, primarily due to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the favorable impact of the July 31, 2019 completion of the Consumer Healthcare joint venture transaction with GSK;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">lower spending on sales and marketing activities due to the impact of the COVID-19 pandemic;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a decrease in field force expense as well as advertising and promotion expenses, primarily related to Lipitor and Norvasc, due to the VBP program in China, which was initially implemented in certain cities in March 2019 and expanded nationwide beginning in December 2019, as well as Lyrica in the U.S. due to generic competition that began in July 2019 and anticipated generic competition for Celebrex in Japan beginning in June 2020; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">lower spending associated with corporate enabling functions; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the favorable impact of foreign exchange,</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">legal entity restructuring, as well as separation costs associated with our planned Upjohn transaction with Mylan.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SI&amp;A expenses </span><span style="font-family:inherit;font-size:10pt;">decreased</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">$947 million</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">the first six months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;text-align:center;">,</span><span style="font-family:inherit;font-size:10pt;"> mostly due to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the favorable impact of the July 31, 2019 completion of the Consumer Healthcare joint venture transaction with GSK;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">72</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a reduction in field force expense as well as advertising and promotion expenses, primarily related to Lyrica in the U.S. due to generic competition that began in July 2019 and the anticipated generic competition for Celebrex in Japan that began in June 2020, as well as a decrease in Lipitor and Norvasc expenses due to the VBP program in China, which was initially implemented in certain cities in March 2019 and expanded nationwide beginning in December 2019;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">lower spending associated with corporate enabling functions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">lower spending on sales and marketing activities due to the impact of the COVID-19 pandemic;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a reduction to expense resulting from the decrease in our liability to be paid to participants of our supplemental savings plan;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">lower investments across the Inflammation &amp; Immunology portfolio; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the favorable impact of foreign exchange,</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">legal entity restructuring, as well as separation costs associated with our planned Upjohn transaction with Mylan.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Research and Development (R&amp;D) Expenses</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%<br/>Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%<br/>Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">2,132</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,842</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">16</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">3,856</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">3,544</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">9</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">As a percentage of </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">18.1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">13.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">16.2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">13.4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">R&amp;D expenses </span><span style="font-family:inherit;font-size:10pt;">increased</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">$290 million</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second quarter</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;">, primarily</span><span style="font-family:inherit;font-size:10pt;text-align:center;"> due to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">costs related to our collaboration agreement with BioNTech to co-develop a COVID-19 vaccine, including an upfront payment to BioNTech; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an upfront payment to Valneva,</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a net reduction of spending across our Oncology, Inflammation &amp; Immunology, Rare Disease, Internal Medicine and Vaccines portfolios, as well as delays in program costs related to COVID-19.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">R&amp;D expenses </span><span style="font-family:inherit;font-size:10pt;">increased</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">$311 million</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">the first six months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;text-align:center;">, mostly due to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">costs related to our collaboration agreement with BioNTech to co-develop a COVID-19 vaccine, including an upfront payment to BioNTech;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an upfront payment to Valneva; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">increased investments towards building new capabilities and driving automation,</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a decrease in the value of the portfolio performance share grants reflecting the decrease in the price of Pfizer&#8217;s common stock in the first half of 2020; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a net reduction of spending across our Oncology, Inflammation &amp; Immunology, Rare Disease, Internal Medicine and Vaccines portfolios, as well as delays in program costs related to COVID-19.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For additional information on Cost of sales, SI&amp;A and R&amp;D expenses by operating segment, see the &#8220;Analysis of Operating Segment Information&#8221; section of this MD&amp;A.</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Amortization of Intangible Assets</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%<br/>Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%<br/>Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">905</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,184</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(24</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,790</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">2,367</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(24</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">As a percentage of </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">7.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">8.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">7.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">9.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of intangible assets </span><span style="font-family:inherit;font-size:10pt;">decreased</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">$279 million</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$577 million</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">the first six months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;">, primarily due to the non-recurrence of amortization expense as a result of fully amortized assets and the impairment of Eucrisa in the fourth quarter of 2019, partially offset by an increase in amortization expense related to intangible assets from our acquisition of Array.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">73</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For additional information, see Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 2A.</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Acquisition, Equity-Method Investment and Licensing Arrangements</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Acquisition </span><span style="font-family:inherit;font-size:10pt;">and</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 9A. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable Intangible Assets and Goodwill</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Identifiable Intangible Assets.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-weight:bold;text-decoration:underline;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%<br/>Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%<br/>Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Restructuring credits&#8212;acquisition-related costs</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(206</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(100</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(214</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(100</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Restructuring charges&#8212;cost reduction initiatives</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">341</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">62</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">396</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">81</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Restructuring charges/(credits)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">340</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(144</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">396</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(134</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Transaction costs</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">11</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">14</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Integration costs and other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">11</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">29</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(62</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">21</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">64</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(67</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">362</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(115</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">431</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(69</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Net periodic benefit costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">24</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">29</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">10</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total additional depreciation&#8212;asset restructuring</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">10</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(36</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">23</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(71</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total implementation costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">75</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">42</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">77</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">99</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">69</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">45</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Costs associated with acquisitions and cost-reduction/productivity initiatives</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">449</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(59</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">*</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">566</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">32</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">*</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="23" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">* Indicates calculation not meaningful or results are equal to or greater than 100%.</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-size:8pt;">Includes employee termination costs, asset impairments and other exit costs associated with business combinations. Credits for the second quarter and the first six months of 2019 were mostly due to the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of</span><span style="font-family:inherit;font-size:8pt;"> an IRS audit for multiple years. See Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 5D. Tax Matters: Tax Contingencies </span><span style="font-family:inherit;font-size:8pt;">in our 2019 Financial Report</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-size:8pt;">Includes employee termination costs, asset impairments and other exit costs not associated with acquisitions. The charges for the second quarter and the first six months of 2020 primarily represent employee termination costs associated with our Transforming to a More Focused Company program.</span><span style="font-family:inherit;font-size:8pt;"> For the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">, the charges were composed of employee termination costs and exit costs, partially offset by lower asset write-downs, and for </span><span style="font-family:inherit;font-size:8pt;">the first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> were mostly related to employee termination costs and exit costs.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For additional information, see Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 3. </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:inherit;font-size:8pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Comprises </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restructuring charges and certain acquisition-related</span><span style="font-family:inherit;font-size:8pt;"> costs as well as costs associated with our cost-reduction/productivity initiatives included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:8pt;">, </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Research and development expenses,</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Selling, informational and administrative expenses</span><span style="font-family:inherit;font-size:8pt;"> and/or </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:inherit;font-size:8pt;">as appropriate. For additional information, see Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 3. </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:inherit;font-size:8pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Transforming to a More Focused Company Program</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">With the formation of the GSK Consumer Healthcare joint venture and the anticipated combination of Upjohn, our global, primarily off-patent branded and generics business, with Mylan, Pfizer is transforming itself into a more focused, global leader in science-based innovative medicines.&#160;As a result, we began, in the fourth quarter of 2019, to identify and undertake efforts to ensure our cost base aligns appropriately with our Biopharmaceutical revenue base, which is expected to be 20% less (based on the midpoint of the range for 2020 New Pfizer revenue guidance, compared to 2019 Total Company reported revenue) as a result of both the completed GSK Consumer Healthcare and expected Upjohn transactions. While certain direct costs have transferred or will transfer to the GSK Consumer Healthcare joint venture and to the Upjohn entities, there are indirect costs which are not expected to transfer. In addition, we are taking steps to restructure our organizations to appropriately support and drive the purpose of the three core functions of our focused innovative medicines business: R&amp;D, Manufacturing and Commercial.</span><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect the costs associated with this multi-year program to be incurred from 2020 through 2022 and to total approximately </span><span style="font-family:inherit;font-size:10pt;">$1.2 billion</span><span style="font-family:inherit;font-size:10pt;"> on a pre-tax basis, with substantially all of the costs to be cash expenditures. Actions may include, among others, changes in location of certain activities, expanded use and co-location of centers of excellence and shared services, and increased use of digital technologies. The associated actions and the specific costs will primarily include severance and benefit plan impacts, exit costs as well as associated implementation costs. We expect gross cost savings of approximately </span><span style="font-family:inherit;font-size:10pt;">$900 million</span><span style="font-family:inherit;font-size:10pt;"> to be achieved primarily over the two-year period 2021-2022.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Also as part of this program, in connection with the legacy cost reduction initiatives, primarily related to manufacturing activities, we expect to incur costs of approximately </span><span style="font-family:inherit;font-size:10pt;">$400 million</span><span style="font-family:inherit;font-size:10pt;">, with approximately </span><span style="font-family:inherit;font-size:10pt;">20%</span><span style="font-family:inherit;font-size:10pt;"> of the costs to be non-cash. The costs associated with this effort are expected to be incurred from 2020 through 2022, and will primarily include implementation costs, product transfer costs, exit costs, as well as accelerated depreciation. We expect targeted net cost savings of approximately </span><span style="font-family:inherit;font-size:10pt;">$200 million</span><span style="font-family:inherit;font-size:10pt;">, with approximately </span><span style="font-family:inherit;font-size:10pt;">30%</span><span style="font-family:inherit;font-size:10pt;"> realized in the first half of 2020, and the remaining expected to be achieved in the second half of 2020 through 2022.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">74</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Savings are expected to be realized primarily in corporate enabling functions and in manufacturing (as described in the Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 14A. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Segment, Geographic and Other Revenue Information</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: </span><span style="font-style:italic;font-weight:normal;text-decoration:none;">Segment Information</span><span style="font-family:inherit;font-size:10pt;">).</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain qualifying costs associated with this program were recorded in the fourth quarter of 2019 and in the first and second quarters of 2020 and are reflected as Certain Significant Items and excluded from our non-GAAP measure of Adjusted Income. See the &#8220;Non-GAAP Financial Measure (Adjusted Income)&#8221; section of this MD&amp;A for additional information.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For additional information about this program and expected and actual total costs, see Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 3. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to this major program, we continuously monitor our operations for cost reduction and/or productivity opportunities, especially in light of the losses of exclusivity and the expiration of collaborative arrangements for various products.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Other (Income)/Deductions&#8212;Net</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%<br/>Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%<br/>Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(862</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">126</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">*</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(641</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">218</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">*</span></div></td></tr><tr><td colspan="21" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">* Indicates calculation not meaningful or results are equal to or greater than 100%.</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For information about the components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:inherit;font-size:10pt;">, see Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 4. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (Income)/Deductions&#8212;Net</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See also the &#8220;Analysis of Operating Segment Information&#8221; section of this MD&amp;A.</span></div><div><a id="s931D11AD61AA54599A068FF5E2A002FB"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Provision/(Benefit) for Taxes on Income</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%<br/>Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%<br/>Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">519</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(915</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">993</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(481</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Effective tax rate on continuing operations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">13.1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(22.1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">12.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(5.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td></tr><tr><td colspan="21" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">* Indicates calculation not meaningful or results are equal to or greater than 100%.</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For information about our effective tax rate and the events and circumstances contributing to the changes between periods, see Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 5. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Tax Matters</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div><a id="sB2A85AA439F458C0992C898083906DF4"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Non-GAAP Financial Measure (Adjusted Income)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">General Description of Non-GAAP Financial Measure (Adjusted Income)</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted income is an alternative view of performance used by management. We measure the performance of the overall Company on this basis in conjunction with other performance metrics. Because Adjusted income is an important internal measurement for Pfizer, we believe that investors&#8217; understanding of our performance is enhanced by disclosing this performance measure. We report Adjusted income, certain components of Adjusted income, and Adjusted diluted earnings per share in order to portray the results of our major operations&#8211;&#8211;the discovery, development, manufacture, marketing and sale of prescription medicines and vaccines&#8211;&#8211;prior to considering certain income statement elements. We have defined Adjusted income as </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net income attributable to Pfizer Inc.</span><span style="font-family:inherit;font-size:10pt;"> before the impact of purchase accounting for acquisitions, acquisition-related costs, discontinued operations and certain significant items, which are described below. Also, see the &#8220;Non-GAAP Financial Measure (Adjusted Income)&#8211;&#8211;General Description of Non-GAAP Financial Measure (Adjusted Income)&#8221; section of our 2019 Financial Report for additional information. Similarly, we have defined the Adjusted income components as </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales, Selling, informational and administrative expenses, Research and development expenses, Amortization of intangible assets </span><span style="font-family:inherit;font-size:10pt;">and</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:10pt;"> each before the impact of purchase accounting for acquisitions, acquisition-related costs and certain significant items. We have defined Adjusted diluted earnings per share as </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Earnings per common share attributable to Pfizer Inc.&#8211;&#8211;diluted</span><span style="font-family:inherit;font-size:9pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">before the impact of purchase accounting for acquisitions, acquisition-related costs, discontinued operations and certain significant items. The Adjusted income measure, the Adjusted income component measures and the Adjusted diluted earnings per share measure are not, and should not be viewed as, substitutes for U.S. GAAP net income, U.S. GAAP net income components or U.S. GAAP diluted earnings per share. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">75</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following are examples of how the Adjusted income and Adjusted diluted earnings per share measures are utilized:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">senior management receives a monthly analysis of our operating results that is prepared on an Adjusted income and Adjusted diluted earnings per share basis;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our annual budgets are prepared on an Adjusted income and Adjusted diluted earnings per share basis; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">senior management&#8217;s annual compensation is derived, in part, using Adjusted income and Adjusted diluted earnings per share measures. </span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective in 2020, the bonus plans for substantially all non-sales-force employees worldwide are funded from a pool based on our performance, measured in significant part by three metrics, one of which is Adjusted diluted earnings per share, which is derived from Adjusted income and accounts for 40% of the bonus pool funding. Additionally, the payout for some Performance Share Awards is determined in part by Adjusted net income, which is derived from Adjusted income.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted income and its components and Adjusted diluted earnings per share are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, are limited in their usefulness to investors. Because of their non-standardized definitions, Adjusted income and its components (unlike U.S. GAAP net income and its components) and Adjusted diluted earnings per share (unlike U.S. GAAP diluted earnings per share) may not be comparable to the calculation of similar measures of other companies. Adjusted income and its components and Adjusted diluted earnings per share are presented solely to permit investors to more fully understand how management assesses performance.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also recognize that, as internal measures of performance, the Adjusted income and its components and Adjusted diluted earnings per share measures have limitations, and we do not restrict our performance-management process solely to these metrics. A limitation of these measures is that they provide a view of our operations without including all events during a period, such as the effects of an acquisition or amortization of purchased intangibles, and they do not provide a comparable view of our performance relative to other companies in the biopharmaceutical industry. We also use other specifically tailored tools designed to achieve the highest levels of performance. For example, our R&amp;D organization has productivity targets, upon which its effectiveness is measured. In addition, total shareholder return, both on an absolute basis and relative to a publicly-traded pharmaceutical index, plays a significant role in determining payouts under certain of Pfizer&#8217;s long-term incentive compensation plans.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See the accompanying reconciliations of certain GAAP reported to non-GAAP adjusted information for the </span><span style="font-family:inherit;font-size:10pt;">second quarter</span><span style="font-family:inherit;font-size:10pt;"> and first six months of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> below.</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Purchase Accounting Adjustments</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted income is calculated prior to considering certain significant purchase accounting impacts resulting from business combinations and net asset acquisitions. These impacts, primarily associated with Wyeth (acquired in 2009), Hospira (acquired in 2015), Anacor (acquired in 2016), Medivation (acquired in 2016) and Array (acquired in 2019), can include the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value, amortization related to the increase in fair value of the acquired finite-lived intangible assets, and to a much lesser extent, depreciation related to the increase/decrease in fair value of the acquired fixed assets (primarily manufacturing facilities), amortization related to the increase in fair value of acquired debt, and the fair value changes associated with contingent consideration. Therefore, the Adjusted income measure includes the revenues earned upon the sale of the acquired products without considering the acquisition cost of those products.</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Acquisition-Related Costs</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted income is calculated prior to considering transaction, integration, restructuring charges and additional depreciation costs associated with business combinations because these costs are unique to each transaction and represent costs that were incurred to restructure and integrate two businesses as a result of the acquisition decision. For additional clarity, only transaction costs, additional depreciation and restructuring and integration activities that are associated with a business combination or a net-asset acquisition are included in acquisition-related costs. We have made no adjustments for the resulting synergies.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Discontinued Operations</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted income is calculated prior to considering the results of operations included in discontinued operations, as well as any related gains or losses on the disposal of such operations.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">76</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Certain Significant Items</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted income is calculated prior to considering certain significant items. Certain significant items represent substantive and/or unusual items that are evaluated on an individual basis. Such evaluation considers both the quantitative and the qualitative aspects of their nature. Certain significant items may be highly variable and difficult to predict. Furthermore, in some cases it is reasonably possible that they could reoccur in future periods. For example, major non-acquisition-related cost-reduction programs stand on their own as they are specific to an event or goal with a defined term, but we may have subsequent programs based on reorganizations of the business, cost productivity or in response to loss of exclusivity or economic conditions. Legal charges to resolve litigation are also related to specific cases, which are facts and circumstances specific and, in some cases, may also be the result of litigation matters at acquired companies that were inestimable, not probable or unresolved at the date of acquisition. Unusual items may represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis; items that would be non-recurring; or items that relate to products we no longer sell. While not all-inclusive, examples of items that could be included as certain significant items would be: (i) gains on the completion of joint venture transactions such as the gain on the completion of the GSK Consumer Healthcare joint venture transaction discussed in Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 2B. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Acquisition, Equity-Method Investment and Licensing Arrangements</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Equity-Method Investment</span><span style="font-family:inherit;font-size:10pt;">, (ii) gains and losses from equity securities because of their inherent volatility, which we do not control and cannot predict with any level of certainty and because we do not believe that including these gains and losses assists investors in understanding our business or is reflective of our core operations and business; (iii) a major non-acquisition-related restructuring charge and associated implementation costs; (iv) amounts related to certain disposals of businesses, products or facilities that do not qualify as discontinued operations under U.S. GAAP; (v) certain intangible asset impairments; (vi) adjustments related to the resolution of certain tax positions; (vii) the impact of adopting certain significant, event-driven tax legislation, such as the TCJA discussed in Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 5A. Tax Matters: Taxes on Income from Continuing Operations</span><span style="font-family:inherit;font-size:10pt;"> in Pfizer&#8217;s 2019 Financial Report;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">or (viii) charges related to certain legal matters, such as certain of those discussed in Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 13A. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Contingencies and Certain Commitments</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Legal Proceedings,</span><span style="font-family:inherit;font-size:10pt;"> included in Part I, Item 1 of this Quarterly Report on Form 10-Q. Normal, ongoing defense costs of the Company or settlements of and accruals for legal matters made in the normal course of our business would not be considered certain significant items.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Reconciliations of GAAP Reported to Non-GAAP Adjusted Information&#8211;&#8211;Certain Line Items</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Three Months Ended June&#160;28, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">IN MILLIONS, EXCEPT PER COMMON SHARE DATA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">GAAP Reported</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Purchase Accounting Adjustments</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Acquisition-Related Items</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Discontinued Operations</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Certain Significant Items</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-GAAP Adjusted</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">11,801</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">11,801</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2,281</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(49</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,236</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">3,030</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(221</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,808</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2,132</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(238</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,895</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">905</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(834</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">71</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">362</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(21</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(341</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(862</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(82</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">582</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(361</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income from continuing operations before provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">3,953</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">910</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">21</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">268</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,152</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Provision/(benefit) for taxes on income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">519</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">187</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">30</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">741</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">3,434</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">723</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">16</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">238</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,411</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income attributable to Pfizer Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">3,426</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">723</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">16</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">238</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,403</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Earnings per common share attributable to Pfizer Inc.&#8211;&#8211;diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">0.61</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.13</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.04</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.78</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">See end of tables for note </span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a) </sup></span><span style="font-family:inherit;font-size:8pt;">and </span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span><span style="font-family:inherit;font-size:8pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">77</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Six Months Ended June 28, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">IN MILLIONS, EXCEPT PER COMMON SHARE DATA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">GAAP Reported</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Purchase Accounting Adjustments</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Acquisition-Related Items</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Discontinued Operations</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Certain Significant Items</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-GAAP Adjusted</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">23,829</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">23,829</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">4,658</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(81</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,586</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">5,903</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(351</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,553</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">3,856</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(236</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,622</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">1,790</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,648</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">142</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">431</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(35</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(396</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(641</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(85</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">179</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(547</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income from continuing operations before provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">7,838</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,722</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">34</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">879</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10,474</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Provision/(benefit) for taxes on income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">993</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">367</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">170</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,539</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">6,845</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,355</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">26</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">709</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8,934</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">17</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">17</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income attributable to Pfizer Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">6,828</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,355</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">26</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">709</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8,917</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Earnings per common share attributable to Pfizer Inc.&#8211;&#8211;diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">1.22</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.24</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.13</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.59</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Three Months Ended June&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">IN MILLIONS, EXCEPT PER COMMON SHARE DATA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">GAAP Reported</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Purchase Accounting Adjustments</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Acquisition-Related Items</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Discontinued Operations</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Certain Significant Items</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-GAAP Adjusted</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">13,264</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">13,264</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2,576</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(26</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,556</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">3,511</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(47</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,464</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">1,842</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(18</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,825</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">1,184</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,117</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">67</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(115</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">177</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(62</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">126</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(70</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(156</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(100</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income from continuing operations before provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">4,141</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,178</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(176</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">309</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,452</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Provision/(benefit) for taxes on income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(915</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">222</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,610</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">923</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">5,056</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">957</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(182</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,301</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,529</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">10</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income attributable to Pfizer Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">5,046</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">957</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(182</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,301</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,520</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Earnings per common share attributable to Pfizer Inc.&#8211;&#8211;diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">0.89</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.17</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(0.03</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(0.23</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.80</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">78</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Six Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">IN MILLIONS, EXCEPT PER COMMON SHARE DATA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">GAAP Reported</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Purchase Accounting Adjustments</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Acquisition-Related Items</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Discontinued Operations</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Certain Significant Items</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-GAAP Adjusted</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">26,382</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">26,382</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">5,009</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(48</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,971</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">6,850</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(74</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6,775</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">3,544</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(29</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,518</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2,367</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2,237</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">130</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(69</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">150</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(81</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">218</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(459</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(235</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income from continuing operations before provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">8,463</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,217</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(148</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">691</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">11,223</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Provision/(benefit) for taxes on income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(481</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">446</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">11</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,822</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,797</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">8,945</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,771</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(159</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,131</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9,426</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">15</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">15</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income attributable to Pfizer Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">8,929</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,771</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(159</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,131</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9,410</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Earnings per common share attributable to Pfizer Inc.&#8211;&#8211;diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">1.56</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.31</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(0.03</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(0.20</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.65</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For details of adjustments, see &#8220;Details of Income Statement Items Included in GAAP Reported but Excluded from Non-GAAP Adjusted Income&#8221; below.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The effective tax rate on Non-GAAP Adjusted income was </span><span style="font-family:inherit;font-size:8pt;">14.4%</span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, compared to </span><span style="font-family:inherit;font-size:8pt;">16.9%</span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:8pt;">. The effective tax rate on Non-GAAP Adjusted income was </span><span style="font-family:inherit;font-size:8pt;">14.7%</span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, compared to </span><span style="font-family:inherit;font-size:8pt;">16.0%</span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">first six months of</span><span style="font-family:inherit;font-size:8pt;"> 2019. The decreases were primarily due to a favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">79</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Details of Income Statement Items Included in GAAP Reported but Excluded from Non-GAAP Adjusted Income</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Purchase accounting adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization, depreciation and other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">915</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,185</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,731</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,227</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(6</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(10</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total purchase accounting adjustments&#8211;&#8211;pre-tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">910</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,178</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,722</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,217</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income taxes</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(187</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(222</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(367</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(446</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total purchase accounting adjustments&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">723</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">957</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,355</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,771</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring credits</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(206</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(214</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Transaction costs</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">11</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">14</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Integration costs and other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">11</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">29</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">21</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">64</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Additional depreciation&#8211;&#8211;asset restructuring</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total acquisition-related costs&#8211;&#8211;pre-tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">21</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(176</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">34</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(148</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income taxes</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(8</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(11</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total acquisition-related costs&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">16</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(182</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">26</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(159</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Discontinued operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc.</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Certain significant items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges</span><span style="font-family:inherit;font-size:9pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:9pt;">cost reduction initiatives</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(g)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">341</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">62</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">396</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">81</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Implementation costs and additional depreciation&#8211;&#8211;asset restructuring</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(h)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">82</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">51</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">106</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">89</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net gains recognized during the period on equity securities</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(i)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(696</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(25</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(501</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(136</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Certain legal matters, net</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(i)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">17</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">15</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">26</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Certain asset impairments</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(i)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">149</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Business and legal entity alignment costs</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(j)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">174</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">141</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">289</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">264</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net losses on early retirement of debt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(i)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">138</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(k)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">350</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">56</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">563</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">97</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total certain significant items&#8211;&#8211;pre-tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">268</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">309</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">879</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">691</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income taxes</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(l)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(30</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,610</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(170</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,822</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total certain significant items&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">238</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,301</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">709</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,131</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total purchase accounting adjustments, acquisition-related costs, discontinued operations and certain significant items&#8211;&#8211;net of tax, attributable to Pfizer Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">977</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(526</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,090</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">481</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Included primarily in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Amortization of intangible assets.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Provision /(benefit) for taxes on income. </span><span style="font-family:inherit;font-size:8pt;">Income taxes includes the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction&#8217;s applicable tax rate.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restructuring charges and certain acquisition-related costs. </span><span style="font-family:inherit;font-size:8pt;">For additional information, see the &#8220;Costs and Expenses&#8212;Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">&#8221; </span><span style="font-family:inherit;font-size:8pt;">section of this MD&amp;A and Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 3. </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Selling, informational and administrative expenses </span><span style="font-family:inherit;font-size:8pt;">for the three and </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> ended </span><span style="font-family:inherit;font-size:8pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">. </span><span style="font-size:8pt;">Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions related to acquisitions.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Provision/(benefit) for taxes on income</span><span style="font-family:inherit;font-size:8pt;">. </span><span style="font-size:8pt;">Income taxes includes the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction&#8217;s applicable tax rate. The second quarter and first six months of 2019 include the impact of the non-taxable reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of an IRS audit for multiple tax years.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Discontinued operations&#8211;&#8211;net of tax.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts relate to employee termination costs, asset impairments and other exit costs not associated with acquisitions, which are included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restructuring charges and certain acquisition-related costs </span><span style="font-family:inherit;font-size:8pt;">(see the &#8220;Costs and Expenses&#8212;Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">&#8221; </span><span style="font-family:inherit;font-size:8pt;">section of this MD&amp;A and Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 3. </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:inherit;font-size:8pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(h)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts relate to our cost-reduction/productivity initiatives not related to acquisitions (see Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 3. </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:inherit;font-size:8pt;">). For the three months ended </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, primarily included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:8pt;"> (</span><span style="font-family:inherit;font-size:8pt;">$16 million</span><span style="font-family:inherit;font-size:8pt;">) and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Selling, informational and administrative expenses</span><span style="font-family:inherit;font-size:8pt;"> (</span><span style="font-family:inherit;font-size:8pt;">$63 million</span><span style="font-family:inherit;font-size:8pt;">). For the </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> ended </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, primarily included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:8pt;"> (</span><span style="font-family:inherit;font-size:8pt;">$31 million</span><span style="font-family:inherit;font-size:8pt;">) and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Selling, informational and administrative expenses</span><span style="font-family:inherit;font-size:8pt;"> (</span><span style="font-family:inherit;font-size:8pt;">$78 million</span><span style="font-family:inherit;font-size:8pt;">). For the three months ended </span><span style="font-family:inherit;font-size:8pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:8pt;">, included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:8pt;"> (</span><span style="font-family:inherit;font-size:8pt;">$24 million</span><span style="font-family:inherit;font-size:8pt;">), </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Selling, informational and administrative expenses</span><span style="font-family:inherit;font-size:8pt;"> (</span><span style="font-family:inherit;font-size:8pt;">$16 million</span><span style="font-family:inherit;font-size:8pt;">) and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Research and development expenses </span><span style="font-family:inherit;font-size:8pt;">(</span><span style="font-family:inherit;font-size:8pt;">$11 million</span><span style="font-family:inherit;font-size:8pt;">). For the </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> ended </span><span style="font-family:inherit;font-size:8pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:8pt;">, included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:8pt;"> (</span><span style="font-family:inherit;font-size:8pt;">$46 million</span><span style="font-family:inherit;font-size:8pt;">), </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Selling, informational and administrative expenses</span><span style="font-family:inherit;font-size:8pt;"> (</span><span style="font-family:inherit;font-size:8pt;">$25 million</span><span style="font-family:inherit;font-size:8pt;">) and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:inherit;font-size:8pt;"> (</span><span style="font-family:inherit;font-size:8pt;">$18 million</span><span style="font-family:inherit;font-size:8pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (income)/deductions</span><span style="font-family:inherit;font-size:8pt;">&#8212;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">net </span><span style="font-family:inherit;font-size:8pt;">(see Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4. </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (Income)/Deductions&#8212;Net</span><span style="font-family:inherit;font-size:8pt;">)</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(j)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the three months ended </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, primarily included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Cost of sales </span><span style="font-family:inherit;font-size:8pt;">(</span><span style="font-family:inherit;font-size:8pt;">$30 million</span><span style="font-family:inherit;font-size:8pt;">) and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Selling, informational and administrative expenses </span><span style="font-family:inherit;font-size:8pt;">(</span><span style="font-family:inherit;font-size:8pt;">$138 million</span><span style="font-family:inherit;font-size:8pt;">), and for the </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> ended </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, primarily included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Cost of sales </span><span style="font-family:inherit;font-size:8pt;">(</span><span style="font-family:inherit;font-size:8pt;">$45 million</span><span style="font-family:inherit;font-size:8pt;">) and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Selling, informational and administrative </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">80</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-left:12px;text-align:left;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">expenses </span><span style="font-family:inherit;font-size:8pt;">(</span><span style="font-family:inherit;font-size:8pt;">$235 million</span><span style="font-family:inherit;font-size:8pt;">) and primarily represents legal entity restructuring, as well as separation costs associated with our planned Upjohn transaction with Mylan, and mainly includes consulting, legal, tax and advisory services. For the three and six months ended </span><span style="font-family:inherit;font-size:8pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:8pt;">, primarily included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:inherit;font-size:8pt;">and represented incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily included consulting, legal, tax and advisory services.</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(k</sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the three months ended </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, primarily included in</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> Selling, informational and administrative expenses </span><span style="font-family:inherit;font-size:8pt;">(</span><span style="font-family:inherit;font-size:8pt;">$21 million</span><span style="font-family:inherit;font-size:8pt;">), </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Research and development expenses </span><span style="font-family:inherit;font-size:8pt;">(</span><span style="font-family:inherit;font-size:8pt;">$229 million</span><span style="font-family:inherit;font-size:8pt;">) and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:8pt;"> (</span><span style="font-family:inherit;font-size:8pt;">$97 million</span><span style="font-family:inherit;font-size:8pt;">). For </span><span style="font-family:inherit;font-size:8pt;">the first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, primarily included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Selling, informational and administrative expenses </span><span style="font-family:inherit;font-size:8pt;">(</span><span style="font-family:inherit;font-size:8pt;">$37 million</span><span style="font-family:inherit;font-size:8pt;">)</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">, Research and development expenses</span><span style="font-family:inherit;font-size:8pt;"> (</span><span style="font-family:inherit;font-size:8pt;">$230 million</span><span style="font-family:inherit;font-size:8pt;">)</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:8pt;">and</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:8pt;"> (</span><span style="font-family:inherit;font-size:8pt;">$296 million</span><span style="font-family:inherit;font-size:8pt;">). For the three months ended </span><span style="font-family:inherit;font-size:8pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:8pt;">, primarily included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Selling, informational and administrative expenses </span><span style="font-family:inherit;font-size:8pt;">(</span><span style="font-family:inherit;font-size:8pt;">$28 million</span><span style="font-family:inherit;font-size:8pt;">) and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:8pt;"> (</span><span style="font-family:inherit;font-size:8pt;">$19 million</span><span style="font-family:inherit;font-size:8pt;">). For </span><span style="font-family:inherit;font-size:8pt;">the first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:8pt;">, primarily included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Selling, informational and administrative expenses </span><span style="font-family:inherit;font-size:8pt;">(</span><span style="font-family:inherit;font-size:8pt;">$41 million</span><span style="font-family:inherit;font-size:8pt;">), </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Research and development expenses </span><span style="font-family:inherit;font-size:8pt;">(</span><span style="font-family:inherit;font-size:8pt;">$11 million</span><span style="font-family:inherit;font-size:8pt;">) and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:inherit;font-size:8pt;">(</span><span style="font-family:inherit;font-size:8pt;">$43 million</span><span style="font-family:inherit;font-size:8pt;">). Among other things, the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of 2020 includes charges of </span><span style="font-family:inherit;font-size:8pt;">$85 million</span><span style="font-family:inherit;font-size:8pt;"> and the first six months of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> includes charges of </span><span style="font-family:inherit;font-size:8pt;">$245 million</span><span style="font-family:inherit;font-size:8pt;"> recorded in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net, </span><span style="font-family:inherit;font-size:8pt;">primarily</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:8pt;">representing our pro rata share of restructuring and business combination accounting charges recorded by the GSK Consumer Healthcare joint venture. The second quarter and first six months of 2020 also include upfront payments of </span><span style="font-family:inherit;font-size:8pt;">$130 million</span><span style="font-family:inherit;font-size:8pt;"> to Valneva SE and </span><span style="font-family:inherit;font-size:8pt;">$72 million</span><span style="font-family:inherit;font-size:8pt;"> to BioNTech SE, which were recorded to </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Research and development expenses.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(l)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-size:8pt;">Included in </span><span style="font-size:8pt;font-style:italic;">Provision/(benefit) for taxes on income</span><span style="font-size:8pt;">. Income taxes includes the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction&#8217;s applicable tax rate.</span><span style="font-family:inherit;font-size:8pt;"> The second quarter and first six months of 2019 were favorably impacted primarily by a benefit recorded of approximately $1.4 billion, representing tax and interest, resulting from the favorable settlement of an IRS audit for multiple tax years, as well as the tax benefit recorded as a result of additional guidance issued by the U.S. Department of Treasury related to the TCJA.</span></div></td></tr></table><div><a id="sA30E594F3C5B544CA232485FF3DF9CE6"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Analysis of Operating Segment Information</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables and associated notes provide additional information about the performance of each of our two reportable operating segments&#8212;Biopharma and Upjohn, and our Consumer Healthcare operating segment through July 31, 2019. For additional information about each operating segment, see the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8212;Our Strategy&#8212;Organizing for Growth&#8221; section of this MD&amp;A and Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 14. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Segment, Geographic and Other Revenue Information</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisitions and other business development activities completed in 2019 and in the first half of 2020, including the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture, impacted financial results in the periods presented.</span><span style="font-family:inherit;font-size:10pt;"> For additional information, see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1A. Basis of Presentation and Significant Accounting Policies: Basis of Presentation</span><span style="font-family:inherit;font-size:10pt;"> in our 2019 Financial Report, and Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 2. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Acquisition, Equity-Method Investment and Licensing Arrangements</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables provide revenue and cost information by reportable operating segment and a reconciliation of that information to our condensed consolidated statements of income:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Second Quarter of 2020</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Biopharma</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Upjohn</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-GAAP</span></div><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Adjusted</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reconciling Items</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">GAAP Reported</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9,795</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,006</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">11,801</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">11,801</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,713</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">506</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">17</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,236</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">44</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2,281</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% of revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">17.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">25.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">18.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">19.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,488</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">273</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,047</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,808</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">222</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">3,030</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">216</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">56</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,623</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,895</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">237</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2,132</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">71</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">71</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">834</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">905</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">362</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">362</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(342</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(21</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(361</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(501</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(862</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income/(loss) from continuing operations before provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6,650</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,168</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2,666</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,152</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,199</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">3,953</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">See end of tables for notes (a) through (d).</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">81</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.44054580896686%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Six Months Ended June 28, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Biopharma</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Upjohn</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-GAAP<br/>Adjusted</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reconciling Items</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">GAAP Reported</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">19,802</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,027</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">23,829</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">23,829</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,488</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,003</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">95</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,586</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">73</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">4,658</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% of revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">17.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">24.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">19.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">19.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,980</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">560</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,013</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,553</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">350</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">5,903</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">401</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">110</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,110</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,622</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">234</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">3,856</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">141</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">142</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,648</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">1,790</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">431</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">431</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(588</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">45</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(547</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(94</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(641</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income/(loss) from continuing operations before provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">13,379</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,359</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(5,264</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10,474</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2,635</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">7,838</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.44054580896686%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Second Quarter of 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Biopharma</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Upjohn</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-GAAP<br/>Adjusted</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reconciling Items</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">GAAP Reported</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9,432</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,970</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">862</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">13,264</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">13,264</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,732</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">551</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">273</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,556</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">20</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2,576</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% of revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">18.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">18.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">19.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">19.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,685</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">385</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,394</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,464</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">48</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">3,511</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">200</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">60</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,565</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,825</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">16</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">1,842</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">67</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">67</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,117</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">1,184</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(115</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(115</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(323</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">222</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(100</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">226</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">126</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income/(loss) from continuing operations before provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6,071</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,973</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2,592</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,452</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,311</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">4,141</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.44054580896686%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Six Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Biopharma</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Upjohn</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-GAAP<br/>Adjusted</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reconciling Items</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">GAAP Reported</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">18,477</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6,184</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,721</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">26,382</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">26,382</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,374</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,088</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">510</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,971</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">38</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">5,009</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% of revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">18.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">17.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">18.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">19.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,201</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">722</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,853</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6,775</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">75</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">6,850</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">364</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">115</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,039</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,518</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">26</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">3,544</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">129</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">130</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,237</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2,367</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(69</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(69</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(545</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">302</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(235</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">453</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">218</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income/(loss) from continuing operations before provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">11,954</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,251</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(4,983</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">11,223</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2,760</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">8,463</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Indicates calculation not meaningful or result is equal to or greater than 100%.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts represent the revenues and costs managed by each of the Biopharma and Upjohn reportable operating segments for the periods presented. The expenses generally include only those costs directly attributable to the operating segment.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">82</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other comprises the revenues and costs included in our Adjusted income components (see footnote (c) below) that are managed outside Biopharma and Upjohn and includes the following:</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.05068226120858%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:43%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Second Quarter of 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other Business Activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">WRDM</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(i)</sup></span><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">GPD</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(ii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(iii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Corporate and Other Unallocated</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(iv)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">17</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">17</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">40</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">107</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">900</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,047</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">646</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">727</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">245</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,623</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(25</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(21</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income/(loss) from continuing operations before provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(685</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(732</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(113</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,136</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2,666</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.05068226120858%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:43%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Six Months Ended June 28, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other Business Activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">WRDM</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(i)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">GPD</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(ii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(iii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Corporate and Other Unallocated</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(iv)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">96</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">95</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">68</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">213</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,732</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,013</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,224</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,498</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">11</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">376</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,110</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">41</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">45</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income/(loss) from continuing operations before provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,293</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,499</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(226</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2,245</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(5,264</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.05068226120858%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:43%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Second Quarter of 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other Business Activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">WRDM</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(i)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">GPD</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(ii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(iii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Corporate and Other Unallocated</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(iv)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">862</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">862</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">276</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">273</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">29</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">407</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">958</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,394</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">548</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">764</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">32</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">221</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,565</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">224</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">222</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income/(loss) from continuing operations before provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(576</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(765</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">148</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,399</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2,592</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">83</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.24561403508771%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:43%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Six Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other Business Activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">WRDM</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(i)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">GPD</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(ii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(iii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Corporate and Other Unallocated</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(iv)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,721</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,721</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">550</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(42</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">510</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">50</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">795</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,008</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,853</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,080</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,490</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">63</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">406</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,039</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">304</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">302</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income/(loss) from continuing operations before provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,128</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,491</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">313</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2,676</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(4,983</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">WRDM&#8212;the R&amp;D and Medical expenses managed by our WRDM organization, which is generally responsible for research projects for our Biopharma portfolio until proof-of-concept is achieved and then for transitioning those projects to the GPD organization for possible clinical and commercial development. R&amp;D spending may include upfront and milestone payments for intellectual property rights. The WRDM organization also has responsibility for certain science-based and other platform-services organizations, which provide end-to-end technical expertise and other services to the various R&amp;D projects, as well as the Worldwide Medical and Safety group, which ensures that Pfizer provides all stakeholders&#8211;&#8211;including patients, healthcare providers, pharmacists, payers and health authorities&#8211;&#8211;with complete and up-to-date information on the risks and benefits associated with Pfizer products so that they can make appropriate decisions on how and when to use Pfizer&#8217;s medicines.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(ii)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">GPD</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;">the costs associated with our GPD organization, which is generally responsible for clinical trials from WRDM in the Biopharma portfolio, including late stage portfolio spend. GPD also provides technical support and other services to Pfizer R&amp;D projects. GPD is responsible for facilitating all regulatory submissions and interactions with regulatory agencies.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(iii)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other&#8212;the operating results of our Consumer Healthcare business, through July 31, 2019, and costs associated with other commercial activities not managed as part of Biopharma or Upjohn, including all strategy, business development, portfolio management and valuation capabilities, which previously had been reported in various parts of the organization. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(iv)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Corporate and Other Unallocated&#8211;&#8211;the costs associated with corporate enabling functions (such as digital, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance and worldwide procurement), patient advocacy activities and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments, as well as overhead expenses associated with our manufacturing (which include manufacturing variances associated with production) and commercial operations that are not directly assessed to an operating segment, as business unit (segment) management does not manage these costs. </span><span style="font-size:8pt;">Corporate and Other Unallocated also includes our share of earnings from the GSK Consumer Healthcare joint venture and other charges related to the GSK Consumer Healthcare joint venture, primarily representing our pro-rata share of restructuring and business combination accounting charges recorded by the GSK Consumer Healthcare joint venture.</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">We recognized the following amounts in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:8pt;"> related to forward-exchange contracts designated as cash flow hedges of a portion of our foreign exchange-denominated forecasted intercompany inventory sales:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">a </span><span style="font-family:inherit;font-size:8pt;">$80 million</span><span style="font-family:inherit;font-size:8pt;"> net </span><span style="font-family:inherit;font-size:8pt;">gain</span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:12px;"><div style="line-height:120%;text-align:left;font-size:8pt;text-indent:-12px;"><span style="font-family:inherit;font-size:8pt;">a </span><span style="font-family:inherit;font-size:8pt;">$150 million</span><span style="font-family:inherit;font-size:8pt;"> net </span><span style="font-family:inherit;font-size:8pt;">gain</span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">a </span><span style="font-family:inherit;font-size:8pt;">$59 million</span><span style="font-family:inherit;font-size:8pt;"> net </span><span style="font-family:inherit;font-size:8pt;">gain</span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">a </span><span style="font-family:inherit;font-size:8pt;">$103 million</span><span style="font-family:inherit;font-size:8pt;"> net </span><span style="font-family:inherit;font-size:8pt;">gain</span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:1px;text-align:left;padding-left:24px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For additional information, see Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7E. </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Financial Instruments</span><span style="font-family:inherit;font-size:8pt;">: </span><span style="font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Derivative Financial Instruments and Hedging Activities</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">See the &#8220;Non-GAAP Financial Measure (Adjusted Income)&#8221; section of this MD&amp;A for a definition of these &#8220;Adjusted Income&#8221; components.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Includes costs associated with (i) purchase accounting adjustments; (ii) acquisition-related costs; and (iii) certain significant items, which are substantive and/or unusual, and in some cases recurring, items (such as gains on the completion of joint venture transactions, restructuring charges, legal charges or gains and losses from equity securities), that are evaluated on an individual basis by management. For additional information about these reconciling items and/or our Non-GAAP adjusted measure of performance, see the &#8220;Non-GAAP Financial Measure (Adjusted Income)&#8221; section of this MD&amp;A.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Second Quarter</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;"> of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-align:center;text-decoration:underline;">2020</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;"> vs. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Second Quarter</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;"> of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-align:center;text-decoration:underline;">2019</span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Biopharma Operating Segment</span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Revenues</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Biopharma </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">$363 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">4%</span><span style="font-family:inherit;font-size:10pt;">, to </span><span style="font-family:inherit;font-size:10pt;">$9.8 billion</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> from </span><span style="font-family:inherit;font-size:10pt;">$9.4 billion</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;">, reflecting an operational </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$593 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">6%</span><span style="font-family:inherit;font-size:10pt;">, partially offset by </span><span style="font-family:inherit;font-size:10pt;">the unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact of foreign exchange of </span><span style="font-family:inherit;font-size:10pt;">$230 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">2%</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">84</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following provides an analysis of the </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in Biopharma worldwide </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Biopharma </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:9pt;">, for the three months ended June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9,432</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Operational growth/(decline):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Continued growth from certain key brands</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">351</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Higher revenues for the rare disease business driven by the U.S. launches of Vyndaqel in May 2019 and Vyndamax in September 2019 for ATTR-CM; and in international markets, primarily driven by the March 2019 launch of the ATTR-CM indication in Japan and the February 2020 approval of the ATTR-CM indication in the EU</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">175</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Higher revenues for Inlyta, primarily in the U.S., driven by increased demand resulting from the second quarter of 2019 U.S. FDA approvals for the combinations of certain immune checkpoint inhibitors plus Inlyta for the first-line treatment of patients with advanced RCC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">93</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Higher revenues for Biosimilars, primarily in the U.S., driven by strong volume performance from Retacrit and new product launches </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">78</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Higher revenues for Xtandi primarily driven by continued strong demand in the metastatic and non-metastatic castration-resistant prostate cancer indications as well as the metastatic (mCSPC) castration-sensitive prostate cancer indication, which was approved in the U.S. in December 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">64</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Lower revenues for Enbrel internationally, primarily reflecting continued biosimilar competition in most developed Europe markets, as well as in Japan and Brazil, all of which is expected to continue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(66</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Decline in Prevnar 13/Prevenar 13 revenues primarily in the U.S., reflecting the expected unfavorable impact of disruptions to wellness visits for pediatric and adult patients due to COVID-19-related mobility restrictions or limitations, partially offset by the favorable impact of timing associated with government purchases for the pediatric indication, compared to the prior-year period. The decline in the U.S. was partially offset by growth in international markets primarily reflecting significantly increased adult uptake in Germany and certain other markets resulting from greater vaccine awareness for respiratory illnesses, including specifically pneumococcal disease, due to the COVID-19 pandemic, as well as continued strong pediatric uptake in China</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(28</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other operational factors, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(74</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operational growth, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">593</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unfavorable impact of foreign exchange</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(230</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Biopharma</span><span style="font-family:inherit;font-size:9pt;font-style:italic;">&#160;Revenues </span><span style="font-family:inherit;font-size:9pt;">increase</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">363</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Biopharma</span><span style="font-family:inherit;font-size:9pt;font-style:italic;">&#160;Revenues</span><span style="font-family:inherit;font-size:9pt;">, for the three months ended June 28, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9,795</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-size:8pt;">Certain key brands represent Ibrance, Eliquis and Xeljanz.</span><span style="font-family:inherit;font-size:8pt;"> See the &#8220;Analysis of the Condensed Consolidated Statements of Income&#8211;&#8211;Revenues&#8211;&#8211;Selected Product Discussion&#8221; section of this MD&amp;A for product analysis information</span><span style="font-family:inherit;font-size:8pt;color:#0000ff;">.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:6px;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Biopharma revenues from emerging markets </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">$80 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">4%</span><span style="font-family:inherit;font-size:10pt;">, to </span><span style="font-family:inherit;font-size:10pt;">$1.9 billion</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> from </span><span style="font-family:inherit;font-size:10pt;">$2.0 billion</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;">, reflecting operational growth of </span><span style="font-family:inherit;font-size:10pt;">$82 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">4%</span><span style="font-family:inherit;font-size:10pt;">. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact of </span><span style="font-family:inherit;font-size:10pt;">8%</span><span style="font-family:inherit;font-size:10pt;"> on total Biopharma revenues from emerging markets. The operational </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in emerging markets was primarily driven by Prevenar 13 and Eliquis, partially offset by Sulperazon.</span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Costs and Expenses</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</span><span style="font-family:inherit;font-size:10pt;"></span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales </span><span style="font-family:inherit;font-size:10pt;">as a percentage of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">0.9</span><span style="font-family:inherit;font-size:10pt;"> percentage points, </span><span style="font-size:10pt;">driven by a favorable change in product mix, which includes an increase in alliance revenue which has no associated cost of sales, and a favorable impact of foreign exchange, partially offset by an increase in royalty expenses based on the mix of products sold.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales </span><span style="font-family:inherit;font-size:10pt;">of </span><span style="font-family:inherit;font-size:10pt;">1%</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-size:10pt;">was mainly driven by a favorable impact of foreign exchange, partially offset by an increase in royalty expense based on the mix of products sold, and an unfavorable change in product mix.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, informational and administrative</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">expenses</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">12%</span><span style="font-size:10pt;"> was mostly driven by lower spending on sales and marketing activities due to the impact of the COVID-19 pandemic, a favorable impact of foreign exchange, and lower investments across the Inflammation &amp; Immunology portfolio, partially offset by additional investment in the Oncology portfolio in developed markets.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"></span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">in</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Research and development</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">expenses </span><span style="font-family:inherit;font-size:10pt;">of </span><span style="font-family:inherit;font-size:10pt;">8%</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-size:10pt;">was mainly related to increased medical spending, primarily for Rare Disease, Internal Medicine, and Hospital.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">favorable</span><span style="font-family:inherit;font-size:10pt;"> change in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-size:10pt;"> includes, among other things, an increase in income from collaborations, out-licensing arrangements and sales of compound/product rights, partially offset by a decrease in royalty- related income mainly due to the non-recurrence of a one-time favorable resolution of a legal dispute in the second quarter of 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">85</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Upjohn Operating Segment</span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Revenues</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upjohn </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">$964 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">32%</span><span style="font-family:inherit;font-size:10pt;">, to </span><span style="font-family:inherit;font-size:10pt;">$2.0 billion</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> from </span><span style="font-family:inherit;font-size:10pt;">$3.0 billion</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;">, reflecting an operational </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$917 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">31%</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">the unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact of foreign exchange of </span><span style="font-family:inherit;font-size:10pt;">$48 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">2%</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following provides an analysis of the </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in Upjohn worldwide </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Upjohn </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:9pt;">, for the three months ended June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,970</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Operational growth/(decline):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Lower worldwide revenues for Lyrica, primarily in the U.S., reflecting the expected significantly lower volumes associated with multi-source generic competition that began in the U.S. in July 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(826</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Decline in revenues for Revatio driven by lower U.S. Oral Suspension formulation sales and pricing pressures due to multi-source generic competition</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(34</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Growth in revenues for Lipitor and Norvasc, reflecting significant revenue declines in the prior-year period associated with the VBP program in China, which was initially implemented in certain cities in March 2019, and expanded nationwide beginning in December 2019, resulting in significant volume and price erosion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">55</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other operational factors, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(111</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operational decline, net</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(917</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unfavorable impact of foreign exchange</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(48</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Upjohn </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:9pt;">&#160;decrease</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(964</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Upjohn </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:9pt;">, for the three months ended June 28, 2020</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,006</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Upjohn revenues from emerging markets </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">$11 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">1%</span><span style="font-family:inherit;font-size:10pt;">, to </span><span style="font-family:inherit;font-size:10pt;">$862 million</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> from </span><span style="font-family:inherit;font-size:10pt;">$851 million</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;">, reflecting operational growth of </span><span style="font-family:inherit;font-size:10pt;">$57 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">7%</span><span style="font-family:inherit;font-size:10pt;">. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact of </span><span style="font-family:inherit;font-size:10pt;">5%</span><span style="font-family:inherit;font-size:10pt;"> on total Upjohn revenues from emerging markets. The operational </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in emerging markets was primarily driven by Lipitor and Norvasc in China.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Costs and Expenses</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales </span><span style="font-family:inherit;font-size:10pt;">as a percentage of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">6.7</span><span style="font-family:inherit;font-size:10pt;"> percentage points, </span><span style="font-size:10pt;">driven by lower Lyrica revenues, primarily in the U.S. due to multi-source generic competition that began in July 2019, partially offset by lower royalty expense for Lyrica due to its U.S. patent expiration.</span><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales </span><span style="font-family:inherit;font-size:10pt;">of </span><span style="font-family:inherit;font-size:10pt;">8%</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-size:10pt;">was mainly driven by a decrease in sales volume and lower royalty expense primarily due to the Lyrica patent expiration and multi-source generic competition that began in the U.S. in July 2019.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, informational and administrative</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">expenses </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">29%</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="color:#000000;font-size:10pt;">driven by a decrease in field force expense as well as advertising and promotion expenses, primarily related to Lipitor and Norvasc, due to the volume-based procurement (VBP) program in China, which was initially implemented in certain cities in March 2019 and expanded nationwide beginning in December 2019, as well as Lyrica in the U.S. due to generic competition that began in July 2019 and anticipated generic competition for Celebrex in Japan beginning in June 2020</span><span style="color:#000000;font-size:10pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">expenses </span><span style="font-family:inherit;font-size:10pt;">and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-size:10pt;">were relatively unchanged.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">First </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Six Months</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;"> of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-align:center;text-decoration:underline;">2020</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;"> vs. First </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Six Months</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;"> of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-align:center;text-decoration:underline;">2019</span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Biopharma Operating Segment</span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Revenues</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Biopharma </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">$1.3 billion</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">7%</span><span style="font-family:inherit;font-size:10pt;">, to </span><span style="font-family:inherit;font-size:10pt;">$19.8 billion</span><span style="font-family:inherit;font-size:10pt;"> in the first </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> from </span><span style="font-family:inherit;font-size:10pt;">$18.5 billion</span><span style="font-family:inherit;font-size:10pt;"> in the first </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, reflecting an operational </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$1.7 billion</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">9%</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact of foreign exchange of </span><span style="font-family:inherit;font-size:10pt;">$345 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">2%</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following provides an analysis of the </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in Biopharma worldwide </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">86</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Biopharma </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:9pt;">, for the six months ended June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">18,477</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Operational growth/(decline):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Continued growth from certain key brands</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">812</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Higher revenues for the rare disease business driven by the U.S. launches of Vyndaqel in May 2019 and Vyndamax in September 2019 for ATTR-CM; and in international markets, primarily driven by the March 2019 launch of the ATTR-CM indication in Japan and the February 2020 approval of the ATTR-CM indication in the EU</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">353</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Higher revenues for the Hospital business in the U.S., primarily driven by increased demand for certain sterile injectable products utilized in the intubation and ongoing treatment of mechanically-ventilated COVID-19 patients as well as continued growth from Panzyga following its November 2018 U.S. launch</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">212</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Higher revenues for Inlyta, primarily in the U.S., driven by increased demand resulting from the second quarter of 2019 U.S. FDA approvals for the combinations of certain immune checkpoint inhibitors plus Inlyta for the first-line treatment of patients with advanced RCC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">191</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Higher revenues for Biosimilars, primarily in the U.S., driven by strong volume performance from Retacrit, new product launches and steady volume and share growth in the U.S. for Inflectra, across hospital channels, clinics and alternate sites of care </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">190</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Higher revenues for Xtandi primarily driven by continued strong demand in the metastatic and non-metastatic castration-resistant prostate cancer indications as well as the metastatic (mCSPC) castration-sensitive prostate cancer indication, which was approved in the U.S. in December 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">106</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Lower revenues for Enbrel internationally, primarily reflecting continued biosimilar competition in most developed Europe markets, as well as in Brazil and Japan, all of which is expected to continue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(159</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Decline in Prevnar 13/Prevenar 13 revenues primarily in the U.S., reflecting the expected unfavorable impact of disruptions to wellness visits for pediatric and adult patients due to COVID-19-related mobility restrictions or limitations, partially offset by the favorable impact of timing associated with government purchases for the pediatric indication, compared to the prior-year period. The decline in the U.S. was partially offset by growth in international markets primarily reflecting significantly increased adult uptake in Germany and certain other markets resulting from greater vaccine awareness for respiratory illnesses, including specifically pneumococcal disease, due to the COVID-19 pandemic, as well as continued strong pediatric uptake in China</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(47</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other operational factors, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">11</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operational growth, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,670</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unfavorable impact of foreign exchange</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(345</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Biopharma</span><span style="font-family:inherit;font-size:9pt;font-style:italic;">&#160;Revenues </span><span style="font-family:inherit;font-size:9pt;">increase</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,325</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Biopharma </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:9pt;">, for the six months ended June 28, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">19,802</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-size:8pt;">Certain key brands represent Ibrance, Eliquis and Xeljanz.</span><span style="font-family:inherit;font-size:8pt;"> See the &#8220;Analysis of the Condensed Consolidated Statements of Income&#8211;&#8211;Revenues&#8211;&#8211;Selected Product Discussion&#8221; section of this MD&amp;A for product analysis information.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:6px;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Biopharma revenues from emerging markets </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">$143 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">4%</span><span style="font-family:inherit;font-size:10pt;">, to </span><span style="font-family:inherit;font-size:10pt;">$4.1 billion</span><span style="font-family:inherit;font-size:10pt;"> in the first </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> from </span><span style="font-family:inherit;font-size:10pt;">$3.9 billion</span><span style="font-family:inherit;font-size:10pt;"> in the first </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, reflecting operational growth of </span><span style="font-family:inherit;font-size:10pt;">$379 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">10%</span><span style="font-family:inherit;font-size:10pt;">. Foreign exchange had an </span><span style="font-family:inherit;font-size:10pt;">unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact of </span><span style="font-family:inherit;font-size:10pt;">6%</span><span style="font-family:inherit;font-size:10pt;"> on total Biopharma revenues from emerging markets. The operational </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in emerging markets was primarily driven by Prevenar 13, Eliquis, certain anti-infective products, primarily Zavicefta and Zithromax, Ibrance and Xalkori, partially offset by Sulperazon.</span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Costs and Expenses</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales </span><span style="font-family:inherit;font-size:10pt;">as a percentage of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">0.6</span><span style="font-family:inherit;font-size:10pt;"> percentage points, </span><span style="font-size:10pt;">driven by a favorable change in product mix, which includes an increase in alliance revenue which has no associated cost of sales, partially offset by an increase in royalty expenses based on the mix of products sold.</span><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales </span><span style="font-family:inherit;font-size:10pt;">of </span><span style="font-family:inherit;font-size:10pt;">3%</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-size:10pt;">was mainly driven by an increase in sales volumes for various products and an increase in royalty expenses based on the mix of products sold, partially offset by a favorable impact of foreign exchange.</span><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, informational and administrative</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">expenses</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">7%</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-size:10pt;">was mostly driven by lower spending on sales and marketing activities due to the impact of the COVID-19 pandemic, lower investments across the Inflammation &amp; Immunology portfolio, a favorable impact of foreign exchange, and lower healthcare reform expenses, partially offset by additional investment in the Oncology portfolio in developed markets.</span><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">expenses </span><span style="font-family:inherit;font-size:10pt;">of </span><span style="font-family:inherit;font-size:10pt;">10%</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-size:10pt;">was mainly related to increased medical spending, primarily for Oncology, Internal Medicine, and Rare Disease.</span><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">favorable</span><span style="font-family:inherit;font-size:10pt;"> change in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-size:10pt;">includes, among other things, an increase in income from collaborations, out-licensing arrangements and sales of compound/product rights, partially offset by a decrease in royalty- related income mainly due to the non-recurrence of a one-time favorable resolution of a legal dispute in the second quarter of 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">87</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Upjohn Operating Segment</span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Revenues</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upjohn </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">$2.2 billion</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">35%</span><span style="font-family:inherit;font-size:10pt;">, to </span><span style="font-family:inherit;font-size:10pt;">$4.0 billion</span><span style="font-family:inherit;font-size:10pt;"> in the first </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> from </span><span style="font-family:inherit;font-size:10pt;">$6.2 billion</span><span style="font-family:inherit;font-size:10pt;"> in the first </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, reflecting an operational </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$2.1 billion</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">34%</span><span style="font-family:inherit;font-size:10pt;">, and the unfavorable impact of foreign exchange of </span><span style="font-family:inherit;font-size:10pt;">$66 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">1%</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following provides an analysis of the </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in Upjohn worldwide </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Upjohn </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:9pt;">, for the six months ended June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6,184</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Operational decline:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Lower worldwide revenues for Lyrica, primarily in the U.S., reflecting the expected significantly lower volumes associated with multi-source generic competition that began in the U.S. in July 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,655</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Declines in revenues for Lipitor and Norvasc, primarily resulting from the VBP program in China, which was initially implemented in certain cities in March 2019, and expanded nationwide beginning in December 2019, resulting in significant volume and price erosion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(254</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Decline in revenues for Revatio driven by lower U.S. Oral Suspension formulation sales and pricing pressures due to multi-source generic competition</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(58</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other operational factors, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(124</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operational decline, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2,090</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unfavorable impact of foreign exchange</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(66</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Upjohn </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:9pt;">&#160;decrease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2,156</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Upjohn </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:9pt;">, for the six months ended June 28, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,027</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Upjohn revenues from emerging markets </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">$307 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">15%</span><span style="font-family:inherit;font-size:10pt;">, to </span><span style="font-family:inherit;font-size:10pt;">$1.7 billion</span><span style="font-family:inherit;font-size:10pt;"> in the first </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> from </span><span style="font-family:inherit;font-size:10pt;">$2.0 billion</span><span style="font-family:inherit;font-size:10pt;"> in the first </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, reflecting an operational decline of </span><span style="font-family:inherit;font-size:10pt;">$247 million</span><span style="font-family:inherit;font-size:10pt;"> or, </span><span style="font-family:inherit;font-size:10pt;">12%</span><span style="font-family:inherit;font-size:10pt;">, and the unfavorable impact of foreign exchange of </span><span style="font-family:inherit;font-size:10pt;">3%</span><span style="font-family:inherit;font-size:10pt;"> on total Upjohn revenues from emerging markets. The operational </span><span style="font-family:inherit;font-size:10pt;">decline</span><span style="font-family:inherit;font-size:10pt;"> in emerging markets was primarily driven by Lipitor and Norvasc in China.</span></div><div style="line-height:120%;padding-bottom:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Costs and Expenses</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales </span><span style="font-family:inherit;font-size:10pt;">as a percentage of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">7.3</span><span style="font-family:inherit;font-size:10pt;"> percentage points, </span><span style="font-size:10pt;">driven by lower Lyrica revenues, primarily in the U.S. due to multi-source generic competition that began in July 2019, lower Lipitor and Norvasc revenues due to the</span><span> </span><span style="font-family:inherit;font-size:10pt;">VBP </span><span style="font-size:10pt;">program in China, which was initially implemented in March 2019 and expanded nationwide beginning in December 2019, and an unfavorable impact of foreign exchange, partially offset by lower royalty expense for Lyrica due to its U.S. patent expiration.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Cost of sales </span><span style="font-family:inherit;font-size:10pt;">of </span><span style="font-family:inherit;font-size:10pt;">8%</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-size:10pt;">was mainly driven by lower royalty expense and a decrease in sales volume primarily due to the Lyrica patent expiration and multi-source generic competition that began in the U.S. in July 2019.</span><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, informational and administrative</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">expenses</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">22%</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="background-color:#ffffff;font-size:10pt;">driven by a reduction in field force expense as well as advertising and promotion expenses, primarily related to Lyrica in the U.S. due to generic competition that began in July 2019 and the anticipated generic competition for Celebrex in Japan that began in June 2020, as well as a decrease in Lipitor and Norvasc expenses due to the VBP program in China</span><span style="font-size:10pt;">, </span><span style="background-color:#ffffff;font-size:10pt;">which was initially implemented </span><span style="font-size:10pt;">in certain cities</span><span style="background-color:#ffffff;font-size:10pt;"> in March 2019 and expanded nationwide beginning in December 2019</span><span style="background-color:#ffffff;color:#2c2c2c;font-size:10pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">expenses</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-size:10pt;">were relatively unchanged.</span></div></td></tr></table><div><a id="s9C39D289ECA35993A0DC1AE940DB481F"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">ANALYSIS OF THE CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%<br/>Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash provided by/(used in):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating activities</span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,688</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,309</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">55</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investing activities</span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(13,082</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,648</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financing activities</span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,959</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(9,318</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(70</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(28</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net increase in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and cash equivalents </span><span style="font-family:inherit;font-size:10pt;">and restricted cash and cash equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">495</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">612</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(19</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">* Calculation not meaningful or results are equal to or greater than 100%.</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">88</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Operating Activities</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in net cash provided by operating activities is driven by the net change in</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Other changes in assets and liabilities, net of acquisitions and divestitures</span><span style="font-family:inherit;font-size:10pt;">, partially offset by a decrease in net income, reflecting the lower contribution from the Consumer Healthcare business as a result of the July 31, 2019 completion of the Consumer Healthcare joint venture transaction with GSK.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In </span><span style="font-family:inherit;font-size:10pt;">the first six months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;">, the change in the line item </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other adjustments, net</span><span style="font-family:inherit;font-size:10pt;"> primarily reflects, among other items:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an increase in equity method dividends received, </span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an increase in net unrealized gains on equity securities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an increase in equity income; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an increase in accreted interest on debt discount. </span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the condensed consolidated statements of cash flows, the line item </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other changes in assets and liabilities, net of acquisitions and divestitures</span><span style="font-family:inherit;font-size:10pt;"> is presented excluding the effects of changes in foreign currency exchange rates, as these changes do not reflect actual cash inflows or outflows, and excluding any other significant non-cash movements. Accordingly, the amounts shown will not necessarily agree with the changes in the assets and liabilities that are presented in our condensed consolidated balance sheets. In </span><span style="font-family:inherit;font-size:10pt;">the first six months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;">, the line item </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other changes in assets and liabilities, net of acquisitions and divestitures,</span><span style="font-family:inherit;font-size:10pt;"> primarily reflects changes, in the normal course of business, in trade accounts receivable, inventories, other current and noncurrent assets, trade accounts payable, accrued compensation, and other current and noncurrent liabilities, as well as in 2019, the adjustment necessary to reflect the non-cash nature of the favorable settlement of an IRS audit for multiple tax years (see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 5D. Tax Matters: Tax Contingencies </span><span style="font-family:inherit;font-size:10pt;">in our 2019 Financial Report).</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Investing Activities</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The change in net cash provided by/(used in) investing activities was mostly attributable to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a </span><span style="font-family:inherit;font-size:10pt;">$16.7 billion</span><span style="font-family:inherit;font-size:10pt;"> increase in net purchases of short-term investments with original maturities of three months or less, largely due to the </span><span style="font-family:inherit;font-size:10pt;">$11.4 billion</span><span style="font-family:inherit;font-size:10pt;"> of proceeds from the Upjohn long-term debt issuances in the second quarter of 2020, which were invested in money market funds (see Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 7D. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: </span><span style="font-style:italic;font-weight:normal;text-decoration:none;">Long-Term Debt</span><span style="font-family:inherit;font-size:10pt;"> and &#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 7A. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments</span><span style="font-family:inherit;font-size:10pt;">: </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurements</span><span style="font-family:inherit;font-size:10pt;">); and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a </span><span style="font-family:inherit;font-size:10pt;">$1.4 billion</span><span style="font-family:inherit;font-size:10pt;"> decrease in proceeds from redemptions and sales of short-term investments.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Financing Activities</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The change in net cash provided by/(used in) financing activities was primarily attributable to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an increase in issuances of long-term debt of </span><span style="font-family:inherit;font-size:10pt;">$11.7 billion</span><span style="font-family:inherit;font-size:10pt;"> (see Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 7D. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: </span><span style="font-style:italic;font-weight:normal;text-decoration:none;">Long-Term Debt</span><span style="font-family:inherit;font-size:10pt;">); </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a decrease in purchases of common stock of </span><span style="font-family:inherit;font-size:10pt;">$8.9 billion</span><span style="font-family:inherit;font-size:10pt;">; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">lower repayments on long-term debt of </span><span style="font-family:inherit;font-size:10pt;">$3.2 billion</span><span style="font-family:inherit;font-size:10pt;">,</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$3.1 billion</span><span style="font-family:inherit;font-size:10pt;"> net payments on short-term borrowings in the first six months of 2020, compared to </span><span style="font-family:inherit;font-size:10pt;">$4.3 billion</span><span style="font-family:inherit;font-size:10pt;"> net proceeds raised from short-term borrowings in the first six months of 2019.</span></div></td></tr></table><div><a id="s683E43952F88598F9D86F87273D7B54F"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">ANALYSIS OF FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We rely largely on operating cash flows, short-term investments, short-term commercial paper borrowings and long-term debt to provide for our liquidity requirements. We continue our efforts to improve cash inflows through working capital efficiencies. We target specific areas of focus including accounts receivable, inventories, accounts payable, and other working capital, which allows us to optimize our operating cash flows. Due to our significant operating cash flows as well as our financial assets, access to capital markets and available lines of credit and revolving credit agreements, we believe that we have, and will maintain, the ability to meet our liquidity needs for the foreseeable future, which can include, among others:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the working capital requirements of our operations, including our R&amp;D activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">investments in our business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">dividend payments and potential increases in the dividend rate;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">share repurchases;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cash requirements associated with our cost-reduction/productivity initiatives;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">paying down outstanding debt;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">89</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">contributions to our pension and postretirement plans; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">business-development activities.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our long-term debt is rated high-quality by both S&amp;P and Moody&#8217;s. See the &#8220;Credit Ratings&#8221; section below. As market conditions change, we continue to monitor our liquidity position. We have taken and will continue to take a conservative approach to our financial investments. Both short-term and long-term debt investments consist primarily of high-quality, highly liquid, well-diversified available-for-sale debt securities.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Selected Measures of Liquidity and Capital Resources</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">The following table provides certain relevant measures of our liquidity and capital resources:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS, EXCEPT RATIOS AND PER COMMON SHARE DATA)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">December&#160;31, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Selected financial assets</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span><span style="font-family:inherit;font-size:9.5pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,801</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,305</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Restricted short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">11,412</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">9,581</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">8,525</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Long-term investments, excluding private equity securities at cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">2,370</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">2,258</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">25,163</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">12,088</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Debt:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Short-term borrowings, including current portion of long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">13,084</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">16,195</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">50,529</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">35,955</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">63,613</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">52,150</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Selected net financial liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(38,450</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(40,062</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Working capital</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">13,701</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(4,501</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Ratio of current assets to current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1.42:1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">0.88:1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total Pfizer Inc. shareholders&#8217; equity per common share</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">11.58</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">11.41</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">See Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7. </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Financial Instruments</span><span style="font-family:inherit;font-size:8pt;"> for a description of certain assets held and for a description of credit risk related to our financial instruments held.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The </span><span style="font-family:inherit;font-size:8pt;">increase</span><span style="font-family:inherit;font-size:8pt;"> in working capital was primarily due to:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">an increase mainly driven by operating cash flow generation and the long-term debt issuances discussed below, partially offset by debt repayment and capital expenditures; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">the timing of accruals, cash receipts and payments in the ordinary course of business.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Represents total Pfizer Inc. shareholders&#8217; equity divided by the actual number of common shares outstanding (which excludes treasury stock).</span></div></td></tr></table><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2020, Upjohn Inc. and Upjohn Finance B.V. (a wholly-owned subsidiary of Upjohn Inc.) completed privately placed debt offerings of </span><span style="font-family:inherit;font-size:10pt;">$7.45 billion</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">&#8364;3.60 billion</span><span style="font-family:inherit;font-size:10pt;"> aggregate principal senior unsecured notes, respectively (the Upjohn Debt Transactions). See the &#8220;Agreement to Combine Upjohn with Mylan&#8221; section below for the discussion on the use of proceeds.</span></div><div style="line-height:120%;padding-bottom:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2020, we completed a public offering of </span><span style="font-family:inherit;font-size:10pt;">$4.0 billion</span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount of senior unsecured notes.</span></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2020, we:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">completed a public offering of </span><span style="font-family:inherit;font-size:10pt;">$1.25 billion</span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount of senior unsecured sustainability notes. The proceeds were initially used to repay outstanding commercial paper and subsequently will be used to help manage our environmental impact and support increased patient access to our medicines and vaccines, especially among underserved populations, and strengthen healthcare systems; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">repurchased at par all </span><span style="font-family:inherit;font-size:10pt;">$1.065 billion</span><span style="font-family:inherit;font-size:10pt;"> principal amount outstanding of senior unsecured notes that were due in 2047 before the maturity date, which did not have a material impact on our condensed consolidated financial statements.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For additional information, see Notes to Condensed Consolidated Financial Statements</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8211;&#8211;Note 7D. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: </span><span style="font-style:italic;font-weight:normal;text-decoration:none;">Long-Term Debt</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For additional information about the sources and uses of our funds, see the &#8220;Analysis of the Condensed Consolidated Statements of Cash Flows&#8221; section of this MD&amp;A.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Agreement to Combine Upjohn with Mylan</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with our agreement to combine Upjohn with Mylan to form a new company, Viatris, discussed in the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Business Development Initiatives&#8221; section of this MD&amp;A, in June 2020, Upjohn Inc. (i) incurred $11.4 billion of debt in the Upjohn Debt Transactions, (ii) entered into a revolving credit agreement for up to $4 billion, $1.5 billion of which will be available in a single draw at or around the closing of the combination of Upjohn with Mylan for the sole purpose of funding the cash payment of $12 billion by Upjohn Inc. to Pfizer as partial consideration for Pfizer&#8217;s contribution of the Upjohn Business to Upjohn Inc. and (iii) entered into a $600 million delayed draw term loan agreement. Immediately prior to the proposed distribution to Pfizer&#8217;s stockholders of all of the </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">90</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">issued and outstanding shares of Upjohn Inc.&#8217;s common stock held by Pfizer (the Distribution), Upjohn Inc. will make a cash distribution of $12 billion to Pfizer. The proceeds of the revolving credit agreement, term loan agreement and the Upjohn Debt Transactions will be used to fund the $12 billion cash distribution from Upjohn Inc. to Pfizer prior to the Distribution. In the interim, the $11.4 billion of proceeds from the Upjohn Debt Transactions were invested by Upjohn Inc. in money market funds and classified as </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted short-term investments</span><span style="font-family:inherit;font-size:10pt;"> in the condensed consolidated balance sheet as of June 28, 2020. Upon completion of the Upjohn Debt Transactions on June 23, 2020, the commitments under the senior unsecured $12 billion bridge facility were fully terminated. Pfizer has guaranteed the notes in the Upjohn Debt Transactions, and such guarantees will automatically and unconditionally terminate without the consent of holders of the notes upon the Distribution. Upjohn Inc. has guaranteed the notes issued by Upjohn Finance B.V., and Upjohn Inc. will remain a guarantor of such notes post Distribution. Following the separation, Upjohn Inc. and Upjohn Finance B.V., as applicable, will remain the obligor with respect to all of the aforementioned debt. See Notes to Condensed Consolidated Financial Statements</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8211;&#8211;Note 7D. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: </span><span style="font-style:italic;font-weight:normal;text-decoration:none;">Long-Term Debt</span><span style="font-family:inherit;font-size:10pt;"> for additional information.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Domestic and International Selected Financial Assets</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Many of our operations are conducted outside the U.S., and significant portions of our selected financial assets are held internationally. The amount of funds held in U.S. tax jurisdictions can fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as business-development activities. As part of our ongoing liquidity assessments, we regularly monitor the mix of domestic and international cash flows (both inflows and outflows). The changes in tax law under the TCJA, which includes transitioning U.S. international taxation from a worldwide tax system to a territorial tax system, allow us to more easily access our selected financial assets globally.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Credit Ratings</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Two major corporate debt-rating organizations, Moody&#8217;s and S&amp;P, assign ratings to our short-term and long-term debt. A security rating is not a recommendation to buy, sell or hold securities and the rating is subject to revision or withdrawal at any time by the rating organization. Each rating should be evaluated independently of any other rating.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2019, S&amp;P placed Pfizer on &#8220;CreditWatch Negative&#8221; following the announcement of Pfizer&#8217;s intention to acquire Array. The CreditWatch placement was resolved with a one-notch downgrade of Pfizer&#8217;s debt rating to &#8216;AA-&#8217; upon the consummation of the transaction. In July 2019, we announced that we entered into a definitive agreement to combine Upjohn with Mylan, which resulted in actions from both Moody&#8217;s and S&amp;P.&#160;Moody&#8217;s placed Pfizer&#8217;s long-term rating under review for downgrade (limited to one-notch, or &#8216;A2&#8217; upon close of the Mylan transaction) while S&amp;P lowered Pfizer&#8217;s rating to &#8216;AA-&#8217; (as a result of the Array transaction) and confirmed it will still remain on CreditWatch Negative (with the expectation the rating will be lowered one additional notch to &#8216;A+&#8217; upon close of the Mylan transaction).</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:22%;"></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the current ratings assigned by these rating agencies to our commercial paper and senior unsecured long-term debt:</span></div></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">NAME OF RATING AGENCY</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Pfizer </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Commercial Paper </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Pfizer</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Long-Term Debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Outlook/Watch</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Date of Last Rating Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Rating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Rating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Moody&#8217;s</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">P-1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">A1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Under Review for Downgrade</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October 2009</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">S&amp;P</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">A-1+</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">AA-</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">CreditWatch Negative</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">July 2019</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Debt Capacity&#8211;&#8211;Lines of Credit</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:10pt;">We have available lines of credit and revolving credit agreements with a group of banks and other financial intermediaries. We typically maintain cash and cash equivalent balances and short-term investments which, together with our available revolving credit facilities, are in excess of our commercial paper and other short-term borrowings. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span><span style="font-family:Arial;font-size:8pt;">,</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:10pt;">we had access to a total of </span><span style="font-family:inherit;font-size:10pt;">$15 billion</span><span style="font-family:inherit;font-size:10pt;"> in U.S. revolving credit facilities consisting of a </span><span style="font-family:inherit;font-size:10pt;">$7 billion</span><span style="font-family:inherit;font-size:10pt;"> facility expiring in 2024 and an </span><span style="font-family:inherit;font-size:10pt;">$8 billion</span><span style="font-family:inherit;font-size:10pt;"> facility expiring in September 2020, which may be used to support our commercial paper borrowings. In addition to the U.S. revolving credit facilities, our lenders have provided us an additional </span><span style="font-family:inherit;font-size:10pt;">$611 million</span><span style="font-family:inherit;font-size:10pt;"> in lines of credit, of which </span><span style="font-family:inherit;font-size:10pt;">$582 million</span><span style="font-family:inherit;font-size:10pt;"> expire within one year. Of these total lines of credit, </span><span style="font-family:inherit;font-size:10pt;">$15.6 billion</span><span style="font-family:inherit;font-size:10pt;"> were unused as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">LIBOR</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, we issue variable rate debt based on LIBOR, or undertake interest rate swaps that contain a variable element based on LIBOR. The U.K. Financial Conduct Authority announced in July 2017 that it will no longer compel banks to submit rates that are currently used to calculate LIBOR after 2021. Various governing parties, including government agencies, are working on a benchmark transition plan for LIBOR (and other interbank offered rates globally). We are monitoring their </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">91</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">progress, and we will likely amend contracts to accommodate any replacement rate where it is not already provided. We do not expect the transition to an alternative rate to have a material impact on our liquidity or financial resources.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Global Economic Conditions&#8211;&#8211;General</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The global economic environment has not had, nor do we anticipate it will have, a material impact on our liquidity or capital resources. Due to our significant operating cash flows, financial assets, access to capital markets and available lines of credit and revolving credit agreements, we continue to believe that we have, and will maintain, the ability to meet our liquidity needs for the foreseeable future. We monitor our liquidity position continuously in the face of evolving economic conditions. For additional information see the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;The Global Economic Environment&#8221; section in this MD&amp;A.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Global Economic Conditions&#8211;&#8211;Venezuela and Argentina Operations</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our Venezuela and Argentina operations function in hyperinflationary economies. The impact to Pfizer is not considered material.</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with a transaction or that are related to events and activities prior to or following a transaction. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss. These indemnification obligations generally are subject to various restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;">, the estimated fair value of our indemnification obligations was not significant.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of our co-promotion or license agreements give our licensors or partners the rights to negotiate for, or in some cases to obtain under certain financial conditions, co-promotion or other rights in specified countries with respect to certain of our products.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Share-Purchase Plans and Accelerated Share Repurchase Agreements</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;">, our remaining share-purchase authorization was approximately </span><span style="font-family:inherit;font-size:10pt;">$5.3 billion</span><span style="font-family:inherit;font-size:10pt;">, with no repurchases in the first six months of 2020 and no repurchases currently planned for the remainder of 2020. See Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 12. Equity</span><span style="font-family:inherit;font-size:10pt;"> in our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> Financial Report for more information on our publicly announced share-purchase plans, including our accelerated share repurchase agreements.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Dividends on Common Stock</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For quarterly cash dividend information, see Notes to Condensed Consolidated Financial Statements</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8211;&#8211;Note 11. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Equity</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our current and projected dividends provide a return to shareholders while maintaining sufficient capital to invest in growing our businesses. Our dividends are not restricted by debt covenants. While the dividend level remains a decision of Pfizer&#8217;s Board of Directors and will continue to be evaluated in the context of future business performance, we currently believe that we can support future annual dividend increases, barring significant unforeseen events. Also, assuming Upjohn is spun off, Pfizer expects that immediately following the closing of the proposed transaction to combine Upjohn with Mylan, the combined dividend dollar amount received by Pfizer shareholders, based upon the combination of continued Pfizer ownership and approximately 0.12 shares of the new company (Viatris) expected to be granted for each Pfizer share in a spin-off, will equate to Pfizer&#8217;s dividend amount in effect immediately prior to closing.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">92</span></div></div><hr style="page-break-after:always"></hr><div><a id="s813CF60B975851DFA03D854F39CC9ADD"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">NEW ACCOUNTING STANDARDS</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Recently Adopted Accounting Standards</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1B. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: </span><span style="font-style:italic;font-weight:normal;text-decoration:none;">Adoption of New Accounting Standards in 2020</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:33%;"></td></tr><tr><td colspan="5" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Recently Issued Accounting Standards, Not Adopted as of June 28, 2020</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Standard/Description</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Effective Date</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Effect on the Financial Statements or Other Significant Matters</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">In December 2019, the FASB issued new guidance that simplifies the </span><span style="font-family:inherit;font-size:9pt;font-weight:bold;">accounting for income taxes</span><span style="font-family:inherit;font-size:9pt;">&#160;by eliminating certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">January 1, 2021. Early adoption is permitted.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">We do not expect this guidance to have a material impact on our consolidated financial statements.</span></div><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">In March 2020, the FASB issued new guidance to address </span><span style="font-family:inherit;font-size:9pt;font-weight:bold;">reference rate reform</span><span style="font-family:inherit;font-size:9pt;">&#160;by providing temporary optional expedients and exceptions to the guidance for contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued after 2021 because of reference rate reform.</span></div><div style="padding-bottom:2px;padding-top:2px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The new guidance provides the following optional expedients: </span></div><div><div style="float:left; width:12px; padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">1.</span></div><span style=""><span style="font-family:inherit;font-size:9pt;">Simplify accounting analyses under current U.S. GAAP for contract modifications.</span></span></div><div><div style="float:left; width:12px; padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">2.</span></div><span style=""><span style="font-family:inherit;font-size:9pt;">Simplify the assessment of hedge effectiveness and allow hedging relationships affected by reference rate reform to continue.</span></span></div><div><div style="float:left; width:12px; padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">3.</span></div><span style=""><span style="font-family:inherit;font-size:9pt;">Allow a one-time election to sell or transfer debt securities classified as held to maturity that reference a rate affected by reference rate reform.</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Elections can be adopted prospectively at any time in the first quarter of 2020 through December 31, 2022.</span></div><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">We are assessing the impact of the provisions of this new guidance on our consolidated financial statements.</span></div><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td></tr></table></div></div><div><a id="sE7A89D218CBF544EB08D3DAA9D030F13"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">FORWARD-LOOKING INFORMATION AND FACTORS THAT MAY AFFECT FUTURE RESULTS</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This report and other written or oral statements that we make from time to time contain forward-looking statements. Such forward-looking statements involve substantial risks and uncertainties. We have tried, wherever possible, to identify such statements by using words such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;likely,&#8221; &#8220;ongoing,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;assume,&#8221; &#8220;target,&#8221; &#8220;forecast,&#8221; &#8220;guidance,&#8221; &#8220;goal,&#8221; &#8220;objective,&#8221; &#8220;aim,&#8221; &#8220;seek&#8221; and other words and terms of similar meaning or by using future dates in connection with any discussion of, among other things, our anticipated operating and financial performance, business plans and prospects, expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, revenue contribution, growth, performance, timing of exclusivity and potential benefits, strategic reviews, capital allocation objectives, plans for and prospects of our acquisitions and other business-development activities, benefits anticipated from the reorganization of our commercial operations in 2019, sales efforts, expenses, interest rates, foreign exchange rates, the outcome of contingencies, such as legal proceedings, government regulation, our ability to successfully capitalize on growth opportunities or prospects, manufacturing and product supply, our efforts to respond to COVID-19, our expectations regarding the impact of COVID-19 on our business, operations and financial results and plans relating to share repurchases and dividends. In particular, these include statements relating to future actions, including, among others, the expected timing of closing of and costs associated with the pending transaction to combine Upjohn with Mylan to create a new global pharmaceutical company set forth in the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Business Development Initiatives&#8221; section of this MD&amp;A, the expected impact of patent expiries on our business set forth in the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Operating Environment&#8211;&#8211;Industry-Specific Challenges&#8211;&#8211;Intellectual Property Rights and Collaboration/Licensing Rights&#8221; and &#8220;&#8211;&#8211;Our Strategy&#8211;&#8211;Organizing for Growth&#8221; sections of this MD&amp;A, our efforts to respond to COVID-19,&#160;including, among other things, expectations regarding our investigational vaccine candidate against SARS-CoV-2 and our investigational protease inhibitor, and the anticipated impact of COVID-19 on our business, operations and financial results set forth in the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;The Global Economic Environment&#8221; and &#8220;&#8211;&#8211;Our Financial Guidance for&#160;2020&#8221; sections of this MD&amp;A, the benefits expected from the reorganization of our commercial operations in 2019 and our expectations regarding growth set forth in the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Strategy&#8211;&#8211;Organizing for Growth&#8221; section of this </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">93</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">MD&amp;A, the anticipated costs and savings from certain of our initiatives, primarily from our Transforming to a More Focused Company program, set forth in the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8212;Our Strategy&#8212;Transforming to a More Focused Company&#8221; and &#8220;Costs and Expenses&#8211;&#8211;Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives&#8221; sections of this MD&amp;A and in Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 3. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:inherit;font-size:10pt;">, the financial guidance set forth in the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Financial Guidance for&#160;2020&#8221; section of this MD&amp;A, the expected impact of ACIP&#8217;s latest recommendation for Prevnar 13 for adults 65 and older on Prevnar 13&#8217;s revenues set forth in the &#8220;Analysis of the Condensed Consolidated Statements of Income&#8211;&#8211;Revenues&#8211;&#8211;Selected Product Discussion&#8211;&#8211;Prevnar 13/Prevenar 13&#8221; section of this MD&amp;A, our anticipated liquidity position set forth in the &#8220;Analysis of Financial Condition, Liquidity and Capital Resources&#8221; section of this MD&amp;A,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">our expectations regarding dividends set forth in the &#8220;Analysis of Financial Condition, Liquidity and Capital Resources&#8221; section of this MD&amp;A and the benefits expected from our business development transactions and the contributions that we expect to make from our general assets to the company&#8217;s pension and postretirement plans during </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> set forth in the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Financial Guidance for&#160;2020&#8221; section of this MD&amp;A and Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 10. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Pension and Postretirement Benefit Plans</span><span style="font-family:inherit;font-size:10pt;">. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the outcome of R&amp;D activities, including, without limitation, the ability to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for our pre-clinical or clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable pre-clinical and clinical trial results, including the possibility of unfavorable new clinical data and further analyses of existing clinical data;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the risk we may not be able to successfully address all of the comments received from regulatory authorities such as the FDA or the EMA, or obtain approval from regulators, which will depend on myriad factors, including such regulator making a determination as to whether a product&#8217;s benefits outweigh its known risks and a determination of the product&#8217;s efficacy; regulatory decisions impacting labeling, manufacturing processes, safety and/or other matters; and recommendations by technical or advisory committees, such as ACIP, that may impact the use of our vaccines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the speed with which regulatory authorizations, pricing approvals and product launches may be achieved;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates, including claims and concerns that may arise from the outcome of post-approval clinical trials, which could result in the loss of marketing approval, changes in product labeling, and/or new or increased concerns about the side effects or efficacy of, a product that could affect its availability or commercial potential, such as the update to the U.S. and EU prescribing information for Xeljanz;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the success of external business-development activities, including the ability to identify and execute on potential business development opportunities, the ability to satisfy the conditions to closing of announced transactions in the anticipated time frame or at all, the ability to realize the anticipated benefits of any such transactions, and the potential need to obtain additional equity or debt financing to pursue these opportunities, which could result in increased leverage and impact our credit ratings;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">competitive developments, including the impact on our competitive position of new product entrants, in-line branded products, generic products, private label products, biosimilars and product candidates that treat diseases and conditions similar to those treated by our in-line drugs and drug candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the implementation by the FDA and regulatory authorities in certain countries of an abbreviated legal pathway to approve biosimilar products, which could subject our biologic products to competition from biosimilar products, with attendant competitive pressures, after the expiration of any applicable exclusivity period and patent rights;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">risks related to our ability to develop and commercialize biosimilars, including risks associated with &#8220;at risk&#8221; launches, defined as the marketing of a product by Pfizer before the final resolution of litigation (including any appeals) brought by a third party alleging that such marketing would infringe one or more patents owned or controlled by the third party, and access challenges for our biosimilar products where our product may not receive appropriate formulary access or remains in a disadvantaged position relative to the innovator product;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ability to meet competition from generic, branded and biosimilar products after the loss or expiration of patent protection for our products or competitor products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ability to successfully market both new and existing products domestically and internationally;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">difficulties or delays in manufacturing, sales or marketing, including delays caused by natural events, such as hurricanes; supply disruptions, shortages or stock-outs at our facilities; and legal or regulatory actions, such as </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">94</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-left:12px;padding-top:4px;text-align:left;"><span style="font-family:inherit;font-size:10pt;">warning letters, suspension of manufacturing, seizure of product, injunctions, debarment, recall of a product, delays or denials of product approvals, import bans or denial of import certifications;</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the impact of public health outbreaks, epidemics or pandemics (such as the COVID-19 pandemic) on our business, operations and financial condition and results, including due to travel limitations and government-mandated work-from-home or shelter-in-place orders, manufacturing disruptions or delays, supply chain interruptions, including challenges related to reliance on third-party suppliers, disruptions to pipeline development and clinical trials, including difficulties or delays in enrollment of certain clinical trials, decreased product demand, including due to reduced numbers of in-person meetings with prescribers, patient visits with physicians, vaccinations and elective surgeries resulting in fewer new prescriptions or refills of existing prescriptions and reduced demand for products used in procedures, further reduced product demand as a result of increased unemployment, challenges presented by reallocating human capital, R&amp;D, manufacturing and other resources to assist in responding to the pandemic without disruption to our operations, costs associated with the COVID-19 pandemic, including protocols intended to reduce the risk of transmission, increased supply chain costs and additional R&amp;D costs incurred in our efforts to develop a potential vaccine and treatment for COVID-19, challenges related to our business development initiatives, including potential delays or disruptions related to regulatory approvals, including the anticipated combination of Upjohn with Mylan, interruptions or delays in the operations of certain regulatory authorities, which may delay the approvals of new products we are developing, potential label expansions for existing products and the launch of newly-approved products, potential increased cyber incidents such as phishing, social engineering and malware attacks, and other challenges presented by disruptions to our normal operations in response to the pandemic, as well as uncertainties regarding the duration and severity of the pandemic and its impacts and government or regulatory actions to contain the virus or control the supply of medicines, each of which may also amplify the impact of the other factors listed in this section; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">uncertainties related to our efforts to develop a potential treatment or vaccine for COVID-19, including uncertainties related to the risk that our development programs may not be successful, commercially viable or receive approval or Emergency Use Authorization from regulatory authorities, risks associated with preliminary data, including the possibility of unfavorable new preclinical or clinical trial data and further analyses of existing preclinical or clinical trial data that may be inconsistent with the data used for selection of the BNT162b2 vaccine candidate and dose level for the Phase 2/3 study, the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities, whether and when data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications, disruptions in the relationships between us and our collaboration partners or third-party suppliers, the risk that other companies may produce superior or competitive products, the risk that demand for any products may no longer exist, risks related to the availability of raw materials to manufacture any such products, the risk that we may not be able to recoup costs associated with our R&amp;D and manufacturing efforts and risks associated with any changes in the way we approach or provide additional research funding for potential drug development related to COVID-19, the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or have access to logistics or supply channels commensurate with global demand for any potential approved vaccine or product candidate, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine candidate within the projected time periods indicated, and pricing and access challenges for such products, including in the U.S.;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">trade buying patterns;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the impact of existing and future legislation and regulatory provisions on product exclusivity;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the impact of any significant spending reductions or cost controls affecting Medicare, Medicaid or other publicly funded or subsidized health programs or changes in the tax treatment of employer-sponsored health insurance that may be implemented;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the impact of any U.S. healthcare reform or legislation, including any replacement, repeal, modification or invalidation of some or all of the provisions of the U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. federal or state legislation or regulatory action and/or policy efforts affecting, among other things, pharmaceutical product pricing, intellectual property, reimbursement or access, including under Medicaid, Medicare and other publicly funded or subsidized health programs; patient out-of-pocket costs for medicines, manufacturer prices and/or price increases that could result in new mandatory rebates and discounts or other pricing restrictions; general budget control actions; the importation of prescription drugs from outside the U.S. at prices that are regulated by governments of various foreign countries; revisions to reimbursement of biopharmaceuticals under </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">95</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-left:12px;padding-top:4px;text-align:left;"><span style="font-family:inherit;font-size:10pt;">government programs; restrictions on U.S. direct-to-consumer advertising; limitations on interactions with healthcare professionals; or the use of comparative effectiveness methodologies that could be implemented in a manner that focuses primarily on the cost differences and minimizes the therapeutic differences among pharmaceutical products and restricts access to innovative medicines; as well as pricing pressures for our products as a result of highly competitive insurance markets;</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">legislation or regulatory action in markets outside the U.S., including China, affecting pharmaceutical product pricing, intellectual property, reimbursement or access, including, in particular, continued government-mandated reductions in prices and access restrictions for certain biopharmaceutical products to control costs in those markets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the exposure of our operations outside the U.S. to possible capital and exchange controls, economic conditions, expropriation and other restrictive government actions, changes in intellectual property legal protections and remedies, as well as political unrest, unstable governments and legal systems and inter-governmental disputes;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">contingencies related to actual or alleged environmental contamination;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any significant breakdown, infiltration or interruption of our information technology systems and infrastructure;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">legal defense costs, insurance expenses and settlement costs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the risk of an adverse decision or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, such as claims that our patents are invalid and/or do not cover the product of the generic drug manufacturer or where one or more third parties seeks damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities, product liability and other product-related litigation, including personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, commercial, environmental, government investigations, employment and other legal proceedings, including various means for resolving asbestos litigation, as well as tax issues;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the risk that our currently pending or future patent applications may not result in issued patents, or be granted on a timely basis, or any patent-term extensions that we seek may not be granted on a timely basis, if at all;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to protect our patents and other intellectual property, both domestically and internationally, including against claims of invalidity that could result in loss of exclusivity, such as claims related to our Lyrica patents in Japan, and in response to any pressure, or legal or regulatory action by, various stakeholders or governments that could potentially result in us not seeking intellectual property protection for or agreeing not to enforce intellectual property related to our medicines, including potential vaccines and treatments for COVID-19;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">interest rate and foreign currency exchange rate fluctuations, including the impact of possible currency devaluations in countries experiencing high inflation rates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">governmental laws and regulations affecting domestic and foreign operations, including, without limitation, tax obligations and changes affecting the tax treatment by the U.S. of income earned outside the U.S. that may result from pending and possible future proposals, including further clarifications and/or interpretations of or changes to the TCJA enacted in 2017;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any significant issues involving our largest wholesale distributors, which account for a substantial portion of our revenues;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the possible impact of the increased presence of counterfeit medicines in the pharmaceutical supply chain on our revenues and on patient confidence in the integrity of our medicines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">uncertainties based on the formal change in relationship between the U.K. government and the EU, which could have implications on our research, commercial and general business operations in the U.K. and the EU, including the approval and supply of our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any significant issues that may arise related to the outsourcing of certain operational and staff functions to third parties, including with regard to quality, timeliness and compliance with applicable legal or regulatory requirements and industry standards;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any significant issues that may arise related to our joint ventures and other third-party business arrangements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">further clarifications and/or changes in interpretations of existing laws and regulations, or changes in laws and regulations, in the U.S. and other countries, including changes in U.S. generally accepted accounting principles;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">uncertainties related to general economic, political, business, industry, regulatory and market conditions including, without limitation, uncertainties related to the impact on us, our customers, suppliers and lenders and counterparties to our foreign-exchange and interest-rate agreements of challenging global economic conditions and recent and possible future changes in global financial markets; the related risk that our allowance for doubtful accounts may not be adequate; and the risks related to volatility of our income due to changes in the market value of equity investments;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">96</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any changes in business, political and economic conditions due to actual or threatened terrorist activity or civil unrest in the U.S. and other parts of the world, and related U.S. military action overseas;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">growth in costs and expenses;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in our product, segment and geographic mix; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the impact of purchase accounting adjustments, acquisition-related costs, discontinued operations and certain significant items;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the impact of product recalls, withdrawals and other unusual items;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the risk of an impairment charge related to our intangible assets, goodwill or equity-method investments; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the impact of, and risks and uncertainties related to, acquisitions and divestitures, such as the acquisition of Array, our transaction with GSK which combined our respective consumer healthcare businesses into a new consumer healthcare joint venture and our agreement to combine Upjohn with Mylan to create a new global pharmaceutical company, Viatris, including, among other things, risks related to the satisfaction of the conditions to closing to any pending transaction (including the failure to obtain any necessary shareholder and regulatory approvals) in the anticipated timeframe or at all and the possibility that such transaction does not close; the ability to realize the anticipated benefits of those transactions, including the possibility that the expected cost savings and/or accretion from certain of those transactions will not be realized or will not be realized within the expected time frame; the risk that the businesses will not be integrated successfully; negative effects of the announcement or the consummation of the transaction on the market price of Pfizer&#8217;s common stock, Pfizer&#8217;s credit ratings and/or Pfizer&#8217;s operating results; disruption from the transactions making it more difficult to maintain business and operational relationships; risks related to our ability to grow revenues for certain acquired products; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the transaction, other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, changes in tax and other laws, regulations, rates and policies, future business combinations or disposals; competitive developments; and as it relates to the Consumer Healthcare JV with GSK, the possibility that a future separation of the joint venture as an independent company via a demerger of GSK&#8217;s equity interest to GSK&#8217;s shareholders and a listing of the joint venture on the U.K. equity market may not occur; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the impact of, and risks and uncertainties related to, restructurings and internal reorganizations, including the reorganization of our commercial operations in 2019, as well as any other corporate strategic initiatives, and cost-reduction and productivity initiatives, each of which requires upfront costs but may fail to yield anticipated benefits and may result in unexpected costs or organizational disruption.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We cannot guarantee that any forward-looking statement will be realized. Achievement of anticipated results is subject to substantial risks, uncertainties and inaccurate assumptions. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors should bear this in mind as they consider forward-looking statements, and are cautioned not to put undue reliance on forward-looking statements.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law or by the rules and regulations of the SEC. You are advised, however, to consult any further disclosures we make on related subjects.</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additional discussion regarding certain risks, uncertainties and assumptions described above, as well as other material risks to our business, is included under the heading entitled &#8220;Risk Factors&#8221; in Part I, Item&#160;1A. of our 2019 Form 10-K and Part II, Item 1A, &#8220;Risk Factors&#8221; of this Quarterly Report on Form 10-Q. These risks could cause actual results to differ materially from past and projected future results. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. We incorporate that section of the 2019 Form 10-K in this filing and investors should refer to it. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties.</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The operating segment information provided in this report does not purport to represent the revenues, costs and income from continuing operations before provision for taxes on income that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented.</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This report includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">97</span></div></div><hr style="page-break-after:always"></hr><div><a id="s8C3F2F5E6C075CE18D73BFD17E93EFAC"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Information required by this item is incorporated by reference from the discussion in Part II, Item 7A, &#8220;Quantitative and Qualitative Disclosures About Market Risk&#8212;Financial Risk Management&#8221;, of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> Form 10-K.</span></div><div><a id="s3B5A6803D1E0568795CF4BE26CFAB647"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 4. Controls and Procedures</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are effective in alerting them in a timely manner to material information required to be disclosed in our periodic reports filed with the SEC.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During our most recent fiscal quarter, there has not been any change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><a id="s15F7FCCC9327523396FEF259E59BAA64"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II - OTHER INFORMATION</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div><a id="s42AFFB7F13E8573A9C54AAFD22B58513"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1. Legal Proceedings</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information required by this Item is incorporated herein by reference to Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 13A. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Contingencies and Certain Commitments</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Legal Proceedings</span><span style="font-family:inherit;font-size:10pt;"> in Part I, Item 1, of this Quarterly Report on Form 10-Q.</span></div><div><a id="sC7FEC17674E758BE9B1A40668E038F1B"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1A. Risk Factors</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We refer to the &#8220;Our Operating Environment&#8221;, &#8220;The Global Economic Environment&#8221; and &#8220;Forward-Looking Information and Factors That May Affect Future Results&#8221; sections of the MD&amp;A of this Quarterly Report on Form 10-Q and Part I, Item 1A, &#8220;Risk Factors&#8221; of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> Form 10-K. We are including the following risk factor, which should be read in conjunction with the risk factors discussed in Part I, Item 1A, &#8220;Risk Factors&#8221; of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">COVID-19 PANDEMIC</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our business, operations and financial condition and results have been and may continue to be impacted by the COVID-19 pandemic to varying degrees. We currently anticipate an ongoing, gradual global recovery from the first-half 2020 macroeconomic and healthcare impacts of the COVID-19 pandemic beginning in the third quarter of 2020. The pandemic continues to present a number of risks and challenges for our business, including, among others, impacts due to travel limitations and government-mandated work-from-home or shelter-in-place orders; manufacturing disruptions and delays; supply chain interruptions, including challenges related to reliance on third-party suppliers; disruptions to pipeline development and clinical trials, including difficulties or delays in enrollment of certain clinical trials; decreased product demand, including due to reduced numbers of in-person meetings with prescribers, patient visits with physicians, vaccinations and elective surgeries resulting in fewer new prescriptions or refills of existing prescriptions and reduced demand for products used in procedures; further reduced product demand as a result of increased unemployment; challenges presented by reallocating human capital, R&amp;D, manufacturing and other resources to assist in responding to the pandemic without disruption to our operations; costs associated with the COVID-19 pandemic, including protocols intended to reduce the risk of transmission; increased supply chain costs and additional R&amp;D costs incurred in our efforts to develop a vaccine and treatment for COVID-19; challenges related to our business development initiatives, including potential delays or disruptions related to regulatory approvals, including the anticipated combination of Upjohn with Mylan; interruptions or delays in the operations of certain regulatory authorities, which may delay the approvals of new products we are developing, potential label expansions for existing products and the launch of newly-approved products; potential increased cyber incidents such as phishing, social engineering and malware attacks; challenges related to our intellectual property, both domestically and internationally, including in response to any pressure or legal or regulatory action, by various stakeholders or governments that could potentially result in us not seeking intellectual property protection for, licensing or agreeing not to enforce our intellectual property rights related to our medicines, including potential vaccines and treatments for COVID-19; and other challenges presented by disruptions to our normal operations in response to the pandemic, as well as uncertainties regarding the duration and severity of the pandemic and its impacts and government or regulatory actions to contain the virus or control the supply of medicines.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">98</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also face uncertainties related to our efforts to develop a potential treatment or vaccine for COVID-19, including uncertainties related to the risk that our development programs may not be successful, commercially viable or receive approval or Emergency Use Authorization from regulatory authorities; risks associated with preliminary data, including the possibility of unfavorable new preclinical or clinical trial data and further analyses of existing preclinical or clinical trial data that may be inconsistent with the data used for selection of the BNT162b2 vaccine candidate and dose level for the Phase 2/3 study; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications; disruptions in the relationships between us and our collaboration partners or third-party suppliers; the risk that other companies may produce superior or competitive products; the risk that demand for any products we may develop may no longer exist; risks related to the availability of raw materials to manufacture any such products; the risk that we may not be able to recoup costs associated with our R&amp;D and manufacturing efforts and risks associated with any changes in the way we approach or provide additional research funding for potential drug development related to COVID-19; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or have access to logistics or supply channels commensurate with global demand for any potential approved vaccine or product candidate, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine candidate within the projected time periods indicated; and pricing and access challenges for such products, including in the U.S.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Further, the COVID-19 pandemic, and the volatile global economic conditions stemming from the pandemic, could precipitate or amplify the other risk factors that we identify in the &#8220;Risk Factors&#8221; section of our 2019 Form 10-K, which could materially adversely affect our business, operations and financial condition and results.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are continuing to monitor the latest developments regarding the COVID-19 pandemic on our business, operations and financial condition and results, and have made certain assumptions regarding the pandemic for purposes of our operational planning and financial projections, including assumptions regarding the duration and severity of the pandemic and the global macroeconomic impact of the pandemic. Despite careful tracking and planning, however, we are unable to accurately predict the extent of the impact of the pandemic on our business, operations and financial condition and results due to the uncertainty of future developments. In particular, we believe the ultimate impact on our business, operations and financial condition and results will be affected by the speed and extent of the continued spread of the coronavirus globally, the duration of the pandemic, new information that may emerge concerning the severity and incidence of COVID-19, the safety, efficacy and availability of a vaccine and treatments for COVID-19, the global macroeconomic impact of the pandemic and governmental or regulatory actions to contain the virus or control supply of medicines. The pandemic may also affect our business, operations or financial condition and results in a manner that is not presently known to us or that we currently do not consider to present significant risks.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For additional information on how the COVID-19 pandemic has already impacted our business, operations and financial condition and results, see the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;The Global Economic Environment&#8221; section of the MD&amp;A of this Quarterly Report on Form 10-Q.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">99</span></div></div><hr style="page-break-after:always"></hr><div><a id="sDF7DE0DF02AA555BA976CA650421A5F4"></a></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides certain information with respect to our purchases of shares of the Company&#8217;s common stock during the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> fiscal quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Issuer Purchases of Equity Securities</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:30%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;">Period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;">Total Number of</span></div><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;">Shares Purchased</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b</sup></span><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;">Average Price</span></div><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;">Paid per Share</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;">Total Number of Shares Purchased as Part of Publicly Announced Plan</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;">Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plan</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">March 30, 2020 through April 26, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">19,649</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">32.65</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">5,292,881,709</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">April 27, 2020 through May 24, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">41,905</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">38.04</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">5,292,881,709</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">May 25, 2020 through June 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">18,583</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">37.24</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">5,292,881,709</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">80,137</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">36.53</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For additional information, see the Notes to Consolidated Financial Statements</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">&#8211;&#8211;Note 12. Equity </span><span style="font-family:inherit;font-size:8pt;">in our 2019 Financial Report, which is</span></div></td></tr></table><div style="line-height:120%;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">incorporated by reference.</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">These columns represent (i) </span><span style="font-family:inherit;font-size:8pt;">73,616</span><span style="font-family:inherit;font-size:8pt;"> shares of common stock surrendered to the Company to satisfy tax withholding obligations in connection with the vesting of awards under our long-term incentive programs and (ii) the open market purchase by the trustee of </span><span style="font-family:inherit;font-size:8pt;">6,521</span><span style="font-family:inherit;font-size:8pt;"> shares of common stock in connection with the reinvestment of dividends paid on common stock held in trust for employees who were granted performance share awards and who deferred receipt of such awards.</span></div></td></tr></table><div><a id="sC2754211509258DBBA8765C657CDD6F0"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 3. Defaults Upon Senior Securities</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div><a id="s1165DBDD5BB35533A4D0604D1CDA39D7"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 4. Mine Safety Disclosures</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Not applicable.</span></div><div><a id="s9F7A6EE2D68F5973BA4CB44B51FD313C"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 5. Other Information</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">100</span></div></div><hr style="page-break-after:always"></hr><div><a id="sD11466CC9AA25E9D8687CB6B5E0C041B"></a></div><div><br/></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 6. Exhibits</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:3%;"></td><td style="width:16%;"></td><td style="width:4%;"></td><td style="width:77%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000119312520157434/d904465dex21.htm"><span style="font-family:inherit;font-size:10pt;">Exhibit 2.1</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amendment No. 1, dated as of May 29, 2020, to the Business Combination Agreement, dated as of July 29, 2019, by and among Pfizer Inc., Upjohn Inc., Utah Acquisition Sub Inc., Mylan N.V., Mylan I B.V. and Mylan II B.V. is incorporated by reference from our Current Report on Form 8-K filed on June 1, 2020 (File No. 001-03619). (Pursuant to Item 601(b)(2) of Regulation S-K, the registrant hereby agrees to supplementally furnish to the Securities and Exchange Commission upon request any omitted schedule or exhibit to the Business Combination Agreement).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000119312520157434/d904465dex22.htm"><span style="font-family:inherit;font-size:10pt;">Exhibit 2.2</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amendment No. 2, dated as of May 29, 2020, to the Separation and Distribution Agreement, dated as of July 29, 2019, by and between Pfizer Inc. and Upjohn Inc. is incorporated by reference from our Current Report on Form 8-K filed on June 1, 2020 (File No. 001-03619). (Pursuant to Item 601(b)(2) of Regulation S-K, the registrant hereby agrees to supplementally furnish to the Securities and Exchange Commission upon request any omitted schedule or exhibit to the Separation and Distribution Agreement).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000119312520154311/d916063dex42.htm"><span style="font-family:inherit;font-size:10pt;">Exhibit 4.1</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fourth Supplemental Indenture, dated May 28, 2020, between Pfizer Inc. and The Bank of New York Mellon, as trustee, is incorporated by reference from our Current Report on Form 8-K filed on May 28, 2020 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pfe-exhibit101x6282020.htm"><span style="font-family:inherit;font-size:10pt;">Exhibit 10.1</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Time Sharing Agreement, dated July 9, 2020, by and between Pfizer Inc. and Albert Bourla.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pfe-exhibit15x06282020.htm"><span style="font-family:inherit;font-size:10pt;">Exhibit 15</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accountants&#8217; Acknowledgment.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pfe-exh311x0628202010q.htm"><span style="font-family:inherit;font-size:10pt;">Exhibit 31.1</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pfe-exh312x0628202010q.htm"><span style="font-family:inherit;font-size:10pt;">Exhibit 31.2</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pfe-exh321x0628202010q.htm"><span style="font-family:inherit;font-size:10pt;">Exhibit 32.1</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pfe-exh322x0628202010q.htm"><span style="font-family:inherit;font-size:10pt;">Exhibit 32.2</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exhibit 101:</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EX-101.INS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EX-101.SCH</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EX-101.CAL</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EX-101.LAB</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EX-101.PRE</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EX-101.DEF</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Schema</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Calculation Linkbase</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Label Linkbase</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Presentation Linkbase</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Definition Document</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exhibit 104</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cover Page Interactive Data File&#8211;&#8211;the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101</span></div></div><hr style="page-break-after:always"></hr><div><a id="s0B0121F1585B59C0886B3FFD8E459558"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SIGNATURE</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:6%;"></td><td style="width:42%;"></td><td style="width:52%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pfizer Inc.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Registrant)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dated:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August&#160;6, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Jennifer Damico</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Jennifer Damico, Senior Vice President and</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Controller</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Principal Accounting Officer and</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Duly Authorized Officer)</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">102</span></div></div>	</div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>pfe-exhibit101x6282020.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s030666B40195A44125B03A26AE1B3681"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 10.1</font></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:center;padding-left:205px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TIME SHARING AGREEMENT</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:181%;text-align:justify;padding-left:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Time Sharing Agreement (this &#8220;Agreement&#8221;) is dated this 9th day of July, 2020, by and between Pfizer Inc., a Delaware corporation (the &#8220;Company&#8221;) and Albert Bourla, an individual (&#8220;Lessee&#8221;).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:9px;text-align:center;padding-left:202px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RECITALS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:181%;text-align:justify;padding-left:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WHEREAS, Company rightfully possesses and operates the aircraft identified on Schedule I hereto (the &#8220;Aircraft&#8221;) under Part 91 of the Federal Aviation Regulations (&#8220;FARs&#8221;) incidental to its primary business; and</font></div><div style="line-height:181%;padding-top:8px;text-align:justify;padding-left:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WHEREAS, Company desires to make the Aircraft available to Lessee, and Lessee desires to utilize the Aircraft, from time to time on a non-exclusive time-sharing basis as authorized under Sections 91.501(b)(6), 91.501(c)(1) and 91.501(d) of the FARs; and</font></div><div style="line-height:181%;padding-top:8px;text-align:justify;padding-left:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WHEREAS, this Agreement is a time sharing agreement as defined in Section 91.501(c)(1) of the FAR, and use of the Aircraft pursuant to this Agreement will comply with the requirements of FAR 91.501(b)(6), 91.501(c)(1) and 91.501(d).</font></div><div style="line-height:181%;padding-top:8px;text-align:justify;padding-left:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NOW, THEREFORE, in consideration of the foregoing, and the other agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby conclusively acknowledged, the parties, intending to be legally bound hereby, agree as follows:</font></div><div style="line-height:181%;padding-left:8px;padding-top:8px;text-align:justify;text-indent:48px;"><font style="padding-top:8px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Provision of Aircraft; Term. </font><font style="font-family:inherit;font-size:10pt;">Company agrees to provide the Aircraft to and operate the Aircraft for Lessee on a non-exclusive basis from time to time as mutually agreed between the parties pursuant to the provisions of FAR 91.501(b)(6), 91.501(c)(1) and 91.501(d) and to provide a fully qualified flight crew for all operations conducted under this Agreement. This Agreement shall be effective on the date set forth above and shall remain in effect until terminated by either party upon ten (10) business days&#8217; prior written notice to the other.</font></div><div style="line-height:181%;padding-left:8px;padding-top:8px;text-align:justify;text-indent:48px;"><font style="padding-top:8px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">2.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lease Fee. </font><font style="font-family:inherit;font-size:10pt;">Lessee shall pay to Company for each flight conducted under this Agreement a lease fee (&#8220;Lease Fee&#8221;) not to exceed the actual expenses of each specific flight as authorized by FAR Part 91.501(d) (including related deadhead flights, if applicable). Such actual expenses shall include and are limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:152px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:108px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;padding-left:22px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-22px;"><font style="font-family:inherit;font-size:10pt;">Fuel, oil, lubricants, and other additives;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:156px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:108px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;padding-left:14.666666666666666px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-14.666666666666666px;"><font style="font-family:inherit;font-size:10pt;">Travel expenses of the crew, including food, lodging and ground transportation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:156px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:108px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;padding-left:14.666666666666666px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-14.666666666666666px;"><font style="font-family:inherit;font-size:10pt;">Hangar and tie-down costs away from the Aircraft&#8217;s base of operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:156px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:108px;"><font style="font-family:inherit;font-size:12pt;">(d)</font></div></td><td style="vertical-align:top;padding-left:14.666666666666666px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-14.666666666666666px;"><font style="font-family:inherit;font-size:10pt;">Insurance obtained for the specific flight;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:156px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:108px;"><font style="font-family:inherit;font-size:12pt;">(e)</font></div></td><td style="vertical-align:top;padding-left:14.666666666666666px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-14.666666666666666px;"><font style="font-family:inherit;font-size:10pt;">Landing fees, airport taxes and similar assessments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:156px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:108px;"><font style="font-family:inherit;font-size:12pt;">(f)</font></div></td><td style="vertical-align:top;padding-left:14.666666666666666px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-14.666666666666666px;"><font style="font-family:inherit;font-size:10pt;">Customs, foreign permit, and similar fees directly related to the flight;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:156px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:108px;"><font style="font-family:inherit;font-size:12pt;">(g)</font></div></td><td style="vertical-align:top;padding-left:14.666666666666666px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-14.666666666666666px;"><font style="font-family:inherit;font-size:10pt;">In flight food and beverages;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:156px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:108px;"><font style="font-family:inherit;font-size:12pt;">(h)</font></div></td><td style="vertical-align:top;padding-left:14.666666666666666px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-14.666666666666666px;"><font style="font-family:inherit;font-size:10pt;">Passenger ground transportation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:156px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:108px;"><font style="font-family:inherit;font-size:12pt;">(i)</font></div></td><td style="vertical-align:top;padding-left:14.666666666666666px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-14.666666666666666px;"><font style="font-family:inherit;font-size:10pt;">Flight planning and weather contract services; and</font></div></td></tr></table><div><br></div><div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:156px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:108px;"><font style="font-family:inherit;font-size:12pt;">(j)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">An additional charge equal to 100 percent of the expenses listed in subparagraph 2(a) above.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:74px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In no event shall the Lease Fee include any costs not listed above.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:181%;padding-left:26px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">3.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Taxes</font><font style="font-family:inherit;font-size:10pt;">. The parties acknowledge that, with the exception of Sections 2(g) and (h) hereof, the payments specified in Section 2 from Lessee to Company are subject to federal excise tax imposed under Article 4261 of the Internal Revenue Code of 1986, as amended (the &#8220;Federal Excise Tax&#8221;). If applicable, Lessee shall pay to Company (for remittance to the appropriate governmental agency) all Federal Excise Tax applicable to flights of the Aircraft conducted hereunder.</font></div><div style="line-height:180%;padding-left:26px;padding-top:8px;text-align:justify;text-indent:48px;"><font style="padding-top:8px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">4.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Prepayment. </font><font style="font-family:inherit;font-size:10pt;">From time to time, Lessee may deliver to Company a mutually agreed sum to fund an account for anticipated Lease Fees (the &#8220;Prepayment Fund&#8221;). No interest shall be paid on the Prepayment Fund. Immediately upon presentment of invoices for time sharing flights, Company shall apply funds from the Prepayment Fund to pay for Lease Fees for such flights. Monthly reconciliations shall be provided to Lessee which shall set forth the expenses comprising the Lease Fees of each specific flight through the last day of the month in which any flight or flights for the account of Lessee occur. In the event Lease Fees exceed the Prepayment Fund in any given month, Lessee shall pay such Lease Fees upon receipt of the invoice for the amounts exceeding the Prepayment Fund, which invoice shall be presented within fifteen (15) days of the time such Lease Fees are incurred. Upon termination of this Agreement, any funds remaining in the Prepayment Fund shall be returned to Lessee within thirty (30) days. As a matter of clarification, the Prepayment Fund is in the nature of a deposit and not payment for transportation unless and until such time as an invoice for Lease Fees is presented and funds are withdrawn to pay such invoice.</font></div><div style="line-height:181%;padding-left:26px;padding-top:4px;text-align:justify;text-indent:48px;"><font style="padding-top:4px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">5.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Expenses. </font><font style="font-family:inherit;font-size:10pt;">Company shall pay all expenses related to the operation of the Aircraft for time-sharing flights when such expenses are incurred.</font></div><div style="line-height:180%;padding-left:26px;padding-top:8px;text-align:justify;text-indent:48px;"><font style="padding-top:8px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">6.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Flight Information. </font><font style="font-family:inherit;font-size:10pt;">Lessee will provide Company with requests for flight time and proposed flight schedules as far in advance of any given flight as possible. Requests for flight time shall be in a form, whether written or oral, mutually convenient to, and agreed upon by the parties. In addition to the proposed schedules and flight times, Lessee shall provide at least the following information for each proposed flight prior to scheduled departure as required by the Company or Company's flight crew:</font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:120px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;proposed departure point;</font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:120px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;destination;</font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:120px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;date and time of flight;</font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:120px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;the number, name, and relationship to the Lessee of anticipated passengers;</font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:120px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;the nature and extent of luggage and/or cargo to be carried; </font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:120px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;the date and time of return flight, if any; and</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:120px;"><font style="font-family:inherit;font-size:12pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">any other information concerning the proposed flight that may be pertinent or required by Company or Company's flight crew.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:181%;padding-left:26px;padding-top:8px;text-align:justify;text-indent:48px;"><font style="padding-top:8px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">7.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Authority to Schedule. </font><font style="font-family:inherit;font-size:10pt;">Company shall have final authority over the scheduling of the Aircraft. It is understood that Company shall not be obligated to retain or contract for additional flight crew or maintenance personnel or equipment in order to accommodate Lessee's schedule requests.</font></div><div style="line-height:181%;padding-left:78px;padding-top:4px;text-align:justify;text-indent:0px;"><font style="padding-top:4px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:44px;">8.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operational Control. </font><font style="font-family:inherit;font-size:10pt;">The Company shall be responsible for all aspects of the physical and </font></div><div style="line-height:181%;padding-top:4px;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">technical operation of the Aircraft and the safe performance of all flights, and shall retain and exercise exclusive operational control of the Aircraft during all phases of flight, including pre-flight and post-flight duties, and including, without limitation, all flights during which Lessee and/or Lessee&#8217;s guests are on-board the Aircraft. Consistent with the Company&#8217;s operational control responsibilities, Company shall be solely responsible to secure maintenance, preventive maintenance and required or otherwise necessary inspections on the Aircraft, and shall take such requirements into account in scheduling the Aircraft. All costs and expenses related to the maintenance of the Aircraft shall be the responsibility of the Company. No period of maintenance, preventative maintenance or inspection shall be delayed or postponed for the purpose of scheduling the Aircraft, unless said maintenance or inspection can be safely conducted at a later time in compliance with all applicable laws and regulations, and within the sound discretion of the pilot in command. All flight operations under this Agreement shall be conducted under Part 91 of the FAR.</font></div><div style="line-height:180%;padding-left:26px;padding-top:8px;text-align:justify;text-indent:48px;"><font style="padding-top:8px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">9.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Authority of Pilot in Command and Flight Crew. </font><font style="font-family:inherit;font-size:10pt;">For each flight conducted under this Agreement, the Aircraft will be operated only by a qualified flight crew. The pilot in command shall have final and complete authority to cancel any flight for any reason or condition that in his or her judgment would compromise the safety of the flight. Lessee specifically agrees that the flight crew, in its sole discretion, may terminate any flight, refuse to commence any flight, or take other action which in the considered judgment of the pilot in command is necessitated by considerations of safety. No such action of the pilot in command shall create or support any liability for loss, injury, damage or delay to Lessee or any other person. The parties further agree that Company shall not be liable for delay or failure to furnish the Aircraft and crew pursuant to this Agreement for any reason whatsoever.</font></div><div style="line-height:181%;padding-left:26px;padding-top:8px;text-align:justify;text-indent:48px;"><font style="padding-top:8px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">10.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lessee&#8217;s Covenants, Representations and Warranties. </font><font style="font-family:inherit;font-size:10pt;">Lessee covenants, represents and warrants to the Company that during the term of this Agreement:</font></div><div style="line-height:179%;text-align:justify;padding-left:122px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Lessee shall use the Aircraft for and on account of Lessee&#8217;s own business or personal use only, and will not use the Aircraft for the purpose of providing transportation of passengers or cargo for compensation or hire or in violation of applicable FARs or any agreements entered into by the Company relating to the Aircraft;</font></div><div style="line-height:181%;text-align:justify;padding-left:122px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Lessee shall refrain from incurring any mechanics or other lien in connection with inspection, preventative maintenance, maintenance or storage of the Aircraft, whether permissible or impermissible under this Agreement, and Lessee shall not attempt to convey, mortgage, assign, lease or any way alienate the Aircraft or create any kind of lien or security interest involving the Aircraft or do anything or take any action that might mature into such a lien; and</font></div><div><br></div><div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:179%;text-align:justify;padding-left:122px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Lessee shall, and shall cause any passengers in Lessee&#8217;s party to, abide by and conform to all such laws, governmental and airport orders, rules and regulations, as shall from time to time be in effect relating in any way to the use of the Aircraft by a timesharing lessee.</font></div><div style="line-height:181%;padding-left:78px;padding-top:4px;text-align:justify;text-indent:0px;"><font style="padding-top:4px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:44px;">11.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk of Loss. </font><font style="font-family:inherit;font-size:10pt;">The Company assumes and shall bear the entire risk of loss, theft, </font></div><div style="line-height:181%;padding-top:4px;text-align:justify;padding-left:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">confiscation, damage to, or destruction of the Aircraft from any cause whatsoever, except to the extent attributable to the gross negligence or willful misconduct of Lessee or Lessee&#8217;s guests on the Aircraft.</font></div><div style="line-height:179%;padding-left:26px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">12.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Insurance. </font><font style="font-family:inherit;font-size:10pt;">During the term of this Agreement, the Company shall maintain and have in force (i) all-risk hull insurance covering the fair market value of the Aircraft which policy shall be deemed primary in the event of any incident or accident and (ii) aviation liability insurance of at least Three Hundred Million Dollars ($300,000,000) combined single limit. Company shall cause Lessee to be added as an additional insured to its aviation liability insurance.</font></div><div style="line-height:181%;padding-left:26px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">13.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Base. </font><font style="font-family:inherit;font-size:10pt;">For purposes of this Agreement, the permanent base of operation of the Aircraft shall be as set forth on Schedule A hereto, or such other location as shall be determined by the Company from time to time.</font></div><div style="line-height:179%;padding-left:26px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">14.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Successors and Assigns. </font><font style="font-family:inherit;font-size:10pt;">Neither this Agreement nor any party's interest herein shall be assignable to any other party whatsoever. This Agreement shall inure to the benefit of and be binding upon the parties hereto, and their respective heirs, representatives, successors and permitted assigns.</font></div><div style="line-height:181%;padding-left:26px;padding-top:1px;text-align:justify;text-indent:48px;"><font style="padding-top:1px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">15.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Governing Law. </font><font style="font-family:inherit;font-size:10pt;">This Agreement constitutes the entire agreement of the parties with respect to the time share of the Aircraft as set forth herein. This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York.</font></div><div style="line-height:180%;padding-left:26px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">16.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subordination. </font><font style="font-family:inherit;font-size:10pt;">All rights and interests of Lessee hereunder and in and to the Aircraft are, and at all times shall be and remain, subject and subordinate to the rights and interests of the owner of each Aircraft under the aircraft lease agreements between such owner and the Company. Notwithstanding anything to the contrary contained herein, this Agreement shall terminate, or be canceled, immediately at the option of the Aircraft owner upon the occurrence of an event of default thereunder.</font></div><div style="line-height:179%;padding-left:26px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">17.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Counterparts</font><font style="font-family:inherit;font-size:10pt;">. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same Agreement, binding on all the parties notwithstanding that all the parties are not signatories to the same counterpart. The parties may effectively deliver an executed counterpart of a signature page of this Agreement by facsimile or in electronic (&#8220;pdf&#8221; or &#8220;tif&#8221;) format.</font></div><div style="line-height:181%;padding-left:26px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">18.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Further Acts</font><font style="font-family:inherit;font-size:10pt;">. Lessor and Lessee shall from time to time perform such other and further acts and execute such other and further instruments as may be required by law or may be reasonably necessary to: (i) carry out the intent and purpose of this Agreement; and (ii) establish, maintain and protect the respective rights and remedies of the other party.</font></div><div style="line-height:179%;padding-left:26px;padding-top:4px;text-align:justify;text-indent:48px;"><font style="padding-top:4px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">19.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Entire Agreement</font><font style="font-family:inherit;font-size:10pt;">. This Agreement constitutes the entire understanding among the Parties with respect to its subject matter, and there are no representations, warranties, rights, obligations, liabilities, conditions, covenants, or agreements other than as expressly set forth herein.</font></div><div><br></div><div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:181%;padding-left:26px;padding-top:1px;text-align:justify;text-indent:48px;"><font style="padding-top:1px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">20.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Severability</font><font style="font-family:inherit;font-size:10pt;">. In the event that any one or more of the provisions of this Agreement shall for any reason be held to be invalid, illegal, or unenforceable, those provisions shall be replaced by provisions acceptable to both Parties to this Agreement.</font></div><div style="line-height:180%;padding-left:26px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">21.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Disclaimer; Consequential Damages</font><font style="font-family:inherit;font-size:10pt;">. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER COMPANY NOR AIRCRAFT OWNER HAVE MADE ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE AIRCRAFT, INCLUDING WITH RESPECT TO ITS DESIGN, CONDITION, QUALITY OF MATERIALS AND WORKMANSHIP, MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, AIRWORTHINESS OR SAFETY. IN NO EVENT SHALL COMPANY OR OWNER BE LIABLE TO THE LESSEE, ITS MEMBERS, MANAGERS, OFFICERS, DIRECTORS, EMPLOYEES, AFFILIATES, GUESTS OR AGENTS (FOR THE PURPOSE OF THIS SECTION 21 HEREOF, COLLECTIVELY, &#8220;LESSEE&#8221;), FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR SPECIAL DAMAGES, HOWEVER ARISING, WHETHER COMPANY KNEW OR SHOULD HAVE KNOWN OF THE POSSIBILITY OF SUCH DAMAGE, LOSS OR EXPENSE INCLUDING, WITHOUT LIMITATION, IN RESPECT OF ANY DELAY IN ARRIVAL OR DEPARTURE.</font></div><div style="line-height:181%;padding-left:26px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">22.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notices. </font><font style="font-family:inherit;font-size:10pt;">All communications, declarations, demands, consents, directions, approvals, instructions, requests and notices required or permitted by this Agreement shall be in writing and shall be deemed to have been duly given or made when delivered personally or transmitted electronically by e-mail or facsimile, receipt acknowledged, or in the case of documented overnight delivery service or registered or certified mail, return receipt requested, delivery charge or postage prepaid, on the date shown on the receipt therefor, in each case at the address set forth on Schedule A hereto.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:104px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:56px;"><font style="font-family:inherit;font-size:10pt;">23.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TRUTH IN LEASING STATEMENT PURSUANT TO 14 CFR PART 91.23</font></div></td></tr></table><div style="line-height:136%;padding-top:9px;text-align:justify;padding-left:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">THE AIRCRAFT HAVE BEEN MAINTAINED AND INSPECTED UNDER FAR PART 91.409(f)(3) DURING THE 12 MONTH PERIOD PRECEDING THE DATE OF THIS AGREEMENT.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">THE COMPANY, A DELAWARE CORPORATION, CERTIFIES THAT THE AIRCRAFT ARE IN COMPLIANCE WITH ALL APPLICABLE MAINTENANCE AND INSPECTION REQUIREMENTS FOR OPERATIONS TO BE CONDUCTED UNDER THIS AGREEMENT. THE AIRCRAFT WILL BE MAINTAINED AND INSPECTED UNDER FAR PART 91.409(f)(3) FOR OPERATIONS TO BE CONDUCTED UNDER THIS AGREEMENT.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">THE COMPANY CERTIFIES AND ACKNOWLEDGES THAT WHENEVER THE AIRCRAFT ARE OPERATED UNDER THIS AGREEMENT, THE COMPANY SHALL BE KNOWN AS, CONSIDERED AND SHALL IN FACT BE RESPONSIBLE FOR OPERATIONAL CONTROL OF THE AIRCRAFT IDENTIFIED AND TO BE OPERATED UNDER THIS AGREEMENT. EACH PARTY CERTIFIES THAT IT UNDERSTANDS ITS RESPECTIVE RESPONSIBILITIES, IF ANY, FOR COMPLIANCE WITH APPLICABLE FEDERAL AVIATION REGULATIONS. I, THE UNDERSIGNED, JOHN D. WITZIG, AS VICE PRESIDENT OF THE COMPANY, CERTIFY THAT THE COMPANY IS RESPONSIBLE FOR OPERATIONAL CONTROL OF THE AIRCRAFT FOR OPERATIONS TO BE CONDUCTED UNDER THIS AGREEMENT AND THAT THE COMPANY UNDERSTANDS ITS RESPONSIBILITIES FOR COMPLIANCE WITH APPLICABLE FEDERAL AVIATION REGULATIONS.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:121%;text-align:justify;padding-left:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EACH PARTY UNDERSTANDS THAT AN EXPLANATION OF FACTORS BEARING ON OPERATIONAL CONTROL AND PERTINENT FEDERAL AVIATION REGULATIONS CAN BE OBTAINED FROM THE NEAREST FAA FLIGHT STANDARDS DISTRICT OFFICE.</font></div><div><br></div><div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:136%;text-align:justify;padding-left:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">THE ADDRESS OF THE COMPANY IS 235 EAST 42</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">nd</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;STREET, NEW YORK, NEW YORK 10017.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:125%;text-align:justify;padding-left:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:205px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PFIZER INC.</font></div><div style="line-height:120%;text-align:center;padding-left:205px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:136%;text-align:left;padding-left:325px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:  </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ JOHN D. WITZIG</font></div><div style="line-height:136%;text-align:left;padding-left:325px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name: John D. Witzig</font></div><div style="line-height:135%;text-align:left;padding-left:325px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:   Vice President</font></div><div style="line-height:135%;text-align:left;padding-left:325px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:135%;text-align:left;padding-left:325px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ ALBERT BOURLA</font></div><div style="line-height:135%;text-align:left;padding-left:325px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Albert Bourla</font></div><div style="line-height:120%;padding-top:4px;text-align:center;padding-left:274px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15
<SEQUENCE>3
<FILENAME>pfe-exhibit15x06282020.htm
<DESCRIPTION>EXHIBIT 15
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sDE015B7EE5C25C8AB75399E2D6468250"></a></div><div style="line-height:120%;text-align:right;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 15</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accountant's Acknowledgment</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the Board of Directors and the Shareholders of Pfizer Inc.:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We hereby acknowledge our awareness of the use therein of our report dated </font><font style="font-family:inherit;font-size:10pt;">August&#160;6, 2020</font><font style="font-family:inherit;font-size:10pt;">, included within the Quarterly Report on Form 10-Q of Pfizer Inc. for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</font><font style="font-family:inherit;font-size:10pt;">&#32;in the following Registration Statements:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated October 27, 1983 (File No. 2-87473),</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated March 22, 1990 (File No. 33-34139),</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated January 24, 1991 (File No. 33-38708),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated November 18, 1991 (File No. 33-44053),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated May 27, 1993 (File No. 33-49631),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated May 19, 1994 (File No. 33-53713),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated October 5, 1994 (File No. 33-55771),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated December 20, 1994 (File No. 33-56979),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated March 29, 1996 (File No. 333-02061),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated September 25, 1997 (File No. 333-36371),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated June 19, 2000 (File No. 333-39606),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated April 27, 2001 (File No. 333-59660),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated April 16, 2003 (File No. 333-104582),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated November 18, 2003 (File No. 333-110571),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated December 18, 2003 (File No. 333-111333),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated April 26, 2004 (File No. 333-114852),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated March 1, 2007 (File No. 333-140987),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-4 dated March 27, 2009 (File No. 333-158237),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated October 16, 2009 (File No. 333-162519),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated October 16, 2009 (File No. 333-162520),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated October 16, 2009 (File No. 333-162521),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated March 1, 2010 (File No. 333-165121),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated March 2, 2015 (File No. 333-202437), </font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-4 dated September 3, 2015 (File No. 333-206758), </font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-3 ASR dated February 26, 2018 (File No. 333-223221), and</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated August 8, 2019 (File No. 333-233166).</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:125%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to Rule 436 under the Securities Act of 1933 (the Act), such report is not considered a part of a registration statement prepared or certified by an independent registered public accounting firm, or a report prepared or certified by an independent registered public accounting firm within the meaning of Sections 7 and 11 of the Act.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ KPMG LLP</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New York, New York </font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August&#160;6, 2020</font></div><div><br></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>pfe-exh311x0628202010q.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s575183155EE45067B295054994E90FFE"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 31.1</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certification by the Chief Executive Officer Pursuant to </font></div><div style="line-height:120%;padding-bottom:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Albert Bourla, certify that:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;"><font style="padding-bottom:6px;padding-top:6px;text-align:left;font-family:inherit;font-size:10pt;padding-right:24px;">1.</font><font style="font-family:inherit;font-size:10pt;">I have reviewed this Quarterly Report on Form 10-Q of Pfizer Inc.;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;"><font style="padding-bottom:6px;padding-top:6px;text-align:left;font-family:inherit;font-size:10pt;padding-right:24px;">2.</font><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;"><font style="padding-bottom:6px;padding-top:6px;text-align:left;font-family:inherit;font-size:10pt;padding-right:24px;">3.</font><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;"><font style="padding-bottom:6px;padding-top:6px;text-align:left;font-family:inherit;font-size:10pt;padding-right:24px;">4.</font><font style="font-family:inherit;font-size:10pt;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:&#160;</font><font style="font-family:inherit;font-size:10pt;">August&#160;6, 2020</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:26%;"></td><td style="width:37%;"></td><td style="width:37%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ ALBERT BOURLA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Albert Bourla</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Chairman and Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>pfe-exh312x0628202010q.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s88A3321058305824A380E78BC99EF9BD"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 31.2</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certification by the Chief Financial Officer Pursuant to </font></div><div style="line-height:120%;padding-bottom:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Frank A. D'Amelio, certify that:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;"><font style="padding-bottom:6px;padding-top:6px;text-align:left;font-family:inherit;font-size:10pt;padding-right:24px;">1.</font><font style="font-family:inherit;font-size:10pt;">I have reviewed this Quarterly Report on Form 10-Q of Pfizer Inc.;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;"><font style="padding-bottom:6px;padding-top:6px;text-align:left;font-family:inherit;font-size:10pt;padding-right:24px;">2.</font><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;"><font style="padding-bottom:6px;padding-top:6px;text-align:left;font-family:inherit;font-size:10pt;padding-right:24px;">3.</font><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;"><font style="padding-bottom:6px;padding-top:6px;text-align:left;font-family:inherit;font-size:10pt;padding-right:24px;">4.</font><font style="font-family:inherit;font-size:10pt;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;"><font style="padding-bottom:6px;padding-top:6px;text-align:left;font-family:inherit;font-size:10pt;padding-right:24px;">5.</font><font style="font-family:inherit;font-size:10pt;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:&#160;</font><font style="font-family:inherit;font-size:10pt;">August&#160;6, 2020</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:26%;"></td><td style="width:38%;"></td><td style="width:36%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ FRANK A. D'AMELIO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Frank A. D'Amelio</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Chief Financial Officer and Executive Vice President,</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Global Supply</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>pfe-exh321x0628202010q.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s2564BB2DCB685C78B000AE866BC1737C"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 32.1</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to 18 U.S.C. Section 1350, I, Albert Bourla, hereby certify that, to the best of my knowledge, the Quarterly Report on Form 10-Q of Pfizer Inc. for the fiscal quarter ended </font><font style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;28, 2020</font><font style="font-family:inherit;font-size:10pt;">&#32;(the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and that the information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of Pfizer Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:26%;"></td><td style="width:37%;"></td><td style="width:37%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ ALBERT BOURLA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Albert Bourla</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Chairman and Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August&#160;6, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>pfe-exh322x0628202010q.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sCE241144DF045439BFD91CF681D2AB86"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 32.2</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to 18 U.S.C. Section 1350, I, Frank A. D'Amelio, hereby certify that, to the best of my knowledge, the Quarterly Report on Form 10-Q of Pfizer Inc. for the fiscal quarter ended </font><font style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;28, 2020</font><font style="font-family:inherit;font-size:10pt;">&#32;(the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and that the information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of Pfizer Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:26%;"></td><td style="width:37%;"></td><td style="width:37%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ FRANK A. D'AMELIO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Frank A. D'Amelio</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Chief Financial Officer and Executive Vice President, </font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Global Supply</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August&#160;6, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>pfe-20200628.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.pfizer.com/20200628" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:pfe="http://www.pfizer.com/20200628" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20200628_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20200628_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20200628_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20200628_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests">
        <link:definition>2109100 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail">
        <link:definition>2409402 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables">
        <link:definition>2309301 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionEquityMethodInvestmentAndLicensingArrangements" roleURI="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangements">
        <link:definition>2103100 - Disclosure - Acquisition, Equity-Method Investment and Licensing Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionEquityMethodInvestmentAndLicensingArrangementsArrayBiopharmaDetails" roleURI="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsArrayBiopharmaDetails">
        <link:definition>2403402 - Disclosure - Acquisition, Equity-Method Investment and Licensing Arrangements  - Array BioPharma (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails" roleURI="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails">
        <link:definition>2403406 - Disclosure - Acquisition, Equity-Method Investment and Licensing Arrangements - BioNTech SE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails" roleURI="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails">
        <link:definition>2403403 - Disclosure - Acquisition, Equity-Method Investment and Licensing Arrangements  - Equity Method Investment Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails" roleURI="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails">
        <link:definition>2403404 - Disclosure - Acquisition, Equity-Method Investment and Licensing Arrangements  - Schedule of Equity-Method Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionEquityMethodInvestmentAndLicensingArrangementsTables" roleURI="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsTables">
        <link:definition>2303301 - Disclosure - Acquisition, Equity-Method Investment and Licensing Arrangements  - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails" roleURI="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails">
        <link:definition>2403405 - Disclosure - Acquisition, Equity-Method Investment and Licensing Arrangements - Valneva SE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPolicies" roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Basis of Presentation and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails" roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails">
        <link:definition>2401404 - Disclosure - Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPoliciesDetails" roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails">
        <link:definition>2401403 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPoliciesPolicies" roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPoliciesTables" roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables">
        <link:definition>2301302 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1003000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.pfizer.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1003001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>1005000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical" roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical">
        <link:definition>1005501 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (PARENTHETICAL)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited">
        <link:definition>1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical" roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical">
        <link:definition>1002001 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - Parenthetical</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfEquityUnaudited" roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited">
        <link:definition>1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfIncomeUnaudited" roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited">
        <link:definition>1001000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesAndCertainCommitments" roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitments">
        <link:definition>2116100 - Disclosure - Contingencies and Certain Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesAndCertainCommitmentsContingentConsiderationDetails" roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsContingentConsiderationDetails">
        <link:definition>2416403 - Disclosure - Contingencies and Certain Commitments - Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesAndCertainCommitmentsPatentLitigationDetails" roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails">
        <link:definition>2416401 - Disclosure - Contingencies and Certain Commitments (Patent Litigation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails" roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails">
        <link:definition>2416402 - Disclosure - Contingencies and Certain Commitments (Product Litigation, Commercial and Other Matters, Resolved Matters) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoverPage" roleURI="http://www.pfizer.com/role/CoverPage">
        <link:definition>0001000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShareAttributableToCommonShareholdersDetails" roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails">
        <link:definition>2415402 - Disclosure - Earnings Per Common Share Attributable to Common Shareholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShareAttributableToCommonShareholdersTables" roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersTables">
        <link:definition>2315301 - Disclosure - Earnings Per Common Share Attributable to Common Shareholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShareAttributableToPfizerIncCommonShareholders" roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholders">
        <link:definition>2115100 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.pfizer.com/role/Equity">
        <link:definition>2114100 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityDividendsDetails" roleURI="http://www.pfizer.com/role/EquityDividendsDetails">
        <link:definition>2414403 - Disclosure - Equity - Dividends (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityPreferredStockDetails" roleURI="http://www.pfizer.com/role/EquityPreferredStockDetails">
        <link:definition>2414402 - Disclosure - Equity  - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.pfizer.com/role/EquityTables">
        <link:definition>2314301 - Disclosure - Equity  - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.pfizer.com/role/FinancialInstruments">
        <link:definition>2110100 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsCreditRiskDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails">
        <link:definition>2410419 - Disclosure - Financial Instruments - Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails">
        <link:definition>2410418 - Disclosure - Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails">
        <link:definition>2410416 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails">
        <link:definition>2410417 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDerivativeNarrativeDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails">
        <link:definition>2410414 - Disclosure - Financial Instruments -  Derivative Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails">
        <link:definition>2410415 - Disclosure - Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
        <link:definition>2410402 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetail" roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetail">
        <link:definition>2410403 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesFootnotesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesFootnotesDetails">
        <link:definition>2410409 - Disclosure - Financial Instruments Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>2410404 - Disclosure - Financial Instruments - Financial Liabilities Not Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInvestmentsDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails">
        <link:definition>2410407 - Disclosure - Financial Instruments - Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInvestmentsDetailsCalc2" roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetailsCalc2">
        <link:definition>2410407 - Disclosure - Financial Instruments - Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails">
        <link:definition>2410408 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsLongTermDebtDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails">
        <link:definition>2410412 - Disclosure - Financial Instruments - Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsLongTermDebtNarrativeDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails">
        <link:definition>2410413 - Disclosure - Financial Instruments - Long-Term Debt Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsLongTermDebtNewIssuancesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails">
        <link:definition>2410411 - Disclosure - Financial Instruments - Long-Term Debt - New Issuances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsShortTermBorrowingsDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails">
        <link:definition>2410410 - Disclosure - Financial Instruments - Short-term Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.pfizer.com/role/FinancialInstrumentsTables">
        <link:definition>2310301 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails">
        <link:definition>2410405 - Disclosure - Financial Instruments - Total Short-Term and Long-Term Investments and Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsFootnotesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsFootnotesDetails">
        <link:definition>2410406 - Disclosure - Financial Instruments - Total Short-Term and Long-Term Investments and Equity Method Investments - Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsAndGoodwill" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill">
        <link:definition>2112100 - Disclosure - Identifiable Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail">
        <link:definition>2412402 - Disclosure - Identifiable Intangible Assets and Goodwill  - Finite-lived and Indefinite-lived Intangible Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails">
        <link:definition>2412403 - Disclosure - Identifiable Intangible Assets and Goodwill  - Finite-lived and Indefinite-lived Intangible Assets Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails">
        <link:definition>2412404 - Disclosure - Identifiable Intangible Assets and Goodwill  - Finite-lived Intangible Assets Percentage of Total Intangibles (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail">
        <link:definition>2412407 - Disclosure - Identifiable Intangible Assets and Goodwill  - Goodwill (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails">
        <link:definition>2412405 - Disclosure - Identifiable Intangible Assets and Goodwill  - Indefinite-lived Intangible Assets Percentage of Total Intangibles (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail">
        <link:definition>2412406 - Disclosure - Identifiable Intangible Assets and Goodwill  - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsAndGoodwillTables" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables">
        <link:definition>2312301 - Disclosure - Identifiable Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.pfizer.com/role/Inventories">
        <link:definition>2111100 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetail" roleURI="http://www.pfizer.com/role/InventoriesDetail">
        <link:definition>2411402 - Disclosure - Inventories (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.pfizer.com/role/InventoriesTables">
        <link:definition>2311301 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNet" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNet">
        <link:definition>2107100 - Disclosure - Other (Income)/Deductions - Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNetDetail" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail">
        <link:definition>2407402 - Disclosure - Other (Income)/Deductions - Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNetFootnotesDetail" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail">
        <link:definition>2407403 - Disclosure - Other (Income)/Deductions - Net - Footnotes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNetTables" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables">
        <link:definition>2307301 - Disclosure - Other (Income)/Deductions - Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAndPostretirementBenefitPlans" roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlans">
        <link:definition>2113100 - Disclosure - Pension and Postretirement Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAndPostretirementBenefitPlansDetail" roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail">
        <link:definition>2413403 - Disclosure - Pension and Postretirement Benefit Plans (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail" roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail">
        <link:definition>2413402 - Disclosure - Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAndPostretirementBenefitPlansTables" roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansTables">
        <link:definition>2313301 - Disclosure - Pension and Postretirement Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives">
        <link:definition>2104100 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail" roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail">
        <link:definition>2404403 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetailCalc2" roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetailCalc2">
        <link:definition>2404403 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetail" roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetail">
        <link:definition>2404404 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Footnotes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails" roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails">
        <link:definition>2404402 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail">
        <link:definition>2404405 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail">
        <link:definition>2404406 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables">
        <link:definition>2304301 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicAndOtherRevenueInformation" roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation">
        <link:definition>2117100 - Disclosure - Segment, Geographic and Other Revenue Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicAndOtherRevenueInformationDetail" roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail">
        <link:definition>2417403 - Disclosure - Segment, Geographic and Other Revenue Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicAndOtherRevenueInformationFootnotesDetail" roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail">
        <link:definition>2417404 - Disclosure - Segment, Geographic and Other Revenue Information - Footnotes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicAndOtherRevenueInformationNarrativeDetail" roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail">
        <link:definition>2417402 - Disclosure - Segment, Geographic and Other Revenue Information - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail">
        <link:definition>2417405 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail">
        <link:definition>2417406 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Geographic Area - Footnotes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail">
        <link:definition>2417407 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Products (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicAndOtherRevenueInformationTables" roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables">
        <link:definition>2317301 - Disclosure - Segment, Geographic and Other Revenue Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMatters" roleURI="http://www.pfizer.com/role/TaxMatters">
        <link:definition>2108100 - Disclosure - Tax Matters</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersDetail" roleURI="http://www.pfizer.com/role/TaxMattersDetail">
        <link:definition>2408403 - Disclosure - Tax Matters (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersNarrativeDetail" roleURI="http://www.pfizer.com/role/TaxMattersNarrativeDetail">
        <link:definition>2408402 - Disclosure - Tax Matters - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersTables" roleURI="http://www.pfizer.com/role/TaxMattersTables">
        <link:definition>2308301 - Disclosure - Tax Matters (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="pfe_AccruedRebates" name="AccruedRebates" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_AllOtherInflammationandImmunologyProductsMember" name="AllOtherInflammationandImmunologyProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AllOtherInternalMedicineMember" name="AllOtherInternalMedicineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AllOtherRareDiseaseProductsMember" name="AllOtherRareDiseaseProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AllOtherUpjohnProductsMember" name="AllOtherUpjohnProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AllogeneMember" name="AllogeneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" name="AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AnacorMember" name="AnacorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ArrayMember" name="ArrayMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AssetImpairmentsMember" name="AssetImpairmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_AssetWriteOffsAndAssetImpairmentCharges" name="AssetWriteOffsAndAssetImpairmentCharges" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" name="AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_BMP2Member" name="BMP2Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BeneFIXMember" name="BeneFIXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BioNTechSEMember" name="BioNTechSEMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BiopharmaSegmentMember" name="BiopharmaSegmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" name="BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BosulifMember" name="BosulifMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BraftoviMember" name="BraftoviMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_BusinessAlignmentCosts" name="BusinessAlignmentCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" name="BusinessCombinationAcquisitionRelatedCostsTransactionCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BusinessCombinationsAcquisitionRelatedCostsMember" name="BusinessCombinationsAcquisitionRelatedCostsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" name="BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock" name="BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BusinessIntegrationCostsMember" name="BusinessIntegrationCostsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_CK1AssetsSoldToBiogenIncMember" name="CK1AssetsSoldToBiogenIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_CelebrexMember" name="CelebrexMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_CertainSignificantItemsMember" name="CertainSignificantItemsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ChantixChampixMember" name="ChantixChampixMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ClassActionVersusWyethMember" name="ClassActionVersusWyethMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ConsumerHealthcareMember" name="ConsumerHealthcareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ConsumerHealthcareReportingUnitMember" name="ConsumerHealthcareReportingUnitMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_CortexymeInc.Member" name="CortexymeInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" name="DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" name="DebtSecuritiesAccumulatedGrossUnrealizedGain" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" name="DebtSecuritiesAccumulatedGrossUnrealizedLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DebtSecuritiesAmortizedCostBasis" name="DebtSecuritiesAmortizedCostBasis" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" name="DebtSecuritiesMaturitiesAfterYearFiveFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" name="DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" name="DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" name="DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_DeconsolidationGainLossAmountNetOfCashConveyed" name="DeconsolidationGainLossAmountNetOfCashConveyed" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_DeconsolidationGainLossAmountNetOfTax" name="DeconsolidationGainLossAmountNetOfTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" name="DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax" name="DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" name="DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_DevelopedEuropeMember" name="DevelopedEuropeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_DevelopedRestOfWorldMember" name="DevelopedRestOfWorldMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss" name="DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_DocetaxelMember" name="DocetaxelMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EffexorMember" name="EffexorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EliLillyCompanyMember" name="EliLillyCompanyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EliquisMember" name="EliquisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EmergingMarketsMember" name="EmergingMarketsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EnbrelMember" name="EnbrelMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EnvironmentalRemediationLitigationMember" name="EnvironmentalRemediationLitigationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EpiPenMember" name="EpiPenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_EquityMethodInvestmentExcessBasisAmortization" name="EquityMethodInvestmentExcessBasisAmortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod" name="EquityMethodInvestmentExcessBasisAmortizationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" name="EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_EquitySecuritiesFVNINoncurrent" name="EquitySecuritiesFVNINoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_EquitySecuritiesFVNIRestrictedNoncurrent" name="EquitySecuritiesFVNIRestrictedNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" name="EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_FeasibilityStudyNumberOfLagoons" name="FeasibilityStudyNumberOfLagoons" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_FinancialInstrumentsAbstract" name="FinancialInstrumentsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_FocusedCompanyPlanMember" name="FocusedCompanyPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract" name="FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ForeignCurrencyLongTermDebtMember" name="ForeignCurrencyLongTermDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ForeignCurrencyShortTermBorrowingsMember" name="ForeignCurrencyShortTermBorrowingsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_FragminMember" name="FragminMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_GSKConsumerHealthcareMember" name="GSKConsumerHealthcareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_GSKMember" name="GSKMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_GainContingencyNumberofDefendants" name="GainContingencyNumberofDefendants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" name="GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_GainContingencyPatentsWithoutCourtProceedingsNumber" name="GainContingencyPatentsWithoutCourtProceedingsNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_GeneTherapiesMember" name="GeneTherapiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_GenotropinMember" name="GenotropinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_HedgedItemAxis" name="HedgedItemAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_HedgedItemDomain" name="HedgedItemDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_HeldToMaturityCashEquivalents" name="HeldToMaturityCashEquivalents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" name="HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_HormoneTherapyProductsMember" name="HormoneTherapyProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_HospiraMember" name="HospiraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_HospitalMember" name="HospitalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_IbranceMember" name="IbranceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock" name="IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ImplementationCostAbstract" name="ImplementationCostAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_ImplementationCosts" name="ImplementationCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" name="IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" name="IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" name="IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" name="IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_IncomeTaxesLineItems" name="IncomeTaxesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_IncomeTaxesPayableMember" name="IncomeTaxesPayableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_IncomeTaxesTable" name="IncomeTaxesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_InflammationandImmunologyMember" name="InflammationandImmunologyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_InflectraRemsimaMember" name="InflectraRemsimaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_InlytaMember" name="InlytaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet" name="IntangibleAssetsNetPercentageofIntangibleAssetsNet" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="pfe_InterestReceivedInterestRateHedges" name="InterestReceivedInterestRateHedges" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_InternalMedicineMember" name="InternalMedicineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_KingMember" name="KingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_LicensingAgreementsAndOtherMember" name="LicensingAgreementsAndOtherMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_LicensingArrangementValueOfSharesPurchased" name="LicensingArrangementValueOfSharesPurchased" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_LipitorMember" name="LipitorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_LongTermDebtIssuedFirstQuarter2020Member" name="LongTermDebtIssuedFirstQuarter2020Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" name="LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" name="LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_LongtermInvestmentsMember" name="LongtermInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_LossContingencyClassActionsFiledNumber" name="LossContingencyClassActionsFiledNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" name="LossContingencyNumberOfDefendantsOtherThanMainDefendant" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_LossContingencyNumberOfLawsuits" name="LossContingencyNumberOfLawsuits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_LyricaMember" name="LyricaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ManufacturingCostReductionMember" name="ManufacturingCostReductionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_MedrolMember" name="MedrolMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_MektoviMember" name="MektoviMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_MylanMember" name="MylanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_NHSScotlandvs.DrReddysMember" name="NHSScotlandvs.DrReddysMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_NimenrixMember" name="NimenrixMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_NorvascMember" name="NorvascMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_NotesDue20220.250Member" name="NotesDue20220.250Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_NotesDue20271.000Member" name="NotesDue20271.000Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_NumberOfAccountingStandardsAdopted" name="NumberOfAccountingStandardsAdopted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_OncologyMember" name="OncologyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherAccruals" name="OtherAccruals" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_OtherAntiinfectivesMember" name="OtherAntiinfectivesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" name="OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" name="OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" name="OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" name="OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" name="OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" name="OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" name="OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax" name="OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_OtherHospitalProductsMember" name="OtherHospitalProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_OtherIncomeDeductionsAndCostOfSalesMember" name="OtherIncomeDeductionsAndCostOfSalesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherNonoperatingIncomeExpenseNet" name="OtherNonoperatingIncomeExpenseNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_OtherOncologyProductsMember" name="OtherOncologyProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_OtherSegmentReconcilingItemsAxis" name="OtherSegmentReconcilingItemsAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_OtherSegmentReconcilingItemsDomain" name="OtherSegmentReconcilingItemsDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherTaxAssetsCurrent" name="OtherTaxAssetsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_OtherVaccinesProductsMember" name="OtherVaccinesProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PanzygaMember" name="PanzygaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PatentInfringementMember" name="PatentInfringementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_PaymentForLicensingArrangement" name="PaymentForLicensingArrangement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_PaymentForRepatriationTax" name="PaymentForRepatriationTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" name="PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" name="PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" name="PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_PercentageChangeInRevenue" name="PercentageChangeInRevenue" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" name="PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PfizerCentreOneMember" name="PfizerCentreOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PfizerVersusGenericCompaniesMember" name="PfizerVersusGenericCompaniesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member" name="PfizerVersusViwitPharmaceuticalCo.Ltd.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PfizerVersusZydusMember" name="PfizerVersusZydusMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" name="PfizerandBMSVersusSeveralGenericManufacturersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember" name="PfizersWorldwideResearchDevelopmentAndMedicalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PrecedexMember" name="PrecedexMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PremarinFamilyMember" name="PremarinFamilyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PrevnarPrevenarFamilyMember" name="PrevnarPrevenarFamilyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_PrivateEquityInvestments" name="PrivateEquityInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_PumaTechnologiesMember" name="PumaTechnologiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PurchaseAccountingAdjustmentsMember" name="PurchaseAccountingAdjustmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_RareDiseaseMember" name="RareDiseaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ReFactoAfXynthaMember" name="ReFactoAfXynthaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_RebatesAndDiscountsAccrual" name="RebatesAndDiscountsAccrual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage" name="ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure" name="ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1" name="ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure" name="ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure" name="ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed" name="ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_RestructuringAssetImpairmentCharges" name="RestructuringAssetImpairmentCharges" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" name="RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_RestructuringChargesAndAcquisitionRelatedCosts" name="RestructuringChargesAndAcquisitionRelatedCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_RestructuringandRelatedCostNoncashChargesPercentage" name="RestructuringandRelatedCostNoncashChargesPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_RetacritMember" name="RetacritMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ScheduleOfAccruedLiabilitiesLineItems" name="ScheduleOfAccruedLiabilitiesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ScheduleOfAccruedLiabilitiesTable" name="ScheduleOfAccruedLiabilitiesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" name="ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" name="ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock" name="ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock" name="ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" name="ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorNotesDue2047Member" name="SeniorNotesDue2047Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member" name="SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member" name="SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member" name="SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member" name="SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member" name="SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member" name="SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member" name="SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member" name="SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member" name="SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member" name="SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member" name="SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member" name="SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member" name="SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member" name="SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member" name="SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_ShorttermDebtGross" name="ShorttermDebtGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" name="ShorttermInvestmentsExcludingHeldToMaturitySecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_SomavertMember" name="SomavertMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" name="StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" name="StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SulperazonMember" name="SulperazonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SutentMember" name="SutentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_TotalAllianceBiopharmaceuticalsMember" name="TotalAllianceBiopharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_TotalBiosimilarsMember" name="TotalBiosimilarsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_TotalSterileInjectablePharmaceuticalsMember" name="TotalSterileInjectablePharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ToviazMember" name="ToviazMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember" name="TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_UpjohnFinanceB.V.Member" name="UpjohnFinanceB.V.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_UpjohnIncMember" name="UpjohnIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_UpjohnReportingUnitMember" name="UpjohnReportingUnitMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_UpjohnSegmentMember" name="UpjohnSegmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_VaccinesMember" name="VaccinesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ValnevaSEMember" name="ValnevaSEMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_VfendMember" name="VfendMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ViagraMember" name="ViagraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ViiVMember" name="ViiVMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_VyndaqelMember" name="VyndaqelMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_XalatanXalacomMember" name="XalatanXalacomMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_XalkoriMember" name="XalkoriMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_XeljanzMember" name="XeljanzMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_XtandiAllianceRevenuesMember" name="XtandiAllianceRevenuesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ZithromaxZmaxMember" name="ZithromaxZmaxMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ZoloftMember" name="ZoloftMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ZyvoxMember" name="ZyvoxMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>pfe-20200628_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:href="pfe-20200628.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" xlink:href="pfe-20200628.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:href="pfe-20200628.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangements" xlink:href="pfe-20200628.xsd#AcquisitionEquityMethodInvestmentAndLicensingArrangements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsArrayBiopharmaDetails" xlink:href="pfe-20200628.xsd#AcquisitionEquityMethodInvestmentAndLicensingArrangementsArrayBiopharmaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails" xlink:href="pfe-20200628.xsd#AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails" xlink:href="pfe-20200628.xsd#AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails" xlink:href="pfe-20200628.xsd#AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsTables" xlink:href="pfe-20200628.xsd#AcquisitionEquityMethodInvestmentAndLicensingArrangementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails" xlink:href="pfe-20200628.xsd#AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:href="pfe-20200628.xsd#BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails" xlink:href="pfe-20200628.xsd#BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails" xlink:href="pfe-20200628.xsd#BasisOfPresentationAndSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:href="pfe-20200628.xsd#BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:href="pfe-20200628.xsd#BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets" xlink:href="pfe-20200628.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="pfe-20200628.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="pfe-20200628.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical" xlink:href="pfe-20200628.xsd#CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="pfe-20200628.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical" xlink:href="pfe-20200628.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" xlink:href="pfe-20200628.xsd#CondensedConsolidatedStatementsOfEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="pfe-20200628.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitments" xlink:href="pfe-20200628.xsd#ContingenciesAndCertainCommitments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsContingentConsiderationDetails" xlink:href="pfe-20200628.xsd#ContingenciesAndCertainCommitmentsContingentConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails" xlink:href="pfe-20200628.xsd#ContingenciesAndCertainCommitmentsPatentLitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails" xlink:href="pfe-20200628.xsd#ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CoverPage" xlink:href="pfe-20200628.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails" xlink:href="pfe-20200628.xsd#EarningsPerCommonShareAttributableToCommonShareholdersDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersTables" xlink:href="pfe-20200628.xsd#EarningsPerCommonShareAttributableToCommonShareholdersTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholders" xlink:href="pfe-20200628.xsd#EarningsPerCommonShareAttributableToPfizerIncCommonShareholders" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/Equity" xlink:href="pfe-20200628.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EquityDividendsDetails" xlink:href="pfe-20200628.xsd#EquityDividendsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EquityPreferredStockDetails" xlink:href="pfe-20200628.xsd#EquityPreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EquityTables" xlink:href="pfe-20200628.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstruments" xlink:href="pfe-20200628.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsCreditRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsDerivativeNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="pfe-20200628.xsd#FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetail" xlink:href="pfe-20200628.xsd#FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesFootnotesDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsFinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsFinancialLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetailsCalc2" xlink:href="pfe-20200628.xsd#FinancialInstrumentsInvestmentsDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsLongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsLongTermDebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsLongTermDebtNewIssuancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsShortTermBorrowingsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsTables" xlink:href="pfe-20200628.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsFootnotesDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill" xlink:href="pfe-20200628.xsd#IdentifiableIntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail" xlink:href="pfe-20200628.xsd#IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" xlink:href="pfe-20200628.xsd#IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:href="pfe-20200628.xsd#IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail" xlink:href="pfe-20200628.xsd#IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:href="pfe-20200628.xsd#IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail" xlink:href="pfe-20200628.xsd#IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables" xlink:href="pfe-20200628.xsd#IdentifiableIntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/Inventories" xlink:href="pfe-20200628.xsd#Inventories" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/InventoriesDetail" xlink:href="pfe-20200628.xsd#InventoriesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/InventoriesTables" xlink:href="pfe-20200628.xsd#InventoriesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNet" xlink:href="pfe-20200628.xsd#OtherIncomeDeductionsNet" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail" xlink:href="pfe-20200628.xsd#OtherIncomeDeductionsNetDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail" xlink:href="pfe-20200628.xsd#OtherIncomeDeductionsNetFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" xlink:href="pfe-20200628.xsd#OtherIncomeDeductionsNetTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlans" xlink:href="pfe-20200628.xsd#PensionAndPostretirementBenefitPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail" xlink:href="pfe-20200628.xsd#PensionAndPostretirementBenefitPlansDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:href="pfe-20200628.xsd#PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansTables" xlink:href="pfe-20200628.xsd#PensionAndPostretirementBenefitPlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" xlink:href="pfe-20200628.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail" xlink:href="pfe-20200628.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetailCalc2" xlink:href="pfe-20200628.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetailCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetail" xlink:href="pfe-20200628.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails" xlink:href="pfe-20200628.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:href="pfe-20200628.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:href="pfe-20200628.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" xlink:href="pfe-20200628.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation" xlink:href="pfe-20200628.xsd#SegmentGeographicAndOtherRevenueInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail" xlink:href="pfe-20200628.xsd#SegmentGeographicAndOtherRevenueInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail" xlink:href="pfe-20200628.xsd#SegmentGeographicAndOtherRevenueInformationFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail" xlink:href="pfe-20200628.xsd#SegmentGeographicAndOtherRevenueInformationNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:href="pfe-20200628.xsd#SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" xlink:href="pfe-20200628.xsd#SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" xlink:href="pfe-20200628.xsd#SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables" xlink:href="pfe-20200628.xsd#SegmentGeographicAndOtherRevenueInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMatters" xlink:href="pfe-20200628.xsd#TaxMatters" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersDetail" xlink:href="pfe-20200628.xsd#TaxMattersDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersNarrativeDetail" xlink:href="pfe-20200628.xsd#TaxMattersNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersTables" xlink:href="pfe-20200628.xsd#TaxMattersTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsArrayBiopharmaDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_26247a2d-7bac-8834-3dc5-06c993b10b2c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_26247a2d-7bac-8834-3dc5-06c993b10b2c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedInvestmentsCurrent" xlink:label="loc_us-gaap_RestrictedInvestmentsCurrent_4b528bf4-4c09-5ba9-ef39-4da77b93631c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:to="loc_us-gaap_RestrictedInvestmentsCurrent_4b528bf4-4c09-5ba9-ef39-4da77b93631c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments_f3de6e36-470b-29d6-6fa5-d272f7c5db4c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:to="loc_us-gaap_OtherShortTermInvestments_f3de6e36-470b-29d6-6fa5-d272f7c5db4c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2107189c-f25f-5667-a3b4-dbf4394a5e32" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2107189c-f25f-5667-a3b4-dbf4394a5e32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_aa7cc103-d668-cf3b-6875-81c99ffeac19" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:to="loc_us-gaap_InventoryNet_aa7cc103-d668-cf3b-6875-81c99ffeac19" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherTaxAssetsCurrent" xlink:label="loc_pfe_OtherTaxAssetsCurrent_8efb2248-74a6-50d6-a518-9475a7f08b75" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:to="loc_pfe_OtherTaxAssetsCurrent_8efb2248-74a6-50d6-a518-9475a7f08b75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_be6829f0-538a-891f-48bc-46140655594e" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:to="loc_us-gaap_OtherAssetsCurrent_be6829f0-538a-891f-48bc-46140655594e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermInvestments" xlink:label="loc_us-gaap_OtherLongTermInvestments_aae951e3-f9c1-c2fa-ecdc-2393c81c52eb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_us-gaap_OtherLongTermInvestments_aae951e3-f9c1-c2fa-ecdc-2393c81c52eb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bf545d72-755b-f46c-4176-2eeaac0328d1" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bf545d72-755b-f46c-4176-2eeaac0328d1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a63bfe00-8c71-75eb-c989-1230f0c1a19e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a63bfe00-8c71-75eb-c989-1230f0c1a19e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_57088d99-3f43-6bbf-c330-0bf0e1b35b0b" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_us-gaap_Goodwill_57088d99-3f43-6bbf-c330-0bf0e1b35b0b" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:label="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_ef0a05d2-2833-38eb-9a23-9475a7540d32" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_ef0a05d2-2833-38eb-9a23-9475a7540d32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_17a41c51-6fe7-c037-64c3-3ef6c9692a94" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_17a41c51-6fe7-c037-64c3-3ef6c9692a94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_ff686380-cb66-3f62-443b-907a193effe8" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_us-gaap_EquityMethodInvestments_ff686380-cb66-3f62-443b-907a193effe8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae7d1998-6654-2677-8e9f-f36b62210000" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae7d1998-6654-2677-8e9f-f36b62210000" xlink:to="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:to="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_535a2650-0afd-ab3b-1421-a50fb29a33a7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:to="loc_us-gaap_DebtCurrent_535a2650-0afd-ab3b-1421-a50fb29a33a7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_95fe5c6d-e90e-6d2c-8e9a-8339666be1b8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:to="loc_us-gaap_AccountsPayableCurrent_95fe5c6d-e90e-6d2c-8e9a-8339666be1b8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent" xlink:label="loc_us-gaap_DividendsPayableCurrent_72fc3045-91c5-4582-58ae-4aa615664758" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:to="loc_us-gaap_DividendsPayableCurrent_72fc3045-91c5-4582-58ae-4aa615664758" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_b6812058-b009-dc0a-a96c-893d68edc838" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:to="loc_us-gaap_TaxesPayableCurrent_b6812058-b009-dc0a-a96c-893d68edc838" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9eef8c70-87b0-cf2a-9025-8b985649a106" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9eef8c70-87b0-cf2a-9025-8b985649a106" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_1c21a626-3d7a-4f23-3b81-d88f79f601a8" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_1c21a626-3d7a-4f23-3b81-d88f79f601a8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_a1517e9b-48ef-ec4d-5351-733e917bf402" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_a1517e9b-48ef-ec4d-5351-733e917bf402" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_fcdd7758-4f7c-ae7b-d565-ba0aa82178b0" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_fcdd7758-4f7c-ae7b-d565-ba0aa82178b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_dcbb8e9f-4b47-f559-bfe9-3dea64d96895" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:to="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_dcbb8e9f-4b47-f559-bfe9-3dea64d96895" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e498812a-ea06-2933-72f6-8e959ed1c719" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e498812a-ea06-2933-72f6-8e959ed1c719" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_44e41183-ff71-8a5d-6bae-236dd27ab6c0" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_44e41183-ff71-8a5d-6bae-236dd27ab6c0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_3809c2d8-d6ec-795a-7dee-7fcff83c5dde" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_3809c2d8-d6ec-795a-7dee-7fcff83c5dde" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c8c1ef7d-82ef-ec40-66d0-45806fc53a6e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae7d1998-6654-2677-8e9f-f36b62210000" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c8c1ef7d-82ef-ec40-66d0-45806fc53a6e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ac757736-b2b3-41b4-5596-13d65c8f73d5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae7d1998-6654-2677-8e9f-f36b62210000" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ac757736-b2b3-41b4-5596-13d65c8f73d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_444cfce6-fc59-0d4d-1ade-0fdec3499b08" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ac757736-b2b3-41b4-5596-13d65c8f73d5" xlink:to="loc_us-gaap_StockholdersEquity_444cfce6-fc59-0d4d-1ade-0fdec3499b08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_844e7c43-dfe0-790d-4f5e-8b1150390e12" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_444cfce6-fc59-0d4d-1ade-0fdec3499b08" xlink:to="loc_us-gaap_PreferredStockValue_844e7c43-dfe0-790d-4f5e-8b1150390e12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_130b8997-2f7a-8192-a853-ff9fb4629d95" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_444cfce6-fc59-0d4d-1ade-0fdec3499b08" xlink:to="loc_us-gaap_CommonStockValue_130b8997-2f7a-8192-a853-ff9fb4629d95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_26982214-e3a4-a834-1e73-cd58ba2d5ac9" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_444cfce6-fc59-0d4d-1ade-0fdec3499b08" xlink:to="loc_us-gaap_AdditionalPaidInCapital_26982214-e3a4-a834-1e73-cd58ba2d5ac9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_af531fdd-0099-f49a-729d-64bccce3d7cd" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_444cfce6-fc59-0d4d-1ade-0fdec3499b08" xlink:to="loc_us-gaap_TreasuryStockValue_af531fdd-0099-f49a-729d-64bccce3d7cd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_18ff0284-4873-6ef0-806f-4fb76051c01f" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_444cfce6-fc59-0d4d-1ade-0fdec3499b08" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_18ff0284-4873-6ef0-806f-4fb76051c01f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_355fc088-038d-3905-0784-91db0d020a77" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_444cfce6-fc59-0d4d-1ade-0fdec3499b08" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_355fc088-038d-3905-0784-91db0d020a77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_02ec7b38-4afa-636c-3b62-de1bd1bf96c1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ac757736-b2b3-41b4-5596-13d65c8f73d5" xlink:to="loc_us-gaap_MinorityInterest_02ec7b38-4afa-636c-3b62-de1bd1bf96c1" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7e98a0be-51ae-18d0-54bf-b32eca8c5c1d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7e98a0be-51ae-18d0-54bf-b32eca8c5c1d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_82a1dba8-8b5a-130a-edce-afbb0d3a199c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_ProfitLoss_82a1dba8-8b5a-130a-edce-afbb0d3a199c" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" xlink:label="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_1afaec46-3f29-7a86-52e0-9475a873b279" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_1afaec46-3f29-7a86-52e0-9475a873b279" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AssetWriteOffsAndAssetImpairmentCharges" xlink:label="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_64ff6ce1-84c4-3023-9d35-9475a661e44e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_64ff6ce1-84c4-3023-9d35-9475a661e44e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_24ae26be-0d67-f62c-f6f8-8c37d7f324e5" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_24ae26be-0d67-f62c-f6f8-8c37d7f324e5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DeconsolidationGainLossAmountNetOfCashConveyed" xlink:label="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_893f80c5-71ae-cb28-a54f-9475a82acadc" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_893f80c5-71ae-cb28-a54f-9475a82acadc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_282d8de6-1466-4351-6593-66c6a3dfd2f5" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_282d8de6-1466-4351-6593-66c6a3dfd2f5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_8e70545b-e41a-5c88-3aeb-15f273c05266" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_ShareBasedCompensation_8e70545b-e41a-5c88-3aeb-15f273c05266" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" xlink:label="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_53ee1fd8-7f36-fe49-a3bb-9475a6bfb9d5" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_53ee1fd8-7f36-fe49-a3bb-9475a6bfb9d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_0f2b9828-5f8e-5896-c7bd-f8b6ab4926af" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_0f2b9828-5f8e-5896-c7bd-f8b6ab4926af" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_4bd6cce4-82bf-a7c4-1028-ad47e749cc21" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_4bd6cce4-82bf-a7c4-1028-ad47e749cc21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2794b8a8-762d-d243-a2f5-a00d52d74432" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7e98a0be-51ae-18d0-54bf-b32eca8c5c1d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2794b8a8-762d-d243-a2f5-a00d52d74432" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ca48a49a-2cde-cf3d-6904-e8f08b6e1fbb" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2794b8a8-762d-d243-a2f5-a00d52d74432" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ca48a49a-2cde-cf3d-6904-e8f08b6e1fbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_7fd6a784-2a6d-75d2-7b24-d11d64876f63" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2794b8a8-762d-d243-a2f5-a00d52d74432" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_7fd6a784-2a6d-75d2-7b24-d11d64876f63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_b48c7dd0-f083-c5cd-5708-25d6b7377dfe" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2794b8a8-762d-d243-a2f5-a00d52d74432" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_b48c7dd0-f083-c5cd-5708-25d6b7377dfe" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" xlink:label="loc_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_888db96d-bbdc-8dba-6bf0-9475a82718da" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2794b8a8-762d-d243-a2f5-a00d52d74432" xlink:to="loc_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_888db96d-bbdc-8dba-6bf0-9475a82718da" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_3d52926a-06eb-6b3a-527c-ff175422ed87" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2794b8a8-762d-d243-a2f5-a00d52d74432" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_3d52926a-06eb-6b3a-527c-ff175422ed87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_f6b48af9-f0db-0b15-e985-611e27f43d51" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2794b8a8-762d-d243-a2f5-a00d52d74432" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_f6b48af9-f0db-0b15-e985-611e27f43d51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_35d4397e-e67f-0c31-eb78-8fc24d8e27e3" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2794b8a8-762d-d243-a2f5-a00d52d74432" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_35d4397e-e67f-0c31-eb78-8fc24d8e27e3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_e33e3b56-416a-9757-52a3-44ee94cae9bf" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2794b8a8-762d-d243-a2f5-a00d52d74432" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_e33e3b56-416a-9757-52a3-44ee94cae9bf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a7e00ec-a1a5-81e8-5255-8844ac6fe87f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7e98a0be-51ae-18d0-54bf-b32eca8c5c1d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a7e00ec-a1a5-81e8-5255-8844ac6fe87f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_0bd45741-2cc6-ce60-1e7c-3836531cc1e2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a7e00ec-a1a5-81e8-5255-8844ac6fe87f" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_0bd45741-2cc6-ce60-1e7c-3836531cc1e2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_07532ed5-11cb-8828-1825-d3d729cffe02" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a7e00ec-a1a5-81e8-5255-8844ac6fe87f" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_07532ed5-11cb-8828-1825-d3d729cffe02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_c837e12a-08a8-6d98-6718-5c7ec2ef2ab7" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a7e00ec-a1a5-81e8-5255-8844ac6fe87f" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_c837e12a-08a8-6d98-6718-5c7ec2ef2ab7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_06529ffd-62cf-ac47-b8f8-c38a666da5ee" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a7e00ec-a1a5-81e8-5255-8844ac6fe87f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_06529ffd-62cf-ac47-b8f8-c38a666da5ee" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_7f9580a9-3805-cc3a-42fd-74ab6d116d7a" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a7e00ec-a1a5-81e8-5255-8844ac6fe87f" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_7f9580a9-3805-cc3a-42fd-74ab6d116d7a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5438f733-2c2e-cb8b-518a-eb0b0108364e" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a7e00ec-a1a5-81e8-5255-8844ac6fe87f" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5438f733-2c2e-cb8b-518a-eb0b0108364e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_5834e2fc-aed5-db80-d714-d94407c943b2" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a7e00ec-a1a5-81e8-5255-8844ac6fe87f" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_5834e2fc-aed5-db80-d714-d94407c943b2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_48d97f34-0a5c-c855-1d88-050ad7d70f97" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a7e00ec-a1a5-81e8-5255-8844ac6fe87f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_48d97f34-0a5c-c855-1d88-050ad7d70f97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_6af9b322-bd28-b53c-6ab5-52bafd228259" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a7e00ec-a1a5-81e8-5255-8844ac6fe87f" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_6af9b322-bd28-b53c-6ab5-52bafd228259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c3fb4920-0b72-7fd0-429d-d910e936dd99" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7e98a0be-51ae-18d0-54bf-b32eca8c5c1d" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c3fb4920-0b72-7fd0-429d-d910e936dd99" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_61cff5eb-6380-0a99-0b9f-2aa494c88658" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b648d0ef-16fe-7d60-a025-6e0cc8ac751c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_61cff5eb-6380-0a99-0b9f-2aa494c88658" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b648d0ef-16fe-7d60-a025-6e0cc8ac751c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_82a1dba8-8b5a-130a-edce-afbb0d3a199c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b648d0ef-16fe-7d60-a025-6e0cc8ac751c" xlink:to="loc_us-gaap_ProfitLoss_82a1dba8-8b5a-130a-edce-afbb0d3a199c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ec9c3aab-da5b-a831-3f37-62a3ea3b00ff" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b648d0ef-16fe-7d60-a025-6e0cc8ac751c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ec9c3aab-da5b-a831-3f37-62a3ea3b00ff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_d7e31c43-cfee-9794-8fce-556bedc57d99" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ec9c3aab-da5b-a831-3f37-62a3ea3b00ff" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_d7e31c43-cfee-9794-8fce-556bedc57d99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_d5685a90-6e69-1ee1-b51f-1fd22888bfad" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_d7e31c43-cfee-9794-8fce-556bedc57d99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_d5685a90-6e69-1ee1-b51f-1fd22888bfad" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_0e91a4ca-5061-f23a-d784-5d6fe839cc78" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_d5685a90-6e69-1ee1-b51f-1fd22888bfad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_0e91a4ca-5061-f23a-d784-5d6fe839cc78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_a4047244-53ab-347b-cd37-2ad0445bc512" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_d5685a90-6e69-1ee1-b51f-1fd22888bfad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_a4047244-53ab-347b-cd37-2ad0445bc512" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_aa848989-af80-b6af-40c1-68bea5e78cc2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_d7e31c43-cfee-9794-8fce-556bedc57d99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_aa848989-af80-b6af-40c1-68bea5e78cc2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_a33e65a0-0973-1518-3fe1-c5852802ea44" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_aa848989-af80-b6af-40c1-68bea5e78cc2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_a33e65a0-0973-1518-3fe1-c5852802ea44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_e64203cf-733e-6031-d4f5-e421b68ab889" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_aa848989-af80-b6af-40c1-68bea5e78cc2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_e64203cf-733e-6031-d4f5-e421b68ab889" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_012bea89-4d32-4dba-7fc4-284343a47ee0" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_d7e31c43-cfee-9794-8fce-556bedc57d99" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_012bea89-4d32-4dba-7fc4-284343a47ee0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_352f17ba-b941-ac2d-17c2-b741a9e67674" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_012bea89-4d32-4dba-7fc4-284343a47ee0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_352f17ba-b941-ac2d-17c2-b741a9e67674" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_0d4c024b-a981-25ec-1157-9e96ad84910b" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_012bea89-4d32-4dba-7fc4-284343a47ee0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_0d4c024b-a981-25ec-1157-9e96ad84910b" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_abdf2d7a-8259-d1ae-a6cc-9475a6aaa5dd" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_012bea89-4d32-4dba-7fc4-284343a47ee0" xlink:to="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_abdf2d7a-8259-d1ae-a6cc-9475a6aaa5dd" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_d20401ac-02cb-3ed9-150c-9475a60ac475" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_012bea89-4d32-4dba-7fc4-284343a47ee0" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_d20401ac-02cb-3ed9-150c-9475a60ac475" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_bb232057-ba46-19e5-5ad4-358a9de178c4" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_d7e31c43-cfee-9794-8fce-556bedc57d99" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_bb232057-ba46-19e5-5ad4-358a9de178c4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_0b6f8adf-7352-7bdd-69d0-cd5b112ef63f" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_bb232057-ba46-19e5-5ad4-358a9de178c4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_0b6f8adf-7352-7bdd-69d0-cd5b112ef63f" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_d4d19fb3-0a1c-f8f0-1a13-9475a59d3578" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_bb232057-ba46-19e5-5ad4-358a9de178c4" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_d4d19fb3-0a1c-f8f0-1a13-9475a59d3578" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_44f4806a-1c1c-7035-1061-0509a32178df" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_bb232057-ba46-19e5-5ad4-358a9de178c4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_44f4806a-1c1c-7035-1061-0509a32178df" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_982a1de3-51f5-bc18-9d24-037fe2750a8c" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_d7e31c43-cfee-9794-8fce-556bedc57d99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_982a1de3-51f5-bc18-9d24-037fe2750a8c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_92b3052c-bc0b-d7f2-fea8-3c4ecc5cf273" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_982a1de3-51f5-bc18-9d24-037fe2750a8c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_92b3052c-bc0b-d7f2-fea8-3c4ecc5cf273" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_10778d66-7bf4-de31-9227-3b06ecfb512c" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_982a1de3-51f5-bc18-9d24-037fe2750a8c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_10778d66-7bf4-de31-9227-3b06ecfb512c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_1d432f33-1efc-c8e6-76f6-47bbd7ba8488" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ec9c3aab-da5b-a831-3f37-62a3ea3b00ff" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_1d432f33-1efc-c8e6-76f6-47bbd7ba8488" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_8d46be56-f4eb-8e22-ebfd-f7827a406c06" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_61cff5eb-6380-0a99-0b9f-2aa494c88658" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_8d46be56-f4eb-8e22-ebfd-f7827a406c06" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_aaf4fade-f652-62f8-cf02-c59447905641" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_82a1dba8-8b5a-130a-edce-afbb0d3a199c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_aaf4fade-f652-62f8-cf02-c59447905641" xlink:to="loc_us-gaap_ProfitLoss_82a1dba8-8b5a-130a-edce-afbb0d3a199c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_419e18eb-9846-bae3-3f9d-aff4dfa5d157" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_82a1dba8-8b5a-130a-edce-afbb0d3a199c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_419e18eb-9846-bae3-3f9d-aff4dfa5d157" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_326571dd-2089-b65a-821d-3163d8518a05" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_419e18eb-9846-bae3-3f9d-aff4dfa5d157" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_326571dd-2089-b65a-821d-3163d8518a05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9ff0f538-863f-dffc-da3e-5378e55a2439" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_326571dd-2089-b65a-821d-3163d8518a05" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9ff0f538-863f-dffc-da3e-5378e55a2439" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_01f4f849-ade5-f04f-1204-64d74a0c2886" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_326571dd-2089-b65a-821d-3163d8518a05" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_01f4f849-ade5-f04f-1204-64d74a0c2886" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89404ae6-0808-876c-4ac7-0c429ea9ed38" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_326571dd-2089-b65a-821d-3163d8518a05" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89404ae6-0808-876c-4ac7-0c429ea9ed38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_f112ed36-ff62-e83b-2851-61cf339c68e8" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_326571dd-2089-b65a-821d-3163d8518a05" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_f112ed36-ff62-e83b-2851-61cf339c68e8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" xlink:label="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_4b2762e6-05d6-29d6-b276-9475a59ad61b" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_326571dd-2089-b65a-821d-3163d8518a05" xlink:to="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_4b2762e6-05d6-29d6-b276-9475a59ad61b" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_3127ab2a-32e1-4879-9cc5-9475a836b767" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_326571dd-2089-b65a-821d-3163d8518a05" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_3127ab2a-32e1-4879-9cc5-9475a836b767" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_61b20b47-ad8c-4810-f94d-4e2e9b69a931" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_326571dd-2089-b65a-821d-3163d8518a05" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_61b20b47-ad8c-4810-f94d-4e2e9b69a931" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_497f98e6-8a11-3c53-7076-ee6aaae664ce" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_326571dd-2089-b65a-821d-3163d8518a05" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_497f98e6-8a11-3c53-7076-ee6aaae664ce" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6a75c878-dfaf-e368-936e-ce293fe86f6f" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_419e18eb-9846-bae3-3f9d-aff4dfa5d157" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6a75c878-dfaf-e368-936e-ce293fe86f6f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_0ab09fdf-5370-1f4f-73d2-70d47822a44b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_82a1dba8-8b5a-130a-edce-afbb0d3a199c" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_0ab09fdf-5370-1f4f-73d2-70d47822a44b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_63bbe84c-b938-87b9-5103-68b80738d584" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_aaf4fade-f652-62f8-cf02-c59447905641" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_63bbe84c-b938-87b9-5103-68b80738d584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9e85e7d0-cdb1-be85-30a7-4b97e01d9c6c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_a5a8f59f-3489-d81e-ae3f-af15a63e70a3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_9e85e7d0-cdb1-be85-30a7-4b97e01d9c6c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_a5a8f59f-3489-d81e-ae3f-af15a63e70a3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_adf027d3-51c6-2963-794a-731ce0c2f2e2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_9e85e7d0-cdb1-be85-30a7-4b97e01d9c6c" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_adf027d3-51c6-2963-794a-731ce0c2f2e2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_c22206b2-daab-f3b4-0979-6d437b372b96" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_59f99e86-3c61-75b6-5e97-31c1c98b37f9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_c22206b2-daab-f3b4-0979-6d437b372b96" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_59f99e86-3c61-75b6-5e97-31c1c98b37f9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_c2e59fd6-6e00-63d7-bc18-2aeb35fedd75" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_c22206b2-daab-f3b4-0979-6d437b372b96" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_c2e59fd6-6e00-63d7-bc18-2aeb35fedd75" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ContingenciesAndCertainCommitments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsContingentConsiderationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CoverPage" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3b4f95d0-4de5-2b2f-e2ec-91daf63ca50c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f60858b4-cb31-daa2-3699-140a0e3df912" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3b4f95d0-4de5-2b2f-e2ec-91daf63ca50c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f60858b4-cb31-daa2-3699-140a0e3df912" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7595492d-e98c-ec24-3583-0c7237508f48" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3b4f95d0-4de5-2b2f-e2ec-91daf63ca50c" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7595492d-e98c-ec24-3583-0c7237508f48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_002f9190-e528-4c20-fecc-961a16ab3d50" xlink:type="locator" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_d4025901-7db6-87ca-6cd0-9475a78b1f4a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_002f9190-e528-4c20-fecc-961a16ab3d50" xlink:to="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_d4025901-7db6-87ca-6cd0-9475a78b1f4a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_9734e242-96e2-288c-5f29-18519f7b91c9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_d4025901-7db6-87ca-6cd0-9475a78b1f4a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_9734e242-96e2-288c-5f29-18519f7b91c9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_419e18eb-9846-bae3-3f9d-aff4dfa5d157" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_9734e242-96e2-288c-5f29-18519f7b91c9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_419e18eb-9846-bae3-3f9d-aff4dfa5d157" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_42d77bb1-dabc-0d0e-4fbf-bd62ad3c8854" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_9734e242-96e2-288c-5f29-18519f7b91c9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_42d77bb1-dabc-0d0e-4fbf-bd62ad3c8854" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_b77c7c67-04a5-f922-bcfc-39f3612287d9" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_d4025901-7db6-87ca-6cd0-9475a78b1f4a" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_b77c7c67-04a5-f922-bcfc-39f3612287d9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_0ab09fdf-5370-1f4f-73d2-70d47822a44b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_002f9190-e528-4c20-fecc-961a16ab3d50" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_0ab09fdf-5370-1f4f-73d2-70d47822a44b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ca4e84d8-4619-6bea-82d1-ff1aa2ecf46c" xlink:type="locator" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_24a0aae0-4020-76ad-9a60-9475a6d0e625" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ca4e84d8-4619-6bea-82d1-ff1aa2ecf46c" xlink:to="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_24a0aae0-4020-76ad-9a60-9475a6d0e625" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_d6abb251-218b-c4ee-4f49-8e51b8373b6d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ca4e84d8-4619-6bea-82d1-ff1aa2ecf46c" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_d6abb251-218b-c4ee-4f49-8e51b8373b6d" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholders" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/Equity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/EquityDividendsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/EquityPreferredStockDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/EquityTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_34294b8c-6491-36d6-dd54-7604deaf3d1f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_ec3a5fbe-8c44-d6ae-171e-f127a93f9731" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_34294b8c-6491-36d6-dd54-7604deaf3d1f" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_ec3a5fbe-8c44-d6ae-171e-f127a93f9731" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_08b96b0b-7bea-6888-8ea9-bea155a704af" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_34294b8c-6491-36d6-dd54-7604deaf3d1f" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_08b96b0b-7bea-6888-8ea9-bea155a704af" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_17a41c51-6fe7-c037-64c3-3ef6c9692a94" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_fde43f77-be41-4e2e-b8b8-614a329bbd8e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_17a41c51-6fe7-c037-64c3-3ef6c9692a94" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_fde43f77-be41-4e2e-b8b8-614a329bbd8e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:label="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_dd11c05c-9d26-c50a-b97a-1d12d44b08d6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_17a41c51-6fe7-c037-64c3-3ef6c9692a94" xlink:to="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_dd11c05c-9d26-c50a-b97a-1d12d44b08d6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:type="locator" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" xlink:label="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_4feb0a50-f8c1-943f-5ef7-9475a83bed26" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_4feb0a50-f8c1-943f-5ef7-9475a83bed26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_0aee1c19-f77f-655a-b96e-557260095c84" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_4feb0a50-f8c1-943f-5ef7-9475a83bed26" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_0aee1c19-f77f-655a-b96e-557260095c84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17e567b0-4e77-385a-6ce4-0f470bbb70c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_4feb0a50-f8c1-943f-5ef7-9475a83bed26" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17e567b0-4e77-385a-6ce4-0f470bbb70c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsCurrent" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_5e89fd19-ff44-0792-8645-5237303334e3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_5e89fd19-ff44-0792-8645-5237303334e3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" xlink:label="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_805e7570-5f87-728f-56f3-9475a7a8987b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_805e7570-5f87-728f-56f3-9475a7a8987b" xlink:type="arc" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_805e7570-5f87-728f-56f3-9475a7a8987b" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_0aee1c19-f77f-655a-b96e-557260095c84" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_805e7570-5f87-728f-56f3-9475a7a8987b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17e567b0-4e77-385a-6ce4-0f470bbb70c3" xlink:type="arc" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_805e7570-5f87-728f-56f3-9475a7a8987b" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_5e89fd19-ff44-0792-8645-5237303334e3" xlink:type="arc" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_fde43f77-be41-4e2e-b8b8-614a329bbd8e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesFootnotesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" xlink:label="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_e8bf7d08-2a41-637c-0cf4-9475a86926ed" xlink:type="locator" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:label="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_35a37571-2608-6737-cefe-9475a6fdd1ae" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_e8bf7d08-2a41-637c-0cf4-9475a86926ed" xlink:to="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_35a37571-2608-6737-cefe-9475a6fdd1ae" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:label="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_01eeaefa-d126-bee7-d2e3-9475a608088b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_e8bf7d08-2a41-637c-0cf4-9475a86926ed" xlink:to="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_01eeaefa-d126-bee7-d2e3-9475a608088b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:label="loc_us-gaap_HeldToMaturitySecurities_bc160df8-f248-557e-f649-3bc817aa7daa" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_b100bd68-9a64-050f-8170-a9f54c67ce5f" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_bc160df8-f248-557e-f649-3bc817aa7daa" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_b100bd68-9a64-050f-8170-a9f54c67ce5f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_35170c44-7711-bfdd-4b6c-1377d19e0492" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_bc160df8-f248-557e-f649-3bc817aa7daa" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_35170c44-7711-bfdd-4b6c-1377d19e0492" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_08034bb7-b29d-ceb2-1940-414d88278df4" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_bc160df8-f248-557e-f649-3bc817aa7daa" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_08034bb7-b29d-ceb2-1940-414d88278df4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8eb340c5-931d-6039-6a0a-c6ca66e2f0f9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a837b31e-1400-d592-c167-ead1d80d260e" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8eb340c5-931d-6039-6a0a-c6ca66e2f0f9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a837b31e-1400-d592-c167-ead1d80d260e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7ef772ef-d0a5-977b-06d1-931f4da1f4a0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8eb340c5-931d-6039-6a0a-c6ca66e2f0f9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7ef772ef-d0a5-977b-06d1-931f4da1f4a0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17e567b0-4e77-385a-6ce4-0f470bbb70c3" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8eb340c5-931d-6039-6a0a-c6ca66e2f0f9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17e567b0-4e77-385a-6ce4-0f470bbb70c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_637161ae-edda-4795-a48b-e7fc200f1f64" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17e567b0-4e77-385a-6ce4-0f470bbb70c3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_637161ae-edda-4795-a48b-e7fc200f1f64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5dc3180f-9781-8308-f5f8-40f910129f38" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17e567b0-4e77-385a-6ce4-0f470bbb70c3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5dc3180f-9781-8308-f5f8-40f910129f38" xlink:type="arc" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17e567b0-4e77-385a-6ce4-0f470bbb70c3" xlink:to="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_35a37571-2608-6737-cefe-9475a6fdd1ae" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtSecuritiesAmortizedCostBasis" xlink:label="loc_pfe_DebtSecuritiesAmortizedCostBasis_d1947c1d-e917-90a0-bafa-9475a628b436" xlink:type="locator" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_e22f79db-8dff-708b-ac49-9475a62b4de5" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAmortizedCostBasis_d1947c1d-e917-90a0-bafa-9475a628b436" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_e22f79db-8dff-708b-ac49-9475a62b4de5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_28f7086d-2d17-13c9-4ab1-9475a7503089" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAmortizedCostBasis_d1947c1d-e917-90a0-bafa-9475a628b436" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_28f7086d-2d17-13c9-4ab1-9475a7503089" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_a55147bc-edaa-19ce-1f4b-6f8090b5b5a7" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAmortizedCostBasis_d1947c1d-e917-90a0-bafa-9475a628b436" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_a55147bc-edaa-19ce-1f4b-6f8090b5b5a7" xlink:type="arc" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_a55147bc-edaa-19ce-1f4b-6f8090b5b5a7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17e567b0-4e77-385a-6ce4-0f470bbb70c3" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_a55147bc-edaa-19ce-1f4b-6f8090b5b5a7" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_08034bb7-b29d-ceb2-1940-414d88278df4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" xlink:label="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_53a3cc7f-c98c-123e-1ae1-9475a7e7b0d9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_53a3cc7f-c98c-123e-1ae1-9475a7e7b0d9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5dc3180f-9781-8308-f5f8-40f910129f38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_a3187123-0b6a-60db-cad7-8df79b7ebd1d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_53a3cc7f-c98c-123e-1ae1-9475a7e7b0d9" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_a3187123-0b6a-60db-cad7-8df79b7ebd1d" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" xlink:label="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_9d2dcd56-270d-3683-aa37-9475a6eea2b6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_9d2dcd56-270d-3683-aa37-9475a6eea2b6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_637161ae-edda-4795-a48b-e7fc200f1f64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_c0cfffd8-72e0-ee5d-7a67-4b7e639f3598" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_9d2dcd56-270d-3683-aa37-9475a6eea2b6" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_c0cfffd8-72e0-ee5d-7a67-4b7e639f3598" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtSecuritiesAmortizedCostBasis" xlink:label="loc_pfe_DebtSecuritiesAmortizedCostBasis_9C291A1C3975BE6E788C94761F56AC56_d1947c1d-e917-90a0-bafa-9475a628b436" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9C291A1C3975BE6E788C94761F56AC56_8eb340c5-931d-6039-6a0a-c6ca66e2f0f9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAmortizedCostBasis_9C291A1C3975BE6E788C94761F56AC56_d1947c1d-e917-90a0-bafa-9475a628b436" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9C291A1C3975BE6E788C94761F56AC56_8eb340c5-931d-6039-6a0a-c6ca66e2f0f9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:label="loc_us-gaap_HeldToMaturitySecurities_9C291A1C3975BE6E788C94761F56AC56_bc160df8-f248-557e-f649-3bc817aa7daa" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAmortizedCostBasis_9C291A1C3975BE6E788C94761F56AC56_d1947c1d-e917-90a0-bafa-9475a628b436" xlink:to="loc_us-gaap_HeldToMaturitySecurities_9C291A1C3975BE6E788C94761F56AC56_bc160df8-f248-557e-f649-3bc817aa7daa" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_a1517e9b-48ef-ec4d-5351-733e917bf402" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ab8937e1-6a3b-4964-dcfa-6e8ddcbfa656" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_a1517e9b-48ef-ec4d-5351-733e917bf402" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ab8937e1-6a3b-4964-dcfa-6e8ddcbfa656" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_72f00b9f-b20f-c20c-b855-9475a8090080" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_a1517e9b-48ef-ec4d-5351-733e917bf402" xlink:to="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_72f00b9f-b20f-c20c-b855-9475a8090080" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0b739b76-84f5-58b3-4051-17eda848f684" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_a1517e9b-48ef-ec4d-5351-733e917bf402" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0b739b76-84f5-58b3-4051-17eda848f684" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaap_OtherLongTermDebt_c92e3ce6-308c-41b9-b422-38477ab06454" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_a1517e9b-48ef-ec4d-5351-733e917bf402" xlink:to="loc_us-gaap_OtherLongTermDebt_c92e3ce6-308c-41b9-b422-38477ab06454" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_535a2650-0afd-ab3b-1421-a50fb29a33a7" xlink:type="locator" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ShorttermDebtGross" xlink:label="loc_pfe_ShorttermDebtGross_e1758a33-0213-2863-27d1-9475a6f6dccd" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent_535a2650-0afd-ab3b-1421-a50fb29a33a7" xlink:to="loc_pfe_ShorttermDebtGross_e1758a33-0213-2863-27d1-9475a6f6dccd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaper" xlink:label="loc_us-gaap_CommercialPaper_8bcc364d-8de8-7a24-a893-500ab952ab8f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_ShorttermDebtGross_e1758a33-0213-2863-27d1-9475a6f6dccd" xlink:to="loc_us-gaap_CommercialPaper_8bcc364d-8de8-7a24-a893-500ab952ab8f" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" xlink:label="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_b922bf67-7c9a-3067-b966-9475a8113308" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_ShorttermDebtGross_e1758a33-0213-2863-27d1-9475a6f6dccd" xlink:to="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_b922bf67-7c9a-3067-b966-9475a8113308" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherShortTermBorrowings" xlink:label="loc_us-gaap_OtherShortTermBorrowings_c2d187d3-444d-67af-6a10-be61a3d2d543" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_ShorttermDebtGross_e1758a33-0213-2863-27d1-9475a6f6dccd" xlink:to="loc_us-gaap_OtherShortTermBorrowings_c2d187d3-444d-67af-6a10-be61a3d2d543" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_72f00b9f-b20f-c20c-b855-9475a8090080" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent_535a2650-0afd-ab3b-1421-a50fb29a33a7" xlink:to="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_72f00b9f-b20f-c20c-b855-9475a8090080" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0b739b76-84f5-58b3-4051-17eda848f684" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent_535a2650-0afd-ab3b-1421-a50fb29a33a7" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0b739b76-84f5-58b3-4051-17eda848f684" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_eecfbaaa-c976-c575-7b2f-92db01e55182" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_0aee1c19-f77f-655a-b96e-557260095c84" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShortTermInvestments_eecfbaaa-c976-c575-7b2f-92db01e55182" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_0aee1c19-f77f-655a-b96e-557260095c84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b49a072d-9bbd-fc1a-97d6-c98455d056b7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShortTermInvestments_eecfbaaa-c976-c575-7b2f-92db01e55182" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b49a072d-9bbd-fc1a-97d6-c98455d056b7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_9dbf8b93-9d0a-abc2-5a18-c3e910928550" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShortTermInvestments_eecfbaaa-c976-c575-7b2f-92db01e55182" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_9dbf8b93-9d0a-abc2-5a18-c3e910928550" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_30a7f09e-9bdf-f419-115d-3a4521db1baa" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermInvestments" xlink:label="loc_us-gaap_OtherLongTermInvestments_aae951e3-f9c1-c2fa-ecdc-2393c81c52eb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_30a7f09e-9bdf-f419-115d-3a4521db1baa" xlink:to="loc_us-gaap_OtherLongTermInvestments_aae951e3-f9c1-c2fa-ecdc-2393c81c52eb" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EquitySecuritiesFVNINoncurrent" xlink:label="loc_pfe_EquitySecuritiesFVNINoncurrent_4d3dc40b-79ce-aa1d-6fdf-9475a699918a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLongTermInvestments_aae951e3-f9c1-c2fa-ecdc-2393c81c52eb" xlink:to="loc_pfe_EquitySecuritiesFVNINoncurrent_4d3dc40b-79ce-aa1d-6fdf-9475a699918a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_f3f53724-f2fc-3f86-6cdc-71265e5dacb5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLongTermInvestments_aae951e3-f9c1-c2fa-ecdc-2393c81c52eb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_f3f53724-f2fc-3f86-6cdc-71265e5dacb5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_6f237bd3-a6f0-2437-169a-eb78c7668ac5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLongTermInvestments_aae951e3-f9c1-c2fa-ecdc-2393c81c52eb" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_6f237bd3-a6f0-2437-169a-eb78c7668ac5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PrivateEquityInvestments" xlink:label="loc_pfe_PrivateEquityInvestments_bc2e30c5-0c56-1eb5-2a86-9475a77f6aae" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLongTermInvestments_aae951e3-f9c1-c2fa-ecdc-2393c81c52eb" xlink:to="loc_pfe_PrivateEquityInvestments_bc2e30c5-0c56-1eb5-2a86-9475a77f6aae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_ff686380-cb66-3f62-443b-907a193effe8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_30a7f09e-9bdf-f419-115d-3a4521db1baa" xlink:to="loc_us-gaap_EquityMethodInvestments_ff686380-cb66-3f62-443b-907a193effe8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsFootnotesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2b295f9a-8c5f-83c2-07a6-989843098928" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_46346561-8cfb-ab6e-79bb-c44fc2165bf6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2b295f9a-8c5f-83c2-07a6-989843098928" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_46346561-8cfb-ab6e-79bb-c44fc2165bf6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_dbdba778-4684-25b5-9c31-40f70d32b8a5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2b295f9a-8c5f-83c2-07a6-989843098928" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_dbdba778-4684-25b5-9c31-40f70d32b8a5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a63bfe00-8c71-75eb-c989-1230f0c1a19e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c124af4a-c1a7-5bd7-f6b9-0a8199d145c1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a63bfe00-8c71-75eb-c989-1230f0c1a19e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c124af4a-c1a7-5bd7-f6b9-0a8199d145c1" xlink:type="arc" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c124af4a-c1a7-5bd7-f6b9-0a8199d145c1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_46346561-8cfb-ab6e-79bb-c44fc2165bf6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_097cbdee-f90d-7331-468c-cf3193d6f1a6" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c124af4a-c1a7-5bd7-f6b9-0a8199d145c1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_097cbdee-f90d-7331-468c-cf3193d6f1a6" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a63bfe00-8c71-75eb-c989-1230f0c1a19e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_dbdba778-4684-25b5-9c31-40f70d32b8a5" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/Inventories" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/InventoriesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_aa7cc103-d668-cf3b-6875-81c99ffeac19" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_25d4a059-00f5-0067-6c2f-cd6b799143d2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_aa7cc103-d668-cf3b-6875-81c99ffeac19" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_25d4a059-00f5-0067-6c2f-cd6b799143d2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_ff2c450d-1c39-96d6-f92a-4eb931224261" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_aa7cc103-d668-cf3b-6875-81c99ffeac19" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_ff2c450d-1c39-96d6-f92a-4eb931224261" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_7078300f-f247-b763-c286-0ec2183dde10" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_aa7cc103-d668-cf3b-6875-81c99ffeac19" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_7078300f-f247-b763-c286-0ec2183dde10" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/InventoriesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNet" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_497f98e6-8a11-3c53-7076-ee6aaae664ce" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRevenueExpenseNet" xlink:label="loc_us-gaap_InterestRevenueExpenseNet_ff7599b0-b9dd-f39c-56b4-71ceef8c33df" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_497f98e6-8a11-3c53-7076-ee6aaae664ce" xlink:to="loc_us-gaap_InterestRevenueExpenseNet_ff7599b0-b9dd-f39c-56b4-71ceef8c33df" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_b70f4f9b-2100-3b9a-22a9-d96a466186ed" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestRevenueExpenseNet_ff7599b0-b9dd-f39c-56b4-71ceef8c33df" xlink:to="loc_us-gaap_InvestmentIncomeInterest_b70f4f9b-2100-3b9a-22a9-d96a466186ed" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_70961961-6a13-30f4-732a-8e29cef0bea0" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestRevenueExpenseNet_ff7599b0-b9dd-f39c-56b4-71ceef8c33df" xlink:to="loc_us-gaap_InterestExpense_70961961-6a13-30f4-732a-8e29cef0bea0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_4c573273-c57c-22a5-e9df-056d3a584ad5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_497f98e6-8a11-3c53-7076-ee6aaae664ce" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_4c573273-c57c-22a5-e9df-056d3a584ad5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_e3e64155-4d85-1e44-ab2b-220248875101" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_497f98e6-8a11-3c53-7076-ee6aaae664ce" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_e3e64155-4d85-1e44-ab2b-220248875101" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_18d5be64-80d5-ed88-4e94-da7559f3e805" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_497f98e6-8a11-3c53-7076-ee6aaae664ce" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_18d5be64-80d5-ed88-4e94-da7559f3e805" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" xlink:label="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_ebb90ea7-8eaa-7ab7-e17b-9475a895d8bc" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_497f98e6-8a11-3c53-7076-ee6aaae664ce" xlink:to="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_ebb90ea7-8eaa-7ab7-e17b-9475a895d8bc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_cb8d6dbd-b574-6655-e1d7-c2591d737603" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_497f98e6-8a11-3c53-7076-ee6aaae664ce" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_cb8d6dbd-b574-6655-e1d7-c2591d737603" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_f8b165ba-23a3-ed13-0d25-fe63b9165d30" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_497f98e6-8a11-3c53-7076-ee6aaae664ce" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_f8b165ba-23a3-ed13-0d25-fe63b9165d30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_85606f35-512d-87bf-8e37-0924416c5c8a" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_497f98e6-8a11-3c53-7076-ee6aaae664ce" xlink:to="loc_us-gaap_AssetImpairmentCharges_85606f35-512d-87bf-8e37-0924416c5c8a" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BusinessAlignmentCosts" xlink:label="loc_pfe_BusinessAlignmentCosts_0551f2c2-b494-1342-b8cc-9475a60c6da1" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_497f98e6-8a11-3c53-7076-ee6aaae664ce" xlink:to="loc_pfe_BusinessAlignmentCosts_0551f2c2-b494-1342-b8cc-9475a60c6da1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11843925-b604-1b74-cbbb-bea6e3ba6b7e" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_497f98e6-8a11-3c53-7076-ee6aaae664ce" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11843925-b604-1b74-cbbb-bea6e3ba6b7e" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" xlink:label="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_fed0a9c9-8c4f-5dff-bf35-9475a64eba3b" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_497f98e6-8a11-3c53-7076-ee6aaae664ce" xlink:to="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_fed0a9c9-8c4f-5dff-bf35-9475a64eba3b" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherNonoperatingIncomeExpenseNet" xlink:label="loc_pfe_OtherNonoperatingIncomeExpenseNet_e14410dd-aa7b-9bec-04a1-9475a85c8711" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_497f98e6-8a11-3c53-7076-ee6aaae664ce" xlink:to="loc_pfe_OtherNonoperatingIncomeExpenseNet_e14410dd-aa7b-9bec-04a1-9475a85c8711" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlans" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9a3e5fa3-f592-9914-8b39-afab44a0e241" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_27774c72-98a2-a6f7-d0a8-185e3342a454" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9a3e5fa3-f592-9914-8b39-afab44a0e241" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_27774c72-98a2-a6f7-d0a8-185e3342a454" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_df78f966-c11b-a83c-f1b8-de344ca8c086" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9a3e5fa3-f592-9914-8b39-afab44a0e241" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_df78f966-c11b-a83c-f1b8-de344ca8c086" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_9b13b176-4622-d6e6-98c2-3ef130650347" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9a3e5fa3-f592-9914-8b39-afab44a0e241" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_9b13b176-4622-d6e6-98c2-3ef130650347" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_185a59fd-e099-2d03-b814-fc3933284ac2" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9a3e5fa3-f592-9914-8b39-afab44a0e241" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_185a59fd-e099-2d03-b814-fc3933284ac2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_e1604a44-6a26-3554-8480-aa43e01733ec" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9a3e5fa3-f592-9914-8b39-afab44a0e241" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_e1604a44-6a26-3554-8480-aa43e01733ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_99b58178-3122-fab7-0905-7a50ceb3b0d3" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9a3e5fa3-f592-9914-8b39-afab44a0e241" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_99b58178-3122-fab7-0905-7a50ceb3b0d3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanSpecialTerminationBenefits" xlink:label="loc_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_7af5c0d8-2842-1517-0296-7072c4715063" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9a3e5fa3-f592-9914-8b39-afab44a0e241" xlink:to="loc_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_7af5c0d8-2842-1517-0296-7072c4715063" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:label="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_7cf4876c-449c-ee50-ec22-9475a6a88d74" xlink:type="locator" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_3127ab2a-32e1-4879-9cc5-9475a836b767" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_7cf4876c-449c-ee50-ec22-9475a6a88d74" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_3127ab2a-32e1-4879-9cc5-9475a836b767" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_0e117598-5e59-61cf-d7cd-38957b1c7098" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_3127ab2a-32e1-4879-9cc5-9475a836b767" xlink:to="loc_us-gaap_RestructuringCharges_0e117598-5e59-61cf-d7cd-38957b1c7098" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_bc82456d-8f04-6add-4452-4fd7d3855aa8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_0e117598-5e59-61cf-d7cd-38957b1c7098" xlink:to="loc_us-gaap_SeveranceCosts1_bc82456d-8f04-6add-4452-4fd7d3855aa8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_RestructuringAssetImpairmentCharges" xlink:label="loc_pfe_RestructuringAssetImpairmentCharges_114a2ca3-2c61-79e5-d127-9475a88b6754" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_0e117598-5e59-61cf-d7cd-38957b1c7098" xlink:to="loc_pfe_RestructuringAssetImpairmentCharges_114a2ca3-2c61-79e5-d127-9475a88b6754" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessExitCosts1" xlink:label="loc_us-gaap_BusinessExitCosts1_3cfa2ca3-767d-14c0-dea8-4700f1bf0ae7" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_0e117598-5e59-61cf-d7cd-38957b1c7098" xlink:to="loc_us-gaap_BusinessExitCosts1_3cfa2ca3-767d-14c0-dea8-4700f1bf0ae7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:label="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_83beba67-851f-f6bb-ae09-9475a7db1271" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_3127ab2a-32e1-4879-9cc5-9475a836b767" xlink:to="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_83beba67-851f-f6bb-ae09-9475a7db1271" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_1bba6cd3-6d5b-5fa5-3eb1-a0496555d13a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_3127ab2a-32e1-4879-9cc5-9475a836b767" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_1bba6cd3-6d5b-5fa5-3eb1-a0496555d13a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9a3e5fa3-f592-9914-8b39-afab44a0e241" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_7cf4876c-449c-ee50-ec22-9475a6a88d74" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9a3e5fa3-f592-9914-8b39-afab44a0e241" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_3bfd6080-01fc-7c6c-0f20-19a138117054" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_7cf4876c-449c-ee50-ec22-9475a6a88d74" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_3bfd6080-01fc-7c6c-0f20-19a138117054" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ImplementationCosts" xlink:label="loc_pfe_ImplementationCosts_91a75bb7-52fe-9820-1187-9475a7e47865" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_7cf4876c-449c-ee50-ec22-9475a6a88d74" xlink:to="loc_pfe_ImplementationCosts_91a75bb7-52fe-9820-1187-9475a7e47865" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetailCalc2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMatters" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMattersDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_1d432f33-1efc-c8e6-76f6-47bbd7ba8488" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_4bc65ac8-c3ad-b496-d2e1-7f2b6817f0a4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_1d432f33-1efc-c8e6-76f6-47bbd7ba8488" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_4bc65ac8-c3ad-b496-d2e1-7f2b6817f0a4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_20bf844d-35a5-8778-9bf4-dfed04b94033" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_1d432f33-1efc-c8e6-76f6-47bbd7ba8488" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_20bf844d-35a5-8778-9bf4-dfed04b94033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_de11d5be-ca5f-141f-d885-00deb4c6e4ba" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_20bf844d-35a5-8778-9bf4-dfed04b94033" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_de11d5be-ca5f-141f-d885-00deb4c6e4ba" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_7d75cd12-5b8a-d648-af09-acbb3c805b46" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_20bf844d-35a5-8778-9bf4-dfed04b94033" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_7d75cd12-5b8a-d648-af09-acbb3c805b46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_fa7d633e-75bb-688d-60e0-d0d7c6b408dc" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_1d432f33-1efc-c8e6-76f6-47bbd7ba8488" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_fa7d633e-75bb-688d-60e0-d0d7c6b408dc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_1de3f4e8-ec86-2825-39d6-dc1dcd72f515" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_fa7d633e-75bb-688d-60e0-d0d7c6b408dc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_1de3f4e8-ec86-2825-39d6-dc1dcd72f515" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_44835666-1b8d-bfdb-a763-6630b8fe0f36" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_fa7d633e-75bb-688d-60e0-d0d7c6b408dc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_44835666-1b8d-bfdb-a763-6630b8fe0f36" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax" xlink:label="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_7f339d85-a7d9-8b8a-ed13-9475a8902547" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_1d432f33-1efc-c8e6-76f6-47bbd7ba8488" xlink:to="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_7f339d85-a7d9-8b8a-ed13-9475a8902547" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_6f5ca24f-686d-f7c3-f7fe-3e8ed9df29c7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_7f339d85-a7d9-8b8a-ed13-9475a8902547" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_6f5ca24f-686d-f7c3-f7fe-3e8ed9df29c7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_65adfc8a-fb25-c9e4-b0f4-ca2065434680" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_7f339d85-a7d9-8b8a-ed13-9475a8902547" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_65adfc8a-fb25-c9e4-b0f4-ca2065434680" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_9e7a38a3-fbff-7cdb-ec7c-9475a610d8e9" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_7f339d85-a7d9-8b8a-ed13-9475a8902547" xlink:to="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_9e7a38a3-fbff-7cdb-ec7c-9475a610d8e9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_7af3b98a-957d-7c01-c7ff-9475a87a113a" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_7f339d85-a7d9-8b8a-ed13-9475a8902547" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_7af3b98a-957d-7c01-c7ff-9475a87a113a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_64fb4972-054c-1a82-94d7-d5a7d1c71722" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_1d432f33-1efc-c8e6-76f6-47bbd7ba8488" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_64fb4972-054c-1a82-94d7-d5a7d1c71722" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_214365e7-2bda-ef4e-a461-5813163534e6" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_64fb4972-054c-1a82-94d7-d5a7d1c71722" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_214365e7-2bda-ef4e-a461-5813163534e6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_ba500cc0-d4ab-692c-7779-9475a66dfd14" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_64fb4972-054c-1a82-94d7-d5a7d1c71722" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_ba500cc0-d4ab-692c-7779-9475a66dfd14" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMattersNarrativeDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMattersTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>pfe-20200628_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:href="pfe-20200628.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" xlink:href="pfe-20200628.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:href="pfe-20200628.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangements" xlink:href="pfe-20200628.xsd#AcquisitionEquityMethodInvestmentAndLicensingArrangements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsArrayBiopharmaDetails" xlink:href="pfe-20200628.xsd#AcquisitionEquityMethodInvestmentAndLicensingArrangementsArrayBiopharmaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails" xlink:href="pfe-20200628.xsd#AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails" xlink:href="pfe-20200628.xsd#AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails" xlink:href="pfe-20200628.xsd#AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsTables" xlink:href="pfe-20200628.xsd#AcquisitionEquityMethodInvestmentAndLicensingArrangementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails" xlink:href="pfe-20200628.xsd#AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:href="pfe-20200628.xsd#BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails" xlink:href="pfe-20200628.xsd#BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails" xlink:href="pfe-20200628.xsd#BasisOfPresentationAndSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:href="pfe-20200628.xsd#BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:href="pfe-20200628.xsd#BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets" xlink:href="pfe-20200628.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="pfe-20200628.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="pfe-20200628.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical" xlink:href="pfe-20200628.xsd#CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="pfe-20200628.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical" xlink:href="pfe-20200628.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" xlink:href="pfe-20200628.xsd#CondensedConsolidatedStatementsOfEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="pfe-20200628.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitments" xlink:href="pfe-20200628.xsd#ContingenciesAndCertainCommitments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsContingentConsiderationDetails" xlink:href="pfe-20200628.xsd#ContingenciesAndCertainCommitmentsContingentConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails" xlink:href="pfe-20200628.xsd#ContingenciesAndCertainCommitmentsPatentLitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails" xlink:href="pfe-20200628.xsd#ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CoverPage" xlink:href="pfe-20200628.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails" xlink:href="pfe-20200628.xsd#EarningsPerCommonShareAttributableToCommonShareholdersDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersTables" xlink:href="pfe-20200628.xsd#EarningsPerCommonShareAttributableToCommonShareholdersTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholders" xlink:href="pfe-20200628.xsd#EarningsPerCommonShareAttributableToPfizerIncCommonShareholders" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/Equity" xlink:href="pfe-20200628.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EquityDividendsDetails" xlink:href="pfe-20200628.xsd#EquityDividendsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EquityPreferredStockDetails" xlink:href="pfe-20200628.xsd#EquityPreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EquityTables" xlink:href="pfe-20200628.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstruments" xlink:href="pfe-20200628.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsCreditRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsDerivativeNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="pfe-20200628.xsd#FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetail" xlink:href="pfe-20200628.xsd#FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesFootnotesDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsFinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsFinancialLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsLongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsLongTermDebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsLongTermDebtNewIssuancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsShortTermBorrowingsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsTables" xlink:href="pfe-20200628.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsFootnotesDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill" xlink:href="pfe-20200628.xsd#IdentifiableIntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail" xlink:href="pfe-20200628.xsd#IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" xlink:href="pfe-20200628.xsd#IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:href="pfe-20200628.xsd#IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail" xlink:href="pfe-20200628.xsd#IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:href="pfe-20200628.xsd#IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail" xlink:href="pfe-20200628.xsd#IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables" xlink:href="pfe-20200628.xsd#IdentifiableIntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/Inventories" xlink:href="pfe-20200628.xsd#Inventories" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/InventoriesDetail" xlink:href="pfe-20200628.xsd#InventoriesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/InventoriesTables" xlink:href="pfe-20200628.xsd#InventoriesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNet" xlink:href="pfe-20200628.xsd#OtherIncomeDeductionsNet" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail" xlink:href="pfe-20200628.xsd#OtherIncomeDeductionsNetDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail" xlink:href="pfe-20200628.xsd#OtherIncomeDeductionsNetFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" xlink:href="pfe-20200628.xsd#OtherIncomeDeductionsNetTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlans" xlink:href="pfe-20200628.xsd#PensionAndPostretirementBenefitPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail" xlink:href="pfe-20200628.xsd#PensionAndPostretirementBenefitPlansDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:href="pfe-20200628.xsd#PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansTables" xlink:href="pfe-20200628.xsd#PensionAndPostretirementBenefitPlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" xlink:href="pfe-20200628.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail" xlink:href="pfe-20200628.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetail" xlink:href="pfe-20200628.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails" xlink:href="pfe-20200628.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:href="pfe-20200628.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:href="pfe-20200628.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" xlink:href="pfe-20200628.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation" xlink:href="pfe-20200628.xsd#SegmentGeographicAndOtherRevenueInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail" xlink:href="pfe-20200628.xsd#SegmentGeographicAndOtherRevenueInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail" xlink:href="pfe-20200628.xsd#SegmentGeographicAndOtherRevenueInformationFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail" xlink:href="pfe-20200628.xsd#SegmentGeographicAndOtherRevenueInformationNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:href="pfe-20200628.xsd#SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" xlink:href="pfe-20200628.xsd#SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" xlink:href="pfe-20200628.xsd#SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables" xlink:href="pfe-20200628.xsd#SegmentGeographicAndOtherRevenueInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMatters" xlink:href="pfe-20200628.xsd#TaxMatters" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersDetail" xlink:href="pfe-20200628.xsd#TaxMattersDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersNarrativeDetail" xlink:href="pfe-20200628.xsd#TaxMattersNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersTables" xlink:href="pfe-20200628.xsd#TaxMattersTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A86A93324B2FCEAED8A29D3A7C0A70AA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D059B0BFCA0BA9B85C69D3A7C071E46" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A86A93324B2FCEAED8A29D3A7C0A70AA" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D059B0BFCA0BA9B85C69D3A7C071E46" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7A7E922FFBFDB180DB969D3A7C07A478" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D059B0BFCA0BA9B85C69D3A7C071E46" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7A7E922FFBFDB180DB969D3A7C07A478" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_65E2AF1C68AD62D7E3909D3A7C08F685_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7A7E922FFBFDB180DB969D3A7C07A478" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_65E2AF1C68AD62D7E3909D3A7C08F685_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_65E2AF1C68AD62D7E3909D3A7C08F685" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7A7E922FFBFDB180DB969D3A7C07A478" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_65E2AF1C68AD62D7E3909D3A7C08F685" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_GSKConsumerHealthcareMember" xlink:label="loc_pfe_GSKConsumerHealthcareMember_D5145EF3A54011EAFF9A9D3A7C08FC5E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_65E2AF1C68AD62D7E3909D3A7C08F685" xlink:to="loc_pfe_GSKConsumerHealthcareMember_D5145EF3A54011EAFF9A9D3A7C08FC5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_A2C2D84D7B6E990DFBB49D3A7C09E613" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D059B0BFCA0BA9B85C69D3A7C071E46" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_A2C2D84D7B6E990DFBB49D3A7C09E613" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_03D270842F7BF853CE829D3A7C09C54D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_A2C2D84D7B6E990DFBB49D3A7C09E613" xlink:to="loc_us-gaap_EquityComponentDomain_03D270842F7BF853CE829D3A7C09C54D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_03D270842F7BF853CE829D3A7C09C54D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_A2C2D84D7B6E990DFBB49D3A7C09E613" xlink:to="loc_us-gaap_EquityComponentDomain_03D270842F7BF853CE829D3A7C09C54D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51486A2FF408EA11D0079D3A7C09267A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_03D270842F7BF853CE829D3A7C09C54D" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51486A2FF408EA11D0079D3A7C09267A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_44FE95122213A80368AA9D3A7C090F6C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51486A2FF408EA11D0079D3A7C09267A" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_44FE95122213A80368AA9D3A7C090F6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_6194EB1987E18EB9649E9D3A7C0A576B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51486A2FF408EA11D0079D3A7C09267A" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_6194EB1987E18EB9649E9D3A7C0A576B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1F44E3662715DFEC74D09D3A7C0A3467" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51486A2FF408EA11D0079D3A7C09267A" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1F44E3662715DFEC74D09D3A7C0A3467" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_2CD290AC6582508D133B9D3A7C0A2329" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51486A2FF408EA11D0079D3A7C09267A" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_2CD290AC6582508D133B9D3A7C0A2329" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_8181A0ECD68310CA47D09D3A7C0A7BFF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51486A2FF408EA11D0079D3A7C09267A" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_8181A0ECD68310CA47D09D3A7C0A7BFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_E65DA0247BA5FF91FA7A9D3A7C0BC7DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A86A93324B2FCEAED8A29D3A7C0A70AA" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_E65DA0247BA5FF91FA7A9D3A7C0BC7DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_43CD307800D6F8DCCE8A9D3A7C0B9AE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_E65DA0247BA5FF91FA7A9D3A7C0BC7DF" xlink:to="loc_us-gaap_StockholdersEquity_43CD307800D6F8DCCE8A9D3A7C0B9AE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_407614195B3E211396FF9D3A7C0B5764" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_E65DA0247BA5FF91FA7A9D3A7C0BC7DF" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_407614195B3E211396FF9D3A7C0B5764" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_9A7A4CC7690D197A64969D3B6FAEB0AC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A86A93324B2FCEAED8A29D3A7C0A70AA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_9A7A4CC7690D197A64969D3B6FAEB0AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7D3F7C0C08FCD3C077FD9D3A7C0CEB39" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A86A93324B2FCEAED8A29D3A7C0A70AA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7D3F7C0C08FCD3C077FD9D3A7C0CEB39" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsArrayBiopharmaDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_B5FE63E7929705ED59A259679290A885" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1E381EAE57FB75F2DB1B5967928FE9F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B5FE63E7929705ED59A259679290A885" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1E381EAE57FB75F2DB1B5967928FE9F9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7BF9C9B6995D8574A8455967928F962F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1E381EAE57FB75F2DB1B5967928FE9F9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7BF9C9B6995D8574A8455967928F962F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_513C3B4C47B95DBD02255967928FFF89_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7BF9C9B6995D8574A8455967928F962F" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_513C3B4C47B95DBD02255967928FFF89_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_513C3B4C47B95DBD02255967928FFF89" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7BF9C9B6995D8574A8455967928F962F" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_513C3B4C47B95DBD02255967928FFF89" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ArrayMember" xlink:label="loc_pfe_ArrayMember_C138B9969204952EBF3159679290CEFC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_513C3B4C47B95DBD02255967928FFF89" xlink:to="loc_pfe_ArrayMember_C138B9969204952EBF3159679290CEFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_5DCD1F94C00E511BFD7B596792909D14" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B5FE63E7929705ED59A259679290A885" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_5DCD1F94C00E511BFD7B596792909D14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_3371BCE21B85AA7DBE65596792909A11" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B5FE63E7929705ED59A259679290A885" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_3371BCE21B85AA7DBE65596792909A11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1060CDDFB11BBB8156D8596792906734" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B5FE63E7929705ED59A259679290A885" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1060CDDFB11BBB8156D8596792906734" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_979178E2C9BB808B353D92DEB957DBE6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D8534B74C129B0196BE392DEB95433AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_979178E2C9BB808B353D92DEB957DBE6" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D8534B74C129B0196BE392DEB95433AA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9254E226A8C4EE9E0A9A92E1EB2B1EB1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D8534B74C129B0196BE392DEB95433AA" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9254E226A8C4EE9E0A9A92E1EB2B1EB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_69BA5F4BAAFECC4E286492E1EB3A5E48_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9254E226A8C4EE9E0A9A92E1EB2B1EB1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_69BA5F4BAAFECC4E286492E1EB3A5E48_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_69BA5F4BAAFECC4E286492E1EB3A5E48" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9254E226A8C4EE9E0A9A92E1EB2B1EB1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_69BA5F4BAAFECC4E286492E1EB3A5E48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_A50319E76D927B68983E92E2204B6B44" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_69BA5F4BAAFECC4E286492E1EB3A5E48" xlink:to="loc_us-gaap_SubsequentEventMember_A50319E76D927B68983E92E2204B6B44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_73B09F4B5E99955189C592DEB955769F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D8534B74C129B0196BE392DEB95433AA" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_73B09F4B5E99955189C592DEB955769F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ADF9699C46AF6CC3CB4492DEB9553D37_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_73B09F4B5E99955189C592DEB955769F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ADF9699C46AF6CC3CB4492DEB9553D37_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ADF9699C46AF6CC3CB4492DEB9553D37" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_73B09F4B5E99955189C592DEB955769F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ADF9699C46AF6CC3CB4492DEB9553D37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_07F1867C45CCE1ABDDB692DEB9557D02" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ADF9699C46AF6CC3CB4492DEB9553D37" xlink:to="loc_us-gaap_LicensingAgreementsMember_07F1867C45CCE1ABDDB692DEB9557D02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_EEA45A08C4F34F8007F992DEB9556866" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D8534B74C129B0196BE392DEB95433AA" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_EEA45A08C4F34F8007F992DEB9556866" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_E45F8E52998EB680742A92DEB956FA9F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_EEA45A08C4F34F8007F992DEB9556866" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_E45F8E52998EB680742A92DEB956FA9F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_E45F8E52998EB680742A92DEB956FA9F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_EEA45A08C4F34F8007F992DEB9556866" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_E45F8E52998EB680742A92DEB956FA9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_C2EFD81608D78E84800992DEB9569302" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_E45F8E52998EB680742A92DEB956FA9F" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_C2EFD81608D78E84800992DEB9569302" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_4C91AEC4F37DE7C5179592DEB956A89A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D8534B74C129B0196BE392DEB95433AA" xlink:to="loc_srt_CounterpartyNameAxis_4C91AEC4F37DE7C5179592DEB956A89A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_70D2B7DDA19EA201EE7992DEB956A067_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4C91AEC4F37DE7C5179592DEB956A89A" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_70D2B7DDA19EA201EE7992DEB956A067_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_70D2B7DDA19EA201EE7992DEB956A067" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4C91AEC4F37DE7C5179592DEB956A89A" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_70D2B7DDA19EA201EE7992DEB956A067" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BioNTechSEMember" xlink:label="loc_pfe_BioNTechSEMember_19D2ECE731BC38F3DE1992DEB957C271" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_70D2B7DDA19EA201EE7992DEB956A067" xlink:to="loc_pfe_BioNTechSEMember_19D2ECE731BC38F3DE1992DEB957C271" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PaymentForLicensingArrangement" xlink:label="loc_pfe_PaymentForLicensingArrangement_9C31A5735FAEC7B156DA92DEB9579500" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_979178E2C9BB808B353D92DEB957DBE6" xlink:to="loc_pfe_PaymentForLicensingArrangement_9C31A5735FAEC7B156DA92DEB9579500" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LicensingArrangementValueOfSharesPurchased" xlink:label="loc_pfe_LicensingArrangementValueOfSharesPurchased_76593D7E8DB202B0CFF892DEB9579061" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_979178E2C9BB808B353D92DEB957DBE6" xlink:to="loc_pfe_LicensingArrangementValueOfSharesPurchased_76593D7E8DB202B0CFF892DEB9579061" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure_63653CC3D27F7A2AE5D592DEB95774B9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_979178E2C9BB808B353D92DEB957DBE6" xlink:to="loc_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure_63653CC3D27F7A2AE5D592DEB95774B9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1_1BCCD9487C25E806265792DEB958E744" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_979178E2C9BB808B353D92DEB957DBE6" xlink:to="loc_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1_1BCCD9487C25E806265792DEB958E744" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed" xlink:label="loc_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_8785140540778E461CA692DEB958A56B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_979178E2C9BB808B353D92DEB957DBE6" xlink:to="loc_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_8785140540778E461CA692DEB958A56B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EBEB49EE3E4FA7CEEAEF7926B2A67D56" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EBEB49EE3E4FA7CEEAEF7926B2A67D56" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_58BB7FA5BC09F14D40FF793378A83652" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EBEB49EE3E4FA7CEEAEF7926B2A67D56" xlink:to="loc_srt_RangeAxis_58BB7FA5BC09F14D40FF793378A83652" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D41C3E672854D230D020793378A92B58_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_58BB7FA5BC09F14D40FF793378A83652" xlink:to="loc_srt_RangeMember_D41C3E672854D230D020793378A92B58_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D41C3E672854D230D020793378A92B58" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_58BB7FA5BC09F14D40FF793378A83652" xlink:to="loc_srt_RangeMember_D41C3E672854D230D020793378A92B58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_49DA6853E42F45A97B1F79341B28B307" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_D41C3E672854D230D020793378A92B58" xlink:to="loc_srt_MinimumMember_49DA6853E42F45A97B1F79341B28B307" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_CED445B2FA4F00DE1416793445BE5A76" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_D41C3E672854D230D020793378A92B58" xlink:to="loc_srt_MaximumMember_CED445B2FA4F00DE1416793445BE5A76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AACDA209AB9A481005007926B2A75FC6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EBEB49EE3E4FA7CEEAEF7926B2A67D56" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AACDA209AB9A481005007926B2A75FC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3D0C4E2AE818A44E79F7926B2A75AD9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AACDA209AB9A481005007926B2A75FC6" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3D0C4E2AE818A44E79F7926B2A75AD9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3D0C4E2AE818A44E79F7926B2A75AD9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AACDA209AB9A481005007926B2A75FC6" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3D0C4E2AE818A44E79F7926B2A75AD9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ConsumerHealthcareMember" xlink:label="loc_pfe_ConsumerHealthcareMember_202904254FAEEDA080797926B2A7A84A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3D0C4E2AE818A44E79F7926B2A75AD9" xlink:to="loc_pfe_ConsumerHealthcareMember_202904254FAEEDA080797926B2A7A84A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_7C37A7A65422032D64E07926B2A8E26D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EBEB49EE3E4FA7CEEAEF7926B2A67D56" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_7C37A7A65422032D64E07926B2A8E26D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_4B1C227ACC3432F7D6607926B2A8065B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_7C37A7A65422032D64E07926B2A8E26D" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_4B1C227ACC3432F7D6607926B2A8065B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_4B1C227ACC3432F7D6607926B2A8065B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_7C37A7A65422032D64E07926B2A8E26D" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_4B1C227ACC3432F7D6607926B2A8065B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_DC9AE322ADDA2D13BAC07926B2A81269" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_4B1C227ACC3432F7D6607926B2A8065B" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_DC9AE322ADDA2D13BAC07926B2A81269" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_18E902ADAF270A4C6EDA7926B2A84754" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EBEB49EE3E4FA7CEEAEF7926B2A67D56" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_18E902ADAF270A4C6EDA7926B2A84754" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ED596F6554B5F544669C7926B2A8DAB7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_18E902ADAF270A4C6EDA7926B2A84754" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ED596F6554B5F544669C7926B2A8DAB7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ED596F6554B5F544669C7926B2A8DAB7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_18E902ADAF270A4C6EDA7926B2A84754" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ED596F6554B5F544669C7926B2A8DAB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_59D100E77C78A698DC297926B2A95E72" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ED596F6554B5F544669C7926B2A8DAB7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_59D100E77C78A698DC297926B2A95E72" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_51819D5843F904D287ED7926B2A937D4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EBEB49EE3E4FA7CEEAEF7926B2A67D56" xlink:to="loc_dei_LegalEntityAxis_51819D5843F904D287ED7926B2A937D4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_47E7559EB0CED57D3F977926B2A9CFF8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_51819D5843F904D287ED7926B2A937D4" xlink:to="loc_dei_EntityDomain_47E7559EB0CED57D3F977926B2A9CFF8_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_47E7559EB0CED57D3F977926B2A9CFF8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_51819D5843F904D287ED7926B2A937D4" xlink:to="loc_dei_EntityDomain_47E7559EB0CED57D3F977926B2A9CFF8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_GSKMember" xlink:label="loc_pfe_GSKMember_B5D3CF3C67EF9A3AF7377926B2AA3D86" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_47E7559EB0CED57D3F977926B2A9CFF8" xlink:to="loc_pfe_GSKMember_B5D3CF3C67EF9A3AF7377926B2AA3D86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_80B44AC75C08746C863A7926B2AA18B0" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EBEB49EE3E4FA7CEEAEF7926B2A67D56" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_80B44AC75C08746C863A7926B2AA18B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_EEA33F00D360C7EB33AD7926B2AA62A8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_80B44AC75C08746C863A7926B2AA18B0" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_EEA33F00D360C7EB33AD7926B2AA62A8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_EEA33F00D360C7EB33AD7926B2AA62A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_80B44AC75C08746C863A7926B2AA18B0" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_EEA33F00D360C7EB33AD7926B2AA62A8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_GSKConsumerHealthcareMember" xlink:label="loc_pfe_GSKConsumerHealthcareMember_12908ED588D18EA315DE7926B2AAB144" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_EEA33F00D360C7EB33AD7926B2AA62A8" xlink:to="loc_pfe_GSKConsumerHealthcareMember_12908ED588D18EA315DE7926B2AAB144" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_24DFB8EA4FDDCFD40D967926B2ABAF34" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_24DFB8EA4FDDCFD40D967926B2ABAF34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_07749ABD6271558FB7687926B2AB25BB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_07749ABD6271558FB7687926B2AB25BB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DeconsolidationGainLossAmountNetOfTax" xlink:label="loc_pfe_DeconsolidationGainLossAmountNetOfTax_0CEDD828CA62504E16637926B2AB0F17" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:to="loc_pfe_DeconsolidationGainLossAmountNetOfTax_0CEDD828CA62504E16637926B2AB0F17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_608AC2DA852518ABEC387926B2ABB1DB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:to="loc_us-gaap_EquityMethodInvestments_608AC2DA852518ABEC387926B2ABB1DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_EC0229AC965591660E577926B2ACBA29" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_EC0229AC965591660E577926B2ACBA29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_4DF624716AD413F061D27926B2ACE6EF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_4DF624716AD413F061D27926B2ACE6EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:label="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_12F323AAB24770BC8C577926B2AC4B37" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:to="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_12F323AAB24770BC8C577926B2AC4B37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_CC230B0EE3DD8F3906617926B2AC5B93" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_CC230B0EE3DD8F3906617926B2AC5B93" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EquityMethodInvestmentExcessBasisAmortization" xlink:label="loc_pfe_EquityMethodInvestmentExcessBasisAmortization_22B5ABA0E595568A11327926B2AC1D70" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:to="loc_pfe_EquityMethodInvestmentExcessBasisAmortization_22B5ABA0E595568A11327926B2AC1D70" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod" xlink:label="loc_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_09571564FEB6ECA07E8C7926B2AD054E" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:to="loc_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_09571564FEB6ECA07E8C7926B2AD054E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" xlink:label="loc_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_0EA334A74D000D818C0D7926B2ADA60D" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:to="loc_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_0EA334A74D000D818C0D7926B2ADA60D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_086948AE7DAE29E1526F7926B2ADEF1D" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_086948AE7DAE29E1526F7926B2ADEF1D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss" xlink:label="loc_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_6D4C0537B00E06F6DF687926B2AD87DC" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:to="loc_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_6D4C0537B00E06F6DF687926B2AD87DC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_27FF6233CF27A29AFFFC596534B7024C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_27FF6233CF27A29AFFFC596534B7024C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_EEF9E788682221770FA4596534B783A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_27FF6233CF27A29AFFFC596534B7024C" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_EEF9E788682221770FA4596534B783A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_0357656CEBE642ECF2A2596534B8C135_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_EEF9E788682221770FA4596534B783A4" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_0357656CEBE642ECF2A2596534B8C135_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_0357656CEBE642ECF2A2596534B8C135" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_EEF9E788682221770FA4596534B783A4" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_0357656CEBE642ECF2A2596534B8C135" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_GSKConsumerHealthcareMember" xlink:label="loc_pfe_GSKConsumerHealthcareMember_18031A6EE0CE9C787B1F596534B892DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_0357656CEBE642ECF2A2596534B8C135" xlink:to="loc_pfe_GSKConsumerHealthcareMember_18031A6EE0CE9C787B1F596534B892DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_C0ABA5F0B7EFC6519FCB596534B91777" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_AssetsCurrent_C0ABA5F0B7EFC6519FCB596534B91777" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_5D96628A93D9620C207F596534B9E238" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_AssetsNoncurrent_5D96628A93D9620C207F596534B9E238" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_D2E410E2259401969341596534B9DC67" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_Assets_D2E410E2259401969341596534B9DC67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_03F34D4869DEC29664B5596534BF0D68" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_LiabilitiesCurrent_03F34D4869DEC29664B5596534BF0D68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_1DA15B75DAADB56816F3596534BFB23E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_1DA15B75DAADB56816F3596534BFB23E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_A29256CB1F50B58BD6A7596534BF3A34" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_Liabilities_A29256CB1F50B58BD6A7596534BF3A34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_EF28E8FD31E532C6C8CF596534BFFEA4" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_StockholdersEquity_EF28E8FD31E532C6C8CF596534BFFEA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_EEE68D7667A093678883596534BF0CB2" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_MinorityInterest_EEE68D7667A093678883596534BF0CB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_294D588497C0ED3E11A7596534C0DFB4" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_294D588497C0ED3E11A7596534C0DFB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_09FC4A9D0D5491E30494596534C0DDF0" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_Revenues_09FC4A9D0D5491E30494596534C0DDF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_1B75DF4B5057AE5B4F89596534C025BF" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_CostOfRevenue_1B75DF4B5057AE5B4F89596534C025BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_D7C4535E722E036ECFBF596534C06CC3" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_GrossProfit_D7C4535E722E036ECFBF596534C06CC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_276687217BE0F21947A5596534C0A820" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_276687217BE0F21947A5596534C0A820" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_91270B63F85DE8F8609F596534C01F78" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_ProfitLoss_91270B63F85DE8F8609F596534C01F78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_D90F2EF67B474070F9E6596534C1C5E3" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_NetIncomeLoss_D90F2EF67B474070F9E6596534C1C5E3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9CC3CF57ED8E6AC3FEBF5981DDAA4AF8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A4DDCE2E2CBACA6BAE825981DDA46F55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9CC3CF57ED8E6AC3FEBF5981DDAA4AF8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A4DDCE2E2CBACA6BAE825981DDA46F55" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2EAABECFE47FFE2C591C598EE676E1D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A4DDCE2E2CBACA6BAE825981DDA46F55" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2EAABECFE47FFE2C591C598EE676E1D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9199795915C6BF1F1D00598EE7805AA3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2EAABECFE47FFE2C591C598EE676E1D2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9199795915C6BF1F1D00598EE7805AA3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9199795915C6BF1F1D00598EE7805AA3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2EAABECFE47FFE2C591C598EE676E1D2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9199795915C6BF1F1D00598EE7805AA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_E0491B165A34AC36B64C598F12C34BF7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9199795915C6BF1F1D00598EE7805AA3" xlink:to="loc_us-gaap_LicensingAgreementsMember_E0491B165A34AC36B64C598F12C34BF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_9B84994D011B5947181C598321C242A7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A4DDCE2E2CBACA6BAE825981DDA46F55" xlink:to="loc_srt_CounterpartyNameAxis_9B84994D011B5947181C598321C242A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2F08D37D57C88444C5555983249C6B7E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9B84994D011B5947181C598321C242A7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2F08D37D57C88444C5555983249C6B7E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2F08D37D57C88444C5555983249C6B7E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9B84994D011B5947181C598321C242A7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2F08D37D57C88444C5555983249C6B7E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ValnevaSEMember" xlink:label="loc_pfe_ValnevaSEMember_663A39A4FC308FB0026B59881AA1A187" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2F08D37D57C88444C5555983249C6B7E" xlink:to="loc_pfe_ValnevaSEMember_663A39A4FC308FB0026B59881AA1A187" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_42633831A939EAEBD2D45981DDA6C5ED" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A4DDCE2E2CBACA6BAE825981DDA46F55" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_42633831A939EAEBD2D45981DDA6C5ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_DF1A6F3A66387E35D2105981DDA6B5B5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_42633831A939EAEBD2D45981DDA6C5ED" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_DF1A6F3A66387E35D2105981DDA6B5B5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_DF1A6F3A66387E35D2105981DDA6B5B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_42633831A939EAEBD2D45981DDA6C5ED" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_DF1A6F3A66387E35D2105981DDA6B5B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_771ECF58F7A387A7002E598857951C37" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_DF1A6F3A66387E35D2105981DDA6B5B5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_771ECF58F7A387A7002E598857951C37" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1_8C514A662ED539609E1659B3BA8D450F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9CC3CF57ED8E6AC3FEBF5981DDAA4AF8" xlink:to="loc_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1_8C514A662ED539609E1659B3BA8D450F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PaymentForLicensingArrangement" xlink:label="loc_pfe_PaymentForLicensingArrangement_E43A9E4E82F700DF26EB598280D427FA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9CC3CF57ED8E6AC3FEBF5981DDAA4AF8" xlink:to="loc_pfe_PaymentForLicensingArrangement_E43A9E4E82F700DF26EB598280D427FA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure_D4289C0073EDCB935E6C59B4A1E9163B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9CC3CF57ED8E6AC3FEBF5981DDAA4AF8" xlink:to="loc_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure_D4289C0073EDCB935E6C59B4A1E9163B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure_846AFEBC4541DB8070C3599C5A3B12ED" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9CC3CF57ED8E6AC3FEBF5981DDAA4AF8" xlink:to="loc_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure_846AFEBC4541DB8070C3599C5A3B12ED" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage_7D16B329EC4E9D9E89B459AFE9DEB415" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9CC3CF57ED8E6AC3FEBF5981DDAA4AF8" xlink:to="loc_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage_7D16B329EC4E9D9E89B459AFE9DEB415" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ScheduleOfAccruedLiabilitiesLineItems" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_CDCFA0776857306176F494761EB64197" xlink:type="locator" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ScheduleOfAccruedLiabilitiesTable" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesTable_C6FD09F7FD2AD8DE104294761EB48200" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_CDCFA0776857306176F494761EB64197" xlink:to="loc_pfe_ScheduleOfAccruedLiabilitiesTable_C6FD09F7FD2AD8DE104294761EB48200" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2498D9343C667CF17AE994761EB4EF77" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesTable_C6FD09F7FD2AD8DE104294761EB48200" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2498D9343C667CF17AE994761EB4EF77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1A15EA1A046DCBE55C7194761EB5D003_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2498D9343C667CF17AE994761EB4EF77" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1A15EA1A046DCBE55C7194761EB5D003_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1A15EA1A046DCBE55C7194761EB5D003" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2498D9343C667CF17AE994761EB4EF77" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1A15EA1A046DCBE55C7194761EB5D003" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_62255A4274E0F0EA0C6994761EB5916D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1A15EA1A046DCBE55C7194761EB5D003" xlink:to="loc_us-gaap_AccountsReceivableMember_62255A4274E0F0EA0C6994761EB5916D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_40488C4661458ED6920594761EB59D1F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1A15EA1A046DCBE55C7194761EB5D003" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_40488C4661458ED6920594761EB59D1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_07D988B1A18B53AC29A594761EB57AB3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1A15EA1A046DCBE55C7194761EB5D003" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_07D988B1A18B53AC29A594761EB57AB3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_RebatesAndDiscountsAccrual" xlink:label="loc_pfe_RebatesAndDiscountsAccrual_DF1F810D456C9356513494761EB6416D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_CDCFA0776857306176F494761EB64197" xlink:to="loc_pfe_RebatesAndDiscountsAccrual_DF1F810D456C9356513494761EB6416D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AccruedRebates" xlink:label="loc_pfe_AccruedRebates_96360C3931DF288C682494761EB68121" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_CDCFA0776857306176F494761EB64197" xlink:to="loc_pfe_AccruedRebates_96360C3931DF288C682494761EB68121" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherAccruals" xlink:label="loc_pfe_OtherAccruals_72216711BE2C644ADF7C94761EB6ED68" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_CDCFA0776857306176F494761EB64197" xlink:to="loc_pfe_OtherAccruals_72216711BE2C644ADF7C94761EB6ED68" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0500906B7BFC9ECFB36892DE5DC5A8E6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_D16F1F94ADDF199958E192DE5DB42B12" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0500906B7BFC9ECFB36892DE5DC5A8E6" xlink:to="loc_us-gaap_StatementTable_D16F1F94ADDF199958E192DE5DB42B12" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_F92FB2BE740EDB7B744E92DE5F636B76" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_D16F1F94ADDF199958E192DE5DB42B12" xlink:to="loc_srt_ConsolidatedEntitiesAxis_F92FB2BE740EDB7B744E92DE5F636B76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_DC32740A5F0AA03E8B9E92DE6092FFA3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_F92FB2BE740EDB7B744E92DE5F636B76" xlink:to="loc_srt_ConsolidatedEntitiesDomain_DC32740A5F0AA03E8B9E92DE6092FFA3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_DC32740A5F0AA03E8B9E92DE6092FFA3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_F92FB2BE740EDB7B744E92DE5F636B76" xlink:to="loc_srt_ConsolidatedEntitiesDomain_DC32740A5F0AA03E8B9E92DE6092FFA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_7C0F3AB027AD7A81FB3F92DE6039BB82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_DC32740A5F0AA03E8B9E92DE6092FFA3" xlink:to="loc_srt_SubsidiariesMember_7C0F3AB027AD7A81FB3F92DE6039BB82" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4DDD07BE98B21ECEC61E92DE5F0826E6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_D16F1F94ADDF199958E192DE5DB42B12" xlink:to="loc_dei_LegalEntityAxis_4DDD07BE98B21ECEC61E92DE5F0826E6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_52E09EB3D96F264FB78692DE60140AA7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_4DDD07BE98B21ECEC61E92DE5F0826E6" xlink:to="loc_dei_EntityDomain_52E09EB3D96F264FB78692DE60140AA7_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_52E09EB3D96F264FB78692DE60140AA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_4DDD07BE98B21ECEC61E92DE5F0826E6" xlink:to="loc_dei_EntityDomain_52E09EB3D96F264FB78692DE60140AA7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnIncMember" xlink:label="loc_pfe_UpjohnIncMember_6700DE4C99B99DAA5DDC92DE5FC3AD35" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_52E09EB3D96F264FB78692DE60140AA7" xlink:to="loc_pfe_UpjohnIncMember_6700DE4C99B99DAA5DDC92DE5FC3AD35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_38FC1951390DEB29593B92DDEB861941" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0500906B7BFC9ECFB36892DE5DC5A8E6" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_38FC1951390DEB29593B92DDEB861941" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_D911CDA1506DF6AE1B1992DE5EA62EBE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0500906B7BFC9ECFB36892DE5DC5A8E6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_D911CDA1506DF6AE1B1992DE5EA62EBE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_95F421D2A3D9663F5FA754457A6347D6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_E47570589F726E3EB27E54457A624420" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_95F421D2A3D9663F5FA754457A6347D6" xlink:to="loc_us-gaap_StatementTable_E47570589F726E3EB27E54457A624420" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CA661A2448E2C2C7275254457A62BCB0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_E47570589F726E3EB27E54457A624420" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CA661A2448E2C2C7275254457A62BCB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_91468BB646DA047A954F54457A631477_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CA661A2448E2C2C7275254457A62BCB0" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_91468BB646DA047A954F54457A631477_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_91468BB646DA047A954F54457A631477" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CA661A2448E2C2C7275254457A62BCB0" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_91468BB646DA047A954F54457A631477" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_GSKConsumerHealthcareMember" xlink:label="loc_pfe_GSKConsumerHealthcareMember_4FE0ECECB6BC3798933554457A639638" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_91468BB646DA047A954F54457A631477" xlink:to="loc_pfe_GSKConsumerHealthcareMember_4FE0ECECB6BC3798933554457A639638" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_5A4C589FBF6A57B2560854457A64FE26" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_95F421D2A3D9663F5FA754457A6347D6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_5A4C589FBF6A57B2560854457A64FE26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5F1E3B2D0A159C8F92DC54457A64E042" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_95F421D2A3D9663F5FA754457A6347D6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5F1E3B2D0A159C8F92DC54457A64E042" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_A7C1A24957B421DA45547DA8645F57C4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_01070F09CF6831D790317DA8645C7AFC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_A7C1A24957B421DA45547DA8645F57C4" xlink:to="loc_us-gaap_StatementTable_01070F09CF6831D790317DA8645C7AFC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1524ED523B403E042DDB7DA8645DFE50" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_01070F09CF6831D790317DA8645C7AFC" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1524ED523B403E042DDB7DA8645DFE50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_105918547EDC2DC094ED7DA8645D9CC7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1524ED523B403E042DDB7DA8645DFE50" xlink:to="loc_us-gaap_EquityComponentDomain_105918547EDC2DC094ED7DA8645D9CC7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_105918547EDC2DC094ED7DA8645D9CC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1524ED523B403E042DDB7DA8645DFE50" xlink:to="loc_us-gaap_EquityComponentDomain_105918547EDC2DC094ED7DA8645D9CC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_C79A81A1B0A1305CA2B97DA8645D53D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_105918547EDC2DC094ED7DA8645D9CC7" xlink:to="loc_us-gaap_PreferredStockMember_C79A81A1B0A1305CA2B97DA8645D53D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4A9215D60A4DC4CD95627DA8645ECC8F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_105918547EDC2DC094ED7DA8645D9CC7" xlink:to="loc_us-gaap_CommonStockMember_4A9215D60A4DC4CD95627DA8645ECC8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_18D5E605821C05CAEC4F7DA8645E09EA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_105918547EDC2DC094ED7DA8645D9CC7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_18D5E605821C05CAEC4F7DA8645E09EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_36C3BD1B9BE0EA9B37A37DA8645EB040" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_105918547EDC2DC094ED7DA8645D9CC7" xlink:to="loc_us-gaap_TreasuryStockMember_36C3BD1B9BE0EA9B37A37DA8645EB040" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_C536E8C4EE979BFBCE057DA8645EAA2F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_105918547EDC2DC094ED7DA8645D9CC7" xlink:to="loc_us-gaap_RetainedEarningsMember_C536E8C4EE979BFBCE057DA8645EAA2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_D128A5845CA8DE3E2C837DA8645E8CEA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_105918547EDC2DC094ED7DA8645D9CC7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_D128A5845CA8DE3E2C837DA8645E8CEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_1DF83A49140E6C2F627F7DA8645E52C8" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_105918547EDC2DC094ED7DA8645D9CC7" xlink:to="loc_us-gaap_ParentMember_1DF83A49140E6C2F627F7DA8645E52C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_4E55536BDAC1C62FC49D7DA8645FF643" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_105918547EDC2DC094ED7DA8645D9CC7" xlink:to="loc_us-gaap_NoncontrollingInterestMember_4E55536BDAC1C62FC49D7DA8645FF643" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_A7C1A24957B421DA45547DA8645F57C4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_E68C4FCF086DE00968F97DA8645FA85B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="loc_us-gaap_SharesIssued_E68C4FCF086DE00968F97DA8645FA85B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5D4258EDB6E134EE176B7DA8645FE1F5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5D4258EDB6E134EE176B7DA8645FE1F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_47900DE4B98B3FAA4FE47DA8645FA4CE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="loc_us-gaap_ProfitLoss_47900DE4B98B3FAA4FE47DA8645FA4CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0285183AF3B08C43D0577DA864607460" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0285183AF3B08C43D0577DA864607460" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCashAbstract" xlink:label="loc_us-gaap_DividendsCashAbstract_FF829DDEBC94DC9184237DA864601B00" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="loc_us-gaap_DividendsCashAbstract_FF829DDEBC94DC9184237DA864601B00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockCash" xlink:label="loc_us-gaap_DividendsCommonStockCash_2E549E81AEAD55B1D7867DA8646056F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsCashAbstract_FF829DDEBC94DC9184237DA864601B00" xlink:to="loc_us-gaap_DividendsCommonStockCash_2E549E81AEAD55B1D7867DA8646056F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="loc_us-gaap_DividendsPreferredStockCash_5346B828047A2DAB76927DA86460472D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsCashAbstract_FF829DDEBC94DC9184237DA864601B00" xlink:to="loc_us-gaap_DividendsPreferredStockCash_5346B828047A2DAB76927DA86460472D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_35DD9BFB35EA594EB31F7DA864608265" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsCashAbstract_FF829DDEBC94DC9184237DA864601B00" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_35DD9BFB35EA594EB31F7DA864608265" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6591817ACDF20F1BF5837DA86461B66E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6591817ACDF20F1BF5837DA86461B66E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_BCC6733C586E4FEB28F87DA864613D12" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_BCC6733C586E4FEB28F87DA864613D12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_6DED250EBEC778DB76267DA86461BDC9" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_6DED250EBEC778DB76267DA86461BDC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_32A748D01614CE80C9ED7DA86461F833" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_32A748D01614CE80C9ED7DA86461F833" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" xlink:label="loc_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_376DC9995DF171FA83327DA86461F0FA" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="loc_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_376DC9995DF171FA83327DA86461F0FA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" xlink:label="loc_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_D4BC0E7BA698E78934537DA86462C042" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="loc_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_D4BC0E7BA698E78934537DA86462C042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOtherShares" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_675F9E7ED2A00EB9013F7DA8646227BD" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_675F9E7ED2A00EB9013F7DA8646227BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_1A15A0C81B6F22F4FF867DA86462D2D7" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="loc_us-gaap_StockholdersEquityOther_1A15A0C81B6F22F4FF867DA86462D2D7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ContingenciesAndCertainCommitments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsContingentConsiderationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesLineItems" xlink:label="loc_us-gaap_GainContingenciesLineItems_12B10E098DED288AFE24BEEA11D61605" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesTable" xlink:label="loc_us-gaap_GainContingenciesTable_A8A240334B7429C19B7DBEEA11CA574D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GainContingenciesLineItems_12B10E098DED288AFE24BEEA11D61605" xlink:to="loc_us-gaap_GainContingenciesTable_A8A240334B7429C19B7DBEEA11CA574D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_0F364E2984BC0F6F5DE5BEEA11CC8638" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_A8A240334B7429C19B7DBEEA11CA574D" xlink:to="loc_us-gaap_GainContingenciesByNatureAxis_0F364E2984BC0F6F5DE5BEEA11CC8638" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaap_GainContingencyNatureDomain_7B6B4D8E0551B32D0B98BEEA11CC5F92_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_0F364E2984BC0F6F5DE5BEEA11CC8638" xlink:to="loc_us-gaap_GainContingencyNatureDomain_7B6B4D8E0551B32D0B98BEEA11CC5F92_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaap_GainContingencyNatureDomain_7B6B4D8E0551B32D0B98BEEA11CC5F92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_0F364E2984BC0F6F5DE5BEEA11CC8638" xlink:to="loc_us-gaap_GainContingencyNatureDomain_7B6B4D8E0551B32D0B98BEEA11CC5F92" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PatentInfringementMember" xlink:label="loc_pfe_PatentInfringementMember_4C8313A3243FE379CC66BEEA11CD7360" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingencyNatureDomain_7B6B4D8E0551B32D0B98BEEA11CC5F92" xlink:to="loc_pfe_PatentInfringementMember_4C8313A3243FE379CC66BEEA11CD7360" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_15101EA29DDAE2081F65BEEA11CD2004" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_A8A240334B7429C19B7DBEEA11CA574D" xlink:to="loc_srt_ProductOrServiceAxis_15101EA29DDAE2081F65BEEA11CD2004" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_8A35944EC7F7CBE63392BEEA11CD8FBB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_15101EA29DDAE2081F65BEEA11CD2004" xlink:to="loc_srt_ProductsAndServicesDomain_8A35944EC7F7CBE63392BEEA11CD8FBB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_8A35944EC7F7CBE63392BEEA11CD8FBB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_15101EA29DDAE2081F65BEEA11CD2004" xlink:to="loc_srt_ProductsAndServicesDomain_8A35944EC7F7CBE63392BEEA11CD8FBB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_XeljanzMember" xlink:label="loc_pfe_XeljanzMember_48AB90B8505718CC27C8BEEA11CDE3DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8A35944EC7F7CBE63392BEEA11CD8FBB" xlink:to="loc_pfe_XeljanzMember_48AB90B8505718CC27C8BEEA11CDE3DD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EliquisMember" xlink:label="loc_pfe_EliquisMember_0B119DAB662E2A756D0BBEEA11CEE6C2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8A35944EC7F7CBE63392BEEA11CD8FBB" xlink:to="loc_pfe_EliquisMember_0B119DAB662E2A756D0BBEEA11CEE6C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_81CFA4C5A0601DC17753BEEA11CE0765" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_A8A240334B7429C19B7DBEEA11CA574D" xlink:to="loc_srt_LitigationCaseAxis_81CFA4C5A0601DC17753BEEA11CE0765" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_EF58290ABF145AC3158FBEEA11CECF2B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_81CFA4C5A0601DC17753BEEA11CE0765" xlink:to="loc_srt_LitigationCaseTypeDomain_EF58290ABF145AC3158FBEEA11CECF2B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_EF58290ABF145AC3158FBEEA11CECF2B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_81CFA4C5A0601DC17753BEEA11CE0765" xlink:to="loc_srt_LitigationCaseTypeDomain_EF58290ABF145AC3158FBEEA11CECF2B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PfizerVersusZydusMember" xlink:label="loc_pfe_PfizerVersusZydusMember_3F5C1910368A2F8901D8BEEA11CEC0E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_EF58290ABF145AC3158FBEEA11CECF2B" xlink:to="loc_pfe_PfizerVersusZydusMember_3F5C1910368A2F8901D8BEEA11CEC0E8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PfizerVersusGenericCompaniesMember" xlink:label="loc_pfe_PfizerVersusGenericCompaniesMember_001D33D5976A5912AE9CBEEA11CF5C7B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_EF58290ABF145AC3158FBEEA11CECF2B" xlink:to="loc_pfe_PfizerVersusGenericCompaniesMember_001D33D5976A5912AE9CBEEA11CF5C7B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member" xlink:label="loc_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_DC26A25730FCC8F23715BEEA11CF4661" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_EF58290ABF145AC3158FBEEA11CECF2B" xlink:to="loc_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_DC26A25730FCC8F23715BEEA11CF4661" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" xlink:label="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_8A24D916C1B7C574EDF0BEEA11CF84B6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_EF58290ABF145AC3158FBEEA11CECF2B" xlink:to="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_8A24D916C1B7C574EDF0BEEA11CF84B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_8797CAF2F85640378709BEEA11CFA5D9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_A8A240334B7429C19B7DBEEA11CA574D" xlink:to="loc_us-gaap_LitigationStatusAxis_8797CAF2F85640378709BEEA11CFA5D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_9944064F705B44B2BBD8BEEA11CF07C7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_8797CAF2F85640378709BEEA11CFA5D9" xlink:to="loc_us-gaap_LitigationStatusDomain_9944064F705B44B2BBD8BEEA11CF07C7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_9944064F705B44B2BBD8BEEA11CF07C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_8797CAF2F85640378709BEEA11CFA5D9" xlink:to="loc_us-gaap_LitigationStatusDomain_9944064F705B44B2BBD8BEEA11CF07C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_JudicialRulingMember" xlink:label="loc_us-gaap_JudicialRulingMember_F0D965BCEB4D78258CB4BEEA11D5A605" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_9944064F705B44B2BBD8BEEA11CF07C7" xlink:to="loc_us-gaap_JudicialRulingMember_F0D965BCEB4D78258CB4BEEA11D5A605" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_E02A4280C7AA036BE31BBEEA11D5380D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_9944064F705B44B2BBD8BEEA11CF07C7" xlink:to="loc_us-gaap_PendingLitigationMember_E02A4280C7AA036BE31BBEEA11D5380D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="loc_us-gaap_SettledLitigationMember_5D66E92C33755DD891DABEEA11D55CE7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_9944064F705B44B2BBD8BEEA11CF07C7" xlink:to="loc_us-gaap_SettledLitigationMember_5D66E92C33755DD891DABEEA11D55CE7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_GainContingencyPatentsWithoutCourtProceedingsNumber" xlink:label="loc_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_6677E18B16E4B402A75FBEEA11D6A548" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_12B10E098DED288AFE24BEEA11D61605" xlink:to="loc_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_6677E18B16E4B402A75FBEEA11D6A548" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyPatentsFoundInfringedUponNumber" xlink:label="loc_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_CB69A48214050E477603BEEA11D62A8C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_12B10E098DED288AFE24BEEA11D61605" xlink:to="loc_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_CB69A48214050E477603BEEA11D62A8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_18D892FB0AF65564CE87BEEA11D6BB1E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_12B10E098DED288AFE24BEEA11D61605" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_18D892FB0AF65564CE87BEEA11D6BB1E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_GainContingencyNumberofDefendants" xlink:label="loc_pfe_GainContingencyNumberofDefendants_5A124AF6CA4B9611DE8DBEEA11D6927C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_12B10E098DED288AFE24BEEA11D61605" xlink:to="loc_pfe_GainContingencyNumberofDefendants_5A124AF6CA4B9611DE8DBEEA11D6927C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" xlink:label="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_7E9BD4A27D5FEE966D90BEEA11D72E69" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_12B10E098DED288AFE24BEEA11D61605" xlink:to="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_7E9BD4A27D5FEE966D90BEEA11D72E69" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_9166BCF6AE6608182894BEEA965DF309" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_5DAED5BA42B73F27EE3CBEEA96598DD5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_9166BCF6AE6608182894BEEA965DF309" xlink:to="loc_us-gaap_LossContingenciesTable_5DAED5BA42B73F27EE3CBEEA96598DD5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7570F66BE8CB0EFCF744BEEBF9FDBBAF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_5DAED5BA42B73F27EE3CBEEA96598DD5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7570F66BE8CB0EFCF744BEEBF9FDBBAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_EA490FDE583EE39E3BB1BEEBFA3CE6F7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7570F66BE8CB0EFCF744BEEBF9FDBBAF" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_EA490FDE583EE39E3BB1BEEBFA3CE6F7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_EA490FDE583EE39E3BB1BEEBFA3CE6F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7570F66BE8CB0EFCF744BEEBF9FDBBAF" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_EA490FDE583EE39E3BB1BEEBFA3CE6F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4343B76856DA3A1607A2BEEBFAF30770" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_EA490FDE583EE39E3BB1BEEBFA3CE6F7" xlink:to="loc_us-gaap_SubsequentEventMember_4343B76856DA3A1607A2BEEBFAF30770" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_A86A851012C45A00F38ABEEA96592387" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_5DAED5BA42B73F27EE3CBEEA96598DD5" xlink:to="loc_srt_RangeAxis_A86A851012C45A00F38ABEEA96592387" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9D48424D9ADB937D174CBEEA9659CE8F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_A86A851012C45A00F38ABEEA96592387" xlink:to="loc_srt_RangeMember_9D48424D9ADB937D174CBEEA9659CE8F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9D48424D9ADB937D174CBEEA9659CE8F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_A86A851012C45A00F38ABEEA96592387" xlink:to="loc_srt_RangeMember_9D48424D9ADB937D174CBEEA9659CE8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_80CC935B1DE3B17B3797BEEA96593695" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9D48424D9ADB937D174CBEEA9659CE8F" xlink:to="loc_srt_MinimumMember_80CC935B1DE3B17B3797BEEA96593695" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_E85047E7D3E801F63914BEEA965A7D18" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_5DAED5BA42B73F27EE3CBEEA96598DD5" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_E85047E7D3E801F63914BEEA965A7D18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_6661524AD9BB9FA76636BEEA965A12F5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_E85047E7D3E801F63914BEEA965A7D18" xlink:to="loc_us-gaap_LossContingencyNatureDomain_6661524AD9BB9FA76636BEEA965A12F5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_6661524AD9BB9FA76636BEEA965A12F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_E85047E7D3E801F63914BEEA965A7D18" xlink:to="loc_us-gaap_LossContingencyNatureDomain_6661524AD9BB9FA76636BEEA965A12F5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PatentInfringementMember" xlink:label="loc_pfe_PatentInfringementMember_711B96585A07A67D817BBEEBFA5DAAA3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_6661524AD9BB9FA76636BEEA965A12F5" xlink:to="loc_pfe_PatentInfringementMember_711B96585A07A67D817BBEEBFA5DAAA3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EnvironmentalRemediationLitigationMember" xlink:label="loc_pfe_EnvironmentalRemediationLitigationMember_24B8195F1F8C12CC2793BEEA965A39E5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_6661524AD9BB9FA76636BEEA965A12F5" xlink:to="loc_pfe_EnvironmentalRemediationLitigationMember_24B8195F1F8C12CC2793BEEA965A39E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_B84566645BA54A1445ABBEEA965A9E85" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_5DAED5BA42B73F27EE3CBEEA96598DD5" xlink:to="loc_srt_ProductOrServiceAxis_B84566645BA54A1445ABBEEA965A9E85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_4AB4BD9216D90C610C31BEEA965B5989_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_B84566645BA54A1445ABBEEA965A9E85" xlink:to="loc_srt_ProductsAndServicesDomain_4AB4BD9216D90C610C31BEEA965B5989_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_4AB4BD9216D90C610C31BEEA965B5989" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_B84566645BA54A1445ABBEEA965A9E85" xlink:to="loc_srt_ProductsAndServicesDomain_4AB4BD9216D90C610C31BEEA965B5989" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_HormoneTherapyProductsMember" xlink:label="loc_pfe_HormoneTherapyProductsMember_FF942F4A2FF1736D3B7FBEEA965B27B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4AB4BD9216D90C610C31BEEA965B5989" xlink:to="loc_pfe_HormoneTherapyProductsMember_FF942F4A2FF1736D3B7FBEEA965B27B6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EpiPenMember" xlink:label="loc_pfe_EpiPenMember_31CBE40091AAEBEA3486BEEA965BAA4D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4AB4BD9216D90C610C31BEEA965B5989" xlink:to="loc_pfe_EpiPenMember_31CBE40091AAEBEA3486BEEA965BAA4D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DocetaxelMember" xlink:label="loc_pfe_DocetaxelMember_FD3D3B972C9FD13B9C18BEEA965BF83A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4AB4BD9216D90C610C31BEEA965B5989" xlink:to="loc_pfe_DocetaxelMember_FD3D3B972C9FD13B9C18BEEA965BF83A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_7936A69B2785FF7478A2BEEA965CCBCE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_5DAED5BA42B73F27EE3CBEEA96598DD5" xlink:to="loc_srt_LitigationCaseAxis_7936A69B2785FF7478A2BEEA965CCBCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_BB9DBA6014A9043D9D6ABEEA965CF4BB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_7936A69B2785FF7478A2BEEA965CCBCE" xlink:to="loc_srt_LitigationCaseTypeDomain_BB9DBA6014A9043D9D6ABEEA965CF4BB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_BB9DBA6014A9043D9D6ABEEA965CF4BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_7936A69B2785FF7478A2BEEA965CCBCE" xlink:to="loc_srt_LitigationCaseTypeDomain_BB9DBA6014A9043D9D6ABEEA965CF4BB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_NHSScotlandvs.DrReddysMember" xlink:label="loc_pfe_NHSScotlandvs.DrReddysMember_43C5F4534C427114E2CBBEEBFAAB4619" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_BB9DBA6014A9043D9D6ABEEA965CF4BB" xlink:to="loc_pfe_NHSScotlandvs.DrReddysMember_43C5F4534C427114E2CBBEEBFAAB4619" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ClassActionVersusWyethMember" xlink:label="loc_pfe_ClassActionVersusWyethMember_8B978BF67595DEAC1FC5BEEA965CBE13" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_BB9DBA6014A9043D9D6ABEEA965CF4BB" xlink:to="loc_pfe_ClassActionVersusWyethMember_8B978BF67595DEAC1FC5BEEA965CBE13" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" xlink:label="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_7DBADCD09438C966389BBEEA965C9202" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_BB9DBA6014A9043D9D6ABEEA965CF4BB" xlink:to="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_7DBADCD09438C966389BBEEA965C9202" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_0B96D608C6F21A949707BEEA965DCD1C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_5DAED5BA42B73F27EE3CBEEA96598DD5" xlink:to="loc_us-gaap_LitigationStatusAxis_0B96D608C6F21A949707BEEA965DCD1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_72A1EA19236314D2ED45BEEA965DC648_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_0B96D608C6F21A949707BEEA965DCD1C" xlink:to="loc_us-gaap_LitigationStatusDomain_72A1EA19236314D2ED45BEEA965DC648_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_72A1EA19236314D2ED45BEEA965DC648" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_0B96D608C6F21A949707BEEA965DCD1C" xlink:to="loc_us-gaap_LitigationStatusDomain_72A1EA19236314D2ED45BEEA965DC648" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="loc_us-gaap_SettledLitigationMember_72AEFCC8DA9C7566F5C7BEEA965D3ED0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_72A1EA19236314D2ED45BEEA965DC648" xlink:to="loc_us-gaap_SettledLitigationMember_72AEFCC8DA9C7566F5C7BEEA965D3ED0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_9911E2E36421DFE8DE43BEEA965DFCCF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_72A1EA19236314D2ED45BEEA965DC648" xlink:to="loc_us-gaap_PendingLitigationMember_9911E2E36421DFE8DE43BEEA965DFCCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_435F2919357205352287BEEBF9D0D305" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9166BCF6AE6608182894BEEA965DF309" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_435F2919357205352287BEEBF9D0D305" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_E966E4E0DC5EAA63192BBEEA965E272E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9166BCF6AE6608182894BEEA965DF309" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_E966E4E0DC5EAA63192BBEEA965E272E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LossContingencyNumberOfLawsuits" xlink:label="loc_pfe_LossContingencyNumberOfLawsuits_67989598F7EB08095016BEEA965EDE8D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9166BCF6AE6608182894BEEA965DF309" xlink:to="loc_pfe_LossContingencyNumberOfLawsuits_67989598F7EB08095016BEEA965EDE8D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" xlink:label="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_198735D799629D87BBC4BEEA965E23D2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9166BCF6AE6608182894BEEA965DF309" xlink:to="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_198735D799629D87BBC4BEEA965E23D2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LossContingencyClassActionsFiledNumber" xlink:label="loc_pfe_LossContingencyClassActionsFiledNumber_0248FC1B6EB0A16E7A15BEEA965ECEF2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9166BCF6AE6608182894BEEA965DF309" xlink:to="loc_pfe_LossContingencyClassActionsFiledNumber_0248FC1B6EB0A16E7A15BEEA965ECEF2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FeasibilityStudyNumberOfLagoons" xlink:label="loc_pfe_FeasibilityStudyNumberOfLagoons_99ED2948E08D611DC62BBEEA965EFAD7" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9166BCF6AE6608182894BEEA965DF309" xlink:to="loc_pfe_FeasibilityStudyNumberOfLagoons_99ED2948E08D611DC62BBEEA965EFAD7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInformationLineItems" xlink:label="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitiesTable" xlink:label="loc_dei_EntitiesTable_6BEF4EB72D27BAC5B3B994762150B47F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntitiesTable_6BEF4EB72D27BAC5B3B994762150B47F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8A5B7FE49AE24C45B38B94762150A41E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_6BEF4EB72D27BAC5B3B994762150B47F" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8A5B7FE49AE24C45B38B94762150A41E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D07E461283C3FA7703E09476215078F5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8A5B7FE49AE24C45B38B94762150A41E" xlink:to="loc_us-gaap_ClassOfStockDomain_D07E461283C3FA7703E09476215078F5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D07E461283C3FA7703E09476215078F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8A5B7FE49AE24C45B38B94762150A41E" xlink:to="loc_us-gaap_ClassOfStockDomain_D07E461283C3FA7703E09476215078F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_D38B5BE3EDDAFFAC83D6947621515092" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_D07E461283C3FA7703E09476215078F5" xlink:to="loc_us-gaap_CommonStockMember_D38B5BE3EDDAFFAC83D6947621515092" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_NotesDue20220.250Member" xlink:label="loc_pfe_NotesDue20220.250Member_F3B4D8FAF1591617D43B94762151DCF1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_D07E461283C3FA7703E09476215078F5" xlink:to="loc_pfe_NotesDue20220.250Member_F3B4D8FAF1591617D43B94762151DCF1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_NotesDue20271.000Member" xlink:label="loc_pfe_NotesDue20271.000Member_1A6E9869FF0AC0C9630B9476215115F2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_D07E461283C3FA7703E09476215078F5" xlink:to="loc_pfe_NotesDue20271.000Member_1A6E9869FF0AC0C9630B9476215115F2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_2CCF0CFCFCAB4E74B092947621515A7F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_DocumentType_2CCF0CFCFCAB4E74B092947621515A7F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_F0B577485A3E2E5958F9947621521F69" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_DocumentQuarterlyReport_F0B577485A3E2E5958F9947621521F69" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_4E5B0B21C4BEB91D16B394762152B53B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_DocumentPeriodEndDate_4E5B0B21C4BEB91D16B394762152B53B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_BC0F4677FBCB403B51DD947621526DFE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_DocumentTransitionReport_BC0F4677FBCB403B51DD947621526DFE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_BD3593FE990C54224595947621527524" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityFileNumber_BD3593FE990C54224595947621527524" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_C970256C3BACADD6AF3C947621523258" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityRegistrantName_C970256C3BACADD6AF3C947621523258" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_CAB2971306A9B6511B0C947621535305" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityIncorporationStateCountryCode_CAB2971306A9B6511B0C947621535305" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_36E6F8DA32CC33A3707E947621531071" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityTaxIdentificationNumber_36E6F8DA32CC33A3707E947621531071" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_6D9ED9007B223EF3D062947621533652" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityAddressAddressLine1_6D9ED9007B223EF3D062947621533652" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_71C8945D294C21B8460E94762153AF8F" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityAddressCityOrTown_71C8945D294C21B8460E94762153AF8F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_2FDC1CD74B2E1BCAC22694762153536F" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityAddressStateOrProvince_2FDC1CD74B2E1BCAC22694762153536F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_F01EC6CB7CC69B7AD71F94762153217D" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityAddressPostalZipCode_F01EC6CB7CC69B7AD71F94762153217D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_0C6BF61FF873887D10B094762153AA73" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_CityAreaCode_0C6BF61FF873887D10B094762153AA73" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_2E6A057828AF2E5AAE2194762154BDED" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_LocalPhoneNumber_2E6A057828AF2E5AAE2194762154BDED" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_7309269DC3ADA72430C8947621543F97" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_Security12bTitle_7309269DC3ADA72430C8947621543F97" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_C4440E09C69BAD5BDDC194762154E383" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_TradingSymbol_C4440E09C69BAD5BDDC194762154E383" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_16D9D6B005F22B21EE9394762154F9C7" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_SecurityExchangeName_16D9D6B005F22B21EE9394762154F9C7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_9759AA759CCB8F031EFA9476215471B0" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityCurrentReportingStatus_9759AA759CCB8F031EFA9476215471B0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_6CB2A44E160280EBA62B94762155CE3B" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityInteractiveDataCurrent_6CB2A44E160280EBA62B94762155CE3B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_FE65E3A11197F9E68ACF94762155FB1B" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityFilerCategory_FE65E3A11197F9E68ACF94762155FB1B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_29E0C615C4E4FF4C74D894762155B832" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntitySmallBusiness_29E0C615C4E4FF4C74D894762155B832" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_7A0ED81080F6634A3053947621554371" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityEmergingGrowthCompany_7A0ED81080F6634A3053947621554371" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_1A6EA84D6B0BC47A22F3947621555998" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityShellCompany_1A6EA84D6B0BC47A22F3947621555998" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_E8227DB2564C0E41A867947621554B0A" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_E8227DB2564C0E41A867947621554B0A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_3AC40381611F3CE6BA3294762155E10D" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityCentralIndexKey_3AC40381611F3CE6BA3294762155E10D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_3901D592D2C0E9AFD00C947621566D2F" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_CurrentFiscalYearEndDate_3901D592D2C0E9AFD00C947621566D2F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_189822777DD5C6CA2D4C94762156729D" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_DocumentFiscalYearFocus_189822777DD5C6CA2D4C94762156729D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_EE848DDD25A98CB3C114947621563EDE" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_DocumentFiscalPeriodFocus_EE848DDD25A98CB3C114947621563EDE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9BC9FAA9051592D4285F94762156C526" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_AmendmentFlag_9BC9FAA9051592D4285F94762156C526" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholders" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/Equity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/EquityDividendsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/EquityPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_AE0D9C43AD7F4A42E454635078D8C6E2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_BBA8C7E20324BC2213F7635078D7A14C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_AE0D9C43AD7F4A42E454635078D8C6E2" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_BBA8C7E20324BC2213F7635078D7A14C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7FC141216C2ED3257027635078D7C999" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_BBA8C7E20324BC2213F7635078D7A14C" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7FC141216C2ED3257027635078D7C999" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4EE967E431B42EF83F9E635078D87155_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7FC141216C2ED3257027635078D7C999" xlink:to="loc_us-gaap_EquityComponentDomain_4EE967E431B42EF83F9E635078D87155_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4EE967E431B42EF83F9E635078D87155" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7FC141216C2ED3257027635078D7C999" xlink:to="loc_us-gaap_EquityComponentDomain_4EE967E431B42EF83F9E635078D87155" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_CB5A65ECE31102262D68635078D81D54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4EE967E431B42EF83F9E635078D87155" xlink:to="loc_us-gaap_CommonStockMember_CB5A65ECE31102262D68635078D81D54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_A9FFBC1F7A40E008D33A635078D8B43B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_AE0D9C43AD7F4A42E454635078D8C6E2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_A9FFBC1F7A40E008D33A635078D8B43B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_E459F6F67A44AD16290E635078D856AE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_AE0D9C43AD7F4A42E454635078D8C6E2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_E459F6F67A44AD16290E635078D856AE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/EquityTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_50D892AF020B7A3BF8AC9476230265BB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_08820D7E77FB99D87C5294762301569A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_50D892AF020B7A3BF8AC9476230265BB" xlink:to="loc_us-gaap_ConcentrationRiskTable_08820D7E77FB99D87C5294762301569A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesByIndustryAxis" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis_DBD79DBEE99F081F1DDD94762301BFAA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_08820D7E77FB99D87C5294762301569A" xlink:to="loc_us-gaap_EquitySecuritiesByIndustryAxis_DBD79DBEE99F081F1DDD94762301BFAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_10BA5A1BA379B5B769B894762301DEDE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_DBD79DBEE99F081F1DDD94762301BFAA" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_10BA5A1BA379B5B769B894762301DEDE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_10BA5A1BA379B5B769B894762301DEDE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_DBD79DBEE99F081F1DDD94762301BFAA" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_10BA5A1BA379B5B769B894762301DEDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialServicesSectorMember" xlink:label="loc_us-gaap_FinancialServicesSectorMember_C46FD2B47D4492A6556094762302859F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember_10BA5A1BA379B5B769B894762301DEDE" xlink:to="loc_us-gaap_FinancialServicesSectorMember_C46FD2B47D4492A6556094762302859F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:label="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_FB52200C400B928C19A094762302E303" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_50D892AF020B7A3BF8AC9476230265BB" xlink:to="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_FB52200C400B928C19A094762302E303" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_74E11EEDC99848508EBBA1BD7313D911" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_8708D1DAD539164BC2D4A1BD73125636" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_74E11EEDC99848508EBBA1BD7313D911" xlink:to="loc_us-gaap_DerivativeTable_8708D1DAD539164BC2D4A1BD73125636" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_E8FDC13E98C1686FA618A1BD73126304" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_8708D1DAD539164BC2D4A1BD73125636" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_E8FDC13E98C1686FA618A1BD73126304" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5C89839DCC2FF6BB946EA1BD73138BD0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_E8FDC13E98C1686FA618A1BD73126304" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5C89839DCC2FF6BB946EA1BD73138BD0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5C89839DCC2FF6BB946EA1BD73138BD0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_E8FDC13E98C1686FA618A1BD73126304" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5C89839DCC2FF6BB946EA1BD73138BD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_7C4CC5F6C7C2EDE3DE54A1CD8BF32B77" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5C89839DCC2FF6BB946EA1BD73138BD0" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_7C4CC5F6C7C2EDE3DE54A1CD8BF32B77" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LongtermInvestmentsMember" xlink:label="loc_pfe_LongtermInvestmentsMember_7470B66828EE361E2315A1BD73131727" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5C89839DCC2FF6BB946EA1BD73138BD0" xlink:to="loc_pfe_LongtermInvestmentsMember_7470B66828EE361E2315A1BD73131727" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMember" xlink:label="loc_us-gaap_LongTermDebtMember_D7ACEC1E0050420AD565A1BD7313643A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5C89839DCC2FF6BB946EA1BD73138BD0" xlink:to="loc_us-gaap_LongTermDebtMember_D7ACEC1E0050420AD565A1BD7313643A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedAssetFairValueHedge" xlink:label="loc_us-gaap_HedgedAssetFairValueHedge_1A361EE3522CAF475DC0A1BD7313BECA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_74E11EEDC99848508EBBA1BD7313D911" xlink:to="loc_us-gaap_HedgedAssetFairValueHedge_1A361EE3522CAF475DC0A1BD7313BECA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_1777D36C16BCA3C6B74AA1BD7314B42D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_74E11EEDC99848508EBBA1BD7313D911" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_1777D36C16BCA3C6B74AA1BD7314B42D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease" xlink:label="loc_us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease_C412280A0378C803F792A1BD7314EBE0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_74E11EEDC99848508EBBA1BD7313D911" xlink:to="loc_us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease_C412280A0378C803F792A1BD7314EBE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_6927C0D37A761040FBB2A1BD7314C9D1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_74E11EEDC99848508EBBA1BD7313D911" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_6927C0D37A761040FBB2A1BD7314C9D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:label="loc_us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_F58240D0C30F9330037DA1BD731472EC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_74E11EEDC99848508EBBA1BD7313D911" xlink:to="loc_us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_F58240D0C30F9330037DA1BD731472EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:label="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_6B063FBE8673370C1CF0A1BD73147491" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_74E11EEDC99848508EBBA1BD7313D911" xlink:to="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_6B063FBE8673370C1CF0A1BD73147491" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_498E68AB86E9E12C97DD9476218390B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_us-gaap_DerivativeTable_498E68AB86E9E12C97DD9476218390B2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_F58F7A0BFCB3E3EFFA47947621847088" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_498E68AB86E9E12C97DD9476218390B2" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_F58F7A0BFCB3E3EFFA47947621847088" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_4BA6CF995377FDF7FD0994762184A2BA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_F58F7A0BFCB3E3EFFA47947621847088" xlink:to="loc_us-gaap_HedgingRelationshipDomain_4BA6CF995377FDF7FD0994762184A2BA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_4BA6CF995377FDF7FD0994762184A2BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_F58F7A0BFCB3E3EFFA47947621847088" xlink:to="loc_us-gaap_HedgingRelationshipDomain_4BA6CF995377FDF7FD0994762184A2BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember" xlink:label="loc_us-gaap_CashFlowHedgingMember_C04C5910B95BB22A5FF894762184FD80" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_4BA6CF995377FDF7FD0994762184A2BA" xlink:to="loc_us-gaap_CashFlowHedgingMember_C04C5910B95BB22A5FF894762184FD80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_4815BFD9F1FB5B90CA1E9476218A84E0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_4BA6CF995377FDF7FD0994762184A2BA" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_4815BFD9F1FB5B90CA1E9476218A84E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_73AFF03B74FFDFAB15529476218A4E6B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_498E68AB86E9E12C97DD9476218390B2" xlink:to="loc_us-gaap_HedgingDesignationAxis_73AFF03B74FFDFAB15529476218A4E6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_8CF9EDD6947FF95ECE879476218AB4A1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_73AFF03B74FFDFAB15529476218A4E6B" xlink:to="loc_us-gaap_HedgingDesignationDomain_8CF9EDD6947FF95ECE879476218AB4A1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_8CF9EDD6947FF95ECE879476218AB4A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_73AFF03B74FFDFAB15529476218A4E6B" xlink:to="loc_us-gaap_HedgingDesignationDomain_8CF9EDD6947FF95ECE879476218AB4A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_88E2889993E533C628E39476218AA9B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_8CF9EDD6947FF95ECE879476218AB4A1" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_88E2889993E533C628E39476218AA9B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_7709232A4B9C1FAFA1CA9476218B88FC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_8CF9EDD6947FF95ECE879476218AB4A1" xlink:to="loc_us-gaap_NondesignatedMember_7709232A4B9C1FAFA1CA9476218B88FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_F424131B3CEB677BDA8B9476218BFEEE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_498E68AB86E9E12C97DD9476218390B2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_F424131B3CEB677BDA8B9476218BFEEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_502FA921A815F1F56E8C9476218BF947_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_F424131B3CEB677BDA8B9476218BFEEE" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_502FA921A815F1F56E8C9476218BF947_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_502FA921A815F1F56E8C9476218BF947" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_F424131B3CEB677BDA8B9476218BFEEE" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_502FA921A815F1F56E8C9476218BF947" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_68540A7994147B62B5689476218B796A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_502FA921A815F1F56E8C9476218BF947" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_68540A7994147B62B5689476218B796A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherIncomeDeductionsAndCostOfSalesMember" xlink:label="loc_pfe_OtherIncomeDeductionsAndCostOfSalesMember_6CEA8C5BF7C12D64ED099476218CA094" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_502FA921A815F1F56E8C9476218BF947" xlink:to="loc_pfe_OtherIncomeDeductionsAndCostOfSalesMember_6CEA8C5BF7C12D64ED099476218CA094" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_05FFD208E0A2A6A253449476218C3DCD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_498E68AB86E9E12C97DD9476218390B2" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_05FFD208E0A2A6A253449476218C3DCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_350E0EA09C54774A23009476218C452E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_05FFD208E0A2A6A253449476218C3DCD" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_350E0EA09C54774A23009476218C452E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_350E0EA09C54774A23009476218C452E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_05FFD208E0A2A6A253449476218C3DCD" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_350E0EA09C54774A23009476218C452E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_060D2016ADB2C92F7BBF9476218C3337" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_350E0EA09C54774A23009476218C452E" xlink:to="loc_us-gaap_ForeignExchangeContractMember_060D2016ADB2C92F7BBF9476218C3337" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember" xlink:label="loc_us-gaap_InterestRateContractMember_3B80C00AE4B6B4480CE19476218DED6D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_350E0EA09C54774A23009476218C452E" xlink:to="loc_us-gaap_InterestRateContractMember_3B80C00AE4B6B4480CE19476218DED6D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:label="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_F28D0B956AB3743B3E579476218DFF4B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_350E0EA09C54774A23009476218C452E" xlink:to="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_F28D0B956AB3743B3E579476218DFF4B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ForeignCurrencyLongTermDebtMember" xlink:label="loc_pfe_ForeignCurrencyLongTermDebtMember_4761DD4BA562EF2598C29476218D7AAE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_350E0EA09C54774A23009476218C452E" xlink:to="loc_pfe_ForeignCurrencyLongTermDebtMember_4761DD4BA562EF2598C29476218D7AAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_D93016AAF3D3A7AD5FBC9476218DE611" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_D93016AAF3D3A7AD5FBC9476218DE611" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_4EF126ED566AE4369DD49476218DFF22" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_4EF126ED566AE4369DD49476218DFF22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_74093AA0910EC4223FFB9476218E657D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_74093AA0910EC4223FFB9476218E657D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_5B0D08C094FF8ED47D629476218EFC45" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_5B0D08C094FF8ED47D629476218EFC45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_D12258B45456B356F7BD9476218EDF42" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_D12258B45456B356F7BD9476218EDF42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_4A6B671B56CAC4AB38FB9476218EB8C5" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_4A6B671B56CAC4AB38FB9476218EB8C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_7D31C2FF8B30092ED3749476218E6789" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_7D31C2FF8B30092ED3749476218E6789" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_D0116DAE828D959CB2799476218EE64C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_D0116DAE828D959CB2799476218EE64C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_B648B6771E498CAA89219476218FB32E" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_B648B6771E498CAA89219476218FB32E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_9C0545DD5C15574507C29476218FB081" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_9C0545DD5C15574507C29476218FB081" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_DCD3EAB805D49F8AD3579476218F89BE" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_DCD3EAB805D49F8AD3579476218F89BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_49644F7EE74FAAD00ECD9476218F00C2" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_49644F7EE74FAAD00ECD9476218F00C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_312F42110A8A60573FA39476218F6175" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_312F42110A8A60573FA39476218F6175" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_2295A4E4B36D2982DEBE9476218F64A2" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_2295A4E4B36D2982DEBE9476218F64A2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_F8E168276EAAA4C99E9A94762190D180" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_F8E168276EAAA4C99E9A94762190D180" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_64EEDA03A8327FBBA3B3947621901730" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_64EEDA03A8327FBBA3B3947621901730" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_9917D736050C0AF351AA6EB03937F6AD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_3391288BDE6468485C586EB03934F338" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_9917D736050C0AF351AA6EB03937F6AD" xlink:to="loc_us-gaap_DerivativeTable_3391288BDE6468485C586EB03934F338" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_7F15C57EC936A259F5F56EB039341B74" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_3391288BDE6468485C586EB03934F338" xlink:to="loc_us-gaap_HedgingDesignationAxis_7F15C57EC936A259F5F56EB039341B74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_DE57B5EBB559184283F46EB03934D5E0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_7F15C57EC936A259F5F56EB039341B74" xlink:to="loc_us-gaap_HedgingDesignationDomain_DE57B5EBB559184283F46EB03934D5E0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_DE57B5EBB559184283F46EB03934D5E0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_7F15C57EC936A259F5F56EB039341B74" xlink:to="loc_us-gaap_HedgingDesignationDomain_DE57B5EBB559184283F46EB03934D5E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_AEA9B1E5C81A46CF66806EB039348DD7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_DE57B5EBB559184283F46EB03934D5E0" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_AEA9B1E5C81A46CF66806EB039348DD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_C67F16783BBD4D21CA526EB0393547FF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_3391288BDE6468485C586EB03934F338" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_C67F16783BBD4D21CA526EB0393547FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_032BD08B3D5D46A5AC5A6EB039356736_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_C67F16783BBD4D21CA526EB0393547FF" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_032BD08B3D5D46A5AC5A6EB039356736_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_032BD08B3D5D46A5AC5A6EB039356736" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_C67F16783BBD4D21CA526EB0393547FF" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_032BD08B3D5D46A5AC5A6EB039356736" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_920EE1AAAC01F47674AE6EB03935F9FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_032BD08B3D5D46A5AC5A6EB039356736" xlink:to="loc_us-gaap_CostOfSalesMember_920EE1AAAC01F47674AE6EB03935F9FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_731ECF566CED49152C056EB039355869" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_3391288BDE6468485C586EB03934F338" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_731ECF566CED49152C056EB039355869" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_57F2079C429FD53B8C746EB039366E36_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_731ECF566CED49152C056EB039355869" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_57F2079C429FD53B8C746EB039366E36_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_57F2079C429FD53B8C746EB039366E36" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_731ECF566CED49152C056EB039355869" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_57F2079C429FD53B8C746EB039366E36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_E885BB8F3CA46A597A066EB039360673" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_57F2079C429FD53B8C746EB039366E36" xlink:to="loc_us-gaap_ForeignExchangeContractMember_E885BB8F3CA46A597A066EB039360673" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ForeignCurrencyLongTermDebtMember" xlink:label="loc_pfe_ForeignCurrencyLongTermDebtMember_DD60DEAD2744D98E8FF46EB03936FD05" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_57F2079C429FD53B8C746EB039366E36" xlink:to="loc_pfe_ForeignCurrencyLongTermDebtMember_DD60DEAD2744D98E8FF46EB03936FD05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_E30C7A1C5CF68C29FC7C6EB03936FCCC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_3391288BDE6468485C586EB03934F338" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_E30C7A1C5CF68C29FC7C6EB03936FCCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5FD065571CBA7560A1AA6EB03937BE3E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E30C7A1C5CF68C29FC7C6EB03936FCCC" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5FD065571CBA7560A1AA6EB03937BE3E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5FD065571CBA7560A1AA6EB03937BE3E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E30C7A1C5CF68C29FC7C6EB03936FCCC" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5FD065571CBA7560A1AA6EB03937BE3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_AD6598315F9322DBAC2D6EB03937A0F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5FD065571CBA7560A1AA6EB03937BE3E" xlink:to="loc_us-gaap_UnsecuredDebtMember_AD6598315F9322DBAC2D6EB03937A0F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_52703259133BF0061E1F6EB03937D96C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9917D736050C0AF351AA6EB03937F6AD" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_52703259133BF0061E1F6EB03937D96C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_37F69DCF9EAD966F73096EB0393D2610" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9917D736050C0AF351AA6EB03937F6AD" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_37F69DCF9EAD966F73096EB0393D2610" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_7645262DC5A670773B516EB0393DD88C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9917D736050C0AF351AA6EB03937F6AD" xlink:to="loc_us-gaap_LongTermDebt_7645262DC5A670773B516EB0393DD88C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_8293004AD726357E64A094761F133F66" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_98BF055BE63E0CAC090A94761F125289" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_8293004AD726357E64A094761F133F66" xlink:to="loc_us-gaap_DerivativeTable_98BF055BE63E0CAC090A94761F125289" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_D59B7E88C686FCA2C5E094761F136170" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_98BF055BE63E0CAC090A94761F125289" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_D59B7E88C686FCA2C5E094761F136170" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_DD1956906A13AC40DBB294761F13F6E1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_D59B7E88C686FCA2C5E094761F136170" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_DD1956906A13AC40DBB294761F13F6E1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_DD1956906A13AC40DBB294761F13F6E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_D59B7E88C686FCA2C5E094761F136170" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_DD1956906A13AC40DBB294761F13F6E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_E57BCA07C23B920D6BDF94761F13C49F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_DD1956906A13AC40DBB294761F13F6E1" xlink:to="loc_us-gaap_ForeignExchangeContractMember_E57BCA07C23B920D6BDF94761F13C49F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTermOfContract" xlink:label="loc_us-gaap_DerivativeTermOfContract_5762C75B3300E1EB1AC494761F142B92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_8293004AD726357E64A094761F133F66" xlink:to="loc_us-gaap_DerivativeTermOfContract_5762C75B3300E1EB1AC494761F142B92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNetLiabilityPositionAggregateFairValue" xlink:label="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_041EB4B08FC7CB84B27894761F148D1A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_8293004AD726357E64A094761F133F66" xlink:to="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_041EB4B08FC7CB84B27894761F148D1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_BD088DF223917C973D3D94761F142AFA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_8293004AD726357E64A094761F133F66" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_BD088DF223917C973D3D94761F142AFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuritiesReceivedAsCollateral" xlink:label="loc_us-gaap_SecuritiesReceivedAsCollateral_EF6A14D8A7DC65EA8BD894761F14B1A3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_8293004AD726357E64A094761F133F66" xlink:to="loc_us-gaap_SecuritiesReceivedAsCollateral_EF6A14D8A7DC65EA8BD894761F14B1A3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_EC3699E4A1D380D01F9794761EA6AEAE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_6AB56A70CFF065F077A594761EA3EDEC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_EC3699E4A1D380D01F9794761EA6AEAE" xlink:to="loc_us-gaap_DerivativeTable_6AB56A70CFF065F077A594761EA3EDEC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_HedgedItemAxis" xlink:label="loc_pfe_HedgedItemAxis_B4D79A00F602BDA6D15A94761EA42A17" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_6AB56A70CFF065F077A594761EA3EDEC" xlink:to="loc_pfe_HedgedItemAxis_B4D79A00F602BDA6D15A94761EA42A17" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_HedgedItemDomain" xlink:label="loc_pfe_HedgedItemDomain_BE06C13024F26F33D7FE94761EA4376F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pfe_HedgedItemAxis_B4D79A00F602BDA6D15A94761EA42A17" xlink:to="loc_pfe_HedgedItemDomain_BE06C13024F26F33D7FE94761EA4376F_default" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_HedgedItemDomain" xlink:label="loc_pfe_HedgedItemDomain_BE06C13024F26F33D7FE94761EA4376F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pfe_HedgedItemAxis_B4D79A00F602BDA6D15A94761EA42A17" xlink:to="loc_pfe_HedgedItemDomain_BE06C13024F26F33D7FE94761EA4376F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_4CCC75A178B51F06392A94761EA4B579" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_HedgedItemDomain_BE06C13024F26F33D7FE94761EA4376F" xlink:to="loc_us-gaap_SalesMember_4CCC75A178B51F06392A94761EA4B579" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_51D26D800027A17D61BA94761EA40310" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_6AB56A70CFF065F077A594761EA3EDEC" xlink:to="loc_us-gaap_HedgingDesignationAxis_51D26D800027A17D61BA94761EA40310" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_973BBD5D2C12393AE5A494761EA44F79_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_51D26D800027A17D61BA94761EA40310" xlink:to="loc_us-gaap_HedgingDesignationDomain_973BBD5D2C12393AE5A494761EA44F79_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_973BBD5D2C12393AE5A494761EA44F79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_51D26D800027A17D61BA94761EA40310" xlink:to="loc_us-gaap_HedgingDesignationDomain_973BBD5D2C12393AE5A494761EA44F79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_01DBAF3D312D42EDD90D94761EA590E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_973BBD5D2C12393AE5A494761EA44F79" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_01DBAF3D312D42EDD90D94761EA590E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_EA2B7541E1C03C1D6AE694761EA5E590" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_973BBD5D2C12393AE5A494761EA44F79" xlink:to="loc_us-gaap_NondesignatedMember_EA2B7541E1C03C1D6AE694761EA5E590" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_CCE4618FA60D9B9D617494761EA538D8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_6AB56A70CFF065F077A594761EA3EDEC" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_CCE4618FA60D9B9D617494761EA538D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_C0DFB171C3ED44BDFD1C94761EA5E11B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_CCE4618FA60D9B9D617494761EA538D8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_C0DFB171C3ED44BDFD1C94761EA5E11B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_C0DFB171C3ED44BDFD1C94761EA5E11B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_CCE4618FA60D9B9D617494761EA538D8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_C0DFB171C3ED44BDFD1C94761EA5E11B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_B471D0C0D9EDB5DEF79F94761EA69B27" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_C0DFB171C3ED44BDFD1C94761EA5E11B" xlink:to="loc_us-gaap_ForeignExchangeContractMember_B471D0C0D9EDB5DEF79F94761EA69B27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember" xlink:label="loc_us-gaap_InterestRateContractMember_EC6F67CF99092946F84494761EA6241A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_C0DFB171C3ED44BDFD1C94761EA5E11B" xlink:to="loc_us-gaap_InterestRateContractMember_EC6F67CF99092946F84494761EA6241A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_FB32BD0BD5996A6676FC94761EA648B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_EC3699E4A1D380D01F9794761EA6AEAE" xlink:to="loc_us-gaap_DerivativeNotionalAmount_FB32BD0BD5996A6676FC94761EA648B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets" xlink:label="loc_us-gaap_DerivativeAssets_011A482D637FC08FCA2D94761EA7EB42" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_EC3699E4A1D380D01F9794761EA6AEAE" xlink:to="loc_us-gaap_DerivativeAssets_011A482D637FC08FCA2D94761EA7EB42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_638B713D4DB36466188794761EA7DABE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_EC3699E4A1D380D01F9794761EA6AEAE" xlink:to="loc_us-gaap_DerivativeLiabilities_638B713D4DB36466188794761EA7DABE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43BD043E8C0F0F942290B09F33269118" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_06BF50534E31840A3171B09F331B0756" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43BD043E8C0F0F942290B09F33269118" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_06BF50534E31840A3171B09F331B0756" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_71F7845C116B3F47FDF0B09F331B1A4C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_06BF50534E31840A3171B09F331B0756" xlink:to="loc_us-gaap_FinancialInstrumentAxis_71F7845C116B3F47FDF0B09F331B1A4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9A2A27622858EAF73841B09F331C5035_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_71F7845C116B3F47FDF0B09F331B1A4C" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9A2A27622858EAF73841B09F331C5035_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9A2A27622858EAF73841B09F331C5035" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_71F7845C116B3F47FDF0B09F331B1A4C" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9A2A27622858EAF73841B09F331C5035" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_B73BD16295B28013420AB09F331C43C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9A2A27622858EAF73841B09F331C5035" xlink:to="loc_us-gaap_MoneyMarketFundsMember_B73BD16295B28013420AB09F331C43C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_B5A8D6B5A9D5BF77C1A1B09F331C7F97" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9A2A27622858EAF73841B09F331C5035" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_B5A8D6B5A9D5BF77C1A1B09F331C7F97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_721465EB5548DC1455E0B09F331C952B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9A2A27622858EAF73841B09F331C5035" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_721465EB5548DC1455E0B09F331C952B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_BA894BE51924BBB795D9B09F331D3A10" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9A2A27622858EAF73841B09F331C5035" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_BA894BE51924BBB795D9B09F331D3A10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_59D6600D57BDAF22C8CCB09F331DBDC6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_06BF50534E31840A3171B09F331B0756" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_59D6600D57BDAF22C8CCB09F331DBDC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DF616621017ECF1E94E4B09F331D1804_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_59D6600D57BDAF22C8CCB09F331DBDC6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DF616621017ECF1E94E4B09F331D1804_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DF616621017ECF1E94E4B09F331D1804" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_59D6600D57BDAF22C8CCB09F331DBDC6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DF616621017ECF1E94E4B09F331D1804" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_66046376D20AAFD10E3AB09F331DF0CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DF616621017ECF1E94E4B09F331D1804" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_66046376D20AAFD10E3AB09F331DF0CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_CE25508B232D2B7DF75FB09F331D22B4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DF616621017ECF1E94E4B09F331D1804" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_CE25508B232D2B7DF75FB09F331D22B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_64AFD1F3F300F730B0FBB09F331D43C9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_06BF50534E31840A3171B09F331B0756" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_64AFD1F3F300F730B0FBB09F331D43C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8F302B4D9E7D5AEE6DCCB09F331EE1C1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_64AFD1F3F300F730B0FBB09F331D43C9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8F302B4D9E7D5AEE6DCCB09F331EE1C1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8F302B4D9E7D5AEE6DCCB09F331EE1C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_64AFD1F3F300F730B0FBB09F331D43C9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8F302B4D9E7D5AEE6DCCB09F331EE1C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_B489E4D7121F2C418AD8B09F331E1AFB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8F302B4D9E7D5AEE6DCCB09F331EE1C1" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_B489E4D7121F2C418AD8B09F331E1AFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_22620DA5E0C1A9D40DD5B09F331E21E1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8F302B4D9E7D5AEE6DCCB09F331EE1C1" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_22620DA5E0C1A9D40DD5B09F331E21E1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LongtermInvestmentsMember" xlink:label="loc_pfe_LongtermInvestmentsMember_CE17EED2495429FBF8DEB09F331E81FA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8F302B4D9E7D5AEE6DCCB09F331EE1C1" xlink:to="loc_pfe_LongtermInvestmentsMember_CE17EED2495429FBF8DEB09F331E81FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_1E9A48CA94E19E470629B09F331F4828" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8F302B4D9E7D5AEE6DCCB09F331EE1C1" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_1E9A48CA94E19E470629B09F331F4828" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_52C64DEFD1F022B5FB21B09F331FE9F4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8F302B4D9E7D5AEE6DCCB09F331EE1C1" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_52C64DEFD1F022B5FB21B09F331FE9F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_478384D142F3C5AF41E3B09F331F4F58" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8F302B4D9E7D5AEE6DCCB09F331EE1C1" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_478384D142F3C5AF41E3B09F331F4F58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_BD6AF62695C20549DA3CB09F331FA73D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_06BF50534E31840A3171B09F331B0756" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_BD6AF62695C20549DA3CB09F331FA73D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5AFAFE1D63CA48D3F04BB09F331FEB64_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_BD6AF62695C20549DA3CB09F331FA73D" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5AFAFE1D63CA48D3F04BB09F331FEB64_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5AFAFE1D63CA48D3F04BB09F331FEB64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_BD6AF62695C20549DA3CB09F331FA73D" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5AFAFE1D63CA48D3F04BB09F331FEB64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_75D2431F2988E87134A4B09F3320BFDD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5AFAFE1D63CA48D3F04BB09F331FEB64" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_75D2431F2988E87134A4B09F3320BFDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_30A45767127EC4A992CCB09F33201285" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_06BF50534E31840A3171B09F331B0756" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_30A45767127EC4A992CCB09F33201285" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_C3C558F5FCDF1A4A2117B09F33200018_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_30A45767127EC4A992CCB09F33201285" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_C3C558F5FCDF1A4A2117B09F33200018_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_C3C558F5FCDF1A4A2117B09F33200018" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_30A45767127EC4A992CCB09F33201285" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_C3C558F5FCDF1A4A2117B09F33200018" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember" xlink:label="loc_us-gaap_InterestRateContractMember_CFAB896C9D83A6824B8CB09F3320A328" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_C3C558F5FCDF1A4A2117B09F33200018" xlink:to="loc_us-gaap_InterestRateContractMember_CFAB896C9D83A6824B8CB09F3320A328" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_45645412FAD4145EFFBDB09F3321D1F2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_C3C558F5FCDF1A4A2117B09F33200018" xlink:to="loc_us-gaap_ForeignExchangeContractMember_45645412FAD4145EFFBDB09F3321D1F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_8D65BAE8481894BAB827B09F332605C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43BD043E8C0F0F942290B09F33269118" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_8D65BAE8481894BAB827B09F332605C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6F40E84ABBC429DB007BB09F3326C131" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43BD043E8C0F0F942290B09F33269118" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6F40E84ABBC429DB007BB09F3326C131" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" xlink:label="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_1D5FF53A60602A71A2E3B09F33261E74" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43BD043E8C0F0F942290B09F33269118" xlink:to="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_1D5FF53A60602A71A2E3B09F33261E74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsCurrent" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_9092E0C133DA413731DAB09F33275449" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43BD043E8C0F0F942290B09F33269118" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_9092E0C133DA413731DAB09F33275449" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" xlink:label="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_48ED3BDDD833AE9D8C79B09F3327B8A5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43BD043E8C0F0F942290B09F33269118" xlink:to="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_48ED3BDDD833AE9D8C79B09F3327B8A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_8E0F8B1DCA2CD0E55D3AB09F3327BF95" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43BD043E8C0F0F942290B09F33269118" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_8E0F8B1DCA2CD0E55D3AB09F3327BF95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:label="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_2FEF5AFE42FB6328EE17B09F33278393" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43BD043E8C0F0F942290B09F33269118" xlink:to="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_2FEF5AFE42FB6328EE17B09F33278393" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8D6270BE6A2D4054670CB09F3327FFA1" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43BD043E8C0F0F942290B09F33269118" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8D6270BE6A2D4054670CB09F3327FFA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_7400EC951C0142AF5B48B09F33274228" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43BD043E8C0F0F942290B09F33269118" xlink:to="loc_us-gaap_Assets_7400EC951C0142AF5B48B09F33274228" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_207606263E5EDC0AE24FB09F332815D3" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43BD043E8C0F0F942290B09F33269118" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_207606263E5EDC0AE24FB09F332815D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_B1DD6372639F84D0D90CB09F33287589" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43BD043E8C0F0F942290B09F33269118" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_B1DD6372639F84D0D90CB09F33287589" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_76F2D410F093A6A8CA33B09F33286A4A" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43BD043E8C0F0F942290B09F33269118" xlink:to="loc_us-gaap_DerivativeLiabilities_76F2D410F093A6A8CA33B09F33286A4A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9903E88AE2FA7BF11F9F6EAB464E544F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E6BDB9FF2A01F07DB7716EAB464B6C12" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9903E88AE2FA7BF11F9F6EAB464E544F" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E6BDB9FF2A01F07DB7716EAB464B6C12" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_003E6CBD65370A2EE6946EACFD27DED9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E6BDB9FF2A01F07DB7716EAB464B6C12" xlink:to="loc_srt_ConsolidatedEntitiesAxis_003E6CBD65370A2EE6946EACFD27DED9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_371724083FCE110136536EACFEE80FE0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_003E6CBD65370A2EE6946EACFD27DED9" xlink:to="loc_srt_ConsolidatedEntitiesDomain_371724083FCE110136536EACFEE80FE0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_371724083FCE110136536EACFEE80FE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_003E6CBD65370A2EE6946EACFD27DED9" xlink:to="loc_srt_ConsolidatedEntitiesDomain_371724083FCE110136536EACFEE80FE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_2BC9A5C9597D78ADFB896EACFDE2AC9E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_371724083FCE110136536EACFEE80FE0" xlink:to="loc_srt_SubsidiariesMember_2BC9A5C9597D78ADFB896EACFDE2AC9E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_BED4609DEDAE4E2EDD0D6EACFBB2FC16" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E6BDB9FF2A01F07DB7716EAB464B6C12" xlink:to="loc_dei_LegalEntityAxis_BED4609DEDAE4E2EDD0D6EACFBB2FC16" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_A7449B62393B07581D9C6EACFDCAE2B8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_BED4609DEDAE4E2EDD0D6EACFBB2FC16" xlink:to="loc_dei_EntityDomain_A7449B62393B07581D9C6EACFDCAE2B8_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_A7449B62393B07581D9C6EACFDCAE2B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_BED4609DEDAE4E2EDD0D6EACFBB2FC16" xlink:to="loc_dei_EntityDomain_A7449B62393B07581D9C6EACFDCAE2B8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnIncMember" xlink:label="loc_pfe_UpjohnIncMember_C4E94FDB38072F2ECC0B6EACFCA194F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_A7449B62393B07581D9C6EACFDCAE2B8" xlink:to="loc_pfe_UpjohnIncMember_C4E94FDB38072F2ECC0B6EACFCA194F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_67212B706D128DE7B74F6EAB464B1F5D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E6BDB9FF2A01F07DB7716EAB464B6C12" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_67212B706D128DE7B74F6EAB464B1F5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2BED64E2771277B901F46EAB464CF60E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_67212B706D128DE7B74F6EAB464B1F5D" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2BED64E2771277B901F46EAB464CF60E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2BED64E2771277B901F46EAB464CF60E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_67212B706D128DE7B74F6EAB464B1F5D" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2BED64E2771277B901F46EAB464CF60E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3C4AD60C881F2AEB60CD6EAB464C8BE9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2BED64E2771277B901F46EAB464CF60E" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_3C4AD60C881F2AEB60CD6EAB464C8BE9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract" xlink:label="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_F716BE1840D54B7D3ACD6EAB464ECB71" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9903E88AE2FA7BF11F9F6EAB464E544F" xlink:to="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_F716BE1840D54B7D3ACD6EAB464ECB71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0B2528D24304456972976EAB464F907E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_F716BE1840D54B7D3ACD6EAB464ECB71" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0B2528D24304456972976EAB464F907E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EquitySecuritiesFVNIRestrictedNoncurrent" xlink:label="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_AAEC6033D0DE0185FE4C6EAB464F72E6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_F716BE1840D54B7D3ACD6EAB464ECB71" xlink:to="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_AAEC6033D0DE0185FE4C6EAB464F72E6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesFootnotesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A53BDA01BC4CF15E82DDB09F32FCA236" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99237E98C02D62F264B0B09F32FAB58D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A53BDA01BC4CF15E82DDB09F32FCA236" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99237E98C02D62F264B0B09F32FAB58D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_EBDD0A07EA4E8209BB99B09F32FADAE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99237E98C02D62F264B0B09F32FAB58D" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_EBDD0A07EA4E8209BB99B09F32FADAE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_A025319F0F29ABD90C8EB09F32FBF698_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_EBDD0A07EA4E8209BB99B09F32FADAE6" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_A025319F0F29ABD90C8EB09F32FBF698_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_33F59BB21BF8842AB6B7B09F32FBE610" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_EBDD0A07EA4E8209BB99B09F32FADAE6" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_33F59BB21BF8842AB6B7B09F32FBE610" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_A025319F0F29ABD90C8EB09F32FBF698" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_33F59BB21BF8842AB6B7B09F32FBE610" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_A025319F0F29ABD90C8EB09F32FBF698" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_61020D3F10543EBE6082B09F32FBFEE5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_A025319F0F29ABD90C8EB09F32FBF698" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_61020D3F10543EBE6082B09F32FBFEE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_82C20E063D6F9F0649ECB09F32FB6056" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_A025319F0F29ABD90C8EB09F32FBF698" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_82C20E063D6F9F0649ECB09F32FB6056" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_101EC425FAFB62753269B09F32FC4DC7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99237E98C02D62F264B0B09F32FAB58D" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_101EC425FAFB62753269B09F32FC4DC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7113C98E3BD9BEE2ED16B09F32FC53C1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_101EC425FAFB62753269B09F32FC4DC7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7113C98E3BD9BEE2ED16B09F32FC53C1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7113C98E3BD9BEE2ED16B09F32FC53C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_101EC425FAFB62753269B09F32FC4DC7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7113C98E3BD9BEE2ED16B09F32FC53C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_E42DD64A8C88B4AD49FDB09F32FCDC88" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7113C98E3BD9BEE2ED16B09F32FC53C1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_E42DD64A8C88B4AD49FDB09F32FCDC88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_56DD2060351A83828E6FB09F32FDA3F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A53BDA01BC4CF15E82DDB09F32FCA236" xlink:to="loc_us-gaap_LongTermDebtFairValue_56DD2060351A83828E6FB09F32FDA3F6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:type="locator" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_CA2B5B8C854A95873A9994761F4CF09B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:to="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_CA2B5B8C854A95873A9994761F4CF09B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_38CCFB635A8D81B992C594761F4CD00B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_CA2B5B8C854A95873A9994761F4CF09B" xlink:to="loc_us-gaap_FinancialInstrumentAxis_38CCFB635A8D81B992C594761F4CD00B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_00FF3560890F02830B2894761F4D0323_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_38CCFB635A8D81B992C594761F4CD00B" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_00FF3560890F02830B2894761F4D0323_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_00FF3560890F02830B2894761F4D0323" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_38CCFB635A8D81B992C594761F4CD00B" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_00FF3560890F02830B2894761F4D0323" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_BE02F085B56FFF030EB394761F4DF691" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_00FF3560890F02830B2894761F4D0323" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_BE02F085B56FFF030EB394761F4DF691" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9AEB7026D69ACE56B16494761F4D94C8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_00FF3560890F02830B2894761F4D0323" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9AEB7026D69ACE56B16494761F4D94C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7102A575EEDD1C168CD394761F4DB00E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_00FF3560890F02830B2894761F4D0323" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7102A575EEDD1C168CD394761F4DB00E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BankTimeDepositsMember" xlink:label="loc_us-gaap_BankTimeDepositsMember_251A0F3B3A689BB4743594761F4D6894" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_00FF3560890F02830B2894761F4D0323" xlink:to="loc_us-gaap_BankTimeDepositsMember_251A0F3B3A689BB4743594761F4D6894" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_A15AAFCBB2C943A17EF194761F4E4DCB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_A15AAFCBB2C943A17EF194761F4E4DCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C8D14F0993497214C47794761F4E1B17" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_A15AAFCBB2C943A17EF194761F4E4DCB" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C8D14F0993497214C47794761F4E1B17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0951A0B54173DA995D8E94761F4ED141" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_A15AAFCBB2C943A17EF194761F4E4DCB" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0951A0B54173DA995D8E94761F4ED141" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_12B80066C35E3C22CF5C94761F4EB945" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_A15AAFCBB2C943A17EF194761F4E4DCB" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_12B80066C35E3C22CF5C94761F4EB945" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9CABC449D39B31F6D9A394761F4F38A6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_A15AAFCBB2C943A17EF194761F4E4DCB" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9CABC449D39B31F6D9A394761F4F38A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_22851EE4F9370F5AD59194761F4F3EEF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_22851EE4F9370F5AD59194761F4F3EEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_513C236D194B7A0120CE94761F4FB538" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_22851EE4F9370F5AD59194761F4F3EEF" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_513C236D194B7A0120CE94761F4FB538" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5D2DDF1307FE3E24083694761F4F0514" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_22851EE4F9370F5AD59194761F4F3EEF" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5D2DDF1307FE3E24083694761F4F0514" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:label="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_D66822D794324A7406FD94761F50E1FB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_22851EE4F9370F5AD59194761F4F3EEF" xlink:to="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_D66822D794324A7406FD94761F50E1FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_CD5834F82D640805A1ED94761F5039FC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_CD5834F82D640805A1ED94761F5039FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:label="loc_us-gaap_HeldToMaturitySecurities_EBCC35C4AC1653C1E04E94761F50D0AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_CD5834F82D640805A1ED94761F5039FC" xlink:to="loc_us-gaap_HeldToMaturitySecurities_EBCC35C4AC1653C1E04E94761F50D0AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_FAAEC7A88E1B0BD55A4E94761F501E23" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_CD5834F82D640805A1ED94761F5039FC" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_FAAEC7A88E1B0BD55A4E94761F501E23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_1795AB6232708D4AB47094761F519548" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_CD5834F82D640805A1ED94761F5039FC" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_1795AB6232708D4AB47094761F519548" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_A51DBD075CEC4FBD43F894761F51943C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_CD5834F82D640805A1ED94761F5039FC" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_A51DBD075CEC4FBD43F894761F51943C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_AAD0FA99EF44D635BACB94761F51E3E6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_AAD0FA99EF44D635BACB94761F51E3E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_C895CF891DC552DE30C194761F518E66" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_AAD0FA99EF44D635BACB94761F51E3E6" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_C895CF891DC552DE30C194761F518E66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_F32B0F48FDD8D6674A7894761F51A252" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_AAD0FA99EF44D635BACB94761F51E3E6" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_F32B0F48FDD8D6674A7894761F51A252" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:label="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_2EA64BCA1E6083D3249194761F5139A6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_AAD0FA99EF44D635BACB94761F51E3E6" xlink:to="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_2EA64BCA1E6083D3249194761F5139A6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtSecuritiesAmortizedCostBasis" xlink:label="loc_pfe_DebtSecuritiesAmortizedCostBasis_2156A1DF20DC07D5B04794761F52C06B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:to="loc_pfe_DebtSecuritiesAmortizedCostBasis_2156A1DF20DC07D5B04794761F52C06B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_C271110664193F20B60094761F5287F4" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_C271110664193F20B60094761F5287F4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_F25681933BEA601401B594761F521BBF" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_F25681933BEA601401B594761F521BBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_080079DBCF14861F742C94761F52B98F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_080079DBCF14861F742C94761F52B98F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" xlink:label="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_251326BA10AB7EC9EF8694761F529E59" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:to="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_251326BA10AB7EC9EF8694761F529E59" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" xlink:label="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_9ED6FA00BE74C4B27C6C94761F5338A0" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:to="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_9ED6FA00BE74C4B27C6C94761F5338A0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" xlink:label="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_72931B06A6D2B52AE25D94761F53E9E8" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:to="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_72931B06A6D2B52AE25D94761F53E9E8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_35410FF488BE88FCB5D0B09F328754BC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_3BEF202520524015A9A4B09F3286FEDA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_35410FF488BE88FCB5D0B09F328754BC" xlink:to="loc_us-gaap_DebtInstrumentTable_3BEF202520524015A9A4B09F3286FEDA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_2B6888A76EBA57574CB3B0A7E1DDE6A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3BEF202520524015A9A4B09F3286FEDA" xlink:to="loc_srt_ConsolidatedEntitiesAxis_2B6888A76EBA57574CB3B0A7E1DDE6A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_D2BC11A99F5C69AE6F9FB0A7E1E257E0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_2B6888A76EBA57574CB3B0A7E1DDE6A9" xlink:to="loc_srt_ConsolidatedEntitiesDomain_D2BC11A99F5C69AE6F9FB0A7E1E257E0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_D2BC11A99F5C69AE6F9FB0A7E1E257E0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_2B6888A76EBA57574CB3B0A7E1DDE6A9" xlink:to="loc_srt_ConsolidatedEntitiesDomain_D2BC11A99F5C69AE6F9FB0A7E1E257E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_FEEE32E6F2ED91986353B0A7E2162B55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_D2BC11A99F5C69AE6F9FB0A7E1E257E0" xlink:to="loc_srt_SubsidiariesMember_FEEE32E6F2ED91986353B0A7E2162B55" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_645FD52B9691F3F62C84B0A7E1A277E7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3BEF202520524015A9A4B09F3286FEDA" xlink:to="loc_dei_LegalEntityAxis_645FD52B9691F3F62C84B0A7E1A277E7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_14E3A11A7D7AA5CAA3F1B0A7E1AA4DAD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_645FD52B9691F3F62C84B0A7E1A277E7" xlink:to="loc_dei_EntityDomain_14E3A11A7D7AA5CAA3F1B0A7E1AA4DAD_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_14E3A11A7D7AA5CAA3F1B0A7E1AA4DAD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_645FD52B9691F3F62C84B0A7E1A277E7" xlink:to="loc_dei_EntityDomain_14E3A11A7D7AA5CAA3F1B0A7E1AA4DAD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnIncMember" xlink:label="loc_pfe_UpjohnIncMember_EE9A40EBAF9A1B4FC73EB0A7E2323674" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_14E3A11A7D7AA5CAA3F1B0A7E1AA4DAD" xlink:to="loc_pfe_UpjohnIncMember_EE9A40EBAF9A1B4FC73EB0A7E2323674" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_99AD09E756DDBBA92003B09F32864E03" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3BEF202520524015A9A4B09F3286FEDA" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_99AD09E756DDBBA92003B09F32864E03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8B2F3425D7A0E426F4D0B09F3287F881_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_99AD09E756DDBBA92003B09F32864E03" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8B2F3425D7A0E426F4D0B09F3287F881_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8B2F3425D7A0E426F4D0B09F3287F881" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_99AD09E756DDBBA92003B09F32864E03" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8B2F3425D7A0E426F4D0B09F3287F881" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_F9B051A223449E9B6708B09F3287551D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8B2F3425D7A0E426F4D0B09F3287F881" xlink:to="loc_us-gaap_UnsecuredDebtMember_F9B051A223449E9B6708B09F3287551D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_9D5869B05A31218D7980B09F3287DA5D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_35410FF488BE88FCB5D0B09F328754BC" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_9D5869B05A31218D7980B09F3287DA5D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_CE2CF810439E57969D1FB09F32884F2C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_35410FF488BE88FCB5D0B09F328754BC" xlink:to="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_CE2CF810439E57969D1FB09F32884F2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_B8FEDB2C1399189CC9C1B09F3288FC4B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_35410FF488BE88FCB5D0B09F328754BC" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_B8FEDB2C1399189CC9C1B09F3288FC4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaap_OtherLongTermDebt_A911E18CD3F8A66DA221B09F32889456" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_35410FF488BE88FCB5D0B09F328754BC" xlink:to="loc_us-gaap_OtherLongTermDebt_A911E18CD3F8A66DA221B09F32889456" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_A4DAEAD4D19FBBA76AC3B09F328847D4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_35410FF488BE88FCB5D0B09F328754BC" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_A4DAEAD4D19FBBA76AC3B09F328847D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_DE6893F339C088789C50B09F32883157" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_35410FF488BE88FCB5D0B09F328754BC" xlink:to="loc_us-gaap_LongTermDebtCurrent_DE6893F339C088789C50B09F32883157" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1F0E893B2391770404FDB0A7E16FE836" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_35410FF488BE88FCB5D0B09F328754BC" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1F0E893B2391770404FDB0A7E16FE836" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_C6C80A985E3879C41D15628A0BC5DE6E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_5162404E95591A48EFA5628A0BC4DCFA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C6C80A985E3879C41D15628A0BC5DE6E" xlink:to="loc_us-gaap_DebtInstrumentTable_5162404E95591A48EFA5628A0BC4DCFA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1C58069A23CA822EB2B5628A0BC48C91" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5162404E95591A48EFA5628A0BC4DCFA" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1C58069A23CA822EB2B5628A0BC48C91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6B137DF186E1ACD9EE5C628A0BC4F970_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1C58069A23CA822EB2B5628A0BC48C91" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6B137DF186E1ACD9EE5C628A0BC4F970_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6B137DF186E1ACD9EE5C628A0BC4F970" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1C58069A23CA822EB2B5628A0BC48C91" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6B137DF186E1ACD9EE5C628A0BC4F970" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_371C49AF9BB357ECA725628A0BC4C21A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6B137DF186E1ACD9EE5C628A0BC4F970" xlink:to="loc_us-gaap_UnsecuredDebtMember_371C49AF9BB357ECA725628A0BC4C21A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_043E896EEEFA1049CE73628A0BC5C537" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5162404E95591A48EFA5628A0BC4DCFA" xlink:to="loc_us-gaap_DebtInstrumentAxis_043E896EEEFA1049CE73628A0BC5C537" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3D14954885623AC2B1E6628A0BC578F4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_043E896EEEFA1049CE73628A0BC5C537" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3D14954885623AC2B1E6628A0BC578F4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3D14954885623AC2B1E6628A0BC578F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_043E896EEEFA1049CE73628A0BC5C537" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3D14954885623AC2B1E6628A0BC578F4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorNotesDue2047Member" xlink:label="loc_pfe_SeniorNotesDue2047Member_3206AC583E5E687169BF628A0BC5EF25" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3D14954885623AC2B1E6628A0BC578F4" xlink:to="loc_pfe_SeniorNotesDue2047Member_3206AC583E5E687169BF628A0BC5EF25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_B019F17FE2A3FAB3B5D7628A0BC5565F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C6C80A985E3879C41D15628A0BC5DE6E" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_B019F17FE2A3FAB3B5D7628A0BC5565F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ADBE9C28E5E8906527F0B7017B67499B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_B8C1A0C8B7243A312A8BB7017B61FBE7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ADBE9C28E5E8906527F0B7017B67499B" xlink:to="loc_us-gaap_DebtInstrumentTable_B8C1A0C8B7243A312A8BB7017B61FBE7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4CAC97DAD32884823C08B7017B61D6DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_B8C1A0C8B7243A312A8BB7017B61FBE7" xlink:to="loc_dei_LegalEntityAxis_4CAC97DAD32884823C08B7017B61D6DB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_11AB6F996945EBABA34AB7017B62E8F4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_4CAC97DAD32884823C08B7017B61D6DB" xlink:to="loc_dei_EntityDomain_11AB6F996945EBABA34AB7017B62E8F4_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_11AB6F996945EBABA34AB7017B62E8F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_4CAC97DAD32884823C08B7017B61D6DB" xlink:to="loc_dei_EntityDomain_11AB6F996945EBABA34AB7017B62E8F4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnIncMember" xlink:label="loc_pfe_UpjohnIncMember_08159DF26464FA2F6D8AB7017B6274E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_11AB6F996945EBABA34AB7017B62E8F4" xlink:to="loc_pfe_UpjohnIncMember_08159DF26464FA2F6D8AB7017B6274E5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnFinanceB.V.Member" xlink:label="loc_pfe_UpjohnFinanceB.V.Member_F33F9E5B7263C42B6C48B7017B6274E7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_11AB6F996945EBABA34AB7017B62E8F4" xlink:to="loc_pfe_UpjohnFinanceB.V.Member_F33F9E5B7263C42B6C48B7017B6274E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_6C523C55848239DB4AB1B7017B623D4D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_B8C1A0C8B7243A312A8BB7017B61FBE7" xlink:to="loc_srt_ConsolidatedEntitiesAxis_6C523C55848239DB4AB1B7017B623D4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_2B25EE9B0434F6105F10B7017B637727_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6C523C55848239DB4AB1B7017B623D4D" xlink:to="loc_srt_ConsolidatedEntitiesDomain_2B25EE9B0434F6105F10B7017B637727_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_2B25EE9B0434F6105F10B7017B637727" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6C523C55848239DB4AB1B7017B623D4D" xlink:to="loc_srt_ConsolidatedEntitiesDomain_2B25EE9B0434F6105F10B7017B637727" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_AF87E36E0CC30EBC8C65B7017B638D1E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_2B25EE9B0434F6105F10B7017B637727" xlink:to="loc_us-gaap_ParentMember_AF87E36E0CC30EBC8C65B7017B638D1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_03A6EF13736485918A57B7017B631B38" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_2B25EE9B0434F6105F10B7017B637727" xlink:to="loc_srt_SubsidiariesMember_03A6EF13736485918A57B7017B631B38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8490681A4C4E2A4C91D5B7017B639CE1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_B8C1A0C8B7243A312A8BB7017B61FBE7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8490681A4C4E2A4C91D5B7017B639CE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_69B81AEEC6A9DC37676DB7017B63EBA4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8490681A4C4E2A4C91D5B7017B639CE1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_69B81AEEC6A9DC37676DB7017B63EBA4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_69B81AEEC6A9DC37676DB7017B63EBA4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8490681A4C4E2A4C91D5B7017B639CE1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_69B81AEEC6A9DC37676DB7017B63EBA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_AEA7189008A36D701988B7017B64F854" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_69B81AEEC6A9DC37676DB7017B63EBA4" xlink:to="loc_us-gaap_SeniorNotesMember_AEA7189008A36D701988B7017B64F854" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_5848E110D3CBE9F0AF6CB7017B644F3A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_B8C1A0C8B7243A312A8BB7017B61FBE7" xlink:to="loc_us-gaap_DebtInstrumentAxis_5848E110D3CBE9F0AF6CB7017B644F3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5848E110D3CBE9F0AF6CB7017B644F3A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5848E110D3CBE9F0AF6CB7017B644F3A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member" xlink:label="loc_pfe_SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member_250225BA72C26BFB4390B7017B64C926" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member_250225BA72C26BFB4390B7017B64C926" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member" xlink:label="loc_pfe_SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member_415142CBC1650E8759EEB7017B6512CB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member_415142CBC1650E8759EEB7017B6512CB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member" xlink:label="loc_pfe_SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member_354F6B2C70C868B1C04BB7017B6564AF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member_354F6B2C70C868B1C04BB7017B6564AF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member" xlink:label="loc_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member_203DF6DB98C258CB3086B7017B6564BD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member_203DF6DB98C258CB3086B7017B6564BD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member" xlink:label="loc_pfe_SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member_A63303D9B2D1E05405B5B7017B65FF7C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member_A63303D9B2D1E05405B5B7017B65FF7C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member" xlink:label="loc_pfe_SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member_88778429BCB496003CE7B7017B65D57B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member_88778429BCB496003CE7B7017B65D57B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member" xlink:label="loc_pfe_SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member_B62E92E4A323F80BE944B7017B66E9D4" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member_B62E92E4A323F80BE944B7017B66E9D4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member" xlink:label="loc_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member_D193563150E51D7D0D09B7017B66720E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member_D193563150E51D7D0D09B7017B66720E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member" xlink:label="loc_pfe_SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member_6A567EE8AF56C154AF0FB7017B66D533" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member_6A567EE8AF56C154AF0FB7017B66D533" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member" xlink:label="loc_pfe_SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member_92727FA06579C6532A4CB7017B66A3C3" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member_92727FA06579C6532A4CB7017B66A3C3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member" xlink:label="loc_pfe_SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member_53CEC6E7126A650309DEB7017B66A93B" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member_53CEC6E7126A650309DEB7017B66A93B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member" xlink:label="loc_pfe_SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member_0D5F463EB9E20E3AE362B7017B66254E" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member_0D5F463EB9E20E3AE362B7017B66254E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member" xlink:label="loc_pfe_SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member_B1F13BF7D4EE2131B4CFB7017B67D8FA" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member_B1F13BF7D4EE2131B4CFB7017B67D8FA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member" xlink:label="loc_pfe_SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member_E9868B10B64D1B822CD8B7017B677446" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member_E9868B10B64D1B822CD8B7017B677446" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member" xlink:label="loc_pfe_SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member_70393EF7027E2BC32F10B7017B67E43C" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member_70393EF7027E2BC32F10B7017B67E43C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LongTermDebtIssuedFirstQuarter2020Member" xlink:label="loc_pfe_LongTermDebtIssuedFirstQuarter2020Member_4AFC00BF85F0A4EA7EB8B704A56CDE53" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_LongTermDebtIssuedFirstQuarter2020Member_4AFC00BF85F0A4EA7EB8B704A56CDE53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_BFB50DDE9B62E6F27576B7017B67B715" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ADBE9C28E5E8906527F0B7017B67499B" xlink:to="loc_us-gaap_LongTermDebt_BFB50DDE9B62E6F27576B7017B67B715" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1180CA6602917BBD6AC9B7017B67D023" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ADBE9C28E5E8906527F0B7017B67499B" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1180CA6602917BBD6AC9B7017B67D023" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2217456977EDA6FDFE57B7017B6865BF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ADBE9C28E5E8906527F0B7017B67499B" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2217456977EDA6FDFE57B7017B6865BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_E614C4589E63FB3246FBB7017B6836C1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ADBE9C28E5E8906527F0B7017B67499B" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_E614C4589E63FB3246FBB7017B6836C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_36A6AD483646D70E170EB7017B68A55B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ADBE9C28E5E8906527F0B7017B67499B" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_36A6AD483646D70E170EB7017B68A55B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_319CC470316AD1A31A0B6EB366D62DBE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_CE053CE7EA167678F37B6EB366C9A1A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_319CC470316AD1A31A0B6EB366D62DBE" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_CE053CE7EA167678F37B6EB366C9A1A9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_7CE63E8D2E15882366826EB18B16AEE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_CE053CE7EA167678F37B6EB366C9A1A9" xlink:to="loc_srt_ConsolidatedEntitiesAxis_7CE63E8D2E15882366826EB18B16AEE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_2B2F63008B7F14F5F13B6EB18C0EE3BC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_7CE63E8D2E15882366826EB18B16AEE6" xlink:to="loc_srt_ConsolidatedEntitiesDomain_2B2F63008B7F14F5F13B6EB18C0EE3BC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_2B2F63008B7F14F5F13B6EB18C0EE3BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_7CE63E8D2E15882366826EB18B16AEE6" xlink:to="loc_srt_ConsolidatedEntitiesDomain_2B2F63008B7F14F5F13B6EB18C0EE3BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_3AF547AA1C2E781BA19C6EB18B44B7AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_2B2F63008B7F14F5F13B6EB18C0EE3BC" xlink:to="loc_srt_SubsidiariesMember_3AF547AA1C2E781BA19C6EB18B44B7AB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_69E160EFC0CF7CA78A7A6EB18AFF348A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_CE053CE7EA167678F37B6EB366C9A1A9" xlink:to="loc_dei_LegalEntityAxis_69E160EFC0CF7CA78A7A6EB18AFF348A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6EAC63A982D8ECD893D46EB18BF70197_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_69E160EFC0CF7CA78A7A6EB18AFF348A" xlink:to="loc_dei_EntityDomain_6EAC63A982D8ECD893D46EB18BF70197_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6EAC63A982D8ECD893D46EB18BF70197" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_69E160EFC0CF7CA78A7A6EB18AFF348A" xlink:to="loc_dei_EntityDomain_6EAC63A982D8ECD893D46EB18BF70197" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnIncMember" xlink:label="loc_pfe_UpjohnIncMember_F22990AFED93063985CC6EB18B2CE70F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6EAC63A982D8ECD893D46EB18BF70197" xlink:to="loc_pfe_UpjohnIncMember_F22990AFED93063985CC6EB18B2CE70F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9ABC36454B959FB79B726EB18AE87576" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_319CC470316AD1A31A0B6EB366D62DBE" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9ABC36454B959FB79B726EB18AE87576" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_3C162757443FDDBD43AD78F25290AD64" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_3A2B15DABAC480709BF178F2528E677D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_3C162757443FDDBD43AD78F25290AD64" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_3A2B15DABAC480709BF178F2528E677D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7311478CAA6D49EDDFCF78F2528ECC31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_3A2B15DABAC480709BF178F2528E677D" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7311478CAA6D49EDDFCF78F2528ECC31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_862DD9009717461EE6A678F2528F5FE3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7311478CAA6D49EDDFCF78F2528ECC31" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_862DD9009717461EE6A678F2528F5FE3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_862DD9009717461EE6A678F2528F5FE3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7311478CAA6D49EDDFCF78F2528ECC31" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_862DD9009717461EE6A678F2528F5FE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_C357E3F607D039FC50EA78F2528FD024" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_862DD9009717461EE6A678F2528F5FE3" xlink:to="loc_us-gaap_TradeNamesMember_C357E3F607D039FC50EA78F2528FD024" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_03ED8CCC53ECEA08E24578F2528FBB15" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_862DD9009717461EE6A678F2528F5FE3" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_03ED8CCC53ECEA08E24578F2528FBB15" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LicensingAgreementsAndOtherMember" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_AB578DDC0A301B88BAA778F252903A55" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_862DD9009717461EE6A678F2528F5FE3" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_AB578DDC0A301B88BAA778F252903A55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_A2077F97A8A46CA3305578F252900E6B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_3C162757443FDDBD43AD78F25290AD64" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_A2077F97A8A46CA3305578F252900E6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_A351D5287E61628E1A8878F2529151A4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2A1A15D136417CC19B4778F25290CCD4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_A351D5287E61628E1A8878F2529151A4" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2A1A15D136417CC19B4778F25290CCD4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9049909EF0567C4AC8E978F25290E24A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2A1A15D136417CC19B4778F25290CCD4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9049909EF0567C4AC8E978F25290E24A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_69C6CC8D741C64C348AE78F25290182C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9049909EF0567C4AC8E978F25290E24A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_69C6CC8D741C64C348AE78F25290182C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_69C6CC8D741C64C348AE78F25290182C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9049909EF0567C4AC8E978F25290E24A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_69C6CC8D741C64C348AE78F25290182C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_A744F287FBF858525A0178F2529167C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_69C6CC8D741C64C348AE78F25290182C" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_A744F287FBF858525A0178F2529167C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_3FE2FB5FA66D016D141278F25291E52C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_69C6CC8D741C64C348AE78F25290182C" xlink:to="loc_us-gaap_TradeNamesMember_3FE2FB5FA66D016D141278F25291E52C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LicensingAgreementsAndOtherMember" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_D8079D372843A061B7AD78F25291995F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_69C6CC8D741C64C348AE78F25290182C" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_D8079D372843A061B7AD78F25291995F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8B0E5C69FFB4DB7F691C78F252925A66" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_A351D5287E61628E1A8878F2529151A4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8B0E5C69FFB4DB7F691C78F252925A66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_41C6073FF631F5F4CA3E78F252923654" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_A351D5287E61628E1A8878F2529151A4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_41C6073FF631F5F4CA3E78F252923654" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_549BF9C3D0811DC8D76E78F25292D7AA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_A351D5287E61628E1A8878F2529151A4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_549BF9C3D0811DC8D76E78F25292D7AA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B6E7BE6C0D8351124AF792D1CA5815B2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4A30979B3116BE9976BE92D1CA5482AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B6E7BE6C0D8351124AF792D1CA5815B2" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4A30979B3116BE9976BE92D1CA5482AC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0EF6DA3D7AC7481E1D8192D1CA54F421" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4A30979B3116BE9976BE92D1CA5482AC" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0EF6DA3D7AC7481E1D8192D1CA54F421" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_89F1A7302A30951866CF92D1CA5547EB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0EF6DA3D7AC7481E1D8192D1CA54F421" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_89F1A7302A30951866CF92D1CA5547EB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_89F1A7302A30951866CF92D1CA5547EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0EF6DA3D7AC7481E1D8192D1CA54F421" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_89F1A7302A30951866CF92D1CA5547EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_6EEA9FA8374582689B7D92D1CA558133" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_89F1A7302A30951866CF92D1CA5547EB" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_6EEA9FA8374582689B7D92D1CA558133" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LicensingAgreementsAndOtherMember" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_34C9B4A5EC29300DA7C492D1CA5578BC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_89F1A7302A30951866CF92D1CA5547EB" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_34C9B4A5EC29300DA7C492D1CA5578BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_22BB391C01B17F4F151692D1CA553C8A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4A30979B3116BE9976BE92D1CA5482AC" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_22BB391C01B17F4F151692D1CA553C8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_713F2C08F3B4D34C3A5192D1CA56ECDB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_22BB391C01B17F4F151692D1CA553C8A" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_713F2C08F3B4D34C3A5192D1CA56ECDB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_713F2C08F3B4D34C3A5192D1CA56ECDB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_22BB391C01B17F4F151692D1CA553C8A" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_713F2C08F3B4D34C3A5192D1CA56ECDB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ArrayMember" xlink:label="loc_pfe_ArrayMember_86B1D87FA2ABC95F022392D1CA56F3C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_713F2C08F3B4D34C3A5192D1CA56ECDB" xlink:to="loc_pfe_ArrayMember_86B1D87FA2ABC95F022392D1CA56F3C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_B30D6B18C617C5B24CA692D1CA56FE5D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4A30979B3116BE9976BE92D1CA5482AC" xlink:to="loc_srt_ProductOrServiceAxis_B30D6B18C617C5B24CA692D1CA56FE5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_52588DC5A700EF2E47B392D1CA56D5F6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_B30D6B18C617C5B24CA692D1CA56FE5D" xlink:to="loc_srt_ProductsAndServicesDomain_52588DC5A700EF2E47B392D1CA56D5F6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_52588DC5A700EF2E47B392D1CA56D5F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_B30D6B18C617C5B24CA692D1CA56FE5D" xlink:to="loc_srt_ProductsAndServicesDomain_52588DC5A700EF2E47B392D1CA56D5F6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BraftoviMember" xlink:label="loc_pfe_BraftoviMember_1C3649674142955437B692D1CA575406" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_52588DC5A700EF2E47B392D1CA56D5F6" xlink:to="loc_pfe_BraftoviMember_1C3649674142955437B692D1CA575406" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0071F2D5E1CA39985A0C92D1CA578FA0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4A30979B3116BE9976BE92D1CA5482AC" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0071F2D5E1CA39985A0C92D1CA578FA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5584176280CC36233FF92D1CA575EEE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0071F2D5E1CA39985A0C92D1CA578FA0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5584176280CC36233FF92D1CA575EEE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5584176280CC36233FF92D1CA575EEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0071F2D5E1CA39985A0C92D1CA578FA0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5584176280CC36233FF92D1CA575EEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_DA0A3F34231442BD935392D1CA58958D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5584176280CC36233FF92D1CA575EEE" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_DA0A3F34231442BD935392D1CA58958D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_38BD350D47E350F4DCB092D1CA58F1EB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5584176280CC36233FF92D1CA575EEE" xlink:to="loc_us-gaap_LicensingAgreementsMember_38BD350D47E350F4DCB092D1CA58F1EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_7B887AEC61B06260D0D792D1CA585718" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B6E7BE6C0D8351124AF792D1CA5815B2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_7B887AEC61B06260D0D792D1CA585718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_DB4B648042AFCC5B721092D1CA5948BE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B6E7BE6C0D8351124AF792D1CA5815B2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_DB4B648042AFCC5B721092D1CA5948BE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_D010520126E6BCB3FC7278F1DC9D1C33" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4917C344277037F7E7FC78F1DC988BFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_D010520126E6BCB3FC7278F1DC9D1C33" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4917C344277037F7E7FC78F1DC988BFF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsAxis" xlink:label="loc_us-gaap_SubsegmentsAxis_A911B8B82546379BDC7F78F1DC99E508" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4917C344277037F7E7FC78F1DC988BFF" xlink:to="loc_us-gaap_SubsegmentsAxis_A911B8B82546379BDC7F78F1DC99E508" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_D85242373447D810C43778F1DC9AE221_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_A911B8B82546379BDC7F78F1DC99E508" xlink:to="loc_us-gaap_SubsegmentsDomain_D85242373447D810C43778F1DC9AE221_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_D85242373447D810C43778F1DC9AE221" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_A911B8B82546379BDC7F78F1DC99E508" xlink:to="loc_us-gaap_SubsegmentsDomain_D85242373447D810C43778F1DC9AE221" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember" xlink:label="loc_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_DAC85EDBC891AA254CF578F1DC9A2203" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_D85242373447D810C43778F1DC9AE221" xlink:to="loc_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_DAC85EDBC891AA254CF578F1DC9A2203" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_E1AD47F560F1F9C6EB3F78F1DC9BB147" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4917C344277037F7E7FC78F1DC988BFF" xlink:to="loc_srt_ConsolidationItemsAxis_E1AD47F560F1F9C6EB3F78F1DC9BB147" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_9034C7FF1C65AE65A46278F1DC9B0982_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_E1AD47F560F1F9C6EB3F78F1DC9BB147" xlink:to="loc_srt_ConsolidationItemsDomain_9034C7FF1C65AE65A46278F1DC9B0982_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_9034C7FF1C65AE65A46278F1DC9B0982" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_E1AD47F560F1F9C6EB3F78F1DC9BB147" xlink:to="loc_srt_ConsolidationItemsDomain_9034C7FF1C65AE65A46278F1DC9B0982" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_0EE7E8AA39432DA3B7D278F1DC9BB61F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_9034C7FF1C65AE65A46278F1DC9B0982" xlink:to="loc_us-gaap_OperatingSegmentsMember_0EE7E8AA39432DA3B7D278F1DC9BB61F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_14B28A8453007AB4FBA078F1DC9B10EB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_9034C7FF1C65AE65A46278F1DC9B0982" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_14B28A8453007AB4FBA078F1DC9B10EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_B8ED024FED11B483A87578F1DC9B2421" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4917C344277037F7E7FC78F1DC988BFF" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_B8ED024FED11B483A87578F1DC9B2421" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4EF7A1407BD7D5092AAA78F1DC9C16E3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_B8ED024FED11B483A87578F1DC9B2421" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4EF7A1407BD7D5092AAA78F1DC9C16E3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4EF7A1407BD7D5092AAA78F1DC9C16E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_B8ED024FED11B483A87578F1DC9B2421" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4EF7A1407BD7D5092AAA78F1DC9C16E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_4134C3888F46ED41714178F1DC9C1AD4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4EF7A1407BD7D5092AAA78F1DC9C16E3" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_4134C3888F46ED41714178F1DC9C1AD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_65262EA26AD8124EA00E78F1DC9C4D02" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4EF7A1407BD7D5092AAA78F1DC9C16E3" xlink:to="loc_us-gaap_TradeNamesMember_65262EA26AD8124EA00E78F1DC9C4D02" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LicensingAgreementsAndOtherMember" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_493C80EF7E2B2A8EFA2F78F1DC9C4760" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4EF7A1407BD7D5092AAA78F1DC9C16E3" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_493C80EF7E2B2A8EFA2F78F1DC9C4760" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_D437D0C9913C89F869B578F1DC9D30F0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4917C344277037F7E7FC78F1DC988BFF" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_D437D0C9913C89F869B578F1DC9D30F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_82C4A4C7760877B8DBD578F1DC9D18B9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_D437D0C9913C89F869B578F1DC9D30F0" xlink:to="loc_us-gaap_SegmentDomain_82C4A4C7760877B8DBD578F1DC9D18B9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_82C4A4C7760877B8DBD578F1DC9D18B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_D437D0C9913C89F869B578F1DC9D30F0" xlink:to="loc_us-gaap_SegmentDomain_82C4A4C7760877B8DBD578F1DC9D18B9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_81EFE2EDE968D756E91C78F1DC9D9407" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_82C4A4C7760877B8DBD578F1DC9D18B9" xlink:to="loc_pfe_BiopharmaSegmentMember_81EFE2EDE968D756E91C78F1DC9D9407" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnSegmentMember" xlink:label="loc_pfe_UpjohnSegmentMember_BD17881AAFA661D59AA878F1DC9D5612" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_82C4A4C7760877B8DBD578F1DC9D18B9" xlink:to="loc_pfe_UpjohnSegmentMember_BD17881AAFA661D59AA878F1DC9D5612" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet" xlink:label="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_BDC6805348A73DA5BDF678F1DC9E1283" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_D010520126E6BCB3FC7278F1DC9D1C33" xlink:to="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_BDC6805348A73DA5BDF678F1DC9E1283" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_27AA658B4FEC9768120578F90C7E8AEF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_23F8A695101D1D2C2BBE78F90C7CFC9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_27AA658B4FEC9768120578F90C7E8AEF" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_23F8A695101D1D2C2BBE78F90C7CFC9A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_C52BD041B7C5A902282B78F90C7CD37D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_23F8A695101D1D2C2BBE78F90C7CFC9A" xlink:to="loc_srt_ConsolidationItemsAxis_C52BD041B7C5A902282B78F90C7CD37D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_7D34BA9E1551480D839678F90C7C9D89_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_C52BD041B7C5A902282B78F90C7CD37D" xlink:to="loc_srt_ConsolidationItemsDomain_7D34BA9E1551480D839678F90C7C9D89_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_7D34BA9E1551480D839678F90C7C9D89" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_C52BD041B7C5A902282B78F90C7CD37D" xlink:to="loc_srt_ConsolidationItemsDomain_7D34BA9E1551480D839678F90C7C9D89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_50A2F305257CFF17537578F90C7DFFC0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_7D34BA9E1551480D839678F90C7C9D89" xlink:to="loc_us-gaap_OperatingSegmentsMember_50A2F305257CFF17537578F90C7DFFC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_96B3A9BD7C3953BA861A78F90C7D55E7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_23F8A695101D1D2C2BBE78F90C7CFC9A" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_96B3A9BD7C3953BA861A78F90C7D55E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_91B8776BB1A6DD8C161C78F90C7D70D0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_96B3A9BD7C3953BA861A78F90C7D55E7" xlink:to="loc_us-gaap_SegmentDomain_91B8776BB1A6DD8C161C78F90C7D70D0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_91B8776BB1A6DD8C161C78F90C7D70D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_96B3A9BD7C3953BA861A78F90C7D55E7" xlink:to="loc_us-gaap_SegmentDomain_91B8776BB1A6DD8C161C78F90C7D70D0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_D1609CDF669C94BF771378F90C7D2BBC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_91B8776BB1A6DD8C161C78F90C7D70D0" xlink:to="loc_pfe_BiopharmaSegmentMember_D1609CDF669C94BF771378F90C7D2BBC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnSegmentMember" xlink:label="loc_pfe_UpjohnSegmentMember_04A0C18EF7754DD3E0BD78F90C7DA156" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_91B8776BB1A6DD8C161C78F90C7D70D0" xlink:to="loc_pfe_UpjohnSegmentMember_04A0C18EF7754DD3E0BD78F90C7DA156" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_186F27DCA580856D5BB478F90C7EEC7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_27AA658B4FEC9768120578F90C7E8AEF" xlink:to="loc_us-gaap_GoodwillRollForward_186F27DCA580856D5BB478F90C7EEC7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_68F0DD63C35F063A3AC178F90C7EC312" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_186F27DCA580856D5BB478F90C7EEC7C" xlink:to="loc_us-gaap_Goodwill_68F0DD63C35F063A3AC178F90C7EC312" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_59BECFB52CE76FF0F77C78F90C7E38DA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_186F27DCA580856D5BB478F90C7EEC7C" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_59BECFB52CE76FF0F77C78F90C7E38DA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_549F7C83BE74098A31B178F9109E4D68" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_4F802C4A5D65DA2520BB78F9109AED02" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_549F7C83BE74098A31B178F9109E4D68" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_4F802C4A5D65DA2520BB78F9109AED02" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsAxis" xlink:label="loc_us-gaap_SubsegmentsAxis_C70A07A40BD186F75F7578F9109BEF78" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_4F802C4A5D65DA2520BB78F9109AED02" xlink:to="loc_us-gaap_SubsegmentsAxis_C70A07A40BD186F75F7578F9109BEF78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_E8CE456DBDD93A01103778F9109B42D9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_C70A07A40BD186F75F7578F9109BEF78" xlink:to="loc_us-gaap_SubsegmentsDomain_E8CE456DBDD93A01103778F9109B42D9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_E8CE456DBDD93A01103778F9109B42D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_C70A07A40BD186F75F7578F9109BEF78" xlink:to="loc_us-gaap_SubsegmentsDomain_E8CE456DBDD93A01103778F9109B42D9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember" xlink:label="loc_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_14FE3BD4400C70A8341D78F9109B2DCE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_E8CE456DBDD93A01103778F9109B42D9" xlink:to="loc_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_14FE3BD4400C70A8341D78F9109B2DCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3B25277619064777F12978F9109CAD4E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_4F802C4A5D65DA2520BB78F9109AED02" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3B25277619064777F12978F9109CAD4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_040A670B0FA7A828253778F9109C120A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3B25277619064777F12978F9109CAD4E" xlink:to="loc_us-gaap_SegmentDomain_040A670B0FA7A828253778F9109C120A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_040A670B0FA7A828253778F9109C120A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3B25277619064777F12978F9109CAD4E" xlink:to="loc_us-gaap_SegmentDomain_040A670B0FA7A828253778F9109C120A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_5FE3A87A2B0CE355B97078F9109CEA46" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_040A670B0FA7A828253778F9109C120A" xlink:to="loc_pfe_BiopharmaSegmentMember_5FE3A87A2B0CE355B97078F9109CEA46" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnSegmentMember" xlink:label="loc_pfe_UpjohnSegmentMember_86FC308C864873C08DC778F9109C1AED" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_040A670B0FA7A828253778F9109C120A" xlink:to="loc_pfe_UpjohnSegmentMember_86FC308C864873C08DC778F9109C1AED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_721563B036A921EE042978F9109CEA23" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_4F802C4A5D65DA2520BB78F9109AED02" xlink:to="loc_srt_ConsolidationItemsAxis_721563B036A921EE042978F9109CEA23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_9C7FAEAB81911C91C7DF78F9109D4B40_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_721563B036A921EE042978F9109CEA23" xlink:to="loc_srt_ConsolidationItemsDomain_9C7FAEAB81911C91C7DF78F9109D4B40_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_9C7FAEAB81911C91C7DF78F9109D4B40" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_721563B036A921EE042978F9109CEA23" xlink:to="loc_srt_ConsolidationItemsDomain_9C7FAEAB81911C91C7DF78F9109D4B40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_E7CC2EE6F27EBE265C9478F9109D2568" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_9C7FAEAB81911C91C7DF78F9109D4B40" xlink:to="loc_us-gaap_OperatingSegmentsMember_E7CC2EE6F27EBE265C9478F9109D2568" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_73E75897B96726AE65F078F9109DE762" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_9C7FAEAB81911C91C7DF78F9109D4B40" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_73E75897B96726AE65F078F9109DE762" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_826D6C5CC0C1473E97BC78F9109DDF1A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_4F802C4A5D65DA2520BB78F9109AED02" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_826D6C5CC0C1473E97BC78F9109DDF1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_E649E6133BFA8248A19F78F9109E91F5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_826D6C5CC0C1473E97BC78F9109DDF1A" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_E649E6133BFA8248A19F78F9109E91F5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_E649E6133BFA8248A19F78F9109E91F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_826D6C5CC0C1473E97BC78F9109DDF1A" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_E649E6133BFA8248A19F78F9109E91F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_07732DAB0A10193F66AE78F9109E2E00" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_E649E6133BFA8248A19F78F9109E91F5" xlink:to="loc_us-gaap_TradeNamesMember_07732DAB0A10193F66AE78F9109E2E00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_468F4C6AF6D2B10C70ED78F9109E456C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_E649E6133BFA8248A19F78F9109E91F5" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_468F4C6AF6D2B10C70ED78F9109E456C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LicensingAgreementsAndOtherMember" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_F9C9643DCD8DCE74E95F78F9109E9A5E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_E649E6133BFA8248A19F78F9109E91F5" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_F9C9643DCD8DCE74E95F78F9109E9A5E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet" xlink:label="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_1F36AE3B45A180AB169578F9109F20C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_549F7C83BE74098A31B178F9109E4D68" xlink:to="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_1F36AE3B45A180AB169578F9109F20C4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_831948143A0CD153A61778F90EA491C5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF1BCEB60C540086458A78F90EA21CFC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_831948143A0CD153A61778F90EA491C5" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF1BCEB60C540086458A78F90EA21CFC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_02DF3EA7EE6AF5C0931B78F90EA315A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF1BCEB60C540086458A78F90EA21CFC" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_02DF3EA7EE6AF5C0931B78F90EA315A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7617A834C1072E6F7CAB78F90EA3E631_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_02DF3EA7EE6AF5C0931B78F90EA315A4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7617A834C1072E6F7CAB78F90EA3E631_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7617A834C1072E6F7CAB78F90EA3E631" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_02DF3EA7EE6AF5C0931B78F90EA315A4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7617A834C1072E6F7CAB78F90EA3E631" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMember_81FA9469C852986949FF78F90EA376A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7617A834C1072E6F7CAB78F90EA3E631" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMember_81FA9469C852986949FF78F90EA376A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3B0D34C761DB304CB51678F90EA44EC8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_831948143A0CD153A61778F90EA491C5" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_3B0D34C761DB304CB51678F90EA44EC8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/Inventories" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/InventoriesDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/InventoriesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNet" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_2CE131CF4595136F1EC678FDDF9C8167" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_2CE131CF4595136F1EC678FDDF9C8167" xlink:to="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_52F6F272535F75A2AC1278FDDF8D06EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_52F6F272535F75A2AC1278FDDF8D06EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E23208D70F7ED51FAFE378FDDF8DF1BD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_52F6F272535F75A2AC1278FDDF8D06EF" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E23208D70F7ED51FAFE378FDDF8DF1BD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E23208D70F7ED51FAFE378FDDF8DF1BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_52F6F272535F75A2AC1278FDDF8D06EF" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E23208D70F7ED51FAFE378FDDF8DF1BD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ViiVMember" xlink:label="loc_pfe_ViiVMember_6C21C3E291F9DB235A4378FDDF8D999B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E23208D70F7ED51FAFE378FDDF8DF1BD" xlink:to="loc_pfe_ViiVMember_6C21C3E291F9DB235A4378FDDF8D999B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_EC9AC499E434ADBE933378FDDF8D57D5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:to="loc_srt_ProductOrServiceAxis_EC9AC499E434ADBE933378FDDF8D57D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_B22A1C94F26CD10CFF0478FDDF8E069F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_EC9AC499E434ADBE933378FDDF8D57D5" xlink:to="loc_srt_ProductsAndServicesDomain_B22A1C94F26CD10CFF0478FDDF8E069F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_B22A1C94F26CD10CFF0478FDDF8E069F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_EC9AC499E434ADBE933378FDDF8D57D5" xlink:to="loc_srt_ProductsAndServicesDomain_B22A1C94F26CD10CFF0478FDDF8E069F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_GeneTherapiesMember" xlink:label="loc_pfe_GeneTherapiesMember_F081BED22814113DE0A878FDDF8E48B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B22A1C94F26CD10CFF0478FDDF8E069F" xlink:to="loc_pfe_GeneTherapiesMember_F081BED22814113DE0A878FDDF8E48B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_11C5E8842F221DEE086B78FDDF8E9CF1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_11C5E8842F221DEE086B78FDDF8E9CF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_4B5DDD5686F934932F2578FDDF8E3866_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_11C5E8842F221DEE086B78FDDF8E9CF1" xlink:to="loc_us-gaap_SegmentDomain_4B5DDD5686F934932F2578FDDF8E3866_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_4B5DDD5686F934932F2578FDDF8E3866" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_11C5E8842F221DEE086B78FDDF8E9CF1" xlink:to="loc_us-gaap_SegmentDomain_4B5DDD5686F934932F2578FDDF8E3866" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_09C9A11A8E45A06CF1BA78FDDF8EDEC1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4B5DDD5686F934932F2578FDDF8E3866" xlink:to="loc_pfe_BiopharmaSegmentMember_09C9A11A8E45A06CF1BA78FDDF8EDEC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_66B4443D0A612EF0B17278FDDF8FDE49" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:to="loc_srt_ConsolidationItemsAxis_66B4443D0A612EF0B17278FDDF8FDE49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_8447C2B0F9667A1516C478FDDF8FC13C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_66B4443D0A612EF0B17278FDDF8FDE49" xlink:to="loc_srt_ConsolidationItemsDomain_8447C2B0F9667A1516C478FDDF8FC13C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_8447C2B0F9667A1516C478FDDF8FC13C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_66B4443D0A612EF0B17278FDDF8FDE49" xlink:to="loc_srt_ConsolidationItemsDomain_8447C2B0F9667A1516C478FDDF8FC13C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_F0FFB335CF903EE9DD0978FDDF8F970D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_8447C2B0F9667A1516C478FDDF8FC13C" xlink:to="loc_us-gaap_OperatingSegmentsMember_F0FFB335CF903EE9DD0978FDDF8F970D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsAxis" xlink:label="loc_us-gaap_SubsegmentsAxis_2BB12DCA1A6ABCEC286F78FDDF9088BD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:to="loc_us-gaap_SubsegmentsAxis_2BB12DCA1A6ABCEC286F78FDDF9088BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_98FCE16A7051F014309E78FDDF90BEC6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_2BB12DCA1A6ABCEC286F78FDDF9088BD" xlink:to="loc_us-gaap_SubsegmentsDomain_98FCE16A7051F014309E78FDDF90BEC6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_98FCE16A7051F014309E78FDDF90BEC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_2BB12DCA1A6ABCEC286F78FDDF9088BD" xlink:to="loc_us-gaap_SubsegmentsDomain_98FCE16A7051F014309E78FDDF90BEC6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember" xlink:label="loc_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_90AD4A79C4B2C45B167778FDDF9024AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_98FCE16A7051F014309E78FDDF90BEC6" xlink:to="loc_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_90AD4A79C4B2C45B167778FDDF9024AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_D504064B43834B0C417478FDDF9026A4" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_D504064B43834B0C417478FDDF9026A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9A2E1AAF92A5274D0EE778FDDF9079C8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_D504064B43834B0C417478FDDF9026A4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9A2E1AAF92A5274D0EE778FDDF9079C8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9A2E1AAF92A5274D0EE778FDDF9079C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_D504064B43834B0C417478FDDF9026A4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9A2E1AAF92A5274D0EE778FDDF9079C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_AF1ED9A3CEF5AD84713E78FDDF91CC3F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9A2E1AAF92A5274D0EE778FDDF9079C8" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_AF1ED9A3CEF5AD84713E78FDDF91CC3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_BB42324196F671542E9E78FDDF912E3C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_BB42324196F671542E9E78FDDF912E3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_95396235E2130E5B73B578FDDF915F3B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_BB42324196F671542E9E78FDDF912E3C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_95396235E2130E5B73B578FDDF915F3B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_95396235E2130E5B73B578FDDF915F3B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_BB42324196F671542E9E78FDDF912E3C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_95396235E2130E5B73B578FDDF915F3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_278E56D4D9DE0B51BEB578FDDF9116D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_95396235E2130E5B73B578FDDF915F3B" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_278E56D4D9DE0B51BEB578FDDF9116D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_A9DF1BCCCCE78D29492078FDDF929F23" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_A9DF1BCCCCE78D29492078FDDF929F23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_F327A7E8C4E71133052278FDDF92DC8E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_A9DF1BCCCCE78D29492078FDDF929F23" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_F327A7E8C4E71133052278FDDF92DC8E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_F327A7E8C4E71133052278FDDF92DC8E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_A9DF1BCCCCE78D29492078FDDF929F23" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_F327A7E8C4E71133052278FDDF92DC8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_8F6D2F0972C38D6A607578FDDF92DF18" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_F327A7E8C4E71133052278FDDF92DC8E" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_8F6D2F0972C38D6A607578FDDF92DF18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_87F4F97638CE59FA783F78FDDF92A078" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_87F4F97638CE59FA783F78FDDF92A078" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_80C16C029C48ECBD08D078FDDF93FABF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_87F4F97638CE59FA783F78FDDF92A078" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_80C16C029C48ECBD08D078FDDF93FABF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_80C16C029C48ECBD08D078FDDF93FABF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_87F4F97638CE59FA783F78FDDF92A078" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_80C16C029C48ECBD08D078FDDF93FABF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_CK1AssetsSoldToBiogenIncMember" xlink:label="loc_pfe_CK1AssetsSoldToBiogenIncMember_90B61E774EFCEF6FEB0F78FDDF93EEE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_80C16C029C48ECBD08D078FDDF93FABF" xlink:to="loc_pfe_CK1AssetsSoldToBiogenIncMember_90B61E774EFCEF6FEB0F78FDDF93EEE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_38F2A12569E4CBBB138378FDDF9366C7" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:to="loc_srt_CounterpartyNameAxis_38F2A12569E4CBBB138378FDDF9366C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A98C943EE96BCA33E4DC78FDDF930D3E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_38F2A12569E4CBBB138378FDDF9366C7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A98C943EE96BCA33E4DC78FDDF930D3E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A98C943EE96BCA33E4DC78FDDF930D3E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_38F2A12569E4CBBB138378FDDF9366C7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A98C943EE96BCA33E4DC78FDDF930D3E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PumaTechnologiesMember" xlink:label="loc_pfe_PumaTechnologiesMember_4A045F9C1FC1E8CCA34A78FDDF948E99" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A98C943EE96BCA33E4DC78FDDF930D3E" xlink:to="loc_pfe_PumaTechnologiesMember_4A045F9C1FC1E8CCA34A78FDDF948E99" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EliLillyCompanyMember" xlink:label="loc_pfe_EliLillyCompanyMember_F8848A67BFBE74A71F3378FDDF993672" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A98C943EE96BCA33E4DC78FDDF930D3E" xlink:to="loc_pfe_EliLillyCompanyMember_F8848A67BFBE74A71F3378FDDF993672" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_MylanMember" xlink:label="loc_pfe_MylanMember_F59F81BE5EB8C382AC5F78FDDF99E8D1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A98C943EE96BCA33E4DC78FDDF930D3E" xlink:to="loc_pfe_MylanMember_F59F81BE5EB8C382AC5F78FDDF99E8D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_DB3FB0692FF0B74F463078FDDF991C0F" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:to="loc_us-gaap_TypeOfArrangementAxis_DB3FB0692FF0B74F463078FDDF991C0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_68EE34F5DFD56226EF6678FDDF9A230B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_DB3FB0692FF0B74F463078FDDF991C0F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_68EE34F5DFD56226EF6678FDDF9A230B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_68EE34F5DFD56226EF6678FDDF9A230B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_DB3FB0692FF0B74F463078FDDF991C0F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_68EE34F5DFD56226EF6678FDDF9A230B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_73FF4EE06B22FF04B44978FDDF9A32B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_68EE34F5DFD56226EF6678FDDF9A230B" xlink:to="loc_us-gaap_CollaborativeArrangementMember_73FF4EE06B22FF04B44978FDDF9A32B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3F2C67A067E99BD5250678FDDF9AAF50" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3F2C67A067E99BD5250678FDDF9AAF50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_F864FE69E51F64EA3D0378FDDF9ADB07_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3F2C67A067E99BD5250678FDDF9AAF50" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_F864FE69E51F64EA3D0378FDDF9ADB07_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_F864FE69E51F64EA3D0378FDDF9ADB07" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3F2C67A067E99BD5250678FDDF9AAF50" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_F864FE69E51F64EA3D0378FDDF9ADB07" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AllogeneMember" xlink:label="loc_pfe_AllogeneMember_02C1E07DB82846574EBB78FDDF9B556F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_F864FE69E51F64EA3D0378FDDF9ADB07" xlink:to="loc_pfe_AllogeneMember_02C1E07DB82846574EBB78FDDF9B556F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BioNTechSEMember" xlink:label="loc_pfe_BioNTechSEMember_BBD9F34220B9E3785F1C78FDDF9B4457" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_F864FE69E51F64EA3D0378FDDF9ADB07" xlink:to="loc_pfe_BioNTechSEMember_BBD9F34220B9E3785F1C78FDDF9B4457" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_CortexymeInc.Member" xlink:label="loc_pfe_CortexymeInc.Member_251078E406455CB0A52878FDDF9B8B35" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_F864FE69E51F64EA3D0378FDDF9ADB07" xlink:to="loc_pfe_CortexymeInc.Member_251078E406455CB0A52878FDDF9B8B35" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_KingMember" xlink:label="loc_pfe_KingMember_6F5D3BAB839D0F7744EC78FDDF9B7F8E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_F864FE69E51F64EA3D0378FDDF9ADB07" xlink:to="loc_pfe_KingMember_6F5D3BAB839D0F7744EC78FDDF9B7F8E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AnacorMember" xlink:label="loc_pfe_AnacorMember_3F3427A5FF2C0DA3818778FDDF9B5257" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_F864FE69E51F64EA3D0378FDDF9ADB07" xlink:to="loc_pfe_AnacorMember_3F3427A5FF2C0DA3818778FDDF9B5257" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ViiVMember" xlink:label="loc_pfe_ViiVMember_2F176FCBF7E0DE0174BC78FDDF9C436D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_F864FE69E51F64EA3D0378FDDF9ADB07" xlink:to="loc_pfe_ViiVMember_2F176FCBF7E0DE0174BC78FDDF9C436D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="loc_us-gaap_ProceedsFromLegalSettlements_77B7CE04FB1CED841F4178FDDF9C171B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2CE131CF4595136F1EC678FDDF9C8167" xlink:to="loc_us-gaap_ProceedsFromLegalSettlements_77B7CE04FB1CED841F4178FDDF9C171B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7626C776657E126AC4FA78FDDF9CD98A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2CE131CF4595136F1EC678FDDF9C8167" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7626C776657E126AC4FA78FDDF9CD98A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_94FDED715D49CB8641C478FDDF9C0AED" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2CE131CF4595136F1EC678FDDF9C8167" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_94FDED715D49CB8641C478FDDF9C0AED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="loc_us-gaap_ProceedsFromCollaborators_C9E0367BF85EDC2FF72C78FDDF9C261D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2CE131CF4595136F1EC678FDDF9C8167" xlink:to="loc_us-gaap_ProceedsFromCollaborators_C9E0367BF85EDC2FF72C78FDDF9C261D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_91860A26E03A971E7CD178FDDF9D3DDD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2CE131CF4595136F1EC678FDDF9C8167" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_91860A26E03A971E7CD178FDDF9D3DDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_90E4EDFBB50803B9F5B278FDDF9DD9A6" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2CE131CF4595136F1EC678FDDF9C8167" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_90E4EDFBB50803B9F5B278FDDF9DD9A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeDividend" xlink:label="loc_us-gaap_InvestmentIncomeDividend_D1004AFAE8A6032C328478FDDF9D57EF" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2CE131CF4595136F1EC678FDDF9C8167" xlink:to="loc_us-gaap_InvestmentIncomeDividend_D1004AFAE8A6032C328478FDDF9D57EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InsuranceRecoveries" xlink:label="loc_us-gaap_InsuranceRecoveries_227B4BC59F17202971AE78FDDF9D2F52" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2CE131CF4595136F1EC678FDDF9C8167" xlink:to="loc_us-gaap_InsuranceRecoveries_227B4BC59F17202971AE78FDDF9D2F52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5D04B06DEF744BD9138078FDDF9DE441" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2CE131CF4595136F1EC678FDDF9C8167" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5D04B06DEF744BD9138078FDDF9DE441" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlans" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_57E118D76609D5287559628A0AD42C2D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51DF12670EA0BFBEF575628A0AD0A94B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_57E118D76609D5287559628A0AD42C2D" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51DF12670EA0BFBEF575628A0AD0A94B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9BEE5BC8C2DC5ECB80A563321A2C6932" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51DF12670EA0BFBEF575628A0AD0A94B" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9BEE5BC8C2DC5ECB80A563321A2C6932" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_AD3B3E74DE2B3D5BACAD63321A3BFEAA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9BEE5BC8C2DC5ECB80A563321A2C6932" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_AD3B3E74DE2B3D5BACAD63321A3BFEAA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_AD3B3E74DE2B3D5BACAD63321A3BFEAA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9BEE5BC8C2DC5ECB80A563321A2C6932" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_AD3B3E74DE2B3D5BACAD63321A3BFEAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_93515747A298A774E07D633242D57CF7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_AD3B3E74DE2B3D5BACAD63321A3BFEAA" xlink:to="loc_us-gaap_SubsequentEventMember_93515747A298A774E07D633242D57CF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_45AA784DEA72111C9017628A0AD00235" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51DF12670EA0BFBEF575628A0AD0A94B" xlink:to="loc_srt_StatementScenarioAxis_45AA784DEA72111C9017628A0AD00235" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_DD910F616A868D7D53C3628A0AD128CA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_45AA784DEA72111C9017628A0AD00235" xlink:to="loc_srt_ScenarioUnspecifiedDomain_DD910F616A868D7D53C3628A0AD128CA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_DD910F616A868D7D53C3628A0AD128CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_45AA784DEA72111C9017628A0AD00235" xlink:to="loc_srt_ScenarioUnspecifiedDomain_DD910F616A868D7D53C3628A0AD128CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_FFA9C0635DE064D8B39A628A0AD133AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_DD910F616A868D7D53C3628A0AD128CA" xlink:to="loc_srt_ScenarioForecastMember_FFA9C0635DE064D8B39A628A0AD133AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_8AFF68E1779C00C2A437628A0AD1B2FB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51DF12670EA0BFBEF575628A0AD0A94B" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_8AFF68E1779C00C2A437628A0AD1B2FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_67BE5728FCA2B1C4BBE5628A0AD1DF08_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8AFF68E1779C00C2A437628A0AD1B2FB" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_67BE5728FCA2B1C4BBE5628A0AD1DF08_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_67BE5728FCA2B1C4BBE5628A0AD1DF08" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8AFF68E1779C00C2A437628A0AD1B2FB" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_67BE5728FCA2B1C4BBE5628A0AD1DF08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_37EF3F74F0F63D24BE44628A0AD29A93" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_67BE5728FCA2B1C4BBE5628A0AD1DF08" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_37EF3F74F0F63D24BE44628A0AD29A93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_99F6490F088BD8E53DAC628A0AD25AFD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_67BE5728FCA2B1C4BBE5628A0AD1DF08" xlink:to="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_99F6490F088BD8E53DAC628A0AD25AFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_B4E57311C55ACEF0FA4C628A0AD2CB81" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_67BE5728FCA2B1C4BBE5628A0AD1DF08" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_B4E57311C55ACEF0FA4C628A0AD2CB81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_0D91188B6219E42A21D9628A0AD2BF0B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51DF12670EA0BFBEF575628A0AD0A94B" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_0D91188B6219E42A21D9628A0AD2BF0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_1968054DED17DE4610CB628A0AD231F3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_0D91188B6219E42A21D9628A0AD2BF0B" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_1968054DED17DE4610CB628A0AD231F3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_1968054DED17DE4610CB628A0AD231F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_0D91188B6219E42A21D9628A0AD2BF0B" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_1968054DED17DE4610CB628A0AD231F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_4CB21BEFBBC1273C4848628A0AD31BB6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_1968054DED17DE4610CB628A0AD231F3" xlink:to="loc_us-gaap_DomesticPlanMember_4CB21BEFBBC1273C4848628A0AD31BB6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_country_US_A0B753B72162624377FB628A0AD3316F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_4CB21BEFBBC1273C4848628A0AD31BB6" xlink:to="loc_country_US_A0B753B72162624377FB628A0AD3316F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_B22335C907574E65952F628A0AD3CEDB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_1968054DED17DE4610CB628A0AD231F3" xlink:to="loc_us-gaap_ForeignPlanMember_B22335C907574E65952F628A0AD3CEDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_18B4BC2481FBCEB61D72628A0AD37B2A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51DF12670EA0BFBEF575628A0AD0A94B" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_18B4BC2481FBCEB61D72628A0AD37B2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_B513E75366818871814D628A0AD3F780_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_18B4BC2481FBCEB61D72628A0AD37B2A" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_B513E75366818871814D628A0AD3F780_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_B513E75366818871814D628A0AD3F780" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_18B4BC2481FBCEB61D72628A0AD37B2A" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_B513E75366818871814D628A0AD3F780" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_17774093E014F5E0A46D628A0AD48395" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_B513E75366818871814D628A0AD3F780" xlink:to="loc_us-gaap_QualifiedPlanMember_17774093E014F5E0A46D628A0AD48395" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonqualifiedPlanMember" xlink:label="loc_us-gaap_NonqualifiedPlanMember_762175F4882B0B993694628A0AD40D66" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_B513E75366818871814D628A0AD3F780" xlink:to="loc_us-gaap_NonqualifiedPlanMember_762175F4882B0B993694628A0AD40D66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_5F735C092181AD45E9E1628A0AD4CC12" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_57E118D76609D5287559628A0AD42C2D" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_5F735C092181AD45E9E1628A0AD4CC12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_84E2789E62FDD42470DC628A0AD55844" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_57E118D76609D5287559628A0AD42C2D" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_84E2789E62FDD42470DC628A0AD55844" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4A3ABA8E3960BEE9A362628A0AE4AD4D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3E9407B81FFADCB78971628A0AE13BD9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4A3ABA8E3960BEE9A362628A0AE4AD4D" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3E9407B81FFADCB78971628A0AE13BD9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_5F8DFC43D8ECD5F3B4E9628A0AE17E9D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3E9407B81FFADCB78971628A0AE13BD9" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_5F8DFC43D8ECD5F3B4E9628A0AE17E9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_3755ED1AC59F303D6D64628A0AE18430_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_5F8DFC43D8ECD5F3B4E9628A0AE17E9D" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_3755ED1AC59F303D6D64628A0AE18430_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_3755ED1AC59F303D6D64628A0AE18430" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_5F8DFC43D8ECD5F3B4E9628A0AE17E9D" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_3755ED1AC59F303D6D64628A0AE18430" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_7CDBA0689F43710AA1C3628A0AE2F86C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3755ED1AC59F303D6D64628A0AE18430" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_7CDBA0689F43710AA1C3628A0AE2F86C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_E3826B52D7D2D3A88973628A0AE2DB4E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3755ED1AC59F303D6D64628A0AE18430" xlink:to="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_E3826B52D7D2D3A88973628A0AE2DB4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_EB1A9E6CC620506C3D59628A0AE27007" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3755ED1AC59F303D6D64628A0AE18430" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_EB1A9E6CC620506C3D59628A0AE27007" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_873A5349A50817F6F780628A0AE244F2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3E9407B81FFADCB78971628A0AE13BD9" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_873A5349A50817F6F780628A0AE244F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_2F862D980FE658762FEA628A0AE24D79_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_873A5349A50817F6F780628A0AE244F2" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_2F862D980FE658762FEA628A0AE24D79_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_2F862D980FE658762FEA628A0AE24D79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_873A5349A50817F6F780628A0AE244F2" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_2F862D980FE658762FEA628A0AE24D79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_6E4F020F05175396102C628A0AE3884E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_2F862D980FE658762FEA628A0AE24D79" xlink:to="loc_us-gaap_DomesticPlanMember_6E4F020F05175396102C628A0AE3884E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_country_US_5CA83C3D5B9880E85558628A0AE3AF76" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_6E4F020F05175396102C628A0AE3884E" xlink:to="loc_country_US_5CA83C3D5B9880E85558628A0AE3AF76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_93612823091DDC1A223C628A0AE3596F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_2F862D980FE658762FEA628A0AE24D79" xlink:to="loc_us-gaap_ForeignPlanMember_93612823091DDC1A223C628A0AE3596F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_178B0A991AA060EFDDBB628A0AE3E144" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3E9407B81FFADCB78971628A0AE13BD9" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_178B0A991AA060EFDDBB628A0AE3E144" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_52047D265623112B6148628A0AE3C345_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_178B0A991AA060EFDDBB628A0AE3E144" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_52047D265623112B6148628A0AE3C345_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_52047D265623112B6148628A0AE3C345" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_178B0A991AA060EFDDBB628A0AE3E144" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_52047D265623112B6148628A0AE3C345" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_74E2AA6EB95BB39DF39B628A0AE4A6C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_52047D265623112B6148628A0AE3C345" xlink:to="loc_us-gaap_QualifiedPlanMember_74E2AA6EB95BB39DF39B628A0AE4A6C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonqualifiedPlanMember" xlink:label="loc_us-gaap_NonqualifiedPlanMember_83D949A11D7C3B45AD65628A0AE41816" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_52047D265623112B6148628A0AE3C345" xlink:to="loc_us-gaap_NonqualifiedPlanMember_83D949A11D7C3B45AD65628A0AE41816" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_F1FB17F4613652D9DDA2628A0AE4333F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4A3ABA8E3960BEE9A362628A0AE4AD4D" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_F1FB17F4613652D9DDA2628A0AE4333F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_9E0006E83CF0F7C78651628A0AE5B8D3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4A3ABA8E3960BEE9A362628A0AE4AD4D" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_9E0006E83CF0F7C78651628A0AE5B8D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_1576F9AFBB60D335F1E8628A0AE5514B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4A3ABA8E3960BEE9A362628A0AE4AD4D" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_1576F9AFBB60D335F1E8628A0AE5514B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_9A097CDC3C5DBEB64CDD628A0AE520DA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4A3ABA8E3960BEE9A362628A0AE4AD4D" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_9A097CDC3C5DBEB64CDD628A0AE520DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_1BDE885221B042E4F56E628A0AE54F0F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_9A097CDC3C5DBEB64CDD628A0AE520DA" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_1BDE885221B042E4F56E628A0AE54F0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_D4FFE27813E7807B1590628A0AE51167" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_9A097CDC3C5DBEB64CDD628A0AE520DA" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_D4FFE27813E7807B1590628A0AE51167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_4E54D10FE1DD94B19A72628A0AE51B51" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4A3ABA8E3960BEE9A362628A0AE4AD4D" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_4E54D10FE1DD94B19A72628A0AE51B51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanSpecialTerminationBenefits" xlink:label="loc_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_663B3A3C6966B7EFBA2C628A0AE63F59" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4A3ABA8E3960BEE9A362628A0AE4AD4D" xlink:to="loc_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_663B3A3C6966B7EFBA2C628A0AE63F59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7F8F14895BE825DB988B628A0AE693E9" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4A3ABA8E3960BEE9A362628A0AE4AD4D" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7F8F14895BE825DB988B628A0AE693E9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_0DDC216E705F309D1A489476227B3398" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E9973313E6D818218E629476227985BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0DDC216E705F309D1A489476227B3398" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E9973313E6D818218E629476227985BE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_FB92AC5F9AF1B54D2CAA947622793F95" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E9973313E6D818218E629476227985BE" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_FB92AC5F9AF1B54D2CAA947622793F95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_FEBAAA722311759CF8839476227ADAE8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_FB92AC5F9AF1B54D2CAA947622793F95" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_FEBAAA722311759CF8839476227ADAE8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_FEBAAA722311759CF8839476227ADAE8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_FB92AC5F9AF1B54D2CAA947622793F95" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_FEBAAA722311759CF8839476227ADAE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_B0FEB0AB99E0124809AE9476227A91DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_FEBAAA722311759CF8839476227ADAE8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_B0FEB0AB99E0124809AE9476227A91DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_D3EC572DDEFC7C95B0F59476227ADF60" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_FEBAAA722311759CF8839476227ADAE8" xlink:to="loc_us-gaap_CostOfSalesMember_D3EC572DDEFC7C95B0F59476227ADF60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_B5FFD3D50B8AEDAB2F009476227A290A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_FEBAAA722311759CF8839476227ADAE8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_B5FFD3D50B8AEDAB2F009476227A290A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3C1DE68EFB3E21EE427F9476227A111C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_FEBAAA722311759CF8839476227ADAE8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3C1DE68EFB3E21EE427F9476227A111C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesAbstract" xlink:label="loc_us-gaap_RestructuringChargesAbstract_554FB9F2415050FF805B9476227B8B64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0DDC216E705F309D1A489476227B3398" xlink:to="loc_us-gaap_RestructuringChargesAbstract_554FB9F2415050FF805B9476227B8B64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_CF75064E0B24F4F812569476227B7971" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringChargesAbstract_554FB9F2415050FF805B9476227B8B64" xlink:to="loc_us-gaap_SeveranceCosts1_CF75064E0B24F4F812569476227B7971" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_RestructuringAssetImpairmentCharges" xlink:label="loc_pfe_RestructuringAssetImpairmentCharges_A8325EDACB115E317DA69476227BBAD2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringChargesAbstract_554FB9F2415050FF805B9476227B8B64" xlink:to="loc_pfe_RestructuringAssetImpairmentCharges_A8325EDACB115E317DA69476227BBAD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessExitCosts1" xlink:label="loc_us-gaap_BusinessExitCosts1_1FD3B7C47A9669537A819476227B1DDF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringChargesAbstract_554FB9F2415050FF805B9476227B8B64" xlink:to="loc_us-gaap_BusinessExitCosts1_1FD3B7C47A9669537A819476227B1DDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_C35951E8DB4A05066CB89476227C0E8F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringChargesAbstract_554FB9F2415050FF805B9476227B8B64" xlink:to="loc_us-gaap_RestructuringCharges_C35951E8DB4A05066CB89476227C0E8F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:label="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_16FE7E3F44FEF3B7D1919476227CFE43" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0DDC216E705F309D1A489476227B3398" xlink:to="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_16FE7E3F44FEF3B7D1919476227CFE43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_4A70149873945FBC89F19476227C10A9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0DDC216E705F309D1A489476227B3398" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_4A70149873945FBC89F19476227C10A9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_1CA7BB76E148589C238A9476227C4CEF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0DDC216E705F309D1A489476227B3398" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_1CA7BB76E148589C238A9476227C4CEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3D6F1CDB9ECD0319265A9476227CC1B4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0DDC216E705F309D1A489476227B3398" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3D6F1CDB9ECD0319265A9476227CC1B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_05F98BC4AB5B442EFC9D9476227DB342" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0DDC216E705F309D1A489476227B3398" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_05F98BC4AB5B442EFC9D9476227DB342" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ImplementationCostAbstract" xlink:label="loc_pfe_ImplementationCostAbstract_11002BD29D6E91B6B6229476227DE0C6" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0DDC216E705F309D1A489476227B3398" xlink:to="loc_pfe_ImplementationCostAbstract_11002BD29D6E91B6B6229476227DE0C6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ImplementationCosts" xlink:label="loc_pfe_ImplementationCosts_00CE778F6BD769E653C69476227D2021" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ImplementationCostAbstract_11002BD29D6E91B6B6229476227DE0C6" xlink:to="loc_pfe_ImplementationCosts_00CE778F6BD769E653C69476227D2021" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:label="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_85341EAF51B71283A4829476227D3AEB" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0DDC216E705F309D1A489476227B3398" xlink:to="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_85341EAF51B71283A4829476227D3AEB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_B8C9FADBD7F23857155C5E4BE8721F70" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_319834433511A9341B135E4BE870BCE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_B8C9FADBD7F23857155C5E4BE8721F70" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_319834433511A9341B135E4BE870BCE6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_C7BB80BACFA54B9840825E4BE870E5AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_319834433511A9341B135E4BE870BCE6" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_C7BB80BACFA54B9840825E4BE870E5AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_4D06B7B987F1DABB77EA5E4BE871FE11_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_C7BB80BACFA54B9840825E4BE870E5AC" xlink:to="loc_us-gaap_SegmentDomain_4D06B7B987F1DABB77EA5E4BE871FE11_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_4D06B7B987F1DABB77EA5E4BE871FE11" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_C7BB80BACFA54B9840825E4BE870E5AC" xlink:to="loc_us-gaap_SegmentDomain_4D06B7B987F1DABB77EA5E4BE871FE11" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_3DDB9ED6E896316BAD9C5E4BE871F784" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4D06B7B987F1DABB77EA5E4BE871FE11" xlink:to="loc_pfe_BiopharmaSegmentMember_3DDB9ED6E896316BAD9C5E4BE871F784" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnSegmentMember" xlink:label="loc_pfe_UpjohnSegmentMember_8BCC7BC0DD448FBACE7D5E4BE8711EF5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4D06B7B987F1DABB77EA5E4BE871FE11" xlink:to="loc_pfe_UpjohnSegmentMember_8BCC7BC0DD448FBACE7D5E4BE8711EF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_8318C07C984405E3EFA55E4BE871ABA0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_319834433511A9341B135E4BE870BCE6" xlink:to="loc_srt_ConsolidationItemsAxis_8318C07C984405E3EFA55E4BE871ABA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_98F7608E15D772BE552A5E4BE872097C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_8318C07C984405E3EFA55E4BE871ABA0" xlink:to="loc_srt_ConsolidationItemsDomain_98F7608E15D772BE552A5E4BE872097C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_98F7608E15D772BE552A5E4BE872097C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_8318C07C984405E3EFA55E4BE871ABA0" xlink:to="loc_srt_ConsolidationItemsDomain_98F7608E15D772BE552A5E4BE872097C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_C0C649F693BA3F93BC035E4BE872EB94" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_98F7608E15D772BE552A5E4BE872097C" xlink:to="loc_us-gaap_OperatingSegmentsMember_C0C649F693BA3F93BC035E4BE872EB94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_B348F4B22EC23ECFF5515E4BE872030C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_98F7608E15D772BE552A5E4BE872097C" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_B348F4B22EC23ECFF5515E4BE872030C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1F0897CB9251134234DB5E4BE87203C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_B8C9FADBD7F23857155C5E4BE8721F70" xlink:to="loc_us-gaap_RestructuringCharges_1F0897CB9251134234DB5E4BE87203C9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_EED7F75156CE3F2BD9E29D36D8818911" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3128A8B5F98FA950D63D9D36D87E6A3D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EED7F75156CE3F2BD9E29D36D8818911" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3128A8B5F98FA950D63D9D36D87E6A3D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_22F965B7D9CF329100F09D36D87FEBB7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3128A8B5F98FA950D63D9D36D87E6A3D" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_22F965B7D9CF329100F09D36D87FEBB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_72F19A7A6B6EDC5C7B719D36D87F74F5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_22F965B7D9CF329100F09D36D87FEBB7" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_72F19A7A6B6EDC5C7B719D36D87F74F5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_72F19A7A6B6EDC5C7B719D36D87F74F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_22F965B7D9CF329100F09D36D87FEBB7" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_72F19A7A6B6EDC5C7B719D36D87F74F5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ManufacturingCostReductionMember" xlink:label="loc_pfe_ManufacturingCostReductionMember_C0D1EEC985364ECE4C909D36D87F3E99" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_72F19A7A6B6EDC5C7B719D36D87F74F5" xlink:to="loc_pfe_ManufacturingCostReductionMember_C0D1EEC985364ECE4C909D36D87F3E99" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BusinessIntegrationCostsMember" xlink:label="loc_pfe_BusinessIntegrationCostsMember_CE00D3D4C91D03DB5E649D36D87F5309" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_72F19A7A6B6EDC5C7B719D36D87F74F5" xlink:to="loc_pfe_BusinessIntegrationCostsMember_CE00D3D4C91D03DB5E649D36D87F5309" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_470E0AA108BBC8024A439D36D880531D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3128A8B5F98FA950D63D9D36D87E6A3D" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_470E0AA108BBC8024A439D36D880531D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07D0726D6A39954C25359D36D8803800_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_470E0AA108BBC8024A439D36D880531D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07D0726D6A39954C25359D36D8803800_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07D0726D6A39954C25359D36D8803800" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_470E0AA108BBC8024A439D36D880531D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07D0726D6A39954C25359D36D8803800" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_HospiraMember" xlink:label="loc_pfe_HospiraMember_945E546E6BFEA44EA1899D36D88042D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07D0726D6A39954C25359D36D8803800" xlink:to="loc_pfe_HospiraMember_945E546E6BFEA44EA1899D36D88042D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_CB08029633875C90B0719D36D8807F26" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3128A8B5F98FA950D63D9D36D87E6A3D" xlink:to="loc_us-gaap_RestructuringPlanAxis_CB08029633875C90B0719D36D8807F26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_3FFCAB00BB3EC4A2851F9D36D880C948_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_CB08029633875C90B0719D36D8807F26" xlink:to="loc_us-gaap_RestructuringPlanDomain_3FFCAB00BB3EC4A2851F9D36D880C948_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_3FFCAB00BB3EC4A2851F9D36D880C948" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_CB08029633875C90B0719D36D8807F26" xlink:to="loc_us-gaap_RestructuringPlanDomain_3FFCAB00BB3EC4A2851F9D36D880C948" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FocusedCompanyPlanMember" xlink:label="loc_pfe_FocusedCompanyPlanMember_B1855A7BF242A7DE65099D36D8819D49" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_3FFCAB00BB3EC4A2851F9D36D880C948" xlink:to="loc_pfe_FocusedCompanyPlanMember_B1855A7BF242A7DE65099D36D8819D49" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember" xlink:label="loc_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_1D2911359B0DD76DBA149D36D881050E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_3FFCAB00BB3EC4A2851F9D36D880C948" xlink:to="loc_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_1D2911359B0DD76DBA149D36D881050E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_5680D04BAEBE3D1E576B9D36D881805B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EED7F75156CE3F2BD9E29D36D8818911" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_5680D04BAEBE3D1E576B9D36D881805B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_RestructuringandRelatedCostNoncashChargesPercentage" xlink:label="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_C5A13503910283CA4A409D36D8829F31" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EED7F75156CE3F2BD9E29D36D8818911" xlink:to="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_C5A13503910283CA4A409D36D8829F31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_7AAE12E998A0C1894B5E9D36D88227F6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EED7F75156CE3F2BD9E29D36D8818911" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_7AAE12E998A0C1894B5E9D36D88227F6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_974D7B3BCF0589DEB09B5E4BE86B6AF2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9345CE3A5B6465A5934D5E4BE86A517B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_974D7B3BCF0589DEB09B5E4BE86B6AF2" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9345CE3A5B6465A5934D5E4BE86A517B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1A317329DCCEC7FC44DB5E4BE86A615E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9345CE3A5B6465A5934D5E4BE86A517B" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_1A317329DCCEC7FC44DB5E4BE86A615E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_675A4F67CEC0EF2753465E4BE86B9402_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1A317329DCCEC7FC44DB5E4BE86A615E" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_675A4F67CEC0EF2753465E4BE86B9402_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_675A4F67CEC0EF2753465E4BE86B9402" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1A317329DCCEC7FC44DB5E4BE86A615E" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_675A4F67CEC0EF2753465E4BE86B9402" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_FE7786157B6C3981FE455E4BE86B4801" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_675A4F67CEC0EF2753465E4BE86B9402" xlink:to="loc_us-gaap_EmployeeSeveranceMember_FE7786157B6C3981FE455E4BE86B4801" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AssetImpairmentsMember" xlink:label="loc_pfe_AssetImpairmentsMember_51C7BACE87279A174D225E4BE86B94C6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_675A4F67CEC0EF2753465E4BE86B9402" xlink:to="loc_pfe_AssetImpairmentsMember_51C7BACE87279A174D225E4BE86B94C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_us-gaap_OtherRestructuringMember_7D058F9AD055CB7861B05E4BE86B5C99" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_675A4F67CEC0EF2753465E4BE86B9402" xlink:to="loc_us-gaap_OtherRestructuringMember_7D058F9AD055CB7861B05E4BE86B5C99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveRollForward" xlink:label="loc_us-gaap_RestructuringReserveRollForward_E066916D2FECFCEEFF225E4BE86C8D0B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_974D7B3BCF0589DEB09B5E4BE86B6AF2" xlink:to="loc_us-gaap_RestructuringReserveRollForward_E066916D2FECFCEEFF225E4BE86C8D0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_FBFAF74349D70157E6855E4BE86C797E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_E066916D2FECFCEEFF225E4BE86C8D0B" xlink:to="loc_us-gaap_RestructuringReserve_FBFAF74349D70157E6855E4BE86C797E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_435A7B2669116D1C47065E4BE86CD413" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_E066916D2FECFCEEFF225E4BE86C8D0B" xlink:to="loc_us-gaap_RestructuringCharges_435A7B2669116D1C47065E4BE86CD413" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" xlink:label="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_9C1CA6033D93F73820EA5E4BE86C2169" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_E066916D2FECFCEEFF225E4BE86C8D0B" xlink:to="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_9C1CA6033D93F73820EA5E4BE86C2169" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_BF257F8CE95131386F6A94761FF55B4E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_32BDFD09AE4574C3F9A794761FF4557A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_BF257F8CE95131386F6A94761FF55B4E" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_32BDFD09AE4574C3F9A794761FF4557A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_CF741FC38A4A8890152894761FF45A60" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_32BDFD09AE4574C3F9A794761FF4557A" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_CF741FC38A4A8890152894761FF45A60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1FC9C6E5AE21DECA4C4694761FF582A7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_CF741FC38A4A8890152894761FF45A60" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1FC9C6E5AE21DECA4C4694761FF582A7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1FC9C6E5AE21DECA4C4694761FF582A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_CF741FC38A4A8890152894761FF45A60" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1FC9C6E5AE21DECA4C4694761FF582A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_439EBAF1F2239BFD1E8A94761FF519D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1FC9C6E5AE21DECA4C4694761FF582A7" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_439EBAF1F2239BFD1E8A94761FF519D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_F6068459B816CB12D64594761FF5EE2A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1FC9C6E5AE21DECA4C4694761FF582A7" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_F6068459B816CB12D64594761FF5EE2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_75CD9635D9A2C251034294761FF6F062" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_BF257F8CE95131386F6A94761FF55B4E" xlink:to="loc_us-gaap_RestructuringReserve_75CD9635D9A2C251034294761FF6F062" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_DE0C810364AA18EF3FE6635078900876" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_47DB69088942C88D679C6350788D5AFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DE0C810364AA18EF3FE6635078900876" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_47DB69088942C88D679C6350788D5AFF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_466F45B6A71E30D02EB16350788D1A1F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_47DB69088942C88D679C6350788D5AFF" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_466F45B6A71E30D02EB16350788D1A1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_9BE8FCAA5D9D6331C87F6350788D2C86_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_466F45B6A71E30D02EB16350788D1A1F" xlink:to="loc_us-gaap_SegmentDomain_9BE8FCAA5D9D6331C87F6350788D2C86_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_9BE8FCAA5D9D6331C87F6350788D2C86" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_466F45B6A71E30D02EB16350788D1A1F" xlink:to="loc_us-gaap_SegmentDomain_9BE8FCAA5D9D6331C87F6350788D2C86" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_DF76E33A53540E0CEAFA6350788EAB14" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9BE8FCAA5D9D6331C87F6350788D2C86" xlink:to="loc_pfe_BiopharmaSegmentMember_DF76E33A53540E0CEAFA6350788EAB14" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnSegmentMember" xlink:label="loc_pfe_UpjohnSegmentMember_DDE3671B719C5E2CCDE26350788E8C7D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9BE8FCAA5D9D6331C87F6350788D2C86" xlink:to="loc_pfe_UpjohnSegmentMember_DDE3671B719C5E2CCDE26350788E8C7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_8C7A732414D6F734F5F46350788EBA4F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_47DB69088942C88D679C6350788D5AFF" xlink:to="loc_srt_ConsolidationItemsAxis_8C7A732414D6F734F5F46350788EBA4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_7B75F4907BA10A3D2D9B6350788ECB8E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_8C7A732414D6F734F5F46350788EBA4F" xlink:to="loc_srt_ConsolidationItemsDomain_7B75F4907BA10A3D2D9B6350788ECB8E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_7B75F4907BA10A3D2D9B6350788ECB8E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_8C7A732414D6F734F5F46350788EBA4F" xlink:to="loc_srt_ConsolidationItemsDomain_7B75F4907BA10A3D2D9B6350788ECB8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_4D6C7E23A7E650C6F8406350788F4E32" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_7B75F4907BA10A3D2D9B6350788ECB8E" xlink:to="loc_us-gaap_OperatingSegmentsMember_4D6C7E23A7E650C6F8406350788F4E32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_9A36AC77270F1C89787B6350788F975A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_7B75F4907BA10A3D2D9B6350788ECB8E" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_9A36AC77270F1C89787B6350788F975A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="loc_us-gaap_CorporateNonSegmentMember_A08467B8F79F2EF581A46350788FF0B8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_7B75F4907BA10A3D2D9B6350788ECB8E" xlink:to="loc_us-gaap_CorporateNonSegmentMember_A08467B8F79F2EF581A46350788FF0B8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherSegmentReconcilingItemsAxis" xlink:label="loc_pfe_OtherSegmentReconcilingItemsAxis_81107C06DEFC9E4BC8DA6350788F0B3F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_47DB69088942C88D679C6350788D5AFF" xlink:to="loc_pfe_OtherSegmentReconcilingItemsAxis_81107C06DEFC9E4BC8DA6350788F0B3F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherSegmentReconcilingItemsDomain" xlink:label="loc_pfe_OtherSegmentReconcilingItemsDomain_B2556FCAD1C7B8A918376350788F9345_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pfe_OtherSegmentReconcilingItemsAxis_81107C06DEFC9E4BC8DA6350788F0B3F" xlink:to="loc_pfe_OtherSegmentReconcilingItemsDomain_B2556FCAD1C7B8A918376350788F9345_default" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherSegmentReconcilingItemsDomain" xlink:label="loc_pfe_OtherSegmentReconcilingItemsDomain_B2556FCAD1C7B8A918376350788F9345" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pfe_OtherSegmentReconcilingItemsAxis_81107C06DEFC9E4BC8DA6350788F0B3F" xlink:to="loc_pfe_OtherSegmentReconcilingItemsDomain_B2556FCAD1C7B8A918376350788F9345" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PurchaseAccountingAdjustmentsMember" xlink:label="loc_pfe_PurchaseAccountingAdjustmentsMember_6CC0148546FD0A3C59DA63507890A625" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_OtherSegmentReconcilingItemsDomain_B2556FCAD1C7B8A918376350788F9345" xlink:to="loc_pfe_PurchaseAccountingAdjustmentsMember_6CC0148546FD0A3C59DA63507890A625" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BusinessCombinationsAcquisitionRelatedCostsMember" xlink:label="loc_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_BF73C039621F772D28F7635078902036" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_OtherSegmentReconcilingItemsDomain_B2556FCAD1C7B8A918376350788F9345" xlink:to="loc_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_BF73C039621F772D28F7635078902036" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_CertainSignificantItemsMember" xlink:label="loc_pfe_CertainSignificantItemsMember_2BE2DF2543371C764FE2635078900132" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_OtherSegmentReconcilingItemsDomain_B2556FCAD1C7B8A918376350788F9345" xlink:to="loc_pfe_CertainSignificantItemsMember_2BE2DF2543371C764FE2635078900132" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E2148BBCA0B6B27E7B1F635078908786" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DE0C810364AA18EF3FE6635078900876" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E2148BBCA0B6B27E7B1F635078908786" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_33AC0AB3FD05F3748EA9635078911A9E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DE0C810364AA18EF3FE6635078900876" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_33AC0AB3FD05F3748EA9635078911A9E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_8AF56E1CEAB1A1E3AABC9AD3C8CF3535" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1DB799DCCA2341A8B8A69AD3C8C83DA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8AF56E1CEAB1A1E3AABC9AD3C8CF3535" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1DB799DCCA2341A8B8A69AD3C8C83DA5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_62A0B96E5632DB3346569AD3C8C95C7E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1DB799DCCA2341A8B8A69AD3C8C83DA5" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_62A0B96E5632DB3346569AD3C8C95C7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_DA1594DD9378A535593B9AD3C8C96527_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_62A0B96E5632DB3346569AD3C8C95C7E" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_DA1594DD9378A535593B9AD3C8C96527_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_DA1594DD9378A535593B9AD3C8C96527" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_62A0B96E5632DB3346569AD3C8C95C7E" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_DA1594DD9378A535593B9AD3C8C96527" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ViiVMember" xlink:label="loc_pfe_ViiVMember_9882A87663C55444CCCF9AD3C8CE86D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_DA1594DD9378A535593B9AD3C8C96527" xlink:to="loc_pfe_ViiVMember_9882A87663C55444CCCF9AD3C8CE86D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeDividend" xlink:label="loc_us-gaap_InvestmentIncomeDividend_1064A3DC510882411B339AD3C8CFAC31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8AF56E1CEAB1A1E3AABC9AD3C8CF3535" xlink:to="loc_us-gaap_InvestmentIncomeDividend_1064A3DC510882411B339AD3C8CFAC31" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_573119C434DA154B2D00635078848B7F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_A2FCB216F508791B78B863507883F389" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_573119C434DA154B2D00635078848B7F" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_A2FCB216F508791B78B863507883F389" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_21D376F4F39B79B35FAE63507883AD8B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_A2FCB216F508791B78B863507883F389" xlink:to="loc_srt_StatementGeographicalAxis_21D376F4F39B79B35FAE63507883AD8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_AD61EBE7A36CEC685330635078836D50_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_21D376F4F39B79B35FAE63507883AD8B" xlink:to="loc_srt_SegmentGeographicalDomain_AD61EBE7A36CEC685330635078836D50_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_AD61EBE7A36CEC685330635078836D50" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_21D376F4F39B79B35FAE63507883AD8B" xlink:to="loc_srt_SegmentGeographicalDomain_AD61EBE7A36CEC685330635078836D50" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_country_US_FE436303D8D841ACAC586350788428D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_AD61EBE7A36CEC685330635078836D50" xlink:to="loc_country_US_FE436303D8D841ACAC586350788428D4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DevelopedEuropeMember" xlink:label="loc_pfe_DevelopedEuropeMember_4995C6E81DF0A88576A2635078843445" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_AD61EBE7A36CEC685330635078836D50" xlink:to="loc_pfe_DevelopedEuropeMember_4995C6E81DF0A88576A2635078843445" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DevelopedRestOfWorldMember" xlink:label="loc_pfe_DevelopedRestOfWorldMember_BFF0DB7C007505E2A058635078847232" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_AD61EBE7A36CEC685330635078836D50" xlink:to="loc_pfe_DevelopedRestOfWorldMember_BFF0DB7C007505E2A058635078847232" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EmergingMarketsMember" xlink:label="loc_pfe_EmergingMarketsMember_DC4C4EBD8A9740D19CB663507884B64E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_AD61EBE7A36CEC685330635078836D50" xlink:to="loc_pfe_EmergingMarketsMember_DC4C4EBD8A9740D19CB663507884B64E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6356D5C47420B7CDCE0363507884A8E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_573119C434DA154B2D00635078848B7F" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6356D5C47420B7CDCE0363507884A8E1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PercentageChangeInRevenue" xlink:label="loc_pfe_PercentageChangeInRevenue_F7E70A69F1F08DFD33C86350788518A3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_573119C434DA154B2D00635078848B7F" xlink:to="loc_pfe_PercentageChangeInRevenue_F7E70A69F1F08DFD33C86350788518A3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_331E0A34E97E2E30B2E66350787F0FE1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_19FA2C6F9135F773D4DF6350787E4E79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_331E0A34E97E2E30B2E66350787F0FE1" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_19FA2C6F9135F773D4DF6350787E4E79" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_3D799A67E7B7DDFCFCA36350787E67C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_19FA2C6F9135F773D4DF6350787E4E79" xlink:to="loc_srt_CurrencyAxis_3D799A67E7B7DDFCFCA36350787E67C1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_3B49161E98DDBB4E4F696350787EBD16_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_3D799A67E7B7DDFCFCA36350787E67C1" xlink:to="loc_currency_AllCurrenciesDomain_3B49161E98DDBB4E4F696350787EBD16_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_3B49161E98DDBB4E4F696350787EBD16" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_3D799A67E7B7DDFCFCA36350787E67C1" xlink:to="loc_currency_AllCurrenciesDomain_3B49161E98DDBB4E4F696350787EBD16" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_C6E3A175275BBA220A896350787E7B6C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_3B49161E98DDBB4E4F696350787EBD16" xlink:to="loc_currency_EUR_C6E3A175275BBA220A896350787E7B6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_690C0B45A89141585C066350787F6F28" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_19FA2C6F9135F773D4DF6350787E4E79" xlink:to="loc_srt_StatementGeographicalAxis_690C0B45A89141585C066350787F6F28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_5596607291BC04D9ED966350787F3484_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_690C0B45A89141585C066350787F6F28" xlink:to="loc_srt_SegmentGeographicalDomain_5596607291BC04D9ED966350787F3484_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_5596607291BC04D9ED966350787F3484" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_690C0B45A89141585C066350787F6F28" xlink:to="loc_srt_SegmentGeographicalDomain_5596607291BC04D9ED966350787F3484" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DevelopedEuropeMember" xlink:label="loc_pfe_DevelopedEuropeMember_DB1906003C7888B5F7BC6350787F3C09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5596607291BC04D9ED966350787F3484" xlink:to="loc_pfe_DevelopedEuropeMember_DB1906003C7888B5F7BC6350787F3C09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F79A343BD6AF2F227B3A6350787F20AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_331E0A34E97E2E30B2E66350787F0FE1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F79A343BD6AF2F227B3A6350787F20AC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9DF7C32BE76DCA92E4E6A56C86C0A4DF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_EB99D1A4AC4FFC9C8F6FA56C86A8D13E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9DF7C32BE76DCA92E4E6A56C86C0A4DF" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_EB99D1A4AC4FFC9C8F6FA56C86A8D13E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitAxis" xlink:label="loc_us-gaap_ReportingUnitAxis_8C00D7FDFCCBC1F60C8CA56C86A91193" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_EB99D1A4AC4FFC9C8F6FA56C86A8D13E" xlink:to="loc_us-gaap_ReportingUnitAxis_8C00D7FDFCCBC1F60C8CA56C86A91193" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_8C00D7FDFCCBC1F60C8CA56C86A91193" xlink:to="loc_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_8C00D7FDFCCBC1F60C8CA56C86A91193" xlink:to="loc_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_InternalMedicineMember" xlink:label="loc_pfe_InternalMedicineMember_F6F5D98D4B06E262880FA56C86AE684B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91" xlink:to="loc_pfe_InternalMedicineMember_F6F5D98D4B06E262880FA56C86AE684B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OncologyMember" xlink:label="loc_pfe_OncologyMember_CB5E0FF8C75B3122B531A56C86AFB15C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91" xlink:to="loc_pfe_OncologyMember_CB5E0FF8C75B3122B531A56C86AFB15C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_HospitalMember" xlink:label="loc_pfe_HospitalMember_86A742C0795AC99C98BAA56C86AF28B4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91" xlink:to="loc_pfe_HospitalMember_86A742C0795AC99C98BAA56C86AF28B4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_VaccinesMember" xlink:label="loc_pfe_VaccinesMember_A0AB6CB62DF46A44BE94A56C86AFADE7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91" xlink:to="loc_pfe_VaccinesMember_A0AB6CB62DF46A44BE94A56C86AFADE7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_InflammationandImmunologyMember" xlink:label="loc_pfe_InflammationandImmunologyMember_6BEBE45E80282D8DF85FA56C86B0794E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91" xlink:to="loc_pfe_InflammationandImmunologyMember_6BEBE45E80282D8DF85FA56C86B0794E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_RareDiseaseMember" xlink:label="loc_pfe_RareDiseaseMember_F14C6BC670D92FF6E1B6A56C86B0ED0A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91" xlink:to="loc_pfe_RareDiseaseMember_F14C6BC670D92FF6E1B6A56C86B0ED0A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnReportingUnitMember" xlink:label="loc_pfe_UpjohnReportingUnitMember_D641FF22EA64057A719FA56C86B054FB" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91" xlink:to="loc_pfe_UpjohnReportingUnitMember_D641FF22EA64057A719FA56C86B054FB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ConsumerHealthcareReportingUnitMember" xlink:label="loc_pfe_ConsumerHealthcareReportingUnitMember_C8AF36EA4CF5E50A9841A56C86B0593F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91" xlink:to="loc_pfe_ConsumerHealthcareReportingUnitMember_C8AF36EA4CF5E50A9841A56C86B0593F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4C26C2E2098943768E61A56C86B019DA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_EB99D1A4AC4FFC9C8F6FA56C86A8D13E" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4C26C2E2098943768E61A56C86B019DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_D0A110AC6DF0E8191272A56C86B0276F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4C26C2E2098943768E61A56C86B019DA" xlink:to="loc_us-gaap_SegmentDomain_D0A110AC6DF0E8191272A56C86B0276F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_D0A110AC6DF0E8191272A56C86B0276F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4C26C2E2098943768E61A56C86B019DA" xlink:to="loc_us-gaap_SegmentDomain_D0A110AC6DF0E8191272A56C86B0276F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" xlink:label="loc_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_0FC68527EF72BF306D48A56C86B1A215" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_D0A110AC6DF0E8191272A56C86B0276F" xlink:to="loc_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_0FC68527EF72BF306D48A56C86B1A215" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_33D6A4F853A99FF830E8A56C86B13309" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_0FC68527EF72BF306D48A56C86B1A215" xlink:to="loc_pfe_BiopharmaSegmentMember_33D6A4F853A99FF830E8A56C86B13309" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnSegmentMember" xlink:label="loc_pfe_UpjohnSegmentMember_15B7D1A055C83A44C8ECA56C86B1C6A9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_0FC68527EF72BF306D48A56C86B1A215" xlink:to="loc_pfe_UpjohnSegmentMember_15B7D1A055C83A44C8ECA56C86B1C6A9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ConsumerHealthcareMember" xlink:label="loc_pfe_ConsumerHealthcareMember_AB4FEC7BA80CD1D35C0FA56C86B1A6F2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_0FC68527EF72BF306D48A56C86B1A215" xlink:to="loc_pfe_ConsumerHealthcareMember_AB4FEC7BA80CD1D35C0FA56C86B1A6F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_024C2084C2516DA75C5EA56C86B1CC15" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_EB99D1A4AC4FFC9C8F6FA56C86A8D13E" xlink:to="loc_srt_ProductOrServiceAxis_024C2084C2516DA75C5EA56C86B1CC15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_024C2084C2516DA75C5EA56C86B1CC15" xlink:to="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_024C2084C2516DA75C5EA56C86B1CC15" xlink:to="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EliquisMember" xlink:label="loc_pfe_EliquisMember_74C148EE7AAD8BC46643A56C86B2AD15" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_EliquisMember_74C148EE7AAD8BC46643A56C86B2AD15" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ChantixChampixMember" xlink:label="loc_pfe_ChantixChampixMember_E8B6C0153F9AE09FC10DA56C86B26AE1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_ChantixChampixMember_E8B6C0153F9AE09FC10DA56C86B26AE1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PremarinFamilyMember" xlink:label="loc_pfe_PremarinFamilyMember_4588C53585AA9FF88A45A56C86B29EE6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_PremarinFamilyMember_4588C53585AA9FF88A45A56C86B29EE6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BMP2Member" xlink:label="loc_pfe_BMP2Member_1AE86B3689D81EA5118DA56C86B335C6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_BMP2Member_1AE86B3689D81EA5118DA56C86B335C6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ToviazMember" xlink:label="loc_pfe_ToviazMember_615A0752A97615972028A56C86B3A51C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_ToviazMember_615A0752A97615972028A56C86B3A51C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AllOtherInternalMedicineMember" xlink:label="loc_pfe_AllOtherInternalMedicineMember_7C848AF0CC6E15FC67E2A56C86B30692" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_AllOtherInternalMedicineMember_7C848AF0CC6E15FC67E2A56C86B30692" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IbranceMember" xlink:label="loc_pfe_IbranceMember_58B49E73E5E26AAF7282A56C86B3D39C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_IbranceMember_58B49E73E5E26AAF7282A56C86B3D39C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_XtandiAllianceRevenuesMember" xlink:label="loc_pfe_XtandiAllianceRevenuesMember_61982F42AA5997949BB0A56C86B3C931" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_XtandiAllianceRevenuesMember_61982F42AA5997949BB0A56C86B3C931" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SutentMember" xlink:label="loc_pfe_SutentMember_D9ABAA0CF4E687D9CA61A56C86B3EEFB" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_SutentMember_D9ABAA0CF4E687D9CA61A56C86B3EEFB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_InlytaMember" xlink:label="loc_pfe_InlytaMember_C9BA3F0F8A3AC2FD495AA56C86B43B85" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_InlytaMember_C9BA3F0F8A3AC2FD495AA56C86B43B85" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_XalkoriMember" xlink:label="loc_pfe_XalkoriMember_1BD7B04F8F7DF9BBCD2EA56C86B4A1D1" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_XalkoriMember_1BD7B04F8F7DF9BBCD2EA56C86B4A1D1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BosulifMember" xlink:label="loc_pfe_BosulifMember_4D20112C50AB734A0462A56C86B40D81" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_BosulifMember_4D20112C50AB734A0462A56C86B40D81" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_RetacritMember" xlink:label="loc_pfe_RetacritMember_5C6338C1277581566DADA56C86B41F10" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_RetacritMember_5C6338C1277581566DADA56C86B41F10" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BraftoviMember" xlink:label="loc_pfe_BraftoviMember_6549E5586ED5FAC9AE94A56C86B4B8EA" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_BraftoviMember_6549E5586ED5FAC9AE94A56C86B4B8EA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_MektoviMember" xlink:label="loc_pfe_MektoviMember_DD760C6FA3AFCB86DBA2A56C86B4D1C2" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_MektoviMember_DD760C6FA3AFCB86DBA2A56C86B4D1C2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherOncologyProductsMember" xlink:label="loc_pfe_OtherOncologyProductsMember_4A1E7F49FAF6BECBFF6EA56C86B4F366" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_OtherOncologyProductsMember_4A1E7F49FAF6BECBFF6EA56C86B4F366" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SulperazonMember" xlink:label="loc_pfe_SulperazonMember_95376C87701E4CAC5F4DA56C86B59DF2" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_SulperazonMember_95376C87701E4CAC5F4DA56C86B59DF2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_MedrolMember" xlink:label="loc_pfe_MedrolMember_522B6988D414D3728327A56C86B5000B" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_MedrolMember_522B6988D414D3728327A56C86B5000B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ZithromaxZmaxMember" xlink:label="loc_pfe_ZithromaxZmaxMember_0CA3815A71E72E827746A56C86B56B65" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_ZithromaxZmaxMember_0CA3815A71E72E827746A56C86B56B65" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PrecedexMember" xlink:label="loc_pfe_PrecedexMember_815148BB9543BEE28EBAA56C86B5E751" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_PrecedexMember_815148BB9543BEE28EBAA56C86B5E751" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_VfendMember" xlink:label="loc_pfe_VfendMember_45BC193A4688F3B4705CA56C86B575E9" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_VfendMember_45BC193A4688F3B4705CA56C86B575E9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PanzygaMember" xlink:label="loc_pfe_PanzygaMember_D41C4107962F48E68B3EA56C86B6FA8A" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_PanzygaMember_D41C4107962F48E68B3EA56C86B6FA8A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ZyvoxMember" xlink:label="loc_pfe_ZyvoxMember_6A99B0F4ACF7EF4E08B6A56C86B6D4ED" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_ZyvoxMember_6A99B0F4ACF7EF4E08B6A56C86B6D4ED" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FragminMember" xlink:label="loc_pfe_FragminMember_49750078F822D097D253A56C86BBD415" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_FragminMember_49750078F822D097D253A56C86BBD415" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PfizerCentreOneMember" xlink:label="loc_pfe_PfizerCentreOneMember_9DE4645951C19EA6057CA56C86BB1B0D" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_PfizerCentreOneMember_9DE4645951C19EA6057CA56C86BB1B0D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherAntiinfectivesMember" xlink:label="loc_pfe_OtherAntiinfectivesMember_7F50880BD594C5F24301A56C86BBB0AE" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_OtherAntiinfectivesMember_7F50880BD594C5F24301A56C86BBB0AE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherHospitalProductsMember" xlink:label="loc_pfe_OtherHospitalProductsMember_AB885C1A853C97AC11A9A56C86BB3891" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_OtherHospitalProductsMember_AB885C1A853C97AC11A9A56C86BB3891" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PrevnarPrevenarFamilyMember" xlink:label="loc_pfe_PrevnarPrevenarFamilyMember_4EEE60C0F50B0C658579A56C86BC8133" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_PrevnarPrevenarFamilyMember_4EEE60C0F50B0C658579A56C86BC8133" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_NimenrixMember" xlink:label="loc_pfe_NimenrixMember_CD0AFA296C250E0761EFA56C86BCB740" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_NimenrixMember_CD0AFA296C250E0761EFA56C86BCB740" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherVaccinesProductsMember" xlink:label="loc_pfe_OtherVaccinesProductsMember_4B49EA2EC8C94B7748E6A56C86BC5703" xlink:type="locator" />
    <link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_OtherVaccinesProductsMember_4B49EA2EC8C94B7748E6A56C86BC5703" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_XeljanzMember" xlink:label="loc_pfe_XeljanzMember_EBFD7FC05AF664C5FF52A56C86BC8017" xlink:type="locator" />
    <link:definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_XeljanzMember_EBFD7FC05AF664C5FF52A56C86BC8017" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EnbrelMember" xlink:label="loc_pfe_EnbrelMember_20D39F0CC56F9508E3D3A56C86BC00A5" xlink:type="locator" />
    <link:definitionArc order="32" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_EnbrelMember_20D39F0CC56F9508E3D3A56C86BC00A5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_InflectraRemsimaMember" xlink:label="loc_pfe_InflectraRemsimaMember_B82802DBC0973FCF58F8A56C86BDBC3C" xlink:type="locator" />
    <link:definitionArc order="33" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_InflectraRemsimaMember_B82802DBC0973FCF58F8A56C86BDBC3C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AllOtherInflammationandImmunologyProductsMember" xlink:label="loc_pfe_AllOtherInflammationandImmunologyProductsMember_AF53FD9E835B8055DB78A56C86BDBD30" xlink:type="locator" />
    <link:definitionArc order="34" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_AllOtherInflammationandImmunologyProductsMember_AF53FD9E835B8055DB78A56C86BDBD30" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_VyndaqelMember" xlink:label="loc_pfe_VyndaqelMember_3685807938B54E561B92A56C86BDB386" xlink:type="locator" />
    <link:definitionArc order="35" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_VyndaqelMember_3685807938B54E561B92A56C86BDB386" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BeneFIXMember" xlink:label="loc_pfe_BeneFIXMember_78AF65605967123A3219A56C86BDCF35" xlink:type="locator" />
    <link:definitionArc order="36" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_BeneFIXMember_78AF65605967123A3219A56C86BDCF35" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_GenotropinMember" xlink:label="loc_pfe_GenotropinMember_7FB36B0DA9ED797D3E48A56C86BD5AF5" xlink:type="locator" />
    <link:definitionArc order="37" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_GenotropinMember_7FB36B0DA9ED797D3E48A56C86BD5AF5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ReFactoAfXynthaMember" xlink:label="loc_pfe_ReFactoAfXynthaMember_864D1C74B465C0E1FF48A56C86BD95F1" xlink:type="locator" />
    <link:definitionArc order="38" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_ReFactoAfXynthaMember_864D1C74B465C0E1FF48A56C86BD95F1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SomavertMember" xlink:label="loc_pfe_SomavertMember_7FFAA229B092ACB08D2DA56C86BD974C" xlink:type="locator" />
    <link:definitionArc order="39" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_SomavertMember_7FFAA229B092ACB08D2DA56C86BD974C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AllOtherRareDiseaseProductsMember" xlink:label="loc_pfe_AllOtherRareDiseaseProductsMember_B66B37B69A6AC133E95CA56C86BECC16" xlink:type="locator" />
    <link:definitionArc order="40" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_AllOtherRareDiseaseProductsMember_B66B37B69A6AC133E95CA56C86BECC16" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LipitorMember" xlink:label="loc_pfe_LipitorMember_7255601AE252E9CD1726A56C86BEDC00" xlink:type="locator" />
    <link:definitionArc order="41" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_LipitorMember_7255601AE252E9CD1726A56C86BEDC00" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LyricaMember" xlink:label="loc_pfe_LyricaMember_1F4C6BE110CA50901141A56C86BEF34F" xlink:type="locator" />
    <link:definitionArc order="42" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_LyricaMember_1F4C6BE110CA50901141A56C86BEF34F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_NorvascMember" xlink:label="loc_pfe_NorvascMember_83556E8FF8ED465CC033A56C86BEA428" xlink:type="locator" />
    <link:definitionArc order="43" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_NorvascMember_83556E8FF8ED465CC033A56C86BEA428" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_CelebrexMember" xlink:label="loc_pfe_CelebrexMember_57C95D9B26AB88948709A56C86BEFBE8" xlink:type="locator" />
    <link:definitionArc order="44" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_CelebrexMember_57C95D9B26AB88948709A56C86BEFBE8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ViagraMember" xlink:label="loc_pfe_ViagraMember_7CEE2623FDD2D09220A7A56C86BE60F2" xlink:type="locator" />
    <link:definitionArc order="45" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_ViagraMember_7CEE2623FDD2D09220A7A56C86BE60F2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EffexorMember" xlink:label="loc_pfe_EffexorMember_46E5E161E30C551D28F5A56C86BF6A41" xlink:type="locator" />
    <link:definitionArc order="46" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_EffexorMember_46E5E161E30C551D28F5A56C86BF6A41" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ZoloftMember" xlink:label="loc_pfe_ZoloftMember_C62851349E163C99B25BA56C86BF3E7D" xlink:type="locator" />
    <link:definitionArc order="47" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_ZoloftMember_C62851349E163C99B25BA56C86BF3E7D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EpiPenMember" xlink:label="loc_pfe_EpiPenMember_ACB821EB72C550D63B71A56C86BF5E7A" xlink:type="locator" />
    <link:definitionArc order="48" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_EpiPenMember_ACB821EB72C550D63B71A56C86BF5E7A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_XalatanXalacomMember" xlink:label="loc_pfe_XalatanXalacomMember_9B3D3217E1FF99B6EDE8A56C86BF49B5" xlink:type="locator" />
    <link:definitionArc order="49" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_XalatanXalacomMember_9B3D3217E1FF99B6EDE8A56C86BF49B5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AllOtherUpjohnProductsMember" xlink:label="loc_pfe_AllOtherUpjohnProductsMember_736420A194EDC34B4B82A56C86BFB1C9" xlink:type="locator" />
    <link:definitionArc order="50" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_AllOtherUpjohnProductsMember_736420A194EDC34B4B82A56C86BFB1C9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_TotalAllianceBiopharmaceuticalsMember" xlink:label="loc_pfe_TotalAllianceBiopharmaceuticalsMember_9BB704103A9A6CC657ADA56C86C0558A" xlink:type="locator" />
    <link:definitionArc order="51" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_TotalAllianceBiopharmaceuticalsMember_9BB704103A9A6CC657ADA56C86C0558A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_TotalBiosimilarsMember" xlink:label="loc_pfe_TotalBiosimilarsMember_798F093E90C7AD7A053DA56C86C0019E" xlink:type="locator" />
    <link:definitionArc order="52" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_TotalBiosimilarsMember_798F093E90C7AD7A053DA56C86C0019E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_TotalSterileInjectablePharmaceuticalsMember" xlink:label="loc_pfe_TotalSterileInjectablePharmaceuticalsMember_B8B920E7FBC004DE5099A56C86C02D22" xlink:type="locator" />
    <link:definitionArc order="53" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_TotalSterileInjectablePharmaceuticalsMember_B8B920E7FBC004DE5099A56C86C02D22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_85F5115624E80735F8F9A56C86C06E8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9DF7C32BE76DCA92E4E6A56C86C0A4DF" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_85F5115624E80735F8F9A56C86C06E8D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/TaxMatters" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/TaxMattersDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/TaxMattersNarrativeDetail" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IncomeTaxesLineItems" xlink:label="loc_pfe_IncomeTaxesLineItems_85ECBE9ED50B2D4854BD78FDDF425FCF" xlink:type="locator" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IncomeTaxesTable" xlink:label="loc_pfe_IncomeTaxesTable_2BA40BB3F2D37B0963D478FDDF40DCB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pfe_IncomeTaxesLineItems_85ECBE9ED50B2D4854BD78FDDF425FCF" xlink:to="loc_pfe_IncomeTaxesTable_2BA40BB3F2D37B0963D478FDDF40DCB2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6CE46DD192EB20B90A0578FDDF404634" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pfe_IncomeTaxesTable_2BA40BB3F2D37B0963D478FDDF40DCB2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6CE46DD192EB20B90A0578FDDF404634" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_AAB6742BE9EF7EAE3F0178FDDF40168C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6CE46DD192EB20B90A0578FDDF404634" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_AAB6742BE9EF7EAE3F0178FDDF40168C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_AAB6742BE9EF7EAE3F0178FDDF40168C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6CE46DD192EB20B90A0578FDDF404634" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_AAB6742BE9EF7EAE3F0178FDDF40168C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_5803903C2C497FF017F778FDDF410C75" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_AAB6742BE9EF7EAE3F0178FDDF40168C" xlink:to="loc_us-gaap_SubsequentEventMember_5803903C2C497FF017F778FDDF410C75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_DCF2C23EFF42EAFA322B78FDDF413708" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pfe_IncomeTaxesTable_2BA40BB3F2D37B0963D478FDDF40DCB2" xlink:to="loc_srt_StatementScenarioAxis_DCF2C23EFF42EAFA322B78FDDF413708" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_6D45E118DAA58125EF4A78FDDF41AB3C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_DCF2C23EFF42EAFA322B78FDDF413708" xlink:to="loc_srt_ScenarioUnspecifiedDomain_6D45E118DAA58125EF4A78FDDF41AB3C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_6D45E118DAA58125EF4A78FDDF41AB3C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_DCF2C23EFF42EAFA322B78FDDF413708" xlink:to="loc_srt_ScenarioUnspecifiedDomain_6D45E118DAA58125EF4A78FDDF41AB3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_AA1230420256FA862B1978FDDF4221FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_6D45E118DAA58125EF4A78FDDF41AB3C" xlink:to="loc_srt_ScenarioForecastMember_AA1230420256FA862B1978FDDF4221FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_53B66C8228F6AA8CB44378FDDF420B0A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pfe_IncomeTaxesTable_2BA40BB3F2D37B0963D478FDDF40DCB2" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_53B66C8228F6AA8CB44378FDDF420B0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6E6B5042D95FAF71357D78FDDF4222A2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_53B66C8228F6AA8CB44378FDDF420B0A" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6E6B5042D95FAF71357D78FDDF4222A2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6E6B5042D95FAF71357D78FDDF4222A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_53B66C8228F6AA8CB44378FDDF420B0A" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6E6B5042D95FAF71357D78FDDF4222A2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IncomeTaxesPayableMember" xlink:label="loc_pfe_IncomeTaxesPayableMember_387B4D90C1E652EEE8F578FDDF4297D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6E6B5042D95FAF71357D78FDDF4222A2" xlink:to="loc_pfe_IncomeTaxesPayableMember_387B4D90C1E652EEE8F578FDDF4297D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B69361CE5F377DC627F278FDDF4362F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_85ECBE9ED50B2D4854BD78FDDF425FCF" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B69361CE5F377DC627F278FDDF4362F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_C01C9F1EC298852E7D8B7910AE908261" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_85ECBE9ED50B2D4854BD78FDDF425FCF" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_C01C9F1EC298852E7D8B7910AE908261" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_B3D5A3AEB5EBFF81E00778FDDF431EED" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_85ECBE9ED50B2D4854BD78FDDF425FCF" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_B3D5A3AEB5EBFF81E00778FDDF431EED" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PaymentForRepatriationTax" xlink:label="loc_pfe_PaymentForRepatriationTax_4D217B235C4F5DBEC5A678FDDF43AF9F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_85ECBE9ED50B2D4854BD78FDDF425FCF" xlink:to="loc_pfe_PaymentForRepatriationTax_4D217B235C4F5DBEC5A678FDDF43AF9F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/TaxMattersTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>pfe-20200628_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_pfe_FinancialInstrumentsAbstract_B9E9D518BB81E35001A06EAB464B245F_label_en-US" xlink:label="lab_pfe_FinancialInstrumentsAbstract_B9E9D518BB81E35001A06EAB464B245F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:label id="lab_pfe_FinancialInstrumentsAbstract_B9E9D518BB81E35001A06EAB464B245F_documentation_en-US" xlink:label="lab_pfe_FinancialInstrumentsAbstract_B9E9D518BB81E35001A06EAB464B245F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_B9E9D518BB81E35001A06EAB464B245F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FinancialInstrumentsAbstract_B9E9D518BB81E35001A06EAB464B245F" xlink:to="lab_pfe_FinancialInstrumentsAbstract_B9E9D518BB81E35001A06EAB464B245F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E6BDB9FF2A01F07DB7716EAB464B6C12_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E6BDB9FF2A01F07DB7716EAB464B6C12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E6BDB9FF2A01F07DB7716EAB464B6C12_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E6BDB9FF2A01F07DB7716EAB464B6C12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E6BDB9FF2A01F07DB7716EAB464B6C12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E6BDB9FF2A01F07DB7716EAB464B6C12" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E6BDB9FF2A01F07DB7716EAB464B6C12" xlink:type="arc" />
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_003E6CBD65370A2EE6946EACFD27DED9_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis_003E6CBD65370A2EE6946EACFD27DED9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_003E6CBD65370A2EE6946EACFD27DED9_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis_003E6CBD65370A2EE6946EACFD27DED9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_003E6CBD65370A2EE6946EACFD27DED9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis_003E6CBD65370A2EE6946EACFD27DED9" xlink:to="lab_srt_ConsolidatedEntitiesAxis_003E6CBD65370A2EE6946EACFD27DED9" xlink:type="arc" />
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_371724083FCE110136536EACFEE80FE0_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain_371724083FCE110136536EACFEE80FE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_371724083FCE110136536EACFEE80FE0_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain_371724083FCE110136536EACFEE80FE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_371724083FCE110136536EACFEE80FE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain_371724083FCE110136536EACFEE80FE0" xlink:to="lab_srt_ConsolidatedEntitiesDomain_371724083FCE110136536EACFEE80FE0" xlink:type="arc" />
    <link:label id="lab_srt_SubsidiariesMember_2BC9A5C9597D78ADFB896EACFDE2AC9E_terseLabel_en-US" xlink:label="lab_srt_SubsidiariesMember_2BC9A5C9597D78ADFB896EACFDE2AC9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiaries [Member]</link:label>
    <link:label id="lab_srt_SubsidiariesMember_2BC9A5C9597D78ADFB896EACFDE2AC9E_label_en-US" xlink:label="lab_srt_SubsidiariesMember_2BC9A5C9597D78ADFB896EACFDE2AC9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiaries [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_2BC9A5C9597D78ADFB896EACFDE2AC9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SubsidiariesMember_2BC9A5C9597D78ADFB896EACFDE2AC9E" xlink:to="lab_srt_SubsidiariesMember_2BC9A5C9597D78ADFB896EACFDE2AC9E" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_BED4609DEDAE4E2EDD0D6EACFBB2FC16_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_BED4609DEDAE4E2EDD0D6EACFBB2FC16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_BED4609DEDAE4E2EDD0D6EACFBB2FC16_label_en-US" xlink:label="lab_dei_LegalEntityAxis_BED4609DEDAE4E2EDD0D6EACFBB2FC16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_BED4609DEDAE4E2EDD0D6EACFBB2FC16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_BED4609DEDAE4E2EDD0D6EACFBB2FC16" xlink:to="lab_dei_LegalEntityAxis_BED4609DEDAE4E2EDD0D6EACFBB2FC16" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_A7449B62393B07581D9C6EACFDCAE2B8_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_A7449B62393B07581D9C6EACFDCAE2B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_A7449B62393B07581D9C6EACFDCAE2B8_label_en-US" xlink:label="lab_dei_EntityDomain_A7449B62393B07581D9C6EACFDCAE2B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_A7449B62393B07581D9C6EACFDCAE2B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_A7449B62393B07581D9C6EACFDCAE2B8" xlink:to="lab_dei_EntityDomain_A7449B62393B07581D9C6EACFDCAE2B8" xlink:type="arc" />
    <link:label id="lab_pfe_UpjohnIncMember_C4E94FDB38072F2ECC0B6EACFCA194F7_terseLabel_en-US" xlink:label="lab_pfe_UpjohnIncMember_C4E94FDB38072F2ECC0B6EACFCA194F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upjohn Inc [Member]</link:label>
    <link:label id="lab_pfe_UpjohnIncMember_C4E94FDB38072F2ECC0B6EACFCA194F7_label_en-US" xlink:label="lab_pfe_UpjohnIncMember_C4E94FDB38072F2ECC0B6EACFCA194F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upjohn Inc [Member]</link:label>
    <link:label id="lab_pfe_UpjohnIncMember_C4E94FDB38072F2ECC0B6EACFCA194F7_documentation_en-US" xlink:label="lab_pfe_UpjohnIncMember_C4E94FDB38072F2ECC0B6EACFCA194F7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upjohn Inc [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnIncMember" xlink:label="loc_pfe_UpjohnIncMember_C4E94FDB38072F2ECC0B6EACFCA194F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_UpjohnIncMember_C4E94FDB38072F2ECC0B6EACFCA194F7" xlink:to="lab_pfe_UpjohnIncMember_C4E94FDB38072F2ECC0B6EACFCA194F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_67212B706D128DE7B74F6EAB464B1F5D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_67212B706D128DE7B74F6EAB464B1F5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_67212B706D128DE7B74F6EAB464B1F5D_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_67212B706D128DE7B74F6EAB464B1F5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_67212B706D128DE7B74F6EAB464B1F5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_67212B706D128DE7B74F6EAB464B1F5D" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_67212B706D128DE7B74F6EAB464B1F5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_2BED64E2771277B901F46EAB464CF60E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_2BED64E2771277B901F46EAB464CF60E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_2BED64E2771277B901F46EAB464CF60E_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_2BED64E2771277B901F46EAB464CF60E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2BED64E2771277B901F46EAB464CF60E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2BED64E2771277B901F46EAB464CF60E" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_2BED64E2771277B901F46EAB464CF60E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_3C4AD60C881F2AEB60CD6EAB464C8BE9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_3C4AD60C881F2AEB60CD6EAB464C8BE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_3C4AD60C881F2AEB60CD6EAB464C8BE9_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_3C4AD60C881F2AEB60CD6EAB464C8BE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3C4AD60C881F2AEB60CD6EAB464C8BE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_3C4AD60C881F2AEB60CD6EAB464C8BE9" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_3C4AD60C881F2AEB60CD6EAB464C8BE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9903E88AE2FA7BF11F9F6EAB464E544F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9903E88AE2FA7BF11F9F6EAB464E544F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9903E88AE2FA7BF11F9F6EAB464E544F_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9903E88AE2FA7BF11F9F6EAB464E544F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9903E88AE2FA7BF11F9F6EAB464E544F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9903E88AE2FA7BF11F9F6EAB464E544F" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9903E88AE2FA7BF11F9F6EAB464E544F" xlink:type="arc" />
    <link:label id="lab_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_F716BE1840D54B7D3ACD6EAB464ECB71_terseLabel_en-US" xlink:label="lab_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_F716BE1840D54B7D3ACD6EAB464ECB71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Footnotes to selected financial assets and liabilities:</link:label>
    <link:label id="lab_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_F716BE1840D54B7D3ACD6EAB464ECB71_label_en-US" xlink:label="lab_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_F716BE1840D54B7D3ACD6EAB464ECB71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Footnotes To Selected Financial Assets And Liabilities [Abstract]</link:label>
    <link:label id="lab_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_F716BE1840D54B7D3ACD6EAB464ECB71_documentation_en-US" xlink:label="lab_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_F716BE1840D54B7D3ACD6EAB464ECB71" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Footnotes to selected financial assets and liabilities [Abstract]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract" xlink:label="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_F716BE1840D54B7D3ACD6EAB464ECB71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_F716BE1840D54B7D3ACD6EAB464ECB71" xlink:to="lab_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_F716BE1840D54B7D3ACD6EAB464ECB71" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0B2528D24304456972976EAB464F907E_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0B2528D24304456972976EAB464F907E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0B2528D24304456972976EAB464F907E_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0B2528D24304456972976EAB464F907E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0B2528D24304456972976EAB464F907E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0B2528D24304456972976EAB464F907E" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0B2528D24304456972976EAB464F907E" xlink:type="arc" />
    <link:label id="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_AAEC6033D0DE0185FE4C6EAB464F72E6_terseLabel_en-US" xlink:label="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_AAEC6033D0DE0185FE4C6EAB464F72E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term equity securities held in trust</link:label>
    <link:label id="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_AAEC6033D0DE0185FE4C6EAB464F72E6_label_en-US" xlink:label="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_AAEC6033D0DE0185FE4C6EAB464F72E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Restricted, Noncurrent</link:label>
    <link:label id="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_AAEC6033D0DE0185FE4C6EAB464F72E6_documentation_en-US" xlink:label="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_AAEC6033D0DE0185FE4C6EAB464F72E6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Restricted, Noncurrent</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EquitySecuritiesFVNIRestrictedNoncurrent" xlink:label="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_AAEC6033D0DE0185FE4C6EAB464F72E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_AAEC6033D0DE0185FE4C6EAB464F72E6" xlink:to="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_AAEC6033D0DE0185FE4C6EAB464F72E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeTable_98BF055BE63E0CAC090A94761F125289_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable_98BF055BE63E0CAC090A94761F125289" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_98BF055BE63E0CAC090A94761F125289_label_en-US" xlink:label="lab_us-gaap_DerivativeTable_98BF055BE63E0CAC090A94761F125289" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_98BF055BE63E0CAC090A94761F125289" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable_98BF055BE63E0CAC090A94761F125289" xlink:to="lab_us-gaap_DerivativeTable_98BF055BE63E0CAC090A94761F125289" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_D59B7E88C686FCA2C5E094761F136170_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_D59B7E88C686FCA2C5E094761F136170" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_D59B7E88C686FCA2C5E094761F136170_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_D59B7E88C686FCA2C5E094761F136170" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_D59B7E88C686FCA2C5E094761F136170" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_D59B7E88C686FCA2C5E094761F136170" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis_D59B7E88C686FCA2C5E094761F136170" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_DD1956906A13AC40DBB294761F13F6E1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_DD1956906A13AC40DBB294761F13F6E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_DD1956906A13AC40DBB294761F13F6E1_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_DD1956906A13AC40DBB294761F13F6E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_DD1956906A13AC40DBB294761F13F6E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_DD1956906A13AC40DBB294761F13F6E1" xlink:to="lab_us-gaap_DerivativeContractTypeDomain_DD1956906A13AC40DBB294761F13F6E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_E57BCA07C23B920D6BDF94761F13C49F_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_E57BCA07C23B920D6BDF94761F13C49F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange contracts [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_E57BCA07C23B920D6BDF94761F13C49F_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_E57BCA07C23B920D6BDF94761F13C49F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_E57BCA07C23B920D6BDF94761F13C49F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember_E57BCA07C23B920D6BDF94761F13C49F" xlink:to="lab_us-gaap_ForeignExchangeContractMember_E57BCA07C23B920D6BDF94761F13C49F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLineItems_8293004AD726357E64A094761F133F66_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems_8293004AD726357E64A094761F133F66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_8293004AD726357E64A094761F133F66_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems_8293004AD726357E64A094761F133F66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_8293004AD726357E64A094761F133F66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems_8293004AD726357E64A094761F133F66" xlink:to="lab_us-gaap_DerivativeLineItems_8293004AD726357E64A094761F133F66" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeTermOfContract_5762C75B3300E1EB1AC494761F142B92_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract_5762C75B3300E1EB1AC494761F142B92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative term of contract</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_5762C75B3300E1EB1AC494761F142B92_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract_5762C75B3300E1EB1AC494761F142B92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTermOfContract" xlink:label="loc_us-gaap_DerivativeTermOfContract_5762C75B3300E1EB1AC494761F142B92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract_5762C75B3300E1EB1AC494761F142B92" xlink:to="lab_us-gaap_DerivativeTermOfContract_5762C75B3300E1EB1AC494761F142B92" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_041EB4B08FC7CB84B27894761F148D1A_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_041EB4B08FC7CB84B27894761F148D1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives in a net liability position</link:label>
    <link:label id="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_041EB4B08FC7CB84B27894761F148D1A_label_en-US" xlink:label="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_041EB4B08FC7CB84B27894761F148D1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Net Liability Position, Aggregate Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNetLiabilityPositionAggregateFairValue" xlink:label="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_041EB4B08FC7CB84B27894761F148D1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_041EB4B08FC7CB84B27894761F148D1A" xlink:to="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_041EB4B08FC7CB84B27894761F148D1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_BD088DF223917C973D3D94761F142AFA_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_BD088DF223917C973D3D94761F142AFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collateral posted</link:label>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_BD088DF223917C973D3D94761F142AFA_label_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_BD088DF223917C973D3D94761F142AFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collateral Already Posted, Aggregate Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_BD088DF223917C973D3D94761F142AFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_BD088DF223917C973D3D94761F142AFA" xlink:to="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_BD088DF223917C973D3D94761F142AFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SecuritiesReceivedAsCollateral_EF6A14D8A7DC65EA8BD894761F14B1A3_terseLabel_en-US" xlink:label="lab_us-gaap_SecuritiesReceivedAsCollateral_EF6A14D8A7DC65EA8BD894761F14B1A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash collateral received</link:label>
    <link:label id="lab_us-gaap_SecuritiesReceivedAsCollateral_EF6A14D8A7DC65EA8BD894761F14B1A3_label_en-US" xlink:label="lab_us-gaap_SecuritiesReceivedAsCollateral_EF6A14D8A7DC65EA8BD894761F14B1A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Received as Collateral</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuritiesReceivedAsCollateral" xlink:label="loc_us-gaap_SecuritiesReceivedAsCollateral_EF6A14D8A7DC65EA8BD894761F14B1A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuritiesReceivedAsCollateral_EF6A14D8A7DC65EA8BD894761F14B1A3" xlink:to="lab_us-gaap_SecuritiesReceivedAsCollateral_EF6A14D8A7DC65EA8BD894761F14B1A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_B8C1A0C8B7243A312A8BB7017B61FBE7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_B8C1A0C8B7243A312A8BB7017B61FBE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_B8C1A0C8B7243A312A8BB7017B61FBE7_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_B8C1A0C8B7243A312A8BB7017B61FBE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_B8C1A0C8B7243A312A8BB7017B61FBE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_B8C1A0C8B7243A312A8BB7017B61FBE7" xlink:to="lab_us-gaap_DebtInstrumentTable_B8C1A0C8B7243A312A8BB7017B61FBE7" xlink:type="arc" />
    <link:label id="lab_pfe_UpjohnFinanceB.V.Member_F33F9E5B7263C42B6C48B7017B6274E7_terseLabel_en-US" xlink:label="lab_pfe_UpjohnFinanceB.V.Member_F33F9E5B7263C42B6C48B7017B6274E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upjohn Finance B.V. [Member]</link:label>
    <link:label id="lab_pfe_UpjohnFinanceB.V.Member_F33F9E5B7263C42B6C48B7017B6274E7_label_en-US" xlink:label="lab_pfe_UpjohnFinanceB.V.Member_F33F9E5B7263C42B6C48B7017B6274E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upjohn Finance B.V. [Member]</link:label>
    <link:label id="lab_pfe_UpjohnFinanceB.V.Member_F33F9E5B7263C42B6C48B7017B6274E7_documentation_en-US" xlink:label="lab_pfe_UpjohnFinanceB.V.Member_F33F9E5B7263C42B6C48B7017B6274E7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upjohn Finance B.V. [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnFinanceB.V.Member" xlink:label="loc_pfe_UpjohnFinanceB.V.Member_F33F9E5B7263C42B6C48B7017B6274E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_UpjohnFinanceB.V.Member_F33F9E5B7263C42B6C48B7017B6274E7" xlink:to="lab_pfe_UpjohnFinanceB.V.Member_F33F9E5B7263C42B6C48B7017B6274E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ParentMember_AF87E36E0CC30EBC8C65B7017B638D1E_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember_AF87E36E0CC30EBC8C65B7017B638D1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:label id="lab_us-gaap_ParentMember_AF87E36E0CC30EBC8C65B7017B638D1E_label_en-US" xlink:label="lab_us-gaap_ParentMember_AF87E36E0CC30EBC8C65B7017B638D1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_AF87E36E0CC30EBC8C65B7017B638D1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember_AF87E36E0CC30EBC8C65B7017B638D1E" xlink:to="lab_us-gaap_ParentMember_AF87E36E0CC30EBC8C65B7017B638D1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_8490681A4C4E2A4C91D5B7017B639CE1_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_8490681A4C4E2A4C91D5B7017B639CE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_8490681A4C4E2A4C91D5B7017B639CE1_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_8490681A4C4E2A4C91D5B7017B639CE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8490681A4C4E2A4C91D5B7017B639CE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8490681A4C4E2A4C91D5B7017B639CE1" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_8490681A4C4E2A4C91D5B7017B639CE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_69B81AEEC6A9DC37676DB7017B63EBA4_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_69B81AEEC6A9DC37676DB7017B63EBA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_69B81AEEC6A9DC37676DB7017B63EBA4_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_69B81AEEC6A9DC37676DB7017B63EBA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_69B81AEEC6A9DC37676DB7017B63EBA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_69B81AEEC6A9DC37676DB7017B63EBA4" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_69B81AEEC6A9DC37676DB7017B63EBA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeniorNotesMember_AEA7189008A36D701988B7017B64F854_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember_AEA7189008A36D701988B7017B64F854" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_AEA7189008A36D701988B7017B64F854_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember_AEA7189008A36D701988B7017B64F854" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_AEA7189008A36D701988B7017B64F854" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember_AEA7189008A36D701988B7017B64F854" xlink:to="lab_us-gaap_SeniorNotesMember_AEA7189008A36D701988B7017B64F854" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_5848E110D3CBE9F0AF6CB7017B644F3A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_5848E110D3CBE9F0AF6CB7017B644F3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_5848E110D3CBE9F0AF6CB7017B644F3A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_5848E110D3CBE9F0AF6CB7017B644F3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_5848E110D3CBE9F0AF6CB7017B644F3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_5848E110D3CBE9F0AF6CB7017B644F3A" xlink:to="lab_us-gaap_DebtInstrumentAxis_5848E110D3CBE9F0AF6CB7017B644F3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member_250225BA72C26BFB4390B7017B64C926_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member_250225BA72C26BFB4390B7017B64C926" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.800% notes [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member_250225BA72C26BFB4390B7017B64C926_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member_250225BA72C26BFB4390B7017B64C926" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Zero Point Eight Zero Zero Percent, Due 2025 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member_250225BA72C26BFB4390B7017B64C926_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member_250225BA72C26BFB4390B7017B64C926" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Zero Point Eight Zero Zero Percent, Due 2025 [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member" xlink:label="loc_pfe_SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member_250225BA72C26BFB4390B7017B64C926" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member_250225BA72C26BFB4390B7017B64C926" xlink:to="lab_pfe_SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member_250225BA72C26BFB4390B7017B64C926" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member_415142CBC1650E8759EEB7017B6512CB_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member_415142CBC1650E8759EEB7017B6512CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.700% notes [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member_415142CBC1650E8759EEB7017B6512CB_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member_415142CBC1650E8759EEB7017B6512CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, One Point Seven Zero Zero Percent, Due 2030 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member_415142CBC1650E8759EEB7017B6512CB_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member_415142CBC1650E8759EEB7017B6512CB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, One Point Seven Zero Zero Percent, Due 2030 [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member" xlink:label="loc_pfe_SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member_415142CBC1650E8759EEB7017B6512CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member_415142CBC1650E8759EEB7017B6512CB" xlink:to="lab_pfe_SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member_415142CBC1650E8759EEB7017B6512CB" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member_354F6B2C70C868B1C04BB7017B6564AF_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member_354F6B2C70C868B1C04BB7017B6564AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.550% notes [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member_354F6B2C70C868B1C04BB7017B6564AF_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member_354F6B2C70C868B1C04BB7017B6564AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Two Point Five Five Zero Percent, Due 2040 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member_354F6B2C70C868B1C04BB7017B6564AF_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member_354F6B2C70C868B1C04BB7017B6564AF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Two Point Five Five Zero Percent, Due 2040 [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member" xlink:label="loc_pfe_SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member_354F6B2C70C868B1C04BB7017B6564AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member_354F6B2C70C868B1C04BB7017B6564AF" xlink:to="lab_pfe_SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member_354F6B2C70C868B1C04BB7017B6564AF" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member_203DF6DB98C258CB3086B7017B6564BD_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member_203DF6DB98C258CB3086B7017B6564BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.700% notes [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member_203DF6DB98C258CB3086B7017B6564BD_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member_203DF6DB98C258CB3086B7017B6564BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Two Point Seven Zero Zero Percent, Due 2050 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member_203DF6DB98C258CB3086B7017B6564BD_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member_203DF6DB98C258CB3086B7017B6564BD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Two Point Seven Zero Zero Percent, Due 2050 [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member" xlink:label="loc_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member_203DF6DB98C258CB3086B7017B6564BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member_203DF6DB98C258CB3086B7017B6564BD" xlink:to="lab_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member_203DF6DB98C258CB3086B7017B6564BD" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member_A63303D9B2D1E05405B5B7017B65FF7C_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member_A63303D9B2D1E05405B5B7017B65FF7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.125% notes [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member_A63303D9B2D1E05405B5B7017B65FF7C_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member_A63303D9B2D1E05405B5B7017B65FF7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, One Point One Two Five Percent, Due 2022 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member_A63303D9B2D1E05405B5B7017B65FF7C_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member_A63303D9B2D1E05405B5B7017B65FF7C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, One Point One Two Five Percent, Due 2022 [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member" xlink:label="loc_pfe_SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member_A63303D9B2D1E05405B5B7017B65FF7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member_A63303D9B2D1E05405B5B7017B65FF7C" xlink:to="lab_pfe_SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member_A63303D9B2D1E05405B5B7017B65FF7C" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member_88778429BCB496003CE7B7017B65D57B_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member_88778429BCB496003CE7B7017B65D57B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.650% notes [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member_88778429BCB496003CE7B7017B65D57B_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member_88778429BCB496003CE7B7017B65D57B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, One Point Six Five Zero Percent, Due 2025 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member_88778429BCB496003CE7B7017B65D57B_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member_88778429BCB496003CE7B7017B65D57B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, One Point Six Five Zero Percent, Due 2025 [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member" xlink:label="loc_pfe_SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member_88778429BCB496003CE7B7017B65D57B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member_88778429BCB496003CE7B7017B65D57B" xlink:to="lab_pfe_SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member_88778429BCB496003CE7B7017B65D57B" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member_B62E92E4A323F80BE944B7017B66E9D4_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member_B62E92E4A323F80BE944B7017B66E9D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.300% notes [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member_B62E92E4A323F80BE944B7017B66E9D4_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member_B62E92E4A323F80BE944B7017B66E9D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Two Point Three Zero Zero Percent, Due 2027 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member_B62E92E4A323F80BE944B7017B66E9D4_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member_B62E92E4A323F80BE944B7017B66E9D4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Two Point Three Zero Zero Percent, Due 2027 [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member" xlink:label="loc_pfe_SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member_B62E92E4A323F80BE944B7017B66E9D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member_B62E92E4A323F80BE944B7017B66E9D4" xlink:to="lab_pfe_SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member_B62E92E4A323F80BE944B7017B66E9D4" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member_D193563150E51D7D0D09B7017B66720E_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member_D193563150E51D7D0D09B7017B66720E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.700% notes [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member_D193563150E51D7D0D09B7017B66720E_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member_D193563150E51D7D0D09B7017B66720E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Two Point Seven Zero Zero Percent, Due 2030 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member_D193563150E51D7D0D09B7017B66720E_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member_D193563150E51D7D0D09B7017B66720E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Two Point Seven Zero Zero Percent, Due 2030 [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member" xlink:label="loc_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member_D193563150E51D7D0D09B7017B66720E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member_D193563150E51D7D0D09B7017B66720E" xlink:to="lab_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member_D193563150E51D7D0D09B7017B66720E" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member_6A567EE8AF56C154AF0FB7017B66D533_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member_6A567EE8AF56C154AF0FB7017B66D533" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.850% notes [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member_6A567EE8AF56C154AF0FB7017B66D533_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member_6A567EE8AF56C154AF0FB7017B66D533" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Three Point Eight Five Zero Percent, Due 2040 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member_6A567EE8AF56C154AF0FB7017B66D533_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member_6A567EE8AF56C154AF0FB7017B66D533" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Three Point Eight Five Zero Percent, Due 2040 [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member" xlink:label="loc_pfe_SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member_6A567EE8AF56C154AF0FB7017B66D533" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member_6A567EE8AF56C154AF0FB7017B66D533" xlink:to="lab_pfe_SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member_6A567EE8AF56C154AF0FB7017B66D533" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member_92727FA06579C6532A4CB7017B66A3C3_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member_92727FA06579C6532A4CB7017B66A3C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.000% notes [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member_92727FA06579C6532A4CB7017B66A3C3_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member_92727FA06579C6532A4CB7017B66A3C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Four Point Zero Zero Zero Percent, Due 2050 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member_92727FA06579C6532A4CB7017B66A3C3_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member_92727FA06579C6532A4CB7017B66A3C3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Four Point Zero Zero Zero Percent, Due 2050 [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member" xlink:label="loc_pfe_SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member_92727FA06579C6532A4CB7017B66A3C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member_92727FA06579C6532A4CB7017B66A3C3" xlink:to="lab_pfe_SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member_92727FA06579C6532A4CB7017B66A3C3" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member_53CEC6E7126A650309DEB7017B66A93B_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member_53CEC6E7126A650309DEB7017B66A93B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.816% notes [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member_53CEC6E7126A650309DEB7017B66A93B_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member_53CEC6E7126A650309DEB7017B66A93B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Zero Point Eight One Six Percent, Due 2022 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member_53CEC6E7126A650309DEB7017B66A93B_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member_53CEC6E7126A650309DEB7017B66A93B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Zero Point Eight One Six Percent, Due 2022 [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member" xlink:label="loc_pfe_SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member_53CEC6E7126A650309DEB7017B66A93B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member_53CEC6E7126A650309DEB7017B66A93B" xlink:to="lab_pfe_SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member_53CEC6E7126A650309DEB7017B66A93B" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member_0D5F463EB9E20E3AE362B7017B66254E_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member_0D5F463EB9E20E3AE362B7017B66254E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.023% notes [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member_0D5F463EB9E20E3AE362B7017B66254E_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member_0D5F463EB9E20E3AE362B7017B66254E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, One Point Zero Two Three Percent, Due 2024 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member_0D5F463EB9E20E3AE362B7017B66254E_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member_0D5F463EB9E20E3AE362B7017B66254E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, One Point Zero Two Three Percent, Due 2024 [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member" xlink:label="loc_pfe_SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member_0D5F463EB9E20E3AE362B7017B66254E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member_0D5F463EB9E20E3AE362B7017B66254E" xlink:to="lab_pfe_SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member_0D5F463EB9E20E3AE362B7017B66254E" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member_B1F13BF7D4EE2131B4CFB7017B67D8FA_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member_B1F13BF7D4EE2131B4CFB7017B67D8FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.362% notes [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member_B1F13BF7D4EE2131B4CFB7017B67D8FA_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member_B1F13BF7D4EE2131B4CFB7017B67D8FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, One Point Three Six Two Percent, Due 2027 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member_B1F13BF7D4EE2131B4CFB7017B67D8FA_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member_B1F13BF7D4EE2131B4CFB7017B67D8FA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, One Point Three Six Two Percent, Due 2027 [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member" xlink:label="loc_pfe_SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member_B1F13BF7D4EE2131B4CFB7017B67D8FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member_B1F13BF7D4EE2131B4CFB7017B67D8FA" xlink:to="lab_pfe_SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member_B1F13BF7D4EE2131B4CFB7017B67D8FA" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member_E9868B10B64D1B822CD8B7017B677446_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member_E9868B10B64D1B822CD8B7017B677446" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.908% notes [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member_E9868B10B64D1B822CD8B7017B677446_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member_E9868B10B64D1B822CD8B7017B677446" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, One Point Nine Zero Eight Percent, Due 2032 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member_E9868B10B64D1B822CD8B7017B677446_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member_E9868B10B64D1B822CD8B7017B677446" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, One Point Nine Zero Eight Percent, Due 2032 [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member" xlink:label="loc_pfe_SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member_E9868B10B64D1B822CD8B7017B677446" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member_E9868B10B64D1B822CD8B7017B677446" xlink:to="lab_pfe_SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member_E9868B10B64D1B822CD8B7017B677446" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member_70393EF7027E2BC32F10B7017B67E43C_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member_70393EF7027E2BC32F10B7017B67E43C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.625% notes [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member_70393EF7027E2BC32F10B7017B67E43C_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member_70393EF7027E2BC32F10B7017B67E43C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Two Point Six Two Five Percent, Due 2030 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member_70393EF7027E2BC32F10B7017B67E43C_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member_70393EF7027E2BC32F10B7017B67E43C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Two Point Six Two Five Percent, Due 2030 [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member" xlink:label="loc_pfe_SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member_70393EF7027E2BC32F10B7017B67E43C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member_70393EF7027E2BC32F10B7017B67E43C" xlink:to="lab_pfe_SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member_70393EF7027E2BC32F10B7017B67E43C" xlink:type="arc" />
    <link:label id="lab_pfe_LongTermDebtIssuedFirstQuarter2020Member_4AFC00BF85F0A4EA7EB8B704A56CDE53_terseLabel_en-US" xlink:label="lab_pfe_LongTermDebtIssuedFirstQuarter2020Member_4AFC00BF85F0A4EA7EB8B704A56CDE53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long Term Debt Issued First Quarter 2020 [Member]</link:label>
    <link:label id="lab_pfe_LongTermDebtIssuedFirstQuarter2020Member_4AFC00BF85F0A4EA7EB8B704A56CDE53_label_en-US" xlink:label="lab_pfe_LongTermDebtIssuedFirstQuarter2020Member_4AFC00BF85F0A4EA7EB8B704A56CDE53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Term Debt Issued First Quarter 2020 [Member]</link:label>
    <link:label id="lab_pfe_LongTermDebtIssuedFirstQuarter2020Member_4AFC00BF85F0A4EA7EB8B704A56CDE53_documentation_en-US" xlink:label="lab_pfe_LongTermDebtIssuedFirstQuarter2020Member_4AFC00BF85F0A4EA7EB8B704A56CDE53" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long Term Debt Issued First Quarter 2020 [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LongTermDebtIssuedFirstQuarter2020Member" xlink:label="loc_pfe_LongTermDebtIssuedFirstQuarter2020Member_4AFC00BF85F0A4EA7EB8B704A56CDE53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LongTermDebtIssuedFirstQuarter2020Member_4AFC00BF85F0A4EA7EB8B704A56CDE53" xlink:to="lab_pfe_LongTermDebtIssuedFirstQuarter2020Member_4AFC00BF85F0A4EA7EB8B704A56CDE53" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_ADBE9C28E5E8906527F0B7017B67499B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_ADBE9C28E5E8906527F0B7017B67499B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_ADBE9C28E5E8906527F0B7017B67499B_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_ADBE9C28E5E8906527F0B7017B67499B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ADBE9C28E5E8906527F0B7017B67499B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ADBE9C28E5E8906527F0B7017B67499B" xlink:to="lab_us-gaap_DebtInstrumentLineItems_ADBE9C28E5E8906527F0B7017B67499B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_BFB50DDE9B62E6F27576B7017B67B715_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_BFB50DDE9B62E6F27576B7017B67B715" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Principal</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_BFB50DDE9B62E6F27576B7017B67B715_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_BFB50DDE9B62E6F27576B7017B67B715" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_BFB50DDE9B62E6F27576B7017B67B715" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_BFB50DDE9B62E6F27576B7017B67B715" xlink:to="lab_us-gaap_LongTermDebt_BFB50DDE9B62E6F27576B7017B67B715" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1180CA6602917BBD6AC9B7017B67D023_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1180CA6602917BBD6AC9B7017B67D023" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1180CA6602917BBD6AC9B7017B67D023_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1180CA6602917BBD6AC9B7017B67D023" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1180CA6602917BBD6AC9B7017B67D023" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1180CA6602917BBD6AC9B7017B67D023" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1180CA6602917BBD6AC9B7017B67D023" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2217456977EDA6FDFE57B7017B6865BF_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2217456977EDA6FDFE57B7017B6865BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2217456977EDA6FDFE57B7017B6865BF_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2217456977EDA6FDFE57B7017B6865BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2217456977EDA6FDFE57B7017B6865BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2217456977EDA6FDFE57B7017B6865BF" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2217456977EDA6FDFE57B7017B6865BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_E614C4589E63FB3246FBB7017B6836C1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_E614C4589E63FB3246FBB7017B6836C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption price percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_E614C4589E63FB3246FBB7017B6836C1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_E614C4589E63FB3246FBB7017B6836C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_E614C4589E63FB3246FBB7017B6836C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_E614C4589E63FB3246FBB7017B6836C1" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_E614C4589E63FB3246FBB7017B6836C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_3B393882576624E64FDC947622809BA6_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_3B393882576624E64FDC947622809BA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_3B393882576624E64FDC947622809BA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_3B393882576624E64FDC947622809BA6" xlink:to="lab_us-gaap_EquityAbstract_3B393882576624E64FDC947622809BA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_B1587BC91E511648C161947622809821_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_B1587BC91E511648C161947622809821" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Accumulated Other Comprehensive Loss, Net of Tax</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_B1587BC91E511648C161947622809821_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_B1587BC91E511648C161947622809821" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_B1587BC91E511648C161947622809821" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_B1587BC91E511648C161947622809821" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_B1587BC91E511648C161947622809821" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_04FC9A1A71A89895BD245967928E4934_label_en-US" xlink:label="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_04FC9A1A71A89895BD245967928E4934" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]</link:label>
    <link:label id="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_04FC9A1A71A89895BD245967928E4934_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_04FC9A1A71A89895BD245967928E4934" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_04FC9A1A71A89895BD245967928E4934" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_04FC9A1A71A89895BD245967928E4934" xlink:to="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_04FC9A1A71A89895BD245967928E4934" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1E381EAE57FB75F2DB1B5967928FE9F9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1E381EAE57FB75F2DB1B5967928FE9F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1E381EAE57FB75F2DB1B5967928FE9F9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1E381EAE57FB75F2DB1B5967928FE9F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1E381EAE57FB75F2DB1B5967928FE9F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1E381EAE57FB75F2DB1B5967928FE9F9" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1E381EAE57FB75F2DB1B5967928FE9F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_7BF9C9B6995D8574A8455967928F962F_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_7BF9C9B6995D8574A8455967928F962F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_7BF9C9B6995D8574A8455967928F962F_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_7BF9C9B6995D8574A8455967928F962F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7BF9C9B6995D8574A8455967928F962F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7BF9C9B6995D8574A8455967928F962F" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_7BF9C9B6995D8574A8455967928F962F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_513C3B4C47B95DBD02255967928FFF89_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_513C3B4C47B95DBD02255967928FFF89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_513C3B4C47B95DBD02255967928FFF89_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_513C3B4C47B95DBD02255967928FFF89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_513C3B4C47B95DBD02255967928FFF89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_513C3B4C47B95DBD02255967928FFF89" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_513C3B4C47B95DBD02255967928FFF89" xlink:type="arc" />
    <link:label id="lab_pfe_ArrayMember_C138B9969204952EBF3159679290CEFC_terseLabel_en-US" xlink:label="lab_pfe_ArrayMember_C138B9969204952EBF3159679290CEFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Array [Member]</link:label>
    <link:label id="lab_pfe_ArrayMember_C138B9969204952EBF3159679290CEFC_label_en-US" xlink:label="lab_pfe_ArrayMember_C138B9969204952EBF3159679290CEFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Array [Member]</link:label>
    <link:label id="lab_pfe_ArrayMember_C138B9969204952EBF3159679290CEFC_documentation_en-US" xlink:label="lab_pfe_ArrayMember_C138B9969204952EBF3159679290CEFC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Array [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ArrayMember" xlink:label="loc_pfe_ArrayMember_C138B9969204952EBF3159679290CEFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ArrayMember_C138B9969204952EBF3159679290CEFC" xlink:to="lab_pfe_ArrayMember_C138B9969204952EBF3159679290CEFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_B5FE63E7929705ED59A259679290A885_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_B5FE63E7929705ED59A259679290A885" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_B5FE63E7929705ED59A259679290A885_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_B5FE63E7929705ED59A259679290A885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_B5FE63E7929705ED59A259679290A885" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B5FE63E7929705ED59A259679290A885" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_B5FE63E7929705ED59A259679290A885" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_5DCD1F94C00E511BFD7B596792909D14_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_5DCD1F94C00E511BFD7B596792909D14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business acquisition, per share in cash (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_5DCD1F94C00E511BFD7B596792909D14_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_5DCD1F94C00E511BFD7B596792909D14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_5DCD1F94C00E511BFD7B596792909D14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice_5DCD1F94C00E511BFD7B596792909D14" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice_5DCD1F94C00E511BFD7B596792909D14" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_3371BCE21B85AA7DBE65596792909A11_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_3371BCE21B85AA7DBE65596792909A11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for acquisition, cash portion</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_3371BCE21B85AA7DBE65596792909A11_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_3371BCE21B85AA7DBE65596792909A11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_3371BCE21B85AA7DBE65596792909A11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_3371BCE21B85AA7DBE65596792909A11" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_3371BCE21B85AA7DBE65596792909A11" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1060CDDFB11BBB8156D8596792906734_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1060CDDFB11BBB8156D8596792906734" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of business, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1060CDDFB11BBB8156D8596792906734_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1060CDDFB11BBB8156D8596792906734" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1060CDDFB11BBB8156D8596792906734" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1060CDDFB11BBB8156D8596792906734" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1060CDDFB11BBB8156D8596792906734" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_C8262AA91094003E8AC0947622E6947C_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_C8262AA91094003E8AC0947622E6947C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_C8262AA91094003E8AC0947622E6947C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_C8262AA91094003E8AC0947622E6947C" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_C8262AA91094003E8AC0947622E6947C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_619BF0412B9E1CF20234947622E63717_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_619BF0412B9E1CF20234947622E63717" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension and Postretirement Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_619BF0412B9E1CF20234947622E63717_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_619BF0412B9E1CF20234947622E63717" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_619BF0412B9E1CF20234947622E63717" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_619BF0412B9E1CF20234947622E63717" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_619BF0412B9E1CF20234947622E63717" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_EBDD0A07EA4E8209BB99B09F32FADAE6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_EBDD0A07EA4E8209BB99B09F32FADAE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_EBDD0A07EA4E8209BB99B09F32FADAE6_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_EBDD0A07EA4E8209BB99B09F32FADAE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_EBDD0A07EA4E8209BB99B09F32FADAE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_EBDD0A07EA4E8209BB99B09F32FADAE6" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis_EBDD0A07EA4E8209BB99B09F32FADAE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_33F59BB21BF8842AB6B7B09F32FBE610_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_33F59BB21BF8842AB6B7B09F32FBE610" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_33F59BB21BF8842AB6B7B09F32FBE610_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_33F59BB21BF8842AB6B7B09F32FBE610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_33F59BB21BF8842AB6B7B09F32FBE610" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_33F59BB21BF8842AB6B7B09F32FBE610" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain_33F59BB21BF8842AB6B7B09F32FBE610" xlink:type="arc" />
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_A025319F0F29ABD90C8EB09F32FBF698_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_A025319F0F29ABD90C8EB09F32FBF698" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_A025319F0F29ABD90C8EB09F32FBF698_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_A025319F0F29ABD90C8EB09F32FBF698" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_A025319F0F29ABD90C8EB09F32FBF698" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_A025319F0F29ABD90C8EB09F32FBF698" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_A025319F0F29ABD90C8EB09F32FBF698" xlink:type="arc" />
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_61020D3F10543EBE6082B09F32FBFEE5_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_61020D3F10543EBE6082B09F32FBFEE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying Value [Member]</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_61020D3F10543EBE6082B09F32FBFEE5_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_61020D3F10543EBE6082B09F32FBFEE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_61020D3F10543EBE6082B09F32FBFEE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_61020D3F10543EBE6082B09F32FBFEE5" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_61020D3F10543EBE6082B09F32FBFEE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_82C20E063D6F9F0649ECB09F32FB6056_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_82C20E063D6F9F0649ECB09F32FB6056" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value [Member]</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_82C20E063D6F9F0649ECB09F32FB6056_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_82C20E063D6F9F0649ECB09F32FB6056" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_82C20E063D6F9F0649ECB09F32FB6056" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_82C20E063D6F9F0649ECB09F32FB6056" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_82C20E063D6F9F0649ECB09F32FB6056" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_101EC425FAFB62753269B09F32FC4DC7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_101EC425FAFB62753269B09F32FC4DC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_101EC425FAFB62753269B09F32FC4DC7_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_101EC425FAFB62753269B09F32FC4DC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_101EC425FAFB62753269B09F32FC4DC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_101EC425FAFB62753269B09F32FC4DC7" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_101EC425FAFB62753269B09F32FC4DC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7113C98E3BD9BEE2ED16B09F32FC53C1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7113C98E3BD9BEE2ED16B09F32FC53C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7113C98E3BD9BEE2ED16B09F32FC53C1_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7113C98E3BD9BEE2ED16B09F32FC53C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7113C98E3BD9BEE2ED16B09F32FC53C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7113C98E3BD9BEE2ED16B09F32FC53C1" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7113C98E3BD9BEE2ED16B09F32FC53C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_E42DD64A8C88B4AD49FDB09F32FCDC88_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_E42DD64A8C88B4AD49FDB09F32FCDC88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_E42DD64A8C88B4AD49FDB09F32FCDC88_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_E42DD64A8C88B4AD49FDB09F32FCDC88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_E42DD64A8C88B4AD49FDB09F32FCDC88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_E42DD64A8C88B4AD49FDB09F32FCDC88" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_E42DD64A8C88B4AD49FDB09F32FCDC88" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtFairValue_56DD2060351A83828E6FB09F32FDA3F6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue_56DD2060351A83828E6FB09F32FDA3F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, excluding the current portion(a)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_56DD2060351A83828E6FB09F32FDA3F6_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue_56DD2060351A83828E6FB09F32FDA3F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_56DD2060351A83828E6FB09F32FDA3F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue_56DD2060351A83828E6FB09F32FDA3F6" xlink:to="lab_us-gaap_LongTermDebtFairValue_56DD2060351A83828E6FB09F32FDA3F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnsecuredDebtMember_371C49AF9BB357ECA725628A0BC4C21A_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember_371C49AF9BB357ECA725628A0BC4C21A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_371C49AF9BB357ECA725628A0BC4C21A_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember_371C49AF9BB357ECA725628A0BC4C21A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_371C49AF9BB357ECA725628A0BC4C21A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember_371C49AF9BB357ECA725628A0BC4C21A" xlink:to="lab_us-gaap_UnsecuredDebtMember_371C49AF9BB357ECA725628A0BC4C21A" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorNotesDue2047Member_3206AC583E5E687169BF628A0BC5EF25_terseLabel_en-US" xlink:label="lab_pfe_SeniorNotesDue2047Member_3206AC583E5E687169BF628A0BC5EF25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes Due 2047 [Member]</link:label>
    <link:label id="lab_pfe_SeniorNotesDue2047Member_3206AC583E5E687169BF628A0BC5EF25_label_en-US" xlink:label="lab_pfe_SeniorNotesDue2047Member_3206AC583E5E687169BF628A0BC5EF25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Due 2047 [Member]</link:label>
    <link:label id="lab_pfe_SeniorNotesDue2047Member_3206AC583E5E687169BF628A0BC5EF25_documentation_en-US" xlink:label="lab_pfe_SeniorNotesDue2047Member_3206AC583E5E687169BF628A0BC5EF25" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Due 2047 [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorNotesDue2047Member" xlink:label="loc_pfe_SeniorNotesDue2047Member_3206AC583E5E687169BF628A0BC5EF25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorNotesDue2047Member_3206AC583E5E687169BF628A0BC5EF25" xlink:to="lab_pfe_SeniorNotesDue2047Member_3206AC583E5E687169BF628A0BC5EF25" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_B019F17FE2A3FAB3B5D7628A0BC5565F_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount_B019F17FE2A3FAB3B5D7628A0BC5565F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_B019F17FE2A3FAB3B5D7628A0BC5565F_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount_B019F17FE2A3FAB3B5D7628A0BC5565F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Repurchase Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_B019F17FE2A3FAB3B5D7628A0BC5565F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchaseAmount_B019F17FE2A3FAB3B5D7628A0BC5565F" xlink:to="lab_us-gaap_DebtInstrumentRepurchaseAmount_B019F17FE2A3FAB3B5D7628A0BC5565F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D059B0BFCA0BA9B85C69D3A7C071E46_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D059B0BFCA0BA9B85C69D3A7C071E46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D059B0BFCA0BA9B85C69D3A7C071E46_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D059B0BFCA0BA9B85C69D3A7C071E46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D059B0BFCA0BA9B85C69D3A7C071E46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D059B0BFCA0BA9B85C69D3A7C071E46" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D059B0BFCA0BA9B85C69D3A7C071E46" xlink:type="arc" />
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7A7E922FFBFDB180DB969D3A7C07A478_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7A7E922FFBFDB180DB969D3A7C07A478" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7A7E922FFBFDB180DB969D3A7C07A478_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7A7E922FFBFDB180DB969D3A7C07A478" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7A7E922FFBFDB180DB969D3A7C07A478" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7A7E922FFBFDB180DB969D3A7C07A478" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7A7E922FFBFDB180DB969D3A7C07A478" xlink:type="arc" />
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_65E2AF1C68AD62D7E3909D3A7C08F685_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain_65E2AF1C68AD62D7E3909D3A7C08F685" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_65E2AF1C68AD62D7E3909D3A7C08F685_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain_65E2AF1C68AD62D7E3909D3A7C08F685" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_65E2AF1C68AD62D7E3909D3A7C08F685" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_65E2AF1C68AD62D7E3909D3A7C08F685" xlink:to="lab_srt_EquityMethodInvesteeNameDomain_65E2AF1C68AD62D7E3909D3A7C08F685" xlink:type="arc" />
    <link:label id="lab_pfe_GSKConsumerHealthcareMember_D5145EF3A54011EAFF9A9D3A7C08FC5E_terseLabel_en-US" xlink:label="lab_pfe_GSKConsumerHealthcareMember_D5145EF3A54011EAFF9A9D3A7C08FC5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK Consumer Healthcare [Member]</link:label>
    <link:label id="lab_pfe_GSKConsumerHealthcareMember_D5145EF3A54011EAFF9A9D3A7C08FC5E_label_en-US" xlink:label="lab_pfe_GSKConsumerHealthcareMember_D5145EF3A54011EAFF9A9D3A7C08FC5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSK Consumer Healthcare [Member]</link:label>
    <link:label id="lab_pfe_GSKConsumerHealthcareMember_D5145EF3A54011EAFF9A9D3A7C08FC5E_documentation_en-US" xlink:label="lab_pfe_GSKConsumerHealthcareMember_D5145EF3A54011EAFF9A9D3A7C08FC5E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GSK Consumer Healthcare [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_GSKConsumerHealthcareMember" xlink:label="loc_pfe_GSKConsumerHealthcareMember_D5145EF3A54011EAFF9A9D3A7C08FC5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GSKConsumerHealthcareMember_D5145EF3A54011EAFF9A9D3A7C08FC5E" xlink:to="lab_pfe_GSKConsumerHealthcareMember_D5145EF3A54011EAFF9A9D3A7C08FC5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_A2C2D84D7B6E990DFBB49D3A7C09E613_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_A2C2D84D7B6E990DFBB49D3A7C09E613" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_A2C2D84D7B6E990DFBB49D3A7C09E613_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_A2C2D84D7B6E990DFBB49D3A7C09E613" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_A2C2D84D7B6E990DFBB49D3A7C09E613" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_A2C2D84D7B6E990DFBB49D3A7C09E613" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_A2C2D84D7B6E990DFBB49D3A7C09E613" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_03D270842F7BF853CE829D3A7C09C54D_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_03D270842F7BF853CE829D3A7C09C54D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_03D270842F7BF853CE829D3A7C09C54D_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_03D270842F7BF853CE829D3A7C09C54D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_03D270842F7BF853CE829D3A7C09C54D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_03D270842F7BF853CE829D3A7C09C54D" xlink:to="lab_us-gaap_EquityComponentDomain_03D270842F7BF853CE829D3A7C09C54D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51486A2FF408EA11D0079D3A7C09267A_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51486A2FF408EA11D0079D3A7C09267A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51486A2FF408EA11D0079D3A7C09267A_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51486A2FF408EA11D0079D3A7C09267A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51486A2FF408EA11D0079D3A7C09267A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51486A2FF408EA11D0079D3A7C09267A" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51486A2FF408EA11D0079D3A7C09267A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_44FE95122213A80368AA9D3A7C090F6C_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_44FE95122213A80368AA9D3A7C090F6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation Adjustment [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_44FE95122213A80368AA9D3A7C090F6C_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_44FE95122213A80368AA9D3A7C090F6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_44FE95122213A80368AA9D3A7C090F6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember_44FE95122213A80368AA9D3A7C090F6C" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember_44FE95122213A80368AA9D3A7C090F6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_6194EB1987E18EB9649E9D3A7C0A576B_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_6194EB1987E18EB9649E9D3A7C0A576B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Financial Instruments [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_6194EB1987E18EB9649E9D3A7C0A576B_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_6194EB1987E18EB9649E9D3A7C0A576B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_6194EB1987E18EB9649E9D3A7C0A576B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_6194EB1987E18EB9649E9D3A7C0A576B" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_6194EB1987E18EB9649E9D3A7C0A576B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1F44E3662715DFEC74D09D3A7C0A3467_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1F44E3662715DFEC74D09D3A7C0A3467" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-For-Sale Securities [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1F44E3662715DFEC74D09D3A7C0A3467_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1F44E3662715DFEC74D09D3A7C0A3467" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1F44E3662715DFEC74D09D3A7C0A3467" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1F44E3662715DFEC74D09D3A7C0A3467" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1F44E3662715DFEC74D09D3A7C0A3467" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_2CD290AC6582508D133B9D3A7C0A2329_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_2CD290AC6582508D133B9D3A7C0A2329" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial Gains/(Losses) [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_2CD290AC6582508D133B9D3A7C0A2329_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_2CD290AC6582508D133B9D3A7C0A2329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_2CD290AC6582508D133B9D3A7C0A2329" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_2CD290AC6582508D133B9D3A7C0A2329" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_2CD290AC6582508D133B9D3A7C0A2329" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_8181A0ECD68310CA47D09D3A7C0A7BFF_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_8181A0ECD68310CA47D09D3A7C0A7BFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Service (Costs)/Credits and Other [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_8181A0ECD68310CA47D09D3A7C0A7BFF_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_8181A0ECD68310CA47D09D3A7C0A7BFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_8181A0ECD68310CA47D09D3A7C0A7BFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_8181A0ECD68310CA47D09D3A7C0A7BFF" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_8181A0ECD68310CA47D09D3A7C0A7BFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A86A93324B2FCEAED8A29D3A7C0A70AA_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A86A93324B2FCEAED8A29D3A7C0A70AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A86A93324B2FCEAED8A29D3A7C0A70AA_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A86A93324B2FCEAED8A29D3A7C0A70AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A86A93324B2FCEAED8A29D3A7C0A70AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A86A93324B2FCEAED8A29D3A7C0A70AA" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A86A93324B2FCEAED8A29D3A7C0A70AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_E65DA0247BA5FF91FA7A9D3A7C0BC7DF_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_E65DA0247BA5FF91FA7A9D3A7C0BC7DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_E65DA0247BA5FF91FA7A9D3A7C0BC7DF_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_E65DA0247BA5FF91FA7A9D3A7C0BC7DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_E65DA0247BA5FF91FA7A9D3A7C0BC7DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_E65DA0247BA5FF91FA7A9D3A7C0BC7DF" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_E65DA0247BA5FF91FA7A9D3A7C0BC7DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_43CD307800D6F8DCCE8A9D3A7C0B9AE1_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_43CD307800D6F8DCCE8A9D3A7C0B9AE1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, December 31, 2019</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_43CD307800D6F8DCCE8A9D3A7C0B9AE1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_43CD307800D6F8DCCE8A9D3A7C0B9AE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_43CD307800D6F8DCCE8A9D3A7C0B9AE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_43CD307800D6F8DCCE8A9D3A7C0B9AE1" xlink:to="lab_us-gaap_StockholdersEquity_43CD307800D6F8DCCE8A9D3A7C0B9AE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_407614195B3E211396FF9D3A7C0B5764_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_407614195B3E211396FF9D3A7C0B5764" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income/(loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_407614195B3E211396FF9D3A7C0B5764_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_407614195B3E211396FF9D3A7C0B5764" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_407614195B3E211396FF9D3A7C0B5764" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_407614195B3E211396FF9D3A7C0B5764" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_407614195B3E211396FF9D3A7C0B5764" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_B8AE25AAB64DE8F123CD9D3A7C0B72E9_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_B8AE25AAB64DE8F123CD9D3A7C0B72E9" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, June 28, 2020</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_B8AE25AAB64DE8F123CD9D3A7C0B72E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_B8AE25AAB64DE8F123CD9D3A7C0B72E9" xlink:to="lab_us-gaap_StockholdersEquity_B8AE25AAB64DE8F123CD9D3A7C0B72E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_9A7A4CC7690D197A64969D3B6FAEB0AC_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_9A7A4CC7690D197A64969D3B6FAEB0AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation income (loss) attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_9A7A4CC7690D197A64969D3B6FAEB0AC_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_9A7A4CC7690D197A64969D3B6FAEB0AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_9A7A4CC7690D197A64969D3B6FAEB0AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_9A7A4CC7690D197A64969D3B6FAEB0AC" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_9A7A4CC7690D197A64969D3B6FAEB0AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7D3F7C0C08FCD3C077FD9D3A7C0CEB39_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7D3F7C0C08FCD3C077FD9D3A7C0CEB39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7D3F7C0C08FCD3C077FD9D3A7C0CEB39_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7D3F7C0C08FCD3C077FD9D3A7C0CEB39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7D3F7C0C08FCD3C077FD9D3A7C0CEB39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7D3F7C0C08FCD3C077FD9D3A7C0CEB39" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7D3F7C0C08FCD3C077FD9D3A7C0CEB39" xlink:type="arc" />
    <link:label id="lab_pfe_HedgedItemAxis_B4D79A00F602BDA6D15A94761EA42A17_terseLabel_en-US" xlink:label="lab_pfe_HedgedItemAxis_B4D79A00F602BDA6D15A94761EA42A17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedged Item [Axis]</link:label>
    <link:label id="lab_pfe_HedgedItemAxis_B4D79A00F602BDA6D15A94761EA42A17_label_en-US" xlink:label="lab_pfe_HedgedItemAxis_B4D79A00F602BDA6D15A94761EA42A17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedged Item [Axis]</link:label>
    <link:label id="lab_pfe_HedgedItemAxis_B4D79A00F602BDA6D15A94761EA42A17_documentation_en-US" xlink:label="lab_pfe_HedgedItemAxis_B4D79A00F602BDA6D15A94761EA42A17" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hedged Item [Axis]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_HedgedItemAxis" xlink:label="loc_pfe_HedgedItemAxis_B4D79A00F602BDA6D15A94761EA42A17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HedgedItemAxis_B4D79A00F602BDA6D15A94761EA42A17" xlink:to="lab_pfe_HedgedItemAxis_B4D79A00F602BDA6D15A94761EA42A17" xlink:type="arc" />
    <link:label id="lab_pfe_HedgedItemDomain_BE06C13024F26F33D7FE94761EA4376F_terseLabel_en-US" xlink:label="lab_pfe_HedgedItemDomain_BE06C13024F26F33D7FE94761EA4376F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedged Item [Domain]</link:label>
    <link:label id="lab_pfe_HedgedItemDomain_BE06C13024F26F33D7FE94761EA4376F_label_en-US" xlink:label="lab_pfe_HedgedItemDomain_BE06C13024F26F33D7FE94761EA4376F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedged Item [Domain]</link:label>
    <link:label id="lab_pfe_HedgedItemDomain_BE06C13024F26F33D7FE94761EA4376F_documentation_en-US" xlink:label="lab_pfe_HedgedItemDomain_BE06C13024F26F33D7FE94761EA4376F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Hedged Item [Axis]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_HedgedItemDomain" xlink:label="loc_pfe_HedgedItemDomain_BE06C13024F26F33D7FE94761EA4376F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HedgedItemDomain_BE06C13024F26F33D7FE94761EA4376F" xlink:to="lab_pfe_HedgedItemDomain_BE06C13024F26F33D7FE94761EA4376F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesMember_4CCC75A178B51F06392A94761EA4B579_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember_4CCC75A178B51F06392A94761EA4B579" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory sales [Member]</link:label>
    <link:label id="lab_us-gaap_SalesMember_4CCC75A178B51F06392A94761EA4B579_label_en-US" xlink:label="lab_us-gaap_SalesMember_4CCC75A178B51F06392A94761EA4B579" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_4CCC75A178B51F06392A94761EA4B579" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember_4CCC75A178B51F06392A94761EA4B579" xlink:to="lab_us-gaap_SalesMember_4CCC75A178B51F06392A94761EA4B579" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationAxis_51D26D800027A17D61BA94761EA40310_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_51D26D800027A17D61BA94761EA40310" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_51D26D800027A17D61BA94761EA40310_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_51D26D800027A17D61BA94761EA40310" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_51D26D800027A17D61BA94761EA40310" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis_51D26D800027A17D61BA94761EA40310" xlink:to="lab_us-gaap_HedgingDesignationAxis_51D26D800027A17D61BA94761EA40310" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationDomain_973BBD5D2C12393AE5A494761EA44F79_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_973BBD5D2C12393AE5A494761EA44F79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_973BBD5D2C12393AE5A494761EA44F79_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_973BBD5D2C12393AE5A494761EA44F79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_973BBD5D2C12393AE5A494761EA44F79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain_973BBD5D2C12393AE5A494761EA44F79" xlink:to="lab_us-gaap_HedgingDesignationDomain_973BBD5D2C12393AE5A494761EA44F79" xlink:type="arc" />
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_01DBAF3D312D42EDD90D94761EA590E5_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_01DBAF3D312D42EDD90D94761EA590E5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivatives designated as hedging instruments [Member]</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_01DBAF3D312D42EDD90D94761EA590E5_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_01DBAF3D312D42EDD90D94761EA590E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_01DBAF3D312D42EDD90D94761EA590E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember_01DBAF3D312D42EDD90D94761EA590E5" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember_01DBAF3D312D42EDD90D94761EA590E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_NondesignatedMember_EA2B7541E1C03C1D6AE694761EA5E590_verboseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember_EA2B7541E1C03C1D6AE694761EA5E590" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivatives not designated as hedging instruments [Member]</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_EA2B7541E1C03C1D6AE694761EA5E590_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember_EA2B7541E1C03C1D6AE694761EA5E590" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_EA2B7541E1C03C1D6AE694761EA5E590" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember_EA2B7541E1C03C1D6AE694761EA5E590" xlink:to="lab_us-gaap_NondesignatedMember_EA2B7541E1C03C1D6AE694761EA5E590" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestRateContractMember_EC6F67CF99092946F84494761EA6241A_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember_EC6F67CF99092946F84494761EA6241A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate contracts [Member]</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_EC6F67CF99092946F84494761EA6241A_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember_EC6F67CF99092946F84494761EA6241A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember" xlink:label="loc_us-gaap_InterestRateContractMember_EC6F67CF99092946F84494761EA6241A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember_EC6F67CF99092946F84494761EA6241A" xlink:to="lab_us-gaap_InterestRateContractMember_EC6F67CF99092946F84494761EA6241A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_FB32BD0BD5996A6676FC94761EA648B3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount_FB32BD0BD5996A6676FC94761EA648B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notional</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_FB32BD0BD5996A6676FC94761EA648B3_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount_FB32BD0BD5996A6676FC94761EA648B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_FB32BD0BD5996A6676FC94761EA648B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount_FB32BD0BD5996A6676FC94761EA648B3" xlink:to="lab_us-gaap_DerivativeNotionalAmount_FB32BD0BD5996A6676FC94761EA648B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeAssets_011A482D637FC08FCA2D94761EA7EB42_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets_011A482D637FC08FCA2D94761EA7EB42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_011A482D637FC08FCA2D94761EA7EB42_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets_011A482D637FC08FCA2D94761EA7EB42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets" xlink:label="loc_us-gaap_DerivativeAssets_011A482D637FC08FCA2D94761EA7EB42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets_011A482D637FC08FCA2D94761EA7EB42" xlink:to="lab_us-gaap_DerivativeAssets_011A482D637FC08FCA2D94761EA7EB42" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLiabilities_638B713D4DB36466188794761EA7DABE_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities_638B713D4DB36466188794761EA7DABE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_638B713D4DB36466188794761EA7DABE_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities_638B713D4DB36466188794761EA7DABE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_638B713D4DB36466188794761EA7DABE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities_638B713D4DB36466188794761EA7DABE" xlink:to="lab_us-gaap_DerivativeLiabilities_638B713D4DB36466188794761EA7DABE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3D961C8B3B6670CA680494762093DADF_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3D961C8B3B6670CA680494762093DADF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3D961C8B3B6670CA680494762093DADF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3D961C8B3B6670CA680494762093DADF" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3D961C8B3B6670CA680494762093DADF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_9BBED01966F0163C1C0F94762093A40B_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_9BBED01966F0163C1C0F94762093A40B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_9BBED01966F0163C1C0F94762093A40B_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_9BBED01966F0163C1C0F94762093A40B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_9BBED01966F0163C1C0F94762093A40B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_9BBED01966F0163C1C0F94762093A40B" xlink:to="lab_us-gaap_NumberOfOperatingSegments_9BBED01966F0163C1C0F94762093A40B" xlink:type="arc" />
    <link:label id="lab_pfe_NumberOfAccountingStandardsAdopted_9943011EC655DF57D69394762093B3F0_terseLabel_en-US" xlink:label="lab_pfe_NumberOfAccountingStandardsAdopted_9943011EC655DF57D69394762093B3F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of accounting standards adopted</link:label>
    <link:label id="lab_pfe_NumberOfAccountingStandardsAdopted_9943011EC655DF57D69394762093B3F0_label_en-US" xlink:label="lab_pfe_NumberOfAccountingStandardsAdopted_9943011EC655DF57D69394762093B3F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Accounting Standards Adopted</link:label>
    <link:label id="lab_pfe_NumberOfAccountingStandardsAdopted_9943011EC655DF57D69394762093B3F0_documentation_en-US" xlink:label="lab_pfe_NumberOfAccountingStandardsAdopted_9943011EC655DF57D69394762093B3F0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Accounting Standards Adopted</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_NumberOfAccountingStandardsAdopted" xlink:label="loc_pfe_NumberOfAccountingStandardsAdopted_9943011EC655DF57D69394762093B3F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NumberOfAccountingStandardsAdopted_9943011EC655DF57D69394762093B3F0" xlink:to="lab_pfe_NumberOfAccountingStandardsAdopted_9943011EC655DF57D69394762093B3F0" xlink:type="arc" />
    <link:label id="lab_pfe_RebatesAndDiscountsAccrual_A4B3C228F303C9A037C294762094E2D5_terseLabel_en-US" xlink:label="lab_pfe_RebatesAndDiscountsAccrual_A4B3C228F303C9A037C294762094E2D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued rebates and other accruals</link:label>
    <link:label id="lab_pfe_RebatesAndDiscountsAccrual_A4B3C228F303C9A037C294762094E2D5_label_en-US" xlink:label="lab_pfe_RebatesAndDiscountsAccrual_A4B3C228F303C9A037C294762094E2D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rebates And Discounts Accrual</link:label>
    <link:label id="lab_pfe_RebatesAndDiscountsAccrual_A4B3C228F303C9A037C294762094E2D5_documentation_en-US" xlink:label="lab_pfe_RebatesAndDiscountsAccrual_A4B3C228F303C9A037C294762094E2D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_RebatesAndDiscountsAccrual" xlink:label="loc_pfe_RebatesAndDiscountsAccrual_A4B3C228F303C9A037C294762094E2D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RebatesAndDiscountsAccrual_A4B3C228F303C9A037C294762094E2D5" xlink:to="lab_pfe_RebatesAndDiscountsAccrual_A4B3C228F303C9A037C294762094E2D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EBEB49EE3E4FA7CEEAEF7926B2A67D56_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EBEB49EE3E4FA7CEEAEF7926B2A67D56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EBEB49EE3E4FA7CEEAEF7926B2A67D56_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EBEB49EE3E4FA7CEEAEF7926B2A67D56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EBEB49EE3E4FA7CEEAEF7926B2A67D56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EBEB49EE3E4FA7CEEAEF7926B2A67D56" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EBEB49EE3E4FA7CEEAEF7926B2A67D56" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_58BB7FA5BC09F14D40FF793378A83652_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_58BB7FA5BC09F14D40FF793378A83652" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_58BB7FA5BC09F14D40FF793378A83652_label_en-US" xlink:label="lab_srt_RangeAxis_58BB7FA5BC09F14D40FF793378A83652" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_58BB7FA5BC09F14D40FF793378A83652" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_58BB7FA5BC09F14D40FF793378A83652" xlink:to="lab_srt_RangeAxis_58BB7FA5BC09F14D40FF793378A83652" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_D41C3E672854D230D020793378A92B58_terseLabel_en-US" xlink:label="lab_srt_RangeMember_D41C3E672854D230D020793378A92B58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_D41C3E672854D230D020793378A92B58_label_en-US" xlink:label="lab_srt_RangeMember_D41C3E672854D230D020793378A92B58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D41C3E672854D230D020793378A92B58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_D41C3E672854D230D020793378A92B58" xlink:to="lab_srt_RangeMember_D41C3E672854D230D020793378A92B58" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_49DA6853E42F45A97B1F79341B28B307_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_49DA6853E42F45A97B1F79341B28B307" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_srt_MinimumMember_49DA6853E42F45A97B1F79341B28B307_label_en-US" xlink:label="lab_srt_MinimumMember_49DA6853E42F45A97B1F79341B28B307" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_49DA6853E42F45A97B1F79341B28B307" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_49DA6853E42F45A97B1F79341B28B307" xlink:to="lab_srt_MinimumMember_49DA6853E42F45A97B1F79341B28B307" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_CED445B2FA4F00DE1416793445BE5A76_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_CED445B2FA4F00DE1416793445BE5A76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label id="lab_srt_MaximumMember_CED445B2FA4F00DE1416793445BE5A76_label_en-US" xlink:label="lab_srt_MaximumMember_CED445B2FA4F00DE1416793445BE5A76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_CED445B2FA4F00DE1416793445BE5A76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_CED445B2FA4F00DE1416793445BE5A76" xlink:to="lab_srt_MaximumMember_CED445B2FA4F00DE1416793445BE5A76" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AACDA209AB9A481005007926B2A75FC6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AACDA209AB9A481005007926B2A75FC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AACDA209AB9A481005007926B2A75FC6_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AACDA209AB9A481005007926B2A75FC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AACDA209AB9A481005007926B2A75FC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AACDA209AB9A481005007926B2A75FC6" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AACDA209AB9A481005007926B2A75FC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3D0C4E2AE818A44E79F7926B2A75AD9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3D0C4E2AE818A44E79F7926B2A75AD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3D0C4E2AE818A44E79F7926B2A75AD9_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3D0C4E2AE818A44E79F7926B2A75AD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3D0C4E2AE818A44E79F7926B2A75AD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3D0C4E2AE818A44E79F7926B2A75AD9" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3D0C4E2AE818A44E79F7926B2A75AD9" xlink:type="arc" />
    <link:label id="lab_pfe_ConsumerHealthcareMember_202904254FAEEDA080797926B2A7A84A_terseLabel_en-US" xlink:label="lab_pfe_ConsumerHealthcareMember_202904254FAEEDA080797926B2A7A84A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consumer Healthcare [Member]</link:label>
    <link:label id="lab_pfe_ConsumerHealthcareMember_202904254FAEEDA080797926B2A7A84A_label_en-US" xlink:label="lab_pfe_ConsumerHealthcareMember_202904254FAEEDA080797926B2A7A84A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consumer Healthcare [Member]</link:label>
    <link:label id="lab_pfe_ConsumerHealthcareMember_202904254FAEEDA080797926B2A7A84A_documentation_en-US" xlink:label="lab_pfe_ConsumerHealthcareMember_202904254FAEEDA080797926B2A7A84A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consumer Healthcare [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ConsumerHealthcareMember" xlink:label="loc_pfe_ConsumerHealthcareMember_202904254FAEEDA080797926B2A7A84A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ConsumerHealthcareMember_202904254FAEEDA080797926B2A7A84A" xlink:to="lab_pfe_ConsumerHealthcareMember_202904254FAEEDA080797926B2A7A84A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_7C37A7A65422032D64E07926B2A8E26D_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis_7C37A7A65422032D64E07926B2A8E26D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_7C37A7A65422032D64E07926B2A8E26D_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis_7C37A7A65422032D64E07926B2A8E26D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_7C37A7A65422032D64E07926B2A8E26D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_7C37A7A65422032D64E07926B2A8E26D" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis_7C37A7A65422032D64E07926B2A8E26D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_4B1C227ACC3432F7D6607926B2A8065B_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain_4B1C227ACC3432F7D6607926B2A8065B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_4B1C227ACC3432F7D6607926B2A8065B_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain_4B1C227ACC3432F7D6607926B2A8065B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_4B1C227ACC3432F7D6607926B2A8065B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_4B1C227ACC3432F7D6607926B2A8065B" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain_4B1C227ACC3432F7D6607926B2A8065B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_DC9AE322ADDA2D13BAC07926B2A81269_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_DC9AE322ADDA2D13BAC07926B2A81269" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held-for-sale [Member]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_DC9AE322ADDA2D13BAC07926B2A81269_label_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_DC9AE322ADDA2D13BAC07926B2A81269" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Held-for-sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_DC9AE322ADDA2D13BAC07926B2A81269" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_DC9AE322ADDA2D13BAC07926B2A81269" xlink:to="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_DC9AE322ADDA2D13BAC07926B2A81269" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_18E902ADAF270A4C6EDA7926B2A84754_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_18E902ADAF270A4C6EDA7926B2A84754" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_18E902ADAF270A4C6EDA7926B2A84754_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_18E902ADAF270A4C6EDA7926B2A84754" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_18E902ADAF270A4C6EDA7926B2A84754" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_18E902ADAF270A4C6EDA7926B2A84754" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_18E902ADAF270A4C6EDA7926B2A84754" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_ED596F6554B5F544669C7926B2A8DAB7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_ED596F6554B5F544669C7926B2A8DAB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_ED596F6554B5F544669C7926B2A8DAB7_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_ED596F6554B5F544669C7926B2A8DAB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ED596F6554B5F544669C7926B2A8DAB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ED596F6554B5F544669C7926B2A8DAB7" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_ED596F6554B5F544669C7926B2A8DAB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_59D100E77C78A698DC297926B2A95E72_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_59D100E77C78A698DC297926B2A95E72" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">OID [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_59D100E77C78A698DC297926B2A95E72_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_59D100E77C78A698DC297926B2A95E72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_59D100E77C78A698DC297926B2A95E72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_59D100E77C78A698DC297926B2A95E72" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_59D100E77C78A698DC297926B2A95E72" xlink:type="arc" />
    <link:label id="lab_pfe_GSKMember_B5D3CF3C67EF9A3AF7377926B2AA3D86_terseLabel_en-US" xlink:label="lab_pfe_GSKMember_B5D3CF3C67EF9A3AF7377926B2AA3D86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK [Member]</link:label>
    <link:label id="lab_pfe_GSKMember_B5D3CF3C67EF9A3AF7377926B2AA3D86_label_en-US" xlink:label="lab_pfe_GSKMember_B5D3CF3C67EF9A3AF7377926B2AA3D86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSK [Member]</link:label>
    <link:label id="lab_pfe_GSKMember_B5D3CF3C67EF9A3AF7377926B2AA3D86_documentation_en-US" xlink:label="lab_pfe_GSKMember_B5D3CF3C67EF9A3AF7377926B2AA3D86" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GSK [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_GSKMember" xlink:label="loc_pfe_GSKMember_B5D3CF3C67EF9A3AF7377926B2AA3D86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GSKMember_B5D3CF3C67EF9A3AF7377926B2AA3D86" xlink:to="lab_pfe_GSKMember_B5D3CF3C67EF9A3AF7377926B2AA3D86" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_24DFB8EA4FDDCFD40D967926B2ABAF34_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_24DFB8EA4FDDCFD40D967926B2ABAF34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment, ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_24DFB8EA4FDDCFD40D967926B2ABAF34_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_24DFB8EA4FDDCFD40D967926B2ABAF34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_24DFB8EA4FDDCFD40D967926B2ABAF34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_24DFB8EA4FDDCFD40D967926B2ABAF34" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_24DFB8EA4FDDCFD40D967926B2ABAF34" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_07749ABD6271558FB7687926B2AB25BB_terseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount_07749ABD6271558FB7687926B2AB25BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on completion of Consumer Healthcare JV transaction</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_07749ABD6271558FB7687926B2AB25BB_label_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount_07749ABD6271558FB7687926B2AB25BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_07749ABD6271558FB7687926B2AB25BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationGainOrLossAmount_07749ABD6271558FB7687926B2AB25BB" xlink:to="lab_us-gaap_DeconsolidationGainOrLossAmount_07749ABD6271558FB7687926B2AB25BB" xlink:type="arc" />
    <link:label id="lab_pfe_DeconsolidationGainLossAmountNetOfTax_0CEDD828CA62504E16637926B2AB0F17_terseLabel_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountNetOfTax_0CEDD828CA62504E16637926B2AB0F17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on completion of Consumer Healthcare JV transaction, after-tax</link:label>
    <link:label id="lab_pfe_DeconsolidationGainLossAmountNetOfTax_0CEDD828CA62504E16637926B2AB0F17_label_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountNetOfTax_0CEDD828CA62504E16637926B2AB0F17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount, Net Of Tax</link:label>
    <link:label id="lab_pfe_DeconsolidationGainLossAmountNetOfTax_0CEDD828CA62504E16637926B2AB0F17_documentation_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountNetOfTax_0CEDD828CA62504E16637926B2AB0F17" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount, Net Of Tax</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DeconsolidationGainLossAmountNetOfTax" xlink:label="loc_pfe_DeconsolidationGainLossAmountNetOfTax_0CEDD828CA62504E16637926B2AB0F17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeconsolidationGainLossAmountNetOfTax_0CEDD828CA62504E16637926B2AB0F17" xlink:to="lab_pfe_DeconsolidationGainLossAmountNetOfTax_0CEDD828CA62504E16637926B2AB0F17" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestments_608AC2DA852518ABEC387926B2ABB1DB_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_608AC2DA852518ABEC387926B2ABB1DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_608AC2DA852518ABEC387926B2ABB1DB_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_608AC2DA852518ABEC387926B2ABB1DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_608AC2DA852518ABEC387926B2ABB1DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments_608AC2DA852518ABEC387926B2ABB1DB" xlink:to="lab_us-gaap_EquityMethodInvestments_608AC2DA852518ABEC387926B2ABB1DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_EC0229AC965591660E577926B2ACBA29_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_EC0229AC965591660E577926B2ACBA29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment earnings</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_EC0229AC965591660E577926B2ACBA29_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_EC0229AC965591660E577926B2ACBA29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_EC0229AC965591660E577926B2ACBA29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_EC0229AC965591660E577926B2ACBA29" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_EC0229AC965591660E577926B2ACBA29" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_4DF624716AD413F061D27926B2ACE6EF_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_4DF624716AD413F061D27926B2ACE6EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of equity method investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_4DF624716AD413F061D27926B2ACE6EF_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_4DF624716AD413F061D27926B2ACE6EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_4DF624716AD413F061D27926B2ACE6EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_4DF624716AD413F061D27926B2ACE6EF" xlink:to="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_4DF624716AD413F061D27926B2ACE6EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_12F323AAB24770BC8C577926B2AC4B37_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_12F323AAB24770BC8C577926B2AC4B37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying equity in net assets</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_12F323AAB24770BC8C577926B2AC4B37_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_12F323AAB24770BC8C577926B2AC4B37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Underlying Equity in Net Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:label="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_12F323AAB24770BC8C577926B2AC4B37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_12F323AAB24770BC8C577926B2AC4B37" xlink:to="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_12F323AAB24770BC8C577926B2AC4B37" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_CC230B0EE3DD8F3906617926B2AC5B93_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_CC230B0EE3DD8F3906617926B2AC5B93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Difference between carrying amount and underlying equity</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_CC230B0EE3DD8F3906617926B2AC5B93_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_CC230B0EE3DD8F3906617926B2AC5B93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_CC230B0EE3DD8F3906617926B2AC5B93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_CC230B0EE3DD8F3906617926B2AC5B93" xlink:to="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_CC230B0EE3DD8F3906617926B2AC5B93" xlink:type="arc" />
    <link:label id="lab_pfe_EquityMethodInvestmentExcessBasisAmortization_22B5ABA0E595568A11327926B2AC1D70_terseLabel_en-US" xlink:label="lab_pfe_EquityMethodInvestmentExcessBasisAmortization_22B5ABA0E595568A11327926B2AC1D70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Excess basis amortization</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentExcessBasisAmortization_22B5ABA0E595568A11327926B2AC1D70_label_en-US" xlink:label="lab_pfe_EquityMethodInvestmentExcessBasisAmortization_22B5ABA0E595568A11327926B2AC1D70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Excess Basis Amortization</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentExcessBasisAmortization_22B5ABA0E595568A11327926B2AC1D70_documentation_en-US" xlink:label="lab_pfe_EquityMethodInvestmentExcessBasisAmortization_22B5ABA0E595568A11327926B2AC1D70" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Excess Basis Amortization</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EquityMethodInvestmentExcessBasisAmortization" xlink:label="loc_pfe_EquityMethodInvestmentExcessBasisAmortization_22B5ABA0E595568A11327926B2AC1D70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquityMethodInvestmentExcessBasisAmortization_22B5ABA0E595568A11327926B2AC1D70" xlink:to="lab_pfe_EquityMethodInvestmentExcessBasisAmortization_22B5ABA0E595568A11327926B2AC1D70" xlink:type="arc" />
    <link:label id="lab_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_09571564FEB6ECA07E8C7926B2AD054E_terseLabel_en-US" xlink:label="lab_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_09571564FEB6ECA07E8C7926B2AD054E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Excess basis amortization period</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_09571564FEB6ECA07E8C7926B2AD054E_label_en-US" xlink:label="lab_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_09571564FEB6ECA07E8C7926B2AD054E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Excess Basis Amortization, Period</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_09571564FEB6ECA07E8C7926B2AD054E_documentation_en-US" xlink:label="lab_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_09571564FEB6ECA07E8C7926B2AD054E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Excess Basis Amortization, Period</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod" xlink:label="loc_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_09571564FEB6ECA07E8C7926B2AD054E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_09571564FEB6ECA07E8C7926B2AD054E" xlink:to="lab_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_09571564FEB6ECA07E8C7926B2AD054E" xlink:type="arc" />
    <link:label id="lab_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_0EA334A74D000D818C0D7926B2ADA60D_negatedTerseLabel_en-US" xlink:label="lab_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_0EA334A74D000D818C0D7926B2ADA60D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease due to foreign currency translation</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_0EA334A74D000D818C0D7926B2ADA60D_label_en-US" xlink:label="lab_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_0EA334A74D000D818C0D7926B2ADA60D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Increase (Decrease), Foreign Currency Translation</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_0EA334A74D000D818C0D7926B2ADA60D_documentation_en-US" xlink:label="lab_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_0EA334A74D000D818C0D7926B2ADA60D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Increase (Decrease), Foreign Currency Translation</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" xlink:label="loc_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_0EA334A74D000D818C0D7926B2ADA60D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_0EA334A74D000D818C0D7926B2ADA60D" xlink:to="lab_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_0EA334A74D000D818C0D7926B2ADA60D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_086948AE7DAE29E1526F7926B2ADEF1D_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_086948AE7DAE29E1526F7926B2ADEF1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend received</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_086948AE7DAE29E1526F7926B2ADEF1D_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_086948AE7DAE29E1526F7926B2ADEF1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_086948AE7DAE29E1526F7926B2ADEF1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_086948AE7DAE29E1526F7926B2ADEF1D" xlink:to="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_086948AE7DAE29E1526F7926B2ADEF1D" xlink:type="arc" />
    <link:label id="lab_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_6D4C0537B00E06F6DF687926B2AD87DC_verboseLabel_en-US" xlink:label="lab_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_6D4C0537B00E06F6DF687926B2AD87DC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Pre-tax income attributable to disposal group</link:label>
    <link:label id="lab_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_6D4C0537B00E06F6DF687926B2AD87DC_label_en-US" xlink:label="lab_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_6D4C0537B00E06F6DF687926B2AD87DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Pre-tax Income (Loss)</link:label>
    <link:label id="lab_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_6D4C0537B00E06F6DF687926B2AD87DC_documentation_en-US" xlink:label="lab_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_6D4C0537B00E06F6DF687926B2AD87DC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Pre-tax Income (Loss)</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss" xlink:label="loc_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_6D4C0537B00E06F6DF687926B2AD87DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_6D4C0537B00E06F6DF687926B2AD87DC" xlink:to="lab_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_6D4C0537B00E06F6DF687926B2AD87DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingAbstract_E21AD8B67B02EC9E05D36350788D2941_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract_E21AD8B67B02EC9E05D36350788D2941" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_E21AD8B67B02EC9E05D36350788D2941" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract_E21AD8B67B02EC9E05D36350788D2941" xlink:to="lab_us-gaap_SegmentReportingAbstract_E21AD8B67B02EC9E05D36350788D2941" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_47DB69088942C88D679C6350788D5AFF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_47DB69088942C88D679C6350788D5AFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_47DB69088942C88D679C6350788D5AFF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_47DB69088942C88D679C6350788D5AFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_47DB69088942C88D679C6350788D5AFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_47DB69088942C88D679C6350788D5AFF" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_47DB69088942C88D679C6350788D5AFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_466F45B6A71E30D02EB16350788D1A1F_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis_466F45B6A71E30D02EB16350788D1A1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_466F45B6A71E30D02EB16350788D1A1F_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis_466F45B6A71E30D02EB16350788D1A1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_466F45B6A71E30D02EB16350788D1A1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_466F45B6A71E30D02EB16350788D1A1F" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis_466F45B6A71E30D02EB16350788D1A1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentDomain_9BE8FCAA5D9D6331C87F6350788D2C86_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain_9BE8FCAA5D9D6331C87F6350788D2C86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_9BE8FCAA5D9D6331C87F6350788D2C86_label_en-US" xlink:label="lab_us-gaap_SegmentDomain_9BE8FCAA5D9D6331C87F6350788D2C86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_9BE8FCAA5D9D6331C87F6350788D2C86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain_9BE8FCAA5D9D6331C87F6350788D2C86" xlink:to="lab_us-gaap_SegmentDomain_9BE8FCAA5D9D6331C87F6350788D2C86" xlink:type="arc" />
    <link:label id="lab_pfe_BiopharmaSegmentMember_DF76E33A53540E0CEAFA6350788EAB14_terseLabel_en-US" xlink:label="lab_pfe_BiopharmaSegmentMember_DF76E33A53540E0CEAFA6350788EAB14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biopharma [Member]</link:label>
    <link:label id="lab_pfe_BiopharmaSegmentMember_DF76E33A53540E0CEAFA6350788EAB14_label_en-US" xlink:label="lab_pfe_BiopharmaSegmentMember_DF76E33A53540E0CEAFA6350788EAB14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biopharma Segment [Member]</link:label>
    <link:label id="lab_pfe_BiopharmaSegmentMember_DF76E33A53540E0CEAFA6350788EAB14_documentation_en-US" xlink:label="lab_pfe_BiopharmaSegmentMember_DF76E33A53540E0CEAFA6350788EAB14" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biopharma Segment [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_DF76E33A53540E0CEAFA6350788EAB14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BiopharmaSegmentMember_DF76E33A53540E0CEAFA6350788EAB14" xlink:to="lab_pfe_BiopharmaSegmentMember_DF76E33A53540E0CEAFA6350788EAB14" xlink:type="arc" />
    <link:label id="lab_pfe_UpjohnSegmentMember_DDE3671B719C5E2CCDE26350788E8C7D_terseLabel_en-US" xlink:label="lab_pfe_UpjohnSegmentMember_DDE3671B719C5E2CCDE26350788E8C7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upjohn [Member]</link:label>
    <link:label id="lab_pfe_UpjohnSegmentMember_DDE3671B719C5E2CCDE26350788E8C7D_label_en-US" xlink:label="lab_pfe_UpjohnSegmentMember_DDE3671B719C5E2CCDE26350788E8C7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upjohn Segment [Member]</link:label>
    <link:label id="lab_pfe_UpjohnSegmentMember_DDE3671B719C5E2CCDE26350788E8C7D_documentation_en-US" xlink:label="lab_pfe_UpjohnSegmentMember_DDE3671B719C5E2CCDE26350788E8C7D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upjohn Segment [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnSegmentMember" xlink:label="loc_pfe_UpjohnSegmentMember_DDE3671B719C5E2CCDE26350788E8C7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_UpjohnSegmentMember_DDE3671B719C5E2CCDE26350788E8C7D" xlink:to="lab_pfe_UpjohnSegmentMember_DDE3671B719C5E2CCDE26350788E8C7D" xlink:type="arc" />
    <link:label id="lab_srt_ConsolidationItemsAxis_8C7A732414D6F734F5F46350788EBA4F_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis_8C7A732414D6F734F5F46350788EBA4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_8C7A732414D6F734F5F46350788EBA4F_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis_8C7A732414D6F734F5F46350788EBA4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_8C7A732414D6F734F5F46350788EBA4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis_8C7A732414D6F734F5F46350788EBA4F" xlink:to="lab_srt_ConsolidationItemsAxis_8C7A732414D6F734F5F46350788EBA4F" xlink:type="arc" />
    <link:label id="lab_srt_ConsolidationItemsDomain_7B75F4907BA10A3D2D9B6350788ECB8E_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain_7B75F4907BA10A3D2D9B6350788ECB8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_7B75F4907BA10A3D2D9B6350788ECB8E_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain_7B75F4907BA10A3D2D9B6350788ECB8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_7B75F4907BA10A3D2D9B6350788ECB8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain_7B75F4907BA10A3D2D9B6350788ECB8E" xlink:to="lab_srt_ConsolidationItemsDomain_7B75F4907BA10A3D2D9B6350788ECB8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingSegmentsMember_4D6C7E23A7E650C6F8406350788F4E32_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember_4D6C7E23A7E650C6F8406350788F4E32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_4D6C7E23A7E650C6F8406350788F4E32_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember_4D6C7E23A7E650C6F8406350788F4E32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_4D6C7E23A7E650C6F8406350788F4E32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember_4D6C7E23A7E650C6F8406350788F4E32" xlink:to="lab_us-gaap_OperatingSegmentsMember_4D6C7E23A7E650C6F8406350788F4E32" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_9A36AC77270F1C89787B6350788F975A_verboseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember_9A36AC77270F1C89787B6350788F975A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_9A36AC77270F1C89787B6350788F975A_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember_9A36AC77270F1C89787B6350788F975A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_9A36AC77270F1C89787B6350788F975A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember_9A36AC77270F1C89787B6350788F975A" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember_9A36AC77270F1C89787B6350788F975A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_A08467B8F79F2EF581A46350788FF0B8_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember_A08467B8F79F2EF581A46350788FF0B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate and other unallocated [Member]</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_A08467B8F79F2EF581A46350788FF0B8_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember_A08467B8F79F2EF581A46350788FF0B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="loc_us-gaap_CorporateNonSegmentMember_A08467B8F79F2EF581A46350788FF0B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember_A08467B8F79F2EF581A46350788FF0B8" xlink:to="lab_us-gaap_CorporateNonSegmentMember_A08467B8F79F2EF581A46350788FF0B8" xlink:type="arc" />
    <link:label id="lab_pfe_OtherSegmentReconcilingItemsAxis_81107C06DEFC9E4BC8DA6350788F0B3F_terseLabel_en-US" xlink:label="lab_pfe_OtherSegmentReconcilingItemsAxis_81107C06DEFC9E4BC8DA6350788F0B3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Segment Reconciling Items [Axis]</link:label>
    <link:label id="lab_pfe_OtherSegmentReconcilingItemsAxis_81107C06DEFC9E4BC8DA6350788F0B3F_label_en-US" xlink:label="lab_pfe_OtherSegmentReconcilingItemsAxis_81107C06DEFC9E4BC8DA6350788F0B3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Segment Reconciling Items [Axis]</link:label>
    <link:label id="lab_pfe_OtherSegmentReconcilingItemsAxis_81107C06DEFC9E4BC8DA6350788F0B3F_documentation_en-US" xlink:label="lab_pfe_OtherSegmentReconcilingItemsAxis_81107C06DEFC9E4BC8DA6350788F0B3F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Segment Reconciling Items [Axis]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherSegmentReconcilingItemsAxis" xlink:label="loc_pfe_OtherSegmentReconcilingItemsAxis_81107C06DEFC9E4BC8DA6350788F0B3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherSegmentReconcilingItemsAxis_81107C06DEFC9E4BC8DA6350788F0B3F" xlink:to="lab_pfe_OtherSegmentReconcilingItemsAxis_81107C06DEFC9E4BC8DA6350788F0B3F" xlink:type="arc" />
    <link:label id="lab_pfe_OtherSegmentReconcilingItemsDomain_B2556FCAD1C7B8A918376350788F9345_terseLabel_en-US" xlink:label="lab_pfe_OtherSegmentReconcilingItemsDomain_B2556FCAD1C7B8A918376350788F9345" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Segment Reconciling Items [Domain]</link:label>
    <link:label id="lab_pfe_OtherSegmentReconcilingItemsDomain_B2556FCAD1C7B8A918376350788F9345_label_en-US" xlink:label="lab_pfe_OtherSegmentReconcilingItemsDomain_B2556FCAD1C7B8A918376350788F9345" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Segment Reconciling Items [Domain]</link:label>
    <link:label id="lab_pfe_OtherSegmentReconcilingItemsDomain_B2556FCAD1C7B8A918376350788F9345_documentation_en-US" xlink:label="lab_pfe_OtherSegmentReconcilingItemsDomain_B2556FCAD1C7B8A918376350788F9345" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Other Segment Reconciling Items [Axis]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherSegmentReconcilingItemsDomain" xlink:label="loc_pfe_OtherSegmentReconcilingItemsDomain_B2556FCAD1C7B8A918376350788F9345" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherSegmentReconcilingItemsDomain_B2556FCAD1C7B8A918376350788F9345" xlink:to="lab_pfe_OtherSegmentReconcilingItemsDomain_B2556FCAD1C7B8A918376350788F9345" xlink:type="arc" />
    <link:label id="lab_pfe_PurchaseAccountingAdjustmentsMember_6CC0148546FD0A3C59DA63507890A625_terseLabel_en-US" xlink:label="lab_pfe_PurchaseAccountingAdjustmentsMember_6CC0148546FD0A3C59DA63507890A625" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Accounting Adjustments [Member]</link:label>
    <link:label id="lab_pfe_PurchaseAccountingAdjustmentsMember_6CC0148546FD0A3C59DA63507890A625_label_en-US" xlink:label="lab_pfe_PurchaseAccountingAdjustmentsMember_6CC0148546FD0A3C59DA63507890A625" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Accounting Adjustments [Member]</link:label>
    <link:label id="lab_pfe_PurchaseAccountingAdjustmentsMember_6CC0148546FD0A3C59DA63507890A625_documentation_en-US" xlink:label="lab_pfe_PurchaseAccountingAdjustmentsMember_6CC0148546FD0A3C59DA63507890A625" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Accounting Adjustments [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PurchaseAccountingAdjustmentsMember" xlink:label="loc_pfe_PurchaseAccountingAdjustmentsMember_6CC0148546FD0A3C59DA63507890A625" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PurchaseAccountingAdjustmentsMember_6CC0148546FD0A3C59DA63507890A625" xlink:to="lab_pfe_PurchaseAccountingAdjustmentsMember_6CC0148546FD0A3C59DA63507890A625" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_BF73C039621F772D28F7635078902036_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_BF73C039621F772D28F7635078902036" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition-Related Costs [Member]</link:label>
    <link:label id="lab_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_BF73C039621F772D28F7635078902036_label_en-US" xlink:label="lab_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_BF73C039621F772D28F7635078902036" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations, Acquisition Related Costs [Member]</link:label>
    <link:label id="lab_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_BF73C039621F772D28F7635078902036_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_BF73C039621F772D28F7635078902036" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combinations, Acquisition Related Costs [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BusinessCombinationsAcquisitionRelatedCostsMember" xlink:label="loc_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_BF73C039621F772D28F7635078902036" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_BF73C039621F772D28F7635078902036" xlink:to="lab_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_BF73C039621F772D28F7635078902036" xlink:type="arc" />
    <link:label id="lab_pfe_CertainSignificantItemsMember_2BE2DF2543371C764FE2635078900132_terseLabel_en-US" xlink:label="lab_pfe_CertainSignificantItemsMember_2BE2DF2543371C764FE2635078900132" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certain Significant Items [Member]</link:label>
    <link:label id="lab_pfe_CertainSignificantItemsMember_2BE2DF2543371C764FE2635078900132_label_en-US" xlink:label="lab_pfe_CertainSignificantItemsMember_2BE2DF2543371C764FE2635078900132" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certain Significant Items [Member]</link:label>
    <link:label id="lab_pfe_CertainSignificantItemsMember_2BE2DF2543371C764FE2635078900132_documentation_en-US" xlink:label="lab_pfe_CertainSignificantItemsMember_2BE2DF2543371C764FE2635078900132" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Certain significant items [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_CertainSignificantItemsMember" xlink:label="loc_pfe_CertainSignificantItemsMember_2BE2DF2543371C764FE2635078900132" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CertainSignificantItemsMember_2BE2DF2543371C764FE2635078900132" xlink:to="lab_pfe_CertainSignificantItemsMember_2BE2DF2543371C764FE2635078900132" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_DE0C810364AA18EF3FE6635078900876_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems_DE0C810364AA18EF3FE6635078900876" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_DE0C810364AA18EF3FE6635078900876_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems_DE0C810364AA18EF3FE6635078900876" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_DE0C810364AA18EF3FE6635078900876" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DE0C810364AA18EF3FE6635078900876" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems_DE0C810364AA18EF3FE6635078900876" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E2148BBCA0B6B27E7B1F635078908786_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E2148BBCA0B6B27E7B1F635078908786" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E2148BBCA0B6B27E7B1F635078908786_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E2148BBCA0B6B27E7B1F635078908786" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E2148BBCA0B6B27E7B1F635078908786" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E2148BBCA0B6B27E7B1F635078908786" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E2148BBCA0B6B27E7B1F635078908786" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_33AC0AB3FD05F3748EA9635078911A9E_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_33AC0AB3FD05F3748EA9635078911A9E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_33AC0AB3FD05F3748EA9635078911A9E_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_33AC0AB3FD05F3748EA9635078911A9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_33AC0AB3FD05F3748EA9635078911A9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_33AC0AB3FD05F3748EA9635078911A9E" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_33AC0AB3FD05F3748EA9635078911A9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestmentsAbstract_8AAC26126D39C5241268B09F32EE29A7_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract_8AAC26126D39C5241268B09F32EE29A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsAbstract_8AAC26126D39C5241268B09F32EE29A7_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract_8AAC26126D39C5241268B09F32EE29A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_8AAC26126D39C5241268B09F32EE29A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_8AAC26126D39C5241268B09F32EE29A7" xlink:to="lab_us-gaap_ShortTermInvestmentsAbstract_8AAC26126D39C5241268B09F32EE29A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_76959CF1EA94B3D8EFDEB09F32EF732A_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi_76959CF1EA94B3D8EFDEB09F32EF732A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities with readily determinable fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_76959CF1EA94B3D8EFDEB09F32EF732A_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi_76959CF1EA94B3D8EFDEB09F32EF732A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_76959CF1EA94B3D8EFDEB09F32EF732A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi_76959CF1EA94B3D8EFDEB09F32EF732A" xlink:to="lab_us-gaap_EquitySecuritiesFvNi_76959CF1EA94B3D8EFDEB09F32EF732A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3614AE3E91ED1854CC84B09F32EFF0A0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3614AE3E91ED1854CC84B09F32EFF0A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3614AE3E91ED1854CC84B09F32EFF0A0_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3614AE3E91ED1854CC84B09F32EFF0A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3614AE3E91ED1854CC84B09F32EFF0A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3614AE3E91ED1854CC84B09F32EFF0A0" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3614AE3E91ED1854CC84B09F32EFF0A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_E53365B304FF4E5D37D2B09F32EFBB00_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent_E53365B304FF4E5D37D2B09F32EFBB00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity debt securities</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_E53365B304FF4E5D37D2B09F32EFBB00_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent_E53365B304FF4E5D37D2B09F32EFBB00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_E53365B304FF4E5D37D2B09F32EFBB00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent_E53365B304FF4E5D37D2B09F32EFBB00" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesCurrent_E53365B304FF4E5D37D2B09F32EFBB00" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestments_F7E7F870351078E698D4B09F32EF21E6_totalLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_F7E7F870351078E698D4B09F32EF21E6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_F7E7F870351078E698D4B09F32EF21E6_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_F7E7F870351078E698D4B09F32EF21E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_F7E7F870351078E698D4B09F32EF21E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments_F7E7F870351078E698D4B09F32EF21E6" xlink:to="lab_us-gaap_ShortTermInvestments_F7E7F870351078E698D4B09F32EF21E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermInvestmentsAbstract_D53C03DE45E2414A805DB09F32EF0926_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestmentsAbstract_D53C03DE45E2414A805DB09F32EF0926" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestmentsAbstract_D53C03DE45E2414A805DB09F32EF0926_label_en-US" xlink:label="lab_us-gaap_LongTermInvestmentsAbstract_D53C03DE45E2414A805DB09F32EF0926" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Investments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestmentsAbstract" xlink:label="loc_us-gaap_LongTermInvestmentsAbstract_D53C03DE45E2414A805DB09F32EF0926" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_D53C03DE45E2414A805DB09F32EF0926" xlink:to="lab_us-gaap_LongTermInvestmentsAbstract_D53C03DE45E2414A805DB09F32EF0926" xlink:type="arc" />
    <link:label id="lab_pfe_EquitySecuritiesFVNINoncurrent_66099B74C2367402059DB09F32EFD1D7_terseLabel_en-US" xlink:label="lab_pfe_EquitySecuritiesFVNINoncurrent_66099B74C2367402059DB09F32EFD1D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities with readily determinable fair values</link:label>
    <link:label id="lab_pfe_EquitySecuritiesFVNINoncurrent_66099B74C2367402059DB09F32EFD1D7_label_en-US" xlink:label="lab_pfe_EquitySecuritiesFVNINoncurrent_66099B74C2367402059DB09F32EFD1D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Noncurrent</link:label>
    <link:label id="lab_pfe_EquitySecuritiesFVNINoncurrent_66099B74C2367402059DB09F32EFD1D7_documentation_en-US" xlink:label="lab_pfe_EquitySecuritiesFVNINoncurrent_66099B74C2367402059DB09F32EFD1D7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Noncurrent</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EquitySecuritiesFVNINoncurrent" xlink:label="loc_pfe_EquitySecuritiesFVNINoncurrent_66099B74C2367402059DB09F32EFD1D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquitySecuritiesFVNINoncurrent_66099B74C2367402059DB09F32EFD1D7" xlink:to="lab_pfe_EquitySecuritiesFVNINoncurrent_66099B74C2367402059DB09F32EFD1D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_889DC52F7BB3A88E8ABBB09F32F0B254_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_889DC52F7BB3A88E8ABBB09F32F0B254" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_889DC52F7BB3A88E8ABBB09F32F0B254_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_889DC52F7BB3A88E8ABBB09F32F0B254" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_889DC52F7BB3A88E8ABBB09F32F0B254" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_889DC52F7BB3A88E8ABBB09F32F0B254" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_889DC52F7BB3A88E8ABBB09F32F0B254" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_DEA2858DBD724629623BB09F32F0A3B3_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_DEA2858DBD724629623BB09F32F0A3B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity debt securities</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_DEA2858DBD724629623BB09F32F0A3B3_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_DEA2858DBD724629623BB09F32F0A3B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_DEA2858DBD724629623BB09F32F0A3B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_DEA2858DBD724629623BB09F32F0A3B3" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_DEA2858DBD724629623BB09F32F0A3B3" xlink:type="arc" />
    <link:label id="lab_pfe_PrivateEquityInvestments_A8BD49A5E0492F388146B09F32F0FAD4_terseLabel_en-US" xlink:label="lab_pfe_PrivateEquityInvestments_A8BD49A5E0492F388146B09F32F0FAD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private equity securities at cost</link:label>
    <link:label id="lab_pfe_PrivateEquityInvestments_A8BD49A5E0492F388146B09F32F0FAD4_label_en-US" xlink:label="lab_pfe_PrivateEquityInvestments_A8BD49A5E0492F388146B09F32F0FAD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Equity Investments</link:label>
    <link:label id="lab_pfe_PrivateEquityInvestments_A8BD49A5E0492F388146B09F32F0FAD4_documentation_en-US" xlink:label="lab_pfe_PrivateEquityInvestments_A8BD49A5E0492F388146B09F32F0FAD4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private Equity Investments</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PrivateEquityInvestments" xlink:label="loc_pfe_PrivateEquityInvestments_A8BD49A5E0492F388146B09F32F0FAD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PrivateEquityInvestments_A8BD49A5E0492F388146B09F32F0FAD4" xlink:to="lab_pfe_PrivateEquityInvestments_A8BD49A5E0492F388146B09F32F0FAD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLongTermInvestments_51E628BE1E59C38D6732B09F32F0E671_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments_51E628BE1E59C38D6732B09F32F0E671" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Long-term investments</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_51E628BE1E59C38D6732B09F32F0E671_label_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments_51E628BE1E59C38D6732B09F32F0E671" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Long-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermInvestments" xlink:label="loc_us-gaap_OtherLongTermInvestments_51E628BE1E59C38D6732B09F32F0E671" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestments_51E628BE1E59C38D6732B09F32F0E671" xlink:to="lab_us-gaap_OtherLongTermInvestments_51E628BE1E59C38D6732B09F32F0E671" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermInvestments_59841D664259ED3F0831B09F32F155AF_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments_59841D664259ED3F0831B09F32F155AF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total long-term investments and equity-method investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_59841D664259ED3F0831B09F32F155AF_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments_59841D664259ED3F0831B09F32F155AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_59841D664259ED3F0831B09F32F155AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments_59841D664259ED3F0831B09F32F155AF" xlink:to="lab_us-gaap_LongTermInvestments_59841D664259ED3F0831B09F32F155AF" xlink:type="arc" />
    <link:label id="lab_pfe_HeldToMaturityCashEquivalents_264F6138AB1EC83EF47CB09F32F1F111_terseLabel_en-US" xlink:label="lab_pfe_HeldToMaturityCashEquivalents_264F6138AB1EC83EF47CB09F32F1F111" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity cash equivalents</link:label>
    <link:label id="lab_pfe_HeldToMaturityCashEquivalents_264F6138AB1EC83EF47CB09F32F1F111_label_en-US" xlink:label="lab_pfe_HeldToMaturityCashEquivalents_264F6138AB1EC83EF47CB09F32F1F111" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Held-To-Maturity Cash Equivalents</link:label>
    <link:label id="lab_pfe_HeldToMaturityCashEquivalents_264F6138AB1EC83EF47CB09F32F1F111_documentation_en-US" xlink:label="lab_pfe_HeldToMaturityCashEquivalents_264F6138AB1EC83EF47CB09F32F1F111" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Held-To-Maturity Cash Equivalents</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_HeldToMaturityCashEquivalents" xlink:label="loc_pfe_HeldToMaturityCashEquivalents_264F6138AB1EC83EF47CB09F32F1F111" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HeldToMaturityCashEquivalents_264F6138AB1EC83EF47CB09F32F1F111" xlink:to="lab_pfe_HeldToMaturityCashEquivalents_264F6138AB1EC83EF47CB09F32F1F111" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_97419A36A4CAB544DA3DBEEA9658BC87_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_97419A36A4CAB544DA3DBEEA9658BC87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_97419A36A4CAB544DA3DBEEA9658BC87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_97419A36A4CAB544DA3DBEEA9658BC87" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_97419A36A4CAB544DA3DBEEA9658BC87" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesTable_5DAED5BA42B73F27EE3CBEEA96598DD5_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_5DAED5BA42B73F27EE3CBEEA96598DD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_5DAED5BA42B73F27EE3CBEEA96598DD5_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_5DAED5BA42B73F27EE3CBEEA96598DD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_5DAED5BA42B73F27EE3CBEEA96598DD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable_5DAED5BA42B73F27EE3CBEEA96598DD5" xlink:to="lab_us-gaap_LossContingenciesTable_5DAED5BA42B73F27EE3CBEEA96598DD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_7570F66BE8CB0EFCF744BEEBF9FDBBAF_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_7570F66BE8CB0EFCF744BEEBF9FDBBAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_7570F66BE8CB0EFCF744BEEBF9FDBBAF_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_7570F66BE8CB0EFCF744BEEBF9FDBBAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7570F66BE8CB0EFCF744BEEBF9FDBBAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7570F66BE8CB0EFCF744BEEBF9FDBBAF" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_7570F66BE8CB0EFCF744BEEBF9FDBBAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_EA490FDE583EE39E3BB1BEEBFA3CE6F7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_EA490FDE583EE39E3BB1BEEBFA3CE6F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_EA490FDE583EE39E3BB1BEEBFA3CE6F7_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_EA490FDE583EE39E3BB1BEEBFA3CE6F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_EA490FDE583EE39E3BB1BEEBFA3CE6F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_EA490FDE583EE39E3BB1BEEBFA3CE6F7" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_EA490FDE583EE39E3BB1BEEBFA3CE6F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_4343B76856DA3A1607A2BEEBFAF30770_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_4343B76856DA3A1607A2BEEBFAF30770" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_4343B76856DA3A1607A2BEEBFAF30770_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_4343B76856DA3A1607A2BEEBFAF30770" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4343B76856DA3A1607A2BEEBFAF30770" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_4343B76856DA3A1607A2BEEBFAF30770" xlink:to="lab_us-gaap_SubsequentEventMember_4343B76856DA3A1607A2BEEBFAF30770" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_E85047E7D3E801F63914BEEA965A7D18_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_E85047E7D3E801F63914BEEA965A7D18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_E85047E7D3E801F63914BEEA965A7D18_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_E85047E7D3E801F63914BEEA965A7D18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_E85047E7D3E801F63914BEEA965A7D18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_E85047E7D3E801F63914BEEA965A7D18" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_E85047E7D3E801F63914BEEA965A7D18" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_6661524AD9BB9FA76636BEEA965A12F5_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain_6661524AD9BB9FA76636BEEA965A12F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_6661524AD9BB9FA76636BEEA965A12F5_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain_6661524AD9BB9FA76636BEEA965A12F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_6661524AD9BB9FA76636BEEA965A12F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain_6661524AD9BB9FA76636BEEA965A12F5" xlink:to="lab_us-gaap_LossContingencyNatureDomain_6661524AD9BB9FA76636BEEA965A12F5" xlink:type="arc" />
    <link:label id="lab_pfe_PatentInfringementMember_711B96585A07A67D817BBEEBFA5DAAA3_terseLabel_en-US" xlink:label="lab_pfe_PatentInfringementMember_711B96585A07A67D817BBEEBFA5DAAA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patent Infringement [Member]</link:label>
    <link:label id="lab_pfe_PatentInfringementMember_711B96585A07A67D817BBEEBFA5DAAA3_label_en-US" xlink:label="lab_pfe_PatentInfringementMember_711B96585A07A67D817BBEEBFA5DAAA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patent Infringement [Member]</link:label>
    <link:label id="lab_pfe_PatentInfringementMember_711B96585A07A67D817BBEEBFA5DAAA3_documentation_en-US" xlink:label="lab_pfe_PatentInfringementMember_711B96585A07A67D817BBEEBFA5DAAA3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Patent Infringement [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PatentInfringementMember" xlink:label="loc_pfe_PatentInfringementMember_711B96585A07A67D817BBEEBFA5DAAA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PatentInfringementMember_711B96585A07A67D817BBEEBFA5DAAA3" xlink:to="lab_pfe_PatentInfringementMember_711B96585A07A67D817BBEEBFA5DAAA3" xlink:type="arc" />
    <link:label id="lab_pfe_EnvironmentalRemediationLitigationMember_24B8195F1F8C12CC2793BEEA965A39E5_terseLabel_en-US" xlink:label="lab_pfe_EnvironmentalRemediationLitigationMember_24B8195F1F8C12CC2793BEEA965A39E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Environmental Remediation Litigation [Member]</link:label>
    <link:label id="lab_pfe_EnvironmentalRemediationLitigationMember_24B8195F1F8C12CC2793BEEA965A39E5_label_en-US" xlink:label="lab_pfe_EnvironmentalRemediationLitigationMember_24B8195F1F8C12CC2793BEEA965A39E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental Remediation Litigation [Member]</link:label>
    <link:label id="lab_pfe_EnvironmentalRemediationLitigationMember_24B8195F1F8C12CC2793BEEA965A39E5_documentation_en-US" xlink:label="lab_pfe_EnvironmentalRemediationLitigationMember_24B8195F1F8C12CC2793BEEA965A39E5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Environmental Remediation Litigation [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EnvironmentalRemediationLitigationMember" xlink:label="loc_pfe_EnvironmentalRemediationLitigationMember_24B8195F1F8C12CC2793BEEA965A39E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EnvironmentalRemediationLitigationMember_24B8195F1F8C12CC2793BEEA965A39E5" xlink:to="lab_pfe_EnvironmentalRemediationLitigationMember_24B8195F1F8C12CC2793BEEA965A39E5" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_B84566645BA54A1445ABBEEA965A9E85_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_B84566645BA54A1445ABBEEA965A9E85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_B84566645BA54A1445ABBEEA965A9E85_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_B84566645BA54A1445ABBEEA965A9E85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_B84566645BA54A1445ABBEEA965A9E85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_B84566645BA54A1445ABBEEA965A9E85" xlink:to="lab_srt_ProductOrServiceAxis_B84566645BA54A1445ABBEEA965A9E85" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_4AB4BD9216D90C610C31BEEA965B5989_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_4AB4BD9216D90C610C31BEEA965B5989" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_4AB4BD9216D90C610C31BEEA965B5989_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_4AB4BD9216D90C610C31BEEA965B5989" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_4AB4BD9216D90C610C31BEEA965B5989" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_4AB4BD9216D90C610C31BEEA965B5989" xlink:to="lab_srt_ProductsAndServicesDomain_4AB4BD9216D90C610C31BEEA965B5989" xlink:type="arc" />
    <link:label id="lab_pfe_HormoneTherapyProductsMember_FF942F4A2FF1736D3B7FBEEA965B27B6_terseLabel_en-US" xlink:label="lab_pfe_HormoneTherapyProductsMember_FF942F4A2FF1736D3B7FBEEA965B27B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hormone Therapy Products [Member]</link:label>
    <link:label id="lab_pfe_HormoneTherapyProductsMember_FF942F4A2FF1736D3B7FBEEA965B27B6_label_en-US" xlink:label="lab_pfe_HormoneTherapyProductsMember_FF942F4A2FF1736D3B7FBEEA965B27B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hormone Therapy Products [Member]</link:label>
    <link:label id="lab_pfe_HormoneTherapyProductsMember_FF942F4A2FF1736D3B7FBEEA965B27B6_documentation_en-US" xlink:label="lab_pfe_HormoneTherapyProductsMember_FF942F4A2FF1736D3B7FBEEA965B27B6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hormone Therapy Products [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_HormoneTherapyProductsMember" xlink:label="loc_pfe_HormoneTherapyProductsMember_FF942F4A2FF1736D3B7FBEEA965B27B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HormoneTherapyProductsMember_FF942F4A2FF1736D3B7FBEEA965B27B6" xlink:to="lab_pfe_HormoneTherapyProductsMember_FF942F4A2FF1736D3B7FBEEA965B27B6" xlink:type="arc" />
    <link:label id="lab_pfe_EpiPenMember_31CBE40091AAEBEA3486BEEA965BAA4D_terseLabel_en-US" xlink:label="lab_pfe_EpiPenMember_31CBE40091AAEBEA3486BEEA965BAA4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EpiPen [Member]</link:label>
    <link:label id="lab_pfe_EpiPenMember_31CBE40091AAEBEA3486BEEA965BAA4D_label_en-US" xlink:label="lab_pfe_EpiPenMember_31CBE40091AAEBEA3486BEEA965BAA4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Epi Pen [Member]</link:label>
    <link:label id="lab_pfe_EpiPenMember_31CBE40091AAEBEA3486BEEA965BAA4D_documentation_en-US" xlink:label="lab_pfe_EpiPenMember_31CBE40091AAEBEA3486BEEA965BAA4D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">EpiPen [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EpiPenMember" xlink:label="loc_pfe_EpiPenMember_31CBE40091AAEBEA3486BEEA965BAA4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EpiPenMember_31CBE40091AAEBEA3486BEEA965BAA4D" xlink:to="lab_pfe_EpiPenMember_31CBE40091AAEBEA3486BEEA965BAA4D" xlink:type="arc" />
    <link:label id="lab_pfe_DocetaxelMember_FD3D3B972C9FD13B9C18BEEA965BF83A_terseLabel_en-US" xlink:label="lab_pfe_DocetaxelMember_FD3D3B972C9FD13B9C18BEEA965BF83A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Docetaxel [Member]</link:label>
    <link:label id="lab_pfe_DocetaxelMember_FD3D3B972C9FD13B9C18BEEA965BF83A_label_en-US" xlink:label="lab_pfe_DocetaxelMember_FD3D3B972C9FD13B9C18BEEA965BF83A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Docetaxel [Member]</link:label>
    <link:label id="lab_pfe_DocetaxelMember_FD3D3B972C9FD13B9C18BEEA965BF83A_documentation_en-US" xlink:label="lab_pfe_DocetaxelMember_FD3D3B972C9FD13B9C18BEEA965BF83A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Docetaxel [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DocetaxelMember" xlink:label="loc_pfe_DocetaxelMember_FD3D3B972C9FD13B9C18BEEA965BF83A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DocetaxelMember_FD3D3B972C9FD13B9C18BEEA965BF83A" xlink:to="lab_pfe_DocetaxelMember_FD3D3B972C9FD13B9C18BEEA965BF83A" xlink:type="arc" />
    <link:label id="lab_srt_LitigationCaseAxis_7936A69B2785FF7478A2BEEA965CCBCE_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis_7936A69B2785FF7478A2BEEA965CCBCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_7936A69B2785FF7478A2BEEA965CCBCE_label_en-US" xlink:label="lab_srt_LitigationCaseAxis_7936A69B2785FF7478A2BEEA965CCBCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_7936A69B2785FF7478A2BEEA965CCBCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis_7936A69B2785FF7478A2BEEA965CCBCE" xlink:to="lab_srt_LitigationCaseAxis_7936A69B2785FF7478A2BEEA965CCBCE" xlink:type="arc" />
    <link:label id="lab_srt_LitigationCaseTypeDomain_BB9DBA6014A9043D9D6ABEEA965CF4BB_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain_BB9DBA6014A9043D9D6ABEEA965CF4BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_BB9DBA6014A9043D9D6ABEEA965CF4BB_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain_BB9DBA6014A9043D9D6ABEEA965CF4BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_BB9DBA6014A9043D9D6ABEEA965CF4BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain_BB9DBA6014A9043D9D6ABEEA965CF4BB" xlink:to="lab_srt_LitigationCaseTypeDomain_BB9DBA6014A9043D9D6ABEEA965CF4BB" xlink:type="arc" />
    <link:label id="lab_pfe_NHSScotlandvs.DrReddysMember_43C5F4534C427114E2CBBEEBFAAB4619_terseLabel_en-US" xlink:label="lab_pfe_NHSScotlandvs.DrReddysMember_43C5F4534C427114E2CBBEEBFAAB4619" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NHS Scotland vs. Dr Reddy's [Member]</link:label>
    <link:label id="lab_pfe_NHSScotlandvs.DrReddysMember_43C5F4534C427114E2CBBEEBFAAB4619_label_en-US" xlink:label="lab_pfe_NHSScotlandvs.DrReddysMember_43C5F4534C427114E2CBBEEBFAAB4619" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NHS Scotland vs. Dr Reddy's [Member]</link:label>
    <link:label id="lab_pfe_NHSScotlandvs.DrReddysMember_43C5F4534C427114E2CBBEEBFAAB4619_documentation_en-US" xlink:label="lab_pfe_NHSScotlandvs.DrReddysMember_43C5F4534C427114E2CBBEEBFAAB4619" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">NHS Scotland vs. Dr Reddy's [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_NHSScotlandvs.DrReddysMember" xlink:label="loc_pfe_NHSScotlandvs.DrReddysMember_43C5F4534C427114E2CBBEEBFAAB4619" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NHSScotlandvs.DrReddysMember_43C5F4534C427114E2CBBEEBFAAB4619" xlink:to="lab_pfe_NHSScotlandvs.DrReddysMember_43C5F4534C427114E2CBBEEBFAAB4619" xlink:type="arc" />
    <link:label id="lab_pfe_ClassActionVersusWyethMember_8B978BF67595DEAC1FC5BEEA965CBE13_terseLabel_en-US" xlink:label="lab_pfe_ClassActionVersusWyethMember_8B978BF67595DEAC1FC5BEEA965CBE13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class Action Versus Wyeth [Member]</link:label>
    <link:label id="lab_pfe_ClassActionVersusWyethMember_8B978BF67595DEAC1FC5BEEA965CBE13_label_en-US" xlink:label="lab_pfe_ClassActionVersusWyethMember_8B978BF67595DEAC1FC5BEEA965CBE13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Action Versus Wyeth [Member]</link:label>
    <link:label id="lab_pfe_ClassActionVersusWyethMember_8B978BF67595DEAC1FC5BEEA965CBE13_documentation_en-US" xlink:label="lab_pfe_ClassActionVersusWyethMember_8B978BF67595DEAC1FC5BEEA965CBE13" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Action Versus Wyeth [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ClassActionVersusWyethMember" xlink:label="loc_pfe_ClassActionVersusWyethMember_8B978BF67595DEAC1FC5BEEA965CBE13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ClassActionVersusWyethMember_8B978BF67595DEAC1FC5BEEA965CBE13" xlink:to="lab_pfe_ClassActionVersusWyethMember_8B978BF67595DEAC1FC5BEEA965CBE13" xlink:type="arc" />
    <link:label id="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_7DBADCD09438C966389BBEEA965C9202_terseLabel_en-US" xlink:label="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_7DBADCD09438C966389BBEEA965C9202" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]</link:label>
    <link:label id="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_7DBADCD09438C966389BBEEA965C9202_label_en-US" xlink:label="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_7DBADCD09438C966389BBEEA965C9202" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]</link:label>
    <link:label id="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_7DBADCD09438C966389BBEEA965C9202_documentation_en-US" xlink:label="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_7DBADCD09438C966389BBEEA965C9202" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" xlink:label="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_7DBADCD09438C966389BBEEA965C9202" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_7DBADCD09438C966389BBEEA965C9202" xlink:to="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_7DBADCD09438C966389BBEEA965C9202" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationStatusAxis_0B96D608C6F21A949707BEEA965DCD1C_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis_0B96D608C6F21A949707BEEA965DCD1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_0B96D608C6F21A949707BEEA965DCD1C_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis_0B96D608C6F21A949707BEEA965DCD1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_0B96D608C6F21A949707BEEA965DCD1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis_0B96D608C6F21A949707BEEA965DCD1C" xlink:to="lab_us-gaap_LitigationStatusAxis_0B96D608C6F21A949707BEEA965DCD1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationStatusDomain_72A1EA19236314D2ED45BEEA965DC648_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain_72A1EA19236314D2ED45BEEA965DC648" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_72A1EA19236314D2ED45BEEA965DC648_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain_72A1EA19236314D2ED45BEEA965DC648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_72A1EA19236314D2ED45BEEA965DC648" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain_72A1EA19236314D2ED45BEEA965DC648" xlink:to="lab_us-gaap_LitigationStatusDomain_72A1EA19236314D2ED45BEEA965DC648" xlink:type="arc" />
    <link:label id="lab_us-gaap_SettledLitigationMember_72AEFCC8DA9C7566F5C7BEEA965D3ED0_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember_72AEFCC8DA9C7566F5C7BEEA965D3ED0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_72AEFCC8DA9C7566F5C7BEEA965D3ED0_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember_72AEFCC8DA9C7566F5C7BEEA965D3ED0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="loc_us-gaap_SettledLitigationMember_72AEFCC8DA9C7566F5C7BEEA965D3ED0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember_72AEFCC8DA9C7566F5C7BEEA965D3ED0" xlink:to="lab_us-gaap_SettledLitigationMember_72AEFCC8DA9C7566F5C7BEEA965D3ED0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PendingLitigationMember_9911E2E36421DFE8DE43BEEA965DFCCF_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember_9911E2E36421DFE8DE43BEEA965DFCCF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_9911E2E36421DFE8DE43BEEA965DFCCF_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember_9911E2E36421DFE8DE43BEEA965DFCCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_9911E2E36421DFE8DE43BEEA965DFCCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember_9911E2E36421DFE8DE43BEEA965DFCCF" xlink:to="lab_us-gaap_PendingLitigationMember_9911E2E36421DFE8DE43BEEA965DFCCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesLineItems_9166BCF6AE6608182894BEEA965DF309_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_9166BCF6AE6608182894BEEA965DF309" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_9166BCF6AE6608182894BEEA965DF309_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_9166BCF6AE6608182894BEEA965DF309" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_9166BCF6AE6608182894BEEA965DF309" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems_9166BCF6AE6608182894BEEA965DF309" xlink:to="lab_us-gaap_LossContingenciesLineItems_9166BCF6AE6608182894BEEA965DF309" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_435F2919357205352287BEEBF9D0D305_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs_435F2919357205352287BEEBF9D0D305" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_435F2919357205352287BEEBF9D0D305_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs_435F2919357205352287BEEBF9D0D305" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_435F2919357205352287BEEBF9D0D305" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs_435F2919357205352287BEEBF9D0D305" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs_435F2919357205352287BEEBF9D0D305" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_E966E4E0DC5EAA63192BBEEA965E272E_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements_E966E4E0DC5EAA63192BBEEA965E272E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement agreed</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_E966E4E0DC5EAA63192BBEEA965E272E_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements_E966E4E0DC5EAA63192BBEEA965E272E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_E966E4E0DC5EAA63192BBEEA965E272E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements_E966E4E0DC5EAA63192BBEEA965E272E" xlink:to="lab_us-gaap_PaymentsForLegalSettlements_E966E4E0DC5EAA63192BBEEA965E272E" xlink:type="arc" />
    <link:label id="lab_pfe_LossContingencyNumberOfLawsuits_67989598F7EB08095016BEEA965EDE8D_terseLabel_en-US" xlink:label="lab_pfe_LossContingencyNumberOfLawsuits_67989598F7EB08095016BEEA965EDE8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of lawsuits</link:label>
    <link:label id="lab_pfe_LossContingencyNumberOfLawsuits_67989598F7EB08095016BEEA965EDE8D_label_en-US" xlink:label="lab_pfe_LossContingencyNumberOfLawsuits_67989598F7EB08095016BEEA965EDE8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number Of Lawsuits</link:label>
    <link:label id="lab_pfe_LossContingencyNumberOfLawsuits_67989598F7EB08095016BEEA965EDE8D_documentation_en-US" xlink:label="lab_pfe_LossContingencyNumberOfLawsuits_67989598F7EB08095016BEEA965EDE8D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number Of Lawsuits</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LossContingencyNumberOfLawsuits" xlink:label="loc_pfe_LossContingencyNumberOfLawsuits_67989598F7EB08095016BEEA965EDE8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LossContingencyNumberOfLawsuits_67989598F7EB08095016BEEA965EDE8D" xlink:to="lab_pfe_LossContingencyNumberOfLawsuits_67989598F7EB08095016BEEA965EDE8D" xlink:type="arc" />
    <link:label id="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_198735D799629D87BBC4BEEA965E23D2_terseLabel_en-US" xlink:label="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_198735D799629D87BBC4BEEA965E23D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of defendants other than main defendant</link:label>
    <link:label id="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_198735D799629D87BBC4BEEA965E23D2_label_en-US" xlink:label="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_198735D799629D87BBC4BEEA965E23D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number Of Defendants Other Than Main Defendant</link:label>
    <link:label id="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_198735D799629D87BBC4BEEA965E23D2_documentation_en-US" xlink:label="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_198735D799629D87BBC4BEEA965E23D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number Of Defendants Other Than Main Defendant</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" xlink:label="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_198735D799629D87BBC4BEEA965E23D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_198735D799629D87BBC4BEEA965E23D2" xlink:to="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_198735D799629D87BBC4BEEA965E23D2" xlink:type="arc" />
    <link:label id="lab_pfe_LossContingencyClassActionsFiledNumber_0248FC1B6EB0A16E7A15BEEA965ECEF2_terseLabel_en-US" xlink:label="lab_pfe_LossContingencyClassActionsFiledNumber_0248FC1B6EB0A16E7A15BEEA965ECEF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of class actions filed</link:label>
    <link:label id="lab_pfe_LossContingencyClassActionsFiledNumber_0248FC1B6EB0A16E7A15BEEA965ECEF2_label_en-US" xlink:label="lab_pfe_LossContingencyClassActionsFiledNumber_0248FC1B6EB0A16E7A15BEEA965ECEF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Class Actions Filed, Number</link:label>
    <link:label id="lab_pfe_LossContingencyClassActionsFiledNumber_0248FC1B6EB0A16E7A15BEEA965ECEF2_documentation_en-US" xlink:label="lab_pfe_LossContingencyClassActionsFiledNumber_0248FC1B6EB0A16E7A15BEEA965ECEF2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Class Actions Filed, Number</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LossContingencyClassActionsFiledNumber" xlink:label="loc_pfe_LossContingencyClassActionsFiledNumber_0248FC1B6EB0A16E7A15BEEA965ECEF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LossContingencyClassActionsFiledNumber_0248FC1B6EB0A16E7A15BEEA965ECEF2" xlink:to="lab_pfe_LossContingencyClassActionsFiledNumber_0248FC1B6EB0A16E7A15BEEA965ECEF2" xlink:type="arc" />
    <link:label id="lab_pfe_FeasibilityStudyNumberOfLagoons_99ED2948E08D611DC62BBEEA965EFAD7_terseLabel_en-US" xlink:label="lab_pfe_FeasibilityStudyNumberOfLagoons_99ED2948E08D611DC62BBEEA965EFAD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of lagoons</link:label>
    <link:label id="lab_pfe_FeasibilityStudyNumberOfLagoons_99ED2948E08D611DC62BBEEA965EFAD7_label_en-US" xlink:label="lab_pfe_FeasibilityStudyNumberOfLagoons_99ED2948E08D611DC62BBEEA965EFAD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Feasibility Study, Number Of Lagoons</link:label>
    <link:label id="lab_pfe_FeasibilityStudyNumberOfLagoons_99ED2948E08D611DC62BBEEA965EFAD7_documentation_en-US" xlink:label="lab_pfe_FeasibilityStudyNumberOfLagoons_99ED2948E08D611DC62BBEEA965EFAD7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Feasibility Study, Number Of Lagoons</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FeasibilityStudyNumberOfLagoons" xlink:label="loc_pfe_FeasibilityStudyNumberOfLagoons_99ED2948E08D611DC62BBEEA965EFAD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FeasibilityStudyNumberOfLagoons_99ED2948E08D611DC62BBEEA965EFAD7" xlink:to="lab_pfe_FeasibilityStudyNumberOfLagoons_99ED2948E08D611DC62BBEEA965EFAD7" xlink:type="arc" />
    <link:label id="lab_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount_10B04D9679A341C65E569476211E66AD_terseLabel_en-US" xlink:label="lab_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount_10B04D9679A341C65E569476211E66AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative impairment losses and downward price adjustments on equity securities</link:label>
    <link:label id="lab_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount_10B04D9679A341C65E569476211E66AD_label_en-US" xlink:label="lab_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount_10B04D9679A341C65E569476211E66AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value, Impairment Loss And Downward Price Adjustment, Cumulative Amount</link:label>
    <link:label id="lab_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount_10B04D9679A341C65E569476211E66AD_documentation_en-US" xlink:label="lab_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount_10B04D9679A341C65E569476211E66AD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value, Impairment Loss And Downward Price Adjustment, Cumulative Amount</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" xlink:label="loc_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount_10B04D9679A341C65E569476211E66AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount_10B04D9679A341C65E569476211E66AD" xlink:to="lab_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount_10B04D9679A341C65E569476211E66AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_D91CA10A06DEA51E83629476211E7F04_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_D91CA10A06DEA51E83629476211E7F04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative upward price adjustments on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_D91CA10A06DEA51E83629476211E7F04_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_D91CA10A06DEA51E83629476211E7F04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_D91CA10A06DEA51E83629476211E7F04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_D91CA10A06DEA51E83629476211E7F04" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_D91CA10A06DEA51E83629476211E7F04" xlink:type="arc" />
    <link:label id="lab_pfe_ViiVMember_9882A87663C55444CCCF9AD3C8CE86D7_terseLabel_en-US" xlink:label="lab_pfe_ViiVMember_9882A87663C55444CCCF9AD3C8CE86D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ViiV [Member]</link:label>
    <link:label id="lab_pfe_ViiVMember_9882A87663C55444CCCF9AD3C8CE86D7_label_en-US" xlink:label="lab_pfe_ViiVMember_9882A87663C55444CCCF9AD3C8CE86D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ViiV [Member]</link:label>
    <link:label id="lab_pfe_ViiVMember_9882A87663C55444CCCF9AD3C8CE86D7_documentation_en-US" xlink:label="lab_pfe_ViiVMember_9882A87663C55444CCCF9AD3C8CE86D7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ViiV [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ViiVMember" xlink:label="loc_pfe_ViiVMember_9882A87663C55444CCCF9AD3C8CE86D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ViiVMember_9882A87663C55444CCCF9AD3C8CE86D7" xlink:to="lab_pfe_ViiVMember_9882A87663C55444CCCF9AD3C8CE86D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeDividend_1064A3DC510882411B339AD3C8CFAC31_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeDividend_1064A3DC510882411B339AD3C8CFAC31" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Dividend income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeDividend_1064A3DC510882411B339AD3C8CFAC31_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeDividend_1064A3DC510882411B339AD3C8CFAC31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Dividend</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeDividend" xlink:label="loc_us-gaap_InvestmentIncomeDividend_1064A3DC510882411B339AD3C8CFAC31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeDividend_1064A3DC510882411B339AD3C8CFAC31" xlink:to="lab_us-gaap_InvestmentIncomeDividend_1064A3DC510882411B339AD3C8CFAC31" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_2328F81890C2CD31F34F635078D00AB3_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_2328F81890C2CD31F34F635078D00AB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2328F81890C2CD31F34F635078D00AB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2328F81890C2CD31F34F635078D00AB3" xlink:to="lab_us-gaap_EarningsPerShareAbstract_2328F81890C2CD31F34F635078D00AB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_31FF26AB80DE33FEEFB6635078D029D1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_31FF26AB80DE33FEEFB6635078D029D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Basic and Diluted Earning Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_31FF26AB80DE33FEEFB6635078D029D1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_31FF26AB80DE33FEEFB6635078D029D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_31FF26AB80DE33FEEFB6635078D029D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_31FF26AB80DE33FEEFB6635078D029D1" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_31FF26AB80DE33FEEFB6635078D029D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_BBA8C7E20324BC2213F7635078D7A14C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_BBA8C7E20324BC2213F7635078D7A14C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_BBA8C7E20324BC2213F7635078D7A14C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_BBA8C7E20324BC2213F7635078D7A14C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_BBA8C7E20324BC2213F7635078D7A14C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_BBA8C7E20324BC2213F7635078D7A14C" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_BBA8C7E20324BC2213F7635078D7A14C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_CB5A65ECE31102262D68635078D81D54_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_CB5A65ECE31102262D68635078D81D54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_CB5A65ECE31102262D68635078D81D54_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_CB5A65ECE31102262D68635078D81D54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_CB5A65ECE31102262D68635078D81D54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_CB5A65ECE31102262D68635078D81D54" xlink:to="lab_us-gaap_CommonStockMember_CB5A65ECE31102262D68635078D81D54" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_AE0D9C43AD7F4A42E454635078D8C6E2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_AE0D9C43AD7F4A42E454635078D8C6E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_AE0D9C43AD7F4A42E454635078D8C6E2_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_AE0D9C43AD7F4A42E454635078D8C6E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_AE0D9C43AD7F4A42E454635078D8C6E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_AE0D9C43AD7F4A42E454635078D8C6E2" xlink:to="lab_us-gaap_ClassOfStockLineItems_AE0D9C43AD7F4A42E454635078D8C6E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_A9FFBC1F7A40E008D33A635078D8B43B_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_A9FFBC1F7A40E008D33A635078D8B43B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued upon conversion of convertible preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_A9FFBC1F7A40E008D33A635078D8B43B_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_A9FFBC1F7A40E008D33A635078D8B43B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_A9FFBC1F7A40E008D33A635078D8B43B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_A9FFBC1F7A40E008D33A635078D8B43B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_A9FFBC1F7A40E008D33A635078D8B43B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_E459F6F67A44AD16290E635078D856AE_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_E459F6F67A44AD16290E635078D856AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_E459F6F67A44AD16290E635078D856AE_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_E459F6F67A44AD16290E635078D856AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_E459F6F67A44AD16290E635078D856AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_E459F6F67A44AD16290E635078D856AE" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_E459F6F67A44AD16290E635078D856AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_9BEE1AE907A0C66EBBBD947620767604_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_9BEE1AE907A0C66EBBBD947620767604" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9BEE1AE907A0C66EBBBD947620767604" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9BEE1AE907A0C66EBBBD947620767604" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_9BEE1AE907A0C66EBBBD947620767604" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_262BA168751F64C46BBF94762076431D_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_262BA168751F64C46BBF94762076431D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_262BA168751F64C46BBF94762076431D_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_262BA168751F64C46BBF94762076431D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_262BA168751F64C46BBF94762076431D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_262BA168751F64C46BBF94762076431D" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_262BA168751F64C46BBF94762076431D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_218130D2FF0800F693C19476207C7C9F_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_218130D2FF0800F693C19476207C7C9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_218130D2FF0800F693C19476207C7C9F_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_218130D2FF0800F693C19476207C7C9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_218130D2FF0800F693C19476207C7C9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_218130D2FF0800F693C19476207C7C9F" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_218130D2FF0800F693C19476207C7C9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_99E166D4D9B018020A5D9476207C8818_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_99E166D4D9B018020A5D9476207C8818" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_99E166D4D9B018020A5D9476207C8818_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_99E166D4D9B018020A5D9476207C8818" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_99E166D4D9B018020A5D9476207C8818" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_99E166D4D9B018020A5D9476207C8818" xlink:to="lab_us-gaap_LongTermDebtCurrent_99E166D4D9B018020A5D9476207C8818" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3E9407B81FFADCB78971628A0AE13BD9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3E9407B81FFADCB78971628A0AE13BD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3E9407B81FFADCB78971628A0AE13BD9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3E9407B81FFADCB78971628A0AE13BD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3E9407B81FFADCB78971628A0AE13BD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3E9407B81FFADCB78971628A0AE13BD9" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3E9407B81FFADCB78971628A0AE13BD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_5F8DFC43D8ECD5F3B4E9628A0AE17E9D_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis_5F8DFC43D8ECD5F3B4E9628A0AE17E9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_5F8DFC43D8ECD5F3B4E9628A0AE17E9D_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis_5F8DFC43D8ECD5F3B4E9628A0AE17E9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_5F8DFC43D8ECD5F3B4E9628A0AE17E9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_5F8DFC43D8ECD5F3B4E9628A0AE17E9D" xlink:to="lab_us-gaap_RetirementPlanTypeAxis_5F8DFC43D8ECD5F3B4E9628A0AE17E9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_3755ED1AC59F303D6D64628A0AE18430_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain_3755ED1AC59F303D6D64628A0AE18430" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_3755ED1AC59F303D6D64628A0AE18430_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain_3755ED1AC59F303D6D64628A0AE18430" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_3755ED1AC59F303D6D64628A0AE18430" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3755ED1AC59F303D6D64628A0AE18430" xlink:to="lab_us-gaap_RetirementPlanTypeDomain_3755ED1AC59F303D6D64628A0AE18430" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_7CDBA0689F43710AA1C3628A0AE2F86C_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember_7CDBA0689F43710AA1C3628A0AE2F86C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_7CDBA0689F43710AA1C3628A0AE2F86C_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember_7CDBA0689F43710AA1C3628A0AE2F86C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_7CDBA0689F43710AA1C3628A0AE2F86C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember_7CDBA0689F43710AA1C3628A0AE2F86C" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember_7CDBA0689F43710AA1C3628A0AE2F86C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_E3826B52D7D2D3A88973628A0AE2DB4E_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_E3826B52D7D2D3A88973628A0AE2DB4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Employee Retirement Plan [Member]</link:label>
    <link:label id="lab_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_E3826B52D7D2D3A88973628A0AE2DB4E_label_en-US" xlink:label="lab_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_E3826B52D7D2D3A88973628A0AE2DB4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Employee Retirement Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_E3826B52D7D2D3A88973628A0AE2DB4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_E3826B52D7D2D3A88973628A0AE2DB4E" xlink:to="lab_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_E3826B52D7D2D3A88973628A0AE2DB4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_EB1A9E6CC620506C3D59628A0AE27007_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_EB1A9E6CC620506C3D59628A0AE27007" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Postretirement Plans [Member]</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_EB1A9E6CC620506C3D59628A0AE27007_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_EB1A9E6CC620506C3D59628A0AE27007" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_EB1A9E6CC620506C3D59628A0AE27007" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_EB1A9E6CC620506C3D59628A0AE27007" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_EB1A9E6CC620506C3D59628A0AE27007" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_873A5349A50817F6F780628A0AE244F2_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis_873A5349A50817F6F780628A0AE244F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_873A5349A50817F6F780628A0AE244F2_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis_873A5349A50817F6F780628A0AE244F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_873A5349A50817F6F780628A0AE244F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_873A5349A50817F6F780628A0AE244F2" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis_873A5349A50817F6F780628A0AE244F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_2F862D980FE658762FEA628A0AE24D79_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain_2F862D980FE658762FEA628A0AE24D79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_2F862D980FE658762FEA628A0AE24D79_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain_2F862D980FE658762FEA628A0AE24D79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_2F862D980FE658762FEA628A0AE24D79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_2F862D980FE658762FEA628A0AE24D79" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain_2F862D980FE658762FEA628A0AE24D79" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticPlanMember_6E4F020F05175396102C628A0AE3884E_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember_6E4F020F05175396102C628A0AE3884E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_6E4F020F05175396102C628A0AE3884E_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember_6E4F020F05175396102C628A0AE3884E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_6E4F020F05175396102C628A0AE3884E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember_6E4F020F05175396102C628A0AE3884E" xlink:to="lab_us-gaap_DomesticPlanMember_6E4F020F05175396102C628A0AE3884E" xlink:type="arc" />
    <link:label id="lab_country_US_5CA83C3D5B9880E85558628A0AE3AF76_terseLabel_en-US" xlink:label="lab_country_US_5CA83C3D5B9880E85558628A0AE3AF76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. [Member]</link:label>
    <link:label id="lab_country_US_5CA83C3D5B9880E85558628A0AE3AF76_label_en-US" xlink:label="lab_country_US_5CA83C3D5B9880E85558628A0AE3AF76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_country_US_5CA83C3D5B9880E85558628A0AE3AF76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_5CA83C3D5B9880E85558628A0AE3AF76" xlink:to="lab_country_US_5CA83C3D5B9880E85558628A0AE3AF76" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignPlanMember_93612823091DDC1A223C628A0AE3596F_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember_93612823091DDC1A223C628A0AE3596F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_93612823091DDC1A223C628A0AE3596F_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember_93612823091DDC1A223C628A0AE3596F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_93612823091DDC1A223C628A0AE3596F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember_93612823091DDC1A223C628A0AE3596F" xlink:to="lab_us-gaap_ForeignPlanMember_93612823091DDC1A223C628A0AE3596F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetirementPlanTaxStatusAxis_178B0A991AA060EFDDBB628A0AE3E144_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTaxStatusAxis_178B0A991AA060EFDDBB628A0AE3E144" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Tax Status [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTaxStatusAxis_178B0A991AA060EFDDBB628A0AE3E144_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTaxStatusAxis_178B0A991AA060EFDDBB628A0AE3E144" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Tax Status [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_178B0A991AA060EFDDBB628A0AE3E144" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_178B0A991AA060EFDDBB628A0AE3E144" xlink:to="lab_us-gaap_RetirementPlanTaxStatusAxis_178B0A991AA060EFDDBB628A0AE3E144" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetirementPlanTaxStatusDomain_52047D265623112B6148628A0AE3C345_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTaxStatusDomain_52047D265623112B6148628A0AE3C345" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Tax Status [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTaxStatusDomain_52047D265623112B6148628A0AE3C345_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTaxStatusDomain_52047D265623112B6148628A0AE3C345" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Tax Status [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_52047D265623112B6148628A0AE3C345" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_52047D265623112B6148628A0AE3C345" xlink:to="lab_us-gaap_RetirementPlanTaxStatusDomain_52047D265623112B6148628A0AE3C345" xlink:type="arc" />
    <link:label id="lab_us-gaap_QualifiedPlanMember_74E2AA6EB95BB39DF39B628A0AE4A6C7_verboseLabel_en-US" xlink:label="lab_us-gaap_QualifiedPlanMember_74E2AA6EB95BB39DF39B628A0AE4A6C7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Qualified [Member]</link:label>
    <link:label id="lab_us-gaap_QualifiedPlanMember_74E2AA6EB95BB39DF39B628A0AE4A6C7_label_en-US" xlink:label="lab_us-gaap_QualifiedPlanMember_74E2AA6EB95BB39DF39B628A0AE4A6C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Qualified Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_74E2AA6EB95BB39DF39B628A0AE4A6C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QualifiedPlanMember_74E2AA6EB95BB39DF39B628A0AE4A6C7" xlink:to="lab_us-gaap_QualifiedPlanMember_74E2AA6EB95BB39DF39B628A0AE4A6C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonqualifiedPlanMember_83D949A11D7C3B45AD65628A0AE41816_terseLabel_en-US" xlink:label="lab_us-gaap_NonqualifiedPlanMember_83D949A11D7C3B45AD65628A0AE41816" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Qualified [Member]</link:label>
    <link:label id="lab_us-gaap_NonqualifiedPlanMember_83D949A11D7C3B45AD65628A0AE41816_label_en-US" xlink:label="lab_us-gaap_NonqualifiedPlanMember_83D949A11D7C3B45AD65628A0AE41816" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonqualified Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonqualifiedPlanMember" xlink:label="loc_us-gaap_NonqualifiedPlanMember_83D949A11D7C3B45AD65628A0AE41816" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonqualifiedPlanMember_83D949A11D7C3B45AD65628A0AE41816" xlink:to="lab_us-gaap_NonqualifiedPlanMember_83D949A11D7C3B45AD65628A0AE41816" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_4A3ABA8E3960BEE9A362628A0AE4AD4D_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_4A3ABA8E3960BEE9A362628A0AE4AD4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_4A3ABA8E3960BEE9A362628A0AE4AD4D_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_4A3ABA8E3960BEE9A362628A0AE4AD4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4A3ABA8E3960BEE9A362628A0AE4AD4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4A3ABA8E3960BEE9A362628A0AE4AD4D" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_4A3ABA8E3960BEE9A362628A0AE4AD4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_F1FB17F4613652D9DDA2628A0AE4333F_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost_F1FB17F4613652D9DDA2628A0AE4333F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_F1FB17F4613652D9DDA2628A0AE4333F_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost_F1FB17F4613652D9DDA2628A0AE4333F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_F1FB17F4613652D9DDA2628A0AE4333F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost_F1FB17F4613652D9DDA2628A0AE4333F" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost_F1FB17F4613652D9DDA2628A0AE4333F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_9E0006E83CF0F7C78651628A0AE5B8D3_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost_9E0006E83CF0F7C78651628A0AE5B8D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_9E0006E83CF0F7C78651628A0AE5B8D3_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost_9E0006E83CF0F7C78651628A0AE5B8D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_9E0006E83CF0F7C78651628A0AE5B8D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost_9E0006E83CF0F7C78651628A0AE5B8D3" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost_9E0006E83CF0F7C78651628A0AE5B8D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_1576F9AFBB60D335F1E8628A0AE5514B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_1576F9AFBB60D335F1E8628A0AE5514B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_1576F9AFBB60D335F1E8628A0AE5514B_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_1576F9AFBB60D335F1E8628A0AE5514B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_1576F9AFBB60D335F1E8628A0AE5514B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_1576F9AFBB60D335F1E8628A0AE5514B" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_1576F9AFBB60D335F1E8628A0AE5514B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_9A097CDC3C5DBEB64CDD628A0AE520DA_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_9A097CDC3C5DBEB64CDD628A0AE520DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_9A097CDC3C5DBEB64CDD628A0AE520DA_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_9A097CDC3C5DBEB64CDD628A0AE520DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_9A097CDC3C5DBEB64CDD628A0AE520DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_9A097CDC3C5DBEB64CDD628A0AE520DA" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_9A097CDC3C5DBEB64CDD628A0AE520DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_1BDE885221B042E4F56E628A0AE54F0F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_1BDE885221B042E4F56E628A0AE54F0F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Actuarial losses</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_1BDE885221B042E4F56E628A0AE54F0F_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_1BDE885221B042E4F56E628A0AE54F0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_1BDE885221B042E4F56E628A0AE54F0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_1BDE885221B042E4F56E628A0AE54F0F" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_1BDE885221B042E4F56E628A0AE54F0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_D4FFE27813E7807B1590628A0AE51167_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_D4FFE27813E7807B1590628A0AE51167" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior service credits</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_D4FFE27813E7807B1590628A0AE51167_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_D4FFE27813E7807B1590628A0AE51167" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_D4FFE27813E7807B1590628A0AE51167" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_D4FFE27813E7807B1590628A0AE51167" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_D4FFE27813E7807B1590628A0AE51167" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_4E54D10FE1DD94B19A72628A0AE51B51_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_4E54D10FE1DD94B19A72628A0AE51B51" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_4E54D10FE1DD94B19A72628A0AE51B51_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_4E54D10FE1DD94B19A72628A0AE51B51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_4E54D10FE1DD94B19A72628A0AE51B51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_4E54D10FE1DD94B19A72628A0AE51B51" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_4E54D10FE1DD94B19A72628A0AE51B51" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_663B3A3C6966B7EFBA2C628A0AE63F59_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_663B3A3C6966B7EFBA2C628A0AE63F59" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Special termination benefits</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_663B3A3C6966B7EFBA2C628A0AE63F59_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_663B3A3C6966B7EFBA2C628A0AE63F59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Special and Contractual Termination Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanSpecialTerminationBenefits" xlink:label="loc_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_663B3A3C6966B7EFBA2C628A0AE63F59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_663B3A3C6966B7EFBA2C628A0AE63F59" xlink:to="lab_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_663B3A3C6966B7EFBA2C628A0AE63F59" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7F8F14895BE825DB988B628A0AE693E9_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7F8F14895BE825DB988B628A0AE693E9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Defined benefit plan, net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7F8F14895BE825DB988B628A0AE693E9_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7F8F14895BE825DB988B628A0AE693E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7F8F14895BE825DB988B628A0AE693E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7F8F14895BE825DB988B628A0AE693E9" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7F8F14895BE825DB988B628A0AE693E9" xlink:type="arc" />
    <link:label id="lab_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock_BFF509054C165641FE0494761E963B3C_terseLabel_en-US" xlink:label="lab_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock_BFF509054C165641FE0494761E963B3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Balance Sheet Classification of Accruals</link:label>
    <link:label id="lab_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock_BFF509054C165641FE0494761E963B3C_label_en-US" xlink:label="lab_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock_BFF509054C165641FE0494761E963B3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Medicare Rebates, Medicaid And Related State Program Rebates, Performance-Based Contract Rebates, Chargebacks, Sales Allowances And Sales Returns And Cash Discounts [Table Text Block]</link:label>
    <link:label id="lab_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock_BFF509054C165641FE0494761E963B3C_documentation_en-US" xlink:label="lab_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock_BFF509054C165641FE0494761E963B3C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Medicare Rebates, Medicaid And Related State Program Rebates, Performance-Based Contract Rebates, Chargebacks, Sales Allowances And Sales Returns And Cash Discounts [Table Text Block]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock" xlink:label="loc_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock_BFF509054C165641FE0494761E963B3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock_BFF509054C165641FE0494761E963B3C" xlink:to="lab_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock_BFF509054C165641FE0494761E963B3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_71F7845C116B3F47FDF0B09F331B1A4C_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_71F7845C116B3F47FDF0B09F331B1A4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_71F7845C116B3F47FDF0B09F331B1A4C_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_71F7845C116B3F47FDF0B09F331B1A4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_71F7845C116B3F47FDF0B09F331B1A4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_71F7845C116B3F47FDF0B09F331B1A4C" xlink:to="lab_us-gaap_FinancialInstrumentAxis_71F7845C116B3F47FDF0B09F331B1A4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9A2A27622858EAF73841B09F331C5035_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9A2A27622858EAF73841B09F331C5035" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9A2A27622858EAF73841B09F331C5035_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9A2A27622858EAF73841B09F331C5035" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9A2A27622858EAF73841B09F331C5035" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9A2A27622858EAF73841B09F331C5035" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9A2A27622858EAF73841B09F331C5035" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_B73BD16295B28013420AB09F331C43C5_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_B73BD16295B28013420AB09F331C43C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds [Member]</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_B73BD16295B28013420AB09F331C43C5_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_B73BD16295B28013420AB09F331C43C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_B73BD16295B28013420AB09F331C43C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_B73BD16295B28013420AB09F331C43C5" xlink:to="lab_us-gaap_MoneyMarketFundsMember_B73BD16295B28013420AB09F331C43C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_B5A8D6B5A9D5BF77C1A1B09F331C7F97_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_B5A8D6B5A9D5BF77C1A1B09F331C7F97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government and agency - non U.S. [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_B5A8D6B5A9D5BF77C1A1B09F331C7F97_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_B5A8D6B5A9D5BF77C1A1B09F331C7F97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_B5A8D6B5A9D5BF77C1A1B09F331C7F97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_B5A8D6B5A9D5BF77C1A1B09F331C7F97" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_B5A8D6B5A9D5BF77C1A1B09F331C7F97" xlink:type="arc" />
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_721465EB5548DC1455E0B09F331C952B_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_721465EB5548DC1455E0B09F331C952B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government and agency - U.S. [Member]</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_721465EB5548DC1455E0B09F331C952B_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_721465EB5548DC1455E0B09F331C952B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_721465EB5548DC1455E0B09F331C952B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_721465EB5548DC1455E0B09F331C952B" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_721465EB5548DC1455E0B09F331C952B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_BA894BE51924BBB795D9B09F331D3A10_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_BA894BE51924BBB795D9B09F331D3A10" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate and other [Member]</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_BA894BE51924BBB795D9B09F331D3A10_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_BA894BE51924BBB795D9B09F331D3A10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_BA894BE51924BBB795D9B09F331D3A10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_BA894BE51924BBB795D9B09F331D3A10" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_BA894BE51924BBB795D9B09F331D3A10" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_66046376D20AAFD10E3AB09F331DF0CC_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_66046376D20AAFD10E3AB09F331DF0CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_66046376D20AAFD10E3AB09F331DF0CC_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_66046376D20AAFD10E3AB09F331DF0CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_66046376D20AAFD10E3AB09F331DF0CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_66046376D20AAFD10E3AB09F331DF0CC" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_66046376D20AAFD10E3AB09F331DF0CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_64AFD1F3F300F730B0FBB09F331D43C9_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_64AFD1F3F300F730B0FBB09F331D43C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_64AFD1F3F300F730B0FBB09F331D43C9_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_64AFD1F3F300F730B0FBB09F331D43C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_64AFD1F3F300F730B0FBB09F331D43C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_64AFD1F3F300F730B0FBB09F331D43C9" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_64AFD1F3F300F730B0FBB09F331D43C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_8F302B4D9E7D5AEE6DCCB09F331EE1C1_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_8F302B4D9E7D5AEE6DCCB09F331EE1C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_8F302B4D9E7D5AEE6DCCB09F331EE1C1_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_8F302B4D9E7D5AEE6DCCB09F331EE1C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8F302B4D9E7D5AEE6DCCB09F331EE1C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8F302B4D9E7D5AEE6DCCB09F331EE1C1" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_8F302B4D9E7D5AEE6DCCB09F331EE1C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_B489E4D7121F2C418AD8B09F331E1AFB_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember_B489E4D7121F2C418AD8B09F331E1AFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments [Member]</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_B489E4D7121F2C418AD8B09F331E1AFB_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember_B489E4D7121F2C418AD8B09F331E1AFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_B489E4D7121F2C418AD8B09F331E1AFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_B489E4D7121F2C418AD8B09F331E1AFB" xlink:to="lab_us-gaap_ShortTermInvestmentsMember_B489E4D7121F2C418AD8B09F331E1AFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_22620DA5E0C1A9D40DD5B09F331E21E1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_22620DA5E0C1A9D40DD5B09F331E21E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_22620DA5E0C1A9D40DD5B09F331E21E1_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_22620DA5E0C1A9D40DD5B09F331E21E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_22620DA5E0C1A9D40DD5B09F331E21E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember_22620DA5E0C1A9D40DD5B09F331E21E1" xlink:to="lab_us-gaap_OtherCurrentAssetsMember_22620DA5E0C1A9D40DD5B09F331E21E1" xlink:type="arc" />
    <link:label id="lab_pfe_LongtermInvestmentsMember_CE17EED2495429FBF8DEB09F331E81FA_terseLabel_en-US" xlink:label="lab_pfe_LongtermInvestmentsMember_CE17EED2495429FBF8DEB09F331E81FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Investments [Member]</link:label>
    <link:label id="lab_pfe_LongtermInvestmentsMember_CE17EED2495429FBF8DEB09F331E81FA_label_en-US" xlink:label="lab_pfe_LongtermInvestmentsMember_CE17EED2495429FBF8DEB09F331E81FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Investments [Member]</link:label>
    <link:label id="lab_pfe_LongtermInvestmentsMember_CE17EED2495429FBF8DEB09F331E81FA_documentation_en-US" xlink:label="lab_pfe_LongtermInvestmentsMember_CE17EED2495429FBF8DEB09F331E81FA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term Investments [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LongtermInvestmentsMember" xlink:label="loc_pfe_LongtermInvestmentsMember_CE17EED2495429FBF8DEB09F331E81FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LongtermInvestmentsMember_CE17EED2495429FBF8DEB09F331E81FA" xlink:to="lab_pfe_LongtermInvestmentsMember_CE17EED2495429FBF8DEB09F331E81FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_1E9A48CA94E19E470629B09F331F4828_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember_1E9A48CA94E19E470629B09F331F4828" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_1E9A48CA94E19E470629B09F331F4828_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember_1E9A48CA94E19E470629B09F331F4828" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_1E9A48CA94E19E470629B09F331F4828" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember_1E9A48CA94E19E470629B09F331F4828" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember_1E9A48CA94E19E470629B09F331F4828" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_52C64DEFD1F022B5FB21B09F331FE9F4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_52C64DEFD1F022B5FB21B09F331FE9F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_52C64DEFD1F022B5FB21B09F331FE9F4_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_52C64DEFD1F022B5FB21B09F331FE9F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_52C64DEFD1F022B5FB21B09F331FE9F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember_52C64DEFD1F022B5FB21B09F331FE9F4" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember_52C64DEFD1F022B5FB21B09F331FE9F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_478384D142F3C5AF41E3B09F331F4F58_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_478384D142F3C5AF41E3B09F331F4F58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_478384D142F3C5AF41E3B09F331F4F58_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_478384D142F3C5AF41E3B09F331F4F58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_478384D142F3C5AF41E3B09F331F4F58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember_478384D142F3C5AF41E3B09F331F4F58" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember_478384D142F3C5AF41E3B09F331F4F58" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6F40E84ABBC429DB007BB09F3326C131_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6F40E84ABBC429DB007BB09F3326C131" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6F40E84ABBC429DB007BB09F3326C131_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6F40E84ABBC429DB007BB09F3326C131" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6F40E84ABBC429DB007BB09F3326C131" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6F40E84ABBC429DB007BB09F3326C131" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6F40E84ABBC429DB007BB09F3326C131" xlink:type="arc" />
    <link:label id="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_1D5FF53A60602A71A2E3B09F33261E74_totalLabel_en-US" xlink:label="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_1D5FF53A60602A71A2E3B09F33261E74" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total short-term investments</link:label>
    <link:label id="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_1D5FF53A60602A71A2E3B09F33261E74_label_en-US" xlink:label="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_1D5FF53A60602A71A2E3B09F33261E74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments Excluding Held-To-Maturity Securities</link:label>
    <link:label id="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_1D5FF53A60602A71A2E3B09F33261E74_documentation_en-US" xlink:label="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_1D5FF53A60602A71A2E3B09F33261E74" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short-term Investments Excluding Held-To-Maturity Securities</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" xlink:label="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_1D5FF53A60602A71A2E3B09F33261E74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_1D5FF53A60602A71A2E3B09F33261E74" xlink:to="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_1D5FF53A60602A71A2E3B09F33261E74" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_9092E0C133DA413731DAB09F33275449_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent_9092E0C133DA413731DAB09F33275449" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_9092E0C133DA413731DAB09F33275449_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent_9092E0C133DA413731DAB09F33275449" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsCurrent" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_9092E0C133DA413731DAB09F33275449" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsCurrent_9092E0C133DA413731DAB09F33275449" xlink:to="lab_us-gaap_DerivativeAssetsCurrent_9092E0C133DA413731DAB09F33275449" xlink:type="arc" />
    <link:label id="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_48ED3BDDD833AE9D8C79B09F3327B8A5_totalLabel_en-US" xlink:label="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_48ED3BDDD833AE9D8C79B09F3327B8A5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total long-term investments</link:label>
    <link:label id="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_48ED3BDDD833AE9D8C79B09F3327B8A5_label_en-US" xlink:label="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_48ED3BDDD833AE9D8C79B09F3327B8A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments</link:label>
    <link:label id="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_48ED3BDDD833AE9D8C79B09F3327B8A5_documentation_en-US" xlink:label="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_48ED3BDDD833AE9D8C79B09F3327B8A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" xlink:label="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_48ED3BDDD833AE9D8C79B09F3327B8A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_48ED3BDDD833AE9D8C79B09F3327B8A5" xlink:to="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_48ED3BDDD833AE9D8C79B09F3327B8A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_8E0F8B1DCA2CD0E55D3AB09F3327BF95_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent_8E0F8B1DCA2CD0E55D3AB09F3327BF95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_8E0F8B1DCA2CD0E55D3AB09F3327BF95_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent_8E0F8B1DCA2CD0E55D3AB09F3327BF95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_8E0F8B1DCA2CD0E55D3AB09F3327BF95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsNoncurrent_8E0F8B1DCA2CD0E55D3AB09F3327BF95" xlink:to="lab_us-gaap_DerivativeAssetsNoncurrent_8E0F8B1DCA2CD0E55D3AB09F3327BF95" xlink:type="arc" />
    <link:label id="lab_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_2FEF5AFE42FB6328EE17B09F33278393_terseLabel_en-US" xlink:label="lab_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_2FEF5AFE42FB6328EE17B09F33278393" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insurance contracts</link:label>
    <link:label id="lab_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_2FEF5AFE42FB6328EE17B09F33278393_label_en-US" xlink:label="lab_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_2FEF5AFE42FB6328EE17B09F33278393" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Life Settlement Contracts, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:label="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_2FEF5AFE42FB6328EE17B09F33278393" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_2FEF5AFE42FB6328EE17B09F33278393" xlink:to="lab_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_2FEF5AFE42FB6328EE17B09F33278393" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_8D6270BE6A2D4054670CB09F3327FFA1_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_8D6270BE6A2D4054670CB09F3327FFA1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_8D6270BE6A2D4054670CB09F3327FFA1_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_8D6270BE6A2D4054670CB09F3327FFA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8D6270BE6A2D4054670CB09F3327FFA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_8D6270BE6A2D4054670CB09F3327FFA1" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_8D6270BE6A2D4054670CB09F3327FFA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_7400EC951C0142AF5B48B09F33274228_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_7400EC951C0142AF5B48B09F33274228" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_7400EC951C0142AF5B48B09F33274228_label_en-US" xlink:label="lab_us-gaap_Assets_7400EC951C0142AF5B48B09F33274228" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_7400EC951C0142AF5B48B09F33274228" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_7400EC951C0142AF5B48B09F33274228" xlink:to="lab_us-gaap_Assets_7400EC951C0142AF5B48B09F33274228" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_207606263E5EDC0AE24FB09F332815D3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_207606263E5EDC0AE24FB09F332815D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_207606263E5EDC0AE24FB09F332815D3_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_207606263E5EDC0AE24FB09F332815D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_207606263E5EDC0AE24FB09F332815D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent_207606263E5EDC0AE24FB09F332815D3" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent_207606263E5EDC0AE24FB09F332815D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_B1DD6372639F84D0D90CB09F33287589_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent_B1DD6372639F84D0D90CB09F33287589" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_B1DD6372639F84D0D90CB09F33287589_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent_B1DD6372639F84D0D90CB09F33287589" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_B1DD6372639F84D0D90CB09F33287589" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent_B1DD6372639F84D0D90CB09F33287589" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent_B1DD6372639F84D0D90CB09F33287589" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLiabilities_76F2D410F093A6A8CA33B09F33286A4A_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities_76F2D410F093A6A8CA33B09F33286A4A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_76F2D410F093A6A8CA33B09F33286A4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities_76F2D410F093A6A8CA33B09F33286A4A" xlink:to="lab_us-gaap_DerivativeLiabilities_76F2D410F093A6A8CA33B09F33286A4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_75DFA4C374C7C8F577E654457A62FD01_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_75DFA4C374C7C8F577E654457A62FD01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_75DFA4C374C7C8F577E654457A62FD01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_75DFA4C374C7C8F577E654457A62FD01" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_75DFA4C374C7C8F577E654457A62FD01" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_E47570589F726E3EB27E54457A624420_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_E47570589F726E3EB27E54457A624420" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_E47570589F726E3EB27E54457A624420_label_en-US" xlink:label="lab_us-gaap_StatementTable_E47570589F726E3EB27E54457A624420" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_E47570589F726E3EB27E54457A624420" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_E47570589F726E3EB27E54457A624420" xlink:to="lab_us-gaap_StatementTable_E47570589F726E3EB27E54457A624420" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_95F421D2A3D9663F5FA754457A6347D6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_95F421D2A3D9663F5FA754457A6347D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_95F421D2A3D9663F5FA754457A6347D6_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_95F421D2A3D9663F5FA754457A6347D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_95F421D2A3D9663F5FA754457A6347D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_95F421D2A3D9663F5FA754457A6347D6" xlink:to="lab_us-gaap_StatementLineItems_95F421D2A3D9663F5FA754457A6347D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_5A4C589FBF6A57B2560854457A64FE26_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_5A4C589FBF6A57B2560854457A64FE26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_5A4C589FBF6A57B2560854457A64FE26_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_5A4C589FBF6A57B2560854457A64FE26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_5A4C589FBF6A57B2560854457A64FE26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_5A4C589FBF6A57B2560854457A64FE26" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_5A4C589FBF6A57B2560854457A64FE26" xlink:type="arc" />
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesTable_C6FD09F7FD2AD8DE104294761EB48200_terseLabel_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesTable_C6FD09F7FD2AD8DE104294761EB48200" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Accrued Liabilities [Table]</link:label>
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesTable_C6FD09F7FD2AD8DE104294761EB48200_label_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesTable_C6FD09F7FD2AD8DE104294761EB48200" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Accrued Liabilities [Table]</link:label>
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesTable_C6FD09F7FD2AD8DE104294761EB48200_documentation_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesTable_C6FD09F7FD2AD8DE104294761EB48200" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Accrued Liabilities [Table]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ScheduleOfAccruedLiabilitiesTable" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesTable_C6FD09F7FD2AD8DE104294761EB48200" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesTable_C6FD09F7FD2AD8DE104294761EB48200" xlink:to="lab_pfe_ScheduleOfAccruedLiabilitiesTable_C6FD09F7FD2AD8DE104294761EB48200" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_62255A4274E0F0EA0C6994761EB5916D_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_62255A4274E0F0EA0C6994761EB5916D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade accounts receivable, less allowance for doubtful accounts [Member]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_62255A4274E0F0EA0C6994761EB5916D_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_62255A4274E0F0EA0C6994761EB5916D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_62255A4274E0F0EA0C6994761EB5916D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_62255A4274E0F0EA0C6994761EB5916D" xlink:to="lab_us-gaap_AccountsReceivableMember_62255A4274E0F0EA0C6994761EB5916D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_40488C4661458ED6920594761EB59D1F_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_40488C4661458ED6920594761EB59D1F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_40488C4661458ED6920594761EB59D1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember_40488C4661458ED6920594761EB59D1F" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember_40488C4661458ED6920594761EB59D1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_07D988B1A18B53AC29A594761EB57AB3_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_07D988B1A18B53AC29A594761EB57AB3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_07D988B1A18B53AC29A594761EB57AB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember_07D988B1A18B53AC29A594761EB57AB3" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember_07D988B1A18B53AC29A594761EB57AB3" xlink:type="arc" />
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems_CDCFA0776857306176F494761EB64197_terseLabel_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems_CDCFA0776857306176F494761EB64197" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Accrued Liabilities [Line Items]</link:label>
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems_CDCFA0776857306176F494761EB64197_label_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems_CDCFA0776857306176F494761EB64197" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Accrued Liabilities [Line Items]</link:label>
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems_CDCFA0776857306176F494761EB64197_documentation_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems_CDCFA0776857306176F494761EB64197" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Schedule Of Accrued Liabilities [Table]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ScheduleOfAccruedLiabilitiesLineItems" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_CDCFA0776857306176F494761EB64197" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_CDCFA0776857306176F494761EB64197" xlink:to="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems_CDCFA0776857306176F494761EB64197" xlink:type="arc" />
    <link:label id="lab_pfe_AccruedRebates_96360C3931DF288C682494761EB68121_terseLabel_en-US" xlink:label="lab_pfe_AccruedRebates_96360C3931DF288C682494761EB68121" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued rebates</link:label>
    <link:label id="lab_pfe_AccruedRebates_96360C3931DF288C682494761EB68121_label_en-US" xlink:label="lab_pfe_AccruedRebates_96360C3931DF288C682494761EB68121" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Rebates</link:label>
    <link:label id="lab_pfe_AccruedRebates_96360C3931DF288C682494761EB68121_documentation_en-US" xlink:label="lab_pfe_AccruedRebates_96360C3931DF288C682494761EB68121" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Rebates</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AccruedRebates" xlink:label="loc_pfe_AccruedRebates_96360C3931DF288C682494761EB68121" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AccruedRebates_96360C3931DF288C682494761EB68121" xlink:to="lab_pfe_AccruedRebates_96360C3931DF288C682494761EB68121" xlink:type="arc" />
    <link:label id="lab_pfe_OtherAccruals_72216711BE2C644ADF7C94761EB6ED68_terseLabel_en-US" xlink:label="lab_pfe_OtherAccruals_72216711BE2C644ADF7C94761EB6ED68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accruals</link:label>
    <link:label id="lab_pfe_OtherAccruals_72216711BE2C644ADF7C94761EB6ED68_label_en-US" xlink:label="lab_pfe_OtherAccruals_72216711BE2C644ADF7C94761EB6ED68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accruals</link:label>
    <link:label id="lab_pfe_OtherAccruals_72216711BE2C644ADF7C94761EB6ED68_documentation_en-US" xlink:label="lab_pfe_OtherAccruals_72216711BE2C644ADF7C94761EB6ED68" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Accruals</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherAccruals" xlink:label="loc_pfe_OtherAccruals_72216711BE2C644ADF7C94761EB6ED68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherAccruals_72216711BE2C644ADF7C94761EB6ED68" xlink:to="lab_pfe_OtherAccruals_72216711BE2C644ADF7C94761EB6ED68" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2EAABECFE47FFE2C591C598EE676E1D2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2EAABECFE47FFE2C591C598EE676E1D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2EAABECFE47FFE2C591C598EE676E1D2_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2EAABECFE47FFE2C591C598EE676E1D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2EAABECFE47FFE2C591C598EE676E1D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2EAABECFE47FFE2C591C598EE676E1D2" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2EAABECFE47FFE2C591C598EE676E1D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9199795915C6BF1F1D00598EE7805AA3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9199795915C6BF1F1D00598EE7805AA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9199795915C6BF1F1D00598EE7805AA3_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9199795915C6BF1F1D00598EE7805AA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9199795915C6BF1F1D00598EE7805AA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9199795915C6BF1F1D00598EE7805AA3" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9199795915C6BF1F1D00598EE7805AA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicensingAgreementsMember_E0491B165A34AC36B64C598F12C34BF7_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember_E0491B165A34AC36B64C598F12C34BF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_E0491B165A34AC36B64C598F12C34BF7_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember_E0491B165A34AC36B64C598F12C34BF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_E0491B165A34AC36B64C598F12C34BF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember_E0491B165A34AC36B64C598F12C34BF7" xlink:to="lab_us-gaap_LicensingAgreementsMember_E0491B165A34AC36B64C598F12C34BF7" xlink:type="arc" />
    <link:label id="lab_srt_CounterpartyNameAxis_9B84994D011B5947181C598321C242A7_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis_9B84994D011B5947181C598321C242A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_9B84994D011B5947181C598321C242A7_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis_9B84994D011B5947181C598321C242A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_9B84994D011B5947181C598321C242A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis_9B84994D011B5947181C598321C242A7" xlink:to="lab_srt_CounterpartyNameAxis_9B84994D011B5947181C598321C242A7" xlink:type="arc" />
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_2F08D37D57C88444C5555983249C6B7E_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_2F08D37D57C88444C5555983249C6B7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_2F08D37D57C88444C5555983249C6B7E_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_2F08D37D57C88444C5555983249C6B7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2F08D37D57C88444C5555983249C6B7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2F08D37D57C88444C5555983249C6B7E" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain_2F08D37D57C88444C5555983249C6B7E" xlink:type="arc" />
    <link:label id="lab_pfe_ValnevaSEMember_663A39A4FC308FB0026B59881AA1A187_terseLabel_en-US" xlink:label="lab_pfe_ValnevaSEMember_663A39A4FC308FB0026B59881AA1A187" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valneva SE [Member]</link:label>
    <link:label id="lab_pfe_ValnevaSEMember_663A39A4FC308FB0026B59881AA1A187_label_en-US" xlink:label="lab_pfe_ValnevaSEMember_663A39A4FC308FB0026B59881AA1A187" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valneva SE [Member]</link:label>
    <link:label id="lab_pfe_ValnevaSEMember_663A39A4FC308FB0026B59881AA1A187_documentation_en-US" xlink:label="lab_pfe_ValnevaSEMember_663A39A4FC308FB0026B59881AA1A187" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valneva SE [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ValnevaSEMember" xlink:label="loc_pfe_ValnevaSEMember_663A39A4FC308FB0026B59881AA1A187" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ValnevaSEMember_663A39A4FC308FB0026B59881AA1A187" xlink:to="lab_pfe_ValnevaSEMember_663A39A4FC308FB0026B59881AA1A187" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_771ECF58F7A387A7002E598857951C37_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_771ECF58F7A387A7002E598857951C37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_771ECF58F7A387A7002E598857951C37_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_771ECF58F7A387A7002E598857951C37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_771ECF58F7A387A7002E598857951C37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_771ECF58F7A387A7002E598857951C37" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_771ECF58F7A387A7002E598857951C37" xlink:type="arc" />
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1_8C514A662ED539609E1659B3BA8D450F_terseLabel_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1_8C514A662ED539609E1659B3BA8D450F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum potential cash payments</link:label>
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1_8C514A662ED539609E1659B3BA8D450F_label_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1_8C514A662ED539609E1659B3BA8D450F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contingent Payments, Maximum Exposure1</link:label>
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1_8C514A662ED539609E1659B3BA8D450F_documentation_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1_8C514A662ED539609E1659B3BA8D450F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contingent Payments, Maximum Exposure1</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1_8C514A662ED539609E1659B3BA8D450F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1_8C514A662ED539609E1659B3BA8D450F" xlink:to="lab_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1_8C514A662ED539609E1659B3BA8D450F" xlink:type="arc" />
    <link:label id="lab_pfe_PaymentForLicensingArrangement_E43A9E4E82F700DF26EB598280D427FA_terseLabel_en-US" xlink:label="lab_pfe_PaymentForLicensingArrangement_E43A9E4E82F700DF26EB598280D427FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment for licensing arrangement</link:label>
    <link:label id="lab_pfe_PaymentForLicensingArrangement_E43A9E4E82F700DF26EB598280D427FA_label_en-US" xlink:label="lab_pfe_PaymentForLicensingArrangement_E43A9E4E82F700DF26EB598280D427FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment For Licensing Arrangement</link:label>
    <link:label id="lab_pfe_PaymentForLicensingArrangement_E43A9E4E82F700DF26EB598280D427FA_documentation_en-US" xlink:label="lab_pfe_PaymentForLicensingArrangement_E43A9E4E82F700DF26EB598280D427FA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment For Licensing Arrangement</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PaymentForLicensingArrangement" xlink:label="loc_pfe_PaymentForLicensingArrangement_E43A9E4E82F700DF26EB598280D427FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaymentForLicensingArrangement_E43A9E4E82F700DF26EB598280D427FA" xlink:to="lab_pfe_PaymentForLicensingArrangement_E43A9E4E82F700DF26EB598280D427FA" xlink:type="arc" />
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure_D4289C0073EDCB935E6C59B4A1E9163B_terseLabel_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure_D4289C0073EDCB935E6C59B4A1E9163B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential development milestones</link:label>
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure_D4289C0073EDCB935E6C59B4A1E9163B_label_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure_D4289C0073EDCB935E6C59B4A1E9163B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Development Milestone, Maximum Exposure</link:label>
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure_D4289C0073EDCB935E6C59B4A1E9163B_documentation_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure_D4289C0073EDCB935E6C59B4A1E9163B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Development Milestone, Maximum Exposure</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure_D4289C0073EDCB935E6C59B4A1E9163B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure_D4289C0073EDCB935E6C59B4A1E9163B" xlink:to="lab_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure_D4289C0073EDCB935E6C59B4A1E9163B" xlink:type="arc" />
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure_846AFEBC4541DB8070C3599C5A3B12ED_terseLabel_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure_846AFEBC4541DB8070C3599C5A3B12ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential early commercialization milestones</link:label>
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure_846AFEBC4541DB8070C3599C5A3B12ED_label_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure_846AFEBC4541DB8070C3599C5A3B12ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Commercialization Milestones, Maximum Exposure</link:label>
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure_846AFEBC4541DB8070C3599C5A3B12ED_documentation_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure_846AFEBC4541DB8070C3599C5A3B12ED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Commercialization Milestones, Maximum Exposure</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure_846AFEBC4541DB8070C3599C5A3B12ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure_846AFEBC4541DB8070C3599C5A3B12ED" xlink:to="lab_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure_846AFEBC4541DB8070C3599C5A3B12ED" xlink:type="arc" />
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage_7D16B329EC4E9D9E89B459AFE9DEB415_terseLabel_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage_7D16B329EC4E9D9E89B459AFE9DEB415" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valneva's development cost ownership percentage</link:label>
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage_7D16B329EC4E9D9E89B459AFE9DEB415_label_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage_7D16B329EC4E9D9E89B459AFE9DEB415" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Collaborator's Development Cost Ownership Percentage</link:label>
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage_7D16B329EC4E9D9E89B459AFE9DEB415_documentation_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage_7D16B329EC4E9D9E89B459AFE9DEB415" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Collaborator's Development Cost Ownership Percentage</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage_7D16B329EC4E9D9E89B459AFE9DEB415" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage_7D16B329EC4E9D9E89B459AFE9DEB415" xlink:to="lab_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage_7D16B329EC4E9D9E89B459AFE9DEB415" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_DCA479848717297E8EF354457A7A5047_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_DCA479848717297E8EF354457A7A5047" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_DCA479848717297E8EF354457A7A5047" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_DCA479848717297E8EF354457A7A5047" xlink:to="lab_us-gaap_IncomeStatementAbstract_DCA479848717297E8EF354457A7A5047" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_738221F0EF1CEE069CE754457A7A227D_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_738221F0EF1CEE069CE754457A7A227D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_738221F0EF1CEE069CE754457A7A227D_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_738221F0EF1CEE069CE754457A7A227D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_738221F0EF1CEE069CE754457A7A227D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_738221F0EF1CEE069CE754457A7A227D" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_738221F0EF1CEE069CE754457A7A227D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_1B2E56A6799A7B62A9F154457A7BD2F6_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_1B2E56A6799A7B62A9F154457A7BD2F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_1B2E56A6799A7B62A9F154457A7BD2F6_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_1B2E56A6799A7B62A9F154457A7BD2F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1B2E56A6799A7B62A9F154457A7BD2F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_1B2E56A6799A7B62A9F154457A7BD2F6" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_1B2E56A6799A7B62A9F154457A7BD2F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_CA0977F9C4E74C8E69B354457A7BFEA3_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_CA0977F9C4E74C8E69B354457A7BFEA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, informational and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_CA0977F9C4E74C8E69B354457A7BFEA3_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_CA0977F9C4E74C8E69B354457A7BFEA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_CA0977F9C4E74C8E69B354457A7BFEA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_CA0977F9C4E74C8E69B354457A7BFEA3" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_CA0977F9C4E74C8E69B354457A7BFEA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9577EE22AB664F2A073754457A7B4CDB_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9577EE22AB664F2A073754457A7B4CDB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9577EE22AB664F2A073754457A7B4CDB_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9577EE22AB664F2A073754457A7B4CDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9577EE22AB664F2A073754457A7B4CDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9577EE22AB664F2A073754457A7B4CDB" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9577EE22AB664F2A073754457A7B4CDB" xlink:type="arc" />
    <link:label id="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_AAE307BF6AD45598F90654457A7BF0C0_terseLabel_en-US" xlink:label="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_AAE307BF6AD45598F90654457A7BF0C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_AAE307BF6AD45598F90654457A7BF0C0_label_en-US" xlink:label="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_AAE307BF6AD45598F90654457A7BF0C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization Of Intangible Assets Not Associated With Single Function</link:label>
    <link:label id="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_AAE307BF6AD45598F90654457A7BF0C0_documentation_en-US" xlink:label="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_AAE307BF6AD45598F90654457A7BF0C0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of amortization that is not associated with a single function. Amounts associated in a single function are included in Cost of sales, Selling, information and administrative expenses and Research and development expenses.</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" xlink:label="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_AAE307BF6AD45598F90654457A7BF0C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_AAE307BF6AD45598F90654457A7BF0C0" xlink:to="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_AAE307BF6AD45598F90654457A7BF0C0" xlink:type="arc" />
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_D0444063F2ABF9DF302354457A7B1020_terseLabel_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_D0444063F2ABF9DF302354457A7B1020" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges and certain acquisition-related costs</link:label>
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_D0444063F2ABF9DF302354457A7B1020_label_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_D0444063F2ABF9DF302354457A7B1020" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges And Acquisition Related Costs</link:label>
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_D0444063F2ABF9DF302354457A7B1020_documentation_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_D0444063F2ABF9DF302354457A7B1020" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities.</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_D0444063F2ABF9DF302354457A7B1020" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_D0444063F2ABF9DF302354457A7B1020" xlink:to="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_D0444063F2ABF9DF302354457A7B1020" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_A452559164C303E95E9654457A7B6A10_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount_A452559164C303E95E9654457A7B6A10" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">(Gain) on completion of Consumer Healthcare JV transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_A452559164C303E95E9654457A7B6A10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationGainOrLossAmount_A452559164C303E95E9654457A7B6A10" xlink:to="lab_us-gaap_DeconsolidationGainOrLossAmount_A452559164C303E95E9654457A7B6A10" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_E62B9AA3C8561564AE3D54457A7CA77B_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_E62B9AA3C8561564AE3D54457A7CA77B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other (income)/deductions&#8211;&#8211;net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_E62B9AA3C8561564AE3D54457A7CA77B_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_E62B9AA3C8561564AE3D54457A7CA77B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_E62B9AA3C8561564AE3D54457A7CA77B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_E62B9AA3C8561564AE3D54457A7CA77B" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_E62B9AA3C8561564AE3D54457A7CA77B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_377772A9B3104931A38454457A7CA563_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_377772A9B3104931A38454457A7CA563" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from continuing operations before provision/(benefit) for taxes on income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_377772A9B3104931A38454457A7CA563" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_377772A9B3104931A38454457A7CA563" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_377772A9B3104931A38454457A7CA563" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_977DA7CA8BCD7B4046DC54457A7C949C_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_977DA7CA8BCD7B4046DC54457A7C949C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision/(benefit) for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_977DA7CA8BCD7B4046DC54457A7C949C_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_977DA7CA8BCD7B4046DC54457A7C949C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_977DA7CA8BCD7B4046DC54457A7C949C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_977DA7CA8BCD7B4046DC54457A7C949C" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_977DA7CA8BCD7B4046DC54457A7C949C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_38CE89A349971AE058C254457A7C0745_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_38CE89A349971AE058C254457A7C0745" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_38CE89A349971AE058C254457A7C0745_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_38CE89A349971AE058C254457A7C0745" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_38CE89A349971AE058C254457A7C0745" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_38CE89A349971AE058C254457A7C0745" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_38CE89A349971AE058C254457A7C0745" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9BB96D3BB0658B3BEF8F54457A7C2BFF_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9BB96D3BB0658B3BEF8F54457A7C2BFF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations&#8211;&#8211;net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9BB96D3BB0658B3BEF8F54457A7C2BFF_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9BB96D3BB0658B3BEF8F54457A7C2BFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9BB96D3BB0658B3BEF8F54457A7C2BFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9BB96D3BB0658B3BEF8F54457A7C2BFF" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9BB96D3BB0658B3BEF8F54457A7C2BFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_FA2ACF3AFC60CF41EB6754457A7C340C_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_FA2ACF3AFC60CF41EB6754457A7C340C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income before allocation to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_FA2ACF3AFC60CF41EB6754457A7C340C_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_FA2ACF3AFC60CF41EB6754457A7C340C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_FA2ACF3AFC60CF41EB6754457A7C340C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_FA2ACF3AFC60CF41EB6754457A7C340C" xlink:to="lab_us-gaap_ProfitLoss_FA2ACF3AFC60CF41EB6754457A7C340C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_EA41C0B3EE8AA5F03BBA54457A7DEE87_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_EA41C0B3EE8AA5F03BBA54457A7DEE87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_EA41C0B3EE8AA5F03BBA54457A7DEE87_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_EA41C0B3EE8AA5F03BBA54457A7DEE87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_EA41C0B3EE8AA5F03BBA54457A7DEE87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_EA41C0B3EE8AA5F03BBA54457A7DEE87" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_EA41C0B3EE8AA5F03BBA54457A7DEE87" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_4BD04AE2DFDD0AD5E39754457A7D2EB9_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_4BD04AE2DFDD0AD5E39754457A7D2EB9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Pfizer Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_4BD04AE2DFDD0AD5E39754457A7D2EB9_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_4BD04AE2DFDD0AD5E39754457A7D2EB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_4BD04AE2DFDD0AD5E39754457A7D2EB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_4BD04AE2DFDD0AD5E39754457A7D2EB9" xlink:to="lab_us-gaap_NetIncomeLoss_4BD04AE2DFDD0AD5E39754457A7D2EB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_AFC592F5D2FA15C7547C54457A7DB183_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_AFC592F5D2FA15C7547C54457A7DB183" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per common share&#8211;&#8211;basic:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_AFC592F5D2FA15C7547C54457A7DB183_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_AFC592F5D2FA15C7547C54457A7DB183" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_AFC592F5D2FA15C7547C54457A7DB183" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_AFC592F5D2FA15C7547C54457A7DB183" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract_AFC592F5D2FA15C7547C54457A7DB183" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_CDDAA9B50B61FF1779E354457A7D01F9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_CDDAA9B50B61FF1779E354457A7D01F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_CDDAA9B50B61FF1779E354457A7D01F9_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_CDDAA9B50B61FF1779E354457A7D01F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_CDDAA9B50B61FF1779E354457A7D01F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_CDDAA9B50B61FF1779E354457A7D01F9" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_CDDAA9B50B61FF1779E354457A7D01F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_85CDB438AE5826D4E81754457A7D3032_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_85CDB438AE5826D4E81754457A7D3032" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations&#8211;&#8211;net of tax (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_85CDB438AE5826D4E81754457A7D3032_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_85CDB438AE5826D4E81754457A7D3032" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_85CDB438AE5826D4E81754457A7D3032" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_85CDB438AE5826D4E81754457A7D3032" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_85CDB438AE5826D4E81754457A7D3032" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_A516F0A07E4BA18823BB54457A7E6C6C_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_A516F0A07E4BA18823BB54457A7E6C6C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_A516F0A07E4BA18823BB54457A7E6C6C_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_A516F0A07E4BA18823BB54457A7E6C6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_A516F0A07E4BA18823BB54457A7E6C6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_A516F0A07E4BA18823BB54457A7E6C6C" xlink:to="lab_us-gaap_EarningsPerShareBasic_A516F0A07E4BA18823BB54457A7E6C6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_A618E608ED797706CF9D54457A7ED3EC_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract_A618E608ED797706CF9D54457A7ED3EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per common share&#8211;&#8211;diluted:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_A618E608ED797706CF9D54457A7ED3EC_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract_A618E608ED797706CF9D54457A7ED3EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_A618E608ED797706CF9D54457A7ED3EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_A618E608ED797706CF9D54457A7ED3EC" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract_A618E608ED797706CF9D54457A7ED3EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9339C82242AEEC12955854457A7E292E_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9339C82242AEEC12955854457A7E292E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9339C82242AEEC12955854457A7E292E_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9339C82242AEEC12955854457A7E292E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9339C82242AEEC12955854457A7E292E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9339C82242AEEC12955854457A7E292E" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9339C82242AEEC12955854457A7E292E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_8CF18542CABD454AF51A54457A7E4853_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_8CF18542CABD454AF51A54457A7E4853" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations&#8211;&#8211;net of tax (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_8CF18542CABD454AF51A54457A7E4853_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_8CF18542CABD454AF51A54457A7E4853" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_8CF18542CABD454AF51A54457A7E4853" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_8CF18542CABD454AF51A54457A7E4853" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_8CF18542CABD454AF51A54457A7E4853" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_439D7F3EBDCD47CAFABE54457A7EFD25_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_439D7F3EBDCD47CAFABE54457A7EFD25" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_439D7F3EBDCD47CAFABE54457A7EFD25_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_439D7F3EBDCD47CAFABE54457A7EFD25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_439D7F3EBDCD47CAFABE54457A7EFD25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_439D7F3EBDCD47CAFABE54457A7EFD25" xlink:to="lab_us-gaap_EarningsPerShareDiluted_439D7F3EBDCD47CAFABE54457A7EFD25" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6E2A7910210963F062C854457A7E2252_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6E2A7910210963F062C854457A7E2252" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares&#8211;&#8211;basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6E2A7910210963F062C854457A7E2252_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6E2A7910210963F062C854457A7E2252" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6E2A7910210963F062C854457A7E2252" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6E2A7910210963F062C854457A7E2252" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6E2A7910210963F062C854457A7E2252" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_58D099219B5D758DF5EF54457A7FE757_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_58D099219B5D758DF5EF54457A7FE757" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares&#8211;&#8211;diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_58D099219B5D758DF5EF54457A7FE757_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_58D099219B5D758DF5EF54457A7FE757" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_58D099219B5D758DF5EF54457A7FE757" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_58D099219B5D758DF5EF54457A7FE757" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_58D099219B5D758DF5EF54457A7FE757" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_803F99C2CDA4BDFCB4FC9476229EC384_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_803F99C2CDA4BDFCB4FC9476229EC384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_803F99C2CDA4BDFCB4FC9476229EC384" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_803F99C2CDA4BDFCB4FC9476229EC384" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_803F99C2CDA4BDFCB4FC9476229EC384" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_A06D92089293E14F3D199476229F97DC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_A06D92089293E14F3D199476229F97DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_A06D92089293E14F3D199476229F97DC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_A06D92089293E14F3D199476229F97DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_A06D92089293E14F3D199476229F97DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_A06D92089293E14F3D199476229F97DC" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_A06D92089293E14F3D199476229F97DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_1F491C7E6BAF83C72F4A9476229FF15C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_1F491C7E6BAF83C72F4A9476229FF15C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of and Changes in Restructuring Accruals</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_1F491C7E6BAF83C72F4A9476229FF15C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_1F491C7E6BAF83C72F4A9476229FF15C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_1F491C7E6BAF83C72F4A9476229FF15C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_1F491C7E6BAF83C72F4A9476229FF15C" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_1F491C7E6BAF83C72F4A9476229FF15C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_FA6605C0AAF7B87557BB9476200895B9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_FA6605C0AAF7B87557BB9476200895B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Financial Assets and Liabilities Measured At Fair Value On a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_FA6605C0AAF7B87557BB9476200895B9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_FA6605C0AAF7B87557BB9476200895B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_FA6605C0AAF7B87557BB9476200895B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_FA6605C0AAF7B87557BB9476200895B9" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_FA6605C0AAF7B87557BB9476200895B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_273F7B0EF5404E9B4B9E947620082BDC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_273F7B0EF5404E9B4B9E947620082BDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Financial Liabilities Not Measured At Fair Value On a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_273F7B0EF5404E9B4B9E947620082BDC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_273F7B0EF5404E9B4B9E947620082BDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_273F7B0EF5404E9B4B9E947620082BDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_273F7B0EF5404E9B4B9E947620082BDC" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_273F7B0EF5404E9B4B9E947620082BDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_5F1D84A221D59E8B806A9476200801C8_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock_5F1D84A221D59E8B806A9476200801C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments by Classification Type</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_5F1D84A221D59E8B806A9476200801C8_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock_5F1D84A221D59E8B806A9476200801C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_5F1D84A221D59E8B806A9476200801C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock_5F1D84A221D59E8B806A9476200801C8" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock_5F1D84A221D59E8B806A9476200801C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesTextBlock_91286CF869CCBCAB4D659476200800AA_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesTextBlock_91286CF869CCBCAB4D659476200800AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Held-to-maturity Securities</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesTextBlock_91286CF869CCBCAB4D659476200800AA_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesTextBlock_91286CF869CCBCAB4D659476200800AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesTextBlock_91286CF869CCBCAB4D659476200800AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesTextBlock_91286CF869CCBCAB4D659476200800AA" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesTextBlock_91286CF869CCBCAB4D659476200800AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_6B121F918F401A479DBE947620080A30_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_6B121F918F401A479DBE947620080A30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_6B121F918F401A479DBE947620080A30_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_6B121F918F401A479DBE947620080A30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_6B121F918F401A479DBE947620080A30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_6B121F918F401A479DBE947620080A30" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_6B121F918F401A479DBE947620080A30" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_FBAFEEA834474B3DFC2794762009BF05_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_FBAFEEA834474B3DFC2794762009BF05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual Maturities of Available-for-sale and Held-to-maturity Debt Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_FBAFEEA834474B3DFC2794762009BF05_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_FBAFEEA834474B3DFC2794762009BF05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_FBAFEEA834474B3DFC2794762009BF05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_FBAFEEA834474B3DFC2794762009BF05" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_FBAFEEA834474B3DFC2794762009BF05" xlink:type="arc" />
    <link:label id="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_8B035658313DF742F46B94762009C8EF_terseLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_8B035658313DF742F46B94762009C8EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Gains and Losses on Investment Securities</link:label>
    <link:label id="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_8B035658313DF742F46B94762009C8EF_label_en-US" xlink:label="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_8B035658313DF742F46B94762009C8EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block]</link:label>
    <link:label id="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_8B035658313DF742F46B94762009C8EF_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_8B035658313DF742F46B94762009C8EF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" xlink:label="loc_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_8B035658313DF742F46B94762009C8EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_8B035658313DF742F46B94762009C8EF" xlink:to="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_8B035658313DF742F46B94762009C8EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTextBlock_02D3BD07586E2CCD5C3D947620099170_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTextBlock_02D3BD07586E2CCD5C3D947620099170" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Short-term Borrowings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTextBlock_02D3BD07586E2CCD5C3D947620099170_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTextBlock_02D3BD07586E2CCD5C3D947620099170" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Short-term Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_02D3BD07586E2CCD5C3D947620099170" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_02D3BD07586E2CCD5C3D947620099170" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTextBlock_02D3BD07586E2CCD5C3D947620099170" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_C64B8BD9805BFC828024947620099194_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_C64B8BD9805BFC828024947620099194" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Principal Amounts of Senior Unsecured Long-Term Debt and Adjustments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_C64B8BD9805BFC828024947620099194_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_C64B8BD9805BFC828024947620099194" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_C64B8BD9805BFC828024947620099194" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_C64B8BD9805BFC828024947620099194" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_C64B8BD9805BFC828024947620099194" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_480754842527B4639F5394762009A61A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_480754842527B4639F5394762009A61A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_480754842527B4639F5394762009A61A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_480754842527B4639F5394762009A61A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_480754842527B4639F5394762009A61A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_480754842527B4639F5394762009A61A" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_480754842527B4639F5394762009A61A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_EB2A5C09E2123DF14DCE94762009F064_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_EB2A5C09E2123DF14DCE94762009F064" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_EB2A5C09E2123DF14DCE94762009F064_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_EB2A5C09E2123DF14DCE94762009F064" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Assets at Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_EB2A5C09E2123DF14DCE94762009F064" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_EB2A5C09E2123DF14DCE94762009F064" xlink:to="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_EB2A5C09E2123DF14DCE94762009F064" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_17BDD968AE491284AE9B9476200AC4D8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_17BDD968AE491284AE9B9476200AC4D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_17BDD968AE491284AE9B9476200AC4D8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_17BDD968AE491284AE9B9476200AC4D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_17BDD968AE491284AE9B9476200AC4D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_17BDD968AE491284AE9B9476200AC4D8" xlink:to="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_17BDD968AE491284AE9B9476200AC4D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_E9485B4515E229F2457B9476200A2762_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_E9485B4515E229F2457B9476200A2762" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Information about Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_E9485B4515E229F2457B9476200A2762_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_E9485B4515E229F2457B9476200A2762" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_E9485B4515E229F2457B9476200A2762" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_E9485B4515E229F2457B9476200A2762" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_E9485B4515E229F2457B9476200A2762" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_4A391E5883E205E81E119476200A782C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_4A391E5883E205E81E119476200A782C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Total Amount of Each Income and Expense Line in which Results of Fair Value Hedges are Recorded</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_4A391E5883E205E81E119476200A782C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_4A391E5883E205E81E119476200A782C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_4A391E5883E205E81E119476200A782C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_4A391E5883E205E81E119476200A782C" xlink:to="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_4A391E5883E205E81E119476200A782C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_CE053CE7EA167678F37B6EB366C9A1A9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_CE053CE7EA167678F37B6EB366C9A1A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_CE053CE7EA167678F37B6EB366C9A1A9_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_CE053CE7EA167678F37B6EB366C9A1A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_CE053CE7EA167678F37B6EB366C9A1A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_CE053CE7EA167678F37B6EB366C9A1A9" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_CE053CE7EA167678F37B6EB366C9A1A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_319CC470316AD1A31A0B6EB366D62DBE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_319CC470316AD1A31A0B6EB366D62DBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_319CC470316AD1A31A0B6EB366D62DBE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_319CC470316AD1A31A0B6EB366D62DBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_319CC470316AD1A31A0B6EB366D62DBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_319CC470316AD1A31A0B6EB366D62DBE" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_319CC470316AD1A31A0B6EB366D62DBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_59CD4C462F198099C6B5635078D2F9A1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_59CD4C462F198099C6B5635078D2F9A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_59CD4C462F198099C6B5635078D2F9A1_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_59CD4C462F198099C6B5635078D2F9A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_59CD4C462F198099C6B5635078D2F9A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_59CD4C462F198099C6B5635078D2F9A1" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_59CD4C462F198099C6B5635078D2F9A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_AEA9B1E5C81A46CF66806EB039348DD7_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_AEA9B1E5C81A46CF66806EB039348DD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_AEA9B1E5C81A46CF66806EB039348DD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember_AEA9B1E5C81A46CF66806EB039348DD7" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember_AEA9B1E5C81A46CF66806EB039348DD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfSalesMember_920EE1AAAC01F47674AE6EB03935F9FB_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember_920EE1AAAC01F47674AE6EB03935F9FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales [Member]</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_920EE1AAAC01F47674AE6EB03935F9FB_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember_920EE1AAAC01F47674AE6EB03935F9FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_920EE1AAAC01F47674AE6EB03935F9FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember_920EE1AAAC01F47674AE6EB03935F9FB" xlink:to="lab_us-gaap_CostOfSalesMember_920EE1AAAC01F47674AE6EB03935F9FB" xlink:type="arc" />
    <link:label id="lab_pfe_ForeignCurrencyLongTermDebtMember_DD60DEAD2744D98E8FF46EB03936FD05_terseLabel_en-US" xlink:label="lab_pfe_ForeignCurrencyLongTermDebtMember_DD60DEAD2744D98E8FF46EB03936FD05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency long-term debt [Member]</link:label>
    <link:label id="lab_pfe_ForeignCurrencyLongTermDebtMember_DD60DEAD2744D98E8FF46EB03936FD05_label_en-US" xlink:label="lab_pfe_ForeignCurrencyLongTermDebtMember_DD60DEAD2744D98E8FF46EB03936FD05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Long Term Debt [Member]</link:label>
    <link:label id="lab_pfe_ForeignCurrencyLongTermDebtMember_DD60DEAD2744D98E8FF46EB03936FD05_documentation_en-US" xlink:label="lab_pfe_ForeignCurrencyLongTermDebtMember_DD60DEAD2744D98E8FF46EB03936FD05" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign currency long - term debt [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ForeignCurrencyLongTermDebtMember" xlink:label="loc_pfe_ForeignCurrencyLongTermDebtMember_DD60DEAD2744D98E8FF46EB03936FD05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ForeignCurrencyLongTermDebtMember_DD60DEAD2744D98E8FF46EB03936FD05" xlink:to="lab_pfe_ForeignCurrencyLongTermDebtMember_DD60DEAD2744D98E8FF46EB03936FD05" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_52703259133BF0061E1F6EB03937D96C_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_52703259133BF0061E1F6EB03937D96C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amount of (Gains)/Losses Reclassified from OCI into OID and COS</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_52703259133BF0061E1F6EB03937D96C_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_52703259133BF0061E1F6EB03937D96C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_52703259133BF0061E1F6EB03937D96C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_52703259133BF0061E1F6EB03937D96C" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_52703259133BF0061E1F6EB03937D96C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_37F69DCF9EAD966F73096EB0393D2610_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_37F69DCF9EAD966F73096EB0393D2610" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Pre-tax gain expected to be reclassified within the next 12 months</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_37F69DCF9EAD966F73096EB0393D2610_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_37F69DCF9EAD966F73096EB0393D2610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_37F69DCF9EAD966F73096EB0393D2610" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_37F69DCF9EAD966F73096EB0393D2610" xlink:to="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_37F69DCF9EAD966F73096EB0393D2610" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_7645262DC5A670773B516EB0393DD88C_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_7645262DC5A670773B516EB0393DD88C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_7645262DC5A670773B516EB0393DD88C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_7645262DC5A670773B516EB0393DD88C" xlink:to="lab_us-gaap_LongTermDebt_7645262DC5A670773B516EB0393DD88C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_6312F101428657492F9394761F27F92C_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_6312F101428657492F9394761F27F92C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_6312F101428657492F9394761F27F92C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6312F101428657492F9394761F27F92C" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_6312F101428657492F9394761F27F92C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_7224E4ECE5C17FB1BB0794761F27F56D_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_7224E4ECE5C17FB1BB0794761F27F56D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_7224E4ECE5C17FB1BB0794761F27F56D_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_7224E4ECE5C17FB1BB0794761F27F56D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_7224E4ECE5C17FB1BB0794761F27F56D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_7224E4ECE5C17FB1BB0794761F27F56D" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_7224E4ECE5C17FB1BB0794761F27F56D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_FB64A065740239974E9BBEEC36DCB768_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_FB64A065740239974E9BBEEC36DCB768" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_FB64A065740239974E9BBEEC36DCB768_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_FB64A065740239974E9BBEEC36DCB768" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_FB64A065740239974E9BBEEC36DCB768" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_FB64A065740239974E9BBEEC36DCB768" xlink:to="lab_us-gaap_AssetsAbstract_FB64A065740239974E9BBEEC36DCB768" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C8072D2514D4E668DA05BEEC36DD6CE3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C8072D2514D4E668DA05BEEC36DD6CE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C8072D2514D4E668DA05BEEC36DD6CE3_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C8072D2514D4E668DA05BEEC36DD6CE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C8072D2514D4E668DA05BEEC36DD6CE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C8072D2514D4E668DA05BEEC36DD6CE3" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C8072D2514D4E668DA05BEEC36DD6CE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherShortTermInvestments_E9A28760654E4992FBB4BF016B222715_terseLabel_en-US" xlink:label="lab_us-gaap_OtherShortTermInvestments_E9A28760654E4992FBB4BF016B222715" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_OtherShortTermInvestments_E9A28760654E4992FBB4BF016B222715_label_en-US" xlink:label="lab_us-gaap_OtherShortTermInvestments_E9A28760654E4992FBB4BF016B222715" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments_E9A28760654E4992FBB4BF016B222715" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermInvestments_E9A28760654E4992FBB4BF016B222715" xlink:to="lab_us-gaap_OtherShortTermInvestments_E9A28760654E4992FBB4BF016B222715" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedInvestmentsCurrent_D77CA76A88BDBE970932BEEC36DDC2E2_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedInvestmentsCurrent_D77CA76A88BDBE970932BEEC36DDC2E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted short-term investments</link:label>
    <link:label id="lab_us-gaap_RestrictedInvestmentsCurrent_D77CA76A88BDBE970932BEEC36DDC2E2_label_en-US" xlink:label="lab_us-gaap_RestrictedInvestmentsCurrent_D77CA76A88BDBE970932BEEC36DDC2E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Investments, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedInvestmentsCurrent" xlink:label="loc_us-gaap_RestrictedInvestmentsCurrent_D77CA76A88BDBE970932BEEC36DDC2E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedInvestmentsCurrent_D77CA76A88BDBE970932BEEC36DDC2E2" xlink:to="lab_us-gaap_RestrictedInvestmentsCurrent_D77CA76A88BDBE970932BEEC36DDC2E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_D3E0D76CB82E92B1EE6EBEEC36DDE437_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_D3E0D76CB82E92B1EE6EBEEC36DDE437" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade accounts receivable, less allowance for doubtful accounts: 2020&#8212;$525; 2019&#8212;$527</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_D3E0D76CB82E92B1EE6EBEEC36DDE437_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_D3E0D76CB82E92B1EE6EBEEC36DDE437" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_D3E0D76CB82E92B1EE6EBEEC36DDE437" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_D3E0D76CB82E92B1EE6EBEEC36DDE437" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_D3E0D76CB82E92B1EE6EBEEC36DDE437" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_F65C5F8422855568AA17BEEC36DD72DB_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_F65C5F8422855568AA17BEEC36DD72DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_F65C5F8422855568AA17BEEC36DD72DB_label_en-US" xlink:label="lab_us-gaap_InventoryNet_F65C5F8422855568AA17BEEC36DD72DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_F65C5F8422855568AA17BEEC36DD72DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_F65C5F8422855568AA17BEEC36DD72DB" xlink:to="lab_us-gaap_InventoryNet_F65C5F8422855568AA17BEEC36DD72DB" xlink:type="arc" />
    <link:label id="lab_pfe_OtherTaxAssetsCurrent_AECE16158C61F4701A94BEEC36DE2CDC_terseLabel_en-US" xlink:label="lab_pfe_OtherTaxAssetsCurrent_AECE16158C61F4701A94BEEC36DE2CDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current tax assets</link:label>
    <link:label id="lab_pfe_OtherTaxAssetsCurrent_AECE16158C61F4701A94BEEC36DE2CDC_label_en-US" xlink:label="lab_pfe_OtherTaxAssetsCurrent_AECE16158C61F4701A94BEEC36DE2CDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Tax Assets, Current</link:label>
    <link:label id="lab_pfe_OtherTaxAssetsCurrent_AECE16158C61F4701A94BEEC36DE2CDC_documentation_en-US" xlink:label="lab_pfe_OtherTaxAssetsCurrent_AECE16158C61F4701A94BEEC36DE2CDC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Tax Assets, Current</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherTaxAssetsCurrent" xlink:label="loc_pfe_OtherTaxAssetsCurrent_AECE16158C61F4701A94BEEC36DE2CDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherTaxAssetsCurrent_AECE16158C61F4701A94BEEC36DE2CDC" xlink:to="lab_pfe_OtherTaxAssetsCurrent_AECE16158C61F4701A94BEEC36DE2CDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_976A91954523C1FB6B20BEEC36DE5FC2_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_976A91954523C1FB6B20BEEC36DE5FC2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_976A91954523C1FB6B20BEEC36DE5FC2_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_976A91954523C1FB6B20BEEC36DE5FC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_976A91954523C1FB6B20BEEC36DE5FC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_976A91954523C1FB6B20BEEC36DE5FC2" xlink:to="lab_us-gaap_OtherAssetsCurrent_976A91954523C1FB6B20BEEC36DE5FC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_F9FA23F605F4B7C7632CBEEC36DEE908_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_F9FA23F605F4B7C7632CBEEC36DEE908" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_F9FA23F605F4B7C7632CBEEC36DEE908_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_F9FA23F605F4B7C7632CBEEC36DEE908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_F9FA23F605F4B7C7632CBEEC36DEE908" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_F9FA23F605F4B7C7632CBEEC36DEE908" xlink:to="lab_us-gaap_AssetsCurrent_F9FA23F605F4B7C7632CBEEC36DEE908" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLongTermInvestments_893BDD7CBE8C0A99B8EEBEEC36DE8E4A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments_893BDD7CBE8C0A99B8EEBEEC36DE8E4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermInvestments" xlink:label="loc_us-gaap_OtherLongTermInvestments_893BDD7CBE8C0A99B8EEBEEC36DE8E4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestments_893BDD7CBE8C0A99B8EEBEEC36DE8E4A" xlink:to="lab_us-gaap_OtherLongTermInvestments_893BDD7CBE8C0A99B8EEBEEC36DE8E4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_9CBBD869AD1FA4E29B16BEEC36DE7E71_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_9CBBD869AD1FA4E29B16BEEC36DE7E71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, less accumulated depreciation: 2020&#8212;$16,889; 2019&#8212;$16,789</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_9CBBD869AD1FA4E29B16BEEC36DE7E71_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_9CBBD869AD1FA4E29B16BEEC36DE7E71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9CBBD869AD1FA4E29B16BEEC36DE7E71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_9CBBD869AD1FA4E29B16BEEC36DE7E71" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_9CBBD869AD1FA4E29B16BEEC36DE7E71" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_29B5F587EF5A36DFC496BEEC36DF5CB1_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_29B5F587EF5A36DFC496BEEC36DF5CB1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Identifiable intangible assets, less accumulated amortization</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_29B5F587EF5A36DFC496BEEC36DF5CB1_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_29B5F587EF5A36DFC496BEEC36DF5CB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_29B5F587EF5A36DFC496BEEC36DF5CB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_29B5F587EF5A36DFC496BEEC36DF5CB1" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_29B5F587EF5A36DFC496BEEC36DF5CB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_CAA40218780149BF1549BEEC36DF60A4_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_CAA40218780149BF1549BEEC36DF60A4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_CAA40218780149BF1549BEEC36DF60A4_label_en-US" xlink:label="lab_us-gaap_Goodwill_CAA40218780149BF1549BEEC36DF60A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_CAA40218780149BF1549BEEC36DF60A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_CAA40218780149BF1549BEEC36DF60A4" xlink:to="lab_us-gaap_Goodwill_CAA40218780149BF1549BEEC36DF60A4" xlink:type="arc" />
    <link:label id="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_B4F3B93D00A229FA676DBEEC36DFAB8A_terseLabel_en-US" xlink:label="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_B4F3B93D00A229FA676DBEEC36DFAB8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent deferred tax assets and other noncurrent tax assets</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_B4F3B93D00A229FA676DBEEC36DFAB8A_label_en-US" xlink:label="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_B4F3B93D00A229FA676DBEEC36DFAB8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_B4F3B93D00A229FA676DBEEC36DFAB8A_documentation_en-US" xlink:label="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_B4F3B93D00A229FA676DBEEC36DFAB8A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:label="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_B4F3B93D00A229FA676DBEEC36DFAB8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_B4F3B93D00A229FA676DBEEC36DFAB8A" xlink:to="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_B4F3B93D00A229FA676DBEEC36DFAB8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_764B8B4DB01778795D95BEEC36DFFC3C_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_764B8B4DB01778795D95BEEC36DFFC3C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_764B8B4DB01778795D95BEEC36DFFC3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_764B8B4DB01778795D95BEEC36DFFC3C" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_764B8B4DB01778795D95BEEC36DFFC3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtCurrent_87BF3C5250A333F69B34BEEC36DF6876_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent_87BF3C5250A333F69B34BEEC36DF6876" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term borrowings, including current portion of long-term debt: 2020&#8212;$1,481; 2019&#8212;$1,462</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_87BF3C5250A333F69B34BEEC36DF6876_label_en-US" xlink:label="lab_us-gaap_DebtCurrent_87BF3C5250A333F69B34BEEC36DF6876" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_87BF3C5250A333F69B34BEEC36DF6876" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent_87BF3C5250A333F69B34BEEC36DF6876" xlink:to="lab_us-gaap_DebtCurrent_87BF3C5250A333F69B34BEEC36DF6876" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_595B3D016382BA6D0AA6BEEC36E0971E_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_595B3D016382BA6D0AA6BEEC36E0971E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_595B3D016382BA6D0AA6BEEC36E0971E_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_595B3D016382BA6D0AA6BEEC36E0971E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_595B3D016382BA6D0AA6BEEC36E0971E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_595B3D016382BA6D0AA6BEEC36E0971E" xlink:to="lab_us-gaap_AccountsPayableCurrent_595B3D016382BA6D0AA6BEEC36E0971E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DividendsPayableCurrent_A6BCEF6A538200C7B31DBEEC36E0ABBD_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent_A6BCEF6A538200C7B31DBEEC36E0ABBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_A6BCEF6A538200C7B31DBEEC36E0ABBD_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent_A6BCEF6A538200C7B31DBEEC36E0ABBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent" xlink:label="loc_us-gaap_DividendsPayableCurrent_A6BCEF6A538200C7B31DBEEC36E0ABBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent_A6BCEF6A538200C7B31DBEEC36E0ABBD" xlink:to="lab_us-gaap_DividendsPayableCurrent_A6BCEF6A538200C7B31DBEEC36E0ABBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxesPayableCurrent_45C0B1253FE8C8AB24E4BEEC36E0821D_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_45C0B1253FE8C8AB24E4BEEC36E0821D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_45C0B1253FE8C8AB24E4BEEC36E0821D_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_45C0B1253FE8C8AB24E4BEEC36E0821D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_45C0B1253FE8C8AB24E4BEEC36E0821D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent_45C0B1253FE8C8AB24E4BEEC36E0821D" xlink:to="lab_us-gaap_TaxesPayableCurrent_45C0B1253FE8C8AB24E4BEEC36E0821D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_C56569FE3D58CCACCD3DBEEC36E0EC93_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_C56569FE3D58CCACCD3DBEEC36E0EC93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and related items</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_C56569FE3D58CCACCD3DBEEC36E0EC93_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_C56569FE3D58CCACCD3DBEEC36E0EC93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_C56569FE3D58CCACCD3DBEEC36E0EC93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_C56569FE3D58CCACCD3DBEEC36E0EC93" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_C56569FE3D58CCACCD3DBEEC36E0EC93" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_5F6FBC8534F5DE8072C7BEEC36E10A0E_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_5F6FBC8534F5DE8072C7BEEC36E10A0E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_5F6FBC8534F5DE8072C7BEEC36E10A0E_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_5F6FBC8534F5DE8072C7BEEC36E10A0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5F6FBC8534F5DE8072C7BEEC36E10A0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_5F6FBC8534F5DE8072C7BEEC36E10A0E" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_5F6FBC8534F5DE8072C7BEEC36E10A0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6775A96BCAC68119B81FBEEC36E129EC_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_6775A96BCAC68119B81FBEEC36E129EC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6775A96BCAC68119B81FBEEC36E129EC_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_6775A96BCAC68119B81FBEEC36E129EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_6775A96BCAC68119B81FBEEC36E129EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_6775A96BCAC68119B81FBEEC36E129EC" xlink:to="lab_us-gaap_LiabilitiesCurrent_6775A96BCAC68119B81FBEEC36E129EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_C35CA1BAE01FDF4E246CBEEC36E11204_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_C35CA1BAE01FDF4E246CBEEC36E11204" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_C35CA1BAE01FDF4E246CBEEC36E11204_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_C35CA1BAE01FDF4E246CBEEC36E11204" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_C35CA1BAE01FDF4E246CBEEC36E11204" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_C35CA1BAE01FDF4E246CBEEC36E11204" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_C35CA1BAE01FDF4E246CBEEC36E11204" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_1653798E9E6C78053166BEEC36E1E7D9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_1653798E9E6C78053166BEEC36E1E7D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension benefit obligations, net</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_1653798E9E6C78053166BEEC36E1E7D9_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_1653798E9E6C78053166BEEC36E1E7D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability, Defined Benefit Pension Plan, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_1653798E9E6C78053166BEEC36E1E7D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_1653798E9E6C78053166BEEC36E1E7D9" xlink:to="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_1653798E9E6C78053166BEEC36E1E7D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_455597F475690A883549BEEC36E1D705_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_455597F475690A883549BEEC36E1D705" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Postretirement benefit obligations, net</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_455597F475690A883549BEEC36E1D705_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_455597F475690A883549BEEC36E1D705" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability, Other Postretirement Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_455597F475690A883549BEEC36E1D705" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_455597F475690A883549BEEC36E1D705" xlink:to="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_455597F475690A883549BEEC36E1D705" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_07ADC8ADB46D510ABEEDBEEC36E1CD85_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_07ADC8ADB46D510ABEEDBEEC36E1CD85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_07ADC8ADB46D510ABEEDBEEC36E1CD85_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_07ADC8ADB46D510ABEEDBEEC36E1CD85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_07ADC8ADB46D510ABEEDBEEC36E1CD85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_07ADC8ADB46D510ABEEDBEEC36E1CD85" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_07ADC8ADB46D510ABEEDBEEC36E1CD85" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_967A22E85B6403307EA2BEEC36E10B89_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_967A22E85B6403307EA2BEEC36E10B89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other taxes payable</link:label>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_967A22E85B6403307EA2BEEC36E10B89_label_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_967A22E85B6403307EA2BEEC36E10B89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_967A22E85B6403307EA2BEEC36E10B89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_967A22E85B6403307EA2BEEC36E10B89" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_967A22E85B6403307EA2BEEC36E10B89" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_8AE096EF7BB02F8E3B9CBEEC36E27F94_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_8AE096EF7BB02F8E3B9CBEEC36E27F94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_8AE096EF7BB02F8E3B9CBEEC36E27F94_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_8AE096EF7BB02F8E3B9CBEEC36E27F94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8AE096EF7BB02F8E3B9CBEEC36E27F94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_8AE096EF7BB02F8E3B9CBEEC36E27F94" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_8AE096EF7BB02F8E3B9CBEEC36E27F94" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_A14804A45C811874F5C0BEEC36E22477_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_A14804A45C811874F5C0BEEC36E22477" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_A14804A45C811874F5C0BEEC36E22477_label_en-US" xlink:label="lab_us-gaap_Liabilities_A14804A45C811874F5C0BEEC36E22477" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_A14804A45C811874F5C0BEEC36E22477" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_A14804A45C811874F5C0BEEC36E22477" xlink:to="lab_us-gaap_Liabilities_A14804A45C811874F5C0BEEC36E22477" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_AAB7D4F6A6071335ACF2BEEC36E218D5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_AAB7D4F6A6071335ACF2BEEC36E218D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_AAB7D4F6A6071335ACF2BEEC36E218D5_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_AAB7D4F6A6071335ACF2BEEC36E218D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_AAB7D4F6A6071335ACF2BEEC36E218D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_AAB7D4F6A6071335ACF2BEEC36E218D5" xlink:to="lab_us-gaap_CommitmentsAndContingencies_AAB7D4F6A6071335ACF2BEEC36E218D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_B03293533393BC24F0DCBEEC36E70217_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_B03293533393BC24F0DCBEEC36E70217" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_B03293533393BC24F0DCBEEC36E70217_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_B03293533393BC24F0DCBEEC36E70217" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_B03293533393BC24F0DCBEEC36E70217" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_B03293533393BC24F0DCBEEC36E70217" xlink:to="lab_us-gaap_PreferredStockValue_B03293533393BC24F0DCBEEC36E70217" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_10AD813D7A1052ED69B1BEEC36E77D90_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_10AD813D7A1052ED69B1BEEC36E77D90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_10AD813D7A1052ED69B1BEEC36E77D90_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_10AD813D7A1052ED69B1BEEC36E77D90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_10AD813D7A1052ED69B1BEEC36E77D90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_10AD813D7A1052ED69B1BEEC36E77D90" xlink:to="lab_us-gaap_CommonStockValue_10AD813D7A1052ED69B1BEEC36E77D90" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_AF0190E432DE54D99733BEEC36E88BB7_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_AF0190E432DE54D99733BEEC36E88BB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_AF0190E432DE54D99733BEEC36E88BB7_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_AF0190E432DE54D99733BEEC36E88BB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_AF0190E432DE54D99733BEEC36E88BB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_AF0190E432DE54D99733BEEC36E88BB7" xlink:to="lab_us-gaap_AdditionalPaidInCapital_AF0190E432DE54D99733BEEC36E88BB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_E0EB43B7A757A121FDAFBEEC36E865D5_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_E0EB43B7A757A121FDAFBEEC36E865D5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_E0EB43B7A757A121FDAFBEEC36E865D5_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_E0EB43B7A757A121FDAFBEEC36E865D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_E0EB43B7A757A121FDAFBEEC36E865D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_E0EB43B7A757A121FDAFBEEC36E865D5" xlink:to="lab_us-gaap_TreasuryStockValue_E0EB43B7A757A121FDAFBEEC36E865D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_BD9DFE60029D0FF99393BEEC36E8C0B1_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_BD9DFE60029D0FF99393BEEC36E8C0B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_BD9DFE60029D0FF99393BEEC36E8C0B1_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_BD9DFE60029D0FF99393BEEC36E8C0B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_BD9DFE60029D0FF99393BEEC36E8C0B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_BD9DFE60029D0FF99393BEEC36E8C0B1" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_BD9DFE60029D0FF99393BEEC36E8C0B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E7C6B46A95F1B5471F82BEEC36E8A6AA_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E7C6B46A95F1B5471F82BEEC36E8A6AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E7C6B46A95F1B5471F82BEEC36E8A6AA_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E7C6B46A95F1B5471F82BEEC36E8A6AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E7C6B46A95F1B5471F82BEEC36E8A6AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E7C6B46A95F1B5471F82BEEC36E8A6AA" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E7C6B46A95F1B5471F82BEEC36E8A6AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_5211BA2CCE328C13B987BEEC36E83159_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_5211BA2CCE328C13B987BEEC36E83159" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Pfizer Inc. shareholders&#8217; equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_5211BA2CCE328C13B987BEEC36E83159" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_5211BA2CCE328C13B987BEEC36E83159" xlink:to="lab_us-gaap_StockholdersEquity_5211BA2CCE328C13B987BEEC36E83159" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_4FB90D0B45BB88D1368CBEEC36E80DC5_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_4FB90D0B45BB88D1368CBEEC36E80DC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_4FB90D0B45BB88D1368CBEEC36E80DC5_label_en-US" xlink:label="lab_us-gaap_MinorityInterest_4FB90D0B45BB88D1368CBEEC36E80DC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_4FB90D0B45BB88D1368CBEEC36E80DC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_4FB90D0B45BB88D1368CBEEC36E80DC5" xlink:to="lab_us-gaap_MinorityInterest_4FB90D0B45BB88D1368CBEEC36E80DC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E468F1A269D25E7E8174BEEC36E949DB_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E468F1A269D25E7E8174BEEC36E949DB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E468F1A269D25E7E8174BEEC36E949DB_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E468F1A269D25E7E8174BEEC36E949DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E468F1A269D25E7E8174BEEC36E949DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E468F1A269D25E7E8174BEEC36E949DB" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E468F1A269D25E7E8174BEEC36E949DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_8F6458EBD855100DFEC3BEEC36E9B980_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_8F6458EBD855100DFEC3BEEC36E9B980" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_8F6458EBD855100DFEC3BEEC36E9B980_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_8F6458EBD855100DFEC3BEEC36E9B980" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8F6458EBD855100DFEC3BEEC36E9B980" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8F6458EBD855100DFEC3BEEC36E9B980" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_8F6458EBD855100DFEC3BEEC36E9B980" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9345CE3A5B6465A5934D5E4BE86A517B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9345CE3A5B6465A5934D5E4BE86A517B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9345CE3A5B6465A5934D5E4BE86A517B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9345CE3A5B6465A5934D5E4BE86A517B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9345CE3A5B6465A5934D5E4BE86A517B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9345CE3A5B6465A5934D5E4BE86A517B" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9345CE3A5B6465A5934D5E4BE86A517B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_1A317329DCCEC7FC44DB5E4BE86A615E_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis_1A317329DCCEC7FC44DB5E4BE86A615E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_1A317329DCCEC7FC44DB5E4BE86A615E_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis_1A317329DCCEC7FC44DB5E4BE86A615E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1A317329DCCEC7FC44DB5E4BE86A615E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1A317329DCCEC7FC44DB5E4BE86A615E" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis_1A317329DCCEC7FC44DB5E4BE86A615E" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_675A4F67CEC0EF2753465E4BE86B9402_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain_675A4F67CEC0EF2753465E4BE86B9402" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_675A4F67CEC0EF2753465E4BE86B9402_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain_675A4F67CEC0EF2753465E4BE86B9402" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_675A4F67CEC0EF2753465E4BE86B9402" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_675A4F67CEC0EF2753465E4BE86B9402" xlink:to="lab_us-gaap_TypeOfRestructuringDomain_675A4F67CEC0EF2753465E4BE86B9402" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_FE7786157B6C3981FE455E4BE86B4801_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember_FE7786157B6C3981FE455E4BE86B4801" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee Termination Costs [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_FE7786157B6C3981FE455E4BE86B4801_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember_FE7786157B6C3981FE455E4BE86B4801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_FE7786157B6C3981FE455E4BE86B4801" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember_FE7786157B6C3981FE455E4BE86B4801" xlink:to="lab_us-gaap_EmployeeSeveranceMember_FE7786157B6C3981FE455E4BE86B4801" xlink:type="arc" />
    <link:label id="lab_pfe_AssetImpairmentsMember_51C7BACE87279A174D225E4BE86B94C6_terseLabel_en-US" xlink:label="lab_pfe_AssetImpairmentsMember_51C7BACE87279A174D225E4BE86B94C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges [Member]</link:label>
    <link:label id="lab_pfe_AssetImpairmentsMember_51C7BACE87279A174D225E4BE86B94C6_label_en-US" xlink:label="lab_pfe_AssetImpairmentsMember_51C7BACE87279A174D225E4BE86B94C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairments [Member]</link:label>
    <link:label id="lab_pfe_AssetImpairmentsMember_51C7BACE87279A174D225E4BE86B94C6_documentation_en-US" xlink:label="lab_pfe_AssetImpairmentsMember_51C7BACE87279A174D225E4BE86B94C6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset impairments [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AssetImpairmentsMember" xlink:label="loc_pfe_AssetImpairmentsMember_51C7BACE87279A174D225E4BE86B94C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AssetImpairmentsMember_51C7BACE87279A174D225E4BE86B94C6" xlink:to="lab_pfe_AssetImpairmentsMember_51C7BACE87279A174D225E4BE86B94C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherRestructuringMember_7D058F9AD055CB7861B05E4BE86B5C99_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember_7D058F9AD055CB7861B05E4BE86B5C99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exit Costs [Member]</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_7D058F9AD055CB7861B05E4BE86B5C99_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember_7D058F9AD055CB7861B05E4BE86B5C99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_us-gaap_OtherRestructuringMember_7D058F9AD055CB7861B05E4BE86B5C99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember_7D058F9AD055CB7861B05E4BE86B5C99" xlink:to="lab_us-gaap_OtherRestructuringMember_7D058F9AD055CB7861B05E4BE86B5C99" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_974D7B3BCF0589DEB09B5E4BE86B6AF2_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_974D7B3BCF0589DEB09B5E4BE86B6AF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_974D7B3BCF0589DEB09B5E4BE86B6AF2_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_974D7B3BCF0589DEB09B5E4BE86B6AF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_974D7B3BCF0589DEB09B5E4BE86B6AF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_974D7B3BCF0589DEB09B5E4BE86B6AF2" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems_974D7B3BCF0589DEB09B5E4BE86B6AF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_E066916D2FECFCEEFF225E4BE86C8D0B_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward_E066916D2FECFCEEFF225E4BE86C8D0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_E066916D2FECFCEEFF225E4BE86C8D0B_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward_E066916D2FECFCEEFF225E4BE86C8D0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveRollForward" xlink:label="loc_us-gaap_RestructuringReserveRollForward_E066916D2FECFCEEFF225E4BE86C8D0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward_E066916D2FECFCEEFF225E4BE86C8D0B" xlink:to="lab_us-gaap_RestructuringReserveRollForward_E066916D2FECFCEEFF225E4BE86C8D0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserve_FBFAF74349D70157E6855E4BE86C797E_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve_FBFAF74349D70157E6855E4BE86C797E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, December 31, 2019</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_FBFAF74349D70157E6855E4BE86C797E_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve_FBFAF74349D70157E6855E4BE86C797E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_FBFAF74349D70157E6855E4BE86C797E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve_FBFAF74349D70157E6855E4BE86C797E" xlink:to="lab_us-gaap_RestructuringReserve_FBFAF74349D70157E6855E4BE86C797E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_435A7B2669116D1C47065E4BE86CD413_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_435A7B2669116D1C47065E4BE86CD413" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_435A7B2669116D1C47065E4BE86CD413_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges_435A7B2669116D1C47065E4BE86CD413" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_435A7B2669116D1C47065E4BE86CD413" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_435A7B2669116D1C47065E4BE86CD413" xlink:to="lab_us-gaap_RestructuringCharges_435A7B2669116D1C47065E4BE86CD413" xlink:type="arc" />
    <link:label id="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_9C1CA6033D93F73820EA5E4BE86C2169_negatedTerseLabel_en-US" xlink:label="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_9C1CA6033D93F73820EA5E4BE86C2169" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Utilization and other</link:label>
    <link:label id="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_9C1CA6033D93F73820EA5E4BE86C2169_label_en-US" xlink:label="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_9C1CA6033D93F73820EA5E4BE86C2169" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment</link:label>
    <link:label id="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_9C1CA6033D93F73820EA5E4BE86C2169_documentation_en-US" xlink:label="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_9C1CA6033D93F73820EA5E4BE86C2169" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" xlink:label="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_9C1CA6033D93F73820EA5E4BE86C2169" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_9C1CA6033D93F73820EA5E4BE86C2169" xlink:to="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_9C1CA6033D93F73820EA5E4BE86C2169" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserve_634924688BE819BAE6025E4BE86DA70D_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve_634924688BE819BAE6025E4BE86DA70D" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, June 28, 2020</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_634924688BE819BAE6025E4BE86DA70D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve_634924688BE819BAE6025E4BE86DA70D" xlink:to="lab_us-gaap_RestructuringReserve_634924688BE819BAE6025E4BE86DA70D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_CBBCC48312A7C5D13A76B09F35006935_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_CBBCC48312A7C5D13A76B09F35006935" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_CBBCC48312A7C5D13A76B09F35006935" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_CBBCC48312A7C5D13A76B09F35006935" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_CBBCC48312A7C5D13A76B09F35006935" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_47A2E354D672C96E3ED1B09F3500DA24_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_47A2E354D672C96E3ED1B09F3500DA24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_47A2E354D672C96E3ED1B09F3500DA24_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_47A2E354D672C96E3ED1B09F3500DA24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_47A2E354D672C96E3ED1B09F3500DA24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_47A2E354D672C96E3ED1B09F3500DA24" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_47A2E354D672C96E3ED1B09F3500DA24" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_A946152AF00756A91B10B09F3501A3A6_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_A946152AF00756A91B10B09F3501A3A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income before allocation to noncontrolling interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_A946152AF00756A91B10B09F3501A3A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_A946152AF00756A91B10B09F3501A3A6" xlink:to="lab_us-gaap_ProfitLoss_A946152AF00756A91B10B09F3501A3A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F6A790BFD51677B9ADA3B09F3501C384_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F6A790BFD51677B9ADA3B09F3501C384" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F6A790BFD51677B9ADA3B09F3501C384_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F6A790BFD51677B9ADA3B09F3501C384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F6A790BFD51677B9ADA3B09F3501C384" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F6A790BFD51677B9ADA3B09F3501C384" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F6A790BFD51677B9ADA3B09F3501C384" xlink:type="arc" />
    <link:label id="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_2E486E0DDC21D0650D5CB09F35017873_terseLabel_en-US" xlink:label="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_2E486E0DDC21D0650D5CB09F35017873" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_2E486E0DDC21D0650D5CB09F35017873_label_en-US" xlink:label="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_2E486E0DDC21D0650D5CB09F35017873" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion And Amortization, Including Discontinued Operation, Depreciation and Amortization</link:label>
    <link:label id="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_2E486E0DDC21D0650D5CB09F35017873_documentation_en-US" xlink:label="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_2E486E0DDC21D0650D5CB09F35017873" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. Includes the amount of expense from discontinued operations, that reflects the allocation of the cost of tangible and intangible assets over the assets' useful lives.</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" xlink:label="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_2E486E0DDC21D0650D5CB09F35017873" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_2E486E0DDC21D0650D5CB09F35017873" xlink:to="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_2E486E0DDC21D0650D5CB09F35017873" xlink:type="arc" />
    <link:label id="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_98F1D5A425BBE4B5D7E3B09F3501D239_verboseLabel_en-US" xlink:label="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_98F1D5A425BBE4B5D7E3B09F3501D239" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Asset write-offs and impairments</link:label>
    <link:label id="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_98F1D5A425BBE4B5D7E3B09F3501D239_label_en-US" xlink:label="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_98F1D5A425BBE4B5D7E3B09F3501D239" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Write-Offs And Asset Impairment Charges</link:label>
    <link:label id="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_98F1D5A425BBE4B5D7E3B09F3501D239_documentation_en-US" xlink:label="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_98F1D5A425BBE4B5D7E3B09F3501D239" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Write-Offs And Asset Impairment Charges</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AssetWriteOffsAndAssetImpairmentCharges" xlink:label="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_98F1D5A425BBE4B5D7E3B09F3501D239" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_98F1D5A425BBE4B5D7E3B09F3501D239" xlink:to="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_98F1D5A425BBE4B5D7E3B09F3501D239" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_0AA8AF257BCEE4EAB848B09F35029DEA_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_0AA8AF257BCEE4EAB848B09F35029DEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TCJA impact</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_0AA8AF257BCEE4EAB848B09F35029DEA_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_0AA8AF257BCEE4EAB848B09F35029DEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act, Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_0AA8AF257BCEE4EAB848B09F35029DEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_0AA8AF257BCEE4EAB848B09F35029DEA" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_0AA8AF257BCEE4EAB848B09F35029DEA" xlink:type="arc" />
    <link:label id="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_B5BA6448712167DD21DEB09F35023979_negatedLabel_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_B5BA6448712167DD21DEB09F35023979" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed</link:label>
    <link:label id="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_B5BA6448712167DD21DEB09F35023979_label_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_B5BA6448712167DD21DEB09F35023979" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount, Net Of Cash Conveyed</link:label>
    <link:label id="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_B5BA6448712167DD21DEB09F35023979_documentation_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_B5BA6448712167DD21DEB09F35023979" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount, Net Of Cash Conveyed</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DeconsolidationGainLossAmountNetOfCashConveyed" xlink:label="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_B5BA6448712167DD21DEB09F35023979" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_B5BA6448712167DD21DEB09F35023979" xlink:to="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_B5BA6448712167DD21DEB09F35023979" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_77BB84B06CF84F6F1CB1B09F350289BC_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_77BB84B06CF84F6F1CB1B09F350289BC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred taxes from continuing operations</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_77BB84B06CF84F6F1CB1B09F350289BC_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_77BB84B06CF84F6F1CB1B09F350289BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_77BB84B06CF84F6F1CB1B09F350289BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_77BB84B06CF84F6F1CB1B09F350289BC" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_77BB84B06CF84F6F1CB1B09F350289BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_40627A89970B55A4FF31B09F350234F2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_40627A89970B55A4FF31B09F350234F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_40627A89970B55A4FF31B09F350234F2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_40627A89970B55A4FF31B09F350234F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_40627A89970B55A4FF31B09F350234F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_40627A89970B55A4FF31B09F350234F2" xlink:to="lab_us-gaap_ShareBasedCompensation_40627A89970B55A4FF31B09F350234F2" xlink:type="arc" />
    <link:label id="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_84E02D2D0362FB50259EB09F35028D0C_negatedTerseLabel_en-US" xlink:label="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_84E02D2D0362FB50259EB09F35028D0C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Benefit plan contributions in excess of expense/income</link:label>
    <link:label id="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_84E02D2D0362FB50259EB09F35028D0C_label_en-US" xlink:label="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_84E02D2D0362FB50259EB09F35028D0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension And Other Postretirement Benefit Contributions, Net Of Pension And Other Postretirement Benefit (Expense)</link:label>
    <link:label id="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_84E02D2D0362FB50259EB09F35028D0C_documentation_en-US" xlink:label="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_84E02D2D0362FB50259EB09F35028D0C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans less the amount of pension and other postretirement benefit costs/income recognized during the period for defined benefit plans (periodic benefit costs/income include the following components: service cost, interest cost, expected return on plan assets, gain or loss on assets, prior service cost or credit, transition asset or obligation, and gain or loss due to settlements or curtailments).</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" xlink:label="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_84E02D2D0362FB50259EB09F35028D0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_84E02D2D0362FB50259EB09F35028D0C" xlink:to="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_84E02D2D0362FB50259EB09F35028D0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_48F38A45A6C6E8FC5387B09F35026505_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_48F38A45A6C6E8FC5387B09F35026505" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other adjustments, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_48F38A45A6C6E8FC5387B09F35026505_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_48F38A45A6C6E8FC5387B09F35026505" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_48F38A45A6C6E8FC5387B09F35026505" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_48F38A45A6C6E8FC5387B09F35026505" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_48F38A45A6C6E8FC5387B09F35026505" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapital_05F33EC8850832168D74B09F3503DDD9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapital_05F33EC8850832168D74B09F3503DDD9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other changes in assets and liabilities, net of acquisitions and divestitures</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapital_05F33EC8850832168D74B09F3503DDD9_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapital_05F33EC8850832168D74B09F3503DDD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_05F33EC8850832168D74B09F3503DDD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital_05F33EC8850832168D74B09F3503DDD9" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapital_05F33EC8850832168D74B09F3503DDD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_FF52CDED793982255DFAB09F3503D382_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_FF52CDED793982255DFAB09F3503D382" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_FF52CDED793982255DFAB09F3503D382_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_FF52CDED793982255DFAB09F3503D382" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_FF52CDED793982255DFAB09F3503D382" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_FF52CDED793982255DFAB09F3503D382" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_FF52CDED793982255DFAB09F3503D382" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_DB38D01B08B80031E442B09F3503515F_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_DB38D01B08B80031E442B09F3503515F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_DB38D01B08B80031E442B09F3503515F_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_DB38D01B08B80031E442B09F3503515F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_DB38D01B08B80031E442B09F3503515F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_DB38D01B08B80031E442B09F3503515F" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_DB38D01B08B80031E442B09F3503515F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1E8CCADD9046C661E8C1B09F350358EB_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1E8CCADD9046C661E8C1B09F350358EB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1E8CCADD9046C661E8C1B09F350358EB_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1E8CCADD9046C661E8C1B09F350358EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1E8CCADD9046C661E8C1B09F350358EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1E8CCADD9046C661E8C1B09F350358EB" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1E8CCADD9046C661E8C1B09F350358EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_C9C40391FFC010854BD2B09F3503B7B2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments_C9C40391FFC010854BD2B09F3503B7B2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_C9C40391FFC010854BD2B09F3503B7B2_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments_C9C40391FFC010854BD2B09F3503B7B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_C9C40391FFC010854BD2B09F3503B7B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments_C9C40391FFC010854BD2B09F3503B7B2" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments_C9C40391FFC010854BD2B09F3503B7B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_B34EA1579E12A751961DB09F3503BD14_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_B34EA1579E12A751961DB09F3503BD14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from redemptions/sales of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_B34EA1579E12A751961DB09F3503BD14_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_B34EA1579E12A751961DB09F3503BD14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_B34EA1579E12A751961DB09F3503BD14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_B34EA1579E12A751961DB09F3503BD14" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_B34EA1579E12A751961DB09F3503BD14" xlink:type="arc" />
    <link:label id="lab_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_87423C22740F160ACE52B09F350494C9_negatedLabel_en-US" xlink:label="lab_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_87423C22740F160ACE52B09F350494C9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less</link:label>
    <link:label id="lab_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_87423C22740F160ACE52B09F350494C9_label_en-US" xlink:label="lab_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_87423C22740F160ACE52B09F350494C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For (Proceeds From) Short Term Investments With Original Maturities Of Three Months Or Less</link:label>
    <link:label id="lab_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_87423C22740F160ACE52B09F350494C9_documentation_en-US" xlink:label="lab_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_87423C22740F160ACE52B09F350494C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For (Proceeds From) Short Term Investments With Original Maturities Of Three Months Or Less</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" xlink:label="loc_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_87423C22740F160ACE52B09F350494C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_87423C22740F160ACE52B09F350494C9" xlink:to="lab_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_87423C22740F160ACE52B09F350494C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_26D80F90FAD77766A1ADB09F350402D7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_26D80F90FAD77766A1ADB09F350402D7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of long-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_26D80F90FAD77766A1ADB09F350402D7_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_26D80F90FAD77766A1ADB09F350402D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_26D80F90FAD77766A1ADB09F350402D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities_26D80F90FAD77766A1ADB09F350402D7" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities_26D80F90FAD77766A1ADB09F350402D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_97388ADC477C7F3E60FFB09F35048137_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_97388ADC477C7F3E60FFB09F35048137" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from redemptions/sales of long-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_97388ADC477C7F3E60FFB09F35048137_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_97388ADC477C7F3E60FFB09F35048137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Long-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_97388ADC477C7F3E60FFB09F35048137" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_97388ADC477C7F3E60FFB09F35048137" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_97388ADC477C7F3E60FFB09F35048137" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_2BAEF67B6B3A30784571B09F35043EBC_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_2BAEF67B6B3A30784571B09F35043EBC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_2BAEF67B6B3A30784571B09F35043EBC_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_2BAEF67B6B3A30784571B09F35043EBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_2BAEF67B6B3A30784571B09F35043EBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_2BAEF67B6B3A30784571B09F35043EBC" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_2BAEF67B6B3A30784571B09F35043EBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_EBD3074CFF9C5C3B13A3B09F3504BEEA_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_EBD3074CFF9C5C3B13A3B09F3504BEEA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other investing activities, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_EBD3074CFF9C5C3B13A3B09F3504BEEA_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_EBD3074CFF9C5C3B13A3B09F3504BEEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_EBD3074CFF9C5C3B13A3B09F3504BEEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_EBD3074CFF9C5C3B13A3B09F3504BEEA" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_EBD3074CFF9C5C3B13A3B09F3504BEEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_BD317FE37EEB5802FCA3B09F350401C9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_BD317FE37EEB5802FCA3B09F350401C9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by/(used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_BD317FE37EEB5802FCA3B09F350401C9_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_BD317FE37EEB5802FCA3B09F350401C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_BD317FE37EEB5802FCA3B09F350401C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_BD317FE37EEB5802FCA3B09F350401C9" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_BD317FE37EEB5802FCA3B09F350401C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9C8C3AA44F654A729E4DB09F35057AFA_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9C8C3AA44F654A729E4DB09F35057AFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9C8C3AA44F654A729E4DB09F35057AFA_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9C8C3AA44F654A729E4DB09F35057AFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9C8C3AA44F654A729E4DB09F35057AFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9C8C3AA44F654A729E4DB09F35057AFA" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9C8C3AA44F654A729E4DB09F35057AFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_7A56D2BE77ECDF49BF1FB09F35054E08_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt_7A56D2BE77ECDF49BF1FB09F35054E08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_7A56D2BE77ECDF49BF1FB09F35054E08_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt_7A56D2BE77ECDF49BF1FB09F35054E08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Short-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_7A56D2BE77ECDF49BF1FB09F35054E08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt_7A56D2BE77ECDF49BF1FB09F35054E08" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt_7A56D2BE77ECDF49BF1FB09F35054E08" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_80B17FD8B9A1026DA937B09F35056760_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt_80B17FD8B9A1026DA937B09F35056760" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Principal payments on short-term borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_80B17FD8B9A1026DA937B09F35056760_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt_80B17FD8B9A1026DA937B09F35056760" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Short-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_80B17FD8B9A1026DA937B09F35056760" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt_80B17FD8B9A1026DA937B09F35056760" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt_80B17FD8B9A1026DA937B09F35056760" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_EE3E5A87C104A6029F4BB09F3505C03E_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_EE3E5A87C104A6029F4BB09F3505C03E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_EE3E5A87C104A6029F4BB09F3505C03E_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_EE3E5A87C104A6029F4BB09F3505C03E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Repayments of) Short-term Debt, Maturing in Three Months or Less</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_EE3E5A87C104A6029F4BB09F3505C03E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_EE3E5A87C104A6029F4BB09F3505C03E" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_EE3E5A87C104A6029F4BB09F3505C03E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_7BBFEBCF4ED1ACFD7F4CB09F3506AE6A_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_7BBFEBCF4ED1ACFD7F4CB09F3506AE6A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Principal payments on long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_7BBFEBCF4ED1ACFD7F4CB09F3506AE6A_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_7BBFEBCF4ED1ACFD7F4CB09F3506AE6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_7BBFEBCF4ED1ACFD7F4CB09F3506AE6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_7BBFEBCF4ED1ACFD7F4CB09F3506AE6A" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_7BBFEBCF4ED1ACFD7F4CB09F3506AE6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_88576BCF49DD42E57142B09F3506B3D8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_88576BCF49DD42E57142B09F3506B3D8" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_88576BCF49DD42E57142B09F3506B3D8_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_88576BCF49DD42E57142B09F3506B3D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_88576BCF49DD42E57142B09F3506B3D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_88576BCF49DD42E57142B09F3506B3D8" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_88576BCF49DD42E57142B09F3506B3D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_098F14C9C88DFECADF9DB09F35062E34_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends_098F14C9C88DFECADF9DB09F35062E34" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_098F14C9C88DFECADF9DB09F35062E34_label_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends_098F14C9C88DFECADF9DB09F35062E34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Ordinary Dividends</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_098F14C9C88DFECADF9DB09F35062E34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfOrdinaryDividends_098F14C9C88DFECADF9DB09F35062E34" xlink:to="lab_us-gaap_PaymentsOfOrdinaryDividends_098F14C9C88DFECADF9DB09F35062E34" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_E3CFAA769C9D314B26E6B09F35065DE5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_E3CFAA769C9D314B26E6B09F35065DE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_E3CFAA769C9D314B26E6B09F35065DE5_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_E3CFAA769C9D314B26E6B09F35065DE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_E3CFAA769C9D314B26E6B09F35065DE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_E3CFAA769C9D314B26E6B09F35065DE5" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_E3CFAA769C9D314B26E6B09F35065DE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_FB23C669B16D99CC73B7B09F35066096_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_FB23C669B16D99CC73B7B09F35066096" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financing activities, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_FB23C669B16D99CC73B7B09F35066096_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_FB23C669B16D99CC73B7B09F35066096" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_FB23C669B16D99CC73B7B09F35066096" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_FB23C669B16D99CC73B7B09F35066096" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_FB23C669B16D99CC73B7B09F35066096" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0738DDC4F5C74CD90825B09F35076607_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0738DDC4F5C74CD90825B09F35076607" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by/(used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0738DDC4F5C74CD90825B09F35076607_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0738DDC4F5C74CD90825B09F35076607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0738DDC4F5C74CD90825B09F35076607" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0738DDC4F5C74CD90825B09F35076607" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0738DDC4F5C74CD90825B09F35076607" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_941081B0388296E687C8B09F35071876_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_941081B0388296E687C8B09F35071876" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_941081B0388296E687C8B09F35071876_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_941081B0388296E687C8B09F35071876" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_941081B0388296E687C8B09F35071876" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_941081B0388296E687C8B09F35071876" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_941081B0388296E687C8B09F35071876" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_FBEF67F3E0C518DD0310B09F35076330_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_FBEF67F3E0C518DD0310B09F35076330" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash and cash equivalents and restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_FBEF67F3E0C518DD0310B09F35076330_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_FBEF67F3E0C518DD0310B09F35076330" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_FBEF67F3E0C518DD0310B09F35076330" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_FBEF67F3E0C518DD0310B09F35076330" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_FBEF67F3E0C518DD0310B09F35076330" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_76EB5B7729FE2845D9C6B09F3507A719_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_76EB5B7729FE2845D9C6B09F3507A719" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents and restricted cash and cash equivalents, beginning</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_76EB5B7729FE2845D9C6B09F3507A719_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_76EB5B7729FE2845D9C6B09F3507A719" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_76EB5B7729FE2845D9C6B09F3507A719" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_76EB5B7729FE2845D9C6B09F3507A719" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_76EB5B7729FE2845D9C6B09F3507A719" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_B119F1D006BC16B78558B09F3507D4A6_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_B119F1D006BC16B78558B09F3507D4A6" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents and restricted cash and cash equivalents, end</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_B119F1D006BC16B78558B09F3507D4A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_B119F1D006BC16B78558B09F3507D4A6" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_B119F1D006BC16B78558B09F3507D4A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_212B882E60CC37F26873B09F35075754_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_212B882E60CC37F26873B09F35075754" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_212B882E60CC37F26873B09F35075754_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_212B882E60CC37F26873B09F35075754" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_212B882E60CC37F26873B09F35075754" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_212B882E60CC37F26873B09F35075754" xlink:to="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_212B882E60CC37F26873B09F35075754" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_0F727EA5C8ECC2B87F0DB09F3507D025_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_0F727EA5C8ECC2B87F0DB09F3507D025" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid (received) during the period for:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_0F727EA5C8ECC2B87F0DB09F3507D025_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_0F727EA5C8ECC2B87F0DB09F3507D025" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_0F727EA5C8ECC2B87F0DB09F3507D025" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0F727EA5C8ECC2B87F0DB09F3507D025" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_0F727EA5C8ECC2B87F0DB09F3507D025" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_016FF852DC5BDF2062FEB09F35085F40_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_016FF852DC5BDF2062FEB09F35085F40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_016FF852DC5BDF2062FEB09F35085F40_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_016FF852DC5BDF2062FEB09F35085F40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_016FF852DC5BDF2062FEB09F35085F40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_016FF852DC5BDF2062FEB09F35085F40" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_016FF852DC5BDF2062FEB09F35085F40" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_EA73C7AE3CEAC80AC5B7B09F35087C17_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_EA73C7AE3CEAC80AC5B7B09F35087C17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_EA73C7AE3CEAC80AC5B7B09F35087C17_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_EA73C7AE3CEAC80AC5B7B09F35087C17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_EA73C7AE3CEAC80AC5B7B09F35087C17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_EA73C7AE3CEAC80AC5B7B09F35087C17" xlink:to="lab_us-gaap_InterestPaidNet_EA73C7AE3CEAC80AC5B7B09F35087C17" xlink:type="arc" />
    <link:label id="lab_pfe_InterestReceivedInterestRateHedges_4AD8909626E96B84DA9AB09F35088C73_terseLabel_en-US" xlink:label="lab_pfe_InterestReceivedInterestRateHedges_4AD8909626E96B84DA9AB09F35088C73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate hedges</link:label>
    <link:label id="lab_pfe_InterestReceivedInterestRateHedges_4AD8909626E96B84DA9AB09F35088C73_label_en-US" xlink:label="lab_pfe_InterestReceivedInterestRateHedges_4AD8909626E96B84DA9AB09F35088C73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Received, Interest Rate Hedges</link:label>
    <link:label id="lab_pfe_InterestReceivedInterestRateHedges_4AD8909626E96B84DA9AB09F35088C73_documentation_en-US" xlink:label="lab_pfe_InterestReceivedInterestRateHedges_4AD8909626E96B84DA9AB09F35088C73" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Received, Interest Rate Hedges</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_InterestReceivedInterestRateHedges" xlink:label="loc_pfe_InterestReceivedInterestRateHedges_4AD8909626E96B84DA9AB09F35088C73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InterestReceivedInterestRateHedges_4AD8909626E96B84DA9AB09F35088C73" xlink:to="lab_pfe_InterestReceivedInterestRateHedges_4AD8909626E96B84DA9AB09F35088C73" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_15F6C1B4DC25B5F65FD2947622E806A6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_15F6C1B4DC25B5F65FD2947622E806A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Inventories, Current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_15F6C1B4DC25B5F65FD2947622E806A6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_15F6C1B4DC25B5F65FD2947622E806A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_15F6C1B4DC25B5F65FD2947622E806A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_15F6C1B4DC25B5F65FD2947622E806A6" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_15F6C1B4DC25B5F65FD2947622E806A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_99EA840B19C0FA39F211947622E8B66F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_99EA840B19C0FA39F211947622E8B66F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Inventories, Noncurrent</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_99EA840B19C0FA39F211947622E8B66F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_99EA840B19C0FA39F211947622E8B66F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Noncurrent [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_99EA840B19C0FA39F211947622E8B66F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_99EA840B19C0FA39F211947622E8B66F" xlink:to="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_99EA840B19C0FA39F211947622E8B66F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3340373767B9A73C3A3194761FD99A7E_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3340373767B9A73C3A3194761FD99A7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3340373767B9A73C3A3194761FD99A7E_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3340373767B9A73C3A3194761FD99A7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3340373767B9A73C3A3194761FD99A7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3340373767B9A73C3A3194761FD99A7E" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3340373767B9A73C3A3194761FD99A7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_505CAA990CCD33F08ED694761FDA6CB6_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_505CAA990CCD33F08ED694761FDA6CB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption of New Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_505CAA990CCD33F08ED694761FDA6CB6_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_505CAA990CCD33F08ED694761FDA6CB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_505CAA990CCD33F08ED694761FDA6CB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_505CAA990CCD33F08ED694761FDA6CB6" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_505CAA990CCD33F08ED694761FDA6CB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_C1986B35B5ED20B8AD72947620A7D880_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_C1986B35B5ED20B8AD72947620A7D880" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_C1986B35B5ED20B8AD72947620A7D880_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_C1986B35B5ED20B8AD72947620A7D880" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_C1986B35B5ED20B8AD72947620A7D880" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_C1986B35B5ED20B8AD72947620A7D880" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_C1986B35B5ED20B8AD72947620A7D880" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_A2FCB216F508791B78B863507883F389_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_A2FCB216F508791B78B863507883F389" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_A2FCB216F508791B78B863507883F389_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_A2FCB216F508791B78B863507883F389" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_A2FCB216F508791B78B863507883F389" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_A2FCB216F508791B78B863507883F389" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_A2FCB216F508791B78B863507883F389" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_21D376F4F39B79B35FAE63507883AD8B_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_21D376F4F39B79B35FAE63507883AD8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_21D376F4F39B79B35FAE63507883AD8B_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_21D376F4F39B79B35FAE63507883AD8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_21D376F4F39B79B35FAE63507883AD8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_21D376F4F39B79B35FAE63507883AD8B" xlink:to="lab_srt_StatementGeographicalAxis_21D376F4F39B79B35FAE63507883AD8B" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_AD61EBE7A36CEC685330635078836D50_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_AD61EBE7A36CEC685330635078836D50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_AD61EBE7A36CEC685330635078836D50_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_AD61EBE7A36CEC685330635078836D50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_AD61EBE7A36CEC685330635078836D50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_AD61EBE7A36CEC685330635078836D50" xlink:to="lab_srt_SegmentGeographicalDomain_AD61EBE7A36CEC685330635078836D50" xlink:type="arc" />
    <link:label id="lab_pfe_DevelopedEuropeMember_4995C6E81DF0A88576A2635078843445_terseLabel_en-US" xlink:label="lab_pfe_DevelopedEuropeMember_4995C6E81DF0A88576A2635078843445" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed Europe [Member]</link:label>
    <link:label id="lab_pfe_DevelopedEuropeMember_4995C6E81DF0A88576A2635078843445_label_en-US" xlink:label="lab_pfe_DevelopedEuropeMember_4995C6E81DF0A88576A2635078843445" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Europe [Member]</link:label>
    <link:label id="lab_pfe_DevelopedEuropeMember_4995C6E81DF0A88576A2635078843445_documentation_en-US" xlink:label="lab_pfe_DevelopedEuropeMember_4995C6E81DF0A88576A2635078843445" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Developed Europe [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DevelopedEuropeMember" xlink:label="loc_pfe_DevelopedEuropeMember_4995C6E81DF0A88576A2635078843445" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DevelopedEuropeMember_4995C6E81DF0A88576A2635078843445" xlink:to="lab_pfe_DevelopedEuropeMember_4995C6E81DF0A88576A2635078843445" xlink:type="arc" />
    <link:label id="lab_pfe_DevelopedRestOfWorldMember_BFF0DB7C007505E2A058635078847232_terseLabel_en-US" xlink:label="lab_pfe_DevelopedRestOfWorldMember_BFF0DB7C007505E2A058635078847232" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed Rest Of World [Member]</link:label>
    <link:label id="lab_pfe_DevelopedRestOfWorldMember_BFF0DB7C007505E2A058635078847232_label_en-US" xlink:label="lab_pfe_DevelopedRestOfWorldMember_BFF0DB7C007505E2A058635078847232" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Rest Of World [Member]</link:label>
    <link:label id="lab_pfe_DevelopedRestOfWorldMember_BFF0DB7C007505E2A058635078847232_documentation_en-US" xlink:label="lab_pfe_DevelopedRestOfWorldMember_BFF0DB7C007505E2A058635078847232" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Developed Rest Of World [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DevelopedRestOfWorldMember" xlink:label="loc_pfe_DevelopedRestOfWorldMember_BFF0DB7C007505E2A058635078847232" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DevelopedRestOfWorldMember_BFF0DB7C007505E2A058635078847232" xlink:to="lab_pfe_DevelopedRestOfWorldMember_BFF0DB7C007505E2A058635078847232" xlink:type="arc" />
    <link:label id="lab_pfe_EmergingMarketsMember_DC4C4EBD8A9740D19CB663507884B64E_terseLabel_en-US" xlink:label="lab_pfe_EmergingMarketsMember_DC4C4EBD8A9740D19CB663507884B64E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Emerging Markets [Member]</link:label>
    <link:label id="lab_pfe_EmergingMarketsMember_DC4C4EBD8A9740D19CB663507884B64E_label_en-US" xlink:label="lab_pfe_EmergingMarketsMember_DC4C4EBD8A9740D19CB663507884B64E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Emerging Markets [Member]</link:label>
    <link:label id="lab_pfe_EmergingMarketsMember_DC4C4EBD8A9740D19CB663507884B64E_documentation_en-US" xlink:label="lab_pfe_EmergingMarketsMember_DC4C4EBD8A9740D19CB663507884B64E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Emerging Markets [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EmergingMarketsMember" xlink:label="loc_pfe_EmergingMarketsMember_DC4C4EBD8A9740D19CB663507884B64E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EmergingMarketsMember_DC4C4EBD8A9740D19CB663507884B64E" xlink:to="lab_pfe_EmergingMarketsMember_DC4C4EBD8A9740D19CB663507884B64E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_573119C434DA154B2D00635078848B7F_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_573119C434DA154B2D00635078848B7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_573119C434DA154B2D00635078848B7F_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_573119C434DA154B2D00635078848B7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_573119C434DA154B2D00635078848B7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_573119C434DA154B2D00635078848B7F" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_573119C434DA154B2D00635078848B7F" xlink:type="arc" />
    <link:label id="lab_pfe_PercentageChangeInRevenue_F7E70A69F1F08DFD33C86350788518A3_terseLabel_en-US" xlink:label="lab_pfe_PercentageChangeInRevenue_F7E70A69F1F08DFD33C86350788518A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage Change In Revenue</link:label>
    <link:label id="lab_pfe_PercentageChangeInRevenue_F7E70A69F1F08DFD33C86350788518A3_label_en-US" xlink:label="lab_pfe_PercentageChangeInRevenue_F7E70A69F1F08DFD33C86350788518A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Change In Revenue</link:label>
    <link:label id="lab_pfe_PercentageChangeInRevenue_F7E70A69F1F08DFD33C86350788518A3_documentation_en-US" xlink:label="lab_pfe_PercentageChangeInRevenue_F7E70A69F1F08DFD33C86350788518A3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage change in revenue.</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PercentageChangeInRevenue" xlink:label="loc_pfe_PercentageChangeInRevenue_F7E70A69F1F08DFD33C86350788518A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PercentageChangeInRevenue_F7E70A69F1F08DFD33C86350788518A3" xlink:to="lab_pfe_PercentageChangeInRevenue_F7E70A69F1F08DFD33C86350788518A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_209FE8CA7FF7D79FC32F92D1CA542EEB_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_209FE8CA7FF7D79FC32F92D1CA542EEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_209FE8CA7FF7D79FC32F92D1CA542EEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_209FE8CA7FF7D79FC32F92D1CA542EEB" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_209FE8CA7FF7D79FC32F92D1CA542EEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4A30979B3116BE9976BE92D1CA5482AC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4A30979B3116BE9976BE92D1CA5482AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4A30979B3116BE9976BE92D1CA5482AC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4A30979B3116BE9976BE92D1CA5482AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4A30979B3116BE9976BE92D1CA5482AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4A30979B3116BE9976BE92D1CA5482AC" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4A30979B3116BE9976BE92D1CA5482AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0EF6DA3D7AC7481E1D8192D1CA54F421_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0EF6DA3D7AC7481E1D8192D1CA54F421" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0EF6DA3D7AC7481E1D8192D1CA54F421_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0EF6DA3D7AC7481E1D8192D1CA54F421" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0EF6DA3D7AC7481E1D8192D1CA54F421" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0EF6DA3D7AC7481E1D8192D1CA54F421" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0EF6DA3D7AC7481E1D8192D1CA54F421" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_89F1A7302A30951866CF92D1CA5547EB_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_89F1A7302A30951866CF92D1CA5547EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_89F1A7302A30951866CF92D1CA5547EB_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_89F1A7302A30951866CF92D1CA5547EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_89F1A7302A30951866CF92D1CA5547EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_89F1A7302A30951866CF92D1CA5547EB" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_89F1A7302A30951866CF92D1CA5547EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_6EEA9FA8374582689B7D92D1CA558133_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_6EEA9FA8374582689B7D92D1CA558133" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_6EEA9FA8374582689B7D92D1CA558133_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_6EEA9FA8374582689B7D92D1CA558133" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_6EEA9FA8374582689B7D92D1CA558133" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember_6EEA9FA8374582689B7D92D1CA558133" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember_6EEA9FA8374582689B7D92D1CA558133" xlink:type="arc" />
    <link:label id="lab_pfe_LicensingAgreementsAndOtherMember_34C9B4A5EC29300DA7C492D1CA5578BC_terseLabel_en-US" xlink:label="lab_pfe_LicensingAgreementsAndOtherMember_34C9B4A5EC29300DA7C492D1CA5578BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreements and Other [Member]</link:label>
    <link:label id="lab_pfe_LicensingAgreementsAndOtherMember_34C9B4A5EC29300DA7C492D1CA5578BC_label_en-US" xlink:label="lab_pfe_LicensingAgreementsAndOtherMember_34C9B4A5EC29300DA7C492D1CA5578BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreements And Other [Member]</link:label>
    <link:label id="lab_pfe_LicensingAgreementsAndOtherMember_34C9B4A5EC29300DA7C492D1CA5578BC_documentation_en-US" xlink:label="lab_pfe_LicensingAgreementsAndOtherMember_34C9B4A5EC29300DA7C492D1CA5578BC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Licensing Agreements And Other [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LicensingAgreementsAndOtherMember" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_34C9B4A5EC29300DA7C492D1CA5578BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LicensingAgreementsAndOtherMember_34C9B4A5EC29300DA7C492D1CA5578BC" xlink:to="lab_pfe_LicensingAgreementsAndOtherMember_34C9B4A5EC29300DA7C492D1CA5578BC" xlink:type="arc" />
    <link:label id="lab_pfe_BraftoviMember_1C3649674142955437B692D1CA575406_terseLabel_en-US" xlink:label="lab_pfe_BraftoviMember_1C3649674142955437B692D1CA575406" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Braftovi [Member]</link:label>
    <link:label id="lab_pfe_BraftoviMember_1C3649674142955437B692D1CA575406_label_en-US" xlink:label="lab_pfe_BraftoviMember_1C3649674142955437B692D1CA575406" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Braftovi [Member]</link:label>
    <link:label id="lab_pfe_BraftoviMember_1C3649674142955437B692D1CA575406_documentation_en-US" xlink:label="lab_pfe_BraftoviMember_1C3649674142955437B692D1CA575406" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Braftovi [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BraftoviMember" xlink:label="loc_pfe_BraftoviMember_1C3649674142955437B692D1CA575406" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BraftoviMember_1C3649674142955437B692D1CA575406" xlink:to="lab_pfe_BraftoviMember_1C3649674142955437B692D1CA575406" xlink:type="arc" />
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_DA0A3F34231442BD935392D1CA58958D_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_DA0A3F34231442BD935392D1CA58958D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_DA0A3F34231442BD935392D1CA58958D_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_DA0A3F34231442BD935392D1CA58958D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_DA0A3F34231442BD935392D1CA58958D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember_DA0A3F34231442BD935392D1CA58958D" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember_DA0A3F34231442BD935392D1CA58958D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_B6E7BE6C0D8351124AF792D1CA5815B2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_B6E7BE6C0D8351124AF792D1CA5815B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_B6E7BE6C0D8351124AF792D1CA5815B2_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_B6E7BE6C0D8351124AF792D1CA5815B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B6E7BE6C0D8351124AF792D1CA5815B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B6E7BE6C0D8351124AF792D1CA5815B2" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_B6E7BE6C0D8351124AF792D1CA5815B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_7B887AEC61B06260D0D792D1CA585718_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_7B887AEC61B06260D0D792D1CA585718" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived intangible assets, period increase (decrease)</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_7B887AEC61B06260D0D792D1CA585718_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_7B887AEC61B06260D0D792D1CA585718" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_7B887AEC61B06260D0D792D1CA585718" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_7B887AEC61B06260D0D792D1CA585718" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_7B887AEC61B06260D0D792D1CA585718" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_DB4B648042AFCC5B721092D1CA5948BE_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_DB4B648042AFCC5B721092D1CA5948BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible assets period increase (decrease)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_DB4B648042AFCC5B721092D1CA5948BE_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_DB4B648042AFCC5B721092D1CA5948BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_DB4B648042AFCC5B721092D1CA5948BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_DB4B648042AFCC5B721092D1CA5948BE" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_DB4B648042AFCC5B721092D1CA5948BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_1038DA6CDB9CD87082199476220FE523_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_1038DA6CDB9CD87082199476220FE523" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment, Geographic and Other Revenue Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_1038DA6CDB9CD87082199476220FE523_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_1038DA6CDB9CD87082199476220FE523" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_1038DA6CDB9CD87082199476220FE523" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock_1038DA6CDB9CD87082199476220FE523" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock_1038DA6CDB9CD87082199476220FE523" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_4EC4487C0B55E76A44A5947622E46AFF_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_4EC4487C0B55E76A44A5947622E46AFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4EC4487C0B55E76A44A5947622E46AFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4EC4487C0B55E76A44A5947622E46AFF" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_4EC4487C0B55E76A44A5947622E46AFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_F6EA285DFED6C8E7549D947622E4987F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_F6EA285DFED6C8E7549D947622E4987F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Matters</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_F6EA285DFED6C8E7549D947622E4987F_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_F6EA285DFED6C8E7549D947622E4987F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_F6EA285DFED6C8E7549D947622E4987F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_F6EA285DFED6C8E7549D947622E4987F" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_F6EA285DFED6C8E7549D947622E4987F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_5C60DB7C2A2BFD48822978FDDF8CF660_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract_5C60DB7C2A2BFD48822978FDDF8CF660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_5C60DB7C2A2BFD48822978FDDF8CF660" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5C60DB7C2A2BFD48822978FDDF8CF660" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract_5C60DB7C2A2BFD48822978FDDF8CF660" xlink:type="arc" />
    <link:label id="lab_pfe_GeneTherapiesMember_F081BED22814113DE0A878FDDF8E48B3_terseLabel_en-US" xlink:label="lab_pfe_GeneTherapiesMember_F081BED22814113DE0A878FDDF8E48B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gene Therapies [Member]</link:label>
    <link:label id="lab_pfe_GeneTherapiesMember_F081BED22814113DE0A878FDDF8E48B3_label_en-US" xlink:label="lab_pfe_GeneTherapiesMember_F081BED22814113DE0A878FDDF8E48B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gene Therapies [Member]</link:label>
    <link:label id="lab_pfe_GeneTherapiesMember_F081BED22814113DE0A878FDDF8E48B3_documentation_en-US" xlink:label="lab_pfe_GeneTherapiesMember_F081BED22814113DE0A878FDDF8E48B3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gene Therapies [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_GeneTherapiesMember" xlink:label="loc_pfe_GeneTherapiesMember_F081BED22814113DE0A878FDDF8E48B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GeneTherapiesMember_F081BED22814113DE0A878FDDF8E48B3" xlink:to="lab_pfe_GeneTherapiesMember_F081BED22814113DE0A878FDDF8E48B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsegmentsAxis_2BB12DCA1A6ABCEC286F78FDDF9088BD_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis_2BB12DCA1A6ABCEC286F78FDDF9088BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_2BB12DCA1A6ABCEC286F78FDDF9088BD_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis_2BB12DCA1A6ABCEC286F78FDDF9088BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsAxis" xlink:label="loc_us-gaap_SubsegmentsAxis_2BB12DCA1A6ABCEC286F78FDDF9088BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis_2BB12DCA1A6ABCEC286F78FDDF9088BD" xlink:to="lab_us-gaap_SubsegmentsAxis_2BB12DCA1A6ABCEC286F78FDDF9088BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsegmentsDomain_98FCE16A7051F014309E78FDDF90BEC6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain_98FCE16A7051F014309E78FDDF90BEC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_98FCE16A7051F014309E78FDDF90BEC6_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain_98FCE16A7051F014309E78FDDF90BEC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_98FCE16A7051F014309E78FDDF90BEC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain_98FCE16A7051F014309E78FDDF90BEC6" xlink:to="lab_us-gaap_SubsegmentsDomain_98FCE16A7051F014309E78FDDF90BEC6" xlink:type="arc" />
    <link:label id="lab_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_90AD4A79C4B2C45B167778FDDF9024AA_verboseLabel_en-US" xlink:label="lab_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_90AD4A79C4B2C45B167778FDDF9024AA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">WRDM [Member]</link:label>
    <link:label id="lab_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_90AD4A79C4B2C45B167778FDDF9024AA_label_en-US" xlink:label="lab_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_90AD4A79C4B2C45B167778FDDF9024AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer's Worldwide Research, Development And Medical [Member]</link:label>
    <link:label id="lab_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_90AD4A79C4B2C45B167778FDDF9024AA_documentation_en-US" xlink:label="lab_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_90AD4A79C4B2C45B167778FDDF9024AA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer's Worldwide Research, Development And Medical [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember" xlink:label="loc_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_90AD4A79C4B2C45B167778FDDF9024AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_90AD4A79C4B2C45B167778FDDF9024AA" xlink:to="lab_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_90AD4A79C4B2C45B167778FDDF9024AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_8F6D2F0972C38D6A607578FDDF92DF18_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_8F6D2F0972C38D6A607578FDDF92DF18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposed of by Sale [Member]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_8F6D2F0972C38D6A607578FDDF92DF18_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_8F6D2F0972C38D6A607578FDDF92DF18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_8F6D2F0972C38D6A607578FDDF92DF18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_8F6D2F0972C38D6A607578FDDF92DF18" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_8F6D2F0972C38D6A607578FDDF92DF18" xlink:type="arc" />
    <link:label id="lab_pfe_CK1AssetsSoldToBiogenIncMember_90B61E774EFCEF6FEB0F78FDDF93EEE1_terseLabel_en-US" xlink:label="lab_pfe_CK1AssetsSoldToBiogenIncMember_90B61E774EFCEF6FEB0F78FDDF93EEE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CK1 assets sold to Biogen, Inc [Member]</link:label>
    <link:label id="lab_pfe_CK1AssetsSoldToBiogenIncMember_90B61E774EFCEF6FEB0F78FDDF93EEE1_label_en-US" xlink:label="lab_pfe_CK1AssetsSoldToBiogenIncMember_90B61E774EFCEF6FEB0F78FDDF93EEE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CK1 Assets Sold To Biogen, Inc [Member]</link:label>
    <link:label id="lab_pfe_CK1AssetsSoldToBiogenIncMember_90B61E774EFCEF6FEB0F78FDDF93EEE1_documentation_en-US" xlink:label="lab_pfe_CK1AssetsSoldToBiogenIncMember_90B61E774EFCEF6FEB0F78FDDF93EEE1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CK1 Assets Sold To Biogen, Inc [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_CK1AssetsSoldToBiogenIncMember" xlink:label="loc_pfe_CK1AssetsSoldToBiogenIncMember_90B61E774EFCEF6FEB0F78FDDF93EEE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CK1AssetsSoldToBiogenIncMember_90B61E774EFCEF6FEB0F78FDDF93EEE1" xlink:to="lab_pfe_CK1AssetsSoldToBiogenIncMember_90B61E774EFCEF6FEB0F78FDDF93EEE1" xlink:type="arc" />
    <link:label id="lab_pfe_PumaTechnologiesMember_4A045F9C1FC1E8CCA34A78FDDF948E99_terseLabel_en-US" xlink:label="lab_pfe_PumaTechnologiesMember_4A045F9C1FC1E8CCA34A78FDDF948E99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Puma Technologies [Member]</link:label>
    <link:label id="lab_pfe_PumaTechnologiesMember_4A045F9C1FC1E8CCA34A78FDDF948E99_label_en-US" xlink:label="lab_pfe_PumaTechnologiesMember_4A045F9C1FC1E8CCA34A78FDDF948E99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Puma Technologies [Member]</link:label>
    <link:label id="lab_pfe_PumaTechnologiesMember_4A045F9C1FC1E8CCA34A78FDDF948E99_documentation_en-US" xlink:label="lab_pfe_PumaTechnologiesMember_4A045F9C1FC1E8CCA34A78FDDF948E99" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Puma Technologies [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PumaTechnologiesMember" xlink:label="loc_pfe_PumaTechnologiesMember_4A045F9C1FC1E8CCA34A78FDDF948E99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PumaTechnologiesMember_4A045F9C1FC1E8CCA34A78FDDF948E99" xlink:to="lab_pfe_PumaTechnologiesMember_4A045F9C1FC1E8CCA34A78FDDF948E99" xlink:type="arc" />
    <link:label id="lab_pfe_EliLillyCompanyMember_F8848A67BFBE74A71F3378FDDF993672_terseLabel_en-US" xlink:label="lab_pfe_EliLillyCompanyMember_F8848A67BFBE74A71F3378FDDF993672" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eli Lilly &amp; Company [Member]</link:label>
    <link:label id="lab_pfe_EliLillyCompanyMember_F8848A67BFBE74A71F3378FDDF993672_label_en-US" xlink:label="lab_pfe_EliLillyCompanyMember_F8848A67BFBE74A71F3378FDDF993672" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eli Lilly &amp; Company [Member]</link:label>
    <link:label id="lab_pfe_EliLillyCompanyMember_F8848A67BFBE74A71F3378FDDF993672_documentation_en-US" xlink:label="lab_pfe_EliLillyCompanyMember_F8848A67BFBE74A71F3378FDDF993672" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eli Lilly &amp; Company [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EliLillyCompanyMember" xlink:label="loc_pfe_EliLillyCompanyMember_F8848A67BFBE74A71F3378FDDF993672" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EliLillyCompanyMember_F8848A67BFBE74A71F3378FDDF993672" xlink:to="lab_pfe_EliLillyCompanyMember_F8848A67BFBE74A71F3378FDDF993672" xlink:type="arc" />
    <link:label id="lab_pfe_MylanMember_F59F81BE5EB8C382AC5F78FDDF99E8D1_terseLabel_en-US" xlink:label="lab_pfe_MylanMember_F59F81BE5EB8C382AC5F78FDDF99E8D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mylan [Member]</link:label>
    <link:label id="lab_pfe_MylanMember_F59F81BE5EB8C382AC5F78FDDF99E8D1_label_en-US" xlink:label="lab_pfe_MylanMember_F59F81BE5EB8C382AC5F78FDDF99E8D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mylan [Member]</link:label>
    <link:label id="lab_pfe_MylanMember_F59F81BE5EB8C382AC5F78FDDF99E8D1_documentation_en-US" xlink:label="lab_pfe_MylanMember_F59F81BE5EB8C382AC5F78FDDF99E8D1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mylan [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_MylanMember" xlink:label="loc_pfe_MylanMember_F59F81BE5EB8C382AC5F78FDDF99E8D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_MylanMember_F59F81BE5EB8C382AC5F78FDDF99E8D1" xlink:to="lab_pfe_MylanMember_F59F81BE5EB8C382AC5F78FDDF99E8D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_DB3FB0692FF0B74F463078FDDF991C0F_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_DB3FB0692FF0B74F463078FDDF991C0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_DB3FB0692FF0B74F463078FDDF991C0F_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_DB3FB0692FF0B74F463078FDDF991C0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_DB3FB0692FF0B74F463078FDDF991C0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_DB3FB0692FF0B74F463078FDDF991C0F" xlink:to="lab_us-gaap_TypeOfArrangementAxis_DB3FB0692FF0B74F463078FDDF991C0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_68EE34F5DFD56226EF6678FDDF9A230B_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_68EE34F5DFD56226EF6678FDDF9A230B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_68EE34F5DFD56226EF6678FDDF9A230B_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_68EE34F5DFD56226EF6678FDDF9A230B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_68EE34F5DFD56226EF6678FDDF9A230B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_68EE34F5DFD56226EF6678FDDF9A230B" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_68EE34F5DFD56226EF6678FDDF9A230B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_73FF4EE06B22FF04B44978FDDF9A32B5_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_73FF4EE06B22FF04B44978FDDF9A32B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_73FF4EE06B22FF04B44978FDDF9A32B5_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_73FF4EE06B22FF04B44978FDDF9A32B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_73FF4EE06B22FF04B44978FDDF9A32B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember_73FF4EE06B22FF04B44978FDDF9A32B5" xlink:to="lab_us-gaap_CollaborativeArrangementMember_73FF4EE06B22FF04B44978FDDF9A32B5" xlink:type="arc" />
    <link:label id="lab_pfe_AllogeneMember_02C1E07DB82846574EBB78FDDF9B556F_terseLabel_en-US" xlink:label="lab_pfe_AllogeneMember_02C1E07DB82846574EBB78FDDF9B556F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allogene [Member]</link:label>
    <link:label id="lab_pfe_AllogeneMember_02C1E07DB82846574EBB78FDDF9B556F_label_en-US" xlink:label="lab_pfe_AllogeneMember_02C1E07DB82846574EBB78FDDF9B556F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allogene [Member]</link:label>
    <link:label id="lab_pfe_AllogeneMember_02C1E07DB82846574EBB78FDDF9B556F_documentation_en-US" xlink:label="lab_pfe_AllogeneMember_02C1E07DB82846574EBB78FDDF9B556F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allogene [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AllogeneMember" xlink:label="loc_pfe_AllogeneMember_02C1E07DB82846574EBB78FDDF9B556F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AllogeneMember_02C1E07DB82846574EBB78FDDF9B556F" xlink:to="lab_pfe_AllogeneMember_02C1E07DB82846574EBB78FDDF9B556F" xlink:type="arc" />
    <link:label id="lab_pfe_BioNTechSEMember_BBD9F34220B9E3785F1C78FDDF9B4457_terseLabel_en-US" xlink:label="lab_pfe_BioNTechSEMember_BBD9F34220B9E3785F1C78FDDF9B4457" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech SE [Member]</link:label>
    <link:label id="lab_pfe_BioNTechSEMember_BBD9F34220B9E3785F1C78FDDF9B4457_label_en-US" xlink:label="lab_pfe_BioNTechSEMember_BBD9F34220B9E3785F1C78FDDF9B4457" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech SE [Member]</link:label>
    <link:label id="lab_pfe_BioNTechSEMember_BBD9F34220B9E3785F1C78FDDF9B4457_documentation_en-US" xlink:label="lab_pfe_BioNTechSEMember_BBD9F34220B9E3785F1C78FDDF9B4457" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech SE [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BioNTechSEMember" xlink:label="loc_pfe_BioNTechSEMember_BBD9F34220B9E3785F1C78FDDF9B4457" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BioNTechSEMember_BBD9F34220B9E3785F1C78FDDF9B4457" xlink:to="lab_pfe_BioNTechSEMember_BBD9F34220B9E3785F1C78FDDF9B4457" xlink:type="arc" />
    <link:label id="lab_pfe_CortexymeInc.Member_251078E406455CB0A52878FDDF9B8B35_terseLabel_en-US" xlink:label="lab_pfe_CortexymeInc.Member_251078E406455CB0A52878FDDF9B8B35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cortexyme, Inc. [Member]</link:label>
    <link:label id="lab_pfe_CortexymeInc.Member_251078E406455CB0A52878FDDF9B8B35_label_en-US" xlink:label="lab_pfe_CortexymeInc.Member_251078E406455CB0A52878FDDF9B8B35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cortexyme, Inc. [Member]</link:label>
    <link:label id="lab_pfe_CortexymeInc.Member_251078E406455CB0A52878FDDF9B8B35_documentation_en-US" xlink:label="lab_pfe_CortexymeInc.Member_251078E406455CB0A52878FDDF9B8B35" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cortexyme, Inc. [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_CortexymeInc.Member" xlink:label="loc_pfe_CortexymeInc.Member_251078E406455CB0A52878FDDF9B8B35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CortexymeInc.Member_251078E406455CB0A52878FDDF9B8B35" xlink:to="lab_pfe_CortexymeInc.Member_251078E406455CB0A52878FDDF9B8B35" xlink:type="arc" />
    <link:label id="lab_pfe_KingMember_6F5D3BAB839D0F7744EC78FDDF9B7F8E_terseLabel_en-US" xlink:label="lab_pfe_KingMember_6F5D3BAB839D0F7744EC78FDDF9B7F8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">King [Member]</link:label>
    <link:label id="lab_pfe_KingMember_6F5D3BAB839D0F7744EC78FDDF9B7F8E_label_en-US" xlink:label="lab_pfe_KingMember_6F5D3BAB839D0F7744EC78FDDF9B7F8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">King [Member]</link:label>
    <link:label id="lab_pfe_KingMember_6F5D3BAB839D0F7744EC78FDDF9B7F8E_documentation_en-US" xlink:label="lab_pfe_KingMember_6F5D3BAB839D0F7744EC78FDDF9B7F8E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">King [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_KingMember" xlink:label="loc_pfe_KingMember_6F5D3BAB839D0F7744EC78FDDF9B7F8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_KingMember_6F5D3BAB839D0F7744EC78FDDF9B7F8E" xlink:to="lab_pfe_KingMember_6F5D3BAB839D0F7744EC78FDDF9B7F8E" xlink:type="arc" />
    <link:label id="lab_pfe_AnacorMember_3F3427A5FF2C0DA3818778FDDF9B5257_terseLabel_en-US" xlink:label="lab_pfe_AnacorMember_3F3427A5FF2C0DA3818778FDDF9B5257" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anacor [Member]</link:label>
    <link:label id="lab_pfe_AnacorMember_3F3427A5FF2C0DA3818778FDDF9B5257_label_en-US" xlink:label="lab_pfe_AnacorMember_3F3427A5FF2C0DA3818778FDDF9B5257" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anacor [Member]</link:label>
    <link:label id="lab_pfe_AnacorMember_3F3427A5FF2C0DA3818778FDDF9B5257_documentation_en-US" xlink:label="lab_pfe_AnacorMember_3F3427A5FF2C0DA3818778FDDF9B5257" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Anacor [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AnacorMember" xlink:label="loc_pfe_AnacorMember_3F3427A5FF2C0DA3818778FDDF9B5257" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AnacorMember_3F3427A5FF2C0DA3818778FDDF9B5257" xlink:to="lab_pfe_AnacorMember_3F3427A5FF2C0DA3818778FDDF9B5257" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromLegalSettlements_77B7CE04FB1CED841F4178FDDF9C171B_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLegalSettlements_77B7CE04FB1CED841F4178FDDF9C171B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from legal dispute</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLegalSettlements_77B7CE04FB1CED841F4178FDDF9C171B_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLegalSettlements_77B7CE04FB1CED841F4178FDDF9C171B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Legal Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="loc_us-gaap_ProceedsFromLegalSettlements_77B7CE04FB1CED841F4178FDDF9C171B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLegalSettlements_77B7CE04FB1CED841F4178FDDF9C171B" xlink:to="lab_us-gaap_ProceedsFromLegalSettlements_77B7CE04FB1CED841F4178FDDF9C171B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7626C776657E126AC4FA78FDDF9CD98A_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7626C776657E126AC4FA78FDDF9CD98A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7626C776657E126AC4FA78FDDF9CD98A_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7626C776657E126AC4FA78FDDF9CD98A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7626C776657E126AC4FA78FDDF9CD98A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7626C776657E126AC4FA78FDDF9CD98A" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7626C776657E126AC4FA78FDDF9CD98A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_94FDED715D49CB8641C478FDDF9C0AED_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_94FDED715D49CB8641C478FDDF9C0AED" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_94FDED715D49CB8641C478FDDF9C0AED_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_94FDED715D49CB8641C478FDDF9C0AED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_94FDED715D49CB8641C478FDDF9C0AED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_94FDED715D49CB8641C478FDDF9C0AED" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_94FDED715D49CB8641C478FDDF9C0AED" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_C9E0367BF85EDC2FF72C78FDDF9C261D_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators_C9E0367BF85EDC2FF72C78FDDF9C261D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_C9E0367BF85EDC2FF72C78FDDF9C261D_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators_C9E0367BF85EDC2FF72C78FDDF9C261D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="loc_us-gaap_ProceedsFromCollaborators_C9E0367BF85EDC2FF72C78FDDF9C261D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators_C9E0367BF85EDC2FF72C78FDDF9C261D" xlink:to="lab_us-gaap_ProceedsFromCollaborators_C9E0367BF85EDC2FF72C78FDDF9C261D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_91860A26E03A971E7CD178FDDF9D3DDD_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_91860A26E03A971E7CD178FDDF9D3DDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset impairment charge</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_91860A26E03A971E7CD178FDDF9D3DDD_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_91860A26E03A971E7CD178FDDF9D3DDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_91860A26E03A971E7CD178FDDF9D3DDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_91860A26E03A971E7CD178FDDF9D3DDD" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_91860A26E03A971E7CD178FDDF9D3DDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetImpairmentCharges_90E4EDFBB50803B9F5B278FDDF9DD9A6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetImpairmentCharges_90E4EDFBB50803B9F5B278FDDF9DD9A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other asset impairments</link:label>
    <link:label id="lab_us-gaap_OtherAssetImpairmentCharges_90E4EDFBB50803B9F5B278FDDF9DD9A6_label_en-US" xlink:label="lab_us-gaap_OtherAssetImpairmentCharges_90E4EDFBB50803B9F5B278FDDF9DD9A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Asset Impairment Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_90E4EDFBB50803B9F5B278FDDF9DD9A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetImpairmentCharges_90E4EDFBB50803B9F5B278FDDF9DD9A6" xlink:to="lab_us-gaap_OtherAssetImpairmentCharges_90E4EDFBB50803B9F5B278FDDF9DD9A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeDividend_D1004AFAE8A6032C328478FDDF9D57EF_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeDividend_D1004AFAE8A6032C328478FDDF9D57EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeDividend" xlink:label="loc_us-gaap_InvestmentIncomeDividend_D1004AFAE8A6032C328478FDDF9D57EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeDividend_D1004AFAE8A6032C328478FDDF9D57EF" xlink:to="lab_us-gaap_InvestmentIncomeDividend_D1004AFAE8A6032C328478FDDF9D57EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InsuranceRecoveries_227B4BC59F17202971AE78FDDF9D2F52_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InsuranceRecoveries_227B4BC59F17202971AE78FDDF9D2F52" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Insurance Recoveries</link:label>
    <link:label id="lab_us-gaap_InsuranceRecoveries_227B4BC59F17202971AE78FDDF9D2F52_label_en-US" xlink:label="lab_us-gaap_InsuranceRecoveries_227B4BC59F17202971AE78FDDF9D2F52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance Recoveries</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InsuranceRecoveries" xlink:label="loc_us-gaap_InsuranceRecoveries_227B4BC59F17202971AE78FDDF9D2F52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceRecoveries_227B4BC59F17202971AE78FDDF9D2F52" xlink:to="lab_us-gaap_InsuranceRecoveries_227B4BC59F17202971AE78FDDF9D2F52" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5D04B06DEF744BD9138078FDDF9DE441_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5D04B06DEF744BD9138078FDDF9DE441" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5D04B06DEF744BD9138078FDDF9DE441_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5D04B06DEF744BD9138078FDDF9DE441" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5D04B06DEF744BD9138078FDDF9DE441" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5D04B06DEF744BD9138078FDDF9DE441" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5D04B06DEF744BD9138078FDDF9DE441" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_609A70B309F58876CE85B5A4AEA8FC9B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_609A70B309F58876CE85B5A4AEA8FC9B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_609A70B309F58876CE85B5A4AEA8FC9B_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_609A70B309F58876CE85B5A4AEA8FC9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_609A70B309F58876CE85B5A4AEA8FC9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_609A70B309F58876CE85B5A4AEA8FC9B" xlink:to="lab_us-gaap_InvestmentIncomeInterest_609A70B309F58876CE85B5A4AEA8FC9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_C49B5D3BB765A0AD2EB2B5A4AEA87F86_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_C49B5D3BB765A0AD2EB2B5A4AEA87F86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_C49B5D3BB765A0AD2EB2B5A4AEA87F86_label_en-US" xlink:label="lab_us-gaap_InterestExpense_C49B5D3BB765A0AD2EB2B5A4AEA87F86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_C49B5D3BB765A0AD2EB2B5A4AEA87F86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_C49B5D3BB765A0AD2EB2B5A4AEA87F86" xlink:to="lab_us-gaap_InterestExpense_C49B5D3BB765A0AD2EB2B5A4AEA87F86" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestRevenueExpenseNet_DC754060A77076AB9901B5A4AEA92FB6_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_InterestRevenueExpenseNet_DC754060A77076AB9901B5A4AEA92FB6" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net interest expense</link:label>
    <link:label id="lab_us-gaap_InterestRevenueExpenseNet_DC754060A77076AB9901B5A4AEA92FB6_label_en-US" xlink:label="lab_us-gaap_InterestRevenueExpenseNet_DC754060A77076AB9901B5A4AEA92FB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Revenue (Expense), Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRevenueExpenseNet" xlink:label="loc_us-gaap_InterestRevenueExpenseNet_DC754060A77076AB9901B5A4AEA92FB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRevenueExpenseNet_DC754060A77076AB9901B5A4AEA92FB6" xlink:to="lab_us-gaap_InterestRevenueExpenseNet_DC754060A77076AB9901B5A4AEA92FB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_AFD2548125BC020E41BBB5A4AEA9C8C8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating_AFD2548125BC020E41BBB5A4AEA9C8C8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Royalty-related income</link:label>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_AFD2548125BC020E41BBB5A4AEA9C8C8_label_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating_AFD2548125BC020E41BBB5A4AEA9C8C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Income, Nonoperating</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_AFD2548125BC020E41BBB5A4AEA9C8C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyIncomeNonoperating_AFD2548125BC020E41BBB5A4AEA9C8C8" xlink:to="lab_us-gaap_RoyaltyIncomeNonoperating_AFD2548125BC020E41BBB5A4AEA9C8C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_2F12A5D990FA674BE439B5A4AEA98BB9_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1_2F12A5D990FA674BE439B5A4AEA98BB9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net (gains)/losses on asset disposals</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_2F12A5D990FA674BE439B5A4AEA98BB9_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1_2F12A5D990FA674BE439B5A4AEA98BB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_2F12A5D990FA674BE439B5A4AEA98BB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1_2F12A5D990FA674BE439B5A4AEA98BB9" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1_2F12A5D990FA674BE439B5A4AEA98BB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_EE59FB08C9492AEC30FBB5A4AEA97AE6_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss_EE59FB08C9492AEC30FBB5A4AEA97AE6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net gains recognized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_EE59FB08C9492AEC30FBB5A4AEA97AE6_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss_EE59FB08C9492AEC30FBB5A4AEA97AE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_EE59FB08C9492AEC30FBB5A4AEA97AE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_EE59FB08C9492AEC30FBB5A4AEA97AE6" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss_EE59FB08C9492AEC30FBB5A4AEA97AE6" xlink:type="arc" />
    <link:label id="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_EEF58D48B34B0B8CD7BCB5A4AEA9D53C_negatedTerseLabel_en-US" xlink:label="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_EEF58D48B34B0B8CD7BCB5A4AEA9D53C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income from collaborations, out-licensing arrangements and sales of compound/product rights</link:label>
    <link:label id="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_EEF58D48B34B0B8CD7BCB5A4AEA9D53C_label_en-US" xlink:label="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_EEF58D48B34B0B8CD7BCB5A4AEA9D53C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights</link:label>
    <link:label id="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_EEF58D48B34B0B8CD7BCB5A4AEA9D53C_documentation_en-US" xlink:label="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_EEF58D48B34B0B8CD7BCB5A4AEA9D53C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" xlink:label="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_EEF58D48B34B0B8CD7BCB5A4AEA9D53C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_EEF58D48B34B0B8CD7BCB5A4AEA9D53C" xlink:to="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_EEF58D48B34B0B8CD7BCB5A4AEA9D53C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_7ADC14CC974CDFEAFBFCB5A4AEAA3AD7_verboseLabel_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_7ADC14CC974CDFEAFBFCB5A4AEAA3AD7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net periodic benefit credits other than service costs</link:label>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_7ADC14CC974CDFEAFBFCB5A4AEAA3AD7_label_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_7ADC14CC974CDFEAFBFCB5A4AEAA3AD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_7ADC14CC974CDFEAFBFCB5A4AEAA3AD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_7ADC14CC974CDFEAFBFCB5A4AEAA3AD7" xlink:to="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_7ADC14CC974CDFEAFBFCB5A4AEAA3AD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_6B4E79AB391FE4DE569AB5A4AEAA74B9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement_6B4E79AB391FE4DE569AB5A4AEAA74B9" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Certain legal matters, net</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_6B4E79AB391FE4DE569AB5A4AEAA74B9_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement_6B4E79AB391FE4DE569AB5A4AEAA74B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_6B4E79AB391FE4DE569AB5A4AEAA74B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement_6B4E79AB391FE4DE569AB5A4AEAA74B9" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement_6B4E79AB391FE4DE569AB5A4AEAA74B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetImpairmentCharges_C92543AC0B28AE7C1235B5A4AEAA777C_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_C92543AC0B28AE7C1235B5A4AEAA777C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certain asset impairments</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_C92543AC0B28AE7C1235B5A4AEAA777C_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_C92543AC0B28AE7C1235B5A4AEAA777C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_C92543AC0B28AE7C1235B5A4AEAA777C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges_C92543AC0B28AE7C1235B5A4AEAA777C" xlink:to="lab_us-gaap_AssetImpairmentCharges_C92543AC0B28AE7C1235B5A4AEAA777C" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessAlignmentCosts_C61F4462AD9643BFF1ECB5A4AEAA7857_terseLabel_en-US" xlink:label="lab_pfe_BusinessAlignmentCosts_C61F4462AD9643BFF1ECB5A4AEAA7857" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business and legal entity alignment costs</link:label>
    <link:label id="lab_pfe_BusinessAlignmentCosts_C61F4462AD9643BFF1ECB5A4AEAA7857_label_en-US" xlink:label="lab_pfe_BusinessAlignmentCosts_C61F4462AD9643BFF1ECB5A4AEAA7857" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Alignment Costs</link:label>
    <link:label id="lab_pfe_BusinessAlignmentCosts_C61F4462AD9643BFF1ECB5A4AEAA7857_documentation_en-US" xlink:label="lab_pfe_BusinessAlignmentCosts_C61F4462AD9643BFF1ECB5A4AEAA7857" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Alignment Costs</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BusinessAlignmentCosts" xlink:label="loc_pfe_BusinessAlignmentCosts_C61F4462AD9643BFF1ECB5A4AEAA7857" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessAlignmentCosts_C61F4462AD9643BFF1ECB5A4AEAA7857" xlink:to="lab_pfe_BusinessAlignmentCosts_C61F4462AD9643BFF1ECB5A4AEAA7857" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_CEE7009105ADA3753F3DB5A4AEAA365A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_CEE7009105ADA3753F3DB5A4AEAA365A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net losses on early retirement of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_CEE7009105ADA3753F3DB5A4AEAA365A_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_CEE7009105ADA3753F3DB5A4AEAA365A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_CEE7009105ADA3753F3DB5A4AEAA365A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_CEE7009105ADA3753F3DB5A4AEAA365A" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_CEE7009105ADA3753F3DB5A4AEAA365A" xlink:type="arc" />
    <link:label id="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_E112696F055625EE2874B5A4AEAAA5DD_negatedTerseLabel_en-US" xlink:label="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_E112696F055625EE2874B5A4AEAAA5DD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">GSK Consumer Healthcare JV equity method (income)/loss</link:label>
    <link:label id="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_E112696F055625EE2874B5A4AEAAA5DD_label_en-US" xlink:label="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_E112696F055625EE2874B5A4AEAAA5DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) From Equity Method Investments, Net Excess Basis Amortization</link:label>
    <link:label id="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_E112696F055625EE2874B5A4AEAAA5DD_documentation_en-US" xlink:label="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_E112696F055625EE2874B5A4AEAAA5DD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income (Loss) From Equity Method Investments, Net Excess Basis Amortization</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" xlink:label="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_E112696F055625EE2874B5A4AEAAA5DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_E112696F055625EE2874B5A4AEAAA5DD" xlink:to="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_E112696F055625EE2874B5A4AEAAA5DD" xlink:type="arc" />
    <link:label id="lab_pfe_OtherNonoperatingIncomeExpenseNet_ED885CD7D01C4818D49EB5A4AEAA734E_negatedTerseLabel_en-US" xlink:label="lab_pfe_OtherNonoperatingIncomeExpenseNet_ED885CD7D01C4818D49EB5A4AEAA734E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_pfe_OtherNonoperatingIncomeExpenseNet_ED885CD7D01C4818D49EB5A4AEAA734E_label_en-US" xlink:label="lab_pfe_OtherNonoperatingIncomeExpenseNet_ED885CD7D01C4818D49EB5A4AEAA734E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense), Net</link:label>
    <link:label id="lab_pfe_OtherNonoperatingIncomeExpenseNet_ED885CD7D01C4818D49EB5A4AEAA734E_documentation_en-US" xlink:label="lab_pfe_OtherNonoperatingIncomeExpenseNet_ED885CD7D01C4818D49EB5A4AEAA734E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense), Net</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherNonoperatingIncomeExpenseNet" xlink:label="loc_pfe_OtherNonoperatingIncomeExpenseNet_ED885CD7D01C4818D49EB5A4AEAA734E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherNonoperatingIncomeExpenseNet_ED885CD7D01C4818D49EB5A4AEAA734E" xlink:to="lab_pfe_OtherNonoperatingIncomeExpenseNet_ED885CD7D01C4818D49EB5A4AEAA734E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_C48F4329431470D4BF7DB5A4AEAA9CA5_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_C48F4329431470D4BF7DB5A4AEAA9CA5" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Other (income)/deductions&#8211;&#8211;net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_C48F4329431470D4BF7DB5A4AEAA9CA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_C48F4329431470D4BF7DB5A4AEAA9CA5" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_C48F4329431470D4BF7DB5A4AEAA9CA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_B348F4B22EC23ECFF5515E4BE872030C_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember_B348F4B22EC23ECFF5515E4BE872030C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_B348F4B22EC23ECFF5515E4BE872030C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember_B348F4B22EC23ECFF5515E4BE872030C" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember_B348F4B22EC23ECFF5515E4BE872030C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_1F0897CB9251134234DB5E4BE87203C9_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_1F0897CB9251134234DB5E4BE87203C9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charge (credit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1F0897CB9251134234DB5E4BE87203C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_1F0897CB9251134234DB5E4BE87203C9" xlink:to="lab_us-gaap_RestructuringCharges_1F0897CB9251134234DB5E4BE87203C9" xlink:type="arc" />
    <link:label id="lab_srt_CurrencyAxis_3D799A67E7B7DDFCFCA36350787E67C1_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis_3D799A67E7B7DDFCFCA36350787E67C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_3D799A67E7B7DDFCFCA36350787E67C1_label_en-US" xlink:label="lab_srt_CurrencyAxis_3D799A67E7B7DDFCFCA36350787E67C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_3D799A67E7B7DDFCFCA36350787E67C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis_3D799A67E7B7DDFCFCA36350787E67C1" xlink:to="lab_srt_CurrencyAxis_3D799A67E7B7DDFCFCA36350787E67C1" xlink:type="arc" />
    <link:label id="lab_currency_AllCurrenciesDomain_3B49161E98DDBB4E4F696350787EBD16_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain_3B49161E98DDBB4E4F696350787EBD16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_3B49161E98DDBB4E4F696350787EBD16_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain_3B49161E98DDBB4E4F696350787EBD16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_3B49161E98DDBB4E4F696350787EBD16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain_3B49161E98DDBB4E4F696350787EBD16" xlink:to="lab_currency_AllCurrenciesDomain_3B49161E98DDBB4E4F696350787EBD16" xlink:type="arc" />
    <link:label id="lab_currency_EUR_C6E3A175275BBA220A896350787E7B6C_terseLabel_en-US" xlink:label="lab_currency_EUR_C6E3A175275BBA220A896350787E7B6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro [Member]</link:label>
    <link:label id="lab_currency_EUR_C6E3A175275BBA220A896350787E7B6C_label_en-US" xlink:label="lab_currency_EUR_C6E3A175275BBA220A896350787E7B6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_C6E3A175275BBA220A896350787E7B6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR_C6E3A175275BBA220A896350787E7B6C" xlink:to="lab_currency_EUR_C6E3A175275BBA220A896350787E7B6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMember_81FA9469C852986949FF78F90EA376A1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMember_81FA9469C852986949FF78F90EA376A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Member]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMember_81FA9469C852986949FF78F90EA376A1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMember_81FA9469C852986949FF78F90EA376A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMember_81FA9469C852986949FF78F90EA376A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMember_81FA9469C852986949FF78F90EA376A1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMember_81FA9469C852986949FF78F90EA376A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_3B0D34C761DB304CB51678F90EA44EC8_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_3B0D34C761DB304CB51678F90EA44EC8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense for finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_3B0D34C761DB304CB51678F90EA44EC8_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_3B0D34C761DB304CB51678F90EA44EC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3B0D34C761DB304CB51678F90EA44EC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_3B0D34C761DB304CB51678F90EA44EC8" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_3B0D34C761DB304CB51678F90EA44EC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_E24C97077350D343C94F94761F369B49_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_E24C97077350D343C94F94761F369B49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (Income)/Deductions - Net</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_E24C97077350D343C94F94761F369B49_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_E24C97077350D343C94F94761F369B49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_E24C97077350D343C94F94761F369B49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_E24C97077350D343C94F94761F369B49" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_E24C97077350D343C94F94761F369B49" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_9AB9339C2DE78F573C85635078D40647_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared_9AB9339C2DE78F573C85635078D40647" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash dividends declared per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_9AB9339C2DE78F573C85635078D40647_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared_9AB9339C2DE78F573C85635078D40647" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_9AB9339C2DE78F573C85635078D40647" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared_9AB9339C2DE78F573C85635078D40647" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared_9AB9339C2DE78F573C85635078D40647" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_2BC3BA7A44BEAA95B306B5A4D04AF461_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_2BC3BA7A44BEAA95B306B5A4D04AF461" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_2BC3BA7A44BEAA95B306B5A4D04AF461_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_2BC3BA7A44BEAA95B306B5A4D04AF461" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_2BC3BA7A44BEAA95B306B5A4D04AF461" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_2BC3BA7A44BEAA95B306B5A4D04AF461" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_2BC3BA7A44BEAA95B306B5A4D04AF461" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_62A4A5BDC6D8341AE16BB5A4D04A5F07_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_62A4A5BDC6D8341AE16BB5A4D04A5F07" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_62A4A5BDC6D8341AE16BB5A4D04A5F07_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_62A4A5BDC6D8341AE16BB5A4D04A5F07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_62A4A5BDC6D8341AE16BB5A4D04A5F07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_62A4A5BDC6D8341AE16BB5A4D04A5F07" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_62A4A5BDC6D8341AE16BB5A4D04A5F07" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_87C34EA5553612F67EADB5A4D04A0271_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_87C34EA5553612F67EADB5A4D04A0271" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_87C34EA5553612F67EADB5A4D04A0271" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_87C34EA5553612F67EADB5A4D04A0271" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_87C34EA5553612F67EADB5A4D04A0271" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_4EF0C60D051CA490CE5BB5A4D04AEA94_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_4EF0C60D051CA490CE5BB5A4D04AEA94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized holding gains/(losses) on derivative financial instruments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_4EF0C60D051CA490CE5BB5A4D04AEA94_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_4EF0C60D051CA490CE5BB5A4D04AEA94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_4EF0C60D051CA490CE5BB5A4D04AEA94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_4EF0C60D051CA490CE5BB5A4D04AEA94" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_4EF0C60D051CA490CE5BB5A4D04AEA94" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_49F72538182A1F8094A3B5A4D04BC83F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_49F72538182A1F8094A3B5A4D04BC83F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments for gains included in net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_49F72538182A1F8094A3B5A4D04BC83F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_49F72538182A1F8094A3B5A4D04BC83F" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_49F72538182A1F8094A3B5A4D04BC83F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_7BAC587B878B48B8B025B5A4D04BAF8E_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_7BAC587B878B48B8B025B5A4D04BAF8E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_7BAC587B878B48B8B025B5A4D04BAF8E_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_7BAC587B878B48B8B025B5A4D04BAF8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_7BAC587B878B48B8B025B5A4D04BAF8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_7BAC587B878B48B8B025B5A4D04BAF8E" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_7BAC587B878B48B8B025B5A4D04BAF8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_E9B51BD744F1A11FA060B5A4D04BC015_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_E9B51BD744F1A11FA060B5A4D04BC015" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized holding gains/(losses) on available-for-sale securities, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_E9B51BD744F1A11FA060B5A4D04BC015_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_E9B51BD744F1A11FA060B5A4D04BC015" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_E9B51BD744F1A11FA060B5A4D04BC015" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_E9B51BD744F1A11FA060B5A4D04BC015" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_E9B51BD744F1A11FA060B5A4D04BC015" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_35438E4476DBE5C16061B5A4D04B5211_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_35438E4476DBE5C16061B5A4D04B5211" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments for losses included in net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_35438E4476DBE5C16061B5A4D04B5211_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_35438E4476DBE5C16061B5A4D04B5211" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_35438E4476DBE5C16061B5A4D04B5211" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_35438E4476DBE5C16061B5A4D04B5211" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_35438E4476DBE5C16061B5A4D04B5211" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_A5AE72E77F295DFB7BB8B5A4D04B4ED2_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_A5AE72E77F295DFB7BB8B5A4D04B4ED2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), available-for-sale securities, before tax, total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_A5AE72E77F295DFB7BB8B5A4D04B4ED2_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_A5AE72E77F295DFB7BB8B5A4D04B4ED2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_A5AE72E77F295DFB7BB8B5A4D04B4ED2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_A5AE72E77F295DFB7BB8B5A4D04B4ED2" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_A5AE72E77F295DFB7BB8B5A4D04B4ED2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_E3476CD69D248AFDCD95B5A4D04B0B3A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_E3476CD69D248AFDCD95B5A4D04B0B3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Benefit plans: actuarial gains/(losses), net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_E3476CD69D248AFDCD95B5A4D04B0B3A_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_E3476CD69D248AFDCD95B5A4D04B0B3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_E3476CD69D248AFDCD95B5A4D04B0B3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_E3476CD69D248AFDCD95B5A4D04B0B3A" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_E3476CD69D248AFDCD95B5A4D04B0B3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_D80C20646178BB1ECFC6B5A4D04C8187_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_D80C20646178BB1ECFC6B5A4D04C8187" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments related to amortization</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_D80C20646178BB1ECFC6B5A4D04C8187_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_D80C20646178BB1ECFC6B5A4D04C8187" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_D80C20646178BB1ECFC6B5A4D04C8187" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_D80C20646178BB1ECFC6B5A4D04C8187" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_D80C20646178BB1ECFC6B5A4D04C8187" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_37CF06AC4DB89FE046F7B5A4D04C94A2_negatedTerseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_37CF06AC4DB89FE046F7B5A4D04C94A2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments related to settlements, net</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_37CF06AC4DB89FE046F7B5A4D04C94A2_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_37CF06AC4DB89FE046F7B5A4D04C94A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Settlement Adjustment From AOCI, Pension And Other Postretirement Benefit Plans, for Net Gain (Loss), Before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_37CF06AC4DB89FE046F7B5A4D04C94A2_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_37CF06AC4DB89FE046F7B5A4D04C94A2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sum of pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans.</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_37CF06AC4DB89FE046F7B5A4D04C94A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_37CF06AC4DB89FE046F7B5A4D04C94A2" xlink:to="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_37CF06AC4DB89FE046F7B5A4D04C94A2" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_616E3F145540E777E4F8B5A4D04CB7C6_negatedLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_616E3F145540E777E4F8B5A4D04CB7C6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_616E3F145540E777E4F8B5A4D04CB7C6_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_616E3F145540E777E4F8B5A4D04CB7C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Other Net Unamortized Gain (Loss) Arising During Period, before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_616E3F145540E777E4F8B5A4D04CB7C6_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_616E3F145540E777E4F8B5A4D04CB7C6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans actuarial gains /losses.</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_616E3F145540E777E4F8B5A4D04CB7C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_616E3F145540E777E4F8B5A4D04CB7C6" xlink:to="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_616E3F145540E777E4F8B5A4D04CB7C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_18EDDC305D0F685DACB5B5A4D04C496F_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_18EDDC305D0F685DACB5B5A4D04C496F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Defined benefit plan, amounts recognized in other comprehensive income (loss), net gain (loss), before tax, total</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_18EDDC305D0F685DACB5B5A4D04C496F_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_18EDDC305D0F685DACB5B5A4D04C496F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_18EDDC305D0F685DACB5B5A4D04C496F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_18EDDC305D0F685DACB5B5A4D04C496F" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_18EDDC305D0F685DACB5B5A4D04C496F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_9B2C6B1305F10426E6B1B5A4D04C8F75_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_9B2C6B1305F10426E6B1B5A4D04C8F75" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Benefit plans: prior service costs and other, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_9B2C6B1305F10426E6B1B5A4D04C8F75_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_9B2C6B1305F10426E6B1B5A4D04C8F75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_9B2C6B1305F10426E6B1B5A4D04C8F75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_9B2C6B1305F10426E6B1B5A4D04C8F75" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_9B2C6B1305F10426E6B1B5A4D04C8F75" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_302FBCE8066458DE4DFAB5A4D04CEE36_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_302FBCE8066458DE4DFAB5A4D04CEE36" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments related to amortization of prior service costs and other, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_302FBCE8066458DE4DFAB5A4D04CEE36_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_302FBCE8066458DE4DFAB5A4D04CEE36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_302FBCE8066458DE4DFAB5A4D04CEE36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_302FBCE8066458DE4DFAB5A4D04CEE36" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_302FBCE8066458DE4DFAB5A4D04CEE36" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_DA8108DB83446E6A2979B5A4D04DFA38_negatedLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_DA8108DB83446E6A2979B5A4D04DFA38" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_DA8108DB83446E6A2979B5A4D04DFA38_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_DA8108DB83446E6A2979B5A4D04DFA38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_DA8108DB83446E6A2979B5A4D04DFA38_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_DA8108DB83446E6A2979B5A4D04DFA38" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans prior service (costs)/credits.</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_DA8108DB83446E6A2979B5A4D04DFA38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_DA8108DB83446E6A2979B5A4D04DFA38" xlink:to="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_DA8108DB83446E6A2979B5A4D04DFA38" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_088CFA4A057A9526A1D2B5A4D04D9408_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_088CFA4A057A9526A1D2B5A4D04D9408" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service cost, before tax</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_088CFA4A057A9526A1D2B5A4D04D9408_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_088CFA4A057A9526A1D2B5A4D04D9408" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_088CFA4A057A9526A1D2B5A4D04D9408" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_088CFA4A057A9526A1D2B5A4D04D9408" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_088CFA4A057A9526A1D2B5A4D04D9408" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_C4F00A7E862F7D1CB69DB5A4D04D275C_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_C4F00A7E862F7D1CB69DB5A4D04D275C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss, before tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_C4F00A7E862F7D1CB69DB5A4D04D275C_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_C4F00A7E862F7D1CB69DB5A4D04D275C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_C4F00A7E862F7D1CB69DB5A4D04D275C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_C4F00A7E862F7D1CB69DB5A4D04D275C" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_C4F00A7E862F7D1CB69DB5A4D04D275C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_3C07E5D1C889D48BA522B5A4D04D8840_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax_3C07E5D1C889D48BA522B5A4D04D8840" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax provision/(benefit) on other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_3C07E5D1C889D48BA522B5A4D04D8840_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax_3C07E5D1C889D48BA522B5A4D04D8840" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_3C07E5D1C889D48BA522B5A4D04D8840" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_3C07E5D1C889D48BA522B5A4D04D8840" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax_3C07E5D1C889D48BA522B5A4D04D8840" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_94A762B5E08703DF9DEFB5A4D05330AC_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_94A762B5E08703DF9DEFB5A4D05330AC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss before allocation to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_94A762B5E08703DF9DEFB5A4D05330AC_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_94A762B5E08703DF9DEFB5A4D05330AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_94A762B5E08703DF9DEFB5A4D05330AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_94A762B5E08703DF9DEFB5A4D05330AC" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_94A762B5E08703DF9DEFB5A4D05330AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_E12DBB874826FB76047EB5A4D053452A_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_E12DBB874826FB76047EB5A4D053452A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income before allocation to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_E12DBB874826FB76047EB5A4D053452A_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_E12DBB874826FB76047EB5A4D053452A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_E12DBB874826FB76047EB5A4D053452A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_E12DBB874826FB76047EB5A4D053452A" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_E12DBB874826FB76047EB5A4D053452A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_18B9673D438E02F5938BB5A4D053DEF0_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_18B9673D438E02F5938BB5A4D053DEF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Comprehensive income/(loss) attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_18B9673D438E02F5938BB5A4D053DEF0_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_18B9673D438E02F5938BB5A4D053DEF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_18B9673D438E02F5938BB5A4D053DEF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_18B9673D438E02F5938BB5A4D053DEF0" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_18B9673D438E02F5938BB5A4D053DEF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_5B7FB56B8B1175DB6ACEB5A4D053245D_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_5B7FB56B8B1175DB6ACEB5A4D053245D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to Pfizer Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_5B7FB56B8B1175DB6ACEB5A4D053245D_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_5B7FB56B8B1175DB6ACEB5A4D053245D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5B7FB56B8B1175DB6ACEB5A4D053245D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5B7FB56B8B1175DB6ACEB5A4D053245D" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_5B7FB56B8B1175DB6ACEB5A4D053245D" xlink:type="arc" />
    <link:label id="lab_pfe_IncomeTaxesTable_2BA40BB3F2D37B0963D478FDDF40DCB2_terseLabel_en-US" xlink:label="lab_pfe_IncomeTaxesTable_2BA40BB3F2D37B0963D478FDDF40DCB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_pfe_IncomeTaxesTable_2BA40BB3F2D37B0963D478FDDF40DCB2_label_en-US" xlink:label="lab_pfe_IncomeTaxesTable_2BA40BB3F2D37B0963D478FDDF40DCB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_pfe_IncomeTaxesTable_2BA40BB3F2D37B0963D478FDDF40DCB2_documentation_en-US" xlink:label="lab_pfe_IncomeTaxesTable_2BA40BB3F2D37B0963D478FDDF40DCB2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IncomeTaxesTable" xlink:label="loc_pfe_IncomeTaxesTable_2BA40BB3F2D37B0963D478FDDF40DCB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeTaxesTable_2BA40BB3F2D37B0963D478FDDF40DCB2" xlink:to="lab_pfe_IncomeTaxesTable_2BA40BB3F2D37B0963D478FDDF40DCB2" xlink:type="arc" />
    <link:label id="lab_srt_StatementScenarioAxis_DCF2C23EFF42EAFA322B78FDDF413708_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis_DCF2C23EFF42EAFA322B78FDDF413708" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_DCF2C23EFF42EAFA322B78FDDF413708_label_en-US" xlink:label="lab_srt_StatementScenarioAxis_DCF2C23EFF42EAFA322B78FDDF413708" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_DCF2C23EFF42EAFA322B78FDDF413708" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis_DCF2C23EFF42EAFA322B78FDDF413708" xlink:to="lab_srt_StatementScenarioAxis_DCF2C23EFF42EAFA322B78FDDF413708" xlink:type="arc" />
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_6D45E118DAA58125EF4A78FDDF41AB3C_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain_6D45E118DAA58125EF4A78FDDF41AB3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_6D45E118DAA58125EF4A78FDDF41AB3C_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain_6D45E118DAA58125EF4A78FDDF41AB3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_6D45E118DAA58125EF4A78FDDF41AB3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain_6D45E118DAA58125EF4A78FDDF41AB3C" xlink:to="lab_srt_ScenarioUnspecifiedDomain_6D45E118DAA58125EF4A78FDDF41AB3C" xlink:type="arc" />
    <link:label id="lab_srt_ScenarioForecastMember_AA1230420256FA862B1978FDDF4221FC_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember_AA1230420256FA862B1978FDDF4221FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_AA1230420256FA862B1978FDDF4221FC_label_en-US" xlink:label="lab_srt_ScenarioForecastMember_AA1230420256FA862B1978FDDF4221FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_AA1230420256FA862B1978FDDF4221FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember_AA1230420256FA862B1978FDDF4221FC" xlink:to="lab_srt_ScenarioForecastMember_AA1230420256FA862B1978FDDF4221FC" xlink:type="arc" />
    <link:label id="lab_pfe_IncomeTaxesPayableMember_387B4D90C1E652EEE8F578FDDF4297D2_terseLabel_en-US" xlink:label="lab_pfe_IncomeTaxesPayableMember_387B4D90C1E652EEE8F578FDDF4297D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes Payable [Member]</link:label>
    <link:label id="lab_pfe_IncomeTaxesPayableMember_387B4D90C1E652EEE8F578FDDF4297D2_label_en-US" xlink:label="lab_pfe_IncomeTaxesPayableMember_387B4D90C1E652EEE8F578FDDF4297D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Payable [Member]</link:label>
    <link:label id="lab_pfe_IncomeTaxesPayableMember_387B4D90C1E652EEE8F578FDDF4297D2_documentation_en-US" xlink:label="lab_pfe_IncomeTaxesPayableMember_387B4D90C1E652EEE8F578FDDF4297D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Taxes Payable [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IncomeTaxesPayableMember" xlink:label="loc_pfe_IncomeTaxesPayableMember_387B4D90C1E652EEE8F578FDDF4297D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeTaxesPayableMember_387B4D90C1E652EEE8F578FDDF4297D2" xlink:to="lab_pfe_IncomeTaxesPayableMember_387B4D90C1E652EEE8F578FDDF4297D2" xlink:type="arc" />
    <link:label id="lab_pfe_IncomeTaxesLineItems_85ECBE9ED50B2D4854BD78FDDF425FCF_terseLabel_en-US" xlink:label="lab_pfe_IncomeTaxesLineItems_85ECBE9ED50B2D4854BD78FDDF425FCF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_pfe_IncomeTaxesLineItems_85ECBE9ED50B2D4854BD78FDDF425FCF_label_en-US" xlink:label="lab_pfe_IncomeTaxesLineItems_85ECBE9ED50B2D4854BD78FDDF425FCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_pfe_IncomeTaxesLineItems_85ECBE9ED50B2D4854BD78FDDF425FCF_documentation_en-US" xlink:label="lab_pfe_IncomeTaxesLineItems_85ECBE9ED50B2D4854BD78FDDF425FCF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Income Taxes [Table]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IncomeTaxesLineItems" xlink:label="loc_pfe_IncomeTaxesLineItems_85ECBE9ED50B2D4854BD78FDDF425FCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeTaxesLineItems_85ECBE9ED50B2D4854BD78FDDF425FCF" xlink:to="lab_pfe_IncomeTaxesLineItems_85ECBE9ED50B2D4854BD78FDDF425FCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B69361CE5F377DC627F278FDDF4362F5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B69361CE5F377DC627F278FDDF4362F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate for income from continuing operations</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B69361CE5F377DC627F278FDDF4362F5_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B69361CE5F377DC627F278FDDF4362F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B69361CE5F377DC627F278FDDF4362F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B69361CE5F377DC627F278FDDF4362F5" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B69361CE5F377DC627F278FDDF4362F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxSettlements_C01C9F1EC298852E7D8B7910AE908261_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxSettlements_C01C9F1EC298852E7D8B7910AE908261" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit due to settlement</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxSettlements_C01C9F1EC298852E7D8B7910AE908261_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxSettlements_C01C9F1EC298852E7D8B7910AE908261" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_C01C9F1EC298852E7D8B7910AE908261" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_C01C9F1EC298852E7D8B7910AE908261" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxSettlements_C01C9F1EC298852E7D8B7910AE908261" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_B3D5A3AEB5EBFF81E00778FDDF431EED_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_B3D5A3AEB5EBFF81E00778FDDF431EED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repatriation tax liability</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_B3D5A3AEB5EBFF81E00778FDDF431EED_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_B3D5A3AEB5EBFF81E00778FDDF431EED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_B3D5A3AEB5EBFF81E00778FDDF431EED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_B3D5A3AEB5EBFF81E00778FDDF431EED" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_B3D5A3AEB5EBFF81E00778FDDF431EED" xlink:type="arc" />
    <link:label id="lab_pfe_PaymentForRepatriationTax_4D217B235C4F5DBEC5A678FDDF43AF9F_terseLabel_en-US" xlink:label="lab_pfe_PaymentForRepatriationTax_4D217B235C4F5DBEC5A678FDDF43AF9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Installment payments for repatriation tax</link:label>
    <link:label id="lab_pfe_PaymentForRepatriationTax_4D217B235C4F5DBEC5A678FDDF43AF9F_label_en-US" xlink:label="lab_pfe_PaymentForRepatriationTax_4D217B235C4F5DBEC5A678FDDF43AF9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment For Repatriation Tax</link:label>
    <link:label id="lab_pfe_PaymentForRepatriationTax_4D217B235C4F5DBEC5A678FDDF43AF9F_documentation_en-US" xlink:label="lab_pfe_PaymentForRepatriationTax_4D217B235C4F5DBEC5A678FDDF43AF9F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment For Repatriation Tax</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PaymentForRepatriationTax" xlink:label="loc_pfe_PaymentForRepatriationTax_4D217B235C4F5DBEC5A678FDDF43AF9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaymentForRepatriationTax_4D217B235C4F5DBEC5A678FDDF43AF9F" xlink:to="lab_pfe_PaymentForRepatriationTax_4D217B235C4F5DBEC5A678FDDF43AF9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_76641FE774A15B4552C094761EE631B7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_76641FE774A15B4552C094761EE631B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other (Income)/Deductions - Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_76641FE774A15B4552C094761EE631B7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_76641FE774A15B4552C094761EE631B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_76641FE774A15B4552C094761EE631B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_76641FE774A15B4552C094761EE631B7" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_76641FE774A15B4552C094761EE631B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_3A2B15DABAC480709BF178F2528E677D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_3A2B15DABAC480709BF178F2528E677D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_3A2B15DABAC480709BF178F2528E677D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_3A2B15DABAC480709BF178F2528E677D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_3A2B15DABAC480709BF178F2528E677D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_3A2B15DABAC480709BF178F2528E677D" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_3A2B15DABAC480709BF178F2528E677D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7311478CAA6D49EDDFCF78F2528ECC31_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7311478CAA6D49EDDFCF78F2528ECC31" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7311478CAA6D49EDDFCF78F2528ECC31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7311478CAA6D49EDDFCF78F2528ECC31" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7311478CAA6D49EDDFCF78F2528ECC31" xlink:type="arc" />
    <link:label id="lab_us-gaap_TradeNamesMember_C357E3F607D039FC50EA78F2528FD024_verboseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember_C357E3F607D039FC50EA78F2528FD024" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Brands [Member]</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_C357E3F607D039FC50EA78F2528FD024_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember_C357E3F607D039FC50EA78F2528FD024" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_C357E3F607D039FC50EA78F2528FD024" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember_C357E3F607D039FC50EA78F2528FD024" xlink:to="lab_us-gaap_TradeNamesMember_C357E3F607D039FC50EA78F2528FD024" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_3C162757443FDDBD43AD78F25290AD64_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_3C162757443FDDBD43AD78F25290AD64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_3C162757443FDDBD43AD78F25290AD64_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_3C162757443FDDBD43AD78F25290AD64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_3C162757443FDDBD43AD78F25290AD64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_3C162757443FDDBD43AD78F25290AD64" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_3C162757443FDDBD43AD78F25290AD64" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_A2077F97A8A46CA3305578F252900E6B_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_A2077F97A8A46CA3305578F252900E6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_A2077F97A8A46CA3305578F252900E6B_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_A2077F97A8A46CA3305578F252900E6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_A2077F97A8A46CA3305578F252900E6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_A2077F97A8A46CA3305578F252900E6B" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_A2077F97A8A46CA3305578F252900E6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_8B0E5C69FFB4DB7F691C78F252925A66_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_8B0E5C69FFB4DB7F691C78F252925A66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible assets, gross carrying amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_8B0E5C69FFB4DB7F691C78F252925A66_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_8B0E5C69FFB4DB7F691C78F252925A66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8B0E5C69FFB4DB7F691C78F252925A66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8B0E5C69FFB4DB7F691C78F252925A66" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_8B0E5C69FFB4DB7F691C78F252925A66" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_41C6073FF631F5F4CA3E78F252923654_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_41C6073FF631F5F4CA3E78F252923654" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_41C6073FF631F5F4CA3E78F252923654_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_41C6073FF631F5F4CA3E78F252923654" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_41C6073FF631F5F4CA3E78F252923654" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_41C6073FF631F5F4CA3E78F252923654" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_41C6073FF631F5F4CA3E78F252923654" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_549BF9C3D0811DC8D76E78F25292D7AA_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_549BF9C3D0811DC8D76E78F25292D7AA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_549BF9C3D0811DC8D76E78F25292D7AA_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_549BF9C3D0811DC8D76E78F25292D7AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_549BF9C3D0811DC8D76E78F25292D7AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_549BF9C3D0811DC8D76E78F25292D7AA" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_549BF9C3D0811DC8D76E78F25292D7AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_217325A6C608D557A6DB78F25292C54F_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_217325A6C608D557A6DB78F25292C54F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, gross carrying amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_217325A6C608D557A6DB78F25292C54F_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_217325A6C608D557A6DB78F25292C54F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_217325A6C608D557A6DB78F25292C54F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_217325A6C608D557A6DB78F25292C54F" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_217325A6C608D557A6DB78F25292C54F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9AB4C205A5672036783578F25292B593_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9AB4C205A5672036783578F25292B593" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible assets, accumulated amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9AB4C205A5672036783578F25292B593" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9AB4C205A5672036783578F25292B593" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9AB4C205A5672036783578F25292B593" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_923918A9CA157FDBB20078F2529359AD_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_923918A9CA157FDBB20078F2529359AD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Identifiable Intangible Assets, less Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_923918A9CA157FDBB20078F2529359AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_923918A9CA157FDBB20078F2529359AD" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_923918A9CA157FDBB20078F2529359AD" xlink:type="arc" />
    <link:label id="lab_pfe_LicensingArrangementValueOfSharesPurchased_76593D7E8DB202B0CFF892DEB9579061_terseLabel_en-US" xlink:label="lab_pfe_LicensingArrangementValueOfSharesPurchased_76593D7E8DB202B0CFF892DEB9579061" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value of shares purchased</link:label>
    <link:label id="lab_pfe_LicensingArrangementValueOfSharesPurchased_76593D7E8DB202B0CFF892DEB9579061_label_en-US" xlink:label="lab_pfe_LicensingArrangementValueOfSharesPurchased_76593D7E8DB202B0CFF892DEB9579061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Arrangement, Value Of Shares Purchased</link:label>
    <link:label id="lab_pfe_LicensingArrangementValueOfSharesPurchased_76593D7E8DB202B0CFF892DEB9579061_documentation_en-US" xlink:label="lab_pfe_LicensingArrangementValueOfSharesPurchased_76593D7E8DB202B0CFF892DEB9579061" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Licensing Arrangement, Value Of Shares Purchased</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LicensingArrangementValueOfSharesPurchased" xlink:label="loc_pfe_LicensingArrangementValueOfSharesPurchased_76593D7E8DB202B0CFF892DEB9579061" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LicensingArrangementValueOfSharesPurchased_76593D7E8DB202B0CFF892DEB9579061" xlink:to="lab_pfe_LicensingArrangementValueOfSharesPurchased_76593D7E8DB202B0CFF892DEB9579061" xlink:type="arc" />
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure_63653CC3D27F7A2AE5D592DEB95774B9_terseLabel_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure_63653CC3D27F7A2AE5D592DEB95774B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential future milestone payments</link:label>
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure_63653CC3D27F7A2AE5D592DEB95774B9_label_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure_63653CC3D27F7A2AE5D592DEB95774B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Future Milestone Payments, Maximum Exposure</link:label>
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure_63653CC3D27F7A2AE5D592DEB95774B9_documentation_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure_63653CC3D27F7A2AE5D592DEB95774B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Future Milestone Payments, Maximum Exposure</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure_63653CC3D27F7A2AE5D592DEB95774B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure_63653CC3D27F7A2AE5D592DEB95774B9" xlink:to="lab_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure_63653CC3D27F7A2AE5D592DEB95774B9" xlink:type="arc" />
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_8785140540778E461CA692DEB958A56B_terseLabel_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_8785140540778E461CA692DEB958A56B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development arrangement, percentage of costs to be reimbursed</link:label>
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_8785140540778E461CA692DEB958A56B_label_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_8785140540778E461CA692DEB958A56B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Percentage of Costs to be Reimbursed</link:label>
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_8785140540778E461CA692DEB958A56B_documentation_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_8785140540778E461CA692DEB958A56B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Percentage of Costs to be Reimbursed</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed" xlink:label="loc_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_8785140540778E461CA692DEB958A56B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_8785140540778E461CA692DEB958A56B" xlink:to="lab_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_8785140540778E461CA692DEB958A56B" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock_B7FC63A5B03BA64497A25967927619EE_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock_B7FC63A5B03BA64497A25967927619EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition, Equity-Method Investment and Licensing Arrangements</link:label>
    <link:label id="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock_B7FC63A5B03BA64497A25967927619EE_label_en-US" xlink:label="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock_B7FC63A5B03BA64497A25967927619EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement Disclosure [Text Block]</link:label>
    <link:label id="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock_B7FC63A5B03BA64497A25967927619EE_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock_B7FC63A5B03BA64497A25967927619EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock_B7FC63A5B03BA64497A25967927619EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock_B7FC63A5B03BA64497A25967927619EE" xlink:to="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock_B7FC63A5B03BA64497A25967927619EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8A5B4015AA3DB54D5EE3633D59A05008_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8A5B4015AA3DB54D5EE3633D59A05008" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8A5B4015AA3DB54D5EE3633D59A05008_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8A5B4015AA3DB54D5EE3633D59A05008" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8A5B4015AA3DB54D5EE3633D59A05008" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8A5B4015AA3DB54D5EE3633D59A05008" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8A5B4015AA3DB54D5EE3633D59A05008" xlink:type="arc" />
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_CA2B5B8C854A95873A9994761F4CF09B_terseLabel_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_CA2B5B8C854A95873A9994761F4CF09B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Available For Sale Securities And Held To Maturity Securities [Table]</link:label>
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_CA2B5B8C854A95873A9994761F4CF09B_label_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_CA2B5B8C854A95873A9994761F4CF09B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Available For Sale Securities And Held To Maturity Securities [Table]</link:label>
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_CA2B5B8C854A95873A9994761F4CF09B_documentation_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_CA2B5B8C854A95873A9994761F4CF09B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Available for sale Securities and Held to maturity Securities [Table]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_CA2B5B8C854A95873A9994761F4CF09B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_CA2B5B8C854A95873A9994761F4CF09B" xlink:to="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_CA2B5B8C854A95873A9994761F4CF09B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BankTimeDepositsMember_251A0F3B3A689BB4743594761F4D6894_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember_251A0F3B3A689BB4743594761F4D6894" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time deposits and other [Member]</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_251A0F3B3A689BB4743594761F4D6894_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember_251A0F3B3A689BB4743594761F4D6894" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BankTimeDepositsMember" xlink:label="loc_us-gaap_BankTimeDepositsMember_251A0F3B3A689BB4743594761F4D6894" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember_251A0F3B3A689BB4743594761F4D6894" xlink:to="lab_us-gaap_BankTimeDepositsMember_251A0F3B3A689BB4743594761F4D6894" xlink:type="arc" />
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF_terseLabel_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Available For Sale Securities And Held To Maturity Securities [Line Items]</link:label>
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF_label_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Available For Sale Securities And Held To Maturity Securities [Line Items]</link:label>
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF_documentation_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Available for sale Securities and Held to maturity Securities [Line Items]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:to="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_A15AAFCBB2C943A17EF194761F4E4DCB_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_A15AAFCBB2C943A17EF194761F4E4DCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_A15AAFCBB2C943A17EF194761F4E4DCB_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_A15AAFCBB2C943A17EF194761F4E4DCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_A15AAFCBB2C943A17EF194761F4E4DCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_A15AAFCBB2C943A17EF194761F4E4DCB" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_A15AAFCBB2C943A17EF194761F4E4DCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C8D14F0993497214C47794761F4E1B17_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C8D14F0993497214C47794761F4E1B17" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale debt securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C8D14F0993497214C47794761F4E1B17_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C8D14F0993497214C47794761F4E1B17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C8D14F0993497214C47794761F4E1B17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C8D14F0993497214C47794761F4E1B17" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C8D14F0993497214C47794761F4E1B17" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0951A0B54173DA995D8E94761F4ED141_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0951A0B54173DA995D8E94761F4ED141" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale debt securities, gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0951A0B54173DA995D8E94761F4ED141_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0951A0B54173DA995D8E94761F4ED141" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0951A0B54173DA995D8E94761F4ED141" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0951A0B54173DA995D8E94761F4ED141" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0951A0B54173DA995D8E94761F4ED141" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_12B80066C35E3C22CF5C94761F4EB945_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_12B80066C35E3C22CF5C94761F4EB945" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale debt securities, gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_12B80066C35E3C22CF5C94761F4EB945_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_12B80066C35E3C22CF5C94761F4EB945" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_12B80066C35E3C22CF5C94761F4EB945" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_12B80066C35E3C22CF5C94761F4EB945" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_12B80066C35E3C22CF5C94761F4EB945" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9CABC449D39B31F6D9A394761F4F38A6_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9CABC449D39B31F6D9A394761F4F38A6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale debt securities, fair value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9CABC449D39B31F6D9A394761F4F38A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9CABC449D39B31F6D9A394761F4F38A6" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9CABC449D39B31F6D9A394761F4F38A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_22851EE4F9370F5AD59194761F4F3EEF_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_22851EE4F9370F5AD59194761F4F3EEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_22851EE4F9370F5AD59194761F4F3EEF_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_22851EE4F9370F5AD59194761F4F3EEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_22851EE4F9370F5AD59194761F4F3EEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_22851EE4F9370F5AD59194761F4F3EEF" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_22851EE4F9370F5AD59194761F4F3EEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_513C236D194B7A0120CE94761F4FB538_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_513C236D194B7A0120CE94761F4FB538" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, debt maturities, within 1 year, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_513C236D194B7A0120CE94761F4FB538_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_513C236D194B7A0120CE94761F4FB538" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_513C236D194B7A0120CE94761F4FB538" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_513C236D194B7A0120CE94761F4FB538" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_513C236D194B7A0120CE94761F4FB538" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5D2DDF1307FE3E24083694761F4F0514_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5D2DDF1307FE3E24083694761F4F0514" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, debt maturities, over 1 to 5 years, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5D2DDF1307FE3E24083694761F4F0514_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5D2DDF1307FE3E24083694761F4F0514" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5D2DDF1307FE3E24083694761F4F0514" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5D2DDF1307FE3E24083694761F4F0514" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5D2DDF1307FE3E24083694761F4F0514" xlink:type="arc" />
    <link:label id="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_D66822D794324A7406FD94761F50E1FB_terseLabel_en-US" xlink:label="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_D66822D794324A7406FD94761F50E1FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, debt maturities, over 5 years, fair value</link:label>
    <link:label id="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_D66822D794324A7406FD94761F50E1FB_label_en-US" xlink:label="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_D66822D794324A7406FD94761F50E1FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value</link:label>
    <link:label id="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_D66822D794324A7406FD94761F50E1FB_documentation_en-US" xlink:label="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_D66822D794324A7406FD94761F50E1FB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:label="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_D66822D794324A7406FD94761F50E1FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_D66822D794324A7406FD94761F50E1FB" xlink:to="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_D66822D794324A7406FD94761F50E1FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_CD5834F82D640805A1ED94761F5039FC_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_CD5834F82D640805A1ED94761F5039FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity, Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_CD5834F82D640805A1ED94761F5039FC_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_CD5834F82D640805A1ED94761F5039FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity, Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_CD5834F82D640805A1ED94761F5039FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_CD5834F82D640805A1ED94761F5039FC" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_CD5834F82D640805A1ED94761F5039FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_EBCC35C4AC1653C1E04E94761F50D0AD_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities_EBCC35C4AC1653C1E04E94761F50D0AD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity securities, debt maturities, total</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_EBCC35C4AC1653C1E04E94761F50D0AD_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities_EBCC35C4AC1653C1E04E94761F50D0AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:label="loc_us-gaap_HeldToMaturitySecurities_EBCC35C4AC1653C1E04E94761F50D0AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecurities_EBCC35C4AC1653C1E04E94761F50D0AD" xlink:to="lab_us-gaap_HeldToMaturitySecurities_EBCC35C4AC1653C1E04E94761F50D0AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_FAAEC7A88E1B0BD55A4E94761F501E23_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_FAAEC7A88E1B0BD55A4E94761F501E23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity securities, gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_FAAEC7A88E1B0BD55A4E94761F501E23_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_FAAEC7A88E1B0BD55A4E94761F501E23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_FAAEC7A88E1B0BD55A4E94761F501E23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_FAAEC7A88E1B0BD55A4E94761F501E23" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_FAAEC7A88E1B0BD55A4E94761F501E23" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_1795AB6232708D4AB47094761F519548_negatedLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_1795AB6232708D4AB47094761F519548" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity securities, gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_1795AB6232708D4AB47094761F519548_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_1795AB6232708D4AB47094761F519548" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_1795AB6232708D4AB47094761F519548" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_1795AB6232708D4AB47094761F519548" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_1795AB6232708D4AB47094761F519548" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_A51DBD075CEC4FBD43F894761F51943C_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue_A51DBD075CEC4FBD43F894761F51943C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity securities, fair value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_A51DBD075CEC4FBD43F894761F51943C_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue_A51DBD075CEC4FBD43F894761F51943C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_A51DBD075CEC4FBD43F894761F51943C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesFairValue_A51DBD075CEC4FBD43F894761F51943C" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesFairValue_A51DBD075CEC4FBD43F894761F51943C" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_AAD0FA99EF44D635BACB94761F51E3E6_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_AAD0FA99EF44D635BACB94761F51E3E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_AAD0FA99EF44D635BACB94761F51E3E6_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_AAD0FA99EF44D635BACB94761F51E3E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_AAD0FA99EF44D635BACB94761F51E3E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_AAD0FA99EF44D635BACB94761F51E3E6" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_AAD0FA99EF44D635BACB94761F51E3E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_C895CF891DC552DE30C194761F518E66_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_C895CF891DC552DE30C194761F518E66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity securities, debt maturities, within 1 year, fair value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_C895CF891DC552DE30C194761F518E66_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_C895CF891DC552DE30C194761F518E66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_C895CF891DC552DE30C194761F518E66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_C895CF891DC552DE30C194761F518E66" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_C895CF891DC552DE30C194761F518E66" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_F32B0F48FDD8D6674A7894761F51A252_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_F32B0F48FDD8D6674A7894761F51A252" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_F32B0F48FDD8D6674A7894761F51A252_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_F32B0F48FDD8D6674A7894761F51A252" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_F32B0F48FDD8D6674A7894761F51A252" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_F32B0F48FDD8D6674A7894761F51A252" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_F32B0F48FDD8D6674A7894761F51A252" xlink:type="arc" />
    <link:label id="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_2EA64BCA1E6083D3249194761F5139A6_terseLabel_en-US" xlink:label="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_2EA64BCA1E6083D3249194761F5139A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity securities, debt maturities, over 5 years, fair value</link:label>
    <link:label id="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_2EA64BCA1E6083D3249194761F5139A6_label_en-US" xlink:label="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_2EA64BCA1E6083D3249194761F5139A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value</link:label>
    <link:label id="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_2EA64BCA1E6083D3249194761F5139A6_documentation_en-US" xlink:label="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_2EA64BCA1E6083D3249194761F5139A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:label="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_2EA64BCA1E6083D3249194761F5139A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_2EA64BCA1E6083D3249194761F5139A6" xlink:to="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_2EA64BCA1E6083D3249194761F5139A6" xlink:type="arc" />
    <link:label id="lab_pfe_DebtSecuritiesAmortizedCostBasis_2156A1DF20DC07D5B04794761F52C06B_totalLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesAmortizedCostBasis_2156A1DF20DC07D5B04794761F52C06B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Debt securities, amortized cost</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAmortizedCostBasis_2156A1DF20DC07D5B04794761F52C06B_label_en-US" xlink:label="lab_pfe_DebtSecuritiesAmortizedCostBasis_2156A1DF20DC07D5B04794761F52C06B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAmortizedCostBasis_2156A1DF20DC07D5B04794761F52C06B_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesAmortizedCostBasis_2156A1DF20DC07D5B04794761F52C06B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtSecuritiesAmortizedCostBasis" xlink:label="loc_pfe_DebtSecuritiesAmortizedCostBasis_2156A1DF20DC07D5B04794761F52C06B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesAmortizedCostBasis_2156A1DF20DC07D5B04794761F52C06B" xlink:to="lab_pfe_DebtSecuritiesAmortizedCostBasis_2156A1DF20DC07D5B04794761F52C06B" xlink:type="arc" />
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_C271110664193F20B60094761F5287F4_terseLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_C271110664193F20B60094761F5287F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, gross unrealized gains</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_C271110664193F20B60094761F5287F4_label_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_C271110664193F20B60094761F5287F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Accumulated Gross Unrealized Gain</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_C271110664193F20B60094761F5287F4_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_C271110664193F20B60094761F5287F4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Accumulated Gross Unrealized Gain</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_C271110664193F20B60094761F5287F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_C271110664193F20B60094761F5287F4" xlink:to="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_C271110664193F20B60094761F5287F4" xlink:type="arc" />
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_F25681933BEA601401B594761F521BBF_negatedLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_F25681933BEA601401B594761F521BBF" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Debt securities, gross unrealized losses</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_F25681933BEA601401B594761F521BBF_label_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_F25681933BEA601401B594761F521BBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Accumulated Gross Unrealized Loss</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_F25681933BEA601401B594761F521BBF_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_F25681933BEA601401B594761F521BBF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Accumulated Gross Unrealized Loss</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_F25681933BEA601401B594761F521BBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_F25681933BEA601401B594761F521BBF" xlink:to="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_F25681933BEA601401B594761F521BBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_080079DBCF14861F742C94761F52B98F_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_080079DBCF14861F742C94761F52B98F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities and held-to-maturity securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_080079DBCF14861F742C94761F52B98F_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_080079DBCF14861F742C94761F52B98F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale and Held-to-maturity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_080079DBCF14861F742C94761F52B98F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_080079DBCF14861F742C94761F52B98F" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_080079DBCF14861F742C94761F52B98F" xlink:type="arc" />
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_251326BA10AB7EC9EF8694761F529E59_totalLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_251326BA10AB7EC9EF8694761F529E59" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Debt securities maturities, within 1 year, fair value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_251326BA10AB7EC9EF8694761F529E59_label_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_251326BA10AB7EC9EF8694761F529E59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities Maturities, Next Twelve Months, Fair Value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_251326BA10AB7EC9EF8694761F529E59_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_251326BA10AB7EC9EF8694761F529E59" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities Maturities, Next Twelve Months, Fair Value</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" xlink:label="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_251326BA10AB7EC9EF8694761F529E59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_251326BA10AB7EC9EF8694761F529E59" xlink:to="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_251326BA10AB7EC9EF8694761F529E59" xlink:type="arc" />
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_9ED6FA00BE74C4B27C6C94761F5338A0_totalLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_9ED6FA00BE74C4B27C6C94761F5338A0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Debt securities maturities, over 1 to 5 years, fair value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_9ED6FA00BE74C4B27C6C94761F5338A0_label_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_9ED6FA00BE74C4B27C6C94761F5338A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities Maturities, Year Two Through Five, Fair Value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_9ED6FA00BE74C4B27C6C94761F5338A0_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_9ED6FA00BE74C4B27C6C94761F5338A0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities Maturities, Year Two Through Five, Fair Value</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" xlink:label="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_9ED6FA00BE74C4B27C6C94761F5338A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_9ED6FA00BE74C4B27C6C94761F5338A0" xlink:to="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_9ED6FA00BE74C4B27C6C94761F5338A0" xlink:type="arc" />
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_72931B06A6D2B52AE25D94761F53E9E8_totalLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_72931B06A6D2B52AE25D94761F53E9E8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Debt securities maturities, over 5 years, fair value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_72931B06A6D2B52AE25D94761F53E9E8_label_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_72931B06A6D2B52AE25D94761F53E9E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities Maturities, After Year Five, Fair Value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_72931B06A6D2B52AE25D94761F53E9E8_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_72931B06A6D2B52AE25D94761F53E9E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities Maturities, After Year Five, Fair Value</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" xlink:label="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_72931B06A6D2B52AE25D94761F53E9E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_72931B06A6D2B52AE25D94761F53E9E8" xlink:to="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_72931B06A6D2B52AE25D94761F53E9E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_9D5869B05A31218D7980B09F3287DA5D_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_9D5869B05A31218D7980B09F3287DA5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total long-term debt, principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_9D5869B05A31218D7980B09F3287DA5D_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_9D5869B05A31218D7980B09F3287DA5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_9D5869B05A31218D7980B09F3287DA5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_9D5869B05A31218D7980B09F3287DA5D" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount_9D5869B05A31218D7980B09F3287DA5D" xlink:type="arc" />
    <link:label id="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_CE2CF810439E57969D1FB09F32884F2C_terseLabel_en-US" xlink:label="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_CE2CF810439E57969D1FB09F32884F2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net fair value adjustments related to hedging and purchase accounting</link:label>
    <link:label id="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_CE2CF810439E57969D1FB09F32884F2C_label_en-US" xlink:label="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_CE2CF810439E57969D1FB09F32884F2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting</link:label>
    <link:label id="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_CE2CF810439E57969D1FB09F32884F2C_documentation_en-US" xlink:label="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_CE2CF810439E57969D1FB09F32884F2C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_CE2CF810439E57969D1FB09F32884F2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_CE2CF810439E57969D1FB09F32884F2C" xlink:to="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_CE2CF810439E57969D1FB09F32884F2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_B8FEDB2C1399189CC9C1B09F3288FC4B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_B8FEDB2C1399189CC9C1B09F3288FC4B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net unamortized discounts, premiums and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_B8FEDB2C1399189CC9C1B09F3288FC4B_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_B8FEDB2C1399189CC9C1B09F3288FC4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_B8FEDB2C1399189CC9C1B09F3288FC4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_B8FEDB2C1399189CC9C1B09F3288FC4B" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_B8FEDB2C1399189CC9C1B09F3288FC4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLongTermDebt_A911E18CD3F8A66DA221B09F32889456_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermDebt_A911E18CD3F8A66DA221B09F32889456" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term debt</link:label>
    <link:label id="lab_us-gaap_OtherLongTermDebt_A911E18CD3F8A66DA221B09F32889456_label_en-US" xlink:label="lab_us-gaap_OtherLongTermDebt_A911E18CD3F8A66DA221B09F32889456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaap_OtherLongTermDebt_A911E18CD3F8A66DA221B09F32889456" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermDebt_A911E18CD3F8A66DA221B09F32889456" xlink:to="lab_us-gaap_OtherLongTermDebt_A911E18CD3F8A66DA221B09F32889456" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_A4DAEAD4D19FBBA76AC3B09F328847D4_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_A4DAEAD4D19FBBA76AC3B09F328847D4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total long-term debt, carried at historical proceeds, as adjusted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_A4DAEAD4D19FBBA76AC3B09F328847D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_A4DAEAD4D19FBBA76AC3B09F328847D4" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_A4DAEAD4D19FBBA76AC3B09F328847D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_DE6893F339C088789C50B09F32883157_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_DE6893F339C088789C50B09F32883157" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_DE6893F339C088789C50B09F32883157" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_DE6893F339C088789C50B09F32883157" xlink:to="lab_us-gaap_LongTermDebtCurrent_DE6893F339C088789C50B09F32883157" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_23F8A695101D1D2C2BBE78F90C7CFC9A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_23F8A695101D1D2C2BBE78F90C7CFC9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_23F8A695101D1D2C2BBE78F90C7CFC9A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_23F8A695101D1D2C2BBE78F90C7CFC9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_23F8A695101D1D2C2BBE78F90C7CFC9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_23F8A695101D1D2C2BBE78F90C7CFC9A" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable_23F8A695101D1D2C2BBE78F90C7CFC9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillLineItems_27AA658B4FEC9768120578F90C7E8AEF_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_27AA658B4FEC9768120578F90C7E8AEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_27AA658B4FEC9768120578F90C7E8AEF_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_27AA658B4FEC9768120578F90C7E8AEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_27AA658B4FEC9768120578F90C7E8AEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems_27AA658B4FEC9768120578F90C7E8AEF" xlink:to="lab_us-gaap_GoodwillLineItems_27AA658B4FEC9768120578F90C7E8AEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillRollForward_186F27DCA580856D5BB478F90C7EEC7C_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_186F27DCA580856D5BB478F90C7EEC7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_186F27DCA580856D5BB478F90C7EEC7C_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_186F27DCA580856D5BB478F90C7EEC7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_186F27DCA580856D5BB478F90C7EEC7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward_186F27DCA580856D5BB478F90C7EEC7C" xlink:to="lab_us-gaap_GoodwillRollForward_186F27DCA580856D5BB478F90C7EEC7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_68F0DD63C35F063A3AC178F90C7EC312_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill_68F0DD63C35F063A3AC178F90C7EC312" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, December 31, 2019</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_68F0DD63C35F063A3AC178F90C7EC312" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_68F0DD63C35F063A3AC178F90C7EC312" xlink:to="lab_us-gaap_Goodwill_68F0DD63C35F063A3AC178F90C7EC312" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_59BECFB52CE76FF0F77C78F90C7E38DA_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_59BECFB52CE76FF0F77C78F90C7E38DA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_59BECFB52CE76FF0F77C78F90C7E38DA_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_59BECFB52CE76FF0F77C78F90C7E38DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_59BECFB52CE76FF0F77C78F90C7E38DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease_59BECFB52CE76FF0F77C78F90C7E38DA" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease_59BECFB52CE76FF0F77C78F90C7E38DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_8966D45DC9031C51945E78F90C7EBAFD_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill_8966D45DC9031C51945E78F90C7EBAFD" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, June 28, 2020</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_8966D45DC9031C51945E78F90C7EBAFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_8966D45DC9031C51945E78F90C7EBAFD" xlink:to="lab_us-gaap_Goodwill_8966D45DC9031C51945E78F90C7EBAFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_22DE9DF6A287C6D33C8F947621B07C2B_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_22DE9DF6A287C6D33C8F947621B07C2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_22DE9DF6A287C6D33C8F947621B07C2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_22DE9DF6A287C6D33C8F947621B07C2B" xlink:to="lab_us-gaap_NumberOfOperatingSegments_22DE9DF6A287C6D33C8F947621B07C2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_A06E874CF0597157F519947621B037F8_terseLabel_en-US" xlink:label="lab_us-gaap_Assets_A06E874CF0597157F519947621B037F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_A06E874CF0597157F519947621B037F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_A06E874CF0597157F519947621B037F8" xlink:to="lab_us-gaap_Assets_A06E874CF0597157F519947621B037F8" xlink:type="arc" />
    <link:label id="lab_pfe_LicensingAgreementsAndOtherMember_493C80EF7E2B2A8EFA2F78F1DC9C4760_verboseLabel_en-US" xlink:label="lab_pfe_LicensingAgreementsAndOtherMember_493C80EF7E2B2A8EFA2F78F1DC9C4760" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Licensing Agreements And Other [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LicensingAgreementsAndOtherMember" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_493C80EF7E2B2A8EFA2F78F1DC9C4760" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LicensingAgreementsAndOtherMember_493C80EF7E2B2A8EFA2F78F1DC9C4760" xlink:to="lab_pfe_LicensingAgreementsAndOtherMember_493C80EF7E2B2A8EFA2F78F1DC9C4760" xlink:type="arc" />
    <link:label id="lab_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_BDC6805348A73DA5BDF678F1DC9E1283_terseLabel_en-US" xlink:label="lab_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_BDC6805348A73DA5BDF678F1DC9E1283" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of total identifiable intangible assets, less accumulated amortization</link:label>
    <link:label id="lab_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_BDC6805348A73DA5BDF678F1DC9E1283_label_en-US" xlink:label="lab_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_BDC6805348A73DA5BDF678F1DC9E1283" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net, Percentage of Intangible Assets, Net</link:label>
    <link:label id="lab_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_BDC6805348A73DA5BDF678F1DC9E1283_documentation_en-US" xlink:label="lab_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_BDC6805348A73DA5BDF678F1DC9E1283" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net, Percentage of Intangible Assets, Net</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet" xlink:label="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_BDC6805348A73DA5BDF678F1DC9E1283" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_BDC6805348A73DA5BDF678F1DC9E1283" xlink:to="lab_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_BDC6805348A73DA5BDF678F1DC9E1283" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_F58F7A0BFCB3E3EFFA47947621847088_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_F58F7A0BFCB3E3EFFA47947621847088" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_F58F7A0BFCB3E3EFFA47947621847088_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_F58F7A0BFCB3E3EFFA47947621847088" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_F58F7A0BFCB3E3EFFA47947621847088" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_F58F7A0BFCB3E3EFFA47947621847088" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_F58F7A0BFCB3E3EFFA47947621847088" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_4BA6CF995377FDF7FD0994762184A2BA_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_4BA6CF995377FDF7FD0994762184A2BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_4BA6CF995377FDF7FD0994762184A2BA_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_4BA6CF995377FDF7FD0994762184A2BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_4BA6CF995377FDF7FD0994762184A2BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain_4BA6CF995377FDF7FD0994762184A2BA" xlink:to="lab_us-gaap_HedgingRelationshipDomain_4BA6CF995377FDF7FD0994762184A2BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowHedgingMember_C04C5910B95BB22A5FF894762184FD80_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember_C04C5910B95BB22A5FF894762184FD80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_C04C5910B95BB22A5FF894762184FD80_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember_C04C5910B95BB22A5FF894762184FD80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember" xlink:label="loc_us-gaap_CashFlowHedgingMember_C04C5910B95BB22A5FF894762184FD80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember_C04C5910B95BB22A5FF894762184FD80" xlink:to="lab_us-gaap_CashFlowHedgingMember_C04C5910B95BB22A5FF894762184FD80" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_4815BFD9F1FB5B90CA1E9476218A84E0_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember_4815BFD9F1FB5B90CA1E9476218A84E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_4815BFD9F1FB5B90CA1E9476218A84E0_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember_4815BFD9F1FB5B90CA1E9476218A84E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_4815BFD9F1FB5B90CA1E9476218A84E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember_4815BFD9F1FB5B90CA1E9476218A84E0" xlink:to="lab_us-gaap_NetInvestmentHedgingMember_4815BFD9F1FB5B90CA1E9476218A84E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NondesignatedMember_7709232A4B9C1FAFA1CA9476218B88FC_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember_7709232A4B9C1FAFA1CA9476218B88FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Financial Instruments Not Designated as Hedges [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_7709232A4B9C1FAFA1CA9476218B88FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember_7709232A4B9C1FAFA1CA9476218B88FC" xlink:to="lab_us-gaap_NondesignatedMember_7709232A4B9C1FAFA1CA9476218B88FC" xlink:type="arc" />
    <link:label id="lab_pfe_OtherIncomeDeductionsAndCostOfSalesMember_6CEA8C5BF7C12D64ED099476218CA094_terseLabel_en-US" xlink:label="lab_pfe_OtherIncomeDeductionsAndCostOfSalesMember_6CEA8C5BF7C12D64ED099476218CA094" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (Income) Deductions And Cost Of Sales [Member]</link:label>
    <link:label id="lab_pfe_OtherIncomeDeductionsAndCostOfSalesMember_6CEA8C5BF7C12D64ED099476218CA094_label_en-US" xlink:label="lab_pfe_OtherIncomeDeductionsAndCostOfSalesMember_6CEA8C5BF7C12D64ED099476218CA094" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other (Income) Deductions And Cost Of Sales [Member]</link:label>
    <link:label id="lab_pfe_OtherIncomeDeductionsAndCostOfSalesMember_6CEA8C5BF7C12D64ED099476218CA094_documentation_en-US" xlink:label="lab_pfe_OtherIncomeDeductionsAndCostOfSalesMember_6CEA8C5BF7C12D64ED099476218CA094" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other (Income) Deductions And Cost Of Sales [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherIncomeDeductionsAndCostOfSalesMember" xlink:label="loc_pfe_OtherIncomeDeductionsAndCostOfSalesMember_6CEA8C5BF7C12D64ED099476218CA094" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherIncomeDeductionsAndCostOfSalesMember_6CEA8C5BF7C12D64ED099476218CA094" xlink:to="lab_pfe_OtherIncomeDeductionsAndCostOfSalesMember_6CEA8C5BF7C12D64ED099476218CA094" xlink:type="arc" />
    <link:label id="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_F28D0B956AB3743B3E579476218DFF4B_terseLabel_en-US" xlink:label="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_F28D0B956AB3743B3E579476218DFF4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency short-term borrowings [Member]</link:label>
    <link:label id="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_F28D0B956AB3743B3E579476218DFF4B_label_en-US" xlink:label="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_F28D0B956AB3743B3E579476218DFF4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Short Term Borrowings [Member]</link:label>
    <link:label id="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_F28D0B956AB3743B3E579476218DFF4B_documentation_en-US" xlink:label="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_F28D0B956AB3743B3E579476218DFF4B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign currency short - term borrowings [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:label="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_F28D0B956AB3743B3E579476218DFF4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_F28D0B956AB3743B3E579476218DFF4B" xlink:to="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_F28D0B956AB3743B3E579476218DFF4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_D93016AAF3D3A7AD5FBC9476218DE611_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_D93016AAF3D3A7AD5FBC9476218DE611" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OID</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_D93016AAF3D3A7AD5FBC9476218DE611_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_D93016AAF3D3A7AD5FBC9476218DE611" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_D93016AAF3D3A7AD5FBC9476218DE611" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_D93016AAF3D3A7AD5FBC9476218DE611" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_D93016AAF3D3A7AD5FBC9476218DE611" xlink:type="arc" />
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_4EF126ED566AE4369DD49476218DFF22_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_4EF126ED566AE4369DD49476218DFF22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedged item</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_4EF126ED566AE4369DD49476218DFF22_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_4EF126ED566AE4369DD49476218DFF22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_4EF126ED566AE4369DD49476218DFF22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_4EF126ED566AE4369DD49476218DFF22" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_4EF126ED566AE4369DD49476218DFF22" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_74093AA0910EC4223FFB9476218E657D_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_74093AA0910EC4223FFB9476218E657D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OID</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_74093AA0910EC4223FFB9476218E657D_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_74093AA0910EC4223FFB9476218E657D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_74093AA0910EC4223FFB9476218E657D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_74093AA0910EC4223FFB9476218E657D" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_74093AA0910EC4223FFB9476218E657D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_5B0D08C094FF8ED47D629476218EFC45_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet_5B0D08C094FF8ED47D629476218EFC45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OID</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_5B0D08C094FF8ED47D629476218EFC45_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet_5B0D08C094FF8ED47D629476218EFC45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_5B0D08C094FF8ED47D629476218EFC45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet_5B0D08C094FF8ED47D629476218EFC45" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet_5B0D08C094FF8ED47D629476218EFC45" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_D12258B45456B356F7BD9476218EDF42_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_D12258B45456B356F7BD9476218EDF42" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OCI</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_D12258B45456B356F7BD9476218EDF42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_D12258B45456B356F7BD9476218EDF42" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_D12258B45456B356F7BD9476218EDF42" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_4A6B671B56CAC4AB38FB9476218EB8C5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_4A6B671B56CAC4AB38FB9476218EB8C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount excluded from effectiveness testing</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_4A6B671B56CAC4AB38FB9476218EB8C5_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_4A6B671B56CAC4AB38FB9476218EB8C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_4A6B671B56CAC4AB38FB9476218EB8C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_4A6B671B56CAC4AB38FB9476218EB8C5" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_4A6B671B56CAC4AB38FB9476218EB8C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_7D31C2FF8B30092ED3749476218E6789_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_7D31C2FF8B30092ED3749476218E6789" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_7D31C2FF8B30092ED3749476218E6789_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_7D31C2FF8B30092ED3749476218E6789" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_7D31C2FF8B30092ED3749476218E6789" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_7D31C2FF8B30092ED3749476218E6789" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_7D31C2FF8B30092ED3749476218E6789" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_D0116DAE828D959CB2799476218EE64C_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_D0116DAE828D959CB2799476218EE64C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OCI</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_D0116DAE828D959CB2799476218EE64C_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_D0116DAE828D959CB2799476218EE64C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_D0116DAE828D959CB2799476218EE64C_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_D0116DAE828D959CB2799476218EE64C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_D0116DAE828D959CB2799476218EE64C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_D0116DAE828D959CB2799476218EE64C" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_D0116DAE828D959CB2799476218EE64C" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_B648B6771E498CAA89219476218FB32E_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_B648B6771E498CAA89219476218FB32E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All other, net - Amount of Gains/(Losses) Recognized in OCI</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_B648B6771E498CAA89219476218FB32E_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_B648B6771E498CAA89219476218FB32E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_B648B6771E498CAA89219476218FB32E_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_B648B6771E498CAA89219476218FB32E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_B648B6771E498CAA89219476218FB32E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_B648B6771E498CAA89219476218FB32E" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_B648B6771E498CAA89219476218FB32E" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_9C0545DD5C15574507C29476218FB081_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_9C0545DD5C15574507C29476218FB081" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OCI</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_9C0545DD5C15574507C29476218FB081_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_9C0545DD5C15574507C29476218FB081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_9C0545DD5C15574507C29476218FB081_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_9C0545DD5C15574507C29476218FB081" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Before Reclassification and Tax</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_9C0545DD5C15574507C29476218FB081" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_9C0545DD5C15574507C29476218FB081" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_9C0545DD5C15574507C29476218FB081" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_DCD3EAB805D49F8AD3579476218F89BE_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_DCD3EAB805D49F8AD3579476218F89BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_DCD3EAB805D49F8AD3579476218F89BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_DCD3EAB805D49F8AD3579476218F89BE" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_DCD3EAB805D49F8AD3579476218F89BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_49644F7EE74FAAD00ECD9476218F00C2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_49644F7EE74FAAD00ECD9476218F00C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount excluded from effectiveness testing</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_49644F7EE74FAAD00ECD9476218F00C2_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_49644F7EE74FAAD00ECD9476218F00C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_49644F7EE74FAAD00ECD9476218F00C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_49644F7EE74FAAD00ECD9476218F00C2" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_49644F7EE74FAAD00ECD9476218F00C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_312F42110A8A60573FA39476218F6175_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_312F42110A8A60573FA39476218F6175" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_312F42110A8A60573FA39476218F6175_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_312F42110A8A60573FA39476218F6175" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_312F42110A8A60573FA39476218F6175" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_312F42110A8A60573FA39476218F6175" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_312F42110A8A60573FA39476218F6175" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_2295A4E4B36D2982DEBE9476218F64A2_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_2295A4E4B36D2982DEBE9476218F64A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_2295A4E4B36D2982DEBE9476218F64A2_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_2295A4E4B36D2982DEBE9476218F64A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_2295A4E4B36D2982DEBE9476218F64A2_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_2295A4E4B36D2982DEBE9476218F64A2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_2295A4E4B36D2982DEBE9476218F64A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_2295A4E4B36D2982DEBE9476218F64A2" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_2295A4E4B36D2982DEBE9476218F64A2" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_F8E168276EAAA4C99E9A94762190D180_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_F8E168276EAAA4C99E9A94762190D180" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_F8E168276EAAA4C99E9A94762190D180_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_F8E168276EAAA4C99E9A94762190D180" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_F8E168276EAAA4C99E9A94762190D180_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_F8E168276EAAA4C99E9A94762190D180" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_F8E168276EAAA4C99E9A94762190D180" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_F8E168276EAAA4C99E9A94762190D180" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_F8E168276EAAA4C99E9A94762190D180" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_64EEDA03A8327FBBA3B3947621901730_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_64EEDA03A8327FBBA3B3947621901730" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_64EEDA03A8327FBBA3B3947621901730_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_64EEDA03A8327FBBA3B3947621901730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_64EEDA03A8327FBBA3B3947621901730_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_64EEDA03A8327FBBA3B3947621901730" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_64EEDA03A8327FBBA3B3947621901730" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_64EEDA03A8327FBBA3B3947621901730" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_64EEDA03A8327FBBA3B3947621901730" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_95BFB6E2830EEDB231887480650823E6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss_95BFB6E2830EEDB231887480650823E6" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net gains recognized during the period on investments in equity securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_95BFB6E2830EEDB231887480650823E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_95BFB6E2830EEDB231887480650823E6" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss_95BFB6E2830EEDB231887480650823E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_75556FB21B1B4563989D748065097D08_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_75556FB21B1B4563989D748065097D08" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Net (gains)/losses recognized during the period on equity securities sold during the period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_75556FB21B1B4563989D748065097D08_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_75556FB21B1B4563989D748065097D08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_75556FB21B1B4563989D748065097D08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_75556FB21B1B4563989D748065097D08" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_75556FB21B1B4563989D748065097D08" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_97DA8890C2936930B27C748065091F82_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_97DA8890C2936930B27C748065091F82" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gains during the reporting period on equity securities still held at the reporting date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_97DA8890C2936930B27C748065091F82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_97DA8890C2936930B27C748065091F82" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_97DA8890C2936930B27C748065091F82" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_7E4F3D5973CB982F5987947620E94EE5_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_7E4F3D5973CB982F5987947620E94EE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_7E4F3D5973CB982F5987947620E94EE5_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_7E4F3D5973CB982F5987947620E94EE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_7E4F3D5973CB982F5987947620E94EE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_7E4F3D5973CB982F5987947620E94EE5" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_7E4F3D5973CB982F5987947620E94EE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTable_08820D7E77FB99D87C5294762301569A_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_08820D7E77FB99D87C5294762301569A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_08820D7E77FB99D87C5294762301569A_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_08820D7E77FB99D87C5294762301569A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_08820D7E77FB99D87C5294762301569A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable_08820D7E77FB99D87C5294762301569A" xlink:to="lab_us-gaap_ConcentrationRiskTable_08820D7E77FB99D87C5294762301569A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesByIndustryAxis_DBD79DBEE99F081F1DDD94762301BFAA_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesByIndustryAxis_DBD79DBEE99F081F1DDD94762301BFAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Industry Sector [Axis]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesByIndustryAxis_DBD79DBEE99F081F1DDD94762301BFAA_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesByIndustryAxis_DBD79DBEE99F081F1DDD94762301BFAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Industry Sector [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesByIndustryAxis" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis_DBD79DBEE99F081F1DDD94762301BFAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_DBD79DBEE99F081F1DDD94762301BFAA" xlink:to="lab_us-gaap_EquitySecuritiesByIndustryAxis_DBD79DBEE99F081F1DDD94762301BFAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesIndustryMember_10BA5A1BA379B5B769B894762301DEDE_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesIndustryMember_10BA5A1BA379B5B769B894762301DEDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Industry Sector [Domain]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesIndustryMember_10BA5A1BA379B5B769B894762301DEDE_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesIndustryMember_10BA5A1BA379B5B769B894762301DEDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Industry Sector [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_10BA5A1BA379B5B769B894762301DEDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember_10BA5A1BA379B5B769B894762301DEDE" xlink:to="lab_us-gaap_EquitySecuritiesIndustryMember_10BA5A1BA379B5B769B894762301DEDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialServicesSectorMember_C46FD2B47D4492A6556094762302859F_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialServicesSectorMember_C46FD2B47D4492A6556094762302859F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bank sector [Member]</link:label>
    <link:label id="lab_us-gaap_FinancialServicesSectorMember_C46FD2B47D4492A6556094762302859F_label_en-US" xlink:label="lab_us-gaap_FinancialServicesSectorMember_C46FD2B47D4492A6556094762302859F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Services Sector [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialServicesSectorMember" xlink:label="loc_us-gaap_FinancialServicesSectorMember_C46FD2B47D4492A6556094762302859F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialServicesSectorMember_C46FD2B47D4492A6556094762302859F" xlink:to="lab_us-gaap_FinancialServicesSectorMember_C46FD2B47D4492A6556094762302859F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_50D892AF020B7A3BF8AC9476230265BB_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_50D892AF020B7A3BF8AC9476230265BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_50D892AF020B7A3BF8AC9476230265BB_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_50D892AF020B7A3BF8AC9476230265BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_50D892AF020B7A3BF8AC9476230265BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_50D892AF020B7A3BF8AC9476230265BB" xlink:to="lab_us-gaap_ConcentrationRiskLineItems_50D892AF020B7A3BF8AC9476230265BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_FB52200C400B928C19A094762302E303_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_FB52200C400B928C19A094762302E303" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum exposure, amount</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_FB52200C400B928C19A094762302E303_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_FB52200C400B928C19A094762302E303" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:label="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_FB52200C400B928C19A094762302E303" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_FB52200C400B928C19A094762302E303" xlink:to="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_FB52200C400B928C19A094762302E303" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_D294F93DED1CA7330FF792DEB7BDD133_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_D294F93DED1CA7330FF792DEB7BDD133" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_D294F93DED1CA7330FF792DEB7BDD133_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_D294F93DED1CA7330FF792DEB7BDD133" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_D294F93DED1CA7330FF792DEB7BDD133" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_D294F93DED1CA7330FF792DEB7BDD133" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_D294F93DED1CA7330FF792DEB7BDD133" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_3071AB24BD5A4A00F7EC92DEB7BDA19E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_3071AB24BD5A4A00F7EC92DEB7BDA19E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized holding gains/(losses) on derivative financial instruments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_3071AB24BD5A4A00F7EC92DEB7BDA19E_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_3071AB24BD5A4A00F7EC92DEB7BDA19E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_3071AB24BD5A4A00F7EC92DEB7BDA19E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_3071AB24BD5A4A00F7EC92DEB7BDA19E" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_3071AB24BD5A4A00F7EC92DEB7BDA19E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_9ED0C3887C48D0F77C8392DEB7BEA0D7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_9ED0C3887C48D0F77C8392DEB7BEA0D7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments for gains included in net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_9ED0C3887C48D0F77C8392DEB7BEA0D7_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_9ED0C3887C48D0F77C8392DEB7BEA0D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_9ED0C3887C48D0F77C8392DEB7BEA0D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_9ED0C3887C48D0F77C8392DEB7BEA0D7" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_9ED0C3887C48D0F77C8392DEB7BEA0D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_0C58A26B3CFCF572C89A92DEB7BE8E72_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_0C58A26B3CFCF572C89A92DEB7BE8E72" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Derivatives qualifying as hedges, tax, total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_0C58A26B3CFCF572C89A92DEB7BE8E72_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_0C58A26B3CFCF572C89A92DEB7BE8E72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_0C58A26B3CFCF572C89A92DEB7BE8E72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_0C58A26B3CFCF572C89A92DEB7BE8E72" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_0C58A26B3CFCF572C89A92DEB7BE8E72" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_BB3093AD971517E3E8A292DEB7BE6BE6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_BB3093AD971517E3E8A292DEB7BE6BE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized holding gains/(losses) on available-for-sale securities, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_BB3093AD971517E3E8A292DEB7BE6BE6_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_BB3093AD971517E3E8A292DEB7BE6BE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_BB3093AD971517E3E8A292DEB7BE6BE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_BB3093AD971517E3E8A292DEB7BE6BE6" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_BB3093AD971517E3E8A292DEB7BE6BE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_644BCE7D7275D971149992DEB7BE98D8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_644BCE7D7275D971149992DEB7BE98D8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments for losses included in net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_644BCE7D7275D971149992DEB7BE98D8_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_644BCE7D7275D971149992DEB7BE98D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_644BCE7D7275D971149992DEB7BE98D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_644BCE7D7275D971149992DEB7BE98D8" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_644BCE7D7275D971149992DEB7BE98D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_1BC37AB1D5295DD2361292DEB7BECE23_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_1BC37AB1D5295DD2361292DEB7BECE23" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, tax, total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_1BC37AB1D5295DD2361292DEB7BECE23_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_1BC37AB1D5295DD2361292DEB7BECE23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_1BC37AB1D5295DD2361292DEB7BECE23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_1BC37AB1D5295DD2361292DEB7BECE23" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_1BC37AB1D5295DD2361292DEB7BECE23" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_D53E80069F61CFBA325E92DEB7BEB3DF_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_D53E80069F61CFBA325E92DEB7BEB3DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Benefit plans: actuarial gains/(losses), net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_D53E80069F61CFBA325E92DEB7BEB3DF_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_D53E80069F61CFBA325E92DEB7BEB3DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_D53E80069F61CFBA325E92DEB7BEB3DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_D53E80069F61CFBA325E92DEB7BEB3DF" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_D53E80069F61CFBA325E92DEB7BEB3DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_4BF0D30ADD5E95B0009792DEB7BFF81F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_4BF0D30ADD5E95B0009792DEB7BFF81F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments related to amortization</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_4BF0D30ADD5E95B0009792DEB7BFF81F_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_4BF0D30ADD5E95B0009792DEB7BFF81F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_4BF0D30ADD5E95B0009792DEB7BFF81F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_4BF0D30ADD5E95B0009792DEB7BFF81F" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_4BF0D30ADD5E95B0009792DEB7BFF81F" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_E796EED094BFAC635A0A92DEB7C46CF3_negatedTerseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_E796EED094BFAC635A0A92DEB7C46CF3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments related to settlements, net</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_E796EED094BFAC635A0A92DEB7C46CF3_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_E796EED094BFAC635A0A92DEB7C46CF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Settlement Adjustment From AOCI, Pension And Other Postretirement Benefit Plans, for Net Gain (Loss), Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_E796EED094BFAC635A0A92DEB7C46CF3_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_E796EED094BFAC635A0A92DEB7C46CF3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Settlement Adjustment From AOCI, Pension And Other Postretirement Benefit Plans, for Net Gain (Loss), Tax</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_E796EED094BFAC635A0A92DEB7C46CF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_E796EED094BFAC635A0A92DEB7C46CF3" xlink:to="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_E796EED094BFAC635A0A92DEB7C46CF3" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_1F371B0BD01C0401DEEE92DEB7C431B8_negatedTerseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_1F371B0BD01C0401DEEE92DEB7C431B8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_1F371B0BD01C0401DEEE92DEB7C431B8_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_1F371B0BD01C0401DEEE92DEB7C431B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Other Net Unamortized Gain (Loss) Arising During Period, Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_1F371B0BD01C0401DEEE92DEB7C431B8_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_1F371B0BD01C0401DEEE92DEB7C431B8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Other Net Unamortized Gain (Loss) Arising During Period, Tax</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_1F371B0BD01C0401DEEE92DEB7C431B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_1F371B0BD01C0401DEEE92DEB7C431B8" xlink:to="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_1F371B0BD01C0401DEEE92DEB7C431B8" xlink:type="arc" />
    <link:label id="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_219A2875FD3414276E6992DEB7C415BE_totalLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_219A2875FD3414276E6992DEB7C415BE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Defined benefit plans, actuarial gain (loss), tax, total</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_219A2875FD3414276E6992DEB7C415BE_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_219A2875FD3414276E6992DEB7C415BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Actuarial Gain (Loss), Tax</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_219A2875FD3414276E6992DEB7C415BE_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_219A2875FD3414276E6992DEB7C415BE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Actuarial Gain (Loss), Tax</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax" xlink:label="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_219A2875FD3414276E6992DEB7C415BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_219A2875FD3414276E6992DEB7C415BE" xlink:to="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_219A2875FD3414276E6992DEB7C415BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_F098FE31685B346AED5F92DEB7C4D186_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_F098FE31685B346AED5F92DEB7C4D186" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments related to amortization of prior service costs and other, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_F098FE31685B346AED5F92DEB7C4D186_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_F098FE31685B346AED5F92DEB7C4D186" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_F098FE31685B346AED5F92DEB7C4D186" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_F098FE31685B346AED5F92DEB7C4D186" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_F098FE31685B346AED5F92DEB7C4D186" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_2726971307AD36947F3292DEB7C5CD04_negatedLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_2726971307AD36947F3292DEB7C5CD04" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_2726971307AD36947F3292DEB7C5CD04_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_2726971307AD36947F3292DEB7C5CD04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_2726971307AD36947F3292DEB7C5CD04_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_2726971307AD36947F3292DEB7C5CD04" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, Tax</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_2726971307AD36947F3292DEB7C5CD04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_2726971307AD36947F3292DEB7C5CD04" xlink:to="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_2726971307AD36947F3292DEB7C5CD04" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_BE85D62D23789BCEBB0F92DEB7C5D4D9_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_BE85D62D23789BCEBB0F92DEB7C5D4D9" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Pension and other postretirement benefit plans, net prior service cost (credit), tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_BE85D62D23789BCEBB0F92DEB7C5D4D9_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_BE85D62D23789BCEBB0F92DEB7C5D4D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_BE85D62D23789BCEBB0F92DEB7C5D4D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_BE85D62D23789BCEBB0F92DEB7C5D4D9" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_BE85D62D23789BCEBB0F92DEB7C5D4D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_650565DF1FCCBDB3F9A692DEB7C58013_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax_650565DF1FCCBDB3F9A692DEB7C58013" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Tax provision/(benefit) on other comprehensive loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_650565DF1FCCBDB3F9A692DEB7C58013" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_650565DF1FCCBDB3F9A692DEB7C58013" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax_650565DF1FCCBDB3F9A692DEB7C58013" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_E2E75739637AEB4E73BD947620117BDC_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_E2E75739637AEB4E73BD947620117BDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Identifiable Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_E2E75739637AEB4E73BD947620117BDC_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_E2E75739637AEB4E73BD947620117BDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_E2E75739637AEB4E73BD947620117BDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_E2E75739637AEB4E73BD947620117BDC" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_E2E75739637AEB4E73BD947620117BDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_AFDFB47E3B70C6F84583947622F4D354_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_AFDFB47E3B70C6F84583947622F4D354" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies and Certain Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_AFDFB47E3B70C6F84583947622F4D354_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_AFDFB47E3B70C6F84583947622F4D354" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_AFDFB47E3B70C6F84583947622F4D354" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_AFDFB47E3B70C6F84583947622F4D354" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_AFDFB47E3B70C6F84583947622F4D354" xlink:type="arc" />
    <link:label id="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_6114E36E34948349AD7494761EE8059A_terseLabel_en-US" xlink:label="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_6114E36E34948349AD7494761EE8059A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)</link:label>
    <link:label id="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_6114E36E34948349AD7494761EE8059A_label_en-US" xlink:label="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_6114E36E34948349AD7494761EE8059A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label id="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_6114E36E34948349AD7494761EE8059A_documentation_en-US" xlink:label="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_6114E36E34948349AD7494761EE8059A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_6114E36E34948349AD7494761EE8059A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_6114E36E34948349AD7494761EE8059A" xlink:to="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_6114E36E34948349AD7494761EE8059A" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_286958FD4BA0683B150B94761F42A95E_netLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_286958FD4BA0683B150B94761F42A95E" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_286958FD4BA0683B150B94761F42A95E_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_286958FD4BA0683B150B94761F42A95E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_286958FD4BA0683B150B94761F42A95E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_286958FD4BA0683B150B94761F42A95E" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_286958FD4BA0683B150B94761F42A95E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5FDE4D403C55802E4CC094761F42C3CB_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5FDE4D403C55802E4CC094761F42C3CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration liability current</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5FDE4D403C55802E4CC094761F42C3CB_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5FDE4D403C55802E4CC094761F42C3CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5FDE4D403C55802E4CC094761F42C3CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5FDE4D403C55802E4CC094761F42C3CB" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5FDE4D403C55802E4CC094761F42C3CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7C34E5059CD00E25A98894761F42DF3B_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7C34E5059CD00E25A98894761F42DF3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration liability noncurrent</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7C34E5059CD00E25A98894761F42DF3B_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7C34E5059CD00E25A98894761F42DF3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7C34E5059CD00E25A98894761F42DF3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7C34E5059CD00E25A98894761F42DF3B" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7C34E5059CD00E25A98894761F42DF3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainContingenciesTable_A8A240334B7429C19B7DBEEA11CA574D_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesTable_A8A240334B7429C19B7DBEEA11CA574D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesTable_A8A240334B7429C19B7DBEEA11CA574D_label_en-US" xlink:label="lab_us-gaap_GainContingenciesTable_A8A240334B7429C19B7DBEEA11CA574D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesTable" xlink:label="loc_us-gaap_GainContingenciesTable_A8A240334B7429C19B7DBEEA11CA574D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesTable_A8A240334B7429C19B7DBEEA11CA574D" xlink:to="lab_us-gaap_GainContingenciesTable_A8A240334B7429C19B7DBEEA11CA574D" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainContingenciesByNatureAxis_0F364E2984BC0F6F5DE5BEEA11CC8638_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesByNatureAxis_0F364E2984BC0F6F5DE5BEEA11CC8638" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain Contingencies, Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesByNatureAxis_0F364E2984BC0F6F5DE5BEEA11CC8638_label_en-US" xlink:label="lab_us-gaap_GainContingenciesByNatureAxis_0F364E2984BC0F6F5DE5BEEA11CC8638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingencies, Nature [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_0F364E2984BC0F6F5DE5BEEA11CC8638" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_0F364E2984BC0F6F5DE5BEEA11CC8638" xlink:to="lab_us-gaap_GainContingenciesByNatureAxis_0F364E2984BC0F6F5DE5BEEA11CC8638" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainContingencyNatureDomain_7B6B4D8E0551B32D0B98BEEA11CC5F92_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyNatureDomain_7B6B4D8E0551B32D0B98BEEA11CC5F92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_GainContingencyNatureDomain_7B6B4D8E0551B32D0B98BEEA11CC5F92_label_en-US" xlink:label="lab_us-gaap_GainContingencyNatureDomain_7B6B4D8E0551B32D0B98BEEA11CC5F92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingency, Nature [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaap_GainContingencyNatureDomain_7B6B4D8E0551B32D0B98BEEA11CC5F92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyNatureDomain_7B6B4D8E0551B32D0B98BEEA11CC5F92" xlink:to="lab_us-gaap_GainContingencyNatureDomain_7B6B4D8E0551B32D0B98BEEA11CC5F92" xlink:type="arc" />
    <link:label id="lab_pfe_XeljanzMember_48AB90B8505718CC27C8BEEA11CDE3DD_terseLabel_en-US" xlink:label="lab_pfe_XeljanzMember_48AB90B8505718CC27C8BEEA11CDE3DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Xeljanz [Member]</link:label>
    <link:label id="lab_pfe_XeljanzMember_48AB90B8505718CC27C8BEEA11CDE3DD_label_en-US" xlink:label="lab_pfe_XeljanzMember_48AB90B8505718CC27C8BEEA11CDE3DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Xeljanz [Member]</link:label>
    <link:label id="lab_pfe_XeljanzMember_48AB90B8505718CC27C8BEEA11CDE3DD_documentation_en-US" xlink:label="lab_pfe_XeljanzMember_48AB90B8505718CC27C8BEEA11CDE3DD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Xeljanz [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_XeljanzMember" xlink:label="loc_pfe_XeljanzMember_48AB90B8505718CC27C8BEEA11CDE3DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_XeljanzMember_48AB90B8505718CC27C8BEEA11CDE3DD" xlink:to="lab_pfe_XeljanzMember_48AB90B8505718CC27C8BEEA11CDE3DD" xlink:type="arc" />
    <link:label id="lab_pfe_EliquisMember_0B119DAB662E2A756D0BBEEA11CEE6C2_terseLabel_en-US" xlink:label="lab_pfe_EliquisMember_0B119DAB662E2A756D0BBEEA11CEE6C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eliquis [Member]</link:label>
    <link:label id="lab_pfe_EliquisMember_0B119DAB662E2A756D0BBEEA11CEE6C2_label_en-US" xlink:label="lab_pfe_EliquisMember_0B119DAB662E2A756D0BBEEA11CEE6C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eliquis [Member]</link:label>
    <link:label id="lab_pfe_EliquisMember_0B119DAB662E2A756D0BBEEA11CEE6C2_documentation_en-US" xlink:label="lab_pfe_EliquisMember_0B119DAB662E2A756D0BBEEA11CEE6C2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eliquis [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EliquisMember" xlink:label="loc_pfe_EliquisMember_0B119DAB662E2A756D0BBEEA11CEE6C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EliquisMember_0B119DAB662E2A756D0BBEEA11CEE6C2" xlink:to="lab_pfe_EliquisMember_0B119DAB662E2A756D0BBEEA11CEE6C2" xlink:type="arc" />
    <link:label id="lab_pfe_PfizerVersusZydusMember_3F5C1910368A2F8901D8BEEA11CEC0E8_terseLabel_en-US" xlink:label="lab_pfe_PfizerVersusZydusMember_3F5C1910368A2F8901D8BEEA11CEC0E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer Versus Zydus [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusZydusMember_3F5C1910368A2F8901D8BEEA11CEC0E8_label_en-US" xlink:label="lab_pfe_PfizerVersusZydusMember_3F5C1910368A2F8901D8BEEA11CEC0E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer Versus Zydus [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusZydusMember_3F5C1910368A2F8901D8BEEA11CEC0E8_documentation_en-US" xlink:label="lab_pfe_PfizerVersusZydusMember_3F5C1910368A2F8901D8BEEA11CEC0E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer Versus Zydus [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PfizerVersusZydusMember" xlink:label="loc_pfe_PfizerVersusZydusMember_3F5C1910368A2F8901D8BEEA11CEC0E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerVersusZydusMember_3F5C1910368A2F8901D8BEEA11CEC0E8" xlink:to="lab_pfe_PfizerVersusZydusMember_3F5C1910368A2F8901D8BEEA11CEC0E8" xlink:type="arc" />
    <link:label id="lab_pfe_PfizerVersusGenericCompaniesMember_001D33D5976A5912AE9CBEEA11CF5C7B_terseLabel_en-US" xlink:label="lab_pfe_PfizerVersusGenericCompaniesMember_001D33D5976A5912AE9CBEEA11CF5C7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer Versus Generic Companies [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusGenericCompaniesMember_001D33D5976A5912AE9CBEEA11CF5C7B_label_en-US" xlink:label="lab_pfe_PfizerVersusGenericCompaniesMember_001D33D5976A5912AE9CBEEA11CF5C7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer Versus Generic Companies [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusGenericCompaniesMember_001D33D5976A5912AE9CBEEA11CF5C7B_documentation_en-US" xlink:label="lab_pfe_PfizerVersusGenericCompaniesMember_001D33D5976A5912AE9CBEEA11CF5C7B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer Versus Generic Companies [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PfizerVersusGenericCompaniesMember" xlink:label="loc_pfe_PfizerVersusGenericCompaniesMember_001D33D5976A5912AE9CBEEA11CF5C7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerVersusGenericCompaniesMember_001D33D5976A5912AE9CBEEA11CF5C7B" xlink:to="lab_pfe_PfizerVersusGenericCompaniesMember_001D33D5976A5912AE9CBEEA11CF5C7B" xlink:type="arc" />
    <link:label id="lab_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_DC26A25730FCC8F23715BEEA11CF4661_terseLabel_en-US" xlink:label="lab_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_DC26A25730FCC8F23715BEEA11CF4661" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer Versus Viwit Pharmaceutical Co. Ltd. [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_DC26A25730FCC8F23715BEEA11CF4661_label_en-US" xlink:label="lab_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_DC26A25730FCC8F23715BEEA11CF4661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer Versus Viwit Pharmaceutical Co. Ltd. [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_DC26A25730FCC8F23715BEEA11CF4661_documentation_en-US" xlink:label="lab_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_DC26A25730FCC8F23715BEEA11CF4661" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer Versus Viwit Pharmaceutical Co. Ltd. [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member" xlink:label="loc_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_DC26A25730FCC8F23715BEEA11CF4661" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_DC26A25730FCC8F23715BEEA11CF4661" xlink:to="lab_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_DC26A25730FCC8F23715BEEA11CF4661" xlink:type="arc" />
    <link:label id="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_8A24D916C1B7C574EDF0BEEA11CF84B6_terseLabel_en-US" xlink:label="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_8A24D916C1B7C574EDF0BEEA11CF84B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer and BMS Versus Several Generic Manufacturers [Member]</link:label>
    <link:label id="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_8A24D916C1B7C574EDF0BEEA11CF84B6_label_en-US" xlink:label="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_8A24D916C1B7C574EDF0BEEA11CF84B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer and BMS Versus Several Generic Manufacturers [Member]</link:label>
    <link:label id="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_8A24D916C1B7C574EDF0BEEA11CF84B6_documentation_en-US" xlink:label="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_8A24D916C1B7C574EDF0BEEA11CF84B6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer and BMS Versus Several Generic Manufacturers [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" xlink:label="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_8A24D916C1B7C574EDF0BEEA11CF84B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_8A24D916C1B7C574EDF0BEEA11CF84B6" xlink:to="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_8A24D916C1B7C574EDF0BEEA11CF84B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_JudicialRulingMember_F0D965BCEB4D78258CB4BEEA11D5A605_terseLabel_en-US" xlink:label="lab_us-gaap_JudicialRulingMember_F0D965BCEB4D78258CB4BEEA11D5A605" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Judicial Ruling [Member]</link:label>
    <link:label id="lab_us-gaap_JudicialRulingMember_F0D965BCEB4D78258CB4BEEA11D5A605_label_en-US" xlink:label="lab_us-gaap_JudicialRulingMember_F0D965BCEB4D78258CB4BEEA11D5A605" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Judicial Ruling [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_JudicialRulingMember" xlink:label="loc_us-gaap_JudicialRulingMember_F0D965BCEB4D78258CB4BEEA11D5A605" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_JudicialRulingMember_F0D965BCEB4D78258CB4BEEA11D5A605" xlink:to="lab_us-gaap_JudicialRulingMember_F0D965BCEB4D78258CB4BEEA11D5A605" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainContingenciesLineItems_12B10E098DED288AFE24BEEA11D61605_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesLineItems_12B10E098DED288AFE24BEEA11D61605" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesLineItems_12B10E098DED288AFE24BEEA11D61605_label_en-US" xlink:label="lab_us-gaap_GainContingenciesLineItems_12B10E098DED288AFE24BEEA11D61605" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesLineItems" xlink:label="loc_us-gaap_GainContingenciesLineItems_12B10E098DED288AFE24BEEA11D61605" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesLineItems_12B10E098DED288AFE24BEEA11D61605" xlink:to="lab_us-gaap_GainContingenciesLineItems_12B10E098DED288AFE24BEEA11D61605" xlink:type="arc" />
    <link:label id="lab_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_6677E18B16E4B402A75FBEEA11D6A548_terseLabel_en-US" xlink:label="lab_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_6677E18B16E4B402A75FBEEA11D6A548" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patents which the Patent Trial and Appeal Board refused to initiate proceedings</link:label>
    <link:label id="lab_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_6677E18B16E4B402A75FBEEA11D6A548_label_en-US" xlink:label="lab_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_6677E18B16E4B402A75FBEEA11D6A548" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingency, Patents Without Court Proceedings, Number</link:label>
    <link:label id="lab_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_6677E18B16E4B402A75FBEEA11D6A548_documentation_en-US" xlink:label="lab_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_6677E18B16E4B402A75FBEEA11D6A548" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain Contingency, Patents Without Court Proceedings, Number</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_GainContingencyPatentsWithoutCourtProceedingsNumber" xlink:label="loc_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_6677E18B16E4B402A75FBEEA11D6A548" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_6677E18B16E4B402A75FBEEA11D6A548" xlink:to="lab_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_6677E18B16E4B402A75FBEEA11D6A548" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_CB69A48214050E477603BEEA11D62A8C_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_CB69A48214050E477603BEEA11D62A8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patents infringed upon</link:label>
    <link:label id="lab_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_CB69A48214050E477603BEEA11D62A8C_label_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_CB69A48214050E477603BEEA11D62A8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingency, Patents Found Infringed upon, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyPatentsFoundInfringedUponNumber" xlink:label="loc_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_CB69A48214050E477603BEEA11D62A8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_CB69A48214050E477603BEEA11D62A8C" xlink:to="lab_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_CB69A48214050E477603BEEA11D62A8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_18D892FB0AF65564CE87BEEA11D6BB1E_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_18D892FB0AF65564CE87BEEA11D6BB1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patents allegedly infringed upon</link:label>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_18D892FB0AF65564CE87BEEA11D6BB1E_label_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_18D892FB0AF65564CE87BEEA11D6BB1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed upon, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_18D892FB0AF65564CE87BEEA11D6BB1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_18D892FB0AF65564CE87BEEA11D6BB1E" xlink:to="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_18D892FB0AF65564CE87BEEA11D6BB1E" xlink:type="arc" />
    <link:label id="lab_pfe_GainContingencyNumberofDefendants_5A124AF6CA4B9611DE8DBEEA11D6927C_terseLabel_en-US" xlink:label="lab_pfe_GainContingencyNumberofDefendants_5A124AF6CA4B9611DE8DBEEA11D6927C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of defendants</link:label>
    <link:label id="lab_pfe_GainContingencyNumberofDefendants_5A124AF6CA4B9611DE8DBEEA11D6927C_label_en-US" xlink:label="lab_pfe_GainContingencyNumberofDefendants_5A124AF6CA4B9611DE8DBEEA11D6927C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingency, Number of Defendants</link:label>
    <link:label id="lab_pfe_GainContingencyNumberofDefendants_5A124AF6CA4B9611DE8DBEEA11D6927C_documentation_en-US" xlink:label="lab_pfe_GainContingencyNumberofDefendants_5A124AF6CA4B9611DE8DBEEA11D6927C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain Contingency, Number of Defendants</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_GainContingencyNumberofDefendants" xlink:label="loc_pfe_GainContingencyNumberofDefendants_5A124AF6CA4B9611DE8DBEEA11D6927C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GainContingencyNumberofDefendants_5A124AF6CA4B9611DE8DBEEA11D6927C" xlink:to="lab_pfe_GainContingencyNumberofDefendants_5A124AF6CA4B9611DE8DBEEA11D6927C" xlink:type="arc" />
    <link:label id="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_7E9BD4A27D5FEE966D90BEEA11D72E69_terseLabel_en-US" xlink:label="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_7E9BD4A27D5FEE966D90BEEA11D72E69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patents allegedly infringed upon due to expire December 2019</link:label>
    <link:label id="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_7E9BD4A27D5FEE966D90BEEA11D72E69_label_en-US" xlink:label="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_7E9BD4A27D5FEE966D90BEEA11D72E69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019</link:label>
    <link:label id="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_7E9BD4A27D5FEE966D90BEEA11D72E69_documentation_en-US" xlink:label="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_7E9BD4A27D5FEE966D90BEEA11D72E69" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" xlink:label="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_7E9BD4A27D5FEE966D90BEEA11D72E69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_7E9BD4A27D5FEE966D90BEEA11D72E69" xlink:to="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_7E9BD4A27D5FEE966D90BEEA11D72E69" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_C635EB3B80589E73895A94761FFDB5D8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_C635EB3B80589E73895A94761FFDB5D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net Periodic Benefit Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_C635EB3B80589E73895A94761FFDB5D8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_C635EB3B80589E73895A94761FFDB5D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_C635EB3B80589E73895A94761FFDB5D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_C635EB3B80589E73895A94761FFDB5D8" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_C635EB3B80589E73895A94761FFDB5D8" xlink:type="arc" />
    <link:label id="lab_pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock_205667885597B4683A5794761FFEA886_terseLabel_en-US" xlink:label="lab_pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock_205667885597B4683A5794761FFEA886" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employer Contributions to Pension and Postretirement Plans</link:label>
    <link:label id="lab_pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock_205667885597B4683A5794761FFEA886_label_en-US" xlink:label="lab_pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock_205667885597B4683A5794761FFEA886" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employer Contributions to Pension and Postretirement Plans [Table Text Block]</link:label>
    <link:label id="lab_pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock_205667885597B4683A5794761FFEA886_documentation_en-US" xlink:label="lab_pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock_205667885597B4683A5794761FFEA886" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Employer Contributions to Pension and Postretirement Plans [Table Text Block]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock" xlink:label="loc_pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock_205667885597B4683A5794761FFEA886" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock_205667885597B4683A5794761FFEA886" xlink:to="lab_pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock_205667885597B4683A5794761FFEA886" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_3B95B715053DA819EDF994762221F03F_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_3B95B715053DA819EDF994762221F03F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_3B95B715053DA819EDF994762221F03F_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_3B95B715053DA819EDF994762221F03F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_3B95B715053DA819EDF994762221F03F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_3B95B715053DA819EDF994762221F03F" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_3B95B715053DA819EDF994762221F03F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_1617CCF41B628EEA7E2A947622219C20_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_1617CCF41B628EEA7E2A947622219C20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_1617CCF41B628EEA7E2A947622219C20_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_1617CCF41B628EEA7E2A947622219C20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_1617CCF41B628EEA7E2A947622219C20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_1617CCF41B628EEA7E2A947622219C20" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_1617CCF41B628EEA7E2A947622219C20" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_24BF0A28E4D80F8CE05494762221C814_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_24BF0A28E4D80F8CE05494762221C814" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenues by Geographic Region</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_24BF0A28E4D80F8CE05494762221C814_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_24BF0A28E4D80F8CE05494762221C814" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_24BF0A28E4D80F8CE05494762221C814" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_24BF0A28E4D80F8CE05494762221C814" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_24BF0A28E4D80F8CE05494762221C814" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4336BD514DF15D436A50947622218EFC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4336BD514DF15D436A50947622218EFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Significant Product Revenues</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4336BD514DF15D436A50947622218EFC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4336BD514DF15D436A50947622218EFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4336BD514DF15D436A50947622218EFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4336BD514DF15D436A50947622218EFC" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4336BD514DF15D436A50947622218EFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserve_75CD9635D9A2C251034294761FF6F062_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve_75CD9635D9A2C251034294761FF6F062" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring reserve</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_75CD9635D9A2C251034294761FF6F062" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve_75CD9635D9A2C251034294761FF6F062" xlink:to="lab_us-gaap_RestructuringReserve_75CD9635D9A2C251034294761FF6F062" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_A1EB3D5846300743B3EA947620A402C0_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_A1EB3D5846300743B3EA947620A402C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_A1EB3D5846300743B3EA947620A402C0_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_A1EB3D5846300743B3EA947620A402C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_A1EB3D5846300743B3EA947620A402C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_A1EB3D5846300743B3EA947620A402C0" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_A1EB3D5846300743B3EA947620A402C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DividendsDeclaredTableTextBlock_E8509AA7F9048196CEFF634003F646C7_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsDeclaredTableTextBlock_E8509AA7F9048196CEFF634003F646C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Dividends</link:label>
    <link:label id="lab_us-gaap_DividendsDeclaredTableTextBlock_E8509AA7F9048196CEFF634003F646C7_label_en-US" xlink:label="lab_us-gaap_DividendsDeclaredTableTextBlock_E8509AA7F9048196CEFF634003F646C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends Declared [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsDeclaredTableTextBlock" xlink:label="loc_us-gaap_DividendsDeclaredTableTextBlock_E8509AA7F9048196CEFF634003F646C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsDeclaredTableTextBlock_E8509AA7F9048196CEFF634003F646C7" xlink:to="lab_us-gaap_DividendsDeclaredTableTextBlock_E8509AA7F9048196CEFF634003F646C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_CD738461CD78FCE0CE1E947620395E3A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_CD738461CD78FCE0CE1E947620395E3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_CD738461CD78FCE0CE1E947620395E3A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_CD738461CD78FCE0CE1E947620395E3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_CD738461CD78FCE0CE1E947620395E3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_CD738461CD78FCE0CE1E947620395E3A" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_CD738461CD78FCE0CE1E947620395E3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_373E259F9F9FEE37C09E947620398BBF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_373E259F9F9FEE37C09E947620398BBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_373E259F9F9FEE37C09E947620398BBF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_373E259F9F9FEE37C09E947620398BBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_373E259F9F9FEE37C09E947620398BBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_373E259F9F9FEE37C09E947620398BBF" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_373E259F9F9FEE37C09E947620398BBF" xlink:type="arc" />
    <link:label id="lab_pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock_D4D5FF5FED925BB3645E94762039CDAE_terseLabel_en-US" xlink:label="lab_pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock_D4D5FF5FED925BB3645E94762039CDAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Identifiable Intangible Assets as a Percentage of Total Identifiable Intangible Assets Less Accumulated Amortization, By Segment</link:label>
    <link:label id="lab_pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock_D4D5FF5FED925BB3645E94762039CDAE_label_en-US" xlink:label="lab_pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock_D4D5FF5FED925BB3645E94762039CDAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Identifiable intangible assets as a percentage of total identifiable intangible assets less accumulated amortization, by segment [Table Text Block]</link:label>
    <link:label id="lab_pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock_D4D5FF5FED925BB3645E94762039CDAE_documentation_en-US" xlink:label="lab_pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock_D4D5FF5FED925BB3645E94762039CDAE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Table Text Block] for Identifiable intangible assets as a percentage of total identifiable intangible assets less accumulated amortization, by segment [Table]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock" xlink:label="loc_pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock_D4D5FF5FED925BB3645E94762039CDAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock_D4D5FF5FED925BB3645E94762039CDAE" xlink:to="lab_pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock_D4D5FF5FED925BB3645E94762039CDAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_0E44DEB7500E95551E659476203A26BC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_0E44DEB7500E95551E659476203A26BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_0E44DEB7500E95551E659476203A26BC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_0E44DEB7500E95551E659476203A26BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_0E44DEB7500E95551E659476203A26BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock_0E44DEB7500E95551E659476203A26BC" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock_0E44DEB7500E95551E659476203A26BC" xlink:type="arc" />
    <link:label id="lab_pfe_LongtermInvestmentsMember_7470B66828EE361E2315A1BD73131727_verboseLabel_en-US" xlink:label="lab_pfe_LongtermInvestmentsMember_7470B66828EE361E2315A1BD73131727" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term investments [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LongtermInvestmentsMember" xlink:label="loc_pfe_LongtermInvestmentsMember_7470B66828EE361E2315A1BD73131727" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LongtermInvestmentsMember_7470B66828EE361E2315A1BD73131727" xlink:to="lab_pfe_LongtermInvestmentsMember_7470B66828EE361E2315A1BD73131727" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMember_D7ACEC1E0050420AD565A1BD7313643A_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMember_D7ACEC1E0050420AD565A1BD7313643A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt [Member]</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMember_D7ACEC1E0050420AD565A1BD7313643A_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMember_D7ACEC1E0050420AD565A1BD7313643A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMember" xlink:label="loc_us-gaap_LongTermDebtMember_D7ACEC1E0050420AD565A1BD7313643A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMember_D7ACEC1E0050420AD565A1BD7313643A" xlink:to="lab_us-gaap_LongTermDebtMember_D7ACEC1E0050420AD565A1BD7313643A" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgedAssetFairValueHedge_1A361EE3522CAF475DC0A1BD7313BECA_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedAssetFairValueHedge_1A361EE3522CAF475DC0A1BD7313BECA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying Amount of Actively Hedged Assets</link:label>
    <link:label id="lab_us-gaap_HedgedAssetFairValueHedge_1A361EE3522CAF475DC0A1BD7313BECA_label_en-US" xlink:label="lab_us-gaap_HedgedAssetFairValueHedge_1A361EE3522CAF475DC0A1BD7313BECA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedged Asset, Fair Value Hedge</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedAssetFairValueHedge" xlink:label="loc_us-gaap_HedgedAssetFairValueHedge_1A361EE3522CAF475DC0A1BD7313BECA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedAssetFairValueHedge_1A361EE3522CAF475DC0A1BD7313BECA" xlink:to="lab_us-gaap_HedgedAssetFairValueHedge_1A361EE3522CAF475DC0A1BD7313BECA" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_1777D36C16BCA3C6B74AA1BD7314B42D_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge_1777D36C16BCA3C6B74AA1BD7314B42D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying Amount of Actively Hedged Liabilities</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_1777D36C16BCA3C6B74AA1BD7314B42D_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge_1777D36C16BCA3C6B74AA1BD7314B42D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedged Liability, Fair Value Hedge</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_1777D36C16BCA3C6B74AA1BD7314B42D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedge_1777D36C16BCA3C6B74AA1BD7314B42D" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedge_1777D36C16BCA3C6B74AA1BD7314B42D" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease_C412280A0378C803F792A1BD7314EBE0_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease_C412280A0378C803F792A1BD7314EBE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Asset</link:label>
    <link:label id="lab_us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease_C412280A0378C803F792A1BD7314EBE0_label_en-US" xlink:label="lab_us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease_C412280A0378C803F792A1BD7314EBE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedged Asset, Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease" xlink:label="loc_us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease_C412280A0378C803F792A1BD7314EBE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease_C412280A0378C803F792A1BD7314EBE0" xlink:to="lab_us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease_C412280A0378C803F792A1BD7314EBE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_6927C0D37A761040FBB2A1BD7314C9D1_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_6927C0D37A761040FBB2A1BD7314C9D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Liability</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_6927C0D37A761040FBB2A1BD7314C9D1_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_6927C0D37A761040FBB2A1BD7314C9D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_6927C0D37A761040FBB2A1BD7314C9D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_6927C0D37A761040FBB2A1BD7314C9D1" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_6927C0D37A761040FBB2A1BD7314C9D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_F58240D0C30F9330037DA1BD731472EC_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_F58240D0C30F9330037DA1BD731472EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Asset</link:label>
    <link:label id="lab_us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_F58240D0C30F9330037DA1BD731472EC_label_en-US" xlink:label="lab_us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_F58240D0C30F9330037DA1BD731472EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedged Asset, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:label="loc_us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_F58240D0C30F9330037DA1BD731472EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_F58240D0C30F9330037DA1BD731472EC" xlink:to="lab_us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_F58240D0C30F9330037DA1BD731472EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_6B063FBE8673370C1CF0A1BD73147491_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_6B063FBE8673370C1CF0A1BD73147491" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Liability</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_6B063FBE8673370C1CF0A1BD73147491_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_6B063FBE8673370C1CF0A1BD73147491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:label="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_6B063FBE8673370C1CF0A1BD73147491" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_6B063FBE8673370C1CF0A1BD73147491" xlink:to="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_6B063FBE8673370C1CF0A1BD73147491" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_E7EAD684BE8B07F1BC8A63636AB28A7E_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_E7EAD684BE8B07F1BC8A63636AB28A7E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">EPS Numerator&#8211;&#8211;Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_E7EAD684BE8B07F1BC8A63636AB28A7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_E7EAD684BE8B07F1BC8A63636AB28A7E" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract_E7EAD684BE8B07F1BC8A63636AB28A7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_F2D0BE7D200A7BB6026563636AB28F5D_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_F2D0BE7D200A7BB6026563636AB28F5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from continuing operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_F2D0BE7D200A7BB6026563636AB28F5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_F2D0BE7D200A7BB6026563636AB28F5D" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_F2D0BE7D200A7BB6026563636AB28F5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_40DDBBD56CEBEC93B25263636AB32A1F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_40DDBBD56CEBEC93B25263636AB32A1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_40DDBBD56CEBEC93B25263636AB32A1F_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_40DDBBD56CEBEC93B25263636AB32A1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_40DDBBD56CEBEC93B25263636AB32A1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_40DDBBD56CEBEC93B25263636AB32A1F" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_40DDBBD56CEBEC93B25263636AB32A1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_2FC796E359FE2B4533E263636AB3B9A6_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations_2FC796E359FE2B4533E263636AB3B9A6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_2FC796E359FE2B4533E263636AB3B9A6_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations_2FC796E359FE2B4533E263636AB3B9A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_2FC796E359FE2B4533E263636AB3B9A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_2FC796E359FE2B4533E263636AB3B9A6" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations_2FC796E359FE2B4533E263636AB3B9A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_5405FDFDF1F8A7E9122663636AB33776_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_5405FDFDF1F8A7E9122663636AB33776" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Preferred stock dividends&#8211;&#8211;net of tax</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_5405FDFDF1F8A7E9122663636AB33776_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_5405FDFDF1F8A7E9122663636AB33776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_5405FDFDF1F8A7E9122663636AB33776" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_5405FDFDF1F8A7E9122663636AB33776" xlink:to="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_5405FDFDF1F8A7E9122663636AB33776" xlink:type="arc" />
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_117EA28D424FFEE6EF8263636AB326DA_totalLabel_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_117EA28D424FFEE6EF8263636AB326DA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc. common shareholders</link:label>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_117EA28D424FFEE6EF8263636AB326DA_label_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_117EA28D424FFEE6EF8263636AB326DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Loss From Continuing Operations Available To Common Stockholders Basic</link:label>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_117EA28D424FFEE6EF8263636AB326DA_documentation_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_117EA28D424FFEE6EF8263636AB326DA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_117EA28D424FFEE6EF8263636AB326DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_117EA28D424FFEE6EF8263636AB326DA" xlink:to="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_117EA28D424FFEE6EF8263636AB326DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_462891029D989C2900F663636AB3D583_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_462891029D989C2900F663636AB3D583" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations&#8211;&#8211;net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_462891029D989C2900F663636AB3D583" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_462891029D989C2900F663636AB3D583" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_462891029D989C2900F663636AB3D583" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_C80BD68C404DB49A861663636AB4DF22_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_C80BD68C404DB49A861663636AB4DF22" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_C80BD68C404DB49A861663636AB4DF22_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_C80BD68C404DB49A861663636AB4DF22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_C80BD68C404DB49A861663636AB4DF22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_C80BD68C404DB49A861663636AB4DF22" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_C80BD68C404DB49A861663636AB4DF22" xlink:type="arc" />
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_FDD44AD5E6A0AC9CFBE263636AB9E7FD_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_FDD44AD5E6A0AC9CFBE263636AB9E7FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EPS Numerator&#8211;&#8211;Diluted</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_FDD44AD5E6A0AC9CFBE263636AB9E7FD_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_FDD44AD5E6A0AC9CFBE263636AB9E7FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_FDD44AD5E6A0AC9CFBE263636AB9E7FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_FDD44AD5E6A0AC9CFBE263636AB9E7FD" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract_FDD44AD5E6A0AC9CFBE263636AB9E7FD" xlink:type="arc" />
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_A651039F945272F3EE1463636AB91819_terseLabel_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_A651039F945272F3EE1463636AB91819" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</link:label>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_A651039F945272F3EE1463636AB91819_label_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_A651039F945272F3EE1463636AB91819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Loss From Continuing Operations Available To Common Stockholders diluted</link:label>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_A651039F945272F3EE1463636AB91819_documentation_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_A651039F945272F3EE1463636AB91819" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_A651039F945272F3EE1463636AB91819" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_A651039F945272F3EE1463636AB91819" xlink:to="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_A651039F945272F3EE1463636AB91819" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_FBF043ACF9337DCE789863636AB96F5A_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_FBF043ACF9337DCE789863636AB96F5A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_FBF043ACF9337DCE789863636AB96F5A_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_FBF043ACF9337DCE789863636AB96F5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_FBF043ACF9337DCE789863636AB96F5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_FBF043ACF9337DCE789863636AB96F5A" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_FBF043ACF9337DCE789863636AB96F5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_DCBFFE4D81F074BAD74263636AB97630_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_DCBFFE4D81F074BAD74263636AB97630" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_DCBFFE4D81F074BAD74263636AB97630_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_DCBFFE4D81F074BAD74263636AB97630" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_DCBFFE4D81F074BAD74263636AB97630" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_DCBFFE4D81F074BAD74263636AB97630" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_DCBFFE4D81F074BAD74263636AB97630" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_388A728F32F123F94D1E63636ABE5BB1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_388A728F32F123F94D1E63636ABE5BB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EPS Denominator</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_388A728F32F123F94D1E63636ABE5BB1_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_388A728F32F123F94D1E63636ABE5BB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_388A728F32F123F94D1E63636ABE5BB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_388A728F32F123F94D1E63636ABE5BB1" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_388A728F32F123F94D1E63636ABE5BB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C29AFD6751C9B038EE5363636ABED154_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C29AFD6751C9B038EE5363636ABED154" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of common shares outstanding&#8211;&#8211;Basic (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C29AFD6751C9B038EE5363636ABED154" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C29AFD6751C9B038EE5363636ABED154" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C29AFD6751C9B038EE5363636ABED154" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_A3F58F9C70C463DDEC0263636ABE6B8C_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_A3F58F9C70C463DDEC0263636ABE6B8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common-share equivalents: stock options, stock issuable under employee compensation plans and convertible preferred stock (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_A3F58F9C70C463DDEC0263636ABE6B8C_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_A3F58F9C70C463DDEC0263636ABE6B8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_A3F58F9C70C463DDEC0263636ABE6B8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_A3F58F9C70C463DDEC0263636ABE6B8C" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_A3F58F9C70C463DDEC0263636ABE6B8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5F42D65F3C074C5ECBFC63636ABE2011_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5F42D65F3C074C5ECBFC63636ABE2011" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5F42D65F3C074C5ECBFC63636ABE2011" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5F42D65F3C074C5ECBFC63636ABE2011" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5F42D65F3C074C5ECBFC63636ABE2011" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_23241517B9E86E374C7263636ABE82BD_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_23241517B9E86E374C7263636ABE82BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive common stock equivalents (shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_23241517B9E86E374C7263636ABE82BD_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_23241517B9E86E374C7263636ABE82BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_23241517B9E86E374C7263636ABE82BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_23241517B9E86E374C7263636ABE82BD" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_23241517B9E86E374C7263636ABE82BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_B0FEB0AB99E0124809AE9476227A91DF_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_B0FEB0AB99E0124809AE9476227A91DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (income)/deductions&#8211;&#8211;net [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_B0FEB0AB99E0124809AE9476227A91DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_B0FEB0AB99E0124809AE9476227A91DF" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_B0FEB0AB99E0124809AE9476227A91DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_B5FFD3D50B8AEDAB2F009476227A290A_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_B5FFD3D50B8AEDAB2F009476227A290A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, informational and administrative expenses [Member]</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_B5FFD3D50B8AEDAB2F009476227A290A_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_B5FFD3D50B8AEDAB2F009476227A290A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_B5FFD3D50B8AEDAB2F009476227A290A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_B5FFD3D50B8AEDAB2F009476227A290A" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_B5FFD3D50B8AEDAB2F009476227A290A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_3C1DE68EFB3E21EE427F9476227A111C_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_3C1DE68EFB3E21EE427F9476227A111C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3C1DE68EFB3E21EE427F9476227A111C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3C1DE68EFB3E21EE427F9476227A111C" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_3C1DE68EFB3E21EE427F9476227A111C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_554FB9F2415050FF805B9476227B8B64_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract_554FB9F2415050FF805B9476227B8B64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges:</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_554FB9F2415050FF805B9476227B8B64_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract_554FB9F2415050FF805B9476227B8B64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesAbstract" xlink:label="loc_us-gaap_RestructuringChargesAbstract_554FB9F2415050FF805B9476227B8B64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesAbstract_554FB9F2415050FF805B9476227B8B64" xlink:to="lab_us-gaap_RestructuringChargesAbstract_554FB9F2415050FF805B9476227B8B64" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeveranceCosts1_CF75064E0B24F4F812569476227B7971_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1_CF75064E0B24F4F812569476227B7971" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee terminations</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_CF75064E0B24F4F812569476227B7971_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1_CF75064E0B24F4F812569476227B7971" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_CF75064E0B24F4F812569476227B7971" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1_CF75064E0B24F4F812569476227B7971" xlink:to="lab_us-gaap_SeveranceCosts1_CF75064E0B24F4F812569476227B7971" xlink:type="arc" />
    <link:label id="lab_pfe_RestructuringAssetImpairmentCharges_A8325EDACB115E317DA69476227BBAD2_netLabel_en-US" xlink:label="lab_pfe_RestructuringAssetImpairmentCharges_A8325EDACB115E317DA69476227BBAD2" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Asset impairments</link:label>
    <link:label id="lab_pfe_RestructuringAssetImpairmentCharges_A8325EDACB115E317DA69476227BBAD2_label_en-US" xlink:label="lab_pfe_RestructuringAssetImpairmentCharges_A8325EDACB115E317DA69476227BBAD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring, Asset Impairment Charges</link:label>
    <link:label id="lab_pfe_RestructuringAssetImpairmentCharges_A8325EDACB115E317DA69476227BBAD2_documentation_en-US" xlink:label="lab_pfe_RestructuringAssetImpairmentCharges_A8325EDACB115E317DA69476227BBAD2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring, Asset Impairment Charges</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_RestructuringAssetImpairmentCharges" xlink:label="loc_pfe_RestructuringAssetImpairmentCharges_A8325EDACB115E317DA69476227BBAD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringAssetImpairmentCharges_A8325EDACB115E317DA69476227BBAD2" xlink:to="lab_pfe_RestructuringAssetImpairmentCharges_A8325EDACB115E317DA69476227BBAD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessExitCosts1_1FD3B7C47A9669537A819476227B1DDF_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1_1FD3B7C47A9669537A819476227B1DDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exit costs</link:label>
    <link:label id="lab_us-gaap_BusinessExitCosts1_1FD3B7C47A9669537A819476227B1DDF_label_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1_1FD3B7C47A9669537A819476227B1DDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Exit Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessExitCosts1" xlink:label="loc_us-gaap_BusinessExitCosts1_1FD3B7C47A9669537A819476227B1DDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessExitCosts1_1FD3B7C47A9669537A819476227B1DDF" xlink:to="lab_us-gaap_BusinessExitCosts1_1FD3B7C47A9669537A819476227B1DDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_C35951E8DB4A05066CB89476227C0E8F_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_C35951E8DB4A05066CB89476227C0E8F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges/(credits)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_C35951E8DB4A05066CB89476227C0E8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_C35951E8DB4A05066CB89476227C0E8F" xlink:to="lab_us-gaap_RestructuringCharges_C35951E8DB4A05066CB89476227C0E8F" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_16FE7E3F44FEF3B7D1919476227CFE43_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_16FE7E3F44FEF3B7D1919476227CFE43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_16FE7E3F44FEF3B7D1919476227CFE43_label_en-US" xlink:label="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_16FE7E3F44FEF3B7D1919476227CFE43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Acquisition Related Costs, Transaction Costs</link:label>
    <link:label id="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_16FE7E3F44FEF3B7D1919476227CFE43_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_16FE7E3F44FEF3B7D1919476227CFE43" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This element represents external costs directly related to effecting a business combination which costs have been expensed during the period. Such costs include advisory, legal, accounting, valuation, and other similar services.</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:label="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_16FE7E3F44FEF3B7D1919476227CFE43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_16FE7E3F44FEF3B7D1919476227CFE43" xlink:to="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_16FE7E3F44FEF3B7D1919476227CFE43" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_4A70149873945FBC89F19476227C10A9_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_4A70149873945FBC89F19476227C10A9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Integration costs and other</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_4A70149873945FBC89F19476227C10A9_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_4A70149873945FBC89F19476227C10A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_4A70149873945FBC89F19476227C10A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_4A70149873945FBC89F19476227C10A9" xlink:to="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_4A70149873945FBC89F19476227C10A9" xlink:type="arc" />
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_1CA7BB76E148589C238A9476227C4CEF_totalLabel_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_1CA7BB76E148589C238A9476227C4CEF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges and certain acquisition-related costs</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_1CA7BB76E148589C238A9476227C4CEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_1CA7BB76E148589C238A9476227C4CEF" xlink:to="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_1CA7BB76E148589C238A9476227C4CEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3D6F1CDB9ECD0319265A9476227CC1B4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3D6F1CDB9ECD0319265A9476227CC1B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net periodic benefit costs recorded in Other (income)/deductions&#8211;&#8211;net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3D6F1CDB9ECD0319265A9476227CC1B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3D6F1CDB9ECD0319265A9476227CC1B4" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3D6F1CDB9ECD0319265A9476227CC1B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_05F98BC4AB5B442EFC9D9476227DB342_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_05F98BC4AB5B442EFC9D9476227DB342" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional depreciation&#8211;&#8211;asset restructuring recorded in our condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_05F98BC4AB5B442EFC9D9476227DB342_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_05F98BC4AB5B442EFC9D9476227DB342" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Accelerated Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_05F98BC4AB5B442EFC9D9476227DB342" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_05F98BC4AB5B442EFC9D9476227DB342" xlink:to="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_05F98BC4AB5B442EFC9D9476227DB342" xlink:type="arc" />
    <link:label id="lab_pfe_ImplementationCostAbstract_11002BD29D6E91B6B6229476227DE0C6_terseLabel_en-US" xlink:label="lab_pfe_ImplementationCostAbstract_11002BD29D6E91B6B6229476227DE0C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Implementation costs recorded in our condensed consolidated statements of income as follows:</link:label>
    <link:label id="lab_pfe_ImplementationCostAbstract_11002BD29D6E91B6B6229476227DE0C6_label_en-US" xlink:label="lab_pfe_ImplementationCostAbstract_11002BD29D6E91B6B6229476227DE0C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Implementation Cost [Abstract]</link:label>
    <link:label id="lab_pfe_ImplementationCostAbstract_11002BD29D6E91B6B6229476227DE0C6_documentation_en-US" xlink:label="lab_pfe_ImplementationCostAbstract_11002BD29D6E91B6B6229476227DE0C6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Implementation Cost [Abstract]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ImplementationCostAbstract" xlink:label="loc_pfe_ImplementationCostAbstract_11002BD29D6E91B6B6229476227DE0C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ImplementationCostAbstract_11002BD29D6E91B6B6229476227DE0C6" xlink:to="lab_pfe_ImplementationCostAbstract_11002BD29D6E91B6B6229476227DE0C6" xlink:type="arc" />
    <link:label id="lab_pfe_ImplementationCosts_00CE778F6BD769E653C69476227D2021_terseLabel_en-US" xlink:label="lab_pfe_ImplementationCosts_00CE778F6BD769E653C69476227D2021" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Implementation costs</link:label>
    <link:label id="lab_pfe_ImplementationCosts_00CE778F6BD769E653C69476227D2021_label_en-US" xlink:label="lab_pfe_ImplementationCosts_00CE778F6BD769E653C69476227D2021" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Implementation Costs</link:label>
    <link:label id="lab_pfe_ImplementationCosts_00CE778F6BD769E653C69476227D2021_documentation_en-US" xlink:label="lab_pfe_ImplementationCosts_00CE778F6BD769E653C69476227D2021" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Implementation costs represent external, incremental costs directly related to Implementing cost-reduction initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services.</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ImplementationCosts" xlink:label="loc_pfe_ImplementationCosts_00CE778F6BD769E653C69476227D2021" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ImplementationCosts_00CE778F6BD769E653C69476227D2021" xlink:to="lab_pfe_ImplementationCosts_00CE778F6BD769E653C69476227D2021" xlink:type="arc" />
    <link:label id="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_85341EAF51B71283A4829476227D3AEB_totalLabel_en-US" xlink:label="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_85341EAF51B71283A4829476227D3AEB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total costs associated with acquisitions and cost-reduction/productivity initiatives</link:label>
    <link:label id="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_85341EAF51B71283A4829476227D3AEB_label_en-US" xlink:label="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_85341EAF51B71283A4829476227D3AEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Acquisition Related Costs and Implementation Costs</link:label>
    <link:label id="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_85341EAF51B71283A4829476227D3AEB_documentation_en-US" xlink:label="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_85341EAF51B71283A4829476227D3AEB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Acquisition Related Costs and Implementation Costs</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:label="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_85341EAF51B71283A4829476227D3AEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_85341EAF51B71283A4829476227D3AEB" xlink:to="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_85341EAF51B71283A4829476227D3AEB" xlink:type="arc" />
    <link:label id="lab_pfe_ManufacturingCostReductionMember_C0D1EEC985364ECE4C909D36D87F3E99_terseLabel_en-US" xlink:label="lab_pfe_ManufacturingCostReductionMember_C0D1EEC985364ECE4C909D36D87F3E99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing Cost Reduction [Member]</link:label>
    <link:label id="lab_pfe_ManufacturingCostReductionMember_C0D1EEC985364ECE4C909D36D87F3E99_label_en-US" xlink:label="lab_pfe_ManufacturingCostReductionMember_C0D1EEC985364ECE4C909D36D87F3E99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing Cost Reduction [Member]</link:label>
    <link:label id="lab_pfe_ManufacturingCostReductionMember_C0D1EEC985364ECE4C909D36D87F3E99_documentation_en-US" xlink:label="lab_pfe_ManufacturingCostReductionMember_C0D1EEC985364ECE4C909D36D87F3E99" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Manufacturing Cost Reduction [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ManufacturingCostReductionMember" xlink:label="loc_pfe_ManufacturingCostReductionMember_C0D1EEC985364ECE4C909D36D87F3E99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ManufacturingCostReductionMember_C0D1EEC985364ECE4C909D36D87F3E99" xlink:to="lab_pfe_ManufacturingCostReductionMember_C0D1EEC985364ECE4C909D36D87F3E99" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessIntegrationCostsMember_CE00D3D4C91D03DB5E649D36D87F5309_terseLabel_en-US" xlink:label="lab_pfe_BusinessIntegrationCostsMember_CE00D3D4C91D03DB5E649D36D87F5309" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Integration Costs [Member]</link:label>
    <link:label id="lab_pfe_BusinessIntegrationCostsMember_CE00D3D4C91D03DB5E649D36D87F5309_label_en-US" xlink:label="lab_pfe_BusinessIntegrationCostsMember_CE00D3D4C91D03DB5E649D36D87F5309" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Integration Costs [Member]</link:label>
    <link:label id="lab_pfe_BusinessIntegrationCostsMember_CE00D3D4C91D03DB5E649D36D87F5309_documentation_en-US" xlink:label="lab_pfe_BusinessIntegrationCostsMember_CE00D3D4C91D03DB5E649D36D87F5309" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Integration Costs [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BusinessIntegrationCostsMember" xlink:label="loc_pfe_BusinessIntegrationCostsMember_CE00D3D4C91D03DB5E649D36D87F5309" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessIntegrationCostsMember_CE00D3D4C91D03DB5E649D36D87F5309" xlink:to="lab_pfe_BusinessIntegrationCostsMember_CE00D3D4C91D03DB5E649D36D87F5309" xlink:type="arc" />
    <link:label id="lab_pfe_HospiraMember_945E546E6BFEA44EA1899D36D88042D1_terseLabel_en-US" xlink:label="lab_pfe_HospiraMember_945E546E6BFEA44EA1899D36D88042D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hospira [Member]</link:label>
    <link:label id="lab_pfe_HospiraMember_945E546E6BFEA44EA1899D36D88042D1_label_en-US" xlink:label="lab_pfe_HospiraMember_945E546E6BFEA44EA1899D36D88042D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hospira [Member]</link:label>
    <link:label id="lab_pfe_HospiraMember_945E546E6BFEA44EA1899D36D88042D1_documentation_en-US" xlink:label="lab_pfe_HospiraMember_945E546E6BFEA44EA1899D36D88042D1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hospira [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_HospiraMember" xlink:label="loc_pfe_HospiraMember_945E546E6BFEA44EA1899D36D88042D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HospiraMember_945E546E6BFEA44EA1899D36D88042D1" xlink:to="lab_pfe_HospiraMember_945E546E6BFEA44EA1899D36D88042D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringPlanAxis_CB08029633875C90B0719D36D8807F26_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis_CB08029633875C90B0719D36D8807F26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_CB08029633875C90B0719D36D8807F26_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis_CB08029633875C90B0719D36D8807F26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_CB08029633875C90B0719D36D8807F26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis_CB08029633875C90B0719D36D8807F26" xlink:to="lab_us-gaap_RestructuringPlanAxis_CB08029633875C90B0719D36D8807F26" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringPlanDomain_3FFCAB00BB3EC4A2851F9D36D880C948_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain_3FFCAB00BB3EC4A2851F9D36D880C948" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_3FFCAB00BB3EC4A2851F9D36D880C948_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain_3FFCAB00BB3EC4A2851F9D36D880C948" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_3FFCAB00BB3EC4A2851F9D36D880C948" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain_3FFCAB00BB3EC4A2851F9D36D880C948" xlink:to="lab_us-gaap_RestructuringPlanDomain_3FFCAB00BB3EC4A2851F9D36D880C948" xlink:type="arc" />
    <link:label id="lab_pfe_FocusedCompanyPlanMember_B1855A7BF242A7DE65099D36D8819D49_terseLabel_en-US" xlink:label="lab_pfe_FocusedCompanyPlanMember_B1855A7BF242A7DE65099D36D8819D49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Focused Company Plan [Member]</link:label>
    <link:label id="lab_pfe_FocusedCompanyPlanMember_B1855A7BF242A7DE65099D36D8819D49_label_en-US" xlink:label="lab_pfe_FocusedCompanyPlanMember_B1855A7BF242A7DE65099D36D8819D49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Focused Company Plan [Member]</link:label>
    <link:label id="lab_pfe_FocusedCompanyPlanMember_B1855A7BF242A7DE65099D36D8819D49_documentation_en-US" xlink:label="lab_pfe_FocusedCompanyPlanMember_B1855A7BF242A7DE65099D36D8819D49" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Focused Company Plan [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FocusedCompanyPlanMember" xlink:label="loc_pfe_FocusedCompanyPlanMember_B1855A7BF242A7DE65099D36D8819D49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FocusedCompanyPlanMember_B1855A7BF242A7DE65099D36D8819D49" xlink:to="lab_pfe_FocusedCompanyPlanMember_B1855A7BF242A7DE65099D36D8819D49" xlink:type="arc" />
    <link:label id="lab_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_1D2911359B0DD76DBA149D36D881050E_terseLabel_en-US" xlink:label="lab_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_1D2911359B0DD76DBA149D36D881050E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017-2019 Initiatives and Organizing for Growth [Member]</link:label>
    <link:label id="lab_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_1D2911359B0DD76DBA149D36D881050E_label_en-US" xlink:label="lab_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_1D2911359B0DD76DBA149D36D881050E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty-Seventeen Through Twenty-Nineteen Initiatives And Organizing For Growth [Member]</link:label>
    <link:label id="lab_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_1D2911359B0DD76DBA149D36D881050E_documentation_en-US" xlink:label="lab_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_1D2911359B0DD76DBA149D36D881050E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty-Seventeen Through Twenty-Nineteen Initiatives And Organizing For Growth [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember" xlink:label="loc_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_1D2911359B0DD76DBA149D36D881050E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_1D2911359B0DD76DBA149D36D881050E" xlink:to="lab_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_1D2911359B0DD76DBA149D36D881050E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_5680D04BAEBE3D1E576B9D36D881805B_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_5680D04BAEBE3D1E576B9D36D881805B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected restructuring cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_5680D04BAEBE3D1E576B9D36D881805B_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_5680D04BAEBE3D1E576B9D36D881805B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_5680D04BAEBE3D1E576B9D36D881805B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_5680D04BAEBE3D1E576B9D36D881805B" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_5680D04BAEBE3D1E576B9D36D881805B" xlink:type="arc" />
    <link:label id="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_C5A13503910283CA4A409D36D8829F31_terseLabel_en-US" xlink:label="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_C5A13503910283CA4A409D36D8829F31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of expected costs to be non-cash</link:label>
    <link:label id="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_C5A13503910283CA4A409D36D8829F31_label_en-US" xlink:label="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_C5A13503910283CA4A409D36D8829F31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Noncash Charges, Percentage</link:label>
    <link:label id="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_C5A13503910283CA4A409D36D8829F31_documentation_en-US" xlink:label="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_C5A13503910283CA4A409D36D8829F31" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Noncash Charges, Percentage</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_RestructuringandRelatedCostNoncashChargesPercentage" xlink:label="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_C5A13503910283CA4A409D36D8829F31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_C5A13503910283CA4A409D36D8829F31" xlink:to="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_C5A13503910283CA4A409D36D8829F31" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_7AAE12E998A0C1894B5E9D36D88227F6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_7AAE12E998A0C1894B5E9D36D88227F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring costs incurred</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_7AAE12E998A0C1894B5E9D36D88227F6_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_7AAE12E998A0C1894B5E9D36D88227F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_7AAE12E998A0C1894B5E9D36D88227F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_7AAE12E998A0C1894B5E9D36D88227F6" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_7AAE12E998A0C1894B5E9D36D88227F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_84B364A2D5022BEC6EEE947620EB6697_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_84B364A2D5022BEC6EEE947620EB6697" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_84B364A2D5022BEC6EEE947620EB6697_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_84B364A2D5022BEC6EEE947620EB6697" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_84B364A2D5022BEC6EEE947620EB6697" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_84B364A2D5022BEC6EEE947620EB6697" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_84B364A2D5022BEC6EEE947620EB6697" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_2083C3D523CDABC65C4E596791F9FDF4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock_2083C3D523CDABC65C4E596791F9FDF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_2083C3D523CDABC65C4E596791F9FDF4_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock_2083C3D523CDABC65C4E596791F9FDF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_2083C3D523CDABC65C4E596791F9FDF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock_2083C3D523CDABC65C4E596791F9FDF4" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock_2083C3D523CDABC65C4E596791F9FDF4" xlink:type="arc" />
    <link:label id="lab_dei_CoverAbstract_ECD77D1D95196DD01ED69476214FA8F7_label_en-US" xlink:label="lab_dei_CoverAbstract_ECD77D1D95196DD01ED69476214FA8F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_ECD77D1D95196DD01ED69476214FA8F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_ECD77D1D95196DD01ED69476214FA8F7" xlink:to="lab_dei_CoverAbstract_ECD77D1D95196DD01ED69476214FA8F7" xlink:type="arc" />
    <link:label id="lab_dei_EntitiesTable_6BEF4EB72D27BAC5B3B994762150B47F_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable_6BEF4EB72D27BAC5B3B994762150B47F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_6BEF4EB72D27BAC5B3B994762150B47F_label_en-US" xlink:label="lab_dei_EntitiesTable_6BEF4EB72D27BAC5B3B994762150B47F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitiesTable" xlink:label="loc_dei_EntitiesTable_6BEF4EB72D27BAC5B3B994762150B47F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable_6BEF4EB72D27BAC5B3B994762150B47F" xlink:to="lab_dei_EntitiesTable_6BEF4EB72D27BAC5B3B994762150B47F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_8A5B7FE49AE24C45B38B94762150A41E_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_8A5B7FE49AE24C45B38B94762150A41E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_8A5B7FE49AE24C45B38B94762150A41E_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_8A5B7FE49AE24C45B38B94762150A41E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8A5B7FE49AE24C45B38B94762150A41E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8A5B7FE49AE24C45B38B94762150A41E" xlink:to="lab_us-gaap_StatementClassOfStockAxis_8A5B7FE49AE24C45B38B94762150A41E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_D07E461283C3FA7703E09476215078F5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_D07E461283C3FA7703E09476215078F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_D07E461283C3FA7703E09476215078F5_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_D07E461283C3FA7703E09476215078F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D07E461283C3FA7703E09476215078F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_D07E461283C3FA7703E09476215078F5" xlink:to="lab_us-gaap_ClassOfStockDomain_D07E461283C3FA7703E09476215078F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_D38B5BE3EDDAFFAC83D6947621515092_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_D38B5BE3EDDAFFAC83D6947621515092" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, $.05 par value [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_D38B5BE3EDDAFFAC83D6947621515092" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_D38B5BE3EDDAFFAC83D6947621515092" xlink:to="lab_us-gaap_CommonStockMember_D38B5BE3EDDAFFAC83D6947621515092" xlink:type="arc" />
    <link:label id="lab_pfe_NotesDue20220.250Member_F3B4D8FAF1591617D43B94762151DCF1_terseLabel_en-US" xlink:label="lab_pfe_NotesDue20220.250Member_F3B4D8FAF1591617D43B94762151DCF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.250% Notes due 2022 [Member]</link:label>
    <link:label id="lab_pfe_NotesDue20220.250Member_F3B4D8FAF1591617D43B94762151DCF1_label_en-US" xlink:label="lab_pfe_NotesDue20220.250Member_F3B4D8FAF1591617D43B94762151DCF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Due 2022, 0.250% [Member]</link:label>
    <link:label id="lab_pfe_NotesDue20220.250Member_F3B4D8FAF1591617D43B94762151DCF1_documentation_en-US" xlink:label="lab_pfe_NotesDue20220.250Member_F3B4D8FAF1591617D43B94762151DCF1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notes Due 2022, 0.250% [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_NotesDue20220.250Member" xlink:label="loc_pfe_NotesDue20220.250Member_F3B4D8FAF1591617D43B94762151DCF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NotesDue20220.250Member_F3B4D8FAF1591617D43B94762151DCF1" xlink:to="lab_pfe_NotesDue20220.250Member_F3B4D8FAF1591617D43B94762151DCF1" xlink:type="arc" />
    <link:label id="lab_pfe_NotesDue20271.000Member_1A6E9869FF0AC0C9630B9476215115F2_terseLabel_en-US" xlink:label="lab_pfe_NotesDue20271.000Member_1A6E9869FF0AC0C9630B9476215115F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.000% Notes due 2027 [Member]</link:label>
    <link:label id="lab_pfe_NotesDue20271.000Member_1A6E9869FF0AC0C9630B9476215115F2_label_en-US" xlink:label="lab_pfe_NotesDue20271.000Member_1A6E9869FF0AC0C9630B9476215115F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Due 2027, 1.000% [Member]</link:label>
    <link:label id="lab_pfe_NotesDue20271.000Member_1A6E9869FF0AC0C9630B9476215115F2_documentation_en-US" xlink:label="lab_pfe_NotesDue20271.000Member_1A6E9869FF0AC0C9630B9476215115F2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notes Due 2027, 1.000% [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_NotesDue20271.000Member" xlink:label="loc_pfe_NotesDue20271.000Member_1A6E9869FF0AC0C9630B9476215115F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NotesDue20271.000Member_1A6E9869FF0AC0C9630B9476215115F2" xlink:to="lab_pfe_NotesDue20271.000Member_1A6E9869FF0AC0C9630B9476215115F2" xlink:type="arc" />
    <link:label id="lab_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E_label_en-US" xlink:label="lab_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInformationLineItems" xlink:label="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="lab_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_2CCF0CFCFCAB4E74B092947621515A7F_terseLabel_en-US" xlink:label="lab_dei_DocumentType_2CCF0CFCFCAB4E74B092947621515A7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_2CCF0CFCFCAB4E74B092947621515A7F_label_en-US" xlink:label="lab_dei_DocumentType_2CCF0CFCFCAB4E74B092947621515A7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_2CCF0CFCFCAB4E74B092947621515A7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_2CCF0CFCFCAB4E74B092947621515A7F" xlink:to="lab_dei_DocumentType_2CCF0CFCFCAB4E74B092947621515A7F" xlink:type="arc" />
    <link:label id="lab_dei_DocumentQuarterlyReport_F0B577485A3E2E5958F9947621521F69_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_F0B577485A3E2E5958F9947621521F69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_F0B577485A3E2E5958F9947621521F69_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_F0B577485A3E2E5958F9947621521F69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_F0B577485A3E2E5958F9947621521F69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport_F0B577485A3E2E5958F9947621521F69" xlink:to="lab_dei_DocumentQuarterlyReport_F0B577485A3E2E5958F9947621521F69" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_4E5B0B21C4BEB91D16B394762152B53B_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_4E5B0B21C4BEB91D16B394762152B53B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_4E5B0B21C4BEB91D16B394762152B53B_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_4E5B0B21C4BEB91D16B394762152B53B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_4E5B0B21C4BEB91D16B394762152B53B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_4E5B0B21C4BEB91D16B394762152B53B" xlink:to="lab_dei_DocumentPeriodEndDate_4E5B0B21C4BEB91D16B394762152B53B" xlink:type="arc" />
    <link:label id="lab_dei_DocumentTransitionReport_BC0F4677FBCB403B51DD947621526DFE_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport_BC0F4677FBCB403B51DD947621526DFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_BC0F4677FBCB403B51DD947621526DFE_label_en-US" xlink:label="lab_dei_DocumentTransitionReport_BC0F4677FBCB403B51DD947621526DFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_BC0F4677FBCB403B51DD947621526DFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_BC0F4677FBCB403B51DD947621526DFE" xlink:to="lab_dei_DocumentTransitionReport_BC0F4677FBCB403B51DD947621526DFE" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_BD3593FE990C54224595947621527524_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_BD3593FE990C54224595947621527524" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_BD3593FE990C54224595947621527524_label_en-US" xlink:label="lab_dei_EntityFileNumber_BD3593FE990C54224595947621527524" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_BD3593FE990C54224595947621527524" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_BD3593FE990C54224595947621527524" xlink:to="lab_dei_EntityFileNumber_BD3593FE990C54224595947621527524" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_C970256C3BACADD6AF3C947621523258_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_C970256C3BACADD6AF3C947621523258" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_C970256C3BACADD6AF3C947621523258_label_en-US" xlink:label="lab_dei_EntityRegistrantName_C970256C3BACADD6AF3C947621523258" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_C970256C3BACADD6AF3C947621523258" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_C970256C3BACADD6AF3C947621523258" xlink:to="lab_dei_EntityRegistrantName_C970256C3BACADD6AF3C947621523258" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_CAB2971306A9B6511B0C947621535305_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_CAB2971306A9B6511B0C947621535305" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_CAB2971306A9B6511B0C947621535305_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_CAB2971306A9B6511B0C947621535305" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_CAB2971306A9B6511B0C947621535305" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_CAB2971306A9B6511B0C947621535305" xlink:to="lab_dei_EntityIncorporationStateCountryCode_CAB2971306A9B6511B0C947621535305" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_36E6F8DA32CC33A3707E947621531071_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_36E6F8DA32CC33A3707E947621531071" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_36E6F8DA32CC33A3707E947621531071_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_36E6F8DA32CC33A3707E947621531071" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_36E6F8DA32CC33A3707E947621531071" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_36E6F8DA32CC33A3707E947621531071" xlink:to="lab_dei_EntityTaxIdentificationNumber_36E6F8DA32CC33A3707E947621531071" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_6D9ED9007B223EF3D062947621533652_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_6D9ED9007B223EF3D062947621533652" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_6D9ED9007B223EF3D062947621533652_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_6D9ED9007B223EF3D062947621533652" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_6D9ED9007B223EF3D062947621533652" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_6D9ED9007B223EF3D062947621533652" xlink:to="lab_dei_EntityAddressAddressLine1_6D9ED9007B223EF3D062947621533652" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_71C8945D294C21B8460E94762153AF8F_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_71C8945D294C21B8460E94762153AF8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_71C8945D294C21B8460E94762153AF8F_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_71C8945D294C21B8460E94762153AF8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_71C8945D294C21B8460E94762153AF8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_71C8945D294C21B8460E94762153AF8F" xlink:to="lab_dei_EntityAddressCityOrTown_71C8945D294C21B8460E94762153AF8F" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_2FDC1CD74B2E1BCAC22694762153536F_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_2FDC1CD74B2E1BCAC22694762153536F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_2FDC1CD74B2E1BCAC22694762153536F_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_2FDC1CD74B2E1BCAC22694762153536F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_2FDC1CD74B2E1BCAC22694762153536F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_2FDC1CD74B2E1BCAC22694762153536F" xlink:to="lab_dei_EntityAddressStateOrProvince_2FDC1CD74B2E1BCAC22694762153536F" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_F01EC6CB7CC69B7AD71F94762153217D_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_F01EC6CB7CC69B7AD71F94762153217D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_F01EC6CB7CC69B7AD71F94762153217D_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_F01EC6CB7CC69B7AD71F94762153217D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_F01EC6CB7CC69B7AD71F94762153217D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_F01EC6CB7CC69B7AD71F94762153217D" xlink:to="lab_dei_EntityAddressPostalZipCode_F01EC6CB7CC69B7AD71F94762153217D" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_0C6BF61FF873887D10B094762153AA73_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_0C6BF61FF873887D10B094762153AA73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_0C6BF61FF873887D10B094762153AA73_label_en-US" xlink:label="lab_dei_CityAreaCode_0C6BF61FF873887D10B094762153AA73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_0C6BF61FF873887D10B094762153AA73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_0C6BF61FF873887D10B094762153AA73" xlink:to="lab_dei_CityAreaCode_0C6BF61FF873887D10B094762153AA73" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_2E6A057828AF2E5AAE2194762154BDED_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_2E6A057828AF2E5AAE2194762154BDED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_2E6A057828AF2E5AAE2194762154BDED_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_2E6A057828AF2E5AAE2194762154BDED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_2E6A057828AF2E5AAE2194762154BDED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_2E6A057828AF2E5AAE2194762154BDED" xlink:to="lab_dei_LocalPhoneNumber_2E6A057828AF2E5AAE2194762154BDED" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_7309269DC3ADA72430C8947621543F97_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_7309269DC3ADA72430C8947621543F97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_7309269DC3ADA72430C8947621543F97_label_en-US" xlink:label="lab_dei_Security12bTitle_7309269DC3ADA72430C8947621543F97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_7309269DC3ADA72430C8947621543F97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_7309269DC3ADA72430C8947621543F97" xlink:to="lab_dei_Security12bTitle_7309269DC3ADA72430C8947621543F97" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_C4440E09C69BAD5BDDC194762154E383_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_C4440E09C69BAD5BDDC194762154E383" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_C4440E09C69BAD5BDDC194762154E383_label_en-US" xlink:label="lab_dei_TradingSymbol_C4440E09C69BAD5BDDC194762154E383" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_C4440E09C69BAD5BDDC194762154E383" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_C4440E09C69BAD5BDDC194762154E383" xlink:to="lab_dei_TradingSymbol_C4440E09C69BAD5BDDC194762154E383" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_16D9D6B005F22B21EE9394762154F9C7_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_16D9D6B005F22B21EE9394762154F9C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_16D9D6B005F22B21EE9394762154F9C7_label_en-US" xlink:label="lab_dei_SecurityExchangeName_16D9D6B005F22B21EE9394762154F9C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_16D9D6B005F22B21EE9394762154F9C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_16D9D6B005F22B21EE9394762154F9C7" xlink:to="lab_dei_SecurityExchangeName_16D9D6B005F22B21EE9394762154F9C7" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_9759AA759CCB8F031EFA9476215471B0_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_9759AA759CCB8F031EFA9476215471B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_9759AA759CCB8F031EFA9476215471B0_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_9759AA759CCB8F031EFA9476215471B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_9759AA759CCB8F031EFA9476215471B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_9759AA759CCB8F031EFA9476215471B0" xlink:to="lab_dei_EntityCurrentReportingStatus_9759AA759CCB8F031EFA9476215471B0" xlink:type="arc" />
    <link:label id="lab_dei_EntityInteractiveDataCurrent_6CB2A44E160280EBA62B94762155CE3B_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_6CB2A44E160280EBA62B94762155CE3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_6CB2A44E160280EBA62B94762155CE3B_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_6CB2A44E160280EBA62B94762155CE3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_6CB2A44E160280EBA62B94762155CE3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_6CB2A44E160280EBA62B94762155CE3B" xlink:to="lab_dei_EntityInteractiveDataCurrent_6CB2A44E160280EBA62B94762155CE3B" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_FE65E3A11197F9E68ACF94762155FB1B_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_FE65E3A11197F9E68ACF94762155FB1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_FE65E3A11197F9E68ACF94762155FB1B_label_en-US" xlink:label="lab_dei_EntityFilerCategory_FE65E3A11197F9E68ACF94762155FB1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_FE65E3A11197F9E68ACF94762155FB1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_FE65E3A11197F9E68ACF94762155FB1B" xlink:to="lab_dei_EntityFilerCategory_FE65E3A11197F9E68ACF94762155FB1B" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_29E0C615C4E4FF4C74D894762155B832_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_29E0C615C4E4FF4C74D894762155B832" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_29E0C615C4E4FF4C74D894762155B832_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_29E0C615C4E4FF4C74D894762155B832" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_29E0C615C4E4FF4C74D894762155B832" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_29E0C615C4E4FF4C74D894762155B832" xlink:to="lab_dei_EntitySmallBusiness_29E0C615C4E4FF4C74D894762155B832" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7A0ED81080F6634A3053947621554371_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_7A0ED81080F6634A3053947621554371" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7A0ED81080F6634A3053947621554371_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_7A0ED81080F6634A3053947621554371" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_7A0ED81080F6634A3053947621554371" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_7A0ED81080F6634A3053947621554371" xlink:to="lab_dei_EntityEmergingGrowthCompany_7A0ED81080F6634A3053947621554371" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_1A6EA84D6B0BC47A22F3947621555998_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_1A6EA84D6B0BC47A22F3947621555998" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_1A6EA84D6B0BC47A22F3947621555998_label_en-US" xlink:label="lab_dei_EntityShellCompany_1A6EA84D6B0BC47A22F3947621555998" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_1A6EA84D6B0BC47A22F3947621555998" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_1A6EA84D6B0BC47A22F3947621555998" xlink:to="lab_dei_EntityShellCompany_1A6EA84D6B0BC47A22F3947621555998" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_E8227DB2564C0E41A867947621554B0A_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_E8227DB2564C0E41A867947621554B0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_E8227DB2564C0E41A867947621554B0A_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_E8227DB2564C0E41A867947621554B0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_E8227DB2564C0E41A867947621554B0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_E8227DB2564C0E41A867947621554B0A" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_E8227DB2564C0E41A867947621554B0A" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_3AC40381611F3CE6BA3294762155E10D_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_3AC40381611F3CE6BA3294762155E10D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_3AC40381611F3CE6BA3294762155E10D_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_3AC40381611F3CE6BA3294762155E10D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_3AC40381611F3CE6BA3294762155E10D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_3AC40381611F3CE6BA3294762155E10D" xlink:to="lab_dei_EntityCentralIndexKey_3AC40381611F3CE6BA3294762155E10D" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3901D592D2C0E9AFD00C947621566D2F_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_3901D592D2C0E9AFD00C947621566D2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3901D592D2C0E9AFD00C947621566D2F_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_3901D592D2C0E9AFD00C947621566D2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_3901D592D2C0E9AFD00C947621566D2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_3901D592D2C0E9AFD00C947621566D2F" xlink:to="lab_dei_CurrentFiscalYearEndDate_3901D592D2C0E9AFD00C947621566D2F" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_189822777DD5C6CA2D4C94762156729D_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_189822777DD5C6CA2D4C94762156729D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_189822777DD5C6CA2D4C94762156729D_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_189822777DD5C6CA2D4C94762156729D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_189822777DD5C6CA2D4C94762156729D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_189822777DD5C6CA2D4C94762156729D" xlink:to="lab_dei_DocumentFiscalYearFocus_189822777DD5C6CA2D4C94762156729D" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_EE848DDD25A98CB3C114947621563EDE_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_EE848DDD25A98CB3C114947621563EDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_EE848DDD25A98CB3C114947621563EDE_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_EE848DDD25A98CB3C114947621563EDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_EE848DDD25A98CB3C114947621563EDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_EE848DDD25A98CB3C114947621563EDE" xlink:to="lab_dei_DocumentFiscalPeriodFocus_EE848DDD25A98CB3C114947621563EDE" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_9BC9FAA9051592D4285F94762156C526_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_9BC9FAA9051592D4285F94762156C526" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_9BC9FAA9051592D4285F94762156C526_label_en-US" xlink:label="lab_dei_AmendmentFlag_9BC9FAA9051592D4285F94762156C526" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9BC9FAA9051592D4285F94762156C526" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_9BC9FAA9051592D4285F94762156C526" xlink:to="lab_dei_AmendmentFlag_9BC9FAA9051592D4285F94762156C526" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_E3598937CEA5A8A016567DA8645CC969_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_E3598937CEA5A8A016567DA8645CC969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_E3598937CEA5A8A016567DA8645CC969" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_E3598937CEA5A8A016567DA8645CC969" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_E3598937CEA5A8A016567DA8645CC969" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_C79A81A1B0A1305CA2B97DA8645D53D3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_C79A81A1B0A1305CA2B97DA8645D53D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_C79A81A1B0A1305CA2B97DA8645D53D3_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember_C79A81A1B0A1305CA2B97DA8645D53D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_C79A81A1B0A1305CA2B97DA8645D53D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_C79A81A1B0A1305CA2B97DA8645D53D3" xlink:to="lab_us-gaap_PreferredStockMember_C79A81A1B0A1305CA2B97DA8645D53D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_18D5E605821C05CAEC4F7DA8645E09EA_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_18D5E605821C05CAEC4F7DA8645E09EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Add'l Paid-in Capital [Member]</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_18D5E605821C05CAEC4F7DA8645E09EA_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_18D5E605821C05CAEC4F7DA8645E09EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_18D5E605821C05CAEC4F7DA8645E09EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_18D5E605821C05CAEC4F7DA8645E09EA" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_18D5E605821C05CAEC4F7DA8645E09EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockMember_36C3BD1B9BE0EA9B37A37DA8645EB040_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_36C3BD1B9BE0EA9B37A37DA8645EB040" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_36C3BD1B9BE0EA9B37A37DA8645EB040_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_36C3BD1B9BE0EA9B37A37DA8645EB040" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_36C3BD1B9BE0EA9B37A37DA8645EB040" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_36C3BD1B9BE0EA9B37A37DA8645EB040" xlink:to="lab_us-gaap_TreasuryStockMember_36C3BD1B9BE0EA9B37A37DA8645EB040" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_C536E8C4EE979BFBCE057DA8645EAA2F_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_C536E8C4EE979BFBCE057DA8645EAA2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_C536E8C4EE979BFBCE057DA8645EAA2F_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_C536E8C4EE979BFBCE057DA8645EAA2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_C536E8C4EE979BFBCE057DA8645EAA2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_C536E8C4EE979BFBCE057DA8645EAA2F" xlink:to="lab_us-gaap_RetainedEarningsMember_C536E8C4EE979BFBCE057DA8645EAA2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_D128A5845CA8DE3E2C837DA8645E8CEA_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_D128A5845CA8DE3E2C837DA8645E8CEA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accum. Other Comp. Loss [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_D128A5845CA8DE3E2C837DA8645E8CEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_D128A5845CA8DE3E2C837DA8645E8CEA" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_D128A5845CA8DE3E2C837DA8645E8CEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ParentMember_1DF83A49140E6C2F627F7DA8645E52C8_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember_1DF83A49140E6C2F627F7DA8645E52C8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shareholders' Equity [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_1DF83A49140E6C2F627F7DA8645E52C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember_1DF83A49140E6C2F627F7DA8645E52C8" xlink:to="lab_us-gaap_ParentMember_1DF83A49140E6C2F627F7DA8645E52C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_4E55536BDAC1C62FC49D7DA8645FF643_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_4E55536BDAC1C62FC49D7DA8645FF643" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interests [Member]</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_4E55536BDAC1C62FC49D7DA8645FF643_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_4E55536BDAC1C62FC49D7DA8645FF643" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_4E55536BDAC1C62FC49D7DA8645FF643" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember_4E55536BDAC1C62FC49D7DA8645FF643" xlink:to="lab_us-gaap_NoncontrollingInterestMember_4E55536BDAC1C62FC49D7DA8645FF643" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_E68C4FCF086DE00968F97DA8645FA85B_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_E68C4FCF086DE00968F97DA8645FA85B" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_E68C4FCF086DE00968F97DA8645FA85B_label_en-US" xlink:label="lab_us-gaap_SharesIssued_E68C4FCF086DE00968F97DA8645FA85B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_E68C4FCF086DE00968F97DA8645FA85B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_E68C4FCF086DE00968F97DA8645FA85B" xlink:to="lab_us-gaap_SharesIssued_E68C4FCF086DE00968F97DA8645FA85B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5D4258EDB6E134EE176B7DA8645FE1F5_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5D4258EDB6E134EE176B7DA8645FE1F5" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5D4258EDB6E134EE176B7DA8645FE1F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5D4258EDB6E134EE176B7DA8645FE1F5" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5D4258EDB6E134EE176B7DA8645FE1F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_47900DE4B98B3FAA4FE47DA8645FA4CE_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_47900DE4B98B3FAA4FE47DA8645FA4CE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_47900DE4B98B3FAA4FE47DA8645FA4CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_47900DE4B98B3FAA4FE47DA8645FA4CE" xlink:to="lab_us-gaap_ProfitLoss_47900DE4B98B3FAA4FE47DA8645FA4CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0285183AF3B08C43D0577DA864607460_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0285183AF3B08C43D0577DA864607460" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income/(loss), net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0285183AF3B08C43D0577DA864607460" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0285183AF3B08C43D0577DA864607460" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0285183AF3B08C43D0577DA864607460" xlink:type="arc" />
    <link:label id="lab_us-gaap_DividendsCashAbstract_FF829DDEBC94DC9184237DA864601B00_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCashAbstract_FF829DDEBC94DC9184237DA864601B00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash dividends declared:</link:label>
    <link:label id="lab_us-gaap_DividendsCashAbstract_FF829DDEBC94DC9184237DA864601B00_label_en-US" xlink:label="lab_us-gaap_DividendsCashAbstract_FF829DDEBC94DC9184237DA864601B00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends, Cash [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCashAbstract" xlink:label="loc_us-gaap_DividendsCashAbstract_FF829DDEBC94DC9184237DA864601B00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCashAbstract_FF829DDEBC94DC9184237DA864601B00" xlink:to="lab_us-gaap_DividendsCashAbstract_FF829DDEBC94DC9184237DA864601B00" xlink:type="arc" />
    <link:label id="lab_us-gaap_DividendsCommonStockCash_2E549E81AEAD55B1D7867DA8646056F7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash_2E549E81AEAD55B1D7867DA8646056F7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_2E549E81AEAD55B1D7867DA8646056F7_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash_2E549E81AEAD55B1D7867DA8646056F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockCash" xlink:label="loc_us-gaap_DividendsCommonStockCash_2E549E81AEAD55B1D7867DA8646056F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash_2E549E81AEAD55B1D7867DA8646056F7" xlink:to="lab_us-gaap_DividendsCommonStockCash_2E549E81AEAD55B1D7867DA8646056F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DividendsPreferredStockCash_5346B828047A2DAB76927DA86460472D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsPreferredStockCash_5346B828047A2DAB76927DA86460472D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_DividendsPreferredStockCash_5346B828047A2DAB76927DA86460472D_label_en-US" xlink:label="lab_us-gaap_DividendsPreferredStockCash_5346B828047A2DAB76927DA86460472D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends, Preferred Stock, Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="loc_us-gaap_DividendsPreferredStockCash_5346B828047A2DAB76927DA86460472D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPreferredStockCash_5346B828047A2DAB76927DA86460472D" xlink:to="lab_us-gaap_DividendsPreferredStockCash_5346B828047A2DAB76927DA86460472D" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_35DD9BFB35EA594EB31F7DA864608265_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_35DD9BFB35EA594EB31F7DA864608265" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_35DD9BFB35EA594EB31F7DA864608265_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_35DD9BFB35EA594EB31F7DA864608265" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_35DD9BFB35EA594EB31F7DA864608265" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_35DD9BFB35EA594EB31F7DA864608265" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_35DD9BFB35EA594EB31F7DA864608265" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6591817ACDF20F1BF5837DA86461B66E_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6591817ACDF20F1BF5837DA86461B66E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment transactions (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6591817ACDF20F1BF5837DA86461B66E_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6591817ACDF20F1BF5837DA86461B66E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6591817ACDF20F1BF5837DA86461B66E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6591817ACDF20F1BF5837DA86461B66E" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6591817ACDF20F1BF5837DA86461B66E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_BCC6733C586E4FEB28F87DA864613D12_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_BCC6733C586E4FEB28F87DA864613D12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment transactions</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_BCC6733C586E4FEB28F87DA864613D12_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_BCC6733C586E4FEB28F87DA864613D12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_BCC6733C586E4FEB28F87DA864613D12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_BCC6733C586E4FEB28F87DA864613D12" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_BCC6733C586E4FEB28F87DA864613D12" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_6DED250EBEC778DB76267DA86461BDC9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_6DED250EBEC778DB76267DA86461BDC9" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_6DED250EBEC778DB76267DA86461BDC9_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_6DED250EBEC778DB76267DA86461BDC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_6DED250EBEC778DB76267DA86461BDC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_6DED250EBEC778DB76267DA86461BDC9" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_6DED250EBEC778DB76267DA86461BDC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_32A748D01614CE80C9ED7DA86461F833_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_32A748D01614CE80C9ED7DA86461F833" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_32A748D01614CE80C9ED7DA86461F833_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_32A748D01614CE80C9ED7DA86461F833" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_32A748D01614CE80C9ED7DA86461F833" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_32A748D01614CE80C9ED7DA86461F833" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_32A748D01614CE80C9ED7DA86461F833" xlink:type="arc" />
    <link:label id="lab_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_376DC9995DF171FA83327DA86461F0FA_negatedTerseLabel_en-US" xlink:label="lab_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_376DC9995DF171FA83327DA86461F0FA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock conversions and redemptions (in shares)</link:label>
    <link:label id="lab_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_376DC9995DF171FA83327DA86461F0FA_label_en-US" xlink:label="lab_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_376DC9995DF171FA83327DA86461F0FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued And Redeemed During Period, Shares, Conversion And Redemption of Stock</link:label>
    <link:label id="lab_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_376DC9995DF171FA83327DA86461F0FA_documentation_en-US" xlink:label="lab_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_376DC9995DF171FA83327DA86461F0FA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued And Redeemed During Period, Shares, Conversion And Redemption of Stock</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" xlink:label="loc_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_376DC9995DF171FA83327DA86461F0FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_376DC9995DF171FA83327DA86461F0FA" xlink:to="lab_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_376DC9995DF171FA83327DA86461F0FA" xlink:type="arc" />
    <link:label id="lab_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_D4BC0E7BA698E78934537DA86462C042_negatedTerseLabel_en-US" xlink:label="lab_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_D4BC0E7BA698E78934537DA86462C042" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock conversions and redemptions</link:label>
    <link:label id="lab_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_D4BC0E7BA698E78934537DA86462C042_label_en-US" xlink:label="lab_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_D4BC0E7BA698E78934537DA86462C042" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued And Redeemed During Period, Value, Conversion And Redemption of Stock</link:label>
    <link:label id="lab_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_D4BC0E7BA698E78934537DA86462C042_documentation_en-US" xlink:label="lab_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_D4BC0E7BA698E78934537DA86462C042" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued And Redeemed During Period, Value, Conversion And Redemption of Stock</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" xlink:label="loc_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_D4BC0E7BA698E78934537DA86462C042" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_D4BC0E7BA698E78934537DA86462C042" xlink:to="lab_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_D4BC0E7BA698E78934537DA86462C042" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_675F9E7ED2A00EB9013F7DA8646227BD_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares_675F9E7ED2A00EB9013F7DA8646227BD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other (in shares)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_675F9E7ED2A00EB9013F7DA8646227BD_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares_675F9E7ED2A00EB9013F7DA8646227BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Other Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOtherShares" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_675F9E7ED2A00EB9013F7DA8646227BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOtherShares_675F9E7ED2A00EB9013F7DA8646227BD" xlink:to="lab_us-gaap_StockholdersEquityOtherShares_675F9E7ED2A00EB9013F7DA8646227BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityOther_1A15A0C81B6F22F4FF867DA86462D2D7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther_1A15A0C81B6F22F4FF867DA86462D2D7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_1A15A0C81B6F22F4FF867DA86462D2D7_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther_1A15A0C81B6F22F4FF867DA86462D2D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_1A15A0C81B6F22F4FF867DA86462D2D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther_1A15A0C81B6F22F4FF867DA86462D2D7" xlink:to="lab_us-gaap_StockholdersEquityOther_1A15A0C81B6F22F4FF867DA86462D2D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_66AC37CC26B3FFF9C0D77DA86462A5EB_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_66AC37CC26B3FFF9C0D77DA86462A5EB" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_66AC37CC26B3FFF9C0D77DA86462A5EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_66AC37CC26B3FFF9C0D77DA86462A5EB" xlink:to="lab_us-gaap_SharesIssued_66AC37CC26B3FFF9C0D77DA86462A5EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_07C43582941B773E1ABE7DA86462BF5D_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_07C43582941B773E1ABE7DA86462BF5D" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_07C43582941B773E1ABE7DA86462BF5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_07C43582941B773E1ABE7DA86462BF5D" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_07C43582941B773E1ABE7DA86462BF5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_5F735C092181AD45E9E1628A0AD4CC12_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_5F735C092181AD45E9E1628A0AD4CC12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributions from our general assets for the six months ended June 28, 2020</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_5F735C092181AD45E9E1628A0AD4CC12_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_5F735C092181AD45E9E1628A0AD4CC12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_5F735C092181AD45E9E1628A0AD4CC12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_5F735C092181AD45E9E1628A0AD4CC12" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_5F735C092181AD45E9E1628A0AD4CC12" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_84E2789E62FDD42470DC628A0AD55844_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_84E2789E62FDD42470DC628A0AD55844" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected contributions from our general assets during 2020</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_84E2789E62FDD42470DC628A0AD55844_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_84E2789E62FDD42470DC628A0AD55844" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_84E2789E62FDD42470DC628A0AD55844" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_84E2789E62FDD42470DC628A0AD55844" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_84E2789E62FDD42470DC628A0AD55844" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaper_398A3E2944D03FE9AAAA9476211A3A8F_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaper_398A3E2944D03FE9AAAA9476211A3A8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaper_398A3E2944D03FE9AAAA9476211A3A8F_label_en-US" xlink:label="lab_us-gaap_CommercialPaper_398A3E2944D03FE9AAAA9476211A3A8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaper" xlink:label="loc_us-gaap_CommercialPaper_398A3E2944D03FE9AAAA9476211A3A8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaper_398A3E2944D03FE9AAAA9476211A3A8F" xlink:to="lab_us-gaap_CommercialPaper_398A3E2944D03FE9AAAA9476211A3A8F" xlink:type="arc" />
    <link:label id="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_26F08A94533062B215659476211A50BB_terseLabel_en-US" xlink:label="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_26F08A94533062B215659476211A50BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt, principal amount</link:label>
    <link:label id="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_26F08A94533062B215659476211A50BB_label_en-US" xlink:label="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_26F08A94533062B215659476211A50BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting</link:label>
    <link:label id="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_26F08A94533062B215659476211A50BB_documentation_en-US" xlink:label="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_26F08A94533062B215659476211A50BB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" xlink:label="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_26F08A94533062B215659476211A50BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_26F08A94533062B215659476211A50BB" xlink:to="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_26F08A94533062B215659476211A50BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherShortTermBorrowings_0B03F68FDFFF70200DCA9476211A283A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherShortTermBorrowings_0B03F68FDFFF70200DCA9476211A283A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other short-term borrowings, principal amount</link:label>
    <link:label id="lab_us-gaap_OtherShortTermBorrowings_0B03F68FDFFF70200DCA9476211A283A_label_en-US" xlink:label="lab_us-gaap_OtherShortTermBorrowings_0B03F68FDFFF70200DCA9476211A283A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Short-term Borrowings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherShortTermBorrowings" xlink:label="loc_us-gaap_OtherShortTermBorrowings_0B03F68FDFFF70200DCA9476211A283A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermBorrowings_0B03F68FDFFF70200DCA9476211A283A" xlink:to="lab_us-gaap_OtherShortTermBorrowings_0B03F68FDFFF70200DCA9476211A283A" xlink:type="arc" />
    <link:label id="lab_pfe_ShorttermDebtGross_4CC3FAC37358D755EFF89476211B916A_totalLabel_en-US" xlink:label="lab_pfe_ShorttermDebtGross_4CC3FAC37358D755EFF89476211B916A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total short-term borrowings, principal amount</link:label>
    <link:label id="lab_pfe_ShorttermDebtGross_4CC3FAC37358D755EFF89476211B916A_label_en-US" xlink:label="lab_pfe_ShorttermDebtGross_4CC3FAC37358D755EFF89476211B916A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt, Gross</link:label>
    <link:label id="lab_pfe_ShorttermDebtGross_4CC3FAC37358D755EFF89476211B916A_documentation_en-US" xlink:label="lab_pfe_ShorttermDebtGross_4CC3FAC37358D755EFF89476211B916A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short-term Debt, Gross</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ShorttermDebtGross" xlink:label="loc_pfe_ShorttermDebtGross_4CC3FAC37358D755EFF89476211B916A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShorttermDebtGross_4CC3FAC37358D755EFF89476211B916A" xlink:to="lab_pfe_ShorttermDebtGross_4CC3FAC37358D755EFF89476211B916A" xlink:type="arc" />
    <link:label id="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_51EBEA2CDCB75B17590F9476211B544A_verboseLabel_en-US" xlink:label="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_51EBEA2CDCB75B17590F9476211B544A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net fair value adjustments related to hedging and purchase accounting</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_51EBEA2CDCB75B17590F9476211B544A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_51EBEA2CDCB75B17590F9476211B544A" xlink:to="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_51EBEA2CDCB75B17590F9476211B544A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_267DF35B04E266CB12FC9476211B57E4_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_267DF35B04E266CB12FC9476211B57E4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net unamortized discounts, premiums and debt issuance costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_267DF35B04E266CB12FC9476211B57E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_267DF35B04E266CB12FC9476211B57E4" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_267DF35B04E266CB12FC9476211B57E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtCurrent_9699BE191B76816BC08C9476211BF1DE_totalLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent_9699BE191B76816BC08C9476211BF1DE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_9699BE191B76816BC08C9476211BF1DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent_9699BE191B76816BC08C9476211BF1DE" xlink:to="lab_us-gaap_DebtCurrent_9699BE191B76816BC08C9476211BF1DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_EEF9E788682221770FA4596534B783A4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_EEF9E788682221770FA4596534B783A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_EEF9E788682221770FA4596534B783A4_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_EEF9E788682221770FA4596534B783A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_EEF9E788682221770FA4596534B783A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_EEF9E788682221770FA4596534B783A4" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_EEF9E788682221770FA4596534B783A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_0357656CEBE642ECF2A2596534B8C135_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_0357656CEBE642ECF2A2596534B8C135" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_0357656CEBE642ECF2A2596534B8C135_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_0357656CEBE642ECF2A2596534B8C135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_0357656CEBE642ECF2A2596534B8C135" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_0357656CEBE642ECF2A2596534B8C135" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_0357656CEBE642ECF2A2596534B8C135" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_C0ABA5F0B7EFC6519FCB596534B91777_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_C0ABA5F0B7EFC6519FCB596534B91777" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_C0ABA5F0B7EFC6519FCB596534B91777" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_C0ABA5F0B7EFC6519FCB596534B91777" xlink:to="lab_us-gaap_AssetsCurrent_C0ABA5F0B7EFC6519FCB596534B91777" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsNoncurrent_5D96628A93D9620C207F596534B9E238_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent_5D96628A93D9620C207F596534B9E238" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_5D96628A93D9620C207F596534B9E238_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent_5D96628A93D9620C207F596534B9E238" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_5D96628A93D9620C207F596534B9E238" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_5D96628A93D9620C207F596534B9E238" xlink:to="lab_us-gaap_AssetsNoncurrent_5D96628A93D9620C207F596534B9E238" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_03F34D4869DEC29664B5596534BF0D68_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_03F34D4869DEC29664B5596534BF0D68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_03F34D4869DEC29664B5596534BF0D68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_03F34D4869DEC29664B5596534BF0D68" xlink:to="lab_us-gaap_LiabilitiesCurrent_03F34D4869DEC29664B5596534BF0D68" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_1DA15B75DAADB56816F3596534BFB23E_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_1DA15B75DAADB56816F3596534BFB23E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_1DA15B75DAADB56816F3596534BFB23E_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_1DA15B75DAADB56816F3596534BFB23E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_1DA15B75DAADB56816F3596534BFB23E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_1DA15B75DAADB56816F3596534BFB23E" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_1DA15B75DAADB56816F3596534BFB23E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_EF28E8FD31E532C6C8CF596534BFFEA4_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_EF28E8FD31E532C6C8CF596534BFFEA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity attributable to shareholders</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_EF28E8FD31E532C6C8CF596534BFFEA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_EF28E8FD31E532C6C8CF596534BFFEA4" xlink:to="lab_us-gaap_StockholdersEquity_EF28E8FD31E532C6C8CF596534BFFEA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_09FC4A9D0D5491E30494596534C0DDF0_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_09FC4A9D0D5491E30494596534C0DDF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales</link:label>
    <link:label id="lab_us-gaap_Revenues_09FC4A9D0D5491E30494596534C0DDF0_label_en-US" xlink:label="lab_us-gaap_Revenues_09FC4A9D0D5491E30494596534C0DDF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_09FC4A9D0D5491E30494596534C0DDF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_09FC4A9D0D5491E30494596534C0DDF0" xlink:to="lab_us-gaap_Revenues_09FC4A9D0D5491E30494596534C0DDF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfRevenue_1B75DF4B5057AE5B4F89596534C025BF_negatedLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue_1B75DF4B5057AE5B4F89596534C025BF" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_1B75DF4B5057AE5B4F89596534C025BF_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue_1B75DF4B5057AE5B4F89596534C025BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_1B75DF4B5057AE5B4F89596534C025BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue_1B75DF4B5057AE5B4F89596534C025BF" xlink:to="lab_us-gaap_CostOfRevenue_1B75DF4B5057AE5B4F89596534C025BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrossProfit_D7C4535E722E036ECFBF596534C06CC3_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit_D7C4535E722E036ECFBF596534C06CC3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_D7C4535E722E036ECFBF596534C06CC3_label_en-US" xlink:label="lab_us-gaap_GrossProfit_D7C4535E722E036ECFBF596534C06CC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_D7C4535E722E036ECFBF596534C06CC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_D7C4535E722E036ECFBF596534C06CC3" xlink:to="lab_us-gaap_GrossProfit_D7C4535E722E036ECFBF596534C06CC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_D90F2EF67B474070F9E6596534C1C5E3_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_D90F2EF67B474070F9E6596534C1C5E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income attributable to shareholders</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_D90F2EF67B474070F9E6596534C1C5E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_D90F2EF67B474070F9E6596534C1C5E3" xlink:to="lab_us-gaap_NetIncomeLoss_D90F2EF67B474070F9E6596534C1C5E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_E10102AD6994EA283CD794761FB8FDB3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_E10102AD6994EA283CD794761FB8FDB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_E10102AD6994EA283CD794761FB8FDB3_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_E10102AD6994EA283CD794761FB8FDB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_E10102AD6994EA283CD794761FB8FDB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_E10102AD6994EA283CD794761FB8FDB3" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_E10102AD6994EA283CD794761FB8FDB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_ED8DFFA15704B8035A2894761FB9F32D_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_ED8DFFA15704B8035A2894761FB9F32D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_ED8DFFA15704B8035A2894761FB9F32D_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_ED8DFFA15704B8035A2894761FB9F32D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_ED8DFFA15704B8035A2894761FB9F32D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves_ED8DFFA15704B8035A2894761FB9F32D" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves_ED8DFFA15704B8035A2894761FB9F32D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_1FC87E8E08EE4676A1B894761FB9ABB4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_1FC87E8E08EE4676A1B894761FB9ABB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_1FC87E8E08EE4676A1B894761FB9ABB4_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_1FC87E8E08EE4676A1B894761FB9ABB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials and Supplies, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_1FC87E8E08EE4676A1B894761FB9ABB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_1FC87E8E08EE4676A1B894761FB9ABB4" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_1FC87E8E08EE4676A1B894761FB9ABB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_831A1EEB8B9745637EB794761FB9DC4B_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_831A1EEB8B9745637EB794761FB9DC4B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_831A1EEB8B9745637EB794761FB9DC4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_831A1EEB8B9745637EB794761FB9DC4B" xlink:to="lab_us-gaap_InventoryNet_831A1EEB8B9745637EB794761FB9DC4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNoncurrent_24C560028A2040C999CF94761FB9E691_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_24C560028A2040C999CF94761FB9E691" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent inventories not included above</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_24C560028A2040C999CF94761FB9E691_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_24C560028A2040C999CF94761FB9E691" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_24C560028A2040C999CF94761FB9E691" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent_24C560028A2040C999CF94761FB9E691" xlink:to="lab_us-gaap_InventoryNoncurrent_24C560028A2040C999CF94761FB9E691" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_EB99D1A4AC4FFC9C8F6FA56C86A8D13E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_EB99D1A4AC4FFC9C8F6FA56C86A8D13E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_EB99D1A4AC4FFC9C8F6FA56C86A8D13E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_EB99D1A4AC4FFC9C8F6FA56C86A8D13E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_EB99D1A4AC4FFC9C8F6FA56C86A8D13E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_EB99D1A4AC4FFC9C8F6FA56C86A8D13E" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_EB99D1A4AC4FFC9C8F6FA56C86A8D13E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReportingUnitAxis_8C00D7FDFCCBC1F60C8CA56C86A91193_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis_8C00D7FDFCCBC1F60C8CA56C86A91193" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_8C00D7FDFCCBC1F60C8CA56C86A91193_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis_8C00D7FDFCCBC1F60C8CA56C86A91193" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitAxis" xlink:label="loc_us-gaap_ReportingUnitAxis_8C00D7FDFCCBC1F60C8CA56C86A91193" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis_8C00D7FDFCCBC1F60C8CA56C86A91193" xlink:to="lab_us-gaap_ReportingUnitAxis_8C00D7FDFCCBC1F60C8CA56C86A91193" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91" xlink:to="lab_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91" xlink:type="arc" />
    <link:label id="lab_pfe_InternalMedicineMember_F6F5D98D4B06E262880FA56C86AE684B_terseLabel_en-US" xlink:label="lab_pfe_InternalMedicineMember_F6F5D98D4B06E262880FA56C86AE684B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Internal Medicine [Member]</link:label>
    <link:label id="lab_pfe_InternalMedicineMember_F6F5D98D4B06E262880FA56C86AE684B_label_en-US" xlink:label="lab_pfe_InternalMedicineMember_F6F5D98D4B06E262880FA56C86AE684B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Internal Medicine [Member]</link:label>
    <link:label id="lab_pfe_InternalMedicineMember_F6F5D98D4B06E262880FA56C86AE684B_documentation_en-US" xlink:label="lab_pfe_InternalMedicineMember_F6F5D98D4B06E262880FA56C86AE684B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Internal Medicine [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_InternalMedicineMember" xlink:label="loc_pfe_InternalMedicineMember_F6F5D98D4B06E262880FA56C86AE684B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InternalMedicineMember_F6F5D98D4B06E262880FA56C86AE684B" xlink:to="lab_pfe_InternalMedicineMember_F6F5D98D4B06E262880FA56C86AE684B" xlink:type="arc" />
    <link:label id="lab_pfe_OncologyMember_CB5E0FF8C75B3122B531A56C86AFB15C_terseLabel_en-US" xlink:label="lab_pfe_OncologyMember_CB5E0FF8C75B3122B531A56C86AFB15C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_pfe_OncologyMember_CB5E0FF8C75B3122B531A56C86AFB15C_label_en-US" xlink:label="lab_pfe_OncologyMember_CB5E0FF8C75B3122B531A56C86AFB15C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_pfe_OncologyMember_CB5E0FF8C75B3122B531A56C86AFB15C_documentation_en-US" xlink:label="lab_pfe_OncologyMember_CB5E0FF8C75B3122B531A56C86AFB15C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Oncology [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OncologyMember" xlink:label="loc_pfe_OncologyMember_CB5E0FF8C75B3122B531A56C86AFB15C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OncologyMember_CB5E0FF8C75B3122B531A56C86AFB15C" xlink:to="lab_pfe_OncologyMember_CB5E0FF8C75B3122B531A56C86AFB15C" xlink:type="arc" />
    <link:label id="lab_pfe_HospitalMember_86A742C0795AC99C98BAA56C86AF28B4_terseLabel_en-US" xlink:label="lab_pfe_HospitalMember_86A742C0795AC99C98BAA56C86AF28B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hospital [Member]</link:label>
    <link:label id="lab_pfe_HospitalMember_86A742C0795AC99C98BAA56C86AF28B4_label_en-US" xlink:label="lab_pfe_HospitalMember_86A742C0795AC99C98BAA56C86AF28B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hospital [Member]</link:label>
    <link:label id="lab_pfe_HospitalMember_86A742C0795AC99C98BAA56C86AF28B4_documentation_en-US" xlink:label="lab_pfe_HospitalMember_86A742C0795AC99C98BAA56C86AF28B4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hospital [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_HospitalMember" xlink:label="loc_pfe_HospitalMember_86A742C0795AC99C98BAA56C86AF28B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HospitalMember_86A742C0795AC99C98BAA56C86AF28B4" xlink:to="lab_pfe_HospitalMember_86A742C0795AC99C98BAA56C86AF28B4" xlink:type="arc" />
    <link:label id="lab_pfe_VaccinesMember_A0AB6CB62DF46A44BE94A56C86AFADE7_terseLabel_en-US" xlink:label="lab_pfe_VaccinesMember_A0AB6CB62DF46A44BE94A56C86AFADE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vaccines [Member]</link:label>
    <link:label id="lab_pfe_VaccinesMember_A0AB6CB62DF46A44BE94A56C86AFADE7_label_en-US" xlink:label="lab_pfe_VaccinesMember_A0AB6CB62DF46A44BE94A56C86AFADE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vaccines [Member]</link:label>
    <link:label id="lab_pfe_VaccinesMember_A0AB6CB62DF46A44BE94A56C86AFADE7_documentation_en-US" xlink:label="lab_pfe_VaccinesMember_A0AB6CB62DF46A44BE94A56C86AFADE7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vaccines [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_VaccinesMember" xlink:label="loc_pfe_VaccinesMember_A0AB6CB62DF46A44BE94A56C86AFADE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_VaccinesMember_A0AB6CB62DF46A44BE94A56C86AFADE7" xlink:to="lab_pfe_VaccinesMember_A0AB6CB62DF46A44BE94A56C86AFADE7" xlink:type="arc" />
    <link:label id="lab_pfe_InflammationandImmunologyMember_6BEBE45E80282D8DF85FA56C86B0794E_terseLabel_en-US" xlink:label="lab_pfe_InflammationandImmunologyMember_6BEBE45E80282D8DF85FA56C86B0794E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inflammation and Immunology (I&amp;I) [Member]</link:label>
    <link:label id="lab_pfe_InflammationandImmunologyMember_6BEBE45E80282D8DF85FA56C86B0794E_label_en-US" xlink:label="lab_pfe_InflammationandImmunologyMember_6BEBE45E80282D8DF85FA56C86B0794E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inflammation and Immunology [Member]</link:label>
    <link:label id="lab_pfe_InflammationandImmunologyMember_6BEBE45E80282D8DF85FA56C86B0794E_documentation_en-US" xlink:label="lab_pfe_InflammationandImmunologyMember_6BEBE45E80282D8DF85FA56C86B0794E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inflammation and Immunology [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_InflammationandImmunologyMember" xlink:label="loc_pfe_InflammationandImmunologyMember_6BEBE45E80282D8DF85FA56C86B0794E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InflammationandImmunologyMember_6BEBE45E80282D8DF85FA56C86B0794E" xlink:to="lab_pfe_InflammationandImmunologyMember_6BEBE45E80282D8DF85FA56C86B0794E" xlink:type="arc" />
    <link:label id="lab_pfe_RareDiseaseMember_F14C6BC670D92FF6E1B6A56C86B0ED0A_terseLabel_en-US" xlink:label="lab_pfe_RareDiseaseMember_F14C6BC670D92FF6E1B6A56C86B0ED0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rare Disease [Member]</link:label>
    <link:label id="lab_pfe_RareDiseaseMember_F14C6BC670D92FF6E1B6A56C86B0ED0A_label_en-US" xlink:label="lab_pfe_RareDiseaseMember_F14C6BC670D92FF6E1B6A56C86B0ED0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rare Disease [Member]</link:label>
    <link:label id="lab_pfe_RareDiseaseMember_F14C6BC670D92FF6E1B6A56C86B0ED0A_documentation_en-US" xlink:label="lab_pfe_RareDiseaseMember_F14C6BC670D92FF6E1B6A56C86B0ED0A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rare Disease [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_RareDiseaseMember" xlink:label="loc_pfe_RareDiseaseMember_F14C6BC670D92FF6E1B6A56C86B0ED0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RareDiseaseMember_F14C6BC670D92FF6E1B6A56C86B0ED0A" xlink:to="lab_pfe_RareDiseaseMember_F14C6BC670D92FF6E1B6A56C86B0ED0A" xlink:type="arc" />
    <link:label id="lab_pfe_UpjohnReportingUnitMember_D641FF22EA64057A719FA56C86B054FB_terseLabel_en-US" xlink:label="lab_pfe_UpjohnReportingUnitMember_D641FF22EA64057A719FA56C86B054FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upjohn [Member]</link:label>
    <link:label id="lab_pfe_UpjohnReportingUnitMember_D641FF22EA64057A719FA56C86B054FB_label_en-US" xlink:label="lab_pfe_UpjohnReportingUnitMember_D641FF22EA64057A719FA56C86B054FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upjohn Reporting Unit [Member]</link:label>
    <link:label id="lab_pfe_UpjohnReportingUnitMember_D641FF22EA64057A719FA56C86B054FB_documentation_en-US" xlink:label="lab_pfe_UpjohnReportingUnitMember_D641FF22EA64057A719FA56C86B054FB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upjohn Reporting Unit [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnReportingUnitMember" xlink:label="loc_pfe_UpjohnReportingUnitMember_D641FF22EA64057A719FA56C86B054FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_UpjohnReportingUnitMember_D641FF22EA64057A719FA56C86B054FB" xlink:to="lab_pfe_UpjohnReportingUnitMember_D641FF22EA64057A719FA56C86B054FB" xlink:type="arc" />
    <link:label id="lab_pfe_ConsumerHealthcareReportingUnitMember_C8AF36EA4CF5E50A9841A56C86B0593F_terseLabel_en-US" xlink:label="lab_pfe_ConsumerHealthcareReportingUnitMember_C8AF36EA4CF5E50A9841A56C86B0593F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consumer Healthcare [Member]</link:label>
    <link:label id="lab_pfe_ConsumerHealthcareReportingUnitMember_C8AF36EA4CF5E50A9841A56C86B0593F_label_en-US" xlink:label="lab_pfe_ConsumerHealthcareReportingUnitMember_C8AF36EA4CF5E50A9841A56C86B0593F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consumer Healthcare Reporting Unit [Member]</link:label>
    <link:label id="lab_pfe_ConsumerHealthcareReportingUnitMember_C8AF36EA4CF5E50A9841A56C86B0593F_documentation_en-US" xlink:label="lab_pfe_ConsumerHealthcareReportingUnitMember_C8AF36EA4CF5E50A9841A56C86B0593F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consumer Healthcare Reporting Unit [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ConsumerHealthcareReportingUnitMember" xlink:label="loc_pfe_ConsumerHealthcareReportingUnitMember_C8AF36EA4CF5E50A9841A56C86B0593F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ConsumerHealthcareReportingUnitMember_C8AF36EA4CF5E50A9841A56C86B0593F" xlink:to="lab_pfe_ConsumerHealthcareReportingUnitMember_C8AF36EA4CF5E50A9841A56C86B0593F" xlink:type="arc" />
    <link:label id="lab_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_0FC68527EF72BF306D48A56C86B1A215_terseLabel_en-US" xlink:label="lab_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_0FC68527EF72BF306D48A56C86B1A215" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biopharma, Upjohn And Consumer Healthcare Segments [Member]</link:label>
    <link:label id="lab_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_0FC68527EF72BF306D48A56C86B1A215_label_en-US" xlink:label="lab_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_0FC68527EF72BF306D48A56C86B1A215" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biopharma, Upjohn And Consumer Healthcare Segments [Member]</link:label>
    <link:label id="lab_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_0FC68527EF72BF306D48A56C86B1A215_documentation_en-US" xlink:label="lab_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_0FC68527EF72BF306D48A56C86B1A215" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biopharma, Upjohn And Consumer Healthcare Segments [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" xlink:label="loc_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_0FC68527EF72BF306D48A56C86B1A215" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_0FC68527EF72BF306D48A56C86B1A215" xlink:to="lab_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_0FC68527EF72BF306D48A56C86B1A215" xlink:type="arc" />
    <link:label id="lab_pfe_ChantixChampixMember_E8B6C0153F9AE09FC10DA56C86B26AE1_terseLabel_en-US" xlink:label="lab_pfe_ChantixChampixMember_E8B6C0153F9AE09FC10DA56C86B26AE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chantix / Champix [Member]</link:label>
    <link:label id="lab_pfe_ChantixChampixMember_E8B6C0153F9AE09FC10DA56C86B26AE1_label_en-US" xlink:label="lab_pfe_ChantixChampixMember_E8B6C0153F9AE09FC10DA56C86B26AE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chantix Champix [Member]</link:label>
    <link:label id="lab_pfe_ChantixChampixMember_E8B6C0153F9AE09FC10DA56C86B26AE1_documentation_en-US" xlink:label="lab_pfe_ChantixChampixMember_E8B6C0153F9AE09FC10DA56C86B26AE1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Chantix / Champix [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ChantixChampixMember" xlink:label="loc_pfe_ChantixChampixMember_E8B6C0153F9AE09FC10DA56C86B26AE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ChantixChampixMember_E8B6C0153F9AE09FC10DA56C86B26AE1" xlink:to="lab_pfe_ChantixChampixMember_E8B6C0153F9AE09FC10DA56C86B26AE1" xlink:type="arc" />
    <link:label id="lab_pfe_PremarinFamilyMember_4588C53585AA9FF88A45A56C86B29EE6_terseLabel_en-US" xlink:label="lab_pfe_PremarinFamilyMember_4588C53585AA9FF88A45A56C86B29EE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Premarin family [Member]</link:label>
    <link:label id="lab_pfe_PremarinFamilyMember_4588C53585AA9FF88A45A56C86B29EE6_label_en-US" xlink:label="lab_pfe_PremarinFamilyMember_4588C53585AA9FF88A45A56C86B29EE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Premarin Family [Member]</link:label>
    <link:label id="lab_pfe_PremarinFamilyMember_4588C53585AA9FF88A45A56C86B29EE6_documentation_en-US" xlink:label="lab_pfe_PremarinFamilyMember_4588C53585AA9FF88A45A56C86B29EE6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Premarin family [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PremarinFamilyMember" xlink:label="loc_pfe_PremarinFamilyMember_4588C53585AA9FF88A45A56C86B29EE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PremarinFamilyMember_4588C53585AA9FF88A45A56C86B29EE6" xlink:to="lab_pfe_PremarinFamilyMember_4588C53585AA9FF88A45A56C86B29EE6" xlink:type="arc" />
    <link:label id="lab_pfe_BMP2Member_1AE86B3689D81EA5118DA56C86B335C6_terseLabel_en-US" xlink:label="lab_pfe_BMP2Member_1AE86B3689D81EA5118DA56C86B335C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BMP2 [Member]</link:label>
    <link:label id="lab_pfe_BMP2Member_1AE86B3689D81EA5118DA56C86B335C6_label_en-US" xlink:label="lab_pfe_BMP2Member_1AE86B3689D81EA5118DA56C86B335C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BMP2 [Member]</link:label>
    <link:label id="lab_pfe_BMP2Member_1AE86B3689D81EA5118DA56C86B335C6_documentation_en-US" xlink:label="lab_pfe_BMP2Member_1AE86B3689D81EA5118DA56C86B335C6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BMP2 [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BMP2Member" xlink:label="loc_pfe_BMP2Member_1AE86B3689D81EA5118DA56C86B335C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BMP2Member_1AE86B3689D81EA5118DA56C86B335C6" xlink:to="lab_pfe_BMP2Member_1AE86B3689D81EA5118DA56C86B335C6" xlink:type="arc" />
    <link:label id="lab_pfe_ToviazMember_615A0752A97615972028A56C86B3A51C_terseLabel_en-US" xlink:label="lab_pfe_ToviazMember_615A0752A97615972028A56C86B3A51C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Toviaz [Member]</link:label>
    <link:label id="lab_pfe_ToviazMember_615A0752A97615972028A56C86B3A51C_label_en-US" xlink:label="lab_pfe_ToviazMember_615A0752A97615972028A56C86B3A51C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Toviaz [Member]</link:label>
    <link:label id="lab_pfe_ToviazMember_615A0752A97615972028A56C86B3A51C_documentation_en-US" xlink:label="lab_pfe_ToviazMember_615A0752A97615972028A56C86B3A51C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Toviaz [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ToviazMember" xlink:label="loc_pfe_ToviazMember_615A0752A97615972028A56C86B3A51C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ToviazMember_615A0752A97615972028A56C86B3A51C" xlink:to="lab_pfe_ToviazMember_615A0752A97615972028A56C86B3A51C" xlink:type="arc" />
    <link:label id="lab_pfe_AllOtherInternalMedicineMember_7C848AF0CC6E15FC67E2A56C86B30692_terseLabel_en-US" xlink:label="lab_pfe_AllOtherInternalMedicineMember_7C848AF0CC6E15FC67E2A56C86B30692" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All other Internal Medicine [Member]</link:label>
    <link:label id="lab_pfe_AllOtherInternalMedicineMember_7C848AF0CC6E15FC67E2A56C86B30692_label_en-US" xlink:label="lab_pfe_AllOtherInternalMedicineMember_7C848AF0CC6E15FC67E2A56C86B30692" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Other Internal Medicine [Member]</link:label>
    <link:label id="lab_pfe_AllOtherInternalMedicineMember_7C848AF0CC6E15FC67E2A56C86B30692_documentation_en-US" xlink:label="lab_pfe_AllOtherInternalMedicineMember_7C848AF0CC6E15FC67E2A56C86B30692" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">All Other Internal Medicine [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AllOtherInternalMedicineMember" xlink:label="loc_pfe_AllOtherInternalMedicineMember_7C848AF0CC6E15FC67E2A56C86B30692" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AllOtherInternalMedicineMember_7C848AF0CC6E15FC67E2A56C86B30692" xlink:to="lab_pfe_AllOtherInternalMedicineMember_7C848AF0CC6E15FC67E2A56C86B30692" xlink:type="arc" />
    <link:label id="lab_pfe_IbranceMember_58B49E73E5E26AAF7282A56C86B3D39C_terseLabel_en-US" xlink:label="lab_pfe_IbranceMember_58B49E73E5E26AAF7282A56C86B3D39C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ibrance [Member]</link:label>
    <link:label id="lab_pfe_IbranceMember_58B49E73E5E26AAF7282A56C86B3D39C_label_en-US" xlink:label="lab_pfe_IbranceMember_58B49E73E5E26AAF7282A56C86B3D39C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ibrance [Member]</link:label>
    <link:label id="lab_pfe_IbranceMember_58B49E73E5E26AAF7282A56C86B3D39C_documentation_en-US" xlink:label="lab_pfe_IbranceMember_58B49E73E5E26AAF7282A56C86B3D39C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ibrance [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IbranceMember" xlink:label="loc_pfe_IbranceMember_58B49E73E5E26AAF7282A56C86B3D39C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IbranceMember_58B49E73E5E26AAF7282A56C86B3D39C" xlink:to="lab_pfe_IbranceMember_58B49E73E5E26AAF7282A56C86B3D39C" xlink:type="arc" />
    <link:label id="lab_pfe_XtandiAllianceRevenuesMember_61982F42AA5997949BB0A56C86B3C931_terseLabel_en-US" xlink:label="lab_pfe_XtandiAllianceRevenuesMember_61982F42AA5997949BB0A56C86B3C931" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Xtandi alliance revenues [Member]</link:label>
    <link:label id="lab_pfe_XtandiAllianceRevenuesMember_61982F42AA5997949BB0A56C86B3C931_label_en-US" xlink:label="lab_pfe_XtandiAllianceRevenuesMember_61982F42AA5997949BB0A56C86B3C931" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Xtandi Alliance Revenues [Member]</link:label>
    <link:label id="lab_pfe_XtandiAllianceRevenuesMember_61982F42AA5997949BB0A56C86B3C931_documentation_en-US" xlink:label="lab_pfe_XtandiAllianceRevenuesMember_61982F42AA5997949BB0A56C86B3C931" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Xtandi Alliance Revenues [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_XtandiAllianceRevenuesMember" xlink:label="loc_pfe_XtandiAllianceRevenuesMember_61982F42AA5997949BB0A56C86B3C931" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_XtandiAllianceRevenuesMember_61982F42AA5997949BB0A56C86B3C931" xlink:to="lab_pfe_XtandiAllianceRevenuesMember_61982F42AA5997949BB0A56C86B3C931" xlink:type="arc" />
    <link:label id="lab_pfe_SutentMember_D9ABAA0CF4E687D9CA61A56C86B3EEFB_terseLabel_en-US" xlink:label="lab_pfe_SutentMember_D9ABAA0CF4E687D9CA61A56C86B3EEFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sutent [Member]</link:label>
    <link:label id="lab_pfe_SutentMember_D9ABAA0CF4E687D9CA61A56C86B3EEFB_label_en-US" xlink:label="lab_pfe_SutentMember_D9ABAA0CF4E687D9CA61A56C86B3EEFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sutent [Member]</link:label>
    <link:label id="lab_pfe_SutentMember_D9ABAA0CF4E687D9CA61A56C86B3EEFB_documentation_en-US" xlink:label="lab_pfe_SutentMember_D9ABAA0CF4E687D9CA61A56C86B3EEFB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sutent [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SutentMember" xlink:label="loc_pfe_SutentMember_D9ABAA0CF4E687D9CA61A56C86B3EEFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SutentMember_D9ABAA0CF4E687D9CA61A56C86B3EEFB" xlink:to="lab_pfe_SutentMember_D9ABAA0CF4E687D9CA61A56C86B3EEFB" xlink:type="arc" />
    <link:label id="lab_pfe_InlytaMember_C9BA3F0F8A3AC2FD495AA56C86B43B85_terseLabel_en-US" xlink:label="lab_pfe_InlytaMember_C9BA3F0F8A3AC2FD495AA56C86B43B85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inlyta [Member]</link:label>
    <link:label id="lab_pfe_InlytaMember_C9BA3F0F8A3AC2FD495AA56C86B43B85_label_en-US" xlink:label="lab_pfe_InlytaMember_C9BA3F0F8A3AC2FD495AA56C86B43B85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inlyta [Member]</link:label>
    <link:label id="lab_pfe_InlytaMember_C9BA3F0F8A3AC2FD495AA56C86B43B85_documentation_en-US" xlink:label="lab_pfe_InlytaMember_C9BA3F0F8A3AC2FD495AA56C86B43B85" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inlyta [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_InlytaMember" xlink:label="loc_pfe_InlytaMember_C9BA3F0F8A3AC2FD495AA56C86B43B85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InlytaMember_C9BA3F0F8A3AC2FD495AA56C86B43B85" xlink:to="lab_pfe_InlytaMember_C9BA3F0F8A3AC2FD495AA56C86B43B85" xlink:type="arc" />
    <link:label id="lab_pfe_XalkoriMember_1BD7B04F8F7DF9BBCD2EA56C86B4A1D1_terseLabel_en-US" xlink:label="lab_pfe_XalkoriMember_1BD7B04F8F7DF9BBCD2EA56C86B4A1D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Xalkori [Member]</link:label>
    <link:label id="lab_pfe_XalkoriMember_1BD7B04F8F7DF9BBCD2EA56C86B4A1D1_label_en-US" xlink:label="lab_pfe_XalkoriMember_1BD7B04F8F7DF9BBCD2EA56C86B4A1D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Xalkori [Member]</link:label>
    <link:label id="lab_pfe_XalkoriMember_1BD7B04F8F7DF9BBCD2EA56C86B4A1D1_documentation_en-US" xlink:label="lab_pfe_XalkoriMember_1BD7B04F8F7DF9BBCD2EA56C86B4A1D1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Xalkori [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_XalkoriMember" xlink:label="loc_pfe_XalkoriMember_1BD7B04F8F7DF9BBCD2EA56C86B4A1D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_XalkoriMember_1BD7B04F8F7DF9BBCD2EA56C86B4A1D1" xlink:to="lab_pfe_XalkoriMember_1BD7B04F8F7DF9BBCD2EA56C86B4A1D1" xlink:type="arc" />
    <link:label id="lab_pfe_BosulifMember_4D20112C50AB734A0462A56C86B40D81_terseLabel_en-US" xlink:label="lab_pfe_BosulifMember_4D20112C50AB734A0462A56C86B40D81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bosulif [Member]</link:label>
    <link:label id="lab_pfe_BosulifMember_4D20112C50AB734A0462A56C86B40D81_label_en-US" xlink:label="lab_pfe_BosulifMember_4D20112C50AB734A0462A56C86B40D81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bosulif [Member]</link:label>
    <link:label id="lab_pfe_BosulifMember_4D20112C50AB734A0462A56C86B40D81_documentation_en-US" xlink:label="lab_pfe_BosulifMember_4D20112C50AB734A0462A56C86B40D81" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bosulif [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BosulifMember" xlink:label="loc_pfe_BosulifMember_4D20112C50AB734A0462A56C86B40D81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BosulifMember_4D20112C50AB734A0462A56C86B40D81" xlink:to="lab_pfe_BosulifMember_4D20112C50AB734A0462A56C86B40D81" xlink:type="arc" />
    <link:label id="lab_pfe_RetacritMember_5C6338C1277581566DADA56C86B41F10_terseLabel_en-US" xlink:label="lab_pfe_RetacritMember_5C6338C1277581566DADA56C86B41F10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retacrit [Member]</link:label>
    <link:label id="lab_pfe_RetacritMember_5C6338C1277581566DADA56C86B41F10_label_en-US" xlink:label="lab_pfe_RetacritMember_5C6338C1277581566DADA56C86B41F10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retacrit [Member]</link:label>
    <link:label id="lab_pfe_RetacritMember_5C6338C1277581566DADA56C86B41F10_documentation_en-US" xlink:label="lab_pfe_RetacritMember_5C6338C1277581566DADA56C86B41F10" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Retacrit [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_RetacritMember" xlink:label="loc_pfe_RetacritMember_5C6338C1277581566DADA56C86B41F10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RetacritMember_5C6338C1277581566DADA56C86B41F10" xlink:to="lab_pfe_RetacritMember_5C6338C1277581566DADA56C86B41F10" xlink:type="arc" />
    <link:label id="lab_pfe_MektoviMember_DD760C6FA3AFCB86DBA2A56C86B4D1C2_terseLabel_en-US" xlink:label="lab_pfe_MektoviMember_DD760C6FA3AFCB86DBA2A56C86B4D1C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mektovi [Member]</link:label>
    <link:label id="lab_pfe_MektoviMember_DD760C6FA3AFCB86DBA2A56C86B4D1C2_label_en-US" xlink:label="lab_pfe_MektoviMember_DD760C6FA3AFCB86DBA2A56C86B4D1C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mektovi [Member]</link:label>
    <link:label id="lab_pfe_MektoviMember_DD760C6FA3AFCB86DBA2A56C86B4D1C2_documentation_en-US" xlink:label="lab_pfe_MektoviMember_DD760C6FA3AFCB86DBA2A56C86B4D1C2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mektovi [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_MektoviMember" xlink:label="loc_pfe_MektoviMember_DD760C6FA3AFCB86DBA2A56C86B4D1C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_MektoviMember_DD760C6FA3AFCB86DBA2A56C86B4D1C2" xlink:to="lab_pfe_MektoviMember_DD760C6FA3AFCB86DBA2A56C86B4D1C2" xlink:type="arc" />
    <link:label id="lab_pfe_OtherOncologyProductsMember_4A1E7F49FAF6BECBFF6EA56C86B4F366_terseLabel_en-US" xlink:label="lab_pfe_OtherOncologyProductsMember_4A1E7F49FAF6BECBFF6EA56C86B4F366" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All other Oncology [Member]</link:label>
    <link:label id="lab_pfe_OtherOncologyProductsMember_4A1E7F49FAF6BECBFF6EA56C86B4F366_label_en-US" xlink:label="lab_pfe_OtherOncologyProductsMember_4A1E7F49FAF6BECBFF6EA56C86B4F366" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Oncology Products [Member]</link:label>
    <link:label id="lab_pfe_OtherOncologyProductsMember_4A1E7F49FAF6BECBFF6EA56C86B4F366_documentation_en-US" xlink:label="lab_pfe_OtherOncologyProductsMember_4A1E7F49FAF6BECBFF6EA56C86B4F366" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Oncology Products [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherOncologyProductsMember" xlink:label="loc_pfe_OtherOncologyProductsMember_4A1E7F49FAF6BECBFF6EA56C86B4F366" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherOncologyProductsMember_4A1E7F49FAF6BECBFF6EA56C86B4F366" xlink:to="lab_pfe_OtherOncologyProductsMember_4A1E7F49FAF6BECBFF6EA56C86B4F366" xlink:type="arc" />
    <link:label id="lab_pfe_SulperazonMember_95376C87701E4CAC5F4DA56C86B59DF2_terseLabel_en-US" xlink:label="lab_pfe_SulperazonMember_95376C87701E4CAC5F4DA56C86B59DF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sulperazon [Member]</link:label>
    <link:label id="lab_pfe_SulperazonMember_95376C87701E4CAC5F4DA56C86B59DF2_label_en-US" xlink:label="lab_pfe_SulperazonMember_95376C87701E4CAC5F4DA56C86B59DF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sulperazon [Member]</link:label>
    <link:label id="lab_pfe_SulperazonMember_95376C87701E4CAC5F4DA56C86B59DF2_documentation_en-US" xlink:label="lab_pfe_SulperazonMember_95376C87701E4CAC5F4DA56C86B59DF2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sulperazon [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SulperazonMember" xlink:label="loc_pfe_SulperazonMember_95376C87701E4CAC5F4DA56C86B59DF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SulperazonMember_95376C87701E4CAC5F4DA56C86B59DF2" xlink:to="lab_pfe_SulperazonMember_95376C87701E4CAC5F4DA56C86B59DF2" xlink:type="arc" />
    <link:label id="lab_pfe_MedrolMember_522B6988D414D3728327A56C86B5000B_terseLabel_en-US" xlink:label="lab_pfe_MedrolMember_522B6988D414D3728327A56C86B5000B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medrol [Member]</link:label>
    <link:label id="lab_pfe_MedrolMember_522B6988D414D3728327A56C86B5000B_label_en-US" xlink:label="lab_pfe_MedrolMember_522B6988D414D3728327A56C86B5000B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medrol [Member]</link:label>
    <link:label id="lab_pfe_MedrolMember_522B6988D414D3728327A56C86B5000B_documentation_en-US" xlink:label="lab_pfe_MedrolMember_522B6988D414D3728327A56C86B5000B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medrol [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_MedrolMember" xlink:label="loc_pfe_MedrolMember_522B6988D414D3728327A56C86B5000B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_MedrolMember_522B6988D414D3728327A56C86B5000B" xlink:to="lab_pfe_MedrolMember_522B6988D414D3728327A56C86B5000B" xlink:type="arc" />
    <link:label id="lab_pfe_ZithromaxZmaxMember_0CA3815A71E72E827746A56C86B56B65_terseLabel_en-US" xlink:label="lab_pfe_ZithromaxZmaxMember_0CA3815A71E72E827746A56C86B56B65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zithromax [Member]</link:label>
    <link:label id="lab_pfe_ZithromaxZmaxMember_0CA3815A71E72E827746A56C86B56B65_label_en-US" xlink:label="lab_pfe_ZithromaxZmaxMember_0CA3815A71E72E827746A56C86B56B65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zithromax Zmax [Member]</link:label>
    <link:label id="lab_pfe_ZithromaxZmaxMember_0CA3815A71E72E827746A56C86B56B65_documentation_en-US" xlink:label="lab_pfe_ZithromaxZmaxMember_0CA3815A71E72E827746A56C86B56B65" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zithromax / Zmax [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ZithromaxZmaxMember" xlink:label="loc_pfe_ZithromaxZmaxMember_0CA3815A71E72E827746A56C86B56B65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ZithromaxZmaxMember_0CA3815A71E72E827746A56C86B56B65" xlink:to="lab_pfe_ZithromaxZmaxMember_0CA3815A71E72E827746A56C86B56B65" xlink:type="arc" />
    <link:label id="lab_pfe_PrecedexMember_815148BB9543BEE28EBAA56C86B5E751_terseLabel_en-US" xlink:label="lab_pfe_PrecedexMember_815148BB9543BEE28EBAA56C86B5E751" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Precedex [Member]</link:label>
    <link:label id="lab_pfe_PrecedexMember_815148BB9543BEE28EBAA56C86B5E751_label_en-US" xlink:label="lab_pfe_PrecedexMember_815148BB9543BEE28EBAA56C86B5E751" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Precedex [Member]</link:label>
    <link:label id="lab_pfe_PrecedexMember_815148BB9543BEE28EBAA56C86B5E751_documentation_en-US" xlink:label="lab_pfe_PrecedexMember_815148BB9543BEE28EBAA56C86B5E751" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Precedex [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PrecedexMember" xlink:label="loc_pfe_PrecedexMember_815148BB9543BEE28EBAA56C86B5E751" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PrecedexMember_815148BB9543BEE28EBAA56C86B5E751" xlink:to="lab_pfe_PrecedexMember_815148BB9543BEE28EBAA56C86B5E751" xlink:type="arc" />
    <link:label id="lab_pfe_VfendMember_45BC193A4688F3B4705CA56C86B575E9_terseLabel_en-US" xlink:label="lab_pfe_VfendMember_45BC193A4688F3B4705CA56C86B575E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vfend [Member]</link:label>
    <link:label id="lab_pfe_VfendMember_45BC193A4688F3B4705CA56C86B575E9_label_en-US" xlink:label="lab_pfe_VfendMember_45BC193A4688F3B4705CA56C86B575E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vfend [Member]</link:label>
    <link:label id="lab_pfe_VfendMember_45BC193A4688F3B4705CA56C86B575E9_documentation_en-US" xlink:label="lab_pfe_VfendMember_45BC193A4688F3B4705CA56C86B575E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vfend [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_VfendMember" xlink:label="loc_pfe_VfendMember_45BC193A4688F3B4705CA56C86B575E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_VfendMember_45BC193A4688F3B4705CA56C86B575E9" xlink:to="lab_pfe_VfendMember_45BC193A4688F3B4705CA56C86B575E9" xlink:type="arc" />
    <link:label id="lab_pfe_PanzygaMember_D41C4107962F48E68B3EA56C86B6FA8A_terseLabel_en-US" xlink:label="lab_pfe_PanzygaMember_D41C4107962F48E68B3EA56C86B6FA8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Panzyga [Member]</link:label>
    <link:label id="lab_pfe_PanzygaMember_D41C4107962F48E68B3EA56C86B6FA8A_label_en-US" xlink:label="lab_pfe_PanzygaMember_D41C4107962F48E68B3EA56C86B6FA8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Panzyga [Member]</link:label>
    <link:label id="lab_pfe_PanzygaMember_D41C4107962F48E68B3EA56C86B6FA8A_documentation_en-US" xlink:label="lab_pfe_PanzygaMember_D41C4107962F48E68B3EA56C86B6FA8A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Panzyga [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PanzygaMember" xlink:label="loc_pfe_PanzygaMember_D41C4107962F48E68B3EA56C86B6FA8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PanzygaMember_D41C4107962F48E68B3EA56C86B6FA8A" xlink:to="lab_pfe_PanzygaMember_D41C4107962F48E68B3EA56C86B6FA8A" xlink:type="arc" />
    <link:label id="lab_pfe_ZyvoxMember_6A99B0F4ACF7EF4E08B6A56C86B6D4ED_terseLabel_en-US" xlink:label="lab_pfe_ZyvoxMember_6A99B0F4ACF7EF4E08B6A56C86B6D4ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zyvox [Member]</link:label>
    <link:label id="lab_pfe_ZyvoxMember_6A99B0F4ACF7EF4E08B6A56C86B6D4ED_label_en-US" xlink:label="lab_pfe_ZyvoxMember_6A99B0F4ACF7EF4E08B6A56C86B6D4ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zyvox [Member]</link:label>
    <link:label id="lab_pfe_ZyvoxMember_6A99B0F4ACF7EF4E08B6A56C86B6D4ED_documentation_en-US" xlink:label="lab_pfe_ZyvoxMember_6A99B0F4ACF7EF4E08B6A56C86B6D4ED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zyvox [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ZyvoxMember" xlink:label="loc_pfe_ZyvoxMember_6A99B0F4ACF7EF4E08B6A56C86B6D4ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ZyvoxMember_6A99B0F4ACF7EF4E08B6A56C86B6D4ED" xlink:to="lab_pfe_ZyvoxMember_6A99B0F4ACF7EF4E08B6A56C86B6D4ED" xlink:type="arc" />
    <link:label id="lab_pfe_FragminMember_49750078F822D097D253A56C86BBD415_terseLabel_en-US" xlink:label="lab_pfe_FragminMember_49750078F822D097D253A56C86BBD415" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fragmin [Member]</link:label>
    <link:label id="lab_pfe_FragminMember_49750078F822D097D253A56C86BBD415_label_en-US" xlink:label="lab_pfe_FragminMember_49750078F822D097D253A56C86BBD415" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fragmin [Member]</link:label>
    <link:label id="lab_pfe_FragminMember_49750078F822D097D253A56C86BBD415_documentation_en-US" xlink:label="lab_pfe_FragminMember_49750078F822D097D253A56C86BBD415" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fragmin [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FragminMember" xlink:label="loc_pfe_FragminMember_49750078F822D097D253A56C86BBD415" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FragminMember_49750078F822D097D253A56C86BBD415" xlink:to="lab_pfe_FragminMember_49750078F822D097D253A56C86BBD415" xlink:type="arc" />
    <link:label id="lab_pfe_PfizerCentreOneMember_9DE4645951C19EA6057CA56C86BB1B0D_terseLabel_en-US" xlink:label="lab_pfe_PfizerCentreOneMember_9DE4645951C19EA6057CA56C86BB1B0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer CentreOne [Member]</link:label>
    <link:label id="lab_pfe_PfizerCentreOneMember_9DE4645951C19EA6057CA56C86BB1B0D_label_en-US" xlink:label="lab_pfe_PfizerCentreOneMember_9DE4645951C19EA6057CA56C86BB1B0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer CentreOne [Member]</link:label>
    <link:label id="lab_pfe_PfizerCentreOneMember_9DE4645951C19EA6057CA56C86BB1B0D_documentation_en-US" xlink:label="lab_pfe_PfizerCentreOneMember_9DE4645951C19EA6057CA56C86BB1B0D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer CentreOne [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PfizerCentreOneMember" xlink:label="loc_pfe_PfizerCentreOneMember_9DE4645951C19EA6057CA56C86BB1B0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerCentreOneMember_9DE4645951C19EA6057CA56C86BB1B0D" xlink:to="lab_pfe_PfizerCentreOneMember_9DE4645951C19EA6057CA56C86BB1B0D" xlink:type="arc" />
    <link:label id="lab_pfe_OtherAntiinfectivesMember_7F50880BD594C5F24301A56C86BBB0AE_terseLabel_en-US" xlink:label="lab_pfe_OtherAntiinfectivesMember_7F50880BD594C5F24301A56C86BBB0AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All other Anti-infectives [Member]</link:label>
    <link:label id="lab_pfe_OtherAntiinfectivesMember_7F50880BD594C5F24301A56C86BBB0AE_label_en-US" xlink:label="lab_pfe_OtherAntiinfectivesMember_7F50880BD594C5F24301A56C86BBB0AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Anti-infectives [Member]</link:label>
    <link:label id="lab_pfe_OtherAntiinfectivesMember_7F50880BD594C5F24301A56C86BBB0AE_documentation_en-US" xlink:label="lab_pfe_OtherAntiinfectivesMember_7F50880BD594C5F24301A56C86BBB0AE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Anti-infectives [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherAntiinfectivesMember" xlink:label="loc_pfe_OtherAntiinfectivesMember_7F50880BD594C5F24301A56C86BBB0AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherAntiinfectivesMember_7F50880BD594C5F24301A56C86BBB0AE" xlink:to="lab_pfe_OtherAntiinfectivesMember_7F50880BD594C5F24301A56C86BBB0AE" xlink:type="arc" />
    <link:label id="lab_pfe_OtherHospitalProductsMember_AB885C1A853C97AC11A9A56C86BB3891_terseLabel_en-US" xlink:label="lab_pfe_OtherHospitalProductsMember_AB885C1A853C97AC11A9A56C86BB3891" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All other Hospital [Member]</link:label>
    <link:label id="lab_pfe_OtherHospitalProductsMember_AB885C1A853C97AC11A9A56C86BB3891_label_en-US" xlink:label="lab_pfe_OtherHospitalProductsMember_AB885C1A853C97AC11A9A56C86BB3891" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Hospital Products [Member]</link:label>
    <link:label id="lab_pfe_OtherHospitalProductsMember_AB885C1A853C97AC11A9A56C86BB3891_documentation_en-US" xlink:label="lab_pfe_OtherHospitalProductsMember_AB885C1A853C97AC11A9A56C86BB3891" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Hospital Products [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherHospitalProductsMember" xlink:label="loc_pfe_OtherHospitalProductsMember_AB885C1A853C97AC11A9A56C86BB3891" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherHospitalProductsMember_AB885C1A853C97AC11A9A56C86BB3891" xlink:to="lab_pfe_OtherHospitalProductsMember_AB885C1A853C97AC11A9A56C86BB3891" xlink:type="arc" />
    <link:label id="lab_pfe_PrevnarPrevenarFamilyMember_4EEE60C0F50B0C658579A56C86BC8133_terseLabel_en-US" xlink:label="lab_pfe_PrevnarPrevenarFamilyMember_4EEE60C0F50B0C658579A56C86BC8133" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prevnar 13/Prevenar 13 [Member]</link:label>
    <link:label id="lab_pfe_PrevnarPrevenarFamilyMember_4EEE60C0F50B0C658579A56C86BC8133_label_en-US" xlink:label="lab_pfe_PrevnarPrevenarFamilyMember_4EEE60C0F50B0C658579A56C86BC8133" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prevnar Prevenar Family [Member]</link:label>
    <link:label id="lab_pfe_PrevnarPrevenarFamilyMember_4EEE60C0F50B0C658579A56C86BC8133_documentation_en-US" xlink:label="lab_pfe_PrevnarPrevenarFamilyMember_4EEE60C0F50B0C658579A56C86BC8133" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prevnar/Prevenar Family 13 [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PrevnarPrevenarFamilyMember" xlink:label="loc_pfe_PrevnarPrevenarFamilyMember_4EEE60C0F50B0C658579A56C86BC8133" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PrevnarPrevenarFamilyMember_4EEE60C0F50B0C658579A56C86BC8133" xlink:to="lab_pfe_PrevnarPrevenarFamilyMember_4EEE60C0F50B0C658579A56C86BC8133" xlink:type="arc" />
    <link:label id="lab_pfe_NimenrixMember_CD0AFA296C250E0761EFA56C86BCB740_terseLabel_en-US" xlink:label="lab_pfe_NimenrixMember_CD0AFA296C250E0761EFA56C86BCB740" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nimenrix [Member]</link:label>
    <link:label id="lab_pfe_NimenrixMember_CD0AFA296C250E0761EFA56C86BCB740_label_en-US" xlink:label="lab_pfe_NimenrixMember_CD0AFA296C250E0761EFA56C86BCB740" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nimenrix [Member]</link:label>
    <link:label id="lab_pfe_NimenrixMember_CD0AFA296C250E0761EFA56C86BCB740_documentation_en-US" xlink:label="lab_pfe_NimenrixMember_CD0AFA296C250E0761EFA56C86BCB740" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nimenrix [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_NimenrixMember" xlink:label="loc_pfe_NimenrixMember_CD0AFA296C250E0761EFA56C86BCB740" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NimenrixMember_CD0AFA296C250E0761EFA56C86BCB740" xlink:to="lab_pfe_NimenrixMember_CD0AFA296C250E0761EFA56C86BCB740" xlink:type="arc" />
    <link:label id="lab_pfe_OtherVaccinesProductsMember_4B49EA2EC8C94B7748E6A56C86BC5703_terseLabel_en-US" xlink:label="lab_pfe_OtherVaccinesProductsMember_4B49EA2EC8C94B7748E6A56C86BC5703" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All other Vaccines [Member]</link:label>
    <link:label id="lab_pfe_OtherVaccinesProductsMember_4B49EA2EC8C94B7748E6A56C86BC5703_label_en-US" xlink:label="lab_pfe_OtherVaccinesProductsMember_4B49EA2EC8C94B7748E6A56C86BC5703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Vaccines Products [Member]</link:label>
    <link:label id="lab_pfe_OtherVaccinesProductsMember_4B49EA2EC8C94B7748E6A56C86BC5703_documentation_en-US" xlink:label="lab_pfe_OtherVaccinesProductsMember_4B49EA2EC8C94B7748E6A56C86BC5703" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Vaccines Products [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherVaccinesProductsMember" xlink:label="loc_pfe_OtherVaccinesProductsMember_4B49EA2EC8C94B7748E6A56C86BC5703" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherVaccinesProductsMember_4B49EA2EC8C94B7748E6A56C86BC5703" xlink:to="lab_pfe_OtherVaccinesProductsMember_4B49EA2EC8C94B7748E6A56C86BC5703" xlink:type="arc" />
    <link:label id="lab_pfe_EnbrelMember_20D39F0CC56F9508E3D3A56C86BC00A5_verboseLabel_en-US" xlink:label="lab_pfe_EnbrelMember_20D39F0CC56F9508E3D3A56C86BC00A5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Enbrel (Outside the U.S. and Canada) [Member]</link:label>
    <link:label id="lab_pfe_EnbrelMember_20D39F0CC56F9508E3D3A56C86BC00A5_label_en-US" xlink:label="lab_pfe_EnbrelMember_20D39F0CC56F9508E3D3A56C86BC00A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Enbrel [Member]</link:label>
    <link:label id="lab_pfe_EnbrelMember_20D39F0CC56F9508E3D3A56C86BC00A5_documentation_en-US" xlink:label="lab_pfe_EnbrelMember_20D39F0CC56F9508E3D3A56C86BC00A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Enbrel [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EnbrelMember" xlink:label="loc_pfe_EnbrelMember_20D39F0CC56F9508E3D3A56C86BC00A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EnbrelMember_20D39F0CC56F9508E3D3A56C86BC00A5" xlink:to="lab_pfe_EnbrelMember_20D39F0CC56F9508E3D3A56C86BC00A5" xlink:type="arc" />
    <link:label id="lab_pfe_InflectraRemsimaMember_B82802DBC0973FCF58F8A56C86BDBC3C_terseLabel_en-US" xlink:label="lab_pfe_InflectraRemsimaMember_B82802DBC0973FCF58F8A56C86BDBC3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inflectra/Remsima [Member]</link:label>
    <link:label id="lab_pfe_InflectraRemsimaMember_B82802DBC0973FCF58F8A56C86BDBC3C_label_en-US" xlink:label="lab_pfe_InflectraRemsimaMember_B82802DBC0973FCF58F8A56C86BDBC3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inflectra/Remsima [Member]</link:label>
    <link:label id="lab_pfe_InflectraRemsimaMember_B82802DBC0973FCF58F8A56C86BDBC3C_documentation_en-US" xlink:label="lab_pfe_InflectraRemsimaMember_B82802DBC0973FCF58F8A56C86BDBC3C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inflectra/Remsima [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_InflectraRemsimaMember" xlink:label="loc_pfe_InflectraRemsimaMember_B82802DBC0973FCF58F8A56C86BDBC3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InflectraRemsimaMember_B82802DBC0973FCF58F8A56C86BDBC3C" xlink:to="lab_pfe_InflectraRemsimaMember_B82802DBC0973FCF58F8A56C86BDBC3C" xlink:type="arc" />
    <link:label id="lab_pfe_AllOtherInflammationandImmunologyProductsMember_AF53FD9E835B8055DB78A56C86BDBD30_terseLabel_en-US" xlink:label="lab_pfe_AllOtherInflammationandImmunologyProductsMember_AF53FD9E835B8055DB78A56C86BDBD30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All other I &amp; I [Member]</link:label>
    <link:label id="lab_pfe_AllOtherInflammationandImmunologyProductsMember_AF53FD9E835B8055DB78A56C86BDBD30_label_en-US" xlink:label="lab_pfe_AllOtherInflammationandImmunologyProductsMember_AF53FD9E835B8055DB78A56C86BDBD30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Other Inflammation and Immunology Products [Member]</link:label>
    <link:label id="lab_pfe_AllOtherInflammationandImmunologyProductsMember_AF53FD9E835B8055DB78A56C86BDBD30_documentation_en-US" xlink:label="lab_pfe_AllOtherInflammationandImmunologyProductsMember_AF53FD9E835B8055DB78A56C86BDBD30" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">All Other Inflammation and Immunology Products [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AllOtherInflammationandImmunologyProductsMember" xlink:label="loc_pfe_AllOtherInflammationandImmunologyProductsMember_AF53FD9E835B8055DB78A56C86BDBD30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AllOtherInflammationandImmunologyProductsMember_AF53FD9E835B8055DB78A56C86BDBD30" xlink:to="lab_pfe_AllOtherInflammationandImmunologyProductsMember_AF53FD9E835B8055DB78A56C86BDBD30" xlink:type="arc" />
    <link:label id="lab_pfe_VyndaqelMember_3685807938B54E561B92A56C86BDB386_terseLabel_en-US" xlink:label="lab_pfe_VyndaqelMember_3685807938B54E561B92A56C86BDB386" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vyndaqel/Vyndamax [Member]</link:label>
    <link:label id="lab_pfe_VyndaqelMember_3685807938B54E561B92A56C86BDB386_label_en-US" xlink:label="lab_pfe_VyndaqelMember_3685807938B54E561B92A56C86BDB386" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vyndaqel [Member]</link:label>
    <link:label id="lab_pfe_VyndaqelMember_3685807938B54E561B92A56C86BDB386_documentation_en-US" xlink:label="lab_pfe_VyndaqelMember_3685807938B54E561B92A56C86BDB386" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vyndaqel [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_VyndaqelMember" xlink:label="loc_pfe_VyndaqelMember_3685807938B54E561B92A56C86BDB386" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_VyndaqelMember_3685807938B54E561B92A56C86BDB386" xlink:to="lab_pfe_VyndaqelMember_3685807938B54E561B92A56C86BDB386" xlink:type="arc" />
    <link:label id="lab_pfe_BeneFIXMember_78AF65605967123A3219A56C86BDCF35_terseLabel_en-US" xlink:label="lab_pfe_BeneFIXMember_78AF65605967123A3219A56C86BDCF35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BeneFIX [Member]</link:label>
    <link:label id="lab_pfe_BeneFIXMember_78AF65605967123A3219A56C86BDCF35_label_en-US" xlink:label="lab_pfe_BeneFIXMember_78AF65605967123A3219A56C86BDCF35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bene F I X [Member]</link:label>
    <link:label id="lab_pfe_BeneFIXMember_78AF65605967123A3219A56C86BDCF35_documentation_en-US" xlink:label="lab_pfe_BeneFIXMember_78AF65605967123A3219A56C86BDCF35" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bene F I X [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BeneFIXMember" xlink:label="loc_pfe_BeneFIXMember_78AF65605967123A3219A56C86BDCF35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BeneFIXMember_78AF65605967123A3219A56C86BDCF35" xlink:to="lab_pfe_BeneFIXMember_78AF65605967123A3219A56C86BDCF35" xlink:type="arc" />
    <link:label id="lab_pfe_GenotropinMember_7FB36B0DA9ED797D3E48A56C86BD5AF5_terseLabel_en-US" xlink:label="lab_pfe_GenotropinMember_7FB36B0DA9ED797D3E48A56C86BD5AF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Genotropin [Member]</link:label>
    <link:label id="lab_pfe_GenotropinMember_7FB36B0DA9ED797D3E48A56C86BD5AF5_label_en-US" xlink:label="lab_pfe_GenotropinMember_7FB36B0DA9ED797D3E48A56C86BD5AF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Genotropin [Member]</link:label>
    <link:label id="lab_pfe_GenotropinMember_7FB36B0DA9ED797D3E48A56C86BD5AF5_documentation_en-US" xlink:label="lab_pfe_GenotropinMember_7FB36B0DA9ED797D3E48A56C86BD5AF5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Genotropin [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_GenotropinMember" xlink:label="loc_pfe_GenotropinMember_7FB36B0DA9ED797D3E48A56C86BD5AF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GenotropinMember_7FB36B0DA9ED797D3E48A56C86BD5AF5" xlink:to="lab_pfe_GenotropinMember_7FB36B0DA9ED797D3E48A56C86BD5AF5" xlink:type="arc" />
    <link:label id="lab_pfe_ReFactoAfXynthaMember_864D1C74B465C0E1FF48A56C86BD95F1_terseLabel_en-US" xlink:label="lab_pfe_ReFactoAfXynthaMember_864D1C74B465C0E1FF48A56C86BD95F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ReFacto AF/Xyntha [Member]</link:label>
    <link:label id="lab_pfe_ReFactoAfXynthaMember_864D1C74B465C0E1FF48A56C86BD95F1_label_en-US" xlink:label="lab_pfe_ReFactoAfXynthaMember_864D1C74B465C0E1FF48A56C86BD95F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Re Facto AF Xyntha [Member]</link:label>
    <link:label id="lab_pfe_ReFactoAfXynthaMember_864D1C74B465C0E1FF48A56C86BD95F1_documentation_en-US" xlink:label="lab_pfe_ReFactoAfXynthaMember_864D1C74B465C0E1FF48A56C86BD95F1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Re Facto AF Xyntha [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ReFactoAfXynthaMember" xlink:label="loc_pfe_ReFactoAfXynthaMember_864D1C74B465C0E1FF48A56C86BD95F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ReFactoAfXynthaMember_864D1C74B465C0E1FF48A56C86BD95F1" xlink:to="lab_pfe_ReFactoAfXynthaMember_864D1C74B465C0E1FF48A56C86BD95F1" xlink:type="arc" />
    <link:label id="lab_pfe_SomavertMember_7FFAA229B092ACB08D2DA56C86BD974C_terseLabel_en-US" xlink:label="lab_pfe_SomavertMember_7FFAA229B092ACB08D2DA56C86BD974C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Somavert [Member]</link:label>
    <link:label id="lab_pfe_SomavertMember_7FFAA229B092ACB08D2DA56C86BD974C_label_en-US" xlink:label="lab_pfe_SomavertMember_7FFAA229B092ACB08D2DA56C86BD974C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Somavert [Member]</link:label>
    <link:label id="lab_pfe_SomavertMember_7FFAA229B092ACB08D2DA56C86BD974C_documentation_en-US" xlink:label="lab_pfe_SomavertMember_7FFAA229B092ACB08D2DA56C86BD974C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Somavert [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SomavertMember" xlink:label="loc_pfe_SomavertMember_7FFAA229B092ACB08D2DA56C86BD974C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SomavertMember_7FFAA229B092ACB08D2DA56C86BD974C" xlink:to="lab_pfe_SomavertMember_7FFAA229B092ACB08D2DA56C86BD974C" xlink:type="arc" />
    <link:label id="lab_pfe_AllOtherRareDiseaseProductsMember_B66B37B69A6AC133E95CA56C86BECC16_terseLabel_en-US" xlink:label="lab_pfe_AllOtherRareDiseaseProductsMember_B66B37B69A6AC133E95CA56C86BECC16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All other Rare Disease [Member]</link:label>
    <link:label id="lab_pfe_AllOtherRareDiseaseProductsMember_B66B37B69A6AC133E95CA56C86BECC16_label_en-US" xlink:label="lab_pfe_AllOtherRareDiseaseProductsMember_B66B37B69A6AC133E95CA56C86BECC16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Other Rare Disease Products [Member]</link:label>
    <link:label id="lab_pfe_AllOtherRareDiseaseProductsMember_B66B37B69A6AC133E95CA56C86BECC16_documentation_en-US" xlink:label="lab_pfe_AllOtherRareDiseaseProductsMember_B66B37B69A6AC133E95CA56C86BECC16" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">All Other Rare Disease Products [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AllOtherRareDiseaseProductsMember" xlink:label="loc_pfe_AllOtherRareDiseaseProductsMember_B66B37B69A6AC133E95CA56C86BECC16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AllOtherRareDiseaseProductsMember_B66B37B69A6AC133E95CA56C86BECC16" xlink:to="lab_pfe_AllOtherRareDiseaseProductsMember_B66B37B69A6AC133E95CA56C86BECC16" xlink:type="arc" />
    <link:label id="lab_pfe_LipitorMember_7255601AE252E9CD1726A56C86BEDC00_terseLabel_en-US" xlink:label="lab_pfe_LipitorMember_7255601AE252E9CD1726A56C86BEDC00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lipitor [Member]</link:label>
    <link:label id="lab_pfe_LipitorMember_7255601AE252E9CD1726A56C86BEDC00_label_en-US" xlink:label="lab_pfe_LipitorMember_7255601AE252E9CD1726A56C86BEDC00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lipitor [Member]</link:label>
    <link:label id="lab_pfe_LipitorMember_7255601AE252E9CD1726A56C86BEDC00_documentation_en-US" xlink:label="lab_pfe_LipitorMember_7255601AE252E9CD1726A56C86BEDC00" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lipitor [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LipitorMember" xlink:label="loc_pfe_LipitorMember_7255601AE252E9CD1726A56C86BEDC00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LipitorMember_7255601AE252E9CD1726A56C86BEDC00" xlink:to="lab_pfe_LipitorMember_7255601AE252E9CD1726A56C86BEDC00" xlink:type="arc" />
    <link:label id="lab_pfe_LyricaMember_1F4C6BE110CA50901141A56C86BEF34F_terseLabel_en-US" xlink:label="lab_pfe_LyricaMember_1F4C6BE110CA50901141A56C86BEF34F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lyrica [Member]</link:label>
    <link:label id="lab_pfe_LyricaMember_1F4C6BE110CA50901141A56C86BEF34F_label_en-US" xlink:label="lab_pfe_LyricaMember_1F4C6BE110CA50901141A56C86BEF34F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lyrica [Member]</link:label>
    <link:label id="lab_pfe_LyricaMember_1F4C6BE110CA50901141A56C86BEF34F_documentation_en-US" xlink:label="lab_pfe_LyricaMember_1F4C6BE110CA50901141A56C86BEF34F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lyrica [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LyricaMember" xlink:label="loc_pfe_LyricaMember_1F4C6BE110CA50901141A56C86BEF34F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LyricaMember_1F4C6BE110CA50901141A56C86BEF34F" xlink:to="lab_pfe_LyricaMember_1F4C6BE110CA50901141A56C86BEF34F" xlink:type="arc" />
    <link:label id="lab_pfe_NorvascMember_83556E8FF8ED465CC033A56C86BEA428_terseLabel_en-US" xlink:label="lab_pfe_NorvascMember_83556E8FF8ED465CC033A56C86BEA428" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Norvasc [Member]</link:label>
    <link:label id="lab_pfe_NorvascMember_83556E8FF8ED465CC033A56C86BEA428_label_en-US" xlink:label="lab_pfe_NorvascMember_83556E8FF8ED465CC033A56C86BEA428" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Norvasc [Member]</link:label>
    <link:label id="lab_pfe_NorvascMember_83556E8FF8ED465CC033A56C86BEA428_documentation_en-US" xlink:label="lab_pfe_NorvascMember_83556E8FF8ED465CC033A56C86BEA428" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Norvasc [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_NorvascMember" xlink:label="loc_pfe_NorvascMember_83556E8FF8ED465CC033A56C86BEA428" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NorvascMember_83556E8FF8ED465CC033A56C86BEA428" xlink:to="lab_pfe_NorvascMember_83556E8FF8ED465CC033A56C86BEA428" xlink:type="arc" />
    <link:label id="lab_pfe_CelebrexMember_57C95D9B26AB88948709A56C86BEFBE8_terseLabel_en-US" xlink:label="lab_pfe_CelebrexMember_57C95D9B26AB88948709A56C86BEFBE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Celebrex [Member]</link:label>
    <link:label id="lab_pfe_CelebrexMember_57C95D9B26AB88948709A56C86BEFBE8_label_en-US" xlink:label="lab_pfe_CelebrexMember_57C95D9B26AB88948709A56C86BEFBE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Celebrex [Member]</link:label>
    <link:label id="lab_pfe_CelebrexMember_57C95D9B26AB88948709A56C86BEFBE8_documentation_en-US" xlink:label="lab_pfe_CelebrexMember_57C95D9B26AB88948709A56C86BEFBE8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Celebrex [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_CelebrexMember" xlink:label="loc_pfe_CelebrexMember_57C95D9B26AB88948709A56C86BEFBE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CelebrexMember_57C95D9B26AB88948709A56C86BEFBE8" xlink:to="lab_pfe_CelebrexMember_57C95D9B26AB88948709A56C86BEFBE8" xlink:type="arc" />
    <link:label id="lab_pfe_ViagraMember_7CEE2623FDD2D09220A7A56C86BE60F2_terseLabel_en-US" xlink:label="lab_pfe_ViagraMember_7CEE2623FDD2D09220A7A56C86BE60F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Viagra [Member]</link:label>
    <link:label id="lab_pfe_ViagraMember_7CEE2623FDD2D09220A7A56C86BE60F2_label_en-US" xlink:label="lab_pfe_ViagraMember_7CEE2623FDD2D09220A7A56C86BE60F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Viagra [Member]</link:label>
    <link:label id="lab_pfe_ViagraMember_7CEE2623FDD2D09220A7A56C86BE60F2_documentation_en-US" xlink:label="lab_pfe_ViagraMember_7CEE2623FDD2D09220A7A56C86BE60F2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Viagra [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ViagraMember" xlink:label="loc_pfe_ViagraMember_7CEE2623FDD2D09220A7A56C86BE60F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ViagraMember_7CEE2623FDD2D09220A7A56C86BE60F2" xlink:to="lab_pfe_ViagraMember_7CEE2623FDD2D09220A7A56C86BE60F2" xlink:type="arc" />
    <link:label id="lab_pfe_EffexorMember_46E5E161E30C551D28F5A56C86BF6A41_terseLabel_en-US" xlink:label="lab_pfe_EffexorMember_46E5E161E30C551D28F5A56C86BF6A41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effexor [Member]</link:label>
    <link:label id="lab_pfe_EffexorMember_46E5E161E30C551D28F5A56C86BF6A41_label_en-US" xlink:label="lab_pfe_EffexorMember_46E5E161E30C551D28F5A56C86BF6A41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effexor [Member]</link:label>
    <link:label id="lab_pfe_EffexorMember_46E5E161E30C551D28F5A56C86BF6A41_documentation_en-US" xlink:label="lab_pfe_EffexorMember_46E5E161E30C551D28F5A56C86BF6A41" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effexor [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EffexorMember" xlink:label="loc_pfe_EffexorMember_46E5E161E30C551D28F5A56C86BF6A41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EffexorMember_46E5E161E30C551D28F5A56C86BF6A41" xlink:to="lab_pfe_EffexorMember_46E5E161E30C551D28F5A56C86BF6A41" xlink:type="arc" />
    <link:label id="lab_pfe_ZoloftMember_C62851349E163C99B25BA56C86BF3E7D_terseLabel_en-US" xlink:label="lab_pfe_ZoloftMember_C62851349E163C99B25BA56C86BF3E7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zoloft [Member]</link:label>
    <link:label id="lab_pfe_ZoloftMember_C62851349E163C99B25BA56C86BF3E7D_label_en-US" xlink:label="lab_pfe_ZoloftMember_C62851349E163C99B25BA56C86BF3E7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zoloft [Member]</link:label>
    <link:label id="lab_pfe_ZoloftMember_C62851349E163C99B25BA56C86BF3E7D_documentation_en-US" xlink:label="lab_pfe_ZoloftMember_C62851349E163C99B25BA56C86BF3E7D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zoloft [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ZoloftMember" xlink:label="loc_pfe_ZoloftMember_C62851349E163C99B25BA56C86BF3E7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ZoloftMember_C62851349E163C99B25BA56C86BF3E7D" xlink:to="lab_pfe_ZoloftMember_C62851349E163C99B25BA56C86BF3E7D" xlink:type="arc" />
    <link:label id="lab_pfe_XalatanXalacomMember_9B3D3217E1FF99B6EDE8A56C86BF49B5_terseLabel_en-US" xlink:label="lab_pfe_XalatanXalacomMember_9B3D3217E1FF99B6EDE8A56C86BF49B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Xalatan/Xalacom [Member]</link:label>
    <link:label id="lab_pfe_XalatanXalacomMember_9B3D3217E1FF99B6EDE8A56C86BF49B5_label_en-US" xlink:label="lab_pfe_XalatanXalacomMember_9B3D3217E1FF99B6EDE8A56C86BF49B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Xalatan Xalacom [Member]</link:label>
    <link:label id="lab_pfe_XalatanXalacomMember_9B3D3217E1FF99B6EDE8A56C86BF49B5_documentation_en-US" xlink:label="lab_pfe_XalatanXalacomMember_9B3D3217E1FF99B6EDE8A56C86BF49B5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Xalatan / Xalacom [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_XalatanXalacomMember" xlink:label="loc_pfe_XalatanXalacomMember_9B3D3217E1FF99B6EDE8A56C86BF49B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_XalatanXalacomMember_9B3D3217E1FF99B6EDE8A56C86BF49B5" xlink:to="lab_pfe_XalatanXalacomMember_9B3D3217E1FF99B6EDE8A56C86BF49B5" xlink:type="arc" />
    <link:label id="lab_pfe_AllOtherUpjohnProductsMember_736420A194EDC34B4B82A56C86BFB1C9_terseLabel_en-US" xlink:label="lab_pfe_AllOtherUpjohnProductsMember_736420A194EDC34B4B82A56C86BFB1C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All other Upjohn [Member]</link:label>
    <link:label id="lab_pfe_AllOtherUpjohnProductsMember_736420A194EDC34B4B82A56C86BFB1C9_label_en-US" xlink:label="lab_pfe_AllOtherUpjohnProductsMember_736420A194EDC34B4B82A56C86BFB1C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Other Upjohn Products [Member]</link:label>
    <link:label id="lab_pfe_AllOtherUpjohnProductsMember_736420A194EDC34B4B82A56C86BFB1C9_documentation_en-US" xlink:label="lab_pfe_AllOtherUpjohnProductsMember_736420A194EDC34B4B82A56C86BFB1C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">All Other Upjohn Products [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AllOtherUpjohnProductsMember" xlink:label="loc_pfe_AllOtherUpjohnProductsMember_736420A194EDC34B4B82A56C86BFB1C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AllOtherUpjohnProductsMember_736420A194EDC34B4B82A56C86BFB1C9" xlink:to="lab_pfe_AllOtherUpjohnProductsMember_736420A194EDC34B4B82A56C86BFB1C9" xlink:type="arc" />
    <link:label id="lab_pfe_TotalAllianceBiopharmaceuticalsMember_9BB704103A9A6CC657ADA56C86C0558A_terseLabel_en-US" xlink:label="lab_pfe_TotalAllianceBiopharmaceuticalsMember_9BB704103A9A6CC657ADA56C86C0558A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Alliance revenues [Member]</link:label>
    <link:label id="lab_pfe_TotalAllianceBiopharmaceuticalsMember_9BB704103A9A6CC657ADA56C86C0558A_label_en-US" xlink:label="lab_pfe_TotalAllianceBiopharmaceuticalsMember_9BB704103A9A6CC657ADA56C86C0558A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Alliance Biopharmaceuticals [Member]</link:label>
    <link:label id="lab_pfe_TotalAllianceBiopharmaceuticalsMember_9BB704103A9A6CC657ADA56C86C0558A_documentation_en-US" xlink:label="lab_pfe_TotalAllianceBiopharmaceuticalsMember_9BB704103A9A6CC657ADA56C86C0558A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Alliance Biopharmaceuticals [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_TotalAllianceBiopharmaceuticalsMember" xlink:label="loc_pfe_TotalAllianceBiopharmaceuticalsMember_9BB704103A9A6CC657ADA56C86C0558A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TotalAllianceBiopharmaceuticalsMember_9BB704103A9A6CC657ADA56C86C0558A" xlink:to="lab_pfe_TotalAllianceBiopharmaceuticalsMember_9BB704103A9A6CC657ADA56C86C0558A" xlink:type="arc" />
    <link:label id="lab_pfe_TotalBiosimilarsMember_798F093E90C7AD7A053DA56C86C0019E_terseLabel_en-US" xlink:label="lab_pfe_TotalBiosimilarsMember_798F093E90C7AD7A053DA56C86C0019E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Biosimilars [Member]</link:label>
    <link:label id="lab_pfe_TotalBiosimilarsMember_798F093E90C7AD7A053DA56C86C0019E_label_en-US" xlink:label="lab_pfe_TotalBiosimilarsMember_798F093E90C7AD7A053DA56C86C0019E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Biosimilars [Member]</link:label>
    <link:label id="lab_pfe_TotalBiosimilarsMember_798F093E90C7AD7A053DA56C86C0019E_documentation_en-US" xlink:label="lab_pfe_TotalBiosimilarsMember_798F093E90C7AD7A053DA56C86C0019E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Biosimilars [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_TotalBiosimilarsMember" xlink:label="loc_pfe_TotalBiosimilarsMember_798F093E90C7AD7A053DA56C86C0019E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TotalBiosimilarsMember_798F093E90C7AD7A053DA56C86C0019E" xlink:to="lab_pfe_TotalBiosimilarsMember_798F093E90C7AD7A053DA56C86C0019E" xlink:type="arc" />
    <link:label id="lab_pfe_TotalSterileInjectablePharmaceuticalsMember_B8B920E7FBC004DE5099A56C86C02D22_terseLabel_en-US" xlink:label="lab_pfe_TotalSterileInjectablePharmaceuticalsMember_B8B920E7FBC004DE5099A56C86C02D22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Sterile Injectable Pharmaceuticals [Member]</link:label>
    <link:label id="lab_pfe_TotalSterileInjectablePharmaceuticalsMember_B8B920E7FBC004DE5099A56C86C02D22_label_en-US" xlink:label="lab_pfe_TotalSterileInjectablePharmaceuticalsMember_B8B920E7FBC004DE5099A56C86C02D22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Sterile Injectable Pharmaceuticals [Member]</link:label>
    <link:label id="lab_pfe_TotalSterileInjectablePharmaceuticalsMember_B8B920E7FBC004DE5099A56C86C02D22_documentation_en-US" xlink:label="lab_pfe_TotalSterileInjectablePharmaceuticalsMember_B8B920E7FBC004DE5099A56C86C02D22" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Sterile Injectable Pharmaceuticals [Member]</link:label>
    <link:loc xlink:href="pfe-20200628.xsd#pfe_TotalSterileInjectablePharmaceuticalsMember" xlink:label="loc_pfe_TotalSterileInjectablePharmaceuticalsMember_B8B920E7FBC004DE5099A56C86C02D22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TotalSterileInjectablePharmaceuticalsMember_B8B920E7FBC004DE5099A56C86C02D22" xlink:to="lab_pfe_TotalSterileInjectablePharmaceuticalsMember_B8B920E7FBC004DE5099A56C86C02D22" xlink:type="arc" />
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9DF7C32BE76DCA92E4E6A56C86C0A4DF_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9DF7C32BE76DCA92E4E6A56C86C0A4DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9DF7C32BE76DCA92E4E6A56C86C0A4DF_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9DF7C32BE76DCA92E4E6A56C86C0A4DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9DF7C32BE76DCA92E4E6A56C86C0A4DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9DF7C32BE76DCA92E4E6A56C86C0A4DF" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9DF7C32BE76DCA92E4E6A56C86C0A4DF" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>pfe-20200628_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:href="pfe-20200628.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" xlink:href="pfe-20200628.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:href="pfe-20200628.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangements" xlink:href="pfe-20200628.xsd#AcquisitionEquityMethodInvestmentAndLicensingArrangements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsArrayBiopharmaDetails" xlink:href="pfe-20200628.xsd#AcquisitionEquityMethodInvestmentAndLicensingArrangementsArrayBiopharmaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails" xlink:href="pfe-20200628.xsd#AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails" xlink:href="pfe-20200628.xsd#AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails" xlink:href="pfe-20200628.xsd#AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsTables" xlink:href="pfe-20200628.xsd#AcquisitionEquityMethodInvestmentAndLicensingArrangementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails" xlink:href="pfe-20200628.xsd#AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:href="pfe-20200628.xsd#BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails" xlink:href="pfe-20200628.xsd#BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails" xlink:href="pfe-20200628.xsd#BasisOfPresentationAndSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:href="pfe-20200628.xsd#BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:href="pfe-20200628.xsd#BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets" xlink:href="pfe-20200628.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="pfe-20200628.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="pfe-20200628.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical" xlink:href="pfe-20200628.xsd#CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="pfe-20200628.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical" xlink:href="pfe-20200628.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" xlink:href="pfe-20200628.xsd#CondensedConsolidatedStatementsOfEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="pfe-20200628.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitments" xlink:href="pfe-20200628.xsd#ContingenciesAndCertainCommitments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsContingentConsiderationDetails" xlink:href="pfe-20200628.xsd#ContingenciesAndCertainCommitmentsContingentConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails" xlink:href="pfe-20200628.xsd#ContingenciesAndCertainCommitmentsPatentLitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails" xlink:href="pfe-20200628.xsd#ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CoverPage" xlink:href="pfe-20200628.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails" xlink:href="pfe-20200628.xsd#EarningsPerCommonShareAttributableToCommonShareholdersDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersTables" xlink:href="pfe-20200628.xsd#EarningsPerCommonShareAttributableToCommonShareholdersTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholders" xlink:href="pfe-20200628.xsd#EarningsPerCommonShareAttributableToPfizerIncCommonShareholders" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/Equity" xlink:href="pfe-20200628.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EquityDividendsDetails" xlink:href="pfe-20200628.xsd#EquityDividendsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EquityPreferredStockDetails" xlink:href="pfe-20200628.xsd#EquityPreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EquityTables" xlink:href="pfe-20200628.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstruments" xlink:href="pfe-20200628.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsCreditRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsDerivativeNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="pfe-20200628.xsd#FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetail" xlink:href="pfe-20200628.xsd#FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesFootnotesDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsFinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsFinancialLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsLongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsLongTermDebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsLongTermDebtNewIssuancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsShortTermBorrowingsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsTables" xlink:href="pfe-20200628.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsFootnotesDetails" xlink:href="pfe-20200628.xsd#FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill" xlink:href="pfe-20200628.xsd#IdentifiableIntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail" xlink:href="pfe-20200628.xsd#IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" xlink:href="pfe-20200628.xsd#IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:href="pfe-20200628.xsd#IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail" xlink:href="pfe-20200628.xsd#IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:href="pfe-20200628.xsd#IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail" xlink:href="pfe-20200628.xsd#IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables" xlink:href="pfe-20200628.xsd#IdentifiableIntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/Inventories" xlink:href="pfe-20200628.xsd#Inventories" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/InventoriesDetail" xlink:href="pfe-20200628.xsd#InventoriesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/InventoriesTables" xlink:href="pfe-20200628.xsd#InventoriesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNet" xlink:href="pfe-20200628.xsd#OtherIncomeDeductionsNet" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail" xlink:href="pfe-20200628.xsd#OtherIncomeDeductionsNetDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail" xlink:href="pfe-20200628.xsd#OtherIncomeDeductionsNetFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" xlink:href="pfe-20200628.xsd#OtherIncomeDeductionsNetTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlans" xlink:href="pfe-20200628.xsd#PensionAndPostretirementBenefitPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail" xlink:href="pfe-20200628.xsd#PensionAndPostretirementBenefitPlansDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:href="pfe-20200628.xsd#PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansTables" xlink:href="pfe-20200628.xsd#PensionAndPostretirementBenefitPlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" xlink:href="pfe-20200628.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail" xlink:href="pfe-20200628.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetail" xlink:href="pfe-20200628.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails" xlink:href="pfe-20200628.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:href="pfe-20200628.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:href="pfe-20200628.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" xlink:href="pfe-20200628.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation" xlink:href="pfe-20200628.xsd#SegmentGeographicAndOtherRevenueInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail" xlink:href="pfe-20200628.xsd#SegmentGeographicAndOtherRevenueInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail" xlink:href="pfe-20200628.xsd#SegmentGeographicAndOtherRevenueInformationFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail" xlink:href="pfe-20200628.xsd#SegmentGeographicAndOtherRevenueInformationNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:href="pfe-20200628.xsd#SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" xlink:href="pfe-20200628.xsd#SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" xlink:href="pfe-20200628.xsd#SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables" xlink:href="pfe-20200628.xsd#SegmentGeographicAndOtherRevenueInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMatters" xlink:href="pfe-20200628.xsd#TaxMatters" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersDetail" xlink:href="pfe-20200628.xsd#TaxMattersDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersNarrativeDetail" xlink:href="pfe-20200628.xsd#TaxMattersNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersTables" xlink:href="pfe-20200628.xsd#TaxMattersTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_AAF94AF557B235194DB6947620A6384F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_C1986B35B5ED20B8AD72947620A7D880" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_AAF94AF557B235194DB6947620A6384F" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_C1986B35B5ED20B8AD72947620A7D880" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_B652B8601BF6EE9223749D3A7C07C544" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D059B0BFCA0BA9B85C69D3A7C071E46" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_B652B8601BF6EE9223749D3A7C07C544" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D059B0BFCA0BA9B85C69D3A7C071E46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7A7E922FFBFDB180DB969D3A7C07A478" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D059B0BFCA0BA9B85C69D3A7C071E46" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7A7E922FFBFDB180DB969D3A7C07A478" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_65E2AF1C68AD62D7E3909D3A7C08F685" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7A7E922FFBFDB180DB969D3A7C07A478" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_65E2AF1C68AD62D7E3909D3A7C08F685" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_GSKConsumerHealthcareMember" xlink:label="loc_pfe_GSKConsumerHealthcareMember_D5145EF3A54011EAFF9A9D3A7C08FC5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_65E2AF1C68AD62D7E3909D3A7C08F685" xlink:to="loc_pfe_GSKConsumerHealthcareMember_D5145EF3A54011EAFF9A9D3A7C08FC5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_A2C2D84D7B6E990DFBB49D3A7C09E613" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D059B0BFCA0BA9B85C69D3A7C071E46" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_A2C2D84D7B6E990DFBB49D3A7C09E613" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_03D270842F7BF853CE829D3A7C09C54D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_A2C2D84D7B6E990DFBB49D3A7C09E613" xlink:to="loc_us-gaap_EquityComponentDomain_03D270842F7BF853CE829D3A7C09C54D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51486A2FF408EA11D0079D3A7C09267A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_03D270842F7BF853CE829D3A7C09C54D" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51486A2FF408EA11D0079D3A7C09267A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_44FE95122213A80368AA9D3A7C090F6C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51486A2FF408EA11D0079D3A7C09267A" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_44FE95122213A80368AA9D3A7C090F6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_6194EB1987E18EB9649E9D3A7C0A576B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51486A2FF408EA11D0079D3A7C09267A" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_6194EB1987E18EB9649E9D3A7C0A576B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1F44E3662715DFEC74D09D3A7C0A3467" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51486A2FF408EA11D0079D3A7C09267A" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1F44E3662715DFEC74D09D3A7C0A3467" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_2CD290AC6582508D133B9D3A7C0A2329" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51486A2FF408EA11D0079D3A7C09267A" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_2CD290AC6582508D133B9D3A7C0A2329" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_8181A0ECD68310CA47D09D3A7C0A7BFF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51486A2FF408EA11D0079D3A7C09267A" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_8181A0ECD68310CA47D09D3A7C0A7BFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A86A93324B2FCEAED8A29D3A7C0A70AA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D059B0BFCA0BA9B85C69D3A7C071E46" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A86A93324B2FCEAED8A29D3A7C0A70AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_E65DA0247BA5FF91FA7A9D3A7C0BC7DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A86A93324B2FCEAED8A29D3A7C0A70AA" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_E65DA0247BA5FF91FA7A9D3A7C0BC7DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_43CD307800D6F8DCCE8A9D3A7C0B9AE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_E65DA0247BA5FF91FA7A9D3A7C0BC7DF" xlink:to="loc_us-gaap_StockholdersEquity_43CD307800D6F8DCCE8A9D3A7C0B9AE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_407614195B3E211396FF9D3A7C0B5764" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_E65DA0247BA5FF91FA7A9D3A7C0BC7DF" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_407614195B3E211396FF9D3A7C0B5764" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_B8AE25AAB64DE8F123CD9D3A7C0B72E9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_E65DA0247BA5FF91FA7A9D3A7C0BC7DF" xlink:to="loc_us-gaap_StockholdersEquity_B8AE25AAB64DE8F123CD9D3A7C0B72E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_9A7A4CC7690D197A64969D3B6FAEB0AC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A86A93324B2FCEAED8A29D3A7C0A70AA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_9A7A4CC7690D197A64969D3B6FAEB0AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7D3F7C0C08FCD3C077FD9D3A7C0CEB39" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A86A93324B2FCEAED8A29D3A7C0A70AA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7D3F7C0C08FCD3C077FD9D3A7C0CEB39" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_3B393882576624E64FDC947622809BA6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_B1587BC91E511648C161947622809821" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3B393882576624E64FDC947622809BA6" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_B1587BC91E511648C161947622809821" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangements" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_3695D77E61409D0D3424596792759174" xlink:type="locator" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock_B7FC63A5B03BA64497A25967927619EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_3695D77E61409D0D3424596792759174" xlink:to="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock_B7FC63A5B03BA64497A25967927619EE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsArrayBiopharmaDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_04FC9A1A71A89895BD245967928E4934" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1E381EAE57FB75F2DB1B5967928FE9F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_04FC9A1A71A89895BD245967928E4934" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1E381EAE57FB75F2DB1B5967928FE9F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7BF9C9B6995D8574A8455967928F962F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1E381EAE57FB75F2DB1B5967928FE9F9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7BF9C9B6995D8574A8455967928F962F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_513C3B4C47B95DBD02255967928FFF89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7BF9C9B6995D8574A8455967928F962F" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_513C3B4C47B95DBD02255967928FFF89" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ArrayMember" xlink:label="loc_pfe_ArrayMember_C138B9969204952EBF3159679290CEFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_513C3B4C47B95DBD02255967928FFF89" xlink:to="loc_pfe_ArrayMember_C138B9969204952EBF3159679290CEFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_B5FE63E7929705ED59A259679290A885" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1E381EAE57FB75F2DB1B5967928FE9F9" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_B5FE63E7929705ED59A259679290A885" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_5DCD1F94C00E511BFD7B596792909D14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B5FE63E7929705ED59A259679290A885" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_5DCD1F94C00E511BFD7B596792909D14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_3371BCE21B85AA7DBE65596792909A11" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B5FE63E7929705ED59A259679290A885" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_3371BCE21B85AA7DBE65596792909A11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1060CDDFB11BBB8156D8596792906734" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B5FE63E7929705ED59A259679290A885" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1060CDDFB11BBB8156D8596792906734" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_F5854988F2613A690F5492DEB954B639" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D8534B74C129B0196BE392DEB95433AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_F5854988F2613A690F5492DEB954B639" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D8534B74C129B0196BE392DEB95433AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9254E226A8C4EE9E0A9A92E1EB2B1EB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D8534B74C129B0196BE392DEB95433AA" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9254E226A8C4EE9E0A9A92E1EB2B1EB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_69BA5F4BAAFECC4E286492E1EB3A5E48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9254E226A8C4EE9E0A9A92E1EB2B1EB1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_69BA5F4BAAFECC4E286492E1EB3A5E48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_A50319E76D927B68983E92E2204B6B44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_69BA5F4BAAFECC4E286492E1EB3A5E48" xlink:to="loc_us-gaap_SubsequentEventMember_A50319E76D927B68983E92E2204B6B44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_73B09F4B5E99955189C592DEB955769F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D8534B74C129B0196BE392DEB95433AA" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_73B09F4B5E99955189C592DEB955769F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ADF9699C46AF6CC3CB4492DEB9553D37" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_73B09F4B5E99955189C592DEB955769F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ADF9699C46AF6CC3CB4492DEB9553D37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_07F1867C45CCE1ABDDB692DEB9557D02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ADF9699C46AF6CC3CB4492DEB9553D37" xlink:to="loc_us-gaap_LicensingAgreementsMember_07F1867C45CCE1ABDDB692DEB9557D02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_EEA45A08C4F34F8007F992DEB9556866" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D8534B74C129B0196BE392DEB95433AA" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_EEA45A08C4F34F8007F992DEB9556866" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_E45F8E52998EB680742A92DEB956FA9F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_EEA45A08C4F34F8007F992DEB9556866" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_E45F8E52998EB680742A92DEB956FA9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_C2EFD81608D78E84800992DEB9569302" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_E45F8E52998EB680742A92DEB956FA9F" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_C2EFD81608D78E84800992DEB9569302" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_4C91AEC4F37DE7C5179592DEB956A89A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D8534B74C129B0196BE392DEB95433AA" xlink:to="loc_srt_CounterpartyNameAxis_4C91AEC4F37DE7C5179592DEB956A89A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_70D2B7DDA19EA201EE7992DEB956A067" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4C91AEC4F37DE7C5179592DEB956A89A" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_70D2B7DDA19EA201EE7992DEB956A067" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BioNTechSEMember" xlink:label="loc_pfe_BioNTechSEMember_19D2ECE731BC38F3DE1992DEB957C271" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_70D2B7DDA19EA201EE7992DEB956A067" xlink:to="loc_pfe_BioNTechSEMember_19D2ECE731BC38F3DE1992DEB957C271" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_979178E2C9BB808B353D92DEB957DBE6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D8534B74C129B0196BE392DEB95433AA" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_979178E2C9BB808B353D92DEB957DBE6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PaymentForLicensingArrangement" xlink:label="loc_pfe_PaymentForLicensingArrangement_9C31A5735FAEC7B156DA92DEB9579500" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_979178E2C9BB808B353D92DEB957DBE6" xlink:to="loc_pfe_PaymentForLicensingArrangement_9C31A5735FAEC7B156DA92DEB9579500" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LicensingArrangementValueOfSharesPurchased" xlink:label="loc_pfe_LicensingArrangementValueOfSharesPurchased_76593D7E8DB202B0CFF892DEB9579061" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_979178E2C9BB808B353D92DEB957DBE6" xlink:to="loc_pfe_LicensingArrangementValueOfSharesPurchased_76593D7E8DB202B0CFF892DEB9579061" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure_63653CC3D27F7A2AE5D592DEB95774B9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_979178E2C9BB808B353D92DEB957DBE6" xlink:to="loc_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure_63653CC3D27F7A2AE5D592DEB95774B9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1_1BCCD9487C25E806265792DEB958E744" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_979178E2C9BB808B353D92DEB957DBE6" xlink:to="loc_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1_1BCCD9487C25E806265792DEB958E744" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed" xlink:label="loc_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_8785140540778E461CA692DEB958A56B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_979178E2C9BB808B353D92DEB957DBE6" xlink:to="loc_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_8785140540778E461CA692DEB958A56B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_EAE6556822874A1218ED7926B2A6AE5F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EBEB49EE3E4FA7CEEAEF7926B2A67D56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_EAE6556822874A1218ED7926B2A6AE5F" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EBEB49EE3E4FA7CEEAEF7926B2A67D56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_58BB7FA5BC09F14D40FF793378A83652" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EBEB49EE3E4FA7CEEAEF7926B2A67D56" xlink:to="loc_srt_RangeAxis_58BB7FA5BC09F14D40FF793378A83652" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D41C3E672854D230D020793378A92B58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_58BB7FA5BC09F14D40FF793378A83652" xlink:to="loc_srt_RangeMember_D41C3E672854D230D020793378A92B58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_49DA6853E42F45A97B1F79341B28B307" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_D41C3E672854D230D020793378A92B58" xlink:to="loc_srt_MinimumMember_49DA6853E42F45A97B1F79341B28B307" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_CED445B2FA4F00DE1416793445BE5A76" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_D41C3E672854D230D020793378A92B58" xlink:to="loc_srt_MaximumMember_CED445B2FA4F00DE1416793445BE5A76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AACDA209AB9A481005007926B2A75FC6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EBEB49EE3E4FA7CEEAEF7926B2A67D56" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AACDA209AB9A481005007926B2A75FC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3D0C4E2AE818A44E79F7926B2A75AD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AACDA209AB9A481005007926B2A75FC6" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3D0C4E2AE818A44E79F7926B2A75AD9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ConsumerHealthcareMember" xlink:label="loc_pfe_ConsumerHealthcareMember_202904254FAEEDA080797926B2A7A84A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3D0C4E2AE818A44E79F7926B2A75AD9" xlink:to="loc_pfe_ConsumerHealthcareMember_202904254FAEEDA080797926B2A7A84A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_7C37A7A65422032D64E07926B2A8E26D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EBEB49EE3E4FA7CEEAEF7926B2A67D56" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_7C37A7A65422032D64E07926B2A8E26D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_4B1C227ACC3432F7D6607926B2A8065B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_7C37A7A65422032D64E07926B2A8E26D" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_4B1C227ACC3432F7D6607926B2A8065B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_DC9AE322ADDA2D13BAC07926B2A81269" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_4B1C227ACC3432F7D6607926B2A8065B" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_DC9AE322ADDA2D13BAC07926B2A81269" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_18E902ADAF270A4C6EDA7926B2A84754" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EBEB49EE3E4FA7CEEAEF7926B2A67D56" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_18E902ADAF270A4C6EDA7926B2A84754" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ED596F6554B5F544669C7926B2A8DAB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_18E902ADAF270A4C6EDA7926B2A84754" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ED596F6554B5F544669C7926B2A8DAB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_59D100E77C78A698DC297926B2A95E72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ED596F6554B5F544669C7926B2A8DAB7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_59D100E77C78A698DC297926B2A95E72" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_51819D5843F904D287ED7926B2A937D4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EBEB49EE3E4FA7CEEAEF7926B2A67D56" xlink:to="loc_dei_LegalEntityAxis_51819D5843F904D287ED7926B2A937D4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_47E7559EB0CED57D3F977926B2A9CFF8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_51819D5843F904D287ED7926B2A937D4" xlink:to="loc_dei_EntityDomain_47E7559EB0CED57D3F977926B2A9CFF8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_GSKMember" xlink:label="loc_pfe_GSKMember_B5D3CF3C67EF9A3AF7377926B2AA3D86" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_47E7559EB0CED57D3F977926B2A9CFF8" xlink:to="loc_pfe_GSKMember_B5D3CF3C67EF9A3AF7377926B2AA3D86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_80B44AC75C08746C863A7926B2AA18B0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EBEB49EE3E4FA7CEEAEF7926B2A67D56" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_80B44AC75C08746C863A7926B2AA18B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_EEA33F00D360C7EB33AD7926B2AA62A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_80B44AC75C08746C863A7926B2AA18B0" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_EEA33F00D360C7EB33AD7926B2AA62A8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_GSKConsumerHealthcareMember" xlink:label="loc_pfe_GSKConsumerHealthcareMember_12908ED588D18EA315DE7926B2AAB144" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_EEA33F00D360C7EB33AD7926B2AA62A8" xlink:to="loc_pfe_GSKConsumerHealthcareMember_12908ED588D18EA315DE7926B2AAB144" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EBEB49EE3E4FA7CEEAEF7926B2A67D56" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_24DFB8EA4FDDCFD40D967926B2ABAF34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_24DFB8EA4FDDCFD40D967926B2ABAF34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_07749ABD6271558FB7687926B2AB25BB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_07749ABD6271558FB7687926B2AB25BB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DeconsolidationGainLossAmountNetOfTax" xlink:label="loc_pfe_DeconsolidationGainLossAmountNetOfTax_0CEDD828CA62504E16637926B2AB0F17" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:to="loc_pfe_DeconsolidationGainLossAmountNetOfTax_0CEDD828CA62504E16637926B2AB0F17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_608AC2DA852518ABEC387926B2ABB1DB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:to="loc_us-gaap_EquityMethodInvestments_608AC2DA852518ABEC387926B2ABB1DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_EC0229AC965591660E577926B2ACBA29" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_EC0229AC965591660E577926B2ACBA29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_4DF624716AD413F061D27926B2ACE6EF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_4DF624716AD413F061D27926B2ACE6EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:label="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_12F323AAB24770BC8C577926B2AC4B37" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:to="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_12F323AAB24770BC8C577926B2AC4B37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_CC230B0EE3DD8F3906617926B2AC5B93" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_CC230B0EE3DD8F3906617926B2AC5B93" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EquityMethodInvestmentExcessBasisAmortization" xlink:label="loc_pfe_EquityMethodInvestmentExcessBasisAmortization_22B5ABA0E595568A11327926B2AC1D70" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:to="loc_pfe_EquityMethodInvestmentExcessBasisAmortization_22B5ABA0E595568A11327926B2AC1D70" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod" xlink:label="loc_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_09571564FEB6ECA07E8C7926B2AD054E" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:to="loc_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_09571564FEB6ECA07E8C7926B2AD054E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" xlink:label="loc_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_0EA334A74D000D818C0D7926B2ADA60D" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:to="loc_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_0EA334A74D000D818C0D7926B2ADA60D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_086948AE7DAE29E1526F7926B2ADEF1D" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_086948AE7DAE29E1526F7926B2ADEF1D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss" xlink:label="loc_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_6D4C0537B00E06F6DF687926B2AD87DC" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1CF15C9858277C61AEF07926B2AB701A" xlink:to="loc_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_6D4C0537B00E06F6DF687926B2AD87DC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_30D19277DE62C1241701596534B73AF8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_27FF6233CF27A29AFFFC596534B7024C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_30D19277DE62C1241701596534B73AF8" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_27FF6233CF27A29AFFFC596534B7024C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_EEF9E788682221770FA4596534B783A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_27FF6233CF27A29AFFFC596534B7024C" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_EEF9E788682221770FA4596534B783A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_0357656CEBE642ECF2A2596534B8C135" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_EEF9E788682221770FA4596534B783A4" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_0357656CEBE642ECF2A2596534B8C135" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_GSKConsumerHealthcareMember" xlink:label="loc_pfe_GSKConsumerHealthcareMember_18031A6EE0CE9C787B1F596534B892DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_0357656CEBE642ECF2A2596534B8C135" xlink:to="loc_pfe_GSKConsumerHealthcareMember_18031A6EE0CE9C787B1F596534B892DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_27FF6233CF27A29AFFFC596534B7024C" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_C0ABA5F0B7EFC6519FCB596534B91777" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_AssetsCurrent_C0ABA5F0B7EFC6519FCB596534B91777" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_5D96628A93D9620C207F596534B9E238" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_AssetsNoncurrent_5D96628A93D9620C207F596534B9E238" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_D2E410E2259401969341596534B9DC67" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_Assets_D2E410E2259401969341596534B9DC67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_03F34D4869DEC29664B5596534BF0D68" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_LiabilitiesCurrent_03F34D4869DEC29664B5596534BF0D68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_1DA15B75DAADB56816F3596534BFB23E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_1DA15B75DAADB56816F3596534BFB23E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_A29256CB1F50B58BD6A7596534BF3A34" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_Liabilities_A29256CB1F50B58BD6A7596534BF3A34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_EF28E8FD31E532C6C8CF596534BFFEA4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_StockholdersEquity_EF28E8FD31E532C6C8CF596534BFFEA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_EEE68D7667A093678883596534BF0CB2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_MinorityInterest_EEE68D7667A093678883596534BF0CB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_294D588497C0ED3E11A7596534C0DFB4" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_294D588497C0ED3E11A7596534C0DFB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_09FC4A9D0D5491E30494596534C0DDF0" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_Revenues_09FC4A9D0D5491E30494596534C0DDF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_1B75DF4B5057AE5B4F89596534C025BF" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_CostOfRevenue_1B75DF4B5057AE5B4F89596534C025BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_D7C4535E722E036ECFBF596534C06CC3" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_GrossProfit_D7C4535E722E036ECFBF596534C06CC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_276687217BE0F21947A5596534C0A820" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_276687217BE0F21947A5596534C0A820" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_91270B63F85DE8F8609F596534C01F78" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_ProfitLoss_91270B63F85DE8F8609F596534C01F78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_D90F2EF67B474070F9E6596534C1C5E3" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ACA815D5A7DAED7643A3596534B9B679" xlink:to="loc_us-gaap_NetIncomeLoss_D90F2EF67B474070F9E6596534C1C5E3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsTables" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_6362A78A8286A341C5F4596791F99867" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_2083C3D523CDABC65C4E596791F9FDF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_6362A78A8286A341C5F4596791F99867" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_2083C3D523CDABC65C4E596791F9FDF4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_04B0FDC911C4EDF6D0A35981DB412FC4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A4DDCE2E2CBACA6BAE825981DDA46F55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_04B0FDC911C4EDF6D0A35981DB412FC4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A4DDCE2E2CBACA6BAE825981DDA46F55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2EAABECFE47FFE2C591C598EE676E1D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A4DDCE2E2CBACA6BAE825981DDA46F55" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2EAABECFE47FFE2C591C598EE676E1D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9199795915C6BF1F1D00598EE7805AA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2EAABECFE47FFE2C591C598EE676E1D2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9199795915C6BF1F1D00598EE7805AA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_E0491B165A34AC36B64C598F12C34BF7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9199795915C6BF1F1D00598EE7805AA3" xlink:to="loc_us-gaap_LicensingAgreementsMember_E0491B165A34AC36B64C598F12C34BF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_9B84994D011B5947181C598321C242A7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A4DDCE2E2CBACA6BAE825981DDA46F55" xlink:to="loc_srt_CounterpartyNameAxis_9B84994D011B5947181C598321C242A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2F08D37D57C88444C5555983249C6B7E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9B84994D011B5947181C598321C242A7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2F08D37D57C88444C5555983249C6B7E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ValnevaSEMember" xlink:label="loc_pfe_ValnevaSEMember_663A39A4FC308FB0026B59881AA1A187" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2F08D37D57C88444C5555983249C6B7E" xlink:to="loc_pfe_ValnevaSEMember_663A39A4FC308FB0026B59881AA1A187" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_42633831A939EAEBD2D45981DDA6C5ED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A4DDCE2E2CBACA6BAE825981DDA46F55" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_42633831A939EAEBD2D45981DDA6C5ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_DF1A6F3A66387E35D2105981DDA6B5B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_42633831A939EAEBD2D45981DDA6C5ED" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_DF1A6F3A66387E35D2105981DDA6B5B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_771ECF58F7A387A7002E598857951C37" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_DF1A6F3A66387E35D2105981DDA6B5B5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_771ECF58F7A387A7002E598857951C37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9CC3CF57ED8E6AC3FEBF5981DDAA4AF8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A4DDCE2E2CBACA6BAE825981DDA46F55" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_9CC3CF57ED8E6AC3FEBF5981DDAA4AF8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1_8C514A662ED539609E1659B3BA8D450F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9CC3CF57ED8E6AC3FEBF5981DDAA4AF8" xlink:to="loc_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1_8C514A662ED539609E1659B3BA8D450F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PaymentForLicensingArrangement" xlink:label="loc_pfe_PaymentForLicensingArrangement_E43A9E4E82F700DF26EB598280D427FA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9CC3CF57ED8E6AC3FEBF5981DDAA4AF8" xlink:to="loc_pfe_PaymentForLicensingArrangement_E43A9E4E82F700DF26EB598280D427FA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure_D4289C0073EDCB935E6C59B4A1E9163B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9CC3CF57ED8E6AC3FEBF5981DDAA4AF8" xlink:to="loc_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure_D4289C0073EDCB935E6C59B4A1E9163B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure_846AFEBC4541DB8070C3599C5A3B12ED" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9CC3CF57ED8E6AC3FEBF5981DDAA4AF8" xlink:to="loc_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure_846AFEBC4541DB8070C3599C5A3B12ED" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage_7D16B329EC4E9D9E89B459AFE9DEB415" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9CC3CF57ED8E6AC3FEBF5981DDAA4AF8" xlink:to="loc_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage_7D16B329EC4E9D9E89B459AFE9DEB415" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CFE40E59302243F2ECD4947620A4E2FD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_A1EB3D5846300743B3EA947620A402C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CFE40E59302243F2ECD4947620A4E2FD" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_A1EB3D5846300743B3EA947620A402C0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7F3547CCE05EDF3C6F7594761EB466D0" xlink:type="locator" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ScheduleOfAccruedLiabilitiesTable" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesTable_C6FD09F7FD2AD8DE104294761EB48200" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7F3547CCE05EDF3C6F7594761EB466D0" xlink:to="loc_pfe_ScheduleOfAccruedLiabilitiesTable_C6FD09F7FD2AD8DE104294761EB48200" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2498D9343C667CF17AE994761EB4EF77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesTable_C6FD09F7FD2AD8DE104294761EB48200" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2498D9343C667CF17AE994761EB4EF77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1A15EA1A046DCBE55C7194761EB5D003" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2498D9343C667CF17AE994761EB4EF77" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1A15EA1A046DCBE55C7194761EB5D003" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_62255A4274E0F0EA0C6994761EB5916D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1A15EA1A046DCBE55C7194761EB5D003" xlink:to="loc_us-gaap_AccountsReceivableMember_62255A4274E0F0EA0C6994761EB5916D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_40488C4661458ED6920594761EB59D1F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1A15EA1A046DCBE55C7194761EB5D003" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_40488C4661458ED6920594761EB59D1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_07D988B1A18B53AC29A594761EB57AB3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1A15EA1A046DCBE55C7194761EB5D003" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_07D988B1A18B53AC29A594761EB57AB3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ScheduleOfAccruedLiabilitiesLineItems" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_CDCFA0776857306176F494761EB64197" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesTable_C6FD09F7FD2AD8DE104294761EB48200" xlink:to="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_CDCFA0776857306176F494761EB64197" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_RebatesAndDiscountsAccrual" xlink:label="loc_pfe_RebatesAndDiscountsAccrual_DF1F810D456C9356513494761EB6416D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_CDCFA0776857306176F494761EB64197" xlink:to="loc_pfe_RebatesAndDiscountsAccrual_DF1F810D456C9356513494761EB6416D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AccruedRebates" xlink:label="loc_pfe_AccruedRebates_96360C3931DF288C682494761EB68121" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_CDCFA0776857306176F494761EB64197" xlink:to="loc_pfe_AccruedRebates_96360C3931DF288C682494761EB68121" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherAccruals" xlink:label="loc_pfe_OtherAccruals_72216711BE2C644ADF7C94761EB6ED68" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_CDCFA0776857306176F494761EB64197" xlink:to="loc_pfe_OtherAccruals_72216711BE2C644ADF7C94761EB6ED68" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3D961C8B3B6670CA680494762093DADF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_9BBED01966F0163C1C0F94762093A40B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3D961C8B3B6670CA680494762093DADF" xlink:to="loc_us-gaap_NumberOfOperatingSegments_9BBED01966F0163C1C0F94762093A40B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_NumberOfAccountingStandardsAdopted" xlink:label="loc_pfe_NumberOfAccountingStandardsAdopted_9943011EC655DF57D69394762093B3F0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3D961C8B3B6670CA680494762093DADF" xlink:to="loc_pfe_NumberOfAccountingStandardsAdopted_9943011EC655DF57D69394762093B3F0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_RebatesAndDiscountsAccrual" xlink:label="loc_pfe_RebatesAndDiscountsAccrual_A4B3C228F303C9A037C294762094E2D5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3D961C8B3B6670CA680494762093DADF" xlink:to="loc_pfe_RebatesAndDiscountsAccrual_A4B3C228F303C9A037C294762094E2D5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5AC805EBCDD580F4EF7994761FD90C0C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3340373767B9A73C3A3194761FD99A7E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5AC805EBCDD580F4EF7994761FD90C0C" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3340373767B9A73C3A3194761FD99A7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_505CAA990CCD33F08ED694761FDA6CB6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5AC805EBCDD580F4EF7994761FD90C0C" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_505CAA990CCD33F08ED694761FDA6CB6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3AB12340513C0C3E3AB694761E969C7B" xlink:type="locator" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock" xlink:label="loc_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock_BFF509054C165641FE0494761E963B3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3AB12340513C0C3E3AB694761E969C7B" xlink:to="loc_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock_BFF509054C165641FE0494761E963B3C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2371A5B406B04589CA38BEEC36DCEFA9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_FB64A065740239974E9BBEEC36DCB768" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2371A5B406B04589CA38BEEC36DCEFA9" xlink:to="loc_us-gaap_AssetsAbstract_FB64A065740239974E9BBEEC36DCB768" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C8072D2514D4E668DA05BEEC36DD6CE3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB64A065740239974E9BBEEC36DCB768" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C8072D2514D4E668DA05BEEC36DD6CE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments_E9A28760654E4992FBB4BF016B222715" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB64A065740239974E9BBEEC36DCB768" xlink:to="loc_us-gaap_OtherShortTermInvestments_E9A28760654E4992FBB4BF016B222715" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedInvestmentsCurrent" xlink:label="loc_us-gaap_RestrictedInvestmentsCurrent_D77CA76A88BDBE970932BEEC36DDC2E2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB64A065740239974E9BBEEC36DCB768" xlink:to="loc_us-gaap_RestrictedInvestmentsCurrent_D77CA76A88BDBE970932BEEC36DDC2E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_D3E0D76CB82E92B1EE6EBEEC36DDE437" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB64A065740239974E9BBEEC36DCB768" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_D3E0D76CB82E92B1EE6EBEEC36DDE437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_F65C5F8422855568AA17BEEC36DD72DB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB64A065740239974E9BBEEC36DCB768" xlink:to="loc_us-gaap_InventoryNet_F65C5F8422855568AA17BEEC36DD72DB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherTaxAssetsCurrent" xlink:label="loc_pfe_OtherTaxAssetsCurrent_AECE16158C61F4701A94BEEC36DE2CDC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB64A065740239974E9BBEEC36DCB768" xlink:to="loc_pfe_OtherTaxAssetsCurrent_AECE16158C61F4701A94BEEC36DE2CDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_976A91954523C1FB6B20BEEC36DE5FC2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB64A065740239974E9BBEEC36DCB768" xlink:to="loc_us-gaap_OtherAssetsCurrent_976A91954523C1FB6B20BEEC36DE5FC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_F9FA23F605F4B7C7632CBEEC36DEE908" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB64A065740239974E9BBEEC36DCB768" xlink:to="loc_us-gaap_AssetsCurrent_F9FA23F605F4B7C7632CBEEC36DEE908" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_BF2909AF86ABFB72C6E4BEEC36DEAA5A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB64A065740239974E9BBEEC36DCB768" xlink:to="loc_us-gaap_EquityMethodInvestments_BF2909AF86ABFB72C6E4BEEC36DEAA5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermInvestments" xlink:label="loc_us-gaap_OtherLongTermInvestments_893BDD7CBE8C0A99B8EEBEEC36DE8E4A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB64A065740239974E9BBEEC36DCB768" xlink:to="loc_us-gaap_OtherLongTermInvestments_893BDD7CBE8C0A99B8EEBEEC36DE8E4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9CBBD869AD1FA4E29B16BEEC36DE7E71" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB64A065740239974E9BBEEC36DCB768" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9CBBD869AD1FA4E29B16BEEC36DE7E71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_29B5F587EF5A36DFC496BEEC36DF5CB1" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB64A065740239974E9BBEEC36DCB768" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_29B5F587EF5A36DFC496BEEC36DF5CB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_CAA40218780149BF1549BEEC36DF60A4" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB64A065740239974E9BBEEC36DCB768" xlink:to="loc_us-gaap_Goodwill_CAA40218780149BF1549BEEC36DF60A4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:label="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_B4F3B93D00A229FA676DBEEC36DFAB8A" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB64A065740239974E9BBEEC36DCB768" xlink:to="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_B4F3B93D00A229FA676DBEEC36DFAB8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_764B8B4DB01778795D95BEEC36DFFC3C" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB64A065740239974E9BBEEC36DCB768" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_764B8B4DB01778795D95BEEC36DFFC3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_D39F2C8263FF9663C391BEEC36DF949E" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB64A065740239974E9BBEEC36DCB768" xlink:to="loc_us-gaap_Assets_D39F2C8263FF9663C391BEEC36DF949E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2371A5B406B04589CA38BEEC36DCEFA9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_87BF3C5250A333F69B34BEEC36DF6876" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:to="loc_us-gaap_DebtCurrent_87BF3C5250A333F69B34BEEC36DF6876" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_595B3D016382BA6D0AA6BEEC36E0971E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:to="loc_us-gaap_AccountsPayableCurrent_595B3D016382BA6D0AA6BEEC36E0971E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent" xlink:label="loc_us-gaap_DividendsPayableCurrent_A6BCEF6A538200C7B31DBEEC36E0ABBD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:to="loc_us-gaap_DividendsPayableCurrent_A6BCEF6A538200C7B31DBEEC36E0ABBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_45C0B1253FE8C8AB24E4BEEC36E0821D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:to="loc_us-gaap_TaxesPayableCurrent_45C0B1253FE8C8AB24E4BEEC36E0821D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_C56569FE3D58CCACCD3DBEEC36E0EC93" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_C56569FE3D58CCACCD3DBEEC36E0EC93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5F6FBC8534F5DE8072C7BEEC36E10A0E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_5F6FBC8534F5DE8072C7BEEC36E10A0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_6775A96BCAC68119B81FBEEC36E129EC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:to="loc_us-gaap_LiabilitiesCurrent_6775A96BCAC68119B81FBEEC36E129EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_C35CA1BAE01FDF4E246CBEEC36E11204" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_C35CA1BAE01FDF4E246CBEEC36E11204" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_1653798E9E6C78053166BEEC36E1E7D9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_1653798E9E6C78053166BEEC36E1E7D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_455597F475690A883549BEEC36E1D705" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:to="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_455597F475690A883549BEEC36E1D705" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_07ADC8ADB46D510ABEEDBEEC36E1CD85" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_07ADC8ADB46D510ABEEDBEEC36E1CD85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_967A22E85B6403307EA2BEEC36E10B89" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_967A22E85B6403307EA2BEEC36E10B89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8AE096EF7BB02F8E3B9CBEEC36E27F94" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8AE096EF7BB02F8E3B9CBEEC36E27F94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_A14804A45C811874F5C0BEEC36E22477" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:to="loc_us-gaap_Liabilities_A14804A45C811874F5C0BEEC36E22477" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_AAB7D4F6A6071335ACF2BEEC36E218D5" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:to="loc_us-gaap_CommitmentsAndContingencies_AAB7D4F6A6071335ACF2BEEC36E218D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_B03293533393BC24F0DCBEEC36E70217" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:to="loc_us-gaap_PreferredStockValue_B03293533393BC24F0DCBEEC36E70217" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_10AD813D7A1052ED69B1BEEC36E77D90" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:to="loc_us-gaap_CommonStockValue_10AD813D7A1052ED69B1BEEC36E77D90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_AF0190E432DE54D99733BEEC36E88BB7" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:to="loc_us-gaap_AdditionalPaidInCapital_AF0190E432DE54D99733BEEC36E88BB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_E0EB43B7A757A121FDAFBEEC36E865D5" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:to="loc_us-gaap_TreasuryStockValue_E0EB43B7A757A121FDAFBEEC36E865D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_BD9DFE60029D0FF99393BEEC36E8C0B1" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_BD9DFE60029D0FF99393BEEC36E8C0B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E7C6B46A95F1B5471F82BEEC36E8A6AA" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E7C6B46A95F1B5471F82BEEC36E8A6AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_5211BA2CCE328C13B987BEEC36E83159" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:to="loc_us-gaap_StockholdersEquity_5211BA2CCE328C13B987BEEC36E83159" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_4FB90D0B45BB88D1368CBEEC36E80DC5" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:to="loc_us-gaap_MinorityInterest_4FB90D0B45BB88D1368CBEEC36E80DC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E468F1A269D25E7E8174BEEC36E949DB" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E468F1A269D25E7E8174BEEC36E949DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8F6458EBD855100DFEC3BEEC36E9B980" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DB1AD9E0A8BBF7E9C3FFBEEC36DFA51D" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_8F6458EBD855100DFEC3BEEC36E9B980" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9BEE1AE907A0C66EBBBD947620767604" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_262BA168751F64C46BBF94762076431D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9BEE1AE907A0C66EBBBD947620767604" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_262BA168751F64C46BBF94762076431D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_218130D2FF0800F693C19476207C7C9F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9BEE1AE907A0C66EBBBD947620767604" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_218130D2FF0800F693C19476207C7C9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_99E166D4D9B018020A5D9476207C8818" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9BEE1AE907A0C66EBBBD947620767604" xlink:to="loc_us-gaap_LongTermDebtCurrent_99E166D4D9B018020A5D9476207C8818" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_CBBCC48312A7C5D13A76B09F35006935" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_47A2E354D672C96E3ED1B09F3500DA24" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_CBBCC48312A7C5D13A76B09F35006935" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_47A2E354D672C96E3ED1B09F3500DA24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_A946152AF00756A91B10B09F3501A3A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_47A2E354D672C96E3ED1B09F3500DA24" xlink:to="loc_us-gaap_ProfitLoss_A946152AF00756A91B10B09F3501A3A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F6A790BFD51677B9ADA3B09F3501C384" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_47A2E354D672C96E3ED1B09F3500DA24" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F6A790BFD51677B9ADA3B09F3501C384" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" xlink:label="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_2E486E0DDC21D0650D5CB09F35017873" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F6A790BFD51677B9ADA3B09F3501C384" xlink:to="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_2E486E0DDC21D0650D5CB09F35017873" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AssetWriteOffsAndAssetImpairmentCharges" xlink:label="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_98F1D5A425BBE4B5D7E3B09F3501D239" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F6A790BFD51677B9ADA3B09F3501C384" xlink:to="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_98F1D5A425BBE4B5D7E3B09F3501D239" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_0AA8AF257BCEE4EAB848B09F35029DEA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F6A790BFD51677B9ADA3B09F3501C384" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_0AA8AF257BCEE4EAB848B09F35029DEA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DeconsolidationGainLossAmountNetOfCashConveyed" xlink:label="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_B5BA6448712167DD21DEB09F35023979" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F6A790BFD51677B9ADA3B09F3501C384" xlink:to="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_B5BA6448712167DD21DEB09F35023979" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_77BB84B06CF84F6F1CB1B09F350289BC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F6A790BFD51677B9ADA3B09F3501C384" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_77BB84B06CF84F6F1CB1B09F350289BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_40627A89970B55A4FF31B09F350234F2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F6A790BFD51677B9ADA3B09F3501C384" xlink:to="loc_us-gaap_ShareBasedCompensation_40627A89970B55A4FF31B09F350234F2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" xlink:label="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_84E02D2D0362FB50259EB09F35028D0C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F6A790BFD51677B9ADA3B09F3501C384" xlink:to="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_84E02D2D0362FB50259EB09F35028D0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_48F38A45A6C6E8FC5387B09F35026505" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F6A790BFD51677B9ADA3B09F3501C384" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_48F38A45A6C6E8FC5387B09F35026505" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_05F33EC8850832168D74B09F3503DDD9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F6A790BFD51677B9ADA3B09F3501C384" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_05F33EC8850832168D74B09F3503DDD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_FF52CDED793982255DFAB09F3503D382" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_47A2E354D672C96E3ED1B09F3500DA24" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_FF52CDED793982255DFAB09F3503D382" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_DB38D01B08B80031E442B09F3503515F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_CBBCC48312A7C5D13A76B09F35006935" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_DB38D01B08B80031E442B09F3503515F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1E8CCADD9046C661E8C1B09F350358EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_DB38D01B08B80031E442B09F3503515F" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1E8CCADD9046C661E8C1B09F350358EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_C9C40391FFC010854BD2B09F3503B7B2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_DB38D01B08B80031E442B09F3503515F" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_C9C40391FFC010854BD2B09F3503B7B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_B34EA1579E12A751961DB09F3503BD14" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_DB38D01B08B80031E442B09F3503515F" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_B34EA1579E12A751961DB09F3503BD14" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" xlink:label="loc_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_87423C22740F160ACE52B09F350494C9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_DB38D01B08B80031E442B09F3503515F" xlink:to="loc_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_87423C22740F160ACE52B09F350494C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_26D80F90FAD77766A1ADB09F350402D7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_DB38D01B08B80031E442B09F3503515F" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_26D80F90FAD77766A1ADB09F350402D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_97388ADC477C7F3E60FFB09F35048137" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_DB38D01B08B80031E442B09F3503515F" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_97388ADC477C7F3E60FFB09F35048137" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_2BAEF67B6B3A30784571B09F35043EBC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_DB38D01B08B80031E442B09F3503515F" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_2BAEF67B6B3A30784571B09F35043EBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_EBD3074CFF9C5C3B13A3B09F3504BEEA" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_DB38D01B08B80031E442B09F3503515F" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_EBD3074CFF9C5C3B13A3B09F3504BEEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_BD317FE37EEB5802FCA3B09F350401C9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_DB38D01B08B80031E442B09F3503515F" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_BD317FE37EEB5802FCA3B09F350401C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9C8C3AA44F654A729E4DB09F35057AFA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_CBBCC48312A7C5D13A76B09F35006935" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9C8C3AA44F654A729E4DB09F35057AFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_7A56D2BE77ECDF49BF1FB09F35054E08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9C8C3AA44F654A729E4DB09F35057AFA" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_7A56D2BE77ECDF49BF1FB09F35054E08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_80B17FD8B9A1026DA937B09F35056760" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9C8C3AA44F654A729E4DB09F35057AFA" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_80B17FD8B9A1026DA937B09F35056760" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_EE3E5A87C104A6029F4BB09F3505C03E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9C8C3AA44F654A729E4DB09F35057AFA" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_EE3E5A87C104A6029F4BB09F3505C03E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_88B0EEDA086DAB29AF2EB09F35059F50" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9C8C3AA44F654A729E4DB09F35057AFA" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_88B0EEDA086DAB29AF2EB09F35059F50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_7BBFEBCF4ED1ACFD7F4CB09F3506AE6A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9C8C3AA44F654A729E4DB09F35057AFA" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_7BBFEBCF4ED1ACFD7F4CB09F3506AE6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_88576BCF49DD42E57142B09F3506B3D8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9C8C3AA44F654A729E4DB09F35057AFA" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_88576BCF49DD42E57142B09F3506B3D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_098F14C9C88DFECADF9DB09F35062E34" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9C8C3AA44F654A729E4DB09F35057AFA" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_098F14C9C88DFECADF9DB09F35062E34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_E3CFAA769C9D314B26E6B09F35065DE5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9C8C3AA44F654A729E4DB09F35057AFA" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_E3CFAA769C9D314B26E6B09F35065DE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_FB23C669B16D99CC73B7B09F35066096" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9C8C3AA44F654A729E4DB09F35057AFA" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_FB23C669B16D99CC73B7B09F35066096" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0738DDC4F5C74CD90825B09F35076607" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9C8C3AA44F654A729E4DB09F35057AFA" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0738DDC4F5C74CD90825B09F35076607" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_941081B0388296E687C8B09F35071876" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_CBBCC48312A7C5D13A76B09F35006935" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_941081B0388296E687C8B09F35071876" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_FBEF67F3E0C518DD0310B09F35076330" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_CBBCC48312A7C5D13A76B09F35006935" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_FBEF67F3E0C518DD0310B09F35076330" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_76EB5B7729FE2845D9C6B09F3507A719" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_CBBCC48312A7C5D13A76B09F35006935" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_76EB5B7729FE2845D9C6B09F3507A719" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_B119F1D006BC16B78558B09F3507D4A6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_CBBCC48312A7C5D13A76B09F35006935" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_B119F1D006BC16B78558B09F3507D4A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_212B882E60CC37F26873B09F35075754" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_CBBCC48312A7C5D13A76B09F35006935" xlink:to="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_212B882E60CC37F26873B09F35075754" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_0F727EA5C8ECC2B87F0DB09F3507D025" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_212B882E60CC37F26873B09F35075754" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_0F727EA5C8ECC2B87F0DB09F3507D025" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_016FF852DC5BDF2062FEB09F35085F40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0F727EA5C8ECC2B87F0DB09F3507D025" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_016FF852DC5BDF2062FEB09F35085F40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_EA73C7AE3CEAC80AC5B7B09F35087C17" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0F727EA5C8ECC2B87F0DB09F3507D025" xlink:to="loc_us-gaap_InterestPaidNet_EA73C7AE3CEAC80AC5B7B09F35087C17" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_InterestReceivedInterestRateHedges" xlink:label="loc_pfe_InterestReceivedInterestRateHedges_4AD8909626E96B84DA9AB09F35088C73" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0F727EA5C8ECC2B87F0DB09F3507D025" xlink:to="loc_pfe_InterestReceivedInterestRateHedges_4AD8909626E96B84DA9AB09F35088C73" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_4951D8191CA8747E226492DDEB86808D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_D16F1F94ADDF199958E192DE5DB42B12" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4951D8191CA8747E226492DDEB86808D" xlink:to="loc_us-gaap_StatementTable_D16F1F94ADDF199958E192DE5DB42B12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_F92FB2BE740EDB7B744E92DE5F636B76" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_D16F1F94ADDF199958E192DE5DB42B12" xlink:to="loc_srt_ConsolidatedEntitiesAxis_F92FB2BE740EDB7B744E92DE5F636B76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_DC32740A5F0AA03E8B9E92DE6092FFA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_F92FB2BE740EDB7B744E92DE5F636B76" xlink:to="loc_srt_ConsolidatedEntitiesDomain_DC32740A5F0AA03E8B9E92DE6092FFA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_7C0F3AB027AD7A81FB3F92DE6039BB82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_DC32740A5F0AA03E8B9E92DE6092FFA3" xlink:to="loc_srt_SubsidiariesMember_7C0F3AB027AD7A81FB3F92DE6039BB82" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4DDD07BE98B21ECEC61E92DE5F0826E6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_D16F1F94ADDF199958E192DE5DB42B12" xlink:to="loc_dei_LegalEntityAxis_4DDD07BE98B21ECEC61E92DE5F0826E6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_52E09EB3D96F264FB78692DE60140AA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4DDD07BE98B21ECEC61E92DE5F0826E6" xlink:to="loc_dei_EntityDomain_52E09EB3D96F264FB78692DE60140AA7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnIncMember" xlink:label="loc_pfe_UpjohnIncMember_6700DE4C99B99DAA5DDC92DE5FC3AD35" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_52E09EB3D96F264FB78692DE60140AA7" xlink:to="loc_pfe_UpjohnIncMember_6700DE4C99B99DAA5DDC92DE5FC3AD35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0500906B7BFC9ECFB36892DE5DC5A8E6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_D16F1F94ADDF199958E192DE5DB42B12" xlink:to="loc_us-gaap_StatementLineItems_0500906B7BFC9ECFB36892DE5DC5A8E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_38FC1951390DEB29593B92DDEB861941" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0500906B7BFC9ECFB36892DE5DC5A8E6" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_38FC1951390DEB29593B92DDEB861941" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_D911CDA1506DF6AE1B1992DE5EA62EBE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0500906B7BFC9ECFB36892DE5DC5A8E6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_D911CDA1506DF6AE1B1992DE5EA62EBE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2E4E13C4D20E6E4BB3D7B5A4D049C02E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_10B6151636593E2ECE89B5A4D04A228E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2E4E13C4D20E6E4BB3D7B5A4D049C02E" xlink:to="loc_us-gaap_ProfitLoss_10B6151636593E2ECE89B5A4D04A228E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_2BC3BA7A44BEAA95B306B5A4D04AF461" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2E4E13C4D20E6E4BB3D7B5A4D049C02E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_2BC3BA7A44BEAA95B306B5A4D04AF461" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_62A4A5BDC6D8341AE16BB5A4D04A5F07" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2E4E13C4D20E6E4BB3D7B5A4D049C02E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_62A4A5BDC6D8341AE16BB5A4D04A5F07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_87C34EA5553612F67EADB5A4D04A0271" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2E4E13C4D20E6E4BB3D7B5A4D049C02E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_87C34EA5553612F67EADB5A4D04A0271" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_4EF0C60D051CA490CE5BB5A4D04AEA94" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2E4E13C4D20E6E4BB3D7B5A4D049C02E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_4EF0C60D051CA490CE5BB5A4D04AEA94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_49F72538182A1F8094A3B5A4D04BC83F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2E4E13C4D20E6E4BB3D7B5A4D049C02E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_49F72538182A1F8094A3B5A4D04BC83F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_7BAC587B878B48B8B025B5A4D04BAF8E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2E4E13C4D20E6E4BB3D7B5A4D049C02E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_7BAC587B878B48B8B025B5A4D04BAF8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_E9B51BD744F1A11FA060B5A4D04BC015" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2E4E13C4D20E6E4BB3D7B5A4D049C02E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_E9B51BD744F1A11FA060B5A4D04BC015" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_35438E4476DBE5C16061B5A4D04B5211" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2E4E13C4D20E6E4BB3D7B5A4D049C02E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_35438E4476DBE5C16061B5A4D04B5211" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_A5AE72E77F295DFB7BB8B5A4D04B4ED2" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2E4E13C4D20E6E4BB3D7B5A4D049C02E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_A5AE72E77F295DFB7BB8B5A4D04B4ED2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_E3476CD69D248AFDCD95B5A4D04B0B3A" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2E4E13C4D20E6E4BB3D7B5A4D049C02E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_E3476CD69D248AFDCD95B5A4D04B0B3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_D80C20646178BB1ECFC6B5A4D04C8187" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2E4E13C4D20E6E4BB3D7B5A4D049C02E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_D80C20646178BB1ECFC6B5A4D04C8187" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_37CF06AC4DB89FE046F7B5A4D04C94A2" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2E4E13C4D20E6E4BB3D7B5A4D049C02E" xlink:to="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_37CF06AC4DB89FE046F7B5A4D04C94A2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_616E3F145540E777E4F8B5A4D04CB7C6" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2E4E13C4D20E6E4BB3D7B5A4D049C02E" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_616E3F145540E777E4F8B5A4D04CB7C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_18EDDC305D0F685DACB5B5A4D04C496F" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2E4E13C4D20E6E4BB3D7B5A4D049C02E" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_18EDDC305D0F685DACB5B5A4D04C496F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_9B2C6B1305F10426E6B1B5A4D04C8F75" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2E4E13C4D20E6E4BB3D7B5A4D049C02E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_9B2C6B1305F10426E6B1B5A4D04C8F75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_302FBCE8066458DE4DFAB5A4D04CEE36" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2E4E13C4D20E6E4BB3D7B5A4D049C02E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_302FBCE8066458DE4DFAB5A4D04CEE36" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_DA8108DB83446E6A2979B5A4D04DFA38" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2E4E13C4D20E6E4BB3D7B5A4D049C02E" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_DA8108DB83446E6A2979B5A4D04DFA38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_088CFA4A057A9526A1D2B5A4D04D9408" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2E4E13C4D20E6E4BB3D7B5A4D049C02E" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_088CFA4A057A9526A1D2B5A4D04D9408" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_C4F00A7E862F7D1CB69DB5A4D04D275C" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2E4E13C4D20E6E4BB3D7B5A4D049C02E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_C4F00A7E862F7D1CB69DB5A4D04D275C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_3C07E5D1C889D48BA522B5A4D04D8840" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2E4E13C4D20E6E4BB3D7B5A4D049C02E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_3C07E5D1C889D48BA522B5A4D04D8840" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_94A762B5E08703DF9DEFB5A4D05330AC" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2E4E13C4D20E6E4BB3D7B5A4D049C02E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_94A762B5E08703DF9DEFB5A4D05330AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_E12DBB874826FB76047EB5A4D053452A" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2E4E13C4D20E6E4BB3D7B5A4D049C02E" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_E12DBB874826FB76047EB5A4D053452A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_18B9673D438E02F5938BB5A4D053DEF0" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2E4E13C4D20E6E4BB3D7B5A4D049C02E" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_18B9673D438E02F5938BB5A4D053DEF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5B7FB56B8B1175DB6ACEB5A4D053245D" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2E4E13C4D20E6E4BB3D7B5A4D049C02E" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_5B7FB56B8B1175DB6ACEB5A4D053245D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_75DFA4C374C7C8F577E654457A62FD01" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_E47570589F726E3EB27E54457A624420" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_75DFA4C374C7C8F577E654457A62FD01" xlink:to="loc_us-gaap_StatementTable_E47570589F726E3EB27E54457A624420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CA661A2448E2C2C7275254457A62BCB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_E47570589F726E3EB27E54457A624420" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CA661A2448E2C2C7275254457A62BCB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_91468BB646DA047A954F54457A631477" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CA661A2448E2C2C7275254457A62BCB0" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_91468BB646DA047A954F54457A631477" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_GSKConsumerHealthcareMember" xlink:label="loc_pfe_GSKConsumerHealthcareMember_4FE0ECECB6BC3798933554457A639638" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_91468BB646DA047A954F54457A631477" xlink:to="loc_pfe_GSKConsumerHealthcareMember_4FE0ECECB6BC3798933554457A639638" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_95F421D2A3D9663F5FA754457A6347D6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_E47570589F726E3EB27E54457A624420" xlink:to="loc_us-gaap_StatementLineItems_95F421D2A3D9663F5FA754457A6347D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_5A4C589FBF6A57B2560854457A64FE26" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_95F421D2A3D9663F5FA754457A6347D6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_5A4C589FBF6A57B2560854457A64FE26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5F1E3B2D0A159C8F92DC54457A64E042" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_95F421D2A3D9663F5FA754457A6347D6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5F1E3B2D0A159C8F92DC54457A64E042" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_E3598937CEA5A8A016567DA8645CC969" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_01070F09CF6831D790317DA8645C7AFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_E3598937CEA5A8A016567DA8645CC969" xlink:to="loc_us-gaap_StatementTable_01070F09CF6831D790317DA8645C7AFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1524ED523B403E042DDB7DA8645DFE50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_01070F09CF6831D790317DA8645C7AFC" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1524ED523B403E042DDB7DA8645DFE50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_105918547EDC2DC094ED7DA8645D9CC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1524ED523B403E042DDB7DA8645DFE50" xlink:to="loc_us-gaap_EquityComponentDomain_105918547EDC2DC094ED7DA8645D9CC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_C79A81A1B0A1305CA2B97DA8645D53D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_105918547EDC2DC094ED7DA8645D9CC7" xlink:to="loc_us-gaap_PreferredStockMember_C79A81A1B0A1305CA2B97DA8645D53D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4A9215D60A4DC4CD95627DA8645ECC8F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_105918547EDC2DC094ED7DA8645D9CC7" xlink:to="loc_us-gaap_CommonStockMember_4A9215D60A4DC4CD95627DA8645ECC8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_18D5E605821C05CAEC4F7DA8645E09EA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_105918547EDC2DC094ED7DA8645D9CC7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_18D5E605821C05CAEC4F7DA8645E09EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_36C3BD1B9BE0EA9B37A37DA8645EB040" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_105918547EDC2DC094ED7DA8645D9CC7" xlink:to="loc_us-gaap_TreasuryStockMember_36C3BD1B9BE0EA9B37A37DA8645EB040" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_C536E8C4EE979BFBCE057DA8645EAA2F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_105918547EDC2DC094ED7DA8645D9CC7" xlink:to="loc_us-gaap_RetainedEarningsMember_C536E8C4EE979BFBCE057DA8645EAA2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_D128A5845CA8DE3E2C837DA8645E8CEA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_105918547EDC2DC094ED7DA8645D9CC7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_D128A5845CA8DE3E2C837DA8645E8CEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_1DF83A49140E6C2F627F7DA8645E52C8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_105918547EDC2DC094ED7DA8645D9CC7" xlink:to="loc_us-gaap_ParentMember_1DF83A49140E6C2F627F7DA8645E52C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_4E55536BDAC1C62FC49D7DA8645FF643" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_105918547EDC2DC094ED7DA8645D9CC7" xlink:to="loc_us-gaap_NoncontrollingInterestMember_4E55536BDAC1C62FC49D7DA8645FF643" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_A7C1A24957B421DA45547DA8645F57C4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_01070F09CF6831D790317DA8645C7AFC" xlink:to="loc_us-gaap_StatementLineItems_A7C1A24957B421DA45547DA8645F57C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_A7C1A24957B421DA45547DA8645F57C4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_E68C4FCF086DE00968F97DA8645FA85B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="loc_us-gaap_SharesIssued_E68C4FCF086DE00968F97DA8645FA85B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5D4258EDB6E134EE176B7DA8645FE1F5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5D4258EDB6E134EE176B7DA8645FE1F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_47900DE4B98B3FAA4FE47DA8645FA4CE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="loc_us-gaap_ProfitLoss_47900DE4B98B3FAA4FE47DA8645FA4CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0285183AF3B08C43D0577DA864607460" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0285183AF3B08C43D0577DA864607460" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCashAbstract" xlink:label="loc_us-gaap_DividendsCashAbstract_FF829DDEBC94DC9184237DA864601B00" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="loc_us-gaap_DividendsCashAbstract_FF829DDEBC94DC9184237DA864601B00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockCash" xlink:label="loc_us-gaap_DividendsCommonStockCash_2E549E81AEAD55B1D7867DA8646056F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsCashAbstract_FF829DDEBC94DC9184237DA864601B00" xlink:to="loc_us-gaap_DividendsCommonStockCash_2E549E81AEAD55B1D7867DA8646056F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="loc_us-gaap_DividendsPreferredStockCash_5346B828047A2DAB76927DA86460472D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsCashAbstract_FF829DDEBC94DC9184237DA864601B00" xlink:to="loc_us-gaap_DividendsPreferredStockCash_5346B828047A2DAB76927DA86460472D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_35DD9BFB35EA594EB31F7DA864608265" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsCashAbstract_FF829DDEBC94DC9184237DA864601B00" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_35DD9BFB35EA594EB31F7DA864608265" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6591817ACDF20F1BF5837DA86461B66E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6591817ACDF20F1BF5837DA86461B66E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_BCC6733C586E4FEB28F87DA864613D12" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_BCC6733C586E4FEB28F87DA864613D12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_6DED250EBEC778DB76267DA86461BDC9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_6DED250EBEC778DB76267DA86461BDC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_32A748D01614CE80C9ED7DA86461F833" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_32A748D01614CE80C9ED7DA86461F833" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" xlink:label="loc_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_376DC9995DF171FA83327DA86461F0FA" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="loc_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_376DC9995DF171FA83327DA86461F0FA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" xlink:label="loc_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_D4BC0E7BA698E78934537DA86462C042" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="loc_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_D4BC0E7BA698E78934537DA86462C042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOtherShares" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_675F9E7ED2A00EB9013F7DA8646227BD" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_675F9E7ED2A00EB9013F7DA8646227BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_1A15A0C81B6F22F4FF867DA86462D2D7" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="loc_us-gaap_StockholdersEquityOther_1A15A0C81B6F22F4FF867DA86462D2D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_66AC37CC26B3FFF9C0D77DA86462A5EB" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="loc_us-gaap_SharesIssued_66AC37CC26B3FFF9C0D77DA86462A5EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_07C43582941B773E1ABE7DA86462BF5D" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25445F03F648E40E99F67DA8645F00E2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_07C43582941B773E1ABE7DA86462BF5D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_DCA479848717297E8EF354457A7A5047" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0E189A7E8A7FD37B124054457A7A24F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DCA479848717297E8EF354457A7A5047" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0E189A7E8A7FD37B124054457A7A24F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_738221F0EF1CEE069CE754457A7A227D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DCA479848717297E8EF354457A7A5047" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_738221F0EF1CEE069CE754457A7A227D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1B2E56A6799A7B62A9F154457A7BD2F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_738221F0EF1CEE069CE754457A7A227D" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1B2E56A6799A7B62A9F154457A7BD2F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_CA0977F9C4E74C8E69B354457A7BFEA3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_738221F0EF1CEE069CE754457A7A227D" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_CA0977F9C4E74C8E69B354457A7BFEA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9577EE22AB664F2A073754457A7B4CDB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_738221F0EF1CEE069CE754457A7A227D" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9577EE22AB664F2A073754457A7B4CDB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" xlink:label="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_AAE307BF6AD45598F90654457A7BF0C0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_738221F0EF1CEE069CE754457A7A227D" xlink:to="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_AAE307BF6AD45598F90654457A7BF0C0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_D0444063F2ABF9DF302354457A7B1020" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_738221F0EF1CEE069CE754457A7A227D" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_D0444063F2ABF9DF302354457A7B1020" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_A452559164C303E95E9654457A7B6A10" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_738221F0EF1CEE069CE754457A7A227D" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_A452559164C303E95E9654457A7B6A10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_E62B9AA3C8561564AE3D54457A7CA77B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_738221F0EF1CEE069CE754457A7A227D" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_E62B9AA3C8561564AE3D54457A7CA77B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_377772A9B3104931A38454457A7CA563" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DCA479848717297E8EF354457A7A5047" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_377772A9B3104931A38454457A7CA563" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_977DA7CA8BCD7B4046DC54457A7C949C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DCA479848717297E8EF354457A7A5047" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_977DA7CA8BCD7B4046DC54457A7C949C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_38CE89A349971AE058C254457A7C0745" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DCA479848717297E8EF354457A7A5047" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_38CE89A349971AE058C254457A7C0745" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9BB96D3BB0658B3BEF8F54457A7C2BFF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DCA479848717297E8EF354457A7A5047" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9BB96D3BB0658B3BEF8F54457A7C2BFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_FA2ACF3AFC60CF41EB6754457A7C340C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DCA479848717297E8EF354457A7A5047" xlink:to="loc_us-gaap_ProfitLoss_FA2ACF3AFC60CF41EB6754457A7C340C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_EA41C0B3EE8AA5F03BBA54457A7DEE87" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DCA479848717297E8EF354457A7A5047" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_EA41C0B3EE8AA5F03BBA54457A7DEE87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_4BD04AE2DFDD0AD5E39754457A7D2EB9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DCA479848717297E8EF354457A7A5047" xlink:to="loc_us-gaap_NetIncomeLoss_4BD04AE2DFDD0AD5E39754457A7D2EB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_AFC592F5D2FA15C7547C54457A7DB183" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DCA479848717297E8EF354457A7A5047" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_AFC592F5D2FA15C7547C54457A7DB183" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_CDDAA9B50B61FF1779E354457A7D01F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_AFC592F5D2FA15C7547C54457A7DB183" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_CDDAA9B50B61FF1779E354457A7D01F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_85CDB438AE5826D4E81754457A7D3032" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_AFC592F5D2FA15C7547C54457A7DB183" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_85CDB438AE5826D4E81754457A7D3032" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_A516F0A07E4BA18823BB54457A7E6C6C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_AFC592F5D2FA15C7547C54457A7DB183" xlink:to="loc_us-gaap_EarningsPerShareBasic_A516F0A07E4BA18823BB54457A7E6C6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_A618E608ED797706CF9D54457A7ED3EC" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DCA479848717297E8EF354457A7A5047" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_A618E608ED797706CF9D54457A7ED3EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9339C82242AEEC12955854457A7E292E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_A618E608ED797706CF9D54457A7ED3EC" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9339C82242AEEC12955854457A7E292E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_8CF18542CABD454AF51A54457A7E4853" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_A618E608ED797706CF9D54457A7ED3EC" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_8CF18542CABD454AF51A54457A7E4853" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_439D7F3EBDCD47CAFABE54457A7EFD25" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_A618E608ED797706CF9D54457A7ED3EC" xlink:to="loc_us-gaap_EarningsPerShareDiluted_439D7F3EBDCD47CAFABE54457A7EFD25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6E2A7910210963F062C854457A7E2252" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DCA479848717297E8EF354457A7A5047" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6E2A7910210963F062C854457A7E2252" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_58D099219B5D758DF5EF54457A7FE757" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DCA479848717297E8EF354457A7A5047" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_58D099219B5D758DF5EF54457A7FE757" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ContingenciesAndCertainCommitments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BEEE0974A06C1200A833947622F45B30" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_AFDFB47E3B70C6F84583947622F4D354" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BEEE0974A06C1200A833947622F45B30" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_AFDFB47E3B70C6F84583947622F4D354" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2F856C9491C12A51A35294761F41ADBF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_286958FD4BA0683B150B94761F42A95E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2F856C9491C12A51A35294761F41ADBF" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_286958FD4BA0683B150B94761F42A95E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5FDE4D403C55802E4CC094761F42C3CB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2F856C9491C12A51A35294761F41ADBF" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5FDE4D403C55802E4CC094761F42C3CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7C34E5059CD00E25A98894761F42DF3B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2F856C9491C12A51A35294761F41ADBF" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7C34E5059CD00E25A98894761F42DF3B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_72993EF9F064456CC75DBEEA11C89B4E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesTable" xlink:label="loc_us-gaap_GainContingenciesTable_A8A240334B7429C19B7DBEEA11CA574D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_72993EF9F064456CC75DBEEA11C89B4E" xlink:to="loc_us-gaap_GainContingenciesTable_A8A240334B7429C19B7DBEEA11CA574D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_0F364E2984BC0F6F5DE5BEEA11CC8638" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_A8A240334B7429C19B7DBEEA11CA574D" xlink:to="loc_us-gaap_GainContingenciesByNatureAxis_0F364E2984BC0F6F5DE5BEEA11CC8638" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaap_GainContingencyNatureDomain_7B6B4D8E0551B32D0B98BEEA11CC5F92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_0F364E2984BC0F6F5DE5BEEA11CC8638" xlink:to="loc_us-gaap_GainContingencyNatureDomain_7B6B4D8E0551B32D0B98BEEA11CC5F92" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PatentInfringementMember" xlink:label="loc_pfe_PatentInfringementMember_4C8313A3243FE379CC66BEEA11CD7360" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingencyNatureDomain_7B6B4D8E0551B32D0B98BEEA11CC5F92" xlink:to="loc_pfe_PatentInfringementMember_4C8313A3243FE379CC66BEEA11CD7360" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_15101EA29DDAE2081F65BEEA11CD2004" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_A8A240334B7429C19B7DBEEA11CA574D" xlink:to="loc_srt_ProductOrServiceAxis_15101EA29DDAE2081F65BEEA11CD2004" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_8A35944EC7F7CBE63392BEEA11CD8FBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_15101EA29DDAE2081F65BEEA11CD2004" xlink:to="loc_srt_ProductsAndServicesDomain_8A35944EC7F7CBE63392BEEA11CD8FBB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_XeljanzMember" xlink:label="loc_pfe_XeljanzMember_48AB90B8505718CC27C8BEEA11CDE3DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8A35944EC7F7CBE63392BEEA11CD8FBB" xlink:to="loc_pfe_XeljanzMember_48AB90B8505718CC27C8BEEA11CDE3DD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EliquisMember" xlink:label="loc_pfe_EliquisMember_0B119DAB662E2A756D0BBEEA11CEE6C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8A35944EC7F7CBE63392BEEA11CD8FBB" xlink:to="loc_pfe_EliquisMember_0B119DAB662E2A756D0BBEEA11CEE6C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_81CFA4C5A0601DC17753BEEA11CE0765" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_A8A240334B7429C19B7DBEEA11CA574D" xlink:to="loc_srt_LitigationCaseAxis_81CFA4C5A0601DC17753BEEA11CE0765" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_EF58290ABF145AC3158FBEEA11CECF2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_81CFA4C5A0601DC17753BEEA11CE0765" xlink:to="loc_srt_LitigationCaseTypeDomain_EF58290ABF145AC3158FBEEA11CECF2B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PfizerVersusZydusMember" xlink:label="loc_pfe_PfizerVersusZydusMember_3F5C1910368A2F8901D8BEEA11CEC0E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_EF58290ABF145AC3158FBEEA11CECF2B" xlink:to="loc_pfe_PfizerVersusZydusMember_3F5C1910368A2F8901D8BEEA11CEC0E8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PfizerVersusGenericCompaniesMember" xlink:label="loc_pfe_PfizerVersusGenericCompaniesMember_001D33D5976A5912AE9CBEEA11CF5C7B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_EF58290ABF145AC3158FBEEA11CECF2B" xlink:to="loc_pfe_PfizerVersusGenericCompaniesMember_001D33D5976A5912AE9CBEEA11CF5C7B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member" xlink:label="loc_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_DC26A25730FCC8F23715BEEA11CF4661" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_EF58290ABF145AC3158FBEEA11CECF2B" xlink:to="loc_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_DC26A25730FCC8F23715BEEA11CF4661" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" xlink:label="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_8A24D916C1B7C574EDF0BEEA11CF84B6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_EF58290ABF145AC3158FBEEA11CECF2B" xlink:to="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_8A24D916C1B7C574EDF0BEEA11CF84B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_8797CAF2F85640378709BEEA11CFA5D9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_A8A240334B7429C19B7DBEEA11CA574D" xlink:to="loc_us-gaap_LitigationStatusAxis_8797CAF2F85640378709BEEA11CFA5D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_9944064F705B44B2BBD8BEEA11CF07C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_8797CAF2F85640378709BEEA11CFA5D9" xlink:to="loc_us-gaap_LitigationStatusDomain_9944064F705B44B2BBD8BEEA11CF07C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_JudicialRulingMember" xlink:label="loc_us-gaap_JudicialRulingMember_F0D965BCEB4D78258CB4BEEA11D5A605" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_9944064F705B44B2BBD8BEEA11CF07C7" xlink:to="loc_us-gaap_JudicialRulingMember_F0D965BCEB4D78258CB4BEEA11D5A605" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_E02A4280C7AA036BE31BBEEA11D5380D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_9944064F705B44B2BBD8BEEA11CF07C7" xlink:to="loc_us-gaap_PendingLitigationMember_E02A4280C7AA036BE31BBEEA11D5380D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="loc_us-gaap_SettledLitigationMember_5D66E92C33755DD891DABEEA11D55CE7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_9944064F705B44B2BBD8BEEA11CF07C7" xlink:to="loc_us-gaap_SettledLitigationMember_5D66E92C33755DD891DABEEA11D55CE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesLineItems" xlink:label="loc_us-gaap_GainContingenciesLineItems_12B10E098DED288AFE24BEEA11D61605" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_A8A240334B7429C19B7DBEEA11CA574D" xlink:to="loc_us-gaap_GainContingenciesLineItems_12B10E098DED288AFE24BEEA11D61605" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_GainContingencyPatentsWithoutCourtProceedingsNumber" xlink:label="loc_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_6677E18B16E4B402A75FBEEA11D6A548" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_12B10E098DED288AFE24BEEA11D61605" xlink:to="loc_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_6677E18B16E4B402A75FBEEA11D6A548" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyPatentsFoundInfringedUponNumber" xlink:label="loc_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_CB69A48214050E477603BEEA11D62A8C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_12B10E098DED288AFE24BEEA11D61605" xlink:to="loc_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_CB69A48214050E477603BEEA11D62A8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_18D892FB0AF65564CE87BEEA11D6BB1E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_12B10E098DED288AFE24BEEA11D61605" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_18D892FB0AF65564CE87BEEA11D6BB1E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_GainContingencyNumberofDefendants" xlink:label="loc_pfe_GainContingencyNumberofDefendants_5A124AF6CA4B9611DE8DBEEA11D6927C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_12B10E098DED288AFE24BEEA11D61605" xlink:to="loc_pfe_GainContingencyNumberofDefendants_5A124AF6CA4B9611DE8DBEEA11D6927C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" xlink:label="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_7E9BD4A27D5FEE966D90BEEA11D72E69" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_12B10E098DED288AFE24BEEA11D61605" xlink:to="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_7E9BD4A27D5FEE966D90BEEA11D72E69" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_97419A36A4CAB544DA3DBEEA9658BC87" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_5DAED5BA42B73F27EE3CBEEA96598DD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_97419A36A4CAB544DA3DBEEA9658BC87" xlink:to="loc_us-gaap_LossContingenciesTable_5DAED5BA42B73F27EE3CBEEA96598DD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7570F66BE8CB0EFCF744BEEBF9FDBBAF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5DAED5BA42B73F27EE3CBEEA96598DD5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7570F66BE8CB0EFCF744BEEBF9FDBBAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_EA490FDE583EE39E3BB1BEEBFA3CE6F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7570F66BE8CB0EFCF744BEEBF9FDBBAF" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_EA490FDE583EE39E3BB1BEEBFA3CE6F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4343B76856DA3A1607A2BEEBFAF30770" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_EA490FDE583EE39E3BB1BEEBFA3CE6F7" xlink:to="loc_us-gaap_SubsequentEventMember_4343B76856DA3A1607A2BEEBFAF30770" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_A86A851012C45A00F38ABEEA96592387" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5DAED5BA42B73F27EE3CBEEA96598DD5" xlink:to="loc_srt_RangeAxis_A86A851012C45A00F38ABEEA96592387" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9D48424D9ADB937D174CBEEA9659CE8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_A86A851012C45A00F38ABEEA96592387" xlink:to="loc_srt_RangeMember_9D48424D9ADB937D174CBEEA9659CE8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_80CC935B1DE3B17B3797BEEA96593695" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9D48424D9ADB937D174CBEEA9659CE8F" xlink:to="loc_srt_MinimumMember_80CC935B1DE3B17B3797BEEA96593695" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_E85047E7D3E801F63914BEEA965A7D18" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5DAED5BA42B73F27EE3CBEEA96598DD5" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_E85047E7D3E801F63914BEEA965A7D18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_6661524AD9BB9FA76636BEEA965A12F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_E85047E7D3E801F63914BEEA965A7D18" xlink:to="loc_us-gaap_LossContingencyNatureDomain_6661524AD9BB9FA76636BEEA965A12F5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PatentInfringementMember" xlink:label="loc_pfe_PatentInfringementMember_711B96585A07A67D817BBEEBFA5DAAA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_6661524AD9BB9FA76636BEEA965A12F5" xlink:to="loc_pfe_PatentInfringementMember_711B96585A07A67D817BBEEBFA5DAAA3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EnvironmentalRemediationLitigationMember" xlink:label="loc_pfe_EnvironmentalRemediationLitigationMember_24B8195F1F8C12CC2793BEEA965A39E5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_6661524AD9BB9FA76636BEEA965A12F5" xlink:to="loc_pfe_EnvironmentalRemediationLitigationMember_24B8195F1F8C12CC2793BEEA965A39E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_B84566645BA54A1445ABBEEA965A9E85" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5DAED5BA42B73F27EE3CBEEA96598DD5" xlink:to="loc_srt_ProductOrServiceAxis_B84566645BA54A1445ABBEEA965A9E85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_4AB4BD9216D90C610C31BEEA965B5989" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_B84566645BA54A1445ABBEEA965A9E85" xlink:to="loc_srt_ProductsAndServicesDomain_4AB4BD9216D90C610C31BEEA965B5989" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_HormoneTherapyProductsMember" xlink:label="loc_pfe_HormoneTherapyProductsMember_FF942F4A2FF1736D3B7FBEEA965B27B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4AB4BD9216D90C610C31BEEA965B5989" xlink:to="loc_pfe_HormoneTherapyProductsMember_FF942F4A2FF1736D3B7FBEEA965B27B6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EpiPenMember" xlink:label="loc_pfe_EpiPenMember_31CBE40091AAEBEA3486BEEA965BAA4D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4AB4BD9216D90C610C31BEEA965B5989" xlink:to="loc_pfe_EpiPenMember_31CBE40091AAEBEA3486BEEA965BAA4D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DocetaxelMember" xlink:label="loc_pfe_DocetaxelMember_FD3D3B972C9FD13B9C18BEEA965BF83A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4AB4BD9216D90C610C31BEEA965B5989" xlink:to="loc_pfe_DocetaxelMember_FD3D3B972C9FD13B9C18BEEA965BF83A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_7936A69B2785FF7478A2BEEA965CCBCE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5DAED5BA42B73F27EE3CBEEA96598DD5" xlink:to="loc_srt_LitigationCaseAxis_7936A69B2785FF7478A2BEEA965CCBCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_BB9DBA6014A9043D9D6ABEEA965CF4BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_7936A69B2785FF7478A2BEEA965CCBCE" xlink:to="loc_srt_LitigationCaseTypeDomain_BB9DBA6014A9043D9D6ABEEA965CF4BB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_NHSScotlandvs.DrReddysMember" xlink:label="loc_pfe_NHSScotlandvs.DrReddysMember_43C5F4534C427114E2CBBEEBFAAB4619" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_BB9DBA6014A9043D9D6ABEEA965CF4BB" xlink:to="loc_pfe_NHSScotlandvs.DrReddysMember_43C5F4534C427114E2CBBEEBFAAB4619" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ClassActionVersusWyethMember" xlink:label="loc_pfe_ClassActionVersusWyethMember_8B978BF67595DEAC1FC5BEEA965CBE13" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_BB9DBA6014A9043D9D6ABEEA965CF4BB" xlink:to="loc_pfe_ClassActionVersusWyethMember_8B978BF67595DEAC1FC5BEEA965CBE13" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" xlink:label="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_7DBADCD09438C966389BBEEA965C9202" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_BB9DBA6014A9043D9D6ABEEA965CF4BB" xlink:to="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_7DBADCD09438C966389BBEEA965C9202" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_0B96D608C6F21A949707BEEA965DCD1C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5DAED5BA42B73F27EE3CBEEA96598DD5" xlink:to="loc_us-gaap_LitigationStatusAxis_0B96D608C6F21A949707BEEA965DCD1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_72A1EA19236314D2ED45BEEA965DC648" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_0B96D608C6F21A949707BEEA965DCD1C" xlink:to="loc_us-gaap_LitigationStatusDomain_72A1EA19236314D2ED45BEEA965DC648" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="loc_us-gaap_SettledLitigationMember_72AEFCC8DA9C7566F5C7BEEA965D3ED0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_72A1EA19236314D2ED45BEEA965DC648" xlink:to="loc_us-gaap_SettledLitigationMember_72AEFCC8DA9C7566F5C7BEEA965D3ED0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_9911E2E36421DFE8DE43BEEA965DFCCF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_72A1EA19236314D2ED45BEEA965DC648" xlink:to="loc_us-gaap_PendingLitigationMember_9911E2E36421DFE8DE43BEEA965DFCCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_9166BCF6AE6608182894BEEA965DF309" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5DAED5BA42B73F27EE3CBEEA96598DD5" xlink:to="loc_us-gaap_LossContingenciesLineItems_9166BCF6AE6608182894BEEA965DF309" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_435F2919357205352287BEEBF9D0D305" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9166BCF6AE6608182894BEEA965DF309" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_435F2919357205352287BEEBF9D0D305" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_E966E4E0DC5EAA63192BBEEA965E272E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9166BCF6AE6608182894BEEA965DF309" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_E966E4E0DC5EAA63192BBEEA965E272E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LossContingencyNumberOfLawsuits" xlink:label="loc_pfe_LossContingencyNumberOfLawsuits_67989598F7EB08095016BEEA965EDE8D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9166BCF6AE6608182894BEEA965DF309" xlink:to="loc_pfe_LossContingencyNumberOfLawsuits_67989598F7EB08095016BEEA965EDE8D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" xlink:label="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_198735D799629D87BBC4BEEA965E23D2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9166BCF6AE6608182894BEEA965DF309" xlink:to="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_198735D799629D87BBC4BEEA965E23D2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LossContingencyClassActionsFiledNumber" xlink:label="loc_pfe_LossContingencyClassActionsFiledNumber_0248FC1B6EB0A16E7A15BEEA965ECEF2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9166BCF6AE6608182894BEEA965DF309" xlink:to="loc_pfe_LossContingencyClassActionsFiledNumber_0248FC1B6EB0A16E7A15BEEA965ECEF2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FeasibilityStudyNumberOfLagoons" xlink:label="loc_pfe_FeasibilityStudyNumberOfLagoons_99ED2948E08D611DC62BBEEA965EFAD7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9166BCF6AE6608182894BEEA965DF309" xlink:to="loc_pfe_FeasibilityStudyNumberOfLagoons_99ED2948E08D611DC62BBEEA965EFAD7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_ECD77D1D95196DD01ED69476214FA8F7" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitiesTable" xlink:label="loc_dei_EntitiesTable_6BEF4EB72D27BAC5B3B994762150B47F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ECD77D1D95196DD01ED69476214FA8F7" xlink:to="loc_dei_EntitiesTable_6BEF4EB72D27BAC5B3B994762150B47F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8A5B7FE49AE24C45B38B94762150A41E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_6BEF4EB72D27BAC5B3B994762150B47F" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8A5B7FE49AE24C45B38B94762150A41E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D07E461283C3FA7703E09476215078F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8A5B7FE49AE24C45B38B94762150A41E" xlink:to="loc_us-gaap_ClassOfStockDomain_D07E461283C3FA7703E09476215078F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_D38B5BE3EDDAFFAC83D6947621515092" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_D07E461283C3FA7703E09476215078F5" xlink:to="loc_us-gaap_CommonStockMember_D38B5BE3EDDAFFAC83D6947621515092" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_NotesDue20220.250Member" xlink:label="loc_pfe_NotesDue20220.250Member_F3B4D8FAF1591617D43B94762151DCF1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_D07E461283C3FA7703E09476215078F5" xlink:to="loc_pfe_NotesDue20220.250Member_F3B4D8FAF1591617D43B94762151DCF1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_NotesDue20271.000Member" xlink:label="loc_pfe_NotesDue20271.000Member_1A6E9869FF0AC0C9630B9476215115F2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_D07E461283C3FA7703E09476215078F5" xlink:to="loc_pfe_NotesDue20271.000Member_1A6E9869FF0AC0C9630B9476215115F2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInformationLineItems" xlink:label="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_6BEF4EB72D27BAC5B3B994762150B47F" xlink:to="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_2CCF0CFCFCAB4E74B092947621515A7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_DocumentType_2CCF0CFCFCAB4E74B092947621515A7F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_F0B577485A3E2E5958F9947621521F69" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_DocumentQuarterlyReport_F0B577485A3E2E5958F9947621521F69" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_4E5B0B21C4BEB91D16B394762152B53B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_DocumentPeriodEndDate_4E5B0B21C4BEB91D16B394762152B53B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_BC0F4677FBCB403B51DD947621526DFE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_DocumentTransitionReport_BC0F4677FBCB403B51DD947621526DFE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_BD3593FE990C54224595947621527524" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityFileNumber_BD3593FE990C54224595947621527524" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_C970256C3BACADD6AF3C947621523258" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityRegistrantName_C970256C3BACADD6AF3C947621523258" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_CAB2971306A9B6511B0C947621535305" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityIncorporationStateCountryCode_CAB2971306A9B6511B0C947621535305" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_36E6F8DA32CC33A3707E947621531071" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityTaxIdentificationNumber_36E6F8DA32CC33A3707E947621531071" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_6D9ED9007B223EF3D062947621533652" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityAddressAddressLine1_6D9ED9007B223EF3D062947621533652" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_71C8945D294C21B8460E94762153AF8F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityAddressCityOrTown_71C8945D294C21B8460E94762153AF8F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_2FDC1CD74B2E1BCAC22694762153536F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityAddressStateOrProvince_2FDC1CD74B2E1BCAC22694762153536F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_F01EC6CB7CC69B7AD71F94762153217D" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityAddressPostalZipCode_F01EC6CB7CC69B7AD71F94762153217D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_0C6BF61FF873887D10B094762153AA73" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_CityAreaCode_0C6BF61FF873887D10B094762153AA73" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_2E6A057828AF2E5AAE2194762154BDED" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_LocalPhoneNumber_2E6A057828AF2E5AAE2194762154BDED" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_7309269DC3ADA72430C8947621543F97" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_Security12bTitle_7309269DC3ADA72430C8947621543F97" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_C4440E09C69BAD5BDDC194762154E383" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_TradingSymbol_C4440E09C69BAD5BDDC194762154E383" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_16D9D6B005F22B21EE9394762154F9C7" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_SecurityExchangeName_16D9D6B005F22B21EE9394762154F9C7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_9759AA759CCB8F031EFA9476215471B0" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityCurrentReportingStatus_9759AA759CCB8F031EFA9476215471B0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_6CB2A44E160280EBA62B94762155CE3B" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityInteractiveDataCurrent_6CB2A44E160280EBA62B94762155CE3B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_FE65E3A11197F9E68ACF94762155FB1B" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityFilerCategory_FE65E3A11197F9E68ACF94762155FB1B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_29E0C615C4E4FF4C74D894762155B832" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntitySmallBusiness_29E0C615C4E4FF4C74D894762155B832" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_7A0ED81080F6634A3053947621554371" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityEmergingGrowthCompany_7A0ED81080F6634A3053947621554371" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_1A6EA84D6B0BC47A22F3947621555998" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityShellCompany_1A6EA84D6B0BC47A22F3947621555998" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_E8227DB2564C0E41A867947621554B0A" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_E8227DB2564C0E41A867947621554B0A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_3AC40381611F3CE6BA3294762155E10D" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_EntityCentralIndexKey_3AC40381611F3CE6BA3294762155E10D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_3901D592D2C0E9AFD00C947621566D2F" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_CurrentFiscalYearEndDate_3901D592D2C0E9AFD00C947621566D2F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_189822777DD5C6CA2D4C94762156729D" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_DocumentFiscalYearFocus_189822777DD5C6CA2D4C94762156729D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_EE848DDD25A98CB3C114947621563EDE" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_DocumentFiscalPeriodFocus_EE848DDD25A98CB3C114947621563EDE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9BC9FAA9051592D4285F94762156C526" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5103F75598F90B9F31C7947621513B1E" xlink:to="loc_dei_AmendmentFlag_9BC9FAA9051592D4285F94762156C526" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_A45204DE3AEABC7A2128635078C8D67A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_9F4455A4CE46CCD7C93B635078C97040" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_A45204DE3AEABC7A2128635078C8D67A" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_9F4455A4CE46CCD7C93B635078C97040" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_DB7347E9600C637539BC635078CA23C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_9F4455A4CE46CCD7C93B635078C97040" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_DB7347E9600C637539BC635078CA23C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_A9A65F260B6DE5AA14A4635078CAA112" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_9F4455A4CE46CCD7C93B635078C97040" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_A9A65F260B6DE5AA14A4635078CAA112" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_469CDCB14FD9E5202D63635078CA1812" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_9F4455A4CE46CCD7C93B635078C97040" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_469CDCB14FD9E5202D63635078CA1812" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_9E16F854312CEA34714E635078CAED21" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_9F4455A4CE46CCD7C93B635078C97040" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_9E16F854312CEA34714E635078CAED21" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_5368068560820C7574B5635078CA94AA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_9F4455A4CE46CCD7C93B635078C97040" xlink:to="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_5368068560820C7574B5635078CA94AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1E88FD3E0B8069180661635078CAA1A2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_9F4455A4CE46CCD7C93B635078C97040" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1E88FD3E0B8069180661635078CAA1A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5CACE49728696D182B01635078CB9CEB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_9F4455A4CE46CCD7C93B635078C97040" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5CACE49728696D182B01635078CB9CEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_558C1A6A2C0A80F8A45B635078CBEB53" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_A45204DE3AEABC7A2128635078C8D67A" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_558C1A6A2C0A80F8A45B635078CBEB53" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_A58AC74D2ED59408352F635078CB1F10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_558C1A6A2C0A80F8A45B635078CBEB53" xlink:to="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_A58AC74D2ED59408352F635078CB1F10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_637E50A76D54145328FA635078CBC916" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_558C1A6A2C0A80F8A45B635078CBEB53" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_637E50A76D54145328FA635078CBC916" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9C61E8581DE207B535EA635078CBAC56" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_558C1A6A2C0A80F8A45B635078CBEB53" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9C61E8581DE207B535EA635078CBAC56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9F367E91DD7917896A7B635078CBC5DE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_A45204DE3AEABC7A2128635078C8D67A" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9F367E91DD7917896A7B635078CBC5DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_73BC2A8B0D7D8AF482FC635078CCAA78" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9F367E91DD7917896A7B635078CBC5DE" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_73BC2A8B0D7D8AF482FC635078CCAA78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_51BAE4ED3B9319B34D00635078CCEDA1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9F367E91DD7917896A7B635078CBC5DE" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_51BAE4ED3B9319B34D00635078CCEDA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_356A20061671E2E4AAEF635078CC7E48" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9F367E91DD7917896A7B635078CBC5DE" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_356A20061671E2E4AAEF635078CC7E48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_217632CF2FFD02D34260635078CC2D43" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9F367E91DD7917896A7B635078CBC5DE" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_217632CF2FFD02D34260635078CC2D43" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2328F81890C2CD31F34F635078D00AB3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_31FF26AB80DE33FEEFB6635078D029D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2328F81890C2CD31F34F635078D00AB3" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_31FF26AB80DE33FEEFB6635078D029D1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholders" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_90A23EB9ED5460C11540635078D277BE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_59CD4C462F198099C6B5635078D2F9A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_90A23EB9ED5460C11540635078D277BE" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_59CD4C462F198099C6B5635078D2F9A1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/Equity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_7BB22718EE9A2131123E633D2A83CC64" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8A5B4015AA3DB54D5EE3633D59A05008" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7BB22718EE9A2131123E633D2A83CC64" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8A5B4015AA3DB54D5EE3633D59A05008" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/EquityDividendsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_EFAEE0F37F8D02901D0A635078D40977" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_9AB9339C2DE78F573C85635078D40647" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_EFAEE0F37F8D02901D0A635078D40977" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_9AB9339C2DE78F573C85635078D40647" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/EquityPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_B2CAC75C14D9BB5FFBC1635078D7674F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_BBA8C7E20324BC2213F7635078D7A14C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_B2CAC75C14D9BB5FFBC1635078D7674F" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_BBA8C7E20324BC2213F7635078D7A14C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7FC141216C2ED3257027635078D7C999" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_BBA8C7E20324BC2213F7635078D7A14C" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7FC141216C2ED3257027635078D7C999" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4EE967E431B42EF83F9E635078D87155" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7FC141216C2ED3257027635078D7C999" xlink:to="loc_us-gaap_EquityComponentDomain_4EE967E431B42EF83F9E635078D87155" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_CB5A65ECE31102262D68635078D81D54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4EE967E431B42EF83F9E635078D87155" xlink:to="loc_us-gaap_CommonStockMember_CB5A65ECE31102262D68635078D81D54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_AE0D9C43AD7F4A42E454635078D8C6E2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_BBA8C7E20324BC2213F7635078D7A14C" xlink:to="loc_us-gaap_ClassOfStockLineItems_AE0D9C43AD7F4A42E454635078D8C6E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_A9FFBC1F7A40E008D33A635078D8B43B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_AE0D9C43AD7F4A42E454635078D8C6E2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_A9FFBC1F7A40E008D33A635078D8B43B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_E459F6F67A44AD16290E635078D856AE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_AE0D9C43AD7F4A42E454635078D8C6E2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_E459F6F67A44AD16290E635078D856AE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_DB845F1598FB60D37579633D2A89600A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsDeclaredTableTextBlock" xlink:label="loc_us-gaap_DividendsDeclaredTableTextBlock_E8509AA7F9048196CEFF634003F646C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_DB845F1598FB60D37579633D2A89600A" xlink:to="loc_us-gaap_DividendsDeclaredTableTextBlock_E8509AA7F9048196CEFF634003F646C7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_BA9F9399E4B45A4A8C85947620EB33E3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_84B364A2D5022BEC6EEE947620EB6697" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_BA9F9399E4B45A4A8C85947620EB33E3" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_84B364A2D5022BEC6EEE947620EB6697" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_76E24FAA064E7559B77594762301344A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_08820D7E77FB99D87C5294762301569A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_76E24FAA064E7559B77594762301344A" xlink:to="loc_us-gaap_ConcentrationRiskTable_08820D7E77FB99D87C5294762301569A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesByIndustryAxis" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis_DBD79DBEE99F081F1DDD94762301BFAA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_08820D7E77FB99D87C5294762301569A" xlink:to="loc_us-gaap_EquitySecuritiesByIndustryAxis_DBD79DBEE99F081F1DDD94762301BFAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_10BA5A1BA379B5B769B894762301DEDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_DBD79DBEE99F081F1DDD94762301BFAA" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_10BA5A1BA379B5B769B894762301DEDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialServicesSectorMember" xlink:label="loc_us-gaap_FinancialServicesSectorMember_C46FD2B47D4492A6556094762302859F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember_10BA5A1BA379B5B769B894762301DEDE" xlink:to="loc_us-gaap_FinancialServicesSectorMember_C46FD2B47D4492A6556094762302859F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_50D892AF020B7A3BF8AC9476230265BB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_08820D7E77FB99D87C5294762301569A" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_50D892AF020B7A3BF8AC9476230265BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:label="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_FB52200C400B928C19A094762302E303" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_50D892AF020B7A3BF8AC9476230265BB" xlink:to="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_FB52200C400B928C19A094762302E303" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_0927B8C5886FBFFAD90BA1BD73120170" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_8708D1DAD539164BC2D4A1BD73125636" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_0927B8C5886FBFFAD90BA1BD73120170" xlink:to="loc_us-gaap_DerivativeTable_8708D1DAD539164BC2D4A1BD73125636" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_E8FDC13E98C1686FA618A1BD73126304" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_8708D1DAD539164BC2D4A1BD73125636" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_E8FDC13E98C1686FA618A1BD73126304" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5C89839DCC2FF6BB946EA1BD73138BD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_E8FDC13E98C1686FA618A1BD73126304" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5C89839DCC2FF6BB946EA1BD73138BD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_7C4CC5F6C7C2EDE3DE54A1CD8BF32B77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5C89839DCC2FF6BB946EA1BD73138BD0" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_7C4CC5F6C7C2EDE3DE54A1CD8BF32B77" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LongtermInvestmentsMember" xlink:label="loc_pfe_LongtermInvestmentsMember_7470B66828EE361E2315A1BD73131727" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5C89839DCC2FF6BB946EA1BD73138BD0" xlink:to="loc_pfe_LongtermInvestmentsMember_7470B66828EE361E2315A1BD73131727" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMember" xlink:label="loc_us-gaap_LongTermDebtMember_D7ACEC1E0050420AD565A1BD7313643A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5C89839DCC2FF6BB946EA1BD73138BD0" xlink:to="loc_us-gaap_LongTermDebtMember_D7ACEC1E0050420AD565A1BD7313643A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_74E11EEDC99848508EBBA1BD7313D911" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_8708D1DAD539164BC2D4A1BD73125636" xlink:to="loc_us-gaap_DerivativeLineItems_74E11EEDC99848508EBBA1BD7313D911" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedAssetFairValueHedge" xlink:label="loc_us-gaap_HedgedAssetFairValueHedge_1A361EE3522CAF475DC0A1BD7313BECA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_74E11EEDC99848508EBBA1BD7313D911" xlink:to="loc_us-gaap_HedgedAssetFairValueHedge_1A361EE3522CAF475DC0A1BD7313BECA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_1777D36C16BCA3C6B74AA1BD7314B42D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_74E11EEDC99848508EBBA1BD7313D911" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_1777D36C16BCA3C6B74AA1BD7314B42D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease" xlink:label="loc_us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease_C412280A0378C803F792A1BD7314EBE0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_74E11EEDC99848508EBBA1BD7313D911" xlink:to="loc_us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease_C412280A0378C803F792A1BD7314EBE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_6927C0D37A761040FBB2A1BD7314C9D1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_74E11EEDC99848508EBBA1BD7313D911" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_6927C0D37A761040FBB2A1BD7314C9D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:label="loc_us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_F58240D0C30F9330037DA1BD731472EC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_74E11EEDC99848508EBBA1BD7313D911" xlink:to="loc_us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_F58240D0C30F9330037DA1BD731472EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:label="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_6B063FBE8673370C1CF0A1BD73147491" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_74E11EEDC99848508EBBA1BD7313D911" xlink:to="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_6B063FBE8673370C1CF0A1BD73147491" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_FD8F331801F4285BFB87947621832E07" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_498E68AB86E9E12C97DD9476218390B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_FD8F331801F4285BFB87947621832E07" xlink:to="loc_us-gaap_DerivativeTable_498E68AB86E9E12C97DD9476218390B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_F58F7A0BFCB3E3EFFA47947621847088" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_498E68AB86E9E12C97DD9476218390B2" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_F58F7A0BFCB3E3EFFA47947621847088" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_4BA6CF995377FDF7FD0994762184A2BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_F58F7A0BFCB3E3EFFA47947621847088" xlink:to="loc_us-gaap_HedgingRelationshipDomain_4BA6CF995377FDF7FD0994762184A2BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember" xlink:label="loc_us-gaap_CashFlowHedgingMember_C04C5910B95BB22A5FF894762184FD80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_4BA6CF995377FDF7FD0994762184A2BA" xlink:to="loc_us-gaap_CashFlowHedgingMember_C04C5910B95BB22A5FF894762184FD80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_4815BFD9F1FB5B90CA1E9476218A84E0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_4BA6CF995377FDF7FD0994762184A2BA" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_4815BFD9F1FB5B90CA1E9476218A84E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_73AFF03B74FFDFAB15529476218A4E6B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_498E68AB86E9E12C97DD9476218390B2" xlink:to="loc_us-gaap_HedgingDesignationAxis_73AFF03B74FFDFAB15529476218A4E6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_8CF9EDD6947FF95ECE879476218AB4A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_73AFF03B74FFDFAB15529476218A4E6B" xlink:to="loc_us-gaap_HedgingDesignationDomain_8CF9EDD6947FF95ECE879476218AB4A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_88E2889993E533C628E39476218AA9B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_8CF9EDD6947FF95ECE879476218AB4A1" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_88E2889993E533C628E39476218AA9B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_7709232A4B9C1FAFA1CA9476218B88FC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_8CF9EDD6947FF95ECE879476218AB4A1" xlink:to="loc_us-gaap_NondesignatedMember_7709232A4B9C1FAFA1CA9476218B88FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_F424131B3CEB677BDA8B9476218BFEEE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_498E68AB86E9E12C97DD9476218390B2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_F424131B3CEB677BDA8B9476218BFEEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_502FA921A815F1F56E8C9476218BF947" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_F424131B3CEB677BDA8B9476218BFEEE" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_502FA921A815F1F56E8C9476218BF947" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_68540A7994147B62B5689476218B796A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_502FA921A815F1F56E8C9476218BF947" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_68540A7994147B62B5689476218B796A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherIncomeDeductionsAndCostOfSalesMember" xlink:label="loc_pfe_OtherIncomeDeductionsAndCostOfSalesMember_6CEA8C5BF7C12D64ED099476218CA094" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_502FA921A815F1F56E8C9476218BF947" xlink:to="loc_pfe_OtherIncomeDeductionsAndCostOfSalesMember_6CEA8C5BF7C12D64ED099476218CA094" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_05FFD208E0A2A6A253449476218C3DCD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_498E68AB86E9E12C97DD9476218390B2" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_05FFD208E0A2A6A253449476218C3DCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_350E0EA09C54774A23009476218C452E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_05FFD208E0A2A6A253449476218C3DCD" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_350E0EA09C54774A23009476218C452E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_060D2016ADB2C92F7BBF9476218C3337" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_350E0EA09C54774A23009476218C452E" xlink:to="loc_us-gaap_ForeignExchangeContractMember_060D2016ADB2C92F7BBF9476218C3337" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember" xlink:label="loc_us-gaap_InterestRateContractMember_3B80C00AE4B6B4480CE19476218DED6D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_350E0EA09C54774A23009476218C452E" xlink:to="loc_us-gaap_InterestRateContractMember_3B80C00AE4B6B4480CE19476218DED6D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:label="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_F28D0B956AB3743B3E579476218DFF4B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_350E0EA09C54774A23009476218C452E" xlink:to="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_F28D0B956AB3743B3E579476218DFF4B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ForeignCurrencyLongTermDebtMember" xlink:label="loc_pfe_ForeignCurrencyLongTermDebtMember_4761DD4BA562EF2598C29476218D7AAE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_350E0EA09C54774A23009476218C452E" xlink:to="loc_pfe_ForeignCurrencyLongTermDebtMember_4761DD4BA562EF2598C29476218D7AAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_498E68AB86E9E12C97DD9476218390B2" xlink:to="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_D93016AAF3D3A7AD5FBC9476218DE611" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_D93016AAF3D3A7AD5FBC9476218DE611" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_4EF126ED566AE4369DD49476218DFF22" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_4EF126ED566AE4369DD49476218DFF22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_74093AA0910EC4223FFB9476218E657D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_74093AA0910EC4223FFB9476218E657D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_5B0D08C094FF8ED47D629476218EFC45" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_5B0D08C094FF8ED47D629476218EFC45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_D12258B45456B356F7BD9476218EDF42" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_D12258B45456B356F7BD9476218EDF42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_4A6B671B56CAC4AB38FB9476218EB8C5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_4A6B671B56CAC4AB38FB9476218EB8C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_7D31C2FF8B30092ED3749476218E6789" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_7D31C2FF8B30092ED3749476218E6789" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_D0116DAE828D959CB2799476218EE64C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_D0116DAE828D959CB2799476218EE64C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_B648B6771E498CAA89219476218FB32E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_B648B6771E498CAA89219476218FB32E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_9C0545DD5C15574507C29476218FB081" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_9C0545DD5C15574507C29476218FB081" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_DCD3EAB805D49F8AD3579476218F89BE" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_DCD3EAB805D49F8AD3579476218F89BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_49644F7EE74FAAD00ECD9476218F00C2" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_49644F7EE74FAAD00ECD9476218F00C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_312F42110A8A60573FA39476218F6175" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_312F42110A8A60573FA39476218F6175" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_2295A4E4B36D2982DEBE9476218F64A2" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_2295A4E4B36D2982DEBE9476218F64A2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_F8E168276EAAA4C99E9A94762190D180" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_F8E168276EAAA4C99E9A94762190D180" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_64EEDA03A8327FBBA3B3947621901730" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_49FE11D00C5981BCDBDA9476218D7CF6" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_64EEDA03A8327FBBA3B3947621901730" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_8FBE1C60D85DE534DB436EB03934FBA9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_3391288BDE6468485C586EB03934F338" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_8FBE1C60D85DE534DB436EB03934FBA9" xlink:to="loc_us-gaap_DerivativeTable_3391288BDE6468485C586EB03934F338" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_7F15C57EC936A259F5F56EB039341B74" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_3391288BDE6468485C586EB03934F338" xlink:to="loc_us-gaap_HedgingDesignationAxis_7F15C57EC936A259F5F56EB039341B74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_DE57B5EBB559184283F46EB03934D5E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_7F15C57EC936A259F5F56EB039341B74" xlink:to="loc_us-gaap_HedgingDesignationDomain_DE57B5EBB559184283F46EB03934D5E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_AEA9B1E5C81A46CF66806EB039348DD7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_DE57B5EBB559184283F46EB03934D5E0" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_AEA9B1E5C81A46CF66806EB039348DD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_C67F16783BBD4D21CA526EB0393547FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_3391288BDE6468485C586EB03934F338" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_C67F16783BBD4D21CA526EB0393547FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_032BD08B3D5D46A5AC5A6EB039356736" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_C67F16783BBD4D21CA526EB0393547FF" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_032BD08B3D5D46A5AC5A6EB039356736" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_920EE1AAAC01F47674AE6EB03935F9FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_032BD08B3D5D46A5AC5A6EB039356736" xlink:to="loc_us-gaap_CostOfSalesMember_920EE1AAAC01F47674AE6EB03935F9FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_731ECF566CED49152C056EB039355869" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_3391288BDE6468485C586EB03934F338" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_731ECF566CED49152C056EB039355869" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_57F2079C429FD53B8C746EB039366E36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_731ECF566CED49152C056EB039355869" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_57F2079C429FD53B8C746EB039366E36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_E885BB8F3CA46A597A066EB039360673" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_57F2079C429FD53B8C746EB039366E36" xlink:to="loc_us-gaap_ForeignExchangeContractMember_E885BB8F3CA46A597A066EB039360673" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ForeignCurrencyLongTermDebtMember" xlink:label="loc_pfe_ForeignCurrencyLongTermDebtMember_DD60DEAD2744D98E8FF46EB03936FD05" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_57F2079C429FD53B8C746EB039366E36" xlink:to="loc_pfe_ForeignCurrencyLongTermDebtMember_DD60DEAD2744D98E8FF46EB03936FD05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_E30C7A1C5CF68C29FC7C6EB03936FCCC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_3391288BDE6468485C586EB03934F338" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_E30C7A1C5CF68C29FC7C6EB03936FCCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5FD065571CBA7560A1AA6EB03937BE3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E30C7A1C5CF68C29FC7C6EB03936FCCC" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5FD065571CBA7560A1AA6EB03937BE3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_AD6598315F9322DBAC2D6EB03937A0F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5FD065571CBA7560A1AA6EB03937BE3E" xlink:to="loc_us-gaap_UnsecuredDebtMember_AD6598315F9322DBAC2D6EB03937A0F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_9917D736050C0AF351AA6EB03937F6AD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_3391288BDE6468485C586EB03934F338" xlink:to="loc_us-gaap_DerivativeLineItems_9917D736050C0AF351AA6EB03937F6AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_52703259133BF0061E1F6EB03937D96C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9917D736050C0AF351AA6EB03937F6AD" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_52703259133BF0061E1F6EB03937D96C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_37F69DCF9EAD966F73096EB0393D2610" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9917D736050C0AF351AA6EB03937F6AD" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_37F69DCF9EAD966F73096EB0393D2610" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_7645262DC5A670773B516EB0393DD88C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9917D736050C0AF351AA6EB03937F6AD" xlink:to="loc_us-gaap_LongTermDebt_7645262DC5A670773B516EB0393DD88C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_056F08FD56DC5BE00E9094761F1200F5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_98BF055BE63E0CAC090A94761F125289" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_056F08FD56DC5BE00E9094761F1200F5" xlink:to="loc_us-gaap_DerivativeTable_98BF055BE63E0CAC090A94761F125289" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_D59B7E88C686FCA2C5E094761F136170" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_98BF055BE63E0CAC090A94761F125289" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_D59B7E88C686FCA2C5E094761F136170" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_DD1956906A13AC40DBB294761F13F6E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_D59B7E88C686FCA2C5E094761F136170" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_DD1956906A13AC40DBB294761F13F6E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_E57BCA07C23B920D6BDF94761F13C49F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_DD1956906A13AC40DBB294761F13F6E1" xlink:to="loc_us-gaap_ForeignExchangeContractMember_E57BCA07C23B920D6BDF94761F13C49F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_8293004AD726357E64A094761F133F66" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_98BF055BE63E0CAC090A94761F125289" xlink:to="loc_us-gaap_DerivativeLineItems_8293004AD726357E64A094761F133F66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTermOfContract" xlink:label="loc_us-gaap_DerivativeTermOfContract_5762C75B3300E1EB1AC494761F142B92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_8293004AD726357E64A094761F133F66" xlink:to="loc_us-gaap_DerivativeTermOfContract_5762C75B3300E1EB1AC494761F142B92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNetLiabilityPositionAggregateFairValue" xlink:label="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_041EB4B08FC7CB84B27894761F148D1A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_8293004AD726357E64A094761F133F66" xlink:to="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_041EB4B08FC7CB84B27894761F148D1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_BD088DF223917C973D3D94761F142AFA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_8293004AD726357E64A094761F133F66" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_BD088DF223917C973D3D94761F142AFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuritiesReceivedAsCollateral" xlink:label="loc_us-gaap_SecuritiesReceivedAsCollateral_EF6A14D8A7DC65EA8BD894761F14B1A3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_8293004AD726357E64A094761F133F66" xlink:to="loc_us-gaap_SecuritiesReceivedAsCollateral_EF6A14D8A7DC65EA8BD894761F14B1A3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_B3DAE578E489CCBC856A94761EA35B1E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_6AB56A70CFF065F077A594761EA3EDEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_B3DAE578E489CCBC856A94761EA35B1E" xlink:to="loc_us-gaap_DerivativeTable_6AB56A70CFF065F077A594761EA3EDEC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_HedgedItemAxis" xlink:label="loc_pfe_HedgedItemAxis_B4D79A00F602BDA6D15A94761EA42A17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_6AB56A70CFF065F077A594761EA3EDEC" xlink:to="loc_pfe_HedgedItemAxis_B4D79A00F602BDA6D15A94761EA42A17" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_HedgedItemDomain" xlink:label="loc_pfe_HedgedItemDomain_BE06C13024F26F33D7FE94761EA4376F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_HedgedItemAxis_B4D79A00F602BDA6D15A94761EA42A17" xlink:to="loc_pfe_HedgedItemDomain_BE06C13024F26F33D7FE94761EA4376F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_4CCC75A178B51F06392A94761EA4B579" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_HedgedItemDomain_BE06C13024F26F33D7FE94761EA4376F" xlink:to="loc_us-gaap_SalesMember_4CCC75A178B51F06392A94761EA4B579" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_51D26D800027A17D61BA94761EA40310" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_6AB56A70CFF065F077A594761EA3EDEC" xlink:to="loc_us-gaap_HedgingDesignationAxis_51D26D800027A17D61BA94761EA40310" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_973BBD5D2C12393AE5A494761EA44F79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_51D26D800027A17D61BA94761EA40310" xlink:to="loc_us-gaap_HedgingDesignationDomain_973BBD5D2C12393AE5A494761EA44F79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_01DBAF3D312D42EDD90D94761EA590E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_973BBD5D2C12393AE5A494761EA44F79" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_01DBAF3D312D42EDD90D94761EA590E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_EA2B7541E1C03C1D6AE694761EA5E590" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_973BBD5D2C12393AE5A494761EA44F79" xlink:to="loc_us-gaap_NondesignatedMember_EA2B7541E1C03C1D6AE694761EA5E590" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_CCE4618FA60D9B9D617494761EA538D8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_6AB56A70CFF065F077A594761EA3EDEC" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_CCE4618FA60D9B9D617494761EA538D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_C0DFB171C3ED44BDFD1C94761EA5E11B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_CCE4618FA60D9B9D617494761EA538D8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_C0DFB171C3ED44BDFD1C94761EA5E11B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_B471D0C0D9EDB5DEF79F94761EA69B27" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_C0DFB171C3ED44BDFD1C94761EA5E11B" xlink:to="loc_us-gaap_ForeignExchangeContractMember_B471D0C0D9EDB5DEF79F94761EA69B27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember" xlink:label="loc_us-gaap_InterestRateContractMember_EC6F67CF99092946F84494761EA6241A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_C0DFB171C3ED44BDFD1C94761EA5E11B" xlink:to="loc_us-gaap_InterestRateContractMember_EC6F67CF99092946F84494761EA6241A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_EC3699E4A1D380D01F9794761EA6AEAE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_6AB56A70CFF065F077A594761EA3EDEC" xlink:to="loc_us-gaap_DerivativeLineItems_EC3699E4A1D380D01F9794761EA6AEAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_FB32BD0BD5996A6676FC94761EA648B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_EC3699E4A1D380D01F9794761EA6AEAE" xlink:to="loc_us-gaap_DerivativeNotionalAmount_FB32BD0BD5996A6676FC94761EA648B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets" xlink:label="loc_us-gaap_DerivativeAssets_011A482D637FC08FCA2D94761EA7EB42" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_EC3699E4A1D380D01F9794761EA6AEAE" xlink:to="loc_us-gaap_DerivativeAssets_011A482D637FC08FCA2D94761EA7EB42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_638B713D4DB36466188794761EA7DABE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_EC3699E4A1D380D01F9794761EA6AEAE" xlink:to="loc_us-gaap_DerivativeLiabilities_638B713D4DB36466188794761EA7DABE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_B1E1B8D415F833813B74B09F331B0ACC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_06BF50534E31840A3171B09F331B0756" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_B1E1B8D415F833813B74B09F331B0ACC" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_06BF50534E31840A3171B09F331B0756" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_71F7845C116B3F47FDF0B09F331B1A4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_06BF50534E31840A3171B09F331B0756" xlink:to="loc_us-gaap_FinancialInstrumentAxis_71F7845C116B3F47FDF0B09F331B1A4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9A2A27622858EAF73841B09F331C5035" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_71F7845C116B3F47FDF0B09F331B1A4C" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9A2A27622858EAF73841B09F331C5035" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_B73BD16295B28013420AB09F331C43C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9A2A27622858EAF73841B09F331C5035" xlink:to="loc_us-gaap_MoneyMarketFundsMember_B73BD16295B28013420AB09F331C43C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_B5A8D6B5A9D5BF77C1A1B09F331C7F97" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9A2A27622858EAF73841B09F331C5035" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_B5A8D6B5A9D5BF77C1A1B09F331C7F97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_721465EB5548DC1455E0B09F331C952B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9A2A27622858EAF73841B09F331C5035" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_721465EB5548DC1455E0B09F331C952B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_BA894BE51924BBB795D9B09F331D3A10" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9A2A27622858EAF73841B09F331C5035" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_BA894BE51924BBB795D9B09F331D3A10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_59D6600D57BDAF22C8CCB09F331DBDC6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_06BF50534E31840A3171B09F331B0756" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_59D6600D57BDAF22C8CCB09F331DBDC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DF616621017ECF1E94E4B09F331D1804" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_59D6600D57BDAF22C8CCB09F331DBDC6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DF616621017ECF1E94E4B09F331D1804" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_66046376D20AAFD10E3AB09F331DF0CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DF616621017ECF1E94E4B09F331D1804" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_66046376D20AAFD10E3AB09F331DF0CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_CE25508B232D2B7DF75FB09F331D22B4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DF616621017ECF1E94E4B09F331D1804" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_CE25508B232D2B7DF75FB09F331D22B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_64AFD1F3F300F730B0FBB09F331D43C9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_06BF50534E31840A3171B09F331B0756" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_64AFD1F3F300F730B0FBB09F331D43C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8F302B4D9E7D5AEE6DCCB09F331EE1C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_64AFD1F3F300F730B0FBB09F331D43C9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8F302B4D9E7D5AEE6DCCB09F331EE1C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_B489E4D7121F2C418AD8B09F331E1AFB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8F302B4D9E7D5AEE6DCCB09F331EE1C1" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_B489E4D7121F2C418AD8B09F331E1AFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_22620DA5E0C1A9D40DD5B09F331E21E1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8F302B4D9E7D5AEE6DCCB09F331EE1C1" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_22620DA5E0C1A9D40DD5B09F331E21E1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LongtermInvestmentsMember" xlink:label="loc_pfe_LongtermInvestmentsMember_CE17EED2495429FBF8DEB09F331E81FA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8F302B4D9E7D5AEE6DCCB09F331EE1C1" xlink:to="loc_pfe_LongtermInvestmentsMember_CE17EED2495429FBF8DEB09F331E81FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_1E9A48CA94E19E470629B09F331F4828" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8F302B4D9E7D5AEE6DCCB09F331EE1C1" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_1E9A48CA94E19E470629B09F331F4828" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_52C64DEFD1F022B5FB21B09F331FE9F4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8F302B4D9E7D5AEE6DCCB09F331EE1C1" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_52C64DEFD1F022B5FB21B09F331FE9F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_478384D142F3C5AF41E3B09F331F4F58" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8F302B4D9E7D5AEE6DCCB09F331EE1C1" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_478384D142F3C5AF41E3B09F331F4F58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_BD6AF62695C20549DA3CB09F331FA73D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_06BF50534E31840A3171B09F331B0756" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_BD6AF62695C20549DA3CB09F331FA73D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5AFAFE1D63CA48D3F04BB09F331FEB64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_BD6AF62695C20549DA3CB09F331FA73D" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5AFAFE1D63CA48D3F04BB09F331FEB64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_75D2431F2988E87134A4B09F3320BFDD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5AFAFE1D63CA48D3F04BB09F331FEB64" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_75D2431F2988E87134A4B09F3320BFDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_30A45767127EC4A992CCB09F33201285" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_06BF50534E31840A3171B09F331B0756" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_30A45767127EC4A992CCB09F33201285" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_C3C558F5FCDF1A4A2117B09F33200018" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_30A45767127EC4A992CCB09F33201285" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_C3C558F5FCDF1A4A2117B09F33200018" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember" xlink:label="loc_us-gaap_InterestRateContractMember_CFAB896C9D83A6824B8CB09F3320A328" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_C3C558F5FCDF1A4A2117B09F33200018" xlink:to="loc_us-gaap_InterestRateContractMember_CFAB896C9D83A6824B8CB09F3320A328" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_45645412FAD4145EFFBDB09F3321D1F2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_C3C558F5FCDF1A4A2117B09F33200018" xlink:to="loc_us-gaap_ForeignExchangeContractMember_45645412FAD4145EFFBDB09F3321D1F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43BD043E8C0F0F942290B09F33269118" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_06BF50534E31840A3171B09F331B0756" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43BD043E8C0F0F942290B09F33269118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_8D65BAE8481894BAB827B09F332605C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43BD043E8C0F0F942290B09F33269118" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_8D65BAE8481894BAB827B09F332605C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6F40E84ABBC429DB007BB09F3326C131" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43BD043E8C0F0F942290B09F33269118" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6F40E84ABBC429DB007BB09F3326C131" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" xlink:label="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_1D5FF53A60602A71A2E3B09F33261E74" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43BD043E8C0F0F942290B09F33269118" xlink:to="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_1D5FF53A60602A71A2E3B09F33261E74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsCurrent" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_9092E0C133DA413731DAB09F33275449" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43BD043E8C0F0F942290B09F33269118" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_9092E0C133DA413731DAB09F33275449" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" xlink:label="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_48ED3BDDD833AE9D8C79B09F3327B8A5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43BD043E8C0F0F942290B09F33269118" xlink:to="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_48ED3BDDD833AE9D8C79B09F3327B8A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_8E0F8B1DCA2CD0E55D3AB09F3327BF95" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43BD043E8C0F0F942290B09F33269118" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_8E0F8B1DCA2CD0E55D3AB09F3327BF95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:label="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_2FEF5AFE42FB6328EE17B09F33278393" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43BD043E8C0F0F942290B09F33269118" xlink:to="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_2FEF5AFE42FB6328EE17B09F33278393" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8D6270BE6A2D4054670CB09F3327FFA1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43BD043E8C0F0F942290B09F33269118" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8D6270BE6A2D4054670CB09F3327FFA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_7400EC951C0142AF5B48B09F33274228" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43BD043E8C0F0F942290B09F33269118" xlink:to="loc_us-gaap_Assets_7400EC951C0142AF5B48B09F33274228" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_207606263E5EDC0AE24FB09F332815D3" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43BD043E8C0F0F942290B09F33269118" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_207606263E5EDC0AE24FB09F332815D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_B1DD6372639F84D0D90CB09F33287589" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43BD043E8C0F0F942290B09F33269118" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_B1DD6372639F84D0D90CB09F33287589" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_76F2D410F093A6A8CA33B09F33286A4A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43BD043E8C0F0F942290B09F33269118" xlink:to="loc_us-gaap_DerivativeLiabilities_76F2D410F093A6A8CA33B09F33286A4A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_B9E9D518BB81E35001A06EAB464B245F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E6BDB9FF2A01F07DB7716EAB464B6C12" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_B9E9D518BB81E35001A06EAB464B245F" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E6BDB9FF2A01F07DB7716EAB464B6C12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_003E6CBD65370A2EE6946EACFD27DED9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E6BDB9FF2A01F07DB7716EAB464B6C12" xlink:to="loc_srt_ConsolidatedEntitiesAxis_003E6CBD65370A2EE6946EACFD27DED9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_371724083FCE110136536EACFEE80FE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_003E6CBD65370A2EE6946EACFD27DED9" xlink:to="loc_srt_ConsolidatedEntitiesDomain_371724083FCE110136536EACFEE80FE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_2BC9A5C9597D78ADFB896EACFDE2AC9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_371724083FCE110136536EACFEE80FE0" xlink:to="loc_srt_SubsidiariesMember_2BC9A5C9597D78ADFB896EACFDE2AC9E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_BED4609DEDAE4E2EDD0D6EACFBB2FC16" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E6BDB9FF2A01F07DB7716EAB464B6C12" xlink:to="loc_dei_LegalEntityAxis_BED4609DEDAE4E2EDD0D6EACFBB2FC16" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_A7449B62393B07581D9C6EACFDCAE2B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_BED4609DEDAE4E2EDD0D6EACFBB2FC16" xlink:to="loc_dei_EntityDomain_A7449B62393B07581D9C6EACFDCAE2B8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnIncMember" xlink:label="loc_pfe_UpjohnIncMember_C4E94FDB38072F2ECC0B6EACFCA194F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_A7449B62393B07581D9C6EACFDCAE2B8" xlink:to="loc_pfe_UpjohnIncMember_C4E94FDB38072F2ECC0B6EACFCA194F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_67212B706D128DE7B74F6EAB464B1F5D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E6BDB9FF2A01F07DB7716EAB464B6C12" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_67212B706D128DE7B74F6EAB464B1F5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2BED64E2771277B901F46EAB464CF60E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_67212B706D128DE7B74F6EAB464B1F5D" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2BED64E2771277B901F46EAB464CF60E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3C4AD60C881F2AEB60CD6EAB464C8BE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2BED64E2771277B901F46EAB464CF60E" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_3C4AD60C881F2AEB60CD6EAB464C8BE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9903E88AE2FA7BF11F9F6EAB464E544F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E6BDB9FF2A01F07DB7716EAB464B6C12" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9903E88AE2FA7BF11F9F6EAB464E544F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract" xlink:label="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_F716BE1840D54B7D3ACD6EAB464ECB71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9903E88AE2FA7BF11F9F6EAB464E544F" xlink:to="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_F716BE1840D54B7D3ACD6EAB464ECB71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0B2528D24304456972976EAB464F907E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_F716BE1840D54B7D3ACD6EAB464ECB71" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0B2528D24304456972976EAB464F907E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EquitySecuritiesFVNIRestrictedNoncurrent" xlink:label="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_AAEC6033D0DE0185FE4C6EAB464F72E6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_F716BE1840D54B7D3ACD6EAB464ECB71" xlink:to="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_AAEC6033D0DE0185FE4C6EAB464F72E6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_8C17A6977F9E70248C859476211EA798" xlink:type="locator" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" xlink:label="loc_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount_10B04D9679A341C65E569476211E66AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_8C17A6977F9E70248C859476211EA798" xlink:to="loc_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount_10B04D9679A341C65E569476211E66AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_D91CA10A06DEA51E83629476211E7F04" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_8C17A6977F9E70248C859476211EA798" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_D91CA10A06DEA51E83629476211E7F04" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_02F13602D296A3E51B28B09F32FA21E0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99237E98C02D62F264B0B09F32FAB58D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_02F13602D296A3E51B28B09F32FA21E0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99237E98C02D62F264B0B09F32FAB58D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_EBDD0A07EA4E8209BB99B09F32FADAE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99237E98C02D62F264B0B09F32FAB58D" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_EBDD0A07EA4E8209BB99B09F32FADAE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_33F59BB21BF8842AB6B7B09F32FBE610" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_EBDD0A07EA4E8209BB99B09F32FADAE6" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_33F59BB21BF8842AB6B7B09F32FBE610" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_A025319F0F29ABD90C8EB09F32FBF698" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_33F59BB21BF8842AB6B7B09F32FBE610" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_A025319F0F29ABD90C8EB09F32FBF698" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_61020D3F10543EBE6082B09F32FBFEE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_A025319F0F29ABD90C8EB09F32FBF698" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_61020D3F10543EBE6082B09F32FBFEE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_82C20E063D6F9F0649ECB09F32FB6056" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_A025319F0F29ABD90C8EB09F32FBF698" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_82C20E063D6F9F0649ECB09F32FB6056" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_101EC425FAFB62753269B09F32FC4DC7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99237E98C02D62F264B0B09F32FAB58D" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_101EC425FAFB62753269B09F32FC4DC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7113C98E3BD9BEE2ED16B09F32FC53C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_101EC425FAFB62753269B09F32FC4DC7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7113C98E3BD9BEE2ED16B09F32FC53C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_E42DD64A8C88B4AD49FDB09F32FCDC88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7113C98E3BD9BEE2ED16B09F32FC53C1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_E42DD64A8C88B4AD49FDB09F32FCDC88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A53BDA01BC4CF15E82DDB09F32FCA236" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99237E98C02D62F264B0B09F32FAB58D" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A53BDA01BC4CF15E82DDB09F32FCA236" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_56DD2060351A83828E6FB09F32FDA3F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A53BDA01BC4CF15E82DDB09F32FCA236" xlink:to="loc_us-gaap_LongTermDebtFairValue_56DD2060351A83828E6FB09F32FDA3F6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_8E5E30E550D312DB37EE94761F4C3B99" xlink:type="locator" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_CA2B5B8C854A95873A9994761F4CF09B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_8E5E30E550D312DB37EE94761F4C3B99" xlink:to="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_CA2B5B8C854A95873A9994761F4CF09B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_38CCFB635A8D81B992C594761F4CD00B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_CA2B5B8C854A95873A9994761F4CF09B" xlink:to="loc_us-gaap_FinancialInstrumentAxis_38CCFB635A8D81B992C594761F4CD00B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_00FF3560890F02830B2894761F4D0323" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_38CCFB635A8D81B992C594761F4CD00B" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_00FF3560890F02830B2894761F4D0323" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_BE02F085B56FFF030EB394761F4DF691" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_00FF3560890F02830B2894761F4D0323" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_BE02F085B56FFF030EB394761F4DF691" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9AEB7026D69ACE56B16494761F4D94C8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_00FF3560890F02830B2894761F4D0323" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9AEB7026D69ACE56B16494761F4D94C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7102A575EEDD1C168CD394761F4DB00E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_00FF3560890F02830B2894761F4D0323" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7102A575EEDD1C168CD394761F4DB00E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BankTimeDepositsMember" xlink:label="loc_us-gaap_BankTimeDepositsMember_251A0F3B3A689BB4743594761F4D6894" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_00FF3560890F02830B2894761F4D0323" xlink:to="loc_us-gaap_BankTimeDepositsMember_251A0F3B3A689BB4743594761F4D6894" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_CA2B5B8C854A95873A9994761F4CF09B" xlink:to="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_A15AAFCBB2C943A17EF194761F4E4DCB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_A15AAFCBB2C943A17EF194761F4E4DCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C8D14F0993497214C47794761F4E1B17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_A15AAFCBB2C943A17EF194761F4E4DCB" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C8D14F0993497214C47794761F4E1B17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0951A0B54173DA995D8E94761F4ED141" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_A15AAFCBB2C943A17EF194761F4E4DCB" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0951A0B54173DA995D8E94761F4ED141" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_12B80066C35E3C22CF5C94761F4EB945" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_A15AAFCBB2C943A17EF194761F4E4DCB" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_12B80066C35E3C22CF5C94761F4EB945" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9CABC449D39B31F6D9A394761F4F38A6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_A15AAFCBB2C943A17EF194761F4E4DCB" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9CABC449D39B31F6D9A394761F4F38A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_22851EE4F9370F5AD59194761F4F3EEF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_22851EE4F9370F5AD59194761F4F3EEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_513C236D194B7A0120CE94761F4FB538" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_22851EE4F9370F5AD59194761F4F3EEF" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_513C236D194B7A0120CE94761F4FB538" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5D2DDF1307FE3E24083694761F4F0514" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_22851EE4F9370F5AD59194761F4F3EEF" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5D2DDF1307FE3E24083694761F4F0514" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:label="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_D66822D794324A7406FD94761F50E1FB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_22851EE4F9370F5AD59194761F4F3EEF" xlink:to="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_D66822D794324A7406FD94761F50E1FB" xlink:type="arc" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_22851EE4F9370F5AD59194761F4F3EEF" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9CABC449D39B31F6D9A394761F4F38A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_CD5834F82D640805A1ED94761F5039FC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_CD5834F82D640805A1ED94761F5039FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:label="loc_us-gaap_HeldToMaturitySecurities_EBCC35C4AC1653C1E04E94761F50D0AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_CD5834F82D640805A1ED94761F5039FC" xlink:to="loc_us-gaap_HeldToMaturitySecurities_EBCC35C4AC1653C1E04E94761F50D0AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_FAAEC7A88E1B0BD55A4E94761F501E23" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_CD5834F82D640805A1ED94761F5039FC" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_FAAEC7A88E1B0BD55A4E94761F501E23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_1795AB6232708D4AB47094761F519548" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_CD5834F82D640805A1ED94761F5039FC" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_1795AB6232708D4AB47094761F519548" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_A51DBD075CEC4FBD43F894761F51943C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_CD5834F82D640805A1ED94761F5039FC" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_A51DBD075CEC4FBD43F894761F51943C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_AAD0FA99EF44D635BACB94761F51E3E6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_AAD0FA99EF44D635BACB94761F51E3E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_C895CF891DC552DE30C194761F518E66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_AAD0FA99EF44D635BACB94761F51E3E6" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_C895CF891DC552DE30C194761F518E66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_F32B0F48FDD8D6674A7894761F51A252" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_AAD0FA99EF44D635BACB94761F51E3E6" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_F32B0F48FDD8D6674A7894761F51A252" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:label="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_2EA64BCA1E6083D3249194761F5139A6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_AAD0FA99EF44D635BACB94761F51E3E6" xlink:to="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_2EA64BCA1E6083D3249194761F5139A6" xlink:type="arc" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_AAD0FA99EF44D635BACB94761F51E3E6" xlink:to="loc_us-gaap_HeldToMaturitySecurities_EBCC35C4AC1653C1E04E94761F50D0AD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtSecuritiesAmortizedCostBasis" xlink:label="loc_pfe_DebtSecuritiesAmortizedCostBasis_2156A1DF20DC07D5B04794761F52C06B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:to="loc_pfe_DebtSecuritiesAmortizedCostBasis_2156A1DF20DC07D5B04794761F52C06B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_C271110664193F20B60094761F5287F4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_C271110664193F20B60094761F5287F4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_F25681933BEA601401B594761F521BBF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_F25681933BEA601401B594761F521BBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_080079DBCF14861F742C94761F52B98F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_080079DBCF14861F742C94761F52B98F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" xlink:label="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_251326BA10AB7EC9EF8694761F529E59" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:to="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_251326BA10AB7EC9EF8694761F529E59" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" xlink:label="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_9ED6FA00BE74C4B27C6C94761F5338A0" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:to="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_9ED6FA00BE74C4B27C6C94761F5338A0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" xlink:label="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_72931B06A6D2B52AE25D94761F53E9E8" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_D872DB63BF4C5CA3A16294761F4DE0AF" xlink:to="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_72931B06A6D2B52AE25D94761F53E9E8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_CA8DAE0A8561AE3EDF85748065084966" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_95BFB6E2830EEDB231887480650823E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_CA8DAE0A8561AE3EDF85748065084966" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_95BFB6E2830EEDB231887480650823E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_75556FB21B1B4563989D748065097D08" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_CA8DAE0A8561AE3EDF85748065084966" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_75556FB21B1B4563989D748065097D08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_97DA8890C2936930B27C748065091F82" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_CA8DAE0A8561AE3EDF85748065084966" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_97DA8890C2936930B27C748065091F82" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_32835EDB36357C75D0E9B09F32860C59" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_3BEF202520524015A9A4B09F3286FEDA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_32835EDB36357C75D0E9B09F32860C59" xlink:to="loc_us-gaap_DebtInstrumentTable_3BEF202520524015A9A4B09F3286FEDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_2B6888A76EBA57574CB3B0A7E1DDE6A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3BEF202520524015A9A4B09F3286FEDA" xlink:to="loc_srt_ConsolidatedEntitiesAxis_2B6888A76EBA57574CB3B0A7E1DDE6A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_D2BC11A99F5C69AE6F9FB0A7E1E257E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_2B6888A76EBA57574CB3B0A7E1DDE6A9" xlink:to="loc_srt_ConsolidatedEntitiesDomain_D2BC11A99F5C69AE6F9FB0A7E1E257E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_FEEE32E6F2ED91986353B0A7E2162B55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_D2BC11A99F5C69AE6F9FB0A7E1E257E0" xlink:to="loc_srt_SubsidiariesMember_FEEE32E6F2ED91986353B0A7E2162B55" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_645FD52B9691F3F62C84B0A7E1A277E7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3BEF202520524015A9A4B09F3286FEDA" xlink:to="loc_dei_LegalEntityAxis_645FD52B9691F3F62C84B0A7E1A277E7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_14E3A11A7D7AA5CAA3F1B0A7E1AA4DAD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_645FD52B9691F3F62C84B0A7E1A277E7" xlink:to="loc_dei_EntityDomain_14E3A11A7D7AA5CAA3F1B0A7E1AA4DAD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnIncMember" xlink:label="loc_pfe_UpjohnIncMember_EE9A40EBAF9A1B4FC73EB0A7E2323674" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_14E3A11A7D7AA5CAA3F1B0A7E1AA4DAD" xlink:to="loc_pfe_UpjohnIncMember_EE9A40EBAF9A1B4FC73EB0A7E2323674" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_99AD09E756DDBBA92003B09F32864E03" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3BEF202520524015A9A4B09F3286FEDA" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_99AD09E756DDBBA92003B09F32864E03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8B2F3425D7A0E426F4D0B09F3287F881" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_99AD09E756DDBBA92003B09F32864E03" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8B2F3425D7A0E426F4D0B09F3287F881" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_F9B051A223449E9B6708B09F3287551D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8B2F3425D7A0E426F4D0B09F3287F881" xlink:to="loc_us-gaap_UnsecuredDebtMember_F9B051A223449E9B6708B09F3287551D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_35410FF488BE88FCB5D0B09F328754BC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3BEF202520524015A9A4B09F3286FEDA" xlink:to="loc_us-gaap_DebtInstrumentLineItems_35410FF488BE88FCB5D0B09F328754BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_9D5869B05A31218D7980B09F3287DA5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_35410FF488BE88FCB5D0B09F328754BC" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_9D5869B05A31218D7980B09F3287DA5D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_CE2CF810439E57969D1FB09F32884F2C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_35410FF488BE88FCB5D0B09F328754BC" xlink:to="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_CE2CF810439E57969D1FB09F32884F2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_B8FEDB2C1399189CC9C1B09F3288FC4B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_35410FF488BE88FCB5D0B09F328754BC" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_B8FEDB2C1399189CC9C1B09F3288FC4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaap_OtherLongTermDebt_A911E18CD3F8A66DA221B09F32889456" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_35410FF488BE88FCB5D0B09F328754BC" xlink:to="loc_us-gaap_OtherLongTermDebt_A911E18CD3F8A66DA221B09F32889456" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_A4DAEAD4D19FBBA76AC3B09F328847D4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_35410FF488BE88FCB5D0B09F328754BC" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_A4DAEAD4D19FBBA76AC3B09F328847D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_DE6893F339C088789C50B09F32883157" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_35410FF488BE88FCB5D0B09F328754BC" xlink:to="loc_us-gaap_LongTermDebtCurrent_DE6893F339C088789C50B09F32883157" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1F0E893B2391770404FDB0A7E16FE836" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_35410FF488BE88FCB5D0B09F328754BC" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1F0E893B2391770404FDB0A7E16FE836" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_DCCBFA9504F5004BF45F628A0BC33FE1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_5162404E95591A48EFA5628A0BC4DCFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_DCCBFA9504F5004BF45F628A0BC33FE1" xlink:to="loc_us-gaap_DebtInstrumentTable_5162404E95591A48EFA5628A0BC4DCFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1C58069A23CA822EB2B5628A0BC48C91" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5162404E95591A48EFA5628A0BC4DCFA" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1C58069A23CA822EB2B5628A0BC48C91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6B137DF186E1ACD9EE5C628A0BC4F970" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1C58069A23CA822EB2B5628A0BC48C91" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6B137DF186E1ACD9EE5C628A0BC4F970" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_371C49AF9BB357ECA725628A0BC4C21A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6B137DF186E1ACD9EE5C628A0BC4F970" xlink:to="loc_us-gaap_UnsecuredDebtMember_371C49AF9BB357ECA725628A0BC4C21A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_043E896EEEFA1049CE73628A0BC5C537" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5162404E95591A48EFA5628A0BC4DCFA" xlink:to="loc_us-gaap_DebtInstrumentAxis_043E896EEEFA1049CE73628A0BC5C537" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3D14954885623AC2B1E6628A0BC578F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_043E896EEEFA1049CE73628A0BC5C537" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3D14954885623AC2B1E6628A0BC578F4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorNotesDue2047Member" xlink:label="loc_pfe_SeniorNotesDue2047Member_3206AC583E5E687169BF628A0BC5EF25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3D14954885623AC2B1E6628A0BC578F4" xlink:to="loc_pfe_SeniorNotesDue2047Member_3206AC583E5E687169BF628A0BC5EF25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_C6C80A985E3879C41D15628A0BC5DE6E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5162404E95591A48EFA5628A0BC4DCFA" xlink:to="loc_us-gaap_DebtInstrumentLineItems_C6C80A985E3879C41D15628A0BC5DE6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_B019F17FE2A3FAB3B5D7628A0BC5565F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C6C80A985E3879C41D15628A0BC5DE6E" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_B019F17FE2A3FAB3B5D7628A0BC5565F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_37C6EBA8FCEB7CC3C74FB7017B5F3222" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_B8C1A0C8B7243A312A8BB7017B61FBE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_37C6EBA8FCEB7CC3C74FB7017B5F3222" xlink:to="loc_us-gaap_DebtInstrumentTable_B8C1A0C8B7243A312A8BB7017B61FBE7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4CAC97DAD32884823C08B7017B61D6DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_B8C1A0C8B7243A312A8BB7017B61FBE7" xlink:to="loc_dei_LegalEntityAxis_4CAC97DAD32884823C08B7017B61D6DB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_11AB6F996945EBABA34AB7017B62E8F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4CAC97DAD32884823C08B7017B61D6DB" xlink:to="loc_dei_EntityDomain_11AB6F996945EBABA34AB7017B62E8F4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnIncMember" xlink:label="loc_pfe_UpjohnIncMember_08159DF26464FA2F6D8AB7017B6274E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_11AB6F996945EBABA34AB7017B62E8F4" xlink:to="loc_pfe_UpjohnIncMember_08159DF26464FA2F6D8AB7017B6274E5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnFinanceB.V.Member" xlink:label="loc_pfe_UpjohnFinanceB.V.Member_F33F9E5B7263C42B6C48B7017B6274E7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_11AB6F996945EBABA34AB7017B62E8F4" xlink:to="loc_pfe_UpjohnFinanceB.V.Member_F33F9E5B7263C42B6C48B7017B6274E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_6C523C55848239DB4AB1B7017B623D4D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_B8C1A0C8B7243A312A8BB7017B61FBE7" xlink:to="loc_srt_ConsolidatedEntitiesAxis_6C523C55848239DB4AB1B7017B623D4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_2B25EE9B0434F6105F10B7017B637727" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6C523C55848239DB4AB1B7017B623D4D" xlink:to="loc_srt_ConsolidatedEntitiesDomain_2B25EE9B0434F6105F10B7017B637727" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_AF87E36E0CC30EBC8C65B7017B638D1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_2B25EE9B0434F6105F10B7017B637727" xlink:to="loc_us-gaap_ParentMember_AF87E36E0CC30EBC8C65B7017B638D1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_03A6EF13736485918A57B7017B631B38" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_2B25EE9B0434F6105F10B7017B637727" xlink:to="loc_srt_SubsidiariesMember_03A6EF13736485918A57B7017B631B38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8490681A4C4E2A4C91D5B7017B639CE1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_B8C1A0C8B7243A312A8BB7017B61FBE7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8490681A4C4E2A4C91D5B7017B639CE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_69B81AEEC6A9DC37676DB7017B63EBA4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8490681A4C4E2A4C91D5B7017B639CE1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_69B81AEEC6A9DC37676DB7017B63EBA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_AEA7189008A36D701988B7017B64F854" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_69B81AEEC6A9DC37676DB7017B63EBA4" xlink:to="loc_us-gaap_SeniorNotesMember_AEA7189008A36D701988B7017B64F854" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_5848E110D3CBE9F0AF6CB7017B644F3A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_B8C1A0C8B7243A312A8BB7017B61FBE7" xlink:to="loc_us-gaap_DebtInstrumentAxis_5848E110D3CBE9F0AF6CB7017B644F3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5848E110D3CBE9F0AF6CB7017B644F3A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member" xlink:label="loc_pfe_SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member_250225BA72C26BFB4390B7017B64C926" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member_250225BA72C26BFB4390B7017B64C926" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member" xlink:label="loc_pfe_SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member_415142CBC1650E8759EEB7017B6512CB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member_415142CBC1650E8759EEB7017B6512CB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member" xlink:label="loc_pfe_SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member_354F6B2C70C868B1C04BB7017B6564AF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member_354F6B2C70C868B1C04BB7017B6564AF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member" xlink:label="loc_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member_203DF6DB98C258CB3086B7017B6564BD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member_203DF6DB98C258CB3086B7017B6564BD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member" xlink:label="loc_pfe_SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member_A63303D9B2D1E05405B5B7017B65FF7C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member_A63303D9B2D1E05405B5B7017B65FF7C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member" xlink:label="loc_pfe_SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member_88778429BCB496003CE7B7017B65D57B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member_88778429BCB496003CE7B7017B65D57B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member" xlink:label="loc_pfe_SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member_B62E92E4A323F80BE944B7017B66E9D4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member_B62E92E4A323F80BE944B7017B66E9D4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member" xlink:label="loc_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member_D193563150E51D7D0D09B7017B66720E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member_D193563150E51D7D0D09B7017B66720E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member" xlink:label="loc_pfe_SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member_6A567EE8AF56C154AF0FB7017B66D533" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member_6A567EE8AF56C154AF0FB7017B66D533" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member" xlink:label="loc_pfe_SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member_92727FA06579C6532A4CB7017B66A3C3" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member_92727FA06579C6532A4CB7017B66A3C3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member" xlink:label="loc_pfe_SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member_53CEC6E7126A650309DEB7017B66A93B" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member_53CEC6E7126A650309DEB7017B66A93B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member" xlink:label="loc_pfe_SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member_0D5F463EB9E20E3AE362B7017B66254E" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member_0D5F463EB9E20E3AE362B7017B66254E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member" xlink:label="loc_pfe_SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member_B1F13BF7D4EE2131B4CFB7017B67D8FA" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member_B1F13BF7D4EE2131B4CFB7017B67D8FA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member" xlink:label="loc_pfe_SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member_E9868B10B64D1B822CD8B7017B677446" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member_E9868B10B64D1B822CD8B7017B677446" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member" xlink:label="loc_pfe_SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member_70393EF7027E2BC32F10B7017B67E43C" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member_70393EF7027E2BC32F10B7017B67E43C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LongTermDebtIssuedFirstQuarter2020Member" xlink:label="loc_pfe_LongTermDebtIssuedFirstQuarter2020Member_4AFC00BF85F0A4EA7EB8B704A56CDE53" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_889B5BB97E8E69F9953FB7017B642AE0" xlink:to="loc_pfe_LongTermDebtIssuedFirstQuarter2020Member_4AFC00BF85F0A4EA7EB8B704A56CDE53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ADBE9C28E5E8906527F0B7017B67499B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_B8C1A0C8B7243A312A8BB7017B61FBE7" xlink:to="loc_us-gaap_DebtInstrumentLineItems_ADBE9C28E5E8906527F0B7017B67499B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_BFB50DDE9B62E6F27576B7017B67B715" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ADBE9C28E5E8906527F0B7017B67499B" xlink:to="loc_us-gaap_LongTermDebt_BFB50DDE9B62E6F27576B7017B67B715" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1180CA6602917BBD6AC9B7017B67D023" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ADBE9C28E5E8906527F0B7017B67499B" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1180CA6602917BBD6AC9B7017B67D023" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2217456977EDA6FDFE57B7017B6865BF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ADBE9C28E5E8906527F0B7017B67499B" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2217456977EDA6FDFE57B7017B6865BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_E614C4589E63FB3246FBB7017B6836C1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ADBE9C28E5E8906527F0B7017B67499B" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_E614C4589E63FB3246FBB7017B6836C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_36A6AD483646D70E170EB7017B68A55B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ADBE9C28E5E8906527F0B7017B67499B" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_36A6AD483646D70E170EB7017B68A55B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_28807E44F02A2A0A6ABF9476211AC910" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaper" xlink:label="loc_us-gaap_CommercialPaper_398A3E2944D03FE9AAAA9476211A3A8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_28807E44F02A2A0A6ABF9476211AC910" xlink:to="loc_us-gaap_CommercialPaper_398A3E2944D03FE9AAAA9476211A3A8F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" xlink:label="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_26F08A94533062B215659476211A50BB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_28807E44F02A2A0A6ABF9476211AC910" xlink:to="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_26F08A94533062B215659476211A50BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherShortTermBorrowings" xlink:label="loc_us-gaap_OtherShortTermBorrowings_0B03F68FDFFF70200DCA9476211A283A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_28807E44F02A2A0A6ABF9476211AC910" xlink:to="loc_us-gaap_OtherShortTermBorrowings_0B03F68FDFFF70200DCA9476211A283A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ShorttermDebtGross" xlink:label="loc_pfe_ShorttermDebtGross_4CC3FAC37358D755EFF89476211B916A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_28807E44F02A2A0A6ABF9476211AC910" xlink:to="loc_pfe_ShorttermDebtGross_4CC3FAC37358D755EFF89476211B916A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_51EBEA2CDCB75B17590F9476211B544A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_28807E44F02A2A0A6ABF9476211AC910" xlink:to="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_51EBEA2CDCB75B17590F9476211B544A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_267DF35B04E266CB12FC9476211B57E4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_28807E44F02A2A0A6ABF9476211AC910" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_267DF35B04E266CB12FC9476211B57E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_9699BE191B76816BC08C9476211BF1DE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_28807E44F02A2A0A6ABF9476211AC910" xlink:to="loc_us-gaap_DebtCurrent_9699BE191B76816BC08C9476211BF1DE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_B718BBD0908CE178C541947620082BE0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_FA6605C0AAF7B87557BB9476200895B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_B718BBD0908CE178C541947620082BE0" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_FA6605C0AAF7B87557BB9476200895B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_273F7B0EF5404E9B4B9E947620082BDC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_B718BBD0908CE178C541947620082BE0" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_273F7B0EF5404E9B4B9E947620082BDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_5F1D84A221D59E8B806A9476200801C8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_B718BBD0908CE178C541947620082BE0" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_5F1D84A221D59E8B806A9476200801C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesTextBlock_91286CF869CCBCAB4D659476200800AA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_B718BBD0908CE178C541947620082BE0" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesTextBlock_91286CF869CCBCAB4D659476200800AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_6B121F918F401A479DBE947620080A30" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_B718BBD0908CE178C541947620082BE0" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_6B121F918F401A479DBE947620080A30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_FBAFEEA834474B3DFC2794762009BF05" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_B718BBD0908CE178C541947620082BE0" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_FBAFEEA834474B3DFC2794762009BF05" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" xlink:label="loc_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_8B035658313DF742F46B94762009C8EF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_B718BBD0908CE178C541947620082BE0" xlink:to="loc_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_8B035658313DF742F46B94762009C8EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_02D3BD07586E2CCD5C3D947620099170" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_B718BBD0908CE178C541947620082BE0" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_02D3BD07586E2CCD5C3D947620099170" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_C64B8BD9805BFC828024947620099194" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_B718BBD0908CE178C541947620082BE0" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_C64B8BD9805BFC828024947620099194" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_480754842527B4639F5394762009A61A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_B718BBD0908CE178C541947620082BE0" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_480754842527B4639F5394762009A61A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_EB2A5C09E2123DF14DCE94762009F064" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_B718BBD0908CE178C541947620082BE0" xlink:to="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_EB2A5C09E2123DF14DCE94762009F064" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_17BDD968AE491284AE9B9476200AC4D8" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_B718BBD0908CE178C541947620082BE0" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_17BDD968AE491284AE9B9476200AC4D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_E9485B4515E229F2457B9476200A2762" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_B718BBD0908CE178C541947620082BE0" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_E9485B4515E229F2457B9476200A2762" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_4A391E5883E205E81E119476200A782C" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_B718BBD0908CE178C541947620082BE0" xlink:to="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_4A391E5883E205E81E119476200A782C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_742C57429A388B840143B09F32EE28CD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_8AAC26126D39C5241268B09F32EE29A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_742C57429A388B840143B09F32EE28CD" xlink:to="loc_us-gaap_ShortTermInvestmentsAbstract_8AAC26126D39C5241268B09F32EE29A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_76959CF1EA94B3D8EFDEB09F32EF732A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_8AAC26126D39C5241268B09F32EE29A7" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_76959CF1EA94B3D8EFDEB09F32EF732A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3614AE3E91ED1854CC84B09F32EFF0A0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_8AAC26126D39C5241268B09F32EE29A7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3614AE3E91ED1854CC84B09F32EFF0A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_E53365B304FF4E5D37D2B09F32EFBB00" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_8AAC26126D39C5241268B09F32EE29A7" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_E53365B304FF4E5D37D2B09F32EFBB00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_F7E7F870351078E698D4B09F32EF21E6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_8AAC26126D39C5241268B09F32EE29A7" xlink:to="loc_us-gaap_ShortTermInvestments_F7E7F870351078E698D4B09F32EF21E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestmentsAbstract" xlink:label="loc_us-gaap_LongTermInvestmentsAbstract_D53C03DE45E2414A805DB09F32EF0926" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_742C57429A388B840143B09F32EE28CD" xlink:to="loc_us-gaap_LongTermInvestmentsAbstract_D53C03DE45E2414A805DB09F32EF0926" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EquitySecuritiesFVNINoncurrent" xlink:label="loc_pfe_EquitySecuritiesFVNINoncurrent_66099B74C2367402059DB09F32EFD1D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_D53C03DE45E2414A805DB09F32EF0926" xlink:to="loc_pfe_EquitySecuritiesFVNINoncurrent_66099B74C2367402059DB09F32EFD1D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_889DC52F7BB3A88E8ABBB09F32F0B254" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_D53C03DE45E2414A805DB09F32EF0926" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_889DC52F7BB3A88E8ABBB09F32F0B254" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_DEA2858DBD724629623BB09F32F0A3B3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_D53C03DE45E2414A805DB09F32EF0926" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_DEA2858DBD724629623BB09F32F0A3B3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PrivateEquityInvestments" xlink:label="loc_pfe_PrivateEquityInvestments_A8BD49A5E0492F388146B09F32F0FAD4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_D53C03DE45E2414A805DB09F32EF0926" xlink:to="loc_pfe_PrivateEquityInvestments_A8BD49A5E0492F388146B09F32F0FAD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermInvestments" xlink:label="loc_us-gaap_OtherLongTermInvestments_51E628BE1E59C38D6732B09F32F0E671" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_D53C03DE45E2414A805DB09F32EF0926" xlink:to="loc_us-gaap_OtherLongTermInvestments_51E628BE1E59C38D6732B09F32F0E671" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_322C143D08394803DEBCB09F32F0C4F0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_742C57429A388B840143B09F32EE28CD" xlink:to="loc_us-gaap_EquityMethodInvestments_322C143D08394803DEBCB09F32F0C4F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_59841D664259ED3F0831B09F32F155AF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_742C57429A388B840143B09F32EE28CD" xlink:to="loc_us-gaap_LongTermInvestments_59841D664259ED3F0831B09F32F155AF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_HeldToMaturityCashEquivalents" xlink:label="loc_pfe_HeldToMaturityCashEquivalents_264F6138AB1EC83EF47CB09F32F1F111" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_742C57429A388B840143B09F32EE28CD" xlink:to="loc_pfe_HeldToMaturityCashEquivalents_264F6138AB1EC83EF47CB09F32F1F111" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_5A327EAFA152916F49966EB18867088A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_CE053CE7EA167678F37B6EB366C9A1A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_5A327EAFA152916F49966EB18867088A" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_CE053CE7EA167678F37B6EB366C9A1A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_7CE63E8D2E15882366826EB18B16AEE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_CE053CE7EA167678F37B6EB366C9A1A9" xlink:to="loc_srt_ConsolidatedEntitiesAxis_7CE63E8D2E15882366826EB18B16AEE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_2B2F63008B7F14F5F13B6EB18C0EE3BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_7CE63E8D2E15882366826EB18B16AEE6" xlink:to="loc_srt_ConsolidatedEntitiesDomain_2B2F63008B7F14F5F13B6EB18C0EE3BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_3AF547AA1C2E781BA19C6EB18B44B7AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_2B2F63008B7F14F5F13B6EB18C0EE3BC" xlink:to="loc_srt_SubsidiariesMember_3AF547AA1C2E781BA19C6EB18B44B7AB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_69E160EFC0CF7CA78A7A6EB18AFF348A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_CE053CE7EA167678F37B6EB366C9A1A9" xlink:to="loc_dei_LegalEntityAxis_69E160EFC0CF7CA78A7A6EB18AFF348A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6EAC63A982D8ECD893D46EB18BF70197" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_69E160EFC0CF7CA78A7A6EB18AFF348A" xlink:to="loc_dei_EntityDomain_6EAC63A982D8ECD893D46EB18BF70197" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnIncMember" xlink:label="loc_pfe_UpjohnIncMember_F22990AFED93063985CC6EB18B2CE70F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6EAC63A982D8ECD893D46EB18BF70197" xlink:to="loc_pfe_UpjohnIncMember_F22990AFED93063985CC6EB18B2CE70F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_319CC470316AD1A31A0B6EB366D62DBE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_CE053CE7EA167678F37B6EB366C9A1A9" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_319CC470316AD1A31A0B6EB366D62DBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9ABC36454B959FB79B726EB18AE87576" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_319CC470316AD1A31A0B6EB366D62DBE" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9ABC36454B959FB79B726EB18AE87576" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C300C102D2092A82A9C8947620116564" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_E2E75739637AEB4E73BD947620117BDC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C300C102D2092A82A9C8947620116564" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_E2E75739637AEB4E73BD947620117BDC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C80083A3B3651773218978F2528EFEFC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_3A2B15DABAC480709BF178F2528E677D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C80083A3B3651773218978F2528EFEFC" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_3A2B15DABAC480709BF178F2528E677D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7311478CAA6D49EDDFCF78F2528ECC31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_3A2B15DABAC480709BF178F2528E677D" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7311478CAA6D49EDDFCF78F2528ECC31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_862DD9009717461EE6A678F2528F5FE3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7311478CAA6D49EDDFCF78F2528ECC31" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_862DD9009717461EE6A678F2528F5FE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_C357E3F607D039FC50EA78F2528FD024" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_862DD9009717461EE6A678F2528F5FE3" xlink:to="loc_us-gaap_TradeNamesMember_C357E3F607D039FC50EA78F2528FD024" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_03ED8CCC53ECEA08E24578F2528FBB15" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_862DD9009717461EE6A678F2528F5FE3" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_03ED8CCC53ECEA08E24578F2528FBB15" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LicensingAgreementsAndOtherMember" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_AB578DDC0A301B88BAA778F252903A55" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_862DD9009717461EE6A678F2528F5FE3" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_AB578DDC0A301B88BAA778F252903A55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_3C162757443FDDBD43AD78F25290AD64" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_3A2B15DABAC480709BF178F2528E677D" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_3C162757443FDDBD43AD78F25290AD64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_A2077F97A8A46CA3305578F252900E6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_3C162757443FDDBD43AD78F25290AD64" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_A2077F97A8A46CA3305578F252900E6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2A1A15D136417CC19B4778F25290CCD4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C80083A3B3651773218978F2528EFEFC" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2A1A15D136417CC19B4778F25290CCD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9049909EF0567C4AC8E978F25290E24A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2A1A15D136417CC19B4778F25290CCD4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9049909EF0567C4AC8E978F25290E24A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_69C6CC8D741C64C348AE78F25290182C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9049909EF0567C4AC8E978F25290E24A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_69C6CC8D741C64C348AE78F25290182C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_A744F287FBF858525A0178F2529167C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_69C6CC8D741C64C348AE78F25290182C" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_A744F287FBF858525A0178F2529167C5" xlink:type="arc" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_69C6CC8D741C64C348AE78F25290182C" xlink:to="loc_us-gaap_TradeNamesMember_C357E3F607D039FC50EA78F2528FD024" xlink:type="arc" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_69C6CC8D741C64C348AE78F25290182C" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_AB578DDC0A301B88BAA778F252903A55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_A351D5287E61628E1A8878F2529151A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2A1A15D136417CC19B4778F25290CCD4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_A351D5287E61628E1A8878F2529151A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8B0E5C69FFB4DB7F691C78F252925A66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_A351D5287E61628E1A8878F2529151A4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8B0E5C69FFB4DB7F691C78F252925A66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_41C6073FF631F5F4CA3E78F252923654" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_A351D5287E61628E1A8878F2529151A4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_41C6073FF631F5F4CA3E78F252923654" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_549BF9C3D0811DC8D76E78F25292D7AA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_A351D5287E61628E1A8878F2529151A4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_549BF9C3D0811DC8D76E78F25292D7AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_217325A6C608D557A6DB78F25292C54F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C80083A3B3651773218978F2528EFEFC" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_217325A6C608D557A6DB78F25292C54F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9AB4C205A5672036783578F25292B593" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C80083A3B3651773218978F2528EFEFC" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9AB4C205A5672036783578F25292B593" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_923918A9CA157FDBB20078F2529359AD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C80083A3B3651773218978F2528EFEFC" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_923918A9CA157FDBB20078F2529359AD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_209FE8CA7FF7D79FC32F92D1CA542EEB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4A30979B3116BE9976BE92D1CA5482AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_209FE8CA7FF7D79FC32F92D1CA542EEB" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4A30979B3116BE9976BE92D1CA5482AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0EF6DA3D7AC7481E1D8192D1CA54F421" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4A30979B3116BE9976BE92D1CA5482AC" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0EF6DA3D7AC7481E1D8192D1CA54F421" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_89F1A7302A30951866CF92D1CA5547EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0EF6DA3D7AC7481E1D8192D1CA54F421" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_89F1A7302A30951866CF92D1CA5547EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_6EEA9FA8374582689B7D92D1CA558133" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_89F1A7302A30951866CF92D1CA5547EB" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_6EEA9FA8374582689B7D92D1CA558133" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LicensingAgreementsAndOtherMember" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_34C9B4A5EC29300DA7C492D1CA5578BC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_89F1A7302A30951866CF92D1CA5547EB" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_34C9B4A5EC29300DA7C492D1CA5578BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_22BB391C01B17F4F151692D1CA553C8A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4A30979B3116BE9976BE92D1CA5482AC" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_22BB391C01B17F4F151692D1CA553C8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_713F2C08F3B4D34C3A5192D1CA56ECDB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_22BB391C01B17F4F151692D1CA553C8A" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_713F2C08F3B4D34C3A5192D1CA56ECDB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ArrayMember" xlink:label="loc_pfe_ArrayMember_86B1D87FA2ABC95F022392D1CA56F3C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_713F2C08F3B4D34C3A5192D1CA56ECDB" xlink:to="loc_pfe_ArrayMember_86B1D87FA2ABC95F022392D1CA56F3C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_B30D6B18C617C5B24CA692D1CA56FE5D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4A30979B3116BE9976BE92D1CA5482AC" xlink:to="loc_srt_ProductOrServiceAxis_B30D6B18C617C5B24CA692D1CA56FE5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_52588DC5A700EF2E47B392D1CA56D5F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_B30D6B18C617C5B24CA692D1CA56FE5D" xlink:to="loc_srt_ProductsAndServicesDomain_52588DC5A700EF2E47B392D1CA56D5F6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BraftoviMember" xlink:label="loc_pfe_BraftoviMember_1C3649674142955437B692D1CA575406" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_52588DC5A700EF2E47B392D1CA56D5F6" xlink:to="loc_pfe_BraftoviMember_1C3649674142955437B692D1CA575406" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0071F2D5E1CA39985A0C92D1CA578FA0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4A30979B3116BE9976BE92D1CA5482AC" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0071F2D5E1CA39985A0C92D1CA578FA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5584176280CC36233FF92D1CA575EEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0071F2D5E1CA39985A0C92D1CA578FA0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5584176280CC36233FF92D1CA575EEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_DA0A3F34231442BD935392D1CA58958D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5584176280CC36233FF92D1CA575EEE" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_DA0A3F34231442BD935392D1CA58958D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_38BD350D47E350F4DCB092D1CA58F1EB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5584176280CC36233FF92D1CA575EEE" xlink:to="loc_us-gaap_LicensingAgreementsMember_38BD350D47E350F4DCB092D1CA58F1EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B6E7BE6C0D8351124AF792D1CA5815B2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4A30979B3116BE9976BE92D1CA5482AC" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B6E7BE6C0D8351124AF792D1CA5815B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_7B887AEC61B06260D0D792D1CA585718" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B6E7BE6C0D8351124AF792D1CA5815B2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_7B887AEC61B06260D0D792D1CA585718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_DB4B648042AFCC5B721092D1CA5948BE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B6E7BE6C0D8351124AF792D1CA5815B2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_DB4B648042AFCC5B721092D1CA5948BE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_FEABD4D62F19EDEBC3CD78F1DC96DC2B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4917C344277037F7E7FC78F1DC988BFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_FEABD4D62F19EDEBC3CD78F1DC96DC2B" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4917C344277037F7E7FC78F1DC988BFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsAxis" xlink:label="loc_us-gaap_SubsegmentsAxis_A911B8B82546379BDC7F78F1DC99E508" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4917C344277037F7E7FC78F1DC988BFF" xlink:to="loc_us-gaap_SubsegmentsAxis_A911B8B82546379BDC7F78F1DC99E508" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_D85242373447D810C43778F1DC9AE221" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_A911B8B82546379BDC7F78F1DC99E508" xlink:to="loc_us-gaap_SubsegmentsDomain_D85242373447D810C43778F1DC9AE221" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember" xlink:label="loc_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_DAC85EDBC891AA254CF578F1DC9A2203" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_D85242373447D810C43778F1DC9AE221" xlink:to="loc_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_DAC85EDBC891AA254CF578F1DC9A2203" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_E1AD47F560F1F9C6EB3F78F1DC9BB147" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4917C344277037F7E7FC78F1DC988BFF" xlink:to="loc_srt_ConsolidationItemsAxis_E1AD47F560F1F9C6EB3F78F1DC9BB147" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_9034C7FF1C65AE65A46278F1DC9B0982" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_E1AD47F560F1F9C6EB3F78F1DC9BB147" xlink:to="loc_srt_ConsolidationItemsDomain_9034C7FF1C65AE65A46278F1DC9B0982" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_0EE7E8AA39432DA3B7D278F1DC9BB61F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_9034C7FF1C65AE65A46278F1DC9B0982" xlink:to="loc_us-gaap_OperatingSegmentsMember_0EE7E8AA39432DA3B7D278F1DC9BB61F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_14B28A8453007AB4FBA078F1DC9B10EB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_9034C7FF1C65AE65A46278F1DC9B0982" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_14B28A8453007AB4FBA078F1DC9B10EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_B8ED024FED11B483A87578F1DC9B2421" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4917C344277037F7E7FC78F1DC988BFF" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_B8ED024FED11B483A87578F1DC9B2421" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4EF7A1407BD7D5092AAA78F1DC9C16E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_B8ED024FED11B483A87578F1DC9B2421" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4EF7A1407BD7D5092AAA78F1DC9C16E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_4134C3888F46ED41714178F1DC9C1AD4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4EF7A1407BD7D5092AAA78F1DC9C16E3" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_4134C3888F46ED41714178F1DC9C1AD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_65262EA26AD8124EA00E78F1DC9C4D02" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4EF7A1407BD7D5092AAA78F1DC9C16E3" xlink:to="loc_us-gaap_TradeNamesMember_65262EA26AD8124EA00E78F1DC9C4D02" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LicensingAgreementsAndOtherMember" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_493C80EF7E2B2A8EFA2F78F1DC9C4760" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4EF7A1407BD7D5092AAA78F1DC9C16E3" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_493C80EF7E2B2A8EFA2F78F1DC9C4760" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_D437D0C9913C89F869B578F1DC9D30F0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4917C344277037F7E7FC78F1DC988BFF" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_D437D0C9913C89F869B578F1DC9D30F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_82C4A4C7760877B8DBD578F1DC9D18B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_D437D0C9913C89F869B578F1DC9D30F0" xlink:to="loc_us-gaap_SegmentDomain_82C4A4C7760877B8DBD578F1DC9D18B9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_81EFE2EDE968D756E91C78F1DC9D9407" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_82C4A4C7760877B8DBD578F1DC9D18B9" xlink:to="loc_pfe_BiopharmaSegmentMember_81EFE2EDE968D756E91C78F1DC9D9407" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnSegmentMember" xlink:label="loc_pfe_UpjohnSegmentMember_BD17881AAFA661D59AA878F1DC9D5612" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_82C4A4C7760877B8DBD578F1DC9D18B9" xlink:to="loc_pfe_UpjohnSegmentMember_BD17881AAFA661D59AA878F1DC9D5612" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_D010520126E6BCB3FC7278F1DC9D1C33" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4917C344277037F7E7FC78F1DC988BFF" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_D010520126E6BCB3FC7278F1DC9D1C33" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet" xlink:label="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_BDC6805348A73DA5BDF678F1DC9E1283" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_D010520126E6BCB3FC7278F1DC9D1C33" xlink:to="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_BDC6805348A73DA5BDF678F1DC9E1283" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D670E0912F925C01761F78F90C7BD9BC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_23F8A695101D1D2C2BBE78F90C7CFC9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D670E0912F925C01761F78F90C7BD9BC" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_23F8A695101D1D2C2BBE78F90C7CFC9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_C52BD041B7C5A902282B78F90C7CD37D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_23F8A695101D1D2C2BBE78F90C7CFC9A" xlink:to="loc_srt_ConsolidationItemsAxis_C52BD041B7C5A902282B78F90C7CD37D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_7D34BA9E1551480D839678F90C7C9D89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_C52BD041B7C5A902282B78F90C7CD37D" xlink:to="loc_srt_ConsolidationItemsDomain_7D34BA9E1551480D839678F90C7C9D89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_50A2F305257CFF17537578F90C7DFFC0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_7D34BA9E1551480D839678F90C7C9D89" xlink:to="loc_us-gaap_OperatingSegmentsMember_50A2F305257CFF17537578F90C7DFFC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_96B3A9BD7C3953BA861A78F90C7D55E7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_23F8A695101D1D2C2BBE78F90C7CFC9A" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_96B3A9BD7C3953BA861A78F90C7D55E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_91B8776BB1A6DD8C161C78F90C7D70D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_96B3A9BD7C3953BA861A78F90C7D55E7" xlink:to="loc_us-gaap_SegmentDomain_91B8776BB1A6DD8C161C78F90C7D70D0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_D1609CDF669C94BF771378F90C7D2BBC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_91B8776BB1A6DD8C161C78F90C7D70D0" xlink:to="loc_pfe_BiopharmaSegmentMember_D1609CDF669C94BF771378F90C7D2BBC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnSegmentMember" xlink:label="loc_pfe_UpjohnSegmentMember_04A0C18EF7754DD3E0BD78F90C7DA156" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_91B8776BB1A6DD8C161C78F90C7D70D0" xlink:to="loc_pfe_UpjohnSegmentMember_04A0C18EF7754DD3E0BD78F90C7DA156" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_27AA658B4FEC9768120578F90C7E8AEF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_23F8A695101D1D2C2BBE78F90C7CFC9A" xlink:to="loc_us-gaap_GoodwillLineItems_27AA658B4FEC9768120578F90C7E8AEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_186F27DCA580856D5BB478F90C7EEC7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_27AA658B4FEC9768120578F90C7E8AEF" xlink:to="loc_us-gaap_GoodwillRollForward_186F27DCA580856D5BB478F90C7EEC7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_68F0DD63C35F063A3AC178F90C7EC312" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_186F27DCA580856D5BB478F90C7EEC7C" xlink:to="loc_us-gaap_Goodwill_68F0DD63C35F063A3AC178F90C7EC312" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_59BECFB52CE76FF0F77C78F90C7E38DA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_186F27DCA580856D5BB478F90C7EEC7C" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_59BECFB52CE76FF0F77C78F90C7E38DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_8966D45DC9031C51945E78F90C7EBAFD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_186F27DCA580856D5BB478F90C7EEC7C" xlink:to="loc_us-gaap_Goodwill_8966D45DC9031C51945E78F90C7EBAFD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_75AD60581D3874C9CB4D78F9109A9461" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_4F802C4A5D65DA2520BB78F9109AED02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_75AD60581D3874C9CB4D78F9109A9461" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_4F802C4A5D65DA2520BB78F9109AED02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsAxis" xlink:label="loc_us-gaap_SubsegmentsAxis_C70A07A40BD186F75F7578F9109BEF78" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_4F802C4A5D65DA2520BB78F9109AED02" xlink:to="loc_us-gaap_SubsegmentsAxis_C70A07A40BD186F75F7578F9109BEF78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_E8CE456DBDD93A01103778F9109B42D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_C70A07A40BD186F75F7578F9109BEF78" xlink:to="loc_us-gaap_SubsegmentsDomain_E8CE456DBDD93A01103778F9109B42D9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember" xlink:label="loc_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_14FE3BD4400C70A8341D78F9109B2DCE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_E8CE456DBDD93A01103778F9109B42D9" xlink:to="loc_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_14FE3BD4400C70A8341D78F9109B2DCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3B25277619064777F12978F9109CAD4E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_4F802C4A5D65DA2520BB78F9109AED02" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3B25277619064777F12978F9109CAD4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_040A670B0FA7A828253778F9109C120A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3B25277619064777F12978F9109CAD4E" xlink:to="loc_us-gaap_SegmentDomain_040A670B0FA7A828253778F9109C120A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_5FE3A87A2B0CE355B97078F9109CEA46" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_040A670B0FA7A828253778F9109C120A" xlink:to="loc_pfe_BiopharmaSegmentMember_5FE3A87A2B0CE355B97078F9109CEA46" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnSegmentMember" xlink:label="loc_pfe_UpjohnSegmentMember_86FC308C864873C08DC778F9109C1AED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_040A670B0FA7A828253778F9109C120A" xlink:to="loc_pfe_UpjohnSegmentMember_86FC308C864873C08DC778F9109C1AED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_721563B036A921EE042978F9109CEA23" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_4F802C4A5D65DA2520BB78F9109AED02" xlink:to="loc_srt_ConsolidationItemsAxis_721563B036A921EE042978F9109CEA23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_9C7FAEAB81911C91C7DF78F9109D4B40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_721563B036A921EE042978F9109CEA23" xlink:to="loc_srt_ConsolidationItemsDomain_9C7FAEAB81911C91C7DF78F9109D4B40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_E7CC2EE6F27EBE265C9478F9109D2568" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_9C7FAEAB81911C91C7DF78F9109D4B40" xlink:to="loc_us-gaap_OperatingSegmentsMember_E7CC2EE6F27EBE265C9478F9109D2568" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_73E75897B96726AE65F078F9109DE762" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_9C7FAEAB81911C91C7DF78F9109D4B40" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_73E75897B96726AE65F078F9109DE762" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_826D6C5CC0C1473E97BC78F9109DDF1A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_4F802C4A5D65DA2520BB78F9109AED02" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_826D6C5CC0C1473E97BC78F9109DDF1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_E649E6133BFA8248A19F78F9109E91F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_826D6C5CC0C1473E97BC78F9109DDF1A" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_E649E6133BFA8248A19F78F9109E91F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_07732DAB0A10193F66AE78F9109E2E00" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_E649E6133BFA8248A19F78F9109E91F5" xlink:to="loc_us-gaap_TradeNamesMember_07732DAB0A10193F66AE78F9109E2E00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_468F4C6AF6D2B10C70ED78F9109E456C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_E649E6133BFA8248A19F78F9109E91F5" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_468F4C6AF6D2B10C70ED78F9109E456C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LicensingAgreementsAndOtherMember" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_F9C9643DCD8DCE74E95F78F9109E9A5E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_E649E6133BFA8248A19F78F9109E91F5" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_F9C9643DCD8DCE74E95F78F9109E9A5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_549F7C83BE74098A31B178F9109E4D68" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_4F802C4A5D65DA2520BB78F9109AED02" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_549F7C83BE74098A31B178F9109E4D68" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet" xlink:label="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_1F36AE3B45A180AB169578F9109F20C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_549F7C83BE74098A31B178F9109E4D68" xlink:to="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_1F36AE3B45A180AB169578F9109F20C4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7206F63DD48D2C91BAB978F90EA2BA2F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF1BCEB60C540086458A78F90EA21CFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7206F63DD48D2C91BAB978F90EA2BA2F" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF1BCEB60C540086458A78F90EA21CFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_02DF3EA7EE6AF5C0931B78F90EA315A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF1BCEB60C540086458A78F90EA21CFC" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_02DF3EA7EE6AF5C0931B78F90EA315A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7617A834C1072E6F7CAB78F90EA3E631" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_02DF3EA7EE6AF5C0931B78F90EA315A4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7617A834C1072E6F7CAB78F90EA3E631" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMember_81FA9469C852986949FF78F90EA376A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7617A834C1072E6F7CAB78F90EA3E631" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMember_81FA9469C852986949FF78F90EA376A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_831948143A0CD153A61778F90EA491C5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF1BCEB60C540086458A78F90EA21CFC" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_831948143A0CD153A61778F90EA491C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3B0D34C761DB304CB51678F90EA44EC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_831948143A0CD153A61778F90EA491C5" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_3B0D34C761DB304CB51678F90EA44EC8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F035DC34837DB3563C3894762038B86C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_CD738461CD78FCE0CE1E947620395E3A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F035DC34837DB3563C3894762038B86C" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_CD738461CD78FCE0CE1E947620395E3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_373E259F9F9FEE37C09E947620398BBF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F035DC34837DB3563C3894762038B86C" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_373E259F9F9FEE37C09E947620398BBF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock" xlink:label="loc_pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock_D4D5FF5FED925BB3645E94762039CDAE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F035DC34837DB3563C3894762038B86C" xlink:to="loc_pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock_D4D5FF5FED925BB3645E94762039CDAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_0E44DEB7500E95551E659476203A26BC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F035DC34837DB3563C3894762038B86C" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_0E44DEB7500E95551E659476203A26BC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_6312F101428657492F9394761F27F92C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_7224E4ECE5C17FB1BB0794761F27F56D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6312F101428657492F9394761F27F92C" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_7224E4ECE5C17FB1BB0794761F27F56D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/InventoriesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_448BCDDFAC181225594594761FB8BB73" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_E10102AD6994EA283CD794761FB8FDB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_448BCDDFAC181225594594761FB8BB73" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_E10102AD6994EA283CD794761FB8FDB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_ED8DFFA15704B8035A2894761FB9F32D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_448BCDDFAC181225594594761FB8BB73" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_ED8DFFA15704B8035A2894761FB9F32D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_1FC87E8E08EE4676A1B894761FB9ABB4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_448BCDDFAC181225594594761FB8BB73" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_1FC87E8E08EE4676A1B894761FB9ABB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_831A1EEB8B9745637EB794761FB9DC4B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_448BCDDFAC181225594594761FB8BB73" xlink:to="loc_us-gaap_InventoryNet_831A1EEB8B9745637EB794761FB9DC4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_24C560028A2040C999CF94761FB9E691" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_448BCDDFAC181225594594761FB8BB73" xlink:to="loc_us-gaap_InventoryNoncurrent_24C560028A2040C999CF94761FB9E691" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_94BAFB318992C0A48DB8947622E8C1F4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_15F6C1B4DC25B5F65FD2947622E806A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_94BAFB318992C0A48DB8947622E8C1F4" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_15F6C1B4DC25B5F65FD2947622E806A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_99EA840B19C0FA39F211947622E8B66F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_94BAFB318992C0A48DB8947622E8C1F4" xlink:to="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_99EA840B19C0FA39F211947622E8B66F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNet" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_99E2D2BB99843EE3A17E94761F365616" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_E24C97077350D343C94F94761F369B49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_99E2D2BB99843EE3A17E94761F365616" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_E24C97077350D343C94F94761F369B49" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_BA2197576EA629C82A53B5A4AEA89B97" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_609A70B309F58876CE85B5A4AEA8FC9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_BA2197576EA629C82A53B5A4AEA89B97" xlink:to="loc_us-gaap_InvestmentIncomeInterest_609A70B309F58876CE85B5A4AEA8FC9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_C49B5D3BB765A0AD2EB2B5A4AEA87F86" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_BA2197576EA629C82A53B5A4AEA89B97" xlink:to="loc_us-gaap_InterestExpense_C49B5D3BB765A0AD2EB2B5A4AEA87F86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRevenueExpenseNet" xlink:label="loc_us-gaap_InterestRevenueExpenseNet_DC754060A77076AB9901B5A4AEA92FB6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_BA2197576EA629C82A53B5A4AEA89B97" xlink:to="loc_us-gaap_InterestRevenueExpenseNet_DC754060A77076AB9901B5A4AEA92FB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_AFD2548125BC020E41BBB5A4AEA9C8C8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_BA2197576EA629C82A53B5A4AEA89B97" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_AFD2548125BC020E41BBB5A4AEA9C8C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_2F12A5D990FA674BE439B5A4AEA98BB9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_BA2197576EA629C82A53B5A4AEA89B97" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_2F12A5D990FA674BE439B5A4AEA98BB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_EE59FB08C9492AEC30FBB5A4AEA97AE6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_BA2197576EA629C82A53B5A4AEA89B97" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_EE59FB08C9492AEC30FBB5A4AEA97AE6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" xlink:label="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_EEF58D48B34B0B8CD7BCB5A4AEA9D53C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_BA2197576EA629C82A53B5A4AEA89B97" xlink:to="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_EEF58D48B34B0B8CD7BCB5A4AEA9D53C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_7ADC14CC974CDFEAFBFCB5A4AEAA3AD7" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_BA2197576EA629C82A53B5A4AEA89B97" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_7ADC14CC974CDFEAFBFCB5A4AEAA3AD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_6B4E79AB391FE4DE569AB5A4AEAA74B9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_BA2197576EA629C82A53B5A4AEA89B97" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_6B4E79AB391FE4DE569AB5A4AEAA74B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_C92543AC0B28AE7C1235B5A4AEAA777C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_BA2197576EA629C82A53B5A4AEA89B97" xlink:to="loc_us-gaap_AssetImpairmentCharges_C92543AC0B28AE7C1235B5A4AEAA777C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BusinessAlignmentCosts" xlink:label="loc_pfe_BusinessAlignmentCosts_C61F4462AD9643BFF1ECB5A4AEAA7857" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_BA2197576EA629C82A53B5A4AEA89B97" xlink:to="loc_pfe_BusinessAlignmentCosts_C61F4462AD9643BFF1ECB5A4AEAA7857" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_CEE7009105ADA3753F3DB5A4AEAA365A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_BA2197576EA629C82A53B5A4AEA89B97" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_CEE7009105ADA3753F3DB5A4AEAA365A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" xlink:label="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_E112696F055625EE2874B5A4AEAAA5DD" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_BA2197576EA629C82A53B5A4AEA89B97" xlink:to="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_E112696F055625EE2874B5A4AEAAA5DD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherNonoperatingIncomeExpenseNet" xlink:label="loc_pfe_OtherNonoperatingIncomeExpenseNet_ED885CD7D01C4818D49EB5A4AEAA734E" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_BA2197576EA629C82A53B5A4AEA89B97" xlink:to="loc_pfe_OtherNonoperatingIncomeExpenseNet_ED885CD7D01C4818D49EB5A4AEAA734E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_C48F4329431470D4BF7DB5A4AEAA9CA5" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_BA2197576EA629C82A53B5A4AEA89B97" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_C48F4329431470D4BF7DB5A4AEAA9CA5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_5C60DB7C2A2BFD48822978FDDF8CF660" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5C60DB7C2A2BFD48822978FDDF8CF660" xlink:to="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_52F6F272535F75A2AC1278FDDF8D06EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_52F6F272535F75A2AC1278FDDF8D06EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E23208D70F7ED51FAFE378FDDF8DF1BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_52F6F272535F75A2AC1278FDDF8D06EF" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E23208D70F7ED51FAFE378FDDF8DF1BD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ViiVMember" xlink:label="loc_pfe_ViiVMember_6C21C3E291F9DB235A4378FDDF8D999B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E23208D70F7ED51FAFE378FDDF8DF1BD" xlink:to="loc_pfe_ViiVMember_6C21C3E291F9DB235A4378FDDF8D999B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_EC9AC499E434ADBE933378FDDF8D57D5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:to="loc_srt_ProductOrServiceAxis_EC9AC499E434ADBE933378FDDF8D57D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_B22A1C94F26CD10CFF0478FDDF8E069F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_EC9AC499E434ADBE933378FDDF8D57D5" xlink:to="loc_srt_ProductsAndServicesDomain_B22A1C94F26CD10CFF0478FDDF8E069F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_GeneTherapiesMember" xlink:label="loc_pfe_GeneTherapiesMember_F081BED22814113DE0A878FDDF8E48B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B22A1C94F26CD10CFF0478FDDF8E069F" xlink:to="loc_pfe_GeneTherapiesMember_F081BED22814113DE0A878FDDF8E48B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_11C5E8842F221DEE086B78FDDF8E9CF1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_11C5E8842F221DEE086B78FDDF8E9CF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_4B5DDD5686F934932F2578FDDF8E3866" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_11C5E8842F221DEE086B78FDDF8E9CF1" xlink:to="loc_us-gaap_SegmentDomain_4B5DDD5686F934932F2578FDDF8E3866" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_09C9A11A8E45A06CF1BA78FDDF8EDEC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4B5DDD5686F934932F2578FDDF8E3866" xlink:to="loc_pfe_BiopharmaSegmentMember_09C9A11A8E45A06CF1BA78FDDF8EDEC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_66B4443D0A612EF0B17278FDDF8FDE49" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:to="loc_srt_ConsolidationItemsAxis_66B4443D0A612EF0B17278FDDF8FDE49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_8447C2B0F9667A1516C478FDDF8FC13C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_66B4443D0A612EF0B17278FDDF8FDE49" xlink:to="loc_srt_ConsolidationItemsDomain_8447C2B0F9667A1516C478FDDF8FC13C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_F0FFB335CF903EE9DD0978FDDF8F970D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_8447C2B0F9667A1516C478FDDF8FC13C" xlink:to="loc_us-gaap_OperatingSegmentsMember_F0FFB335CF903EE9DD0978FDDF8F970D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsAxis" xlink:label="loc_us-gaap_SubsegmentsAxis_2BB12DCA1A6ABCEC286F78FDDF9088BD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:to="loc_us-gaap_SubsegmentsAxis_2BB12DCA1A6ABCEC286F78FDDF9088BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_98FCE16A7051F014309E78FDDF90BEC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_2BB12DCA1A6ABCEC286F78FDDF9088BD" xlink:to="loc_us-gaap_SubsegmentsDomain_98FCE16A7051F014309E78FDDF90BEC6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember" xlink:label="loc_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_90AD4A79C4B2C45B167778FDDF9024AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_98FCE16A7051F014309E78FDDF90BEC6" xlink:to="loc_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_90AD4A79C4B2C45B167778FDDF9024AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_D504064B43834B0C417478FDDF9026A4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_D504064B43834B0C417478FDDF9026A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9A2E1AAF92A5274D0EE778FDDF9079C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_D504064B43834B0C417478FDDF9026A4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9A2E1AAF92A5274D0EE778FDDF9079C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_AF1ED9A3CEF5AD84713E78FDDF91CC3F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9A2E1AAF92A5274D0EE778FDDF9079C8" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_AF1ED9A3CEF5AD84713E78FDDF91CC3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_BB42324196F671542E9E78FDDF912E3C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_BB42324196F671542E9E78FDDF912E3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_95396235E2130E5B73B578FDDF915F3B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_BB42324196F671542E9E78FDDF912E3C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_95396235E2130E5B73B578FDDF915F3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_278E56D4D9DE0B51BEB578FDDF9116D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_95396235E2130E5B73B578FDDF915F3B" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_278E56D4D9DE0B51BEB578FDDF9116D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_A9DF1BCCCCE78D29492078FDDF929F23" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_A9DF1BCCCCE78D29492078FDDF929F23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_F327A7E8C4E71133052278FDDF92DC8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_A9DF1BCCCCE78D29492078FDDF929F23" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_F327A7E8C4E71133052278FDDF92DC8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_8F6D2F0972C38D6A607578FDDF92DF18" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_F327A7E8C4E71133052278FDDF92DC8E" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_8F6D2F0972C38D6A607578FDDF92DF18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_87F4F97638CE59FA783F78FDDF92A078" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_87F4F97638CE59FA783F78FDDF92A078" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_80C16C029C48ECBD08D078FDDF93FABF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_87F4F97638CE59FA783F78FDDF92A078" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_80C16C029C48ECBD08D078FDDF93FABF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_CK1AssetsSoldToBiogenIncMember" xlink:label="loc_pfe_CK1AssetsSoldToBiogenIncMember_90B61E774EFCEF6FEB0F78FDDF93EEE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_80C16C029C48ECBD08D078FDDF93FABF" xlink:to="loc_pfe_CK1AssetsSoldToBiogenIncMember_90B61E774EFCEF6FEB0F78FDDF93EEE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_38F2A12569E4CBBB138378FDDF9366C7" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:to="loc_srt_CounterpartyNameAxis_38F2A12569E4CBBB138378FDDF9366C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A98C943EE96BCA33E4DC78FDDF930D3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_38F2A12569E4CBBB138378FDDF9366C7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A98C943EE96BCA33E4DC78FDDF930D3E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PumaTechnologiesMember" xlink:label="loc_pfe_PumaTechnologiesMember_4A045F9C1FC1E8CCA34A78FDDF948E99" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A98C943EE96BCA33E4DC78FDDF930D3E" xlink:to="loc_pfe_PumaTechnologiesMember_4A045F9C1FC1E8CCA34A78FDDF948E99" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EliLillyCompanyMember" xlink:label="loc_pfe_EliLillyCompanyMember_F8848A67BFBE74A71F3378FDDF993672" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A98C943EE96BCA33E4DC78FDDF930D3E" xlink:to="loc_pfe_EliLillyCompanyMember_F8848A67BFBE74A71F3378FDDF993672" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_MylanMember" xlink:label="loc_pfe_MylanMember_F59F81BE5EB8C382AC5F78FDDF99E8D1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A98C943EE96BCA33E4DC78FDDF930D3E" xlink:to="loc_pfe_MylanMember_F59F81BE5EB8C382AC5F78FDDF99E8D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_DB3FB0692FF0B74F463078FDDF991C0F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:to="loc_us-gaap_TypeOfArrangementAxis_DB3FB0692FF0B74F463078FDDF991C0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_68EE34F5DFD56226EF6678FDDF9A230B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_DB3FB0692FF0B74F463078FDDF991C0F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_68EE34F5DFD56226EF6678FDDF9A230B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_73FF4EE06B22FF04B44978FDDF9A32B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_68EE34F5DFD56226EF6678FDDF9A230B" xlink:to="loc_us-gaap_CollaborativeArrangementMember_73FF4EE06B22FF04B44978FDDF9A32B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3F2C67A067E99BD5250678FDDF9AAF50" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3F2C67A067E99BD5250678FDDF9AAF50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_F864FE69E51F64EA3D0378FDDF9ADB07" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3F2C67A067E99BD5250678FDDF9AAF50" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_F864FE69E51F64EA3D0378FDDF9ADB07" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AllogeneMember" xlink:label="loc_pfe_AllogeneMember_02C1E07DB82846574EBB78FDDF9B556F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_F864FE69E51F64EA3D0378FDDF9ADB07" xlink:to="loc_pfe_AllogeneMember_02C1E07DB82846574EBB78FDDF9B556F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BioNTechSEMember" xlink:label="loc_pfe_BioNTechSEMember_BBD9F34220B9E3785F1C78FDDF9B4457" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_F864FE69E51F64EA3D0378FDDF9ADB07" xlink:to="loc_pfe_BioNTechSEMember_BBD9F34220B9E3785F1C78FDDF9B4457" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_CortexymeInc.Member" xlink:label="loc_pfe_CortexymeInc.Member_251078E406455CB0A52878FDDF9B8B35" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_F864FE69E51F64EA3D0378FDDF9ADB07" xlink:to="loc_pfe_CortexymeInc.Member_251078E406455CB0A52878FDDF9B8B35" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_KingMember" xlink:label="loc_pfe_KingMember_6F5D3BAB839D0F7744EC78FDDF9B7F8E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_F864FE69E51F64EA3D0378FDDF9ADB07" xlink:to="loc_pfe_KingMember_6F5D3BAB839D0F7744EC78FDDF9B7F8E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AnacorMember" xlink:label="loc_pfe_AnacorMember_3F3427A5FF2C0DA3818778FDDF9B5257" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_F864FE69E51F64EA3D0378FDDF9ADB07" xlink:to="loc_pfe_AnacorMember_3F3427A5FF2C0DA3818778FDDF9B5257" xlink:type="arc" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_F864FE69E51F64EA3D0378FDDF9ADB07" xlink:to="loc_pfe_ViiVMember_6C21C3E291F9DB235A4378FDDF8D999B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_2CE131CF4595136F1EC678FDDF9C8167" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_53EA87B5EFD95551ADBF78FDDF8CC021" xlink:to="loc_us-gaap_LossContingenciesLineItems_2CE131CF4595136F1EC678FDDF9C8167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="loc_us-gaap_ProceedsFromLegalSettlements_77B7CE04FB1CED841F4178FDDF9C171B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2CE131CF4595136F1EC678FDDF9C8167" xlink:to="loc_us-gaap_ProceedsFromLegalSettlements_77B7CE04FB1CED841F4178FDDF9C171B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7626C776657E126AC4FA78FDDF9CD98A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2CE131CF4595136F1EC678FDDF9C8167" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7626C776657E126AC4FA78FDDF9CD98A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_94FDED715D49CB8641C478FDDF9C0AED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2CE131CF4595136F1EC678FDDF9C8167" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_94FDED715D49CB8641C478FDDF9C0AED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="loc_us-gaap_ProceedsFromCollaborators_C9E0367BF85EDC2FF72C78FDDF9C261D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2CE131CF4595136F1EC678FDDF9C8167" xlink:to="loc_us-gaap_ProceedsFromCollaborators_C9E0367BF85EDC2FF72C78FDDF9C261D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_91860A26E03A971E7CD178FDDF9D3DDD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2CE131CF4595136F1EC678FDDF9C8167" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_91860A26E03A971E7CD178FDDF9D3DDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_90E4EDFBB50803B9F5B278FDDF9DD9A6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2CE131CF4595136F1EC678FDDF9C8167" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_90E4EDFBB50803B9F5B278FDDF9DD9A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeDividend" xlink:label="loc_us-gaap_InvestmentIncomeDividend_D1004AFAE8A6032C328478FDDF9D57EF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2CE131CF4595136F1EC678FDDF9C8167" xlink:to="loc_us-gaap_InvestmentIncomeDividend_D1004AFAE8A6032C328478FDDF9D57EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InsuranceRecoveries" xlink:label="loc_us-gaap_InsuranceRecoveries_227B4BC59F17202971AE78FDDF9D2F52" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2CE131CF4595136F1EC678FDDF9C8167" xlink:to="loc_us-gaap_InsuranceRecoveries_227B4BC59F17202971AE78FDDF9D2F52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5D04B06DEF744BD9138078FDDF9DE441" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2CE131CF4595136F1EC678FDDF9C8167" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5D04B06DEF744BD9138078FDDF9DE441" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_286BAE0AA59CA916074994761EE5F1FD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_76641FE774A15B4552C094761EE631B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_286BAE0AA59CA916074994761EE5F1FD" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_76641FE774A15B4552C094761EE631B7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlans" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_C8262AA91094003E8AC0947622E6947C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_619BF0412B9E1CF20234947622E63717" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_C8262AA91094003E8AC0947622E6947C" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_619BF0412B9E1CF20234947622E63717" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_03BDA393836478B5CC4C628A0AD001E5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51DF12670EA0BFBEF575628A0AD0A94B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_03BDA393836478B5CC4C628A0AD001E5" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51DF12670EA0BFBEF575628A0AD0A94B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9BEE5BC8C2DC5ECB80A563321A2C6932" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51DF12670EA0BFBEF575628A0AD0A94B" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9BEE5BC8C2DC5ECB80A563321A2C6932" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_AD3B3E74DE2B3D5BACAD63321A3BFEAA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9BEE5BC8C2DC5ECB80A563321A2C6932" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_AD3B3E74DE2B3D5BACAD63321A3BFEAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_93515747A298A774E07D633242D57CF7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_AD3B3E74DE2B3D5BACAD63321A3BFEAA" xlink:to="loc_us-gaap_SubsequentEventMember_93515747A298A774E07D633242D57CF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_45AA784DEA72111C9017628A0AD00235" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51DF12670EA0BFBEF575628A0AD0A94B" xlink:to="loc_srt_StatementScenarioAxis_45AA784DEA72111C9017628A0AD00235" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_DD910F616A868D7D53C3628A0AD128CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_45AA784DEA72111C9017628A0AD00235" xlink:to="loc_srt_ScenarioUnspecifiedDomain_DD910F616A868D7D53C3628A0AD128CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_FFA9C0635DE064D8B39A628A0AD133AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_DD910F616A868D7D53C3628A0AD128CA" xlink:to="loc_srt_ScenarioForecastMember_FFA9C0635DE064D8B39A628A0AD133AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_8AFF68E1779C00C2A437628A0AD1B2FB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51DF12670EA0BFBEF575628A0AD0A94B" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_8AFF68E1779C00C2A437628A0AD1B2FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_67BE5728FCA2B1C4BBE5628A0AD1DF08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8AFF68E1779C00C2A437628A0AD1B2FB" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_67BE5728FCA2B1C4BBE5628A0AD1DF08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_37EF3F74F0F63D24BE44628A0AD29A93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_67BE5728FCA2B1C4BBE5628A0AD1DF08" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_37EF3F74F0F63D24BE44628A0AD29A93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_99F6490F088BD8E53DAC628A0AD25AFD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_67BE5728FCA2B1C4BBE5628A0AD1DF08" xlink:to="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_99F6490F088BD8E53DAC628A0AD25AFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_B4E57311C55ACEF0FA4C628A0AD2CB81" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_67BE5728FCA2B1C4BBE5628A0AD1DF08" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_B4E57311C55ACEF0FA4C628A0AD2CB81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_0D91188B6219E42A21D9628A0AD2BF0B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51DF12670EA0BFBEF575628A0AD0A94B" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_0D91188B6219E42A21D9628A0AD2BF0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_1968054DED17DE4610CB628A0AD231F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_0D91188B6219E42A21D9628A0AD2BF0B" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_1968054DED17DE4610CB628A0AD231F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_4CB21BEFBBC1273C4848628A0AD31BB6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_1968054DED17DE4610CB628A0AD231F3" xlink:to="loc_us-gaap_DomesticPlanMember_4CB21BEFBBC1273C4848628A0AD31BB6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_country_US_A0B753B72162624377FB628A0AD3316F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_4CB21BEFBBC1273C4848628A0AD31BB6" xlink:to="loc_country_US_A0B753B72162624377FB628A0AD3316F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_B22335C907574E65952F628A0AD3CEDB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_1968054DED17DE4610CB628A0AD231F3" xlink:to="loc_us-gaap_ForeignPlanMember_B22335C907574E65952F628A0AD3CEDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_18B4BC2481FBCEB61D72628A0AD37B2A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51DF12670EA0BFBEF575628A0AD0A94B" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_18B4BC2481FBCEB61D72628A0AD37B2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_B513E75366818871814D628A0AD3F780" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_18B4BC2481FBCEB61D72628A0AD37B2A" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_B513E75366818871814D628A0AD3F780" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_17774093E014F5E0A46D628A0AD48395" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_B513E75366818871814D628A0AD3F780" xlink:to="loc_us-gaap_QualifiedPlanMember_17774093E014F5E0A46D628A0AD48395" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonqualifiedPlanMember" xlink:label="loc_us-gaap_NonqualifiedPlanMember_762175F4882B0B993694628A0AD40D66" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_B513E75366818871814D628A0AD3F780" xlink:to="loc_us-gaap_NonqualifiedPlanMember_762175F4882B0B993694628A0AD40D66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_57E118D76609D5287559628A0AD42C2D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51DF12670EA0BFBEF575628A0AD0A94B" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_57E118D76609D5287559628A0AD42C2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_5F735C092181AD45E9E1628A0AD4CC12" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_57E118D76609D5287559628A0AD42C2D" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_5F735C092181AD45E9E1628A0AD4CC12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_84E2789E62FDD42470DC628A0AD55844" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_57E118D76609D5287559628A0AD42C2D" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_84E2789E62FDD42470DC628A0AD55844" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3ACA52D03A645281A890628A0AE08679" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3E9407B81FFADCB78971628A0AE13BD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3ACA52D03A645281A890628A0AE08679" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3E9407B81FFADCB78971628A0AE13BD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_5F8DFC43D8ECD5F3B4E9628A0AE17E9D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3E9407B81FFADCB78971628A0AE13BD9" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_5F8DFC43D8ECD5F3B4E9628A0AE17E9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_3755ED1AC59F303D6D64628A0AE18430" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_5F8DFC43D8ECD5F3B4E9628A0AE17E9D" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_3755ED1AC59F303D6D64628A0AE18430" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_7CDBA0689F43710AA1C3628A0AE2F86C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3755ED1AC59F303D6D64628A0AE18430" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_7CDBA0689F43710AA1C3628A0AE2F86C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_E3826B52D7D2D3A88973628A0AE2DB4E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3755ED1AC59F303D6D64628A0AE18430" xlink:to="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_E3826B52D7D2D3A88973628A0AE2DB4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_EB1A9E6CC620506C3D59628A0AE27007" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3755ED1AC59F303D6D64628A0AE18430" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_EB1A9E6CC620506C3D59628A0AE27007" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_873A5349A50817F6F780628A0AE244F2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3E9407B81FFADCB78971628A0AE13BD9" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_873A5349A50817F6F780628A0AE244F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_2F862D980FE658762FEA628A0AE24D79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_873A5349A50817F6F780628A0AE244F2" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_2F862D980FE658762FEA628A0AE24D79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_6E4F020F05175396102C628A0AE3884E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_2F862D980FE658762FEA628A0AE24D79" xlink:to="loc_us-gaap_DomesticPlanMember_6E4F020F05175396102C628A0AE3884E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_country_US_5CA83C3D5B9880E85558628A0AE3AF76" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_6E4F020F05175396102C628A0AE3884E" xlink:to="loc_country_US_5CA83C3D5B9880E85558628A0AE3AF76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_93612823091DDC1A223C628A0AE3596F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_2F862D980FE658762FEA628A0AE24D79" xlink:to="loc_us-gaap_ForeignPlanMember_93612823091DDC1A223C628A0AE3596F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_178B0A991AA060EFDDBB628A0AE3E144" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3E9407B81FFADCB78971628A0AE13BD9" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_178B0A991AA060EFDDBB628A0AE3E144" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_52047D265623112B6148628A0AE3C345" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_178B0A991AA060EFDDBB628A0AE3E144" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_52047D265623112B6148628A0AE3C345" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_74E2AA6EB95BB39DF39B628A0AE4A6C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_52047D265623112B6148628A0AE3C345" xlink:to="loc_us-gaap_QualifiedPlanMember_74E2AA6EB95BB39DF39B628A0AE4A6C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonqualifiedPlanMember" xlink:label="loc_us-gaap_NonqualifiedPlanMember_83D949A11D7C3B45AD65628A0AE41816" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_52047D265623112B6148628A0AE3C345" xlink:to="loc_us-gaap_NonqualifiedPlanMember_83D949A11D7C3B45AD65628A0AE41816" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4A3ABA8E3960BEE9A362628A0AE4AD4D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3E9407B81FFADCB78971628A0AE13BD9" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4A3ABA8E3960BEE9A362628A0AE4AD4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_F1FB17F4613652D9DDA2628A0AE4333F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4A3ABA8E3960BEE9A362628A0AE4AD4D" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_F1FB17F4613652D9DDA2628A0AE4333F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_9E0006E83CF0F7C78651628A0AE5B8D3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4A3ABA8E3960BEE9A362628A0AE4AD4D" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_9E0006E83CF0F7C78651628A0AE5B8D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_1576F9AFBB60D335F1E8628A0AE5514B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4A3ABA8E3960BEE9A362628A0AE4AD4D" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_1576F9AFBB60D335F1E8628A0AE5514B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_9A097CDC3C5DBEB64CDD628A0AE520DA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4A3ABA8E3960BEE9A362628A0AE4AD4D" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_9A097CDC3C5DBEB64CDD628A0AE520DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_1BDE885221B042E4F56E628A0AE54F0F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_9A097CDC3C5DBEB64CDD628A0AE520DA" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_1BDE885221B042E4F56E628A0AE54F0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_D4FFE27813E7807B1590628A0AE51167" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_9A097CDC3C5DBEB64CDD628A0AE520DA" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_D4FFE27813E7807B1590628A0AE51167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_4E54D10FE1DD94B19A72628A0AE51B51" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4A3ABA8E3960BEE9A362628A0AE4AD4D" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_4E54D10FE1DD94B19A72628A0AE51B51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanSpecialTerminationBenefits" xlink:label="loc_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_663B3A3C6966B7EFBA2C628A0AE63F59" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4A3ABA8E3960BEE9A362628A0AE4AD4D" xlink:to="loc_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_663B3A3C6966B7EFBA2C628A0AE63F59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7F8F14895BE825DB988B628A0AE693E9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4A3ABA8E3960BEE9A362628A0AE4AD4D" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7F8F14895BE825DB988B628A0AE693E9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_425EBFE16F9045F9670294761FFD4FFF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_C635EB3B80589E73895A94761FFDB5D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_425EBFE16F9045F9670294761FFD4FFF" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_C635EB3B80589E73895A94761FFDB5D8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock" xlink:label="loc_pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock_205667885597B4683A5794761FFEA886" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_425EBFE16F9045F9670294761FFD4FFF" xlink:to="loc_pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock_205667885597B4683A5794761FFEA886" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_FFC744371C4F9DF186EA947620E96888" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_7E4F3D5973CB982F5987947620E94EE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_FFC744371C4F9DF186EA947620E96888" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_7E4F3D5973CB982F5987947620E94EE5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_01AF91B9BDAFE75BF22D94762279A43D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E9973313E6D818218E629476227985BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_01AF91B9BDAFE75BF22D94762279A43D" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E9973313E6D818218E629476227985BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_FB92AC5F9AF1B54D2CAA947622793F95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E9973313E6D818218E629476227985BE" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_FB92AC5F9AF1B54D2CAA947622793F95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_FEBAAA722311759CF8839476227ADAE8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_FB92AC5F9AF1B54D2CAA947622793F95" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_FEBAAA722311759CF8839476227ADAE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_B0FEB0AB99E0124809AE9476227A91DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_FEBAAA722311759CF8839476227ADAE8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_B0FEB0AB99E0124809AE9476227A91DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_D3EC572DDEFC7C95B0F59476227ADF60" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_FEBAAA722311759CF8839476227ADAE8" xlink:to="loc_us-gaap_CostOfSalesMember_D3EC572DDEFC7C95B0F59476227ADF60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_B5FFD3D50B8AEDAB2F009476227A290A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_FEBAAA722311759CF8839476227ADAE8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_B5FFD3D50B8AEDAB2F009476227A290A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3C1DE68EFB3E21EE427F9476227A111C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_FEBAAA722311759CF8839476227ADAE8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3C1DE68EFB3E21EE427F9476227A111C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_0DDC216E705F309D1A489476227B3398" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E9973313E6D818218E629476227985BE" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_0DDC216E705F309D1A489476227B3398" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesAbstract" xlink:label="loc_us-gaap_RestructuringChargesAbstract_554FB9F2415050FF805B9476227B8B64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0DDC216E705F309D1A489476227B3398" xlink:to="loc_us-gaap_RestructuringChargesAbstract_554FB9F2415050FF805B9476227B8B64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_CF75064E0B24F4F812569476227B7971" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_554FB9F2415050FF805B9476227B8B64" xlink:to="loc_us-gaap_SeveranceCosts1_CF75064E0B24F4F812569476227B7971" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_RestructuringAssetImpairmentCharges" xlink:label="loc_pfe_RestructuringAssetImpairmentCharges_A8325EDACB115E317DA69476227BBAD2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_554FB9F2415050FF805B9476227B8B64" xlink:to="loc_pfe_RestructuringAssetImpairmentCharges_A8325EDACB115E317DA69476227BBAD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessExitCosts1" xlink:label="loc_us-gaap_BusinessExitCosts1_1FD3B7C47A9669537A819476227B1DDF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_554FB9F2415050FF805B9476227B8B64" xlink:to="loc_us-gaap_BusinessExitCosts1_1FD3B7C47A9669537A819476227B1DDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_C35951E8DB4A05066CB89476227C0E8F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_554FB9F2415050FF805B9476227B8B64" xlink:to="loc_us-gaap_RestructuringCharges_C35951E8DB4A05066CB89476227C0E8F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:label="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_16FE7E3F44FEF3B7D1919476227CFE43" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0DDC216E705F309D1A489476227B3398" xlink:to="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_16FE7E3F44FEF3B7D1919476227CFE43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_4A70149873945FBC89F19476227C10A9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0DDC216E705F309D1A489476227B3398" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_4A70149873945FBC89F19476227C10A9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_1CA7BB76E148589C238A9476227C4CEF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0DDC216E705F309D1A489476227B3398" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_1CA7BB76E148589C238A9476227C4CEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3D6F1CDB9ECD0319265A9476227CC1B4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0DDC216E705F309D1A489476227B3398" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3D6F1CDB9ECD0319265A9476227CC1B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_05F98BC4AB5B442EFC9D9476227DB342" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0DDC216E705F309D1A489476227B3398" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_05F98BC4AB5B442EFC9D9476227DB342" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ImplementationCostAbstract" xlink:label="loc_pfe_ImplementationCostAbstract_11002BD29D6E91B6B6229476227DE0C6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0DDC216E705F309D1A489476227B3398" xlink:to="loc_pfe_ImplementationCostAbstract_11002BD29D6E91B6B6229476227DE0C6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ImplementationCosts" xlink:label="loc_pfe_ImplementationCosts_00CE778F6BD769E653C69476227D2021" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ImplementationCostAbstract_11002BD29D6E91B6B6229476227DE0C6" xlink:to="loc_pfe_ImplementationCosts_00CE778F6BD769E653C69476227D2021" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:label="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_85341EAF51B71283A4829476227D3AEB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0DDC216E705F309D1A489476227B3398" xlink:to="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_85341EAF51B71283A4829476227D3AEB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_42CC2672E11531B2360C5E4BE870D3D0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_319834433511A9341B135E4BE870BCE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_42CC2672E11531B2360C5E4BE870D3D0" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_319834433511A9341B135E4BE870BCE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_C7BB80BACFA54B9840825E4BE870E5AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_319834433511A9341B135E4BE870BCE6" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_C7BB80BACFA54B9840825E4BE870E5AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_4D06B7B987F1DABB77EA5E4BE871FE11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_C7BB80BACFA54B9840825E4BE870E5AC" xlink:to="loc_us-gaap_SegmentDomain_4D06B7B987F1DABB77EA5E4BE871FE11" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_3DDB9ED6E896316BAD9C5E4BE871F784" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4D06B7B987F1DABB77EA5E4BE871FE11" xlink:to="loc_pfe_BiopharmaSegmentMember_3DDB9ED6E896316BAD9C5E4BE871F784" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnSegmentMember" xlink:label="loc_pfe_UpjohnSegmentMember_8BCC7BC0DD448FBACE7D5E4BE8711EF5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4D06B7B987F1DABB77EA5E4BE871FE11" xlink:to="loc_pfe_UpjohnSegmentMember_8BCC7BC0DD448FBACE7D5E4BE8711EF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_8318C07C984405E3EFA55E4BE871ABA0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_319834433511A9341B135E4BE870BCE6" xlink:to="loc_srt_ConsolidationItemsAxis_8318C07C984405E3EFA55E4BE871ABA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_98F7608E15D772BE552A5E4BE872097C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_8318C07C984405E3EFA55E4BE871ABA0" xlink:to="loc_srt_ConsolidationItemsDomain_98F7608E15D772BE552A5E4BE872097C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_C0C649F693BA3F93BC035E4BE872EB94" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_98F7608E15D772BE552A5E4BE872097C" xlink:to="loc_us-gaap_OperatingSegmentsMember_C0C649F693BA3F93BC035E4BE872EB94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_B348F4B22EC23ECFF5515E4BE872030C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_98F7608E15D772BE552A5E4BE872097C" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_B348F4B22EC23ECFF5515E4BE872030C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_B8C9FADBD7F23857155C5E4BE8721F70" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_319834433511A9341B135E4BE870BCE6" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_B8C9FADBD7F23857155C5E4BE8721F70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1F0897CB9251134234DB5E4BE87203C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_B8C9FADBD7F23857155C5E4BE8721F70" xlink:to="loc_us-gaap_RestructuringCharges_1F0897CB9251134234DB5E4BE87203C9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_729C2DD16CA43E641E2D9D36D87E2932" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3128A8B5F98FA950D63D9D36D87E6A3D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_729C2DD16CA43E641E2D9D36D87E2932" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3128A8B5F98FA950D63D9D36D87E6A3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_22F965B7D9CF329100F09D36D87FEBB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3128A8B5F98FA950D63D9D36D87E6A3D" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_22F965B7D9CF329100F09D36D87FEBB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_72F19A7A6B6EDC5C7B719D36D87F74F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_22F965B7D9CF329100F09D36D87FEBB7" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_72F19A7A6B6EDC5C7B719D36D87F74F5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ManufacturingCostReductionMember" xlink:label="loc_pfe_ManufacturingCostReductionMember_C0D1EEC985364ECE4C909D36D87F3E99" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_72F19A7A6B6EDC5C7B719D36D87F74F5" xlink:to="loc_pfe_ManufacturingCostReductionMember_C0D1EEC985364ECE4C909D36D87F3E99" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BusinessIntegrationCostsMember" xlink:label="loc_pfe_BusinessIntegrationCostsMember_CE00D3D4C91D03DB5E649D36D87F5309" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_72F19A7A6B6EDC5C7B719D36D87F74F5" xlink:to="loc_pfe_BusinessIntegrationCostsMember_CE00D3D4C91D03DB5E649D36D87F5309" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_470E0AA108BBC8024A439D36D880531D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3128A8B5F98FA950D63D9D36D87E6A3D" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_470E0AA108BBC8024A439D36D880531D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07D0726D6A39954C25359D36D8803800" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_470E0AA108BBC8024A439D36D880531D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07D0726D6A39954C25359D36D8803800" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_HospiraMember" xlink:label="loc_pfe_HospiraMember_945E546E6BFEA44EA1899D36D88042D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07D0726D6A39954C25359D36D8803800" xlink:to="loc_pfe_HospiraMember_945E546E6BFEA44EA1899D36D88042D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_CB08029633875C90B0719D36D8807F26" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3128A8B5F98FA950D63D9D36D87E6A3D" xlink:to="loc_us-gaap_RestructuringPlanAxis_CB08029633875C90B0719D36D8807F26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_3FFCAB00BB3EC4A2851F9D36D880C948" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_CB08029633875C90B0719D36D8807F26" xlink:to="loc_us-gaap_RestructuringPlanDomain_3FFCAB00BB3EC4A2851F9D36D880C948" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FocusedCompanyPlanMember" xlink:label="loc_pfe_FocusedCompanyPlanMember_B1855A7BF242A7DE65099D36D8819D49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_3FFCAB00BB3EC4A2851F9D36D880C948" xlink:to="loc_pfe_FocusedCompanyPlanMember_B1855A7BF242A7DE65099D36D8819D49" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember" xlink:label="loc_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_1D2911359B0DD76DBA149D36D881050E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_3FFCAB00BB3EC4A2851F9D36D880C948" xlink:to="loc_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_1D2911359B0DD76DBA149D36D881050E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_EED7F75156CE3F2BD9E29D36D8818911" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3128A8B5F98FA950D63D9D36D87E6A3D" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_EED7F75156CE3F2BD9E29D36D8818911" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_5680D04BAEBE3D1E576B9D36D881805B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EED7F75156CE3F2BD9E29D36D8818911" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_5680D04BAEBE3D1E576B9D36D881805B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_RestructuringandRelatedCostNoncashChargesPercentage" xlink:label="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_C5A13503910283CA4A409D36D8829F31" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EED7F75156CE3F2BD9E29D36D8818911" xlink:to="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_C5A13503910283CA4A409D36D8829F31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_7AAE12E998A0C1894B5E9D36D88227F6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EED7F75156CE3F2BD9E29D36D8818911" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_7AAE12E998A0C1894B5E9D36D88227F6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_CB9DE25E2F7FD83F31185E4BE86AAB7F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9345CE3A5B6465A5934D5E4BE86A517B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_CB9DE25E2F7FD83F31185E4BE86AAB7F" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9345CE3A5B6465A5934D5E4BE86A517B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1A317329DCCEC7FC44DB5E4BE86A615E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9345CE3A5B6465A5934D5E4BE86A517B" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_1A317329DCCEC7FC44DB5E4BE86A615E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_675A4F67CEC0EF2753465E4BE86B9402" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1A317329DCCEC7FC44DB5E4BE86A615E" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_675A4F67CEC0EF2753465E4BE86B9402" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_FE7786157B6C3981FE455E4BE86B4801" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_675A4F67CEC0EF2753465E4BE86B9402" xlink:to="loc_us-gaap_EmployeeSeveranceMember_FE7786157B6C3981FE455E4BE86B4801" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AssetImpairmentsMember" xlink:label="loc_pfe_AssetImpairmentsMember_51C7BACE87279A174D225E4BE86B94C6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_675A4F67CEC0EF2753465E4BE86B9402" xlink:to="loc_pfe_AssetImpairmentsMember_51C7BACE87279A174D225E4BE86B94C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_us-gaap_OtherRestructuringMember_7D058F9AD055CB7861B05E4BE86B5C99" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_675A4F67CEC0EF2753465E4BE86B9402" xlink:to="loc_us-gaap_OtherRestructuringMember_7D058F9AD055CB7861B05E4BE86B5C99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_974D7B3BCF0589DEB09B5E4BE86B6AF2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9345CE3A5B6465A5934D5E4BE86A517B" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_974D7B3BCF0589DEB09B5E4BE86B6AF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveRollForward" xlink:label="loc_us-gaap_RestructuringReserveRollForward_E066916D2FECFCEEFF225E4BE86C8D0B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_974D7B3BCF0589DEB09B5E4BE86B6AF2" xlink:to="loc_us-gaap_RestructuringReserveRollForward_E066916D2FECFCEEFF225E4BE86C8D0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_FBFAF74349D70157E6855E4BE86C797E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_E066916D2FECFCEEFF225E4BE86C8D0B" xlink:to="loc_us-gaap_RestructuringReserve_FBFAF74349D70157E6855E4BE86C797E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_435A7B2669116D1C47065E4BE86CD413" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_E066916D2FECFCEEFF225E4BE86C8D0B" xlink:to="loc_us-gaap_RestructuringCharges_435A7B2669116D1C47065E4BE86CD413" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" xlink:label="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_9C1CA6033D93F73820EA5E4BE86C2169" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_E066916D2FECFCEEFF225E4BE86C8D0B" xlink:to="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_9C1CA6033D93F73820EA5E4BE86C2169" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_634924688BE819BAE6025E4BE86DA70D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_E066916D2FECFCEEFF225E4BE86C8D0B" xlink:to="loc_us-gaap_RestructuringReserve_634924688BE819BAE6025E4BE86DA70D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7E36568B16AFF7815BB594761FF43765" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_32BDFD09AE4574C3F9A794761FF4557A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7E36568B16AFF7815BB594761FF43765" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_32BDFD09AE4574C3F9A794761FF4557A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_CF741FC38A4A8890152894761FF45A60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_32BDFD09AE4574C3F9A794761FF4557A" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_CF741FC38A4A8890152894761FF45A60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1FC9C6E5AE21DECA4C4694761FF582A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_CF741FC38A4A8890152894761FF45A60" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1FC9C6E5AE21DECA4C4694761FF582A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_439EBAF1F2239BFD1E8A94761FF519D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1FC9C6E5AE21DECA4C4694761FF582A7" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_439EBAF1F2239BFD1E8A94761FF519D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_F6068459B816CB12D64594761FF5EE2A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1FC9C6E5AE21DECA4C4694761FF582A7" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_F6068459B816CB12D64594761FF5EE2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_BF257F8CE95131386F6A94761FF55B4E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_32BDFD09AE4574C3F9A794761FF4557A" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_BF257F8CE95131386F6A94761FF55B4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_75CD9635D9A2C251034294761FF6F062" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_BF257F8CE95131386F6A94761FF55B4E" xlink:to="loc_us-gaap_RestructuringReserve_75CD9635D9A2C251034294761FF6F062" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_803F99C2CDA4BDFCB4FC9476229EC384" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_A06D92089293E14F3D199476229F97DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_803F99C2CDA4BDFCB4FC9476229EC384" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_A06D92089293E14F3D199476229F97DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_1F491C7E6BAF83C72F4A9476229FF15C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_803F99C2CDA4BDFCB4FC9476229EC384" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_1F491C7E6BAF83C72F4A9476229FF15C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_467F2BEC781972B9DAE79476220EE933" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_1038DA6CDB9CD87082199476220FE523" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_467F2BEC781972B9DAE79476220EE933" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_1038DA6CDB9CD87082199476220FE523" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_E21AD8B67B02EC9E05D36350788D2941" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_47DB69088942C88D679C6350788D5AFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_E21AD8B67B02EC9E05D36350788D2941" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_47DB69088942C88D679C6350788D5AFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_466F45B6A71E30D02EB16350788D1A1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_47DB69088942C88D679C6350788D5AFF" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_466F45B6A71E30D02EB16350788D1A1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_9BE8FCAA5D9D6331C87F6350788D2C86" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_466F45B6A71E30D02EB16350788D1A1F" xlink:to="loc_us-gaap_SegmentDomain_9BE8FCAA5D9D6331C87F6350788D2C86" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_DF76E33A53540E0CEAFA6350788EAB14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9BE8FCAA5D9D6331C87F6350788D2C86" xlink:to="loc_pfe_BiopharmaSegmentMember_DF76E33A53540E0CEAFA6350788EAB14" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnSegmentMember" xlink:label="loc_pfe_UpjohnSegmentMember_DDE3671B719C5E2CCDE26350788E8C7D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9BE8FCAA5D9D6331C87F6350788D2C86" xlink:to="loc_pfe_UpjohnSegmentMember_DDE3671B719C5E2CCDE26350788E8C7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_8C7A732414D6F734F5F46350788EBA4F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_47DB69088942C88D679C6350788D5AFF" xlink:to="loc_srt_ConsolidationItemsAxis_8C7A732414D6F734F5F46350788EBA4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_7B75F4907BA10A3D2D9B6350788ECB8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_8C7A732414D6F734F5F46350788EBA4F" xlink:to="loc_srt_ConsolidationItemsDomain_7B75F4907BA10A3D2D9B6350788ECB8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_4D6C7E23A7E650C6F8406350788F4E32" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_7B75F4907BA10A3D2D9B6350788ECB8E" xlink:to="loc_us-gaap_OperatingSegmentsMember_4D6C7E23A7E650C6F8406350788F4E32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_9A36AC77270F1C89787B6350788F975A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_7B75F4907BA10A3D2D9B6350788ECB8E" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_9A36AC77270F1C89787B6350788F975A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="loc_us-gaap_CorporateNonSegmentMember_A08467B8F79F2EF581A46350788FF0B8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_7B75F4907BA10A3D2D9B6350788ECB8E" xlink:to="loc_us-gaap_CorporateNonSegmentMember_A08467B8F79F2EF581A46350788FF0B8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherSegmentReconcilingItemsAxis" xlink:label="loc_pfe_OtherSegmentReconcilingItemsAxis_81107C06DEFC9E4BC8DA6350788F0B3F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_47DB69088942C88D679C6350788D5AFF" xlink:to="loc_pfe_OtherSegmentReconcilingItemsAxis_81107C06DEFC9E4BC8DA6350788F0B3F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherSegmentReconcilingItemsDomain" xlink:label="loc_pfe_OtherSegmentReconcilingItemsDomain_B2556FCAD1C7B8A918376350788F9345" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherSegmentReconcilingItemsAxis_81107C06DEFC9E4BC8DA6350788F0B3F" xlink:to="loc_pfe_OtherSegmentReconcilingItemsDomain_B2556FCAD1C7B8A918376350788F9345" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PurchaseAccountingAdjustmentsMember" xlink:label="loc_pfe_PurchaseAccountingAdjustmentsMember_6CC0148546FD0A3C59DA63507890A625" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherSegmentReconcilingItemsDomain_B2556FCAD1C7B8A918376350788F9345" xlink:to="loc_pfe_PurchaseAccountingAdjustmentsMember_6CC0148546FD0A3C59DA63507890A625" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BusinessCombinationsAcquisitionRelatedCostsMember" xlink:label="loc_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_BF73C039621F772D28F7635078902036" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherSegmentReconcilingItemsDomain_B2556FCAD1C7B8A918376350788F9345" xlink:to="loc_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_BF73C039621F772D28F7635078902036" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_CertainSignificantItemsMember" xlink:label="loc_pfe_CertainSignificantItemsMember_2BE2DF2543371C764FE2635078900132" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherSegmentReconcilingItemsDomain_B2556FCAD1C7B8A918376350788F9345" xlink:to="loc_pfe_CertainSignificantItemsMember_2BE2DF2543371C764FE2635078900132" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_DE0C810364AA18EF3FE6635078900876" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_47DB69088942C88D679C6350788D5AFF" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_DE0C810364AA18EF3FE6635078900876" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E2148BBCA0B6B27E7B1F635078908786" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DE0C810364AA18EF3FE6635078900876" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E2148BBCA0B6B27E7B1F635078908786" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_33AC0AB3FD05F3748EA9635078911A9E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DE0C810364AA18EF3FE6635078900876" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_33AC0AB3FD05F3748EA9635078911A9E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_CC83D942D59D4C5FA0789AD3C8C73663" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1DB799DCCA2341A8B8A69AD3C8C83DA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_CC83D942D59D4C5FA0789AD3C8C73663" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1DB799DCCA2341A8B8A69AD3C8C83DA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_62A0B96E5632DB3346569AD3C8C95C7E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1DB799DCCA2341A8B8A69AD3C8C83DA5" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_62A0B96E5632DB3346569AD3C8C95C7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_DA1594DD9378A535593B9AD3C8C96527" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_62A0B96E5632DB3346569AD3C8C95C7E" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_DA1594DD9378A535593B9AD3C8C96527" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ViiVMember" xlink:label="loc_pfe_ViiVMember_9882A87663C55444CCCF9AD3C8CE86D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_DA1594DD9378A535593B9AD3C8C96527" xlink:to="loc_pfe_ViiVMember_9882A87663C55444CCCF9AD3C8CE86D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_8AF56E1CEAB1A1E3AABC9AD3C8CF3535" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1DB799DCCA2341A8B8A69AD3C8C83DA5" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_8AF56E1CEAB1A1E3AABC9AD3C8CF3535" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeDividend" xlink:label="loc_us-gaap_InvestmentIncomeDividend_1064A3DC510882411B339AD3C8CFAC31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8AF56E1CEAB1A1E3AABC9AD3C8CF3535" xlink:to="loc_us-gaap_InvestmentIncomeDividend_1064A3DC510882411B339AD3C8CFAC31" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_306C13F15AAD4FF78D0E947621AF548F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_22DE9DF6A287C6D33C8F947621B07C2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_306C13F15AAD4FF78D0E947621AF548F" xlink:to="loc_us-gaap_NumberOfOperatingSegments_22DE9DF6A287C6D33C8F947621B07C2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_A06E874CF0597157F519947621B037F8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_306C13F15AAD4FF78D0E947621AF548F" xlink:to="loc_us-gaap_Assets_A06E874CF0597157F519947621B037F8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_DF2519579BA2E9EC6A246350788390E2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_A2FCB216F508791B78B863507883F389" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_DF2519579BA2E9EC6A246350788390E2" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_A2FCB216F508791B78B863507883F389" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_21D376F4F39B79B35FAE63507883AD8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_A2FCB216F508791B78B863507883F389" xlink:to="loc_srt_StatementGeographicalAxis_21D376F4F39B79B35FAE63507883AD8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_AD61EBE7A36CEC685330635078836D50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_21D376F4F39B79B35FAE63507883AD8B" xlink:to="loc_srt_SegmentGeographicalDomain_AD61EBE7A36CEC685330635078836D50" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_country_US_FE436303D8D841ACAC586350788428D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_AD61EBE7A36CEC685330635078836D50" xlink:to="loc_country_US_FE436303D8D841ACAC586350788428D4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DevelopedEuropeMember" xlink:label="loc_pfe_DevelopedEuropeMember_4995C6E81DF0A88576A2635078843445" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_AD61EBE7A36CEC685330635078836D50" xlink:to="loc_pfe_DevelopedEuropeMember_4995C6E81DF0A88576A2635078843445" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DevelopedRestOfWorldMember" xlink:label="loc_pfe_DevelopedRestOfWorldMember_BFF0DB7C007505E2A058635078847232" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_AD61EBE7A36CEC685330635078836D50" xlink:to="loc_pfe_DevelopedRestOfWorldMember_BFF0DB7C007505E2A058635078847232" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EmergingMarketsMember" xlink:label="loc_pfe_EmergingMarketsMember_DC4C4EBD8A9740D19CB663507884B64E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_AD61EBE7A36CEC685330635078836D50" xlink:to="loc_pfe_EmergingMarketsMember_DC4C4EBD8A9740D19CB663507884B64E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_573119C434DA154B2D00635078848B7F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_A2FCB216F508791B78B863507883F389" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_573119C434DA154B2D00635078848B7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6356D5C47420B7CDCE0363507884A8E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_573119C434DA154B2D00635078848B7F" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6356D5C47420B7CDCE0363507884A8E1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PercentageChangeInRevenue" xlink:label="loc_pfe_PercentageChangeInRevenue_F7E70A69F1F08DFD33C86350788518A3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_573119C434DA154B2D00635078848B7F" xlink:to="loc_pfe_PercentageChangeInRevenue_F7E70A69F1F08DFD33C86350788518A3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_469AD2A46A351AFC963D6350787D9556" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_19FA2C6F9135F773D4DF6350787E4E79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_469AD2A46A351AFC963D6350787D9556" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_19FA2C6F9135F773D4DF6350787E4E79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_3D799A67E7B7DDFCFCA36350787E67C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_19FA2C6F9135F773D4DF6350787E4E79" xlink:to="loc_srt_CurrencyAxis_3D799A67E7B7DDFCFCA36350787E67C1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_3B49161E98DDBB4E4F696350787EBD16" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_3D799A67E7B7DDFCFCA36350787E67C1" xlink:to="loc_currency_AllCurrenciesDomain_3B49161E98DDBB4E4F696350787EBD16" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_C6E3A175275BBA220A896350787E7B6C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_3B49161E98DDBB4E4F696350787EBD16" xlink:to="loc_currency_EUR_C6E3A175275BBA220A896350787E7B6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_690C0B45A89141585C066350787F6F28" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_19FA2C6F9135F773D4DF6350787E4E79" xlink:to="loc_srt_StatementGeographicalAxis_690C0B45A89141585C066350787F6F28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_5596607291BC04D9ED966350787F3484" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_690C0B45A89141585C066350787F6F28" xlink:to="loc_srt_SegmentGeographicalDomain_5596607291BC04D9ED966350787F3484" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DevelopedEuropeMember" xlink:label="loc_pfe_DevelopedEuropeMember_DB1906003C7888B5F7BC6350787F3C09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5596607291BC04D9ED966350787F3484" xlink:to="loc_pfe_DevelopedEuropeMember_DB1906003C7888B5F7BC6350787F3C09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_331E0A34E97E2E30B2E66350787F0FE1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_19FA2C6F9135F773D4DF6350787E4E79" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_331E0A34E97E2E30B2E66350787F0FE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F79A343BD6AF2F227B3A6350787F20AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_331E0A34E97E2E30B2E66350787F0FE1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F79A343BD6AF2F227B3A6350787F20AC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_CE77CA5C2AB1EAFF3EC6A56C86A6A69B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_EB99D1A4AC4FFC9C8F6FA56C86A8D13E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_CE77CA5C2AB1EAFF3EC6A56C86A6A69B" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_EB99D1A4AC4FFC9C8F6FA56C86A8D13E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitAxis" xlink:label="loc_us-gaap_ReportingUnitAxis_8C00D7FDFCCBC1F60C8CA56C86A91193" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_EB99D1A4AC4FFC9C8F6FA56C86A8D13E" xlink:to="loc_us-gaap_ReportingUnitAxis_8C00D7FDFCCBC1F60C8CA56C86A91193" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_8C00D7FDFCCBC1F60C8CA56C86A91193" xlink:to="loc_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_InternalMedicineMember" xlink:label="loc_pfe_InternalMedicineMember_F6F5D98D4B06E262880FA56C86AE684B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91" xlink:to="loc_pfe_InternalMedicineMember_F6F5D98D4B06E262880FA56C86AE684B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OncologyMember" xlink:label="loc_pfe_OncologyMember_CB5E0FF8C75B3122B531A56C86AFB15C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91" xlink:to="loc_pfe_OncologyMember_CB5E0FF8C75B3122B531A56C86AFB15C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_HospitalMember" xlink:label="loc_pfe_HospitalMember_86A742C0795AC99C98BAA56C86AF28B4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91" xlink:to="loc_pfe_HospitalMember_86A742C0795AC99C98BAA56C86AF28B4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_VaccinesMember" xlink:label="loc_pfe_VaccinesMember_A0AB6CB62DF46A44BE94A56C86AFADE7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91" xlink:to="loc_pfe_VaccinesMember_A0AB6CB62DF46A44BE94A56C86AFADE7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_InflammationandImmunologyMember" xlink:label="loc_pfe_InflammationandImmunologyMember_6BEBE45E80282D8DF85FA56C86B0794E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91" xlink:to="loc_pfe_InflammationandImmunologyMember_6BEBE45E80282D8DF85FA56C86B0794E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_RareDiseaseMember" xlink:label="loc_pfe_RareDiseaseMember_F14C6BC670D92FF6E1B6A56C86B0ED0A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91" xlink:to="loc_pfe_RareDiseaseMember_F14C6BC670D92FF6E1B6A56C86B0ED0A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnReportingUnitMember" xlink:label="loc_pfe_UpjohnReportingUnitMember_D641FF22EA64057A719FA56C86B054FB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91" xlink:to="loc_pfe_UpjohnReportingUnitMember_D641FF22EA64057A719FA56C86B054FB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ConsumerHealthcareReportingUnitMember" xlink:label="loc_pfe_ConsumerHealthcareReportingUnitMember_C8AF36EA4CF5E50A9841A56C86B0593F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_CF0A6F0A9AD1DA8A0F2BA56C86AE9A91" xlink:to="loc_pfe_ConsumerHealthcareReportingUnitMember_C8AF36EA4CF5E50A9841A56C86B0593F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4C26C2E2098943768E61A56C86B019DA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_EB99D1A4AC4FFC9C8F6FA56C86A8D13E" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4C26C2E2098943768E61A56C86B019DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_D0A110AC6DF0E8191272A56C86B0276F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4C26C2E2098943768E61A56C86B019DA" xlink:to="loc_us-gaap_SegmentDomain_D0A110AC6DF0E8191272A56C86B0276F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" xlink:label="loc_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_0FC68527EF72BF306D48A56C86B1A215" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_D0A110AC6DF0E8191272A56C86B0276F" xlink:to="loc_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_0FC68527EF72BF306D48A56C86B1A215" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_33D6A4F853A99FF830E8A56C86B13309" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_0FC68527EF72BF306D48A56C86B1A215" xlink:to="loc_pfe_BiopharmaSegmentMember_33D6A4F853A99FF830E8A56C86B13309" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_UpjohnSegmentMember" xlink:label="loc_pfe_UpjohnSegmentMember_15B7D1A055C83A44C8ECA56C86B1C6A9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_0FC68527EF72BF306D48A56C86B1A215" xlink:to="loc_pfe_UpjohnSegmentMember_15B7D1A055C83A44C8ECA56C86B1C6A9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ConsumerHealthcareMember" xlink:label="loc_pfe_ConsumerHealthcareMember_AB4FEC7BA80CD1D35C0FA56C86B1A6F2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_0FC68527EF72BF306D48A56C86B1A215" xlink:to="loc_pfe_ConsumerHealthcareMember_AB4FEC7BA80CD1D35C0FA56C86B1A6F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_024C2084C2516DA75C5EA56C86B1CC15" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_EB99D1A4AC4FFC9C8F6FA56C86A8D13E" xlink:to="loc_srt_ProductOrServiceAxis_024C2084C2516DA75C5EA56C86B1CC15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_024C2084C2516DA75C5EA56C86B1CC15" xlink:to="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EliquisMember" xlink:label="loc_pfe_EliquisMember_74C148EE7AAD8BC46643A56C86B2AD15" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_EliquisMember_74C148EE7AAD8BC46643A56C86B2AD15" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ChantixChampixMember" xlink:label="loc_pfe_ChantixChampixMember_E8B6C0153F9AE09FC10DA56C86B26AE1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_ChantixChampixMember_E8B6C0153F9AE09FC10DA56C86B26AE1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PremarinFamilyMember" xlink:label="loc_pfe_PremarinFamilyMember_4588C53585AA9FF88A45A56C86B29EE6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_PremarinFamilyMember_4588C53585AA9FF88A45A56C86B29EE6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BMP2Member" xlink:label="loc_pfe_BMP2Member_1AE86B3689D81EA5118DA56C86B335C6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_BMP2Member_1AE86B3689D81EA5118DA56C86B335C6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ToviazMember" xlink:label="loc_pfe_ToviazMember_615A0752A97615972028A56C86B3A51C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_ToviazMember_615A0752A97615972028A56C86B3A51C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AllOtherInternalMedicineMember" xlink:label="loc_pfe_AllOtherInternalMedicineMember_7C848AF0CC6E15FC67E2A56C86B30692" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_AllOtherInternalMedicineMember_7C848AF0CC6E15FC67E2A56C86B30692" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IbranceMember" xlink:label="loc_pfe_IbranceMember_58B49E73E5E26AAF7282A56C86B3D39C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_IbranceMember_58B49E73E5E26AAF7282A56C86B3D39C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_XtandiAllianceRevenuesMember" xlink:label="loc_pfe_XtandiAllianceRevenuesMember_61982F42AA5997949BB0A56C86B3C931" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_XtandiAllianceRevenuesMember_61982F42AA5997949BB0A56C86B3C931" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SutentMember" xlink:label="loc_pfe_SutentMember_D9ABAA0CF4E687D9CA61A56C86B3EEFB" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_SutentMember_D9ABAA0CF4E687D9CA61A56C86B3EEFB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_InlytaMember" xlink:label="loc_pfe_InlytaMember_C9BA3F0F8A3AC2FD495AA56C86B43B85" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_InlytaMember_C9BA3F0F8A3AC2FD495AA56C86B43B85" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_XalkoriMember" xlink:label="loc_pfe_XalkoriMember_1BD7B04F8F7DF9BBCD2EA56C86B4A1D1" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_XalkoriMember_1BD7B04F8F7DF9BBCD2EA56C86B4A1D1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BosulifMember" xlink:label="loc_pfe_BosulifMember_4D20112C50AB734A0462A56C86B40D81" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_BosulifMember_4D20112C50AB734A0462A56C86B40D81" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_RetacritMember" xlink:label="loc_pfe_RetacritMember_5C6338C1277581566DADA56C86B41F10" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_RetacritMember_5C6338C1277581566DADA56C86B41F10" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BraftoviMember" xlink:label="loc_pfe_BraftoviMember_6549E5586ED5FAC9AE94A56C86B4B8EA" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_BraftoviMember_6549E5586ED5FAC9AE94A56C86B4B8EA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_MektoviMember" xlink:label="loc_pfe_MektoviMember_DD760C6FA3AFCB86DBA2A56C86B4D1C2" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_MektoviMember_DD760C6FA3AFCB86DBA2A56C86B4D1C2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherOncologyProductsMember" xlink:label="loc_pfe_OtherOncologyProductsMember_4A1E7F49FAF6BECBFF6EA56C86B4F366" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_OtherOncologyProductsMember_4A1E7F49FAF6BECBFF6EA56C86B4F366" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SulperazonMember" xlink:label="loc_pfe_SulperazonMember_95376C87701E4CAC5F4DA56C86B59DF2" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_SulperazonMember_95376C87701E4CAC5F4DA56C86B59DF2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_MedrolMember" xlink:label="loc_pfe_MedrolMember_522B6988D414D3728327A56C86B5000B" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_MedrolMember_522B6988D414D3728327A56C86B5000B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ZithromaxZmaxMember" xlink:label="loc_pfe_ZithromaxZmaxMember_0CA3815A71E72E827746A56C86B56B65" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_ZithromaxZmaxMember_0CA3815A71E72E827746A56C86B56B65" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PrecedexMember" xlink:label="loc_pfe_PrecedexMember_815148BB9543BEE28EBAA56C86B5E751" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_PrecedexMember_815148BB9543BEE28EBAA56C86B5E751" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_VfendMember" xlink:label="loc_pfe_VfendMember_45BC193A4688F3B4705CA56C86B575E9" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_VfendMember_45BC193A4688F3B4705CA56C86B575E9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PanzygaMember" xlink:label="loc_pfe_PanzygaMember_D41C4107962F48E68B3EA56C86B6FA8A" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_PanzygaMember_D41C4107962F48E68B3EA56C86B6FA8A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ZyvoxMember" xlink:label="loc_pfe_ZyvoxMember_6A99B0F4ACF7EF4E08B6A56C86B6D4ED" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_ZyvoxMember_6A99B0F4ACF7EF4E08B6A56C86B6D4ED" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_FragminMember" xlink:label="loc_pfe_FragminMember_49750078F822D097D253A56C86BBD415" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_FragminMember_49750078F822D097D253A56C86BBD415" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PfizerCentreOneMember" xlink:label="loc_pfe_PfizerCentreOneMember_9DE4645951C19EA6057CA56C86BB1B0D" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_PfizerCentreOneMember_9DE4645951C19EA6057CA56C86BB1B0D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherAntiinfectivesMember" xlink:label="loc_pfe_OtherAntiinfectivesMember_7F50880BD594C5F24301A56C86BBB0AE" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_OtherAntiinfectivesMember_7F50880BD594C5F24301A56C86BBB0AE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherHospitalProductsMember" xlink:label="loc_pfe_OtherHospitalProductsMember_AB885C1A853C97AC11A9A56C86BB3891" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_OtherHospitalProductsMember_AB885C1A853C97AC11A9A56C86BB3891" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PrevnarPrevenarFamilyMember" xlink:label="loc_pfe_PrevnarPrevenarFamilyMember_4EEE60C0F50B0C658579A56C86BC8133" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_PrevnarPrevenarFamilyMember_4EEE60C0F50B0C658579A56C86BC8133" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_NimenrixMember" xlink:label="loc_pfe_NimenrixMember_CD0AFA296C250E0761EFA56C86BCB740" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_NimenrixMember_CD0AFA296C250E0761EFA56C86BCB740" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherVaccinesProductsMember" xlink:label="loc_pfe_OtherVaccinesProductsMember_4B49EA2EC8C94B7748E6A56C86BC5703" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_OtherVaccinesProductsMember_4B49EA2EC8C94B7748E6A56C86BC5703" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_XeljanzMember" xlink:label="loc_pfe_XeljanzMember_EBFD7FC05AF664C5FF52A56C86BC8017" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_XeljanzMember_EBFD7FC05AF664C5FF52A56C86BC8017" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EnbrelMember" xlink:label="loc_pfe_EnbrelMember_20D39F0CC56F9508E3D3A56C86BC00A5" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_EnbrelMember_20D39F0CC56F9508E3D3A56C86BC00A5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_InflectraRemsimaMember" xlink:label="loc_pfe_InflectraRemsimaMember_B82802DBC0973FCF58F8A56C86BDBC3C" xlink:type="locator" />
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_InflectraRemsimaMember_B82802DBC0973FCF58F8A56C86BDBC3C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AllOtherInflammationandImmunologyProductsMember" xlink:label="loc_pfe_AllOtherInflammationandImmunologyProductsMember_AF53FD9E835B8055DB78A56C86BDBD30" xlink:type="locator" />
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_AllOtherInflammationandImmunologyProductsMember_AF53FD9E835B8055DB78A56C86BDBD30" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_VyndaqelMember" xlink:label="loc_pfe_VyndaqelMember_3685807938B54E561B92A56C86BDB386" xlink:type="locator" />
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_VyndaqelMember_3685807938B54E561B92A56C86BDB386" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_BeneFIXMember" xlink:label="loc_pfe_BeneFIXMember_78AF65605967123A3219A56C86BDCF35" xlink:type="locator" />
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_BeneFIXMember_78AF65605967123A3219A56C86BDCF35" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_GenotropinMember" xlink:label="loc_pfe_GenotropinMember_7FB36B0DA9ED797D3E48A56C86BD5AF5" xlink:type="locator" />
    <link:presentationArc order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_GenotropinMember_7FB36B0DA9ED797D3E48A56C86BD5AF5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ReFactoAfXynthaMember" xlink:label="loc_pfe_ReFactoAfXynthaMember_864D1C74B465C0E1FF48A56C86BD95F1" xlink:type="locator" />
    <link:presentationArc order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_ReFactoAfXynthaMember_864D1C74B465C0E1FF48A56C86BD95F1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_SomavertMember" xlink:label="loc_pfe_SomavertMember_7FFAA229B092ACB08D2DA56C86BD974C" xlink:type="locator" />
    <link:presentationArc order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_SomavertMember_7FFAA229B092ACB08D2DA56C86BD974C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AllOtherRareDiseaseProductsMember" xlink:label="loc_pfe_AllOtherRareDiseaseProductsMember_B66B37B69A6AC133E95CA56C86BECC16" xlink:type="locator" />
    <link:presentationArc order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_AllOtherRareDiseaseProductsMember_B66B37B69A6AC133E95CA56C86BECC16" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LipitorMember" xlink:label="loc_pfe_LipitorMember_7255601AE252E9CD1726A56C86BEDC00" xlink:type="locator" />
    <link:presentationArc order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_LipitorMember_7255601AE252E9CD1726A56C86BEDC00" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_LyricaMember" xlink:label="loc_pfe_LyricaMember_1F4C6BE110CA50901141A56C86BEF34F" xlink:type="locator" />
    <link:presentationArc order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_LyricaMember_1F4C6BE110CA50901141A56C86BEF34F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_NorvascMember" xlink:label="loc_pfe_NorvascMember_83556E8FF8ED465CC033A56C86BEA428" xlink:type="locator" />
    <link:presentationArc order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_NorvascMember_83556E8FF8ED465CC033A56C86BEA428" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_CelebrexMember" xlink:label="loc_pfe_CelebrexMember_57C95D9B26AB88948709A56C86BEFBE8" xlink:type="locator" />
    <link:presentationArc order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_CelebrexMember_57C95D9B26AB88948709A56C86BEFBE8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ViagraMember" xlink:label="loc_pfe_ViagraMember_7CEE2623FDD2D09220A7A56C86BE60F2" xlink:type="locator" />
    <link:presentationArc order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_ViagraMember_7CEE2623FDD2D09220A7A56C86BE60F2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EffexorMember" xlink:label="loc_pfe_EffexorMember_46E5E161E30C551D28F5A56C86BF6A41" xlink:type="locator" />
    <link:presentationArc order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_EffexorMember_46E5E161E30C551D28F5A56C86BF6A41" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ZoloftMember" xlink:label="loc_pfe_ZoloftMember_C62851349E163C99B25BA56C86BF3E7D" xlink:type="locator" />
    <link:presentationArc order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_ZoloftMember_C62851349E163C99B25BA56C86BF3E7D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_EpiPenMember" xlink:label="loc_pfe_EpiPenMember_ACB821EB72C550D63B71A56C86BF5E7A" xlink:type="locator" />
    <link:presentationArc order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_EpiPenMember_ACB821EB72C550D63B71A56C86BF5E7A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_XalatanXalacomMember" xlink:label="loc_pfe_XalatanXalacomMember_9B3D3217E1FF99B6EDE8A56C86BF49B5" xlink:type="locator" />
    <link:presentationArc order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_XalatanXalacomMember_9B3D3217E1FF99B6EDE8A56C86BF49B5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_AllOtherUpjohnProductsMember" xlink:label="loc_pfe_AllOtherUpjohnProductsMember_736420A194EDC34B4B82A56C86BFB1C9" xlink:type="locator" />
    <link:presentationArc order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_AllOtherUpjohnProductsMember_736420A194EDC34B4B82A56C86BFB1C9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_TotalAllianceBiopharmaceuticalsMember" xlink:label="loc_pfe_TotalAllianceBiopharmaceuticalsMember_9BB704103A9A6CC657ADA56C86C0558A" xlink:type="locator" />
    <link:presentationArc order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_TotalAllianceBiopharmaceuticalsMember_9BB704103A9A6CC657ADA56C86C0558A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_TotalBiosimilarsMember" xlink:label="loc_pfe_TotalBiosimilarsMember_798F093E90C7AD7A053DA56C86C0019E" xlink:type="locator" />
    <link:presentationArc order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_TotalBiosimilarsMember_798F093E90C7AD7A053DA56C86C0019E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_TotalSterileInjectablePharmaceuticalsMember" xlink:label="loc_pfe_TotalSterileInjectablePharmaceuticalsMember_B8B920E7FBC004DE5099A56C86C02D22" xlink:type="locator" />
    <link:presentationArc order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ECA121BA7729144F3A1A56C86B2AFDD" xlink:to="loc_pfe_TotalSterileInjectablePharmaceuticalsMember_B8B920E7FBC004DE5099A56C86C02D22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9DF7C32BE76DCA92E4E6A56C86C0A4DF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_EB99D1A4AC4FFC9C8F6FA56C86A8D13E" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9DF7C32BE76DCA92E4E6A56C86C0A4DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_85F5115624E80735F8F9A56C86C06E8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9DF7C32BE76DCA92E4E6A56C86C0A4DF" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_85F5115624E80735F8F9A56C86C06E8D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_CE14599BDF420A0F5B3F947622201217" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_3B95B715053DA819EDF994762221F03F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_CE14599BDF420A0F5B3F947622201217" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_3B95B715053DA819EDF994762221F03F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_1617CCF41B628EEA7E2A947622219C20" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_CE14599BDF420A0F5B3F947622201217" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_1617CCF41B628EEA7E2A947622219C20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_24BF0A28E4D80F8CE05494762221C814" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_CE14599BDF420A0F5B3F947622201217" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_24BF0A28E4D80F8CE05494762221C814" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4336BD514DF15D436A50947622218EFC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_CE14599BDF420A0F5B3F947622201217" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4336BD514DF15D436A50947622218EFC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMatters" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4EC4487C0B55E76A44A5947622E46AFF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_F6EA285DFED6C8E7549D947622E4987F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4EC4487C0B55E76A44A5947622E46AFF" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_F6EA285DFED6C8E7549D947622E4987F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_98F5BF803E3CD5EE653E92DEB7BD7597" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_D294F93DED1CA7330FF792DEB7BDD133" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_98F5BF803E3CD5EE653E92DEB7BD7597" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_D294F93DED1CA7330FF792DEB7BDD133" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_3071AB24BD5A4A00F7EC92DEB7BDA19E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_98F5BF803E3CD5EE653E92DEB7BD7597" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_3071AB24BD5A4A00F7EC92DEB7BDA19E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_9ED0C3887C48D0F77C8392DEB7BEA0D7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_98F5BF803E3CD5EE653E92DEB7BD7597" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_9ED0C3887C48D0F77C8392DEB7BEA0D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_0C58A26B3CFCF572C89A92DEB7BE8E72" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_98F5BF803E3CD5EE653E92DEB7BD7597" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_0C58A26B3CFCF572C89A92DEB7BE8E72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_BB3093AD971517E3E8A292DEB7BE6BE6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_98F5BF803E3CD5EE653E92DEB7BD7597" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_BB3093AD971517E3E8A292DEB7BE6BE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_644BCE7D7275D971149992DEB7BE98D8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_98F5BF803E3CD5EE653E92DEB7BD7597" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_644BCE7D7275D971149992DEB7BE98D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_1BC37AB1D5295DD2361292DEB7BECE23" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_98F5BF803E3CD5EE653E92DEB7BD7597" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_1BC37AB1D5295DD2361292DEB7BECE23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_D53E80069F61CFBA325E92DEB7BEB3DF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_98F5BF803E3CD5EE653E92DEB7BD7597" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_D53E80069F61CFBA325E92DEB7BEB3DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_4BF0D30ADD5E95B0009792DEB7BFF81F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_98F5BF803E3CD5EE653E92DEB7BD7597" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_4BF0D30ADD5E95B0009792DEB7BFF81F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_E796EED094BFAC635A0A92DEB7C46CF3" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_98F5BF803E3CD5EE653E92DEB7BD7597" xlink:to="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_E796EED094BFAC635A0A92DEB7C46CF3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_1F371B0BD01C0401DEEE92DEB7C431B8" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_98F5BF803E3CD5EE653E92DEB7BD7597" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_1F371B0BD01C0401DEEE92DEB7C431B8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax" xlink:label="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_219A2875FD3414276E6992DEB7C415BE" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_98F5BF803E3CD5EE653E92DEB7BD7597" xlink:to="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_219A2875FD3414276E6992DEB7C415BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_F098FE31685B346AED5F92DEB7C4D186" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_98F5BF803E3CD5EE653E92DEB7BD7597" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_F098FE31685B346AED5F92DEB7C4D186" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_2726971307AD36947F3292DEB7C5CD04" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_98F5BF803E3CD5EE653E92DEB7BD7597" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_2726971307AD36947F3292DEB7C5CD04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_BE85D62D23789BCEBB0F92DEB7C5D4D9" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_98F5BF803E3CD5EE653E92DEB7BD7597" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_BE85D62D23789BCEBB0F92DEB7C5D4D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_650565DF1FCCBDB3F9A692DEB7C58013" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_98F5BF803E3CD5EE653E92DEB7BD7597" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_650565DF1FCCBDB3F9A692DEB7C58013" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersNarrativeDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_E772F7809ED767B9265E78FDDF40B834" xlink:type="locator" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IncomeTaxesTable" xlink:label="loc_pfe_IncomeTaxesTable_2BA40BB3F2D37B0963D478FDDF40DCB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E772F7809ED767B9265E78FDDF40B834" xlink:to="loc_pfe_IncomeTaxesTable_2BA40BB3F2D37B0963D478FDDF40DCB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6CE46DD192EB20B90A0578FDDF404634" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesTable_2BA40BB3F2D37B0963D478FDDF40DCB2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6CE46DD192EB20B90A0578FDDF404634" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_AAB6742BE9EF7EAE3F0178FDDF40168C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6CE46DD192EB20B90A0578FDDF404634" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_AAB6742BE9EF7EAE3F0178FDDF40168C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_5803903C2C497FF017F778FDDF410C75" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_AAB6742BE9EF7EAE3F0178FDDF40168C" xlink:to="loc_us-gaap_SubsequentEventMember_5803903C2C497FF017F778FDDF410C75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_DCF2C23EFF42EAFA322B78FDDF413708" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesTable_2BA40BB3F2D37B0963D478FDDF40DCB2" xlink:to="loc_srt_StatementScenarioAxis_DCF2C23EFF42EAFA322B78FDDF413708" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_6D45E118DAA58125EF4A78FDDF41AB3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_DCF2C23EFF42EAFA322B78FDDF413708" xlink:to="loc_srt_ScenarioUnspecifiedDomain_6D45E118DAA58125EF4A78FDDF41AB3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_AA1230420256FA862B1978FDDF4221FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_6D45E118DAA58125EF4A78FDDF41AB3C" xlink:to="loc_srt_ScenarioForecastMember_AA1230420256FA862B1978FDDF4221FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_53B66C8228F6AA8CB44378FDDF420B0A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesTable_2BA40BB3F2D37B0963D478FDDF40DCB2" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_53B66C8228F6AA8CB44378FDDF420B0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6E6B5042D95FAF71357D78FDDF4222A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_53B66C8228F6AA8CB44378FDDF420B0A" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6E6B5042D95FAF71357D78FDDF4222A2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IncomeTaxesPayableMember" xlink:label="loc_pfe_IncomeTaxesPayableMember_387B4D90C1E652EEE8F578FDDF4297D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6E6B5042D95FAF71357D78FDDF4222A2" xlink:to="loc_pfe_IncomeTaxesPayableMember_387B4D90C1E652EEE8F578FDDF4297D2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_IncomeTaxesLineItems" xlink:label="loc_pfe_IncomeTaxesLineItems_85ECBE9ED50B2D4854BD78FDDF425FCF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesTable_2BA40BB3F2D37B0963D478FDDF40DCB2" xlink:to="loc_pfe_IncomeTaxesLineItems_85ECBE9ED50B2D4854BD78FDDF425FCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B69361CE5F377DC627F278FDDF4362F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_85ECBE9ED50B2D4854BD78FDDF425FCF" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B69361CE5F377DC627F278FDDF4362F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_C01C9F1EC298852E7D8B7910AE908261" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_85ECBE9ED50B2D4854BD78FDDF425FCF" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_C01C9F1EC298852E7D8B7910AE908261" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_B3D5A3AEB5EBFF81E00778FDDF431EED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_85ECBE9ED50B2D4854BD78FDDF425FCF" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_B3D5A3AEB5EBFF81E00778FDDF431EED" xlink:type="arc" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_PaymentForRepatriationTax" xlink:label="loc_pfe_PaymentForRepatriationTax_4D217B235C4F5DBEC5A678FDDF43AF9F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_85ECBE9ED50B2D4854BD78FDDF425FCF" xlink:to="loc_pfe_PaymentForRepatriationTax_4D217B235C4F5DBEC5A678FDDF43AF9F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_710423B7FB32A7FEEC9194761EE73F67" xlink:type="locator" />
    <link:loc xlink:href="pfe-20200628.xsd#pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_6114E36E34948349AD7494761EE8059A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_710423B7FB32A7FEEC9194761EE73F67" xlink:to="loc_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_6114E36E34948349AD7494761EE8059A" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>chart-69c730ef7bbe3f2b2ca.jpg
<TEXT>
begin 644 chart-69c730ef7bbe3f2b2ca.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $! 5$# 2(  A$! Q$!_\0
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M+KQEK-GI[7-]I7@OPKI]Y>ZA:Z9J=QJ6IZ##%9/J'W[7YD?\%,?A3^W1\<?
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MJ!]UL<^^,8]3G [XK^>#Q+^R%^V5%X3\4:?)H/Q6\;:SX?\ V=+R+X(7]O\
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M_P""@NJ/!JGB_P *1^#_  OX.^(OBSX?_$;]EJ\F\">$?B5-'<>$M$U&QO\
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M+G1=2G:;DHHHKY,^M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP3,\*>"O%OB?Q'KECKVD7?[%W[6'Q%_:"^($.G(?AYK,WAW1!X+\>VOPV^$
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M &B=+ETCXW?$JUE1T,_B:?58]X8;H-:M;358G4GJC&[?:1Q\I X45XO7K_\
MP51^+WPS_9D\<>$_'GQ!NM=@M_B;H-S;Z/9Z+H%]K%WJ^N>"C;6FJVUO,@M]
M)M'ATK5= D?^TM3LRZNSQ+(L<A3^?KXE?\%4O$%V9[+X1?#?3=$A)VPZ_P"/
M;MM<U(KGB2+P]H\MEI5J^.0MWJFJJ,X9"1Q_I/X9Y?FG%?!G#&98#"RJ4*N3
MX*A4Q524:.'^LX&E' 8Q1G-WJ>SQ>&KPDJ4:DHN$DXIJQ_F5XH9AE7"7&O%.
M6YAB8TJU+.<;7IX6$95<0\-CJKQ^#DX034/:83$T:B=24(M3BU)IIO\ :< L
M&(!(0%G8 E44=6=APB@ DLQ  !). :^<?B5^UK^SS\*'GM/%7Q,T.XUB NLG
MAWPJTGB_7EE0$^3-::"+NVL9"1M U.]L K$!V49-?SS?$K]I/XY?%MY5\=?$
MGQ+J>GR,Y&@V5Y_8/AN-6)PB:!H2Z?IKJH)4&ZANI2IP\KDDGPT<#:H"K_=4
M!5SZX4 9]\9-?L6 \.E[L\SQ[?>C@8):_P#817B[KNEAXOM+2[_&,P\2/BAE
MF7]=*^-GNO+#T6N5KHW7DO[NFO[%_$C_ (*JONGL_A'\,45,.L/B#XB7[.Y/
M(66+POX=N%1 #A@MYXBER/ED@&2!\ ?$K]K/]H3XK&X@\5_$S7XM(N=ROX<\
M-SCPIX>\I^L#Z9H/V+[9'V/]I3WTC#AY&YS\YT5]G@.',ERWEEAL!1]K'55Z
MZ>(KIZ>]&I6<W3;MJJ7)'LD?$YAQ/G>97CB,?6C2EO0H-8>BUT4H4N55$N]3
MG?5NXN3SCC<26P -Q)R6;&-S$G)9LDGJ:2BBO</!"BBB@ HHHH *]9^ O@R[
M^(OQQ^#7@"QMY[N[\:_%?X<^%H+>UCDEGE.N>,M%L)!&D+)(62"::0E'1D1&
M<.NW</)J_6/_ ((J_ ^[^,W[?WPGU&2PFNO#GP9AUGXR^([E(U,-G+X8LVT[
MP:)7<A5DN/'.LZ#) B[I76RN)$0K!(R?,<:YW2X;X0XFSZM45*.4Y'F>-C*3
MMS5J&$JRP]*-VKSK8CV5&G&]YSG&*U:/K.!,BK<3<:<+9#0INK/-,^RO"2BE
M=1HU,926(JST=J=&A[2K5E9J-.$I/1,_OD&<<^K?EDX_3%+2 8 &<X &3U/O
M2U_B<?[AK1+T04444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#\IO^"QW[*5S^U'^QCXQ_X1G3&U+XD_!F
MY_X6]X$MX$#7NICP]8W</C+PW;=9)I=>\&W.K?8;*)2]YKNG:)$.<5_ AP<%
M3N5@&5AT96 96&><,I!&>>>:_P!4=@&!!Z$8]?S'0CU!X(X((K^%+_@L?_P3
MUU#]D7XVW7Q5\ :.J?L]_&S7]4U/PRFFVKI9?#KQI<C^T]=^'MZ(U-O9:?=R
MRWFN>!3^YCGT87^B0Q>=X;D>X_N;Z(WB7A\/]>\-<VQ,:4L3B*V;<,3JRM&I
M6G3B\SRJ$GI&<U268X2FK*I+^T;R]I*E"?\ "'TP?##$XJ.!\3,GPTJJPF'I
M95Q1"E&\J>'A4MEF:S25Y0A*K+ 8JHW>$/J%HN$:DH?C+1117]Y'^?P4444
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MZ3BHI2I8_,JF,QE*3Y(N3I5X.35Y7=K( !T__7[D]2?<\TM%%?G9^C!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
:4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>chart-279c9b6159565ded8a4.jpg
<TEXT>
begin 644 chart-279c9b6159565ded8a4.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $! 5$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX"_X*'_MH>//V%_@CK/Q
MY\+_ ++?Q!_:3\%_#S1?$/C_ .-5QX)\=?#KP(/A?\)?!UG'J'BOQFS>/=3M
M+KQEK-GI[7-]I7@OPKI]Y>ZA:Z9J=QJ6IZ##%9/J'W[7YD?\%,?A3^W1\<?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\*6-PE10Q.%J2C>4%7I0]I%.=-SA[Q)1117SI](%%%% !1110 4444 %%%%
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M5D=6 97C97C=6 97C=25DC=2'CD4E'0JZDJP)< 20 "22%4 9+,3@*!W))
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M5BC$J64E3C(."*?7^&W]=_R/]W8ZI>B_(****!A1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXQ>TT)+;4TT349GU+2M7BLF\.ZC:ZS)UGPV_:(^&?Q+^#U]\<++4-4\)^"-
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MP)K_ (2-QH=O:R:;XY /T#HH^M% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!5O+&RU
M&'[/?VEK>P;UD\F[MX;F+>H(5_+G21-ZAF"MMW $@$9.;0      & !P !T
M'8"BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
G "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>chart-27876a64791f5b87818.jpg
<TEXT>
begin 644 chart-27876a64791f5b87818.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $! 5$# 2(  A$! Q$!_\0
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M+KQEK-GI[7-]I7@OPKI]Y>ZA:Z9J=QJ6IZ##%9/J'W[7YD?\%,?A3^W1\<?
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MJ!]UL<^^,8]3G [XK^>#Q+^R%^V5%X3\4:?)H/Q6\;:SX?\ V=+R+X(7]O\
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M_P""@NJ/!JGB_P *1^#_  OX.^(OBSX?_$;]EJ\F\">$?B5-'<>$M$U&QO\
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M&L_&OQ'U;6O$AT6#Q=X"^'NOC1H[U=.TJX\5B:"TMCJ7[X _::BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DP,8P,
M>F!C\NE+10 F!Z#TZ=O2C YX'/7@<_7UI:* $P/0?E1@>@YZ\=:6B@ I,#T'
M/7CK2T4 &!Z#IC\/3Z4F!Z#MV].GY=J6B@!,#T'Y>^?Y\_7FC YX'/!XZCT/
MK2T4 &!Z"C ]!R<GZ^OUHHH **** "C '08[_CZT5\L?%[]J[P'\-9;K1='
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M\%:M=:9=72RZSX=L_*TK5+US%'J6J6.HW5K!!;E+:W /6Z*^1?VKOVW?@/\
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M4;RIX>%2V69K-)7E"$JLL!BJC=X0^H6BX1J2A^,M%%%?WD?Y_!1110 4444
M%%%% !1110 H!) '))  ]STK^TS_ (-_OV5)_A-^S9XA_:&\4:<EMXL_:*U*
MTN/#0G@07EC\*/",E[9>'I [@7%LOBOQ!<:[XB,( AN])C\-WH+[DV_S#?\
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MMK?M"?\ !-CQ%HOP4_X*K:[8>-/V?-4U:#PU\$O^"I.BZ1#H/@/57NF\G0/
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M]I07G"=Q[?I/[37@3^WO%EIXJ\4Z3X6GT#PE\!M8NOAEJVA>(+?XO^$]=^.
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MLEK<?!?X)^$= \1VT7EMX[U6VE\5_$*X+*5F=_&WB:74]?MEN,DR6NFW=A8
M82*TCC54'V'17Y_Q/XL^(_&-*>'XAXNS?&X2JFJN!HU:>79?53Z5L!EM/!X2
MM;9>UHS:6B:6A^A<+^$?AMP95AB.'.#\GP.*I\OL\=5HSS''TG%12E2Q^95,
M9C*4GR1<G2KP<FKRN[60 #I_^OW)ZD^YYI:**_.S]&"BBB@ HHHH *3 SNP-
MV,9P,X],]<>U+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
>4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>chart-e6285fd93bdf59a14df.jpg
<TEXT>
begin 644 chart-e6285fd93bdf59a14df.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $! 5$# 2(  A$! Q$!_\0
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M+KQEK-GI[7-]I7@OPKI]Y>ZA:Z9J=QJ6IZ##%9/J'W[7YD?\%,?A3^W1\<?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ/\ "V3PUXX_9<_:%NU_:%T[P'I_B!;'4O@5^UYX@U>/1_CIX?TRV%A>PO\
M#/XTV,&F?&"\@T^^>X\)?%J'QW;'1H;?QQ'<67KY+D.<<18V&7Y+E^(S#%3L
MW"C%<E*+:C[3$5IN-'#4DVDZM>I3IIM)RNTGXV><09-PW@9YCG>88?+\)%V4
MZTFYU9VO[+#T8*=?$UFKR5&A3J57%2DH\L6U^VE<-XD^)OP\\(&5/$WC7PQH
ML\*-(]I?ZS8Q7H5 "VVQ$S7CM@C") SL>%4FOR!\?_M)_%SXA-<0W_B:XT/1
MYQ(G]A>%C+HM@8).'ANKB&5M5U!67AQ>:A)"QW%+>(-L'@W5V?\ C8EF?^-R
M3G+O]YS[L2?>OWW(_H]8FI"%;B+/:>&DTG+!951>(G%.SY9XW$^RIQG%:25/
M"UX7^&K)*[_GW/?I&86G4G1X<R&IBHQ;4<;FU?ZO"5NL,#AE5J2IR?PRJ8NA
M4Y?BI1D[1_:>X_:N^ MO.MN/'<5T[$*'LM#\1W<&XOL"B>'2&B;+8(*NRE2'
M#;3FOD"7_@L[_P $X;3Q!?>&]2_:#.E:CIFHZCI.H-J7PR^+5O96E_I5S/:7
MD$M__P (.]KA;FWEACE1WAF8*T<C(ZN?AZW)-S;DDD_:(.O/_+5*_D=^*1(^
M)WQ'P2/^+@>-^A(_YFG5Z_7>$OHO\ Y[/'4L9FW%M-X>C0E3GA\=E$+SJRJQ
MDY1J9'532Y$XQ375-NY^/<7?2G\0,AIX*OA,HX2J1Q%>K&I3Q&!SB=H4U2DE
M"5//*33?-).33WT6]_\ 1@^&'[<G['OQFGL[/X:?M*?!GQ3JFH.\=EH5MX]T
M*P\27,D<PMRD7AO6+K3=>9FE($2_V=F92LD(DC8,?JH,K $$$,,J1T8>J^HP
M001D$$$'%?Y7#8<@N%D(.09%5R".A!8$@CL000>00:^Y?V;O^"C_ .V1^RM+
MIUM\+?C3XEF\(Z>54?#?QS/+X\^'<EJ9A/-9V_AWQ!//)H$=R^?.N/"6H^'=
M0PS".\3>V>7B?Z&E6%&I6X.XNC7K13<,OXBPGLE4M=I+-,OYXQFTE&,997&$
MI.\JM*.W9PK]-7#U:].AQGPA+#49.*GF/#V+==TKN*;>68_DE*"NYRE',N>,
M5RQI5)6O_HQT5^!?[$__  7E^!7QTN=,\!_M(:;8?L\_$:[^S6=GXGN-4>^^
M#OB:_D\F':OB*^2&_P# -W=7$DC0V'BU;C0X846,>-+BZ=+=OWPAFAN(HYH)
M8YH9426*6)UDCDCD4/')&Z%E>.1&5T=25=&#*2I!/\B<7\#<5<!YD\JXJR;%
M95B9*4J$ZJC5PF,IQ:3JX'&T95,+BZ:YHJ;H59NE*2A6C3J7@O[#X.XZX4X]
MRQ9MPIG.%S;"KEC7A2E*GB\'4DFU1QV"K1IXK"5'RRY%7I056,7.BZE.TW)1
M117R9]:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %,EECACDFFD2**)&DDDD94CCC12SN[L0J
M(B@L[L0JJ"S$ $T^OSL_;#^/,D!N?A%X2O6BE9%'CO4+9BK""XABG@\,6]PC
M!@;F&1+C73'@BV>#3&?%S?1I]/PAPKF'&.>8;)L N3GO6QF*E%RI8'!4Y15?
M%54FK\O-&G2I\T?;8BI2HJ474YE\MQCQ9EW!F18K.LP?/[.U'!X2,E&KCL=4
M4O886DVG;FY95*L[2]CAZ=:MRR5/E?*?M$?M8WVNSW_@GX7:A+8:!$[VNJ^+
M[*5XK_7"IV36VA7$922PTC(:.34XF%YJB[OL;VMD5FO/@XDDY/N?Q)))]R22
M23DEB6)))-)_GT_(#@#T X%%?WAPSPODW"66T\LR;"QHTTHRQ&(DE+%8VNHV
MEB,76LI5:DM>6/NTJ,7[.A3I4E&"_@/BCBO.>+\TJYIG.*E6J2<HX?#Q;CA,
M#0;O'#82C=QI4HI*[]ZK5DO:5ZE6JY391117T)\X36W_ !\VW_7Q!_Z-2OY'
M?BG_ ,E.^(__ &4#QO\ ^I5J]?UQ6W_'S;?]?$'_ *-2OY'?BG_R4[XC_P#9
M0/&__J5:O7Z3X<?[SFW_ %XPG_IS$'YKXE?[GE?_ &$8G_TW0.#HHHK]7/R$
M,]?<$$=001@@@\$$$@@Y!!(((K]P/^"9G_!8CXA_LG:EH7PB^.=_K?Q(_9NN
M+FTTZUGNKB[U?QE\&[9VCMUU#PE+,UQ>:WX*L8P'U#P"[&2R@5[WP?-:W$4N
M@ZS^']'3I7S'%W!W#O'.2XG(>)<NI9A@,0FX.24<3@Z]FJ>,P.(2=3"XNBW>
M%6F_>BY4JL:E"I5I3^KX-XUXDX"SO#9_PQF-7 8ZA**J13Y\+C</S*53!X[#
M-^SQ.%JV2G3FKQ:C4I2IUH4ZD/\ 4C\&^,O"OQ"\*^'_ !QX(\0:3XJ\(^*M
M)LM<\.^(M"O8=1TC6=(U"%9[._T^]MV:*>WGB8,K*0RL&CE2.5)(UZ6OXPO^
M"(W_  4BNO@3X^TS]E'XQ:_*WP7^)>N16GPUU74I3);_  Q^)>OZA###IOVF
M64?V=X'\>7UQY-[%@V.A>+YK;652UM=<\072_P!GH.?\_F/P/!K_ ":\5O#3
M-?"[BK$9#CG/$Y?64L7D>:\G)3S++93<83DE[M/%X>7[C'8=-^RK1YX.>'JT
M*M3_ %W\)O$W*?%3A/#9_@%'#8^BXX3/,JY^:IEN90A&52"O:53"5T_;X*O:
MU2C+DDXUZ5>G3****_,S]."BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAGC*L 58>JLI#*1PP(()!!I*^2/KB:V_X^;;_KX@_P#1J5_([\4_^2G?$?\
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M ,YP ,GJ?>EK_$X_W#6B7H@HHHH&%%%% !1110 4444 %%%% !1110 4444
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MUJVO:Q+#%#=^(/$^MWKS:IX@U^]2&);G4M2N)94ACALK5+6PMK:T@_E[Q?\
MI*\.<%X?%9-PAB<)Q'Q9*,Z+JX>:Q&39).R3JXS$TVZ6.Q=-R:AE^%J34*M.
M<<?5P[A&A7_JOP;^C%Q)QIB<)G?&>&Q?#?"<94ZRP^(@\/G.=T[\RI87#5$J
MN!PE1).>/Q5.$ITYP>"I5U.5>AQO['W[(_PL_8N^"V@_!SX76<DL%HS:KXL\
M6ZA!;1^(O'OB^\AB35?%'B&6V14-Q.(HK+3+",M:Z'HEII^C61-O:>9+]2T4
M5_FMF>9YAG.88S-LUQ=?'YEF&(JXO&XS$3<ZV(Q%:3G4J3EM=MV48I0A%*$(
MQA&,5_IKE>69?DN78+*<JPE# 9;E^'I83!8/#05.CA\/1@H4Z<(KM%:RDW.<
MFYSE*<G)E%%%<)WA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !00",$ CT/(HHH ^=OCQ^R7^S
M?^TUI?\ 97QT^#G@?XBB.![>SU;6M'BB\3Z5')&\9_L7Q=IQLO$^C.%<E&TW
M5K<*X1]I9%(_&CXK_P#!N=^S+XFN;F^^$OQ>^+/PJ>:*<PZ1K"Z%\3/#]K<%
M&%MY/]JP:'XG^RQR;6GAN/$MY/*F5BN8'(<?T045]WPQXG<?\&0C1X:XKS?+
M<+%WC@576*RZ,KW<HY;C88G *3>\EAU)]6SX+BGPO\/N-)NKQ-PGD^9XF7Q8
MV6'^JYA))))2S'!2PV.E&*248O$.,>B3U/Y$=>_X-L?B_!>E/#/[3_PSU/3O
MGVW&O?#OQ=HE]D-A UIIVOZ_;'<GS.5O $;Y%5Q\]9ND_P#!MK\>)I;4:[^T
ME\(=.@=,WKZ1X.\<ZS-;R;"=EK'>76A1WB>9A?,EDLCL)D\HD>6?[ **_28_
M2B\98T_9OB'!2E:WMI9!DGM+V^*T<#&E?6_\+ENEI:_-^:/Z+'@LZG.N&\7&
M/-?V*SW.73M>/NWEC95K:-7=7FM)^\VDU_-K\,O^#;SX(:-=6-U\6OVA?B;X
M]CA$CWFE>"_#OAKX;V%W)OS#']MOI/'.L0VZI\LXM[J"XF8YBN+905/[#_LZ
M?L"_LC_LK):W'P7^"?A'0/$=M%Y;>.]5MI?%?Q"N"RE9G?QMXFEU/7[9;C),
MEKIMW86 &$BM(XU5!]AT5^?\3^+/B/QC2GA^(>+LWQN$JIJK@:-6GEV7U4^E
M; 9;3P>$K6V7M:,VEHFEH?H7"_A'X;<&588CAS@_)\#BJ?+[/'5:,\QQ])Q4
M4I4L?F53&8RE)\D7)TJ\')J\KNUOG;]K#]FCX>_M?_L\?%3]G+XFI>P^%?B=
MX9FT@:WH\K6WB3P9XDLKFVUGP7\1?"-\K*^F^-OASXQTS0O&_@_5$.^P\1:#
MIUQAD5T;Y<_X)\?M<^(/B7\*?$_PD_:DUSPYX8_;(_9/\:3_   _:BTFZNM-
M\.6?B3QCH>FVNJ>"OC?X2L+ZYLWE^'G[1?PVO?#GQ>\(W=K:PV-I/K^O^%8U
M2\\+7T,7Z65\2_M"?\$W/V"OVK_'-O\ $S]I#]D7X _&GXA6NA67AF+QI\0O
MAMX?\0^)CX?TV>ZN=-TB;6+FV%[<V&G37UXUA!<RS+9BZGCMO*CE9#^=GZ,?
M0WQ*^*ND> ?A#\1/B]IULOC72OA]X)\7^-Y]-\.ZMI+7&MVO@O1;_7=3TK2M
M2GN?['35)[73;FVLQ?WEK8B_,,-_>6,#2W,/RY\-OV[-$\>76@^'-8^&VO?#
M?QGX[_91U3]L3X=67CCQ;X(3PAK_ ,*-)D\(V>HMXB\=>'M4UNU^'^JZ'J?Q
M \$V_B'_ (2?1H=*ALM<N=3\-ZIXK@\.>)8]*[>X_9(^&WPH_9)^*'[,?[)G
MPP^&?P;\/>)/A_\ %7P_X*\&:!9/X*^'VE>*?B5H>M6-UJM\FA:7J]SI]I<:
MQJYU75[G3])O[R39*8+269D4?G+IW_!,#XMVW@ZYTOPO8_L_? K46_X)H?%+
M]B#QAX?^%.J>)KWPW^T7\0?%_@KPQX3^'7Q%^,E\WPP\&6^F^'/@Y<Z5XQU3
MPC]B\(^+O';_ /"U/&%M+K=MIBRZ1K8!^T%G\1?!SZAH/AW4O%?@^P\9:_H,
M7B"R\))XMT6[U>[TX6/VZ]O](M/M%M?ZSH]FB3N=9M-/%G);0M>,88=XC\0^
M,/[7'PM^&GPV\0_$/PUKOACXK?\ "*^)_@9X?U_P_P"!_''A?4-2TFT^/'Q,
M\%_#SPKKFI-976J)I]A)#XQ3Q1I_VV*W7Q#HVF7G]CSR%DG7XQTO]ACXM0:Y
M%!XQ\2^ 8/",/[2_[)/[74'C[3=7UJ7QQ\.]:_9P^"_PC^&?C3X.>'X+WPW9
M6M]X"\6_\*IU6RTOQ4NL>'YXOAW\7OB9X?UOPP+PB3Q-\:?!+]@KXF_'W]DW
M]G;QII&A?"SP!XET;]E/X%?!B#P]J[>*]"/C73/"/[6OP5_:,\27'Q2MG\ 0
MZIX>U/PAIOP<UCPWX-\+3Z'XD-KXK^)OCV6[U+2=)NY+K4P#]^U^,/PG;1_#
MWB%?B=\/&T'Q=K,_AWPIK2^-O#!TCQ/KUMJDVB3:)X>U+^U?L6M:O%J]O/I<
MNF:;/=7T6HPRV$D"W<;PJRX^,OPBM-5O="NOBC\.;;6M.N)+34-(N/'/A6'5
M+&ZBO+S3I;:\T^75EO+6>._T^^L7AGACE2\LKNV9!/;3QQ_D1\8_^"?O[3'C
M+PE\;_ G@]/V>K3P_P#%KQ3^VKXBTV[U#Q+XKT'Q'H$GQV\?_!CXD?#2&;7=
M)^%&K7\'AO4M9^'&L2?&#P)H5Q9Z?>^*%\$>,)]=\?6VAW'AQO53^PI\596E
MNY;?X.0ZC<?\%3-,_;8N;J+5=>GN+GX1V]U;:A/HD]VW@*WFG^)5K<I+'8:3
M(!X8D6.VN)/%UK(TD40!^DV@_%_X4>*!*?#7Q-^'WB 0^#].^(4IT3QKX8U;
MRO 6L+<OI/C:3^S]5N=GA'5$L[M].\3/MT2^6UN&M;Z58)2FEHOQ(^'OB.#P
MY=>'O'7@W7;;Q@=7'A*XT;Q1H6J0>*/^$?\ ,.N_\([+8W]Q'K?]BB*4ZM_9
MC71TWRY/MH@V-C\:](_X)W?M%>#O!.BZ=X2T[]F&;Q'H7P(_X*)_#'^S?$TW
MB#6O VM:G^U;^U=X"^/_ ,)=-UG1KGX726NI^%?"?A/PCJ7A?7UU?3-1L?#'
MBK5]/U;1/"7C;P_IE]I&K?<_[*GP-^*?P1'CJP\9^'_AQJMOXZ_:-^//QBBU
MW3/'OB/Q!KOA30/BI_8_B/3[2)M>^'.ES:SXBNO$TVO:)XF$&I:'ID6E6MAK
MVGS7?]IMX5T4 [+Q!^UQX'T+XV7GP4CT#Q+J^JZ%XD^$O@_Q;JNEC2)QX:\0
M?'&QU_4?AL]QX<?4D\6:AX:U.V\,ZR-5\7Z=H\^@Z-+9:@)+BZB\.>,YO#'<
M_#?XUWGCKXE?$_X8ZS\*OB+\/-4^'>F^#?$FG:YXIB\+7WA;Q[X1\=W7BW3]
M$UCPWK'A+Q+XB&FZK;7_ ((UR/7O!?B^#P[XNT:RGT#5Y=+FTW7;6XC^8_B9
M^QUXS\??M9>$_P!HM?$?AJQU?P)XI^'.H?#SXC:?-JN@_$OX?_"W3+2.U^-?
M[.ESI.FZ/-H/Q0^%GQVEBO-9U4>+_$-BOA/Q-K5IXHTW0;WQ%\/? NIV_>>!
M?@1XZ\*?%GXC_M,Q^$OAUX<^+WQ)^&W@[P)XV^'W@GXA^*8OAO\ $C6_!GBK
M5+O1/B3XU\2WWPWTV\E\9:-X/U)O"^AZD?A]J.M6N@B3PMJ?B+6-'MO#[:
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? HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>pfizerlogo2816.jpg
<TEXT>
begin 644 pfizerlogo2816.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X1$T17AI9@  34T *@    @ " $.  (
M   ,   (>@$2  ,    !  $   $Q  (    >   (A@$R  (    4   (I(=I
M  0    !   (N)R;  $    8   0_)R?  $    8   1%.H<  <   @,
M;@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                     %!F:7IE
M<B!L;V=O $%D;V)E(%!H;W1O<VAO<"!#4S0@36%C:6YT;W-H #(P,#DZ,3 Z
M,#4@,34Z-#8Z,#<   2@ 0 #     ?__  "@ @ $     0   @2@ P $
M 0   2SJ'  '   (#   ".X     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                 %  9@!I 'H 90!R "  ; !O &< ;P   %  9@!I 'H
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M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(_\  $0@
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MC<+Y-PG6_=Y;3HS:[<LG^-V?B?'?$W'U%*IGE;$0C/;F<HQ?Y(M>(_B)X_\
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( !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>upjohnlogo.jpg
<TEXT>
begin 644 upjohnlogo.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@"_P?0 P$1  (1 0,1 ?_$ 18  0 !! (# 0
M       * P0("0<+ 0(&!0$!  $$ P$!              @! @<) P4&! H0
M  $$ @$# @($!@H)# T"%P ! @,$!08'$1(($PDA%#%!(A5189$6%PKP<8&A
M,B.V=SAXL>$DM=8WA[<YP?%",Y-'I\<82%@9T=)#-"4F=I97E]>X&E+31-1%
ME=568I)3LS6&V&-S@U24-F;G:"<1  (! P($ P,$!Q$)"@P!#0 ! A$#! 4&
M(3$2!T$3"%%A(G&!,A210E(CLQ46H;%B<H*R,W.3)'0U=38W& G!DJ)#4],T
MM%71PF.#HY34A487\-+#1%2DQ"5%I<56=C@9X?%FA.3E9)6U)K;_V@ , P$
M A$#$0 _ )_
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                           !^?E<MBL#C,AF\YDL?AL-B:=G(Y7+Y6Y7
MQV,QF/IPOL7+^0OW)(:M*G5@C<^261[6,8U5<J(G4NA"=V:MVTY7).B256V^
M227%ME)2C&+E)I12XM\D1_N:OUE3V]^*-MY&T_6XN5>:;&E,QM+!;)QG@,#/
MI&_;!8=E8\O4U_9-@V3"(FOZY+4K-FROH207$LJ^@RW%&DDF3]/[2;HS;%J_
M>\G'5RK<;DI=<(\*.48Q?Q2JZ1K54^+I;HO*9.\M)L7)VX>9<<>3BETR?&M&
MVN"X<?&O"IGCB/<BXVX^\/\ 2?+7S7PE'PSBW^C?S6M\1[AMR[IR5D</)9G?
MJE>AKN-UG [#E=NV3 I!D9<15QTTV)KV6I<DC6*=8O-3VGEY6NW-#V])Z@[3
M2E=C'HMI_;5DY2BHQ=8J3DE)KX4ZJO:1UBS:T^.?J26-UJJ@WU2:\."2;;7&
MB7"O'Q,FO&7F/=.?>-(.5MJXCSW"V%VO(RWN-M3W#+83)[QE..I:=*?7MTVZ
MKKEW)8;5\CM?KRSPXB.U<EITTA?-.LLSX8.GU? Q],R_J5F_'(N05+DHIJ"N
M5?5"+DDY*/!.5$FZT5%5_;A9%S*L^?.V[<9/X4VG)Q\&Z52K[*NBYOP60QU9
M]8
M
M
M
M
M
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MZ5K1I^)D;%R[&;863C2ZK,N3HU7[*3.8SX#Z
M
M
M
M
M
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MB5S4D?'$Z-LLC6=>YS(W3,1RHG1%>G7Z4,8T=*^!ZL]R@
M
M
M
M
M
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M=EW\.75:4G&M&N*H^3X\FN:,I3IC[@
M
M
M
M
M
M                          #@SR4\BN+?$_A'D#G[F7.MP.@\=X27*Y*2
M-(I<GE[TCV5<+K.O4YIJ[,CLFS9>>&C0KJ]C9+,[>][(T<]O9:1I69K>HVM,
MP(]63=E1>Q+FY2?A&*JV_8O%GRYF98P,:>7D.EJ"J_:_8E[V^".K?\XO,;D[
MSM\C]\\A^4)G5K>R6TQ^HZE!;?:Q''V@XN2:/5M)PSW15V25\32D5]FPV*%U
M_(36+<C&R3O0F1MW0</;>DVM+PU6,%64J4<YOZ4W\KY*KZ8I17!&$M3U&_JF
M9++O\Y<EX1BN45\GYKJ_$Q'.\/@          !L+]O#W*O(+VW^3;^Z<16<?
ML>E;=]VU>3^)-HDMKJ&]X[&S2NJ6/4J/;:U[;,3#:G3'9:NCY*RS.9+%9K/E
MK2>6W3M+2]V8:Q\Y.&1;J[=V-.J#?/GPE%T75%\Z<&G1KMM(UG+T>\[F/1VY
M4ZH/E*GYS7@_SUP.R \&/-/BGSY\=]6\A>)4R%#'92S:UW;=3S"-7-:'ON'K
MT9]AT_*6(F,JWWT8\C7GKVX42.Y1LP3=L;I'1,B?N/;^;MG59Z7G4<XI2C)<
MIP=>F2]E:--/DTUQI5Y@TS4K&JXD<O'JHO@T^<9+FG]GGXIIF8!T1V
M
M
M
M
M
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MIT7-I-\B5:87/<@
M
M
M
M
M
M        $5;]9(]RN7B'CJ#P1X>S[JW(W+^!CR_.F8Q5OMMZEQ+?>^/'Z,LT
M"J^KE^37P/==C5[)(\#$K)(W0Y.-Z9H[3;16=E/<F?&N)8E2RFN$KJYS^2WX
M?HW5.L&>&WCK+Q[/XKQW]^N*LVO"'W/RR\?T/Z8@NDCC&0
M!V.?ZNGP/K7$?MH<;;SCH:LFU>0>T[URCN62CC<L[W4-HRO'VL8CYJ5$F?2Q
M>M:;!*D*(V&&Y<M*Q'+(Z62*/=74KV=NZ]C3KY.+"%N"^6*G)T]KE-JO-I+V
M467]HXL,?1H75^R792DW\[BE\R7V6S>P8W/3@
M
M
M
M
M
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M=LJS'2,EM75)^6Z-IIMOI=.33KQ?"G#A0E]&"S(
M
M
M
M
M
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MG[28 8*,@
M
M
M
M
M
M&I+WG?/V#P&\.MFV+6,JRISGRY\_QKP?6C<GSN/SU^BJ[!OS6='*RMQ[@YUM
MLD<UT2Y.6C"].V<]QL#;#W-KT+5Z-=-L4N7O8XI_##Y9OA^E4GX'0[CU5:5I
M\IP?[ZN?##Y?&7ZE<?EHO$ZR>S9L7+$]NW/-:MVII;-JU9E?/8LV)WNEFGGF
ME<Z2:::1RN<YRJYSE557J2]244HQ5(HPNVVZOF42H               />..
M2:2.&&-\LLKVQQ11M<^221[D:R.-C45SWO<J(B(BJJJ4;257R!V=GLJ^*.W>
M'WM[</\ '7(N+EP7).W6-@Y:WW 6($KW=?S&_P!UES%8#*1*ULT6;PFGU,95
MOQR?;@NQ2Q?0Q"'_ '!UNQKNZ;^7B2ZL2VHVH2\)*"HY+W.3DX^U-/Q,T[;P
M+FGZ3;LWE2]*LI+V.7)/WI43]YM</%'>@
M
M
M
M
M
M                      ]))(X8Y)II&111,=)++(YK(XXV-5SY)'N5&L8Q
MJ*JJJHB(A5)MT7,'6->\OY[S^?'F9M^UZWE9K?"'%/S?%_!U5K^E&[K.'ORK
MF][CA9(L3[/(NP-EOQS.8RQ]U)0KRIUK(B2^V#ME;9T"W8O1IJ-^ER\_%2:X
M0_41^&G+JZFN9A;<6JO5=1E<@_WM;^&'R+G+]4^/R47@:G#VYT0
M       ) OL-^V%O_EWSOA/([:GYC2_';@G9ZF1GV>M7^5RW(>_T6+9H:7HF
M3M4IV8^7"]\=K*9FF^/(X7OKK0FKY"6"W4QAW*WABZ'ILM)L]-S5<F%.GFH0
M?.<TGQKRC!_#/CU)Q3C+U>U]%NZAE+,G6.):E6OC*7LB_=S;7%<*-.C78@P0
MQ5H8:\#&Q0P11PPQM_@QQ1,1D;&]>J]K&-1$(LMMNKYLRVN'!<BJ4
M
M
M
M
M
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M27!)<$DDN",SXV/9Q+$<;'BHV8*B7_AS;YM\V^+.3SXSG
M
M
M
M
M
M                                  !8Y3)X["8S(YG,7JF+Q&(HV\GE
M,G?L15*..QU"O):O7KMJ=S(:U2I6B=))(]4:QC5551$+H0G<FK=M-SDTDEQ;
M;X)+WLI*2C%RDZ12JV=6A[I/FQEO/7S*Y/YL2[=DX\H77:%PKB;7J1MPW$^J
MW+L.NO;4E1'TKFT6K%G.78G*Y8[V3F8BJQC$296S=O0VUH%G3Z+ZTUUW6O&Y
M)+JX^*BJ07NBF80UO4I:KJ,\FK\E/I@O9%<OL\9/WMFO$]4=2
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M =B
M
M
M
M
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MZ,>'!N5<Q;=T..D8W7=2>=<7Q/V+[A/V+QIS?N2-T)C\]&
M
M
M
M
M
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MWO[7W<?%4ESF#CWP
M
M
M
M
M
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M!7K5X&-BA@@AB:V.&&&-J-:UJ(UK41$3H15;<FY2=9,RZDDJ+D5BA4
M
M
M
M
M
M                                              '7!?K!WE^[R?\
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M8F.J6X*GO;\6_>WQ9D =8?6
M
M
M
M
M
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M>Q
M
M
M
M
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M6HB(G0B VY-RDZR9FA))47(K%"H
M
M
M
M
M
M                    !U9_NS^3C_+3W ?(SE.CG'Y[3,?NUSCCC.RUR+CT
MX]XX>[5,#9P[&OD2/&;#+CY\NWJJ.DER,DCFL<]S4F7LC1_Q)MC$PI1Z<AVU
M<N>WKN?$Z^^-5']2D80U[-^OZK>OIUMJ73']+'@J>Y\_G-<AZLZ@
M     '9?>Q[X(S>#OA/JU3<L)]U<W\X35N5^78[,369/#39*DV/2M"MO^,D?
MYEZO(Q+%=RJD&7NW^U>CR(O<7<BW'N&<L>75IV-][M>QT?QS7Z>7)^,5$S+M
MK2_Q9IL5<5,F[\4_:O9'YE^:V;C3P9Z$
M
M
M
M
M
M                          UX>Z[Y(S^*7M]^3/+V+N/I;7%H%C1M$L03
M^A=K;OR=<J<?:[EJ"HJ.?9UJWL?WJK4^/I47K]"*>IV5I*UK=&'@S5;'F]<_
M9T6TYR3_ $RCT_.=1KN8\#2;V1%TN='3']-+X4_FK7YCJPR9IA
M    &YSV*/"23S)\Z](N;)A69/A[Q\?0YEY/6[7=/BLE8PE]B\?:9::O]SV7
M[3N$,,DU67JRSBJ%Y%:Y&JU? =R-PK0-MW(V94S\JMJW3FJKXY_J8UHURE*)
MZ+;&F_C'5(N:KCVOCE[.'T5\[\/%)G97D2#,@
M
M
M
M
M
M                                (@OZUEY'_=^E^-/B9A[_ &V-ESF;
MYYWJE%+Z4S,5K=:[HW';)T8OJ6,?ELGFMAE=&_I'Z^+B?T<]C5CSIV6TGKR,
MO6[BX0BK,'[Y4G/YTE#YI/Y\?[ZS*6[.!%\9-SE\B^&/V6Y?8(5Q((QR
M         #LBO8%\+8_$OP0U/;=DP[:'+7DT['<R[Q+8KO@RE#6,A05O%6I6
MO69#8CBPVI6UR#X)6-DK9'-7(UZ]$(F]S=P/6]R3L6I5P<.MJ'L<D_ODE\LE
MTU\8PBS,.U=-^H:7&Y-4R+WQR]M/M5\RX^YMF\$QV>E
M
M
M
M
M
M                                      !UDOOE^0[O(OW+_(?*5+K;
MNL\49BGP+J79*LT5>CQ7'+AME;#*DLD,E>YR--F[<:Q]K%993X*O5SI>]N=*
M_%6T<6$E2]?B[TOEN<8_8M]"^8PON;+^N:S>DG\%M]"_4\'_ (74S4<>Y.A
M           -@OM;^(T_FSYQ<'<(6Z$US1G[''O'+,L<?=#5XLT9T>>VRO9E
M^*5/SEC@BPE>96O;'=RD"JUR=4/+[RUQ;>V[DZC%I9/1T6O?<GPC\O3QFU[(
ML[71-/>I:G:QFOO5>J7Z6/%_9Y?*T=J!6K5Z=>"I4@AJU*L,5:K5K1,@KUJ\
M#&Q0P00Q-;'###&U&M:U$:UJ(B)T(9-N3<I.LF9P225%R*Q0J
M
M
M
M
M
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M:A-?'<?3']+'G3Y9</U)*[,*GN@
M
M
M
M
M
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M:YOYW5_.<\G6GU
M
M
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M_#J==>Q<G'2=^W<@GRZHM5^RD=MCYN%E-QQ;UJY)+BH3C*GRT;H?I' ?4
M
M
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M[& BH9>
M
M
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M_*6>61,YR5O^921(VR)EMQV+(H](E1T2/^<R,W<D;DZMZ_0OT'H<;;FWL/\
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MFN:J*CD5.J*BI\%14/$--.CYF0TTU5<CR"H
M
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MX[\V_P!3&L5^;U/YR2,8F/8@
M
M
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ML5',]GP62QC;;E5.J]5ZJN&-?],/;O55*YI+R]-OODK=SS;=7[87NN=/=&Y
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M#>5CZQM;4L/.@EQ5J[&4X_I[=?,@_=.,7Q1R^>=/4@
M
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M8?1MP4?EHJ5^?F<T'7GT@
M
M
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M<)S@
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M-KXOUO6K2:K"W6;_ %/+_"Z3LQ2(IF8
M
M
M                                      'A51J*YRHC415557HB(GQ5
M55?@B(@2;=%S*-I*KY&'?+WGCXS\.+:IY7?:^W[#55['ZQQZR':LFV:/U&R5
M[5ZO9@US&68I6=CX;=Z"9JJGV.G54RSM3LEW%W;TWL;!EB8$J??LJMF%'2CC
M%IW9IIU4H6Y1?MY$>>X/JE[+]NW/&S]5AJ&KPJGC8"65<35:QE.,HX]N2:HX
M7;\)IOZ/.FKOEKW;.4L_\UC^(=,P/'N/>U\4.=S[F[=M'P5WIVZU::&IK6.D
M<U4ZPS5<BU%3^&I)/:WI:VU@]-_=>9?S[ZXNW:^\6??%M.5Z?Z:,[3_0D(=^
M^OG?&K.>)V^T[%TC$::5^_\ OO)]TXQ:CCVW3G"=O(2^Z9K2Y$YCY4Y9N_>'
M)._[5N4S'K)!#F\O;LXZDY>[X8[$I(S%XR/J]?LUX8F]57X?%20N@[3VSM>U
MY&WL'&Q(-4;MPBI2_3SIUS?OE)LAQNWN'OG?N3]:WCJV=J-Q.L5>NRE;A^UV
MJJU;7%\+<(KB^'$XO<IZ)^P\>^+H457HA4N7,HK]!1<SD7,HN7X#FSE1;O4J
M%Q=2BY1X5.2)2=]01R(H/4>)>N"*#OI*OD5CR*+OI')'(N117Z5*+D<BY%!R
M_7^Z$7/V%!?H+GS+T45^A0SD7,HN^@+F<BYEN_\ U0BOB47?4/$OB6[U^G\7
M^N#D\"U>5\3DB6;U^G]LJBZ):R+\5_$@\#D7,M)/J3]G[/B5+RT>OP4>)R+D
M6C_K_:*^)?$M7CP+US+23Z_V_P#5_M%? O\ %%I)]?[17V'(N1:N^H>)?$LW
M_7^W_JE47QYEK)]?XD"Y%_B6C_J*G)X%H_Z_V_\ 5*^)R1+1_P!?[07,NB6C
M_I'@<GB6DG^J5+_89'>/GF'Y&^+657(<+<G9W6<?-898R>I69&9K2,TYKVN>
MN4U/+-M8:2Q*Q%C^:BCBNQL<Y(YF*O4\7N[MYL[?-A6MR85J]>2:C=7P7H?I
M;L:3HN?2VX-KC%F0=D=S]\]O+_G;4U"]CV').=EOS+%SCQZ[,ZPJUPZTE-)O
MIDB1KXF^^AQ%R3+B]/\ )K 1<+[=8].LW>\.MW+<69*TK>B27XY%M;'I/S$R
MHQJ3?>-.-.KYKD+/HAWO[TP;@T97-0V5=>I:?'CY$Z1RHK]#2EN]1<73RYOE
M&W)DZNVWJZVUKSMZ9OZRM*U*5%]8AU3Q)/VR3K=L5?!=7FP7.5V*-ZF"SV#V
MC#8W8M9S.)V+7\U3@R.'SN"R-/+X;+8^RQ)*U[&Y/'S6*5ZG8C5',EB>]CT^
M**J$7LK%RL'(GAYMNY9R[<G&<)Q<)QDN<91DE*+7BFDT2\P\S$U#%MYV!=MW
M\*[%2A<MRC.$XOBI1G%N,HOP:;3/UC@/I
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MF(F!S(0
M
M
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MBJEE9/5CXJ?A*%KADWE[8S6*_%29J4YB\N?('G-UFOO7(66^X+*O3\T-??\
MF[JC87M5OH38C&+"W*L:USD1]Y]J5$<J=_3X$I-I]J]B[+49Z+@6OKT?\?=^
M^WZ^U3G7H^2VH1X<B W</O\ ]V.Y[G:W1J]_\53K^]+#^KXJ3X=+M6Z>:E5T
M=]W9<6NJAC89",-'JY?J*^!=$HN4HCD7M+=R_P#9*^\+VE)R_4&<D?:47*.2
MJ<D2BY0B_DBW<O52I5<BDY?B'R.1<BBOTJ.2.1<B@Y0BY\J%!5^E0^9<BDJ_
M65?L.1%%?@B@Y%S+=R_]@(NYLH.^@>)>BD[Z SDB47%? O7M+=P15%%WT@Y%
MR+9Z_3^,JN9R>Q%J]?I_$@+UR+1WU%? OB6;U^G\:CV(O7,M7K\?VD*EY:/^
M@JN9R>!:O7Z0CDB6CQX%T2T?]7[/V?25.3Q+21?I_;*KF7^"+5Z_O)U!>N1:
M.^@KX')$M)/K_;*^"+US+5Z_']I 7^!:/^@KXG(N1:/^L%\2T?\ 2/ O1:/^
MHN+_ !+23Z_VQXG(N1:N^G]HJ7KD9>^*/GAY&>'.;BL\5;C-9TZQ=2YG^+MH
M=8S''^>5W:EF1V'=/%+@\I88QJ.OXV6I<=Z;&ODDC18UQWOOM;L_N'BN&NXZ
M6HJ-(9-ND+\/9\='UQ7'X+BG#BVDI<3*7;CN]O?MEEJYM[*<M+<ZW,2[6>/<
M]KZ*IVYOA]\M.$W1)MQ72Y:_A'[HO 'F3!2U=EIG%_-7H,2YQ=M.1KN?F9V0
M>K9GT#/N94J[=3C['N6!(Z^2B8QSY*J1(DKH#]RNR.Z^W<I9KC]>VW7ADVHO
MX%6B5^'%VGRXUE;;:2GU?"MD/:GO]L[N?"& I?B_=/3\6)=DOC=*MX]S@KT>
M?PTC=23;MJ/Q/9>89,[
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MF/5W<&5Q3<K=?AO8\W&#O6Z45Q="G:GPFNF5N<]B!A@DF
M      1 ?ULGD!]73/"_BR"S*L>;V?F/D#*4VND2%K]6Q6AZ[@K,S/A%)*]N
MX9%L2IW.8C9.O:CD[LZ]DL52R-0S6N,86H)_IG.3_61_,,?[\NTMXUA>,IR?
MS**7Y[(61($QR            =FC[$_!GZ"O;!\;:=NG\KGN4\-E^<\_)Z?I
M?/?I3R]G/:A<[%3N_P 6WW'%W*KN_P!+N3HUR-;$/N1J7XRWAERBZVK,E9C[
MO+73)?NG6_G,S;8Q?JNB64U\<TYO]4ZK_!Z3;T>%/0
M
M
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MB\M7_05.1%H]?I_9^(K["^):/7X@O1:/^HJO%G)XEJ]?@[\G^H%R+UR+5_\
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MX-2C*,E52C)-J46N*:;37%%^<1S
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M=F,?R]NY&2^=S,:^:%N%/'VREX+Y^!BW?%SJU.U:\(V4_G<I?W$B,49@/%@
M         ^LT+3<QR+O6E\?:]%Z^?WO;-<TW!P].[ULQL^8IX3&1=J*BKZEV
M\Q.G5/I.#)R+>)C7,J[^Q6H2F_DBFW^8B^U;E>NQM0^G*22^5NB.WQT#2\+Q
MOH>D\=ZW VMKNA:CK>EX&LUJ,;7PNK8:E@\7 UC>K6-BHT8VHB?!.A!?*R+F
M7DW,J[QNW;DIR^63;?YK,_VK<;-J-F'T(127R)41]<<!R
M
M
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MX#L0
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MVXG2=RVK2]_FR4)+^\<G\B.]VUC_ %G6[$7]&,NM_J$Y+\U([.LA^9I
M
M
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MQ',
M   >'.:UJN<J-:U%<YSE1&M:B=5557X(B($FW1<RC:2J^1KZYX]T#PWX"?=Q
MV9Y.K[]M5%9(Y-0XIB@W;*-L1,ZOJV<K6MU=1QEJ-ZHQ\5O)02L>JHK?LNZ9
MCVEV&[F;O4+V-@/#T^=*7LMNQ"C\5!IWI+Q3A:DFO'BB.?<'U6]D^W;N8V;J
ML=1U:W5/'T]+*N57.,KD91QX23X.-R_"2?!K@Z:J^3/?ZS-B#*4>'_'NABY7
M0V8L1LO(>Y2Y5S)7HUM6Y<T_7\/C8FK!]ISH6YF1KU5$[T1J]T@-"](&+"5N
M[N369W(U3G:Q[*AP\5&]<G)\?;Y*I[./"(^Z?[1+.NV[V/LO;=NU-QDK=_,R
M7<HW]&4L:S;@N'%N*R9)\/B23KSQXO>^-Q=OMG'ZKY+:HG$6P6GP58][UE;^
M<XWM69>R-9,I0F6UL^GPR3O1&JYV5K1L17SV86HJGDM^^E/7](A/4-CY'XRP
MXIOR+O3;R4EX1DJ6KSIS_8I-\(0DV9![4>O7:>X;MO2.Z.'^)M2FU%9=CKNX
M4I/A6Y!]5_&3;HJO(@E65R[!*IQU[KG@5AN6M;F\TO&B'%[-;GQ<.:Y-P^EN
M@R]#>M>;$G9R;K$N'=9K9'*XZLU%RB0]S;E-BVNY)H9OF.Z]/?=W)V[G+MAO
MEW+%M7'#%G?K"5BY7_1;JG1QA)_L5?H3?ETZ91Z/,^KST]X6\=+EWQ[71LY5
MZ5E7<ZWC4N0RK-.&=8=OJC.Y"/[/TU5RVG>KUPGYD9TG,:M@    ;FO;C\\<
M;@V9KQ)\KLK/M_CKS!2N:I2R>V7;609Q_DL]"N.?1L9&S.ZU0TG.I-VO<UW3
M$WO3MQ+"Q;4A&7O7VDOY;M=Q>WMM8V]--FKLHV8J/UB-M]74HI4E?MTJDU]^
MM]5N74_+B3>],WJ"Q<!7^SO=Z]+-[:ZU;ECQGD2E-8D[RZ'"4Y/JABW:T;3_
M 'O=Z;T';B[LC ;S$\9MD\3.>-NXDS;I[V(K2MSNA['+&QC-KT++3V%U_-L]
M-71I91L$E6XQJJV.]6F8U7-:URY>[:[ZP>XFTL;<6+2&3)>7D6U_BLB"7F0]
MM.*G!OB[<HMT;:4>.]7:S4^SW<',V=GN5S#B_-Q+S5%D8EQR\F[PX=7"5NXE
MPC=A.*JDF\7CWAB@SA\)/-O=/$+<KT+ZLVZ<+;TBXSE;BVU.BT<YB[4"T+69
MP;9W)6QVU4Z$CF,D7MBN0I\O87L].2'%7=/M9I?<?3(24EB[HQ/BQ,I+XK<T
M^I0G3C*TY*K7%PE\<.-5+/78GOOKG9G6[D)0EG;&U#X,_ D_ANVY+HE<M5^&
M&1&#:3X1N1^]W.'3*&_7VO\ S]U7DK+9OQ3VC;;><R^G7LU%P%N^P^K7R_)7
M%6*FL283"9YMQ&SIONKZW%$Z5KE?):J1R*JODJRRS1"[\]G]0T/'M=P<#'C:
MQLF$'J%BW1PQLN:2G.W3A]7NW6Z-44)M<E<C&.P[TI>HG2-T9E_M%JN9/(S<
M*Y=6DY5ZL;F;@6VW:M7>KC];L65%R3;=RW&3;<K4YSW9D6R=8
M   !U;'O![0_;_<Y\U,M(]\CJG-VP:NCI&5V.1FD5<?I<3$;51(U9%'@$:U5
M_C'-1%D_C%<3)V)95C9^GP7CCQE_?MS_ -]_N<#".X)^9K63+_A6O[WA_<-;
M9ZTZ<          $J3]5.XG9L'E!Y*<SSP^M%QCPI@M%JJZ)71U<KRUN,64@
MMLE_@Q6DQ7%=V%J?2Z.>3I]"F&.].;Y6CXFGKG>R'-^]6HTI]FXG\R/<;&L=
M>;>R7RA;4?GFZ_G19.G(X&3@
M
M
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M+UZ=?@C24OI2U&]:WCJ.E)OZM?TUW6N-.NS>M1BZ<OHWI\?F\2#/KPT?&O\
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MI&Y%]5N3_3+DWX1DHR:XT/3Z;K.GZK']Z3K<2XQ?"2^;Q7O55[S/0\T=H
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M\N]:DE.W.G)2BE)?%!RBU)\UGESW0                          !KO\
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M/A"TKLWP4+=^%R[8<I.BA"=RW<N-J,(.3H;+C!I*,
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MQEQ7"E^"59I<*1O1<;L:<(]3A5N#,]#&!E<
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M]NUIUK/N^5J.E)K]X9[C*YUXZHNK"RXPN7++BJ6IPN6FK?PVXX5&4#!@
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M_>ED;BT"]#'E<F^JY<QKD92Q9W'S<TH7;/4ZN:LJ<I2G*3-MQ'4F,
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MCU^/[14O1:/4+FV7EJ]?X2_L_ $<BY%J\KX%\2S>O[ZE?<7KF6LB_257,O\
M8BU>H7.IR+D6CU^"_C4%\46CU^DKX%ZXLM9/J0J7FXSV1?*B7@/R\Q?&N=RO
MRG'GD;'2X\RD%B3MIUM^BEL3<999&][4^=L9FW-AF?2U6YE5<B]K5;'SU(;)
MCNC8<]8QH=6K:16_%KF[#261'Y%!*Z_VKAS=9)^F'?<MI]P;>BY5SIT?65''
MDGR5]-O&G^F<V[*_;N/)-3@S6X;/P
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M3/N'9^KX=JQ]Q;C'^]BE_<.:3KSZ0             =27YI?TQ?++^LOSO\
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MK!W_ #1O\O?_ !+$V_1Q_P!H_P#J_P#]M-8O]HY_V-_ZV_\ IA&Z)MFL8
MD"^P'<LLY3\A\>R9S:=GC_3KD]=.G9+9H[%D8:DSOAW=T$60F:G1>G21>OU=
M(>>L"W;>@:->:^^QS+R3]BE;BVOG<8_8-B_]G9>NQW;N3'4GY$].QI->#E"]
M-1?S*<E\[)0A PVN
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MOG-S^R-R6MW[1T[<UFB69B6[DDN4;CC2[#]1<4H?J3G4\R>I
M                                              !J,]XKQ9L<\^-R
M\CZMCTM\@<!OR>X5XH8FON9?0+-6/\^\3"K6>K)-0K4:^5C;W+U;CY8V-=),
MA(STU;_AM'>_XDU"?3H^KJ-EMOX89";\B;\*2<I6G^V1DVE%D-_6KVEN=P>V
M/Y3:3;Z]Q[><\E)+XKF)**^MVUXMPC"&1%5Y69QBG*:(=)LJ-*@
M          )<'LX^:GZ;N*E\?=^RRS\I<-X>NS7[EZPQ]S<.,()8J.+L-[E;
M+8R.E/EAQUI>U5=5?3D<Y\CYG)KJ]2W:_P#)7<'Y8Z/;IH&IW'YD8KX;.4TY
M27L4;])7(_HU<BDHJ*-QOHH[Y_EYM'_NXW%>ZMV:)97DRG)=63@IJ%M^USQ:
MQLSX<;;LR;E)S:W4D7B<P        !\;R-_B]WO_ ,C=H_O)>/HQ?]*M_MD?
MST<=[]BE^E?YQT\Q.XCZ          #GSQ3X_;RQY0^-_%KXFS1\D<\\0Z'+
M$]J/8^';N0->P$R2-6:LU8O2OKW=9(T[>O5S4^*=9K65]1T;+S5SLXUV?]["
M4O[A]6#:\_-LV/N[L(_9DD=N>0<,^               '4G^;$,U;S,\MZ]B
M&6O8K^3G/4,\$T;XIH9HN5-KCEAFBD1KXY8WM5'-5$5%3HI-[;S3T#!:XIX=
MG\'$P-J2:U'(3Y^?/]<S&0[@^(   [%/]6K_ -&#JW\\O+O]]L>16[M_SQG_
M  >U^<S+FS?XEC^V3_/1OX,9'J@       1</UK#^AUXZ_UEX?\ -;R 9D[+
M?Q]E?P/_ ,I \3OG^+K/[=_O9$$,DD8O   -R7ZOW_I=/$K_ "\_^[+S.>![
MG_S&SO\ B?\ 6+1Z':G\?X_ZO\',[+DB.9E
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M!?\ &_Y ?S;:S_*>0B!ZO_YMZ/\ PZ[^"-B7]G=_/3<7\EV/P[)1I @VP@
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M*_27KLM2[:W=(NNL].U"["*]EJ\HWX_9NSO?8KXF](C22B
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M_P"ET\2O\O/_ +LO,YX'N?\ S&SO^)_UBT>AVI_'^/\ J_P<SLN2(YF4
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M=#VYB8^#H]B-+=FS"-NW%>-(Q256^,I.LI2;E)MML^K.O.W
M              (W?ZP=_P T;_+W_P 2Q-OT<?\ :/\ ZO\ _;36+_:.?]C?
M^MO_ *81NB;9K&   -_GL"_XW_(#^;;6?Y3R$0/5_P#S;T?^'7?P1L2_L[OY
MZ;B_DNQ^'9*-($&V$
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MV=2OA0N1:/7Z@7^):O7X+^,KXG)[BU<OQ_:!>N1:/7]]2I?'F6LB_3^+X%?
MO\:%H]?J!R>!:N7X+^,J^9?$M7K\5_$5+D6CU^A O:<GB6CU^"_C^'[/W <A
M:O4KX%\2T>O[ZE?$O1)N_5MMMFAVKRNT5ZO?7R6 XIVRNBMZLKS8/([OA[JM
M=WHC76V;#!U16N[D@3HK>BHZ&OJ\P8RPM#U-?2A=R;3]ZG&S-?8Z)?9^Q-WT
M:9\HYVO:6_H3LXMU>YPE>@_L^9'^]\/&5H0B)W@
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MW=O^3M!VZ_LN3:C]CJG_ +SP_.J>KV9;Z]:4ON+4G^='_?'8AD63+8
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M7JR2)[F.3XHJGB;ENY9F[5V,HW8NC3333]C3XIG>QE&<5.#3B^37%,_4+"X
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MJ2(QLG&S,>&7AW(7<6Y%2A.$E*$HOBI1E%M237%--IEZ<1S@
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MRXU3V?BK_P!HLDQ$@(;#P
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M3O?P_I'<.?S)1_R[VXV">D3^9.I_RJ_P%DU%_P!H9_2;HG\A+_6\@T3DLB
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M-/ZK%8.[\6">5A2FI22X+S[$N#NX[D^GJHIVY-0N175;E<SX,0DA@
M            ? \H<E:EQ!H>R<C;QD6XW6]8Q[[UR5.UUFU,YS8:.,Q\+GL2
MSD\K=ECKUHNJ=\TC4543JJ=WMS;VJ;JUO'T#1K?F:ADW.F*\$N<IR?&D(13E
M-^$4^?(\MO;>6@]O]KYF[]RWE9T?"M.<WPZI/E"W;3:ZKEV;C;MQJJSDE5*K
M42_R+Y^V[R-Y.S/(>U2R002N=0UC7VS.EI:OK5>:5^/P]3X-:][?4=+9E[6K
M8LR22*B(Y&MVA[!V1I.P-N6=!TQ)S7Q7KM*2O7FEU7)>[@E"-?A@HQXT;>AO
MN[W4U[N_O3(W;KK<;<GY>-83K#&QXMNW:ARJ^+E<E1.=R4I454EP5W_C/:T1
MC#X3SW_M"B*<!W_M"B' \=WXQ1%?A)#'M%<>)A.&][Y(LPHRYONY1XBE(Z-.
MZ3 Z92]*&6.5?BC)<WF[\;FI\.L"*JK\$2!WJGU_Z[NS"V_:E6S@XCG)5Y7<
MB56FO=;MVVG^B?S[:/0+M%:9V\U3>-V-,C5=15J#ISL8<*)I^QWKU^+2^X3=
M?#;61=)Z  _"VG8<=J.L[%MF7D2'$ZQ@LOL.4F5S6I%CL+C[&2NR*YW1K496
MK.7JOP3H?;IN!D:KJ./I>*JY63?A:@O;.Y)0BOG;1UFMZMB:!HV7KNH/IP,+
M%NW[C]ENS"5R;^:,6R%EMVRY'<]KV;<,Q(LN6VO8<ULN4D5[GK)D<[DK.4NO
M5[OM/5UFTY>J_%3;QI>G8^D:9C:5B*F+BV+=J"]D+<%"*^PD?G-U[6,O<6NY
MNX,]]6?G9=[(N.M:W+UR5R;KS=92?$^<5R)^,^XZNC/57*HJ522/151!0NH9
M\^VIQB_D?RJT_(3UWS8;C6ED^0\F]&_Q;+.*9'0UQJRN:Z-)F[+E*DS6_P -
MS('JWIVJYN$?4)N..@=M,NQ;DEEZA.&+#VTG65WA[/)A.->2<E7G1RF]'FRW
MNWO=I^7=@Y:?H]NYG7'X*5I*%CC2E?K%RU-+FXPE3DVI3)K:-V   !H\]YK=
MXXL3PCQS!)&^:UD-IW;)P_\ =((Z%;'X+!R_A[+3LED$_;A)A^D[1W+)UC7Y
MIJ$;=G'@_!N3E<N+Y5T6O[XUQ_V@6X81PMN;2MM.<[N3EW%XI0C"S9?R2\R_
M_>&E3C#2+G)G).A<>4721VMWW#7=6CFC:CG5DSF6JX^6XJ*BM2.E#.Z5ZK]E
MK&*J_!%);[CUFUM_0,W7+U':P\6[>:?CY<')1^6322]K9KTV9MR_N_=NF;5Q
M:J]J.?8QTUQZ?.N1@Y_)!2<FWP23;X$V.A1IXNC2QF/KQU*&.J5J-&K$BI%6
MIU(65ZU>-%552.&&-K4ZJOP0U%7[UW)O3R+\G*]<DY2;YN4G5M^]MU/T08N-
M8PL:WAXL5#&M0C"$5RC&*48Q7N222+LXCG !B#YJ^/&Y>3W$E+C#4=OPVG,D
MV[%9_.W,S2OW8LAC<33R25\9%'0>US%=E+4%A5<BI_<Z=#*':7?.E=O-S3W#
MJ>+=RFL6=NW&W*,7&<Y0K-N7Z!2CP^Z,&>H'M;KW>#9%O9^AYV/@1>=;O7IW
M83FIV[4;G3;2@^'WR4)MO[A&J%?9=Y/7_?JT/_ZP;#_VY)3^MCM[PTG-_=+1
M"W^H'N__ .X--_<;_P#NGHOLM\H+_OU:%_\ 6#8?^W*+U8;>_P!DYO[I:+EZ
M!=WK_M!IO[C>_P!T]5]EGE!?]^K0D_\ S?V'_MQ_6PV]_LG-_=+1<O0-N]?_
M !_3?W&]_NE-?96Y07_?KT+_ ,W]A_[<JO5CMU?_  G-_=+07H&W=S>OZ;^X
MWO\ =/1?94Y17_?LT'_S?V'_ +<?UL=O5K^*<W]TM?[A<O0/NY?_ !_3?W&]
M_NGJOLI<H]/AS9H/_F_L/_;C^MCM[_9.;^Z6BY>@G=W^W]-_<;W^Z8W^4OMP
M[5XK\62\H;1RMJ&?K.V##ZUCL'C,3EZ=_)Y/+?-3)%7FN/6!%JX^A8L.1455
MCA=T/==O.^NF]Q=Q+;VGZ;E69^1.[*Y.<)1A"%%5J/'C*48KWR1C+NYZ7-8[
M0[1>[=7UG"R;3R;=B%JW;N1G<G<ZG2+DZ?#"$YOW19K4<IGCFR+3XNAL3\3_
M &X^0O*WC?(<F8;>=<TK#U=IR&L4Z^>QF4NV,H_&4,9;MY&LZ@Y&-IMFR7H)
MW?%987_4A@[N1WST7MSKL- RL._EY4L>-V3MSA%0ZY3BHOJ^VI'J^22).]G/
M3#N3O!M>YNK!U#%P,*&7.Q&-VW<D[CMPMRE./1PZ:SZ./'JC+V&3:^R1RG_Z
M;] Z_P#D]L7_ &YC_P#K8[=_V3F_NEHRTO0=NW_;VG?N-[_=*2^R)RHO^_AQ
M^G_YO;'_ -N%ZL=O?[)S?W2U_N%W]0_=M?X^T[]QO?[I2=[(/*J_[^/'_P"+
M_P 7MC_[<?UL=O?[)S?W2T7?U$-V4_C[3OW&]_NE%?8\Y57_ '\N/O\ S=V/
M_MQ_6RV]_LG-_=+15>A'=B_^/:=^XWO]TI.]CCE9?C^G/CW_ ,W=C_\ G!_6
MRV]2GXIS?W2T7?U$MV?[>T[]QO?[I1=[&G*ZIT_3IQ[_ .;NR?\ ;E?ZV6WO
M]DYO[I:+OZBF[/\ ;VG?N-[_ '2DOL8<L+_OZ\>?^;FR?]N/ZV6WO]DYO[I:
M_P!PJO0KNQ?_ !W3OW&]_NE%WL5\L+_O[<>?^;FR_P#SA7^MGM[_ &1F_NEH
MN7H6W76OX]T[]QO?[IK-\PO%N[XB\E8SB_,[_K^^9^UJU':,F_7:%VE6P<63
MNY"KC\;=^>D?*N1GKX];*LZ-[:\T3OBCTZ9R[;;^M=Q]#GKV-AWL3#CD2M1\
MR49.XXQBY2CTJG2G+IKXRC)>!&WN[VNO=I-R6MKYF?CY^?+%C?F[,915I3E.
M,(2ZFWUM0ZZ<*1E!_;&)#U,A<W4Q<N'$M'+]*_D*E\46KU^H+@JEYG?P+[:7
MEWY"0U,KKW'$NDZE=5BP[GRA-/IN&E@D5O;;HX^Q4M;5F*;F*KFS4L=8A=T5
M._K\#$F[>]W;K9\I8^9FK*U&/.SBI7II^R4DU:@_T,[D9>XSKL;TZ=UM^0AD
MX&G/"TJ=*9&8WCVVG]M&+B[UR/LE;M3C[ZFU?C;V$=4AAK6.8.?=AREA_:ZY
MB.-=:QN!AK]'M[XJVQ;1)LC[G=&B])'8N#M5R?87I]K &M^K34)RE#;FD6;<
M/">3=E<;][MVO+I\BNR^7CPE#MWT/:7;A&YNS7+]VX_I0Q+,+27N5V\[KE\K
MLQ^3AQRKPGLJ^$&*2!,AB.3-G6+O]1V;Y!M5UM]T:L;\Q^;>/UYK?3<O>WTD
MB^TGQZMZM7P&5ZFNZ.17RKF#83Y=&.G3CX>9*YSY<:_9XF4<+T@=F\7I\^UJ
M.2US\S*DNKA3CY4;7+G\-./.JX%'8?9/\(,U'99CL9RAJ;IT1(I=?Y!FLR4U
M2#TE=63:L5LT3U63^-_CFRIW_#IV?8*XGJ;[H8SB[T\'(2YJYCI5XUX^5*V_
M=P:X>_B,[T@=G<N,HX]O4L5RY.UE-N/"G#SH7ES^+XE+C[N!A'S%[!,S*UF]
MP'SJVS9:CEK:SRUAD@9-T^*=^Z:A!(D;^B*B-^XU:JJG5[4,F[=]6<93C:W9
MI73#QN8DZT_XF\^/[O\ ,S$6Z?1+*-N5[9.L]5Q<K.;;I7Y;]A.GR?5_G1HN
MY^\9.<_&/9FZOS5Q]F=.MV73_<^5E;%D-9V.&NY$?8U[9L;):PN6:QCV.DCB
MF6Q721J31QO7M)1[3WOM;>^%]?VUF6\FW&G7%5C<MM^%RW)*</%)M=,J/I<E
MQ(=[T[>;Q[>:@M-W=@W<6[)OHFZ2M74N;M78-VY\*-I2ZHU2G&+X&/3U^H]8
MN53Q_B6SU^G\@7(O]Q=8;#9/9,UA]=PM5][,9[*8_#8FE%T]6YD\I;AHT*L?
M<J-]2Q:G8Q.JHG5QPY639P\6YEY,E''M0E.4GX1BG*3^9*I]>%B9&=E6L+%B
MYY5ZY&$(KG*4VHQ2^5M(WZ?_  ]W,KFIW>0O&2.5$5R)K.U.1%Z?%$<KVJY$
M7Z^B=?P$4'ZMMN>&D9M/VRT31CZ*=T>.MZ?7]JO%-WZO3S*[_G#\9?\ FOM/
M_P X/ZVVW?\ 9&;^ZVO]PN_J5[H_VW@?N5[_ '2B[]7EYF7_ )Q'&7_FOM7_
M ,X5_K;;=K7\49O[K:+OZEFY_P#;>!^Y7?\ =-9_GGX'Y[P1V#CS6-HY/U;D
M'-[_ (;.Y[Y+6\5EL8_ XK$W:&.HVKRY-SDG;FK<]ID/I_P%I2=W\)IF/M=W
M1Q>Z&)F9V%A7\3&Q;D(5N2C+KE-2DU'IY="46Z\^M4Y,P?W;[0Y?:/,PM/U#
M/Q\W*S+5RYTVH3CY<(2C&+EU<^MN25.70Z\T8 QPS6IX:U:&6Q8L2QP0001O
MEFGFF>D<4,,4:.?)+(]R-:UJ*KE7HAE.4HVX.<VE!*K;X))<VWX(Q';A.Y-0
M@FYR=$EQ;;Y)+Q;\#<-XL^R5Y5<_U*&T<D?)^.FA7VP3U[>]8VUD>0,C3F1K
MDLXWCBM9QUVDUK.O5N8N8B5>K7,9(QW<D>][^I'8VU9SP='ZM7U2-4U9DHV(
MM>$LAJ2?_%0NKFFT^!)G8'I;[@;OMPS];Z=%TB233OQ<LB2?C'&3C*/_ !T[
M+Y-)IU-LNO\ ZO#XI5\7!%MG,?D)FLTW_OF_KV4XWUC%R_88G\1B,EQWMUNO
M]M'+]J]+\%1/J55P1E^K+?,[SE@Z?I-O&\(W(Y%R2^6<;]I/^\1(C"]&_;^W
MCJ.H:EK%W*\96Y8UJ+^2$L>\U_?LXPY4_5T>,KF/N3<)^0N]X#*QPN?0Q_*>
M"U_;L?<L-8O96N9G4JFDV<;#-)TZSLHVW1I_W)ZG<Z)ZM]9A>C'<FDXMVPW\
M4L:<[4DO:H77>4FO8YQK]TCIM=]&FASLREM?6,NS?2^&.5;MWHM^QSM*PXI_
M=*W.GW+([7EEX=<Z^&6_,T/FO6HJ"Y.*Q;U/;L)8DRFE[KC:LC(;%[6LTZO5
MDE?4DE8EBI9AK7ZOJ1K- QLL3GRPV-W VSW#TMZIMV\Y=#2NVIKIO69/BE<A
M5\Z/IE%RA*CZ9-II0]W]VWW5VVU=:3N:PH.:;M7H/JLWHIT<K<Z*M*KJA)1N
M1JNJ*4HMXH/4]LN39X@M'K\/VRI>B1=^K@X:>QY!>0VQ-67Y;%<.8;"RHVN]
MT'KY_=<=>KK);1R1P2I'K<O9&K565.YR*GIKUB7ZM\B,-JZ3B.G7/4)S7'C2
M%F47P\5]\57X</:3$]'.-*6Z]7S%7HAIT(/APK.]&2X^#^]NB\>+\"7T0,-@
MP
M  /B>2>.]0Y;T+;.--]Q$&=T_=<)=P&>QD_P]:E=C5GK5YD19*F0I3(R>K8C
MZ2UK,;)8U:]C53M=$UK4MNZOCZYI%QVM2Q;L;EN2\)1?)KQC)5C*+X2BW%II
MM'1;GVUHV\=O9FU]PV8Y&BYUB5F[!^,9+G%\XSBZ3A-?%"<8SBU**9!)\O?&
M';_$CG#:.(MI=+?HU'-S&E[.L'H5]NTK(RS?<N<AC17,BL_Q,E:Y"BN2"]7F
MC1SFM:]VV;MQOS3>XNU<?<>!2%V7P7[5:NS?BEUVW[5Q4H/[:$HMI-M+\_O>
M;M5K/9S?N7LW5JW+$'YF-?I19&+-ORKJ7A+@X7(IOHNPG%-I*3QB/=F*P
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M7=VKU;(YSU3[36HUBNCYWMO]67I^-]S;NR_OG!?[PR/L.W2SDW?;*"^PI/\
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M+)M\3>AV%VG^1?:'0M#G'HROJ,;]U-4:O93>1<C+WPE=\OY()+@D95&.C+P
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M.UH^MZW)?#>R<>Q%\/\ $PN7))/GQ\^#EX.D?829"'A-$
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M=_W%]DREL:--+NS]M]_F0A_NDF\Q >T               .I]]Q?_2#^=O\
M7)\GO\]N\$U]J?S7TW^ 8_X&!@G5_P"-LK^$7/U\C#8[\Z\   [%/]6K_P!&
M#JW\\O+O]]L>16[M_P \9_P>U^<S+FS?XEC^V3_/1OX,9'J@       1</UK
M#^AUXZ_UEX?\UO(!F3LM_'V5_ __ "D#Q.^?XNL_MW^]D00R21B\   W)?J_
M?^ET\2O\O/\ [LO,YX'N?_,;._XG_6+1Z':G\?X_ZO\ !S.RY(CF90 =27YI
M?TQ?++^LOSO_ )TMJ)O[?_B'!_@=G\'$P+J7\8W_ -NG^N9C0=N?&
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M=[<;!/2)_,G4_P"57^ LFHO^T,_I-T3^0E_K>0:)R61
M $@_V&>>+.*WOE7QRRUY?NG;,*SD[3Z\TG2*OLNNR4L+M%2FSZ7VL[@+M2P]
M/H2/#JJ=%5>L./5QM*&1I.G[UQX?OC'N_5;S2XNU<ZIVG+W6[D9Q7OO?8V._
MV?'<&[B;@U?MGF7/WGF6%G8T6^"OV7&U?C%?=7;,K<W^AQG\\GH@@;5@
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MV]+ L:/' =V?EJ>/=<E;ZGT*360DY*-%)I*KJZ'Y;O=^\KD_^IW$G_F?FO\
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M15%<$EC7?^D%-?>3\MT_^IO$'_F;F_\ "\/TO]MO\IJ=?V^W_F2Y>MCO(_\
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MJ-JGIPV^] [2Z<[D>G)SG<RY^_S94M/Y[$+3^?V&U4PF9T
M                                                  !&4]ZGP@9@
M,G_RON,\,V+#YVW4QG-N+Q\*,BQ^?MR,J87D)((F(QD&P3/92R;T[?[N6"94
M=)9GD2=7I?[J/,L?]V^NW:Y-J+E@SD^,K:59X]7XVU6=I?Y/KCP5N"-6/KE[
M#1T[*_[Y]K6$L+(G&&J6X*BA>DU&UF47!*\VK5]\/OOES:<KMR2CPDS#6T
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MG9;^/LK^!_\ E('B=\_Q=9_;O][(@ADDC%X  !N2_5^_]+IXE?Y>?_=EYG/
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M[^']([AS^9*/^7>W&P3TB?S)U/\ E5_@+)J+_M#/Z3=$_D)?ZWD&B<ED0
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M:&=_3)N">VN_6V,^#:5[4X8C\:K-C+#HUQ\;Z?N:4N%*J=::G#?X
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M)MLW+]MNVVV>UNV;6VMM6J6U25Z])+S<B[2DKMV2YM\HQ7PPC2$$DCGL\>9
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MNSN3E]U.<G*3^>3;-T&GX.+I>!8TS"CT8>/9A:MQ^YA;BH17S121]$?(?6
M
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MDOS2_IB^67]9?G?_ #I;43?V_P#Q#@_P.S^#B8%U+^,;_P"W3_7,QH.W/C
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M<QM"1TF<^TN[[L,C\E\^;E9FF[#;^C)*LK?'[623E%>$DTOI*G@-XZ+"5O\
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MA-5FW??;M6637],Q,SGKZUI[71-O9B['#(VC0C>V:U(U558X6331> [A=Q=
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MRX/ZGIL'9L-\GD7HM3:]OE6&U)<&G>@UXDPH@.;"@
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M8VY2?-RN8TK%R3?%RFZM\WL),-DCP    =?K^M$:4FN>X;I.T0QN^7Y!\9M
MS-B?[2-=EL'NW)6J6:Z(^U.JN@Q6%HO5S60QKZR(C7/1[W2>[.9'F[6N67SM
M9DU\SA;E^>W[>1BG>UOHU>,URG9B_G3DOSDB-\98/'@        '9#?JZ?\
MHIN#_P#RRYK_ ,[&V$3NZO\ /7)_:[7X*)F#:/\ $5K]-/\ 7LWBF.CTP
M           !U/ON+_Z0?SM_KD^3W^>W>":^U/YKZ;_ ,?\  P,$ZO\ QME?
MPBY^OD8;'?G7@  '8I_JU?\ HP=6_GEY=_OMCR*W=O\ GC/^#VOSF9<V;_$L
M?VR?YZ-_!C(]4       "+A^M8?T.O'7^LO#_FMY ,R=EOX^ROX'_P"4@>)W
MS_%UG]N_WLB"&22,7@  &Y+]7[_TNGB5_EY_]V7F<\#W/_F-G?\ $_ZQ:/0[
M4_C_ !_U?X.9V7)$<S* #J2_-+^F+Y9?UE^=_P#.EM1-_;_\0X/\#L_@XF!=
M2_C&_P#MT_US,:#MSXP  #L>/U=KQ[H<)^VMQWM\E&*#:_(;9]MYAV.RK%6T
M_'RY.33=*J+.]K9%HLU'5*MR*)/XN.:_,YOVI'N=%#NIJDM0W;=L)ULXL(VH
M_+3KF_EZI-5]D5[#+^T<18VC0N4^^7I.;^S1?F)/YV;TS'!Z<    'PO*''6
MK\O\:\@<4;O1;DM.Y+TO9]"VF@Y&_P!UZ_MN%NX'+PL5[7-9*^C>?V.Z=6NZ
M*GQ0^G#R[V!EVLW'=+]FY&<7[)1::_-1Q7[,,BS.Q=5;<XN+^1JC.HPY<XWS
MG#?*W)W$.SJQ=EXKY"W3C?85C8Z.-<YH^R9+6,LL<;U<]C/G\7)T15543Z2<
M>#EV\_"LYUG]AO6H7(_).*DOS&8#R+,L>_/'G].W-Q?RQ;3_ #CCT^HX@  #
MLV/8EY"L<C^U7XHY&]---D-9P&[<>VO7D?,Z&OH')FY:M@H8YGQ0H^%FL8VC
MV-:BMB:J1=SE8JK$+N1BK$WIFPC]&<H3_O[<)2_PF_EYF9]L77>T.PWSBI1_
MO9-+\Q(VYGACOR'#[UO].7/?S;\>?WOMFR[TN_T4V?X=D?KD:4/7/_3YD?R9
MA_K)&I0D00[   )6/L'_ -''F/\ GMD_D)J)K[]7?\]M,_DI?A[QMT_L\_Z,
MM;_EU_ZICF]@B:3_ #2Q[Z'(LVK^)NL:+3G6.?D_E7!4<C#U5$L:[J>-RNSV
MVKT7[2Q[%4Q3D1?A\%7Z40E!Z4-%CG]P[^K756&!I]R47[+EV4+2^S;=U$&_
M7WN6YI/9_$T"Q*ES5=7M0FO;9QX7+\OL7HX[(CIL6-.   !DEX@<'.\C_)3B
M'AR1EAV)VW;*J[3)5>^&>#3,'#/L&XRP66-=\M:_-K%VFP/7X)8<Q/I5$/$=
MR-UK9.Q]2W+%KZQCX[\JO%.]<:MV4UXKS9Q<E]RF9/[,;"?<[NAHVR9*7U/,
MS(^>XNC6-:3O9+4OM9>1;FH/[MQ)].,QN/PV-Q^'Q-*MC<5B:-3&XS'4X65Z
M=#'T8(ZM*E4@C1L<%:K6B:R-C41K6M1$^"&H6_?O95^>3D2E/(N3<I2DZN4I
M.LI-OBVVVV_%GZ'<7%QL'%MX6'"-K$LVXPA"*2C"$$HQC%+@HQBDDEP25"^.
M(YP     #67[L_CW3YT\/]YS%6A!/N?"T$_*VK75C_NJ/'8"L^3><8R9B+,M
M;(:>EF;T$ZLFMU*RN3JQKFYT].^\KNT^Y.)C7)M:9JC6)=CX.5Q_>)4Y5C>Z
M5U<U"<Z<VG%CUA=N+&_^R^?FV;<9:YH<7J%B5/B4+,:Y4$UQZ9XW7+IY2N6[
M556*:A5&T(T9@  'U&D;9E-"W34-YPCUCS6E[1@-LQ$C9'Q.CRFN96IF*#TE
MCZ21*RW38O<WXM^E/B?#JNG6-7TO)TG*5<7*L7+,US^&Y!PEP?/A)G:Z#K&7
MM[7,+7\!TSL'+LY%MU:I<LW(W(.JXKXHKBN*.Q-P>8I;%A,/L&-<Y^.SF+Q^
M8H/>C6O?2R=2&[5<]&.>U'.@G:JHCE3K]:FE_+QKN%E7<._PO6KDH2_31;B_
MS4?I3P,VQJ6#8U'%;>-D687(-\W&<5*/*O@UXLCG_K!W_-&_R]_\2Q-/T<?]
MH_\ J_\ ]M-:']HY_P!C?^MO_IA&Z)MFL8   Y7X*XFS7.O,7&W#^OO6#)\A
M;=A];;=2+UVXNE=LM7+9F6'N8LM?"8ED]N1J*BK'"J(>>W9N'%VGMK.W)F*M
MC#QIW>FM.J45\$$_!SGTP7ODCU^P-GYV_P#>NE[+TY].5J6;;L=5*^7&4OOE
MUKA56K:E<DJ\HL[ #CS0=7XLT74N.-)QL6(U/2=?QFM8''QHSK#CL55CJPOL
M2,9'\S>L^FLMB9R=\\[WR/57.55T^ZSJ^?K^K9.MZI-W-1RKTKMR3\93;;I[
M(KE&/*,4HK@D?HIVWM[2=I:!A[9T*TK.CX&-"Q:@J<(6XJ*;:2ZI2IU3D^,Y
MN4I5;;/LCK#NP  "QR>/KY;&Y#%6T<M3)T;>/LHQ6H]:]V"2M,C%<U[4<L<B
M].J*G7ZE.6Q>GCWX9%O]DMS4E\L75?FHX,K&MYF+<Q+U?)NVY0E3G22<7[?!
MG7"&[$_,F    #L0.&O\4'%7\VVC?R8Q9IDW-_.34/X=?_"S/TF;(_F7I'\E
MXOX"V<DG2'IR*=[^']([AS^9*/\ EWMQL$](G\R=3_E5_@+)J+_M#/Z3=$_D
M)?ZWD&B<ED0    ,J?"?@'_E->3O%'$-IDRZ]FL\N5W.6%[XG0Z5K-6?8-F8
MVS&CEJ6,CC,>^G7D^AMJS%^$\!W2WA^0NQ-0W';:^N6K/193XUOW6K=KAXJ,
MI*<E]S&1EOL7V[_[T^ZND;,NJ7XMOY'F9+553%L1=Z^NI?1<X0=N$O"Y.!/5
MQ^/HXFA2Q>,IUL?C<;4K8_'T*4,=:G1HTX65ZE.I7A:R*O6K5XVLC8U$:QK4
M1$Z(:C+UZ[D7IY%^4IWYR<I2DVW*4G5MM\6VW5M\6S]"6/CV,/'MXF+"-O%M
M0C"$(I1C&,4E&,8K@HQ2227!)41=G&<P  !C!YLX^OD_#KRGK64<L<?CYR_D
M&]BM1?F,3H6=RM15[FN3M2W29W?#JJ=>BHOQ3WG:V].QW*V_.W])ZSAQ^:>1
M;@_S),Q3WUQK>5V5W;:NUZ5MS49_/;Q+MR/^%%5]WL("IMZ/SQ   ')'#?\
MC?XJ_G(T;^4^+.DW-_-O4/X#?_!3/3[)_GGI'\IXOX>V=B":9#])@
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M:^&QR-D7.?VK%3TQL;V)VJOJ.7(9>A$K.J=/LN5W5?HZ=5,F6O3-W-N2:G'
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M?P0?/RX07@9=GA#(
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M%-P?_P"67-?^=C;")W=7^>N3^UVOP43,&T?XBM?II_KV;Q3'1Z8
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MK5N^$M5O1K^*]'R;\'[+ER5K$5/8W;R+OS)DP UNFY\      ZW8W;'YC
M  =B!PU_B@XJ_FVT;^3&+-,FYOYR:A_#K_X69^DS9'\R](_DO%_ 6SDDZ0].
M13O?P_I'<.?S)1_R[VXV">D3^9.I_P JO\!9-1?]H9_2;HG\A+_6\@T3DLB
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M6G='7=R0DIV,C4+D;4N=;%FEC'?[C;M^[V<#&]SCV_N7(QLD6[W?4G[J@O\
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MPN9#5)W>/.-B+I%T_99)IJ5IHEZ$#38(
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M5$7N:Y>US,M]F\OR=S7<9_1O8DJ?IHSA)?X/4>-WO9Z]*A=7.%Y?8:DOSZ$
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M^*OYR-&_E/BSI-S?S;U#^ W_ ,%,]/LG^>>D?RGB_A[9V()ID/TF
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M]H&F;7T3&V]HUORM,Q+2MVX^-%SE)_;3G)N<Y<Y3DY/BSDDZ@[D
M
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M?\4'D!_.1K/\F)"!/J__ )R:/_ ;OX5&V#^SN_F9N/\ E.Q^ 9O\(?FQ,
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MR<8QV7&'S-
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MD<KG*JJJDL+=N%J$;5I*-N*227!)+@DEX)+D8?E*4Y.4FW)NK;YMGYQ>4
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M?SD:-_*?%G2;F_FWJ'\!O_@IGI]D_P \](_E/%_#VSL033(?I,
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M6_;KCV9+CBVIKZ<EX7[D71KG:@^ETG.<8R"2+!+0
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M4*_5H\>7G=4LAM<)0N6:JL#<81J)K$;O]8._YHW^7O\ XEB;?HX_[1_]7_\
MMIK%_M'/^QO_ %M_],(W1-LUC   &_SV!?\ &_Y ?S;:S_*>0B!ZO_YMZ/\
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MHE;Z-=HK<G>G&U.]#JP]'Q+V7*OT>MQ5BRG[U<O*[&G&MJO)-$J URFY
MBL^ZGR6W??+/8,'5G2;&<7ZWKVB5E8_K ^^D$NS9R1K%Z=MBOE=BDIRJJ=56
MHB=5:C5-CGIQT!Z+VTL9=Q4R-1R+N0_:HU5JVOD<+2FOT_MJ:;O61NS\I>]6
M5I]F75B:/B6<.-.3G1W[SI[8W+\K4O?;]B1K>[D_"9Y(J49X[T*5*])X5X%$
M>BN JO ]5=^Q"M!Q9ZJY2M$N96AZJOX17V%:'HKOW2G%\RZAZJJJ5HBM$2@O
M:$XV34?&&WO%B!67^5-WS67BF<U&N?@=9<FJ8R'IT[E9'E<=D9&JOTI/\/A\
M5U[>IS7OQGW!CI$'6QIV);@U_P )=^_3?SPE:7ZDVY>B;:JT7M)/<%V-,G6-
M0NW4_;9L?O>VOD5R%Z2?Z(VJD<B8@ /DM^V_'<?:-N6^9AS6XK2]6S^U9%7/
M2-%IX#%6LI88CU^#72155:GT_%4.RT;3+^M:OBZ/B_Z1E9%NS'Q^*Y-07YK.
MFW'K6+MO;^=N'-:6'@XE[(GQI\-FW*Y+C[U&A!;S^<R.RYS,[%F+#K>7S^5R
M.:REIZJKK.1RMR:]>L.5RN<KIK,[G+U55ZK])M[PL.Q@8EK!QH].-9MQMP7L
MC"*C%?,DD?GUU'.RM6U"_JF=)SS,F].[<E]U.Y)SF_GDVS\95^M3ZN1\B7L*
M:NZ_04Y\R](W]>R1QI_%<V<Q68>O=)@^,\)8[/H]-K=IVF'U%^GKZN'=VI]'
M3JOU$,_5CKWQ:3M>V^2N95Q?+]YLNGS7S8SZ#]JTAKN]KT>;M8-IT]GW_(5?
MGQG3[/@;]"&IL2 !0M6JU*M8NW)XJM2I!-:M69WMB@KUJ\;I9YYI'JC(XHHF
M*YSE5$1$ZJ7V[<[MR-JTG*Y)I)+BVVZ))>+;Y''=NVK%J5^])0LPBY2DW1**
M56V_!)<6R"5SCR/8Y<YAY/Y.LN?UWK>=FV6O&]'(M7'9/+6K&*H-:]5>V+'8
MQT,#$<JN1D:(JJO55VZ[3T2&VMLZ?H%NG[TQ+5I^^4()3E\LI]4GX59H.WUN
M.YO#>FJ[INUKGY]^_%/[6$[DG;AQXTA#I@J\:)5.)GO_ "?V3T'+Y3RW,F;>
MW/Q'6X>\0.(<4E=L.7W+!1<G;'+V)'-8RN^Q0YJHEIB*O2QC-<DH45Z_'I43
MJB+U0U?=[=R7-S=RM2R'*N-BWGBVES2ACMP=/=*XKES]6;J_3?L^ULSL[H^)
MTJ.9FV%FWG2CE<RDKD>KWPLNU:_XM5XF;YB@SF          #05[\7+"8GC/
MACA>E91+.X;;E]_S<,:JDK,7IN-3#8B*S\41:N1R6U32,3X]9,?U^':G66_I
M/V_]8US4]S7(_!C8\,>#?+JO2ZYM>^,;23]USWD&?6[NCZMMW1]GV9??,O*N
M95Q+FH8\/+MI^Z<[TFO?:KX<8P[E_*OTDYN7$UQ)&]SVGO<@Q7$:4O&?GC.-
MH<<9').7C#?,G82.AH64REB2:YJ^QVIGI'4T[+Y"99JUMW:S&6Y9?77Y6;U*
M<4/4!V7O[AZM[[4M=>M0A^^;$5\5^,517;:7%WH173*'.[!1Z?OD:7)M^F#U
M XVU5#MWO:]T;?N7/WGDS=(XTYMN5FZWPC8G)]4)\K,Y2Z_O<^JU*.BECGCC
MFAD9-#,QDL4L3VR1RQR-1[)(WL56O8]JHJ*BJBHI!*491DXR34DZ-/FF;)XR
MC.*G!IP:JFN*:?)IGN4*@     %O<N5,?4M7[]JO1HT:\]R[=N3Q5JE.I6B=
M-9M6K,SF0UZ]>%CGO>]R-8U%551$+[=NY>N1M6HN5V3222;;;=$DEQ;;X)+B
MV67;MNQ;E>O2C"S"+E*4FDHI*K;;X))<6WP2(\/N'^\[@=5I9WASP^SE38=N
ME6;%['S=3;!>UO7(^U8[5;CF1_J5=CS;G=6?>JMDQ]=O5U;YB1S)H)==H_3C
MEYURUN+N%:E9T]4E;PG6-RY['D<G;AX^5PN2?"?0DXRA)WL]4V'I]N]M;MC>
MC?U)UA=SXTE:M+DUBOBKMSP\ZCMQYV^MM2A%JR>2R&6OWLKE;US)Y7*7+60R
M>2R%F:[D,A?NS/LW;UZY9?)8MW+=F5TDLLCG/D>Y7.5555)PV;-K'M1Q\>,8
M6(148QBDHQC%448I4222HDN"7!&OJ]>O9-Z>1D3E<R+DG*4I-RE*4G64I2=6
MY-MMMMMMU9,6]BGB%-"\-[/(MNLD>5YLY"V'8H;#FN9,_5]2D32,+5D8Y$7T
MX\SA\K8C7_9,MHJ=45#7AZH-P?C7N)'2+<JV--Q+=MKP\V[]^F_GA.U%^QP]
MIL\](NV?Q/VPEK=V-,G5<VY=3\?*L_>+:?R3A>DO:IUY4-TI' E. #B_F[DW
M'<+\.\I<MY9(7T.-M VS=9:\\GI,NOUS!W<I6QK7(K7+-D[59E>-K5[WR2M:
MW[2H=WMK1;VX]PX.@V*^;F95JRFN-/,FHN7R13<GX))M\#H=TZ[8VQMK/W%D
M4=G!P[M]ING5Y<)24?EDTHI<VVDN)UM6;S&2V#+Y7.YFW+D,OFLC>R^5OS]O
MK7<EDK,MR];F[&M9ZMFS,][NB(G5R]$-PF/CV<6Q#%QXJ&/:A&$8KDHQ222]
MR22-)61D7\S)N9F3)SR;LY3E)\Y2DW*3?O;;9^(]W[YS+C\A9[BU<OY$'O+U
MP1:O=]*_A^@JBY(MGK]7X/BH7M.0E0>SS[3"XK\SO+_R9P:+E'QT-HX0XLR4
M37-QD<T;+F%Y)W6K(BHN3?&]EC#8YZ?W+U9;G3U_2C@A+W][Y^?]8V%LZY]Y
M3E;S,F+^DUPGCV7]S6L;MQ?2XPC\/4Y3O]._8+ZO]6[A;UM??Z1NX6+)?1KQ
MAD7E]URE9MOZ/"Y+XNE1D^D,R;P
M                                              (87NY^,K?'[RIS
M.S8'',I<>\YLN<B:RRNQ&5:&Q23Q1\@X*-J(QD:UMAM)?9'&UL4%3*01-_@+
MTV<^G/?3WCV_M8.9-SUG27'&NUYRMI/ZO<?RVUY;;=93M3D^9H_]9/:Q=N>[
M=_5=/M*WMO7U+,L45(PO-I9EI>"Z;TO.44E&-N_;@OHLU9F?2)@
M    ,E?#?D).*O*OQ]WR2RM2C@^5]-9F;".<Q8M=R^8KX/9%ZM^*HN R5E%3
MZ'(O1?@IX?N7HWY0=O\ 6=(C'JNW=/O="]MR$'<M?\I&)E#LGN3\D>[FW-PR
MET6,?6,;S)>RS<N1M7_^1G/Y>1/T-0)^B,    $"G]:8X5_,SS,X>YKI5O0Q
MG-O"D6(OR^ET^<W+B?8+6+R]CUVM:R3LU':-?B[%[GL]+JJ]KV-;);LUJ'UC
M0+^GR=9X^15>Z%R*:_PHS9BW>^-Y>HV\E?1NVZ?/%T?YCB1BC,!XL
M$K_]5!VYM+R&\L-#61J/V3AG3-N;%T3N>W2=W?AG2([UFJC8EY 1%3TW=>]/
MM-Z='X3[UV.K2\+)^XR)Q_OX5_WA[K8ERF7?M?=6T_[V5/\ ?$XPCJ9,
M            ! V_6*_; R/!?+&3\XN'-??)PMS1L'K<PXW$T^L'&?,&9L(M
MC8;<5>)J5-6Y4ORK82P[N9#L#[$4CV?.T8G24[5;QAJ6$MNY\_\ WACQ^]-O
M]DM+[5>V5M<*>,*-?1DS%V[M$>+?>IXZ_>UQ_'3[6;\?DE^NK[41?3,1XH
M              $TO]6V]L#(ZO7@]PSF_7WT<IG,3?Q'C'K>7I^G<J:]F:DN
M/V+F26O8B]:M^<N,L2XS OZL=+C9KEKM?!:I3+'[NSO&%Y_DMITZPC)/(DGP
M<DZQM?J7\4_T2BN<9(R-L[1'!?C;)5)-4MI^Q\Y_.N$?=5\FF3 #!1D    Z
MDOS2_IB^67]9?G?_ #I;43?V_P#Q#@_P.S^#B8%U+^,;_P"W3_7,QH.W/C
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M%3DKF^Q_<\DV*SERBV'7N/8K-=TK9*/'N$D2M)TEFBDRT]^>)R13M:V(>_\
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M7V3L:K>U[ S\O5M1G9C&5A6>F%FRIOI;N78/JE.XW*BI2,>/@MBW_70<$?\
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MNX]NY=\A0MN]!VY3;A>E*L8RDXTB_B2\"/,Y_P#K$T>7+F:ZDJE!SNGQ7]Q
M7)4)*6M^]?X]:]KFOX"/B/E]L>$PF*Q$;86::Z)&8VC!2:D2R[5ZBQHV#[*N
M^TJ?3\2#&=Z6=YYN;>S):EIM;MV<^/GU^*3EQI:I7CX&S32_6SV\T_3<?3XZ
M1K'38L6[:HL:GP14>%;]:<.%>/M/V%]\GQ\3_>DYD_W/2?\ "H^1>E#>3_\
MB.F?9O\ ^:/O_KR=O?\ 9&L_8QO\^>B^^9X]I_O1\R_[GI'^%8_JH;R_VCIG
MV;_^:*_UX^WS_P#A&L_8QO\ /GHOOH>/2?[T?,O^YZ1_A65_JH;R_P!I:9_R
M_P#FBO\ 7C[??[(UG[&-_GST7WT_'E/]Z+F;_<](_P *Q_50WE_M+3/LW_\
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MQMV9+X/I7%UTC"3L0T)O
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M*<DN/M/P7-<URM<BM<U5:YKD5'-<B]%147XHJ*?6FFJKD? TTZ/F> 4
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MM1-_;_\ $.#_  .S^#B8%U+^,;_[=/\ 7,QH.W/C               )GOL
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M
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M[:KMQWDSUA6^C0-7_?\ C47PI7Y2\^VO!>7D*YTQ7T;4K7!)HUQ&:R,H
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M5Q7;4G&[%IIIM--<FFN*:\&BV48SBX32<&J-/BFO8T1/?<2_5F].WVYGN5O
M?.XOC78[+;.1R'CYN%JRG'V5NK_&R,X[VZ1UF]H\MES7=F-R#+>,6:5&QV,?
M78D:9LVKW=R,:,<+<T97K2X*_'Z:7Z./*?Z:-)4YJ3XGA-7V9;NMW]*:A/\
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M+IBU!;23"AG4
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MC;&%G2=;KLJ,W^CM_!)OY91;^<P=KF)]2U:_CI4@IMK]++XE]A.A@(>G.J
M    .1>']\L\6<M<7<G4U>VWQQR+I.^55C9'+(EG4-EQFP0+''*BQ2/27')T
M:[[*K\%^!\F?C+-P;V'+Z-VU.#_51<?[IRX]UV,B%]<X3C+[#3.W^J6ZU^K6
MO4IXK5.Y7AMU+,+TDAL5K$;9H)X9&]6OBEB>CFJGP5%(*RBXR<9*DDZ,D FF
MJKD7!0J                   #Y7==$TCDK6\CIO(NFZKOVH9B+T,OJNZZ]
MB-JUO*0]%3T<C@\[3OXR]%T5?LRQ.3XG-CY.1B75D8ER=J_'E*$G&2^1IIK[
M)QW+5J]!V[T8SMOFFDT_E3X&FKG?]7F]LCFV>[DL5Q7M/!6=OO?+/E>#=TNZ
MY425WQ;\KI^U5=TT#&0M^CTZ>)K,5/Q_%/?:;W2W?IR4)WH9-M>%Z"D_[Z/1
M-_/)GGLK:6BY+<HVY6I/Q@Z?F.L5\R-7/(/ZIKJEF>Q8XJ\T]APM5)7K4P_(
M/#&-V>=T+YH$CCL;)KG(.HQLEKP>JYSVXIR3/[6HV).KCV6+WMOI)9NGPE+Q
M<+KC_@RA+]=P]YTEW8=MNMC):7LE!/\ -4E^<8RYC]5&\GH&QK@/*'@;)O65
MZ2MS&"Y"P;60HG\7)&^EB-A625R_2Q48C?J<IV]OO5H[_9</)7R.#_/<3XI;
M%S5]"_:?RJ2_N,N,#^JB>2ECT_SG\I^#L1UNL9-]PZSONQ]F/7T?4M1_>%/5
MO5NM[I.D"]C'=K>LR=R]E+O>O2%^PX63+A]M*$>/LX.7#W_F"&Q<U_3OVEQ\
M%)_[G_AXF47'/ZIQQ_3FAGY;\R]QV.NYK5L8OCGB/"Z5-$[O9WQPY_9MTW]E
MAJL1W1[L;%\7)]G[*H[ILOO9E25,' MP?MN77/\ P8PA^N/NL[$M)UR,F37L
MC!+\UN7YQM<\?O8+]LG@">GE/T(6N:MDHO:^'8.?=BL\@,=VJUW;8TNO7P'&
M-K[;$=W28)TB+\$<B*J'BM4[F;OU-.'UA8]I_:V8]'^'\5S_  SO<3:NBXCZ
MO*\R:\;CZOS.$?\ !-P. U[ :IAL?KNK8/#ZUK^(KI4Q6"P&,I8?#8RJUSGM
MK8_%XZ"M2I5VN>JHR-C6HJK\#PMV[=OW'=O2E.[)U;DVV_E;XL]!"$+<5""4
M8+DDJ)?,?L'&7        ZDOS2_IB^67]9?G?_.EM1-_;_\ $.#_  .S^#B8
M%U+^,;_[=/\ 7,QH.W/C   .U/\ :L_T;OA!_5HXG_DICR%^\_YV:C_#+OZY
MF<=#_B?&_:8?G%?RT]LCPB\V&SW>?."M9S&Y20K%7Y-U=UK2.3*SFP^C6?/N
M&KS8W(9^&BQ?XFKEOO"BQ?CZ"E-$W?N+;U(Z9DSCC_Y.7QV_[V55&OBX]+]Y
M7/T73=2XY5J+N?=+X9?95*_(ZKW&A7E_]5!XFRUVU=X'\M-]T>FZ59:^ Y2X
M]P/)*HQ[U5:R;'K&=XSDKQ0M=]A[\?9>J-1KNJN5Z9+P>]>="*CJ6#:N2^ZM
MSE;_ ,&2N?KE_</+9&Q+$G7%R)Q7LE%2_-3C^<8;YC]5)\J8+#&X#R;\?LG4
M5BJ^;,8SD;!V&R=[D1K*U+7=AC>Q8T:JN69JHY53HJ)W+W]OO5HK7WW#RE+W
M.V_SY1_..NEL7.3^"]::]ZDO[C.0=-_5..5+=J#](/F3Q]K]+I7=973>)]CW
M"UW+#,ZU# W-[?HT2(V=L<<<KE^TQ[I%C16)&_Y<CO9A13^JX%V4OT=V,?DY
M1G_X<*^*Y;>Q+[?W[(@E[HM_GN)LNX#_ %8WP%XQLTLOR[G^7?(K+5W-=/B=
MEV.#0-"G?&J/BD9@./Z^*VQ'=_\ #9-L-B"1J(U8^G=W>1U/N_N;,3A@QL8D
M'XQCUS_OIUC]B"?O.ZQ=EZ59:ED.Y>E[&^F/V(T?^$;X^'^#.&O'[4JVB<'\
M6Z'Q/J%;L<F T+6,1K-&Q.QJM6]D6XNK7DRN3F5SG2VK+IK,SW.<][G.55QK
MGZEGZI?>3J-Z[?OO[:<G)_(JO@O<J)>!ZC'Q<?$M^5C0C;M^R*2_.YOWLY5/
MB.<      A;>\/MN.VGSPY-KXU[9H]1P6AZE:L1N[HY<C3U3'93(,;\$Z.I6
M<PZL]/JD@<;/O37IU_3^TF!.^J/)O9%Y+V1E=E"/]\H=2]TD:.?6GK.+JWJ"
MU6WBM2CAX^)CR:Y.<<>%R:_4RN.#_119J_,\$4@  "5[["5*>/QBY:R3D;\M
M;YXR5*%4<BO6?'\?:#/81S/I:U(\G%T7ZU5?P&O?U=78/?>G6%^R1TB,G\DL
MC(2_6LV]?V>MBY'M5K&4Z>5/<$XKVUAAXCE^9./YOL-YA%$GR       #&CF
MOPY\8_(?UYN7>&=,VG+6$:DFT149=?W)4CC2.)J[EK4^'V>2&%K4[8GVG1?!
M.K50]SM?N7OO9E([<U/*Q\>/*TY*Y9]K^\W5.U5^U03]YB[?793M7W)ZI[RT
M/!R\R7.^HNSD\%1?OFP[=]I>$7<<?<:Q.1/89\=L]+8L\;\J<H<>33JYS*69
MCP.^82HJN;VLJUGU=8S:PM8BITFR,SU547NZ)T7.^B^K?>F)%6];T_ S8K[:
M#N8\W\KK=A7]+;BO<14W+_9\]M=0E*[MC5]6TV<N4;BLY=J/NC%QL7:?IKTG
M[_ Q6SGL <CUY94UKR.TG+0(V98),YHF=UZ61[>OR[98:&=V=D+94Z=ZI(]6
M?4C_ *\@8GK!T2<4\[1,JW/A56[]NXO?1RMVJT\."K[C$F?_ &=>Y[<VM+W-
M@7K='1W<2[9;]E5"[?2KX\73P3/E*7L&<_R3HW(\V</5:W:Y5FI5MUR$Z/3^
M U*\^!QD:M<OTKZJ*GX%.PN^KS9ZA6QI>I2G[).Q%?95R7YQU%C^SQ[BRN4R
M==T6%JG.,<J;K\CM07^%\S.7M2_5_)?4BFWOR9C2)$9Z^-U+C)SI'N7M61(L
MWF=R:V-&]%:U5Q[N[JCE1.G:OG-1]84:..DZ$^KPE>ROL5A"SQ_=%[./,]GH
MW]G3+J4]P;I73PK#'P>/OI=N9/#Q2K9=>?#D9Q<5>R]X5\=RU;VR83=.7LG7
M<V9'\@;3)#B4G;\45N"TZKJU*Q63_P# W%ML7_9=QBG<'J=[H:U&5K!NXNFV
M)</WO:3G3]LO.[)/WPZ'[*&>MH^A[L;MJ<+^J6,[6<J+K7,OM6Z_M6-&Q%Q_
M0W/,7MJ;-])X_P!%XUP5?6./--U?1M=J(B5\)J6"QFOXN-4;V^I\EBJU6!TS
MD_A/5JO<OQ555>I@K5-8U;7,N6?K.3D9>;+G.]<E<F_U4VW3W<EX$J-"V[H&
MU]/CI6V\+$P-,ARM8]J%FVO?TVXQ5?:VJOQ9]>=:=R      8W>0?B+X\^5/
MYH_IYX^_/O\ ,3[_ /S4_P#&S>-7^ZOSH^Y?OW_^C=EUWY[Y[\W:?_?/K>EZ
M/\7V=[^[V^S>XV\^W_UG\D<SZI];\OS?O5B[U^5U^7^S6KG3T^9/Z-*UXUHJ
M8Q[C]F^V_=OZG_WA:;^,/Q?YWU?]\95CR_/\KS?]&OV>KJ\FW]/JZ>GX:5E7
M&[_JB_;S_P"CY_PK\W_^TH]O_6,[R_[9_P#5,'_HQC#^IMZ;O_MS_P"8:I_T
MT?\ 5%^WG_T?/^%?F_\ ]I0_K&=Y?]L_^J8/_1A_4V]-W_VY_P#,-4_Z:/\
MJB_;S_Z/G_"OS?\ ^TH?UC.\O^V?_5,'_HP_J;>F[_[<_P#F&J?]-.?^ ?"[
MQH\7<QL&>X*XV_,;+;3C:V(SMO\ /'?MF^>QU.TMVM7]#<-JV"M5].RO=WPL
MC>OT*Y4^!X_>'<_?._<:SA[LSOK>/CS<[:\G'M=,I+I;K9M6VZKA23:]QD7M
MWV.[6]I\W)U'8&E_4,S+M1MW9?6<N_UPC+JBJ9.1>C&DN-8I-\FZ&49X$RP
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M]D8KX81C!**R$/*'KP
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M(0HW5A_4-R9V(E2,,JY3]*Y-Q_P6C.ND7OK&EX][Q=F-?E22?YJ9F2= =B
M                                      #J2_-+^F+Y9?UE^=_\Z6U$
MW]O_ ,0X/\#L_@XF!=2_C&_^W3_7,QH.W/C   .U/]JS_1N^$']6CB?^2F/(
M7[S_ )V:C_#+OZYF<=#_ (GQOVF'YQGX>9.U             !@KYM^>7$_A
MMHN1M9;)XO9N6\CCW_F-Q74R$4F9R-VPR1E',;'7KR+:P&GUYFJ^:W,D:V&Q
MNBK>I-]E,L=K.TFX>YFK0MX]NY8V["?W_+<7T1BOI0MMJER\UP4%7IJI3Z8\
M7@'OMZ@]G]DM NW<R[9RMXW;;^JX$9IW9RDFH7+RB^JSC)\97)4ZU%PM=4^"
MA";EMVP[_MVS[UMN1ER^T[EL&8VC8LI,V-DF0S>=OV,GD[CHXFLAB^8N67N1
MC&M8Q%[6HB(B&U'3-.P]'TZQI.G05O QK,+5N"Y1A;BHQ57Q=(I*KXOF^)H>
MUO6=2W%K.7K^L77>U;-R;E^]<=$YW;LW.<J*B592;HDDN221\V?:=6   3)O
M9:TF?4_!K6LQ/ D"\B\@\@;M%]B..2:"#)5M%BGE1C&2.65FD_8=)U<Z+L5%
M[.PUG^I_5(:CW7OXT'7ZEAX]A\Z)N+OM+PX>?QIPK6O&INS]#>A7-'[!XN;<
MCTO4]1R\I<$FTIQQ4WPKQ^J\&ZMQHT^GI-L9'DF
M
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M!)+@DN"1<EA>
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M%D6;5S_!\M_9=M_.9>V??\[1(0\;<Y1_-ZOSI&^$QL>H
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M,U*WIN!9L.2Y3G""5RYR7[)<ZIO@N,N2.6SSI[$
M
M       'Q')''6H<M:-LW'.^8F'-ZIMN+FQ67H2_9<L4G:^&W4G1/4IY+'VH
MV6*MAG22O8C9(Q4<U%.VT+7-3VWJ^/KFCW79U+&N*<)+VKFI+E*,E6,XOA*+
M<7P9T.Z-LZ+O+;^7MC<-F.1H^9:=NY!^Q\5*+YQG"24[<U\4)QC*+32(=/EK
MXN[KXH\J7]&V-)LEK>0=9R6@;BVNZ*EM>N-F:V.7X)Z5;-XQ)60Y&JBJM>=4
M<U7PR0RR;/\ MMW"TKN-MV&KX-+>="D<BQ6LK-VG%>UVYT<K4_MH\'2<9QCI
M+[R=I-<[0;NN:!J:E=TNZY3P\FE(Y%BO!^R-VW51O6_M)T:K;E"<L7NY?Q&0
M3$W2CSW*.(Z1W?B'$ITCN_$.(Z1W#B5Z3QW+^(#I0[E HCQW?C_U!0K0]>Y/
MP@K1GCN0%>D]5>!1'JK_ ,?[/W"O$?(CT5XI[2O$]%?^/]G]D</ KTF;/MT\
M:?I3\P^&L5/!ZN,U?/2<B9=SF>I'%7T.M+L6.29GT/AM[#3I5G(OV?X_XHJ=
M47%'>_7WM_MCJF1!TOY%E8T/!MY#5N5'[5;E.7ZDSOZ:MJ_E7WHT3$N1KB8F
M0\RYPJDL2+O0JO9*]&U!^'Q<?83(S5^;KP  "-![VW)ZYOF7BWBFK81]/0-'
MN[/D(XW*B,SV^9)L+JUEJ+]N6KA-5IRQJY/L-N.[5^TXG=Z4]!^J;8U#<4XT
MNYF7&U%O_)X\:U7N=R[-/VN"KR1K"]<FZ/K^]=*VE:E6SIV!*_-+PNY<Z=,O
M:XVK%N2]BN.G-FDI7_N?V255$N?,@Z4E=^ <2Y1]I2<]$_&O[/R%2XI.?^%?
MA^ %4JE%SOW$'R%RB47/_<0K2G/F7?(45=^X@YE4OLE)S_P?E!=R^4H.=_KE
M>7/F74KS*+G_ .N.?,NI0H.=U^CZ 74KS*#G?D*_)S+TJ<R@YW7]H<OE*\RB
MYWY/[(][+TJ%NYW7Z?H_!^SZRI5%!SOP_N(.?!<B]*A;N=^7^P5]R+DJ_(4'
M._*"_D6[G?VQR*I5XE!SBOO?,Y.7RELYWUK^X@+DBW>_\O\ 8*^]\B[W+D4'
M.'/Y"]+Q9;.=U_:0J7(MWN_M(.?!<B]<"V<[\I7\XN2+=[OJ_*"XMW.^OZD'
MN.1(M7N_*I7W%R5?D+=[OJ_*"_E\I;.<5?L+DB@O<YR,:BN>Y4:UK457.55Z
M(C43XJJK] =$N/(O2ZG1&Y?PK]EKR#\D%Q&[\PQW^ N'[7HW(Y\_CGMY,VN@
MYS7M76M.NLB?A:5R!%]/(9;T6]KXYH*UR)Q';N-ZB]J;0\S3=ON.JZ_&J:A+
M][VI?\)=5>MI\[=JO)QE.W)$G>U_ICWAO3R]5W(IZ1MR5'6Y']\W8_\ !694
MZ(R7*Y=Z51J4(7(LEC^,_B+P%XCZ>W3^$=$Q^NI9AK,V':K;8\EN^X6*S$1M
MS:=HFB;?R*^JKY(ZS/1H57R/^7@A:Y6D%=Y;]W3OS4/QAN3*G>HWY=I?#9M)
M^%NVGTQX43DZSDDNN4FJFP;8_;O:/;O3?Q;M;$A9ZDO,NOXK]YKQNW6NJ7&K
M452W%M]$(IT,E3QQ[<
M                                                   CT>_KQ/\
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MPN?3PBI;M_E'V%N27QYVV-PQ?+C'#UBQTTKXPMY> N''IGE/BNM)X>&23"P
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M^S6?V#WVQ,E=.1B/G6,U^ME_O28J8',A
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M-D>M3U!W=:O:5I<\"]>5^Y"W;A@J<Y*,I<%&+<I-1571<DV?O_\ 6D>Z)_\
M:1_P!Y?_ .ECX_\ N#["_P#I7_S"'^Z=C_6Q]5__ *!_\IN?^*<J<$>^KROA
M=MQ^!\F>.-6S6IR6Z]#,;%HF-RNL[IKK>K8;>4M8+(Y3)X?8/EU;WOIQ,QDG
MQ<K9%Z-B7S^[?2=M[*TZ>7L7-R+6HJ+E"W?E"[8N>*BKD8QG;KR4V[JY57.1
MZWM_Z_=WX.L6]/[I:9B7]'<XPN7L2%RQDV?"4Y6ISN6[U.;MQ5A\Z2=% DR:
MOL^O[KK6 W'5,M4SNL;3AL;L.O9J@]9*65PN8IPW\;D*KU:URP6Z<['MZHCD
M1WQ1%ZH08S\#,TO.O:;J%N5G/Q[LK=R$N$H3@W&47[TTT;2])U73M=TO'UK2
M+T,C2LNQ"]9NP=8W+5R*G"<7[)1::KQX\41W/,7W?^<\#Y![5P5XLZGK5JKI
MNT6M!DS.0UK*;IMVX[MB,A)C,U6US$5+L-&+&19:&2E7B;5N6+:Q+.R5K961
MLF?VT]-^U,O9V/NS?^1?C<R<=9'1&[&Q9LV)QZH.Y-Q<G)P:G)N<(PKT.+<7
M)ZU^]?K/W]I_<;+V!VEP\6=G!RY8CNSL7,G(R<JW-PNQLVXR4%;5Q.U"*MW)
MW.GS%-*:C'9W[=?,_E%S1Q?NF5\K=!R?'V\X#>EPF%Q^8XZV#C6_DM<?K^'R
M462EPVP,AEM([(79XFSPQQPJD?;T5S7*N".]&V-A;8U[%Q^WV9;S-*O8G7.4
M,FWDQC<\R<7%3MU2^&,7TR;?&O)HE5Z:M[]V-\;3SLSN]IUW3M?Q]0\JU"YA
MWL*<[/DVYJ;M7DG+XY2BIQ2CPI2J;-?/MS>X)Y?>1GDMB^-.9JV&BTFUJ&V9
MB=U+CUVN3_>.)J02X]$R:KT:U9)%ZL_V9F/O5V=[;[*V-<US;$KKU6.39@NK
M(\Q=,VU+X?[O@1R],_J,[S]R^Z-K:^]XV%H,\+(N/IP_)?7;BG#X_E?+Q)!A
M#DV-@              $2#<_=_\ .BGR?N.D:I<TG)?=N[;-KV"QE/C6OE,I
M9KXO-7Z5.".&O/)9N64K5DZ]K5<Y45>AL6TSTW=I[N@XVJZA'*AUXMJY<D\E
MP@G.$92;;2455^TTY:YZS^_UC=>;H6D3P+OE9]^S:A'"C<N2C;NSC%))N4I=
M,?!5?,\7?=6]S;&U9;V1U2K0I5T:Z>Y=X+R-6K"U[VQM66Q/#'%&CI'HU.JI
MU543Z5%KT_=BK]Q6K.1*=U\E'/BV_D2=64O^KGU48MIW\G$A;L1YREI4XQ7&
MG%M)+CPX^)S'P+[\?(E'/4,9Y'<9ZML&J6)XH+>T\8U\A@=HQ$+W(DF0FP&9
MS.6PVQ^E_P#@(9<6O;\4<YR=KO-;N]).BW<2=_9.=D6=0BFU:RG&Y:F_"*N0
MA"=NOW35WCX)<5[;M[_:"[EQ]0MXO<W2L3)TB4DI7\%3M7[:?.;M7;ERU>I]
MS&5CAQJVJ.29Q]R!IW*FEZWR)Q]GZ&T:9MN,AR^ SN->Y]6]2F5S%ZLD;'/6
MM5IXWPV()6,GK6(WQ2L9(QS4A!K&CZGM_5+^BZQ9GCZGC7'"Y;ESC)?)P::I
M*,DW&46I1;BTS9]MS<6B;MT/%W)MS(MY>B9EI7+-V#^&<7P\:.,HM.,X22E"
M:E":4HM+1Y[EGGQY:^-7D32X[X2KX>739^.-9V.5U[0';--]]9/*;'5O(F11
M>C6)!C8>D?\ L5ZK]9*OL=VA[=;XV7+6MTRN+4UFW;:Z<CRET1A;<?A^64N/
MC\Q OU1>H;O%VO[E6]M;$C9>B2TRQ>?7B>>_-G<O1E\?LI"/P^'SF\3CW,9'
M8=!T?/YA&IE\YI^LYC*(R'Y=B9')X6E=O(RO_P!P:EF=W1G^Q3X?414UG&L8
M>L9>'C?Z-:R;L(<:_#&<HQX^/!+CXD]-MYN3J6W<#4<VGUS(PK%RY1=*ZYVH
MREP\/B;X>'(^P.M.Z   (^>C^X)Y?9SW$[OCOE*V&3AN'R/Y"XXBE9QZZ"[^
M9>O;3LN+P[EV/KT=.M#&0=UG_NB]7?[(F-JO9WMOB]EX[SQY7?RF>B8^2U]8
MK'S[EJU.?WOV=4I?#X<O UR:#ZC.\^?ZE+G;7+C8_(F.Y\S"3^ITE]6LW[]N
MW]^]O1"-9^//Q)!A#DV-@  ''',>QYK3N(N5-NUM&.V+5>.-XV/ I+6^<C7-
M8/6,ID\6DE/_ .BV+>JQ]8_^Z)]GZSN]M86+J>X]/T[.K]2R,VQ;N4?2^BY=
MC&?'P^%OCX<SS.]=3SM%V;J^LZ93\98FF95ZU6/4O-M6+D[=8_;+KBOA\>1J
M"]KKSA\I/*+EWD'4>=H,5%KNO\</V/#K0T9VK2+FDV? XQ$?<5?[H9\C?E_B
M_P /VOJ)(=^^U6P=A;<P]1VD[CS;V;Y<^J_YJZ/*N2Y>'Q17'YB&/I/[\]V>
MZ^\M2T;N!&RM-QM,\ZWT8OD/S?/M0XR\5T3E\/S^!O$(J$]
M                <!^2'CIQ]Y.<9Y;CC?J3$29DMO6MD@KQRYG3MB;"]E+/
M8B1SHW=\+G=L\"O;';KJZ*3[+NJ>RV+OC6M@:_;UW1IO@TKMIMJ%ZU7XK<UQ
MY\XRHW"5)+BC'G<[MIMSNKM6]MC<-M?$G*Q?23N8UZC4;MM\.*Y3A51N0K"7
M!U40+R-\;^3O%_D"UH7).*6'U%L6=9V6DV237MPPL4ZQ1Y?!W%;T<G16^O6D
M[;-1[T;*QJJU7;,MC;ZT'N!HL=8T*Y6E%=M2IYEF;5>BY'[/3)5C-*L6Z.FE
M_N9VPW5VIW'/;VY[-*UE8OQXV<FTG17+4OL=4'2=MM*<555X!]3\:_OGLZ,Q
MW\QY[_Q_OE.)3A[!W_C_ 'QQ*\/8>/4_&O[Y6C*?,/4_&O[XHROS'CO%&.)X
M[Q1#B>.]2G 49ZJ_\97YBO2>JO\ VU'$KTGJK_VD!6B*:R)^%5_:' J>BO7Z
MD -\_L?\:):V+FWF*W"O_@K$8'CC!6%:CF229NV[9=F8U53[$M6/"8KXI\5;
M85/@GTP_]6.O.&#I6V+;_9+MS)N+W6X^5:^9NY=^>)L#]"6UE<U+7=Z7H_L-
MFUA6G[7=EYU_Y'%6K'S39(@(4&R    A%^;7)[N7O*SG+=F6?FJ$^]Y3 8.=
M'(L4FO:;Z6H8&:!K?LLCM8K!Q3=$^ETBJO5RJJ[6.U6@_DUV\TG26NF\L.%R
MXO%7+U;UQ/WJ=QQ^1)+@:..^&YWO'NSKVNJ77CRSYVK3\'9QJ8]IKV*5NU&7
MRMM\6S%5ST3Z^J_@_9]!D$Q64G/7\/1/P?L^D I*[\'P!<HE)7_@_**>++N!
M15_[O]@K\A6C?,I.=^'X@O2^P47/_"5*_(4G._UA\A<HE!SQ2GREWR%%SOP_
MD*E4OLE!S_\ 6'/D7\OE*+G?A_(.7!<RJ10<_P##^0?GEZ5"@YWUK^XA4JE4
MH.=^7\ Y_(<B5"@YWY2OR<BJ52@YW3Z/I!?R+=SBO+Y2Y+Q90<X>]\R_E\I;
MN<"J1;O<5Y_(7^Y%NYWY1S^0N2^P6[G=?@GT%2[F6[G?D'N1R)4^4MG._*/<
MBJ52@]W3X)]/[/WRI>6SG?D'YY>D6SW?VBO+Y2[F6[G=/VP<B7CX%LYQ7E\I
M5+Q\385XC>V'Y3^8#L?GM5U1-#XLM31^MRMR"RUAM=LU.K'2S:KCO1=F]TD6
M)7)&^C ZAZS?3FM0+U5,2;][T[([?J>+G7_K6N17#&L4G<3\%=E7HL\>:G+K
MHZQA(S5VY[$;^[C]&5I^/]4T"3XY>16%MKQ=J-.N]PK1PCY?4NF5R!*H\./:
MB\8/$3[KV>+"IRWS!12.9>4=]Q]2>7%7V.5WS.CZLK[N'TQ6+_M<['6LFQJN
M:MQS'*T@[W"[Y[UW]UX4KGU#;\N'U:Q)I2C[+UWA.][XOIMO@_+3538!VU]/
MNQ.W*MYT;7XQW'"C^M9$4W"7ML6OBA9]TDY75Q7FM.ALX,,&=
M
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M5NXTX7E^I?3+[$)R?S';;3ROJVM6XOA&[&4'\ZJO\)([),B:9B
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MIF],:SYKM*YYEG(M)J,IV)-1FI0<H]=F2;49*49W$I]&T<P(2P
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M2&6_/41OC>'7AZ;/\5:+*J\NQ)^;*/LN9%(S?#@U;5J+7"49<R=7;OTR]O\
M9/EYVJP_'&NQH_,R(KR82]MK&K*"XT:=UW9IJL91Y&W1C&1,9'&QL<<;6LCC
M8U&,8QB(UC&,:B-:UK4Z(B?!$,"-N3ZI<6R1B2BE&*I%'L4*@
M
M                          ]7L9(Q\<C&R1R-<R2-[4>Q['HK7,>UR*US
M7-7HJ+\%0JFXM2BZ21248RBXR2<6J-/DT0A\-7=X0>Y?1I/>N/P7$OD2S'^L
MYSXG?HNV++K3;8>LBJL;[O&>QH]R*YS4614[G-^TNT_*FNZG8V=U+KR]1T7J
MIS_?5N'53]3E6Z>#X<D^!H?P;;[#>J2W8D_*T_1]R]%>*_>%ZYTU=>3E@WJO
MBUQI5KB\K.7-,9H?@SYV\$MJHE;@'SXQV<P4+G.KKC]2VYM;6-7L00?-?:JW
M<;4[XXO2[6_,O>CGJG6/'VW-3>K]U]I;L<OCUC:$H7'SZKUFMVZFZ<XR=&ZU
M^%*B\<N[QT1;?[!]P.WZA]ZV[W#A=M+ET8^1TV+#2ZOHRA&JCTT76Y)RI6.M
M_P +]VBX\\L?'K:K/8N-J\KZ?B\VDK&R1NUS9LK!K&R-DB>BLG8[ YFRBQN^
MS(B]J_!5,V]S]+EK/;S6=/MU\^6GWIPIP?F6H.[:X^'WR$>/-<R,G8_78;;[
MO[;U>[3ZK#6,:W=KQ7DW[BL7ZI\&O*N3JGP?)\&<1<K:<_COE'DGC^1KV2:+
MOVXZ=(R5LK)6/UC8LCA'MD;/_'->UU'HJ/\ M(OT_$]'M[4UK6@8.L1HXY>'
M9O<*4^^VXSX4X?;>' \;N_1);:W9JFW))J6GZCDXS3K5.Q>G:XUXU^'QX^T^
M!.W/.@     &X_V-OZ:.4_F2WG^_^DD:?5;_ $86_P"5;'X.^37]!'].-W^0
MLK\-BDOHUOFYP      UU>ZYXG_\LSP.YZX<QN.^\=ZKZR[D+BMD:?W7^DKC
MU7;)KN/I.5?3CFVJ.I8PCW/16M@RDB_!R(YOJME:W^(-RXV?-TQG/HN>SRY_
M#)O]+53^6*.HUW _&.EW<>*K=Z>J/Z:/%+Y_H_.=64YKF.<Q[7,>QRM<UR*U
MS7-7HYKFKT5'(J=%129?,P@>"H   -X/+,>O<O\ L)>*NZTXJ3MO\2/-/EK@
MK,.].&+)+@.;<!DN7Y;\TCGML6X9):V#I1N[7]T=-(VJC:JM;CK!=W![EYN/
M*OD9VGVKR]G59DK5/=]N_GK]L>EO]&1M:Q<7[)CY,X/Y)KK_ /%7S>XT]\5<
MB9[B#E#C?EG57MCV?B_?=/Y$UR1SWQMCSVD[#CMEP[W/C_C&-9D,9&JJWXI]
M7Q/=YN+:S\.]@WOV&]:E"7Z6<7%_F,\_8O3Q[\+]OZ<)J2^5.J_..W<XYWO7
M^4N/=$Y-U*S\YJO(NFZOO>LW.L;OF]?V["4=@PUGNB?)$OKX[(1NZM<YOQ^"
MJGQ(-Y>-=P\J[AWU2]:N2A)>R46XO\U&?;-V%^U&];XVYQ4E\C54?9'SG(
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M&&3.@
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M3G%_8=/U)OQ,9GJ@
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MD5J*K6)+KE+#.3X(Y?K^':3_ /2UH/XOV/DZY-4O:AF.C]MK'7EQ^Q=E>_\
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MOS<KLUXTE-I/DD9"GDCV@
M
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M-A]-/M>F[7XDO"496J3]T[7B=KL>]&$KMCA6XJU\:P\'[FIUC\DR9Z8!,B@
M
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MU+D2:VEZ+]2O.%_>VK6K%OF[.'%W)M>QWKJA"$EXTLW57DVN)N1X+]L?PKX
M6E=U;A?!;5LU/T7MW'D__P#Z#L'S5?HL5^I%GF3:_@KS7)U]3&4*/Q^/0CKN
MCO5W(W9U6\[4KMC"E7[SC?>+='SB^BER<?=<G,E#M'L'VJV9T7=.TJSD9\:?
M?\K]\W*KE)*Y6W;E[[5NV9\-:UK4:U$:UJ(UK6HB-:U$Z(B(GP1$0Q4VVZOF
M9C225%R/(
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MD_EVG";S%=M/Z-R/4O=)-*5/=\4'['<B_ [#$BV9:
M
M
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M<NKYII&4YX8R(
M
M        #A?R1PC-E\=^>]<>V)[,_P +\I81[9I)H87,RNCYVBYLLM=%L11*
MD_1SF?;:GQ;\>AZ?9&4\'>>D9JK6SJF+/@DW\%^W+@GP;X<GP]IX?N=@K5.V
MNX=,DDXY&AY]IU;2^^8MV'%KBEQXM<5X<2.?[!&=?7YNYWUE'=(\OQ7ALZ]G
M?&G<_7-MIX^-WIJU97=C=I<G<CD:WNZ*BJK>DU/5]B*>UM)SOMK>H3M_NEER
MY\O\4O[G)FM#^SOU"5O?>X-*K\-[2+=VE5SLY$8+ASX>>^*=%7C6JIKPR5"+
M7Z'N%Z.[Y5L>"SF(M5H(+%A49:U3R1PFJ1RU6R21NLTH:6T3L5TL:N19(UZM
M5>CLS6+TLR]LW55U5O6IIMI<KNFSNM.E:2<K47P=.#Y^$;<G'AIV/W(T%]"C
MCY%N44F_I8^M6L=.-6NJ*C?FJRBW\47P?/<U[-/'6@\Z>$?.G#O*FKXS;]&R
M?.61M7\1D%G;(LM[0^/?0M5;5:>&YB[F/LX5DU6S6?%/%-W.:_J1D]3.M:OM
M/NGI.Y=OY%S&U6WI,5&<:<HY&15---2C)3<9QDG%JB:)N^B3;6WM_P#8C7]E
M;MQ+6;H%W7YRG;G6M98F'2491:E;E"5I2MS@XSC*K4C19YM<"8GQC\HN6>%-
M?OW\GKFI9;#V=<NY-S9<@_ ;3K&$V_$U;MB.O4BN7,73SS:DTS(F,EF@<Y&I
MUZ)+'M;N_(WWL+3MT9D(6\W)MS5R,>$?,M79V9N*JVHRE;<XQ;;49)5(!]]N
MWF'VK[KZQL73KER[IF'>MRLRGQGY5^Q:R;<9248J4K<;JMRDHI2E!M)<C%8]
M^8D    !)-_5^,"C:OE)M$D:*LUCB+ TY>LZ+&E>/D3(9.-4^%9Z2K:J*B_:
M>SL_V*.^U"'UB9=;F@8$7RCF7)+AXO&C'W\*3]SKXTX;/O[.?3TK.[-5DN+E
MIUJ+X\*+,G-?<NO5;]K5/!/C(\(3FS4         ZS[WYO'QOC[[FO/4-"@V
MAK?,LN&Y^UI&QI$VRWDJ">;<K;6M56]LG*&+SS45.G7L^A%^!+KMKJGXTVAC
M.3K>QZV9?\7]!?N;@8:W3B?5-:NT5(7*7%^JY_X2D:=3WAYX   EH?J]&$UC
MR!\>O,WPHW>>%NE>1''6TT5@2*.>77MKUBK0Q-_<6(Z5K?OS-8KE?"S8N%R,
M?W:-/-$Z1(YO0PCW1N7M+U33]PXZ?UC%NQ?Z:,JM0^1.W-2?_#).E57WFTHP
MR\3)TV[^QWH/YFN%?E:DJ?I&_;36S[8_*W(WM9>Z%J.#YRH2Z)A[FR6?'7GN
MO?F[\=B]<WNQC%HYNU<KO=%'1UO9ZF)S4CW,65*E*>)8V2I(UGK=X86)O/9T
M[FG/S;B@K]FG-RA6JI[91<H?*TZTI7IM%OWM#UN,<I=,:^7/W*5./S.C^1,[
M*$B49C
M
M
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M=S_",FFM:UJ-:B-:U$:UK41&M:B=$1$3X(B(>);;=7S,@I)*BY'D
M
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M,E**]R1ZK;NH?C'2K=V3K>A\$OECX_.J/YS:H>+.\
M
M
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M1.4[KYN3<F_G=6>SL8^/BVU9QH0MV5RC&*BE\B22+XXCF
M
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M\4%<@O\ )R<N!YK:.0\?4[N%;3>+>AYD?&B7%5^:73)_=)(FJD?3(X
M
M
M
M
M
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M
M
M
M
M
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MA<BW]+JEXQ:7%HOF8UJ6F7GU.S^QR^[M2^@U^E^BTN5%[4;3#QAW@
M
M
M
M
M
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M?7QJ;5/0[H/XG[!8>:X],M3U#,RGPHW2XL1/V\8XJHWS5&N%#01[P.59DO<
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MJ+W+V?F+[!^B6%0
M
M
M
M
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MD?%)\)*O'I:9D"=6?4
M
M
M
M
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MG0_4.EV*Y*/G29DVZ_JV;&]_B+U(2]TU]!_JE6#]K\M&8QT)V
M
M
M
M
M
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M"OSO6G"]_I-N71/],OME[IIJ:]TDC)$ZD^P
M
M
M
M
M
M         'R6_P"ZX3C?1=RY"V6?Y;7M&U;/[=G)^J=T>*UW%VLO?<Q%_A2_
M+5'(UOTN=T1/BIV.CZ7E:WJV-HV"NK-R\BW9@O;.Y-0C\U6J^XZ?<6N8&V-
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M*$5<7L=II*LW7WUZ/U?+AEQ_8YTMW/L_>Y?-)N/R3J^$3,,Z$[
M
M
M
M
M
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M]
M
M
M
M
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M::;!=5V\Z1O2E2Y"GT;B7Q.+Y],UTS2]_5SDS/\ /,':@
M
M
M
M
M
M                    &B?/44\R_=[Q>-1C<CQ1X.ZS4O921J-L8R[R/6M-
MR<$#7N;/'#EH-[RE:&6-S6]\6KSHG1R=ZRRQ+O\ W9>G"Y?KT;AW7?<8+E*.
M,UTM^#<'8C)IKD\J-:K@0 U"Q_WV^LVUBT5W:&PL6,[CYPEFQEYB5>*5Q9=R
M$91:58X$TJ/B;V")I/\ (Z'OR^0J5,3Q9XR8.\J3Y:9>5M_B@E5JMQM)][!:
M-B['I]6S0WLA]Y7)87JBL?2JR=J]S52:?I(V;YF1J&^\N'P6U]4QVU]M+IN7
MY+V.,?*@FN:G<C7@T]:/]H-W(\G#TGM7@7/OEZ7XPRTG]I%RM8MMTYJ4_/N2
MB^3MVI4=4U&OHT;F3NT\;CZTUR_D+5>C1J5V+)/:N6YF05JT$;>KI)IYI&M:
MU/BKE1"<%V[;L6I7[TE&S"+E)O@DDJMOW)<6:P,>Q>RK\,7&C*>1<FHQBE5R
ME)I1BEXMMI)>TDG>YOE:'B5[?/CQX88"U7BSVVTL%4VYE*9CF7,5HB4=IW?)
M/C;_ !T,>R\I92K9A<O:R5K)VIW=KND(.Q6/>[B=X]:[G9D6\3&E<=GJ7*=_
MJM6(^Q^5BPG%^*;@^%4;/O51EX_9WTY;:['Z=.*U#,A:CD=+X2MXG3?RITYI
M7\^Y;G%OA)*XE6CIHL\ANW6\OI/#T'1K>%]'QVJ9]K6LC<_D?-V[N[<G-N-C
MEE9+?U_;MDGP'K=4=)4PE?JC>U&I+#9E<W&RMRSYZIERNV_X-!1L8M*I4C<L
MVXY%/"=^?.M2 ?<BFF9F!LNWRT/ ACWO"N;=E+*SNJC:<[.1>EB=7.5O%MU2
MI1;??8C\=7[#R'R#Y,9RDJXKCZA)Q[HLTK&K'/N&S4V6-IR%5_\ MC+& U.6
M*J[KT:]F;7IU5B](W^K3>BP]&P]C8DOWQF361?2YJS:E2U%^ZY=3DO%.Q[^,
MS?[/[MJ]2W)J7=+/M_O33K;P\1M<'DWXIWYQ?-.SCN-M^#64^;3I*'(%FUX
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M:TM7??TOX9/QB^I\$B3X8>/:@
M
M
M
M
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M7C8ZEDSCQ5S*NOS,B:?-Q\R3C;KRMQA'DC)D\*93
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MHRK7JASBW[^FB;\6F_$Y\.L/J
M
M
M
M
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MY+;M.LL>3\8<W"OMCQ^:O)=)OC,:GJ
M
M
M
M
M
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M21VND:C^,<:MQ=&9;?1=AXQFN?#V/FOL5JF9]'F3M0
M
M
M
M
M
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M&(I+X;N<XI]:3YK%MR4T_"]<M2BZVY)2M#7T;=@
M       :5?<+T[=_#CF?7?=:X"UK([)7U3"8WCKSQXHP#8UM<M^.,4\,.-Y+
MQE%?3BL<C\'SJRQ%9<YCY<1&V.>>&A4L,ER#M;(Q]>T^>RM3FH.<G/#N2Y6K
M_C;;_P G>Y->$N*3E)4\WJUN[IV2M=Q8MJ*Z;\5]O;^Z_30]OLYM),^/\E<3
M?XXW;0O>>\"HXN6].VCCO")Y<\7:;,C8?(OQMBHQVZ7)NN4)FP.;S'PSCHO6
M9%,R&])5INI2HQ8;-6USZ1..7CW=@;E^\7X77]6N3_Q%^M';D_\ )77PJJJK
MZES4H\>;%V;L-QZ5]\MR@O-BO\9;^Z7Z.'V:*G@T]R7#_+O'?/?&&D<R<3;/
MC]QXZY$P%/9-4V+&O5T%['7$<UT4\+T;/0R>.MQR5;M29K+-.Y#+!,QDL;V)
MX+/P<K3,RY@9T';R[4G&47X-?GIKBFN#337!GHL?(LY5B.18DI69JJ:_\.?@
MUS3X,Y(/D.8
M
M
M
M
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MEI.$OI<9J3E6/3Z#'PH8EYO%I'&G5RAX*;=>J/LK5J2Y<(TI1URM.E/N
M
M
M
M
M
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MKZ9>YHV:GD#N@
M
M
M
M
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M&J\&T^3]JXI.M&UQ?UVY3E;4KD>F;7%5K1_*N:]C_,7(^F.$O
M
M
M
M
M
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M?[:;0PMF;9M^7I6':Z4W3KNS?Q7+UUI+JN79MSFZ))OIBHP48KEX\V>S
M
M
M
M
M
M
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M&HJ4(0SC,4F>@
M
M
M
M
M
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MQMVZAB?5H8.']3T7!FOXLP'QG<G%K^,]0E6]GW:>9'J6,Y2Z+D[F>1B0D$
M
M
M
M
M
M
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MBVMNPA9RM=ORMW\[)<4_.R8-3AT=2JK6-))8ZHG%Q\ZBNSFWFR8M,Z@
M
M
M
M
M
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M5N,I)7+M_8F87)*@
M
M
M
M
M
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MLQ5Z,6P_I0QNJ+^LY$4Z0C<C:K*,Y6Y GAYXP_HGJY7SA\MJF,FYLVG#X?\
M,C2<-K]E^-X)TS(5JV$TOBOC?3JC+$L>W6J5RIAJ6/IP26X%>S'P.EGGM268
M>=RM^?E#<M]JNW4KBVMCW)^??G<75GWHMSOY>3>=%Y*E&=Z=R<E"5'>FHPC;
MC#8MV6[4_DA:O=^N\4+4M]Y=FW]5Q;=F71I6-.,;6-@86-%-K(E&5O&MV;<'
M<A58]MSN7+LKN4O&O .U\B\Q4/*CR0@8S<<#4OT.".&66V9#7N!M<RR+';RN
M5FKV+&-V#F+9*+8_O:] KJ=%R)6JOG9!!8;X'7-X:?HNVI]O]DMO3+THRS\V
MG3<S[D.4()I2MX=J5?*A*DY_3N*#G.#RSM?MWJ^Y=ZV^[?<Z*6MX\)PTG35)
M3LZ39N<)7+C3<+VI7X]/UB["MNT_O5J5Q6[=Q9P&*C/(
M
M
M
M
M
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M3H_%)\T2\E;MSE&4XQ<H2K%M)N+HXU7L?3*4:KC1M<FRL6EX
M
M
M
M
M
M                                                     !C?Y9>1
M^L>*G!>Y\P[(D-NSB:OW9I^OR2/9)MF\Y2*:/6=;A])%G1ERW&LME[$<Z"C#
M/-T5(U0]MV\V3G]P-V8NV\*L87)=5ZYX6;$&G=N.O#@G2*?"4Y0C]L8Q[P=S
M=*[1[ SMZ:GTSNV8=&-9;:>1E7$U8LJG&DI+JFTFX6HW)T?2:6/!SVQMQYHW
MBWY=><U*W?R&Y9ZUO6'XHS\,D.0V+*Y2W'E:^P<AT'N1V,U^-TBI5UU[6.?$
MUC+3(Z[%JS2@[K=]M-VQI4>W/:B486<:RK$\NVTXVX170[>/+[:X_M\A-T;;
MMN4WYD8-]A/2MK6^->GWD[^6YW,G-R)95O3[R:G>N7)*Y&]F0?T+*K][PVDW
M%1C=4;4?*G(QKUX*D$%6K!#6JUH8Z]:M7C9#!7@A8V.&""&-K8XH8HVHUK6H
MC6M1$1.A"N<YW)NY<;E<DVVVZMM\6VWQ;;YLV7V[=NS;C9LQC"U"*48I)))*
MB22X))<$EP2*Q:7@
M
M
M
M
M
M                        '!>X<!:?R/RIIW)W(B?G>SC*M-)QEIN1JQKJ
MNK;/D',^]=[MT7R3LV'<'00104)[")!BX6.=7A2R]UA?6:;N_4M$V_DZ%HO[
MV>=)+*O1;\V[:C]"PI</+LU;E<C'XKLFE.3@E \#K7;O1=S;MPMU;E_?L=*B
MW@XTXKZO8OSIYF7*#;\[)HHPM3G\-B*;MP5V3N'.AY,]\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
9                              ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>pfe-06282020x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pfe="http://www.pfizer.com/20200628"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pfe-20200628.xsd" xlink:type="simple"/>
    <context id="FD2020Q2YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="I2020Q3Aug3-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20271.000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20271.000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20220.250Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20220.250Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FI2020Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FI2020Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FI2019Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FI2018Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="D2019Q3Jan1-Jul31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="I2020Q1Jan1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="I2019Q1Jan01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="D2020Q2Jan1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="D2020Q2Oct1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="I2020Q2Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-29</endDate>
        </period>
    </context>
    <context id="I2020Q2Apr9_srt_CounterpartyNameAxis_pfe_BioNTechSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechSEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-09</instant>
        </period>
    </context>
    <context id="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="I2020Q2Apr30_srt_CounterpartyNameAxis_pfe_ValnevaSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ValnevaSEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_CounterpartyNameAxis_pfe_BioNTechSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechSEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="D2020Q2Apr9-9_srt_CounterpartyNameAxis_pfe_BioNTechSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechSEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-09</startDate>
            <endDate>2020-04-09</endDate>
        </period>
    </context>
    <context id="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_CounterpartyNameAxis_pfe_BioNTechSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechSEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="D2019Q3Jul30-Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-30</startDate>
            <endDate>2019-07-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_CounterpartyNameAxis_pfe_ValnevaSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ValnevaSEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="I2019Q3Jul31_dei_LegalEntityAxis_pfe_GSKMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_CounterpartyNameAxis_pfe_ValnevaSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ValnevaSEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_RangeAxis_srt_MinimumMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="D2020Q3Jul1-31_srt_CounterpartyNameAxis_pfe_BioNTechSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechSEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-30</instant>
        </period>
    </context>
    <context id="D2020Q2Jun1-28_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_RangeAxis_srt_MaximumMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_ManufacturingCostReductionMember_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:ManufacturingCostReductionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_BusinessIntegrationCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:BusinessIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RestructuringCostAndReserveAxis_pfe_BusinessIntegrationCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:BusinessIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_RestructuringCostAndReserveAxis_pfe_ManufacturingCostReductionMember_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:ManufacturingCostReductionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_RestructuringPlanAxis_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="D2020Q2Oct1-Jun28_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViiVMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViiVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_CounterpartyNameAxis_pfe_MylanMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MylanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViiVMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViiVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_CK1AssetsSoldToBiogenIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:CK1AssetsSoldToBiogenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_GeneTherapiesMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GeneTherapiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchDevelopmentAndMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AllogeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_BusinessAcquisitionAxis_pfe_ViiVMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ViiVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_CounterpartyNameAxis_pfe_PumaTechnologiesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:PumaTechnologiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_BioNTechSEMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:BioNTechSEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AllogeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CortexymeInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CortexymeInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_KingMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:KingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_BioNTechSEMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:BioNTechSEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_BusinessAcquisitionAxis_pfe_ViiVMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ViiVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AnacorMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AnacorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViiVMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViiVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:EliLillyCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViiVMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViiVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_CounterpartyNameAxis_pfe_PumaTechnologiesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:PumaTechnologiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:EliLillyCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="D2021Q2Apr1-30_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-01</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_IncomeTaxesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:IncomeTaxesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="D2020Q3Jul1-31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_DebtInstrumentAxis_pfe_LongTermDebtIssuedFirstQuarter2020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:LongTermDebtIssuedFirstQuarter2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnFinanceB.V.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_DebtInstrumentAxis_pfe_SeniorNotesDue2047Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorNotesDue2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:ParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnFinanceB.V.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:ParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnFinanceB.V.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnFinanceB.V.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnFinanceB.V.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:ParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:ParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_pfe_HedgedItemAxis_us-gaap_SalesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:HedgedItemAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FI2019Q4_pfe_HedgedItemAxis_us-gaap_SalesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:HedgedItemAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_EquitySecuritiesByIndustryAxis_us-gaap_FinancialServicesSectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">us-gaap:FinancialServicesSectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchDevelopmentAndMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchDevelopmentAndMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchDevelopmentAndMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchDevelopmentAndMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchDevelopmentAndMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchDevelopmentAndMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="D2020Q4Jun29-Dec31_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="D2020Q2May4-4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-04</startDate>
            <endDate>2020-05-04</endDate>
        </period>
    </context>
    <context id="I2020Q2May4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2020-05-04</instant>
        </period>
    </context>
    <context id="D2018Q4Dec14-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2018-12-14</startDate>
            <endDate>2018-12-14</endDate>
        </period>
    </context>
    <context id="D2019Q2Jun27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2019-06-27</startDate>
            <endDate>2019-06-27</endDate>
        </period>
    </context>
    <context id="D2019Q3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2019-09-24</startDate>
            <endDate>2019-09-24</endDate>
        </period>
    </context>
    <context id="D2019Q2Apr25-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2019-04-25</startDate>
            <endDate>2019-04-25</endDate>
        </period>
    </context>
    <context id="D2020Q2Apr23_Apr232020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2020-04-23</startDate>
            <endDate>2020-04-23</endDate>
        </period>
    </context>
    <context id="D2019Q4Dec13-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2019-12-13</startDate>
            <endDate>2019-12-13</endDate>
        </period>
    </context>
    <context id="D2020Q2Jun25-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2020-06-25</startDate>
            <endDate>2020-06-25</endDate>
        </period>
    </context>
    <context id="D2017Q1Mar01-Mar31_srt_LitigationCaseAxis_pfe_PfizerVersusZydusMember_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerVersusZydusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="D2017Q2Feb01-Apr30_srt_LitigationCaseAxis_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerandBMSVersusSeveralGenericManufacturersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-01</startDate>
            <endDate>2017-04-30</endDate>
        </period>
    </context>
    <context id="D2020Q1Jan1-31_srt_LitigationCaseAxis_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerVersusViwitPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="D2017Q4Oct01-Oct31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="D2020Q3Jul1-31_srt_LitigationCaseAxis_pfe_NHSScotlandvs.DrReddysMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_PatentInfringementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:NHSScotlandvs.DrReddysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="D2018Q2Jun01-Jun30_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="D2013Q1MonthOfMarch_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_EnvironmentalRemediationLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:EnvironmentalRemediationLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-03-01</startDate>
            <endDate>2013-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q2_srt_ProductOrServiceAxis_pfe_EpiPenMember_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="D2018Q4Oct01-Oct31_srt_LitigationCaseAxis_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_srt_ProductOrServiceAxis_pfe_DocetaxelMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:DocetaxelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="D2019Q1Mar01-Mar31_srt_LitigationCaseAxis_pfe_PfizerVersusGenericCompaniesMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerVersusGenericCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="D2017Q4Nov2017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_LitigationCaseAxis_pfe_ClassActionVersusWyethMember_srt_ProductOrServiceAxis_pfe_HormoneTherapyProductsMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:ClassActionVersusWyethMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:HormoneTherapyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q3Sep01-Sep30_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_EnvironmentalRemediationLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:EnvironmentalRemediationLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:BusinessCombinationsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:PurchaseAccountingAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:CertainSignificantItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:PurchaseAccountingAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:BusinessCombinationsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:BusinessCombinationsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:CertainSignificantItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:CertainSignificantItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:PurchaseAccountingAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:BusinessCombinationsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:PurchaseAccountingAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:CertainSignificantItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EffexorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_FragminMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalatanXalacomMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_PanzygaMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PanzygaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_TotalSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_PfizerCentreOneMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_MektoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LipitorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EffexorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_OtherAntiinfectivesMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NorvascMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_TotalAllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_TotalSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_SutentMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherUpjohnProductsMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherUpjohnProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherUpjohnProductsMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherUpjohnProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_RetacritMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_VfendMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_XtandiAllianceRevenuesMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LipitorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_TotalAllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_MektoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_MektoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_TotalAllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LipitorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_MektoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_OtherHospitalProductsMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_TotalAllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_OtherAntiinfectivesMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_OtherHospitalProductsMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EffexorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_NimenrixMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalatanXalacomMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_OtherHospitalProductsMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZoloftMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZoloftMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_RetacritMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_PanzygaMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PanzygaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_ConsumerHealthcareReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:ConsumerHealthcareReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_XtandiAllianceRevenuesMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NorvascMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_NimenrixMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_PfizerCentreOneMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_SutentMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_VyndaqelMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_FragminMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_TotalBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalBiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_OtherAntiinfectivesMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_FragminMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_SutentMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_PfizerCentreOneMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LipitorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_TotalSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherUpjohnProductsMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherUpjohnProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_NimenrixMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_FragminMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalatanXalacomMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_RetacritMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_OtherHospitalProductsMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_ConsumerHealthcareReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:ConsumerHealthcareReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_VyndaqelMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_SutentMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_OtherAntiinfectivesMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_PanzygaMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PanzygaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalatanXalacomMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EffexorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_PfizerCentreOneMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_VyndaqelMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_VfendMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_NimenrixMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_ConsumerHealthcareReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:ConsumerHealthcareReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZoloftMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_VfendMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NorvascMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherUpjohnProductsMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherUpjohnProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_VyndaqelMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_RetacritMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZoloftMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NorvascMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_ConsumerHealthcareReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:ConsumerHealthcareReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_XtandiAllianceRevenuesMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_VfendMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_TotalSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_TotalBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalBiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_PanzygaMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PanzygaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_TotalBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalBiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_XtandiAllianceRevenuesMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_TotalBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalBiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <unit id="Accounting_standard">
        <measure>pfe:Accounting_standard</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="Operating_Segment">
        <measure>pfe:Operating_Segment</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="iso4217_EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="class_action">
        <measure>pfe:class_action</measure>
    </unit>
    <unit id="plaintiff">
        <measure>pfe:plaintiff</measure>
    </unit>
    <unit id="lawsuit">
        <measure>pfe:lawsuit</measure>
    </unit>
    <unit id="lagoon">
        <measure>pfe:lagoon</measure>
    </unit>
    <unit id="Patent">
        <measure>pfe:Patents</measure>
    </unit>
    <unit id="Defendant">
        <measure>pfe:Defendant</measure>
    </unit>
    <unit id="manufacturer">
        <measure>pfe:manufacturer</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="FD2020Q2YTD"
      id="Fact-B0D389DC799E7D024A3694757D9E3A03-wk-Fact-B0D389DC799E7D024A3694757D9E3A03">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2020Q2YTD"
      id="Fact-7E16EF88150545EF367C94757D9D24AD-wk-Fact-7E16EF88150545EF367C94757D9D24AD">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2020Q2YTD"
      id="Fact-CEDB9E353C5AB597A42394757D9D22C6-wk-Fact-CEDB9E353C5AB597A42394757D9D22C6">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2020Q2YTD"
      id="Fact-046AEFF956A35C8C2CCA94757D9E446D-wk-Fact-046AEFF956A35C8C2CCA94757D9E446D">2020</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="FD2020Q2YTD"
      id="Fact-C91EA2BD30816293114B94757D9D34F0-wk-Fact-C91EA2BD30816293114B94757D9D34F0">0000078003</dei:EntityCentralIndexKey>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2019Q4"
      decimals="-6"
      id="Fact-AA58F5E3D16407426BC394757CD865C7-wk-Fact-AA58F5E3D16407426BC394757CD865C7"
      unitRef="usd">16789000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2020Q2"
      decimals="-6"
      id="Fact-43361FC2439255EC9C0794757CD9C825-wk-Fact-43361FC2439255EC9C0794757CD9C825"
      unitRef="usd">16889000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="Fact-8F6198A5B84A323EA04194757CDD184D-wk-Fact-8F6198A5B84A323EA04194757CDD184D"
      unitRef="usd">527000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="Fact-EA1E0B8D16648EC1813394757CDA0B29-wk-Fact-EA1E0B8D16648EC1813394757CDA0B29"
      unitRef="usd">525000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="Fact-B2C9D3D493F51DFD6D8D94757CAD8A87-wk-Fact-B2C9D3D493F51DFD6D8D94757CAD8A87"
      unitRef="number">0.02625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-8"
      id="Fact-B8025FEC587092737E4492D05287317F-wk-Fact-B8025FEC587092737E4492D05287317F"
      unitRef="usd">-1400000000</us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="FD2020Q2YTD_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember"
      decimals="-6"
      id="Fact-409A4875BAFBBD8061B892D06CF3BC98-wk-Fact-409A4875BAFBBD8061B892D06CF3BC98"
      unitRef="usd">-550000000</us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <us-gaap:LongTermDebtCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="Fact-354E4103E704EECCE02B94757CDB72E6-wk-Fact-354E4103E704EECCE02B94757CDB72E6"
      unitRef="usd">1462000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="Fact-A775AC2F22450F075D8194757CD9A894-wk-Fact-A775AC2F22450F075D8194757CD9A894"
      unitRef="usd">1481000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:ProceedsFromCollaborators
      contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="Fact-0E193E757E07794025F679147DDD6D3D-wk-Fact-0E193E757E07794025F679147DDD6D3D"
      unitRef="usd">30000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_pfe_PumaTechnologiesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="Fact-7575AC2390FECF899875791421411CBB-wk-Fact-7575AC2390FECF899875791421411CBB"
      unitRef="usd">40000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromLegalSettlements
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="Fact-B8C9A592AB43457FFC677912F0F2CFCD-wk-Fact-B8C9A592AB43457FFC677912F0F2CFCD"
      unitRef="usd">82000000</us-gaap:ProceedsFromLegalSettlements>
    <dei:DocumentType
      contextRef="FD2020Q2YTD"
      id="d8381580e699-wk-Fact-9122839B392AAF7E7FFA94757D0DD201">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="FD2020Q2YTD"
      id="d8381580e706-wk-Fact-3D854C892B013741F6B394757CF248B4">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="FD2020Q2YTD"
      id="d8381580e718-wk-Fact-BCE549B69EAD65703B6D94757CF755BF">2020-06-28</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="FD2020Q2YTD"
      id="d8381580e731-wk-Fact-EAC1BEE25111358FD8B194757CFF1422">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="FD2020Q2YTD"
      id="d8381580e754-wk-Fact-7738B390E76E8D29FE8294757CFE63ED">1-3619</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="FD2020Q2YTD"
      id="d8381580e765-wk-Fact-026972AF1D09401A73AF94757D0E4D6C">PFIZER INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="FD2020Q2YTD"
      id="d8381580e787-wk-Fact-D4967F601D50F5887E9A94757D45823E">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="FD2020Q2YTD"
      id="d8381580e792-wk-Fact-99165F3B6A3ECCFF8C7194757D46D4A6">13-5315170</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="FD2020Q2YTD"
      id="d8381580e808-wk-Fact-32BB57587E166179116294757CFABAD7">235 East 42nd Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="FD2020Q2YTD"
      id="d8381580e817-wk-Fact-A5BB1E4C2B71E53BD3B594757CF908D4">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="FD2020Q2YTD"
      id="d8381580e821-wk-Fact-5F4D1CCD96E5E775185394757D0FD2F5">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="FD2020Q2YTD"
      id="d8381580e825-wk-Fact-59B35C0105F507E50A6C94757CF8A235">10017</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="FD2020Q2YTD"
      id="d8381580e835-wk-Fact-811ACF767DE29BC0C7EB94757CFFDC83">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="FD2020Q2YTD"
      id="d8381580e839-wk-Fact-7FB4896AA6793DC9FEE594757CFC2A44">733-2323</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      id="d8381580e940-wk-Fact-0CA0E2EC622CC66D534D94757D09FC9D">Common Stock, $.05 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      id="d8381580e950-wk-Fact-C1521C6A7D703728D9F094757D32F534">PFE</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      id="d8381580e960-wk-Fact-EFE7045D207191EA2DD594757D058D76">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20220.250Member"
      id="d8381580e966-wk-Fact-2668CCB3778360302DC194757D088972">0.250% Notes due 2022</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20220.250Member"
      id="d8381580e976-wk-Fact-EF4BB0BA7A970CA879D794757D0DDD25">PFE22</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20220.250Member"
      id="d8381580e986-wk-Fact-C78E5881EF1E22925E7494757D01407C">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20271.000Member"
      id="d8381580e992-wk-Fact-7B961DE3B1216737233094757D0BDB35">1.000% Notes due 2027</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20271.000Member"
      id="d8381580e1002-wk-Fact-6DE3DA4E4E7B6758238694757D0EA031">PFE27</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20271.000Member"
      id="d8381580e1012-wk-Fact-6755B97D0B42CD6B6B5294757D023A52">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="FD2020Q2YTD"
      id="d8381580e1032-wk-Fact-4ED87A94A6CA73A8670194757D413861">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="FD2020Q2YTD"
      id="d8381580e1070-wk-Fact-645DEF4892946DFA62F994757CC2B68C">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="FD2020Q2YTD"
      id="d8381580e1095-wk-Fact-1D9058BA707BC2875EFF94757CFF5085">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="FD2020Q2YTD"
      id="d8381580e1111-wk-Fact-56FC8E8299454E0DA54994757CF57E98">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="FD2020Q2YTD"
      id="d8381580e1116-wk-Fact-6B9B899BB0E7540658BC94757CF68316">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="FD2020Q2YTD"
      id="d8381580e1154-wk-Fact-847DBDFA2E2D9BC031A094757D3F2790">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2020Q3Aug3-3"
      decimals="INF"
      id="d8381580e1177-wk-Fact-152085F06FE866B029B994757CF87340"
      unitRef="shares">5556879807</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8340406e908-wk-Fact-4DB60D98BED9F2D7592094757D057DF4"
      unitRef="usd">11801000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8340406e927-wk-Fact-1769F431190664966C6E94757D75CC58"
      unitRef="usd">13264000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8340406e947-wk-Fact-6D0243B400427DDF73DD94757D73B062"
      unitRef="usd">23829000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8340406e966-wk-Fact-1987ADB564F749FC403294757D32C9CF"
      unitRef="usd">26382000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8340406e1075-wk-Fact-3E4926A75899DF8AB69294757D02E114"
      unitRef="usd">2281000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8340406e1094-wk-Fact-0F4E421B90BAC3CEFBC094757D951011"
      unitRef="usd">2576000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8340406e1113-wk-Fact-536622A1B5CBD4FE87F994757D2524BD"
      unitRef="usd">4658000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8340406e1133-wk-Fact-2457446A2FA3FC6A69CC94757D187F7E"
      unitRef="usd">5009000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8340406e1160-wk-Fact-3F6D04965D3F8AC6296C94757D442373"
      unitRef="usd">3030000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8340406e1179-wk-Fact-8B3A1BD0379B26183EE994757D074D8C"
      unitRef="usd">3511000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8340406e1198-wk-Fact-46F68B2D547259497F6A94757CB8B7C5"
      unitRef="usd">5903000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8340406e1218-wk-Fact-93E10BD448FBEAA578FD94757D709889"
      unitRef="usd">6850000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8340406e1245-wk-Fact-04615CE3AF3CBC3B5C8794757D5092E9"
      unitRef="usd">2132000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8340406e1264-wk-Fact-FB5675ACB41E944F604C94757D1A61F2"
      unitRef="usd">1842000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8340406e1283-wk-Fact-59753A9A46BF0BDDA65E94757CBF6EA3"
      unitRef="usd">3856000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8340406e1303-wk-Fact-9C03A5BC963DD5615ABA94757D2C3607"
      unitRef="usd">3544000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8340406e1328-wk-Fact-A2D758AD8E8FD5AADF3B94757CF0099C"
      unitRef="usd">905000000</pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction>
    <pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8340406e1347-wk-Fact-56CEFFBCED15FDD6F4D194757CDCF5D5"
      unitRef="usd">1184000000</pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction>
    <pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8340406e1366-wk-Fact-A332B2F7F76D0113E2A094757CC0E90D"
      unitRef="usd">1790000000</pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction>
    <pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8340406e1386-wk-Fact-64EEACF271CD8A6661EF94757CA9B5E3"
      unitRef="usd">2367000000</pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8340406e1411-wk-Fact-7E093B7D90D64F5B13A494757D3BA82F"
      unitRef="usd">362000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8340406e1430-wk-Fact-788604D6690A503EC72D94757D52CBCB"
      unitRef="usd">-115000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8340406e1450-wk-Fact-BB8522BC4D5C3EA5BD8694757CB166F6"
      unitRef="usd">431000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8340406e1470-wk-Fact-C8984FE48C4ADA9BA0CA94757CCB4FED"
      unitRef="usd">-69000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8340406e1496-wk-Fact-D68E718B4C6944A5CD6A94757CD29C96"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8340406e1515-wk-Fact-26DE7C056ED7F6339E0F94757D946476"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8340406e1534-wk-Fact-13980DEBF0DE0B3F0CC794757D1BBA04"
      unitRef="usd">6000000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8340406e1555-wk-Fact-42AE1B3E358159102DA894757CCA438F"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8340406e1580-wk-Fact-361AD8CFC0B46CF2632394757D0A716D"
      unitRef="usd">862000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8340406e1600-wk-Fact-115B1B8C87DB19F5829C94757D60A004"
      unitRef="usd">-126000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8340406e1619-wk-Fact-82FCBDB83EA92437E26C94757D5A5E10"
      unitRef="usd">641000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8340406e1640-wk-Fact-CF088F9FE2A75408C8A794757D1586DE"
      unitRef="usd">-218000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8340406e1666-wk-Fact-2A0EE9005DC8F1672AF194757D5C8E60"
      unitRef="usd">3953000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8340406e1685-wk-Fact-5210DA15DEEFCDAFC83494757D61140E"
      unitRef="usd">4141000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8340406e1704-wk-Fact-239CF4E3D5F1905A2F0794757CB54D24"
      unitRef="usd">7838000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8340406e1724-wk-Fact-57301CD194F92FB7EE9A94757CC61DC1"
      unitRef="usd">8463000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8340406e1749-wk-Fact-2BC7C8565E04B1B2A1F794757D407F8C"
      unitRef="usd">519000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8340406e1768-wk-Fact-F92309C5686C80B6F12094757D26F9AA"
      unitRef="usd">-915000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8340406e1788-wk-Fact-7D400BB69B8260DBFA0194757D7158A5"
      unitRef="usd">993000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8340406e1808-wk-Fact-F8480927DA2450FB9AB294757D637386"
      unitRef="usd">-481000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8340406e1834-wk-Fact-2979655C6D134159C89394757D499DAA"
      unitRef="usd">3434000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8340406e1853-wk-Fact-C920A45D5E66EC197B2A94757CF0CD54"
      unitRef="usd">5056000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8340406e1872-wk-Fact-A90E01F4F7B0E1568EDA94757D6D8CFD"
      unitRef="usd">6845000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8340406e1892-wk-Fact-603FB52F232889DFBADE94757D592C93"
      unitRef="usd">8945000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8340406e1917-wk-Fact-D0B1BB14EB1C0097910C94757D5D09B2"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8340406e1936-wk-Fact-05DE67BF183EFC3302F894757D673D16"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8340406e1955-wk-Fact-8CA5088693E8928A2F7194757D5C8489"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8340406e1975-wk-Fact-7F22D0DB6525173F13B494757CADCE97"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8340406e2000-wk-Fact-B56556CFBF45225D098894757D0D84DC"
      unitRef="usd">3434000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8340406e2019-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B"
      unitRef="usd">5056000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8340406e2038-wk-Fact-F55F7448D6FD457E7D3094757CC42D99"
      unitRef="usd">6845000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8340406e2058-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9"
      unitRef="usd">8945000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8340406e2083-wk-Fact-10C0D76C934B5C1793A994757D4985D4"
      unitRef="usd">8000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8340406e2102-wk-Fact-BE013A8321BCFA54741E94757D80A8CE"
      unitRef="usd">10000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8340406e2121-wk-Fact-ED12AC0ED4563B7B91D294757D6E4FFF"
      unitRef="usd">17000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8340406e2141-wk-Fact-1226C5A8B6BDD831984C94757CAB3BF0"
      unitRef="usd">15000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8340406e2171-wk-Fact-5855D3292457CBC841DF94757D03D95D"
      unitRef="usd">3426000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8340406e2190-wk-Fact-E80F3653B15E3D94B76194757D344502"
      unitRef="usd">5046000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8340406e2210-wk-Fact-629B718CAC92C35F38D794757D1FE07E"
      unitRef="usd">6828000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8340406e2229-wk-Fact-3AC307C0C4ECA1CCA0B494757CC80CD1"
      unitRef="usd">8929000000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="FD2020Q2QTD"
      decimals="2"
      id="d8340406e2426-wk-Fact-263AD80EFD0DF942862794757CB97E50"
      unitRef="usdPerShare">0.62</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d8340406e2445-wk-Fact-BDC31C12896D043747B194757D5B35D6"
      unitRef="usdPerShare">0.91</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="FD2020Q2YTD"
      decimals="2"
      id="d8340406e2465-wk-Fact-B98065EB23404AACB87094757D6BD6BE"
      unitRef="usdPerShare">1.23</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d8340406e2484-wk-Fact-527CDF2F111A3CFDCAC094757CB3C447"
      unitRef="usdPerShare">1.59</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="FD2020Q2QTD"
      decimals="2"
      id="d8340406e2504-wk-Fact-7BA1645714435EB2B3AB94757CC0F691"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d8340406e2523-wk-Fact-E756C4C43674CBFEFEA494757CE1093D"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="FD2020Q2YTD"
      decimals="2"
      id="d8340406e2542-wk-Fact-B5E50DD48766F6B1EB8294757CBDBCD9"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d8340406e2562-wk-Fact-7A14B07B1D3BB0FC8DEC94757D153837"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2020Q2QTD"
      decimals="2"
      id="d8340406e2593-wk-Fact-4F381BE015AE04126EB994757CB534B2"
      unitRef="usdPerShare">0.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d8340406e2612-wk-Fact-57D63ECE81675F0F4F2394757D0586AC"
      unitRef="usdPerShare">0.91</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2020Q2YTD"
      decimals="2"
      id="d8340406e2632-wk-Fact-E8B0E5833864611B38D294757CAF72E7"
      unitRef="usdPerShare">1.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d8340406e2651-wk-Fact-375CE2F1DA250039888894757D5B5BA6"
      unitRef="usdPerShare">1.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="FD2020Q2QTD"
      decimals="2"
      id="d8340406e2848-wk-Fact-0DEB9E1626C9961FC0CB94757D4307A4"
      unitRef="usdPerShare">0.61</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d8340406e2867-wk-Fact-0DADC806FCB0F8DE89E394757CFF07B6"
      unitRef="usdPerShare">0.89</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="FD2020Q2YTD"
      decimals="2"
      id="d8340406e2887-wk-Fact-C6F72F041602CA931A9F94757D2D2964"
      unitRef="usdPerShare">1.22</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d8340406e2906-wk-Fact-31ABED2FAA0C5EDD3D7994757D5F8CB1"
      unitRef="usdPerShare">1.56</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="FD2020Q2QTD"
      decimals="2"
      id="d8340406e2926-wk-Fact-D5B6EF098B9CCBC6106394757D9FD69A"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d8340406e2945-wk-Fact-5CBFB8246EFB61DA16CD94757CE0475C"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="FD2020Q2YTD"
      decimals="2"
      id="d8340406e2964-wk-Fact-DAA4B71118EB1D4285A994757D1B59B8"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d8340406e2984-wk-Fact-B33CD1A22EADB7B396EE94757D139837"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2020Q2QTD"
      decimals="2"
      id="d8340406e3014-wk-Fact-F0D947E3D319A071650894757D8FBF1A"
      unitRef="usdPerShare">0.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d8340406e3033-wk-Fact-2F0D93C254F8FED5D44E94757CFAFADA"
      unitRef="usdPerShare">0.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2020Q2YTD"
      decimals="2"
      id="d8340406e3053-wk-Fact-2F018DCBB03DFD12F06194757D0FC6D9"
      unitRef="usdPerShare">1.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d8340406e3072-wk-Fact-D797AF9402BF1599A6F594757D5776AE"
      unitRef="usdPerShare">1.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8340406e3179-wk-Fact-CEDDD667A11CAC08820D94757D0E749E"
      unitRef="shares">5554000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8340406e3198-wk-Fact-4083035A9265D74B487394757CDE895C"
      unitRef="shares">5562000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8340406e3217-wk-Fact-3E9B45FC40C0B53734B894757D6021C6"
      unitRef="shares">5550000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8340406e3237-wk-Fact-05B58E4BDA3C96C172AE94757D61A5B0"
      unitRef="shares">5598000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8340406e3262-wk-Fact-CDED57DD355FBFDCE83394757D0D0D08"
      unitRef="shares">5619000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8340406e3281-wk-Fact-C825A8BB25BE38B63BB194757D30A6AC"
      unitRef="shares">5672000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8340406e3300-wk-Fact-8EF576E428EEA952509894757D5DA535"
      unitRef="shares">5616000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8340406e3320-wk-Fact-4E46F2B386CE7BF8977294757CBBCA8A"
      unitRef="shares">5711000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8301124e911-wk-Fact-B56556CFBF45225D098894757D0D84DC"
      unitRef="usd">3434000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8301124e930-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B"
      unitRef="usd">5056000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8301124e950-wk-Fact-F55F7448D6FD457E7D3094757CC42D99"
      unitRef="usd">6845000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8301124e969-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9"
      unitRef="usd">8945000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8301124e1076-wk-Fact-B436D7020EEC746BCB4A94757D090189"
      unitRef="usd">-242000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8301124e1096-wk-Fact-519D1AE2B3692880237794757CFE232A"
      unitRef="usd">-485000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8301124e1116-wk-Fact-C54AB828E036C88403BC94757CCD9057"
      unitRef="usd">-1513000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8301124e1137-wk-Fact-F13DA5DDDB9A69F13A7994757D8778B5"
      unitRef="usd">-161000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8301124e1163-wk-Fact-592D27AEE4D0FDEDCA3094757CFE923B"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8301124e1182-wk-Fact-59195E3D3D8D530EB03F94757D003A33"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8301124e1201-wk-Fact-B756BD8131D12427D5A094757CC10C5E"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8301124e1221-wk-Fact-137D234567F2A002B07194757D5099CA"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8301124e1246-wk-Fact-B7AFA2301099E9BDE10E94757D091A88"
      unitRef="usd">-242000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8301124e1266-wk-Fact-F5E011F8B735031318D994757D0A265D"
      unitRef="usd">-485000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8301124e1286-wk-Fact-F618699466962C9B165B94757CEEF703"
      unitRef="usd">-1513000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8301124e1307-wk-Fact-24C0070845257F719EAD94757D4D72E4"
      unitRef="usd">-159000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8301124e1333-wk-Fact-6B2383F2FE5E4F5C1F8094757D03DB8C"
      unitRef="usd">213000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8301124e1352-wk-Fact-C73E7DEFCE404DDC8E6A94757CFD4810"
      unitRef="usd">-176000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8301124e1372-wk-Fact-4ECA9E2FD645BEFF2FE194757CB235DC"
      unitRef="usd">-288000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8301124e1393-wk-Fact-16EB2E72AB574E14B22194757CD34D79"
      unitRef="usd">91000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8301124e1420-wk-Fact-8B19463082CE6440AD3394757D03C123"
      unitRef="usd">186000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8301124e1440-wk-Fact-2DD85B64A9010E6C213294757D013277"
      unitRef="usd">81000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8301124e1460-wk-Fact-C78E60BC91B631C2A94794757CC3905D"
      unitRef="usd">167000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8301124e1481-wk-Fact-EAC3B24ACD51EAB9C1FF94757CE2E89A"
      unitRef="usd">343000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8301124e1507-wk-Fact-08ABD4A7A57B250F299B94757D04A592"
      unitRef="usd">27000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8301124e1526-wk-Fact-72309F9168907BDAA94794757D07D3DF"
      unitRef="usd">-256000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8301124e1546-wk-Fact-08DD19481DA8379F656094757D9154A8"
      unitRef="usd">-455000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8301124e1567-wk-Fact-4FABC049EDFD60A33BC994757D951454"
      unitRef="usd">-252000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8301124e1593-wk-Fact-3983BB3504AC4457A05494757D01EDF0"
      unitRef="usd">42000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8301124e1612-wk-Fact-9116D9DA0452E7895E8B94757D09EEB9"
      unitRef="usd">-7000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8301124e1632-wk-Fact-C461CCF052CAC13CE0B494757D759AEB"
      unitRef="usd">-9000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8301124e1653-wk-Fact-A82EF1B25256A6FE603294757D5228D4"
      unitRef="usd">33000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8301124e1681-wk-Fact-82F380CF07CFB5944E8F94757D071BF6"
      unitRef="usd">-44000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8301124e1700-wk-Fact-8DE79CAD5240FF8E772794757CFDD19F"
      unitRef="usd">-26000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8301124e1719-wk-Fact-64D918D7F7D3CCF5532194757CC5E46E"
      unitRef="usd">-59000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8301124e1739-wk-Fact-610F8D5433DAF2EB576E94757CAC2094"
      unitRef="usd">-37000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8301124e1764-wk-Fact-961167284F5E861B1C9094757D0AD393"
      unitRef="usd">87000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8301124e1783-wk-Fact-5B9F6B76D55DFFB89B5094757D04FD74"
      unitRef="usd">19000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8301124e1802-wk-Fact-B1C06142FF81EF258FE994757DA46AF3"
      unitRef="usd">50000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8301124e1822-wk-Fact-EC1267F1CEEA206E48DB94757D3D71EF"
      unitRef="usd">70000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8301124e1847-wk-Fact-54C9F8EBEE78F97A618894757D000BCB"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8301124e1866-wk-Fact-8C29FB80663D2D3FF01694757D04376B"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8301124e1886-wk-Fact-F175F1A05A293F5B33DF94757DA50565"
      unitRef="usd">-160000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8301124e1907-wk-Fact-7C3725C3864FB58D26F294757DA59FB9"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8301124e1933-wk-Fact-3508D42A7ED6A8C436DE94757D080CE2"
      unitRef="usd">-67000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8301124e1952-wk-Fact-926EAF034EA59D57AB4A94757D085C80"
      unitRef="usd">-60000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8301124e1971-wk-Fact-960E53D0B504F694E33294757D577481"
      unitRef="usd">-133000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8301124e1991-wk-Fact-4205FA0CADA9C7C75F1194757CAF3BC4"
      unitRef="usd">-121000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8301124e2016-wk-Fact-1E7D497146AE795F1C1994757D095745"
      unitRef="usd">-13000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8301124e2035-wk-Fact-D6F7C72544CA78BD37CE94757D0672FB"
      unitRef="usd">-2000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8301124e2054-wk-Fact-792F383C3FEE0FE8090C94757CAF87DA"
      unitRef="usd">-66000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8301124e2074-wk-Fact-44A3EBC245B59B1EDEFE94757CA83343"
      unitRef="usd">-2000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8301124e2099-wk-Fact-C5EA1CFA2BAB5B0EAA7094757D07F215"
      unitRef="usd">-68000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8301124e2118-wk-Fact-D9A205E489D5B6E9EB3A94757D04C021"
      unitRef="usd">-41000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8301124e2137-wk-Fact-E5B2171A194CD45335C794757CE7F3C1"
      unitRef="usd">-84000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8301124e2157-wk-Fact-1BF4E8A74A053F182A6294757CB3BD1E"
      unitRef="usd">-18000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8301124e2182-wk-Fact-B5BD6F0023F06259AE3494757D06AF3E"
      unitRef="usd">153000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8301124e2201-wk-Fact-9786DDF8A69B3054F6C594757D0258B2"
      unitRef="usd">100000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8301124e2220-wk-Fact-2EE2705D1EB743C59AA194757CB0642B"
      unitRef="usd">122000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8301124e2240-wk-Fact-ED78EBC18DA3BA3A4CA194757DA645DC"
      unitRef="usd">137000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8301124e2265-wk-Fact-50D4A8FFA49F4D1E126994757CD3C559"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8301124e2284-wk-Fact-9A3535709176CD3B928494757D5A0A52"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8301124e2304-wk-Fact-458F8B2744B5838D7DD994757D5BA906"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8301124e2324-wk-Fact-E5344C9D61E5386447CC94757D5DBD84"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8301124e2350-wk-Fact-457A42E5EFF17C82E7B994757D023187"
      unitRef="usd">-45000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8301124e2370-wk-Fact-7BD0F552906AEDAE43AB94757D064290"
      unitRef="usd">-46000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8301124e2390-wk-Fact-CD69F0255956248BF5A794757CDCB6CF"
      unitRef="usd">-89000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8301124e2411-wk-Fact-8570BDBA5E94557A549C94757D4F36AD"
      unitRef="usd">-93000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8301124e2437-wk-Fact-D6AF3AA50A2C3B4FED5094757D009316"
      unitRef="usd">-5000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8301124e2456-wk-Fact-B8780C1262D682FB127794757D09FED8"
      unitRef="usd">-1000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8301124e2475-wk-Fact-781D2814C0D7F0668EE394757D69DD6C"
      unitRef="usd">-4000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8301124e2495-wk-Fact-78F48FB31891A5F2CA2794757CAAA5B9"
      unitRef="usd">-2000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8301124e2520-wk-Fact-126B087E9A05FE5529B194757D03D1C9"
      unitRef="usd">40000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8301124e2540-wk-Fact-E7D7D44563418D8D6DC894757D062085"
      unitRef="usd">46000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8301124e2560-wk-Fact-6B0D0523D801B89879B094757D4B3266"
      unitRef="usd">85000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8301124e2581-wk-Fact-1891EFA6F636FA196DF794757D4ABF57"
      unitRef="usd">92000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8301124e2608-wk-Fact-62DE4C98CF58FC6052F494757D0396A6"
      unitRef="usd">-14000000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8301124e2628-wk-Fact-7ECB63F5AF06861C1CE494757D0884D8"
      unitRef="usd">-669000000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8301124e2648-wk-Fact-4B4218478A969AE4E17A94757D59AFA8"
      unitRef="usd">-1882000000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8301124e2669-wk-Fact-A66CB11E7205BECF278B94757D98ABC2"
      unitRef="usd">-296000000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8301124e2695-wk-Fact-EA79252BF7CF8534CF3894757D00B0A3"
      unitRef="usd">113000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8301124e2714-wk-Fact-8F362BEF2AB5D5597E6394757CFFD802"
      unitRef="usd">-59000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8301124e2734-wk-Fact-98256D21B98CE406359794757D62CC7A"
      unitRef="usd">-265000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8301124e2755-wk-Fact-EF6B358EA8E9123BB65194757D5C81E7"
      unitRef="usd">-34000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8301124e2786-wk-Fact-066BFF2F5B504A5CD41294757D064180"
      unitRef="usd">-127000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8301124e2806-wk-Fact-0AC5548725395D35A56C94757D003303"
      unitRef="usd">-610000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8301124e2827-wk-Fact-F996AE0BB974A9291E5D94757CB473E1"
      unitRef="usd">-1617000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8301124e2847-wk-Fact-920C774D6C3160546F7D94757DA37E07"
      unitRef="usd">-262000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8301124e2873-wk-Fact-F25133D545839D7AE1D294757D02FFFC"
      unitRef="usd">3307000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8301124e2892-wk-Fact-D2B6E10475D8BB804CE094757CFEFBD9"
      unitRef="usd">4446000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8301124e2912-wk-Fact-A1F913431B3403C9FEC994757D9D5A01"
      unitRef="usd">5227000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8301124e2931-wk-Fact-8F56B752B32B070AE71194757D815A0F"
      unitRef="usd">8683000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8301124e2951-wk-Fact-DB5758891218A2CD53FA94757D09D2D4"
      unitRef="usd">-4000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8301124e2971-wk-Fact-8BC82C6DDA70A7A2CF9894757D0335F3"
      unitRef="usd">12000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8301124e2990-wk-Fact-E8491F91CE829080A31A94757CDF3CE5"
      unitRef="usd">5000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8301124e3010-wk-Fact-86D8DED1361AFC8ED58C94757D5FCC72"
      unitRef="usd">13000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8301124e3040-wk-Fact-EA0DB488C3931FDD51EB94757D052620"
      unitRef="usd">3312000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8301124e3059-wk-Fact-623288D955847BE5D34C94757D0703C1"
      unitRef="usd">4434000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8301124e3079-wk-Fact-1AC328FD09CA718A54B294757CAD4A93"
      unitRef="usd">5222000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8301124e3098-wk-Fact-5BE19AFA21A4738F24FF94757D6A31FE"
      unitRef="usd">8669000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d8301124e3125-wk-Fact-9BF42E717180B5F1346794757D9BF953"
      unitRef="usd">380000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d8301124e3129-wk-Fact-2763BBDB57DA534C711D94757D9AD50C"
      unitRef="usd">291000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-8"
      id="d8301124e3146-wk-Fact-7D2CDF570E4A165119D754555A079873"
      unitRef="usd">-1200000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d8301124e3150-wk-Fact-EC4BE606149B17B66782545594D6136A"
      unitRef="usd">-902000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e864-wk-Fact-39CFEE5D7F0B06CD9DA094757D10AD76"
      unitRef="usd">1801000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e883-wk-Fact-B816481FF01850756E6D94757D1C86F4"
      unitRef="usd">1305000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherShortTermInvestments
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e903-wk-Fact-FCEFDC9E796190874A2D94757D27BB31"
      unitRef="usd">9581000000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e922-wk-Fact-B28669D670A8C56C545994757D2ED7A9"
      unitRef="usd">8525000000</us-gaap:OtherShortTermInvestments>
    <us-gaap:RestrictedInvestmentsCurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e949-wk-Fact-785332B79AA4618521F26EDD705A45C3"
      unitRef="usd">11412000000</us-gaap:RestrictedInvestmentsCurrent>
    <us-gaap:RestrictedInvestmentsCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e968-wk-Fact-438C70CDE0164785DD1D6EDE8D2EB280"
      unitRef="usd">0</us-gaap:RestrictedInvestmentsCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e993-wk-Fact-2564D80CF4863AD3560094757D2FB6D5"
      unitRef="usd">9128000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e1012-wk-Fact-52692B1D3913040E2AAA94757D1705E9"
      unitRef="usd">8724000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e1037-wk-Fact-E854D651F5C65603680B94757D20C5D0"
      unitRef="usd">8564000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e1056-wk-Fact-A72909DE8208FAB8084794757D31B877"
      unitRef="usd">8283000000</us-gaap:InventoryNet>
    <pfe:OtherTaxAssetsCurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e1081-wk-Fact-62FCD6839EDD133C913794757D242018"
      unitRef="usd">3426000000</pfe:OtherTaxAssetsCurrent>
    <pfe:OtherTaxAssetsCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e1100-wk-Fact-3CE8433BEC1FEF1715C594757D56EECD"
      unitRef="usd">3344000000</pfe:OtherTaxAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e1125-wk-Fact-E50549595D0042E610B994757D288E28"
      unitRef="usd">2513000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e1144-wk-Fact-7647F4EED80B8447B7B494757D2B6C57"
      unitRef="usd">2622000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e1169-wk-Fact-B99B2E1079DF1F86DF1A94757D24E100"
      unitRef="usd">46424000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e1188-wk-Fact-C1A3AA27451A8B8C11F594757D159C90"
      unitRef="usd">32803000000</us-gaap:AssetsCurrent>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e1214-wk-Fact-06B216BCF27965D7A6A694757D11CF28"
      unitRef="usd">15578000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e1233-wk-Fact-CFF1903136C1AC56DF3A94757D2B131B"
      unitRef="usd">17133000000</us-gaap:EquityMethodInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e1258-wk-Fact-FFBCEDF314C46C81ABEE94757D18EE64"
      unitRef="usd">3142000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e1277-wk-Fact-BCE8A138729B45E61B7F94757D2C3132"
      unitRef="usd">3014000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e1302-wk-Fact-D948D8A0A120E105480A94757D261CF9"
      unitRef="usd">14113000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e1321-wk-Fact-1E1B5B900670A3CC9D3594757D1F6A23"
      unitRef="usd">13967000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e1346-wk-Fact-9C96864A6997B214807194757D2B762A"
      unitRef="usd">33541000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e1365-wk-Fact-59E2FF5E7ACF702D9F4B94757D3339C6"
      unitRef="usd">35370000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e1390-wk-Fact-4B0A3E94BBBA400AC84C94757D168B19"
      unitRef="usd">58449000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e1409-wk-Fact-FAA57939ED1473B9187894757D259554"
      unitRef="usd">58653000000</us-gaap:Goodwill>
    <pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e1434-wk-Fact-BA35612EAE6C91BF6D5494757D30D0C0"
      unitRef="usd">2360000000</pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent>
    <pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e1453-wk-Fact-B5534107AC881736B01B94757D23BE41"
      unitRef="usd">2099000000</pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e1478-wk-Fact-A40179DC2229E8A9AD6B94757D2F9DF6"
      unitRef="usd">4327000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e1497-wk-Fact-DAA11F34E77442AAEC1894757D191631"
      unitRef="usd">4450000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e1527-wk-Fact-CCE3024E0C6DEE0D773194757D1EE899"
      unitRef="usd">177934000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e1546-wk-Fact-C2CB94D8321D93BAD2DD94757D57F0A3"
      unitRef="usd">167489000000</us-gaap:Assets>
    <us-gaap:DebtCurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e1661-wk-Fact-FA941197011A51FBD4DF94757D289899"
      unitRef="usd">13084000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e1680-wk-Fact-E1C7AF863456D04209EB94757D12EC91"
      unitRef="usd">16195000000</us-gaap:DebtCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e1701-wk-Fact-31B843C71D5C57C7970294757D210FDA"
      unitRef="usd">3872000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e1720-wk-Fact-0C05260CF79B14B3930694757D1319B9"
      unitRef="usd">4220000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e1745-wk-Fact-551A923D6EEA0DEA4EF694757D1C99C3"
      unitRef="usd">2111000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e1764-wk-Fact-014A34208FA34FFBCC4994757D221D12"
      unitRef="usd">2104000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e1789-wk-Fact-82FFBC9E02C7EA63F21C94757D1C5F54"
      unitRef="usd">1445000000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e1808-wk-Fact-AA0D8DE25A28BD3E886994757D30BAE9"
      unitRef="usd">980000000</us-gaap:TaxesPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e1833-wk-Fact-F28698BCE434ADB508FA94757D1736FA"
      unitRef="usd">2042000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e1852-wk-Fact-4C76179C274DDE6FE76E94757D246CA2"
      unitRef="usd">2720000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e1877-wk-Fact-76D99E72799A7D1A6EEF94757D204BD6"
      unitRef="usd">10168000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e1896-wk-Fact-DC5D094960D8362E8AE194757D1CEABE"
      unitRef="usd">11083000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e1921-wk-Fact-7815B96C1DE73848E04C94757D28CB62"
      unitRef="usd">32723000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e1940-wk-Fact-3CC60BCCBCF2CF508B1694757D16B042"
      unitRef="usd">37304000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e2013-wk-Fact-9B484215869CDB3979AE94757D159E88"
      unitRef="usd">50529000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e2032-wk-Fact-599CD01F617B5421030A94757D29E0E8"
      unitRef="usd">35955000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e2057-wk-Fact-B2CACAAABE963B0BFD8F94757D10087A"
      unitRef="usd">5344000000</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e2076-wk-Fact-F3EB43E530A63806272994757D14737C"
      unitRef="usd">5638000000</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e2101-wk-Fact-9072FFD068100079F81B94757D26A3EC"
      unitRef="usd">1086000000</us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent>
    <us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e2120-wk-Fact-2325A2D864C8B2E0F2E194757D22414D"
      unitRef="usd">1124000000</us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e2145-wk-Fact-1DC168387E9062FD753994757D57860A"
      unitRef="usd">5409000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e2164-wk-Fact-5CC1D14D1DDE8826CA7B94757D19D277"
      unitRef="usd">5578000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e2190-wk-Fact-D935FF0C642A1173F2D694757D1F4344"
      unitRef="usd">11468000000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e2209-wk-Fact-7C60FDCC13DD0DFF94DB94757D194622"
      unitRef="usd">12126000000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e2234-wk-Fact-795A73536189346A46BA94757D101516"
      unitRef="usd">6812000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e2253-wk-Fact-F30E96B44D3E4509219994757D1F511F"
      unitRef="usd">6317000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e2278-wk-Fact-2296B04F377E05B8D07C94757D190B3D"
      unitRef="usd">113370000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e2297-wk-Fact-A25CEEC8C1AE2DADBEC594757D293164"
      unitRef="usd">104042000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2020Q2"
      id="d8307028e2368-wk-Fact-A21DC12905CBC163AED994757D2EAC03"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2019Q4"
      id="d8307028e2386-wk-Fact-324F49A292903AEB38B894757D2BD1AB"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e2456-wk-Fact-D037126BFACE01B81D3B94757D11D201"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e2475-wk-Fact-10EDC1B88A166120EB9394757D13AAEA"
      unitRef="usd">17000000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e2500-wk-Fact-D7ECD9F4548C3411A1AB94757D1B3553"
      unitRef="usd">470000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e2519-wk-Fact-19C43A79023CA42B86EA94757D12F049"
      unitRef="usd">468000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e2544-wk-Fact-E75C406B14955CDB7D3B94757D138744"
      unitRef="usd">87886000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e2563-wk-Fact-B17D04EC8E4349EFFEF394757D1A00C1"
      unitRef="usd">87428000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockValue
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e2588-wk-Fact-BCA7EB2A102DF56C060B94757D2C4CD4"
      unitRef="usd">110978000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e2608-wk-Fact-E78126B8699A77F8DCC594757D1B1CAA"
      unitRef="usd">110801000000</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e2634-wk-Fact-FC09E3AC9855BA04E2AC94757D2ED7CA"
      unitRef="usd">100203000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e2653-wk-Fact-A8DB7D24D8C907F2E56094757D1D1AC3"
      unitRef="usd">97670000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e2679-wk-Fact-2E87EA97E71121C08FCB94757D27917E"
      unitRef="usd">-13246000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e2699-wk-Fact-47E4B6DB5C9B3F16044E94757D1BCF19"
      unitRef="usd">-11640000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e2725-wk-Fact-DD3041593AC72587B67894757D2924BD"
      unitRef="usd">64336000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e2744-wk-Fact-F68119AE4BA283A0E74494757D5699A2"
      unitRef="usd">63143000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e2769-wk-Fact-648A257E45E63BD933AE94757D2F45DA"
      unitRef="usd">228000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e2788-wk-Fact-2C16CBC888D1DBA772D994757D213C35"
      unitRef="usd">303000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e2813-wk-Fact-39B247651891576D7B7A94757D210D60"
      unitRef="usd">64564000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e2832-wk-Fact-6AE9A7E5A8423D56EB6794757D15EE65"
      unitRef="usd">63447000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8307028e2862-wk-Fact-82EF2E3D703744E0C13B94757D266699"
      unitRef="usd">177934000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8307028e2881-wk-Fact-0D1CD905D92C101F2A7094757D18615E"
      unitRef="usd">167489000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="0"
      id="d8336633e1467-wk-Fact-D58E0C9AEC0FAB141C2794757D361983"
      unitRef="shares">417</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-6"
      id="d8336633e1486-wk-Fact-F17EC0EBDAE2EB6346E094757D109BAC"
      unitRef="usd">17000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d8336633e1500-wk-Fact-F3A733B52C3E9E10B03494757CDA0945"
      unitRef="shares">9393000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d8336633e1520-wk-Fact-F3381BD200AEE22A790894757D7247BF"
      unitRef="usd">470000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-6"
      id="d8336633e1539-wk-Fact-B35D2CD0AC8469F52A1194757DA775AF"
      unitRef="usd">87680000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e1553-wk-Fact-B628E15DE73F0869904394757D92C37B"
      unitRef="shares">3841000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e1574-wk-Fact-B38C1AE72C31DF2CFAFA94757CDDB0D8"
      unitRef="usd">-111010000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d8336633e1594-wk-Fact-6BC4DEBEF668519175DE94757D1D6772"
      unitRef="usd">101000000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d8336633e1613-wk-Fact-C7083099744AE4148D4994757D2CC599"
      unitRef="usd">-13131000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e1634-wk-Fact-03460BEA869B48E0CF7894757D6EE332"
      unitRef="usd">65026000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d8336633e1653-wk-Fact-146CA4CF4749BABED82294757D1CFAEF"
      unitRef="usd">312000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1"
      decimals="-6"
      id="d8336633e1673-wk-Fact-FC3B1DFA5581B90199D694757D2565A3"
      unitRef="usd">65338000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d8336633e1820-wk-Fact-871135383070AF575BE394757CEC460F"
      unitRef="usd">3426000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e1860-wk-Fact-1EB64412D2D80070B55B94757D5A4E16"
      unitRef="usd">3426000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d8336633e1879-wk-Fact-273C64BCA1A40F3A50D394757CD85863"
      unitRef="usd">8000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8336633e1898-wk-Fact-B56556CFBF45225D098894757D0D84DC"
      unitRef="usd">3434000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d8336633e2071-wk-Fact-7AA1C77DB5A3B4644A4C94757CE5FE83"
      unitRef="usd">-115000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e2092-wk-Fact-2298D4CD7D2F6AE1C57E94757D628353"
      unitRef="usd">-115000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d8336633e2112-wk-Fact-0EA469F78A7AA9B0154B94757D0F21D4"
      unitRef="usd">-12000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8336633e2132-wk-Fact-066BFF2F5B504A5CD41294757D064180"
      unitRef="usd">-127000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d8336633e2517-wk-Fact-0A439D2D9035C084D32594757D7076B0"
      unitRef="usd">4223000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e2558-wk-Fact-6E65BB85082AE89519F994757CADB602"
      unitRef="usd">4223000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8336633e2598-wk-Fact-C938A9B7922E6371EB0F94757CEF9930"
      unitRef="usd">4223000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d8336633e2752-wk-Fact-920B734C19194AC1B01F94757D8C8380"
      unitRef="usd">0</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e2792-wk-Fact-9FD771621D23274287A294757D1BC8FA"
      unitRef="usd">0</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8336633e2831-wk-Fact-02FDFD3FA6ACE12CEA1F94757D6D0CCF"
      unitRef="usd">0</us-gaap:DividendsPreferredStockCash>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d8336633e3044-wk-Fact-B0814DE9CC612AE11DD594757D3226D5"
      unitRef="usd">80000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8336633e3064-wk-Fact-2C0450D46BE2A068263194757CADD7DF"
      unitRef="usd">80000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d8336633e3126-wk-Fact-FAD43102CBD17909063494757CE9364E"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d8336633e3141-wk-Fact-6538F77FA787A6ABAE0994757CB51CDA"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-6"
      id="d8336633e3160-wk-Fact-6B111BE422485683C25B94757D205012"
      unitRef="usd">221000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e3179-wk-Fact-74F211B6DF9332B7854594757CED7C21"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e3194-wk-Fact-7055D02214C4DCDBF2D794757D530978"
      unitRef="usd">1000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e3254-wk-Fact-2934BA4BF607819E093694757D2AAA19"
      unitRef="usd">222000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8336633e3293-wk-Fact-382681D10D85986FB7E894757D20CDB3"
      unitRef="usd">222000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e3411-wk-Fact-B92928DFC343D1C01A7994757D3B4E3A"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e3426-wk-Fact-2B5CC988DB54D9E2126D94757D6035E4"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e3486-wk-Fact-3C3F27909C4BDBE69AF194757CE1FE25"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8336633e3525-wk-Fact-5340A136A6910F813F5A94757D1D656C"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="0"
      id="d8336633e3553-wk-Fact-112FF7A0087A9422819094757D2BF4D9"
      unitRef="shares">417</pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-6"
      id="d8336633e3568-wk-Fact-D21BDBDB5A3496D15C0F94757CC0FECE"
      unitRef="usd">17000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-6"
      id="d8336633e3624-wk-Fact-6B84B600E6054E02ECF394757CEEFFA4"
      unitRef="usd">14000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e3644-wk-Fact-DDAEB6E7FE68CC5DB4FB7DAAEFDFB98D"
      unitRef="shares">1000000</pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e3659-wk-Fact-3A9B32710A1CE30C5C917DAAF1BA82D7"
      unitRef="usd">-31000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e3719-wk-Fact-A88ABBED02CE57879DE594757CE47EAA"
      unitRef="usd">0</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8336633e3758-wk-Fact-7E6C55D0D09E306D959A94757D35315B"
      unitRef="usd">0</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d8336633e3904-wk-Fact-B82DC8F0C3F61B78FD6994757D46FE68"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e3944-wk-Fact-A6C23BB629BE687A706594757D7617FA"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d8336633e3963-wk-Fact-AAD74F0EFA0B4EA93F7D94757D17DF5B"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8336633e3982-wk-Fact-7E9393AC0EF93702DEB094757D86B0EE"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesIssued
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="0"
      id="d8336633e4008-wk-Fact-B39352F261C00A65738694757D51EB5C"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-6"
      id="d8336633e4027-wk-Fact-7527AF621EA7D105014694757D491C4F"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d8336633e4041-wk-Fact-780C5B60A58937B5CFA594757D14130D"
      unitRef="shares">9394000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d8336633e4061-wk-Fact-565D7337C380201E7A3794757D2441F6"
      unitRef="usd">470000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-6"
      id="d8336633e4080-wk-Fact-9F791EE0835763BF87F894757D6D6836"
      unitRef="usd">87886000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e4094-wk-Fact-F12EBCA49A1647F7C9C194757CB75C07"
      unitRef="shares">3840000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e4115-wk-Fact-A8241CECE526F96581AE94757CF0E2F1"
      unitRef="usd">-110978000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d8336633e4135-wk-Fact-DFF13E5F684FBEC9822394757D143E71"
      unitRef="usd">100203000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d8336633e4154-wk-Fact-0311E1C11EAA0D64120894757D282E1A"
      unitRef="usd">-13246000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e4175-wk-Fact-D2F433B8AA4C0088F7B694757DA65630"
      unitRef="usd">64336000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d8336633e4194-wk-Fact-E682A060B9E084CD78DB94757CBF7369"
      unitRef="usd">228000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8336633e4214-wk-Fact-39B247651891576D7B7A94757D210D60"
      unitRef="usd">64564000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="0"
      id="d8336633e5167-wk-Fact-20A8453F774E2321859294757CD699F4"
      unitRef="shares">466</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-6"
      id="d8336633e5186-wk-Fact-2C4A0D66E79C36E0AD3A94757CD125ED"
      unitRef="usd">19000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d8336633e5200-wk-Fact-6B2DEA1574A1AAC388A194757D2E9D03"
      unitRef="shares">9358000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d8336633e5220-wk-Fact-2F4D955985202F933AFB94757DA34DE9"
      unitRef="usd">468000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-6"
      id="d8336633e5239-wk-Fact-FD9AFC22FEA2E091BFC594757D404E95"
      unitRef="usd">86635000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e5253-wk-Fact-11AD19C653F542C874C794757D691F63"
      unitRef="shares">3801000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e5274-wk-Fact-BBC46AA267DCADC2619E94757D4B1DD3"
      unitRef="usd">-110781000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d8336633e5294-wk-Fact-562BF7F5C92ED48A7C3D94757D41E597"
      unitRef="usd">93388000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d8336633e5313-wk-Fact-4B8ABD514A7533B0DD2D94757CEB8E0E"
      unitRef="usd">-10923000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e5334-wk-Fact-5C78C5042C9CAAB17DD594757D1E08DF"
      unitRef="usd">58806000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d8336633e5353-wk-Fact-82E28E032D731899B0B694757D3E73D0"
      unitRef="usd">352000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1"
      decimals="-6"
      id="d8336633e5373-wk-Fact-917DA1C330410587B66094757D7DD34A"
      unitRef="usd">59158000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d8336633e5520-wk-Fact-1FD9113D58C3CC135A9A94757D26E7FF"
      unitRef="usd">5046000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e5560-wk-Fact-B54EEE815409E49E0D1894757D4EDBA5"
      unitRef="usd">5046000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d8336633e5579-wk-Fact-594699073675166A837B94757D1BBB71"
      unitRef="usd">10000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8336633e5598-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B"
      unitRef="usd">5056000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d8336633e5769-wk-Fact-070B56B824B87F2A371A94757D18F7F9"
      unitRef="usd">-613000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e5790-wk-Fact-CFA8D8DE9A17CA78BDB894757CE71BFF"
      unitRef="usd">-613000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d8336633e5810-wk-Fact-4311DCC0A7382F4BE88494757D3C948A"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8336633e5829-wk-Fact-0AC5548725395D35A56C94757D003303"
      unitRef="usd">-610000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d8336633e6219-wk-Fact-886DF198F4CB9AB4242C94757D9970F3"
      unitRef="usd">3994000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e6260-wk-Fact-DDE80D633A2B28C2D4B194757D63F34A"
      unitRef="usd">3994000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8336633e6300-wk-Fact-9D649DDE4C8F1EF5140994757D200949"
      unitRef="usd">3994000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d8336633e6454-wk-Fact-7693E162BA55D1667FBC94757D2195F2"
      unitRef="usd">0</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e6494-wk-Fact-9864AFACC9ABDC5E1CF694757CC9DE4C"
      unitRef="usd">0</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8336633e6533-wk-Fact-73F49BAF1651352ADB8A94757D370266"
      unitRef="usd">0</us-gaap:DividendsPreferredStockCash>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d8336633e6746-wk-Fact-1E1B86E2273523F6FBAD94757D16A070"
      unitRef="usd">8000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8336633e6766-wk-Fact-36A1278749B1A6EBD0EE94757D199E89"
      unitRef="usd">8000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d8336633e6828-wk-Fact-93E2B34C852B38B85FA394757D2258B2"
      unitRef="shares">5000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d8336633e6843-wk-Fact-C1DE3E07544739B2E3BC94757CEAD328"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-6"
      id="d8336633e6862-wk-Fact-1437F24F4D59D041AD5194757D907B35"
      unitRef="usd">329000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e6896-wk-Fact-2C8B37C90E999E0983A494757D3A0FE2"
      unitRef="usd">-6000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e6955-wk-Fact-8333570EE1A66789FB2C94757D365212"
      unitRef="usd">324000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8336633e6994-wk-Fact-7BEE24816749E03906BD94757D9C4726"
      unitRef="usd">324000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e7111-wk-Fact-A1B634793474C63E20E77DAA79965C6D"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e7126-wk-Fact-CA0C786AD2F0B41A91817DAA79E6E7CB"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e7184-wk-Fact-F2F1A0934B119BCED20494757D9F5C1A"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8336633e7223-wk-Fact-3F6A0F8D36D9FD50EACD94757D9D5AA4"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="0"
      id="d8336633e7249-wk-Fact-8F5ED7D1B0A0EF78888F94757D1CDBFD"
      unitRef="shares">8</pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-6"
      id="d8336633e7264-wk-Fact-75FF99F8C13B7B51000994757D64A357"
      unitRef="usd">0</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-6"
      id="d8336633e7319-wk-Fact-BE33935DCA8AF32376B994757D5F4D6D"
      unitRef="usd">1000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e7412-wk-Fact-A21E82052DF984C0370594757D762D70"
      unitRef="usd">1000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8336633e7452-wk-Fact-A5C037C17E00CF7C78FE94757D5EE39D"
      unitRef="usd">1000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d8336633e7601-wk-Fact-F53C3D63E9620E8FB80594757CCA75EE"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e7641-wk-Fact-A5D88487E443ABA949BF94757D39E6F7"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8336633e7679-wk-Fact-C3E7A0CC1F9E87A7290394757D55B8EE"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesIssued
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="0"
      id="d8336633e7705-wk-Fact-D37856BCED8C1D2C7F3494757D99EE35"
      unitRef="shares">458</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-6"
      id="d8336633e7724-wk-Fact-FB813AC829F4A188FEBA94757D2D36C8"
      unitRef="usd">18000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d8336633e7738-wk-Fact-0C3EA3961095E3F8A34994757CCEFE8A"
      unitRef="shares">9363000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d8336633e7758-wk-Fact-ED5AE72D950E62950F0794757CE72E3D"
      unitRef="usd">468000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-6"
      id="d8336633e7777-wk-Fact-59A686060A7AF1F7275494757D530630"
      unitRef="usd">86963000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e7791-wk-Fact-427A772CBA10468F664594757D453976"
      unitRef="shares">3801000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e7812-wk-Fact-F6DA9F6F4CDC4D1208C294757D3DEB55"
      unitRef="usd">-110786000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d8336633e7832-wk-Fact-B00A363AE1BB1F3479D994757D183B47"
      unitRef="usd">94440000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d8336633e7851-wk-Fact-41A19ED1C18BA2C59FD594757CC95BFE"
      unitRef="usd">-11535000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e7872-wk-Fact-C6B8B0E3BE0B6E14FCC394757D2F7284"
      unitRef="usd">59568000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d8336633e7891-wk-Fact-066E69F57B7DF80E550194757D597E52"
      unitRef="usd">357000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2"
      decimals="-6"
      id="d8336633e7911-wk-Fact-5570A8AC6555BCC3538194757CDE6165"
      unitRef="usd">59924000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="0"
      id="d8336633e8715-wk-Fact-DF376F2902A29228A30394757D95B369"
      unitRef="shares">431</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-6"
      id="d8336633e8734-wk-Fact-E53668C499D5B6EED42794757CBA0E04"
      unitRef="usd">17000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d8336633e8748-wk-Fact-A73DD4823D1FAAF157BF94757CB25343"
      unitRef="shares">9369000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d8336633e8768-wk-Fact-D9ACACC3158032862FBC94757CBB3D3D"
      unitRef="usd">468000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-6"
      id="d8336633e8787-wk-Fact-DFAA9788CAC84F0B9CBE94757D9006BC"
      unitRef="usd">87428000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e8801-wk-Fact-D86287A5407ADF62135F94757CB299CF"
      unitRef="shares">3835000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e8822-wk-Fact-0A9DF58A6CB5A7F6545994757D8DB53B"
      unitRef="usd">-110801000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d8336633e8842-wk-Fact-5FF93BEF0CD0E0592D9894757CB94FC4"
      unitRef="usd">97670000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d8336633e8861-wk-Fact-5A3DCFE782B686C3474B94757CB5ED2D"
      unitRef="usd">-11640000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e8882-wk-Fact-82E5812A435DA211399494757D905CAA"
      unitRef="usd">63143000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d8336633e8901-wk-Fact-CC73D199AFE6851BDA0294757CAED89E"
      unitRef="usd">303000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8336633e8921-wk-Fact-6AE9A7E5A8423D56EB6794757D15EE65"
      unitRef="usd">63447000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d8336633e9068-wk-Fact-36E7CFCCB407CFADF4BD94757D88D126"
      unitRef="usd">6828000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e9108-wk-Fact-68B318E9C2DB946F864A94757D889244"
      unitRef="usd">6828000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d8336633e9127-wk-Fact-69B5FF4C482B5ABEA96994757CA8B7DD"
      unitRef="usd">17000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8336633e9146-wk-Fact-F55F7448D6FD457E7D3094757CC42D99"
      unitRef="usd">6845000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d8336633e9319-wk-Fact-7015F6E30333F20A4CA094757D862B59"
      unitRef="usd">-1605000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e9340-wk-Fact-BFBC825D4CA85CD2E41D94757CB1220B"
      unitRef="usd">-1605000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d8336633e9360-wk-Fact-1A38F0D11E57E09F813994757D942D38"
      unitRef="usd">-12000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8336633e9380-wk-Fact-F996AE0BB974A9291E5D94757CB473E1"
      unitRef="usd">-1617000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d8336633e9767-wk-Fact-34BB026C07BB62277DBC94757CB6F69E"
      unitRef="usd">4294000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e9808-wk-Fact-2AFFCF1916589B62C56494757D956455"
      unitRef="usd">4294000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8336633e9848-wk-Fact-208A12CB637A2CA687FC94757D93B898"
      unitRef="usd">4294000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d8336633e10002-wk-Fact-FABFB96784AE0E40057C94757CBC23CF"
      unitRef="usd">0</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e10042-wk-Fact-0ACF20D2E36512CA3FFF94757CB9E5D6"
      unitRef="usd">0</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8336633e10081-wk-Fact-469C94508C3D19FD04B494757D87315E"
      unitRef="usd">0</us-gaap:DividendsPreferredStockCash>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d8336633e10294-wk-Fact-FE201EAFE1503AB0772B94757D8F33AD"
      unitRef="usd">80000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8336633e10314-wk-Fact-699171B0726A36F4B73394757CB0310F"
      unitRef="usd">80000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d8336633e10376-wk-Fact-639B93DD7566754E1E9694757D832F48"
      unitRef="shares">25000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d8336633e10391-wk-Fact-D75B034453F0D830B56B94757CB44AE9"
      unitRef="usd">1000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-6"
      id="d8336633e10410-wk-Fact-F2364CCA95BCB9FF67BA94757CBE23AB"
      unitRef="usd">473000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e10429-wk-Fact-EE5FCC32DD1F49FD716794757D8499D5"
      unitRef="shares">6000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e10445-wk-Fact-CF51E0E503957DBEE07394757CACD840"
      unitRef="usd">-208000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e10506-wk-Fact-E6A6BB806B084AB6D48994757D8EAE58"
      unitRef="usd">266000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8336633e10545-wk-Fact-3F18B676756C784E4C0D94757CB66A64"
      unitRef="usd">266000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e10663-wk-Fact-550D4302BA6804DA1DE694757D9284DA"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e10678-wk-Fact-62CBE8210B463E54DCAE94757D849437"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e10738-wk-Fact-62CBE8210B463E54DCAE94757D849437"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8336633e10777-wk-Fact-FFD71DCF3ECC62BAAB9494757CB88D9F"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="0"
      id="d8336633e10805-wk-Fact-17964A9D32951C373D6394757D89737D"
      unitRef="shares">431</pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-6"
      id="d8336633e10820-wk-Fact-E82571DEE2C15F9E1D7094757D82377C"
      unitRef="usd">17000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-6"
      id="d8336633e10876-wk-Fact-87E8BDB2D145CE8F51DF94757CB079E4"
      unitRef="usd">15000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e10896-wk-Fact-D75526E67D4914D634987DAA85CEF4A3"
      unitRef="shares">1000000</pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e10911-wk-Fact-F3B0AC6951DEEF5E98DC94757CA9786E"
      unitRef="usd">-31000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e10971-wk-Fact-E660298A415643D957F994757D82F91C"
      unitRef="usd">1000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8336633e11011-wk-Fact-3C10FB8DF4A946A1047094757CB010DE"
      unitRef="usd">1000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-6"
      id="d8336633e11105-wk-Fact-8AA71470C6F49FFEF87594757CBC671E"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e11124-wk-Fact-1E0FA72C88E0180817A294757D917CD7"
      unitRef="shares">0</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d8336633e11158-wk-Fact-C3A560E1E22FD2CFF01C94757CA92EB0"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e11196-wk-Fact-B742EA2DDFFBC1EE5A0694757CB11B81"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d8336633e11215-wk-Fact-C04FC7C13AC6C8C6DD6594757CB52AB5"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8336633e11234-wk-Fact-1F784513FF9C94CFD4A694757D890961"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesIssued
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="0"
      id="d8336633e11260-wk-Fact-B39352F261C00A65738694757D51EB5C"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-6"
      id="d8336633e11279-wk-Fact-7527AF621EA7D105014694757D491C4F"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d8336633e11293-wk-Fact-780C5B60A58937B5CFA594757D14130D"
      unitRef="shares">9394000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d8336633e11313-wk-Fact-565D7337C380201E7A3794757D2441F6"
      unitRef="usd">470000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-6"
      id="d8336633e11332-wk-Fact-9F791EE0835763BF87F894757D6D6836"
      unitRef="usd">87886000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e11346-wk-Fact-F12EBCA49A1647F7C9C194757CB75C07"
      unitRef="shares">3840000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e11367-wk-Fact-A8241CECE526F96581AE94757CF0E2F1"
      unitRef="usd">-110978000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d8336633e11387-wk-Fact-DFF13E5F684FBEC9822394757D143E71"
      unitRef="usd">100203000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d8336633e11406-wk-Fact-0311E1C11EAA0D64120894757D282E1A"
      unitRef="usd">-13246000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e11427-wk-Fact-D2F433B8AA4C0088F7B694757DA65630"
      unitRef="usd">64336000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d8336633e11446-wk-Fact-E682A060B9E084CD78DB94757CBF7369"
      unitRef="usd">228000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8336633e11466-wk-Fact-39B247651891576D7B7A94757D210D60"
      unitRef="usd">64564000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="0"
      id="d8336633e12419-wk-Fact-7DD25CF4297877D69E8D94757CAEE705"
      unitRef="shares">478</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-6"
      id="d8336633e12438-wk-Fact-C4994D3207A335AAB81294757D8D7CB7"
      unitRef="usd">19000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d8336633e12452-wk-Fact-B058DCB1AE06D394D07494757D832A1B"
      unitRef="shares">9332000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d8336633e12472-wk-Fact-354E12AEFC04C5034D5B94757D921C80"
      unitRef="usd">467000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-6"
      id="d8336633e12491-wk-Fact-AAF16B56D807C054332894757CBC5D15"
      unitRef="usd">86253000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e12505-wk-Fact-7710E5E7409968676DDF94757CB9616B"
      unitRef="shares">3615000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e12526-wk-Fact-11CE3C1F979CA5EE8A3C94757CAC8219"
      unitRef="usd">-101610000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d8336633e12546-wk-Fact-25E3F63155D4E5079AF694757D939426"
      unitRef="usd">89554000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d8336633e12565-wk-Fact-FB658162A265137F4D2C94757D910349"
      unitRef="usd">-11275000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e12586-wk-Fact-C072E92255A07EC2BC3294757CB644FB"
      unitRef="usd">63407000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d8336633e12605-wk-Fact-FB4B7F31E75AF61C8C1B94757CB6CB4D"
      unitRef="usd">351000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4"
      decimals="-6"
      id="d8336633e12625-wk-Fact-C3BB46722B4E99BC08FB94757D912C94"
      unitRef="usd">63758000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d8336633e12772-wk-Fact-6A6B16B2145812FF4A4D94757D88E004"
      unitRef="usd">8929000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e12812-wk-Fact-FC6199412C81449DCEDC94757CB8CF8E"
      unitRef="usd">8929000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d8336633e12831-wk-Fact-044F5FDB0329BCA40A6794757CBD27D2"
      unitRef="usd">15000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8336633e12850-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9"
      unitRef="usd">8945000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d8336633e13021-wk-Fact-4F58C9049DEAAC5BA58594757CB32E71"
      unitRef="usd">-260000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e13042-wk-Fact-6D6F3CF5110AF0381DE894757D81F105"
      unitRef="usd">-260000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d8336633e13062-wk-Fact-41F806F874E498F7473D94757D8FFC10"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8336633e13082-wk-Fact-920C774D6C3160546F7D94757DA37E07"
      unitRef="usd">-262000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d8336633e13472-wk-Fact-97B0ABF7AD141BFC956394757D9158BA"
      unitRef="usd">4062000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e13513-wk-Fact-2D5D0BDDCB3AC167E0BC94757D826702"
      unitRef="usd">4062000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8336633e13553-wk-Fact-884749ED8C7327C2FD2094757D8E56E9"
      unitRef="usd">4062000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d8336633e13707-wk-Fact-D73A14317FBAE5FF36E694757CA8E1DF"
      unitRef="usd">1000000</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e13748-wk-Fact-24C95C268DFE3FCA16AE94757D94AA45"
      unitRef="usd">1000000</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8336633e13788-wk-Fact-56FFC68F0A60EB61A79194757CB4018F"
      unitRef="usd">1000000</us-gaap:DividendsPreferredStockCash>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d8336633e14002-wk-Fact-5D5C63A4F1FD671C14E194757CAF5BD0"
      unitRef="usd">8000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8336633e14022-wk-Fact-1361821B6A5511EF50EA94757CB26293"
      unitRef="usd">8000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d8336633e14084-wk-Fact-D10B00BA2429F63E86A694757CAB096A"
      unitRef="shares">31000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d8336633e14099-wk-Fact-3217AF55C96F288D0DBD94757CBAA3B1"
      unitRef="usd">2000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-6"
      id="d8336633e14118-wk-Fact-772E453E27BB5E8A941894757D862BB8"
      unitRef="usd">712000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e14137-wk-Fact-0EDCB34EA1247F2C3A2394757D8F0EC3"
      unitRef="shares">7000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e14153-wk-Fact-52053A7518B63417490094757CA936F0"
      unitRef="usd">-312000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e14214-wk-Fact-4BC9CEEA08F3A0DD592F94757CB7DE38"
      unitRef="usd">402000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8336633e14253-wk-Fact-46C30A88DFF3DBBC269A94757D92355F"
      unitRef="usd">402000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e14370-wk-Fact-892DE8B531A6E01C09E194757CBBECA5"
      unitRef="shares">180000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e14386-wk-Fact-CCC935C176C282D817B794757CBC059A"
      unitRef="usd">8865000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e14447-wk-Fact-9CEB92503A38A9B5DBE094757CB7FA3C"
      unitRef="usd">8865000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8336633e14487-wk-Fact-0401261FCCFCA256A06E94757CBC98A8"
      unitRef="usd">8865000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="0"
      id="d8336633e14514-wk-Fact-EFC543C17B8D59BB663F94757CAE19EF"
      unitRef="shares">20</pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-6"
      id="d8336633e14529-wk-Fact-25E53374D4007C779F5294757D853F4E"
      unitRef="usd">1000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-6"
      id="d8336633e14585-wk-Fact-7F0F15290F5E885CE3D794757CBEF8C8"
      unitRef="usd">1000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e14680-wk-Fact-AF977AD81CDE8A1EAB0994757CABF14E"
      unitRef="usd">2000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8336633e14720-wk-Fact-6CC9C84BFB612CF3CEE194757D856D94"
      unitRef="usd">2000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d8336633e14869-wk-Fact-6101468A882D99277B2994757CB9521F"
      unitRef="usd">-19000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e14907-wk-Fact-8376F4C46168FF741E3C94757D90B25B"
      unitRef="usd">-19000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8336633e14945-wk-Fact-E4A62043A54AC1E498B094757CACAA7C"
      unitRef="usd">-19000000</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesIssued
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="0"
      id="d8336633e14971-wk-Fact-D37856BCED8C1D2C7F3494757D99EE35"
      unitRef="shares">458</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-6"
      id="d8336633e14990-wk-Fact-FB813AC829F4A188FEBA94757D2D36C8"
      unitRef="usd">18000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d8336633e15004-wk-Fact-0C3EA3961095E3F8A34994757CCEFE8A"
      unitRef="shares">9363000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d8336633e15024-wk-Fact-ED5AE72D950E62950F0794757CE72E3D"
      unitRef="usd">468000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-6"
      id="d8336633e15043-wk-Fact-59A686060A7AF1F7275494757D530630"
      unitRef="usd">86963000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e15057-wk-Fact-427A772CBA10468F664594757D453976"
      unitRef="shares">3801000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d8336633e15078-wk-Fact-F6DA9F6F4CDC4D1208C294757D3DEB55"
      unitRef="usd">-110786000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d8336633e15098-wk-Fact-B00A363AE1BB1F3479D994757D183B47"
      unitRef="usd">94440000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d8336633e15117-wk-Fact-41A19ED1C18BA2C59FD594757CC95BFE"
      unitRef="usd">-11535000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8336633e15138-wk-Fact-C6B8B0E3BE0B6E14FCC394757D2F7284"
      unitRef="usd">59568000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d8336633e15157-wk-Fact-066E69F57B7DF80E550194757D597E52"
      unitRef="usd">357000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2"
      decimals="-6"
      id="d8336633e15177-wk-Fact-5570A8AC6555BCC3538194757CDE6165"
      unitRef="usd">59924000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e858-wk-Fact-F55F7448D6FD457E7D3094757CC42D99"
      unitRef="usd">6845000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e877-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9"
      unitRef="usd">8945000000</us-gaap:ProfitLoss>
    <pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e941-wk-Fact-7B3C46A754BAB4A857A994757D1275BE"
      unitRef="usd">2469000000</pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization>
    <pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e960-wk-Fact-A6719A6CE4DE88C80E8394757D222E89"
      unitRef="usd">3073000000</pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization>
    <pfe:AssetWriteOffsAndAssetImpairmentCharges
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e985-wk-Fact-D1A152F767D859E8CCE694757CBAD374"
      unitRef="usd">58000000</pfe:AssetWriteOffsAndAssetImpairmentCharges>
    <pfe:AssetWriteOffsAndAssetImpairmentCharges
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e1004-wk-Fact-D5D209CEACE094C3706A94757D602BEE"
      unitRef="usd">178000000</pfe:AssetWriteOffsAndAssetImpairmentCharges>
    <us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e1031-wk-Fact-E717A38DCA77168761C894757CC8AD9A"
      unitRef="usd">0</us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit>
    <us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e1050-wk-Fact-9485DE235A3009893D3694757CC67D4F"
      unitRef="usd">-285000000</us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit>
    <pfe:DeconsolidationGainLossAmountNetOfCashConveyed
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e1076-wk-Fact-4A938A8D8BA21B630E4F94757CBAE369"
      unitRef="usd">6000000</pfe:DeconsolidationGainLossAmountNetOfCashConveyed>
    <pfe:DeconsolidationGainLossAmountNetOfCashConveyed
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e1096-wk-Fact-B2C102786FCBB8D401A594757D1B8EEE"
      unitRef="usd">0</pfe:DeconsolidationGainLossAmountNetOfCashConveyed>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e1121-wk-Fact-7B3AE2978F7C733A20D394757D149216"
      unitRef="usd">71000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e1140-wk-Fact-31FAC3AF75C5A095FC3294757D6F298C"
      unitRef="usd">-160000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e1166-wk-Fact-B1D6C20091518E36CFA194757CC3358D"
      unitRef="usd">258000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e1185-wk-Fact-B42383D404EA70302F8C94757D686185"
      unitRef="usd">384000000</us-gaap:ShareBasedCompensation>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e1211-wk-Fact-6511CCFA698C5A19F60894757CB5C2AF"
      unitRef="usd">418000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e1231-wk-Fact-03C451138AD2D3E686ED94757CA8870B"
      unitRef="usd">313000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e1257-wk-Fact-902EBA952C8391060B6994757CB1FFC1"
      unitRef="usd">361000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e1277-wk-Fact-E385EE5548C3D0B6620294757D260E17"
      unitRef="usd">462000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInOperatingCapital
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e1303-wk-Fact-267AF4FFCF5DAE94DBAA94757CC00E91"
      unitRef="usd">2229000000</us-gaap:IncreaseDecreaseInOperatingCapital>
    <us-gaap:IncreaseDecreaseInOperatingCapital
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e1323-wk-Fact-A9E0B30BE08222818D3E94757CCA5EEE"
      unitRef="usd">7051000000</us-gaap:IncreaseDecreaseInOperatingCapital>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e1349-wk-Fact-C06B1B3B80ECC6BED32E94757D69AF05"
      unitRef="usd">6688000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e1368-wk-Fact-4FD042AF6C7E165B3EAF94757D1120B8"
      unitRef="usd">4309000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e1483-wk-Fact-CAC433338BBE1188257594757D6FCE44"
      unitRef="usd">942000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e1503-wk-Fact-B07226375662B3FA103594757D67E5BF"
      unitRef="usd">939000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e1529-wk-Fact-DBC68DCD2CB0DEC8D8FB94757D61B962"
      unitRef="usd">5141000000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e1549-wk-Fact-2F3BC9DA02E9792A81E594757D1AA1BE"
      unitRef="usd">4063000000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e1575-wk-Fact-648B9F5A2071A01EE88194757D23C23C"
      unitRef="usd">4595000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e1594-wk-Fact-C1DCC252D5C1E6770C2A94757D2726E3"
      unitRef="usd">6001000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e1621-wk-Fact-DEA22D82FF9A17E3E27894757D6F6298"
      unitRef="usd">11949000000</pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess>
    <pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e1641-wk-Fact-E3F1771420A95515D37594757D7358CA"
      unitRef="usd">-4717000000</pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e1666-wk-Fact-7DBB915490EEA28AD34F94757D1C965F"
      unitRef="usd">168000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e1686-wk-Fact-CB3CE131F76D1BC5C4AF94757D6BFF4D"
      unitRef="usd">123000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e1713-wk-Fact-69B15CEEDF1C91237BB494757CA88761"
      unitRef="usd">536000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e1732-wk-Fact-112070D1A1180C6F8D5194757D199924"
      unitRef="usd">142000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e1757-wk-Fact-BDC4E0314FD64F1F888394757D72DA26"
      unitRef="usd">33000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e1777-wk-Fact-A31D6CBE4C3463BD783494757D2A1AEA"
      unitRef="usd">267000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e1803-wk-Fact-44B0C90D865A67954DB694757D580795"
      unitRef="usd">-19000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e1822-wk-Fact-C7C942686CBC263C1D7194757CC2FF25"
      unitRef="usd">-179000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e1847-wk-Fact-5C2821D98F34452F3A6F94757D2D141F"
      unitRef="usd">-13082000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e1867-wk-Fact-715B435D745D4142E92394757CBCE93E"
      unitRef="usd">5648000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e1982-wk-Fact-78F2B6044F533AECF79494757D13E2F0"
      unitRef="usd">12352000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e2001-wk-Fact-F2E6F2C6A9C76A98DCDF94757D59E284"
      unitRef="usd">3956000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e2026-wk-Fact-483AF33471D66FEACAE994757D64E37B"
      unitRef="usd">13166000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e2046-wk-Fact-267FFBCE28C10DEF50F494757D2204BE"
      unitRef="usd">2375000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e2072-wk-Fact-3FC60AB14A091D74606194757D68E2E6"
      unitRef="usd">-2273000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e2092-wk-Fact-D6CFF981EC1FB58C377894757D2A6D00"
      unitRef="usd">2719000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e2119-wk-Fact-CCC6307773ADBF2D8B0394757D147293"
      unitRef="usd">16606000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e2138-wk-Fact-269B485E7EDA949BAD5F94757D657E36"
      unitRef="usd">4942000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e2163-wk-Fact-479C56CF0F843B8D425E94757CC58178"
      unitRef="usd">2181000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e2183-wk-Fact-68D0815BB8658ED83E2294757CBEB1FA"
      unitRef="usd">5355000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e2210-wk-Fact-DE8B64A6B5C352DD3FEB94757D21E4DC"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e2229-wk-Fact-2F9D078A1939922E232F94757CC0E69B"
      unitRef="usd">8865000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e2255-wk-Fact-84746CEAE1028754282894757D242276"
      unitRef="usd">4216000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e2275-wk-Fact-41DCE73B8353AB2C4A8294757CC7A0E2"
      unitRef="usd">4047000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e2301-wk-Fact-4825D5CD0C1E297EA03E94757D6ECCCE"
      unitRef="usd">158000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e2320-wk-Fact-9BECE1ABEA4FD6DB7B8A94757D65CB34"
      unitRef="usd">248000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e2345-wk-Fact-14555130D0BB52E432C294757D65777B"
      unitRef="usd">-321000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e2365-wk-Fact-68FD1EE0237F3359546394757CC70A3B"
      unitRef="usd">-541000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e2391-wk-Fact-0AB8223F29C3E844972694757CBD7239"
      unitRef="usd">6959000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e2410-wk-Fact-BFED46F6560D1E80618094757D5C3010"
      unitRef="usd">-9318000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e2436-wk-Fact-1C81E7C063C3183FB22C94757D26F7B6"
      unitRef="usd">-70000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e2456-wk-Fact-9509BBD7999258CA6CC694757D1611AA"
      unitRef="usd">-28000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e2482-wk-Fact-1DAA0E1B0E6665C79D5F94757CCA5C7B"
      unitRef="usd">495000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e2501-wk-Fact-7DFB45BE4A92C05A7CE494757D5BC48C"
      unitRef="usd">612000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8308070e2526-wk-Fact-669B95F4C67830F92DEA94757D66C77B"
      unitRef="usd">1350000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-6"
      id="d8308070e2545-wk-Fact-91CD03BF7899EC259FA294757CBB3C78"
      unitRef="usd">1225000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8308070e2575-wk-Fact-F181CF0072905CD126F394757D6959D8"
      unitRef="usd">1845000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q2"
      decimals="-6"
      id="d8308070e2594-wk-Fact-92C5E71226171D8AEF1294757CAFE14B"
      unitRef="usd">1837000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e2756-wk-Fact-C0AA245678498A8977C494757D60CCA2"
      unitRef="usd">1290000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e2775-wk-Fact-2F748880967716EA5ADE94757D1C1B2D"
      unitRef="usd">2136000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e2795-wk-Fact-B48CBE8AC02E90DAEA4594757D145DE6"
      unitRef="usd">910000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e2814-wk-Fact-4A7A8328763CC8358F7194757D1D40BA"
      unitRef="usd">809000000</us-gaap:InterestPaidNet>
    <pfe:InterestReceivedInterestRateHedges
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8308070e2839-wk-Fact-A62E7998A018A606CB9B94757D1FEF54"
      unitRef="usd">-66000000</pfe:InterestReceivedInterestRateHedges>
    <pfe:InterestReceivedInterestRateHedges
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e2859-wk-Fact-80889F71FE2525C70D9194757D2B8EDC"
      unitRef="usd">-72000000</pfe:InterestReceivedInterestRateHedges>
    <us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8308070e2910-wk-Fact-9485DE235A3009893D3694757CC67D4F"
      unitRef="usd">-285000000</us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="FD2020Q2QTD_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember"
      decimals="-8"
      id="d8308070e2937-wk-Fact-8877DD9876BC33FFFCE292DDB7C09E1E"
      unitRef="usd">11400000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-E1BD266DE2FA7BA8580994757DB6202A-0-wk-Fact-4AF9ADB3EED08BD12E8E94757CC45897">&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Basis of Presentation and Significant Accounting Policies&lt;/span&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;A. Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes in this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;May&#160;24, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;May&#160;26, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Financial Report.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At the beginning of our 2019 fiscal year, we began to manage our commercial operations through a new global structure consisting of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; business segments&#x2013;&#x2013;Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and through &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;July&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, Consumer Healthcare. Biopharma and Upjohn are the only reportable segments. For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 14&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan).&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As a result, revenues and expenses associated with Meridian and Mylan-Japan are reported in our Upjohn business beginning in the first quarter of 2020. In 2019, revenues and expenses from Meridian and Mylan-Japan were recorded in our Biopharma business. We performed certain reclassifications between the Biopharma and Upjohn segments to conform 2019 segment revenues and expenses associated with Meridian and Mylan-Japan to the current presentation. There was no impact to our consolidated financial statements.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 14.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Acquisitions and other business development activities completed in 2019 and in the first half of 2020, including the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture, impacted financial results in the periods presented.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span&gt;For additional information, see Notes to Consolidated Financial Statements&#x2014;&lt;/span&gt;&lt;span style="font-style:italic;"&gt;Note 1A. Basis of Presentation and Significant Accounting Policies: Basis of Presentation&lt;/span&gt;&lt;span&gt; in our 2019 Financial Report, and &lt;/span&gt;&lt;span style="font-style:italic;"&gt;Note 2&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In the first quarter of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, as of January 1, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we adopted &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; new accounting standards. See &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 1B&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for further information.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;B. &lt;/span&gt;&lt;span style="font-weight:bold;text-decoration:underline;"&gt;Adoption of New Accounting Standards in 2020&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On January 1, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we adopted &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; new accounting standards.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2013;&#x2013;We adopted a new accounting standard for credit losses on financial instruments, which replaces the probable initial recognition threshold for incurred loss estimates under prior guidance with a methodology that reflects expected credit loss estimates. The standard generally impacts financial assets that have a contractual right to receive cash and are not accounted for at fair value through net income, such as accounts receivable and held-to-maturity debt securities. The new guidance requires us to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for certain financial instruments, using information such as historical experience, current economic conditions and information, and the use of reasonable and supportable forecasted information. The standard also &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;amends existing impairment guidance for available-for-sale debt securities to incorporate a credit loss allowance and allows for reversals of credit impairments in the event the issuer&#x2019;s credit improves.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We adopted the new accounting standard utilizing the modified retrospective method and, therefore, no adjustments were made to amounts in our prior period financial statements. The cumulative effect of adopting the standard as an adjustment to the opening balance of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Retained earnings&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was not material. The impact of adoption did not have a material impact on our condensed consolidated statement of income for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; or condensed consolidated statement of cash flows for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, nor on our condensed consolidated balance sheet as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 1C&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Goodwill Impairment Testing&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2013;&#x2013;We prospectively adopted the new standard, which eliminates the requirement to perform a hypothetical purchase price allocation to measure goodwill impairment. Under the new guidance, the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount, and recognizing an impairment charge for the amount by which the carrying amount of the reporting unit exceeds its fair value. There was no impact to our condensed consolidated financial statements from the adoption of this new standard.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Implementation Costs in a Cloud Computing Arrangement&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2013;&#x2013;We prospectively adopted the new standard related to customers&#x2019; accounting for implementation costs incurred in a cloud computing arrangement that is considered a service contract. The new guidance aligns the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The adoption of this guidance did not have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Collaboration Agreements&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2013;&#x2013;We prospectively adopted the new standard, which provides new guidance clarifying the interaction between the accounting for collaborative arrangements and revenue from contracts with customers. There was no impact to our condensed consolidated financial statements from the adoption of this new standard.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On January 1, 2019, we adopted &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; new accounting standards. For additional information, see Notes to Consolidated Financial Statements&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2019 &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;included in our 2019 Financial Report.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;C. Revenues and Trade Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Deductions from Revenues&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides information about the balance sheet classification of these accruals:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:4px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Reserve against &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Trade accounts receivable, less allowance for doubtful accounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,129&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:4px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Other current liabilities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,210&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,285&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other accruals&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;576&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;581&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;598&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;565&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total accrued rebates and other accruals&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,512&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,689&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Trade Accounts Receivable&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Trade accounts receivable are stated at their net realizable value. The allowance for credit losses against gross trade accounts receivable reflects the best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-8BB7502059171F7F3C4094757DB61183-0-wk-Fact-69F6A976652BF56BDEEA94757CC3AAFF">Basis of Presentation&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes in this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;May&#160;24, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;May&#160;26, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Financial Report.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At the beginning of our 2019 fiscal year, we began to manage our commercial operations through a new global structure consisting of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; business segments&#x2013;&#x2013;Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and through &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;July&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, Consumer Healthcare. Biopharma and Upjohn are the only reportable segments. For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 14&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan).&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As a result, revenues and expenses associated with Meridian and Mylan-Japan are reported in our Upjohn business beginning in the first quarter of 2020. In 2019, revenues and expenses from Meridian and Mylan-Japan were recorded in our Biopharma business. We performed certain reclassifications between the Biopharma and Upjohn segments to conform 2019 segment revenues and expenses associated with Meridian and Mylan-Japan to the current presentation. There was no impact to our consolidated financial statements.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 14.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Acquisitions and other business development activities completed in 2019 and in the first half of 2020, including the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture, impacted financial results in the periods presented.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span&gt;For additional information, see Notes to Consolidated Financial Statements&#x2014;&lt;/span&gt;&lt;span style="font-style:italic;"&gt;Note 1A. Basis of Presentation and Significant Accounting Policies: Basis of Presentation&lt;/span&gt;&lt;span&gt; in our 2019 Financial Report, and &lt;/span&gt;&lt;span style="font-style:italic;"&gt;Note 2&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="D2019Q3Jan1-Jul31"
      decimals="INF"
      id="d8305411e780-wk-Fact-E7763423A0FDBAB3799A94757CC3EC7A"
      unitRef="Operating_Segment">3</us-gaap:NumberOfOperatingSegments>
    <pfe:NumberOfAccountingStandardsAdopted
      contextRef="I2020Q1Jan1"
      decimals="INF"
      id="d8305411e839-wk-Fact-4ED1B6A1CF428384FF4C94757CC3AA54"
      unitRef="Accounting_standard">4</pfe:NumberOfAccountingStandardsAdopted>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-7CC50CB94F4F1836879A94757DB62CA3-0-wk-Fact-4D3457EC6890D7C927BB94757CC54A08">&lt;span style="font-weight:bold;text-decoration:underline;"&gt;Adoption of New Accounting Standards in 2020&lt;/span&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On January 1, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we adopted &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; new accounting standards.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2013;&#x2013;We adopted a new accounting standard for credit losses on financial instruments, which replaces the probable initial recognition threshold for incurred loss estimates under prior guidance with a methodology that reflects expected credit loss estimates. The standard generally impacts financial assets that have a contractual right to receive cash and are not accounted for at fair value through net income, such as accounts receivable and held-to-maturity debt securities. The new guidance requires us to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for certain financial instruments, using information such as historical experience, current economic conditions and information, and the use of reasonable and supportable forecasted information. The standard also &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;amends existing impairment guidance for available-for-sale debt securities to incorporate a credit loss allowance and allows for reversals of credit impairments in the event the issuer&#x2019;s credit improves.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We adopted the new accounting standard utilizing the modified retrospective method and, therefore, no adjustments were made to amounts in our prior period financial statements. The cumulative effect of adopting the standard as an adjustment to the opening balance of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Retained earnings&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was not material. The impact of adoption did not have a material impact on our condensed consolidated statement of income for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; or condensed consolidated statement of cash flows for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, nor on our condensed consolidated balance sheet as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 1C&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Goodwill Impairment Testing&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2013;&#x2013;We prospectively adopted the new standard, which eliminates the requirement to perform a hypothetical purchase price allocation to measure goodwill impairment. Under the new guidance, the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount, and recognizing an impairment charge for the amount by which the carrying amount of the reporting unit exceeds its fair value. There was no impact to our condensed consolidated financial statements from the adoption of this new standard.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Implementation Costs in a Cloud Computing Arrangement&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2013;&#x2013;We prospectively adopted the new standard related to customers&#x2019; accounting for implementation costs incurred in a cloud computing arrangement that is considered a service contract. The new guidance aligns the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The adoption of this guidance did not have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Collaboration Agreements&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2013;&#x2013;We prospectively adopted the new standard, which provides new guidance clarifying the interaction between the accounting for collaborative arrangements and revenue from contracts with customers. There was no impact to our condensed consolidated financial statements from the adoption of this new standard.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On January 1, 2019, we adopted &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; new accounting standards. For additional information, see Notes to Consolidated Financial Statements&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2019 &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;included in our 2019 Financial Report.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;C. Revenues and Trade Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Deductions from Revenues&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides information about the balance sheet classification of these accruals:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:4px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Reserve against &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Trade accounts receivable, less allowance for doubtful accounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,129&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:4px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Other current liabilities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,210&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,285&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other accruals&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;576&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;581&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;598&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;565&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total accrued rebates and other accruals&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,512&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,689&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Trade Accounts Receivable&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Trade accounts receivable are stated at their net realizable value. The allowance for credit losses against gross trade accounts receivable reflects the best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <pfe:NumberOfAccountingStandardsAdopted
      contextRef="I2020Q1Jan1"
      decimals="INF"
      id="d8305411e862-wk-Fact-4ED1B6A1CF428384FF4C94757CC3AA54"
      unitRef="Accounting_standard">4</pfe:NumberOfAccountingStandardsAdopted>
    <pfe:NumberOfAccountingStandardsAdopted
      contextRef="I2019Q1Jan01"
      decimals="INF"
      id="d8305411e967-wk-Fact-3F0AFADB8C5F5A9A448C94757CC49AF8"
      unitRef="Accounting_standard">4</pfe:NumberOfAccountingStandardsAdopted>
    <pfe:RebatesAndDiscountsAccrual
      contextRef="FI2020Q2"
      decimals="-8"
      id="d8305411e995-wk-Fact-74056B78B0612109EF7094757CC5D9C0"
      unitRef="usd">5500000000</pfe:RebatesAndDiscountsAccrual>
    <pfe:RebatesAndDiscountsAccrual
      contextRef="FI2019Q4"
      decimals="-8"
      id="d8305411e1003-wk-Fact-8D3FE40E2EC5A09D209D94757CC3F970"
      unitRef="usd">5700000000</pfe:RebatesAndDiscountsAccrual>
    <pfe:ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-B6B09B0F56D7AD09960C94757DB61718-0-wk-Fact-4411AC0DD4256C93E76D94757CC3AF57">&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides information about the balance sheet classification of these accruals:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:4px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Reserve against &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Trade accounts receivable, less allowance for doubtful accounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,129&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:4px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Other current liabilities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,210&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,285&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other accruals&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;576&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;581&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;598&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;565&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total accrued rebates and other accruals&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,512&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,689&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</pfe:ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock>
    <pfe:RebatesAndDiscountsAccrual
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember"
      decimals="-6"
      id="d8305411e1140-wk-Fact-10512A2C50EB9E54210794757D042EAD"
      unitRef="usd">1129000000</pfe:RebatesAndDiscountsAccrual>
    <pfe:RebatesAndDiscountsAccrual
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember"
      decimals="-6"
      id="d8305411e1159-wk-Fact-C22F5A4B00C48E6E2C6794757D03D5BF"
      unitRef="usd">1257000000</pfe:RebatesAndDiscountsAccrual>
    <pfe:AccruedRebates
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-6"
      id="d8305411e1227-wk-Fact-52230EEF4B30BB42551E94757D059357"
      unitRef="usd">3210000000</pfe:AccruedRebates>
    <pfe:AccruedRebates
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-6"
      id="d8305411e1246-wk-Fact-FC0D1467FED43488377394757D067F69"
      unitRef="usd">3285000000</pfe:AccruedRebates>
    <pfe:OtherAccruals
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-6"
      id="d8305411e1271-wk-Fact-5D45C986E5309044F54094757D041546"
      unitRef="usd">576000000</pfe:OtherAccruals>
    <pfe:OtherAccruals
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-6"
      id="d8305411e1290-wk-Fact-6F3D79DAE47BD65700D394757D04FDB0"
      unitRef="usd">581000000</pfe:OtherAccruals>
    <pfe:RebatesAndDiscountsAccrual
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember"
      decimals="-6"
      id="d8305411e1315-wk-Fact-3B46D7493FD1D060E11394757D0669E0"
      unitRef="usd">598000000</pfe:RebatesAndDiscountsAccrual>
    <pfe:RebatesAndDiscountsAccrual
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember"
      decimals="-6"
      id="d8305411e1334-wk-Fact-5E20B65AD8FA8FA778AD94757D05EA97"
      unitRef="usd">565000000</pfe:RebatesAndDiscountsAccrual>
    <pfe:RebatesAndDiscountsAccrual
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8305411e1364-wk-Fact-6D53FDF95DA77A948DA694757D0531FD"
      unitRef="usd">5512000000</pfe:RebatesAndDiscountsAccrual>
    <pfe:RebatesAndDiscountsAccrual
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8305411e1383-wk-Fact-03FFCDBA53AB458CE1DC94757D03645E"
      unitRef="usd">5689000000</pfe:RebatesAndDiscountsAccrual>
    <pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-2771421B13C7460A0EBF94757DB79F23-0-wk-Fact-60CCE39456C7465BA0E394757D88F911">&lt;span style="font-weight:bold;text-decoration:underline;"&gt;Acquisition, Equity-Method Investment and Licensing Arrangements&lt;/span&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;A. &lt;/span&gt;&lt;span style="font-weight:bold;text-decoration:underline;"&gt;Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Array BioPharma Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;July&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$48&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share in cash. The total fair value of the consideration transferred for Array was approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$11.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, net of cash acquired). Array&#x2019;s portfolio includes Braftovi (encorafenib) and Mektovi (binimetinib). The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not yet been finalized.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;B. &lt;/span&gt;&lt;span style="font-weight:bold;text-decoration:underline;"&gt;Equity-Method Investment&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Formation of GSK Consumer Healthcare Joint Venture&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;July&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name. In exchange for contributing our Consumer Healthcare business to the joint venture, we received a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; equity stake in the new company and GSK owns the remaining &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;68%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Upon the closing of the transaction, we deconsolidated our Consumer Healthcare business and recognized a pre-tax gain of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$8.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, net of tax) in our fiscal third quarter of 2019 in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;(Gain) on completion of Consumer Healthcare JV transaction&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the difference in the fair value of our &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; equity stake in the new company and the carrying value of our Consumer Healthcare business. We may record additional adjustments to the gain in future periods, which we do not expect to have a material impact on our consolidated financial statements. Our financial results, and our Consumer Healthcare segment&#x2019;s operating results, for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; reflect three months of Consumer Healthcare segment operations&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;and for&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;the first six months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;2019 reflect six months of Consumer Healthcare segment operations,&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; while financial results for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;and first&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; do not reflect any contribution from the Consumer Healthcare business.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We are accounting for our interest in GSK Consumer Healthcare as an equity-method investment. The carrying value of our&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;investment in GSK Consumer Healthcare is approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$15.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$17.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and is reported as a private equity investment in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Equity-method investments &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;line in our condensed consolidated balance sheet. We record our share of earnings from the GSK Consumer Healthcare joint venture on a quarterly basis on a one-quarter lag in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; commencing from August 1, 2019. Therefore, we recorded our share of the joint venture&#x2019;s earnings generated in the first quarter of 2020, which totaled approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$129 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, in our operating results in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Our total share of the joint venture&#x2019;s earnings generated in the fourth quarter of 2019 and the first quarter of 2020, which we recorded in our operating results for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the first six months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, was approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$140 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. See &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. As of the July 31, 2019 closing date, we estimated that the fair value of our investment in GSK Consumer Healthcare was approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$15.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and that &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the underlying equity in the carrying value of the net assets of GSK Consumer Healthcare was approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$11.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, resulting in an initial basis difference of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. In the fourth quarter of 2019, we preliminarily completed the allocation of the basis difference, which resulted from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the joint venture, primarily to inventory, definite-lived intangible assets, indefinite-lived intangible assets, related deferred tax liabilities and equity method goodwill within the investment account. We recorded the amortization of basis differences allocated to inventory, definite-lived intangible assets and related deferred tax liabilities in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; commencing August 1, 2019. During the fourth quarter of 2019, GSK Consumer Healthcare revised the initial carrying value of the net assets of the joint venture and our &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; share of the underlying equity in the carrying value of the net assets of GSK Consumer Healthcare was reduced to approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$11.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and our initial basis difference was increased to approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The adjustment was allocated to equity method goodwill within the investment account. The amortization of these basis differences for the first quarter of 2020 totaling approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of expense is included in our operating results in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;in&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The total amortization of these basis differences for the fourth quarter of 2019 and the first quarter of 2020, which was included in our operating results in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the first six months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, was approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$48 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of expense. See &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 4. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization of &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;basis differences on inventory and related deferred tax liabilities has been completely recognized by the second quarter of 2020. Basis differences on definite-lived intangible assets and related deferred tax liabilities are being amortized over the lives of the underlying assets, which range from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. GSK Consumer Healthcare is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;decrease&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in the value of our investment from December 31, 2019 to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is primarily due to approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in pre-tax foreign currency translation adjustments (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 6&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;), as well as a dividend of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$519 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which was received from the GSK Consumer Healthcare joint venture in June 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As a part of Pfizer, pre-tax income on a management business unit basis for the Consumer Healthcare business was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$274 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$554 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.05068226120858%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:77%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Summarized financial information for our equity method investee, GSK Consumer Healthcare, as of and for the three and six months ending March 31, 2020, the most recent period available, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March 31, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,213&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37,627&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;45,840&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,524&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,677&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Equity attributable to shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,031&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Equity attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total net equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,163&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.05068226120858%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:54%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Three Months Ended March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Six Months Ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,503&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,691&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,394&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,205&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross profit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,109&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,486&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income from continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;425&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;425&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income attributable to shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;405&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;441&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;C. &lt;/span&gt;&lt;span style="font-weight:bold;text-decoration:underline;"&gt;Licensing Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Agreement with Valneva SE&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;April&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we signed an agreement to co-develop and commercialize Valneva&#x2019;s Lyme disease vaccine candidate VLA15. VLA15 is the only active Lyme disease vaccine program in clinical development today, and covers six serotypes that are prevalent in North America and Europe. Valneva and Pfizer will work closely together throughout the development of VLA15. Valneva is eligible to receive a total of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$308 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in cash payments consisting of a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$130 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; upfront payment, which was paid and recorded in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Research and development expenses &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;in our fiscal second quarter of 2020, as well as &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$35 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in development milestones and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$143 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in early commercialization milestones. Under the terms of the agreement, Valneva will fund &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of all development costs through completion of the development program, and in return we will pay Valneva tiered royalties. We will lead late-stage development and have sole control over commercialization.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Agreement with BioNTech SE&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;April&#160;9, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we signed a global agreement with BioNTech to co-develop a potential first-in-class, mRNA-based coronavirus vaccine program, BNT162, aimed at preventing COVID-19 infection. The collaboration aims to rapidly advance multiple COVID-19 vaccine candidates into human clinical testing based on BioNTech&#x2019;s proprietary mRNA vaccine platforms, with the objective of ensuring rapid worldwide access to the vaccine, if approved. The collaboration will leverage our broad expertise in vaccine R&amp;amp;D, regulatory capabilities, and global manufacturing and distribution network. In connection with the agreement, we paid BioNTech an upfront cash payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$72 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which was recorded in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Research and development expenses &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;in our fiscal second quarter of 2020, and we made an equity investment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$113 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in common stock of BioNTech. BioNTech is eligible to receive potential future milestone payments of up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$563 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for a total consideration of &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$748 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. While Pfizer and BioNTech will share development costs equally if the vaccine is approved and successfully commercialized, Pfizer will be responsible for all of the development costs until commercialization of the vaccine. Thereafter, BioNTech would repay Pfizer its &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50 percent&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; share of these development costs through reductions in gross profit sharing and milestone payments to BioNTech over time. BioNTech and Pfizer will also work jointly to commercialize the vaccine worldwide (excluding China, which is subject to a separate collaboration between BioNTech and Shanghai Fosun Pharmaceutical (Group) Co., Ltd) if development is successful and regulatory approval is obtained. We made an additional investment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$50 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in common stock of BioNTech as part of an underwritten equity offering by BioNTech, which closed in July 2020 in our fiscal third quarter of 2020.&lt;/span&gt;&lt;/div&gt;</pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember"
      decimals="INF"
      id="d8302032e719-wk-Fact-3B7CF3078C2C97E5B55894757D8885E8"
      unitRef="usdPerShare">48</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="D2019Q3Jul30-Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember"
      decimals="-8"
      id="d8302032e723-wk-Fact-9688C7D5006E3F63EA6E94757D89E7FC"
      unitRef="usd">11200000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="D2019Q3Jul30-Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember"
      decimals="-8"
      id="d8302032e727-wk-Fact-4C3F3AFBD3CBFE139E4D94757D89A634"
      unitRef="usd">10900000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="2"
      id="d8302032e749-wk-Fact-923536071B10D741FA9C94757D85FCA9"
      unitRef="number">0.32</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="I2019Q3Jul31_dei_LegalEntityAxis_pfe_GSKMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="2"
      id="d8302032e753-wk-Fact-3638E46AA0F8C173472594757D8C98B4"
      unitRef="number">0.68</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-8"
      id="d8302032e757-wk-Fact-C6406BA65157010AD90494757D8B1E4E"
      unitRef="usd">8100000000</us-gaap:DeconsolidationGainOrLossAmount>
    <pfe:DeconsolidationGainLossAmountNetOfTax
      contextRef="FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-8"
      id="d8302032e761-wk-Fact-632DBB6A57751E7AADD894757D88AADE"
      unitRef="usd">5400000000</pfe:DeconsolidationGainLossAmountNetOfTax>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="2"
      id="d8302032e770-wk-Fact-923536071B10D741FA9C94757D85FCA9"
      unitRef="number">0.32</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2020Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-8"
      id="d8302032e823-wk-Fact-534D98444857F49F204094757D88F403"
      unitRef="usd">15400000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-8"
      id="d8302032e831-wk-Fact-1ED723775ACC5C8A35DA94757D8995B3"
      unitRef="usd">17000000000.0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d8302032e848-wk-Fact-35111911F7F1C01D532E94757D8BB804"
      unitRef="usd">129000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d8302032e869-wk-Fact-CF98C918B1FD647F8163596FD20366C9"
      unitRef="usd">140000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-8"
      id="d8302032e877-wk-Fact-74F5A63BAFC58E7A74C794757D8A4E69"
      unitRef="usd">15700000000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="2"
      id="d8302032e881-wk-Fact-923536071B10D741FA9C94757D85FCA9"
      unitRef="number">0.32</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets
      contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-8"
      id="d8302032e886-wk-Fact-F2EFF4229B0DB1A000BE94757D8705DB"
      unitRef="usd">11200000000</us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-8"
      id="d8302032e890-wk-Fact-9F171483A009A8689B7494757D88C84E"
      unitRef="usd">4500000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="2"
      id="d8302032e898-wk-Fact-923536071B10D741FA9C94757D85FCA9"
      unitRef="number">0.32</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-8"
      id="d8302032e902-wk-Fact-A55474F99E0F2AF6917794757D8C49C6"
      unitRef="usd">11000000000.0</us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-8"
      id="d8302032e906-wk-Fact-7008CF61FF0FA949279D94757D8AC958"
      unitRef="usd">4800000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <pfe:EquityMethodInvestmentExcessBasisAmortization
      contextRef="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d8302032e911-wk-Fact-17A4AF4B11945BBDB47294757D874363"
      unitRef="usd">4000000</pfe:EquityMethodInvestmentExcessBasisAmortization>
    <pfe:EquityMethodInvestmentExcessBasisAmortization
      contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d8302032e940-wk-Fact-FB81F282C8061B0BD248596860BF46DA"
      unitRef="usd">48000000</pfe:EquityMethodInvestmentExcessBasisAmortization>
    <pfe:EquityMethodInvestmentExcessBasisAmortizationPeriod
      contextRef="FD2020Q2YTD_srt_RangeAxis_srt_MinimumMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      id="d8302032e951-wk-Fact-BB67015EAA9964FC846C79339BCE6373">P6Y</pfe:EquityMethodInvestmentExcessBasisAmortizationPeriod>
    <pfe:EquityMethodInvestmentExcessBasisAmortizationPeriod
      contextRef="FD2020Q2YTD_srt_RangeAxis_srt_MaximumMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      id="d8302032e955-wk-Fact-D88B17FB8BC382BCAC7894757D8A021A">P20Y</pfe:EquityMethodInvestmentExcessBasisAmortizationPeriod>
    <pfe:EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation
      contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-8"
      id="d8302032e972-wk-Fact-B5BFC10FBD677AADEEAB5E4E6E80CBE3"
      unitRef="usd">-1100000000</pfe:EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="D2020Q2Jun1-28_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d8302032e980-wk-Fact-CEC9202BBFBA0680D58E5E4934805AA6"
      unitRef="usd">519000000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <pfe:DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss
      contextRef="FD2019Q2QTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d8302032e1060-wk-Fact-5E6EE1EC31AF006B10B394757D8A38B1"
      unitRef="usd">274000000</pfe:DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss>
    <pfe:DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss
      contextRef="FD2019Q2YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d8302032e1072-wk-Fact-962139B23FDF72F0728C955D6E007AD2"
      unitRef="usd">554000000</pfe:DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-7D37DC0F77D0555B705F94757DB61FCD-0-wk-Fact-C06EEAAB58F0373F802894757D87D5B4">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.05068226120858%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:77%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Summarized financial information for our equity method investee, GSK Consumer Healthcare, as of and for the three and six months ending March 31, 2020, the most recent period available, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March 31, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,213&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37,627&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;45,840&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,524&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,677&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Equity attributable to shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,031&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Equity attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total net equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,163&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.05068226120858%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:54%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Three Months Ended March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Six Months Ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,503&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,691&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,394&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,205&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross profit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,109&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,486&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income from continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;425&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;425&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income attributable to shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;405&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;441&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:AssetsCurrent
      contextRef="I2020Q2Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d8302032e1169-wk-Fact-BD6650750B49E38F1BD694757DA1B96E"
      unitRef="usd">8213000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="I2020Q2Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d8302032e1189-wk-Fact-2E96A5AE76D12A2A44E894757D9FBC46"
      unitRef="usd">37627000000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="I2020Q2Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d8302032e1219-wk-Fact-F3872A27A7CDFD4E71F294757DA0EF87"
      unitRef="usd">45840000000</us-gaap:Assets>
    <us-gaap:LiabilitiesCurrent
      contextRef="I2020Q2Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d8302032e1270-wk-Fact-8744AD2F441C0FD2719394757DA0261A"
      unitRef="usd">5524000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="I2020Q2Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d8302032e1290-wk-Fact-F8A2CA4DF6FC65A31AAB94757DA2B97A"
      unitRef="usd">5152000000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="I2020Q2Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d8302032e1320-wk-Fact-23970D49D92D797BCAC194757DA016DB"
      unitRef="usd">10677000000</us-gaap:Liabilities>
    <us-gaap:StockholdersEquity
      contextRef="I2020Q2Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d8302032e1371-wk-Fact-77F8A3C973FF1BC63CB894757D9FE048"
      unitRef="usd">35031000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="I2020Q2Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d8302032e1392-wk-Fact-0F9D4325CE6DF69F5FC794757DA1AD23"
      unitRef="usd">133000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2020Q2Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d8302032e1422-wk-Fact-181ACBA773F2BD3296D794757DA05DF4"
      unitRef="usd">35163000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:Revenues
      contextRef="D2020Q2Jan1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d8302032e1510-wk-Fact-8B7D97748BECD855AC4294757D425CB1"
      unitRef="usd">3503000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="D2020Q2Oct1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d8302032e1529-wk-Fact-230BFF8F7536A1E2C3C259652FBAE6D8"
      unitRef="usd">6691000000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="D2020Q2Jan1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d8302032e1549-wk-Fact-7CFB77353A6D493129C194757D410F81"
      unitRef="usd">1394000000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="D2020Q2Oct1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d8302032e1569-wk-Fact-7BCDF0748EC9489D86BA596531159DDC"
      unitRef="usd">3205000000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="D2020Q2Jan1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d8302032e1600-wk-Fact-E91F453C2EB917CE78F494757D4210EC"
      unitRef="usd">2109000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="D2020Q2Oct1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d8302032e1619-wk-Fact-509C963AEDDB4A3BC16D596532BE05CD"
      unitRef="usd">3486000000</us-gaap:GrossProfit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="D2020Q2Jan1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d8302032e1639-wk-Fact-B9D541C3B888CD647C9294757D4160D6"
      unitRef="usd">425000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="D2020Q2Oct1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d8302032e1658-wk-Fact-6472BE53B0F023B4060459653454BDC9"
      unitRef="usd">471000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="D2020Q2Jan1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d8302032e1683-wk-Fact-DC5193E7F7CCB9B8399494757D42FBFE"
      unitRef="usd">425000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D2020Q2Oct1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d8302032e1702-wk-Fact-DC267EA5300FF89BDC25596535E4AED6"
      unitRef="usd">471000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2020Q2Jan1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d8302032e1727-wk-Fact-6B8672F42AD20E9A05B594757D424936"
      unitRef="usd">405000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2020Q2Oct1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d8302032e1746-wk-Fact-33DF8D0157C77FF21068596537AA9905"
      unitRef="usd">441000000</us-gaap:NetIncomeLoss>
    <pfe:ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1
      contextRef="I2020Q2Apr30_srt_CounterpartyNameAxis_pfe_ValnevaSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="-6"
      id="d8302032e1776-wk-Fact-CF1D1EAA5DFFB410710E599315B3AC09"
      unitRef="usd">308000000</pfe:ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1>
    <pfe:PaymentForLicensingArrangement
      contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_pfe_ValnevaSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-6"
      id="d8302032e1780-wk-Fact-8E238C10486452CF3D09598280E84FD3"
      unitRef="usd">130000000</pfe:PaymentForLicensingArrangement>
    <pfe:ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure
      contextRef="I2020Q2Apr30_srt_CounterpartyNameAxis_pfe_ValnevaSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="-6"
      id="d8302032e1788-wk-Fact-2733350B2DACC996A0D7599956D0D18A"
      unitRef="usd">35000000</pfe:ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure>
    <pfe:ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure
      contextRef="I2020Q2Apr30_srt_CounterpartyNameAxis_pfe_ValnevaSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="-6"
      id="d8302032e1793-wk-Fact-993C8C7240EDCA4A29EE599C5A5C89A7"
      unitRef="usd">143000000</pfe:ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure>
    <pfe:ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage
      contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_pfe_ValnevaSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="2"
      id="d8302032e1797-wk-Fact-75E701D64E989BEC52F859AFEA3015A3"
      unitRef="number">0.30</pfe:ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage>
    <pfe:PaymentForLicensingArrangement
      contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_pfe_BioNTechSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-6"
      id="d8302032e1811-wk-Fact-EFBFCC97311C8789023B59BE7193DA52"
      unitRef="usd">72000000</pfe:PaymentForLicensingArrangement>
    <pfe:LicensingArrangementValueOfSharesPurchased
      contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_pfe_BioNTechSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="-6"
      id="d8302032e1819-wk-Fact-EC82D6293102A225E84C5A51735B8A05"
      unitRef="usd">113000000</pfe:LicensingArrangementValueOfSharesPurchased>
    <pfe:ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure
      contextRef="I2020Q2Apr9_srt_CounterpartyNameAxis_pfe_BioNTechSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="-6"
      id="d8302032e1823-wk-Fact-70E8C2166B9CBC5236F15A323FA672AF"
      unitRef="usd">563000000</pfe:ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure>
    <pfe:ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1
      contextRef="I2020Q2Apr9_srt_CounterpartyNameAxis_pfe_BioNTechSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="-6"
      id="d8302032e1828-wk-Fact-730FE25CAE8F28A2B32A59C2853A6479"
      unitRef="usd">748000000</pfe:ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1>
    <pfe:ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed
      contextRef="D2020Q2Apr9-9_srt_CounterpartyNameAxis_pfe_BioNTechSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="2"
      id="d8302032e1832-wk-Fact-3FEB43AAAF175E5DEB2A5A556CB430BA"
      unitRef="number">0.50</pfe:ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed>
    <pfe:LicensingArrangementValueOfSharesPurchased
      contextRef="D2020Q3Jul1-31_srt_CounterpartyNameAxis_pfe_BioNTechSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="-6"
      id="d8302032e1836-wk-Fact-A1B7E8A165028C93312692E0ECD772A0"
      unitRef="usd">50000000</pfe:LicensingArrangementValueOfSharesPurchased>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-7FA28E1BF698ADFB2C6E94757DB8599C-0-wk-Fact-6B1D7E9364894BE5981494757D6A75FD">&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives&lt;/span&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For example: &lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and R&amp;amp;D, as well as groups such as information technology, shared services and corporate operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Transforming to a More Focused Company Program&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;With the formation of the GSK Consumer Healthcare joint venture and the anticipated combination of Upjohn, our global, primarily off-patent branded and generics business, with Mylan, Pfizer is transforming itself into a more focused, global leader in science-based innovative medicines.&#160;As a result, we began in the fourth quarter of 2019, to identify and undertake efforts to ensure our cost base aligns appropriately with our Biopharmaceutical revenue base as a result of both the completed GSK Consumer Healthcare and expected Upjohn transactions.&#160;While certain direct costs have transferred or will transfer to the GSK Consumer Healthcare joint venture and to the Upjohn entities, there are indirect costs which are not expected to transfer. In addition, we are taking steps to restructure our organizations to appropriately support and drive the purpose of the three core functions of our focused innovative medicines business: R&amp;amp;D, Manufacturing and Commercial.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We expect the costs associated with this multi-year program to be incurred from 2020 through 2022 and to total approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on a pre-tax basis, with substantially all of the costs to be cash expenditures. Actions may include, among others, changes in location of certain activities, expanded use and co-location of centers of excellence and shared services, and increased use of digital technologies. The associated actions and the specific costs will primarily include severance and benefit plan impacts, exit costs as well as associated implementation costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Also as part of this program, in connection with the legacy cost reduction initiatives, primarily related to manufacturing activities, we expect to incur costs of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$400 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, with approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the costs to be non-cash. The costs associated with this effort are expected to be incurred from 2020 through 2022, and will primarily include implementation costs, product transfer costs, exit costs, as well as accelerated depreciation. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;From the start of this program in the fourth quarter of 2019 through &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we incurred approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$549 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; associated with this program.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Current-Period Key Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For the first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we incurred costs of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$566 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; composed primarily of the Transforming to a More Focused Company program. For the first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of 2019, we incurred costs of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$32 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; composed of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$180 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; associated with the 2017-2019 and Organizing for Growth initiatives, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$51 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; associated with the integration of Hospira, and income of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$199 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; primarily due to the reversal of certain accruals upon the effective favorable settlement of an IRS audit for multiple tax years and other acquisition-related initiatives.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:Arial;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Six Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restructuring charges/(credits):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Arial;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Arial;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Employee terminations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;346&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(166&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(167&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset impairments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exit costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restructuring charges&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;340&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(144&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;396&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(134&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Transaction costs&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Integration costs and other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;362&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;431&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net periodic benefit costs recorded in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Additional depreciation&#x2013;&#x2013;asset restructuring&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#160;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;recorded in our condensed consolidated statements of income as follows&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total additional depreciation&#x2013;&#x2013;asset restructuring&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Implementation costs recorded in our condensed consolidated statements of income as follows&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;78&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total implementation costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total costs associated with acquisitions and cost-reduction/productivity initiatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;449&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;566&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and first six months of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, restructuring charges mainly represent employee termination costs associated with our Transforming to a More Focused Company cost reduction program. In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, restructuring credits mostly represent the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of an IRS audit for multiple tax years. See Notes to Consolidated Financial Statements&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 5D. Tax Matters: Tax Contingencies &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;in our 2019 Financial Report.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:1px;padding-top:2px;padding-left:24px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The restructuring activities for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; are associated with the following:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, Biopharma (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$12 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; credit); Upjohn (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; credit); and Other (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$352 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; charge).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;For the first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, Biopharma (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; credit); Upjohn (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$12 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; charge); and Other (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$393 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; charge).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:1px;padding-left:12px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The restructuring activities for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; are associated with the following:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, Biopharma (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$62 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; credit); Upjohn (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; credit); and Other (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$74 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; credit).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;For the first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, Biopharma (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$48 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; credit); Upjohn (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$22 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; credit); and Other (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$63 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; credit).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:12px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Restructuring costs identified as Other are for restructuring activities associated with corporate enabling functions, WRDM, GPD and other manufacturing and commercial operations, as applicable. For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, restructuring costs identified as Other primarily relate to corporate enabling functions.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Transaction costs represent external costs for banking, legal, accounting and other similar services.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Integration costs and other represent external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, integration costs and other were mostly related to our acquisition of Array. In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, integration costs and other were primarily related to our acquisition of Hospira.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Additional depreciation&#x2013;&#x2013;asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.05068226120858%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of and changes in our restructuring accruals:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Employee&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Termination&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Asset&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Charges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Exit Costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Accrual&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;887&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;396&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Utilization and other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(341&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(378&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Balance, June 28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;918&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;951&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Other current liabilities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$714 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;) and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$219 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Includes adjustments for foreign currency translation.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Other current liabilities &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$625 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;) and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Other noncurrent liabilities &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$326 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;).&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="FI2020Q2_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember"
      decimals="-8"
      id="d8312059e735-wk-Fact-3044648FBF0869E18E3D94757D690C20"
      unitRef="usd">1200000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="FI2020Q2_us-gaap_RestructuringCostAndReserveAxis_pfe_ManufacturingCostReductionMember_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember"
      decimals="-6"
      id="d8312059e742-wk-Fact-8CEB189489541EA402C392E3F246022C"
      unitRef="usd">400000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <pfe:RestructuringandRelatedCostNoncashChargesPercentage
      contextRef="FD2020Q2YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_ManufacturingCostReductionMember_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember"
      decimals="2"
      id="d8312059e746-wk-Fact-2048BE2E605F41EAFDC792E8102BD13E"
      unitRef="number">0.20</pfe:RestructuringandRelatedCostNoncashChargesPercentage>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="D2020Q2Oct1-Jun28_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember"
      decimals="-6"
      id="d8312059e758-wk-Fact-71E37D7C4239114B57BC94757D688F90"
      unitRef="usd">549000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="FD2020Q2YTD_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember"
      decimals="-6"
      id="d8312059e776-wk-Fact-9EE2124DE8C10D3059A894757D6C98F4"
      unitRef="usd">566000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8312059e784-wk-Fact-2A534AEA1951A5F2C0C894757D678690"
      unitRef="usd">32000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="FD2019Q2YTD_us-gaap_RestructuringPlanAxis_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember"
      decimals="-6"
      id="d8312059e789-wk-Fact-8BAE85BFD1B5B8B966645E5EEC6A6155"
      unitRef="usd">180000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RestructuringCostAndReserveAxis_pfe_BusinessIntegrationCostsMember"
      decimals="-6"
      id="d8312059e793-wk-Fact-F96984E379A064B8E7D35E5F2BC626FB"
      unitRef="usd">51000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="FD2019Q2YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_BusinessIntegrationCostsMember"
      decimals="-6"
      id="d8312059e797-wk-Fact-741446EAC586E57B9EED5E619FA50919"
      unitRef="usd">-199000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-19802FF900512064EAC594757DB8DA56-0-wk-Fact-601C5DF99DAD43FCA07594757D67D3AB">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:Arial;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Six Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restructuring charges/(credits):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Arial;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Arial;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Employee terminations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;346&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(166&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(167&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset impairments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exit costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restructuring charges&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;340&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(144&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;396&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(134&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Transaction costs&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Integration costs and other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;362&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;431&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net periodic benefit costs recorded in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Additional depreciation&#x2013;&#x2013;asset restructuring&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#160;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;recorded in our condensed consolidated statements of income as follows&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total additional depreciation&#x2013;&#x2013;asset restructuring&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Implementation costs recorded in our condensed consolidated statements of income as follows&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;78&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total implementation costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total costs associated with acquisitions and cost-reduction/productivity initiatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;449&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;566&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and first six months of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, restructuring charges mainly represent employee termination costs associated with our Transforming to a More Focused Company cost reduction program. In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, restructuring credits mostly represent the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of an IRS audit for multiple tax years. See Notes to Consolidated Financial Statements&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 5D. Tax Matters: Tax Contingencies &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;in our 2019 Financial Report.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:1px;padding-top:2px;padding-left:24px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The restructuring activities for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; are associated with the following:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, Biopharma (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$12 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; credit); Upjohn (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; credit); and Other (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$352 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; charge).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;For the first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, Biopharma (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; credit); Upjohn (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$12 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; charge); and Other (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$393 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; charge).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:1px;padding-left:12px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The restructuring activities for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; are associated with the following:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, Biopharma (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$62 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; credit); Upjohn (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; credit); and Other (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$74 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; credit).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;For the first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, Biopharma (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$48 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; credit); Upjohn (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$22 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; credit); and Other (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$63 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; credit).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:12px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Restructuring costs identified as Other are for restructuring activities associated with corporate enabling functions, WRDM, GPD and other manufacturing and commercial operations, as applicable. For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, restructuring costs identified as Other primarily relate to corporate enabling functions.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Transaction costs represent external costs for banking, legal, accounting and other similar services.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Integration costs and other represent external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, integration costs and other were mostly related to our acquisition of Array. In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, integration costs and other were primarily related to our acquisition of Hospira.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Additional depreciation&#x2013;&#x2013;asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8312059e1193-wk-Fact-A8FBB11639AD83895C4894757CDEA58B"
      unitRef="usd">346000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8312059e1212-wk-Fact-7D82876FC21450C441F094757CE0617F"
      unitRef="usd">-166000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8312059e1233-wk-Fact-4BFF46406B679E0E244394757D43CFE3"
      unitRef="usd">371000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8312059e1252-wk-Fact-C9858E63429CB08F8D3494757D394EAE"
      unitRef="usd">-167000000</us-gaap:SeveranceCosts1>
    <pfe:RestructuringAssetImpairmentCharges
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8312059e1273-wk-Fact-C868499F38EA8FF492E494757CDAFCD5"
      unitRef="usd">-8000000</pfe:RestructuringAssetImpairmentCharges>
    <pfe:RestructuringAssetImpairmentCharges
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8312059e1293-wk-Fact-E7AD67D5365008E93D0894757CE22B3E"
      unitRef="usd">-9000000</pfe:RestructuringAssetImpairmentCharges>
    <pfe:RestructuringAssetImpairmentCharges
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8312059e1313-wk-Fact-32CED524A743CA91703C94757CEB29A2"
      unitRef="usd">23000000</pfe:RestructuringAssetImpairmentCharges>
    <pfe:RestructuringAssetImpairmentCharges
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8312059e1333-wk-Fact-1AA9902274635EAEF3A494757CF00987"
      unitRef="usd">0</pfe:RestructuringAssetImpairmentCharges>
    <us-gaap:BusinessExitCosts1
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8312059e1358-wk-Fact-D6E7AF49487BBF1CE4B094757CDCAEFE"
      unitRef="usd">1000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8312059e1377-wk-Fact-25C401F2C40DB5B7A09E94757CE4D3D3"
      unitRef="usd">31000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8312059e1396-wk-Fact-821797DEB7FD7085AAE994757CED2C67"
      unitRef="usd">1000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8312059e1416-wk-Fact-4070C352C0113B782C2494757D4564CA"
      unitRef="usd">34000000</us-gaap:BusinessExitCosts1>
    <us-gaap:RestructuringCharges
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8312059e1443-wk-Fact-9D9F803549723F3037FC94757CE1E2E0"
      unitRef="usd">340000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8312059e1462-wk-Fact-E911ACF0DB03AEB6DA8594757CE5E26F"
      unitRef="usd">-144000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8312059e1482-wk-Fact-DD70750D757F8E36AEFE94757D511014"
      unitRef="usd">396000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8312059e1502-wk-Fact-2A97CB7CBC5000EECE0F94757CE3B4C8"
      unitRef="usd">-134000000</us-gaap:RestructuringCharges>
    <pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8312059e1530-wk-Fact-E0F430906659E697076D94757CE4D373"
      unitRef="usd">11000000</pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts>
    <pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8312059e1549-wk-Fact-DEE82D8D87D1D1AA50F194757CE0C55D"
      unitRef="usd">0</pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts>
    <pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8312059e1568-wk-Fact-348F989B829127D79CF794757D4C6631"
      unitRef="usd">14000000</pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts>
    <pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8312059e1588-wk-Fact-6F4079F311DB52E2A33594757D365375"
      unitRef="usd">0</pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8312059e1615-wk-Fact-CD30CA356357FE6A950B94757CE59164"
      unitRef="usd">11000000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8312059e1634-wk-Fact-F7DAC00A60C60846547B94757CE11E6F"
      unitRef="usd">29000000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8312059e1653-wk-Fact-C9BE48676477EEA3C2DA94757CE814D1"
      unitRef="usd">21000000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8312059e1673-wk-Fact-1AB5EE46A517FE80526894757CDD6A28"
      unitRef="usd">64000000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8312059e1698-wk-Fact-7E093B7D90D64F5B13A494757D3BA82F"
      unitRef="usd">362000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8312059e1717-wk-Fact-788604D6690A503EC72D94757D52CBCB"
      unitRef="usd">-115000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8312059e1737-wk-Fact-BB8522BC4D5C3EA5BD8694757CB166F6"
      unitRef="usd">431000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8312059e1757-wk-Fact-C8984FE48C4ADA9BA0CA94757CCB4FED"
      unitRef="usd">-69000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d8312059e1786-wk-Fact-AF06A50586873888380194757CE6EDA3"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d8312059e1805-wk-Fact-81D3D22CEB2AD8305E7C94757CDB83C9"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d8312059e1824-wk-Fact-42CF5714248F45F16C4994757D4AE685"
      unitRef="usd">29000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d8312059e1844-wk-Fact-35C52AB5F0D672D4BCB394757CDACC01"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d8312059e1960-wk-Fact-5A9323DDE96F467D4EB294757CDEBFD7"
      unitRef="usd">4000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d8312059e1979-wk-Fact-D32BE49AC04B6AB1E7A894757CE0BC21"
      unitRef="usd">7000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d8312059e1998-wk-Fact-C6C094F211EFE1192A7994757D666DEC"
      unitRef="usd">10000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d8312059e2018-wk-Fact-392A8B2D61CA7072524094757D40CAB7"
      unitRef="usd">15000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-6"
      id="d8312059e2043-wk-Fact-2FD155A9458FEA78C7F194757CE25240"
      unitRef="usd">0</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-6"
      id="d8312059e2062-wk-Fact-9F156B344E4DD52CA8B394757CE34982"
      unitRef="usd">1000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-6"
      id="d8312059e2081-wk-Fact-294468E799E3C655921694757D428F2B"
      unitRef="usd">0</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-6"
      id="d8312059e2101-wk-Fact-0D9B88019461C261B2D994757D33A088"
      unitRef="usd">2000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-6"
      id="d8312059e2126-wk-Fact-D607D2703E69C5FECFE694757CDCD329"
      unitRef="usd">2000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-6"
      id="d8312059e2145-wk-Fact-81D654407A04152B766994757CDD8A45"
      unitRef="usd">2000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-6"
      id="d8312059e2164-wk-Fact-476B18F8EF4E7B05E20394757CD2DBCA"
      unitRef="usd">-3000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-6"
      id="d8312059e2185-wk-Fact-A724B0094E4DB323816594757D52FEEC"
      unitRef="usd">5000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8312059e2210-wk-Fact-B87A51A9779CD1CF018694757CE399DF"
      unitRef="usd">6000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8312059e2229-wk-Fact-F5BC31DCC6B0367BD58894757CDB9BE9"
      unitRef="usd">10000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8312059e2248-wk-Fact-9209A09A308FD4F6E18194757D3C8964"
      unitRef="usd">6000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8312059e2268-wk-Fact-5813093241A54AAC971594757D47CE74"
      unitRef="usd">23000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <pfe:ImplementationCosts
      contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d8312059e2380-wk-Fact-24B4A8ECAE3E2474912094757CDF68AE"
      unitRef="usd">11000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d8312059e2399-wk-Fact-9F6032E503A2CA1767B194757CDC4DEA"
      unitRef="usd">17000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d8312059e2418-wk-Fact-10C0D0D972663C0BC95494757CF12E8C"
      unitRef="usd">21000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d8312059e2438-wk-Fact-40B5B65787722B300CCA94757D4E39DB"
      unitRef="usd">31000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-6"
      id="d8312059e2463-wk-Fact-1AE830A789111962733194757CE1B056"
      unitRef="usd">63000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-6"
      id="d8312059e2482-wk-Fact-6846E2B46425F1D8EBA694757CDA487C"
      unitRef="usd">16000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-6"
      id="d8312059e2501-wk-Fact-1D95D82D28060BA3A08A94757CE1514E"
      unitRef="usd">78000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-6"
      id="d8312059e2521-wk-Fact-33CF13183D5E3D8446A994757CD4AE22"
      unitRef="usd">25000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-6"
      id="d8312059e2546-wk-Fact-2DA0B9B079BAAF2177CF94757CDF2206"
      unitRef="usd">1000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-6"
      id="d8312059e2565-wk-Fact-1A602D6AF23843C2BB1894757CDAEB96"
      unitRef="usd">9000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-6"
      id="d8312059e2584-wk-Fact-127515899B5DE626CC8194757D3ECA81"
      unitRef="usd">1000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-6"
      id="d8312059e2604-wk-Fact-7B35AE5A591127B6882494757D496AF1"
      unitRef="usd">13000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8312059e2629-wk-Fact-73C8A01061ED49259E2594757CE5569D"
      unitRef="usd">75000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8312059e2648-wk-Fact-17AFA0CD14201AA75F3794757CE4EBFE"
      unitRef="usd">42000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8312059e2667-wk-Fact-57AFB05C46254859A5D694757D6FE43D"
      unitRef="usd">99000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8312059e2687-wk-Fact-469E3365E76E79BE433894757CCE1E1E"
      unitRef="usd">69000000</pfe:ImplementationCosts>
    <pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8312059e2718-wk-Fact-19F02225A57F3A01328394757CDECC6E"
      unitRef="usd">449000000</pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts>
    <pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8312059e2737-wk-Fact-1EC7B4190567F243D63094757CE366F4"
      unitRef="usd">-59000000</pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts>
    <pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8312059e2758-wk-Fact-0D4CA64BE5B7259FDCE694757CCFF5C7"
      unitRef="usd">566000000</pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts>
    <pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8312059e2777-wk-Fact-5DB4753E6EBACF12BB1C94757D3AF655"
      unitRef="usd">32000000</pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts>
    <us-gaap:RestructuringCharges
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8312059e2848-wk-Fact-EA59B8E893033E1F5A8D5E68C1B993BF"
      unitRef="usd">-12000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8312059e2852-wk-Fact-E32201E74992D57252A65E688511FFF3"
      unitRef="usd">-1000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8312059e2856-wk-Fact-B76088ECB4E3516973635E68F242648C"
      unitRef="usd">352000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8312059e2876-wk-Fact-AD3D4D1457A07D882DF15E6940659B3D"
      unitRef="usd">-9000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8312059e2880-wk-Fact-B9D87D308F85678EFCE25E698F32FDD1"
      unitRef="usd">12000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8312059e2884-wk-Fact-0A8242825A1620571D405E69D496F26A"
      unitRef="usd">393000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8312059e2911-wk-Fact-E34D5EF6437025BF0CF25E6808A5B9D8"
      unitRef="usd">-62000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8312059e2915-wk-Fact-10BEF3BA9211D48E0BFB5E67A380452C"
      unitRef="usd">-9000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8312059e2919-wk-Fact-707CA11A39A1C8DEB50B5E684038ABA9"
      unitRef="usd">-74000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8312059e2942-wk-Fact-1D406BE4FDC47F4798D25E695FB21A0B"
      unitRef="usd">-48000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8312059e2946-wk-Fact-ACC1801CE3C4D765E1F25E69AC7D9821"
      unitRef="usd">-22000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8312059e2950-wk-Fact-8BDC7532509814BA5BC25E69F424ADEA"
      unitRef="usd">-63000000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-E4FF1A51E74D6B89167094757DB83453-0-wk-Fact-955F718C8503DFDAE6D294757D682D5E">&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.05068226120858%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of and changes in our restructuring accruals:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Employee&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Termination&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Asset&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Charges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Exit Costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Accrual&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;887&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;396&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Utilization and other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(341&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(378&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Balance, June 28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;918&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;951&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Other current liabilities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$714 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;) and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$219 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Includes adjustments for foreign currency translation.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Other current liabilities &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$625 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;) and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Other noncurrent liabilities &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$326 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;).&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember"
      decimals="-6"
      id="d8312059e3347-wk-Fact-A0AE794A669CD8E4D60C94757D85F3D2"
      unitRef="usd">887000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember"
      decimals="-6"
      id="d8312059e3366-wk-Fact-9D99FC5004F5F45EB50094757D8BBD01"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember"
      decimals="-6"
      id="d8312059e3386-wk-Fact-E5ED2D8BFF7F93B9B97494757D832764"
      unitRef="usd">46000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8312059e3405-wk-Fact-8DD16E5EDE18E934E20F94757D84AC18"
      unitRef="usd">933000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="FD2020Q2YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember"
      decimals="-6"
      id="d8312059e3425-wk-Fact-FEFDA0AF1539302FEE1294757D86CE6B"
      unitRef="usd">371000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2020Q2YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember"
      decimals="-6"
      id="d8312059e3444-wk-Fact-91AF3B300F81D255EED394757D8345EF"
      unitRef="usd">23000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2020Q2YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember"
      decimals="-6"
      id="d8312059e3463-wk-Fact-C410BE51BDC1C8EC170F94757D84A449"
      unitRef="usd">1000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8312059e3483-wk-Fact-DD70750D757F8E36AEFE94757D511014"
      unitRef="usd">396000000</us-gaap:RestructuringCharges>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="FD2020Q2YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember"
      decimals="-6"
      id="d8312059e3510-wk-Fact-F040B63D0E69CA163CDE94757D8588FB"
      unitRef="usd">341000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="FD2020Q2YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember"
      decimals="-6"
      id="d8312059e3530-wk-Fact-981984D45830B3785BF594757D89A644"
      unitRef="usd">23000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="FD2020Q2YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember"
      decimals="-6"
      id="d8312059e3550-wk-Fact-51F33580094F704AE1CA94757D87F7E8"
      unitRef="usd">14000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8312059e3571-wk-Fact-3796F5D99D503A9EF47494757D899973"
      unitRef="usd">378000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <us-gaap:RestructuringReserve
      contextRef="FI2020Q2_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember"
      decimals="-6"
      id="d8312059e3604-wk-Fact-1B231CD712DFE5467E5994757D88041A"
      unitRef="usd">918000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2020Q2_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember"
      decimals="-6"
      id="d8312059e3623-wk-Fact-A331008C1C4E5584FBBC94757D85F6B9"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2020Q2_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember"
      decimals="-6"
      id="d8312059e3643-wk-Fact-22FE89F9AF8C0AF9DC8494757D8695DC"
      unitRef="usd">34000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8312059e3662-wk-Fact-372F8BB1048027009D0C94757D85F7F7"
      unitRef="usd">951000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-6"
      id="d8312059e3716-wk-Fact-F23B221CCF86FFDD224494757D67DF89"
      unitRef="usd">714000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember"
      decimals="-6"
      id="d8312059e3724-wk-Fact-7D5A017C9059415B7FB094757D69E3E9"
      unitRef="usd">219000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-6"
      id="d8312059e3802-wk-Fact-E77EE9F302EB09217A6794757D6CF63D"
      unitRef="usd">625000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember"
      decimals="-6"
      id="d8312059e3810-wk-Fact-7B25C61B791D15A8074C94757D6AD164"
      unitRef="usd">326000000</us-gaap:RestructuringReserve>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-5A0F3A58699358E2ABB894757DB9FB98-0-wk-Fact-99AF92853BA2C59D8A1E94757D76F712">&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Other (Income)/Deductions&#x2014;Net&lt;/span&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides components of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Six Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Interest income&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(125&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Interest expense&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;372&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;389&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;762&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Net interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;353&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;330&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;709&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;625&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Royalty-related income&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(191&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(231&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(311&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(320&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Net (gains)/losses on asset disposals&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Net gains recognized during the period on equity securities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(732&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(478&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Income from collaborations, out-licensing arrangements and sales of compound/product rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(104&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:18px;text-indent:-18px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Net periodic benefit credits other than service costs&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(108&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(175&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Certain legal matters, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:18px;text-indent:-18px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Certain asset impairments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;160&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Business and legal entity alignment costs&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(g)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;256&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net losses on early retirement of debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;138&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;GSK Consumer Healthcare JV equity method (income)/loss&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(h)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(126&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(92&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Other, net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(i)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(107&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(318&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(862&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;126&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(641&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Interest income decreased in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and first six months of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, primarily driven by a lower investment balance and lower short-term interest rates. Interest expense decreased in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; mainly as a result of the retirement of higher-coupon debt and the issuance of new debt with a lower coupon than the debt outstanding for the comparative prior year period. Interest expense increased in the first six months of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, mainly as a result of an increased commercial paper balance due to the acquisition of Array. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Royalty-related income for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;first six months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; included a one-time favorable resolution in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of a legal dispute for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$82 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The gains in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; include, among other things, unrealized gains of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$508 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; related to our investment in Allogene and unrealized gains of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$61 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; related to our investment in BioNTech. The gains in the first six months of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; include, among other things, unrealized gains of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$374 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; related to our investment in Allogene and unrealized gains of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$127 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; related to our investment in BioNTech. The gains in the first six months of 2019 included, among other things, unrealized gains of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$104 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; related to our investment in Cortexyme, Inc. For additional information on investments, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 7B&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; quarter and first six months of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, mainly includes, among other things, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$40 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of milestone income from Puma Biotechnology, Inc. related to Neratinib regulatory approvals in the EU, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$30 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of milestone income from Lilly related to the first commercial sale in the U.S. of LOXO-292 for the treatment of RET fusion-positive NSCLC. The first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; also includes an upfront payment to us of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$75 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; from our sale of our CK1 assets to Biogen, Inc. In the first six months of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, primarily included &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$68 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in milestone income from Mylan Pharmaceuticals Inc. related to the FDA&#x2019;s approval and launch of Wixela Inhub&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, a generic of Advair Diskus&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 10&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The first six months of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; included intangible asset impairment charges of: (i) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$90 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; related to WRDM IPR&amp;amp;D, for a pre-clinical stage asset from our acquisition of Bamboo for gene therapies for the potential treatment of patients with certain rare diseases, which was the result of a determination to not use certain Bamboo IPR&amp;amp;D acquired in future rare disease development, (ii) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$40 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; related to an Upjohn finite-lived developed technology right, acquired in connection with our acquisition of King, for government defense products and reflected, among other things, updated commercial forecasts including manufacturing cost assumptions, and (iii) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$10 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; related to a finite-lived developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus marketed in the U.S. market only, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;associated with Biopharma and reflected&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, among other things, updated commercial forecasts. In addition, the first six months of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; included other asset impairments of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$20 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(g)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and first six months of 2019, represents incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(h)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Includes our share of the GSK Consumer Healthcare joint venture&#x2019;s earnings and the amortization of basis differences, which resulted from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the joint venture. See &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 2B&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(i)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; includes, among other things, dividend income of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$76 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; from our investment in ViiV, and charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$86 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, reflecting the change in the fair value of contingent consideration. The first six months of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; includes, among other things, dividend income of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$153 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; from our investment in ViiV and charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$99 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, reflecting the change in the fair value of contingent consideration. The &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; included, among other things, charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$81 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, reflecting the change in the fair value of contingent consideration, dividend income of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$76&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; from our investment in ViiV, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$25 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of income from insurance recoveries related to Hurricane Maria. The first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; included, among other things, dividend income of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$140 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; from our investment in ViiV and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$50 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of income from insurance recoveries related to Hurricane Maria.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-503969B88D57E7238BC594757DB9CE05-0-wk-Fact-E4E2306FB0148534334A94757D7811E0">&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides components of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Six Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Interest income&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(125&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Interest expense&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;372&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;389&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;762&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Net interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;353&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;330&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;709&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;625&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Royalty-related income&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(191&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(231&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(311&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(320&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Net (gains)/losses on asset disposals&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Net gains recognized during the period on equity securities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(732&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(478&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Income from collaborations, out-licensing arrangements and sales of compound/product rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(104&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:18px;text-indent:-18px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Net periodic benefit credits other than service costs&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(108&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(175&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Certain legal matters, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:18px;text-indent:-18px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Certain asset impairments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;160&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Business and legal entity alignment costs&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(g)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;256&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net losses on early retirement of debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;138&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;GSK Consumer Healthcare JV equity method (income)/loss&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(h)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(126&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(92&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Other, net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(i)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(107&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(318&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(862&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;126&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(641&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Interest income decreased in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and first six months of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, primarily driven by a lower investment balance and lower short-term interest rates. Interest expense decreased in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; mainly as a result of the retirement of higher-coupon debt and the issuance of new debt with a lower coupon than the debt outstanding for the comparative prior year period. Interest expense increased in the first six months of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, mainly as a result of an increased commercial paper balance due to the acquisition of Array. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Royalty-related income for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;first six months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; included a one-time favorable resolution in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of a legal dispute for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$82 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The gains in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; include, among other things, unrealized gains of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$508 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; related to our investment in Allogene and unrealized gains of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$61 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; related to our investment in BioNTech. The gains in the first six months of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; include, among other things, unrealized gains of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$374 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; related to our investment in Allogene and unrealized gains of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$127 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; related to our investment in BioNTech. The gains in the first six months of 2019 included, among other things, unrealized gains of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$104 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; related to our investment in Cortexyme, Inc. For additional information on investments, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 7B&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; quarter and first six months of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, mainly includes, among other things, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$40 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of milestone income from Puma Biotechnology, Inc. related to Neratinib regulatory approvals in the EU, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$30 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of milestone income from Lilly related to the first commercial sale in the U.S. of LOXO-292 for the treatment of RET fusion-positive NSCLC. The first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; also includes an upfront payment to us of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$75 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; from our sale of our CK1 assets to Biogen, Inc. In the first six months of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, primarily included &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$68 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in milestone income from Mylan Pharmaceuticals Inc. related to the FDA&#x2019;s approval and launch of Wixela Inhub&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, a generic of Advair Diskus&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 10&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The first six months of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; included intangible asset impairment charges of: (i) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$90 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; related to WRDM IPR&amp;amp;D, for a pre-clinical stage asset from our acquisition of Bamboo for gene therapies for the potential treatment of patients with certain rare diseases, which was the result of a determination to not use certain Bamboo IPR&amp;amp;D acquired in future rare disease development, (ii) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$40 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; related to an Upjohn finite-lived developed technology right, acquired in connection with our acquisition of King, for government defense products and reflected, among other things, updated commercial forecasts including manufacturing cost assumptions, and (iii) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$10 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; related to a finite-lived developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus marketed in the U.S. market only, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;associated with Biopharma and reflected&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, among other things, updated commercial forecasts. In addition, the first six months of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; included other asset impairments of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$20 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(g)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and first six months of 2019, represents incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(h)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Includes our share of the GSK Consumer Healthcare joint venture&#x2019;s earnings and the amortization of basis differences, which resulted from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the joint venture. See &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 2B&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(i)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; includes, among other things, dividend income of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$76 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; from our investment in ViiV, and charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$86 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, reflecting the change in the fair value of contingent consideration. The first six months of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; includes, among other things, dividend income of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$153 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; from our investment in ViiV and charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$99 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, reflecting the change in the fair value of contingent consideration. The &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; included, among other things, charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$81 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, reflecting the change in the fair value of contingent consideration, dividend income of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$76&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; from our investment in ViiV, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$25 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of income from insurance recoveries related to Hurricane Maria. The first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; included, among other things, dividend income of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$140 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; from our investment in ViiV and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$50 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of income from insurance recoveries related to Hurricane Maria.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8316808e1016-wk-Fact-964F368B32E366CCC9BC94757CFB473E"
      unitRef="usd">19000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8316808e1036-wk-Fact-4C72B86F9525A44C403B94757CF4AB54"
      unitRef="usd">59000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8316808e1057-wk-Fact-9F5350C0F6B6CC70CC8D94757CEE92D7"
      unitRef="usd">53000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8316808e1077-wk-Fact-8594983BDE02438B8CB794757D6E309D"
      unitRef="usd">125000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8316808e1100-wk-Fact-D29057E6A396E534364794757CF999F3"
      unitRef="usd">372000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8316808e1119-wk-Fact-EE4346B259E22FC41F1F94757CFCEB7F"
      unitRef="usd">389000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8316808e1138-wk-Fact-7AFC70661380E28E616594757CC3AFAE"
      unitRef="usd">762000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8316808e1158-wk-Fact-3499C6CE8F54FB430EAD94757D6E3CBC"
      unitRef="usd">750000000</us-gaap:InterestExpense>
    <us-gaap:InterestRevenueExpenseNet
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8316808e1183-wk-Fact-404EAFCD30C367D1A17894757CF808CB"
      unitRef="usd">-353000000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:InterestRevenueExpenseNet
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8316808e1202-wk-Fact-B87245E261CCD989C48994757CF6E0A0"
      unitRef="usd">-330000000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:InterestRevenueExpenseNet
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8316808e1221-wk-Fact-EC26EAE54B3545FD00DE94757CD8339C"
      unitRef="usd">-709000000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:InterestRevenueExpenseNet
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8316808e1241-wk-Fact-F4F93786AF3B88CEBCFD94757CEFAE24"
      unitRef="usd">-625000000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8316808e1268-wk-Fact-B96D2283B28701563E7A94757CF94EFC"
      unitRef="usd">191000000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8316808e1288-wk-Fact-FB5C3E831211DA67818F94757CFBBA25"
      unitRef="usd">231000000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8316808e1308-wk-Fact-0C70E0AC22CEB94822F594757CC8BF0F"
      unitRef="usd">311000000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8316808e1329-wk-Fact-A00DF4727012C4B9EC3194757D104907"
      unitRef="usd">320000000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8316808e1355-wk-Fact-1A4578D74B4E3B2593EF94757CF70411"
      unitRef="usd">-1000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8316808e1374-wk-Fact-9F69DC0C27E0F6B8AA8794757CF6D438"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8316808e1393-wk-Fact-F2F76B3D89CC29CA91F794757CE5AC52"
      unitRef="usd">-2000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8316808e1413-wk-Fact-6D9DFD763F138C2C847894757D0A7A8D"
      unitRef="usd">1000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8316808e1441-wk-Fact-BE2B9931D467A3220D4894757CFCC65C"
      unitRef="usd">732000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8316808e1460-wk-Fact-A89179620F4ADD5E911294757CF30C7B"
      unitRef="usd">36000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8316808e1479-wk-Fact-98787FFB4C950A5BBD0194757CE6C4FB"
      unitRef="usd">478000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8316808e1499-wk-Fact-05F41C05FF959B0D282094757CDBBAC3"
      unitRef="usd">147000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8316808e1527-wk-Fact-64508C9369D213E8ACFA94757CCC5964"
      unitRef="usd">100000000</pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights>
    <pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8316808e1547-wk-Fact-CBF2AF5A3799937C03F394757CFD6A73"
      unitRef="usd">22000000</pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights>
    <pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8316808e1567-wk-Fact-629F8031543C0F8CAEA494757CD21E49"
      unitRef="usd">215000000</pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights>
    <pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8316808e1588-wk-Fact-38DB99ED289778FC0EC794757CF0235A"
      unitRef="usd">104000000</pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8316808e1616-wk-Fact-2024C15FEA8B459878AD94757CF5A215"
      unitRef="usd">-108000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8316808e1636-wk-Fact-6FB75BBD46792B84303694757CCB8587"
      unitRef="usd">-51000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8316808e1656-wk-Fact-DE3B1C32E7AF56EA37C694757CFE73CD"
      unitRef="usd">-175000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8316808e1677-wk-Fact-CF4867B1F96B94735AD594757D0E90B4"
      unitRef="usd">-91000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8316808e1704-wk-Fact-D0135C395BAED2FE95EC94757CF4F3E2"
      unitRef="usd">-17000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8316808e1723-wk-Fact-8E42A3831E1D14364FEE94757CFB1583"
      unitRef="usd">-15000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8316808e1742-wk-Fact-CBBE8EDA374D1CE7F34694757CE7FAA0"
      unitRef="usd">-26000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8316808e1762-wk-Fact-778A41E9A7F0F3B927E394757D176908"
      unitRef="usd">-19000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:AssetImpairmentCharges
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8316808e1789-wk-Fact-A5431E8C2912D62E362094757CF2BE8E"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8316808e1808-wk-Fact-71E3A38CC9A24B60F06494757CF5F71C"
      unitRef="usd">10000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8316808e1827-wk-Fact-EF93AF87BA61CC2CECEB94757CBC24E3"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8316808e1847-wk-Fact-F581216089FF320C328694757CD49968"
      unitRef="usd">160000000</us-gaap:AssetImpairmentCharges>
    <pfe:BusinessAlignmentCosts
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8316808e1874-wk-Fact-AF679C0C7A88919A718094757CFBF4E0"
      unitRef="usd">0</pfe:BusinessAlignmentCosts>
    <pfe:BusinessAlignmentCosts
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8316808e1893-wk-Fact-7973D60AC4E2ED9EA6D394757CF8B7E7"
      unitRef="usd">137000000</pfe:BusinessAlignmentCosts>
    <pfe:BusinessAlignmentCosts
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8316808e1912-wk-Fact-3B846BC02192BD53F89B94757CDEE0F4"
      unitRef="usd">0</pfe:BusinessAlignmentCosts>
    <pfe:BusinessAlignmentCosts
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8316808e1932-wk-Fact-40152B99BE243EC4A4DA94757CE024F4"
      unitRef="usd">256000000</pfe:BusinessAlignmentCosts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8316808e1957-wk-Fact-2F9CB48F881108F84DE494757CF6F586"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8316808e1976-wk-Fact-9B6666350119AE83397C5E7247581F5B"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8316808e1995-wk-Fact-03E558327BD22A84183494757D078BB7"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8316808e2015-wk-Fact-80B2E8867002EBA1C8C25E7247542FCD"
      unitRef="usd">-138000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8316808e2042-wk-Fact-3502C1166F5ABE6DC55E94757CCC6B1B"
      unitRef="usd">126000000</pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization>
    <pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8316808e2062-wk-Fact-13DB6A96944CAA1A9DE694757CF73050"
      unitRef="usd">0</pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization>
    <pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8316808e2081-wk-Fact-8631DD50CCB968472578955D6DC81456"
      unitRef="usd">92000000</pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization>
    <pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8316808e2102-wk-Fact-7104406F477A093FDE41955D6E1319E3"
      unitRef="usd">0</pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization>
    <pfe:OtherNonoperatingIncomeExpenseNet
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8316808e2129-wk-Fact-48DD10795AE6A50CB75294757CF3076B"
      unitRef="usd">-25000000</pfe:OtherNonoperatingIncomeExpenseNet>
    <pfe:OtherNonoperatingIncomeExpenseNet
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8316808e2147-wk-Fact-D71486B20EB7956A050C94757CCBBD46"
      unitRef="usd">27000000</pfe:OtherNonoperatingIncomeExpenseNet>
    <pfe:OtherNonoperatingIncomeExpenseNet
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8316808e2166-wk-Fact-98D14E7EA5371F942F3394757CCE8CDC"
      unitRef="usd">107000000</pfe:OtherNonoperatingIncomeExpenseNet>
    <pfe:OtherNonoperatingIncomeExpenseNet
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8316808e2186-wk-Fact-5864C6C0C3A1C625197294757D73F154"
      unitRef="usd">318000000</pfe:OtherNonoperatingIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8316808e2217-wk-Fact-361AD8CFC0B46CF2632394757D0A716D"
      unitRef="usd">862000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8316808e2237-wk-Fact-115B1B8C87DB19F5829C94757D60A004"
      unitRef="usd">-126000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8316808e2257-wk-Fact-82FCBDB83EA92437E26C94757D5A5E10"
      unitRef="usd">641000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8316808e2277-wk-Fact-CF088F9FE2A75408C8A794757D1586DE"
      unitRef="usd">-218000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:ProceedsFromLegalSettlements
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8316808e2387-wk-Fact-BC8FD17D240F881485EF955D6E14938E"
      unitRef="usd">82000000</us-gaap:ProceedsFromLegalSettlements>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember"
      decimals="-6"
      id="d8316808e2412-wk-Fact-40CA1F17BEB2D0A8797794757D7513C7"
      unitRef="usd">508000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_BioNTechSEMember"
      decimals="-6"
      id="d8316808e2416-wk-Fact-76C1FFB30BC3D7CAB9DD5E86ECE05D86"
      unitRef="usd">61000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember"
      decimals="-6"
      id="d8316808e2425-wk-Fact-99A0E87C3E7ACC2850CE955D6EE5B821"
      unitRef="usd">374000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_BioNTechSEMember"
      decimals="-6"
      id="d8316808e2429-wk-Fact-3AA2852FACA286ED4B105E88C274918E"
      unitRef="usd">127000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CortexymeInc.Member"
      decimals="-6"
      id="d8316808e2433-wk-Fact-2E7CCABE8F52D073CFF95E890E465015"
      unitRef="usd">104000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ProceedsFromCollaborators
      contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_pfe_PumaTechnologiesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d8316808e2480-wk-Fact-076A4EF6E989B0D0BF915EA36245A333"
      unitRef="usd">40000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d8316808e2484-wk-Fact-46C080B02D09D39370335EA5F6BBED9F"
      unitRef="usd">30000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="FI2020Q2_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_CK1AssetsSoldToBiogenIncMember"
      decimals="-6"
      id="d8316808e2497-wk-Fact-E30C39F1D1B0A522812494757D759DA6"
      unitRef="usd">75000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:ProceedsFromCollaborators
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_pfe_MylanMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d8316808e2505-wk-Fact-09145C555748A1AAD94394757D7A865F"
      unitRef="usd">68000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_GeneTherapiesMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember"
      decimals="-6"
      id="d8316808e2562-wk-Fact-2B4544E46E026330A34D94757D777099"
      unitRef="usd">90000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_KingMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8316808e2566-wk-Fact-84E9DF43D0B1B29C362C94757D772A85"
      unitRef="usd">40000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AnacorMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8316808e2570-wk-Fact-DF65CCCD5564D3A109FC5EAB28D92765"
      unitRef="usd">10000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8316808e2583-wk-Fact-B69E12C6AA0189ADD97B94757D77BC32"
      unitRef="usd">20000000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:InvestmentIncomeDividend
      contextRef="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViiVMember"
      decimals="-6"
      id="d8316808e2662-wk-Fact-71D18AE80705CBBAADD594757D794DFA"
      unitRef="usd">76000000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="FD2020Q2QTD_us-gaap_BusinessAcquisitionAxis_pfe_ViiVMember"
      decimals="-6"
      id="d8316808e2666-wk-Fact-097E9B6C0D40541553845EAFD3825BC7"
      unitRef="usd">86000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:InvestmentIncomeDividend
      contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViiVMember"
      decimals="-6"
      id="d8316808e2675-wk-Fact-D5D32FD407DDC5273865955D6DF4E00F"
      unitRef="usd">153000000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="FD2020Q2YTD_us-gaap_BusinessAcquisitionAxis_pfe_ViiVMember"
      decimals="-6"
      id="d8316808e2679-wk-Fact-D38805B1BD1B06E9E56E5EAEEB8EF0D8"
      unitRef="usd">99000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8316808e2691-wk-Fact-9C052873C6DAE7D4D52194757D783D82"
      unitRef="usd">81000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:InvestmentIncomeDividend
      contextRef="FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViiVMember"
      decimals="-6"
      id="d8316808e2696-wk-Fact-68BAAAE2FACDAD5DABE694757D76ACC5"
      unitRef="usd">76000000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InsuranceRecoveries
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8316808e2812-wk-Fact-9A10E6CBB57ACDEDCA0A5EB812D6A565"
      unitRef="usd">25000000</us-gaap:InsuranceRecoveries>
    <us-gaap:InvestmentIncomeDividend
      contextRef="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViiVMember"
      decimals="-6"
      id="d8316808e2824-wk-Fact-625787D364A8EDA65710955D6DFF81D9"
      unitRef="usd">140000000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InsuranceRecoveries
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8316808e2828-wk-Fact-D83B6F01F3FE9AE97EAE5EB85E463C5E"
      unitRef="usd">50000000</us-gaap:InsuranceRecoveries>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-15E468F2F9C33B25026F94757DBA81D5-0-wk-Fact-291E90AB2E484902A29E94757CE7D93E">&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Tax Matters&lt;/span&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;A. Taxes on Income from Continuing Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our effective tax rate for continuing operations was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.1%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;second&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; quarter of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, compared to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(22.1)%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;second&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; quarter of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.7%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the first six months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, compared to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5.7)%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the first six months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;higher&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; effective tax rate for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;second&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; quarter and first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in comparison with the same periods in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was primarily due to:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the non-recurrence of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; tax benefit, representing taxes and interest, recorded in the second quarter of 2019 due to the favorable settlement of an IRS audit for multiple tax years (see Notes to Consolidated Financial Statements&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 5D. Tax Matters: Tax Contingencies &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;in our 2019 Financial Report); and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the non-recurrence of the tax benefit recorded in the first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of 2019 as a result of additional guidance issued by the U.S. Department of Treasury related to the TCJA,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:4px;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;partially offset by:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our initial estimated &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$15 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; repatriation tax liability on accumulated post-1986 foreign earnings for which we elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, payment over eight years through 2026 is reported in current &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;taxes payable &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;) and the remaining liability is reported in noncurrent &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other taxes payable&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in our condensed consolidated balance sheet as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The second installment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$680 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was paid in July 2020, which was originally due to be paid in April 2020 but was extended to July 2020 by the IRS in response to the COVID-19 pandemic. The third installment of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$750 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is due in April 2021. Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was signed into law in the U.S. to provide certain relief as a result of the COVID-19 pandemic. In addition, governments around the world have enacted or implemented various forms of tax relief measures in response to the economic conditions in the wake of COVID-19. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, neither the CARES Act nor changes to income tax laws or regulations in other jurisdictions had a significant impact on our effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;B. Tax Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. With respect to Pfizer, the IRS has issued a Revenue Agent&#x2019;s Report (RAR) for tax years 2011-2013. We are not in agreement with the RAR and are currently appealing certain disputed issues. Tax years 2014-2015 are currently under audit. Tax years 2016-2020 are open, but not under audit. All other tax years are closed.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In addition to the open audit years in the U.S., we have open audit years in other major tax jurisdictions, such as Canada (2013-2020), Japan (2017-2020), Europe (2011-2020, primarily reflecting Ireland, the U.K., France, Italy, Spain and Germany), Latin America (1998-2020, primarily reflecting Brazil) and Puerto Rico (2015-2020).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;C. &lt;/span&gt;&lt;span style="font-weight:bold;text-decoration:underline;"&gt;Tax Provision/(Benefit) on Other Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Tax provision/(benefit) on&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;other comprehensive loss&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Six Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency translation adjustments, net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Unrealized holding gains/(losses) on derivative financial instruments, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Reclassification adjustments for gains included in net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Unrealized holding gains/(losses) on available-for-sale securities, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Reclassification adjustments for losses included in net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Benefit plans: actuarial gains/(losses), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Reclassification adjustments related to amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Reclassification adjustments related to settlements, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Reclassification adjustments related to amortization of prior service costs and other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Tax provision/(benefit) on other comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;113&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(265&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2020Q2QTD"
      decimals="3"
      id="d8314038e710-wk-Fact-F3062759B0719C4D154794757CE7292C"
      unitRef="number">0.131</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2019Q2QTD"
      decimals="3"
      id="d8314038e722-wk-Fact-E82F9EC034F593DFD41F94757CE8EA3D"
      unitRef="number">-0.221</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2020Q2YTD"
      decimals="3"
      id="d8314038e735-wk-Fact-AC6996334D6D144D39925EC2B6F5DD76"
      unitRef="number">0.127</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2019Q2YTD"
      decimals="3"
      id="d8314038e747-wk-Fact-89826C68E211AFDE37EF5EC2D0EE6F95"
      unitRef="number">-0.057</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxReconciliationTaxSettlements
      contextRef="FD2019Q2QTD"
      decimals="-8"
      id="d8314038e790-wk-Fact-E53DDF0FDCEB9B4100797910AEA53F64"
      unitRef="usd">-1400000000</us-gaap:IncomeTaxReconciliationTaxSettlements>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability
      contextRef="FI2020Q2"
      decimals="-9"
      id="d8314038e822-wk-Fact-1A09897409F217F67ED394757CE74368"
      unitRef="usd">15000000000</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_IncomeTaxesPayableMember"
      decimals="-8"
      id="d8314038e834-wk-Fact-891F41E413F59F55794B94757CE57245"
      unitRef="usd">1400000000</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability>
    <pfe:PaymentForRepatriationTax
      contextRef="D2020Q3Jul1-31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="-6"
      id="d8314038e847-wk-Fact-295400FBD13AB0A2871494757CE7779A"
      unitRef="usd">680000000</pfe:PaymentForRepatriationTax>
    <pfe:PaymentForRepatriationTax
      contextRef="D2021Q2Apr1-30_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="-6"
      id="d8314038e851-wk-Fact-36CEB3B6DC27263F50EF5EC6452042D4"
      unitRef="usd">750000000</pfe:PaymentForRepatriationTax>
    <pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-90B5518319E8C393415B94757DBAA12D-0-wk-Fact-98291030996B49A589F494757CE619EA">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Tax provision/(benefit) on&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;other comprehensive loss&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Six Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency translation adjustments, net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Unrealized holding gains/(losses) on derivative financial instruments, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Reclassification adjustments for gains included in net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Unrealized holding gains/(losses) on available-for-sale securities, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Reclassification adjustments for losses included in net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Benefit plans: actuarial gains/(losses), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Reclassification adjustments related to amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Reclassification adjustments related to settlements, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Reclassification adjustments related to amortization of prior service costs and other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Tax provision/(benefit) on other comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;113&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(265&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.&lt;/span&gt;&lt;/div&gt;</pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8314038e1196-wk-Fact-A19967903AAC6CD9F1E494757D7857A3"
      unitRef="usd">60000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8314038e1215-wk-Fact-432173AA1624AC93425594757D771AAC"
      unitRef="usd">-17000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8314038e1236-wk-Fact-A7A8B2FD88766217F16094757D50D04F"
      unitRef="usd">-192000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8314038e1256-wk-Fact-261CF8B516535CC742D694757D9DD941"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8314038e1276-wk-Fact-7ECA69C30539623284F694757D74480C"
      unitRef="usd">51000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8314038e1295-wk-Fact-6D54B018E862C618DAA594757D740800"
      unitRef="usd">-53000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8314038e1315-wk-Fact-33CE4984F56A06364F7594757D96B5B7"
      unitRef="usd">-82000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8314038e1336-wk-Fact-12514F8D64CDE8BD49E994757D461B29"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8314038e1361-wk-Fact-8469778C9496064B650A94757D6F3848"
      unitRef="usd">35000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8314038e1381-wk-Fact-B8AEA80006F385C431D594757D7673CB"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8314038e1401-wk-Fact-ED0FA601498740142B1294757D44BC1F"
      unitRef="usd">20000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8314038e1422-wk-Fact-BE0F972996B4BF2E6DAF94757D9AD5AB"
      unitRef="usd">59000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8314038e1448-wk-Fact-250B8DF8DC8AE23FEEA594757D713EE2"
      unitRef="usd">16000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8314038e1467-wk-Fact-26E2276B08CF0FDDC10D94757D72686F"
      unitRef="usd">-57000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8314038e1487-wk-Fact-CEE926E74E46FC8E8EBC94757D9F2ADF"
      unitRef="usd">-102000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8314038e1508-wk-Fact-4EC5A96B399A0E1069A194757D9EA225"
      unitRef="usd">-53000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8314038e1534-wk-Fact-37FCAEDBC81E29660E8194757D6DA92F"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8314038e1553-wk-Fact-36BA777B033023E3144C94757D73F9AF"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8314038e1573-wk-Fact-9890B6F9995AD4D3B51F94757D9B01C6"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8314038e1594-wk-Fact-8BDC84BB493C463CE09094757DA3F18E"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8314038e1619-wk-Fact-6F1C173D3634D81DAB1194757D6FC35E"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8314038e1638-wk-Fact-0A08A6B4BBFBEF80962694757D782477"
      unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8314038e1657-wk-Fact-1A514B2A7E5889BF73CA94757D33BD55"
      unitRef="usd">-7000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8314038e1677-wk-Fact-802037155B7EA521C51094757DA20C29"
      unitRef="usd">-5000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8314038e1702-wk-Fact-237FCAEA250F9CAFEC9C94757D717036"
      unitRef="usd">11000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8314038e1721-wk-Fact-2992F030458BE4293ADC94757D706AAD"
      unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8314038e1740-wk-Fact-1D57517A1FA0183AD32A94757D3C5422"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8314038e1760-wk-Fact-65C4D29FFC7384C8E4ED94757DA267EB"
      unitRef="usd">9000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8314038e1785-wk-Fact-EFF9593C2CF339BCA5E694757D793695"
      unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8314038e1804-wk-Fact-2D01765BD69A58F6B10A94757D7991BE"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8314038e1824-wk-Fact-8FEB1D1A2D1774BA1FFC94757DA63FE6"
      unitRef="usd">-19000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8314038e1845-wk-Fact-1460135BE6B8CC010F6D94757D9A06B3"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8314038e1872-wk-Fact-E57D12E5194ADC5D1D6C94757D77F40E"
      unitRef="usd">-16000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8314038e1891-wk-Fact-D3D74205CA9F62CD361494757D6E4120"
      unitRef="usd">-15000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8314038e1910-wk-Fact-D103D04106A9A45B07B494757D4E04D6"
      unitRef="usd">-31000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8314038e1930-wk-Fact-5E6118860B4C7943D56994757DA067E8"
      unitRef="usd">-18000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8314038e1955-wk-Fact-9DA7CBFC1C8970B733E194757D76D2E0"
      unitRef="usd">-2000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8314038e1974-wk-Fact-45E661C0E049AC539B9294757D703381"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8314038e1993-wk-Fact-6FEEBB85CA4AA07D99E494757DA4457E"
      unitRef="usd">-12000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8314038e2013-wk-Fact-EF6ED68B565FE86766BC94757D4C9567"
      unitRef="usd">-1000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8314038e2038-wk-Fact-B35A64CE926FA5048A1894757D7302EB"
      unitRef="usd">-16000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8314038e2057-wk-Fact-1E060F47EED4E5F9A0D494757D703D42"
      unitRef="usd">-8000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8314038e2076-wk-Fact-5B9D9874245E2957311294757D997810"
      unitRef="usd">-20000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8314038e2096-wk-Fact-583617E730ECC7E2AAAB94757D3D0708"
      unitRef="usd">-3000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax>
    <pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8314038e2121-wk-Fact-56116A021CEB432C2C7194757D788CBF"
      unitRef="usd">35000000</pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax>
    <pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8314038e2140-wk-Fact-6408796BA5CA5F8FAA2A94757D70751A"
      unitRef="usd">23000000</pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax>
    <pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8314038e2159-wk-Fact-48D1689CB46364E7E3DB94757DA2976A"
      unitRef="usd">43000000</pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax>
    <pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8314038e2179-wk-Fact-2EC9420EBF5445C3F59294757D41DDF6"
      unitRef="usd">21000000</pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8314038e2204-wk-Fact-330011D48BA279F8FD1094757D78B0B2"
      unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8314038e2224-wk-Fact-82F14DEA001DE85F18CE94757D72A58A"
      unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8314038e2244-wk-Fact-0D828A1C0764262CFE9D94757D374336"
      unitRef="usd">-21000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8314038e2265-wk-Fact-C84E67B2A279ABF75BC294757DA345B7"
      unitRef="usd">-22000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8314038e2291-wk-Fact-507422AE0FC0B21956FC94757D7198E6"
      unitRef="usd">-1000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8314038e2310-wk-Fact-98E482B40D23703F660694757D70A15D"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8314038e2329-wk-Fact-E9EB3C88390D38C8A9BF94757D98AC98"
      unitRef="usd">-1000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8314038e2349-wk-Fact-D416CF92B5509B2832CD94757D494FC5"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8314038e2374-wk-Fact-C9826BB516E3180B5A5B94757D6C4A44"
      unitRef="usd">9000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8314038e2394-wk-Fact-12A30AB8B561EA3E3F3994757D6FD842"
      unitRef="usd">11000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8314038e2414-wk-Fact-67D1A8A636603075FCC494757D4BA7A5"
      unitRef="usd">20000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8314038e2435-wk-Fact-FAD95AB970A6CE84727B94757D9C4B1E"
      unitRef="usd">22000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8314038e2466-wk-Fact-EA79252BF7CF8534CF3894757D00B0A3"
      unitRef="usd">113000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8314038e2485-wk-Fact-8F362BEF2AB5D5597E6394757CFFD802"
      unitRef="usd">-59000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8314038e2506-wk-Fact-98256D21B98CE406359794757D62CC7A"
      unitRef="usd">-265000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8314038e2526-wk-Fact-EF6B358EA8E9123BB65194757D5C81E7"
      unitRef="usd">-34000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-8D3803783B1470E396CB94757DBA2793-0-wk-Fact-DE14FC49D22B1F8120C594757D8A07BC">&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests&lt;/span&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the changes, net of tax, in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Net Unrealized Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Benefit Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Foreign Currency Translation Adjustments &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Available-For-Sale Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Actuarial Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Prior Service (Costs)/Credits and Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Accumulated Other Comprehensive Income/(Loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Balance, December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(5,952&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(6,257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;584&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(11,640&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-12px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,310&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(353&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;44&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,605&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Balance, June&#160;28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(7,262&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(333&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(6,178&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;518&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(13,246&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$12 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; loss for the first six months of 2020. Includes after-tax &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;losses&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$902 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; related to foreign currency translation adjustments and the impact of our net investment hedging program, both attributable to our equity method investment in GSK Consumer Healthcare (see&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt; Note 2B&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;), and losses from the weakening of certain major currencies against the U.S. dollar. These &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;losses&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; were partially offset by the results of our net investment hedging program.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-3116A04D009548FDA44D94757DBA339D-0-wk-Fact-ED90C3E03342B294461D94757D86C50E">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the changes, net of tax, in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Net Unrealized Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Benefit Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Foreign Currency Translation Adjustments &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Available-For-Sale Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Actuarial Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Prior Service (Costs)/Credits and Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Accumulated Other Comprehensive Income/(Loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Balance, December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(5,952&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(6,257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;584&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(11,640&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-12px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,310&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(353&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;44&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,605&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Balance, June&#160;28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(7,262&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(333&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(6,178&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;518&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(13,246&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$12 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; loss for the first six months of 2020. Includes after-tax &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;losses&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$902 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; related to foreign currency translation adjustments and the impact of our net investment hedging program, both attributable to our equity method investment in GSK Consumer Healthcare (see&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt; Note 2B&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;), and losses from the weakening of certain major currencies against the U.S. dollar. These &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;losses&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; were partially offset by the results of our net investment hedging program.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-6"
      id="d8312053e1146-wk-Fact-DE8475D255C7EE89398594757CE61C72"
      unitRef="usd">-5952000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-6"
      id="d8312053e1166-wk-Fact-7B301604CAA13A7C621694757CE446A3"
      unitRef="usd">20000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-6"
      id="d8312053e1186-wk-Fact-AFC9897520C6B134970B94757CE358B3"
      unitRef="usd">-35000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"
      decimals="-6"
      id="d8312053e1206-wk-Fact-A60457FD9E7B53D7995094757CE25F58"
      unitRef="usd">-6257000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember"
      decimals="-6"
      id="d8312053e1226-wk-Fact-7C4D0C0B86297CAA096494757CE1826F"
      unitRef="usd">584000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d8312053e1246-wk-Fact-75EDE949855DDE71A06D94757CE8D911"
      unitRef="usd">-11640000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-6"
      id="d8312053e1269-wk-Fact-93B22A2A5674F48F52DF94757CE4EB2F"
      unitRef="usd">-1310000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-6"
      id="d8312053e1289-wk-Fact-964325EF1A54729D824194757CE58552"
      unitRef="usd">-353000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-6"
      id="d8312053e1309-wk-Fact-1D4A2167CADD270AD7B494757CE56E80"
      unitRef="usd">44000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"
      decimals="-6"
      id="d8312053e1329-wk-Fact-2B2DFC11DDDCB317D2C994757CE2E0A2"
      unitRef="usd">79000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember"
      decimals="-6"
      id="d8312053e1348-wk-Fact-0D58D4B7AB8E12C40B7994757CE6D530"
      unitRef="usd">-65000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d8312053e1369-wk-Fact-4A51A364B44D351B488B94757CE2261B"
      unitRef="usd">-1605000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-6"
      id="d8312053e1400-wk-Fact-01070978017D3A5955FA94757CE3B710"
      unitRef="usd">-7262000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-6"
      id="d8312053e1420-wk-Fact-5D626F8BA3AF19C7FDA494757CE4D631"
      unitRef="usd">-333000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-6"
      id="d8312053e1441-wk-Fact-F37B775487717C15831194757CE1E675"
      unitRef="usd">9000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"
      decimals="-6"
      id="d8312053e1460-wk-Fact-39B9C9FB9AF4AE93494994757CE694B6"
      unitRef="usd">-6178000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember"
      decimals="-6"
      id="d8312053e1480-wk-Fact-2607F27CC1B9FA6307A494757CE398B6"
      unitRef="usd">518000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d8312053e1500-wk-Fact-B09FAC91CEFCADA6B17C94757CE170B9"
      unitRef="usd">-13246000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8312053e1545-wk-Fact-BE6E404B25AA5E89CECF9D3B7019A5B9"
      unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d8312053e1555-wk-Fact-EC4BE606149B17B66782545594D6136A"
      unitRef="usd">-902000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-A660979E9FD00EF5F81A94757DBB7351-0-wk-Fact-CC5462AAB66C01ED4A7894757CC9C69B">&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Financial Instruments&lt;/span&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;A. &lt;/span&gt;&lt;span style="font-weight:bold;text-decoration:underline;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents the financial assets and liabilities measured at fair value using a market approach on a recurring basis by balance sheet categories and fair value hierarchy level as defined in Notes to Consolidated Financial Statements&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 1E. Basis of Presentation and Significant Accounting Policies: Fair Value &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;in our 2019 Financial Report: &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:inherit;font-size:7pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Financial assets measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Classified as equity securities with readily determinable fair values:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Money market funds&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;13,033&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;13,033&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;705&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;705&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Classified as available-for-sale debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Government and agency&#x2014;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;6,218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;6,218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;4,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;4,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Government and agency&#x2014;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;811&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;811&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Corporate and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,440&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,440&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,013&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,013&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;7,672&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;7,672&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;6,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;6,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Total short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;20,705&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;20,705&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;7,392&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;7,392&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Derivative assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;413&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;413&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;413&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;413&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Total other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;431&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;431&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;465&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;465&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Classified as equity securities with readily determinable fair values&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;2,072&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;2,046&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,902&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Classified as available-for-sale debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Government and agency&#x2014;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;243&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;243&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;303&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;303&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Corporate and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;254&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;254&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Total long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;2,326&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;2,046&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;280&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;2,216&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;354&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Derivative assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;261&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;261&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Total derivative assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;362&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;362&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;526&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;526&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Insurance contracts&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;578&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;578&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;575&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;575&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Total other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;940&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;940&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;24,402&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;2,046&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;22,355&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;11,176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;9,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Financial liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Derivative liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Total other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Derivative liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;866&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;866&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;604&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;604&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Total other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;866&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;866&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;604&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;604&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;993&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;993&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;718&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;718&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$11.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of proceeds from the Upjohn debt transactions (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 7D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;) are invested in money market funds and included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Restricted short-term investments &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;in the condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, long-term equity securities of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$163 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, long-term equity securities of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$176 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; were held in restricted trusts for benefits attributable to various U.S. non-qualified employee benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Other noncurrent assets include life insurance policies held in restricted trusts attributable to the funding of various U.S. non-qualified employee benefit plans. The underlying invested assets in these insurance contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in the condensed consolidated statements of income (see&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt; Note 4&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:42%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents the financial liabilities not measured at fair value on a recurring basis, including the carrying values and estimated fair values using a market approach:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Carrying Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Carrying Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:inherit;font-size:7pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Financial Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Long-term debt, excluding the current portion&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50,529&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;59,121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;59,121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,955&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40,842&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40,842&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$11.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of proceeds from the Upjohn debt transactions (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 7D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;) are invested in money market funds and included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Restricted short-term investments &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;in the condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, and short-term borrowings not measured at fair value on a recurring basis were not significant as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; or &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs. The fair value measurements of our private equity securities, which represent investments in the life sciences sector, are based on Level 3 inputs using a market approach.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In addition, as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we had long-term receivables whose fair value is based on Level 3 inputs. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the differences between the estimated fair values and carrying values of these receivables were not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Total Short-Term and Long-Term Investments and Equity-Method Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table represents our investments by classification type:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,033&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;705&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,672&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;288&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total Short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,993&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,525&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,072&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,902&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;254&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Private equity securities at cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;772&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;756&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Total Long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,142&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,014&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Equity-method investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,578&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total long-term investments and equity-method investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18,720&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Held-to-maturity cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;119&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;163&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, equity securities with readily determinable fair values included money market funds primarily invested in U.S. Treasury and government debt. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$11.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of proceeds from the Upjohn debt transactions (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 7D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;) are invested in money market funds and included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Restricted short-term investments &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;in the condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;B. Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="49"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="49" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;At June 28, 2020, our investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt securities at June 28, 2020 and December 31, 2019 is as follows, including, as of June 28, 2020, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Gross Unrealized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Maturities (in Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Gross Unrealized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:6.5pt;"&gt;&lt;span style="font-family:inherit;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Within 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Over 1&lt;br/&gt;to 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Over 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:inherit;font-size:7pt;text-decoration:underline;"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Government and agency&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;6,209&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;6,218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;6,218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;6,218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;4,895&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;4,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Government and agency&#x2013;&#x2013;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;243&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Corporate and other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,451&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,440&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,451&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;text-decoration:underline;"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Time deposits and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;189&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Government and agency&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;803&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;803&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Total debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;8,366&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;8,376&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;8,079&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;263&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;8,376&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;8,380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;8,340&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Primarily issued by a diverse group of corporations.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For our portfolio of available-for-sale and held-to-maturity debt securities, any expected credit losses would be immaterial to the financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Equity Securities&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:52%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents the calculation of the portion of unrealized gains for the period that relates to equity securities, excluding equity method investments, still held at the reporting date:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Six Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net gains recognized during the period on equity securities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(732&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(478&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: Net (gains)/losses recognized during the period on equity securities sold during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net unrealized gains during the reporting period on equity securities still held at the reporting date&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(733&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(459&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The net gains on investments in equity securities are reported in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;net.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b) &lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. Since January 1, 2018, there were cumulative impairments and downward adjustments of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$67 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and upward adjustments of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$66 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;. Impairments, downward and upward adjustments were not significant in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and the first six months of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;C. Short-Term Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Short-term borrowings include:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,660&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,915&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current portion of long-term debt, principal amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,481&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,458&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other short-term borrowings, principal amount&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;956&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;860&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total short-term borrowings, principal amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,097&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,233&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net fair value adjustments related to hedging and purchase accounting&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net unamortized discounts, premiums and debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Short-term borrowings, including current portion of long-term debt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, carried at historical proceeds, as adjusted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,084&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,195&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Other short-term borrowings primarily include cash collateral. For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 7E&lt;/span&gt;.&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;D. &lt;/span&gt;&lt;span style="font-weight:bold;text-decoration:underline;"&gt;Long-Term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;New Issuances&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:60%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In the second quarter of 2020, we issued the following senior unsecured notes:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Principal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Maturity Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of June&#160;28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Pfizer Inc.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.800%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;May&#160;28, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.700%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;May&#160;28, 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.550%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;May&#160;28, 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.700%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;May&#160;28, 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Upjohn Inc., a wholly-owned subsidiary of Pfizer Inc.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.125%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 22, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.650%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 22, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.300%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 22, 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.700%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 22, 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.850%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 22, 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.000%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 22, 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Upjohn Finance B.V., a wholly-owned subsidiary of Upjohn Inc.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.816%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 23, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x20ac;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.023%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 23, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.362%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 23, 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;850&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.908%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 23, 2032&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x20ac;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The notes may be redeemed by us at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest. The weighted-average effective interest rate for the notes at issuance was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;2.11%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;In June 2020, Upjohn Inc. and Upjohn Finance B.V. completed privately placed debt offerings in connection with the previously announced proposed Reverse Morris Trust transaction that will ultimately combine Upjohn and Mylan to form a new company, Viatris. The notes may be redeemed by Upjohn Inc. and Upjohn Finance B.V., as applicable, at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest. The weighted-average effective interest rates at issuance were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;2.95%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$7.45 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; notes and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1.37%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x20ac;3.60 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; notes. If the proposed transaction with Mylan does not close on or prior to February 1, 2021, or if, prior to such date, Upjohn Inc. and Mylan notify the trustee that the business combination agreement for the proposed transaction with Mylan is terminated, or the transaction will not otherwise be pursued, the notes must be redeemed at redemption prices equal to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;101%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of their respective principal amounts, plus accrued and unpaid interest. Pfizer has guaranteed these notes, and such guarantees will automatically and unconditionally terminate without the consent of holders of the notes upon the proposed distribution to Pfizer&#x2019;s stockholders of all of the issued and outstanding shares of Upjohn Inc.&#x2019;s common stock held by Pfizer (the Distribution). Upjohn Inc. has guaranteed the notes issued by Upjohn Finance B.V., and Upjohn Inc. will remain a guarantor of such notes post Distribution. Following the separation, Upjohn Inc. and Upjohn Finance B.V., as applicable, will remain the obligor. The proceeds from the financings will be used in part to fund a cash distribution from Upjohn Inc. to Pfizer immediately prior to the Distribution. In the interim, the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$11.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of proceeds are classified as &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Restricted short-term investments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in the condensed consolidated balance sheet as of June 28, 2020 pursuant to the terms of the transaction agreements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:60%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In the first quarter of 2020, we issued the following senior unsecured notes:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Principal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Maturity Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of June 28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2.625%&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;April&#160;1, 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total long-term debt issued in the first quarter of 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The notes may be redeemed by us at any time, in whole, or in part, at a redemption price plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The effective interest rate for the notes at issuance was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;2.67%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;December&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total long-term debt, principal amount&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;49,187&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34,820&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net fair value adjustments related to hedging and purchase accounting&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,654&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,305&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net unamortized discounts, premiums and debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(317&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other long-term debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total long-term debt, carried at historical proceeds, as adjusted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50,529&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,955&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,481&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,462&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$11.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of proceeds from the Upjohn debt transactions are invested in money market funds and included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Restricted short-term investments &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;in the condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Retirements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In March 2020, we repurchased at par all &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.065 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; principal amount outstanding of our senior unsecured notes that were due in 2047 before the maturity date, which did not have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;E. &lt;/span&gt;&lt;span style="font-weight:bold;text-decoration:underline;"&gt;Derivative Financial Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Foreign Exchange Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. We manage our foreign exchange risk, in part, through operational means, including managing same-currency revenues in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. We also manage our foreign exchange risk, depending on market conditions, through fair value, cash flow, and net investment hedging programs through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to protect net income against the impact of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The derivative financial instruments primarily hedge or offset exposures in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;euro, U.K. pound, Japanese yen, Swedish krona and Chinese renminbi&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As a part of our cash flow hedging program, we designate foreign exchange contracts to hedge a portion of our forecasted &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;euro, Japanese yen, Chinese renminbi, Canadian dollar, U.K. pound and Australian dollar&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-denominated intercompany inventory sales expected to occur no more than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; from the date of each hedge. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Interest Rate Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our interest-bearing investments and borrowings are subject to interest rate risk. With respect to our investments, we strive to maintain a predominantly floating-rate basis position, but our strategy may change based on prevailing market conditions. We currently borrow primarily on a long-term, fixed-rate basis. From time to time, depending on market conditions, we will change the profile of our outstanding debt by entering into derivative financial instruments like interest rate swaps. We entered into derivative financial instruments to hedge or offset the fixed interest rates on the hedged item, matching the amount and timing of the hedged item. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Notional&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Notional&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,543&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;551&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;914&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,193&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;591&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;662&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,995&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;158&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,645&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;318&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;708&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;914&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;909&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;662&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,433&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,623&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;792&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;993&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;718&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$5.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$5.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; as of December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:34%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Amount of&lt;br/&gt;Gains/(Losses)&lt;br/&gt;Recognized in OID&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Amount of Gains/(Losses)&lt;br/&gt;Recognized in OCI&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;,&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#160;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Amount of Gains/(Losses)&lt;br/&gt;Reclassified from&lt;br/&gt;OCI into OID and COS&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a), (b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Derivative Financial Instruments in Cash Flow Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;187&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(204&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;172&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Amount excluded from effectiveness testing recognized in earnings based on an amortization approach&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Derivative Financial Instruments in Fair Value Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;483&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Hedged item &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(483&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Hedged item &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(144&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;The portion on foreign exchange contracts excluded from the assessment of hedge effectiveness&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Non-Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Foreign currency short-term borrowings&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Foreign currency long-term debt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Derivative Financial Instruments Not Designated as Hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;All other net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(216&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:34%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Amount of&lt;br/&gt;Gains/(Losses)&lt;br/&gt;Recognized in OID&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Amount of Gains/(Losses)&lt;br/&gt;Recognized in OCI&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:pt"&gt;,&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:pt"&gt;&#160;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Amount of Gains/(Losses)&lt;br/&gt;Reclassified from&lt;br/&gt;OCI into OID and COS&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:pt"&gt;(a), (b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;"&gt;Six Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Derivative Financial Instruments in Cash Flow Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(341&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;126&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Amount excluded from effectiveness testing recognized in earnings based on an amortization approach&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;86&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Derivative Financial Instruments in Fair Value Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;392&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;813&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Hedged item&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(392&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(813&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Hedged item&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;240&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:18px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;The portion of foreign exchange contracts excluded from the assessment of hedge effectiveness&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;93&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Non-Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Foreign currency short-term borrowings&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Foreign currency long-term debt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Derivative Financial Instruments Not Designated as Hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;All other net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;139&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;188&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;251&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;OID = Other (income)/deductions&#x2014;net, included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in the condensed consolidated statements of income&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; COS = Cost of Sales, included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Cost of sales&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Other comprehensive loss&#x2013;&#x2013;Unrealized holding gains/(losses) on derivative financial instruments, net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the gains and losses are included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Other comprehensive loss&#x2013;&#x2013;Foreign currency translation adjustments, net.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The amounts reclassified from OCI into COS were:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:12px;"&gt;&lt;div style="line-height:120%;font-size:8pt;text-indent:-12px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;a net &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;gain&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$80 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:12px;"&gt;&lt;div style="line-height:120%;font-size:8pt;text-indent:-12px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;a net &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;gain&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$150 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in the first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:12px;"&gt;&lt;div style="line-height:120%;font-size:8pt;text-indent:-12px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;a net &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;gain&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$59 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;; and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:12px;"&gt;&lt;div style="line-height:120%;font-size:8pt;text-indent:-12px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;a net &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;gain&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$103 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in the first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:12px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;gain&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$102 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; within the next 12 months into income&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The maximum length of time over which we are hedging future foreign exchange cash flow relates to our &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; U.K. pound debt maturing in 2043.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The amounts reclassified from OCI were reclassified into OID.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Long-term debt includes foreign currency long-term borrowings with carrying values of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$2.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, which are used as hedging instruments in net investment hedges.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:1px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the amounts recorded in our condensed consolidated balance sheet related to cumulative basis adjustments for fair value hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Carrying Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Carrying Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Carrying Amount of Hedged Assets/Liabilities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Active Hedging Relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Discontinued Hedging Relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Carrying Amount of Hedged Assets/Liabilities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Active Hedging Relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Discontinued Hedging Relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Long-term debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2,023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,181&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;7,092&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;690&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Carrying amounts exclude the cumulative amount of fair value hedging adjustments.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certain of our derivative financial instruments are covered by associated credit-support agreements that have credit-risk-related contingent features designed to reduce both counterparties&#x2019; exposure to risk of defaulting on amounts owed by the other party. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the aggregate fair value of these derivative financial instruments that are in a net liability position was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$928 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, for which we have posted collateral of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$922 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in the normal course of business. If there had been a downgrade to below an A rating by S&amp;amp;P or the equivalent rating by Moody&#x2019;s, we would not have been required to post any additional collateral to our counterparties.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we received cash collateral of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$858 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; from various counterparties. The collateral primarily supports the approximate fair value of our derivative contracts. With respect to the collateral received, the obligations are reported in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Short-term borrowings, including current portion of long-term debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;F. Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On an ongoing basis, we review the creditworthiness of counterparties to our foreign exchange and interest rate agreements and do not expect to incur a significant loss from failure of any counterparties to perform under the agreements. There are no significant concentrations of credit risk related to our financial instruments with any individual counterparty. For additional information about concentrations of certain credit risk related to certain significant customers, see Notes to Consolidated Financial Statements&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 17C. Segment, Geographic and Other Revenue Information: Other Revenue Information &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;in Pfizer&#x2019;s &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Financial Report. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we had amounts due from a well-diversified, high quality group of banks (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;) from around the world. For details about our investments, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 7B &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;above&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In general, there is no requirement for collateral from customers. However, derivative financial instruments are executed under credit-support agreements that provide for the ability to request to receive cash collateral, depending on levels of exposure, our credit rating and the credit rating of the counterparty, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 7E&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; above.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-37FC76D858F979F1748C94757DBB18E5-0-wk-Fact-9E5BBB26E31C14AFFE9C94757CC9794B">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents the financial assets and liabilities measured at fair value using a market approach on a recurring basis by balance sheet categories and fair value hierarchy level as defined in Notes to Consolidated Financial Statements&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 1E. Basis of Presentation and Significant Accounting Policies: Fair Value &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;in our 2019 Financial Report: &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:inherit;font-size:7pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Financial assets measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Classified as equity securities with readily determinable fair values:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Money market funds&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;13,033&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;13,033&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;705&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;705&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Classified as available-for-sale debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Government and agency&#x2014;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;6,218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;6,218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;4,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;4,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Government and agency&#x2014;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;811&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;811&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Corporate and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,440&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,440&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,013&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,013&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;7,672&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;7,672&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;6,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;6,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Total short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;20,705&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;20,705&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;7,392&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;7,392&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Derivative assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;413&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;413&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;413&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;413&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Total other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;431&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;431&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;465&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;465&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Classified as equity securities with readily determinable fair values&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;2,072&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;2,046&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,902&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Classified as available-for-sale debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Government and agency&#x2014;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;243&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;243&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;303&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;303&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Corporate and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;254&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;254&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Total long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;2,326&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;2,046&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;280&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;2,216&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;354&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Derivative assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;261&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;261&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Total derivative assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;362&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;362&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;526&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;526&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Insurance contracts&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;578&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;578&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;575&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;575&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Total other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;940&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;940&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;24,402&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;2,046&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;22,355&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;11,176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;9,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Financial liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Derivative liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Total other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Derivative liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;866&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;866&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;604&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;604&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Total other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;866&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;866&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;604&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;604&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;993&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;993&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;718&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;718&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$11.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of proceeds from the Upjohn debt transactions (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 7D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;) are invested in money market funds and included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Restricted short-term investments &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;in the condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, long-term equity securities of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$163 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, long-term equity securities of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$176 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; were held in restricted trusts for benefits attributable to various U.S. non-qualified employee benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Other noncurrent assets include life insurance policies held in restricted trusts attributable to the funding of various U.S. non-qualified employee benefit plans. The underlying invested assets in these insurance contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in the condensed consolidated statements of income (see&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt; Note 4&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;).&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-6"
      id="d8351242e1548-wk-Fact-66612970542295C5EAA894757D5D6124"
      unitRef="usd">13033000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-6"
      id="d8351242e1566-wk-Fact-20C9854FC8CD379D96E594757D4BB09E"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-6"
      id="d8351242e1585-wk-Fact-03AFF2EF3B741A9220ED94757D3DA6D1"
      unitRef="usd">13033000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-6"
      id="d8351242e1603-wk-Fact-32BCE63F2B148B65B2BD94757D4ABD8F"
      unitRef="usd">705000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-6"
      id="d8351242e1621-wk-Fact-1EA60045B6EB866A340E94757D49440D"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-6"
      id="d8351242e1640-wk-Fact-A2CF9469A723FA507B4C94757D43EBF4"
      unitRef="usd">705000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e1916-wk-Fact-51729F8A79FB6212C36894757CBE9483"
      unitRef="usd">6218000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e1935-wk-Fact-5F45C619AC7AF9BCD93F94757D3847E9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e1954-wk-Fact-6A7C8F68DED7856BBFFA94757D518133"
      unitRef="usd">6218000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e1974-wk-Fact-68EFE825964CAF71402694757D7139E7"
      unitRef="usd">4863000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e1993-wk-Fact-D9A14445EA184E4B100F94757D3CE6C1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e2013-wk-Fact-DEC1FCCCEA01D2CFAAC994757D3CEBF6"
      unitRef="usd">4863000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e2038-wk-Fact-17BFBFFC8E726CC3B4A394757D651B12"
      unitRef="usd">14000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e2057-wk-Fact-4AF966115F483B95688B94757D2E066F"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e2076-wk-Fact-FEC3A79B68EE2EE85D7294757CBC320E"
      unitRef="usd">14000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e2096-wk-Fact-CEEDD0609A221494410A94757CB23075"
      unitRef="usd">811000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e2115-wk-Fact-A8B4BE78EEF25DAFE36994757D84843B"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e2135-wk-Fact-6FAA6A750D8C3D55345D94757CBD839E"
      unitRef="usd">811000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e2161-wk-Fact-5286C28D1D7D770F116C94757D40F903"
      unitRef="usd">1440000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e2180-wk-Fact-660E1616C4AF57FB4AA394757CBB9A76"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e2199-wk-Fact-4D7AD80601DC4DA481B094757D42F529"
      unitRef="usd">1440000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e2219-wk-Fact-91744BF98375B7AEA12294757D38E50D"
      unitRef="usd">1013000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e2238-wk-Fact-3DAFBDEA26361F49311894757D4C2EE3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e2258-wk-Fact-C249FF18F1801C52A43394757D3FC69C"
      unitRef="usd">1013000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e2283-wk-Fact-BFE2CDEBB87C375E3C7394757D84D268"
      unitRef="usd">7672000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e2302-wk-Fact-2582DE260411A2124ECA94757D4DBF9D"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e2321-wk-Fact-C6DB2032032BC607F2B494757D536B73"
      unitRef="usd">7672000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e2341-wk-Fact-614AEDA00527EAFB0D5394757D4A4E7C"
      unitRef="usd">6687000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e2360-wk-Fact-B824D2FB2B2EBC47F81394757D44A7D5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e2380-wk-Fact-C2A260126E20D20AA72394757D30C5B9"
      unitRef="usd">6687000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e2405-wk-Fact-0532EA1A1B46197D465794757CBD7C6E"
      unitRef="usd">20705000000</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e2424-wk-Fact-CB9227A016A7DB50211D94757D4DEC6C"
      unitRef="usd">0</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e2443-wk-Fact-85F07BE5D1FF8956526294757CC038D5"
      unitRef="usd">20705000000</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e2463-wk-Fact-6D361B65F37A1ACA792594757D4788AF"
      unitRef="usd">7392000000</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e2482-wk-Fact-FDFD684E645EFEDC403794757D3DD52E"
      unitRef="usd">0</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e2502-wk-Fact-CB9F8F402A96B52914E994757CC1B3E3"
      unitRef="usd">7392000000</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e2783-wk-Fact-DC8F00FE7B58DC0B667594757D45DB5C"
      unitRef="usd">17000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e2802-wk-Fact-6511075C43A530FD0B7F94757CC48D76"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e2821-wk-Fact-A995F45E600C7F97576394757D4B05E6"
      unitRef="usd">17000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e2841-wk-Fact-5AE6E6E0728B5DF3760394757D3FE9AD"
      unitRef="usd">53000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e2860-wk-Fact-64AC7894DBF70816399C94757D4C42B6"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e2880-wk-Fact-FBFE7903BD0565772AB094757CB2B274"
      unitRef="usd">53000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e2905-wk-Fact-94EEDF40906E2824AE7B94757D406B3E"
      unitRef="usd">413000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e2924-wk-Fact-4CDAA1A423E12BF41DAA94757D3E809C"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e2943-wk-Fact-98D1E7C4F67D902463E494757D473F9F"
      unitRef="usd">413000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e2963-wk-Fact-B5925ABFDC28B9B400E994757D2F1F06"
      unitRef="usd">413000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e2982-wk-Fact-C87F260438FB28B4601A94757D4D1604"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e3002-wk-Fact-EBE3169E637E0897012694757D327C27"
      unitRef="usd">413000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e3027-wk-Fact-15EAF0775B81FCAC127E94757CE7D74C"
      unitRef="usd">431000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e3046-wk-Fact-79A1AAE466C9780A86E494757D3D3E4D"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e3065-wk-Fact-EEBD25D39F530AF0EDBF94757CAFCFC1"
      unitRef="usd">431000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e3085-wk-Fact-24B749F75EEA8C6DF6B594757D444B4A"
      unitRef="usd">465000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e3104-wk-Fact-563B941649E081FD464F94757CBE79D1"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e3124-wk-Fact-77E0D5059B7D34A0C09994757D834902"
      unitRef="usd">465000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e3279-wk-Fact-591CA5BD37BEF066C61294757D3FA07C"
      unitRef="usd">2072000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e3297-wk-Fact-9AC586B89CDBD7EC4F6194757CAFC880"
      unitRef="usd">2046000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e3315-wk-Fact-E1670DD42B676FA2293C94757D4E7C71"
      unitRef="usd">26000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e3334-wk-Fact-0FAA0A010479FD1F2D6594757CB8122B"
      unitRef="usd">1902000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e3352-wk-Fact-B02201B22AB44168B6C494757CC5A140"
      unitRef="usd">1863000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e3371-wk-Fact-D62B36AD2263CAB0455594757CBD05B4"
      unitRef="usd">39000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e3653-wk-Fact-4EC64304994653C6A6D694757D423313"
      unitRef="usd">243000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e3672-wk-Fact-3F825C3786DBB61EB71094757D73A5BD"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e3691-wk-Fact-282FD8B27D5D311E0D3994757D4D8B7D"
      unitRef="usd">243000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e3711-wk-Fact-22743DEE50EEB948B87094757CD75A97"
      unitRef="usd">303000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e3730-wk-Fact-A7F95BF63AE551CBAB6794757D5481AE"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e3750-wk-Fact-819276D963F06D06C0AE94757D33284A"
      unitRef="usd">303000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e3775-wk-Fact-47B3867FBEDC456EDB9594757D4B193D"
      unitRef="usd">11000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e3794-wk-Fact-4C589702EEC16BCB9BE594757CC4C550"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e3813-wk-Fact-7404D5E4A5E94CC28EFB94757CC50427"
      unitRef="usd">11000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e3833-wk-Fact-FC69E5804CC59567EF2894757CE901DB"
      unitRef="usd">11000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e3852-wk-Fact-9E5DC4DC043B84742E6694757D3D30BA"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d8351242e3872-wk-Fact-75D5577BAE2F9A5617C594757CEA0726"
      unitRef="usd">11000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e3897-wk-Fact-C50717BF44CB082CCF7494757D3A7813"
      unitRef="usd">254000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e3916-wk-Fact-D9838C40189706C10B5294757D353F5D"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e3935-wk-Fact-308B871F5C8A79BC7A5494757D7F4265"
      unitRef="usd">254000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e3955-wk-Fact-C4B64F882E730CDAE36794757D7B7670"
      unitRef="usd">315000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e3974-wk-Fact-6B3C4A6B9AE9E8A2163A94757CEA3F7E"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e3994-wk-Fact-9AF1DEC5331BF586BBD294757D3E38BE"
      unitRef="usd">315000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4019-wk-Fact-35892B83D888A8B6714994757D461936"
      unitRef="usd">2326000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4038-wk-Fact-24873C8C77CEDC8D2EB494757D4E6E1B"
      unitRef="usd">2046000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4057-wk-Fact-48594DAEBE1A181E2B2394757D52CB08"
      unitRef="usd">280000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4077-wk-Fact-BAF4BFDB71207EA0981A94757CBBC1DC"
      unitRef="usd">2216000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4096-wk-Fact-A4CA4BB921F4C21D4A5894757D7F1B02"
      unitRef="usd">1863000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4116-wk-Fact-5CE5F239710C3B64F09C94757D48C905"
      unitRef="usd">354000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4397-wk-Fact-0D0CA3F9E67E30CEBE5394757CC43F65"
      unitRef="usd">140000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4416-wk-Fact-480817A8340F413FD79F94757D4F2C56"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4435-wk-Fact-5684F36778A54D13329194757D5386DC"
      unitRef="usd">140000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4455-wk-Fact-CB746A9A3946D79B39E694757CB9F8F6"
      unitRef="usd">266000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4474-wk-Fact-21E220FF02E91EBD575E94757D3BA7C7"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4494-wk-Fact-A71CD6E5722C55626DC394757D46691A"
      unitRef="usd">266000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4519-wk-Fact-05693C9F74B7C7AA7AF694757D43DB56"
      unitRef="usd">221000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4538-wk-Fact-420357463B0346814B6F94757D44D606"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4557-wk-Fact-2101E561A5879EB0864394757D2FAC26"
      unitRef="usd">221000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4577-wk-Fact-BAE5E7824F189D809C3294757CE8ECEA"
      unitRef="usd">261000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4596-wk-Fact-5016F686151C62EAF2DD94757D41914A"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4616-wk-Fact-D8B2DF1FCAE6F04D8A5194757D55E63B"
      unitRef="usd">261000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4641-wk-Fact-FCA57C3A4681DF490FE894757D4BDFD1"
      unitRef="usd">362000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4660-wk-Fact-2182225A97E74833536B94757CC21CA9"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4679-wk-Fact-48EC434550E294D18A9A94757D459E4D"
      unitRef="usd">362000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4699-wk-Fact-97E928B41B23FDFD0C1294757CBFFA3C"
      unitRef="usd">526000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4718-wk-Fact-72F9B29990F7570325A794757CC1BD1B"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4738-wk-Fact-541C9156D603BBB6AF8794757D373ADE"
      unitRef="usd">526000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4765-wk-Fact-B0EAB8BEE5D94E16A4A394757CB05C4E"
      unitRef="usd">578000000</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4784-wk-Fact-2C55CE6AF1C796A4ED5994757D51DA44"
      unitRef="usd">0</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4803-wk-Fact-C5258C9AE0E9A683474194757D833A8F"
      unitRef="usd">578000000</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4823-wk-Fact-787DD497342D45C6DCBD94757D3F332F"
      unitRef="usd">575000000</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4842-wk-Fact-9A214797BCD7FFF4A83494757D3BB1A1"
      unitRef="usd">0</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4862-wk-Fact-290DB7E326ACD87BB2AE94757D855347"
      unitRef="usd">575000000</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4888-wk-Fact-51CCF3E36BF136D5A51494757D4FE3A5"
      unitRef="usd">940000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4907-wk-Fact-B028417E4A072B8DE74194757D531D30"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4926-wk-Fact-3CFF9A3F87977020AC4994757CE93BE6"
      unitRef="usd">940000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4946-wk-Fact-13E2EB9C3878BFD2FFAF94757D6BCD5D"
      unitRef="usd">1102000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4965-wk-Fact-33B72E9B20D5A269E79694757D7DE89E"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e4985-wk-Fact-38380FC548FAF9688FB394757D47998B"
      unitRef="usd">1102000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e5015-wk-Fact-458BC42ACF56C0C00F1294757D42AD7D"
      unitRef="usd">24402000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e5034-wk-Fact-944ACA21902C1A615DB094757CE82B87"
      unitRef="usd">2046000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e5054-wk-Fact-52DAB6D7B762C84FF97C94757D4A6101"
      unitRef="usd">22355000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e5073-wk-Fact-DF18E25DE31D735CE5FF94757D4FDA1E"
      unitRef="usd">11176000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e5092-wk-Fact-3258FBBE5C6610BD68E194757CC5B5F3"
      unitRef="usd">1863000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e5112-wk-Fact-706538E2BA2E54652D3994757D52E7F5"
      unitRef="usd">9313000000</us-gaap:Assets>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e5649-wk-Fact-AC0B296B5A6EBA950F3A94757D441EA5"
      unitRef="usd">127000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e5668-wk-Fact-9EE02906DA7A45C5999594757D480F42"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e5688-wk-Fact-FF84F4185DEB7268441694757D489D66"
      unitRef="usd">127000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e5707-wk-Fact-76DE5EB5C5DF5A372F9494757CE8411F"
      unitRef="usd">114000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e5726-wk-Fact-DB8EB962F643334319A294757D29A1B3"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e5746-wk-Fact-7F33E3EEEB2C7F9E5D4F94757D72F332"
      unitRef="usd">114000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e5766-wk-Fact-338149ABCEA12CB85EDB94757D54B0B1"
      unitRef="usd">127000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e5785-wk-Fact-19AC8AC5EEBE14C5C86994757D505B0F"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e5804-wk-Fact-FA7CDAD2E0FE077D2B2294757CC1AF75"
      unitRef="usd">127000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e5824-wk-Fact-1A411667652C4392098B94757D523BBF"
      unitRef="usd">114000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e5843-wk-Fact-53787B8006C71FE8452294757D50AFAC"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e5863-wk-Fact-3028F4451F2736AFFB6794757DA44501"
      unitRef="usd">114000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e6144-wk-Fact-FBBDED7A6E85BF92687494757CAFE1C6"
      unitRef="usd">866000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e6163-wk-Fact-3D22450D16FCE8002B9394757D513D01"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e6182-wk-Fact-B81FAC97C51D75C709A194757D47E2FD"
      unitRef="usd">866000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e6202-wk-Fact-1D8300B1655962B921EB94757CECE556"
      unitRef="usd">604000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e6221-wk-Fact-92F86B087211FF5A96AA94757D32F1F3"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e6241-wk-Fact-F4B0A1C5A397D314C2E894757CBFB71E"
      unitRef="usd">604000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e6267-wk-Fact-02DA181659C62C2D5C2A94757D502B5A"
      unitRef="usd">866000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e6286-wk-Fact-AEE02E937098A502470A94757CE35BB1"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e6305-wk-Fact-71959F1BE99285069A2894757D388B97"
      unitRef="usd">866000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e6325-wk-Fact-F3BE67581CC42400330694757D42EF3A"
      unitRef="usd">604000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e6344-wk-Fact-7E5CDB1865C1203E189994757D44B473"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e6364-wk-Fact-412197EC6F0B972C673894757D54E628"
      unitRef="usd">604000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e6394-wk-Fact-BE27B78E4B159A0D9E3694757D3659AB"
      unitRef="usd">993000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e6413-wk-Fact-CCC80B4399231D05F2B494757D47F1A1"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e6433-wk-Fact-BB8921A12446F45BA5E594757CB2D1AF"
      unitRef="usd">993000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e6452-wk-Fact-4EBF22B3432CAEA9026F94757CC6832F"
      unitRef="usd">718000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e6471-wk-Fact-6C42D62A74E4224FDB1194757D7CFB35"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e6491-wk-Fact-B5DA7287E69D1D5E313294757D5434CB"
      unitRef="usd">718000000</us-gaap:DerivativeLiabilities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="FD2020Q2YTD_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember"
      decimals="-8"
      id="d8351242e6509-wk-Fact-FF9524E6BB352641CEF36EAEF8842218"
      unitRef="usd">11400000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <pfe:EquitySecuritiesFVNIRestrictedNoncurrent
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e6538-wk-Fact-7BE740157FA0927B8E5B94757CC92FDA"
      unitRef="usd">163000000</pfe:EquitySecuritiesFVNIRestrictedNoncurrent>
    <pfe:EquitySecuritiesFVNIRestrictedNoncurrent
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d8351242e6546-wk-Fact-61F25B81E0B8ABC9E44E94757CC98438"
      unitRef="usd">176000000</pfe:EquitySecuritiesFVNIRestrictedNoncurrent>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-1F9EE9D6AB95F5A422F294757DBB78B8-0-wk-Fact-9636B1A5E02F4FABACF194757CC938AB">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:42%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents the financial liabilities not measured at fair value on a recurring basis, including the carrying values and estimated fair values using a market approach:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Carrying Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Carrying Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:inherit;font-size:7pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Financial Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Long-term debt, excluding the current portion&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50,529&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;59,121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;59,121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,955&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40,842&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40,842&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$11.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of proceeds from the Upjohn debt transactions (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 7D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;) are invested in money market funds and included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Restricted short-term investments &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;in the condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:LongTermDebtFairValue
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember"
      decimals="-6"
      id="d8351242e7282-wk-Fact-8289F953B8E0A1E31F6E94757D81004F"
      unitRef="usd">50529000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember"
      decimals="-6"
      id="d8351242e7301-wk-Fact-F107D07691956E457F2694757D819FCD"
      unitRef="usd">59121000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember"
      decimals="-6"
      id="d8351242e7321-wk-Fact-1FEE3FFA0E7F81909D6294757D83017E"
      unitRef="usd">59121000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember"
      decimals="-6"
      id="d8351242e7340-wk-Fact-0572F3E504E5D75C810D94757D8292B7"
      unitRef="usd">35955000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember"
      decimals="-6"
      id="d8351242e7359-wk-Fact-C0B91802E709F9C8087C94757D805460"
      unitRef="usd">40842000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember"
      decimals="-6"
      id="d8351242e7379-wk-Fact-7A8A1B93604E236BB74394757D812BD2"
      unitRef="usd">40842000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="FD2020Q2YTD_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember"
      decimals="-8"
      id="d8351242e7403-wk-Fact-FF9524E6BB352641CEF36EAEF8842218"
      unitRef="usd">11400000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-3B041622CBA2D9F043B794757DBB6046-0-wk-Fact-C699C2159CA77457850594757CC79FB9">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table represents our investments by classification type:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,033&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;705&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,672&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;288&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total Short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,993&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,525&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,072&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,902&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;254&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Private equity securities at cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;772&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;756&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Total Long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,142&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,014&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Equity-method investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,578&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total long-term investments and equity-method investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18,720&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Held-to-maturity cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;119&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;163&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, equity securities with readily determinable fair values included money market funds primarily invested in U.S. Treasury and government debt. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$11.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of proceeds from the Upjohn debt transactions (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 7D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;) are invested in money market funds and included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Restricted short-term investments &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;in the condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8351242e7848-wk-Fact-6C93273338F344A1EC9D94757D345F29"
      unitRef="usd">13033000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8351242e7867-wk-Fact-0062B855A4905ABE3A7094757D9632CA"
      unitRef="usd">705000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8351242e7887-wk-Fact-D12088AF2B84A688720E94757D923060"
      unitRef="usd">7672000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8351242e7906-wk-Fact-58D249F71657AAA7951094757D3404E9"
      unitRef="usd">6687000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8351242e7931-wk-Fact-8D13847D02CC85F4058794757D32681D"
      unitRef="usd">288000000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8351242e7950-wk-Fact-B94608FCBEAED35CAC0E94757D95E893"
      unitRef="usd">1133000000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:ShortTermInvestments
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8351242e7980-wk-Fact-34460712EBCE8630161A94757D364700"
      unitRef="usd">20993000000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8351242e7999-wk-Fact-461073F79378DD0C88EA94757D96B544"
      unitRef="usd">8525000000</us-gaap:ShortTermInvestments>
    <pfe:EquitySecuritiesFVNINoncurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8351242e8116-wk-Fact-94EB0312C6CB9501083E94757D938FCF"
      unitRef="usd">2072000000</pfe:EquitySecuritiesFVNINoncurrent>
    <pfe:EquitySecuritiesFVNINoncurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8351242e8135-wk-Fact-746631D92A859C874D8394757D93611C"
      unitRef="usd">1902000000</pfe:EquitySecuritiesFVNINoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8351242e8155-wk-Fact-3CEF4A6CEC73C33FCCF994757D365ED1"
      unitRef="usd">254000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8351242e8174-wk-Fact-B2C06F5604F95B6F1D8C94757D94EC08"
      unitRef="usd">315000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8351242e8200-wk-Fact-FEC0DC267FE14F73E80594757D95A805"
      unitRef="usd">43000000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8351242e8219-wk-Fact-6FED084D74B1A999735694757D332573"
      unitRef="usd">42000000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <pfe:PrivateEquityInvestments
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8351242e8244-wk-Fact-E0E1AB7E6C9E4707573094757D94F890"
      unitRef="usd">772000000</pfe:PrivateEquityInvestments>
    <pfe:PrivateEquityInvestments
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8351242e8263-wk-Fact-24C59A7A7528D3CCBAAF94757D349138"
      unitRef="usd">756000000</pfe:PrivateEquityInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8351242e8293-wk-Fact-FFBCEDF314C46C81ABEE94757D18EE64"
      unitRef="usd">3142000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8351242e8312-wk-Fact-BCE8A138729B45E61B7F94757D2C3132"
      unitRef="usd">3014000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8351242e8332-wk-Fact-06B216BCF27965D7A6A694757D11CF28"
      unitRef="usd">15578000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8351242e8351-wk-Fact-CFF1903136C1AC56DF3A94757D2B131B"
      unitRef="usd">17133000000</us-gaap:EquityMethodInvestments>
    <us-gaap:LongTermInvestments
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8351242e8381-wk-Fact-E78BCC7A156D3417B34F94757D9245CF"
      unitRef="usd">18720000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8351242e8400-wk-Fact-B55C00037C5C2F34E16594757D3A1262"
      unitRef="usd">20147000000</us-gaap:LongTermInvestments>
    <pfe:HeldToMaturityCashEquivalents
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8351242e8425-wk-Fact-B7DE41EB9B150DFDE59C94757D963CFC"
      unitRef="usd">119000000</pfe:HeldToMaturityCashEquivalents>
    <pfe:HeldToMaturityCashEquivalents
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8351242e8444-wk-Fact-2B031016A863CE33C3D994757D367D09"
      unitRef="usd">163000000</pfe:HeldToMaturityCashEquivalents>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="FD2020Q2YTD_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember"
      decimals="-8"
      id="d8351242e8700-wk-Fact-FF9524E6BB352641CEF36EAEF8842218"
      unitRef="usd">11400000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:HeldToMaturitySecuritiesTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-ACE664A967E79929E92C94757DBC57EC-0-wk-Fact-6342866ADBAFBEFF4FA894757D947A24">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="49"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="49" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;At June 28, 2020, our investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt securities at June 28, 2020 and December 31, 2019 is as follows, including, as of June 28, 2020, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Gross Unrealized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Maturities (in Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Gross Unrealized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:6.5pt;"&gt;&lt;span style="font-family:inherit;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Within 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Over 1&lt;br/&gt;to 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Over 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:inherit;font-size:7pt;text-decoration:underline;"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Government and agency&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;6,209&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;6,218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;6,218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;6,218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;4,895&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;4,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Government and agency&#x2013;&#x2013;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;243&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Corporate and other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,451&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,440&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,451&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;text-decoration:underline;"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Time deposits and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;189&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Government and agency&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;803&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;803&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Total debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;8,366&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;8,376&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;8,079&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;263&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;8,376&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;8,380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;8,340&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Primarily issued by a diverse group of corporations.&lt;/span&gt;&lt;/div&gt;</us-gaap:HeldToMaturitySecuritiesTextBlock>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-342B0A6E8A0919B04A6194757DBCFF59-0-wk-Fact-9E6D2AADD6AAA49E56FB94757D955EEE">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="49"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="49" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;At June 28, 2020, our investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt securities at June 28, 2020 and December 31, 2019 is as follows, including, as of June 28, 2020, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Gross Unrealized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Maturities (in Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Gross Unrealized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:6.5pt;"&gt;&lt;span style="font-family:inherit;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Within 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Over 1&lt;br/&gt;to 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Over 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:inherit;font-size:7pt;text-decoration:underline;"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Government and agency&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;6,209&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;6,218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;6,218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;6,218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;4,895&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;4,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Government and agency&#x2013;&#x2013;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;243&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Corporate and other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,451&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,440&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,451&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;text-decoration:underline;"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Time deposits and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;189&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Government and agency&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;803&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;803&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Total debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;8,366&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;8,376&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;8,079&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;263&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;8,376&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;8,380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;8,340&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Primarily issued by a diverse group of corporations.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-E91C0C0879A4EDF21B7994757DBCB0F1-0-wk-Fact-AE06CE06638E6BD9FF3994757D96FCDD">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="49"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="49" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;At June 28, 2020, our investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt securities at June 28, 2020 and December 31, 2019 is as follows, including, as of June 28, 2020, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Gross Unrealized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Maturities (in Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Gross Unrealized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:6.5pt;"&gt;&lt;span style="font-family:inherit;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Within 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Over 1&lt;br/&gt;to 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Over 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:inherit;font-size:7pt;text-decoration:underline;"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Government and agency&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;6,209&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;6,218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;6,218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;6,218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;4,895&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;4,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Government and agency&#x2013;&#x2013;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;243&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Corporate and other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,451&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,440&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,451&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;text-decoration:underline;"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Time deposits and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;189&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Government and agency&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;803&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;803&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Total debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;8,366&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;8,376&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;8,079&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;263&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;8,376&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;8,380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;(47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;8,340&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Primarily issued by a diverse group of corporations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2031-wk-Fact-1E07A332CF81E75EE89194757D6ADCD5"
      unitRef="usd">6209000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2050-wk-Fact-E66B31F2784722FE09B194757D65E6DC"
      unitRef="usd">12000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2070-wk-Fact-40916FC0ADB6E253C26C94757D741209"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2090-wk-Fact-4A18193DE354B450296194757D62FA67"
      unitRef="usd">6218000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2109-wk-Fact-6414B3AAA36AB6F8996C94757D70F52B"
      unitRef="usd">6218000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2129-wk-Fact-F75DADC0A525A623B0ED94757CACD9F0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2148-wk-Fact-EA6B7B499B7AE194F97C94757D648C7E"
      unitRef="usd">0</pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2167-wk-Fact-4A18193DE354B450296194757D62FA67"
      unitRef="usd">6218000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2187-wk-Fact-642C8BB986C4F5B5C73194757CAE6A32"
      unitRef="usd">4895000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2206-wk-Fact-0EDA6E34A013B2EEDB5594757D75DD41"
      unitRef="usd">6000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2225-wk-Fact-BB099DC5543875AE717E94757D78C4A1"
      unitRef="usd">38000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2246-wk-Fact-7FBDD6E8D622F1C7D81C94757CAD2655"
      unitRef="usd">4863000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2266-wk-Fact-2C86808B55E15957B66894757CAA2949"
      unitRef="usd">257000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2285-wk-Fact-90AE9B5AC2525DE17E8F94757D72B1FD"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2304-wk-Fact-DF2A674AE873D015FD5394757D6572B0"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2325-wk-Fact-6487B8AC6FEFCF90D47A94757CA831E7"
      unitRef="usd">257000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2344-wk-Fact-9EA1ABD3FD2E807E66E994757D648183"
      unitRef="usd">14000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2364-wk-Fact-514FF59A5657F6BD97C394757D714DD4"
      unitRef="usd">243000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2383-wk-Fact-D85C48A562FC506974F694757D64E0B9"
      unitRef="usd">0</pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2402-wk-Fact-6487B8AC6FEFCF90D47A94757CA831E7"
      unitRef="usd">257000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2422-wk-Fact-297354A5E6681F5E817394757CABD662"
      unitRef="usd">1120000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2441-wk-Fact-1043055DC7FA32531FF894757CAC00DE"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2460-wk-Fact-09ED68A78CE22A2CB6B194757D62D846"
      unitRef="usd">6000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2481-wk-Fact-9B9C8C3919447C777A6294757D768CC6"
      unitRef="usd">1114000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2508-wk-Fact-732C702072B79FA479FA94757D6913F9"
      unitRef="usd">1450000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2527-wk-Fact-74E1087E683DE833774594757D710EBE"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2546-wk-Fact-578926C69776E0961EBC94757D74A38D"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2567-wk-Fact-F4AF4992B1DFCF6708C794757D66A5A2"
      unitRef="usd">1451000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2586-wk-Fact-13FB46151EC8E0F07C8894757D671597"
      unitRef="usd">1440000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2606-wk-Fact-C2D1AFE34B96F2CC1CC194757D6DD63A"
      unitRef="usd">11000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2625-wk-Fact-2617EC9BFAF0558F600394757D657721"
      unitRef="usd">0</pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2644-wk-Fact-F4AF4992B1DFCF6708C794757D66A5A2"
      unitRef="usd">1451000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2664-wk-Fact-F783B181694B408C809794757D6B5422"
      unitRef="usd">1027000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2683-wk-Fact-F98C90F9224CC0E01A5794757D69B0D8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2702-wk-Fact-2D9E3E8DD330C83B27D894757D6B6917"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e2723-wk-Fact-B6FF2688963BD7DB8BDA94757D710150"
      unitRef="usd">1025000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember"
      decimals="-6"
      id="d8336625e2998-wk-Fact-DC6E4AEFC0FD552F3D5894757D624BB9"
      unitRef="usd">228000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember"
      decimals="-6"
      id="d8336625e3017-wk-Fact-F094CA2E41682574DB4194757D63D0B4"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember"
      decimals="-6"
      id="d8336625e3036-wk-Fact-1F32493351FB24825AF894757D6C959A"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember"
      decimals="-6"
      id="d8336625e3056-wk-Fact-756D80E9EED3D31D746694757D6159D7"
      unitRef="usd">228000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember"
      decimals="-6"
      id="d8336625e3075-wk-Fact-A82459496C31F2967C7D94757D71FCBD"
      unitRef="usd">189000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember"
      decimals="-6"
      id="d8336625e3095-wk-Fact-251A625674A554C58A6794757D6FED0B"
      unitRef="usd">9000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember"
      decimals="-6"
      id="d8336625e3114-wk-Fact-2944C8AA1DFD1C47A10394757D653615"
      unitRef="usd">30000000</pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember"
      decimals="-6"
      id="d8336625e3133-wk-Fact-DC6E4AEFC0FD552F3D5894757D624BB9"
      unitRef="usd">228000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember"
      decimals="-6"
      id="d8336625e3153-wk-Fact-3D41AF66A3C3EEB4111794757D72423B"
      unitRef="usd">535000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember"
      decimals="-6"
      id="d8336625e3172-wk-Fact-A3F186CD360BA4F4CE3894757CAC5CC1"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember"
      decimals="-6"
      id="d8336625e3191-wk-Fact-198D3E938169E4A6D18994757D6A0AF7"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember"
      decimals="-6"
      id="d8336625e3211-wk-Fact-4D094E88040B9ACC57F594757CAA8B54"
      unitRef="usd">535000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e3240-wk-Fact-E557914714CCF575AD4794757D61A03B"
      unitRef="usd">222000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e3259-wk-Fact-11E715FD31BB5FDBC8AC94757D6A7D51"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e3278-wk-Fact-0E253A74A2AF0E86559494757D6CA87D"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e3298-wk-Fact-63F766BB1A3D4C74BD4394757D6258FD"
      unitRef="usd">222000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e3317-wk-Fact-4C132DEE5FABD0C31FF294757D62258F"
      unitRef="usd">218000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e3337-wk-Fact-9D80D3A1CB3B1C0CE4C794757CAADF76"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e3356-wk-Fact-3E18E44D9F965ECBDA2294757D6C5D67"
      unitRef="usd">4000000</pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e3375-wk-Fact-E557914714CCF575AD4794757D61A03B"
      unitRef="usd">222000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e3395-wk-Fact-CD83713B6DCDE515E8E994757D78ACCF"
      unitRef="usd">803000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e3414-wk-Fact-436E153961D73D91280494757D74B323"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e3433-wk-Fact-A5FB5537AFEEE69F806794757D65FD6E"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d8336625e3453-wk-Fact-03B7F5A9F53949E7B9D794757D756D0E"
      unitRef="usd">803000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <pfe:DebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8336625e3484-wk-Fact-D78AE22FD9CF08F60B3A94757D6B9F16"
      unitRef="usd">8366000000</pfe:DebtSecuritiesAmortizedCostBasis>
    <pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8336625e3503-wk-Fact-03AAD0BFD65906FA4EA494757D637ADD"
      unitRef="usd">16000000</pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain>
    <pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8336625e3523-wk-Fact-F63BBA7676F4DC45582394757D6F20F3"
      unitRef="usd">5000000</pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8336625e3543-wk-Fact-3B838EA6B866B17EB04F94757D6778DC"
      unitRef="usd">8376000000</us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity>
    <pfe:DebtSecuritiesMaturitiesNextTwelveMonthsFairValue
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8336625e3562-wk-Fact-6B5CC83C4CEC57792B4194757D6CFAD4"
      unitRef="usd">8079000000</pfe:DebtSecuritiesMaturitiesNextTwelveMonthsFairValue>
    <pfe:DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8336625e3582-wk-Fact-164570A44E7F8FB9FF2494757CA8AC8A"
      unitRef="usd">263000000</pfe:DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue>
    <pfe:DebtSecuritiesMaturitiesAfterYearFiveFairValue
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8336625e3601-wk-Fact-0850F78FA1C2AD5E1A9194757D73BE92"
      unitRef="usd">35000000</pfe:DebtSecuritiesMaturitiesAfterYearFiveFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8336625e3620-wk-Fact-3B838EA6B866B17EB04F94757D6778DC"
      unitRef="usd">8376000000</us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity>
    <pfe:DebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8336625e3640-wk-Fact-6CA713A3D04E0BED22CE94757D6CF866"
      unitRef="usd">8380000000</pfe:DebtSecuritiesAmortizedCostBasis>
    <pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8336625e3659-wk-Fact-8DFB2F34A68C8EAB957C94757D66DDC5"
      unitRef="usd">6000000</pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain>
    <pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8336625e3678-wk-Fact-2B36A65E8537353058C394757D763B9F"
      unitRef="usd">47000000</pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8336625e3699-wk-Fact-1CD5ADB0CDE00D32B6EF94757CA97228"
      unitRef="usd">8340000000</us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity>
    <pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-A377257B9B0B656B51C394757DBBAB24-0-wk-Fact-2E7A01FAF70A61FF2B1A94757D9468F8">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:52%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents the calculation of the portion of unrealized gains for the period that relates to equity securities, excluding equity method investments, still held at the reporting date:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Six Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net gains recognized during the period on equity securities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(732&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(478&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: Net (gains)/losses recognized during the period on equity securities sold during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net unrealized gains during the reporting period on equity securities still held at the reporting date&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(733&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(459&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The net gains on investments in equity securities are reported in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;net.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b) &lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. Since January 1, 2018, there were cumulative impairments and downward adjustments of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$67 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and upward adjustments of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$66 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;. Impairments, downward and upward adjustments were not significant in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and the first six months of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8336625e4068-wk-Fact-BE2B9931D467A3220D4894757CFCC65C"
      unitRef="usd">732000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8336625e4088-wk-Fact-A89179620F4ADD5E911294757CF30C7B"
      unitRef="usd">36000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8336625e4109-wk-Fact-98787FFB4C950A5BBD0194757CE6C4FB"
      unitRef="usd">478000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8336625e4129-wk-Fact-05F41C05FF959B0D282094757CDBBAC3"
      unitRef="usd">147000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8336625e4150-wk-Fact-2B90710458B1C6E419A294757D18ECC2"
      unitRef="usd">-1000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8336625e4169-wk-Fact-C57EB7AF3932DFA034B094757D1A76BF"
      unitRef="usd">6000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8336625e4189-wk-Fact-98B4C3B5DE39A4626AC594757D79586E"
      unitRef="usd">18000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8336625e4210-wk-Fact-98DD9B148BF5E010632094757D2EB733"
      unitRef="usd">10000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8336625e4243-wk-Fact-E5773A2CC07AA52848B394757D195108"
      unitRef="usd">733000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8336625e4263-wk-Fact-B993CE1535AAAD9D78CF94757D18D0D5"
      unitRef="usd">31000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8336625e4284-wk-Fact-0EF563315BCCD33D4EF194757D29687F"
      unitRef="usd">459000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8336625e4304-wk-Fact-3BF504D49EB0EC30CF2A94757D310539"
      unitRef="usd">137000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <pfe:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8336625e4355-wk-Fact-E2553A8C3F43098D69D594757D95713F"
      unitRef="usd">67000000</pfe:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8336625e4359-wk-Fact-B9FF9F4B358898BA15B394757D9701CE"
      unitRef="usd">66000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount>
    <us-gaap:ScheduleOfShortTermDebtTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-D9E14A665243AE9FA93894757DBC6979-0-wk-Fact-1579A4B384940F22B93494757CEA17CD">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Short-term borrowings include:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,660&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,915&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current portion of long-term debt, principal amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,481&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,458&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other short-term borrowings, principal amount&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;956&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;860&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total short-term borrowings, principal amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,097&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,233&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net fair value adjustments related to hedging and purchase accounting&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net unamortized discounts, premiums and debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Short-term borrowings, including current portion of long-term debt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, carried at historical proceeds, as adjusted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,084&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,195&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Other short-term borrowings primarily include cash collateral. For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 7E&lt;/span&gt;.</us-gaap:ScheduleOfShortTermDebtTextBlock>
    <us-gaap:CommercialPaper
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8329819e825-wk-Fact-DB3D21B5305018AF1C3A94757D0AD6DD"
      unitRef="usd">10660000000</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8329819e844-wk-Fact-2AFA9323EC10EA5807E894757D0CD47F"
      unitRef="usd">13915000000</us-gaap:CommercialPaper>
    <pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8329819e864-wk-Fact-A1A9572C0E944C54F3F994757D0B7204"
      unitRef="usd">1481000000</pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting>
    <pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8329819e883-wk-Fact-2E3ED2641721F5EFED6494757D0C9F62"
      unitRef="usd">1458000000</pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting>
    <us-gaap:OtherShortTermBorrowings
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8329819e910-wk-Fact-9A056798B17100CAB31894757D0A17AE"
      unitRef="usd">956000000</us-gaap:OtherShortTermBorrowings>
    <us-gaap:OtherShortTermBorrowings
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8329819e929-wk-Fact-25892BA475209169BE1A94757D0BD496"
      unitRef="usd">860000000</us-gaap:OtherShortTermBorrowings>
    <pfe:ShorttermDebtGross
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8329819e954-wk-Fact-6AE38239D4219F1C41B294757D0B22C0"
      unitRef="usd">13097000000</pfe:ShorttermDebtGross>
    <pfe:ShorttermDebtGross
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8329819e973-wk-Fact-B60F013139C457A9ECBF94757D0A9191"
      unitRef="usd">16233000000</pfe:ShorttermDebtGross>
    <pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8329819e998-wk-Fact-9450C9ACB6D8D6019CA794757D0C7E34"
      unitRef="usd">1000000</pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting>
    <pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8329819e1017-wk-Fact-C68FFFD1E9EDF6A3DB1994757D0C6D02"
      unitRef="usd">5000000</pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8329819e1042-wk-Fact-7B9F2AA22ADCA16F04FC94757D0C05F8"
      unitRef="usd">14000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8329819e1062-wk-Fact-34052216BDBE13832D7F94757D0BA7C7"
      unitRef="usd">43000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtCurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8329819e1097-wk-Fact-FA941197011A51FBD4DF94757D289899"
      unitRef="usd">13084000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8329819e1116-wk-Fact-E1C7AF863456D04209EB94757D12EC91"
      unitRef="usd">16195000000</us-gaap:DebtCurrent>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-0B0F3640B427F8D79BCD94757DBD3BDC-0-wk-Fact-033CF5F0A842F012BE0F94757D8BEAE7">&lt;div style="line-height:120%;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:60%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In the second quarter of 2020, we issued the following senior unsecured notes:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Principal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Maturity Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of June&#160;28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Pfizer Inc.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.800%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;May&#160;28, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.700%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;May&#160;28, 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.550%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;May&#160;28, 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.700%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;May&#160;28, 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Upjohn Inc., a wholly-owned subsidiary of Pfizer Inc.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.125%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 22, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.650%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 22, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.300%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 22, 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.700%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 22, 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.850%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 22, 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.000%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 22, 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Upjohn Finance B.V., a wholly-owned subsidiary of Upjohn Inc.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.816%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 23, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x20ac;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.023%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 23, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.362%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 23, 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;850&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.908%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 23, 2032&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x20ac;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The notes may be redeemed by us at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest. The weighted-average effective interest rate for the notes at issuance was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;2.11%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;In June 2020, Upjohn Inc. and Upjohn Finance B.V. completed privately placed debt offerings in connection with the previously announced proposed Reverse Morris Trust transaction that will ultimately combine Upjohn and Mylan to form a new company, Viatris. The notes may be redeemed by Upjohn Inc. and Upjohn Finance B.V., as applicable, at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest. The weighted-average effective interest rates at issuance were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;2.95%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$7.45 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; notes and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1.37%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x20ac;3.60 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; notes. If the proposed transaction with Mylan does not close on or prior to February 1, 2021, or if, prior to such date, Upjohn Inc. and Mylan notify the trustee that the business combination agreement for the proposed transaction with Mylan is terminated, or the transaction will not otherwise be pursued, the notes must be redeemed at redemption prices equal to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;101%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of their respective principal amounts, plus accrued and unpaid interest. Pfizer has guaranteed these notes, and such guarantees will automatically and unconditionally terminate without the consent of holders of the notes upon the proposed distribution to Pfizer&#x2019;s stockholders of all of the issued and outstanding shares of Upjohn Inc.&#x2019;s common stock held by Pfizer (the Distribution). Upjohn Inc. has guaranteed the notes issued by Upjohn Finance B.V., and Upjohn Inc. will remain a guarantor of such notes post Distribution. Following the separation, Upjohn Inc. and Upjohn Finance B.V., as applicable, will remain the obligor. The proceeds from the financings will be used in part to fund a cash distribution from Upjohn Inc. to Pfizer immediately prior to the Distribution. In the interim, the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$11.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of proceeds are classified as &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Restricted short-term investments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in the condensed consolidated balance sheet as of June 28, 2020 pursuant to the terms of the transaction agreements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:60%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In the first quarter of 2020, we issued the following senior unsecured notes:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Principal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Maturity Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of June 28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2.625%&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;April&#160;1, 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total long-term debt issued in the first quarter of 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The notes may be redeemed by us at any time, in whole, or in part, at a redemption price plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The effective interest rate for the notes at issuance was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;2.67%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;December&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total long-term debt, principal amount&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;49,187&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34,820&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net fair value adjustments related to hedging and purchase accounting&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,654&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,305&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net unamortized discounts, premiums and debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(317&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other long-term debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total long-term debt, carried at historical proceeds, as adjusted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50,529&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,955&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,481&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,462&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$11.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of proceeds from the Upjohn debt transactions are invested in money market funds and included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Restricted short-term investments &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;in the condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d8342313e903-wk-Fact-2B3D4239B5C3D2E4BACE6E2AB54F9572"
      unitRef="number">0.00800</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d8342313e928-wk-Fact-EC3D95B498D732C8A49062B280E47D49"
      unitRef="usd">750000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d8342313e938-wk-Fact-3112A444D5581CE12B086E2AB58B2CFA"
      unitRef="number">0.01700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d8342313e958-wk-Fact-1FA46A2434BD4037312A62B27FA8DC06"
      unitRef="usd">1000000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d8342313e973-wk-Fact-F8B0F7DF3DF169D49D4B6E2AB5E2F31A"
      unitRef="number">0.02550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d8342313e993-wk-Fact-16F6402C3D27347AC27362B27FB48AF9"
      unitRef="usd">1000000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d8342313e1008-wk-Fact-1B68A2021D10A36356186E2AB5F43958"
      unitRef="number">0.02700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d8342313e1028-wk-Fact-4FE832EE652DB0BFC19C62B27FAE9490"
      unitRef="usd">1250000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d8342313e1068-wk-Fact-52255E4494E199DFF13A62B27FFFDA86"
      unitRef="usd">4000000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d8342313e1117-wk-Fact-3A3F9E9573BED94CECE96E2AB576ACEA"
      unitRef="number">0.01125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d8342313e1142-wk-Fact-0FC0F209129EAE86AC5062B5823DDFE3"
      unitRef="usd">1000000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d8342313e1152-wk-Fact-13D7F474D284315AAC0F6E2AB5FAB98A"
      unitRef="number">0.01650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d8342313e1172-wk-Fact-69D18EA5F2F06ECBB85462B5818CB8E2"
      unitRef="usd">750000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d8342313e1187-wk-Fact-436D89FE9F0C79B3488A6E2AB60CED32"
      unitRef="number">0.02300</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d8342313e1207-wk-Fact-9E0105460CD66A26DA3E62B57F93D91C"
      unitRef="usd">750000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d8342313e1222-wk-Fact-DCB68471D8E265A85F006E2AB6067B11"
      unitRef="number">0.02700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d8342313e1242-wk-Fact-97E3E87FDB73BAA7FF9162B582261B0C"
      unitRef="usd">1450000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d8342313e1257-wk-Fact-80C9C7989035C441E8F66E2AB600433E"
      unitRef="number">0.03850</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d8342313e1277-wk-Fact-0580CEB5C775C240F53E62B57F7CDA48"
      unitRef="usd">1500000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d8342313e1292-wk-Fact-55A7A50436A17875DA886E2AB591F4F0"
      unitRef="number">0.04000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d8342313e1312-wk-Fact-A14C3D5F01779D1B472A62B580A23EAF"
      unitRef="usd">2000000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember"
      decimals="-6"
      id="d8342313e1352-wk-Fact-023145D17C9F66D6842662B57FE27319"
      unitRef="usd">7450000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d8342313e1400-wk-Fact-259A75EBC5B9155331DD6E2AB5DA7B6B"
      unitRef="number">0.00816</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d8342313e1425-wk-Fact-2CC741B37468B4EB7E7962B74D4B9AA4"
      unitRef="iso4217_EUR">750000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d8342313e1435-wk-Fact-D84A9DFE6BD8F1408DE66E2AB597194A"
      unitRef="number">0.01023</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d8342313e1455-wk-Fact-31DC3AA563E6F9E64E1962B74CB9AD9B"
      unitRef="iso4217_EUR">750000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d8342313e1470-wk-Fact-DE86B0DC7A72F0243B116E2AB5E89C96"
      unitRef="number">0.01362</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d8342313e1490-wk-Fact-B36932A918E6F9598D8462B74D5B37B3"
      unitRef="iso4217_EUR">850000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d8342313e1506-wk-Fact-C7DC185FDB6E6BBA96466E2AB5EEE427"
      unitRef="number">0.01908</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d8342313e1526-wk-Fact-CED0DD1F7C325FCC944962B74C8C03F8"
      unitRef="iso4217_EUR">1250000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember"
      decimals="-6"
      id="d8342313e1566-wk-Fact-317E8464F89DC9096D5F62B74C5A83F5"
      unitRef="iso4217_EUR">3600000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="FI2020Q2_srt_ConsolidatedEntitiesAxis_us-gaap_ParentMember"
      decimals="4"
      id="d8342313e1580-wk-Fact-3E37264C56735C7578BD62D32C3B71E9"
      unitRef="number">0.0211</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember"
      decimals="4"
      id="d8342313e1593-wk-Fact-D7A09F7BBFEFBA72380962D5CEF4A3EF"
      unitRef="number">0.0295</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember"
      decimals="-7"
      id="d8342313e1597-wk-Fact-F2F00160251F404AA6566E2BC2FFDD9D"
      unitRef="usd">7450000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember"
      decimals="4"
      id="d8342313e1601-wk-Fact-008FBC80BEA7A0F99CA162D6766AA699"
      unitRef="number">0.0137</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_UpjohnFinanceB.V.Member_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember"
      decimals="-7"
      id="d8342313e1605-wk-Fact-A4DDA4433ECD4D0ED61A6E2BE65231D9"
      unitRef="iso4217_EUR">3600000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="FD2020Q2YTD_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d8342313e1609-wk-Fact-6AC4751F84A34A0941906E2E3C048870"
      unitRef="number">1.01</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="FD2020Q2YTD_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember"
      decimals="-8"
      id="d8342313e1614-wk-Fact-FF9524E6BB352641CEF36EAEF8842218"
      unitRef="usd">11400000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d8342313e1780-wk-Fact-200E77F96A765ED4495194757CB8CCE6"
      unitRef="usd">1250000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_pfe_LongTermDebtIssuedFirstQuarter2020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d8342313e1817-wk-Fact-6AFEFA4A1DCA7261A60294757D43054F"
      unitRef="usd">1250000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="4"
      id="d8342313e1849-wk-Fact-B319AD60CC511A7847B494757D8A64AF"
      unitRef="number">0.0267</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d8342313e1993-wk-Fact-13C462C75A1858B9415654402D698FE6"
      unitRef="usd">49187000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d8342313e2012-wk-Fact-0639ADEDE6FCAADD47BB54402D928BD5"
      unitRef="usd">34820000000</us-gaap:DebtInstrumentCarryingAmount>
    <pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting
      contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d8342313e2032-wk-Fact-FFC12129B6F28DF504F954402D4881FE"
      unitRef="usd">1654000000</pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting>
    <pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting
      contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d8342313e2051-wk-Fact-E503C53E22F263FD701354402D601BE4"
      unitRef="usd">1305000000</pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d8342313e2076-wk-Fact-98F2869D66E178D172FC54402DA3E361"
      unitRef="usd">317000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d8342313e2096-wk-Fact-3BB24A30AC901CF8B5B754402D7AD3ED"
      unitRef="usd">176000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:OtherLongTermDebt
      contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d8342313e2122-wk-Fact-5FBAF0E5470A0CAAD6C154402D71F64B"
      unitRef="usd">5000000</us-gaap:OtherLongTermDebt>
    <us-gaap:OtherLongTermDebt
      contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d8342313e2141-wk-Fact-51B29DDE9738C408543854402D9B17CF"
      unitRef="usd">5000000</us-gaap:OtherLongTermDebt>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d8342313e2171-wk-Fact-F6C8BEC9CD637723D29154402D51F517"
      unitRef="usd">50529000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d8342313e2190-wk-Fact-2356819B47B4A00067B154402D88D0A0"
      unitRef="usd">35955000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d8342313e2215-wk-Fact-0D58C0B8EC08D7F1C42C54402D3F5E59"
      unitRef="usd">1481000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d8342313e2234-wk-Fact-60933D7A9C1B93239F0054402D225C0A"
      unitRef="usd">1462000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="FD2020Q2YTD_dei_LegalEntityAxis_pfe_UpjohnIncMember_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember"
      decimals="-8"
      id="d8342313e2257-wk-Fact-FF9524E6BB352641CEF36EAEF8842218"
      unitRef="usd">11400000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_pfe_SeniorNotesDue2047Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d8342313e2276-wk-Fact-1FD189B7CE185C6CBE3594757D8B58C8"
      unitRef="usd">1065000000.000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DerivativeTermOfContract
      contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember"
      id="d8372444e723-wk-Fact-CBBF9E28054D0C08337794757D338FA9">P2Y</us-gaap:DerivativeTermOfContract>
    <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-A1EEAC2FB1F1AFE84C2194757DBE3C80-0-wk-Fact-6F79B03E992FD4039AF494757CF01171">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Notional&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Notional&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,543&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;551&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;914&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,193&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;591&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;662&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,995&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;158&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,645&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;318&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;708&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;914&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;909&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;662&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,433&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,623&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;792&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;993&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;718&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$5.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$5.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; as of December 31, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-51EDC22604A5FE04526F94757DBE6A95-0-wk-Fact-E2DD91C7FC6D6FA9DE3D94757CEF6B40">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Notional&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Notional&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,543&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;551&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;914&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,193&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;591&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;662&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,995&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;158&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,645&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;318&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;708&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;914&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;909&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;662&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,433&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,623&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;792&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;993&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;718&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$5.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$5.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; as of December 31, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-5FC4DFE1885069BB918694757DBED53E-0-wk-Fact-36D4F1AA1B952255D0C994757CF076FA">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Notional&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Notional&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,543&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;551&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;914&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,193&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;591&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;662&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,995&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;158&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,645&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;318&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;708&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;914&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;909&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;662&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,433&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,623&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;792&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;993&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;718&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$5.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$5.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; as of December 31, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e1440-wk-Fact-2FCF66786C77668C7F1694757CC07AEE"
      unitRef="usd">22543000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e1459-wk-Fact-C74CEACCB68A148A68AC94757CC0788F"
      unitRef="usd">551000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e1479-wk-Fact-1369E6DF1C524EDEE9A694757CC1938A"
      unitRef="usd">914000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e1498-wk-Fact-6F2CE97D1E80554AD52594757CBE2E5A"
      unitRef="usd">25193000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e1517-wk-Fact-3C967CCCA2C5A8BFE04094757CC4026C"
      unitRef="usd">591000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e1537-wk-Fact-4A6F9B60CE268B4FFEDC94757CBF9263"
      unitRef="usd">662000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e1557-wk-Fact-E3C7635147C52DD5C13094757CC7FE0E"
      unitRef="usd">1995000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e1576-wk-Fact-541D729563AD559BF79894757CC2BE5E"
      unitRef="usd">158000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e1595-wk-Fact-1A72D71D4E26F80408FC94757CC9544D"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e1615-wk-Fact-2C5F07B2692C4575353D94757CC17F26"
      unitRef="usd">6645000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e1634-wk-Fact-F4DB9395DC431A691DF494757CBE344E"
      unitRef="usd">318000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e1654-wk-Fact-B8DA90B6BC0F3BF38AF094757CC22601"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="FI2020Q2_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e1699-wk-Fact-EF59D41F05B564884D4B94757CC503FD"
      unitRef="usd">708000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2020Q2_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e1718-wk-Fact-FEF5FC1AB63FCEC3FDD494757CC7CD11"
      unitRef="usd">914000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e1758-wk-Fact-D15D4211FBE5F3D7085C94757CC1EC75"
      unitRef="usd">909000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e1778-wk-Fact-94564ED7564E7B20826394757CBF7C4E"
      unitRef="usd">662000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-6"
      id="d8372444e2064-wk-Fact-C84426DB7ABC017AB03994757CC65974"
      unitRef="usd">14433000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-6"
      id="d8372444e2078-wk-Fact-67655BF5CE81FCA534DC94757CBF2DDD"
      unitRef="usd">84000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-6"
      id="d8372444e2097-wk-Fact-712E7CF93E1F174A1A0494757CC56179"
      unitRef="usd">79000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-6"
      id="d8372444e2122-wk-Fact-8FFEB3B89F44DFC327BB94757CC6E444"
      unitRef="usd">19623000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-6"
      id="d8372444e2136-wk-Fact-25070E1B903A800EB04C94757CC7F381"
      unitRef="usd">82000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-6"
      id="d8372444e2156-wk-Fact-F9E1092602035AC060FE94757CC4C361"
      unitRef="usd">55000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8372444e2335-wk-Fact-5E159B347A43D21021F294757CBED907"
      unitRef="usd">792000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8372444e2355-wk-Fact-A07DF5A15792C8E6AC2394757CC6B50C"
      unitRef="usd">993000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8372444e2394-wk-Fact-5998C1A606152BA5557594757CC2A2DB"
      unitRef="usd">992000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8372444e2414-wk-Fact-719C354B7E0D7018DC5494757CBFB673"
      unitRef="usd">718000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2020Q2_pfe_HedgedItemAxis_us-gaap_SalesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-8"
      id="d8372444e2432-wk-Fact-578F2DA28EA41AE9382194757CEEAB1C"
      unitRef="usd">5200000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_pfe_HedgedItemAxis_us-gaap_SalesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-8"
      id="d8372444e2440-wk-Fact-0DCDEC1F3DFA047B631094757CEF6953"
      unitRef="usd">5900000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-18635C5601A80E7FBC4B94757DBE47F2-0-wk-Fact-143CB97F9A8120B20D4E94757CF17487">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:34%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Amount of&lt;br/&gt;Gains/(Losses)&lt;br/&gt;Recognized in OID&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Amount of Gains/(Losses)&lt;br/&gt;Recognized in OCI&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;,&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#160;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Amount of Gains/(Losses)&lt;br/&gt;Reclassified from&lt;br/&gt;OCI into OID and COS&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a), (b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Derivative Financial Instruments in Cash Flow Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;187&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(204&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;172&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Amount excluded from effectiveness testing recognized in earnings based on an amortization approach&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Derivative Financial Instruments in Fair Value Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;483&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Hedged item &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(483&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Hedged item &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(144&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;The portion on foreign exchange contracts excluded from the assessment of hedge effectiveness&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Non-Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Foreign currency short-term borrowings&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Foreign currency long-term debt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Derivative Financial Instruments Not Designated as Hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;All other net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(216&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:34%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Amount of&lt;br/&gt;Gains/(Losses)&lt;br/&gt;Recognized in OID&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Amount of Gains/(Losses)&lt;br/&gt;Recognized in OCI&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:pt"&gt;,&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:pt"&gt;&#160;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Amount of Gains/(Losses)&lt;br/&gt;Reclassified from&lt;br/&gt;OCI into OID and COS&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:pt"&gt;(a), (b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;"&gt;Six Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Derivative Financial Instruments in Cash Flow Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(341&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;126&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Amount excluded from effectiveness testing recognized in earnings based on an amortization approach&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;86&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Derivative Financial Instruments in Fair Value Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;392&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;813&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Hedged item&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(392&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(813&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Hedged item&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;240&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:18px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;The portion of foreign exchange contracts excluded from the assessment of hedge effectiveness&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;93&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Non-Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Foreign currency short-term borrowings&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Foreign currency long-term debt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Derivative Financial Instruments Not Designated as Hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;All other net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;(124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;139&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;188&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;251&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;OID = Other (income)/deductions&#x2014;net, included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in the condensed consolidated statements of income&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; COS = Cost of Sales, included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Cost of sales&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Other comprehensive loss&#x2013;&#x2013;Unrealized holding gains/(losses) on derivative financial instruments, net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the gains and losses are included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Other comprehensive loss&#x2013;&#x2013;Foreign currency translation adjustments, net.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The amounts reclassified from OCI into COS were:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:12px;"&gt;&lt;div style="line-height:120%;font-size:8pt;text-indent:-12px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;a net &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;gain&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$80 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:12px;"&gt;&lt;div style="line-height:120%;font-size:8pt;text-indent:-12px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;a net &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;gain&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$150 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in the first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:12px;"&gt;&lt;div style="line-height:120%;font-size:8pt;text-indent:-12px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;a net &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;gain&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$59 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;; and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:12px;"&gt;&lt;div style="line-height:120%;font-size:8pt;text-indent:-12px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;a net &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;gain&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$103 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in the first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:12px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;gain&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$102 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; within the next 12 months into income&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The maximum length of time over which we are hedging future foreign exchange cash flow relates to our &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; U.K. pound debt maturing in 2043.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The amounts reclassified from OCI were reclassified into OID.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Long-term debt includes foreign currency long-term borrowings with carrying values of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$2.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, which are used as hedging instruments in net investment hedges.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e3204-wk-Fact-23913CAAF810667AF3C194757D16D9A2"
      unitRef="usd">187000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e3223-wk-Fact-DD2C0BC1E91919220B7394757CCC3C6C"
      unitRef="usd">-204000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e3243-wk-Fact-32E4A4F33D07CCC35B5994757D24CC85"
      unitRef="usd">172000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e3263-wk-Fact-8AC90BDE6611C4D9613F94757D10F366"
      unitRef="usd">48000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e3323-wk-Fact-08FE59EF359A8EB1141294757D17D52E"
      unitRef="usd">13000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e3343-wk-Fact-F7F177E6405946748C2A94757D258C32"
      unitRef="usd">28000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
      contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e3362-wk-Fact-D581CDA4BE4F221B6C2C94757D180462"
      unitRef="usd">14000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e3382-wk-Fact-482EC9E9C634BBA5161694757D0F9FAE"
      unitRef="usd">32000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d8372444e3535-wk-Fact-0FE975CFD0CEBAC8988A94757CCB8E12"
      unitRef="usd">6000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d8372444e3554-wk-Fact-0F151736606908F5607394757D16AC47"
      unitRef="usd">483000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d8372444e3657-wk-Fact-D46584CE1C6A5715E12694757D220D63"
      unitRef="usd">-6000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d8372444e3677-wk-Fact-8434DE738E1AB342D96E94757CCBDE53"
      unitRef="usd">-483000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d8372444e3781-wk-Fact-75ED33FE12B125B9E0C094757D134293"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d8372444e3800-wk-Fact-1E53EA3EE5FA31F56ABC94757CCC7BB4"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d8372444e3904-wk-Fact-7E1F4D7F45796F888D3994757D152AA2"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d8372444e3923-wk-Fact-CAF86E02454555A404D294757CCA9409"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e4186-wk-Fact-7E8FD767BFA321ADA8D194757D17C3EB"
      unitRef="usd">-144000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e4207-wk-Fact-69643034125B7437E33E94757D134BD5"
      unitRef="usd">-48000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e4227-wk-Fact-65591C40B6FF9A07FC1694757D0FFC2A"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e4247-wk-Fact-366496A263381BEBAC8094757D116F08"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e4312-wk-Fact-1CECC326E870388701E494757D14ABBF"
      unitRef="usd">29000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e4332-wk-Fact-40A2A359765A16FF703294757D1A2BA3"
      unitRef="usd">52000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
      contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e4351-wk-Fact-2C546F3214B511F790B394757D11B2FB"
      unitRef="usd">42000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e4371-wk-Fact-5073FE007ED4EF41D79494757D16D857"
      unitRef="usd">31000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
      contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e4558-wk-Fact-B4AE696827B3D39F948494757D114B10"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e4578-wk-Fact-E8B92084BD875BA1E86894757D134EDA"
      unitRef="usd">-16000000</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e4598-wk-Fact-772041FC75DDB73FA59D94757D1262E8"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e4618-wk-Fact-E7A174C8A21CBC1EF5C394757D1205B4"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
      contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e4683-wk-Fact-3C17EF2AE779923FF12094757D2065E5"
      unitRef="usd">-42000000</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e4704-wk-Fact-9B5EAA42679A56C367D494757D12A858"
      unitRef="usd">-27000000</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e4724-wk-Fact-7F531F08E0D50D0C134294757D23AAA5"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e4744-wk-Fact-76C2DA9EBF5CD4536E0394757D100987"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d8372444e4897-wk-Fact-BD0329CC1D00D62B9E9F94757D234485"
      unitRef="usd">8000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d8372444e4916-wk-Fact-EB1FC1F3016D395DFAD794757D2A199B"
      unitRef="usd">-4000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8372444e5060-wk-Fact-0133CD4E7227C37B6E9194757D1DFC1C"
      unitRef="usd">12000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8372444e5080-wk-Fact-7AE0949565F5D585B74E94757D172848"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax
      contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e5099-wk-Fact-573125655D86999E611594757D0F25B4"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e5119-wk-Fact-73E5652390B0B6E33FBC94757CCAE2A9"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d8372444e5149-wk-Fact-5D38E93A2B498707F2E694757D15B8FB"
      unitRef="usd">8000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d8372444e5168-wk-Fact-7F7EA65841FA3F8EDE9D94757D1F6A7C"
      unitRef="usd">-4000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8372444e5189-wk-Fact-7E38933CC8C6B3F78FD894757D1176A3"
      unitRef="usd">56000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8372444e5208-wk-Fact-436FB3A1151F0EA4A92E94757CCA2C1F"
      unitRef="usd">-216000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax
      contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e5228-wk-Fact-CC96A91FB3B7AD21FC6E94757CCDA70E"
      unitRef="usd">228000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e5248-wk-Fact-CD7B6D54813C77F7056C94757CCBF9C3"
      unitRef="usd">111000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e5856-wk-Fact-30F55F47EE0BC5CF4FF794757D0F23CF"
      unitRef="usd">-341000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e5876-wk-Fact-BCDF3704B801D84F71C794757D8BEE37"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e5895-wk-Fact-D529846875F26AE83EA994757D27042F"
      unitRef="usd">126000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e5915-wk-Fact-75007AA8D5BB2FDFE2F694757D2299DA"
      unitRef="usd">257000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e5973-wk-Fact-334697846783F070800594757CEB5638"
      unitRef="usd">42000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e5992-wk-Fact-42F54CD6BB1EE7437A9894757D251875"
      unitRef="usd">84000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
      contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e6010-wk-Fact-B541C3D3DAB4589EDF8994757D7AA019"
      unitRef="usd">41000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e6029-wk-Fact-0415E305501AF9B9FFBB94757D23F5EF"
      unitRef="usd">86000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d8372444e6286-wk-Fact-29FB03A603A2B2F710FD94757D2DA0BB"
      unitRef="usd">392000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d8372444e6305-wk-Fact-E0BAE04C3F7AAC74123D94757D287414"
      unitRef="usd">813000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d8372444e6408-wk-Fact-78E877E7F508BB5A1CBD94757D8CBBF4"
      unitRef="usd">-392000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d8372444e6428-wk-Fact-DFF51302F0E70A31845B94757D802056"
      unitRef="usd">-813000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d8372444e6551-wk-Fact-D43F780191672677C09E94757CEA1326"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d8372444e6674-wk-Fact-76B77AEDB628C2C133C594757CF2E937"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e7059-wk-Fact-2723AAC37A7D7F6511E094757D2E3BF6"
      unitRef="usd">240000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e7079-wk-Fact-28D2817A0C35A9673F5F94757D2009C5"
      unitRef="usd">-25000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e7099-wk-Fact-7D1153C7730B6D08B22194757D258E58"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e7119-wk-Fact-DC149FAE791DF73A9F4E94757CEB25E2"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e7182-wk-Fact-52E1818462885A5EFE0D94757D8CDA9B"
      unitRef="usd">176000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e7201-wk-Fact-AF4E88391CCB32EE29BF94757D2B4EC4"
      unitRef="usd">93000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
      contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e7219-wk-Fact-D17741D648E58B172B9E94757D81B725"
      unitRef="usd">84000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e7238-wk-Fact-FC494931B0AF7CE356B794757D314170"
      unitRef="usd">55000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
      contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e7539-wk-Fact-48A6C3F999379D6B924394757D7AF0E5"
      unitRef="usd">8000000</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e7559-wk-Fact-5FFC27FB28BF9BC0914794757D12B245"
      unitRef="usd">19000000</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e7578-wk-Fact-A4F33B25B1F596F9D7C294757D2733CF"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e7598-wk-Fact-A7CCC86802BC2190FB1994757CEDE354"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
      contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e7663-wk-Fact-5832CEAF471BE71C047B94757D1A7F51"
      unitRef="usd">3000000</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d8372444e7683-wk-Fact-47CB9748E3671019B33694757D79B9D0"
      unitRef="usd">11000000</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e7702-wk-Fact-653C3FF814F712F87A4D94757D2002AC"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e7722-wk-Fact-9F5CE5F094EEBC828DF194757D8C0D9D"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d8372444e7988-wk-Fact-4BFC2EA8E8A0BCD7965C94757D916146"
      unitRef="usd">-51000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d8372444e8008-wk-Fact-AF62571E69854E8457D694757D8D5035"
      unitRef="usd">-124000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8372444e8152-wk-Fact-7B71E458C4CB31B9B78E94757CEB94F1"
      unitRef="usd">12000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8372444e8172-wk-Fact-73D648F5F2FEA3A8D53594757D2191CE"
      unitRef="usd">1000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax
      contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e8191-wk-Fact-23F2FB78F6495A427ED994757D2D3461"
      unitRef="usd">-1000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e8212-wk-Fact-8EC2BB5B4C87C28113B894757D7D006B"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d8372444e8242-wk-Fact-338E913FDA175BCEBC1794757D8FAE73"
      unitRef="usd">-51000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d8372444e8262-wk-Fact-FB427E54FB33B137568A94757D7D2609"
      unitRef="usd">-124000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8372444e8283-wk-Fact-A078219576BC94A6431D94757D13F215"
      unitRef="usd">139000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8372444e8302-wk-Fact-7D6E2CB63598393A1F6E94757D15BA01"
      unitRef="usd">188000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax
      contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e8321-wk-Fact-5E91C36A351B5607652E94757D8FBDF9"
      unitRef="usd">251000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d8372444e8341-wk-Fact-BA21BD3D4A33641CD2FE94757D8EFCEB"
      unitRef="usd">398000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d8372444e8423-wk-Fact-E3F86E54DF8A3C6FC08F6EB5A5D2AC70"
      unitRef="usd">80000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d8372444e8446-wk-Fact-691E55F5092FFE3D19E994757CF0D6A1"
      unitRef="usd">150000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d8372444e8469-wk-Fact-7493B3439B8F389A067B94757CEE6BD1"
      unitRef="usd">59000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d8372444e8492-wk-Fact-31146AA67167AA79BC2062F40C176931"
      unitRef="usd">103000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8372444e8515-wk-Fact-21D05D3EA5186FE09E3A94757D344954"
      unitRef="usd">102000000</us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-8"
      id="d8372444e8523-wk-Fact-D2A6EC924DA5C0E8196B94757D33D0FA"
      unitRef="usd">1800000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember"
      decimals="-8"
      id="d8372444e8557-wk-Fact-37558442FE4310FB963594757D3574C5"
      unitRef="usd">2000000000.0</us-gaap:LongTermDebt>
    <us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-F7D096FD0FC21C6DABBF94757DBEA7B0-0-wk-Fact-B62669295182431200B794757D3571FA">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:1px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the amounts recorded in our condensed consolidated balance sheet related to cumulative basis adjustments for fair value hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Carrying Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Carrying Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Carrying Amount of Hedged Assets/Liabilities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Active Hedging Relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Discontinued Hedging Relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Carrying Amount of Hedged Assets/Liabilities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Active Hedging Relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Discontinued Hedging Relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Long-term debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2,023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,181&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;7,092&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;690&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Carrying amounts exclude the cumulative amount of fair value hedging adjustments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:HedgedAssetFairValueHedge
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember"
      decimals="-6"
      id="d8372444e9149-wk-Fact-9686F21840EBB7B77D77A1CD25DC8AFE"
      unitRef="usd">45000000</us-gaap:HedgedAssetFairValueHedge>
    <us-gaap:HedgedAssetFairValueHedgeCumulativeIncreaseDecrease
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember"
      decimals="-6"
      id="d8372444e9168-wk-Fact-36E9EBB96B319DFEBB5AA1CD293A8034"
      unitRef="usd">0</us-gaap:HedgedAssetFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember"
      decimals="-6"
      id="d8372444e9188-wk-Fact-D2FC78130C87782A35B0A1CD2BB5F206"
      unitRef="usd">0</us-gaap:HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedAssetFairValueHedge
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember"
      decimals="-6"
      id="d8372444e9207-wk-Fact-7BC374D8582E6B3D7CE3A1CD2E1DD218"
      unitRef="usd">0</us-gaap:HedgedAssetFairValueHedge>
    <us-gaap:HedgedAssetFairValueHedgeCumulativeIncreaseDecrease
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember"
      decimals="-6"
      id="d8372444e9226-wk-Fact-BBA7101DDA6802CF087FA1CD3193BA19"
      unitRef="usd">0</us-gaap:HedgedAssetFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember"
      decimals="-6"
      id="d8372444e9246-wk-Fact-16785AEB31C380870D01A1CD33F8267B"
      unitRef="usd">0</us-gaap:HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedAssetFairValueHedge
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember"
      decimals="-6"
      id="d8372444e9265-wk-Fact-493830DEE8D1E80A700694757D1E02C5"
      unitRef="usd">0</us-gaap:HedgedAssetFairValueHedge>
    <us-gaap:HedgedAssetFairValueHedgeCumulativeIncreaseDecrease
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember"
      decimals="-6"
      id="d8372444e9283-wk-Fact-355795BCB10BB5225D5E94757D1E22D3"
      unitRef="usd">0</us-gaap:HedgedAssetFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember"
      decimals="-6"
      id="d8372444e9302-wk-Fact-88338D8D5B185C52242D94757D1B3210"
      unitRef="usd">0</us-gaap:HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedAssetFairValueHedge
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember"
      decimals="-6"
      id="d8372444e9322-wk-Fact-D7D683B723E19620193294757D1D9320"
      unitRef="usd">45000000</us-gaap:HedgedAssetFairValueHedge>
    <us-gaap:HedgedAssetFairValueHedgeCumulativeIncreaseDecrease
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember"
      decimals="-6"
      id="d8372444e9341-wk-Fact-D1B69DB071FAA5ADCF1994757D211902"
      unitRef="usd">0</us-gaap:HedgedAssetFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember"
      decimals="-6"
      id="d8372444e9361-wk-Fact-AF6B866DA26DF755DDAA94757D1EF422"
      unitRef="usd">0</us-gaap:HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember"
      decimals="-6"
      id="d8372444e9385-wk-Fact-490104B7571E3A2E212094757D19310E"
      unitRef="usd">2023000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember"
      decimals="-6"
      id="d8372444e9403-wk-Fact-EDCFA3618A0D30F9383B94757D1F6393"
      unitRef="usd">140000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember"
      decimals="-6"
      id="d8372444e9422-wk-Fact-61695B3584E82F04120494757D1DD692"
      unitRef="usd">1181000000</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember"
      decimals="-6"
      id="d8372444e9442-wk-Fact-B269C96FEDB20D2F2CE794757D1AD759"
      unitRef="usd">7092000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember"
      decimals="-6"
      id="d8372444e9461-wk-Fact-20C138C5667734B8A40694757D1E9B82"
      unitRef="usd">266000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember"
      decimals="-6"
      id="d8372444e9481-wk-Fact-DBC865FEEF9FF10BA2C694757D213432"
      unitRef="usd">690000000</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:DerivativeNetLiabilityPositionAggregateFairValue
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8372444e9529-wk-Fact-DC960FFC71EF6609219A94757CEE3ADC"
      unitRef="usd">928000000</us-gaap:DerivativeNetLiabilityPositionAggregateFairValue>
    <us-gaap:CollateralAlreadyPostedAggregateFairValue
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8372444e9533-wk-Fact-78C3BA81B60B25E6BA7794757CF1AEE8"
      unitRef="usd">922000000</us-gaap:CollateralAlreadyPostedAggregateFairValue>
    <us-gaap:SecuritiesReceivedAsCollateral
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8372444e9544-wk-Fact-212F7BE47AEBD1EEBC9D94757CF1A261"
      unitRef="usd">858000000</us-gaap:SecuritiesReceivedAsCollateral>
    <us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure
      contextRef="FD2020Q2YTD_us-gaap_EquitySecuritiesByIndustryAxis_us-gaap_FinancialServicesSectorMember"
      decimals="-8"
      id="d8342403e713-wk-Fact-A6A9DDBC3438CEEC8F9794757D24DA9B"
      unitRef="usd">1900000000</us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-7B0F479523B1900F5BF894757DBF9BFE-0-wk-Fact-1BF47749336033CA94DA94757D48645D">&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Inventories&lt;/span&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Inventories&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,002&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Work-in-process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,810&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,743&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Raw materials and supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;752&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;790&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Inventories&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,564&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Noncurrent inventories not included above&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;962&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;714&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The change from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; reflects increases for certain products, including inventory build for new product launches, network strategy and market demand, partially offset by a decrease due to foreign exchange.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Other noncurrent assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;. There are no recoverability issues associated with these amounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-5F0194A0A7C538E0DF7194757DBF5ACF-0-wk-Fact-02EF8C57A827F6DCD67A94757D47A039">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Inventories&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,002&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Work-in-process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,810&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,743&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Raw materials and supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;752&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;790&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Inventories&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,564&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Noncurrent inventories not included above&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;962&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;714&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The change from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; reflects increases for certain products, including inventory build for new product launches, network strategy and market demand, partially offset by a decrease due to foreign exchange.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Other noncurrent assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;. There are no recoverability issues associated with these amounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-8AC5724F2353C663019C94757DBF307C-0-wk-Fact-590F03BDB685195392F294757D482348">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Inventories&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,002&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Work-in-process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,810&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,743&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Raw materials and supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;752&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;790&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Inventories&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,564&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Noncurrent inventories not included above&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;962&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;714&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The change from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; reflects increases for certain products, including inventory build for new product launches, network strategy and market demand, partially offset by a decrease due to foreign exchange.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Other noncurrent assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;. There are no recoverability issues associated with these amounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8342960e851-wk-Fact-14CA00AE18E4FD4C971E94757CCC8D07"
      unitRef="usd">3002000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8342960e870-wk-Fact-96EDE76DCE3E91132D8394757CC73DFD"
      unitRef="usd">2750000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8342960e890-wk-Fact-1C7BE7FA88F770FEB3FB94757CC71AF7"
      unitRef="usd">4810000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8342960e909-wk-Fact-40F7DC6CA5FF5132288194757CC83DEE"
      unitRef="usd">4743000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8342960e934-wk-Fact-E398DF098C9F6EDE1E3794757CC6DF55"
      unitRef="usd">752000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8342960e953-wk-Fact-A8FCCB5A5E91619D1A7F94757CCD8102"
      unitRef="usd">790000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8342960e985-wk-Fact-E854D651F5C65603680B94757D20C5D0"
      unitRef="usd">8564000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8342960e1004-wk-Fact-A72909DE8208FAB8084794757D31B877"
      unitRef="usd">8283000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8342960e1031-wk-Fact-05F3838F2F88BF0B809094757CC6BB77"
      unitRef="usd">962000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8342960e1050-wk-Fact-69F9CBEEF2E7911E725F94757CC7E199"
      unitRef="usd">714000000</us-gaap:InventoryNoncurrent>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-10CDD905D95D20A8B03994757DBF955D-0-wk-Fact-C516E0E5F64A4D7C866594757D5FFDDF">&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Identifiable Intangible Assets and Goodwill&lt;/span&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;A. Identifiable Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Balance Sheet Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Identifiable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangible&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assets, less&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Identifiable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangible&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assets, less&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Finite-lived intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;89,927&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(64,683&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,244&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;88,730&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(63,106&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,625&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Brands&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;922&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(757&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;165&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;922&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(741&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;181&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Licensing agreements and other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,327&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,101&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,772&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,191&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;582&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;93,176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(66,667&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,509&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;91,425&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(65,037&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,387&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Brands&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,518&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,518&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,919&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,919&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Licensing agreements&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;&#160;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;and other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;523&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;523&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,073&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,073&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,032&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,032&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,983&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,983&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100,208&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(66,667&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,541&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100,408&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(65,037&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,370&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The changes in the gross carrying amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; primarily reflect the transfer of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; to reflect the approval of Braftovi in combination with Erbitux&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; (cetuximab), for the treatment of BRAF&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;V600E&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;-mutant metastatic colorectal cancer after prior therapy.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The changes in the gross carrying amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Licensing agreements and other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; primarily reflect the transfer of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$550 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; from Indefinite-lived &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Licensing agreements and other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; to finite-lived &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Licensing agreements and other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; to reflect the approval in the U.S. of several products subject to out-licensing arrangements acquired from Array.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;decrease&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;I&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;text-align:right;"&gt;dentifiable intangible assets, less accumulated amortization&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:right;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;is primarily due to amortization.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Upjohn&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;WRDM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Developed technology rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Brands, finite-lived&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Brands, indefinite-lived&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Licensing agreements and other, finite-lived&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Licensing agreements and other, indefinite-lived&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total amortization expense for finite-lived intangible assets was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$917 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;second&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; quarter of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;second&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; quarter of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;B. Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of and changes in the carrying amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Goodwill&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Upjohn&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance, December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;48,202&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,451&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,653&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(155&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(204&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance, June&#160;28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;48,047&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,401&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,449&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Primarily represents the impact of foreign exchange.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-49F443CEDF83606E5E8D94757DBFBF87-0-wk-Fact-202C33A0DE1DDFB3F2FD94757D5ECF3E">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Identifiable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangible&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assets, less&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Identifiable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangible&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assets, less&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Finite-lived intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;89,927&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(64,683&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,244&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;88,730&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(63,106&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,625&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Brands&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;922&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(757&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;165&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;922&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(741&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;181&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Licensing agreements and other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,327&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,101&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,772&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,191&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;582&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;93,176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(66,667&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,509&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;91,425&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(65,037&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,387&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Brands&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,518&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,518&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,919&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,919&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Licensing agreements&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;&#160;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;and other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;523&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;523&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,073&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,073&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,032&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,032&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,983&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,983&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100,208&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(66,667&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,541&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100,408&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(65,037&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,370&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The changes in the gross carrying amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; primarily reflect the transfer of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; to reflect the approval of Braftovi in combination with Erbitux&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; (cetuximab), for the treatment of BRAF&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;V600E&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;-mutant metastatic colorectal cancer after prior therapy.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The changes in the gross carrying amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Licensing agreements and other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; primarily reflect the transfer of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$550 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; from Indefinite-lived &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Licensing agreements and other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; to finite-lived &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Licensing agreements and other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; to reflect the approval in the U.S. of several products subject to out-licensing arrangements acquired from Array.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;decrease&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;I&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;text-align:right;"&gt;dentifiable intangible assets, less accumulated amortization&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:right;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;is primarily due to amortization.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-BA125A605A5CDA1D10A294757DC0412F-0-wk-Fact-FF8B4A8FFBC9C6AF34B094757D5F18E6">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Identifiable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangible&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assets, less&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Identifiable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangible&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assets, less&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Finite-lived intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;89,927&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(64,683&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,244&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;88,730&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(63,106&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,625&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Brands&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;922&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(757&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;165&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;922&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(741&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;181&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Licensing agreements and other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,327&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,101&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,772&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,191&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;582&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;93,176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(66,667&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,509&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;91,425&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(65,037&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,387&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Brands&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,518&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,518&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,919&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,919&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Licensing agreements&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;&#160;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;and other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;523&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;523&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,073&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,073&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,032&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,032&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,983&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,983&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100,208&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(66,667&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,541&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100,408&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(65,037&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,370&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The changes in the gross carrying amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; primarily reflect the transfer of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; to reflect the approval of Braftovi in combination with Erbitux&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; (cetuximab), for the treatment of BRAF&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;V600E&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;-mutant metastatic colorectal cancer after prior therapy.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The changes in the gross carrying amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Licensing agreements and other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; primarily reflect the transfer of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$550 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; from Indefinite-lived &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Licensing agreements and other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; to finite-lived &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Licensing agreements and other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; to reflect the approval in the U.S. of several products subject to out-licensing arrangements acquired from Array.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;decrease&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;I&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;text-align:right;"&gt;dentifiable intangible assets, less accumulated amortization&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:right;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;is primarily due to amortization.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d8357160e1370-wk-Fact-0F2346B28DB4629CBB7594757CCA9BA4"
      unitRef="usd">89927000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d8357160e1389-wk-Fact-C6E2684E0011DA4FD7EC94757CCDA666"
      unitRef="usd">64683000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d8357160e1410-wk-Fact-24A5AF8F393541B6128994757CD2381D"
      unitRef="usd">25244000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d8357160e1429-wk-Fact-744F5D509D408BC3A18C94757CC8DCAC"
      unitRef="usd">88730000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d8357160e1448-wk-Fact-26C4DDEC9074D8280D9794757CCF8BA1"
      unitRef="usd">63106000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d8357160e1469-wk-Fact-B95DB11055F98712D70094757CD0068E"
      unitRef="usd">25625000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d8357160e1489-wk-Fact-DFEAAD4DBDBA20E4EAF994757CFA7DD2"
      unitRef="usd">922000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d8357160e1508-wk-Fact-2E81D311A44E1DD6F32A94757CF7843D"
      unitRef="usd">757000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d8357160e1528-wk-Fact-B87FFF5883EBC20842DD94757CFA6E1A"
      unitRef="usd">165000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d8357160e1548-wk-Fact-5C7BFE7506CDA1FB98F194757CCF076B"
      unitRef="usd">922000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d8357160e1567-wk-Fact-FC92CCED3441A49415F894757CF8785A"
      unitRef="usd">741000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d8357160e1588-wk-Fact-A54987DFE8FA57948EA394757CFB3A67"
      unitRef="usd">181000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember"
      decimals="-6"
      id="d8357160e1615-wk-Fact-F5BA4E904B30B0A0A9DC94757CCE56D0"
      unitRef="usd">2327000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember"
      decimals="-6"
      id="d8357160e1634-wk-Fact-B35C636D04B27499B3AB94757CCFE464"
      unitRef="usd">1226000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember"
      decimals="-6"
      id="d8357160e1654-wk-Fact-ED8B7846450D797501C094757CFAC023"
      unitRef="usd">1101000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember"
      decimals="-6"
      id="d8357160e1674-wk-Fact-3A788F544AFD2EC09A8A94757CF7CB44"
      unitRef="usd">1772000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember"
      decimals="-6"
      id="d8357160e1693-wk-Fact-CAF20A4833F6E5216BE394757CF277B4"
      unitRef="usd">1191000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember"
      decimals="-6"
      id="d8357160e1714-wk-Fact-43BAC5F7B8A55604118A94757CF8D187"
      unitRef="usd">582000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8357160e1739-wk-Fact-1DA1AC35DA188A5457BD94757CCD218C"
      unitRef="usd">93176000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8357160e1758-wk-Fact-96604F15C352A725BF5594757CF6074A"
      unitRef="usd">66667000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8357160e1778-wk-Fact-8D951462795DF6FEFC9194757CF33569"
      unitRef="usd">26509000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8357160e1798-wk-Fact-A3BA229A6FAF723BE35294757CF962D3"
      unitRef="usd">91425000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8357160e1817-wk-Fact-C88BA43C1A9DADCD4A5494757CC8E62B"
      unitRef="usd">65037000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8357160e1838-wk-Fact-856C564E1C2A8B11731F94757CCE776F"
      unitRef="usd">26387000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d8357160e1991-wk-Fact-62B9B1AE8FA3F7D9F7C194757CF49ABC"
      unitRef="usd">1991000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d8357160e2028-wk-Fact-62B9B1AE8FA3F7D9F7C194757CF49ABC"
      unitRef="usd">1991000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d8357160e2048-wk-Fact-C0DC43D9DE8D413F569094757CC94870"
      unitRef="usd">1991000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d8357160e2086-wk-Fact-C0DC43D9DE8D413F569094757CC94870"
      unitRef="usd">1991000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d8357160e2113-wk-Fact-4EA24C13139AF186ABC594757CFF3B82"
      unitRef="usd">4518000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d8357160e2150-wk-Fact-4EA24C13139AF186ABC594757CFF3B82"
      unitRef="usd">4518000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d8357160e2170-wk-Fact-B43FA979F49F2E3A20DE94757CFC75DD"
      unitRef="usd">5919000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d8357160e2208-wk-Fact-B43FA979F49F2E3A20DE94757CFC75DD"
      unitRef="usd">5919000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember"
      decimals="-6"
      id="d8357160e2240-wk-Fact-B8329B46741B139CE66594757CCCCF54"
      unitRef="usd">523000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember"
      decimals="-6"
      id="d8357160e2277-wk-Fact-B8329B46741B139CE66594757CCCCF54"
      unitRef="usd">523000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember"
      decimals="-6"
      id="d8357160e2297-wk-Fact-9571AA75C6659383FDA794757CCEA9E9"
      unitRef="usd">1073000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember"
      decimals="-6"
      id="d8357160e2335-wk-Fact-9571AA75C6659383FDA794757CCEA9E9"
      unitRef="usd">1073000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8357160e2360-wk-Fact-43135ACDDC4EC0B4420494757CF927EE"
      unitRef="usd">7032000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8357160e2397-wk-Fact-43135ACDDC4EC0B4420494757CF927EE"
      unitRef="usd">7032000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8357160e2417-wk-Fact-42A981469076412426ED94757CF567DE"
      unitRef="usd">8983000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8357160e2455-wk-Fact-42A981469076412426ED94757CF567DE"
      unitRef="usd">8983000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8357160e2487-wk-Fact-08957AC6DAC01F29518A94757CFC95E1"
      unitRef="usd">100208000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8357160e2506-wk-Fact-96604F15C352A725BF5594757CF6074A"
      unitRef="usd">66667000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8357160e2527-wk-Fact-9C96864A6997B214807194757D2B762A"
      unitRef="usd">33541000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8357160e2546-wk-Fact-AA5991AA2CE0B64BF6CF94757CCBAA43"
      unitRef="usd">100408000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8357160e2565-wk-Fact-C88BA43C1A9DADCD4A5494757CC8E62B"
      unitRef="usd">65037000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8357160e2586-wk-Fact-59E2FF5E7ACF702D9F4B94757D3339C6"
      unitRef="usd">35370000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-8"
      id="d8357160e2621-wk-Fact-87DFE98F10CC2B76E9EC78FADA508540"
      unitRef="usd">1400000000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="FD2020Q2YTD_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="-6"
      id="d8357160e2655-wk-Fact-729E6527626A1D3D2C7E78FF439D6A1C"
      unitRef="usd">550000000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <pfe:IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-08AC202A9CCE3AD0769794757DC05F25-0-wk-Fact-12E6B9FA1B79EDB423B394757D5EC71A">&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Upjohn&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;WRDM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Developed technology rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Brands, finite-lived&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Brands, indefinite-lived&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Licensing agreements and other, finite-lived&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Licensing agreements and other, indefinite-lived&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</pfe:IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="2"
      id="d8357160e2899-wk-Fact-C05530C48EF422038F3194757CE98766"
      unitRef="number">0.99</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="2"
      id="d8357160e2914-wk-Fact-48816A42EEC8706CBB6394757CEB4B9C"
      unitRef="number">0.01</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember"
      decimals="2"
      id="d8357160e2929-wk-Fact-6E0933952A2F4C2D7D8094757CEB2A66"
      unitRef="number">0</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="2"
      id="d8357160e2949-wk-Fact-518DBC410B98B13882F794757CEA7CD3"
      unitRef="number">1</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="2"
      id="d8357160e2964-wk-Fact-227DB37883E433CEDCF694757CEBB345"
      unitRef="number">0</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember"
      decimals="2"
      id="d8357160e2978-wk-Fact-2E181D99BE28FF78B3E894757CE42FD7"
      unitRef="number">0</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="2"
      id="d8357160e2998-wk-Fact-3082ED9734599A94B50A94757CED4D82"
      unitRef="number">0.42</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="2"
      id="d8357160e3013-wk-Fact-98288C8E81572474464B94757CECACFB"
      unitRef="number">0.58</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember"
      decimals="2"
      id="d8357160e3028-wk-Fact-AF0769565EF8181AFD4894757CEBA65F"
      unitRef="number">0</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="2"
      id="d8357160e3048-wk-Fact-05AD82C65540CA72613394757CEDE78A"
      unitRef="number">0.94</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="2"
      id="d8357160e3063-wk-Fact-78B3D1B0B3D3AFCAF40694757CEF8D24"
      unitRef="number">0</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember"
      decimals="2"
      id="d8357160e3077-wk-Fact-FB04F19E48FE01964E1994757CEBE30C"
      unitRef="number">0.06</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="2"
      id="d8357160e3098-wk-Fact-A549B1016CA7309F974094757CEA875C"
      unitRef="number">0.99</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="2"
      id="d8357160e3113-wk-Fact-5F6D653ADEEB5971D01794757CEA1228"
      unitRef="number">0.01</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember"
      decimals="2"
      id="d8357160e3128-wk-Fact-306AE6B24654A4D62E4B94757CEBE091"
      unitRef="number">0.01</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="2"
      id="d8357160e3149-wk-Fact-079A48DF84909BAEA7D394757CE946FD"
      unitRef="number">1</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="2"
      id="d8357160e3164-wk-Fact-657913F2C5061D6C890294757CE91CC1"
      unitRef="number">0</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember"
      decimals="2"
      id="d8357160e3178-wk-Fact-A6E574FCC51CCD75D29294757CEBAEB5"
      unitRef="number">0</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2020Q2QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember"
      decimals="-6"
      id="d8357160e3224-wk-Fact-BB2256684D5DC3777F8494757D5E87D2"
      unitRef="usd">917000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q2QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember"
      decimals="-8"
      id="d8357160e3236-wk-Fact-27AB05FFCC8FCC591C3B630426E68474"
      unitRef="usd">1200000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2020Q2YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember"
      decimals="-8"
      id="d8357160e3249-wk-Fact-5506CA5C5545248CD29A955D6E4CA9A4"
      unitRef="usd">1800000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q2YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember"
      decimals="-8"
      id="d8357160e3261-wk-Fact-0C2D3BAB4843F275163F94757D5F317B"
      unitRef="usd">2400000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-08D273A33DB896673DF094757DC0C104-0-wk-Fact-CAE1323C919A6D60245594757D5F6AF1">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of and changes in the carrying amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Goodwill&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Upjohn&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance, December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;48,202&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,451&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,653&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(155&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(204&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance, June&#160;28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;48,047&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,401&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,449&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Primarily represents the impact of foreign exchange.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8357160e3461-wk-Fact-8FC69D5980FE7976569094757D543340"
      unitRef="usd">48202000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8357160e3480-wk-Fact-FF500880D4BEE88ACA9394757D52EE76"
      unitRef="usd">10451000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8357160e3500-wk-Fact-FAA57939ED1473B9187894757D259554"
      unitRef="usd">58653000000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8357160e3522-wk-Fact-C25CFEE5C6642AEA5F2D94757D52C936"
      unitRef="usd">-155000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8357160e3542-wk-Fact-0B05DCE0E371ABB7EA7494757D52B21E"
      unitRef="usd">-49000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8357160e3562-wk-Fact-AD667A5DC0327AE34FF994757D53D517"
      unitRef="usd">-204000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8357160e3594-wk-Fact-9152D12DFE1CD004F9C494757D54DF86"
      unitRef="usd">48047000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8357160e3613-wk-Fact-D96511AD0232BE6F815594757D54642A"
      unitRef="usd">10401000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8357160e3633-wk-Fact-4B0A3E94BBBA400AC84C94757D168B19"
      unitRef="usd">58449000000</us-gaap:Goodwill>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-6C66A73D1B4F00798FF594757DC040AD-0-wk-Fact-F9A10F362D481545A0F894757D3B2676">&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Pension and Postretirement Benefit Plans&lt;/span&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.635477582846%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="33"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of net periodic benefit cost/(credit):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Qualified&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;U.S. Supplemental&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;(Non-Qualified)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Postretirement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Service cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Interest cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;157&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Expected return on plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(251&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(223&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Amortization of:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Actuarial losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Prior service credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Settlements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Special termination benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Net periodic benefit cost/(credit) reported in income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(83&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Six Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Qualified&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;U.S. Supplemental&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;(Non-Qualified)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Postretirement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Service cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Interest cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;262&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;109&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Expected return on plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(503&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(445&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(153&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(160&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Amortization of:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Actuarial losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;74&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;62&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Prior service credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(86&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Settlements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;44&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Special termination benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Net periodic benefit cost/(credit) reported in income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(159&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:47%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the amounts we contributed, and the amounts we expect to contribute during 2020, to our pension and postretirement plans from our general assets for the periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;U.S. Qualified&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;U.S. Supplemental (Non-Qualified)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Postretirement Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Contributions from our general assets for the six months ended June 28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-12px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Expected contributions from our general assets during 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;1,253&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;183&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;185&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Contributions expected to be made for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; are inclusive of amounts contributed during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;six months ended June 28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;. The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments. For the U.S. qualified plans, we plan to make a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.25 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; voluntary contribution in the second half of 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-862EFA995A276D89561494757DC04291-0-wk-Fact-E87FF9778565EAF99F2C94757CBA563F">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.635477582846%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="33"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of net periodic benefit cost/(credit):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Qualified&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;U.S. Supplemental&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;(Non-Qualified)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Postretirement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Service cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Interest cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;157&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Expected return on plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(251&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(223&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Amortization of:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Actuarial losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Prior service credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Settlements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Special termination benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Net periodic benefit cost/(credit) reported in income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(83&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Six Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Qualified&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;U.S. Supplemental&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;(Non-Qualified)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Postretirement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Service cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Interest cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;262&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;109&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Expected return on plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(503&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(445&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(153&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(160&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Amortization of:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Actuarial losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;74&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;62&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Prior service credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(86&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Settlements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;44&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Special termination benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Net periodic benefit cost/(credit) reported in income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(159&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:47%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the amounts we contributed, and the amounts we expect to contribute during 2020, to our pension and postretirement plans from our general assets for the periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;U.S. Qualified&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;U.S. Supplemental (Non-Qualified)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Postretirement Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Contributions from our general assets for the six months ended June 28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-12px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Expected contributions from our general assets during 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;1,253&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;183&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;185&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e1607-wk-Fact-8A0E6BA550C63AF3006894757D7743C2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e1626-wk-Fact-CED160251840E4E9757A94757CF3394F"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e1646-wk-Fact-67AE548A712CDDD394F494757CF3F858"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e1665-wk-Fact-5F30C7B2C6EF0625FB9794757D988854"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e1684-wk-Fact-45D00912EC3174F4988794757D5F6E7E"
      unitRef="usd">36000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e1704-wk-Fact-F358B7D86D437E784A0C94757D6C5E83"
      unitRef="usd">31000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e1723-wk-Fact-1223798DED1AE5B8B44B94757CFDAFBC"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e1742-wk-Fact-D18AB70D2243CD2B790194757D50152C"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e1762-wk-Fact-CFFD731946630FA5173294757D0EC603"
      unitRef="usd">131000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e1781-wk-Fact-E04A84A75625863ABCB694757CF76FD7"
      unitRef="usd">157000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e1800-wk-Fact-5520EADB6F6532501EF394757CF3215F"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e1820-wk-Fact-9696A2CF54209646707A94757DA65D25"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e1839-wk-Fact-D2A42FAB207E3BB8165C94757CF71001"
      unitRef="usd">40000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e1859-wk-Fact-5ECCBF7D71F1C10F58F994757CCE5AD5"
      unitRef="usd">54000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e1878-wk-Fact-844CDA821062E6BD53F794757DA1758B"
      unitRef="usd">13000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e1897-wk-Fact-0A4CE2493D02F490DE6794757CFE8BA1"
      unitRef="usd">19000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e1922-wk-Fact-B06E1980D09EE18796F594757D98AB4D"
      unitRef="usd">251000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e1942-wk-Fact-BAFFDD51D66E4249CC7F94757DA1B948"
      unitRef="usd">223000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e1962-wk-Fact-4CCE979448BE3880158494757D550DF3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e1982-wk-Fact-802AE66AED266C8725E294757D5173E1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2001-wk-Fact-126176494D5B335BE1C494757D0C4549"
      unitRef="usd">75000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2022-wk-Fact-49590B14C26E8646597594757D759878"
      unitRef="usd">80000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2042-wk-Fact-C15417592F592AB2F92994757CEBB96E"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2062-wk-Fact-AF90CA6D6B01D206093194757DA7AD4C"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2249-wk-Fact-93B311D39123F3627B7894757CFDB31D"
      unitRef="usd">-32000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2268-wk-Fact-6CA79F4CBC2771D45A8694757D664BE5"
      unitRef="usd">-37000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2287-wk-Fact-33917F70688B36ADD36494757CD2FBCC"
      unitRef="usd">-4000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2307-wk-Fact-FCDCE881061046BC909894757D0A7065"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2326-wk-Fact-13288FECE518570E807894757CD4BA82"
      unitRef="usd">-30000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2346-wk-Fact-CE2FEC4590F4B32F0AFE94757D6DA566"
      unitRef="usd">-20000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2365-wk-Fact-15912605162B0B27D62794757CF85C35"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2384-wk-Fact-5F88E5DDF560425747C494757D9FBF5E"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2409-wk-Fact-C662480C0E50DA054C1994757D9013FF"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2429-wk-Fact-F1857CF94326E015313C94757CB87D38"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2449-wk-Fact-E00D3615F4D81E96B8B294757D7BBA3D"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2469-wk-Fact-2BAC77BAF82AA411D39894757D9E6A08"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2488-wk-Fact-F77193A231B7FA21F36994757D77F0DE"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2509-wk-Fact-597CFD180CE6C5E6A85C94757D982444"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2529-wk-Fact-7F2E26BF854F77C2CC9094757D99CE84"
      unitRef="usd">-43000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2549-wk-Fact-DCA93998C4A3F799735794757D982123"
      unitRef="usd">-45000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2576-wk-Fact-6CBF864E2961504A12DB94757CD2806F"
      unitRef="usd">-6000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2595-wk-Fact-43962E984AB2A62DA7C694757DA10000"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2614-wk-Fact-5F2E809FE189F196C55694757D306A7C"
      unitRef="usd">-6000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2634-wk-Fact-CFA766634729A8F6300E94757D619106"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2653-wk-Fact-8BB84DDD0005CCE0C40894757D4FACE5"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2673-wk-Fact-D0D7F0F7707B3E87906094757D0A1D69"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2692-wk-Fact-C1661600E4448EFBD0AB94757DA7CBB2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2711-wk-Fact-E976B7ECD21D7D7B2E0894757CAAF95F"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanSpecialTerminationBenefits
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2736-wk-Fact-FEF1DA28980DC329CE8C94757D9DC823"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanSpecialTerminationBenefits
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2755-wk-Fact-F61FAFB8F521C98C7C4294757D082A31"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanSpecialTerminationBenefits
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2774-wk-Fact-618CBFA355001747A53F94757D8EA4E9"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanSpecialTerminationBenefits
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2794-wk-Fact-6D11C4A43914FD02D6DE94757CF59807"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanSpecialTerminationBenefits
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2813-wk-Fact-0D267565F8548AD0F4B094757D79A699"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanSpecialTerminationBenefits
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2833-wk-Fact-735E91E10251837304A394757D6D4282"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanSpecialTerminationBenefits
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2852-wk-Fact-818B45C59E5295D57CEC94757DA3E1BE"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanSpecialTerminationBenefits
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2871-wk-Fact-E31B6E1B030324C2785A94757D908F5F"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2901-wk-Fact-03638A3FE9F6DEABE42094757CF66E73"
      unitRef="usd">-83000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2921-wk-Fact-569ABF20101276D3F33394757CB2B9DD"
      unitRef="usd">-27000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2942-wk-Fact-A79A69EE5FF1341B264F94757D55549B"
      unitRef="usd">19000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2961-wk-Fact-0484268376D2F2A3A68D94757CFF7FF1"
      unitRef="usd">17000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e2980-wk-Fact-FE4AAA62177D49B766D194757D7ADFB0"
      unitRef="usd">32000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e3000-wk-Fact-858B05D1EC7B77F4C37594757D6E6FBF"
      unitRef="usd">25000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2020Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e3019-wk-Fact-0CCCC7C6B12548EF9A2E94757D530CED"
      unitRef="usd">-30000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2019Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e3039-wk-Fact-04FF5CFA56B2C55F794094757CF522A1"
      unitRef="usd">-23000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e3899-wk-Fact-C966FE1217910DE3ABE694757CC3106C"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e3918-wk-Fact-7DF4148F3A92339C0A3F94757CB7E54B"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e3938-wk-Fact-D43F7EB6258E84BF7E5694757D2BE9F0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e3957-wk-Fact-394A995203A612A26E0994757D28CC73"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e3976-wk-Fact-7C66E5B3FAC766AE22B794757CEEC058"
      unitRef="usd">72000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e3996-wk-Fact-97881A4FB86B00148A2B94757D261E26"
      unitRef="usd">63000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4015-wk-Fact-1CA2C7F4D12568AAED6994757D7BE3EF"
      unitRef="usd">19000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4034-wk-Fact-53B245957441E22EE4A594757CDBEEFC"
      unitRef="usd">19000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4054-wk-Fact-A023A66317D5ED5867FB94757CB18D04"
      unitRef="usd">262000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4073-wk-Fact-5AE2182B13B4CEF4C73794757D2CF199"
      unitRef="usd">315000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4092-wk-Fact-C06CABC15DA14C11FF5594757D2AE2FF"
      unitRef="usd">18000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4112-wk-Fact-1A9BAC56131373D1A8C494757D3375BF"
      unitRef="usd">25000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4131-wk-Fact-42AE4996AE177FA236A394757CD11CBD"
      unitRef="usd">82000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4151-wk-Fact-DA44B2F63C0376FF208194757CD0CB29"
      unitRef="usd">109000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4170-wk-Fact-0986444DADBF5856B95694757CB9C5CE"
      unitRef="usd">25000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4189-wk-Fact-578F006D640F90FE6D6994757CED7830"
      unitRef="usd">38000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4214-wk-Fact-4FA4F93E26ADD0787AA694757D101185"
      unitRef="usd">503000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4234-wk-Fact-D2E448D40BAAF65BAC8894757CB569ED"
      unitRef="usd">445000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4254-wk-Fact-86387ADB0CDA28791A3294757CD390BC"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4274-wk-Fact-B911AAAF89C2FE235BCA94757D21CD37"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4293-wk-Fact-3942B825C87E1470A01094757CD14464"
      unitRef="usd">153000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4314-wk-Fact-55A505C832573019983194757CD4C565"
      unitRef="usd">160000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4334-wk-Fact-BF26E6FFFF77B2936C1394757D251B69"
      unitRef="usd">18000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4354-wk-Fact-B11719A8D4E495C277B194757CD4A6A5"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4549-wk-Fact-2EC458A90E1B56D867AE94757CD1D3AA"
      unitRef="usd">-64000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4568-wk-Fact-DC691DF21ACF6174AF3094757CD547B2"
      unitRef="usd">-74000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4587-wk-Fact-0CFC631FFCB8BDA9416C94757D2C8121"
      unitRef="usd">-7000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4607-wk-Fact-E17FE0E5DD807040E21594757D231D49"
      unitRef="usd">-5000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4626-wk-Fact-5FF15C7FD69DACE707E394757CB3D138"
      unitRef="usd">-62000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4646-wk-Fact-99A89FB4D21C1D68F53494757CCD0A0F"
      unitRef="usd">-41000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4665-wk-Fact-DFF679DE86AA442135FA94757D2A2469"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4684-wk-Fact-9395603C040D04A3E29894757CF282C8"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4709-wk-Fact-018F7777F5A4988D2FD294757D121DCA"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4729-wk-Fact-6A9B12BC065B471F391B94757D277E0E"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4749-wk-Fact-FA02EE27136AFA6D96F094757CD55AE6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4769-wk-Fact-8600724A667F7C107E7F94757D1E1F98"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4788-wk-Fact-3407605A9D652DFE90CA94757CDF90AB"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4809-wk-Fact-741D4D9739EDAA66166594757D043AD2"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4829-wk-Fact-71EF664358F7AC4D77F294757D7D3040"
      unitRef="usd">-86000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4849-wk-Fact-7AB287253C2826281A4E94757CB7A875"
      unitRef="usd">-89000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4875-wk-Fact-EE0CC097563E8EE1C71694757CEC1429"
      unitRef="usd">-20000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4894-wk-Fact-107324D1959BD11060E994757D31C047"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4913-wk-Fact-E1C3EC8BA4E738E81A4B94757CEE03E3"
      unitRef="usd">-44000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4933-wk-Fact-DAEC64A519CE1A4EBC0A94757CD30823"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4952-wk-Fact-8D6BE01FBE41D16A6CDE94757CED03D5"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4972-wk-Fact-46A8399C200FF03D695894757CC1B39D"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e4991-wk-Fact-AB9B2C9037487774B82494757D2BDF3C"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e5010-wk-Fact-695280579C624DE4737894757D3F4332"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanSpecialTerminationBenefits
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e5035-wk-Fact-69697D056FD8BE2650F394757CB775CD"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanSpecialTerminationBenefits
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e5054-wk-Fact-CCF8EF89DBF6968FDE9B94757CCB90CB"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanSpecialTerminationBenefits
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e5073-wk-Fact-3246F936E711F93EDC5794757D1E99E6"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanSpecialTerminationBenefits
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e5093-wk-Fact-D88A927EE32742928CF594757CD5C32D"
      unitRef="usd">-9000000</us-gaap:DefinedBenefitPlanSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanSpecialTerminationBenefits
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e5112-wk-Fact-9CF0B0C1C64F07BA8B3294757D232E83"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanSpecialTerminationBenefits
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e5132-wk-Fact-0A109F12214E8787069B94757D2DCD8B"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanSpecialTerminationBenefits
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e5151-wk-Fact-FBA6799618AA470B679094757CB47DD9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanSpecialTerminationBenefits
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e5170-wk-Fact-C6ABBF9E804027B403D294757D2FD3AA"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e5200-wk-Fact-5A97434FFD808A04AB1794757D2D057B"
      unitRef="usd">-159000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e5220-wk-Fact-4D2A5C653703ADAEF66194757CDAD6E1"
      unitRef="usd">-55000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e5241-wk-Fact-43E0AE005A8224139B4894757D24D0D3"
      unitRef="usd">71000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e5260-wk-Fact-0243292AC7ECF384807094757D29F0B1"
      unitRef="usd">37000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e5279-wk-Fact-B22726FB6CA500CEABE294757D1613CA"
      unitRef="usd">63000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e5299-wk-Fact-6855CF96A7F97DB0DA4594757CB1DFD3"
      unitRef="usd">51000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e5318-wk-Fact-7421330FDB0F5938BC4F94757D164088"
      unitRef="usd">-60000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2019Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e5338-wk-Fact-B447540A0E9C595AEFFE94757D2F88DB"
      unitRef="usd">-46000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <pfe:ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-B1B1FE4E46EFE71E586B94757DC0F9B6-0-wk-Fact-64E2770B8AF780A808AD94757D2925FF">&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:47%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the amounts we contributed, and the amounts we expect to contribute during 2020, to our pension and postretirement plans from our general assets for the periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;U.S. Qualified&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;U.S. Supplemental (Non-Qualified)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Postretirement Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Contributions from our general assets for the six months ended June 28, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-12px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Expected contributions from our general assets during 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;1,253&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;183&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;185&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Contributions expected to be made for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; are inclusive of amounts contributed during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;six months ended June 28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;. The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments. For the U.S. qualified plans, we plan to make a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.25 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; voluntary contribution in the second half of 2020.&lt;/span&gt;&lt;/div&gt;</pfe:ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e5685-wk-Fact-BEA910CC7097248EF9BD94757D8D24B6"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e5704-wk-Fact-6919A01C1B8A8058F9D694757D90E44C"
      unitRef="usd">150000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e5724-wk-Fact-6E1144FFE02DFD09A16794757D82DC24"
      unitRef="usd">116000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="FD2020Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e5743-wk-Fact-ADF0D5020F8FD777B95294757D8F440B"
      unitRef="usd">64000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear
      contextRef="FI2020Q2_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e5765-wk-Fact-E864359E96F7D020F0CE94757D7CD99F"
      unitRef="usd">1253000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear
      contextRef="FI2020Q2_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d8372420e5784-wk-Fact-7363C996912428EF761094757D8CDD06"
      unitRef="usd">183000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear
      contextRef="FI2020Q2_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e5803-wk-Fact-35AE4CA011AF5ED4C8B994757D74E218"
      unitRef="usd">185000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear
      contextRef="FI2020Q2_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d8372420e5823-wk-Fact-2DB662656B0870E5C58B94757D7A7265"
      unitRef="usd">137000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="D2020Q4Jun29-Dec31_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="-7"
      id="d8372420e5919-wk-Fact-5A101E66210BE38BFEC894757DA5C6AD"
      unitRef="usd">1250000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-2C0862EB3E45679CF8E1633CB04B10A3-0-wk-Fact-BB3667F91051469F2EBF633D59A78119">&lt;span style="font-weight:bold;text-decoration:underline;"&gt;Equity&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt; &lt;/span&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;A. Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prior to May 4, 2020, Pfizer&#x2019;s Series A convertible perpetual preferred stock (the Series A Preferred Stock) was held by an employee stock ownership plan trust (the Trust). All outstanding shares of Series A Preferred Stock were converted, at the direction of the independent fiduciary under the Trust and in accordance with the certificate of designations for the Series A Preferred Stock, into shares of Pfizer common stock on May 4, 2020. The Trust received an aggregate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,070,369&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of Pfizer common stock upon conversion, with &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;zero&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of Series A Preferred Stock remaining outstanding as a result of the conversion.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;B. Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes quarterly cash dividends:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Date Declared&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Payment Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Dividend Per&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Date Declared&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Payment Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Dividend Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 13, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March 6, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 14, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March 1, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;April 23, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 5, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;April 25, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 7, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 25, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September 1, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 27, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September 3, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September 24, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 2, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="D2020Q2May4-4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d8352055e702-wk-Fact-837037F981A4F7FE313994757D9F0609"
      unitRef="shares">1070369</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="I2020Q2May4"
      decimals="INF"
      id="d8352055e706-wk-Fact-139531B224829D473DC094757DA47D96"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:DividendsDeclaredTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-B33D97891A4C134539C6633F51057236-0-wk-Fact-25B646872BA1E732B3F4634004069935">&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes quarterly cash dividends:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Date Declared&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Payment Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Dividend Per&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Date Declared&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Payment Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Dividend Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 13, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March 6, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 14, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March 1, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;April 23, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 5, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;April 25, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 7, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 25, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September 1, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 27, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September 3, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September 24, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 2, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DividendsDeclaredTableTextBlock>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="D2019Q4Dec13-13"
      decimals="2"
      id="d8352055e962-wk-Fact-85F65DD82325B178C66594757CFD849B"
      unitRef="usdPerShare">0.38</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="D2018Q4Dec14-14"
      decimals="2"
      id="d8352055e997-wk-Fact-2CF0A869020E2EEBB6EB634AD40A53A7"
      unitRef="usdPerShare">0.36</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="D2020Q2Apr23_Apr232020"
      decimals="2"
      id="d8352055e1027-wk-Fact-38FFB29DB2E02FCAD7CF634AAC8B3855"
      unitRef="usdPerShare">0.38</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="D2019Q2Apr25-25"
      decimals="2"
      id="d8352055e1062-wk-Fact-FA418604F1FC47CDDF3F634AD7AD39AC"
      unitRef="usdPerShare">0.36</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="D2020Q2Jun25-25"
      decimals="2"
      id="d8352055e1092-wk-Fact-3085C64D47708F3D1BD5634AAC9340F6"
      unitRef="usdPerShare">0.38</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="D2019Q2Jun27"
      decimals="2"
      id="d8352055e1127-wk-Fact-4143CB1C95950518012A634ADB63B785"
      unitRef="usdPerShare">0.36</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="D2019Q3"
      decimals="2"
      id="d8352055e1193-wk-Fact-7BE8DA4E56FB81F33720634ADF329259"
      unitRef="usdPerShare">0.36</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-4380F86A09A2E4DDA07194757DC07F50-0-wk-Fact-8FD19B660B534F4C402D94757CFCBDBE">&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders&lt;/span&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:52%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the detailed calculation of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;EPS&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Six Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(IN MILLIONS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;EPS Numerator&#x2013;&#x2013;Basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income from continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,434&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,056&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,845&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,945&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income from continuing operations attributable to Pfizer Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,046&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,828&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,929&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: Preferred stock dividends&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,828&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,929&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net income attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,828&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,929&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;EPS Numerator&#x2013;&#x2013;Diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,046&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,828&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,929&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Discontinued operations&#x2013;&#x2013;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net income attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,046&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,828&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,929&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;EPS Denominator&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average number of common shares outstanding&#x2013;&#x2013;Basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,554&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,562&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,550&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,598&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Common-share equivalents: stock options, stock issuable under employee compensation plans and convertible preferred stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;110&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;66&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;112&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average number of common shares outstanding&#x2013;&#x2013;Diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,619&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,672&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,616&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,711&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Anti-dilutive common stock equivalents&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-BAAAF81361CEA24550F094757DC11387-0-wk-Fact-34877EB99C4970166C2794757CFBE271">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:52%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the detailed calculation of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;EPS&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Six Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(IN MILLIONS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;EPS Numerator&#x2013;&#x2013;Basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income from continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,434&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,056&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,845&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,945&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income from continuing operations attributable to Pfizer Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,046&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,828&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,929&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: Preferred stock dividends&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,828&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,929&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net income attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,828&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,929&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;EPS Numerator&#x2013;&#x2013;Diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,046&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,828&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,929&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Discontinued operations&#x2013;&#x2013;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net income attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,046&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,828&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,929&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;EPS Denominator&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average number of common shares outstanding&#x2013;&#x2013;Basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,554&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,562&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,550&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,598&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Common-share equivalents: stock options, stock issuable under employee compensation plans and convertible preferred stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;110&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;66&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;112&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average number of common shares outstanding&#x2013;&#x2013;Diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,619&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,672&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,616&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,711&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Anti-dilutive common stock equivalents&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8356748e1102-wk-Fact-2979655C6D134159C89394757D499DAA"
      unitRef="usd">3434000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8356748e1121-wk-Fact-C920A45D5E66EC197B2A94757CF0CD54"
      unitRef="usd">5056000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8356748e1141-wk-Fact-A90E01F4F7B0E1568EDA94757D6D8CFD"
      unitRef="usd">6845000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8356748e1160-wk-Fact-603FB52F232889DFBADE94757D592C93"
      unitRef="usd">8945000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8356748e1180-wk-Fact-AC8A94205E4FF68F9F3694757D49E298"
      unitRef="usd">8000000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8356748e1199-wk-Fact-7A36A559DC490566437C94757D3C7471"
      unitRef="usd">10000000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8356748e1218-wk-Fact-C329D124C5801810FE0C94757D347999"
      unitRef="usd">17000000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8356748e1238-wk-Fact-604FE0F79757762E5E8C94757CCFB893"
      unitRef="usd">15000000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8356748e1263-wk-Fact-1CF3FF61B59C9EBB9C9994757D3E3AB3"
      unitRef="usd">3426000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8356748e1282-wk-Fact-E7ECE7800082856A7A1094757D39605C"
      unitRef="usd">5046000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8356748e1301-wk-Fact-4A9CCA0D3C475FAD52C694757D3900B8"
      unitRef="usd">6828000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8356748e1321-wk-Fact-465C45AD0AF6E5F0BC6C94757D2C168A"
      unitRef="usd">8929000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8356748e1346-wk-Fact-F9E6F4AE79CD02D810A994757D401975"
      unitRef="usd">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8356748e1365-wk-Fact-F7CCA6E7C71004067D5E94757D402809"
      unitRef="usd">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8356748e1384-wk-Fact-A0F2B8C76CEC5D3EEADE94757D28154B"
      unitRef="usd">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8356748e1404-wk-Fact-A0593EA50670403DBD0194757D33B2B7"
      unitRef="usd">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8356748e1429-wk-Fact-E9B299C5DCCAC1091C9C94757D3B698F"
      unitRef="usd">3426000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8356748e1448-wk-Fact-BB4B1F24703C7617826494757D4169BB"
      unitRef="usd">5045000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8356748e1467-wk-Fact-23F8672CEEE9B2454CCC94757D355E2C"
      unitRef="usd">6828000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8356748e1487-wk-Fact-CD9F62E0AB686EA2160894757D38EB6F"
      unitRef="usd">8929000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8356748e1512-wk-Fact-D0B1BB14EB1C0097910C94757D5D09B2"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8356748e1531-wk-Fact-05DE67BF183EFC3302F894757D673D16"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8356748e1550-wk-Fact-8CA5088693E8928A2F7194757D5C8489"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8356748e1570-wk-Fact-7F22D0DB6525173F13B494757CADCE97"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8356748e1600-wk-Fact-11A391AB7EC29FE56C8194757D44B325"
      unitRef="usd">3426000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8356748e1619-wk-Fact-E8DC3F36C1484A7598DD94757D412AB0"
      unitRef="usd">5045000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8356748e1639-wk-Fact-CBE74642929D5FE6AE4E94757CED0E9A"
      unitRef="usd">6828000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8356748e1658-wk-Fact-D566F33C0450F49C95E994757D7B3B2F"
      unitRef="usd">8929000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8356748e1767-wk-Fact-E0F82560F34C81B9ADE594757D47F841"
      unitRef="usd">3426000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8356748e1786-wk-Fact-B9F608288C5AC6E377DC94757D3E37FA"
      unitRef="usd">5046000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8356748e1806-wk-Fact-48548F0A6A5A6C9A7DA994757D37EE18"
      unitRef="usd">6828000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8356748e1825-wk-Fact-5CF1FB104F54EA6CCDE094757D2A8412"
      unitRef="usd">8929000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8356748e1845-wk-Fact-C570458300ACBEDF93DD94757D39134F"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8356748e1864-wk-Fact-A46A2B659FBFF5DE296C94757D3E1EC5"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8356748e1883-wk-Fact-4244BE93446A2982839C94757D8068CB"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8356748e1903-wk-Fact-2233B315E6E073D059A694757D7AFB08"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8356748e1933-wk-Fact-FC0A7ED4816CF00DCA6494757D460073"
      unitRef="usd">3426000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8356748e1952-wk-Fact-A572FAF534B34CC5432094757D3FA3CE"
      unitRef="usd">5046000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8356748e1972-wk-Fact-0A993D6EBB97EDD9C20D94757D312BB1"
      unitRef="usd">6828000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8356748e1991-wk-Fact-2D0FCD88B17D4D8FA67594757CD6DAC9"
      unitRef="usd">8929000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8356748e2094-wk-Fact-CEDDD667A11CAC08820D94757D0E749E"
      unitRef="shares">5554000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8356748e2113-wk-Fact-4083035A9265D74B487394757CDE895C"
      unitRef="shares">5562000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8356748e2132-wk-Fact-3E9B45FC40C0B53734B894757D6021C6"
      unitRef="shares">5550000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8356748e2152-wk-Fact-05B58E4BDA3C96C172AE94757D61A5B0"
      unitRef="shares">5598000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8356748e2177-wk-Fact-9575A68D8FEC4A1DD04394757D38012E"
      unitRef="shares">65000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8356748e2196-wk-Fact-EC2E7F8D528A88AAC11994757D3D9309"
      unitRef="shares">110000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8356748e2215-wk-Fact-71C844C0735999FB98A094757D7BE586"
      unitRef="shares">66000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8356748e2235-wk-Fact-EDC8EE2FFDAD42D9FF4E94757D7E3374"
      unitRef="shares">112000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8356748e2260-wk-Fact-CDED57DD355FBFDCE83394757D0D0D08"
      unitRef="shares">5619000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8356748e2279-wk-Fact-C825A8BB25BE38B63BB194757D30A6AC"
      unitRef="shares">5672000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8356748e2298-wk-Fact-8EF576E428EEA952509894757D5DA535"
      unitRef="shares">5616000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8356748e2318-wk-Fact-4E46F2B386CE7BF8977294757CBBCA8A"
      unitRef="shares">5711000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8356748e2345-wk-Fact-1F9015BD5A5A1530EFBA94757D43CEBC"
      unitRef="shares">6000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8356748e2364-wk-Fact-B3F82E5E9DDB5FAA6C2D94757D393DCC"
      unitRef="shares">1000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8356748e2383-wk-Fact-4140131424BB26DB8A6194757CD6155F"
      unitRef="shares">4000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8356748e2403-wk-Fact-2183DCBEF0EE0B13B7AC94757CC13062"
      unitRef="shares">2000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-54520FF336DB7E29D5B594757DC1F14C-0-wk-Fact-FBB0BAD5276EFDAC3BF194757CBD1883">&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Contingencies and Certain Commitments&lt;/span&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies. For a discussion of our tax contingencies, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 5B.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; For a discussion of our legal contingencies, see below.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;A. Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our legal contingencies include, but are not limited to, the following:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. We are the plaintiff in the majority of these actions. An adverse outcome in actions in which we are the plaintiff could result in loss of patent protection for a drug, a significant loss of revenues from that drug or impairment of the value of associated assets.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial and other matters, which can include merger-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, which could be substantial, and/or criminal charges.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations in the period in which the amounts are accrued and/or our cash flows in the period in which the amounts are paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader&#x2019;s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. As a result of considering qualitative factors in our determination of principal matters, there are some matters discussed below with respect to which management believes that the likelihood of possible loss in excess of amounts accrued is remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-weight:bold;text-decoration:underline;"&gt;A1.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt; &lt;/span&gt;&lt;span style="font-weight:bold;text-decoration:underline;"&gt;Legal Proceedings&#x2013;&#x2013;Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Like other pharmaceutical companies, we are involved in numerous suits relating to our patents, including but not limited to, those discussed below. Most of the suits involve claims by generic drug manufacturers that patents covering our products, processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents on a number of our products that are discussed below, patent rights to certain of our products are being challenged in various other jurisdictions. We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for allegedly causing delay of generic entry. Additionally, our licensing and collaboration partners face challenges by generic drug manufacturers to patents covering products for which we have licenses or co-promotion rights. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the U.S. In October 2017, the Patent Trial and Appeal Board (PTAB) refused to initiate proceedings as to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; patents. In June 2018, the PTAB ruled on another patent, holding that &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; claim was valid and that all other claims were invalid. The party challenging that patent appealed the decision. In November 2019, the U.S. Court of Appeals for the Federal Circuit vacated the PTAB&#x2019;s ruling and requested that the PTAB redecide the challenge.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In March and June 2019, an additional patent was found invalid in separate proceedings by the PTAB. We appealed. In January 2020, the U.S. Court of Appeals for the Federal Circuit vacated the original decision and requested that the PTAB redecide the case. Challenges to other patents remain pending in jurisdictions outside the U.S.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;color:#1f497d;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The invalidation of all of the patents in our pneumococcal portfolio could potentially allow a competitor pneumococcal vaccine into the marketplace. In the event that any of the patents are found valid and infringed, a competitor pneumococcal vaccine might be prohibited from entering the market or required to pay Pfizer a royalty. We are also subject to patent litigation pursuant to which one or more third parties seek damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our Hospira subsidiaries are involved in patent and patent-related disputes over their attempts to bring generic pharmaceutical and biosimilar products to market. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold in the event that we or one of our subsidiaries, like Hospira, is found to have willfully infringed valid patent rights of a third party.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Actions In Which We Are The Plaintiff&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;EpiPen&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In July 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz in the U.S. District Court for the District of New Jersey in connection with Sandoz&#x2019;s abbreviated new drug application filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Xeljanz (tofacitinib)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Beginning in 2017, we brought patent-infringement actions against several generic manufacturers that filed separate abbreviated new drug applications with the FDA seeking approval to market their generic versions of tofacitinib tablets in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;one&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; or both of 5 mg and 10 mg dosage strengths, and in both immediate and extended release forms. To date, actions against the following generic manufacturers have been settled on terms not material to Pfizer: (i) MicroLabs USA Inc. and MicroLabs Ltd.; (ii) Sun Pharmaceutical Industries Ltd.; (iii) Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., Huahai US Inc. and Solco Healthcare US, LLC; (iv) Breckenridge Pharmaceutical Inc., Pensa Pharma S.A. and Laboratorios Del Dr. Esteve, S.A.; and (v) Ajanta Pharma Ltd. and Ajanta Pharma USA Inc. The remaining actions continue as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In March 2017, we brought a patent-infringement action against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, Zydus) in the U.S. District Court for the District of Delaware asserting the infringement and validity of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; patents: the patent covering the active ingredient expiring in December 2025, the patent covering an enantiomer of tofacitinib expiring in 2022, and the patent covering a polymorphic form of tofacitinib expiring in 2023, which Zydus challenged in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In December 2018, we brought a separate patent infringement action against Teva Pharmaceuticals USA, Inc. (Teva) in the U.S. District Court for the District of Delaware asserting the infringement and validity of our patent covering extended release &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;formulations of tofacitinib that was challenged by Teva in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 11 mg extended release tablets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Inlyta (axitinib)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In April 2018, Apotex Inc. notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Inlyta. Apotex Inc. asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In May 2018, we filed suit against Apotex Inc. in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In May 2019, Glenmark Pharmaceuticals Limited (Glenmark) notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Inlyta. Glenmark asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In June 2019, we filed suit against Glenmark in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Kerydin (tavaborole)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In September 2018, several generic companies notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Kerydin. The generic companies&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;assert the invalidity and non-infringement of methods of use and formulation patents for tavaborole that expire in 2026 and 2027, including pediatric exclusivity. In October 2018, Anacor, our wholly-owned subsidiary&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;,&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; filed infringement lawsuits against each of the generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Ibrance (palbociclib)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In March 2019, several generic companies notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Ibrance. The generic companies assert the invalidity and non-infringement of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; composition of matter patents and a method of use patent covering palbociclib, each of which expire in 2023. In April 2019, we brought patent infringement actions against each of the generic filers in various federal courts, asserting the validity and infringement of the patents challenged by the generic companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Chantix (varenicline)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In January 2020, we brought a patent infringement action against Viwit Pharmaceutical Co. Ltd. (Viwit) in the U.S. District Court for the District of Delaware asserting the validity and infringement of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; patents challenged by Viwit in its abbreviated new drug application seeking approval to market a generic version of varenicline, 0.5 mg and 1.0 mg tablets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Lyrica (pregabalin)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2014, Generics (U.K.) Ltd (trading as Mylan) filed an invalidity action against the Lyrica pain use patent in the High Court of Justice in London. Subsequently, Actavis Group PTC ehf filed an invalidity action in the same court, and Pfizer sued for infringement against Actavis Group PTC ehf, Actavis U.K. Ltd and Caduceus Pharma Ltd (together, Actavis), in addition to requesting preliminary relief. Our request for preliminary relief was denied in a January 2015 hearing, and the denial subsequently was confirmed on appeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February 2015, the National Health Service (NHS) England was ordered by the High Court, as an intermediary, to issue guidance for prescribers and pharmacists directing the prescription and dispensing of Lyrica by brand when pregabalin was prescribed for the treatment of neuropathic pain. NHS Wales and NHS Northern Ireland also issued prescribing guidance. The guidance to prescribe and dispense Lyrica for neuropathic pain was withdrawn upon patent expiration in July 2017. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We also filed infringement actions against (i) Teva UK Ltd, and (ii) Dr. Reddy&#x2019;s Laboratories (UK) Ltd and Caduceus Pharma Ltd (together, Dr. Reddy&#x2019;s) in February 2015, seeking the same relief as in the action against Actavis. Dr. Reddy&#x2019;s filed an invalidity counterclaim. These actions were stayed pending the outcome of the Mylan and Actavis cases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Mylan and Actavis invalidity actions were heard in the High Court at the same time as the Actavis infringement action. The High Court ruled against us, holding that the asserted claims were either not infringed or invalid, and appeals followed. In November 2018, the U.K. Supreme Court ruled that all the relevant claims directed to neuropathic pain were invalid.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In October 2015, after Sandoz GmbH and Sandoz Ltd (together, Sandoz) launched a full label generic pregabalin product, we obtained from the High Court a preliminary injunction enjoining Sandoz from further sales of the product and ordering Sandoz to identify the parties holding its product. Sandoz identified wholesaler AAH Pharmaceuticals Ltd and pharmacy chain Lloyds Pharmacy Ltd (supplied by AAH), and we requested that these parties cease further sales and withdraw the Sandoz full label product. In October 2015, Lloyds was added to the Sandoz action, and we obtained a preliminary order from the High Court requiring Lloyds to advise its pharmacists that the Sandoz full label product should not be dispensed. In November 2015, the High Court confirmed the preliminary injunction against Sandoz and Lloyds. Sandoz filed an invalidity counterclaim. Upon &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;agreement of the parties, in December 2015, the proceedings against Lloyds were discontinued, and the proceedings against Sandoz were stayed pending outcome of the Mylan and Actavis cases. The preliminary injunction against Sandoz remained in place until patent expiration in July 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In May 2020, Dr. Reddy&#x2019;s filed a claim for damages in connection with the above-referenced legal actions. In July 2020, the Scottish Ministers and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;fourteen&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Scottish Health Boards (together, NHS Scotland) filed a claim for damages in connection with the above-referenced legal action concerning Sandoz.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Matter Involving Our Collaboration/Licensing Partners&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Eliquis&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February, March, and April 2017, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;twenty-five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed abbreviated new drug applications seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; patents listed in the Orange Book for Eliquis. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;One&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the patents expired in December 2019 and the remaining patents currently are set to expire in 2026 and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. In April 2017, BMS and Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia, asserting that each of the generic companies&#x2019; proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the 2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; patents. In August 2020, the U.S. District Court for the District of Delaware ruled that both the 2026 patent and the 2031 patent are valid and infringed by the proposed generic products. The decision is subject to appeal. Prior to the August 2020 ruling, we and BMS settled with certain of the generic companies on terms not material to Pfizer, and we and BMS may settle with other generic companies in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;A2. Legal Proceedings&#x2013;&#x2013;Product Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Like other pharmaceutical companies, we are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Asbestos&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. Claims against American Optical and numerous other defendants are pending in various federal and state courts seeking damages for alleged personal injury from exposure to asbestos and other allegedly hazardous materials. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Numerous lawsuits are pending against Pfizer in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;There also&#160;are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Effexor&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Beginning in May 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants&#x2019; allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In October 2014, the District Court dismissed the direct purchaser plaintiffs&#x2019; claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff claims. In January 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court&#x2019;s decisions and remanded the claims to the District Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Lipitor&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Antitrust Actions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:4px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Beginning in November 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain affiliates of Pfizer, and, in most of the actions, Ranbaxy, Inc. (Ranbaxy) and certain affiliates of Ranbaxy. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants&#x2019; allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor, and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;In re Lipitor Antitrust Litigation MDL-2332&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;) in the U.S. District&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;color:#0000ff;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Court for the District of New Jersey. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In September 2013 and 2014, the District Court dismissed with prejudice the claims by direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs have appealed the District Court&#x2019;s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court&#x2019;s decisions and remanded the claims to the District Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Also, in January 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Personal Injury Actions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed type 2 diabetes purportedly as a result of the ingestion of Lipitor. Plaintiffs seek compensatory and punitive damages. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February 2014, the federal actions were transferred for consolidated pre-trial proceedings to a Multi-District Litigation (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;In re Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Products Liability Litigation (No. II) MDL-2502&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;) in the U.S. District Court for the District of South Carolina. Since 2016, certain cases in the Multi-District Litigation were remanded to certain state courts. In January 2017, the District Court granted our motion for summary judgment, dismissing substantially all of the remaining cases pending in the Multi-District Litigation. In January 2017, the plaintiffs appealed the District Court&#x2019;s decision to the U.S. Court of Appeals for the Fourth Circuit. In June 2018, the U.S. Court of Appeals for the Fourth Circuit affirmed the District Court&#x2019;s decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Viagra&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Since April 2016, a Multi-District Litigation has been pending in the U.S. District Court for the Northern District of California (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;In Re: Viagra (Sildenafil Citrate) Products Liability Litigation, MDL-2691&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;), in which plaintiffs allege that they developed melanoma and/or the exacerbation of melanoma purportedly as a result of the ingestion of Viagra. Additional cases filed against Lilly with respect to Cialis have also been consolidated in the Multi-District Litigation &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;(In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation, MDL-2691&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;). In January 2020, the District Court granted our and Lilly&#x2019;s motion to exclude all of plaintiffs&#x2019; general causation opinions. As a result, in April 2020, the District Court entered summary judgment in favor of defendants and dismissed all of plaintiffs&#x2019; claims. In April 2020, plaintiffs filed a notice of appeal in the U.S. Court of Appeals for the Ninth Circuit. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;EpiPen&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Beginning in February 2017, purported class actions were filed in various federal courts by indirect purchasers of EpiPen against Pfizer, and/or its affiliates King and Meridian, and/or various entities affiliated with Mylan, and Mylan Chief Executive Officer, Heather Bresch. The plaintiffs in these actions seek to represent U.S. nationwide classes comprising persons or entities who paid for any portion of the end-user purchase price of an EpiPen between 2009 until the cessation of the defendants&#x2019; allegedly unlawful conduct. In February 2020, a similar lawsuit was filed in the U.S. District Court for the District of Kansas against Pfizer, King, Meridian and the Mylan entities on behalf of a purported U.S. nationwide class of direct purchaser plaintiffs who purchased EpiPen devices directly from the defendants (the 2020 Lawsuit). Against Pfizer and/or its affiliates, plaintiffs in these actions generally allege that Pfizer&#x2019;s and/or its affiliates&#x2019; settlement of patent litigation regarding EpiPen delayed market entry of generic EpiPen in violation of federal antitrust laws and various state antitrust laws. At least &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; lawsuit also alleges that Pfizer and/or Mylan violated the federal Racketeer Influenced and Corrupt Organizations Act (RICO). Plaintiffs also filed various federal antitrust, state consumer protection and unjust enrichment claims against, and relating to conduct attributable solely to, Mylan and/or its affiliates regarding EpiPen. Plaintiffs seek treble damages for alleged overcharges for EpiPen since 2011. In August 2017, all of these actions, except for the 2020 Lawsuit, were consolidated for coordinated pre-trial proceedings in a Multi-District Litigation (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;In re: EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation, MDL-2785&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;) in the U.S. District Court for the District of Kansas with other EpiPen-related actions against Mylan and/or its affiliates to which Pfizer, King and Meridian are not parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In July 2020, a new lawsuit was filed in the District of Colorado on behalf of indirect purchasers. Plaintiff represents a putative U.S. nationwide class of persons or entities who paid for any portion of the end-user purchase price of certain refill or replacement EpiPens since 2010. Plaintiff alleges that Pfizer and Meridian misrepresented the shelf-life and expiration date of EpiPen, in violation of the federal RICO statute. Plaintiff seeks treble damages for alleged unnecessary replacement or refill purchases of EpiPens by members of the putative class.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Nexium 24HR and Protonix&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A number of individual and multi-plaintiff lawsuits have been filed against Pfizer, certain of its subsidiaries and/or other pharmaceutical manufacturers in various federal and state courts alleging that the plaintiffs developed kidney-related injuries purportedly as a result of the ingestion of certain proton pump inhibitors. The cases against Pfizer involve Protonix and/or Nexium 24HR and seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement. In August 2017, the federal actions were ordered transferred for coordinated pre-trial proceedings to a Multi-District Litigation (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;In re: Proton-Pump Inhibitor Products Liability Litigation&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (No. II)) in the U.S. District Court for the District of New Jersey. On July&#160;31, 2019, we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name. As part of the joint venture transaction, the joint venture has agreed to assume, and to indemnify Pfizer for, liabilities arising out of such litigation to the extent related to Nexium 24HR.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Docetaxel&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Personal Injury Actions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed permanent hair loss. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek compensatory and punitive damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In October 2016, the federal cases were transferred for coordinated pre-trial proceedings to a Multi-District Litigation (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;In re Taxotere (Docetaxel) Products Liability Litigation, MDL-2740&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;) in the U.S. District Court for the Eastern District of Louisiana.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Mississippi Attorney General Government Action&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In October 2018, the Attorney General of Mississippi filed a complaint in Mississippi state court against the manufacturer of the branded product and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;eight&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; other manufacturers including Pfizer and Hospira, alleging, with respect to Pfizer and Hospira, a failure to warn about a risk of permanent hair loss in violation of the Mississippi Consumer Protection Act. The action seeks civil penalties and injunctive relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Array Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In November 2017, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; purported class actions were filed in the U.S. District Court for the District of Colorado alleging that Array, which we acquired in July 2019 and is our wholly owned subsidiary, and certain of its former officers violated federal securities laws in connection with certain disclosures made, or omitted, by Array regarding the NRAS-mutant melanoma program. In March 2018, the actions were consolidated into a single proceeding. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Zantac &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A number of lawsuits have been filed against Pfizer in various federal and state courts alleging that plaintiffs developed various types of cancer, or face an increased risk of developing cancer, purportedly as a result of the ingestion of Zantac. The significant majority of these cases also name other defendants that have historically manufactured and/or sold Zantac. Pfizer has not sold Zantac since 2006, and only sold an over-the-counter version of the product. Plaintiffs seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February 2020, the federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;In re Zantac/Ranitidine NDMA Litigation, MDL-2924&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;) in the U.S. District Court for the Southern District of Florida. In June 2020: (i) plaintiffs in the Multi-District Litigation filed against Pfizer and many other defendants a consolidated consumer class action complaint alleging, among other things, violations of the RICO statute and consumer protection statutes of all 50 states, and a consolidated third-party payor class action complaint alleging violation of the RICO statute and seeking reimbursement for payments made for the prescription version of Zantac; (ii) Pfizer received service of a Canadian class action complaint naming Pfizer and other defendants, and seeking compensatory and punitive damages for personal injury and economic loss, allegedly arising from the defendants&#x2019; sale of Zantac in Canada; and (iii) the State of New Mexico filed a civil action against Pfizer and many other defendants, alleging various state statutory and common law claims in connection with the defendants&#x2019; alleged sale of Zantac in New Mexico.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;A3. Legal Proceedings&#x2013;&#x2013;Commercial and Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Monsanto-Related Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia &amp;amp; Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operations to a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia&#x2019;s former agricultural business. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business, and has been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto&#x2019;s chemical businesses. As the result of its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia&#x2019;s indemnification obligations relating to Former Monsanto&#x2019;s chemical businesses are primarily limited to sites that Solutia has owned or operated. In addition, in connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities primarily related to Former Monsanto&#x2019;s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia&#x2019;s and New Monsanto&#x2019;s assumption of, and agreement to indemnify Pharmacia for, these liabilities apply to pending actions and any future actions related to Former Monsanto&#x2019;s chemical businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia and/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto&#x2019;s chemical businesses, and have been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Environmental Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In 2009, we submitted to the U.S. Environmental Protection Agency (EPA) a corrective measures study report with regard to Pharmacia&#x2019;s discontinued industrial chemical facility in North Haven, Connecticut. In September 2010, our corrective measures study report was approved by the EPA, and we commenced construction of the site remedy in late 2011 under an Updated Administrative Order on Consent with the EPA. In September 2019, the EPA acknowledged that construction of the site remedy has been completed.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Also, in 2009, we submitted a revised site-wide feasibility study with regard to Wyeth Holdings Corporation&#x2019;s (formerly, American Cyanamid Company) discontinued industrial chemical facility in Bound Brook, New Jersey. In July 2011, Wyeth Holdings Corporation finalized an Administrative Settlement Agreement and Order on Consent for Removal Action (the 2011 Administrative Settlement Agreement) with the EPA with regard to the Bound Brook facility. In May 2012, we completed construction of an interim remedy to address the discharge of impacted groundwater from that facility to the Raritan River. In September 2012, the EPA issued a final remediation plan for the Bound Brook facility&#x2019;s main plant area, which is generally in accordance with one of the remedies evaluated in our revised site-wide feasibility study. In March 2013, Wyeth Holdings Corporation (now Wyeth Holdings LLC) entered into an Administrative Settlement Agreement and Order on Consent with the &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;EPA to allow us to undertake detailed engineering design of the remedy for the main plant area and to perform a focused feasibility study for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; adjacent lagoons. In September 2015, the U.S., on behalf of the EPA, filed a complaint and consent decree with the federal District Court for the District of New Jersey that allows Wyeth Holdings LLC to complete the design and to implement the remedy for the main plant area. In December 2015, the consent decree (which supersedes the 2011 Administrative Settlement Agreement) was entered by the District Court. In September 2018, the EPA issued a final remediation plan for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; adjacent lagoons, which is generally in accordance with one of the remedies evaluated in our focused feasibility study, and in September 2019, Wyeth Holdings LLC entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the lagoons. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We have accrued for the estimated costs of the site remedies for the North Haven and Bound Brook facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We are a party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Contracts with Iraqi Ministry of Health&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In October 2017, a number of United States service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia against a number of pharmaceutical and medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health, and seeks monetary relief. In July 2020, the District Court granted defendants&#x2019; motions to dismiss and dismissed all of plaintiffs&#x2019; claims. In July 2018, the U.S. Department of Justice requested documents related to this matter, which have been provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Allergan Complaint for Indemnity&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In August 2018, Pfizer was named as a defendant in a third-party complaint for indemnity, along with King, filed by Allergan Finance LLC (Allergan) in a Multi-District Litigation (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;In re National Prescription Opiate Litigation MDL 2804&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;) in the U.S. District Court for the Northern District of Ohio. The lawsuit asserted claims for indemnity related to Kadian, which was owned for a short period by King in 2008, prior to Pfizer's acquisition of King in 2010. In December 2018, the District Court dismissed the lawsuit. In February 2019, Allergan filed a similar complaint in the Supreme Court of the State of New York, asserting claims for indemnity related to Kadian.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Breach of Contract&#x2013;&#x2013;Xalkori&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Pfizer is a defendant in a breach of contract action brought by New York University (NYU) in the Supreme Court of the State of New York (Supreme Court). NYU alleges that it is entitled to royalties on Pfizer&#x2019;s sales of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Xalkori under the terms of a Research and License Agreement between NYU and Sugen, Inc. Sugen, Inc. was acquired by Pharmacia in August 1999, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;color:#212529;"&gt;Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; The action was originally filed in 2013. In December 2015, the Supreme Court dismissed the action and, in May 2017, the New York State Appellate Division reversed the decision and remanded the proceedings to the Supreme Court. In January 2020, the Supreme Court denied both parties&#x2019; summary judgment motions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;A4. Legal Proceedings&#x2013;&#x2013;Government Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Like other pharmaceutical companies, we are subject to extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. Criminal charges, substantial fines and/or civil penalties, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as reputational harm and increased public interest in the matter could result from government investigations in the U.S. and other jurisdictions in which we do business. In addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Among the investigations by government agencies are the matters discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Greenstone Investigations&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;U.S. Department of Justice Antitrust Division Investigation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Since July 2017, the U.S. Department of Justice's Antitrust Division has been investigating our Greenstone generics business. We believe this is related to an ongoing broader antitrust investigation of the generic pharmaceutical industry. The government has been obtaining information from Greenstone.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;State Attorneys General Generics Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In April 2018, Greenstone received requests for information from the Antitrust Department of the Connecticut Office of the Attorney General. In May 2019, Attorneys General of more than 40 states plus the District of Columbia and Puerto Rico filed a &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;complaint against a number of pharmaceutical companies, including Greenstone and Pfizer. The matter has been consolidated with a Multi-District Litigation (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;In re: Generic Pharmaceuticals Pricing Antitrust Litigation MDL No. 2724)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in the Eastern District of Pennsylvania. As to Greenstone and Pfizer, the complaint alleges anticompetitive conduct in violation of federal and state antitrust laws and state consumer protection laws. In June 2020, the State Attorneys General filed a new complaint against a large number of companies, including Greenstone and Pfizer, making similar allegations, but concerning a new set of drugs. This complaint was transferred to the Multi-District Litigation in July 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Subpoena relating to Manufacturing of Quillivant XR&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In October 2018, we received a subpoena from the U.S. Attorney&#x2019;s Office for the Southern District of New York (SDNY) seeking records relating to our relationship with another drug manufacturer and its production and manufacturing of drugs including, but not limited to, Quillivant XR. We have produced records pursuant to the subpoena.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Government Inquiries relating to Meridian Medical Technologies &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February 2019, we received a civil investigative demand from the U.S. Attorney&#x2019;s Office for the SDNY. The civil investigative demand seeks records and information related to alleged quality issues involving the manufacture of auto-injectors at our Meridian site. In August 2019, we received a HIPAA subpoena from the U.S. Attorney&#x2019;s Office for the Eastern District of Missouri seeking similar records and information. We are producing records in response to these requests. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;U.S. Department of Justice/SEC Inquiry relating to Russian Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2019, we received an informal request from the U.S. Department of Justice&#x2019;s FCPA Unit seeking documents relating to our operations in Russia. In September 2019, we received a similar request from the SEC&#x2019;s FCPA unit. We are producing records pursuant to these requests. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Contracts with Iraqi Ministry of Health&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;See &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 13A3. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Contingencies and Certain Commitments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;: Legal Proceedings&#x2013;&#x2013;Commercial and Other Matters&#x2013;&#x2013;Contracts with Iraqi Ministry of Health&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; above for information regarding U.S. government investigations related to contracts with the Iraqi Ministry of Health.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Docetaxel&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Mississippi Attorney General Government Action&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;See &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 13A2. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Contingencies and Certain Commitments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;: Legal Proceedings&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Product Litigation&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Docetaxel&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Mississippi Attorney General Government Action&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; above for information regarding a government action related to Docetaxel marketing practices.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;U.S. Department of Justice Inquiries relating to India Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In March 2020, we received an informal request from the U.S. Department of Justice's Consumer Protection Branch seeking documents relating to our manufacturing operations in India, including at our former facility located at Irrungattukottai in India. In April 2020, we received a similar request from the U.S. Attorney&#x2019;s Office for the SDNY regarding a civil investigation concerning operations at our facilities in India. We are producing records pursuant to these requests.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;U.S. Department of Justice Inquiry relating to China Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2020, we received an informal request from the U.S. Department of Justice's FCPA Unit seeking documents relating to our operations in China. We will be producing records pursuant to this request.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Zantac&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;State of New Mexico Civil Action&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;See &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 13A2. Contingencies and Certain Commitments: Legal Proceedings&#x2013;&#x2013;Product Litigation&#x2013;&#x2013;Zantac&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; above for information regarding a civil action filed by the State of New Mexico alleging various state statutory and common law claims in connection with the defendants&#x2019; alleged sale of Zantac in New Mexico.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;A5. Legal Proceedings&#x2013;&#x2013;Matters Resolved During the First Six Months of 2020&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During the first six months of 2020, certain matters, including the matter discussed below, were resolved or were the subject of definitive settlement agreements or settlement agreements-in-principle.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Hormone Therapy Consumer Class Action&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A certified consumer class action was pending against Wyeth in the U.S. District Court for the Southern District of California based on the alleged off-label marketing of its hormone therapy products. The case was originally filed in December 2003. The class consisted of California consumers who purchased Wyeth&#x2019;s hormone-replacement products between January 1995 and January 2003 and who did not seek personal injury damages therefrom. The class sought compensatory and punitive damages, including a full refund of the purchase price. In March 2020, the parties reached an agreement, and obtained preliminary court approval, to resolve this matter for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$200 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which was paid in full in the second quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;B. Guarantees and Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss. These indemnifications are generally subject to various restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the estimated fair value of these indemnification obligations was not significant. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In addition, in connection with our entry into certain agreements, our counterparties may agree to indemnify us. For example, our collaboration agreement with EMD Serono, Inc. to co-promote Rebif in the U.S. expired at the end of 2015 and included certain indemnity provisions. Patent litigation brought by Biogen Idec MA Inc. against EMD Serono Inc. and Pfizer is pending in the U.S. District Court for the District of New Jersey and the United States Court of Appeals for the Federal Circuit. EMD Serono Inc. has acknowledged that it is obligated to satisfy any award of damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Pfizer Inc. has also guaranteed the long-term debt of certain companies that it acquired and that now are subsidiaries of Pfizer. See &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 7D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;C. Contingent Consideration for Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We may be required to make contingent consideration payments to sellers for certain prior business combinations. For additional information, see Notes to Consolidated Financial Statements&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 1D. Basis of Presentation and Significant Accounting Policies: Acquisition&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;s in our 2019 Financial Report. The estimated fair value of contingent consideration as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$727 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, of which &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$157 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is recorded in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other current liabilities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$570 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is recorded in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other noncurrent liabilities &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;in our condensed consolidated balance sheet. The estimated fair value of contingent consideration as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$711 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, of which &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$160 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was recorded in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other current liabilities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$551 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was recorded in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other noncurrent liabilities &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;in our condensed consolidated balance sheet. The increase in the contingent consideration balance from December 31, 2019 is primarily due to fair value adjustments, partially offset by payments made upon the achievement of certain milestones.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <pfe:GainContingencyPatentsWithoutCourtProceedingsNumber
      contextRef="D2017Q4Oct01-Oct31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember"
      decimals="INF"
      id="d8383765e789-wk-Fact-5C8CB8F598CAEF84107894757DA7A368"
      unitRef="Patent">2</pfe:GainContingencyPatentsWithoutCourtProceedingsNumber>
    <us-gaap:GainContingencyPatentsFoundInfringedUponNumber
      contextRef="D2018Q2Jun01-Jun30_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember"
      decimals="INF"
      id="d8383765e793-wk-Fact-D5F27759E5862BD4204694757CD11378"
      unitRef="Patent">1</us-gaap:GainContingencyPatentsFoundInfringedUponNumber>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="D2017Q1Mar01-Mar31_srt_LitigationCaseAxis_pfe_PfizerVersusZydusMember_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember"
      decimals="INF"
      id="d8383765e835-wk-Fact-98F60AD39D22D47828D894757D5BF72E"
      unitRef="Patent">3</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="D2019Q1Mar01-Mar31_srt_LitigationCaseAxis_pfe_PfizerVersusGenericCompaniesMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember"
      decimals="INF"
      id="d8383765e881-wk-Fact-517DC4A0A8649EF8390394757DA7F672"
      unitRef="Patent">2</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="D2020Q1Jan1-31_srt_LitigationCaseAxis_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember"
      decimals="INF"
      id="d8383765e891-wk-Fact-80F2A51C6FD70B3273D494757DA0166E"
      unitRef="Patent">3</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="D2020Q3Jul1-31_srt_LitigationCaseAxis_pfe_NHSScotlandvs.DrReddysMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_PatentInfringementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="d8383765e931-wk-Fact-417259D790620A289744A1BB5E08E13A"
      unitRef="plaintiff">14</us-gaap:LossContingencyNumberOfPlaintiffs>
    <pfe:GainContingencyNumberofDefendants
      contextRef="D2017Q2Feb01-Apr30_srt_LitigationCaseAxis_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember"
      decimals="INF"
      id="d8383765e944-wk-Fact-717593CB12402352612B94757CEBB13E"
      unitRef="Defendant">25</pfe:GainContingencyNumberofDefendants>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="D2017Q2Feb01-Apr30_srt_LitigationCaseAxis_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember"
      decimals="INF"
      id="d8383765e948-wk-Fact-3AFB1E118B1118EB033F94757DA25F8B"
      unitRef="Patent">3</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <pfe:GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019
      contextRef="D2017Q2Feb01-Apr30_srt_LitigationCaseAxis_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember"
      decimals="INF"
      id="d8383765e952-wk-Fact-565D1C6B35A0D674DBB494757CB69824"
      unitRef="Patent">1</pfe:GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="D2017Q2Feb01-Apr30_srt_LitigationCaseAxis_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember"
      decimals="INF"
      id="d8383765e956-wk-Fact-3AFB1E118B1118EB033F94757DA25F8B"
      unitRef="Patent">3</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <pfe:LossContingencyNumberOfLawsuits
      contextRef="FI2020Q2_srt_ProductOrServiceAxis_pfe_EpiPenMember_srt_RangeAxis_srt_MinimumMember"
      decimals="INF"
      id="d8383765e1067-wk-Fact-CE168D9156E09ED8FE0C94757DA7922B"
      unitRef="lawsuit">1</pfe:LossContingencyNumberOfLawsuits>
    <pfe:LossContingencyNumberOfDefendantsOtherThanMainDefendant
      contextRef="D2018Q4Oct01-Oct31_srt_LitigationCaseAxis_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_srt_ProductOrServiceAxis_pfe_DocetaxelMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember"
      decimals="INF"
      id="d8383765e1121-wk-Fact-E30ECA96C0BC87F811C194757DA214BE"
      unitRef="manufacturer">8</pfe:LossContingencyNumberOfDefendantsOtherThanMainDefendant>
    <pfe:LossContingencyClassActionsFiledNumber
      contextRef="D2017Q4Nov2017"
      decimals="INF"
      id="d8383765e1131-wk-Fact-3A3F4CD6AC452C84201794757CD805EA"
      unitRef="class_action">2</pfe:LossContingencyClassActionsFiledNumber>
    <pfe:FeasibilityStudyNumberOfLagoons
      contextRef="D2013Q1MonthOfMarch_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_EnvironmentalRemediationLitigationMember"
      decimals="INF"
      id="d8383765e1176-wk-Fact-1C233DE5CB2F27196C1694757DA33716"
      unitRef="lagoon">2</pfe:FeasibilityStudyNumberOfLagoons>
    <pfe:FeasibilityStudyNumberOfLagoons
      contextRef="D2018Q3Sep01-Sep30_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_EnvironmentalRemediationLitigationMember"
      decimals="INF"
      id="d8383765e1180-wk-Fact-BF50E52F0CC2EDC892A694757DA027BB"
      unitRef="lagoon">2</pfe:FeasibilityStudyNumberOfLagoons>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="FD2020Q2QTD_srt_LitigationCaseAxis_pfe_ClassActionVersusWyethMember_srt_ProductOrServiceAxis_pfe_HormoneTherapyProductsMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember"
      decimals="-6"
      id="d8383765e1362-wk-Fact-2CB88DD71658CFBC7A8294757D9AB161"
      unitRef="usd">200000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8383765e1400-wk-Fact-92DEA2F2246A94F90A3A94757D98A723"
      unitRef="usd">727000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8383765e1404-wk-Fact-608994AE6B240429000194757D450F9C"
      unitRef="usd">157000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2020Q2"
      decimals="-6"
      id="d8383765e1413-wk-Fact-D95F57A84F39F1F4220994757DA6074A"
      unitRef="usd">570000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8383765e1425-wk-Fact-32A10D3C33BFD555F97494757CEE5C77"
      unitRef="usd">711000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8383765e1429-wk-Fact-B1DFC7B7CC3736C71BA994757CF15ABB"
      unitRef="usd">160000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d8383765e1438-wk-Fact-4C6C0A417E2429DF131394757DA20891"
      unitRef="usd">551000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-31CB92B2FCB9ECA4894394757DC257B4-0-wk-Fact-A6ED1071B2B6B7FCE64494757D46BD01">&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Segment, Geographic and Other Revenue Information&lt;/span&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;A. &lt;/span&gt;&lt;span style="font-weight:bold;text-decoration:underline;"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At the beginning of our fiscal year 2019, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; distinct business segments: Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and through &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;July&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, Pfizer&#x2019;s Consumer Healthcare business (Consumer Healthcare), each led by a single manager. Each operating segment has responsibility for its commercial activities. Upjohn is, and through &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;July&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Consumer Healthcare was, responsible for its own R&amp;amp;D activities while Biopharma receives its R&amp;amp;D services from GPD and WRDM. These services include IPR&amp;amp;D projects for new investigational products and additional indications for in-line products. Each business has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation. Biopharma and Upjohn are the only reportable segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan).&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; As a result, revenues and expenses associated with Meridian and Mylan-Japan are reported in our Upjohn business beginning in the first quarter of 2020. In 2019, revenues and expenses from Meridian and Mylan-Japan were recorded in our Biopharma business. We have revised prior-period information (Revenues and Earnings, as defined by management) to conform to the current management structure.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Acquisitions and other business development activities completed in 2019 and in the first half of 2020, including the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture, impacted financial results in the periods presented.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span&gt;For additional information, see Notes to Consolidated Financial Statements&#x2014;&lt;/span&gt;&lt;span style="font-style:italic;"&gt;Note 1A. Basis of Presentation and Significant Accounting Policies: Basis of Presentation&lt;/span&gt;&lt;span&gt; in our 2019 Financial Report, and &lt;/span&gt;&lt;span style="font-style:italic;"&gt;Note 2&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Operating Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:16pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:49%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Some additional information about our Biopharma and Upjohn business segments follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;"&gt;&lt;img alt="pfizerlogo2816.jpg" src="pfizerlogo2816.jpg" style="height:33px;width:57px;"/&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:16pt;"&gt;&lt;span style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Pfizer&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72px;text-indent:-72px;font-size:16pt;"&gt;&lt;span style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Biopharmaceuticals&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72px;text-indent:-72px;font-size:16pt;"&gt;&lt;span style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Group&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;"&gt;&lt;img alt="upjohnlogo.jpg" src="upjohnlogo.jpg" style="height:77px;width:201px;"/&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px dotted #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Biopharma is a science-based innovative medicines business that includes six business units &#x2013; Oncology, Inflammation &amp;amp; Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. The Hospital unit commercializes our global portfolio of sterile injectable and anti-infective medicines and includes Pfizer&#x2019;s contract manufacturing operation, Pfizer CentreOne. Each business unit is committed to delivering breakthroughs that change patients&#x2019; lives.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px dotted #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Upjohn is a global, primarily off-patent branded and generic medicines business, which includes a portfolio of 20 globally recognized solid oral dose brands, as well as a U.S.-based generics platform, Greenstone.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Select products include:&lt;br/&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;- Ibrance&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;- &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Eliquis&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;- &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Prevnar 13/Prevenar 13&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;- &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Xeljanz&lt;br/&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;- &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Enbrel &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;(outside the U.S. and Canada)&lt;br/&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;- Vyndaqel/Vyndamax&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;- &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Chantix/Champix&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;- Xtandi&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;- &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Sutent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Select products include:&lt;br/&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;- Lipitor&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;- &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Lyrica&lt;br/&gt;- Norvasc&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;- Celebrex&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;- Viagra&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;- &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Certain generic medicines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Other Costs and Business Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certain pre-tax costs are not allocated to our operating segment results, such as costs associated with the following:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;WRDM&#x2013;&#x2013;the R&amp;amp;D and Medical expenses managed by our WRDM organization, which is generally responsible for research projects for our Biopharma portfolio until proof-of-concept is achieved and then for transitioning those projects to the GPD organization for possible clinical and commercial development. R&amp;amp;D spending may include upfront and milestone payments for intellectual property rights. The WRDM organization also has responsibility for certain science-based and other platform-services organizations, which provide end-to-end technical expertise and other services to the various R&amp;amp;D projects, as well as the Worldwide Medical and Safety group, which ensures that Pfizer provides all stakeholders&#x2013;&#x2013;including patients, healthcare providers, pharmacists, payers and health authorities&#x2013;&#x2013;with complete and up-to-date information on the risks and benefits associated with Pfizer products so that they can make appropriate decisions on how and when to use Pfizer&#x2019;s medicines.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;GPD&#x2013;&#x2013;the costs associated with our GPD organization, which is generally responsible for clinical trials from WRDM in the Biopharma portfolio, including late stage portfolio spend. GPD also provides technical support and other services to Pfizer R&amp;amp;D projects. GPD is responsible for facilitating all regulatory submissions and interactions with regulatory agencies.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&#x2013;&#x2013;the operating results of our Consumer Healthcare business, through July 31, 2019, and costs associated with other commercial activities not managed as part of Biopharma or Upjohn, including all strategy, business development, portfolio management and valuation capabilities, which previously had been reported in various parts of the organization.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate and Other Unallocated&#x2013;&#x2013;the costs associated with corporate enabling functions (such as digital, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance, and worldwide procurement), patient advocacy activities and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments, as well as overhead expenses associated with our manufacturing (which include manufacturing variances associated with production) and commercial operations that are not directly assessed to an operating segment, as business unit (segment) management does not manage these costs. &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;Corporate and Other Unallocated also includes our share of earnings from the GSK Consumer Healthcare joint venture and other charges related to the GSK Consumer Healthcare joint venture, primarily representing our pro-rata share of restructuring and business combination accounting charges recorded by the GSK Consumer Healthcare joint venture.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and PP&amp;amp;E; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) certain significant items, representing substantive and/or unusual, and in some cases recurring, items (such as gains on the completion of joint venture transactions, restructuring charges, legal charges or gains and losses from equity securities) that &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:12px;text-align:left;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Segment Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:inherit;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We manage our assets on a Total Company basis, not by operating segment, as many of our operating assets are shared or commingled (such as accounts receivable, as many of our customers are served by multiple operating segments). Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$178 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$167 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Selected Income Statement Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides selected income statement information by reportable segment:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Earnings&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Reportable Segments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;9,795&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;9,432&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;6,650&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;6,071&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Upjohn&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;2,006&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;2,970&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;1,168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;1,973&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Total reportable segments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;11,801&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;12,402&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;7,818&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;8,044&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-12px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Other business activities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;862&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,530&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,193&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Reconciling Items:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Corporate and other unallocated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,399&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Purchase accounting adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(910&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,178&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Acquisition-related costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Certain significant items&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(268&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(309&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;11,801&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;13,264&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;3,953&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;4,141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Six Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Earnings&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Reportable Segments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;19,802&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;18,477&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;13,379&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;11,954&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Upjohn&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;4,027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;6,184&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;2,359&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;4,251&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Total reportable segments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;23,829&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;24,661&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;15,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;16,206&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Other business activities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;1,721&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(3,019&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(2,306&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Reconciling Items:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Corporate and other unallocated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(2,245&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(2,676&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Purchase accounting adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,722&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(2,217&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Acquisition-related costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;148&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Certain significant items&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(879&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(691&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;23,829&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;26,382&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;7,838&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;8,463&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Income from continuing operations before provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;. Biopharma&#x2019;s earnings &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;include d&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;ividend income of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$76 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$76&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$153 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;the first six months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$140 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;the first six months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; from our investment in ViiV. For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 4.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Equity in the net income of investees accounted for by the equity method is not significant for any of our operating segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The operating segment information does not purport to represent the revenues, costs and income from continuing operations before provision for taxes on income that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;B. Geographic Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="23"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides revenues by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Six Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Change&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Change&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,402&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,335&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,053&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,510&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Developed Europe&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,088&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,009&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Developed Rest of World&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,552&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,639&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,008&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,174&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Emerging Markets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,759&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,062&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,759&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,383&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,801&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,264&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,829&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,382&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; Revenues denominated in euros were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, and were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$3.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;the first six months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$3.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;the first six months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;C. &lt;/span&gt;&lt;span style="font-weight:bold;text-decoration:underline;"&gt;Other Revenue Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Significant Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides detailed revenue information for several of our major products:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:29%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:38%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:inherit;font-size:7pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Six Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;PRODUCT&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;PRIMARY INDICATION OR CLASS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;TOTAL REVENUES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;11,801&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;13,264&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;23,829&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;26,382&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;9,795&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;9,432&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;19,802&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;18,477&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;Internal Medicine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,279&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,243&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;4,610&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;4,380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Eliquis alliance revenues and direct sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,272&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,085&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;2,572&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;2,096&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Chantix/Champix&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;An aid to smoking cessation treatment in adults 18 years of age or older&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;235&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;505&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;549&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Premarin family&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Symptoms of menopause&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;193&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;304&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;361&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;BMP2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Development of bone and cartilage&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;145&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Toviaz&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Overactive bladder&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;125&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;All other Internal Medicine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;498&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;544&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;978&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,103&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;Oncology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,647&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,236&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;5,082&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;4,198&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Ibrance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Metastatic breast cancer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,349&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,261&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;2,598&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;2,394&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Xtandi alliance revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Non-metastatic and metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;475&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;369&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Sutent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;209&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;248&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;414&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;480&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Inlyta&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Advanced RCC&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;195&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;104&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;364&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;177&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Xalkori&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;ALK-positive and ROS1-positive advanced NSCLC&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;138&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;287&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;255&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Bosulif&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Philadelphia&#160;chromosome&#x2013;positive&#160;chronic myelogenous leukemia&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;113&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;213&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;177&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Retacrit&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Anemia&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;87&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Braftovi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;In combination with Mektovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation and, in combination with Erbitux&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&#160;(cetuximab), for the treatment of BRAF&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;V600E&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;-mutant metastatic colorectal cancer after prior therapy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;74&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Mektovi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;In combination with Braftovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;All other Oncology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;412&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;262&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;Hospital&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a), (c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;1,794&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;1,838&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;3,807&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;3,665&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Sulperazon&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Bacterial infections&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;165&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;289&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;342&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Medrol&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Anti-inflammatory glucocorticoid&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;78&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;207&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;240&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Zithromax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Bacterial infections&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;193&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;177&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Precedex&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Sedation agent in surgery or intensive care&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;156&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Vfend&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Fungal infections&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;149&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;178&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Panzyga&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Primary humoral immunodeficiency&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;44&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;61&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:29%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:38%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:inherit;font-size:7pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Six Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;PRODUCT&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;PRIMARY INDICATION OR CLASS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Zyvox&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Bacterial infections&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;125&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;134&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Fragmin&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Treatment/prevention of venous thromboembolism&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;118&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;123&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Pfizer CentreOne&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;204&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;376&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;All other Anti-infectives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;367&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;420&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;811&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;825&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;All other Hospital&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;603&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;544&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,245&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;Vaccines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;1,247&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;1,375&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,857&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,988&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Prevnar 13/Prevenar 13&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Pneumococcal disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,179&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;2,566&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;2,665&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Nimenrix&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Meningococcal disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;130&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;107&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;All other Vaccines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;138&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;Inflammation &amp;amp; Immunology (I&amp;amp;I)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;1,149&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;1,219&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,256&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Xeljanz&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;RA, PsA, UC&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;635&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;613&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,086&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,036&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Enbrel (Outside the U.S. and Canada)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;337&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;420&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;684&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;871&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Inflectra/Remsima&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Crohn&#x2019;s disease, pediatric Crohn&#x2019;s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;153&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;308&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;All other I&amp;amp;I&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;Rare Disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;681&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;521&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;1,319&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Vyndaqel/Vyndamax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;ATTR-cardiomyopathy and polyneuropathy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;277&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;508&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;104&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;BeneFIX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Hemophilia B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;109&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;230&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;247&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Genotropin&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Replacement of human growth hormone&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;106&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;125&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;209&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;232&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Refacto AF/Xyntha&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Hemophilia A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;108&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;181&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;214&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Somavert&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Acromegaly&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;128&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;All other Rare Disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;61&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;66&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;UPJOHN&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,006&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,970&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;4,027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;6,184&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Lipitor&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Reduction of LDL cholesterol&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;431&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;407&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;836&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,029&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Lyrica&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;349&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,175&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;706&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;2,362&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Norvasc&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Hypertension&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;216&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;419&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;516&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Celebrex&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Arthritis pain and inflammation, acute pain&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;139&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;174&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;295&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;347&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Viagra&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Erectile dysfunction&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;259&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Effexor&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Depression and certain anxiety disorders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;86&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;86&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;163&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;163&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Zoloft&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Depression and certain anxiety disorders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;157&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;143&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;EpiPen&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Epinephrine injection used in treatment of life-threatening allergic reactions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;123&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Xalatan/Xalacom&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Glaucoma and ocular hypertension&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;126&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;All other Upjohn&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;476&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;587&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;968&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,109&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;CONSUMER HEALTHCARE BUSINESS&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;862&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;1,721&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;Total Alliance revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;1,404&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;1,187&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,786&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,277&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;Total Biosimilars&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;289&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;217&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;578&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;396&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;Total Sterile Injectable Pharmaceuticals&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;1,237&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;1,218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,644&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,455&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan).&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt; As a result, revenues associated with our Meridian subsidiary, except for product revenues for EpiPen sold in Canada, and Mylan-Japan, are reported in our Upjohn business beginning in the first quarter of 2020. We have reclassified revenues associated with our Meridian subsidiary and Mylan-Japan from the Hospital and Internal Medicine categories to the Upjohn business to conform 2019 product revenues to the current presentation.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. Hospital also includes Pfizer CentreOne&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;. All other Hospital primarily includes revenues from legacy Sterile Injectables Pharmaceuticals (SIP) products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in &#x201c;All other Anti-infectives&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;On &lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;July&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;, Pfizer&#x2019;s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK&#x2019;s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-style:italic;"&gt;Note 2B&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:7.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(f)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="D2019Q3Jan1-Jul31"
      decimals="INF"
      id="d8415180e721-wk-Fact-E7763423A0FDBAB3799A94757CC3EC7A"
      unitRef="Operating_Segment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:Assets
      contextRef="FI2020Q2"
      decimals="-9"
      id="d8415180e973-wk-Fact-8056831472C93DFFBF7B94757D474450"
      unitRef="usd">178000000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2019Q4"
      decimals="-9"
      id="d8415180e981-wk-Fact-7DC06283FD051672522094757D4872EE"
      unitRef="usd">167000000000</us-gaap:Assets>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-D872EE9AAC4BBFF119BA94757DC2771E-0-wk-Fact-9BC8623A09DFCF83535694757D4A5C9E">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides selected income statement information by reportable segment:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Earnings&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Reportable Segments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;9,795&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;9,432&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;6,650&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;6,071&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Upjohn&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;2,006&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;2,970&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;1,168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;1,973&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Total reportable segments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;11,801&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;12,402&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;7,818&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;8,044&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-12px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Other business activities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;862&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,530&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,193&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Reconciling Items:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Corporate and other unallocated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,399&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Purchase accounting adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(910&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,178&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Acquisition-related costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Certain significant items&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(268&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(309&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;11,801&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;13,264&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;3,953&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;4,141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Six Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Earnings&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Reportable Segments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;19,802&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;18,477&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;13,379&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;11,954&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Upjohn&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;4,027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;6,184&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;2,359&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;4,251&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Total reportable segments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;23,829&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;24,661&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;15,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;16,206&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Other business activities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;1,721&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(3,019&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(2,306&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Reconciling Items:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Corporate and other unallocated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(2,245&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(2,676&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Purchase accounting adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,722&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(2,217&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Acquisition-related costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;148&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Certain significant items&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(879&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(691&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;23,829&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;26,382&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;7,838&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;8,463&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Income from continuing operations before provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;. Biopharma&#x2019;s earnings &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;include d&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;ividend income of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$76 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$76&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$153 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;the first six months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$140 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;the first six months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; from our investment in ViiV. For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 4.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-4B4807FB53EBB4E5981F94757DC3223D-0-wk-Fact-6821C7B4B9BCFF4BF38494757D45D00C">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides selected income statement information by reportable segment:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Earnings&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Reportable Segments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;9,795&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;9,432&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;6,650&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;6,071&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Upjohn&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;2,006&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;2,970&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;1,168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;1,973&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Total reportable segments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;11,801&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;12,402&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;7,818&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;8,044&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-12px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Other business activities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;862&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,530&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,193&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Reconciling Items:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Corporate and other unallocated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,399&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Purchase accounting adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(910&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,178&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Acquisition-related costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Certain significant items&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(268&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(309&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;11,801&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;13,264&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;3,953&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;4,141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Six Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Earnings&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Reportable Segments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;19,802&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;18,477&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;13,379&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;11,954&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Upjohn&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;4,027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;6,184&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;2,359&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;4,251&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Total reportable segments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;23,829&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;24,661&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;15,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;16,206&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Other business activities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;1,721&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(3,019&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(2,306&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Reconciling Items:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Corporate and other unallocated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(2,245&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(2,676&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Purchase accounting adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,722&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(2,217&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Acquisition-related costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;148&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Certain significant items&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(879&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(691&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;23,829&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;26,382&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;7,838&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;8,463&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Income from continuing operations before provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;. Biopharma&#x2019;s earnings &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;include d&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;ividend income of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$76 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$76&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$153 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;the first six months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$140 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;the first six months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; from our investment in ViiV. For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 4.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e1487-wk-Fact-E530D6E39D8505E5003694757CCFA73A"
      unitRef="usd">9795000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e1506-wk-Fact-18B80BD812B25AC11E4B94757D931F40"
      unitRef="usd">9432000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e1526-wk-Fact-F24CEBFF8EB173EDA53294757CD99979"
      unitRef="usd">6650000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e1545-wk-Fact-B36E26A497B12F4F06CB94757CFB7641"
      unitRef="usd">6071000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e1565-wk-Fact-A21C28FF8A57FE35FCD194757CD6CDBA"
      unitRef="usd">2006000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e1584-wk-Fact-D592491E3EF4A54AF04994757CD40AAC"
      unitRef="usd">2970000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e1603-wk-Fact-A8FD8B76C5AB70D75DBF94757CDE77D4"
      unitRef="usd">1168000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e1623-wk-Fact-DD285CCCCC909E22C8F494757CF80EDC"
      unitRef="usd">1973000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember"
      decimals="-6"
      id="d8415180e1648-wk-Fact-E6C7B7DCAE845EA31C2194757CDF5928"
      unitRef="usd">11801000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember"
      decimals="-6"
      id="d8415180e1667-wk-Fact-64E767AB6C7D8A4A5A7494757CD12DBF"
      unitRef="usd">12402000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember"
      decimals="-6"
      id="d8415180e1686-wk-Fact-B46A5ED3FA0B101BE7A594757CD525E3"
      unitRef="usd">7818000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember"
      decimals="-6"
      id="d8415180e1706-wk-Fact-6A34EC9ACE0CB4BA0A7B94757D93E196"
      unitRef="usd">8044000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e1731-wk-Fact-243B7A41AFF6BF2DF5A994757CD78EDF"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e1750-wk-Fact-81BF6740D6D17855E9B394757CF0E3F6"
      unitRef="usd">862000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e1769-wk-Fact-E484E0BFE436CFD6A91994757CF4398D"
      unitRef="usd">-1530000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e1790-wk-Fact-57807C2334726A33D68294757CD97546"
      unitRef="usd">-1193000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-6"
      id="d8415180e1901-wk-Fact-46B4B5A3C9CD840FB17E94757CD3097A"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-6"
      id="d8415180e1920-wk-Fact-1FBA4709E25A6997DE7594757CD0F723"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-6"
      id="d8415180e1939-wk-Fact-13F1515D747E5BC2D79E94757CDD1906"
      unitRef="usd">-1136000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-6"
      id="d8415180e1960-wk-Fact-8971E1C78383330CB40E94757CD5511C"
      unitRef="usd">-1399000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e1987-wk-Fact-F86D74D8E948CB139FC994757CF9C767"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e2006-wk-Fact-1BC8D13D40A2D1BF93BA94757D9688FD"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2020Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e2025-wk-Fact-011D17ED46D6C704909994757CE026FE"
      unitRef="usd">-910000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e2046-wk-Fact-D38C84ADA6DF1DEBDA9794757CDF6D15"
      unitRef="usd">-1178000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e2072-wk-Fact-806DF2F3D85134AC6CAC94757CCFBA02"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e2091-wk-Fact-971D0CC8CD08BAD2A4F394757D97DDC1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2020Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e2110-wk-Fact-A1C25D709E6E2BCC622F94757CE0C08D"
      unitRef="usd">-21000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e2131-wk-Fact-D01BD086F56ADFA6D29E94757CD09A97"
      unitRef="usd">176000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e2158-wk-Fact-290DFAF3630836A5405894757D92CBB7"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e2177-wk-Fact-8F668F0BF6E37C3A8D6394757D92EEEB"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2020Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e2196-wk-Fact-AA84F6B275E57DCDD15C94757CF155B2"
      unitRef="usd">-268000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q2QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e2217-wk-Fact-33B4F9AF3A76075CF90094757CD1C085"
      unitRef="usd">-309000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8415180e2248-wk-Fact-4DB60D98BED9F2D7592094757D057DF4"
      unitRef="usd">11801000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8415180e2267-wk-Fact-1769F431190664966C6E94757D75CC58"
      unitRef="usd">13264000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8415180e2287-wk-Fact-2A0EE9005DC8F1672AF194757D5C8E60"
      unitRef="usd">3953000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8415180e2306-wk-Fact-5210DA15DEEFCDAFC83494757D61140E"
      unitRef="usd">4141000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e2761-wk-Fact-ACEB1288AC96A67A007394757D7A8456"
      unitRef="usd">19802000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e2780-wk-Fact-EF53E62F4536F95DB71494757CF24DD5"
      unitRef="usd">18477000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e2800-wk-Fact-7EC912EE8439671A25BF94757D7D989C"
      unitRef="usd">13379000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e2819-wk-Fact-D2552EB7B44850CC209094757CF5FB9B"
      unitRef="usd">11954000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e2839-wk-Fact-9907871A98EACE7FAB8F94757D7CC4C8"
      unitRef="usd">4027000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e2858-wk-Fact-1682782C7F68183CECD594757D5D9095"
      unitRef="usd">6184000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e2877-wk-Fact-29D102D394E88CA6D8DC94757D641310"
      unitRef="usd">2359000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e2897-wk-Fact-CFC646220F28061D991894757D5C03BB"
      unitRef="usd">4251000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember"
      decimals="-6"
      id="d8415180e2923-wk-Fact-ACE67986053B3153CF0794757D68C5BD"
      unitRef="usd">23829000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember"
      decimals="-6"
      id="d8415180e2942-wk-Fact-836FD402E1CA513AB7A194757D284A21"
      unitRef="usd">24661000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember"
      decimals="-6"
      id="d8415180e2961-wk-Fact-8CCA7F0CCF44F7EE009F94757CB0EAEE"
      unitRef="usd">15738000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember"
      decimals="-6"
      id="d8415180e2981-wk-Fact-59F11DF08C5C36F85F9694757CF96B93"
      unitRef="usd">16206000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e3006-wk-Fact-3DECA58B1AC0CB1EADC2637BE6201433"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e3025-wk-Fact-678267F9DCD3A09FF48494757D724476"
      unitRef="usd">1721000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e3044-wk-Fact-51872B65420AB7367EDA94757D7EDA33"
      unitRef="usd">-3019000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e3065-wk-Fact-B187FB0A3E73BF7B3DE094757D8267D6"
      unitRef="usd">-2306000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-6"
      id="d8415180e3178-wk-Fact-3B9E4BFE42603B35260C955D6E6EE07F"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-6"
      id="d8415180e3197-wk-Fact-5AD8B6162EC4B7A4D4FB955D6E5FA6F2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-6"
      id="d8415180e3216-wk-Fact-53C5AB131903D4621F5994757D60BCAC"
      unitRef="usd">-2245000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-6"
      id="d8415180e3237-wk-Fact-5FC136C8E0978EE4BFD794757D39F20F"
      unitRef="usd">-2676000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e3263-wk-Fact-E4FFEDBB5DC5F854F56E94757D7EEB40"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e3282-wk-Fact-2EEA4C28DE78F55C998494757D8D18BB"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2020Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e3301-wk-Fact-DF27017CA613A930B87894757D82C5EA"
      unitRef="usd">-1722000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e3322-wk-Fact-FF8C7011D05EB3AB087F94757D62A58B"
      unitRef="usd">-2217000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e3348-wk-Fact-7DA4198AE266BF0806EC94757D7C2F5A"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e3367-wk-Fact-FA7984ECC1DFE7CFBAFA94757D910C75"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2020Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e3386-wk-Fact-C42CFD3A1CA3D15C54F494757D5933EF"
      unitRef="usd">-34000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e3407-wk-Fact-CE26F77FF346C4DE6B0594757D644E3B"
      unitRef="usd">148000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e3434-wk-Fact-F86B001A7C15B351060B94757CD7A389"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e3453-wk-Fact-10F3E77A26DA7DA0E29F94757D3034FC"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2020Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e3472-wk-Fact-B0FAADCDDE37BDAB2D9594757D5E794A"
      unitRef="usd">-879000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q2YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d8415180e3493-wk-Fact-40DBE0BFFEA0FFC750D994757D7B3215"
      unitRef="usd">-691000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8415180e3524-wk-Fact-6D0243B400427DDF73DD94757D73B062"
      unitRef="usd">23829000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8415180e3543-wk-Fact-1987ADB564F749FC403294757D32C9CF"
      unitRef="usd">26382000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8415180e3563-wk-Fact-239CF4E3D5F1905A2F0794757CB54D24"
      unitRef="usd">7838000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8415180e3582-wk-Fact-57301CD194F92FB7EE9A94757CC61DC1"
      unitRef="usd">8463000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:InvestmentIncomeDividend
      contextRef="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViiVMember"
      decimals="-6"
      id="d8415180e3615-wk-Fact-71D18AE80705CBBAADD594757D794DFA"
      unitRef="usd">76000000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeDividend
      contextRef="FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViiVMember"
      decimals="-6"
      id="d8415180e3628-wk-Fact-68BAAAE2FACDAD5DABE694757D76ACC5"
      unitRef="usd">76000000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeDividend
      contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViiVMember"
      decimals="-6"
      id="d8415180e3640-wk-Fact-D5D32FD407DDC5273865955D6DF4E00F"
      unitRef="usd">153000000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeDividend
      contextRef="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViiVMember"
      decimals="-6"
      id="d8415180e3653-wk-Fact-625787D364A8EDA65710955D6DFF81D9"
      unitRef="usd">140000000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-620403C2A4D86FC8D65B94757DC2C501-0-wk-Fact-A49954CEA3CD402E4E6194757D4B0E45">&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="23"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides revenues by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Six Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Change&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Change&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,402&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,335&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,053&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,510&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Developed Europe&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,088&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,009&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Developed Rest of World&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,552&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,639&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,008&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,174&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Emerging Markets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,759&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,062&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,759&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,383&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,801&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,264&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,829&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,382&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; Revenues denominated in euros were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;second quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, and were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$3.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;the first six months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$3.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;the first six months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_StatementGeographicalAxis_country_US"
      decimals="-6"
      id="d8415180e4198-wk-Fact-A2312FBD3DF36214454394757D4E99B6"
      unitRef="usd">5402000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_country_US"
      decimals="-6"
      id="d8415180e4217-wk-Fact-D1AE1A5ED765BE15987994757D582336"
      unitRef="usd">6335000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pfe:PercentageChangeInRevenue
      contextRef="FD2020Q2QTD_srt_StatementGeographicalAxis_country_US"
      decimals="2"
      id="d8415180e4231-wk-Fact-B9F4556D7FB1F41A2C9C94757D4ED4CD"
      unitRef="number">-0.15</pfe:PercentageChangeInRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_StatementGeographicalAxis_country_US"
      decimals="-6"
      id="d8415180e4251-wk-Fact-81D003F6CDA6BD349D8094757CDF84A9"
      unitRef="usd">11053000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_country_US"
      decimals="-6"
      id="d8415180e4269-wk-Fact-1675732881C58BA8354494757CFAB9D4"
      unitRef="usd">12510000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pfe:PercentageChangeInRevenue
      contextRef="FD2020Q2YTD_srt_StatementGeographicalAxis_country_US"
      decimals="2"
      id="d8415180e4282-wk-Fact-FDCAA086490708B3C91C94757D7F0A2D"
      unitRef="number">-0.12</pfe:PercentageChangeInRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="-6"
      id="d8415180e4306-wk-Fact-73FE98C3916C85F549F794757D5AEA40"
      unitRef="usd">2088000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="-6"
      id="d8415180e4325-wk-Fact-994F255F78B05FBADDEC94757D595A9A"
      unitRef="usd">2228000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pfe:PercentageChangeInRevenue
      contextRef="FD2020Q2QTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="2"
      id="d8415180e4344-wk-Fact-2CF63F468B7D0CABA3CE94757D561921"
      unitRef="number">-0.06</pfe:PercentageChangeInRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="-6"
      id="d8415180e4359-wk-Fact-6FB75C33A442EECAAC2194757CF9FAAF"
      unitRef="usd">4009000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="-6"
      id="d8415180e4377-wk-Fact-22F02950F23AAC5E6D9094757CD8334C"
      unitRef="usd">4315000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pfe:PercentageChangeInRevenue
      contextRef="FD2020Q2YTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="2"
      id="d8415180e4395-wk-Fact-14DF655044E2528ED8EB94757D99A922"
      unitRef="number">-0.07</pfe:PercentageChangeInRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember"
      decimals="-6"
      id="d8415180e4419-wk-Fact-ADE35C801D052BCE925B94757D577C42"
      unitRef="usd">1552000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember"
      decimals="-6"
      id="d8415180e4438-wk-Fact-757B28C92C06735A064A94757D563E75"
      unitRef="usd">1639000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pfe:PercentageChangeInRevenue
      contextRef="FD2020Q2QTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember"
      decimals="2"
      id="d8415180e4457-wk-Fact-BC8DE56F3BD25EC7962894757D5CD864"
      unitRef="number">-0.05</pfe:PercentageChangeInRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember"
      decimals="-6"
      id="d8415180e4472-wk-Fact-7948B0B6844BD3D387BA94757CDB9B0C"
      unitRef="usd">3008000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember"
      decimals="-6"
      id="d8415180e4490-wk-Fact-2730F9B3BF2B3A2553D594757D809149"
      unitRef="usd">3174000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pfe:PercentageChangeInRevenue
      contextRef="FD2020Q2YTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember"
      decimals="2"
      id="d8415180e4508-wk-Fact-DE2B16204B073DAB2AEC94757CBCDCAA"
      unitRef="number">-0.05</pfe:PercentageChangeInRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember"
      decimals="-6"
      id="d8415180e4532-wk-Fact-30276A818E374D50F86494757D58EE99"
      unitRef="usd">2759000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember"
      decimals="-6"
      id="d8415180e4551-wk-Fact-BB799260ED60F412F4DC94757D59055E"
      unitRef="usd">3062000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pfe:PercentageChangeInRevenue
      contextRef="FD2020Q2QTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember"
      decimals="2"
      id="d8415180e4570-wk-Fact-78CEBCE2B596295642A894757D5C66CC"
      unitRef="number">-0.10</pfe:PercentageChangeInRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember"
      decimals="-6"
      id="d8415180e4585-wk-Fact-BBF6210C8041EAAE938194757D0EFB62"
      unitRef="usd">5759000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember"
      decimals="-6"
      id="d8415180e4603-wk-Fact-5312CAFDB12F1C38667794757CD7C311"
      unitRef="usd">6383000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pfe:PercentageChangeInRevenue
      contextRef="FD2020Q2YTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember"
      decimals="2"
      id="d8415180e4621-wk-Fact-F4C1ADE521CCDFE17FBB94757D99CF2B"
      unitRef="number">-0.10</pfe:PercentageChangeInRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD"
      decimals="-6"
      id="d8415180e4648-wk-Fact-4DB60D98BED9F2D7592094757D057DF4"
      unitRef="usd">11801000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d8415180e4667-wk-Fact-1769F431190664966C6E94757D75CC58"
      unitRef="usd">13264000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pfe:PercentageChangeInRevenue
      contextRef="FD2020Q2QTD"
      decimals="2"
      id="d8415180e4681-wk-Fact-0EA461F9F4B025BD6D7094757D4CA694"
      unitRef="number">-0.11</pfe:PercentageChangeInRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD"
      decimals="-6"
      id="d8415180e4701-wk-Fact-6D0243B400427DDF73DD94757D73B062"
      unitRef="usd">23829000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD"
      decimals="-6"
      id="d8415180e4719-wk-Fact-1987ADB564F749FC403294757D32C9CF"
      unitRef="usd">26382000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pfe:PercentageChangeInRevenue
      contextRef="FD2020Q2YTD"
      decimals="2"
      id="d8415180e4732-wk-Fact-82EB19D656D93F3B117F94757D984AB6"
      unitRef="number">-0.10</pfe:PercentageChangeInRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="-8"
      id="d8415180e4765-wk-Fact-9908DE2B11A192768D8694757D3DA691"
      unitRef="usd">1700000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="-8"
      id="d8415180e4777-wk-Fact-9F332E38931F452BA65294757D49B5C4"
      unitRef="usd">1800000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="-8"
      id="d8415180e4800-wk-Fact-9E9085FF3B339F6A258F955D6F0DE764"
      unitRef="usd">3200000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="-8"
      id="d8415180e4812-wk-Fact-47E858153D87071D86D9955D6F108090"
      unitRef="usd">3500000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-4B6CE4DCEEAA26D6AD9D94757DC302F1-0-wk-Fact-9B9A6A1E9ED3CFE5FE4E94757D4A9303">&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides detailed revenue information for several of our major products:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:29%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:38%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:inherit;font-size:7pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Six Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;PRODUCT&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;PRIMARY INDICATION OR CLASS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;TOTAL REVENUES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;11,801&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;13,264&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;23,829&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;26,382&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;9,795&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;9,432&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;19,802&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;18,477&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;Internal Medicine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,279&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,243&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;4,610&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;4,380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Eliquis alliance revenues and direct sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,272&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,085&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;2,572&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;2,096&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Chantix/Champix&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;An aid to smoking cessation treatment in adults 18 years of age or older&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;235&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;505&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;549&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Premarin family&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Symptoms of menopause&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;193&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;304&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;361&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;BMP2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Development of bone and cartilage&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;145&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Toviaz&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Overactive bladder&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;125&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;All other Internal Medicine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;498&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;544&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;978&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,103&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;Oncology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,647&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,236&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;5,082&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;4,198&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Ibrance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Metastatic breast cancer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,349&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,261&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;2,598&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;2,394&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Xtandi alliance revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Non-metastatic and metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;475&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;369&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Sutent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;209&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;248&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;414&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;480&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Inlyta&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Advanced RCC&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;195&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;104&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;364&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;177&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Xalkori&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;ALK-positive and ROS1-positive advanced NSCLC&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;138&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;287&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;255&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Bosulif&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Philadelphia&#160;chromosome&#x2013;positive&#160;chronic myelogenous leukemia&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;113&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;213&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;177&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Retacrit&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Anemia&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;87&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Braftovi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;In combination with Mektovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation and, in combination with Erbitux&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&#160;(cetuximab), for the treatment of BRAF&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;V600E&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;-mutant metastatic colorectal cancer after prior therapy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;74&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Mektovi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;In combination with Braftovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;All other Oncology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;412&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;262&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;Hospital&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a), (c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;1,794&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;1,838&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;3,807&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;3,665&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Sulperazon&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Bacterial infections&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;165&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;289&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;342&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Medrol&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Anti-inflammatory glucocorticoid&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;78&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;207&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;240&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Zithromax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Bacterial infections&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;193&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;177&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Precedex&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Sedation agent in surgery or intensive care&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;156&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Vfend&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Fungal infections&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;149&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;178&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Panzyga&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Primary humoral immunodeficiency&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;44&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;61&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:29%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:38%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:inherit;font-size:7pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Six Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;PRODUCT&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;PRIMARY INDICATION OR CLASS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;June&#160;28, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Zyvox&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Bacterial infections&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;125&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;134&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Fragmin&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Treatment/prevention of venous thromboembolism&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;118&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;123&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Pfizer CentreOne&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;204&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;376&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;All other Anti-infectives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;367&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;420&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;811&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;825&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;All other Hospital&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;603&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;544&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,245&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;Vaccines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;1,247&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;1,375&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,857&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,988&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Prevnar 13/Prevenar 13&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Pneumococcal disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,179&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;2,566&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;2,665&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Nimenrix&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Meningococcal disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;130&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;107&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;All other Vaccines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;138&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;Inflammation &amp;amp; Immunology (I&amp;amp;I)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;1,149&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;1,219&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,256&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Xeljanz&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;RA, PsA, UC&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;635&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;613&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,086&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,036&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Enbrel (Outside the U.S. and Canada)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;337&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;420&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;684&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;871&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Inflectra/Remsima&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Crohn&#x2019;s disease, pediatric Crohn&#x2019;s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;153&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;308&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;All other I&amp;amp;I&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;Rare Disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;681&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;521&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;1,319&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Vyndaqel/Vyndamax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;ATTR-cardiomyopathy and polyneuropathy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;277&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;508&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;104&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;BeneFIX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Hemophilia B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;109&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;230&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;247&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Genotropin&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Replacement of human growth hormone&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;106&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;125&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;209&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;232&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Refacto AF/Xyntha&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Hemophilia A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;108&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;181&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;214&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Somavert&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Acromegaly&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;128&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;All other Rare Disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;61&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;66&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;UPJOHN&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,006&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,970&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;4,027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;6,184&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Lipitor&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Reduction of LDL cholesterol&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;431&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;407&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;836&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,029&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Lyrica&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;349&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,175&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;706&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;2,362&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Norvasc&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Hypertension&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;216&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;419&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;516&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Celebrex&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Arthritis pain and inflammation, acute pain&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;139&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;174&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;295&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;347&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Viagra&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Erectile dysfunction&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;259&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Effexor&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Depression and certain anxiety disorders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;86&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;86&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;163&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;163&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Zoloft&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Depression and certain anxiety disorders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;157&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;143&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;EpiPen&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Epinephrine injection used in treatment of life-threatening allergic reactions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;123&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Xalatan/Xalacom&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Glaucoma and ocular hypertension&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;126&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;All other Upjohn&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;476&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;587&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;968&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;span&gt;1,109&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;CONSUMER HEALTHCARE BUSINESS&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;862&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;1,721&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;Total Alliance revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;1,404&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;1,187&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,786&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,277&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;Total Biosimilars&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;289&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;217&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;578&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;396&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;Total Sterile Injectable Pharmaceuticals&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;1,237&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;1,218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,644&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,455&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan).&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt; As a result, revenues associated with our Meridian subsidiary, except for product revenues for EpiPen sold in Canada, and Mylan-Japan, are reported in our Upjohn business beginning in the first quarter of 2020. We have reclassified revenues associated with our Meridian subsidiary and Mylan-Japan from the Hospital and Internal Medicine categories to the Upjohn business to conform 2019 product revenues to the current presentation.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. Hospital also includes Pfizer CentreOne&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;. All other Hospital primarily includes revenues from legacy Sterile Injectables Pharmaceuticals (SIP) products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in &#x201c;All other Anti-infectives&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;On &lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;July&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;, Pfizer&#x2019;s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK&#x2019;s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;font-style:italic;"&gt;Note 2B&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:7.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(f)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember"
      decimals="-6"
      id="d8415180e5171-wk-Fact-9D6F9F14A64FFA2B405D94757D4F07B3"
      unitRef="usd">11801000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember"
      decimals="-6"
      id="d8415180e5190-wk-Fact-4AB009D1627E97C45D0294757D5E0C6F"
      unitRef="usd">13264000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember"
      decimals="-6"
      id="d8415180e5210-wk-Fact-F9FD6AF468DA8EF60C5994757CE277D8"
      unitRef="usd">23829000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember"
      decimals="-6"
      id="d8415180e5229-wk-Fact-43D2DA21439F004C93D694757D0B7C53"
      unitRef="usd">26382000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5264-wk-Fact-51315BFC3EFD807B35A494757D79D615"
      unitRef="usd">9795000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5283-wk-Fact-A054FF6C23099D448D2294757CD9B526"
      unitRef="usd">9432000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5303-wk-Fact-7A65F06A8B6D89F3196D94757D3ED197"
      unitRef="usd">19802000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5322-wk-Fact-2B1B9101B3EF21429F7894757D7FE12F"
      unitRef="usd">18477000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5359-wk-Fact-9B8010AEEE0CA7C861B494757D62CEEB"
      unitRef="usd">2279000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5378-wk-Fact-68D35D8323640620312994757D5EC94F"
      unitRef="usd">2243000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5398-wk-Fact-99DCC47DA679E57EDCE694757D4966B0"
      unitRef="usd">4610000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5417-wk-Fact-4D4D0A148BCFEEA47A9894757D551B15"
      unitRef="usd">4380000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5447-wk-Fact-38BF97B5966F919766EC94757CA703FC"
      unitRef="usd">1272000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5466-wk-Fact-2AB8FDBDC0EF4D28AFBE94757CD8C9DF"
      unitRef="usd">1085000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5486-wk-Fact-423E2315CDCB857D87F794757D3B33EB"
      unitRef="usd">2572000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5505-wk-Fact-02A1D5D7B6684CF717F394757CCC45F0"
      unitRef="usd">2096000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5540-wk-Fact-40BFA256F2604E1D69E694757D5745F9"
      unitRef="usd">235000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5559-wk-Fact-066F1B2C39D1A83ADDB294757D9EC44C"
      unitRef="usd">276000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5579-wk-Fact-1C6897C10CB6E03B97C094757D014B98"
      unitRef="usd">505000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5598-wk-Fact-D2F686C8FF4197FE1E1D94757D4328BD"
      unitRef="usd">549000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5633-wk-Fact-E4061A0544587530FE5694757D9C3208"
      unitRef="usd">152000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5652-wk-Fact-FC2B2CD24A88257F990394757CB35835"
      unitRef="usd">193000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5672-wk-Fact-28CC293C11C25B9C4E6E94757D8F7B1C"
      unitRef="usd">304000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5691-wk-Fact-8ACA3083C920B54F8AEC94757D564AB6"
      unitRef="usd">361000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5726-wk-Fact-A617E7F74433A22C70F794757DA55FFF"
      unitRef="usd">57000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5745-wk-Fact-F90EF4CFE321BC6F7A3494757D56ED60"
      unitRef="usd">79000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5765-wk-Fact-C5B823B21E48CD41CEFE94757CE0A878"
      unitRef="usd">127000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5784-wk-Fact-F44ADBD39CBA320A835394757D7CED0E"
      unitRef="usd">145000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5819-wk-Fact-97E6BE9DD3E7475F229D94757D38F45F"
      unitRef="usd">64000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5838-wk-Fact-44C12AC03CA4B50FB0EC94757D37E891"
      unitRef="usd">65000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5858-wk-Fact-0E667667A379AE13037394757D3C7D79"
      unitRef="usd">124000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5877-wk-Fact-CAAA50A9A982EC80885B94757CFEC886"
      unitRef="usd">125000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5912-wk-Fact-8F10AC75EAF3DB11CBFC94757D61D1B8"
      unitRef="usd">498000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5931-wk-Fact-8C0A92F009A247D99EC694757D0E2AFB"
      unitRef="usd">544000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5951-wk-Fact-8756F2FE82655E80079594757D3B1E62"
      unitRef="usd">978000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e5970-wk-Fact-45009E6C6C76A6D4EBFD94757D064F15"
      unitRef="usd">1103000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6011-wk-Fact-B3ED622B6D5333AADB4C94757D4DE93E"
      unitRef="usd">2647000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6030-wk-Fact-4A8A6D2C43101EDB612F94757D38DA90"
      unitRef="usd">2236000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6050-wk-Fact-BBFDDD0F99EBDF64EB1694757D9ECC85"
      unitRef="usd">5082000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6069-wk-Fact-91B475D5B7F71E7C7FAB94757D49A574"
      unitRef="usd">4198000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6099-wk-Fact-292A39A61B95A38DAE4294757D641FCC"
      unitRef="usd">1349000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6118-wk-Fact-1D7D14E19D54858958AD94757D7F7B9C"
      unitRef="usd">1261000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6138-wk-Fact-BA188523CDC08C3BD91894757D830D48"
      unitRef="usd">2598000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6157-wk-Fact-F0BFBC7B811B1816201694757CB6F0E5"
      unitRef="usd">2394000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_XtandiAllianceRevenuesMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6192-wk-Fact-75BFCA05A7149AE95CBC94757D351323"
      unitRef="usd">266000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_XtandiAllianceRevenuesMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6211-wk-Fact-1ABC18BB58EC4350C49A94757DA469FD"
      unitRef="usd">201000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_XtandiAllianceRevenuesMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6231-wk-Fact-8E0A3D13B1EAB4274CE094757CF24199"
      unitRef="usd">475000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_XtandiAllianceRevenuesMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6250-wk-Fact-790962E6E46F5DAE16C594757D8B4C11"
      unitRef="usd">369000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_SutentMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6285-wk-Fact-BD96C76E9201FF7471B894757CBB75BF"
      unitRef="usd">209000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_SutentMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6304-wk-Fact-A328552D6AA9AECA214D94757D7B82D3"
      unitRef="usd">248000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_SutentMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6324-wk-Fact-BB5180129FF25C4F156F94757CF77B4B"
      unitRef="usd">414000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_SutentMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6343-wk-Fact-D710DD8F9085F4C6427994757D0D2639"
      unitRef="usd">480000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6378-wk-Fact-7AF794137FFB59B04D9F94757CFF8758"
      unitRef="usd">195000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6397-wk-Fact-2273A659770771A4C8E794757D3A8C78"
      unitRef="usd">104000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6417-wk-Fact-BBAF1253B0331C702CFD94757DA1EAEE"
      unitRef="usd">364000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6436-wk-Fact-2A64A333F62F8B0205CF94757DA2BE21"
      unitRef="usd">177000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6471-wk-Fact-EDF0BD718B103083D4FF94757CF1661F"
      unitRef="usd">138000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6490-wk-Fact-0EEA33BB8E1D16B6B52C94757D0D7D9B"
      unitRef="usd">133000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6510-wk-Fact-B63690318E396E789ECB94757D9C1E5B"
      unitRef="usd">287000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6529-wk-Fact-FAD26D1BF97B169BA9FF94757D99D923"
      unitRef="usd">255000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6564-wk-Fact-EB3DFF950D41939251B594757D31A223"
      unitRef="usd">113000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6583-wk-Fact-DDAB8DA858C2046EFB9194757D6613BB"
      unitRef="usd">97000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6603-wk-Fact-1769FC90ED8A5212B02994757CDC0199"
      unitRef="usd">213000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6622-wk-Fact-8C0B1A948B1F38EC51F194757CF43642"
      unitRef="usd">177000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_RetacritMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6659-wk-Fact-1C41D8D03DE049895B2094757D9C99B7"
      unitRef="usd">87000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_RetacritMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6678-wk-Fact-EC785A34B39A8E6060B794757DA5646C"
      unitRef="usd">51000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_RetacritMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6698-wk-Fact-A40FA5F841627A3B361294757D3A0A50"
      unitRef="usd">176000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_RetacritMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6717-wk-Fact-1A182C74458013C503BA94757D323D60"
      unitRef="usd">82000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6760-wk-Fact-8228BFAFD6135B5FE0EB94757CFE18C3"
      unitRef="usd">36000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6779-wk-Fact-28494D2507D848DC656E94757D06BDB4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6799-wk-Fact-29DB3832C423CF07297E955D6F26B078"
      unitRef="usd">74000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6818-wk-Fact-1BBA8D8FF8C715716BEF955D6DE660AB"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_MektoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6853-wk-Fact-FC0002C8DB53C863C0BF94757CD36F6D"
      unitRef="usd">32000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_MektoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6872-wk-Fact-962C0D7F7FA2360CD92194757CFD68D9"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_MektoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6892-wk-Fact-6E956A6B353850312446955D6DCF921A"
      unitRef="usd">69000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_MektoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6911-wk-Fact-A7D9E8CC87E296B446CB955D6F275827"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6946-wk-Fact-3FF1B5A349253F7F72E994757CF3173A"
      unitRef="usd">221000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6965-wk-Fact-51B9585A97281577F55894757D56D291"
      unitRef="usd">140000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e6985-wk-Fact-082321B1195122177BB094757D5150F1"
      unitRef="usd">412000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7004-wk-Fact-8EADFB562DCF6F518C5D94757D7A8BBF"
      unitRef="usd">262000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7047-wk-Fact-60CA995A5DF3128B16AC94757CF80B83"
      unitRef="usd">1794000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7066-wk-Fact-9FF11DED732028F079FF94757D67BC5A"
      unitRef="usd">1838000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7086-wk-Fact-49D11DC2C94C1C47212E94757D5FB74C"
      unitRef="usd">3807000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7105-wk-Fact-F48D67680627D6924C7394757D8E45FB"
      unitRef="usd">3665000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7135-wk-Fact-0746A502EECEDB0C1D9394757D555939"
      unitRef="usd">102000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7154-wk-Fact-4872D1EBBF4E1852EC3494757D07D096"
      unitRef="usd">165000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7174-wk-Fact-76C07D2D66C0388F0C0594757D012C55"
      unitRef="usd">289000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7193-wk-Fact-0B2C64A2B5311E2D9BF394757D63AA66"
      unitRef="usd">342000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7228-wk-Fact-75A819750D40D13F5F4D94757D59DF46"
      unitRef="usd">78000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7247-wk-Fact-DDBF519A26B8B268AC5394757D7DE917"
      unitRef="usd">120000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7267-wk-Fact-EB6D0A7F7C143C2F6D1E94757D00635E"
      unitRef="usd">207000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7286-wk-Fact-61F05B8390D8DD312E7E94757D01400F"
      unitRef="usd">240000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7321-wk-Fact-BD41F7186105B7884BC694757D5BC2AE"
      unitRef="usd">55000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7340-wk-Fact-0739ED261CA0E3B259D394757D5A4733"
      unitRef="usd">73000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7360-wk-Fact-2AF25534B2A95420B2CC94757D5E2E55"
      unitRef="usd">193000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7379-wk-Fact-2460B59E617CE183933A94757CDEE668"
      unitRef="usd">177000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7414-wk-Fact-39C4783BCFAA4ABC800E6391E2F164B1"
      unitRef="usd">114000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7433-wk-Fact-5DF4EF1F1BCC2D34B6F86391E6AAE21C"
      unitRef="usd">40000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7453-wk-Fact-399031A0BA1EB364EEE6955D6DD9525C"
      unitRef="usd">156000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7472-wk-Fact-DD66129D925AD6B2D1A4955D6DF5306E"
      unitRef="usd">80000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_VfendMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7507-wk-Fact-477D98C4B7AC60774FF994757DA3ED14"
      unitRef="usd">75000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_VfendMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7526-wk-Fact-F438821E9550CEA8E25A94757D043BA1"
      unitRef="usd">94000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_VfendMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7546-wk-Fact-196CA4F9D93284F17A0194757CFB1334"
      unitRef="usd">149000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_VfendMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7565-wk-Fact-7F5B6E7E28432773681794757D7346F3"
      unitRef="usd">178000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_PanzygaMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7600-wk-Fact-B7B4528B4555854FBA2594757D748585"
      unitRef="usd">63000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_PanzygaMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7619-wk-Fact-2B65B5D59AAE94EB07C394757D4A2A4B"
      unitRef="usd">44000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_PanzygaMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7639-wk-Fact-C8791891FDD5606F4FF0955D6DF370FF"
      unitRef="usd">136000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_PanzygaMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7658-wk-Fact-72D47C5CC041D7DBF47F955D6F25B06E"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7912-wk-Fact-1156EEDC3AF7E03F6D9894757D9E9130"
      unitRef="usd">55000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7931-wk-Fact-F35FE93745C53320FB9394757D667FF4"
      unitRef="usd">71000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7951-wk-Fact-E7F68194ACA2953195D194757D3ADA6D"
      unitRef="usd">125000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e7970-wk-Fact-EBD6CF2E62976239B60E94757D5080D2"
      unitRef="usd">134000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_FragminMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8005-wk-Fact-3A87DB55E2FD4B6878A094757D7E9E08"
      unitRef="usd">58000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_FragminMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8024-wk-Fact-AF51AD4BAD86F0B6155B94757D5FA1C5"
      unitRef="usd">63000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_FragminMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8044-wk-Fact-2434BB068F426C5FA43394757D97AF9A"
      unitRef="usd">118000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_FragminMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8063-wk-Fact-CB1E1E66274A527AAF7194757D9AD724"
      unitRef="usd">123000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_PfizerCentreOneMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8100-wk-Fact-6E0224238BF2056CE73A94757CD9F96F"
      unitRef="usd">224000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_PfizerCentreOneMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8119-wk-Fact-4B0483818642973A551F94757D019625"
      unitRef="usd">204000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_PfizerCentreOneMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8139-wk-Fact-146D88A01BA77360B4DB94757DA58B4B"
      unitRef="usd">376000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_PfizerCentreOneMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8158-wk-Fact-2E372A7C63982BD2808894757D9722C9"
      unitRef="usd">380000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_OtherAntiinfectivesMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8193-wk-Fact-983ACA3C5EAC7B373D6394757D08EA2C"
      unitRef="usd">367000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_OtherAntiinfectivesMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8212-wk-Fact-73D86692FF1AB4C6A16994757D919ACA"
      unitRef="usd">420000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_OtherAntiinfectivesMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8232-wk-Fact-8936184B1403F72707B294757CFAA700"
      unitRef="usd">811000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_OtherAntiinfectivesMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8251-wk-Fact-E5ACC24ECADCC36DF22594757D7E0534"
      unitRef="usd">825000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_OtherHospitalProductsMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8288-wk-Fact-ACC0B84B657C3CD00CFC94757D4FE802"
      unitRef="usd">603000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_OtherHospitalProductsMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8307-wk-Fact-B0C69CDE8303781F976E94757D9A42B7"
      unitRef="usd">544000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_OtherHospitalProductsMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8327-wk-Fact-BEED3353022DC3D9583494757DA5ED38"
      unitRef="usd">1245000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_OtherHospitalProductsMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8346-wk-Fact-5412E02A9288B4E9968694757D311429"
      unitRef="usd">1124000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8386-wk-Fact-74E4240EE356FD32937194757D598199"
      unitRef="usd">1247000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8405-wk-Fact-9219053E894437AE654A94757CA730AC"
      unitRef="usd">1375000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8425-wk-Fact-ED21A5999CE70D92B7B894757D82FAD8"
      unitRef="usd">2857000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8444-wk-Fact-30A55A76D09149193DEF94757CF9F6E0"
      unitRef="usd">2988000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8474-wk-Fact-F0FB32A7863EE7ED7F4694757D7AEFEA"
      unitRef="usd">1116000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8493-wk-Fact-DDDCDB827DE1BA9AE0A094757D605ED8"
      unitRef="usd">1179000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8513-wk-Fact-3464C800C7CFB593F5A094757D025356"
      unitRef="usd">2566000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8532-wk-Fact-5482D0C9A48409F518C294757CD32973"
      unitRef="usd">2665000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_NimenrixMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8567-wk-Fact-35F819121227A1B2716394757CD7F3B5"
      unitRef="usd">56000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_NimenrixMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8586-wk-Fact-EB493894E6854666775C94757DA43288"
      unitRef="usd">58000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_NimenrixMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8606-wk-Fact-9BCD3F039A9501E12FF494757D93C184"
      unitRef="usd">130000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_NimenrixMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8625-wk-Fact-6A8F17526ED378430AC394757D37D095"
      unitRef="usd">107000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8660-wk-Fact-B7370F44810A4DAB73E594757D4E7849"
      unitRef="usd">75000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8679-wk-Fact-4439A451532C5A8CA16A94757CD79850"
      unitRef="usd">138000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8699-wk-Fact-DC223973F9A5716A8E8A94757CD62EB0"
      unitRef="usd">161000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8718-wk-Fact-C24556ADCE00898BD21594757D0D7A3A"
      unitRef="usd">215000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8759-wk-Fact-A2939B732AE13241120294757D09B001"
      unitRef="usd">1149000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8778-wk-Fact-8E31E2F76BD952A8034B94757D5D45BC"
      unitRef="usd">1219000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8798-wk-Fact-6C9BC4C3EBFF03DDD76D94757D620C88"
      unitRef="usd">2127000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8817-wk-Fact-5E3946E8DF0B8A26D57594757D5D19AE"
      unitRef="usd">2256000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8847-wk-Fact-CB4934D4AC7BE3EE5C8B94757DA16687"
      unitRef="usd">635000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8866-wk-Fact-34DF1ED7A975EB8009FD94757CFCA377"
      unitRef="usd">613000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8886-wk-Fact-6AECEE089D57AA13D6BC94757D97FE05"
      unitRef="usd">1086000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8905-wk-Fact-F08B0F8C37F8C93A4C4094757DA47314"
      unitRef="usd">1036000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8940-wk-Fact-5FB2575DB6C40C4A523694757CD6C03F"
      unitRef="usd">337000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8959-wk-Fact-EF95E23BF627189BD8D394757CD6C3BC"
      unitRef="usd">420000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8979-wk-Fact-855E65BE498CA482464E94757D972E8A"
      unitRef="usd">684000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e8998-wk-Fact-901FD30A6584FD962DA994757CDAFF61"
      unitRef="usd">871000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9035-wk-Fact-DB4CC75A37E92F7B141794757D9F9E31"
      unitRef="usd">150000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9054-wk-Fact-67200BFFCD97D83C7D8E94757D555E87"
      unitRef="usd">153000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9074-wk-Fact-099EACAC9FBD97BB278994757CD0F95C"
      unitRef="usd">308000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9093-wk-Fact-96E3B27F72377D1E7FE194757D98AE8A"
      unitRef="usd">291000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9128-wk-Fact-F9ECD4E61F7F416505A994757D4CE755"
      unitRef="usd">26000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9147-wk-Fact-A47F0900AE72842784C694757D57B6DC"
      unitRef="usd">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9167-wk-Fact-D9342B24F3BFBFBB0B2C94757CF2922B"
      unitRef="usd">48000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9186-wk-Fact-E28730D95B8DDFD41B3A94757DA7C4C1"
      unitRef="usd">59000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9226-wk-Fact-E3472375FCBC04FE226794757CFEC2C2"
      unitRef="usd">681000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9245-wk-Fact-7B91BBEA47E9777B17C594757D58AE44"
      unitRef="usd">521000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9265-wk-Fact-32B84237D873D169405294757D4B1427"
      unitRef="usd">1319000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9284-wk-Fact-08811F0E0890B477F67294757D0E6EA8"
      unitRef="usd">991000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_VyndaqelMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9314-wk-Fact-16BA4BA96D497FE8841494757D0E0F19"
      unitRef="usd">277000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_VyndaqelMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9333-wk-Fact-1DEBA46DDE9F43EFD62794757D56A729"
      unitRef="usd">63000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_VyndaqelMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9353-wk-Fact-E43590991626F7E0420C94757D7D244F"
      unitRef="usd">508000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_VyndaqelMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9372-wk-Fact-2B8C407B0F9D1E1697FF94757D8D7AFF"
      unitRef="usd">104000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9407-wk-Fact-FADD415BA7D4A949D7E294757CD85B2F"
      unitRef="usd">109000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9426-wk-Fact-35DD337C5BA3CE10748094757D38DE10"
      unitRef="usd">121000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9446-wk-Fact-B601AC275D35D91FAA5B94757D96646A"
      unitRef="usd">230000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9465-wk-Fact-9E28BED123C461A036F694757D3A4E75"
      unitRef="usd">247000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9500-wk-Fact-EA6415464295103AEF2B94757DA2049F"
      unitRef="usd">106000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9519-wk-Fact-6E0A84456242D8C091A194757CB4E6D0"
      unitRef="usd">125000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9539-wk-Fact-12D147AF9E825EFFF01094757D7C5FF5"
      unitRef="usd">209000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9558-wk-Fact-8FEC3BDE742F3804D88D94757CFF667C"
      unitRef="usd">232000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9593-wk-Fact-3033AFEEE9DAC2AA502F94757D5A3A33"
      unitRef="usd">91000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9612-wk-Fact-1008A58E5163A037E91694757DA76A0E"
      unitRef="usd">108000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9632-wk-Fact-57B4C0AD54F70ED15DEB94757D0994FB"
      unitRef="usd">181000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9651-wk-Fact-3F107AD41D30272FF55994757D9AE730"
      unitRef="usd">214000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9686-wk-Fact-C3FC40ABABE9A40ADF4194757D2AFAF8"
      unitRef="usd">67000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9705-wk-Fact-3E2ECD68BC9BCE0AEB1994757DA672E1"
      unitRef="usd">68000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9725-wk-Fact-04D691259FB1FD1AF5E494757D0719B5"
      unitRef="usd">131000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9744-wk-Fact-A36E93BCD1D69A5C434B94757D27570F"
      unitRef="usd">128000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9780-wk-Fact-6BB9C2EB3E8AA601D81B94757D4D8A03"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9799-wk-Fact-F91FD24844F3AF40238A94757D7F6262"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9819-wk-Fact-DB477F1734A1E9EA210A94757D0C3C05"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d8415180e9838-wk-Fact-DE40C96E4948EABC1B9994757D9FA9A4"
      unitRef="usd">66000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e9880-wk-Fact-8A47D4A42EA4801E113F94757D561064"
      unitRef="usd">2006000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e9899-wk-Fact-C5060A64152E4CD16E7D94757D9B8FAB"
      unitRef="usd">2970000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e9919-wk-Fact-BFD0D11A54AFC7EC342E94757D4DA77D"
      unitRef="usd">4027000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e9938-wk-Fact-3383068A828B707166B194757D4D0A42"
      unitRef="usd">6184000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e9968-wk-Fact-B6F824A1D38474F2D25894757CD26487"
      unitRef="usd">431000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e9987-wk-Fact-F43BB2EB7D4C6E45428094757CDA03D2"
      unitRef="usd">407000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10007-wk-Fact-AD3188356864105593EE94757CDE3AA3"
      unitRef="usd">836000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10026-wk-Fact-7097BD769E5D82E2973294757D7E414B"
      unitRef="usd">1029000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10061-wk-Fact-4E6EDE18D87BADEBD5D594757DA51E46"
      unitRef="usd">349000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10080-wk-Fact-C076F9FF805FD19B813594757D054DF5"
      unitRef="usd">1175000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10100-wk-Fact-4D1BE9253D5F410A0D8294757D39F930"
      unitRef="usd">706000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10119-wk-Fact-8DE5439DE42185EAD27394757D638D67"
      unitRef="usd">2362000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10154-wk-Fact-AAF3C1C15A87A9E0791F94757D585239"
      unitRef="usd">222000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10173-wk-Fact-30038D93D81522EF2C4494757CB8E85E"
      unitRef="usd">216000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10193-wk-Fact-72CA6214585A5C8E5F0694757D4CBC86"
      unitRef="usd">419000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10212-wk-Fact-F2DA33B091A2333965BF94757D0DA3A2"
      unitRef="usd">516000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10247-wk-Fact-1A5FECFDC88986C24EF594757D80E29D"
      unitRef="usd">139000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10266-wk-Fact-E2B7192F841B652DD3E194757D025EED"
      unitRef="usd">174000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10286-wk-Fact-358A86952AF68F57BF8A94757D2D05E3"
      unitRef="usd">295000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10305-wk-Fact-4332974BA308B68F084594757D7E748A"
      unitRef="usd">347000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10340-wk-Fact-CB04EC46BE3C2AE76E6E94757D59A008"
      unitRef="usd">94000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10359-wk-Fact-87D917DF76C4DF6A2AA894757D7F7619"
      unitRef="usd">114000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10379-wk-Fact-14DC4260C1A11D0782B494757D550824"
      unitRef="usd">222000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10398-wk-Fact-03DE33E0BDCBEEE2BFF194757D58A455"
      unitRef="usd">259000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10433-wk-Fact-F7818AB402D4FDFA360A94757D088A7E"
      unitRef="usd">86000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10452-wk-Fact-1C3E607A0B96B4E13C6A94757D7DBECB"
      unitRef="usd">86000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10472-wk-Fact-EE3B286DC2CC60A1348594757D084ADB"
      unitRef="usd">163000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10491-wk-Fact-3EA1514AE1ADA2AD3F6494757D8089A9"
      unitRef="usd">163000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10526-wk-Fact-D299C7D480FAACA386FA94757CA95699"
      unitRef="usd">79000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10545-wk-Fact-5EE554E0F23105B14A0A94757CD8E1B6"
      unitRef="usd">73000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10565-wk-Fact-4B82DFDFC48F6984C14894757CBA0C82"
      unitRef="usd">157000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10584-wk-Fact-5FFC08B63DBE9AEB9BB794757CFD2C69"
      unitRef="usd">143000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10621-wk-Fact-B53EC4023A670C9BFD9694757CFA2072"
      unitRef="usd">64000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10640-wk-Fact-E5461C2F47C5805246B594757CD11E3E"
      unitRef="usd">67000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10660-wk-Fact-964D5983FAFE8F814A6063A28D7FB945"
      unitRef="usd">136000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10679-wk-Fact-4530C68B63EB9C8D923963A2911A73D6"
      unitRef="usd">123000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10714-wk-Fact-07227B9D4AC3775762FA94757CFC4DBE"
      unitRef="usd">65000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10733-wk-Fact-F1157F3F3D62CE169F0094757CD5A45F"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10753-wk-Fact-1085284E00DE2A425A0894757DA63E92"
      unitRef="usd">126000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10772-wk-Fact-61E83372368ABBBF6C3294757D74D153"
      unitRef="usd">133000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherUpjohnProductsMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10808-wk-Fact-1A1E0EDA654D59F9D7FD94757D7CE696"
      unitRef="usd">476000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_AllOtherUpjohnProductsMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10827-wk-Fact-054BF18A0129DBDADDAA94757D7C3D2F"
      unitRef="usd">587000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherUpjohnProductsMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10847-wk-Fact-371E5DEB4BB6100754FB94757DA1FAFE"
      unitRef="usd">968000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_AllOtherUpjohnProductsMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d8415180e10866-wk-Fact-4D23F6FF7E43AD5A2E8294757CB25D84"
      unitRef="usd">1109000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_us-gaap_ReportingUnitAxis_pfe_ConsumerHealthcareReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d8415180e10908-wk-Fact-D421852A3121926EC88F94757D45D1D2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_us-gaap_ReportingUnitAxis_pfe_ConsumerHealthcareReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d8415180e10927-wk-Fact-71BC4F00B5A98A968BFB94757D63CCD9"
      unitRef="usd">862000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_us-gaap_ReportingUnitAxis_pfe_ConsumerHealthcareReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d8415180e10947-wk-Fact-871E915D2D6F3FDC5AE494757D0F306E"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_us-gaap_ReportingUnitAxis_pfe_ConsumerHealthcareReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d8415180e10966-wk-Fact-FAE23785D8D757DC211B94757D5BFB03"
      unitRef="usd">1721000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_TotalAllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember"
      decimals="-6"
      id="d8415180e11001-wk-Fact-7D53DA141A1661E350C494757CD27C31"
      unitRef="usd">1404000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_TotalAllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember"
      decimals="-6"
      id="d8415180e11020-wk-Fact-19FE32C2E94B0BB6335F94757DA09738"
      unitRef="usd">1187000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_TotalAllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember"
      decimals="-6"
      id="d8415180e11040-wk-Fact-764DE6C24A3192A6595F94757CD7F4D4"
      unitRef="usd">2786000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_TotalAllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember"
      decimals="-6"
      id="d8415180e11059-wk-Fact-086484E238165C35805A94757CD31940"
      unitRef="usd">2277000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_TotalBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember"
      decimals="-6"
      id="d8415180e11096-wk-Fact-CB195E4B49470C94E41C94757D5B8154"
      unitRef="usd">289000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_TotalBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember"
      decimals="-6"
      id="d8415180e11115-wk-Fact-ACE7D9A9276B682B9DB094757D5AF1D5"
      unitRef="usd">217000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_TotalBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember"
      decimals="-6"
      id="d8415180e11135-wk-Fact-B698D162AA64B4E9F22494757CB607DE"
      unitRef="usd">578000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_TotalBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember"
      decimals="-6"
      id="d8415180e11154-wk-Fact-3A37D8CBC7B234B9BABE94757CAB9E45"
      unitRef="usd">396000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_pfe_TotalSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember"
      decimals="-6"
      id="d8415180e11191-wk-Fact-4A39A4BCF3749653D06D94757D00D6F3"
      unitRef="usd">1237000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_pfe_TotalSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember"
      decimals="-6"
      id="d8415180e11210-wk-Fact-B09391D35897D9D4E22494757D809B12"
      unitRef="usd">1218000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_TotalSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember"
      decimals="-6"
      id="d8415180e11230-wk-Fact-6F6B5B603006C5DC41F794757D7CCE24"
      unitRef="usd">2644000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_pfe_TotalSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember"
      decimals="-6"
      id="d8415180e11249-wk-Fact-076F89258C6280289A5E94757D34A300"
      unitRef="usd">2455000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#d8351242e7867-wk-Fact-0062B855A4905ABE3A7094757D9632CA"
          xlink:label="d8351242e7867-wk-Fact-0062B855A4905ABE3A7094757D9632CA"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-2167C2B3C67E3F1A9F6094757DBA8899-0-wk-Footnote-2167C2B3C67E3F1A9F6094757DBA8899_lbl" xlink:label="TextSelection-2167C2B3C67E3F1A9F6094757DBA8899-0-wk-Footnote-2167C2B3C67E3F1A9F6094757DBA8899_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">As of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">December&#160;31, 2019</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, equity securities with readily determinable fair values included money market funds primarily invested in U.S. Treasury and government debt. As of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$11.4 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn debt transactions (see </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7D</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">) are invested in money market funds and included in </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">in the condensed consolidated balance sheet.</xhtml:span></xhtml:div><xhtml:div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:br/></xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e7867-wk-Fact-0062B855A4905ABE3A7094757D9632CA"
          xlink:to="TextSelection-2167C2B3C67E3F1A9F6094757DBA8899-0-wk-Footnote-2167C2B3C67E3F1A9F6094757DBA8899_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e2025-wk-Fact-011D17ED46D6C704909994757CE026FE"
          xlink:label="d8415180e2025-wk-Fact-011D17ED46D6C704909994757CE026FE"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl" xlink:label="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Income from continuing operations before provision/(benefit) for taxes on income</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">. Biopharma&#x2019;s earnings </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">include d</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">ividend income of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$76 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> in the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">second quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$76&#160;million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> in the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">second quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">2019</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$153 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> in </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">the first six months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$140 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> in </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">the first six months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">2019</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> from our investment in ViiV. For additional information, see </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e2025-wk-Fact-011D17ED46D6C704909994757CE026FE"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e5060-wk-Fact-0133CD4E7227C37B6E9194757D1DFC1C"
          xlink:label="d8372444e5060-wk-Fact-0133CD4E7227C37B6E9194757D1DFC1C"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl" xlink:label="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">OID = Other (income)/deductions&#x2014;net, included in </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (income)/deductions&#x2014;net</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> in the condensed consolidated statements of income</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">.</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> COS = Cost of Sales, included in </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Cost of sales</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5060-wk-Fact-0133CD4E7227C37B6E9194757D1DFC1C"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl" xlink:label="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">The amounts reclassified from OCI were reclassified into OID.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5060-wk-Fact-0133CD4E7227C37B6E9194757D1DFC1C"
          xlink:to="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl" xlink:label="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Other comprehensive loss&#x2013;&#x2013;Unrealized holding gains/(losses) on derivative financial instruments, net</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the gains and losses are included in </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Other comprehensive loss&#x2013;&#x2013;Foreign currency translation adjustments, net.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5060-wk-Fact-0133CD4E7227C37B6E9194757D1DFC1C"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1764-wk-Fact-014A34208FA34FFBCC4994757D221D12"
          xlink:label="d8307028e1764-wk-Fact-014A34208FA34FFBCC4994757D221D12"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl" xlink:label="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;padding-bottom:16px;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1764-wk-Fact-014A34208FA34FFBCC4994757D221D12"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e5505-wk-Fact-02A1D5D7B6684CF717F394757CCC45F0"
          xlink:label="d8415180e5505-wk-Fact-02A1D5D7B6684CF717F394757CCC45F0"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl" xlink:label="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7.5pt;"><xhtml:span style="font-family:inherit;font-size:7.5pt;">Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan).</xhtml:span><xhtml:span style="font-family:inherit;font-size:7.5pt;"> As a result, revenues associated with our Meridian subsidiary, except for product revenues for EpiPen sold in Canada, and Mylan-Japan, are reported in our Upjohn business beginning in the first quarter of 2020. We have reclassified revenues associated with our Meridian subsidiary and Mylan-Japan from the Hospital and Internal Medicine categories to the Upjohn business to conform 2019 product revenues to the current presentation.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e5505-wk-Fact-02A1D5D7B6684CF717F394757CCC45F0"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e2831-wk-Fact-02FDFD3FA6ACE12CEA1F94757D6D0CCF"
          xlink:label="d8336633e2831-wk-Fact-02FDFD3FA6ACE12CEA1F94757D6D0CCF"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl" xlink:label="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;padding-bottom:266px;padding-left:12px;text-indent:-12px;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e2831-wk-Fact-02FDFD3FA6ACE12CEA1F94757D6D0CCF"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e11406-wk-Fact-0311E1C11EAA0D64120894757D282E1A"
          xlink:label="d8336633e11406-wk-Fact-0311E1C11EAA0D64120894757D282E1A"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e4154-wk-Fact-0311E1C11EAA0D64120894757D282E1A"
          xlink:label="d8336633e4154-wk-Fact-0311E1C11EAA0D64120894757D282E1A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e11406-wk-Fact-0311E1C11EAA0D64120894757D282E1A"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e4154-wk-Fact-0311E1C11EAA0D64120894757D282E1A"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e1634-wk-Fact-03460BEA869B48E0CF7894757D6EE332"
          xlink:label="d8336633e1634-wk-Fact-03460BEA869B48E0CF7894757D6EE332"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e1634-wk-Fact-03460BEA869B48E0CF7894757D6EE332"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8351242e1585-wk-Fact-03AFF2EF3B741A9220ED94757D3DA6D1"
          xlink:label="d8351242e1585-wk-Fact-03AFF2EF3B741A9220ED94757D3DA6D1"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-A2DA5EF7B6FED024F0D494757DBA101E-0-wk-Footnote-A2DA5EF7B6FED024F0D494757DBA101E_lbl" xlink:label="TextSelection-A2DA5EF7B6FED024F0D494757DBA101E-0-wk-Footnote-A2DA5EF7B6FED024F0D494757DBA101E_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">As of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$11.4 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn debt transactions (see </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7D</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">) are invested in money market funds and included in </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">in the condensed consolidated balance sheet.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e1585-wk-Fact-03AFF2EF3B741A9220ED94757D3DA6D1"
          xlink:to="TextSelection-A2DA5EF7B6FED024F0D494757DBA101E-0-wk-Footnote-A2DA5EF7B6FED024F0D494757DBA101E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1231-wk-Fact-03C451138AD2D3E686ED94757CA8870B"
          xlink:label="d8308070e1231-wk-Fact-03C451138AD2D3E686ED94757CA8870B"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl" xlink:label="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;padding-bottom:20px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1231-wk-Fact-03C451138AD2D3E686ED94757CA8870B"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10398-wk-Fact-03DE33E0BDCBEEE2BFF194757D58A455"
          xlink:label="d8415180e10398-wk-Fact-03DE33E0BDCBEEE2BFF194757D58A455"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10398-wk-Fact-03DE33E0BDCBEEE2BFF194757D58A455"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e14487-wk-Fact-0401261FCCFCA256A06E94757CBC98A8"
          xlink:label="d8336633e14487-wk-Fact-0401261FCCFCA256A06E94757CBC98A8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e14487-wk-Fact-0401261FCCFCA256A06E94757CBC98A8"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e6029-wk-Fact-0415E305501AF9B9FFBB94757D23F5EF"
          xlink:label="d8372444e6029-wk-Fact-0415E305501AF9B9FFBB94757D23F5EF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e6029-wk-Fact-0415E305501AF9B9FFBB94757D23F5EF"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e6029-wk-Fact-0415E305501AF9B9FFBB94757D23F5EF"
          xlink:to="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e6029-wk-Fact-0415E305501AF9B9FFBB94757D23F5EF"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e12831-wk-Fact-044F5FDB0329BCA40A6794757CBD27D2"
          xlink:label="d8336633e12831-wk-Fact-044F5FDB0329BCA40A6794757CBD27D2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e12831-wk-Fact-044F5FDB0329BCA40A6794757CBD27D2"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1245-wk-Fact-04615CE3AF3CBC3B5C8794757D5092E9"
          xlink:label="d8340406e1245-wk-Fact-04615CE3AF3CBC3B5C8794757D5092E9"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-04B9B25659DF96CA86BF94757DB5CCE1-0-wk-Footnote-04B9B25659DF96CA86BF94757DB5CCE1_lbl" xlink:label="TextSelection-04B9B25659DF96CA86BF94757DB5CCE1-0-wk-Footnote-04B9B25659DF96CA86BF94757DB5CCE1_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;">Excludes amortization of intangible assets, except as disclosed in </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1245-wk-Fact-04615CE3AF3CBC3B5C8794757D5092E9"
          xlink:to="TextSelection-04B9B25659DF96CA86BF94757DB5CCE1-0-wk-Footnote-04B9B25659DF96CA86BF94757DB5CCE1_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl" xlink:label="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;padding-bottom:53px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;">Amounts may not add due to rounding.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1245-wk-Fact-04615CE3AF3CBC3B5C8794757D5092E9"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10827-wk-Fact-054BF18A0129DBDADDAA94757D7C3D2F"
          xlink:label="d8415180e10827-wk-Fact-054BF18A0129DBDADDAA94757D7C3D2F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10827-wk-Fact-054BF18A0129DBDADDAA94757D7C3D2F"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8351242e7340-wk-Fact-0572F3E504E5D75C810D94757D8292B7"
          xlink:label="d8351242e7340-wk-Fact-0572F3E504E5D75C810D94757D8292B7"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-DA70407E988FF7F4292CB0A472718D04-0-wk-Footnote-DA70407E988FF7F4292CB0A472718D04_lbl" xlink:label="TextSelection-DA70407E988FF7F4292CB0A472718D04-0-wk-Footnote-DA70407E988FF7F4292CB0A472718D04_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">As of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$11.4 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn debt transactions (see </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7D</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">) are invested in money market funds and included in </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">in the condensed consolidated balance sheet.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e7340-wk-Fact-0572F3E504E5D75C810D94757D8292B7"
          xlink:to="TextSelection-DA70407E988FF7F4292CB0A472718D04-0-wk-Footnote-DA70407E988FF7F4292CB0A472718D04_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e3237-wk-Fact-05B58E4BDA3C96C172AE94757D61A5B0"
          xlink:label="d8340406e3237-wk-Fact-05B58E4BDA3C96C172AE94757D61A5B0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8356748e2152-wk-Fact-05B58E4BDA3C96C172AE94757D61A5B0"
          xlink:label="d8356748e2152-wk-Fact-05B58E4BDA3C96C172AE94757D61A5B0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e3237-wk-Fact-05B58E4BDA3C96C172AE94757D61A5B0"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8356748e2152-wk-Fact-05B58E4BDA3C96C172AE94757D61A5B0"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1936-wk-Fact-05DE67BF183EFC3302F894757D673D16"
          xlink:label="d8340406e1936-wk-Fact-05DE67BF183EFC3302F894757D673D16"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8356748e1531-wk-Fact-05DE67BF183EFC3302F894757D673D16"
          xlink:label="d8356748e1531-wk-Fact-05DE67BF183EFC3302F894757D673D16"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1936-wk-Fact-05DE67BF183EFC3302F894757D673D16"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8356748e1531-wk-Fact-05DE67BF183EFC3302F894757D673D16"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8342960e1031-wk-Fact-05F3838F2F88BF0B809094757CC6BB77"
          xlink:label="d8342960e1031-wk-Fact-05F3838F2F88BF0B809094757CC6BB77"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-BA004C096D54F3EE7B8394757DBF9C64-0-wk-Footnote-BA004C096D54F3EE7B8394757DBF9C64_lbl" xlink:label="TextSelection-BA004C096D54F3EE7B8394757DBF9C64-0-wk-Footnote-BA004C096D54F3EE7B8394757DBF9C64_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Included in </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Other noncurrent assets</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">. There are no recoverability issues associated with these amounts.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8342960e1031-wk-Fact-05F3838F2F88BF0B809094757CC6BB77"
          xlink:to="TextSelection-BA004C096D54F3EE7B8394757DBF9C64-0-wk-Footnote-BA004C096D54F3EE7B8394757DBF9C64_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336625e4129-wk-Fact-05F41C05FF959B0D282094757CDBBAC3"
          xlink:label="d8336625e4129-wk-Fact-05F41C05FF959B0D282094757CDBBAC3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8316808e1499-wk-Fact-05F41C05FF959B0D282094757CDBBAC3"
          xlink:label="d8316808e1499-wk-Fact-05F41C05FF959B0D282094757CDBBAC3"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-467F12A5D203A9A15C3A94757DB81B0A-0-wk-Footnote-467F12A5D203A9A15C3A94757DB81B0A_lbl" xlink:label="TextSelection-467F12A5D203A9A15C3A94757DB81B0A-0-wk-Footnote-467F12A5D203A9A15C3A94757DB81B0A_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">The gains in the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">second quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> include, among other things, unrealized gains of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$508 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> related to our investment in Allogene and unrealized gains of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$61 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> related to our investment in BioNTech. The gains in the first six months of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> include, among other things, unrealized gains of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$374 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> related to our investment in Allogene and unrealized gains of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$127 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> related to our investment in BioNTech. The gains in the first six months of 2019 included, among other things, unrealized gains of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$104 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> related to our investment in Cortexyme, Inc. For additional information on investments, see </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7B</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336625e4129-wk-Fact-05F41C05FF959B0D282094757CDBBAC3"
          xlink:to="TextSelection-467F12A5D203A9A15C3A94757DB81B0A-0-wk-Footnote-467F12A5D203A9A15C3A94757DB81B0A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1499-wk-Fact-05F41C05FF959B0D282094757CDBBAC3"
          xlink:to="TextSelection-467F12A5D203A9A15C3A94757DB81B0A-0-wk-Footnote-467F12A5D203A9A15C3A94757DB81B0A_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-9F5C431DBFAA147134E594757DBBC55E-0-wk-Footnote-9F5C431DBFAA147134E594757DBBC55E_lbl" xlink:label="TextSelection-9F5C431DBFAA147134E594757DBBC55E-0-wk-Footnote-9F5C431DBFAA147134E594757DBBC55E_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">The net gains on investments in equity securities are reported in </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (income)/deductions</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">&#x2013;&#x2013;</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">net.</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> For additional information, see </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336625e4129-wk-Fact-05F41C05FF959B0D282094757CDBBAC3"
          xlink:to="TextSelection-9F5C431DBFAA147134E594757DBBC55E-0-wk-Footnote-9F5C431DBFAA147134E594757DBBC55E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1499-wk-Fact-05F41C05FF959B0D282094757CDBBAC3"
          xlink:to="TextSelection-9F5C431DBFAA147134E594757DBBC55E-0-wk-Footnote-9F5C431DBFAA147134E594757DBBC55E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8342313e2012-wk-Fact-0639ADEDE6FCAADD47BB54402D928BD5"
          xlink:label="d8342313e2012-wk-Fact-0639ADEDE6FCAADD47BB54402D928BD5"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-9FA189BA88B1C6F34587B0A6A8B90D7C-0-wk-Footnote-9FA189BA88B1C6F34587B0A6A8B90D7C_lbl" xlink:label="TextSelection-9FA189BA88B1C6F34587B0A6A8B90D7C-0-wk-Footnote-9FA189BA88B1C6F34587B0A6A8B90D7C_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">As of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$11.4 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn debt transactions are invested in money market funds and included in </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">in the condensed consolidated balance sheet.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8342313e2012-wk-Fact-0639ADEDE6FCAADD47BB54402D928BD5"
          xlink:to="TextSelection-9FA189BA88B1C6F34587B0A6A8B90D7C-0-wk-Footnote-9FA189BA88B1C6F34587B0A6A8B90D7C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e2132-wk-Fact-066BFF2F5B504A5CD41294757D064180"
          xlink:label="d8336633e2132-wk-Fact-066BFF2F5B504A5CD41294757D064180"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8301124e2786-wk-Fact-066BFF2F5B504A5CD41294757D064180"
          xlink:label="d8301124e2786-wk-Fact-066BFF2F5B504A5CD41294757D064180"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl" xlink:label="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;padding-bottom:13px;padding-left:12px;text-indent:-12px;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;">Amounts may not add due to rounding.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e2132-wk-Fact-066BFF2F5B504A5CD41294757D064180"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2786-wk-Fact-066BFF2F5B504A5CD41294757D064180"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e2132-wk-Fact-066BFF2F5B504A5CD41294757D064180"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2786-wk-Fact-066BFF2F5B504A5CD41294757D064180"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e15157-wk-Fact-066E69F57B7DF80E550194757D597E52"
          xlink:label="d8336633e15157-wk-Fact-066E69F57B7DF80E550194757D597E52"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e7891-wk-Fact-066E69F57B7DF80E550194757D597E52"
          xlink:label="d8336633e7891-wk-Fact-066E69F57B7DF80E550194757D597E52"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e15157-wk-Fact-066E69F57B7DF80E550194757D597E52"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e7891-wk-Fact-066E69F57B7DF80E550194757D597E52"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e5559-wk-Fact-066F1B2C39D1A83ADDB294757D9EC44C"
          xlink:label="d8415180e5559-wk-Fact-066F1B2C39D1A83ADDB294757D9EC44C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e5559-wk-Fact-066F1B2C39D1A83ADDB294757D9EC44C"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8351242e8332-wk-Fact-06B216BCF27965D7A6A694757D11CF28"
          xlink:label="d8351242e8332-wk-Fact-06B216BCF27965D7A6A694757D11CF28"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8307028e1214-wk-Fact-06B216BCF27965D7A6A694757D11CF28"
          xlink:label="d8307028e1214-wk-Fact-06B216BCF27965D7A6A694757D11CF28"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e8332-wk-Fact-06B216BCF27965D7A6A694757D11CF28"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1214-wk-Fact-06B216BCF27965D7A6A694757D11CF28"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e5769-wk-Fact-070B56B824B87F2A371A94757D18F7F9"
          xlink:label="d8336633e5769-wk-Fact-070B56B824B87F2A371A94757D18F7F9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e5769-wk-Fact-070B56B824B87F2A371A94757D18F7F9"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10714-wk-Fact-07227B9D4AC3775762FA94757CFC4DBE"
          xlink:label="d8415180e10714-wk-Fact-07227B9D4AC3775762FA94757CFC4DBE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10714-wk-Fact-07227B9D4AC3775762FA94757CFC4DBE"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7340-wk-Fact-0739ED261CA0E3B259D394757D5A4733"
          xlink:label="d8415180e7340-wk-Fact-0739ED261CA0E3B259D394757D5A4733"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl" xlink:label="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7.5pt;"><xhtml:span style="font-family:inherit;font-size:7.5pt;">Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. Hospital also includes Pfizer CentreOne</xhtml:span><xhtml:span style="font-family:inherit;font-size:7.5pt;"><xhtml:sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</xhtml:sup></xhtml:span><xhtml:span style="font-family:inherit;font-size:7.5pt;">. All other Hospital primarily includes revenues from legacy Sterile Injectables Pharmaceuticals (SIP) products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in &#x201c;All other Anti-infectives&#x201d;.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7340-wk-Fact-0739ED261CA0E3B259D394757D5A4733"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7340-wk-Fact-0739ED261CA0E3B259D394757D5A4733"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7135-wk-Fact-0746A502EECEDB0C1D9394757D555939"
          xlink:label="d8415180e7135-wk-Fact-0746A502EECEDB0C1D9394757D555939"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7135-wk-Fact-0746A502EECEDB0C1D9394757D555939"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7135-wk-Fact-0746A502EECEDB0C1D9394757D555939"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e11249-wk-Fact-076F89258C6280289A5E94757D34A300"
          xlink:label="d8415180e11249-wk-Fact-076F89258C6280289A5E94757D34A300"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-33990A088D8DAE29233C94757DC283BE-0-wk-Footnote-33990A088D8DAE29233C94757DC283BE_lbl" xlink:label="TextSelection-33990A088D8DAE29233C94757DC283BE-0-wk-Footnote-33990A088D8DAE29233C94757DC283BE_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7.5pt;"><xhtml:span style="font-family:inherit;font-size:7.5pt;">Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e11249-wk-Fact-076F89258C6280289A5E94757D34A300"
          xlink:to="TextSelection-33990A088D8DAE29233C94757DC283BE-0-wk-Footnote-33990A088D8DAE29233C94757DC283BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8357160e2487-wk-Fact-08957AC6DAC01F29518A94757CFC95E1"
          xlink:label="d8357160e2487-wk-Fact-08957AC6DAC01F29518A94757CFC95E1"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-76B1871DA30219820FCB63105DB9E5C3-0-wk-Footnote-76B1871DA30219820FCB63105DB9E5C3_lbl" xlink:label="TextSelection-76B1871DA30219820FCB63105DB9E5C3-0-wk-Footnote-76B1871DA30219820FCB63105DB9E5C3_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">The </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">decrease</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> in </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">I</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;text-align:right;">dentifiable intangible assets, less accumulated amortization</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:right;">, </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">is primarily due to amortization.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e2487-wk-Fact-08957AC6DAC01F29518A94757CFC95E1"
          xlink:to="TextSelection-76B1871DA30219820FCB63105DB9E5C3-0-wk-Footnote-76B1871DA30219820FCB63105DB9E5C3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1507-wk-Fact-08ABD4A7A57B250F299B94757D04A592"
          xlink:label="d8301124e1507-wk-Fact-08ABD4A7A57B250F299B94757D04A592"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1507-wk-Fact-08ABD4A7A57B250F299B94757D04A592"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1546-wk-Fact-08DD19481DA8379F656094757D9154A8"
          xlink:label="d8301124e1546-wk-Fact-08DD19481DA8379F656094757D9154A8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1546-wk-Fact-08DD19481DA8379F656094757D9154A8"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e3323-wk-Fact-08FE59EF359A8EB1141294757D17D52E"
          xlink:label="d8372444e3323-wk-Fact-08FE59EF359A8EB1141294757D17D52E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3323-wk-Fact-08FE59EF359A8EB1141294757D17D52E"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3323-wk-Fact-08FE59EF359A8EB1141294757D17D52E"
          xlink:to="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3323-wk-Fact-08FE59EF359A8EB1141294757D17D52E"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e9074-wk-Fact-099EACAC9FBD97BB278994757CD0F95C"
          xlink:label="d8415180e9074-wk-Fact-099EACAC9FBD97BB278994757CD0F95C"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-FE68345D83BB191130EF94757DC1B5E5-0-wk-Footnote-FE68345D83BB191130EF94757DC1B5E5_lbl" xlink:label="TextSelection-FE68345D83BB191130EF94757DC1B5E5-0-wk-Footnote-FE68345D83BB191130EF94757DC1B5E5_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7.5pt;"><xhtml:span style="font-family:inherit;font-size:7.5pt;">Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e9074-wk-Fact-099EACAC9FBD97BB278994757CD0F95C"
          xlink:to="TextSelection-FE68345D83BB191130EF94757DC1B5E5-0-wk-Footnote-FE68345D83BB191130EF94757DC1B5E5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e2517-wk-Fact-0A439D2D9035C084D32594757D7076B0"
          xlink:label="d8336633e2517-wk-Fact-0A439D2D9035C084D32594757D7076B0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e2517-wk-Fact-0A439D2D9035C084D32594757D7076B0"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e8822-wk-Fact-0A9DF58A6CB5A7F6545994757D8DB53B"
          xlink:label="d8336633e8822-wk-Fact-0A9DF58A6CB5A7F6545994757D8DB53B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e8822-wk-Fact-0A9DF58A6CB5A7F6545994757D8DB53B"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2391-wk-Fact-0AB8223F29C3E844972694757CBD7239"
          xlink:label="d8308070e2391-wk-Fact-0AB8223F29C3E844972694757CBD7239"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2391-wk-Fact-0AB8223F29C3E844972694757CBD7239"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2806-wk-Fact-0AC5548725395D35A56C94757D003303"
          xlink:label="d8301124e2806-wk-Fact-0AC5548725395D35A56C94757D003303"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e5829-wk-Fact-0AC5548725395D35A56C94757D003303"
          xlink:label="d8336633e5829-wk-Fact-0AC5548725395D35A56C94757D003303"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2806-wk-Fact-0AC5548725395D35A56C94757D003303"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e5829-wk-Fact-0AC5548725395D35A56C94757D003303"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2806-wk-Fact-0AC5548725395D35A56C94757D003303"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e5829-wk-Fact-0AC5548725395D35A56C94757D003303"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e10042-wk-Fact-0ACF20D2E36512CA3FFF94757CB9E5D6"
          xlink:label="d8336633e10042-wk-Fact-0ACF20D2E36512CA3FFF94757CB9E5D6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e10042-wk-Fact-0ACF20D2E36512CA3FFF94757CB9E5D6"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8357160e3542-wk-Fact-0B05DCE0E371ABB7EA7494757D52B21E"
          xlink:label="d8357160e3542-wk-Fact-0B05DCE0E371ABB7EA7494757D52B21E"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-2DE900A873C344A165FE94757DBF7A4D-0-wk-Footnote-2DE900A873C344A165FE94757DBF7A4D_lbl" xlink:label="TextSelection-2DE900A873C344A165FE94757DBF7A4D-0-wk-Footnote-2DE900A873C344A165FE94757DBF7A4D_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Primarily represents the impact of foreign exchange.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e3542-wk-Fact-0B05DCE0E371ABB7EA7494757D52B21E"
          xlink:to="TextSelection-2DE900A873C344A165FE94757DBF7A4D-0-wk-Footnote-2DE900A873C344A165FE94757DBF7A4D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7193-wk-Fact-0B2C64A2B5311E2D9BF394757D63AA66"
          xlink:label="d8415180e7193-wk-Fact-0B2C64A2B5311E2D9BF394757D63AA66"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7193-wk-Fact-0B2C64A2B5311E2D9BF394757D63AA66"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7193-wk-Fact-0B2C64A2B5311E2D9BF394757D63AA66"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1720-wk-Fact-0C05260CF79B14B3930694757D1319B9"
          xlink:label="d8307028e1720-wk-Fact-0C05260CF79B14B3930694757D1319B9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1720-wk-Fact-0C05260CF79B14B3930694757D1319B9"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e7738-wk-Fact-0C3EA3961095E3F8A34994757CCEFE8A"
          xlink:label="d8336633e7738-wk-Fact-0C3EA3961095E3F8A34994757CCEFE8A"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e15004-wk-Fact-0C3EA3961095E3F8A34994757CCEFE8A"
          xlink:label="d8336633e15004-wk-Fact-0C3EA3961095E3F8A34994757CCEFE8A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e7738-wk-Fact-0C3EA3961095E3F8A34994757CCEFE8A"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e15004-wk-Fact-0C3EA3961095E3F8A34994757CCEFE8A"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1308-wk-Fact-0C70E0AC22CEB94822F594757CC8BF0F"
          xlink:label="d8316808e1308-wk-Fact-0C70E0AC22CEB94822F594757CC8BF0F"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-CDCE760DEFA7F631840C94757DB86187-0-wk-Footnote-CDCE760DEFA7F631840C94757DB86187_lbl" xlink:label="TextSelection-CDCE760DEFA7F631840C94757DB86187-0-wk-Footnote-CDCE760DEFA7F631840C94757DB86187_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Royalty-related income for the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">second quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">first six months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">2019</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> included a one-time favorable resolution in the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">second quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">2019</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of a legal dispute for </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$82 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1308-wk-Fact-0C70E0AC22CEB94822F594757CC8BF0F"
          xlink:to="TextSelection-CDCE760DEFA7F631840C94757DB86187-0-wk-Footnote-CDCE760DEFA7F631840C94757DB86187_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2881-wk-Fact-0D1CD905D92C101F2A7094757D18615E"
          xlink:label="d8307028e2881-wk-Fact-0D1CD905D92C101F2A7094757D18615E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2881-wk-Fact-0D1CD905D92C101F2A7094757D18615E"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312053e1348-wk-Fact-0D58D4B7AB8E12C40B7994757CE6D530"
          xlink:label="d8312053e1348-wk-Fact-0D58D4B7AB8E12C40B7994757CE6D530"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-9459A99A0EC8DD1CD04094757DBA4F65-0-wk-Footnote-9459A99A0EC8DD1CD04094757DBA4F65_lbl" xlink:label="TextSelection-9459A99A0EC8DD1CD04094757DBA4F65-0-wk-Footnote-9459A99A0EC8DD1CD04094757DBA4F65_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:justify;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$12 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> loss for the first six months of 2020. Includes after-tax </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">losses</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of approximately </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$902 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> related to foreign currency translation adjustments and the impact of our net investment hedging program, both attributable to our equity method investment in GSK Consumer Healthcare (see</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;"> Note 2B</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">), and losses from the weakening of certain major currencies against the U.S. dollar. These </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">losses</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> were partially offset by the results of our net investment hedging program.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312053e1348-wk-Fact-0D58D4B7AB8E12C40B7994757CE6D530"
          xlink:to="TextSelection-9459A99A0EC8DD1CD04094757DBA4F65-0-wk-Footnote-9459A99A0EC8DD1CD04094757DBA4F65_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2101-wk-Fact-0D9B88019461C261B2D994757D33A088"
          xlink:label="d8312059e2101-wk-Fact-0D9B88019461C261B2D994757D33A088"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl" xlink:label="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Additional depreciation&#x2013;&#x2013;asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2101-wk-Fact-0D9B88019461C261B2D994757D33A088"
          xlink:to="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2867-wk-Fact-0DADC806FCB0F8DE89E394757CFF07B6"
          xlink:label="d8340406e2867-wk-Fact-0DADC806FCB0F8DE89E394757CFF07B6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2867-wk-Fact-0DADC806FCB0F8DE89E394757CFF07B6"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e2440-wk-Fact-0DCDEC1F3DFA047B631094757CEF6953"
          xlink:label="d8372444e2440-wk-Fact-0DCDEC1F3DFA047B631094757CEF6953"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-D29E26CC6CF7C6248CEE94757DBD9743-0-wk-Footnote-D29E26CC6CF7C6248CEE94757DBD9743_lbl" xlink:label="TextSelection-D29E26CC6CF7C6248CEE94757DBD9743-0-wk-Footnote-D29E26CC6CF7C6248CEE94757DBD9743_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$5.2 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> as of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$5.9 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> as of December 31, 2019.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e2440-wk-Fact-0DCDEC1F3DFA047B631094757CEF6953"
          xlink:to="TextSelection-D29E26CC6CF7C6248CEE94757DBD9743-0-wk-Footnote-D29E26CC6CF7C6248CEE94757DBD9743_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2848-wk-Fact-0DEB9E1626C9961FC0CB94757D4307A4"
          xlink:label="d8340406e2848-wk-Fact-0DEB9E1626C9961FC0CB94757D4307A4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2848-wk-Fact-0DEB9E1626C9961FC0CB94757D4307A4"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e5858-wk-Fact-0E667667A379AE13037394757D3C7D79"
          xlink:label="d8415180e5858-wk-Fact-0E667667A379AE13037394757D3C7D79"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e5858-wk-Fact-0E667667A379AE13037394757D3C7D79"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e2112-wk-Fact-0EA469F78A7AA9B0154B94757D0F21D4"
          xlink:label="d8336633e2112-wk-Fact-0EA469F78A7AA9B0154B94757D0F21D4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e2112-wk-Fact-0EA469F78A7AA9B0154B94757D0F21D4"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e14137-wk-Fact-0EDCB34EA1247F2C3A2394757D8F0EC3"
          xlink:label="d8336633e14137-wk-Fact-0EDCB34EA1247F2C3A2394757D8F0EC3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e14137-wk-Fact-0EDCB34EA1247F2C3A2394757D8F0EC3"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336625e4284-wk-Fact-0EF563315BCCD33D4EF194757D29687F"
          xlink:label="d8336625e4284-wk-Fact-0EF563315BCCD33D4EF194757D29687F"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-F8EDCEC3C21F54D90F7894757DBBCD6D-0-wk-Footnote-F8EDCEC3C21F54D90F7894757DBBCD6D_lbl" xlink:label="TextSelection-F8EDCEC3C21F54D90F7894757DBBCD6D-0-wk-Footnote-F8EDCEC3C21F54D90F7894757DBBCD6D_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"> &#160;<xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. Since January 1, 2018, there were cumulative impairments and downward adjustments of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$67 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and upward adjustments of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$66 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">. Impairments, downward and upward adjustments were not significant in the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">second quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and the first six months of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">2019</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336625e4284-wk-Fact-0EF563315BCCD33D4EF194757D29687F"
          xlink:to="TextSelection-F8EDCEC3C21F54D90F7894757DBBCD6D-0-wk-Footnote-F8EDCEC3C21F54D90F7894757DBBCD6D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e3554-wk-Fact-0F151736606908F5607394757D16AC47"
          xlink:label="d8372444e3554-wk-Fact-0F151736606908F5607394757D16AC47"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3554-wk-Fact-0F151736606908F5607394757D16AC47"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8357160e1370-wk-Fact-0F2346B28DB4629CBB7594757CCA9BA4"
          xlink:label="d8357160e1370-wk-Fact-0F2346B28DB4629CBB7594757CCA9BA4"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-B511D685B8F037FD258094757DBFC8C5-0-wk-Footnote-B511D685B8F037FD258094757DBFC8C5_lbl" xlink:label="TextSelection-B511D685B8F037FD258094757DBFC8C5-0-wk-Footnote-B511D685B8F037FD258094757DBFC8C5_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">The changes in the gross carrying amount of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Developed technology rights</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">IPR&amp;D</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> primarily reflect the transfer of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$1.4 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> from </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">IPR&amp;D</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> to </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Developed technology rights</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> to reflect the approval of Braftovi in combination with Erbitux</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:sup style="vertical-align:top;line-height:120%;font-size:5pt">&#xae;</xhtml:sup></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> (cetuximab), for the treatment of BRAF</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:sup style="vertical-align:top;line-height:120%;font-size:5pt">V600E</xhtml:sup></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">-mutant metastatic colorectal cancer after prior therapy.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e1370-wk-Fact-0F2346B28DB4629CBB7594757CCA9BA4"
          xlink:to="TextSelection-B511D685B8F037FD258094757DBFC8C5-0-wk-Footnote-B511D685B8F037FD258094757DBFC8C5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1094-wk-Fact-0F4E421B90BAC3CEFBC094757D951011"
          xlink:label="d8340406e1094-wk-Fact-0F4E421B90BAC3CEFBC094757D951011"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1094-wk-Fact-0F4E421B90BAC3CEFBC094757D951011"
          xlink:to="TextSelection-04B9B25659DF96CA86BF94757DB5CCE1-0-wk-Footnote-04B9B25659DF96CA86BF94757DB5CCE1_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1094-wk-Fact-0F4E421B90BAC3CEFBC094757D951011"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8351242e3334-wk-Fact-0FAA0A010479FD1F2D6594757CB8122B"
          xlink:label="d8351242e3334-wk-Fact-0FAA0A010479FD1F2D6594757CB8122B"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-8224B42439E7CCC8C3C594757DBA701B-0-wk-Footnote-8224B42439E7CCC8C3C594757DBA701B_lbl" xlink:label="TextSelection-8224B42439E7CCC8C3C594757DBA701B-0-wk-Footnote-8224B42439E7CCC8C3C594757DBA701B_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">As of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, long-term equity securities of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$163 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and as of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">December&#160;31, 2019</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, long-term equity securities of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$176 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> were held in restricted trusts for benefits attributable to various U.S. non-qualified employee benefit plans.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e3334-wk-Fact-0FAA0A010479FD1F2D6594757CB8122B"
          xlink:to="TextSelection-8224B42439E7CCC8C3C594757DBA701B-0-wk-Footnote-8224B42439E7CCC8C3C594757DBA701B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e3535-wk-Fact-0FE975CFD0CEBAC8988A94757CCB8E12"
          xlink:label="d8372444e3535-wk-Fact-0FE975CFD0CEBAC8988A94757CCB8E12"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3535-wk-Fact-0FE975CFD0CEBAC8988A94757CCB8E12"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10753-wk-Fact-1085284E00DE2A425A0894757DA63E92"
          xlink:label="d8415180e10753-wk-Fact-1085284E00DE2A425A0894757DA63E92"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10753-wk-Fact-1085284E00DE2A425A0894757DA63E92"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2418-wk-Fact-10C0D0D972663C0BC95494757CF12E8C"
          xlink:label="d8312059e2418-wk-Fact-10C0D0D972663C0BC95494757CF12E8C"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl" xlink:label="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2418-wk-Fact-10C0D0D972663C0BC95494757CF12E8C"
          xlink:to="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2083-wk-Fact-10C0D76C934B5C1793A994757D4985D4"
          xlink:label="d8340406e2083-wk-Fact-10C0D76C934B5C1793A994757D4985D4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2083-wk-Fact-10C0D76C934B5C1793A994757D4985D4"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2475-wk-Fact-10EDC1B88A166120EB9394757D13AAEA"
          xlink:label="d8307028e2475-wk-Fact-10EDC1B88A166120EB9394757D13AAEA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2475-wk-Fact-10EDC1B88A166120EB9394757D13AAEA"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e3453-wk-Fact-10F3E77A26DA7DA0E29F94757D3034FC"
          xlink:label="d8415180e3453-wk-Fact-10F3E77A26DA7DA0E29F94757D3034FC"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-9BC3436E7B9C00975CD394757DC16C56-0-wk-Footnote-9BC3436E7B9C00975CD394757DC16C56_lbl" xlink:label="TextSelection-9BC3436E7B9C00975CD394757DC16C56-0-wk-Footnote-9BC3436E7B9C00975CD394757DC16C56_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e3453-wk-Fact-10F3E77A26DA7DA0E29F94757D3034FC"
          xlink:to="TextSelection-9BC3436E7B9C00975CD394757DC16C56-0-wk-Footnote-9BC3436E7B9C00975CD394757DC16C56_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1732-wk-Fact-112070D1A1180C6F8D5194757D199924"
          xlink:label="d8308070e1732-wk-Fact-112070D1A1180C6F8D5194757D199924"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1732-wk-Fact-112070D1A1180C6F8D5194757D199924"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e3553-wk-Fact-112FF7A0087A9422819094757D2BF4D9"
          xlink:label="d8336633e3553-wk-Fact-112FF7A0087A9422819094757D2BF4D9"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl" xlink:label="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">&#160;<xhtml:div style="line-height:120%;text-align:left;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">On May 4, 2020, all outstanding shares of Pfizer&#x2019;s Series A convertible perpetual preferred stock were converted into shares of Pfizer common stock. See </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 11.</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> </xhtml:span><xhtml:span style="font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Equity</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> for additional information.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3553-wk-Fact-112FF7A0087A9422819094757D2BF4D9"
          xlink:to="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3553-wk-Fact-112FF7A0087A9422819094757D2BF4D9"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7912-wk-Fact-1156EEDC3AF7E03F6D9894757D9E9130"
          xlink:label="d8415180e7912-wk-Fact-1156EEDC3AF7E03F6D9894757D9E9130"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7912-wk-Fact-1156EEDC3AF7E03F6D9894757D9E9130"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7912-wk-Fact-1156EEDC3AF7E03F6D9894757D9E9130"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e2237-wk-Fact-115B1B8C87DB19F5829C94757D60A004"
          xlink:label="d8316808e2237-wk-Fact-115B1B8C87DB19F5829C94757D60A004"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8340406e1600-wk-Fact-115B1B8C87DB19F5829C94757D60A004"
          xlink:label="d8340406e1600-wk-Fact-115B1B8C87DB19F5829C94757D60A004"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e2237-wk-Fact-115B1B8C87DB19F5829C94757D60A004"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1600-wk-Fact-115B1B8C87DB19F5829C94757D60A004"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e5253-wk-Fact-11AD19C653F542C874C794757D691F63"
          xlink:label="d8336633e5253-wk-Fact-11AD19C653F542C874C794757D691F63"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e5253-wk-Fact-11AD19C653F542C874C794757D691F63"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e12526-wk-Fact-11CE3C1F979CA5EE8A3C94757CAC8219"
          xlink:label="d8336633e12526-wk-Fact-11CE3C1F979CA5EE8A3C94757CAC8219"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e12526-wk-Fact-11CE3C1F979CA5EE8A3C94757CAC8219"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2141-wk-Fact-1226C5A8B6BDD831984C94757CAB3BF0"
          xlink:label="d8340406e2141-wk-Fact-1226C5A8B6BDD831984C94757CAB3BF0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2141-wk-Fact-1226C5A8B6BDD831984C94757CAB3BF0"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2520-wk-Fact-126B087E9A05FE5529B194757D03D1C9"
          xlink:label="d8301124e2520-wk-Fact-126B087E9A05FE5529B194757D03D1C9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2520-wk-Fact-126B087E9A05FE5529B194757D03D1C9"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2584-wk-Fact-127515899B5DE626CC8194757D3ECA81"
          xlink:label="d8312059e2584-wk-Fact-127515899B5DE626CC8194757D3ECA81"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2584-wk-Fact-127515899B5DE626CC8194757D3ECA81"
          xlink:to="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e14022-wk-Fact-1361821B6A5511EF50EA94757CB26293"
          xlink:label="d8336633e14022-wk-Fact-1361821B6A5511EF50EA94757CB26293"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e14022-wk-Fact-1361821B6A5511EF50EA94757CB26293"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e1479-wk-Fact-1369E6DF1C524EDEE9A694757CC1938A"
          xlink:label="d8372444e1479-wk-Fact-1369E6DF1C524EDEE9A694757CC1938A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e1479-wk-Fact-1369E6DF1C524EDEE9A694757CC1938A"
          xlink:to="TextSelection-D29E26CC6CF7C6248CEE94757DBD9743-0-wk-Footnote-D29E26CC6CF7C6248CEE94757DBD9743_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1221-wk-Fact-137D234567F2A002B07194757D5099CA"
          xlink:label="d8301124e1221-wk-Fact-137D234567F2A002B07194757D5099CA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1221-wk-Fact-137D234567F2A002B07194757D5099CA"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-8C3C45B5D6B304AC979B94757DB5023F-0-wk-Footnote-8C3C45B5D6B304AC979B94757DB5023F_lbl" xlink:label="TextSelection-8C3C45B5D6B304AC979B94757DB5023F-0-wk-Footnote-8C3C45B5D6B304AC979B94757DB5023F_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;">Amounts in the </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">second quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> of 2020 include losses from the weakening of certain major currencies against the U.S. dollar, partially offset by a </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">gain</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> of approximately </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$380 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> pre-tax (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$291 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> after-tax) related to foreign currency translation adjustments and the impact of our net investment hedging program, both attributable to our equity method investment in the GSK Consumer Healthcare joint venture. Amounts in </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">the first six months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> include a </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">loss</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> of approximately </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$1.2 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> pre-tax (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$902 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> after-tax) related to foreign currency translation adjustments and the impact of our net investment hedging program, both attributable to our equity method investment in the GSK Consumer Healthcare joint venture and losses from the weakening of certain major currencies against the U.S. dollar, partially offset by the results of our net investment hedging program. For additional information on the GSK Consumer Healthcare joint venture, see </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 2B</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">. </xhtml:span><xhtml:span style="font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Acquisition, Equity-Method Investment and Licensing Arrangements</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">: </xhtml:span><xhtml:span style="font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Equity-Method Investment</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1221-wk-Fact-137D234567F2A002B07194757D5099CA"
          xlink:to="TextSelection-8C3C45B5D6B304AC979B94757DB5023F-0-wk-Footnote-8C3C45B5D6B304AC979B94757DB5023F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1534-wk-Fact-13980DEBF0DE0B3F0CC794757D1BBA04"
          xlink:label="d8340406e1534-wk-Fact-13980DEBF0DE0B3F0CC794757D1BBA04"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1534-wk-Fact-13980DEBF0DE0B3F0CC794757D1BBA04"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8342313e1993-wk-Fact-13C462C75A1858B9415654402D698FE6"
          xlink:label="d8342313e1993-wk-Fact-13C462C75A1858B9415654402D698FE6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8342313e1993-wk-Fact-13C462C75A1858B9415654402D698FE6"
          xlink:to="TextSelection-9FA189BA88B1C6F34587B0A6A8B90D7C-0-wk-Footnote-9FA189BA88B1C6F34587B0A6A8B90D7C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e2062-wk-Fact-13DB6A96944CAA1A9DE694757CF73050"
          xlink:label="d8316808e2062-wk-Fact-13DB6A96944CAA1A9DE694757CF73050"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-9161826AA31A3194474594757DB9E2CF-0-wk-Footnote-9161826AA31A3194474594757DB9E2CF_lbl" xlink:label="TextSelection-9161826AA31A3194474594757DB9E2CF-0-wk-Footnote-9161826AA31A3194474594757DB9E2CF_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Includes our share of the GSK Consumer Healthcare joint venture&#x2019;s earnings and the amortization of basis differences, which resulted from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the joint venture. See </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 2B</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> for additional information.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e2062-wk-Fact-13DB6A96944CAA1A9DE694757CF73050"
          xlink:to="TextSelection-9161826AA31A3194474594757DB9E2CF-0-wk-Footnote-9161826AA31A3194474594757DB9E2CF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e1939-wk-Fact-13F1515D747E5BC2D79E94757CDD1906"
          xlink:label="d8415180e1939-wk-Fact-13F1515D747E5BC2D79E94757CDD1906"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e1939-wk-Fact-13F1515D747E5BC2D79E94757CDD1906"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336625e2586-wk-Fact-13FB46151EC8E0F07C8894757D671597"
          xlink:label="d8336625e2586-wk-Fact-13FB46151EC8E0F07C8894757D671597"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-83180A323F26770F5F9D94757DBB7831-0-wk-Footnote-83180A323F26770F5F9D94757DBB7831_lbl" xlink:label="TextSelection-83180A323F26770F5F9D94757DBB7831-0-wk-Footnote-83180A323F26770F5F9D94757DBB7831_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Primarily issued by a diverse group of corporations.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336625e2586-wk-Fact-13FB46151EC8E0F07C8894757D671597"
          xlink:to="TextSelection-83180A323F26770F5F9D94757DBB7831-0-wk-Footnote-83180A323F26770F5F9D94757DBB7831_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e6862-wk-Fact-1437F24F4D59D041AD5194757D907B35"
          xlink:label="d8336633e6862-wk-Fact-1437F24F4D59D041AD5194757D907B35"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e6862-wk-Fact-1437F24F4D59D041AD5194757D907B35"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2345-wk-Fact-14555130D0BB52E432C294757D65777B"
          xlink:label="d8308070e2345-wk-Fact-14555130D0BB52E432C294757D65777B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2345-wk-Fact-14555130D0BB52E432C294757D65777B"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e1653-wk-Fact-146CA4CF4749BABED82294757D1CFAEF"
          xlink:label="d8336633e1653-wk-Fact-146CA4CF4749BABED82294757D1CFAEF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e1653-wk-Fact-146CA4CF4749BABED82294757D1CFAEF"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e8139-wk-Fact-146D88A01BA77360B4DB94757DA58B4B"
          xlink:label="d8415180e8139-wk-Fact-146D88A01BA77360B4DB94757DA58B4B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8139-wk-Fact-146D88A01BA77360B4DB94757DA58B4B"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-4F6B4AE2D2C9909DF73D94757DC29A3E-0-wk-Footnote-4F6B4AE2D2C9909DF73D94757DC29A3E_lbl" xlink:label="TextSelection-4F6B4AE2D2C9909DF73D94757DC29A3E-0-wk-Footnote-4F6B4AE2D2C9909DF73D94757DC29A3E_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7.5pt;"><xhtml:span style="font-family:inherit;font-size:7.5pt;">Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8139-wk-Fact-146D88A01BA77360B4DB94757DA58B4B"
          xlink:to="TextSelection-4F6B4AE2D2C9909DF73D94757DC29A3E-0-wk-Footnote-4F6B4AE2D2C9909DF73D94757DC29A3E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8139-wk-Fact-146D88A01BA77360B4DB94757DA58B4B"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10379-wk-Fact-14DC4260C1A11D0782B494757D550824"
          xlink:label="d8415180e10379-wk-Fact-14DC4260C1A11D0782B494757D550824"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10379-wk-Fact-14DC4260C1A11D0782B494757D550824"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e4395-wk-Fact-14DF655044E2528ED8EB94757D99A922"
          xlink:label="d8415180e4395-wk-Fact-14DF655044E2528ED8EB94757D99A922"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-859D29FA558EAC3F73C294757DC172D8-0-wk-Footnote-859D29FA558EAC3F73C294757DC172D8_lbl" xlink:label="TextSelection-859D29FA558EAC3F73C294757DC172D8-0-wk-Footnote-859D29FA558EAC3F73C294757DC172D8_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> Revenues denominated in euros were </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$1.7 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> in the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">second quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$1.8 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> in the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">second quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">2019</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, and were </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$3.2 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> in </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">the first six months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$3.5 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> in </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">the first six months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">2019</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e4395-wk-Fact-14DF655044E2528ED8EB94757D99A922"
          xlink:to="TextSelection-859D29FA558EAC3F73C294757DC172D8-0-wk-Footnote-859D29FA558EAC3F73C294757DC172D8_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1393-wk-Fact-16EB2E72AB574E14B22194757CD34D79"
          xlink:label="d8301124e1393-wk-Fact-16EB2E72AB574E14B22194757CD34D79"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1393-wk-Fact-16EB2E72AB574E14B22194757CD34D79"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e2267-wk-Fact-1769F431190664966C6E94757D75CC58"
          xlink:label="d8415180e2267-wk-Fact-1769F431190664966C6E94757D75CC58"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8415180e4667-wk-Fact-1769F431190664966C6E94757D75CC58"
          xlink:label="d8415180e4667-wk-Fact-1769F431190664966C6E94757D75CC58"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8340406e927-wk-Fact-1769F431190664966C6E94757D75CC58"
          xlink:label="d8340406e927-wk-Fact-1769F431190664966C6E94757D75CC58"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e2267-wk-Fact-1769F431190664966C6E94757D75CC58"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e4667-wk-Fact-1769F431190664966C6E94757D75CC58"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e927-wk-Fact-1769F431190664966C6E94757D75CC58"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e10805-wk-Fact-17964A9D32951C373D6394757D89737D"
          xlink:label="d8336633e10805-wk-Fact-17964A9D32951C373D6394757D89737D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e10805-wk-Fact-17964A9D32951C373D6394757D89737D"
          xlink:to="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e10805-wk-Fact-17964A9D32951C373D6394757D89737D"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2648-wk-Fact-17AFA0CD14201AA75F3794757CE4EBFE"
          xlink:label="d8312059e2648-wk-Fact-17AFA0CD14201AA75F3794757CE4EBFE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2648-wk-Fact-17AFA0CD14201AA75F3794757CE4EBFE"
          xlink:to="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2581-wk-Fact-1891EFA6F636FA196DF794757D4ABF57"
          xlink:label="d8301124e2581-wk-Fact-1891EFA6F636FA196DF794757D4ABF57"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2581-wk-Fact-1891EFA6F636FA196DF794757D4ABF57"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7546-wk-Fact-196CA4F9D93284F17A0194757CFB1334"
          xlink:label="d8415180e7546-wk-Fact-196CA4F9D93284F17A0194757CFB1334"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7546-wk-Fact-196CA4F9D93284F17A0194757CFB1334"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7546-wk-Fact-196CA4F9D93284F17A0194757CFB1334"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e4719-wk-Fact-1987ADB564F749FC403294757D32C9CF"
          xlink:label="d8415180e4719-wk-Fact-1987ADB564F749FC403294757D32C9CF"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8415180e3543-wk-Fact-1987ADB564F749FC403294757D32C9CF"
          xlink:label="d8415180e3543-wk-Fact-1987ADB564F749FC403294757D32C9CF"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8340406e966-wk-Fact-1987ADB564F749FC403294757D32C9CF"
          xlink:label="d8340406e966-wk-Fact-1987ADB564F749FC403294757D32C9CF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e4719-wk-Fact-1987ADB564F749FC403294757D32C9CF"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e3543-wk-Fact-1987ADB564F749FC403294757D32C9CF"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e966-wk-Fact-1987ADB564F749FC403294757D32C9CF"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2519-wk-Fact-19C43A79023CA42B86EA94757D12F049"
          xlink:label="d8307028e2519-wk-Fact-19C43A79023CA42B86EA94757D12F049"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2519-wk-Fact-19C43A79023CA42B86EA94757D12F049"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e6717-wk-Fact-1A182C74458013C503BA94757D323D60"
          xlink:label="d8415180e6717-wk-Fact-1A182C74458013C503BA94757D323D60"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e6717-wk-Fact-1A182C74458013C503BA94757D323D60"
          xlink:to="TextSelection-FE68345D83BB191130EF94757DC1B5E5-0-wk-Footnote-FE68345D83BB191130EF94757DC1B5E5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10808-wk-Fact-1A1E0EDA654D59F9D7FD94757D7CE696"
          xlink:label="d8415180e10808-wk-Fact-1A1E0EDA654D59F9D7FD94757D7CE696"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10808-wk-Fact-1A1E0EDA654D59F9D7FD94757D7CE696"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e9360-wk-Fact-1A38F0D11E57E09F813994757D942D38"
          xlink:label="d8336633e9360-wk-Fact-1A38F0D11E57E09F813994757D942D38"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e9360-wk-Fact-1A38F0D11E57E09F813994757D942D38"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10247-wk-Fact-1A5FECFDC88986C24EF594757D80E29D"
          xlink:label="d8415180e10247-wk-Fact-1A5FECFDC88986C24EF594757D80E29D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10247-wk-Fact-1A5FECFDC88986C24EF594757D80E29D"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2565-wk-Fact-1A602D6AF23843C2BB1894757CDAEB96"
          xlink:label="d8312059e2565-wk-Fact-1A602D6AF23843C2BB1894757CDAEB96"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2565-wk-Fact-1A602D6AF23843C2BB1894757CDAEB96"
          xlink:to="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e1673-wk-Fact-1AB5EE46A517FE80526894757CDD6A28"
          xlink:label="d8312059e1673-wk-Fact-1AB5EE46A517FE80526894757CDD6A28"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-B06D4F08D7061C0CFA5894757DB76AD8-0-wk-Footnote-B06D4F08D7061C0CFA5894757DB76AD8_lbl" xlink:label="TextSelection-B06D4F08D7061C0CFA5894757DB76AD8-0-wk-Footnote-B06D4F08D7061C0CFA5894757DB76AD8_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Integration costs and other represent external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">second quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and first </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">six months</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, integration costs and other were mostly related to our acquisition of Array. In the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">second quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and first </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">six months</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">2019</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, integration costs and other were primarily related to our acquisition of Hospira.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e1673-wk-Fact-1AB5EE46A517FE80526894757CDD6A28"
          xlink:to="TextSelection-B06D4F08D7061C0CFA5894757DB76AD8-0-wk-Footnote-B06D4F08D7061C0CFA5894757DB76AD8_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e3079-wk-Fact-1AC328FD09CA718A54B294757CAD4A93"
          xlink:label="d8301124e3079-wk-Fact-1AC328FD09CA718A54B294757CAD4A93"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e3079-wk-Fact-1AC328FD09CA718A54B294757CAD4A93"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2463-wk-Fact-1AE830A789111962733194757CE1B056"
          xlink:label="d8312059e2463-wk-Fact-1AE830A789111962733194757CE1B056"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2463-wk-Fact-1AE830A789111962733194757CE1B056"
          xlink:to="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e3604-wk-Fact-1B231CD712DFE5467E5994757D88041A"
          xlink:label="d8312059e3604-wk-Fact-1B231CD712DFE5467E5994757D88041A"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-2B5AD3FFF4626D02F1E394757DB79B83-0-wk-Footnote-2B5AD3FFF4626D02F1E394757DB79B83_lbl" xlink:label="TextSelection-2B5AD3FFF4626D02F1E394757DB79B83-0-wk-Footnote-2B5AD3FFF4626D02F1E394757DB79B83_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Included in </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Other current liabilities </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">(</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$625 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">) and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Other noncurrent liabilities </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">(</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$326 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">).</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e3604-wk-Fact-1B231CD712DFE5467E5994757D88041A"
          xlink:to="TextSelection-2B5AD3FFF4626D02F1E394757DB79B83-0-wk-Footnote-2B5AD3FFF4626D02F1E394757DB79B83_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2157-wk-Fact-1BF4E8A74A053F182A6294757CB3BD1E"
          xlink:label="d8301124e2157-wk-Fact-1BF4E8A74A053F182A6294757CB3BD1E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2157-wk-Fact-1BF4E8A74A053F182A6294757CB3BD1E"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10452-wk-Fact-1C3E607A0B96B4E13C6A94757D7DBECB"
          xlink:label="d8415180e10452-wk-Fact-1C3E607A0B96B4E13C6A94757D7DBECB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10452-wk-Fact-1C3E607A0B96B4E13C6A94757D7DBECB"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e6659-wk-Fact-1C41D8D03DE049895B2094757D9C99B7"
          xlink:label="d8415180e6659-wk-Fact-1C41D8D03DE049895B2094757D9C99B7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e6659-wk-Fact-1C41D8D03DE049895B2094757D9C99B7"
          xlink:to="TextSelection-FE68345D83BB191130EF94757DC1B5E5-0-wk-Footnote-FE68345D83BB191130EF94757DC1B5E5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e5579-wk-Fact-1C6897C10CB6E03B97C094757D014B98"
          xlink:label="d8415180e5579-wk-Fact-1C6897C10CB6E03B97C094757D014B98"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e5579-wk-Fact-1C6897C10CB6E03B97C094757D014B98"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2436-wk-Fact-1C81E7C063C3183FB22C94757D26F7B6"
          xlink:label="d8308070e2436-wk-Fact-1C81E7C063C3183FB22C94757D26F7B6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2436-wk-Fact-1C81E7C063C3183FB22C94757D26F7B6"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e4312-wk-Fact-1CECC326E870388701E494757D14ABBF"
          xlink:label="d8372444e4312-wk-Fact-1CECC326E870388701E494757D14ABBF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4312-wk-Fact-1CECC326E870388701E494757D14ABBF"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4312-wk-Fact-1CECC326E870388701E494757D14ABBF"
          xlink:to="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4312-wk-Fact-1CECC326E870388701E494757D14ABBF"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312053e1309-wk-Fact-1D4A2167CADD270AD7B494757CE56E80"
          xlink:label="d8312053e1309-wk-Fact-1D4A2167CADD270AD7B494757CE56E80"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312053e1309-wk-Fact-1D4A2167CADD270AD7B494757CE56E80"
          xlink:to="TextSelection-9459A99A0EC8DD1CD04094757DBA4F65-0-wk-Footnote-9459A99A0EC8DD1CD04094757DBA4F65_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2501-wk-Fact-1D95D82D28060BA3A08A94757CE1514E"
          xlink:label="d8312059e2501-wk-Fact-1D95D82D28060BA3A08A94757CE1514E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2501-wk-Fact-1D95D82D28060BA3A08A94757CE1514E"
          xlink:to="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2482-wk-Fact-1DAA0E1B0E6665C79D5F94757CCA5C7B"
          xlink:label="d8308070e2482-wk-Fact-1DAA0E1B0E6665C79D5F94757CCA5C7B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2482-wk-Fact-1DAA0E1B0E6665C79D5F94757CCA5C7B"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2145-wk-Fact-1DC168387E9062FD753994757D57860A"
          xlink:label="d8307028e2145-wk-Fact-1DC168387E9062FD753994757D57860A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2145-wk-Fact-1DC168387E9062FD753994757D57860A"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e11124-wk-Fact-1E0FA72C88E0180817A294757D917CD7"
          xlink:label="d8336633e11124-wk-Fact-1E0FA72C88E0180817A294757D917CD7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e11124-wk-Fact-1E0FA72C88E0180817A294757D917CD7"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1321-wk-Fact-1E1B5B900670A3CC9D3594757D1F6A23"
          xlink:label="d8307028e1321-wk-Fact-1E1B5B900670A3CC9D3594757D1F6A23"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1321-wk-Fact-1E1B5B900670A3CC9D3594757D1F6A23"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e6746-wk-Fact-1E1B86E2273523F6FBAD94757D16A070"
          xlink:label="d8336633e6746-wk-Fact-1E1B86E2273523F6FBAD94757D16A070"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e6746-wk-Fact-1E1B86E2273523F6FBAD94757D16A070"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e3800-wk-Fact-1E53EA3EE5FA31F56ABC94757CCC7BB4"
          xlink:label="d8372444e3800-wk-Fact-1E53EA3EE5FA31F56ABC94757CCC7BB4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3800-wk-Fact-1E53EA3EE5FA31F56ABC94757CCC7BB4"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2016-wk-Fact-1E7D497146AE795F1C1994757D095745"
          xlink:label="d8301124e2016-wk-Fact-1E7D497146AE795F1C1994757D095745"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2016-wk-Fact-1E7D497146AE795F1C1994757D095745"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8351242e1621-wk-Fact-1EA60045B6EB866A340E94757D49440D"
          xlink:label="d8351242e1621-wk-Fact-1EA60045B6EB866A340E94757D49440D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e1621-wk-Fact-1EA60045B6EB866A340E94757D49440D"
          xlink:to="TextSelection-A2DA5EF7B6FED024F0D494757DBA101E-0-wk-Footnote-A2DA5EF7B6FED024F0D494757DBA101E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e1860-wk-Fact-1EB64412D2D80070B55B94757D5A4E16"
          xlink:label="d8336633e1860-wk-Fact-1EB64412D2D80070B55B94757D5A4E16"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e1860-wk-Fact-1EB64412D2D80070B55B94757D5A4E16"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e11234-wk-Fact-1F784513FF9C94CFD4A694757D890961"
          xlink:label="d8336633e11234-wk-Fact-1F784513FF9C94CFD4A694757D890961"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e11234-wk-Fact-1F784513FF9C94CFD4A694757D890961"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8356748e2345-wk-Fact-1F9015BD5A5A1530EFBA94757D43CEBC"
          xlink:label="d8356748e2345-wk-Fact-1F9015BD5A5A1530EFBA94757D43CEBC"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-6979FD063E456189966A94757DC072A0-0-wk-Footnote-6979FD063E456189966A94757DC072A0_lbl" xlink:label="TextSelection-6979FD063E456189966A94757DC072A0-0-wk-Footnote-6979FD063E456189966A94757DC072A0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8356748e2345-wk-Fact-1F9015BD5A5A1530EFBA94757D43CEBC"
          xlink:to="TextSelection-6979FD063E456189966A94757DC072A0-0-wk-Footnote-6979FD063E456189966A94757DC072A0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e5520-wk-Fact-1FD9113D58C3CC135A9A94757D26E7FF"
          xlink:label="d8336633e5520-wk-Fact-1FD9113D58C3CC135A9A94757D26E7FF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e5520-wk-Fact-1FD9113D58C3CC135A9A94757D26E7FF"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8351242e7321-wk-Fact-1FEE3FFA0E7F81909D6294757D83017E"
          xlink:label="d8351242e7321-wk-Fact-1FEE3FFA0E7F81909D6294757D83017E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e7321-wk-Fact-1FEE3FFA0E7F81909D6294757D83017E"
          xlink:to="TextSelection-DA70407E988FF7F4292CB0A472718D04-0-wk-Footnote-DA70407E988FF7F4292CB0A472718D04_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8342313e1780-wk-Fact-200E77F96A765ED4495194757CB8CCE6"
          xlink:label="d8342313e1780-wk-Fact-200E77F96A765ED4495194757CB8CCE6"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-A197F5EE18ACAFCFDBE294757DBCD32F-0-wk-Footnote-A197F5EE18ACAFCFDBE294757DBCD32F_lbl" xlink:label="TextSelection-A197F5EE18ACAFCFDBE294757DBCD32F-0-wk-Footnote-A197F5EE18ACAFCFDBE294757DBCD32F_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">The notes may be redeemed by us at any time, in whole, or in part, at a redemption price plus accrued and unpaid interest.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8342313e1780-wk-Fact-200E77F96A765ED4495194757CB8CCE6"
          xlink:to="TextSelection-A197F5EE18ACAFCFDBE294757DBCD32F-0-wk-Footnote-A197F5EE18ACAFCFDBE294757DBCD32F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1616-wk-Fact-2024C15FEA8B459878AD94757CF5A215"
          xlink:label="d8316808e1616-wk-Fact-2024C15FEA8B459878AD94757CF5A215"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-16CE381F2099EFC2DA1C94757DB87C39-0-wk-Footnote-16CE381F2099EFC2DA1C94757DB87C39_lbl" xlink:label="TextSelection-16CE381F2099EFC2DA1C94757DB87C39-0-wk-Footnote-16CE381F2099EFC2DA1C94757DB87C39_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">For additional information, see </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 10</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1616-wk-Fact-2024C15FEA8B459878AD94757CF5A215"
          xlink:to="TextSelection-16CE381F2099EFC2DA1C94757DB87C39-0-wk-Footnote-16CE381F2099EFC2DA1C94757DB87C39_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e9848-wk-Fact-208A12CB637A2CA687FC94757D93B898"
          xlink:label="d8336633e9848-wk-Fact-208A12CB637A2CA687FC94757D93B898"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e9848-wk-Fact-208A12CB637A2CA687FC94757D93B898"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e5167-wk-Fact-20A8453F774E2321859294757CD699F4"
          xlink:label="d8336633e5167-wk-Fact-20A8453F774E2321859294757CD699F4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e5167-wk-Fact-20A8453F774E2321859294757CD699F4"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8351242e1566-wk-Fact-20C9854FC8CD379D96E594757D4BB09E"
          xlink:label="d8351242e1566-wk-Fact-20C9854FC8CD379D96E594757D4BB09E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e1566-wk-Fact-20C9854FC8CD379D96E594757D4BB09E"
          xlink:to="TextSelection-A2DA5EF7B6FED024F0D494757DBA101E-0-wk-Footnote-A2DA5EF7B6FED024F0D494757DBA101E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8356748e2403-wk-Fact-2183DCBEF0EE0B13B7AC94757CC13062"
          xlink:label="d8356748e2403-wk-Fact-2183DCBEF0EE0B13B7AC94757CC13062"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8356748e2403-wk-Fact-2183DCBEF0EE0B13B7AC94757CC13062"
          xlink:to="TextSelection-6979FD063E456189966A94757DC072A0-0-wk-Footnote-6979FD063E456189966A94757DC072A0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2278-wk-Fact-2296B04F377E05B8D07C94757D190B3D"
          xlink:label="d8307028e2278-wk-Fact-2296B04F377E05B8D07C94757D190B3D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2278-wk-Fact-2296B04F377E05B8D07C94757D190B3D"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e2092-wk-Fact-2298D4CD7D2F6AE1C57E94757D628353"
          xlink:label="d8336633e2092-wk-Fact-2298D4CD7D2F6AE1C57E94757D628353"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e2092-wk-Fact-2298D4CD7D2F6AE1C57E94757D628353"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e4377-wk-Fact-22F02950F23AAC5E6D9094757CD8334C"
          xlink:label="d8415180e4377-wk-Fact-22F02950F23AAC5E6D9094757CD8334C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e4377-wk-Fact-22F02950F23AAC5E6D9094757CD8334C"
          xlink:to="TextSelection-859D29FA558EAC3F73C294757DC172D8-0-wk-Footnote-859D29FA558EAC3F73C294757DC172D8_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e3643-wk-Fact-22FE89F9AF8C0AF9DC8494757D8695DC"
          xlink:label="d8312059e3643-wk-Fact-22FE89F9AF8C0AF9DC8494757D8695DC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e3643-wk-Fact-22FE89F9AF8C0AF9DC8494757D8695DC"
          xlink:to="TextSelection-2B5AD3FFF4626D02F1E394757DB79B83-0-wk-Footnote-2B5AD3FFF4626D02F1E394757DB79B83_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2120-wk-Fact-2325A2D864C8B2E0F2E194757D22414D"
          xlink:label="d8307028e2120-wk-Fact-2325A2D864C8B2E0F2E194757D22414D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2120-wk-Fact-2325A2D864C8B2E0F2E194757D22414D"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e3204-wk-Fact-23913CAAF810667AF3C194757D16D9A2"
          xlink:label="d8372444e3204-wk-Fact-23913CAAF810667AF3C194757D16D9A2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3204-wk-Fact-23913CAAF810667AF3C194757D16D9A2"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-6EDC28E4739B45A7AA7C94757DBD8D30-0-wk-Footnote-6EDC28E4739B45A7AA7C94757DBD8D30_lbl" xlink:label="TextSelection-6EDC28E4739B45A7AA7C94757DBD8D30-0-wk-Footnote-6EDC28E4739B45A7AA7C94757DBD8D30_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">The amounts reclassified from OCI into COS were:</xhtml:span></xhtml:div><xhtml:table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><xhtml:tr><xhtml:td style="width:24px;"/><xhtml:td/></xhtml:tr><xhtml:tr><xhtml:td style="vertical-align:top"><xhtml:div style="line-height:120%;font-size:8pt;padding-left:12px;"><xhtml:span style="font-family:inherit;font-size:8pt;">&#x2022;</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:top;padding-left:12px;"><xhtml:div style="line-height:120%;font-size:8pt;text-indent:-12px;"><xhtml:span style="font-family:inherit;font-size:8pt;">a net </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">gain</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$80 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> in the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">second quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">;</xhtml:span></xhtml:div></xhtml:td></xhtml:tr></xhtml:table><xhtml:table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><xhtml:tr><xhtml:td style="width:24px;"/><xhtml:td/></xhtml:tr><xhtml:tr><xhtml:td style="vertical-align:top"><xhtml:div style="line-height:120%;font-size:8pt;padding-left:12px;"><xhtml:span style="font-family:inherit;font-size:8pt;">&#x2022;</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:top;padding-left:12px;"><xhtml:div style="line-height:120%;font-size:8pt;text-indent:-12px;"><xhtml:span style="font-family:inherit;font-size:8pt;">a net </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">gain</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$150 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> in the first </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">six months</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">;</xhtml:span></xhtml:div></xhtml:td></xhtml:tr></xhtml:table><xhtml:table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><xhtml:tr><xhtml:td style="width:24px;"/><xhtml:td/></xhtml:tr><xhtml:tr><xhtml:td style="vertical-align:top"><xhtml:div style="line-height:120%;font-size:8pt;padding-left:12px;"><xhtml:span style="font-family:inherit;font-size:8pt;">&#x2022;</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:top;padding-left:12px;"><xhtml:div style="line-height:120%;font-size:8pt;text-indent:-12px;"><xhtml:span style="font-family:inherit;font-size:8pt;">a net </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">gain</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$59 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> in the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">second quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">2019</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">; and</xhtml:span></xhtml:div></xhtml:td></xhtml:tr></xhtml:table><xhtml:table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><xhtml:tr><xhtml:td style="width:24px;"/><xhtml:td/></xhtml:tr><xhtml:tr><xhtml:td style="vertical-align:top"><xhtml:div style="line-height:120%;font-size:8pt;padding-left:12px;"><xhtml:span style="font-family:inherit;font-size:8pt;">&#x2022;</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:top;padding-left:12px;"><xhtml:div style="line-height:120%;font-size:8pt;text-indent:-12px;"><xhtml:span style="font-family:inherit;font-size:8pt;">a net </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">gain</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$103 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> in the first </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">six months</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">2019</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">.</xhtml:span></xhtml:div></xhtml:td></xhtml:tr></xhtml:table><xhtml:div style="line-height:120%;padding-left:12px;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">gain</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$102 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> within the next 12 months into income</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">. </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">The maximum length of time over which we are hedging future foreign exchange cash flow relates to our </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$1.8 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> U.K. pound debt maturing in 2043.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3204-wk-Fact-23913CAAF810667AF3C194757D16D9A2"
          xlink:to="TextSelection-6EDC28E4739B45A7AA7C94757DBD8D30-0-wk-Footnote-6EDC28E4739B45A7AA7C94757DBD8D30_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3204-wk-Fact-23913CAAF810667AF3C194757D16D9A2"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e3563-wk-Fact-239CF4E3D5F1905A2F0794757CB54D24"
          xlink:label="d8415180e3563-wk-Fact-239CF4E3D5F1905A2F0794757CB54D24"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8340406e1704-wk-Fact-239CF4E3D5F1905A2F0794757CB54D24"
          xlink:label="d8340406e1704-wk-Fact-239CF4E3D5F1905A2F0794757CB54D24"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e3563-wk-Fact-239CF4E3D5F1905A2F0794757CB54D24"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1704-wk-Fact-239CF4E3D5F1905A2F0794757CB54D24"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e3563-wk-Fact-239CF4E3D5F1905A2F0794757CB54D24"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1704-wk-Fact-239CF4E3D5F1905A2F0794757CB54D24"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e8191-wk-Fact-23F2FB78F6495A427ED994757D2D3461"
          xlink:label="d8372444e8191-wk-Fact-23F2FB78F6495A427ED994757D2D3461"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e8191-wk-Fact-23F2FB78F6495A427ED994757D2D3461"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e8191-wk-Fact-23F2FB78F6495A427ED994757D2D3461"
          xlink:to="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e8191-wk-Fact-23F2FB78F6495A427ED994757D2D3461"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e8044-wk-Fact-2434BB068F426C5FA43394757D97AF9A"
          xlink:label="d8415180e8044-wk-Fact-2434BB068F426C5FA43394757D97AF9A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8044-wk-Fact-2434BB068F426C5FA43394757D97AF9A"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8044-wk-Fact-2434BB068F426C5FA43394757D97AF9A"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1133-wk-Fact-2457446A2FA3FC6A69CC94757D187F7E"
          xlink:label="d8340406e1133-wk-Fact-2457446A2FA3FC6A69CC94757D187F7E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1133-wk-Fact-2457446A2FA3FC6A69CC94757D187F7E"
          xlink:to="TextSelection-04B9B25659DF96CA86BF94757DB5CCE1-0-wk-Footnote-04B9B25659DF96CA86BF94757DB5CCE1_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1133-wk-Fact-2457446A2FA3FC6A69CC94757D187F7E"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7379-wk-Fact-2460B59E617CE183933A94757CDEE668"
          xlink:label="d8415180e7379-wk-Fact-2460B59E617CE183933A94757CDEE668"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7379-wk-Fact-2460B59E617CE183933A94757CDEE668"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7379-wk-Fact-2460B59E617CE183933A94757CDEE668"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8357160e1410-wk-Fact-24A5AF8F393541B6128994757CD2381D"
          xlink:label="d8357160e1410-wk-Fact-24A5AF8F393541B6128994757CD2381D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e1410-wk-Fact-24A5AF8F393541B6128994757CD2381D"
          xlink:to="TextSelection-B511D685B8F037FD258094757DBFC8C5-0-wk-Footnote-B511D685B8F037FD258094757DBFC8C5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2380-wk-Fact-24B4A8ECAE3E2474912094757CDF68AE"
          xlink:label="d8312059e2380-wk-Fact-24B4A8ECAE3E2474912094757CDF68AE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2380-wk-Fact-24B4A8ECAE3E2474912094757CDF68AE"
          xlink:to="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1307-wk-Fact-24C0070845257F719EAD94757D4D72E4"
          xlink:label="d8301124e1307-wk-Fact-24C0070845257F719EAD94757D4D72E4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1307-wk-Fact-24C0070845257F719EAD94757D4D72E4"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e13748-wk-Fact-24C95C268DFE3FCA16AE94757D94AA45"
          xlink:label="d8336633e13748-wk-Fact-24C95C268DFE3FCA16AE94757D94AA45"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e13748-wk-Fact-24C95C268DFE3FCA16AE94757D94AA45"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e993-wk-Fact-2564D80CF4863AD3560094757D2FB6D5"
          xlink:label="d8307028e993-wk-Fact-2564D80CF4863AD3560094757D2FB6D5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e993-wk-Fact-2564D80CF4863AD3560094757D2FB6D5"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8329819e929-wk-Fact-25892BA475209169BE1A94757D0BD496"
          xlink:label="d8329819e929-wk-Fact-25892BA475209169BE1A94757D0BD496"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-09307D44CBA12BFE03A594757DBC3C9D-0-wk-Footnote-09307D44CBA12BFE03A594757DBC3C9D_lbl" xlink:label="TextSelection-09307D44CBA12BFE03A594757DBC3C9D-0-wk-Footnote-09307D44CBA12BFE03A594757DBC3C9D_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Other short-term borrowings primarily include cash collateral. For additional information, see </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7E</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">. </xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8329819e929-wk-Fact-25892BA475209169BE1A94757D0BD496"
          xlink:to="TextSelection-09307D44CBA12BFE03A594757DBC3C9D-0-wk-Footnote-09307D44CBA12BFE03A594757DBC3C9D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e12546-wk-Fact-25E3F63155D4E5079AF694757D939426"
          xlink:label="d8336633e12546-wk-Fact-25E3F63155D4E5079AF694757D939426"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e12546-wk-Fact-25E3F63155D4E5079AF694757D939426"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e14529-wk-Fact-25E53374D4007C779F5294757D853F4E"
          xlink:label="d8336633e14529-wk-Fact-25E53374D4007C779F5294757D853F4E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e14529-wk-Fact-25E53374D4007C779F5294757D853F4E"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336625e2625-wk-Fact-2617EC9BFAF0558F600394757D657721"
          xlink:label="d8336625e2625-wk-Fact-2617EC9BFAF0558F600394757D657721"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336625e2625-wk-Fact-2617EC9BFAF0558F600394757D657721"
          xlink:to="TextSelection-83180A323F26770F5F9D94757DBB7831-0-wk-Footnote-83180A323F26770F5F9D94757DBB7831_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8314038e1256-wk-Fact-261CF8B516535CC742D694757D9DD941"
          xlink:label="d8314038e1256-wk-Fact-261CF8B516535CC742D694757D9DD941"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-681F29FE9DC6BC582B6D94757DB90D8C-0-wk-Footnote-681F29FE9DC6BC582B6D94757DB90D8C_lbl" xlink:label="TextSelection-681F29FE9DC6BC582B6D94757DB90D8C-0-wk-Footnote-681F29FE9DC6BC582B6D94757DB90D8C_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8314038e1256-wk-Fact-261CF8B516535CC742D694757D9DD941"
          xlink:to="TextSelection-681F29FE9DC6BC582B6D94757DB90D8C-0-wk-Footnote-681F29FE9DC6BC582B6D94757DB90D8C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2426-wk-Fact-263AD80EFD0DF942862794757CB97E50"
          xlink:label="d8340406e2426-wk-Fact-263AD80EFD0DF942862794757CB97E50"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2426-wk-Fact-263AD80EFD0DF942862794757CB97E50"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1303-wk-Fact-267AF4FFCF5DAE94DBAA94757CC00E91"
          xlink:label="d8308070e1303-wk-Fact-267AF4FFCF5DAE94DBAA94757CC00E91"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1303-wk-Fact-267AF4FFCF5DAE94DBAA94757CC00E91"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2046-wk-Fact-267FFBCE28C10DEF50F494757D2204BE"
          xlink:label="d8308070e2046-wk-Fact-267FFBCE28C10DEF50F494757D2204BE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2046-wk-Fact-267FFBCE28C10DEF50F494757D2204BE"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2138-wk-Fact-269B485E7EDA949BAD5F94757D657E36"
          xlink:label="d8308070e2138-wk-Fact-269B485E7EDA949BAD5F94757D657E36"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2138-wk-Fact-269B485E7EDA949BAD5F94757D657E36"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-4E9FC68D27E299B9BB2A92DC4EB2F91A-0-wk-Footnote-4E9FC68D27E299B9BB2A92DC4EB2F91A_lbl" xlink:label="TextSelection-4E9FC68D27E299B9BB2A92DC4EB2F91A-0-wk-Footnote-4E9FC68D27E299B9BB2A92DC4EB2F91A_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Includes </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$11.4 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn long-term debt issuances in the second quarter of 2020, which are included in </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> in the condensed consolidated balance sheet. For additional information, see </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Notes 7A. Financial Instruments: </xhtml:span><xhtml:span style="font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Fair Value Measurements</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Financial Instruments: 7D. </xhtml:span><xhtml:span style="font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Long-Term Debt</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">).</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2138-wk-Fact-269B485E7EDA949BAD5F94757D657E36"
          xlink:to="TextSelection-4E9FC68D27E299B9BB2A92DC4EB2F91A-0-wk-Footnote-4E9FC68D27E299B9BB2A92DC4EB2F91A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8357160e1448-wk-Fact-26C4DDEC9074D8280D9794757CCF8BA1"
          xlink:label="d8357160e1448-wk-Fact-26C4DDEC9074D8280D9794757CCF8BA1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e1448-wk-Fact-26C4DDEC9074D8280D9794757CCF8BA1"
          xlink:to="TextSelection-B511D685B8F037FD258094757DBFC8C5-0-wk-Footnote-B511D685B8F037FD258094757DBFC8C5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1515-wk-Fact-26DE7C056ED7F6339E0F94757D946476"
          xlink:label="d8340406e1515-wk-Fact-26DE7C056ED7F6339E0F94757D946476"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1515-wk-Fact-26DE7C056ED7F6339E0F94757D946476"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e7059-wk-Fact-2723AAC37A7D7F6511E094757D2E3BF6"
          xlink:label="d8372444e7059-wk-Fact-2723AAC37A7D7F6511E094757D2E3BF6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7059-wk-Fact-2723AAC37A7D7F6511E094757D2E3BF6"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7059-wk-Fact-2723AAC37A7D7F6511E094757D2E3BF6"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e4490-wk-Fact-2730F9B3BF2B3A2553D594757D809149"
          xlink:label="d8415180e4490-wk-Fact-2730F9B3BF2B3A2553D594757D809149"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-C185F8237D4ED950685B94757DC105E4-0-wk-Footnote-C185F8237D4ED950685B94757DC105E4_lbl" xlink:label="TextSelection-C185F8237D4ED950685B94757DC105E4-0-wk-Footnote-C185F8237D4ED950685B94757DC105E4_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e4490-wk-Fact-2730F9B3BF2B3A2553D594757D809149"
          xlink:to="TextSelection-C185F8237D4ED950685B94757DC105E4-0-wk-Footnote-C185F8237D4ED950685B94757DC105E4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e1879-wk-Fact-273C64BCA1A40F3A50D394757CD85863"
          xlink:label="d8336633e1879-wk-Fact-273C64BCA1A40F3A50D394757CD85863"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e1879-wk-Fact-273C64BCA1A40F3A50D394757CD85863"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e5672-wk-Fact-28CC293C11C25B9C4E6E94757D8F7B1C"
          xlink:label="d8415180e5672-wk-Fact-28CC293C11C25B9C4E6E94757D8F7B1C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e5672-wk-Fact-28CC293C11C25B9C4E6E94757D8F7B1C"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e7079-wk-Fact-28D2817A0C35A9673F5F94757D2009C5"
          xlink:label="d8372444e7079-wk-Fact-28D2817A0C35A9673F5F94757D2009C5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7079-wk-Fact-28D2817A0C35A9673F5F94757D2009C5"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7079-wk-Fact-28D2817A0C35A9673F5F94757D2009C5"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8351242e4862-wk-Fact-290DB7E326ACD87BB2AE94757D855347"
          xlink:label="d8351242e4862-wk-Fact-290DB7E326ACD87BB2AE94757D855347"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-11358084CF50DEC3FF92628C52236CBA-0-wk-Footnote-11358084CF50DEC3FF92628C52236CBA_lbl" xlink:label="TextSelection-11358084CF50DEC3FF92628C52236CBA-0-wk-Footnote-11358084CF50DEC3FF92628C52236CBA_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Other noncurrent assets include life insurance policies held in restricted trusts attributable to the funding of various U.S. non-qualified employee benefit plans. The underlying invested assets in these insurance contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (income)/deductions</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">&#x2013;&#x2013;</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">net</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> in the condensed consolidated statements of income (see</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;"> Note 4</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">).</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e4862-wk-Fact-290DB7E326ACD87BB2AE94757D855347"
          xlink:to="TextSelection-11358084CF50DEC3FF92628C52236CBA-0-wk-Footnote-11358084CF50DEC3FF92628C52236CBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e2158-wk-Fact-290DFAF3630836A5405894757D92CBB7"
          xlink:label="d8415180e2158-wk-Fact-290DFAF3630836A5405894757D92CBB7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e2158-wk-Fact-290DFAF3630836A5405894757D92CBB7"
          xlink:to="TextSelection-9BC3436E7B9C00975CD394757DC16C56-0-wk-Footnote-9BC3436E7B9C00975CD394757DC16C56_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e3254-wk-Fact-2934BA4BF607819E093694757D2AAA19"
          xlink:label="d8336633e3254-wk-Fact-2934BA4BF607819E093694757D2AAA19"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3254-wk-Fact-2934BA4BF607819E093694757D2AAA19"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2081-wk-Fact-294468E799E3C655921694757D428F2B"
          xlink:label="d8312059e2081-wk-Fact-294468E799E3C655921694757D428F2B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2081-wk-Fact-294468E799E3C655921694757D428F2B"
          xlink:to="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8356748e1102-wk-Fact-2979655C6D134159C89394757D499DAA"
          xlink:label="d8356748e1102-wk-Fact-2979655C6D134159C89394757D499DAA"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8340406e1834-wk-Fact-2979655C6D134159C89394757D499DAA"
          xlink:label="d8340406e1834-wk-Fact-2979655C6D134159C89394757D499DAA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8356748e1102-wk-Fact-2979655C6D134159C89394757D499DAA"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1834-wk-Fact-2979655C6D134159C89394757D499DAA"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e2877-wk-Fact-29D102D394E88CA6D8DC94757D641310"
          xlink:label="d8415180e2877-wk-Fact-29D102D394E88CA6D8DC94757D641310"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e2877-wk-Fact-29D102D394E88CA6D8DC94757D641310"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e6286-wk-Fact-29FB03A603A2B2F710FD94757D2DA0BB"
          xlink:label="d8372444e6286-wk-Fact-29FB03A603A2B2F710FD94757D2DA0BB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e6286-wk-Fact-29FB03A603A2B2F710FD94757D2DA0BB"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1666-wk-Fact-2A0EE9005DC8F1672AF194757D5C8E60"
          xlink:label="d8340406e1666-wk-Fact-2A0EE9005DC8F1672AF194757D5C8E60"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8415180e2287-wk-Fact-2A0EE9005DC8F1672AF194757D5C8E60"
          xlink:label="d8415180e2287-wk-Fact-2A0EE9005DC8F1672AF194757D5C8E60"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1666-wk-Fact-2A0EE9005DC8F1672AF194757D5C8E60"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e2287-wk-Fact-2A0EE9005DC8F1672AF194757D5C8E60"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1666-wk-Fact-2A0EE9005DC8F1672AF194757D5C8E60"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e2287-wk-Fact-2A0EE9005DC8F1672AF194757D5C8E60"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e1502-wk-Fact-2A97CB7CBC5000EECE0F94757CE3B4C8"
          xlink:label="d8312059e1502-wk-Fact-2A97CB7CBC5000EECE0F94757CE3B4C8"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-A2331388F2C895076E3994757DB73022-0-wk-Footnote-A2331388F2C895076E3994757DB73022_lbl" xlink:label="TextSelection-A2331388F2C895076E3994757DB73022-0-wk-Footnote-A2331388F2C895076E3994757DB73022_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">In the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">second quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and first six months of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, restructuring charges mainly represent employee termination costs associated with our Transforming to a More Focused Company cost reduction program. In the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">second quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and first </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">six months</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">2019</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, restructuring credits mostly represent the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of an IRS audit for multiple tax years. See Notes to Consolidated Financial Statements&#x2013;&#x2013;</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 5D. Tax Matters: Tax Contingencies </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">in our 2019 Financial Report.</xhtml:span></xhtml:div><xhtml:div style="line-height:120%;padding-bottom:1px;padding-top:2px;padding-left:24px;text-indent:-12px;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">The restructuring activities for </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> are associated with the following:</xhtml:span></xhtml:div><xhtml:table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><xhtml:tr><xhtml:td style="width:24px;"/><xhtml:td/></xhtml:tr><xhtml:tr><xhtml:td style="vertical-align:top"><xhtml:div style="line-height:120%;font-size:8pt;padding-left:12px;"><xhtml:span style="font-family:inherit;font-size:8pt;">&#x2022;</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:top;"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">For the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">second quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, Biopharma (</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$12 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> credit); Upjohn (</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$1 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> credit); and Other (</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$352 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> charge).</xhtml:span></xhtml:div></xhtml:td></xhtml:tr></xhtml:table><xhtml:table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><xhtml:tr><xhtml:td style="width:24px;"/><xhtml:td/></xhtml:tr><xhtml:tr><xhtml:td style="vertical-align:top"><xhtml:div style="line-height:120%;font-size:8pt;padding-left:12px;"><xhtml:span style="font-family:inherit;font-size:8pt;">&#x2022;</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:top;"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">For the first </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">six months</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, Biopharma (</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$9 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> credit); Upjohn (</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$12 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> charge); and Other (</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$393 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> charge).</xhtml:span></xhtml:div></xhtml:td></xhtml:tr></xhtml:table><xhtml:div style="line-height:120%;padding-bottom:1px;padding-left:12px;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">The restructuring activities for </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">2019</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> are associated with the following:</xhtml:span></xhtml:div><xhtml:table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><xhtml:tr><xhtml:td style="width:24px;"/><xhtml:td/></xhtml:tr><xhtml:tr><xhtml:td style="vertical-align:top"><xhtml:div style="line-height:120%;font-size:8pt;padding-left:12px;"><xhtml:span style="font-family:inherit;font-size:8pt;">&#x2022;</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:top;"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">For the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">second quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">2019</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, Biopharma (</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$62 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> credit); Upjohn (</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$9 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> credit); and Other (</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$74 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> credit).</xhtml:span></xhtml:div></xhtml:td></xhtml:tr></xhtml:table><xhtml:table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><xhtml:tr><xhtml:td style="width:24px;"/><xhtml:td/></xhtml:tr><xhtml:tr><xhtml:td style="vertical-align:top"><xhtml:div style="line-height:120%;font-size:8pt;padding-left:12px;"><xhtml:span style="font-family:inherit;font-size:8pt;">&#x2022;</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:top;"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">For the first </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">six months</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">2019</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, Biopharma (</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$48 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> credit); Upjohn (</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$22 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> credit); and Other (</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$63 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> credit).</xhtml:span></xhtml:div></xhtml:td></xhtml:tr></xhtml:table><xhtml:div style="line-height:120%;padding-left:12px;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Restructuring costs identified as Other are for restructuring activities associated with corporate enabling functions, WRDM, GPD and other manufacturing and commercial operations, as applicable. For the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">second quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and first </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">six months</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, restructuring costs identified as Other primarily relate to corporate enabling functions.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e1502-wk-Fact-2A97CB7CBC5000EECE0F94757CE3B4C8"
          xlink:to="TextSelection-A2331388F2C895076E3994757DB73022-0-wk-Footnote-A2331388F2C895076E3994757DB73022_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e5466-wk-Fact-2AB8FDBDC0EF4D28AFBE94757CD8C9DF"
          xlink:label="d8415180e5466-wk-Fact-2AB8FDBDC0EF4D28AFBE94757CD8C9DF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e5466-wk-Fact-2AB8FDBDC0EF4D28AFBE94757CD8C9DF"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7360-wk-Fact-2AF25534B2A95420B2CC94757D5E2E55"
          xlink:label="d8415180e7360-wk-Fact-2AF25534B2A95420B2CC94757D5E2E55"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7360-wk-Fact-2AF25534B2A95420B2CC94757D5E2E55"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7360-wk-Fact-2AF25534B2A95420B2CC94757D5E2E55"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e9808-wk-Fact-2AFFCF1916589B62C56494757D956455"
          xlink:label="d8336633e9808-wk-Fact-2AFFCF1916589B62C56494757D956455"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e9808-wk-Fact-2AFFCF1916589B62C56494757D956455"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312053e1329-wk-Fact-2B2DFC11DDDCB317D2C994757CE2E0A2"
          xlink:label="d8312053e1329-wk-Fact-2B2DFC11DDDCB317D2C994757CE2E0A2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312053e1329-wk-Fact-2B2DFC11DDDCB317D2C994757CE2E0A2"
          xlink:to="TextSelection-9459A99A0EC8DD1CD04094757DBA4F65-0-wk-Footnote-9459A99A0EC8DD1CD04094757DBA4F65_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e3426-wk-Fact-2B5CC988DB54D9E2126D94757D6035E4"
          xlink:label="d8336633e3426-wk-Fact-2B5CC988DB54D9E2126D94757D6035E4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3426-wk-Fact-2B5CC988DB54D9E2126D94757D6035E4"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7619-wk-Fact-2B65B5D59AAE94EB07C394757D4A2A4B"
          xlink:label="d8415180e7619-wk-Fact-2B65B5D59AAE94EB07C394757D4A2A4B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7619-wk-Fact-2B65B5D59AAE94EB07C394757D4A2A4B"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7619-wk-Fact-2B65B5D59AAE94EB07C394757D4A2A4B"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1749-wk-Fact-2BC7C8565E04B1B2A1F794757D407F8C"
          xlink:label="d8340406e1749-wk-Fact-2BC7C8565E04B1B2A1F794757D407F8C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1749-wk-Fact-2BC7C8565E04B1B2A1F794757D407F8C"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e3064-wk-Fact-2C0450D46BE2A068263194757CADD7DF"
          xlink:label="d8336633e3064-wk-Fact-2C0450D46BE2A068263194757CADD7DF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3064-wk-Fact-2C0450D46BE2A068263194757CADD7DF"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2788-wk-Fact-2C16CBC888D1DBA772D994757D213C35"
          xlink:label="d8307028e2788-wk-Fact-2C16CBC888D1DBA772D994757D213C35"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2788-wk-Fact-2C16CBC888D1DBA772D994757D213C35"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e5186-wk-Fact-2C4A0D66E79C36E0AD3A94757CD125ED"
          xlink:label="d8336633e5186-wk-Fact-2C4A0D66E79C36E0AD3A94757CD125ED"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e5186-wk-Fact-2C4A0D66E79C36E0AD3A94757CD125ED"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e4351-wk-Fact-2C546F3214B511F790B394757D11B2FB"
          xlink:label="d8372444e4351-wk-Fact-2C546F3214B511F790B394757D11B2FB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4351-wk-Fact-2C546F3214B511F790B394757D11B2FB"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4351-wk-Fact-2C546F3214B511F790B394757D11B2FB"
          xlink:to="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4351-wk-Fact-2C546F3214B511F790B394757D11B2FB"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8351242e4784-wk-Fact-2C55CE6AF1C796A4ED5994757D51DA44"
          xlink:label="d8351242e4784-wk-Fact-2C55CE6AF1C796A4ED5994757D51DA44"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e4784-wk-Fact-2C55CE6AF1C796A4ED5994757D51DA44"
          xlink:to="TextSelection-11358084CF50DEC3FF92628C52236CBA-0-wk-Footnote-11358084CF50DEC3FF92628C52236CBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e6896-wk-Fact-2C8B37C90E999E0983A494757D3A0FE2"
          xlink:label="d8336633e6896-wk-Fact-2C8B37C90E999E0983A494757D3A0FE2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e6896-wk-Fact-2C8B37C90E999E0983A494757D3A0FE2"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e4344-wk-Fact-2CF63F468B7D0CABA3CE94757D561921"
          xlink:label="d8415180e4344-wk-Fact-2CF63F468B7D0CABA3CE94757D561921"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e4344-wk-Fact-2CF63F468B7D0CABA3CE94757D561921"
          xlink:to="TextSelection-859D29FA558EAC3F73C294757DC172D8-0-wk-Footnote-859D29FA558EAC3F73C294757DC172D8_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e13513-wk-Fact-2D5D0BDDCB3AC167E0BC94757D826702"
          xlink:label="d8336633e13513-wk-Fact-2D5D0BDDCB3AC167E0BC94757D826702"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e13513-wk-Fact-2D5D0BDDCB3AC167E0BC94757D826702"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336625e2702-wk-Fact-2D9E3E8DD330C83B27D894757D6B6917"
          xlink:label="d8336625e2702-wk-Fact-2D9E3E8DD330C83B27D894757D6B6917"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336625e2702-wk-Fact-2D9E3E8DD330C83B27D894757D6B6917"
          xlink:to="TextSelection-83180A323F26770F5F9D94757DBB7831-0-wk-Footnote-83180A323F26770F5F9D94757DBB7831_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2546-wk-Fact-2DA0B9B079BAAF2177CF94757CDF2206"
          xlink:label="d8312059e2546-wk-Fact-2DA0B9B079BAAF2177CF94757CDF2206"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2546-wk-Fact-2DA0B9B079BAAF2177CF94757CDF2206"
          xlink:to="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372420e5823-wk-Fact-2DB662656B0870E5C58B94757D7A7265"
          xlink:label="d8372420e5823-wk-Fact-2DB662656B0870E5C58B94757D7A7265"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-286F4719195A28A9913594757DC0B1B8-0-wk-Footnote-286F4719195A28A9913594757DC0B1B8_lbl" xlink:label="TextSelection-286F4719195A28A9913594757DC0B1B8-0-wk-Footnote-286F4719195A28A9913594757DC0B1B8_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Contributions expected to be made for </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> are inclusive of amounts contributed during the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">six months ended June 28, 2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">. The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments. For the U.S. qualified plans, we plan to make a </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$1.25 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> voluntary contribution in the second half of 2020.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372420e5823-wk-Fact-2DB662656B0870E5C58B94757D7A7265"
          xlink:to="TextSelection-286F4719195A28A9913594757DC0B1B8-0-wk-Footnote-286F4719195A28A9913594757DC0B1B8_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1440-wk-Fact-2DD85B64A9010E6C213294757D013277"
          xlink:label="d8301124e1440-wk-Fact-2DD85B64A9010E6C213294757D013277"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1440-wk-Fact-2DD85B64A9010E6C213294757D013277"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-A6080F3BC2CE36268D0F94757DB590DE-0-wk-Footnote-A6080F3BC2CE36268D0F94757DB590DE_lbl" xlink:label="TextSelection-A6080F3BC2CE36268D0F94757DB590DE-0-wk-Footnote-A6080F3BC2CE36268D0F94757DB590DE_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;">Reclassified into </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions&#x2014;net </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">and </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> in the condensed consolidated statements of income. For additional information on amounts reclassified into </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions&#x2014;net </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">and </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">, see </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 7E. Financial Instruments: Derivative Financial Instruments and Hedging Activities.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1440-wk-Fact-2DD85B64A9010E6C213294757D013277"
          xlink:to="TextSelection-A6080F3BC2CE36268D0F94757DB590DE-0-wk-Footnote-A6080F3BC2CE36268D0F94757DB590DE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e8158-wk-Fact-2E372A7C63982BD2808894757D9722C9"
          xlink:label="d8415180e8158-wk-Fact-2E372A7C63982BD2808894757D9722C9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8158-wk-Fact-2E372A7C63982BD2808894757D9722C9"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8158-wk-Fact-2E372A7C63982BD2808894757D9722C9"
          xlink:to="TextSelection-4F6B4AE2D2C9909DF73D94757DC29A3E-0-wk-Footnote-4F6B4AE2D2C9909DF73D94757DC29A3E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8158-wk-Fact-2E372A7C63982BD2808894757D9722C9"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2679-wk-Fact-2E87EA97E71121C08FCB94757D27917E"
          xlink:label="d8307028e2679-wk-Fact-2E87EA97E71121C08FCB94757D27917E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2679-wk-Fact-2E87EA97E71121C08FCB94757D27917E"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2220-wk-Fact-2EE2705D1EB743C59AA194757CB0642B"
          xlink:label="d8301124e2220-wk-Fact-2EE2705D1EB743C59AA194757CB0642B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2220-wk-Fact-2EE2705D1EB743C59AA194757CB0642B"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e3053-wk-Fact-2F018DCBB03DFD12F06194757D0FC6D9"
          xlink:label="d8340406e3053-wk-Fact-2F018DCBB03DFD12F06194757D0FC6D9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e3053-wk-Fact-2F018DCBB03DFD12F06194757D0FC6D9"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e3033-wk-Fact-2F0D93C254F8FED5D44E94757CFAFADA"
          xlink:label="d8340406e3033-wk-Fact-2F0D93C254F8FED5D44E94757CFAFADA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e3033-wk-Fact-2F0D93C254F8FED5D44E94757CFAFADA"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1549-wk-Fact-2F3BC9DA02E9792A81E594757D1AA1BE"
          xlink:label="d8308070e1549-wk-Fact-2F3BC9DA02E9792A81E594757D1AA1BE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1549-wk-Fact-2F3BC9DA02E9792A81E594757D1AA1BE"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e5220-wk-Fact-2F4D955985202F933AFB94757DA34DE9"
          xlink:label="d8336633e5220-wk-Fact-2F4D955985202F933AFB94757DA34DE9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e5220-wk-Fact-2F4D955985202F933AFB94757DA34DE9"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2775-wk-Fact-2F748880967716EA5ADE94757D1C1B2D"
          xlink:label="d8308070e2775-wk-Fact-2F748880967716EA5ADE94757D1C1B2D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2775-wk-Fact-2F748880967716EA5ADE94757D1C1B2D"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2229-wk-Fact-2F9D078A1939922E232F94757CC0E69B"
          xlink:label="d8308070e2229-wk-Fact-2F9D078A1939922E232F94757CC0E69B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2229-wk-Fact-2F9D078A1939922E232F94757CC0E69B"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e1440-wk-Fact-2FCF66786C77668C7F1694757CC07AEE"
          xlink:label="d8372444e1440-wk-Fact-2FCF66786C77668C7F1694757CC07AEE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e1440-wk-Fact-2FCF66786C77668C7F1694757CC07AEE"
          xlink:to="TextSelection-D29E26CC6CF7C6248CEE94757DBD9743-0-wk-Footnote-D29E26CC6CF7C6248CEE94757DBD9743_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2043-wk-Fact-2FD155A9458FEA78C7F194757CE25240"
          xlink:label="d8312059e2043-wk-Fact-2FD155A9458FEA78C7F194757CE25240"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2043-wk-Fact-2FD155A9458FEA78C7F194757CE25240"
          xlink:to="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10173-wk-Fact-30038D93D81522EF2C4494757CB8E85E"
          xlink:label="d8415180e10173-wk-Fact-30038D93D81522EF2C4494757CB8E85E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10173-wk-Fact-30038D93D81522EF2C4494757CB8E85E"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e4532-wk-Fact-30276A818E374D50F86494757D58EE99"
          xlink:label="d8415180e4532-wk-Fact-30276A818E374D50F86494757D58EE99"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-AFB627DC6F652A9A0A0594757DC251B0-0-wk-Footnote-AFB627DC6F652A9A0A0594757DC251B0_lbl" xlink:label="TextSelection-AFB627DC6F652A9A0A0594757DC251B0-0-wk-Footnote-AFB627DC6F652A9A0A0594757DC251B0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e4532-wk-Fact-30276A818E374D50F86494757D58EE99"
          xlink:to="TextSelection-AFB627DC6F652A9A0A0594757DC251B0-0-wk-Footnote-AFB627DC6F652A9A0A0594757DC251B0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e5856-wk-Fact-30F55F47EE0BC5CF4FF794757D0F23CF"
          xlink:label="d8372444e5856-wk-Fact-30F55F47EE0BC5CF4FF794757D0F23CF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5856-wk-Fact-30F55F47EE0BC5CF4FF794757D0F23CF"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5856-wk-Fact-30F55F47EE0BC5CF4FF794757D0F23CF"
          xlink:to="TextSelection-6EDC28E4739B45A7AA7C94757DBD8D30-0-wk-Footnote-6EDC28E4739B45A7AA7C94757DBD8D30_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5856-wk-Fact-30F55F47EE0BC5CF4FF794757D0F23CF"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2906-wk-Fact-31ABED2FAA0C5EDD3D7994757D5F8CB1"
          xlink:label="d8340406e2906-wk-Fact-31ABED2FAA0C5EDD3D7994757D5F8CB1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2906-wk-Fact-31ABED2FAA0C5EDD3D7994757D5F8CB1"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1701-wk-Fact-31B843C71D5C57C7970294757D210FDA"
          xlink:label="d8307028e1701-wk-Fact-31B843C71D5C57C7970294757D210FDA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1701-wk-Fact-31B843C71D5C57C7970294757D210FDA"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1140-wk-Fact-31FAC3AF75C5A095FC3294757D6F298C"
          xlink:label="d8308070e1140-wk-Fact-31FAC3AF75C5A095FC3294757D6F298C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1140-wk-Fact-31FAC3AF75C5A095FC3294757D6F298C"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e14099-wk-Fact-3217AF55C96F288D0DBD94757CBAA3B1"
          xlink:label="d8336633e14099-wk-Fact-3217AF55C96F288D0DBD94757CBAA3B1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e14099-wk-Fact-3217AF55C96F288D0DBD94757CBAA3B1"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2386-wk-Fact-324F49A292903AEB38B894757D2BD1AB"
          xlink:label="d8307028e2386-wk-Fact-324F49A292903AEB38B894757D2BD1AB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2386-wk-Fact-324F49A292903AEB38B894757D2BD1AB"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8351242e1603-wk-Fact-32BCE63F2B148B65B2BD94757D4ABD8F"
          xlink:label="d8351242e1603-wk-Fact-32BCE63F2B148B65B2BD94757D4ABD8F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e1603-wk-Fact-32BCE63F2B148B65B2BD94757D4ABD8F"
          xlink:to="TextSelection-A2DA5EF7B6FED024F0D494757DBA101E-0-wk-Footnote-A2DA5EF7B6FED024F0D494757DBA101E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e3243-wk-Fact-32E4A4F33D07CCC35B5994757D24CC85"
          xlink:label="d8372444e3243-wk-Fact-32E4A4F33D07CCC35B5994757D24CC85"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3243-wk-Fact-32E4A4F33D07CCC35B5994757D24CC85"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3243-wk-Fact-32E4A4F33D07CCC35B5994757D24CC85"
          xlink:to="TextSelection-6EDC28E4739B45A7AA7C94757DBD8D30-0-wk-Footnote-6EDC28E4739B45A7AA7C94757DBD8D30_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3243-wk-Fact-32E4A4F33D07CCC35B5994757D24CC85"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e5973-wk-Fact-334697846783F070800594757CEB5638"
          xlink:label="d8372444e5973-wk-Fact-334697846783F070800594757CEB5638"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5973-wk-Fact-334697846783F070800594757CEB5638"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5973-wk-Fact-334697846783F070800594757CEB5638"
          xlink:to="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5973-wk-Fact-334697846783F070800594757CEB5638"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e9938-wk-Fact-3383068A828B707166B194757D4D0A42"
          xlink:label="d8415180e9938-wk-Fact-3383068A828B707166B194757D4D0A42"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e9938-wk-Fact-3383068A828B707166B194757D4D0A42"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e8242-wk-Fact-338E913FDA175BCEBC1794757D8FAE73"
          xlink:label="d8372444e8242-wk-Fact-338E913FDA175BCEBC1794757D8FAE73"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e8242-wk-Fact-338E913FDA175BCEBC1794757D8FAE73"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e2217-wk-Fact-33B4F9AF3A76075CF90094757CD1C085"
          xlink:label="d8415180e2217-wk-Fact-33B4F9AF3A76075CF90094757CD1C085"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e2217-wk-Fact-33B4F9AF3A76075CF90094757CD1C085"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e2217-wk-Fact-33B4F9AF3A76075CF90094757CD1C085"
          xlink:to="TextSelection-9BC3436E7B9C00975CD394757DC16C56-0-wk-Footnote-9BC3436E7B9C00975CD394757DC16C56_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2521-wk-Fact-33CF13183D5E3D8446A994757CD4AE22"
          xlink:label="d8312059e2521-wk-Fact-33CF13183D5E3D8446A994757CD4AE22"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2521-wk-Fact-33CF13183D5E3D8446A994757CD4AE22"
          xlink:to="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e1568-wk-Fact-348F989B829127D79CF794757D4C6631"
          xlink:label="d8312059e1568-wk-Fact-348F989B829127D79CF794757D4C6631"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-AB3DF04F3446139615AC94757DB7D909-0-wk-Footnote-AB3DF04F3446139615AC94757DB7D909_lbl" xlink:label="TextSelection-AB3DF04F3446139615AC94757DB7D909-0-wk-Footnote-AB3DF04F3446139615AC94757DB7D909_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Transaction costs represent external costs for banking, legal, accounting and other similar services.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e1568-wk-Fact-348F989B829127D79CF794757D4C6631"
          xlink:to="TextSelection-AB3DF04F3446139615AC94757DB7D909-0-wk-Footnote-AB3DF04F3446139615AC94757DB7D909_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1158-wk-Fact-3499C6CE8F54FB430EAD94757D6E3CBC"
          xlink:label="d8316808e1158-wk-Fact-3499C6CE8F54FB430EAD94757D6E3CBC"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-4E74A09462C596E2363694757DB8EB14-0-wk-Footnote-4E74A09462C596E2363694757DB8EB14_lbl" xlink:label="TextSelection-4E74A09462C596E2363694757DB8EB14-0-wk-Footnote-4E74A09462C596E2363694757DB8EB14_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family:inherit;font-size:8pt;">Interest income decreased in the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">second quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and first six months of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, primarily driven by a lower investment balance and lower short-term interest rates. Interest expense decreased in the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">second quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> mainly as a result of the retirement of higher-coupon debt and the issuance of new debt with a lower coupon than the debt outstanding for the comparative prior year period. Interest expense increased in the first six months of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">2020</xhtml:span>, mainly as a result of an increased commercial paper balance due to the acquisition of Array.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1158-wk-Fact-3499C6CE8F54FB430EAD94757D6E3CBC"
          xlink:to="TextSelection-4E74A09462C596E2363694757DB8EB14-0-wk-Footnote-4E74A09462C596E2363694757DB8EB14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e9767-wk-Fact-34BB026C07BB62277DBC94757CB6F69E"
          xlink:label="d8336633e9767-wk-Fact-34BB026C07BB62277DBC94757CB6F69E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e9767-wk-Fact-34BB026C07BB62277DBC94757CB6F69E"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e2042-wk-Fact-3502C1166F5ABE6DC55E94757CCC6B1B"
          xlink:label="d8316808e2042-wk-Fact-3502C1166F5ABE6DC55E94757CCC6B1B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e2042-wk-Fact-3502C1166F5ABE6DC55E94757CCC6B1B"
          xlink:to="TextSelection-9161826AA31A3194474594757DB9E2CF-0-wk-Footnote-9161826AA31A3194474594757DB9E2CF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1933-wk-Fact-3508D42A7ED6A8C436DE94757D080CE2"
          xlink:label="d8301124e1933-wk-Fact-3508D42A7ED6A8C436DE94757D080CE2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1933-wk-Fact-3508D42A7ED6A8C436DE94757D080CE2"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e12472-wk-Fact-354E12AEFC04C5034D5B94757D921C80"
          xlink:label="d8336633e12472-wk-Fact-354E12AEFC04C5034D5B94757D921C80"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e12472-wk-Fact-354E12AEFC04C5034D5B94757D921C80"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-354E4103E704EECCE02B94757CDB72E6-wk-Fact-354E4103E704EECCE02B94757CDB72E6"
          xlink:label="Fact-354E4103E704EECCE02B94757CDB72E6-wk-Fact-354E4103E704EECCE02B94757CDB72E6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-354E4103E704EECCE02B94757CDB72E6-wk-Fact-354E4103E704EECCE02B94757CDB72E6"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10286-wk-Fact-358A86952AF68F57BF8A94757D2D05E3"
          xlink:label="d8415180e10286-wk-Fact-358A86952AF68F57BF8A94757D2D05E3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10286-wk-Fact-358A86952AF68F57BF8A94757D2D05E3"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372420e5803-wk-Fact-35AE4CA011AF5ED4C8B994757D74E218"
          xlink:label="d8372420e5803-wk-Fact-35AE4CA011AF5ED4C8B994757D74E218"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372420e5803-wk-Fact-35AE4CA011AF5ED4C8B994757D74E218"
          xlink:to="TextSelection-286F4719195A28A9913594757DC0B1B8-0-wk-Footnote-286F4719195A28A9913594757DC0B1B8_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e2217-wk-Fact-361AD8CFC0B46CF2632394757D0A716D"
          xlink:label="d8316808e2217-wk-Fact-361AD8CFC0B46CF2632394757D0A716D"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8340406e1580-wk-Fact-361AD8CFC0B46CF2632394757D0A716D"
          xlink:label="d8340406e1580-wk-Fact-361AD8CFC0B46CF2632394757D0A716D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e2217-wk-Fact-361AD8CFC0B46CF2632394757D0A716D"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1580-wk-Fact-361AD8CFC0B46CF2632394757D0A716D"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e4247-wk-Fact-366496A263381BEBAC8094757D116F08"
          xlink:label="d8372444e4247-wk-Fact-366496A263381BEBAC8094757D116F08"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4247-wk-Fact-366496A263381BEBAC8094757D116F08"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4247-wk-Fact-366496A263381BEBAC8094757D116F08"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e6766-wk-Fact-36A1278749B1A6EBD0EE94757D199E89"
          xlink:label="d8336633e6766-wk-Fact-36A1278749B1A6EBD0EE94757D199E89"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e6766-wk-Fact-36A1278749B1A6EBD0EE94757D199E89"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e9068-wk-Fact-36E7CFCCB407CFADF4BD94757D88D126"
          xlink:label="d8336633e9068-wk-Fact-36E7CFCCB407CFADF4BD94757D88D126"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e9068-wk-Fact-36E7CFCCB407CFADF4BD94757D88D126"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10847-wk-Fact-371E5DEB4BB6100754FB94757DA1FAFE"
          xlink:label="d8415180e10847-wk-Fact-371E5DEB4BB6100754FB94757DA1FAFE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10847-wk-Fact-371E5DEB4BB6100754FB94757DA1FAFE"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e3662-wk-Fact-372F8BB1048027009D0C94757D85F7F7"
          xlink:label="d8312059e3662-wk-Fact-372F8BB1048027009D0C94757D85F7F7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e3662-wk-Fact-372F8BB1048027009D0C94757D85F7F7"
          xlink:to="TextSelection-2B5AD3FFF4626D02F1E394757DB79B83-0-wk-Footnote-2B5AD3FFF4626D02F1E394757DB79B83_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2651-wk-Fact-375CE2F1DA250039888894757D5B5BA6"
          xlink:label="d8340406e2651-wk-Fact-375CE2F1DA250039888894757D5B5BA6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2651-wk-Fact-375CE2F1DA250039888894757D5B5BA6"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e3571-wk-Fact-3796F5D99D503A9EF47494757D899973"
          xlink:label="d8312059e3571-wk-Fact-3796F5D99D503A9EF47494757D899973"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-823D9AE8DB976ECBCA9594757DB72C08-0-wk-Footnote-823D9AE8DB976ECBCA9594757DB72C08_lbl" xlink:label="TextSelection-823D9AE8DB976ECBCA9594757DB72C08-0-wk-Footnote-823D9AE8DB976ECBCA9594757DB72C08_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Includes adjustments for foreign currency translation.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e3571-wk-Fact-3796F5D99D503A9EF47494757D899973"
          xlink:to="TextSelection-823D9AE8DB976ECBCA9594757DB72C08-0-wk-Footnote-823D9AE8DB976ECBCA9594757DB72C08_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e3293-wk-Fact-382681D10D85986FB7E894757D20CDB3"
          xlink:label="d8336633e3293-wk-Fact-382681D10D85986FB7E894757D20CDB3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3293-wk-Fact-382681D10D85986FB7E894757D20CDB3"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e5447-wk-Fact-38BF97B5966F919766EC94757CA703FC"
          xlink:label="d8415180e5447-wk-Fact-38BF97B5966F919766EC94757CA703FC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e5447-wk-Fact-38BF97B5966F919766EC94757CA703FC"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1588-wk-Fact-38DB99ED289778FC0EC794757CF0235A"
          xlink:label="d8316808e1588-wk-Fact-38DB99ED289778FC0EC794757CF0235A"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-1DD42ADAC2DF4C519E7594757DB84698-0-wk-Footnote-1DD42ADAC2DF4C519E7594757DB84698_lbl" xlink:label="TextSelection-1DD42ADAC2DF4C519E7594757DB84698-0-wk-Footnote-1DD42ADAC2DF4C519E7594757DB84698_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">second</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> quarter and first six months of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, mainly includes, among other things, </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$40 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of milestone income from Puma Biotechnology, Inc. related to Neratinib regulatory approvals in the EU, and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$30 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of milestone income from Lilly related to the first commercial sale in the U.S. of LOXO-292 for the treatment of RET fusion-positive NSCLC. The first </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">six months</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> also includes an upfront payment to us of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$75 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> from our sale of our CK1 assets to Biogen, Inc. In the first six months of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">2019</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, primarily included </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$68 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> in milestone income from Mylan Pharmaceuticals Inc. related to the FDA&#x2019;s approval and launch of Wixela Inhub</xhtml:span><xhtml:span style="font-family:inherit;font-size:7.5pt;"><xhtml:sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</xhtml:sup></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, a generic of Advair Diskus</xhtml:span><xhtml:span style="font-family:inherit;font-size:7.5pt;"><xhtml:sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</xhtml:sup></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1588-wk-Fact-38DB99ED289778FC0EC794757CF0235A"
          xlink:to="TextSelection-1DD42ADAC2DF4C519E7594757DB84698-0-wk-Footnote-1DD42ADAC2DF4C519E7594757DB84698_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2018-wk-Fact-392A8B2D61CA7072524094757D40CAB7"
          xlink:label="d8312059e2018-wk-Fact-392A8B2D61CA7072524094757D40CAB7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2018-wk-Fact-392A8B2D61CA7072524094757D40CAB7"
          xlink:to="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1593-wk-Fact-3983BB3504AC4457A05494757D01EDF0"
          xlink:label="d8301124e1593-wk-Fact-3983BB3504AC4457A05494757D01EDF0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1593-wk-Fact-3983BB3504AC4457A05494757D01EDF0"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7453-wk-Fact-399031A0BA1EB364EEE6955D6DD9525C"
          xlink:label="d8415180e7453-wk-Fact-399031A0BA1EB364EEE6955D6DD9525C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7453-wk-Fact-399031A0BA1EB364EEE6955D6DD9525C"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7453-wk-Fact-399031A0BA1EB364EEE6955D6DD9525C"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e11466-wk-Fact-39B247651891576D7B7A94757D210D60"
          xlink:label="d8336633e11466-wk-Fact-39B247651891576D7B7A94757D210D60"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8307028e2813-wk-Fact-39B247651891576D7B7A94757D210D60"
          xlink:label="d8307028e2813-wk-Fact-39B247651891576D7B7A94757D210D60"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e4214-wk-Fact-39B247651891576D7B7A94757D210D60"
          xlink:label="d8336633e4214-wk-Fact-39B247651891576D7B7A94757D210D60"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e11466-wk-Fact-39B247651891576D7B7A94757D210D60"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2813-wk-Fact-39B247651891576D7B7A94757D210D60"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e4214-wk-Fact-39B247651891576D7B7A94757D210D60"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e11466-wk-Fact-39B247651891576D7B7A94757D210D60"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2813-wk-Fact-39B247651891576D7B7A94757D210D60"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e4214-wk-Fact-39B247651891576D7B7A94757D210D60"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7414-wk-Fact-39C4783BCFAA4ABC800E6391E2F164B1"
          xlink:label="d8415180e7414-wk-Fact-39C4783BCFAA4ABC800E6391E2F164B1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7414-wk-Fact-39C4783BCFAA4ABC800E6391E2F164B1"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7414-wk-Fact-39C4783BCFAA4ABC800E6391E2F164B1"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e864-wk-Fact-39CFEE5D7F0B06CD9DA094757D10AD76"
          xlink:label="d8307028e864-wk-Fact-39CFEE5D7F0B06CD9DA094757D10AD76"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e864-wk-Fact-39CFEE5D7F0B06CD9DA094757D10AD76"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e11154-wk-Fact-3A37D8CBC7B234B9BABE94757CAB9E45"
          xlink:label="d8415180e11154-wk-Fact-3A37D8CBC7B234B9BABE94757CAB9E45"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e11154-wk-Fact-3A37D8CBC7B234B9BABE94757CAB9E45"
          xlink:to="TextSelection-FE68345D83BB191130EF94757DC1B5E5-0-wk-Footnote-FE68345D83BB191130EF94757DC1B5E5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8357160e1674-wk-Fact-3A788F544AFD2EC09A8A94757CF7CB44"
          xlink:label="d8357160e1674-wk-Fact-3A788F544AFD2EC09A8A94757CF7CB44"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-84058C93858F4EB1F00C631013E8EF74-0-wk-Footnote-84058C93858F4EB1F00C631013E8EF74_lbl" xlink:label="TextSelection-84058C93858F4EB1F00C631013E8EF74-0-wk-Footnote-84058C93858F4EB1F00C631013E8EF74_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">The changes in the gross carrying amount of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Licensing agreements and other</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> primarily reflect the transfer of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$550 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> from Indefinite-lived </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Licensing agreements and other</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> to finite-lived </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Licensing agreements and other</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> to reflect the approval in the U.S. of several products subject to out-licensing arrangements acquired from Array.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e1674-wk-Fact-3A788F544AFD2EC09A8A94757CF7CB44"
          xlink:to="TextSelection-84058C93858F4EB1F00C631013E8EF74-0-wk-Footnote-84058C93858F4EB1F00C631013E8EF74_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e8005-wk-Fact-3A87DB55E2FD4B6878A094757D7E9E08"
          xlink:label="d8415180e8005-wk-Fact-3A87DB55E2FD4B6878A094757D7E9E08"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8005-wk-Fact-3A87DB55E2FD4B6878A094757D7E9E08"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8005-wk-Fact-3A87DB55E2FD4B6878A094757D7E9E08"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e3659-wk-Fact-3A9B32710A1CE30C5C917DAAF1BA82D7"
          xlink:label="d8336633e3659-wk-Fact-3A9B32710A1CE30C5C917DAAF1BA82D7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3659-wk-Fact-3A9B32710A1CE30C5C917DAAF1BA82D7"
          xlink:to="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3659-wk-Fact-3A9B32710A1CE30C5C917DAAF1BA82D7"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2229-wk-Fact-3AC307C0C4ECA1CCA0B494757CC80CD1"
          xlink:label="d8340406e2229-wk-Fact-3AC307C0C4ECA1CCA0B494757CC80CD1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2229-wk-Fact-3AC307C0C4ECA1CCA0B494757CC80CD1"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1912-wk-Fact-3B846BC02192BD53F89B94757CDEE0F4"
          xlink:label="d8316808e1912-wk-Fact-3B846BC02192BD53F89B94757CDEE0F4"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-3F1FDE51F00C4F037BC194757DB9000C-0-wk-Footnote-3F1FDE51F00C4F037BC194757DB9000C_lbl" xlink:label="TextSelection-3F1FDE51F00C4F037BC194757DB9000C-0-wk-Footnote-3F1FDE51F00C4F037BC194757DB9000C_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">In the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">second quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and first six months of 2019, represents incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1912-wk-Fact-3B846BC02192BD53F89B94757CDEE0F4"
          xlink:to="TextSelection-3F1FDE51F00C4F037BC194757DB9000C-0-wk-Footnote-3F1FDE51F00C4F037BC194757DB9000C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336625e4304-wk-Fact-3BF504D49EB0EC30CF2A94757D310539"
          xlink:label="d8336625e4304-wk-Fact-3BF504D49EB0EC30CF2A94757D310539"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336625e4304-wk-Fact-3BF504D49EB0EC30CF2A94757D310539"
          xlink:to="TextSelection-F8EDCEC3C21F54D90F7894757DBBCD6D-0-wk-Footnote-F8EDCEC3C21F54D90F7894757DBBCD6D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e11011-wk-Fact-3C10FB8DF4A946A1047094757CB010DE"
          xlink:label="d8336633e11011-wk-Fact-3C10FB8DF4A946A1047094757CB010DE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e11011-wk-Fact-3C10FB8DF4A946A1047094757CB010DE"
          xlink:to="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e11011-wk-Fact-3C10FB8DF4A946A1047094757CB010DE"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e4683-wk-Fact-3C17EF2AE779923FF12094757D2065E5"
          xlink:label="d8372444e4683-wk-Fact-3C17EF2AE779923FF12094757D2065E5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4683-wk-Fact-3C17EF2AE779923FF12094757D2065E5"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl" xlink:label="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Long-term debt includes foreign currency long-term borrowings with carrying values of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$2.0 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> as of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, which are used as hedging instruments in net investment hedges.</xhtml:span></xhtml:div><xhtml:div style="line-height:120%;text-align:left;font-size:10pt;"><xhtml:div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><xhtml:table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><xhtml:tr><xhtml:td colspan="25"/></xhtml:tr><xhtml:tr><xhtml:td style="width:26%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:10%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:9%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:9%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:10%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:9%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:9%;"/><xhtml:td style="width:1%;"/></xhtml:tr><xhtml:tr><xhtml:td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="padding-top:1px;text-align:left;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">The following table provides the amounts recorded in our condensed consolidated balance sheet related to cumulative basis adjustments for fair value hedges:</xhtml:span></xhtml:div></xhtml:td></xhtml:tr><xhtml:tr><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="overflow:hidden;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="overflow:hidden;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;</xhtml:span></xhtml:div></xhtml:td><xhtml:td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><xhtml:div style="padding-top:1px;text-align:center;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;">June&#160;28, 2020</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><xhtml:div style="overflow:hidden;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;</xhtml:span></xhtml:div></xhtml:td><xhtml:td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><xhtml:div style="padding-top:1px;text-align:center;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;">December&#160;31, 2019</xhtml:span></xhtml:div></xhtml:td></xhtml:tr><xhtml:tr><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="overflow:hidden;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="overflow:hidden;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;</xhtml:span></xhtml:div></xhtml:td><xhtml:td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="overflow:hidden;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="overflow:hidden;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;</xhtml:span></xhtml:div></xhtml:td><xhtml:td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><xhtml:div style="text-align:center;font-size:8.5pt;"><xhtml:span style="font-family:inherit;font-size:8.5pt;">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to </xhtml:span></xhtml:div><xhtml:div style="text-align:center;font-size:8.5pt;"><xhtml:span style="font-family:inherit;font-size:8.5pt;">Carrying Amount</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="overflow:hidden;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;</xhtml:span></xhtml:div></xhtml:td><xhtml:td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="overflow:hidden;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="overflow:hidden;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;</xhtml:span></xhtml:div></xhtml:td><xhtml:td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><xhtml:div style="text-align:center;font-size:8.5pt;"><xhtml:span style="font-family:inherit;font-size:8.5pt;">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to </xhtml:span></xhtml:div><xhtml:div style="text-align:center;font-size:8.5pt;"><xhtml:span style="font-family:inherit;font-size:8.5pt;">Carrying Amount</xhtml:span></xhtml:div></xhtml:td></xhtml:tr><xhtml:tr><xhtml:td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="text-align:left;font-size:9.5pt;"><xhtml:span style="font-family:inherit;font-size:9.5pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td><xhtml:td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><xhtml:div style="text-align:right;font-size:8.5pt;"><xhtml:span style="font-family:inherit;font-size:8.5pt;">Carrying Amount of Hedged Assets/Liabilities</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</xhtml:sup></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;border-bottom:1px solid #000000;"><xhtml:div style="text-align:left;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="text-align:left;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td><xhtml:td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><xhtml:div style="text-align:right;font-size:8.5pt;"><xhtml:span style="font-family:inherit;font-size:8.5pt;">Active Hedging Relationships</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;border-bottom:1px solid #000000;"><xhtml:div style="text-align:left;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="overflow:hidden;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;</xhtml:span></xhtml:div></xhtml:td><xhtml:td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><xhtml:div style="text-align:right;font-size:8.5pt;"><xhtml:span style="font-family:inherit;font-size:8.5pt;">Discontinued Hedging Relationships</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;border-bottom:1px solid #000000;"><xhtml:div style="text-align:left;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="overflow:hidden;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;</xhtml:span></xhtml:div></xhtml:td><xhtml:td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><xhtml:div style="text-align:right;font-size:8.5pt;"><xhtml:span style="font-family:inherit;font-size:8.5pt;">Carrying Amount of Hedged Assets/Liabilities</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</xhtml:sup></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;border-bottom:1px solid #000000;"><xhtml:div style="text-align:left;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="overflow:hidden;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;</xhtml:span></xhtml:div></xhtml:td><xhtml:td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><xhtml:div style="text-align:right;font-size:8.5pt;"><xhtml:span style="font-family:inherit;font-size:8.5pt;">Active Hedging Relationships</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;border-bottom:1px solid #000000;"><xhtml:div style="text-align:left;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="overflow:hidden;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;</xhtml:span></xhtml:div></xhtml:td><xhtml:td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><xhtml:div style="text-align:right;font-size:8.5pt;"><xhtml:span style="font-family:inherit;font-size:8.5pt;">Discontinued Hedging Relationships</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;border-bottom:1px solid #000000;"><xhtml:div style="text-align:left;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td></xhtml:tr><xhtml:tr><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="text-align:left;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Short-term investments</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="overflow:hidden;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><xhtml:div style="text-align:left;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;">$</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><xhtml:div style="text-align:right;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>45</xhtml:span></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;border-top:1px solid #000000;"><xhtml:div style="text-align:left;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="overflow:hidden;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><xhtml:div style="text-align:left;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;">$</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><xhtml:div style="text-align:right;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>&#x2014;</xhtml:span></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;border-top:1px solid #000000;"><xhtml:div style="text-align:left;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="overflow:hidden;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><xhtml:div style="text-align:left;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;">$</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><xhtml:div style="text-align:right;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>&#x2014;</xhtml:span></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;border-top:1px solid #000000;"><xhtml:div style="text-align:left;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="overflow:hidden;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><xhtml:div style="text-align:left;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;">$</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><xhtml:div style="text-align:right;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>&#x2014;</xhtml:span></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;border-top:1px solid #000000;"><xhtml:div style="text-align:left;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="overflow:hidden;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><xhtml:div style="text-align:left;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;">$</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><xhtml:div style="text-align:right;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>&#x2014;</xhtml:span></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;border-top:1px solid #000000;"><xhtml:div style="text-align:left;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="overflow:hidden;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><xhtml:div style="text-align:left;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;">$</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><xhtml:div style="text-align:right;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>&#x2014;</xhtml:span></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;border-top:1px solid #000000;"><xhtml:div style="text-align:left;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td></xhtml:tr><xhtml:tr><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="text-align:left;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Long-term investments</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="text-align:left;font-size:9.5pt;"><xhtml:span style="font-family:inherit;font-size:9.5pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td><xhtml:td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><xhtml:div style="text-align:right;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>&#x2014;</xhtml:span></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;"><xhtml:div style="text-align:left;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="text-align:left;font-size:9.5pt;"><xhtml:span style="font-family:inherit;font-size:9.5pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td><xhtml:td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><xhtml:div style="text-align:right;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>&#x2014;</xhtml:span></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;"><xhtml:div style="text-align:left;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="overflow:hidden;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;</xhtml:span></xhtml:div></xhtml:td><xhtml:td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><xhtml:div style="text-align:right;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>&#x2014;</xhtml:span></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;"><xhtml:div style="text-align:left;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="overflow:hidden;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;</xhtml:span></xhtml:div></xhtml:td><xhtml:td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><xhtml:div style="text-align:right;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>45</xhtml:span></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;"><xhtml:div style="text-align:left;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="overflow:hidden;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;</xhtml:span></xhtml:div></xhtml:td><xhtml:td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><xhtml:div style="text-align:right;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>&#x2014;</xhtml:span></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;"><xhtml:div style="text-align:left;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="overflow:hidden;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;</xhtml:span></xhtml:div></xhtml:td><xhtml:td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><xhtml:div style="text-align:right;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>&#x2014;</xhtml:span></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;"><xhtml:div style="text-align:left;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td></xhtml:tr><xhtml:tr><xhtml:td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="text-align:left;font-size:8.5pt;"><xhtml:span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Long-term debt</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="text-align:left;font-size:9.5pt;"><xhtml:span style="font-family:inherit;font-size:9.5pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td><xhtml:td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><xhtml:div style="text-align:right;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>2,023</xhtml:span></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;border-bottom:3px double #000000;"><xhtml:div style="text-align:left;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="text-align:left;font-size:9.5pt;"><xhtml:span style="font-family:inherit;font-size:9.5pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td><xhtml:td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><xhtml:div style="text-align:right;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>140</xhtml:span></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;border-bottom:3px double #000000;"><xhtml:div style="text-align:left;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="overflow:hidden;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;</xhtml:span></xhtml:div></xhtml:td><xhtml:td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><xhtml:div style="text-align:right;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>1,181</xhtml:span></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;border-bottom:3px double #000000;"><xhtml:div style="text-align:left;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="overflow:hidden;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;</xhtml:span></xhtml:div></xhtml:td><xhtml:td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><xhtml:div style="text-align:right;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>7,092</xhtml:span></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;border-bottom:3px double #000000;"><xhtml:div style="text-align:left;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="overflow:hidden;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;</xhtml:span></xhtml:div></xhtml:td><xhtml:td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><xhtml:div style="text-align:right;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>266</xhtml:span></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;border-bottom:3px double #000000;"><xhtml:div style="text-align:left;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><xhtml:div style="overflow:hidden;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;</xhtml:span></xhtml:div></xhtml:td><xhtml:td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><xhtml:div style="text-align:right;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>690</xhtml:span></xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:bottom;border-bottom:3px double #000000;"><xhtml:div style="text-align:left;font-size:10pt;"><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:br/></xhtml:span></xhtml:div></xhtml:td></xhtml:tr></xhtml:table></xhtml:div><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:br/></xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4683-wk-Fact-3C17EF2AE779923FF12094757D2065E5"
          xlink:to="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4683-wk-Fact-3C17EF2AE779923FF12094757D2065E5"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e3486-wk-Fact-3C3F27909C4BDBE69AF194757CE1FE25"
          xlink:label="d8336633e3486-wk-Fact-3C3F27909C4BDBE69AF194757CE1FE25"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3486-wk-Fact-3C3F27909C4BDBE69AF194757CE1FE25"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e1517-wk-Fact-3C967CCCA2C5A8BFE04094757CC4026C"
          xlink:label="d8372444e1517-wk-Fact-3C967CCCA2C5A8BFE04094757CC4026C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e1517-wk-Fact-3C967CCCA2C5A8BFE04094757CC4026C"
          xlink:to="TextSelection-D29E26CC6CF7C6248CEE94757DBD9743-0-wk-Footnote-D29E26CC6CF7C6248CEE94757DBD9743_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1940-wk-Fact-3CC60BCCBCF2CF508B1694757D16B042"
          xlink:label="d8307028e1940-wk-Fact-3CC60BCCBCF2CF508B1694757D16B042"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1940-wk-Fact-3CC60BCCBCF2CF508B1694757D16B042"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1100-wk-Fact-3CE8433BEC1FEF1715C594757D56EECD"
          xlink:label="d8307028e1100-wk-Fact-3CE8433BEC1FEF1715C594757D56EECD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1100-wk-Fact-3CE8433BEC1FEF1715C594757D56EECD"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1075-wk-Fact-3E4926A75899DF8AB69294757D02E114"
          xlink:label="d8340406e1075-wk-Fact-3E4926A75899DF8AB69294757D02E114"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1075-wk-Fact-3E4926A75899DF8AB69294757D02E114"
          xlink:to="TextSelection-04B9B25659DF96CA86BF94757DB5CCE1-0-wk-Footnote-04B9B25659DF96CA86BF94757DB5CCE1_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1075-wk-Fact-3E4926A75899DF8AB69294757D02E114"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e3217-wk-Fact-3E9B45FC40C0B53734B894757D6021C6"
          xlink:label="d8340406e3217-wk-Fact-3E9B45FC40C0B53734B894757D6021C6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8356748e2132-wk-Fact-3E9B45FC40C0B53734B894757D6021C6"
          xlink:label="d8356748e2132-wk-Fact-3E9B45FC40C0B53734B894757D6021C6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e3217-wk-Fact-3E9B45FC40C0B53734B894757D6021C6"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8356748e2132-wk-Fact-3E9B45FC40C0B53734B894757D6021C6"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10491-wk-Fact-3EA1514AE1ADA2AD3F6494757D8089A9"
          xlink:label="d8415180e10491-wk-Fact-3EA1514AE1ADA2AD3F6494757D8089A9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10491-wk-Fact-3EA1514AE1ADA2AD3F6494757D8089A9"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e10545-wk-Fact-3F18B676756C784E4C0D94757CB66A64"
          xlink:label="d8336633e10545-wk-Fact-3F18B676756C784E4C0D94757CB66A64"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e10545-wk-Fact-3F18B676756C784E4C0D94757CB66A64"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e7223-wk-Fact-3F6A0F8D36D9FD50EACD94757D9D5AA4"
          xlink:label="d8336633e7223-wk-Fact-3F6A0F8D36D9FD50EACD94757D9D5AA4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e7223-wk-Fact-3F6A0F8D36D9FD50EACD94757D9D5AA4"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1160-wk-Fact-3F6D04965D3F8AC6296C94757D442373"
          xlink:label="d8340406e1160-wk-Fact-3F6D04965D3F8AC6296C94757D442373"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1160-wk-Fact-3F6D04965D3F8AC6296C94757D442373"
          xlink:to="TextSelection-04B9B25659DF96CA86BF94757DB5CCE1-0-wk-Footnote-04B9B25659DF96CA86BF94757DB5CCE1_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1160-wk-Fact-3F6D04965D3F8AC6296C94757D442373"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2072-wk-Fact-3FC60AB14A091D74606194757D68E2E6"
          xlink:label="d8308070e2072-wk-Fact-3FC60AB14A091D74606194757D68E2E6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2072-wk-Fact-3FC60AB14A091D74606194757D68E2E6"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1932-wk-Fact-40152B99BE243EC4A4DA94757CE024F4"
          xlink:label="d8316808e1932-wk-Fact-40152B99BE243EC4A4DA94757CE024F4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1932-wk-Fact-40152B99BE243EC4A4DA94757CE024F4"
          xlink:to="TextSelection-3F1FDE51F00C4F037BC194757DB9000C-0-wk-Footnote-3F1FDE51F00C4F037BC194757DB9000C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8356748e2113-wk-Fact-4083035A9265D74B487394757CDE895C"
          xlink:label="d8356748e2113-wk-Fact-4083035A9265D74B487394757CDE895C"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8340406e3198-wk-Fact-4083035A9265D74B487394757CDE895C"
          xlink:label="d8340406e3198-wk-Fact-4083035A9265D74B487394757CDE895C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8356748e2113-wk-Fact-4083035A9265D74B487394757CDE895C"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e3198-wk-Fact-4083035A9265D74B487394757CDE895C"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e4332-wk-Fact-40A2A359765A16FF703294757D1A2BA3"
          xlink:label="d8372444e4332-wk-Fact-40A2A359765A16FF703294757D1A2BA3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4332-wk-Fact-40A2A359765A16FF703294757D1A2BA3"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4332-wk-Fact-40A2A359765A16FF703294757D1A2BA3"
          xlink:to="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4332-wk-Fact-40A2A359765A16FF703294757D1A2BA3"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2438-wk-Fact-40B5B65787722B300CCA94757D4E39DB"
          xlink:label="d8312059e2438-wk-Fact-40B5B65787722B300CCA94757D4E39DB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2438-wk-Fact-40B5B65787722B300CCA94757D4E39DB"
          xlink:to="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e5540-wk-Fact-40BFA256F2604E1D69E694757D5745F9"
          xlink:label="d8415180e5540-wk-Fact-40BFA256F2604E1D69E694757D5745F9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e5540-wk-Fact-40BFA256F2604E1D69E694757D5745F9"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e3493-wk-Fact-40DBE0BFFEA0FFC750D994757D7B3215"
          xlink:label="d8415180e3493-wk-Fact-40DBE0BFFEA0FFC750D994757D7B3215"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e3493-wk-Fact-40DBE0BFFEA0FFC750D994757D7B3215"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e3493-wk-Fact-40DBE0BFFEA0FFC750D994757D7B3215"
          xlink:to="TextSelection-9BC3436E7B9C00975CD394757DC16C56-0-wk-Footnote-9BC3436E7B9C00975CD394757DC16C56_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8356748e2383-wk-Fact-4140131424BB26DB8A6194757CD6155F"
          xlink:label="d8356748e2383-wk-Fact-4140131424BB26DB8A6194757CD6155F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8356748e2383-wk-Fact-4140131424BB26DB8A6194757CD6155F"
          xlink:to="TextSelection-6979FD063E456189966A94757DC072A0-0-wk-Footnote-6979FD063E456189966A94757DC072A0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e15117-wk-Fact-41A19ED1C18BA2C59FD594757CC95BFE"
          xlink:label="d8336633e15117-wk-Fact-41A19ED1C18BA2C59FD594757CC95BFE"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e7851-wk-Fact-41A19ED1C18BA2C59FD594757CC95BFE"
          xlink:label="d8336633e7851-wk-Fact-41A19ED1C18BA2C59FD594757CC95BFE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e15117-wk-Fact-41A19ED1C18BA2C59FD594757CC95BFE"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e7851-wk-Fact-41A19ED1C18BA2C59FD594757CC95BFE"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2275-wk-Fact-41DCE73B8353AB2C4A8294757CC7A0E2"
          xlink:label="d8308070e2275-wk-Fact-41DCE73B8353AB2C4A8294757CC7A0E2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2275-wk-Fact-41DCE73B8353AB2C4A8294757CC7A0E2"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e13062-wk-Fact-41F806F874E498F7473D94757D8FFC10"
          xlink:label="d8336633e13062-wk-Fact-41F806F874E498F7473D94757D8FFC10"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e13062-wk-Fact-41F806F874E498F7473D94757D8FFC10"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e930-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B"
          xlink:label="d8301124e930-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e5598-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B"
          xlink:label="d8336633e5598-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8340406e2019-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B"
          xlink:label="d8340406e2019-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e930-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e5598-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2019-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e930-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e5598-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2019-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e930-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e5598-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2019-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e930-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e5598-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2019-wk-Fact-42057CEB2FEBF4916A0894757D00CD4B"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1991-wk-Fact-4205FA0CADA9C7C75F1194757CAF3BC4"
          xlink:label="d8301124e1991-wk-Fact-4205FA0CADA9C7C75F1194757CAF3BC4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1991-wk-Fact-4205FA0CADA9C7C75F1194757CAF3BC4"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e5486-wk-Fact-423E2315CDCB857D87F794757D3B33EB"
          xlink:label="d8415180e5486-wk-Fact-423E2315CDCB857D87F794757D3B33EB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e5486-wk-Fact-423E2315CDCB857D87F794757D3B33EB"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e7791-wk-Fact-427A772CBA10468F664594757D453976"
          xlink:label="d8336633e7791-wk-Fact-427A772CBA10468F664594757D453976"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e15057-wk-Fact-427A772CBA10468F664594757D453976"
          xlink:label="d8336633e15057-wk-Fact-427A772CBA10468F664594757D453976"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e7791-wk-Fact-427A772CBA10468F664594757D453976"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e15057-wk-Fact-427A772CBA10468F664594757D453976"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1555-wk-Fact-42AE1B3E358159102DA894757CCA438F"
          xlink:label="d8340406e1555-wk-Fact-42AE1B3E358159102DA894757CCA438F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1555-wk-Fact-42AE1B3E358159102DA894757CCA438F"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e5992-wk-Fact-42F54CD6BB1EE7437A9894757D251875"
          xlink:label="d8372444e5992-wk-Fact-42F54CD6BB1EE7437A9894757D251875"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5992-wk-Fact-42F54CD6BB1EE7437A9894757D251875"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5992-wk-Fact-42F54CD6BB1EE7437A9894757D251875"
          xlink:to="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5992-wk-Fact-42F54CD6BB1EE7437A9894757D251875"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e5810-wk-Fact-4311DCC0A7382F4BE88494757D3C948A"
          xlink:label="d8336633e5810-wk-Fact-4311DCC0A7382F4BE88494757D3C948A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e5810-wk-Fact-4311DCC0A7382F4BE88494757D3C948A"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8314038e1215-wk-Fact-432173AA1624AC93425594757D771AAC"
          xlink:label="d8314038e1215-wk-Fact-432173AA1624AC93425594757D771AAC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8314038e1215-wk-Fact-432173AA1624AC93425594757D771AAC"
          xlink:to="TextSelection-681F29FE9DC6BC582B6D94757DB90D8C-0-wk-Footnote-681F29FE9DC6BC582B6D94757DB90D8C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10305-wk-Fact-4332974BA308B68F084594757D7E748A"
          xlink:label="d8415180e10305-wk-Fact-4332974BA308B68F084594757D7E748A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10305-wk-Fact-4332974BA308B68F084594757D7E748A"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-43361FC2439255EC9C0794757CD9C825-wk-Fact-43361FC2439255EC9C0794757CD9C825"
          xlink:label="Fact-43361FC2439255EC9C0794757CD9C825-wk-Fact-43361FC2439255EC9C0794757CD9C825"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-43361FC2439255EC9C0794757CD9C825-wk-Fact-43361FC2439255EC9C0794757CD9C825"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e5208-wk-Fact-436FB3A1151F0EA4A92E94757CCA2C1F"
          xlink:label="d8372444e5208-wk-Fact-436FB3A1151F0EA4A92E94757CCA2C1F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5208-wk-Fact-436FB3A1151F0EA4A92E94757CCA2C1F"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5208-wk-Fact-436FB3A1151F0EA4A92E94757CCA2C1F"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e968-wk-Fact-438C70CDE0164785DD1D6EDE8D2EB280"
          xlink:label="d8307028e968-wk-Fact-438C70CDE0164785DD1D6EDE8D2EB280"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-A69940B73F64268F0EB092D9B88F9F01-0-wk-Footnote-A69940B73F64268F0EB092D9B88F9F01_lbl" xlink:label="TextSelection-A69940B73F64268F0EB092D9B88F9F01-0-wk-Footnote-A69940B73F64268F0EB092D9B88F9F01_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family:inherit;font-size:8pt;">The balance as of June 28, 2020 reflects the Upjohn Inc. and Upjohn Finance B.V. debt issuances. For additional information see </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7D. Financial Instruments: </xhtml:span><xhtml:span style="font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Long-Term Debt</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e968-wk-Fact-438C70CDE0164785DD1D6EDE8D2EB280"
          xlink:to="TextSelection-A69940B73F64268F0EB092D9B88F9F01-0-wk-Footnote-A69940B73F64268F0EB092D9B88F9F01_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e968-wk-Fact-438C70CDE0164785DD1D6EDE8D2EB280"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8357160e1714-wk-Fact-43BAC5F7B8A55604118A94757CF8D187"
          xlink:label="d8357160e1714-wk-Fact-43BAC5F7B8A55604118A94757CF8D187"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e1714-wk-Fact-43BAC5F7B8A55604118A94757CF8D187"
          xlink:to="TextSelection-84058C93858F4EB1F00C631013E8EF74-0-wk-Footnote-84058C93858F4EB1F00C631013E8EF74_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2074-wk-Fact-44A3EBC245B59B1EDEFE94757CA83343"
          xlink:label="d8301124e2074-wk-Fact-44A3EBC245B59B1EDEFE94757CA83343"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2074-wk-Fact-44A3EBC245B59B1EDEFE94757CA83343"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1803-wk-Fact-44B0C90D865A67954DB694757D580795"
          xlink:label="d8308070e1803-wk-Fact-44B0C90D865A67954DB694757D580795"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1803-wk-Fact-44B0C90D865A67954DB694757D580795"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e5838-wk-Fact-44C12AC03CA4B50FB0EC94757D37E891"
          xlink:label="d8415180e5838-wk-Fact-44C12AC03CA4B50FB0EC94757D37E891"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e5838-wk-Fact-44C12AC03CA4B50FB0EC94757D37E891"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e5970-wk-Fact-45009E6C6C76A6D4EBFD94757D064F15"
          xlink:label="d8415180e5970-wk-Fact-45009E6C6C76A6D4EBFD94757D064F15"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e5970-wk-Fact-45009E6C6C76A6D4EBFD94757D064F15"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10679-wk-Fact-4530C68B63EB9C8D923963A2911A73D6"
          xlink:label="d8415180e10679-wk-Fact-4530C68B63EB9C8D923963A2911A73D6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10679-wk-Fact-4530C68B63EB9C8D923963A2911A73D6"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2350-wk-Fact-457A42E5EFF17C82E7B994757D023187"
          xlink:label="d8301124e2350-wk-Fact-457A42E5EFF17C82E7B994757D023187"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2350-wk-Fact-457A42E5EFF17C82E7B994757D023187"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2304-wk-Fact-458F8B2744B5838D7DD994757D5BA906"
          xlink:label="d8301124e2304-wk-Fact-458F8B2744B5838D7DD994757D5BA906"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2304-wk-Fact-458F8B2744B5838D7DD994757D5BA906"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e10081-wk-Fact-469C94508C3D19FD04B494757D87315E"
          xlink:label="d8336633e10081-wk-Fact-469C94508C3D19FD04B494757D87315E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e10081-wk-Fact-469C94508C3D19FD04B494757D87315E"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2687-wk-Fact-469E3365E76E79BE433894757CCE1E1E"
          xlink:label="d8312059e2687-wk-Fact-469E3365E76E79BE433894757CCE1E1E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2687-wk-Fact-469E3365E76E79BE433894757CCE1E1E"
          xlink:to="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e14253-wk-Fact-46C30A88DFF3DBBC269A94757D92355F"
          xlink:label="d8336633e14253-wk-Fact-46C30A88DFF3DBBC269A94757D92355F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e14253-wk-Fact-46C30A88DFF3DBBC269A94757D92355F"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1198-wk-Fact-46F68B2D547259497F6A94757CB8B7C5"
          xlink:label="d8340406e1198-wk-Fact-46F68B2D547259497F6A94757CB8B7C5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1198-wk-Fact-46F68B2D547259497F6A94757CB8B7C5"
          xlink:to="TextSelection-04B9B25659DF96CA86BF94757DB5CCE1-0-wk-Footnote-04B9B25659DF96CA86BF94757DB5CCE1_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1198-wk-Fact-46F68B2D547259497F6A94757CB8B7C5"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2164-wk-Fact-476B18F8EF4E7B05E20394757CD2DBCA"
          xlink:label="d8312059e2164-wk-Fact-476B18F8EF4E7B05E20394757CD2DBCA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2164-wk-Fact-476B18F8EF4E7B05E20394757CD2DBCA"
          xlink:to="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7507-wk-Fact-477D98C4B7AC60774FF994757DA3ED14"
          xlink:label="d8415180e7507-wk-Fact-477D98C4B7AC60774FF994757DA3ED14"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7507-wk-Fact-477D98C4B7AC60774FF994757DA3ED14"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7507-wk-Fact-477D98C4B7AC60774FF994757DA3ED14"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2163-wk-Fact-479C56CF0F843B8D425E94757CC58178"
          xlink:label="d8308070e2163-wk-Fact-479C56CF0F843B8D425E94757CC58178"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2163-wk-Fact-479C56CF0F843B8D425E94757CC58178"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e7683-wk-Fact-47CB9748E3671019B33694757D79B9D0"
          xlink:label="d8372444e7683-wk-Fact-47CB9748E3671019B33694757D79B9D0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7683-wk-Fact-47CB9748E3671019B33694757D79B9D0"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7683-wk-Fact-47CB9748E3671019B33694757D79B9D0"
          xlink:to="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7683-wk-Fact-47CB9748E3671019B33694757D79B9D0"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2699-wk-Fact-47E4B6DB5C9B3F16044E94757D1BCF19"
          xlink:label="d8307028e2699-wk-Fact-47E4B6DB5C9B3F16044E94757D1BCF19"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2699-wk-Fact-47E4B6DB5C9B3F16044E94757D1BCF19"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2301-wk-Fact-4825D5CD0C1E297EA03E94757D6ECCCE"
          xlink:label="d8308070e2301-wk-Fact-4825D5CD0C1E297EA03E94757D6ECCCE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2301-wk-Fact-4825D5CD0C1E297EA03E94757D6ECCCE"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e3382-wk-Fact-482EC9E9C634BBA5161694757D0F9FAE"
          xlink:label="d8372444e3382-wk-Fact-482EC9E9C634BBA5161694757D0F9FAE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3382-wk-Fact-482EC9E9C634BBA5161694757D0F9FAE"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3382-wk-Fact-482EC9E9C634BBA5161694757D0F9FAE"
          xlink:to="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3382-wk-Fact-482EC9E9C634BBA5161694757D0F9FAE"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2026-wk-Fact-483AF33471D66FEACAE994757D64E37B"
          xlink:label="d8308070e2026-wk-Fact-483AF33471D66FEACAE994757D64E37B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2026-wk-Fact-483AF33471D66FEACAE994757D64E37B"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7154-wk-Fact-4872D1EBBF4E1852EC3494757D07D096"
          xlink:label="d8415180e7154-wk-Fact-4872D1EBBF4E1852EC3494757D07D096"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7154-wk-Fact-4872D1EBBF4E1852EC3494757D07D096"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7154-wk-Fact-4872D1EBBF4E1852EC3494757D07D096"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e7539-wk-Fact-48A6C3F999379D6B924394757D7AF0E5"
          xlink:label="d8372444e7539-wk-Fact-48A6C3F999379D6B924394757D7AF0E5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7539-wk-Fact-48A6C3F999379D6B924394757D7AF0E5"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7539-wk-Fact-48A6C3F999379D6B924394757D7AF0E5"
          xlink:to="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7539-wk-Fact-48A6C3F999379D6B924394757D7AF0E5"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e2129-wk-Fact-48DD10795AE6A50CB75294757CF3076B"
          xlink:label="d8316808e2129-wk-Fact-48DD10795AE6A50CB75294757CF3076B"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-420C4A044883B0052AE85E76395259A9-0-wk-Footnote-420C4A044883B0052AE85E76395259A9_lbl" xlink:label="TextSelection-420C4A044883B0052AE85E76395259A9-0-wk-Footnote-420C4A044883B0052AE85E76395259A9_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">The </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">second quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> includes, among other things, dividend income of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$76 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> from our investment in ViiV, and charges of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$86 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, reflecting the change in the fair value of contingent consideration. The first six months of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">2020</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> includes, among other things, dividend income of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$153 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> from our investment in ViiV and charges of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$99 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, reflecting the change in the fair value of contingent consideration. The </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">second quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">2019</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> included, among other things, charges of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$81 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, reflecting the change in the fair value of contingent consideration, dividend income of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$76&#160;million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> from our investment in ViiV, and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$25 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of income from insurance recoveries related to Hurricane Maria. The first </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">six months</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">2019</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> included, among other things, dividend income of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$140 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> from our investment in ViiV and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$50 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of income from insurance recoveries related to Hurricane Maria.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e2129-wk-Fact-48DD10795AE6A50CB75294757CF3076B"
          xlink:to="TextSelection-420C4A044883B0052AE85E76395259A9-0-wk-Footnote-420C4A044883B0052AE85E76395259A9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e9385-wk-Fact-490104B7571E3A2E212094757D19310E"
          xlink:label="d8372444e9385-wk-Fact-490104B7571E3A2E212094757D19310E"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-A6E5E77EFF2BB738D44C94757DBDF083-0-wk-Footnote-A6E5E77EFF2BB738D44C94757DBDF083_lbl" xlink:label="TextSelection-A6E5E77EFF2BB738D44C94757DBDF083-0-wk-Footnote-A6E5E77EFF2BB738D44C94757DBDF083_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e9385-wk-Fact-490104B7571E3A2E212094757D19310E"
          xlink:to="TextSelection-A6E5E77EFF2BB738D44C94757DBDF083-0-wk-Footnote-A6E5E77EFF2BB738D44C94757DBDF083_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e9265-wk-Fact-493830DEE8D1E80A700694757D1E02C5"
          xlink:label="d8372444e9265-wk-Fact-493830DEE8D1E80A700694757D1E02C5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e9265-wk-Fact-493830DEE8D1E80A700694757D1E02C5"
          xlink:to="TextSelection-A6E5E77EFF2BB738D44C94757DBDF083-0-wk-Footnote-A6E5E77EFF2BB738D44C94757DBDF083_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7086-wk-Fact-49D11DC2C94C1C47212E94757D5FB74C"
          xlink:label="d8415180e7086-wk-Fact-49D11DC2C94C1C47212E94757D5FB74C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7086-wk-Fact-49D11DC2C94C1C47212E94757D5FB74C"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7086-wk-Fact-49D11DC2C94C1C47212E94757D5FB74C"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e11191-wk-Fact-4A39A4BCF3749653D06D94757D00D6F3"
          xlink:label="d8415180e11191-wk-Fact-4A39A4BCF3749653D06D94757D00D6F3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e11191-wk-Fact-4A39A4BCF3749653D06D94757D00D6F3"
          xlink:to="TextSelection-33990A088D8DAE29233C94757DC283BE-0-wk-Footnote-33990A088D8DAE29233C94757DC283BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312053e1369-wk-Fact-4A51A364B44D351B488B94757CE2261B"
          xlink:label="d8312053e1369-wk-Fact-4A51A364B44D351B488B94757CE2261B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312053e1369-wk-Fact-4A51A364B44D351B488B94757CE2261B"
          xlink:to="TextSelection-9459A99A0EC8DD1CD04094757DBA4F65-0-wk-Footnote-9459A99A0EC8DD1CD04094757DBA4F65_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e1537-wk-Fact-4A6F9B60CE268B4FFEDC94757CBF9263"
          xlink:label="d8372444e1537-wk-Fact-4A6F9B60CE268B4FFEDC94757CBF9263"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e1537-wk-Fact-4A6F9B60CE268B4FFEDC94757CBF9263"
          xlink:to="TextSelection-D29E26CC6CF7C6248CEE94757DBD9743-0-wk-Footnote-D29E26CC6CF7C6248CEE94757DBD9743_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2814-wk-Fact-4A7A8328763CC8358F7194757D1D40BA"
          xlink:label="d8308070e2814-wk-Fact-4A7A8328763CC8358F7194757D1D40BA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2814-wk-Fact-4A7A8328763CC8358F7194757D1D40BA"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1076-wk-Fact-4A938A8D8BA21B630E4F94757CBAE369"
          xlink:label="d8308070e1076-wk-Fact-4A938A8D8BA21B630E4F94757CBAE369"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1076-wk-Fact-4A938A8D8BA21B630E4F94757CBAE369"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e8119-wk-Fact-4B0483818642973A551F94757D019625"
          xlink:label="d8415180e8119-wk-Fact-4B0483818642973A551F94757D019625"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8119-wk-Fact-4B0483818642973A551F94757D019625"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8119-wk-Fact-4B0483818642973A551F94757D019625"
          xlink:to="TextSelection-4F6B4AE2D2C9909DF73D94757DC29A3E-0-wk-Footnote-4F6B4AE2D2C9909DF73D94757DC29A3E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8119-wk-Fact-4B0483818642973A551F94757D019625"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1390-wk-Fact-4B0A3E94BBBA400AC84C94757D168B19"
          xlink:label="d8307028e1390-wk-Fact-4B0A3E94BBBA400AC84C94757D168B19"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8357160e3633-wk-Fact-4B0A3E94BBBA400AC84C94757D168B19"
          xlink:label="d8357160e3633-wk-Fact-4B0A3E94BBBA400AC84C94757D168B19"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1390-wk-Fact-4B0A3E94BBBA400AC84C94757D168B19"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e3633-wk-Fact-4B0A3E94BBBA400AC84C94757D168B19"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2648-wk-Fact-4B4218478A969AE4E17A94757D59AFA8"
          xlink:label="d8301124e2648-wk-Fact-4B4218478A969AE4E17A94757D59AFA8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2648-wk-Fact-4B4218478A969AE4E17A94757D59AFA8"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10565-wk-Fact-4B82DFDFC48F6984C14894757CBA0C82"
          xlink:label="d8415180e10565-wk-Fact-4B82DFDFC48F6984C14894757CBA0C82"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10565-wk-Fact-4B82DFDFC48F6984C14894757CBA0C82"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e5313-wk-Fact-4B8ABD514A7533B0DD2D94757CEB8E0E"
          xlink:label="d8336633e5313-wk-Fact-4B8ABD514A7533B0DD2D94757CEB8E0E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e5313-wk-Fact-4B8ABD514A7533B0DD2D94757CEB8E0E"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e14214-wk-Fact-4BC9CEEA08F3A0DD592F94757CB7DE38"
          xlink:label="d8336633e14214-wk-Fact-4BC9CEEA08F3A0DD592F94757CB7DE38"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e14214-wk-Fact-4BC9CEEA08F3A0DD592F94757CB7DE38"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e7988-wk-Fact-4BFC2EA8E8A0BCD7965C94757D916146"
          xlink:label="d8372444e7988-wk-Fact-4BFC2EA8E8A0BCD7965C94757D916146"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7988-wk-Fact-4BFC2EA8E8A0BCD7965C94757D916146"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1036-wk-Fact-4C72B86F9525A44C403B94757CF4AB54"
          xlink:label="d8316808e1036-wk-Fact-4C72B86F9525A44C403B94757CF4AB54"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1036-wk-Fact-4C72B86F9525A44C403B94757CF4AB54"
          xlink:to="TextSelection-4E74A09462C596E2363694757DB8EB14-0-wk-Footnote-4E74A09462C596E2363694757DB8EB14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1852-wk-Fact-4C76179C274DDE6FE76E94757D246CA2"
          xlink:label="d8307028e1852-wk-Fact-4C76179C274DDE6FE76E94757D246CA2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1852-wk-Fact-4C76179C274DDE6FE76E94757D246CA2"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10100-wk-Fact-4D1BE9253D5F410A0D8294757D39F930"
          xlink:label="d8415180e10100-wk-Fact-4D1BE9253D5F410A0D8294757D39F930"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10100-wk-Fact-4D1BE9253D5F410A0D8294757D39F930"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10866-wk-Fact-4D23F6FF7E43AD5A2E8294757CB25D84"
          xlink:label="d8415180e10866-wk-Fact-4D23F6FF7E43AD5A2E8294757CB25D84"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10866-wk-Fact-4D23F6FF7E43AD5A2E8294757CB25D84"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e5417-wk-Fact-4D4D0A148BCFEEA47A9894757D551B15"
          xlink:label="d8415180e5417-wk-Fact-4D4D0A148BCFEEA47A9894757D551B15"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e5417-wk-Fact-4D4D0A148BCFEEA47A9894757D551B15"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e4648-wk-Fact-4DB60D98BED9F2D7592094757D057DF4"
          xlink:label="d8415180e4648-wk-Fact-4DB60D98BED9F2D7592094757D057DF4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8415180e2248-wk-Fact-4DB60D98BED9F2D7592094757D057DF4"
          xlink:label="d8415180e2248-wk-Fact-4DB60D98BED9F2D7592094757D057DF4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8340406e908-wk-Fact-4DB60D98BED9F2D7592094757D057DF4"
          xlink:label="d8340406e908-wk-Fact-4DB60D98BED9F2D7592094757D057DF4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e4648-wk-Fact-4DB60D98BED9F2D7592094757D057DF4"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e2248-wk-Fact-4DB60D98BED9F2D7592094757D057DF4"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e908-wk-Fact-4DB60D98BED9F2D7592094757D057DF4"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8356748e2318-wk-Fact-4E46F2B386CE7BF8977294757CBBCA8A"
          xlink:label="d8356748e2318-wk-Fact-4E46F2B386CE7BF8977294757CBBCA8A"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8340406e3320-wk-Fact-4E46F2B386CE7BF8977294757CBBCA8A"
          xlink:label="d8340406e3320-wk-Fact-4E46F2B386CE7BF8977294757CBBCA8A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8356748e2318-wk-Fact-4E46F2B386CE7BF8977294757CBBCA8A"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e3320-wk-Fact-4E46F2B386CE7BF8977294757CBBCA8A"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10061-wk-Fact-4E6EDE18D87BADEBD5D594757DA51E46"
          xlink:label="d8415180e10061-wk-Fact-4E6EDE18D87BADEBD5D594757DA51E46"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10061-wk-Fact-4E6EDE18D87BADEBD5D594757DA51E46"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8357160e2113-wk-Fact-4EA24C13139AF186ABC594757CFF3B82"
          xlink:label="d8357160e2113-wk-Fact-4EA24C13139AF186ABC594757CFF3B82"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8357160e2150-wk-Fact-4EA24C13139AF186ABC594757CFF3B82"
          xlink:label="d8357160e2150-wk-Fact-4EA24C13139AF186ABC594757CFF3B82"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e2113-wk-Fact-4EA24C13139AF186ABC594757CFF3B82"
          xlink:to="TextSelection-B511D685B8F037FD258094757DBFC8C5-0-wk-Footnote-B511D685B8F037FD258094757DBFC8C5_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e2150-wk-Fact-4EA24C13139AF186ABC594757CFF3B82"
          xlink:to="TextSelection-B511D685B8F037FD258094757DBFC8C5-0-wk-Footnote-B511D685B8F037FD258094757DBFC8C5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1372-wk-Fact-4ECA9E2FD645BEFF2FE194757CB235DC"
          xlink:label="d8301124e1372-wk-Fact-4ECA9E2FD645BEFF2FE194757CB235DC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1372-wk-Fact-4ECA9E2FD645BEFF2FE194757CB235DC"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2593-wk-Fact-4F381BE015AE04126EB994757CB534B2"
          xlink:label="d8340406e2593-wk-Fact-4F381BE015AE04126EB994757CB534B2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2593-wk-Fact-4F381BE015AE04126EB994757CB534B2"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e13021-wk-Fact-4F58C9049DEAAC5BA58594757CB32E71"
          xlink:label="d8336633e13021-wk-Fact-4F58C9049DEAAC5BA58594757CB32E71"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e13021-wk-Fact-4F58C9049DEAAC5BA58594757CB32E71"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1567-wk-Fact-4FABC049EDFD60A33BC994757D951454"
          xlink:label="d8301124e1567-wk-Fact-4FABC049EDFD60A33BC994757D951454"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1567-wk-Fact-4FABC049EDFD60A33BC994757D951454"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1368-wk-Fact-4FD042AF6C7E165B3EAF94757D1120B8"
          xlink:label="d8308070e1368-wk-Fact-4FD042AF6C7E165B3EAF94757D1120B8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1368-wk-Fact-4FD042AF6C7E165B3EAF94757D1120B8"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e4371-wk-Fact-5073FE007ED4EF41D79494757D16D857"
          xlink:label="d8372444e4371-wk-Fact-5073FE007ED4EF41D79494757D16D857"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4371-wk-Fact-5073FE007ED4EF41D79494757D16D857"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4371-wk-Fact-5073FE007ED4EF41D79494757D16D857"
          xlink:to="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4371-wk-Fact-5073FE007ED4EF41D79494757D16D857"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2265-wk-Fact-50D4A8FFA49F4D1E126994757CD3C559"
          xlink:label="d8301124e2265-wk-Fact-50D4A8FFA49F4D1E126994757CD3C559"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2265-wk-Fact-50D4A8FFA49F4D1E126994757CD3C559"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e3044-wk-Fact-51872B65420AB7367EDA94757D7EDA33"
          xlink:label="d8415180e3044-wk-Fact-51872B65420AB7367EDA94757D7EDA33"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e3044-wk-Fact-51872B65420AB7367EDA94757D7EDA33"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1096-wk-Fact-519D1AE2B3692880237794757CFE232A"
          xlink:label="d8301124e1096-wk-Fact-519D1AE2B3692880237794757CFE232A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1096-wk-Fact-519D1AE2B3692880237794757CFE232A"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1096-wk-Fact-519D1AE2B3692880237794757CFE232A"
          xlink:to="TextSelection-8C3C45B5D6B304AC979B94757DB5023F-0-wk-Footnote-8C3C45B5D6B304AC979B94757DB5023F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e3550-wk-Fact-51F33580094F704AE1CA94757D87F7E8"
          xlink:label="d8312059e3550-wk-Fact-51F33580094F704AE1CA94757D87F7E8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e3550-wk-Fact-51F33580094F704AE1CA94757D87F7E8"
          xlink:to="TextSelection-823D9AE8DB976ECBCA9594757DB72C08-0-wk-Footnote-823D9AE8DB976ECBCA9594757DB72C08_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e14153-wk-Fact-52053A7518B63417490094757CA936F0"
          xlink:label="d8336633e14153-wk-Fact-52053A7518B63417490094757CA936F0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e14153-wk-Fact-52053A7518B63417490094757CA936F0"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1685-wk-Fact-5210DA15DEEFCDAFC83494757D61140E"
          xlink:label="d8340406e1685-wk-Fact-5210DA15DEEFCDAFC83494757D61140E"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8415180e2306-wk-Fact-5210DA15DEEFCDAFC83494757D61140E"
          xlink:label="d8415180e2306-wk-Fact-5210DA15DEEFCDAFC83494757D61140E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1685-wk-Fact-5210DA15DEEFCDAFC83494757D61140E"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e2306-wk-Fact-5210DA15DEEFCDAFC83494757D61140E"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1685-wk-Fact-5210DA15DEEFCDAFC83494757D61140E"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e2306-wk-Fact-5210DA15DEEFCDAFC83494757D61140E"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1012-wk-Fact-52692B1D3913040E2AAA94757D1705E9"
          xlink:label="d8307028e1012-wk-Fact-52692B1D3913040E2AAA94757D1705E9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1012-wk-Fact-52692B1D3913040E2AAA94757D1705E9"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2484-wk-Fact-527CDF2F111A3CFDCAC094757CB3C447"
          xlink:label="d8340406e2484-wk-Fact-527CDF2F111A3CFDCAC094757CB3C447"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2484-wk-Fact-527CDF2F111A3CFDCAC094757CB3C447"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e7182-wk-Fact-52E1818462885A5EFE0D94757D8CDA9B"
          xlink:label="d8372444e7182-wk-Fact-52E1818462885A5EFE0D94757D8CDA9B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7182-wk-Fact-52E1818462885A5EFE0D94757D8CDA9B"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7182-wk-Fact-52E1818462885A5EFE0D94757D8CDA9B"
          xlink:to="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7182-wk-Fact-52E1818462885A5EFE0D94757D8CDA9B"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e4603-wk-Fact-5312CAFDB12F1C38667794757CD7C311"
          xlink:label="d8415180e4603-wk-Fact-5312CAFDB12F1C38667794757CD7C311"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e4603-wk-Fact-5312CAFDB12F1C38667794757CD7C311"
          xlink:to="TextSelection-AFB627DC6F652A9A0A0594757DC251B0-0-wk-Footnote-AFB627DC6F652A9A0A0594757DC251B0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e3525-wk-Fact-5340A136A6910F813F5A94757D1D656C"
          xlink:label="d8336633e3525-wk-Fact-5340A136A6910F813F5A94757D1D656C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3525-wk-Fact-5340A136A6910F813F5A94757D1D656C"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1113-wk-Fact-536622A1B5CBD4FE87F994757D2524BD"
          xlink:label="d8340406e1113-wk-Fact-536622A1B5CBD4FE87F994757D2524BD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1113-wk-Fact-536622A1B5CBD4FE87F994757D2524BD"
          xlink:to="TextSelection-04B9B25659DF96CA86BF94757DB5CCE1-0-wk-Footnote-04B9B25659DF96CA86BF94757DB5CCE1_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1113-wk-Fact-536622A1B5CBD4FE87F994757D2524BD"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e3216-wk-Fact-53C5AB131903D4621F5994757D60BCAC"
          xlink:label="d8415180e3216-wk-Fact-53C5AB131903D4621F5994757D60BCAC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e3216-wk-Fact-53C5AB131903D4621F5994757D60BCAC"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e8346-wk-Fact-5412E02A9288B4E9968694757D311429"
          xlink:label="d8415180e8346-wk-Fact-5412E02A9288B4E9968694757D311429"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8346-wk-Fact-5412E02A9288B4E9968694757D311429"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8346-wk-Fact-5412E02A9288B4E9968694757D311429"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1847-wk-Fact-54C9F8EBEE78F97A618894757D000BCB"
          xlink:label="d8301124e1847-wk-Fact-54C9F8EBEE78F97A618894757D000BCB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1847-wk-Fact-54C9F8EBEE78F97A618894757D000BCB"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e10663-wk-Fact-550D4302BA6804DA1DE694757D9284DA"
          xlink:label="d8336633e10663-wk-Fact-550D4302BA6804DA1DE694757D9284DA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e10663-wk-Fact-550D4302BA6804DA1DE694757D9284DA"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1745-wk-Fact-551A923D6EEA0DEA4EF694757D1C99C3"
          xlink:label="d8307028e1745-wk-Fact-551A923D6EEA0DEA4EF694757D1C99C3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1745-wk-Fact-551A923D6EEA0DEA4EF694757D1C99C3"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e15177-wk-Fact-5570A8AC6555BCC3538194757CDE6165"
          xlink:label="d8336633e15177-wk-Fact-5570A8AC6555BCC3538194757CDE6165"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e7911-wk-Fact-5570A8AC6555BCC3538194757CDE6165"
          xlink:label="d8336633e7911-wk-Fact-5570A8AC6555BCC3538194757CDE6165"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e15177-wk-Fact-5570A8AC6555BCC3538194757CDE6165"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e7911-wk-Fact-5570A8AC6555BCC3538194757CDE6165"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e5294-wk-Fact-562BF7F5C92ED48A7C3D94757D41E597"
          xlink:label="d8336633e5294-wk-Fact-562BF7F5C92ED48A7C3D94757D41E597"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e5294-wk-Fact-562BF7F5C92ED48A7C3D94757D41E597"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e11313-wk-Fact-565D7337C380201E7A3794757D2441F6"
          xlink:label="d8336633e11313-wk-Fact-565D7337C380201E7A3794757D2441F6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e4061-wk-Fact-565D7337C380201E7A3794757D2441F6"
          xlink:label="d8336633e4061-wk-Fact-565D7337C380201E7A3794757D2441F6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e11313-wk-Fact-565D7337C380201E7A3794757D2441F6"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e4061-wk-Fact-565D7337C380201E7A3794757D2441F6"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1347-wk-Fact-56CEFFBCED15FDD6F4D194757CDCF5D5"
          xlink:label="d8340406e1347-wk-Fact-56CEFFBCED15FDD6F4D194757CDCF5D5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1347-wk-Fact-56CEFFBCED15FDD6F4D194757CDCF5D5"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e13788-wk-Fact-56FFC68F0A60EB61A79194757CB4018F"
          xlink:label="d8336633e13788-wk-Fact-56FFC68F0A60EB61A79194757CB4018F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e13788-wk-Fact-56FFC68F0A60EB61A79194757CB4018F"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e3582-wk-Fact-57301CD194F92FB7EE9A94757CC61DC1"
          xlink:label="d8415180e3582-wk-Fact-57301CD194F92FB7EE9A94757CC61DC1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8340406e1724-wk-Fact-57301CD194F92FB7EE9A94757CC61DC1"
          xlink:label="d8340406e1724-wk-Fact-57301CD194F92FB7EE9A94757CC61DC1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e3582-wk-Fact-57301CD194F92FB7EE9A94757CC61DC1"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1724-wk-Fact-57301CD194F92FB7EE9A94757CC61DC1"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e3582-wk-Fact-57301CD194F92FB7EE9A94757CC61DC1"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1724-wk-Fact-57301CD194F92FB7EE9A94757CC61DC1"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e5099-wk-Fact-573125655D86999E611594757D0F25B4"
          xlink:label="d8372444e5099-wk-Fact-573125655D86999E611594757D0F25B4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5099-wk-Fact-573125655D86999E611594757D0F25B4"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5099-wk-Fact-573125655D86999E611594757D0F25B4"
          xlink:to="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5099-wk-Fact-573125655D86999E611594757D0F25B4"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e1790-wk-Fact-57807C2334726A33D68294757CD97546"
          xlink:label="d8415180e1790-wk-Fact-57807C2334726A33D68294757CD97546"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e1790-wk-Fact-57807C2334726A33D68294757CD97546"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336625e2546-wk-Fact-578926C69776E0961EBC94757D74A38D"
          xlink:label="d8336625e2546-wk-Fact-578926C69776E0961EBC94757D74A38D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336625e2546-wk-Fact-578926C69776E0961EBC94757D74A38D"
          xlink:to="TextSelection-83180A323F26770F5F9D94757DBB7831-0-wk-Footnote-83180A323F26770F5F9D94757DBB7831_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e2432-wk-Fact-578F2DA28EA41AE9382194757CEEAB1C"
          xlink:label="d8372444e2432-wk-Fact-578F2DA28EA41AE9382194757CEEAB1C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e2432-wk-Fact-578F2DA28EA41AE9382194757CEEAB1C"
          xlink:to="TextSelection-D29E26CC6CF7C6248CEE94757DBD9743-0-wk-Footnote-D29E26CC6CF7C6248CEE94757DBD9743_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2667-wk-Fact-57AFB05C46254859A5D694757D6FE43D"
          xlink:label="d8312059e2667-wk-Fact-57AFB05C46254859A5D694757D6FE43D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2667-wk-Fact-57AFB05C46254859A5D694757D6FE43D"
          xlink:to="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2612-wk-Fact-57D63ECE81675F0F4F2394757D0586AC"
          xlink:label="d8340406e2612-wk-Fact-57D63ECE81675F0F4F2394757D0586AC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2612-wk-Fact-57D63ECE81675F0F4F2394757D0586AC"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2268-wk-Fact-5813093241A54AAC971594757D47CE74"
          xlink:label="d8312059e2268-wk-Fact-5813093241A54AAC971594757D47CE74"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2268-wk-Fact-5813093241A54AAC971594757D47CE74"
          xlink:to="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e7663-wk-Fact-5832CEAF471BE71C047B94757D1A7F51"
          xlink:label="d8372444e7663-wk-Fact-5832CEAF471BE71C047B94757D1A7F51"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7663-wk-Fact-5832CEAF471BE71C047B94757D1A7F51"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7663-wk-Fact-5832CEAF471BE71C047B94757D1A7F51"
          xlink:to="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7663-wk-Fact-5832CEAF471BE71C047B94757D1A7F51"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2171-wk-Fact-5855D3292457CBC841DF94757D03D95D"
          xlink:label="d8340406e2171-wk-Fact-5855D3292457CBC841DF94757D03D95D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2171-wk-Fact-5855D3292457CBC841DF94757D03D95D"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e2186-wk-Fact-5864C6C0C3A1C625197294757D73F154"
          xlink:label="d8316808e2186-wk-Fact-5864C6C0C3A1C625197294757D73F154"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e2186-wk-Fact-5864C6C0C3A1C625197294757D73F154"
          xlink:to="TextSelection-420C4A044883B0052AE85E76395259A9-0-wk-Footnote-420C4A044883B0052AE85E76395259A9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1182-wk-Fact-59195E3D3D8D530EB03F94757D003A33"
          xlink:label="d8301124e1182-wk-Fact-59195E3D3D8D530EB03F94757D003A33"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1182-wk-Fact-59195E3D3D8D530EB03F94757D003A33"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8351242e3279-wk-Fact-591CA5BD37BEF066C61294757D3FA07C"
          xlink:label="d8351242e3279-wk-Fact-591CA5BD37BEF066C61294757D3FA07C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e3279-wk-Fact-591CA5BD37BEF066C61294757D3FA07C"
          xlink:to="TextSelection-8224B42439E7CCC8C3C594757DBA701B-0-wk-Footnote-8224B42439E7CCC8C3C594757DBA701B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1163-wk-Fact-592D27AEE4D0FDEDCA3094757CFE923B"
          xlink:label="d8301124e1163-wk-Fact-592D27AEE4D0FDEDCA3094757CFE923B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1163-wk-Fact-592D27AEE4D0FDEDCA3094757CFE923B"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e5579-wk-Fact-594699073675166A837B94757D1BBB71"
          xlink:label="d8336633e5579-wk-Fact-594699073675166A837B94757D1BBB71"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e5579-wk-Fact-594699073675166A837B94757D1BBB71"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1283-wk-Fact-59753A9A46BF0BDDA65E94757CBF6EA3"
          xlink:label="d8340406e1283-wk-Fact-59753A9A46BF0BDDA65E94757CBF6EA3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1283-wk-Fact-59753A9A46BF0BDDA65E94757CBF6EA3"
          xlink:to="TextSelection-04B9B25659DF96CA86BF94757DB5CCE1-0-wk-Footnote-04B9B25659DF96CA86BF94757DB5CCE1_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1283-wk-Fact-59753A9A46BF0BDDA65E94757CBF6EA3"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2032-wk-Fact-599CD01F617B5421030A94757D29E0E8"
          xlink:label="d8307028e2032-wk-Fact-599CD01F617B5421030A94757D29E0E8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2032-wk-Fact-599CD01F617B5421030A94757D29E0E8"
          xlink:to="TextSelection-A69940B73F64268F0EB092D9B88F9F01-0-wk-Footnote-A69940B73F64268F0EB092D9B88F9F01_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2032-wk-Fact-599CD01F617B5421030A94757D29E0E8"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e15043-wk-Fact-59A686060A7AF1F7275494757D530630"
          xlink:label="d8336633e15043-wk-Fact-59A686060A7AF1F7275494757D530630"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e7777-wk-Fact-59A686060A7AF1F7275494757D530630"
          xlink:label="d8336633e7777-wk-Fact-59A686060A7AF1F7275494757D530630"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e15043-wk-Fact-59A686060A7AF1F7275494757D530630"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e7777-wk-Fact-59A686060A7AF1F7275494757D530630"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8357160e2586-wk-Fact-59E2FF5E7ACF702D9F4B94757D3339C6"
          xlink:label="d8357160e2586-wk-Fact-59E2FF5E7ACF702D9F4B94757D3339C6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8307028e1365-wk-Fact-59E2FF5E7ACF702D9F4B94757D3339C6"
          xlink:label="d8307028e1365-wk-Fact-59E2FF5E7ACF702D9F4B94757D3339C6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e2586-wk-Fact-59E2FF5E7ACF702D9F4B94757D3339C6"
          xlink:to="TextSelection-76B1871DA30219820FCB63105DB9E5C3-0-wk-Footnote-76B1871DA30219820FCB63105DB9E5C3_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1365-wk-Fact-59E2FF5E7ACF702D9F4B94757D3339C6"
          xlink:to="TextSelection-76B1871DA30219820FCB63105DB9E5C3-0-wk-Footnote-76B1871DA30219820FCB63105DB9E5C3_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e2586-wk-Fact-59E2FF5E7ACF702D9F4B94757D3339C6"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1365-wk-Fact-59E2FF5E7ACF702D9F4B94757D3339C6"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e2981-wk-Fact-59F11DF08C5C36F85F9694757CF96B93"
          xlink:label="d8415180e2981-wk-Fact-59F11DF08C5C36F85F9694757CF96B93"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e2981-wk-Fact-59F11DF08C5C36F85F9694757CF96B93"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e8861-wk-Fact-5A3DCFE782B686C3474B94757CB5ED2D"
          xlink:label="d8336633e8861-wk-Fact-5A3DCFE782B686C3474B94757CB5ED2D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e8861-wk-Fact-5A3DCFE782B686C3474B94757CB5ED2D"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e1960-wk-Fact-5A9323DDE96F467D4EB294757CDEBFD7"
          xlink:label="d8312059e1960-wk-Fact-5A9323DDE96F467D4EB294757CDEBFD7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e1960-wk-Fact-5A9323DDE96F467D4EB294757CDEBFD7"
          xlink:to="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1783-wk-Fact-5B9F6B76D55DFFB89B5094757D04FD74"
          xlink:label="d8301124e1783-wk-Fact-5B9F6B76D55DFFB89B5094757D04FD74"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1783-wk-Fact-5B9F6B76D55DFFB89B5094757D04FD74"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e3098-wk-Fact-5BE19AFA21A4738F24FF94757D6A31FE"
          xlink:label="d8301124e3098-wk-Fact-5BE19AFA21A4738F24FF94757D6A31FE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e3098-wk-Fact-5BE19AFA21A4738F24FF94757D6A31FE"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1847-wk-Fact-5C2821D98F34452F3A6F94757D2D141F"
          xlink:label="d8308070e1847-wk-Fact-5C2821D98F34452F3A6F94757D2D141F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1847-wk-Fact-5C2821D98F34452F3A6F94757D2D141F"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e5334-wk-Fact-5C78C5042C9CAAB17DD594757D1E08DF"
          xlink:label="d8336633e5334-wk-Fact-5C78C5042C9CAAB17DD594757D1E08DF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e5334-wk-Fact-5C78C5042C9CAAB17DD594757D1E08DF"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2945-wk-Fact-5CBFB8246EFB61DA16CD94757CE0475C"
          xlink:label="d8340406e2945-wk-Fact-5CBFB8246EFB61DA16CD94757CE0475C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2945-wk-Fact-5CBFB8246EFB61DA16CD94757CE0475C"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2164-wk-Fact-5CC1D14D1DDE8826CA7B94757D19D277"
          xlink:label="d8307028e2164-wk-Fact-5CC1D14D1DDE8826CA7B94757D19D277"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2164-wk-Fact-5CC1D14D1DDE8826CA7B94757D19D277"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e5149-wk-Fact-5D38E93A2B498707F2E694757D15B8FB"
          xlink:label="d8372444e5149-wk-Fact-5D38E93A2B498707F2E694757D15B8FB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5149-wk-Fact-5D38E93A2B498707F2E694757D15B8FB"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e14002-wk-Fact-5D5C63A4F1FD671C14E194757CAF5BD0"
          xlink:label="d8336633e14002-wk-Fact-5D5C63A4F1FD671C14E194757CAF5BD0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e14002-wk-Fact-5D5C63A4F1FD671C14E194757CAF5BD0"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7433-wk-Fact-5DF4EF1F1BCC2D34B6F86391E6AAE21C"
          xlink:label="d8415180e7433-wk-Fact-5DF4EF1F1BCC2D34B6F86391E6AAE21C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7433-wk-Fact-5DF4EF1F1BCC2D34B6F86391E6AAE21C"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7433-wk-Fact-5DF4EF1F1BCC2D34B6F86391E6AAE21C"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e8321-wk-Fact-5E91C36A351B5607652E94757D8FBDF9"
          xlink:label="d8372444e8321-wk-Fact-5E91C36A351B5607652E94757D8FBDF9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e8321-wk-Fact-5E91C36A351B5607652E94757D8FBDF9"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e8321-wk-Fact-5E91C36A351B5607652E94757D8FBDF9"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10545-wk-Fact-5EE554E0F23105B14A0A94757CD8E1B6"
          xlink:label="d8415180e10545-wk-Fact-5EE554E0F23105B14A0A94757CD8E1B6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10545-wk-Fact-5EE554E0F23105B14A0A94757CD8E1B6"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e3237-wk-Fact-5FC136C8E0978EE4BFD794757D39F20F"
          xlink:label="d8415180e3237-wk-Fact-5FC136C8E0978EE4BFD794757D39F20F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e3237-wk-Fact-5FC136C8E0978EE4BFD794757D39F20F"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e8842-wk-Fact-5FF93BEF0CD0E0592D9894757CB94FC4"
          xlink:label="d8336633e8842-wk-Fact-5FF93BEF0CD0E0592D9894757CB94FC4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e8842-wk-Fact-5FF93BEF0CD0E0592D9894757CB94FC4"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10584-wk-Fact-5FFC08B63DBE9AEB9BB794757CFD2C69"
          xlink:label="d8415180e10584-wk-Fact-5FFC08B63DBE9AEB9BB794757CFD2C69"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10584-wk-Fact-5FFC08B63DBE9AEB9BB794757CFD2C69"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e7559-wk-Fact-5FFC27FB28BF9BC0914794757D12B245"
          xlink:label="d8372444e7559-wk-Fact-5FFC27FB28BF9BC0914794757D12B245"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7559-wk-Fact-5FFC27FB28BF9BC0914794757D12B245"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7559-wk-Fact-5FFC27FB28BF9BC0914794757D12B245"
          xlink:to="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7559-wk-Fact-5FFC27FB28BF9BC0914794757D12B245"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8356748e1160-wk-Fact-603FB52F232889DFBADE94757D592C93"
          xlink:label="d8356748e1160-wk-Fact-603FB52F232889DFBADE94757D592C93"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8340406e1892-wk-Fact-603FB52F232889DFBADE94757D592C93"
          xlink:label="d8340406e1892-wk-Fact-603FB52F232889DFBADE94757D592C93"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8356748e1160-wk-Fact-603FB52F232889DFBADE94757D592C93"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1892-wk-Fact-603FB52F232889DFBADE94757D592C93"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7047-wk-Fact-60CA995A5DF3128B16AC94757CF80B83"
          xlink:label="d8415180e7047-wk-Fact-60CA995A5DF3128B16AC94757CF80B83"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7047-wk-Fact-60CA995A5DF3128B16AC94757CF80B83"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7047-wk-Fact-60CA995A5DF3128B16AC94757CF80B83"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e14869-wk-Fact-6101468A882D99277B2994757CB9521F"
          xlink:label="d8336633e14869-wk-Fact-6101468A882D99277B2994757CB9521F"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-DD7734E5853B41ABE8C8546D7049626E-0-wk-Footnote-DD7734E5853B41ABE8C8546D7049626E_lbl" xlink:label="TextSelection-DD7734E5853B41ABE8C8546D7049626E-0-wk-Footnote-DD7734E5853B41ABE8C8546D7049626E_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">The increase to </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Retained earnings </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">represents the cumulative effect of the adoption of a new accounting standard in the first quarter of 2019 for leases. For additional information, see Notes to Consolidated Financial Statements&#x2013;&#x2013;</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2019</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> in our 2019 Financial Report.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e14869-wk-Fact-6101468A882D99277B2994757CB9521F"
          xlink:to="TextSelection-DD7734E5853B41ABE8C8546D7049626E-0-wk-Footnote-DD7734E5853B41ABE8C8546D7049626E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e14869-wk-Fact-6101468A882D99277B2994757CB9521F"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1739-wk-Fact-610F8D5433DAF2EB576E94757CAC2094"
          xlink:label="d8301124e1739-wk-Fact-610F8D5433DAF2EB576E94757CAC2094"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1739-wk-Fact-610F8D5433DAF2EB576E94757CAC2094"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-68FC3C25B884A32675EA544FA892CE0F-0-wk-Footnote-68FC3C25B884A32675EA544FA892CE0F_lbl" xlink:label="TextSelection-68FC3C25B884A32675EA544FA892CE0F-0-wk-Footnote-68FC3C25B884A32675EA544FA892CE0F_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;">Reclassified into </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions&#x2014;net.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1739-wk-Fact-610F8D5433DAF2EB576E94757CAC2094"
          xlink:to="TextSelection-68FC3C25B884A32675EA544FA892CE0F-0-wk-Footnote-68FC3C25B884A32675EA544FA892CE0F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10772-wk-Fact-61E83372368ABBBF6C3294757D74D153"
          xlink:label="d8415180e10772-wk-Fact-61E83372368ABBBF6C3294757D74D153"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10772-wk-Fact-61E83372368ABBBF6C3294757D74D153"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7286-wk-Fact-61F05B8390D8DD312E7E94757D01400F"
          xlink:label="d8415180e7286-wk-Fact-61F05B8390D8DD312E7E94757D01400F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7286-wk-Fact-61F05B8390D8DD312E7E94757D01400F"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7286-wk-Fact-61F05B8390D8DD312E7E94757D01400F"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e3059-wk-Fact-623288D955847BE5D34C94757D0703C1"
          xlink:label="d8301124e3059-wk-Fact-623288D955847BE5D34C94757D0703C1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e3059-wk-Fact-623288D955847BE5D34C94757D0703C1"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2210-wk-Fact-629B718CAC92C35F38D794757D1FE07E"
          xlink:label="d8340406e2210-wk-Fact-629B718CAC92C35F38D794757D1FE07E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2210-wk-Fact-629B718CAC92C35F38D794757D1FE07E"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1567-wk-Fact-629F8031543C0F8CAEA494757CD21E49"
          xlink:label="d8316808e1567-wk-Fact-629F8031543C0F8CAEA494757CD21E49"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1567-wk-Fact-629F8031543C0F8CAEA494757CD21E49"
          xlink:to="TextSelection-1DD42ADAC2DF4C519E7594757DB84698-0-wk-Footnote-1DD42ADAC2DF4C519E7594757DB84698_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e10678-wk-Fact-62CBE8210B463E54DCAE94757D849437"
          xlink:label="d8336633e10678-wk-Fact-62CBE8210B463E54DCAE94757D849437"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e10738-wk-Fact-62CBE8210B463E54DCAE94757D849437"
          xlink:label="d8336633e10738-wk-Fact-62CBE8210B463E54DCAE94757D849437"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e10678-wk-Fact-62CBE8210B463E54DCAE94757D849437"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e10738-wk-Fact-62CBE8210B463E54DCAE94757D849437"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2608-wk-Fact-62DE4C98CF58FC6052F494757D0396A6"
          xlink:label="d8301124e2608-wk-Fact-62DE4C98CF58FC6052F494757D0396A6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2608-wk-Fact-62DE4C98CF58FC6052F494757D0396A6"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1081-wk-Fact-62FCD6839EDD133C913794757D242018"
          xlink:label="d8307028e1081-wk-Fact-62FCD6839EDD133C913794757D242018"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1081-wk-Fact-62FCD6839EDD133C913794757D242018"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e10376-wk-Fact-639B93DD7566754E1E9694757D832F48"
          xlink:label="d8336633e10376-wk-Fact-639B93DD7566754E1E9694757D832F48"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e10376-wk-Fact-639B93DD7566754E1E9694757D832F48"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1527-wk-Fact-64508C9369D213E8ACFA94757CCC5964"
          xlink:label="d8316808e1527-wk-Fact-64508C9369D213E8ACFA94757CCC5964"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1527-wk-Fact-64508C9369D213E8ACFA94757CCC5964"
          xlink:to="TextSelection-1DD42ADAC2DF4C519E7594757DB84698-0-wk-Footnote-1DD42ADAC2DF4C519E7594757DB84698_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2769-wk-Fact-648A257E45E63BD933AE94757D2F45DA"
          xlink:label="d8307028e2769-wk-Fact-648A257E45E63BD933AE94757D2F45DA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2769-wk-Fact-648A257E45E63BD933AE94757D2F45DA"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1575-wk-Fact-648B9F5A2071A01EE88194757D23C23C"
          xlink:label="d8308070e1575-wk-Fact-648B9F5A2071A01EE88194757D23C23C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1575-wk-Fact-648B9F5A2071A01EE88194757D23C23C"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1719-wk-Fact-64D918D7F7D3CCF5532194757CC5E46E"
          xlink:label="d8301124e1719-wk-Fact-64D918D7F7D3CCF5532194757CC5E46E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1719-wk-Fact-64D918D7F7D3CCF5532194757CC5E46E"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1719-wk-Fact-64D918D7F7D3CCF5532194757CC5E46E"
          xlink:to="TextSelection-68FC3C25B884A32675EA544FA892CE0F-0-wk-Footnote-68FC3C25B884A32675EA544FA892CE0F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1386-wk-Fact-64EEACF271CD8A6661EF94757CA9B5E3"
          xlink:label="d8340406e1386-wk-Fact-64EEACF271CD8A6661EF94757CA9B5E3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1386-wk-Fact-64EEACF271CD8A6661EF94757CA9B5E3"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1211-wk-Fact-6511CCFA698C5A19F60894757CB5C2AF"
          xlink:label="d8308070e1211-wk-Fact-6511CCFA698C5A19F60894757CB5C2AF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1211-wk-Fact-6511CCFA698C5A19F60894757CB5C2AF"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e3141-wk-Fact-6538F77FA787A6ABAE0994757CB51CDA"
          xlink:label="d8336633e3141-wk-Fact-6538F77FA787A6ABAE0994757CB51CDA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3141-wk-Fact-6538F77FA787A6ABAE0994757CB51CDA"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e7702-wk-Fact-653C3FF814F712F87A4D94757D2002AC"
          xlink:label="d8372444e7702-wk-Fact-653C3FF814F712F87A4D94757D2002AC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7702-wk-Fact-653C3FF814F712F87A4D94757D2002AC"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7702-wk-Fact-653C3FF814F712F87A4D94757D2002AC"
          xlink:to="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7702-wk-Fact-653C3FF814F712F87A4D94757D2002AC"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e4227-wk-Fact-65591C40B6FF9A07FC1694757D0FFC2A"
          xlink:label="d8372444e4227-wk-Fact-65591C40B6FF9A07FC1694757D0FFC2A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4227-wk-Fact-65591C40B6FF9A07FC1694757D0FFC2A"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4227-wk-Fact-65591C40B6FF9A07FC1694757D0FFC2A"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8351242e1548-wk-Fact-66612970542295C5EAA894757D5D6124"
          xlink:label="d8351242e1548-wk-Fact-66612970542295C5EAA894757D5D6124"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e1548-wk-Fact-66612970542295C5EAA894757D5D6124"
          xlink:to="TextSelection-A2DA5EF7B6FED024F0D494757DBA101E-0-wk-Footnote-A2DA5EF7B6FED024F0D494757DBA101E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2526-wk-Fact-669B95F4C67830F92DEA94757D66C77B"
          xlink:label="d8308070e2526-wk-Fact-669B95F4C67830F92DEA94757D66C77B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2526-wk-Fact-669B95F4C67830F92DEA94757D66C77B"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e9054-wk-Fact-67200BFFCD97D83C7D8E94757D555E87"
          xlink:label="d8415180e9054-wk-Fact-67200BFFCD97D83C7D8E94757D555E87"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e9054-wk-Fact-67200BFFCD97D83C7D8E94757D555E87"
          xlink:to="TextSelection-FE68345D83BB191130EF94757DC1B5E5-0-wk-Footnote-FE68345D83BB191130EF94757DC1B5E5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2482-wk-Fact-6846E2B46425F1D8EBA694757CDA487C"
          xlink:label="d8312059e2482-wk-Fact-6846E2B46425F1D8EBA694757CDA487C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2482-wk-Fact-6846E2B46425F1D8EBA694757CDA487C"
          xlink:to="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e9108-wk-Fact-68B318E9C2DB946F864A94757D889244"
          xlink:label="d8336633e9108-wk-Fact-68B318E9C2DB946F864A94757D889244"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e9108-wk-Fact-68B318E9C2DB946F864A94757D889244"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2183-wk-Fact-68D0815BB8658ED83E2294757CBEB1FA"
          xlink:label="d8308070e2183-wk-Fact-68D0815BB8658ED83E2294757CBEB1FA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2183-wk-Fact-68D0815BB8658ED83E2294757CBEB1FA"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e5378-wk-Fact-68D35D8323640620312994757D5EC94F"
          xlink:label="d8415180e5378-wk-Fact-68D35D8323640620312994757D5EC94F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e5378-wk-Fact-68D35D8323640620312994757D5EC94F"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2365-wk-Fact-68FD1EE0237F3359546394757CC70A3B"
          xlink:label="d8308070e2365-wk-Fact-68FD1EE0237F3359546394757CC70A3B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2365-wk-Fact-68FD1EE0237F3359546394757CC70A3B"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e4207-wk-Fact-69643034125B7437E33E94757D134BD5"
          xlink:label="d8372444e4207-wk-Fact-69643034125B7437E33E94757D134BD5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4207-wk-Fact-69643034125B7437E33E94757D134BD5"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4207-wk-Fact-69643034125B7437E33E94757D134BD5"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e10314-wk-Fact-699171B0726A36F4B73394757CB0310F"
          xlink:label="d8336633e10314-wk-Fact-699171B0726A36F4B73394757CB0310F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e10314-wk-Fact-699171B0726A36F4B73394757CB0310F"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1713-wk-Fact-69B15CEEDF1C91237BB494757CA88761"
          xlink:label="d8308070e1713-wk-Fact-69B15CEEDF1C91237BB494757CA88761"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1713-wk-Fact-69B15CEEDF1C91237BB494757CA88761"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e9127-wk-Fact-69B5FF4C482B5ABEA96994757CA8B7DD"
          xlink:label="d8336633e9127-wk-Fact-69B5FF4C482B5ABEA96994757CA8B7DD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e9127-wk-Fact-69B5FF4C482B5ABEA96994757CA8B7DD"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8342960e1050-wk-Fact-69F9CBEEF2E7911E725F94757CC7E199"
          xlink:label="d8342960e1050-wk-Fact-69F9CBEEF2E7911E725F94757CC7E199"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8342960e1050-wk-Fact-69F9CBEEF2E7911E725F94757CC7E199"
          xlink:to="TextSelection-BA004C096D54F3EE7B8394757DBF9C64-0-wk-Footnote-BA004C096D54F3EE7B8394757DBF9C64_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e1706-wk-Fact-6A34EC9ACE0CB4BA0A7B94757D93E196"
          xlink:label="d8415180e1706-wk-Fact-6A34EC9ACE0CB4BA0A7B94757D93E196"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e1706-wk-Fact-6A34EC9ACE0CB4BA0A7B94757D93E196"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e12772-wk-Fact-6A6B16B2145812FF4A4D94757D88E004"
          xlink:label="d8336633e12772-wk-Fact-6A6B16B2145812FF4A4D94757D88E004"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e12772-wk-Fact-6A6B16B2145812FF4A4D94757D88E004"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e8921-wk-Fact-6AE9A7E5A8423D56EB6794757D15EE65"
          xlink:label="d8336633e8921-wk-Fact-6AE9A7E5A8423D56EB6794757D15EE65"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8307028e2832-wk-Fact-6AE9A7E5A8423D56EB6794757D15EE65"
          xlink:label="d8307028e2832-wk-Fact-6AE9A7E5A8423D56EB6794757D15EE65"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e8921-wk-Fact-6AE9A7E5A8423D56EB6794757D15EE65"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2832-wk-Fact-6AE9A7E5A8423D56EB6794757D15EE65"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e8921-wk-Fact-6AE9A7E5A8423D56EB6794757D15EE65"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2832-wk-Fact-6AE9A7E5A8423D56EB6794757D15EE65"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8342313e1817-wk-Fact-6AFEFA4A1DCA7261A60294757D43054F"
          xlink:label="d8342313e1817-wk-Fact-6AFEFA4A1DCA7261A60294757D43054F"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-EF26E2A19056A9953CCA94757DBCDE30-0-wk-Footnote-EF26E2A19056A9953CCA94757DBCDE30_lbl" xlink:label="TextSelection-EF26E2A19056A9953CCA94757DBCDE30-0-wk-Footnote-EF26E2A19056A9953CCA94757DBCDE30_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">The effective interest rate for the notes at issuance was </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>2.67%</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8342313e1817-wk-Fact-6AFEFA4A1DCA7261A60294757D43054F"
          xlink:to="TextSelection-EF26E2A19056A9953CCA94757DBCDE30-0-wk-Footnote-EF26E2A19056A9953CCA94757DBCDE30_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2560-wk-Fact-6B0D0523D801B89879B094757D4B3266"
          xlink:label="d8301124e2560-wk-Fact-6B0D0523D801B89879B094757D4B3266"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2560-wk-Fact-6B0D0523D801B89879B094757D4B3266"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e3160-wk-Fact-6B111BE422485683C25B94757D205012"
          xlink:label="d8336633e3160-wk-Fact-6B111BE422485683C25B94757D205012"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3160-wk-Fact-6B111BE422485683C25B94757D205012"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1333-wk-Fact-6B2383F2FE5E4F5C1F8094757D03DB8C"
          xlink:label="d8301124e1333-wk-Fact-6B2383F2FE5E4F5C1F8094757D03DB8C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1333-wk-Fact-6B2383F2FE5E4F5C1F8094757D03DB8C"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e5200-wk-Fact-6B2DEA1574A1AAC388A194757D2E9D03"
          xlink:label="d8336633e5200-wk-Fact-6B2DEA1574A1AAC388A194757D2E9D03"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e5200-wk-Fact-6B2DEA1574A1AAC388A194757D2E9D03"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e3624-wk-Fact-6B84B600E6054E02ECF394757CEEFFA4"
          xlink:label="d8336633e3624-wk-Fact-6B84B600E6054E02ECF394757CEEFFA4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3624-wk-Fact-6B84B600E6054E02ECF394757CEEFFA4"
          xlink:to="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3624-wk-Fact-6B84B600E6054E02ECF394757CEEFFA4"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e1594-wk-Fact-6BC4DEBEF668519175DE94757D1D6772"
          xlink:label="d8336633e1594-wk-Fact-6BC4DEBEF668519175DE94757D1D6772"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e1594-wk-Fact-6BC4DEBEF668519175DE94757D1D6772"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8351242e7848-wk-Fact-6C93273338F344A1EC9D94757D345F29"
          xlink:label="d8351242e7848-wk-Fact-6C93273338F344A1EC9D94757D345F29"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e7848-wk-Fact-6C93273338F344A1EC9D94757D345F29"
          xlink:to="TextSelection-2167C2B3C67E3F1A9F6094757DBA8899-0-wk-Footnote-2167C2B3C67E3F1A9F6094757DBA8899_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e14720-wk-Fact-6CC9C84BFB612CF3CEE194757D856D94"
          xlink:label="d8336633e14720-wk-Fact-6CC9C84BFB612CF3CEE194757D856D94"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e14720-wk-Fact-6CC9C84BFB612CF3CEE194757D856D94"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e947-wk-Fact-6D0243B400427DDF73DD94757D73B062"
          xlink:label="d8340406e947-wk-Fact-6D0243B400427DDF73DD94757D73B062"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8415180e3524-wk-Fact-6D0243B400427DDF73DD94757D73B062"
          xlink:label="d8415180e3524-wk-Fact-6D0243B400427DDF73DD94757D73B062"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8415180e4701-wk-Fact-6D0243B400427DDF73DD94757D73B062"
          xlink:label="d8415180e4701-wk-Fact-6D0243B400427DDF73DD94757D73B062"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e947-wk-Fact-6D0243B400427DDF73DD94757D73B062"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e3524-wk-Fact-6D0243B400427DDF73DD94757D73B062"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e4701-wk-Fact-6D0243B400427DDF73DD94757D73B062"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e13042-wk-Fact-6D6F3CF5110AF0381DE894757D81F105"
          xlink:label="d8336633e13042-wk-Fact-6D6F3CF5110AF0381DE894757D81F105"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e13042-wk-Fact-6D6F3CF5110AF0381DE894757D81F105"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e8100-wk-Fact-6E0224238BF2056CE73A94757CD9F96F"
          xlink:label="d8415180e8100-wk-Fact-6E0224238BF2056CE73A94757CD9F96F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8100-wk-Fact-6E0224238BF2056CE73A94757CD9F96F"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8100-wk-Fact-6E0224238BF2056CE73A94757CD9F96F"
          xlink:to="TextSelection-4F6B4AE2D2C9909DF73D94757DC29A3E-0-wk-Footnote-4F6B4AE2D2C9909DF73D94757DC29A3E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8100-wk-Fact-6E0224238BF2056CE73A94757CD9F96F"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e2558-wk-Fact-6E65BB85082AE89519F994757CADB602"
          xlink:label="d8336633e2558-wk-Fact-6E65BB85082AE89519F994757CADB602"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e2558-wk-Fact-6E65BB85082AE89519F994757CADB602"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e1498-wk-Fact-6F2CE97D1E80554AD52594757CBE2E5A"
          xlink:label="d8372444e1498-wk-Fact-6F2CE97D1E80554AD52594757CBE2E5A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e1498-wk-Fact-6F2CE97D1E80554AD52594757CBE2E5A"
          xlink:to="TextSelection-D29E26CC6CF7C6248CEE94757DBD9743-0-wk-Footnote-D29E26CC6CF7C6248CEE94757DBD9743_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e1588-wk-Fact-6F4079F311DB52E2A33594757D365375"
          xlink:label="d8312059e1588-wk-Fact-6F4079F311DB52E2A33594757D365375"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e1588-wk-Fact-6F4079F311DB52E2A33594757D365375"
          xlink:to="TextSelection-AB3DF04F3446139615AC94757DB7D909-0-wk-Footnote-AB3DF04F3446139615AC94757DB7D909_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e11230-wk-Fact-6F6B5B603006C5DC41F794757D7CCE24"
          xlink:label="d8415180e11230-wk-Fact-6F6B5B603006C5DC41F794757D7CCE24"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e11230-wk-Fact-6F6B5B603006C5DC41F794757D7CCE24"
          xlink:to="TextSelection-33990A088D8DAE29233C94757DC283BE-0-wk-Footnote-33990A088D8DAE29233C94757DC283BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1636-wk-Fact-6FB75BBD46792B84303694757CCB8587"
          xlink:label="d8316808e1636-wk-Fact-6FB75BBD46792B84303694757CCB8587"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1636-wk-Fact-6FB75BBD46792B84303694757CCB8587"
          xlink:to="TextSelection-16CE381F2099EFC2DA1C94757DB87C39-0-wk-Footnote-16CE381F2099EFC2DA1C94757DB87C39_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e4359-wk-Fact-6FB75C33A442EECAAC2194757CF9FAAF"
          xlink:label="d8415180e4359-wk-Fact-6FB75C33A442EECAAC2194757CF9FAAF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e4359-wk-Fact-6FB75C33A442EECAAC2194757CF9FAAF"
          xlink:to="TextSelection-859D29FA558EAC3F73C294757DC172D8-0-wk-Footnote-859D29FA558EAC3F73C294757DC172D8_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e9319-wk-Fact-7015F6E30333F20A4CA094757D862B59"
          xlink:label="d8336633e9319-wk-Fact-7015F6E30333F20A4CA094757D862B59"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e9319-wk-Fact-7015F6E30333F20A4CA094757D862B59"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e3194-wk-Fact-7055D02214C4DCDBF2D794757D530978"
          xlink:label="d8336633e3194-wk-Fact-7055D02214C4DCDBF2D794757D530978"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3194-wk-Fact-7055D02214C4DCDBF2D794757D530978"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10026-wk-Fact-7097BD769E5D82E2973294757D7E414B"
          xlink:label="d8415180e10026-wk-Fact-7097BD769E5D82E2973294757D7E414B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10026-wk-Fact-7097BD769E5D82E2973294757D7E414B"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e2102-wk-Fact-7104406F477A093FDE41955D6E1319E3"
          xlink:label="d8316808e2102-wk-Fact-7104406F477A093FDE41955D6E1319E3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e2102-wk-Fact-7104406F477A093FDE41955D6E1319E3"
          xlink:to="TextSelection-9161826AA31A3194474594757DB9E2CF-0-wk-Footnote-9161826AA31A3194474594757DB9E2CF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1867-wk-Fact-715B435D745D4142E92394757CBCE93E"
          xlink:label="d8308070e1867-wk-Fact-715B435D745D4142E92394757CBCE93E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1867-wk-Fact-715B435D745D4142E92394757CBCE93E"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10927-wk-Fact-71BC4F00B5A98A968BFB94757D63CCD9"
          xlink:label="d8415180e10927-wk-Fact-71BC4F00B5A98A968BFB94757D63CCD9"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-D895C9E8DF19B244540094757DC27744-0-wk-Footnote-D895C9E8DF19B244540094757DC27744_lbl" xlink:label="TextSelection-D895C9E8DF19B244540094757DC27744-0-wk-Footnote-D895C9E8DF19B244540094757DC27744_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7.5pt;"><xhtml:span style="font-family:inherit;font-size:7.5pt;">On </xhtml:span><xhtml:span style="font-family:inherit;font-size:7.5pt;">July&#160;31, 2019</xhtml:span><xhtml:span style="font-family:inherit;font-size:7.5pt;">, Pfizer&#x2019;s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK&#x2019;s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see </xhtml:span><xhtml:span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Note 2B</xhtml:span><xhtml:span style="font-family:inherit;font-size:7.5pt;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10927-wk-Fact-71BC4F00B5A98A968BFB94757D63CCD9"
          xlink:to="TextSelection-D895C9E8DF19B244540094757DC27744-0-wk-Footnote-D895C9E8DF19B244540094757DC27744_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1808-wk-Fact-71E3A38CC9A24B60F06494757CF5F71C"
          xlink:label="d8316808e1808-wk-Fact-71E3A38CC9A24B60F06494757CF5F71C"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-23DF6508A1F2A3B1745994757DB98CA0-0-wk-Footnote-23DF6508A1F2A3B1745994757DB98CA0_lbl" xlink:label="TextSelection-23DF6508A1F2A3B1745994757DB98CA0-0-wk-Footnote-23DF6508A1F2A3B1745994757DB98CA0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">The first six months of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">2019</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> included intangible asset impairment charges of: (i) </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$90 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> related to WRDM IPR&amp;D, for a pre-clinical stage asset from our acquisition of Bamboo for gene therapies for the potential treatment of patients with certain rare diseases, which was the result of a determination to not use certain Bamboo IPR&amp;D acquired in future rare disease development, (ii) </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$40 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> related to an Upjohn finite-lived developed technology right, acquired in connection with our acquisition of King, for government defense products and reflected, among other things, updated commercial forecasts including manufacturing cost assumptions, and (iii) </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$10 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> related to a finite-lived developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus marketed in the U.S. market only, </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">associated with Biopharma and reflected</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, among other things, updated commercial forecasts. In addition, the first six months of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">2019</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> included other asset impairments of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$20 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:8pt;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1808-wk-Fact-71E3A38CC9A24B60F06494757CF5F71C"
          xlink:to="TextSelection-23DF6508A1F2A3B1745994757DB98CA0-0-wk-Footnote-23DF6508A1F2A3B1745994757DB98CA0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1526-wk-Fact-72309F9168907BDAA94794757D07D3DF"
          xlink:label="d8301124e1526-wk-Fact-72309F9168907BDAA94794757D07D3DF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1526-wk-Fact-72309F9168907BDAA94794757D07D3DF"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10193-wk-Fact-72CA6214585A5C8E5F0694757D4CBC86"
          xlink:label="d8415180e10193-wk-Fact-72CA6214585A5C8E5F0694757D4CBC86"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10193-wk-Fact-72CA6214585A5C8E5F0694757D4CBC86"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7658-wk-Fact-72D47C5CC041D7DBF47F955D6F25B06E"
          xlink:label="d8415180e7658-wk-Fact-72D47C5CC041D7DBF47F955D6F25B06E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7658-wk-Fact-72D47C5CC041D7DBF47F955D6F25B06E"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7658-wk-Fact-72D47C5CC041D7DBF47F955D6F25B06E"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336625e2508-wk-Fact-732C702072B79FA479FA94757D6913F9"
          xlink:label="d8336625e2508-wk-Fact-732C702072B79FA479FA94757D6913F9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336625e2508-wk-Fact-732C702072B79FA479FA94757D6913F9"
          xlink:to="TextSelection-83180A323F26770F5F9D94757DBB7831-0-wk-Footnote-83180A323F26770F5F9D94757DBB7831_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372420e5784-wk-Fact-7363C996912428EF761094757D8CDD06"
          xlink:label="d8372420e5784-wk-Fact-7363C996912428EF761094757D8CDD06"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372420e5784-wk-Fact-7363C996912428EF761094757D8CDD06"
          xlink:to="TextSelection-286F4719195A28A9913594757DC0B1B8-0-wk-Footnote-286F4719195A28A9913594757DC0B1B8_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2629-wk-Fact-73C8A01061ED49259E2594757CE5569D"
          xlink:label="d8312059e2629-wk-Fact-73C8A01061ED49259E2594757CE5569D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2629-wk-Fact-73C8A01061ED49259E2594757CE5569D"
          xlink:to="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e8172-wk-Fact-73D648F5F2FEA3A8D53594757D2191CE"
          xlink:label="d8372444e8172-wk-Fact-73D648F5F2FEA3A8D53594757D2191CE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e8172-wk-Fact-73D648F5F2FEA3A8D53594757D2191CE"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e8172-wk-Fact-73D648F5F2FEA3A8D53594757D2191CE"
          xlink:to="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e8172-wk-Fact-73D648F5F2FEA3A8D53594757D2191CE"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e8212-wk-Fact-73D86692FF1AB4C6A16994757D919ACA"
          xlink:label="d8415180e8212-wk-Fact-73D86692FF1AB4C6A16994757D919ACA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8212-wk-Fact-73D86692FF1AB4C6A16994757D919ACA"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8212-wk-Fact-73D86692FF1AB4C6A16994757D919ACA"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e5119-wk-Fact-73E5652390B0B6E33FBC94757CCAE2A9"
          xlink:label="d8372444e5119-wk-Fact-73E5652390B0B6E33FBC94757CCAE2A9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5119-wk-Fact-73E5652390B0B6E33FBC94757CCAE2A9"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5119-wk-Fact-73E5652390B0B6E33FBC94757CCAE2A9"
          xlink:to="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5119-wk-Fact-73E5652390B0B6E33FBC94757CCAE2A9"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e6533-wk-Fact-73F49BAF1651352ADB8A94757D370266"
          xlink:label="d8336633e6533-wk-Fact-73F49BAF1651352ADB8A94757D370266"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e6533-wk-Fact-73F49BAF1651352ADB8A94757D370266"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e4306-wk-Fact-73FE98C3916C85F549F794757D5AEA40"
          xlink:label="d8415180e4306-wk-Fact-73FE98C3916C85F549F794757D5AEA40"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e4306-wk-Fact-73FE98C3916C85F549F794757D5AEA40"
          xlink:to="TextSelection-859D29FA558EAC3F73C294757DC172D8-0-wk-Footnote-859D29FA558EAC3F73C294757DC172D8_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8357160e1429-wk-Fact-744F5D509D408BC3A18C94757CC8DCAC"
          xlink:label="d8357160e1429-wk-Fact-744F5D509D408BC3A18C94757CC8DCAC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e1429-wk-Fact-744F5D509D408BC3A18C94757CC8DCAC"
          xlink:to="TextSelection-B511D685B8F037FD258094757DBFC8C5-0-wk-Footnote-B511D685B8F037FD258094757DBFC8C5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336625e2527-wk-Fact-74E1087E683DE833774594757D710EBE"
          xlink:label="d8336625e2527-wk-Fact-74E1087E683DE833774594757D710EBE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336625e2527-wk-Fact-74E1087E683DE833774594757D710EBE"
          xlink:to="TextSelection-83180A323F26770F5F9D94757DBB7831-0-wk-Footnote-83180A323F26770F5F9D94757DBB7831_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e3179-wk-Fact-74F211B6DF9332B7854594757CED7C21"
          xlink:label="d8336633e3179-wk-Fact-74F211B6DF9332B7854594757CED7C21"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3179-wk-Fact-74F211B6DF9332B7854594757CED7C21"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e5915-wk-Fact-75007AA8D5BB2FDFE2F694757D2299DA"
          xlink:label="d8372444e5915-wk-Fact-75007AA8D5BB2FDFE2F694757D2299DA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5915-wk-Fact-75007AA8D5BB2FDFE2F694757D2299DA"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5915-wk-Fact-75007AA8D5BB2FDFE2F694757D2299DA"
          xlink:to="TextSelection-6EDC28E4739B45A7AA7C94757DBD8D30-0-wk-Footnote-6EDC28E4739B45A7AA7C94757DBD8D30_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5915-wk-Fact-75007AA8D5BB2FDFE2F694757D2299DA"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e11279-wk-Fact-7527AF621EA7D105014694757D491C4F"
          xlink:label="d8336633e11279-wk-Fact-7527AF621EA7D105014694757D491C4F"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e4027-wk-Fact-7527AF621EA7D105014694757D491C4F"
          xlink:label="d8336633e4027-wk-Fact-7527AF621EA7D105014694757D491C4F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e11279-wk-Fact-7527AF621EA7D105014694757D491C4F"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e4027-wk-Fact-7527AF621EA7D105014694757D491C4F"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e4438-wk-Fact-757B28C92C06735A064A94757D563E75"
          xlink:label="d8415180e4438-wk-Fact-757B28C92C06735A064A94757D563E75"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e4438-wk-Fact-757B28C92C06735A064A94757D563E75"
          xlink:to="TextSelection-C185F8237D4ED950685B94757DC105E4-0-wk-Footnote-C185F8237D4ED950685B94757DC105E4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7228-wk-Fact-75A819750D40D13F5F4D94757D59DF46"
          xlink:label="d8415180e7228-wk-Fact-75A819750D40D13F5F4D94757D59DF46"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7228-wk-Fact-75A819750D40D13F5F4D94757D59DF46"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7228-wk-Fact-75A819750D40D13F5F4D94757D59DF46"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e3781-wk-Fact-75ED33FE12B125B9E0C094757D134293"
          xlink:label="d8372444e3781-wk-Fact-75ED33FE12B125B9E0C094757D134293"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3781-wk-Fact-75ED33FE12B125B9E0C094757D134293"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e7264-wk-Fact-75FF99F8C13B7B51000994757D64A357"
          xlink:label="d8336633e7264-wk-Fact-75FF99F8C13B7B51000994757D64A357"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e7264-wk-Fact-75FF99F8C13B7B51000994757D64A357"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1144-wk-Fact-7647F4EED80B8447B7B494757D2B6C57"
          xlink:label="d8307028e1144-wk-Fact-7647F4EED80B8447B7B494757D2B6C57"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1144-wk-Fact-7647F4EED80B8447B7B494757D2B6C57"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e6454-wk-Fact-7693E162BA55D1667FBC94757D2195F2"
          xlink:label="d8336633e6454-wk-Fact-7693E162BA55D1667FBC94757D2195F2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e6454-wk-Fact-7693E162BA55D1667FBC94757D2195F2"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e6674-wk-Fact-76B77AEDB628C2C133C594757CF2E937"
          xlink:label="d8372444e6674-wk-Fact-76B77AEDB628C2C133C594757CF2E937"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e6674-wk-Fact-76B77AEDB628C2C133C594757CF2E937"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7174-wk-Fact-76C07D2D66C0388F0C0594757D012C55"
          xlink:label="d8415180e7174-wk-Fact-76C07D2D66C0388F0C0594757D012C55"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7174-wk-Fact-76C07D2D66C0388F0C0594757D012C55"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7174-wk-Fact-76C07D2D66C0388F0C0594757D012C55"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e4744-wk-Fact-76C2DA9EBF5CD4536E0394757D100987"
          xlink:label="d8372444e4744-wk-Fact-76C2DA9EBF5CD4536E0394757D100987"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4744-wk-Fact-76C2DA9EBF5CD4536E0394757D100987"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4744-wk-Fact-76C2DA9EBF5CD4536E0394757D100987"
          xlink:to="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4744-wk-Fact-76C2DA9EBF5CD4536E0394757D100987"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1877-wk-Fact-76D99E72799A7D1A6EEF94757D204BD6"
          xlink:label="d8307028e1877-wk-Fact-76D99E72799A7D1A6EEF94757D204BD6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1877-wk-Fact-76D99E72799A7D1A6EEF94757D204BD6"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e12505-wk-Fact-7710E5E7409968676DDF94757CB9616B"
          xlink:label="d8336633e12505-wk-Fact-7710E5E7409968676DDF94757CB9616B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e12505-wk-Fact-7710E5E7409968676DDF94757CB9616B"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e4598-wk-Fact-772041FC75DDB73FA59D94757D1262E8"
          xlink:label="d8372444e4598-wk-Fact-772041FC75DDB73FA59D94757D1262E8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4598-wk-Fact-772041FC75DDB73FA59D94757D1262E8"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4598-wk-Fact-772041FC75DDB73FA59D94757D1262E8"
          xlink:to="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4598-wk-Fact-772041FC75DDB73FA59D94757D1262E8"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e14118-wk-Fact-772E453E27BB5E8A941894757D862BB8"
          xlink:label="d8336633e14118-wk-Fact-772E453E27BB5E8A941894757D862BB8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e14118-wk-Fact-772E453E27BB5E8A941894757D862BB8"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e11293-wk-Fact-780C5B60A58937B5CFA594757D14130D"
          xlink:label="d8336633e11293-wk-Fact-780C5B60A58937B5CFA594757D14130D"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e4041-wk-Fact-780C5B60A58937B5CFA594757D14130D"
          xlink:label="d8336633e4041-wk-Fact-780C5B60A58937B5CFA594757D14130D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e11293-wk-Fact-780C5B60A58937B5CFA594757D14130D"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e4041-wk-Fact-780C5B60A58937B5CFA594757D14130D"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1921-wk-Fact-7815B96C1DE73848E04C94757D28CB62"
          xlink:label="d8307028e1921-wk-Fact-7815B96C1DE73848E04C94757D28CB62"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1921-wk-Fact-7815B96C1DE73848E04C94757D28CB62"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2475-wk-Fact-781D2814C0D7F0668EE394757D69DD6C"
          xlink:label="d8301124e2475-wk-Fact-781D2814C0D7F0668EE394757D69DD6C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2475-wk-Fact-781D2814C0D7F0668EE394757D69DD6C"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e949-wk-Fact-785332B79AA4618521F26EDD705A45C3"
          xlink:label="d8307028e949-wk-Fact-785332B79AA4618521F26EDD705A45C3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e949-wk-Fact-785332B79AA4618521F26EDD705A45C3"
          xlink:to="TextSelection-A69940B73F64268F0EB092D9B88F9F01-0-wk-Footnote-A69940B73F64268F0EB092D9B88F9F01_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e949-wk-Fact-785332B79AA4618521F26EDD705A45C3"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8351242e4823-wk-Fact-787DD497342D45C6DCBD94757D3F332F"
          xlink:label="d8351242e4823-wk-Fact-787DD497342D45C6DCBD94757D3F332F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e4823-wk-Fact-787DD497342D45C6DCBD94757D3F332F"
          xlink:to="TextSelection-11358084CF50DEC3FF92628C52236CBA-0-wk-Footnote-11358084CF50DEC3FF92628C52236CBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e1717-wk-Fact-788604D6690A503EC72D94757D52CBCB"
          xlink:label="d8312059e1717-wk-Fact-788604D6690A503EC72D94757D52CBCB"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8340406e1430-wk-Fact-788604D6690A503EC72D94757D52CBCB"
          xlink:label="d8340406e1430-wk-Fact-788604D6690A503EC72D94757D52CBCB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e1717-wk-Fact-788604D6690A503EC72D94757D52CBCB"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1430-wk-Fact-788604D6690A503EC72D94757D52CBCB"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e4570-wk-Fact-78CEBCE2B596295642A894757D5C66CC"
          xlink:label="d8415180e4570-wk-Fact-78CEBCE2B596295642A894757D5C66CC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e4570-wk-Fact-78CEBCE2B596295642A894757D5C66CC"
          xlink:to="TextSelection-AFB627DC6F652A9A0A0594757DC251B0-0-wk-Footnote-AFB627DC6F652A9A0A0594757DC251B0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e6408-wk-Fact-78E877E7F508BB5A1CBD94757D8CBBF4"
          xlink:label="d8372444e6408-wk-Fact-78E877E7F508BB5A1CBD94757D8CBBF4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e6408-wk-Fact-78E877E7F508BB5A1CBD94757D8CBBF4"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1982-wk-Fact-78F2B6044F533AECF79494757D13E2F0"
          xlink:label="d8308070e1982-wk-Fact-78F2B6044F533AECF79494757D13E2F0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1982-wk-Fact-78F2B6044F533AECF79494757D13E2F0"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2495-wk-Fact-78F48FB31891A5F2CA2794757CAAA5B9"
          xlink:label="d8301124e2495-wk-Fact-78F48FB31891A5F2CA2794757CAAA5B9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2495-wk-Fact-78F48FB31891A5F2CA2794757CAAA5B9"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2054-wk-Fact-792F383C3FEE0FE8090C94757CAF87DA"
          xlink:label="d8301124e2054-wk-Fact-792F383C3FEE0FE8090C94757CAF87DA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2054-wk-Fact-792F383C3FEE0FE8090C94757CAF87DA"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e4472-wk-Fact-7948B0B6844BD3D387BA94757CDB9B0C"
          xlink:label="d8415180e4472-wk-Fact-7948B0B6844BD3D387BA94757CDB9B0C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e4472-wk-Fact-7948B0B6844BD3D387BA94757CDB9B0C"
          xlink:to="TextSelection-C185F8237D4ED950685B94757DC105E4-0-wk-Footnote-C185F8237D4ED950685B94757DC105E4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2234-wk-Fact-795A73536189346A46BA94757D101516"
          xlink:label="d8307028e2234-wk-Fact-795A73536189346A46BA94757D101516"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2234-wk-Fact-795A73536189346A46BA94757D101516"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1893-wk-Fact-7973D60AC4E2ED9EA6D394757CF8B7E7"
          xlink:label="d8316808e1893-wk-Fact-7973D60AC4E2ED9EA6D394757CF8B7E7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1893-wk-Fact-7973D60AC4E2ED9EA6D394757CF8B7E7"
          xlink:to="TextSelection-3F1FDE51F00C4F037BC194757DB9000C-0-wk-Footnote-3F1FDE51F00C4F037BC194757DB9000C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2562-wk-Fact-7A14B07B1D3BB0FC8DEC94757D153837"
          xlink:label="d8340406e2562-wk-Fact-7A14B07B1D3BB0FC8DEC94757D153837"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2562-wk-Fact-7A14B07B1D3BB0FC8DEC94757D153837"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8351242e7379-wk-Fact-7A8A1B93604E236BB74394757D812BD2"
          xlink:label="d8351242e7379-wk-Fact-7A8A1B93604E236BB74394757D812BD2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e7379-wk-Fact-7A8A1B93604E236BB74394757D812BD2"
          xlink:to="TextSelection-DA70407E988FF7F4292CB0A472718D04-0-wk-Footnote-DA70407E988FF7F4292CB0A472718D04_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e2071-wk-Fact-7AA1C77DB5A3B4644A4C94757CE5FE83"
          xlink:label="d8336633e2071-wk-Fact-7AA1C77DB5A3B4644A4C94757CE5FE83"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e2071-wk-Fact-7AA1C77DB5A3B4644A4C94757CE5FE83"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e5080-wk-Fact-7AE0949565F5D585B74E94757D172848"
          xlink:label="d8372444e5080-wk-Fact-7AE0949565F5D585B74E94757D172848"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5080-wk-Fact-7AE0949565F5D585B74E94757D172848"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5080-wk-Fact-7AE0949565F5D585B74E94757D172848"
          xlink:to="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5080-wk-Fact-7AE0949565F5D585B74E94757D172848"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1138-wk-Fact-7AFC70661380E28E616594757CC3AFAE"
          xlink:label="d8316808e1138-wk-Fact-7AFC70661380E28E616594757CC3AFAE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1138-wk-Fact-7AFC70661380E28E616594757CC3AFAE"
          xlink:to="TextSelection-4E74A09462C596E2363694757DB8EB14-0-wk-Footnote-4E74A09462C596E2363694757DB8EB14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2604-wk-Fact-7B35AE5A591127B6882494757D496AF1"
          xlink:label="d8312059e2604-wk-Fact-7B35AE5A591127B6882494757D496AF1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2604-wk-Fact-7B35AE5A591127B6882494757D496AF1"
          xlink:to="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1121-wk-Fact-7B3AE2978F7C733A20D394757D149216"
          xlink:label="d8308070e1121-wk-Fact-7B3AE2978F7C733A20D394757D149216"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1121-wk-Fact-7B3AE2978F7C733A20D394757D149216"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e941-wk-Fact-7B3C46A754BAB4A857A994757D1275BE"
          xlink:label="d8308070e941-wk-Fact-7B3C46A754BAB4A857A994757D1275BE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e941-wk-Fact-7B3C46A754BAB4A857A994757D1275BE"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e8152-wk-Fact-7B71E458C4CB31B9B78E94757CEB94F1"
          xlink:label="d8372444e8152-wk-Fact-7B71E458C4CB31B9B78E94757CEB94F1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e8152-wk-Fact-7B71E458C4CB31B9B78E94757CEB94F1"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e8152-wk-Fact-7B71E458C4CB31B9B78E94757CEB94F1"
          xlink:to="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e8152-wk-Fact-7B71E458C4CB31B9B78E94757CEB94F1"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2504-wk-Fact-7BA1645714435EB2B3AB94757CC0F691"
          xlink:label="d8340406e2504-wk-Fact-7BA1645714435EB2B3AB94757CC0F691"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2504-wk-Fact-7BA1645714435EB2B3AB94757CC0F691"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e9207-wk-Fact-7BC374D8582E6B3D7CE3A1CD2E1DD218"
          xlink:label="d8372444e9207-wk-Fact-7BC374D8582E6B3D7CE3A1CD2E1DD218"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e9207-wk-Fact-7BC374D8582E6B3D7CE3A1CD2E1DD218"
          xlink:to="TextSelection-A6E5E77EFF2BB738D44C94757DBDF083-0-wk-Footnote-A6E5E77EFF2BB738D44C94757DBDF083_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2370-wk-Fact-7BD0F552906AEDAE43AB94757D064290"
          xlink:label="d8301124e2370-wk-Fact-7BD0F552906AEDAE43AB94757D064290"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2370-wk-Fact-7BD0F552906AEDAE43AB94757D064290"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e6994-wk-Fact-7BEE24816749E03906BD94757D9C4726"
          xlink:label="d8336633e6994-wk-Fact-7BEE24816749E03906BD94757D9C4726"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e6994-wk-Fact-7BEE24816749E03906BD94757D9C4726"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1907-wk-Fact-7C3725C3864FB58D26F294757DA59FB9"
          xlink:label="d8301124e1907-wk-Fact-7C3725C3864FB58D26F294757DA59FB9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1907-wk-Fact-7C3725C3864FB58D26F294757DA59FB9"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2209-wk-Fact-7C60FDCC13DD0DFF94DB94757D194622"
          xlink:label="d8307028e2209-wk-Fact-7C60FDCC13DD0DFF94DB94757D194622"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2209-wk-Fact-7C60FDCC13DD0DFF94DB94757D194622"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e7099-wk-Fact-7D1153C7730B6D08B22194757D258E58"
          xlink:label="d8372444e7099-wk-Fact-7D1153C7730B6D08B22194757D258E58"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7099-wk-Fact-7D1153C7730B6D08B22194757D258E58"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7099-wk-Fact-7D1153C7730B6D08B22194757D258E58"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1788-wk-Fact-7D400BB69B8260DBFA0194757D7158A5"
          xlink:label="d8340406e1788-wk-Fact-7D400BB69B8260DBFA0194757D7158A5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1788-wk-Fact-7D400BB69B8260DBFA0194757D7158A5"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e8302-wk-Fact-7D6E2CB63598393A1F6E94757D15BA01"
          xlink:label="d8372444e8302-wk-Fact-7D6E2CB63598393A1F6E94757D15BA01"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e8302-wk-Fact-7D6E2CB63598393A1F6E94757D15BA01"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e8302-wk-Fact-7D6E2CB63598393A1F6E94757D15BA01"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1666-wk-Fact-7DBB915490EEA28AD34F94757D1C965F"
          xlink:label="d8308070e1666-wk-Fact-7DBB915490EEA28AD34F94757D1C965F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1666-wk-Fact-7DBB915490EEA28AD34F94757D1C965F"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e981-wk-Fact-7DC06283FD051672522094757D4872EE"
          xlink:label="d8415180e981-wk-Fact-7DC06283FD051672522094757D4872EE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e981-wk-Fact-7DC06283FD051672522094757D4872EE"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e12419-wk-Fact-7DD25CF4297877D69E8D94757CAEE705"
          xlink:label="d8336633e12419-wk-Fact-7DD25CF4297877D69E8D94757CAEE705"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e12419-wk-Fact-7DD25CF4297877D69E8D94757CAEE705"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2501-wk-Fact-7DFB45BE4A92C05A7CE494757D5BC48C"
          xlink:label="d8308070e2501-wk-Fact-7DFB45BE4A92C05A7CE494757D5BC48C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2501-wk-Fact-7DFB45BE4A92C05A7CE494757D5BC48C"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1411-wk-Fact-7E093B7D90D64F5B13A494757D3BA82F"
          xlink:label="d8340406e1411-wk-Fact-7E093B7D90D64F5B13A494757D3BA82F"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8312059e1698-wk-Fact-7E093B7D90D64F5B13A494757D3BA82F"
          xlink:label="d8312059e1698-wk-Fact-7E093B7D90D64F5B13A494757D3BA82F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1411-wk-Fact-7E093B7D90D64F5B13A494757D3BA82F"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e1698-wk-Fact-7E093B7D90D64F5B13A494757D3BA82F"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e3904-wk-Fact-7E1F4D7F45796F888D3994757D152AA2"
          xlink:label="d8372444e3904-wk-Fact-7E1F4D7F45796F888D3994757D152AA2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3904-wk-Fact-7E1F4D7F45796F888D3994757D152AA2"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e5189-wk-Fact-7E38933CC8C6B3F78FD894757D1176A3"
          xlink:label="d8372444e5189-wk-Fact-7E38933CC8C6B3F78FD894757D1176A3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5189-wk-Fact-7E38933CC8C6B3F78FD894757D1176A3"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5189-wk-Fact-7E38933CC8C6B3F78FD894757D1176A3"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e3758-wk-Fact-7E6C55D0D09E306D959A94757D35315B"
          xlink:label="d8336633e3758-wk-Fact-7E6C55D0D09E306D959A94757D35315B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3758-wk-Fact-7E6C55D0D09E306D959A94757D35315B"
          xlink:to="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3758-wk-Fact-7E6C55D0D09E306D959A94757D35315B"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e4186-wk-Fact-7E8FD767BFA321ADA8D194757D17C3EB"
          xlink:label="d8372444e4186-wk-Fact-7E8FD767BFA321ADA8D194757D17C3EB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4186-wk-Fact-7E8FD767BFA321ADA8D194757D17C3EB"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4186-wk-Fact-7E8FD767BFA321ADA8D194757D17C3EB"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e3982-wk-Fact-7E9393AC0EF93702DEB094757D86B0EE"
          xlink:label="d8336633e3982-wk-Fact-7E9393AC0EF93702DEB094757D86B0EE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3982-wk-Fact-7E9393AC0EF93702DEB094757D86B0EE"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e2800-wk-Fact-7EC912EE8439671A25BF94757D7D989C"
          xlink:label="d8415180e2800-wk-Fact-7EC912EE8439671A25BF94757D7D989C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e2800-wk-Fact-7EC912EE8439671A25BF94757D7D989C"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2628-wk-Fact-7ECB63F5AF06861C1CE494757D0884D8"
          xlink:label="d8301124e2628-wk-Fact-7ECB63F5AF06861C1CE494757D0884D8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2628-wk-Fact-7ECB63F5AF06861C1CE494757D0884D8"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e14585-wk-Fact-7F0F15290F5E885CE3D794757CBEF8C8"
          xlink:label="d8336633e14585-wk-Fact-7F0F15290F5E885CE3D794757CBEF8C8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e14585-wk-Fact-7F0F15290F5E885CE3D794757CBEF8C8"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8356748e1570-wk-Fact-7F22D0DB6525173F13B494757CADCE97"
          xlink:label="d8356748e1570-wk-Fact-7F22D0DB6525173F13B494757CADCE97"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8340406e1975-wk-Fact-7F22D0DB6525173F13B494757CADCE97"
          xlink:label="d8340406e1975-wk-Fact-7F22D0DB6525173F13B494757CADCE97"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8356748e1570-wk-Fact-7F22D0DB6525173F13B494757CADCE97"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1975-wk-Fact-7F22D0DB6525173F13B494757CADCE97"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e4724-wk-Fact-7F531F08E0D50D0C134294757D23AAA5"
          xlink:label="d8372444e4724-wk-Fact-7F531F08E0D50D0C134294757D23AAA5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4724-wk-Fact-7F531F08E0D50D0C134294757D23AAA5"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4724-wk-Fact-7F531F08E0D50D0C134294757D23AAA5"
          xlink:to="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4724-wk-Fact-7F531F08E0D50D0C134294757D23AAA5"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7565-wk-Fact-7F5B6E7E28432773681794757D7346F3"
          xlink:label="d8415180e7565-wk-Fact-7F5B6E7E28432773681794757D7346F3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7565-wk-Fact-7F5B6E7E28432773681794757D7346F3"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7565-wk-Fact-7F5B6E7E28432773681794757D7346F3"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e5168-wk-Fact-7F7EA65841FA3F8EDE9D94757D1F6A7C"
          xlink:label="d8372444e5168-wk-Fact-7F7EA65841FA3F8EDE9D94757D1F6A7C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5168-wk-Fact-7F7EA65841FA3F8EDE9D94757D1F6A7C"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e973-wk-Fact-8056831472C93DFFBF7B94757D474450"
          xlink:label="d8415180e973-wk-Fact-8056831472C93DFFBF7B94757D474450"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e973-wk-Fact-8056831472C93DFFBF7B94757D474450"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2859-wk-Fact-80889F71FE2525C70D9194757D2B8EDC"
          xlink:label="d8308070e2859-wk-Fact-80889F71FE2525C70D9194757D2B8EDC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2859-wk-Fact-80889F71FE2525C70D9194757D2B8EDC"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2145-wk-Fact-81D654407A04152B766994757CDD8A45"
          xlink:label="d8312059e2145-wk-Fact-81D654407A04152B766994757CDD8A45"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2145-wk-Fact-81D654407A04152B766994757CDD8A45"
          xlink:to="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8351242e7282-wk-Fact-8289F953B8E0A1E31F6E94757D81004F"
          xlink:label="d8351242e7282-wk-Fact-8289F953B8E0A1E31F6E94757D81004F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e7282-wk-Fact-8289F953B8E0A1E31F6E94757D81004F"
          xlink:to="TextSelection-DA70407E988FF7F4292CB0A472718D04-0-wk-Footnote-DA70407E988FF7F4292CB0A472718D04_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e5353-wk-Fact-82E28E032D731899B0B694757D3E73D0"
          xlink:label="d8336633e5353-wk-Fact-82E28E032D731899B0B694757D3E73D0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e5353-wk-Fact-82E28E032D731899B0B694757D3E73D0"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e8882-wk-Fact-82E5812A435DA211399494757D905CAA"
          xlink:label="d8336633e8882-wk-Fact-82E5812A435DA211399494757D905CAA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e8882-wk-Fact-82E5812A435DA211399494757D905CAA"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2862-wk-Fact-82EF2E3D703744E0C13B94757D266699"
          xlink:label="d8307028e2862-wk-Fact-82EF2E3D703744E0C13B94757D266699"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2862-wk-Fact-82EF2E3D703744E0C13B94757D266699"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1681-wk-Fact-82F380CF07CFB5944E8F94757D071BF6"
          xlink:label="d8301124e1681-wk-Fact-82F380CF07CFB5944E8F94757D071BF6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1681-wk-Fact-82F380CF07CFB5944E8F94757D071BF6"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1681-wk-Fact-82F380CF07CFB5944E8F94757D071BF6"
          xlink:to="TextSelection-68FC3C25B884A32675EA544FA892CE0F-0-wk-Footnote-68FC3C25B884A32675EA544FA892CE0F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1619-wk-Fact-82FCBDB83EA92437E26C94757D5A5E10"
          xlink:label="d8340406e1619-wk-Fact-82FCBDB83EA92437E26C94757D5A5E10"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8316808e2257-wk-Fact-82FCBDB83EA92437E26C94757D5A5E10"
          xlink:label="d8316808e2257-wk-Fact-82FCBDB83EA92437E26C94757D5A5E10"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1619-wk-Fact-82FCBDB83EA92437E26C94757D5A5E10"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e2257-wk-Fact-82FCBDB83EA92437E26C94757D5A5E10"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1789-wk-Fact-82FFBC9E02C7EA63F21C94757D1C5F54"
          xlink:label="d8307028e1789-wk-Fact-82FFBC9E02C7EA63F21C94757D1C5F54"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1789-wk-Fact-82FFBC9E02C7EA63F21C94757D1C5F54"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e6955-wk-Fact-8333570EE1A66789FB2C94757D365212"
          xlink:label="d8336633e6955-wk-Fact-8333570EE1A66789FB2C94757D365212"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e6955-wk-Fact-8333570EE1A66789FB2C94757D365212"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e14907-wk-Fact-8376F4C46168FF741E3C94757D90B25B"
          xlink:label="d8336633e14907-wk-Fact-8376F4C46168FF741E3C94757D90B25B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e14907-wk-Fact-8376F4C46168FF741E3C94757D90B25B"
          xlink:to="TextSelection-DD7734E5853B41ABE8C8546D7049626E-0-wk-Footnote-DD7734E5853B41ABE8C8546D7049626E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e14907-wk-Fact-8376F4C46168FF741E3C94757D90B25B"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e3677-wk-Fact-8434DE738E1AB342D96E94757CCBDE53"
          xlink:label="d8372444e3677-wk-Fact-8434DE738E1AB342D96E94757CCBDE53"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3677-wk-Fact-8434DE738E1AB342D96E94757CCBDE53"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2255-wk-Fact-84746CEAE1028754282894757D242276"
          xlink:label="d8308070e2255-wk-Fact-84746CEAE1028754282894757D242276"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2255-wk-Fact-84746CEAE1028754282894757D242276"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2411-wk-Fact-8570BDBA5E94557A549C94757D4F36AD"
          xlink:label="d8301124e2411-wk-Fact-8570BDBA5E94557A549C94757D4F36AD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2411-wk-Fact-8570BDBA5E94557A549C94757D4F36AD"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1077-wk-Fact-8594983BDE02438B8CB794757D6E309D"
          xlink:label="d8316808e1077-wk-Fact-8594983BDE02438B8CB794757D6E309D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1077-wk-Fact-8594983BDE02438B8CB794757D6E309D"
          xlink:to="TextSelection-4E74A09462C596E2363694757DB8EB14-0-wk-Footnote-4E74A09462C596E2363694757DB8EB14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e2081-wk-Fact-8631DD50CCB968472578955D6DC81456"
          xlink:label="d8316808e2081-wk-Fact-8631DD50CCB968472578955D6DC81456"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e2081-wk-Fact-8631DD50CCB968472578955D6DC81456"
          xlink:to="TextSelection-9161826AA31A3194474594757DB9E2CF-0-wk-Footnote-9161826AA31A3194474594757DB9E2CF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e3010-wk-Fact-86D8DED1361AFC8ED58C94757D5FCC72"
          xlink:label="d8301124e3010-wk-Fact-86D8DED1361AFC8ED58C94757D5FCC72"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e3010-wk-Fact-86D8DED1361AFC8ED58C94757D5FCC72"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e1820-wk-Fact-871135383070AF575BE394757CEC460F"
          xlink:label="d8336633e1820-wk-Fact-871135383070AF575BE394757CEC460F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e1820-wk-Fact-871135383070AF575BE394757CEC460F"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10947-wk-Fact-871E915D2D6F3FDC5AE494757D0F306E"
          xlink:label="d8415180e10947-wk-Fact-871E915D2D6F3FDC5AE494757D0F306E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10947-wk-Fact-871E915D2D6F3FDC5AE494757D0F306E"
          xlink:to="TextSelection-D895C9E8DF19B244540094757DC27744-0-wk-Footnote-D895C9E8DF19B244540094757DC27744_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e5951-wk-Fact-8756F2FE82655E80079594757D3B1E62"
          xlink:label="d8415180e5951-wk-Fact-8756F2FE82655E80079594757D3B1E62"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e5951-wk-Fact-8756F2FE82655E80079594757D3B1E62"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10359-wk-Fact-87D917DF76C4DF6A2AA894757D7F7619"
          xlink:label="d8415180e10359-wk-Fact-87D917DF76C4DF6A2AA894757D7F7619"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10359-wk-Fact-87D917DF76C4DF6A2AA894757D7F7619"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e10876-wk-Fact-87E8BDB2D145CE8F51DF94757CB079E4"
          xlink:label="d8336633e10876-wk-Fact-87E8BDB2D145CE8F51DF94757CB079E4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e10876-wk-Fact-87E8BDB2D145CE8F51DF94757CB079E4"
          xlink:to="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e10876-wk-Fact-87E8BDB2D145CE8F51DF94757CB079E4"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e13553-wk-Fact-884749ED8C7327C2FD2094757D8E56E9"
          xlink:label="d8336633e13553-wk-Fact-884749ED8C7327C2FD2094757D8E56E9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e13553-wk-Fact-884749ED8C7327C2FD2094757D8E56E9"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e6219-wk-Fact-886DF198F4CB9AB4242C94757D9970F3"
          xlink:label="d8336633e6219-wk-Fact-886DF198F4CB9AB4242C94757D9970F3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e6219-wk-Fact-886DF198F4CB9AB4242C94757D9970F3"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e14370-wk-Fact-892DE8B531A6E01C09E194757CBBECA5"
          xlink:label="d8336633e14370-wk-Fact-892DE8B531A6E01C09E194757CBBECA5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e14370-wk-Fact-892DE8B531A6E01C09E194757CBBECA5"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e8232-wk-Fact-8936184B1403F72707B294757CFAA700"
          xlink:label="d8415180e8232-wk-Fact-8936184B1403F72707B294757CFAA700"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8232-wk-Fact-8936184B1403F72707B294757CFAA700"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8232-wk-Fact-8936184B1403F72707B294757CFAA700"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e1960-wk-Fact-8971E1C78383330CB40E94757CD5511C"
          xlink:label="d8415180e1960-wk-Fact-8971E1C78383330CB40E94757CD5511C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e1960-wk-Fact-8971E1C78383330CB40E94757CD5511C"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e9880-wk-Fact-8A47D4A42EA4801E113F94757D561064"
          xlink:label="d8415180e9880-wk-Fact-8A47D4A42EA4801E113F94757D561064"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e9880-wk-Fact-8A47D4A42EA4801E113F94757D561064"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e11105-wk-Fact-8AA71470C6F49FFEF87594757CBC671E"
          xlink:label="d8336633e11105-wk-Fact-8AA71470C6F49FFEF87594757CBC671E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e11105-wk-Fact-8AA71470C6F49FFEF87594757CBC671E"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e3263-wk-Fact-8AC90BDE6611C4D9613F94757D10F366"
          xlink:label="d8372444e3263-wk-Fact-8AC90BDE6611C4D9613F94757D10F366"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3263-wk-Fact-8AC90BDE6611C4D9613F94757D10F366"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3263-wk-Fact-8AC90BDE6611C4D9613F94757D10F366"
          xlink:to="TextSelection-6EDC28E4739B45A7AA7C94757DBD8D30-0-wk-Footnote-6EDC28E4739B45A7AA7C94757DBD8D30_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3263-wk-Fact-8AC90BDE6611C4D9613F94757D10F366"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e5691-wk-Fact-8ACA3083C920B54F8AEC94757D564AB6"
          xlink:label="d8415180e5691-wk-Fact-8ACA3083C920B54F8AEC94757D564AB6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e5691-wk-Fact-8ACA3083C920B54F8AEC94757D564AB6"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1420-wk-Fact-8B19463082CE6440AD3394757D03C123"
          xlink:label="d8301124e1420-wk-Fact-8B19463082CE6440AD3394757D03C123"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1420-wk-Fact-8B19463082CE6440AD3394757D03C123"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1420-wk-Fact-8B19463082CE6440AD3394757D03C123"
          xlink:to="TextSelection-A6080F3BC2CE36268D0F94757DB590DE-0-wk-Footnote-A6080F3BC2CE36268D0F94757DB590DE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1179-wk-Fact-8B3A1BD0379B26183EE994757D074D8C"
          xlink:label="d8340406e1179-wk-Fact-8B3A1BD0379B26183EE994757D074D8C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1179-wk-Fact-8B3A1BD0379B26183EE994757D074D8C"
          xlink:to="TextSelection-04B9B25659DF96CA86BF94757DB5CCE1-0-wk-Footnote-04B9B25659DF96CA86BF94757DB5CCE1_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1179-wk-Fact-8B3A1BD0379B26183EE994757D074D8C"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2971-wk-Fact-8BC82C6DDA70A7A2CF9894757D0335F3"
          xlink:label="d8301124e2971-wk-Fact-8BC82C6DDA70A7A2CF9894757D0335F3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2971-wk-Fact-8BC82C6DDA70A7A2CF9894757D0335F3"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e5931-wk-Fact-8C0A92F009A247D99EC694757D0E2AFB"
          xlink:label="d8415180e5931-wk-Fact-8C0A92F009A247D99EC694757D0E2AFB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e5931-wk-Fact-8C0A92F009A247D99EC694757D0E2AFB"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1866-wk-Fact-8C29FB80663D2D3FF01694757D04376B"
          xlink:label="d8301124e1866-wk-Fact-8C29FB80663D2D3FF01694757D04376B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1866-wk-Fact-8C29FB80663D2D3FF01694757D04376B"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1955-wk-Fact-8CA5088693E8928A2F7194757D5C8489"
          xlink:label="d8340406e1955-wk-Fact-8CA5088693E8928A2F7194757D5C8489"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8356748e1550-wk-Fact-8CA5088693E8928A2F7194757D5C8489"
          xlink:label="d8356748e1550-wk-Fact-8CA5088693E8928A2F7194757D5C8489"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1955-wk-Fact-8CA5088693E8928A2F7194757D5C8489"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8356748e1550-wk-Fact-8CA5088693E8928A2F7194757D5C8489"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e2961-wk-Fact-8CCA7F0CCF44F7EE009F94757CB0EAEE"
          xlink:label="d8415180e2961-wk-Fact-8CCA7F0CCF44F7EE009F94757CB0EAEE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e2961-wk-Fact-8CCA7F0CCF44F7EE009F94757CB0EAEE"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e3405-wk-Fact-8DD16E5EDE18E934E20F94757D84AC18"
          xlink:label="d8312059e3405-wk-Fact-8DD16E5EDE18E934E20F94757D84AC18"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-B92DE04072B96160C46394757DB7ADA1-0-wk-Footnote-B92DE04072B96160C46394757DB7ADA1_lbl" xlink:label="TextSelection-B92DE04072B96160C46394757DB7ADA1-0-wk-Footnote-B92DE04072B96160C46394757DB7ADA1_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">Included in </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Other current liabilities</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> (</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$714 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">) and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Other noncurrent liabilities</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> (</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$219 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">).</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e3405-wk-Fact-8DD16E5EDE18E934E20F94757D84AC18"
          xlink:to="TextSelection-B92DE04072B96160C46394757DB7ADA1-0-wk-Footnote-B92DE04072B96160C46394757DB7ADA1_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10119-wk-Fact-8DE5439DE42185EAD27394757D638D67"
          xlink:label="d8415180e10119-wk-Fact-8DE5439DE42185EAD27394757D638D67"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10119-wk-Fact-8DE5439DE42185EAD27394757D638D67"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1700-wk-Fact-8DE79CAD5240FF8E772794757CFDD19F"
          xlink:label="d8301124e1700-wk-Fact-8DE79CAD5240FF8E772794757CFDD19F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1700-wk-Fact-8DE79CAD5240FF8E772794757CFDD19F"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1700-wk-Fact-8DE79CAD5240FF8E772794757CFDD19F"
          xlink:to="TextSelection-68FC3C25B884A32675EA544FA892CE0F-0-wk-Footnote-68FC3C25B884A32675EA544FA892CE0F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e8212-wk-Fact-8EC2BB5B4C87C28113B894757D7D006B"
          xlink:label="d8372444e8212-wk-Fact-8EC2BB5B4C87C28113B894757D7D006B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e8212-wk-Fact-8EC2BB5B4C87C28113B894757D7D006B"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e8212-wk-Fact-8EC2BB5B4C87C28113B894757D7D006B"
          xlink:to="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e8212-wk-Fact-8EC2BB5B4C87C28113B894757D7D006B"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8356748e2298-wk-Fact-8EF576E428EEA952509894757D5DA535"
          xlink:label="d8356748e2298-wk-Fact-8EF576E428EEA952509894757D5DA535"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8340406e3300-wk-Fact-8EF576E428EEA952509894757D5DA535"
          xlink:label="d8340406e3300-wk-Fact-8EF576E428EEA952509894757D5DA535"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8356748e2298-wk-Fact-8EF576E428EEA952509894757D5DA535"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e3300-wk-Fact-8EF576E428EEA952509894757D5DA535"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e5912-wk-Fact-8F10AC75EAF3DB11CBFC94757D61D1B8"
          xlink:label="d8415180e5912-wk-Fact-8F10AC75EAF3DB11CBFC94757D61D1B8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e5912-wk-Fact-8F10AC75EAF3DB11CBFC94757D61D1B8"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8314038e2485-wk-Fact-8F362BEF2AB5D5597E6394757CFFD802"
          xlink:label="d8314038e2485-wk-Fact-8F362BEF2AB5D5597E6394757CFFD802"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8301124e2714-wk-Fact-8F362BEF2AB5D5597E6394757CFFD802"
          xlink:label="d8301124e2714-wk-Fact-8F362BEF2AB5D5597E6394757CFFD802"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8314038e2485-wk-Fact-8F362BEF2AB5D5597E6394757CFFD802"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2714-wk-Fact-8F362BEF2AB5D5597E6394757CFFD802"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2931-wk-Fact-8F56B752B32B070AE71194757D815A0F"
          xlink:label="d8301124e2931-wk-Fact-8F56B752B32B070AE71194757D815A0F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2931-wk-Fact-8F56B752B32B070AE71194757D815A0F"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e7249-wk-Fact-8F5ED7D1B0A0EF78888F94757D1CDBFD"
          xlink:label="d8336633e7249-wk-Fact-8F5ED7D1B0A0EF78888F94757D1CDBFD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e7249-wk-Fact-8F5ED7D1B0A0EF78888F94757D1CDBFD"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-8F6198A5B84A323EA04194757CDD184D-wk-Fact-8F6198A5B84A323EA04194757CDD184D"
          xlink:label="Fact-8F6198A5B84A323EA04194757CDD184D-wk-Fact-8F6198A5B84A323EA04194757CDD184D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-8F6198A5B84A323EA04194757CDD184D-wk-Fact-8F6198A5B84A323EA04194757CDD184D"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e2177-wk-Fact-8F668F0BF6E37C3A8D6394757D92EEEB"
          xlink:label="d8415180e2177-wk-Fact-8F668F0BF6E37C3A8D6394757D92EEEB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e2177-wk-Fact-8F668F0BF6E37C3A8D6394757D92EEEB"
          xlink:to="TextSelection-9BC3436E7B9C00975CD394757DC16C56-0-wk-Footnote-9BC3436E7B9C00975CD394757DC16C56_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1257-wk-Fact-902EBA952C8391060B6994757CB1FFC1"
          xlink:label="d8308070e1257-wk-Fact-902EBA952C8391060B6994757CB1FFC1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1257-wk-Fact-902EBA952C8391060B6994757CB1FFC1"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2101-wk-Fact-9072FFD068100079F81B94757D26A3EC"
          xlink:label="d8307028e2101-wk-Fact-9072FFD068100079F81B94757D26A3EC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2101-wk-Fact-9072FFD068100079F81B94757D26A3EC"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1612-wk-Fact-9116D9DA0452E7895E8B94757D09EEB9"
          xlink:label="d8301124e1612-wk-Fact-9116D9DA0452E7895E8B94757D09EEB9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1612-wk-Fact-9116D9DA0452E7895E8B94757D09EEB9"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e5373-wk-Fact-917DA1C330410587B66094757D7DD34A"
          xlink:label="d8336633e5373-wk-Fact-917DA1C330410587B66094757D7DD34A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e5373-wk-Fact-917DA1C330410587B66094757D7DD34A"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2545-wk-Fact-91CD03BF7899EC259FA294757CBB3C78"
          xlink:label="d8308070e2545-wk-Fact-91CD03BF7899EC259FA294757CBB3C78"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2545-wk-Fact-91CD03BF7899EC259FA294757CBB3C78"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2248-wk-Fact-9209A09A308FD4F6E18194757D3C8964"
          xlink:label="d8312059e2248-wk-Fact-9209A09A308FD4F6E18194757D3C8964"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2248-wk-Fact-9209A09A308FD4F6E18194757D3C8964"
          xlink:to="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e2752-wk-Fact-920B734C19194AC1B01F94757D8C8380"
          xlink:label="d8336633e2752-wk-Fact-920B734C19194AC1B01F94757D8C8380"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e2752-wk-Fact-920B734C19194AC1B01F94757D8C8380"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e13082-wk-Fact-920C774D6C3160546F7D94757DA37E07"
          xlink:label="d8336633e13082-wk-Fact-920C774D6C3160546F7D94757DA37E07"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8301124e2847-wk-Fact-920C774D6C3160546F7D94757DA37E07"
          xlink:label="d8301124e2847-wk-Fact-920C774D6C3160546F7D94757DA37E07"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e13082-wk-Fact-920C774D6C3160546F7D94757DA37E07"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2847-wk-Fact-920C774D6C3160546F7D94757DA37E07"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e13082-wk-Fact-920C774D6C3160546F7D94757DA37E07"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2847-wk-Fact-920C774D6C3160546F7D94757DA37E07"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1952-wk-Fact-926EAF034EA59D57AB4A94757D085C80"
          xlink:label="d8301124e1952-wk-Fact-926EAF034EA59D57AB4A94757D085C80"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1952-wk-Fact-926EAF034EA59D57AB4A94757D085C80"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2594-wk-Fact-92C5E71226171D8AEF1294757CAFE14B"
          xlink:label="d8308070e2594-wk-Fact-92C5E71226171D8AEF1294757CAFE14B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2594-wk-Fact-92C5E71226171D8AEF1294757CAFE14B"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312053e1269-wk-Fact-93B22A2A5674F48F52DF94757CE4EB2F"
          xlink:label="d8312053e1269-wk-Fact-93B22A2A5674F48F52DF94757CE4EB2F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312053e1269-wk-Fact-93B22A2A5674F48F52DF94757CE4EB2F"
          xlink:to="TextSelection-9459A99A0EC8DD1CD04094757DBA4F65-0-wk-Footnote-9459A99A0EC8DD1CD04094757DBA4F65_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1218-wk-Fact-93E10BD448FBEAA578FD94757D709889"
          xlink:label="d8340406e1218-wk-Fact-93E10BD448FBEAA578FD94757D709889"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1218-wk-Fact-93E10BD448FBEAA578FD94757D709889"
          xlink:to="TextSelection-04B9B25659DF96CA86BF94757DB5CCE1-0-wk-Footnote-04B9B25659DF96CA86BF94757DB5CCE1_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1218-wk-Fact-93E10BD448FBEAA578FD94757D709889"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e6828-wk-Fact-93E2B34C852B38B85FA394757D2258B2"
          xlink:label="d8336633e6828-wk-Fact-93E2B34C852B38B85FA394757D2258B2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e6828-wk-Fact-93E2B34C852B38B85FA394757D2258B2"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2910-wk-Fact-9485DE235A3009893D3694757CC67D4F"
          xlink:label="d8308070e2910-wk-Fact-9485DE235A3009893D3694757CC67D4F"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8308070e1050-wk-Fact-9485DE235A3009893D3694757CC67D4F"
          xlink:label="d8308070e1050-wk-Fact-9485DE235A3009893D3694757CC67D4F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2910-wk-Fact-9485DE235A3009893D3694757CC67D4F"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1050-wk-Fact-9485DE235A3009893D3694757CC67D4F"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-FE05511B3F59D62E086994757DB6CDC4-0-wk-Footnote-FE05511B3F59D62E086994757DB6CDC4_lbl" xlink:label="TextSelection-FE05511B3F59D62E086994757DB6CDC4-0-wk-Footnote-FE05511B3F59D62E086994757DB6CDC4_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">As a result of the enactment of the TCJA in December 2017, Pfizer&#x2019;s </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Provision/(benefit) for taxes on income</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> for the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">six months ended June 30, 2019</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> was favorably impacted by approximately </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$285 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, primarily as a result of additional guidance issued by the U.S. Department of Treasury.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2910-wk-Fact-9485DE235A3009893D3694757CC67D4F"
          xlink:to="TextSelection-FE05511B3F59D62E086994757DB6CDC4-0-wk-Footnote-FE05511B3F59D62E086994757DB6CDC4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1050-wk-Fact-9485DE235A3009893D3694757CC67D4F"
          xlink:to="TextSelection-FE05511B3F59D62E086994757DB6CDC4-0-wk-Footnote-FE05511B3F59D62E086994757DB6CDC4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2456-wk-Fact-9509BBD7999258CA6CC694757D1611AA"
          xlink:label="d8308070e2456-wk-Fact-9509BBD7999258CA6CC694757D1611AA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2456-wk-Fact-9509BBD7999258CA6CC694757D1611AA"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8357160e2335-wk-Fact-9571AA75C6659383FDA794757CCEA9E9"
          xlink:label="d8357160e2335-wk-Fact-9571AA75C6659383FDA794757CCEA9E9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8357160e2297-wk-Fact-9571AA75C6659383FDA794757CCEA9E9"
          xlink:label="d8357160e2297-wk-Fact-9571AA75C6659383FDA794757CCEA9E9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e2335-wk-Fact-9571AA75C6659383FDA794757CCEA9E9"
          xlink:to="TextSelection-84058C93858F4EB1F00C631013E8EF74-0-wk-Footnote-84058C93858F4EB1F00C631013E8EF74_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e2297-wk-Fact-9571AA75C6659383FDA794757CCEA9E9"
          xlink:to="TextSelection-84058C93858F4EB1F00C631013E8EF74-0-wk-Footnote-84058C93858F4EB1F00C631013E8EF74_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1971-wk-Fact-960E53D0B504F694E33294757D577481"
          xlink:label="d8301124e1971-wk-Fact-960E53D0B504F694E33294757D577481"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1971-wk-Fact-960E53D0B504F694E33294757D577481"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1764-wk-Fact-961167284F5E861B1C9094757D0AD393"
          xlink:label="d8301124e1764-wk-Fact-961167284F5E861B1C9094757D0AD393"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1764-wk-Fact-961167284F5E861B1C9094757D0AD393"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312053e1289-wk-Fact-964325EF1A54729D824194757CE58552"
          xlink:label="d8312053e1289-wk-Fact-964325EF1A54729D824194757CE58552"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312053e1289-wk-Fact-964325EF1A54729D824194757CE58552"
          xlink:to="TextSelection-9459A99A0EC8DD1CD04094757DBA4F65-0-wk-Footnote-9459A99A0EC8DD1CD04094757DBA4F65_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10660-wk-Fact-964D5983FAFE8F814A6063A28D7FB945"
          xlink:label="d8415180e10660-wk-Fact-964D5983FAFE8F814A6063A28D7FB945"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10660-wk-Fact-964D5983FAFE8F814A6063A28D7FB945"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1016-wk-Fact-964F368B32E366CCC9BC94757CFB473E"
          xlink:label="d8316808e1016-wk-Fact-964F368B32E366CCC9BC94757CFB473E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1016-wk-Fact-964F368B32E366CCC9BC94757CFB473E"
          xlink:to="TextSelection-4E74A09462C596E2363694757DB8EB14-0-wk-Footnote-4E74A09462C596E2363694757DB8EB14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8357160e2506-wk-Fact-96604F15C352A725BF5594757CF6074A"
          xlink:label="d8357160e2506-wk-Fact-96604F15C352A725BF5594757CF6074A"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8357160e1758-wk-Fact-96604F15C352A725BF5594757CF6074A"
          xlink:label="d8357160e1758-wk-Fact-96604F15C352A725BF5594757CF6074A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e2506-wk-Fact-96604F15C352A725BF5594757CF6074A"
          xlink:to="TextSelection-76B1871DA30219820FCB63105DB9E5C3-0-wk-Footnote-76B1871DA30219820FCB63105DB9E5C3_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e1758-wk-Fact-96604F15C352A725BF5594757CF6074A"
          xlink:to="TextSelection-76B1871DA30219820FCB63105DB9E5C3-0-wk-Footnote-76B1871DA30219820FCB63105DB9E5C3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e9149-wk-Fact-9686F21840EBB7B77D77A1CD25DC8AFE"
          xlink:label="d8372444e9149-wk-Fact-9686F21840EBB7B77D77A1CD25DC8AFE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e9149-wk-Fact-9686F21840EBB7B77D77A1CD25DC8AFE"
          xlink:to="TextSelection-A6E5E77EFF2BB738D44C94757DBDF083-0-wk-Footnote-A6E5E77EFF2BB738D44C94757DBDF083_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e9093-wk-Fact-96E3B27F72377D1E7FE194757D98AE8A"
          xlink:label="d8415180e9093-wk-Fact-96E3B27F72377D1E7FE194757D98AE8A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e9093-wk-Fact-96E3B27F72377D1E7FE194757D98AE8A"
          xlink:to="TextSelection-FE68345D83BB191130EF94757DC1B5E5-0-wk-Footnote-FE68345D83BB191130EF94757DC1B5E5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2201-wk-Fact-9786DDF8A69B3054F6C594757D0258B2"
          xlink:label="d8301124e2201-wk-Fact-9786DDF8A69B3054F6C594757D0258B2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2201-wk-Fact-9786DDF8A69B3054F6C594757D0258B2"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e13472-wk-Fact-97B0ABF7AD141BFC956394757D9158BA"
          xlink:label="d8336633e13472-wk-Fact-97B0ABF7AD141BFC956394757D9158BA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e13472-wk-Fact-97B0ABF7AD141BFC956394757D9158BA"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e5819-wk-Fact-97E6BE9DD3E7475F229D94757D38F45F"
          xlink:label="d8415180e5819-wk-Fact-97E6BE9DD3E7475F229D94757D38F45F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e5819-wk-Fact-97E6BE9DD3E7475F229D94757D38F45F"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e3530-wk-Fact-981984D45830B3785BF594757D89A644"
          xlink:label="d8312059e3530-wk-Fact-981984D45830B3785BF594757D89A644"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e3530-wk-Fact-981984D45830B3785BF594757D89A644"
          xlink:to="TextSelection-823D9AE8DB976ECBCA9594757DB72C08-0-wk-Footnote-823D9AE8DB976ECBCA9594757DB72C08_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2734-wk-Fact-98256D21B98CE406359794757D62CC7A"
          xlink:label="d8301124e2734-wk-Fact-98256D21B98CE406359794757D62CC7A"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8314038e2506-wk-Fact-98256D21B98CE406359794757D62CC7A"
          xlink:label="d8314038e2506-wk-Fact-98256D21B98CE406359794757D62CC7A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2734-wk-Fact-98256D21B98CE406359794757D62CC7A"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8314038e2506-wk-Fact-98256D21B98CE406359794757D62CC7A"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e8193-wk-Fact-983ACA3C5EAC7B373D6394757D08EA2C"
          xlink:label="d8415180e8193-wk-Fact-983ACA3C5EAC7B373D6394757D08EA2C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8193-wk-Fact-983ACA3C5EAC7B373D6394757D08EA2C"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8193-wk-Fact-983ACA3C5EAC7B373D6394757D08EA2C"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e6494-wk-Fact-9864AFACC9ABDC5E1CF694757CC9DE4C"
          xlink:label="d8336633e6494-wk-Fact-9864AFACC9ABDC5E1CF694757CC9DE4C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e6494-wk-Fact-9864AFACC9ABDC5E1CF694757CC9DE4C"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336625e4109-wk-Fact-98787FFB4C950A5BBD0194757CE6C4FB"
          xlink:label="d8336625e4109-wk-Fact-98787FFB4C950A5BBD0194757CE6C4FB"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8316808e1479-wk-Fact-98787FFB4C950A5BBD0194757CE6C4FB"
          xlink:label="d8316808e1479-wk-Fact-98787FFB4C950A5BBD0194757CE6C4FB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336625e4109-wk-Fact-98787FFB4C950A5BBD0194757CE6C4FB"
          xlink:to="TextSelection-467F12A5D203A9A15C3A94757DB81B0A-0-wk-Footnote-467F12A5D203A9A15C3A94757DB81B0A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1479-wk-Fact-98787FFB4C950A5BBD0194757CE6C4FB"
          xlink:to="TextSelection-467F12A5D203A9A15C3A94757DB81B0A-0-wk-Footnote-467F12A5D203A9A15C3A94757DB81B0A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336625e4109-wk-Fact-98787FFB4C950A5BBD0194757CE6C4FB"
          xlink:to="TextSelection-9F5C431DBFAA147134E594757DBBC55E-0-wk-Footnote-9F5C431DBFAA147134E594757DBBC55E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1479-wk-Fact-98787FFB4C950A5BBD0194757CE6C4FB"
          xlink:to="TextSelection-9F5C431DBFAA147134E594757DBBC55E-0-wk-Footnote-9F5C431DBFAA147134E594757DBBC55E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e2166-wk-Fact-98D14E7EA5371F942F3394757CCE8CDC"
          xlink:label="d8316808e2166-wk-Fact-98D14E7EA5371F942F3394757CCE8CDC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e2166-wk-Fact-98D14E7EA5371F942F3394757CCE8CDC"
          xlink:to="TextSelection-420C4A044883B0052AE85E76395259A9-0-wk-Footnote-420C4A044883B0052AE85E76395259A9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e4325-wk-Fact-994F255F78B05FBADDEC94757D595A9A"
          xlink:label="d8415180e4325-wk-Fact-994F255F78B05FBADDEC94757D595A9A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e4325-wk-Fact-994F255F78B05FBADDEC94757D595A9A"
          xlink:to="TextSelection-859D29FA558EAC3F73C294757DC172D8-0-wk-Footnote-859D29FA558EAC3F73C294757DC172D8_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e5398-wk-Fact-99DCC47DA679E57EDCE694757D4966B0"
          xlink:label="d8415180e5398-wk-Fact-99DCC47DA679E57EDCE694757D4966B0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e5398-wk-Fact-99DCC47DA679E57EDCE694757D4966B0"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8329819e910-wk-Fact-9A056798B17100CAB31894757D0A17AE"
          xlink:label="d8329819e910-wk-Fact-9A056798B17100CAB31894757D0A17AE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8329819e910-wk-Fact-9A056798B17100CAB31894757D0A17AE"
          xlink:to="TextSelection-09307D44CBA12BFE03A594757DBC3C9D-0-wk-Footnote-09307D44CBA12BFE03A594757DBC3C9D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8351242e4842-wk-Fact-9A214797BCD7FFF4A83494757D3BB1A1"
          xlink:label="d8351242e4842-wk-Fact-9A214797BCD7FFF4A83494757D3BB1A1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e4842-wk-Fact-9A214797BCD7FFF4A83494757D3BB1A1"
          xlink:to="TextSelection-11358084CF50DEC3FF92628C52236CBA-0-wk-Footnote-11358084CF50DEC3FF92628C52236CBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2284-wk-Fact-9A3535709176CD3B928494757D5A0A52"
          xlink:label="d8301124e2284-wk-Fact-9A3535709176CD3B928494757D5A0A52"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2284-wk-Fact-9A3535709176CD3B928494757D5A0A52"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8351242e3297-wk-Fact-9AC586B89CDBD7EC4F6194757CAFC880"
          xlink:label="d8351242e3297-wk-Fact-9AC586B89CDBD7EC4F6194757CAFC880"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e3297-wk-Fact-9AC586B89CDBD7EC4F6194757CAFC880"
          xlink:to="TextSelection-8224B42439E7CCC8C3C594757DBA701B-0-wk-Footnote-8224B42439E7CCC8C3C594757DBA701B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2013-wk-Fact-9B484215869CDB3979AE94757D159E88"
          xlink:label="d8307028e2013-wk-Fact-9B484215869CDB3979AE94757D159E88"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2013-wk-Fact-9B484215869CDB3979AE94757D159E88"
          xlink:to="TextSelection-A69940B73F64268F0EB092D9B88F9F01-0-wk-Footnote-A69940B73F64268F0EB092D9B88F9F01_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2013-wk-Fact-9B484215869CDB3979AE94757D159E88"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e4704-wk-Fact-9B5EAA42679A56C367D494757D12A858"
          xlink:label="d8372444e4704-wk-Fact-9B5EAA42679A56C367D494757D12A858"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4704-wk-Fact-9B5EAA42679A56C367D494757D12A858"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4704-wk-Fact-9B5EAA42679A56C367D494757D12A858"
          xlink:to="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4704-wk-Fact-9B5EAA42679A56C367D494757D12A858"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2058-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9"
          xlink:label="d8340406e2058-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8308070e877-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9"
          xlink:label="d8308070e877-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e12850-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9"
          xlink:label="d8336633e12850-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8301124e969-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9"
          xlink:label="d8301124e969-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2058-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e877-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e12850-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e969-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2058-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e877-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e12850-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e969-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2058-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e877-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e12850-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e969-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2058-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e877-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e12850-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e969-wk-Fact-9B6D4ACB22DCB006826794757D66ACC9"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e5359-wk-Fact-9B8010AEEE0CA7C861B494757D62CEEB"
          xlink:label="d8415180e5359-wk-Fact-9B8010AEEE0CA7C861B494757D62CEEB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e5359-wk-Fact-9B8010AEEE0CA7C861B494757D62CEEB"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2320-wk-Fact-9BECE1ABEA4FD6DB7B8A94757D65CB34"
          xlink:label="d8308070e2320-wk-Fact-9BECE1ABEA4FD6DB7B8A94757D65CB34"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2320-wk-Fact-9BECE1ABEA4FD6DB7B8A94757D65CB34"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1303-wk-Fact-9C03A5BC963DD5615ABA94757D2C3607"
          xlink:label="d8340406e1303-wk-Fact-9C03A5BC963DD5615ABA94757D2C3607"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1303-wk-Fact-9C03A5BC963DD5615ABA94757D2C3607"
          xlink:to="TextSelection-04B9B25659DF96CA86BF94757DB5CCE1-0-wk-Footnote-04B9B25659DF96CA86BF94757DB5CCE1_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1303-wk-Fact-9C03A5BC963DD5615ABA94757D2C3607"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8357160e2527-wk-Fact-9C96864A6997B214807194757D2B762A"
          xlink:label="d8357160e2527-wk-Fact-9C96864A6997B214807194757D2B762A"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8307028e1346-wk-Fact-9C96864A6997B214807194757D2B762A"
          xlink:label="d8307028e1346-wk-Fact-9C96864A6997B214807194757D2B762A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e2527-wk-Fact-9C96864A6997B214807194757D2B762A"
          xlink:to="TextSelection-76B1871DA30219820FCB63105DB9E5C3-0-wk-Footnote-76B1871DA30219820FCB63105DB9E5C3_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1346-wk-Fact-9C96864A6997B214807194757D2B762A"
          xlink:to="TextSelection-76B1871DA30219820FCB63105DB9E5C3-0-wk-Footnote-76B1871DA30219820FCB63105DB9E5C3_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e2527-wk-Fact-9C96864A6997B214807194757D2B762A"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1346-wk-Fact-9C96864A6997B214807194757D2B762A"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e14447-wk-Fact-9CEB92503A38A9B5DBE094757CB7FA3C"
          xlink:label="d8336633e14447-wk-Fact-9CEB92503A38A9B5DBE094757CB7FA3C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e14447-wk-Fact-9CEB92503A38A9B5DBE094757CB7FA3C"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e6300-wk-Fact-9D649DDE4C8F1EF5140994757D200949"
          xlink:label="d8336633e6300-wk-Fact-9D649DDE4C8F1EF5140994757D200949"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e6300-wk-Fact-9D649DDE4C8F1EF5140994757D200949"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e3366-wk-Fact-9D99FC5004F5F45EB50094757D8BBD01"
          xlink:label="d8312059e3366-wk-Fact-9D99FC5004F5F45EB50094757D8BBD01"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e3366-wk-Fact-9D99FC5004F5F45EB50094757D8BBD01"
          xlink:to="TextSelection-B92DE04072B96160C46394757DB7ADA1-0-wk-Footnote-B92DE04072B96160C46394757DB7ADA1_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e1443-wk-Fact-9D9F803549723F3037FC94757CE1E2E0"
          xlink:label="d8312059e1443-wk-Fact-9D9F803549723F3037FC94757CE1E2E0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e1443-wk-Fact-9D9F803549723F3037FC94757CE1E2E0"
          xlink:to="TextSelection-A2331388F2C895076E3994757DB73022-0-wk-Footnote-A2331388F2C895076E3994757DB73022_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2062-wk-Fact-9F156B344E4DD52CA8B394757CE34982"
          xlink:label="d8312059e2062-wk-Fact-9F156B344E4DD52CA8B394757CE34982"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2062-wk-Fact-9F156B344E4DD52CA8B394757CE34982"
          xlink:to="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1057-wk-Fact-9F5350C0F6B6CC70CC8D94757CEE92D7"
          xlink:label="d8316808e1057-wk-Fact-9F5350C0F6B6CC70CC8D94757CEE92D7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1057-wk-Fact-9F5350C0F6B6CC70CC8D94757CEE92D7"
          xlink:to="TextSelection-4E74A09462C596E2363694757DB8EB14-0-wk-Footnote-4E74A09462C596E2363694757DB8EB14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e7722-wk-Fact-9F5CE5F094EEBC828DF194757D8C0D9D"
          xlink:label="d8372444e7722-wk-Fact-9F5CE5F094EEBC828DF194757D8C0D9D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7722-wk-Fact-9F5CE5F094EEBC828DF194757D8C0D9D"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7722-wk-Fact-9F5CE5F094EEBC828DF194757D8C0D9D"
          xlink:to="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7722-wk-Fact-9F5CE5F094EEBC828DF194757D8C0D9D"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2399-wk-Fact-9F6032E503A2CA1767B194757CDC4DEA"
          xlink:label="d8312059e2399-wk-Fact-9F6032E503A2CA1767B194757CDC4DEA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2399-wk-Fact-9F6032E503A2CA1767B194757CDC4DEA"
          xlink:to="TextSelection-9CBFE5EF9D5753DAB35394757DB8E7A4-0-wk-Footnote-9CBFE5EF9D5753DAB35394757DB8E7A4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e11332-wk-Fact-9F791EE0835763BF87F894757D6D6836"
          xlink:label="d8336633e11332-wk-Fact-9F791EE0835763BF87F894757D6D6836"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e4080-wk-Fact-9F791EE0835763BF87F894757D6D6836"
          xlink:label="d8336633e4080-wk-Fact-9F791EE0835763BF87F894757D6D6836"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e11332-wk-Fact-9F791EE0835763BF87F894757D6D6836"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e4080-wk-Fact-9F791EE0835763BF87F894757D6D6836"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e2792-wk-Fact-9FD771621D23274287A294757D1BC8FA"
          xlink:label="d8336633e2792-wk-Fact-9FD771621D23274287A294757D1BC8FA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e2792-wk-Fact-9FD771621D23274287A294757D1BC8FA"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7066-wk-Fact-9FF11DED732028F079FF94757D67BC5A"
          xlink:label="d8415180e7066-wk-Fact-9FF11DED732028F079FF94757D67BC5A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7066-wk-Fact-9FF11DED732028F079FF94757D67BC5A"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7066-wk-Fact-9FF11DED732028F079FF94757D67BC5A"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1329-wk-Fact-A00DF4727012C4B9EC3194757D104907"
          xlink:label="d8316808e1329-wk-Fact-A00DF4727012C4B9EC3194757D104907"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1329-wk-Fact-A00DF4727012C4B9EC3194757D104907"
          xlink:to="TextSelection-CDCE760DEFA7F631840C94757DB86187-0-wk-Footnote-CDCE760DEFA7F631840C94757DB86187_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e8283-wk-Fact-A078219576BC94A6431D94757D13F215"
          xlink:label="d8372444e8283-wk-Fact-A078219576BC94A6431D94757D13F215"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e8283-wk-Fact-A078219576BC94A6431D94757D13F215"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e8283-wk-Fact-A078219576BC94A6431D94757D13F215"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e3347-wk-Fact-A0AE794A669CD8E4D60C94757D85F3D2"
          xlink:label="d8312059e3347-wk-Fact-A0AE794A669CD8E4D60C94757D85F3D2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e3347-wk-Fact-A0AE794A669CD8E4D60C94757D85F3D2"
          xlink:to="TextSelection-B92DE04072B96160C46394757DB7ADA1-0-wk-Footnote-B92DE04072B96160C46394757DB7ADA1_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8314038e1196-wk-Fact-A19967903AAC6CD9F1E494757D7857A3"
          xlink:label="d8314038e1196-wk-Fact-A19967903AAC6CD9F1E494757D7857A3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8314038e1196-wk-Fact-A19967903AAC6CD9F1E494757D7857A3"
          xlink:to="TextSelection-681F29FE9DC6BC582B6D94757DB90D8C-0-wk-Footnote-681F29FE9DC6BC582B6D94757DB90D8C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e7111-wk-Fact-A1B634793474C63E20E77DAA79965C6D"
          xlink:label="d8336633e7111-wk-Fact-A1B634793474C63E20E77DAA79965C6D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e7111-wk-Fact-A1B634793474C63E20E77DAA79965C6D"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e2110-wk-Fact-A1C25D709E6E2BCC622F94757CE0C08D"
          xlink:label="d8415180e2110-wk-Fact-A1C25D709E6E2BCC622F94757CE0C08D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e2110-wk-Fact-A1C25D709E6E2BCC622F94757CE0C08D"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2912-wk-Fact-A1F913431B3403C9FEC994757D9D5A01"
          xlink:label="d8301124e2912-wk-Fact-A1F913431B3403C9FEC994757D9D5A01"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2912-wk-Fact-A1F913431B3403C9FEC994757D9D5A01"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2368-wk-Fact-A21DC12905CBC163AED994757D2EAC03"
          xlink:label="d8307028e2368-wk-Fact-A21DC12905CBC163AED994757D2EAC03"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2368-wk-Fact-A21DC12905CBC163AED994757D2EAC03"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e7412-wk-Fact-A21E82052DF984C0370594757D762D70"
          xlink:label="d8336633e7412-wk-Fact-A21E82052DF984C0370594757D762D70"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e7412-wk-Fact-A21E82052DF984C0370594757D762D70"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2297-wk-Fact-A25CEEC8C1AE2DADBEC594757D293164"
          xlink:label="d8307028e2297-wk-Fact-A25CEEC8C1AE2DADBEC594757D293164"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2297-wk-Fact-A25CEEC8C1AE2DADBEC594757D293164"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8351242e1640-wk-Fact-A2CF9469A723FA507B4C94757D43EBF4"
          xlink:label="d8351242e1640-wk-Fact-A2CF9469A723FA507B4C94757D43EBF4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e1640-wk-Fact-A2CF9469A723FA507B4C94757D43EBF4"
          xlink:to="TextSelection-A2DA5EF7B6FED024F0D494757DBA101E-0-wk-Footnote-A2DA5EF7B6FED024F0D494757DBA101E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1328-wk-Fact-A2D758AD8E8FD5AADF3B94757CF0099C"
          xlink:label="d8340406e1328-wk-Fact-A2D758AD8E8FD5AADF3B94757CF0099C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1328-wk-Fact-A2D758AD8E8FD5AADF3B94757CF0099C"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1777-wk-Fact-A31D6CBE4C3463BD783494757D2A1AEA"
          xlink:label="d8308070e1777-wk-Fact-A31D6CBE4C3463BD783494757D2A1AEA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1777-wk-Fact-A31D6CBE4C3463BD783494757D2A1AEA"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e3623-wk-Fact-A331008C1C4E5584FBBC94757D85F6B9"
          xlink:label="d8312059e3623-wk-Fact-A331008C1C4E5584FBBC94757D85F6B9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e3623-wk-Fact-A331008C1C4E5584FBBC94757D85F6B9"
          xlink:to="TextSelection-2B5AD3FFF4626D02F1E394757DB79B83-0-wk-Footnote-2B5AD3FFF4626D02F1E394757DB79B83_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1366-wk-Fact-A332B2F7F76D0113E2A094757CC0E90D"
          xlink:label="d8340406e1366-wk-Fact-A332B2F7F76D0113E2A094757CC0E90D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1366-wk-Fact-A332B2F7F76D0113E2A094757CC0E90D"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1478-wk-Fact-A40179DC2229E8A9AD6B94757D2F9DF6"
          xlink:label="d8307028e1478-wk-Fact-A40179DC2229E8A9AD6B94757D2F9DF6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1478-wk-Fact-A40179DC2229E8A9AD6B94757D2F9DF6"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e6698-wk-Fact-A40FA5F841627A3B361294757D3A0A50"
          xlink:label="d8415180e6698-wk-Fact-A40FA5F841627A3B361294757D3A0A50"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e6698-wk-Fact-A40FA5F841627A3B361294757D3A0A50"
          xlink:to="TextSelection-FE68345D83BB191130EF94757DC1B5E5-0-wk-Footnote-FE68345D83BB191130EF94757DC1B5E5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e7578-wk-Fact-A4F33B25B1F596F9D7C294757D2733CF"
          xlink:label="d8372444e7578-wk-Fact-A4F33B25B1F596F9D7C294757D2733CF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7578-wk-Fact-A4F33B25B1F596F9D7C294757D2733CF"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7578-wk-Fact-A4F33B25B1F596F9D7C294757D2733CF"
          xlink:to="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7578-wk-Fact-A4F33B25B1F596F9D7C294757D2733CF"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1789-wk-Fact-A5431E8C2912D62E362094757CF2BE8E"
          xlink:label="d8316808e1789-wk-Fact-A5431E8C2912D62E362094757CF2BE8E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1789-wk-Fact-A5431E8C2912D62E362094757CF2BE8E"
          xlink:to="TextSelection-23DF6508A1F2A3B1745994757DB98CA0-0-wk-Footnote-23DF6508A1F2A3B1745994757DB98CA0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e7452-wk-Fact-A5C037C17E00CF7C78FE94757D5EE39D"
          xlink:label="d8336633e7452-wk-Fact-A5C037C17E00CF7C78FE94757D5EE39D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e7452-wk-Fact-A5C037C17E00CF7C78FE94757D5EE39D"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e7641-wk-Fact-A5D88487E443ABA949BF94757D39E6F7"
          xlink:label="d8336633e7641-wk-Fact-A5D88487E443ABA949BF94757D39E6F7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e7641-wk-Fact-A5D88487E443ABA949BF94757D39E6F7"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e5726-wk-Fact-A617E7F74433A22C70F794757DA55FFF"
          xlink:label="d8415180e5726-wk-Fact-A617E7F74433A22C70F794757DA55FFF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e5726-wk-Fact-A617E7F74433A22C70F794757DA55FFF"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2839-wk-Fact-A62E7998A018A606CB9B94757D1FEF54"
          xlink:label="d8308070e2839-wk-Fact-A62E7998A018A606CB9B94757D1FEF54"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2839-wk-Fact-A62E7998A018A606CB9B94757D1FEF54"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2669-wk-Fact-A66CB11E7205BECF278B94757D98ABC2"
          xlink:label="d8301124e2669-wk-Fact-A66CB11E7205BECF278B94757D98ABC2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2669-wk-Fact-A66CB11E7205BECF278B94757D98ABC2"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e960-wk-Fact-A6719A6CE4DE88C80E8394757D222E89"
          xlink:label="d8308070e960-wk-Fact-A6719A6CE4DE88C80E8394757D222E89"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e960-wk-Fact-A6719A6CE4DE88C80E8394757D222E89"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e3944-wk-Fact-A6C23BB629BE687A706594757D7617FA"
          xlink:label="d8336633e3944-wk-Fact-A6C23BB629BE687A706594757D7617FA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3944-wk-Fact-A6C23BB629BE687A706594757D7617FA"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2185-wk-Fact-A724B0094E4DB323816594757D52FEEC"
          xlink:label="d8312059e2185-wk-Fact-A724B0094E4DB323816594757D52FEEC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2185-wk-Fact-A724B0094E4DB323816594757D52FEEC"
          xlink:to="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8342960e1004-wk-Fact-A72909DE8208FAB8084794757D31B877"
          xlink:label="d8342960e1004-wk-Fact-A72909DE8208FAB8084794757D31B877"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8307028e1056-wk-Fact-A72909DE8208FAB8084794757D31B877"
          xlink:label="d8307028e1056-wk-Fact-A72909DE8208FAB8084794757D31B877"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-6816050F6F7DBFCD3C5B94757DBEA485-0-wk-Footnote-6816050F6F7DBFCD3C5B94757DBEA485_lbl" xlink:label="TextSelection-6816050F6F7DBFCD3C5B94757DBEA485-0-wk-Footnote-6816050F6F7DBFCD3C5B94757DBEA485_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">The change from </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">December&#160;31, 2019</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> reflects increases for certain products, including inventory build for new product launches, network strategy and market demand, partially offset by a decrease due to foreign exchange.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8342960e1004-wk-Fact-A72909DE8208FAB8084794757D31B877"
          xlink:to="TextSelection-6816050F6F7DBFCD3C5B94757DBEA485-0-wk-Footnote-6816050F6F7DBFCD3C5B94757DBEA485_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1056-wk-Fact-A72909DE8208FAB8084794757D31B877"
          xlink:to="TextSelection-6816050F6F7DBFCD3C5B94757DBEA485-0-wk-Footnote-6816050F6F7DBFCD3C5B94757DBEA485_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8342960e1004-wk-Fact-A72909DE8208FAB8084794757D31B877"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1056-wk-Fact-A72909DE8208FAB8084794757D31B877"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e8748-wk-Fact-A73DD4823D1FAAF157BF94757CB25343"
          xlink:label="d8336633e8748-wk-Fact-A73DD4823D1FAAF157BF94757CB25343"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e8748-wk-Fact-A73DD4823D1FAAF157BF94757CB25343"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-A775AC2F22450F075D8194757CD9A894-wk-Fact-A775AC2F22450F075D8194757CD9A894"
          xlink:label="Fact-A775AC2F22450F075D8194757CD9A894-wk-Fact-A775AC2F22450F075D8194757CD9A894"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-A775AC2F22450F075D8194757CD9A894-wk-Fact-A775AC2F22450F075D8194757CD9A894"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8314038e1236-wk-Fact-A7A8B2FD88766217F16094757D50D04F"
          xlink:label="d8314038e1236-wk-Fact-A7A8B2FD88766217F16094757D50D04F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8314038e1236-wk-Fact-A7A8B2FD88766217F16094757D50D04F"
          xlink:to="TextSelection-681F29FE9DC6BC582B6D94757DB90D8C-0-wk-Footnote-681F29FE9DC6BC582B6D94757DB90D8C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e7598-wk-Fact-A7CCC86802BC2190FB1994757CEDE354"
          xlink:label="d8372444e7598-wk-Fact-A7CCC86802BC2190FB1994757CEDE354"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7598-wk-Fact-A7CCC86802BC2190FB1994757CEDE354"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7598-wk-Fact-A7CCC86802BC2190FB1994757CEDE354"
          xlink:to="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7598-wk-Fact-A7CCC86802BC2190FB1994757CEDE354"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e4115-wk-Fact-A8241CECE526F96581AE94757CF0E2F1"
          xlink:label="d8336633e4115-wk-Fact-A8241CECE526F96581AE94757CF0E2F1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e11367-wk-Fact-A8241CECE526F96581AE94757CF0E2F1"
          xlink:label="d8336633e11367-wk-Fact-A8241CECE526F96581AE94757CF0E2F1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e4115-wk-Fact-A8241CECE526F96581AE94757CF0E2F1"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e11367-wk-Fact-A8241CECE526F96581AE94757CF0E2F1"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1653-wk-Fact-A82EF1B25256A6FE603294757D5228D4"
          xlink:label="d8301124e1653-wk-Fact-A82EF1B25256A6FE603294757D5228D4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1653-wk-Fact-A82EF1B25256A6FE603294757D5228D4"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e3719-wk-Fact-A88ABBED02CE57879DE594757CE47EAA"
          xlink:label="d8336633e3719-wk-Fact-A88ABBED02CE57879DE594757CE47EAA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3719-wk-Fact-A88ABBED02CE57879DE594757CE47EAA"
          xlink:to="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3719-wk-Fact-A88ABBED02CE57879DE594757CE47EAA"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1460-wk-Fact-A89179620F4ADD5E911294757CF30C7B"
          xlink:label="d8316808e1460-wk-Fact-A89179620F4ADD5E911294757CF30C7B"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336625e4088-wk-Fact-A89179620F4ADD5E911294757CF30C7B"
          xlink:label="d8336625e4088-wk-Fact-A89179620F4ADD5E911294757CF30C7B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1460-wk-Fact-A89179620F4ADD5E911294757CF30C7B"
          xlink:to="TextSelection-467F12A5D203A9A15C3A94757DB81B0A-0-wk-Footnote-467F12A5D203A9A15C3A94757DB81B0A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336625e4088-wk-Fact-A89179620F4ADD5E911294757CF30C7B"
          xlink:to="TextSelection-467F12A5D203A9A15C3A94757DB81B0A-0-wk-Footnote-467F12A5D203A9A15C3A94757DB81B0A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1460-wk-Fact-A89179620F4ADD5E911294757CF30C7B"
          xlink:to="TextSelection-9F5C431DBFAA147134E594757DBBC55E-0-wk-Footnote-9F5C431DBFAA147134E594757DBBC55E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336625e4088-wk-Fact-A89179620F4ADD5E911294757CF30C7B"
          xlink:to="TextSelection-9F5C431DBFAA147134E594757DBBC55E-0-wk-Footnote-9F5C431DBFAA147134E594757DBBC55E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2653-wk-Fact-A8DB7D24D8C907F2E56094757D1D1AC3"
          xlink:label="d8307028e2653-wk-Fact-A8DB7D24D8C907F2E56094757D1D1AC3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2653-wk-Fact-A8DB7D24D8C907F2E56094757D1D1AC3"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e1603-wk-Fact-A8FD8B76C5AB70D75DBF94757CDE77D4"
          xlink:label="d8415180e1603-wk-Fact-A8FD8B76C5AB70D75DBF94757CDE77D4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e1603-wk-Fact-A8FD8B76C5AB70D75DBF94757CDE77D4"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8356748e1141-wk-Fact-A90E01F4F7B0E1568EDA94757D6D8CFD"
          xlink:label="d8356748e1141-wk-Fact-A90E01F4F7B0E1568EDA94757D6D8CFD"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8340406e1872-wk-Fact-A90E01F4F7B0E1568EDA94757D6D8CFD"
          xlink:label="d8340406e1872-wk-Fact-A90E01F4F7B0E1568EDA94757D6D8CFD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8356748e1141-wk-Fact-A90E01F4F7B0E1568EDA94757D6D8CFD"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1872-wk-Fact-A90E01F4F7B0E1568EDA94757D6D8CFD"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1323-wk-Fact-A9E0B30BE08222818D3E94757CCA5EEE"
          xlink:label="d8308070e1323-wk-Fact-A9E0B30BE08222818D3E94757CCA5EEE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1323-wk-Fact-A9E0B30BE08222818D3E94757CCA5EEE"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1808-wk-Fact-AA0D8DE25A28BD3E886994757D30BAE9"
          xlink:label="d8307028e1808-wk-Fact-AA0D8DE25A28BD3E886994757D30BAE9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1808-wk-Fact-AA0D8DE25A28BD3E886994757D30BAE9"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-AA58F5E3D16407426BC394757CD865C7-wk-Fact-AA58F5E3D16407426BC394757CD865C7"
          xlink:label="Fact-AA58F5E3D16407426BC394757CD865C7-wk-Fact-AA58F5E3D16407426BC394757CD865C7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-AA58F5E3D16407426BC394757CD865C7-wk-Fact-AA58F5E3D16407426BC394757CD865C7"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8357160e2546-wk-Fact-AA5991AA2CE0B64BF6CF94757CCBAA43"
          xlink:label="d8357160e2546-wk-Fact-AA5991AA2CE0B64BF6CF94757CCBAA43"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e2546-wk-Fact-AA5991AA2CE0B64BF6CF94757CCBAA43"
          xlink:to="TextSelection-76B1871DA30219820FCB63105DB9E5C3-0-wk-Footnote-76B1871DA30219820FCB63105DB9E5C3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e2196-wk-Fact-AA84F6B275E57DCDD15C94757CF155B2"
          xlink:label="d8415180e2196-wk-Fact-AA84F6B275E57DCDD15C94757CF155B2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e2196-wk-Fact-AA84F6B275E57DCDD15C94757CF155B2"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e2196-wk-Fact-AA84F6B275E57DCDD15C94757CF155B2"
          xlink:to="TextSelection-9BC3436E7B9C00975CD394757DC16C56-0-wk-Footnote-9BC3436E7B9C00975CD394757DC16C56_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e3963-wk-Fact-AAD74F0EFA0B4EA93F7D94757D17DF5B"
          xlink:label="d8336633e3963-wk-Fact-AAD74F0EFA0B4EA93F7D94757D17DF5B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3963-wk-Fact-AAD74F0EFA0B4EA93F7D94757D17DF5B"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e12491-wk-Fact-AAF16B56D807C054332894757CBC5D15"
          xlink:label="d8336633e12491-wk-Fact-AAF16B56D807C054332894757CBC5D15"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e12491-wk-Fact-AAF16B56D807C054332894757CBC5D15"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10154-wk-Fact-AAF3C1C15A87A9E0791F94757D585239"
          xlink:label="d8415180e10154-wk-Fact-AAF3C1C15A87A9E0791F94757D585239"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10154-wk-Fact-AAF3C1C15A87A9E0791F94757D585239"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e8288-wk-Fact-ACC0B84B657C3CD00CFC94757D4FE802"
          xlink:label="d8415180e8288-wk-Fact-ACC0B84B657C3CD00CFC94757D4FE802"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8288-wk-Fact-ACC0B84B657C3CD00CFC94757D4FE802"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8288-wk-Fact-ACC0B84B657C3CD00CFC94757D4FE802"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e11115-wk-Fact-ACE7D9A9276B682B9DB094757D5AF1D5"
          xlink:label="d8415180e11115-wk-Fact-ACE7D9A9276B682B9DB094757D5AF1D5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e11115-wk-Fact-ACE7D9A9276B682B9DB094757D5AF1D5"
          xlink:to="TextSelection-FE68345D83BB191130EF94757DC1B5E5-0-wk-Footnote-FE68345D83BB191130EF94757DC1B5E5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10007-wk-Fact-AD3188356864105593EE94757CDE3AA3"
          xlink:label="d8415180e10007-wk-Fact-AD3188356864105593EE94757CDE3AA3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10007-wk-Fact-AD3188356864105593EE94757CDE3AA3"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8357160e3562-wk-Fact-AD667A5DC0327AE34FF994757D53D517"
          xlink:label="d8357160e3562-wk-Fact-AD667A5DC0327AE34FF994757D53D517"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e3562-wk-Fact-AD667A5DC0327AE34FF994757D53D517"
          xlink:to="TextSelection-2DE900A873C344A165FE94757DBF7A4D-0-wk-Footnote-2DE900A873C344A165FE94757DBF7A4D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e4419-wk-Fact-ADE35C801D052BCE925B94757D577C42"
          xlink:label="d8415180e4419-wk-Fact-ADE35C801D052BCE925B94757D577C42"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e4419-wk-Fact-ADE35C801D052BCE925B94757D577C42"
          xlink:to="TextSelection-C185F8237D4ED950685B94757DC105E4-0-wk-Footnote-C185F8237D4ED950685B94757DC105E4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e7201-wk-Fact-AF4E88391CCB32EE29BF94757D2B4EC4"
          xlink:label="d8372444e7201-wk-Fact-AF4E88391CCB32EE29BF94757D2B4EC4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7201-wk-Fact-AF4E88391CCB32EE29BF94757D2B4EC4"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7201-wk-Fact-AF4E88391CCB32EE29BF94757D2B4EC4"
          xlink:to="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7201-wk-Fact-AF4E88391CCB32EE29BF94757D2B4EC4"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e8024-wk-Fact-AF51AD4BAD86F0B6155B94757D5FA1C5"
          xlink:label="d8415180e8024-wk-Fact-AF51AD4BAD86F0B6155B94757D5FA1C5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8024-wk-Fact-AF51AD4BAD86F0B6155B94757D5FA1C5"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8024-wk-Fact-AF51AD4BAD86F0B6155B94757D5FA1C5"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e8008-wk-Fact-AF62571E69854E8457D694757D8D5035"
          xlink:label="d8372444e8008-wk-Fact-AF62571E69854E8457D694757D8D5035"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e8008-wk-Fact-AF62571E69854E8457D694757D8D5035"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1874-wk-Fact-AF679C0C7A88919A718094757CFBF4E0"
          xlink:label="d8316808e1874-wk-Fact-AF679C0C7A88919A718094757CFBF4E0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1874-wk-Fact-AF679C0C7A88919A718094757CFBF4E0"
          xlink:to="TextSelection-3F1FDE51F00C4F037BC194757DB9000C-0-wk-Footnote-3F1FDE51F00C4F037BC194757DB9000C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e14680-wk-Fact-AF977AD81CDE8A1EAB0994757CABF14E"
          xlink:label="d8336633e14680-wk-Fact-AF977AD81CDE8A1EAB0994757CABF14E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e14680-wk-Fact-AF977AD81CDE8A1EAB0994757CABF14E"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e7832-wk-Fact-B00A363AE1BB1F3479D994757D183B47"
          xlink:label="d8336633e7832-wk-Fact-B00A363AE1BB1F3479D994757D183B47"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e15098-wk-Fact-B00A363AE1BB1F3479D994757D183B47"
          xlink:label="d8336633e15098-wk-Fact-B00A363AE1BB1F3479D994757D183B47"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e7832-wk-Fact-B00A363AE1BB1F3479D994757D183B47"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e15098-wk-Fact-B00A363AE1BB1F3479D994757D183B47"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8351242e3352-wk-Fact-B02201B22AB44168B6C494757CC5A140"
          xlink:label="d8351242e3352-wk-Fact-B02201B22AB44168B6C494757CC5A140"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e3352-wk-Fact-B02201B22AB44168B6C494757CC5A140"
          xlink:to="TextSelection-8224B42439E7CCC8C3C594757DBA701B-0-wk-Footnote-8224B42439E7CCC8C3C594757DBA701B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e12452-wk-Fact-B058DCB1AE06D394D07494757D832A1B"
          xlink:label="d8336633e12452-wk-Fact-B058DCB1AE06D394D07494757D832A1B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e12452-wk-Fact-B058DCB1AE06D394D07494757D832A1B"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1503-wk-Fact-B07226375662B3FA103594757D67E5BF"
          xlink:label="d8308070e1503-wk-Fact-B07226375662B3FA103594757D67E5BF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1503-wk-Fact-B07226375662B3FA103594757D67E5BF"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e3044-wk-Fact-B0814DE9CC612AE11DD594757D3226D5"
          xlink:label="d8336633e3044-wk-Fact-B0814DE9CC612AE11DD594757D3226D5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3044-wk-Fact-B0814DE9CC612AE11DD594757D3226D5"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e11210-wk-Fact-B09391D35897D9D4E22494757D809B12"
          xlink:label="d8415180e11210-wk-Fact-B09391D35897D9D4E22494757D809B12"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e11210-wk-Fact-B09391D35897D9D4E22494757D809B12"
          xlink:to="TextSelection-33990A088D8DAE29233C94757DC283BE-0-wk-Footnote-33990A088D8DAE29233C94757DC283BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e8307-wk-Fact-B0C69CDE8303781F976E94757D9A42B7"
          xlink:label="d8415180e8307-wk-Fact-B0C69CDE8303781F976E94757D9A42B7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8307-wk-Fact-B0C69CDE8303781F976E94757D9A42B7"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8307-wk-Fact-B0C69CDE8303781F976E94757D9A42B7"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8351242e4765-wk-Fact-B0EAB8BEE5D94E16A4A394757CB05C4E"
          xlink:label="d8351242e4765-wk-Fact-B0EAB8BEE5D94E16A4A394757CB05C4E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e4765-wk-Fact-B0EAB8BEE5D94E16A4A394757CB05C4E"
          xlink:to="TextSelection-11358084CF50DEC3FF92628C52236CBA-0-wk-Footnote-11358084CF50DEC3FF92628C52236CBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e3472-wk-Fact-B0FAADCDDE37BDAB2D9594757D5E794A"
          xlink:label="d8415180e3472-wk-Fact-B0FAADCDDE37BDAB2D9594757D5E794A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e3472-wk-Fact-B0FAADCDDE37BDAB2D9594757D5E794A"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e3472-wk-Fact-B0FAADCDDE37BDAB2D9594757D5E794A"
          xlink:to="TextSelection-9BC3436E7B9C00975CD394757DC16C56-0-wk-Footnote-9BC3436E7B9C00975CD394757DC16C56_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2563-wk-Fact-B17D04EC8E4349EFFEF394757D1A00C1"
          xlink:label="d8307028e2563-wk-Fact-B17D04EC8E4349EFFEF394757D1A00C1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2563-wk-Fact-B17D04EC8E4349EFFEF394757D1A00C1"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e3065-wk-Fact-B187FB0A3E73BF7B3DE094757D8267D6"
          xlink:label="d8415180e3065-wk-Fact-B187FB0A3E73BF7B3DE094757D8267D6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e3065-wk-Fact-B187FB0A3E73BF7B3DE094757D8267D6"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1802-wk-Fact-B1C06142FF81EF258FE994757DA46AF3"
          xlink:label="d8301124e1802-wk-Fact-B1C06142FF81EF258FE994757DA46AF3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1802-wk-Fact-B1C06142FF81EF258FE994757DA46AF3"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1166-wk-Fact-B1D6C20091518E36CFA194757CC3358D"
          xlink:label="d8308070e1166-wk-Fact-B1D6C20091518E36CFA194757CC3358D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1166-wk-Fact-B1D6C20091518E36CFA194757CC3358D"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e9442-wk-Fact-B269C96FEDB20D2F2CE794757D1AD759"
          xlink:label="d8372444e9442-wk-Fact-B269C96FEDB20D2F2CE794757D1AD759"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e9442-wk-Fact-B269C96FEDB20D2F2CE794757D1AD759"
          xlink:to="TextSelection-A6E5E77EFF2BB738D44C94757DBDF083-0-wk-Footnote-A6E5E77EFF2BB738D44C94757DBDF083_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e922-wk-Fact-B28669D670A8C56C545994757D2ED7A9"
          xlink:label="d8307028e922-wk-Fact-B28669D670A8C56C545994757D2ED7A9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e922-wk-Fact-B28669D670A8C56C545994757D2ED7A9"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1096-wk-Fact-B2C102786FCBB8D401A594757D1B8EEE"
          xlink:label="d8308070e1096-wk-Fact-B2C102786FCBB8D401A594757D1B8EEE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1096-wk-Fact-B2C102786FCBB8D401A594757D1B8EEE"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2057-wk-Fact-B2CACAAABE963B0BFD8F94757D10087A"
          xlink:label="d8307028e2057-wk-Fact-B2CACAAABE963B0BFD8F94757D10087A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2057-wk-Fact-B2CACAAABE963B0BFD8F94757D10087A"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2984-wk-Fact-B33CD1A22EADB7B396EE94757D139837"
          xlink:label="d8340406e2984-wk-Fact-B33CD1A22EADB7B396EE94757D139837"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2984-wk-Fact-B33CD1A22EADB7B396EE94757D139837"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8357160e1634-wk-Fact-B35C636D04B27499B3AB94757CCFE464"
          xlink:label="d8357160e1634-wk-Fact-B35C636D04B27499B3AB94757CCFE464"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e1634-wk-Fact-B35C636D04B27499B3AB94757CCFE464"
          xlink:to="TextSelection-84058C93858F4EB1F00C631013E8EF74-0-wk-Footnote-84058C93858F4EB1F00C631013E8EF74_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e1539-wk-Fact-B35D2CD0AC8469F52A1194757DA775AF"
          xlink:label="d8336633e1539-wk-Fact-B35D2CD0AC8469F52A1194757DA775AF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e1539-wk-Fact-B35D2CD0AC8469F52A1194757DA775AF"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e1545-wk-Fact-B36E26A497B12F4F06CB94757CFB7641"
          xlink:label="d8415180e1545-wk-Fact-B36E26A497B12F4F06CB94757CFB7641"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e1545-wk-Fact-B36E26A497B12F4F06CB94757CFB7641"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e1574-wk-Fact-B38C1AE72C31DF2CFAFA94757CDDB0D8"
          xlink:label="d8336633e1574-wk-Fact-B38C1AE72C31DF2CFAFA94757CDDB0D8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e1574-wk-Fact-B38C1AE72C31DF2CFAFA94757CDDB0D8"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e4008-wk-Fact-B39352F261C00A65738694757D51EB5C"
          xlink:label="d8336633e4008-wk-Fact-B39352F261C00A65738694757D51EB5C"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e11260-wk-Fact-B39352F261C00A65738694757D51EB5C"
          xlink:label="d8336633e11260-wk-Fact-B39352F261C00A65738694757D51EB5C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e4008-wk-Fact-B39352F261C00A65738694757D51EB5C"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e11260-wk-Fact-B39352F261C00A65738694757D51EB5C"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8356748e2364-wk-Fact-B3F82E5E9DDB5FAA6C2D94757D393DCC"
          xlink:label="d8356748e2364-wk-Fact-B3F82E5E9DDB5FAA6C2D94757D393DCC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8356748e2364-wk-Fact-B3F82E5E9DDB5FAA6C2D94757D393DCC"
          xlink:to="TextSelection-6979FD063E456189966A94757DC072A0-0-wk-Footnote-6979FD063E456189966A94757DC072A0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1185-wk-Fact-B42383D404EA70302F8C94757D686185"
          xlink:label="d8308070e1185-wk-Fact-B42383D404EA70302F8C94757D686185"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1185-wk-Fact-B42383D404EA70302F8C94757D686185"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1076-wk-Fact-B436D7020EEC746BCB4A94757D090189"
          xlink:label="d8301124e1076-wk-Fact-B436D7020EEC746BCB4A94757D090189"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1076-wk-Fact-B436D7020EEC746BCB4A94757D090189"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1076-wk-Fact-B436D7020EEC746BCB4A94757D090189"
          xlink:to="TextSelection-8C3C45B5D6B304AC979B94757DB5023F-0-wk-Footnote-8C3C45B5D6B304AC979B94757DB5023F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8357160e2208-wk-Fact-B43FA979F49F2E3A20DE94757CFC75DD"
          xlink:label="d8357160e2208-wk-Fact-B43FA979F49F2E3A20DE94757CFC75DD"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8357160e2170-wk-Fact-B43FA979F49F2E3A20DE94757CFC75DD"
          xlink:label="d8357160e2170-wk-Fact-B43FA979F49F2E3A20DE94757CFC75DD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e2208-wk-Fact-B43FA979F49F2E3A20DE94757CFC75DD"
          xlink:to="TextSelection-B511D685B8F037FD258094757DBFC8C5-0-wk-Footnote-B511D685B8F037FD258094757DBFC8C5_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e2170-wk-Fact-B43FA979F49F2E3A20DE94757CFC75DD"
          xlink:to="TextSelection-B511D685B8F037FD258094757DBFC8C5-0-wk-Footnote-B511D685B8F037FD258094757DBFC8C5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e1686-wk-Fact-B46A5ED3FA0B101BE7A594757CD525E3"
          xlink:label="d8415180e1686-wk-Fact-B46A5ED3FA0B101BE7A594757CD525E3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e1686-wk-Fact-B46A5ED3FA0B101BE7A594757CD525E3"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2795-wk-Fact-B48CBE8AC02E90DAEA4594757D145DE6"
          xlink:label="d8308070e2795-wk-Fact-B48CBE8AC02E90DAEA4594757D145DE6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2795-wk-Fact-B48CBE8AC02E90DAEA4594757D145DE6"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e4558-wk-Fact-B4AE696827B3D39F948494757D114B10"
          xlink:label="d8372444e4558-wk-Fact-B4AE696827B3D39F948494757D114B10"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4558-wk-Fact-B4AE696827B3D39F948494757D114B10"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4558-wk-Fact-B4AE696827B3D39F948494757D114B10"
          xlink:to="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4558-wk-Fact-B4AE696827B3D39F948494757D114B10"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10621-wk-Fact-B53EC4023A670C9BFD9694757CFA2072"
          xlink:label="d8415180e10621-wk-Fact-B53EC4023A670C9BFD9694757CFA2072"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10621-wk-Fact-B53EC4023A670C9BFD9694757CFA2072"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e6010-wk-Fact-B541C3D3DAB4589EDF8994757D7AA019"
          xlink:label="d8372444e6010-wk-Fact-B541C3D3DAB4589EDF8994757D7AA019"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e6010-wk-Fact-B541C3D3DAB4589EDF8994757D7AA019"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e6010-wk-Fact-B541C3D3DAB4589EDF8994757D7AA019"
          xlink:to="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e6010-wk-Fact-B541C3D3DAB4589EDF8994757D7AA019"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e5560-wk-Fact-B54EEE815409E49E0D1894757D4EDBA5"
          xlink:label="d8336633e5560-wk-Fact-B54EEE815409E49E0D1894757D4EDBA5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e5560-wk-Fact-B54EEE815409E49E0D1894757D4EDBA5"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1453-wk-Fact-B5534107AC881736B01B94757D23BE41"
          xlink:label="d8307028e1453-wk-Fact-B5534107AC881736B01B94757D23BE41"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1453-wk-Fact-B5534107AC881736B01B94757D23BE41"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2000-wk-Fact-B56556CFBF45225D098894757D0D84DC"
          xlink:label="d8340406e2000-wk-Fact-B56556CFBF45225D098894757D0D84DC"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8301124e911-wk-Fact-B56556CFBF45225D098894757D0D84DC"
          xlink:label="d8301124e911-wk-Fact-B56556CFBF45225D098894757D0D84DC"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e1898-wk-Fact-B56556CFBF45225D098894757D0D84DC"
          xlink:label="d8336633e1898-wk-Fact-B56556CFBF45225D098894757D0D84DC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2000-wk-Fact-B56556CFBF45225D098894757D0D84DC"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e911-wk-Fact-B56556CFBF45225D098894757D0D84DC"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e1898-wk-Fact-B56556CFBF45225D098894757D0D84DC"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2000-wk-Fact-B56556CFBF45225D098894757D0D84DC"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e911-wk-Fact-B56556CFBF45225D098894757D0D84DC"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e1898-wk-Fact-B56556CFBF45225D098894757D0D84DC"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2000-wk-Fact-B56556CFBF45225D098894757D0D84DC"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e911-wk-Fact-B56556CFBF45225D098894757D0D84DC"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e1898-wk-Fact-B56556CFBF45225D098894757D0D84DC"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2000-wk-Fact-B56556CFBF45225D098894757D0D84DC"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e911-wk-Fact-B56556CFBF45225D098894757D0D84DC"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e1898-wk-Fact-B56556CFBF45225D098894757D0D84DC"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2182-wk-Fact-B5BD6F0023F06259AE3494757D06AF3E"
          xlink:label="d8301124e2182-wk-Fact-B5BD6F0023F06259AE3494757D06AF3E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2182-wk-Fact-B5BD6F0023F06259AE3494757D06AF3E"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2542-wk-Fact-B5E50DD48766F6B1EB8294757CBDBCD9"
          xlink:label="d8340406e2542-wk-Fact-B5E50DD48766F6B1EB8294757CBDBCD9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2542-wk-Fact-B5E50DD48766F6B1EB8294757CBDBCD9"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e1553-wk-Fact-B628E15DE73F0869904394757D92C37B"
          xlink:label="d8336633e1553-wk-Fact-B628E15DE73F0869904394757D92C37B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e1553-wk-Fact-B628E15DE73F0869904394757D92C37B"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e11135-wk-Fact-B698D162AA64B4E9F22494757CB607DE"
          xlink:label="d8415180e11135-wk-Fact-B698D162AA64B4E9F22494757CB607DE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e11135-wk-Fact-B698D162AA64B4E9F22494757CB607DE"
          xlink:to="TextSelection-FE68345D83BB191130EF94757DC1B5E5-0-wk-Footnote-FE68345D83BB191130EF94757DC1B5E5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e9968-wk-Fact-B6F824A1D38474F2D25894757CD26487"
          xlink:label="d8415180e9968-wk-Fact-B6F824A1D38474F2D25894757CD26487"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e9968-wk-Fact-B6F824A1D38474F2D25894757CD26487"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336625e2723-wk-Fact-B6FF2688963BD7DB8BDA94757D710150"
          xlink:label="d8336625e2723-wk-Fact-B6FF2688963BD7DB8BDA94757D710150"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336625e2723-wk-Fact-B6FF2688963BD7DB8BDA94757D710150"
          xlink:to="TextSelection-83180A323F26770F5F9D94757DBB7831-0-wk-Footnote-83180A323F26770F5F9D94757DBB7831_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e11196-wk-Fact-B742EA2DDFFBC1EE5A0694757CB11B81"
          xlink:label="d8336633e11196-wk-Fact-B742EA2DDFFBC1EE5A0694757CB11B81"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e11196-wk-Fact-B742EA2DDFFBC1EE5A0694757CB11B81"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1201-wk-Fact-B756BD8131D12427D5A094757CC10C5E"
          xlink:label="d8301124e1201-wk-Fact-B756BD8131D12427D5A094757CC10C5E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1201-wk-Fact-B756BD8131D12427D5A094757CC10C5E"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1201-wk-Fact-B756BD8131D12427D5A094757CC10C5E"
          xlink:to="TextSelection-8C3C45B5D6B304AC979B94757DB5023F-0-wk-Footnote-8C3C45B5D6B304AC979B94757DB5023F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1246-wk-Fact-B7AFA2301099E9BDE10E94757D091A88"
          xlink:label="d8301124e1246-wk-Fact-B7AFA2301099E9BDE10E94757D091A88"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1246-wk-Fact-B7AFA2301099E9BDE10E94757D091A88"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7600-wk-Fact-B7B4528B4555854FBA2594757D748585"
          xlink:label="d8415180e7600-wk-Fact-B7B4528B4555854FBA2594757D748585"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7600-wk-Fact-B7B4528B4555854FBA2594757D748585"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7600-wk-Fact-B7B4528B4555854FBA2594757D748585"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e883-wk-Fact-B816481FF01850756E6D94757D1C86F4"
          xlink:label="d8307028e883-wk-Fact-B816481FF01850756E6D94757D1C86F4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e883-wk-Fact-B816481FF01850756E6D94757D1C86F4"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e883-wk-Fact-B816481FF01850756E6D94757D1C86F4"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e3904-wk-Fact-B82DC8F0C3F61B78FD6994757D46FE68"
          xlink:label="d8336633e3904-wk-Fact-B82DC8F0C3F61B78FD6994757D46FE68"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3904-wk-Fact-B82DC8F0C3F61B78FD6994757D46FE68"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8357160e2240-wk-Fact-B8329B46741B139CE66594757CCCCF54"
          xlink:label="d8357160e2240-wk-Fact-B8329B46741B139CE66594757CCCCF54"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8357160e2277-wk-Fact-B8329B46741B139CE66594757CCCCF54"
          xlink:label="d8357160e2277-wk-Fact-B8329B46741B139CE66594757CCCCF54"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e2240-wk-Fact-B8329B46741B139CE66594757CCCCF54"
          xlink:to="TextSelection-84058C93858F4EB1F00C631013E8EF74-0-wk-Footnote-84058C93858F4EB1F00C631013E8EF74_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e2277-wk-Fact-B8329B46741B139CE66594757CCCCF54"
          xlink:to="TextSelection-84058C93858F4EB1F00C631013E8EF74-0-wk-Footnote-84058C93858F4EB1F00C631013E8EF74_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2456-wk-Fact-B8780C1262D682FB127794757D09FED8"
          xlink:label="d8301124e2456-wk-Fact-B8780C1262D682FB127794757D09FED8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2456-wk-Fact-B8780C1262D682FB127794757D09FED8"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2210-wk-Fact-B87A51A9779CD1CF018694757CE399DF"
          xlink:label="d8312059e2210-wk-Fact-B87A51A9779CD1CF018694757CE399DF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2210-wk-Fact-B87A51A9779CD1CF018694757CE399DF"
          xlink:to="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e3411-wk-Fact-B92928DFC343D1C01A7994757D3B4E3A"
          xlink:label="d8336633e3411-wk-Fact-B92928DFC343D1C01A7994757D3B4E3A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3411-wk-Fact-B92928DFC343D1C01A7994757D3B4E3A"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8357160e1469-wk-Fact-B95DB11055F98712D70094757CD0068E"
          xlink:label="d8357160e1469-wk-Fact-B95DB11055F98712D70094757CD0068E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e1469-wk-Fact-B95DB11055F98712D70094757CD0068E"
          xlink:to="TextSelection-B511D685B8F037FD258094757DBFC8C5-0-wk-Footnote-B511D685B8F037FD258094757DBFC8C5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1268-wk-Fact-B96D2283B28701563E7A94757CF94EFC"
          xlink:label="d8316808e1268-wk-Fact-B96D2283B28701563E7A94757CF94EFC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1268-wk-Fact-B96D2283B28701563E7A94757CF94EFC"
          xlink:to="TextSelection-CDCE760DEFA7F631840C94757DB86187-0-wk-Footnote-CDCE760DEFA7F631840C94757DB86187_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2465-wk-Fact-B98065EB23404AACB87094757D6BD6BE"
          xlink:label="d8340406e2465-wk-Fact-B98065EB23404AACB87094757D6BD6BE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2465-wk-Fact-B98065EB23404AACB87094757D6BD6BE"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336625e4263-wk-Fact-B993CE1535AAAD9D78CF94757D18D0D5"
          xlink:label="d8336625e4263-wk-Fact-B993CE1535AAAD9D78CF94757D18D0D5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336625e4263-wk-Fact-B993CE1535AAAD9D78CF94757D18D0D5"
          xlink:to="TextSelection-F8EDCEC3C21F54D90F7894757DBBCD6D-0-wk-Footnote-F8EDCEC3C21F54D90F7894757DBBCD6D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1169-wk-Fact-B99B2E1079DF1F86DF1A94757D24E100"
          xlink:label="d8307028e1169-wk-Fact-B99B2E1079DF1F86DF1A94757D24E100"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1169-wk-Fact-B99B2E1079DF1F86DF1A94757D24E100"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e8341-wk-Fact-BA21BD3D4A33641CD2FE94757D8EFCEB"
          xlink:label="d8372444e8341-wk-Fact-BA21BD3D4A33641CD2FE94757D8EFCEB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e8341-wk-Fact-BA21BD3D4A33641CD2FE94757D8EFCEB"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e8341-wk-Fact-BA21BD3D4A33641CD2FE94757D8EFCEB"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1434-wk-Fact-BA35612EAE6C91BF6D5494757D30D0C0"
          xlink:label="d8307028e1434-wk-Fact-BA35612EAE6C91BF6D5494757D30D0C0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1434-wk-Fact-BA35612EAE6C91BF6D5494757D30D0C0"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e4551-wk-Fact-BB799260ED60F412F4DC94757D59055E"
          xlink:label="d8415180e4551-wk-Fact-BB799260ED60F412F4DC94757D59055E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e4551-wk-Fact-BB799260ED60F412F4DC94757D59055E"
          xlink:to="TextSelection-AFB627DC6F652A9A0A0594757DC251B0-0-wk-Footnote-AFB627DC6F652A9A0A0594757DC251B0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1450-wk-Fact-BB8522BC4D5C3EA5BD8694757CB166F6"
          xlink:label="d8340406e1450-wk-Fact-BB8522BC4D5C3EA5BD8694757CB166F6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8312059e1737-wk-Fact-BB8522BC4D5C3EA5BD8694757CB166F6"
          xlink:label="d8312059e1737-wk-Fact-BB8522BC4D5C3EA5BD8694757CB166F6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1450-wk-Fact-BB8522BC4D5C3EA5BD8694757CB166F6"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e1737-wk-Fact-BB8522BC4D5C3EA5BD8694757CB166F6"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e5274-wk-Fact-BBC46AA267DCADC2619E94757D4B1DD3"
          xlink:label="d8336633e5274-wk-Fact-BBC46AA267DCADC2619E94757D4B1DD3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e5274-wk-Fact-BBC46AA267DCADC2619E94757D4B1DD3"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e4585-wk-Fact-BBF6210C8041EAAE938194757D0EFB62"
          xlink:label="d8415180e4585-wk-Fact-BBF6210C8041EAAE938194757D0EFB62"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e4585-wk-Fact-BBF6210C8041EAAE938194757D0EFB62"
          xlink:to="TextSelection-AFB627DC6F652A9A0A0594757DC251B0-0-wk-Footnote-AFB627DC6F652A9A0A0594757DC251B0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e4457-wk-Fact-BC8DE56F3BD25EC7962894757D5CD864"
          xlink:label="d8415180e4457-wk-Fact-BC8DE56F3BD25EC7962894757D5CD864"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e4457-wk-Fact-BC8DE56F3BD25EC7962894757D5CD864"
          xlink:to="TextSelection-C185F8237D4ED950685B94757DC105E4-0-wk-Footnote-C185F8237D4ED950685B94757DC105E4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2588-wk-Fact-BCA7EB2A102DF56C060B94757D2C4CD4"
          xlink:label="d8307028e2588-wk-Fact-BCA7EB2A102DF56C060B94757D2C4CD4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2588-wk-Fact-BCA7EB2A102DF56C060B94757D2C4CD4"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e5876-wk-Fact-BCDF3704B801D84F71C794757D8BEE37"
          xlink:label="d8372444e5876-wk-Fact-BCDF3704B801D84F71C794757D8BEE37"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5876-wk-Fact-BCDF3704B801D84F71C794757D8BEE37"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5876-wk-Fact-BCDF3704B801D84F71C794757D8BEE37"
          xlink:to="TextSelection-6EDC28E4739B45A7AA7C94757DBD8D30-0-wk-Footnote-6EDC28E4739B45A7AA7C94757DBD8D30_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5876-wk-Fact-BCDF3704B801D84F71C794757D8BEE37"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1277-wk-Fact-BCE8A138729B45E61B7F94757D2C3132"
          xlink:label="d8307028e1277-wk-Fact-BCE8A138729B45E61B7F94757D2C3132"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8351242e8312-wk-Fact-BCE8A138729B45E61B7F94757D2C3132"
          xlink:label="d8351242e8312-wk-Fact-BCE8A138729B45E61B7F94757D2C3132"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1277-wk-Fact-BCE8A138729B45E61B7F94757D2C3132"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e8312-wk-Fact-BCE8A138729B45E61B7F94757D2C3132"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e4897-wk-Fact-BD0329CC1D00D62B9E9F94757D234485"
          xlink:label="d8372444e4897-wk-Fact-BD0329CC1D00D62B9E9F94757D234485"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4897-wk-Fact-BD0329CC1D00D62B9E9F94757D234485"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7321-wk-Fact-BD41F7186105B7884BC694757D5BC2AE"
          xlink:label="d8415180e7321-wk-Fact-BD41F7186105B7884BC694757D5BC2AE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7321-wk-Fact-BD41F7186105B7884BC694757D5BC2AE"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7321-wk-Fact-BD41F7186105B7884BC694757D5BC2AE"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2445-wk-Fact-BDC31C12896D043747B194757D5B35D6"
          xlink:label="d8340406e2445-wk-Fact-BDC31C12896D043747B194757D5B35D6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2445-wk-Fact-BDC31C12896D043747B194757D5B35D6"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1757-wk-Fact-BDC4E0314FD64F1F888394757D72DA26"
          xlink:label="d8308070e1757-wk-Fact-BDC4E0314FD64F1F888394757D72DA26"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1757-wk-Fact-BDC4E0314FD64F1F888394757D72DA26"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2102-wk-Fact-BE013A8321BCFA54741E94757D80A8CE"
          xlink:label="d8340406e2102-wk-Fact-BE013A8321BCFA54741E94757D80A8CE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2102-wk-Fact-BE013A8321BCFA54741E94757D80A8CE"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336625e4068-wk-Fact-BE2B9931D467A3220D4894757CFCC65C"
          xlink:label="d8336625e4068-wk-Fact-BE2B9931D467A3220D4894757CFCC65C"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8316808e1441-wk-Fact-BE2B9931D467A3220D4894757CFCC65C"
          xlink:label="d8316808e1441-wk-Fact-BE2B9931D467A3220D4894757CFCC65C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336625e4068-wk-Fact-BE2B9931D467A3220D4894757CFCC65C"
          xlink:to="TextSelection-467F12A5D203A9A15C3A94757DB81B0A-0-wk-Footnote-467F12A5D203A9A15C3A94757DB81B0A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1441-wk-Fact-BE2B9931D467A3220D4894757CFCC65C"
          xlink:to="TextSelection-467F12A5D203A9A15C3A94757DB81B0A-0-wk-Footnote-467F12A5D203A9A15C3A94757DB81B0A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336625e4068-wk-Fact-BE2B9931D467A3220D4894757CFCC65C"
          xlink:to="TextSelection-9F5C431DBFAA147134E594757DBBC55E-0-wk-Footnote-9F5C431DBFAA147134E594757DBBC55E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1441-wk-Fact-BE2B9931D467A3220D4894757CFCC65C"
          xlink:to="TextSelection-9F5C431DBFAA147134E594757DBBC55E-0-wk-Footnote-9F5C431DBFAA147134E594757DBBC55E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e7319-wk-Fact-BE33935DCA8AF32376B994757D5F4D6D"
          xlink:label="d8336633e7319-wk-Fact-BE33935DCA8AF32376B994757D5F4D6D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e7319-wk-Fact-BE33935DCA8AF32376B994757D5F4D6D"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e8327-wk-Fact-BEED3353022DC3D9583494757DA5ED38"
          xlink:label="d8415180e8327-wk-Fact-BEED3353022DC3D9583494757DA5ED38"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8327-wk-Fact-BEED3353022DC3D9583494757DA5ED38"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8327-wk-Fact-BEED3353022DC3D9583494757DA5ED38"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e9340-wk-Fact-BFBC825D4CA85CD2E41D94757CB1220B"
          xlink:label="d8336633e9340-wk-Fact-BFBC825D4CA85CD2E41D94757CB1220B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e9340-wk-Fact-BFBC825D4CA85CD2E41D94757CB1220B"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e9919-wk-Fact-BFD0D11A54AFC7EC342E94757D4DA77D"
          xlink:label="d8415180e9919-wk-Fact-BFD0D11A54AFC7EC342E94757D4DA77D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e9919-wk-Fact-BFD0D11A54AFC7EC342E94757D4DA77D"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2410-wk-Fact-BFED46F6560D1E80618094757D5C3010"
          xlink:label="d8308070e2410-wk-Fact-BFED46F6560D1E80618094757D5C3010"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2410-wk-Fact-BFED46F6560D1E80618094757D5C3010"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e11215-wk-Fact-C04FC7C13AC6C8C6DD6594757CB52AB5"
          xlink:label="d8336633e11215-wk-Fact-C04FC7C13AC6C8C6DD6594757CB52AB5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e11215-wk-Fact-C04FC7C13AC6C8C6DD6594757CB52AB5"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1349-wk-Fact-C06B1B3B80ECC6BED32E94757D69AF05"
          xlink:label="d8308070e1349-wk-Fact-C06B1B3B80ECC6BED32E94757D69AF05"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1349-wk-Fact-C06B1B3B80ECC6BED32E94757D69AF05"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e12586-wk-Fact-C072E92255A07EC2BC3294757CB644FB"
          xlink:label="d8336633e12586-wk-Fact-C072E92255A07EC2BC3294757CB644FB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e12586-wk-Fact-C072E92255A07EC2BC3294757CB644FB"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10080-wk-Fact-C076F9FF805FD19B813594757D054DF5"
          xlink:label="d8415180e10080-wk-Fact-C076F9FF805FD19B813594757D054DF5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10080-wk-Fact-C076F9FF805FD19B813594757D054DF5"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2756-wk-Fact-C0AA245678498A8977C494757D60CCA2"
          xlink:label="d8308070e2756-wk-Fact-C0AA245678498A8977C494757D60CCA2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2756-wk-Fact-C0AA245678498A8977C494757D60CCA2"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8351242e7359-wk-Fact-C0B91802E709F9C8087C94757D805460"
          xlink:label="d8351242e7359-wk-Fact-C0B91802E709F9C8087C94757D805460"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e7359-wk-Fact-C0B91802E709F9C8087C94757D805460"
          xlink:to="TextSelection-DA70407E988FF7F4292CB0A472718D04-0-wk-Footnote-DA70407E988FF7F4292CB0A472718D04_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1188-wk-Fact-C1A3AA27451A8B8C11F594757D159C90"
          xlink:label="d8307028e1188-wk-Fact-C1A3AA27451A8B8C11F594757D159C90"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1188-wk-Fact-C1A3AA27451A8B8C11F594757D159C90"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1594-wk-Fact-C1DCC252D5C1E6770C2A94757D2726E3"
          xlink:label="d8308070e1594-wk-Fact-C1DCC252D5C1E6770C2A94757D2726E3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1594-wk-Fact-C1DCC252D5C1E6770C2A94757D2726E3"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e6843-wk-Fact-C1DE3E07544739B2E3BC94757CEAD328"
          xlink:label="d8336633e6843-wk-Fact-C1DE3E07544739B2E3BC94757CEAD328"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e6843-wk-Fact-C1DE3E07544739B2E3BC94757CEAD328"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8357160e3522-wk-Fact-C25CFEE5C6642AEA5F2D94757D52C936"
          xlink:label="d8357160e3522-wk-Fact-C25CFEE5C6642AEA5F2D94757D52C936"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e3522-wk-Fact-C25CFEE5C6642AEA5F2D94757D52C936"
          xlink:to="TextSelection-2DE900A873C344A165FE94757DBF7A4D-0-wk-Footnote-2DE900A873C344A165FE94757DBF7A4D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1546-wk-Fact-C2CB94D8321D93BAD2DD94757D57F0A3"
          xlink:label="d8307028e1546-wk-Fact-C2CB94D8321D93BAD2DD94757D57F0A3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1546-wk-Fact-C2CB94D8321D93BAD2DD94757D57F0A3"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336625e2606-wk-Fact-C2D1AFE34B96F2CC1CC194757D6DD63A"
          xlink:label="d8336625e2606-wk-Fact-C2D1AFE34B96F2CC1CC194757D6DD63A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336625e2606-wk-Fact-C2D1AFE34B96F2CC1CC194757D6DD63A"
          xlink:to="TextSelection-83180A323F26770F5F9D94757DBB7831-0-wk-Footnote-83180A323F26770F5F9D94757DBB7831_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e11158-wk-Fact-C3A560E1E22FD2CFF01C94757CA92EB0"
          xlink:label="d8336633e11158-wk-Fact-C3A560E1E22FD2CFF01C94757CA92EB0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e11158-wk-Fact-C3A560E1E22FD2CFF01C94757CA92EB0"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e12625-wk-Fact-C3BB46722B4E99BC08FB94757D912C94"
          xlink:label="d8336633e12625-wk-Fact-C3BB46722B4E99BC08FB94757D912C94"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e12625-wk-Fact-C3BB46722B4E99BC08FB94757D912C94"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e7679-wk-Fact-C3E7A0CC1F9E87A7290394757D55B8EE"
          xlink:label="d8336633e7679-wk-Fact-C3E7A0CC1F9E87A7290394757D55B8EE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e7679-wk-Fact-C3E7A0CC1F9E87A7290394757D55B8EE"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e3386-wk-Fact-C42CFD3A1CA3D15C54F494757D5933EF"
          xlink:label="d8415180e3386-wk-Fact-C42CFD3A1CA3D15C54F494757D5933EF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e3386-wk-Fact-C42CFD3A1CA3D15C54F494757D5933EF"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1632-wk-Fact-C461CCF052CAC13CE0B494757D759AEB"
          xlink:label="d8301124e1632-wk-Fact-C461CCF052CAC13CE0B494757D759AEB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1632-wk-Fact-C461CCF052CAC13CE0B494757D759AEB"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e12438-wk-Fact-C4994D3207A335AAB81294757D8D7CB7"
          xlink:label="d8336633e12438-wk-Fact-C4994D3207A335AAB81294757D8D7CB7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e12438-wk-Fact-C4994D3207A335AAB81294757D8D7CB7"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e9899-wk-Fact-C5060A64152E4CD16E7D94757D9B8FAB"
          xlink:label="d8415180e9899-wk-Fact-C5060A64152E4CD16E7D94757D9B8FAB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e9899-wk-Fact-C5060A64152E4CD16E7D94757D9B8FAB"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8351242e4803-wk-Fact-C5258C9AE0E9A683474194757D833A8F"
          xlink:label="d8351242e4803-wk-Fact-C5258C9AE0E9A683474194757D833A8F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e4803-wk-Fact-C5258C9AE0E9A683474194757D833A8F"
          xlink:to="TextSelection-11358084CF50DEC3FF92628C52236CBA-0-wk-Footnote-11358084CF50DEC3FF92628C52236CBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1116-wk-Fact-C54AB828E036C88403BC94757CCD9057"
          xlink:label="d8301124e1116-wk-Fact-C54AB828E036C88403BC94757CCD9057"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1116-wk-Fact-C54AB828E036C88403BC94757CCD9057"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1116-wk-Fact-C54AB828E036C88403BC94757CCD9057"
          xlink:to="TextSelection-8C3C45B5D6B304AC979B94757DB5023F-0-wk-Footnote-8C3C45B5D6B304AC979B94757DB5023F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e5765-wk-Fact-C5B823B21E48CD41CEFE94757CE0A878"
          xlink:label="d8415180e5765-wk-Fact-C5B823B21E48CD41CEFE94757CE0A878"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e5765-wk-Fact-C5B823B21E48CD41CEFE94757CE0A878"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2099-wk-Fact-C5EA1CFA2BAB5B0EAA7094757D07F215"
          xlink:label="d8301124e2099-wk-Fact-C5EA1CFA2BAB5B0EAA7094757D07F215"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2099-wk-Fact-C5EA1CFA2BAB5B0EAA7094757D07F215"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e7872-wk-Fact-C6B8B0E3BE0B6E14FCC394757D2F7284"
          xlink:label="d8336633e7872-wk-Fact-C6B8B0E3BE0B6E14FCC394757D2F7284"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e15138-wk-Fact-C6B8B0E3BE0B6E14FCC394757D2F7284"
          xlink:label="d8336633e15138-wk-Fact-C6B8B0E3BE0B6E14FCC394757D2F7284"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e7872-wk-Fact-C6B8B0E3BE0B6E14FCC394757D2F7284"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e15138-wk-Fact-C6B8B0E3BE0B6E14FCC394757D2F7284"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e1998-wk-Fact-C6C094F211EFE1192A7994757D666DEC"
          xlink:label="d8312059e1998-wk-Fact-C6C094F211EFE1192A7994757D666DEC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e1998-wk-Fact-C6C094F211EFE1192A7994757D666DEC"
          xlink:to="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8357160e1389-wk-Fact-C6E2684E0011DA4FD7EC94757CCDA666"
          xlink:label="d8357160e1389-wk-Fact-C6E2684E0011DA4FD7EC94757CCDA666"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e1389-wk-Fact-C6E2684E0011DA4FD7EC94757CCDA666"
          xlink:to="TextSelection-B511D685B8F037FD258094757DBFC8C5-0-wk-Footnote-B511D685B8F037FD258094757DBFC8C5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2887-wk-Fact-C6F72F041602CA931A9F94757D2D2964"
          xlink:label="d8340406e2887-wk-Fact-C6F72F041602CA931A9F94757D2D2964"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2887-wk-Fact-C6F72F041602CA931A9F94757D2D2964"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e1613-wk-Fact-C7083099744AE4148D4994757D2CC599"
          xlink:label="d8336633e1613-wk-Fact-C7083099744AE4148D4994757D2CC599"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e1613-wk-Fact-C7083099744AE4148D4994757D2CC599"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1352-wk-Fact-C73E7DEFCE404DDC8E6A94757CFD4810"
          xlink:label="d8301124e1352-wk-Fact-C73E7DEFCE404DDC8E6A94757CFD4810"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1352-wk-Fact-C73E7DEFCE404DDC8E6A94757CFD4810"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e1459-wk-Fact-C74CEACCB68A148A68AC94757CC0788F"
          xlink:label="d8372444e1459-wk-Fact-C74CEACCB68A148A68AC94757CC0788F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e1459-wk-Fact-C74CEACCB68A148A68AC94757CC0788F"
          xlink:to="TextSelection-D29E26CC6CF7C6248CEE94757DBD9743-0-wk-Footnote-D29E26CC6CF7C6248CEE94757DBD9743_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1460-wk-Fact-C78E60BC91B631C2A94794757CC3905D"
          xlink:label="d8301124e1460-wk-Fact-C78E60BC91B631C2A94794757CC3905D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1460-wk-Fact-C78E60BC91B631C2A94794757CC3905D"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1460-wk-Fact-C78E60BC91B631C2A94794757CC3905D"
          xlink:to="TextSelection-A6080F3BC2CE36268D0F94757DB590DE-0-wk-Footnote-A6080F3BC2CE36268D0F94757DB590DE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1822-wk-Fact-C7C942686CBC263C1D7194757CC2FF25"
          xlink:label="d8308070e1822-wk-Fact-C7C942686CBC263C1D7194757CC2FF25"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1822-wk-Fact-C7C942686CBC263C1D7194757CC2FF25"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e3281-wk-Fact-C825A8BB25BE38B63BB194757D30A6AC"
          xlink:label="d8340406e3281-wk-Fact-C825A8BB25BE38B63BB194757D30A6AC"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8356748e2279-wk-Fact-C825A8BB25BE38B63BB194757D30A6AC"
          xlink:label="d8356748e2279-wk-Fact-C825A8BB25BE38B63BB194757D30A6AC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e3281-wk-Fact-C825A8BB25BE38B63BB194757D30A6AC"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8356748e2279-wk-Fact-C825A8BB25BE38B63BB194757D30A6AC"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7639-wk-Fact-C8791891FDD5606F4FF0955D6DF370FF"
          xlink:label="d8415180e7639-wk-Fact-C8791891FDD5606F4FF0955D6DF370FF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7639-wk-Fact-C8791891FDD5606F4FF0955D6DF370FF"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7639-wk-Fact-C8791891FDD5606F4FF0955D6DF370FF"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8357160e1817-wk-Fact-C88BA43C1A9DADCD4A5494757CC8E62B"
          xlink:label="d8357160e1817-wk-Fact-C88BA43C1A9DADCD4A5494757CC8E62B"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8357160e2565-wk-Fact-C88BA43C1A9DADCD4A5494757CC8E62B"
          xlink:label="d8357160e2565-wk-Fact-C88BA43C1A9DADCD4A5494757CC8E62B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e1817-wk-Fact-C88BA43C1A9DADCD4A5494757CC8E62B"
          xlink:to="TextSelection-76B1871DA30219820FCB63105DB9E5C3-0-wk-Footnote-76B1871DA30219820FCB63105DB9E5C3_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e2565-wk-Fact-C88BA43C1A9DADCD4A5494757CC8E62B"
          xlink:to="TextSelection-76B1871DA30219820FCB63105DB9E5C3-0-wk-Footnote-76B1871DA30219820FCB63105DB9E5C3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1470-wk-Fact-C8984FE48C4ADA9BA0CA94757CCB4FED"
          xlink:label="d8340406e1470-wk-Fact-C8984FE48C4ADA9BA0CA94757CCB4FED"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8312059e1757-wk-Fact-C8984FE48C4ADA9BA0CA94757CCB4FED"
          xlink:label="d8312059e1757-wk-Fact-C8984FE48C4ADA9BA0CA94757CCB4FED"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1470-wk-Fact-C8984FE48C4ADA9BA0CA94757CCB4FED"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e1757-wk-Fact-C8984FE48C4ADA9BA0CA94757CCB4FED"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1853-wk-Fact-C920A45D5E66EC197B2A94757CF0CD54"
          xlink:label="d8340406e1853-wk-Fact-C920A45D5E66EC197B2A94757CF0CD54"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8356748e1121-wk-Fact-C920A45D5E66EC197B2A94757CF0CD54"
          xlink:label="d8356748e1121-wk-Fact-C920A45D5E66EC197B2A94757CF0CD54"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1853-wk-Fact-C920A45D5E66EC197B2A94757CF0CD54"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8356748e1121-wk-Fact-C920A45D5E66EC197B2A94757CF0CD54"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e2598-wk-Fact-C938A9B7922E6371EB0F94757CEF9930"
          xlink:label="d8336633e2598-wk-Fact-C938A9B7922E6371EB0F94757CEF9930"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e2598-wk-Fact-C938A9B7922E6371EB0F94757CEF9930"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e1653-wk-Fact-C9BE48676477EEA3C2DA94757CE814D1"
          xlink:label="d8312059e1653-wk-Fact-C9BE48676477EEA3C2DA94757CE814D1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e1653-wk-Fact-C9BE48676477EEA3C2DA94757CE814D1"
          xlink:to="TextSelection-B06D4F08D7061C0CFA5894757DB76AD8-0-wk-Footnote-B06D4F08D7061C0CFA5894757DB76AD8_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e7126-wk-Fact-CA0C786AD2F0B41A91817DAA79E6E7CB"
          xlink:label="d8336633e7126-wk-Fact-CA0C786AD2F0B41A91817DAA79E6E7CB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e7126-wk-Fact-CA0C786AD2F0B41A91817DAA79E6E7CB"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e5877-wk-Fact-CAAA50A9A982EC80885B94757CFEC886"
          xlink:label="d8415180e5877-wk-Fact-CAAA50A9A982EC80885B94757CFEC886"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e5877-wk-Fact-CAAA50A9A982EC80885B94757CFEC886"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1483-wk-Fact-CAC433338BBE1188257594757D6FCE44"
          xlink:label="d8308070e1483-wk-Fact-CAC433338BBE1188257594757D6FCE44"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1483-wk-Fact-CAC433338BBE1188257594757D6FCE44"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8357160e1693-wk-Fact-CAF20A4833F6E5216BE394757CF277B4"
          xlink:label="d8357160e1693-wk-Fact-CAF20A4833F6E5216BE394757CF277B4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e1693-wk-Fact-CAF20A4833F6E5216BE394757CF277B4"
          xlink:to="TextSelection-84058C93858F4EB1F00C631013E8EF74-0-wk-Footnote-84058C93858F4EB1F00C631013E8EF74_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e3923-wk-Fact-CAF86E02454555A404D294757CCA9409"
          xlink:label="d8372444e3923-wk-Fact-CAF86E02454555A404D294757CCA9409"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3923-wk-Fact-CAF86E02454555A404D294757CCA9409"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10340-wk-Fact-CB04EC46BE3C2AE76E6E94757D59A008"
          xlink:label="d8415180e10340-wk-Fact-CB04EC46BE3C2AE76E6E94757D59A008"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10340-wk-Fact-CB04EC46BE3C2AE76E6E94757D59A008"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e11096-wk-Fact-CB195E4B49470C94E41C94757D5B8154"
          xlink:label="d8415180e11096-wk-Fact-CB195E4B49470C94E41C94757D5B8154"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e11096-wk-Fact-CB195E4B49470C94E41C94757D5B8154"
          xlink:to="TextSelection-FE68345D83BB191130EF94757DC1B5E5-0-wk-Footnote-FE68345D83BB191130EF94757DC1B5E5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e8063-wk-Fact-CB1E1E66274A527AAF7194757D9AD724"
          xlink:label="d8415180e8063-wk-Fact-CB1E1E66274A527AAF7194757D9AD724"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8063-wk-Fact-CB1E1E66274A527AAF7194757D9AD724"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8063-wk-Fact-CB1E1E66274A527AAF7194757D9AD724"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1686-wk-Fact-CB3CE131F76D1BC5C4AF94757D6BFF4D"
          xlink:label="d8308070e1686-wk-Fact-CB3CE131F76D1BC5C4AF94757D6BFF4D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1686-wk-Fact-CB3CE131F76D1BC5C4AF94757D6BFF4D"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1547-wk-Fact-CBF2AF5A3799937C03F394757CFD6A73"
          xlink:label="d8316808e1547-wk-Fact-CBF2AF5A3799937C03F394757CFD6A73"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1547-wk-Fact-CBF2AF5A3799937C03F394757CFD6A73"
          xlink:to="TextSelection-1DD42ADAC2DF4C519E7594757DB84698-0-wk-Footnote-1DD42ADAC2DF4C519E7594757DB84698_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e8901-wk-Fact-CC73D199AFE6851BDA0294757CAED89E"
          xlink:label="d8336633e8901-wk-Fact-CC73D199AFE6851BDA0294757CAED89E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e8901-wk-Fact-CC73D199AFE6851BDA0294757CAED89E"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e5228-wk-Fact-CC96A91FB3B7AD21FC6E94757CCDA70E"
          xlink:label="d8372444e5228-wk-Fact-CC96A91FB3B7AD21FC6E94757CCDA70E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5228-wk-Fact-CC96A91FB3B7AD21FC6E94757CCDA70E"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5228-wk-Fact-CC96A91FB3B7AD21FC6E94757CCDA70E"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2119-wk-Fact-CCC6307773ADBF2D8B0394757D147293"
          xlink:label="d8308070e2119-wk-Fact-CCC6307773ADBF2D8B0394757D147293"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2119-wk-Fact-CCC6307773ADBF2D8B0394757D147293"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2119-wk-Fact-CCC6307773ADBF2D8B0394757D147293"
          xlink:to="TextSelection-4E9FC68D27E299B9BB2A92DC4EB2F91A-0-wk-Footnote-4E9FC68D27E299B9BB2A92DC4EB2F91A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e14386-wk-Fact-CCC935C176C282D817B794757CBC059A"
          xlink:label="d8336633e14386-wk-Fact-CCC935C176C282D817B794757CBC059A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e14386-wk-Fact-CCC935C176C282D817B794757CBC059A"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1527-wk-Fact-CCE3024E0C6DEE0D773194757D1EE899"
          xlink:label="d8307028e1527-wk-Fact-CCE3024E0C6DEE0D773194757D1EE899"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1527-wk-Fact-CCE3024E0C6DEE0D773194757D1EE899"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e1615-wk-Fact-CD30CA356357FE6A950B94757CE59164"
          xlink:label="d8312059e1615-wk-Fact-CD30CA356357FE6A950B94757CE59164"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e1615-wk-Fact-CD30CA356357FE6A950B94757CE59164"
          xlink:to="TextSelection-B06D4F08D7061C0CFA5894757DB76AD8-0-wk-Footnote-B06D4F08D7061C0CFA5894757DB76AD8_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2390-wk-Fact-CD69F0255956248BF5A794757CDCB6CF"
          xlink:label="d8301124e2390-wk-Fact-CD69F0255956248BF5A794757CDCB6CF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2390-wk-Fact-CD69F0255956248BF5A794757CDCB6CF"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e5248-wk-Fact-CD7B6D54813C77F7056C94757CCBF9C3"
          xlink:label="d8372444e5248-wk-Fact-CD7B6D54813C77F7056C94757CCBF9C3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5248-wk-Fact-CD7B6D54813C77F7056C94757CCBF9C3"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5248-wk-Fact-CD7B6D54813C77F7056C94757CCBF9C3"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e3262-wk-Fact-CDED57DD355FBFDCE83394757D0D0D08"
          xlink:label="d8340406e3262-wk-Fact-CDED57DD355FBFDCE83394757D0D0D08"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8356748e2260-wk-Fact-CDED57DD355FBFDCE83394757D0D0D08"
          xlink:label="d8356748e2260-wk-Fact-CDED57DD355FBFDCE83394757D0D0D08"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e3262-wk-Fact-CDED57DD355FBFDCE83394757D0D0D08"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8356748e2260-wk-Fact-CDED57DD355FBFDCE83394757D0D0D08"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e3407-wk-Fact-CE26F77FF346C4DE6B0594757D644E3B"
          xlink:label="d8415180e3407-wk-Fact-CE26F77FF346C4DE6B0594757D644E3B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e3407-wk-Fact-CE26F77FF346C4DE6B0594757D644E3B"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e3179-wk-Fact-CEDDD667A11CAC08820D94757D0E749E"
          xlink:label="d8340406e3179-wk-Fact-CEDDD667A11CAC08820D94757D0E749E"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8356748e2094-wk-Fact-CEDDD667A11CAC08820D94757D0E749E"
          xlink:label="d8356748e2094-wk-Fact-CEDDD667A11CAC08820D94757D0E749E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e3179-wk-Fact-CEDDD667A11CAC08820D94757D0E749E"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8356748e2094-wk-Fact-CEDDD667A11CAC08820D94757D0E749E"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1640-wk-Fact-CF088F9FE2A75408C8A794757D1586DE"
          xlink:label="d8340406e1640-wk-Fact-CF088F9FE2A75408C8A794757D1586DE"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8316808e2277-wk-Fact-CF088F9FE2A75408C8A794757D1586DE"
          xlink:label="d8316808e2277-wk-Fact-CF088F9FE2A75408C8A794757D1586DE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1640-wk-Fact-CF088F9FE2A75408C8A794757D1586DE"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e2277-wk-Fact-CF088F9FE2A75408C8A794757D1586DE"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1677-wk-Fact-CF4867B1F96B94735AD594757D0E90B4"
          xlink:label="d8316808e1677-wk-Fact-CF4867B1F96B94735AD594757D0E90B4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1677-wk-Fact-CF4867B1F96B94735AD594757D0E90B4"
          xlink:to="TextSelection-16CE381F2099EFC2DA1C94757DB87C39-0-wk-Footnote-16CE381F2099EFC2DA1C94757DB87C39_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e10445-wk-Fact-CF51E0E503957DBEE07394757CACD840"
          xlink:label="d8336633e10445-wk-Fact-CF51E0E503957DBEE07394757CACD840"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e10445-wk-Fact-CF51E0E503957DBEE07394757CACD840"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e5790-wk-Fact-CFA8D8DE9A17CA78BDB894757CE71BFF"
          xlink:label="d8336633e5790-wk-Fact-CFA8D8DE9A17CA78BDB894757CE71BFF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e5790-wk-Fact-CFA8D8DE9A17CA78BDB894757CE71BFF"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e2897-wk-Fact-CFC646220F28061D991894757D5C03BB"
          xlink:label="d8415180e2897-wk-Fact-CFC646220F28061D991894757D5C03BB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e2897-wk-Fact-CFC646220F28061D991894757D5C03BB"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8351242e8351-wk-Fact-CFF1903136C1AC56DF3A94757D2B131B"
          xlink:label="d8351242e8351-wk-Fact-CFF1903136C1AC56DF3A94757D2B131B"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8307028e1233-wk-Fact-CFF1903136C1AC56DF3A94757D2B131B"
          xlink:label="d8307028e1233-wk-Fact-CFF1903136C1AC56DF3A94757D2B131B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e8351-wk-Fact-CFF1903136C1AC56DF3A94757D2B131B"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1233-wk-Fact-CFF1903136C1AC56DF3A94757D2B131B"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e2131-wk-Fact-D01BD086F56ADFA6D29E94757CD09A97"
          xlink:label="d8415180e2131-wk-Fact-D01BD086F56ADFA6D29E94757CD09A97"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e2131-wk-Fact-D01BD086F56ADFA6D29E94757CD09A97"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2456-wk-Fact-D037126BFACE01B81D3B94757D11D201"
          xlink:label="d8307028e2456-wk-Fact-D037126BFACE01B81D3B94757D11D201"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2456-wk-Fact-D037126BFACE01B81D3B94757D11D201"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8356748e1512-wk-Fact-D0B1BB14EB1C0097910C94757D5D09B2"
          xlink:label="d8356748e1512-wk-Fact-D0B1BB14EB1C0097910C94757D5D09B2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8340406e1917-wk-Fact-D0B1BB14EB1C0097910C94757D5D09B2"
          xlink:label="d8340406e1917-wk-Fact-D0B1BB14EB1C0097910C94757D5D09B2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8356748e1512-wk-Fact-D0B1BB14EB1C0097910C94757D5D09B2"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1917-wk-Fact-D0B1BB14EB1C0097910C94757D5D09B2"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e14084-wk-Fact-D10B00BA2429F63E86A694757CAB096A"
          xlink:label="d8336633e14084-wk-Fact-D10B00BA2429F63E86A694757CAB096A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e14084-wk-Fact-D10B00BA2429F63E86A694757CAB096A"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e7219-wk-Fact-D17741D648E58B172B9E94757D81B725"
          xlink:label="d8372444e7219-wk-Fact-D17741D648E58B172B9E94757D81B725"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7219-wk-Fact-D17741D648E58B172B9E94757D81B725"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7219-wk-Fact-D17741D648E58B172B9E94757D81B725"
          xlink:to="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7219-wk-Fact-D17741D648E58B172B9E94757D81B725"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e985-wk-Fact-D1A152F767D859E8CCE694757CBAD374"
          xlink:label="d8308070e985-wk-Fact-D1A152F767D859E8CCE694757CBAD374"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e985-wk-Fact-D1A152F767D859E8CCE694757CBAD374"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e3568-wk-Fact-D21BDBDB5A3496D15C0F94757CC0FECE"
          xlink:label="d8336633e3568-wk-Fact-D21BDBDB5A3496D15C0F94757CC0FECE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3568-wk-Fact-D21BDBDB5A3496D15C0F94757CC0FECE"
          xlink:to="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3568-wk-Fact-D21BDBDB5A3496D15C0F94757CC0FECE"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e2819-wk-Fact-D2552EB7B44850CC209094757CF5FB9B"
          xlink:label="d8415180e2819-wk-Fact-D2552EB7B44850CC209094757CF5FB9B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e2819-wk-Fact-D2552EB7B44850CC209094757CF5FB9B"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1100-wk-Fact-D29057E6A396E534364794757CF999F3"
          xlink:label="d8316808e1100-wk-Fact-D29057E6A396E534364794757CF999F3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1100-wk-Fact-D29057E6A396E534364794757CF999F3"
          xlink:to="TextSelection-4E74A09462C596E2363694757DB8EB14-0-wk-Footnote-4E74A09462C596E2363694757DB8EB14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10526-wk-Fact-D299C7D480FAACA386FA94757CA95699"
          xlink:label="d8415180e10526-wk-Fact-D299C7D480FAACA386FA94757CA95699"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10526-wk-Fact-D299C7D480FAACA386FA94757CA95699"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2892-wk-Fact-D2B6E10475D8BB804CE094757CFEFBD9"
          xlink:label="d8301124e2892-wk-Fact-D2B6E10475D8BB804CE094757CFEFBD9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2892-wk-Fact-D2B6E10475D8BB804CE094757CFEFBD9"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e11427-wk-Fact-D2F433B8AA4C0088F7B694757DA65630"
          xlink:label="d8336633e11427-wk-Fact-D2F433B8AA4C0088F7B694757DA65630"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e4175-wk-Fact-D2F433B8AA4C0088F7B694757DA65630"
          xlink:label="d8336633e4175-wk-Fact-D2F433B8AA4C0088F7B694757DA65630"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e11427-wk-Fact-D2F433B8AA4C0088F7B694757DA65630"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e4175-wk-Fact-D2F433B8AA4C0088F7B694757DA65630"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e5598-wk-Fact-D2F686C8FF4197FE1E1D94757D4328BD"
          xlink:label="d8415180e5598-wk-Fact-D2F686C8FF4197FE1E1D94757D4328BD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e5598-wk-Fact-D2F686C8FF4197FE1E1D94757D4328BD"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e1979-wk-Fact-D32BE49AC04B6AB1E7A894757CE0BC21"
          xlink:label="d8312059e1979-wk-Fact-D32BE49AC04B6AB1E7A894757CE0BC21"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e1979-wk-Fact-D32BE49AC04B6AB1E7A894757CE0BC21"
          xlink:to="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e7705-wk-Fact-D37856BCED8C1D2C7F3494757D99EE35"
          xlink:label="d8336633e7705-wk-Fact-D37856BCED8C1D2C7F3494757D99EE35"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e14971-wk-Fact-D37856BCED8C1D2C7F3494757D99EE35"
          xlink:label="d8336633e14971-wk-Fact-D37856BCED8C1D2C7F3494757D99EE35"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e7705-wk-Fact-D37856BCED8C1D2C7F3494757D99EE35"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e14971-wk-Fact-D37856BCED8C1D2C7F3494757D99EE35"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e2046-wk-Fact-D38C84ADA6DF1DEBDA9794757CDF6D15"
          xlink:label="d8415180e2046-wk-Fact-D38C84ADA6DF1DEBDA9794757CDF6D15"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e2046-wk-Fact-D38C84ADA6DF1DEBDA9794757CDF6D15"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10908-wk-Fact-D421852A3121926EC88F94757D45D1D2"
          xlink:label="d8415180e10908-wk-Fact-D421852A3121926EC88F94757D45D1D2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10908-wk-Fact-D421852A3121926EC88F94757D45D1D2"
          xlink:to="TextSelection-D895C9E8DF19B244540094757DC27744-0-wk-Footnote-D895C9E8DF19B244540094757DC27744_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e6551-wk-Fact-D43F780191672677C09E94757CEA1326"
          xlink:label="d8372444e6551-wk-Fact-D43F780191672677C09E94757CEA1326"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e6551-wk-Fact-D43F780191672677C09E94757CEA1326"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e3657-wk-Fact-D46584CE1C6A5715E12694757D220D63"
          xlink:label="d8372444e3657-wk-Fact-D46584CE1C6A5715E12694757D220D63"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3657-wk-Fact-D46584CE1C6A5715E12694757D220D63"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e5895-wk-Fact-D529846875F26AE83EA994757D27042F"
          xlink:label="d8372444e5895-wk-Fact-D529846875F26AE83EA994757D27042F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5895-wk-Fact-D529846875F26AE83EA994757D27042F"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5895-wk-Fact-D529846875F26AE83EA994757D27042F"
          xlink:to="TextSelection-6EDC28E4739B45A7AA7C94757DBD8D30-0-wk-Footnote-6EDC28E4739B45A7AA7C94757DBD8D30_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e5895-wk-Fact-D529846875F26AE83EA994757D27042F"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e3362-wk-Fact-D581CDA4BE4F221B6C2C94757D180462"
          xlink:label="d8372444e3362-wk-Fact-D581CDA4BE4F221B6C2C94757D180462"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3362-wk-Fact-D581CDA4BE4F221B6C2C94757D180462"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3362-wk-Fact-D581CDA4BE4F221B6C2C94757D180462"
          xlink:to="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3362-wk-Fact-D581CDA4BE4F221B6C2C94757D180462"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e1467-wk-Fact-D58E0C9AEC0FAB141C2794757D361983"
          xlink:label="d8336633e1467-wk-Fact-D58E0C9AEC0FAB141C2794757D361983"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e1467-wk-Fact-D58E0C9AEC0FAB141C2794757D361983"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2926-wk-Fact-D5B6EF098B9CCBC6106394757D9FD69A"
          xlink:label="d8340406e2926-wk-Fact-D5B6EF098B9CCBC6106394757D9FD69A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2926-wk-Fact-D5B6EF098B9CCBC6106394757D9FD69A"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1004-wk-Fact-D5D209CEACE094C3706A94757D602BEE"
          xlink:label="d8308070e1004-wk-Fact-D5D209CEACE094C3706A94757D602BEE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1004-wk-Fact-D5D209CEACE094C3706A94757D602BEE"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2126-wk-Fact-D607D2703E69C5FECFE694757CDCD329"
          xlink:label="d8312059e2126-wk-Fact-D607D2703E69C5FECFE694757CDCD329"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2126-wk-Fact-D607D2703E69C5FECFE694757CDCD329"
          xlink:to="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8351242e3371-wk-Fact-D62B36AD2263CAB0455594757CBD05B4"
          xlink:label="d8351242e3371-wk-Fact-D62B36AD2263CAB0455594757CBD05B4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e3371-wk-Fact-D62B36AD2263CAB0455594757CBD05B4"
          xlink:to="TextSelection-8224B42439E7CCC8C3C594757DBA701B-0-wk-Footnote-8224B42439E7CCC8C3C594757DBA701B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1496-wk-Fact-D68E718B4C6944A5CD6A94757CD29C96"
          xlink:label="d8340406e1496-wk-Fact-D68E718B4C6944A5CD6A94757CD29C96"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1496-wk-Fact-D68E718B4C6944A5CD6A94757CD29C96"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2437-wk-Fact-D6AF3AA50A2C3B4FED5094757D009316"
          xlink:label="d8301124e2437-wk-Fact-D6AF3AA50A2C3B4FED5094757D009316"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2437-wk-Fact-D6AF3AA50A2C3B4FED5094757D009316"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2092-wk-Fact-D6CFF981EC1FB58C377894757D2A6D00"
          xlink:label="d8308070e2092-wk-Fact-D6CFF981EC1FB58C377894757D2A6D00"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2092-wk-Fact-D6CFF981EC1FB58C377894757D2A6D00"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2035-wk-Fact-D6F7C72544CA78BD37CE94757D0672FB"
          xlink:label="d8301124e2035-wk-Fact-D6F7C72544CA78BD37CE94757D0672FB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2035-wk-Fact-D6F7C72544CA78BD37CE94757D0672FB"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e2147-wk-Fact-D71486B20EB7956A050C94757CCBBD46"
          xlink:label="d8316808e2147-wk-Fact-D71486B20EB7956A050C94757CCBBD46"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e2147-wk-Fact-D71486B20EB7956A050C94757CCBBD46"
          xlink:to="TextSelection-420C4A044883B0052AE85E76395259A9-0-wk-Footnote-420C4A044883B0052AE85E76395259A9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e13707-wk-Fact-D73A14317FBAE5FF36E694757CA8E1DF"
          xlink:label="d8336633e13707-wk-Fact-D73A14317FBAE5FF36E694757CA8E1DF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e13707-wk-Fact-D73A14317FBAE5FF36E694757CA8E1DF"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e10896-wk-Fact-D75526E67D4914D634987DAA85CEF4A3"
          xlink:label="d8336633e10896-wk-Fact-D75526E67D4914D634987DAA85CEF4A3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e10896-wk-Fact-D75526E67D4914D634987DAA85CEF4A3"
          xlink:to="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e10896-wk-Fact-D75526E67D4914D634987DAA85CEF4A3"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e10391-wk-Fact-D75B034453F0D830B56B94757CB44AE9"
          xlink:label="d8336633e10391-wk-Fact-D75B034453F0D830B56B94757CB44AE9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e10391-wk-Fact-D75B034453F0D830B56B94757CB44AE9"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e3072-wk-Fact-D797AF9402BF1599A6F594757D5776AE"
          xlink:label="d8340406e3072-wk-Fact-D797AF9402BF1599A6F594757D5776AE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e3072-wk-Fact-D797AF9402BF1599A6F594757D5776AE"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e9322-wk-Fact-D7D683B723E19620193294757D1D9320"
          xlink:label="d8372444e9322-wk-Fact-D7D683B723E19620193294757D1D9320"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e9322-wk-Fact-D7D683B723E19620193294757D1D9320"
          xlink:to="TextSelection-A6E5E77EFF2BB738D44C94757DBDF083-0-wk-Footnote-A6E5E77EFF2BB738D44C94757DBDF083_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2500-wk-Fact-D7ECD9F4548C3411A1AB94757D1B3553"
          xlink:label="d8307028e2500-wk-Fact-D7ECD9F4548C3411A1AB94757D1B3553"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2500-wk-Fact-D7ECD9F4548C3411A1AB94757D1B3553"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e8801-wk-Fact-D86287A5407ADF62135F94757CB299CF"
          xlink:label="d8336633e8801-wk-Fact-D86287A5407ADF62135F94757CB299CF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e8801-wk-Fact-D86287A5407ADF62135F94757CB299CF"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2190-wk-Fact-D935FF0C642A1173F2D694757D1F4344"
          xlink:label="d8307028e2190-wk-Fact-D935FF0C642A1173F2D694757D1F4344"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2190-wk-Fact-D935FF0C642A1173F2D694757D1F4344"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1302-wk-Fact-D948D8A0A120E105480A94757D261CF9"
          xlink:label="d8307028e1302-wk-Fact-D948D8A0A120E105480A94757D261CF9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1302-wk-Fact-D948D8A0A120E105480A94757D261CF9"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2118-wk-Fact-D9A205E489D5B6E9EB3A94757D04C021"
          xlink:label="d8301124e2118-wk-Fact-D9A205E489D5B6E9EB3A94757D04C021"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2118-wk-Fact-D9A205E489D5B6E9EB3A94757D04C021"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e8768-wk-Fact-D9ACACC3158032862FBC94757CBB3D3D"
          xlink:label="d8336633e8768-wk-Fact-D9ACACC3158032862FBC94757CBB3D3D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e8768-wk-Fact-D9ACACC3158032862FBC94757CBB3D3D"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1497-wk-Fact-DAA11F34E77442AAEC1894757D191631"
          xlink:label="d8307028e1497-wk-Fact-DAA11F34E77442AAEC1894757D191631"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1497-wk-Fact-DAA11F34E77442AAEC1894757D191631"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2964-wk-Fact-DAA4B71118EB1D4285A994757D1B59B8"
          xlink:label="d8340406e2964-wk-Fact-DAA4B71118EB1D4285A994757D1B59B8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2964-wk-Fact-DAA4B71118EB1D4285A994757D1B59B8"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e9035-wk-Fact-DB4CC75A37E92F7B141794757D9F9E31"
          xlink:label="d8415180e9035-wk-Fact-DB4CC75A37E92F7B141794757D9F9E31"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e9035-wk-Fact-DB4CC75A37E92F7B141794757D9F9E31"
          xlink:to="TextSelection-FE68345D83BB191130EF94757DC1B5E5-0-wk-Footnote-FE68345D83BB191130EF94757DC1B5E5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2951-wk-Fact-DB5758891218A2CD53FA94757D09D2D4"
          xlink:label="d8301124e2951-wk-Fact-DB5758891218A2CD53FA94757D09D2D4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2951-wk-Fact-DB5758891218A2CD53FA94757D09D2D4"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1529-wk-Fact-DBC68DCD2CB0DEC8D8FB94757D61B962"
          xlink:label="d8308070e1529-wk-Fact-DBC68DCD2CB0DEC8D8FB94757D61B962"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1529-wk-Fact-DBC68DCD2CB0DEC8D8FB94757D61B962"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e7119-wk-Fact-DC149FAE791DF73A9F4E94757CEB25E2"
          xlink:label="d8372444e7119-wk-Fact-DC149FAE791DF73A9F4E94757CEB25E2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7119-wk-Fact-DC149FAE791DF73A9F4E94757CEB25E2"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7119-wk-Fact-DC149FAE791DF73A9F4E94757CEB25E2"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1896-wk-Fact-DC5D094960D8362E8AE194757D1CEABE"
          xlink:label="d8307028e1896-wk-Fact-DC5D094960D8362E8AE194757D1CEABE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1896-wk-Fact-DC5D094960D8362E8AE194757D1CEABE"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e1623-wk-Fact-DD285CCCCC909E22C8F494757CF80EDC"
          xlink:label="d8415180e1623-wk-Fact-DD285CCCCC909E22C8F494757CF80EDC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e1623-wk-Fact-DD285CCCCC909E22C8F494757CF80EDC"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e3223-wk-Fact-DD2C0BC1E91919220B7394757CCC3C6C"
          xlink:label="d8372444e3223-wk-Fact-DD2C0BC1E91919220B7394757CCC3C6C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3223-wk-Fact-DD2C0BC1E91919220B7394757CCC3C6C"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3223-wk-Fact-DD2C0BC1E91919220B7394757CCC3C6C"
          xlink:to="TextSelection-6EDC28E4739B45A7AA7C94757DBD8D30-0-wk-Footnote-6EDC28E4739B45A7AA7C94757DBD8D30_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3223-wk-Fact-DD2C0BC1E91919220B7394757CCC3C6C"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2725-wk-Fact-DD3041593AC72587B67894757D2924BD"
          xlink:label="d8307028e2725-wk-Fact-DD3041593AC72587B67894757D2924BD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2725-wk-Fact-DD3041593AC72587B67894757D2924BD"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7472-wk-Fact-DD66129D925AD6B2D1A4955D6DF5306E"
          xlink:label="d8415180e7472-wk-Fact-DD66129D925AD6B2D1A4955D6DF5306E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7472-wk-Fact-DD66129D925AD6B2D1A4955D6DF5306E"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7472-wk-Fact-DD66129D925AD6B2D1A4955D6DF5306E"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e1482-wk-Fact-DD70750D757F8E36AEFE94757D511014"
          xlink:label="d8312059e1482-wk-Fact-DD70750D757F8E36AEFE94757D511014"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8312059e3483-wk-Fact-DD70750D757F8E36AEFE94757D511014"
          xlink:label="d8312059e3483-wk-Fact-DD70750D757F8E36AEFE94757D511014"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e1482-wk-Fact-DD70750D757F8E36AEFE94757D511014"
          xlink:to="TextSelection-A2331388F2C895076E3994757DB73022-0-wk-Footnote-A2331388F2C895076E3994757DB73022_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e3483-wk-Fact-DD70750D757F8E36AEFE94757D511014"
          xlink:to="TextSelection-A2331388F2C895076E3994757DB73022-0-wk-Footnote-A2331388F2C895076E3994757DB73022_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e3644-wk-Fact-DDAEB6E7FE68CC5DB4FB7DAAEFDFB98D"
          xlink:label="d8336633e3644-wk-Fact-DDAEB6E7FE68CC5DB4FB7DAAEFDFB98D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3644-wk-Fact-DDAEB6E7FE68CC5DB4FB7DAAEFDFB98D"
          xlink:to="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3644-wk-Fact-DDAEB6E7FE68CC5DB4FB7DAAEFDFB98D"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7247-wk-Fact-DDBF519A26B8B268AC5394757D7DE917"
          xlink:label="d8415180e7247-wk-Fact-DDBF519A26B8B268AC5394757D7DE917"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7247-wk-Fact-DDBF519A26B8B268AC5394757D7DE917"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7247-wk-Fact-DDBF519A26B8B268AC5394757D7DE917"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e6260-wk-Fact-DDE80D633A2B28C2D4B194757D63F34A"
          xlink:label="d8336633e6260-wk-Fact-DDE80D633A2B28C2D4B194757D63F34A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e6260-wk-Fact-DDE80D633A2B28C2D4B194757D63F34A"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e4508-wk-Fact-DE2B16204B073DAB2AEC94757CBCDCAA"
          xlink:label="d8415180e4508-wk-Fact-DE2B16204B073DAB2AEC94757CBCDCAA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e4508-wk-Fact-DE2B16204B073DAB2AEC94757CBCDCAA"
          xlink:to="TextSelection-C185F8237D4ED950685B94757DC105E4-0-wk-Footnote-C185F8237D4ED950685B94757DC105E4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1656-wk-Fact-DE3B1C32E7AF56EA37C694757CFE73CD"
          xlink:label="d8316808e1656-wk-Fact-DE3B1C32E7AF56EA37C694757CFE73CD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1656-wk-Fact-DE3B1C32E7AF56EA37C694757CFE73CD"
          xlink:to="TextSelection-16CE381F2099EFC2DA1C94757DB87C39-0-wk-Footnote-16CE381F2099EFC2DA1C94757DB87C39_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2210-wk-Fact-DE8B64A6B5C352DD3FEB94757D21E4DC"
          xlink:label="d8308070e2210-wk-Fact-DE8B64A6B5C352DD3FEB94757D21E4DC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2210-wk-Fact-DE8B64A6B5C352DD3FEB94757D21E4DC"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1621-wk-Fact-DEA22D82FF9A17E3E27894757D6F6298"
          xlink:label="d8308070e1621-wk-Fact-DEA22D82FF9A17E3E27894757D6F6298"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1621-wk-Fact-DEA22D82FF9A17E3E27894757D6F6298"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1621-wk-Fact-DEA22D82FF9A17E3E27894757D6F6298"
          xlink:to="TextSelection-4E9FC68D27E299B9BB2A92DC4EB2F91A-0-wk-Footnote-4E9FC68D27E299B9BB2A92DC4EB2F91A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e1549-wk-Fact-DEE82D8D87D1D1AA50F194757CE0C55D"
          xlink:label="d8312059e1549-wk-Fact-DEE82D8D87D1D1AA50F194757CE0C55D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e1549-wk-Fact-DEE82D8D87D1D1AA50F194757CE0C55D"
          xlink:to="TextSelection-AB3DF04F3446139615AC94757DB7D909-0-wk-Footnote-AB3DF04F3446139615AC94757DB7D909_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e3301-wk-Fact-DF27017CA613A930B87894757D82C5EA"
          xlink:label="d8415180e3301-wk-Fact-DF27017CA613A930B87894757D82C5EA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e3301-wk-Fact-DF27017CA613A930B87894757D82C5EA"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e8715-wk-Fact-DF376F2902A29228A30394757D95B369"
          xlink:label="d8336633e8715-wk-Fact-DF376F2902A29228A30394757D95B369"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e8715-wk-Fact-DF376F2902A29228A30394757D95B369"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e8787-wk-Fact-DFAA9788CAC84F0B9CBE94757D9006BC"
          xlink:label="d8336633e8787-wk-Fact-DFAA9788CAC84F0B9CBE94757D9006BC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e8787-wk-Fact-DFAA9788CAC84F0B9CBE94757D9006BC"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e4135-wk-Fact-DFF13E5F684FBEC9822394757D143E71"
          xlink:label="d8336633e4135-wk-Fact-DFF13E5F684FBEC9822394757D143E71"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e11387-wk-Fact-DFF13E5F684FBEC9822394757D143E71"
          xlink:label="d8336633e11387-wk-Fact-DFF13E5F684FBEC9822394757D143E71"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e4135-wk-Fact-DFF13E5F684FBEC9822394757D143E71"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e11387-wk-Fact-DFF13E5F684FBEC9822394757D143E71"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e6428-wk-Fact-DFF51302F0E70A31845B94757D802056"
          xlink:label="d8372444e6428-wk-Fact-DFF51302F0E70A31845B94757D802056"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e6428-wk-Fact-DFF51302F0E70A31845B94757D802056"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e6305-wk-Fact-E0BAE04C3F7AAC74123D94757D287414"
          xlink:label="d8372444e6305-wk-Fact-E0BAE04C3F7AAC74123D94757D287414"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e6305-wk-Fact-E0BAE04C3F7AAC74123D94757D287414"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e1530-wk-Fact-E0F430906659E697076D94757CE4D373"
          xlink:label="d8312059e1530-wk-Fact-E0F430906659E697076D94757CE4D373"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e1530-wk-Fact-E0F430906659E697076D94757CE4D373"
          xlink:to="TextSelection-AB3DF04F3446139615AC94757DB7D909-0-wk-Footnote-AB3DF04F3446139615AC94757DB7D909_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8351242e3315-wk-Fact-E1670DD42B676FA2293C94757D4E7C71"
          xlink:label="d8351242e3315-wk-Fact-E1670DD42B676FA2293C94757D4E7C71"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e3315-wk-Fact-E1670DD42B676FA2293C94757D4E7C71"
          xlink:to="TextSelection-8224B42439E7CCC8C3C594757DBA701B-0-wk-Footnote-8224B42439E7CCC8C3C594757DBA701B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8329819e1116-wk-Fact-E1C7AF863456D04209EB94757D12EC91"
          xlink:label="d8329819e1116-wk-Fact-E1C7AF863456D04209EB94757D12EC91"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8307028e1680-wk-Fact-E1C7AF863456D04209EB94757D12EC91"
          xlink:label="d8307028e1680-wk-Fact-E1C7AF863456D04209EB94757D12EC91"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8329819e1116-wk-Fact-E1C7AF863456D04209EB94757D12EC91"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1680-wk-Fact-E1C7AF863456D04209EB94757D12EC91"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10266-wk-Fact-E2B7192F841B652DD3E194757D025EED"
          xlink:label="d8415180e10266-wk-Fact-E2B7192F841B652DD3E194757D025EED"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10266-wk-Fact-E2B7192F841B652DD3E194757D025EED"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1277-wk-Fact-E385EE5548C3D0B6620294757D260E17"
          xlink:label="d8308070e1277-wk-Fact-E385EE5548C3D0B6620294757D260E17"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1277-wk-Fact-E385EE5548C3D0B6620294757D260E17"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1641-wk-Fact-E3F1771420A95515D37594757D7358CA"
          xlink:label="d8308070e1641-wk-Fact-E3F1771420A95515D37594757D7358CA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1641-wk-Fact-E3F1771420A95515D37594757D7358CA"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1641-wk-Fact-E3F1771420A95515D37594757D7358CA"
          xlink:to="TextSelection-4E9FC68D27E299B9BB2A92DC4EB2F91A-0-wk-Footnote-4E9FC68D27E299B9BB2A92DC4EB2F91A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e5633-wk-Fact-E4061A0544587530FE5694757D9C3208"
          xlink:label="d8415180e5633-wk-Fact-E4061A0544587530FE5694757D9C3208"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e5633-wk-Fact-E4061A0544587530FE5694757D9C3208"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e1769-wk-Fact-E484E0BFE436CFD6A91994757CF4398D"
          xlink:label="d8415180e1769-wk-Fact-E484E0BFE436CFD6A91994757CF4398D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e1769-wk-Fact-E484E0BFE436CFD6A91994757CF4398D"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e14945-wk-Fact-E4A62043A54AC1E498B094757CACAA7C"
          xlink:label="d8336633e14945-wk-Fact-E4A62043A54AC1E498B094757CACAA7C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e14945-wk-Fact-E4A62043A54AC1E498B094757CACAA7C"
          xlink:to="TextSelection-DD7734E5853B41ABE8C8546D7049626E-0-wk-Footnote-DD7734E5853B41ABE8C8546D7049626E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e14945-wk-Fact-E4A62043A54AC1E498B094757CACAA7C"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1125-wk-Fact-E50549595D0042E610B994757D288E28"
          xlink:label="d8307028e1125-wk-Fact-E50549595D0042E610B994757D288E28"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1125-wk-Fact-E50549595D0042E610B994757D288E28"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2324-wk-Fact-E5344C9D61E5386447CC94757D5DBD84"
          xlink:label="d8301124e2324-wk-Fact-E5344C9D61E5386447CC94757D5DBD84"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2324-wk-Fact-E5344C9D61E5386447CC94757D5DBD84"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e8734-wk-Fact-E53668C499D5B6EED42794757CBA0E04"
          xlink:label="d8336633e8734-wk-Fact-E53668C499D5B6EED42794757CBA0E04"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e8734-wk-Fact-E53668C499D5B6EED42794757CBA0E04"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10640-wk-Fact-E5461C2F47C5805246B594757CD11E3E"
          xlink:label="d8415180e10640-wk-Fact-E5461C2F47C5805246B594757CD11E3E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10640-wk-Fact-E5461C2F47C5805246B594757CD11E3E"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336625e4243-wk-Fact-E5773A2CC07AA52848B394757D195108"
          xlink:label="d8336625e4243-wk-Fact-E5773A2CC07AA52848B394757D195108"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336625e4243-wk-Fact-E5773A2CC07AA52848B394757D195108"
          xlink:to="TextSelection-F8EDCEC3C21F54D90F7894757DBBCD6D-0-wk-Footnote-F8EDCEC3C21F54D90F7894757DBBCD6D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e8251-wk-Fact-E5ACC24ECADCC36DF22594757D7E0534"
          xlink:label="d8415180e8251-wk-Fact-E5ACC24ECADCC36DF22594757D7E0534"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8251-wk-Fact-E5ACC24ECADCC36DF22594757D7E0534"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e8251-wk-Fact-E5ACC24ECADCC36DF22594757D7E0534"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2137-wk-Fact-E5B2171A194CD45335C794757CE7F3C1"
          xlink:label="d8301124e2137-wk-Fact-E5B2171A194CD45335C794757CE7F3C1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2137-wk-Fact-E5B2171A194CD45335C794757CE7F3C1"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e3386-wk-Fact-E5ED2D8BFF7F93B9B97494757D832764"
          xlink:label="d8312059e3386-wk-Fact-E5ED2D8BFF7F93B9B97494757D832764"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e3386-wk-Fact-E5ED2D8BFF7F93B9B97494757D832764"
          xlink:to="TextSelection-B92DE04072B96160C46394757DB7ADA1-0-wk-Footnote-B92DE04072B96160C46394757DB7ADA1_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e10971-wk-Fact-E660298A415643D957F994757D82F91C"
          xlink:label="d8336633e10971-wk-Fact-E660298A415643D957F994757D82F91C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e10971-wk-Fact-E660298A415643D957F994757D82F91C"
          xlink:to="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e10971-wk-Fact-E660298A415643D957F994757D82F91C"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e11446-wk-Fact-E682A060B9E084CD78DB94757CBF7369"
          xlink:label="d8336633e11446-wk-Fact-E682A060B9E084CD78DB94757CBF7369"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e4194-wk-Fact-E682A060B9E084CD78DB94757CBF7369"
          xlink:label="d8336633e4194-wk-Fact-E682A060B9E084CD78DB94757CBF7369"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e11446-wk-Fact-E682A060B9E084CD78DB94757CBF7369"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e4194-wk-Fact-E682A060B9E084CD78DB94757CBF7369"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e10506-wk-Fact-E6A6BB806B084AB6D48994757D8EAE58"
          xlink:label="d8336633e10506-wk-Fact-E6A6BB806B084AB6D48994757D8EAE58"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e10506-wk-Fact-E6A6BB806B084AB6D48994757D8EAE58"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e1031-wk-Fact-E717A38DCA77168761C894757CC8AD9A"
          xlink:label="d8308070e1031-wk-Fact-E717A38DCA77168761C894757CC8AD9A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1031-wk-Fact-E717A38DCA77168761C894757CC8AD9A"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e1031-wk-Fact-E717A38DCA77168761C894757CC8AD9A"
          xlink:to="TextSelection-FE05511B3F59D62E086994757DB6CDC4-0-wk-Footnote-FE05511B3F59D62E086994757DB6CDC4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2523-wk-Fact-E756C4C43674CBFEFEA494757CE1093D"
          xlink:label="d8340406e2523-wk-Fact-E756C4C43674CBFEFEA494757CE1093D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2523-wk-Fact-E756C4C43674CBFEFEA494757CE1093D"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2544-wk-Fact-E75C406B14955CDB7D3B94757D138744"
          xlink:label="d8307028e2544-wk-Fact-E75C406B14955CDB7D3B94757D138744"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2544-wk-Fact-E75C406B14955CDB7D3B94757D138744"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2608-wk-Fact-E78126B8699A77F8DCC594757D1B1CAA"
          xlink:label="d8307028e2608-wk-Fact-E78126B8699A77F8DCC594757D1B1CAA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2608-wk-Fact-E78126B8699A77F8DCC594757D1B1CAA"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e4618-wk-Fact-E7A174C8A21CBC1EF5C394757D1205B4"
          xlink:label="d8372444e4618-wk-Fact-E7A174C8A21CBC1EF5C394757D1205B4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4618-wk-Fact-E7A174C8A21CBC1EF5C394757D1205B4"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4618-wk-Fact-E7A174C8A21CBC1EF5C394757D1205B4"
          xlink:to="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4618-wk-Fact-E7A174C8A21CBC1EF5C394757D1205B4"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2540-wk-Fact-E7D7D44563418D8D6DC894757D062085"
          xlink:label="d8301124e2540-wk-Fact-E7D7D44563418D8D6DC894757D062085"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2540-wk-Fact-E7D7D44563418D8D6DC894757D062085"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7951-wk-Fact-E7F68194ACA2953195D194757D3ADA6D"
          xlink:label="d8415180e7951-wk-Fact-E7F68194ACA2953195D194757D3ADA6D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7951-wk-Fact-E7F68194ACA2953195D194757D3ADA6D"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7951-wk-Fact-E7F68194ACA2953195D194757D3ADA6D"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2190-wk-Fact-E80F3653B15E3D94B76194757D344502"
          xlink:label="d8340406e2190-wk-Fact-E80F3653B15E3D94B76194757D344502"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2190-wk-Fact-E80F3653B15E3D94B76194757D344502"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e10820-wk-Fact-E82571DEE2C15F9E1D7094757D82377C"
          xlink:label="d8336633e10820-wk-Fact-E82571DEE2C15F9E1D7094757D82377C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e10820-wk-Fact-E82571DEE2C15F9E1D7094757D82377C"
          xlink:to="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e10820-wk-Fact-E82571DEE2C15F9E1D7094757D82377C"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2990-wk-Fact-E8491F91CE829080A31A94757CDF3CE5"
          xlink:label="d8301124e2990-wk-Fact-E8491F91CE829080A31A94757CDF3CE5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2990-wk-Fact-E8491F91CE829080A31A94757CDF3CE5"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1037-wk-Fact-E854D651F5C65603680B94757D20C5D0"
          xlink:label="d8307028e1037-wk-Fact-E854D651F5C65603680B94757D20C5D0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8342960e985-wk-Fact-E854D651F5C65603680B94757D20C5D0"
          xlink:label="d8342960e985-wk-Fact-E854D651F5C65603680B94757D20C5D0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1037-wk-Fact-E854D651F5C65603680B94757D20C5D0"
          xlink:to="TextSelection-6816050F6F7DBFCD3C5B94757DBEA485-0-wk-Footnote-6816050F6F7DBFCD3C5B94757DBEA485_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8342960e985-wk-Fact-E854D651F5C65603680B94757D20C5D0"
          xlink:to="TextSelection-6816050F6F7DBFCD3C5B94757DBEA485-0-wk-Footnote-6816050F6F7DBFCD3C5B94757DBEA485_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1037-wk-Fact-E854D651F5C65603680B94757D20C5D0"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8342960e985-wk-Fact-E854D651F5C65603680B94757D20C5D0"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372420e5765-wk-Fact-E864359E96F7D020F0CE94757D7CD99F"
          xlink:label="d8372420e5765-wk-Fact-E864359E96F7D020F0CE94757D7CD99F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372420e5765-wk-Fact-E864359E96F7D020F0CE94757D7CD99F"
          xlink:to="TextSelection-286F4719195A28A9913594757DC0B1B8-0-wk-Footnote-286F4719195A28A9913594757DC0B1B8_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2632-wk-Fact-E8B0E5833864611B38D294757CAF72E7"
          xlink:label="d8340406e2632-wk-Fact-E8B0E5833864611B38D294757CAF72E7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2632-wk-Fact-E8B0E5833864611B38D294757CAF72E7"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e4578-wk-Fact-E8B92084BD875BA1E86894757D134EDA"
          xlink:label="d8372444e4578-wk-Fact-E8B92084BD875BA1E86894757D134EDA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4578-wk-Fact-E8B92084BD875BA1E86894757D134EDA"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4578-wk-Fact-E8B92084BD875BA1E86894757D134EDA"
          xlink:to="TextSelection-9149DABDF9B4B24ECB5894757DBE171F-0-wk-Footnote-9149DABDF9B4B24ECB5894757DBE171F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4578-wk-Fact-E8B92084BD875BA1E86894757D134EDA"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e1462-wk-Fact-E911ACF0DB03AEB6DA8594757CE5E26F"
          xlink:label="d8312059e1462-wk-Fact-E911ACF0DB03AEB6DA8594757CE5E26F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e1462-wk-Fact-E911ACF0DB03AEB6DA8594757CE5E26F"
          xlink:to="TextSelection-A2331388F2C895076E3994757DB73022-0-wk-Footnote-A2331388F2C895076E3994757DB73022_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e3040-wk-Fact-EA0DB488C3931FDD51EB94757D052620"
          xlink:label="d8301124e3040-wk-Fact-EA0DB488C3931FDD51EB94757D052620"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e3040-wk-Fact-EA0DB488C3931FDD51EB94757D052620"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-EA1E0B8D16648EC1813394757CDA0B29-wk-Fact-EA1E0B8D16648EC1813394757CDA0B29"
          xlink:label="Fact-EA1E0B8D16648EC1813394757CDA0B29-wk-Fact-EA1E0B8D16648EC1813394757CDA0B29"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-EA1E0B8D16648EC1813394757CDA0B29-wk-Fact-EA1E0B8D16648EC1813394757CDA0B29"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8314038e2466-wk-Fact-EA79252BF7CF8534CF3894757D00B0A3"
          xlink:label="d8314038e2466-wk-Fact-EA79252BF7CF8534CF3894757D00B0A3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8301124e2695-wk-Fact-EA79252BF7CF8534CF3894757D00B0A3"
          xlink:label="d8301124e2695-wk-Fact-EA79252BF7CF8534CF3894757D00B0A3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8314038e2466-wk-Fact-EA79252BF7CF8534CF3894757D00B0A3"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2695-wk-Fact-EA79252BF7CF8534CF3894757D00B0A3"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1481-wk-Fact-EAC3B24ACD51EAB9C1FF94757CE2E89A"
          xlink:label="d8301124e1481-wk-Fact-EAC3B24ACD51EAB9C1FF94757CE2E89A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1481-wk-Fact-EAC3B24ACD51EAB9C1FF94757CE2E89A"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1481-wk-Fact-EAC3B24ACD51EAB9C1FF94757CE2E89A"
          xlink:to="TextSelection-A6080F3BC2CE36268D0F94757DB590DE-0-wk-Footnote-A6080F3BC2CE36268D0F94757DB590DE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e4916-wk-Fact-EB1FC1F3016D395DFAD794757D2A199B"
          xlink:label="d8372444e4916-wk-Fact-EB1FC1F3016D395DFAD794757D2A199B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e4916-wk-Fact-EB1FC1F3016D395DFAD794757D2A199B"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7267-wk-Fact-EB6D0A7F7C143C2F6D1E94757D00635E"
          xlink:label="d8415180e7267-wk-Fact-EB6D0A7F7C143C2F6D1E94757D00635E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7267-wk-Fact-EB6D0A7F7C143C2F6D1E94757D00635E"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7267-wk-Fact-EB6D0A7F7C143C2F6D1E94757D00635E"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7970-wk-Fact-EBD6CF2E62976239B60E94757D5080D2"
          xlink:label="d8415180e7970-wk-Fact-EBD6CF2E62976239B60E94757D5080D2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7970-wk-Fact-EBD6CF2E62976239B60E94757D5080D2"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7970-wk-Fact-EBD6CF2E62976239B60E94757D5080D2"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1822-wk-Fact-EC1267F1CEEA206E48DB94757D3D71EF"
          xlink:label="d8301124e1822-wk-Fact-EC1267F1CEEA206E48DB94757D3D71EF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1822-wk-Fact-EC1267F1CEEA206E48DB94757D3D71EF"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e6678-wk-Fact-EC785A34B39A8E6060B794757DA5646C"
          xlink:label="d8415180e6678-wk-Fact-EC785A34B39A8E6060B794757DA5646C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e6678-wk-Fact-EC785A34B39A8E6060B794757DA5646C"
          xlink:to="TextSelection-FE68345D83BB191130EF94757DC1B5E5-0-wk-Footnote-FE68345D83BB191130EF94757DC1B5E5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e2121-wk-Fact-ED12AC0ED4563B7B91D294757D6E4FFF"
          xlink:label="d8340406e2121-wk-Fact-ED12AC0ED4563B7B91D294757D6E4FFF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2121-wk-Fact-ED12AC0ED4563B7B91D294757D6E4FFF"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e15024-wk-Fact-ED5AE72D950E62950F0794757CE72E3D"
          xlink:label="d8336633e15024-wk-Fact-ED5AE72D950E62950F0794757CE72E3D"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e7758-wk-Fact-ED5AE72D950E62950F0794757CE72E3D"
          xlink:label="d8336633e7758-wk-Fact-ED5AE72D950E62950F0794757CE72E3D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e15024-wk-Fact-ED5AE72D950E62950F0794757CE72E3D"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e7758-wk-Fact-ED5AE72D950E62950F0794757CE72E3D"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2240-wk-Fact-ED78EBC18DA3BA3A4CA194757DA645DC"
          xlink:label="d8301124e2240-wk-Fact-ED78EBC18DA3BA3A4CA194757DA645DC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2240-wk-Fact-ED78EBC18DA3BA3A4CA194757DA645DC"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8357160e1654-wk-Fact-ED8B7846450D797501C094757CFAC023"
          xlink:label="d8357160e1654-wk-Fact-ED8B7846450D797501C094757CFAC023"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e1654-wk-Fact-ED8B7846450D797501C094757CFAC023"
          xlink:to="TextSelection-84058C93858F4EB1F00C631013E8EF74-0-wk-Footnote-84058C93858F4EB1F00C631013E8EF74_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10472-wk-Fact-EE3B286DC2CC60A1348594757D084ADB"
          xlink:label="d8415180e10472-wk-Fact-EE3B286DC2CC60A1348594757D084ADB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10472-wk-Fact-EE3B286DC2CC60A1348594757D084ADB"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1119-wk-Fact-EE4346B259E22FC41F1F94757CFCEB7F"
          xlink:label="d8316808e1119-wk-Fact-EE4346B259E22FC41F1F94757CFCEB7F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1119-wk-Fact-EE4346B259E22FC41F1F94757CFCEB7F"
          xlink:to="TextSelection-4E74A09462C596E2363694757DB8EB14-0-wk-Footnote-4E74A09462C596E2363694757DB8EB14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e10429-wk-Fact-EE5FCC32DD1F49FD716794757D8499D5"
          xlink:label="d8336633e10429-wk-Fact-EE5FCC32DD1F49FD716794757D8499D5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e10429-wk-Fact-EE5FCC32DD1F49FD716794757D8499D5"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2755-wk-Fact-EF6B358EA8E9123BB65194757D5C81E7"
          xlink:label="d8301124e2755-wk-Fact-EF6B358EA8E9123BB65194757D5C81E7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8314038e2526-wk-Fact-EF6B358EA8E9123BB65194757D5C81E7"
          xlink:label="d8314038e2526-wk-Fact-EF6B358EA8E9123BB65194757D5C81E7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2755-wk-Fact-EF6B358EA8E9123BB65194757D5C81E7"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8314038e2526-wk-Fact-EF6B358EA8E9123BB65194757D5C81E7"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1827-wk-Fact-EF93AF87BA61CC2CECEB94757CBC24E3"
          xlink:label="d8316808e1827-wk-Fact-EF93AF87BA61CC2CECEB94757CBC24E3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1827-wk-Fact-EF93AF87BA61CC2CECEB94757CBC24E3"
          xlink:to="TextSelection-23DF6508A1F2A3B1745994757DB98CA0-0-wk-Footnote-23DF6508A1F2A3B1745994757DB98CA0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e14514-wk-Fact-EFC543C17B8D59BB663F94757CAE19EF"
          xlink:label="d8336633e14514-wk-Fact-EFC543C17B8D59BB663F94757CAE19EF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e14514-wk-Fact-EFC543C17B8D59BB663F94757CAE19EF"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e3510-wk-Fact-F040B63D0E69CA163CDE94757D8588FB"
          xlink:label="d8312059e3510-wk-Fact-F040B63D0E69CA163CDE94757D8588FB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e3510-wk-Fact-F040B63D0E69CA163CDE94757D8588FB"
          xlink:to="TextSelection-823D9AE8DB976ECBCA9594757DB72C08-0-wk-Footnote-823D9AE8DB976ECBCA9594757DB72C08_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e3014-wk-Fact-F0D947E3D319A071650894757D8FBF1A"
          xlink:label="d8340406e3014-wk-Fact-F0D947E3D319A071650894757D8FBF1A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e3014-wk-Fact-F0D947E3D319A071650894757D8FBF1A"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8351242e7301-wk-Fact-F107D07691956E457F2694757D819FCD"
          xlink:label="d8351242e7301-wk-Fact-F107D07691956E457F2694757D819FCD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e7301-wk-Fact-F107D07691956E457F2694757D819FCD"
          xlink:to="TextSelection-DA70407E988FF7F4292CB0A472718D04-0-wk-Footnote-DA70407E988FF7F4292CB0A472718D04_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10733-wk-Fact-F1157F3F3D62CE169F0094757CD5A45F"
          xlink:label="d8415180e10733-wk-Fact-F1157F3F3D62CE169F0094757CD5A45F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10733-wk-Fact-F1157F3F3D62CE169F0094757CD5A45F"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e4094-wk-Fact-F12EBCA49A1647F7C9C194757CB75C07"
          xlink:label="d8336633e4094-wk-Fact-F12EBCA49A1647F7C9C194757CB75C07"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e11346-wk-Fact-F12EBCA49A1647F7C9C194757CB75C07"
          xlink:label="d8336633e11346-wk-Fact-F12EBCA49A1647F7C9C194757CB75C07"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e4094-wk-Fact-F12EBCA49A1647F7C9C194757CB75C07"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e11346-wk-Fact-F12EBCA49A1647F7C9C194757CB75C07"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1137-wk-Fact-F13DA5DDDB9A69F13A7994757D8778B5"
          xlink:label="d8301124e1137-wk-Fact-F13DA5DDDB9A69F13A7994757D8778B5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1137-wk-Fact-F13DA5DDDB9A69F13A7994757D8778B5"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1137-wk-Fact-F13DA5DDDB9A69F13A7994757D8778B5"
          xlink:to="TextSelection-8C3C45B5D6B304AC979B94757DB5023F-0-wk-Footnote-8C3C45B5D6B304AC979B94757DB5023F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1886-wk-Fact-F175F1A05A293F5B33DF94757DA50565"
          xlink:label="d8301124e1886-wk-Fact-F175F1A05A293F5B33DF94757DA50565"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1886-wk-Fact-F175F1A05A293F5B33DF94757DA50565"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e1486-wk-Fact-F17EC0EBDAE2EB6346E094757D109BAC"
          xlink:label="d8336633e1486-wk-Fact-F17EC0EBDAE2EB6346E094757D109BAC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e1486-wk-Fact-F17EC0EBDAE2EB6346E094757D109BAC"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2575-wk-Fact-F181CF0072905CD126F394757D6959D8"
          xlink:label="d8308070e2575-wk-Fact-F181CF0072905CD126F394757D6959D8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2575-wk-Fact-F181CF0072905CD126F394757D6959D8"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e10410-wk-Fact-F2364CCA95BCB9FF67BA94757CBE23AB"
          xlink:label="d8336633e10410-wk-Fact-F2364CCA95BCB9FF67BA94757CBE23AB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e10410-wk-Fact-F2364CCA95BCB9FF67BA94757CBE23AB"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e1526-wk-Fact-F24CEBFF8EB173EDA53294757CD99979"
          xlink:label="d8415180e1526-wk-Fact-F24CEBFF8EB173EDA53294757CD99979"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e1526-wk-Fact-F24CEBFF8EB173EDA53294757CD99979"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2873-wk-Fact-F25133D545839D7AE1D294757D02FFFC"
          xlink:label="d8301124e2873-wk-Fact-F25133D545839D7AE1D294757D02FFFC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2873-wk-Fact-F25133D545839D7AE1D294757D02FFFC"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1833-wk-Fact-F28698BCE434ADB508FA94757D1736FA"
          xlink:label="d8307028e1833-wk-Fact-F28698BCE434ADB508FA94757D1736FA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1833-wk-Fact-F28698BCE434ADB508FA94757D1736FA"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10212-wk-Fact-F2DA33B091A2333965BF94757D0DA3A2"
          xlink:label="d8415180e10212-wk-Fact-F2DA33B091A2333965BF94757D0DA3A2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10212-wk-Fact-F2DA33B091A2333965BF94757D0DA3A2"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e2001-wk-Fact-F2E6F2C6A9C76A98DCDF94757D59E284"
          xlink:label="d8308070e2001-wk-Fact-F2E6F2C6A9C76A98DCDF94757D59E284"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e2001-wk-Fact-F2E6F2C6A9C76A98DCDF94757D59E284"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e7184-wk-Fact-F2F1A0934B119BCED20494757D9F5C1A"
          xlink:label="d8336633e7184-wk-Fact-F2F1A0934B119BCED20494757D9F5C1A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e7184-wk-Fact-F2F1A0934B119BCED20494757D9F5C1A"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2253-wk-Fact-F30E96B44D3E4509219994757D1F511F"
          xlink:label="d8307028e2253-wk-Fact-F30E96B44D3E4509219994757D1F511F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2253-wk-Fact-F30E96B44D3E4509219994757D1F511F"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e1520-wk-Fact-F3381BD200AEE22A790894757D7247BF"
          xlink:label="d8336633e1520-wk-Fact-F3381BD200AEE22A790894757D7247BF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e1520-wk-Fact-F3381BD200AEE22A790894757D7247BF"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7931-wk-Fact-F35FE93745C53320FB9394757D667FF4"
          xlink:label="d8415180e7931-wk-Fact-F35FE93745C53320FB9394757D667FF4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7931-wk-Fact-F35FE93745C53320FB9394757D667FF4"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7931-wk-Fact-F35FE93745C53320FB9394757D667FF4"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e1500-wk-Fact-F3A733B52C3E9E10B03494757CDA0945"
          xlink:label="d8336633e1500-wk-Fact-F3A733B52C3E9E10B03494757CDA0945"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e1500-wk-Fact-F3A733B52C3E9E10B03494757CDA0945"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e10911-wk-Fact-F3B0AC6951DEEF5E98DC94757CA9786E"
          xlink:label="d8336633e10911-wk-Fact-F3B0AC6951DEEF5E98DC94757CA9786E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e10911-wk-Fact-F3B0AC6951DEEF5E98DC94757CA9786E"
          xlink:to="TextSelection-16D720E2797C387B08C294757DB6E91E-0-wk-Footnote-16D720E2797C387B08C294757DB6E91E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e10911-wk-Fact-F3B0AC6951DEEF5E98DC94757CA9786E"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2076-wk-Fact-F3EB43E530A63806272994757D14737C"
          xlink:label="d8307028e2076-wk-Fact-F3EB43E530A63806272994757D14737C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2076-wk-Fact-F3EB43E530A63806272994757D14737C"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7526-wk-Fact-F438821E9550CEA8E25A94757D043BA1"
          xlink:label="d8415180e7526-wk-Fact-F438821E9550CEA8E25A94757D043BA1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7526-wk-Fact-F438821E9550CEA8E25A94757D043BA1"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7526-wk-Fact-F438821E9550CEA8E25A94757D043BA1"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e9987-wk-Fact-F43BB2EB7D4C6E45428094757CDA03D2"
          xlink:label="d8415180e9987-wk-Fact-F43BB2EB7D4C6E45428094757CDA03D2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e9987-wk-Fact-F43BB2EB7D4C6E45428094757CDA03D2"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e5784-wk-Fact-F44ADBD39CBA320A835394757D7CED0E"
          xlink:label="d8415180e5784-wk-Fact-F44ADBD39CBA320A835394757D7CED0E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e5784-wk-Fact-F44ADBD39CBA320A835394757D7CED0E"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e7105-wk-Fact-F48D67680627D6924C7394757D8E45FB"
          xlink:label="d8415180e7105-wk-Fact-F48D67680627D6924C7394757D8E45FB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7105-wk-Fact-F48D67680627D6924C7394757D8E45FB"
          xlink:to="TextSelection-367557D7FE99680F9D4594757DC26A78-0-wk-Footnote-367557D7FE99680F9D4594757DC26A78_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e7105-wk-Fact-F48D67680627D6924C7394757D8E45FB"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336625e2644-wk-Fact-F4AF4992B1DFCF6708C794757D66A5A2"
          xlink:label="d8336625e2644-wk-Fact-F4AF4992B1DFCF6708C794757D66A5A2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336625e2567-wk-Fact-F4AF4992B1DFCF6708C794757D66A5A2"
          xlink:label="d8336625e2567-wk-Fact-F4AF4992B1DFCF6708C794757D66A5A2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336625e2644-wk-Fact-F4AF4992B1DFCF6708C794757D66A5A2"
          xlink:to="TextSelection-83180A323F26770F5F9D94757DBB7831-0-wk-Footnote-83180A323F26770F5F9D94757DBB7831_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336625e2567-wk-Fact-F4AF4992B1DFCF6708C794757D66A5A2"
          xlink:to="TextSelection-83180A323F26770F5F9D94757DBB7831-0-wk-Footnote-83180A323F26770F5F9D94757DBB7831_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e4621-wk-Fact-F4C1ADE521CCDFE17FBB94757D99CF2B"
          xlink:label="d8415180e4621-wk-Fact-F4C1ADE521CCDFE17FBB94757D99CF2B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e4621-wk-Fact-F4C1ADE521CCDFE17FBB94757D99CF2B"
          xlink:to="TextSelection-AFB627DC6F652A9A0A0594757DC251B0-0-wk-Footnote-AFB627DC6F652A9A0A0594757DC251B0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e7601-wk-Fact-F53C3D63E9620E8FB80594757CCA75EE"
          xlink:label="d8336633e7601-wk-Fact-F53C3D63E9620E8FB80594757CCA75EE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e7601-wk-Fact-F53C3D63E9620E8FB80594757CCA75EE"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8308070e858-wk-Fact-F55F7448D6FD457E7D3094757CC42D99"
          xlink:label="d8308070e858-wk-Fact-F55F7448D6FD457E7D3094757CC42D99"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8301124e950-wk-Fact-F55F7448D6FD457E7D3094757CC42D99"
          xlink:label="d8301124e950-wk-Fact-F55F7448D6FD457E7D3094757CC42D99"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8340406e2038-wk-Fact-F55F7448D6FD457E7D3094757CC42D99"
          xlink:label="d8340406e2038-wk-Fact-F55F7448D6FD457E7D3094757CC42D99"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e9146-wk-Fact-F55F7448D6FD457E7D3094757CC42D99"
          xlink:label="d8336633e9146-wk-Fact-F55F7448D6FD457E7D3094757CC42D99"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e858-wk-Fact-F55F7448D6FD457E7D3094757CC42D99"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e950-wk-Fact-F55F7448D6FD457E7D3094757CC42D99"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2038-wk-Fact-F55F7448D6FD457E7D3094757CC42D99"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e9146-wk-Fact-F55F7448D6FD457E7D3094757CC42D99"
          xlink:to="TextSelection-097C5E1EDD8B5F62CC5C94757DB6DD0B-0-wk-Footnote-097C5E1EDD8B5F62CC5C94757DB6DD0B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e858-wk-Fact-F55F7448D6FD457E7D3094757CC42D99"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e950-wk-Fact-F55F7448D6FD457E7D3094757CC42D99"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2038-wk-Fact-F55F7448D6FD457E7D3094757CC42D99"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e9146-wk-Fact-F55F7448D6FD457E7D3094757CC42D99"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e858-wk-Fact-F55F7448D6FD457E7D3094757CC42D99"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e950-wk-Fact-F55F7448D6FD457E7D3094757CC42D99"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2038-wk-Fact-F55F7448D6FD457E7D3094757CC42D99"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e9146-wk-Fact-F55F7448D6FD457E7D3094757CC42D99"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8308070e858-wk-Fact-F55F7448D6FD457E7D3094757CC42D99"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e950-wk-Fact-F55F7448D6FD457E7D3094757CC42D99"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e2038-wk-Fact-F55F7448D6FD457E7D3094757CC42D99"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e9146-wk-Fact-F55F7448D6FD457E7D3094757CC42D99"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1847-wk-Fact-F581216089FF320C328694757CD49968"
          xlink:label="d8316808e1847-wk-Fact-F581216089FF320C328694757CD49968"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1847-wk-Fact-F581216089FF320C328694757CD49968"
          xlink:to="TextSelection-23DF6508A1F2A3B1745994757DB98CA0-0-wk-Footnote-23DF6508A1F2A3B1745994757DB98CA0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8357160e1615-wk-Fact-F5BA4E904B30B0A0A9DC94757CCE56D0"
          xlink:label="d8357160e1615-wk-Fact-F5BA4E904B30B0A0A9DC94757CCE56D0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e1615-wk-Fact-F5BA4E904B30B0A0A9DC94757CCE56D0"
          xlink:to="TextSelection-84058C93858F4EB1F00C631013E8EF74-0-wk-Footnote-84058C93858F4EB1F00C631013E8EF74_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e2229-wk-Fact-F5BC31DCC6B0367BD58894757CDB9BE9"
          xlink:label="d8312059e2229-wk-Fact-F5BC31DCC6B0367BD58894757CDB9BE9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e2229-wk-Fact-F5BC31DCC6B0367BD58894757CDB9BE9"
          xlink:to="TextSelection-4E7C1B693E988F464A3D94757DB7F8A9-0-wk-Footnote-4E7C1B693E988F464A3D94757DB7F8A9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1266-wk-Fact-F5E011F8B735031318D994757D0A265D"
          xlink:label="d8301124e1266-wk-Fact-F5E011F8B735031318D994757D0A265D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1266-wk-Fact-F5E011F8B735031318D994757D0A265D"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e1286-wk-Fact-F618699466962C9B165B94757CEEF703"
          xlink:label="d8301124e1286-wk-Fact-F618699466962C9B165B94757CEEF703"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e1286-wk-Fact-F618699466962C9B165B94757CEEF703"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2744-wk-Fact-F68119AE4BA283A0E74494757D5699A2"
          xlink:label="d8307028e2744-wk-Fact-F68119AE4BA283A0E74494757D5699A2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2744-wk-Fact-F68119AE4BA283A0E74494757D5699A2"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e15078-wk-Fact-F6DA9F6F4CDC4D1208C294757D3DEB55"
          xlink:label="d8336633e15078-wk-Fact-F6DA9F6F4CDC4D1208C294757D3DEB55"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e7812-wk-Fact-F6DA9F6F4CDC4D1208C294757D3DEB55"
          xlink:label="d8336633e7812-wk-Fact-F6DA9F6F4CDC4D1208C294757D3DEB55"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e15078-wk-Fact-F6DA9F6F4CDC4D1208C294757D3DEB55"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e7812-wk-Fact-F6DA9F6F4CDC4D1208C294757D3DEB55"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10433-wk-Fact-F7818AB402D4FDFA360A94757D088A7E"
          xlink:label="d8415180e10433-wk-Fact-F7818AB402D4FDFA360A94757D088A7E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10433-wk-Fact-F7818AB402D4FDFA360A94757D088A7E"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336625e2664-wk-Fact-F783B181694B408C809794757D6B5422"
          xlink:label="d8336625e2664-wk-Fact-F783B181694B408C809794757D6B5422"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336625e2664-wk-Fact-F783B181694B408C809794757D6B5422"
          xlink:to="TextSelection-83180A323F26770F5F9D94757DBB7831-0-wk-Footnote-83180A323F26770F5F9D94757DBB7831_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8312059e1634-wk-Fact-F7DAC00A60C60846547B94757CE11E6F"
          xlink:label="d8312059e1634-wk-Fact-F7DAC00A60C60846547B94757CE11E6F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8312059e1634-wk-Fact-F7DAC00A60C60846547B94757CE11E6F"
          xlink:to="TextSelection-B06D4F08D7061C0CFA5894757DB76AD8-0-wk-Footnote-B06D4F08D7061C0CFA5894757DB76AD8_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e3343-wk-Fact-F7F177E6405946748C2A94757D258C32"
          xlink:label="d8372444e3343-wk-Fact-F7F177E6405946748C2A94757D258C32"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3343-wk-Fact-F7F177E6405946748C2A94757D258C32"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3343-wk-Fact-F7F177E6405946748C2A94757D258C32"
          xlink:to="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e3343-wk-Fact-F7F177E6405946748C2A94757D258C32"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1808-wk-Fact-F8480927DA2450FB9AB294757D637386"
          xlink:label="d8340406e1808-wk-Fact-F8480927DA2450FB9AB294757D637386"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1808-wk-Fact-F8480927DA2450FB9AB294757D637386"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e3434-wk-Fact-F86B001A7C15B351060B94757CD7A389"
          xlink:label="d8415180e3434-wk-Fact-F86B001A7C15B351060B94757CD7A389"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e3434-wk-Fact-F86B001A7C15B351060B94757CD7A389"
          xlink:to="TextSelection-9BC3436E7B9C00975CD394757DC16C56-0-wk-Footnote-9BC3436E7B9C00975CD394757DC16C56_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e5745-wk-Fact-F90EF4CFE321BC6F7A3494757D56ED60"
          xlink:label="d8415180e5745-wk-Fact-F90EF4CFE321BC6F7A3494757D56ED60"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e5745-wk-Fact-F90EF4CFE321BC6F7A3494757D56ED60"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1768-wk-Fact-F92309C5686C80B6F12094757D26F9AA"
          xlink:label="d8340406e1768-wk-Fact-F92309C5686C80B6F12094757D26F9AA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1768-wk-Fact-F92309C5686C80B6F12094757D26F9AA"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336625e2683-wk-Fact-F98C90F9224CC0E01A5794757D69B0D8"
          xlink:label="d8336625e2683-wk-Fact-F98C90F9224CC0E01A5794757D69B0D8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336625e2683-wk-Fact-F98C90F9224CC0E01A5794757D69B0D8"
          xlink:to="TextSelection-83180A323F26770F5F9D94757DBB7831-0-wk-Footnote-83180A323F26770F5F9D94757DBB7831_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8301124e2827-wk-Fact-F996AE0BB974A9291E5D94757CB473E1"
          xlink:label="d8301124e2827-wk-Fact-F996AE0BB974A9291E5D94757CB473E1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e9380-wk-Fact-F996AE0BB974A9291E5D94757CB473E1"
          xlink:label="d8336633e9380-wk-Fact-F996AE0BB974A9291E5D94757CB473E1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2827-wk-Fact-F996AE0BB974A9291E5D94757CB473E1"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e9380-wk-Fact-F996AE0BB974A9291E5D94757CB473E1"
          xlink:to="TextSelection-49C720EAA10A4C08A87094757DB589BE-0-wk-Footnote-49C720EAA10A4C08A87094757DB589BE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8301124e2827-wk-Fact-F996AE0BB974A9291E5D94757CB473E1"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e9380-wk-Fact-F996AE0BB974A9291E5D94757CB473E1"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8329819e1097-wk-Fact-FA941197011A51FBD4DF94757D289899"
          xlink:label="d8329819e1097-wk-Fact-FA941197011A51FBD4DF94757D289899"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8307028e1661-wk-Fact-FA941197011A51FBD4DF94757D289899"
          xlink:label="d8307028e1661-wk-Fact-FA941197011A51FBD4DF94757D289899"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8329819e1097-wk-Fact-FA941197011A51FBD4DF94757D289899"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1661-wk-Fact-FA941197011A51FBD4DF94757D289899"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1409-wk-Fact-FAA57939ED1473B9187894757D259554"
          xlink:label="d8307028e1409-wk-Fact-FAA57939ED1473B9187894757D259554"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8357160e3500-wk-Fact-FAA57939ED1473B9187894757D259554"
          xlink:label="d8357160e3500-wk-Fact-FAA57939ED1473B9187894757D259554"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1409-wk-Fact-FAA57939ED1473B9187894757D259554"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8357160e3500-wk-Fact-FAA57939ED1473B9187894757D259554"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e10002-wk-Fact-FABFB96784AE0E40057C94757CBC23CF"
          xlink:label="d8336633e10002-wk-Fact-FABFB96784AE0E40057C94757CBC23CF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e10002-wk-Fact-FABFB96784AE0E40057C94757CBC23CF"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e3126-wk-Fact-FAD43102CBD17909063494757CE9364E"
          xlink:label="d8336633e3126-wk-Fact-FAD43102CBD17909063494757CE9364E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e3126-wk-Fact-FAD43102CBD17909063494757CE9364E"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e10966-wk-Fact-FAE23785D8D757DC211B94757D5BFB03"
          xlink:label="d8415180e10966-wk-Fact-FAE23785D8D757DC211B94757D5BFB03"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e10966-wk-Fact-FAE23785D8D757DC211B94757D5BFB03"
          xlink:to="TextSelection-D895C9E8DF19B244540094757DC27744-0-wk-Footnote-D895C9E8DF19B244540094757DC27744_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e8262-wk-Fact-FB427E54FB33B137568A94757D7D2609"
          xlink:label="d8372444e8262-wk-Fact-FB427E54FB33B137568A94757D7D2609"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e8262-wk-Fact-FB427E54FB33B137568A94757D7D2609"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e12605-wk-Fact-FB4B7F31E75AF61C8C1B94757CB6CB4D"
          xlink:label="d8336633e12605-wk-Fact-FB4B7F31E75AF61C8C1B94757CB6CB4D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e12605-wk-Fact-FB4B7F31E75AF61C8C1B94757CB6CB4D"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8340406e1264-wk-Fact-FB5675ACB41E944F604C94757D1A61F2"
          xlink:label="d8340406e1264-wk-Fact-FB5675ACB41E944F604C94757D1A61F2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1264-wk-Fact-FB5675ACB41E944F604C94757D1A61F2"
          xlink:to="TextSelection-04B9B25659DF96CA86BF94757DB5CCE1-0-wk-Footnote-04B9B25659DF96CA86BF94757DB5CCE1_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8340406e1264-wk-Fact-FB5675ACB41E944F604C94757D1A61F2"
          xlink:to="TextSelection-772D2AE5277ACCB6501894757DB5818F-0-wk-Footnote-772D2AE5277ACCB6501894757DB5818F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8316808e1288-wk-Fact-FB5C3E831211DA67818F94757CFBBA25"
          xlink:label="d8316808e1288-wk-Fact-FB5C3E831211DA67818F94757CFBBA25"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8316808e1288-wk-Fact-FB5C3E831211DA67818F94757CFBBA25"
          xlink:to="TextSelection-CDCE760DEFA7F631840C94757DB86187-0-wk-Footnote-CDCE760DEFA7F631840C94757DB86187_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e12565-wk-Fact-FB658162A265137F4D2C94757D910349"
          xlink:label="d8336633e12565-wk-Fact-FB658162A265137F4D2C94757D910349"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e12565-wk-Fact-FB658162A265137F4D2C94757D910349"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e14990-wk-Fact-FB813AC829F4A188FEBA94757D2D36C8"
          xlink:label="d8336633e14990-wk-Fact-FB813AC829F4A188FEBA94757D2D36C8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8336633e7724-wk-Fact-FB813AC829F4A188FEBA94757D2D36C8"
          xlink:label="d8336633e7724-wk-Fact-FB813AC829F4A188FEBA94757D2D36C8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e14990-wk-Fact-FB813AC829F4A188FEBA94757D2D36C8"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e7724-wk-Fact-FB813AC829F4A188FEBA94757D2D36C8"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e2634-wk-Fact-FC09E3AC9855BA04E2AC94757D2ED7CA"
          xlink:label="d8307028e2634-wk-Fact-FC09E3AC9855BA04E2AC94757D2ED7CA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e2634-wk-Fact-FC09E3AC9855BA04E2AC94757D2ED7CA"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e5652-wk-Fact-FC2B2CD24A88257F990394757CB35835"
          xlink:label="d8415180e5652-wk-Fact-FC2B2CD24A88257F990394757CB35835"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e5652-wk-Fact-FC2B2CD24A88257F990394757CB35835"
          xlink:to="TextSelection-EF44A586CB1BA75225ED94757DC1808F-0-wk-Footnote-EF44A586CB1BA75225ED94757DC1808F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e1673-wk-Fact-FC3B1DFA5581B90199D694757D2565A3"
          xlink:label="d8336633e1673-wk-Fact-FC3B1DFA5581B90199D694757D2565A3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e1673-wk-Fact-FC3B1DFA5581B90199D694757D2565A3"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8372444e7238-wk-Fact-FC494931B0AF7CE356B794757D314170"
          xlink:label="d8372444e7238-wk-Fact-FC494931B0AF7CE356B794757D314170"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7238-wk-Fact-FC494931B0AF7CE356B794757D314170"
          xlink:to="TextSelection-069C548EB4617746C9FE94757DBDB9D2-0-wk-Footnote-069C548EB4617746C9FE94757DBDB9D2_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7238-wk-Fact-FC494931B0AF7CE356B794757D314170"
          xlink:to="TextSelection-80A370FFE8953196F42594757DBDE300-0-wk-Footnote-80A370FFE8953196F42594757DBDE300_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8372444e7238-wk-Fact-FC494931B0AF7CE356B794757D314170"
          xlink:to="TextSelection-CBD318C130FFAF30E7E494757DBD985B-0-wk-Footnote-CBD318C130FFAF30E7E494757DBD985B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e12812-wk-Fact-FC6199412C81449DCEDC94757CB8CF8E"
          xlink:label="d8336633e12812-wk-Fact-FC6199412C81449DCEDC94757CB8CF8E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e12812-wk-Fact-FC6199412C81449DCEDC94757CB8CF8E"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e903-wk-Fact-FCEFDC9E796190874A2D94757D27BB31"
          xlink:label="d8307028e903-wk-Fact-FCEFDC9E796190874A2D94757D27BB31"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e903-wk-Fact-FCEFDC9E796190874A2D94757D27BB31"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e5239-wk-Fact-FD9AFC22FEA2E091BFC594757D404E95"
          xlink:label="d8336633e5239-wk-Fact-FD9AFC22FEA2E091BFC594757D404E95"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e5239-wk-Fact-FD9AFC22FEA2E091BFC594757D404E95"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e10294-wk-Fact-FE201EAFE1503AB0772B94757D8F33AD"
          xlink:label="d8336633e10294-wk-Fact-FE201EAFE1503AB0772B94757D8F33AD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e10294-wk-Fact-FE201EAFE1503AB0772B94757D8F33AD"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8415180e3322-wk-Fact-FF8C7011D05EB3AB087F94757D62A58B"
          xlink:label="d8415180e3322-wk-Fact-FF8C7011D05EB3AB087F94757D62A58B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8415180e3322-wk-Fact-FF8C7011D05EB3AB087F94757D62A58B"
          xlink:to="TextSelection-16C8E91E8B46059CD77B94757DC1E784-0-wk-Footnote-16C8E91E8B46059CD77B94757DC1E784_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8307028e1258-wk-Fact-FFBCEDF314C46C81ABEE94757D18EE64"
          xlink:label="d8307028e1258-wk-Fact-FFBCEDF314C46C81ABEE94757D18EE64"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8351242e8293-wk-Fact-FFBCEDF314C46C81ABEE94757D18EE64"
          xlink:label="d8351242e8293-wk-Fact-FFBCEDF314C46C81ABEE94757D18EE64"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8307028e1258-wk-Fact-FFBCEDF314C46C81ABEE94757D18EE64"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8351242e8293-wk-Fact-FFBCEDF314C46C81ABEE94757D18EE64"
          xlink:to="TextSelection-D5A155A45285D707888C94757DB5A896-0-wk-Footnote-D5A155A45285D707888C94757DB5A896_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8336633e10777-wk-Fact-FFD71DCF3ECC62BAAB9494757CB88D9F"
          xlink:label="d8336633e10777-wk-Fact-FFD71DCF3ECC62BAAB9494757CB88D9F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8336633e10777-wk-Fact-FFD71DCF3ECC62BAAB9494757CB88D9F"
          xlink:to="TextSelection-EEE4FF1214C2D6FDF65F94757DB6B196-0-wk-Footnote-EEE4FF1214C2D6FDF65F94757DB6B196_lbl"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818724970536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Aug. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 28,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-3619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PFIZER INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-5315170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">235 East 42nd Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">733-2323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,556,879,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000078003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, $.05 par value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.05 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PFE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pfe_NotesDue20220.250Member', window );">0.250% Notes due 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.250% Notes due 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PFE22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pfe_NotesDue20271.000Member', window );">1.000% Notes due 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.000% Notes due 2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PFE27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pfe_NotesDue20220.250Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pfe_NotesDue20220.250Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pfe_NotesDue20271.000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pfe_NotesDue20271.000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818804017544">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 11,801<span></span>
</td>
<td class="nump">$ 13,264<span></span>
</td>
<td class="nump">$ 23,829<span></span>
</td>
<td class="nump">$ 26,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">2,281<span></span>
</td>
<td class="nump">2,576<span></span>
</td>
<td class="nump">4,658<span></span>
</td>
<td class="nump">5,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, informational and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">3,030<span></span>
</td>
<td class="nump">3,511<span></span>
</td>
<td class="nump">5,903<span></span>
</td>
<td class="nump">6,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">2,132<span></span>
</td>
<td class="nump">1,842<span></span>
</td>
<td class="nump">3,856<span></span>
</td>
<td class="nump">3,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction', window );">Amortization of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">905<span></span>
</td>
<td class="nump">1,184<span></span>
</td>
<td class="nump">1,790<span></span>
</td>
<td class="nump">2,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringChargesAndAcquisitionRelatedCosts', window );">Restructuring charges and certain acquisition-related costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">362<span></span>
</td>
<td class="num">(115)<span></span>
</td>
<td class="nump">431<span></span>
</td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">(Gain) on completion of Consumer Healthcare JV transaction</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income)/deductions&#8211;&#8211;net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(862)<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="num">(641)<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before provision/(benefit) for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="nump">3,953<span></span>
</td>
<td class="nump">4,141<span></span>
</td>
<td class="nump">7,838<span></span>
</td>
<td class="nump">8,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision/(benefit) for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">519<span></span>
</td>
<td class="num">(915)<span></span>
</td>
<td class="nump">993<span></span>
</td>
<td class="num">(481)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,434<span></span>
</td>
<td class="nump">5,056<span></span>
</td>
<td class="nump">6,845<span></span>
</td>
<td class="nump">8,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income before allocation to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4],[5],[6]</sup></td>
<td class="nump">3,434<span></span>
</td>
<td class="nump">5,056<span></span>
</td>
<td class="nump">6,845<span></span>
</td>
<td class="nump">8,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net income attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Pfizer Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 3,426<span></span>
</td>
<td class="nump">$ 5,046<span></span>
</td>
<td class="nump">$ 6,828<span></span>
</td>
<td class="nump">$ 8,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings per common share&#8211;&#8211;basic:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0.62<span></span>
</td>
<td class="nump">$ 0.91<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="nump">$ 1.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations&#8211;&#8211;net of tax (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0.62<span></span>
</td>
<td class="nump">0.91<span></span>
</td>
<td class="nump">1.23<span></span>
</td>
<td class="nump">1.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Earnings per common share&#8211;&#8211;diluted:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0.61<span></span>
</td>
<td class="nump">0.89<span></span>
</td>
<td class="nump">1.22<span></span>
</td>
<td class="nump">1.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations&#8211;&#8211;net of tax (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0.61<span></span>
</td>
<td class="nump">$ 0.89<span></span>
</td>
<td class="nump">$ 1.22<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares&#8211;&#8211;basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,554<span></span>
</td>
<td class="nump">5,562<span></span>
</td>
<td class="nump">5,550<span></span>
</td>
<td class="nump">5,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares&#8211;&#8211;diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,619<span></span>
</td>
<td class="nump">5,672<span></span>
</td>
<td class="nump">5,616<span></span>
</td>
<td class="nump">5,711<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:53px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Excludes amortization of intangible assets, except as disclosed in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="font-family:inherit;font-size:8pt;">. Biopharma&#8217;s earnings </span><span style="font-family:inherit;font-size:8pt;text-align:center;">include d</span><span style="font-family:inherit;font-size:8pt;">ividend income of </span><span style="font-family:inherit;font-size:8pt;"><span>$76 million</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$76&#160;million</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:8pt;">, and </span><span style="font-family:inherit;font-size:8pt;"><span>$153 million</span></span><span style="font-family:inherit;font-size:8pt;"> in </span><span style="font-family:inherit;font-size:8pt;">the first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$140 million</span></span><span style="font-family:inherit;font-size:8pt;"> in </span><span style="font-family:inherit;font-size:8pt;">the first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:8pt;"> from our investment in ViiV. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:13px;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:20px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:266px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of amortization that is not associated with a single function. Amounts associated in a single function are included in Cost of sales, Selling, information and administrative expenses and Research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringChargesAndAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringChargesAndAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818813258840">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th" colspan="2"><div>Jun. 28, 2020</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income before allocation to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2],[3],[4]</sup></td>
<td class="nump">$ 3,434<span></span>
</td>
<td class="nump">$ 5,056<span></span>
</td>
<td class="nump">$ 6,845<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 8,945<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax', window );">Foreign currency translation adjustments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[5]</sup></td>
<td class="num">(242)<span></span>
</td>
<td class="num">(485)<span></span>
</td>
<td class="num">(1,513)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(161)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax', window );">Reclassification adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(242)<span></span>
</td>
<td class="num">(485)<span></span>
</td>
<td class="num">(1,513)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(159)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Unrealized holding gains/(losses) on derivative financial instruments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">213<span></span>
</td>
<td class="num">(176)<span></span>
</td>
<td class="num">(288)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">91<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Reclassification adjustments for gains included in net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[6]</sup></td>
<td class="num">(186)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="num">(167)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(343)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax', window );">Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">27<span></span>
</td>
<td class="num">(256)<span></span>
</td>
<td class="num">(455)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(252)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized holding gains/(losses) on available-for-sale securities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">42<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">33<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax', window );">Reclassification adjustments for losses included in net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[7]</sup></td>
<td class="nump">44<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">37<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax', window );">Other comprehensive income (loss), available-for-sale securities, before tax, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">87<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">70<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Benefit plans: actuarial gains/(losses), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(160)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax', window );">Reclassification adjustments related to amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">67<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">121<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax', window );">Reclassification adjustments related to settlements, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">13<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">68<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax', window );">Defined benefit plan, amounts recognized in other comprehensive income (loss), net gain (loss), before tax, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">153<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">137<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Benefit plans: prior service costs and other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Reclassification adjustments related to amortization of prior service costs and other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(45)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(93)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service cost, before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(92)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other comprehensive loss, before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(669)<span></span>
</td>
<td class="num">(1,882)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(296)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Tax provision/(benefit) on other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">113<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="num">(265)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(34)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss before allocation to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="num">(127)<span></span>
</td>
<td class="num">(610)<span></span>
</td>
<td class="num">(1,617)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(262)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income before allocation to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,307<span></span>
</td>
<td class="nump">4,446<span></span>
</td>
<td class="nump">5,227<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,683<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Comprehensive income/(loss) attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Pfizer Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 3,312<span></span>
</td>
<td class="nump">$ 4,434<span></span>
</td>
<td class="nump">$ 5,222<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 8,669<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:13px;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:20px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:266px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:53px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts in the </span><span style="font-family:inherit;font-size:9pt;">second quarter</span><span style="font-family:inherit;font-size:9pt;"> of 2020 include losses from the weakening of certain major currencies against the U.S. dollar, partially offset by a </span><span style="font-family:inherit;font-size:9pt;">gain</span><span style="font-family:inherit;font-size:9pt;"> of approximately </span><span style="font-family:inherit;font-size:9pt;"><span>$380 million</span></span><span style="font-family:inherit;font-size:9pt;"> pre-tax (</span><span style="font-family:inherit;font-size:9pt;"><span>$291 million</span></span><span style="font-family:inherit;font-size:9pt;"> after-tax) related to foreign currency translation adjustments and the impact of our net investment hedging program, both attributable to our equity method investment in the GSK Consumer Healthcare joint venture. Amounts in </span><span style="font-family:inherit;font-size:9pt;">the first six months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;">2020</span><span style="font-family:inherit;font-size:9pt;"> include a </span><span style="font-family:inherit;font-size:9pt;">loss</span><span style="font-family:inherit;font-size:9pt;"> of approximately </span><span style="font-family:inherit;font-size:9pt;"><span>$1.2 billion</span></span><span style="font-family:inherit;font-size:9pt;"> pre-tax (</span><span style="font-family:inherit;font-size:9pt;"><span>$902 million</span></span><span style="font-family:inherit;font-size:9pt;"> after-tax) related to foreign currency translation adjustments and the impact of our net investment hedging program, both attributable to our equity method investment in the GSK Consumer Healthcare joint venture and losses from the weakening of certain major currencies against the U.S. dollar, partially offset by the results of our net investment hedging program. For additional information on the GSK Consumer Healthcare joint venture, see </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 2B</span><span style="font-family:inherit;font-size:9pt;">. </span><span style="font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Acquisition, Equity-Method Investment and Licensing Arrangements</span><span style="font-family:inherit;font-size:9pt;">: </span><span style="font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Equity-Method Investment</span><span style="font-family:inherit;font-size:9pt;font-style:italic;">.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassified into </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions&#8212;net </span><span style="font-family:inherit;font-size:9pt;">and </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:9pt;"> in the condensed consolidated statements of income. For additional information on amounts reclassified into </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions&#8212;net </span><span style="font-family:inherit;font-size:9pt;">and </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:9pt;">, see </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 7E. Financial Instruments: Derivative Financial Instruments and Hedging Activities.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassified into </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions&#8212;net.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans prior service (costs)/credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans actuarial gains /losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of increase (decrease) in accumulated other comprehensive income from gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income from prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30304-110892<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724391-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33775-111570<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116633155&amp;loc=d3e31531-110899<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724391-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e709-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818804387144">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - Parenthetical - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (242)<span></span>
</td>
<td class="num">$ (1,513)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember', window );">GSK Consumer Healthcare [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">380<span></span>
</td>
<td class="num">(1,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 291<span></span>
</td>
<td class="num">$ (902)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:13px;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts may not add due to rounding.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818729931336">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,801<span></span>
</td>
<td class="nump">$ 1,305<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">9,581<span></span>
</td>
<td class="nump">8,525<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsCurrent', window );">Restricted short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="nump">11,412<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable, less allowance for doubtful accounts: 2020&#8212;$525; 2019&#8212;$527</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">9,128<span></span>
</td>
<td class="nump">8,724<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
<td class="nump">8,564<span></span>
</td>
<td class="nump">8,283<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherTaxAssetsCurrent', window );">Current tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,426<span></span>
</td>
<td class="nump">3,344<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,513<span></span>
</td>
<td class="nump">2,622<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">46,424<span></span>
</td>
<td class="nump">32,803<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity-method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">15,578<span></span>
</td>
<td class="nump">17,133<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,142<span></span>
</td>
<td class="nump">3,014<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, less accumulated depreciation: 2020&#8212;$16,889; 2019&#8212;$16,789</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">14,113<span></span>
</td>
<td class="nump">13,967<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Identifiable intangible assets, less accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[5]</sup></td>
<td class="nump">33,541<span></span>
</td>
<td class="nump">35,370<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">58,449<span></span>
</td>
<td class="nump">58,653<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent', window );">Noncurrent deferred tax assets and other noncurrent tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,360<span></span>
</td>
<td class="nump">2,099<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,327<span></span>
</td>
<td class="nump">4,450<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">177,934<span></span>
</td>
<td class="nump">167,489<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term borrowings, including current portion of long-term debt: 2020&#8212;$1,481; 2019&#8212;$1,462</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">13,084<span></span>
</td>
<td class="nump">16,195<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,872<span></span>
</td>
<td class="nump">4,220<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,111<span></span>
</td>
<td class="nump">2,104<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,445<span></span>
</td>
<td class="nump">980<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and related items</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,042<span></span>
</td>
<td class="nump">2,720<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">10,168<span></span>
</td>
<td class="nump">11,083<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">32,723<span></span>
</td>
<td class="nump">37,304<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="nump">50,529<span></span>
</td>
<td class="nump">35,955<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent', window );">Pension benefit obligations, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,344<span></span>
</td>
<td class="nump">5,638<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent', window );">Postretirement benefit obligations, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,086<span></span>
</td>
<td class="nump">1,124<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Noncurrent deferred tax liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,409<span></span>
</td>
<td class="nump">5,578<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent', window );">Other taxes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">11,468<span></span>
</td>
<td class="nump">12,126<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,812<span></span>
</td>
<td class="nump">6,317<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">113,370<span></span>
</td>
<td class="nump">104,042<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">470<span></span>
</td>
<td class="nump">468<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">87,886<span></span>
</td>
<td class="nump">87,428<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(110,978)<span></span>
</td>
<td class="num">(110,801)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">100,203<span></span>
</td>
<td class="nump">97,670<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(13,246)<span></span>
</td>
<td class="num">(11,640)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Pfizer Inc. shareholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">64,336<span></span>
</td>
<td class="nump">63,143<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Equity attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">228<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[6]</sup></td>
<td class="nump">64,564<span></span>
</td>
<td class="nump">63,447<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 177,934<span></span>
</td>
<td class="nump">$ 167,489<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:20px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family:inherit;font-size:8pt;">The balance as of June 28, 2020 reflects the Upjohn Inc. and Upjohn Finance B.V. debt issuances. For additional information see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7D. Financial Instruments: </span><span style="font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Long-Term Debt</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The change from </span><span style="font-family:inherit;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:8pt;"> reflects increases for certain products, including inventory build for new product launches, network strategy and market demand, partially offset by a decrease due to foreign exchange.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The </span><span style="font-family:inherit;font-size:8pt;">decrease</span><span style="font-family:inherit;font-size:8pt;"> in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">I</span><span style="font-family:inherit;font-size:8pt;font-style:italic;text-align:right;">dentifiable intangible assets, less accumulated amortization</span><span style="font-family:inherit;font-size:8pt;text-align:right;">, </span><span style="font-family:inherit;font-size:8pt;">is primarily due to amortization.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:266px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherTaxAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Tax Assets, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherTaxAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit other postretirement plan, classified as noncurrent. Excludes pension plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the current portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818732103976">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 525<span></span>
</td>
<td class="nump">$ 527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property, plant and equipment, accumulated depreciation</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">16,889<span></span>
</td>
<td class="nump">16,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,481<span></span>
</td>
<td class="nump">$ 1,462<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818828009544">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2"><div>Total</div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Add'l Paid-in Capital [Member]</div></th>
<th class="th"><div>Treasury Stock [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Accum. Other Comp. Loss [Member]</div></th>
<th class="th"><div>Shareholders' Equity [Member]</div></th>
<th class="th"><div>Noncontrolling Interests [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">478<span></span>
</td>
<td class="nump">9,332,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,615,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 63,758<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 467<span></span>
</td>
<td class="nump">$ 86,253<span></span>
</td>
<td class="num">$ (101,610)<span></span>
</td>
<td class="nump">$ 89,554<span></span>
</td>
<td class="num">$ (11,275)<span></span>
</td>
<td class="nump">$ 63,407<span></span>
</td>
<td class="nump">$ 351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8,945<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3],[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,929<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss), net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(262)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(260)<span></span>
</td>
<td class="num">(260)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCashAbstract', window );"><strong>Cash dividends declared:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(4,062)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,062)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,062)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based payment transactions (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based payment transactions</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">402<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">712<span></span>
</td>
<td class="num">$ (312)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of common stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(180,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchases of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(8,865)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,865)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,865)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock', window );">Preferred stock conversions and redemptions (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock', window );">Preferred stock conversions and redemptions</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(2)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[5]</sup></td>
<td class="nump">19<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">458<span></span>
</td>
<td class="nump">9,363,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,801,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">59,924<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 468<span></span>
</td>
<td class="nump">86,963<span></span>
</td>
<td class="num">$ (110,786)<span></span>
</td>
<td class="nump">94,440<span></span>
</td>
<td class="num">(11,535)<span></span>
</td>
<td class="nump">59,568<span></span>
</td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">466<span></span>
</td>
<td class="nump">9,358,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,801,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">59,158<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 468<span></span>
</td>
<td class="nump">86,635<span></span>
</td>
<td class="num">$ (110,781)<span></span>
</td>
<td class="nump">93,388<span></span>
</td>
<td class="num">(10,923)<span></span>
</td>
<td class="nump">58,806<span></span>
</td>
<td class="nump">352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,056<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3],[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,046<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss), net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(610)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(613)<span></span>
</td>
<td class="num">(613)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCashAbstract', window );"><strong>Cash dividends declared:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(3,994)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,994)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,994)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based payment transactions (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based payment transactions</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">324<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of common stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchases of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock', window );">Preferred stock conversions and redemptions (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock', window );">Preferred stock conversions and redemptions</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">458<span></span>
</td>
<td class="nump">9,363,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,801,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">59,924<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 468<span></span>
</td>
<td class="nump">86,963<span></span>
</td>
<td class="num">$ (110,786)<span></span>
</td>
<td class="nump">94,440<span></span>
</td>
<td class="num">(11,535)<span></span>
</td>
<td class="nump">59,568<span></span>
</td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">431<span></span>
</td>
<td class="nump">9,369,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,835,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">63,447<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 468<span></span>
</td>
<td class="nump">87,428<span></span>
</td>
<td class="num">$ (110,801)<span></span>
</td>
<td class="nump">97,670<span></span>
</td>
<td class="num">(11,640)<span></span>
</td>
<td class="nump">63,143<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">431<span></span>
</td>
<td class="nump">9,369,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,835,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">63,447<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 468<span></span>
</td>
<td class="nump">87,428<span></span>
</td>
<td class="num">$ (110,801)<span></span>
</td>
<td class="nump">97,670<span></span>
</td>
<td class="num">(11,640)<span></span>
</td>
<td class="nump">63,143<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,845<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3],[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,828<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss), net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1,617)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,605)<span></span>
</td>
<td class="num">(1,605)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCashAbstract', window );"><strong>Cash dividends declared:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(4,294)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,294)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,294)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(80)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based payment transactions (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based payment transactions</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">266<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">473<span></span>
</td>
<td class="num">$ (208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of common stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchases of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock', window );">Preferred stock conversions and redemptions (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[7]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(431)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock', window );">Preferred stock conversions and redemptions</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[7]</sup></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Other (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 28, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,394,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,840,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 28, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">64,564<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 470<span></span>
</td>
<td class="nump">87,886<span></span>
</td>
<td class="num">$ (110,978)<span></span>
</td>
<td class="nump">100,203<span></span>
</td>
<td class="num">(13,246)<span></span>
</td>
<td class="nump">64,336<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 29, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">417<span></span>
</td>
<td class="nump">9,393,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,841,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 29, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">65,338<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 470<span></span>
</td>
<td class="nump">87,680<span></span>
</td>
<td class="num">$ (111,010)<span></span>
</td>
<td class="nump">101,000<span></span>
</td>
<td class="num">(13,131)<span></span>
</td>
<td class="nump">65,026<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,434<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3],[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,426<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss), net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(127)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(115)<span></span>
</td>
<td class="num">(115)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCashAbstract', window );"><strong>Cash dividends declared:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(4,223)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,223)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,223)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(80)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based payment transactions (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based payment transactions</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">222<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of common stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchases of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock', window );">Preferred stock conversions and redemptions (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[7]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(417)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock', window );">Preferred stock conversions and redemptions</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[7]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 28, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,394,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,840,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 28, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 64,564<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 470<span></span>
</td>
<td class="nump">$ 87,886<span></span>
</td>
<td class="num">$ (110,978)<span></span>
</td>
<td class="nump">$ 100,203<span></span>
</td>
<td class="num">$ (13,246)<span></span>
</td>
<td class="nump">$ 64,336<span></span>
</td>
<td class="nump">$ 228<span></span>
</td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:266px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:13px;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:20px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:53px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:8pt;">The increase to </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Retained earnings </span><span style="font-family:inherit;font-size:8pt;">represents the cumulative effect of the adoption of a new accounting standard in the first quarter of 2019 for leases. For additional information, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2019</span><span style="font-family:inherit;font-size:8pt;"> in our 2019 Financial Report.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">&#160;<div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:8pt;">On May 4, 2020, all outstanding shares of Pfizer&#8217;s Series A convertible perpetual preferred stock were converted into shares of Pfizer common stock. See </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 11.</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Equity</span><span style="font-family:inherit;font-size:8pt;"> for additional information.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued And Redeemed During Period, Shares, Conversion And Redemption of Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued And Redeemed During Period, Value, Conversion And Redemption of Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOtherShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of increase (decrease) in shares of stock classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOtherShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818731295464">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income before allocation to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2],[3],[4]</sup></td>
<td class="nump">$ 6,845<span></span>
</td>
<td class="nump">$ 8,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">2,469<span></span>
</td>
<td class="nump">3,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AssetWriteOffsAndAssetImpairmentCharges', window );">Asset write-offs and impairments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">58<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit', window );">TCJA impact</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[5]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(285)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeconsolidationGainLossAmountNetOfCashConveyed', window );">Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">71<span></span>
</td>
<td class="num">(160)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">258<span></span>
</td>
<td class="nump">384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense', window );">Benefit plan contributions in excess of expense/income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(418)<span></span>
</td>
<td class="num">(313)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other adjustments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(361)<span></span>
</td>
<td class="num">(462)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapital', window );">Other changes in assets and liabilities, net of acquisitions and divestitures</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(2,229)<span></span>
</td>
<td class="num">(7,051)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">6,688<span></span>
</td>
<td class="nump">4,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(942)<span></span>
</td>
<td class="num">(939)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(5,141)<span></span>
</td>
<td class="num">(4,063)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Proceeds from redemptions/sales of short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">4,595<span></span>
</td>
<td class="nump">6,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess', window );">Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[6]</sup></td>
<td class="num">(11,949)<span></span>
</td>
<td class="nump">4,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(168)<span></span>
</td>
<td class="num">(123)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments', window );">Proceeds from redemptions/sales of long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">536<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisitions of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(267)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">19<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by/(used in) investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(13,082)<span></span>
</td>
<td class="nump">5,648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">12,352<span></span>
</td>
<td class="nump">3,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Principal payments on short-term borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(13,166)<span></span>
</td>
<td class="num">(2,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess', window );">Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(2,273)<span></span>
</td>
<td class="nump">2,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[6]</sup></td>
<td class="nump">16,606<span></span>
</td>
<td class="nump">4,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments on long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(2,181)<span></span>
</td>
<td class="num">(5,355)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,865)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfOrdinaryDividends', window );">Cash dividends paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(4,216)<span></span>
</td>
<td class="num">(4,047)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">158<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(321)<span></span>
</td>
<td class="num">(541)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by/(used in) financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">6,959<span></span>
</td>
<td class="num">(9,318)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(70)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents and restricted cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">495<span></span>
</td>
<td class="nump">612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash and cash equivalents, beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,350<span></span>
</td>
<td class="nump">1,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash and cash equivalents, end</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,845<span></span>
</td>
<td class="nump">1,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Cash paid (received) during the period for:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,290<span></span>
</td>
<td class="nump">2,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">910<span></span>
</td>
<td class="nump">809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InterestReceivedInterestRateHedges', window );">Interest rate hedges</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">$ (66)<span></span>
</td>
<td class="num">$ (72)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:13px;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:20px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:266px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:53px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As a result of the enactment of the TCJA in December 2017, Pfizer&#8217;s </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Provision/(benefit) for taxes on income</span><span style="font-family:inherit;font-size:8pt;"> for the </span><span style="font-family:inherit;font-size:8pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:8pt;"> was favorably impacted by approximately </span><span style="font-family:inherit;font-size:8pt;"><span>$285 million</span></span><span style="font-family:inherit;font-size:8pt;">, primarily as a result of additional guidance issued by the U.S. Department of Treasury.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Includes </span><span style="font-family:inherit;font-size:8pt;"><span>$11.4 billion</span></span><span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn long-term debt issuances in the second quarter of 2020, which are included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments</span><span style="font-family:inherit;font-size:8pt;"> in the condensed consolidated balance sheet. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Notes 7A. Financial Instruments: </span><span style="font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Fair Value Measurements</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Financial Instruments: 7D. </span><span style="font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Long-Term Debt</span><span style="font-family:inherit;font-size:8pt;">).</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AssetWriteOffsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Write-Offs And Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AssetWriteOffsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeconsolidationGainLossAmountNetOfCashConveyed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deconsolidation, Gain (Loss), Amount, Net Of Cash Conveyed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeconsolidationGainLossAmountNetOfCashConveyed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. Includes the amount of expense from discontinued operations, that reflects the allocation of the cost of tangible and intangible assets over the assets' useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_InterestReceivedInterestRateHedges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Received, Interest Rate Hedges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_InterestReceivedInterestRateHedges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For (Proceeds From) Short Term Investments With Original Maturities Of Three Months Or Less</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans less the amount of pension and other postretirement benefit costs/income recognized during the period for defined benefit plans (periodic benefit costs/income include the following components: service cost, interest cost, expected return on plan assets, gain or loss on assets, prior service cost or credit, transition asset or obligation, and gain or loss due to settlements or curtailments).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfOrdinaryDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfOrdinaryDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing net of the cash outflow from repayment of a borrowing having initial term of repayment within three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3098-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, beyond the current operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) from effect of Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818723403880">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (PARENTHETICAL) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit', window );">TCJA impact</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (285)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,606<span></span>
</td>
<td class="nump">$ 4,942<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember', window );">Subsidiaries [Member] | Upjohn Inc [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11,400<span></span>
</td>
<td class="nump">$ 11,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:20px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As a result of the enactment of the TCJA in December 2017, Pfizer&#8217;s </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Provision/(benefit) for taxes on income</span><span style="font-family:inherit;font-size:8pt;"> for the </span><span style="font-family:inherit;font-size:8pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:8pt;"> was favorably impacted by approximately </span><span style="font-family:inherit;font-size:8pt;"><span>$285 million</span></span><span style="font-family:inherit;font-size:8pt;">, primarily as a result of additional guidance issued by the U.S. Department of Treasury.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Includes </span><span style="font-family:inherit;font-size:8pt;"><span>$11.4 billion</span></span><span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn long-term debt issuances in the second quarter of 2020, which are included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments</span><span style="font-family:inherit;font-size:8pt;"> in the condensed consolidated balance sheet. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Notes 7A. Financial Instruments: </span><span style="font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Fair Value Measurements</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Financial Instruments: 7D. </span><span style="font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Long-Term Debt</span><span style="font-family:inherit;font-size:8pt;">).</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) from effect of Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pfe_UpjohnIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pfe_UpjohnIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818719903480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Basis of Presentation and Significant Accounting Policies</span><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. Basis of Presentation</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes in this Quarterly Report on Form 10-Q.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the </span><span style="font-family:inherit;font-size:10pt;">three and six months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;">May&#160;24, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">May&#160;26, 2019</span><span style="font-family:inherit;font-size:10pt;">. The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the </span><span style="font-family:inherit;font-size:10pt;">three and six months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> Financial Report.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the beginning of our 2019 fiscal year, we began to manage our commercial operations through a new global structure consisting of </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> business segments&#8211;&#8211;Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and through </span><span style="font-family:inherit;font-size:10pt;">July&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, Consumer Healthcare. Biopharma and Upjohn are the only reportable segments. For additional information, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 14</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan).</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">As a result, revenues and expenses associated with Meridian and Mylan-Japan are reported in our Upjohn business beginning in the first quarter of 2020. In 2019, revenues and expenses from Meridian and Mylan-Japan were recorded in our Biopharma business. We performed certain reclassifications between the Biopharma and Upjohn segments to conform 2019 segment revenues and expenses associated with Meridian and Mylan-Japan to the current presentation. There was no impact to our consolidated financial statements.</span><span style="font-family:inherit;font-size:10pt;"> For additional information, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 14.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisitions and other business development activities completed in 2019 and in the first half of 2020, including the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture, impacted financial results in the periods presented.</span><span style="font-family:inherit;font-size:10pt;"> </span><span>For additional information, see Notes to Consolidated Financial Statements&#8212;</span><span style="font-style:italic;">Note 1A. Basis of Presentation and Significant Accounting Policies: Basis of Presentation</span><span> in our 2019 Financial Report, and </span><span style="font-style:italic;">Note 2</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the first quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, as of January 1, </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, we adopted </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> new accounting standards. See </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1B</span><span style="font-family:inherit;font-size:10pt;"> for further information.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. </span><span style="font-weight:bold;text-decoration:underline;">Adoption of New Accounting Standards in 2020</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 1, </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, we adopted </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> new accounting standards.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Credit Losses on Financial Instruments</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;We adopted a new accounting standard for credit losses on financial instruments, which replaces the probable initial recognition threshold for incurred loss estimates under prior guidance with a methodology that reflects expected credit loss estimates. The standard generally impacts financial assets that have a contractual right to receive cash and are not accounted for at fair value through net income, such as accounts receivable and held-to-maturity debt securities. The new guidance requires us to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for certain financial instruments, using information such as historical experience, current economic conditions and information, and the use of reasonable and supportable forecasted information. The standard also </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">amends existing impairment guidance for available-for-sale debt securities to incorporate a credit loss allowance and allows for reversals of credit impairments in the event the issuer&#8217;s credit improves.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We adopted the new accounting standard utilizing the modified retrospective method and, therefore, no adjustments were made to amounts in our prior period financial statements. The cumulative effect of adopting the standard as an adjustment to the opening balance of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Retained earnings</span><span style="font-family:inherit;font-size:10pt;"> was not material. The impact of adoption did not have a material impact on our condensed consolidated statement of income for the </span><span style="font-family:inherit;font-size:10pt;">three and six months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;"> or condensed consolidated statement of cash flows for the </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;">, nor on our condensed consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;">. For additional information, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1C</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Goodwill Impairment Testing</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;We prospectively adopted the new standard, which eliminates the requirement to perform a hypothetical purchase price allocation to measure goodwill impairment. Under the new guidance, the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount, and recognizing an impairment charge for the amount by which the carrying amount of the reporting unit exceeds its fair value. There was no impact to our condensed consolidated financial statements from the adoption of this new standard.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Implementation Costs in a Cloud Computing Arrangement</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;We prospectively adopted the new standard related to customers&#8217; accounting for implementation costs incurred in a cloud computing arrangement that is considered a service contract. The new guidance aligns the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The adoption of this guidance did not have a material impact on our condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Collaboration Agreements</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;We prospectively adopted the new standard, which provides new guidance clarifying the interaction between the accounting for collaborative arrangements and revenue from contracts with customers. There was no impact to our condensed consolidated financial statements from the adoption of this new standard.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 1, 2019, we adopted </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> new accounting standards. For additional information, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2019 </span><span style="font-family:inherit;font-size:10pt;">included in our 2019 Financial Report.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">C. Revenues and Trade Accounts Receivable</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Deductions from Revenues&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;">Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled </span><span style="font-family:inherit;font-size:10pt;"><span>$5.5 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$5.7 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides information about the balance sheet classification of these accruals:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reserve against </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Trade accounts receivable, less allowance for doubtful accounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,129</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued rebates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,210</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,285</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accruals</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>576</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>581</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>598</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>565</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accrued rebates and other accruals</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,512</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,689</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Trade Accounts Receivable&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;">Trade accounts receivable are stated at their net realizable value. The allowance for credit losses against gross trade accounts receivable reflects the best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">three and six months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;">, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818722324760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition, Equity-Method Investment and Licensing Arrangements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract', window );"><strong>Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock', window );">Acquisition, Equity-Method Investment and Licensing Arrangements</a></td>
<td class="text"><span style="font-weight:bold;text-decoration:underline;">Acquisition, Equity-Method Investment and Licensing Arrangements</span><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. </span><span style="font-weight:bold;text-decoration:underline;">Acquisition</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Array BioPharma Inc.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">July&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for </span><span style="font-family:inherit;font-size:10pt;"><span>$48</span></span><span style="font-family:inherit;font-size:10pt;"> per share in cash. The total fair value of the consideration transferred for Array was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$11.2 billion</span></span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;"><span>$10.9 billion</span></span><span style="font-family:inherit;font-size:10pt;">, net of cash acquired). Array&#8217;s portfolio includes Braftovi (encorafenib) and Mektovi (binimetinib). The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not yet been finalized.</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. </span><span style="font-weight:bold;text-decoration:underline;">Equity-Method Investment</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Formation of GSK Consumer Healthcare Joint Venture</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">July&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name. In exchange for contributing our Consumer Healthcare business to the joint venture, we received a </span><span style="font-family:inherit;font-size:10pt;"><span>32%</span></span><span style="font-family:inherit;font-size:10pt;"> equity stake in the new company and GSK owns the remaining </span><span style="font-family:inherit;font-size:10pt;"><span>68%</span></span><span style="font-family:inherit;font-size:10pt;">. Upon the closing of the transaction, we deconsolidated our Consumer Healthcare business and recognized a pre-tax gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.1 billion</span></span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;"><span>$5.4 billion</span></span><span style="font-family:inherit;font-size:10pt;">, net of tax) in our fiscal third quarter of 2019 in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">(Gain) on completion of Consumer Healthcare JV transaction</span><span style="font-family:inherit;font-size:10pt;"> for the difference in the fair value of our </span><span style="font-family:inherit;font-size:10pt;"><span>32%</span></span><span style="font-family:inherit;font-size:10pt;"> equity stake in the new company and the carrying value of our Consumer Healthcare business. We may record additional adjustments to the gain in future periods, which we do not expect to have a material impact on our consolidated financial statements. Our financial results, and our Consumer Healthcare segment&#8217;s operating results, for the </span><span style="font-family:inherit;font-size:10pt;">second quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> reflect three months of Consumer Healthcare segment operations</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">and for</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">the first six months of</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">2019 reflect six months of Consumer Healthcare segment operations,</span><span style="font-family:inherit;font-size:10pt;"> while financial results for the </span><span style="font-family:inherit;font-size:10pt;">second quarter</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">and first</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">six months</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> do not reflect any contribution from the Consumer Healthcare business.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are accounting for our interest in GSK Consumer Healthcare as an equity-method investment. The carrying value of our</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:inherit;font-size:10pt;">investment in GSK Consumer Healthcare is approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$15.4 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$17.0 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and is reported as a private equity investment in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Equity-method investments </span><span style="font-family:inherit;font-size:10pt;">line in our condensed consolidated balance sheet. We record our share of earnings from the GSK Consumer Healthcare joint venture on a quarterly basis on a one-quarter lag in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:10pt;"> commencing from August 1, 2019. Therefore, we recorded our share of the joint venture&#8217;s earnings generated in the first quarter of 2020, which totaled approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$129 million</span></span><span style="font-family:inherit;font-size:10pt;">, in our operating results in the </span><span style="font-family:inherit;font-size:10pt;">second quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">. Our total share of the joint venture&#8217;s earnings generated in the fourth quarter of 2019 and the first quarter of 2020, which we recorded in our operating results for </span><span style="font-family:inherit;font-size:10pt;">the first six months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$140 million</span></span><span style="font-family:inherit;font-size:10pt;">. See </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 4</span><span style="font-family:inherit;font-size:10pt;">. As of the July 31, 2019 closing date, we estimated that the fair value of our investment in GSK Consumer Healthcare was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$15.7 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and that </span><span style="font-family:inherit;font-size:10pt;"><span>32%</span></span><span style="font-family:inherit;font-size:10pt;"> of the underlying equity in the carrying value of the net assets of GSK Consumer Healthcare was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$11.2 billion</span></span><span style="font-family:inherit;font-size:10pt;">, resulting in an initial basis difference of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$4.5 billion</span></span><span style="font-family:inherit;font-size:10pt;">. In the fourth quarter of 2019, we preliminarily completed the allocation of the basis difference, which resulted from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the joint venture, primarily to inventory, definite-lived intangible assets, indefinite-lived intangible assets, related deferred tax liabilities and equity method goodwill within the investment account. We recorded the amortization of basis differences allocated to inventory, definite-lived intangible assets and related deferred tax liabilities in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:10pt;"> commencing August 1, 2019. During the fourth quarter of 2019, GSK Consumer Healthcare revised the initial carrying value of the net assets of the joint venture and our </span><span style="font-family:inherit;font-size:10pt;"><span>32%</span></span><span style="font-family:inherit;font-size:10pt;"> share of the underlying equity in the carrying value of the net assets of GSK Consumer Healthcare was reduced to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$11.0 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and our initial basis difference was increased to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$4.8 billion</span></span><span style="font-family:inherit;font-size:10pt;">. The adjustment was allocated to equity method goodwill within the investment account. The amortization of these basis differences for the first quarter of 2020 totaling approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of expense is included in our operating results in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:inherit;font-size:10pt;">in</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">the </span><span style="font-family:inherit;font-size:10pt;">second quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">. The total amortization of these basis differences for the fourth quarter of 2019 and the first quarter of 2020, which was included in our operating results in </span><span style="font-family:inherit;font-size:10pt;">the first six months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$48 million</span></span><span style="font-family:inherit;font-size:10pt;"> of expense. See </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 4. </span><span style="font-family:inherit;font-size:10pt;">Amortization of </span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">basis differences on inventory and related deferred tax liabilities has been completely recognized by the second quarter of 2020. Basis differences on definite-lived intangible assets and related deferred tax liabilities are being amortized over the lives of the underlying assets, which range from </span><span style="font-family:inherit;font-size:10pt;"><span>6</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>20 years</span></span><span style="font-family:inherit;font-size:10pt;">. GSK Consumer Healthcare is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other comprehensive income</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in the value of our investment from December 31, 2019 to </span><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;"> is primarily due to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 billion</span></span><span style="font-family:inherit;font-size:10pt;"> in pre-tax foreign currency translation adjustments (see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 6</span><span style="font-family:inherit;font-size:10pt;">), as well as a dividend of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$519 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was received from the GSK Consumer Healthcare joint venture in June 2020.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a part of Pfizer, pre-tax income on a management business unit basis for the Consumer Healthcare business was </span><span style="font-family:inherit;font-size:10pt;"><span>$274 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">second quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$554 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.05068226120858%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Summarized financial information for our equity method investee, GSK Consumer Healthcare, as of and for the three and six months ending March 31, 2020, the most recent period available, is as follows:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 31, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,213</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,627</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,840</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,524</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,152</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,677</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity attributable to shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,031</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>133</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,163</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.05068226120858%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:54%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,503</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,691</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,394</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,205</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross profit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,109</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,486</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>425</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>471</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>425</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>471</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income attributable to shareholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>405</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>441</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">C. </span><span style="font-weight:bold;text-decoration:underline;">Licensing Arrangements</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Agreement with Valneva SE</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">April&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, we signed an agreement to co-develop and commercialize Valneva&#8217;s Lyme disease vaccine candidate VLA15. VLA15 is the only active Lyme disease vaccine program in clinical development today, and covers six serotypes that are prevalent in North America and Europe. Valneva and Pfizer will work closely together throughout the development of VLA15. Valneva is eligible to receive a total of </span><span style="font-family:inherit;font-size:10pt;"><span>$308 million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash payments consisting of a </span><span style="font-family:inherit;font-size:10pt;"><span>$130 million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment, which was paid and recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expenses </span><span style="font-family:inherit;font-size:10pt;">in our fiscal second quarter of 2020, as well as </span><span style="font-family:inherit;font-size:10pt;"><span>$35 million</span></span><span style="font-family:inherit;font-size:10pt;"> in development milestones and </span><span style="font-family:inherit;font-size:10pt;"><span>$143 million</span></span><span style="font-family:inherit;font-size:10pt;"> in early commercialization milestones. Under the terms of the agreement, Valneva will fund </span><span style="font-family:inherit;font-size:10pt;"><span>30%</span></span><span style="font-family:inherit;font-size:10pt;"> of all development costs through completion of the development program, and in return we will pay Valneva tiered royalties. We will lead late-stage development and have sole control over commercialization.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Agreement with BioNTech SE</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">April&#160;9, 2020</span><span style="font-family:inherit;font-size:10pt;">, we signed a global agreement with BioNTech to co-develop a potential first-in-class, mRNA-based coronavirus vaccine program, BNT162, aimed at preventing COVID-19 infection. The collaboration aims to rapidly advance multiple COVID-19 vaccine candidates into human clinical testing based on BioNTech&#8217;s proprietary mRNA vaccine platforms, with the objective of ensuring rapid worldwide access to the vaccine, if approved. The collaboration will leverage our broad expertise in vaccine R&amp;D, regulatory capabilities, and global manufacturing and distribution network. In connection with the agreement, we paid BioNTech an upfront cash payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$72 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expenses </span><span style="font-family:inherit;font-size:10pt;">in our fiscal second quarter of 2020, and we made an equity investment of </span><span style="font-family:inherit;font-size:10pt;"><span>$113 million</span></span><span style="font-family:inherit;font-size:10pt;"> in common stock of BioNTech. BioNTech is eligible to receive potential future milestone payments of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$563 million</span></span><span style="font-family:inherit;font-size:10pt;"> for a total consideration of </span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$748 million</span></span><span style="font-family:inherit;font-size:10pt;">. While Pfizer and BioNTech will share development costs equally if the vaccine is approved and successfully commercialized, Pfizer will be responsible for all of the development costs until commercialization of the vaccine. Thereafter, BioNTech would repay Pfizer its </span><span style="font-family:inherit;font-size:10pt;"><span>50 percent</span></span><span style="font-family:inherit;font-size:10pt;"> share of these development costs through reductions in gross profit sharing and milestone payments to BioNTech over time. BioNTech and Pfizer will also work jointly to commercialize the vaccine worldwide (excluding China, which is subject to a separate collaboration between BioNTech and Shanghai Fosun Pharmaceutical (Group) Co., Ltd) if development is successful and regulatory approval is obtained. We made an additional investment of </span><span style="font-family:inherit;font-size:10pt;"><span>$50 million</span></span><span style="font-family:inherit;font-size:10pt;"> in common stock of BioNTech as part of an underwritten equity offering by BioNTech, which closed in July 2020 in our fiscal third quarter of 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818804262664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For example: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and R&amp;D, as well as groups such as information technology, shared services and corporate operations.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Transforming to a More Focused Company Program</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">With the formation of the GSK Consumer Healthcare joint venture and the anticipated combination of Upjohn, our global, primarily off-patent branded and generics business, with Mylan, Pfizer is transforming itself into a more focused, global leader in science-based innovative medicines.&#160;As a result, we began in the fourth quarter of 2019, to identify and undertake efforts to ensure our cost base aligns appropriately with our Biopharmaceutical revenue base as a result of both the completed GSK Consumer Healthcare and expected Upjohn transactions.&#160;While certain direct costs have transferred or will transfer to the GSK Consumer Healthcare joint venture and to the Upjohn entities, there are indirect costs which are not expected to transfer. In addition, we are taking steps to restructure our organizations to appropriately support and drive the purpose of the three core functions of our focused innovative medicines business: R&amp;D, Manufacturing and Commercial.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect the costs associated with this multi-year program to be incurred from 2020 through 2022 and to total approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 billion</span></span><span style="font-family:inherit;font-size:10pt;"> on a pre-tax basis, with substantially all of the costs to be cash expenditures. Actions may include, among others, changes in location of certain activities, expanded use and co-location of centers of excellence and shared services, and increased use of digital technologies. The associated actions and the specific costs will primarily include severance and benefit plan impacts, exit costs as well as associated implementation costs.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Also as part of this program, in connection with the legacy cost reduction initiatives, primarily related to manufacturing activities, we expect to incur costs of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$400 million</span></span><span style="font-family:inherit;font-size:10pt;">, with approximately </span><span style="font-family:inherit;font-size:10pt;"><span>20%</span></span><span style="font-family:inherit;font-size:10pt;"> of the costs to be non-cash. The costs associated with this effort are expected to be incurred from 2020 through 2022, and will primarily include implementation costs, product transfer costs, exit costs, as well as accelerated depreciation. </span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From the start of this program in the fourth quarter of 2019 through </span><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;">, we incurred approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$549 million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with this program.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Current-Period Key Activities</span></div><div style="line-height:120%;padding-top:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;">, we incurred costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$566 million</span></span><span style="font-family:inherit;font-size:10pt;"> composed primarily of the Transforming to a More Focused Company program. For the first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of 2019, we incurred costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$32 million</span></span><span style="font-family:inherit;font-size:10pt;"> composed of </span><span style="font-family:inherit;font-size:10pt;"><span>$180 million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with the 2017-2019 and Organizing for Growth initiatives, </span><span style="font-family:inherit;font-size:10pt;"><span>$51 million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with the integration of Hospira, and income of </span><span style="font-family:inherit;font-size:10pt;"><span>$199 million</span></span><span style="font-family:inherit;font-size:10pt;"> primarily due to the reversal of certain accruals upon the effective favorable settlement of an IRS audit for multiple tax years and other acquisition-related initiatives.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Arial;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restructuring charges/(credits):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee terminations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>346</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(166</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>371</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(167</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset impairments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exit costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restructuring charges</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>340</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(144</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>396</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(134</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transaction costs</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Integration costs and other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>362</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(115</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>431</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(69</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net periodic benefit costs recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additional depreciation&#8211;&#8211;asset restructuring</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;</sup></span><span style="font-family:inherit;font-size:10pt;">recorded in our condensed consolidated statements of income as follows</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span><span style="font-family:inherit;font-size:10pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total additional depreciation&#8211;&#8211;asset restructuring</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Implementation costs recorded in our condensed consolidated statements of income as follows</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup></span><span style="font-family:inherit;font-size:10pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total implementation costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>99</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total costs associated with acquisitions and cost-reduction/productivity initiatives</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>449</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(59</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>566</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first six months of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, restructuring charges mainly represent employee termination costs associated with our Transforming to a More Focused Company cost reduction program. In the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">, restructuring credits mostly represent the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of an IRS audit for multiple tax years. See Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 5D. Tax Matters: Tax Contingencies </span><span style="font-family:inherit;font-size:8pt;">in our 2019 Financial Report.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:1px;padding-top:2px;padding-left:24px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The restructuring activities for </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, Biopharma (</span><span style="font-family:inherit;font-size:8pt;"><span>$12 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); Upjohn (</span><span style="font-family:inherit;font-size:8pt;"><span>$1 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); and Other (</span><span style="font-family:inherit;font-size:8pt;"><span>$352 million</span></span><span style="font-family:inherit;font-size:8pt;"> charge).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, Biopharma (</span><span style="font-family:inherit;font-size:8pt;"><span>$9 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); Upjohn (</span><span style="font-family:inherit;font-size:8pt;"><span>$12 million</span></span><span style="font-family:inherit;font-size:8pt;"> charge); and Other (</span><span style="font-family:inherit;font-size:8pt;"><span>$393 million</span></span><span style="font-family:inherit;font-size:8pt;"> charge).</span></div></td></tr></table><div style="line-height:120%;padding-bottom:1px;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The restructuring activities for </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">, Biopharma (</span><span style="font-family:inherit;font-size:8pt;"><span>$62 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); Upjohn (</span><span style="font-family:inherit;font-size:8pt;"><span>$9 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); and Other (</span><span style="font-family:inherit;font-size:8pt;"><span>$74 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">, Biopharma (</span><span style="font-family:inherit;font-size:8pt;"><span>$48 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); Upjohn (</span><span style="font-family:inherit;font-size:8pt;"><span>$22 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); and Other (</span><span style="font-family:inherit;font-size:8pt;"><span>$63 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit).</span></div></td></tr></table><div style="line-height:120%;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Restructuring costs identified as Other are for restructuring activities associated with corporate enabling functions, WRDM, GPD and other manufacturing and commercial operations, as applicable. For the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, restructuring costs identified as Other primarily relate to corporate enabling functions.</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Transaction costs represent external costs for banking, legal, accounting and other similar services.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Integration costs and other represent external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, integration costs and other were mostly related to our acquisition of Array. In the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">, integration costs and other were primarily related to our acquisition of Hospira.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Additional depreciation&#8211;&#8211;asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.05068226120858%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of and changes in our restructuring accruals:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Employee</span></div><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Termination</span></div><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Costs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Asset</span></div><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Impairment</span></div><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Charges</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Exit Costs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Accrual</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Balance, December 31, 2019</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>887</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>933</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Provision</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>371</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>396</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Utilization and other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(341</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(378</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Balance, June 28, 2020</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>918</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>951</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:8pt;"> (</span><span style="font-family:inherit;font-size:8pt;"><span>$714 million</span></span><span style="font-family:inherit;font-size:8pt;">) and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:inherit;font-size:8pt;"> (</span><span style="font-family:inherit;font-size:8pt;"><span>$219 million</span></span><span style="font-family:inherit;font-size:8pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Includes adjustments for foreign currency translation.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other current liabilities </span><span style="font-family:inherit;font-size:8pt;">(</span><span style="font-family:inherit;font-size:8pt;"><span>$625 million</span></span><span style="font-family:inherit;font-size:8pt;">) and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other noncurrent liabilities </span><span style="font-family:inherit;font-size:8pt;">(</span><span style="font-family:inherit;font-size:8pt;"><span>$326 million</span></span><span style="font-family:inherit;font-size:8pt;">).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818718981656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">Other (Income)/Deductions - Net</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Other (Income)/Deductions&#8212;Net</span><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Interest income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(59</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(53</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(125</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Interest expense</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>372</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>389</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>762</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Net interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>353</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>330</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>709</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>625</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Royalty-related income</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(191</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(231</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(311</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(320</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Net (gains)/losses on asset disposals</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Net gains recognized during the period on equity securities</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(732</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(36</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(478</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(147</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Income from collaborations, out-licensing arrangements and sales of compound/product rights</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(100</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(22</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(215</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(104</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Net periodic benefit credits other than service costs</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(108</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(51</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(175</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(91</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Certain legal matters, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Certain asset impairments</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>160</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Business and legal entity alignment costs</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(g)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>137</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>256</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net losses on early retirement of debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>138</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">GSK Consumer Healthcare JV equity method (income)/loss</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(h)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(126</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(92</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Other, net</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(i)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(107</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(318</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(862</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>126</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(641</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>218</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest income decreased in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first six months of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;">, primarily driven by a lower investment balance and lower short-term interest rates. Interest expense decreased in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> mainly as a result of the retirement of higher-coupon debt and the issuance of new debt with a lower coupon than the debt outstanding for the comparative prior year period. Interest expense increased in the first six months of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;">, mainly as a result of an increased commercial paper balance due to the acquisition of Array. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Royalty-related income for the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;">first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> included a one-time favorable resolution in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> of a legal dispute for </span><span style="font-family:inherit;font-size:8pt;"><span>$82 million</span></span><span style="font-family:inherit;font-size:8pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The gains in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> include, among other things, unrealized gains of </span><span style="font-family:inherit;font-size:8pt;"><span>$508 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to our investment in Allogene and unrealized gains of </span><span style="font-family:inherit;font-size:8pt;"><span>$61 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to our investment in BioNTech. The gains in the first six months of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> include, among other things, unrealized gains of </span><span style="font-family:inherit;font-size:8pt;"><span>$374 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to our investment in Allogene and unrealized gains of </span><span style="font-family:inherit;font-size:8pt;"><span>$127 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to our investment in BioNTech. The gains in the first six months of 2019 included, among other things, unrealized gains of </span><span style="font-family:inherit;font-size:8pt;"><span>$104 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to our investment in Cortexyme, Inc. For additional information on investments, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7B</span><span style="font-family:inherit;font-size:8pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In the </span><span style="font-family:inherit;font-size:8pt;">second</span><span style="font-family:inherit;font-size:8pt;"> quarter and first six months of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;">, mainly includes, among other things, </span><span style="font-family:inherit;font-size:8pt;"><span>$40 million</span></span><span style="font-family:inherit;font-size:8pt;"> of milestone income from Puma Biotechnology, Inc. related to Neratinib regulatory approvals in the EU, and </span><span style="font-family:inherit;font-size:8pt;"><span>$30 million</span></span><span style="font-family:inherit;font-size:8pt;"> of milestone income from Lilly related to the first commercial sale in the U.S. of LOXO-292 for the treatment of RET fusion-positive NSCLC. The first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> also includes an upfront payment to us of </span><span style="font-family:inherit;font-size:8pt;"><span>$75 million</span></span><span style="font-family:inherit;font-size:8pt;"> from our sale of our CK1 assets to Biogen, Inc. In the first six months of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">, primarily included </span><span style="font-family:inherit;font-size:8pt;"><span>$68 million</span></span><span style="font-family:inherit;font-size:8pt;"> in milestone income from Mylan Pharmaceuticals Inc. related to the FDA&#8217;s approval and launch of Wixela Inhub</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:8pt;">, a generic of Advair Diskus</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:8pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 10</span><span style="font-family:inherit;font-size:8pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The first six months of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> included intangible asset impairment charges of: (i) </span><span style="font-family:inherit;font-size:8pt;"><span>$90 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to WRDM IPR&amp;D, for a pre-clinical stage asset from our acquisition of Bamboo for gene therapies for the potential treatment of patients with certain rare diseases, which was the result of a determination to not use certain Bamboo IPR&amp;D acquired in future rare disease development, (ii) </span><span style="font-family:inherit;font-size:8pt;"><span>$40 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to an Upjohn finite-lived developed technology right, acquired in connection with our acquisition of King, for government defense products and reflected, among other things, updated commercial forecasts including manufacturing cost assumptions, and (iii) </span><span style="font-family:inherit;font-size:8pt;"><span>$10 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to a finite-lived developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus marketed in the U.S. market only, </span><span style="font-family:inherit;font-size:8pt;text-align:center;">associated with Biopharma and reflected</span><span style="font-family:inherit;font-size:8pt;">, among other things, updated commercial forecasts. In addition, the first six months of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> included other asset impairments of </span><span style="font-family:inherit;font-size:8pt;"><span>$20 million</span></span><span style="font-family:Arial;font-size:8pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first six months of 2019, represents incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(h)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Includes our share of the GSK Consumer Healthcare joint venture&#8217;s earnings and the amortization of basis differences, which resulted from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the joint venture. See </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 2B</span><span style="font-family:inherit;font-size:8pt;"> for additional information.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> includes, among other things, dividend income of </span><span style="font-family:inherit;font-size:8pt;"><span>$76 million</span></span><span style="font-family:inherit;font-size:8pt;"> from our investment in ViiV, and charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$86 million</span></span><span style="font-family:inherit;font-size:8pt;">, reflecting the change in the fair value of contingent consideration. The first six months of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> includes, among other things, dividend income of </span><span style="font-family:inherit;font-size:8pt;"><span>$153 million</span></span><span style="font-family:inherit;font-size:8pt;"> from our investment in ViiV and charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$99 million</span></span><span style="font-family:inherit;font-size:8pt;">, reflecting the change in the fair value of contingent consideration. The </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> included, among other things, charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$81 million</span></span><span style="font-family:inherit;font-size:8pt;">, reflecting the change in the fair value of contingent consideration, dividend income of </span><span style="font-family:inherit;font-size:8pt;"><span>$76&#160;million</span></span><span style="font-family:inherit;font-size:8pt;"> from our investment in ViiV, and </span><span style="font-family:inherit;font-size:8pt;"><span>$25 million</span></span><span style="font-family:inherit;font-size:8pt;"> of income from insurance recoveries related to Hurricane Maria. The first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> included, among other things, dividend income of </span><span style="font-family:inherit;font-size:8pt;"><span>$140 million</span></span><span style="font-family:inherit;font-size:8pt;"> from our investment in ViiV and </span><span style="font-family:inherit;font-size:8pt;"><span>$50 million</span></span><span style="font-family:inherit;font-size:8pt;"> of income from insurance recoveries related to Hurricane Maria.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI http://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI http://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818718889240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax Matters<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Tax Matters</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Tax Matters</span><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. Taxes on Income from Continuing Operations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our effective tax rate for continuing operations was </span><span style="font-family:inherit;font-size:10pt;"><span>13.1%</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;">, compared to </span><span style="font-family:inherit;font-size:10pt;"><span>(22.1)%</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> and was </span><span style="font-family:inherit;font-size:10pt;"><span>12.7%</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">the first six months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;">, compared to </span><span style="font-family:inherit;font-size:10pt;"><span>(5.7)%</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">the first six months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">higher</span><span style="font-family:inherit;font-size:10pt;"> effective tax rate for the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter and first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> in comparison with the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> was primarily due to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the non-recurrence of the </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 billion</span></span><span style="font-family:inherit;font-size:10pt;"> tax benefit, representing taxes and interest, recorded in the second quarter of 2019 due to the favorable settlement of an IRS audit for multiple tax years (see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 5D. Tax Matters: Tax Contingencies </span><span style="font-family:inherit;font-size:10pt;">in our 2019 Financial Report); and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the non-recurrence of the tax benefit recorded in the first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of 2019 as a result of additional guidance issued by the U.S. Department of Treasury related to the TCJA,</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our initial estimated </span><span style="font-family:inherit;font-size:10pt;"><span>$15 billion</span></span><span style="font-family:inherit;font-size:10pt;"> repatriation tax liability on accumulated post-1986 foreign earnings for which we elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, payment over eight years through 2026 is reported in current </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">taxes payable </span><span style="font-family:inherit;font-size:10pt;">(approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 billion</span></span><span style="font-family:inherit;font-size:10pt;">) and the remaining liability is reported in noncurrent </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other taxes payable</span><span style="font-family:inherit;font-size:10pt;"> in our condensed consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;">. The second installment of </span><span style="font-family:inherit;font-size:10pt;"><span>$680 million</span></span><span style="font-family:inherit;font-size:10pt;"> was paid in July 2020, which was originally due to be paid in April 2020 but was extended to July 2020 by the IRS in response to the COVID-19 pandemic. The third installment of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$750 million</span></span><span style="font-family:inherit;font-size:10pt;"> is due in April 2021. Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was signed into law in the U.S. to provide certain relief as a result of the COVID-19 pandemic. In addition, governments around the world have enacted or implemented various forms of tax relief measures in response to the economic conditions in the wake of COVID-19. As of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;">, neither the CARES Act nor changes to income tax laws or regulations in other jurisdictions had a significant impact on our effective tax rate.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. Tax Contingencies</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. With respect to Pfizer, the IRS has issued a Revenue Agent&#8217;s Report (RAR) for tax years 2011-2013. We are not in agreement with the RAR and are currently appealing certain disputed issues. Tax years 2014-2015 are currently under audit. Tax years 2016-2020 are open, but not under audit. All other tax years are closed.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the open audit years in the U.S., we have open audit years in other major tax jurisdictions, such as Canada (2013-2020), Japan (2017-2020), Europe (2011-2020, primarily reflecting Ireland, the U.K., France, Italy, Spain and Germany), Latin America (1998-2020, primarily reflecting Brazil) and Puerto Rico (2015-2020).</span></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">C. </span><span style="font-weight:bold;text-decoration:underline;">Tax Provision/(Benefit) on Other Comprehensive Loss</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Tax provision/(benefit) on</span><span style="font-family:inherit;font-size:10pt;">&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">other comprehensive loss</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency translation adjustments, net</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(192</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unrealized holding gains/(losses) on derivative financial instruments, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(53</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(82</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments for gains included in net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(35</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(20</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(59</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(57</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(53</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unrealized holding gains/(losses) on available-for-sale securities, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments for losses included in net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Benefit plans: actuarial gains/(losses), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments related to amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments related to settlements, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments related to amortization of prior service costs and other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(22</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(20</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Tax provision/(benefit) on other comprehensive loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(59</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(265</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818720922680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</span><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the changes, net of tax, in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive loss</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Net Unrealized Gains/(Losses)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Benefit Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Foreign Currency Translation Adjustments </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Derivative Financial Instruments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Available-For-Sale Securities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Actuarial Gains/(Losses)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Prior Service (Costs)/Credits and Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Accumulated Other Comprehensive Income/(Loss)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Balance, December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(5,952</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(35</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(6,257</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>584</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(11,640</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other comprehensive income/(loss)</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,310</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(353</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(65</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,605</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Balance, June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(7,262</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(333</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(6,178</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>518</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(13,246</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of </span><span style="font-family:inherit;font-size:8pt;"><span>$12 million</span></span><span style="font-family:inherit;font-size:8pt;"> loss for the first six months of 2020. Includes after-tax </span><span style="font-family:inherit;font-size:8pt;">losses</span><span style="font-family:inherit;font-size:8pt;"> of approximately </span><span style="font-family:inherit;font-size:8pt;"><span>$902 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to foreign currency translation adjustments and the impact of our net investment hedging program, both attributable to our equity method investment in GSK Consumer Healthcare (see</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> Note 2B</span><span style="font-family:inherit;font-size:8pt;">), and losses from the weakening of certain major currencies against the U.S. dollar. These </span><span style="font-family:inherit;font-size:8pt;">losses</span><span style="font-family:inherit;font-size:8pt;"> were partially offset by the results of our net investment hedging program.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818718892152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Financial Instruments</span><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. </span><span style="font-weight:bold;text-decoration:underline;">Fair Value Measurements</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"> </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the financial assets and liabilities measured at fair value using a market approach on a recurring basis by balance sheet categories and fair value hierarchy level as defined in Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1E. Basis of Presentation and Significant Accounting Policies: Fair Value </span><span style="font-family:inherit;font-size:10pt;">in our 2019 Financial Report: </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Level 2</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Financial assets measured at fair value on a recurring basis:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Classified as equity securities with readily determinable fair values:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Money market funds</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>13,033</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>13,033</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>705</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>705</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Classified as available-for-sale debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Government and agency&#8212;non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>6,218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>6,218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>4,863</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>4,863</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Government and agency&#8212;U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>811</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>811</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Corporate and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,440</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,440</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,013</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,013</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>7,672</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>7,672</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>6,687</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>6,687</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>20,705</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>20,705</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>7,392</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>7,392</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Derivative assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>413</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>413</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>413</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>413</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>431</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>431</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>465</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>465</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Classified as equity securities with readily determinable fair values</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,072</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,046</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,902</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,863</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Classified as available-for-sale debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Government and agency&#8212;U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>243</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>243</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>303</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>303</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Corporate and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>254</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>254</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>315</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>315</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,326</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,046</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>280</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,216</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,863</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>354</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Derivative assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>266</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>266</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>221</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>221</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>261</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>261</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total derivative assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>362</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>362</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>526</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>526</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Insurance contracts</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>578</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>578</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>575</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>575</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total other noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>940</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>940</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>24,402</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,046</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>22,355</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>11,176</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,863</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>9,313</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Financial liabilities measured at fair value on a recurring basis:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Derivative liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Derivative liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>866</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>866</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>604</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>604</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>866</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>866</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>604</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>604</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>993</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>993</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>718</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>718</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, </span><span style="font-family:inherit;font-size:8pt;"><span>$11.4 billion</span></span><span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn debt transactions (see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7D</span><span style="font-family:inherit;font-size:8pt;">) are invested in money market funds and included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments </span><span style="font-family:inherit;font-size:8pt;">in the condensed consolidated balance sheet.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, long-term equity securities of </span><span style="font-family:inherit;font-size:8pt;"><span>$163 million</span></span><span style="font-family:inherit;font-size:8pt;"> and as of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:8pt;">, long-term equity securities of </span><span style="font-family:inherit;font-size:8pt;"><span>$176 million</span></span><span style="font-family:inherit;font-size:8pt;"> were held in restricted trusts for benefits attributable to various U.S. non-qualified employee benefit plans.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other noncurrent assets include life insurance policies held in restricted trusts attributable to the funding of various U.S. non-qualified employee benefit plans. The underlying invested assets in these insurance contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (income)/deductions</span><span style="font-family:inherit;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">net</span><span style="font-family:inherit;font-size:8pt;"> in the condensed consolidated statements of income (see</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> Note 4</span><span style="font-family:inherit;font-size:8pt;">).</span></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the financial liabilities not measured at fair value on a recurring basis, including the carrying values and estimated fair values using a market approach:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Estimated Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt, excluding the current portion</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,529</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,121</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,121</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,955</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,842</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,842</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, </span><span style="font-family:inherit;font-size:8pt;"><span>$11.4 billion</span></span><span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn debt transactions (see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7D</span><span style="font-family:inherit;font-size:8pt;">) are invested in money market funds and included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments </span><span style="font-family:inherit;font-size:8pt;">in the condensed consolidated balance sheet.</span></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, and short-term borrowings not measured at fair value on a recurring basis were not significant as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs. The fair value measurements of our private equity securities, which represent investments in the life sciences sector, are based on Level 3 inputs using a market approach.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had long-term receivables whose fair value is based on Level 3 inputs. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the differences between the estimated fair values and carrying values of these receivables were not significant.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Total Short-Term and Long-Term Investments and Equity-Method Investments</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table represents our investments by classification type:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity securities with readily determinable fair values</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,033</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>705</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,672</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,687</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Held-to-maturity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>288</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,993</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,525</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity securities with readily determinable fair values</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,072</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,902</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>254</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>315</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Held-to-maturity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Private equity securities at cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>772</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>756</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Total Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,142</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,014</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity-method investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,578</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,133</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term investments and equity-method investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,720</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,147</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Held-to-maturity cash equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>163</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:8pt;">, equity securities with readily determinable fair values included money market funds primarily invested in U.S. Treasury and government debt. As of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, </span><span style="font-family:inherit;font-size:8pt;"><span>$11.4 billion</span></span><span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn debt transactions (see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7D</span><span style="font-family:inherit;font-size:8pt;">) are invested in money market funds and included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments </span><span style="font-family:inherit;font-size:8pt;">in the condensed consolidated balance sheet.</span></div></td></tr></table><div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. Investments</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Debt Securities</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="49"/></tr><tr><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/></tr><tr><td colspan="49" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">At June 28, 2020, our investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt securities at June 28, 2020 and December 31, 2019 is as follows, including, as of June 28, 2020, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Gross Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Maturities (in Years)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Gross Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Amortized Cost</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Fair Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Within 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Over 1<br/>to 5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Over 5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Amortized Cost</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Fair Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;text-decoration:underline;">Available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Government and agency</span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:7.5pt;">non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>6,209</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>6,218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>6,218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>6,218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>4,895</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(38</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>4,863</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Government and agency&#8211;&#8211;U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>243</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,120</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Corporate and other</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,450</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,451</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,440</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,451</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,027</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,025</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;text-decoration:underline;">Held-to-maturity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Time deposits and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>189</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>535</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>535</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Government and agency</span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:7.5pt;">non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>803</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>803</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Total debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>8,366</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>8,376</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>8,079</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>263</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>8,376</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>8,380</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(47</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>8,340</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Primarily issued by a diverse group of corporations.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For our portfolio of available-for-sale and held-to-maturity debt securities, any expected credit losses would be immaterial to the financial statements. </span></div><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Equity Securities</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the calculation of the portion of unrealized gains for the period that relates to equity securities, excluding equity method investments, still held at the reporting date:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net gains recognized during the period on equity securities</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a</sup></span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(732</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(36</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(478</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(147</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Net (gains)/losses recognized during the period on equity securities sold during the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unrealized gains during the reporting period on equity securities still held at the reporting date</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(733</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(31</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(459</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(137</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The net gains on investments in equity securities are reported in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (income)/deductions</span><span style="font-family:inherit;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">net.</span><span style="font-family:inherit;font-size:8pt;"> For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:inherit;font-size:8pt;">.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b) </sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. Since January 1, 2018, there were cumulative impairments and downward adjustments of </span><span style="font-family:inherit;font-size:8pt;"><span>$67 million</span></span><span style="font-family:inherit;font-size:8pt;"> and upward adjustments of </span><span style="font-family:inherit;font-size:8pt;"><span>$66 million</span></span><span style="font-family:inherit;font-size:8pt;">. Impairments, downward and upward adjustments were not significant in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and the first six months of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">C. Short-Term Borrowings</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term borrowings include:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,660</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,915</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of long-term debt, principal amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,481</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,458</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other short-term borrowings, principal amount</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>956</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>860</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total short-term borrowings, principal amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,097</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,233</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net fair value adjustments related to hedging and purchase accounting</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unamortized discounts, premiums and debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(43</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Short-term borrowings, including current portion of long-term debt</span><span style="font-family:inherit;font-size:10pt;">, carried at historical proceeds, as adjusted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,084</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,195</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><span style="font-family:inherit;font-size:8pt;">Other short-term borrowings primarily include cash collateral. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7E</span>.<div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">D. </span><span style="font-weight:bold;text-decoration:underline;">Long-Term Debt</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">New Issuances</span></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the second quarter of 2020, we issued the following senior unsecured notes:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturity Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of June&#160;28, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Pfizer Inc.</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.800%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;28, 2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.700%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;28, 2030</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.550%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;28, 2040</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.700%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;28, 2050</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Upjohn Inc., a wholly-owned subsidiary of Pfizer Inc.</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.125%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 22, 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.650%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 22, 2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.300%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 22, 2027</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.700%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 22, 2030</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,450</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.850%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 22, 2040</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.000%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 22, 2050</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,450</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Upjohn Finance B.V., a wholly-owned subsidiary of Upjohn Inc.</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.816%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 23, 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8364;</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.023%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 23, 2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.362%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 23, 2027</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>850</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.908%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 23, 2032</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8364;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,600</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The notes may be redeemed by us at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest. The weighted-average effective interest rate for the notes at issuance was </span><span style="font-family:inherit;font-size:8pt;"><span>2.11%</span></span><span style="font-family:inherit;font-size:8pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In June 2020, Upjohn Inc. and Upjohn Finance B.V. completed privately placed debt offerings in connection with the previously announced proposed Reverse Morris Trust transaction that will ultimately combine Upjohn and Mylan to form a new company, Viatris. The notes may be redeemed by Upjohn Inc. and Upjohn Finance B.V., as applicable, at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest. The weighted-average effective interest rates at issuance were </span><span style="font-family:inherit;font-size:8pt;"><span>2.95%</span></span><span style="font-family:inherit;font-size:8pt;"> for the </span><span style="font-family:inherit;font-size:8pt;"><span>$7.45 billion</span></span><span style="font-family:inherit;font-size:8pt;"> notes and </span><span style="font-family:inherit;font-size:8pt;"><span>1.37%</span></span><span style="font-family:inherit;font-size:8pt;"> for the </span><span style="font-family:inherit;font-size:8pt;"><span>&#8364;3.60 billion</span></span><span style="font-family:inherit;font-size:8pt;"> notes. If the proposed transaction with Mylan does not close on or prior to February 1, 2021, or if, prior to such date, Upjohn Inc. and Mylan notify the trustee that the business combination agreement for the proposed transaction with Mylan is terminated, or the transaction will not otherwise be pursued, the notes must be redeemed at redemption prices equal to </span><span style="font-family:inherit;font-size:8pt;"><span>101%</span></span><span style="font-family:inherit;font-size:8pt;"> of their respective principal amounts, plus accrued and unpaid interest. Pfizer has guaranteed these notes, and such guarantees will automatically and unconditionally terminate without the consent of holders of the notes upon the proposed distribution to Pfizer&#8217;s stockholders of all of the issued and outstanding shares of Upjohn Inc.&#8217;s common stock held by Pfizer (the Distribution). Upjohn Inc. has guaranteed the notes issued by Upjohn Finance B.V., and Upjohn Inc. will remain a guarantor of such notes post Distribution. Following the separation, Upjohn Inc. and Upjohn Finance B.V., as applicable, will remain the obligor. The proceeds from the financings will be used in part to fund a cash distribution from Upjohn Inc. to Pfizer immediately prior to the Distribution. In the interim, the </span><span style="font-family:inherit;font-size:8pt;"><span>$11.4 billion</span></span><span style="font-family:inherit;font-size:8pt;"> of proceeds are classified as </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments</span><span style="font-family:inherit;font-size:8pt;"> in the condensed consolidated balance sheet as of June 28, 2020 pursuant to the terms of the transaction agreements.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the first quarter of 2020, we issued the following senior unsecured notes:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturity Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of June 28, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.625%</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April&#160;1, 2030</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term debt issued in the first quarter of 2020</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The notes may be redeemed by us at any time, in whole, or in part, at a redemption price plus accrued and unpaid interest.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The effective interest rate for the notes at issuance was </span><span style="font-family:inherit;font-size:8pt;"><span>2.67%</span></span><span style="font-family:inherit;font-size:8pt;">.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">December&#160;31, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term debt, principal amount</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,187</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,820</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net fair value adjustments related to hedging and purchase accounting</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,654</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,305</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unamortized discounts, premiums and debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(317</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(176</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term debt, carried at historical proceeds, as adjusted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,529</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,955</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,481</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,462</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, </span><span style="font-family:inherit;font-size:8pt;"><span>$11.4 billion</span></span><span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn debt transactions are invested in money market funds and included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments </span><span style="font-family:inherit;font-size:8pt;">in the condensed consolidated balance sheet.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Retirements</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2020, we repurchased at par all </span><span style="font-family:inherit;font-size:10pt;"><span>$1.065 billion</span></span><span style="font-family:inherit;font-size:10pt;"> principal amount outstanding of our senior unsecured notes that were due in 2047 before the maturity date, which did not have a material impact on our condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">E. </span><span style="font-weight:bold;text-decoration:underline;">Derivative Financial Instruments and Hedging Activities</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Foreign Exchange Risk</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. We manage our foreign exchange risk, in part, through operational means, including managing same-currency revenues in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. We also manage our foreign exchange risk, depending on market conditions, through fair value, cash flow, and net investment hedging programs through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to protect net income against the impact of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The derivative financial instruments primarily hedge or offset exposures in the </span><span style="font-family:inherit;font-size:10pt;">euro, U.K. pound, Japanese yen, Swedish krona and Chinese renminbi</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a part of our cash flow hedging program, we designate foreign exchange contracts to hedge a portion of our forecasted </span><span style="font-family:inherit;font-size:10pt;">euro, Japanese yen, Chinese renminbi, Canadian dollar, U.K. pound and Australian dollar</span><span style="font-family:inherit;font-size:10pt;">-denominated intercompany inventory sales expected to occur no more than </span><span style="font-family:inherit;font-size:10pt;"><span>two years</span></span><span style="font-family:inherit;font-size:10pt;"> from the date of each hedge. </span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Interest Rate Risk</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our interest-bearing investments and borrowings are subject to interest rate risk. With respect to our investments, we strive to maintain a predominantly floating-rate basis position, but our strategy may change based on prevailing market conditions. We currently borrow primarily on a long-term, fixed-rate basis. From time to time, depending on market conditions, we will change the profile of our outstanding debt by entering into derivative financial instruments like interest rate swaps. We entered into derivative financial instruments to hedge or offset the fixed interest rates on the hedged item, matching the amount and timing of the hedged item. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Notional</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Notional</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liability</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign exchange contracts</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,543</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>551</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>914</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,193</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>591</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>662</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,995</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>158</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,645</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>318</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>708</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>914</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>909</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>662</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives not designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,433</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,623</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>792</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>993</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>718</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was </span><span style="font-family:inherit;font-size:8pt;"><span>$5.2 billion</span></span><span style="font-family:inherit;font-size:8pt;"> as of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$5.9 billion</span></span><span style="font-family:inherit;font-size:8pt;"> as of December 31, 2019.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:34%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Amount of<br/>Gains/(Losses)<br/>Recognized in OID</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Amount of Gains/(Losses)<br/>Recognized in OCI</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">,</sup></span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#160;(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Amount of Gains/(Losses)<br/>Reclassified from<br/>OCI into OID and COS</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a), (b)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign exchange contracts</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>187</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(204</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>172</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Amount excluded from effectiveness testing recognized in earnings based on an amortization approach</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Derivative Financial Instruments in Fair Value Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>483</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Hedged item </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(483</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Hedged item </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(144</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(48</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">The portion on foreign exchange contracts excluded from the assessment of hedge effectiveness</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign currency short-term borrowings</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign currency long-term debt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(42</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">All other net</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(216</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>111</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:34%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Amount of<br/>Gains/(Losses)<br/>Recognized in OID</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Amount of Gains/(Losses)<br/>Recognized in OCI</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:pt">(a)</sup></span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:pt">,</sup></span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:pt">&#160;(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Amount of Gains/(Losses)<br/>Reclassified from<br/>OCI into OID and COS</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:pt">(a), (b)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Six Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign exchange contracts</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(341</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Amount excluded from effectiveness testing recognized in earnings based on an amortization approach</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Derivative Financial Instruments in Fair Value Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>392</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>813</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Hedged item</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(392</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(813</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Hedged item</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>240</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:18px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">The portion of foreign exchange contracts excluded from the assessment of hedge effectiveness</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>176</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign currency short-term borrowings</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign currency long-term debt</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(51</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(124</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">All other net</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(51</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(124</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>139</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>188</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>251</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>398</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">OID = Other (income)/deductions&#8212;net, included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:inherit;font-size:8pt;"> in the condensed consolidated statements of income</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">.</span><span style="font-family:inherit;font-size:8pt;"> COS = Cost of Sales, included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:8pt;"> in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other comprehensive loss&#8211;&#8211;Unrealized holding gains/(losses) on derivative financial instruments, net</span><span style="font-family:inherit;font-size:8pt;">. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the gains and losses are included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other comprehensive loss&#8211;&#8211;Foreign currency translation adjustments, net.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The amounts reclassified from OCI into COS were:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:12px;"><div style="line-height:120%;font-size:8pt;text-indent:-12px;"><span style="font-family:inherit;font-size:8pt;">a net </span><span style="font-family:inherit;font-size:8pt;">gain</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;"><span>$80 million</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:12px;"><div style="line-height:120%;font-size:8pt;text-indent:-12px;"><span style="font-family:inherit;font-size:8pt;">a net </span><span style="font-family:inherit;font-size:8pt;">gain</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;"><span>$150 million</span></span><span style="font-family:inherit;font-size:8pt;"> in the first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:12px;"><div style="line-height:120%;font-size:8pt;text-indent:-12px;"><span style="font-family:inherit;font-size:8pt;">a net </span><span style="font-family:inherit;font-size:8pt;">gain</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;"><span>$59 million</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:12px;"><div style="line-height:120%;font-size:8pt;text-indent:-12px;"><span style="font-family:inherit;font-size:8pt;">a net </span><span style="font-family:inherit;font-size:8pt;">gain</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;"><span>$103 million</span></span><span style="font-family:inherit;font-size:8pt;"> in the first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax </span><span style="font-family:inherit;font-size:8pt;">gain</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;"><span>$102 million</span></span><span style="font-family:inherit;font-size:8pt;"> within the next 12 months into income</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">. </span><span style="font-family:inherit;font-size:8pt;">The maximum length of time over which we are hedging future foreign exchange cash flow relates to our </span><span style="font-family:inherit;font-size:8pt;"><span>$1.8 billion</span></span><span style="font-family:inherit;font-size:8pt;"> U.K. pound debt maturing in 2043.</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The amounts reclassified from OCI were reclassified into OID.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Long-term debt includes foreign currency long-term borrowings with carrying values of </span><span style="font-family:inherit;font-size:8pt;"><span>$2.0 billion</span></span><span style="font-family:inherit;font-size:8pt;"> as of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, which are used as hedging instruments in net investment hedges.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:26%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:1px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the amounts recorded in our condensed consolidated balance sheet related to cumulative basis adjustments for fair value hedges:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to </span></div><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to </span></div><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Carrying Amount</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Carrying Amount of Hedged Assets/Liabilities</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Active Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Discontinued Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Carrying Amount of Hedged Assets/Liabilities</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Active Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Discontinued Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,023</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,181</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7,092</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>266</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>690</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of our derivative financial instruments are covered by associated credit-support agreements that have credit-risk-related contingent features designed to reduce both counterparties&#8217; exposure to risk of defaulting on amounts owed by the other party. As of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;">, the aggregate fair value of these derivative financial instruments that are in a net liability position was </span><span style="font-family:inherit;font-size:10pt;"><span>$928 million</span></span><span style="font-family:inherit;font-size:10pt;">, for which we have posted collateral of </span><span style="font-family:inherit;font-size:10pt;"><span>$922 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the normal course of business. If there had been a downgrade to below an A rating by S&amp;P or the equivalent rating by Moody&#8217;s, we would not have been required to post any additional collateral to our counterparties.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;">, we received cash collateral of </span><span style="font-family:inherit;font-size:10pt;"><span>$858 million</span></span><span style="font-family:inherit;font-size:10pt;"> from various counterparties. The collateral primarily supports the approximate fair value of our derivative contracts. With respect to the collateral received, the obligations are reported in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Short-term borrowings, including current portion of long-term debt.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">F. Credit Risk</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On an ongoing basis, we review the creditworthiness of counterparties to our foreign exchange and interest rate agreements and do not expect to incur a significant loss from failure of any counterparties to perform under the agreements. There are no significant concentrations of credit risk related to our financial instruments with any individual counterparty. For additional information about concentrations of certain credit risk related to certain significant customers, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 17C. Segment, Geographic and Other Revenue Information: Other Revenue Information </span><span style="font-family:inherit;font-size:10pt;">in Pfizer&#8217;s </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> Financial Report. As of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had amounts due from a well-diversified, high quality group of banks (</span><span style="font-family:inherit;font-size:10pt;"><span>$1.9 billion</span></span><span style="font-family:inherit;font-size:10pt;">) from around the world. For details about our investments, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 7B </span><span style="font-family:inherit;font-size:10pt;">above</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">. </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In general, there is no requirement for collateral from customers. However, derivative financial instruments are executed under credit-support agreements that provide for the ability to request to receive cash collateral, depending on levels of exposure, our credit rating and the credit rating of the counterparty, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 7E</span><span style="font-family:inherit;font-size:10pt;"> above.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818719186792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Inventories</span><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inventories</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,002</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,750</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,810</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,743</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials and supplies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>752</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>790</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inventories</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,564</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,283</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncurrent inventories not included above</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>962</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>714</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The change from </span><span style="font-family:inherit;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:8pt;"> reflects increases for certain products, including inventory build for new product launches, network strategy and market demand, partially offset by a decrease due to foreign exchange.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other noncurrent assets</span><span style="font-family:inherit;font-size:8pt;">. There are no recoverability issues associated with these amounts.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818804122568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Identifiable Intangible Assets and Goodwill</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Identifiable Intangible Assets and Goodwill</span><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. Identifiable Intangible Assets</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Balance Sheet Information</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identifiable</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets, less</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identifiable</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets, less</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Finite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed technology rights</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,927</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(64,683</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,244</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,730</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(63,106</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,625</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brands</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>922</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(757</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>165</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>922</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(741</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>181</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing agreements and other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,327</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,226</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,101</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,772</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,191</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>582</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93,176</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(66,667</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,509</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91,425</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(65,037</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,387</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Indefinite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brands</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,991</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,991</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,991</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,991</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,518</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,518</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,919</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,919</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing agreements</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#160;</sup></span><span style="font-family:inherit;font-size:10pt;">and other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>523</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>523</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,073</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,073</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,032</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,032</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,983</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,983</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100,208</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(66,667</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,541</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100,408</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(65,037</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,370</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The changes in the gross carrying amount of </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8pt;"> primarily reflect the transfer of </span><span style="font-family:inherit;font-size:8pt;"><span>$1.4 billion</span></span><span style="font-family:inherit;font-size:8pt;"> from </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8pt;"> to </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8pt;"> to reflect the approval of Braftovi in combination with Erbitux</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:inherit;font-size:8pt;"> (cetuximab), for the treatment of BRAF</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">V600E</sup></span><span style="font-family:inherit;font-size:8pt;">-mutant metastatic colorectal cancer after prior therapy.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The changes in the gross carrying amount of </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Licensing agreements and other</span><span style="font-family:inherit;font-size:8pt;"> primarily reflect the transfer of </span><span style="font-family:inherit;font-size:8pt;"><span>$550 million</span></span><span style="font-family:inherit;font-size:8pt;"> from Indefinite-lived </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Licensing agreements and other</span><span style="font-family:inherit;font-size:8pt;"> to finite-lived </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Licensing agreements and other</span><span style="font-family:inherit;font-size:8pt;"> to reflect the approval in the U.S. of several products subject to out-licensing arrangements acquired from Array.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The </span><span style="font-family:inherit;font-size:8pt;">decrease</span><span style="font-family:inherit;font-size:8pt;"> in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">I</span><span style="font-family:inherit;font-size:8pt;font-style:italic;text-align:right;">dentifiable intangible assets, less accumulated amortization</span><span style="font-family:inherit;font-size:8pt;text-align:right;">, </span><span style="font-family:inherit;font-size:8pt;">is primarily due to amortization.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Biopharma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">WRDM</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed technology rights</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>99</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brands, finite-lived</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brands, indefinite-lived</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing agreements and other, finite-lived</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>99</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing agreements and other, indefinite-lived</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Amortization</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total amortization expense for finite-lived intangible assets was </span><span style="font-family:inherit;font-size:10pt;"><span>$917 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 billion</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">second</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.8 billion</span></span><span style="font-family:inherit;font-size:10pt;"> for the first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.4 billion</span></span><span style="font-family:inherit;font-size:10pt;"> for the first </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. Goodwill</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of and changes in the carrying amount of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Biopharma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,202</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,451</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,653</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(155</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(49</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(204</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,047</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,401</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,449</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Primarily represents the impact of foreign exchange.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818813255320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pension and Postretirement Benefit Plans</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Pension and Postretirement Benefit Plans</span><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.635477582846%;border-collapse:collapse;text-align:left;"><tr><td colspan="33"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td colspan="33" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of net periodic benefit cost/(credit):</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S.</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Supplemental</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Postretirement</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>131</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>157</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expected return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(251</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(223</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(75</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(80</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Actuarial losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prior service credits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(43</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(45</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Special termination benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net periodic benefit cost/(credit) reported in income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(83</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(30</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(23</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td colspan="33" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S.</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Supplemental</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Postretirement</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>262</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>315</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>109</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expected return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(503</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(445</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(153</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(160</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Actuarial losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prior service credits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(86</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(89</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Special termination benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net periodic benefit cost/(credit) reported in income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(159</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(55</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(60</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(46</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the amounts we contributed, and the amounts we expect to contribute during 2020, to our pension and postretirement plans from our general assets for the periods indicated:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S. Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S. Supplemental (Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Postretirement Plans</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Contributions from our general assets for the six months ended June 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>116</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Expected contributions from our general assets during 2020</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1,253</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>183</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>185</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>137</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Contributions expected to be made for </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> are inclusive of amounts contributed during the </span><span style="font-family:inherit;font-size:8pt;">six months ended June 28, 2020</span><span style="font-family:inherit;font-size:8pt;">. The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments. For the U.S. qualified plans, we plan to make a </span><span style="font-family:inherit;font-size:8pt;"><span>$1.25 billion</span></span><span style="font-family:inherit;font-size:8pt;"> voluntary contribution in the second half of 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818719902920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><span style="font-weight:bold;text-decoration:underline;">Equity</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"> </span><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. Preferred Stock</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to May 4, 2020, Pfizer&#8217;s Series A convertible perpetual preferred stock (the Series A Preferred Stock) was held by an employee stock ownership plan trust (the Trust). All outstanding shares of Series A Preferred Stock were converted, at the direction of the independent fiduciary under the Trust and in accordance with the certificate of designations for the Series A Preferred Stock, into shares of Pfizer common stock on May 4, 2020. The Trust received an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>1,070,369</span></span><span style="font-family:inherit;font-size:10pt;"> shares of Pfizer common stock upon conversion, with </span><span style="font-family:inherit;font-size:10pt;"><span>zero</span></span><span style="font-family:inherit;font-size:10pt;"> shares of Series A Preferred Stock remaining outstanding as a result of the conversion.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. Dividends</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:15%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes quarterly cash dividends:</span></div></td></tr><tr><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date Declared</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividend Per</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date Declared</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividend Per Share</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 13, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 6, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.38</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 14, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 1, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 23, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 5, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.38</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 25, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 7, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 25, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.38</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 3, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 24, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 2, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.36</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818804111176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</span><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the detailed calculation of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">EPS</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(IN MILLIONS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">EPS Numerator&#8211;&#8211;Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,434</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,056</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,845</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,945</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Net income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to Pfizer Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,426</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,046</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,828</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,929</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Preferred stock dividends&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,426</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,045</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,828</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,929</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,426</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,045</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,828</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,929</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">EPS Numerator&#8211;&#8211;Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,426</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,046</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,828</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,929</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,426</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,046</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,828</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,929</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">EPS Denominator</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,554</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,562</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,550</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,598</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common-share equivalents: stock options, stock issuable under employee compensation plans and convertible preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>110</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,619</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,672</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,616</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,711</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Anti-dilutive common stock equivalents</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818804255544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Certain Commitments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies and Certain Commitments</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Contingencies and Certain Commitments</span><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies. For a discussion of our tax contingencies, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 5B.</span><span style="font-family:inherit;font-size:10pt;"> For a discussion of our legal contingencies, see below.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. Legal Proceedings</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our legal contingencies include, but are not limited to, the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. We are the plaintiff in the majority of these actions. An adverse outcome in actions in which we are the plaintiff could result in loss of patent protection for a drug, a significant loss of revenues from that drug or impairment of the value of associated assets.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial and other matters, which can include merger-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other jurisdictions.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, which could be substantial, and/or criminal charges.</span><span style="font-family:Arial;font-size:8pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations in the period in which the amounts are accrued and/or our cash flows in the period in which the amounts are paid.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader&#8217;s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. As a result of considering qualitative factors in our determination of principal matters, there are some matters discussed below with respect to which management believes that the likelihood of possible loss in excess of amounts accrued is remote.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-weight:bold;text-decoration:underline;">A1.</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"> </span><span style="font-weight:bold;text-decoration:underline;">Legal Proceedings&#8211;&#8211;Patent Litigation</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Like other pharmaceutical companies, we are involved in numerous suits relating to our patents, including but not limited to, those discussed below. Most of the suits involve claims by generic drug manufacturers that patents covering our products, processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents on a number of our products that are discussed below, patent rights to certain of our products are being challenged in various other jurisdictions. We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for allegedly causing delay of generic entry. Additionally, our licensing and collaboration partners face challenges by generic drug manufacturers to patents covering products for which we have licenses or co-promotion rights. </span><span style="font-family:inherit;font-size:10pt;">We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others.</span><span style="font-family:inherit;font-size:10pt;"> Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the U.S. In October 2017, the Patent Trial and Appeal Board (PTAB) refused to initiate proceedings as to </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> patents. In June 2018, the PTAB ruled on another patent, holding that </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> claim was valid and that all other claims were invalid. The party challenging that patent appealed the decision. In November 2019, the U.S. Court of Appeals for the Federal Circuit vacated the PTAB&#8217;s ruling and requested that the PTAB redecide the challenge.</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">In March and June 2019, an additional patent was found invalid in separate proceedings by the PTAB. We appealed. In January 2020, the U.S. Court of Appeals for the Federal Circuit vacated the original decision and requested that the PTAB redecide the case. Challenges to other patents remain pending in jurisdictions outside the U.S.</span><span style="font-family:inherit;font-size:10pt;color:#1f497d;"> </span><span style="font-family:inherit;font-size:10pt;">The invalidation of all of the patents in our pneumococcal portfolio could potentially allow a competitor pneumococcal vaccine into the marketplace. In the event that any of the patents are found valid and infringed, a competitor pneumococcal vaccine might be prohibited from entering the market or required to pay Pfizer a royalty. We are also subject to patent litigation pursuant to which one or more third parties seek damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our Hospira subsidiaries are involved in patent and patent-related disputes over their attempts to bring generic pharmaceutical and biosimilar products to market. </span><span style="font-family:inherit;font-size:10pt;">If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold in the event that we or one of our subsidiaries, like Hospira, is found to have willfully infringed valid patent rights of a third party.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Actions In Which We Are The Plaintiff</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">EpiPen</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz in the U.S. District Court for the District of New Jersey in connection with Sandoz&#8217;s abbreviated new drug application filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Xeljanz (tofacitinib)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning in 2017, we brought patent-infringement actions against several generic manufacturers that filed separate abbreviated new drug applications with the FDA seeking approval to market their generic versions of tofacitinib tablets in </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> or both of 5 mg and 10 mg dosage strengths, and in both immediate and extended release forms. To date, actions against the following generic manufacturers have been settled on terms not material to Pfizer: (i) MicroLabs USA Inc. and MicroLabs Ltd.; (ii) Sun Pharmaceutical Industries Ltd.; (iii) Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., Huahai US Inc. and Solco Healthcare US, LLC; (iv) Breckenridge Pharmaceutical Inc., Pensa Pharma S.A. and Laboratorios Del Dr. Esteve, S.A.; and (v) Ajanta Pharma Ltd. and Ajanta Pharma USA Inc. The remaining actions continue as described below.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2017, we brought a patent-infringement action against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, Zydus) in the U.S. District Court for the District of Delaware asserting the infringement and validity of </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> patents: the patent covering the active ingredient expiring in December 2025, the patent covering an enantiomer of tofacitinib expiring in 2022, and the patent covering a polymorphic form of tofacitinib expiring in 2023, which Zydus challenged in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2018, we brought a separate patent infringement action against Teva Pharmaceuticals USA, Inc. (Teva) in the U.S. District Court for the District of Delaware asserting the infringement and validity of our patent covering extended release </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">formulations of tofacitinib that was challenged by Teva in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 11 mg extended release tablets.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Inlyta (axitinib)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2018, Apotex Inc. notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Inlyta. Apotex Inc. asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In May 2018, we filed suit against Apotex Inc. in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2019, Glenmark Pharmaceuticals Limited (Glenmark) notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Inlyta. Glenmark asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In June 2019, we filed suit against Glenmark in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Kerydin (tavaborole)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2018, several generic companies notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Kerydin. The generic companies</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span><span style="font-family:inherit;font-size:10pt;">assert the invalidity and non-infringement of methods of use and formulation patents for tavaborole that expire in 2026 and 2027, including pediatric exclusivity. In October 2018, Anacor, our wholly-owned subsidiary</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">,</span><span style="font-family:inherit;font-size:10pt;"> filed infringement lawsuits against each of the generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia.</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Ibrance (palbociclib)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2019, several generic companies notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Ibrance. The generic companies assert the invalidity and non-infringement of </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> composition of matter patents and a method of use patent covering palbociclib, each of which expire in 2023. In April 2019, we brought patent infringement actions against each of the generic filers in various federal courts, asserting the validity and infringement of the patents challenged by the generic companies.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Chantix (varenicline)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020, we brought a patent infringement action against Viwit Pharmaceutical Co. Ltd. (Viwit) in the U.S. District Court for the District of Delaware asserting the validity and infringement of </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> patents challenged by Viwit in its abbreviated new drug application seeking approval to market a generic version of varenicline, 0.5 mg and 1.0 mg tablets.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Lyrica (pregabalin)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2014, Generics (U.K.) Ltd (trading as Mylan) filed an invalidity action against the Lyrica pain use patent in the High Court of Justice in London. Subsequently, Actavis Group PTC ehf filed an invalidity action in the same court, and Pfizer sued for infringement against Actavis Group PTC ehf, Actavis U.K. Ltd and Caduceus Pharma Ltd (together, Actavis), in addition to requesting preliminary relief. Our request for preliminary relief was denied in a January 2015 hearing, and the denial subsequently was confirmed on appeal.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2015, the National Health Service (NHS) England was ordered by the High Court, as an intermediary, to issue guidance for prescribers and pharmacists directing the prescription and dispensing of Lyrica by brand when pregabalin was prescribed for the treatment of neuropathic pain. NHS Wales and NHS Northern Ireland also issued prescribing guidance. The guidance to prescribe and dispense Lyrica for neuropathic pain was withdrawn upon patent expiration in July 2017. </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also filed infringement actions against (i) Teva UK Ltd, and (ii) Dr. Reddy&#8217;s Laboratories (UK) Ltd and Caduceus Pharma Ltd (together, Dr. Reddy&#8217;s) in February 2015, seeking the same relief as in the action against Actavis. Dr. Reddy&#8217;s filed an invalidity counterclaim. These actions were stayed pending the outcome of the Mylan and Actavis cases.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Mylan and Actavis invalidity actions were heard in the High Court at the same time as the Actavis infringement action. The High Court ruled against us, holding that the asserted claims were either not infringed or invalid, and appeals followed. In November 2018, the U.K. Supreme Court ruled that all the relevant claims directed to neuropathic pain were invalid.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2015, after Sandoz GmbH and Sandoz Ltd (together, Sandoz) launched a full label generic pregabalin product, we obtained from the High Court a preliminary injunction enjoining Sandoz from further sales of the product and ordering Sandoz to identify the parties holding its product. Sandoz identified wholesaler AAH Pharmaceuticals Ltd and pharmacy chain Lloyds Pharmacy Ltd (supplied by AAH), and we requested that these parties cease further sales and withdraw the Sandoz full label product. In October 2015, Lloyds was added to the Sandoz action, and we obtained a preliminary order from the High Court requiring Lloyds to advise its pharmacists that the Sandoz full label product should not be dispensed. In November 2015, the High Court confirmed the preliminary injunction against Sandoz and Lloyds. Sandoz filed an invalidity counterclaim. Upon </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">agreement of the parties, in December 2015, the proceedings against Lloyds were discontinued, and the proceedings against Sandoz were stayed pending outcome of the Mylan and Actavis cases. The preliminary injunction against Sandoz remained in place until patent expiration in July 2017.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2020, Dr. Reddy&#8217;s filed a claim for damages in connection with the above-referenced legal actions. In July 2020, the Scottish Ministers and </span><span style="font-family:inherit;font-size:10pt;"><span>fourteen</span></span><span style="font-family:inherit;font-size:10pt;"> Scottish Health Boards (together, NHS Scotland) filed a claim for damages in connection with the above-referenced legal action concerning Sandoz.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Matter Involving Our Collaboration/Licensing Partners</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Eliquis</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February, March, and April 2017, </span><span style="font-family:inherit;font-size:10pt;"><span>twenty-five</span></span><span style="font-family:inherit;font-size:10pt;"> generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed abbreviated new drug applications seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> patents listed in the Orange Book for Eliquis. </span><span style="font-family:inherit;font-size:10pt;"><span>One</span></span><span style="font-family:inherit;font-size:10pt;"> of the patents expired in December 2019 and the remaining patents currently are set to expire in 2026 and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. In April 2017, BMS and Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia, asserting that each of the generic companies&#8217; proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the 2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> patents. In August 2020, the U.S. District Court for the District of Delaware ruled that both the 2026 patent and the 2031 patent are valid and infringed by the proposed generic products. The decision is subject to appeal. Prior to the August 2020 ruling, we and BMS settled with certain of the generic companies on terms not material to Pfizer, and we and BMS may settle with other generic companies in the future.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A2. Legal Proceedings&#8211;&#8211;Product Litigation</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Like other pharmaceutical companies, we are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Asbestos</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. Claims against American Optical and numerous other defendants are pending in various federal and state courts seeking damages for alleged personal injury from exposure to asbestos and other allegedly hazardous materials. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerous lawsuits are pending against Pfizer in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There also&#160;are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Effexor</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning in May 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants&#8217; allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2014, the District Court dismissed the direct purchaser plaintiffs&#8217; claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff claims. In January 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court&#8217;s decisions and remanded the claims to the District Court.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Lipitor</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Antitrust Actions</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning in November 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain affiliates of Pfizer, and, in most of the actions, Ranbaxy, Inc. (Ranbaxy) and certain affiliates of Ranbaxy. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants&#8217; allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor, and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re Lipitor Antitrust Litigation MDL-2332</span><span style="font-family:inherit;font-size:10pt;">) in the U.S. District</span><span style="font-family:inherit;font-size:10pt;color:#0000ff;"> </span><span style="font-family:inherit;font-size:10pt;">Court for the District of New Jersey. </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2013 and 2014, the District Court dismissed with prejudice the claims by direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs have appealed the District Court&#8217;s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court&#8217;s decisions and remanded the claims to the District Court.</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Also, in January 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Personal Injury Actions</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed type 2 diabetes purportedly as a result of the ingestion of Lipitor. Plaintiffs seek compensatory and punitive damages. </span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2014, the federal actions were transferred for consolidated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Products Liability Litigation (No. II) MDL-2502</span><span style="font-family:inherit;font-size:10pt;">) in the U.S. District Court for the District of South Carolina. Since 2016, certain cases in the Multi-District Litigation were remanded to certain state courts. In January 2017, the District Court granted our motion for summary judgment, dismissing substantially all of the remaining cases pending in the Multi-District Litigation. In January 2017, the plaintiffs appealed the District Court&#8217;s decision to the U.S. Court of Appeals for the Fourth Circuit. In June 2018, the U.S. Court of Appeals for the Fourth Circuit affirmed the District Court&#8217;s decision.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Viagra</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since April 2016, a Multi-District Litigation has been pending in the U.S. District Court for the Northern District of California (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In Re: Viagra (Sildenafil Citrate) Products Liability Litigation, MDL-2691</span><span style="font-family:inherit;font-size:10pt;">), in which plaintiffs allege that they developed melanoma and/or the exacerbation of melanoma purportedly as a result of the ingestion of Viagra. Additional cases filed against Lilly with respect to Cialis have also been consolidated in the Multi-District Litigation </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">(In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation, MDL-2691</span><span style="font-family:inherit;font-size:10pt;">). In January 2020, the District Court granted our and Lilly&#8217;s motion to exclude all of plaintiffs&#8217; general causation opinions. As a result, in April 2020, the District Court entered summary judgment in favor of defendants and dismissed all of plaintiffs&#8217; claims. In April 2020, plaintiffs filed a notice of appeal in the U.S. Court of Appeals for the Ninth Circuit. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">EpiPen</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning in February 2017, purported class actions were filed in various federal courts by indirect purchasers of EpiPen against Pfizer, and/or its affiliates King and Meridian, and/or various entities affiliated with Mylan, and Mylan Chief Executive Officer, Heather Bresch. The plaintiffs in these actions seek to represent U.S. nationwide classes comprising persons or entities who paid for any portion of the end-user purchase price of an EpiPen between 2009 until the cessation of the defendants&#8217; allegedly unlawful conduct. In February 2020, a similar lawsuit was filed in the U.S. District Court for the District of Kansas against Pfizer, King, Meridian and the Mylan entities on behalf of a purported U.S. nationwide class of direct purchaser plaintiffs who purchased EpiPen devices directly from the defendants (the 2020 Lawsuit). Against Pfizer and/or its affiliates, plaintiffs in these actions generally allege that Pfizer&#8217;s and/or its affiliates&#8217; settlement of patent litigation regarding EpiPen delayed market entry of generic EpiPen in violation of federal antitrust laws and various state antitrust laws. At least </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> lawsuit also alleges that Pfizer and/or Mylan violated the federal Racketeer Influenced and Corrupt Organizations Act (RICO). Plaintiffs also filed various federal antitrust, state consumer protection and unjust enrichment claims against, and relating to conduct attributable solely to, Mylan and/or its affiliates regarding EpiPen. Plaintiffs seek treble damages for alleged overcharges for EpiPen since 2011. In August 2017, all of these actions, except for the 2020 Lawsuit, were consolidated for coordinated pre-trial proceedings in a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re: EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation, MDL-2785</span><span style="font-family:inherit;font-size:10pt;">) in the U.S. District Court for the District of Kansas with other EpiPen-related actions against Mylan and/or its affiliates to which Pfizer, King and Meridian are not parties.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2020, a new lawsuit was filed in the District of Colorado on behalf of indirect purchasers. Plaintiff represents a putative U.S. nationwide class of persons or entities who paid for any portion of the end-user purchase price of certain refill or replacement EpiPens since 2010. Plaintiff alleges that Pfizer and Meridian misrepresented the shelf-life and expiration date of EpiPen, in violation of the federal RICO statute. Plaintiff seeks treble damages for alleged unnecessary replacement or refill purchases of EpiPens by members of the putative class.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nexium 24HR and Protonix</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A number of individual and multi-plaintiff lawsuits have been filed against Pfizer, certain of its subsidiaries and/or other pharmaceutical manufacturers in various federal and state courts alleging that the plaintiffs developed kidney-related injuries purportedly as a result of the ingestion of certain proton pump inhibitors. The cases against Pfizer involve Protonix and/or Nexium 24HR and seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement. In August 2017, the federal actions were ordered transferred for coordinated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re: Proton-Pump Inhibitor Products Liability Litigation</span><span style="font-family:inherit;font-size:10pt;"> (No. II)) in the U.S. District Court for the District of New Jersey. On July&#160;31, 2019, we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name. As part of the joint venture transaction, the joint venture has agreed to assume, and to indemnify Pfizer for, liabilities arising out of such litigation to the extent related to Nexium 24HR.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Docetaxel</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Personal Injury Actions</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed permanent hair loss. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek compensatory and punitive damages.</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2016, the federal cases were transferred for coordinated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re Taxotere (Docetaxel) Products Liability Litigation, MDL-2740</span><span style="font-family:inherit;font-size:10pt;">) in the U.S. District Court for the Eastern District of Louisiana.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Mississippi Attorney General Government Action</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2018, the Attorney General of Mississippi filed a complaint in Mississippi state court against the manufacturer of the branded product and </span><span style="font-family:inherit;font-size:10pt;"><span>eight</span></span><span style="font-family:inherit;font-size:10pt;"> other manufacturers including Pfizer and Hospira, alleging, with respect to Pfizer and Hospira, a failure to warn about a risk of permanent hair loss in violation of the Mississippi Consumer Protection Act. The action seeks civil penalties and injunctive relief.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Array Securities Litigation</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2017, </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> purported class actions were filed in the U.S. District Court for the District of Colorado alleging that Array, which we acquired in July 2019 and is our wholly owned subsidiary, and certain of its former officers violated federal securities laws in connection with certain disclosures made, or omitted, by Array regarding the NRAS-mutant melanoma program. In March 2018, the actions were consolidated into a single proceeding. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Zantac </span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A number of lawsuits have been filed against Pfizer in various federal and state courts alleging that plaintiffs developed various types of cancer, or face an increased risk of developing cancer, purportedly as a result of the ingestion of Zantac. The significant majority of these cases also name other defendants that have historically manufactured and/or sold Zantac. Pfizer has not sold Zantac since 2006, and only sold an over-the-counter version of the product. Plaintiffs seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement.</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2020, the federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re Zantac/Ranitidine NDMA Litigation, MDL-2924</span><span style="font-family:inherit;font-size:10pt;">) in the U.S. District Court for the Southern District of Florida. In June 2020: (i) plaintiffs in the Multi-District Litigation filed against Pfizer and many other defendants a consolidated consumer class action complaint alleging, among other things, violations of the RICO statute and consumer protection statutes of all 50 states, and a consolidated third-party payor class action complaint alleging violation of the RICO statute and seeking reimbursement for payments made for the prescription version of Zantac; (ii) Pfizer received service of a Canadian class action complaint naming Pfizer and other defendants, and seeking compensatory and punitive damages for personal injury and economic loss, allegedly arising from the defendants&#8217; sale of Zantac in Canada; and (iii) the State of New Mexico filed a civil action against Pfizer and many other defendants, alleging various state statutory and common law claims in connection with the defendants&#8217; alleged sale of Zantac in New Mexico.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A3. Legal Proceedings&#8211;&#8211;Commercial and Other Matters</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Monsanto-Related Matters</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia &amp; Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operations to a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia&#8217;s former agricultural business. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business, and has been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto&#8217;s chemical businesses. As the result of its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia&#8217;s indemnification obligations relating to Former Monsanto&#8217;s chemical businesses are primarily limited to sites that Solutia has owned or operated. In addition, in connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities primarily related to Former Monsanto&#8217;s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia&#8217;s and New Monsanto&#8217;s assumption of, and agreement to indemnify Pharmacia for, these liabilities apply to pending actions and any future actions related to Former Monsanto&#8217;s chemical businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia and/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto&#8217;s chemical businesses, and have been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Environmental Matters</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2009, we submitted to the U.S. Environmental Protection Agency (EPA) a corrective measures study report with regard to Pharmacia&#8217;s discontinued industrial chemical facility in North Haven, Connecticut. In September 2010, our corrective measures study report was approved by the EPA, and we commenced construction of the site remedy in late 2011 under an Updated Administrative Order on Consent with the EPA. In September 2019, the EPA acknowledged that construction of the site remedy has been completed.</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Also, in 2009, we submitted a revised site-wide feasibility study with regard to Wyeth Holdings Corporation&#8217;s (formerly, American Cyanamid Company) discontinued industrial chemical facility in Bound Brook, New Jersey. In July 2011, Wyeth Holdings Corporation finalized an Administrative Settlement Agreement and Order on Consent for Removal Action (the 2011 Administrative Settlement Agreement) with the EPA with regard to the Bound Brook facility. In May 2012, we completed construction of an interim remedy to address the discharge of impacted groundwater from that facility to the Raritan River. In September 2012, the EPA issued a final remediation plan for the Bound Brook facility&#8217;s main plant area, which is generally in accordance with one of the remedies evaluated in our revised site-wide feasibility study. In March 2013, Wyeth Holdings Corporation (now Wyeth Holdings LLC) entered into an Administrative Settlement Agreement and Order on Consent with the </span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EPA to allow us to undertake detailed engineering design of the remedy for the main plant area and to perform a focused feasibility study for </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> adjacent lagoons. In September 2015, the U.S., on behalf of the EPA, filed a complaint and consent decree with the federal District Court for the District of New Jersey that allows Wyeth Holdings LLC to complete the design and to implement the remedy for the main plant area. In December 2015, the consent decree (which supersedes the 2011 Administrative Settlement Agreement) was entered by the District Court. In September 2018, the EPA issued a final remediation plan for the </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> adjacent lagoons, which is generally in accordance with one of the remedies evaluated in our focused feasibility study, and in September 2019, Wyeth Holdings LLC entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the lagoons. </span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have accrued for the estimated costs of the site remedies for the North Haven and Bound Brook facilities.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contracts with Iraqi Ministry of Health</span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2017, a number of United States service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia against a number of pharmaceutical and medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health, and seeks monetary relief. In July 2020, the District Court granted defendants&#8217; motions to dismiss and dismissed all of plaintiffs&#8217; claims. In July 2018, the U.S. Department of Justice requested documents related to this matter, which have been provided.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Allergan Complaint for Indemnity</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, Pfizer was named as a defendant in a third-party complaint for indemnity, along with King, filed by Allergan Finance LLC (Allergan) in a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re National Prescription Opiate Litigation MDL 2804</span><span style="font-family:inherit;font-size:10pt;">) in the U.S. District Court for the Northern District of Ohio. The lawsuit asserted claims for indemnity related to Kadian, which was owned for a short period by King in 2008, prior to Pfizer's acquisition of King in 2010. In December 2018, the District Court dismissed the lawsuit. In February 2019, Allergan filed a similar complaint in the Supreme Court of the State of New York, asserting claims for indemnity related to Kadian.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Breach of Contract&#8211;&#8211;Xalkori</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pfizer is a defendant in a breach of contract action brought by New York University (NYU) in the Supreme Court of the State of New York (Supreme Court). NYU alleges that it is entitled to royalties on Pfizer&#8217;s sales of</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">Xalkori under the terms of a Research and License Agreement between NYU and Sugen, Inc. Sugen, Inc. was acquired by Pharmacia in August 1999, and </span><span style="font-family:inherit;font-size:10pt;color:#212529;">Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.</span><span style="font-family:inherit;font-size:10pt;"> The action was originally filed in 2013. In December 2015, the Supreme Court dismissed the action and, in May 2017, the New York State Appellate Division reversed the decision and remanded the proceedings to the Supreme Court. In January 2020, the Supreme Court denied both parties&#8217; summary judgment motions.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A4. Legal Proceedings&#8211;&#8211;Government Investigations</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Like other pharmaceutical companies, we are subject to extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. Criminal charges, substantial fines and/or civil penalties, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as reputational harm and increased public interest in the matter could result from government investigations in the U.S. and other jurisdictions in which we do business. In addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government.</span><span style="font-family:inherit;font-size:10pt;"> Among the investigations by government agencies are the matters discussed below.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Greenstone Investigations</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">U.S. Department of Justice Antitrust Division Investigation</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since July 2017, the U.S. Department of Justice's Antitrust Division has been investigating our Greenstone generics business. We believe this is related to an ongoing broader antitrust investigation of the generic pharmaceutical industry. The government has been obtaining information from Greenstone.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">State Attorneys General Generics Antitrust Litigation</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2018, Greenstone received requests for information from the Antitrust Department of the Connecticut Office of the Attorney General. In May 2019, Attorneys General of more than 40 states plus the District of Columbia and Puerto Rico filed a </span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">complaint against a number of pharmaceutical companies, including Greenstone and Pfizer. The matter has been consolidated with a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re: Generic Pharmaceuticals Pricing Antitrust Litigation MDL No. 2724)</span><span style="font-family:inherit;font-size:10pt;"> in the Eastern District of Pennsylvania. As to Greenstone and Pfizer, the complaint alleges anticompetitive conduct in violation of federal and state antitrust laws and state consumer protection laws. In June 2020, the State Attorneys General filed a new complaint against a large number of companies, including Greenstone and Pfizer, making similar allegations, but concerning a new set of drugs. This complaint was transferred to the Multi-District Litigation in July 2020.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Subpoena relating to Manufacturing of Quillivant XR</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2018, we received a subpoena from the U.S. Attorney&#8217;s Office for the Southern District of New York (SDNY) seeking records relating to our relationship with another drug manufacturer and its production and manufacturing of drugs including, but not limited to, Quillivant XR. We have produced records pursuant to the subpoena.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Government Inquiries relating to Meridian Medical Technologies </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2019, we received a civil investigative demand from the U.S. Attorney&#8217;s Office for the SDNY. The civil investigative demand seeks records and information related to alleged quality issues involving the manufacture of auto-injectors at our Meridian site. In August 2019, we received a HIPAA subpoena from the U.S. Attorney&#8217;s Office for the Eastern District of Missouri seeking similar records and information. We are producing records in response to these requests. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">U.S. Department of Justice/SEC Inquiry relating to Russian Operations</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2019, we received an informal request from the U.S. Department of Justice&#8217;s FCPA Unit seeking documents relating to our operations in Russia. In September 2019, we received a similar request from the SEC&#8217;s FCPA unit. We are producing records pursuant to these requests. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contracts with Iraqi Ministry of Health</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 13A3. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Contingencies and Certain Commitments</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Legal Proceedings&#8211;&#8211;Commercial and Other Matters&#8211;&#8211;Contracts with Iraqi Ministry of Health</span><span style="font-family:inherit;font-size:10pt;"> above for information regarding U.S. government investigations related to contracts with the Iraqi Ministry of Health.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Docetaxel</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Mississippi Attorney General Government Action</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 13A2. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Contingencies and Certain Commitments</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Legal Proceedings</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Product Litigation</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Docetaxel</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Mississippi Attorney General Government Action</span><span style="font-family:inherit;font-size:10pt;"> above for information regarding a government action related to Docetaxel marketing practices.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">U.S. Department of Justice Inquiries relating to India Operations</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2020, we received an informal request from the U.S. Department of Justice's Consumer Protection Branch seeking documents relating to our manufacturing operations in India, including at our former facility located at Irrungattukottai in India. In April 2020, we received a similar request from the U.S. Attorney&#8217;s Office for the SDNY regarding a civil investigation concerning operations at our facilities in India. We are producing records pursuant to these requests.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">U.S. Department of Justice Inquiry relating to China Operations</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2020, we received an informal request from the U.S. Department of Justice's FCPA Unit seeking documents relating to our operations in China. We will be producing records pursuant to this request.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Zantac</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">State of New Mexico Civil Action</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 13A2. Contingencies and Certain Commitments: Legal Proceedings&#8211;&#8211;Product Litigation&#8211;&#8211;Zantac</span><span style="font-family:inherit;font-size:10pt;"> above for information regarding a civil action filed by the State of New Mexico alleging various state statutory and common law claims in connection with the defendants&#8217; alleged sale of Zantac in New Mexico.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A5. Legal Proceedings&#8211;&#8211;Matters Resolved During the First Six Months of 2020</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the first six months of 2020, certain matters, including the matter discussed below, were resolved or were the subject of definitive settlement agreements or settlement agreements-in-principle.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Hormone Therapy Consumer Class Action</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A certified consumer class action was pending against Wyeth in the U.S. District Court for the Southern District of California based on the alleged off-label marketing of its hormone therapy products. The case was originally filed in December 2003. The class consisted of California consumers who purchased Wyeth&#8217;s hormone-replacement products between January 1995 and January 2003 and who did not seek personal injury damages therefrom. The class sought compensatory and punitive damages, including a full refund of the purchase price. In March 2020, the parties reached an agreement, and obtained preliminary court approval, to resolve this matter for </span><span style="font-family:inherit;font-size:10pt;"><span>$200 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was paid in full in the second quarter of 2020.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. Guarantees and Indemnifications</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss. These indemnifications are generally subject to various restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;">, the estimated fair value of these indemnification obligations was not significant. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, in connection with our entry into certain agreements, our counterparties may agree to indemnify us. For example, our collaboration agreement with EMD Serono, Inc. to co-promote Rebif in the U.S. expired at the end of 2015 and included certain indemnity provisions. Patent litigation brought by Biogen Idec MA Inc. against EMD Serono Inc. and Pfizer is pending in the U.S. District Court for the District of New Jersey and the United States Court of Appeals for the Federal Circuit. EMD Serono Inc. has acknowledged that it is obligated to satisfy any award of damages.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pfizer Inc. has also guaranteed the long-term debt of certain companies that it acquired and that now are subsidiaries of Pfizer. See </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 7D</span><span style="font-family:inherit;font-size:10pt;"> for additional information.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">C. Contingent Consideration for Acquisitions</span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may be required to make contingent consideration payments to sellers for certain prior business combinations. For additional information, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1D. Basis of Presentation and Significant Accounting Policies: Acquisition</span><span style="font-family:inherit;font-size:10pt;">s in our 2019 Financial Report. The estimated fair value of contingent consideration as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;"> is </span><span style="font-family:inherit;font-size:10pt;"><span>$727 million</span></span><span style="font-family:inherit;font-size:10pt;">, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$157 million</span></span><span style="font-family:inherit;font-size:10pt;"> is recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$570 million</span></span><span style="font-family:inherit;font-size:10pt;"> is recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other noncurrent liabilities </span><span style="font-family:inherit;font-size:10pt;">in our condensed consolidated balance sheet. The estimated fair value of contingent consideration as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$711 million</span></span><span style="font-family:inherit;font-size:10pt;">, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$160 million</span></span><span style="font-family:inherit;font-size:10pt;"> was recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$551 million</span></span><span style="font-family:inherit;font-size:10pt;"> was recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other noncurrent liabilities </span><span style="font-family:inherit;font-size:10pt;">in our condensed consolidated balance sheet. The increase in the contingent consideration balance from December 31, 2019 is primarily due to fair value adjustments, partially offset by payments made upon the achievement of certain milestones.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818720983128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment, Geographic and Other Revenue Information</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Segment, Geographic and Other Revenue Information</span><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. </span><span style="font-weight:bold;text-decoration:underline;">Segment Information</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the beginning of our fiscal year 2019, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> distinct business segments: Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and through </span><span style="font-family:inherit;font-size:10pt;">July&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, Pfizer&#8217;s Consumer Healthcare business (Consumer Healthcare), each led by a single manager. Each operating segment has responsibility for its commercial activities. Upjohn is, and through </span><span style="font-family:inherit;font-size:10pt;">July&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> Consumer Healthcare was, responsible for its own R&amp;D activities while Biopharma receives its R&amp;D services from GPD and WRDM. These services include IPR&amp;D projects for new investigational products and additional indications for in-line products. Each business has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation. Biopharma and Upjohn are the only reportable segments.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan).</span><span style="font-family:inherit;font-size:10pt;"> As a result, revenues and expenses associated with Meridian and Mylan-Japan are reported in our Upjohn business beginning in the first quarter of 2020. In 2019, revenues and expenses from Meridian and Mylan-Japan were recorded in our Biopharma business. We have revised prior-period information (Revenues and Earnings, as defined by management) to conform to the current management structure.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisitions and other business development activities completed in 2019 and in the first half of 2020, including the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture, impacted financial results in the periods presented.</span><span style="font-family:inherit;font-size:10pt;"> </span><span>For additional information, see Notes to Consolidated Financial Statements&#8212;</span><span style="font-style:italic;">Note 1A. Basis of Presentation and Significant Accounting Policies: Basis of Presentation</span><span> in our 2019 Financial Report, and </span><span style="font-style:italic;">Note 2</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Operating Segments</span></div><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:16pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:10%;"/><td style="width:40%;"/><td style="width:1%;"/><td style="width:49%;"/></tr><tr><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Some additional information about our Biopharma and Upjohn business segments follows:</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img alt="pfizerlogo2816.jpg" src="pfizerlogo2816.jpg" style="height:33px;width:57px;"/></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:16pt;"><span style="font-family:inherit;font-size:16pt;font-weight:bold;">Pfizer</span></div><div style="padding-left:72px;text-indent:-72px;font-size:16pt;"><span style="font-family:inherit;font-size:16pt;font-weight:bold;">Biopharmaceuticals</span></div><div style="padding-left:72px;text-indent:-72px;font-size:16pt;"><span style="font-family:inherit;font-size:16pt;font-weight:bold;">Group</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img alt="upjohnlogo.jpg" src="upjohnlogo.jpg" style="height:77px;width:201px;"/></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px dotted #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Biopharma is a science-based innovative medicines business that includes six business units &#8211; Oncology, Inflammation &amp; Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. The Hospital unit commercializes our global portfolio of sterile injectable and anti-infective medicines and includes Pfizer&#8217;s contract manufacturing operation, Pfizer CentreOne. Each business unit is committed to delivering breakthroughs that change patients&#8217; lives.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px dotted #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Upjohn is a global, primarily off-patent branded and generic medicines business, which includes a portfolio of 20 globally recognized solid oral dose brands, as well as a U.S.-based generics platform, Greenstone.</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Select products include:<br/></span><span style="font-family:inherit;font-size:9pt;font-style:italic;">- Ibrance</span></div><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">- </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Eliquis</span></div><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">- </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Prevnar 13/Prevenar 13</span></div><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">- </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Xeljanz<br/></span><span style="font-family:inherit;font-size:9pt;">- </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Enbrel </span><span style="font-family:inherit;font-size:9pt;">(outside the U.S. and Canada)<br/></span><span style="font-family:inherit;font-size:9pt;font-style:italic;">- Vyndaqel/Vyndamax</span></div><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">- </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Chantix/Champix</span></div><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">- Xtandi</span></div><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">- </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Sutent</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Select products include:<br/></span><span style="font-family:inherit;font-size:9pt;font-style:italic;">- Lipitor</span></div><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">- </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Lyrica<br/>- Norvasc</span></div><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">- Celebrex</span></div><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">- Viagra</span></div><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">- </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Certain generic medicines</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Other Costs and Business Activities</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain pre-tax costs are not allocated to our operating segment results, such as costs associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">WRDM&#8211;&#8211;the R&amp;D and Medical expenses managed by our WRDM organization, which is generally responsible for research projects for our Biopharma portfolio until proof-of-concept is achieved and then for transitioning those projects to the GPD organization for possible clinical and commercial development. R&amp;D spending may include upfront and milestone payments for intellectual property rights. The WRDM organization also has responsibility for certain science-based and other platform-services organizations, which provide end-to-end technical expertise and other services to the various R&amp;D projects, as well as the Worldwide Medical and Safety group, which ensures that Pfizer provides all stakeholders&#8211;&#8211;including patients, healthcare providers, pharmacists, payers and health authorities&#8211;&#8211;with complete and up-to-date information on the risks and benefits associated with Pfizer products so that they can make appropriate decisions on how and when to use Pfizer&#8217;s medicines.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">GPD&#8211;&#8211;the costs associated with our GPD organization, which is generally responsible for clinical trials from WRDM in the Biopharma portfolio, including late stage portfolio spend. GPD also provides technical support and other services to Pfizer R&amp;D projects. GPD is responsible for facilitating all regulatory submissions and interactions with regulatory agencies.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other&#8211;&#8211;the operating results of our Consumer Healthcare business, through July 31, 2019, and costs associated with other commercial activities not managed as part of Biopharma or Upjohn, including all strategy, business development, portfolio management and valuation capabilities, which previously had been reported in various parts of the organization.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate and Other Unallocated&#8211;&#8211;the costs associated with corporate enabling functions (such as digital, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance, and worldwide procurement), patient advocacy activities and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments, as well as overhead expenses associated with our manufacturing (which include manufacturing variances associated with production) and commercial operations that are not directly assessed to an operating segment, as business unit (segment) management does not manage these costs. </span><span style="font-size:10pt;">Corporate and Other Unallocated also includes our share of earnings from the GSK Consumer Healthcare joint venture and other charges related to the GSK Consumer Healthcare joint venture, primarily representing our pro-rata share of restructuring and business combination accounting charges recorded by the GSK Consumer Healthcare joint venture.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and PP&amp;E; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) certain significant items, representing substantive and/or unusual, and in some cases recurring, items (such as gains on the completion of joint venture transactions, restructuring charges, legal charges or gains and losses from equity securities) that </span></div></td></tr></table><div style="line-height:120%;padding-left:12px;text-align:left;"><span style="font-family:inherit;font-size:10pt;">are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Segment Assets</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We manage our assets on a Total Company basis, not by operating segment, as many of our operating assets are shared or commingled (such as accounts receivable, as many of our customers are served by multiple operating segments). Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$178 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$167 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Selected Income Statement Information</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides selected income statement information by reportable segment:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Earnings</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reportable Segments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Biopharma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>9,795</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>9,432</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>6,650</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>6,071</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>2,006</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>2,970</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>1,168</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>1,973</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Total reportable segments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>11,801</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>12,402</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>7,818</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>8,044</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other business activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>862</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,530</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,193</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reconciling Items:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Corporate and other unallocated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,136</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,399</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Purchase accounting adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(910</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,178</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>176</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Certain significant items</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(268</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(309</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>11,801</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>13,264</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>3,953</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>4,141</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Earnings</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reportable Segments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Biopharma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>19,802</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>18,477</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>13,379</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>11,954</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>4,027</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>6,184</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>2,359</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>4,251</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Total reportable segments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>23,829</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>24,661</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>15,738</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>16,206</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other business activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>1,721</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(3,019</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(2,306</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reconciling Items:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Corporate and other unallocated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(2,245</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(2,676</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Purchase accounting adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,722</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(2,217</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>148</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Certain significant items</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(879</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(691</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>23,829</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>26,382</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>7,838</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>8,463</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="font-family:inherit;font-size:8pt;">. Biopharma&#8217;s earnings </span><span style="font-family:inherit;font-size:8pt;text-align:center;">include d</span><span style="font-family:inherit;font-size:8pt;">ividend income of </span><span style="font-family:inherit;font-size:8pt;"><span>$76 million</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$76&#160;million</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:8pt;">, and </span><span style="font-family:inherit;font-size:8pt;"><span>$153 million</span></span><span style="font-family:inherit;font-size:8pt;"> in </span><span style="font-family:inherit;font-size:8pt;">the first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$140 million</span></span><span style="font-family:inherit;font-size:8pt;"> in </span><span style="font-family:inherit;font-size:8pt;">the first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:8pt;"> from our investment in ViiV. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity in the net income of investees accounted for by the equity method is not significant for any of our operating segments.</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The operating segment information does not purport to represent the revenues, costs and income from continuing operations before provision for taxes on income that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. Geographic Information</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides revenues by geographic area:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,402</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,335</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,053</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,510</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed Europe</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,088</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,009</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,315</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed Rest of World</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,552</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,639</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,008</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,174</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging Markets</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,759</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,062</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,759</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,383</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,801</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,264</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,829</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,382</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.</span><span style="font-family:inherit;font-size:8pt;"> Revenues denominated in euros were </span><span style="font-family:inherit;font-size:8pt;"><span>$1.7 billion</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$1.8 billion</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:8pt;">, and were </span><span style="font-family:inherit;font-size:8pt;"><span>$3.2 billion</span></span><span style="font-family:inherit;font-size:8pt;"> in </span><span style="font-family:inherit;font-size:8pt;">the first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$3.5 billion</span></span><span style="font-family:inherit;font-size:8pt;"> in </span><span style="font-family:inherit;font-size:8pt;">the first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:8pt;text-align:center;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">C. </span><span style="font-weight:bold;text-decoration:underline;">Other Revenue Information</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Significant Product Revenues</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides detailed revenue information for several of our major products:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:38%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">PRODUCT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">PRIMARY INDICATION OR CLASS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">TOTAL REVENUES</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>11,801</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>13,264</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>23,829</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>26,382</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>9,795</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>9,432</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>19,802</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>18,477</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Internal Medicine</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>2,279</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>2,243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>4,610</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>4,380</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Eliquis alliance revenues and direct sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,272</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,085</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>2,572</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>2,096</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Chantix/Champix</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">An aid to smoking cessation treatment in adults 18 years of age or older</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>235</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>276</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>505</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>549</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Premarin family</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Symptoms of menopause</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>152</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>193</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>304</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>361</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">BMP2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Development of bone and cartilage</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Toviaz</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Overactive bladder</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>124</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>125</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other Internal Medicine</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>498</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>544</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>978</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,103</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Oncology</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>2,647</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>2,236</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>5,082</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>4,198</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Ibrance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Metastatic breast cancer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,349</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,261</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>2,598</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>2,394</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Xtandi alliance revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Non-metastatic and metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>266</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>201</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>475</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>369</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Sutent</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>248</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>414</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>480</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Inlyta</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Advanced RCC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>104</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>364</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>177</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Xalkori</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">ALK-positive and ROS1-positive advanced NSCLC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>138</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>287</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>255</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Bosulif</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Philadelphia&#160;chromosome&#8211;positive&#160;chronic myelogenous leukemia</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>213</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>177</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Retacrit</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Anemia</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>87</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>176</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Braftovi</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">In combination with Mektovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation and, in combination with Erbitux</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:7.5pt;">&#160;(cetuximab), for the treatment of BRAF</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">V600E</sup></span><span style="font-family:inherit;font-size:7.5pt;">-mutant metastatic colorectal cancer after prior therapy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Mektovi</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">In combination with Braftovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other Oncology</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>221</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>412</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>262</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Hospital</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a), (c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>1,794</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>1,838</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>3,807</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>3,665</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Sulperazon</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Bacterial infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>165</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>289</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>342</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Medrol</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Anti-inflammatory glucocorticoid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>207</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>240</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Zithromax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Bacterial infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>193</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>177</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Precedex</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Sedation agent in surgery or intensive care</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>156</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Vfend</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Fungal infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>149</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>178</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Panzyga</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Primary humoral immunodeficiency</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:38%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">PRODUCT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">PRIMARY INDICATION OR CLASS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Zyvox</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Bacterial infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>125</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>134</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Fragmin</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Treatment/prevention of venous thromboembolism</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>123</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:7.5pt;">Pfizer CentreOne</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>204</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>376</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>380</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other Anti-infectives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>367</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>420</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>811</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>825</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:7.5pt;">All other Hospital</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>603</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>544</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,245</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,124</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Vaccines</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>1,247</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>1,375</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>2,857</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>2,988</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Prevnar 13/Prevenar 13</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Pneumococcal disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,116</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,179</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>2,566</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>2,665</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Nimenrix</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Meningococcal disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>130</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other Vaccines</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>138</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>161</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>215</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Inflammation &amp; Immunology (I&amp;I)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>1,149</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>1,219</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>2,127</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>2,256</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Xeljanz</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">RA, PsA, UC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>635</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>613</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,086</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,036</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Enbrel (Outside the U.S. and Canada)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>337</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>420</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>684</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>871</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Inflectra/Remsima</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Crohn&#8217;s disease, pediatric Crohn&#8217;s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>153</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>308</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>291</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other I&amp;I</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Rare Disease</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>681</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>521</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>1,319</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>991</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Vyndaqel/Vyndamax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">ATTR-cardiomyopathy and polyneuropathy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>277</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>508</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>104</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">BeneFIX</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Hemophilia B</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>109</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>121</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>230</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>247</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Genotropin</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Replacement of human growth hormone</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>106</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>125</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>232</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Refacto AF/Xyntha</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Hemophilia A</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>108</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>181</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>214</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Somavert</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Acromegaly</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>67</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>131</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other Rare Disease</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>61</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>66</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">UPJOHN</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>2,006</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>2,970</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>4,027</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>6,184</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Lipitor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Reduction of LDL cholesterol</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>431</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>407</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>836</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,029</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Lyrica</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>349</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,175</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>706</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>2,362</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Norvasc</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Hypertension</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>216</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>419</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>516</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Celebrex</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Arthritis pain and inflammation, acute pain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>139</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>174</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>295</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>347</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Viagra</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Erectile dysfunction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>259</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Effexor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Depression and certain anxiety disorders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>163</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>163</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Zoloft</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Depression and certain anxiety disorders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>157</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>143</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:7.5pt;">EpiPen</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Epinephrine injection used in treatment of life-threatening allergic reactions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>67</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>123</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Xalatan/Xalacom</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Glaucoma and ocular hypertension</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>587</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>968</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,109</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">CONSUMER HEALTHCARE BUSINESS</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>862</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>1,721</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Total Alliance revenues</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>1,404</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>1,187</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>2,786</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>2,277</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Total Biosimilars</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>289</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>217</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>578</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>396</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Total Sterile Injectable Pharmaceuticals</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(f)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>1,237</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>1,218</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>2,644</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>2,455</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan).</span><span style="font-family:inherit;font-size:7.5pt;"> As a result, revenues associated with our Meridian subsidiary, except for product revenues for EpiPen sold in Canada, and Mylan-Japan, are reported in our Upjohn business beginning in the first quarter of 2020. We have reclassified revenues associated with our Meridian subsidiary and Mylan-Japan from the Hospital and Internal Medicine categories to the Upjohn business to conform 2019 product revenues to the current presentation.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. Hospital also includes Pfizer CentreOne</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span><span style="font-family:inherit;font-size:7.5pt;">. All other Hospital primarily includes revenues from legacy Sterile Injectables Pharmaceuticals (SIP) products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in &#8220;All other Anti-infectives&#8221;.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">On </span><span style="font-family:inherit;font-size:7.5pt;">July&#160;31, 2019</span><span style="font-family:inherit;font-size:7.5pt;">, Pfizer&#8217;s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK&#8217;s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Note 2B</span><span style="font-family:inherit;font-size:7.5pt;">.</span></div></td></tr></table><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(f)</sup>&#160;</span></div><div style="line-height:120%;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818804242728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation<div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes in this Quarterly Report on Form 10-Q.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the </span><span style="font-family:inherit;font-size:10pt;">three and six months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;">May&#160;24, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">May&#160;26, 2019</span><span style="font-family:inherit;font-size:10pt;">. The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the </span><span style="font-family:inherit;font-size:10pt;">three and six months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:10pt;"> Financial Report.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the beginning of our 2019 fiscal year, we began to manage our commercial operations through a new global structure consisting of </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> business segments&#8211;&#8211;Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and through </span><span style="font-family:inherit;font-size:10pt;">July&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, Consumer Healthcare. Biopharma and Upjohn are the only reportable segments. For additional information, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 14</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan).</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">As a result, revenues and expenses associated with Meridian and Mylan-Japan are reported in our Upjohn business beginning in the first quarter of 2020. In 2019, revenues and expenses from Meridian and Mylan-Japan were recorded in our Biopharma business. We performed certain reclassifications between the Biopharma and Upjohn segments to conform 2019 segment revenues and expenses associated with Meridian and Mylan-Japan to the current presentation. There was no impact to our consolidated financial statements.</span><span style="font-family:inherit;font-size:10pt;"> For additional information, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 14.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisitions and other business development activities completed in 2019 and in the first half of 2020, including the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture, impacted financial results in the periods presented.</span><span style="font-family:inherit;font-size:10pt;"> </span><span>For additional information, see Notes to Consolidated Financial Statements&#8212;</span><span style="font-style:italic;">Note 1A. Basis of Presentation and Significant Accounting Policies: Basis of Presentation</span><span> in our 2019 Financial Report, and </span><span style="font-style:italic;">Note 2</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adoption of New Accounting Standards</a></td>
<td class="text"><span style="font-weight:bold;text-decoration:underline;">Adoption of New Accounting Standards in 2020</span><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 1, </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, we adopted </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> new accounting standards.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Credit Losses on Financial Instruments</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;We adopted a new accounting standard for credit losses on financial instruments, which replaces the probable initial recognition threshold for incurred loss estimates under prior guidance with a methodology that reflects expected credit loss estimates. The standard generally impacts financial assets that have a contractual right to receive cash and are not accounted for at fair value through net income, such as accounts receivable and held-to-maturity debt securities. The new guidance requires us to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for certain financial instruments, using information such as historical experience, current economic conditions and information, and the use of reasonable and supportable forecasted information. The standard also </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">amends existing impairment guidance for available-for-sale debt securities to incorporate a credit loss allowance and allows for reversals of credit impairments in the event the issuer&#8217;s credit improves.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We adopted the new accounting standard utilizing the modified retrospective method and, therefore, no adjustments were made to amounts in our prior period financial statements. The cumulative effect of adopting the standard as an adjustment to the opening balance of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Retained earnings</span><span style="font-family:inherit;font-size:10pt;"> was not material. The impact of adoption did not have a material impact on our condensed consolidated statement of income for the </span><span style="font-family:inherit;font-size:10pt;">three and six months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;"> or condensed consolidated statement of cash flows for the </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;">, nor on our condensed consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;">. For additional information, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1C</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Goodwill Impairment Testing</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;We prospectively adopted the new standard, which eliminates the requirement to perform a hypothetical purchase price allocation to measure goodwill impairment. Under the new guidance, the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount, and recognizing an impairment charge for the amount by which the carrying amount of the reporting unit exceeds its fair value. There was no impact to our condensed consolidated financial statements from the adoption of this new standard.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Implementation Costs in a Cloud Computing Arrangement</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;We prospectively adopted the new standard related to customers&#8217; accounting for implementation costs incurred in a cloud computing arrangement that is considered a service contract. The new guidance aligns the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The adoption of this guidance did not have a material impact on our condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Collaboration Agreements</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;We prospectively adopted the new standard, which provides new guidance clarifying the interaction between the accounting for collaborative arrangements and revenue from contracts with customers. There was no impact to our condensed consolidated financial statements from the adoption of this new standard.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 1, 2019, we adopted </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> new accounting standards. For additional information, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2019 </span><span style="font-family:inherit;font-size:10pt;">included in our 2019 Financial Report.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">C. Revenues and Trade Accounts Receivable</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Deductions from Revenues&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;">Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled </span><span style="font-family:inherit;font-size:10pt;"><span>$5.5 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$5.7 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides information about the balance sheet classification of these accruals:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reserve against </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Trade accounts receivable, less allowance for doubtful accounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,129</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued rebates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,210</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,285</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accruals</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>576</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>581</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>598</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>565</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accrued rebates and other accruals</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,512</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,689</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Trade Accounts Receivable&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;">Trade accounts receivable are stated at their net realizable value. The allowance for credit losses against gross trade accounts receivable reflects the best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">three and six months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;text-align:center;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:10pt;">, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818819958552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock', window );">Schedule of Balance Sheet Classification of Accruals</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides information about the balance sheet classification of these accruals:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reserve against </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Trade accounts receivable, less allowance for doubtful accounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,129</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued rebates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,210</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,285</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accruals</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>576</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>581</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>598</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>565</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accrued rebates and other accruals</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,512</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,689</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Medicare Rebates, Medicaid And Related State Program Rebates, Performance-Based Contract Rebates, Chargebacks, Sales Allowances And Sales Returns And Cash Discounts [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818725119672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition, Equity-Method Investment and Licensing Arrangements  - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract', window );"><strong>Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Equity Method Investment</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.05068226120858%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Summarized financial information for our equity method investee, GSK Consumer Healthcare, as of and for the three and six months ending March 31, 2020, the most recent period available, is as follows:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 31, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,213</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,627</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,840</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,524</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,152</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,677</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity attributable to shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,031</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>133</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,163</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.05068226120858%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:54%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,503</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,691</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,394</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,205</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross profit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,109</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,486</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>425</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>471</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>425</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>471</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income attributable to shareholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>405</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>441</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818722335512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Components of Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Arial;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restructuring charges/(credits):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee terminations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>346</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(166</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>371</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(167</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset impairments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exit costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restructuring charges</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>340</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(144</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>396</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(134</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transaction costs</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Integration costs and other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>362</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(115</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>431</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(69</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net periodic benefit costs recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additional depreciation&#8211;&#8211;asset restructuring</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;</sup></span><span style="font-family:inherit;font-size:10pt;">recorded in our condensed consolidated statements of income as follows</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span><span style="font-family:inherit;font-size:10pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total additional depreciation&#8211;&#8211;asset restructuring</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Implementation costs recorded in our condensed consolidated statements of income as follows</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup></span><span style="font-family:inherit;font-size:10pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total implementation costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>99</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total costs associated with acquisitions and cost-reduction/productivity initiatives</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>449</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(59</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>566</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first six months of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, restructuring charges mainly represent employee termination costs associated with our Transforming to a More Focused Company cost reduction program. In the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">, restructuring credits mostly represent the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of an IRS audit for multiple tax years. See Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 5D. Tax Matters: Tax Contingencies </span><span style="font-family:inherit;font-size:8pt;">in our 2019 Financial Report.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:1px;padding-top:2px;padding-left:24px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The restructuring activities for </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, Biopharma (</span><span style="font-family:inherit;font-size:8pt;"><span>$12 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); Upjohn (</span><span style="font-family:inherit;font-size:8pt;"><span>$1 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); and Other (</span><span style="font-family:inherit;font-size:8pt;"><span>$352 million</span></span><span style="font-family:inherit;font-size:8pt;"> charge).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, Biopharma (</span><span style="font-family:inherit;font-size:8pt;"><span>$9 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); Upjohn (</span><span style="font-family:inherit;font-size:8pt;"><span>$12 million</span></span><span style="font-family:inherit;font-size:8pt;"> charge); and Other (</span><span style="font-family:inherit;font-size:8pt;"><span>$393 million</span></span><span style="font-family:inherit;font-size:8pt;"> charge).</span></div></td></tr></table><div style="line-height:120%;padding-bottom:1px;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The restructuring activities for </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">, Biopharma (</span><span style="font-family:inherit;font-size:8pt;"><span>$62 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); Upjohn (</span><span style="font-family:inherit;font-size:8pt;"><span>$9 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); and Other (</span><span style="font-family:inherit;font-size:8pt;"><span>$74 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">, Biopharma (</span><span style="font-family:inherit;font-size:8pt;"><span>$48 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); Upjohn (</span><span style="font-family:inherit;font-size:8pt;"><span>$22 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); and Other (</span><span style="font-family:inherit;font-size:8pt;"><span>$63 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit).</span></div></td></tr></table><div style="line-height:120%;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Restructuring costs identified as Other are for restructuring activities associated with corporate enabling functions, WRDM, GPD and other manufacturing and commercial operations, as applicable. For the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, restructuring costs identified as Other primarily relate to corporate enabling functions.</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Transaction costs represent external costs for banking, legal, accounting and other similar services.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Integration costs and other represent external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, integration costs and other were mostly related to our acquisition of Array. In the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">, integration costs and other were primarily related to our acquisition of Hospira.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Additional depreciation&#8211;&#8211;asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Components of and Changes in Restructuring Accruals</a></td>
<td class="text"><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.05068226120858%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of and changes in our restructuring accruals:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Employee</span></div><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Termination</span></div><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Costs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Asset</span></div><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Impairment</span></div><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Charges</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Exit Costs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Accrual</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Balance, December 31, 2019</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>887</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>933</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Provision</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>371</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>396</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Utilization and other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(341</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(378</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Balance, June 28, 2020</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>918</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>951</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:8pt;"> (</span><span style="font-family:inherit;font-size:8pt;"><span>$714 million</span></span><span style="font-family:inherit;font-size:8pt;">) and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:inherit;font-size:8pt;"> (</span><span style="font-family:inherit;font-size:8pt;"><span>$219 million</span></span><span style="font-family:inherit;font-size:8pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Includes adjustments for foreign currency translation.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other current liabilities </span><span style="font-family:inherit;font-size:8pt;">(</span><span style="font-family:inherit;font-size:8pt;"><span>$625 million</span></span><span style="font-family:inherit;font-size:8pt;">) and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other noncurrent liabilities </span><span style="font-family:inherit;font-size:8pt;">(</span><span style="font-family:inherit;font-size:8pt;"><span>$326 million</span></span><span style="font-family:inherit;font-size:8pt;">).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818804143976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Other (Income)/Deductions - Net</a></td>
<td class="text"><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Interest income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(59</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(53</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(125</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Interest expense</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>372</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>389</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>762</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Net interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>353</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>330</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>709</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>625</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Royalty-related income</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(191</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(231</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(311</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(320</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Net (gains)/losses on asset disposals</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Net gains recognized during the period on equity securities</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(732</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(36</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(478</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(147</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Income from collaborations, out-licensing arrangements and sales of compound/product rights</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(100</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(22</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(215</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(104</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Net periodic benefit credits other than service costs</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(108</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(51</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(175</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(91</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Certain legal matters, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Certain asset impairments</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>160</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Business and legal entity alignment costs</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(g)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>137</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>256</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net losses on early retirement of debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>138</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">GSK Consumer Healthcare JV equity method (income)/loss</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(h)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(126</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(92</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Other, net</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(i)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(107</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(318</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(862</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>126</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(641</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>218</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest income decreased in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first six months of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;">, primarily driven by a lower investment balance and lower short-term interest rates. Interest expense decreased in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> mainly as a result of the retirement of higher-coupon debt and the issuance of new debt with a lower coupon than the debt outstanding for the comparative prior year period. Interest expense increased in the first six months of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;">, mainly as a result of an increased commercial paper balance due to the acquisition of Array. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Royalty-related income for the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;">first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> included a one-time favorable resolution in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> of a legal dispute for </span><span style="font-family:inherit;font-size:8pt;"><span>$82 million</span></span><span style="font-family:inherit;font-size:8pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The gains in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> include, among other things, unrealized gains of </span><span style="font-family:inherit;font-size:8pt;"><span>$508 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to our investment in Allogene and unrealized gains of </span><span style="font-family:inherit;font-size:8pt;"><span>$61 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to our investment in BioNTech. The gains in the first six months of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> include, among other things, unrealized gains of </span><span style="font-family:inherit;font-size:8pt;"><span>$374 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to our investment in Allogene and unrealized gains of </span><span style="font-family:inherit;font-size:8pt;"><span>$127 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to our investment in BioNTech. The gains in the first six months of 2019 included, among other things, unrealized gains of </span><span style="font-family:inherit;font-size:8pt;"><span>$104 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to our investment in Cortexyme, Inc. For additional information on investments, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7B</span><span style="font-family:inherit;font-size:8pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In the </span><span style="font-family:inherit;font-size:8pt;">second</span><span style="font-family:inherit;font-size:8pt;"> quarter and first six months of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;">, mainly includes, among other things, </span><span style="font-family:inherit;font-size:8pt;"><span>$40 million</span></span><span style="font-family:inherit;font-size:8pt;"> of milestone income from Puma Biotechnology, Inc. related to Neratinib regulatory approvals in the EU, and </span><span style="font-family:inherit;font-size:8pt;"><span>$30 million</span></span><span style="font-family:inherit;font-size:8pt;"> of milestone income from Lilly related to the first commercial sale in the U.S. of LOXO-292 for the treatment of RET fusion-positive NSCLC. The first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> also includes an upfront payment to us of </span><span style="font-family:inherit;font-size:8pt;"><span>$75 million</span></span><span style="font-family:inherit;font-size:8pt;"> from our sale of our CK1 assets to Biogen, Inc. In the first six months of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">, primarily included </span><span style="font-family:inherit;font-size:8pt;"><span>$68 million</span></span><span style="font-family:inherit;font-size:8pt;"> in milestone income from Mylan Pharmaceuticals Inc. related to the FDA&#8217;s approval and launch of Wixela Inhub</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:8pt;">, a generic of Advair Diskus</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:8pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 10</span><span style="font-family:inherit;font-size:8pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The first six months of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> included intangible asset impairment charges of: (i) </span><span style="font-family:inherit;font-size:8pt;"><span>$90 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to WRDM IPR&amp;D, for a pre-clinical stage asset from our acquisition of Bamboo for gene therapies for the potential treatment of patients with certain rare diseases, which was the result of a determination to not use certain Bamboo IPR&amp;D acquired in future rare disease development, (ii) </span><span style="font-family:inherit;font-size:8pt;"><span>$40 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to an Upjohn finite-lived developed technology right, acquired in connection with our acquisition of King, for government defense products and reflected, among other things, updated commercial forecasts including manufacturing cost assumptions, and (iii) </span><span style="font-family:inherit;font-size:8pt;"><span>$10 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to a finite-lived developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus marketed in the U.S. market only, </span><span style="font-family:inherit;font-size:8pt;text-align:center;">associated with Biopharma and reflected</span><span style="font-family:inherit;font-size:8pt;">, among other things, updated commercial forecasts. In addition, the first six months of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> included other asset impairments of </span><span style="font-family:inherit;font-size:8pt;"><span>$20 million</span></span><span style="font-family:Arial;font-size:8pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first six months of 2019, represents incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(h)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Includes our share of the GSK Consumer Healthcare joint venture&#8217;s earnings and the amortization of basis differences, which resulted from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the joint venture. See </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 2B</span><span style="font-family:inherit;font-size:8pt;"> for additional information.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> includes, among other things, dividend income of </span><span style="font-family:inherit;font-size:8pt;"><span>$76 million</span></span><span style="font-family:inherit;font-size:8pt;"> from our investment in ViiV, and charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$86 million</span></span><span style="font-family:inherit;font-size:8pt;">, reflecting the change in the fair value of contingent consideration. The first six months of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> includes, among other things, dividend income of </span><span style="font-family:inherit;font-size:8pt;"><span>$153 million</span></span><span style="font-family:inherit;font-size:8pt;"> from our investment in ViiV and charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$99 million</span></span><span style="font-family:inherit;font-size:8pt;">, reflecting the change in the fair value of contingent consideration. The </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> included, among other things, charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$81 million</span></span><span style="font-family:inherit;font-size:8pt;">, reflecting the change in the fair value of contingent consideration, dividend income of </span><span style="font-family:inherit;font-size:8pt;"><span>$76&#160;million</span></span><span style="font-family:inherit;font-size:8pt;"> from our investment in ViiV, and </span><span style="font-family:inherit;font-size:8pt;"><span>$25 million</span></span><span style="font-family:inherit;font-size:8pt;"> of income from insurance recoveries related to Hurricane Maria. The first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> included, among other things, dividend income of </span><span style="font-family:inherit;font-size:8pt;"><span>$140 million</span></span><span style="font-family:inherit;font-size:8pt;"> from our investment in ViiV and </span><span style="font-family:inherit;font-size:8pt;"><span>$50 million</span></span><span style="font-family:inherit;font-size:8pt;"> of income from insurance recoveries related to Hurricane Maria.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818804188616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax Matters (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Tax provision/(benefit) on</span><span style="font-family:inherit;font-size:10pt;">&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">other comprehensive loss</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency translation adjustments, net</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(192</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unrealized holding gains/(losses) on derivative financial instruments, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(53</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(82</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments for gains included in net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(35</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(20</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(59</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(57</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(53</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unrealized holding gains/(losses) on available-for-sale securities, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments for losses included in net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Benefit plans: actuarial gains/(losses), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments related to amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments related to settlements, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments related to amortization of prior service costs and other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(22</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(20</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Tax provision/(benefit) on other comprehensive loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(59</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(265</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818720874824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Changes in Accumulated Other Comprehensive Loss, Net of Tax</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the changes, net of tax, in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive loss</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Net Unrealized Gains/(Losses)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Benefit Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Foreign Currency Translation Adjustments </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Derivative Financial Instruments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Available-For-Sale Securities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Actuarial Gains/(Losses)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Prior Service (Costs)/Credits and Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Accumulated Other Comprehensive Income/(Loss)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Balance, December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(5,952</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(35</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(6,257</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>584</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(11,640</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other comprehensive income/(loss)</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,310</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(353</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(65</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,605</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Balance, June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(7,262</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(333</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(6,178</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>518</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(13,246</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of </span><span style="font-family:inherit;font-size:8pt;"><span>$12 million</span></span><span style="font-family:inherit;font-size:8pt;"> loss for the first six months of 2020. Includes after-tax </span><span style="font-family:inherit;font-size:8pt;">losses</span><span style="font-family:inherit;font-size:8pt;"> of approximately </span><span style="font-family:inherit;font-size:8pt;"><span>$902 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to foreign currency translation adjustments and the impact of our net investment hedging program, both attributable to our equity method investment in GSK Consumer Healthcare (see</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> Note 2B</span><span style="font-family:inherit;font-size:8pt;">), and losses from the weakening of certain major currencies against the U.S. dollar. These </span><span style="font-family:inherit;font-size:8pt;">losses</span><span style="font-family:inherit;font-size:8pt;"> were partially offset by the results of our net investment hedging program.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818804310744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured At Fair Value On a Recurring Basis</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the financial assets and liabilities measured at fair value using a market approach on a recurring basis by balance sheet categories and fair value hierarchy level as defined in Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1E. Basis of Presentation and Significant Accounting Policies: Fair Value </span><span style="font-family:inherit;font-size:10pt;">in our 2019 Financial Report: </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Level 2</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Financial assets measured at fair value on a recurring basis:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Classified as equity securities with readily determinable fair values:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Money market funds</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>13,033</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>13,033</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>705</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>705</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Classified as available-for-sale debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Government and agency&#8212;non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>6,218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>6,218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>4,863</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>4,863</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Government and agency&#8212;U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>811</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>811</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Corporate and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,440</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,440</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,013</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,013</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>7,672</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>7,672</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>6,687</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>6,687</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>20,705</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>20,705</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>7,392</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>7,392</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Derivative assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>413</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>413</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>413</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>413</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>431</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>431</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>465</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>465</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Classified as equity securities with readily determinable fair values</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,072</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,046</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,902</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,863</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Classified as available-for-sale debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Government and agency&#8212;U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>243</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>243</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>303</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>303</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Corporate and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>254</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>254</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>315</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>315</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,326</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,046</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>280</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,216</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,863</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>354</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Derivative assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>266</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>266</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>221</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>221</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>261</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>261</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total derivative assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>362</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>362</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>526</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>526</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Insurance contracts</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>578</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>578</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>575</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>575</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total other noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>940</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>940</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>24,402</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,046</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>22,355</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>11,176</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,863</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>9,313</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Financial liabilities measured at fair value on a recurring basis:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Derivative liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Derivative liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>866</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>866</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>604</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>604</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>866</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>866</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>604</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>604</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>993</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>993</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>718</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>718</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, </span><span style="font-family:inherit;font-size:8pt;"><span>$11.4 billion</span></span><span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn debt transactions (see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7D</span><span style="font-family:inherit;font-size:8pt;">) are invested in money market funds and included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments </span><span style="font-family:inherit;font-size:8pt;">in the condensed consolidated balance sheet.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, long-term equity securities of </span><span style="font-family:inherit;font-size:8pt;"><span>$163 million</span></span><span style="font-family:inherit;font-size:8pt;"> and as of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:8pt;">, long-term equity securities of </span><span style="font-family:inherit;font-size:8pt;"><span>$176 million</span></span><span style="font-family:inherit;font-size:8pt;"> were held in restricted trusts for benefits attributable to various U.S. non-qualified employee benefit plans.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other noncurrent assets include life insurance policies held in restricted trusts attributable to the funding of various U.S. non-qualified employee benefit plans. The underlying invested assets in these insurance contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (income)/deductions</span><span style="font-family:inherit;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">net</span><span style="font-family:inherit;font-size:8pt;"> in the condensed consolidated statements of income (see</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> Note 4</span><span style="font-family:inherit;font-size:8pt;">).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Financial Liabilities Not Measured At Fair Value On a Recurring Basis</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the financial liabilities not measured at fair value on a recurring basis, including the carrying values and estimated fair values using a market approach:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Estimated Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt, excluding the current portion</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,529</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,121</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,121</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,955</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,842</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,842</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, </span><span style="font-family:inherit;font-size:8pt;"><span>$11.4 billion</span></span><span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn debt transactions (see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7D</span><span style="font-family:inherit;font-size:8pt;">) are invested in money market funds and included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments </span><span style="font-family:inherit;font-size:8pt;">in the condensed consolidated balance sheet.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Investments by Classification Type</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table represents our investments by classification type:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity securities with readily determinable fair values</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,033</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>705</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,672</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,687</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Held-to-maturity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>288</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,993</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,525</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity securities with readily determinable fair values</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,072</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,902</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>254</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>315</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Held-to-maturity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Private equity securities at cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>772</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>756</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Total Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,142</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,014</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity-method investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,578</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,133</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term investments and equity-method investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,720</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,147</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Held-to-maturity cash equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>163</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:8pt;">, equity securities with readily determinable fair values included money market funds primarily invested in U.S. Treasury and government debt. As of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, </span><span style="font-family:inherit;font-size:8pt;"><span>$11.4 billion</span></span><span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn debt transactions (see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7D</span><span style="font-family:inherit;font-size:8pt;">) are invested in money market funds and included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments </span><span style="font-family:inherit;font-size:8pt;">in the condensed consolidated balance sheet.</span></div></td></tr></table><div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesTextBlock', window );">Schedule of Held-to-maturity Securities</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="49"/></tr><tr><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/></tr><tr><td colspan="49" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">At June 28, 2020, our investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt securities at June 28, 2020 and December 31, 2019 is as follows, including, as of June 28, 2020, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Gross Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Maturities (in Years)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Gross Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Amortized Cost</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Fair Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Within 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Over 1<br/>to 5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Over 5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Amortized Cost</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Fair Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;text-decoration:underline;">Available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Government and agency</span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:7.5pt;">non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>6,209</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>6,218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>6,218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>6,218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>4,895</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(38</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>4,863</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Government and agency&#8211;&#8211;U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>243</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,120</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Corporate and other</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,450</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,451</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,440</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,451</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,027</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,025</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;text-decoration:underline;">Held-to-maturity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Time deposits and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>189</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>535</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>535</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Government and agency</span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:7.5pt;">non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>803</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>803</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Total debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>8,366</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>8,376</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>8,079</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>263</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>8,376</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>8,380</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(47</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>8,340</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Primarily issued by a diverse group of corporations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Available-for-sale Securities</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="49"/></tr><tr><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/></tr><tr><td colspan="49" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">At June 28, 2020, our investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt securities at June 28, 2020 and December 31, 2019 is as follows, including, as of June 28, 2020, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Gross Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Maturities (in Years)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Gross Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Amortized Cost</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Fair Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Within 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Over 1<br/>to 5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Over 5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Amortized Cost</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Fair Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;text-decoration:underline;">Available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Government and agency</span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:7.5pt;">non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>6,209</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>6,218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>6,218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>6,218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>4,895</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(38</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>4,863</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Government and agency&#8211;&#8211;U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>243</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,120</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Corporate and other</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,450</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,451</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,440</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,451</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,027</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,025</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;text-decoration:underline;">Held-to-maturity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Time deposits and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>189</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>535</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>535</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Government and agency</span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:7.5pt;">non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>803</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>803</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Total debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>8,366</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>8,376</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>8,079</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>263</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>8,376</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>8,380</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(47</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>8,340</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Primarily issued by a diverse group of corporations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Contractual Maturities of Available-for-sale and Held-to-maturity Debt Securities</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="49"/></tr><tr><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/></tr><tr><td colspan="49" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">At June 28, 2020, our investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt securities at June 28, 2020 and December 31, 2019 is as follows, including, as of June 28, 2020, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Gross Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Maturities (in Years)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Gross Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:6.5pt;"><span style="font-family:inherit;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Amortized Cost</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Fair Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Within 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Over 1<br/>to 5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Over 5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Amortized Cost</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Fair Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;text-decoration:underline;">Available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Government and agency</span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:7.5pt;">non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>6,209</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>6,218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>6,218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>6,218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>4,895</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(38</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>4,863</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Government and agency&#8211;&#8211;U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>243</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,120</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Corporate and other</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,450</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,451</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,440</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,451</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,027</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,025</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;text-decoration:underline;">Held-to-maturity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Time deposits and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>189</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>535</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>535</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Government and agency</span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:7.5pt;">non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>803</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>803</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Total debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>8,366</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>8,376</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>8,079</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>263</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>8,376</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>8,380</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(47</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>8,340</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Primarily issued by a diverse group of corporations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock', window );">Schedule of Gains and Losses on Investment Securities</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the calculation of the portion of unrealized gains for the period that relates to equity securities, excluding equity method investments, still held at the reporting date:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net gains recognized during the period on equity securities</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a</sup></span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(732</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(36</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(478</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(147</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Net (gains)/losses recognized during the period on equity securities sold during the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unrealized gains during the reporting period on equity securities still held at the reporting date</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(733</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(31</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(459</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(137</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The net gains on investments in equity securities are reported in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (income)/deductions</span><span style="font-family:inherit;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">net.</span><span style="font-family:inherit;font-size:8pt;"> For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:inherit;font-size:8pt;">.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b) </sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. Since January 1, 2018, there were cumulative impairments and downward adjustments of </span><span style="font-family:inherit;font-size:8pt;"><span>$67 million</span></span><span style="font-family:inherit;font-size:8pt;"> and upward adjustments of </span><span style="font-family:inherit;font-size:8pt;"><span>$66 million</span></span><span style="font-family:inherit;font-size:8pt;">. Impairments, downward and upward adjustments were not significant in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and the first six months of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShortTermDebtTextBlock', window );">Schedule of Short-term Borrowings</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term borrowings include:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,660</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,915</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of long-term debt, principal amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,481</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,458</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other short-term borrowings, principal amount</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>956</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>860</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total short-term borrowings, principal amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,097</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,233</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net fair value adjustments related to hedging and purchase accounting</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unamortized discounts, premiums and debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(43</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Short-term borrowings, including current portion of long-term debt</span><span style="font-family:inherit;font-size:10pt;">, carried at historical proceeds, as adjusted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,084</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,195</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><span style="font-family:inherit;font-size:8pt;">Other short-term borrowings primarily include cash collateral. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7E</span>.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Principal Amounts of Senior Unsecured Long-Term Debt and Adjustments</a></td>
<td class="text"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the second quarter of 2020, we issued the following senior unsecured notes:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturity Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of June&#160;28, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Pfizer Inc.</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.800%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;28, 2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.700%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;28, 2030</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.550%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;28, 2040</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.700%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;28, 2050</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Upjohn Inc., a wholly-owned subsidiary of Pfizer Inc.</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.125%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 22, 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.650%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 22, 2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.300%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 22, 2027</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.700%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 22, 2030</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,450</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.850%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 22, 2040</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.000%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 22, 2050</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,450</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Upjohn Finance B.V., a wholly-owned subsidiary of Upjohn Inc.</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.816%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 23, 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8364;</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.023%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 23, 2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.362%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 23, 2027</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>850</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.908%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 23, 2032</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8364;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,600</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The notes may be redeemed by us at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest. The weighted-average effective interest rate for the notes at issuance was </span><span style="font-family:inherit;font-size:8pt;"><span>2.11%</span></span><span style="font-family:inherit;font-size:8pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In June 2020, Upjohn Inc. and Upjohn Finance B.V. completed privately placed debt offerings in connection with the previously announced proposed Reverse Morris Trust transaction that will ultimately combine Upjohn and Mylan to form a new company, Viatris. The notes may be redeemed by Upjohn Inc. and Upjohn Finance B.V., as applicable, at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest. The weighted-average effective interest rates at issuance were </span><span style="font-family:inherit;font-size:8pt;"><span>2.95%</span></span><span style="font-family:inherit;font-size:8pt;"> for the </span><span style="font-family:inherit;font-size:8pt;"><span>$7.45 billion</span></span><span style="font-family:inherit;font-size:8pt;"> notes and </span><span style="font-family:inherit;font-size:8pt;"><span>1.37%</span></span><span style="font-family:inherit;font-size:8pt;"> for the </span><span style="font-family:inherit;font-size:8pt;"><span>&#8364;3.60 billion</span></span><span style="font-family:inherit;font-size:8pt;"> notes. If the proposed transaction with Mylan does not close on or prior to February 1, 2021, or if, prior to such date, Upjohn Inc. and Mylan notify the trustee that the business combination agreement for the proposed transaction with Mylan is terminated, or the transaction will not otherwise be pursued, the notes must be redeemed at redemption prices equal to </span><span style="font-family:inherit;font-size:8pt;"><span>101%</span></span><span style="font-family:inherit;font-size:8pt;"> of their respective principal amounts, plus accrued and unpaid interest. Pfizer has guaranteed these notes, and such guarantees will automatically and unconditionally terminate without the consent of holders of the notes upon the proposed distribution to Pfizer&#8217;s stockholders of all of the issued and outstanding shares of Upjohn Inc.&#8217;s common stock held by Pfizer (the Distribution). Upjohn Inc. has guaranteed the notes issued by Upjohn Finance B.V., and Upjohn Inc. will remain a guarantor of such notes post Distribution. Following the separation, Upjohn Inc. and Upjohn Finance B.V., as applicable, will remain the obligor. The proceeds from the financings will be used in part to fund a cash distribution from Upjohn Inc. to Pfizer immediately prior to the Distribution. In the interim, the </span><span style="font-family:inherit;font-size:8pt;"><span>$11.4 billion</span></span><span style="font-family:inherit;font-size:8pt;"> of proceeds are classified as </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments</span><span style="font-family:inherit;font-size:8pt;"> in the condensed consolidated balance sheet as of June 28, 2020 pursuant to the terms of the transaction agreements.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the first quarter of 2020, we issued the following senior unsecured notes:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturity Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of June 28, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.625%</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April&#160;1, 2030</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term debt issued in the first quarter of 2020</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The notes may be redeemed by us at any time, in whole, or in part, at a redemption price plus accrued and unpaid interest.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The effective interest rate for the notes at issuance was </span><span style="font-family:inherit;font-size:8pt;"><span>2.67%</span></span><span style="font-family:inherit;font-size:8pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">December&#160;31, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term debt, principal amount</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,187</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,820</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net fair value adjustments related to hedging and purchase accounting</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,654</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,305</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unamortized discounts, premiums and debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(317</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(176</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term debt, carried at historical proceeds, as adjusted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,529</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,955</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,481</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,462</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, </span><span style="font-family:inherit;font-size:8pt;"><span>$11.4 billion</span></span><span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn debt transactions are invested in money market funds and included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments </span><span style="font-family:inherit;font-size:8pt;">in the condensed consolidated balance sheet.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Schedule of Derivative Instruments</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Notional</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Notional</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liability</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign exchange contracts</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,543</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>551</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>914</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,193</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>591</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>662</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,995</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>158</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,645</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>318</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>708</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>914</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>909</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>662</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives not designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,433</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,623</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>792</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>993</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>718</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was </span><span style="font-family:inherit;font-size:8pt;"><span>$5.2 billion</span></span><span style="font-family:inherit;font-size:8pt;"> as of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$5.9 billion</span></span><span style="font-family:inherit;font-size:8pt;"> as of December 31, 2019.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock', window );">Schedule of Derivative Assets</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Notional</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Notional</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liability</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign exchange contracts</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,543</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>551</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>914</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,193</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>591</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>662</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,995</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>158</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,645</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>318</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>708</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>914</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>909</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>662</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives not designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,433</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,623</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>792</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>993</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>718</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was </span><span style="font-family:inherit;font-size:8pt;"><span>$5.2 billion</span></span><span style="font-family:inherit;font-size:8pt;"> as of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$5.9 billion</span></span><span style="font-family:inherit;font-size:8pt;"> as of December 31, 2019.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Derivative Liabilities</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Notional</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Notional</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liability</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign exchange contracts</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,543</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>551</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>914</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,193</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>591</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>662</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,995</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>158</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,645</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>318</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>708</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>914</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>909</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>662</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives not designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,433</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,623</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>792</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>993</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>718</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was </span><span style="font-family:inherit;font-size:8pt;"><span>$5.2 billion</span></span><span style="font-family:inherit;font-size:8pt;"> as of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$5.9 billion</span></span><span style="font-family:inherit;font-size:8pt;"> as of December 31, 2019.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Information about Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:34%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Amount of<br/>Gains/(Losses)<br/>Recognized in OID</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Amount of Gains/(Losses)<br/>Recognized in OCI</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">,</sup></span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#160;(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Amount of Gains/(Losses)<br/>Reclassified from<br/>OCI into OID and COS</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a), (b)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign exchange contracts</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>187</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(204</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>172</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Amount excluded from effectiveness testing recognized in earnings based on an amortization approach</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Derivative Financial Instruments in Fair Value Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>483</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Hedged item </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(483</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Hedged item </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(144</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(48</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">The portion on foreign exchange contracts excluded from the assessment of hedge effectiveness</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign currency short-term borrowings</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign currency long-term debt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(42</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">All other net</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(216</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>111</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:34%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Amount of<br/>Gains/(Losses)<br/>Recognized in OID</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Amount of Gains/(Losses)<br/>Recognized in OCI</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:pt">(a)</sup></span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:pt">,</sup></span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:pt">&#160;(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Amount of Gains/(Losses)<br/>Reclassified from<br/>OCI into OID and COS</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:pt">(a), (b)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Six Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign exchange contracts</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(341</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Amount excluded from effectiveness testing recognized in earnings based on an amortization approach</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Derivative Financial Instruments in Fair Value Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>392</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>813</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Hedged item</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(392</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(813</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Hedged item</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>240</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:18px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">The portion of foreign exchange contracts excluded from the assessment of hedge effectiveness</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>176</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign currency short-term borrowings</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign currency long-term debt</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(51</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(124</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">All other net</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(51</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(124</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>139</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>188</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>251</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>398</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">OID = Other (income)/deductions&#8212;net, included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:inherit;font-size:8pt;"> in the condensed consolidated statements of income</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">.</span><span style="font-family:inherit;font-size:8pt;"> COS = Cost of Sales, included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:8pt;"> in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other comprehensive loss&#8211;&#8211;Unrealized holding gains/(losses) on derivative financial instruments, net</span><span style="font-family:inherit;font-size:8pt;">. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the gains and losses are included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other comprehensive loss&#8211;&#8211;Foreign currency translation adjustments, net.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The amounts reclassified from OCI into COS were:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:12px;"><div style="line-height:120%;font-size:8pt;text-indent:-12px;"><span style="font-family:inherit;font-size:8pt;">a net </span><span style="font-family:inherit;font-size:8pt;">gain</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;"><span>$80 million</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:12px;"><div style="line-height:120%;font-size:8pt;text-indent:-12px;"><span style="font-family:inherit;font-size:8pt;">a net </span><span style="font-family:inherit;font-size:8pt;">gain</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;"><span>$150 million</span></span><span style="font-family:inherit;font-size:8pt;"> in the first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:12px;"><div style="line-height:120%;font-size:8pt;text-indent:-12px;"><span style="font-family:inherit;font-size:8pt;">a net </span><span style="font-family:inherit;font-size:8pt;">gain</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;"><span>$59 million</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:12px;"><div style="line-height:120%;font-size:8pt;text-indent:-12px;"><span style="font-family:inherit;font-size:8pt;">a net </span><span style="font-family:inherit;font-size:8pt;">gain</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;"><span>$103 million</span></span><span style="font-family:inherit;font-size:8pt;"> in the first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax </span><span style="font-family:inherit;font-size:8pt;">gain</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;"><span>$102 million</span></span><span style="font-family:inherit;font-size:8pt;"> within the next 12 months into income</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">. </span><span style="font-family:inherit;font-size:8pt;">The maximum length of time over which we are hedging future foreign exchange cash flow relates to our </span><span style="font-family:inherit;font-size:8pt;"><span>$1.8 billion</span></span><span style="font-family:inherit;font-size:8pt;"> U.K. pound debt maturing in 2043.</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The amounts reclassified from OCI were reclassified into OID.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Long-term debt includes foreign currency long-term borrowings with carrying values of </span><span style="font-family:inherit;font-size:8pt;"><span>$2.0 billion</span></span><span style="font-family:inherit;font-size:8pt;"> as of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, which are used as hedging instruments in net investment hedges.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Total Amount of Each Income and Expense Line in which Results of Fair Value Hedges are Recorded</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:26%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:1px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the amounts recorded in our condensed consolidated balance sheet related to cumulative basis adjustments for fair value hedges:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to </span></div><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to </span></div><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Carrying Amount</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Carrying Amount of Hedged Assets/Liabilities</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Active Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Discontinued Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Carrying Amount of Hedged Assets/Liabilities</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Active Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Discontinued Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,023</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,181</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7,092</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>266</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>690</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269825-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269820-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative assets at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41620-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41638-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41678-113959<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41641-113959<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818719962136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Components of Inventories, Current</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inventories</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,002</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,750</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,810</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,743</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials and supplies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>752</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>790</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inventories</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,564</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,283</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncurrent inventories not included above</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>962</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>714</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The change from </span><span style="font-family:inherit;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:8pt;"> reflects increases for certain products, including inventory build for new product launches, network strategy and market demand, partially offset by a decrease due to foreign exchange.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other noncurrent assets</span><span style="font-family:inherit;font-size:8pt;">. There are no recoverability issues associated with these amounts.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock', window );">Schedule of Components of Inventories, Noncurrent</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inventories</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,002</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,750</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,810</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,743</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials and supplies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>752</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>790</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inventories</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,564</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,283</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncurrent inventories not included above</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>962</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>714</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The change from </span><span style="font-family:inherit;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:8pt;"> reflects increases for certain products, including inventory build for new product launches, network strategy and market demand, partially offset by a decrease due to foreign exchange.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other noncurrent assets</span><span style="font-family:inherit;font-size:8pt;">. There are no recoverability issues associated with these amounts.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818722175320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identifiable</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets, less</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identifiable</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets, less</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Finite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed technology rights</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,927</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(64,683</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,244</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,730</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(63,106</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,625</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brands</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>922</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(757</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>165</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>922</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(741</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>181</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing agreements and other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,327</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,226</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,101</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,772</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,191</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>582</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93,176</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(66,667</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,509</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91,425</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(65,037</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,387</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Indefinite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brands</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,991</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,991</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,991</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,991</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,518</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,518</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,919</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,919</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing agreements</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#160;</sup></span><span style="font-family:inherit;font-size:10pt;">and other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>523</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>523</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,073</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,073</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,032</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,032</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,983</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,983</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100,208</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(66,667</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,541</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100,408</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(65,037</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,370</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The changes in the gross carrying amount of </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8pt;"> primarily reflect the transfer of </span><span style="font-family:inherit;font-size:8pt;"><span>$1.4 billion</span></span><span style="font-family:inherit;font-size:8pt;"> from </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8pt;"> to </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8pt;"> to reflect the approval of Braftovi in combination with Erbitux</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:inherit;font-size:8pt;"> (cetuximab), for the treatment of BRAF</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">V600E</sup></span><span style="font-family:inherit;font-size:8pt;">-mutant metastatic colorectal cancer after prior therapy.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The changes in the gross carrying amount of </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Licensing agreements and other</span><span style="font-family:inherit;font-size:8pt;"> primarily reflect the transfer of </span><span style="font-family:inherit;font-size:8pt;"><span>$550 million</span></span><span style="font-family:inherit;font-size:8pt;"> from Indefinite-lived </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Licensing agreements and other</span><span style="font-family:inherit;font-size:8pt;"> to finite-lived </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Licensing agreements and other</span><span style="font-family:inherit;font-size:8pt;"> to reflect the approval in the U.S. of several products subject to out-licensing arrangements acquired from Array.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The </span><span style="font-family:inherit;font-size:8pt;">decrease</span><span style="font-family:inherit;font-size:8pt;"> in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">I</span><span style="font-family:inherit;font-size:8pt;font-style:italic;text-align:right;">dentifiable intangible assets, less accumulated amortization</span><span style="font-family:inherit;font-size:8pt;text-align:right;">, </span><span style="font-family:inherit;font-size:8pt;">is primarily due to amortization.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Indefinite Lived Intangible Assets</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identifiable</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets, less</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identifiable</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets, less</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Finite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed technology rights</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,927</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(64,683</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,244</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,730</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(63,106</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,625</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brands</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>922</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(757</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>165</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>922</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(741</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>181</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing agreements and other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,327</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,226</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,101</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,772</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,191</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>582</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93,176</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(66,667</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,509</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91,425</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(65,037</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,387</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Indefinite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brands</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,991</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,991</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,991</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,991</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,518</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,518</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,919</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,919</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing agreements</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#160;</sup></span><span style="font-family:inherit;font-size:10pt;">and other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>523</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>523</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,073</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,073</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,032</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,032</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,983</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,983</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100,208</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(66,667</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,541</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100,408</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(65,037</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,370</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The changes in the gross carrying amount of </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8pt;"> primarily reflect the transfer of </span><span style="font-family:inherit;font-size:8pt;"><span>$1.4 billion</span></span><span style="font-family:inherit;font-size:8pt;"> from </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8pt;"> to </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8pt;"> to reflect the approval of Braftovi in combination with Erbitux</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:inherit;font-size:8pt;"> (cetuximab), for the treatment of BRAF</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">V600E</sup></span><span style="font-family:inherit;font-size:8pt;">-mutant metastatic colorectal cancer after prior therapy.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The changes in the gross carrying amount of </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Licensing agreements and other</span><span style="font-family:inherit;font-size:8pt;"> primarily reflect the transfer of </span><span style="font-family:inherit;font-size:8pt;"><span>$550 million</span></span><span style="font-family:inherit;font-size:8pt;"> from Indefinite-lived </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Licensing agreements and other</span><span style="font-family:inherit;font-size:8pt;"> to finite-lived </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Licensing agreements and other</span><span style="font-family:inherit;font-size:8pt;"> to reflect the approval in the U.S. of several products subject to out-licensing arrangements acquired from Array.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The </span><span style="font-family:inherit;font-size:8pt;">decrease</span><span style="font-family:inherit;font-size:8pt;"> in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">I</span><span style="font-family:inherit;font-size:8pt;font-style:italic;text-align:right;">dentifiable intangible assets, less accumulated amortization</span><span style="font-family:inherit;font-size:8pt;text-align:right;">, </span><span style="font-family:inherit;font-size:8pt;">is primarily due to amortization.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock', window );">Identifiable Intangible Assets as a Percentage of Total Identifiable Intangible Assets Less Accumulated Amortization, By Segment</a></td>
<td class="text"><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Biopharma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">WRDM</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed technology rights</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>99</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brands, finite-lived</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brands, indefinite-lived</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing agreements and other, finite-lived</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>99</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing agreements and other, indefinite-lived</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of and changes in the carrying amount of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Biopharma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,202</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,451</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,653</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(155</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(49</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(204</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,047</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,401</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,449</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Primarily represents the impact of foreign exchange.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Identifiable intangible assets as a percentage of total identifiable intangible assets less accumulated amortization, by segment [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818804889512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Schedule of Net Periodic Benefit Costs</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.635477582846%;border-collapse:collapse;text-align:left;"><tr><td colspan="33"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td colspan="33" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of net periodic benefit cost/(credit):</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S.</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Supplemental</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Postretirement</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>131</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>157</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expected return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(251</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(223</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(75</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(80</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Actuarial losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prior service credits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(43</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(45</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Special termination benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net periodic benefit cost/(credit) reported in income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(83</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(30</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(23</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td colspan="33" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S.</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Supplemental</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Postretirement</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>262</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>315</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>109</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expected return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(503</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(445</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(153</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(160</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Actuarial losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prior service credits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(86</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(89</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Special termination benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net periodic benefit cost/(credit) reported in income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(159</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(55</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(60</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(46</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the amounts we contributed, and the amounts we expect to contribute during 2020, to our pension and postretirement plans from our general assets for the periods indicated:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S. Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S. Supplemental (Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Postretirement Plans</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Contributions from our general assets for the six months ended June 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>116</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Expected contributions from our general assets during 2020</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1,253</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>183</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>185</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>137</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock', window );">Schedule of Employer Contributions to Pension and Postretirement Plans</a></td>
<td class="text"><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the amounts we contributed, and the amounts we expect to contribute during 2020, to our pension and postretirement plans from our general assets for the periods indicated:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S. Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S. Supplemental (Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Postretirement Plans</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Contributions from our general assets for the six months ended June 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>116</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Expected contributions from our general assets during 2020</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1,253</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>183</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>185</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>137</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Contributions expected to be made for </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> are inclusive of amounts contributed during the </span><span style="font-family:inherit;font-size:8pt;">six months ended June 28, 2020</span><span style="font-family:inherit;font-size:8pt;">. The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments. For the U.S. qualified plans, we plan to make a </span><span style="font-family:inherit;font-size:8pt;"><span>$1.25 billion</span></span><span style="font-family:inherit;font-size:8pt;"> voluntary contribution in the second half of 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Employer Contributions to Pension and Postretirement Plans [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818719436168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity  - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsDeclaredTableTextBlock', window );">Schedule of Dividends</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:15%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes quarterly cash dividends:</span></div></td></tr><tr><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date Declared</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividend Per</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date Declared</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividend Per Share</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 13, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 6, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.38</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 14, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 1, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 23, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 5, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.38</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 25, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 7, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 25, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.38</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 3, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 24, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 2, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.36</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsDeclaredTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsDeclaredTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818720975016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Common Share Attributable to Common Shareholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Earning Per Share</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the detailed calculation of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">EPS</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(IN MILLIONS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">EPS Numerator&#8211;&#8211;Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,434</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,056</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,845</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,945</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Net income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to Pfizer Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,426</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,046</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,828</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,929</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Preferred stock dividends&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,426</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,045</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,828</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,929</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,426</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,045</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,828</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,929</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">EPS Numerator&#8211;&#8211;Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,426</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,046</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,828</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,929</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,426</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,046</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,828</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,929</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">EPS Denominator</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,554</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,562</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,550</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,598</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common-share equivalents: stock options, stock issuable under employee compensation plans and convertible preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>110</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,619</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,672</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,616</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,711</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Anti-dilutive common stock equivalents</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818804889512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Revenue from Segments to Consolidated</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides selected income statement information by reportable segment:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Earnings</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reportable Segments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Biopharma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>9,795</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>9,432</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>6,650</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>6,071</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>2,006</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>2,970</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>1,168</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>1,973</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Total reportable segments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>11,801</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>12,402</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>7,818</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>8,044</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other business activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>862</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,530</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,193</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reconciling Items:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Corporate and other unallocated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,136</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,399</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Purchase accounting adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(910</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,178</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>176</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Certain significant items</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(268</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(309</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>11,801</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>13,264</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>3,953</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>4,141</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Earnings</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reportable Segments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Biopharma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>19,802</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>18,477</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>13,379</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>11,954</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>4,027</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>6,184</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>2,359</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>4,251</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Total reportable segments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>23,829</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>24,661</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>15,738</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>16,206</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other business activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>1,721</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(3,019</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(2,306</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reconciling Items:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Corporate and other unallocated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(2,245</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(2,676</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Purchase accounting adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,722</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(2,217</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>148</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Certain significant items</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(879</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(691</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>23,829</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>26,382</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>7,838</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>8,463</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="font-family:inherit;font-size:8pt;">. Biopharma&#8217;s earnings </span><span style="font-family:inherit;font-size:8pt;text-align:center;">include d</span><span style="font-family:inherit;font-size:8pt;">ividend income of </span><span style="font-family:inherit;font-size:8pt;"><span>$76 million</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$76&#160;million</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:8pt;">, and </span><span style="font-family:inherit;font-size:8pt;"><span>$153 million</span></span><span style="font-family:inherit;font-size:8pt;"> in </span><span style="font-family:inherit;font-size:8pt;">the first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$140 million</span></span><span style="font-family:inherit;font-size:8pt;"> in </span><span style="font-family:inherit;font-size:8pt;">the first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:8pt;"> from our investment in ViiV. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Operating Profit (Loss) from Segments to Consolidated</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides selected income statement information by reportable segment:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Earnings</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reportable Segments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Biopharma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>9,795</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>9,432</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>6,650</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>6,071</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>2,006</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>2,970</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>1,168</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>1,973</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Total reportable segments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>11,801</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>12,402</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>7,818</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>8,044</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other business activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>862</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,530</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,193</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reconciling Items:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Corporate and other unallocated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,136</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,399</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Purchase accounting adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(910</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,178</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>176</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Certain significant items</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(268</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(309</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>11,801</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>13,264</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>3,953</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>4,141</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Earnings</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reportable Segments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Biopharma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>19,802</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>18,477</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>13,379</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>11,954</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>4,027</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>6,184</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>2,359</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>4,251</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Total reportable segments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>23,829</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>24,661</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>15,738</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>16,206</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other business activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>1,721</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(3,019</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(2,306</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reconciling Items:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Corporate and other unallocated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(2,245</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(2,676</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Purchase accounting adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,722</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(2,217</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>148</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Certain significant items</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;color:#2c2c2c;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(879</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(691</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>23,829</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>26,382</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>7,838</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>8,463</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="font-family:inherit;font-size:8pt;">. Biopharma&#8217;s earnings </span><span style="font-family:inherit;font-size:8pt;text-align:center;">include d</span><span style="font-family:inherit;font-size:8pt;">ividend income of </span><span style="font-family:inherit;font-size:8pt;"><span>$76 million</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$76&#160;million</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:8pt;">, and </span><span style="font-family:inherit;font-size:8pt;"><span>$153 million</span></span><span style="font-family:inherit;font-size:8pt;"> in </span><span style="font-family:inherit;font-size:8pt;">the first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$140 million</span></span><span style="font-family:inherit;font-size:8pt;"> in </span><span style="font-family:inherit;font-size:8pt;">the first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:8pt;"> from our investment in ViiV. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenues by Geographic Region</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides revenues by geographic area:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,402</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,335</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,053</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,510</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed Europe</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,088</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,009</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,315</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed Rest of World</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,552</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,639</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,008</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,174</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging Markets</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,759</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,062</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,759</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,383</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,801</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,264</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,829</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,382</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.</span><span style="font-family:inherit;font-size:8pt;"> Revenues denominated in euros were </span><span style="font-family:inherit;font-size:8pt;"><span>$1.7 billion</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$1.8 billion</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:8pt;">, and were </span><span style="font-family:inherit;font-size:8pt;"><span>$3.2 billion</span></span><span style="font-family:inherit;font-size:8pt;"> in </span><span style="font-family:inherit;font-size:8pt;">the first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$3.5 billion</span></span><span style="font-family:inherit;font-size:8pt;"> in </span><span style="font-family:inherit;font-size:8pt;">the first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:8pt;text-align:center;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Significant Product Revenues</a></td>
<td class="text"><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides detailed revenue information for several of our major products:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:38%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">PRODUCT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">PRIMARY INDICATION OR CLASS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">TOTAL REVENUES</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>11,801</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>13,264</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>23,829</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>26,382</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>9,795</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>9,432</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>19,802</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>18,477</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Internal Medicine</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>2,279</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>2,243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>4,610</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>4,380</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Eliquis alliance revenues and direct sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,272</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,085</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>2,572</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>2,096</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Chantix/Champix</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">An aid to smoking cessation treatment in adults 18 years of age or older</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>235</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>276</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>505</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>549</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Premarin family</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Symptoms of menopause</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>152</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>193</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>304</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>361</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">BMP2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Development of bone and cartilage</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Toviaz</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Overactive bladder</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>124</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>125</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other Internal Medicine</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>498</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>544</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>978</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,103</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Oncology</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>2,647</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>2,236</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>5,082</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>4,198</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Ibrance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Metastatic breast cancer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,349</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,261</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>2,598</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>2,394</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Xtandi alliance revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Non-metastatic and metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>266</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>201</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>475</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>369</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Sutent</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>248</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>414</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>480</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Inlyta</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Advanced RCC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>104</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>364</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>177</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Xalkori</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">ALK-positive and ROS1-positive advanced NSCLC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>138</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>287</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>255</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Bosulif</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Philadelphia&#160;chromosome&#8211;positive&#160;chronic myelogenous leukemia</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>213</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>177</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Retacrit</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Anemia</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>87</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>176</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Braftovi</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">In combination with Mektovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation and, in combination with Erbitux</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:7.5pt;">&#160;(cetuximab), for the treatment of BRAF</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">V600E</sup></span><span style="font-family:inherit;font-size:7.5pt;">-mutant metastatic colorectal cancer after prior therapy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Mektovi</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">In combination with Braftovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other Oncology</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>221</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>412</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>262</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Hospital</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a), (c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>1,794</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>1,838</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>3,807</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>3,665</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Sulperazon</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Bacterial infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>165</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>289</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>342</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Medrol</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Anti-inflammatory glucocorticoid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>207</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>240</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Zithromax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Bacterial infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>193</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>177</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Precedex</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Sedation agent in surgery or intensive care</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>156</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Vfend</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Fungal infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>149</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>178</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Panzyga</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Primary humoral immunodeficiency</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:38%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">PRODUCT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">PRIMARY INDICATION OR CLASS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June&#160;28, <br/>2020</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Zyvox</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Bacterial infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>125</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>134</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Fragmin</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Treatment/prevention of venous thromboembolism</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>123</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:7.5pt;">Pfizer CentreOne</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>204</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>376</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>380</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other Anti-infectives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>367</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>420</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>811</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>825</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:7.5pt;">All other Hospital</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>603</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>544</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,245</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,124</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Vaccines</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>1,247</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>1,375</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>2,857</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>2,988</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Prevnar 13/Prevenar 13</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Pneumococcal disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,116</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,179</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>2,566</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>2,665</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Nimenrix</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Meningococcal disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>130</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other Vaccines</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>138</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>161</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>215</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Inflammation &amp; Immunology (I&amp;I)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>1,149</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>1,219</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>2,127</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>2,256</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Xeljanz</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">RA, PsA, UC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>635</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>613</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,086</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,036</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Enbrel (Outside the U.S. and Canada)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>337</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>420</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>684</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>871</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Inflectra/Remsima</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Crohn&#8217;s disease, pediatric Crohn&#8217;s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>153</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>308</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>291</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other I&amp;I</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Rare Disease</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>681</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>521</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>1,319</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>991</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Vyndaqel/Vyndamax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">ATTR-cardiomyopathy and polyneuropathy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>277</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>508</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>104</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">BeneFIX</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Hemophilia B</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>109</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>121</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>230</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>247</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Genotropin</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Replacement of human growth hormone</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>106</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>125</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>232</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Refacto AF/Xyntha</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Hemophilia A</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>108</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>181</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>214</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Somavert</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Acromegaly</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>67</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>131</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other Rare Disease</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>61</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>66</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">UPJOHN</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>2,006</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>2,970</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>4,027</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>6,184</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Lipitor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Reduction of LDL cholesterol</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>431</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>407</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>836</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,029</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Lyrica</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>349</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,175</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>706</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>2,362</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Norvasc</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Hypertension</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>216</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>419</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>516</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Celebrex</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Arthritis pain and inflammation, acute pain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>139</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>174</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>295</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>347</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Viagra</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Erectile dysfunction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>259</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Effexor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Depression and certain anxiety disorders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>163</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>163</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Zoloft</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Depression and certain anxiety disorders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>157</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>143</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:7.5pt;">EpiPen</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Epinephrine injection used in treatment of life-threatening allergic reactions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>67</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>123</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Xalatan/Xalacom</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Glaucoma and ocular hypertension</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>587</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>968</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>1,109</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">CONSUMER HEALTHCARE BUSINESS</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>862</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>1,721</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Total Alliance revenues</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>1,404</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>1,187</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>2,786</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>2,277</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Total Biosimilars</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>289</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>217</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>578</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>396</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Total Sterile Injectable Pharmaceuticals</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(f)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>1,237</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>1,218</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>2,644</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span>2,455</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan).</span><span style="font-family:inherit;font-size:7.5pt;"> As a result, revenues associated with our Meridian subsidiary, except for product revenues for EpiPen sold in Canada, and Mylan-Japan, are reported in our Upjohn business beginning in the first quarter of 2020. We have reclassified revenues associated with our Meridian subsidiary and Mylan-Japan from the Hospital and Internal Medicine categories to the Upjohn business to conform 2019 product revenues to the current presentation.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. Hospital also includes Pfizer CentreOne</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span><span style="font-family:inherit;font-size:7.5pt;">. All other Hospital primarily includes revenues from legacy Sterile Injectables Pharmaceuticals (SIP) products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in &#8220;All other Anti-infectives&#8221;.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">On </span><span style="font-family:inherit;font-size:7.5pt;">July&#160;31, 2019</span><span style="font-family:inherit;font-size:7.5pt;">, Pfizer&#8217;s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK&#8217;s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Note 2B</span><span style="font-family:inherit;font-size:7.5pt;">.</span></div></td></tr></table><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(f)</sup>&#160;</span></div><div style="line-height:120%;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818804573432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>Operating_Segment</div>
</th>
<th class="th">
<div>Jun. 28, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2020 </div>
<div>Accounting_standard</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>Accounting_standard</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segments | Operating_Segment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_NumberOfAccountingStandardsAdopted', window );">Number of accounting standards adopted | Accounting_standard</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RebatesAndDiscountsAccrual', window );">Accrued rebates and other accruals | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_NumberOfAccountingStandardsAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Accounting Standards Adopted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_NumberOfAccountingStandardsAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RebatesAndDiscountsAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RebatesAndDiscountsAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818723106072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ScheduleOfAccruedLiabilitiesLineItems', window );"><strong>Schedule Of Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RebatesAndDiscountsAccrual', window );">Accrued rebates and other accruals</a></td>
<td class="nump">$ 5,512<span></span>
</td>
<td class="nump">$ 5,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Trade accounts receivable, less allowance for doubtful accounts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ScheduleOfAccruedLiabilitiesLineItems', window );"><strong>Schedule Of Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RebatesAndDiscountsAccrual', window );">Accrued rebates and other accruals</a></td>
<td class="nump">1,129<span></span>
</td>
<td class="nump">1,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other current liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ScheduleOfAccruedLiabilitiesLineItems', window );"><strong>Schedule Of Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AccruedRebates', window );">Accrued rebates</a></td>
<td class="nump">3,210<span></span>
</td>
<td class="nump">3,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherAccruals', window );">Other accruals</a></td>
<td class="nump">576<span></span>
</td>
<td class="nump">581<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other noncurrent liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ScheduleOfAccruedLiabilitiesLineItems', window );"><strong>Schedule Of Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RebatesAndDiscountsAccrual', window );">Accrued rebates and other accruals</a></td>
<td class="nump">$ 598<span></span>
</td>
<td class="nump">$ 565<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AccruedRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Rebates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AccruedRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Accruals</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RebatesAndDiscountsAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RebatesAndDiscountsAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ScheduleOfAccruedLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Schedule Of Accrued Liabilities [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ScheduleOfAccruedLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818722142936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisition, Equity-Method Investment and Licensing Arrangements  - Array BioPharma (Details) - Array [Member]<br> $ / shares in Units, $ in Billions</strong></div></th>
<th class="th">
<div>Jul. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, per share in cash (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments for acquisition, cash portion</a></td>
<td class="nump">$ 11.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of business, net of cash acquired</a></td>
<td class="nump">$ 10.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818804512488">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Acquisition, Equity-Method Investment and Licensing Arrangements  - Equity Method Investment Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Sep. 29, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on completion of Consumer Healthcare JV transaction</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity-method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 15,578<span></span>
</td>
<td class="nump">15,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember', window );">GSK Consumer Healthcare [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on completion of Consumer Healthcare JV transaction</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeconsolidationGainLossAmountNetOfTax', window );">Gain on completion of Consumer Healthcare JV transaction, after-tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity-method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,400<span></span>
</td>
<td class="nump">15,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity method investment earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Fair value of equity method investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets', window );">Underlying equity in net assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="nump">11,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Difference between carrying amount and underlying equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation', window );">Decrease due to foreign currency translation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Dividend received</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pfe_GSKMember', window );">GSK [Member] | GSK Consumer Healthcare [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">OID [Member] | GSK Consumer Healthcare [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquityMethodInvestmentExcessBasisAmortization', window );">Excess basis amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_ConsumerHealthcareMember', window );">Consumer Healthcare [Member] | Held-for-sale [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss', window );">Pre-tax income attributable to disposal group</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | GSK Consumer Healthcare [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod', window );">Excess basis amortization period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | GSK Consumer Healthcare [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod', window );">Excess basis amortization period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:53px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeconsolidationGainLossAmountNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deconsolidation, Gain (Loss), Amount, Net Of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeconsolidationGainLossAmountNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Not Discontinued Operation, Pre-tax Income (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquityMethodInvestmentExcessBasisAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Excess Basis Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquityMethodInvestmentExcessBasisAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Excess Basis Amortization, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Increase (Decrease), Foreign Currency Translation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's ownership percentage in the investee multiplied by the investee's total equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investments accounted under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117311354&amp;loc=d3e32014-111567<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pfe_GSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pfe_GSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_ConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_ConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818805425784">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Acquisition, Equity-Method Investment and Licensing Arrangements  - Schedule of Equity-Method Investment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="4">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th" colspan="2"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 46,424<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,424<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,803<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">177,934<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,934<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,489<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">32,723<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,723<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,304<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">113,370<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,370<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,042<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity attributable to shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">64,336<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,336<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,143<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Equity attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">228<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">64,564<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,924<span></span>
</td>
<td class="nump">64,564<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,924<span></span>
</td>
<td class="nump">$ 65,338<span></span>
</td>
<td class="nump">$ 63,447<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 59,158<span></span>
</td>
<td class="nump">$ 63,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">3,434<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,056<span></span>
</td>
<td class="nump">6,845<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income before allocation to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3],[4],[5]</sup></td>
<td class="nump">3,434<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,056<span></span>
</td>
<td class="nump">6,845<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Income attributable to shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 3,426<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,046<span></span>
</td>
<td class="nump">$ 6,828<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=pfe_GSKConsumerHealthcareMember', window );">GSK Consumer Healthcare [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 8,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 8,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">37,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">37,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">45,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">45,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Noncurrent liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity attributable to shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">35,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">35,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Equity attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">35,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">35,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,394)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,205)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income before allocation to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Income attributable to shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="14"></td></tr>
<tr><td colspan="14"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:266px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:53px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:13px;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:20px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=pfe_GSKConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=pfe_GSKConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818723467656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition, Equity-Method Investment and Licensing Arrangements - Valneva SE (Details) - Licensing Agreements [Member] - Valneva SE [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1', window );">Maximum potential cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure', window );">Potential development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure', window );">Potential early commercialization milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage', window );">Valneva's development cost ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentForLicensingArrangement', window );">Upfront payment for licensing arrangement</a></td>
<td class="nump">$ 130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentForLicensingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment For Licensing Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentForLicensingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Collaborator's Development Cost Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Commercialization Milestones, Maximum Exposure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contingent Payments, Maximum Exposure1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Development Milestone, Maximum Exposure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_ValnevaSEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_ValnevaSEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818722817896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition, Equity-Method Investment and Licensing Arrangements - BioNTech SE (Details) - Licensing Agreements [Member] - BioNTech SE [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 09, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LicensingArrangementValueOfSharesPurchased', window );">Value of shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure', window );">Potential future milestone payments</a></td>
<td class="nump">$ 563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1', window );">Maximum potential cash payments</a></td>
<td class="nump">$ 748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed', window );">Research and development arrangement, percentage of costs to be reimbursed</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentForLicensingArrangement', window );">Upfront payment for licensing arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LicensingArrangementValueOfSharesPurchased', window );">Value of shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LicensingArrangementValueOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licensing Arrangement, Value Of Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LicensingArrangementValueOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentForLicensingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment For Licensing Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentForLicensingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contingent Payments, Maximum Exposure1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Future Milestone Payments, Maximum Exposure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Percentage of Costs to be Reimbursed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_BioNTechSEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_BioNTechSEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818717819608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pfe_FocusedCompanyPlanMember', window );">Focused Company Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected restructuring cost</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs incurred</a></td>
<td class="nump">566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">549<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember', window );">2017-2019 Initiatives and Organizing for Growth [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pfe_ManufacturingCostReductionMember', window );">Manufacturing Cost Reduction [Member] | Focused Company Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected restructuring cost</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringandRelatedCostNoncashChargesPercentage', window );">Percentage of expected costs to be non-cash</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pfe_BusinessIntegrationCostsMember', window );">Business Integration Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(199)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pfe_BusinessIntegrationCostsMember', window );">Business Integration Costs [Member] | Hospira [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringandRelatedCostNoncashChargesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Noncash Charges, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringandRelatedCostNoncashChargesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=pfe_FocusedCompanyPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=pfe_FocusedCompanyPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pfe_ManufacturingCostReductionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pfe_ManufacturingCostReductionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pfe_BusinessIntegrationCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pfe_BusinessIntegrationCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818804764088">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee terminations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 346<span></span>
</td>
<td class="num">$ (166)<span></span>
</td>
<td class="nump">$ 371<span></span>
</td>
<td class="num">$ (167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringAssetImpairmentCharges', window );">Asset impairments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Exit costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges/(credits)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">340<span></span>
</td>
<td class="num">(144)<span></span>
</td>
<td class="nump">396<span></span>
</td>
<td class="num">(134)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts', window );">Transaction costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">11<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Integration costs and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">11<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringChargesAndAcquisitionRelatedCosts', window );">Restructuring charges and certain acquisition-related costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">362<span></span>
</td>
<td class="num">(115)<span></span>
</td>
<td class="nump">431<span></span>
</td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Additional depreciation&#8211;&#8211;asset restructuring recorded in our condensed consolidated statements of income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">6<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCostAbstract', window );"><strong>Implementation costs recorded in our condensed consolidated statements of income as follows:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCosts', window );">Implementation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">75<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts', window );">Total costs associated with acquisitions and cost-reduction/productivity initiatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">449<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="nump">566<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other (income)/deductions&#8211;&#8211;net [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit costs recorded in Other (income)/deductions&#8211;&#8211;net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Additional depreciation&#8211;&#8211;asset restructuring recorded in our condensed consolidated statements of income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">4<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCostAbstract', window );"><strong>Implementation costs recorded in our condensed consolidated statements of income as follows:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCosts', window );">Implementation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">11<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, informational and administrative expenses [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Additional depreciation&#8211;&#8211;asset restructuring recorded in our condensed consolidated statements of income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCostAbstract', window );"><strong>Implementation costs recorded in our condensed consolidated statements of income as follows:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCosts', window );">Implementation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">63<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Additional depreciation&#8211;&#8211;asset restructuring recorded in our condensed consolidated statements of income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCostAbstract', window );"><strong>Implementation costs recorded in our condensed consolidated statements of income as follows:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCosts', window );">Implementation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first six months of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, restructuring charges mainly represent employee termination costs associated with our Transforming to a More Focused Company cost reduction program. In the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">, restructuring credits mostly represent the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of an IRS audit for multiple tax years. See Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 5D. Tax Matters: Tax Contingencies </span><span style="font-family:inherit;font-size:8pt;">in our 2019 Financial Report.</span></div><div style="line-height:120%;padding-bottom:1px;padding-top:2px;padding-left:24px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The restructuring activities for </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, Biopharma (</span><span style="font-family:inherit;font-size:8pt;"><span>$12 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); Upjohn (</span><span style="font-family:inherit;font-size:8pt;"><span>$1 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); and Other (</span><span style="font-family:inherit;font-size:8pt;"><span>$352 million</span></span><span style="font-family:inherit;font-size:8pt;"> charge).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, Biopharma (</span><span style="font-family:inherit;font-size:8pt;"><span>$9 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); Upjohn (</span><span style="font-family:inherit;font-size:8pt;"><span>$12 million</span></span><span style="font-family:inherit;font-size:8pt;"> charge); and Other (</span><span style="font-family:inherit;font-size:8pt;"><span>$393 million</span></span><span style="font-family:inherit;font-size:8pt;"> charge).</span></div></td></tr></table><div style="line-height:120%;padding-bottom:1px;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The restructuring activities for </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">, Biopharma (</span><span style="font-family:inherit;font-size:8pt;"><span>$62 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); Upjohn (</span><span style="font-family:inherit;font-size:8pt;"><span>$9 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); and Other (</span><span style="font-family:inherit;font-size:8pt;"><span>$74 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">, Biopharma (</span><span style="font-family:inherit;font-size:8pt;"><span>$48 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); Upjohn (</span><span style="font-family:inherit;font-size:8pt;"><span>$22 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); and Other (</span><span style="font-family:inherit;font-size:8pt;"><span>$63 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit).</span></div></td></tr></table><div style="line-height:120%;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Restructuring costs identified as Other are for restructuring activities associated with corporate enabling functions, WRDM, GPD and other manufacturing and commercial operations, as applicable. For the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, restructuring costs identified as Other primarily relate to corporate enabling functions.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Transaction costs represent external costs for banking, legal, accounting and other similar services.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Integration costs and other represent external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, integration costs and other were mostly related to our acquisition of Array. In the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">, integration costs and other were primarily related to our acquisition of Hospira.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:53px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Additional depreciation&#8211;&#8211;asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents external costs directly related to effecting a business combination which costs have been expensed during the period. Such costs include advisory, legal, accounting, valuation, and other similar services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ImplementationCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Implementation Cost [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ImplementationCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ImplementationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Implementation costs represent external, incremental costs directly related to Implementing cost-reduction initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ImplementationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring, Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges, Acquisition Related Costs and Implementation Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringChargesAndAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringChargesAndAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAcceleratedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAcceleratedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818723662152">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Footnotes (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charge (credit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 340<span></span>
</td>
<td class="num">$ (144)<span></span>
</td>
<td class="nump">$ 396<span></span>
</td>
<td class="num">$ (134)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charge (credit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">352<span></span>
</td>
<td class="num">(74)<span></span>
</td>
<td class="nump">393<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember', window );">Biopharma [Member] | Operating Segments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charge (credit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember', window );">Upjohn [Member] | Operating Segments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charge (credit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="num">$ (22)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first six months of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, restructuring charges mainly represent employee termination costs associated with our Transforming to a More Focused Company cost reduction program. In the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">, restructuring credits mostly represent the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of an IRS audit for multiple tax years. See Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 5D. Tax Matters: Tax Contingencies </span><span style="font-family:inherit;font-size:8pt;">in our 2019 Financial Report.</span></div><div style="line-height:120%;padding-bottom:1px;padding-top:2px;padding-left:24px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The restructuring activities for </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, Biopharma (</span><span style="font-family:inherit;font-size:8pt;"><span>$12 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); Upjohn (</span><span style="font-family:inherit;font-size:8pt;"><span>$1 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); and Other (</span><span style="font-family:inherit;font-size:8pt;"><span>$352 million</span></span><span style="font-family:inherit;font-size:8pt;"> charge).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, Biopharma (</span><span style="font-family:inherit;font-size:8pt;"><span>$9 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); Upjohn (</span><span style="font-family:inherit;font-size:8pt;"><span>$12 million</span></span><span style="font-family:inherit;font-size:8pt;"> charge); and Other (</span><span style="font-family:inherit;font-size:8pt;"><span>$393 million</span></span><span style="font-family:inherit;font-size:8pt;"> charge).</span></div></td></tr></table><div style="line-height:120%;padding-bottom:1px;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The restructuring activities for </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">, Biopharma (</span><span style="font-family:inherit;font-size:8pt;"><span>$62 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); Upjohn (</span><span style="font-family:inherit;font-size:8pt;"><span>$9 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); and Other (</span><span style="font-family:inherit;font-size:8pt;"><span>$74 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">, Biopharma (</span><span style="font-family:inherit;font-size:8pt;"><span>$48 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); Upjohn (</span><span style="font-family:inherit;font-size:8pt;"><span>$22 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); and Other (</span><span style="font-family:inherit;font-size:8pt;"><span>$63 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit).</span></div></td></tr></table><div style="line-height:120%;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Restructuring costs identified as Other are for restructuring activities associated with corporate enabling functions, WRDM, GPD and other manufacturing and commercial operations, as applicable. For the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, restructuring costs identified as Other primarily relate to corporate enabling functions.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818812956696">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, December 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 340<span></span>
</td>
<td class="num">$ (144)<span></span>
</td>
<td class="nump">396<span></span>
</td>
<td class="num">$ (134)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(378)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, June 28, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Termination Costs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, December 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(341)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, June 28, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pfe_AssetImpairmentsMember', window );">Asset Impairment Charges [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, December 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, June 28, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Exit Costs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, December 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, June 28, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:8pt;"> (</span><span style="font-family:inherit;font-size:8pt;"><span>$714 million</span></span><span style="font-family:inherit;font-size:8pt;">) and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:inherit;font-size:8pt;"> (</span><span style="font-family:inherit;font-size:8pt;"><span>$219 million</span></span><span style="font-family:inherit;font-size:8pt;">).</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first six months of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, restructuring charges mainly represent employee termination costs associated with our Transforming to a More Focused Company cost reduction program. In the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">, restructuring credits mostly represent the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of an IRS audit for multiple tax years. See Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 5D. Tax Matters: Tax Contingencies </span><span style="font-family:inherit;font-size:8pt;">in our 2019 Financial Report.</span></div><div style="line-height:120%;padding-bottom:1px;padding-top:2px;padding-left:24px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The restructuring activities for </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, Biopharma (</span><span style="font-family:inherit;font-size:8pt;"><span>$12 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); Upjohn (</span><span style="font-family:inherit;font-size:8pt;"><span>$1 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); and Other (</span><span style="font-family:inherit;font-size:8pt;"><span>$352 million</span></span><span style="font-family:inherit;font-size:8pt;"> charge).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, Biopharma (</span><span style="font-family:inherit;font-size:8pt;"><span>$9 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); Upjohn (</span><span style="font-family:inherit;font-size:8pt;"><span>$12 million</span></span><span style="font-family:inherit;font-size:8pt;"> charge); and Other (</span><span style="font-family:inherit;font-size:8pt;"><span>$393 million</span></span><span style="font-family:inherit;font-size:8pt;"> charge).</span></div></td></tr></table><div style="line-height:120%;padding-bottom:1px;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The restructuring activities for </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">, Biopharma (</span><span style="font-family:inherit;font-size:8pt;"><span>$62 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); Upjohn (</span><span style="font-family:inherit;font-size:8pt;"><span>$9 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); and Other (</span><span style="font-family:inherit;font-size:8pt;"><span>$74 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">, Biopharma (</span><span style="font-family:inherit;font-size:8pt;"><span>$48 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); Upjohn (</span><span style="font-family:inherit;font-size:8pt;"><span>$22 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit); and Other (</span><span style="font-family:inherit;font-size:8pt;"><span>$63 million</span></span><span style="font-family:inherit;font-size:8pt;"> credit).</span></div></td></tr></table><div style="line-height:120%;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Restructuring costs identified as Other are for restructuring activities associated with corporate enabling functions, WRDM, GPD and other manufacturing and commercial operations, as applicable. For the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">, restructuring costs identified as Other primarily relate to corporate enabling functions.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Includes adjustments for foreign currency translation.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other current liabilities </span><span style="font-family:inherit;font-size:8pt;">(</span><span style="font-family:inherit;font-size:8pt;"><span>$625 million</span></span><span style="font-family:inherit;font-size:8pt;">) and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other noncurrent liabilities </span><span style="font-family:inherit;font-size:8pt;">(</span><span style="font-family:inherit;font-size:8pt;"><span>$326 million</span></span><span style="font-family:inherit;font-size:8pt;">).</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pfe_AssetImpairmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pfe_AssetImpairmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818720934280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2"><div>Jun. 28, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="nump">$ 951<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 933<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="nump">625<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">714<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="nump">$ 326<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 219<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other current liabilities </span><span style="font-family:inherit;font-size:8pt;">(</span><span style="font-family:inherit;font-size:8pt;"><span>$625 million</span></span><span style="font-family:inherit;font-size:8pt;">) and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other noncurrent liabilities </span><span style="font-family:inherit;font-size:8pt;">(</span><span style="font-family:inherit;font-size:8pt;"><span>$326 million</span></span><span style="font-family:inherit;font-size:8pt;">).</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:8pt;"> (</span><span style="font-family:inherit;font-size:8pt;"><span>$714 million</span></span><span style="font-family:inherit;font-size:8pt;">) and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:inherit;font-size:8pt;"> (</span><span style="font-family:inherit;font-size:8pt;"><span>$219 million</span></span><span style="font-family:inherit;font-size:8pt;">).</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818804421880">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (19)<span></span>
</td>
<td class="num">$ (59)<span></span>
</td>
<td class="num">$ (53)<span></span>
</td>
<td class="num">$ (125)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">372<span></span>
</td>
<td class="nump">389<span></span>
</td>
<td class="nump">762<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRevenueExpenseNet', window );">Net interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">353<span></span>
</td>
<td class="nump">330<span></span>
</td>
<td class="nump">709<span></span>
</td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyIncomeNonoperating', window );">Royalty-related income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(191)<span></span>
</td>
<td class="num">(231)<span></span>
</td>
<td class="num">(311)<span></span>
</td>
<td class="num">(320)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Net (gains)/losses on asset disposals</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net gains recognized during the period on equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[4]</sup></td>
<td class="num">(732)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="num">(478)<span></span>
</td>
<td class="num">(147)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights', window );">Income from collaborations, out-licensing arrangements and sales of compound/product rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">(100)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="num">(215)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent', window );">Net periodic benefit credits other than service costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="num">(108)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="num">(175)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Certain legal matters, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Certain asset impairments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessAlignmentCosts', window );">Business and legal entity alignment costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Net losses on early retirement of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization', window );">GSK Consumer Healthcare JV equity method (income)/loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[9]</sup></td>
<td class="num">(126)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(92)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherNonoperatingIncomeExpenseNet', window );">Other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[10]</sup></td>
<td class="nump">25<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(107)<span></span>
</td>
<td class="num">(318)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income)/deductions&#8211;&#8211;net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[11]</sup></td>
<td class="num">$ (862)<span></span>
</td>
<td class="nump">$ 126<span></span>
</td>
<td class="num">$ (641)<span></span>
</td>
<td class="nump">$ 218<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family:inherit;font-size:8pt;">Interest income decreased in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first six months of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;">, primarily driven by a lower investment balance and lower short-term interest rates. Interest expense decreased in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> mainly as a result of the retirement of higher-coupon debt and the issuance of new debt with a lower coupon than the debt outstanding for the comparative prior year period. Interest expense increased in the first six months of </span><span style="font-family:inherit;font-size:8pt;">2020</span>, mainly as a result of an increased commercial paper balance due to the acquisition of Array.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Royalty-related income for the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;">first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> included a one-time favorable resolution in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> of a legal dispute for </span><span style="font-family:inherit;font-size:8pt;"><span>$82 million</span></span><span style="font-family:inherit;font-size:8pt;">.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The gains in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> include, among other things, unrealized gains of </span><span style="font-family:inherit;font-size:8pt;"><span>$508 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to our investment in Allogene and unrealized gains of </span><span style="font-family:inherit;font-size:8pt;"><span>$61 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to our investment in BioNTech. The gains in the first six months of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> include, among other things, unrealized gains of </span><span style="font-family:inherit;font-size:8pt;"><span>$374 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to our investment in Allogene and unrealized gains of </span><span style="font-family:inherit;font-size:8pt;"><span>$127 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to our investment in BioNTech. The gains in the first six months of 2019 included, among other things, unrealized gains of </span><span style="font-family:inherit;font-size:8pt;"><span>$104 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to our investment in Cortexyme, Inc. For additional information on investments, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7B</span><span style="font-family:inherit;font-size:8pt;">.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The net gains on investments in equity securities are reported in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (income)/deductions</span><span style="font-family:inherit;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">net.</span><span style="font-family:inherit;font-size:8pt;"> For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:inherit;font-size:8pt;">.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In the </span><span style="font-family:inherit;font-size:8pt;">second</span><span style="font-family:inherit;font-size:8pt;"> quarter and first six months of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;">, mainly includes, among other things, </span><span style="font-family:inherit;font-size:8pt;"><span>$40 million</span></span><span style="font-family:inherit;font-size:8pt;"> of milestone income from Puma Biotechnology, Inc. related to Neratinib regulatory approvals in the EU, and </span><span style="font-family:inherit;font-size:8pt;"><span>$30 million</span></span><span style="font-family:inherit;font-size:8pt;"> of milestone income from Lilly related to the first commercial sale in the U.S. of LOXO-292 for the treatment of RET fusion-positive NSCLC. The first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> also includes an upfront payment to us of </span><span style="font-family:inherit;font-size:8pt;"><span>$75 million</span></span><span style="font-family:inherit;font-size:8pt;"> from our sale of our CK1 assets to Biogen, Inc. In the first six months of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">, primarily included </span><span style="font-family:inherit;font-size:8pt;"><span>$68 million</span></span><span style="font-family:inherit;font-size:8pt;"> in milestone income from Mylan Pharmaceuticals Inc. related to the FDA&#8217;s approval and launch of Wixela Inhub</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:8pt;">, a generic of Advair Diskus</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:8pt;">.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 10</span><span style="font-family:inherit;font-size:8pt;">.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The first six months of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> included intangible asset impairment charges of: (i) </span><span style="font-family:inherit;font-size:8pt;"><span>$90 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to WRDM IPR&amp;D, for a pre-clinical stage asset from our acquisition of Bamboo for gene therapies for the potential treatment of patients with certain rare diseases, which was the result of a determination to not use certain Bamboo IPR&amp;D acquired in future rare disease development, (ii) </span><span style="font-family:inherit;font-size:8pt;"><span>$40 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to an Upjohn finite-lived developed technology right, acquired in connection with our acquisition of King, for government defense products and reflected, among other things, updated commercial forecasts including manufacturing cost assumptions, and (iii) </span><span style="font-family:inherit;font-size:8pt;"><span>$10 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to a finite-lived developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus marketed in the U.S. market only, </span><span style="font-family:inherit;font-size:8pt;text-align:center;">associated with Biopharma and reflected</span><span style="font-family:inherit;font-size:8pt;">, among other things, updated commercial forecasts. In addition, the first six months of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> included other asset impairments of </span><span style="font-family:inherit;font-size:8pt;"><span>$20 million</span></span><span style="font-family:Arial;font-size:8pt;">.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and first six months of 2019, represents incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[9]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Includes our share of the GSK Consumer Healthcare joint venture&#8217;s earnings and the amortization of basis differences, which resulted from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the joint venture. See </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 2B</span><span style="font-family:inherit;font-size:8pt;"> for additional information.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[10]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> includes, among other things, dividend income of </span><span style="font-family:inherit;font-size:8pt;"><span>$76 million</span></span><span style="font-family:inherit;font-size:8pt;"> from our investment in ViiV, and charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$86 million</span></span><span style="font-family:inherit;font-size:8pt;">, reflecting the change in the fair value of contingent consideration. The first six months of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> includes, among other things, dividend income of </span><span style="font-family:inherit;font-size:8pt;"><span>$153 million</span></span><span style="font-family:inherit;font-size:8pt;"> from our investment in ViiV and charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$99 million</span></span><span style="font-family:inherit;font-size:8pt;">, reflecting the change in the fair value of contingent consideration. The </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> included, among other things, charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$81 million</span></span><span style="font-family:inherit;font-size:8pt;">, reflecting the change in the fair value of contingent consideration, dividend income of </span><span style="font-family:inherit;font-size:8pt;"><span>$76&#160;million</span></span><span style="font-family:inherit;font-size:8pt;"> from our investment in ViiV, and </span><span style="font-family:inherit;font-size:8pt;"><span>$25 million</span></span><span style="font-family:inherit;font-size:8pt;"> of income from insurance recoveries related to Hurricane Maria. The first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;"> included, among other things, dividend income of </span><span style="font-family:inherit;font-size:8pt;"><span>$140 million</span></span><span style="font-family:inherit;font-size:8pt;"> from our investment in ViiV and </span><span style="font-family:inherit;font-size:8pt;"><span>$50 million</span></span><span style="font-family:inherit;font-size:8pt;"> of income from insurance recoveries related to Hurricane Maria.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[11]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:53px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessAlignmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Alignment Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessAlignmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) From Equity Method Investments, Net Excess Basis Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherNonoperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Nonoperating Income (Expense), Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherNonoperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRevenueExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest revenue (income derived from investments in debt securities and on cash and cash equivalents) net of interest expense (cost of borrowed funds accounted for as interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRevenueExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818806534760">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net - Footnotes (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLegalSettlements', window );">Proceeds from legal dispute</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 733<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">$ 459<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Other asset impairments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceRecoveries', window );">Insurance Recoveries</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AllogeneMember', window );">Allogene [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_BioNTechSEMember', window );">BioNTech SE [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CortexymeInc.Member', window );">Cortexyme, Inc. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViiVMember', window );">ViiV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeDividend', window );">Dividend income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">76<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_PumaTechnologiesMember', window );">Puma Technologies [Member] | Collaborative Arrangement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Milestone payment received</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_EliLillyCompanyMember', window );">Eli Lilly &amp; Company [Member] | Collaborative Arrangement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Milestone payment received</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_MylanMember', window );">Mylan [Member] | Collaborative Arrangement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Milestone payment received</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposed of by Sale [Member] | CK1 assets sold to Biogen, Inc [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration transferred</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember', window );">Biopharma [Member] | Operating Segments [Member] | Developed Technology Rights [Member] | King [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairment charge</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember', window );">Biopharma [Member] | Operating Segments [Member] | Developed Technology Rights [Member] | Anacor [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairment charge</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_GeneTherapiesMember', window );">Gene Therapies [Member] | WRDM [Member] | In Process Research and Development [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairment charge</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_ViiVMember', window );">ViiV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">&#160;<div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. Since January 1, 2018, there were cumulative impairments and downward adjustments of </span><span style="font-family:inherit;font-size:8pt;"><span>$67 million</span></span><span style="font-family:inherit;font-size:8pt;"> and upward adjustments of </span><span style="font-family:inherit;font-size:8pt;"><span>$66 million</span></span><span style="font-family:inherit;font-size:8pt;">. Impairments, downward and upward adjustments were not significant in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and the first six months of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received for the settlement of litigation during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AllogeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AllogeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_BioNTechSEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_BioNTechSEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CortexymeInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CortexymeInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViiVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViiVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_PumaTechnologiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_PumaTechnologiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_EliLillyCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_EliLillyCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_MylanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_MylanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_CK1AssetsSoldToBiogenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_CK1AssetsSoldToBiogenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_KingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_KingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AnacorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AnacorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_GeneTherapiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_GeneTherapiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_ViiVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_ViiVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818717790584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax Matters - Narrative (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate for income from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
<td class="num">(22.10%)<span></span>
</td>
<td class="nump">12.70%<span></span>
</td>
<td class="num">(5.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxSettlements', window );">Tax benefit due to settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability', window );">Repatriation tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_IncomeTaxesPayableMember', window );">Income Taxes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability', window );">Repatriation tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentForRepatriationTax', window );">Installment payments for repatriation tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentForRepatriationTax', window );">Installment payments for repatriation tax</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Income Taxes [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentForRepatriationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment For Repatriation Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentForRepatriationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_IncomeTaxesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_IncomeTaxesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818804016504">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Tax Matters (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 60<span></span>
</td>
<td class="num">$ (17)<span></span>
</td>
<td class="num">$ (192)<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax', window );">Unrealized holding gains/(losses) on derivative financial instruments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">51<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="num">(82)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax', window );">Reclassification adjustments for gains included in net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax', window );">Derivatives qualifying as hedges, tax, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Unrealized holding gains/(losses) on available-for-sale securities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax', window );">Reclassification adjustments for losses included in net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax', window );">Available-for-sale securities, tax, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax', window );">Benefit plans: actuarial gains/(losses), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax', window );">Reclassification adjustments related to amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax', window );">Reclassification adjustments related to settlements, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax', window );">Defined benefit plans, actuarial gain (loss), tax, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax', window );">Reclassification adjustments related to amortization of prior service costs and other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect', window );">Pension and other postretirement benefit plans, net prior service cost (credit), tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Tax provision/(benefit) on other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 113<span></span>
</td>
<td class="num">$ (59)<span></span>
</td>
<td class="num">$ (265)<span></span>
</td>
<td class="num">$ (34)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:13px;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Actuarial Gain (Loss), Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Other Net Unamortized Gain (Loss) Arising During Period, Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Settlement Adjustment From AOCI, Pension And Other Postretirement Benefit Plans, for Net Gain (Loss), Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax (expense) benefit of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax (expense) benefit for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818804790584">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, December 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, June 28, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 64,336<span></span>
</td>
<td class="nump">64,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Foreign currency translation income (loss) attributable to noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Income (Loss) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, December 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,640)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,605)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, June 28, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(13,246)<span></span>
</td>
<td class="num">(13,246)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation Adjustment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, December 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,952)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,310)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, June 28, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,262)<span></span>
</td>
<td class="num">(7,262)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Derivative Financial Instruments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, December 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(353)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, June 28, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(333)<span></span>
</td>
<td class="num">(333)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Available-For-Sale Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, December 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, June 28, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember', window );">Actuarial Gains/(Losses) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, December 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,257)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, June 28, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,178)<span></span>
</td>
<td class="num">(6,178)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember', window );">Prior Service (Costs)/Credits and Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, December 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, June 28, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">518<span></span>
</td>
<td class="nump">518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember', window );">GSK Consumer Healthcare [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 291<span></span>
</td>
<td class="num">$ (902)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of </span><span style="font-family:inherit;font-size:8pt;"><span>$12 million</span></span><span style="font-family:inherit;font-size:8pt;"> loss for the first six months of 2020. Includes after-tax </span><span style="font-family:inherit;font-size:8pt;">losses</span><span style="font-family:inherit;font-size:8pt;"> of approximately </span><span style="font-family:inherit;font-size:8pt;"><span>$902 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to foreign currency translation adjustments and the impact of our net investment hedging program, both attributable to our equity method investment in GSK Consumer Healthcare (see</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> Note 2B</span><span style="font-family:inherit;font-size:8pt;">), and losses from the weakening of certain major currencies against the U.S. dollar. These </span><span style="font-family:inherit;font-size:8pt;">losses</span><span style="font-family:inherit;font-size:8pt;"> were partially offset by the results of our net investment hedging program.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818723215176">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 13,033<span></span>
</td>
<td class="nump">$ 705<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">4,327<span></span>
</td>
<td class="nump">4,450<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">177,934<span></span>
</td>
<td class="nump">167,489<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">993<span></span>
</td>
<td class="nump">718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,402<span></span>
</td>
<td class="nump">11,176<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">993<span></span>
</td>
<td class="nump">718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,672<span></span>
</td>
<td class="nump">6,687<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities', window );">Total short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,705<span></span>
</td>
<td class="nump">7,392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">431<span></span>
</td>
<td class="nump">465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">413<span></span>
</td>
<td class="nump">413<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">2,072<span></span>
</td>
<td class="nump">1,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">254<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments', window );">Total long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,326<span></span>
</td>
<td class="nump">2,216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">362<span></span>
</td>
<td class="nump">526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount', window );">Insurance contracts</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">578<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">940<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">140<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">221<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">127<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">127<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">866<span></span>
</td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">866<span></span>
</td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,046<span></span>
</td>
<td class="nump">1,863<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities', window );">Total short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Other Current Assets [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Other Current Assets [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Other Current Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">2,046<span></span>
</td>
<td class="nump">1,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments', window );">Total long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,046<span></span>
</td>
<td class="nump">1,863<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Other Noncurrent Assets [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount', window );">Insurance contracts</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Other Current Liabilities [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Other Current Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,355<span></span>
</td>
<td class="nump">9,313<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">993<span></span>
</td>
<td class="nump">718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,672<span></span>
</td>
<td class="nump">6,687<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities', window );">Total short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,705<span></span>
</td>
<td class="nump">7,392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Other Current Assets [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">431<span></span>
</td>
<td class="nump">465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Other Current Assets [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Other Current Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">413<span></span>
</td>
<td class="nump">413<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">26<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">254<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments', window );">Total long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">280<span></span>
</td>
<td class="nump">354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Other Noncurrent Assets [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">362<span></span>
</td>
<td class="nump">526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount', window );">Insurance contracts</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">578<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">940<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">140<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">221<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Other Current Liabilities [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">127<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Other Current Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">127<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">866<span></span>
</td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">866<span></span>
</td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">13,033<span></span>
</td>
<td class="nump">705<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member] | Level 1 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member] | Level 2 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">13,033<span></span>
</td>
<td class="nump">705<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Government and agency - non U.S. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,218<span></span>
</td>
<td class="nump">4,863<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Government and agency - non U.S. [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,218<span></span>
</td>
<td class="nump">4,863<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Government and agency - non U.S. [Member] | Level 1 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Government and agency - non U.S. [Member] | Level 2 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,218<span></span>
</td>
<td class="nump">4,863<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency - U.S. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">257<span></span>
</td>
<td class="nump">1,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency - U.S. [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14<span></span>
</td>
<td class="nump">811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency - U.S. [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">243<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency - U.S. [Member] | Level 1 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency - U.S. [Member] | Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency - U.S. [Member] | Level 2 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14<span></span>
</td>
<td class="nump">811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency - U.S. [Member] | Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">243<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate and other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">1,451<span></span>
</td>
<td class="nump">1,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate and other [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,440<span></span>
</td>
<td class="nump">1,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate and other [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate and other [Member] | Level 1 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate and other [Member] | Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate and other [Member] | Level 2 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,440<span></span>
</td>
<td class="nump">1,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate and other [Member] | Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:8pt;">, equity securities with readily determinable fair values included money market funds primarily invested in U.S. Treasury and government debt. As of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, </span><span style="font-family:inherit;font-size:8pt;"><span>$11.4 billion</span></span><span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn debt transactions (see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7D</span><span style="font-family:inherit;font-size:8pt;">) are invested in money market funds and included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments </span><span style="font-family:inherit;font-size:8pt;">in the condensed consolidated balance sheet.</span></div><div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, long-term equity securities of </span><span style="font-family:inherit;font-size:8pt;"><span>$163 million</span></span><span style="font-family:inherit;font-size:8pt;"> and as of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:8pt;">, long-term equity securities of </span><span style="font-family:inherit;font-size:8pt;"><span>$176 million</span></span><span style="font-family:inherit;font-size:8pt;"> were held in restricted trusts for benefits attributable to various U.S. non-qualified employee benefit plans.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other noncurrent assets include life insurance policies held in restricted trusts attributable to the funding of various U.S. non-qualified employee benefit plans. The underlying invested assets in these insurance contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (income)/deductions</span><span style="font-family:inherit;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">net</span><span style="font-family:inherit;font-size:8pt;"> in the condensed consolidated statements of income (see</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> Note 4</span><span style="font-family:inherit;font-size:8pt;">).</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, </span><span style="font-family:inherit;font-size:8pt;"><span>$11.4 billion</span></span><span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn debt transactions (see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7D</span><span style="font-family:inherit;font-size:8pt;">) are invested in money market funds and included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments </span><span style="font-family:inherit;font-size:8pt;">in the condensed consolidated balance sheet.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Primarily issued by a diverse group of corporations.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-term Investments Excluding Held-To-Maturity Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of life settlement contracts accounted for under the fair value method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -SubTopic 30<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73718008&amp;loc=d3e42732-111610<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818724838008">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract', window );"><strong>Footnotes to selected financial assets and liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,606<span></span>
</td>
<td class="nump">$ 4,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract', window );"><strong>Footnotes to selected financial assets and liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquitySecuritiesFVNIRestrictedNoncurrent', window );">Long-term equity securities held in trust</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 163<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember', window );">Subsidiaries [Member] | Upjohn Inc [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract', window );"><strong>Footnotes to selected financial assets and liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11,400<span></span>
</td>
<td class="nump">$ 11,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:20px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Includes </span><span style="font-family:inherit;font-size:8pt;"><span>$11.4 billion</span></span><span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn long-term debt issuances in the second quarter of 2020, which are included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments</span><span style="font-family:inherit;font-size:8pt;"> in the condensed consolidated balance sheet. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Notes 7A. Financial Instruments: </span><span style="font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Fair Value Measurements</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Financial Instruments: 7D. </span><span style="font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Long-Term Debt</span><span style="font-family:inherit;font-size:8pt;">).</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquitySecuritiesFVNIRestrictedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Restricted, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquitySecuritiesFVNIRestrictedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Footnotes to selected financial assets and liabilities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pfe_UpjohnIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pfe_UpjohnIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818720331528">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Financial Liabilities Not Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, excluding the current portion(a)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 50,529<span></span>
</td>
<td class="nump">$ 35,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimated Fair Value [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, excluding the current portion(a)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">59,121<span></span>
</td>
<td class="nump">40,842<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimated Fair Value [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, excluding the current portion(a)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 59,121<span></span>
</td>
<td class="nump">$ 40,842<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, </span><span style="font-family:inherit;font-size:8pt;"><span>$11.4 billion</span></span><span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn debt transactions (see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7D</span><span style="font-family:inherit;font-size:8pt;">) are invested in money market funds and included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments </span><span style="font-family:inherit;font-size:8pt;">in the condensed consolidated balance sheet.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818724836200">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Total Short-Term and Long-Term Investments and Equity Method Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 13,033<span></span>
</td>
<td class="nump">$ 705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,672<span></span>
</td>
<td class="nump">6,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Held-to-maturity debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">288<span></span>
</td>
<td class="nump">1,133<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total Short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,993<span></span>
</td>
<td class="nump">8,525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>Long-term investments</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquitySecuritiesFVNINoncurrent', window );">Equity securities with readily determinable fair values</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,072<span></span>
</td>
<td class="nump">1,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">254<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Held-to-maturity debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">43<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PrivateEquityInvestments', window );">Private equity securities at cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">772<span></span>
</td>
<td class="nump">756<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Total Long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">3,142<span></span>
</td>
<td class="nump">3,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity-method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">15,578<span></span>
</td>
<td class="nump">17,133<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Total long-term investments and equity-method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,720<span></span>
</td>
<td class="nump">20,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_HeldToMaturityCashEquivalents', window );">Held-to-maturity cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 119<span></span>
</td>
<td class="nump">$ 163<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:8pt;">, equity securities with readily determinable fair values included money market funds primarily invested in U.S. Treasury and government debt. As of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, </span><span style="font-family:inherit;font-size:8pt;"><span>$11.4 billion</span></span><span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn debt transactions (see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7D</span><span style="font-family:inherit;font-size:8pt;">) are invested in money market funds and included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments </span><span style="font-family:inherit;font-size:8pt;">in the condensed consolidated balance sheet.</span></div><div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquitySecuritiesFVNINoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquitySecuritiesFVNINoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_HeldToMaturityCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Held-To-Maturity Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_HeldToMaturityCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PrivateEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Private Equity Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PrivateEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818821149368">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Total Short-Term and Long-Term Investments and Equity Method Investments - Footnotes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,606<span></span>
</td>
<td class="nump">$ 4,942<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember', window );">Subsidiaries [Member] | Upjohn Inc [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11,400<span></span>
</td>
<td class="nump">$ 11,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:20px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Includes </span><span style="font-family:inherit;font-size:8pt;"><span>$11.4 billion</span></span><span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn long-term debt issuances in the second quarter of 2020, which are included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments</span><span style="font-family:inherit;font-size:8pt;"> in the condensed consolidated balance sheet. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Notes 7A. Financial Instruments: </span><span style="font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Fair Value Measurements</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Financial Instruments: 7D. </span><span style="font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Long-Term Debt</span><span style="font-family:inherit;font-size:8pt;">).</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pfe_UpjohnIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pfe_UpjohnIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818723928776">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8,366<span></span>
</td>
<td class="nump">$ 8,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain', window );">Debt securities, gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss', window );">Debt securities, gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity', window );">Available-for-sale securities and held-to-maturity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,376<span></span>
</td>
<td class="nump">8,340<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue', window );">Debt securities maturities, within 1 year, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue', window );">Debt securities maturities, over 1 to 5 years, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue', window );">Debt securities maturities, over 5 years, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Government and agency - non U.S. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale debt securities, amortized cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,209<span></span>
</td>
<td class="nump">4,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale debt securities, gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale debt securities, gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,218<span></span>
</td>
<td class="nump">4,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Available-for-sale Securities, Debt Maturities [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Available-for-sale securities, debt maturities, within 1 year, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Available-for-sale securities, debt maturities, over 1 to 5 years, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue', window );">Available-for-sale securities, debt maturities, over 5 years, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,218<span></span>
</td>
<td class="nump">4,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract', window );"><strong>Debt Securities, Held-to-maturity, Maturity [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity securities, debt maturities, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">222<span></span>
</td>
<td class="nump">803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity securities, gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity securities, gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity securities, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">222<span></span>
</td>
<td class="nump">803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Held-to-maturity securities, debt maturities, within 1 year, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue', window );">Held-to-maturity securities, debt maturities, over 5 years, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity securities, debt maturities, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">222<span></span>
</td>
<td class="nump">803<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency - U.S. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale debt securities, amortized cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">257<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale debt securities, gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale debt securities, gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">257<span></span>
</td>
<td class="nump">1,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Available-for-sale Securities, Debt Maturities [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Available-for-sale securities, debt maturities, within 1 year, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Available-for-sale securities, debt maturities, over 1 to 5 years, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue', window );">Available-for-sale securities, debt maturities, over 5 years, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">257<span></span>
</td>
<td class="nump">1,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate and other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale debt securities, amortized cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,450<span></span>
</td>
<td class="nump">1,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale debt securities, gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale debt securities, gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,451<span></span>
</td>
<td class="nump">1,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Available-for-sale Securities, Debt Maturities [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Available-for-sale securities, debt maturities, within 1 year, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Available-for-sale securities, debt maturities, over 1 to 5 years, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue', window );">Available-for-sale securities, debt maturities, over 5 years, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,451<span></span>
</td>
<td class="nump">1,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_BankTimeDepositsMember', window );">Time deposits and other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract', window );"><strong>Debt Securities, Held-to-maturity, Maturity [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity securities, debt maturities, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">228<span></span>
</td>
<td class="nump">535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity securities, gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity securities, gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity securities, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">228<span></span>
</td>
<td class="nump">535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Held-to-maturity securities, debt maturities, within 1 year, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue', window );">Held-to-maturity securities, debt maturities, over 5 years, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity securities, debt maturities, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 228<span></span>
</td>
<td class="nump">$ 535<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Primarily issued by a diverse group of corporations.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Accumulated Gross Unrealized Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Accumulated Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Amortized Cost Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities Maturities, After Year Five, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities Maturities, Next Twelve Months, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities Maturities, Year Two Through Five, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269825-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269825-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818809318024">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net gains recognized during the period on investments in equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">$ (732)<span></span>
</td>
<td class="num">$ (36)<span></span>
</td>
<td class="num">$ (478)<span></span>
</td>
<td class="num">$ (147)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Less: Net (gains)/losses recognized during the period on equity securities sold during the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gains during the reporting period on equity securities still held at the reporting date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">$ (733)<span></span>
</td>
<td class="num">$ (31)<span></span>
</td>
<td class="num">$ (459)<span></span>
</td>
<td class="num">$ (137)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The gains in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> include, among other things, unrealized gains of </span><span style="font-family:inherit;font-size:8pt;"><span>$508 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to our investment in Allogene and unrealized gains of </span><span style="font-family:inherit;font-size:8pt;"><span>$61 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to our investment in BioNTech. The gains in the first six months of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> include, among other things, unrealized gains of </span><span style="font-family:inherit;font-size:8pt;"><span>$374 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to our investment in Allogene and unrealized gains of </span><span style="font-family:inherit;font-size:8pt;"><span>$127 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to our investment in BioNTech. The gains in the first six months of 2019 included, among other things, unrealized gains of </span><span style="font-family:inherit;font-size:8pt;"><span>$104 million</span></span><span style="font-family:inherit;font-size:8pt;"> related to our investment in Cortexyme, Inc. For additional information on investments, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7B</span><span style="font-family:inherit;font-size:8pt;">.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The net gains on investments in equity securities are reported in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (income)/deductions</span><span style="font-family:inherit;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">net.</span><span style="font-family:inherit;font-size:8pt;"> For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:inherit;font-size:8pt;">.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">&#160;<div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. Since January 1, 2018, there were cumulative impairments and downward adjustments of </span><span style="font-family:inherit;font-size:8pt;"><span>$67 million</span></span><span style="font-family:inherit;font-size:8pt;"> and upward adjustments of </span><span style="font-family:inherit;font-size:8pt;"><span>$66 million</span></span><span style="font-family:inherit;font-size:8pt;">. Impairments, downward and upward adjustments were not significant in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> and the first six months of </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818720027000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 28, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount', window );">Cumulative impairment losses and downward price adjustments on equity securities</a></td>
<td class="nump">$ 67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount', window );">Cumulative upward price adjustments on equity securities</a></td>
<td class="nump">$ 66<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value, Impairment Loss And Downward Price Adjustment, Cumulative Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818722912936">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Short-term Borrowings (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Commercial paper</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10,660<span></span>
</td>
<td class="nump">$ 13,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting', window );">Current portion of long-term debt, principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,481<span></span>
</td>
<td class="nump">1,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherShortTermBorrowings', window );">Other short-term borrowings, principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">956<span></span>
</td>
<td class="nump">860<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShorttermDebtGross', window );">Total short-term borrowings, principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,097<span></span>
</td>
<td class="nump">16,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting', window );">Net fair value adjustments related to hedging and purchase accounting</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Net unamortized discounts, premiums and debt issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 13,084<span></span>
</td>
<td class="nump">$ 16,195<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other short-term borrowings primarily include cash collateral. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7E</span><span style="font-family:inherit;font-size:8pt;">. </span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ShorttermDebtGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-term Debt, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ShorttermDebtGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818730959768">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Long-Term Debt - New Issuances (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 28, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 28, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 28, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,606<span></span>
</td>
<td class="nump">$ 4,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.67%<span></span>
</td>
<td class="nump">2.67%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.67%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member] | 2.625% notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.625%<span></span>
</td>
<td class="nump">2.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.625%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member] | Long Term Debt Issued First Quarter 2020 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_ParentMember', window );">Parent [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.11%<span></span>
</td>
<td class="nump">2.11%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.11%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_ParentMember', window );">Parent [Member] | Senior Notes [Member] | 0.800% notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_ParentMember', window );">Parent [Member] | Senior Notes [Member] | 1.700% notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_ParentMember', window );">Parent [Member] | Senior Notes [Member] | 2.550% notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.55%<span></span>
</td>
<td class="nump">2.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.55%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_ParentMember', window );">Parent [Member] | Senior Notes [Member] | 2.700% notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember', window );">Subsidiaries [Member] | Senior Notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pfe_UpjohnIncMember', window );">Upjohn Inc [Member] | Subsidiaries [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,450<span></span>
</td>
<td class="nump">$ 7,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.95%<span></span>
</td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.95%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11,400<span></span>
</td>
<td class="nump">$ 11,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pfe_UpjohnIncMember', window );">Upjohn Inc [Member] | Subsidiaries [Member] | Senior Notes [Member] | 1.125% notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.125%<span></span>
</td>
<td class="nump">1.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.125%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pfe_UpjohnIncMember', window );">Upjohn Inc [Member] | Subsidiaries [Member] | Senior Notes [Member] | 1.650% notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pfe_UpjohnIncMember', window );">Upjohn Inc [Member] | Subsidiaries [Member] | Senior Notes [Member] | 2.300% notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pfe_UpjohnIncMember', window );">Upjohn Inc [Member] | Subsidiaries [Member] | Senior Notes [Member] | 2.700% notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,450<span></span>
</td>
<td class="nump">$ 1,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pfe_UpjohnIncMember', window );">Upjohn Inc [Member] | Subsidiaries [Member] | Senior Notes [Member] | 3.850% notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.85%<span></span>
</td>
<td class="nump">3.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.85%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pfe_UpjohnIncMember', window );">Upjohn Inc [Member] | Subsidiaries [Member] | Senior Notes [Member] | 4.000% notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pfe_UpjohnFinanceB.V.Member', window );">Upjohn Finance B.V. [Member] | Subsidiaries [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal | &#8364;</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.37%<span></span>
</td>
<td class="nump">1.37%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.37%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pfe_UpjohnFinanceB.V.Member', window );">Upjohn Finance B.V. [Member] | Subsidiaries [Member] | Senior Notes [Member] | 0.816% notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal | &#8364;</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.816%<span></span>
</td>
<td class="nump">0.816%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.816%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pfe_UpjohnFinanceB.V.Member', window );">Upjohn Finance B.V. [Member] | Subsidiaries [Member] | Senior Notes [Member] | 1.023% notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal | &#8364;</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.023%<span></span>
</td>
<td class="nump">1.023%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.023%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pfe_UpjohnFinanceB.V.Member', window );">Upjohn Finance B.V. [Member] | Subsidiaries [Member] | Senior Notes [Member] | 1.362% notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal | &#8364;</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.362%<span></span>
</td>
<td class="nump">1.362%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.362%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pfe_UpjohnFinanceB.V.Member', window );">Upjohn Finance B.V. [Member] | Subsidiaries [Member] | Senior Notes [Member] | 1.908% notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal | &#8364;</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.908%<span></span>
</td>
<td class="nump">1.908%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.908%<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:20px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Includes </span><span style="font-family:inherit;font-size:8pt;"><span>$11.4 billion</span></span><span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn long-term debt issuances in the second quarter of 2020, which are included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments</span><span style="font-family:inherit;font-size:8pt;"> in the condensed consolidated balance sheet. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Notes 7A. Financial Instruments: </span><span style="font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Fair Value Measurements</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Financial Instruments: 7D. </span><span style="font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Long-Term Debt</span><span style="font-family:inherit;font-size:8pt;">).</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The notes may be redeemed by us at any time, in whole, or in part, at a redemption price plus accrued and unpaid interest.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The effective interest rate for the notes at issuance was </span><span style="font-family:inherit;font-size:8pt;"><span>2.67%</span></span><span style="font-family:inherit;font-size:8pt;">.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_LongTermDebtIssuedFirstQuarter2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_LongTermDebtIssuedFirstQuarter2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pfe_UpjohnIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pfe_UpjohnIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pfe_UpjohnFinanceB.V.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pfe_UpjohnFinanceB.V.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818721814280">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting', window );">Net fair value adjustments related to hedging and purchase accounting</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Net unamortized discounts, premiums and debt issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt, carried at historical proceeds, as adjusted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">50,529<span></span>
</td>
<td class="nump">50,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,481<span></span>
</td>
<td class="nump">1,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,606<span></span>
</td>
<td class="nump">$ 4,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total long-term debt, principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">49,187<span></span>
</td>
<td class="nump">49,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting', window );">Net fair value adjustments related to hedging and purchase accounting</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,654<span></span>
</td>
<td class="nump">1,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Net unamortized discounts, premiums and debt issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(317)<span></span>
</td>
<td class="num">(317)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(176)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Other long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt, carried at historical proceeds, as adjusted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50,529<span></span>
</td>
<td class="nump">50,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,481<span></span>
</td>
<td class="nump">1,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember', window );">Subsidiaries [Member] | Upjohn Inc [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11,400<span></span>
</td>
<td class="nump">$ 11,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family:inherit;font-size:8pt;">The balance as of June 28, 2020 reflects the Upjohn Inc. and Upjohn Finance B.V. debt issuances. For additional information see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7D. Financial Instruments: </span><span style="font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Long-Term Debt</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:20px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Includes </span><span style="font-family:inherit;font-size:8pt;"><span>$11.4 billion</span></span><span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn long-term debt issuances in the second quarter of 2020, which are included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments</span><span style="font-family:inherit;font-size:8pt;"> in the condensed consolidated balance sheet. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Notes 7A. Financial Instruments: </span><span style="font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Fair Value Measurements</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Financial Instruments: 7D. </span><span style="font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Long-Term Debt</span><span style="font-family:inherit;font-size:8pt;">).</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, </span><span style="font-family:inherit;font-size:8pt;"><span>$11.4 billion</span></span><span style="font-family:inherit;font-size:8pt;"> of proceeds from the Upjohn debt transactions are invested in money market funds and included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Restricted short-term investments </span><span style="font-family:inherit;font-size:8pt;">in the condensed consolidated balance sheet.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pfe_UpjohnIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pfe_UpjohnIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818719068952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Long-Term Debt Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 29, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Senior Notes Due 2047 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Repurchase amount</a></td>
<td class="nump">$ 1,065<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorNotesDue2047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorNotesDue2047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818719037352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments -  Derivative Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 28, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue', window );">Derivatives in a net liability position</a></td>
<td class="nump">$ 928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral posted</a></td>
<td class="nump">922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesReceivedAsCollateral', window );">Cash collateral received</a></td>
<td class="nump">$ 858<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Derivative term of contract</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAlreadyPostedAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAlreadyPostedAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value amounts of derivative instruments that contain credit-risk-related contingent features that are in a net liability position at the end of the reporting period. For nonderivative instruments that are designated and qualify as hedging instruments, the fair value amounts are the carrying value of the nonderivative hedging instrument, including the adjustment for the foreign currency transaction gain (loss) on that instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNetLiabilityPositionAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesReceivedAsCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the assets received as collateral against securities loaned to other broker-dealers. Borrowers of securities generally are required to provide collateral to the lenders of securities, commonly cash but sometimes other securities or standby letters of credit, with a value slightly higher than that of the securities borrowed. In instances where the entity is permitted to sell or re-pledge these securities, the entity reports the fair value of the collateral received and the related obligation to return the collateral as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109249958&amp;loc=SL6224234-111729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesReceivedAsCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818721656840">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 792<span></span>
</td>
<td class="nump">$ 992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">993<span></span>
</td>
<td class="nump">718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">708<span></span>
</td>
<td class="nump">909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">914<span></span>
</td>
<td class="nump">662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">22,543<span></span>
</td>
<td class="nump">25,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">551<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">914<span></span>
</td>
<td class="nump">662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Interest rate contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,995<span></span>
</td>
<td class="nump">6,645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">158<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,433<span></span>
</td>
<td class="nump">19,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">84<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">79<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_HedgedItemAxis=us-gaap_SalesMember', window );">Inventory sales [Member] | Derivatives designated as hedging instruments [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was </span><span style="font-family:inherit;font-size:8pt;"><span>$5.2 billion</span></span><span style="font-family:inherit;font-size:8pt;"> as of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$5.9 billion</span></span><span style="font-family:inherit;font-size:8pt;"> as of December 31, 2019.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_HedgedItemAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_HedgedItemAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818724524664">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 213<span></span>
</td>
<td class="num">$ (176)<span></span>
</td>
<td class="num">$ (288)<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax', window );">All other, net - Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3],[4]</sup></td>
<td class="nump">12<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax', window );">Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="nump">56<span></span>
</td>
<td class="num">(216)<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[5]</sup></td>
<td class="nump">186<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">OID [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Amount of Gains/(Losses) Recognized in OID</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">8<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="num">(124)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pfe_OtherIncomeDeductionsAndCostOfSalesMember', window );">Other (Income) Deductions And Cost Of Sales [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3],[4]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="nump">228<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="nump">398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3],[6]</sup></td>
<td class="nump">187<span></span>
</td>
<td class="num">(204)<span></span>
</td>
<td class="num">(341)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="num">(144)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign currency short-term borrowings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax', window );">Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3],[7]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign currency long-term debt [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax', window );">Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3],[7]</sup></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | OID [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Amount of Gains/(Losses) Recognized in OID</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1', window );">Hedged item</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | OID [Member] | Interest rate contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Amount of Gains/(Losses) Recognized in OID</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">6<span></span>
</td>
<td class="nump">483<span></span>
</td>
<td class="nump">392<span></span>
</td>
<td class="nump">813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1', window );">Hedged item</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(483)<span></span>
</td>
<td class="num">(392)<span></span>
</td>
<td class="num">(813)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3],[6]</sup></td>
<td class="nump">172<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="nump">257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign currency short-term borrowings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3],[7]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign currency long-term debt [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3],[7]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivative Financial Instruments Not Designated as Hedges [Member] | OID [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Amount of Gains/(Losses) Recognized in OID</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">8<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="num">(124)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Amount excluded from effectiveness testing</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3],[4]</sup></td>
<td class="nump">13<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax', window );">Amount excluded from effectiveness testing</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3],[4]</sup></td>
<td class="nump">14<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Amount excluded from effectiveness testing</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3],[4]</sup></td>
<td class="nump">29<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax', window );">Amount excluded from effectiveness testing</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3],[4]</sup></td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:13px;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other comprehensive loss&#8211;&#8211;Unrealized holding gains/(losses) on derivative financial instruments, net</span><span style="font-family:inherit;font-size:8pt;">. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the gains and losses are included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other comprehensive loss&#8211;&#8211;Foreign currency translation adjustments, net.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">OID = Other (income)/deductions&#8212;net, included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:inherit;font-size:8pt;"> in the condensed consolidated statements of income</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">.</span><span style="font-family:inherit;font-size:8pt;"> COS = Cost of Sales, included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:8pt;"> in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The amounts reclassified from OCI were reclassified into OID.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassified into </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions&#8212;net </span><span style="font-family:inherit;font-size:9pt;">and </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:9pt;"> in the condensed consolidated statements of income. For additional information on amounts reclassified into </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions&#8212;net </span><span style="font-family:inherit;font-size:9pt;">and </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:9pt;">, see </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 7E. Financial Instruments: Derivative Financial Instruments and Hedging Activities.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The amounts reclassified from OCI into COS were:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:12px;"><div style="line-height:120%;font-size:8pt;text-indent:-12px;"><span style="font-family:inherit;font-size:8pt;">a net </span><span style="font-family:inherit;font-size:8pt;">gain</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;"><span>$80 million</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:12px;"><div style="line-height:120%;font-size:8pt;text-indent:-12px;"><span style="font-family:inherit;font-size:8pt;">a net </span><span style="font-family:inherit;font-size:8pt;">gain</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;"><span>$150 million</span></span><span style="font-family:inherit;font-size:8pt;"> in the first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:12px;"><div style="line-height:120%;font-size:8pt;text-indent:-12px;"><span style="font-family:inherit;font-size:8pt;">a net </span><span style="font-family:inherit;font-size:8pt;">gain</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;"><span>$59 million</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:12px;"><div style="line-height:120%;font-size:8pt;text-indent:-12px;"><span style="font-family:inherit;font-size:8pt;">a net </span><span style="font-family:inherit;font-size:8pt;">gain</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;"><span>$103 million</span></span><span style="font-family:inherit;font-size:8pt;"> in the first </span><span style="font-family:inherit;font-size:8pt;">six months</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;">2019</span><span style="font-family:inherit;font-size:8pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax </span><span style="font-family:inherit;font-size:8pt;">gain</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;"><span>$102 million</span></span><span style="font-family:inherit;font-size:8pt;"> within the next 12 months into income</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">. </span><span style="font-family:inherit;font-size:8pt;">The maximum length of time over which we are hedging future foreign exchange cash flow relates to our </span><span style="font-family:inherit;font-size:8pt;"><span>$1.8 billion</span></span><span style="font-family:inherit;font-size:8pt;"> U.K. pound debt maturing in 2043.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Long-term debt includes foreign currency long-term borrowings with carrying values of </span><span style="font-family:inherit;font-size:8pt;"><span>$2.0 billion</span></span><span style="font-family:inherit;font-size:8pt;"> as of </span><span style="font-family:inherit;font-size:8pt;">June&#160;28, 2020</span><span style="font-family:inherit;font-size:8pt;">, which are used as hedging instruments in net investment hedges.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:26%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:1px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the amounts recorded in our condensed consolidated balance sheet related to cumulative basis adjustments for fair value hedges:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June&#160;28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to </span></div><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to </span></div><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Carrying Amount</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Carrying Amount of Hedged Assets/Liabilities</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Active Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Discontinued Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Carrying Amount of Hedged Assets/Liabilities</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Active Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Discontinued Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,023</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,181</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7,092</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>266</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>690</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Before Reclassification and Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), Reclassification, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), before Reclassification and Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pfe_OtherIncomeDeductionsAndCostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pfe_OtherIncomeDeductionsAndCostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyShortTermBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyShortTermBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818728758968">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Amount of (Gains)/Losses Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">$ (186)<span></span>
</td>
<td class="num">$ (81)<span></span>
</td>
<td class="num">$ (167)<span></span>
</td>
<td class="num">$ (343)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months', window );">Pre-tax gain expected to be reclassified within the next 12 months</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyLongTermDebtMember', window );">Foreign currency long-term debt [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Cost of sales [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Amount of (Gains)/Losses Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (80)<span></span>
</td>
<td class="num">$ (59)<span></span>
</td>
<td class="num">$ (150)<span></span>
</td>
<td class="num">$ (103)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:13px;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassified into </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions&#8212;net </span><span style="font-family:inherit;font-size:9pt;">and </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:9pt;"> in the condensed consolidated statements of income. For additional information on amounts reclassified into </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions&#8212;net </span><span style="font-family:inherit;font-size:9pt;">and </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:9pt;">, see </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 7E. Financial Instruments: Derivative Financial Instruments and Hedging Activities.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818723540648">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedAssetFairValueHedge', window );">Carrying Amount of Actively Hedged Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term investments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedAssetFairValueHedge', window );">Carrying Amount of Actively Hedged Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember', window );">Long-term debt [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Carrying Amount of Actively Hedged Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,023<span></span>
</td>
<td class="nump">7,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">140<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,181<span></span>
</td>
<td class="nump">$ 690<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged asset in fair value hedge, attributable to hedged risk, remaining after discontinued hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedAssetFairValueHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset hedged in fair value hedging relationship.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedAssetFairValueHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged asset in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk, remaining after discontinued hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability hedged in fair value hedging relationship.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818719865736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Credit Risk (Details)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 28, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesByIndustryAxis=us-gaap_FinancialServicesSectorMember', window );">Bank sector [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure', window );">Maximum exposure, amount</a></td>
<td class="nump">$ 1.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesByIndustryAxis=us-gaap_FinancialServicesSectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesByIndustryAxis=us-gaap_FinancialServicesSectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818804192888">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Inventories (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,002<span></span>
</td>
<td class="nump">$ 2,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,810<span></span>
</td>
<td class="nump">4,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials and supplies</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">752<span></span>
</td>
<td class="nump">790<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">8,564<span></span>
</td>
<td class="nump">8,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Noncurrent inventories not included above</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 962<span></span>
</td>
<td class="nump">$ 714<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The change from </span><span style="font-family:inherit;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:8pt;"> reflects increases for certain products, including inventory build for new product launches, network strategy and market demand, partially offset by a decrease due to foreign exchange.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Included in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other noncurrent assets</span><span style="font-family:inherit;font-size:8pt;">. There are no recoverability issues associated with these amounts.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818725155576">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill  - Finite-lived and Indefinite-lived Intangible Assets (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,032<span></span>
</td>
<td class="nump">$ 8,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">93,176<span></span>
</td>
<td class="nump">91,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(66,667)<span></span>
</td>
<td class="num">(65,037)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">26,509<span></span>
</td>
<td class="nump">26,387<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible assets, gross carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">100,208<span></span>
</td>
<td class="nump">100,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(66,667)<span></span>
</td>
<td class="num">(65,037)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Identifiable Intangible Assets, less Accumulated Amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">33,541<span></span>
</td>
<td class="nump">35,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Brands [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,991<span></span>
</td>
<td class="nump">1,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">4,518<span></span>
</td>
<td class="nump">5,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember', window );">License Agreements and Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">523<span></span>
</td>
<td class="nump">1,073<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">89,927<span></span>
</td>
<td class="nump">88,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(64,683)<span></span>
</td>
<td class="num">(63,106)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">25,244<span></span>
</td>
<td class="nump">25,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(64,683)<span></span>
</td>
<td class="num">(63,106)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Brands [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">922<span></span>
</td>
<td class="nump">922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(757)<span></span>
</td>
<td class="num">(741)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">165<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(757)<span></span>
</td>
<td class="num">(741)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember', window );">License Agreements and Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">2,327<span></span>
</td>
<td class="nump">1,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="num">(1,226)<span></span>
</td>
<td class="num">(1,191)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">1,101<span></span>
</td>
<td class="nump">582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="num">$ (1,226)<span></span>
</td>
<td class="num">$ (1,191)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The </span><span style="font-family:inherit;font-size:8pt;">decrease</span><span style="font-family:inherit;font-size:8pt;"> in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">I</span><span style="font-family:inherit;font-size:8pt;font-style:italic;text-align:right;">dentifiable intangible assets, less accumulated amortization</span><span style="font-family:inherit;font-size:8pt;text-align:right;">, </span><span style="font-family:inherit;font-size:8pt;">is primarily due to amortization.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The changes in the gross carrying amount of </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8pt;"> primarily reflect the transfer of </span><span style="font-family:inherit;font-size:8pt;"><span>$1.4 billion</span></span><span style="font-family:inherit;font-size:8pt;"> from </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8pt;"> to </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8pt;"> to reflect the approval of Braftovi in combination with Erbitux</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:inherit;font-size:8pt;"> (cetuximab), for the treatment of BRAF</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">V600E</sup></span><span style="font-family:inherit;font-size:8pt;">-mutant metastatic colorectal cancer after prior therapy.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The changes in the gross carrying amount of </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Licensing agreements and other</span><span style="font-family:inherit;font-size:8pt;"> primarily reflect the transfer of </span><span style="font-family:inherit;font-size:8pt;"><span>$550 million</span></span><span style="font-family:inherit;font-size:8pt;"> from Indefinite-lived </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Licensing agreements and other</span><span style="font-family:inherit;font-size:8pt;"> to finite-lived </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Licensing agreements and other</span><span style="font-family:inherit;font-size:8pt;"> to reflect the approval in the U.S. of several products subject to out-licensing arrangements acquired from Array.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818722235496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill  - Finite-lived and Indefinite-lived Intangible Assets Footnotes (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 28, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_BraftoviMember', window );">Braftovi [Member] | Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Finite-lived intangible assets period increase (decrease)</a></td>
<td class="nump">$ 1,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember', window );">Array [Member] | Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Finite-lived intangible assets period increase (decrease)</a></td>
<td class="nump">550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member] | Braftovi [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Indefinite-lived intangible assets, period increase (decrease)</a></td>
<td class="num">(1,400)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember', window );">License Agreements and Other [Member] | Array [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Indefinite-lived intangible assets, period increase (decrease)</a></td>
<td class="num">$ (550)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BraftoviMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BraftoviMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818722259944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill  - Finite-lived Intangible Assets Percentage of Total Intangibles (Details)<br></strong></div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Developed Technology Rights [Member] | Biopharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">99.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Developed Technology Rights [Member] | Upjohn [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Brands [Member] | Biopharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Brands [Member] | Upjohn [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Licensing Agreements And Other [Member] | Biopharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">99.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Licensing Agreements And Other [Member] | Upjohn [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember', window );">WRDM [Member] | Segment Reconciling Items [Member] | Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember', window );">WRDM [Member] | Segment Reconciling Items [Member] | Brands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember', window );">WRDM [Member] | Segment Reconciling Items [Member] | Licensing Agreements And Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets, Net, Percentage of Intangible Assets, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818804456680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill  - Indefinite-lived Intangible Assets Percentage of Total Intangibles (Details)<br></strong></div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember', window );">Biopharma [Member] | Operating Segments [Member] | Brands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">42.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember', window );">Biopharma [Member] | Operating Segments [Member] | In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">94.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember', window );">Biopharma [Member] | Operating Segments [Member] | Licensing Agreements And Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember', window );">Upjohn [Member] | Operating Segments [Member] | Brands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">58.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember', window );">Upjohn [Member] | Operating Segments [Member] | In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember', window );">Upjohn [Member] | Operating Segments [Member] | Licensing Agreements And Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember', window );">WRDM [Member] | Segment Reconciling Items [Member] | Brands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember', window );">WRDM [Member] | Segment Reconciling Items [Member] | In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember', window );">WRDM [Member] | Segment Reconciling Items [Member] | Licensing Agreements And Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets, Net, Percentage of Intangible Assets, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818804332152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill  - Narrative (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember', window );">Finite-Lived Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense for finite-lived intangible assets</a></td>
<td class="nump">$ 917<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818723433192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill  - Goodwill (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Jun. 28, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance, December 31, 2019</a></td>
<td class="nump">$ 58,653<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="num">(204)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance, June 28, 2020</a></td>
<td class="nump">58,449<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Biopharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance, December 31, 2019</a></td>
<td class="nump">48,202<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="num">(155)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance, June 28, 2020</a></td>
<td class="nump">48,047<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Upjohn [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance, December 31, 2019</a></td>
<td class="nump">10,451<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="num">(49)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance, June 28, 2020</a></td>
<td class="nump">$ 10,401<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Primarily represents the impact of foreign exchange.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818804777912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan [Member] | U.S. [Member] | Qualified [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="nump">262<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(251)<span></span>
</td>
<td class="num">(223)<span></span>
</td>
<td class="num">(503)<span></span>
</td>
<td class="num">(445)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Amortization of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Actuarial losses</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Prior service credits</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits', window );">Special termination benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Defined benefit plan, net periodic benefit cost</a></td>
<td class="num">(83)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(159)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan [Member] | International [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(75)<span></span>
</td>
<td class="num">(80)<span></span>
</td>
<td class="num">(153)<span></span>
</td>
<td class="num">(160)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Amortization of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Actuarial losses</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Prior service credits</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits', window );">Special termination benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Defined benefit plan, net periodic benefit cost</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember', window );">Supplemental Employee Retirement Plan [Member] | U.S. [Member] | Non-Qualified [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Amortization of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Actuarial losses</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Prior service credits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits', window );">Special termination benefits</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Defined benefit plan, net periodic benefit cost</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Amortization of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Actuarial losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Prior service credits</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="num">(86)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits', window );">Special termination benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Defined benefit plan, net periodic benefit cost</a></td>
<td class="num">$ (30)<span></span>
</td>
<td class="num">$ (23)<span></span>
</td>
<td class="num">$ (60)<span></span>
</td>
<td class="num">$ (46)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in benefit obligation for benefits provided to employees payable from defined benefit plan or payable upon retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSpecialTerminationBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818721826264">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan [Member] | U.S. [Member] | Qualified [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contributions from our general assets for the six months ended June 28, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear', window );">Expected contributions from our general assets during 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan [Member] | International [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contributions from our general assets for the six months ended June 28, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear', window );">Expected contributions from our general assets during 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember', window );">Supplemental Employee Retirement Plan [Member] | U.S. [Member] | Non-Qualified [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contributions from our general assets for the six months ended June 28, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear', window );">Expected contributions from our general assets during 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Plans [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contributions from our general assets for the six months ended June 28, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear', window );">Expected contributions from our general assets during 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Forecast [Member] | Pension Plan [Member] | U.S. [Member] | Qualified [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contributions from our general assets for the six months ended June 28, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Contributions expected to be made for </span><span style="font-family:inherit;font-size:8pt;">2020</span><span style="font-family:inherit;font-size:8pt;"> are inclusive of amounts contributed during the </span><span style="font-family:inherit;font-size:8pt;">six months ended June 28, 2020</span><span style="font-family:inherit;font-size:8pt;">. The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments. For the U.S. qualified plans, we plan to make a </span><span style="font-family:inherit;font-size:8pt;"><span>$1.25 billion</span></span><span style="font-family:inherit;font-size:8pt;"> voluntary contribution in the second half of 2020.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution expected to be received by defined benefit plan from employer in remainder of current fiscal year. Excludes contribution previously paid by employer in current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818804227064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity  - Preferred Stock (Details)<br></strong></div></th>
<th class="th">
<div>May 04, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued upon conversion of convertible preferred stock (in shares)</a></td>
<td class="nump">1,070,369<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818720845496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity - Dividends (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 25, 2020</div></th>
<th class="th"><div>Apr. 23, 2020</div></th>
<th class="th"><div>Dec. 13, 2019</div></th>
<th class="th"><div>Sep. 24, 2019</div></th>
<th class="th"><div>Jun. 27, 2019</div></th>
<th class="th"><div>Apr. 25, 2019</div></th>
<th class="th"><div>Dec. 14, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared per share (in dollars per share)</a></td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818723096952">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Common Share Attributable to Common Shareholders (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>EPS Numerator&#8211;&#8211;Basic</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 3,434<span></span>
</td>
<td class="nump">$ 5,056<span></span>
</td>
<td class="nump">$ 6,845<span></span>
</td>
<td class="nump">$ 8,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Less: Net income attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Income from continuing operations attributable to Pfizer Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,426<span></span>
</td>
<td class="nump">5,046<span></span>
</td>
<td class="nump">6,828<span></span>
</td>
<td class="nump">8,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Less: Preferred stock dividends&#8211;&#8211;net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,426<span></span>
</td>
<td class="nump">5,045<span></span>
</td>
<td class="nump">6,828<span></span>
</td>
<td class="nump">8,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income attributable to Pfizer Inc. common shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,426<span></span>
</td>
<td class="nump">5,045<span></span>
</td>
<td class="nump">6,828<span></span>
</td>
<td class="nump">8,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>EPS Numerator&#8211;&#8211;Diluted</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,426<span></span>
</td>
<td class="nump">5,046<span></span>
</td>
<td class="nump">6,828<span></span>
</td>
<td class="nump">8,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,426<span></span>
</td>
<td class="nump">$ 5,046<span></span>
</td>
<td class="nump">$ 6,828<span></span>
</td>
<td class="nump">$ 8,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>EPS Denominator</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares outstanding&#8211;&#8211;Basic (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,554<span></span>
</td>
<td class="nump">5,562<span></span>
</td>
<td class="nump">5,550<span></span>
</td>
<td class="nump">5,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Common-share equivalents: stock options, stock issuable under employee compensation plans and convertible preferred stock (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">65<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,619<span></span>
</td>
<td class="nump">5,672<span></span>
</td>
<td class="nump">5,616<span></span>
</td>
<td class="nump">5,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive common stock equivalents (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">6<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:53px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818804699832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Certain Commitments (Patent Litigation) (Details) - Patent Infringement [Member]<br></strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Apr. 30, 2017 </div>
<div>Patents </div>
<div>Defendant</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber', window );">Number of patents which the Patent Trial and Appeal Board refused to initiate proceedings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember', window );">Judicial Ruling [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsFoundInfringedUponNumber', window );">Number of patents infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember', window );">Pfizer Versus Generic Companies [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember', window );">Pfizer Versus Viwit Pharmaceutical Co. Ltd. [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed upon</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember', window );">Xeljanz [Member] | Pfizer Versus Zydus [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember', window );">Eliquis [Member] | Pfizer and BMS Versus Several Generic Manufacturers [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_GainContingencyNumberofDefendants', window );">Number of defendants | Defendant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019', window );">Number of patents allegedly infringed upon due to expire December 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_GainContingencyNumberofDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Number of Defendants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_GainContingencyNumberofDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Patents Without Court Proceedings, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_GainContingencyPatentsWithoutCourtProceedingsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of entity's patents that another entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyPatentsFoundInfringedUponNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of entity's patents that another entity was found to have infringed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyPatentsFoundInfringedUponNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_PfizerVersusGenericCompaniesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_PfizerVersusGenericCompaniesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_XeljanzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_XeljanzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_PfizerVersusZydusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_PfizerVersusZydusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EliquisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EliquisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_PfizerandBMSVersusSeveralGenericManufacturersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_PfizerandBMSVersusSeveralGenericManufacturersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818804449928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Certain Commitments (Product Litigation, Commercial and Other Matters, Resolved Matters) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>plaintiff</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>manufacturer</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>lagoon</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>class_action</div>
</th>
<th class="th">
<div>Mar. 31, 2013 </div>
<div>lagoon</div>
</th>
<th class="th">
<div>Jun. 28, 2020 </div>
<div>USD ($) </div>
<div>lawsuit</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LossContingencyClassActionsFiledNumber', window );">Number of class actions filed | class_action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_HormoneTherapyProductsMember', window );">Hormone Therapy Products [Member] | Class Action Versus Wyeth [Member] | Settled Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Settlement agreed | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_DocetaxelMember', window );">Docetaxel [Member] | Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant', window );">Number of defendants other than main defendant | manufacturer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_EnvironmentalRemediationLitigationMember', window );">Environmental Remediation Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FeasibilityStudyNumberOfLagoons', window );">Number of lagoons | lagoon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | EpiPen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LossContingencyNumberOfLawsuits', window );">Number of lawsuits | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Patent Infringement [Member] | NHS Scotland vs. Dr Reddy's [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_FeasibilityStudyNumberOfLagoons">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Feasibility Study, Number Of Lagoons</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_FeasibilityStudyNumberOfLagoons</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LossContingencyClassActionsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Class Actions Filed, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LossContingencyClassActionsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Defendants Other Than Main Defendant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LossContingencyNumberOfLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Lawsuits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LossContingencyNumberOfLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_HormoneTherapyProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_HormoneTherapyProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_ClassActionVersusWyethMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_ClassActionVersusWyethMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_DocetaxelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_DocetaxelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_EnvironmentalRemediationLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_EnvironmentalRemediationLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EpiPenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EpiPenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_PatentInfringementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_PatentInfringementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_NHSScotlandvs.DrReddysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_NHSScotlandvs.DrReddysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818724809944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingencies and Certain Commitments - Contingent Consideration (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">$ 727<span></span>
</td>
<td class="nump">$ 711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration liability current</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration liability noncurrent</a></td>
<td class="nump">$ 570<span></span>
</td>
<td class="nump">$ 551<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818719941176">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information - Narrative (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>Operating_Segment</div>
</th>
<th class="th">
<div>Jun. 28, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of segments | Operating_Segment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 177,934<span></span>
</td>
<td class="nump">$ 167,489<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818807166712">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 11,801<span></span>
</td>
<td class="nump">$ 13,264<span></span>
</td>
<td class="nump">$ 23,829<span></span>
</td>
<td class="nump">$ 26,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">3,953<span></span>
</td>
<td class="nump">4,141<span></span>
</td>
<td class="nump">7,838<span></span>
</td>
<td class="nump">8,463<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,801<span></span>
</td>
<td class="nump">12,402<span></span>
</td>
<td class="nump">23,829<span></span>
</td>
<td class="nump">24,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">7,818<span></span>
</td>
<td class="nump">8,044<span></span>
</td>
<td class="nump">15,738<span></span>
</td>
<td class="nump">16,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">862<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(1,530)<span></span>
</td>
<td class="num">(1,193)<span></span>
</td>
<td class="num">(3,019)<span></span>
</td>
<td class="num">(2,306)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items [Member] | Purchase Accounting Adjustments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(910)<span></span>
</td>
<td class="num">(1,178)<span></span>
</td>
<td class="num">(1,722)<span></span>
</td>
<td class="num">(2,217)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items [Member] | Acquisition-Related Costs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(21)<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items [Member] | Certain Significant Items [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="num">(268)<span></span>
</td>
<td class="num">(309)<span></span>
</td>
<td class="num">(879)<span></span>
</td>
<td class="num">(691)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate and other unallocated [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(1,136)<span></span>
</td>
<td class="num">(1,399)<span></span>
</td>
<td class="num">(2,245)<span></span>
</td>
<td class="num">(2,676)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember', window );">Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,795<span></span>
</td>
<td class="nump">9,432<span></span>
</td>
<td class="nump">19,802<span></span>
</td>
<td class="nump">18,477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember', window );">Biopharma [Member] | Operating Segments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,795<span></span>
</td>
<td class="nump">9,432<span></span>
</td>
<td class="nump">19,802<span></span>
</td>
<td class="nump">18,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">6,650<span></span>
</td>
<td class="nump">6,071<span></span>
</td>
<td class="nump">13,379<span></span>
</td>
<td class="nump">11,954<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember', window );">Upjohn [Member] | Operating Segments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,006<span></span>
</td>
<td class="nump">2,970<span></span>
</td>
<td class="nump">4,027<span></span>
</td>
<td class="nump">6,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 1,168<span></span>
</td>
<td class="nump">$ 1,973<span></span>
</td>
<td class="nump">$ 2,359<span></span>
</td>
<td class="nump">$ 4,251<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:53px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="font-family:inherit;font-size:8pt;">. Biopharma&#8217;s earnings </span><span style="font-family:inherit;font-size:8pt;text-align:center;">include d</span><span style="font-family:inherit;font-size:8pt;">ividend income of </span><span style="font-family:inherit;font-size:8pt;"><span>$76 million</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$76&#160;million</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:8pt;">, and </span><span style="font-family:inherit;font-size:8pt;"><span>$153 million</span></span><span style="font-family:inherit;font-size:8pt;"> in </span><span style="font-family:inherit;font-size:8pt;">the first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$140 million</span></span><span style="font-family:inherit;font-size:8pt;"> in </span><span style="font-family:inherit;font-size:8pt;">the first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:8pt;"> from our investment in ViiV. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherSegmentReconcilingItemsAxis=pfe_PurchaseAccountingAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherSegmentReconcilingItemsAxis=pfe_PurchaseAccountingAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherSegmentReconcilingItemsAxis=pfe_BusinessCombinationsAcquisitionRelatedCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherSegmentReconcilingItemsAxis=pfe_BusinessCombinationsAcquisitionRelatedCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherSegmentReconcilingItemsAxis=pfe_CertainSignificantItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherSegmentReconcilingItemsAxis=pfe_CertainSignificantItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818719125384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information - Footnotes (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViiVMember', window );">ViiV [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeDividend', window );">Dividend income</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">$ 153<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViiVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViiVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818724152168">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 11,801<span></span>
</td>
<td class="nump">$ 13,264<span></span>
</td>
<td class="nump">$ 23,829<span></span>
</td>
<td class="nump">$ 26,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PercentageChangeInRevenue', window );">Percentage Change In Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5,402<span></span>
</td>
<td class="nump">6,335<span></span>
</td>
<td class="nump">$ 11,053<span></span>
</td>
<td class="nump">12,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PercentageChangeInRevenue', window );">Percentage Change In Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(15.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pfe_DevelopedEuropeMember', window );">Developed Europe [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 2,088<span></span>
</td>
<td class="nump">2,228<span></span>
</td>
<td class="nump">$ 4,009<span></span>
</td>
<td class="nump">4,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PercentageChangeInRevenue', window );">Percentage Change In Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(6.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pfe_DevelopedRestOfWorldMember', window );">Developed Rest Of World [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 1,552<span></span>
</td>
<td class="nump">1,639<span></span>
</td>
<td class="nump">$ 3,008<span></span>
</td>
<td class="nump">3,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PercentageChangeInRevenue', window );">Percentage Change In Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pfe_EmergingMarketsMember', window );">Emerging Markets [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 2,759<span></span>
</td>
<td class="nump">$ 3,062<span></span>
</td>
<td class="nump">$ 5,759<span></span>
</td>
<td class="nump">$ 6,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PercentageChangeInRevenue', window );">Percentage Change In Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="num">(10.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:53px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.</span><span style="font-family:inherit;font-size:8pt;"> Revenues denominated in euros were </span><span style="font-family:inherit;font-size:8pt;"><span>$1.7 billion</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$1.8 billion</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:8pt;">, and were </span><span style="font-family:inherit;font-size:8pt;"><span>$3.2 billion</span></span><span style="font-family:inherit;font-size:8pt;"> in </span><span style="font-family:inherit;font-size:8pt;">the first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$3.5 billion</span></span><span style="font-family:inherit;font-size:8pt;"> in </span><span style="font-family:inherit;font-size:8pt;">the first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:8pt;text-align:center;">.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PercentageChangeInRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage change in revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PercentageChangeInRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pfe_DevelopedEuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pfe_DevelopedEuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pfe_DevelopedRestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pfe_DevelopedRestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pfe_EmergingMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pfe_EmergingMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818806333064">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information - Revenues By Geographic Area - Footnotes (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 11,801<span></span>
</td>
<td class="nump">$ 13,264<span></span>
</td>
<td class="nump">$ 23,829<span></span>
</td>
<td class="nump">$ 26,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pfe_DevelopedEuropeMember', window );">Developed Europe [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">2,088<span></span>
</td>
<td class="nump">2,228<span></span>
</td>
<td class="nump">4,009<span></span>
</td>
<td class="nump">4,315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro Member Countries, Euro [Member] | Developed Europe [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:53px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.</span><span style="font-family:inherit;font-size:8pt;"> Revenues denominated in euros were </span><span style="font-family:inherit;font-size:8pt;"><span>$1.7 billion</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$1.8 billion</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">second quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:8pt;">, and were </span><span style="font-family:inherit;font-size:8pt;"><span>$3.2 billion</span></span><span style="font-family:inherit;font-size:8pt;"> in </span><span style="font-family:inherit;font-size:8pt;">the first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2020</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$3.5 billion</span></span><span style="font-family:inherit;font-size:8pt;"> in </span><span style="font-family:inherit;font-size:8pt;">the first six months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2019</span><span style="font-family:inherit;font-size:8pt;text-align:center;">.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pfe_DevelopedEuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pfe_DevelopedEuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139818726838056">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 11,801<span></span>
</td>
<td class="nump">$ 13,264<span></span>
</td>
<td class="nump">$ 23,829<span></span>
</td>
<td class="nump">$ 26,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember', window );">Biopharma, Upjohn And Consumer Healthcare Segments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,801<span></span>
</td>
<td class="nump">13,264<span></span>
</td>
<td class="nump">23,829<span></span>
</td>
<td class="nump">26,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember', window );">Biopharma, Upjohn And Consumer Healthcare Segments [Member] | Total Alliance revenues [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,404<span></span>
</td>
<td class="nump">1,187<span></span>
</td>
<td class="nump">2,786<span></span>
</td>
<td class="nump">2,277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember', window );">Biopharma, Upjohn And Consumer Healthcare Segments [Member] | Total Biosimilars [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">289<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="nump">578<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember', window );">Biopharma, Upjohn And Consumer Healthcare Segments [Member] | Total Sterile Injectable Pharmaceuticals [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">1,237<span></span>
</td>
<td class="nump">1,218<span></span>
</td>
<td class="nump">2,644<span></span>
</td>
<td class="nump">2,455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember', window );">Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,795<span></span>
</td>
<td class="nump">9,432<span></span>
</td>
<td class="nump">19,802<span></span>
</td>
<td class="nump">18,477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">2,279<span></span>
</td>
<td class="nump">2,243<span></span>
</td>
<td class="nump">4,610<span></span>
</td>
<td class="nump">4,380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Biopharma [Member] | Eliquis [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">1,272<span></span>
</td>
<td class="nump">1,085<span></span>
</td>
<td class="nump">2,572<span></span>
</td>
<td class="nump">2,096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Biopharma [Member] | Chantix / Champix [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">235<span></span>
</td>
<td class="nump">276<span></span>
</td>
<td class="nump">505<span></span>
</td>
<td class="nump">549<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Biopharma [Member] | Premarin family [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">152<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">304<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Biopharma [Member] | BMP2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">57<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Biopharma [Member] | Toviaz [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">64<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Biopharma [Member] | All other Internal Medicine [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">498<span></span>
</td>
<td class="nump">544<span></span>
</td>
<td class="nump">978<span></span>
</td>
<td class="nump">1,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,647<span></span>
</td>
<td class="nump">2,236<span></span>
</td>
<td class="nump">5,082<span></span>
</td>
<td class="nump">4,198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Biopharma [Member] | Ibrance [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,349<span></span>
</td>
<td class="nump">1,261<span></span>
</td>
<td class="nump">2,598<span></span>
</td>
<td class="nump">2,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Biopharma [Member] | Xtandi alliance revenues [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">266<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="nump">475<span></span>
</td>
<td class="nump">369<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Biopharma [Member] | Sutent [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">209<span></span>
</td>
<td class="nump">248<span></span>
</td>
<td class="nump">414<span></span>
</td>
<td class="nump">480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Biopharma [Member] | Inlyta [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">195<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="nump">364<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Biopharma [Member] | Xalkori [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">138<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="nump">287<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Biopharma [Member] | Bosulif [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">113<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Biopharma [Member] | Retacrit [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">87<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Biopharma [Member] | Braftovi [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">36<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Biopharma [Member] | Mektovi [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Biopharma [Member] | All other Oncology [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">221<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">412<span></span>
</td>
<td class="nump">262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4],[5]</sup></td>
<td class="nump">1,794<span></span>
</td>
<td class="nump">1,838<span></span>
</td>
<td class="nump">3,807<span></span>
</td>
<td class="nump">3,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Biopharma [Member] | Sulperazon [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4],[5]</sup></td>
<td class="nump">102<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="nump">289<span></span>
</td>
<td class="nump">342<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Biopharma [Member] | Medrol [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4],[5]</sup></td>
<td class="nump">78<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Biopharma [Member] | Zithromax [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4],[5]</sup></td>
<td class="nump">55<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Biopharma [Member] | Precedex [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4],[5]</sup></td>
<td class="nump">114<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Biopharma [Member] | Vfend [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4],[5]</sup></td>
<td class="nump">75<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Biopharma [Member] | Panzyga [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4],[5]</sup></td>
<td class="nump">63<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Biopharma [Member] | Zyvox [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4],[5]</sup></td>
<td class="nump">55<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Biopharma [Member] | Fragmin [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4],[5]</sup></td>
<td class="nump">58<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Biopharma [Member] | Pfizer CentreOne [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4],[5],[6]</sup></td>
<td class="nump">224<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">376<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Biopharma [Member] | All other Anti-infectives [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4],[5]</sup></td>
<td class="nump">367<span></span>
</td>
<td class="nump">420<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="nump">825<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Biopharma [Member] | All other Hospital [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4],[5]</sup></td>
<td class="nump">603<span></span>
</td>
<td class="nump">544<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
<td class="nump">1,124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_VaccinesMember', window );">Vaccines [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,247<span></span>
</td>
<td class="nump">1,375<span></span>
</td>
<td class="nump">2,857<span></span>
</td>
<td class="nump">2,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_VaccinesMember', window );">Vaccines [Member] | Biopharma [Member] | Prevnar 13/Prevenar 13 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,116<span></span>
</td>
<td class="nump">1,179<span></span>
</td>
<td class="nump">2,566<span></span>
</td>
<td class="nump">2,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_VaccinesMember', window );">Vaccines [Member] | Biopharma [Member] | Nimenrix [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">56<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_VaccinesMember', window );">Vaccines [Member] | Biopharma [Member] | All other Vaccines [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">75<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember', window );">Inflammation and Immunology (I&amp;I) [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,149<span></span>
</td>
<td class="nump">1,219<span></span>
</td>
<td class="nump">2,127<span></span>
</td>
<td class="nump">2,256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember', window );">Inflammation and Immunology (I&amp;I) [Member] | Biopharma [Member] | Xeljanz [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">635<span></span>
</td>
<td class="nump">613<span></span>
</td>
<td class="nump">1,086<span></span>
</td>
<td class="nump">1,036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember', window );">Inflammation and Immunology (I&amp;I) [Member] | Biopharma [Member] | Enbrel (Outside the U.S. and Canada) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">337<span></span>
</td>
<td class="nump">420<span></span>
</td>
<td class="nump">684<span></span>
</td>
<td class="nump">871<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember', window );">Inflammation and Immunology (I&amp;I) [Member] | Biopharma [Member] | Inflectra/Remsima [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">150<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="nump">291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember', window );">Inflammation and Immunology (I&amp;I) [Member] | Biopharma [Member] | All other I &amp; I [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">26<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">681<span></span>
</td>
<td class="nump">521<span></span>
</td>
<td class="nump">1,319<span></span>
</td>
<td class="nump">991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | Biopharma [Member] | Vyndaqel/Vyndamax [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">277<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">508<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | Biopharma [Member] | BeneFIX [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">109<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | Biopharma [Member] | Genotropin [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">106<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | Biopharma [Member] | ReFacto AF/Xyntha [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">91<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | Biopharma [Member] | Somavert [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">67<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | Biopharma [Member] | All other Rare Disease [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">31<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_UpjohnReportingUnitMember', window );">Upjohn [Member] | Upjohn [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">2,006<span></span>
</td>
<td class="nump">2,970<span></span>
</td>
<td class="nump">4,027<span></span>
</td>
<td class="nump">6,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_UpjohnReportingUnitMember', window );">Upjohn [Member] | Upjohn [Member] | Lipitor [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">431<span></span>
</td>
<td class="nump">407<span></span>
</td>
<td class="nump">836<span></span>
</td>
<td class="nump">1,029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_UpjohnReportingUnitMember', window );">Upjohn [Member] | Upjohn [Member] | Lyrica [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">349<span></span>
</td>
<td class="nump">1,175<span></span>
</td>
<td class="nump">706<span></span>
</td>
<td class="nump">2,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_UpjohnReportingUnitMember', window );">Upjohn [Member] | Upjohn [Member] | Norvasc [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">222<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="nump">419<span></span>
</td>
<td class="nump">516<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_UpjohnReportingUnitMember', window );">Upjohn [Member] | Upjohn [Member] | Celebrex [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">139<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="nump">295<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_UpjohnReportingUnitMember', window );">Upjohn [Member] | Upjohn [Member] | Viagra [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">94<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_UpjohnReportingUnitMember', window );">Upjohn [Member] | Upjohn [Member] | Effexor [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">86<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_UpjohnReportingUnitMember', window );">Upjohn [Member] | Upjohn [Member] | Zoloft [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">79<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_UpjohnReportingUnitMember', window );">Upjohn [Member] | Upjohn [Member] | EpiPen [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">64<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_UpjohnReportingUnitMember', window );">Upjohn [Member] | Upjohn [Member] | Xalatan/Xalacom [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">65<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_UpjohnReportingUnitMember', window );">Upjohn [Member] | Upjohn [Member] | All other Upjohn [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">476<span></span>
</td>
<td class="nump">587<span></span>
</td>
<td class="nump">968<span></span>
</td>
<td class="nump">1,109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_ConsumerHealthcareReportingUnitMember', window );">Consumer Healthcare [Member] | Consumer Healthcare [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 862<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,721<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;padding-bottom:53px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts may not add due to rounding.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan).</span><span style="font-family:inherit;font-size:7.5pt;"> As a result, revenues associated with our Meridian subsidiary, except for product revenues for EpiPen sold in Canada, and Mylan-Japan, are reported in our Upjohn business beginning in the first quarter of 2020. We have reclassified revenues associated with our Meridian subsidiary and Mylan-Japan from the Hospital and Internal Medicine categories to the Upjohn business to conform 2019 product revenues to the current presentation.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. Hospital also includes Pfizer CentreOne</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span><span style="font-family:inherit;font-size:7.5pt;">. All other Hospital primarily includes revenues from legacy Sterile Injectables Pharmaceuticals (SIP) products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in &#8220;All other Anti-infectives&#8221;.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">On </span><span style="font-family:inherit;font-size:7.5pt;">July&#160;31, 2019</span><span style="font-family:inherit;font-size:7.5pt;">, Pfizer&#8217;s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK&#8217;s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Note 2B</span><span style="font-family:inherit;font-size:7.5pt;">.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_TotalAllianceBiopharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_TotalAllianceBiopharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_TotalBiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_TotalBiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_TotalSterileInjectablePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_TotalSterileInjectablePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EliquisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EliquisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ChantixChampixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ChantixChampixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_PremarinFamilyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_PremarinFamilyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BMP2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BMP2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ToviazMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ToviazMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_AllOtherInternalMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_AllOtherInternalMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_IbranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_IbranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_XtandiAllianceRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_XtandiAllianceRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_SutentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_SutentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_InlytaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_InlytaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_XalkoriMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_XalkoriMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BosulifMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BosulifMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_RetacritMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_RetacritMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BraftoviMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BraftoviMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_MektoviMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_MektoviMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_OtherOncologyProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_OtherOncologyProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_HospitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_SulperazonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_SulperazonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_MedrolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_MedrolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ZithromaxZmaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ZithromaxZmaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_PrecedexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_PrecedexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_VfendMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_VfendMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_PanzygaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_PanzygaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ZyvoxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ZyvoxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_FragminMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_FragminMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_PfizerCentreOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_PfizerCentreOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_OtherAntiinfectivesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_OtherAntiinfectivesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_OtherHospitalProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_OtherHospitalProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_VaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_VaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_PrevnarPrevenarFamilyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_PrevnarPrevenarFamilyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_NimenrixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_NimenrixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_OtherVaccinesProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_OtherVaccinesProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_XeljanzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_XeljanzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EnbrelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EnbrelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_InflectraRemsimaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_InflectraRemsimaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_AllOtherInflammationandImmunologyProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_AllOtherInflammationandImmunologyProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_VyndaqelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_VyndaqelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BeneFIXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BeneFIXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_GenotropinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_GenotropinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ReFactoAfXynthaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ReFactoAfXynthaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_SomavertMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_SomavertMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_AllOtherRareDiseaseProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_AllOtherRareDiseaseProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_UpjohnReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_UpjohnReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_LipitorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_LipitorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_LyricaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_LyricaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_NorvascMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_NorvascMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_CelebrexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_CelebrexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ViagraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ViagraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EffexorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EffexorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ZoloftMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ZoloftMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EpiPenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EpiPenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_XalatanXalacomMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_XalatanXalacomMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_AllOtherUpjohnProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_AllOtherUpjohnProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_ConsumerHealthcareReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_ConsumerHealthcareReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_ConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_ConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>113
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MUN^XRJD/BAHK]*%UR:>Y&&IL=AS[6*5RWW[2*FMK'_EZV6-UD>:K3'"2AO]
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M-_Y:5NK+GS=A\11#2$K8'!@RAF/PFZ*^3UG_$/FRNO_WF N1I]77!0M!AY8
M*)_GL-::'V4#ZUNMY_\!4$L#!!0    ( $^!!E$ZY]P#+PH  -XQ   8
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&ULW5M=4^,Z$OTK*G9J"ZH(B67'<;)
M%2$9X.[ 3 W#W8>I>1")DGC&'QE+X>/^^FW))DZDM@UA=Q_V 4BLTRWYJ-WJ
M(XOCQS3[)1:<2_(41XDXV5M(N1RTVV*RX#$31^F2)] R2[.82?B:S=MBF7$V
MU49QU*:=CM^.69CLG1[K:U^RT^-T):,PX5\R(E9QS++G(8_2QY,]9^_EPM=P
MOI#J0OOT>,GF_);+N^67#+ZUUUZF8<P3$:8)R?CL9._,&5RZOC+0B#]#_B@V
M/A-U*_=I^DM]N9J>['74B'C$)U*Y8/#G@9_S*%*>8!R_"Z=[ZSZ5X>;G%^\?
M]<W#S=PSP<_3Z%_A5"Y.]H(],N4SMHKDU_3QDA<WU%7^)FDD]&_R6& [>V2R
M$C*-"V,801PF^5_V5!#Q&@-:&%## #K&#=S"P#4-O H#KS#P7MM#MS#HF@9N
MA8%?&/BO'5*O,.B]MH>@, CT[.;3H>=RQ"0[/<[21Y(I-'A3'W1 :&N8PC!1
ML7LK,V@-P4Z>GG^^&8UO;L<C I]N/W^Z&IU]@R^WW^#/]?CFVRWY_!&:KK]\
M'5\"[NK/,;FZ@>]CLG]W<W8WN@+T 6F1N]L1V?]P0#Z0,"'7811!8(KCMH0A
MJH[:DV(XY_EP:,5P7'*=)G(AR#B9\BEB/ZZW]VOLVT#-FA_ZPL\YK77XQRHY
M(C0X)+1#.\AX1J\P=SO*W.ECM_.^WB]V[GV+#'<=+*[VYU;XNY5,<DA<DJ0S
M<I[&D"T7*HT]<'*53-*8D^]G]T)FD)!^U'3GK;OS='=>17<WD+K#W.\]AS3-
M"8NB=,)TTI,I25)H3&260K0E<X!*GG$AL; ;UO?TW?EQ^)W"CPL_W@\L;G,'
MOG:@%H2'4]=SO>/VPV8PV*!NI^MO@\8VR ^\[C;HP@8%_0W0%I_=-9_=VKN$
M9 ^I/(&TDF4\F3P3F*E$1#F?;/H3LHV:7'%($BXQ$NO=:Q*[*'FY87?C;EK4
MHP9Y",@+#%[&",CI.J[!'H;R'9P]?\V>7WM[7_DD8D*$LW!B,8:15>\-R,*(
M\JV!=PR6&A'C1L3'AJ&A<WAANS4F\/*-;K=FH;>>A5ZME\]RP3,RV<H]18[8
MCU(A#@[)# US5M1*R;0B[ ]?DHQD3]A\UH^K8CY[KPE\!&0'/@)" A]%]?'
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M4TC+#"3J$GH)855\!O.9  EQ_TQ8ONT"_M@2*KVG, ;]"X@/;M A<7X"#4I
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M"[)F^E9L;V@63\W8\P53R1>VF:YC@;]66L09&#V((Y[^R4O&PQZ@TO@ X&8
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M#J'2*.#Z0@B]$\P&^<NF^QM02P,$%     @ 3X$&4<$*F_9,"@  /S   !@
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M9[?Q>E%^SAXO6!.05_F;98NB_C]Z;+#. 9JMBS);-L:\!<LDW?R-_VP2T<7
M;0Q<R0 3C0%I#$A7 ]H84,G ]30&7F/@R0:NQL!O#'S)@&"-0= 8!/(9J,8@
M; Q"V2#0&$2-020W29<E[#SUG".;:/MZV]ER;Q-='/BINW'=W\/-P*I'Y5E<
MQL=O\^P1Y16>^ZM>U$.[MN>#,4FK*KPI<WXTX7;E\>C3U=GXZF9\AOBKFT_3
MR[.3+_S-S1?^Y^/XZLL-^G2.QO_X>OGEW^C5UZN3KV>7_/AK-$!?;\[0JU]>
MHU]0DJ*/R6+!BZIX.RQYHRK7PUG3@-&F :ZF 5^R,EX 9F.SV34O5I;G;(YN
MRFSV._KVD2V_L_P_@*=SLZ=1MESRZ<#JYKW9S<E\_NL"7<?)?,#S,8I7"8_+
MY._"DA<^IQ;K_(>]89=F1Y]9R2=CGJAQG*=)>E>8?'VP!#F;K9>'Z%-YSW+$
M$[<Z1-.L,'J<F#W>W,<YN\\6<Y87OZ+Q'^ND_&%R-S6[N\K269:6><:'8WJ'
M+M.2Y:PH=2T<\FK9EHR[+1FW/@?5G..4W25IE4D^_2_B=,;0*][C115(\1K%
M)3ICLT-$\!OD.C@$8C@U^_^&H<#'&R.O-JJNK0_'-.#>'W9'NHJ)".$7Y.J_
M-O1"A1(?>Q*TE1^RS0]Y9GZZY,3L$\[):&/D[P3AD\"3LC)643B2$J="J!^T
M,>]53.B['I'RJJ(&V,$^EO)_"7B+/(^V41\@;]@-O#9L N6!.E( 4Q5%/ SW
M-=WV-:V-B*9?+M-9-4_Q$N =7+]Z75T.ZCE+J>K/O"H1YTZ/<3XW%:*W/;EG
M'!17G*0FO-Z7#!I09EO-@/*4J@@C*F7[S.+9_<^;;X3_H^!D#9W!E8;CI MH
MJH*P!_>FOTVH;VSZ9E[G">6$_KYBV@^L2?#PU8+/\Z_?H)3G/+M%9?PGE'.S
M>TW.?26.@>N[4LXMGEWP8@9ZE@IQT@4TA4!PKH-MK@-CY8SBXA[-DX=DSM)Y
MP1<.LP6_@,R/#'41;EV'QFPTC*:HBA#J);.UII="-0/4D;OILA-J8D.UHHZV
M44?&=@M&J W<[$ 3>*0V%DM1VR$3(Z05+W8$=7?,\U^;["1/9 <*W>)*$WMC
MU6JV='6=FC'MT'96)=C8GIH6#JKE]1RMXA]\V5^B,H_3(JX7[\4NY0+#-;N'
MPSUOK%JD"(/L"4 &)NZ$!;G$9O9GBQR,M@^A'&& 43I2J9XWH%W2($'> WX"
M[,H)4_T,B(R:6)K43JG@H]A,'J_7^>R>)[2HKERSG<G1.HKZD-*+QJI=ZZ%C
M'!Z";V':+Q:P_69?NG%!@8(.?4_N4:KVJ J;6+VU$R&X'S;3+&FZY[E('SC;
MK">'.)TC?H0M5]TFBSY4<8Q5_C5P=?TK&!@V,YEGA 6&THN!82.]:<+U@:6(
M/!, ?N0+H?E<[:P)+H4#.W$%\V&VX_EX\\V#<Q*H]%IBX)<=,!,SIAVO('C8
MS-'&Z=R@/WQ8IWRM[=1K[0C,2A\&.,8J;:/R6OL< $7$)_!%5,62T)$ON.T4
M"3:(S6Q.2E&GM/3BAUBE=EX4N52NGTA5(93DJ1CJAW*1J><+_<B7=0C UP!C
M)PA]>1"K_B)*J=19'P 8]^<19;Z'TN')44P!&/$"N--=P8A=,XVU2G,?XWPK
M0X%CP'("G3:G<F#J2XD^!T 1\4)8G5.QMM)P!;EVS>P7%.CLF>E#J4>N2I2]
M""L270,S:G0 1JT.X'RA[\NC] +PM:D.>6D'^(L(":73?@!@ ^Q$KE25$R@=
M8>A(0V4*P(BGN4JZ.[JU^]>+=:Z@X:Z9+IOE.HNQ;GBI7-MS/"F=9S;?9L4.
M/ ?UY9[M@IH"**RK9[$F<,T\?F_9SN)?EWN V2LZ]YG--ZS<P;Z5:NJ"F@(H
MHDFY6'VXWDNK=ZY8 [AFEF[3[RSFNNX"B#>)(BI/>)U@$RNL';M@\JZ9D7=0
M\2P>=.&K/%R^)6.'3(R0=LB"S+MFNOT<&<_B2A<[(+C*A,R,:8<F2+AKILS[
MRG@6]QH9SP4HJ/'&IN"7Q$S_^HAS%I>Z.YL  937%.<-R-</V/>@'XE970!^
M!O+US=*@=D(%%25FUMA;FK/XU4AS1.55NC$A6!4QJZO/4N0LOG2#095%Y04#
M4?55>>XR>FD'OW.KWR*MOIP*9SF39N5% +%5,VT10:B(163=3X2S>-=U,D!F
MI-7(F*B:JU+P=C<3,Z:=-$&)B%DFU6IP%CM=.E1Y5=E"885,C)!VH(*>$3._
MVE-\LWC7C7.5;ZGB&P#2BF\ UJ8P$,'BB)F#]1#?+!YUHT3E8Y#XUL",XAN
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MG8+CB[6$C_]Z1=07ZP#?S-W-BJC%6#>^@.=;4")/V3;?9D44/(?<99-.J"F
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MX,=O,]YIS9OJ!-N?OSC^'U!+ P04    " !/@091 A!-P,D*  #%,   &
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;+6;;7/;J!;'OPJ3V[F3S,2Q 4FV
M<]/,.'9SFTZ;9)JV^V)G7V )QVSUX"(Y#_OI[P&IDB,!RKI[7W1CFP/B?X!S
M?B#V[#&3W_,UYP5Z2N(T?WNP+HK-Z7"8AVN>L/PDV_ 42E:93%@!7^7],-](
MSB)=*8F'9#0*A@D3Z<'YF?[M5IZ?9=LB%BF_E2C?)@F3SQ<\SA[?'N"#GS]\
M%O?K0OTP/#_;L'M^QXNOFUL)WX9U*Y%(>)J++$62K]X>S/#IPM<5M,4WP1_S
MG<](25EFV7?UY2IZ>S!2/>(Q#PO5!(,_#WS.XUBU!/WX435Z4#]35=S]_+/U
M2RT>Q"Q9SN=9_)N(BO7;@\D!BOB*;>/B<_;XGE>"?-5>F,6Y_B]ZK&Q'!RC<
MYD665)6A!XE(R[_LJ7+$:RJ0J@)I58 'FRO0J@)M5_ L%;RJ@J<]4TK1?EBP
M@IV?R>P1264-K:D/VIFZ-L@7J1KWNT)"J8!ZQ?G\YGKQ[OKNW0+!I[N;CU>+
MV1?X<O<%_GQZ=_WE#MU<HOGL[CVZ_'CSVQTZ_'H]^[JX ILC-$!?[Q;H\,T1
M>H-$BCZ).(:AS,^&!71,-3\,JT[,RTX02R<"]"E+BW6.WJ41CU[6'X*@6A7Y
MJ6I.G U^V*8GB$R.$1F1D:$_BU=4IR-5'4\=W:&UDZENCUK:N]EPR0J1WJ.9
MFN:B$#QW-.O5S7JZ6<_2[#6$!9&&6<+1DD,(X(C%<18RO:"*#*49%*:%S&!<
MX-DB+;CD>6$:H OWDW['?QS_3N ?A7_>'Z81+AL(= ,JV#R<!Q///QL^[+J]
M:S29[AB]\()?>\%W.G<6_0G+!$)1D2O1DH/F4,0<I7NZ1Y=!W9#E:[21V8.
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M.2YX;6RU5VUOXC@0_BLCKCJU4DM>H+Q=BT0)55GU305V/U3[P1 #ODWLK.U
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M/%B6^#>NV&)AJ]JDB+RUOZ2&O5K=DX/0K*F$ETA!$&<I$F@0C"_&BWA-Q80
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MB=0)$@Z3J]-SU!D5PYQC#^S^&/X0Q'+Z!HLEXR"*KJL),$8$.;*6889F%7O
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M3<X_I\@?E*4!^#XV )SP0!O4MXB?_P]02P,$%     @ 3X$&46YT,AVW#
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M8#1SE=1LTX<:+M'V7I,4$FWU',57M$R&<FIW3$!S1= XK3VO5_=>49>GE:W
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MEAC&*F[S6S^1_Y7QQ/7M["D9K<1U-$D@X;4G#$2X414'W_DTPB2XM@,S!EB
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M7+CNYP+1_='(3O9N2WBZC&\"AT9 R347Y^YT]^R8-K?M=_'FS?)16)ASI+B
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M<(2 X.!Q7&<Z'2IW:!^;'PV&0+Q^,NY/>.!I?\ICV3B<2/3'SXP.G('OJ\E
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MAS9F0?P9'@6YZ?4F\(49)65/G<0&XAXMR@@;1(XRPZ2]LJ'Z/.X+J0-6?(8
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MY<3[!X<_)6[MT1I\)1G1D]^LBV64>$*H,'<^@N#',WY$I7P@IO'//F;4I_3
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M&X8FP]DT M.)8[=QU 1!RLBQO(5EQ=\3--Z![1LB=]CX!/T7:O4O4$L#!!0
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M1$G"6HD\=*,DI#UT48RN,=?TW7'"PDG [;X?HCG)M7'J+X\A$GE )PM7":.
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M]!=IVM(KQ1=_#O3I;)M'[W[K;,W:'M> MPH4<_$)M4%OPCZ.R;G*,G;W1F<
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MI_4=AEVJ-7DW(L8,'1Q3KM.$0QJ%V@^/LUH W8![I5F1L4?\(@%':=JR7Z*
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MGOS-@(B,!(02G=#/WPI/WD*0)!X9D(0G^:\"A0E!)\7!-.89I@<9BC]=PX,
M"%=8CSV#M32[J2/\#N #=XZQW_3]=!=I")ZF560/ >E^6-<*'@H((=6;G"U(
M+AEOA1L7B3((+]Z:BT7<:/FY=\ Z$O]3VU2X3X55S[%Z^+@$$VY<\1,(QZHX
M^WQ2Z,7\IIG(,$XMI5R/8S-)[CM?DYW+EL=Z8X/%.2!QB#82%_<@>"X)[S'M
M=4%%;>&9W0D==$KJ,V1CB'=6=4WG$T +..W/]<S2A.:YV89BCPHXSR&A2A3I
M\!&6R+:4:O4> %MBK5="58Y>;#/'\TZ\6TG[761\?M2S-G3'H?%'.28B20
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M@[,0S9INQDN2:)C)[BD#[Q-[DJ+ RWG#M4A2@W-T</#L6V7DAJ@()5$% "O
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MJ0).STT.36W+S>?^]/@S?W FWB6W<71F,G:.@X]"P"=*F;D8B'N]CF\)YS2
MV3QCY;N,[^'#.J-*7I6S-%V'=6]XGP,1.7^I[\=/Q^=[RY[> 1BSZJV]:-4R
MOY]8]":C\R#_378$'5"=7@,P+?Z)]R67=W07+_:[ER_VC8/_E/#_UE[!?R%
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MY[103 @1D,91R*+YH9IA5N !ZS([,.\=]Q NL,"%A%NE=4[T=+4!F47+)%K
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MFU['S,+.-$B7&B:S6@JXJ5B$*5 /3Z;-Y2,B4\$ Y$M[UC929PB &8AE03H
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MA5@0E@9K6TG2)I7L!+76$!&E=1JC(;(UVR_3;$.ANFHD*;\DE?]]K5X$U3!
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MZ#QHA86SW7R!X,#4*@OS&_JB*AK&PZPHT_?*)*T[U? "8P, J,T-.!B+OY1
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MA\?U*=Q91:_IU5Q9E1IXX$^Y<9KD1J4R<6H9BY]LZ>$>&UR\"@M0GG38D8M
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MI+Z$<G0%G0PC&Q"I_5@8I&*/$T4KKB0V.UX/'Y9,Y6Q1V^?UI<U96NYAZ%'
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M5',SF<(8>PLM("8GIHH9L F[[-K>B)FRUX^5=7"4B-54Q@ YASC"$LK(WDA
M>C 4R)%JF_>\3C*IK3=L:[)=>[_77=P.N^*H@!]4[HWW D!"[I:QGJ9$7^DX
M;3#ICQ;AW!VRU8O0*VGC.:+JM&7/DCLC-78UR<-KK[\G?K_^+(X1H2*!BSXI
M).(LE%:)/[Y5\4^4FR$AZDHE@6)K1LX** <J;EO[0>,?E[=WUI;>AK8(V,C'
M:^13F;S^"A! X>T- ZY DHN_PT&/_P9@1<7WL(PCA01 AZ2*XM1&)ANX^V<A
M+7:RZR?:@B 'EB0>2^ SPG/1 FYIS 4:+HTL.G4JQ@@.W'T'4IW>0A [>2QC
MF88>L?W#?&:LVX&$9%'[J .5MQ^#QG,Z5NK0/ --)!(&$<[1X^D1$2S'>X9J
M478G- 6@UD>?%*.-.L\+UA3;4HPG_/!.NUEM54G%A4(4O .%FSOPH++%T,4/
MJ$@EE?8MP;O&ZAS)5Q;@"BL1D&4KGW#[:DNAT8()Q"-;0XVBR22$UC&("B6<
M80DR1/;FFD<MT!\"<.9MQM0U<%O9]N(D0>F#-"ZH]TC4G]IQFOC(6Z >-3YH
M;^*"-7@BN&!#]I4@0,!=.*_-YEZ $2N.B4&;L9?:J\?NI[.EU*LE)!2>UOB'
M$ *_BA1NC!GV/2]0;>X"!"M9E6/@25,LY3JD'J*Y3X&O[)B5K(:]EW$ZTN;\
M1H6S]F.SUJ;'ZPWKCP:_RK > .R?L:R12J\PC3K?B_0Y!AZI^WFB:-0)VP+G
M!R&CB(L#.:=3?YCB4DD;M!"<8^PZ-TC(T1'E8,1-GA3-Z[JA;E]DN*0>:Z 2
MZ%$/*,ZY;X2\A_1:F@KPW+H4/97)FNS^YK! "/1_ 'Z)/&4D\M61V!QT:Z>#
M=&%L4__+(I&4!0Y)D!KDU;ST?"-,YXJ\D.HQ%J<%EHT%ZF4T+=/<5N;+AZ\M
M5GNS_P*Q9]@P;\I89%P#,LE[%?NO[>LV\3N[^/?%3H &7J&@0[ZYJJE<?;@1
MDX+.O3N8*C7#_OGU\=FQ3_"U+H4=IG8G07B5)F5BD(J%SV6,795Y=;*PHGA(
M]\>?>W[ RHD(KD6IECX]?::RFIV\!NS-X0+OX(O5_OPR1UL1ES.)Z@@5D#RD
MR#P,) G_>'+(H\KH;5['T$\$LDC#&>GR7=^#!M2S8HPIJ3<:O(5J4A#F6 RM
MU*2B6\R.XD3G/^"6<D^;I]3U)=NH4<R8;1XZUT>EV;0PG*"N-+6JA[.K"&'T
ME(OL#<]OF_O=55CS_>KDBSB]O/I-)MG;DQ:GCX2_U4Z(HR'Y2V!XF%8"ZM ^
MZ,Y',AD;P]0,P51Q,J,31Y6/&>S#? Q^2YF9P04,"SS'A.4D;FF 12>E:0$E
M>S?3",$=)@H_+]4S!08<FM)TZN$(]J3&(2-5S:E4K+;0*V[](#,I7 %!36G@
M>*MBDY%^+3B./#=8Z3DDUM?L3S,#&SC**>#=+1W$/#WMJ;'#HUIK239P+2U?
M)+'I*YSZ&8#E(S(UM\KZ,T6D)CR1E8#I\=2J";V56MM\LHBU;F (N*I0TO'$
M9Q/!="+38B)#YX^2='BAJ!=)5IX 21(\0B[IK7;)/^:*PU2&QK96H!NO&)5*
M#:.*=(JZ U3\4&XQJS)&^D6TQQA0#K,,W$![6"+@*&.06/:F>+T[&<VJ.F^]
M;&(HV3\^?A*N!MWF"#G=?G5G[.VW8!$J.F>>/(03>VCMSZ</G>$/#CD.L0!>
MX&?*+9P:?)+%GK0*"T6*3B+&3F6J_Y(EN.7.%I1&&%?49*+X/6D5C+&::L^R
MUHYX/T)X>MN44J%S$?!L#7?*>]XMHUN=4[LMWP; [72>K2<;;CXS*NORC+7N
MD/RG 88*G U)V[H!X"A$&N;UR0M98%UI'[$<RUSG@ P89Q7.+35&>6R")QDH
MB53=A_26H-2#RH/SA=H$6DQ1]\?&P$?%SKLQ&"D;S\E9Y5&^=")TM[Q<LZ!5
M.F27+;9<63*O+:ZK/A,<>:!?V8_:W"]NGCV<K)FO(DTO"Q?S( \'P\?#P?*$
M^TWK;SX3%HT+YZ<%7:LJR^HU%_9AIJS'\B6'0FW:Y]_!8 :-E"U->W+<>;UA
MO=W^2RQ[9-C^_C]AV)K3Z=,GDR5_]WZM6G\_&S:#W>;8W!SN<(HJ++\UH/>@
MJ!D:-QK=Z%-A,99)3"-?@"SRJ=@_ZZ25L6_,!<_%'L?S7V7&JB\(G<;W&B#<
ME+]*$8(6J?.?;NK5^L/7H?_>L]CNOYI!R)3.I[&:@+3;'NUN^)Y=_7$FXZ\_
M8^.<2?AVIB0B3AOP?&* ,.4?$E!_#GS_/U!+ P04    " !/@091 D733A($
M  !R"0  &0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6R=5FU3XS80_BL[
M[DW'S'#8EI,0:,@,+[TI'2@,X=H/G7Y0['6LGBSY)#F!^_5=R4D(<T"9^R)+
MLO;99U^ER4J;+[9&=/#02&5/HMJY]CA);%%CP^V!;E'1GTJ;ACM:FD5B6X.\
M#$*-3%B:CI*&"Q5-)V'OUDPGNG-2*+PU8+NFX>;Q#*5>G419M-FX$XO:^8UD
M.FGY F?H/K>WAE;)%J44#2HKM *#U4ETFAV?#?SY<.!/@2N[,P=OR5SK+WYQ
M69Y$J2>$$@OG$3A]EGB.4GH@HO%UC1EM57K!W?D&_5.PG6R9<XOG6OXE2E>?
M1.,(2JQX)]V=7OV&:WN&'J_0TH815OW9PSR"HK-.-VMA8M (U7_YP]H/.P+C
M]!4!MA9@@7>O*+"\X(Y/)T:OP/C3A.8GP=0@3>2$\D&9.4-_!<FYZ3U_@&ON
M'!H+\3V?2[1[D\01LO^?%&N4LQZ%O8(R@FNM7&WA5U5B^5P^(49;6FQ#ZXR]
M"?A[IPZ C?>!I2Q] R_?FID'O/P5O$M5Z ;!6WLA;"&U[0S"WZ=SZPPEQC]O
MJ!AL50R"BL$K*F94+V4G$705]-P:O10^=Y/X#!56PNT!I>&-J]' N6ZHAFJ?
MW$N$GET27VG[LO??UGQ?(U1:4GT)M0#G@PBMUUZB!5('A-YJA<K9#;GVB=Q\
MAYP.Y(IGY,A7%H[AOC:(S\(,,_'P?".^OKRZNKSY8P8WG^#BYNKJ]&ZV!Q1+
M#+$,DSS=?V&'*HSJ1U'&&X.J> 0*B[*2]Y5;_DN%T'C^^Z"H4<5\#S[ **4A
MS@YA+WR/6)AD*7Q6U)ZD^$:,:BU+[Y0%M2>;Q-X62G!O:HE&++EO"5 )Q54A
MN 0ZY$RWHVF803S,"3@>>_@1W&$AN;6B$L5WY"@(IM=$0(7LO$N$"CBBS[\X
M'WJL@1]8ZL?A$8W9B";>CCA+6=CU*M]E!E]R(7W$/Y+RCY93Z"V2%X43N+&!
M8 ,V#8/_-Z '?\V"$>1P2)!9!HP61[#.;6@E!>S8=]F.&^_+YUQ[*FQ#Y6A#
MZ$TZ!BD#B(+3P!MMG/C6GR%_94/(,\C&[P:PZ)S$G= R^/FG,<O8+Y QR-9U
M2<ACZCED)$6*Y3#(@64_1I(JK36"'&K1+$7AJ]#2<:[*OLS6J9SU#@DCZT>?
M FLZ3QRWL_AH1R#="OQ(55.U9+DOGI"%]&6C83_)0XKR $O)P*E9*NTV7:4,
MB5*]LV9[#X76I"F-EKC9I\P2BFX>%40H96PWMZ(4E#^A<7%'EZ&4,$>H4?I,
MI.M6*.%0/AZ\U+&3G7NP0;,(M[TERSOE^BMQN[M]4)SV]^C3\?XU<LW-PA>R
MQ(I$TX/#802FO^'[A=-MN%7GVM$=':8U/8K0^ /TO]+:;19>P?:9-?T/4$L#
M!!0    ( $^!!E$8;6"#;00  %<)   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;(U6VW+;-A#]E1U-'N091I2HBR]C>T96;F[MV!,Y[4.G#Q"Y%)&
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M$,#[TN!:=YM@8/\M=?XO4$L#!!0    ( $^!!E%.<C.BNA<  .UK   9
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M2&.ZW' ?##8L .]7:5I4-]A _0M?K_\?4$L#!!0    ( $^!!E$"LMCZ?@,
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M@MKH%\'IY!QM%A\9A0LXN5_<W2T>OBSAX19N'N[N+I^6IT!!QA#D&RRPRM'
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M8Y(DL[BB3$2KA?=MU6HA&\.9P*T"W5055:<-<GE<1N.H<]RS0VF<(UXM:GK
M'9IO]599*^Y5<E:AT$P*4%@LH_7X:C-Q> _XSO"H!WMPE>RE?'3&EWP9)2XA
MY)@9IT#M\ANOD7,G9--X"II1'](1A_M._9.OW=:RIQJO)?_!<E,NHWD$.1:T
MX>9>'C]CJ&?J]#+)M?_"L<42$D'6:".K0+895$RT*WT.]S @S),W""00B,^[
M#>2SO*&&KA9*'D$YM%5S&U^J9]ODF'"/LC/*GC++,ZO;IX:9$\ '>/= ]QSU
M^T5LK*X[C;.@L6DUR!L:,[B3PI0:;D6.^;_\V.;3)T6ZI#;DK.#71HR S"^
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MCZF\BII<JZ9PP0S/@<D"KKBH+1;0:E\K?\G#NQ4\E A3):CJ'% 3QKE63[Q
M Y9^%F@9%Z0L9R*O!?-50FRN1V,XA8=2(VX%"<;\>7MC_^8>[FYN;V\^W(\/
M@"* /@)^THV"%W8<]GU=H696Z9]_ZB=Q_*X=&B?<R%Q51%RK"G+2Q67MZ-,E
MI#U! WO0#7K='HUI$*49C5G0[Z4T]H,3&F_1F%.XI_N,-UCLJT262CID3;YQ
MT%Q:U&BL@3[$$<3'$*??0>-KU-&4_T7!(L$C1S#)'+U>YL@E?4<M.6FIC>C>
M0:W)?U3=^2,4W,5$%F;;'Y(LH&A8]@Q^)WGWZOC?V.9-89O-PEY;D&Y9<,5-
MJX#HK_%_F/F.,/T3Q;V6Y%Y+<Z\ENM=2W9%JRRI[>[^Y&F:&7CA75DH^T=XZ
M:5=DLV_(_DN_!F]&['\,T(_ZP@7N"J6BU\Z%#C[YEQ6+0T80U"B K*L)*297
M;*HU0#V'L:258OC2U9(&:=ISWRSQ\\A]3_KMPW;H00 _U_R)"926*K6I3S7W
ML0C:)2>3O MJN@,U8#47Z@M=E<2%.B737*-SP63C@<9RRYOK=[ORLQ1BNG*R
MC(;D#>Q<YG4:9/&)^QXG?NXJ^3B.X9PR[+!PAZ@36H%Z*AMVPSX[ *($/4C\
MG%X2L^/X@J[/34[TZFC_P% :<U489[:ADU@$0.G3G)?*YY6HW3O"I3_O/$CI
MM7R'BN5;2/G00"JS!IU@SFI:DR#7#91O%!>J%@64Y$/Z4 )2X[=E-4ZGU! >
MO?2"AQMM%-T;,]\L&J)52]MT5*O=53]ZWK1AZ^--,WO'](Q3!@B<DFAT=)QV
M0#<-8K.P:NZ;LHFRU.+Y:4D]-6IW@/Y/E;++A5.PZM*'?P-02P,$%     @
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M1M]DV$6Z@MO/$1OPPT15WU6*8;;MPAF%@S=:X!A*QR9+3NC#C!^!5%3PU.:
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M,1!0:A$@$WJ8W$/D]UV.-!25IROJ%HB3)8)H6:PLROWE/A:W5 T'E<F\;H'
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M;65ZO#$ =*TA4S^.A.O6X;I%N/,#X;8A9$-S46A.*LW;%"U]]@J?]L->CX,
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M>?DH)UJLBO]W)+2Y#13#I;FP@;0&9C\50F\G]DI07P''OP%02P,$%     @
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MPDBG+!C^/4,;PC#EA'K\RIE65C)3X/KUDOM=9CP:,V0*VB+\FP=Z>EEI5D@
M8Y:$^JN8]R W*%-P)$*5_9)Y3NM4R"A16D0Y&#6(>+SX9R_Y1JP!O$8)@.8
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MBP]&BQLM9MFG@:'06D39Y1083O I :Z/A=#+FU3 ZK/=U7]02P,$%     @
M3X$&48(1(IH%!P  D20  !D   !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL
MO5I=<]HX%/TK&J8/[4P:+,F?3)*90$A""FFGV>X^9/I@0 1/;8O*(FG__<K&
M8&Q]V$UV]J$-2.=(YUY)]UX9G[U0]B-;$\+!KR1.L_/>FO/-H-_/%FN2A-DI
MW9!4]*PH2T(NOK*G?K9A)%P6I"3N(\MR^TD8I;V+LZ+M"[LXHUL>1RGYPD"V
M39*0_1Z2F+Z<]V!OW_ U>EKSO*%_<;8)G\@#X=\V7YCXUC^,LHP2DF8130$C
MJ_/>)1Q\QFY.*!!_1^0E._H,<E/FE/[(OTR6YSTK5T1BLN#Y$*'X\TQ&)([S
MD82.G^6@O<.<.?'X\W[TZ\)X8<P\S,B(QO]$2[X^[_D]L"2K<!OSK_3EEI0&
M.?EX"QIGQ?_@I<1:/;#89IPF)5DH2*)T]S?\53KBB( ]#0&5!-0@B(G5!%P2
M<). -02[)-A-@JTA."7!Z4IP2X+;U0:O)'A=;?!+@M]54E 2@JX$:.U7SNI,
M.2QV<[7UE/UR0VF]=:;#_8)#:<6UL^R7''9><[A?]-V&[^]V?'%<KD(>7IPQ
M^@)8CA?CY1^*,U?PQ2F)TCP\/' F>B/!XQ>7BY_;*(ORHWH"QN(S__UQ1OB:
M+L$D?289%Z& @S!=@FFTR*-"^@0N&0O3)Y+W9 !\! \B9BVW,0%TI1_B_17A
M811G'P3AV\,5>/_N W@'HA3,HC@6LV=G?2[LR57U%Z7VT4X[TFC'8$93OL[
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M^838S21[K4 YEM.,4PJ4Z]M.'76G0/G!$:KN,U3Y#!GMNR=<Q*'";W.RHHR
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M8% [!3K?*:K^9N,<M-]$JU]02P,$%     @ 3X$&41G01\0W P  HPD  !D
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M!+0^%U15BX%14+[AC?X%4$L#!!0    ( $^!!E&P,;8$- <  /4=   9
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M*)VZHT_H+O[&UY%IW6\LJ GM;G\+;M;P47O/$0L+2JZ,K)[L#;3KRLC==^6
MY,*DO%-R#1M*$7G6Y%;$6XIHT-OM<&AN]SWI#6V>X H_2ZYX[KXKY3U4JDEL
M"3QA*P99)#*#Z^SJ5-?.PV[J?2Z &G"/: 3$UKU7262D2AZC+XO9]3'Z[696
M[!) -J-D17+3\-SG84B%(1J/J2 9&)PB<1PP7PM&NVXVWR;=M8''@H5$,*."
M6MJTQMABL]:PXDT -VS@*_<_DP945J<A/<MOB51&[LRLP1]ECU%6MOT7I'2)
M"4Q";0Z[Q1[?;3C9J=SZ3!I0!V\L/-Q_X\;"Q5[#QJ*S]4T(EMFC^7HG87*3
M2*7'??G3_ OAQ'P7VWD^=<8SI^+YW!E?5CV_P-YXCKV*%MB(0<N@LF4(+</*
MEA&TC*I:W.YXGG[2[!0!IA]$KT%;62110%<0;+<]@/VG2+\QIC>*Q^:;V -7
MBH?F<DW)D@K= =I7' IG=J,'R+_TGO\'4$L#!!0    ( $^!!E&8KWDC5P,
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ME$LRX^I;JG8RC7>][ 6X+2_(K/W":8O62>'(Z37OL2S;W99JVMJZFK9H'??
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MP5@-J5AC",L[*L<:Q7\(R!=D T@"1D5B9U0B+JKHLX#'2YVCBE,NJ.(*PB-
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M["4B4]4O6=:RG19)2J5%7BMC!#GCZW_ZI0;B&(6P5@AW%-"Q6R&J%:)=A?B
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M1@"_3X70+R_&P>:R]_I_4$L#!!0    ( $^!!E'7],&03P,  "$,   9
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MS3Z\ 9;!.>/<I) :^MI8MQS^K+)T5%H*-UCZD,L.!.0=A$%(&N#'[?#/!>]
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M4=H-9CT10M\/;(=5_RL8_P-02P,$%     @ 3X$&4;B;W;/T!0  PA@  !D
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MG5T4=XL#R5%Z#+=]W^N]&T/OEI] ^\$3M_()AB>I-\=.GIV-WE )X!4*V12
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MA!2[>H,]]=<LTU(8859HQJP]/&'H:0%!5CC.3<40_R[20:XJ=J"G,,NT%$8
M9F&HZ.<(!UW;([H*",>Y)X@8*B R!TX[>D*DV,B35@8*(?W* )%6@(6U8@]G
M&'A60!06$(US*Q!15D!TD*W 2,&Q)"\6%%+ZQ0*BL0 +C\5E7MSGS:7"NJ-6
MERL[F0ZA4#3.33Q$2P'1 3;Q+FRU7@?J;?Q(=2/1E^ZBJ<0<JOVU/ 1?-I(+
M@\T/,.-'^(?\QKFWAR@L(#K(WEZD^%E73[Z&JA)SM+DXB-@";,P69IL//+$C
M(@N(Q[F!AY@M(#[(!EZLNF;8-KA9J*4RPB(+V87-W(</_1#9!<3CW/U#O!80
M'V3W+[83UIIE6@HC1+,07?1W@*&G (1'\3AW !%!!L0'V0&,[41_9IF6POB'
M9\TPU<G^APSTJ(-_A':4.X$4L6=0"WO&CC]#Z2@X9V785XII89\BF@WJ6.[0
M]W:#@7^%%?%M4&>4.X 4<6M0"[?&KEZPJC4PK00L0BV5:^1J?85^3M:QQ"6@
MBDLN;,7>E22_)3\N>:?2Z)APUW.:KK]BD\8/B OUMQ"38\)VNBM5\IEG,E].
MN8$7\MVU^R+EG^OBJ_F)2Z7KX^E?B\8QGAI][L3^1FV<$Z)2_)B\ #CQ"'>M
M><J]B0O<%_F$,?ZBVR)?$#Y4R)?[?^>S;&7BJDBR,IE47+@D+TO&N,OQ815>
MD5<D*=B63@KE:\4VC4MK[RVK(IW4!=14+;50K<,DSZ8L*[D<_ZO,Y^DTJ0O=
M)/,FS[.<,5:=&-T;_=2NA5GDFFH<P[(=NLB7M<:+Y(ED>462Z91,EXQ4.2GX
MDRD?DF8-T6_K6OA$U(GK%[9B:@\0:=NRNW+Q%Q"X9+'VCV:GK/E:Y>[6FL)@
M4],CX]XR8_/&#0KA!E6Q+'DG\HF%W+",W:;U_%?QIS?+JADGO#L?N/_GRW+E
M]%F>O?YCF<S3VY079XO[>?[$W7)=F-QS!RG-_8Y^)]@Q+R?4&<$7MF(_JY-U
MGT<"X;K7(^<Y:?F>N_>D[C-]][1[I!XBMRL?JWNZ?P>17WD-O )6S)_J2C;C
M>*-J_8X2JRD2,NJ!OQKFC3["ZL?D<99.9HW ).&H5%=8H:GN>#4AKE(\FK>(
M9[S9D_PN2_^SFBI6G?B2]UF^8*].^02R7$]#?_U+1 '^MOZ/9'RV,<\:9<7_
M6TTOO+-6-:+)S".OC Z#:&JHA:9&?87UPE;L_WNJ1N0ZU$*NH]Y;O+ 5^R0P
MM"R7M7(<,\DTY8C)7?R.3]?W=?].ULO&N@>5&I\VC;E*JN3\;,&*.W;)YO.2
ME^- \/:HGL\WWW)OOJT#EC<7<'0J?\_7,F\NZP6-_*Q>D=3/ O6SL'X6JI]%
M];-(_2RNG\7*9^#P9]Q%E<^@?M:TX50T^?SL/KEC'Y/BCL\/9,YN>?.=D_I<
MMDCO9IL/57[/X[<C<I-75;YH_ISQM1 K:@'^_#;G'KK^4+_@,2^^-EU\_C]0
M2P,$%     @ 3X$&4::EP PM!   .@T  !D   !X;"]W;W)K<VAE971S+W-H
M965T-38N>&ULO5?=3^,X$/]71A4/B\0V'VU30*42M%2WJ^6$X-A[0#RXS;3Q
MK6,7VZ&+='_\C9TTI5P(2*?;E]8>SV^^/9Z,-DK_,!FBA9^YD.:LDUF[/@T"
ML\@P9Z:KUBCI9*ETSBQM]2HP:XTL]:!<!'$8)D'.N.R,1YYVK<<C55C!)5YK
M,$6>,_U\@4)MSCI19TNXX:O,.D(P'JW9"F_1WJVO->V"6DK*<Y2&*PD:EV>=
M\^AT%O4<P'-\Y[@Q+];@7)DK]<-MOJ1GG=!9A (7UHE@]/>$$Q3"22(['BNA
MG5JG [Y<;Z7/O//DS)P9G"CQ)T]M=M8Y[D"*2U8(>Z,VOV'ET,#)6RAA_"]L
M*MZP XO"6)578+(@Y[+\9S^K0'P$$%> ^!6 %#<#>A6@]U% OP+T7P/Z;P &
M%6#P44!2 1(?^S)8/M)39MEXI-4&M.,F:6[AT^71%& N767=6DVGG'!V/..2
MR05G KY(8W5!16,-?(8=_=P8)!*3*7SC;,X%MQP-7"$SA<84F(49XQJ^,U$@
MN&*!&UP46G.Y@@MFN!>GE)7*$N[3%"WCXI"(=[=3^'1P" ? )5QQ(:C4S"BP
MY)8S+EA4+DQ*%^(W7.C!E9(V,W I4TP;\--V?-*"#RB<=4SC;4PG<:O KX7L
M0GQ\!'$8ATWV_#?XY0?@O=#!HY,&^*P=/L4%P:,F^%XP>G6!];R\WEL%5F?>
M*B@["A7-LBXOMBLOL2NOTQ;-_5ISWVONOZ'Y6JL%8FI@J54.W)B"5%*%+D$H
MN?IL4>?4@^:V(487[9+OHX>C^_BA*;4E,/% U]6?QE&2A,DH>'J9P7]S]4_Z
M<<VTY^Z@=G?0:M3NTMU?83Y'_= 2PZ06FOSB[ UKS<-6=[[5.<+'@MMGTD[^
ME;TG0Y&ZGD']RC2E;S)LR$)O/P?3DF?0QC-KD#-,FM-T7/MUW.K7;3$W/.5,
M.T>VF8*_X6[]E\HD=>'%1_)W4FL[^<7YB\+=RQ+^7_=O4HG>BWS4#\-7.7R7
M;=]T]RCN4^*=,_%[5[ZI3[R#.L]5X=[3G#T#I0%8FD)*KR0E0]-)2K>UVQ;K
M79.->NWF-7:CBW=05&RB2*DX#J*HVX=Y^02[#*WW<F<SW-;G?NKJK!I_'8F-
M;JFB8GHLF"8N)\J]8D>PR?@B Z:1&+U2?X%OD&8.[FO29$K;4C*73T0O)Y%*
MK!-*XRSQT<HHP5/F0',F?$WY^:=+4X9V(>9N9J7BYK*<O&EW1(8A_.YOPO"\
M"XUCS^G+0:::;THKW/UX S*<=L'WJC^<Z5,7E,/&G 8OAK0<]<J/TX;\H0HI
MNWQ-K4?V"S^HOJ)/H]/+J(%^'KF#IA,J4SIIDD450B=^N@UV1I5?%5=,K[@T
M('!)!H;=(?5*70[JY<:JM1\LY\K2F.J7&7W<H'8,=+ZDYK/=. 7UY]+X'U!+
M P04    " !/@0917K123JX#  "G"P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970U-RYX;6S-5MMN(CD0_952*P^)E*$O7 (1( 78:#-*1E&BS#Y$\V"Z"_#&
M;;.V&Q)I/W[+[IZ&)$"BE4::%_"E3MU.M:OZ:Z6?S +1PG,NI!D$"VN7YV%H
MT@7FS#34$B7=S)3.F:6MGH=FJ9%E'I2+,(FB3I@S+H-AWY_=ZF%?%59PB;<:
M3)'G3+^,4*CU((B#GP=W?+ZP[B <]I=LCO=H'Y:WFG9AK27C.4K#E02-LT%P
M$9]/XL0!O,1WCFNSM087RE2I)[>YR@9!Y#Q"@:EU*AC]K7",0CA-Y,<_E=*@
MMNF V^N?VB]]\!3,E!D<*_$7S^QB$'0#R'#&"F'OU/I/K )J.WVI$L;_PKJ2
MC0)("V-57H')@YS+\I\]5XGX#""I ,D;0-S: VA6@.9G :T*T/*9*4/Q>9@P
MRX9]K=:@G31I<PN?3(^F\+ETO-];3;><<'9XR263*6<"KJ2QNB!*K8$OL#F_
MYFS*!;<<#7Q3%FZ0F4)C!LS")>,:OC-1(#@.X0[30FLNYS!BAALXGJ!E7)@3
MTOAP/X'CHQ,X B[AA@M!M)M^:"D(YTJ85@Z/2X>3/0Y_+60#DNXI)%$2[8!/
M#L,GF#:@&3MXW'L-#REU=?Z2.G^)U]?:HV_,M'YQ 9=9>+S!?(KZQP'-S5IS
MTVMN[F.FSNTI7!B#1 N3V2LZ:BHH^9O4.ZEO2NHW7#Q>DP&XLIB;0^ZU:O=:
M!P._5G+^Q:+.Z2N;VE/ YU04F3-G%PC.-%42+)5VG_<Q.]E!U>BPA<?XQZ[R
M*$$=#W*OVFK8CMH)<;G:KH+W4LUVK]VNI5[%W*YC;A_TZ ]C.3TUE/"MPO\$
MY9U:?^=WI/RL=N_LEU-^V,(>RDM0>YOR7IS$;RA_+]6*NJUD-^7=.N;N_Z<<
M_H5K7*& Y#-5T*M-]G['*HBC3<N(?GD=?&!B3R%4J,X'E;!#[$ IQ*Y7OC[9
MO/[QX>=_MY^C#U 7!M0,J)-AW<G@%([BN-&":=D9G<!2JQ0Q,S#3*O>Y?5C^
MK1;2IQVL9M(P/SU1HS6(KCLCG$W@!)A&ZK(K-*YPJ=WF2N(+C0WZB2;)62&S
MLJ2X=,25(G<DK'GJ &9!U)4$ETK*H8"$/+]*9C3WD1RMC!(\\Y_'E D:&!#\
M*-+856?AUI22HY[[:<^0ED+:LBW6I_5$.?*#U[OS^'P<[[JAQ-.-G[W"C8ER
MA+UA>LXI50)G9"YJG-%+H<NIL-Q8M?1STE19FKK\<D&3-&HG0/<S1?FM-LY
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M.@/J8JI:NJJ+D2NW5<REH1W%'3-:5%%9!GI?T-1_N5@%]>H[^0=02P,$%
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MZI\+%L]941G(YP^<BY\750/-$?[+?P%02P,$%     @ 3X$&43=$Q+L-!0
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MIOV ?3^'/E]AE M?:/O8)(*B<62J'LP,*JF[OWCJ==@"I/NO -(>D ;>7:'
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M41=%1 @&=A.%$@8E3; (I):"1Y3&X 0BJPRPUH%Q^Y*/^$OWT?UB<]1@Q\#
M"=S3+5<=)17N2GG!:; G,8:UNX:M>Y\40NC3M=29 3S+YR_Q'7J;<\B?/$J+
M6"-F_(F>V!S:OBEPJ,V9PQT'8'^T?;B.$0IM0@/7[LE1[<E1ZZ;O*H>@N>!9
M<X9V'&IS1[OF1P_RR[>Y9#K:-60P< :;YEZ/=LJ)?^KO,?>T-O>T=5,/N:11
M(2#*IE _WM)L1D5;9<9.TQ$XKU'Z\5K+@?]#D5@*R%RVA!DHE% <;9$ZH/@Q
ML&9NA0HV(H!'PZW</4XLM(AY_DA3OBV@V&V\XOX:2JS6W4S38)LPCI(*;5*>
MLZ<*XJ;9P-[_29#5:AO,YN&=>!\C%=JD\'"PQ^*F_\'M#= ?*J'B<&V:5&HV
MV&G;CH,B8:O(I@5-3X/;FYK7H/H)WNU);)1]G%AH$6LA;=PT.;B]Y?@UM#W!
MNSV(A8*/D@HKJ<%1)(R;?@:W]P[WQ4RRF!&P7=:LA/Y&#\NO/,F!5:*CN*IA
M?3QZ%:YJ>!:W$^T+^HI)I7K#Q]AWG.V '1+;_)K5/+XYTA"O>X ?K9W=^ #J
MRM"Q1!GYB72FDA@*,3 4L)& F1AHI]?V^=TPH-O.@/8N?GP ]2FA:$92$Q8X
M51 9^)2F]9>XOO[2UU@20<5=R\.>(93JO;P%H6C<^]S;)!G90R$7VF:FCSJ<
M89:7]WGZX$M*T0>N*!I.>\AZE7*V=9/2YJB&+MUVNH26U.JH=M1+X]APF]O.
M;?9N>7P =5,60(G>8-SST:R\6-+Q7&Z<P;4P;A[!)F;Z8DJ+08_,(<C?"R)
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M_0%0^P1WOE>NJ6W@I[+[IV1_ %!+ P04    " !/@091D]AFPYT"  #+!@
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M+#4_/RSHM4'M#&A_H93=3AQ!^WZEOP!02P,$%     @ 3X$&4;T6#/>:!
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MS HP6I!QD?^S54'$/H"H $0[ -S8#V@4@,8NH/D.H%D FOONT"H K7UW:!>
MMN,^)\LQ/62&]7M*+HFRTJC-#MQQ.302S(6-K >C<)4CSO1'7# 1<Y:2*Z&-
M6F#0&$V.R1 4?V'VU(E?A(F$?(5DRL64G-OPX(:#18ZD-$(:'!\,P3">ZD.<
M?7P8DH,OA^0+X8+<\#3%L-*]P* +UI @+LP=Y.9&[YC;(#=2F)DFER*!Q(._
MK,:W*_ !4E?R%[WQ-X@J%?ZQ$'42=8](%$:AQY[A'O!&:.'TQ.?.S^T^^N'=
MM\AHE,'4</H:[^C;")JG:UPC5P8R_5RAN5EJ;CK-S7<TGV=R(0R1$W+P.Z9+
M?1A<2ZTQQNXA3IG6?,(A(1,E,W([N,(8,Y+<7@U=E YN'SS47%1O^$2?CYZB
M9U^$YL"V ]K$_=(_IMUV+WC9/':/4)=NRUSZ%+4[VT(CCU"CV2B%MMALE6RV
M*IV[4W!LV(I,D4H"JSEF>60/*1L#5HL-0I?<S%#$S( (6!E"(Y*Y^^/C)=^S
MM6$I#:,=EZMEMIQIE\ZT*YUY%!KBA4)KAS VY.D&LC&HJJ#KE)H[GQS.W5)S
MM]+F:RFFQP94AD5P;'QD=O]+5#<,=]C\0&C+M)/2M)-*T[!>8S466'N4 A&_
MDG3+UGWXI>&Z^(2?S##=*&ST)SDN%&SRAP^R79(_DMHV+UJ;%U6:-P2--#-[
M\9@N*^FZPI9$DW_(0&J7^S1+,>5M++P=%JSB&1-3(#'>3H6O-;W7.:WS.OWL
MQ$[7F9W^WZE]0'W9=^=<ASZAULGNX?MR=&M'U<@K%;Z3I*G-TMLSZU1'JW,=
M5B5?*?L E3.L\=GX2O!E1EB2D&0!-N$K7$DP\.I51[G.E[13;9ZW8%Y\@-HZ
MY_QXL> H<L!%+#,X#/"EMG!]B/[UEVY$H]\$=ESN^+?N15&H\ HDV/F@+AQI
MF?+$73)M\"]_NB(B5UVW%\C2P:UV?.!RD?=JMN>Q;4]!G/HD"X^(!B!_XN.8
M="[K_H?UZ8\^O;U'&&QT!AFHJ>OA-#*#?N4EMIPM^\0+UQWMS _HZ9!ZYB]M
M7^F9/Z>MT\N\G]M9P6C%E;9WI8,KKDD-UL;F+>X-4^BO)BE,T/"PWL%\K/*N
M,?\P<NZZG+$TV#.YX0P[;5!6 -<GV):\?=@-RMZ]_R]02P,$%     @ 3X$&
M4<FNGRO3 P  61   !D   !X;"]W;W)K<VAE971S+W-H965T-S$N>&ULU5A9
M;]LX$/XKA-"'!D@M4;X#VX /!,TB 8($[3X$?:"EL<4M)7I)RD[^?4E*IGPJ
MV1[8]B66R/GF^&;&X\E@P\57F0 H])RR3 Z]1*G5E>_+*(&4R 9?0:9O%ERD
M1.E7L?3E2@")+2AE?A@$'3\E-/-& WMV+T8#GBM&,[@72.9I2L3+!!C?##WL
M;0\>Z#)1YL ?#59D"8^@/JWNA7[SG9:8II!)RC,D8#'TQOAJAGL&8"4^4]C(
MG6=D0IES_M6\W,1#+S > 8-(&15$?ZQA"HP93=J/?TNEGK-I@+O/6^W7-G@=
MS)Q(F'+V-XU5,O1Z'HIA07*F'OCF(Y0!M8V^B#-I_Z)-*1MX*,JEXFD)UAZD
M-"L^R7-)Q%L 80D(#P"X=0;0+ '-MP):):!EF2E"L3S,B"*C@> ;)(RTUF8>
M+)D6K<.GF<G[HQ+ZEFJ<&EW3C&01)0S=9%*)7*=42?0!3?,T9\3D!$V(I!*-
MXW^T-\6U+C=T3:A GPG+ 7V$> D2O9^!(I3)"PW_]#A#[]]=H'>(9NB.,J9S
M+ >^TAX;NWY4>C<MO O/>/=7GC50V+M$81 &)^"S>O@,H@9J8@/'_7VXKWER
M9(6.K-#J:YW1]YAPH3XH$*D.:PU;.I[N()V#^%)CH>DL-*V%YEF/!5T7M#_=
MZCMTHR"5=9I;3G.KUO<I$>*%9DLT3GF>*<07:&Q[CKT4"8S16$I0I[(TJ5?]
MA+^<2FT!ZEB0^?I9CUKM@;_>3=^Q2. D]J)LNRC;]5%695O%>5"JE@17S;KN
M(_V%*<'7]5L\72#%T0%?ER5;3L,#&#NZJA.ZDI<%=Z=8*/QMGPRQ(*%.8H^$
MCB.A\W^1,*,RXIFB6:[KY;]2T7F5BCJ)/2JZCHIN+16W/%M^5\/VG('>3V[8
MOM/<_W4-6Z_Z3,/V7\W/L<1.2^]%B8-J  5_6,N6#M<142NR3\3.),9_9-N6
M;M?242>R3T<U:W']L*U:-X:Y>DO/XFK*XI\]9G$U9_$/#]I;2N:4447A9/.^
M8N!,]Y:HW1SH7TW-PTP=2W6#?G@F6=78Q;_IW-U2^7*2DN/1BEM'M7LL%'8Z
M9PBI1C#^K6=P/2V=HY]=&/?P(2_'4IW^N:XV\WC_I!J@N/<=Y3QY!>58(985
MB> Y8GD,2"6@]R9'/G'D+PSY:TM^4I)&JIVF<:KW_9V]*@6QM/NI1)%16?RF
M=Z=N!Y[85?'HO'LUU20=W^@X]8U=F_W*1+%TWQ&AW92(P4*;"QI=7:.BV&.+
M%\57=K.;<Z7W1/N8Z-T?A!'0]PO.U?;%&'#_31A] U!+ P04    " !/@091
M. *\\#<"  ##!   &0   'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q]5-UO
MVC 0_U=.41]:J2,A0-=6(5*AJ]9J2%51MX=J#R8YB(4_,OL"[+^?[4#&I,%+
MXK/O]^'+7;*M-FM;(1+LI%!V'%5$]7T<VZ)"R6Q/UZC<R5(;R<B%9A7;VB K
M TB*.$V2FU@RKJ(\"WNO)L]T0X(K?#5@&RF9^3U!H;?CJ!\=-M[XJB*_$>=9
MS58X1WJO7XV+XHZEY!*5Y5J!P>4X>NC?3T8^/R1\Y[BU1VOP-UEHO?;!<SF.
M$F\(!1;D&9A[;7"*0G@B9^/7GC/J)#WP>'U@?PIW=W=9,(M3+7[PDJIQ=!M!
MB4O6"'K3VZ^XOT\P6&AAPQ.V;>Y-$D'16-)R#W8.)%?MF^WV=3@"I/T3@'0/
M2(/O5BBX?&3$\LSH+1B?[=C\(EPUH)TYKOQ'F9-QI]SA*'_BBJF",P'/RI)I
M7+W)PB>8&BPYP1NW:[A\1&)<V"NX *Y@PH5P!;593,Z IXF+O=BD%4M/B-W
M3"NJ+'Q1)9;_XF-GO'.?'MQ/TK.$+XWJ07I[#6F2)N_S1[B\N#I#.^B*,@BT
MPQ.T$Z;68%W?: ,?,Y0+-#_/T X[VF&@'9R@G6I5N/(:%OHQE/;CF\N!9T)I
MSRF,.H716>,SMN.RD8"[6MO&X#4PJ1M%__M4+=-=8/*CN\G[O;LLWAS+QT>-
M)=&LPOA8*#QGVV/=;C>A#VUC_DUOQWO&S(HK"P*7#IKT/CM]TXY,&Y"N0YLN
M-+FF#\O*_670^ 1WOM2:#H$7Z/Y;^1]02P,$%     @ 3X$&47S[QVW> P
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M4QH-4N'!H=)H\ (WE_$7IK$%&UQ[&JM5WR.TG,4J$7;\FC:7&& @S84Z?_;
MP4\\F"<B$K-'E,W2.]5(8NHNP0?HJ$EAPB$'Z:E'+7IJ'LV<JYBNP7!(RGAO
M(QOXM ;EB$$'THP.O[+?:5%5%X JAASWW?Z@O*^M=!0[_9H0&+0AS6CSLI9\
MU"*USENWVJ-[Q'7+SMK(^G6C%S% 1_8;()^5[F95=0&H#I7V=-OH&M)M<)<T
M0^3N?1TQ$$?\0]0L W2D>7+Z9>< I#I%#4GYW*2%:-L' YSD8)/6);&,0[Y7
MJ:$V*K>F6Z4&&6DS,KYPI*?5N07WO?*1E85H4&>Q@5C:/-K\RM#GJEI";Z6J
M#;W!;MJ,J?NVEK1P*DD/\(13 TIT/U#:N2MIT5/3:5(+_M!*4V*APKY?4QFH
M 2EZ.)!J457GO@5\,"'E\U$K&:Z;?ZF!*+K?$6E-1](BM<[7ZM2'L5.>]"U4
MWJ NTP8WZ7ZGH<_*=+.J.N_]RDL!:Z9M9/69UD"^?<? (GW)L>"HA>O3G*,)
M#R1G4 W#!-V@XCF>);+9.5Y=>-$1"E.TD&',9!@]HLF2(R6V2+H-5<XUT.FV
MG/Y93_Y&+5P76;%+4<P>42(48I/)DXD25B90$!O-,SCI-N.DO84=M7#I7 1S
M"#A/=2H B^S5&HDI,E.U,E.U7$_5V3O(V[O7+%Z\NRID0_*I?K6<"5;0S*93
M #N0]0IW731>OWE$4RGB C>$IDF5CEQ!*ELLI'A@D98*[?)4B8=0NQ*(>!PF
MZRVR"M4<O9?C4"U_HM>_8=]]A]X$'*[ SO';(S05,C>1,Y4=V6EI=Q?7Z$O?
M<=ZCXW@)NU*AF"N6*A :@/Q(2# "- <L"< MT U_P?>U,,D6CXVI-9V#VS*-
M6\O!J(7K.:E=]R;9O>WN1&3=R0[Y]#P'Q5OY+)\UM>B M#Z3W+H+<D\_=^^[
MVJX4-I*$V[ Z608@(5V._\F8!!)+!;HV6J34L<KU!#^6H00K,E<N8,F>RE[A
MC7_,Y2S[<@(BK..Z?LNXN;OY.F.4?<10OD\')Y=0BJLK4$UA96A;<9V32R@_
MMA4,*S8]L&E@)?LJHF<,7G]<\I')69BD4&ZG8+S3]0% Y?I[C?6%$HOL"X:Q
M4$K$V<\Y9Q,N-0&L3X503Q=:P>:KF?/_ %!+ P04    " !/@091.JAF;1H#
M   /"@  &0   'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6R]5LENVS 0_96!
MD$,")-'B)0ML W;<M"YB-$B:]A#T0$MCB0A%NB1M)T _OB2ER$H=J^W%%XO;
MS'OSQC-D;RWDD\H0-3SGC*N^EVF]N/1]%6>8$W4J%LC-SES(G&@SE:FO%A))
MXHQRYD=!T/5S0KDWZ+FU6SGHB:5FE..M!+7,<R)?1LC$NN^%WNO"'4TS;1?\
M06]!4KQ'_;"XE6;F5UX2FB-75'"0..][P_!R%+:M@3OQC>):U<9@0YD)\60G
MDZ3O!981,HRU=4',9X57R)CU9'C\+)UZ%:8UK(]?O5^[X$TP,Z+P2K#O--%9
MWSOW(,$Y63)])]:?L RH8_W%@BGW"^OR;.!!O%1:Y*6Q89!37GS)<RE$S2 *
M=QA$I4'D>!= CN68:#+H2;$&:4\;;W;@0G76AASE-BOW6II=:NST8)(@UW1.
MR8PA3+@F/*5V.%0*M0+"$_@H1+*FC &<P#7E5.,),THF;G/"C03UQ6T?UT)H
M+C0J.!RC)I2I(S@ RF%JG)K,J)ZO3226CQ^7K$<%ZV@'ZRY,!=>9@@\&/GEK
M[QL%*AFB5QE&4:/#STM^"M'Y,41!%#S<C^'PX*C!;:M2M^7<MG>X'4DRUV)%
MX7&*^0SE#_@%8UR96E@8J;YBG''!1/H"KAI4=:P!NEU!MQUT:P=TF:F;'4EY
MO#'G8:(Q5TUHG0JMTQCHF_\%W:"1 FV!D@J[$9O.H1 .$RQ&1^_EOH#J.BC;
M55:#L!T$/7_U#L%N1;#;2' H)7FII^&&QK:W\!2&J40TC>;?]#^K ,_VH/]Y
MA7:^/_T+J$Y-_TYGA_P7%;^+1GX3#K=2Q*@4W*%"(N/,M8^R&*SZ]>1LU4V#
M1&&P:77!'E(2UEIK^)>@_^B-6XDY_L_,E(#UU)SLKHTPVC"-&ID6Q8#U4K#9
M^:(SE/6\O*VB)I$V'3)L[2,IF[88MO>=E/96OSK9+AB_=D?G*%/W$E$0BR77
MQ75=K5:OG6%QQV^.%T^E*9$IY0H8SHUI<'IF_@^R>'T4$RT6[L:?"6W>#VZ8
MF1<;2GO [,_-C?PZL0#5&W#P&U!+ P04    " !/@091FB<6Z80#  "8$P
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MY,P>';6_1]IWC*S]W<U*&B,KWRR!%J#<!#N^EM+<=MQU4'.;-_L,4$L#!!0
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M#^8W[_C-K?S"KSLI1;),Y(*V+S(DJW57%4I4EER "]+<N(D3XNF,(1"A&F4
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M(/HF*0#1#1D &7@2HTJ?J5V?7\&CM"WT^"_U#@ P^L8)@)GKAAO '&V<]OM
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MR-/ZYR./-KRH /+Z-L_%X:!JH/L^[_(_4$L#!!0    ( $^!!E%4$<G&?P0
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M[ NTOI#2; 86H/B^-/P'4$L#!!0    ( $^!!E&/_=+\,@(  #@%   9
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M\A9^\JITZK5-IT'QYE%H[)H'4/Z>.I!$!S5"JBSJ-6?1]J8A00KFQ0)/"9.
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M2&9/N>Q#B\2^)!8"SI78-E?P_"723(#Q2 B]_3 .B@?UZ%]02P,$%     @
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MYRO*GEY.%,]MTUIRI5N@'2;Z&41A$O3ZBG.UG9@-ZH=U_!=02P,$%     @
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MG=<=FNKZ(ID4U5_T7&.=$8K*0LFT)L,3I"+;_6<OM1"G$$A-("T"-&PFT)I
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M\MWW0+L+)3?5]RL+J91,JY]KSF*>:P"4+R4,9'VA&]A_E77S/U!+ P04
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M 13@3AD%N1- J=T9G4XQ^F^YT_H_ZU]%38;_(\FW2;[ A/C;-&W@\?AT@/$
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MC.IVT^+S ^%?Q4.:?#,*!49>[A JH<NXR>VM$XXUIJI0D,4^436<0ACQ'@+
M($?*"1!(%0J,0-UN%GQ^*'S,,JMHW@*I;;O\Q4C,'4)3]!A+>;TUQ;'&5!$?
MGJP+>K'P_#\%0+[X^#\#0+&D, $@A&P7#A&/L:G738F?\D61%>NGW@^;'F,H
M;PA1T6-LY/46%2<>H/P%GICI(93CBK>" ,JW(_$A 4!YB(N7\Y/D7I%U\YB9
M_\C"Z_NR>4%@XE+&-=X08I_'6,7K+?9-/$"0<SU1"8!03H!$EP*"G"]>W',(
MY<:>PJ6,RKQN/C)VZ6]UDB]3*^GS[L=C).(-(?=YC!F\_G*?)VMO3A"(+@9
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M4*AX_1PSOHR[2<\\&23YMZ>UT5-#S#@I'D*1BQD'Q?T5.8UI5QC(0ED@*K,
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M =>F FF:31@EA%UZB\UD!:X-!(H&4?^XQ@\HZC_K5F>KC - #Y28 0))3Y$
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M@*Q?%<1U[1]T!X]%^6?CKP__#U!+ P04    " !/@091FX\5BE "  !Z"P
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M3DC%KMM9]Z81;E9G?S;+\Y=-P>ZU'?T&4$L#!!0    ( $^!!E&7BKL<P
M !,"   +    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6
MH@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.
MD4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,
M<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW'
M]I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 3X$&
M48Z$SKPM!@  DST   \   !X;"]W;W)K8F]O:RYX;6S%FUMOVS@01O\*X:<6
M:-:Q[BZ: JF==@.DB5$;?2T8F;:)RF*6I-/+KR\E)^T033[LRT!/L2A%/AZ*
M/,.+WGPS]NNM,5_%]WW3NK/1SON[U^.QJW=J+]T_YDZUX<S&V+WTX=!NQ^[.
M*KEV.Z7\OADGIZ?%>"]U.WK[YO%>"SNF!\:KVFO3AL*NX+-6W]R?\]VAN-=.
MW^I&^Q]GH_YSHT9BKUN]US_5^FQT.A)N9[[]:ZS^:5HOFV5M3=.<C2;'$Y^5
M];K^JWC90:[DK>M+O+S]) /(V:@X#3?<:.M\?T5_?QD8[U6X^'AT\.:];KRR
M<^G5!VL.=[K==K<)OV),?D8?A\>_QR"^MO\GC&:ST;6:F_JP5ZT_QM&JI@-L
MW4[?N9%HY5Z=C6;F7EFQD%O5_:CP+9?KXP_T@8R$R[[6X82]7/>,C#PWU_.+
MZ^7%7(1/RYNKR_GY*APL5^'/QXMK ID R&1 R"\)@4P!9#HD9$H@,P"9#0+Y
M[OSJ_'IV(0AD#B#S 2&CZBX 9#%D=6<$L@20Y9"0.8&L &0U)&1!(*< <LH+
M^4XZ[839B(55+ES:7R%DNQ9+O6TU[<Q/46]^RHMY7O]W"%_:E;\2%^&S_W'R
M4?F=68O+]CYR#I0.LW4^*>?MH?8'&SPL9CMIM\KUT;SQ.V4I)M+.A-D[/8QX
M<=G69J]>?IFK]:'/?9PX$=?*4TPDG@FS>5;RN_@H?4AO'$5"FIDP>^:\#I<<
MP@GU4*5B9O8AU=RIUNGX.42BF3";YKUN95MKV836T3V1W>51#)%@)LR&Z1IL
MZT.2K"(DI),)LT\NU^&\WF@9OC:$S,MVVQ&(<^="WDS3APD2RH39*(ON*7OH
MGA<F5*SRVJKNG\0[U49/'U+*A-DIQ_Z9IMA('0FS.BZD;4-O[,3BV%KW(8#+
MT#.'VO7>4L,E2!T)]X EC!@#I@K-]D$9LS!<#$/6GCG"A",69G4LU;:[XI7X
MH,S6RKN=KO_X37RBF$@=";,Z8%H3I=H)TDG"K!.,2<=6"=))PJP3F'W%T41B
M29C% K.O&!/))F&6#<R^8DPDFX19-B3[$B]6G1G=2\J&#),P&P:F8?'$"5)/
MRJR>)].PIX*9(O.DS.8A^=B3;$@W*;-N8&(65S2<(F/6#4S,8DRDFY19-\>N
M6X1^YJEZ1H9)F0T#D[0X@,@P*;-A8/838R+#I,R&P6D%G<-+D6%29L-@3#J+
MER+9I.RR0=E/- &.9),-.44657J&;),QVP9CTDK/D'@R9O%@3#IYFR'Q9,SB
MP9@EQ82K,\SBP9EYU(20A3)F"V',J DA"V6#CG.B)H0LE#%;"&-&30A9*&.V
M$,:,FA"R4,9L(3QJI$TH1Q;*F2V$,6D3RI&%<F8+T<%M )/6RFYCA7@Q5U[J
MAF(B"^7,%HK&X$<TFK+G2#TYNWK0&#QZ()%Z<F;U/#T&/Q$/Y103;@T88L7F
M$3,:6>1(/3FS>C!F5.E(/3FS>I[#7!D?RI84$ZDG9U8/Q(PK':DG9U;/<YC=
MQ)'S>[IO!:FG&&2V[0$SWEZ#U%,PJ^=IS-^E%!.IIV!6SW/17.Z,]2=TCT"!
M+%0P6^@YS"O3;D]6=$FT0!8J!K)0CQD_F\A"Q4 6.F+2[KV 6]0&LI"8*ZOO
M)<5$%BH&LM![J:WX'&$B"Q4#6>@8S*BE(PL5 UFHQXR:4(DL5 YDH=DQ6::8
MR$+E(!8*F%:MM:<[7DIDH9)[_8>N3?T] "J1>DIF]>"U*=I9ED@]);-Z,&:T
MH1>IIV16#\:DDUHE4D_)O7D-8M))K1+NCQYR0ULTJ54B]93,ZL&8%<5$ZBF9
MU8.7=VE+KY!Z*F;U8$S:TBNDGHI9/7]6H1=6;90-QA%+;^JOQQZ>8B+U5,SJ
M>< ,"8:^U^$Y7?\V4+1L7B$%5<P*PLOFT8.)%%1QOYV#]C9&J5N%%%1QOY\#
M,:-H(@55W&_H0,RHF2,%5<P*PGLEHFC"EW28%80QHV@B!57,"L*8-#V:(@5-
MF16$,:-WGI""ILP*PI@T/9HB!4V'W&P=I4=39*%I;Z%Q?[%[^V:M-KI5Z^OP
M%2Z4U[*I%U9T?[H[39(L[]X>V!R:9A;*;MHK(]>/[Q0_O@_]]A=02P,$%
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M"^HM!'H+ZBT$>BOJK01Z*^JM!'HKZJT$>NMDLX1 ;T6]E4!O1;V50&]%O95
M;T6]E4!O1;V50&]%O95 [XAZ1P*](^H="?2.J'<DT#NBWI% [SC9[";0.Z+>
MD4#OB'I' KTCZAT)](ZH=R30.Z+>D4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]#
MO8U ;YO\64F@MZ'>1J"WH=Y&H+>AWD:@MZ'>1J"WH]Y.H+>CWDZ@MZ/>3J"W
MH]Y.H+>CWDZ@MZ/>3J"W3PZ;$.CMJ+<3Z.VHMQ/H[:BW$^B=4.]$H'="O1.!
MW@GU3@1Z)]0[$>B=4.]$H'="O1.!W@GU3@1ZI\EA00*]$^J="/1.J'<BT#NC
MWIE [XQZ9P*],^J="?3.J'<FT#NCWIE [XQZ9P*],^J="?3.J'<FT#M/#GL3
MZ)U1[TR@=X-Z-P1Z-ZAW0Z!W@WHW!'HWJ'?SDWH/X]>A#+>>[S4^_R>I'B_?
M+;?'7Y??%R>ORA7G^KYB>/H+4$L#!!0    ( $^!!E%]\^X_0P(   ,U   3
M    6T-O;G1E;G1?5'EP97-=+GAM;,W;WV[:,!3'\5=!N:U(B!W;82J]:7>[
M]6(OD"6F1.2?;+>C;S\3VDJ;.K2*2?O>$('M\SOQD3YW7'][GJQ?'/IN\)MD
M%\+T*<M\O;-]Y=-QLD-<V8ZNKT+\ZAZRJ:KWU8/-Q&JELWH<@AW",AQK)#?7
M=W9;/79A\?D0?_;M.&P29SN?+&Y/&X]9FZ2:IJZMJQ#7LZ>A^2UE^9*0QI/S
M'K]K)W\5-R39NPG'E3\'O)S[^F2=:QN[N*]<^%+U<5=VZ#(?GCOKT_,EWNEQ
MW&[;VC9C_=C'(ZF?G*T:O[,V]%UZ*GIU/CG$&[:GS_SB_+G,N<"X\]Z-DX\3
M<_;C<:\C.9Y>3K&0=:$]_XIOB;'TQ>]GC]-N;/.7V?%Z?XQN/\_#9_/C\CO^
M=<9O]3_8AX#T(2%]%) ^%*0/#>G#0/HH(7VL(7WD*THC%%%S"JDYQ=2<@FI.
M436GL)I37,TIL.84605%5D&155!D%119!45609%54&05%%D%159!D5529)44
M625%5DF155)DE119)45629%54F25%%D+BJP%1=:"(FM!D;6@R%I09"THLA84
M60N*K 5%5D6155%D5119%45619%54615%%D5159%D5519-44635%5DV155-D
MU119-45639%54V35%%DU159#D=509#4460U%5D.1U5!D-119#4560Y'54&0M
M*;*6%%E+BJPE1=:2(FM)D;6DR%I29"TILI846=<46=<46=<46=?_4];OX[C_
MQ_'S,^VK=GC-S^;_/MW\!%!+ 0(4 Q0    ( $^!!E$'04UB@0   +$    0
M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
M3X$&42]:%[#M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ 3X$&49E<G",0!@  G"<  !,
M ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !/@091SR3W
MH\L%   X&P  &               @($,"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ 3X$&40AYQ[O3"   X2H  !@
M ("!#0X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( $^!
M!E$ZY]P#+PH  -XQ   8              " @187  !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6Q02P$"% ,4    " !/@091<,L_5QT#  #E"   &
M        @(%[(0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%
M  @ 3X$&4<$*F_9,"@  /S   !@              ("!SB0  'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( $^!!E$'HV^F"P,  .T'   8
M              " @5 O  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"
M% ,4    " !/@091#?4("#0/   *8P  &               @(&1,@  >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ 3X$&40(03<#)"@
MQ3   !@              ("!^T$  'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;%!+ 0(4 Q0    ( $^!!E&%T+^ZE00  'H,   8              " @?I,
M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !/@091S^'\
M KT.  #N*P  &0              @('%40  >&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;%!+ 0(4 Q0    ( $^!!E%MS*F^\PX  %$L   9
M  " @;E@  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @
M3X$&46YT,AVW#   M28  !D              ("!XV\  'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6Q02P$"% ,4    " !/@091.P +!^T)   I'   &0
M            @('1?   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4
M Q0    ( $^!!E'*I\0SM@H  - 9   9              " @?6&  !X;"]W
M;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ 3X$&43H2-TY:!
MF D  !D              ("!XI$  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6Q02P$"% ,4    " !/@091B;X%?:$<   M:   &0              @(%S
ME@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( $^!!E'9
M"J,-2 ,  *T&   9              " @4NS  !X;"]W;W)K<VAE971S+W-H
M965T,3<N>&UL4$L! A0#%     @ 3X$&43KTP__B!0   A   !D
M     ("!RK8  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $^!!E&#M[$"'!P  )9,   9              "
M@8OQ  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ 3X$&
M4=BQO:2U#@  IRL  !D              ("!W@T! 'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6Q02P$"% ,4    " !/@091I I_S@X#  !F!@  &0
M        @('*' $ >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0
M   ( $^!!E':2B9"NP,  !((   9              " @0\@ 0!X;"]W;W)K
M<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ 3X$&40^C(HT="   PQ<
M !D              ("! 20! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q0
M2P$"% ,4    " !/@091#<05Z?L)   :'   &0              @(%5+ $
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( $^!!E$"1=-.
M$@0  '()   9              " @8<V 0!X;"]W;W)K<VAE971S+W-H965T
M,CDN>&UL4$L! A0#%     @ 3X$&41AM8(-M!   5PD  !D
M ("!T#H! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " !/
M@0913G(SHKH7  #M:P  &0              @(%T/P$ >&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( $^!!E$"LMCZ?@,  -X)   9
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M970S-BYX;6Q02P$"% ,4    " !/@091CCMFJO<2  #Z-   &0
M    @('P;0$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (
M $^!!E%%FA ; @,  #L(   9              " @1Z! 0!X;"]W;W)K<VAE
M971S+W-H965T,S@N>&UL4$L! A0#%     @ 3X$&41/=&Y$, P  #@H  !D
M             ("!5X0! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"
M% ,4    " !/@091MMW1F'\"  "7!0  &0              @(&:AP$ >&PO
M=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( $^!!E',M- 3W04
M ,(;   9              " @5"* 0!X;"]W;W)K<VAE971S+W-H965T-#$N
M>&UL4$L! A0#%     @ 3X$&48(1(IH%!P  D20  !D              ("!
M9) ! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " !/@091
M6=2-QS0#   ?"0  &0              @(&@EP$ >&PO=V]R:W-H965T<R]S
M:&5E=#0S+GAM;%!+ 0(4 Q0    ( $^!!E$9T$?$-P,  *,)   9
M      " @0N; 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%
M  @ 3X$&4528;&_: P  N X  !D              ("!>9X! 'AL+W=O<FMS
M:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " !/@091%=>H5<D)  "++0
M&0              @(&*H@$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+
M 0(4 Q0    ( $^!!E')S#.RJ04  ,\3   9              " @8JL 0!X
M;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ 3X$&4; QM@0T
M!P  ]1T  !D              ("!:K(! 'AL+W=O<FMS:&5E=',O<VAE970T
M."YX;6Q02P$"% ,4    " !/@091F*]Y(U<#   @"P  &0
M@('5N0$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( $^!
M!E'J3&W%> P  -$P   9              " @6.] 0!X;"]W;W)K<VAE971S
M+W-H965T-3 N>&UL4$L! A0#%     @ 3X$&4;,3K]/D!@  ^!T  !D
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M=#4U+GAM;%!+ 0(4 Q0    ( $^!!E&FI< ,+00  #H-   9
M  " @8/R 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @
M3X$&45ZT4DZN P  IPL  !D              ("!Y_8! 'AL+W=O<FMS:&5E
M=',O<VAE970U-RYX;6Q02P$"% ,4    " !/@091S0=[,LP$  #M$   &0
M            @(',^@$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4
M Q0    ( $^!!E%+U @\W@,   8+   9              " @<__ 0!X;"]W
M;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ 3X$&4; X5/5)!P
MSB\  !D              ("!Y ," 'AL+W=O<FMS:&5E=',O<VAE970V,"YX
M;6Q02P$"% ,4    " !/@091-T3$NPT%  "M$   &0              @(%D
M"P( >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( $^!!E$'
M302V3 (  !,%   9              " @:@0 @!X;"]W;W)K<VAE971S+W-H
M965T-C(N>&UL4$L! A0#%     @ 3X$&4;=;=H;[ P  %PP  !D
M     ("!*Q," 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $^!!E&]%@SWF@0  / 3   9              "
M@7 L @!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ 3X$&
M48SLW73B"P  ]$(  !D              ("!03$" 'AL+W=O<FMS:&5E=',O
M<VAE970V.2YX;6Q02P$"% ,4    " !/@091\(_3QH<$  #'#P  &0
M        @(%:/0( >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0
M   ( $^!!E')KI\KTP,  %D0   9              " @1A" @!X;"]W;W)K
M<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ 3X$&43@"O/ W @  PP0
M !D              ("!(D8" 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q0
M2P$"% ,4    " !/@091?/O';=X#   &"P  &0              @(&02 (
M>&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( $^!!E&9:+BO
M]@8  $$C   9              " @:5, @!X;"]W;W)K<VAE971S+W-H965T
M-S0N>&UL4$L! A0#%     @ 3X$&43JH9FT: P  #PH  !D
M ("!TE," 'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"% ,4    " !/
M@091FB<6Z80#  "8$P  &0              @($C5P( >&PO=V]R:W-H965T
M<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( $^!!E&^<I7>A ,  -D3   9
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M970X,2YX;6Q02P$"% ,4    " !/@091C_W2_#("   X!0  &0
M    @($C<0( >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    (
M $^!!E%<]",>7 (  %@'   9              " @8QS @!X;"]W;W)K<VAE
M971S+W-H965T.#,N>&UL4$L! A0#%     @ 3X$&414TKQ+M!0  YQD  !D
M             ("!'W8" 'AL+W=O<FMS:&5E=',O<VAE970X-"YX;6Q02P$"
M% ,4    " !/@091#A+@-!D$   Z$   &0              @(%#? ( >&PO
M=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4 Q0    ( $^!!E$]K39M=P0
M %P/   9              " @9.  @!X;"]W;W)K<VAE971S+W-H965T.#8N
M>&UL4$L! A0#%     @ 3X$&4?VI-M9G @  (P8  !D              ("!
M084" 'AL+W=O<FMS:&5E=',O<VAE970X-RYX;6Q02P$"% ,4    " !/@091
M[!^(G<L"  !D!P  &0              @('?AP( >&PO=V]R:W-H965T<R]S
M:&5E=#@X+GAM;%!+ 0(4 Q0    ( $^!!E&!N>F7M <  *$E   9
M      " @>&* @!X;"]W;W)K<VAE971S+W-H965T.#DN>&UL4$L! A0#%
M  @ 3X$&42YJ1YR3 @  ! <  !D              ("!S)(" 'AL+W=O<FMS
M:&5E=',O<VAE970Y,"YX;6Q02P$"% ,4    " !/@091=#)[,]<%   )&0
M&0              @(&6E0( >&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+
M 0(4 Q0    ( $^!!E'N:*%2'00   8.   9              " @:2; @!X
M;"]W;W)K<VAE971S+W-H965T.3(N>&UL4$L! A0#%     @ 3X$&46:4#R=9
M%0  [H\  !D              ("!^)\" 'AL+W=O<FMS:&5E=',O<VAE970Y
M,RYX;6Q02P$"% ,4    " !/@091FX\5BE "  !Z"P  #0
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:+GAM;%!+!08     90!E +H;  "CQ (    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>822</ContextCount>
  <ElementCount>512</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>214</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>14</UnitCount>
  <MyReports>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002001 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - Parenthetical</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - Parenthetical</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1003001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1005000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1005501 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (PARENTHETICAL)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (PARENTHETICAL)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Basis of Presentation and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Acquisition, Equity-Method Investment and Licensing Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangements</Role>
      <ShortName>Acquisition, Equity-Method Investment and Licensing Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Other (Income)/Deductions - Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNet</Role>
      <ShortName>Other (Income)/Deductions - Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Tax Matters</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMatters</Role>
      <ShortName>Tax Matters</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests</Role>
      <ShortName>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Identifiable Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Pension and Postretirement Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlans</Role>
      <ShortName>Pension and Postretirement Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2115100 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholders</Role>
      <ShortName>Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Contingencies and Certain Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ContingenciesAndCertainCommitments</Role>
      <ShortName>Contingencies and Certain Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2117100 - Disclosure - Segment, Geographic and Other Revenue Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation</Role>
      <ShortName>Segment, Geographic and Other Revenue Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2301302 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Acquisition, Equity-Method Investment and Licensing Arrangements  - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsTables</Role>
      <ShortName>Acquisition, Equity-Method Investment and Licensing Arrangements  - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Other (Income)/Deductions - Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNetTables</Role>
      <ShortName>Other (Income)/Deductions - Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherIncomeDeductionsNet</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Tax Matters (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersTables</Role>
      <ShortName>Tax Matters (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/TaxMatters</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables</Role>
      <ShortName>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/FinancialInstruments</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/Inventories</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Identifiable Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Pension and Postretirement Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansTables</Role>
      <ShortName>Pension and Postretirement Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlans</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2314301 - Disclosure - Equity  - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/EquityTables</Role>
      <ShortName>Equity  - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2315301 - Disclosure - Earnings Per Common Share Attributable to Common Shareholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersTables</Role>
      <ShortName>Earnings Per Common Share Attributable to Common Shareholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2317301 - Disclosure - Segment, Geographic and Other Revenue Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables</Role>
      <ShortName>Segment, Geographic and Other Revenue Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2401403 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2401404 - Disclosure - Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Acquisition, Equity-Method Investment and Licensing Arrangements  - Array BioPharma (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsArrayBiopharmaDetails</Role>
      <ShortName>Acquisition, Equity-Method Investment and Licensing Arrangements  - Array BioPharma (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Acquisition, Equity-Method Investment and Licensing Arrangements  - Equity Method Investment Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails</Role>
      <ShortName>Acquisition, Equity-Method Investment and Licensing Arrangements  - Equity Method Investment Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2403404 - Disclosure - Acquisition, Equity-Method Investment and Licensing Arrangements  - Schedule of Equity-Method Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails</Role>
      <ShortName>Acquisition, Equity-Method Investment and Licensing Arrangements  - Schedule of Equity-Method Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2403405 - Disclosure - Acquisition, Equity-Method Investment and Licensing Arrangements - Valneva SE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails</Role>
      <ShortName>Acquisition, Equity-Method Investment and Licensing Arrangements - Valneva SE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2403406 - Disclosure - Acquisition, Equity-Method Investment and Licensing Arrangements - BioNTech SE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails</Role>
      <ShortName>Acquisition, Equity-Method Investment and Licensing Arrangements - BioNTech SE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2404404 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Footnotes (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetail</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Footnotes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2404405 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2404406 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Other (Income)/Deductions - Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail</Role>
      <ShortName>Other (Income)/Deductions - Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherIncomeDeductionsNetTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Other (Income)/Deductions - Net - Footnotes (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail</Role>
      <ShortName>Other (Income)/Deductions - Net - Footnotes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherIncomeDeductionsNetTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Tax Matters - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersNarrativeDetail</Role>
      <ShortName>Tax Matters - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Tax Matters (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersDetail</Role>
      <ShortName>Tax Matters (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/TaxMattersTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail</Role>
      <ShortName>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail</Role>
      <ShortName>Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetail</Role>
      <ShortName>Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Financial Instruments - Financial Liabilities Not Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Financial Instruments - Financial Liabilities Not Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Financial Instruments - Total Short-Term and Long-Term Investments and Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails</Role>
      <ShortName>Financial Instruments - Total Short-Term and Long-Term Investments and Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Financial Instruments - Total Short-Term and Long-Term Investments and Equity Method Investments - Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsFootnotesDetails</Role>
      <ShortName>Financial Instruments - Total Short-Term and Long-Term Investments and Equity Method Investments - Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2410407 - Disclosure - Financial Instruments - Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails</Role>
      <ShortName>Financial Instruments - Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2410408 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails</Role>
      <ShortName>Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2410409 - Disclosure - Financial Instruments Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsFinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesFootnotesDetails</Role>
      <ShortName>Financial Instruments Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2410410 - Disclosure - Financial Instruments - Short-term Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails</Role>
      <ShortName>Financial Instruments - Short-term Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2410411 - Disclosure - Financial Instruments - Long-Term Debt - New Issuances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails</Role>
      <ShortName>Financial Instruments - Long-Term Debt - New Issuances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2410412 - Disclosure - Financial Instruments - Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails</Role>
      <ShortName>Financial Instruments - Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2410413 - Disclosure - Financial Instruments - Long-Term Debt Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails</Role>
      <ShortName>Financial Instruments - Long-Term Debt Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2410414 - Disclosure - Financial Instruments -  Derivative Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails</Role>
      <ShortName>Financial Instruments -  Derivative Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2410415 - Disclosure - Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails</Role>
      <ShortName>Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2410416 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails</Role>
      <ShortName>Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2410417 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails</Role>
      <ShortName>Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2410418 - Disclosure - Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails</Role>
      <ShortName>Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2410419 - Disclosure - Financial Instruments - Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails</Role>
      <ShortName>Financial Instruments - Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Inventories (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/InventoriesDetail</Role>
      <ShortName>Inventories (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/InventoriesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Identifiable Intangible Assets and Goodwill  - Finite-lived and Indefinite-lived Intangible Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill  - Finite-lived and Indefinite-lived Intangible Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Identifiable Intangible Assets and Goodwill  - Finite-lived and Indefinite-lived Intangible Assets Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill  - Finite-lived and Indefinite-lived Intangible Assets Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Identifiable Intangible Assets and Goodwill  - Finite-lived Intangible Assets Percentage of Total Intangibles (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill  - Finite-lived Intangible Assets Percentage of Total Intangibles (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Identifiable Intangible Assets and Goodwill  - Indefinite-lived Intangible Assets Percentage of Total Intangibles (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill  - Indefinite-lived Intangible Assets Percentage of Total Intangibles (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Identifiable Intangible Assets and Goodwill  - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill  - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2412407 - Disclosure - Identifiable Intangible Assets and Goodwill  - Goodwill (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill  - Goodwill (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail</Role>
      <ShortName>Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2413403 - Disclosure - Pension and Postretirement Benefit Plans (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail</Role>
      <ShortName>Pension and Postretirement Benefit Plans (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2414402 - Disclosure - Equity  - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/EquityPreferredStockDetails</Role>
      <ShortName>Equity  - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2414403 - Disclosure - Equity - Dividends (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/EquityDividendsDetails</Role>
      <ShortName>Equity - Dividends (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2415402 - Disclosure - Earnings Per Common Share Attributable to Common Shareholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails</Role>
      <ShortName>Earnings Per Common Share Attributable to Common Shareholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2416401 - Disclosure - Contingencies and Certain Commitments (Patent Litigation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails</Role>
      <ShortName>Contingencies and Certain Commitments (Patent Litigation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/ContingenciesAndCertainCommitments</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2416402 - Disclosure - Contingencies and Certain Commitments (Product Litigation, Commercial and Other Matters, Resolved Matters) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails</Role>
      <ShortName>Contingencies and Certain Commitments (Product Litigation, Commercial and Other Matters, Resolved Matters) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/ContingenciesAndCertainCommitments</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2416403 - Disclosure - Contingencies and Certain Commitments - Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsContingentConsiderationDetails</Role>
      <ShortName>Contingencies and Certain Commitments - Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>2417402 - Disclosure - Segment, Geographic and Other Revenue Information - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail</Role>
      <ShortName>Segment, Geographic and Other Revenue Information - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>2417403 - Disclosure - Segment, Geographic and Other Revenue Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail</Role>
      <ShortName>Segment, Geographic and Other Revenue Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>2417404 - Disclosure - Segment, Geographic and Other Revenue Information - Footnotes (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail</Role>
      <ShortName>Segment, Geographic and Other Revenue Information - Footnotes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>2417405 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail</Role>
      <ShortName>Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>2417406 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Geographic Area - Footnotes (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail</Role>
      <ShortName>Segment, Geographic and Other Revenue Information - Revenues By Geographic Area - Footnotes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="pfe-06282020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Products (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail</Role>
      <ShortName>Segment, Geographic and Other Revenue Information - Revenues By Products (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="pfe-06282020x10q.htm">pfe-06282020x10q.htm</File>
    <File>pfe-20200628.xsd</File>
    <File>pfe-20200628_cal.xml</File>
    <File>pfe-20200628_def.xml</File>
    <File>pfe-20200628_lab.xml</File>
    <File>pfe-20200628_pre.xml</File>
    <File>pfe-exh311x0628202010q.htm</File>
    <File>pfe-exh312x0628202010q.htm</File>
    <File>pfe-exh321x0628202010q.htm</File>
    <File>pfe-exh322x0628202010q.htm</File>
    <File>pfe-exhibit101x6282020.htm</File>
    <File>pfe-exhibit15x06282020.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>chart-27876a64791f5b87818.jpg</File>
    <File>chart-279c9b6159565ded8a4.jpg</File>
    <File>chart-69c730ef7bbe3f2b2ca.jpg</File>
    <File>chart-e6285fd93bdf59a14df.jpg</File>
    <File>pfizerlogo2816.jpg</File>
    <File>upjohnlogo.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>119
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "pfe-06282020x10q.htm": {
   "axisCustom": 2,
   "axisStandard": 44,
   "contextCount": 822,
   "dts": {
    "calculationLink": {
     "local": [
      "pfe-20200628_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pfe-20200628_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "pfe-06282020x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pfe-20200628_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pfe-20200628_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "pfe-20200628.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 839,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 12,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 17
   },
   "keyCustom": 88,
   "keyStandard": 424,
   "memberCustom": 131,
   "memberStandard": 73,
   "nsprefix": "pfe",
   "nsuri": "http://www.pfizer.com/20200628",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover Page",
     "role": "http://www.pfizer.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - Basis of Presentation and Significant Accounting Policies",
     "role": "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103100 - Disclosure - Acquisition, Equity-Method Investment and Licensing Arrangements",
     "role": "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangements",
     "shortName": "Acquisition, Equity-Method Investment and Licensing Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104100 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives",
     "role": "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107100 - Disclosure - Other (Income)/Deductions - Net",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNet",
     "shortName": "Other (Income)/Deductions - Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108100 - Disclosure - Tax Matters",
     "role": "http://www.pfizer.com/role/TaxMatters",
     "shortName": "Tax Matters",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109100 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests",
     "role": "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests",
     "shortName": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110100 - Disclosure - Financial Instruments",
     "role": "http://www.pfizer.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111100 - Disclosure - Inventories",
     "role": "http://www.pfizer.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112100 - Disclosure - Identifiable Intangible Assets and Goodwill",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill",
     "shortName": "Identifiable Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113100 - Disclosure - Pension and Postretirement Benefit Plans",
     "role": "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlans",
     "shortName": "Pension and Postretirement Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)",
     "role": "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114100 - Disclosure - Equity",
     "role": "http://www.pfizer.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115100 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders",
     "role": "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholders",
     "shortName": "Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116100 - Disclosure - Contingencies and Certain Commitments",
     "role": "http://www.pfizer.com/role/ContingenciesAndCertainCommitments",
     "shortName": "Contingencies and Certain Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117100 - Disclosure - Segment, Geographic and Other Revenue Information",
     "role": "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation",
     "shortName": "Segment, Geographic and Other Revenue Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2201201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)",
     "role": "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pfe:ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2301302 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)",
     "role": "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pfe:ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Acquisition, Equity-Method Investment and Licensing Arrangements  - (Tables)",
     "role": "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsTables",
     "shortName": "Acquisition, Equity-Method Investment and Licensing Arrangements  - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)",
     "role": "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Other (Income)/Deductions - Net (Tables)",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetTables",
     "shortName": "Other (Income)/Deductions - Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308301 - Disclosure - Tax Matters (Tables)",
     "role": "http://www.pfizer.com/role/TaxMattersTables",
     "shortName": "Tax Matters (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)",
     "role": "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309301 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)",
     "role": "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables",
     "shortName": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310301 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311301 - Disclosure - Inventories (Tables)",
     "role": "http://www.pfizer.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312301 - Disclosure - Identifiable Intangible Assets and Goodwill (Tables)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables",
     "shortName": "Identifiable Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313301 - Disclosure - Pension and Postretirement Benefit Plans (Tables)",
     "role": "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansTables",
     "shortName": "Pension and Postretirement Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DividendsDeclaredTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314301 - Disclosure - Equity  - (Tables)",
     "role": "http://www.pfizer.com/role/EquityTables",
     "shortName": "Equity  - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DividendsDeclaredTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315301 - Disclosure - Earnings Per Common Share Attributable to Common Shareholders (Tables)",
     "role": "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersTables",
     "shortName": "Earnings Per Common Share Attributable to Common Shareholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317301 - Disclosure - Segment, Geographic and Other Revenue Information (Tables)",
     "role": "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables",
     "shortName": "Segment, Geographic and Other Revenue Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "D2019Q3Jan1-Jul31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "Operating_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401403 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details)",
     "role": "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "I2020Q1Jan1",
      "decimals": "INF",
      "lang": null,
      "name": "pfe:NumberOfAccountingStandardsAdopted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Accounting_standard",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "pfe:ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "pfe:RebatesAndDiscountsAccrual",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401404 - Disclosure - Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details)",
     "role": "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "pfe:ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember",
      "decimals": "-6",
      "lang": null,
      "name": "pfe:RebatesAndDiscountsAccrual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002001 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - Parenthetical",
     "role": "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - Parenthetical",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionSharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403402 - Disclosure - Acquisition, Equity-Method Investment and Licensing Arrangements  - Array BioPharma (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsArrayBiopharmaDetails",
     "shortName": "Acquisition, Equity-Method Investment and Licensing Arrangements  - Array BioPharma (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionSharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeconsolidationGainOrLossAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403403 - Disclosure - Acquisition, Equity-Method Investment and Licensing Arrangements  - Equity Method Investment Narrative (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails",
     "shortName": "Acquisition, Equity-Method Investment and Licensing Arrangements  - Equity Method Investment Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403404 - Disclosure - Acquisition, Equity-Method Investment and Licensing Arrangements  - Schedule of Equity-Method Investment (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails",
     "shortName": "Acquisition, Equity-Method Investment and Licensing Arrangements  - Schedule of Equity-Method Investment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "D2020Q2Jan1-Mar31_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_pfe_GSKConsumerHealthcareMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "I2020Q2Apr30_srt_CounterpartyNameAxis_pfe_ValnevaSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "pfe:ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403405 - Disclosure - Acquisition, Equity-Method Investment and Licensing Arrangements - Valneva SE (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails",
     "shortName": "Acquisition, Equity-Method Investment and Licensing Arrangements - Valneva SE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "I2020Q2Apr30_srt_CounterpartyNameAxis_pfe_ValnevaSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "pfe:ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD_srt_CounterpartyNameAxis_pfe_BioNTechSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "pfe:LicensingArrangementValueOfSharesPurchased",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403406 - Disclosure - Acquisition, Equity-Method Investment and Licensing Arrangements - BioNTech SE (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails",
     "shortName": "Acquisition, Equity-Method Investment and Licensing Arrangements - BioNTech SE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD_srt_CounterpartyNameAxis_pfe_BioNTechSEMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "pfe:LicensingArrangementValueOfSharesPurchased",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404402 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details)",
     "role": "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404403 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Detail)",
     "role": "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404404 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Footnotes (Detail)",
     "role": "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetail",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Footnotes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404405 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail)",
     "role": "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "-6",
      "lang": null,
      "name": "pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404406 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail)",
     "role": "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "link:footnote",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Other (Income)/Deductions - Net (Detail)",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail",
     "shortName": "Other (Income)/Deductions - Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromLegalSettlements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Other (Income)/Deductions - Net - Footnotes (Detail)",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
     "shortName": "Other (Income)/Deductions - Net - Footnotes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromLegalSettlements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408402 - Disclosure - Tax Matters - Narrative (Detail)",
     "role": "http://www.pfizer.com/role/TaxMattersNarrativeDetail",
     "shortName": "Tax Matters - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Tax Matters (Detail)",
     "role": "http://www.pfizer.com/role/TaxMattersDetail",
     "shortName": "Tax Matters (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409402 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail)",
     "role": "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail",
     "shortName": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "link:footnote",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410402 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
     "shortName": "Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410403 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Detail)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetail",
     "shortName": "Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember",
      "decimals": "-6",
      "lang": "en-US",
      "name": "pfe:EquitySecuritiesFVNIRestrictedNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Financial Instruments - Financial Liabilities Not Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Financial Instruments - Financial Liabilities Not Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Financial Instruments - Total Short-Term and Long-Term Investments and Equity Method Investments (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails",
     "shortName": "Financial Instruments - Total Short-Term and Long-Term Investments and Equity Method Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Financial Instruments - Total Short-Term and Long-Term Investments and Equity Method Investments - Footnotes (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsFootnotesDetails",
     "shortName": "Financial Instruments - Total Short-Term and Long-Term Investments and Equity Method Investments - Footnotes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)",
     "role": "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:HeldToMaturitySecuritiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "pfe:DebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410407 - Disclosure - Financial Instruments - Investments (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails",
     "shortName": "Financial Instruments - Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:HeldToMaturitySecuritiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "pfe:DebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410408 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails",
     "shortName": "Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:EquitySecuritiesFvNiRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "pfe:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410409 - Disclosure - Financial Instruments Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsFinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesFootnotesDetails",
     "shortName": "Financial Instruments Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "pfe:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommercialPaper",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410410 - Disclosure - Financial Instruments - Short-term Borrowings (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails",
     "shortName": "Financial Instruments - Short-term Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommercialPaper",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410411 - Disclosure - Financial Instruments - Long-Term Debt - New Issuances (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails",
     "shortName": "Financial Instruments - Long-Term Debt - New Issuances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:DebtInstrumentRedemptionPricePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410412 - Disclosure - Financial Instruments - Long-Term Debt (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
     "shortName": "Financial Instruments - Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q1_us-gaap_DebtInstrumentAxis_pfe_SeniorNotesDue2047Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentRepurchaseAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410413 - Disclosure - Financial Instruments - Long-Term Debt Narrative (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
     "shortName": "Financial Instruments - Long-Term Debt Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q1_us-gaap_DebtInstrumentAxis_pfe_SeniorNotesDue2047Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentRepurchaseAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeNetLiabilityPositionAggregateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410414 - Disclosure - Financial Instruments -  Derivative Narrative (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails",
     "shortName": "Financial Instruments -  Derivative Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeNetLiabilityPositionAggregateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410415 - Disclosure - Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails",
     "shortName": "Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410416 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
     "shortName": "Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-6",
      "lang": null,
      "name": "pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED)",
     "role": "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410417 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
     "shortName": "Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:HedgedAssetFairValueHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410418 - Disclosure - Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails",
     "shortName": "Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:HedgedAssetFairValueHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD_us-gaap_EquitySecuritiesByIndustryAxis_us-gaap_FinancialServicesSectorMember",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410419 - Disclosure - Financial Instruments - Credit Risk (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails",
     "shortName": "Financial Instruments - Credit Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD_us-gaap_EquitySecuritiesByIndustryAxis_us-gaap_FinancialServicesSectorMember",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411402 - Disclosure - Inventories (Detail)",
     "role": "http://www.pfizer.com/role/InventoriesDetail",
     "shortName": "Inventories (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412402 - Disclosure - Identifiable Intangible Assets and Goodwill  - Finite-lived and Indefinite-lived Intangible Assets (Detail)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail",
     "shortName": "Identifiable Intangible Assets and Goodwill  - Finite-lived and Indefinite-lived Intangible Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412403 - Disclosure - Identifiable Intangible Assets and Goodwill  - Finite-lived and Indefinite-lived Intangible Assets Footnotes (Details)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
     "shortName": "Identifiable Intangible Assets and Goodwill  - Finite-lived and Indefinite-lived Intangible Assets Footnotes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "pfe:IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412404 - Disclosure - Identifiable Intangible Assets and Goodwill  - Finite-lived Intangible Assets Percentage of Total Intangibles (Details)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
     "shortName": "Identifiable Intangible Assets and Goodwill  - Finite-lived Intangible Assets Percentage of Total Intangibles (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "pfe:IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "pfe:IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Identifiable Intangible Assets and Goodwill  - Indefinite-lived Intangible Assets Percentage of Total Intangibles (Details)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
     "shortName": "Identifiable Intangible Assets and Goodwill  - Indefinite-lived Intangible Assets Percentage of Total Intangibles (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "pfe:IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Identifiable Intangible Assets and Goodwill  - Narrative (Detail)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail",
     "shortName": "Identifiable Intangible Assets and Goodwill  - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412407 - Disclosure - Identifiable Intangible Assets and Goodwill  - Goodwill (Detail)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail",
     "shortName": "Identifiable Intangible Assets and Goodwill  - Goodwill (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:GoodwillOtherIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "role": "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "-6",
      "lang": null,
      "name": "pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413402 - Disclosure - Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail)",
     "role": "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail",
     "shortName": "Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "pfe:ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock",
       "ix:continuation",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413403 - Disclosure - Pension and Postretirement Benefit Plans (Detail)",
     "role": "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
     "shortName": "Pension and Postretirement Benefit Plans (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "pfe:ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock",
       "ix:continuation",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "I2020Q2May4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414402 - Disclosure - Equity  - Preferred Stock (Details)",
     "role": "http://www.pfizer.com/role/EquityPreferredStockDetails",
     "shortName": "Equity  - Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "I2020Q2May4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:DividendsDeclaredTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "D2020Q2Jun25-25",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414403 - Disclosure - Equity - Dividends (Details)",
     "role": "http://www.pfizer.com/role/EquityDividendsDetails",
     "shortName": "Equity - Dividends (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:DividendsDeclaredTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "D2020Q2Jun25-25",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415402 - Disclosure - Earnings Per Common Share Attributable to Common Shareholders (Details)",
     "role": "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails",
     "shortName": "Earnings Per Common Share Attributable to Common Shareholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "D2017Q4Oct01-Oct31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pfe:GainContingencyPatentsWithoutCourtProceedingsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Patent",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416401 - Disclosure - Contingencies and Certain Commitments (Patent Litigation) (Details)",
     "role": "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails",
     "shortName": "Contingencies and Certain Commitments (Patent Litigation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "D2017Q4Oct01-Oct31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pfe:GainContingencyPatentsWithoutCourtProceedingsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Patent",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "D2017Q4Nov2017",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pfe:LossContingencyClassActionsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "class_action",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416402 - Disclosure - Contingencies and Certain Commitments (Product Litigation, Commercial and Other Matters, Resolved Matters) (Details)",
     "role": "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails",
     "shortName": "Contingencies and Certain Commitments (Product Litigation, Commercial and Other Matters, Resolved Matters) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "D2017Q4Nov2017",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pfe:LossContingencyClassActionsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "class_action",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416403 - Disclosure - Contingencies and Certain Commitments - Contingent Consideration (Details)",
     "role": "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsContingentConsiderationDetails",
     "shortName": "Contingencies and Certain Commitments - Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "D2019Q3Jan1-Jul31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "Operating_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417402 - Disclosure - Segment, Geographic and Other Revenue Information - Narrative (Detail)",
     "role": "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail",
     "shortName": "Segment, Geographic and Other Revenue Information - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417403 - Disclosure - Segment, Geographic and Other Revenue Information (Detail)",
     "role": "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
     "shortName": "Segment, Geographic and Other Revenue Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005501 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (PARENTHETICAL)",
     "role": "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (PARENTHETICAL)",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViiVMember",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeDividend",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417404 - Disclosure - Segment, Geographic and Other Revenue Information - Footnotes (Detail)",
     "role": "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail",
     "shortName": "Segment, Geographic and Other Revenue Information - Footnotes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417405 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)",
     "role": "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail",
     "shortName": "Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "2",
      "lang": null,
      "name": "pfe:PercentageChangeInRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417406 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Geographic Area - Footnotes (Detail)",
     "role": "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail",
     "shortName": "Segment, Geographic and Other Revenue Information - Revenues By Geographic Area - Footnotes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Products (Detail)",
     "role": "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail",
     "shortName": "Segment, Geographic and Other Revenue Information - Revenues By Products (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-06282020x10q.htm",
      "contextRef": "FD2020Q2QTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 214,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S. [Member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "terseLabel": "Euro Member Countries, Euro [Member]"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r750"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r751"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r751"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r751"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r752"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r751"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r751"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r751"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r751"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r748"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "pfe_AccruedRebates": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Rebates",
        "label": "Accrued Rebates",
        "terseLabel": "Accrued rebates"
       }
      }
     },
     "localname": "AccruedRebates",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_AllOtherInflammationandImmunologyProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All Other Inflammation and Immunology Products [Member]",
        "label": "All Other Inflammation and Immunology Products [Member]",
        "terseLabel": "All other I &amp; I [Member]"
       }
      }
     },
     "localname": "AllOtherInflammationandImmunologyProductsMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AllOtherInternalMedicineMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All Other Internal Medicine [Member]",
        "label": "All Other Internal Medicine [Member]",
        "terseLabel": "All other Internal Medicine [Member]"
       }
      }
     },
     "localname": "AllOtherInternalMedicineMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AllOtherRareDiseaseProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All Other Rare Disease Products [Member]",
        "label": "All Other Rare Disease Products [Member]",
        "terseLabel": "All other Rare Disease [Member]"
       }
      }
     },
     "localname": "AllOtherRareDiseaseProductsMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AllOtherUpjohnProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All Other Upjohn Products [Member]",
        "label": "All Other Upjohn Products [Member]",
        "terseLabel": "All other Upjohn [Member]"
       }
      }
     },
     "localname": "AllOtherUpjohnProductsMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AllogeneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allogene [Member]",
        "label": "Allogene [Member]",
        "terseLabel": "Allogene [Member]"
       }
      }
     },
     "localname": "AllogeneMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of amortization that is not associated with a single function. Amounts associated in a single function are included in Cost of sales, Selling, information and administrative expenses and Research and development expenses.",
        "label": "Amortization Of Intangible Assets Not Associated With Single Function",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_AnacorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Anacor [Member]",
        "label": "Anacor [Member]",
        "terseLabel": "Anacor [Member]"
       }
      }
     },
     "localname": "AnacorMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ArrayMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Array [Member]",
        "label": "Array [Member]",
        "terseLabel": "Array [Member]"
       }
      }
     },
     "localname": "ArrayMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsArrayBiopharmaDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AssetImpairmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset impairments [Member]",
        "label": "Asset Impairments [Member]",
        "terseLabel": "Asset Impairment Charges [Member]"
       }
      }
     },
     "localname": "AssetImpairmentsMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AssetWriteOffsAndAssetImpairmentCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Write-Offs And Asset Impairment Charges",
        "label": "Asset Write-Offs And Asset Impairment Charges",
        "verboseLabel": "Asset write-offs and impairments"
       }
      }
     },
     "localname": "AssetWriteOffsAndAssetImpairmentCharges",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value",
        "label": "Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value",
        "terseLabel": "Available-for-sale securities, debt maturities, over 5 years, fair value"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_BMP2Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BMP2 [Member]",
        "label": "BMP2 [Member]",
        "terseLabel": "BMP2 [Member]"
       }
      }
     },
     "localname": "BMP2Member",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BeneFIXMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bene F I X [Member]",
        "label": "Bene F I X [Member]",
        "terseLabel": "BeneFIX [Member]"
       }
      }
     },
     "localname": "BeneFIXMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BioNTechSEMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BioNTech SE [Member]",
        "label": "BioNTech SE [Member]",
        "terseLabel": "BioNTech SE [Member]"
       }
      }
     },
     "localname": "BioNTechSEMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BiopharmaSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biopharma Segment [Member]",
        "label": "Biopharma Segment [Member]",
        "terseLabel": "Biopharma [Member]"
       }
      }
     },
     "localname": "BiopharmaSegmentMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biopharma, Upjohn And Consumer Healthcare Segments [Member]",
        "label": "Biopharma, Upjohn And Consumer Healthcare Segments [Member]",
        "terseLabel": "Biopharma, Upjohn And Consumer Healthcare Segments [Member]"
       }
      }
     },
     "localname": "BiopharmaUpjohnAndConsumerHealthcareSegmentsMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BosulifMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bosulif [Member]",
        "label": "Bosulif [Member]",
        "terseLabel": "Bosulif [Member]"
       }
      }
     },
     "localname": "BosulifMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BraftoviMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Braftovi [Member]",
        "label": "Braftovi [Member]",
        "terseLabel": "Braftovi [Member]"
       }
      }
     },
     "localname": "BraftoviMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BusinessAlignmentCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail": {
       "order": 9.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Alignment Costs",
        "label": "Business Alignment Costs",
        "terseLabel": "Business and legal entity alignment costs"
       }
      }
     },
     "localname": "BusinessAlignmentCosts",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail": {
       "order": 2.0,
       "parentTag": "pfe_RestructuringChargesAndAcquisitionRelatedCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents external costs directly related to effecting a business combination which costs have been expensed during the period. Such costs include advisory, legal, accounting, valuation, and other similar services.",
        "label": "Business Combination, Acquisition Related Costs, Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCostsTransactionCosts",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_BusinessCombinationsAcquisitionRelatedCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combinations, Acquisition Related Costs [Member]",
        "label": "Business Combinations, Acquisition Related Costs [Member]",
        "terseLabel": "Acquisition-Related Costs [Member]"
       }
      }
     },
     "localname": "BusinessCombinationsAcquisitionRelatedCostsMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]",
        "label": "Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract",
     "nsuri": "http://www.pfizer.com/20200628",
     "xbrltype": "stringItemType"
    },
    "pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement Disclosure [Text Block]",
        "label": "Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement Disclosure [Text Block]",
        "terseLabel": "Acquisition, Equity-Method Investment and Licensing Arrangements"
       }
      }
     },
     "localname": "BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_BusinessIntegrationCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Integration Costs [Member]",
        "label": "Business Integration Costs [Member]",
        "terseLabel": "Business Integration Costs [Member]"
       }
      }
     },
     "localname": "BusinessIntegrationCostsMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CK1AssetsSoldToBiogenIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "CK1 Assets Sold To Biogen, Inc [Member]",
        "label": "CK1 Assets Sold To Biogen, Inc [Member]",
        "terseLabel": "CK1 assets sold to Biogen, Inc [Member]"
       }
      }
     },
     "localname": "CK1AssetsSoldToBiogenIncMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CelebrexMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Celebrex [Member]",
        "label": "Celebrex [Member]",
        "terseLabel": "Celebrex [Member]"
       }
      }
     },
     "localname": "CelebrexMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CertainSignificantItemsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Certain significant items [Member]",
        "label": "Certain Significant Items [Member]",
        "terseLabel": "Certain Significant Items [Member]"
       }
      }
     },
     "localname": "CertainSignificantItemsMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ChantixChampixMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Chantix / Champix [Member]",
        "label": "Chantix Champix [Member]",
        "terseLabel": "Chantix / Champix [Member]"
       }
      }
     },
     "localname": "ChantixChampixMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ClassActionVersusWyethMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class Action Versus Wyeth [Member]",
        "label": "Class Action Versus Wyeth [Member]",
        "terseLabel": "Class Action Versus Wyeth [Member]"
       }
      }
     },
     "localname": "ClassActionVersusWyethMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ConsumerHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consumer Healthcare [Member]",
        "label": "Consumer Healthcare [Member]",
        "terseLabel": "Consumer Healthcare [Member]"
       }
      }
     },
     "localname": "ConsumerHealthcareMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ConsumerHealthcareReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consumer Healthcare Reporting Unit [Member]",
        "label": "Consumer Healthcare Reporting Unit [Member]",
        "terseLabel": "Consumer Healthcare [Member]"
       }
      }
     },
     "localname": "ConsumerHealthcareReportingUnitMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CortexymeInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cortexyme, Inc. [Member]",
        "label": "Cortexyme, Inc. [Member]",
        "terseLabel": "Cortexyme, Inc. [Member]"
       }
      }
     },
     "localname": "CortexymeInc.Member",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting",
        "label": "Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting",
        "terseLabel": "Net fair value adjustments related to hedging and purchase accounting",
        "verboseLabel": "Net fair value adjustments related to hedging and purchase accounting"
       }
      }
     },
     "localname": "DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "pfe_DebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities, Accumulated Gross Unrealized Gain",
        "label": "Debt Securities, Accumulated Gross Unrealized Gain",
        "terseLabel": "Debt securities, gross unrealized gains"
       }
      }
     },
     "localname": "DebtSecuritiesAccumulatedGrossUnrealizedGain",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "pfe_DebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities, Accumulated Gross Unrealized Loss",
        "label": "Debt Securities, Accumulated Gross Unrealized Loss",
        "negatedLabel": "Debt securities, gross unrealized losses"
       }
      }
     },
     "localname": "DebtSecuritiesAccumulatedGrossUnrealizedLoss",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities, Amortized Cost Basis",
        "label": "Debt Securities, Amortized Cost Basis",
        "totalLabel": "Debt securities, amortized cost"
       }
      }
     },
     "localname": "DebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities Maturities, After Year Five, Fair Value",
        "label": "Debt Securities Maturities, After Year Five, Fair Value",
        "totalLabel": "Debt securities maturities, over 5 years, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesMaturitiesAfterYearFiveFairValue",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities Maturities, Next Twelve Months, Fair Value",
        "label": "Debt Securities Maturities, Next Twelve Months, Fair Value",
        "totalLabel": "Debt securities maturities, within 1 year, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesMaturitiesNextTwelveMonthsFairValue",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities Maturities, Year Two Through Five, Fair Value",
        "label": "Debt Securities Maturities, Year Two Through Five, Fair Value",
        "totalLabel": "Debt securities maturities, over 1 to 5 years, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block]",
        "label": "Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block]",
        "terseLabel": "Schedule of Gains and Losses on Investment Securities"
       }
      }
     },
     "localname": "DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_DeconsolidationGainLossAmountNetOfCashConveyed": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deconsolidation, Gain (Loss), Amount, Net Of Cash Conveyed",
        "label": "Deconsolidation, Gain (Loss), Amount, Net Of Cash Conveyed",
        "negatedLabel": "Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed"
       }
      }
     },
     "localname": "DeconsolidationGainLossAmountNetOfCashConveyed",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DeconsolidationGainLossAmountNetOfTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deconsolidation, Gain (Loss), Amount, Net Of Tax",
        "label": "Deconsolidation, Gain (Loss), Amount, Net Of Tax",
        "terseLabel": "Gain on completion of Consumer Healthcare JV transaction, after-tax"
       }
      }
     },
     "localname": "DeconsolidationGainLossAmountNetOfTax",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent",
        "label": "Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent",
        "terseLabel": "Noncurrent deferred tax assets and other noncurrent tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Actuarial Gain (Loss), Tax",
        "label": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Actuarial Gain (Loss), Tax",
        "totalLabel": "Defined benefit plans, actuarial gain (loss), tax, total"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. Includes the amount of expense from discontinued operations, that reflects the allocation of the cost of tangible and intangible assets over the assets' useful lives.",
        "label": "Depreciation, Depletion And Amortization, Including Discontinued Operation, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DevelopedEuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Developed Europe [Member]",
        "label": "Developed Europe [Member]",
        "terseLabel": "Developed Europe [Member]"
       }
      }
     },
     "localname": "DevelopedEuropeMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DevelopedRestOfWorldMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Developed Rest Of World [Member]",
        "label": "Developed Rest Of World [Member]",
        "terseLabel": "Developed Rest Of World [Member]"
       }
      }
     },
     "localname": "DevelopedRestOfWorldMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Not Discontinued Operation, Pre-tax Income (Loss)",
        "label": "Disposal Group, Not Discontinued Operation, Pre-tax Income (Loss)",
        "verboseLabel": "Pre-tax income attributable to disposal group"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DocetaxelMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Docetaxel [Member]",
        "label": "Docetaxel [Member]",
        "terseLabel": "Docetaxel [Member]"
       }
      }
     },
     "localname": "DocetaxelMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EffexorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effexor [Member]",
        "label": "Effexor [Member]",
        "terseLabel": "Effexor [Member]"
       }
      }
     },
     "localname": "EffexorMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EliLillyCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eli Lilly &amp; Company [Member]",
        "label": "Eli Lilly &amp; Company [Member]",
        "terseLabel": "Eli Lilly &amp; Company [Member]"
       }
      }
     },
     "localname": "EliLillyCompanyMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EliquisMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eliquis [Member]",
        "label": "Eliquis [Member]",
        "terseLabel": "Eliquis [Member]"
       }
      }
     },
     "localname": "EliquisMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EmergingMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Emerging Markets [Member]",
        "label": "Emerging Markets [Member]",
        "terseLabel": "Emerging Markets [Member]"
       }
      }
     },
     "localname": "EmergingMarketsMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EnbrelMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Enbrel [Member]",
        "label": "Enbrel [Member]",
        "verboseLabel": "Enbrel (Outside the U.S. and Canada) [Member]"
       }
      }
     },
     "localname": "EnbrelMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EnvironmentalRemediationLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Environmental Remediation Litigation [Member]",
        "label": "Environmental Remediation Litigation [Member]",
        "terseLabel": "Environmental Remediation Litigation [Member]"
       }
      }
     },
     "localname": "EnvironmentalRemediationLitigationMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EpiPenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "EpiPen [Member]",
        "label": "Epi Pen [Member]",
        "terseLabel": "EpiPen [Member]"
       }
      }
     },
     "localname": "EpiPenMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EquityMethodInvestmentExcessBasisAmortization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Excess Basis Amortization",
        "label": "Equity Method Investment, Excess Basis Amortization",
        "terseLabel": "Excess basis amortization"
       }
      }
     },
     "localname": "EquityMethodInvestmentExcessBasisAmortization",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Excess Basis Amortization, Period",
        "label": "Equity Method Investment, Excess Basis Amortization, Period",
        "terseLabel": "Excess basis amortization period"
       }
      }
     },
     "localname": "EquityMethodInvestmentExcessBasisAmortizationPeriod",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Increase (Decrease), Foreign Currency Translation",
        "label": "Equity Method Investment, Increase (Decrease), Foreign Currency Translation",
        "negatedTerseLabel": "Decrease due to foreign currency translation"
       }
      }
     },
     "localname": "EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_EquitySecuritiesFVNINoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Noncurrent",
        "label": "Equity Securities, FV-NI, Noncurrent",
        "terseLabel": "Equity securities with readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesFVNINoncurrent",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_EquitySecuritiesFVNIRestrictedNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Restricted, Noncurrent",
        "label": "Equity Securities, FV-NI, Restricted, Noncurrent",
        "terseLabel": "Long-term equity securities held in trust"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIRestrictedNoncurrent",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value, Impairment Loss And Downward Price Adjustment, Cumulative Amount",
        "label": "Equity Securities Without Readily Determinable Fair Value, Impairment Loss And Downward Price Adjustment, Cumulative Amount",
        "terseLabel": "Cumulative impairment losses and downward price adjustments on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_FeasibilityStudyNumberOfLagoons": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Feasibility Study, Number Of Lagoons",
        "label": "Feasibility Study, Number Of Lagoons",
        "terseLabel": "Number of lagoons"
       }
      }
     },
     "localname": "FeasibilityStudyNumberOfLagoons",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_FinancialInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial Instruments [Abstract]",
        "label": "Financial Instruments [Abstract]"
       }
      }
     },
     "localname": "FinancialInstrumentsAbstract",
     "nsuri": "http://www.pfizer.com/20200628",
     "xbrltype": "stringItemType"
    },
    "pfe_FocusedCompanyPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Focused Company Plan [Member]",
        "label": "Focused Company Plan [Member]",
        "terseLabel": "Focused Company Plan [Member]"
       }
      }
     },
     "localname": "FocusedCompanyPlanMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Footnotes to selected financial assets and liabilities [Abstract]",
        "label": "Footnotes To Selected Financial Assets And Liabilities [Abstract]",
        "terseLabel": "Footnotes to selected financial assets and liabilities:"
       }
      }
     },
     "localname": "FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ForeignCurrencyLongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign currency long - term debt [Member]",
        "label": "Foreign Currency Long Term Debt [Member]",
        "terseLabel": "Foreign currency long-term debt [Member]"
       }
      }
     },
     "localname": "ForeignCurrencyLongTermDebtMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ForeignCurrencyShortTermBorrowingsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign currency short - term borrowings [Member]",
        "label": "Foreign Currency Short Term Borrowings [Member]",
        "terseLabel": "Foreign currency short-term borrowings [Member]"
       }
      }
     },
     "localname": "ForeignCurrencyShortTermBorrowingsMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_FragminMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fragmin [Member]",
        "label": "Fragmin [Member]",
        "terseLabel": "Fragmin [Member]"
       }
      }
     },
     "localname": "FragminMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_GSKConsumerHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "GSK Consumer Healthcare [Member]",
        "label": "GSK Consumer Healthcare [Member]",
        "terseLabel": "GSK Consumer Healthcare [Member]"
       }
      }
     },
     "localname": "GSKConsumerHealthcareMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail",
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_GSKMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "GSK [Member]",
        "label": "GSK [Member]",
        "terseLabel": "GSK [Member]"
       }
      }
     },
     "localname": "GSKMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_GainContingencyNumberofDefendants": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain Contingency, Number of Defendants",
        "label": "Gain Contingency, Number of Defendants",
        "terseLabel": "Number of defendants"
       }
      }
     },
     "localname": "GainContingencyNumberofDefendants",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019",
        "label": "Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019",
        "terseLabel": "Number of patents allegedly infringed upon due to expire December 2019"
       }
      }
     },
     "localname": "GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_GainContingencyPatentsWithoutCourtProceedingsNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain Contingency, Patents Without Court Proceedings, Number",
        "label": "Gain Contingency, Patents Without Court Proceedings, Number",
        "terseLabel": "Number of patents which the Patent Trial and Appeal Board refused to initiate proceedings"
       }
      }
     },
     "localname": "GainContingencyPatentsWithoutCourtProceedingsNumber",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_GeneTherapiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gene Therapies [Member]",
        "label": "Gene Therapies [Member]",
        "terseLabel": "Gene Therapies [Member]"
       }
      }
     },
     "localname": "GeneTherapiesMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_GenotropinMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Genotropin [Member]",
        "label": "Genotropin [Member]",
        "terseLabel": "Genotropin [Member]"
       }
      }
     },
     "localname": "GenotropinMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_HedgedItemAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hedged Item [Axis]",
        "label": "Hedged Item [Axis]",
        "terseLabel": "Hedged Item [Axis]"
       }
      }
     },
     "localname": "HedgedItemAxis",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_HedgedItemDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Hedged Item [Axis]",
        "label": "Hedged Item [Domain]",
        "terseLabel": "Hedged Item [Domain]"
       }
      }
     },
     "localname": "HedgedItemDomain",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_HeldToMaturityCashEquivalents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Held-To-Maturity Cash Equivalents",
        "label": "Held-To-Maturity Cash Equivalents",
        "terseLabel": "Held-to-maturity cash equivalents"
       }
      }
     },
     "localname": "HeldToMaturityCashEquivalents",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value",
        "label": "Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value",
        "terseLabel": "Held-to-maturity securities, debt maturities, over 5 years, fair value"
       }
      }
     },
     "localname": "HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_HormoneTherapyProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hormone Therapy Products [Member]",
        "label": "Hormone Therapy Products [Member]",
        "terseLabel": "Hormone Therapy Products [Member]"
       }
      }
     },
     "localname": "HormoneTherapyProductsMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_HospiraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hospira [Member]",
        "label": "Hospira [Member]",
        "terseLabel": "Hospira [Member]"
       }
      }
     },
     "localname": "HospiraMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_HospitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hospital [Member]",
        "label": "Hospital [Member]",
        "terseLabel": "Hospital [Member]"
       }
      }
     },
     "localname": "HospitalMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_IbranceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ibrance [Member]",
        "label": "Ibrance [Member]",
        "terseLabel": "Ibrance [Member]"
       }
      }
     },
     "localname": "IbranceMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Table Text Block] for Identifiable intangible assets as a percentage of total identifiable intangible assets less accumulated amortization, by segment [Table]",
        "label": "Identifiable intangible assets as a percentage of total identifiable intangible assets less accumulated amortization, by segment [Table Text Block]",
        "terseLabel": "Identifiable Intangible Assets as a Percentage of Total Identifiable Intangible Assets Less Accumulated Amortization, By Segment"
       }
      }
     },
     "localname": "IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_ImplementationCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Implementation Cost [Abstract]",
        "label": "Implementation Cost [Abstract]",
        "terseLabel": "Implementation costs recorded in our condensed consolidated statements of income as follows:"
       }
      }
     },
     "localname": "ImplementationCostAbstract",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ImplementationCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail": {
       "order": 4.0,
       "parentTag": "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Implementation costs represent external, incremental costs directly related to Implementing cost-reduction initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services.",
        "label": "Implementation Costs",
        "terseLabel": "Implementation costs"
       }
      }
     },
     "localname": "ImplementationCosts",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights",
        "label": "Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights",
        "negatedTerseLabel": "Income from collaborations, out-licensing arrangements and sales of compound/product rights"
       }
      }
     },
     "localname": "IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.",
        "label": "Income Loss From Continuing Operations Available To Common Stockholders Basic",
        "totalLabel": "Income from continuing operations attributable to Pfizer Inc. common shareholders"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.",
        "label": "Income Loss From Continuing Operations Available To Common Stockholders diluted",
        "terseLabel": "Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail": {
       "order": 11.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income (Loss) From Equity Method Investments, Net Excess Basis Amortization",
        "label": "Income (Loss) From Equity Method Investments, Net Excess Basis Amortization",
        "negatedTerseLabel": "GSK Consumer Healthcare JV equity method (income)/loss"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Line Items] for Income Taxes [Table]",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_IncomeTaxesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income Taxes Payable [Member]",
        "label": "Income Taxes Payable [Member]",
        "terseLabel": "Income Taxes Payable [Member]"
       }
      }
     },
     "localname": "IncomeTaxesPayableMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_InflammationandImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inflammation and Immunology [Member]",
        "label": "Inflammation and Immunology [Member]",
        "terseLabel": "Inflammation and Immunology (I&amp;I) [Member]"
       }
      }
     },
     "localname": "InflammationandImmunologyMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_InflectraRemsimaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inflectra/Remsima [Member]",
        "label": "Inflectra/Remsima [Member]",
        "terseLabel": "Inflectra/Remsima [Member]"
       }
      }
     },
     "localname": "InflectraRemsimaMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_InlytaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inlyta [Member]",
        "label": "Inlyta [Member]",
        "terseLabel": "Inlyta [Member]"
       }
      }
     },
     "localname": "InlytaMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intangible Assets, Net, Percentage of Intangible Assets, Net",
        "label": "Intangible Assets, Net, Percentage of Intangible Assets, Net",
        "terseLabel": "Percentage of total identifiable intangible assets, less accumulated amortization"
       }
      }
     },
     "localname": "IntangibleAssetsNetPercentageofIntangibleAssetsNet",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_InterestReceivedInterestRateHedges": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest Received, Interest Rate Hedges",
        "label": "Interest Received, Interest Rate Hedges",
        "terseLabel": "Interest rate hedges"
       }
      }
     },
     "localname": "InterestReceivedInterestRateHedges",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_InternalMedicineMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Internal Medicine [Member]",
        "label": "Internal Medicine [Member]",
        "terseLabel": "Internal Medicine [Member]"
       }
      }
     },
     "localname": "InternalMedicineMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_KingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "King [Member]",
        "label": "King [Member]",
        "terseLabel": "King [Member]"
       }
      }
     },
     "localname": "KingMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LicensingAgreementsAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Licensing Agreements And Other [Member]",
        "label": "Licensing Agreements And Other [Member]",
        "terseLabel": "License Agreements and Other [Member]",
        "verboseLabel": "Licensing Agreements And Other [Member]"
       }
      }
     },
     "localname": "LicensingAgreementsAndOtherMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LicensingArrangementValueOfSharesPurchased": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Licensing Arrangement, Value Of Shares Purchased",
        "label": "Licensing Arrangement, Value Of Shares Purchased",
        "terseLabel": "Value of shares purchased"
       }
      }
     },
     "localname": "LicensingArrangementValueOfSharesPurchased",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_LipitorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lipitor [Member]",
        "label": "Lipitor [Member]",
        "terseLabel": "Lipitor [Member]"
       }
      }
     },
     "localname": "LipitorMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LongTermDebtIssuedFirstQuarter2020Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long Term Debt Issued First Quarter 2020 [Member]",
        "label": "Long Term Debt Issued First Quarter 2020 [Member]",
        "terseLabel": "Long Term Debt Issued First Quarter 2020 [Member]"
       }
      }
     },
     "localname": "LongTermDebtIssuedFirstQuarter2020Member",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails": {
       "order": 2.0,
       "parentTag": "pfe_ShorttermDebtGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting",
        "label": "Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting",
        "terseLabel": "Current portion of long-term debt, principal amount"
       }
      }
     },
     "localname": "LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments",
        "label": "Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments",
        "totalLabel": "Total long-term investments"
       }
      }
     },
     "localname": "LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_LongtermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-term Investments [Member]",
        "label": "Long-term Investments [Member]",
        "terseLabel": "Long-term Investments [Member]",
        "verboseLabel": "Long-term investments [Member]"
       }
      }
     },
     "localname": "LongtermInvestmentsMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LossContingencyClassActionsFiledNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loss Contingency, Class Actions Filed, Number",
        "label": "Loss Contingency, Class Actions Filed, Number",
        "terseLabel": "Number of class actions filed"
       }
      }
     },
     "localname": "LossContingencyClassActionsFiledNumber",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loss Contingency, Number Of Defendants Other Than Main Defendant",
        "label": "Loss Contingency, Number Of Defendants Other Than Main Defendant",
        "terseLabel": "Number of defendants other than main defendant"
       }
      }
     },
     "localname": "LossContingencyNumberOfDefendantsOtherThanMainDefendant",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_LossContingencyNumberOfLawsuits": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loss Contingency, Number Of Lawsuits",
        "label": "Loss Contingency, Number Of Lawsuits",
        "terseLabel": "Number of lawsuits"
       }
      }
     },
     "localname": "LossContingencyNumberOfLawsuits",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_LyricaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lyrica [Member]",
        "label": "Lyrica [Member]",
        "terseLabel": "Lyrica [Member]"
       }
      }
     },
     "localname": "LyricaMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ManufacturingCostReductionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Manufacturing Cost Reduction [Member]",
        "label": "Manufacturing Cost Reduction [Member]",
        "terseLabel": "Manufacturing Cost Reduction [Member]"
       }
      }
     },
     "localname": "ManufacturingCostReductionMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_MedrolMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medrol [Member]",
        "label": "Medrol [Member]",
        "terseLabel": "Medrol [Member]"
       }
      }
     },
     "localname": "MedrolMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_MektoviMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mektovi [Member]",
        "label": "Mektovi [Member]",
        "terseLabel": "Mektovi [Member]"
       }
      }
     },
     "localname": "MektoviMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_MylanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mylan [Member]",
        "label": "Mylan [Member]",
        "terseLabel": "Mylan [Member]"
       }
      }
     },
     "localname": "MylanMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NHSScotlandvs.DrReddysMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "NHS Scotland vs. Dr Reddy's [Member]",
        "label": "NHS Scotland vs. Dr Reddy's [Member]",
        "terseLabel": "NHS Scotland vs. Dr Reddy's [Member]"
       }
      }
     },
     "localname": "NHSScotlandvs.DrReddysMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NimenrixMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nimenrix [Member]",
        "label": "Nimenrix [Member]",
        "terseLabel": "Nimenrix [Member]"
       }
      }
     },
     "localname": "NimenrixMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NorvascMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Norvasc [Member]",
        "label": "Norvasc [Member]",
        "terseLabel": "Norvasc [Member]"
       }
      }
     },
     "localname": "NorvascMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NotesDue20220.250Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Notes Due 2022, 0.250% [Member]",
        "label": "Notes Due 2022, 0.250% [Member]",
        "terseLabel": "0.250% Notes due 2022 [Member]"
       }
      }
     },
     "localname": "NotesDue20220.250Member",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NotesDue20271.000Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Notes Due 2027, 1.000% [Member]",
        "label": "Notes Due 2027, 1.000% [Member]",
        "terseLabel": "1.000% Notes due 2027 [Member]"
       }
      }
     },
     "localname": "NotesDue20271.000Member",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NumberOfAccountingStandardsAdopted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Accounting Standards Adopted",
        "label": "Number Of Accounting Standards Adopted",
        "terseLabel": "Number of accounting standards adopted"
       }
      }
     },
     "localname": "NumberOfAccountingStandardsAdopted",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_OncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Oncology [Member]",
        "label": "Oncology [Member]",
        "terseLabel": "Oncology [Member]"
       }
      }
     },
     "localname": "OncologyMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherAccruals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Accruals",
        "label": "Other Accruals",
        "terseLabel": "Other accruals"
       }
      }
     },
     "localname": "OtherAccruals",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherAntiinfectivesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Anti-infectives [Member]",
        "label": "Other Anti-infectives [Member]",
        "terseLabel": "All other Anti-infectives [Member]"
       }
      }
     },
     "localname": "OtherAntiinfectivesMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax",
        "terseLabel": "Amount of Gains/(Losses) Reclassified from OCI into OID and COS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax",
        "terseLabel": "Amount of Gains/(Losses) Reclassified from OCI into OID and COS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Before Reclassification and Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), Reclassification, Before Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), Reclassification, Before Tax",
        "terseLabel": "Amount of Gains/(Losses) Reclassified from OCI into OID and COS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), before Reclassification and Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "All other, net - Amount of Gains/(Losses) Recognized in OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, Tax",
        "label": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, Tax",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans prior service (costs)/credits.",
        "label": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, before Tax",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 4.0,
       "parentTag": "pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Other Net Unamortized Gain (Loss) Arising During Period, Tax",
        "label": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Other Net Unamortized Gain (Loss) Arising During Period, Tax",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans actuarial gains /losses.",
        "label": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Other Net Unamortized Gain (Loss) Arising During Period, before Tax",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans.",
        "label": "Other Comprehensive Income (Loss), Settlement Adjustment From AOCI, Pension And Other Postretirement Benefit Plans, for Net Gain (Loss), Before Tax",
        "negatedTerseLabel": "Reclassification adjustments related to settlements, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 3.0,
       "parentTag": "pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Settlement Adjustment From AOCI, Pension And Other Postretirement Benefit Plans, for Net Gain (Loss), Tax",
        "label": "Other Comprehensive Income (Loss), Settlement Adjustment From AOCI, Pension And Other Postretirement Benefit Plans, for Net Gain (Loss), Tax",
        "negatedTerseLabel": "Reclassification adjustments related to settlements, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherHospitalProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Hospital Products [Member]",
        "label": "Other Hospital Products [Member]",
        "terseLabel": "All other Hospital [Member]"
       }
      }
     },
     "localname": "OtherHospitalProductsMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherIncomeDeductionsAndCostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other (Income) Deductions And Cost Of Sales [Member]",
        "label": "Other (Income) Deductions And Cost Of Sales [Member]",
        "terseLabel": "Other (Income) Deductions And Cost Of Sales [Member]"
       }
      }
     },
     "localname": "OtherIncomeDeductionsAndCostOfSalesMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherNonoperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail": {
       "order": 12.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Nonoperating Income (Expense), Net",
        "label": "Other Nonoperating Income (Expense), Net",
        "negatedTerseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseNet",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherOncologyProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Oncology Products [Member]",
        "label": "Other Oncology Products [Member]",
        "terseLabel": "All other Oncology [Member]"
       }
      }
     },
     "localname": "OtherOncologyProductsMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherSegmentReconcilingItemsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Segment Reconciling Items [Axis]",
        "label": "Other Segment Reconciling Items [Axis]",
        "terseLabel": "Other Segment Reconciling Items [Axis]"
       }
      }
     },
     "localname": "OtherSegmentReconcilingItemsAxis",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_OtherSegmentReconcilingItemsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Other Segment Reconciling Items [Axis]",
        "label": "Other Segment Reconciling Items [Domain]",
        "terseLabel": "Other Segment Reconciling Items [Domain]"
       }
      }
     },
     "localname": "OtherSegmentReconcilingItemsDomain",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherTaxAssetsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Tax Assets, Current",
        "label": "Other Tax Assets, Current",
        "terseLabel": "Current tax assets"
       }
      }
     },
     "localname": "OtherTaxAssetsCurrent",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherVaccinesProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Vaccines Products [Member]",
        "label": "Other Vaccines Products [Member]",
        "terseLabel": "All other Vaccines [Member]"
       }
      }
     },
     "localname": "OtherVaccinesProductsMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PanzygaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Panzyga [Member]",
        "label": "Panzyga [Member]",
        "terseLabel": "Panzyga [Member]"
       }
      }
     },
     "localname": "PanzygaMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PatentInfringementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Patent Infringement [Member]",
        "label": "Patent Infringement [Member]",
        "terseLabel": "Patent Infringement [Member]"
       }
      }
     },
     "localname": "PatentInfringementMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PaymentForLicensingArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment For Licensing Arrangement",
        "label": "Payment For Licensing Arrangement",
        "terseLabel": "Upfront payment for licensing arrangement"
       }
      }
     },
     "localname": "PaymentForLicensingArrangement",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails",
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PaymentForRepatriationTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment For Repatriation Tax",
        "label": "Payment For Repatriation Tax",
        "terseLabel": "Installment payments for repatriation tax"
       }
      }
     },
     "localname": "PaymentForRepatriationTax",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments For (Proceeds From) Short Term Investments With Original Maturities Of Three Months Or Less",
        "label": "Payments For (Proceeds From) Short Term Investments With Original Maturities Of Three Months Or Less",
        "negatedLabel": "Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less"
       }
      }
     },
     "localname": "PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment",
        "label": "Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment",
        "negatedTerseLabel": "Utilization and other"
       }
      }
     },
     "localname": "PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans less the amount of pension and other postretirement benefit costs/income recognized during the period for defined benefit plans (periodic benefit costs/income include the following components: service cost, interest cost, expected return on plan assets, gain or loss on assets, prior service cost or credit, transition asset or obligation, and gain or loss due to settlements or curtailments).",
        "label": "Pension And Other Postretirement Benefit Contributions, Net Of Pension And Other Postretirement Benefit (Expense)",
        "negatedTerseLabel": "Benefit plan contributions in excess of expense/income"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PercentageChangeInRevenue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage change in revenue.",
        "label": "Percentage Change In Revenue",
        "terseLabel": "Percentage Change In Revenue"
       }
      }
     },
     "localname": "PercentageChangeInRevenue",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]",
        "label": "Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]",
        "terseLabel": "Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]"
       }
      }
     },
     "localname": "PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerCentreOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer CentreOne [Member]",
        "label": "Pfizer CentreOne [Member]",
        "terseLabel": "Pfizer CentreOne [Member]"
       }
      }
     },
     "localname": "PfizerCentreOneMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerVersusGenericCompaniesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer Versus Generic Companies [Member]",
        "label": "Pfizer Versus Generic Companies [Member]",
        "terseLabel": "Pfizer Versus Generic Companies [Member]"
       }
      }
     },
     "localname": "PfizerVersusGenericCompaniesMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer Versus Viwit Pharmaceutical Co. Ltd. [Member]",
        "label": "Pfizer Versus Viwit Pharmaceutical Co. Ltd. [Member]",
        "terseLabel": "Pfizer Versus Viwit Pharmaceutical Co. Ltd. [Member]"
       }
      }
     },
     "localname": "PfizerVersusViwitPharmaceuticalCo.Ltd.Member",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerVersusZydusMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer Versus Zydus [Member]",
        "label": "Pfizer Versus Zydus [Member]",
        "terseLabel": "Pfizer Versus Zydus [Member]"
       }
      }
     },
     "localname": "PfizerVersusZydusMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerandBMSVersusSeveralGenericManufacturersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer and BMS Versus Several Generic Manufacturers [Member]",
        "label": "Pfizer and BMS Versus Several Generic Manufacturers [Member]",
        "terseLabel": "Pfizer and BMS Versus Several Generic Manufacturers [Member]"
       }
      }
     },
     "localname": "PfizerandBMSVersusSeveralGenericManufacturersMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer's Worldwide Research, Development And Medical [Member]",
        "label": "Pfizer's Worldwide Research, Development And Medical [Member]",
        "verboseLabel": "WRDM [Member]"
       }
      }
     },
     "localname": "PfizersWorldwideResearchDevelopmentAndMedicalMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PrecedexMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Precedex [Member]",
        "label": "Precedex [Member]",
        "terseLabel": "Precedex [Member]"
       }
      }
     },
     "localname": "PrecedexMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PremarinFamilyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Premarin family [Member]",
        "label": "Premarin Family [Member]",
        "terseLabel": "Premarin family [Member]"
       }
      }
     },
     "localname": "PremarinFamilyMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PrevnarPrevenarFamilyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prevnar/Prevenar Family 13 [Member]",
        "label": "Prevnar Prevenar Family [Member]",
        "terseLabel": "Prevnar 13/Prevenar 13 [Member]"
       }
      }
     },
     "localname": "PrevnarPrevenarFamilyMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PrivateEquityInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherLongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Private Equity Investments",
        "label": "Private Equity Investments",
        "terseLabel": "Private equity securities at cost"
       }
      }
     },
     "localname": "PrivateEquityInvestments",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PumaTechnologiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Puma Technologies [Member]",
        "label": "Puma Technologies [Member]",
        "terseLabel": "Puma Technologies [Member]"
       }
      }
     },
     "localname": "PumaTechnologiesMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PurchaseAccountingAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase Accounting Adjustments [Member]",
        "label": "Purchase Accounting Adjustments [Member]",
        "terseLabel": "Purchase Accounting Adjustments [Member]"
       }
      }
     },
     "localname": "PurchaseAccountingAdjustmentsMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_RareDiseaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rare Disease [Member]",
        "label": "Rare Disease [Member]",
        "terseLabel": "Rare Disease [Member]"
       }
      }
     },
     "localname": "RareDiseaseMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ReFactoAfXynthaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Re Facto AF Xyntha [Member]",
        "label": "Re Facto AF Xyntha [Member]",
        "terseLabel": "ReFacto AF/Xyntha [Member]"
       }
      }
     },
     "localname": "ReFactoAfXynthaMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_RebatesAndDiscountsAccrual": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts",
        "label": "Rebates And Discounts Accrual",
        "terseLabel": "Accrued rebates and other accruals"
       }
      }
     },
     "localname": "RebatesAndDiscountsAccrual",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Collaborator's Development Cost Ownership Percentage",
        "label": "Research And Development Arrangement, Collaborator's Development Cost Ownership Percentage",
        "terseLabel": "Valneva's development cost ownership percentage"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Commercialization Milestones, Maximum Exposure",
        "label": "Research And Development Arrangement, Commercialization Milestones, Maximum Exposure",
        "terseLabel": "Potential early commercialization milestones"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contingent Payments, Maximum Exposure1",
        "label": "Research And Development Arrangement, Contingent Payments, Maximum Exposure1",
        "terseLabel": "Maximum potential cash payments"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails",
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Development Milestone, Maximum Exposure",
        "label": "Research And Development Arrangement, Development Milestone, Maximum Exposure",
        "terseLabel": "Potential development milestones"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Future Milestone Payments, Maximum Exposure",
        "label": "Research And Development Arrangement, Future Milestone Payments, Maximum Exposure",
        "terseLabel": "Potential future milestone payments"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and Development Arrangement, Percentage of Costs to be Reimbursed",
        "label": "Research and Development Arrangement, Percentage of Costs to be Reimbursed",
        "terseLabel": "Research and development arrangement, percentage of costs to be reimbursed"
       }
      }
     },
     "localname": "ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_RestructuringAssetImpairmentCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restructuring, Asset Impairment Charges",
        "label": "Restructuring, Asset Impairment Charges",
        "netLabel": "Asset impairments"
       }
      }
     },
     "localname": "RestructuringAssetImpairmentCharges",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restructuring Charges, Acquisition Related Costs and Implementation Costs",
        "label": "Restructuring Charges, Acquisition Related Costs and Implementation Costs",
        "totalLabel": "Total costs associated with acquisitions and cost-reduction/productivity initiatives"
       }
      }
     },
     "localname": "RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_RestructuringChargesAndAcquisitionRelatedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail": {
       "order": 1.0,
       "parentTag": "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities.",
        "label": "Restructuring Charges And Acquisition Related Costs",
        "terseLabel": "Restructuring charges and certain acquisition-related costs",
        "totalLabel": "Restructuring charges and certain acquisition-related costs"
       }
      }
     },
     "localname": "RestructuringChargesAndAcquisitionRelatedCosts",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_RestructuringandRelatedCostNoncashChargesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restructuring and Related Cost, Noncash Charges, Percentage",
        "label": "Restructuring and Related Cost, Noncash Charges, Percentage",
        "terseLabel": "Percentage of expected costs to be non-cash"
       }
      }
     },
     "localname": "RestructuringandRelatedCostNoncashChargesPercentage",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_RetacritMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Retacrit [Member]",
        "label": "Retacrit [Member]",
        "terseLabel": "Retacrit [Member]"
       }
      }
     },
     "localname": "RetacritMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ScheduleOfAccruedLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Line Items] for Schedule Of Accrued Liabilities [Table]",
        "label": "Schedule Of Accrued Liabilities [Line Items]",
        "terseLabel": "Schedule Of Accrued Liabilities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesLineItems",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ScheduleOfAccruedLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule Of Accrued Liabilities [Table]",
        "label": "Schedule Of Accrued Liabilities [Table]",
        "terseLabel": "Schedule Of Accrued Liabilities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTable",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Available for sale Securities and Held to maturity Securities [Line Items]",
        "label": "Schedule Of Available For Sale Securities And Held To Maturity Securities [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities And Held To Maturity Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Available for sale Securities and Held to maturity Securities [Table]",
        "label": "Schedule Of Available For Sale Securities And Held To Maturity Securities [Table]",
        "terseLabel": "Schedule Of Available For Sale Securities And Held To Maturity Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule Of Medicare Rebates, Medicaid And Related State Program Rebates, Performance-Based Contract Rebates, Chargebacks, Sales Allowances And Sales Returns And Cash Discounts [Table Text Block]",
        "label": "Schedule Of Medicare Rebates, Medicaid And Related State Program Rebates, Performance-Based Contract Rebates, Chargebacks, Sales Allowances And Sales Returns And Cash Discounts [Table Text Block]",
        "terseLabel": "Schedule of Balance Sheet Classification of Accruals"
       }
      }
     },
     "localname": "ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Employer Contributions to Pension and Postretirement Plans [Table Text Block]",
        "label": "Schedule of Employer Contributions to Pension and Postretirement Plans [Table Text Block]",
        "terseLabel": "Schedule of Employer Contributions to Pension and Postretirement Plans"
       }
      }
     },
     "localname": "ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]",
        "label": "Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)"
       }
      }
     },
     "localname": "ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_SeniorNotesDue2047Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes Due 2047 [Member]",
        "label": "Senior Notes Due 2047 [Member]",
        "terseLabel": "Senior Notes Due 2047 [Member]"
       }
      }
     },
     "localname": "SeniorNotesDue2047Member",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, Four Point Zero Zero Zero Percent, Due 2050 [Member]",
        "label": "Senior Unsecured Debt, Four Point Zero Zero Zero Percent, Due 2050 [Member]",
        "terseLabel": "4.000% notes [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Member",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, One Point Nine Zero Eight Percent, Due 2032 [Member]",
        "label": "Senior Unsecured Debt, One Point Nine Zero Eight Percent, Due 2032 [Member]",
        "terseLabel": "1.908% notes [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Member",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, One Point One Two Five Percent, Due 2022 [Member]",
        "label": "Senior Unsecured Debt, One Point One Two Five Percent, Due 2022 [Member]",
        "terseLabel": "1.125% notes [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Member",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, One Point Seven Zero Zero Percent, Due 2030 [Member]",
        "label": "Senior Unsecured Debt, One Point Seven Zero Zero Percent, Due 2030 [Member]",
        "terseLabel": "1.700% notes [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, One Point Six Five Zero Percent, Due 2025 [Member]",
        "label": "Senior Unsecured Debt, One Point Six Five Zero Percent, Due 2025 [Member]",
        "terseLabel": "1.650% notes [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Member",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, One Point Three Six Two Percent, Due 2027 [Member]",
        "label": "Senior Unsecured Debt, One Point Three Six Two Percent, Due 2027 [Member]",
        "terseLabel": "1.362% notes [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Member",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, One Point Zero Two Three Percent, Due 2024 [Member]",
        "label": "Senior Unsecured Debt, One Point Zero Two Three Percent, Due 2024 [Member]",
        "terseLabel": "1.023% notes [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Member",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, Three Point Eight Five Zero Percent, Due 2040 [Member]",
        "label": "Senior Unsecured Debt, Three Point Eight Five Zero Percent, Due 2040 [Member]",
        "terseLabel": "3.850% notes [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, Two Point Five Five Zero Percent, Due 2040 [Member]",
        "label": "Senior Unsecured Debt, Two Point Five Five Zero Percent, Due 2040 [Member]",
        "terseLabel": "2.550% notes [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Member",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, Two Point Seven Zero Zero Percent, Due 2030 [Member]",
        "label": "Senior Unsecured Debt, Two Point Seven Zero Zero Percent, Due 2030 [Member]",
        "terseLabel": "2.700% notes [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Member",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, Two Point Seven Zero Zero Percent, Due 2050 [Member]",
        "label": "Senior Unsecured Debt, Two Point Seven Zero Zero Percent, Due 2050 [Member]",
        "terseLabel": "2.700% notes [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, Two Point Six Two Five Percent, Due 2030 [Member]",
        "label": "Senior Unsecured Debt, Two Point Six Two Five Percent, Due 2030 [Member]",
        "terseLabel": "2.625% notes [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, Two Point Three Zero Zero Percent, Due 2027 [Member]",
        "label": "Senior Unsecured Debt, Two Point Three Zero Zero Percent, Due 2027 [Member]",
        "terseLabel": "2.300% notes [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Member",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, Zero Point Eight One Six Percent, Due 2022 [Member]",
        "label": "Senior Unsecured Debt, Zero Point Eight One Six Percent, Due 2022 [Member]",
        "terseLabel": "0.816% notes [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, Zero Point Eight Zero Zero Percent, Due 2025 [Member]",
        "label": "Senior Unsecured Debt, Zero Point Eight Zero Zero Percent, Due 2025 [Member]",
        "terseLabel": "0.800% notes [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Member",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ShorttermDebtGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short-term Debt, Gross",
        "label": "Short-term Debt, Gross",
        "totalLabel": "Total short-term borrowings, principal amount"
       }
      }
     },
     "localname": "ShorttermDebtGross",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short-term Investments Excluding Held-To-Maturity Securities",
        "label": "Short-term Investments Excluding Held-To-Maturity Securities",
        "totalLabel": "Total short-term investments"
       }
      }
     },
     "localname": "ShorttermInvestmentsExcludingHeldToMaturitySecurities",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_SomavertMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Somavert [Member]",
        "label": "Somavert [Member]",
        "terseLabel": "Somavert [Member]"
       }
      }
     },
     "localname": "SomavertMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued And Redeemed During Period, Shares, Conversion And Redemption of Stock",
        "label": "Stock Issued And Redeemed During Period, Shares, Conversion And Redemption of Stock",
        "negatedTerseLabel": "Preferred stock conversions and redemptions (in shares)"
       }
      }
     },
     "localname": "StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued And Redeemed During Period, Value, Conversion And Redemption of Stock",
        "label": "Stock Issued And Redeemed During Period, Value, Conversion And Redemption of Stock",
        "negatedTerseLabel": "Preferred stock conversions and redemptions"
       }
      }
     },
     "localname": "StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_SulperazonMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sulperazon [Member]",
        "label": "Sulperazon [Member]",
        "terseLabel": "Sulperazon [Member]"
       }
      }
     },
     "localname": "SulperazonMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SutentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sutent [Member]",
        "label": "Sutent [Member]",
        "terseLabel": "Sutent [Member]"
       }
      }
     },
     "localname": "SutentMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TotalAllianceBiopharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total Alliance Biopharmaceuticals [Member]",
        "label": "Total Alliance Biopharmaceuticals [Member]",
        "terseLabel": "Total Alliance revenues [Member]"
       }
      }
     },
     "localname": "TotalAllianceBiopharmaceuticalsMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TotalBiosimilarsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total Biosimilars [Member]",
        "label": "Total Biosimilars [Member]",
        "terseLabel": "Total Biosimilars [Member]"
       }
      }
     },
     "localname": "TotalBiosimilarsMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TotalSterileInjectablePharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total Sterile Injectable Pharmaceuticals [Member]",
        "label": "Total Sterile Injectable Pharmaceuticals [Member]",
        "terseLabel": "Total Sterile Injectable Pharmaceuticals [Member]"
       }
      }
     },
     "localname": "TotalSterileInjectablePharmaceuticalsMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ToviazMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Toviaz [Member]",
        "label": "Toviaz [Member]",
        "terseLabel": "Toviaz [Member]"
       }
      }
     },
     "localname": "ToviazMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Twenty-Seventeen Through Twenty-Nineteen Initiatives And Organizing For Growth [Member]",
        "label": "Twenty-Seventeen Through Twenty-Nineteen Initiatives And Organizing For Growth [Member]",
        "terseLabel": "2017-2019 Initiatives and Organizing for Growth [Member]"
       }
      }
     },
     "localname": "TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_UpjohnFinanceB.V.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upjohn Finance B.V. [Member]",
        "label": "Upjohn Finance B.V. [Member]",
        "terseLabel": "Upjohn Finance B.V. [Member]"
       }
      }
     },
     "localname": "UpjohnFinanceB.V.Member",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_UpjohnIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upjohn Inc [Member]",
        "label": "Upjohn Inc [Member]",
        "terseLabel": "Upjohn Inc [Member]"
       }
      }
     },
     "localname": "UpjohnIncMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_UpjohnReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upjohn Reporting Unit [Member]",
        "label": "Upjohn Reporting Unit [Member]",
        "terseLabel": "Upjohn [Member]"
       }
      }
     },
     "localname": "UpjohnReportingUnitMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_UpjohnSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upjohn Segment [Member]",
        "label": "Upjohn Segment [Member]",
        "terseLabel": "Upjohn [Member]"
       }
      }
     },
     "localname": "UpjohnSegmentMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_VaccinesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vaccines [Member]",
        "label": "Vaccines [Member]",
        "terseLabel": "Vaccines [Member]"
       }
      }
     },
     "localname": "VaccinesMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ValnevaSEMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valneva SE [Member]",
        "label": "Valneva SE [Member]",
        "terseLabel": "Valneva SE [Member]"
       }
      }
     },
     "localname": "ValnevaSEMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_VfendMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vfend [Member]",
        "label": "Vfend [Member]",
        "terseLabel": "Vfend [Member]"
       }
      }
     },
     "localname": "VfendMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ViagraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Viagra [Member]",
        "label": "Viagra [Member]",
        "terseLabel": "Viagra [Member]"
       }
      }
     },
     "localname": "ViagraMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ViiVMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ViiV [Member]",
        "label": "ViiV [Member]",
        "terseLabel": "ViiV [Member]"
       }
      }
     },
     "localname": "ViiVMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_VyndaqelMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vyndaqel [Member]",
        "label": "Vyndaqel [Member]",
        "terseLabel": "Vyndaqel/Vyndamax [Member]"
       }
      }
     },
     "localname": "VyndaqelMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_XalatanXalacomMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Xalatan / Xalacom [Member]",
        "label": "Xalatan Xalacom [Member]",
        "terseLabel": "Xalatan/Xalacom [Member]"
       }
      }
     },
     "localname": "XalatanXalacomMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_XalkoriMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Xalkori [Member]",
        "label": "Xalkori [Member]",
        "terseLabel": "Xalkori [Member]"
       }
      }
     },
     "localname": "XalkoriMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_XeljanzMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Xeljanz [Member]",
        "label": "Xeljanz [Member]",
        "terseLabel": "Xeljanz [Member]"
       }
      }
     },
     "localname": "XeljanzMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_XtandiAllianceRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Xtandi Alliance Revenues [Member]",
        "label": "Xtandi Alliance Revenues [Member]",
        "terseLabel": "Xtandi alliance revenues [Member]"
       }
      }
     },
     "localname": "XtandiAllianceRevenuesMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ZithromaxZmaxMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Zithromax / Zmax [Member]",
        "label": "Zithromax Zmax [Member]",
        "terseLabel": "Zithromax [Member]"
       }
      }
     },
     "localname": "ZithromaxZmaxMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ZoloftMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Zoloft [Member]",
        "label": "Zoloft [Member]",
        "terseLabel": "Zoloft [Member]"
       }
      }
     },
     "localname": "ZoloftMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ZyvoxMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Zyvox [Member]",
        "label": "Zyvox [Member]",
        "terseLabel": "Zyvox [Member]"
       }
      }
     },
     "localname": "ZyvoxMember",
     "nsuri": "http://www.pfizer.com/20200628",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r527",
      "r528",
      "r535",
      "r536",
      "r746"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r527",
      "r528",
      "r535",
      "r536"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r208",
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r228",
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r208",
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r228",
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r82",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails",
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail",
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r468",
      "r474",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r658",
      "r721",
      "r724"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r468",
      "r474",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r658",
      "r721",
      "r724"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r235",
      "r378",
      "r379",
      "r659",
      "r720",
      "r722"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r235",
      "r378",
      "r379",
      "r659",
      "r720",
      "r722"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r409",
      "r468",
      "r474",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r658",
      "r721",
      "r724"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r409",
      "r468",
      "r474",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r658",
      "r721",
      "r724"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails",
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/TaxMattersNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/TaxMattersNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail",
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r236",
      "r237",
      "r378",
      "r380",
      "r723",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r236",
      "r237",
      "r378",
      "r380",
      "r723",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r346",
      "r469",
      "r626"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/TaxMattersNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SubsidiariesMember": {
     "auth_ref": [
      "r436",
      "r622",
      "r623",
      "r624"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsidiaries [Member]",
        "terseLabel": "Subsidiaries [Member]"
       }
      }
     },
     "localname": "SubsidiariesMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Trade accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Trade accounts receivable, less allowance for doubtful accounts [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r12",
      "r40",
      "r242",
      "r243"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Trade accounts receivable, less allowance for doubtful accounts: 2020\u2014$525; 2019\u2014$527"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember": {
     "auth_ref": [
      "r91",
      "r96",
      "r100",
      "r533"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to prior service cost (credit) component of defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member]",
        "terseLabel": "Prior Service (Costs)/Credits and Other [Member]"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember": {
     "auth_ref": [
      "r90",
      "r96",
      "r100",
      "r533"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) related to gain (loss) component of defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member]",
        "terseLabel": "Actuarial Gains/(Losses) [Member]"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r58",
      "r322"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Property, plant and equipment, accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r96",
      "r107",
      "r532"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Derivative Financial Instruments [Member]"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r96",
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Available-For-Sale Securities [Member]"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r43",
      "r93",
      "r95",
      "r96",
      "r700",
      "r729",
      "r730"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r615"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r92",
      "r96",
      "r100",
      "r165",
      "r166",
      "r167",
      "r533",
      "r725",
      "r726"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]",
        "verboseLabel": "Accum. Other Comp. Loss [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r84",
      "r96",
      "r100",
      "r533",
      "r609",
      "r610",
      "r611",
      "r612",
      "r615"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation Adjustment [Member]"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r41",
      "r482"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r479",
      "r480",
      "r481"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Add'l Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r47",
      "r244",
      "r284"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r151",
      "r306",
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization expense for finite-lived intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive common stock equivalents (shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r151",
      "r320"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Certain asset impairments"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r159",
      "r216",
      "r223",
      "r230",
      "r280",
      "r527",
      "r535",
      "r601",
      "r664",
      "r698"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r79",
      "r159",
      "r280",
      "r527",
      "r535",
      "r601"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "terseLabel": "Current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r27",
      "r28",
      "r29",
      "r159",
      "r280",
      "r527",
      "r535",
      "r601"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "terseLabel": "Noncurrent assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r251"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Available-for-sale debt securities, gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r252"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Available-for-sale debt securities, gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r249",
      "r291"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetailsCalc2": {
       "order": 1.0,
       "parentTag": "pfe_DebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Available-for-sale debt securities, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Available-for-sale Securities, Debt Maturities [Abstract]",
        "terseLabel": "Available-for-sale Securities, Debt Maturities [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r253",
      "r255",
      "r692"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Available-for-sale securities, debt maturities, over 1 to 5 years, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r253",
      "r254",
      "r691"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Available-for-sale securities, debt maturities, within 1 year, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r246",
      "r250",
      "r291",
      "r672"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail": {
       "order": 2.0,
       "parentTag": "pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Available-for-sale debt securities",
        "totalLabel": "Available-for-sale debt securities, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r248",
      "r291"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Available-for-sale debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r248",
      "r291"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Available-for-sale debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail",
      "http://www.pfizer.com/role/TaxMattersNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r549",
      "r554"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail",
      "http://www.pfizer.com/role/TaxMattersNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BankTimeDepositsMember": {
     "auth_ref": [
      "r686"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
        "label": "Bank Time Deposits [Member]",
        "terseLabel": "Time deposits and other [Member]"
       }
      }
     },
     "localname": "BankTimeDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r464",
      "r470"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsArrayBiopharmaDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r464",
      "r470",
      "r509",
      "r510"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsArrayBiopharmaDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsArrayBiopharmaDetails",
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails",
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Business acquisition, per share in cash (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsArrayBiopharmaDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r150",
      "r519"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r514",
      "r515",
      "r518"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "netLabel": "Fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r514",
      "r516"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Contingent consideration liability current"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r514",
      "r516"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration liability noncurrent"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationIntegrationRelatedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail": {
       "order": 3.0,
       "parentTag": "pfe_RestructuringChargesAndAcquisitionRelatedCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.",
        "label": "Business Combination, Integration Related Costs",
        "verboseLabel": "Integration costs and other"
       }
      }
     },
     "localname": "BusinessCombinationIntegrationRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessExitCosts1": {
     "auth_ref": [
      "r151",
      "r328",
      "r334",
      "r339"
     ],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Business Exit Costs",
        "terseLabel": "Exit costs"
       }
      }
     },
     "localname": "BusinessExitCosts1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r596",
      "r597"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Value [Member]"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r10",
      "r56",
      "r153"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r144",
      "r153",
      "r156"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents and restricted cash and cash equivalents, end",
        "periodStartLabel": "Cash and cash equivalents and restricted cash and cash equivalents, beginning"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r144",
      "r605"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents and restricted cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r581"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OID"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": {
     "auth_ref": [
      "r581"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge",
        "terseLabel": "Hedged item"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r157",
      "r159",
      "r181",
      "r182",
      "r183",
      "r186",
      "r188",
      "r196",
      "r197",
      "r198",
      "r280",
      "r601"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollateralAlreadyPostedAggregateFairValue": {
     "auth_ref": [
      "r576"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.",
        "label": "Collateral Already Posted, Aggregate Fair Value",
        "terseLabel": "Collateral posted"
       }
      }
     },
     "localname": "CollateralAlreadyPostedAggregateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaper": {
     "auth_ref": [
      "r30",
      "r665",
      "r699"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails": {
       "order": 1.0,
       "parentTag": "pfe_ShorttermDebtGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.",
        "label": "Commercial Paper",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaper",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r70",
      "r345",
      "r673",
      "r705"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r353"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies and Certain Commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Cash dividends declared per share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityDividendsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r165",
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "verboseLabel": "Common Stock, $.05 par value [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited",
      "http://www.pfizer.com/role/CoverPage",
      "http://www.pfizer.com/role/EquityPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r103",
      "r105",
      "r106",
      "r118",
      "r683",
      "r715"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income attributable to Pfizer Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r103",
      "r105",
      "r117",
      "r525",
      "r526",
      "r539",
      "r682",
      "r714"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Comprehensive income/(loss) attributable to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r103",
      "r105",
      "r116",
      "r524",
      "r539",
      "r681",
      "r713"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income before allocation to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r115",
      "r130",
      "r680",
      "r712"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure": {
     "auth_ref": [
      "r599"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity.",
        "label": "Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure",
        "terseLabel": "Maximum exposure, amount"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r202",
      "r598",
      "r600"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r410",
      "r458",
      "r731"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "verboseLabel": "Corporate and other [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r232",
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate and other unallocated [Member]"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r122",
      "r659"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r123",
      "r159",
      "r280",
      "r601"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "negatedLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of sales [Member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Debt, Current",
        "totalLabel": "Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted",
        "verboseLabel": "Short-term borrowings, including current portion of long-term debt: 2020\u2014$1,481; 2019\u2014$1,462"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r31",
      "r33",
      "r34",
      "r666",
      "r667",
      "r696"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r34",
      "r357",
      "r667",
      "r696"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Total long-term debt, principal amount"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r67",
      "r360",
      "r619"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRepurchaseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value amount of debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchase Amount",
        "terseLabel": "Repurchase amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r68",
      "r162",
      "r367",
      "r370",
      "r371",
      "r372",
      "r618",
      "r619",
      "r621",
      "r695"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r358",
      "r620"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtCurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Net unamortized discounts, premiums and debt issuance costs",
        "negatedTerseLabel": "Net unamortized discounts, premiums and debt issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity": {
     "auth_ref": [
      "r672"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "pfe_DebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale and Held-to-maturity",
        "totalLabel": "Available-for-sale securities and held-to-maturity securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAndHeldToMaturity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "auth_ref": [
      "r534"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.",
        "label": "Deconsolidation, Gain (Loss), Amount",
        "negatedTerseLabel": "(Gain) on completion of Consumer Healthcare JV transaction",
        "terseLabel": "Gain on completion of Consumer Healthcare JV transaction"
       }
      }
     },
     "localname": "DeconsolidationGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r151",
      "r160",
      "r492",
      "r498",
      "r499",
      "r500"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "verboseLabel": "Deferred taxes from continuing operations"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r485",
      "r486"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Noncurrent deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent": {
     "auth_ref": [
      "r36",
      "r384",
      "r385",
      "r408"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan.",
        "label": "Liability, Defined Benefit Pension Plan, Noncurrent",
        "terseLabel": "Pension benefit obligations, net"
       }
      }
     },
     "localname": "DefinedBenefitPensionPlanLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r386",
      "r425",
      "r452",
      "r458",
      "r459"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedTerseLabel": "Actuarial losses"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r386",
      "r426",
      "r453",
      "r458",
      "r459"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Prior service credits"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax": {
     "auth_ref": [
      "r90",
      "r93",
      "r429"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, after reclassification adjustment, of increase (decrease) in accumulated other comprehensive income from gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax",
        "totalLabel": "Defined benefit plan, amounts recognized in other comprehensive income (loss), net gain (loss), before tax, total"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r91",
      "r93",
      "r429"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income from prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax",
        "negatedTotalLabel": "Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service cost, before tax"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r402",
      "r410",
      "r412",
      "r456",
      "r458",
      "r459"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Contributions from our general assets for the six months ended June 28, 2020"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear": {
     "auth_ref": [
      "r456",
      "r459"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in remainder of current fiscal year. Excludes contribution previously paid by employer in current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year",
        "terseLabel": "Expected contributions from our general assets during 2020"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r386",
      "r424",
      "r451",
      "r458",
      "r459"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedTerseLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r386",
      "r391",
      "r423",
      "r450",
      "r458",
      "r459"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r421",
      "r448",
      "r458",
      "r459"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail": {
       "order": 2.0,
       "parentTag": "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "terseLabel": "Net periodic benefit costs recorded in Other (income)/deductions\u2013\u2013net",
        "totalLabel": "Defined benefit plan, net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]",
        "terseLabel": "Amortization of:"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": {
     "auth_ref": [
      "r387",
      "r428",
      "r455"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r389",
      "r422",
      "r449",
      "r458",
      "r459"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanSpecialTerminationBenefits": {
     "auth_ref": [
      "r390"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in benefit obligation for benefits provided to employees payable from defined benefit plan or payable upon retirement.",
        "label": "Defined Benefit Plan, Benefit Obligation, Special and Contractual Termination Benefits",
        "negatedLabel": "Special termination benefits"
       }
      }
     },
     "localname": "DefinedBenefitPlanSpecialTerminationBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r80",
      "r81",
      "r595"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Asset"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsCurrent": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail": {
       "order": 3.0,
       "parentTag": "pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Current",
        "terseLabel": "Current derivative assets"
       }
      }
     },
     "localname": "DerivativeAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsNoncurrent": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Noncurrent",
        "terseLabel": "Noncurrent derivative assets"
       }
      }
     },
     "localname": "DerivativeAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r551"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OID"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r550",
      "r553",
      "r562",
      "r570"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r547",
      "r550",
      "r562"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r561",
      "r563"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OID"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r80",
      "r81",
      "r595"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Liability",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Current",
        "terseLabel": "Current derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Noncurrent derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNetLiabilityPositionAggregateFairValue": {
     "auth_ref": [
      "r575"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate fair value amounts of derivative instruments that contain credit-risk-related contingent features that are in a net liability position at the end of the reporting period. For nonderivative instruments that are designated and qualify as hedging instruments, the fair value amounts are the carrying value of the nonderivative hedging instrument, including the adjustment for the foreign currency transaction gain (loss) on that instrument.",
        "label": "Derivative, Net Liability Position, Aggregate Fair Value",
        "terseLabel": "Derivatives in a net liability position"
       }
      }
     },
     "localname": "DerivativeNetLiabilityPositionAggregateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r542",
      "r544"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Notional"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r541",
      "r543",
      "r544",
      "r547",
      "r548",
      "r555",
      "r562",
      "r577",
      "r578",
      "r582"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Derivative term of contract"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument [Member]",
        "verboseLabel": "Derivatives designated as hedging instruments [Member]"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed Technology Rights [Member]"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "terseLabel": "EPS Numerator\u2013\u2013Diluted"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r321",
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposed of by Sale [Member]"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r7",
      "r319",
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Held-for-sale, Not Discontinued Operations [Member]",
        "terseLabel": "Held-for-sale [Member]"
       }
      }
     },
     "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "verboseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r464",
      "r470"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Dividends, Cash [Abstract]",
        "terseLabel": "Cash dividends declared:"
       }
      }
     },
     "localname": "DividendsCashAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r373"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedTerseLabel": "Common stock"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsDeclaredTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.",
        "label": "Dividends Declared [Table Text Block]",
        "terseLabel": "Schedule of Dividends"
       }
      }
     },
     "localname": "DividendsDeclaredTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r17",
      "r65"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPreferredStockCash": {
     "auth_ref": [
      "r373",
      "r693"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Preferred Stock, Cash",
        "negatedTerseLabel": "Preferred stock"
       }
      }
     },
     "localname": "DividendsPreferredStockCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r463",
      "r467",
      "r473"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan [Member]"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r119",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r178",
      "r181",
      "r186",
      "r187",
      "r188",
      "r192",
      "r193",
      "r684",
      "r716"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Net income attributable to Pfizer Inc. common shareholders (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Earnings per common share\u2013\u2013basic:",
        "verboseLabel": "EPS Numerator\u2013\u2013Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r119",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r181",
      "r186",
      "r187",
      "r188",
      "r192",
      "r193",
      "r684",
      "r716"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Net income attributable to Pfizer Inc. common shareholders (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Earnings per common share\u2013\u2013diluted:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r605"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate for income from continuing operations"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and related items"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "verboseLabel": "Employee Termination Costs [Member]"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r169",
      "r175",
      "r177",
      "r195",
      "r283",
      "r366",
      "r373",
      "r479",
      "r480",
      "r481",
      "r494",
      "r495",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r615",
      "r725",
      "r726",
      "r727"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited",
      "http://www.pfizer.com/role/EquityPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": {
     "auth_ref": [
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.",
        "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity",
        "terseLabel": "Difference between carrying amount and underlying equity"
       }
      }
     },
     "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentDividendsOrDistributions": {
     "auth_ref": [
      "r112",
      "r143",
      "r151",
      "r708"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.",
        "label": "Proceeds from Equity Method Investment, Distribution",
        "terseLabel": "Dividend received"
       }
      }
     },
     "localname": "EquityMethodInvestmentDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "auth_ref": [
      "r9",
      "r159",
      "r280",
      "r601"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "auth_ref": [
      "r9",
      "r159",
      "r280",
      "r601"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method investment, ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets": {
     "auth_ref": [
      "r278"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the entity's ownership percentage in the investee multiplied by the investee's total equity.",
        "label": "Equity Method Investment, Underlying Equity in Net Assets",
        "terseLabel": "Underlying equity in net assets"
       }
      }
     },
     "localname": "EquityMethodInvestmentUnderlyingEquityInNetAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r57",
      "r217",
      "r275"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity-method investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of investments accounted under the equity method.",
        "label": "Equity Method Investments, Fair Value Disclosure",
        "terseLabel": "Fair value of equity method investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "terseLabel": "Equity Method Investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesByIndustryAxis": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by industry sector, examples include but are not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate.",
        "label": "Industry Sector [Axis]",
        "terseLabel": "Industry Sector [Axis]"
       }
      }
     },
     "localname": "EquitySecuritiesByIndustryAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r593"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail": {
       "order": 1.0,
       "parentTag": "pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Equity securities with readily determinable fair value"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r273"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "negatedLabel": "Net gains recognized during the period on equity securities",
        "negatedTerseLabel": "Net gains recognized during the period on investments in equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r273",
      "r717"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "negatedTerseLabel": "Less: Net (gains)/losses recognized during the period on equity securities sold during the period"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r273",
      "r717"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedLabel": "Net unrealized gains during the reporting period on equity securities still held at the reporting date",
        "verboseLabel": "Unrealized gain (loss) on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesIndustryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Industry sector consisting of government, private and corporate entities engaged in business activities, including but not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate.",
        "label": "Industry Sector [Domain]",
        "terseLabel": "Industry Sector [Domain]"
       }
      }
     },
     "localname": "EquitySecuritiesIndustryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount",
        "terseLabel": "Cumulative upward price adjustments on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimated Fair Value [Member]"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r584",
      "r585",
      "r586",
      "r590"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r410",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r458",
      "r585",
      "r630",
      "r631",
      "r632"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r584",
      "r591"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r584",
      "r585",
      "r587",
      "r588",
      "r592"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r410",
      "r412",
      "r417",
      "r458",
      "r585",
      "r630"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r410",
      "r412",
      "r417",
      "r458",
      "r585",
      "r631"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r410",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r458",
      "r630",
      "r631",
      "r632"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r589",
      "r592"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r262",
      "r266",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r292",
      "r293",
      "r294",
      "r295",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialServicesSectorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sector of the economy consisting of companies engaged in financial services.",
        "label": "Financial Services Sector [Member]",
        "terseLabel": "Bank sector [Member]"
       }
      }
     },
     "localname": "FinancialServicesSectorMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r312"
     ],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Finite-lived intangible assets, accumulated amortization",
        "negatedTerseLabel": "Finite-lived intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r307",
      "r309",
      "r312",
      "r315",
      "r660",
      "r661"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails",
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r312",
      "r661"
     ],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Finite-lived intangible assets, gross carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r307",
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails",
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-Lived Intangible Assets [Member]",
        "terseLabel": "Finite-Lived Intangible Assets [Member]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r312",
      "r660"
     ],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Finite-lived intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Period Increase (Decrease)",
        "terseLabel": "Finite-lived intangible assets period increase (decrease)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": {
     "auth_ref": [
      "r583"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
        "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months",
        "verboseLabel": "Pre-tax gain expected to be reclassified within the next 12 months"
       }
      }
     },
     "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r410",
      "r568"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign exchange contracts [Member]"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r410",
      "r731"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Debt Security, Government, Non-US [Member]",
        "terseLabel": "Government and agency - non U.S. [Member]"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r463",
      "r467",
      "r473"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "International [Member]"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainContingenciesByNatureAxis": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by nature of gain contingency.",
        "label": "Gain Contingencies, Nature [Axis]",
        "terseLabel": "Gain Contingencies, Nature [Axis]"
       }
      }
     },
     "localname": "GainContingenciesByNatureAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Gain Contingencies [Line Items]",
        "terseLabel": "Gain Contingencies [Line Items]"
       }
      }
     },
     "localname": "GainContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingenciesTable": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sets forth the existing conditions, situations, or sets of circumstances involving uncertainties as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization, and previously disclosed contingent gains that were recognized as income in the period.",
        "label": "Gain Contingencies [Table]",
        "terseLabel": "Gain Contingencies [Table]"
       }
      }
     },
     "localname": "GainContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingencyNatureDomain": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization.",
        "label": "Gain Contingency, Nature [Domain]",
        "terseLabel": "Gain Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "GainContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of entity's patents that another entity has allegedly infringed.",
        "label": "Gain Contingency, Patents Allegedly Infringed upon, Number",
        "terseLabel": "Number of patents allegedly infringed upon"
       }
      }
     },
     "localname": "GainContingencyPatentsAllegedlyInfringedUponNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_GainContingencyPatentsFoundInfringedUponNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of entity's patents that another entity was found to have infringed.",
        "label": "Gain Contingency, Patents Found Infringed upon, Number",
        "terseLabel": "Number of patents infringed upon"
       }
      }
     },
     "localname": "GainContingencyPatentsFoundInfringedUponNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Net (gains)/losses on asset disposals"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedTerseLabel": "Certain legal matters, net"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r151",
      "r361",
      "r362"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail": {
       "order": 10.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Net losses on early retirement of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r298",
      "r299",
      "r663"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance, June 28, 2020",
        "periodStartLabel": "Balance, December 31, 2019",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Identifiable Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r120",
      "r159",
      "r216",
      "r222",
      "r226",
      "r229",
      "r232",
      "r280",
      "r601"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r574"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged asset in fair value hedge, attributable to hedged risk, remaining after discontinued hedge.",
        "label": "Hedged Asset, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Asset"
       }
      }
     },
     "localname": "HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedAssetFairValueHedge": {
     "auth_ref": [
      "r572"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset hedged in fair value hedging relationship.",
        "label": "Hedged Asset, Fair Value Hedge",
        "terseLabel": "Carrying Amount of Actively Hedged Assets"
       }
      }
     },
     "localname": "HedgedAssetFairValueHedge",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r573"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged asset in fair value hedge, attributable to hedged risk.",
        "label": "Hedged Asset, Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Asset"
       }
      }
     },
     "localname": "HedgedAssetFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r574"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk, remaining after discontinued hedge.",
        "label": "Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Liability"
       }
      }
     },
     "localname": "HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedge": {
     "auth_ref": [
      "r572"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability hedged in fair value hedging relationship.",
        "label": "Hedged Liability, Fair Value Hedge",
        "terseLabel": "Carrying Amount of Actively Hedged Liabilities"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedge",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r573"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.",
        "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Liability"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r547",
      "r571"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HeldToMaturitySecurities": {
     "auth_ref": [
      "r246",
      "r256",
      "r672"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetailsCalc2": {
       "order": 2.0,
       "parentTag": "pfe_DebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity",
        "totalLabel": "Held-to-maturity securities, debt maturities, total"
       }
      }
     },
     "localname": "HeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": {
     "auth_ref": [
      "r258",
      "r264"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain",
        "terseLabel": "Held-to-maturity securities, gross unrealized gains"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": {
     "auth_ref": [
      "r259",
      "r265"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss",
        "negatedLabel": "Held-to-maturity securities, gross unrealized losses"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesCurrent": {
     "auth_ref": [
      "r248"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_ShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as current.",
        "label": "Debt Securities, Held-to-maturity, Current",
        "terseLabel": "Held-to-maturity debt securities"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Securities, Held-to-maturity, Maturity [Abstract]",
        "terseLabel": "Debt Securities, Held-to-maturity, Maturity [Abstract]"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r261",
      "r268",
      "r690",
      "r692"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]",
        "terseLabel": "Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r260",
      "r267",
      "r689",
      "r691"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Held-to-maturity securities, debt maturities, within 1 year, fair value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "auth_ref": [
      "r257",
      "r263",
      "r672"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity, Fair Value",
        "terseLabel": "Held-to-maturity securities, fair value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesNoncurrent": {
     "auth_ref": [
      "r248"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.",
        "label": "Debt Securities, Held-to-maturity, Noncurrent",
        "terseLabel": "Held-to-maturity debt securities"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesTextBlock": {
     "auth_ref": [
      "r262",
      "r266",
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity [Table Text Block]",
        "terseLabel": "Schedule of Held-to-maturity Securities"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r151",
      "r316"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Intangible asset impairment charge"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development [Member]"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r121",
      "r152",
      "r170",
      "r171",
      "r172",
      "r173",
      "r184",
      "r188",
      "r523"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails": {
       "order": 1.0,
       "parentTag": "pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "totalLabel": "Income from continuing operations attributable to Pfizer Inc."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": {
     "auth_ref": [
      "r521",
      "r524"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r111",
      "r216",
      "r222",
      "r226",
      "r229",
      "r232",
      "r662",
      "r677",
      "r687",
      "r718"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income from continuing operations before provision/(benefit) for taxes on income",
        "verboseLabel": "Earnings"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r159",
      "r168",
      "r216",
      "r222",
      "r226",
      "r229",
      "r232",
      "r280",
      "r524",
      "r601"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Income from continuing operations",
        "totalLabel": "Income from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r108",
      "r119",
      "r168",
      "r170",
      "r171",
      "r172",
      "r173",
      "r181",
      "r186",
      "r187",
      "r675",
      "r678",
      "r684",
      "r709"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r108",
      "r119",
      "r168",
      "r170",
      "r171",
      "r172",
      "r173",
      "r181",
      "r186",
      "r187",
      "r188",
      "r684",
      "r709",
      "r712",
      "r716"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r8",
      "r9",
      "r505",
      "r710"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Discontinued operations\u2013\u2013net of tax",
        "verboseLabel": "Discontinued operations\u2013\u2013net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r6",
      "r8",
      "r524"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "verboseLabel": "Discontinued operations\u2013\u2013net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r113",
      "r119",
      "r182",
      "r186",
      "r187",
      "r684",
      "r710",
      "r712",
      "r716"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Discontinued operations\u2013\u2013net of tax (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r182",
      "r186",
      "r187",
      "r540"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Discontinued operations\u2013\u2013net of tax (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r112",
      "r151",
      "r213",
      "r275",
      "r676",
      "r708"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "terseLabel": "Equity method investment earnings"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r464",
      "r470"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails",
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails",
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r489",
      "r490",
      "r491",
      "r496",
      "r501",
      "r506",
      "r507",
      "r508"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Tax Matters"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMatters"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r160",
      "r176",
      "r177",
      "r214",
      "r487",
      "r497",
      "r503",
      "r719"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision/(benefit) for taxes on income"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxSettlements": {
     "auth_ref": [
      "r488"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Amount",
        "negatedTerseLabel": "Tax benefit due to settlement"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxSettlements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r155"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapital": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.",
        "label": "Increase (Decrease) in Operating Capital",
        "negatedLabel": "Other changes in assets and liabilities, net of acquisitions and divestitures"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r308",
      "r314"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]",
        "verboseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived intangible assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r308",
      "r314"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets, Period Increase (Decrease)",
        "terseLabel": "Indefinite-lived intangible assets, period increase (decrease)"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InsuranceRecoveries": {
     "auth_ref": [
      "r124"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.",
        "label": "Insurance Recoveries",
        "negatedTerseLabel": "Insurance Recoveries"
       }
      }
     },
     "localname": "InsuranceRecoveries",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Intangible assets, gross carrying amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r305",
      "r310"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Identifiable Intangible Assets, less Accumulated Amortization",
        "verboseLabel": "Identifiable intangible assets, less accumulated amortization"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r109",
      "r210",
      "r617",
      "r620",
      "r685"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestRevenueExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r141",
      "r147",
      "r155"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [
      "r410",
      "r567"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest rate contracts [Member]"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRevenueExpenseNet": {
     "auth_ref": [
      "r216"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest revenue (income derived from investments in debt securities and on cash and cash equivalents) net of interest expense (cost of borrowed funds accounted for as interest).",
        "label": "Interest Revenue (Expense), Net",
        "negatedTotalLabel": "Net interest expense"
       }
      }
     },
     "localname": "InterestRevenueExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r48",
      "r296"
     ],
     "calculation": {
      "http://www.pfizer.com/role/InventoriesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/InventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r11",
      "r76"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/InventoriesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/InventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Noncurrent inventories not included above"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/InventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "auth_ref": [
      "r50",
      "r51",
      "r296"
     ],
     "calculation": {
      "http://www.pfizer.com/role/InventoriesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.",
        "label": "Inventory, Raw Materials and Supplies, Net of Reserves",
        "terseLabel": "Raw materials and supplies"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/InventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r49",
      "r296"
     ],
     "calculation": {
      "http://www.pfizer.com/role/InventoriesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/InventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeDividend": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of dividend income on nonoperating securities.",
        "label": "Investment Income, Dividend",
        "terseLabel": "Dividend income",
        "verboseLabel": "Dividend income"
       }
      }
     },
     "localname": "InvestmentIncomeDividend",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r127",
      "r209"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestRevenueExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedTerseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Contractual Maturities of Available-for-sale and Held-to-maturity Debt Securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_JudicialRulingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Litigation outcome that occurs as a result of judicial intervention, supervision, or approval.",
        "label": "Judicial Ruling [Member]",
        "terseLabel": "Judicial Ruling [Member]"
       }
      }
     },
     "localname": "JudicialRulingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r64",
      "r159",
      "r224",
      "r280",
      "r528",
      "r535",
      "r536",
      "r601"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r46",
      "r159",
      "r280",
      "r601",
      "r669",
      "r703"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r66",
      "r159",
      "r280",
      "r528",
      "r535",
      "r536",
      "r601"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "terseLabel": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r34",
      "r35",
      "r159",
      "r280",
      "r528",
      "r535",
      "r536",
      "r601"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "terseLabel": "Noncurrent liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent.",
        "label": "Liability for Uncertainty in Income Taxes, Noncurrent",
        "terseLabel": "Other taxes payable"
       }
      }
     },
     "localname": "LiabilityForUncertainTaxPositionsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements [Member]"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails",
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value amount of life settlement contracts accounted for under the fair value method.",
        "label": "Life Settlement Contracts, Fair Value",
        "terseLabel": "Insurance contracts"
       }
      }
     },
     "localname": "LifeSettlementContractsFairValueMethodCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r34",
      "r359",
      "r667",
      "r699"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt",
        "verboseLabel": "Principal"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt",
        "verboseLabel": "Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above)"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Long-term debt, excluding the current portion(a)"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.",
        "label": "Long-term Debt [Member]",
        "terseLabel": "Long-term debt [Member]"
       }
      }
     },
     "localname": "LongTermDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt",
        "totalLabel": "Total long-term debt, carried at historical proceeds, as adjusted"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "totalLabel": "Total long-term investments and equity-method investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Long-term Investments [Abstract]",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r68",
      "r356"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r355"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r355"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r355"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Number of plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Investments by Classification Type"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.",
        "label": "Segment Reconciling Items [Member]",
        "terseLabel": "Other [Member]",
        "verboseLabel": "Segment Reconciling Items [Member]"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r75",
      "r159",
      "r280",
      "r601",
      "r668",
      "r702"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Equity attributable to noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r373"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by/(used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by/(used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r144",
      "r149",
      "r152"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r9",
      "r101",
      "r104",
      "r114",
      "r152",
      "r159",
      "r168",
      "r170",
      "r171",
      "r172",
      "r173",
      "r176",
      "r177",
      "r184",
      "r216",
      "r222",
      "r226",
      "r229",
      "r232",
      "r280",
      "r601",
      "r679",
      "r711"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Income attributable to shareholders",
        "totalLabel": "Net income attributable to Pfizer Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r101",
      "r104",
      "r176",
      "r177",
      "r530",
      "r538"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r173",
      "r178",
      "r179",
      "r185",
      "r188",
      "r216",
      "r222",
      "r226",
      "r229",
      "r232"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net income attributable to Pfizer Inc. common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r180",
      "r185",
      "r188"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income attributable to Pfizer Inc. common shareholders and assumed conversions"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging [Member]"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent": {
     "auth_ref": [
      "r386"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.",
        "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component",
        "verboseLabel": "Net periodic benefit credits other than service costs"
       }
      }
     },
     "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Adoption of New Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r373",
      "r521"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivative Financial Instruments Not Designated as Hedges [Member]",
        "verboseLabel": "Derivatives not designated as hedging instruments [Member]"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonqualifiedPlanMember": {
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r436",
      "r439",
      "r443",
      "r444",
      "r445",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan without tax-exempt status in accordance with applicable tax provision of designated taxing authority. Taxing authority includes, but is not limited to, U.S. Internal Revenue Service (IRS). Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Nonqualified Plan [Member]",
        "terseLabel": "Non-Qualified [Member]"
       }
      }
     },
     "localname": "NonqualifiedPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of segments",
        "verboseLabel": "Number of business segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments [Member]"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetImpairmentCharges": {
     "auth_ref": [
      "r151",
      "r324"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.",
        "label": "Other Asset Impairment Charges",
        "terseLabel": "Other asset impairments"
       }
      }
     },
     "localname": "OtherAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "totalLabel": "Total other noncurrent assets",
        "verboseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r91",
      "r93",
      "r429"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax",
        "negatedLabel": "Benefit plans: prior service costs and other, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 1.0,
       "parentTag": "pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Tax",
        "terseLabel": "Benefit plans: actuarial gains/(losses), net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r524",
      "r525",
      "r532"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to noncontrolling interests.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Foreign currency translation income (loss) attributable to noncontrolling interest"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r83",
      "r93",
      "r602",
      "r603",
      "r607"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Foreign currency translation adjustments, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r93",
      "r97",
      "r99",
      "r429"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax",
        "verboseLabel": "Reclassification adjustments related to amortization of prior service costs and other, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax (expense) benefit of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, Tax",
        "terseLabel": "Reclassification adjustments related to amortization of prior service costs and other, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax": {
     "auth_ref": [
      "r87",
      "r88",
      "r93"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax",
        "totalLabel": "Other comprehensive income (loss), available-for-sale securities, before tax, total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": {
     "auth_ref": [
      "r87",
      "r88",
      "r94"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax",
        "totalLabel": "Available-for-sale securities, tax, total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTax": {
     "auth_ref": [
      "r115",
      "r276",
      "r608",
      "r613",
      "r615",
      "r680",
      "r712"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Tax",
        "totalLabel": "Other comprehensive loss, before tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax": {
     "auth_ref": [
      "r85",
      "r93"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax",
        "totalLabel": "Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax",
        "totalLabel": "Derivatives qualifying as hedges, tax, total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r85",
      "r93",
      "r552",
      "r557",
      "r580"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Unrealized holding gains/(losses) on derivative financial instruments, net",
        "verboseLabel": "Amount of Gains/(Losses) Recognized in OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax",
        "terseLabel": "Unrealized holding gains/(losses) on derivative financial instruments, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r93",
      "r97",
      "r559"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "negatedLabel": "Amount of (Gains)/Losses Reclassified from OCI into OID and COS",
        "negatedTerseLabel": "Reclassification adjustments for gains included in net income",
        "terseLabel": "Amount of Gains/(Losses) Reclassified from OCI into OID and COS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax",
        "negatedTerseLabel": "Reclassification adjustments for gains included in net income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax": {
     "auth_ref": [
      "r86",
      "r93",
      "r97",
      "r560"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax",
        "terseLabel": "Amount excluded from effectiveness testing"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": {
     "auth_ref": [
      "r86",
      "r93",
      "r558",
      "r566",
      "r580"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax",
        "terseLabel": "Amount excluded from effectiveness testing"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": {
     "auth_ref": [
      "r83",
      "r93"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax",
        "terseLabel": "Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax",
        "totalLabel": "Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax": {
     "auth_ref": [
      "r93",
      "r97",
      "r98",
      "r99",
      "r606"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax",
        "negatedTerseLabel": "Reclassification adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r83",
      "r94",
      "r604",
      "r614"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "terseLabel": "Foreign currency translation adjustments, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r564"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r565"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Amount of Gains/(Losses) Reclassified from OCI into OID and COS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r102",
      "r105",
      "r107",
      "r115",
      "r366",
      "r608",
      "r613",
      "r615",
      "r680",
      "r712"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income/(loss), net of tax",
        "totalLabel": "Other comprehensive loss before allocation to noncontrolling interests"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r102",
      "r105",
      "r524",
      "r525",
      "r532"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income/(loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect": {
     "auth_ref": [
      "r94",
      "r524"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax (expense) benefit for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Tax",
        "negatedTotalLabel": "Pension and other postretirement benefit plans, net prior service cost (credit), tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r90",
      "r93",
      "r429"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax",
        "terseLabel": "Benefit plans: actuarial gains/(losses), net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax": {
     "auth_ref": [
      "r93",
      "r97",
      "r99",
      "r270"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax",
        "negatedTerseLabel": "Reclassification adjustments for losses included in net income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax": {
     "auth_ref": [
      "r94",
      "r270"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax",
        "negatedTerseLabel": "Reclassification adjustments for losses included in net income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax": {
     "auth_ref": [
      "r93",
      "r97",
      "r99",
      "r429"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax",
        "negatedTerseLabel": "Reclassification adjustments related to amortization"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 2.0,
       "parentTag": "pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, Tax",
        "negatedTerseLabel": "Reclassification adjustments related to amortization"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r94",
      "r115",
      "r487",
      "r502",
      "r504",
      "r608",
      "r611",
      "r615",
      "r680",
      "r712"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      },
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "terseLabel": "Tax provision/(benefit) on other comprehensive loss",
        "totalLabel": "Tax provision/(benefit) on other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited",
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r87",
      "r93",
      "r270"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax",
        "terseLabel": "Unrealized holding gains/(losses) on available-for-sale securities, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r88",
      "r94"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Unrealized holding gains/(losses) on available-for-sale securities, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r549",
      "r579"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other Current Assets [Member]"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other Current Liabilities [Member]",
        "verboseLabel": "Other current liabilities [Member]"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r381",
      "r483"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "Other (Income)/Deductions - Net"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r15",
      "r16",
      "r65"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "verboseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermDebt": {
     "auth_ref": [
      "r34",
      "r667",
      "r699"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt classified as other.",
        "label": "Other Long-term Debt",
        "terseLabel": "Other long-term debt"
       }
      }
     },
     "localname": "OtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermInvestments": {
     "auth_ref": [
      "r57",
      "r706"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term investments classified as other.",
        "label": "Other Long-term Investments",
        "terseLabel": "Long-term investments",
        "totalLabel": "Total Long-term investments"
       }
      }
     },
     "localname": "OtherLongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other adjustments, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Noncurrent Assets [Member]"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities [Member]",
        "verboseLabel": "Other noncurrent liabilities [Member]"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income)/deductions\u2013\u2013net",
        "negatedTotalLabel": "Other (income)/deductions\u2013\u2013net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other (income)/deductions\u2013\u2013net [Member]",
        "verboseLabel": "OID [Member]"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r383",
      "r384",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r433",
      "r434",
      "r436",
      "r439",
      "r443",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Postretirement Plans [Member]"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent": {
     "auth_ref": [
      "r36",
      "r384",
      "r385",
      "r408"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit other postretirement plan, classified as noncurrent. Excludes pension plan.",
        "label": "Liability, Other Postretirement Defined Benefit Plan, Noncurrent",
        "terseLabel": "Postretirement benefit obligations, net"
       }
      }
     },
     "localname": "OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Exit Costs [Member]"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherShortTermBorrowings": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails": {
       "order": 3.0,
       "parentTag": "pfe_ShorttermDebtGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.",
        "label": "Other Short-term Borrowings",
        "terseLabel": "Other short-term borrowings, principal amount"
       }
      }
     },
     "localname": "OtherShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherShortTermInvestments": {
     "auth_ref": [
      "r78",
      "r674",
      "r707"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term investments classified as other.",
        "label": "Other Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "OtherShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Parent [Member]",
        "verboseLabel": "Shareholders' Equity [Member]"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r148"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Settlement agreed"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r131",
      "r134",
      "r163"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other investing activities, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Purchases of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfOrdinaryDividends": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.",
        "label": "Payments of Ordinary Dividends",
        "negatedLabel": "Cash dividends paid"
       }
      }
     },
     "localname": "PaymentsOfOrdinaryDividends",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r132",
      "r517"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payments for acquisition, cash portion"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsArrayBiopharmaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "terseLabel": "Acquisition of business, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsArrayBiopharmaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Acquisitions of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r247"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of long-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation [Member]"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r409",
      "r411",
      "r417",
      "r435",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r458",
      "r460",
      "r461",
      "r462",
      "r475"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Pension and Postretirement Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r382",
      "r384",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r433",
      "r434",
      "r436",
      "r439",
      "r443",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r462",
      "r463",
      "r470",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Pension Plan [Member]"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement [Member]"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails": {
       "order": 2.0,
       "parentTag": "pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "terseLabel": "Less: Preferred stock dividends\u2013\u2013net of tax"
       }
      }
     },
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r145"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds from Collaborators",
        "verboseLabel": "Milestone payment received"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLegalSettlements": {
     "auth_ref": [
      "r146"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received for the settlement of litigation during the current period.",
        "label": "Proceeds from Legal Settlements",
        "terseLabel": "Proceeds from legal dispute"
       }
      }
     },
     "localname": "ProceedsFromLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r137",
      "r140",
      "r163"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other financing activities, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess": {
     "auth_ref": [
      "r136",
      "r139",
      "r154"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a borrowing net of the cash outflow from repayment of a borrowing having initial term of repayment within three months.",
        "label": "Proceeds from (Repayments of) Short-term Debt, Maturing in Three Months or Less",
        "terseLabel": "Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, beyond the current operating cycle.",
        "label": "Proceeds from Sale, Maturity and Collection of Long-term Investments",
        "terseLabel": "Proceeds from redemptions/sales of long-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale, Maturity and Collection of Short-term Investments",
        "terseLabel": "Proceeds from redemptions/sales of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-term Debt",
        "terseLabel": "Proceeds from short-term borrowings"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r135",
      "r478"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r9",
      "r101",
      "r104",
      "r142",
      "r159",
      "r168",
      "r176",
      "r177",
      "r216",
      "r222",
      "r226",
      "r229",
      "r232",
      "r280",
      "r524",
      "r529",
      "r531",
      "r538",
      "r539",
      "r601",
      "r687"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income before allocation to noncontrolling interests",
        "totalLabel": "Net income before allocation to noncontrolling interests",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r25",
      "r26",
      "r323",
      "r704"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, less accumulated depreciation: 2020\u2014$16,889; 2019\u2014$16,789"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_QualifiedPlanMember": {
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r436",
      "r439",
      "r443",
      "r444",
      "r445",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan with tax-exempt status designed and operated in accordance with applicable tax provision of designated taxing authority. Taxing authority includes, but is not limited to, U.S. Internal Revenue Service (IRS). Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Qualified Plan [Member]",
        "verboseLabel": "Qualified [Member]"
       }
      }
     },
     "localname": "QualifiedPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r222",
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r221",
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Revenue from Segments to Consolidated"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Principal payments on long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "negatedLabel": "Principal payments on short-term borrowings"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]",
        "terseLabel": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]",
        "terseLabel": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r484"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense [Member]",
        "verboseLabel": "Research and development expenses [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails",
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedInvestmentsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the current portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.",
        "label": "Restricted Investments, Current",
        "terseLabel": "Restricted short-term investments"
       }
      }
     },
     "localname": "RestrictedInvestmentsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r329",
      "r331",
      "r337",
      "r340"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Expected restructuring cost"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "auth_ref": [
      "r329",
      "r331",
      "r337",
      "r340"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "terseLabel": "Restructuring costs incurred"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r151",
      "r328",
      "r334",
      "r339"
     ],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail": {
       "order": 1.0,
       "parentTag": "pfe_RestructuringChargesAndAcquisitionRelatedCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Provision",
        "totalLabel": "Restructuring charges/(credits)",
        "verboseLabel": "Restructuring charge (credit)"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restructuring Charges [Abstract]",
        "terseLabel": "Restructuring charges:"
       }
      }
     },
     "localname": "RestructuringChargesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r330",
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Balance, June 28, 2020",
        "periodStartLabel": "Balance, December 31, 2019",
        "terseLabel": "Restructuring reserve"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveAcceleratedDepreciation": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail": {
       "order": 3.0,
       "parentTag": "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.",
        "label": "Restructuring and Related Cost, Accelerated Depreciation",
        "terseLabel": "Additional depreciation\u2013\u2013asset restructuring recorded in our condensed consolidated statements of income"
       }
      }
     },
     "localname": "RestructuringReserveAcceleratedDepreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r42",
      "r373",
      "r482",
      "r701",
      "r728",
      "r730"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r169",
      "r175",
      "r177",
      "r283",
      "r479",
      "r480",
      "r481",
      "r494",
      "r495",
      "r725",
      "r727"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r436",
      "r439",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r463",
      "r467",
      "r473"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r436",
      "r439",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r463",
      "r467",
      "r473"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTaxStatusAxis": {
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r436",
      "r439",
      "r443",
      "r444",
      "r445",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax status of plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Tax Status [Axis]",
        "terseLabel": "Retirement Plan Tax Status [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTaxStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTaxStatusDomain": {
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r436",
      "r439",
      "r443",
      "r444",
      "r445",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax status of plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Tax Status [Domain]",
        "terseLabel": "Retirement Plan Tax Status [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTaxStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r382",
      "r383",
      "r384",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r433",
      "r434",
      "r436",
      "r439",
      "r443",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r470",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r382",
      "r383",
      "r384",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r433",
      "r434",
      "r436",
      "r439",
      "r443",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r470",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r207",
      "r208",
      "r221",
      "r227",
      "r228",
      "r235",
      "r236",
      "r240",
      "r377",
      "r378",
      "r659"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of Revenues by Geographic Region"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r110",
      "r159",
      "r207",
      "r208",
      "r221",
      "r227",
      "r228",
      "r235",
      "r236",
      "r240",
      "r280",
      "r601",
      "r687"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Net sales"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyIncomeNonoperating": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.",
        "label": "Royalty Income, Nonoperating",
        "negatedTerseLabel": "Royalty-related income"
       }
      }
     },
     "localname": "RoyaltyIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Inventory sales [Member]"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r96",
      "r613",
      "r615"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Changes in Accumulated Other Comprehensive Loss, Net of Tax"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Available-for-sale Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r509",
      "r510"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsArrayBiopharmaDetails",
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails",
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsValnevaSeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Financial Liabilities Not Measured At Fair Value On a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r68",
      "r162",
      "r367",
      "r370",
      "r371",
      "r372",
      "r618",
      "r619",
      "r621",
      "r695"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Principal Amounts of Senior Unsecured Long-Term Debt and Adjustments"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r442",
      "r443",
      "r446",
      "r447",
      "r458"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of derivative assets at fair value.",
        "label": "Schedule of Derivative Assets at Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Derivative Assets"
       }
      }
     },
     "localname": "ScheduleOfDerivativeAssetsAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r550",
      "r562",
      "r571"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "terseLabel": "Information about Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
     "auth_ref": [
      "r541",
      "r543",
      "r544",
      "r547",
      "r548",
      "r555",
      "r562",
      "r577",
      "r578"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Schedule of Derivative Instruments [Table Text Block]",
        "terseLabel": "Schedule of Derivative Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of derivative liabilities at fair value.",
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Derivative Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Earning Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of Significant Product Revenues"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r9",
      "r159",
      "r279",
      "r280",
      "r601"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r584",
      "r585"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured At Fair Value On a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of Total Amount of Each Income and Expense Line in which Results of Fair Value Hedges are Recorded"
       }
      }
     },
     "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r307",
      "r311",
      "r660"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r307",
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r301",
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r301",
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r314",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r314",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Indefinite Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r18",
      "r52",
      "r53",
      "r54"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Components of Inventories, Current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock": {
     "auth_ref": [
      "r18",
      "r52",
      "r53",
      "r54",
      "r55"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.",
        "label": "Schedule of Inventory, Noncurrent [Table Text Block]",
        "terseLabel": "Schedule of Components of Inventories, Noncurrent"
       }
      }
     },
     "localname": "ScheduleOfInventoryNoncurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Schedule of Net Periodic Benefit Costs"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of Other (Income)/Deductions - Net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r332",
      "r333",
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r332",
      "r333",
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Schedule of Components of Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r330",
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Components of and Changes in Restructuring Accruals"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r110",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r216",
      "r219",
      "r225",
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTextBlock": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Short-term Borrowings"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r71",
      "r157",
      "r196",
      "r197",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecuritiesReceivedAsCollateral": {
     "auth_ref": [
      "r641"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the assets received as collateral against securities loaned to other broker-dealers. Borrowers of securities generally are required to provide collateral to the lenders of securities, commonly cash but sometimes other securities or standby letters of credit, with a value slightly higher than that of the securities borrowed. In instances where the entity is permitted to sell or re-pledge these securities, the entity reports the fair value of the collateral received and the related obligation to return the collateral as a liability.",
        "label": "Securities Received as Collateral",
        "terseLabel": "Cash collateral received"
       }
      }
     },
     "localname": "SecuritiesReceivedAsCollateral",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r203",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r240",
      "r720"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r203",
      "r205",
      "r206",
      "r216",
      "r220",
      "r226",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r239",
      "r240",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment, Geographic and Other Revenue Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, informational and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, informational and administrative expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes [Member]"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation [Member]"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r151",
      "r328",
      "r334",
      "r339"
     ],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Employee terminations"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r32",
      "r670",
      "r671",
      "r697"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "totalLabel": "Total Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Short-term Investments [Abstract]",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsAndEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r732",
      "r733",
      "r734",
      "r735"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Short-term investments [Member]"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r5",
      "r203",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r240",
      "r301",
      "r326",
      "r331",
      "r340",
      "r720"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r37",
      "r38",
      "r39",
      "r157",
      "r159",
      "r181",
      "r182",
      "r183",
      "r186",
      "r188",
      "r196",
      "r197",
      "r198",
      "r280",
      "r366",
      "r601"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r74",
      "r165",
      "r166",
      "r167",
      "r169",
      "r175",
      "r177",
      "r195",
      "r283",
      "r366",
      "r373",
      "r479",
      "r480",
      "r481",
      "r494",
      "r495",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r615",
      "r725",
      "r726",
      "r727"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited",
      "http://www.pfizer.com/role/EquityPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r195",
      "r659"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r73",
      "r366",
      "r367",
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Shares issued upon conversion of convertible preferred stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r38",
      "r39",
      "r366",
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based payment transactions (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r38",
      "r39",
      "r373",
      "r476",
      "r477"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based payment transactions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r39",
      "r44",
      "r45",
      "r159",
      "r245",
      "r280",
      "r601"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance, June 28, 2020",
        "periodStartLabel": "Balance, December 31, 2019",
        "terseLabel": "Equity attributable to shareholders",
        "totalLabel": "Total Pfizer Inc. shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail",
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r159",
      "r165",
      "r166",
      "r167",
      "r169",
      "r175",
      "r280",
      "r283",
      "r373",
      "r479",
      "r480",
      "r481",
      "r494",
      "r495",
      "r521",
      "r522",
      "r537",
      "r601",
      "r608",
      "r609",
      "r615",
      "r726",
      "r727"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsScheduleOfEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r158",
      "r373",
      "r376"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityOtherShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of increase (decrease) in shares of stock classified as other.",
        "label": "Stockholders' Equity, Other Shares",
        "negatedTerseLabel": "Other (in shares)"
       }
      }
     },
     "localname": "StockholdersEquityOtherShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]",
        "terseLabel": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]",
        "terseLabel": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r616",
      "r625"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/TaxMattersNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r616",
      "r625"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/TaxMattersNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r616",
      "r625"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionEquityMethodInvestmentAndLicensingArrangementsBiontechSeDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsProductLitigationCommercialAndOtherMattersResolvedMattersDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/TaxMattersNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Cash paid (received) during the period for:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan designed to provide limited group of employees with supplemental retirement benefits, in addition to other pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Supplemental Employee Retirement Plan [Member]",
        "terseLabel": "Supplemental Employee Retirement Plan [Member]"
       }
      }
     },
     "localname": "SupplementalEmployeeRetirementPlanDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income tax expense (benefit) from effect of Tax Cuts and Jobs Act.",
        "label": "Tax Cuts and Jobs Act, Income Tax Expense (Benefit)",
        "terseLabel": "TCJA impact"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability": {
     "auth_ref": [
      "r508"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.",
        "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability",
        "terseLabel": "Repatriation tax liability"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "verboseLabel": "Brands [Member]"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r262",
      "r266",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r72",
      "r374"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock [Member]"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r39",
      "r366",
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Purchases of common stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r72",
      "r374",
      "r375"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r366",
      "r373",
      "r374"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Purchases of common stock"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r410",
      "r688"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "Government and agency - U.S. [Member]"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]",
        "terseLabel": "Unsecured Debt [Member]"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Common-share equivalents: stock options, stock issuable under employee compensation plans and convertible preferred stock (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r180",
      "r188"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares\u2013\u2013diluted",
        "totalLabel": "Weighted-average number of common shares outstanding\u2013\u2013Diluted (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "EPS Denominator"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r178",
      "r188"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average number of common shares outstanding\u2013\u2013Basic (shares)",
        "verboseLabel": "Weighted-average shares\u2013\u2013basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 14
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868656-224227"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=SL94080555-108585"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3098-108585"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8475-108599"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269825-111563"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269825-111563"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269825-111563"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=117311354&loc=d3e32014-111567"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33775-111570"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "325",
   "URI": "http://asc.fasb.org/extlink&oid=73718008&loc=d3e42732-111610"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82921835-210448"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2599-110228"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "http://asc.fasb.org/topic&trid=49130413"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=SL108413299-114919"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=SL108413299-114919"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2919-114920"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4587-114921"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "http://asc.fasb.org/topic&trid=2122503"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e39076-109324"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613673-111683"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998890-113959"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109999712-113959"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109999712-113959"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109999712-113959"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624258-113959"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624258-113959"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30304-110892"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30755-110894"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=116633155&loc=d3e31531-110899"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.5)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Subparagraph": "b.",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=121551529&loc=d3e60009-112784"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r747": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r748": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r749": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r750": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r751": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r752": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e709-108580"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724391-108580"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>120
<FILENAME>0000078003-20-000060-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000078003-20-000060-xbrl.zip
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MQ'VX)#R ,%/8/R\!)CTG].)3=]NRA+@B<R\QYJ_CZ)M)NOYC,&V.^W8541-
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M=3Q9+;5T)01#8"1^'2<+ACLV?20&O.P(F<)%8ZZ"1=48BYT::J7@1FZ% Z#
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MT6< FK@!L*JN@Z,839H%3&6_;_#F?K1_-XQOW!Q5!>KTQ+AO8 LK++Z5Q^$
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M#5K:2%1TE,%(>+C.<;5WAJ.G6FQG_RG]=E%H@=2*RGA9Z,+"D6>#<9]6F3>
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M]VUP9P'#@HGW;X640YL[GXYHRZ9C[C'T4W8T<=>A+Q93F9Q(^H+L>V:'\B%
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MN'+<V6+^2>P1# IT!UPHROO 6+H*A(,&RU@CW8A@O&?3&,>=YI2P(("5X80
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M?]L@Z\+Z0+.>%,39^O^W_PW&QYO^/P!02P,$%     @ 3X$&47!G$202,
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M[OE@B(^X;;<^I&Z4=@YUU752;81]VU6ZOGZJ_;R+C\B/C!*?$(D$YLB]VLJ
M:P \_L(U3GV00(><20"YR2XV@-30>A35_0.*EX#HJIX5)(WT5PO<:6N(W>>,
MP7#2(7YP[ &&19_'&"V'\0L(K0:KC9H;<_KH$)Y6/3TZ),ZA1^),76BRC V@
MD2@5U\,\5H< 99\VK>#FUSL[/F%ZJV>#B<$]<&:J-[FC#\>%9C@N5(,*4G4
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M=6/+K/FRA]0-&7+X)8+R18*NA:(&EX=F:[-C_' Q3YVS'T%ELFPD+>BQ8V.
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MSN-#@P&NGT*)G'RH$J=)JA%1+]CFS0_8?FZP<UN.]52=^<!"5B;QZ(@8&O=
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MKW+<6VI?71DIV796(YQD!NKU?$0_\L.&<RW;0;*.;5U#4^ICA^1C[\2-[GN
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M;;6?V=/G&AXT58JQ>R%<3HJ]S,T[:J&T![1$&IMV^]CCI2LJ;<=) 0O;L\X
MNB%3W<[YT-EB*L#,:JGM#1G> P/5?ZW$)@>Y!P$^!S%@#ND;@4=O+6.EXQSH
M0VB+6<CYQ8[Q:T_OU\:K;^$4B4M;; FOUQ2P'F>L=N [FY13M"]TR.?/S@MH
M05"&(,Z(?SKVS(_49C^'X*<:-"H6/0@&&A**)O<I'HT#5YPW&YX*0-PNUJ:H
MW8:ZC2%P !RK?PE(EB. <=@:]".>#]Y53,G.SYXB[/0S/@K[Z4KPU-6[3B?-
M.4MGQFV@801H[(*PO5"*V H5QYA8,K@#3#T<4>D?][<VN_WI3\;-!U=>X23_
MSI4G/_'^V5+W J*-.3H>V+)J6LM,5/A5\_ON?T>T_A-AJ!S%M.*.1&96XZ@\
M#,]/@IOT=PTJ;H_*M_=>BPYY&Q4^%O<9AUC3CDJ=.L4@I/^.=CZ2<^6:?EZK
MPW?E$VYS^N9QRNI,JT<E*K@/4Y_:TX(40ZWW([CK,&QHE>/6#A]X'(VE'@C&
M5_-NM:L"]27O09T>#-].K9+0-DU^>M_OZ0&;PE\)^VR4A*?43@AG1SB<-DKC
M/\Y378YK3DW\UTL1G@;\7J(^-ZA#<.%D?#CWJ 8#3T$''KX G?MH>E:NHTJU
M\QR66]VAQM/*5>D6'W%?:>.-M8D/B^Z#'A0C4(=X7-]QPM8%XDA*MHYDF=Z<
MCD@Z1$!7I73CP%48@'5;B3BB@BT CRW4_$U O;HPH;:(O!ZO*U7EZ.UZKA'P
M=3T_AG8GM/GT&#J.*_] ^M+\CEOT&5'K1&1/QVQ!-Y2#*DA$Q-M#V3J\X;-[
M1 36SY<F.8N"]UI3]4&34 RF?,D1'$0 B%@UGSW^1=F/B5_FP=@^.N1V6]J:
MGXE#;<QZ)N9E*R]%('S<E1=@RBA]V ZM'VT77:1#NFZI0N=RNJ&<^_#X[.#D
M]O-4>= VE*()8@G]>"0?V@C,K48L>'?PZ3H1,4DABX<IM2.G%U#I1*G^Z%;>
M@$(4U S(H$7E;TJ(DT'F'_)6?+'74JK&X%GR9>SNZ=[PK/,V3V\(_'4O.99U
MX]O<EE4:F$5"1*.5@%""9U>8\;Q+3B]4$*T"6/6&"TTJ5BJND??K<>1XE'"K
M!5--F'0!QVKEZCB*#C$.XU<*G-_V^>17AFTI9XZ<A<%/A</"AQ$B-([PX24N
M8*_73^8FN;YR!1$-_8SHA*=RNZ!OC*=D41S"1YVANV,456]M:/_^=.4^FT=]
M>_/8;T1"UM,\&> 8%]N*&@$Z[,D_&AZH=K"'E1[AL)B57#J$+\@BM)>MF"HR
M*@5>)\;#5PJR.R+UV9? FJ[R]V@1>*U&=^IS"3'0<X5B<78_ :U44I+8KH16
M!N. )S\&NQHT:(*@/Q$:GWF8&;P=YJ,V]8YY;P_'^=:/.OD+?\_V'&$M/D%>
M2N68#E'\*"O9U[WR3B>"H<^Q<R"H;R779%F13X:R&G\+A_K$RB#)",J1.&?A
M!Q^!8*SJ4 B)(#BKUH)D1$UTMDL#@0@^ZMG21?1?H]2P$W]9^@@:G5Z2GZQ+
MY;J#^NQG]==QH>K#WWJ8;FV/X1AR]_ P)P?:<30P5035X@QT8"NT]K =9"M<
MTMQACY8JG)'*1:Z,B[>B\O(:@2YW,]M5R,98]1R*EU<'ERX'<1LJ*'Y/R5@&
M*;(QAXM[ .AU]+-\SW+ VM8D_AQQ3K_=XO&.<T/://ZBH6*ZB=@]H_@O/SY$
M&K_XZU/F/<%0LT&>XF#5PK_>?3&8S,G*,SES7?B[P'G92Z4#EX2K>ZR2X)_V
M^L6#,%[(4R!L1?GY,AM-F38.Y6W%K"CXP$5!9@,$9/;$%@X8R!W=H&YP$:B\
M;I?3=7G!>[EV.H,X/R)A6OEP20Y0CLU33B?BGK>JE8+SCI-H0T+')'1VOB>;
M%D7@8(6)H*\@F:F&</9P5B^:/A S7480#[ ]";Z_$1 GKZ.AV((J$.,P%93\
M8+NS.=M;1'@JJ-[%_(_R]U;RZE)!B872(N0!2N>@ ;0@S>Z;(UGID.X[%1;0
MJ+J.> F>E,'ND(P)JCG9,Z[5X20H*)=7H_531A?,*URZ2(*UHVGSMA:\UF_V
ME10<$@=:=4KGMJ\$X3@Z'J;&8GAHG CTX\^3:E9GP4O7D/'J-%4X=Z"%86?V
M3,^Q%4&_B7BBN)OCK<B";:#+_]TB>,F%7!VON/]F<7U\-<XBS,%L,DA)9&W0
MN@F$'2"/<]IU:$,T%; $D+$DWW:. M=[1(YG>J$Q$@( '1)7T<H,,).*/P$1
M=0#@>1#<,+,D /(2%H,[Y^@0[#XF 7IN#TF]1%CF0QOZ\>*Y'BJ0_K2& >Y$
MZ#OG\ %7E:@#8W"=(J[^B:13S4P;/=+8=2)PLH%8O/YE;-]<Z@ZP8I6<)P[(
M@^X]VNL)K:;5'2GM%_H+MEVEIB0G2A)_]8;$OLJ.1#U=_[MY5-4"[O2:<6P_
M%92%=HH+=D^@T@A4?Z4=3Z,V;)<7@2T'(;8(NN 1K.A08,((J*N/^+#DU4/C
M]C,A,'<OQ[=KU#?F'7#8]4>V&A(8"ZKQY@+D@# K0D=\GB 07E@O(=3F]XB)
MW!=%K)_:X;X_1IQ VW*WDK]?N5,;OUVZ+>)<7X>\>_YJ3Z%:W?Y&'?;6A/[\
MGU^$Y5D=?#L<T.@]60Y$K4PWCA&,<@#@G9C9AI7JF'#NJC:)DI/TY(=FJ0=)
MSXA0P;]1D4LNMR>H>B2+X(-((#6ZTN]\X-0^9U2]0W,PMM:N"<C\M(*U_&4)
MNE"L08V#+! 30.C@<5FBLE/T(S  4V#6M0G5Y =$##/5KP$LG%N/O5F"=Y!0
MF6X-?D;1:NC&YG+!8W6YR?.=V71(=')?'-)'.H?T@G-46_9H[#_^+)P?J>A;
M)Q0^@O'R"67:3Q]H:8A=4]IB<?BY;LH;$GNWLN'QZ>?&EG[_]5N,$.0Q1!PB
M_OQ_X[\D_U\*??;_ %!+ P04    " !/@091(&Y2L&T[  #W0   '0   &-H
M87)T+38Y8S<S,&5F-V)B93-F,F(R8V$N:G!G[;II4%-;U#881&06F6>XRCRK
M@,B4J @("!&0>8B(R"0B(A(@) )*F+F"@**0RRQC9!8("9  *BHR"\B01&42
MR%&!(X3DXW:_]7;_Z*KW>_NKKJ[JZI-:Y]2IL_=.GNRUUWJ>=3;[,WL1<LS6
MRL8*PL$!@7 <?"#L68C%P=W_VO'O(/^K8W"P>R#"/ =71TZ.$Y!#PAR<PAQL
M"D3QX'=R_>\-(/]Q<!SB/,QUA)N'EX__H$'K,<@A#D[.0X<YN;@.'SYX&G_P
M'')8F$OD^*GS1T0=_;A/1(B=3GA<PJ-TH;%7W&F$H:Q__6XB+Y^$I)2TC(JJ
MFKJ&IH'A&:.SQB86%RVMK"_9V#I?=7%U<_?P]+\1<#,P*#@D\E[4_6AD3&S2
MPT?)V)34M)S<)WGY!4^?%9:6E5=45KVLKFEJ;FEM:W_=T=E'IO0/#+YY^VYT
M;'QB<NKS] R51O_Z[?O2\LHJ\//7[ZWM'?#/[K^X.""<_PG]_Q*7\ &N0X</
M<Q[F_A<7QZ'H?QL('^8Z?NJ(R'E';K\(T1.G$WC$+CPN:>SE5=)W8HA?OSO"
M)Z%L0%4!_H7VOR'[GP.6^'\+V7\"^S]PS4 $.#D.)H]3& *#L%CJI6F0_[=,
M:U$/5,>LE]"'/R,6LYJ!I3XVI&F!HC@#[\4(&2".@6P(W64P$17%6.M)HF+Z
M$-P>@R^1^(%;\^;CZ[J$@+KIE?7(^ JD7E]G_+>-DM#*D&B9_*I_R.*YJXKH
MJ>_63+%!*GQ]!!CL41  _?:.@T;;^D!VTE98U!8FJU!R/9VNF#$C^8C@7P+&
MALH[]T$AK9]81Y'ZON.&PP)KOJIM;1/$O[Q"93;RJD)C%5*Y$S=;ZB// ;"4
MX^>$S$$J&\*5"@HQW)P G8G-)*9_#5*4ZM:+GY:E3PWB)7Q:25A#H4<8(38D
M#)8^B>%!BPR@U.)#H^+Q(-ZR\_7S 39$!&5NSH9@W<A0KM:X3"4GP"A-!4OF
M7E%G0VZ3#@_NW4)Y[:='80Z!P^29J8.1O2[NUZ'L #W7Y^1?(,R-H=!-MW?K
MG9QD28X9Z#A[ N;K'_*&L00+U9>['Y__X]-_)K]M4L:AC&NKX1\VY 6L%<X4
M$:5EK[O4HZ(G4%[TA>1.N85VMQ]LR!XG2F<?WV!F*IFZ7L*HRH+YLR%99V 2
M9@&TA20)HWRC)C#I')A+O3F.E@=#+0"'*FKM)O><>Q!1>WP+<<S"</M1^+9>
M,AMR@PW)-(EFBE?1\.LD##=YA.$\@&M4)+,ATX%6HV%,GSIOE+6"!D.M?U,*
MY?0:4*BF=IA)AU.'POE#MHO5[(],A#$#7X8PYF9LHJ(K5<I7E2!O]C,PBS5L
MB"#LEE JAI\H/<TT!@+)'ZSI;,B/1WY[=U \A,DH'SUO;#_FL#+X+([1Y3G&
M]"P,:ZU#\X)EU")?./_J;OO#L-L$CW_@![,FZ0XO0TXYC[=D"P=WAJ]VH[U8
M[V ,>QPGZM#^2V;4G@OF&LC9,U5&528UXWJ$$A9X;AF:"CU"0%B\(1B15G@&
MVBS)5J;4?785:@0V Q;."AJ Y6 R2F,1P0TB;,<,PGF0@>2=S",=-+PPJ_P*
MAZ78_R>-NXAY!:Q?A"<52RKH@4D-JJGE]O5@=-_NC0B/$!EB(TU('"1Y-#,V
M'S)5J!BAH,GVW<U4@@LM/NY*TZB!T-'EV'A6;0WBB_*9R08)MVQ8#T+20$@Q
MU%>9T4_$TG&"R+(^S\#DUJ(X"P"?&,6&" P=>4[[P[3DQF[\7G?=F(0?16:9
MMC/:6MK]R2;S3;O:;6]#&QJ>Q42&AZE]0+1+]H:G8$3]]_.)2BC#T>?]NTL_
M6O?<0:%M[#A:QKIF)=9PBC+,]QDI1,/V8<3!."O2U,;OA:.#M#E^"[ Q&N#N
ME9@_,=$2)GH5"$RZURW!AOA\DKQJ'P[/WDYM!QL!+3()@K*@*B:C3Y(8W,DL
M,Q#CO?\/5"ADG?I!LG]!F"A >@!50=X-,S8P9EKK9M=[(.UH-[L9"S1H\V*1
MLULR7'I907#B=Y>IO>M*G8$YDG.CFYS=_=%$2Z%*;O'.><639[68[A5?]+.?
MOU2,:APFGLIV?G$4Q"\E44A-DNMYD@^9CE5O_V&Z FW-!UX]/?I3+U%RFPV1
MULZJHNHI!)':V[-9.DP^QM7"XE; R*XX/&6!!W-S/;2G6&R<@*F9FP^:*<K&
M1F$$AN@^\0W?QJ)@,<!4[\),N@WX"$CJ1XLP)#.9<50OH>R%PT0C\'Y,!0.;
M2#3V62$>VV\PTZ$C4A;XF<8T4\6T-O1AL)>QXP+J1=)#AY/)@R88,D8&U.ME
M!),.,3WJD<1AY\8Q@C+'GAW!_^QM-J3G*R/BDV[LWEVHWZ#!;2FUXJ/0M1O%
M)/4!=_\7#>>7N),0#V"BL #\S/.!>1$0^P^^#Y=VV(;!S>*;*T>9O4JB[6"U
M_<>@FDRW_1J"&H#8EM@3GZCJM[O1.&& $PAJ+\0F&OZ9,=>G6IR7R'R) $.D
M=8['X\280ONO"*=>,J]U?H)*,+T M3ZX".K._@NT"MA.Q2>;A3&\O  ,95-@
M#=84G<+DV#NGE\2$ <_[=]B0HYM1'V2WDW$]1"B81,7)KD(%F\!'BLE;]=&]
MGAO5>)O@R#H(^F?RX0?ZPQ:MC6-F+ZZAU?#R2'PNTV4O!,7'<,.20G#BR )'
MH+BH!-W_LP_7HK+)U,+(SF'Z5 3FN4;0:JT;V>'!9? H^A _!HM6^D3PBXY:
M=$>=EV_+J^Z5JXA2W[CUUQ_2]OG]9X1PQ@*](,,0GS(#[U_'D-'\H/B>!M)B
M<9@"RU04^2VD +9?F6*>.O V[H=076(G2WAJ(#<"X/Q1B']H@%$ NUC"\K*7
M@?ZM3&)%^0(R]7?EI-:WX9FD;5/P%X#IA3$\*@X6+O3,9Q"[G=G<. H+A/,A
M,;2"!*8Q53$C1^]'' ._^)0P?N^96:!$0=G*.L#?9_*]J*&=XH7C^S*/=%B
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M\0:T_'S_G%_&8#2C42I51=OU3&=F14K_9%.>9\Y4/G1=\Q3ZXR.3JT^ND1Z
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MJPF>/!%F^IMA>>RO%/IAN43A\X?O_45/U")#5= ?%OC0VB ;TH,3(_@%T,6
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M+3CU1J'"J&L=T61,%YS3K?<M$M=S;_;"Z(9&FT_5Y,K&P\A2I&972^2OS<+
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M/D/D=*I9VRC22Z@H!*+=&9,3ZSI*"+"M]=C0^+Y1N>%LP]V/#7H1[+F33?
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M+JPH6IXQ<@ZP)D_$&VNB+ '$_-91Y!1Y+PHM!Y1IQC%!@KIX#F3E]=8AX]/
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MG]1,X7X9-,R8/JE;O08P9G5@!'\61@W+O7Y6\Z)OZ19;)18E"8+XYM>/'VY
MX><!?6T61!.RU=IP_U*4!E#!F14OGL:*).H['[QZ>?[1\IM\Q/;S%@F94+[8
M^!KS39!,*&UXLQV\J]>-7W;SN$:?HP;_&M59GFG#ZDYK]3FW)7&6/NRW-G1$
MG>O_-GG8OPKE$8UP;X%Z/<R!HN7BKN=OQ<-Z:[Z?GFZ>UTEXL[;B'DUH4 ,
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M=\L92(=2I/0+F9#P,;B=D=Q6EJ9K^)IH&I9J&V"Z)=FS!$7,9^&*AK)%;-O
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ME;>\#B7W3H^J(7\NZ2H^PA]?GQ9DYQTJS]G!!&;:5R=AU2_O]@O4KN_E,'G
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M*:W20=4&!%@]16R4)X)MM&#K')$AV!!L;(.-@6CL.B'S( FC _8$8-*C?F_
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MT7@Z%!^9O79"ASN=<:?S .'3OQ?JE'SX0K)@DCQ+&R!^6O&S*SD$T/@2"IT
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M<$;>1[^321;<SLCU2FH3LLS"23"KYGYXW#C6=MM%9RGVH/T#V\#6?QJT.S)
MAFDX#V=!@B#H!()G D-]'X:^MU/_7X()36B\0-&9HD<MG&57&LA9!D3Z?PF#
M^R3H1/EQ9W%=HJ<DO_,2?]XW%O>_C: ]68I@0C -'DS#2)^V[VP.HK^?[KNA
M"6L/Y:W,9<%A]6&<(4@K?%9MS 7Q/J@;G+/8I4,W>+T8SPLM7F.F_IOZVH\%
MB.YF9)(EP1<R3\-Y-Q?%^T:CE@,#:D5Z7H3AWJ9!-%!UN_48;^A[V?YLO*&/
MBS1%)S!A-0:K,7SI^V,8_-V1I7'9I]NF_EOYG9N2\=L0/ PP_82'&H_!*O>?
MH,(SE_#,);3+EX/3K\'LCSC!YMV#8;0CN//""'MW!ULNP8W:)T(3;M3FBNIU
MZHO!A!,FG$Y6K;ALZ\H2;,Q*V:W))%Y&U.S\EE(;%R33LH[-29 N$[*27LW0
MXMV+8=O/HQ_P[,.B956'BQ?FWQK^>N!;?H:9!JOOE"]<T[=_-O# #UJFM8()
MTUB11/WMSS?N@6^8@B:2M%D8Z^>'?\MKDMS0EY;?>1H^ KS+VD1?\8EJ?I#%
M9:AUG-G_['R-W3<J?8)+HG@>1HV?L7^FNQ]2>:_BT69J>^623^8W[^<O^U81
M'A\H\,DL2-/?@@FMMC:I7GG,@6^_F 4AM<IW3>^]&7#@&\^"O])EV(B6_/'!
M;WH?-XMA_?3 M[P&P]8,ZO730T'B$KJ-/6A^V\V  ]]X'D3+.UAG&%IKY>A[
ME\>TO7WX[6U"9JM*?OH0+EX%R22)9[M>G8[_+D[NWTC@R]_D(][03[BZB^,L
MBC/R^M4LC/[XLO^5JY?1<:]?Q<F4)/]X+;Y^=9?$\R_D+OW'ZZDAJZ*D2$0W
M-/WJKS^N?/H)@J!)MJ&JEF(*JF5[LJ4+IJ*KNFMJLN18KU]E\?KU7\'YW!#:
M# &3N9)$37<D6W8TW9-]T3)]+7^=;1F&"?YM]1'Y]V\=_MOL=O;ZW?=O*O(:
MF  5414-@0!?5;<"%$57U#U7T5S-T040HVFN9N9X@J3Y7I, 1<TQ/%/T#%O1
M!-5T7%VWUQ)Q1$\WE(H VX8/5(!R10-U25$4H@J:4!*@+#NNXNF2I#NR;FLP
MS?7,1-=W1*=)@()F.JIB>" 04=<5S3%]+U<IUS9=J2+ MN$#%:!T/@$:@B7K
M@N][AJG*HJGYBJ06$O%D0:@(L&WX0 58M8$G%*!CN[)H.*(,4K%\6?!T3RDD
M8AJJ71%@VW!&!"CH@F004=>4D@ 52U8DP?#AA^_;CJ.L;: K26 =I28!NJHE
M4M>C2H;JZA#,&H:32T2U#%.K"+!M.!L"S)V(J@HE)R)9H@MSLC7-4!Q?%W5?
M7CL1$*7J"TT"]'Q%L51#<VS1MG15DE3/+;R" <M1$6#;<#8$*,N:)LM$,F2Q
M)$#?]5W9MS3+\43)\2S17\],<P7'\1L%Z'F@L*(D*H[D:O >FIJ_SM9L\9D&
MM@UG2H"@B"4(RZ+HB0[\85F"JRDBH#F'L"%YHO5J\S)15 2M\^M0\,\%+VIR
M6?! Z&S/,C33!GHB /IS 6J>)\N-MI-/ :XC&%$U2K93MGQ?\GS9UA4(+"1)
M*(R:[%J:*S8)T))<2_5\L+F^YPJ2X@MNX8XM41"]B@#;AC,B0,$ _TU$J6P[
M9? QHB@;EBNYLJ<96BY !T(S7; ;";BI.ZHG>JYKV*JO28ZC%NY8<UVA2G_:
MAK,AP-Q[BX)L&B4) @.6/<%V'1N )MF M/745 /HBHKNN\8(*HI12D,H@BAI
MH@^NVK$D5;,$;1V=.;9C&I;!MQ6LCZ(U03)+ A15B,* 58J6;]HFL/ \/R#)
M/M@MC*+/)$">H^B3")#/*#HW@KM!C*+XJN_:@BR9MF,I@J7IN1%T)1 CWT:P
M*D$%?(8&$E1*5!"LDNIX0 AE\!NRK3J&GOMAP90\L]$(*K9I@]=13=<W-: ]
MFEU(1'4@GJP:P9;A Q5@U0B>4("Z+KF2Y:F2KEN.8VM@ XQ"(H;XC,BT#1^H
M )NHH"&5B(RJV+YH6$!G3+!(ENM:UGIJNB.[4G,B@DLJF!>D0!5+ M0E7_94
M0?%45P<%%(5\9H9D2K;>F$NT=-!GW3,-P_=U<*NFY-B"I>B2+AJN4*VGM UG
M1(!K#,N27-9  )&G@.[)#E@G40>DY0D%T5)M@69R5$U7#"*)JM3Y90C]&MMI
MRJ5,F.IZFD[!+WN^(\N"Y!>)'%UV16TK=U$M._V6EZ'<=^0NF=HJ^BX+T)<-
MV?!!;H;M"[8AF$*>.]=L6V\T&+8E"(HCF)JK*F!P/-TVY%PBONEH58/1-IP1
M 8H:N <(ODVS+$!%=.!/WU1-6Z")VUR KFU;CIRG?B65**+4_65-<E<T'<BG
MI;J2(%NF!7Q#SCVD;8A@@BMR;QL^4+E7R5;_<C=]U5%D$=35LD1%%V5PL+D@
M;4=5J_G.MN$#E?MS@R&+,I& CFT%J,FFY7I@=GW' H*FZ+:M*HH@N:9DV&YC
MML[T+;"9M%_%%AW-EQ75T$$!-<NP30'HW3,![A_.B  %$3@:D72CY.DT"'C
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M]UBXERZB1G%514+1/N>I#$!-;<\#*3:24J1T8^'D0FE?A<IHA.B6!SXX_B(
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M #Q9+_0I )Y<EK-@8TEHV9?8,V1TUK#K*.#<M3 ]EX[;8=\SZTK3B3 LV81
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M/G-+TS0,;,CO.>"[.VOUUQ7VH-P;@+;JC*-@U>BNHD\-?BOJ=$:V;K<U^0D
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MBZGEF/.EWERIR.'R*9M>9._C-P!)>Z:0>\P%(KIYAY$RN>T<]1E^>-.+_ P
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M*[M9[04%WHLSG>E%9EL#X1+-4<QJ\:TQ:"KL.X<K%XN]@;YWZMP92/VV#]@
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M'\4 K5,A.D=!V4^)'4$$-U[$+WH!JF9JV(OZ6K-R3_XJ$R$)M>V@XM%>Y!D
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MP"U%<FPAG<R[Y9,1-_CG:ZK>HB_]XY^=G47<Z#MK^(;[V,S5@,J(!+D37N)
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MS2G'['Q2,^0O"==0^5:T^='QOQ3 37'N&0">/&;B)>(*8&((7")!]JZ'="V
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MP*86)N=FGD.O3?8&:BYOO:H[%AB7_2Y)%&.2TEQM%ET%:.%K&R&UW^S#/-(
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M%4$N6-"\H0ZVJ!'GI_G@B?>ZMR>V%E[[UVG-3I0".3B+&K1PJ:-%^!KT["W
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M^ ,E8(L+R++EBDX"YI!-TW0$Q<M\<DU "AY,:WEF-Q&X0P(:@12*X"\2%Z@
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M$-P! ;MA"+85GXFL>L\'#[?A*>?11N\"*.NZ_RC]3^7%9WG5Y(;3^I3\F@$
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M) \*>0EF,6@ ;Z@U% 2;J<LQC !6;67]3LI.RB46:=0.SQ&HK%0,B(7 =9'
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M*95RA8DW'/XX*%B'2A3)MA5&RX@,G$5+J<54@K]0ATJ2HX#:B^LZ$:QKD8)
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MB)(\Q&9]8.1(K>G+36;MU,'#_329GF_1WEQ69U=X.*K/3@'-5Q6FS%7(W,.
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M"^E\(7JY]$XQ%B1!F@=/C.)$<\RLQ2(ZJ9_]S*\*PUY<//%[?5CBXM*7K'I
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MW\O1Y&RI_I?1JZ,J#)>Z]N#]12]8MP+XY%,Y7B<3>ES?I.=KNA7OX?W!6;D
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MM@[2_?PP2[_(7@U&R?O,?WY[EI]=SS=P.M]8_$OYGU$^ ])Y<*W[.4'U:8:
MJG5B$MAXY:)#E@D7B:"$ELUCC,1BI4/C7+Z.QZ/Q55X4Y8_^.)I+V@XZ,*E&
MCUV?NKU@*0!HVV!)"%1A%F-NL55.26^QCEP5D:,Y9@4R:-5X7Q>SVSC:)4V:
M\:V=[@Q8[ 86'U&@ M>ZKY'HK+>*!J,)HS*092M#;GC J D%VI CS9H\W@4%
M"J!M%V@?P2RK'2='I%34,1 C.4-)DYIE](LKX5>Z*F^B0!L^0B:XR0[EK56@
M!^FS+Z0I.Y^,+^>B-!A=%_G2I;0EWSW[DB?1R+.KR?C/P32]\_;5EWR4GP]F
M/Q<RD\WZW_)I<>2\</N!XSH:3A2U\BEB4 @:(>Z=BEA(8B(N[0ZG@EBQ.Q9"
M5L0/EQ--%V+VX4;*[%S(%M=]+B0J?)M-^HDI!J/^Y/O1++^<)@XL!'0RGO?I
M.TJL-\FWVZF*]C2'[I: P+8@4%4!?4XP\@9S'T)TWD27KBK=<(P96K$B=HK
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M)^/SP:P@*S@A!M4/4'L,:K56/XR@9 ,$2V)(:--8&+2$&G*>V76@!J>Z #6
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MD.+C?YHC\WP\GHW&LWP.R\])AD[R83X7W=>(69UL8,&UCUHD  I;=BZTW+F
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M5JWT2'N(0UU_>A'33OV:G_V1[Z28Y*%P2Z-&%)SZ .*>9;;PVO!Z28/T(;K
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M89=5T?L3X030'P;HZV63TDO/&!>48>65%]ZI9=H"06IEXOG.0=]<G4.C20@
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M&Y?(*GJDG9%8&<XL*8>=>F;T.J';;2>;[-0Z>EGA!2(#(@,B>YS(=-6ZG-N
MBQ[E!!LFJ8J$Q5BV3#/)[PO/-KH:RXEI=%S GA+9/';W=AZB6K[?Q&<O8EZG
M^7!8"O3_^U/R[XO7Z:K3Y>M[ON3SX#*?9L?YU^S3^+(_^B5;_;;;D<:O@[/9
MQ2*.]]/-5CTY,)EVX_:C'PY&^>N+?,ZPF*"_UE:KK^X$#]'B.Y_^O'2Y>==7
M/[Z=7QZX W$U^^EOK_K%6?_UU0;<7'S\3W,HGX_'L]%XEL]Q_#F)VTD^S.<0
M>*T<=8Q;[H6EB!FGI2[#-)8C0N/K142G_(!'+__G\,NP .+B\D_CXK8N9K.K
M=V_??OWZ]<VW+Y/AF_'DC[<$(?IVDG[]=GGM3]FWR^&[8;\0EGST^O>31W;J
MQZC1ZX)F\0?E6+5L,,IF%WFV?-+K?LPT3RQVEOW/=7\RRR>;?DHV/L\*0ZX(
M+@^OSQ:-QA)4SB?CR_GM?<W[_\I'1<)7NO(T;7P_W?=E_[_'D^ST>C+)1Z>#
M='G_C_3V=#;_B]_?G+Q)+#4<]B>]["K=W: _''Y/?WX^S6?9E^]9?^,U%]_R
MG)7VKZXFXV^)J6=YNJ--/VFANO[RL.["I.HWJ&UD)$B<#'!D><24B;+=9_J-
MYFNU>XGC21+.D5L\^^^?)_W1='$#9G0V?S6<EV*:L_^^GLXN\]$3!G?_<SJ9
M_?/D]"(_NQ[F'\[#_UP/9M]_RV<7X[.CT9_YXF-6W\WSXW3;YMM@^L^K\_R?
M_W'RO]UX-+V^S">_YOWA[.*T/\E_RR^_Y),FXJ=JM?-,EK9IF/YQ1[VN+1GI
M.;^>];]EK[8L$95;1J2@UA8Y<]X4+=(EQF7!N#:>HY7:PV8EXM%X]SX(!-%X
M:P+1/Y\5-E7_V\_9)$]/+S\K#MK.%P]ZR7O?LUGU<+/^S=--;)AXN6#"P66R
M2F8%\8RO)]DHL=_@YNEEZ>'^4=!J8J0_)OW+7I9LO(N5P[WB#_/Y@\XNYT^Z
M_A&E!DG/.5L^Z*QZTME_CP?IHC_3E=>3_$U6TSN;/ICBV\X'DT3TT\&W[#+]
M]F*:EK?Q<][T#PM!W?A+EYIN<S54'W71=C7$JJYCTA/G(Y<H,(,%QUA[R1GG
MW""IE7Q9-?2/EV4==<,Z^HDM@MZLQJNR+WNECWCM$-4Q&P02F&F+I15"*E*(
MAF9>8"K6:DC>M#YZ8<E8.VM<HWLD Q33CQ33_*9VX'44%TWRZ?5P-GW:PM]D
M29*SPC,OGF-_F"Y=['KQ5,=KK+"73?--_;S%J^+J=X-9\D)/DQ0<%QXVL9L*
MT9L?W\H#7SM_Y^O"+QX5CV&X\(R3V(\G\V=2"'Q>^+>G22RF\X?6RQ:@?+U
M95:!=;[K[P>G!7FD1VXF26+_R.=2NNFZWFUY73]:2G,;>S=_JQ91N2^N!M&P
M[47#OFPW&F8$4BA2ZX@+5!"A/(K+\)9&/MR)ACUV^1Y'PS[EI\/^=#HX'^2%
M"DF:I3D\+1KIOUKD3?[\]BR9#_/'/_U__I<BF/Q2\/^F;%/P5W-WZL;3N3J>
M)D-C<]>B5+M%7##Q:EZD<(_F!P)S0V$Z2_]9V 'IFQ8/Y3$=UR]]Q@GL4E.[
MM!5K0(:TDX-1/]E%:1./DE$TN9YO];O,I\_Y,VWHG_G]5\PU\:^EZ6/2D_\S
MR4(^!5W4&EUTNEU=)%1TU!%NE6*&$B%Y,)RQ:)1.Z@;=/9EY['+019NRW)J0
M>WA7F7:2H& ,1H8YI(R2:&DR*&WO6AB/7;Z[7;V3JH!I+7WA:3T1GGDN=]G_
MGJ4;+[1B=G8]=W8GZ3?%#3RX0T\4U>3R)!]^5VT>3I*N*33$M%B&NS$,7-TP
MJ-3"R8V)<&>E\Q^+\_CEZWNR"LJE/9E@-UZ5N+,/\Y\7D^5G7/7_R%]_F>3]
M?[V>!TS>]8=?^]^GA;JXF)2+Z<\Q,TW\14.,ON@!R97U6B5*B\IC9H+31A5_
MTW_"4WC"CC>P[H_QZ+_"I^SHV+W)S+'/3GZW)T?^R'SZ1^8^_/;1'!^%DY6-
MV^TMN@_'/AR?!)_NZ/CDP_LC;SZG%]:\-\<N9">_AO!YLWO\0<Y*[:]7E'4=
M4L7K^L>7SGX]4PJ7"KXQ8^;.W9:F"TKK*M-V3HN U=4T?[?\Q\J"*_OGIAY3
M__1C<V?Q%9+]M68<W;&<-OL5:OP3G_UE.V[;\V"F55.M -2ZL%O\P:O?CMZ_
M/TJ RS[$S']X_]Y\.GFYWAUKY*1UJ::YF8S*#:V7_[P>Y8N5$]7+YEJJ?DJZ
M?LIARS(*07)?2G(WIK:&)-OGI_,SNL73H?A&NK%N6KI;V]#E13O4M:D H /K
MNT$RW0*2GT5I#SD$&X+WU>^C_O79(+F9A]Y*;#>[_7)K;543S6?*[=T3X.OD
M0DX*Y[$($TVG^<$WO>RZ,,->=F>M72*FG_[F^M.+^9'=:?&/(@/KS_ZPGC9S
M6%+<^/JVO'TOW?=\P]M^N%I3(J)R)=A-.BG5+H; O8S((N&\]J8\3<+(>"E6
MBC63+)O16?&?4$FTF;G^9/(]+?7O_>%U?B<[]&B1'=I$N[2>0JNU!'O8,0WP
M#GC?'=Y5-4K-*BR8PC$BK#B27 11EC-AIT1<;?Z]&=ZQ_C^L$;Q3U(DFI-VR
M;$XNQI/9ZUD^N:PE91^H6=..WJO;(P^-:G,878C>Z2"UP!HIR0PIR8-(:^G]
M4\+GPO(YR4J5ASW=FH&@>UR!@0#(:05R2#5]S!(EA/9"(J,<%XXS7DX?(\%+
MLS*?< WD-*1J58\34+6M4[6?TL9/!J?SK/ 'M>ZN4UV734B NSK)7:SJ@" 5
MIY18J8UA(GD-!$<B@O<2<<.X6RE&KD2VQEN+&M.[O=0;C S@'FNT:R]H?D#/
MQN@153<T1I63R/F DN.=H.0]]@D]027-GZR"E:;7ZZ%G4^7_[WPR/DL^?;%/
M\Z3V+B"G6YK_\Z1?M+XX/;VIZ\H'?Q;IKKULF$^G67^8 -L?G>;%QLY[S<W.
MKX<W?_!NWBRJW-V_)-ONEZP0E^H-"=S32>[1E;].N&!>(1>9$M1XR@4J@_LD
M6N%71A&94G8^W<C:<3[;MN;6/4Q4%^@'P+/WX,&H-C&<$Z&)Q9YJ7(RQ",28
M<DXF3J9O6/'9UT-/8VZ[)$VVC@?EW8CR+FRWT6P\&>00%N\H4U!9&_G'F1<<
M1^Y$TK%4*%2V0"7(<;]BXR^EXWLBB*WI5=5+VK\+S !HZ0!:>-7<SDBBD4X>
M,$$J&JN08F6/58JMDG(]M#2F1XDZK%E\>Z%'2_,I*WKL]2&=M\,$H7!M:E-T
M7BBJ@_>84I?L[Y(@"$N 5TN"N#K/%P=EQ2#/N7!LVU>E/49$%U@"(+/_D,&H
MZ@I*75",4AL<CB%BB;GCY4A<$8+S&T"F(<5*>Y1UP@SMEF)=-+DY+=4KJ-8N
M\T1MOD'@B#/-=7)*$2-!X.2HEJI5J4#4O7DHN]&MI,>[,0T;,-,!S+"J1$(*
M)B,+P2MD%6/22LM*S%CA^(J_^A3,-*1<24\T.HQOWY0K:JEV_3R>]8>@73O=
MQN5)-"*J-*JD:"T)&$GM(XY*I)]FZ=6FMU>"Q+O1NDPDEW8+LX</LB<-(.WE
MD*:JE"N'#36&2,:Q458YC&/I#&.NG5X7:4TYPJ2G4),&;CN1UBTWN9PDL#(W
M [1Y-^U^@BN['PE+L+ N$JD%]](((TH:P>G-%5_Y_EDWVZMUPKS')61. 7+:
M@1Q:Y1VZ&+%&%%.15+'CR=2E2U/78HKMQLAIJJQ8]C#M1*RI6]KV_;BX(2@K
M/@B^X)7!'J-U(9$$9HX)I["Q(92:5H4@5IH2S"-LA;#LJJR8]C#K1)P-D-,!
MY,@J\S#A1AE,E23:,AX$MK(<-T5<TK]D<^0T=OR+,!S_MD[3?IR,K]+=?^]E
M5\-^.>.OZ%!V54C#LL#H]/3Z\GHQNO(LOYJD+5WT6+Q5681%3RE]N[@HO2?5
M)BU_@7[:3S\452427C/EE4$&$Q0PXDRAI:$ODH^\4B*Q%+N/A="9T5E8BMPV
M$Z$QZV$X60;XM 0^I$ITQ %;;C5"15\0ZISV=!FHCL*0E<KZ]>#3E+-,>UK(
M+L"G6RK\J)B5,S@?S"?@#$:S_NB/0?'/Q6GS/3J\?SE.B_WW7(<#N7237%A5
M9J&=%DHP([26EN"DFB5>!N&D("N#XH]N1&AQ'I8X)7P['5X7Z_R/\?CLZV X
MW)Z#37N<0>,N@%$[8"2JC$FN XF1!VE<3+_U.K*RMH]2JMU*@]S-8-24M\U[
M5*(NP*A;NGJY\< 7W>0+755B,)M,^:"9M=8PA(Q3S)4VO5 6K[C$6U>M7/48
MTUW@!(#*_D.%H2HC,AK#I2[*_#"3U&JLI"HM5*XY7SGVV;KZ3% 1O!.1HFZI
MS^/Q:)E+?9:?Y^E?9[6*X'GP>CRO9QI5%T+%<->9A%:I6M90+C ))@BGL8W"
M\[)$@R*/'*J7/_I2@FXJ().%;D9GMZLB*XG;8KT3%9TPU0%,'0 3KXV(X)PR
MC)+#JQ265%B$E]ULJ T,-PJFQ@JAD.Z$C=LMQ?WAKE8&C;S= HWRG7;6:#!9
MI7PEWQA+[1TA1 =EM/%B23)1^[@25JL55>Y -[,>)4T>>;5V6C' [@!@IZM\
M,6\,QI&R("5CQ)C@<.ER8XW%#R:X[$R+LQ[C39K$K85=)\N=#UFW;YE8:!+=
MHL/W,%];=MLU#6_S9>V0,#FI"-.Y0!%A 3GA0T!>2EJ>HN,0E%YM CP'P?9R
MV:3L:;J%>NWG"QK8)D ;ATT;M>0;1UQR9[RB!'M-K?'$EY/RN(S(K&3V_8@V
MFLKA$[+'5),!DO;2QHM&4.[R1SE!BZ<+]XU*VKO4&X^.;L&C:^^R#VBIA[C#
M78K\SC\N:9_Q9%$Q=#U*RJ(8*9@^ZOV@_V4P',P&^>+D=E'\W5*1W^?8U+9M
MHHVY"CP*D*B.2%272/O67/=DWT_&7].W3WO98%3F+]]T-+PJ*DF2 S0^SX8W
M/1O.\B^S.[6AR>G =TI#>TR0PX3F[N#8:E^^#:ZZ$+B6A:@9QEHBC W'T7KF
MER7T2M\3X?-)S+<^S9;VD.I$V3S@&G"]0URK*A$_8"=-5((R+CQB!.E09AA@
M$IQ>.>I\$->-Q>%Z6/,NX+I;AL^=6;M7_>]%5>UATME>>Q!/(8FDZ:NY*=@J
M1IW$GCLNG4QF "F5/T;1KQ3)+F=\?EQ(R/;G#2D)?:< -^W #:F4*W*($X%<
ME-IB9JFF:-D;E6)M?S@;]S'<-)9(1$@G<NN[I6;]X,]!0N(9:-B.,P6KU<]S
M;#2A7H1@D ^&A;AD"J>U6SD)OY&1':E8TL,8&D\ <-H!'%%K/XZ9H6P^(Y>R
MHD.J8\M1700G'W9CX#16<H-1)T)4W=*Q1Z/3\65>E+_FH&8[SA:JJJ57I* (
M'1!Q,AA!(\'+MA..Q]5:^L^%?.Q(Q>(>8YT(>@%H]A\T"M6*T))%JGP@W!!E
M/0U*";TL&[<FK'BQ3P)-0^I5*W!@6Z=<S>GIY#HO4')YE8^F\^2F>1+3)%_T
M6!S,\LL#+8'I/G/4)IQ$DJA"61<89<9;7ECII;J55,25N'&XO!J.O^?YIX6<
MU'+@MN_?(AA= !!J"81XU3N<.2FPU(Y(YGT0,4@1EO,PA3,K_NT&$&K,TY40
M36Z?,KX]PGY8R0.01S?)HS;W1 JO=9!$:FV2SC4BA&72%F+6W]\^8H=:%Z,>
M%C";#Y#3#N3HJC+1.^Z19EHDUY<*$I0)RX)F%XP-&R.GJ10IW$/JD'LPMKO)
M ZA;&+>=&$77IIA(A;G5PF$?)%5,!;3L>$R4LV+%D-^A&J:%Z=[]F=L MZ[#
MC56I5]0Y@:QSQ6!J%SE2%B\3*H1%;".X-35^0/9HHV?"[80;=!CH^E(/L?X<
M=KCKR^Y6^._]K<+3Y7+7U[[75S]X&&FQOQ0]"UZ7VX,)^FOM[\75[*>_O>K_
MG+[Y^@JLLDY&3I)E5)WY:<L4(Y@KH9VW5$MMEE/*N0Y*K1A>Y9CEHK!L!SUK
M.>IQTHD>V "<#@"'DMH(M008A*/ TO*$($1OI@3K@,+&P&EN:)KFG<A/ZY:"
M_YB/IH5@?<E'^?E@EHV_I ^?I]Q,>]DHGP%S=),Y>'7,9XDSSAAC@Q;4(AN]
M*H_Y,$)*KJ39^"0HH_S,+B2F%*!B6G(M"+(+5=RCK!.I\8"G#N!)5H=_D0;+
M:.!) 0NJD""2E FOQ00VZ9K&4U-SV7KI;KN IXXIZ/%T-LEG@TE>S* '/7U8
MO()K;10TDB1&CX1*>AE)'=7-R"AA:%CAE7E2P6WQN4,U.]?91=J!Z +' +8Z
M@*U:JP5"B_H4KP1SRI* (EDF[!#",//;Q%93.3T]3#IA#W=+?_]HK"KD]G2>
M7VH-&K!W6"BJ9-#)(8A><JJ7HPJ40/?YV'-1610:?^Y_JW-)ODVGFB$(;P.
MV@&@6J,&[AQ._K/'W@>EB'!&+AL-:D^D?#: &O.B$Z"[ *!N:>%%&0OT:S@
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M4C6;I\;-!RJ ;+5*MO93GH"EVB=)>\]2'_L3H"@0K.8%RYR=E>U>A]GM)>Y
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M55\K]6AR65R@,?ON5O.!)P1'P8K30*RT<IR8/@Y[@JTECU'GI'1"0YSRE$(
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M.92)%$-AI48FE80YP8A:<JA$9"/KLGD.;7K[/3)G1%NKT(;JDZA,IM0YHHE
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MKK^MPOD!8_LQ:$NV7ER)(F89-T1"XCUF(@4W2@D/=$<4;J_3O+/"$;'BTF$
MM",+\2-@E;"NA.9P"I1FD@87V%$KA:EZS2O)!;.M78=W7!.BT2A7A&ST@UII
M/[1,OCB7W9&O(TOI8SZMY'"MP ,#2 I%(&4$&TFY6Q9X0$["%H>2FZWW$#>(
MNH_JR- '+]]Q,#0$:]X.UA"X5!A'E"1,04"JS3Z= @C,'KV=2+-;TVRK*DPT
M(N6'N?\DDM"#LEY,IH-\NI0$WGQ-9I/1<)#\%RC^Z\)8Q+G>X5SO94':,@SS
MF+PQ?M11I6S96,2YC@04"2@JY?[WI+R;5F=="Z4X])Z99J'3@+-.<%IY:9IQ
M:.^MXW=5]M0LXUR%0=W:C(]=GDN)2&[I\MEM]**ZFRZTP"F.M! 60 $$Y I5
MM6$@UV;CO.UWT'M695NT+;,C@K>;X.W\,KQ2UZB642W;HY9/6U]H7<]!8T49
ML- BY-<#[1R JXPE9-/[V];LSCK\E,^SX3@?V&PZ]L,WBV9AA/"Q03A&':)2
MMDXIG[2NK*6MIYP@JY QSJ4:6DL58%74 <)4P#VO*R_-R8FK201N=X&+X%H?
M0T"<YAIBI9D6FAG#EN%"BE1Z?V?2W0'W=#(.%YI.1B,_>B?^DM-\%H$<@1R!
M?!^0\5KDT'%!*,3.2>_1:6>(8LMJ*T"R%Z_ $7U/1-^3,ZQN2X"]!(/)XF*4
M[W13_)6:_*39*!OW\U[RZV*<)TCTDJ!8+Y[V/0U:>[="&AJ ZJ+A&\] TM[I
MCM659U(L,44.,:@!4(QR+"JZH]"F5&_07;%+46:DWN&XDY+C7JU&U/Y8\AYM
MV6[F7]N"B2S0'A9H+I/WOW<Y$(?/?ERNV(]3Q)5C"%K%36B4"TG%?D1"33:J
MAVX:>R?C_F@1!N+C9!KNIN;SZ?!B,<_\V)U/[G?#]L&;+;0M(VM&UCQ\]I!U
M R(N@*8I XH*B;DWEIPJ8SX&$HB!V;GMI(LNGXT7"I$]+$FD@4@#AT,#T7C:
M#_UAN-9_C5'#,>8:"T]>T'*%>4E_B!#H6(N-IX>(<]N3D(2#R)F1,R-G1LZ\
MPYD8K3A3.BZAM4!@RAE.G>!.E)S)#!.XS9S9^ F$._PI>$\(%BDT4NCA4.C>
MZTA@4N<*.8ALJA61"C+"'==2PRKE@%,--L\X-.U^[JQ2)>X)LE=C:E/]#V#5
MW:;Z3R2/]I!'M+_V19JL[A>F!")06VTI8DXR*F#5B%$[8)%[0GK'JQE@.RXV
M"B'H22XB[4;:C;0;:??E;J^H6=<X![&EC@GB4JNE0 @O=TJPY6UFW>:.5MWE
M6P!Z".#H\$;RC.1Y=.3YF,U*0.WH PRAA=K_H10PC$ $JJ A$LA"U6+V5/W^
MXGHQ\E\=%&G1X6O3_"H?SX:_Y_ZI)M?Y#BQ9W$-DKY'$:,A&+HY<?*A<_!@5
MHS5#%CF"<2J4(AH (1Q/JX1!Q2C#3SCW_WH)@\W65V>DYT<H6J^1,2-C1L:\
MPYAKNU26":0  ZFT0!!MN#!IM4OE.&:RQ8S9]"':.PR*T%Z#K9$^(WU&^CP(
M^F0U?6*9(L(9A4)"RIGA*5>5[P^!87LU.)NQ&BF+N>6W#C>OSN 3UH)^-E=Y
M\45ZZ\1R\[2WY_X9S]""-I%_UX6O.SD]IOJ[J#^Q'37T\T"2:W+RYPY,^8./
M[N1_[:?DY%2_3<[^HC[9OWQX9^RGLZ@F#ZC)7@BRO0-QU,)'+7CUQE/=4_=V
M:/1KK'Y/7^!>X.^L3JDGA6,2I[F;TUR>IXMS''N2=D&^[N-UF4H<$1L1VP7Y
MXEQV1[XXE]V1+\YE=^0[FKG<LO#L?IJQOE+=V1_?G[Q[=_+A]*R7V/^G[<?S
MY.,GZ^RG3]:4P>NS;;))#UU3NMINKSPIWJ5BTD>@B9TOY5XD;0V2OV6C11YU
M\Z!TLYOZ>'0L>03=YSO/HA^S::30J)CM4TPU&!05J/DOH]LCL =(# =O3L9)
M5=$L N.@@-%),$3;(MH6AZ>U>C*;'Y/.1IULOTXNZ[<DRP(N44&C@K9)08L2
M&6^3HCQ&$DXBOMVS^?MN,HN@B*!H%2@*^_?-GH%0'9NKO-"D/#X7D1&1T29D
MG$[&;]9.;";#ZLAFI/"HJ*U2U//)/!MUD$1?]0#.J[<=SL:+;/JM5&P8N@]#
M>9SX;5R^?6#R*>4'$(%K#3*-050[@B07G!LFK3!E]19E+0?T>3T&H/@K>;7V
MP!OMFIJLOA)7RBX@[74+G!P41V"QX@A-I"0&(\ 5QE2I5$!4EB@1)O0BV5>)
MDN;99>O2SC)22Z26UP4HK9N.I8 *HU.H+& &>ZP"3BJ 8J1@NO-%?'=]:C&*
M2(M(BXOX=AS!:X[ E%B(E'4:$$T!)H:691J-1%"+O=49:YA=MF[FRG@DED@L
MD5BV(Q8)ZX9;RD&64F8$X!I0XI=L4=5_U=3 S0A">XA%#7;<\93U$&VR 4SD
MF2[PS+Y[C2 *:!WPXQ!8:CD!4C+!.#/&57"5S -YY[["#IN*,D@;!-NF?K9C
M<8D',:,=T!IF074E8PBUQ1HZR:56U%JAL*ZV$K1 <&^%X!OGI)?W*P+0<U.3
M#8\C-T5N.G9N>HR:UGI4(&JQ8QA2:HBE@$OEJJX^$DN"6(NI:6?M*87L4=ID
MI?;HG$2"Z13!/&K\L-JM<FEH-<Z00HQ"S!TQ2%<, P$F;39^7J>%(^PA'KVU
M2%@MFJJ#)ZS'^$K4%I$&'%F)$*4*<*M1JC&JPD",$+<9!FH/7S7=YQ#W"(B;
M09%6(JUL1RL,K)M!).4.0\NI=[&@%AHNFP$RG1+38EK9<3- 3&'DF,@QD6.V
MXQA4<XS&:4H81R@E5LI4 ^&6F2PP.%W[Y)AF[ ]..Y&JWJJ#,XWHYFD^3X:%
M!WR<5/CD,VP=D+7K\AU->>=CFLN(RX.7+^*R._+%N>R.?)%CNR-?Q&5WY-LI
M+EL3\.!K1W>88BED*8*$"HB<(XJ8ZGB?L !L!#P^3B>7PWFH^G4G:&%"-8>_
MHO\Y-ZU)0NE)%,_2'ACP(HD>O'S'0:*>+>N=*<V@E 0B+2 ATFAKJNSD5&@G
M[.Y)M.%]ZTB=$6XM@QNN3P4"0AQU)@48R50K A3C%=P,X@;M'FX[WL]M]*A1
MQ%[$W@NQ1\$*>S)EABB=(F1T"@ 3J,*>84QIO9&+^@3L-;->D4Y@IE7;G+?N
ML;OZ@$5B<(FR_GIZ<+4[^M./(Z\]?^PEXWR>3"Z3>?8UDDW79>VZ?-'?[8Y\
M$9?=D2_BLCORQ;GLCGR18[LC7\1E=^0[_ #(EL&K&%6+2O6R(]X8H#JD31P5
M6@(BC55*TU110:N0-D:6P[MAM>\=I@Z!MM-\_N'R//O:5+#[5<YP(Q9+VD2
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MY]]\7$S[5UY79LGDTFM(W? V,D_79>VZ?-$BZ(Y\$9?=D2_BLCORQ;F,\K7
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M#$D=#L#0*8V5XU13!21U&E>%.IE#4N@7HV@'_K^?OR,UDSNXK!?=AM]<9*$
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MM<.\7&KJ?1/@!,&I, 116QT7I )R\5"$=%_+,NI!$=N:1= =-NC66@TS88"
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M\-)5!PHW#\D=%+ZFY%@AN:6E '9C*MRZ";O93RWL^XR*2%X/RGJL!7 1EG6
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M+KQ%_J\WV:5_I)^ST9?LVRS8O5?32IJL ,@,I# U5& MC%=RK^#^#:8DT89
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M3&**#%(8%].>,*.8TUW*K#;G^.78LK6!E.4\GW+$XG-9M=W6JGW=.2@,TJH
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MB&G,*!><(Q1C '0QX#<A!LLDWDC"'0+@&AWFW5JZ;0^JEG<=!.]B50\JJ(S
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M6SUYC NJ07_3E\4TOY#1V??Y5OW+?MJ+.EE!;MX#Y-U/=_JFEMU#W=%D/'*
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M-D,,PH#9&$#B#H]@3(IJ-"X@-.#^8WOH.:O']K!6]1A:V(:4'AH-_!K'N$(
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MUHD44A,A"R Q Q38 DA/-%@?!23<I#1O@=0":3L@H6KXJ=&(&64HB3$EU"8
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M5,B>&ST1E#KW11WNB%QG9*NEOJ+:?GV_=(!D4<0,"-!8M/C7OYFUH(H$5Q
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MT]ABN)"[U8CMFN'L#B2"ZS>K/O7'+Z9Y\IHMBEXZ(_C5K_^59[$KWVQQ\H]
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MNEFX?# ^RR:1:5,*_SZ'.>_O*()0JZ,7Q@! :(G0"G$9K ];CQGA0@/]M,[
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MD4;QX[LH'D%>F@#639VA8,"UJ'A\>I&?+4;YQ_/62]ZO1@8QN9?(N.CI32P
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M>AR66AKIM52>*"=Q4.*6H19)--L]BG6DBA)RD=2[I-XE9.P5,CX C*(!1L0
M]X@; [7TBF' EP8NEJ*+P+CMDDNX4T!,>E]"MX1N&]7[:"MVH4% -2.A<=XH
MJYB.0V\KZS6V!]H]O.TPM(V/$&%)NUMCBOWJG.7VC-J^3;%_S/39YPRO?=RH
M\$?,FWW6N%I\G='2%/O'3+&7A$HEI0+."&NAL8" >E>)9_3&%/N'+M_U%/M=
ML>9#O-5"M:C)#L]_W,(L3^0N=3E9Q %39Y-BDOUP'$=NYX\?8C]HI7+%0?;C
MZY.ZA_6D[CC?=(U*[M9Y_:\/G->$-N>U8XX HA%5BCHAC3->6JPY@%+1U?/Z
MKM.T&L]53^<J$@;*AZOQ[>D#]R:Z79]B7@\QOS/Q;0-F"%Q-/,C"5H_"/VX<
MX$^E23$Y-CZZF&1[/IS.YD&=^)Y=ANLN"FK'=;R)S?8C0P5&.9_'!@N#[VNS
MP:B8DK+V"X=7&EQ=32??P];,\]&/+;,C;=C1&1(X$C!(9- <-6-<H,"N5!++
M(&;J*9F4Z[/DW0F6L^G\SV;L?:F"_I;/+R:MN,CJMWG^(;QUH:!>G>=__NWX
M/\QD/(O:S=_SP6A^<3J8;D$=E6![+#W-RZ$1 <8>CW_CLT("AI=!:2NF.$\6
MTV*@\W"Y=UG8VB\1#0/W?9D.+H^RH+A>K$!G_&%>;'-V6>QS^Q;#<19V.*NW
M.&OV./MIEN?KK;G\%*]N)D9G'^(9CO2ZN_C7HV)/2F'-SJ>3RV)_ON6#?^;C
MN EABTZ##C$(*[H<_", 2+7'PP@27^) I'GQBS_>'+\)Q])H-)B^R3Y?Y+/\
MI9#C6\#I[&H0$'TP"K@Q.3^?!?J>_"A>,T#X8E2>;P]3_LT:ZE=+M;K-Z"AN
M5'IGBG_>;@55PW,?K;RN[2A9F;M1_/?%M+[)U>!+_OID&KCA=7$BO!V,O@U^
MS*)=<C&M5C,HL'0&K=388"ZY"0>Y@$IIY12540'#&,GXFT%KV8]6GE8F":.G
M+A;=Y11;]PW6WN_?_;O_YSYE[SZ8-YGZ8+/C/_3Q._M.??KOS'S\[7?UX9T[
M?OPKWC2TM_+*'SY^=L?9YX_A!3]8]^'8V?BOXX_OWUGU.7SP[SZH#^:=>I\=
M?PY?_.8^?.[:$G[ZXX/ZP[X+;WO3*= PX^TR>1]7;,996WS\5C[A9#(Z*Y\0
M#M#)M("4MXOQ63Z-[Q%I$<&>OUDBZS4?Q=V*Z75]93DAM#4@U YGIP%V%],\
M&D%Z-#G]YZM;;"+%&)!<NB#4 #A/?1#SRB;2'%/XNG'"&4,)0P$$&#, .DL4
M%Z43SDC#I+[7KG_P.?!5E@=-Y"K"YG21;WG;[Y^I>L-15/+0P_;E8];XG"U"
M3W)]K./I6!M/7T!RU)N[U9%'L\%@.,W^<S!:Y-EO^2 *RS5&V.;K9YO8YSVE
M\^,D4P6=L5+PWP\')\-1,4NV)M194-^S%OVB69!]BB-GIU'?TX/9\,;<V;6@
MM3'+XK.*1Y7O%:R]UEO5+_5QO'R%X@T^%XZ'^P 8<V\XLX(*'X3?0TZ$J:4>
M"D=; "P=U5HCYC TD"COG30U '-)[@?@!Y^S"L#/XXF[>AF"J^NM#./G]NW'
MT?8<75,C8.6YW9C'_L;;5OYY$-95!4=.H]ES-<O?UO]867#CY&\J5^FK7^]T
MZI?/(/ OK1# C?C 6G]BF[[A/7_BZ5D]?%:;6=N\_)0HXF;*L!_**]B X? Y
M.DN#3$^^Q5.B!)2K:3XK?$FE)[4^?P;-^3-JG3^7K?/G/)X_7XOS9S&+-QQD
MEX/I/_-YZ>D<G%Z4Y])T>2Z=Q%,ANBY.RA+5;':1A\M/!_/\RV1:N&#"\UKW
MO1CFT\'T].)'-LJ_YO&MLK,RM2:ZI*+Y,(N^J^B7BOM?^,^:,W09UY[]GW\1
M",)?JO]YCH9SPU]56##0O2F/W.B&^;W<S\I7%Y9S'/AF>!YX:#S/U.EI#'C$
MO?@]O'#T.KUMG^-KOMFK7\-N1/]/;+S<VH!/^=5D.G^;W14Z?JGVOEU*D>G!
M^I:X%7MU[QRW[LQ]6'%XK*FP;Z2,/9&YZV1^]!SE-5LZ[.:4OMLTX$_=EO('
M/_WV[OW[=Q\_'&<??68_OG^O/AT?>I<<W$'U; L2\7D2U(Q$ZD,@]?M"O86)
MV(=#;)2(?0C$3B!^,*1.('YPQ+X-Q%_4M;+A<-E*5*\=HZI\A'?X!&_S_;U-
MLM'WM?9]?8F6_5E?HF5_UI=HV9_U)5KV9WT'0\N>J_W'%Y/I_'4PG2Y;%0:S
MQ--]7VO?UY=HV9_U)5KV9WV)EOU97Z)E?]9W,+3LDS[_ZE<S&LQFP_-A=-//
MZD+O6?3.EXF]WX;SBVR:#\["3;*S/.KYPW&1(-RX])/[ON<LGVC9J[7V?7V)
MEOU97Z)E?]:7:-F?]1T,+5]4W;]V3Q;^_&Q]_[?)./]1U^.=+\9G:S<@VE0'
MR,.4GYVGPFW9CGQ^9^:[E[F1QLSK+>O>EO,4(H)BC\=F[#EC#"+) 24(26JH
M4ZIL!V.I#7\A-SLIE WLCI?VMO_Z8?A 5^9JC.MQ+)%]/SDM^^JU&S(7$;G/
MP5!O^N15XS66ERS;-N@?K18??AKL_]A7[MKMEM>VFX$L&SK<O/%JTYUK-RO@
MY[<"?7P$GXVUMH?X"&QQFMLJ<SY6GM9&CW6;V^^%VVDSG?L3,G8<&1EKAG$
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M!#-(6&BYY1QX"%G=^11X"?8D&7VWT+J4I&UYI8X( 8?0PS2!S0& C0"ML9[
M!?!AABA/N==$5=D!1FNI^ ;SMKKH8.^,B;IQ_$JM[A-X]1.\I&RR%"Q75@ &
MH#7$*B*@!I6FA#Q%/:\=[HQ=FY2OA%\)OQZ)7P' EO@E(2=$>RDPIYHKIR!"
M=>\#1U>'"773+]<WL $PS:5,8-,/L&GE@6.KO+9.(889]$1B"$6E+!GDW ;=
M2ET, B1++X%7 J_] B_:@)=!1'H/1?@/@(8B17!5Q(*]8=+T&[P.R-([$.6K
M4Z/"M@QD?5]? FK1U(%K[Y"Q3FO!3;!J'38<UREO%C&Q'RZYC:#J)@8G'C&.
M#@$/$TST'R8P0$N8"+H=L@XQ0"!4P6@ASE0-]XC57F[0\]5%S_VVC=%D1B;8
M2;!3PPYJ4JL,LQH!'/^C#0/<(TVJ/I^8:;XGJ55=-2.3PI.0IRO(4]TS7O$$
MJN\2ED@#2PP2Y:P"@"+NE-<@P%&E#2GB^)YXM[J"(>R(";Y##%F/U1+ )(#9
M+L"P)LM3"T0L\AIIY+0AW M8 PQ10?G9#X!)YE8"K 18_06L5EJZ00HQ !%S
M"%@$E.*HCO<!0_4&,SN["%A[8*@E)>O%PW@;G]C]>3(?C+)99/'7\\#CV;!A
M\@38!^D\(Z"I(@<4(Z>@@IHP*(/JR"BOJ\BY8<LJ\JOS_&V!D_/K..F^GXX6
M<9%_ST=GGR>_#>81E'\<>HP/@2,.:/)Y)<#H!6"@9IJ-T1(AK@!DP<;4%" (
M;1WD<X:9/0.,9'XF_$GXTW7\(4TNDJ ><.VHA=X+21E%K&H>:@ 6C=>KY_BS
M!]9DTH$2!O4(@UB#0<QB!C6C'O-@.AG%):*5#L2%4'X+&'0(,3Y^A&7*$TAX
MT0^\$$UBI+?>,D$<(]1Y9PT!F%>.;VLIVH:3I8L>\&0S)?Q)^+,C_*&MQ&RC
MI1>> *0DTQ1)2)RL;":H<5,EW'/\V0.;Z6!4H#X%V8I/W_+B82>3T5FXP\?8
M]C.+W%%,Z9O-\H./MN$M]&3NV%K[OKY$R_ZL+]&R/^M+M.S/^A(M^[.^@Z%E
MG[3Y5[_:\.W78*1^S2O-_6UBW[ZOM>_K2[3LS_H2+?NSOD3+_JPOT;(_ZSL8
M6G9*=;_VC(U,XWHWGN?3?#;/BHE<,4H5@RJ'[HOOZWQ$WFI:9XWP 'C'-176
M ,T8KY.TJ-5TI?]"8_6IPN@S9?#FN>F@122HNE=YXQM1R.:Y37_.3\/9/Z_=
MI6;C3X&+3<7$W8]FPDT6$Z9LB00,:P.#:&5#, HAX-00K"@&W@+-?94-081=
MG8[5(V!(F5L):Q+6;!MK6KWIE)34$^H8 ":@3  95O=HT2!\G;!F'[.TDEZ3
ML*8C6--J.$>58^'_ 8Z$IM9CSL!RG(*3:J7][J.QYFFYG(=L\-!-SCE(P)"
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M^E1]3,XO_!>_V[.+IDWAEZ]GZJLY]:/]]3&J?<A:R\6R8@QX>6RE,P!81YV
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MA7XI!N&>GG_%<-@:_"PN]D/LW.9>M;E+K_,?6XM5><,H;Y;4__O0M%3#)@5
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MQ;W<G_G%O=R?^<6]W)_YQ;W<G_G%O=R?^<6]W)_YQ;W<G_G%O=R?^1W,7AY
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M1L,A6*J1<\9(LS.IYGRZ<?+Y:+03LKAOR:5'(?_':[>O5+8\KV^2-QF 5:D
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M<\AK-LR8("=U\"9]*6O2&K1IL@DH+2JY+B47K\5XVO7/R:DO"QO6O[[V3%,
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M2$6"USH=W@;L;-'Z/G[804=AB ?8.1+88=-.:)H*F&A%8D,L0C!F"4I*;4<
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M EF%PL'+"P=?I@/WU1_IJ)YW*!Y\3$RZ8?7# /V!J@)5!:H*5!6H*E!5H*I
M58&J E4%JCK!P)&0+W5T;'9PGJM 5H&L EF=)%F]II(1@8+-1+T)JSGCL548
M0:65T+",>N,)-O$Z#2$OT\'4,5SXA2<=%HNFC]_29J?1[[?OVF7<QPL=M&L=
M$%=E62)(JFP4N\A+;R'*4)8H8,DKL 2!:54T)AG! !.?)\X)Y@9C,TD5CS7=
M!Y;4.C"NVA)G 4H"E-0:2E8@"9I!$DHE3 B(F;52 6X3.&E3;1.DJD&2>0Q9
MTIJZUBI)/;I'AP#; "[U!1<R!1?,&)%,(8:Q@''1(&U<T08R"\3.P:76.DH
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M)0*"Q%IP&BMH!!.3S'^CU5[A8:W3Z9K#PZNJBK!0"2! 2ZVA906RR"FR<(X
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M;).K_*C<CNC4%Q1>;'HQ_CYMJ7YYZ?25U?>\P*3*PFZ+3%\/3CK1Q,D >GL
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M*"8 2BP0W'KP<48<CA646S'; BP%6 JP%&!I#I9F>M! Q@55)L8PP<)A$M
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M)6<4BF/ T<"YM>?<H#\'DMJ#,* @"(,@# +G'A[G\BGGQ@1;);FT1%IDL$)
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MXZD? )TR<) I<( 84)T88#"'*HZY47P<F8YB!,TA <<;C+?7H :ILOI6 (T
M&H<%&FP*&DHSQI7##8 15P83:V4)&EA3R*L!C2IY%X$J*Z4?#_.>7+V:R5'A
M?PZ[Z8CGD?#'A-.(['TG&=<,_':_ (?G$WOU,ARXTTQ.4QHEI$A#I*V!B0:
M6)F,%4>BK5C#NU]528O]GD0"LIC:N,7\[GIZ] )>!KP,>#G!2S93_E9+1B%4
M&B",8L.L@)-4"^)]=G7$R^V=AH(MG(8&L Q@&<#R<,$23\&2Q$!A(TD<QXH
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MP.*@\NGT-J]E\^\TSUJ-_KWG"8$@^JW"FA!!(PDH=0HHA=BT;KW1;L\0A8(
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M$:0$2J9'J?Q_$:(T0#;O*0G#@&W0P6IW.D%/PK.[C,XZOG9\_7Q\W7$:BC0
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MK*]BI. KSTSX4HZ*TJO,,%]O4.;#D>N@>K"P]4!5(@%M?D+$&"(<1""A(!:
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MS<MA3=!)V^!<!,A/$HQ\@@+$HY36C7HBC'9L";E4C0VQ9I=U.0YK'-:\&-9
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MR,>Y/OSWH1 BY1 S&"4"$4I!:M/^(@@Q]]]#0X]ZTH&8/?KK:*-5$,Q!RID
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M:))4[);69=Q-&DO3#+^C]+PUJ1((>!_-?DB%3ZQXW5=I^N1>VK):G#'K&]/
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M:; 2 ZS83R0:/'SA6COPMDCI[;BUM-)Q<:=P>+6)S>5+/:>?TW$@ SHV9.B
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M6].WB!68'D.^Y12'I<]/U?V&9U_R4-TP,HN;9+4XI,ALK_W'HOVTECSA6#"
MS+*QC3$6>9V@T'[3A/!@ZE)?2/NQXYRH]I]D<.'+/!O>1GEL1,-A.A>R?F-$
MH]^Y!=K7KQXJ2.X47*C1X(<VY;:2;W.8M)D'L1.R(J/%81:U6@TNB )ZF9BL
M,6[Y+KJLLB\DURT%UZWD5M?L]VFEO6-T*EJ_D9XC4">:]YCM0RP(O9 /O=#!
MGJNK7:AMARN9:XV&*WH][_6\U_/67"!^H%8,GP!"'UJ!3ZA/F06( QQ]H <
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MQV<^=KEO$1);$X9;B!"KG7K"+:R'YE5SV8@86*C)N$&OG;UV/JO!*@:$5$X
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M*JU$0> 2AFP_L.S0-)GC%(F2M@_M59:)1@,4O9[W>M[K>7M.#P95W94?(@M
MB[D48M?!P+,MN\BW8F;@=B+D<9B L(D;)?*QFVS2<DAN5(\GQX(GJ#(<PM!F
M'%"@#\S PZX';$NSV%(DBJ(Z$40Y7CQ! P2;),,])#PYR;",._S//,D3L<UG
M63P6F1U<[/,^('/0@/L$WI(JO\/R70(=VPT0I5X(;$ #5K"&H]!<L=_V$Y I
M./Q8>G?%85OB>DUR+Y3@,B&WO=O6NVV]UJ_3>EI=586NY=@D8 SZ86"QT'-#
M72CG0,"L=FG!>ZWOM;[7^A=SKNPJ/X41Q$(?NY"YV(<F,TFHH[*F@W&PWQOJ
M8S(*-BJ];;*_P"'Y63VT' JT/(XL!-18Q;G_$%I6&&)"&?$#Z@&S:#E  GQ@
M89L.(\MCL6#2)*_?WBR/DPS#,#[#*)G(@R.YYG.=S(Q$2$>Q0+NH\'SZP +R
M]?F)RU]\=AO+98 (_+GVA.GLU<^OKP1TSZ>];?CX7 ^S;02?7IJ]_R\T%/^[
M*=SCBF@EM#G  ^A:#)H>-B&@P%-LB[[E8MOI1M1(*]5EI5,UP#T^7[&SG2)Z
MO#ATO-@0(<PJT0^"$ >6Y2+JNY;O@@!I)F8? TS"E5*(_428>H3H$:)'B!>,
M1A&KNNKW0.BZ/O/] %N>[WK(=XK>E('ED -+'>H(E&P2>;*M%IJY/"FO?6BJ
MQZ'NX)!3F2H$^%X O# ,7!"&S#*!KZLV+0\CN'(9UNW8U0'A$'5>LE'>(>'0
MQC&PQ4EC/NE1.A>=ZYZCI=O&R!I9AIV)E/:R!%UBDFIE 5Y@Q__4YEP[<0@]
M?@:9J JH41\@@CT" $&6[X<6]GU]!F$/T'8(/;2-V^$.@0_O<V==U1Z.>C@Z
M3#@BM>B=8UNN[YF4A!9Q0D8 1CIZAYC#VF']TJ9N$W!$!]ANLBRFAZ,>CGHX
M>EDXJK$&(,PQAP38-T/H --%1>MEYIG$1Z0+D<(&8,L:V&VT9NQ1JT>M'K5>
M"+5J' BFA0%D/G1(Z*#0LX+ 44GVC%'HLY7VTON(*S: 6O: 4'P2J"6C<N]F
M$1],^7OYG_)7QC >C[5H_L\K\$K^S)\Q+'[60UB27EBDD.E1?4WNXMSX%'\W
M+M*[:/*3L3J\Q<#@]V0TNU7Y;Z_*)=XXCLAU:G$]'\D+LZ=+^7! O7,+57IF
M9IHI4],BG9JV/;J*Q[^2*GR=IK-).HNE_G[E,G09CV,INF=0<+@Y,+ ]0H'I
M,-^R5'(3U]G LLD9D"JN'_#DQ_\]OAH+!5(?OTC%L&YGL^G[=^^^?__^]L=5
M-GZ;9C?O$ #X'=?;^%WQV5?&C[OQ^W$DY">>G/UV^<1./8+H6V/>M/A)?/I]
M,N./%8EB"GN,:PY0$E(40AEI"5'&E<0H8YJEWY*<_^;=ZZMX$E\GLS<"1(R9
M@"U#X*9\T@[IC7(J;PTO2:>W$4<EF29A_90;<91-^&!R8[>'UE9O& O<Y*_A
M@^2.:VR,=AUG\BWAIL1(S]9(KW<<7''Z_.GQXX?"JA.2!7UHNX$-+& RSW-=
MW]?7Z]QV]L,UU^O?8E69KC;9UV-?;_'^37,)7@YOX]%\''^^#OXS3V;W'^/9
M;3JJGK7ZVSC^Q-];WE?]/4G^WE@*]!I*08.OZIC_8^E VG;Y^0X:L]MXY^W+
MQ6W:R/C//,JX:.T\BIT%:)UTBYW<>22B*4"[LHRJ*F5J<_EU Q2ZS'=]TW>]
M@&I9IBYC:ZYH-Y5E80<=C"RK Z\7Z(<%6C0SW&TD@Q>0: (JWB33QRCT";!\
MGYG(PC8U)8.['Y( K".+W0:=_]5)B8;FJI_0(#SO^EVA!==)EL^,//EAW/&_
MWG(+Y7KGH9P,0-?2?2DR+=ORN8B[=N"[U+0@T.(<VM!?*0C8#J [*LX$].+\
M4O"L7(YTGO&E*;9;K)+8T;=&R#T+X9B*/8C&_/=JV_A/ R./=SWDUCE GX3/
M2-XN.9TUAW)=K&"K^$ ?#-@J&'#5;C# \1@FF ;<IV< .);)?%QX]Y29="D8
M\-3'FPP&% YX/')G6P\;;K71.^SK@Q6-1I3%1CZ_RF?\5\DWV5[L72IZB\WS
M>316=ICXHG"8AU'.%2"+A_,LXY(VT(]X'>6&6)21$5VEW^(WW)*-9@,C3F27
M,O['B'\GGX]GPK[DOTLR?O[,YOS%_$5BD /C>SH?C\1#C*O8B'],^<+QQ\U2
M(QWREXEG3+EE*[XO0&<B\&1L7.G"8!' $*^XF8^CS+B*\B3?$A+TP?%I?L=7
M;[CZ\V-[4X^'ER6I#8= ^7"T>$7ET;^#B#W]&-^VD(B,NXQX7AA"Z'B:BH8A
MRX+!AH\A'K&!%7HF#CR/!*9C0UUOQ#!"V)>/>;?TG(U^HXR*PEV:Q+-:,"?1
M1D9>L-IS$1)1KJM[^>%8??5.&B1&(F5V02'$9Z/)?2%E.HPVN>&'ELSR79:J
M3:6"M",57_F<5L98/VV-41JK64[GHHG$3"A4%D^Y,HI/BC7)5*I(/E T<UK;
MMXTJKHLE2A PXFAX^_!Z:K6_C;Z)D0S%58/X::2^5LQ(?4^@BT 2 52C:)Q.
M.!RE=U.Q7Z.Y0",Y'_[1)!UQM%!SC$=K@&!1PN2OU17#\J:NLYHVA.F=-Y6@
MI0'+_[S-JON*F_CL*HNC/\ZB:SZD]]'X>W2?"W6ZS?1L-HQ*ZSE50T#;CAD]
M=$&SZPAV7K8OX?G_!A?&^2?VUG _^<;E;][EN7_N7OS+8)\_?G$_G0>7NRDO
M6E3>YH;\Z?/7X-+X^ID/\),??+H,?/&OR\\?SGWW*_\A//_D?F+G[@?C\BO_
MQ<?@T]>N3>'U;Y_<W_QS/MKEM/EB? NJ]?2Y@2'S'.2AD/]7P%QB.Z0XQ;A+
MZY$S\JB=]>37S2<4N/6S7/[X7;WQ*AV/U!M& OODFKR?3T9Q)L;%'^Z]-7Z)
MTYLLFMXF0^.\ O;%Q5ZP51Y.B'DP1S#XP<6!.VI%?F#NW5>O=3G4Y%^%E226
MVANGPS]>K=DXB@ !F"&7^#8-F>U3L[AV0\P$\*R*M;G$<4S" A<SGP 4D(!"
M]5'B@8"8C^[PD^^!KXPX'T93 =_9/&Y\OVM/6_&WZF0DXN?ZZY3)NO!"J'VT
MQOS1I=%J[Q/P>>I;_&$Z'D?3/'Y?_&-EPI4+6U6FX5</NZSJ'<C^<\W!7?)^
M=_O3CE_KR,OH08^^@TM5%[VZ9&Z3O-),T>3NY5C/,O2ON<:FWZ69*^%"VMXC
MZ8TK"UYX.3?5:<'=^NA]8WQ.W5V;G7/ZCB!GL50$"+I4/=R<??GU-HMCXZ,*
MF@?\8.U*G_M69OM(>N[1[_1E\N.I?=ZQ"G??J+]CP/;UQ_,/'\ZY/VA\#@W_
M\X</[L5ESY'0_%PW3E7>>6I_F4]B-3UD#PRIY/6;Y$,@@>R%['"$#(-2R*K[
MW5[(.B%D!RA8?WXPY-C&V]AM-+F)>ZG=V-AH;.4W,3X/'1K[\W>_OOHIR%A_
M_'96Q@Y0KOK3][GL]'?<L!O'AR*]OTT2D>AP.8MF\8GV_&M\&W4X2-ZXO3S'
M[E8EV$NS;'Q2S5F+:DZ/):2+/H;5G2_"$(6>C_T04P0),8N+>1(XCD=;(]0J
MBXF$1HELHNIF.QK+1'29*);=_UND<#X["=T<$- "T\V>9+=+ID*/0CT*[8)"
M"%9MD7SH!M U ]^BIA= T[$M32UKV@CC=E!HH:3Q95"(#C V>Q3J4:B;"OLX
M&33AID)%2N^$Q#2I;X4># ET!=U=83?XA)59;=/K^/V7.!/WD=%-K/R8\XG6
MWT8M ZYJLEZM4DM4:N49VHQI&3:BG$MBL!61\GXU>JM[S)=QX%XBCMH1;>YM
MBF?;%&:%4#;T < A9;Y+N7]#'-\&NO=6:!.WW=Y;+VA30#@ :PK&3\:HZ&&H
MAZ&NP1!U*HI@RB$'(]N&S+0]U\8F4;VD6>AZCK_"R=EH@Z^7A"$T,.%JH7\/
M0ST,=4)CG_)M:H24H<]<%]B4., "MH>9 [5O8X7 1<_Q;794RD9\FT;"G\?E
MVQS;+97/96^<3N.1$<PS_M_;\WDXSR2;H O,DZ<9''HZ9>(94M4-"P<#6A$H
MXC!P;(8=P?!IAB9Q0DL';]W )6"/5TB"RZC4":42C=$:H0&PCZ*1?*^11Z&1
MJ*(T=1P2(M,,+=L#9NBYOA]H \9T3-=9H31]P>N4=C42H5XC#T,C#S#E:R,_
M I.J61EB(<4AH;9G^8"YGHM9H-600@?!5N](-E&T)MR*5?;5W15N)Z^BOQ39
M5^+OX9^99A6GHZ%GF0QCEQ 4!,QU&8(Z3N>$KMM.*Z_-0@)MGIED $"3#0F[
M=V;V&GE(&FE524$(A0 Y)@@1YMIH!M1WB@L\&V/"]A@Y;U<C<3-I"+U&'EZH
MO"M6K%,YDY#X(35-0$B 3&0'OAUH8B?'<1V$6HV&OY05:^T[-MZ'OQL-?U_$
MN>2D_4>:C7=H2M-,%/RJCX(?M[5"8.4_N'Z 368#Z ,3>=S11P7_G6E9C+37
MF7S+4(#0C,_74B^:8_@?F&:3Q17=,UEZM3PDM<15?1-70 _9S$$,4 N;+J#$
M+6)P.+!6.B+M*Q3>CEI2?-R^_?&HY;'&PXE9.?0>L_W I"'V?&0&S'(HLK4N
M<I>>DI>+AS^F;4VX$TWZ[X?C3IR PW\*IZ=59<)9#K$]X%&;$%$BC&U+-YU@
MON=XH)T0W Z1@39.3SP X+AODWNU/"2U="JB=F1A$#H>]D+D81>9)BY:UMK
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MM+?$_S]LA_E.1SZ:X=6T 6R>T.YA$3@PQKL>X7J$.T&$HU5",[2H$Q+N9CJ
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M""E@IJ-ZS03(LOQVV'Z+&M:.PV1/S==C:(^A/8:NQ5!4\?,1["/?19!@)P2
M, ?[FND%>!8SV_&KB[KHKF-H3_ZW$H(OKU3P0U<J(AS_$N'VA7?0HLRR^1R<
M\/Q_@PO#.__\Y5?WXJ/+@M^^GC/WPZ7QR\7GW[X8K\N_["]E^E".GY8OUCI]
MP#P\]T.,5G 7O&KY"#$TO9#A(/1M$8LU7:))K!V?0K-KH5G]E\:."6=@.:L\
M&DV=$ATZ!WHPZ\'L*,',KOK7NL D84@9PL!Q?$)L'R'=O];Q..QU+?3:/)@1
MW)[)VX-9#V8]F+4*9KC6C-MRJ1D"ZMH>]6TGQ-"A^M(<!SYTK*X%2)L&,^@,
M;-"C68]F/9H=*IJABL(1>=!S(( >=S01),@)+5O[F6$ 4:NM1#J!9O: 6*L4
MU$>(9BWD_,+]5@5N36'UH-:<3Q1)C_$Q'B5#+H*[4Z@VT[R@(VC]K(T[]J/L
M:!:GMV/ZV]I=C9S#O*S%IE.C3+,!!&X0!("Y%K,I]'2DG2(6!-Z+1-HOXFG*
M=VAR\QLW:$JKISB6BE-)63U=,)O0 %GM)<+TU7X]L/; >I# :ME5'U[;QZ9O
M8X0I 10!#)%3)%PSA[Q,PO4! BO!/;">.+">+' >+S Z=JT1G,\8L7R76DY@
M6H'/ EJTQJ+4:Z=MRO(-PJ$!(QG0-CJ/]L#7 U\/?"T"'X%53T#B$Q^XD-@>
M"X/ )9;KZ,L&TX1>2TEMRY<-AP=\V#Y^X-OL=F+_MP^K(ZCSMY\UE#+]ZN=@
MG/QGGN1&-!XGT608%R3VJB_N*,GBX<S(N?CD_2G2@33Y=H3@4SKY%HV_S<=1
M9D2S+(G&QG5RE27CL6QB,.!P$D^-;[%L_<E!\BK-DWQ@3.?CNW029?<&QR N
MV_G=:<K(QDQ5+V=U-$A3M='A2ZK#%]M>Z%B>R5V,T(&.1:F(PH@D3-<".&2M
MMY_6;4\^9[KI27ET:JQ;.G(/[9R& V2UD!;5L7.ZAXU3@ U*JP0AU[-#W_,9
M"$+B(]L-O4#G;MO,\=N-XIX$; "[A4*7'C9ZV'AQV+ KV" (!PA#D_G,L[F#
M;UNAI;.D/8Q;O%7_UVG !AJ8O;71P\8QP(8)S!(V '*A;_J61ZE-6&A!*\3*
MVF",F&'['>6/'C: 0X\>-EXTF-B->"&[C2:SY,<[_M]WT^3':6+I200%W8D1
M):*GLI'?I7_P%QI##B&JJ^DLBZ.9  PCX9\:S<>SW("V<1]'62[:G$8WL9%F
M1CKF2GN:(O+T<;NKN'3F."4USDO@A2XR:8@H( 'TJ5-D&I@6/TZ=_<7\-%YI
MN#KT4Q4WZ<'WUG:O_L]0_UIJ.Z TA!YBV/&A:V/7]SU->>L$C)!V0OX;Q>Z.
M2_VM)DWJ7OU[]7^&^EN5^D-&;<=B$#"/!@![_-] TQ!"XCGM4KF>COJ;H#_]
M>_7OB/K7THQ]%%*;,CL,"71$-3]W '2:,4:VY^\OEG9<ZD^:+(3K8V8O%S/[
MDL5W499,#/7)T\3$_<;,&MG'R_N[*1^ C'!QU4ZGT3R/3W,W6[U-ZLHA1W'%
MQA400*'@%R2F;9D8A(&I(UP.PPBT9^,^Z>(6Z!+**1_X(0?-)B^;>QNW1X#G
M(8!9,5B%#'F(^8BXMHU,*W0<H*^,/6S:N+VBDA-# *?)LN0> 7H$>!X"6#4.
M.YLQY& &(4.FYS 24)6BZMNAY<'V,MN?='2/"@$P:+)#7(\ /0(\#P&<JI&M
M[3(7 QLS!P'/)*'MZMH6WZ3$]=HC&#\Q!*!--L3M0UTO%^KR/GY!IXF%1Q#?
M\CE:C=.IS.M*KXVK=!++*N!AQ.<TCF[Z6-?QGG(6JFHJ7 JMP HM0C!V$6(6
M*&HJ7-,,PW9*L3:*=0EX.?"SS6R2!+HW;GNU?Y[:$[/6D5>47K(PP AZC(:6
MBTEAW 8^;:\FXA34OE$6TU[M>[5_GMK32NV9Z=D(>P@&Q&8^@2P(=>%U %S;
MVF/VUA&H/43]<=_K?7?TWJXZ?X:$N+[G8X=Y+D9<U;&)=4<6%O@@V%\LZQCT
MGAQ%KN8)1K"^IM^2Z/].$P./((;UF0]>Z-NWV+@:\P'T]8='?)S9L-9>PPJH
M%SB^CP.+GV(A0D[1+M$.B;G'H)5"E ,_T&A_)]LK?G<4'U?E!X0PB%P&,'.)
M9X+0 \6=++8"VX'["UL=A^(?A2';*_Z1*+Y9*3X(*+7X_[G8<MP 8H M[<!B
MQIW8]D@'GG1@CT+Q(>J/_%[SNZ/Y5D4QS%S7-8'KN(Z- F8#VS8]%;(.^8_V
M'M.PCD3SC^+,[U0CXFX$M]SQV$AG_*_&@YV(.]?LMJ,1L7U,OI6(V=^C+$GG
M)]K>8>.CLXWM[LK1ZL"JQL$.(7"9909NB'T/0N:%VINFT(?>'NL<.79]%M#U
MQ+EY:(<M<>P7;,/8F^$]EK2+);A6+<&XC8Y" !P7$<MWG(#IFFD0(#=LAYM[
MH\C<D6*)29ITV7LL.0 L.6BL,&M880GVT#"P$37-P ; <LR"QQ\&%.TOF'>D
M6.%83=H=/1;T6/ \++!J;,(F-QD"RBBSJ$M]$GBAOLH'E(0MM^\\12R  PB.
M@G7A@$)^#6B6_'FQ4^[G"4>+]&87CK&3C>;U\S^6D[([7G?'NGYO.O>]&@IK
MYKJ!Y4 !K+P(#P<^1<BCOHDQ=EW?(SIZ2?S P>WDM!?1R\=/_P*9NW/JHP$E
M35:G]/&"'OEZY'M)Y,,UG\FUN:N$&,$0P,#W*$1AD?[LNTZ[Q;N'AWP(M]"=
MK$>^4T"^1EK1'0$L[KGGXZZ8:5:8Z7FA[_L@=)S \T-* @_2LFT-L]N),Q4Q
MYT/#3', [!8:P3XH@=WL^-@#:@^H/: N "JMU>!!C\.G;WI6:,' 8E;H>MK]
M=ES3(JT&[@\-4,D OFCJ3S<!]44KS)^Q! LC:"P?]_PJBR;#$^75VW"[NWO_
M\NKGC_$LRCF$)$/C*HOY/XVAV,^^YKSYN1Y"BWD*G.HP1 YRL>-2Z#FF*X(P
M =%-,2F!(6N/+?S)[#>-.AM=6G?OW(0#W&@GK&Z>BSU<G !<0%A5LT+?\B$)
MH..;Q#9MQ[1=G?3"C6G/V6,/W4.'"]0HFW@/%SU<[ LN:JP7G@MMVT28^0S8
M#'N^ VW=BP0#G^R1M?&PX0(-S#:\\AXN>KAX<;@PJXKY$'BAQRS/AM"#-J3\
MZ*>Z>1D-0;#'E-I#APOLM%!STS&XZ"H-9&-QN'_.HLDH,:+Q.!'":&1*_$^T
M*'J_@;F5'6Z'"N%3.CF[J\)WHL])[<<A_T<6"64^R^(\X;^=S(QIEHH_QSK(
M]\AW\GB2)Y*$<ND[IRE0IU#!0J%35=%;IA<R%YBN!8GC!H[)O(*3SH08X?W%
M_A32N1KH]'OS0SU]:9-97+TUWB/ LQ  U3+1H>LQ:'N>:0>,8!,PC@.ZAQ*A
M3NCO+YQW7 @ CJ)38(\ 1X( =?:+ +C8AZ)\W?4(L@@+@":I0P0Z>Z2G/"H$
MX"O:(T"/ )U!@%I^L>4 AZ* !H2&IN\&D#+-:6%[A,'VF*E/"P$P/8K>:D<?
M9+N<S_BVGR;VG41(S1U]$W R$H&Q=VE6CXU=,#8PHM'O\V\BD"9_RN)KH:UI
M=F_\<G[YU7@=7<_BS!@E>1SE,G!VDW$<$1";3@8&?UXRF:7C6%X7&+-T8'#U
MY_"47/$7Y?=CCC]O9$@N*H;!)S#,8OG^23S/TG@R2H<91R=C-K]+^UC<$9_"
M=M7?T/,=0203./QL#$.+6-"S]=67)^)T^XO%*4 \T%,7@:,X=7N-/PZ-QZ#J
M;.ABKO\F\JGK.F[ 7 1)D4KGV<AO)_J^4>SML#6>](QQO<9W1^,1J57RBM]!
MY(0A,IG@B*.ACK59ED?:89K=*-9VT!I/8-\"IM?X[F@\P:7&^Q8$OF^'#K#-
MD#!*D.5HCD@?4=Q.='VCV-IA:[P-CD'CCSZ6=CX9W\^BT\2Z_<;2FHV473!V
MFIMX&@>6515L6&YH.01B*PP]T_$ =TD+$S6T+7./C544EASH@06=_OJWU_CN
M:+Q3U5P@9&&7FHYE <N"+F%V8.DD4-=F5CL:OUE%YT%K/.B=TE[C.Z/Q!%JU
M,)0;0F1B#V ,F040*QH7N#!P@_;HAY^NLCIDC<>TU_A>X[NC\9A69[Q+B8LQ
M#BD*;8_KHLDT[:Z+O #M,<7KH#4>6DT2D_=AJ-;J)J/Q'VF6G";8G49.UX>_
MGDU37<PHLJLN/E_"VF^*0-:G2_:A#V4=\:%G594-@1\"S[>@[4& @8U]$A:A
M+$@IW&-&E<:C0SWU<)]@T:M\=U3>J4H90!!P,]?S[ #ZD'K4,Q$KKELMW]EC
M*]]#5_FCZ+O7J_QQJ+P):]T1**8.P- .L$,#RW8"ILF\'08#<X\Y58>M\L@^
M"M^V5_DC47E441:'KH^H#[W0L40K%,]UM&'O.X[OM$1;LEG!XF&KO'D4E]1'
M'\[RTGP^3JY/$^U.(ISUY3891Z-X/+U-(K48PUN.7FG.\>J__\M&$/Y4Q+:J
M/T^2H7%W'W-,B2?I/#?&\?R/^"XYT?2[IT_%766F,T<BK2H+ @_[_! T@4^@
M@QUD0D_7\&/HHGTR>6FP.M C$<+>\>WUO2/Z;M?J"GS7LWW7-FV& *%!Z#E0
M=^V@$'M[#'0=MKX[O=/;JWLWU)V"2MVA19V0.2#P;==$$'D J3(BP:N_5Y*N
MPU9WU!_OO;YW1=]11<QK,^!!UR&V!T-L!\R$(=17UP13@O87X3IL?>\3M@XC
MPG41SZ(A_U,Q]UTT;CY]9&W&7/#.;E4768C GVM/F,Y>_?SZZ@U_]7QZHF"[
MWQA;,PEADS[T==070M2L+H0@(]"W?8#] !#'=DP/@>(.V'$\:W_1KP+(#O2\
M[.^ >Y7OD,K7ZI0#9MFFBXF''=<.**# TU6+KDD)W6,?R@-7>;-GJN]5OCLJ
M[U0J[Q(0NF;(_T:1Y6(/4XB*0F7@FF!_0; #5WEH]?UI>IWOC,Y;M5)EZ$(;
M,8L0TP80,Q-@3_>GP0C[M!V=WR@0=N Z;Z-C4/FC#X1Y670]2[_UI8LO$(=Z
MH=RN\PD'G+NK9")[,!K?.3P9'^,_Q"X+A:W3T=_%XVB2WD7R]U/^*X$-QO?;
MU)C%^<PHRQO%GZ/_S]Z;-K>-9.G"?P7A[IZP(R@;N2 !V#$=D=BJU.UM+%?-
MW/[R!D1"$JI @@V0EM6__CV92! @M5$4(9)@]KWC$DDLN9WG[.<8WC<>&9?)
M))&WSF?5\^/):&"D=[PS+,[3V?SGKDRLL.\V_;!L97WZ&*K3\WJ8P$P V,[?
M#.1BS*X28R9JZ@O,-/(+N3:[FNGOS#3#YT[T1&PHS*7=R!-82I$,9W&VZ/0I
M6Q-,B[1:@B*>WAPG<!R'G,2:+!@'8\>+>!0P1"S/BD(S])3#,$2.O\OX/\7!
M#E1.(EHUTB2_/R1O-TX/[%"7!M@R[<"A3N SBX4JUY5Y@4=W& )X8"3_GP1F
M$I=7XH Y&.$/FN0UR>\-R;LMDG<#CS@$^Q03/S)M[-JA:UD!BS#SS(Y*-:X7
M!GA@)+_"Y6U=N4V3_-Z0O(,:IP?R/.X$3A0YOHTL&S$OC"3)!R%C)N\NT+]W
M)-]++M][ ZBRC!TGVNTV#F^']M :6SHPB![G23H.OFDU&3.1;YHF]IW LXCO
M,.*;GBK^%A 6L6!W!C&%:(?"-E?M8;WP&VJ*[PG%VTW.C,NP;P9V9$<<$V;Z
M@8OKG)F .4%WK;;Z1O&]%)0UQ?>$XMV&XEGH6HPSCUC$L4R",*6LTHW]"(B?
M[\X<=F 4O\+CF6Z9K2E^;RC>14U)9VX';NCXOF.'V&4>T+OO*0.X;3FXFT2?
MM:QA!T;QO>3QZQG#SO-BE!3U24?3GT:99^G(^(LI_W?(QC*>948N G^,^HAM
ML'U/6I_#Q,TM'8Y]SG_]/2[2?%YJOOCB9WUO^"9M^O^0*$*>2)=SL45 0[9Q
MJ.K'1 39I#M)^5'=^(N JQJMU%7EH7#1U6HR>)NY<X^=32U8:P#I%D"8M0 0
M"X&<[5C<M;&#+-N.+,NI@LTL%F"WNP9B1P4@B&ZSK;T&D , D(,&"*<!"-/!
M!",/(=="P =MV_-4"0X+66;4#4"L98OK$T!0I-UO&@#V!0!LTVPJ4#LA#R+/
M8CCP(Q;![[ZEF@K;W/&\;KJMK66:ZQ, 8-8+ -@K2YUZC;AG<R')V8S.Y.?K
M*G7P/,]&\(Q?\W*:SN+LZ;F"]1@V35:T9.F[^,W >#W<O/[=RYC0GK!I>V%<
MU(MS%&S_Q3=_*^"UL9AP!WS]M<.%V?HZ;$U>NF,AUA*@:%/JA)D^=UV+6T%$
M$'8\Q+BO;+2.Z3G=IO ^+ ?5+&E_Y" TL-UMYNP\=@*W0F9:C]* J@&U6T!E
MC=/+C2*$@C"P">"<$YGVHDT@LSW?ZL;I5=NL#P]0G:VV]=: >HB >K2 V5]
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MD.J)'YBF'_FJTW$4.F8WU0O6M_#5>*JN.E0VS\QMQG_O;=5-#2#' 2#$M!<
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M#@MF]@@\\,!B6O+0X-$'\&B5(K&H@P/3=SEUJ.E&<(&O2I&(<!B;[+#D9J_
M@[$./+U[!AZ/V_G&0.%9LJT(WHWK$3R#OCZG<#"*].=Q8N=N[7>W=K2;//Y/
MR03>HDU\QU*:QV)-SARQ(@>Y"".,;8X\;"-5E],/[(AXW?2=6,N*5P//@7)
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M349ZX>35&- 3#&"L5<DLB% 8V-RUK=!S3-.- E4[W.?$WF'+\[YA@"A K3%
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MX\0+/.K[ML6)';HXLCU$D:TT@\@-2;=9\ ^*!0N 5OC<%P$!6=I,H,%@?\#
M:OJC,QN;IA=%?N#:@4-\^$>9"2S+"CN*[UW+4MA?,-!!?AH,]@<,[ 8,3-<-
MN<]]-_( #CP/VTYM,# CU^K&;;"6S;"O8$!,W8U)@\'^@(';]"]W64@  2(;
M$]L.4&A'(5)J@L.[<B"L93WL*QA@]XCLB"]4VW$7=L:F98NJU'B<B+FEO>]H
MZ[>RT[K?RI'W2W 1;OQMD1OZ 0T9BNR((F:9EO*W!=0/;6N'78H!D61!Y'N9
MX),J)!\"*WW)$A1:[-8@TRW(M!+R.;4CTS5-'MK8H:"A4Y\I@YWML6"'H7U'
M!S)DFY$_&F0. &0.&D18 R*!2RCV,(V(%\'_\TP/^RJC'[L8>[LS]!T=B%!M
M -0@L3\@T4KY#[%C$S-P+<\)@BB@R"-<)?O:/O5W&#YX="!A;;,JM#8,BF_V
MKE[GM[A(C* *^=J3FJ;/6K6]L#;JQ3D*WOSBF[]WZ*&K_:Y?[1<TG):40ZCP
M<%J1[_DFC4+XS5:J4.AC'^^P)Y#@"(HA[(\HPIQM.BD/L[JO1E2-J!I1EQ"5
M-O'EMN<BSPLYM4/7MFT/V7Y=/]WA(>VN2-2!(JJ%-:)J1-6(JA%U"5%9@Z@$
M>PX%(35P;!(@YE+34GTKJ8<H[JX(]^,=*?824=& Z#YJ&E,UIFI,7<94IY7K
MX#@(1:8H:6QZU+8C9M>]@$,6\F[ZJ*W7Y6<O,=7=:G#R82)J[RLD_'XS&<7_
M3K)W\H]Q_%.SE>X+%'02F<R_?_]V,HR+49J/;V0!TILJYS_/;B;)O*B^.L[M
M/0I//D$-KT/,X]3C+@NHJ-;OP$6TYG5FA-S=!2;7@+.6HWXO^2*V=1503?;[
M0_:DR>!#00ATSX(@="-*PBA@6!7ZL!@':7=WH<*'3_9,)_%KJM\?JK<:J@\I
ML5P3U#6&662')L6FZM1C!YC2[LI_/QJV=_A4;^ET?4WV>T3V-EZ0/?8<GYJV
M9T9N@$+$0-"/*K)W IM'W9#]6M&ZAT_VR.Q%C=_>FZ^\9))$I_]WG(C7 Z/5
MK\D8*#C-TMCPCG,3CX)M 9MJ<N9Y$,#W'K<#REWJ!G:(5<DIQ_+P#IO5*# Y
M9*[5BZP13?4]H?I6T#6Q@H 0VP>Z)WZ(3)LZJH\D<0+XO#O+U.%3_5:C"375
M:ZI_'M73ANH]9B+N8]L*@/Y=%'%N>:JB'&.4[; ES<%3/2:ZPK2F^OVA^E;P
MJAMBQPL#A(E/&>(F89$J6$,X#>UNJF*M99@Z?*JGO? ]]]XN]4LRR6=%/DTG
MQXEY/3!- 2ID\5#2N9%?&%?S,3SALLBO9U?&%5!H/MDD:;\'>WL4_,PRF_;*
M(6?P-644NQ8R"0\CK*18CDWJ[M!BU<#,X;(T9&ZS<J,69#7A/X_P4=-1E84F
M=RBU&*8X<'S31;PJB.Y[-&3!#HU6O2!\;&G"UX2_-X1/&L)'.$#4YI$;.M@*
MHR@RD;)6V[X51=W5=7Y4@^T#X6/MIM*$OT>$;S4%W9TH](D7A#;%$7%,&CA.
MH&H#18S9W=5:/@[")[@/A-][ZQ5L,NQ.;O#HW?_=3&97\7&B7P^,6*WX*GZ<
MFW@<+*S5Q8N8A/ H#$,WX#[FW#*Q"@NV..&$[,Y:]2T1 \SY104JA\O'^M&U
M2Q-_/XB?H28G )FFPRTGM! CW!3]OA&K*W@S;H:[LUCUAOB1S@C2U+]'U$\:
MZK=LC_HF#RP:V688("L(E:/*=%T:[;#)1W^H?ZO%<#7U:^I_'O5;J!'\(V3:
M/* H(":V<119EFI&Z/+0)MUYJXZ'^C'2:8&'8, ZR\>QF-%Q(E\/[%9\"*B4
M7,:9+EC58^;5:CWED\BG)O>X%[H<_@@BJGK/8Q[QJ)OBC&M9K6HL.5RNQ7H1
M,ZRIOA]4;YNM,M<A#OV .9[O>GYH\M!#2F3ES,9A=PWGCH'JM9E*4_W^4#UN
MJ-ZD 7,1MMS(0U& >&2%=7%*&[G>#J.K#I_J$='V*4WV^T/VM*E)RPD+7>+Y
M 0+RYY9/"576:0S_F#NL5]4#LL>]X/8=](M]";N5-(YMQ^Z1948N&AT;!]$<
M=D_-7/MP0+9R''Z/BS2?EYI!OOA9WQL&ZC1YB,SS7!^''@D=SIF) @<I!DH#
MAYL[C.RJV[.W>..3&K+O)4_=JB3]V!G=6TG["!B)!AH!-&Z3_A2YH)=CZE :
M$1Y1$Q.'J_2GB&'638?DM<QR_02:;>9!'BS0:"#I!Y XK03J0/990S:A'(5N
MR#$R%9"8/O'-'5KZ>@DD3$LL&DCZ R2DR<L,0FKZ+A-^ B?DG@^*3QW;%G&7
M=]=A_$B!9)LE6?862/;)VOB,]I</A- YF]&G_+S<;/6WK__X\NOG>A'7?V ]
M@OGT@27.X'B?7%7O0]C\6^M^&,ZKO[^.W\";Y]/]U5^?L'U[8275BW,4<L2+
M;[[NEGW(W;*=EK'9X50T:* XY-0Q48@0J=.(&3)9-Q)7;6Q^6&3Z;?I'?C59
M^NW)HE/UC*WG!PS,K5:S.\RFV1I8-;!J8%T"UI9QW;=,9LJ*HCBD?H!8: =*
ME?6<B'>3I%D;UP\76%U[F_7N-; >(K >+7#V%AC=EK/ BP(S0(A;E$>^'?H$
M9,\ZO(';=M"IL^!0@9$.3+S-]!X-?!KX-/"] /"UG!N$.,1D#G>PX]FFC1CS
M4 U\)FC@G3HW#A7XV  YVTS&WT_@ZWVF_L=TFL[R0F/^@2;J?TN$JU/@6WYA
M? P^&L.K/$O*65+DV7%NZE'D];C,:37YBQQ,.0J(0VT:X0!;CFKHBQEU[-V%
M)2MP6<L/O[^<CNJ4/DWZ>T3Z3JN7-R6>AT,/)%6?A=2B6'7U]0-NDF"'@<(]
M(7U3E^[0I+]K%7<M7$ PE@88>$"0XQ"+.8PBT[)<$H8*&$+">7>I2H_&Z_4#
M&!S2@9MYSW1?C1I'@1JX*0)FFZ[M!39S0RMP<(A=FV"5=Q121+MSC1X):J"!
MB;?9>FD_<:/_-K.; B9SG(BY6Y/9K?V4%Z03F/CL_<G6-CB<IEDR+6\&QC0O
M9R=PV32!Z1J39%[$V64:&_%D9(S2^%Q^/87'3.&B.)-7Y--X=@7W7J3G (PW
M\H9!\XNX(4XGQFB>&+/<**?I!&X< BD;Z>2/>:$K;O96=P=NRYIZT31D81 B
M)W!LCP>A%UB!I8KO62BD;(=V.PEP!\YL"=5=#C7I[Q'IMX*[?=-FD1M%CFE%
M 7(]!Q%%^J9%@X[ZFZYGM^L#Z:,!LG5O8TW\^T/\0/X-WP^0%[K8(H$5461R
M$W3MBOB)&[D=]8E8SS;7!^*WMYH!HDE?D_XS2;\58NL$H46)&X04(\<*>8!M
M4I$^(T[ NG'5KV=@ZP/IXP%ANL/Q(9C0/N?%C[@<'B?N]2#L[->;*8P^F91
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MZ0.KDL%Y.[E*Y/00-O_6NA_>_NKOK^,W\.;Y]$@A=[<FM%NGJ;,NC)-D>E7
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ML$1;#8/68*G!4H/EBX)EJ\ROS6@0,A]33I"+.;-<!99^8$<TZ"96=*VP\5Z
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MZCS@:V#;@JD9@F'?7CAUWW!>%, LQ2$JX;_RL+Q=08D6 MS%"C2 OTBB8$<
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MD[5&09#ON=C#$?PG]#EU7$IJP+%LCPK/UP.C>/1V^Q!YPL5#/&&-H[H--9^
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MMGM/N.ABG^B#]7?CX9^7@%N3D3@$>?&^X]Z(-47%SS/+&%>%*)#PEQ(Y&-:
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M?D]C@&C W=\6"I8(>EZT!UJ\M>5$7]18&*FP.]#0@.3RX9\#67"@*!/C4U[
M8XWOPC?>UBL7:=BI3(VL:K*+@CL@)4WG0AN_$!]7:HFW O%4;95T+ K= ,!G
M-U6LKXP.&C0J:K,D;^O4ZJ6G7,MB<B+6<N,-MNR_/4O/D>'?]7@K[5CMBA+7
M!9.L#N*VAT[)YD.OE.PE6\&MO12-P2^$TK38RRJ'[/9&W'[:=1W"_J,*O)<K
M</=12%MQ&K6>+4(RANDTKF-PL[SRODA] S1D.!8K:>,BPE'ZAN3U<& !NH5+
M!NX4=+2(Z%@JN22".]+I(LFQ2,9Q.JE^ /8F:*/EW:FF$V>W0DL4,9Q.AF_;
MB>&5$),8'N"/\3H&TLNS[.8$MAR>VQ0I$"]O/>%-RYPS+43LI:".:18+@)'5
M_G-1(E%&NXH(D7PR4?4P%CZRUCX<HBAF!V];;SV="*22KWUO?,R![7T':#,"
ML1+;*C?RW"8QJY5)5K-,I6.O(BZQTG#^9.Y$6>4=R'/U,QU7._U7VS0-&'VF
M['>K&UPFTUC9?:I3,Q#/J&!]^4G$_)MQ%9>J6O5$1DV)/"YQ)L4_TT6F<[NX
M6:7-;ZY_;D%OVK;UZ!D*T5OC3,1-#P&O+IL 3[5W2_4<ZM Q$9RMMJ@Z"5ER
M*1*G18Q9;4A<0K<6:,K'/BKGKIN,TE%LK 24N\J^RM((=T3-KL2T5T<M2LX+
M / ZQ](>*"RMCF FCK>,_=O;=.H[T]8?R\ZY RCV:W8KV>^'66+NA2ID;K#,
M3W[/F33GO<2;ZBS_[4YKZ70^]/H-4?KIT]PP:.')+XHD'ST#=OCI&5;QS;/S
M>KI]K4"@3;#)?BHTV)M@TTLDJ3RT2JI@X :U>U^TP-M=&L#JT%_0Z@Z+68A
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M1#.0R !7YP", ,>P_2 _?I,%SY28V2JB]N[CHGS:MZ6::,^9E?W42=E[L:J
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MIN@H K%O;,^77@]<+T5%YISR-X=8>(J["[.60 KJ(3F/$-O$UDZ,( AV;+!
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MKXQ'Y%DTV^=\D59;>_I(G+<'RFZ?ZV\%R^!CUMSSF8=7<H65 LO]V.\I*F-
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M'BF'A)Z/BT()PZTRK4GJD%2=H(2C0J0HI5H_&:C6^[HS./WP>MF24SQ6%F+
M2D?AXIH[(5CT-JUT<2'RS:#AH8P#\][/UIJL9"^X$=+XI6[$,G0=YZU);6]*
M(W5 3.GS)"U9@@Y1&6S/C.ILCW!;5BRE,LFHI&;^!-_)4@MD7H%'Y004RA1F
MR/=!>E">ACP-0455MRNB5SD%66I74VK3D8LR]JASLO((V>AY(NE 3/#."S]]
M%=B6%XWT77UJ-<E>>HR\8)?\9AUK>OGI1&5;&\QIW0 3J:"AS"9\]^EK[Q D
M)? 8:H[$+!/-K"-YOJ3 X4E,1^O,H9(/Q\19RE)BA<Q1ISZR,8;=B+,^4,_8
MF1"N.E6X^11S2]"LR)KG=[5..^([9ANH%MN@25Y;7R8HO/H_#:S8'@N532(P
MS\)V[N:E@YFV9.L*ER!U?!%B^=?N-'2E"W**/M7@&F8"ZXIQ79=:S,)ZX/D4
M3N\)Y@_=X'2U,PR/6OIM9*OJ#Z3JI&5'8^W]U,]_3$CV=53"IJS;\5495B80
MWY^=9)X@6;5%*P!K"#H>\ZW/\S1\?-"E<E,88>[,]:CD4[RX$PXEE>#.R<,=
MO5K2RZB?45*V%I*$\1IC"W"5.TA6H&:ZUM__UAOVWF*W\%BHSN!8LF;UY3<P
M&*!"(#+]$DU&>&B%Q76M]]B;_FMD.]\L5Z OVJA/TYD[Q4(^$3BA2\+8"F<)
M6!N8FVT8->B@LM#A!$L;SU -7OMW3DA:T N,;%M2&%@(110HN2F TS?E_4NU
MGGBCT"7W]L5X;B%H6_$Q>1[QXH+K=NV4SHLN][NL3/U\*J)KRI+_%9YXDB:3
M,,H2[2-Y&B<SA1J\+^@<9#Y!=5+PQV<G"?,^\S!4>_YQV6TPX'"$6?_(J>ID
MIM,A<B<WJ&<<)Z8FW66!&.)-904HUDQG>%VOFQ_G<-MC[>,3,@,Z\_/2*+[K
M8M[>WL :W7];#]A1VA.2 @C (;U.@68RDVB%K,D$KF%VY-E/1MW?&VO'>YU?
M@V5])LX<LN%@?GXP.BUFY=ZZ8/?>*+&?SQ=G4+ ^<F$EB6:514%;9NXA%@ 5
M1WEECK*C2ACR5N]S%\B,,ZS$_J&W=WR@UYT\5FCOP?ZJ5+)<HX 9A6=63Y69
M9%/L9'5]LIIB<?N-Y3$FOV*>]S&"*08ZE.@I?")],B*5;:U',S]E*CVF)%-%
MIW9@QDP.YH=-:VPNLO$LF!&5>!ILT>L_;MJ/W7,X?(&T# )E-2/MR'R4'>]F
MY:!DP:DQJL<.0%<(R_OS,>#3E5S \LZ<#^^/..'YL^A]+)@YSYB"I%/VK3/#
MB+F0)5M OPO)_]KLV6"JBPY)T4!+1X*Q^SPYODXQXS5 NP\/MXA_3R'@/)_F
M"JN2B7VWUI\=!V/U3T$<(T?%ZKA_#G\G=[L?!?"L"XN,A[X,1>>#YZ %!;MX
M$D68M*JD[?+O-]7O??'P]<P5*V<"P4&$2HW(8^M>MCJQ-F##"%-U*15_T>!6
MJ;C!G0E1HDO@46YJ,4V6LK;K,9:$Q4TC8=8W*8$985(1(;/(O'PT7HP1JKR!
MB"Q ?$(0ZF+$Y$YE[:M12W5RYPD??5/&FW2R(HEDZ:B-=54AW6. >8QD ^%T
MALG1!3>2 D>1N<[24PL?;T46RZ-2=%4Q;P@E';P#&S!P-7)!OGQ4\*#@%/3J
MF2MOX#OD#J5E< <2V-84@:2H0B-^J-Q3E,(_$H$8>]()IJQTN8Y2*U)*N_1@
M(-I)(:)CEF;"]GGS[N#JA[DOEN8AS 6_,Z%-HCU/^:C09+, >-&9. T#\J@9
ME7\&2<T!]2R)3BS4;^0)+YW'9+QT<J2'J>V*K'K8CN-TJE)YBF/(7DW,H>"<
M=3)7]G;T;_JVM$:*PYC)([\<H5&&NO*%;AKE!U<J\3 \HMEH=-:28I!B?DR>
MS&+><W_2LTIN(7\D6A\XO7P6URFH4:IC$&3C4Z;!\U@HN>+^60\"MP)/#0\F
MN5A:O:!((+@P/#IG@&!JQSK6)+S%A<Z\LFF@TPM [N%^H  &0>-Z3J(J5!/#
M=;U\O>\CUD=E9[EIYJG%0YI6+:B24O)>FZRCW<LF9%:.J"8R33('QU9Z<"3E
M,0]CK%(OU&F4O%I291?62"L$H&F939=]GSOG]-&Y4V2$N77M4-Z(J4ZRO!!!
MAR-\%RQ7D&>J*2921<"(:R3Q(+2 D2^4_K).[BRC0[@$1\OB$G:F"[.<F&F&
M=U5\WA-XDQZ6GU56E?"9, 1Y:(> M"20C#K6F&B'$N8,4Y%")U7A*IN.A3,=
M"38)005]C7)JF92C0$(R-^D42.):,C4E;<0*D4%7(IK";H0X)!)A\)J0X QD
M$'*,(@0"Q>5R&M1H)!@*%Q$28F>^,/&2N/Q,$AMRK(P\J;K$/".VVJE _8VF
M G%X>[V36TU")XM#O[?L&_CH-/1!PU^7:KSX8%WY&B VGY4K1(Y-!@K2. D)
MJTNF#X:)= U'GB!?Y5S>M5&:>4MUQF,"6 /B@/-W(BT"T'VBD[E=U+LPV(J
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MM8IT6 R]H!AR:R6&LGI^NWQU6P\]GNO6WMR$?@JB -/FC.-NH50-#%/?&WO
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M.FS6*?E\/!9.XMT(/!=;D9WP@?C^N=81)J W*)5#44>4BY9F5S2:?'?ZY7*
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M@6G:7F!]$W?6*+(#-WZZUS@?5-G09B&RV4Y>V_C\*II%6I'LC<%!&:3(RB:
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M.FV?A5YKA-[.\+!,+LWBUFUR#19ERC:7H.V@5JTB]_U2@3<F=R;W>I+[8)U
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MK1Y%[\1N8G=-V7UT7N".$+&;V*UK\-8]-J7]!( ];U+D%=7$)NY50/-AMIU
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MOPLH"4@.CR ]AX'OLA$4A&:YYY8%A&'\ >BFW H2$[X\D8!=/X"7)NY&@"^
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MVQ$Z;YIUNSO1YC)S6Y>X3=RN$[>+''0B;A.W]0C.BR^'K6DLX;11.*UFB;[
M-2VR_W[\E/EAQEX6@$O('45.F$A()"QRCF WX3R1D$A8[4;.MLTU8;V=P%U?
M<._$#9L$[E($8)?M6Z+@Z\-LF\>?B" ]55ZY#&SN LJ2?M5)<S400T=84<A"
M*%0.@2Y>E&W*,5M8")XPZ[E)(/V@/14\8&!/Z=N,AZ%O21X)FSW(:*R^]>W=
M9Q0\'07<Q0<OQ]+CBS*GTI.1Y(XS9=*=.,+%ABC-4POXRO%O^#QYZ0<>P$.8
M-ZZEA%R7&:#^2$*:5<ROZZAMQ$;S(+Z_ZHW4G^,@*V3"1Z(]" 3_WN9#J-(;
M[CSP:0BO^GD</-F::A@L?L 3-I@FN0^B>#P0(^EY\*I'NK0M0$T8.U'ZV2*<
M[GTG=H4R("#($DP$?@@E'K(=.(D4LX6]!&DS+]5EKLN<F!E@,0Q\]Q'AD<U@
M0?B8#R#(64G?16+%+^]T]6-=Q(KOX@B D1]^!^^D/QGSP.4D5[QWN>+S5YN)
M0G+%:SZJ2$]7T]YH0,\W+"\G)58BD=KUF9E)R9A \AQ(2,FX4=<02&BQ/NTC
M6]:G?22:24K&1.0:M(]L69_VD5,F)6-UM(&4C+=.-6AJ3@=2,B:8&@534C(V
M%Z:EMV\?T"/!/P)2*4 R3O"O 4"JD=(M"2H3S R(OPAF-"Q2?$5 HOBJ:0>W
M2%"9M*MVT:P274B?M*N(5D2KLFEU5B"Y(-&JH;0J51)N;WE]JW8AM$^K62BM
M!7GK8VA-G!.-^<^UJ],ID+"1!GWB%?%J/:]ZQ"OB%073%$Q3,+W3CB!]Y49"
M6W.)HL[)F4E;7 0I R#U*'<804K'H%'S[?>#3I[-LUQQ(85^A+Q%Y.7Q7P0\
MK8!7>_'<XZ,"9POHM@I!<@>0[!97IB%(5C\\:SZ_.-AJQFJ@J"X!3U/@G=0<
M>*3F3&K.Y4SM2/%UVX[0>8NN>[03X1TS-Y&)V\3M.G$[UP80<9NXK5=L3O)9
M!.[Z@GLG8N4$;@)WY<:NL[3N26>K%:.7MH[")R(AD?#%)#PKGGV22$@DW$>8
MMY/A@L(\ K<.X"Y^7L5P<#=*W[HLZ=K<!90E<(U*OZ2?NU27F<XV]' DO5C8
MF0HRXR'CJ:HN5EEZ5B!X*/#TDSL1D4189:;%!$ZJ>[^+*?QNX3()L\6]< "'
M-G-Y\%U$88M-P!R)TK8_'(8B8H,I2T34%^6VA2N"$? C>XXT>TFS%VM^XSG3
MB.>'/&GVKL?]2FUWH]G;>[69**39N^:C_AZ?HC[<\%3#TC&2CNZS$JF=1NH@
MD8XN@>19D)".;J/.?Y/,7WW:1[:L3_M>;,O]"!-6/RZ1LBY1NQ[M(UO6IWWD
MIE_NIDEKMZ%W3!LD8DI:NP13 V!*6KOFPG3O[=-+'8XLJ(L%\\JRU<""-9+]
M)'59@ID!$0?!C,8CBBAJ;L%-$47##O"0GBJ)U>RB666F%C\FY4?B%?&J;%[U
M"RP:$ZV,IU59L4B)B/P?,FWU86;]&J]A^V@XU&XX+)03C\9#XA7Q:FV[SDEJ
MM,FTHC!3;],V(<PD%<X:PMEXR<1^GH&1QCY"U.:L=WE2B1&BC!YR]X*K/)Z*
MS*>-^?(L;-3 ?+77WNN4D/^>IM<$R1(A>58\FRDALOHQKM0%GWW@[KBA8UQ-
MS'>R[H@/*1.2,F$YL3JIEVW;$3KO*'7.>Z1>1MPF;M>1VT<[D4,@;A.WJXUP
MSTY-:3\!8#< V(F<,@&@S(4P\P?PO:RU]$GACDA()*QV[^=T)P$%D;!1)*PF
M%,IS )/L7V_[EZ*3ED=H9VL+[D W+9&T(MFTM_6337O@(9L$TN4!?(_9L6"1
MOZ"09@L7.VU1'&T8^*[ZZ?W5!>.32>#?<R?,OI*8:M;CT%3,<L.&?H!J:P.9
M' H.\8-,'DVZ;NP)9HV%]7WB2R^"LL9R(",_@+HY<<@2H2Q5"+Y#F;"-;&,1
MU#-RH2NPP F4#?\,V8.,QHS;]]RSH U?+B]U4UP[FQBCN&:VP)K2! SXSU^$
M&P+(\_.>M-8JU%H[>[69(J2UMN:CGA["8]2]I1;8L-Q/=%GL65VN*M(S5Y]8
MG\3;M@))%7H,U8.$Q-L:=="4E&3JTSZR97W:-[/E22-'(9)J(R+7HWUDR_JT
M;V;+'CEE$F8C8;87W7S=H>'WL:E-PFP$4Z-@2L)LYL*T]/;M WIY15,(2 8!
MJ9H39:0/5P?A+M*'(Y@9$/@0S P:CRBP(2 9 Z2\84QE0&K8B2E2RR.YA5TT
MJT07<DIB>40KHE7IM"IPY9UHU5!:E8B_@ZU2<*^T=&X5 SQ(0_=']8J>Z]=X
M#=M'P[QV;K;3*Y!1G<9YXA7Q:CVO2,.=>%4I $G<U2#\[72ST9C F&0+&PEM
MS47F3O-X4G*6A"A"E"F(,G+O'+,H=;IY6D10,@A*6\0M)8(KC^!(#:Q7>[FZ
M3B^/M"G=?"!([A"2=!G'+$@:&70?;'6@H<B&,NT9$_ 6@=>I.?!(MI)D*\N9
M'Y&TW;8=H?465*]X,@"2MB-N$[=UY';Q=03B-G&[ZMB\P"F=YUMK0O!.V-:Q
M W;DM$UI?NWM7^/09!] /CXJ<+IM<^LHP" 2$@E?VK;N^4[&$R(AD;!DI!:X
MXD(X)9SN#:?U"FI*$3A=-M7.!4W3S1L2-B5ATT=U61$V#21 A0VF+'R0D34&
MQ+8'T@\EE,(#^*)OQU8$3_B.M*0(F70GCD!A4:'43R^YQVVN^CF,!+>G[-YW
M8E<DOQGS0+ $2TM2J=P*_#!D8S^<R CP:HVYYPDG;#$+J"2M4#W.G>36@6"A
MC$0BC0H%MM@$C"NY ]7WA\-01%A]:!+*,\+?(@QC^(.-''^@O@0-?A".@W];
MOCL1D8R@T0O?E(O7&YSI(5MV ]L0?2]*QO\>2_",,Q%/-H:6<6LL@?4V=HZ,
MH-&6!<U#T=HOP@5_:XO<D/D_83S9X+VAV6^?T%H]G41J #P]P0$PGOR2'[8'
M$IHK?P!N!Z\12Q^$+1$-[#. @;UK+>*KQ3S! [#\F#M#A U8%4WOBL "W,SU
M</%YSX^8$OV$KDH[;=ZSJ>ZO^&$Y<8CP"*8,/1-P D'W^S^X.WG[^R$\P>[$
M)!+N )Q.]ZASVF*?AU#] +R/ T8)8QDM,>!*AA$@-F*7?@SUSQ1\KWF(4)Q_
M#)7_+#POG#KWW)- M!&7'KBS],W8,C%"W$=C/ONM.E)]^C9\5&]H$I(9R>7#
MZ] _@C67. %?D- )^&T+:H)%9P!B]])WD(Y# 6,U]",^'04Q5,?A#Z'J!<S6
MJ)2-9QT0"$M(!"9GE_)>.O"M>Q%&<L35&Z\2(>6Y>'):]M< WW@)1I,AMH =
MO/]Z^9J%0GS'.MF^%;N)#94,\Q E79' \#ZHH^H17Q6H>DC8,[/A]\'Y?0>W
M@;^2B>PR=!Z\!ZP-1DHJ/NM$;!N:;Z7K#[,&QA[4.(R@W#"Q@FK&U\M9 7+>
M8*B?#,':5HPBTO#3JL4>U7;[>BT[K\HEG=.H,XT"7WS6)B))Y^=BOYS.5/VX
MK ?].1 8#WCYW7/R!24VGH4,I R]GC@KM=V-,O3YJ\U,(V7H-1]5)%VL:6\T
MH.<;E@*5<EB1'O#Z)-@D&DT@>0XD)!K=J LJI&E9G_:1+>O3/M(G)=%H(G(-
MVD>VK$_[R"F3:+2ZA$&BT5OG@30UV0>)1A-,C8(IB4:;"]/2V[</Z)&V(@&I
M%" 9IZW8 "#52%28M*L)9@;$7P0S&A8IOB(@47S5M(-;I%U-*F&[:%:9"5E.
M2"6,>$6\*IU79\0KXE6% #SH;@5 DJ\V#K.DV-<00VOBG&C0?S8?U5F!E+0T
MZ!.OB%?KDRV>%#B>0[QJ**]*%5 YI6"ZUIBE8+KRBX D?UT5M#67K^K0X0Y"
M5+F(RI,WF!!ET!+.7J+"K8+"E<;409F#@%>1^R+OI16(:B^03->C")&:(;*X
M\@,ALOJ!5O-YPL%6^SD&"B<3\/0$GE$1'JEOD_IV.1,N4NC=MB-TWC7K]':B
M;6KFOBYQF[A=)VZ?D_HV<=MXO;.#$M812'Z;P$W@)G 3N/=H[#K+&A\?G>RB
M=10^$0F)A"\F89^TQ8F$1H1YG9VHBU.81^ F<&L [J=4S#-WG_V\IG(S[>DG
ME1I+ &=_]3BD^G,<9(5,^$BT!X'@W]M\"%5ZPYT'/@WA53^/@R=;HX=T\V;-
M]MS:F[9 T>S\\LXDUKY<'1/$VE'+67JQ$@I>KVB^((;],);6&'6'Q8^)L%"X
M/?)G)9!<</WE@M6/RXJ_E\(1X$9_Y*?:P1^3/_VQ1]J^I.VK^[M(V[=A/=^P
M%)&D[4NRK>N3!).V+X'D.9"0MF^CCK*3]&!]VD>VK$_[2$:2M'V)R#5H']FR
M/NTCITS:OFJQF[1]MTYR9VI6 -+V)9@:!5/2]C47IJ6W;Q_0(^TY E(I0#).
M>ZX!0*J1Z"II^Q+,#(B_"&8T+%)\14"B^*II![=(VY=DDW;1K*IU$\S,P$.T
M(EKMC58%;B02K1I*JU*3$N\M*W'5+H3V:34+I;4@;WT,K8ESHC'_6;F! IEL
M:<PG6A&M-F0Z(UH1K2H,I;MG%$K7&K,42E=^"9!T?:N"MNXB-UW:<B=(E2PY
MLM6 3I R;PEG+W%A)P^,<L6%%/H1\I:01Z+2QB.O_NJKI\4SU-/:#4&RS*7$
M7(Z3(*G;^*SY!..@LY7G(TE@0EYIR*N[&#7I")..<#FS.](:W;8C=-ZEZQP7
MOQI/6J/$;>*VAMPN826!N$W<KCHX+R')D.$R103NVH([UVX8@9O 31*FE>[2
MG/=VT3H*GXB$1,(7[TN=%-^7(A(2"?<1YNUDN* PC\"M [AWLLYD$KB?TA'.
M2B>EW0W/D]+N<G5,4-H%GPD==N\[L2O0?A9PG,/?MK@7#J#*9O#(=Q&%K87'
MX?/?.52AA?_B'C@%.5'HPR:/A =UL.;*O3ZB@D=L($90:WPV]@3#YK38YR%4
M,D"=V<[IVQ"^)P-[9L:A'\#7%^ZPL# >A-*64 L!%1KZ#E0?F,7@[=!-*  L
M$QK@:S["H. .H!S,6PC5AT(E=Z#Z_G 8B@A;/P82SYJO9(4OQ]+CAPS910AZ
MNC@&R!&,.Z'/I#OA2GD9^A1@8BF;S-2:D8Z+. L7@>9': 'ABF"$3Z5H.V3+
MSIETFU]N*_7CLARRN4+.=[&#0]O?OI>?10?OI#\9\\#EI.9,:LZZOXO4G!O6
M\PU+"DIJSB34NSXM-*DY$TB> PFI.3?J%@*)3=:G?63+^K2/A$-)S9F(7(/V
MD2WKTSYRRJ3FK/;Q2<UYZ]2&IJ9T(#5G@JE1,"4U9W-A6GK[]@$]4ALD()4"
M)./4!AL I!K)[)*:,\',@/B+8$;#(L57!"2*KYIV<(O4G$DK:Q?-*M&%J(LD
MW0*7]@Q+AD3<(FX1MXA;>G.+0-AD$)*Z7$,,K8FWH9&<G"AQB[A%W")NF<0M
M F&304A1<N57]TB#N2IH:ZXJU#GJFK0M19 R %+]/'DD"5(&K<[L T8'QZ3!
M3,BK!GE]0I[IR*N]X&WWC*Z8$"2U@N3Q29[)!$%2M_%9\PG&06>K\=E )5Q"
MGJ[((PWFM5Z;-)BUZ!\M.+S+#C!J:W?;CM!YVRW?.C'IM!*WB=O:<SO7@CUQ
MF[BM5W">:\.@5A)/!.[Z@CO/G@2!F\!-\J^F[]*0_"N1D$A8\;X4D9!(J-W6
M%H5Y!&Z3P+W5[ED=P5V*!O.R?4O47%X6I"7=Y;>DN_Q479[67;:%BWV6Z0XS
M.Q8L\M,/I3<4EA(S!HB)<.'AH<#/A8,?WPL6QL$(?0*\R+>$C9J[+1:.?643
MZ;51FQGED<=^.)$1RBA'?)K(\DH7GKD7]L++  I1X#M*OYD'\!%4"-$%K? #
M-A4\8 !ZZ=LKR:!(HO?EP% _UD6B]S_<^>X',C_G29]W/?!7:KL;?=[^J\U,
M(7W>-1^5KA+;U[[)^WQ7OM[HDYQN-><C-;U(O.CB.E6(:E0OAT1RNEN!I--(
MD)"<;J,.E)/:7WW:1[:L3_MFMCQIY"A$<KI$Y'JTCVQ9G_:]V);[$8W5VDV3
MP&Y#KZ@V2+F4!'8)I@; E 1VS85IZ>W;!_1( *X!0-HBQM) $JX&%JR1Y"@I
MVQ+,# A\"&8T'NTHU"$+ZF+!31%%PTX-D98K*>GLHEEE7D@\)?T2HA71JF1:
MG72(5D2KZO!WL%4"HB+90:OV( W=$=0K>JY?XS5L'PWSVKG94XJ>B59$J])I
M52 +*-'*>%J5M9!79O(T,FVSHDS22*TAG,T7M#RBG7V"5*F0.B?57;T09>3Y
M$#H)4G,057..H'.B2?-T'55,/4C?[=#=#H*D5I#LG!$DS8+D'A:>]@*\/)L(
M9#Y=S-===]2#Q"M)O+*<8)T$[K;M")UWMCJ[408S<^^+N$W<KA6W=R(J0-PF
M;N]S'IQGR8T$B@BGU<_$"AS&(_OOQT^9'V;L94GA;"=0)B=,)"02OIB$O9UH
MT1,)&T7"BK84=J(R2@ P!P#K?)?>DG\/L^V"4N3^1H'_$(U)[>]M_=3^YDI_
M@0AC)Q+00X'OLL3D,YV_%AOZ#K@60*LRI70GW(JP)=*SG#A$&3[X(1-62PV.
M:8W8QPQ^7X1T!W$0"A>E_:Z">,1N91B1*!^)\F'-OTD^"G@!3;X_)G_Z8X\$
M^?8NR'?^:C-+2)!OS4>E"_*57B#U?*D%-BQ7%UV#>U:\K0J%ANKU&$CACT!"
M"G^:7S_15;2F!FVM>_O(EO5IW\R6O4:.0J3P1T2N1_O(EO5I'SEETO-3B]VD
MY_?RR[0[-/P^]I])SX]@:A1,2<_/7)B6WKY]0(_T_ A(I0 IKWH? 4F#@5-7
M4)&L(,',J/B+8$;#(L57!"2*KYIV<(M$%DG/8A?-*O,V#JG!$:V(5N4GW"%:
M$:VJP]_!VEN6+VTJJ2SJC]F=+K 4"J6U(&]]#*V)<Z(Q__G4.#3F$ZV(5B73
MJE<@80C1JJ&T*C.4/NE3*%UKS%(H7?DE0)*5K K:FFL GN592*,!GA"U>6GV
MB&0E]8*4D7OO!YT\T_U<82%%?H2\_&O[A#P=D5=_S<+SXI(CM'1#D"QS@?ZH
M>.YZ@F3UX[/F$XR#O:T7TO!,P%M:J:XY\$BZE*1+RYG;D;SAMAVA\Q;=^4Z$
MX<S<0R9J$[5K1.U.A[A-W#9>N33?;L&+FVM"\$[@KB^X=R)'1^ F<%=N[%K+
M2'9WHL5'X1.1D$CX8A+VBN?T(Q(2"2G,HS"/P%T W,6/JQ@.[D9I\-K"PK;D
M?IY$>)>KHY,([P,/%X1X[4#>"X\-IDRX(A@!.!E\\EU$86OA6ZDL;Z+:B]]1
MLKVN/Y".C)2:;Q1("U$7,CL6+/+9Y:=O-U?MSODATQB?!(U'T.!.Z*>*R\)&
M7  1P>0Q_'#O.[$KF A\)<&<&MI%2+1#/PXLP4;"@[(M>,B=B$BBG;.^QG1?
M;-FQJC^22'G5E:YKW).NM@1'VE]=A59_CH.LD D?B?8@$/Q[FP^A2F^X\\"G
M(;SJYW'PN#4D+OWRSE<_UD5<^L)Q)/>LQV=0MF?DP3OI3\8\</FNI:97Q:,?
M=\Q"^8\LW@CIZ=ZKS1PBZ>DU'_7W^!3UX8:G],TJ6LI<S1SYYYU,59]8:)Q+
M^W8:J=]EIO[SCCJ#<+*Q:W27@"Y=STVG*S.5.453E1?R&D_;+2]"%:&*4/4D
MJI[3TMV/RFCU([5F,MD5AFI5J"OOO[D-:")9M&Y-)*_]<J]-.MJZW"#7-F(V
M-9T&"6D33LW"*2EI&XS3*ANH@?BC.2VLOPWSZBZ:T\(ZKP22@+01_KY&.",%
M:8UQ5A./37&%^2W<%%?H>\!)"]GD FGYS'!&I$I53K/*3#EVOE66S^4%!%/2
M#NV'6%4.$<0L[9AU=ES@FC$QJP;,*BLB*36;/5FWOM8E^M+ J/_ V&T=%<DB
M2$,C<8NXM6E\;_4[!4XN$+=JP"T- Y/N5E,ALJY9UMW4?$WO8A5H:6XEWAHM
M[1HOG'IRE"?ZI$&00/5$VXY[]5#CK1.H:K*;VLFS0V-.\QI@P,8NNM9>BO.T
MWXSSUP1*@T#9[Q?8TR=0:C34&=?"[5)K&]>\!AAPW=R8]$I-UBO5X^S?+GO
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MD#'MK[K+\#=WX@B/LFY_5;<IG?7<3.GQ'N\\*X\%_TA6H-JA\!+?C1O+^+'
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M=GE[\_'F\N*6??[RZ=<O%Q_NV/M/7]C%U=4-:KW#[_^XN[YC%Q^OV-6G.WP
M/OYPI\B#7[SYV(8"KM47X-]?KG^]N?OZY4+IQ$.)5W]<?KW+M5795,'XM-.V
M&25-A_GN>O+SI[MKQ.45(!PA69?3RG0U1-OCD!?,]3W?<GR/.^JBL4HQ'8UY
M!)/ZL1S(*&2?K]JWG6>O@<#T;"38S<W-X.>;;^K@5 C1@,.2,U&Q-WI^;[W(
M%1$CB5&*"9^2#Z]LPXJHF(.*8$14C/(4%13Y?*#+NEM:<]5R=2;0YC$$W_%
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M.:!MJK*LOYQ^*;L60BO R=HEM!D#UZP P7AVFWT1"K]=*.O"_C.^1V(D/7
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M!6I$@1*!=-#)XTD?][P>C&[H_A YW[URYJ35[YV1\R4*-)<"O=;149Z5*J)
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MC77/8M;,2^&(02!^J*<YFG&IFGC11*5$?,N(O$3>M4/$0K8O%4]8?C#!G%G
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M:DPY%S(X@P2VP+28F#:J4TQKR+-<+DR+/'3F".L;U<47:AW.<7;T$>DC#)O
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M=Z4G0;;;1,Y'A@,EM?5T/892Y-33L9EQSB[MZ40"\>WX5%<%Y\BQY R<*_S
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M62[1-FV?VW>F3%///4_X<)/+)E(I;G)-Z_32LD 75L9 6)$)(YNAIK6;638
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MCG+B!_@ W[XFFW!H%FC*494U.U!FP&]?^/6R[+\&?:!O2Q& 3'M)B\=CWC&
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M@<8E5L%D\[##&LICW_$22$6QI>+?DY_.R(9(0"2.9(5-M MC;\0/LA,/H@M
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M4U/K94I2!*  5+H%A=$.-&W/XVUIU6K:%KK"$E9<AU>E4-Q8WM](=]<-E[]
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M]8ZZH [H%$,6([PN_-*-GM=MT.B*M:5;0[1'#?#/*U0I5@VZ-9SOI%O#8J%
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ME)]NS&XG&S7 X T"V\"_*+!+2/HBAO\A@Q+=%?(U,:HI6ILV97?M0*+'',(
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MW0A$NU*'#I]P+PB)"C(G>Z,I8!LJ#KW%B-1L4C5Y HXU@MD=(O 6:OP^_+\
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M#C#+B ))PAV''MXFBT+CS-5>O>!46:9<!W0?;N-U>,Q^E#'-+W*\TY]:''-
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M^H,9>W!.U#@YEY.> Q922:*R+Y#AI/WD)!FXRR%<S>3+*R6D)+?V==#^RJF
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M:4'A" 9;QC>&AB!;R5H;9U3W71Z?D<) ;\@3#7V[I8>4,95T#F#_H7H*O8K
M\4Y$1"ESBU"E-8=W>@&*C;(?)B:)8R'?%TVC9 6"DN/V,#)965#T8VK'51T^
M$W$:):;G@K!('8L+G[&LK39#IT*"J\+V$8;D=&)S4(<:8G!58\*Z^4V:>5CL
MX*0>$WC/ 1QAP#"E'C&>>=A8^"X)K=&'?!]HGJZ*,+OIW,EX'TC-BB4Z"SC=
MM9)PKH1A5X3!"0RU#VD-ZT,/3Q;Y5GI8^STV.KH9);&:Y"JIVE&I2A$1)D\
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MS??/Q86" 7&\ZTI8=U-8762+,<HF-]A-"96&'>10 473!+X>P"?[__>&T]_
M*?/3WURL?!R9AFX_;=>U!-/,MYU:)20:W4#+.$HN1HZ^N7W'$@R2 M' "I#&
MI*D&JRK9W^ <K!"M.< ,X/<"?EI(6/6J2TW+I9*T7'K6T--N$).<<HLMIMAB
M2]A-\+D_"S_";!$F/DGL&8U_P0B!A+!@"!_6)7]2(#0BUFU5, \*Z=8L86UQ
M(&]6"7XE^'<3?-"6?P +M0?(Q=C:;'*L-KJ*UM-^FOI<"ZS$;$?%[.98OM3[
M6 KK]8C_NMQ(K31\NOXS%H:(#<NG<G,E0%9U+?RXAE'"[N0%G (._ZB_'Y "
M%U'E->^J9&_$@U/^JNH2KIFVW)H%<:Q,<<VIUB#*4DKS;)HR[9;<WHW(=(8T
MKH S@Q7@+$_FC#?.0%C<$AP'ZM\<CZK&$-;_G'BLZY2Y+IF)+*]3BAT*/7KB
M3&']P)%AN*,US=.*KUO%#>4LH74T^2(&$%IU^1M\,!&42MX E'N%/M,4&VB*
M<3XM(G6:'60^A=!PK*.)%62NRP2T2V0%T)P49<#CTD \OTTH#F"@SQ23U!AR
M-].X;4-TO2<=HJO4XT^I'DO8;T;OF1D%G*Y8HPWX()D>\WR&,&U0<H VX20%
MO&KN&2-"9ODO-?.PP>:#)M,#_%=)&C% F3K9^/$YG&O?5,T3[ KT*QN_HT)\
MD297B%1B@8JK=N)*)G93)BRE9B40H8OT0B<^+P3,8B]F4J_-P^L*FWI'1:5,
MFI).$%G8"B/]X(^"W4!ICB;2-R1"1MWAS-,,B#:A1FM+Y"@J_>AD<V!$IM)0
ME=@9@B>BA&*:X2#UKP#%P_A'15QDX&Y5DK/CDF--Q8 0A2D-2\V@0:*<#P:$
M0QG<@RP J#G2R2=)@.#@P-&!L6Z=<#^<D+>RB+LK8%HUU6SH\#C8F,=R+*-"
M7\*YFIR8EFQV,>NC(,7]-/67E/="\B .[+!X]M?SO^O2-'#CB$ 5HA=,):6A
M<BSP&Q7)H@L(82J"1*W[I%,M,6"A*D'&8U1PXU4V'@N<G&[ B:]2*PA!U<L'
M_#WT\S1T^P#7X7RM!9K/I#>137V'-L&*QV$I49*%1 N%7>?<TF=OZ1NWYC[U
MPP@>VV"BPA=C 4 ?$&%G\D&X";V,U:MI@MZJ6-[F,8**Z#3U&:8/QT!TLLZF
MK#!,WO8J@T10 SL\D:"LH35) *Q:4EQ7;CH6L9B&*H$ Z"+615?ZA%>6P5@4
M!)>.H$69#ZUGNA B7<)4&"(/75%>=S?B7N"$)2\8,=/6_MY";-<K0,!VW,/C
M$DH^_&0)N'U%ZAO"W;!I=H\UYCRC/>DDBQ_'"1QIA1[#4B6/R=RW)<U^/8F3
M-"6(-ODQ(H '+=<Z."8H_0043S+Y7EOY8RJDX$)GM;W!I0^Q"TU@;4 A>&PS
MFVD&#&?;YSY-/.0T.:E)](B)@<%^3?$S#IR& (>ZXGCU')9&6B#S8)JZ;"P<
M5'"I16=U['C^]F[2A+/4J]_CY"K6$Y4(^&:;>C,^J+9K#=]326=8]ZFQCM'/
MSH)0/A:6?)CB![WJVKIJ2:F9P09;X<+ VCH$-=4[P"K0TVS-6_I76<VM$Z8:
MUP]A$T-A[J&?RB)04[QLU+M\[(!W6;P4S,4K+5.H."ITA_) &8R_&8/QR^_:
M,-76*Q)?K2H3!+)FCE')VF3HP,6! %U-G8!H*H!C2%XF$$@FE,*WY>WTP=#E
M"=Y+N5K[SY;69N0FY./B1IC59216?Q9?FL^V*KHDDTF1XCY5+F'E$M[=)418
MI8)I6BP (]*U27KAQ\R-M:*'W#^K*IX]E^XT&+:;P"9CC57#*5*-!.DBP;)G
M!F FXB*<N,R.5$J%VJB"/F-6%%3=5+]PON"2XW'_5N85"VF3%&:%5$ET?L#'
M@A.Z#$44K/=7J*#L#/#%CB="^*76?A#L$YO"QAUJDQN%Q3Z#O36 ET\@//]$
M<AK0(Q>%CP/#C"8.[TA:30#UKT=)@I8;\7/GQ!U&[%7*2VIX_<DLE(I;X1;8
M>\D>@@=D@X;BRV[^1WDMU^%)(GU0;^C%9U+=$YM5PSN?82\LF>4DU1::!!]_
M85]*D3Z!9XKTQ/AM1&"-E@0$H"^.<-7"NG--%=+4<U ?[B4XX>K" +V+HSI^
MENO/D5,-WJ>U&S6+-HCHB(@$J.%]Q/ >&!IY?6/AI\31"+B%(1E">6S0DL/<
M4+KY#?'10=H%OX ' YHB&AU=2.F7SUX(ARUY\Z5*,OPP]=:]KX#R%ZC0?=?[
M/\V)0,& &5_@&3-#7[1WC+1<+ +&[MCX C0[G(M7"L&H!<UD?+%+8:,A7X69
M % \:)V"2[ J0UABZ8 A:@#-EJ5%)%9'W]B=.#\=-+Q_)06*@A]<RJM*&9PE
M5\!E6F/T1UP:GGCN-H-T>900_BH2?WU'&5'V@X_Q?23C%4I"W_"IP7X4"-AK
M\<-J!M]-VLO6*@%3<\O?CJ5^<>PAV4*E2UB)E<B/:UZH^I@$JRY\OS/AXV)@
ME#N/Y)_0;VD>?X709$24K_BKUC&HD3,_S;V/->^CE-+_^:]6KWG<ZC>4!0=#
M[8V &*#5K/\='X$^SU_P6OW:3=='D9/+_(<T)3FH5N^K@+DN$!UUV7\TO&\S
MD:F^(-*E4D5A6<=1LYH&<KV693> *=3X#/%W&]X_X>SFF(?(A*:^G1)A :M9
MP'L4Z3S,<T,K<):&EW"NSS6DC?>K">Z^$FU"GPH#K:.C+MX)^I>4'T-9$Y=!
ML[2OBGEW*N,2'NL,R[H_%?#@ )B<T_&U;1;VGM.=0F@\1L6N>[X0SP%&DC!I
M@&3,0 L,:1[,YO!F-#""DDH%P4QJWM+<A/"1V,1H7D2(4^#BT.5%??0"_#9!
M]CZ*+$"!]69XB[7%,WA6WPSC-]@%+F[;F'S,VVBHF%,Z+3K%MBA2_ 7FU9C_
MFAUPRFO4K+8*;J*C]!>5.C&J-*[X&*37HN,@OE;_6C!@.7X?I4HYT1;DJWF&
MC*D2<1 )Z"]3>(:9']#7U)/2]T1 YH_&)2) SE)QM$/72MR'FN-[BT5%.>7C
M),^3.;SMZZ<1%R, K.8SV^Q88S*:/Q?8=758Q]EEA5$2QO6(^68U(ON[=?R7
MF5+(ZFKY<J'P7!#2**4#3A.^TB E 39NZE4@YZV]!(>0<BWG)GNG\.JM1P1L
M-2C#*^]7ZR!U1 A"6!Y5I5A+2X*5@!^MF5!KC^(:KA'?+IPU8MN] I9VZ;W1
M52":@0QFR*4(Z 7&TXH%@:D@X#78<Q?%'S=S94LP&<^^8:#X=8C2M/PNW89G
MPT>L4T*89"("4KE<.X9%%](FBL5'0;(U0."(E]:H7Y0G%^C KA[&K>JF/7A\
M-ZTOS>1?]K+#06?4'G5/>X/F07=PVCH<'G1.1L/6P>E1YW34'\!W?&<;GOG9
MUJBF6]_!C5D$U%9/;NSPQRNZY3B) GD)=!<[#7 %P3&E^@;(X3]P,(]^'EI1
M1G\,7?F?*+<)SN5#+,#AS<OO@PY8_?CC]?\SN \?+4?!#OTH'P"[2_& <CR9
MIYSI.4P%QM*OVOU7[OR!<><?_IXPM=T^'NF! HP,/B$/)#@"'!S4E#^A=OJ>
M.[).M8!?_<#+[7TP#ODZ_<8:H7/2[?<.FYUAZ[39[1T>''4'H_V3TW9O,.J?
M]/8/RAKAY1S,36=N'_UZ9BR$  Y0,0-X==MZH)[A\/1U^D- T6IJ.9D$_&J=
M)?*Y:F#<)WZ:A@3+ V;7 %+5K( ;:>S9@88-QH(37A]I/"#+9R7%><P-QG:N
M94B)QRD!KX&K]N;O9B*'_U[3SU!V'_!<"RA:NE52=5.3O;'8*RE<9EGPWJ#[
M K5]0),,(3\QQ08.J22^8CZIU?'KK>X;\1:_VNH&_)/9B5-5/)3Q\-N&=V)P
M#^3U[,U[Y$; 0W#>0X\DW>$1P0?26X><2!&4:RCDF!-)$L-B*JZDQ"1APG7Z
MEZ)?OC=M%CX;2E8X85G"R%Y8D@$YN*<X#[><QM7CL,T&;DCA'P*H))@UQ_&U
MJ=Q<N?U_4@H)J[CR/<[\C-LH!/7!&$ -;J.CPI5BLD%P9R-(]%[@=G>6^ZDC
M]].-<D\B">NSLE0$" :)5LC @([Q 5!Y+/\4A=]!XBQ1TY^OW>]9;C!;K>[H
M8#08#(XZ[8-NN],YZHU.1^WNT6GWZ*3?[^UOE=DZZW_])GT2K^Y]^?:WTZ_>
MQ\^C+U\_];]]_/+Y&4S6_0Z)WM']=G\T.CD8M3JGA]V#3O]HT-WO]T?#=OND
M>]AM=;9J1RE7V_!^142+,X.+_2 E! WVX73YL^JA;PCI=(.S_7&=L\VY"L?G
MEF?Z<\(=*M('"V#**< L:X(,N?('XR6?ZT(1.M"M8_[/ _U9^A$^_AZ(E\*)
M?#)8C%1G_<9#?>YU%QTD-J,-J,@!IZ4&R7P>4GOR$][O_68IOK_+7RJ >*W:
M'6L6FQ7#X&!T.F@=] [V3P^ZAR>G1R>M_GZSUSL\;78.1ZV3.RN&%Q'WC<I"
M"HE=T=FZ4_I/84HB8(,Y;/TB#>87G: ^-30".NKD#\(I_RMU )^JB=G5CZ,\
M\S=&7-G]E2N[=D .'^.=\KZ!_?_D+X&X&C**(ZI$?:5*E+IPIJC'V'W_-/P?
M?[XX[M]-_JQ2W)TK<5L::T.]C%@YG&;G!" &L)T4GH9*5 KWS"2$I1\5T# I
M4VJH3G3=C*DJ?9SV(,?NY]BY+3N3:U2)P@KWSOJ?AZ>?/@Y>M%S_Q:F6EV;\
MC/^LNV 51RT6F[&8Q=$%)<O5N" '?=1A9PK%^EGE,@,!ZH2*+]A.% B84: R
MM.&+,%U D%U(XHL$IPPN4C^ NC</*$!%37K\2Y/"FX9IEM=G?C3UVLUV4ZYN
MDB9Z[A_6:\U,T#JUGEE=YEA<A'%,Y0XF^ 5(-0ZXX'MP$RP*F2^IS<BXNHR5
M2-^+B_F8OF,Z#A5BB<7<:V.VK!NN@#_PLAFZ($_E^X@<3F4<"U[#B7J5I-_K
ML%?U63+G]BX1 1-C&-<7D0_=32D4S8\M-A]\2;I)CT=B1.0OH1G<1@>U>=7*
M:$?J,:W&;KNARH;TTC@QQ\YM83/#!>+3V6W/M(].Y<JYM^Z<!Q<,&JEQY? ^
M12PCQD@UX:T4#.E2Q\#2I"%4J0XE7S,6NZR;T)O ODOH'<-7S;WG=6((\N9"
MT)  *F%F71_C"U7XJ9 IR]4'9LM,G@ ?=I(X!ZQW*R+.U&0%%/6HK@F'DT5U
M*JZDJ$&!S&9WSZC'?1I&D0MYY7Z(CCH]"3TJ"J<N4A9L*4SZZ%CW0JGON5M5
M[NHRJ+1%;$B*CFTYT=5M"AL 56="CLNLD)=4I*DU[ROZ!L-:26 =2E2 3Z3C
MZ&=92*@=Q&T1<!DVMP^P@CVRAC2XP<@HRF/539!EB7Q+N9W"6M$C#I-$FN3)
M!%)P<%SB0)T%V#=G3@)G'N8AEB..K2USCIQI:;#JE+PEFJ(8M:I.P(GI%/-N
M4,VE8R3?#;-:N*06+J?%AE-LZRSG7#J=QNN8-/@DTG"#/N:.@EB=TEI!6[5Z
M9ZV9"=C E3&W8U=#N=H@-RTH['KJEK6U!63E<%$Q6%[% 7_-5/.B/C57Y,KQ
M#J%6-UM!+&'B6@I,IOFHK>-I$<53*5\Z=#.^1;2LTUV=*1US;2,YD^48&6HF
MV.>4Z4G&A?2I9[@BE&6Y$,#0$D(?I#F4@:$6GN?^Y'MVDR@\%?_-#>PS-Y//
MU$!A_"CRF9JTPA/@FB*FJTT\-!LW2AY^Z>6M;.I34-+8B(0;U&S)VL*=8X)D
M=F<4[!=C*TZG3[,\3*$:0;$>4Z0F-LR@N98!SAPUC!(""HS='=>I6?OR-4.[
MSR=:!JT%OGF5(.:J%(,RZXW=\K:-P\>W;;RV[HO>T[2*000=90G$NF(S=N%&
MNV@.F;&*4IJ4N;1/F'TV;P1)=/$";9,IU8 ,<.8.2* 9?[6QRB,<K8,.5CP&
M$X&M"*H=2?[N%"?N@"OH-WE0^V2W> 8)@Z7U5DW-BI;=F@4XZT"Q+3\.;5 W
M#2'+<U7$4_\R27&![(5JOQH.X[I&,W SV8OTI3E8PDAPR4F][1H:3WA,?<8Q
M.'LT@L.N&7X,'=@IDJY&;O/QR>=OK5Y[W-8OV+2<8=0#\RD1O#!J!X4>: 39
M:;_K8$O@LCSB_)B6.M46+]\^#TG8 8?5#XI.+G2OO:.)"]TQ.^$XDK0>-M_!
MY"[*41'#N]*XL]1DB+[V>KG0 QI0QH<&/WP6'7?3SGGSKY_[>O-8G/4 %*Y.
M!ISHBEK+^4.> _!;K=5GU$X83J5+4J/[Z?Z!*WS+26 0?MU D9_7F8'6[ %%
MIK$1I!,N_:Z$31'$GC&["1NBT=+AY:$\:-!5#87D?W'?0TAD=/:XKO'/W&M9
M819Y.L9I)/^2]!&I!2]*8NCDQ).Q9K@;_=!+/XQ\<R!3_TK74#,JJ&JR7M.U
MOFEYO P%6\J-\Y!\*18;XB#88!6'D MI1V=*UUKSEZ7OEQ =$4=1+N&*M1SV
M7*>J*]P.?A2S T#A$\$3?,X$'<!4;.M<:^.,KW27QV? #% C$Z#P*1:EAY0A
MJC_!_2^3BL*7,(GFHVY',N?D O3<!/]F0KPX%A%!$ BD&,\9BI_S7V6YT8^I
M(P)U%M=U%JL0AEK4%;*"O+&:D'51 GA5V&6CQ_*L5 =HQTSEA%<5J(4-8491
M$!Q"=;1S,Z\(CE67RT1%(+Q1I7R9([2EZ$&A<MX_$_R,$Z0C,G"U36D"%> Q
M[*^X"<986K;Y' 5<Z6!S'0YKY D-(4W"'=/ YC"E%\BI$;L*H$1=#\'P)MZ0
M_[=&=U9'HEPF%KN!@^C/=2M'*>UYOV3T=KU?KM=8(R6@:A-I:ME=0%2&W(%M
M*,5&JTEHIJQYZ Z15*&ZF?N!,- >UL"=NP1]9U2=,%=C'6P;9F01^90==Y?!
MQ[N<!=Y\P[O'@_ +/A-N9M^EO5+?:7A#&:N&.;8K"L#A!E[U[VK):OW6C">G
M:8I8J7DUV1PM]:08P=ODG#AV( 7<%3_RS>D$_\P.77!C>(3/EB,<YJ"^2NG
MT:.,I=<N/T)7B$AG6R#MCUJ<\NI4_Y8J]F32(0T8O-;>(P,IF2VP-JE_GTIA
MHD"=7BUXHXY8E/:U5AX+-HX_ 8U@$Z1(8R5?6J1X]HLYRN1E3?!F)E%JX)Y(
M0S2ASY==J0W)TJP4#-Y34DO9C0W)K=OS&^MR&VYY"OE6("2^3?LFZ:TR@'VA
MJB$41RQY&(_22G(A!#4@5UVP9TU&QA3Z@L0=H;1J9C;2$'J)VZ7L1V!3C>-I
MRR,,:"57&_0Y]#_Z$1R!I:F4/D[#9T(XG1Z7T'4MSX@4 ZCTGHD4UR:%OK:^
M!:3FG1.F",G\ER*'(7VWV^J.;2&E>=[[-6]L>1[NZ/%Y.&Z%&HX.AJ?-X:C9
M[O>[W>Y)_^B@-^CWNLW]=JO?':UTG=XYA_9B;5#MAO=;+#44I%B@O'3N1^0E
MG!+TDC45#B(%:2@ 5Z/6M.<8L'BB5LIG:ILT73L$+<6A:Z;],5M_,$$;0D.J
M_*1"=,8]QJE%T[A 4\)K(>OL5-&#.VLRL%[!PQMSW$9U6/:3]@RUFP]>VOM7
M(8C\K,]REH&*39H(6[I63O#]M_>(UU<L;L#_NF&+>XM\[\,;_ZV\<['X0.@;
M3WF&K6^O(*#AMT,$LL.?[<M306QU3G3OGI!Q]NZ5(>)*JV5 N*9\KC%VY]0Q
M<[G(Q'OUCY4'-JART&H@=^TO>ZVN@I-;@R)']^C(6QC,N1(@W0U_.GC8UQ[V
MI\Z37W$+EW\[T!_U*RJ)4-V+BVL/&^B]_VKB_UQX/\ 4M"77_IFO8/\*B]'X
M&[X+2OO*+?8V^67EB:S&O4$GZ"OKYF P97@?O$'>KQ??#PCIIM+ROY^%@=0H
M3^%.K-.&=WKXYQ"6AXD&;N4SR<:W!,+GSZK=<J/5>*'EG).KI@SL [PHLYJ'
M6E,TIF.RI0^]_YI'>]R"WKKK>4(Y?A)U]:2M$)5JLCR1]EZEIO8^].7#^Q>(
MHC81/UI)G?ER.Q927Z*V^G$JJM()NZ43*CU0=E>\LK\ S91G#"QVIA!5^TQW
M$'AGD1]7QV5'CDME0ET3"ETNUU35'$(J)/5^5]3'?(STQ.F_1.Z=".M8_:8Q
M*NPC].(FS]\UDW?GU,8/3UTX"T!"!CLS6,??/(%@[WWXA UKG6:-9A;S69H4
M%S.OOTC#R&OWZ-<_3!UNKX/PD.=[?D6U]Z%U5.OMEVN%=WF@G]RP[H@D/57>
M<^_#?S_B47[P&>BT&[UN=01V] @\H2 Q9F8E2CLJ2I4VE5_IUMI'[=KA8:MV
MT'Q5CL4+>_M;XM"SYWY0<N@A#FWO5^[\*[- ^ZW:4;/R9795DBH#!.[\8:.Y
M7QV!'3T"E3M?B5*E32MW?D?=>?3;NR5G_I<B%E[[L/+F7[ $^2+)^\-:][#S
M# ]<V:_*?OTD]JMST&A7T< K.@*O51D_/%JHM/&6BF*EC:MHXK[1A'N8._(P
M!TD!TW9/.^;T F*&W9Z/5F<OM /;I#:>90->XG0>-FNM3IEW]4F>>&M-6"6L
M+RJL/]8(WOE9?W3,TFMT'Q_65\>P.H:O)^RII'6[I%7/;W3N-;_Q$VX&NO[O
M$#)#_Q[__\E0-+S5Y:_#O&CQ/O KNG-D(O?9W;U;\&*<%\:((?=0#(\<->G>
M"J=R\QF%R]_RN$].Q;L97\T GMD<DC<S1SY@P$<-'>&G#<NBBXI&Q)'MA@+-
M>=A]]CXP.PMAJ!I^>$6XC5"J87;;2;KI!:V6RQ[]BAR:3YO?LX3C5AWJYSO4
MXU=UJ+_-1 ;XG%$Q1QA8A?7X)GS[X*-ST*GU6KV'?MO"4G-PTS*$J Q$:E#5
M&6<-P;"E(LH 3-F_1K0V()D)@?5E+#?+4*5,DC@6)>[%2T&$!H E"JR9&=-E
MP_$':/<ZT6W' /K%H/'$"@$P>F_"\*WB*HJ]N9]^%[F&AE,0K'E:9+D0#\-9
MHUWIU;KMUE-OZ88- 79@V!1%Q28%$A!:Y<8L )8@B=VKS$2$# +XE,24A!QB
M0M[Q:I9X5T""+G<,:6T6!OJ25J7VG'@,@.M#JBQXQ\BBL< %$#$2?JYQ!XUK
M^&W;!]U]:12ZS:-V]W!X<M(_/.AU![WNP6 X[(V:H)'NQ6^KX<5>#-6Q Y#)
M4Q_177];R#T_%S$0&:QBP6T?8%[)Y7V>C0.JZ+ALWVPA:+5ZW>')<-@].>ET
MNYU.?W_8[#7WAZW!L-\Y&A[<60B>[1WO-[Q/@%]\CG#'WC#,)E$"S%K5NY7>
M'' G  V)/-TWO.6CT4&_=WK:'O8.1]VC@\Y)?W]PLK]_TFV-AIU69W#GM_QB
M)[O;\+X@ZK]%SKR][_O%SNU+KF#]'FP3PG&K66YE"QX.<=QJ[?=Z@\%1O]_N
MGAX-#WN'!X.3WDGWM#EH[J^RO3\8XKB>B4E=_B[U)_G[K)A+KVCY?.>H)T.]
MZUDX#DU,:2UV)2+82C#1HZ/&8;/;[!VVVSVYI8?=QT&+[N]]V!AA,;+H#:B7
MO<U_V]_\IX.#!Z!EOO:LV8VAW',\W.K#^(YZ"L2$";3>8Q #TGTLY2))WV.F
M<C1R3Z>@DW.\Y\U2,?W+WBS/%^_?O;NZNFK(CS4NDLMW?1G+ &GL.Q%<^.D[
MH!E[=W#8;';>R>NU6D>=5KO;;K:Z!_N=_7?!47-_O]<-Q'6[U9CE\X?L-I]F
MK]W0 8_12S]FVY\!^GGO0WU+FI&>P;#V9>@88/CX.6EXK9I'>4 ?0U#LWCZB
M/NV:"N5/%&7QP"(-[@-?*]$AV!?XI8C4%8#98\R\(,C)?C:5RP"?:M*H*<9A
M_B'W9UY_\F<!I-YP]?-BS']"-F+O<^-W_>^/WHG\":_+O^#?A$C@O#[)1LQ/
MD#88$)U&F5'AL/YW;QI& F-H[%=O<1/[FQ&P2\%FR3-5;W9ZK:.W#>_-69%F
M!=!MR%TB8]=LO1F_?=-^"_OPE>A(\%F WXEB=R  @&!;QN6I@+V!3<PT89@@
M.A.Y@],BC<-LIMY B1_@])KHWN"%,.NU5T  FHH_"^!,@L1+,@]SV(5L,A-!
M0>R7K%+N]F+?;HSG*_.QV^:C_7CST:[,QPL^V?/8CO8=;,>Y6/@68=D0%& X
M+NYO0A0IJ65$B"O%V)'* -S7 -SI[51VH+(#9 ?V.ZV6M -RIWH=:0?V'VT'
M]JLPXE7:@5$"Y*S22S<Z2VI@R-L4J5#:'.W!H;('F_0W\#V=^/%WT)F0B?E7
MDG[W/HDH@M8%:1"X/E=[0N5N+VR]<J\4WLL^WW/KO,54U/EWK6;KNM<^A'?_
M6.W5:MY??55"LDUZ#!+ B'X,/08K[B@ZHMJAO<4/[4=CN1/>B51"D?\P!?**
M#,#NN$NVZNA>-Y]*=70KO^<5BGU_,DD*Z>W$><8$DEY_ K2]TK.X -51'?R?
M[>#+D$>?^E;SS\<>_$ZK"GE>I> /8.5 L(W)$6X>',Q",?5.K\6DP/;#+T"&
M3@RA.C5TSBU\G69;<=">^^G8CT56_W(=B:54(=A)UVXVVY7^^/GT1_N)]4>5
M.G^-@G^#_C C#)7^J/1'67^TG];_J#HW?HALO)R_T3KT?FN<-P8-I3DVMG$^
M10]DI]O$-&T_2!:0,UFGN8Z:O4IS[:+F>EK/IVH:>/6:ZV9/I])<E>9Z\8<S
MQ9S6^Y_T$7_J]W<S:L).%VQ?T5L\_;^Z/("-CY_/MZ386+W ^SW<_YU\_=7[
M&&<Y3@\/DTF!;8)UM)VA^GV@?A\D(O-B&B 4?HHCRO*#'\&7DBXEQ#9#/_<]
M;,X8BXE?9/(R>>;A?7+_(O-@/EG,QT*^G@#GH_4UP%^E#ZK[52;Z-3F0K S.
M!W][3@>0[S+H__H"=_FU?_("=SG[>OH"=QF>CK9!T*I3=//#V'KPFW^=Q,E\
MZ9U>YR+&=N'SR4S,_><4EUL6,/"CB>J0_C6,OX_]3/S Y?SJCT6T#0LY(Y27
MK=F8H9B&,4UE*;->>=NO6\^9F/<AQ 35&_SQ;W  &^:=^1<;?&87=PW<X@E^
M R )I+-MO@&]_M@9O34N^3J@P_L@'#AO\':FH_N^@ <A=-SY?OTT]*,[WFV[
ML#!:I?<9/!@+HWG2;+5;HU;WL'O2/1HT#P][)YW1:'AXNM\]ZG8/]SX\'@OC
MZ;+VYQ__^KG_[;<;/.\?C@_S!$]I)\=IDNW/(DP)+5)GR,V,FIY/XS1YZZBS
MOSH"YV=> "W6J$H"^><04>Y@;D/>9BR\3+XJ&MD /3,6,S^:JH("5J;X P#5
M(XI8?@FOYQ?Y+$GEZH-[0-@\RQ&]QRNQ/NUHL%W!1>GL;?8DZ88W89^T-_^M
MVZ[ 3UZEC[-5!$X_I")LS9A4(=>."O.K$=8W7[5I?UM):R6MK_+Y*BFMI'3[
MGV];F*7++"X/?M(AS-O>J_WF=;W)?G%19#F]S]Z#6;!_&K_V7?;.^T7$<3B5
MWNU0?GB2;)N45[KXY]#%3R>T)8&M*;3WW\.)P*(=X/ #\E*P,0WT+.L:R%^D
M212)]&7O^^8L#>-)N/ CC\>BY2O1?;TOO@U#R/SU=>9/+61C*+*AS+!=2?7V
MFJ3Z?Z@?QDFP_/"?__MNEL^C#_\/4$L#!!0    ( $^!!E%->?3[LR$  .2J
M 0 0    <&9E+3(P,C P-C(X+GAS9.U=69,;M[5^SZ_H.T])56:7;$ME.<79
M+%9F84A*=OR2 KM!$E83H-%HSM"__AZ@]WWA!IJLLDL<-'#PG04'^\&/_WJ;
MV<8"<X<P^NGD\NSBQ,#49!:ADT\G7P:GG<%MMWORKY_^]N/_G9[^>M-_-.Z8
MZ<XP%<8MQTA@RW@E8FK\8F'GFS'F;&;\PO@WLD"GIUXA0_UX<ZR/CCG%,V0@
M(3@9N0(_,#Z[PV/DVN+3B4O_<)%-Q@1; ,'&LHI$AMAG@?@$BV<TP\X<F?C3
MR52(^<?S\]?7U[/YF/R)^9G)9N=7%U<7%]]=_7!B )/4^6@3^BV1]VW$[3/&
M)Y#SXOI<?AXA!P?9*:/4G>47L 0_%\LY/H=,IY +<V*&Y:H+)0O,Q[59D+0L
M$>:.,_#^W/L8STI*V"74$8B:(;MO&?&\7JO<EQ\^?#A77\.LCI67$<A>GO_Z
M]#A0>C[YZ6^&H?1.9G/&A4$S^AHC9Z1*.ER<2LDXBN'3B\O3Z\L3P[.71V8B
MH:PSSG2\J"ITCFWA1(1.(T)G@.'$.&\&9QU 5H'@.J<3A.;-8<0+>E#\E%7A
M<&:WT4\N'D5K54 M#2874&N;*6M7!7"R1>1?IT&Y4YET>GFU&HK(F35#$91;
M!XH/YXB;4M6@-E.<XK>YC2@2C"\?X.]ZR&S.$U3N(R(2X@<)\?*[%2 JRA1/
M9%=6'U*\U%IQ-!!+4&+E^O,[LSHPXB6?O8)K1-,.27L8^;UIS?83%) 5OV]6
MI8/-LPE;G)O,I8(O*UV:4U8P^*.-,TL2=3F'H6 ;./&2X5\K [(P 8J7'QIA
M"0K)'Z=1Z78(\)LY;2Z.L)3ZM;(8*"*F[/8NOZ_3[65+>3]/(P+M8#C$;"Z*
MH)#\L;(@'#'GDJ,?FD$(2JE?IU'Y- A$*1.*DDP*$N=S0L?,2X$TV5U^#/K,
M/AX;:IS\T>^QRD?3YW/.YI@+ J.8V-Q#$9AR//YT A.#TV &\#\3V6<P_ YR
M9.@G.W/5.4 1T[45#X\1QH""=)>?3AP0MHU]QK?-DX7'37F"(H02?5FRT:@I
M2U $VWIR,^>X*3=0Q(&Y>RNKDP2&D,$@,,'LF*8[D^:+K1<QQ?R6S8#V%%.'
M+/ C<YS[-]-VY4K%,Z,F@TZ/V4!ETJ4" P;AG!B2WI=^MVAVK?"N7DW 0\!%
M9*(_75U>?+B\N#!.C3OBF#9S7([ACUB=AJK42-1JR&K_:805&\F:C;#J'\_3
M%::@N YP17]2O].*\0O[64H*IMQ([7+)III;S$\,]+Y):[C# A%[2S;A5U9F
M&>\N/KR[N-J491A_]R#\XV@B];4V1",;;\MM^)65F<CUQ8?KB\O-F8@'X;!,
MY ^7.(K:/?P2RR<LILSJT@5(1"XY=ZCU2$PI23KI<([H1*U$US:*MN3+^Y#K
MW#XDK NTK6H[]:HSHOH,1"TCK-&(5WG4>K5:Y._E#6'S*>(SY'G439M"?IWE
M/<EU;D^RFGT8DH;$8@"8G@(3="I'EU%'D2 V<+7F=("W8SC9^BJ-YKNU&\VI
MM);G(< P!O='>VFBO_S<SPBR".C7MV-$-4%46M;U)MR15\S(%@OQ'2VNB;+E
M1JWEVOAEG%]N.R97%T6ES;W;A,T%Z PV+B9QM+H&^FXVRUJMDO+9U77N[&IU
MFSE.K.HKZBNR*5Z@;0V2,M55>I7W&Q@C^2@.=8AT@QSBO(Q[,29 7P,RH61,
M3 3:,]4N)DBNQVQBDKKNH@WA\IGW9<[,6]4B^X-X/4KAL9J,J"HCJ.NHXC)-
M0 IWL=7'(R3@+^JMJZE49#N-W,/&:B_W%I<Y8Y#6QN*M]$E,A@]*E?)6_ )<
M1_=13[N;MI[:]I&9%[6WCZ/J:ZEFXSU(K9[DZN+R*CO87$'YP:^C]DN5TV2R
MT9Y\^33C\CJ[.KN"Y@]O<G'+J 4#:6S!#P?D8,F]KQMDR^.R@RG&=;=G:M I
MT22,!*\OU&AP ()48WGX??OR?'?_/+B_D[\&+X_=N\X0_KCI/':>;^^-P>?[
M^^'@J*N8C'N( WM3+,#&:^['-R5:J<7+-EH$I]OIWS\//]\/N[>=QX-O@:$
MP6G>(F?Z8+-7YPM%KD748>K6FJT@7*[=][7;Z& (_SR!0@?&RX-QVQE\-AX>
M7WX!/7]Y[GRYZT*>HXY+5;&NIMRDE@KMOZ_;MNMH_]CB2_04/W32I:!@O/:V
M7U9%N1U<M?4"+T^]_OUGR-?]>F]TG^'O^Z,_:*Z>C7B&VO55VD8['U%A&T G
M >-H*Y'NO'7R=3N(--5RO;]KZ1/N__.E._SOT0ODZV SKK^9M[]LJ=E#]^]R
M90%3M?Q-K5O,!2(4O.R,B :''FO0*=UCN?PN9X\E052MB_ADC1C=H[)BP@AS
M"-FFB(6Y@MQHY7OE6DK7OR^_RUG_KJ7H>#YA)&H^R&7P:CWUP!-2\0@53C9A
M!D7D*_6?60*OI_^_>Q4:48W_."H^7S.<6:X94XW\AKE)D!UL:CXA(3!W^AAZ
MW@6V_#_7;2&KXJ@TI<R:>EU3\I#%;.F?1@0NMLGJ _JG$2 ,4@[5]A:8]] $
MUS61('N))B_"L5L85DCJ$4H:LN@!2?<><0K&Z_345:(9HX,IS"4[?JPDN>4S
M9+$/4V9;31OM:E64M\?W.>TQJ,_H>7>4@+"A*!OQ.@W!$A_]:@^RB;734),]
MSI5J*-WFO'R?<YIR11,XO*W..OKI*9W"##FKJ/4905DEY=.Y]SG3N?IVX-5K
M0,5G>39Q2*:@%K=J:M3+6ZZ8=WF*404/3JIW9 $S2&HU[$#SRY;WC.]R)KW^
M11:9ZM,ZS.Y.B:''\1AS+M?_F/FMA4+R"51J)3M>\;0BE_$#BH8B><#*:32V
MB)<H'RN\RQLKA.(_P'[_@5!$Y?RS2QW!W0;+K[DERSN"BYR.("1CQ.@<N )N
MP0,0T2=.,Z]4CU2Y?[IX=_FAEHKD?%G1-B3Q@_14N?+V0F20!58G+3O6[ZYW
M,<=Y8/P!$?X5V2[^C*U)P\/AZZJL4OT_U%9_6+M_JC16OS%FW) (# 7!\# <
MK<27WAWF9*%$E_>U0RTI+WF#S(0\1#2]2+#>*BLM)G.;O\AB(@P%6>0:J(_#
MB( <S::U#A\8$Y2)G=A/INY*0_I^TX8$% -01Z/**+9=R(>&-"N-('.3K<@(
MXE9PV($8\E00=O\OX\JFV\<JJM<SDWB0W9G)RQ^KNXSU0:@TFLQEZ2*CB8U)
MV+B>'_&A&0$VPP=W-+5 ST%:QW&PTN8C02-B*Y_[A)%4B=41D3G0/I;1F<$Y
MJX%CDPB)&ZR_RLBR"S>%1A:F>XC\2_DA)B, 92"1L$AJ("/$YH^J#S"@XB:4
MG!J-[,[:TD JS2ZSBKL5L\L9*AU-,)L61=YPOE".D0T&9/V,"%6&P4 /CM]_
M#)FWT#B0@E[SX'SCR"J-M.:B49'IQL#"7Q%>0P'V#%E!#GMCP8*%VPCV<7Q?
M9ALQ3P!#F=K]XCK,LG75E797>[80I<<](J!ITQD?O%'%VNO*5I)#JU+MM5<*
MXH[EJ+PB@=\"U*MU:M C>%3CEM38N(-?9Z-M77FE>=3>BEC3\.%H69Y$'QF=
M#+%\ W/4+!9G76*5ZSFUI]J2^JDD;TCZ1PWF"'U]R[JE5"MU6GL>F]+I<6VW
M5 _XM>LXKHQ(LKI7KR)<J>/,X9J:.CXUH#HCK.^H:5]2@RGC0HKIAG'.7N51
MUI657$*S4K_UCN_(*[&RDE,A%1Q5<U2K+Z FI]M*RI>?=;O(.>N6KZ[CN3=/
MJDP@.VP=:ASKN</8\!)2\P/_KMXNUU-]Y:"Z]E:9PN,W9.6IO6%TX+?C8V[Y
MI2A(_K'5KT?!ZULM7C..2HNK?3YH;19WZ.O 70NPDS&1;KT+7- )@5_AAM7/
MC%FOQ*ZY"5:76/G9WZN<L[]QRD9$.KY]%5 _*B\M[P=9(WZ$>9$%J5WJ8_!2
MTN6:;'INL/YR5W&5L\7>P$0,S[, A%-;8E ?(UQ^8I;& >YN;D+%[?JGK2"I
M-+O,TL06S.[80S73>SI7#W-3\C_!+V,U<(@R;-H$VT"IM,',3N8J-IC-'F&4
M!]^\D58,YM$(BS4?_+N!3C1%NM)(,AMF#8TD_'WL](I44M&Y;-OMK %.I55E
ME@0:6E6-WN[H?EH;9&JG9:W6E:9=:2J9N7Q#4\ELYAP5GE%*D]7A9B3+%XRO
M<A:,FZCW )>1Y:(3%8S7?N<E7J!\P23O!;!8Z<,4<B,7F"E6[MTN\Y8?(AH'
MZ; B]ALYI4RQ<L=SF>=XXI(_/,>B(@%ZP8COL P;"&2=9RSJ*:"P=*G+N?@^
MQ^5X(0G_[A'[QWE$3NW9BZ-*1!.?5$&CU$%=?)_CH"K4<XA.JTC&K6X U256
MJ;G,$F.5Y@[\ DZ1X)OT0Q4T2CNEB^]S.J7*UG9X'55//HNA'JSK,4=P+ A7
MH?!O,(5J1,]&M*:V:E$J'S-?YW1@/EDU54D2-GS*AB)]U%E"TDV<9 -ZY4/P
MZQP_65=_A^@DZP@>_%(/<\(L8OK)MY!WW>HMK:52Z9EA36VE>WXWJ#K\*"L_
M&D2^JIKTH WHE4_QKG-ZT_HM^_"ZU3Z6!Z-,X<K+A[=3Q"?1X^#2N)V.XS"3
MR+LLOQ Q[9A_N,11E:NP^)"C'PQ._+CS,@;.LBL!JO77F@:P!1SE<]*\X+$)
M4(:/*A9 7P$S(F3&*T SXMB\*/V0[32$=Q['9\0 'JUNC=INTN]L#4WYY"TO
MD.YV+? 0>[)M*;_!U=?M0CH:Y2$:9:M%JNW#JC3.S&FF+1OG@:^>;=XBVMTJ
MW0&N2E/-3#ZW;JJ'?<-U\S:1J*%CFMQ%MF8.M@QBI05GSF]MW8*3%0;XCYYW
M:Z:BZ;BA%M9*^\X<.M/%OH^CC W;3Y.URJVA*=\WS'MB9-LSL\-;+QW@B5PX
M_AFS"4?S*3$#S??Q E,7=^F8\9D"6<^:FA LWY3,.U7C4_^G$=&/F8-?A1&K
MXZC*/,DWZ>R:DRW?MLH[T]%8K8?8:S101*M1S0KT*S6>6=9HKO$#'S,TT$ZK
MBP\KT*_4?F:EH(WV#_H&1 /M^"G.S3*6FV.T(6.HJ*[2-C)S\#:V$8 P;I;Q
M8A+'T5I:J6_3/4C=>BOM)S/'7;?]'/N=YCKU9UB;-YY41976DKD'O*JU! ".
MIE&JL2;K$<W)EA^ARCN0W&+"<7AK T/T]H2$J/U,>2Q_^=FD'W)F]E#8\$L?
MI(B;N,I,J?*5X!]R9MPQ<1^BZXHDV&JR5%R\4A.9N5!<$P<^RXG$VJ2_R)0J
M7V?^(:<[2+2&O[2C__'\S;$^HOF<0-\FD_P$"@-<%'#YHTS"MG>D6"IF/L;_
M4YLWV.KC$1)2-13-\*>33"JQ;2F_3R<"TD\,QQTY@@A7DOZ9,W?^Z>1MQ&WR
MD0@\.S$$  M29HR"Q?-E%[Y(P">&ESY"M@QN_.G$5.\F!\ES=79]J @0Z@A$
MX=-Y!CZ"^CDR10 H9,>V_6M.8QO-O$X>1@#=V<RES&:3<&CYA&<CS$-^&Q=K
M(Q#**'5G'RTV0X2FY1%GW'*YOS;?AG.P=XKL)Y"J22@N8K0@E[9\]1''T+HQ
M<G"Y#LLR:LO=E_GO;$K+&2O(HR-/;()S+"^9NC/<(<X9XX+\J?*]C-/A0IZ9
M2.Z0#@B=V/C!I:9'V&=K12(;=*P6'N7[U59*I<AD/*729)I^A@B#KF4*<B))
M/\32:KJS.2)<A>Y-@2_ZNONF))']PH'^RW@LSP^DH/I[_ E&:F77K7F$#"]@
M$"^1C1EWD(WCS_F,! PZ_;\Z8^AG_XL1?Y"/_0;ONX5R6)7*+L338E1V\]2[
M2IIR(D6[9BCOVSUT?TU!3B7JAYJPYR$VIX/[%/!LNH[8Y]#H9\A?PLMPD/]5
M7SZ\P9HZ244==X;Y9XQL,35A<.HSX13PV*2D?OS#W-LFXQ1KJ43]4',T%FQ!
M4K#3J3OO9F]<!^9JCM.QR82JCE*>E OQ%GW5M1,- -^RV8A0E3UVR,]_FTXQ
M,>2(.DB-F7-9;D5!-[$46F>62:> RY0!MRBH7]O,80*F]W,& R:%R.E2TW8M
MF%C)Q3]&!:$NMEZ@7B]SP<,=X&#[V($QE3F%GW=X@6TVEU_D%(%.%*B.CZE,
MH#O TMYP@01@6Y<;VH48H@7>(7X3-S8SO^F@G7Q8*S0F$9#95'N2*X 3KWB)
MZRC,I9V?N/WWI;?F,F"V-60PG)I@"@I/\E692S^^(,.(X[<4'^E4#7%S 60'
M,!8A8V+"C%'6X*39*,^D'U=3P$C>X)_9G*1UDO]-/QYL!(-$-13ZBKGC.K\L
MP>6E>"G/HQ]/F;E2BI_B[WO 2Q_/Y2HSG7RA1%0QEI]90RXY]''+&0;O>Y;F
M*>_3SF=?<DTN>J$M7(;K6+^[_DCA,[8F('A$K9X+HP7DX(YI,E<.-"8!<RM3
MT6TK-BZ>: $3(+LS5TTP )63>A8]+HP&9?:==?GJ>E/6_3*:K?06<.YMAGES
MRAODD")N\_+M!8=U5_8;E]HS[I]A>C)\Q?8"/\$\:NK4%D!9P3V3@53C\)4-
MIX!M,FUD!N5%]T(.0X[D3+H3O(P:?7GX^MQ5IZTR,_25*.QR,AV)P(3Q%K.)
MI;+*;DGZ9_!GT#T_8_$ROD7.%,9D"[S$5L1VPU([Z>?6P_\0O=5GV\NL,;=C
MS($"P/2/<V 1G%J/TA@%L^68BHCOIL6T;?!C0K$5BV[JZ<[I@V9AQ@X=.*%^
M0('9G..IC&"ZP%X\<*EJR;@I7,0)L@/U)PQD8_1U6]N/1 I\R.- 1-ZKGMM8
M;5E0*WZ,J'R5,DX!)0M&<MUL);H)MVB*Z2_58NO>Y?!/<I)9]%&[B7((5(;-
M>!G_PKAM%;"2EV/WT^;X$OPS$[D&U^-@%V]1RPY9:UE8NSZE4+O,E."QG5)I
M)ED[N[P?C_%;^DA@.E$_U#9Y!%!+V:,@FCH=6/111R[D-FX&?2)1/]0SS.7*
MUA/BWW!ZQZGHHWY<T!%/-]=4FH:8%X0S=2@$V7W(:Q'_<HH@$_4KS4_M_/KQ
M.B<]G.8GF;;S/C%_I_G^S<2.H];#\H9U30OI-DQKQ;SWED4K$81%VPLB8&<S
M^H81"Y?75&"BK/Y]8!R3";U5\T)SJ8XLV35,H!$=O:TBN0:4G5M7YM)T*IV'
M6X7!(Z; 5CT^"_+O"<?R]@MS11\CB]C+.RPPGQ$JD8=+G]$% +5.1*T[]DI?
M$;=ZP'9LA^S6VRHA"^RM%Q0);;-5:BKW!_  9$1L*0GA6LMG5W9Z+^-'-&&,
MAA.KZFSM^2/RT!#FZ^[8'T!WU"3R4?=@^]1)G]"KR+.KDW.%+#%3WN[UYQMR
M!2PY;BGYKMVX*XRG,V0#R"O]5*B-\ 7N1X*4T<FML+3JVI?73ZV)#OB1T<D0
M?(^ZU)/2;W5&#16= #V8PI!+HKYAG+-7$*=3RF19?OUXY6@"?4:*H52B=JA_
M'OR[ZD!4>18=.<K@WSW:$!W0N%7+DA-IX5Y?RL9R(XA:T%^'O6Z=C#OK=PNX
MZ2&A>E';!N*6O>S2L?29V/HR9]3CX,[%0W;_-B<<=RG,0I1BKBXN/Q3PO2))
M327D#S=OF<M%CS,3R^VKB>/Q4RZ)JJ+:C<5^QA0/IYBCN3S7D&R9N9_T\R@8
M!AN<S=/./2==.^SRA""V)-7.6W3&*I-:#[<E/EIDYCT^V=W2 "F">J<$E&4A
M3-^Y<_^,Y4T!_^S.4I[4D//,!;)QS+%79=)TLBAA"Y"2![O=)?85:6@FF4*+
M95S6YSFV@BA"%7GT<R/,@?X5I9E()NJ)6B [!W8\53O<W1&79IF$G4[<N;?K
M6O 7&1.)@H31;)":?R,' 3E3;@I-,!L+!O(F)?EM[#@H.MB,8FOSHZ7CW67/
M/RBX<Q0ZWMSKSN9>CO Z7GH)I33'KF^-9L$YQ;AUO)\=,A(>-'G@;';+)$SF
M7R%])*8<2=%)9\(Q#JZ/#F <X+R,Y3(><ZGE]PQ],IG&9+!NJMH=@2F2GSK.
M \Q%%W'#N#A#!MP!G(& ]C1EMH6YVN<SBZ36DM9?5586L5T1'41>&[4]D5?!
MA>YG7+75OCH9[214V*LH5H?H#8.;H5C6FO))F6^Z+;?'8/;04D)+#;**O^LW
M2HRPJD%)#@]!>NWI_70I!TSN"&]K>E\81C6MEZIL&JIG++>F..I#4R SE&4H
M]ZN&?-A+D4&?2-O]5"0=3!.+7FS@G_,YXJ1%R5;\ K/^9*2,VQHK,2H@+Y:/
M+IJ8++ 5_@US%K4J%G/*-7+J-G8NML.R:,7[$Z7XW_+D:@)[(D4[O/DS"G77
M)LE&G8P[]Q01R"@BCUI??!D/I@@:1W"1WLJR5:/$WHSE'LF<B/21_'2B?K88
M._70=1Q7GOO@COB/B[B0>WY7%RF&ZN??O64"5N%C]0Y Q-;$8?;@W<&"#B@O
M$(0?H&W(_(@0G;*X$ENI2=< # 'SL=E9R')R:R86A$ NF9 %\.W-[V)ETS)=
M']D]V>W(83S;!HLR:-#H9!"X<(\]%LO(>2 VMI([\K5S[_S800II<&0S.CWB
M73&>(OH$4@R3"QAM4%Q7SA_1JP-MS*G@,)9MHYRT:6A+3LS4/"R5IEU__82H
M.T;!R_+QA^*3?-3(IQ]OV.(LM;682M,0\[=L\.)THGZHEYG3SLDD[1 _?QX,
M3"8 H[5PSNXXF+.U3/6+%7GTXTF>_.'I2(:95/UP,[Y 3BJX9SI10]3R"5P7
MPQSEZN+LZOU%&G_19YTY^?[R[.*BF)/4YYT/#H-!032O&4"G;2%N.1V+S6.[
M9;5RZC:@>*%FSDI[)G7G:E!C3?7,'++#\5LZ4;?I9J'0%6XP$4+'V)2WQ%+=
M0ED&/511%&%'QH)1TUE(?L8BFN^II>8@Z$X?FW+:I&+XRNINY(LV.!;J9\-U
MZ+;<O4;1CA2;:>;!#ZU7NA75:+<$VEC"ZG)G]-?Z+;=%!7MOM@4\K]5FV]7Q
MES-856[C5EN[EK^:Z288WZ3]-JEH+XVXYUTE0?XN88_!F D+PA6%6*P_3Q)R
M:Q[JY@/,%\3$<IGH5D'K<"+WY^[4ZI$7RJ.F]#<-X*B5A%!&37S/=F#LHW-J
M+)DO% 5AM,/0JMMK,TUJ/XP&4T\BFVTMS3'L8U,98"&\[-$6MCRGVWFY[?HB
MZU2*#$0  @NDU&@ M>'ZCRI)!PK>2<W:>:W2U:?@_EO^S<3R+-JM+BNXGHKO
M@CU#1[V(*N/;JGLO.?S5+*#'>AM,$9AWZX)./.#W;W,P5QP[QEHGXWY9:; .
M76*EA5GTM%+_25X9L9R:Q/8/TSOQ>_DU\NE[4[\,?/+N?JV<>C2^, K_;3+J
M7M''/3FUI>!_1:8\*NV4-+'"+-HUL1ZB?RXGJ?,QZ40-4<N@+D%0&YDUS4#A
M]YVWCQY:JA$4XWE'I",.*G)IURUE^>OC.0*7J4K$QIIE&73GR@'4?O@@=7$Q
M#+46.Z8I0PV]<#(A\EY%>$#X93R<<NR_R?3"'W$4@G]#M+67Y5A:@ PBZ9]@
M4ZXSD>(]#!S]'0NT&\U%TF)<'UE])5ACVB6/:7(R4F@=]1A0G5+^T#>4Z18J
MTEC*P8TV^?#L!*;$?;S U(U)ISC#!B^[M>HQQ^1/>4#"\J//P*^O"$BZWLI6
M=)(4<\=[C_:).([\;SXG'2$8IW@I X_Q=%R8C5#6;\2AN+R%+!R_I&_1%7W4
ME M/"TKDQ/0BWV9BS-7*J35_7\DK$;TIXC-D8L!D(ON6G3T*ZZR8TQIEM.;Y
MMZ7EEB@R^5E33A"U;IX&'N !N%-P"[X!)EQ)'I=-BVHJ 4>]+_5*+ RC%(RX
M.?7?GU)KL-12EW7SW7#3HOI)@&,36SAU7#J3JB/N&?1Z] '-B+W,H,_[IB,/
M"XJX_ ?#OP6LE&39_=RZXKKA_M\;[+DS-,3F5(7QR/;:15_UL[7,Y=?89=DT
M4W6R:L=A'W%\1QSY7$R2G[P/^J''#Y#*.N-?EU1,4^N#11]WWO[[> 3-6YT'
MD\\8RI=._</N$?22'+J=AH_8\OIR=<XMZLZC]< HF!WC3BR+VIU[A1&0,R7S
M:+8:"6/M='<T[6T@J=D,JB+(]B.)/1$;>@%0G_.$WLC,G=V_S9D#X\0&0FI
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MS8M1M87AB18(6PZ<" D6[7D0TC"0QB40SBDJE4)OKH$T]!/\;%L=M 957^*
M_GFJ+PH[OJZ\,I01:7##)!9B( Z<52COED=E4@R&-Q"#?B*<+8M!.S#UYO=>
M?9K.OZ6TK<I_E$%XL&UE4\HF: )&>_3X<K&G").(HS52">LH46,/A[8L'EV
MUN]9ZC$B\D2+B@9&G6(*>-0.1&8<N#<4HC%9VZP(=0WT1C^!TY8%HSVH>O,>
M[S^X4"=BNKM!Y:BD.ED/PJ0,*8@(:$Y3T)PG2[7/@C2(HO=N63;S(MN"J#]/
M,D]F*=[4%]R4'RQGP0_>)*HA',=U5.40HT;+"5>$#N"2]A"EDN =<<XPJHUO
M$'KHW0!M)#2=0]?K!O.P<.5WO)T@6*=W6L7@_3KD)[S0D*6TX'.RJ(J34R):
M96R#C+_>S=M&0M8KC#UJK_7IY::*,)KN]QG8FQITH&65A#5H]#M(CBA@EG-
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MWJ$9SK.-B' 6,3L9J6Q00[8?T3M58.8C17@\,KSQ;3;?H>F0EJ^^KA9NOJW
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MWCD<;?5VLII<C(:DQ3Q>AWLTE7]+BS!99V>LHZ&_NA6Z@N7Q]/GT<XK;O_9
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M;,)%$#-D@7J64AF!.R$9C9[Z(:O#/CCVJ<?D4TTJYY*5-''(-E#T>+*#%&(
MQBT/A@;)4H.*ROTFD)P\@_N.U9J!=6*(X=&6_Q^_O=F;&'6X424BCT&4-X[+
MA4/G2C)G1FPV01=K+34-$AA[?!6W\<S,.\1L;%96K72ZXSNK,L^2:R8@LQR
M9Z- %< U1=<YR>B";U#/HL='<=N2IEZQ'-KDJB55AQM7*C.NRX,Y3F4"3' -
M5%E$VVL3M%+&A092U(_AU8D4=8+=B9O1D2_T/?EZ%%J(B9>+!/C_"FCR$I@S
MV^,:]&*5:_(V2#])/*UO0"VBU9=2>"+"=C#6\ZA%E;,RBAL"P2N%BD\Q$()[
ML$0[:GG*.8WVN+0KX[,]K(:)##>*TO;W=-:;B.--\J3LU&]F*S>[F.!/M\^7
M_3*?QR^3:8<OD=4D #%&^7L[^9PB_O8-CI[O?O-]N[VOIW6O&+XG9WW8>WO4
M_SVD._1$O0XJYIF5&;<Z$V0&PP,#7 2H&HTU@A/\#ZNE-KI!X?73\_-4@EK=
MII507"BI*'*>/3BO$GHFWD,0(@=&E?1Y]-<]NICD>><X]K6Y'ECAQZVFX[JJ
MHH\>30L#0AD!3*+)80.GI;"+)I$S;]SH?;H>I*L'7/N3MH>T_Y963?3UKN:5
M4]SG1 A"K2EHF7PY2["E  S))%"T7FJ9_;UKZ_UI$_L;5H$RX;)P@ QJD#YJ
MR,I;(,Y0:R,5,M#GIJF;3V]]/7T:AN,JMM<F>W^<'6X/Z?>J>VXOJ*]A/FT5
M/M%91:P./J:$GCJ)Y9H-+7HY0,@<_:BH,G4-;"C63[[2,*+5'J3C*N#8N:+K
MU63HR-OOPF$=G;^_1_C?I47 /MQ%.L_K*,?=!Z,A_^:_73^C7I.< [/_'!#]
M[G;BX/1TG7E9@G$SW.PF/0TR>,AJ0\FW_<;^_<\JYW0(E'"(2IFRQWE01DLP
M-%B;<W*!#OC@WRVI194M+]-:<LJ.=I[?IV5:?-Y;'ZE&ZXK)*!R1:$V0+/$/
MI4$%EB%$Y;6U5/#8X#76OER;4R?TT<[>!6#]^?];ZO\^7_SCS>S=8A[2\GAA
M>;IUE3,+0J)52 .W8%54:"0R!R)YRREC@JD&?G!?YF';PM(J8+T+RWOWY5?T
M 183-RU;TX?K3Y^FZRJ81XI-G7XJ3;3AN'!*_2\-7BL.@1D%)*$;:WB,B8X^
M-[-] >H(NNZ=B+N=OVM+9GU4_V:&?T?;+5Z'TOY^3*^_$0>V<=9D_3:?S3^E
M8LK.+C8DOOKZ*<V6^VK][F]8":NS-4F!<10'#9(#2IR"E)1S+BDEPH"!7;2A
MTR(M5^\32MSU#=&'S+PGVJ!6UM):3\#;&"%S&T J+T#3D%(V@?,XVN(!74SG
M([W4'G!];F>;M(,-#C<\'-BY=C6IO"999.N!44* >^N ,6<A6N6$4M2H-/I2
M(BW-X8X=JR7(>CP46Y-X6$%^]R5NN%91_%^Y>,Z!(X.@.=IN)C$;4B8^M?0<
M=)>AY:[DH"E4?4W_^_DW-RVY>$5<[ZO+/8+P9)M*!(E\:5XNWX0BX1*2C1F(
M5)$[:82+HS]3[W#C:!.XO@2D5/4M%7W/9R\GRT_SY:1 >)XWH3JZ1TKV-ZP2
M3TI0*4%$(X$F(<!YA@H2Z1 &701*&KC*/29#=R,JK:/7;[[LP_N[-\P<3)K=
MW:RB)DJ/#(,A$1=&- 9$L@*BTU+:S),A#=1*C[G4W<A*R]B=F#B_X:>,^1J9
M/YM/<9;GBS4TR[>3@%R6TD87BY1NTF++A9'E>3Z;7WV:7\_BN\6\N)'ORU0\
ME6[?[B!5\MZ2Y#1NQ,Z!=EY#HMIO*Z!8&8T/IPN6?*Z"-0JD^U)8:.N]2XO)
M/$["RW)^E^+/:88_E(/J-83%-"Q/5)_G[2]N#[ _I,7GR::>R9KKV?XK0BV/
M5 5OHHH^@I=:@%*X'20:-00F+?Z7:T4:U,I2_1C@'>K%X?'NVTB[K23W%C>"
MBS7\'])J-5VOT1JVVM[V53:^I%*AZ\H=QZT$71D2F82<%'JT^$^1-W#X]'/5
MEEV#V-LEVV);OKGZY":+]3L"EVYQL?=H8W>#RDA%5.82)&41C/89E3[70"P3
M@JH@0Y.KU^;9JZ768#O14/OY&K?NM%R^F$XN9FL*2CVN)PRNW1]71$J:66#@
M!=J2E O\R82PO2I.@HJN@?=FG^T<MPI9G[O'<O-JS_GLU=>"Q/5D>5E(/\\'
MJM<?;%M1:@2WJ.&\(LBWQZTS>._!)Z<2]TYYW> B;#G3>_[;1ML(MN+"/7%K
M<9,NBO*]?DCK0.9R"[U6.47B;+!@@L@@8\[@BY[<+!R1O.--BK8\V^.H8; ]
M4;3V\[_[H+)6NRI1W!Y)C.!<\2=]"D"$VY;7-;AK:MKD[LFS#3IWA5[G61-/
M)19\ES[=?V9#USD<[TI0!:5O%M^AQ;!(J\EB[3-LO=9W4S<;>/2ND:]#PSVO
M?OOK8E\-G'7R,+Y0Z-Q-YAY+JFX7E74\R8S.8Y:60<FH!..Y!9>=%\*1Q$0M
MA=<7$O=B*4>Q?Z]=Q;36(FADUSA6:L!HP(W+ #4R<32E7:,GD?IZO:2+"7Y4
MDKE=&/OR01[3?7.&?K3<W&]8Q:Q-+L\D!$H].,,#9.H-Q,2%",X$8MJY__;'
M$YR&. XG.<6\":L4WZ?5]6)V/BN_VQR<'B5'3W=364^YIVB "<481)7*77IT
M[7G*E!,E"1<-:N_V5@5^$+%J%=;AA.R^&W6>[SGQ1\G8D[U4J)*=M#E"(M8"
MBX2#-XA\#MQRSHQPH<&]$_&'%K$V41V+A+U#T!;WCZ46*4Z.VQCK=(@.H4('
M4 A0CBG@4N),"$/0/Q0\$5H>:AS]D?@HQ*XU?(>3P/<IS"]FY4$/Q._F>.OE
M=?HXOSO0VIL#=FJ7E;5>&JH-E$M D$NZ +%$@G:2A.2Y)W'\1]L#B6%G$ \G
MB!_09)BX::FL-YFMH;\YR3_.HWRRFTJ[+ .)!G /8%!>J07"K"IA-A:$II*H
M!@*G_] "URJLG8<7Z\28NH[TO4^EA&0H]6YG%]L#8"1H'7A<GQ:B03Q'3-%,
M_OMD=?DB_/?U9),"6CXK7[R_"4QNTZPFG]<55?&;]?W]9TW[R;&\G2</.^F]
M(VJ;K;&FW,WBFZM/&PVYQF7?R7CC?BL=LC!:!1#"!DA)$D@!=?'F\,49$W6M
MH-;I,,SB$Q0?P_.3G52XLVCGF0/.$@7DU8(-X>:!.:Z\5@W<Y.X?H>UYBN<]
M MW;_9(=C.R[6K+C\XHD2K6T!F22%A0-&:(.$;BQ4GL:-+$-"B</)$8M3>;W
M-TS:P:\OZ?A0$C!OGP3<YTE\]V7E@V%"J@@FD^)+Q8A+3#(0.>K(C93.C58F
MVINL>=L@G7BZ_X"3VGF$-5M6E K' EJK+"@*VB8)$=?(=D$8KW23PY]^8OBM
MS75WH/6UZ&_RXUY]W7@C>]?]XX\K'O*&,]2#$:@(!&)R!H0F)%.?B4OM!-^?
M@SBTBE/#A-*S^97?.H!/[&T?43LM73AD6I_>866X3]XI#4;27,I >G")V.U#
M$M'C$AAM!9Z>;(7>$>Y;L=QCJIQA7FQN+1UP;X[OI*(><0B1@XK2@\Q. D^>
M@B/"*BEEI+Q!HGOW;]7W:)=VBNIP<<GQ)_F,2H]U[CKW /,@CO.VR-6+$-*T
M9'*F^#)]6I2HZQ-YUR?T4G&?HR*F$),#Z(#0DXRT4>LH-VB:D"9F]D#JK#>1
MZQ;I4Q/Z:T<S=\%AJ=/2>PV28>?6% JIV;H0.@EMU&BOW0\;OFL'S<Z/0OH*
MY9\A>=^E53RO$XG>4L^[9^6[$L_/^J#H81PDA,6UF_X!IF@G6W\@$>SZ=/5#
MNBBZ]Y<T1__BT^4DW)"_+?+U9I;GBZL'IM.@1'0]HT>0TIN4'4%3;T7ICZ!I
M^YOES]_N?;U([AF0.,8IOJ-UJS+&1%S7ZNJC^_JK6ZW2HI<QQE">MY146:3+
MDHCS.=U=844B][BR!UI6- K.,N= $SI5H=R6U"HK$-K[J+TSP@SX3N8^ZE_/
M%^@(S<[63UV';^N(Z]9=BO]UO;G$>SHV-7NOA ]*NF @<!=+D0(%L03Z=&9>
M&:HS<:._8M6JC,S'@'%?X:9]W)VYY>7KZ?S+WU*\2#<)I2_RJBC+,'7+Y21/
MPE95GBJE1XU1,>*S$2("ETZ"*4]'69\%Q'*?77@K"&^0K=GCE>\!9+5KI$<K
ML3\GW-)3QR+[Y"!53)264HP0G,Q !<T0C2DOI,3D15!)^ :G1</KUP[EJJET
MMSDIHQ7OC@5[%WHZ:ADB92"]<1"5,. RL>""]SP8(KT8_^.2SU2FVYF/,4CS
MB\_HD!0?"ZVH4D/TKI#MZ2*\M\\J.QT5YPE*0!Z4,1$4200BB3HH+XB)#>ZX
M]5A[>@#SH6UDAY; WV>+Y*;EMM3?YM/UJZ2WE;?O6'NQF)1RMR_7,='-.?)I
MLME@-)S1Q+-(!E(P"IAA$KB-Z$$$&D/4+$O:X#AN> .B1<FJ*<_]SL;0DKYK
MU[AS3TO]L!?G9V^VX)_G-M3PJ<-50A@NE5) /4ZTS]&#*R]Z*<6)-SF1S)^W
M9=&_L/<\'R=F+.R\57T]6RWO;K5.9OM8_"VM7H35M2N/Q=TLY]T"W.5PE<:M
MUY:W&7 F+9ABCZUK_6[KG1,FFU0(Z?')@I9-C)&!/K1.?@Q%8>[WF=N4$DCQ
MUNEHRP)I.&*EL@R.B8Q:247(.G#\ U<R3R9%&S.S8=1W^L8A?#5U=O^3-?2"
MJ+=+W=WA7O?S]$5NW,[N%4'HTI YG:1*21=S0'G)'JW(8), 7YX(PZDC2@HN
ME!GO0VK/;DV-<#J;U-1]@L.[4A\->,LU5L\PA%0V:<=-2=SV.8,.:)"FH&^J
MJ5,23:KU+/T@%=A&MV:>S21VL%*V]+N#]&^**3>SSH8CII1BX=ZB-%BI(X*-
M>W+0"/M&+K2CC6XK=5Q0[MFMF%%-Y!B,NMIJXGX%4NQI_CEMLR=>Y9S"OLM5
M?0Q?*9&]L)H!D2( =:;<!H@:8KG\2(.FFC6HRRB'CTQU>7@PX"R,80W<+Q#8
MV.3<75^PP9%9+\15C JN9-+ ?$0]FT4")Q0%:2BGBDLN4H/(+AU^_0PCX\><
MX(UUHL=@W.WF9SC[[AAZ*N\D(:'4>1#.@[(L@-9Z>S5?J9@C'7VAE-$NK><V
MM9W?'KS+*>_MAL;=D >3\K=,ES^\6Z9__Y?_#U!+ P04    " !/@091*>9N
MZORR  #A[0@ %    '!F92TR,#(P,#8R.%]D968N>&UL[+U9E^,XDB;Z/K\B
M;\YS9F)?^G3-'*Q9,1W;#8^JZCLO/ R)[LXJN1A%29'A_>LO*(GR);10)$C1
MO;J7#+D$@+#//@(&@\'P[__[^]WLIV]9N<B+^9]^AK^"GW_*YI-BFL]O_O3S
M7ZY^45?FS9N?__?_^A___O_\\LM_ZD]O?[+%9'67S9<_F3)+E]GTIS_RY>U/
M?YMFBW_\=%T6=S_]K2C_D7]+?_EE4^FG]8=9/O_'OU7_^9(NLI^^+_)_6TQN
ML[OT;3%)E^MGWRZ77__MM]_^^../7[]_*6>_%N7-;P@ _-NNUL$2U5^_U,5^
MJ;[Z!:)?,/SU^V+Z\T]!POEB_>P&#ZF+5[].E[L*CPO3WS8_[HK^T/0?>%T6
M2BE_6_^Z*[K(]Q4,C<+?_O/=VZLU)+_D\\4RG4^RG__7__CIIPUR93'+/F77
M/U7__N73FR>-?+W._RLK?YT4=[]5/_^F)D%!JUFEFP_+VZPTQ=W7,KO-YHO\
M6_:V6"S<]\EL56GX?1%4/5^&6N$A-V_FRZS,%LM%Z.WZH;=E=OVGG[]>5Y"&
M+C(D*D#_9[3VE_=?LS_]O,COOLX"[K]=2%J;+=-\UK?,3Y\R#LD_IU]F6>_:
M?OJ42)+_<Y4O\FK<<.'3\OY=MKPMIF_FW\(#J[%)S:=O\TG5Q_F-*LMT?I-5
M7Y^6M6.[EY6N^GRO\^+K;5K>I1O&]2;RT8==%H?0JT"^R>U5UC,&!Q]T6?GW
MEWZ?AB++\-+V#,IY3[\L4M6$.UW-L@_7^^OU#-69C[\L5@UGBRBM7U;2OZ:S
M>?8M[7WX./2<*-+K=)$O/EQ_#'-P>-;:Q@[]N,IOYOEU/DE#KR:38C5?ACY]
M+&;Y)#^IVPXM7DJB\$VYRJ:?LB_!?EF$TFL39OUM.ELT4V_?C[T4-KU)/Q+Y
M^F/U6-C=:$3NW&X4Z4PQGX8!,)N&#XOPF&FUGM#IK%KF7MUFV4G3O'D# _7W
M8UH&/&^S90#QU.JQ96O]27(5B+"9@SY<FW1QZV?%'XN_S-.PC@N_MI&F68N7
MDJBSLEHT/Y"LCY?C;\("_"Z+I\<&;5]>RKBZ/?=!P\B_L2NC*?9 <\/($IFD
M/?.RFA>S^=JHFT]-5@;39AY(<I<OFSB4FC<P4']W)985GODT*]<603-;,%;S
M \GZ,9!DOGP;%F8W484\T>Y0TI7%=#5YU(WJMZR<Y.FL7G"\2Y?+K%Q\RL*+
M\RV;;O^,!D.D#D3"ZUM6?DQOLI-B/2L7Y>DN+><!K,7'M7O\KIA?W8:Y0BV7
M9?YEM:RLZ<_%HQ]NB]FTL2*BM'U!*1LM4F(T/9B,']=UPKSS8X\BB-F@]3B2
MKFV 4QU^4BCB<VW^+<P.\VG3E^!HI8C]"LODZZPL*Q.CF/SCG,X=K1FQA\W>
MISU%H_3!Y_.P: U#_)OY8EFNFMA QZKTUB<3%)$O/^6+ACH\JXW^>KW9:0U+
MC[771DW_OMIXD!>^*'V:EW]-9ZOLS]GTIJG[+O)3>I/<9F7^;=VG?;\&>Z+J
M3N4^GX0RP>+H(G_G9XT(!5\4RWFQ'!:.0P\= )<S-S';-=:;'+N7Z\/U2=0_
M9>N8B_=%95H'D_JN<M)V4'/T9_>'4OV=6BRR=7_>YNF7?+;FWKLL7:S"P*R6
M#P+-/V6355D&CJX'M$8!/?T_>+3X/'M]+P#4@1[TC]BC[QZV9Q=_F9=9.@O-
M3'\/2]RU.$40;+%]#3X7&W/JJI(AUJ@[5)?ZQ_21ZL. T?@UZ01:UV?VALHC
M%;87\W C0_3[;.I%$;3K4WM#YFTQO_F<E7<V^](P'.C,5@;I>02[J4ESP\B2
M_?%FL5A5FZ<=N->PQ=XDNKHMRF75 5V49?%'Y19J+\SIQGJ3HY$_XG3%_OI7
M+-/9#I_UN+)1_*/!)WR[/W*K@TJB/G>DZ$2P@_KI0!2\WDS#(_+KO.+IF_DR
MG=_DX=/.Y/V]**9_Y+-3]O.9K0S9\Z"/?)F]#</X-'S[9C[-KA^^>5ZOT6*A
M_P>/%I\SWX4ANW AS)Z7^IB5DRH$[2;[<+U^[1\*] 9:ASX,B5K];\R7;'^;
M0TIU@JZ#\2%>/X9$[YF-'0>* XT.*5<C@[%56W&D"-;%?%F4IR.']Y2,W8-F
MJC]4/G9OFFGN4/DHO5F'E6Q"OFQ6A9_DQ7SQ/EN>Z-2I:KWVK9$2FU7NM9_G
M^87/;*77GC<B9K/*4?KYL8H?7<?9?RS"2B=;YN4Z7%%G\S 1+3_.TOFIWI[3
MQ&!];D2,\QL:K/]!VV&RSXMI/ME^;4+9:%(U:7XP61N]$^<W%*7_G[)J_3]9
MKBK_O+E-RYN'4U(59(LPT1>3O'+\_BU?WCXZ8+<.10PE/M5O\#8*L=J9OG\3
M3+Q\;=V<DGNX#KP0O!J] T-WXX5@=]Z\>;'^O! TS]RIN%R'7@B>3Y[P] CJ
MQ:%MT+>7C/+8!H9S.OE"<&]DY0S=C2C8764WE27V>U;<E.G7VWQ2]_A3%A;8
MJ^S-_+HH[]8'+TZ(WZ*EH25H](*T;F]H:<Y[[[LW/+1\YWDFNS<\M'S;;Q;Z
M_E'I,DMCB]OL.6.1OC=6G_G R^&Q'?Q[!&#_$X:6N-&DVKJ]*-)\3K]O3Q.>
MZ.:/!2,_OQ$9#A6/W)?S!N:3]2+WKA&M#A4_V)>TG-3=V7Y\W*-=WLY\OOQM
MFM_]MBWS6_H\<.- 9M ZV6>5592N>Y@V"-9HV:GP>>.0^V6:7:>KV;)E%P^V
MTV.'B[LTGW?O[Y-FHG=WW?HO=]G=EZQLV]=];<3NZ&UHKYRLOF2_[*!IV=TC
M+1WL]':W/!1]&_[<EJ[Z-4S:V4V_LN_+;#ZM$CI<OF?[AL5=_ZK>U?V;%9-]
M:EJKZ#I=?%GK:;7XY29-O_Y6C7N_9;/EHOYF/1+^ N V<_'_W'Z='.W_9D>K
MDB) DKU99G<[(&?IEVSVIY]#IY*V325*,"4Q1D0C;YQR5B@D+5;< ,6!4D]!
MF579G(MRJ[-1H+*>1KHCLFXF$190J8'V1@&MI!;4L"T:'#K"FJ#QP&%53GXJ
MRFE6_NEG6-?<C@!G36!5UNVAU%P,AEX0-'RQ'L[^;3(K%MGT3S\ORU7V\&65
M?/7[TLW66U9A)-M8I&W(MRB7CX@7_GI.NO!5<BI;YX_?9MG[]"Y3W_-]KV37
M)A.NN),(>:^]U5  J^4.3D6X&)",1V:9UN0\DS/%15!=D[0GOAWJIGUB(SUC
MU/%*":,.*0\-$\HR9+G#$FRE$YX)FNPU&'OESD%C]8$YPRFUZ!G)U\:7R_#D
MB4 OFR;GTN.'!7/X(OG]ZC^J?%NKNZS\<Y;.EK>3M,S>/5FA/%+[B1J)I9!0
MY[&B!$#HE/=2[;ILJ!M2Y_L66T\5'@O_H@]P6K[N9]O"NX1X&S2J&;68KX_.
M[+<]&M5+%#+("F*Y9DY*8+W69"NK= SBUD1 +]C Z .ZH6CRK*L')X:CY1.
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M2[-^T1HR>C[&*W8B4.U C81K+XW43$IJ!>5$"4)K4"1#0_J$S@I1ZT_[11_
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MC.1KX\NH+("72)-8!L29\0U':B0022#"'"V$A2)T'U+KZBYK.*8TXS'Q+_H
M9RBGS'ZN?_ACGI6+V_SKP^'&(YZ9QFTDB%BO@_#$6VN\)<"N;VM:G[!2OL,E
M5_WEH>__^%A?\ VV&YE- N>+63Y=>ZY^#[!^**L[Z]5=E1'FV*[C\9H)X)Q(
MI2U#'%(JO.9,U/(BJMMO5O>626, NL0%K>6\L:<3#UU87]3V.?U^8 9I5#>I
M%GM6(&'"8$L!<9 Q7(L!/&SOZN\M&4:/NN\+MLO.,L<VD@_42!@0RB"K!$44
M"J6=P3MV:VC;#PF]9;6XV QR+EC#;@U6W/4!K/.IT:A^X@Q 2"HCJPM%PUL
M'*W]/D8KU#XRI;?4%0,0I0_H+CR&^#0OUZFE'F+7SQ]6]C22!%N+(<(A4Y;
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MC-..$>2"(A3:XB(,Q'2< 9\#\* +XSIA^]_<J_$95?#HZZ#<&,-)!<!0,>>
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M50O%H>YPO/OE.*&B0-.SYWF9E>EDF7_+;+I,MQT^X7+>5R4))CM2A#C( !+
M:<50'4Q"C>NPS0M?CBLJ"C2][P66)JRM;XKR_N1VX*YDXAVC#BL(H>1>.B:4
MJ5=EU&O87KOHY7BANB#2JU*O[M+93*\60<;%\;'Z2<D$25=EDZ6&..(],9S8
MVB2D6N#VSF/T<OQ-71#I5:GN+BMOPISQ>UG\L;PUQ=W7='[\C=U;(^$*."L@
M$-5ELI@H#&AM7 3#O\->$'HYCJ88R/3[!M]FLUD3'3\NN([?5()4IJ,VA"N$
M_$X *F7[/7WT$KQ.G0'IUY!^B'*_NDW+;/%AM5PLTW7BE^/F])&*B1,(<:L1
M9<0 1Z 2C.\HJT'[A.;H)?BGH@/4+P."Z5>FLS?S:?;]/[+CK_6SL@E6A@ L
M((/05W<^:X7K_4OJ(.APN<!+\%W%P*2OC8&-2>_SQ22=_7]96AZ/B#U4/,$2
M0$LELBC05"IOP2[PA#&+.N3 >@ENK4BP]!P8^] ]'[XY9%@?*)U (:NQB'-K
MJ6%&(4MVHG D.[S"+\'/%0>5012\"<UNKN)'Y1/G!!'66D25%$9C R&IQ<'.
M=DA7]1*<7+%PZ4G-*O1MNN[?+#UD<STIDTAMI%=* @JK08@@0>LU/3,4M;^!
M";T$'U87+!Y4V$MN$I>6\V#>+0+'MN9?9?FIY;+,OZR65:J!S\6C'VZ+68!]
M8;-EFL\63WNZRV>R[>[@O5IG1KALIS8IRM_,)S_VKK]^_7,5R-IS\S;_ED]#
MD_VK?OVXCV%PRH(I,]V<T#SZS&%S$.Q&@CWCWM'RB7+ 2D.PLMP319 CE#!<
M'2ZUPC#7R"G8CWQ7D]MLNIIEVR[K3<JL0XEV&M1*M%;"<(< 1D0;A& 8,[>R
M<@5)^^SSD5+O1-+4\^0JT1!)7T0NGLV[6OF(BGGX\]0]!4?K)=P;2"""S"!G
M,:(<H!U 1LHAK[<YZ\*"*$H_E*4G E+-;,#NK'C6U9.Y6O:63XASDG%',-3A
MO?,"5SM VU>/0_I2\O5TTUO1'U*OBPV784'3Y#TC(,%EE-\MAX_15*U3<&((
M 4(,629JF:"E[<_(]I;#IZ-N3J;Q.0^1H;2\[N&;Q6*53>VJ#"NCC9]BLW5@
MBOFWL.@)"OAPO?F\S,.,N(W2RK/C=D*7AA,EO=<&>JZJF#X@+,:J1DN3+O$R
M??$GLA4Z)'Q#D>WI@K#)QE_#FDF 57KF69"7* L9DF#WFE*F1I@8/RY=XN+3
MM[MJ/=+V[.CQ^3R=3_)JAVP1%EU/;ET8Y&$F:"-??LH7E_=\%//)>K=PG8 C
M=*B1^^-@I80"*R12/CQ-<X6U%VJS2X$!8K393;0#27K*_;&_0@*$0,!R5R4H
MD54>>4/15D)(F6P?2!#;\Q%!23\8+A$0&;7G8S/\/$R6^O[-?+H*[^W]"=?'
M\8J)U99+JX/!*#T0T$.[S6D3(*KNL1VK[Z.KQO>N<2*A-.Q*]Z'3=9=/KGR.
M5TP@T(HJJ!7F4E/-F=2BEM8ZZ\;M"8FERA,,B8+9:V?**+TDXR3(98BQLP&O
MLO);/LD6H?]!12=Y<;1>8@CS%FG"+2%A.F>4,E!/XR+8].-;!\=27M$?3,.Y
MT)[-K ]K@CTKAG?I]_QN=>>^?RT6J_(LJ_6<=A.O*4( & * ED@8*-4.*X=!
MAS.CO:V5!S!S>X2PY^7TWL7GZFXU2ZN35CI=Y LU_7MX!^M;\WR:EW]-9ZOL
MS]GT)CL1#-#_6V*S,O^V[FN3=>F>T@DG#D+GK)%2$$&!<%J'(<9R#+&5L-$A
MCKYE.[42?58R$1P("ZVR%$O(JHU'2[8R(<IP^V"KR$O03OHH8F(PZD6G3F?A
M)<VN;K-L^;;8Y%P[L=P\5"5QHDKW@YT, P\3S"L&10T+PV#(O96S%IJMU5OT
M LQ05L"^[I[<2CU<*:%&2(&E-09YS[26A+GZ[1+:@G&O*;LKKP$;.B'U6GDQ
MRA7DF.APH1W8VZ)<?L[*NS?S;]G62#NY:#Q<*>&&&$,],[P*3G#8.AI&56.%
M]AAIWB&#2%_F?0R5/=\^C87/:18<N")V?K-LJ-.CY8,MQ8%F3"#A'&;0(0QI
MC0#DJ+TZ>]O9C*C.F- ,]3Y7_:V89[,ORY/O\8^%$\N5<08Z "@@" 3KB.VD
M8@2WWT;H[1Z>'M[?SK@,I>WU$GJJ%HML^719?43I!^LD4%4\=I@B9)0GG%H#
M:AFU,T-N(374?<SE7RQ<AM7]VSS=W&%\IOX/U$M@=?P/LV#U:*.P89H3M965
M:((ZG(Q\.1R(@\W%QX '+]R;^:3,TD5FL\V_;4:'PZTEAD"$!%  <V%$=;9-
MHAH7IUU[T[^W.6.0<2,:8J,843JPZ>P6$R81-\!BKCB#@ "O]0X?(VW[O#C1
M,VD,/@I%0^T"XY/-%Y47-)^OLFG<L:I-RXFG A%@@<' 2XQ!>!MMC1='KOT)
ML^AY/'H>MP9 [T)C6"^,Z]1ZPC1@V&LG&,>8 P.-!SO<B&P_MD5/+C+ V#8
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M0/H<9]L]+.$6PRI3G="5^Z"ZVY.3G3'#1?OKB_E+I^P@@':)MCC4[^*I;7)
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MK[-,5-QG1)TE*7+ISZ#/85AY4 GODID4-V51QV1)Y(C""'L!@H%)R(YHYN2
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M(*O#.PC!WEIM"58VZ'V(HK!56=8IYW!LW_4)PDZY;?M-%$P3I"&U2BM#!.!
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M&+, ,@L)1 U%C@[81$;SBTTE"P.ARL[]907@TF*.1+#A 8.:[RUY*"7-L.S
MV)P> [<,U(Y?EM4JTDC:#"V$!HX:)KW7Q&KNF81F1W'8\5B&07FC&N2)\<I
M0M35U?W7^[LZ@4-]K9;K^7]FZT<V9S^9.3)94;^$@&/O&8:>>F(4;MY&A-F
M%I[G.%E&E:(T"&8@5^_*MG#@]H$%)5)[:; % D);;^-L3ZWE*MX?<X[S:51Y
MZ8]6'M&_O:)OLZF2,,45@ [,TXX98$40%QAL6\\#'Z%15$"J41?9?QU7 $1A
M(+G4&$*FG92\_O\M$D0@-:538_@50&>VQE\!],,KZRN \\72 N>953CLFX83
M 1VT C8@>H(N()8VG9P,C*/M!V4F@0)31#-*#Q7' -5\H% P9OP.%TJXTWE?
M"XPF!2G"&J.0_4OR&GRRO":X9(%[S6&4S#DEO1*8$RH0$U)SV] NX(#V4'E%
MW';E<%0893\,L_,C8V*D)HHZ@R0&P"IN2+-\+@;4HLDKDK:G"(R!W51;A[X/
MBPY2JZ[^?3]?;=G2KF ?&5$@I#66T "H(??$0PI90Q\V^58_F4"13@/9.46B
M_C'(]4DEY>38@D/LD0'"8TUL>">PHLUIS9RQF2O#@SG903)2X/5SR$J6ZFM^
M(I)$J5#+Y>Q'J_KPZ(E",!W4<.X54MI(Z@%"N%F2QV;2:CO=%(6$,%<I,(E\
M@SO5JPN:ZO7]U?K]\E.Y_!X4EY:JI(<>+30&EM65W1CDAFI$C&)[2AR-+X30
M_[HFEZ,^$583<+W62W<+;*])>?3Y@B(JA#54<1",;^0(UWM)MM2S/,_PX2QZ
MR>MDX+P.QF=U(&?"[R2GKU[.OJRK[_/6 _CI0P6L2T1)Q@DD2 ;+M:[8N%L8
MIP1D%,J3". J$1091%.,E/<" (<>6>H"Y5A*014P#0["*Q M$OW;R>1R<(\/
M8P;B-'(V@J=4$,C#A@5,>-,0QM[O7R_G7)[ZP*B<'YB6$(?H7Y*6E0)RR0)V
M'L$:+^_%*J"PQP1A2 C25F+:*!%"4C%E[;Z1(N [<[1GWDL_Y*:2E /W+2=E
MY.B8 @MM,066<!?^\<0:#1H:/1QP3YY-)DRL=*3"+).8BP_E<EXWY+I:EK-5
M:<OMO_%1%X?G*[@6@BL7#$P=S#@&++#[X#_*H;BHW>;MX)C&*4#,0/?I+5R]
MYRJL)IH1 0A2WABJ.8+-2R>)Z-9 +9N-:KA@C0U@=K'S!ZC<-4!]_V73F?#A
M@9\B>-X"""@"$#''M-'8&U[G94)K9.!IMYBD5Q(\+R$W.&AHG /,/7?<FQT2
M0F@_90N%X<'SG=DZ('B^%UY9!\_7792V7W?*5_CLR4))"+70 E'",)?:&NYW
M($A'P91ZRFC^P*Y\?BY*@Z":2AMYM,J3OI87SQ964!3L.A[@X59 8 CF.YJ4
M0PCF[;>+YM!Q3@_"Y77P/$L/VOE8G>3V[L-&[UO]5Q6.BC_FUV43(OPH/CBH
M>[^6U_.KV5WK%5_$3(551E!GM1$2*A4@,YXV)"($,HS;'L"F:DJLQKRT?^BT
M&$#?:$6=>@<_?KAP4%G"/67 0[]IHXB;UT1K2.*CL#(*R>UYO"=#:UK>=VP>
M^_3Q0@),PL[HH6%4N? ?88T:K8$4*,_S/06+6KD]")W7P/>LSOA<V'T>9>Y]
MV!;#4A<WGW8'WLE;C",C"N <=T(I+ E&5F'-[9X^S6!&/133L*D: Y:IV/[K
M;%TNY[.[C^55M;B:A_EO-B"<Y'[[P (2C802A&( N-+$:P4::B'(Z2)K%"%(
MBDX&-PHCA8%IX>J>'][98$81@57=-'*' QI2\R"C^.U(M\]X,&8@3B,'YQ#G
MN8($<&VYI4 BI=0.#P-9[OW"1N'\P"B=.$3_DK2L%-Q+%K#7%@9&8)VX)83P
MA#E+((<$[NE5DW:9&"G0IS-'>X:!]4-N*DD94OZ84<204X@I*R B3@'@&HI(
M>/ORT96GEH6!4&57MH)(; 0(8#BDD1+.*^3WR^<L/NTAF_+'?3D]!FZ3W7^M
M@Y57+[=)V?W4\?*[;5QA">86&"EAH%EZP:1N3ER+@7\5J3&Q5^$)@9M,2+9+
M/'U!^OBY0B!#%#$\R+;@7 NK[9X6*+3,VX))Q*?GW$^ T&5S/4MK(@=F)SGV
M];SZ=CM;?IWMOKL]Q?7@PX6 SCODK)-,6$Z9VU9AWRQ4AE,Q/[4^$N@J,121
M//OMV[^JVT47AAUXLM V6 X"*E6WTX"62J5$LT3*8(:*]W!N#<<ADE4'"H@_
M! U77[J5<8^;*!!HF "T;L;!L5546\]V!#J(1(:1)Z-$ITZ"7AZAZLV_V]CS
MIRN<,/2\6<;;#G'F+YXM$%>*4:&)=T9R%BQ>4+_?$ICZ)M%UNDD=.ZB\677W
M"/(G(PJ$O5!,4@B@A189I+7;T6B\D5-VP&P-%Q_ G:.QX4.0F#(0?+(X,4.1
MMH! S0U5$B DD&X@L$&1G% 8(FW?2):>#@KK!\TE! =QBXE6X0BA%!)19UQ)
MUE DK<C4QDW!HBY10G'HO :^9V7EYL+N2P\*HT ACX.V2L/.YR&GF#>'I?7>
MQ'LUIPT*Z\RFCD%A_6"Y;,>V9!HKJ2TW6%*LE6!0-;12ZBX@"'S8X3X&2GG[
M,R74@G.F-53,6F$@V[B -K1P8$&>)WQB/K4Z-N,0NFRN9W6^Y\3L;+S8%C(@
MC?6,22.)]IQ#W"PT['*3-G6/\8MV!OJT%[L?%&?Q8@.B@('"A;518BUV0-MF
MB0K2^/*:$WFQ8[@U'(>I]M!&9_A8W=WY:OG';'G=P0?XZ.D""N81MW4)$B#J
M2J-:D\;/Y(*ND=_;F,Y7-AR/J?G<@;D%$QY8R[#!U .&%58&-A08/.#>:72.
M1O'A"$][PC U(S?Q1SUJ*+6.*ZC4SGA-D7&<>0_")M5L<@X+.V53FC.R/ 4V
M>=POG:XDEFTYI!YM[=YVN+:*F:[N'.VY$3A8S 1(H7#=BR2P' +IB&6=ZKV,
M?;-U@K#N%UY=)BJ(%Z"^SJ>64:L014#K'2+*#0D"3GP/-BZ[CUZ5C8#AE#=H
M_<4PNI22X4 !KDC0?NOMFE._=2D&$'30C2^@E%):7I\HI]0/KLD\+X-*ZSAA
M' G'L[968@4@!)LB)1N:"+*9WJP-YM#)&CMQN+P.GN?I=3L;JY/X;<Y;3@D&
M8QIK2P@ -6X"$V@;$I$UDY:@CRVGU)E- \LI]</JLN_9L ZG(><,2L (Y]Q#
M)'>T&F7)E*5YLU0 $H*7]T4,($ Q#C3PBBN!!*+[E\M !%3F:D :/K7>R,0A
M=-E<SU,1R(#9V5R_T7!6*<$5TL X3*F6'#0+=8IDU"]M(-"GK]_Z07&6Z[>@
MIQH,A!&,"(X-$-8\4!M.HOP\N\.Y-1R':0,5^T<B<P0IPQI@IB2"S@'RL.4X
MA>(S1B:K3#2*$I4,L4L(5)6&>^64%E!":.KT->MW%%FB2:;A2RE8U*F,810Z
MKX'O66E0N;#[/"IRN@!EQXU!SM7WFTX[Q*B1I*$/T6XW4AD$*'=F4\< Y7ZP
M3,7VL:I6<NPX%9)KR3AB=<%'WZB;UG&644+P*$*0%)VI9*''A>0)MUK/F0J!
MF&6&&@,,) &<@(QI\+ >QEO:DU5J&=71-BZ<F8A7S_J"$;,5CA'I&,18^V"?
M$:&@;-YF)Z&G>:JAHTM!/VE+B.Q?DM?@DY4B_!H$[CR"-J1V(>"\KF:N@8(
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M_Y&?B"2Y+?[G?/[/UHB AP<*9A TV"$)O;0:8:K(?D%22CTEW[H9E E!KA)
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MCI)N-0(#JL001?+2W<W?SN_N?ICJZ[?9XD<K*P\^6W@AB%",:U]WP%(<^J8
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M:R?'%B!8AS"\/@Q!Z0A2"-KF0AEI/Z#05/_H]^R-GN'X92$S/57?@Z,+*)D
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M4$)0SE23]QC4HP&1A:.D"Z3C5"I$AC*N+E[T_LM_54&CZ\:]%P,*[3VPFAL
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MS<*4=?$E!I+'#Z?FT" @HL^G+W>SKUO%>[:X?O/UZ_WB]+9W8E3!M-..4"<
M$L@*ZP7=;= Z"-R &'":.P_3(A/)U(^S96GGJW*V:M<W7CQ7>$@,TX9Q8"7R
MGCFH6;,\9T%\LPV6.^.&8A')JFWKMB=$=&AY=^#YPC("O4?(*48 Y8K7]\6[
MY5+BX[5$GCOK4F$2R<*ZX<?]UW+YCW)VM[Z]"G+4G9V=QA9&*(^94\1XZF@
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M[2Q*LX^8ON<T7U9Y3LO'K-@L N@E'O$3/R0\,J&.Z^[CIFDDU;C3CS:!#]V
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M(2D.&8WP5,R[/AT+@L0 TVAE(G*L;[O%<]4L.6E/?B,^#6/L."ER7$(QHC#
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MW1+'-O2"$!PE(7,=S_5)XKK02\,^8HBA+W70M4Z<$8VW%0?NOO<K=[MW6O;
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M>)M77XMEGI3U=I'"E, P]1'T4.#2F%*\C^EYGM1\FEXDRZ[72P%+KD77U:0
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MKX!J)'I82<8,QYK+,E/2JZ<^8X9FM1K-(9WUG'+JHDW?DK1^8N==O%'P1["
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M<ZXLUW:BX8IUF4AUF=+*G@9MFEZ,)!5(F,#YRHZX"P):(\F'VA2QJ8(O?"]
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M\: P_2'T>)B'<IJL@4UQ7?Y:E<MLPZ]_S-@?\8L?VYXH7DMNU^Y#0E!$$?2
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MM^T_@.8I]=)JCY&8'DX9GO&5<I+V74F*>U345+#FH:_&O"O'>>3E-/GHR3R
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M;FZ*Y7:_P\G:_)IOBZRNMF6U*ZO;SP_%INU1S0)%J1^Y&0FI'\<XB[R8>CT
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MFLQG$D=V@-X0,%AR!3Z^ZE4C8JW/!Q<4?09'VR'[<QA>SS[(Q%=ZO^0_VS<
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M%&2>$\(PBCW'C^+$'U8N/12FOL*M& 90*,RJ%:[(T#ZU_K><S8GZRH[A;M+
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M4!_Y,$I2A((X\,.^,<R^(G7-J&(3A@,O1P16/:1V(-?M@RYJ5QFKTB@V99F
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M7GK:,C[QVD,$!XR @>SG%;]W.(57ZEX\(_(J#2_T?;WTS7_20Z,MM8D.)CZ
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M!-S):: ";6:>'7^1F L:-I)).U1JK!%/WP37P8GJY!#]_%"M=DP(?\(?9;/
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M+*-24["KI%1[8':HU1F>7E6LL?S:I%JC;7E1N?0P-#JERKHU73: /U1+?I%
M@8ONST46N)Z7.-#QXR1+')_&J3<@(8A(G>8RT;YII=LC.]*Z)V.R%<+5?^^Z
MF3483/CUW6#$+^T54*>:>=4KYOX3OA;K=BF]N2L?FJLN6=&4VXUQ[\BL;R+/
MZLP'K\"1TP?4X.!,2_+%\\RJ9)(:_&236ANR4#3[U,:FEKST IKV/34'^S&,
M(]<)'(K0'DV68E=;QCH"P[^KPN^9TI@?CW&UALQY(B_KSJEM5'QIAE6S<0T^
MLTGY#5HID\%K8U4AM\=ELVR?W-H5*V%4-$R\P,%.YCLT]7W&?XP'5+%'I.HF
M3&-YNQ'AF XSF;\9YTO/ F;W^Y@9P8F7WD*P4*9<;*I@U)DV!8\)K#T_A9B
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M,+-7[="1N4FHK1IINI7K$KCN;NH%FRQCA' 89021+/61%WH]--^#KM0%-),
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MG)_M7<X^DV'-USQJO[(8VZ)_.)>9,E3]BRRLX8>\7'%3N+M8<V6]N@+E#?N
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MW?YEN'1:K/+M]MWM+[NZ06S/[:2,\D2K*&,JB$14YY?R(3\6^4:;)>US<0R
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M&%"C!S#0B4\#@2=17J,*"@*H8:8P<.@5"@BF-HT'A><.G 4#TJQK@0-6_G>
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MSDZE=R 3O&ICY:[QVLU4QN)6<+">CKB2<\:@\^LY8SA[+5@:)YCOUW;&\PB
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M_'P,/(>)0=(_J62%$I"!4)BX\LX.)T:VC0^4 S.,D((Q[]J@@HKA)%;PCIB
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MN,]4G4X8IYE,?<6H[Z<#GL.0"F-N I)T/1U2*\$,K &>&$Q<N+$#."'AW@G
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MC'NHL%0=<[H7@SFU!3/G,H+=^0(C[F26 (ZM.;,&>4C-U"*C VF'P9W (LZ
M^2F(U%W9%KTYX_Z\R]?+LD9KV6337[B\W7>.LS304< 8S;(DBS+.R9"=R$+C
M%6VK3!P3L-/FY;TX;].K0]1_.R\O$W(R&V' [!T<='D?YG+0'*B3.8GC*]Y1
M$^">"_X$?T?Q:WX<CQ-&-?)W9 [K7QYW];<T'.'(&&>,"!VI.$UD)E@\;-8-
ME3(_S09*U#&,.RT(<,"<N8Q:9Z; T#J1'^;@=.8+#I2F_IA@\3"T$QA$13\_
M]G"R*\M2AUQ5L_JVRX<S"!EGH28Z92$3@9911ONKOW@4\M1X^S\H4=>C[%8+
MZFH4B#,&8VQ7I@"'V-/X ;D7QI$OV$M@S/PQN^_E*;13HVM,]/-C#2>[LBQU
MP- Z7_VMVI3#^CF7"2>13G4B==T5%#)00_K,E^9C:5"JK@?/G1C,2 ]FCL'@
MV)DOP-'P5)8 1KO.K$$.;TTM,AK-'@9W:OB*,F!^PB%U5[9%#]B 6&T?5^7M
ML,%1!L3W T$)XTD8,1+%P_1D1&1JS#A8JHX9UXO![+^#F7.9<>Y\@3%N,DL
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M3FZW%>E,.9L$ YA/P@_S\)E)7$_HT30N<S_<YOE!U[QY SWU]VI4!3QO\T4
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MH!GV@MJPGA8L> RU%-#SI(2=/^9V^LG@]D61M_EB[W6+K>4R*P/+G6=<$TX
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M[U.+>OILV?0+F2!,!?P-H01:+0 '!E,I#5580Y2T:S% 9^T<LV9'JNB.G=-
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MH_7=]<?1U_W1Q,>TE#ENF"9,2>JAIH1#+^JEAE!,I5RS0S_B/GFW^/?%Q^?
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M>564D^=7<]<Y"1^CMT)TSTCHMR-A'HQA31X[8"@,9@C@34I<SC!.V;0<X -
MG0R206OL18R?KH9#QIG35/,P;7N'!*%6FEJE7'&8$A1T=.CNYZ6F P.KQ0_&
M\2/5\&-35D,H/;1!'=I IKF@=#,]6I*4![[YOMAWE'6S;G?&!DC8XY30%V'5
M9+)\9F4TK7%RT]6;(_&QN?O/GU?_>OCSJ]EU6=V-&KZ1UD;S&8)(!\?.,6 ,
MYAX%]ZX. >24TY1MW0'NM75"W3/HH;<DA<DD;2H_\!QQIZ@1SI@ !?? ;D8P
M0"E[O@,,C>N7,D_3%G:BDAZS9:VR?.;SJU$Q>9OO8]_SPAF S'M!D3546X\
M0[Z./!#4DY0%U ")UKJNGZ>W2@.X/]JL'@UNPIGO2F9.<6RX<M@X90100:QZ
MYSE&3*7LN0XQ_4_GA$E!]\0$ ?5'5R]WQGW=];^#-_#W?++[)8?#%3.BK)!
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MO0=J=:&,!'\$6$>T%!I[I8AWFQE$$9/RHM[1^]Q]+/_Z(MG)$ \A9K&M%!H
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MG->LP@A)FV.TC="SR*?*\_N)!X%])(O%A\V8-XNKEZO&)-8+"13"3DMG*6'
M0$C);@6WB'-=*\(SC)1U5H2C8P*5QA)#&/)0"B"E857]BT5>9CEJK^F;KZWN
M,T<OV@([Q%?]/_>/DDC#?YR;GZ_S23YY,'"M$>)0."<5@AC"J">&L45*8&-8
MK0NH>MJX'X7*MY-.M\RF?,]=N;JO]V'6?L?F%G0"(%4*6TV)I<[AA .5"E
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M/9NJ+;_.YH?N)SOY?"#1F&7<$0PU0<X+G%K/;F43'-*<FS''R)UN]/S<_>X
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M2*NE1'.+U?ZS=T;SB;4ROQ!1RL$5-=3Z_&%97A7%]<I'J-^L5O>ID>'[+^F
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M,RP(I0QB$#&+I:&(Q#^)O;123>1>^NZ4_GQYZ [;H?;"%V'N[^_F)]ASZ/'
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MZY4IF:?3FFG@]9].LPHH[#%!&!*"M)685CN)D%1,K#-D;VQH>#JM&>I#L>Q
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MH=9(@*&A4!):;<!.*S]H_?[]@N)6-V^.'1?".)Y3U?,UV_YWX:AG)W&<*LL
M%=!BP8F11I.=*0*!5)*P1NES?9_$GA%J\P/:)@\*Q N0PJRH9=0J1!'0ND+$
MY65"C%A![9@M)\]M>Q#!%6H"75A$RG"@ %<DFOEI9>;4[P\+XGRT\WRR1:2Z
M%?:90E*7@7P%TK0H).6$<23NW]I:B16 $.QJX^SF1)"=R#%OMD3/%I*Z#,>6
M?M7K%I*"Q#NL+2$ )-P$)K!:FC6R9M +'*Y32*JQD#,+25V&]-L^^L4Z+LB<
M,R@!(YQS#Y$\S-4H2R96N7>HG:M#R,=](@P(4(P##;SB2B"!Z/&5-!"!B<5
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M:HY&9.6&-/=U3V3?Z@KEH9CTRVRQ>E]N-A]646^^+S>+?4[+/B0-UM"IOF-
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MQ&H#="37']F2@6C;2(%%>?]UMKZ;';Z[=EMYO7$ ,NZE$*JX]E$%6)R@5M5
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MS'% /0;20D7$8>8:8YFCQH]POQS"0.P!]NL0[N#LO-#]]T.W0"F)!I)'!%)
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MM_,(6=69Q,M^\&UY\O#K;/5P.WLRK:/J4GL,<:Y;,,!"YXP4%#/BC"-&'N'
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M<"D4:G)W30_$H"Y!?QL'!E.,[28I@ 0IPA2F4'DC&;9[.7$K*6V4^_-SG1Q
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M,%(K[($7"BN#O"62'H*K-<%:9'E/P)1%FX%BV^5[MOQ'N5[4K]=/VP2H+=>
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MDW;M9>'8-AZU6!7^W?^L#T=]VB9$EGE&&:"2<8BPP@A6AJ4U'F=M_I/VW>7
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MNZV;F9EMOOIE^:__*FZ^%+_,%JOTH2ZBME-$HW0YVVP6MXOYP2'9EL27?4G
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M+"<'N 2@,L<]-R(%N5/BE&.32H,%X_"+])\_9YOB__X__G]02P,$%     @
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M#((ZGBZ$B$7_A*="I2/K!5]*/35J"D2:FH_+AUNV#'+()LK, 4=GJ2DBFZ_
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ML+)+BPQM=DN.TT@7;9:&2+9WU$6#;^;K#.^2J+,:C/@<TP]CD4M.:H"+4:R
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M/!0;L)SB%8GL")P^0(-F0R0[P4'V:EJ\E^: AGU:T 3&*WPWM<3<-@5LXQS
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M!A(-O(9PK&(/:*PBX=6LQI]$MG4B$S\(D76YC!Z!/X/VG(=I+?!=^!<5_T_
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MM _L\<MT$OZDOXQ#=_G^S^\.9NG<?___4$L#!!0    ( $^!!E%=%%AZ] 0
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MZN0+V[X'9Z20JTVH_2AJD/!"K_6.I&\<)I!=QW&:^)/0"5N.?Z<0-#=Y5!%
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M] IXC>79EKU9PIX3S+1<\5&6T41*B$S3 Z%UA5Z9Y:WZV NUB^S2AC]/COZ
MP\.35P6B6[W?N;C8@O6_!R;G%\+S/SV7:SRK[=/_WJVDMNEJ;_1,N[W_'U!+
M P04    " !/@091I#SFVO<A   T/0  $@   '!F:7IE<FQO9V\R.#$V+FIP
M9^UY!U236]/N2Q>D"D@3XA$$-4"D(P(YBH#(@8@%1$I$:J2$)@0(B2B"%(F
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M"_#S\0GP\_+R"_(+[/D!/GY!(<$]0C\:/R;Y:R@W+^>[AS-JS_\RV!\ B3W
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M3M.+/EDFKWEYE,]]OD8@:RE'R^@Q1O4^'.!QC9F=3L%*L]00PUDP'"/J+:W
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MZ>+N\ARB.]W6%7 ]P<@C<FTL1G3SJ16/4_J*T<"1;E:-O9A$OSAG*KB+WH<
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MK]D@++E($1-IV<6AXK?60.#U!$;_WO'VIYGXEX/SQL& I=KQ>/9>WY0=^RG
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MVG8 /(#([SN68)^_X-=DJJS?M\,RVH?1IBQM?Z$.#<-S.6M5D_*T4P_<UN2
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M$^*GJ8;I.U1FTCL%W.W5P5#]'T-E%6C.$M?..5]*N[3_)9!X# _J)"&@.Z]
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M6ND3G)][^:X]IM >:U(QFH=5X&Q) C]=&0CU D!UE*'8"]^Q&4TU@4*> <.
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MY5*R6D5?Y!UU?6Y6C,<]>]ZY?'I\4[7_:M4CK+ZD94HA6&L'F'(B.S/YSJE
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MUBS31I2[W[?^KD^B230P2NY[VV6+?V=S\.%( :F^FC#Q&1EM"5V^=TM5XY<
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M]=!@@+4")%>C](^R&*^-XB/C^/J@T6>3@+38$7'\%WXMD(;(%Y&ZUX^A%+Z
MWN"45MR<_;S\:5IL8=Y@\$8Q0#7UOJ^B5=O+3,@^0CJ25A_*\GK:<4\'M[OJ
M-E+%.+!.2,T\F<JAB\.#EJ"H&U(/\1!2;%%I\VQQ^;$"/5K[Y<,__S6P5U3V
M)V>D?P\BD,9Q#WU;9Z.D_ZI8<):1TQ>04057@9]'' UM]<LA+;_-_1YSQR*_
M$?M>RX7-:?W;[H'::M7K\".<K,($[CH=9/9NP#8 7'@H#8Q@B8H4S)^]9LZ<
M'''&5*/600TOF0C*&O2D+O:TITD!O5#![(*C68G^4@$,H94RX;P 5OQ574#?
M7P?MSS858[9/_Z2CSIB4T5ZU8ROE5KG,,U^47Q%CNCV":^W#XLHSFNP\?L!+
MT(YII8+@,,-XQM#(VGAF31=56=7;^@, _&C1#)3U,<P^X.96=,> 4=BPFV!A
M)O",:77NA'+23=X'#GK9+ _*28J^KO,?KZVUJ? 7/@2/_R_:WC.@J6QM&\X<
M1]&Q#2*]S8!()X(4Z6,!! 2D]V2D0R@2FK1D1A&D2Y<^TB% #)! @!!%"!VD
M! BA)Z'W$D(++\XYS_,^[_.=/^?'M_\E>^VUUUYKW?>ZKK7NDOM"H5TE0*O[
M5ES^O3PW^E__->U9C.IEG$L'H/6BKEY2DJX*G;8E-JVC6EX!^<(U3M5ZGQ3
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M_CL6%S^SR@+OXSW!G0':4(JG?/ )S2/\&<!+(?:T,)^NQ,2< 98CO*,Q$"X
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M[W67;6K1?^GT/5[KX#D#7'1.4/T9,:@AEN@#+LN93J"Q_(E\J+ @.1Z/Y'E
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MT[$\\5_SKA1Z?NJ[5F6A?QNESM<EE)1@YF?.SLY9D*%M$I$Z.Y$58/#2O=I
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MTII/,]!X#L1* #C61M]'SX8E%^$1FC7/\+2*5.,]1M3LRIC.<$V\]LD5->*
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M2*J // I&IH&3*Q#AYR*A(6W,[_'Z:FEPW[!%3//L?/!EZY_F3OM:/5\3WR
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M?:%_[ ^B!579HL*@3&_5#E89F;=6KEC>45QVA7C5Y <XJHXPQ9 )]&?A";O
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M[W)?U^?G]?F57.A]-U^NILT4'#524E8.A6.!X_TO@/ &'ON%E:9A6=^'GS.
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M8<S&.7OBK6!G6Y@?G>9=^3(>75LJIV&7K$5ZBA >'7/OYFW[CVOF-HAI:F>
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M/?DBKF9C;[F$@J$$N$=QEOM2CM@@0 AVU#2UK7T*D(G:?&! U!'82V:ASR#
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ME;*Q4SPB]T9QO4_ZCRWA36X-KR'X^@B!&TK;QTN_ I/RX?%B<?5]BZ.9-SF
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MSD._>+="MYVZ9X??+W?8@L>F'0M]XS]B]+VIY0W=7%]17 PTP50YX;C8%FO
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MREI[T"O$]*^9J3&M(+P8,$] E=HM_%2?-OFE+/.:!USU(D = ORZH)8TZ^@
M^^Y+K<1MW\P?%9_#3?7'/7E^1ZNB7")T3A;[RZ7QHL6M)FT._Y-X0_+$VZ[2
MOM7IY(4[X<?=469?6<8+A^795?OC2ID@=Z: Z=,Q>\Q8VT;M>,.'#XL1A-@,
M&[:*=^S[H%H6JG+.O_&IY;@) O5Q^!S #]:PRT5,3EG&1'-]0G/X%DX>3:-K
M5AH*??>O9G2UYO:WFV[OR/7<[\9SS?&'3,L=XF6R\4]2[C[BYQ?Z+P=RU>",
M@SVDG&&X="!;[<Y.3LVKK-U+\I'P)09.,AARX<W6!BH[6IHU,(X-TB)0;0-[
MN;!V,^S$V*RPCGTZJC$N^63D(NCCSG["IW- F^%9E@OC$R <5O7_?>F&]IE=
MM4GHIM]4%J\T+1A><.0BJR0P7@SJOJ99<UDXT6I^25-&VF.MY<YR5>2E=W:,
MC6DF//[$$03:'V:M9N(\?(IM*<'FNUG,RQ=O-_['9?^?\<OH"4.>]3%**ZK&
M/&UV&1\JWCS* JVV_*UP#OCMM]]_WL.D29=6.42S/K_@$?G?@(MNA6MCYX#B
MBT!66%C("3U9&!]\#BA08MT$[69GJ?IORT3Y%2X71UU0U/Y/RM"E>@0V9D]S
MFWS<V\8"A0'Z\C-9.CVLB^> ]-?S(8/;0864%FK7&U[1!&< @#_US*5EKR$T
M@^4<Q?1<@OW-U#U*S#\'<+ P+_>TK [/ 4+[46^S)Z%/8(K_OE'2HMQ2)I_I
M,N[R<\I YJCI6<OIX[>G-P9_S+]P,CXDG0/H(V<PA;_H@PD_">$?/^@ZD-BY
M.)@'E,_")_36<Y!Z:YL.FQ:D8Q .,%IHU500'+R0;PFZ?>@28_AG)L\2VIQ+
MU21V9XL*-.G:;MYDZ&?AO&4$7IYY QU_Y-_UC[FIZ!AZN"=F#PN8<S$OHD<T
M :6%UW>^S$JJV,H/H[V;M@YL8V4&>,Y<DD'4/TG6Z)0?&X6*WJ#6%'/L[IWM
M.C^U3?FBPY+42+@+L6J%39M51."6>>#;&0BLDK:PNNPK.$C5V(7P2M^AG#@\
M2[ \LTXO/_" -X(KB]Q)22,$>3_:[)*4P>X-*TID2F1UB(S)1$)RS!2WG*0]
MH[<A$X8841RCK9$57T)S<)38^IK8#3W]I\SVS7CG3I4!WU.@5DSC]O+28YUU
M1/<]T\A8/30CCZDZ'@/5EK]SE08UWRA+_.6(>?SE2-O8I1]J^YH?%Q5Z4LO/
MRS]]L1L?8#X% <;I E_6[T8B':XF]CHE6E@*> &;PCS< L%'91MQ)ODX^+>K
M3/=8 HHTX\2U[K.''FF+-Z;<P[4\RN):#'+*D'X5\K52PXHN9L0J<Y3>T:VS
M%#Y*T'%Q[J%]T3AU-KB8U^:,C>]SK>/T6U"LK\[@+;1G:(DE$3EY[E'+W=0,
M9!0QM?H'2,</%17>_"%W@Z_0*R4=4JM\QI2/E,D7"K]N*29\EN 5+\GGBQC1
M56_\"P#P[]P/BFC"+V05'-Z0[*,57N0_LDN.CU.R7LSO*W;XN-Y,LHJMJ_S-
M1MLO=Y=1^-M-E]J4#7:"A0W*FA0Y^KT8"<[VHMCTMB+<$-H"->BTLK2H$H/*
M*<VW;6,VL;J-LT[R>],_6/:GNE5:W!^J/+__[ZIQ =@Q!S=920\Z3P^Z3]^-
MFD8>$UEPG\)NXRUF8D.4=^&>)^H<(->R;P*#_VXJ<0CXL-QT,3.3$)(W\F\5
MOX26XN:K>)4'-)MEF\HOT)*M8[OU3%[^E%2\.5)^YKZJ/O,;6+Y*"F>]BHDR
M<2+B\:J%B^\C>!90]I+?L"2J<! NJVX U)]FEAJ3ML!A=J<>W@8/V]P\:1B&
MM'2C?H6H649=WSBH##:5N[DV%&4;Y_N%L!^G:<IG)WITX6_ ;[WV/Z'7J*U&
MST]+.ZX&EA$N+"S186.MFHJDV8C/\"@%L43@<K"+2NX8!_*#)=E7[^-3WDM_
M#4(3<V'IN]:E_C A'6%FJ8'A>R\-@4X/=GA%1<6Q+"AG/SZ?M*^-.^A8SS$;
MP@K: M\&9%"KW%J-)]7';:>V@<>N&PU3+_,%<_>TFM2:5?*CZM7*_UKA<2N]
M*BAHQW0[4H,$OI<"Q86D,]#\EU5$0B)\Z!H_\/S6:*&58-D3R9LE==X$>>WL
M*?#,<\=DMXFVT@:^=Y&.\=2/[G<-V>#.2?Y/GF)JPM\S2 2HY:G'UH;F,%6E
MWMX"71N8L<Q8(TK!K",,Y[!G0@<7_>P2HMA1!G+*J&D*WK_'>KX!M?]8$'XL
MHZ=CAGS=FWW3?_#RCHU8J3M)3BB)-X5MLW--64%UB"W\', 5Q3T5\I<+J9NO
M/*^.*K?ZO+ZFS7DT+VO&.9T\R+NO=[IRH'$G[X0KPW."B VTN0Q[U1E-B!C!
MCZCL&MXV[&=U.4MO[J$FYV7>D[_EBC0TEW?1H/S4O%HD8LJ9?-"81^CP2Y4
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MY\[?%'6BK;_]SM[&2\N:_!#QPP%ZYP%9SJ@VC5:O+ZFG)^?P8'5M\ 94A6O
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M=$\I\7J>GSN^N.<-H3EZ\QBI/,=W*(_,Y_@H7F[V/<1@#J,'X>9<GL"9,_"
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ME(601'>>.LMX D)J!4F;&EO?7BL4BKVP?TUC]8BY)<?J=MNCMV2R!T3E>6^
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MKZ?3UQ",$'X^M;G@+.4^X[@OJV:8_J:+K9%@6[[ID1CSV:FTC/++HK<^3$X
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M>=%L[YB7U<RUE,*N[<TH_^O@]4JFIPG*7;,_3@YA4[8CIYN*0[5:+]58I7D
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M&:JF>-1(?;1D*YO192Z&G!3(?-2>B78F>-EJVFU,U?U7.,AQ6:H2(^/H%_$
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M_4C.,L[E5B%W\8\D@Y\@!943EQ-'R\XD^J=VH[$I"VKJG1;9T)2B:4XZU?L
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M](_E4&T<*$:-=]!8^;'M5P@-#AY-W%;G.;H@"K'#7^:>#WM6..-6A2P<&RG
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MK;OB9''IB1#/:VLT@YTYN=H3917!J&\#%<@6YU=#K7-R0S,O0P/D=I['5T@
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M)\_\K+>]"Q&B<FZ9*BK;R<]8_(@-K+9!MM!A>A%"9);UZWB'V)-0J/@42W!
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MK"Q;E(2D2R2#3^'',EF]SE+GV/"#2^\*^ R0[%@_C+/I*CGZEDKR:>NF&#T
M3\R)EX9%-QADPK\<FV[UD>K8WZL2YQX>.-75/\QQW9(16S5_C[I\[)HTVZ^
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M,T?K462RD7VS+IYY>S6P%LM5G7FUI"L#]_AVZ0(_C^VNYY\G%D7^LR4MJVO
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ML]T#/@\[[14>:5Y?I!M$4;NCDK$/9%3L['Q/>_VCY@.^-Y&2IE,K7?6IBF>
MAICT?6,;@>[%KX!S7P9W7;?P\EH3)J4*=[V"9>^J67.8]2LQPU+G6SUL"5J=
M#?JX;9'Z[@I=3[F&;+M<]0)BOP]IX]GDI"$N31K/ZAY=$'Z9FRZZXZE]90"4
MR74Z\&A>6M/C_^'8Q$->GY&+/42W31<'Y  N+C;#/VBBJGFQ<XF_=4BN-QZ"
M?B'R^EY-@L^X<Q$25%.ZY[9>6 \<Q,S7 >M5963*\FU3:J&%Y?</&JZEQW\Y
M ]2X:Q*9TO+2.\6?)]//ZX-*']T*6RZ%HM\<I*MTJM#'E3X" +RXO7O#GB]/
M*J>#P'["E4.JI@]/H.6&Z^F=[D$]VMQI]BHM560Y;34NGX&];C)7(9!3^JAF
M2,8E:/_F[]2"CF'I7;\%WB ?PY3-@R/!NM@)D[[5TP&I>1C\V;"L1+WTY94H
M=FL9NLOCLH9K7=M")MX&Q[>E'SN6S/PK0QEA K\2/^X;D@N3_=7VV\*F&I^,
M>?7>3E5\YV 6<HR+6.EC #:9/S&SF-L1U!,%KO*1;&O[4/=ZVGMEQ^\KW:=D
M%H6%1K(KE[Y&/.U.<!+0S9P@"GK)Z#89+<2^6LGI<IF.[J1OFC\9+VIUE9F;
MEKQNUP$RZ4[-%>)9KT'""Y<_4 1B((4"6^UMA$0.7>CU5,U< _4(C\-/W:UI
M HXT T6&)_WO"3K-=0Z4%[60T]8- -P\W%A09L9^H]SVEW^*EW+\82(<.)ZF
M%.W:WESP'.V:CL5]CM[>:(_NUP!JB6\L>IP!B,'H*[59:Q*.#^(QZ0/$$YG3
M-L$-.VT=<DIO:+X[OC*@>!@Z/S5XE"MN6VYDEG]ML!1.SF$3^7>ZX$;ZO],%
M Y?^#UT@;-^.!5_A]O(55KU&_M9'\?@IK]2X+/C#DZXV.$]=T$&6PP8Z2IJ9
MA#K9,\#=2M-R9$09SF/IM"K^/,$4XZDL;0!_<1YZ?)BR2CU<-#;],^M\A7W#
MC6$?/4K,3ECV1D17N@CXNL789'TL1=[U*QLD._^?ISM7,399=?C/_+\+SA?8
M$#'L$BSO&A]ZJ]2@Z#P+ZBG8C&%QNB\IN"+D=Q+H]:"O]FK"2]=,=#6FFX_T
M?1>V102WUB'*EY9N'B:7G@$D*%]ME;A./^4/0*)/WE%&MMAN)K7_U(F_W+GV
M/$(3G<)P"F>(SZYC2UYE528GA,7IZ[5!V?WO9I 5)=;?>K5<$]#G(9;2QA;\
M@68"GQ?#EX]MB2X^BT>_\=]-30\ZH9Q.T5[<.NVAJ^@WUJ)Z?,<P>S FR19.
M\H-TQ1!\ T[";("^( >21A)XQ^!%,;!%'&=9W&HF?%GYGX^#KT*VQ8[N'%J?
MVA.[3L:\+Q"8^3N)A)^&8P,Q4L'=1J9\[UT[ VRTHEF%87^I$;:W:P  OL1F
MQ!PBAI*#Y#TTC54W[CFA#FG_-7URJ\^T&I$7JK^5)SO#S/T@FGEMX/F_S<N!
MB=GDBA^&9_WDO5]5!^C)8)!QZ4;7Y/@+7YO8D/O+.RY9^^I#."JO65F\?\Z'
M? Z-7%*1 XV'Q1GE61:2&50^'!R2',=[F(P1X+NF4D_@R"VLP6D.AHN!3;Y2
MD@89LJ)#E?<W"@]R+,T=[ -T1.75)#/CD"=XPZXU5VBZMRN4D\'<]78D::Q.
M5(EY*C44;7<NR.KH+)=,^JV.MU1=]0K^;$,XS]T"-8LQ$%DS>':R]9).7WCI
MV-N53$P/I5>:F.:@E!GBZL%XZDL4\$1,Y?>PH8?[]PO$=4+63AZ]>4O:O'QK
MB;_CH/.9668^\[#M4D>#[::6>NB2EH)55U>[&H1NK<_'8WFM>\[*"F49YK_Z
M;."]W7IUJ:SN<O[Y;Z<;HWE3S#14Q(T2/>-BY#5PR+6N7,WE0:*L#_MOKW=(
M-0C)X^E/LY,Q:0(<^]FPL31A1VJ@D_BTU=^#/XYJ-WX8^8[<K?^I\)!MI'7A
M"*C_&JHML%S=T,&]Z+%T+<<9P*VAC60# =U!.JN9-522]6\P@(L+$>P?8K K
M U-O:DY34RMI,=:XJZT%I_BJ49V(EG$G$ OO:3WJMGKB0Z/QHSV!;?T[='K#
M/,LA=7QC?RQ2 :.R)>SI4A9QPQCX1TP4!GJYFBRU:YTR>S]=8=CQ^%;%^?"H
M LJ^X< ;Y+8F1V=!0U.-?EG971,IHE _T!+SFT/B8J6.N%57DG#V*K--,#OG
M2AU4,R-<HSZ]OJ["0$,]]&@-"3R8N!$:VP\:S^]DV XN^O@,#@-OG#LJ'FV@
MU&\J\D+P-2?J'7 9NA81T='4==CSY8AC(C\&[IU?5]F:R8,O'.0R+7:Y(4/C
M#Q^M=,4$:JY22[D[Z@':0L][77!Q[#XONXVW#G+AUY-Z7TH%Z.[(C67Y@T@J
M^FH5($,<3&/V<_ZUHB/?*MGEVVF^<M96QL=5A//,%'HAQS8^(=9\2"X@5T,(
MV)MNPJD4/5E[^I' I4;)$J]FT^B=3)Z&&9."NTD4.:+7^"3J_AHC-'SFRTOI
MEY  *([<8\1)B]XPC1K*_Y- %GI:5;AD4Z<G>]7! 1[TXLC>]UG"O*Y@7@_"
MMHN6M0>9Z0OLZ>LB)_JWS9&AUB*L6YE;,12[W'2A,J/&6\.A*;*&D<OA:0>C
MZQ'/&!!KG".FHGA9E?F80ZI\>:@;$L)!]FS1ET!,WZI2;YY--+/ :TRJR\*:
M[H>6CS94$&HF"1!+8GJRY*#1FI1^L=A:REH)>>_TV\Z.$$Z+2 I$,D+%)QJ;
M(I7P9X#.EZ:5Y@D-RJNJ%.>?3.;V9[+[5\ OEV2E#[5WFNDH12A?$"\DT@?>
M;=4X[G*JUU<![G/#HI_$+].=F/[7K!>!GN$@]L@Q#>^_(YZN:DH^]ELBN;.S
MSS*,"%K'@1$K:L>G]<;780F!$78P?4?:QZ3<..0CNK=1KI=M<1SL&$F*6'<_
MQTN;HQZG"_$*VY.GS2.6WYP!>N7]O_5QJ$Q+AZB7($OQ3ZU("3L^Z_!O.PQL
M])"O"?P,@$SEJ6KS5TJVR>?42GK2-I[)T3G_F&]0-^$X@68L2.#Y#>>MB\X<
M+/=;%1?1&-6,S7\J9+EF@M13-%#KO)YFNWH&\%"Y "/H*$J+:-@%UIE*BK>0
M@O?0/5OF)'75<9SE@@1^[F*O7X;/A0T$_\%V6["3_)R4I!P/ZVY>1>R-/>/T
M/L:\JS?ERZH*E<^D?1XJ$XT6CAFIB@/?BTYLYO/#VF9C@\#P07L2!CSJV$V-
MCY;Y@W#>*3MHSGKPXNB;62K$')I3+$:LB*Y2GH8$32(QN%5)]<!4JTG^+@*/
M(PQC$EM)7RQ;3#)X=/E!G#/1=]O]"X#':/_.OE+;IK3#_F\'I]DQ^U+M>-_C
MRNT$?[?BUJHZQ9?U3C<&X7\3Z\N>5#7H269^@*IQ'5=H/$^93%HU9K9 >YE3
MRCG*RT6K-NF77#=GU"K]JII*U35HXOL-"N]8A:=/YY@:(;PW"?O#/6,K/F*B
M?"Z1I0:/:$0C220OT(:I?GIH3GL!5;LR;D2 AFC@J]6D4M%<U;>O[(D20G=7
MDK5:2.G28V')$P3/$+Y#87C./KF3 00NFUY1]G891\9>CY-Z)"$79VX6Y_PY
MQ;S 0$(X_;=:(5L5S%0'^6%Y:>^\;@?1! HQSRE:$3<TJ31/]L93O?'3-[=H
MZ\R<^@;S;_5A1NZU4-E]7H\]VW[GB9/V$WK5.>$$I&HS= )M?$^B2.UA32V2
MY_>6_DK3C&1!O+WE2K\&-V-E^#JGQE'N<#%J;W3Y@;>1AE9/27K<<U3XZ.2P
MIZ"&3M6.SZ<VR[7].<E$$W5(9F*H]($)9$H>16XZ8;F>O#+Z,/H"]_T?6Z<Z
M&C ?(3@7S$C_>&B/W'GRPPKO#M%HQ58(0V"A<@G'"V(&9NLV-*3/ $-71Z-"
MP1LB[?%Y\> VT7AKR\N1>-2.[5NF8L&OKD-' Z6NWF_+ST_T'-8.R F/C[RT
MA2&-ON5[P=&^O!6^9M)MN6Y*5"4Y="Q,ON@VK4[%2V4_L+/L@3=<G&=P+:[L
M!*RD*@J:.O:/BG ]Y/XQ9\3<JM2;U++W6ZEO@.OQTO(^P]4(A?<GAMP_,_1/
MG/A+:9B.H @GC4,,3^8"):+7=.PY)7)S(?9+CH^=FX%3PP+9+L%_(F.T\%AV
M;G?Q3C':649WF"Q40\P(Q0'-S"9O:GF;&MH)\,TED[8KYWO42<I<R>"=ZEI:
M9:\L55 4)*+:FKNP\MC/O34X6] $^]J[)/4D$C/EU*$W88:]).MZ<G""FRDT
M,67$&\X[ELPS.TFM711OE5"\5V]?*C89>XM_+2S@5;5[19B;?!W97 *7R?'*
M?@.)-'TMMF-\3I>:(3<8P&>OFG&=<<7,S/ATJ+35/$(^&1I&]?H0RJ*/[EL5
M:H*@;JYNRPH+&EA_CV ]I9F+LKAWYG$APHFM\; !RL<U]LQ[PRN[$0 RZJXD
M9I@U*]C#NCXO R:!JM>%US.8&NR'O,,K&+\I>2/YB7*&S]@;%@*"O?HA_MBG
M#65Y+ U\/87>OS"RKYR+9]91FUM2EUCCB1+"IYOO/^-6K357Q]8+^;&[TL6E
M:^BJ8MI)^]A[1,><7@4FH-(I!X2C NG1OUQ_F/GUW);_8;<;]DV/5R9:&A4U
M6J7&-V\W=P9X;7$[&J5TO ?ZIPY]%)Z^>;<O%@E7D9@2D%]N)T$?Q.QU&NM)
M+G@++71W5KV-AFE(.*J.>'?Z1[0WR9@CY(US(0X]'2$1KHP\0T;<3A)%MIW:
MVD=T\.H%YSH>LSM/&:H_U4-P\8>%<?+^]M1=[Y_N'S.>#Y$SRGO(!$*-E/0%
M#EGTS"RUNG2.T:A'D<I:]M[TQA]DZ=/JYDWF:;;4*#E"8G9ZT YZ9MZX0W_\
M24E!TH\D U_5BI7-T\(Z=2!3VHG2P*5^P)<W.]ZU@_DAL+7;R!D/FI8 W;(C
M1^1_>ZAE?@:X,;RRL71@F'YP0VF/;2/D>/^N:U@[_>$CDLD<;]HNZTYI*)8?
M])P> E;G:QWEE5)BYL5'(VNJK$+ES* CV<)09;MKGM\P%J?M=DZI[--+UMK[
MD:Z66SD@;AN3+[CF%(R!E2&E2K<D!U+RU,<PO#JTI$)KUG/O#+ ?="NW7E>D
M:?ZQ9>[4PSEGF<2 TS2#DF*/ J=W;,H7_V_B8("Y7MM9IG96+=5_-O>8+]-1
M/Z21VNCF65 HZFI1Z%H1D=(Y&H8WY0B]7V&9>=V1+<,E44OZ,9%:MU>,VZUW
M;"SLZQJJDD%_C.!PX'.M=U$E7&IC%HK6FZK4*Y?$-@2U!O73K.J9O-H"5I5M
MR85SMUM.RYD]>@RB?]S<;9G[KZ.2IK37M.3\]5::[;&<#I&81-AD2)IU>*B]
M'LZ_ HEP:Y-;2[Q1">*;)_<73N$6#.[ R4_RH@ELR'K%GGV\'$PY;<G]GB"?
MI*T=28!+VBB=V["LQM%L*<LR25N+OY\Y@INHV,RM5AIVR#&BP&N3S2C.(([L
M#8<(WH^%GI@"1ROJ\EO5.[LEVO]!D:NO-TTS1'YH"]6"T^VE$BT&]NN5:.L%
M9P 36YS]%HFMUA)YRC^Q,H$WI&L".;3C#@I07S=/&ZE^D\=B%E2DF+_D#3^"
MD^&JM6/Z47;5NP87H:#84%-";D^_2I:W;>.0M"%3525!A>':HMUOD]M^<I(Y
M=N5651^?_V,AT4@W>9OB:&:2FDOBYST#WK&RT2JFI:4E4%=7<?=^I[Q?DJ=!
M/ZI'VT5;US<'HFO"9G@#:.QGK&6L?:L/^OXGW.'!C"3,Y?<B?E6=B\!<;MCG
M/KQ=VN<)&4O]LD**S*T'C_]>1LS#.LJ$^VEJ."$M==? Z;CNKO#LKBV8$LU]
MQ\?9,+\D;D:$=<UL#D;.(TMP6:LZ@5Z4RO9] B099Y3_BT#GJ@IW?>0'7<,K
M:N=SJKZU/@]YG+&IE"N("/O>4SO6JVYPG$/?-6]UTQ/SO!<D1V$G YWS@^Y\
MJJ_L\$_--CVYC/#MHFJ9V ES5?N#LD%KV7-RI<O_0?]S95RTR.*LB)F(P&;(
M)7#G&>!!?3*^?=ZY:JT"D;'/.X32@>G:5%A4\96#/G6'2H3=RJ*:&-K;&_L%
M@IY]:6CY+'98<GGDIAT>B-B)S<>X<0G\M?(7X-R7KEU7O$.$/Q5X4.;C.3%8
M_Y:AB9#HW2-V$_UY2Y@?RZK4U94I_-6-@YC!?NN]@FG8:N_4VDIZ/S$68D0W
M\3LYP$JM$DM?34KF^!AH?\E?D'\L*JWYZK^/?#$Y B\Z;9?/%AS^29IH[_^"
M/F5,G?M[_/K=+'QVV4JM1T7/-1BTR\Z1&1<]6?8AJ3W7 M.FLF?2G!818:S%
M;4O@8>69!YP!SFTGG&]8$TE( +?TFJX*4Z;_0 JK(7\>WE\;S;3[QEK3$C>Z
M>M.87S5DJH=X+WI+O@(63.W:Y=5,KRH;NQM(,M.)A^F5)RF10XG7PR[X3]@+
M*JFT'"KNG[(&3^BATI^S1U<M=OZI\';5>2L/^!]6>/N=/!GS])X2#^[ S1UK
M/7;?7'^_Q^.4TX,5['2KG;;OL-I9E:MP7=WQ(A3V7^?+OV4:?2&PR[RJPLTF
M?2 2.$9)=4A2F,I7\O^UI:73ZCFKV^QCE-6_II %IL W%I97&U;S0*X>Y49L
M7OM</P07Q^,'M<"6/WH?#&/N==T0LI=P;.Z8YCG]#!I1"2\IE85[>UKA3:Z*
M]+32R3DBH?3T>>W\S$@5G:'=U4BBE>3J(\GCR((^:   \,N8XU'5V'$*&5<Q
MCKV&8K=O;[!H=YE>UCD#9* $;CYNT8*,3>VW4!&W'X9C](APC;H@--!Y ;9P
M&S*4KCIK;\HHGUY0?)F;EM6?'9:[%!%@O7^)/>/+;I%J^ H")0,_),SUK8=C
M7TZE(PJRM9NKM1V0]T,76/GRVLD/S@"V0N;O/MP= P ,V\:TCU2W!;>I8ELW
MS93VE]</F24($=GF*>6ETSQ$?QKAI.X,,"S7LWI=,9_N2;$1NBT5XL.QK=FY
MZ.U"C.4N?S))O5HCM5E<0MP.M"H;AQB852S&GEBDS^V:R.K#9C?W?Y>EZ@5#
M%WH,7"N=UO)DIY!.B%>]4H69-5BTC<E(\66+Y'=?BOMV',.X%D$]?-6>/'T
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MYT\Q\I5'&Y3M3*F-!J=Y6K\W([ -/42?BL:/H].%11,Q8<'BKKH=%NE<%P^
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M\'"?]7WV?A1B5OQ;0/;WO9=S[\,;7!G'P.$;/ =.RHT3BS$)]O(*[A-_6TO
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MI*7?A=1VP*?;;GGI# 5=N0116H5LAMZV'LXLJ_SVC>)>3, -%^N_.!8YU-6
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MBQ1T/G_\$XJ76AM=4H^AV)64K%RDX!]ZB[;^H!Y-N&29+O0:YKU]VO.6^QT
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MC;U9(*%TX>&YW>K*3(' FD6'E03^E;9X*>?M';&+&.I$C'OO(+2NYJ!<'_L
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M['#>QD/)*_<8:[QTN%G[$^(^88!8AW?];N8+*41$)T6E55IG28>G^CT!S=Y
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MG@L_&_:>HB_UTL,6)""2%,V.ZV*G/%(>D4RHYK%<;7'D+'([%/W,OM-34!]
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MYWCV]!29TDI3NU;_Z.3*% >@[#6U/$PFTHU0="4\,9TTN?P7+VN1$<\BFG$
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M>Z)48>M9,+?TT\/SRGF%7;[NV,O'S5%>LIYU@7>0J7<\O1A1EG=%9-0-GMQ
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MV^@$5LQ \L@MI8J^:YJ=Q%T?T)7FA\\-6T!U(U+_/-+E[:BWA55;)S^@%ES
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M&U5*_DH)BV>V'>];KS[7FZ3-DY*C$# ?2'TM_Z<AAPRLA;D5&Q?UAW#^%4Y
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M83LF&,P4)"I/A?O!,&3X%RE#6Q,%$P-?B%BJ(Q>H;DA9'V/Z-,"_= *(U+Q
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M#:1 WRQPX1.A"TQ'/&QD*:S'U26*KZ:8FMX^^;H(5HC$L"2%W1<A?&[DN"C
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MPLF=(('#3FIW8*>WFQ**MW[ZZN.XI* REO8U0X'4C/?)]AM0PS; N836 $"
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MZ-355AX8_H\6$E4.MGH_X[W,G3V*DWI(/.?SI#Y[8'L^\W%^ Q*J_T>Y;H7
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M+N.?U^3.T4\+$5YE6B:'&2H8C);>W74AV$U[ASP$U]OI(<%//6\BO<=2&?;
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M!8#&&IV)1QZ5[;O-Z!!=!6>K->MU4+6+LQ_5:0GL)*,W4A_LRZ!4.=W\"O+
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MF2H8M^5&JPX6NR_C%&0R?@],[[@P9WJ;/V%9OZ^=:X%ZZL>=9N'VQT*>8X7
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M.BD%G=/# I&0/D=R)7#/,O8]4UHC=,=>LL9^_0 "FE!^1.2\FV\[87L@22,
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M AR6L[./WQS.LK1[7VW?-TK7-GNS]G57!P5M-!O4L/(ZTC;(AS?2*Y84:A^
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M7T.TVR"+5*NED2&KW+/<^2N\*AM]ICMI&1_((+/JD#5@XW1YS-_?2:O@0,Q
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M.K$*?[.(/9%*P+Z #=+,,#2P&K=Q6A@]$0-ISE YWHORUY].]%8CC3Y6L=J
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M-JN2GC =#K!!3Z!Y$X=*&ND>[IEFBV_>'[#]8SJY\F]=*^AI1=TECKB1&&K
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M6R@C(HR>PV[ ?D2M+L]5M!"[+D_3 KK*!-4<Y91&(Y\;C;X"5WS<PN^'/U[
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M%KW6\:K#K4M&36K,L4\DJY5Y01;"'!56^Z55Z8KV8L-;NH']VD+(84A8Z07
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M-U2ICOY6\XD:KFXOOX=A3;"X-RDIG!=PRX$D9;1M_<*QWMU)->?%V?D>8<)
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M02S.$H-($]H]>I<K@K5T7&[=;_#[8=;/L:O*W8R3'5KF,C'L.UX6(>FE;<^
M8^FH^V%@6;M\2I[P38MBS_2K@O>Q3_Y*&XW0=YG$@>.N5H80X)37.OB*NTXV
MM5G&<NU*RHG\XR[[RO:D+E2X?>^?VR[AY6Z%Y6L%8<;J:UE!TUF>VD>K>%T^
MWP]J!;9>Z41?RF(L>;K8NT7S^8N[U'7)? >1-#_'Y%4M2QYM5.'70*[EWK)
MV19:J7%( /[#_;;&0?BV2YNPNKOL;&%FJE5 RRSOMR>=UY04"QM&,YL.27WV
M??>-?_,MN,GF$C7LE,9-<VF_NG4;:JMP?8VG!.:'.[5,7E$#WK(3%\<64WGB
ML^PC5JICQ ?Z2D SJDY=H25B:!CDY-1*+S%X56PPP)2?5@\4->UN.0$172N2
MO+*_6L@-R:"L(+?]DO**QSC!A4FK=K>-=6^X"_]E1]42N_^:I"7N'',YL(4K
M0DN@W)AK!D72:8N[7DT[K+D[..&"/\EM9B>_K.#T._8BNX9:BWIV,&\AG O
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MX6SB'$?4;[HX(K48,YO9RTAYW.&  I<Q[S;;[]^!E(]B>K9\Q4TKQ/^L3YX
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M%9=@(':@ZEZ/56!Z)5Z7K&#6)BC'A$_U*(0_=E<' T*<%LE9^JXZ6:ST.NT
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MB[@0CH:#.'T(@L3>3*YZE(_;;+O7_<W(2^9!RP#Y>73TL0HS#S;*&S*?=,P
M@[7U,I\N=(%ZFT[ZXTH':/WI24W;9"'3- V/S1*[_V/!?>2GP]^AK.2F=**G
MG6@18I-&+S?9&PDY6E?<NL!HWRU->0/.XH#MVC08:9D^4I,M2E&\]21^RF&9
MXBFJ$C^Z\#2VEG0E8@W  Q-4<<;&/ 7CK6=*/%VUH"F;M"U?I3<([]SQ *XS
MCHJZX20ON8+G\0I&(,IV_N$ZK3Y"L\O'09:BWM^,PZQ^Z7K8B];?3A&=TW$:
MQ&E*FF&_(V9C60,6DK$?R4O!A^X;==E?2RC@D@<95.76$/4]/QG^%98]IX$V
MAO!;Y/W@LTVOJYALXLX--.D_<\R%*8)_"8*IO"K*P( *(X#5&%\D64)QK3/O
MMEIU,\F('\J4L Q<Q-WTVF[Q]&J'O-O3T\7UELJ]^#[JKK. @7K>4@/(;XGW
M[FVWN%"\8$@M'C)<S^H![BD)O\K*-R_>7S!Y"-.93 Y&^2P/.G*: :+'[(9R
M]C1(]3<URIIE5V0E,&%!8,@Z9JQF'B^K4UVD.%XA-C_;5A+7)I"[I;NY=KWL
MWR#S_PS.B89VO/,+K)KLTIL9!@MN<I/J'O>&O]/V>9X*&.@ AKLO$(T8,JG;
MEH3YVDSY?K:+ONC5N/*O5:/9:< GD:T,UM>I,.1'W.]3+ I20B5;Y@=?^&0S
M36X;*XL,L*F#XLG\^O1(5>VCFG<GDX* LYIBGYQZNTEG80MCN:NE>RVYU[*<
M1Y)<D"HL1$]K28:W4@AO'.09_% FY5>/G7^A=]!/2J^&-,L+O5 M%BW]X*3B
M,ZP-(/B-?E7W(Z"B6@??+^EB"5/EL>&2]%:QRF3??=/-U+-L;5.V]BF09P\M
M>;GE5%"S:%Y#2UD%XA;'%8#Q$3(/U5RF!T_B. ^G&F^MC /$V(EE9W?G76PR
M0>,Q<GBX<.F@[DUHXI-04?G[M6:W.B_.;<I/'6=&%/?)3T>4#P4HZ7#23<9<
MK;,2I E;R@&?E]7'I-Y,LS('Y/V2]@+@CQ^9:G(>6"WJHE!M>LAVVO'2[(CD
M1HYQ;'02JV$VVE>[QNF"!6'BP&^Y[D9L:;4YD(;4--IK1OURNI13W%@^01^Q
MPIC;MN5]'W=X5T:0T'LT0-B5E-P4BI/41.9'##5'#5!WM+QB$^N5#G'>%@1Y
M-^);R^8(-)+3*.^XKWDIH;8ST /:8Y-@"0D!]R09"ZX(H*NOB4DX/GJ!/ 9+
MAM*V[UPR36]+O6"2\X]WD<A]6,VGXD62?T?J7G-+2*68V71-DJ!UPGXW9(S+
M>KOBD! 7+%><79/BF2+09M%R"L]KB$!5%[U2Z_50-U87# 95WUV<5%OJ5-\O
MU(8/ %,',.%9W*-]X<<@7&V6$^/\V4G>Y-94UJT2(F%,LVCABC-] #ZYU$!4
MW,P0GPJ(DSV]RLO='FI,GVTB5A'/P8,&9VT/8-X#QG<4=XY:[&M%K3XUUJR6
M:[B>IR3U_)^C*\!;=6AS'!!E$*:+D"T,53OR%:0OD^ %>.A&RMG1VAP"AX K
MPR7BQ[4<^/EO5WK>[3%7*9>W'[_?>S^G:#[[XY#H;@O@;:L)PIN$TG 7KCUX
MP6XU3D/]X+N$GSP-![)%]*\(P@.'WJ.6<![VQVG*]9-/]2&:$"V%66E\&GLT
M61E#\ "Q]!QPR[\? <Y?)E]IS;\)N^^(<.I[+/SJV[BL$.,P0C^ 'BC_<5&5
MJ'_'W!':ET*O/S-GA%/7&WD'+%[*WTXRIR)+0MOTP^7_8%7CV!"XJM4$L:DK
MB1FGPFS&3.KHWTE+K:$9+73?TN[_^H (723RXZ%NY?L>UB7?:764^O?P2#T%
MCQ+BLDO\D>#+#+CL/D!'[K3*@#W&",I-'ZGS_&.Q@:/7)V'=+<92XJ1(YK1@
MS5HU1?+_^!_WS'\0;XV;C#^@(G[?N9#F&=_;9C??DC0H18?27C0HJJBHR:,S
M4>JNFWVR9O3G4Z[(_D#:L$?)*L<!8GE[*NHY+YA8P/03ZKT_&GS15&/'-Z5B
MUUWI5;!9M>KX(Q!$88]D7O?PK#(\):J1^ITA?\G)=$2USZK;;,Q0AYX'8UD"
M!)<A.U[%%":27FVN3NM"G^\_5!]B^70(!9%NNR [7'.OF1?[AV\"W^E6]7"R
MNY[=^NJ^-2&2WGH[U:9V<G?>JBJUK)49Q5WW3ZK7)!M96V1J8=E=;9-J%G,D
M.',+%&"59Q^&[]$41J:3)Z='N'+8FLVFT4 -6ZI.1;/SYL&VZM:<,S"1!?UL
MMQ*K*\/;X-:UVK$W[H0XM8/O-2>--<[&U#26^ U64K6HYAM+NTCX8JU*THC4
M\\;P]]_U1BMH89CYG'68;ZO1VX#=XV)79CC GMM-%9X=VS,;ZJU>QQ8MV:HG
M^>SW]_?<K=A,=RS&"6N<NL(NBPY11 2?(XLY;IRD:PP2NN#30E^/;=X2!KU7
MLO(5)4.OE%;:\JWY6&)E,:F\HZ8\F6[YV</HH<*'/U_FN9:UWWS6:S?Z*3C@
M""*ZRGE7H01;8KZAC;SK3"4W<?8M- I;G11[J-?/BWK#NO5P$Z%C<X@SAZ65
M"V$+F)-<4I2)A$?IW=)=E3):ALU%E$DY*GSCDL6CFL#5_:IGG7_2+"H6 S@F
M0A.."I)X5&],V:"9(V=9H2W>+W?H;;ZV^XGM5EO*0:8.0;7G9_Z)P^O2SYQY
M[- +SY,ONXBM&$1Y,?S<LP6TBZDW(":)XG;5=H[B])G]YFAJ'>!V7FOA,GNA
MZ[3$L(%!LKZ@"I!K407A=$2_K5O[J3<_9HKK>S\VW2KV/YQ,3Y+,S@Y5  =#
MS.\5^S&Q203'M<Z^6Q+"O_\W\_MB*.],9CZB^UM$J<1ON>BD7F"5]ZV>5N-M
MAAI0>?S7G7<8I5J@Q$X"R:&*<D5KHY#1^J4M,5?<"TECJI7P4,Q 4'YTN:D"
MK;\CS[5YK$"IP?OS*[188W=+,2;$01Q9^EK<E'_2NN0$B*&$? Y8$%8;1"\-
M^'INAD:AKE_Q<T- 75X;]K=(+;Z-@3NMTY9UK/NNW8_0'.]9\-.J!7K_NA/I
M9^](L)0<=(?\??A+%]5(MB+L.^@=;7QT#H3[6#;)'@!W4[[]X)OS8Y0TFI=7
MQSQ=P0M#CU!/6_<J%ZR78R8.JK]:84#CO?/>;63O[)XETXN3;4W/Z?_<-H[5
M%LTS8PO> ,:-(O)0_2(=[(_93[;JK+U"]I+RS=-<N_K3)A)J/ EK9H86XJW>
MP2\EWP?SBX6&-ED]XF>%MXQR_CIG]VV(,HU&5G%FXG_MTIEZ-[%K.-M_US4V
MT8NRR3."KCN69^^&II/^IZ7TG\/G#>.3C-BN%$'*Y=0*X&'DD()-$%K+W2&_
MCCQ02&J:(&PUF#0IB!)'WPT"3?0+S?@OF"2P>(6+9T/KH?#3X]A"5HIC-@R,
MMJY;Y>4$)FP=KP74YBQRY7LT+X3%<]_J6TPE600^*[ B(R4=/H.-7=J$35B,
M$&,IQ=";UBLF]!3M]S+4C=2---,F,YG  ID4!'4CG %:I@XZ!.8MJSDX'%3D
M>IL]OMME>_?D!Y^Y;49>,3,]V'_'[\-R@W9!]4'T?*S.<<QVL !^O:HYE1%2
M+>S?!_:K$DAVI.JLV2-VP_0_Z$I0S:]&^38)J1,T@N,?VPKO,VW[N::OZJL&
M7MH=,YJ'F[&R70\0T<%1[5MY7"W>2%/1;F%26ICC<!"W'QD-V;O31*RN!'?C
M$B]:1%-\!6_;NR\<;VBYU..4A)P#CVYZE6QPP\7!!FQ5%&M;8X9=(-\0B77X
M[,$^!CPK,_O@!<_5GA AS#ZXFB"/DJP<#K\U7&,"FG:LB&C.>0+5\^(?\+:>
M GK<UN9&NS$FNR(E=4V+SO<=E\+4*9C[9W<'W%A1EAJ2'M <'(Y,0)US:>3"
MKXYCHB1&9T><N6A8Z8>6Y]56CJ_\M38'1^LX<BT-24G'\@=ON4\6C\^LN%G5
M3N;S%D/=W]69<>(00 _=WJ.ZYQ&ML.'E_0C7[L%Q17G8 X9W-_= (B[&T&9?
M_&7.%6TY+"*GI.A:Y;L"(;=2*^PZ:EE0,K)Q0,NL\.F1P'H?Z[AJ.3BX3^MK
M/10G%&\QUYPW7P"TSNDBR]X_40.1[C8QTVSKM7;]__L?R40<]B_3R5'7= M<
M]X'?5*#2M4Z,>UDS>CNT^'M7D_P1L\GJUE=T9BRZ;2!62F(I[3L$Y<>>@^[L
M3I.)Y7P1?F4-4#2I5GV/8Q2N9)<3G9>WR;7 $,ZTF3_XY,/3P3?GTS,P!C-$
M&!>71F(Y-Q0VP;LBJ6U-I_<-6P?]9892MIUN124#_"_/A/]9-L^FZK]<:)$*
M#>R:\OLR$9&PU:"HSL3W-+$OY9[+[8_03$X8\[#3$!UQ*%FU+1(0U?(/7+F5
M##:<?DU!;Z$%(8PJZY/'1\/,]!]\LL&;%16$5=!H$2U7T&L=(('9[T.\V7%K
MZW8YQA_I1.8HAMS?E^TX::9%['>+F&H$: ^EL$+64N_=YEG:N75377]>#^X,
M=+V]214UO)*OQT(X--MZU0[H?^C[>[]'#37N6]TFHKZ_+TOX*W*;8]9M@[Z*
M#H/&0Z,MM=KS$R2E!AW>+SJG8;(K2MHVE[^-WS_03+O^8>E_V"3_,?SM5TCH
MD$+4T[.'M(Z<0=.E^ZKG#EG\U5AL4Y5+VL:1<3Y <J)L,@J0"Q:S$-EU^NM^
M(+GQ^JG(WU92GI\]]:-1 C_2":NG 'XG(7>3UJ>1,YZNR]9X89>*2DOUHUGN
M$)N&<.P9X>[Y<YH9OO915_M7Z&L:<T,]Q0$COC5Y:CI-3]O;KK=8+UY7/8R%
M+ Q8BZ8G.*=(/QB2AFW:I1X0)>V?061/8IJKXW:SLRBV]<,+BE_*UC*'1=ZG
M-CC5*:'D&X'&,.UICK<-CIP_)YOTHB=XMMG<1%%K]7N"SW3.W$6'G0#KGY N
M]:(I+<UT4?_OO"JB@NO;.D2&"SDA!3B(P(@Y])AH)"7 D_HR((^M;*9^\#4Y
M'MI]"%6+CFR,0!^3KY9L>3A?;/#=F@QV15W.B>9+G5M;VJ@.=/\<D"(9T6VG
MX#.86G/"&LP]6*U>D6C^N1@T7&_H0LVE57%+R_23Z;YD^0N(NE<ITVR/H"F2
M!/_W^)2.@)O'C,RYNL9]J]<KZ62P0](M,T>'73S=B\'PRF1,'@#;.];:T O^
M:AJP*/%22WM58O9VWY<!^7<'5DG9I!]\3M<[3RR NZI56?D&8XZL!H#8*9+0
MNI&K-)LVM3/@1A']\ 7D/!Q60_A':UL"<P"#H9"?SM<I&+20!<$M"?7F V1>
MKV18)PV&(</&'71JI0WE]5O$^_^<U!=@X4L=9PI*N\WSP>+))=MP4XYX[^RH
MQ@A1#=Q&!Q9;+K]NA%AO+;^O!XL-0X_T>"EOHX7%L5UBCCNZ\A1>G8N F=29
MRJ1EM)K!OK(2NM="H\A&*.D1 \UE'67NL$+#L8Z80$051<MQ5+I78 %23_Y9
MR+0[U6'!$1Y-9DH^YK0.T'F.LRE6N:]?_&96C$?"YYO#@N:6P(UL1- <0PYS
MTPRQLGS=X[^=Y<L6NW?9+Z>[V KV/>X:#LI?ORQ4C[UCB^["'ASQ5ES+7Z0Y
MD6P9H>)BJ5_&U=<1I"]E%3'#&1]E=;1+<'8@$6BZ=7MADH*\L&)7*OMK((^*
MB:@L^I.9:<)"3YR!N(>73RY3EKS3(JS?GVQ\FLSDNL=K3N:J02@'=3!<GZ%N
M)>5Y.4.%RMD-1,GV/M,N8HGSKSJOH)V?,\UW!0URU;]5/0YAI<AA!7<C_+M"
ME>S"X;I_Y>H8*P4Y%T&TW$E WT#SLX<^/V72KA[0JD,VON1>Y5Z"R3_]-F-*
M^.3';+ON8&$1W;5SS?J%ET\+CO:$X*5\#G %:<56B;X]7B>R6Q2?\]9^^N>Q
MF4W*4=>TDX#Z:%.5KW:>^^4J##+#A_U7B3+3W[9BA<MU'0V-HB5_$<+F=A4'
ME#K=#5$@@\N.E1R+*:^2%$Q!1#T[[O^PA/Y3.'>1VFY ^#AOG"SJM>_(B!JY
MUMES?U"I^PLQ(A-@T&5QZ=J+/49:6"/'*A&Q6(DJ?*PXGMQ$K:Z1!)5.SLRZ
M<E5YM!&8"22NDA2N:I%6=Y[PRV9QM7EFD952^6#2 Y.+>\+3+/0@LD_S%3 O
MZNZV7?>?T?/L=(0J5NSEVI60<C#.-K%)VK_'?/&)UGBT?L/R-X)KMF&"UV3=
MC?:_OVQ A.9Q45K!-=V=3LICV\(&^0]ZY;M<96K;UA"YP+RM^^L !&PZ3U2
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MF% =6&2_K\PF3N+9#(/J$PYT\07HFYMU:[E4F JXIS-*E1RUFY"5:'<GE"[
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MK,I"G4 4.C.B(0'SV03$/$?.(9H1T?[^M8*Y*9)4G$&X->X,XF5WX^(M"QN
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M6F#YZ>^>EO_UO_Y?G?XZ_7\!4$L! A0#%     @ 3X$&43SO2 QS.P  ^T
M !T              ( !     &-H87)T+3(W.#<V838T-SDQ9C5B.#<X,3@N
M:G!G4$L! A0#%     @ 3X$&47!G$202,   ES4  !T              ( !
MKCL  &-H87)T+3(W.6,Y8C8Q-3DU-C5D960X830N:G!G4$L! A0#%     @
M3X$&42!N4K!M.P  ]T   !T              ( !^VL  &-H87)T+38Y8S<S
M,&5F-V)B93-F,F(R8V$N:G!G4$L! A0#%     @ 3X$&48%A9;N7+P  -34
M !T              ( !HZ<  &-H87)T+64V,C@U9F0Y,V)D9C4Y83$T9&8N
M:G!G4$L! A0#%     @ 3X$&43^/#>U-) 8 )NIL !0              ( !
M==<  '!F92TP-C(X,C R,'@Q,'$N:'1M4$L! A0#%     @ 3X$&44UY]/NS
M(0  Y*H! !               ( !]/L& '!F92TR,#(P,#8R."YX<V102P$"
M% ,4    " !/@091>Y9]&L$]  !"SP( %               @ '5'0< <&9E
M+3(P,C P-C(X7V-A;"YX;6Q02P$"% ,4    " !/@091*>9NZORR  #A[0@
M%               @ '(6P< <&9E+3(P,C P-C(X7V1E9BYX;6Q02P$"% ,4
M    " !/@091E^]!:TMB 0 $FA( %               @ 'V#@@ <&9E+3(P
M,C P-C(X7VQA8BYX;6Q02P$"% ,4    " !/@091&.U]2HGQ   [(PP %
M            @ %S<0D <&9E+3(P,C P-C(X7W!R92YX;6Q02P$"% ,4
M" !/@091 OPE(O$'  # )0  &@              @ $N8PH <&9E+65X:#,Q
M,7@P-C(X,C R,#$P<2YH=&U02P$"% ,4    " !/@091*3L6F/0'   Q)@
M&@              @ %7:PH <&9E+65X:#,Q,G@P-C(X,C R,#$P<2YH=&U0
M2P$"% ,4    " !/@091IJR.^AT%   ]&0  &@              @ &#<PH
M<&9E+65X:#,R,7@P-C(X,C R,#$P<2YH=&U02P$"% ,4    " !/@091MI@2
MT#X%  #U&   &@              @ '8> H <&9E+65X:#,R,G@P-C(X,C R
M,#$P<2YH=&U02P$"% ,4    " !/@091OLWC:A@>  !EG@  &@
M    @ %.?@H <&9E+65X:&EB:70Q,#%X-C(X,C R,"YH=&U02P$"% ,4
M" !/@0917118>O0$  #)'P  &@              @ &>G H <&9E+65X:&EB
M:70Q-7@P-C(X,C R,"YH=&U02P$"% ,4    " !/@091I#SFVO<A   T/0
M$@              @ '*H0H <&9I>F5R;&]G;S(X,38N:G!G4$L! A0#%
M  @ 3X$&4;0WU23O) , S80#  X              ( !\<,* '5P:F]H;FQO
<9V\N:G!G4$L%!@     2 !( X 0   SI#0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
